diff --git "a/clinical_evidence_data/drug_organ_trials_clean.csv" "b/clinical_evidence_data/drug_organ_trials_clean.csv" new file mode 100644--- /dev/null +++ "b/clinical_evidence_data/drug_organ_trials_clean.csv" @@ -0,0 +1,15440 @@ +,nct_id,title,status,phase,conditions,interventions,pubchem_id,drug_name,standardized_condition,matched_organ,drug,targets,moa-broad,moa-fine,human-approved,clinical-trials,gpt-notes-approval,canonical_smiles,mean_serious_flag,ae_severity_score +0,NCT00565266,Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC),COMPLETED,PHASE3,Asthma,tiotropium bromide (DRUG); salmeterol xinafoate (DRUG); beclomethasone dipropionate (DRUG),165411828,STERITALC,Asthma,Lung,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +1,NCT06744946,Thoracoscopic Talc Pleurodesis Versus Bleomycin -Tranxemic Acid Mixture Injection in Chest Tube in Malignant Pleural Effusion,COMPLETED,PHASE4,Malignant Pleural Effusions (Mpe)- Pleurodesis; Pleurodesis,thoracoscope (PROCEDURE),165411828,STERITALC,Malignant Pleural Effusions (Mpe)- Pleurodesis; Pleurodesis,Lung,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +2,NCT05106127,Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem,NOT_YET_RECRUITING,PHASE2,Advanced Endometrial Cancer,EG-007 (DRUG); Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection (DRUG); Lenvatinib Capsules (DRUG),165411828,STERITALC,Advanced Endometrial Cancer,Uterus,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +3,NCT00637676,Tunneled Pleural Catheter in Partially Entrapped Lung,COMPLETED,PHASE2,Malignant Pleural Effusion,"VATS, Talc-Pleurodesis, tunneled pleural drainage (PROCEDURE); VATS, Talc-pleurodesis (PROCEDURE)",165411828,STERITALC,Malignant Pleural Effusion,Lung,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +4,NCT00821860,Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma,COMPLETED,PHASE3,Malignant Mesothelioma; Metastatic Cancer,talc (OTHER); therapeutic thoracoscopy (PROCEDURE); therapeutic videothoracoscopy (PROCEDURE),165411828,STERITALC,Malignant Mesothelioma; Metastatic Cancer,Lung,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +5,NCT04400539,The IMmunotherapy Pleural 5-ALA PDT,RECRUITING,PHASE2,Mesotheliomas Pleural; Malignant Pleural Mesothelioma,intrapleural photodynamic therapy with videothoracoscopy (DEVICE); Nivolumab Injection (DRUG),165411828,STERITALC,Mesotheliomas Pleural; Malignant Pleural Mesothelioma,Lung,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +6,NCT04806373,Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis,COMPLETED,PHASE4,Pleural Effusion,Cathflo Activase (DRUG); Talc Slurry Pleurodesis (DRUG),165411828,STERITALC,Pleural Effusion,Lung,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +7,NCT02340962,Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection,COMPLETED,PHASE2,"Hepatitis C, Chronic",TG-2349 (DRUG); Ribavirin (DRUG); Interferon Alfa-2a (DRUG),165411828,STERITALC,Chronic Hepatitis C,Liver,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +8,NCT00758316,"A Prospective, Randomized Controlled Trial for a Rapid Pleurodesis Protocol for the Management of Pleural Effusions",COMPLETED,PHASE3,Malignant Pleural Effusions,Thoracoscopy and Pleurx (OTHER); Thoracoscopy (PROCEDURE),165411828,STERITALC,Malignant Pleural Effusions,Lung,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +9,NCT00730067,Sildenafil for Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension,WITHDRAWN,PHASE4,COPD; Pulmonary Hypertension,sildenafil (DRUG); placebo (DRUG),165411828,STERITALC,COPD with Pulmonary Hypertension,Lung,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +10,NCT02674243,Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion,COMPLETED,PHASE3,Malignant Pleural Effusion,Iodopovidone solution (DRUG); Talc (DRUG),165411828,STERITALC,Malignant Pleural Effusion,Lung,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +11,NCT02825095,Management of Malignant Pleural Effusion - Indwelling Pleural Catheter or Talc Pleurodesis,UNKNOWN,EARLY_PHASE1,"Pleural Effusion, Malignant; Lung Neoplasms",Talc Pleurodesis (PROCEDURE); Indwelling Pleural Catheter (PROCEDURE); chest ultrasound (PROCEDURE); Local anesthesia (DRUG); Chest Tube (PROCEDURE),165411828,STERITALC,"Pleural Effusion, Malignant; Lung Neoplasms",Lung,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +12,NCT03827070,Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma,UNKNOWN,PHASE1,Non Small Cell Lung Cancer,Afatinib (DRUG); Talcum powder (DRUG),165411828,STERITALC,Non Small Cell Lung Cancer,Lung,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +13,NCT00090402,Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease,COMPLETED,PHASE1,Alzheimer's Disease; Oxidative Stress; Dementia; Hyperlipidemia; Inflammation,Fish Oil (DIETARY_SUPPLEMENT); Lipoic Acid (DIETARY_SUPPLEMENT); Fish Oil Placebo (OTHER); Lipoic Acid Placebo (OTHER),165411828,STERITALC,Alzheimer's Disease; Oxidative Stress; Dementia; Hyperlipidemia; Inflammation,CNS/Brain,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +14,NCT00950248,Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS),COMPLETED,PHASE1,Primary Progressive Multiple Sclerosis,Idebenone (DRUG); placebo (OTHER),165411828,STERITALC,Primary Progressive Multiple Sclerosis,CNS/Brain,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +15,NCT04792970,Randomized Controlled Trial of Talc Instillation In Addition To Daily Drainage Through a Tunneled Pleural Catheter to Improve Rates of Outpatient Pleurodesis in Patients With Malignant Pleural Effusion,TERMINATED,PHASE4,Malignant Pleural Effusion,Talc (DRUG),165411828,STERITALC,Malignant Pleural Effusion,Lung,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +16,NCT02511600,Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication,WITHDRAWN,PHASE3,Lung Diseases; Mesothelioma,Progel Sealant (OTHER); Talcum Powder (OTHER); Pain Questionnaire (BEHAVIORAL),165411828,STERITALC,Lung Diseases; Mesothelioma,Lung,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +17,NCT00789087,Talc Pleurodesis in Patients With Recurrent Malignant Pleural Effusion,COMPLETED,PHASE4,Recurrent Malignant Pleural Effusion.,Videothoracoscopic talc poudrage (VT). (PROCEDURE); Talc slurry through a chest tube (DT). (PROCEDURE),165411828,STERITALC,Recurrent Malignant Pleural Effusion.,Lung,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +18,NCT06742099,The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion,NOT_YET_RECRUITING,EARLY_PHASE1,Malignant Pleural Effusions (Mpe),Intercostal chest tube (PROCEDURE); Pleurodesis (COMBINATION_PRODUCT),165411828,STERITALC,Malignant Pleural Effusions (Mpe),Lung,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +19,NCT02930161,Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome,TERMINATED,PHASE2,Non-alcoholic Fatty Liver Disease,Runihol (DRUG); Placebo (OTHER),165411828,STERITALC,Non-alcoholic Fatty Liver Disease,Liver,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +20,NCT01469728,Comparison of Thoracoscopic Talc Pleurodesis by Thoracic Epidural or General Anesthesia,COMPLETED,PHASE2,Pleural Effusion,Non-awake VATS talc pleurodesis (PROCEDURE); Awake VATS talc pleurodesis (PROCEDURE),165411828,STERITALC,Pleural Effusion,Lung,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +21,NCT05077215,Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer,NOT_YET_RECRUITING,PHASE3,Advanced Endometrial Cancer,EG-007 (DRUG); Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection (DRUG); Lenvatinib Capsules (DRUG),165411828,STERITALC,Advanced Endometrial Cancer,Uterus,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +22,NCT04057547,Efficacy and Safety of Modified Gegen Qinlian Decoction for Ulcerative Colitis With Damp-heat Syndrome,UNKNOWN,EARLY_PHASE1,Ulcerative Colitis,Modified Gegen Qinlian Decoction (DRUG),165411828,STERITALC,Ulcerative Colitis,Bowel,Talc,,unclear,unclear,yes,yes,Talc used in pharma and cosmetics; safety under review for some uses.,[OH-].[OH-].[O-][Si]12O[Si]3(O[Si](O1)(O[Si](O2)(O3)[O-])[O-])[O-].[Mg+2].[Mg+2].[Mg+2],1.07,274.0 +23,NCT00200382,Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer,TERMINATED,PHASE2,Non-small Cell Lung Cancer,PS-341 (Velcade-drug) (DRUG),387447,DPBA,Non-small Cell Lung Cancer,Lung,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +24,NCT00798720,Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer,COMPLETED,PHASE2,"Carcinoma, Non Small Cell Lung",vorinostat (DRUG); bortezomib (DRUG),387447,DPBA,Non-small Cell Lung Cancer (NSCLC),Lung,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +25,NCT00051974,Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,VELCADE™ (bortezomib) for Injection (formerly PS-341) (DRUG),387447,DPBA,Advanced Non-Small Cell Lung Cancer,Lung,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +26,NCT00622674,Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors,COMPLETED,PHASE1,"Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Pancreatic Cancer; Sarcoma; Unspecified Adult Solid Tumor, Protocol Specific",cetuximab (BIOLOGICAL); bortezomib (DRUG),387447,DPBA,"Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Pancreatic Cancer; Sarcoma; Unspecified Adult Solid Tumor, Protocol Specific",Bowel,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +27,NCT00580320,Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma,COMPLETED,PHASE1,Melanoma; Soft Tissue Sarcoma; Parathyroid Carcinoma; Small Cell Carcinoma of the Lung; Carcinoid Tumors,Dacarbazine and bortezomib (DRUG),387447,DPBA,Melanoma; Soft Tissue Sarcoma; Parathyroid Carcinoma; Small Cell Carcinoma of the Lung; Carcinoid Tumors,Skin,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +28,NCT01873157,Bortezomib in Late Antibody-mediated Kidney Transplant Rejection,COMPLETED,PHASE2,Late Rejection of Renal Transplant; Antibody-mediated Rejection,Bortezomib (DRUG); Placebo (DRUG),387447,DPBA,Late Rejection of Renal Transplant; Antibody-mediated Rejection,Kidney,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +29,NCT00098982,"Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer",COMPLETED,PHASE1,Colorectal Cancer,bortezomib (DRUG); fluorouracil (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG),387447,DPBA,Colorectal Cancer,Bowel,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +30,NCT00343720,Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,VELCADE (DRUG); Alimta (DRUG),387447,DPBA,Advanced Non-Small Cell Lung Cancer,Lung,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +31,NCT00103103,"Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer",TERMINATED,PHASE2,Gastric Cancer,bortezomib (DRUG); fluorouracil (DRUG); leucovorin calcium (DRUG),387447,DPBA,Gastric Cancer,Esophagus/Stomach,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +32,NCT00313690,Cancer Treatment Followed by Surgery for Early Stage Non-small Cell Lung Cancer,WITHDRAWN,PHASE1,Lung Cancer,"Bortezomib, Docetaxel and Cisplatin (DRUG)",387447,DPBA,Lung Cancer,Lung,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +33,NCT01056601,Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy,TERMINATED,PHASE2,Pancreatic Cancer,Bortezomib (DRUG); Panobinostat (DRUG),387447,DPBA,Pancreatic Cancer,Pancreas,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +34,NCT00108069,Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors,COMPLETED,PHASE2,Glioma,Tamoxifen citrate (DRUG); Bortezomib (DRUG),387447,DPBA,Glioma,CNS/Brain,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +35,NCT00025376,PS-341 in Treating Patients With Metastatic Kidney Cancer,COMPLETED,PHASE2,Kidney Cancer,PS-341 (DRUG); Tumor Biopsy (PROCEDURE),387447,DPBA,Kidney Cancer,Kidney,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +36,NCT00006773,Bortezomib in Treating Patients With Recurrent Glioma,TERMINATED,PHASE1,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor,bortezomib (DRUG),387447,DPBA,Adult Malignant Gliomas,CNS/Brain,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +37,NCT00237627,Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer,COMPLETED,PHASE1,"Breast Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific",PS-341 (DRUG); Doxil (DRUG); Velcade (DRUG),387447,DPBA,"Breast Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Breast,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +38,NCT00106262,"Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer",TERMINATED,PHASE2,Cervical Cancer,Velcade (bortezomib) (DRUG); Irinotecan (DRUG),387447,DPBA,Cervical Cancer,Cervix,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +39,NCT02351427,Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney Transplantation,UNKNOWN,PHASE3,Kidney Transplantation,Bortezomib (DRUG); Steroid (DRUG),387447,DPBA,Kidney Transplantation,Kidney,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +40,NCT00362882,Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,docetaxel (DRUG); bortezomib (DRUG); laboratory biomarker analysis (OTHER); immunoenzyme technique (OTHER); immunohistochemistry staining method (OTHER); pharmacological study (OTHER),387447,DPBA,Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Lung,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +41,NCT01783522,Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib,TERMINATED,PHASE2,Chemotherapeutic Agent Toxicity; Multiple Myeloma; Peripheral Neuropathy,glutamine (DRUG); quality-of-life assessment (OTHER); placebo (OTHER),387447,DPBA,Chemotherapeutic Agent Toxicity; Multiple Myeloma; Peripheral Neuropathy,Peripheral Nervous System,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +42,NCT00611325,Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma,COMPLETED,PHASE2,Glioblastoma; Gliosarcoma,Avastin (DRUG); Bortezomib (DRUG),387447,DPBA,Glioblastoma,CNS/Brain,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +43,NCT00028639,PS-341 in Treating Women With Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,bortezomib (DRUG),387447,DPBA,Breast Cancer,Breast,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +44,NCT00280176,"Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer",COMPLETED,PHASE1,Colorectal Cancer,bortezomib (DRUG); fluorouracil (DRUG); radiation therapy (RADIATION),387447,DPBA,Colorectal Cancer,Bowel,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +45,NCT00722722,The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates,COMPLETED,PHASE2,Kidney Transplantation,Bortezomib (DRUG),387447,DPBA,Kidney Transplantation,Kidney,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +46,NCT01163786,A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD,TERMINATED,PHASE2,Bronchiolitis Obliterans,Bortezomib (DRUG),387447,DPBA,Bronchiolitis Obliterans,Lung,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +47,NCT00068289,Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy,COMPLETED,PHASE2,Lung Cancer,bortezomib (DRUG),387447,DPBA,Lung Cancer,Lung,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +48,NCT00052689,Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Duct Cell Adenocarcinoma of the Pancreas; Stage IV Pancreatic Cancer,bortezomib (DRUG); gemcitabine hydrochloride (DRUG),387447,DPBA,Duct Cell Adenocarcinoma of the Pancreas; Stage IV Pancreatic Cancer,Pancreas,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +49,NCT00017329,PS-341 in Treating Patients With Metastatic Kidney Cancer,COMPLETED,PHASE2,Kidney Cancer,bortezomib (DRUG),387447,DPBA,Kidney Cancer,Kidney,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +50,NCT00644696,Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma,COMPLETED,PHASE1,Neuroblastoma,Irinotecan and Bortezomib (DRUG),387447,DPBA,Neuroblastoma,CNS/Brain,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +51,NCT06142396,Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure,RECRUITING,EARLY_PHASE1,Multiple Myeloma; Renal Failure,"Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (COMBINATION_PRODUCT)",387447,DPBA,Multiple Myeloma; Renal Failure,Kidney,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +52,NCT01633281,Acupuncture for Peripheral Neuropathy,TERMINATED,PHASE2,Peripheral Neuropathy Grade 2 or Greater,acupuncture (PROCEDURE),387447,DPBA,Peripheral Neuropathy Grade 2 or Greater,Peripheral Nervous System,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +53,NCT00118144,Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer,COMPLETED,PHASE2,Adenocarcinoma of the Lung; Bronchoalveolar Cell Lung Cancer; Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,bortezomib (DRUG),387447,DPBA,Adenocarcinoma of the Lung; Bronchoalveolar Cell Lung Cancer; Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Lung,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +54,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,75 approved agents (DRUG); COXEN (OTHER),387447,DPBA,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,Bladder/Urinary Tract,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +55,NCT01142401,Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Carcinoma; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7,Bortezomib (DRUG); Fulvestrant (DRUG); Laboratory Biomarker Analysis (OTHER),387447,DPBA,Metastatic Breast Carcinoma; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7,Breast,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +56,NCT04265872,Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC,RECRUITING,EARLY_PHASE1,Breast Cancer,Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis (DRUG),387447,DPBA,Breast Cancer,Breast,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +57,NCT03057340,The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells,UNKNOWN,PHASE1,"Carcinoma, Non-Small-Cell Lung",Dribble vaccine (BIOLOGICAL),387447,DPBA,"Carcinoma, Non-Small-Cell Lung",Lung,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +58,NCT01502267,Desensitization Protocol for Highly Sensitized Patients on the Waiting List for Kidney Transplant,UNKNOWN,PHASE2,End Stage Renal Disease,High dose IVIG and B cell depleting agents (DRUG),387447,DPBA,End Stage Renal Disease,Kidney,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +59,NCT00610792,Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens,WITHDRAWN,PHASE2,Ovarian Cancer,bortezomib (DRUG); pegylated liposomal doxorubicin (DRUG),387447,DPBA,Ovarian Cancer,Ovary/Fallopian Tube,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +60,NCT00388089,Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors,COMPLETED,PHASE1,"Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",bortezomib (DRUG); topotecan hydrochloride (DRUG); flow cytometry (OTHER); immunoenzyme technique (OTHER); immunohistochemistry staining method (OTHER); laboratory biomarker analysis (OTHER),387447,DPBA,"Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Lung,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +61,NCT01462773,"Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma",COMPLETED,PHASE1,Melanoma,Bortezomib (DRUG); Interferon Alfa-2b (DRUG),387447,DPBA,Melanoma,Skin,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +62,NCT03944304,"Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.",RECRUITING,PHASE2,Gastrointestinal Stromal Tumors,Paclitaxel (DRUG),387447,DPBA,Gastrointestinal Stromal Tumors,Bowel,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +63,NCT02563340,Effect of BM-MSCs on Chronic AMR After Kidney Transplantation,UNKNOWN,PHASE1,Kidney Transplantation,"BM-MSCs (OTHER); Desensitization therapy (PP, IVIG, rituximab or Bortezomib) (OTHER)",387447,DPBA,Kidney Transplantation,Kidney,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +64,NCT00424840,Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy,TERMINATED,PHASE1,Lung Cancer,Bortezomib 1.3 mg/m2 (DRUG); Bortezomib 1.6 mg/m2 (DRUG); Bortezomib 1.8 mg/m2 (DRUG); Carboplatin AUC 6 (DRUG); Bevacizumab (DRUG); Taxotere (DRUG),387447,DPBA,Lung Cancer,Lung,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +65,NCT00714246,Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer,TERMINATED,PHASE1,Non Small Cell Lung Cancer,Bortezomib (DRUG); Carboplatin (DRUG); Docetaxel (DRUG),387447,DPBA,Non Small Cell Lung Cancer,Lung,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +66,NCT00040768,Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer,TERMINATED,PHASE2,Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,bortezomib (DRUG),387447,DPBA,Advanced Non-Small Cell Lung Cancer,Lung,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +67,NCT00288041,"Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma",COMPLETED,PHASE2,"Ciliary Body and Choroid Melanoma, Medium/Large Size; Extraocular Extension Melanoma; Iris Melanoma; Recurrent Intraocular Melanoma; Recurrent Melanoma; Stage IV Melanoma",carboplatin (DRUG); paclitaxel (DRUG); bortezomib (DRUG),387447,DPBA,"Ciliary Body and Choroid Melanoma, Medium/Large Size; Extraocular Extension Melanoma; Iris Melanoma; Recurrent Intraocular Melanoma; Recurrent Melanoma; Stage IV Melanoma",Skin,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +68,NCT00458913,Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma,COMPLETED,PHASE2,Malignant Mesothelioma,bortezomib (DRUG); cisplatin (DRUG),387447,DPBA,Malignant Mesothelioma,Lung,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +69,NCT00077441,Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer),COMPLETED,PHASE2,Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer,bortezomib (DRUG); laboratory biomarker analysis (OTHER),387447,DPBA,Primary Hepatocellular Carcinoma,Liver,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +70,NCT00107341,"Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction",COMPLETED,PHASE2,Esophageal Cancer,bortezomib (DRUG); carboplatin (DRUG); paclitaxel (DRUG),387447,DPBA,Esophageal Cancer,Esophagus/Stomach,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +71,NCT00667641,Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors,COMPLETED,PHASE1,"Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Lung Cancer; Melanoma (Skin); Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",bortezomib (DRUG); paclitaxel (DRUG),387447,DPBA,"Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Lung Cancer; Melanoma (Skin); Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Bowel,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +72,NCT06572813,Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer,RECRUITING,PHASE1,Pancreas Cancer,Bortezomib Injection (DRUG); Sintilimab (DRUG); mFOLFIRINOX (DRUG),387447,DPBA,Pancreas Cancer,Pancreas,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +73,NCT00059618,"PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer",COMPLETED,PHASE1,Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer,PS-341 (Bortezomib) (DRUG); Carboplatin (DRUG),387447,DPBA,Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer,Ovary/Fallopian Tube,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +74,NCT01208818,Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy,COMPLETED,PHASE3,Chronic Renal Failure With Uremic Nephropathy,Cyclophosphamide + Bortezomib + Dexamethasone regimen (DRUG); Bortezomib +Dexamethasone regimen (DRUG); HCO group (DEVICE); conventional high-flux dialyzer (DEVICE),387447,DPBA,Chronic Renal Failure With Uremic Nephropathy,Kidney,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +75,NCT00891618,Acupuncture for Chemo-Induced Peripheral Neuropathy,COMPLETED,PHASE2,Lymphoma; Myeloma; Peripheral Neuropathy,Acupuncture (OTHER),387447,DPBA,Lymphoma; Myeloma; Peripheral Neuropathy,Peripheral Nervous System,Bortezomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma and mantle cell lymphoma.,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,1.0,208.0 +76,NCT02384746,Phase I Study of the Combination of MLN9708 and Fulvestrant,TERMINATED,PHASE1,Breast Cancer,Fulvestrant (DRUG); MLN9708 (DRUG),25183872,Ixazomib,Breast Cancer,Breast,Ixazomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment.,B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O,1.02,351.0 +77,NCT02176486,"Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)",TERMINATED,PHASE1,Lupus Nephritis,Ixazomib (DRUG); Placebo (DRUG),25183872,Ixazomib,Lupus Nephritis,Kidney,Ixazomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment.,B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O,1.02,351.0 +78,NCT02630030,Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma,COMPLETED,EARLY_PHASE1,Glioblastoma,Ixazomib (DRUG),25183872,Ixazomib,Glioblastoma,CNS/Brain,Ixazomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment.,B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O,1.02,351.0 +79,NCT03587662,"Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients with Locally Advanced or Metastatic Kidney Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Kidney Medullary Carcinoma; Metastatic Renal Cell Carcinoma; SMARCB1 Negative; Stage III Renal Cell Cancer AJCC V8; Stage IV Renal Cell Cancer AJCC V8,Doxorubicin (DRUG); Doxorubicin Hydrochloride (DRUG); Gemcitabine (DRUG); Gemcitabine Hydrochloride (DRUG); Ixazomib (DRUG); Ixazomib Citrate (DRUG),25183872,Ixazomib,Metastatic Kidney Medullary Carcinoma; Metastatic Renal Cell Carcinoma; SMARCB1 Negative; Stage III Renal Cell Cancer AJCC V8; Stage IV Renal Cell Cancer AJCC V8,Kidney,Ixazomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment.,B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O,1.02,351.0 +80,NCT02993094,Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer,TERMINATED,PHASE1,Triple-Negative Breast Cancer,Ixazomib (DRUG); Carboplatin (DRUG),25183872,Ixazomib,Triple-Negative Breast Cancer,Breast,Ixazomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment.,B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O,1.02,351.0 +81,NCT03783416,SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis,RECRUITING,PHASE1,Relapsing Remitting Multiple Sclerosis; Primary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis,Ixazomib (NINLARO®) capsules / Matching placebo capsules (DRUG),25183872,Ixazomib,Relapsing Remitting Multiple Sclerosis; Primary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis,CNS/Brain,Ixazomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment.,B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O,1.02,351.0 +82,NCT03213158,Ixazomib for Desensitization,COMPLETED,PHASE2,Kidney Diseases; End Stage Renal Disease,Ixazomib Oral Capsule (DRUG),25183872,Ixazomib,Kidney Diseases; End Stage Renal Disease,Kidney,Ixazomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment.,B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O,1.02,351.0 +83,NCT03619252,Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents,COMPLETED,PHASE4,Multiple Myeloma; Pneumococcal Infection; Febrile Neutropenia; Pneumococcal Pneumonia,Vaccination with pneumococcal conjugate vaccine (PCV13) (BIOLOGICAL); Standard Antibacterial Prophylaxis (DRUG),25183872,Ixazomib,Multiple Myeloma; Pneumococcal Infection; Febrile Neutropenia; Pneumococcal Pneumonia,Lung,Ixazomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment.,B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O,1.02,351.0 +84,NCT02420847,Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Urothelial Carcinoma; Transitional Cell Carcinoma; Unresectable Transitional Cell Carcinoma,Doxorubicin Hydrochloride (DRUG); Gemcitabine Hydrochloride (DRUG); Ixazomib Citrate (DRUG),25183872,Ixazomib,Metastatic Urothelial Carcinoma; Transitional Cell Carcinoma; Unresectable Transitional Cell Carcinoma,Bladder/Urinary Tract,Ixazomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment.,B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O,1.02,351.0 +85,NCT02447887,Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC),TERMINATED,PHASE1,Metastatic Renal Cell Carcinoma; RCC,Ixazomib (DRUG); Pegylated IFN-alpha 2b (DRUG),25183872,Ixazomib,Metastatic Renal Cell Carcinoma; RCC,Kidney,Ixazomib,PSMB5,inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment.,B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O,1.02,351.0 +86,NCT02384746,Phase I Study of the Combination of MLN9708 and Fulvestrant,TERMINATED,PHASE1,Breast Cancer,Fulvestrant (DRUG); MLN9708 (DRUG),56844015,NINLARO,Breast Cancer,Breast,Ixazomib citrate,"PSMB1, PSMB2, PSMB5",inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment as part of a combination therapy.,B1(OC(=O)C(O1)(CC(=O)O)CC(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl,1.0208333333333333,1591.0 +87,NCT02176486,"Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)",TERMINATED,PHASE1,Lupus Nephritis,Ixazomib (DRUG); Placebo (DRUG),56844015,NINLARO,Lupus Nephritis,Kidney,Ixazomib citrate,"PSMB1, PSMB2, PSMB5",inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment as part of a combination therapy.,B1(OC(=O)C(O1)(CC(=O)O)CC(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl,1.0208333333333333,1591.0 +88,NCT02630030,Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma,COMPLETED,EARLY_PHASE1,Glioblastoma,Ixazomib (DRUG),56844015,NINLARO,Glioblastoma,CNS/Brain,Ixazomib citrate,"PSMB1, PSMB2, PSMB5",inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment as part of a combination therapy.,B1(OC(=O)C(O1)(CC(=O)O)CC(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl,1.0208333333333333,1591.0 +89,NCT03587662,"Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients with Locally Advanced or Metastatic Kidney Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Kidney Medullary Carcinoma; Metastatic Renal Cell Carcinoma; SMARCB1 Negative; Stage III Renal Cell Cancer AJCC V8; Stage IV Renal Cell Cancer AJCC V8,Doxorubicin (DRUG); Doxorubicin Hydrochloride (DRUG); Gemcitabine (DRUG); Gemcitabine Hydrochloride (DRUG); Ixazomib (DRUG); Ixazomib Citrate (DRUG),56844015,NINLARO,Metastatic Kidney Medullary Carcinoma; Metastatic Renal Cell Carcinoma; SMARCB1 Negative; Stage III Renal Cell Cancer AJCC V8; Stage IV Renal Cell Cancer AJCC V8,Kidney,Ixazomib citrate,"PSMB1, PSMB2, PSMB5",inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment as part of a combination therapy.,B1(OC(=O)C(O1)(CC(=O)O)CC(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl,1.0208333333333333,1591.0 +90,NCT02993094,Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer,TERMINATED,PHASE1,Triple-Negative Breast Cancer,Ixazomib (DRUG); Carboplatin (DRUG),56844015,NINLARO,Triple-Negative Breast Cancer,Breast,Ixazomib citrate,"PSMB1, PSMB2, PSMB5",inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment as part of a combination therapy.,B1(OC(=O)C(O1)(CC(=O)O)CC(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl,1.0208333333333333,1591.0 +91,NCT03783416,SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis,RECRUITING,PHASE1,Relapsing Remitting Multiple Sclerosis; Primary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis,Ixazomib (NINLARO®) capsules / Matching placebo capsules (DRUG),56844015,NINLARO,Relapsing Remitting Multiple Sclerosis; Primary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis,CNS/Brain,Ixazomib citrate,"PSMB1, PSMB2, PSMB5",inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment as part of a combination therapy.,B1(OC(=O)C(O1)(CC(=O)O)CC(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl,1.0208333333333333,1591.0 +92,NCT03213158,Ixazomib for Desensitization,COMPLETED,PHASE2,Kidney Diseases; End Stage Renal Disease,Ixazomib Oral Capsule (DRUG),56844015,NINLARO,Kidney Diseases; End Stage Renal Disease,Kidney,Ixazomib citrate,"PSMB1, PSMB2, PSMB5",inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment as part of a combination therapy.,B1(OC(=O)C(O1)(CC(=O)O)CC(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl,1.0208333333333333,1591.0 +93,NCT03619252,Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents,COMPLETED,PHASE4,Multiple Myeloma; Pneumococcal Infection; Febrile Neutropenia; Pneumococcal Pneumonia,Vaccination with pneumococcal conjugate vaccine (PCV13) (BIOLOGICAL); Standard Antibacterial Prophylaxis (DRUG),56844015,NINLARO,Multiple Myeloma; Pneumococcal Infection; Febrile Neutropenia; Pneumococcal Pneumonia,Lung,Ixazomib citrate,"PSMB1, PSMB2, PSMB5",inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment as part of a combination therapy.,B1(OC(=O)C(O1)(CC(=O)O)CC(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl,1.0208333333333333,1591.0 +94,NCT02420847,Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Urothelial Carcinoma; Transitional Cell Carcinoma; Unresectable Transitional Cell Carcinoma,Doxorubicin Hydrochloride (DRUG); Gemcitabine Hydrochloride (DRUG); Ixazomib Citrate (DRUG),56844015,NINLARO,Metastatic Urothelial Carcinoma; Transitional Cell Carcinoma; Unresectable Transitional Cell Carcinoma,Bladder/Urinary Tract,Ixazomib citrate,"PSMB1, PSMB2, PSMB5",inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment as part of a combination therapy.,B1(OC(=O)C(O1)(CC(=O)O)CC(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl,1.0208333333333333,1591.0 +95,NCT02447887,Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC),TERMINATED,PHASE1,Metastatic Renal Cell Carcinoma; RCC,Ixazomib (DRUG); Pegylated IFN-alpha 2b (DRUG),56844015,NINLARO,Metastatic Renal Cell Carcinoma; RCC,Kidney,Ixazomib citrate,"PSMB1, PSMB2, PSMB5",inhibitor/antagonist,Proteasome inhibitor,yes,yes,Approved for multiple myeloma treatment as part of a combination therapy.,B1(OC(=O)C(O1)(CC(=O)O)CC(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl,1.0208333333333333,1591.0 +96,NCT00267748,Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC),COMPLETED,PHASE2,"Carcinoma, Renal Cell",Sunitinib Malate Continuous Daily Dosing (DRUG); Sunitinib Malate Schedule 4/2 (DRUG),168311648,Lactate (calcium),"Carcinoma, Renal Cell",Kidney,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +97,NCT00065182,Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer,COMPLETED,PHASE2,"Lung Cancer, Non-Small Cell; Non-Small-Cell Lung Cancer",Topotecan/Docetaxel combination (DRUG); Docetaxel (DRUG),168311648,Lactate (calcium),"Lung Cancer, Non-Small Cell; Non-Small-Cell Lung Cancer",Lung,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +98,NCT06284590,"Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients",RECRUITING,PHASE2,Melanoma Stage III; Melanoma Stage IV,L19IL2 (DRUG); L19TNF (DRUG); L19IL2/L19TNF (DRUG); KEYTRUDA® (DRUG),168311648,Lactate (calcium),Melanoma Stage III; Melanoma Stage IV,Skin,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +99,NCT05261490,Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer,TERMINATED,PHASE1,Ovarian Cancer; Ovarian Neoplasms; Ovarian Carcinoma; Fallopian Tube Cancer; Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma,maplirpacept (PF-07901801) (DRUG); Pegylated Liposomal Doxorubicin (PLD) (DRUG),168311648,Lactate (calcium),Ovarian Cancer; Ovarian Neoplasms; Ovarian Carcinoma; Fallopian Tube Cancer; Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +100,NCT04040621,Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia,TERMINATED,PHASE1,Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia,Ceftazidime-avibactam (DRUG),168311648,Lactate (calcium),Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia,Lung,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +101,NCT03359850,Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients,COMPLETED,PHASE1,Ovarian Neoplasms; Neoplasms; Solid Tumor; Hepatic Impairment,Niraparib (DRUG),168311648,Lactate (calcium),Ovarian Neoplasms; Neoplasms; Solid Tumor; Hepatic Impairment,Ovary/Fallopian Tube,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +102,NCT02314143,Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib,TERMINATED,PHASE2,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),168311648,Lactate (calcium),Melanoma,Skin,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +103,NCT03674827,Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC,TERMINATED,PHASE1,Non-Small Cell Lung Cancer; Triple-negative Breast Cancer,PF-06936308 (BIOLOGICAL),168311648,Lactate (calcium),Non-Small Cell Lung Cancer; Triple-negative Breast Cancer,Lung,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +104,NCT00350727,Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma,COMPLETED,PHASE2,Glioma,pazopanib (DRUG); lapatinib (DRUG),168311648,Lactate (calcium),Glioma,CNS/Brain,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +105,NCT06663176,Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients with Pseudomonas Aeruginosa (Pa),RECRUITING,PHASE1,Non-Cystic Fibrosis Bronchiectasis,RESP302 (DRUG); RESP303 (DRUG),168311648,Lactate (calcium),Non-Cystic Fibrosis Bronchiectasis,Lung,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +106,NCT00603382,A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.,COMPLETED,PHASE2,Asthma,GW685698X (DRUG); Placebo (DRUG),168311648,Lactate (calcium),Asthma,Lung,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +107,NCT03934827,MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour,UNKNOWN,PHASE1,Melanoma; Breast Cancer; Uterine Cancer; Ovarian Cancer; Prostate Cancer; Urethral Cancer; Bladder Cancer; Renal Cancer; Lung Cancer; Head and Neck Cancer,MRx0518 Capsules (DRUG); MRx0518/placebo Capsules (DRUG),168311648,Lactate (calcium),Melanoma; Breast Cancer; Uterine Cancer; Ovarian Cancer; Prostate Cancer; Urethral Cancer; Bladder Cancer; Renal Cancer; Lung Cancer; Head and Neck Cancer,Lung,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +108,NCT00532948,A Study of Xeloda (Capecitabine) Plus Radiation Therapy in Children With Newly Diagnosed Gliomas,COMPLETED,PHASE1,Glioma,capecitabine [Xeloda] (DRUG),168311648,Lactate (calcium),Glioma,CNS/Brain,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +109,NCT04151225,"Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease",WITHDRAWN,PHASE2,Crohns Disease; Crohn's Disease,GSK2330811 (DRUG); Placebo (DRUG),168311648,Lactate (calcium),Crohns Disease; Crohn's Disease,Bowel,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +110,NCT01316939,GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease,TERMINATED,PHASE3,Crohn's Disease,GSK1605786A (DRUG); Placebo (DRUG); GSK1605786A (DRUG),168311648,Lactate (calcium),Crohn's Disease,Bowel,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +111,NCT01777139,"A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures",COMPLETED,PHASE3,Epilepsy,Retigabine IR (DRUG),168311648,Lactate (calcium),Epilepsy,CNS/Brain,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +112,NCT04604548,The KHENEREXT Study,COMPLETED,PHASE2,"Mitochondrial Diseases; Mitochondrial DNA tRNALeu(UUR) m.3243A= 12 Years Old) With POS or LGS",TERMINATED,PHASE3,Epilepsy,retigabine/ezogabine (DRUG),168311648,Lactate (calcium),Epilepsy,CNS/Brain,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +196,NCT05905133,A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD,ACTIVE_NOT_RECRUITING,PHASE2,Atopic Dermatitis,CBP-201 (DRUG),168311648,Lactate (calcium),Atopic Dermatitis,Skin,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +197,NCT03271047,Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation,COMPLETED,PHASE2,MSS; RAS-mutant Colorectal Cancer,binimetinib (DRUG); nivolumab (DRUG); ipilimumab (DRUG),168311648,Lactate (calcium),MSS; RAS-mutant Colorectal Cancer,Bowel,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +198,NCT05376553,Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck,ENROLLING_BY_INVITATION,PHASE1,Locally Advanced Head and Neck Squamous Cell Carcinoma,Cemiplimab (DRUG); Cisplatin (DRUG); Docetaxel (DRUG),168311648,Lactate (calcium),Locally Advanced Head and Neck Squamous Cell Carcinoma,Skin,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +199,NCT04493333,Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors,TERMINATED,PHASE2,Vaginal Atrophy; Postmenopausal Symptoms; Breast Cancer Female; Long-term Survivors,Vaginal Dehydroepiandrosterone (DRUG); Vaginal Polycarbophil Moisturizer (COMBINATION_PRODUCT),168311648,Lactate (calcium),Vaginal Atrophy; Postmenopausal Symptoms; Breast Cancer Female; Long-term Survivors,Breast,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +200,NCT02319577,GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,oral vinorelbine (DRUG); Gefitinib (DRUG),168311648,Lactate (calcium),Non Small Cell Lung Cancer,Lung,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +201,NCT03499353,Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer,TERMINATED,PHASE2,Early Breast Cancer,TALAZOPARIB (DRUG),168311648,Lactate (calcium),Early Breast Cancer,Breast,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +202,NCT01842607,A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects,COMPLETED,PHASE3,Asthma,Mepolizumab (BIOLOGICAL),168311648,Lactate (calcium),Asthma,Lung,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +203,NCT04528888,Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection,UNKNOWN,PHASE3,"Covid19; SARS-CoV Infection; Pneumonia, Viral; Coagulopathy",Enoxaparin (DRUG); Methylprednisolone (DRUG); unfractionated heparin (DRUG),168311648,Lactate (calcium),"Covid19; SARS-CoV Infection; Pneumonia, Viral; Coagulopathy",Lung,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +204,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,COMPLETED,PHASE3,Multiple Sclerosis,ALKS 8700 (DRUG),168311648,Lactate (calcium),Multiple Sclerosis,CNS/Brain,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +205,NCT03749109,Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis,COMPLETED,PHASE2,Endometriosis,Quinagolide 1080 µg (DRUG); Placebo (DRUG),168311648,Lactate (calcium),Endometriosis,Uterus,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +206,NCT05383378,"A First-In-Human Study to Evaluate the Safety, Tolerability, and Efficacy of Si-544 in Adults With Atopic Dermatitis",COMPLETED,PHASE1,Atopic Dermatitis,si-544 (DRUG); Placebo (DRUG),168311648,Lactate (calcium),Atopic Dermatitis,Skin,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +207,NCT00269087,"GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)",COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",fluticasone propionate/salmeterol combination DISKUS (DRUG),168311648,Lactate (calcium),"Pulmonary Disease, Chronic Obstructive",Lung,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +208,NCT05299554,Long-term Safety Study of Chronocort in the Treatment of Participants with Congenital Adrenal Hyperplasia,ENROLLING_BY_INVITATION,PHASE3,Congenital Adrenal Hyperplasia,Chronocort (DRUG),168311648,Lactate (calcium),Congenital Adrenal Hyperplasia,Kidney,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +209,NCT05016687,First-in-human Clinical Trial Evaluating CUR-N399 in Healthy Volunteers.,COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive; Enterovirus Infections; Rhinovirus",CUR-N399 (DRUG); Placebo (DRUG),168311648,Lactate (calcium),"Pulmonary Disease, Chronic Obstructive; Enterovirus Infections; Rhinovirus",Lung,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +210,NCT00425061,Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma,COMPLETED,PHASE2,Asthma,IMA-638 (BIOLOGICAL); IMA-638 (BIOLOGICAL); placebo (OTHER),168311648,Lactate (calcium),Asthma,Lung,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +211,NCT04338061,Study of Evobrutinib in Participants With RMS (evolutionRMS 2),TERMINATED,PHASE3,Relapsing Multiple Sclerosis,Teriflunomide (DRUG); Evobrutinib (DRUG),168311648,Lactate (calcium),Relapsing Multiple Sclerosis,CNS/Brain,Lactate (calcium),,unclear,unclear,yes,yes,"Used in medical settings, but not specifically approved as a standalone drug.",C.CC(C(=O)[O-])O.[Ca+2],1.1,1416.0 +212,NCT00254982,Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED),COMPLETED,PHASE3,Psoriasis,Infliximab (BIOLOGICAL),444972,Boletate,Psoriasis,Skin,Fumaric acid,,inhibitor/antagonist,unclear,yes,yes,Used in psoriasis treatment as part of fumaric acid esters.,C(=CC(=O)O)C(=O)O,1.08,996.0 +213,NCT02474082,Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.,COMPLETED,PHASE3,Psoriasis,Secukinumab (BIOLOGICAL); Fumaric acid (DRUG),444972,Boletate,Psoriasis,Skin,Fumaric acid,,inhibitor/antagonist,unclear,yes,yes,Used in psoriasis treatment as part of fumaric acid esters.,C(=CC(=O)O)C(=O)O,1.08,996.0 +214,NCT02337426,"Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",COMPLETED,PHASE1,Adult Brain Glioblastoma; Adult Giant Cell Glioblastoma; Adult Gliosarcoma,Dimethyl Fumarate (DRUG); Temozolomide (DRUG); Radiation Therapy (RADIATION),444972,Boletate,Adult Brain Glioblastoma; Adult Giant Cell Glioblastoma; Adult Gliosarcoma,CNS/Brain,Fumaric acid,,inhibitor/antagonist,unclear,yes,yes,Used in psoriasis treatment as part of fumaric acid esters.,C(=CC(=O)O)C(=O)O,1.08,996.0 +215,NCT01088165,The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis,UNKNOWN,PHASE4,"Psoriasis; Cardiovascular Diseases; Diabetes Mellitus, Type 2",Adalimumab treatment arm (DRUG); Fumaric acid esters treatment group (DRUG); Narrow band UVB radiation (OTHER),444972,Boletate,"Psoriasis; Cardiovascular Diseases; Diabetes Mellitus, Type 2",Skin,Fumaric acid,,inhibitor/antagonist,unclear,yes,yes,Used in psoriasis treatment as part of fumaric acid esters.,C(=CC(=O)O)C(=O)O,1.08,996.0 +216,NCT03331835,A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis,COMPLETED,PHASE4,Psoriasis Vulgaris,Brodalumab (BIOLOGICAL); Fumaric acid esters (DRUG),444972,Boletate,Psoriasis Vulgaris,Skin,Fumaric acid,,inhibitor/antagonist,unclear,yes,yes,Used in psoriasis treatment as part of fumaric acid esters.,C(=CC(=O)O)C(=O)O,1.08,996.0 +217,NCT02634801,A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment,COMPLETED,PHASE3,Plaque Psoriasis,Fumaric Acid Esters (DRUG); Methotrexate (DRUG); Ixekizumab (DRUG),444972,Boletate,Plaque Psoriasis,Skin,Fumaric acid,,inhibitor/antagonist,unclear,yes,yes,Used in psoriasis treatment as part of fumaric acid esters.,C(=CC(=O)O)C(=O)O,1.08,996.0 +218,NCT01321164,Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis,COMPLETED,PHASE3,Plaque Psoriasis,Full Body UV Therapy System UV 7002 plus fumaric acid esters (DEVICE); Fumaric acid esters (DRUG),444972,Boletate,Plaque Psoriasis,Skin,Fumaric acid,,inhibitor/antagonist,unclear,yes,yes,Used in psoriasis treatment as part of fumaric acid esters.,C(=CC(=O)O)C(=O)O,1.08,996.0 +219,NCT02951533,A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis,COMPLETED,PHASE3,Psoriasis,Guselkumab (DRUG); Fumaric Acid Esters (DRUG),444972,Boletate,Psoriasis,Skin,Fumaric acid,,inhibitor/antagonist,unclear,yes,yes,Used in psoriasis treatment as part of fumaric acid esters.,C(=CC(=O)O)C(=O)O,1.08,996.0 +220,NCT00811005,Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis,UNKNOWN,PHASE3,Pustular Palmoplantar Psoriasis,8-methoxypsoralen or 5- methoxypsoralen (RADIATION); 8-methoxypsoralen or 5methoxypsoralen (RADIATION),444972,Boletate,Pustular Palmoplantar Psoriasis,Skin,Fumaric acid,,inhibitor/antagonist,unclear,yes,yes,Used in psoriasis treatment as part of fumaric acid esters.,C(=CC(=O)O)C(=O)O,1.08,996.0 +221,NCT00079066,Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer,COMPLETED,PHASE3,Colorectal Cancer; Quality of Life,cetuximab (BIOLOGICAL); quality-of-life assessment (PROCEDURE),3657,HU,Colorectal Cancer; Quality of Life,Bowel,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +222,NCT06801457,Adjuvant Cerebroprotection Using Normobaric Hyperoxia in Pre-hospital Patients with Suspected Stroke,NOT_YET_RECRUITING,PHASE3,Stroke Acute,NBO (OTHER); Control (OTHER),3657,HU,Stroke Acute,CNS/Brain,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +223,NCT02794948,Chinese Medicine(Hu Yang Yang Kun Formula) for Primary Ovarian Insufficiency,COMPLETED,PHASE1,Primary Ovarian Insufficiency,Chinese medicine granules (HuYang Yang Kun Formula) (OTHER); dehydroepiandrosterone (DIETARY_SUPPLEMENT),3657,HU,Primary Ovarian Insufficiency,Ovary/Fallopian Tube,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +224,NCT01653574,A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms,Famitinib Malate (DRUG),3657,HU,Breast Neoplasms,Breast,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +225,NCT05476965,Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma,UNKNOWN,PHASE2,Head and Neck Squamous Cell Carcinoma; Radiotherapy; Immunotherapy; Surgery,induction therapy; surgery; radiotherapy (COMBINATION_PRODUCT),3657,HU,Head and Neck Squamous Cell Carcinoma; Radiotherapy; Immunotherapy; Surgery,Skin,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +226,NCT04310774,"CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer",NOT_YET_RECRUITING,PHASE1,Cervical Cancer; Chemotherapy,"Tegafur, Gimeracil and Oteracil Potassium Capsules (one drug) (DRUG)",3657,HU,Cervical Cancer; Chemotherapy,Cervix,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +227,NCT03326674,"Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC",TERMINATED,PHASE3,Breast Cancer,Tesetaxel and Capecitabine (DRUG); Capecitabine (DRUG),3657,HU,Breast Cancer,Breast,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +228,NCT04310865,Yinhu Qingwen Granula for the Treatment of Severe CoVID-19,SUSPENDED,PHASE2,COVID-19; Severe Pneumonia; Chinese Medicine,Yinhu Qingwen Granula (DRUG); Yin Hu Qing Wen Granula(low does) (DRUG); standard medical treatment (OTHER),3657,HU,COVID-19; Severe Pneumonia; Chinese Medicine,Lung,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +229,NCT00720226,Efficacy of Losartan in Preventing Progression of COPD,COMPLETED,PHASE4,COPD; Emphysema; Chronic Bronchitis; Smoking,Losartan (DRUG); Placebo (DRUG),3657,HU,COPD; Emphysema; Chronic Bronchitis; Smoking,Lung,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +230,NCT04140526,"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC",RECRUITING,PHASE1,Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Colorectal Cancer; Sarcomas; Metastatic Prostate Cancer; Ovarian Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Pancreas Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Junction Adenocarcinoma; Cervical Cancer; Adenoid Cystic Carcinoma; Salivary Gland Cancer; Urothelial Carcinoma,ONC-392 (DRUG); Pembrolizumab (DRUG); Docetaxel (DRUG),3657,HU,Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Colorectal Cancer; Sarcomas; Metastatic Prostate Cancer; Ovarian Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Pancreas Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Junction Adenocarcinoma; Cervical Cancer; Adenoid Cystic Carcinoma; Salivary Gland Cancer; Urothelial Carcinoma,Bowel,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +231,NCT00841126,Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate,TERMINATED,PHASE3,Chronic Kidney Failure,Magnesium iron hydroxycarbonate (DRUG); Lanthanum carbonate (DRUG); Placebo (DRUG),3657,HU,Chronic Kidney Failure,Kidney,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +232,NCT06714266,Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,NOT_YET_RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma (HNSCC),Trilaciclib (DRUG),3657,HU,Head and Neck Squamous Cell Carcinoma (HNSCC),Skin,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +233,NCT02596373,A Study of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer,UNKNOWN,PHASE2,Advanced Recurrent or Metastatic Breast Cancer,Mitoxantrone Hydrochloride Liposome Injection (DRUG),3657,HU,Advanced Recurrent or Metastatic Breast Cancer,Breast,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +234,NCT05734482,"Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers",COMPLETED,PHASE1,Psoriasis,Secukinumab (BIOLOGICAL),3657,HU,Psoriasis,Skin,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +235,NCT04750382,A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer,UNKNOWN,PHASE1,Triple-negative Breast Cancer,HX008+Cisplatin+Gemcitabine (DRUG),3657,HU,Triple-negative Breast Cancer,Breast,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +236,NCT05622890,"A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer",UNKNOWN,PHASE3,Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer,Mirvetuximab Soravtansine (DRUG),3657,HU,Epithelial Ovarian and Related Cancers,Ovary/Fallopian Tube,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +237,NCT04439890,A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer,UNKNOWN,PHASE3,Advanced Non-squamous Cell Non-small Cell Lung Cancer,Anlotinib hydrochloride capsule (DRUG); Carboplatin injection (DRUG); Pemetrexed disodium f Injection (DRUG); Placebo (DRUG),3657,HU,Advanced Non-squamous Cell Non-small Cell Lung Cancer,Skin,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +238,NCT02687490,Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Abraxane (DRUG),3657,HU,Metastatic Breast Cancer,Breast,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +239,NCT02675790,Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa,COMPLETED,PHASE3,Sickle Cell Disease; Sickle Cell Anemia; Stroke,Moderate Dose Hydroxyurea (DRUG); Low Dose Hydroxyurea (DRUG),3657,HU,Sickle Cell Disease; Sickle Cell Anemia; Stroke,CNS/Brain,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +240,NCT00955890,Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Dexrazoxane hydrochloride (DRUG); Dexrazoxane hydrochloride (DRUG),3657,HU,Breast Cancer,Breast,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +241,NCT02336750,Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis,COMPLETED,PHASE3,Breast Cancer,Aprepitant (DRUG); Mirtazapine (DRUG),3657,HU,Breast Cancer,Breast,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +242,NCT04297995,Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors,ACTIVE_NOT_RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma,HLX10 (DRUG); HLX07 (DRUG); HLX07 placebo (DRUG); Cisplatin/Carboplatin (DRUG); 5-FU (DRUG),3657,HU,Head and Neck Squamous Cell Carcinoma,Skin,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +243,NCT03792269,Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC,UNKNOWN,PHASE2,Colorectal Cancer Metastatic; Chemotherapy Effect; Chemotherapeutic Toxicity,Irinotecan (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG),3657,HU,Metastatic Colorectal Cancer with Chemotherapy Effects,Bowel,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +244,NCT01720901,Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy,SUSPENDED,PHASE4,Non-small Cell Lung Cancer,Icotinib (DRUG),3657,HU,Non-small Cell Lung Cancer,Lung,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +245,NCT01853501,Effects of ADSC Therapy in Women With POF,UNKNOWN,PHASE4,Premature Ovarian Failure,Autologous fat grafting (PROCEDURE),3657,HU,Premature Ovarian Failure,Ovary/Fallopian Tube,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +246,NCT06006169,"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors",RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma,BL-B01D1 (DRUG); SI-B003 (DRUG),3657,HU,Head and Neck Squamous Cell Carcinoma,Skin,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +247,NCT01176669,Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients,COMPLETED,PHASE2,Metastatic Breast Cancer,Apatinib (DRUG),3657,HU,Metastatic Breast Cancer,Breast,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +248,NCT03293069,Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis,UNKNOWN,PHASE2,Amyotrophic Lateral Sclerosis,Deferiprone (DRUG); Placebo Oral Tablet (DRUG),3657,HU,Amyotrophic Lateral Sclerosis,CNS/Brain,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +249,NCT01580046,Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction,UNKNOWN,PHASE4,"Kidney Failure, Chronic",iodixanol (DRUG); iopromide (DRUG),3657,HU,"Kidney Failure, Chronic",Kidney,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +250,NCT01224327,Umbilical Cord Mesenchymal Stem Cells Infusion Via Hepatic Artery in Cirrhosis Patients,UNKNOWN,PHASE1,Liver Cirrhosis; Radiology; Mesenchymal Stem Cells; Umbilical Cord,umbilical cord Mesenchymal Stem Cells (BIOLOGICAL); Conserved therapy (DRUG),3657,HU,Liver Cirrhosis; Radiology; Mesenchymal Stem Cells; Umbilical Cord,Liver,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +251,NCT02356276,Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2,UNKNOWN,PHASE3,Gastric Cancer,D2 lymphadenectomy (PROCEDURE); Hyperthermic Intraperitoneal Chemotherapy (PROCEDURE); Systemic chemotherapy (XELOX or SOX regimens) (DRUG),3657,HU,Gastric Cancer,Esophagus/Stomach,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +252,NCT03654027,Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,Anlotinib Plus Docetaxel (DRUG); Docetaxel (DRUG),3657,HU,Non-small Cell Lung Cancer,Lung,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +253,NCT01263327,Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine,COMPLETED,PHASE1,Cervical Cancer,HPV 16/18 (BIOLOGICAL),3657,HU,Cervical Cancer,Cervix,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +254,NCT05659927,Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects,ACTIVE_NOT_RECRUITING,PHASE1,Asthma,MG-ZG122 Humanized Monoclonal Antibody Injection (DRUG); Placebo (DRUG),3657,HU,Asthma,Lung,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +255,NCT05004727,Multi-Center PAMPA Study,RECRUITING,PHASE4,Psoriasis,Guselkumab (DRUG); Placebo (DRUG),3657,HU,Psoriasis,Skin,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +256,NCT01964027,The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer,UNKNOWN,PHASE2,Stage IV Gastric Cancer With Metastasis,second line chemoregime for advanced gastric cancer (DRUG),3657,HU,Stage IV Gastric Cancer With Metastasis,Esophagus/Stomach,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +257,NCT06908031,SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer,RECRUITING,PHASE3,Rectal Adenocarcinoma; High-Risk Cancer; MSS,Short-Course Radiotherapy (RADIATION); PD-1 monoclonal antibody (DRUG); mFOLFOX6 regimen (DRUG); Cetuximab (DRUG); Bevacizumab (DRUG); Surgical resection (PROCEDURE),3657,HU,Rectal Adenocarcinoma; High-Risk Cancer; MSS,Bowel,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +258,NCT05018676,ARX788 in Breast Cancer With Low Expression of HER2,UNKNOWN,PHASE2,Breast Cancer With Low Expression of HER2,ARX788 (DRUG),3657,HU,Breast Cancer With Low Expression of HER2,Breast,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +259,NCT06732531,"Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer",RECRUITING,PHASE1,Bladder Cancer; Non Muscle Invasive,BH011 (DRUG),3657,HU,Bladder Cancer; Non Muscle Invasive,Bladder/Urinary Tract,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +260,NCT04581473,"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection",RECRUITING,PHASE1,Gastric Adenocarcinoma; Pancreatic Cancer; Gastroesophageal Junction Adenocarcinoma,CT041 autologous CAR T-cell injection (DRUG); Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody） (DRUG),3657,HU,Gastric and Pancreatic Cancer,Pancreas,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +261,NCT02969473,Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma,UNKNOWN,PHASE2,Esophageal Neoplasm; Chemoradiation,Docetaxel (DRUG); Fluorouracil (DRUG),3657,HU,Esophageal Neoplasm,Esophagus/Stomach,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +262,NCT02085031,Intracorporeal Versus Extracorporeal Roux-en-Y Esophagojejunostomy During Laparoscopic Total Gastrectomy for Gastric Cancer,UNKNOWN,PHASE2,Stomach Neoplasms; Minimally Invasive Surgery; Anastomosis,Intracorporeal Roux-en-Y esophagojejunostomy (PROCEDURE); Extracorporeal Roux-en-Y esophagojejunostomy (PROCEDURE),3657,HU,Stomach Neoplasms; Minimally Invasive Surgery; Anastomosis,Esophagus/Stomach,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +263,NCT06077331,A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis,RECRUITING,PHASE2,Psoriasis,HS-10374 tablets 1mg (DRUG); HS-10374 tablets 5mg (DRUG); HS-10374-matched placebo tablets (DRUG),3657,HU,Psoriasis,Skin,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +264,NCT01655992,A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC),TERMINATED,PHASE3,Metastatic Breast Cancer,capecitabine (DRUG); S1 generic (DRUG),3657,HU,Metastatic Breast Cancer,Breast,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +265,NCT05442060,"To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer",RECRUITING,PHASE2,Non-small Cell Lung Cancer,30 μg OBI-833/100 μg OBI-821 (BIOLOGICAL); Erlotinib (150 mg daily) (DRUG),3657,HU,Non-small Cell Lung Cancer,Lung,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +266,NCT05861167,SIIT Based on UST CDST in Patients With CD,RECRUITING,PHASE4,Crohn Disease,selective intensive induction therapy based on ustekinumab clinical decision-making tools (BIOLOGICAL),3657,HU,Crohn Disease,Bowel,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +267,NCT05598268,A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.,UNKNOWN,PHASE1,Advanced Solid Tumor; Lung Cancer; Liver Cancer; Lymphoma; Mesothelioma of Pleura,T3011 (BIOLOGICAL),3657,HU,Advanced Solid Tumor; Lung Cancer; Liver Cancer; Lymphoma; Mesothelioma of Pleura,Lung,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +268,NCT05041257,"Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)",COMPLETED,PHASE2,Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer,Mirvetuximab soravtansine (DRUG),3657,HU,Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer,Ovary/Fallopian Tube,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +269,NCT00629148,Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC),COMPLETED,PHASE2,"Breast Cancer; Metastasis, Neoplasm",Vinorelbine and Capecitabine (DRUG); Vinorelbine and Capecitabine (DRUG),3657,HU,"Breast Cancer; Metastasis, Neoplasm",Breast,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +270,NCT03092648,Autologous Bronchial Basal Cells Transplantation for Treatment of Chronic Obstructive Pulmonary Disease (COPD),UNKNOWN,PHASE1,Chronic Obstructive Pulmonary Disease,Bronchial basal cell (BIOLOGICAL),3657,HU,Chronic Obstructive Pulmonary Disease,Lung,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +271,NCT00003748,Irinotecan in Treating Patients With Esophageal or Stomach Cancer,COMPLETED,PHASE2,Esophageal Cancer; Gastric Cancer,irinotecan hydrochloride (DRUG),3657,HU,Esophageal and Gastric Cancer,Esophagus/Stomach,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +272,NCT01550848,A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Abraxane and Gemcitabine (DRUG),3657,HU,Metastatic Breast Cancer,Breast,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +273,NCT05755048,FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer,RECRUITING,PHASE3,Breast Cancer,"Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502) (BIOLOGICAL); Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) (BIOLOGICAL)",3657,HU,Breast Cancer,Breast,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +274,NCT03571126,Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer,UNKNOWN,PHASE4,Chemotherapy-induced Nausea and Vomiting; Lung Cancer,Olanzapine (DRUG); Placebos (DRUG),3657,HU,Chemotherapy-induced Nausea and Vomiting; Lung Cancer,Lung,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +275,NCT06540326,Clinical Study of Second-line Treatment in Advanced Colorectal Cancer with Chemotherapy with Bevacizumab or Cetuximab,RECRUITING,PHASE2,Colorectal Cancer Metastatic,irinotecan liposome (II) (DRUG); fluorouracil (DRUG); cetuximab (DRUG); bevacizumab (DRUG),3657,HU,Colorectal Cancer Metastatic,Bowel,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +276,NCT01847326,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer,COMPLETED,PHASE1,Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Tongue Cancer,carboplatin (DRUG); paclitaxel albumin-stabilized nanoparticle formulation (DRUG); fluorouracil (DRUG); hydroxyurea (DRUG); therapeutic conventional surgery (PROCEDURE); radiation therapy (RADIATION); hyperfractionated radiation therapy (RADIATION); laboratory biomarker analysis (OTHER),3657,HU,Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Tongue Cancer,Skin,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +277,NCT06437522,A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors,RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma,BL-B01D1 (DRUG); PD-1 monoclonal antibody (DRUG),3657,HU,Head and Neck Squamous Cell Carcinoma,Skin,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +278,NCT02423239,A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours,UNKNOWN,PHASE1,Hepatocellular Carcinoma; Pancreatic Cancer,Dexanabinol (DRUG); Sorafenib (DRUG); Nab-paclitaxel (DRUG); Gemcitabine (DRUG),3657,HU,Hepatocellular Carcinoma; Pancreatic Cancer,Pancreas,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +279,NCT03071926,Metronomic PLD in Patients With Primary Endocrine Resistant ABC,UNKNOWN,PHASE2,Advanced Breast Cancer,Pegylated Liposomal Doxorubicin (DRUG),3657,HU,Advanced Breast Cancer,Breast,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +280,NCT01683786,36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8,UNKNOWN,PHASE4,Hepatitis C Infection,Pegintron + Riba (DRUG),3657,HU,Hepatitis C Infection,Liver,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +281,NCT06313086,DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer,RECRUITING,PHASE3,HER2-positive Breast Cancer,DP303c (DRUG); trastuzumab emtansine (DRUG),3657,HU,HER2-positive Breast Cancer,Breast,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +282,NCT01012427,Percutaneous Renal Tumor Cryoablation Followed by Biopsy,COMPLETED,PHASE1,Renal Cancer,percutaneous cryoablation (PROCEDURE),3657,HU,Renal Cancer,Kidney,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +283,NCT04396366,"Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis",TERMINATED,PHASE2,Bronchiectasis,QBW251 (DRUG); Placebo (DRUG),3657,HU,Bronchiectasis,Lung,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +284,NCT00129857,Dexanabinol in Severe Traumatic Brain Injury,COMPLETED,PHASE3,Traumatic Brain Injury,Dexanabinol (DRUG),3657,HU,Traumatic Brain Injury,CNS/Brain,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +285,NCT06962865,A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC,NOT_YET_RECRUITING,PHASE2,Non-Small Cell Lung Cancer,RC108 plus Furmonertinib Mesilate Tablets (DRUG); Furmonertinib Mesilate Tablets Monotherapy (DRUG),3657,HU,Advanced Non-Small Cell Lung Cancer,Lung,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +286,NCT02491658,Safety and Efficacy of UC-MSCs in Patients With Psoriasis Vulgaris,UNKNOWN,PHASE1,Psoriasis Vulgaris,UC-MSCs (BIOLOGICAL),3657,HU,Psoriasis Vulgaris,Skin,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +287,NCT06134622,Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis (ASSET-IT),COMPLETED,PHASE3,Acute Ischemic Stroke,Intravenous thrombolysis plus tirofiban (DRUG); Intravenous thrombolysis plus placebo (DRUG),3657,HU,Acute Ischemic Stroke,CNS/Brain,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +288,NCT06788626,Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment,NOT_YET_RECRUITING,PHASE3,Acute Ischemic Stroke; Large Vessel Occlusion; Neuroprotective Drugs; Endovascular Treatment,Semaglutide 0.5 mg (DRUG); Standard medical treatment (OTHER),3657,HU,Acute Ischemic Stroke; Large Vessel Occlusion; Neuroprotective Drugs; Endovascular Treatment,CNS/Brain,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +289,NCT03820830,Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer Recurrent,Palbociclib 125mg (DRUG); Standard endocrine therapy (DRUG),3657,HU,Recurrent Breast Cancer,Breast,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +290,NCT03703596,Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC,UNKNOWN,PHASE2,Lung Cancer; Lung Cancer Metastatic,Anlotinib Hydrochloride (DRUG); Docetaxel (DRUG),3657,HU,Lung Cancer; Lung Cancer Metastatic,Lung,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +291,NCT06204835,ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery,RECRUITING,PHASE1,Hepatocellular Carcinoma,RD-Cy7 fluorophore (DRUG),3657,HU,Hepatocellular Carcinoma,Liver,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +292,NCT05723991,Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma,RECRUITING,PHASE4,Radical Cystectomy; Urothelial Carcinoma,Disitamab Vedotin and Gemcitabine (DRUG),3657,HU,Radical Cystectomy; Urothelial Carcinoma,Bladder/Urinary Tract,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +293,NCT03567889,Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients,RECRUITING,PHASE3,Melanoma Stage IIIB/C,Daromun (DRUG); Surgery (PROCEDURE); Adjuvant therapy (DRUG),3657,HU,Melanoma Stage IIIB/C,Skin,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +294,NCT01531829,Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD,UNKNOWN,PHASE4,Pulmonary Thromboembolisms; Pulmonary Embolism,Recombinant tissue plasminogen activator (rt-PA) (DRUG); Low Molecular Weight Heparin (DRUG),3657,HU,Pulmonary Thromboembolisms; Pulmonary Embolism,Lung,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +295,NCT05433480,"A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,BPI-16350 (DRUG); placebo (DRUG); Fulvestrant (DRUG),3657,HU,Breast Cancer,Breast,Hydroxyurea,"RRM2, RRM1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for sickle cell anemia and certain cancers.,C(=O)(N)NO,1.47,151.0 +296,NCT05212662,Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19,WITHDRAWN,PHASE2,COVID-19; COVID-19 Acute Respiratory Distress Syndrome,TTI-0102 (DRUG); Placebo (DRUG),9082,Bekaptan,COVID-19; COVID-19 Acute Respiratory Distress Syndrome,Lung,Cysteamine (hydrochloride),,unclear,unclear,yes,yes,FDA-approved for cystinosis treatment.,C(CS)N.Cl,1.03125,770.0 +297,NCT01529268,Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children,COMPLETED,PHASE2,Nonalcoholic Fatty Liver Disease (NAFLD),DR cysteamine bitartrate capsule (DRUG); DR cysteamine bitartrate placebo (OTHER),9082,Bekaptan,Nonalcoholic Fatty Liver Disease (NAFLD),Liver,Cysteamine (hydrochloride),,unclear,unclear,yes,yes,FDA-approved for cystinosis treatment.,C(CS)N.Cl,1.03125,770.0 +298,NCT03883984,Cysteamine for Asthma,COMPLETED,PHASE1,Asthma,Cysteamine Bitartrate (DRUG); Placebo Oral Tablet (DRUG),9082,Bekaptan,Asthma,Lung,Cysteamine (hydrochloride),,unclear,unclear,yes,yes,FDA-approved for cystinosis treatment.,C(CS)N.Cl,1.03125,770.0 +299,NCT06644534,A Study to Assess TTI-0102 Vs Placebo in MELAS Patients,NOT_YET_RECRUITING,PHASE2,"MELAS Syndrome; Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)",TTI-0102 (DRUG); Placebo (DRUG),9082,Bekaptan,"MELAS Syndrome; Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)",CNS/Brain,Cysteamine (hydrochloride),,unclear,unclear,yes,yes,FDA-approved for cystinosis treatment.,C(CS)N.Cl,1.03125,770.0 +300,NCT06910813,DFT383 in Pediatric Participants With Nephropathic Cystinosis,RECRUITING,PHASE1,Nephropathic Cystinosis,DFT383 (GENETIC),9082,Bekaptan,Nephropathic Cystinosis,Kidney,Cysteamine (hydrochloride),,unclear,unclear,yes,yes,FDA-approved for cystinosis treatment.,C(CS)N.Cl,1.03125,770.0 +301,NCT05867056,Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection,WITHDRAWN,PHASE1,"Hepatitis B, Chronic",IMC-I109V Single Ascending Dose (DRUG); IMC-I109V Multiple Ascending Doses (DRUG); HBV HCC Module MAD (DRUG),9082,Bekaptan,Chronic Hepatitis B,Liver,Cysteamine (hydrochloride),,unclear,unclear,yes,yes,FDA-approved for cystinosis treatment.,C(CS)N.Cl,1.03125,770.0 +302,NCT02735707,"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",RECRUITING,PHASE3,"Community-acquired Pneumonia, Influenza, COVID-19",Ceftriaxone (DRUG); Moxifloxacin or Levofloxacin (DRUG); Piperacillin-tazobactam (DRUG); Ceftaroline (DRUG); Amoxicillin-clavulanate (DRUG); Standard course macrolide (DRUG); Extended course macrolide (DRUG); No systemic corticosteroid (OTHER); Fixed-duration Hydrocortisone (DRUG); Shock-dependent hydrocortisone (DRUG); Fixed-duration higher dose Hydrocortisone (DRUG); No antiviral agent for influenza (OTHER); Five-days oseltamivir (DRUG); Ten-days oseltamivir (DRUG); No antiviral agent for COVID-19 (OTHER); Lopinavir / Ritonavir (DRUG); Hydroxychloroquine (DRUG); Hydroxychloroquine + lopinavir/ritonavir (DRUG); Ivermectin (DRUG); No immune modulation for COVID-19 (OTHER); Interferon beta-1a (DRUG); Anakinra (DRUG); Tocilizumab (DRUG); Sarilumab (DRUG); Local standard venous thromboprophylaxis (DRUG); Therapeutic dose anticoagulation (DRUG); Conventional low dose thromboprophylaxis (DRUG); Intermediate dose thromboprophylaxis (DRUG); Continuation of therapeutic dose anticoagulation (DRUG); No immunoglobulin (OTHER); Convalescent plasma (BIOLOGICAL); Delayed administration of convalescent plasma (BIOLOGICAL); No vitamin C (OTHER); Vitamin C (DRUG); No antiplatelet (OTHER); Aspirin (DRUG); P2Y12 inhibitor (DRUG); No simvastatin (OTHER); Simvastatin (DRUG); Eritoran (DRUG); Apremilast (DRUG); Clinician-preferred mechanical ventilation strategy (PROCEDURE); Protocolised mechanical ventilation strategy (PROCEDURE); No renin-angiotensin system inhibitor (OTHER); Angiotensin converting enzyme inhibitor (DRUG); Angiotensin Receptor Blockers (DRUG); ARB + DMX-200 (DRUG); No cysteamine (OTHER); Cysteamine (DRUG); Fixed-duration dexamethasone (DRUG); Baloxavir Marboxil (DRUG); Five-days oseltamivir + baloxavir marboxil (DRUG); Ten-days oseltamivir + baloxavir marboxil (DRUG); No endothelial modulator (OTHER); Imatinib (DRUG); No Immune Modulator for Influenza (OTHER); Tocilizumab (DRUG); Baricitinib (DRUG); No antiviral agent for COVID-19 (OTHER); Nirmatrelvir/ritonavir (DRUG); Remdesivir (DRUG); Nirmatrelvir/ritonavir + remdesivir (DRUG),9082,Bekaptan,Community-acquired Respiratory Infections,Lung,Cysteamine (hydrochloride),,unclear,unclear,yes,yes,FDA-approved for cystinosis treatment.,C(CS)N.Cl,1.03125,770.0 +303,NCT00799578,A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH),COMPLETED,PHASE1,Fatty Liver,Cysteamine (DRUG),9082,Bekaptan,Fatty Liver,Liver,Cysteamine (hydrochloride),,unclear,unclear,yes,yes,FDA-approved for cystinosis treatment.,C(CS)N.Cl,1.03125,770.0 +304,NCT01480284,Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue,COMPLETED,PHASE3,"Hepatitis B, Chronic",GSK548470 300 mg tablet (DRUG); ETV 0.5 mg capsule (DRUG),135526609,Baraclud,Chronic Hepatitis B,Liver,Entecavir (monohydrate),,unclear,unclear,yes,yes,Approved for treating hepatitis B infection.,C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N.O,1.024390243902439,271.0 +305,NCT01475851,Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs,COMPLETED,PHASE3,"Hepatitis B, Chronic",GSK548470 300 mg tablet (DRUG),135526609,Baraclud,Chronic Hepatitis B,Liver,Entecavir (monohydrate),,unclear,unclear,yes,yes,Approved for treating hepatitis B infection.,C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N.O,1.024390243902439,271.0 +306,NCT04667104,"A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection",COMPLETED,PHASE2,"Hepatitis B, Chronic",JNJ-73763989 (DRUG); Tenofovir disoproxil (DRUG); Tenofovir alafenamide (TAF) (DRUG); Entecavir (ETV) monohydrate (DRUG); PegIFN-alpha2a (DRUG),135526609,Baraclud,Chronic Hepatitis B,Liver,Entecavir (monohydrate),,unclear,unclear,yes,yes,Approved for treating hepatitis B infection.,C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N.O,1.024390243902439,271.0 +307,NCT04535544,A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus,COMPLETED,PHASE2,"Hepatitis D, Chronic",JNJ-73763989 (DRUG); Placebo (DRUG); Entecavir (ETV) monohydrate (DRUG); Tenofovir disoproxil (DRUG); Tenofovir alafenamide (TAF) (DRUG),135526609,Baraclud,Chronic Hepatitis D,Liver,Entecavir (monohydrate),,unclear,unclear,yes,yes,Approved for treating hepatitis B infection.,C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N.O,1.024390243902439,271.0 +308,NCT02195518,Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nucleos(t)Ide Analogues (NAs) Failure Points Pts PH4 PMS Study,COMPLETED,PHASE4,"Hepatitis B, Chronic",Tenofovir disoproxil fumarate (DRUG),135526609,Baraclud,Chronic Hepatitis B,Liver,Entecavir (monohydrate),,unclear,unclear,yes,yes,Approved for treating hepatitis B infection.,C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N.O,1.024390243902439,271.0 +309,NCT05123599,"A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection",COMPLETED,PHASE1,"Hepatitis B, Chronic",JNJ-73763989 (DRUG); JNJ-64300535 (BIOLOGICAL); ETV monohydrate (DRUG); Tenofovir disoproxil (DRUG); TAF (DRUG),135526609,Baraclud,Chronic Hepatitis B,Liver,Entecavir (monohydrate),,unclear,unclear,yes,yes,Approved for treating hepatitis B infection.,C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N.O,1.024390243902439,271.0 +310,NCT04129554,A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection,COMPLETED,PHASE2,"Hepatitis B, Chronic",JNJ-73763989 (DRUG); JNJ-56136379 (DRUG); Placebo for JNJ-73763989 (DRUG); Placebo for JNJ-56136379 (DRUG); Entecavir (ETV) monohydrate (DRUG); Tenofovir disoproxil fumarate (TDF) (DRUG); Tenofovir alafenamide (TAF) (DRUG),135526609,Baraclud,Chronic Hepatitis B,Liver,Entecavir (monohydrate),,unclear,unclear,yes,yes,Approved for treating hepatitis B infection.,C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N.O,1.024390243902439,271.0 +311,NCT03543774,Lipid-lowering Therapies in Vietnamese Chronic Kidney Disease Population,UNKNOWN,PHASE4,Hypercholesterolemia; Chronic Kidney Diseases,Simvastatin 40mg (DRUG); Ezetimibe/simvastatin 10/20 mg/day (DRUG); Ezetimibe/simvastatin 10/40 mg/day (DRUG),204,SEUK,Hypercholesterolemia; Chronic Kidney Diseases,Kidney,Allantoin,,unclear,unclear,yes,yes,Allantoin is approved as a skin protectant by the FDA.,C1(C(=O)NC(=O)N1)NC(=O)N,1.05,1400.0 +312,NCT06170346,Effect of Topical Agents With Various Antioxidant Containts on Photodamage Skin Induced,COMPLETED,PHASE2,Photodamaged Skin,Antioxidants (COMBINATION_PRODUCT); Vehicle (COMBINATION_PRODUCT),204,SEUK,Photodamaged Skin,Skin,Allantoin,,unclear,unclear,yes,yes,Allantoin is approved as a skin protectant by the FDA.,C1(C(=O)NC(=O)N1)NC(=O)N,1.05,1400.0 +313,NCT05589402,Temporary Inactivation of Strong Muscle Sensation to Improve Rehabilitation Interventions in SCI,RECRUITING,PHASE1,Spinal Cord Injuries; Spine Disease; Stroke,Lidocaine Cream 5% (DRUG); Rehabilitation Movement Training (OTHER),204,SEUK,Spinal Cord Injuries; Spine Disease; Stroke,CNS/Brain,Allantoin,,unclear,unclear,yes,yes,Allantoin is approved as a skin protectant by the FDA.,C1(C(=O)NC(=O)N1)NC(=O)N,1.05,1400.0 +314,NCT01490866,A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC),COMPLETED,PHASE2,Colorectal Cancer,Axitinib (DRUG); Bevacizumab (DRUG); 5-Fluorouracil (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG),3385,FU,Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +315,NCT06615726,Regular Physical Activity in Patients With Symptomatic Intracranial Arterial Stenosis,RECRUITING,PHASE3,Ischemic Stroke; Transient Ischemic Attack,Regular physical activity (BEHAVIORAL); Control group (OTHER),3385,FU,Ischemic Stroke,CNS/Brain,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +316,NCT00942266,"Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment",COMPLETED,PHASE2,Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer,fluorouracil (DRUG); leucovorin calcium (DRUG); vorinostat (DRUG); pharmacological study (OTHER),3385,FU,Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +317,NCT02882126,An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension,WITHDRAWN,PHASE4,Pulmonary Arterial Hypertension,Subcutaneous Treprostinil (DRUG),3385,FU,Pulmonary Arterial Hypertension,Lung,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +318,NCT05696626,Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation,RECRUITING,PHASE3,Metastatic Breast Cancer,Lasofoxifene in combination with abemaciclib (DRUG); Fulvestrant in combination with abemaciclib (DRUG),3385,FU,Metastatic Breast Cancer,Breast,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +319,NCT05610657,A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function,COMPLETED,PHASE1,Moderate Hepatic Impairment,Mitapivat (DRUG),3385,FU,Moderate Hepatic Impairment,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +320,NCT01594957,Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment,COMPLETED,PHASE1,Hepatic Impairment,LCQ908 (DRUG),3385,FU,Hepatic Impairment,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +321,NCT03563157,QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine,TERMINATED,PHASE1,Colorectal Cancer Metastatic; mCRC,Aldoxorubicin Hydrochloride (BIOLOGICAL); ALT-803 (BIOLOGICAL); ETBX-011 (BIOLOGICAL); ETBX-021 (BIOLOGICAL); ETBX-051 (BIOLOGICAL); ETBX-061 (BIOLOGICAL); GI-4000 (BIOLOGICAL); GI-6207 (BIOLOGICAL); GI-6301 (BIOLOGICAL); haNK (BIOLOGICAL); Avelumab (DRUG); Capecitabine (DRUG); Cetuximab (DRUG); Cyclophosphamide (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG); Nab-paclitaxel (DRUG); Oxaliplatin (DRUG); Regorafenib (DRUG); SBRT (PROCEDURE),3385,FU,Colorectal Cancer Metastatic; mCRC,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +322,NCT02624726,Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,5 Fluorouracil (DRUG); Leucovorin (DRUG); Irinotecan (DRUG); Aflibercept (DRUG),3385,FU,Metastatic Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +323,NCT05065957,Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer,RECRUITING,PHASE2,Biliary Tract Cancer,D07001-softgel capsules + Xeloda (or TS-1) (DRUG); mFOLFOX (DRUG),3385,FU,Biliary Tract Cancer,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +324,NCT06226857,Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer,RECRUITING,PHASE3,Colorectal Neoplasms; Chemotherapy Effect; Molecular Sequence Variation,Cetuximab (DRUG),3385,FU,Colorectal Neoplasms; Chemotherapy Effect; Molecular Sequence Variation,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +325,NCT04617457,Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas,RECRUITING,PHASE2,Pancreatic Cancer; Metastasis; Surgery; Oligometastatic Disease,"nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA) (DRUG)",3385,FU,Pancreatic Cancer; Metastasis; Surgery; Oligometastatic Disease,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +326,NCT03563248,Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Pancreatic Cancer,FOLFIRINOX (DRUG); Losartan (DRUG); Nivolumab (DRUG); SBRT (RADIATION); Surgery (PROCEDURE),3385,FU,Pancreatic Cancer,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +327,NCT00770874,Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer,COMPLETED,PHASE3,Cervical Cancer,S-1 + Cisplatin (arm A) (DRUG); Cisplatin (arm B) (DRUG),3385,FU,Cervical Cancer,Cervix,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +328,NCT02047474,Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Stage I Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,oxaliplatin (DRUG); leucovorin calcium (DRUG); irinotecan hydrochloride (DRUG); fluorouracil (DRUG); therapeutic conventional surgery (PROCEDURE); laboratory biomarker analysis (OTHER),3385,FU,Pancreatic Cancer,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +329,NCT05018182,FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer,UNKNOWN,PHASE2,High-risk Locally Advanced Colorectal Cancer; Neoadjuvant Chemotherapy; FOLFOXIRI Regimen,Oxaliplatin (DRUG); Irinotecan (DRUG); Folinic Acid (DRUG); 5FU (DRUG); Capecitabine (DRUG),3385,FU,High-risk Locally Advanced Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +330,NCT01171482,Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma,TERMINATED,PHASE2,"Carcinoma, Hepatocellular",5-FU (DRUG); Mitomycin (DRUG); sorafenib (DRUG),3385,FU,"Carcinoma, Hepatocellular",Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +331,NCT00079274,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,COMPLETED,PHASE3,Adenocarcinoma of the Colon; Stage III Colon Cancer,irinotecan hydrochloride (DRUG); oxaliplatin (DRUG); leucovorin calcium (DRUG); fluorouracil (DRUG); cetuximab (BIOLOGICAL); Locally Directed Therapy (DRUG),3385,FU,Colon Adenocarcinoma,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +332,NCT03161574,FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for Circumferential Radial Margin (CRM) Positive Rectal Cancer,WITHDRAWN,PHASE2,Rectal Cancer,FOLFOXIRI (DRUG),3385,FU,Rectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +333,NCT01154920,"Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma",ACTIVE_NOT_RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma,Paclitaxel (DRUG); Carboplatin (DRUG); Cetuximab (DRUG); Docetaxel (DRUG); Cisplatin (DRUG); Fluorouracil (DRUG); Radiotherapy (RT) (RADIATION); Chemotherapy (OTHER),3385,FU,Head and Neck Squamous Cell Carcinoma,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +334,NCT00555620,Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer,COMPLETED,PHASE1,Stomach Neoplasms,capecitabine (DRUG); oxaliplatin (DRUG); sunitinib malate (DRUG); capecitabine (DRUG); cisplatin (DRUG); sunitinib malate (DRUG),3385,FU,Stomach Neoplasms,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +335,NCT00202774,Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer,COMPLETED,PHASE3,Colorectal Cancer,"(capecitabine, oxaliplatin, 5-fluorouracil) (DRUG)",3385,FU,Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +336,NCT06206720,A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV,RECRUITING,PHASE2,Respiratory Syncytial Virus Infection,Deuremidevir Hydrobromide for Suspension (DRUG); Placebo (DRUG),3385,FU,Respiratory Syncytial Virus Infection,Lung,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +337,NCT06625320,Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),RECRUITING,PHASE3,Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma,RMC-6236 (DRUG); Gemcitabine (DRUG); nab-paclitaxel (DRUG); Irinotecan (DRUG); Liposomal irinotecan (DRUG); 5-fluorouracil (DRUG); leucovorin (DRUG); Oxaliplatin (DRUG),3385,FU,Pancreatic Ductal Adenocarcinoma,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +338,NCT01640782,Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach,COMPLETED,PHASE3,Adenocarcinoma of the Stomach; Adenocarcinoma of the Gastroesophageal Junction,"Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin (DRUG); Leucovorin, 5-Fluorouracil (DRUG)",3385,FU,Gastric Adenocarcinoma,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +339,NCT01379482,Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer,COMPLETED,PHASE2,Peritoneal Carcinomatosis; Gastric Cancer,Multimodal treatment (DRUG),3385,FU,Gastric Cancer,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +340,NCT01362582,Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With Pancreatic Cancer,TERMINATED,PHASE3,Pancreatic Cancer,SMOF Kabiven (DRUG),3385,FU,Pancreatic Cancer,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +341,NCT01420874,Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer),COMPLETED,PHASE1,Colorectal Cancer; Cancer of Pancreas; Pancreatic Neoplasm; Malignant Neoplasm of Large Intestine; Malignant Tumor of Colon; Colon Carcinoma; Cancer of Colon; Pancreatic Cancer,FOLFOX6 (DRUG); EGFRBi armed ATC Infusions (BIOLOGICAL),3385,FU,Colorectal Cancer; Cancer of Pancreas; Pancreatic Neoplasm; Malignant Neoplasm of Large Intestine; Malignant Tumor of Colon; Colon Carcinoma; Cancer of Colon; Pancreatic Cancer,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +342,NCT02573220,Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer,WITHDRAWN,PHASE1,Stage IVA Colorectal Cancer; Stage IVB Colorectal Cancer,Cetuximab (BIOLOGICAL); Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Leucovorin Calcium (DRUG),3385,FU,Stage IV Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +343,NCT01232374,Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma,UNKNOWN,PHASE2,Squamous Cell Carcinoma,Nimotuzumab (DRUG); Placebo (DRUG); cisplatin (DRUG); Radiotherapy (RADIATION),3385,FU,Squamous Cell Carcinoma,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +344,NCT02576574,Avelumab in First-line NSCLC (JAVELIN Lung 100),COMPLETED,PHASE3,First Line Non-Small Cell Lung Cancer,Avelumab (DRUG); Pemetrexed (DRUG); Paclitaxel (DRUG); Gemcitabine (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Avelumab Weekly (DRUG),3385,FU,First Line Non-Small Cell Lung Cancer,Lung,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +345,NCT00058474,Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer,UNKNOWN,PHASE3,Colorectal Cancer,capecitabine (DRUG); fluorouracil (DRUG); oxaliplatin (DRUG); radiation therapy (RADIATION),3385,FU,Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +346,NCT00699374,Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer,TERMINATED,PHASE3,"Carcinoma, Hepatocellular",sunitinib malate (DRUG); sorafenib (DRUG),3385,FU,"Carcinoma, Hepatocellular",Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +347,NCT02529774,Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer,UNKNOWN,PHASE2,Resected Liver Metastases From Colorectal Cancer,"Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6) (DRUG); Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6) (DRUG)",3385,FU,Resected Liver Metastases From Colorectal Cancer,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +348,NCT01219920,FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer,COMPLETED,PHASE3,Metastatic Colorectal Cancer,FOLFIRI (DRUG); FOLFOXIRI (DRUG),3385,FU,Metastatic Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +349,NCT03727074,Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream,COMPLETED,PHASE3,Actinic Keratosis (AK),5-FU Cream (DRUG); Efudex® (DRUG); Vehicle (DRUG),3385,FU,Actinic Keratosis (AK),Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +350,NCT05913674,Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC),RECRUITING,PHASE2,Peritoneal Carcinomatosis; Appendiceal Neoplasms; Colorectal Cancer Metastatic,Modified early post-operative intraperitoneal chemotherapy (mEPIC) (DRUG),3385,FU,Peritoneal Carcinomatosis; Appendiceal Neoplasms; Colorectal Cancer Metastatic,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +351,NCT03000374,Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery,COMPLETED,PHASE2,Rectal Cancer,Panitumumab (DRUG); 5Fluorouracil (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG),3385,FU,Rectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +352,NCT04518774,"Allogeneic ""Gammadelta T Cells (γδ T Cells)"" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial",UNKNOWN,EARLY_PHASE1,Hepatocellular Carcinoma,Ex-vivo expanded allogeneic γδT cells (BIOLOGICAL),3385,FU,Hepatocellular Carcinoma,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +353,NCT00115765,PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study,COMPLETED,PHASE3,Colorectal Cancer,Oxaliplatin Based Chemotherapy (DRUG); Panitumumab (DRUG); Irinotecan Based Chemotherapy (DRUG); Bevacizumab (DRUG),3385,FU,Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +354,NCT01966120,Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT),COMPLETED,PHASE3,Actinic Keratosis,BF-200 ALA gel (DRUG); Placebo to BF-200 ALA gel (DRUG); Photodynamic therapy with BF-RhodoLED (PROCEDURE),3385,FU,Actinic Keratosis,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +355,NCT03500874,Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM,TERMINATED,PHASE3,Colorectal Cancer; Liver Metastases; HAI,FUDR (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); 5FU (DRUG); Irinotecan (DRUG),3385,FU,Colorectal Cancer with Liver Metastases,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +356,NCT02620865,BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer,COMPLETED,PHASE1,Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Aldesleukin (BIOLOGICAL); Antibody Therapy (BIOLOGICAL); Fluorouracil (DRUG); Gemcitabine Hydrochloride (DRUG); Irinotecan Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Leucovorin Calcium (DRUG); Oxaliplatin (DRUG); Paclitaxel Albumin-Stabilized Nanoparticle Formulation (DRUG); Sargramostim (BIOLOGICAL),3385,FU,Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +357,NCT00176774,"Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma",COMPLETED,PHASE2,Colorectal Carcinoma,Irinotecan (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG); Tetrathiomolybdate (DRUG),3385,FU,Colorectal Carcinoma,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +358,NCT05171166,Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.,RECRUITING,PHASE2,Hepatocellular Carcinoma,HAIC (PROCEDURE); TACE (PROCEDURE); FOLFOX (DRUG); cTACE or DEB-TACE (DRUG); Donafenib (DRUG),3385,FU,Hepatocellular Carcinoma,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +359,NCT02432365,Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy,UNKNOWN,PHASE2,Cervical Cancer,paclitaxel (DRUG); cisplatin (DRUG); Radical hysterectomy and bilateral pelvic lymphadenectomy (PROCEDURE),3385,FU,Cervical Cancer,Cervix,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +360,NCT00513266,Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery,UNKNOWN,PHASE2,Colorectal Cancer; Metastatic Cancer,bevacizumab (BIOLOGICAL); cetuximab (BIOLOGICAL); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG); laboratory biomarker analysis (OTHER); adjuvant therapy (PROCEDURE); biopsy (PROCEDURE); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE),3385,FU,Colorectal Cancer; Metastatic Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +361,NCT04643366,Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer,RECRUITING,PHASE2,Rectal Cancer,Chemotherapy (DRUG); Radiation Therapy (RADIATION),3385,FU,Rectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +362,NCT00290966,Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer,COMPLETED,PHASE2,Stomach Neoplasm,XRP6976 (DRUG),3385,FU,Stomach Neoplasm,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +363,NCT00188266,Study of Adjuvant Radiochemotherapy for Gastric Cancer,COMPLETED,PHASE1,Stomach Neoplasms,cisplatinum combined with infusional fluorouracil (5 FU) (DRUG),3385,FU,Stomach Neoplasms,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +364,NCT03929666,"A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer",ACTIVE_NOT_RECRUITING,PHASE2,"HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer",ZW25 (Zanidatamab) (DRUG); Capecitabine (DRUG); Cisplatin (DRUG); Fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Bevacizumab (DRUG); Gemcitabine (DRUG),3385,FU,HER2-expressing Gastrointestinal Cancers,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +365,NCT03775265,Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Bladder Urothelial Carcinoma; Muscle Invasive Bladder Carcinoma; Stage II Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8,Atezolizumab (DRUG); Biopsy of Bladder (PROCEDURE); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Cystoscopy (PROCEDURE); Fluorouracil (DRUG); Gemcitabine (DRUG); Magnetic Resonance Imaging (PROCEDURE); Mitomycin (DRUG); Quality-of-Life Assessment (OTHER); Radiation Therapy (RADIATION); Survey Administration (OTHER); Transurethral Resection of Bladder Tumor (PROCEDURE),3385,FU,Muscle Invasive Bladder Cancer,Bladder/Urinary Tract,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +366,NCT05833126,Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation,RECRUITING,PHASE2,Recurrent Liver Cancer After Liver Transplantation,Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab (DRUG),3385,FU,Recurrent Liver Cancer After Liver Transplantation,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +367,NCT01286766,Neoadjuvant Combination Chemotherapy of DCS and DCF in Patients With Locally Advanced Gastric Adenocarcinoma,COMPLETED,PHASE2,Gastric Cancer,DCS (docetaxel with cisplatin with TS-1) (DRUG); DCF (docetaxel with cisplatin with 5-FU) (DRUG),3385,FU,Gastric Cancer,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +368,NCT06393166,Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer,RECRUITING,PHASE2,Non-Resectable Pancreas Carcinoma,Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection (DRUG),3385,FU,Non-Resectable Pancreas Carcinoma,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +369,NCT04233866,"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Fluorouracil (DRUG); Gemcitabine (DRUG); Gemcitabine Hydrochloride (DRUG); Leucovorin (DRUG); Leucovorin Calcium (DRUG); Liposomal Irinotecan (DRUG); Nab-paclitaxel (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),3385,FU,Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +370,NCT06521866,"Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer",RECRUITING,PHASE2,Advanced Colorectal Carcinoma; Immunotherapy,Serplulimab (DRUG); Chemotherapy (DRUG); SABR (RADIATION); Targeted therapy (DRUG),3385,FU,Advanced Colorectal Carcinoma; Immunotherapy,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +371,NCT06714266,Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,NOT_YET_RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma (HNSCC),Trilaciclib (DRUG),3385,FU,Head and Neck Squamous Cell Carcinoma (HNSCC),Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +372,NCT01878565,The Treatment With HBIG+GM-CSF+HBV Vaccine for Chronic Hepatitis B Patients With HBeAg Seroconversion,UNKNOWN,PHASE1,Chronic Hepatitis B,Drug (DRUG); GM-CSF control (DRUG),3385,FU,Chronic Hepatitis B,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +373,NCT01710020,"Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease",COMPLETED,PHASE1,End-Stage Renal Disease; Hemodialysis,"CP-690,550 (DRUG)",3385,FU,End-Stage Renal Disease,Kidney,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +374,NCT02753127,A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer,COMPLETED,PHASE3,Colorectal Cancer,Napabucasin (DRUG); Fluorouracil (DRUG); Leucovorin (DRUG); Irinotecan (DRUG); Bevacizumab (DRUG),3385,FU,Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +375,NCT01216527,Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer,UNKNOWN,PHASE3,Squamous Cell Esophageal Carcinoma,Neo-adjuvant Chemoradiotherapy followed by Surgery (PROCEDURE); surgery (PROCEDURE),3385,FU,Squamous Cell Esophageal Carcinoma,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +376,NCT01044420,mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial,UNKNOWN,PHASE2,Advanced Esophageal Carcinoma,mFOLFIRI (DRUG),3385,FU,Advanced Esophageal Carcinoma,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +377,NCT05504720,"Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma",ACTIVE_NOT_RECRUITING,PHASE2,Esophagogastric Adenocarcinoma,Pembrolizumab (DRUG); Trastuzumab (DRUG); FLOT (DRUG),3385,FU,Esophagogastric Adenocarcinoma,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +378,NCT06319820,A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer,RECRUITING,PHASE3,Non-Muscle Invasive Bladder Cancer,TAR-210 (COMBINATION_PRODUCT); Gemcitabine (DRUG); MMC (DRUG),3385,FU,Non-Muscle Invasive Bladder Cancer,Bladder/Urinary Tract,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +379,NCT04431674,Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients With Chest-wall and Breast Cancer,COMPLETED,PHASE1,Breast Cancer,Definity Suspension for Injection (DRUG),3385,FU,Breast Cancer,Breast,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +380,NCT06708520,Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants,RECRUITING,PHASE1,Renal Impairment,Rupatadine (DRUG),3385,FU,Renal Impairment,Kidney,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +381,NCT02873520,Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer,UNKNOWN,PHASE1,Precision Cell Immunotherapy; Chemotherapy; Advanced Gastric Cancer,Chemotherapy (DRUG); Precision Cell Immunotherapy (BIOLOGICAL),3385,FU,Precision Cell Immunotherapy; Chemotherapy; Advanced Gastric Cancer,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +382,NCT05431582,Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors,WITHDRAWN,PHASE1,Tumors; Ovarian Cancer; Breast Cancer; Lung Cancer; Pancreatic Cancer,ZN-c3 (DRUG); Bevacizumab (DRUG); Pembrolizumab (DRUG),3385,FU,Tumors; Ovarian Cancer; Breast Cancer; Lung Cancer; Pancreatic Cancer,Lung,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +383,NCT00422773,Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer,COMPLETED,PHASE1,Metastatic Colorectal Cancer,Cetuximab (DRUG),3385,FU,Metastatic Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +384,NCT04215731,Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer,RECRUITING,PHASE3,Rectal Cancer,Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab (DRUG); Restaging (PROCEDURE); Concomitant Chemoradiotherapy (RADIATION); Surgery (PROCEDURE); Chemoradiotherapy (only when patients with MRF involved or ycT4a/b by restaging) (RADIATION); Induction chemotherpay with FOLFOX (DRUG),3385,FU,Rectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +385,NCT06841731,A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia,RECRUITING,PHASE2,Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP),HRS-8427 (DRUG); Meropenem (DRUG),3385,FU,Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP),Lung,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +386,NCT00833131,The Randomised Study of Preoperative Radiotherapy With Consolidating Chemotherapy for Unresectable Rectal Cancer,UNKNOWN,PHASE3,Rectal Cancer,Short course of radiotherapy (RADIATION); Radiochemotherapy (RADIATION),3385,FU,Rectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +387,NCT06199973,"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan",RECRUITING,PHASE3,Advanced Colorectal Cancer,"SHR-A1811 (DRUG); TAS-102, Regorafenib , Fruquintinib (DRUG)",3385,FU,Advanced Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +388,NCT04839731,Combination 5-FU / Calcipotriene Cream for SCCIS/SCC,UNKNOWN,EARLY_PHASE1,Squamous Cell Carcinoma,Combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream (DRUG); Nourivan Base Cream (DRUG),3385,FU,Squamous Cell Carcinoma,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +389,NCT00197431,Pharmacokinetic and Pharmacodynamic Study of S-1 in Patients With Digestive Organ Cancer,UNKNOWN,PHASE2,Gastric Cancer; Esophageal Cancer; Pancreatic Cancer; Colon Cancer,S-1 (DRUG),3385,FU,Gastric Cancer; Esophageal Cancer; Pancreatic Cancer; Colon Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +390,NCT05006573,Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis,TERMINATED,PHASE3,Non-cystic Fibrosis Bronchiectasis,Benralizumab (BIOLOGICAL); Placebo to Benralizumab (BIOLOGICAL),3385,FU,Non-cystic Fibrosis Bronchiectasis,Lung,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +391,NCT00615173,"Prospective, Randomized, Multicenter, Control Study to Assess the Efficacy and Safety of Tacrolimus in Induction and Maintenance Phase Treatment in Lupus Nephritis",COMPLETED,PHASE3,Kidney Diseases; Lupus Nephritis; Tacrolimus; Induction Phase; Maintenance Phase,tacrolimus (FK506) (DRUG); cyclophosphamide or azathioprine (DRUG),3385,FU,Kidney Diseases; Lupus Nephritis; Tacrolimus; Induction Phase; Maintenance Phase,Kidney,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +392,NCT01662973,Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis,UNKNOWN,PHASE1,Primary Biliary Cirrhosis,conventional plus UC-MSC treatment (OTHER); Conventional plus placebo treatment (OTHER),3385,FU,Primary Biliary Cirrhosis,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +393,NCT02350530,FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,FOLFOXIRI + Bevacizumab (DRUG); FOLFOXIRI (DRUG),3385,FU,Metastatic Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +394,NCT01321957,Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,"Oxaliplatin, 5FU/LV, Bevacizumab (DRUG); 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan (DRUG)",3385,FU,Metastatic Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +395,NCT06941857,NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer,NOT_YET_RECRUITING,PHASE2,Pancreatic Cancer,Oxaliplatin (DRUG); Irinotecan (DRUG); Folinic Acid (DRUG); 5-Fluorouracil (5-FU) (DRUG); NC410 (DRUG); Nivolumab (DRUG); Ipilimumab (DRUG),3385,FU,Pancreatic Cancer,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +396,NCT01523457,Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer,COMPLETED,PHASE2,Metastatic Pancreatic Cancer; Pancreatic Cancer,Folfirinox (DRUG),3385,FU,Metastatic Pancreatic Cancer; Pancreatic Cancer,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +397,NCT03777657,"Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma",COMPLETED,PHASE3,"Gastric, or Gastroesophageal Junction Adenocarcinoma",Tislelizumab (DRUG); Placebo (DRUG); Cisplatin (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG); 5-Fluorouracil (DRUG),3385,FU,"Gastric, or Gastroesophageal Junction Adenocarcinoma",Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +398,NCT04756648,Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma,RECRUITING,PHASE1,Advanced Hepatocellular Carcinoma,CT0180 Cells (DRUG),3385,FU,Advanced Hepatocellular Carcinoma,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +399,NCT00596830,"Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology",TERMINATED,PHASE3,"Carcinoma, Squamous Cell; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung","CP-751,871 (Figitumumab) (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG)",3385,FU,"Carcinoma, Squamous Cell; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung",Lung,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +400,NCT00244348,Hepatic Artery Infusion With Oxaliplatin,WITHDRAWN,PHASE1,Colorectal Cancer; Metastasis; Liver Cancer,Oxaliplatin (via HAI) (DRUG); 5 Fluorouracil (systemic) (DRUG),3385,FU,Colorectal Cancer with Liver Metastasis,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +401,NCT00539630,TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN,COMPLETED,PHASE3,"Carcinoma, Squamous Cell",Docetaxel (DRUG),3385,FU,Squamous Cell Carcinoma,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +402,NCT00934882,"Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI",COMPLETED,PHASE1,Colorectal Neoplasms,Regorafenib (BAY73-4506) (DRUG),3385,FU,Colorectal Neoplasms,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +403,NCT05313282,A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification,RECRUITING,PHASE3,C-staged Hepatocellular Carcinoma in BCLC Classification,Hepatic Arterial Infusion combined with Apatinib and Camrelizumab (COMBINATION_PRODUCT); Apatinib combined with Camrelizumab (COMBINATION_PRODUCT),3385,FU,C-staged Hepatocellular Carcinoma in BCLC Classification,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +404,NCT05444673,"A Prospective, Single-arm Clinical Study of Pabrolizumab in Combination With Cisplatin + 5-FU for the Neoadjuvant Treatment of Unresectable, Advanced Squamous Carcinoma of the Temporal Bone Single-arm Clinical Study",UNKNOWN,PHASE4,Temporal Bone Squamous Cell Carcinoma,Paprizumab combined with cisplatin and 5-FU (DRUG),3385,FU,Temporal Bone Squamous Cell Carcinoma,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +405,NCT01133990,FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer,TERMINATED,PHASE1,Colorectal Cancer,FOLFIRI (DRUG); E7820 (DRUG); Bevacizumab (DRUG),3385,FU,Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +406,NCT04068103,Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery,ACTIVE_NOT_RECRUITING,PHASE2,Colon Adenocarcinoma; Stage IIA Colon Cancer AJCC v8,Capecitabine (DRUG); Fluorouracil (DRUG); Leucovorin (DRUG); Leucovorin Calcium (DRUG); Oxaliplatin (DRUG); Patient Observation (OTHER),3385,FU,Stage IIA Colon Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +407,NCT00689390,Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063),TERMINATED,PHASE2,"Hepatitis C, Chronic; Hepacivirus",Boceprevir (BIOLOGICAL); Narlaprevir (BIOLOGICAL); Peginterferon alfa-2b (BIOLOGICAL); Ribavirin (DRUG); Blood/Plasma Collection (OTHER),3385,FU,"Hepatitis C, Chronic; Hepacivirus",Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +408,NCT01703390,Biomarker Directed Treatment in Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,FOLFIRI + Cetuximab (DRUG); modifiedFOLFOX6 + Cetuximab (DRUG),3385,FU,Metastatic Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +409,NCT06700603,Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer,NOT_YET_RECRUITING,PHASE2,Pancreatic Cancer,Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate (DRUG),3385,FU,Pancreatic Cancer,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +410,NCT02173990,Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).,TERMINATED,PHASE2,Metastatic Colorectal Cancer,Aflibercept-FOLFIRI (DRUG),3385,FU,Metastatic Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +411,NCT05345990,Treatment of Patients with Chronic Hepatitis B with Hepatitis B Immunoglobulins,RECRUITING,PHASE2,Chronic Hepatitis B,Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®) (DRUG),3385,FU,Chronic Hepatitis B,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +412,NCT04216290,"A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial",ACTIVE_NOT_RECRUITING,PHASE2,Bladder Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8,Biopsy of Bladder (PROCEDURE); Biospecimen Collection (PROCEDURE); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Cystoscopy (PROCEDURE); Durvalumab (BIOLOGICAL); Fluorouracil (DRUG); Gemcitabine Hydrochloride (DRUG); Magnetic Resonance Imaging (PROCEDURE); Mitomycin (DRUG); Patient Observation (OTHER); Radiation Therapy (RADIATION),3385,FU,Bladder Urothelial Carcinoma,Bladder/Urinary Tract,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +413,NCT05478603,A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction,COMPLETED,PHASE1,Hepatic Impairment; Healthy Volunteers,PF-07081532 (DRUG),3385,FU,Hepatic Impairment; Healthy Volunteers,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +414,NCT05699603,Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients,RECRUITING,PHASE2,Actinic Keratosis,Biopsy (PROCEDURE); Calcipotriene (DRUG); Fluorouracil (DRUG),3385,FU,Actinic Keratosis,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +415,NCT03855384,Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN）,UNKNOWN,PHASE3,Squamous Cell Carcinoma of the Head and Neck,TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU) (DRUG); placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU) (DRUG),3385,FU,Squamous Cell Carcinoma of the Head and Neck,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +416,NCT01053390,New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma,COMPLETED,PHASE3,Gallbladder Neoplasms,"Somatostatin (DRUG); epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil） (DRUG)",3385,FU,Gallbladder Neoplasms,Bladder/Urinary Tract,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +417,NCT01070290,A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen,WITHDRAWN,PHASE2,Gastric Cancer,"ARQ 197 (DRUG); Oxaliplatin, capecitabine or irinotecan (DRUG)",3385,FU,Gastric Cancer,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +418,NCT01588990,A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer,COMPLETED,PHASE4,Colorectal Neoplasms,Oxaliplatin (DRUG); Capecitabine (DRUG); Bevacizumab (DRUG); Leucovorin (DRUG); 5-Fluouracil (DRUG); Irinotecan (DRUG),3385,FU,Colorectal Neoplasms,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +419,NCT04439890,A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer,UNKNOWN,PHASE3,Advanced Non-squamous Cell Non-small Cell Lung Cancer,Anlotinib hydrochloride capsule (DRUG); Carboplatin injection (DRUG); Pemetrexed disodium f Injection (DRUG); Placebo (DRUG),3385,FU,Advanced Non-squamous Cell Non-small Cell Lung Cancer,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +420,NCT01928290,"Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer",COMPLETED,PHASE2,Stomach Neoplasms; Esophageal Neoplasms,Irinotecan (DRUG); Trastuzumab (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); Fluorouracil (DRUG),3385,FU,Gastrointestinal Neoplasms,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +421,NCT00499603,Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Paclitaxel (DRUG); 5-Fluorouracil (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); RAD001 (DRUG),3385,FU,Breast Cancer,Breast,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +422,NCT02790190,Individualized Adaptive Radiotherapy Based on PET/CT and IMRT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC),UNKNOWN,PHASE3,Lung Neoplasms,Radiotherapy dose (OTHER),3385,FU,Lung Neoplasms,Lung,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +423,NCT04480190,Neoadjuvant Therapy in Biliary Adenocarcinoma,WITHDRAWN,PHASE1,Cholangiocarcinoma; Biliary Cancer,Gemcitabine (DRUG); Cisplatin (DRUG); Fluorouracil (DRUG); Short course ChemoRT (RADIATION),3385,FU,Cholangiocarcinoma; Biliary Cancer,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +424,NCT00940303,OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,5-FU (DRUG); bevacizumab [Avastin] (DRUG); irinotecan (DRUG); leucovorin (DRUG); oxaliplatin (DRUG),3385,FU,Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +425,NCT01704690,Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer,TERMINATED,PHASE2,Esophageal Cancer,S-1 and Paclitaxel (DRUG); Paclitaxel and Cisplatin (DRUG); 5-FU and Cisplatin (DRUG),3385,FU,Esophageal Cancer,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +426,NCT02688803,Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC),COMPLETED,PHASE4,Breast Cancer,Dose dense AC-P (DRUG); Dose dense AC (DRUG); FEC-D (DRUG),3385,FU,Breast Cancer,Breast,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +427,NCT02002390,Efficacy and Safety of FTY720 for Acute Stroke,COMPLETED,PHASE2,"Stroke; Vascular Accident; Cerebral Stroke; Ischemic Cerebrovascular Accident; Stroke, Acute",Fingolimod (DRUG),3385,FU,"Stroke; Vascular Accident; Cerebral Stroke; Ischemic Cerebrovascular Accident; Stroke, Acute",CNS/Brain,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +428,NCT00209690,Phase I/II Study of TPF as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer.,COMPLETED,PHASE1,Esophageal Cancer,Taxotere (DRUG); 5-FU (DRUG); Briplatin (DRUG),3385,FU,Esophageal Cancer,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +429,NCT03958890,A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC),UNKNOWN,PHASE3,Esophageal Squamous Cell Carcinoma,HLX10 100 mg in 10 ml Injection (DRUG); Placebos (DRUG),3385,FU,Esophageal Squamous Cell Carcinoma,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +430,NCT00103103,"Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer",TERMINATED,PHASE2,Gastric Cancer,bortezomib (DRUG); fluorouracil (DRUG); leucovorin calcium (DRUG),3385,FU,Gastric Cancer,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +431,NCT00460603,Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE1,Colorectal Neoplasms,bevacizumab (DRUG); AG-013726 (DRUG); AG-013736 (axitinib) (DRUG),3385,FU,Colorectal Neoplasms,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +432,NCT01704703,"Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques",COMPLETED,PHASE2,Stage IV Colorectal Cancer,panitumumab (DRUG); FOLFIRI (DRUG),3385,FU,Stage IV Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +433,NCT01095003,Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Vinflunine plus Capecitabine (DRUG); Capecitabine (DRUG),3385,FU,Breast Cancer,Breast,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +434,NCT01383343,"Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer",COMPLETED,PHASE1,Recurrent Colon Carcinoma; Recurrent Rectal Carcinoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,Bevacizumab (BIOLOGICAL); Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Leucovorin Calcium (DRUG); Sorafenib Tosylate (DRUG),3385,FU,Recurrent Colon Carcinoma; Recurrent Rectal Carcinoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +435,NCT05677490,"mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma",RECRUITING,PHASE3,Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Metastatic Esophageal Adenocarcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Unresectable Esophageal Adenocarcinoma; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma,Fluorouracil (DRUG); Leucovorin Calcium (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG); Nivolumab (BIOLOGICAL); Magnetic Resonance Imaging (PROCEDURE); Computed Tomography (PROCEDURE); Biospecimen Collection (PROCEDURE); Questionnaire Administration (OTHER),3385,FU,Advanced Gastroesophageal Adenocarcinoma,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +436,NCT01315990,FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema,UNKNOWN,PHASE4,Colorectal Cancer Metastatic,FOLFIRI + Cetuximab (DRUG),3385,FU,Colorectal Cancer Metastatic,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +437,NCT01972490,Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases,COMPLETED,PHASE4,Colorectal Neoplasms,avastin (DRUG); mFOLFOX6 (DRUG),3385,FU,Colorectal Neoplasms,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +438,NCT04510064,Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial,COMPLETED,PHASE2,Metastatic Gastric Cancer; Locally Advanced Gastric Adenocarcinoma; Gastric Cancer Adenocarcinoma Metastatic,Camrelizumab plus mFLOT regimen (DRUG); R0 surgery (PROCEDURE),3385,FU,Metastatic Gastric Cancer; Locally Advanced Gastric Adenocarcinoma; Gastric Cancer Adenocarcinoma Metastatic,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +439,NCT01172964,A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas,COMPLETED,PHASE1,Adult Anaplastic Astrocytoma; Recurrent Grade III Glioma; Recurrent Grade IV Glioma; Adult Anaplastic Oligodendroglioma; Adult Brain Tumor; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Tumor; Adult Anaplastic Oligoastrocytoma; Recurrent High Grade Glioma,flucytosine (DRUG); polymerase chain reaction (OTHER); immunohistochemistry staining method (OTHER); gene therapy (BIOLOGICAL); pharmacological study (OTHER); 3-Tesla magnetic resonance imaging (OTHER); laboratory biomarker analysis (OTHER); therapeutic conventional surgery (PROCEDURE); E. coli CD-expressing genetically modified neural stem cells (BIOLOGICAL),3385,FU,Adult Anaplastic Astrocytoma; Recurrent Grade III Glioma; Recurrent Grade IV Glioma; Adult Anaplastic Oligodendroglioma; Adult Brain Tumor; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Tumor; Adult Anaplastic Oligoastrocytoma; Recurrent High Grade Glioma,CNS/Brain,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +440,NCT06123338,A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer,RECRUITING,PHASE2,Esophageal Cancer; Gastric Adenocarcinoma; HER2 Gene Mutation,Pembrolizumab (DRUG); Trastuzumab (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG); 5-Fluorouracil (DRUG); Docetaxel (DRUG),3385,FU,Gastroesophageal Cancer with HER2 Mutation,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +441,NCT03003338,MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV,TERMINATED,PHASE4,"Hepatitis C, Chronic",OBV/PTV/r and DSV (DRUG); Placebo to match OBV/PTV/r and DSV (DRUG),3385,FU,Chronic Hepatitis C,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +442,NCT00003950,"Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer",COMPLETED,PHASE2,Colorectal Cancer,cyclosporine (DRUG); CPT-11 (DRUG),3385,FU,Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +443,NCT03359850,Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients,COMPLETED,PHASE1,Ovarian Neoplasms; Neoplasms; Solid Tumor; Hepatic Impairment,Niraparib (DRUG),3385,FU,Ovarian Neoplasms; Neoplasms; Solid Tumor; Hepatic Impairment,Ovary/Fallopian Tube,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +444,NCT00612495,Endometrial Cancer - LOHP Alone and With 5FU,COMPLETED,PHASE2,Endometrial Cancer,"oxaliplatin, 5 FU (DRUG)",3385,FU,Endometrial Cancer,Uterus,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +445,NCT04297995,Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors,ACTIVE_NOT_RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma,HLX10 (DRUG); HLX07 (DRUG); HLX07 placebo (DRUG); Cisplatin/Carboplatin (DRUG); 5-FU (DRUG),3385,FU,Head and Neck Squamous Cell Carcinoma,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +446,NCT02714595,Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens,COMPLETED,PHASE3,Healthcare-associated Pneumonia (HCAP); Bloodstream Infections (BSI); Hospital Acquired Pneumonia (HAP); Complicated Urinary Tract Infection (cUTI); Sepsis; Ventilator Associated Pneumonia (VAP),Cefiderocol (DRUG); Best Available Therapy (DRUG),3385,FU,Healthcare-associated Pneumonia (HCAP); Bloodstream Infections (BSI); Hospital Acquired Pneumonia (HAP); Complicated Urinary Tract Infection (cUTI); Sepsis; Ventilator Associated Pneumonia (VAP),Lung,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +447,NCT03167112,A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer,UNKNOWN,PHASE2,Pancreatic Cancer,Oxaliplatin (DRUG); Irinotecan (DRUG); Leucovorin (DRUG); Fluorouracil (DRUG),3385,FU,Pancreatic Cancer,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +448,NCT02218164,Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma,COMPLETED,PHASE2,"Squamous Cell Carcinoma of Skin; Carcinoma, Squamous Cell",Pegylated Interferon alpha-2b (DRUG); Capecitabine (DRUG); 5-FU (DRUG),3385,FU,"Squamous Cell Carcinoma of Skin; Carcinoma, Squamous Cell",Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +449,NCT02042443,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,COMPLETED,PHASE2,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Capecitabine (DRUG); Fluorouracil (DRUG); Laboratory Biomarker Analysis (OTHER); Leucovorin Calcium (DRUG); Trametinib (DRUG),3385,FU,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +450,NCT04082364,"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer",COMPLETED,PHASE2,Gastric Cancer; Gastroesophageal Junction Cancer; HER2-positive Gastric Cancer,margetuximab (BIOLOGICAL); Retifanlimab (BIOLOGICAL); Tebotelimab (BIOLOGICAL); Trastuzumab (BIOLOGICAL); Chemotherapy (OTHER),3385,FU,Gastric Cancer; Gastroesophageal Junction Cancer; HER2-positive Gastric Cancer,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +451,NCT06225843,Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis,RECRUITING,PHASE2,Metastatic Colorectal Cancer,Sotevtamab (BIOLOGICAL); FOLFOX (COMBINATION_PRODUCT),3385,FU,Metastatic Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +452,NCT01532843,Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Treatment to Ncrease Sustained Response in CHB,COMPLETED,PHASE4,Chronic Hepatitis B,PegIFN alfa-2b (DRUG),3385,FU,Chronic Hepatitis B,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +453,NCT02782312,Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis,COMPLETED,PHASE4,Bronchiectasis,ICS+LABA (DRUG); routine therapy (OTHER),3385,FU,Bronchiectasis,Lung,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +454,NCT04052412,Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer,UNKNOWN,PHASE1,Non-small Cell Lung Cancer,18F-AraG (DRUG),3385,FU,Non-small Cell Lung Cancer,Lung,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +455,NCT02688712,ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Rectal Adenocarcinoma,LY2157299 (DRUG); Capecitabine (DRUG); Fluorouracil (DRUG); Tumor specific mesorectal excision (PROCEDURE),3385,FU,Rectal Adenocarcinoma,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +456,NCT00274768,Capecitabine in Treating Patients With Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,capecitabine (DRUG),3385,FU,Breast Cancer,Breast,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +457,NCT00799968,12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China,COMPLETED,PHASE4,Pulmonary Embolism; Thromboembolism,Urokinase (DRUG); Urokinase (DRUG),3385,FU,Pulmonary Embolism; Thromboembolism,Lung,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +458,NCT02017704,Chemoradiation or Brachytherapy for Rectal Cancer,COMPLETED,PHASE2,Rectal Cancer,Endo-HDR (if randomized to this arm) (RADIATION); capecitabine and IMRT (if randomized to this arm) (DRUG); IMRT (intensity modulated radiation therapy) (RADIATION); FOLFOX6 (DRUG); Surgery (PROCEDURE),3385,FU,Rectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +459,NCT02616601,"Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis",COMPLETED,PHASE3,Actinic Keratosis,Generic Fluorouracil Cream (DRUG); Carac® (Fluorouracil) Cream (DRUG); Vehicle Cream (DRUG),3385,FU,Actinic Keratosis,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +460,NCT01181401,InductionChemo-Radio-Antibody-Treatment,COMPLETED,PHASE2,Squamous Cell Carcinoma of the Head; Squamous Cell Carcinoma of the Neck,TPF induction chemotherapy (DRUG); TPF experimental (DRUG); Standard Radiochemotherapy (HART) (RADIATION),3385,FU,Squamous Cell Carcinoma of the Head; Squamous Cell Carcinoma of the Neck,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +461,NCT06084104,DZD9008 PK Study in Hepatic Impairment Subjects,COMPLETED,PHASE1,Hepatic Impairment,DZD9008 (DRUG); DZD9008 (DRUG),3385,FU,Hepatic Impairment,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +462,NCT02977169,To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer,UNKNOWN,PHASE2,Non-small Cell Lung Cancer Stage IIIA; Radiotherapy,PORT (RADIATION); Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen) (DRUG),3385,FU,Non-small Cell Lung Cancer Stage IIIA; Radiotherapy,Lung,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +463,NCT00499369,Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy,TERMINATED,PHASE3,Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); fluorouracil (DRUG); cetuximab (BIOLOGICAL); bevacizumab (BIOLOGICAL),3385,FU,Advanced Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +464,NCT05009069,A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Rectal Neoplasms; Rectal Cancer,Radiotherapy (RADIATION); Capecitabine (DRUG); Fluorouracil (DRUG); Atezolizumab (DRUG); Tiragolumab (DRUG),3385,FU,Rectal Neoplasms; Rectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +465,NCT01896869,FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Metastatic Pancreatic Adenocarcinoma,Ipilimumab (DRUG); Vaccine (BIOLOGICAL); FOLFIRINOX (DRUG),3385,FU,Metastatic Pancreatic Adenocarcinoma,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +466,NCT00780169,Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer,COMPLETED,PHASE1,Metastatic Colorectal Cancer,sorafenib + FOLFIRI (DRUG),3385,FU,Metastatic Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +467,NCT04205968,Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers,RECRUITING,PHASE2,Metastatic Small Intestinal Adenocarcinoma; Stage III Small Intestinal Adenocarcinoma AJCC v8; Stage IIIA Small Intestinal Adenocarcinoma AJCC v8; Stage IIIB Small Intestinal Adenocarcinoma AJCC v8; Stage IV Small Intestinal Adenocarcinoma AJCC v8,Fluorouracil (DRUG); Irinotecan (DRUG); Irinotecan Hydrochloride (DRUG); Leucovorin (DRUG); Leucovorin Calcium (DRUG); Paclitaxel (DRUG); Ramucirumab (BIOLOGICAL),3385,FU,Small Intestinal Adenocarcinoma,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +468,NCT00114946,A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer,TERMINATED,PHASE4,Colorectal Cancer,Avastin (DRUG),3385,FU,Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +469,NCT05227846,Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1),UNKNOWN,PHASE1,Decompensated Cirrhosis,Human Umbilical Cord-derived Mesenchymal Stem Cells (BIOLOGICAL),3385,FU,Decompensated Cirrhosis,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +470,NCT04269369,Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients,UNKNOWN,PHASE4,Colon Cancer; Stomach Tumor; Anal Tumor; Pancreas Cancer; Esophageal Cancer,5-Fluorouracil (DRUG),3385,FU,Colon Cancer; Stomach Tumor; Anal Tumor; Pancreas Cancer; Esophageal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +471,NCT03196869,the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer,UNKNOWN,PHASE2,Locally Advanced Head and Neck Squamous Cell Carcinoma,Chrono-chemotherapy (DEVICE); Routine intravenous drip (DEVICE); induction Chrono-chemotherapy (DRUG); induction Routine-chemotherapy (DRUG); cisplatin chrono-chemotherapy (DRUG); cisplatin routine-chemotherapy (DRUG); intensity-modulated radiation therapy (RADIATION),3385,FU,Locally Advanced Head and Neck Squamous Cell Carcinoma,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +472,NCT00139269,Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck,COMPLETED,PHASE1,Advanced Squamous Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; SSCHN,Docetaxel (DRUG); Cisplatin (DRUG); 5-Fluorouracil (DRUG),3385,FU,Advanced Squamous Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; SSCHN,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +473,NCT04048876,Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis,TERMINATED,PHASE2,Non-alcoholic Fatty Liver Disease; Liver Cirrhosis,CC-90001 (DRUG); Placebo (DRUG),3385,FU,Non-alcoholic Fatty Liver Disease; Liver Cirrhosis,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +474,NCT00349076,Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy With 5-Fluorouracil and Oxaliplatin Versus 5-Fluorouracil Alone in Rectal Cancer,COMPLETED,PHASE3,Rectal Neoplasms,5-FU and oxaliplatin (DRUG); 5-FU (DRUG),3385,FU,Rectal Neoplasms,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +475,NCT02783573,A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia,TERMINATED,PHASE3,Alzheimer's Disease,Lanabecestat (DRUG); Placebo (DRUG),3385,FU,Alzheimer's Disease,CNS/Brain,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +476,NCT04116476,"Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function",COMPLETED,PHASE1,Mild and Moderate Hepatic Impairment,MT-7117 (DRUG),3385,FU,Mild and Moderate Hepatic Impairment,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +477,NCT05554276,Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer,RECRUITING,PHASE2,Neoadjuvant Chemotherapy; PD-1 Antibody; Radiotherapy; Cervical Cancer,neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy (COMBINATION_PRODUCT),3385,FU,Neoadjuvant Chemotherapy; PD-1 Antibody; Radiotherapy; Cervical Cancer,Cervix,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +478,NCT02924376,Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202),COMPLETED,PHASE2,Cholangiocarcinoma,Pemigatinib (DRUG),3385,FU,Cholangiocarcinoma,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +479,NCT01679327,Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer,UNKNOWN,PHASE2,Colorectal Cancer,Oxaliplatin (DRUG); Xeloda (DRUG); Calcium folinate (CF) (DRUG); 5-FU (DRUG); Bevacizumab (DRUG),3385,FU,Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +480,NCT05653427,A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma,TERMINATED,PHASE2,"Carcinoma, Hepatocellular",Amivantamab (DRUG),3385,FU,"Carcinoma, Hepatocellular",Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +481,NCT01068327,"Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer",COMPLETED,PHASE1,Adenocarcinoma of the Pancreas; Stage III Pancreatic Cancer,gemcitabine hydrochloride (DRUG); leucovorin calcium (DRUG); fluorouracil (DRUG); nelfinavir mesylate (DRUG); stereotactic body radiation therapy (RADIATION); hypofractionated radiation therapy (RADIATION); therapeutic conventional surgery (PROCEDURE),3385,FU,Adenocarcinoma of the Pancreas; Stage III Pancreatic Cancer,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +482,NCT01652976,"Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma",COMPLETED,PHASE2,Pancreatic Cancer Metastatic,Dasatinib (DRUG); mFOLFOX6 (DRUG),3385,FU,Pancreatic Cancer Metastatic,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +483,NCT01360827,EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck,TERMINATED,PHASE1,Squamous Cell Carcinoma of the Head and Neck,EMD 1201081 + 5-FU + Cisplatin + Cetuximab (DRUG); EMD 1201081 + 5-FU + Cisplatin + Cetuximab (DRUG),3385,FU,Squamous Cell Carcinoma of the Head and Neck,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +484,NCT00707473,"Docetaxel, Cisplatin and Fluorouracil in Treating Patients with Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma; Sinonasal Undifferentiated Carcinoma; Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC V8; Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC V8; Stage IVA Nasal Cavity and Paranasal Sinus Cancer AJCC V8; Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC V8,Carboplatin (DRUG); Chemoradiotherapy (OTHER); Cisplatin (DRUG); Definitive Surgical Resection (PROCEDURE); Docetaxel (DRUG); Fluorouracil (DRUG); Quality-of-Life Assessment (PROCEDURE); Radiation Therapy (RADIATION),3385,FU,Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma; Sinonasal Undifferentiated Carcinoma; Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC V8; Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC V8; Stage IVA Nasal Cavity and Paranasal Sinus Cancer AJCC V8; Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC V8,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +485,NCT05251727,Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients,TERMINATED,PHASE1,Chemotherapy-induced Peripheral Neuropathy,thrombomodulin alfa (DRUG); Placebo (DRUG),3385,FU,Chemotherapy-induced Peripheral Neuropathy,Peripheral Nervous System,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +486,NCT06936527,XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation,NOT_YET_RECRUITING,PHASE1,Colorectal Cancer; Metastatic Colorectal Cancer With RAS Mutation,"Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI (BIOLOGICAL); Drug: XS-03 (BIOLOGICAL); Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI (BIOLOGICAL)",3385,FU,Colorectal Cancer; Metastatic Colorectal Cancer With RAS Mutation,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +487,NCT02281682,IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis,UNKNOWN,PHASE4,"Keratosis, Actinic",Imiquimod (DRUG); 5-fluorouracil (DRUG); Ingenol mebutate (DRUG); methylaminolevulinate photodynamic therapy (PROCEDURE),3385,FU,Actinic Keratosis,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +488,NCT05815082,ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer,RECRUITING,PHASE3,Colorectal Cancer; Liver Metastases; Circulating Tumor Cell; Chemotherapy Effect,Colorectal cancer resection combined with liver metastasis resection. (PROCEDURE); FOLFOX chemotherapy regimen (DRUG),3385,FU,Colorectal Cancer; Liver Metastases; Circulating Tumor Cell; Chemotherapy Effect,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +489,NCT00004931,Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer,COMPLETED,PHASE3,Stage II Colon Cancer; Stage III Colon Cancer,leucovorin calcium (DRUG); fluorouracil (DRUG); oxaliplatin (DRUG); laboratory biomarker analysis (OTHER),3385,FU,Stage II-III Colon Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +490,NCT01765582,Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer,TERMINATED,PHASE2,Colorectal Neoplasms,5-fluorouracil (DRUG); bevacizumab (DRUG); capecitabine (DRUG); irinotecan (DRUG); folinic acid (DRUG); oxaliplatin (DRUG),3385,FU,Colorectal Neoplasms,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +491,NCT05231382,Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma,UNKNOWN,PHASE3,Hepatocellular Carcinoma,"Raltitrexed, oxaliplatin (SALOX) treatment (PROCEDURE); Oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment (PROCEDURE)",3385,FU,Hepatocellular Carcinoma,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +492,NCT00443573,Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer,SUSPENDED,PHASE1,Colon Cancer,recombinant nematode anticoagulant protein c2 (rNAPc2) (DRUG),3385,FU,Colon Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +493,NCT01803282,Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors,COMPLETED,PHASE1,Pancreatic Cancer; Non-small Cell Lung Cancer; Esophagogastric Cancer; Colorectal Cancer; Breast Cancer,Andecaliximab (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); 5-FU (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG); Paclitaxel (DRUG),3385,FU,"Multiple Cancers (Pancreatic, Lung, Esophagogastric, Colorectal, Breast)",Breast,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +494,NCT06081582,Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC,RECRUITING,PHASE2,Squamous Cell Carcinoma of Head and Neck,Toripalimab (DRUG),3385,FU,Squamous Cell Carcinoma of Head and Neck,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +495,NCT00921531,Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma,UNKNOWN,PHASE3,Hepatocellular Carcinoma,Thalidomide (DRUG); TACE (DRUG),3385,FU,Hepatocellular Carcinoma,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +496,NCT01136031,Paclitaxel and Irinotecan in Advanced Gastric Cancer,COMPLETED,PHASE1,Advanced Gastric Cancer,Paclitaxel and irinotecan (DRUG),3385,FU,Advanced Gastric Cancer,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +497,NCT01195831,Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis,COMPLETED,PHASE3,Scalp Psoriasis,Xamiol® gel (DRUG); Calcipotriol scalp solution (DRUG),3385,FU,Scalp Psoriasis,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +498,NCT00486460,"Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer",UNKNOWN,PHASE3,Pancreatic Cancer,Gemcitabine (DRUG); Curcumin (DRUG); Celebrex (DRUG),3385,FU,Pancreatic Cancer,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +499,NCT06925360,IVIG Trial for the Treatment of Bronchopulmonary Dysplasia,RECRUITING,PHASE2,Bronchopulmonary Dysplasia,intravenous immunoglobulin (DRUG),3385,FU,Bronchopulmonary Dysplasia,Lung,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +500,NCT06603376,"Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer",RECRUITING,PHASE2,Colorectal Carcinoma,FOLFIRI + Vemurafenib + Cetuximab (DRUG); FOLFIRI ± Bevacizumab (DRUG),3385,FU,Colorectal Carcinoma,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +501,NCT00424827,A Trial of Chemo & Radiation Therapy for Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,Gemcitabine/Fluorouracil with External Beam Radiation (DRUG),3385,FU,Pancreatic Cancer,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +502,NCT00081627,Clinical Trial in Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colon Cancer; Rectal Cancer,CoFactor and 5FU (DRUG),3385,FU,Colon Cancer; Rectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +503,NCT02721576,A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC,TERMINATED,PHASE4,Esophageal Neoplasms,Sodium Glycididazole (DRUG),3385,FU,Esophageal Neoplasms,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +504,NCT02172976,Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma,COMPLETED,PHASE2,Resectable Prancreas Carcinoma,Gemcitabine (DRUG); Oxaliplatin (DRUG); 5-Fluorouracil (DRUG); Irinotecan (DRUG); Natriumfolinate (DRUG),3385,FU,Pancreatic Carcinoma,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +505,NCT05885776,"Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research",RECRUITING,PHASE2,Breast Cancer,Pyrrolidine、trastuzumab、AI (DRUG),3385,FU,Breast Cancer,Breast,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +506,NCT01313676,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",fluticasone furoate/vilanterol (DRUG); fluticasone furoate (DRUG); vilanterol (DRUG); Placebo (OTHER),3385,FU,"Pulmonary Disease, Chronic Obstructive",Lung,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +507,NCT03485027,Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer; Chemotherapy Effect,the rechallenge regimen (DRUG),3385,FU,Metastatic Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +508,NCT00384176,First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX,COMPLETED,PHASE2,Colorectal Cancer,Cediranib (DRUG); Bevacizumab (DRUG); 5-fluorouracil ( in FOLFOX) (DRUG); Leucovorin (in FOLFOX) (DRUG); Oxaliplatin (in FOLFOX) (DRUG),3385,FU,Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +509,NCT03751176,Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal,UNKNOWN,PHASE2,Colorectal Cancer Metastatic,Panitumumab (DRUG); Irinotecan (DRUG); Folinic acid (DRUG); 5-FU (DRUG),3385,FU,Colorectal Cancer Metastatic,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +510,NCT06901531,A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer,NOT_YET_RECRUITING,PHASE3,Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma,zolbetuximab (DRUG); Pembrolizumab (DRUG); Capecitabine (DRUG); Oxaliplatin (DRUG); Folinic acid (leucovorin or local equivalent) (DRUG); 5-fluorouracil (5-FU) (DRUG); Placebo (DRUG),3385,FU,Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +511,NCT01085331,MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC),TERMINATED,PHASE1,Metastatic Colorectal Cancer,Pimasertib (DRUG); Placebo (DRUG); FOLFIRI (DRUG),3385,FU,Metastatic Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +512,NCT01523431,Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Irinotecan Injection [Camptosar] (DRUG); 5-fluorouracil (DRUG); Leucovorin (DRUG),3385,FU,Metastatic Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +513,NCT01652482,Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC),COMPLETED,PHASE2,Colorectal Cancer,5-fluorouracil (DRUG); Cetuximab (DRUG); Irinotecan (DRUG); Leucovorin (DRUG); MEHD7945A (DRUG),3385,FU,Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +514,NCT00919282,Gemcitabine (GFF) in Patients With Pancreatic Cancer,COMPLETED,PHASE2,Metastatic Pancreatic Cancer,"gemcitabine, folinic acid, 5-FU (DRUG)",3385,FU,Metastatic Pancreatic Cancer,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +515,NCT00660582,FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Cetuximab (Erbitux) (DRUG); Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid (DRUG),3385,FU,Metastatic Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +516,NCT00927082,"A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B",COMPLETED,PHASE4,"Hepatitis B, Chronic",peginterferon alfa-2a [Pegasys] (DRUG),3385,FU,Chronic Hepatitis B,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +517,NCT02969473,Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma,UNKNOWN,PHASE2,Esophageal Neoplasm; Chemoradiation,Docetaxel (DRUG); Fluorouracil (DRUG),3385,FU,Esophageal Neoplasm,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +518,NCT05905731,Autologous T-cells Transfected With mRNA Encoding HBV-TCR T Cell Therapy in Combination With NUC for Chronic Hepatitis B,ACTIVE_NOT_RECRUITING,PHASE1,Chronic Hepatitis B,TCR-T (BIOLOGICAL),3385,FU,Chronic Hepatitis B,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +519,NCT00573131,Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer,TERMINATED,PHASE2,Esophageal Cancer; Adenocarcinoma of the Esophagus; Squamous Cell Carcinoma,OncoGel (Paclitaxel gel) (DRUG); cisplatin (DRUG); 5-FU (DRUG); radiation therapy (RADIATION); esophageal resection (PROCEDURE),3385,FU,Esophageal Cancer; Adenocarcinoma of the Esophagus; Squamous Cell Carcinoma,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +520,NCT03505320,A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Pharmacokinetics of Zolbetuximab; Gastric Cancer; Gastro-esophageal Junction (GEJ) Cancer; Pharmacokinetics of Oxaliplatin; Pharmacokinetics of Fluorouracil Bolus (5-FU),zolbetuximab (DRUG); oxaliplatin (DRUG); leucovorin (DRUG); fluorouracil (DRUG); Pembrolizumab (DRUG); folinic acid (DRUG); nivolumab (DRUG); Docetaxel (DRUG),3385,FU,Gastric and Gastro-esophageal Junction Cancer,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +521,NCT00673673,FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer,COMPLETED,PHASE2,Gastroesophageal Cancer; Gastric Cancer,FOLFOX (DRUG); bevacizumab (DRUG),3385,FU,Gastroesophageal Cancer; Gastric Cancer,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +522,NCT03533582,Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery,ACTIVE_NOT_RECRUITING,PHASE3,"Childhood Hepatocellular Carcinoma; Childhood Malignant Liver Neoplasm; Fibrolamellar Carcinoma; Hepatoblastoma; Hepatocellular Malignant Neoplasm, Not Otherwise Specified",Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Doxorubicin (DRUG); Etoposide (DRUG); Fluorouracil (DRUG); Gemcitabine (DRUG); Irinotecan (DRUG); Oxaliplatin (DRUG); Patient Observation (OTHER); Resection (PROCEDURE); Sorafenib (DRUG); Vincristine Sulfate (DRUG),3385,FU,Childhood Liver Malignancies,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +523,NCT06620731,Clinical Trial of FCN-437c Capsule in Patients With Hepatic Insufficiency,COMPLETED,PHASE1,Hepatic Insufficiency,FCN-437c capsule (DRUG),3385,FU,Hepatic Insufficiency,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +524,NCT01542931,TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma,COMPLETED,PHASE2,Stage III Oral Cavity Squamous Cell Carcinoma; Stage IVA Oral Cavity Squamous Cell Carcinoma,TPF induction chemotherapy (DRUG),3385,FU,Stage III Oral Cavity Squamous Cell Carcinoma; Stage IVA Oral Cavity Squamous Cell Carcinoma,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +525,NCT04892173,JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC,RECRUITING,PHASE3,Locally Advanced Head and Neck Squamous Cell Carcinoma; Aged,JNJ-90301900 (NBTXR3) (DRUG); Cetuximab (DRUG); Radiation Therapy (RADIATION),3385,FU,Locally Advanced Head and Neck Squamous Cell Carcinoma; Aged,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +526,NCT05715931,Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma,RECRUITING,PHASE2,Adenocarcinoma of the Stomach; Adenocarcinoma of Esophagogastric Junction; HER2-positive Gastric Cancer,"Toripalimab (DRUG); Trastuzumab (DRUG); 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT) (DRUG)",3385,FU,Gastric and Gastroesophageal Junction Cancer,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +527,NCT04479527,Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma,UNKNOWN,PHASE2,Hepatocellular Carcinoma,Camrelizumab (DRUG),3385,FU,Hepatocellular Carcinoma,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +528,NCT06730373,First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2),RECRUITING,PHASE2,HER2-positive Gastric Cancer; Metastatic Gastric Cancer; Unresectable Gastric Carcinoma,Disitamab Vedotin (DRUG); Sintilimab (DRUG); S-1 (DRUG); Trastuzumab (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG); 5-FU (DRUG); Cisplatin (DRUG),3385,FU,HER2-positive Gastric Cancer; Metastatic Gastric Cancer; Unresectable Gastric Carcinoma,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +529,NCT02641873,A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE1,Metastatic Colorectal Cancer,BBI608 (DRUG); 5-FU (DRUG); Irinotecan (DRUG); Levofolinate (DRUG); Bevacizumab (DRUG),3385,FU,Metastatic Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +530,NCT04009876,A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer,COMPLETED,PHASE2,Locally Advanced Rectal Cancer (LARC),nal-IRI (DRUG); Surgical resection (PROCEDURE); Watch-and-wait (OTHER); 5-FU/LV (DRUG); Oxaliplatin (DRUG),3385,FU,Locally Advanced Rectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +531,NCT03801876,Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer,RECRUITING,PHASE3,Clinical Stage I Esophageal Adenocarcinoma AJCC v8; Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage I Esophageal Adenocarcinoma AJCC v8; Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage II Esophageal Adenocarcinoma AJCC v8; Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage III Esophageal Adenocarcinoma AJCC v8; Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Thoracic Esophagus Squamous Cell Carcinoma,Carboplatin (DRUG); Esophagectomy (PROCEDURE); Intensity-Modulated Radiation Therapy (RADIATION); Paclitaxel (DRUG); Proton Beam Radiation Therapy (RADIATION); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); FOLFOX regimen (DRUG); CAPOX regimen (DRUG); Docetaxel (DRUG); 5FU (DRUG),3385,FU,Esophageal and Gastroesophageal Junction Cancer,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +532,NCT03299660,Avelumab With Chemoradiation in Locally Advanced Rectal Cancer,COMPLETED,PHASE2,Rectal Cancer,Avelumab (DRUG); 5 Fluorouracil (DRUG); Capecitabine Pill (DRUG); Radiotherapy (RADIATION); Surgical Resection (PROCEDURE),3385,FU,Rectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +533,NCT05727176,Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement,RECRUITING,PHASE2,Advanced Cholangiocarcinoma; FGFR2 Fusions; Gene Rearrangement,TAS-120 (DRUG),3385,FU,Advanced Cholangiocarcinoma; FGFR2 Fusions; Gene Rearrangement,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +534,NCT00980460,Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer,ACTIVE_NOT_RECRUITING,PHASE3,PRETEXT I Hepatoblastoma; PRETEXT II Hepatoblastoma; PRETEXT III Hepatoblastoma; PRETEXT IV Hepatoblastoma,Cisplatin (DRUG); Dexrazoxane (DRUG); Doxorubicin Hydrochloride (DRUG); Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Liver Transplantation (PROCEDURE); Temsirolimus (DRUG); Therapeutic Conventional Surgery (PROCEDURE); Vincristine Sulfate (DRUG),3385,FU,Hepatoblastoma,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +535,NCT05193292,Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer,UNKNOWN,PHASE2,Colorectal Neoplasms; Intestinal Neoplasms,Camrelizumab (DRUG); Trastuzumab (DRUG); XELOX regimen (DRUG); mFOLFOX6 regimen (DRUG); FOLFIRI regimen (DRUG); mXELIRI regimen (DRUG); mIRIS regimen (DRUG),3385,FU,Intestinal Neoplasms,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +536,NCT03059992,Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment,COMPLETED,PHASE3,Invasive Candidiasis; Mucocutaneous Candidiasis; Coccidioidomycosis; Histoplasmosis; Blastomycosis; Chronic Pulmonary Aspergillosis; Allergic Bronchopulmonary Aspergillosis; Invasive Pulmonary Aspergillosis; Recurrent Vulvovaginal Candidiasis; Other Emerging Fungi,Ibrexafungerp (DRUG),3385,FU,Invasive Candidiasis; Mucocutaneous Candidiasis; Coccidioidomycosis; Histoplasmosis; Blastomycosis; Chronic Pulmonary Aspergillosis; Allergic Bronchopulmonary Aspergillosis; Invasive Pulmonary Aspergillosis; Recurrent Vulvovaginal Candidiasis; Other Emerging Fungi,Lung,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +537,NCT05606692,Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics),RECRUITING,PHASE4,Ovarian Cancer,Propofol 1% (DRUG); Sevoflurane/Ultane (DRUG),3385,FU,Ovarian Cancer,Ovary/Fallopian Tube,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +538,NCT04032392,Immunotherapy of Advanced Hepatitis B Related Hepatocellular Carcinoma With γδT Cells,UNKNOWN,PHASE1,Hepatocellular Carcinoma,autologous γδT cells (BIOLOGICAL),3385,FU,Hepatocellular Carcinoma,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +539,NCT01867892,A Phase II Study of Locally Advanced Pancreatic Cancer,UNKNOWN,PHASE2,Pancreatic Cancer,"ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT (DRUG); ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT (DRUG)",3385,FU,Pancreatic Cancer,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +540,NCT04677192,Microwave Ablation Combined With Chemotherapy in the Treatment of Pancreatic Cancer Oligohepatic Metastasis,UNKNOWN,PHASE2,Pancreatic Cancer Metastatic to Liver; Oligometastasis,Microwave Ablation combination with chemotherapy (COMBINATION_PRODUCT),3385,FU,Pancreatic Cancer Metastatic to Liver; Oligometastasis,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +541,NCT01954992,Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer,RECRUITING,PHASE3,Metastatic Pancreatic Adenocarcinoma,Glufosfamide (DRUG); Fluorouracil (DRUG),3385,FU,Metastatic Pancreatic Adenocarcinoma,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +542,NCT00982592,Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer,COMPLETED,PHASE2,Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach; Recurrent Gastric Cancer; Stage IIIA Gastric Cancer; Stage IIIB Gastric Cancer; Stage IIIC Gastric Cancer; Stage IV Gastric Cancer,oxaliplatin (DRUG); leucovorin calcium (DRUG); fluorouracil (DRUG); placebo (OTHER); vismodegib (DRUG); laboratory biomarker analysis (OTHER),3385,FU,Gastric and Gastroesophageal Junction Cancer,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +543,NCT01183494,A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients,COMPLETED,PHASE1,Metastatic Colorectal Cancer,"FOLFIRI, Avastin, Irinotecan (DRUG)",3385,FU,Metastatic Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +544,NCT06210360,Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX,NOT_YET_RECRUITING,PHASE2,Pancreatic Cancer,Irinotecan liposome injection (DRUG); Oxaliplatin (DRUG); 5-FU (DRUG); LV (DRUG),3385,FU,Pancreatic Cancer,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +545,NCT01246960,"A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer",COMPLETED,PHASE2,Stomach Cancer; Esophageal Cancer,Ramucirumab (BIOLOGICAL); Placebo (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); 5-Fluorouracil (DRUG),3385,FU,Stomach Cancer; Esophageal Cancer,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +546,NCT01821612,Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer,COMPLETED,EARLY_PHASE1,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer,oxaliplatin (DRUG); irinotecan (DRUG); leucovorin (DRUG); 5-fluorouracil (DRUG); capecitabine (DRUG); radiation (RADIATION); surgery (PROCEDURE); gemcitabine (DRUG),3385,FU,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer,Pancreas,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +547,NCT01695772,A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer,COMPLETED,PHASE4,Colorectal Cancer,5-FU based doublet chemotherapy (DRUG); bevacizumab (DRUG),3385,FU,Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +548,NCT05866172,HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC,RECRUITING,PHASE3,Hepatocellular Carcinoma,HAIC (PROCEDURE); Zoledronic acid (DRUG),3385,FU,Hepatocellular Carcinoma,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +549,NCT00021268,Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer,UNKNOWN,PHASE1,Colorectal Cancer,tocladesine (DRUG),3385,FU,Colorectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +550,NCT00632268,Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric Cancer,COMPLETED,PHASE2,Metastatic Gastric Cancer,RAD001; Cisplatin; 5-FU; Leucovorin (DRUG),3385,FU,Metastatic Gastric Cancer,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +551,NCT00037180,For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy,TERMINATED,PHASE2,Neoplasm Metastasis; Colorectal Neoplasms,Celecoxib (DRUG); Irinotecan (DRUG); 5-fluorouracil (DRUG); Leucovorin (DRUG),3385,FU,Metastatic Colorectal Neoplasms,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +552,NCT03982680,Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma,UNKNOWN,PHASE2,Advanced Cholangiocarcinoma,Toripalimab (DRUG); Gemcitabine (DRUG); 5- fluorine pyrimidine (DRUG),3385,FU,Advanced Cholangiocarcinoma,Liver,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +553,NCT06705192,"Study in Asymptomatic GRN-FTD Patients to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001",ENROLLING_BY_INVITATION,PHASE1,Dementia; Frontotemporal Dementia; Asymptomatic Condition,VES001 (DRUG),3385,FU,Dementia; Frontotemporal Dementia; Asymptomatic Condition,CNS/Brain,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +554,NCT01224392,Simultaneous Integrated Boost Preoperative Radiotherapy for Rectum Cancer,COMPLETED,PHASE3,Rectal Cancer,Chemoradiotherapy (OTHER); Radiotherapy with boost (RADIATION),3385,FU,Rectal Cancer,Bowel,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +555,NCT00615667,"Prospective, Multicenter Study of the Efficacy and Tolerance of Tacrolimus on Refractory Nephrotic Syndrome (RNS)",COMPLETED,PHASE3,Kidney Diseases; Nephrotic Syndrome; Tacrolimus,tacrolimus (FK506) (DRUG),3385,FU,Kidney Diseases; Nephrotic Syndrome; Tacrolimus,Kidney,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +556,NCT00661167,Phase II Study of ABI-007 for Gastric Cancer,COMPLETED,PHASE2,Gastric Cancer,ABI-007 (DRUG),3385,FU,Gastric Cancer,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +557,NCT05446467,Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC,RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma,pembrolizumab+cisplatin + 5-FU (COMBINATION_PRODUCT),3385,FU,Head and Neck Squamous Cell Carcinoma,Skin,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +558,NCT00555672,Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer,COMPLETED,PHASE1,Stomach Neoplasms,5-fluorouracil (DRUG); cisplatin (DRUG); sunitinib malate (DRUG),3385,FU,Stomach Neoplasms,Esophagus/Stomach,5-Fluorouracil,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used chemotherapy drug. Approved for cancer treatment.,C1=C(C(=O)NC(=O)N1)F,1.13,285.0 +559,NCT05798520,A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS),RECRUITING,PHASE2,Relapsing Forms of Multiple Sclerosis,BIIB091 (DRUG); DRF (DRUG); Placebo (DRUG),370,GDE,Relapsing Forms of Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +560,NCT04711148,A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis,ACTIVE_NOT_RECRUITING,PHASE2,Relapsing Remitting Multiple Sclerosis,placebo (OTHER); orelabrutinib (DRUG),370,GDE,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +561,NCT06396039,A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis,ACTIVE_NOT_RECRUITING,PHASE4,Relapsing Multiple Sclerosis,BMS-986374 (DRUG),370,GDE,Relapsing Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +562,NCT04783935,Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension),COMPLETED,PHASE4,Multiple Sclerosis,Mavenclad® (DRUG),370,GDE,Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +563,NCT04486716,"A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis",COMPLETED,PHASE3,Relapsing Multiple Sclerosis,Ofatumumab (DRUG),370,GDE,Relapsing Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +564,NCT02294058,Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS),COMPLETED,PHASE3,Multiple Sclerosis,Ozanimod (DRUG); Interferon beta-1a (DRUG); Placebo to ozanimod (DRUG); Placebo to interferon beta-1a (DRUG),370,GDE,Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +565,NCT05906992,"A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis",RECRUITING,PHASE3,Relapsing-remitting Multiple Sclerosis,CT-P53 (BIOLOGICAL); US-Ocrevus (BIOLOGICAL); EU-Ocrevus (BIOLOGICAL),370,GDE,Relapsing-remitting Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +566,NCT01457924,Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis,COMPLETED,PHASE2,Multiple Sclerosis,Ofatumumab 3mg (DRUG); Ofatumumab 30mg (DRUG); Ofatumumab 60mg (DRUG); Placebo (DRUG),370,GDE,Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +567,NCT06220669,A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis,RECRUITING,PHASE2,Multiple Sclerosis,LY3541860 (DRUG); Placebo (DRUG),370,GDE,Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +568,NCT02047734,Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis,COMPLETED,PHASE3,Relapsing Multiple Sclerosis,Ozanimod (DRUG); Ozanimod placebo (DRUG); Interferon beta-1a (DRUG); Interferon beta-1a placebo (DRUG),370,GDE,Relapsing Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +569,NCT02576717,"A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis",COMPLETED,PHASE3,Multiple Sclerosis,RPC1063 (DRUG),370,GDE,Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +570,NCT06700343,Comparison Between ABP 692 and Ocrevus® (Ocrelizumab),RECRUITING,PHASE3,Relapsing-remitting Multiple Sclerosis (RRMS),Ocrelizumab (US) (DRUG); Ocrelizumab (EU) (DRUG); ABP 692 (DRUG),370,GDE,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +571,NCT01772199,Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis,COMPLETED,PHASE2,"Multiple Sclerosis, Relapsing-Remitting",GSK239512 (DRUG); Placebo (DRUG),370,GDE,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +572,NCT05658484,A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China,ACTIVE_NOT_RECRUITING,PHASE4,Multiple Sclerosis,Dimethyl fumarate (DRUG),370,GDE,Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +573,NCT06408259,Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis,RECRUITING,PHASE3,"Multiple Sclerosis, Relapsing-Remitting",Ozanimod (DRUG); Fingolimod (DRUG); Placebo (OTHER),370,GDE,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +574,NCT06847724,An Efficacy and Safety Study With Integrated Pharmacokinetics (PK) and Pharmacodynamic (PD) Assessment to Compare the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis (RMS),NOT_YET_RECRUITING,PHASE3,Relapsing Multiple Sclerosis,CYB704 (BIOLOGICAL); Ocrevus-EU (BIOLOGICAL); Ocrevus-US (BIOLOGICAL),370,GDE,Relapsing Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +575,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,COMPLETED,PHASE3,Multiple Sclerosis,ALKS 8700 (DRUG),370,GDE,Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +576,NCT01037907,A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS),TERMINATED,PHASE2,Relapsing Remitting Multiple Sclerosis,Pleneva TM BGC20-0134 (DRUG); Placebo (DRUG),370,GDE,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +577,NCT04115488,Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®,COMPLETED,PHASE3,Relapsing-Remitting Multiple Sclerosis (RRMS),Intravenous (IV) infusions (BIOLOGICAL),370,GDE,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +578,NCT06564311,A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone),RECRUITING,PHASE2,Relapsing Multiple Sclerosis,Obexelimab (DRUG); Placebo (DRUG),370,GDE,Relapsing Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +579,NCT04879628,Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis,ACTIVE_NOT_RECRUITING,PHASE2,Multiple Sclerosis,SAR441344 IV (DRUG); placebo IV (DRUG); SAR441344 SC (DRUG); placebo SC (DRUG); MRI contrast-enhancing preparations (DRUG),370,GDE,Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +580,NCT01628393,Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients,COMPLETED,PHASE2,Relapsing Multiple Sclerosis,Ozanimod (DRUG); Placebo (DRUG),370,GDE,Relapsing Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +581,NCT04140305,Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063),ACTIVE_NOT_RECRUITING,PHASE3,Multiple Sclerosis,RPC-1063 (DRUG),370,GDE,Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +582,NCT03046251,Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis,COMPLETED,PHASE4,Multiple Sclerosis,Natalizumab (DRUG),370,GDE,Multiple Sclerosis,CNS/Brain,Gallic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in supplements, studied for antioxidant properties.",C1=C(C=C(C(=C1O)O)O)C(=O)O,2.0,30.0 +583,NCT02105974,Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",Fluticasone Furoate/Vilanterol (DRUG); Vilanterol (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +584,NCT01716520,"Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg",COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",Umeclidinium/Vilanterol 62.5/25 mcg (DEVICE); Umeclidinium 62.5 mcg (DEVICE); Vilanterol 25 mcg (DEVICE),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +585,NCT02570165,Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE2,"Pulmonary Disease, Chronic Obstructive",Batefenterol (DRUG); Umeclidinium/ Vilanterol (DRUG); Placebo (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +586,NCT01147848,HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents,COMPLETED,PHASE3,Asthma,Fluticasone furoate/Vilanterol Inhalation Powder (DRUG); Fluticasone propionate/salmeterol Inhalation Powder (DRUG); Placebo (1) (DRUG); Placebo (2) (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +587,NCT03378648,"A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366",COMPLETED,PHASE1,Asthma; Chronic Obstructive Pulmonary Disease,CHF6366 (DRUG); Placebo CHF6366 (DRUG); umeclidinium bromide and vilanterol trifenatate (DRUG),10184665,Vilanterol,Asthma; Chronic Obstructive Pulmonary Disease,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +588,NCT01627327,Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",fluticasone furoate/vilanterol 100/25mcg (DRUG); tiotropium bromide 18mcg (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +589,NCT01313676,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",fluticasone furoate/vilanterol (DRUG); fluticasone furoate (DRUG); vilanterol (DRUG); Placebo (OTHER),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +590,NCT01577680,A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers,COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",Inhaled GSK573719/vilanterol (DRUG); Inhaled GSK573719 (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +591,NCT01573767,Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children,COMPLETED,PHASE2,Asthma,Fluticasone propionate 100mcg (DRUG); Placebo (DRUG); Vilanterol (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +592,NCT03467425,INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design,COMPLETED,PHASE4,"Pulmonary Disease, Chronic Obstructive",FF/UMEC/VI (DRUG); Inhaled Corticosteroid (DRUG); LAMA (DRUG); LABA (DRUG); COPD rescue medications (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +593,NCT01287065,A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function,COMPLETED,PHASE2,Asthma,FF(100mcg)/Vilanterol(25mcg) AM (DRUG); FF(100mcg)/Vilanterol(25mcg) PM (DRUG); Placebo AM (DRUG); Placebo PM (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +594,NCT06474039,The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD,RECRUITING,PHASE3,COPD,Trelegy or Anoro (DRUG),10184665,Vilanterol,COPD,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +595,NCT02164539,Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component,COMPLETED,PHASE2,"Pulmonary Disease, Chronic Obstructive",FF (DRUG); UMEC (DRUG); VI (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +596,NCT01894386,"Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses",COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",FF 400 mcg (DRUG); UMEC 500 mcg (DRUG); UMEC 250 mcg (DRUG); VI 100 mcg (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +597,NCT02119286,"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2",COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",FF (DRUG); VI (DRUG); UMEC (DRUG); Placebo (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +598,NCT02014480,"A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",Umeclidinium 62.5 mcg (DEVICE); Vilanterol 25 mcg (DEVICE); Umeclidinium/Vilanterol 62.5/25 mcg (DEVICE),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +599,NCT03363191,The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma,WITHDRAWN,PHASE4,Asthma,Fluticasone Furoate/Vilanterol (DRUG); Fluticasone Furoate (DRUG); Salbutamol/Albuterol (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +600,NCT02837380,A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects,COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",FF (DRUG); VI/UMEC (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +601,NCT01957163,"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",FF (DRUG); VI (DRUG); UMEC (DRUG); Placebo (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +602,NCT01711463,Relovair PD PK in Chinese Healthy Subjects,COMPLETED,PHASE1,Asthma,Fluticasone Furoate/Vilanterol (DRUG); Placebo (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +603,NCT01573624,"Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma",COMPLETED,PHASE2,Asthma,FF/GSK573719 (DRUG); FF/GSK573719 (DRUG); FF/GSK573719 (DRUG); FF/GSK573719 (DRUG); FF/GSK573719 (DRUG); FF (DRUG); FF/VI (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +604,NCT03478696,"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",COMPLETED,PHASE4,"Pulmonary Disease, Chronic Obstructive",budesonide/formoterol (DRUG); albuterol/salbutamol (DRUG); FF/UMEC/VI (DRUG); Placebo to match budesonide/formoterol (DRUG); tiotropium (DRUG); Placebo to match FF/UMEC/VI (DRUG); placebo to match tiotropium (DRUG); ELLIPTA (DEVICE); MDI (DEVICE); HandiHaler (DEVICE),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +605,NCT06372496,Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma,ACTIVE_NOT_RECRUITING,PHASE4,Asthma,Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (DRUG); Inhaled corticosteroids/long-acting beta-2 agonists (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +606,NCT04522596,"Effect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart Failure",RECRUITING,PHASE4,Copd; Heart Failure,Umeclidinium/vilanterol (DRUG); Placebo (OTHER),10184665,Vilanterol,Copd; Heart Failure,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +607,NCT01837316,A Study to Assess the Bronchodilator Effect of a Single Dose of Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 Micrograms (mcg) Combination When Administered in Adult Patients With Asthma,COMPLETED,PHASE1,Asthma,FF/VI 100/25 mcg (DRUG); Placebo (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +608,NCT02989935,"RELVAR Effects on Parasternal Muscle Activity, Diaphragm, and Ventilation in Severe COPD",ACTIVE_NOT_RECRUITING,PHASE4,Copd,Ventilation (PROCEDURE); Parasternal EMG (PROCEDURE); Phrenic magnetic stimulation (PROCEDURE),10184665,Vilanterol,Copd,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +609,NCT01551758,"A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)",COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",FF/VI (DRUG); Existing Maintenance Therapy (OTHER),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +610,NCT05342558,Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes.,COMPLETED,PHASE4,COPD,Fluticasone Furoate/Vilanterol 100/25 mcgs (DRUG); Umeclidinium/Vilanterol 62.5/25 mcgs (DRUG),10184665,Vilanterol,COPD,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +611,NCT02257372,A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE4,"Pulmonary Disease, Chronic Obstructive",UMEC DPI (DRUG); Placebo DPI (DRUG); ICS/LABA medication (DRUG); Albuterol/salbutamol Metered Dose Inhaler (MDI) (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +612,NCT05535972,To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD,COMPLETED,PHASE4,"Pulmonary Disease, Chronic Obstructive",FF/UMEC/VI (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +613,NCT03002389,Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics,ACTIVE_NOT_RECRUITING,PHASE2,Chronic Obstructive Pulmonary Disease,Anoro Ellipta (DRUG); Arnuity Ellipta (DRUG),10184665,Vilanterol,Chronic Obstructive Pulmonary Disease,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +614,NCT00625196,Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects,COMPLETED,PHASE1,Asthma,Fluticasone foroate/ vilanterol (DRUG); Fluticasone foroate (DRUG); Vilanterol (DRUG); Placebo (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +615,NCT01128569,Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response,COMPLETED,PHASE2,Asthma,Fluticasone Furoate (DRUG); FF/Vilanterol (VI; GW642444M) (DRUG); Placebo (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +616,NCT02731846,"A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",WITHDRAWN,PHASE3,"Pulmonary Disease, Chronic Obstructive",Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg (DRUG); Fluticasone furoate 100 mcg + Vilanterol 25 mcg (DRUG); Umeclidinium 62.5 mcg (DRUG); Placebo ELLIPTA inhaler (DEVICE); Albuterol/Salbutamol (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +617,NCT02487446,Efficacy and Safety Study of QVA149 in COPD Patients,COMPLETED,PHASE3,Chronic Obstructive Pulmonary Disease,QVA149 (DRUG); Umeclidinium/vilanterol (DRUG); Placebo (umeclidinium/vilanterol) (DRUG); Placebo (QVA149) (DRUG),10184665,Vilanterol,Chronic Obstructive Pulmonary Disease,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +618,NCT02753712,A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma,COMPLETED,PHASE3,Asthma,Fluticasone/Formoterol BAI (DRUG); Fluticasone/Vilanterol DPI (Relvar Ellipta DPI) (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +619,NCT03645434,"A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.",COMPLETED,PHASE2,Chronic Obstructive Pulmonary Disease,AZD8871 (DRUG); Anoro® Ellipta® (DRUG),10184665,Vilanterol,Chronic Obstructive Pulmonary Disease,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +620,NCT01323634,Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg (DRUG); Fluticasone Propionate 250mcg/ salmeterol 50mcg (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +621,NCT01342913,A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP)),COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",Fluticasone Furoate 100mcg/Vilanterol 25mcg (DRUG); Fluticaosne Propionate 500mcg/Salmeterol 50mcg (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +622,NCT02446418,A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma,COMPLETED,PHASE3,Asthma,Fluticasone Furoate (DRUG); Vilanterol (DRUG); Fluticasone propionate (DRUG); Salmeterol (DRUG); Budesonide (DRUG); Formoterol Fumarate (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +623,NCT02164513,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",fluticasone furoate (FF) (DRUG); vilanterol (VI) (DRUG); umeclidinium bromide (UMEC) (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +624,NCT01879410,A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI (DRUG); FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS (DRUG); Placebo DISKUS (DRUG); Placebo NDPI (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +625,NCT03474081,A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE4,"Pulmonary Disease, Chronic Obstructive",FF/UMEC/VI (DRUG); Tiotropium (DRUG); Albuterol/salbutamol (DRUG); Placebo to match FF/UMEC/VI (DRUG); Placebo to match tiotropium (DRUG); ELLIPTA inhaler (DEVICE); HANDIHALER (DEVICE); MDI (DEVICE),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +626,NCT04671355,TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD,WITHDRAWN,PHASE4,COPD,Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg (DRUG); Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg (DRUG),10184665,Vilanterol,COPD,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +627,NCT01336608,A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",Fluticasone Furoate/Vilanterol (DRUG); Vilanterol (DRUG); Placebo (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +628,NCT01453023,"Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study",COMPLETED,PHASE2,Asthma,Fluticasone Furoate (DRUG); Fluticasone Furoate/Vilanterol (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +629,NCT03162055,Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,COMPLETED,PHASE3,Chronic Obstructive Pulmonary Disease COPD,Glycopyrronium/Formoterol Fumarate (DRUG); umeclidinium/vilanterol (DRUG),10184665,Vilanterol,Chronic Obstructive Pulmonary Disease COPD,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +630,NCT01181895,Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma,COMPLETED,PHASE3,Asthma,Vilanterol (DRUG); Salmeterol Inhalation Powder (DRUG); Placebo Inhalation Powder NDPI (DRUG); Placebo Inhalation Powder Diskus (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +631,NCT01313650,A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",62.5/25mcg (DRUG); 62.5mcg (DRUG); 25mcg (DRUG); Placebo (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +632,NCT01957150,Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).,COMPLETED,PHASE4,"Pulmonary Disease, Chronic Obstructive",Fluticasone Furoate/Vilanterol (DRUG); Vilanterol (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +633,NCT01165138,Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics,COMPLETED,PHASE3,Asthma,Fluticasone furoate/Vilanterol Inhalation Powder (DRUG); Fluticasone Furoate Inhalation Powder (DRUG); Placebo Inhaltion Powder (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +634,NCT03152149,"INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol",COMPLETED,PHASE4,Chronic Obstructive Pulmonary Disease,Tiotropium & olodaterol (DRUG); fluticasone furoate & vilanterol (DRUG),10184665,Vilanterol,Chronic Obstructive Pulmonary Disease,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +635,NCT01213849,Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler,COMPLETED,PHASE1,Asthma,Fluticasone furoate 50 mcg (4 inhalations) (DRUG); Fluticasone furoate 100 mcg (4 inhalations) (DRUG); Fluticasone furoate 200 mcg (4 inhalations) (DRUG); Vilanterol 25 mcg (4 inhalations) (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +636,NCT04536675,Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery,UNKNOWN,PHASE3,Chronic Obstructive Pulmonary Disease; Non Small Cell Lung Cancer,Vilanterol and Umeclidinium Bromide (DRUG); Placebo (DRUG),10184665,Vilanterol,Chronic Obstructive Pulmonary Disease; Non Small Cell Lung Cancer,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +637,NCT01134042,Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics,COMPLETED,PHASE3,Asthma,Fluticasone Furoate/Vilanterol Inhalation Powder (DRUG); Fluticasone Furoate Inhalation Powder (DRUG); Fluticasone Propionate Inhalation Powder (DRUG); Placebo Inhalation Powder 1 (OTHER); Placebo Inhalation Powder 2 (OTHER),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +638,NCT03611699,Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients,COMPLETED,PHASE4,COPD,Umeclidinium / Vilanterol Dry Powder Inhaler (DRUG); Placebo (DRUG),10184665,Vilanterol,COPD,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +639,NCT01571999,Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment,COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",Inhaled GSK573719 (DRUG); Inhaled GSK573719/vilanterol (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +640,NCT06571942,Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure,RECRUITING,PHASE4,COPD Bronchitis; Pollution Related Respiratory Disorder,Vilanterol / Umeclidinium (25/62.5 mcg) (DRUG); Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg) (DRUG); Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg (DRUG); Budesonide / Formoterol / Glycopyrronyum 160/4.8/7.2 mcg (DRUG),10184665,Vilanterol,COPD Bronchitis; Pollution Related Respiratory Disorder,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +641,NCT01899742,The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",Umeclidinium/Vilanterol 62.5/25 mcg (DRUG); Tiotropium 18 mcg (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +642,NCT01822899,A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",Umeclidinium bromide/Vilanterol (DRUG); Placebo ACCUHALER/DISKUS (DRUG); Fluticasone propionate/Salmeterol (DRUG); Placebo NDPI (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +643,NCT01498679,Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.,COMPLETED,PHASE3,Asthma,GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate) (DRUG); Placebo (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +644,NCT02799784,An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients,COMPLETED,PHASE4,"Pulmonary Disease, Chronic Obstructive",UMEC/VI (DRUG); TIO/OLO (DRUG); Albuterol/salbutamol (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +645,NCT05757102,"A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma",RECRUITING,PHASE3,Asthma,FF/UMEC/VI (DRUG); ELLIPTA (DEVICE); FF/VI (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +646,NCT01435902,A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise,WITHDRAWN,PHASE3,Asthma,Fluticasone Furoate/Vilanterol Inhalation Powder (DRUG); Fluticasone Propionate Inhalation Powder (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +647,NCT01491802,Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD,COMPLETED,PHASE3,COPD,LAMA/LABA (DRUG); LAMA (DRUG),10184665,Vilanterol,COPD,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +648,NCT01323621,Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg (DRUG); Fluticasone Propionate 250mcg / salmeterol 50mcg (DRUG); Double-dummy placebo (DRUG); Salbutamol as needed (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +649,NCT06552364,Air Pollution and Inhaled Corticosteroids in COPD,NOT_YET_RECRUITING,PHASE4,COPD,LABA+LAMA (DRUG); LABA+LAMA+ICS (DRUG); Filtered Air (OTHER); Diesel Exhaust (OTHER),10184665,Vilanterol,COPD,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +650,NCT04750603,Effect of Fluticasone Furoate/Vilanterol on EIA in Adolescents,COMPLETED,PHASE4,Asthma in Children,Fluticasone furoate (FF)/Vilanterol (VI) (DRUG); Salbutamol (DRUG),10184665,Vilanterol,Pediatric Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +651,NCT01817764,A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",Umeclidinium/vilanterol (DRUG); Fluticasone propionate/salmeterol (DRUG); Placebo (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +652,NCT01899638,"Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study.",COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",UMEC/VI 125/25 mcg (DRUG); UMEC/VI 62.5/25 mcg (DRUG); UMEC 125 mcg (DRUG); UMEC 62.5 mcg (DRUG); VI 25 mcg (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +653,NCT01777334,The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",Umeclidinium/Vilanterol 62.5/25 mcg (DRUG); Tiotropium 18 mcg (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +654,NCT02301975,"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma",COMPLETED,PHASE3,Asthma,Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler (DRUG); Placebo inhalation powders via ELLIPTA inhaler (DRUG); Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler (DRUG); Placebo inhalation powder via ACCUHALER/DISKUS inhaler (DRUG); Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +655,NCT02467452,Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE3,Chronic Obstructive Pulmonary Disease,BDP/FF/GB (DRUG); FlF/VI + Tiotropium (DRUG),10184665,Vilanterol,Chronic Obstructive Pulmonary Disease,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +656,NCT03949842,Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study,WITHDRAWN,PHASE4,"Pulmonary Disease, Chronic Obstructive",Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists (DRUG); Fluticasone furoate/umeclidinium/vilanterol (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +657,NCT01316913,24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",GSK573719/GW642444 125/25 (DRUG); GSK573719/GW642444 62.5/25 (DRUG); GSK573719 (DRUG); tiotropium bromide (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +658,NCT03315000,Effect of Vilanterol on Methacholine Challenge Results,COMPLETED,PHASE4,Asthma,Vilanterol and Fluticasone Furoate (DRUG); Fluticasone Furoate (DRUG); Placebos (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +659,NCT04072887,Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients,COMPLETED,PHASE2,"Pulmonary Disease, Chronic Obstructive",QBW251 (DRUG); Placebo (DRUG); COPD maintenance background therapy (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +660,NCT03184987,A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma,COMPLETED,PHASE3,Asthma,FF/UMEC/VI 100/62.5/25 mcg (DRUG); FF/UMEC/VI 200/62.5/25 mcg (DRUG); Salbutamol (DRUG); ACQ-7 (OTHER),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +661,NCT02275052,A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE4,"Pulmonary Disease, Chronic Obstructive",UMEC/VI DPI (DRUG); Placebo DPI (DRUG); Albuterol/salbutamol MDI (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +662,NCT01316900,24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",GSK573719/GW642444 125/25 (DRUG); GSK573719/GW642444 62.5/25 (DRUG); GW642444 (DRUG); tiotropium bromide (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +663,NCT01313637,A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",GSK573719/GW642444 125/25mcg (DRUG); GSK573719 125mcg (DRUG); GW642444 25mcg (DRUG); Placebo only (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +664,NCT02257385,Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",UMEC/VI (DRUG); UMEC/VI matching placebo (DRUG); Tiotropium (DRUG); Tiotropium matching placebo (DRUG); Indacaterol (DRUG); Indacaterol matching placebo (DRUG); Albuterol/salbutamol Metered Dose Inhaler (MDI) (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +665,NCT03376932,Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma,WITHDRAWN,PHASE3,Asthma,FF/UMEC/VI (DRUG); FP/SAL (DRUG); Tiotropium (DRUG); Albuterol/salbutamol (DRUG); ELLIPTA DPI (DEVICE); DISKUS DPI (DEVICE); RESPIMAT inhaler (DEVICE); Metered Dose Inhaler (DEVICE); Connected Inhaler System (DEVICE),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +666,NCT01868009,DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",ELLIPTA (DEVICE); DISKUS (DEVICE),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +667,NCT04923347,A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE4,"Pulmonary Disease, Chronic Obstructive",FF/UMEC/VI (DRUG); ELLIPTA (DEVICE),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +668,NCT02712047,A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.,COMPLETED,PHASE2,Asthma,Fluticasone furoate (FF) (100 mcg) (DRUG); Vilanterol (VI) (25 mcg) (DRUG); Placebo (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +669,NCT02666287,"GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)",COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",BAT/FF (DRUG); BAT (DRUG); FF (DRUG); FF (MgSt) (DRUG); FF/Vilanterol (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +670,NCT01691547,"A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects",COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",UMEC /VI (DRUG); UMEC (DRUG); VI (DRUG); FF (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +671,NCT02730351,Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB),COMPLETED,PHASE4,Asthma,Fluticasone furoate/ Vilanterol 100 mcg/25 mcg (DRUG); Fluticasone propionate 250 mcg (DRUG); Placebo via ELLIPTA inhaler (DRUG); Placebo via DISKUS / ACCUHALER (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +672,NCT05292053,Outcomes of Once-Daily ICS/LABA/LAMA Plus PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations,UNKNOWN,PHASE4,Copd,TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation (DRUG),10184665,Vilanterol,Copd,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +673,NCT01686633,"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.",COMPLETED,PHASE3,Asthma,Fluticasone Furoate/ Vilanterol 200/25 mcg (DRUG); Fluticasone Furoate/ Vilanterol 100/25 mcg (DRUG); Fluticasone Furoate 100 mcg (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +674,NCT04651777,Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma,ACTIVE_NOT_RECRUITING,PHASE3,Asthma,FF/UMEC/VI (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +675,NCT01498653,Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry,COMPLETED,PHASE3,Asthma,GW685698/GW642444 (DRUG); CCI18781 (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +676,NCT01521377,QTc Study GSK573719+GW642444,COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",Placebo Moxifloxacin (DRUG); Moxifloxacin (DRUG); GSK573719/Vilanterol 125/25mcg (DRUG); GSK573719 (DRUG); GSK573719/Vilanterol 500/100mcg (DRUG); Placebo DPI (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +677,NCT02094937,A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects,COMPLETED,PHASE3,Asthma,Fluticasone Furoate/Vilanterol (DRUG); Fluticasone Furoate 100 mcg (DRUG); Fluticasone Propionate 250 mcg (DRUG); Fluticasone Propionate 100 mcg (DRUG); Fluticasone Furoate Placebo (DRUG); Fluticasone Propionate Placebo (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +678,NCT02924688,"A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma",COMPLETED,PHASE3,Asthma,FF/UMEC/VI (100/31.25/25) mcg (DRUG); FF/UMEC/VI (100/62.5/25) mcg (DRUG); FF/UMEC/VI (200/31.25/25) mcg (DRUG); FF/UMEC/VI (200/62.5/25) mcg (DRUG); FF/VI (100/25) mcg (DRUG); FF/VI (200/25) mcg (DRUG); Fluticasone/salmeterol (FSC) (DRUG); Albuterol/salbutamol (DRUG); ELLIPTA DPI (DEVICE); DISKUS DPI (DEVICE); METERED-DOSE INHALER (MDI) (DEVICE),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +679,NCT01691885,RELOVAIR® Lung Deflation Study,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",Fluticasone Furoate (DRUG); Vilanterol (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +680,NCT01395888,A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive","fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI) (DRUG); Tiotropium (DRUG)",10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +681,NCT04937387,Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma,COMPLETED,PHASE3,Asthma,FF/VI (DRUG); FF/UMEC/VI (DRUG); ELLIPTA (DEVICE),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +682,NCT03662711,Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease,TERMINATED,PHASE4,"Pulmonary Disease, Chronic Obstructive",Bronchodilator Agents (DRUG); Bronchodilator Agents (DRUG); Bronchodilator Agents (DRUG); Bronchodilator Agents (DRUG); Bronchodilator Agents (DRUG); Bronchodilator Agents (DRUG); Bronchodilator Agents (DRUG); Bronchodilator Agents (DRUG); Bronchodilator Agents (DRUG); Bronchodilator Agents (DRUG); Bronchodilator Agents (DRUG); Bronchodilator Agents (DRUG); Bronchodilator Agents (DRUG); Bronchodilator Agents (DRUG); Bronchodilator Agents (DRUG); Bronchodilator Agents (DRUG); Bronchodilator Agents (DRUG); Bronchodilator Agents (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +683,NCT03248128,Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma,COMPLETED,PHASE3,Asthma,FF/VI via ELLIPTA DPI (DRUG); FF via ELLIPTA DPI (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +684,NCT03478683,"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",COMPLETED,PHASE4,"Pulmonary Disease, Chronic Obstructive",budesonide/formoterol (DRUG); albuterol/salbutamol (DRUG); FF/UMEC/VI (DRUG); Placebo to match budesonide/formoterol (DRUG); tiotropium (DRUG); Placebo to match FF/UMEC/VI (DRUG); placebo to match tiotropium (DRUG); ELLIPTA (DEVICE); MDI (DEVICE); HandiHaler (DEVICE),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +685,NCT02345161,A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",Triple FF/UMEC/VI (DRUG); Placebo to match FF/UMEC/VI (DRUG); Budesonide/Formoterol (DRUG); Placebo to match Budesonide/Formoterol combination (DRUG); Albuterol/salbutamol (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +686,NCT06905483,Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study,RECRUITING,PHASE4,COPD; Chronic Obstructive Pulmonary Disease (COPD); Small Airway Disease; Triple Therapy; Lung Function,Budesonide/Glycopyrronium/Formoterol (BGF) (DRUG); Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) (DRUG),10184665,Vilanterol,COPD; Chronic Obstructive Pulmonary Disease (COPD); Small Airway Disease; Triple Therapy; Lung Function,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +687,NCT01706328,A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",FF/VI 100/25 Inhalation Powder NDPI (DRUG); Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS (DRUG); Placebo Inhalation Powder NDPI (DRUG); Placebo Inhalation Powder ACCUHALER/DISKUS (DRUG); Salbutamol as needed (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +688,NCT01376245,A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",fluticasone furoate/vilanterol (DRUG); Placebo (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +689,NCT01485445,Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF/Vilanterol Combination,COMPLETED,PHASE1,Asthma,Fluticasone Furoate (200mcg unit strength) (DRUG); Fluticasone Furoate/Vilanterol (200/25mcg unit strength) (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +690,NCT03034915,"A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",COMPLETED,PHASE4,"Pulmonary Disease, Chronic Obstructive",UMEC/VI 62.5/25 mcg via ELLIPTA (DRUG); UMEC 62.5 mcg via ELLIPTA (DRUG); Salmeterol 50 mcg via DISKUS (DRUG); Placebo via ELLIPTA (DRUG); Placebo via DISKUS (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +691,NCT04265105,Fluticasone-Vilanterol Once Daily Dose for the Treatment of Mild Asthma in Adults,COMPLETED,PHASE2,Asthma,fluticasone-vilanterol (DRUG); Standard Preparation (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +692,NCT01706198,"An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma",COMPLETED,PHASE3,Asthma,fluticasone furoate + vilanterol (DRUG); inhaled corticosteroid with or without a long acting beta2-agonist (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +693,NCT02487498,Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.,COMPLETED,PHASE3,Chronic Obstructive Pulmonary Disease,QVA149 (DRUG); Umeclidinium/vilanterol (DRUG); Placebo (umeclidinium/vilanterol ) (DRUG); Placebo (QVA149) (DRUG),10184665,Vilanterol,Chronic Obstructive Pulmonary Disease,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +694,NCT02152605,A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",UMEC/VI (DRUG); Placebo (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +695,NCT02729051,Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",FF/UMEC/VI (DRUG); FF/VI (DRUG); UMEC (DRUG); Placebo (DRUG); Albuterol/salbutamol (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +696,NCT01086384,Asthma Exacerbation Study,COMPLETED,PHASE3,Asthma,Fluticasone Furoate/GW642444 (DRUG); Fluticasone furoate (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +697,NCT00783003,A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects,COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",GSK233705 and GW642444 (DRUG); GW642444 (DRUG); GSK233705 (DRUG); Placebo (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +698,NCT00519376,A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients.,COMPLETED,PHASE2,"Pulmonary Disease, Chronic Obstructive",GW642444M (DRUG); GW642444H (DRUG); placebo (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +699,NCT01286831,"A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444.",COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",[14C]GW642444 (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +700,NCT01323660,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",GSK573719/GW642444 125/25 (DRUG); GSK573719/GW642444 62.5/25 (DRUG); GSK573719 125 (DRUG); GSK573719 62.5 (DRUG); GW642444 25 (DRUG); placebo (DEVICE),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +701,NCT00381667,Study to Assess GW642444 in Asthma Patients,COMPLETED,PHASE2,"Pulmonary Disease, Chronic Obstructive",GW642444M (DRUG); GW642444H (DRUG); placebo (OTHER),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +702,NCT00711126,"A Study To Investigate Safety, Blood Levels And Effects Of Giving GW642444, By Mouth, By Inhalation & By Injection",COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",GW642444 (DRUG); GW642444 (DRUG); GW642444 (DRUG); GW642444 (DRUG); GW642444 (DRUG); GW642444 (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +703,NCT01209026,Corrected QT (QTc) Study With Flucticasone Furoate and GW642444,COMPLETED,PHASE1,Asthma,Fluticasone furoate (200 mcg)/GW642444 (25mcg) combination (DRUG); Fluticasone furoate (400 mcg)/GW642444 (50mcg) combination (DRUG); Placebo Inhaler (DRUG); Moxifloxacin 400mg (DRUG); Moxifloxacin placebo (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +704,NCT00731822,A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE2,"Pulmonary Disease, Chronic Obstructive",GW685698/GW642444 (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +705,NCT01165125,A Drug Interaction Study With Fluticasone Furoate/GW642444 Inhalation Powder and Ketoconazole,COMPLETED,PHASE1,Asthma,FF / GW642444 (DRUG); ketoconazole (DRUG); ketoconazole (placebo to match) (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +706,NCT01192191,A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg (DRUG); Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +707,NCT01266980,A Study to Assess the Effects of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Severe Impairment.,COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",Inhaled FF/ GW642444M (200/25mcg) (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +708,NCT00671216,A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.,COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",GSK233705 (DRUG); GW642444 (DRUG); GSK233705 and GW642444 (DRUG); Placebo (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +709,NCT01453296,Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects,COMPLETED,PHASE2,Asthma,GW642444 (DRUG); Placebo (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +710,NCT00347139,Repeat Doses Of A New Medication (GW642444) In Asthmatic Patients,COMPLETED,PHASE2,"Pulmonary Disease, Chronic Obstructive","GW642444 (25, 100 & 400 mcg/day) (DRUG); Salmeterol 50mcg (DRUG)",10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +711,NCT01018186,Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study,COMPLETED,PHASE3,Asthma,Fluticasone Furoate/GW642444 (DRUG); Fluticasone propionate (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +712,NCT01009463,A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",FF/GW642444 Inhalation Powder (DRUG); GW642444 Inhalation Powder (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +713,NCT01299558,Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects,COMPLETED,PHASE1,Asthma,fluticasone furoate//GW642444 (DRUG); fluticasone furoate (DRUG); GW642444 (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +714,NCT00469040,"Safety, Blood Levels and Effects of GW642444",COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",GW642444M for 14 days (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +715,NCT00976144,"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects",COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",GSK573719 (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +716,NCT01328444,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",GSK 573719 +GW642444 125/25 (DRUG); GSK573719 + GW642444 62.5/25 (DRUG); GSK 573719 125 (DRUG); GSK 573719 62.5 (DRUG); GW642444 25 (DRUG); Plb (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +717,NCT00372112,A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE2,"Pulmonary Disease, Chronic Obstructive",GW642444 (DRUG); Placebo (OTHER),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +718,NCT00702910,A Study to Investigate the Effect of Inhaling Single Doses of Different Formulations of GW642444M in Asthmatic Patients,COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",Placebo (DRUG); GW642444 (DRUG); Magnesium Stearate (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +719,NCT01128634,"Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually and Concurrently, With Verapamilin in Healthy Subjects",COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",GSK573719 (DRUG); GW573719/GW573719 (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +720,NCT01636713,A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",GSK573719/VI 62.5/25 (DRUG); GSK573719/VI 125/25 (DRUG); Placebo (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +721,NCT01266941,"A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.",COMPLETED,PHASE1,Asthma,Inhaled FF 200mcg/GW642444M 25mcg (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +722,NCT01086410,Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis,COMPLETED,PHASE3,Asthma,Placebo Inhalation Powder (DRUG); Fluticasone Furoate/GW642444 Inhalation Powder (DRUG); Fluticasone Furoate/GW642444 Inhalation Powder (DRUG); Placebo Oral Capsule (DRUG); Prednisolone Oral Capsule (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +723,NCT01072149,"A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo",COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",Fluticasone Furoate (FF)/GW642444 Inhalation Powder (DRUG); placebo (DEVICE),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +724,NCT00964249,Phase I Study of GW642444M in Healthy Japanese Male Subjects,COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",GW642444 (DRUG); Placebo (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +725,NCT00606684,A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE2,"Pulmonary Disease, Chronic Obstructive",GW642444 6.25 (DRUG); GW642444 3mcg (DRUG); GW642444 12.5mcg (DRUG); GW642444 25mcg (DRUG); GW642444 50mcg (DRUG); placebo (OTHER),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +726,NCT01244984,A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma,COMPLETED,PHASE3,Asthma,Fluticasone Furoate/GW642444 Inhalation Powder (DRUG); Fluticasone Furoate Inhalation Powder (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +727,NCT01039675,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD",COMPLETED,PHASE2,"Pulmonary Disease, Chronic Obstructive",500mcg/25mcg once daily (DRUG); Placebo once daily (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +728,NCT00980200,Efficacy and Safety Study in Subjects With Asthma,COMPLETED,PHASE2,Asthma,Dose 4 QD (DRUG); Dose 3 QD (DRUG); placebo (DRUG); Dose 2 QD (DRUG); Dose 1 BD (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +729,NCT01054885,Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",FF Inhalation Powder (DRUG); FF/GW642444 Inhalation Powder (DRUG); GW642444 Inhalation Powder (DRUG); Placebo (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +730,NCT01017952,A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",FF/GW642444 Inhalation Powder (DRUG); GW642444 Inhalation Powder (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +731,NCT01053988,A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",FF/GW642444 Inhalation Powder (DRUG); FF Inhalation Powder (DRUG); GW642444 Inhalation Powder (DRUG); Placebo (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +732,NCT01376388,Long-term Safety Study for GSK573719/GW642444 in Japanese,COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",GSK573719/GW642444 Inhalation Powder (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +733,NCT01316887,"A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",125/25 mcg once-daily GSK573719/GW642444 (DRUG); 125mcg once-daily GSK573719 (DRUG); Placebo once-daily (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +734,NCT00749411,Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD,COMPLETED,PHASE2,"Pulmonary Disease, Chronic Obstructive",Placebo (DRUG); GSK233705/GW642444 (DRUG),10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +735,NCT00463697,A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In Asthmatic Patients,COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive","GW642444H (100mcg) (DRUG); placebo (DRUG); GW642444M (25, 100 & 400 mcg) (DRUG)",10184665,Vilanterol,"Pulmonary Disease, Chronic Obstructive",Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +736,NCT00354874,Investigation Of A New Medication (GW642444) In Asthmatic Patients,COMPLETED,PHASE2,Asthma,GW642444 (DRUG); Placebo (DRUG); salmeterol 50mcg (DRUG),10184665,Vilanterol,Asthma,Lung,Vilanterol,ADRB2,activator/agonist,Adrenoceptor agonist,yes,yes,Combined with fluticasone furoate for asthma and COPD treatment.,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,1.06,481.0 +737,NCT01189903,Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients,UNKNOWN,PHASE2,Asian Colorectal Cancer Patients,Regorafenib (DRUG),14992,Mollutox,Asian Colorectal Cancer Patients,Bowel,Niclosamide (olamine),STAT3,inhibitor/antagonist,unclear,yes,yes,"Approved for parasitic infections, investigated for other uses.",C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O.C(CO)N,, +738,NCT02519582,Drug Trial to Investigate the Safety and Efficacy of Niclosamide Tablets in Patients With Metastases of a Colorectal Cancer Progressing After Therapy,UNKNOWN,PHASE2,Colorectal Cancer,Niclosamide (DRUG),14992,Mollutox,Colorectal Cancer,Bowel,Niclosamide (olamine),STAT3,inhibitor/antagonist,unclear,yes,yes,"Approved for parasitic infections, investigated for other uses.",C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O.C(CO)N,, +739,NCT04317430,Niclosamide Role in Diabetic Nephropathy,COMPLETED,PHASE3,Diabetic Nephropathies,Niclosamide (DRUG); Placebo oral tablet (DRUG),14992,Mollutox,Diabetic Nephropathies,Kidney,Niclosamide (olamine),STAT3,inhibitor/antagonist,unclear,yes,yes,"Approved for parasitic infections, investigated for other uses.",C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O.C(CO)N,, +740,NCT04753619,Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management,UNKNOWN,PHASE2,Covid-19; SARS Pneumonia,Niclosamide Oral Tablet (DRUG),14992,Mollutox,Covid-19; SARS Pneumonia,Lung,Niclosamide (olamine),STAT3,inhibitor/antagonist,unclear,yes,yes,"Approved for parasitic infections, investigated for other uses.",C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O.C(CO)N,, +741,NCT03521232,A Study of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative Proctosigmoiditis,TERMINATED,PHASE1,Ulcerative Colitis; Ulcerative Proctitis; Ulcerative Proctosigmoiditis,Niclosamide (DRUG),14992,Mollutox,Ulcerative Colitis; Ulcerative Proctitis; Ulcerative Proctosigmoiditis,Bowel,Niclosamide (olamine),STAT3,inhibitor/antagonist,unclear,yes,yes,"Approved for parasitic infections, investigated for other uses.",C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O.C(CO)N,, +742,NCT02687009,A Study of Niclosamide in Patients With Resectable Colon Cancer,TERMINATED,PHASE1,Colon Cancer,Niclosamide (DRUG),14992,Mollutox,Colon Cancer,Bowel,Niclosamide (olamine),STAT3,inhibitor/antagonist,unclear,yes,yes,"Approved for parasitic infections, investigated for other uses.",C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O.C(CO)N,, +743,NCT00603265,Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy,COMPLETED,PHASE2,Peripheral Neuropathy; Neuropathic Pain,ADL5859 (DRUG); Duloxetine (DRUG); Placebo (DRUG),11672905,ATERENOL,Peripheral Neuropathy; Neuropathic Pain,Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +744,NCT00086190,Study of Antidepressants in Parkinson's Disease,COMPLETED,PHASE3,Parkinson Disease; Depression,paroxetine (DRUG); venlafaxine (DRUG); placebo (OTHER),11672905,ATERENOL,Parkinson Disease with Depression,CNS/Brain,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +745,NCT04970121,Efficacy and Safety of Duloxetine in Chinese Solid Tumor Patients with Taxanes-induced Painful Peripheral Neuropathy,RECRUITING,PHASE2,Chemotherapy-induced Peripheral Neuropathy; Pain; Solid Tumor,Duloxetine (DRUG),11672905,ATERENOL,Chemotherapy-induced Peripheral Neuropathy; Pain; Solid Tumor,Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +746,NCT01116531,"Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin",WITHDRAWN,PHASE4,Diabetic Polyneuropathy; Postherpetic Neuralgia,Tramadol (DRUG); Duloxetine (DRUG); Pregabalin (DRUG),11672905,ATERENOL,Diabetic Polyneuropathy; Postherpetic Neuralgia,Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +747,NCT00058968,A Study for the Treatment of Painful Diabetic Neuropathy,COMPLETED,PHASE3,"Diabetic Neuropathy, Painful",Duloxetine hydrochloride (DRUG); placebo (DRUG),11672905,ATERENOL,"Diabetic Neuropathy, Painful",Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +748,NCT04737967,The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy,UNKNOWN,PHASE2,Oncology Pain; Chemotherapy-induced Peripheral Neuropathy,Venlafaxine (DRUG); Memantine (DRUG),11672905,ATERENOL,Oncology Pain; Chemotherapy-induced Peripheral Neuropathy,Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +749,NCT00863057,Combination Pain Therapy in HIV Neuropathy,TERMINATED,PHASE2,HIV Infections; Peripheral Neuropathy,Duloxetine (DRUG); Duloxetine placebo (DRUG); Methadone (DRUG); Methadone placebo (DRUG),11672905,ATERENOL,HIV Infections; Peripheral Neuropathy,Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +750,NCT00437125,Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease,COMPLETED,PHASE4,Major Depressive Disorder; Idiopathic Parkinson Disease,Duloxetine hydrochloride (DRUG),11672905,ATERENOL,Major Depressive Disorder; Idiopathic Parkinson Disease,CNS/Brain,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +751,NCT00457730,A Study to Test the Use of Duloxetine for Pain in MS,COMPLETED,PHASE2,Multiple Sclerosis,Duloxetine (DRUG); Placebo (DRUG),11672905,ATERENOL,Multiple Sclerosis,CNS/Brain,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +752,NCT04973930,Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Major Depressive Disorder; Breast Cancer; Venlafaxine,Interpersonal Psychotherapy (BEHAVIORAL); Venlafaxine HCl ER (DRUG),11672905,ATERENOL,Major Depressive Disorder; Breast Cancer; Venlafaxine,Breast,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +753,NCT06614322,SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.,NOT_YET_RECRUITING,PHASE2,Painful Peripheral Neuropathy; Diabetic Peripheral Neuropathic Pain (DPN); Chemotherapy Induced Peripheral Neuropathy (CIPN); Idiopathic Peripheral Neuropathy,Pregabalin (DRUG); Duloxetine (DRUG); Placebo (OTHER),11672905,ATERENOL,Painful Peripheral Neuropathy; Diabetic Peripheral Neuropathic Pain (DPN); Chemotherapy Induced Peripheral Neuropathy (CIPN); Idiopathic Peripheral Neuropathy,Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +754,NCT06715462,Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy,NOT_YET_RECRUITING,PHASE3,Painful Diabetic Peripheral Neuropathy (PDPN),N0750 (DRUG); Cymbalta® (DRUG); Lyrica® (DRUG),11672905,ATERENOL,Painful Diabetic Peripheral Neuropathy (PDPN),Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +755,NCT00205491,Pharmacological Intervention in Depression After Traumatic Brain Injury,COMPLETED,PHASE4,TBI (Traumatic Brain Injury),Venlafaxine (DRUG),11672905,ATERENOL,TBI (Traumatic Brain Injury),CNS/Brain,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +756,NCT06106529,REDucing Hot FLASHes in Women Using Endocrine Therapy.,RECRUITING,PHASE3,Breast Cancer; Hot Flash Due to Medication,Oxybutynin (DRUG); Venlafaxine (DRUG),11672905,ATERENOL,Breast Cancer; Hot Flash Due to Medication,Breast,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +757,NCT05840562,Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy,RECRUITING,PHASE3,Chemotherapy-induced Peripheral Neuropathy,Capsaicin (DRUG); Duloxetine (DRUG),11672905,ATERENOL,Chemotherapy-induced Peripheral Neuropathy,Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +758,NCT00401258,An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome,COMPLETED,PHASE4,Irritable Bowel Syndrome,duloxetine (DRUG),11672905,ATERENOL,Irritable Bowel Syndrome,Bowel,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +759,NCT05711810,Medicine-induced Cardiac Hemodialysis on COVID-19,COMPLETED,PHASE4,Severe Acute Respiratory Syndrome-related Coronavirus; Renal Dialysis; Vaccines; Myocarditis Allergic; Infection Viral,"Nifedipine 30 MG (DRUG); Kangzhu BPCB0A-3A (DIAGNOSTIC_TEST); Low Mobility (BEHAVIORAL); Enalapril Maleate 10Mg Tab (DRUG); Lansoprazole 30Mg Ec Cap (DRUG); Metoprolol Succinate (DRUG); Coenzyme Q10 (DIETARY_SUPPLEMENT); d-alpha tocopherol acetate (DIETARY_SUPPLEMENT); Omega-3 (DIETARY_SUPPLEMENT); Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release (DRUG); Superoxide Dismutase (DRUG)",11672905,ATERENOL,Severe Acute Respiratory Syndrome-related Coronavirus; Renal Dialysis; Vaccines; Myocarditis Allergic; Infection Viral,Lung,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +760,NCT02857244,A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients,WITHDRAWN,PHASE2,Parkinson's Disease,Duloxetine (DRUG); Donepezil (DRUG); Modafinil (DRUG),11672905,ATERENOL,Parkinson's Disease,CNS/Brain,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +761,NCT06407401,Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer,NOT_YET_RECRUITING,PHASE3,ER+ Breast Cancer; HER2-negative Breast Cancer; Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer Stage III; Drug-Related Side Effects and Adverse Reactions; Musculoskeletal Pain,Duloxetine 60 MG (DRUG); Furosemide 40 mg (DRUG); Booklet for healthy behaviors (BEHAVIORAL),11672905,ATERENOL,ER+ Breast Cancer; HER2-negative Breast Cancer; Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer Stage III; Drug-Related Side Effects and Adverse Reactions; Musculoskeletal Pain,Breast,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +762,NCT04560673,Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy,RECRUITING,PHASE2,Chemotherapy-Induced Peripheral Neuropathy; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm,Duloxetine (DRUG); Neurofeedback (BEHAVIORAL); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),11672905,ATERENOL,Chemotherapy-Induced Peripheral Neuropathy; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm,Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +763,NCT05875610,Preventive Approach Using Venlafaxine,UNKNOWN,PHASE4,Peripheral Neuropathy Due to Chemotherapy,Venlafaxine 75 MG (DRUG); Gabapentin 400 mg (DRUG),11672905,ATERENOL,Peripheral Neuropathy Due to Chemotherapy,Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +764,NCT01223001,Feasibility Study of Duloxetine in the Treatment of Depression in Patients With Traumatic Brain Injury,TERMINATED,PHASE2,Traumatic Brain Injury; Depression,Duloxetine (DRUG); Sugar pill (DRUG),11672905,ATERENOL,Traumatic Brain Injury; Depression,CNS/Brain,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +765,NCT01179672,A Study in Participants With Diabetic Peripheral Neuropathic Pain in China,COMPLETED,PHASE3,"Diabetic Neuropathy, Painful",Duloxetine (DRUG); Placebo (DRUG),11672905,ATERENOL,"Diabetic Neuropathy, Painful",Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +766,NCT00837941,A Study of Single Dose Pain Therapy in Patients With Painful Diabetic Neuropathy (0000-115),WITHDRAWN,PHASE2,Painful Diabetic Neuropathy,Comparator: A: Pregabalin (DRUG); Comparator: B: Duloxetine (DRUG); Comparator: C: Diphenhydramine hydrochloride (DRUG),11672905,ATERENOL,Painful Diabetic Neuropathy,Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +767,NCT04246619,"Efficacy of Pregabalin and Duloxetine in Patients With PDPN: the Effect of Pain on Cognitive Function, Sleep and Quality of Life",TERMINATED,PHASE4,Painful Diabetic Peripheral Neuropathy,Pregabalin (DRUG); Duloxetine (DRUG),11672905,ATERENOL,Painful Diabetic Peripheral Neuropathy,Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +768,NCT00507936,Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain,COMPLETED,PHASE2,"Diabetic Neuralgia; Diabetic Neuropathies; Diabetic Neuropathy, Painful; Diabetic Polyneuropathy; Neuralgia, Diabetic",ABT-894 (DRUG); ABT-894 (DRUG); ABT-894 (DRUG); placebo (DRUG); Duloxetine (DRUG),11672905,ATERENOL,"Diabetic Neuralgia; Diabetic Neuropathies; Diabetic Neuropathy, Painful; Diabetic Polyneuropathy; Neuralgia, Diabetic",Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +769,NCT00198250,Venlafaxine for Hot Flashes After Breast Cancer,COMPLETED,PHASE2,Breast Cancer,venlafaxine (DRUG),11672905,ATERENOL,Breast Cancer,Breast,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +770,NCT03812523,Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy,UNKNOWN,PHASE2,Chemotherapy-Induced Peripheral Neuropathy,Duloxetine 60 mg qd (DRUG); Lorcaserin (DRUG),11672905,ATERENOL,Chemotherapy-Induced Peripheral Neuropathy,Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +771,NCT01688570,Mechanisms of Neuromuscular Fatigue Post Stroke,COMPLETED,EARLY_PHASE1,Stroke,duloxetine (DRUG); Cyproheptadine (DRUG); Placebo (DRUG),11672905,ATERENOL,Stroke,CNS/Brain,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +772,NCT00266643,Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain,COMPLETED,PHASE4,"Diabetic Neuropathy, Painful",duloxetine hydrochloride (DRUG),11672905,ATERENOL,"Diabetic Neuropathy, Painful",Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +773,NCT01436643,Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression,TERMINATED,PHASE4,Depression; Relapsing-remitting Multiple Sclerosis,Venlafaxine (DRUG); Fluoxetine (DRUG); Citalopram (DRUG); Fingolimod (DRUG),11672905,ATERENOL,Depression; Relapsing-remitting Multiple Sclerosis,CNS/Brain,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +774,NCT03274817,A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol,TERMINATED,PHASE1,Alzheimer Disease,Escitalopram Pill (DRUG); Venlafaxine Pill (DRUG); Placebo Oral Tablet (DRUG),11672905,ATERENOL,Alzheimer Disease,CNS/Brain,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +775,NCT01089556,A Study in Painful Diabetic Neuropathy,COMPLETED,PHASE3,"Diabetic Neuropathy, Painful",Duloxetine (DRUG); Pregabalin (DRUG); Placebo (DRUG),11672905,ATERENOL,"Diabetic Neuropathy, Painful",Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +776,NCT05786599,Methadone to Treat Painful Chemotherapy Induced Peripheral Neuropathy,RECRUITING,PHASE2,Chemotherapy-induced Peripheral Neuropathy,methadone (DRUG); duloxetine (DRUG),11672905,ATERENOL,Chemotherapy-induced Peripheral Neuropathy,Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +777,NCT04294953,Efficacy of Perioperative Duloxetine as a Part of Multimodal Analgesia in Laparoscopic Colorectal Cancer Surgery,UNKNOWN,PHASE2,Colorectal Cancer,Duloxetine (DRUG); Placebo oral tablet (DRUG),11672905,ATERENOL,Colorectal Cancer,Bowel,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +778,NCT04137107,Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients with Stage II-III Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Stage II Colorectal Cancer AJCC V8; Stage III Colorectal Cancer AJCC V8,Oxaliplatin (DRUG); Duloxetine Hydrochloride (DRUG); Duloxetine (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); Placebo (OTHER),11672905,ATERENOL,Stage II Colorectal Cancer AJCC V8; Stage III Colorectal Cancer AJCC V8,Bowel,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +779,NCT00755807,Duloxetine for Multiple Sclerosis Pain,COMPLETED,PHASE3,Multiple Sclerosis,Duloxetine Hydrochloride (HCI) (DRUG); Placebo (DRUG),11672905,ATERENOL,Multiple Sclerosis,CNS/Brain,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +780,NCT00489411,Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer,COMPLETED,PHASE3,"Neurotoxicity; Pain; Peripheral Neuropathy; Unspecified Adult Solid Tumor, Protocol Specific",duloxetine hydrochloride (DRUG); placebo (OTHER),11672905,ATERENOL,"Neurotoxicity; Pain; Peripheral Neuropathy; Unspecified Adult Solid Tumor, Protocol Specific",Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +781,NCT01504178,Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease,COMPLETED,PHASE3,Parkinson's Disease,duloxetine (DRUG); placebo of duloxetine (DRUG); injection of apomorphine (DRUG); injection of placebo of apomorphine (DRUG); L-Dopa (DRUG); injection of placebo of L-Dopa (DRUG),11672905,ATERENOL,Parkinson's Disease,CNS/Brain,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +782,NCT00385671,An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain,COMPLETED,PHASE4,"Diabetic Neuropathy, Painful",duloxetine hydrochloride (DRUG); pregabalin (DRUG); gabapentin (DRUG),11672905,ATERENOL,"Diabetic Neuropathy, Painful",Peripheral Nervous System,Norepinephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1",activator/agonist,Adrenoceptor agonist,yes,yes,Approved for human use as a medication to treat low blood pressure.,C1=CC(=C(C=C1C(CN)O)O)O.Cl,1.03,2095.0 +783,NCT03131648,Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1),COMPLETED,PHASE3,Atopic Dermatitis,Tralokinumab (DRUG); Placebo (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +784,NCT06311682,A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis,RECRUITING,PHASE3,Atopic Dermatitis,Tralokinumab + TCS (DRUG); Placebo + TCS (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +785,NCT01297166,A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris,COMPLETED,PHASE1,Psoriasis Vulgaris,LEO 27989 ointment (DRUG); Calcipotriol plus LEO 27989 ointment (DRUG); Calcipotriol ointment (DRUG); Vehicle ointment (DRUG),5564,TCS,Psoriasis Vulgaris,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +786,NCT06224348,A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids,ACTIVE_NOT_RECRUITING,PHASE3,Dermatitis Atopic,Amlitelimab (DRUG); Placebo (DRUG); Topical corticosteroids (DRUG); Topical calcineurin inhibitors (DRUG),5564,TCS,Dermatitis Atopic,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +787,NCT05578482,Staphylococcus Aureus and The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis,UNKNOWN,PHASE4,Atopic Dermatitis; Atopic Dermatitis Eczema; Atopic Dermatitis Flare,Dicloxacillin Oral Capsule (DRUG); Elocon 0.1 % Topical Cream (DRUG),5564,TCS,Atopic Dermatitis; Atopic Dermatitis Eczema; Atopic Dermatitis Flare,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +788,NCT02008227,A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy,COMPLETED,PHASE3,Non-Squamous Non-Small Cell Lung Cancer,Atezolizumab (DRUG); Docetaxel (DRUG),5564,TCS,Non-Squamous Non-Small Cell Lung Cancer,Lung,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +789,NCT06701331,Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis,RECRUITING,PHASE3,Atopic Dermatitis,Placebo (DRUG); Upadacitinib (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +790,NCT02317276,A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal,TERMINATED,PHASE4,"Dermatitis, Atopic",Triamcinolone 0.1% (DRUG),5564,TCS,"Dermatitis, Atopic",Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +791,NCT04678882,Dupilumab in Japanese Patients With Atopic Dermatitis,COMPLETED,PHASE3,Atopic Dermatitis,Placebo (DRUG); Dupilumab SAR231893 (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +792,NCT01837576,An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris,COMPLETED,PHASE1,Psoriasis Vulgaris,Calcipotriol plus BDP gel in different doses (DRUG),5564,TCS,Psoriasis Vulgaris,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +793,NCT03733301,A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis,COMPLETED,PHASE3,Atopic Dermatitis,Baricitinib (DRUG); Topical corticosteroid (DRUG); Placebo (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +794,NCT01973322,"Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized ""Proof-of-principle"" Phase II Study",COMPLETED,PHASE2,Malignant Melanoma of Skin Stage III; Malignant Melanoma of Skin Stage IV,arm 1: DC Vaccine + RT (OTHER); arm 2: DC Vaccine + IFN-alfa (OTHER); arm 3: both arm 1 and 2 + RT (OTHER); arm 4: DC Vaccine (BIOLOGICAL),5564,TCS,Malignant Melanoma of Skin Stage III; Malignant Melanoma of Skin Stage IV,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +795,NCT05259722,A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema,COMPLETED,PHASE3,Chronic Hand Eczema,Delgocitinib (DRUG); Toctino (DRUG),5564,TCS,Chronic Hand Eczema,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +796,NCT04475939,Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE3,"Lung Cancer, Non-Small Cell",Niraparib (DRUG); Pembrolizumab (BIOLOGICAL); Placebo (DRUG),5564,TCS,"Lung Cancer, Non-Small Cell",Lung,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +797,NCT03864627,"A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis",TERMINATED,PHASE2,Atopic Dermatitis,MOR106 (DRUG); Placebo (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +798,NCT02718391,Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients.,TERMINATED,PHASE2,Malignant Melanoma; Adjuvant Drug Therapy; Vaccin Therapy,Autologous Dendritic Cell vaccine (BIOLOGICAL),5564,TCS,Malignant Melanoma; Adjuvant Drug Therapy; Vaccin Therapy,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +799,NCT02260986,Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis,COMPLETED,PHASE3,Atopic Dermatitis,Dupilumab (DRUG); Placebo (for Dupilumab) (DRUG); Topical Corticosteroid (TCS) (OTHER),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +800,NCT05222516,Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD,TERMINATED,PHASE2,Atopic Dermatitis,Broncho-Vaxom (DRUG); Placebo (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +801,NCT00121316,Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients,COMPLETED,PHASE4,Atopic Dermatitis,Pimecrolimus (DRUG); Placebo (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +802,NCT06280716,A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis,RECRUITING,PHASE3,Atopic Dermatitis,Placebo (DRUG); Lebrikizumab (DRUG); Topical Corticosteroid (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +803,NCT01539096,Brain Stimulation-aided Stroke Rehabilitation: Neural Mechanisms of Recovery,COMPLETED,PHASE1,Stroke,tDCS: noninvasive brain stimulation (PROCEDURE); Constraint induced movement therapy (CIMT) (BEHAVIORAL); Sham tDCS: placebo noninvasive brain stimulation (PROCEDURE),5564,TCS,Stroke,CNS/Brain,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +804,NCT06504160,Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2),RECRUITING,PHASE1,Atopic Dermatitis,ShA9 Topical Gel (DRUG); Hydrocortisone Ointment (DRUG); Clobetasol Ointment (DRUG); Fluocinonide Ointment (DRUG); Placebo (Vehicle) Topical Gel (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +805,NCT04263610,Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy,COMPLETED,PHASE4,Plaque Psoriasis,Dimethyl fumarate (DMF) standard scheme (DRUG); Dimethyl fumarate (DMF) simplified scheme (DRUG); Tildrakizumab (DRUG),5564,TCS,Plaque Psoriasis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +806,NCT00845481,A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris,COMPLETED,PHASE2,Psoriasis Vulgaris,Daivobet® ointment (DRUG); Betnovat® ointment (DRUG); Diprosalic ointment (DRUG); Dermovat ointment (DRUG); Elocon ointment (DRUG); Daivobet® ointment vehicle (DRUG),5564,TCS,Psoriasis Vulgaris,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +807,NCT03100344,Dose-ranging Study of Nemolizumab in Atopic Dermatitis,COMPLETED,PHASE2,Atopic Dermatitis,Nemolizumab (DRUG); Placebo (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +808,NCT01639040,Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD),COMPLETED,PHASE2,Atopic Dermatitis,Dupilumab (DRUG); Placebo (for Dupilumab) (DRUG); Topical Corticosteroid (TCS) (OTHER),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +809,NCT02919644,Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.,RECRUITING,PHASE2,Stage IV Colorectal Cancer; Curative Resection,autologous dendritic cells loaded with autologous tumour homogenate (BIOLOGICAL); IL2 (DRUG),5564,TCS,Stage IV Colorectal Cancer; Curative Resection,Bowel,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +810,NCT03539601,"A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD",TERMINATED,PHASE4,Atopic Dermatitis,"Crisaborole ointment, 2% (DRUG); Hydrocortisone butyrate cream, 0.1% (DRUG); Pimecrolimus cream, 1% (DRUG); Crisaborole Vehicle (DRUG)",5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +811,NCT05916365,Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis,ACTIVE_NOT_RECRUITING,PHASE3,Atopic Dermatitis,Lebrikizumab (BIOLOGICAL),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +812,NCT02416258,A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123),COMPLETED,PHASE2,Skin and Connective Tissue Diseases,LP0113 aerosol spray (DRUG); Aerosol spray vehicle (DRUG); LEO 90100 aerosol foam (DRUG); Betamethasone dipropionate aerosol spray (DRUG); Calcipotriol aerosol spray (DRUG); Daivobet® gel (DRUG),5564,TCS,Skin and Connective Tissue Diseases,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +813,NCT02340234,A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis,COMPLETED,PHASE2,Atopic Dermatitis,Lebrikizumab (DRUG); Placebo (DRUG); TCS Cream (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +814,NCT06238817,"A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis",RECRUITING,PHASE3,Atopic Dermatitis,Ruxolitinib Cream (DRUG); Vehicle Cream (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +815,NCT03346434,"Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)",COMPLETED,PHASE2,"Dermatitis, Atopic",Dupilumab (DRUG); Matching placebo (DRUG),5564,TCS,"Dermatitis, Atopic",Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +816,NCT03568318,A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis,ENROLLING_BY_INVITATION,PHASE3,Atopic Dermatitis,Placebo (DRUG); Upadacitinib (DRUG); Topical corticosteroids (TCS) (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +817,NCT06241118,A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor,RECRUITING,PHASE3,Dermatitis Atopic,Amlitelimab (DRUG); Placebo (DRUG); Topical corticosteroids (DRUG); Topical tacrolimus or pimecrolimus (DRUG),5564,TCS,Dermatitis Atopic,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +818,NCT02755649,A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable,COMPLETED,PHASE3,Atopic Dermatitis,Dupilumab (DRUG); Matching Placebo (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +819,NCT01759810,Proteome-based Personalized Immunotherapy of Glioblastoma,UNKNOWN,PHASE2,Glioblastoma,"Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes (BIOLOGICAL); Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes (BIOLOGICAL)",5564,TCS,Glioblastoma,CNS/Brain,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +820,NCT00121381,Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis,COMPLETED,PHASE4,"Dermatitis, Atopic",Pimecrolimus plus topical corticosteroid (TCS) (DRUG); Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS) (DRUG),5564,TCS,"Dermatitis, Atopic",Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +821,NCT01347255,"A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris",COMPLETED,PHASE2,Psoriasis Vulgaris,"LEO90100 cutaneous spray, ointment (DRUG); LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate (DRUG); LEO 90100 cutaneous spray, ointment, vehicle (DRUG); Daivobet® ointment (DRUG)",5564,TCS,Psoriasis Vulgaris,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +822,NCT00120523,5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis,COMPLETED,PHASE3,Atopic Dermatitis,Pimecrolimus (DRUG); Topical corticosteroids (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +823,NCT03553823,Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab,COMPLETED,PHASE2,Chronic Plaque-type Psoriasis,Skin biopsies (PROCEDURE),5564,TCS,Chronic Plaque-type Psoriasis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +824,NCT03345914,Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD),COMPLETED,PHASE3,"Dermatitis, Atopic",Dupilumab (DRUG); Matching Placebo (DRUG); Background Treatment: Topical Corticosteroids (OTHER); Background Treatment: Moisturizers (OTHER),5564,TCS,"Dermatitis, Atopic",Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +825,NCT03226236,Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC,WITHDRAWN,PHASE2,"Carcinoma, Renal Cell; Vaccination; Secondary",boost radiotherapy (XRT) (RADIATION); Autologous DC vaccine (BIOLOGICAL); High-Dose IL-2 (DRUG),5564,TCS,"Carcinoma, Renal Cell; Vaccination; Secondary",Kidney,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +826,NCT05724199,A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD),COMPLETED,PHASE3,Atopic Dermatitis,Rocatinlimab (DRUG); Placebo (OTHER),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +827,NCT05018806,Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis,COMPLETED,PHASE2,Atopic Dermatitis,Placebo (DRUG); Rilzabrutinib (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +828,NCT02465606,A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis,COMPLETED,PHASE2,Atopic Dermatitis,Lebrikizumab (DRUG); Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%) (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +829,NCT04202679,"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)",COMPLETED,PHASE3,Neurodermatitis,Dupilumab SAR231893 (DRUG); Placebo (DRUG); Moisturizers (DRUG); Low to medium potent topical corticosteroids (DRUG); Topical calcineurin inhibitors (DRUG),5564,TCS,Neurodermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +830,NCT06193421,High-Dose Ambroxol in GBA1-Related Parkinson,RECRUITING,PHASE1,Parkinson Disease; GBA Gene Mutation,Ambroxol Hydrochloride (DRUG),5564,TCS,Parkinson Disease; GBA Gene Mutation,CNS/Brain,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +831,NCT00422903,Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer,COMPLETED,PHASE2,"Neoplasms, Breast",lapatinib (DRUG); letrozole (DRUG); placebo (OTHER),5564,TCS,"Neoplasms, Breast",Breast,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +832,NCT03661138,A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis,COMPLETED,PHASE3,Atopic Dermatitis,Upadacitinib (DRUG); Placebo for upadacitinib (DRUG); Topical Corticosteroids (TCS) (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +833,NCT05056779,Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable,WITHDRAWN,PHASE3,Moderate-to-severe Atopic Dermatitis,Nemolizumab (DRUG); CD14152 placebo (DRUG),5564,TCS,Moderate-to-severe Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +834,NCT05704738,A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD),ACTIVE_NOT_RECRUITING,PHASE3,Atopic Dermatitis,Rocatinlimab (DRUG); Placebo (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +835,NCT02518048,A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris,COMPLETED,PHASE2,Skin and Connective Tissue Diseases,LEO 90100 Aerosol foam (DRUG); Betesil® 2.25 mg (DRUG),5564,TCS,Skin and Connective Tissue Diseases,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +836,NCT03952559,A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis,ACTIVE_NOT_RECRUITING,PHASE3,Atopic Dermatitis,Baricitinib (DRUG); Placebo (DRUG); Topical corticosteroid (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +837,NCT04183335,"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)",COMPLETED,PHASE3,Neurodermatitis,Dupilumab SAR231893 (DRUG); Placebo (DRUG); Moisturizers (DRUG); Low to medium potent topical corticosteroids (DRUG); Topical calcineurin inhibitors (DRUG),5564,TCS,Neurodermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +838,NCT03809663,A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis,TERMINATED,PHASE2,Atopic Dermatitis,Tezepelumab (DRUG); Placebo (OTHER),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +839,NCT03948334,A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients,TERMINATED,PHASE2,Atopic Dermatitis,ZPL389 30mg (DRUG); ZPL389 50mg (DRUG); TCS and/or TCI (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +840,NCT05149313,A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine,COMPLETED,PHASE3,"Dermatitis, Atopic; Eczema",Lebrikizumab (BIOLOGICAL); Lebrikizumab-matching Placebo (DRUG),5564,TCS,"Dermatitis, Atopic; Eczema",Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +841,NCT05559359,A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis,RECRUITING,PHASE3,Atopic Dermatitis; Eczema,Lebrikizumab (DRUG); Placebo (DRUG); Topical Corticosteroid (TCS) (DRUG),5564,TCS,Atopic Dermatitis; Eczema,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +842,NCT03428100,A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable,COMPLETED,PHASE3,Atopic Dermatitis,Baricitinib (DRUG); Placebo (DRUG); Topical corticosteroid (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +843,NCT03160885,Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2),COMPLETED,PHASE3,Atopic Dermatitis,Tralokinumab (DRUG); Placebo (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +844,NCT03761537,Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7,COMPLETED,PHASE3,Atopic Dermatitis,Tralokinumab (DRUG); Placebo (OTHER),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +845,NCT04776447,Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO),ACTIVE_NOT_RECRUITING,PHASE2,"Lung Diseases; Carcinoma, Non-Small-Cell Lung; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Respiratory Tract Neoplasms; Carcinoma Bronchiogenic Stage III; Thoracic Neoplasms",Carboplatin (DRUG); Placlitaxel (DRUG); Atezolizumab (DRUG),5564,TCS,"Lung Diseases; Carcinoma, Non-Small-Cell Lung; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Respiratory Tract Neoplasms; Carcinoma Bronchiogenic Stage III; Thoracic Neoplasms",Lung,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +846,NCT05905133,A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD,ACTIVE_NOT_RECRUITING,PHASE2,Atopic Dermatitis,CBP-201 (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +847,NCT04587453,Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis,COMPLETED,PHASE3,Atopic Dermatitis,Tralokinumab (DRUG); Placebo (DRUG); Topical corticosteroids (TCS) (OTHER),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +848,NCT00875277,A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products,COMPLETED,PHASE2,Psoriasis Vulgaris,LEO 29102 cream (DRUG); LEO 29102 Cream Vehicle (DRUG); Betamethasone Dipropionate Cream (DRUG); LEO 29102 Plus Calcipotriol Cream (DRUG); LEO 29102 Plus Betamethasone Dipropionate (DRUG); Daivobet® Ointment (DRUG),5564,TCS,Psoriasis Vulgaris,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +849,NCT04250337,Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.,COMPLETED,PHASE3,Atopic Dermatitis,Lebrikizumab (BIOLOGICAL); Placebo (OTHER); Topical Corticosteroid (OTHER),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +850,NCT02577185,An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A,COMPLETED,PHASE1,Psoriasis Vulgaris,Botulinum Toxin Type A (DRUG); Sodium chloride 9 mg/ml (DRUG),5564,TCS,Psoriasis Vulgaris,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +851,NCT05387707,Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis,TERMINATED,PHASE3,Pruritus; Atopic Dermatitis,difelikefalin 0.25 mg (DRUG); difelikefalin 0.5 mg (DRUG); TCS Cream (DRUG); Placebo (DRUG); Vehicle Cream (DRUG),5564,TCS,Pruritus; Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +852,NCT03921411,A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD),COMPLETED,PHASE2,Atopic Dermatitis,Nemolizumab (BIOLOGICAL),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +853,NCT03942211,A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag,TERMINATED,PHASE2,Sarcoidosis-associated Pulmonary Hypertension,Selexipag (DRUG); Placebo (DRUG),5564,TCS,Sarcoidosis-associated Pulmonary Hypertension,Lung,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +854,NCT02655198,Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy,ACTIVE_NOT_RECRUITING,PHASE2,Epilepsy; Lennox Gastaut Syndrome,Fenfluramine (DRUG),5564,TCS,Epilepsy; Lennox Gastaut Syndrome,CNS/Brain,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +855,NCT06554847,Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis,RECRUITING,PHASE3,"Dermatitis, Atopic; Eczema, Atopic",611 (DRUG); Placebo (DRUG); Topical corticosteroid (DRUG),5564,TCS,"Dermatitis, Atopic; Eczema, Atopic",Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +856,NCT01466478,"An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris",COMPLETED,PHASE1,Psoriasis Vulgaris,Ointment A: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment (DRUG); Ointment B: LEO 29102 2.5 mg/g ointment (DRUG); Ointment C: Calcipotriol 50 µg/g ointment (DRUG); Ointment D: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment (DRUG); Ointment G: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment (DRUG); Daivonex® ointment (DRUG); Diprosone® ointment (DRUG),5564,TCS,Psoriasis Vulgaris,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +857,NCT06850311,Herbal Ointment in Treating Atopic Dermatitis Topically,RECRUITING,PHASE2,"Atopic Dermatitis; Atopic Dermatitis (AD); Atopic Dermatitis (Eczema); Atopic Dermatitis Eczema; TCM; Skin Diseases; Skin Diseases, Eczematous; Skin Diseases, Genetic",herbal ointment (DRUG); Placebo (DRUG),5564,TCS,"Atopic Dermatitis; Atopic Dermatitis (AD); Atopic Dermatitis (Eczema); Atopic Dermatitis Eczema; TCM; Skin Diseases; Skin Diseases, Eczematous; Skin Diseases, Genetic",Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +858,NCT03363854,Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3,COMPLETED,PHASE3,Atopic Dermatitis,Tralokinumab (DRUG); Placebo (DRUG),5564,TCS,Atopic Dermatitis,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +859,NCT03246776,Microbial Colonization and Change of Chronic Keratinized Hand Eczema After Using Halometasone Triclosan,COMPLETED,PHASE4,Chronic Hand Eczema,Halometasone Triclosan (DRUG),5564,TCS,Chronic Hand Eczema,Skin,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +860,NCT00768222,Coated VICRYL* Plus Suture Compared to Chinese Silk in Scheduled Breast Cancer Surgery,COMPLETED,PHASE4,Breast Cancer,silk suture (DEVICE); VICRYL* Plus suture (DEVICE),5564,TCS,Breast Cancer,Breast,Triclosan,,inhibitor/antagonist,unclear,no,yes,Banned in soaps; used in some consumer products and healthcare settings.,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,1.1,1232.0 +861,NCT00002474,Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer,COMPLETED,PHASE2,Ovarian Cancer,carboplatin (DRUG); cyclophosphamide (DRUG); mitoxantrone hydrochloride (DRUG); autologous bone marrow transplantation (PROCEDURE); bone marrow ablation with stem cell support (PROCEDURE),51082,DHAD,Ovarian Cancer,Ovary/Fallopian Tube,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +862,NCT02596373,A Study of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer,UNKNOWN,PHASE2,Advanced Recurrent or Metastatic Breast Cancer,Mitoxantrone Hydrochloride Liposome Injection (DRUG),51082,DHAD,Advanced Recurrent or Metastatic Breast Cancer,Breast,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +863,NCT00203073,A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.,COMPLETED,PHASE2,Relapsing Remitting Multiple Sclerosis,"glatiramer acetate 20 mg (DRUG); glatiramer acetate 20 mg, with mitoxantrone (DRUG)",51082,DHAD,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +864,NCT04718376,A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer,TERMINATED,PHASE1,Platinum-resistant Ovarian Cancer,"Mitoxantrone Hydrochloride Liposome, intravenous injection (IV) (DRUG)",51082,DHAD,Platinum-resistant Ovarian Cancer,Ovary/Fallopian Tube,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +865,NCT00003068,"High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer",COMPLETED,PHASE2,Breast Cancer; Drug/Agent Toxicity by Tissue/Organ,amifostine trihydrate (DRUG); cyclophosphamide (DRUG); mitoxantrone hydrochloride (DRUG); thiotepa (DRUG); peripheral blood stem cell transplantation (PROCEDURE),51082,DHAD,Breast Cancer; Drug/Agent Toxicity by Tissue/Organ,Breast,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +866,NCT01142466,A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone,COMPLETED,PHASE4,"Multiple Sclerosis, Relapsing-Remitting",Interferon beta-1a (Rebif) (DRUG),51082,DHAD,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +867,NCT05100329,A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer,UNKNOWN,PHASE2,Advanced Pancreatic Cancer,Mitoxantrone Hydrochloride Liposome injection (DRUG),51082,DHAD,Advanced Pancreatic Cancer,Pancreas,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +868,NCT00003080,Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer,COMPLETED,PHASE1,Ovarian Cancer,endocrine-modulating drug therapy (DRUG); melphalan (DRUG); mitoxantrone hydrochloride (DRUG); tamoxifen citrate (DRUG); thiotepa (DRUG); peripheral blood stem cell transplantation (PROCEDURE),51082,DHAD,Ovarian Cancer,Ovary/Fallopian Tube,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +869,NCT05496894,A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis,WITHDRAWN,PHASE2,Relapsing Multiple Sclerosis,Mitoxantrone Hydrochloride Liposome Injection (DRUG),51082,DHAD,Relapsing Multiple Sclerosis,CNS/Brain,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +870,NCT00002544,Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer,COMPLETED,PHASE3,Breast Cancer,docetaxel (DRUG); mitoxantrone hydrochloride (DRUG),51082,DHAD,Breast Cancer,Breast,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +871,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,75 approved agents (DRUG); COXEN (OTHER),51082,DHAD,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,Bladder/Urinary Tract,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +872,NCT00002819,Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer,TERMINATED,PHASE3,Ovarian Cancer,carboplatin (DRUG); cyclophosphamide (DRUG); mitoxantrone hydrochloride (DRUG); paclitaxel (DRUG); autologous bone marrow transplantation (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE),51082,DHAD,Ovarian Cancer,Ovary/Fallopian Tube,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +873,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,COMPLETED,PHASE4,Multiple Sclerosis,Several diagnostic procedures (PROCEDURE),51082,DHAD,Multiple Sclerosis,CNS/Brain,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +874,NCT04352413,A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy,TERMINATED,PHASE2,Small Cell Lung Cancer,PLM60 (DRUG),51082,DHAD,Small Cell Lung Cancer,Lung,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +875,NCT00219908,Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis,TERMINATED,PHASE2,Relapsing-Remitting Multiple Sclerosis,Mitoxantrone (DRUG),51082,DHAD,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +876,NCT04927481,A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Mitoxantrone Hydrochloride Liposome Injection (DRUG),51082,DHAD,Breast Cancer,Breast,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +877,NCT00273364,Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study,COMPLETED,PHASE2,Multiple Sclerosis,Hematopoietic Stem Cell Therapy (PROCEDURE); Standard treatment with a conventional drug (DRUG),51082,DHAD,Multiple Sclerosis,CNS/Brain,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +878,NCT01779479,Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE),COMPLETED,PHASE2,Primary Breast Cancer,Cabacitaxel (DRUG); Paclitaxel (DRUG),51082,DHAD,Primary Breast Cancer,Breast,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +879,NCT04331743,A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC,UNKNOWN,PHASE1,Advanced Hepatocellular Carcinoma,Liposome-entrapped Mitoxantrone Hydrochloride Injection (DRUG),51082,DHAD,Advanced Hepatocellular Carcinoma,Liver,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +880,NCT01627938,Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in Combination,UNKNOWN,PHASE2,Multiple Sclerosis,Dexrazoxane (DRZ) plus Mitoxantrone (MX) (DRUG); Placebo plus Mitoxantrone (MX) (DRUG),51082,DHAD,Multiple Sclerosis,CNS/Brain,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +881,NCT00146159,Study Evaluating Mitoxantrone in Multiple Sclerosis,TERMINATED,PHASE3,Secondary Progressive Multiple Sclerosis,Mitoxantrone (DRUG),51082,DHAD,Secondary Progressive Multiple Sclerosis,CNS/Brain,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +882,NCT00010075,Combination Chemotherapy in Treating Older Women With Metastatic Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,fluorouracil (DRUG); leucovorin calcium (DRUG); mitoxantrone hydrochloride (DRUG),51082,DHAD,Breast Cancer,Breast,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +883,NCT02937285,"National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis",COMPLETED,PHASE3,Multiple Sclerosis,Interferon beta 1a (DRUG); Mitoxantrone (DRUG),51082,DHAD,Multiple Sclerosis,CNS/Brain,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +884,NCT00004237,Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer,COMPLETED,PHASE2,Breast Cancer,cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); epirubicin hydrochloride (DRUG); mitoxantrone hydrochloride (DRUG); vinorelbine tartrate (DRUG); conventional surgery (PROCEDURE); radiation therapy (RADIATION),51082,DHAD,Breast Cancer,Breast,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +885,NCT00003032,High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer,COMPLETED,PHASE3,Breast Cancer,filgrastim (BIOLOGICAL); cisplatin (DRUG); cyclophosphamide (DRUG); mitoxantrone hydrochloride (DRUG); tamoxifen citrate (DRUG),51082,DHAD,Breast Cancer,Breast,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +886,NCT06475287,HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma,NOT_YET_RECRUITING,PHASE2,Hepatocellular Carcinoma,HAIC（Mitoxantrone+Raltitrexed）、anlotinib、TQB2450 (DRUG),51082,DHAD,Hepatocellular Carcinoma,Liver,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +887,NCT00003893,Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer,COMPLETED,PHASE3,Breast Cancer,CMF regimen (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); methotrexate (DRUG); mitomycin C (DRUG); mitoxantrone hydrochloride (DRUG); adjuvant therapy (PROCEDURE); radiation therapy (RADIATION),51082,DHAD,Breast Cancer,Breast,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +888,NCT00003297,Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer,COMPLETED,PHASE1,Ovarian Cancer,mitoxantrone hydrochloride (DRUG); thiotepa (DRUG); topotecan hydrochloride (DRUG); peripheral blood stem cell transplantation (PROCEDURE),51082,DHAD,Ovarian Cancer,Ovary/Fallopian Tube,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +889,NCT00002498,Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,CMF regimen (DRUG); cyclophosphamide (DRUG); fluorouracil (DRUG); methotrexate (DRUG); mitoxantrone hydrochloride (DRUG),51082,DHAD,Breast Cancer,Breast,Mitoxantrone (dihydrochloride),"TOP2A, TOP2B, PRKCA",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer and multiple sclerosis treatment.,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,, +890,NCT00000974,A Study of Two Forms of Pentamidine in HIV-Infected Children Who May Have Pneumocystis Carinii Pneumonia,COMPLETED,PHASE1,"Pneumonia, Pneumocystis Carinii; HIV Infections",Pentamidine isethionate (DRUG),8813,PENTAM,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +891,NCT02210182,A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma,COMPLETED,PHASE1,Hepatocellular Carcinoma,Oral Pentamidine (DRUG); Placebo (OTHER),8813,PENTAM,Hepatocellular Carcinoma,Liver,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +892,NCT00001027,A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Children Who Cannot Take Trimethoprim-Sulfamethoxazole,COMPLETED,PHASE1,"Pneumonia, Pneumocystis Carinii; HIV Infections",Pentamidine isethionate (DRUG),8813,PENTAM,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +893,NCT00000730,Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients,TERMINATED,PHASE3,"Pneumonia, Pneumocystis Carinii; HIV Infections",Trimetrexate glucuronate (DRUG); Methylprednisolone (DRUG); Pentamidine isethionate (DRUG); Sulfamethoxazole-Trimethoprim (DRUG); Leucovorin calcium (DRUG),8813,PENTAM,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +894,NCT00000739,Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection,COMPLETED,PHASE1,"Pneumonia, Pneumocystis Carinii; HIV Infections",Dapsone (DRUG),8813,PENTAM,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +895,NCT00000991,A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients,COMPLETED,PHASE3,"Pneumonia, Pneumocystis Carinii; HIV Infections",Pentamidine isethionate (DRUG); Sulfamethoxazole-Trimethoprim (DRUG); Dapsone (DRUG); Zidovudine (DRUG),8813,PENTAM,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +896,NCT01844791,An Exploratory Study of OCZ103-OS in Combination With Standard of Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients,COMPLETED,PHASE2,Non-small Cell Lung Cancer,OCZ103-OS (DRUG); Platinum (DRUG); Gemcitabine (DRUG),8813,PENTAM,Non-small Cell Lung Cancer,Lung,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +897,NCT00636935,Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP),WITHDRAWN,PHASE4,Pneumocystis Carinii Pneumonia,Antibiotics only (DRUG); Antibiotics + Corticosteroids (DRUG); Corticosteroids + antibiotics (DRUG),8813,PENTAM,Pneumocystis Carinii Pneumonia,Lung,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +898,NCT00001996,A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole,COMPLETED,PHASE2,"Pneumonia, Pneumocystis Carinii; HIV Infections",Atovaquone (DRUG); Pentamidine isethionate (DRUG),8813,PENTAM,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +899,NCT00001016,A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies,COMPLETED,PHASE3,"Pneumonia, Pneumocystis Carinii; HIV Infections",Trimetrexate glucuronate (DRUG); Leucovorin calcium (DRUG),8813,PENTAM,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +900,NCT00809796,A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment,COMPLETED,PHASE1,Colorectal Cancer,pentamidine (DRUG),8813,PENTAM,Colorectal Cancer,Bowel,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +901,NCT00000727,A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT),COMPLETED,PHASE3,"Pneumonia, Pneumocystis Carinii; HIV Infections",Pentamidine isethionate (DRUG); Pyrimethamine (DRUG); Sulfamethoxazole/Trimethoprim (DRUG); Sulfadoxine/Pyrimethamine (DRUG); Zidovudine (DRUG),8813,PENTAM,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +902,NCT00000724,A Study of Trimetrexate With Leucovorin Rescue for AIDS Patients Who Are Refractory to Standard Therapies for Pneumocystis Carinii Pneumonia,COMPLETED,PHASE3,"Pneumonia, Pneumocystis Carinii; HIV Infections",Trimetrexate glucuronate (DRUG); Leucovorin calcium (DRUG),8813,PENTAM,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +903,NCT00002340,A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX,COMPLETED,PHASE3,"Pneumonia, Pneumocystis Carinii; HIV Infections",Atovaquone (DRUG); Pentamidine isethionate (DRUG),8813,PENTAM,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +904,NCT00000655,"A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients",COMPLETED,PHASE2,"Pneumonia, Pneumocystis Carinii; HIV Infections",Atovaquone (DRUG); Sulfamethoxazole-Trimethoprim (DRUG),8813,PENTAM,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +905,NCT00000714,"An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies",COMPLETED,PHASE3,"Pneumonia, Pneumocystis Carinii; HIV Infections",Trimetrexate glucuronate (DRUG); Leucovorin calcium (DRUG),8813,PENTAM,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +906,NCT01378143,Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy,COMPLETED,PHASE2,Colorectal Cancer,"OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI (DRUG)",8813,PENTAM,Colorectal Cancer,Bowel,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +907,NCT03403621,Hypertrophic Scar Prevention by Novel Topical Gel Application,TERMINATED,PHASE1,Hypertrophic Scar,Pentamidine Isethionate (DRUG); Placebo (DRUG),8813,PENTAM,Hypertrophic Scar,Skin,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +908,NCT00078559,Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults,COMPLETED,PHASE1,Kidney Transplantation; Kidney Disease,"Alemtuzumab (DRUG); Sirolimus (DRUG); Tacrolimus (DRUG); Kidney transplant (PROCEDURE); Methylprednisolone (or equivalent) (DRUG); Acetaminophen (DRUG); Diphenhydramine (DRUG); Trimethoprim (TMP)/Sulfa (Bactrim, Septra) (DRUG); Valgancyclovir (DRUG); Acyclovir (DRUG); Pentamidine (DRUG); Clotrimazole (DRUG); Nystatin (DRUG)",8813,PENTAM,Kidney Transplantation; Kidney Disease,Kidney,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +909,NCT00001013,Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS,COMPLETED,PHASE3,"Pneumonia, Pneumocystis Carinii; HIV Infections",Trimetrexate glucuronate (DRUG); Pentamidine isethionate (DRUG); Sulfamethoxazole-Trimethoprim (DRUG); Leucovorin calcium (DRUG),8813,PENTAM,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +910,NCT00141037,Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation,COMPLETED,PHASE1,Kidney Diseases; Kidney Transplantation; Kidney Transplant; Renal Transplantation; Renal Transplant,Daclizumab (DRUG); Mycophenolate mofetil (MMF) (DRUG); Prednisone (DRUG); Tacrolimus (DRUG); Ganciclovir (DRUG); Valganciclovir (DRUG); Trimethoprim and sulfamethoxazole (DRUG),8813,PENTAM,Kidney Diseases; Kidney Transplantation; Kidney Transplant; Renal Transplantation; Renal Transplant,Kidney,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +911,NCT00000715,A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia in AIDS,COMPLETED,PHASE3,"Pneumonia, Pneumocystis Carinii; HIV Infections",Pentamidine isethionate (DRUG); Sulfamethoxazole-Trimethoprim (DRUG),8813,PENTAM,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +912,NCT00810953,A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy,COMPLETED,PHASE1,Pancreatic Cancer,Pentamidine (DRUG),8813,PENTAM,Pancreatic Cancer,Pancreas,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +913,NCT00729807,0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma,TERMINATED,PHASE2,Melanoma (Skin),pentamidine (DRUG),8813,PENTAM,Melanoma (Skin),Skin,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +914,NCT00001028,A Study of Pentamidine Plus Dapsone in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients Who Cannot Take Trimethoprim or Sulfonamides,COMPLETED,PHASE3,"Pneumonia, Pneumocystis Carinii; HIV Infections",Pentamidine isethionate (DRUG); Dapsone (DRUG),8813,PENTAM,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Pentamidine (isethionate),PRLR,inhibitor/antagonist,unclear,yes,yes,Used to treat Pneumocystis pneumonia and African trypanosomiasis.,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,1.08,371.0 +915,NCT03175666,QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy,WITHDRAWN,PHASE1,Triple Negative Breast Cancer,avelumab (BIOLOGICAL); bevacizumab (BIOLOGICAL); capecitabine (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG); nab-paclitaxel (DRUG); Lovaza (DRUG); Stereotactic Body Radiation Therapy (RADIATION); ALT-803 (BIOLOGICAL); ETBX-011 (BIOLOGICAL); ETBX-051 (BIOLOGICAL); ETBX-061 (BIOLOGICAL); GI-4000 (BIOLOGICAL); GI-6207 (BIOLOGICAL); GI-6301 (BIOLOGICAL); haNK (BIOLOGICAL),135398658,PGA,Triple Negative Breast Cancer,Breast,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +916,NCT01490866,A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC),COMPLETED,PHASE2,Colorectal Cancer,Axitinib (DRUG); Bevacizumab (DRUG); 5-Fluorouracil (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG),135398658,PGA,Colorectal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +917,NCT02315326,"Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)",RECRUITING,PHASE1,Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL); Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL),Ibrutinib (DRUG); HD- Methotrexate (MTX) (DRUG); Rituximab + HD- Methotrexate (MTX) (DRUG); procarbazine (DRUG),135398658,PGA,Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL); Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL),CNS/Brain,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +918,NCT01303926,Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer,UNKNOWN,PHASE3,Non-squamous Nonsmall Cell Neoplasm of Lung,cisplatin pemetrexed (DRUG); carboplatin paclitaxel bevacizumab (DRUG),135398658,PGA,Non-squamous Nonsmall Cell Neoplasm of Lung,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +919,NCT00942266,"Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment",COMPLETED,PHASE2,Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer,fluorouracil (DRUG); leucovorin calcium (DRUG); vorinostat (DRUG); pharmacological study (OTHER),135398658,PGA,Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +920,NCT04198766,Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist),RECRUITING,PHASE1,Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer; Melanoma; Gastric Cancer; Renal Cell Carcinoma; Urothelial Carcinoma,INBRX-106 - Hexavalent OX40 agonist antibody (DRUG); pembrolizumab 200 mg (DRUG); pembrolizumab 400 mg (DRUG); Carboplatin AUC-5 (DRUG); Carboplatin AUC-6 (DRUG); Pemetrexed 500 mg/m2 (DRUG); Cisplatin 75mg/m2 (DRUG); Paclitaxel 200mg/m2 (DRUG); Nab paclitaxel 100mg/m2 (DRUG),135398658,PGA,Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer; Melanoma; Gastric Cancer; Renal Cell Carcinoma; Urothelial Carcinoma,Bladder/Urinary Tract,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +921,NCT01107457,A Study in Participants With Moderate to Severe Psoriasis,COMPLETED,PHASE2,Psoriasis,Ixekizumab (BIOLOGICAL); Placebo (DRUG),135398658,PGA,Psoriasis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +922,NCT00470548,Abraxane and Alimta in Advanced Solid Tumors,TERMINATED,PHASE1,"Breast Cancer; Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Abraxane (DRUG); Alimta (DRUG),135398658,PGA,Breast and Lung Cancer,Breast,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +923,NCT03563157,QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine,TERMINATED,PHASE1,Colorectal Cancer Metastatic; mCRC,Aldoxorubicin Hydrochloride (BIOLOGICAL); ALT-803 (BIOLOGICAL); ETBX-011 (BIOLOGICAL); ETBX-021 (BIOLOGICAL); ETBX-051 (BIOLOGICAL); ETBX-061 (BIOLOGICAL); GI-4000 (BIOLOGICAL); GI-6207 (BIOLOGICAL); GI-6301 (BIOLOGICAL); haNK (BIOLOGICAL); Avelumab (DRUG); Capecitabine (DRUG); Cetuximab (DRUG); Cyclophosphamide (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG); Nab-paclitaxel (DRUG); Oxaliplatin (DRUG); Regorafenib (DRUG); SBRT (PROCEDURE),135398658,PGA,Colorectal Cancer Metastatic; mCRC,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +924,NCT03398148,"A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis",COMPLETED,PHASE2,Ulcerative Colitis (UC),risankizumab IV (DRUG); placebo for risankizumab (DRUG); risankizumab SC (DRUG),135398658,PGA,Ulcerative Colitis,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +925,NCT03122457,Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide,COMPLETED,PHASE2,Actinic Keratosis,lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination (DRUG),135398658,PGA,Actinic Keratosis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +926,NCT02624726,Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,5 Fluorouracil (DRUG); Leucovorin (DRUG); Irinotecan (DRUG); Aflibercept (DRUG),135398658,PGA,Metastatic Colorectal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +927,NCT00475657,Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer,TERMINATED,PHASE2,Small Cell Lung Cancer,pemetrexed (DRUG); cisplatin (DRUG),135398658,PGA,Small Cell Lung Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +928,NCT04396457,Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901,UNKNOWN,PHASE2,"Non-squamous Non-small-cell Lung Cancer; Cancer, Lung",Pembrolizumab (DRUG); Pemetrexed (DRUG),135398658,PGA,"Non-squamous Non-small-cell Lung Cancer; Cancer, Lung",Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +929,NCT04617457,Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas,RECRUITING,PHASE2,Pancreatic Cancer; Metastasis; Surgery; Oligometastatic Disease,"nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA) (DRUG)",135398658,PGA,Pancreatic Cancer; Metastasis; Surgery; Oligometastatic Disease,Pancreas,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +930,NCT00004748,Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis,COMPLETED,PHASE3,"Liver Cirrhosis, Biliary",colchicine (DRUG); methotrexate (DRUG); ursodiol (DRUG),135398658,PGA,Biliary Liver Cirrhosis,Liver,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +931,NCT06334757,Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure,RECRUITING,PHASE2,Non-Squamous Non-Small Cell Lung Cancer,Serplulimab (DRUG); Bevacizumab Biosimilar HLX04 (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),135398658,PGA,Non-Squamous Non-Small Cell Lung Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +932,NCT06758557,A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor,RECRUITING,PHASE1,Advanced NSCLC; Advanced Endometrial Cancer,HB0025 (DRUG); Pemetrexed (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG),135398658,PGA,Advanced Non-Small Cell Lung Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +933,NCT03765957,Clinical Research on Treatment of Psoriasis by Human Umbilical Cord-derived Mesenchymal Stem Cells,UNKNOWN,EARLY_PHASE1,Psoriasis,Mesenchymal Stem Cells (BIOLOGICAL),135398658,PGA,Psoriasis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +934,NCT01064648,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,ACTIVE_NOT_RECRUITING,PHASE1,Epithelioid Mesothelioma; Pleural Malignant Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Cediranib Maleate (DRUG); Cisplatin (DRUG); Laboratory Biomarker Analysis (OTHER); Pemetrexed Disodium (DRUG); Placebo Administration (OTHER),135398658,PGA,Epithelioid Mesothelioma; Pleural Malignant Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +935,NCT03011320,An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery,COMPLETED,PHASE1,Ovary Cancer,EC1456 (DRUG); 99mTc-Etarfolatide (DRUG),135398658,PGA,Ovary Cancer,Ovary/Fallopian Tube,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +936,NCT06277674,Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI,RECRUITING,PHASE2,Non-small Cell Lung Cancer,Cadonilimab plus Pemetrexed and Anlotinib (DRUG),135398658,PGA,Non-small Cell Lung Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +937,NCT02047474,Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Stage I Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,oxaliplatin (DRUG); leucovorin calcium (DRUG); irinotecan hydrochloride (DRUG); fluorouracil (DRUG); therapeutic conventional surgery (PROCEDURE); laboratory biomarker analysis (OTHER),135398658,PGA,Pancreatic Cancer,Pancreas,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +938,NCT00548574,"Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis",COMPLETED,PHASE3,Ulcerative Colitis,SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine (DRUG); Mesalazine (DRUG),135398658,PGA,Ulcerative Colitis,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +939,NCT06151574,Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment,RECRUITING,PHASE3,"Lung Cancer, Non-squamous, Non-small Cell",zongertinib (DRUG); pembrolizumab (DRUG); cisplatin (DRUG); carboplatin (DRUG); pemetrexed (DRUG),135398658,PGA,"Lung Cancer, Non-squamous, Non-small Cell",Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +940,NCT01345682,LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy,COMPLETED,PHASE3,"Head and Neck Neoplasms; Carcinoma, Squamous Cell",Afatinib (DRUG); Methotrexate (DRUG),135398658,PGA,"Head and Neck Neoplasms; Carcinoma, Squamous Cell",Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +941,NCT05018182,FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer,UNKNOWN,PHASE2,High-risk Locally Advanced Colorectal Cancer; Neoadjuvant Chemotherapy; FOLFOXIRI Regimen,Oxaliplatin (DRUG); Irinotecan (DRUG); Folinic Acid (DRUG); 5FU (DRUG); Capecitabine (DRUG),135398658,PGA,High-risk Locally Advanced Colorectal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +942,NCT01836120,A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer,UNKNOWN,PHASE2,Gastric Cancer,Raltitrexed plus Docetaxel (DRUG); Docetaxel (DRUG),135398658,PGA,Gastric Cancer,Esophagus/Stomach,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +943,NCT00079274,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,COMPLETED,PHASE3,Adenocarcinoma of the Colon; Stage III Colon Cancer,irinotecan hydrochloride (DRUG); oxaliplatin (DRUG); leucovorin calcium (DRUG); fluorouracil (DRUG); cetuximab (BIOLOGICAL); Locally Directed Therapy (DRUG),135398658,PGA,Colon Adenocarcinoma,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +944,NCT03061474,Nicotinamide as an Early Alzheimer's Disease Treatment,COMPLETED,PHASE2,Alzheimer's Disease; Mild Cognitive Impairment,Nicotinamide (DRUG); Placebo Comparator (DRUG),135398658,PGA,Alzheimer's Disease; Mild Cognitive Impairment,CNS/Brain,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +945,NCT03597620,Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis,COMPLETED,PHASE4,Psoriasis,Metaderm (DRUG),135398658,PGA,Psoriasis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +946,NCT01492920,"Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy",WITHDRAWN,PHASE3,Fatigue; Malignant Ovarian Mixed Epithelial Tumor; Neuropathy; Neurotoxicity Syndrome; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Pain; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Acetyl-L-Carnitine Hydrochloride (DIETARY_SUPPLEMENT); Placebo (OTHER); Questionnaire Administration (OTHER); Quality-of-Life Assessment (OTHER),135398658,PGA,Fatigue; Malignant Ovarian Mixed Epithelial Tumor; Neuropathy; Neurotoxicity Syndrome; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Pain; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +947,NCT01425320,Pharmacokinetics Study of Dapsone-Adapalene Fixed Combination Gel in Acne,WITHDRAWN,PHASE1,Acne Vulgaris,Fixed Combination dapsone/adapalene Formulation A Gel (DRUG); Fixed Combination dapsone/adapalene Formulation B Gel (DRUG); dapsone 5% gel (DRUG); adapalene 0.3% gel (DRUG),135398658,PGA,Acne Vulgaris,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +948,NCT06042920,A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis,ACTIVE_NOT_RECRUITING,PHASE4,Palmoplantar Psoriasis; Genital Psoriasis,Deucravacitinib (DRUG); Placebo (DRUG),135398658,PGA,Palmoplantar Psoriasis; Genital Psoriasis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +949,NCT04405674,Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,Tislelizumab (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Bevacizumab (DRUG); Nab paclitaxel (DRUG),135398658,PGA,Non Small Cell Lung Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +950,NCT00002120,Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia,COMPLETED,PHASE1,"Pneumonia, Pneumocystis Carinii; HIV Infections",Trimetrexate glucuronate (DRUG); Trimethoprim (DRUG); Sulfamethoxazole (DRUG); Dapsone (DRUG); Leucovorin calcium (DRUG),135398658,PGA,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +951,NCT05772520,The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis,COMPLETED,PHASE2,Plaque Psoriasis,TLL018 tablets (DRUG),135398658,PGA,Plaque Psoriasis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +952,NCT00428974,Safety and Efficacy Study of CF101 to Treat Psoriasis,COMPLETED,PHASE2,Plaque Psoriasis,CF101 1mg (DRUG); CF101 2mg (DRUG); CF101 4mg (DRUG); Placebo (DRUG),135398658,PGA,Plaque Psoriasis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +953,NCT02241174,0.005% Sodium Hypochlorite Final Rinse Solution in Atopic Dermatitis,WITHDRAWN,PHASE1,Atopic Dermatitis,Sodium Hypochlorite (DRUG),135398658,PGA,Atopic Dermatitis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +954,NCT06625320,Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),RECRUITING,PHASE3,Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma,RMC-6236 (DRUG); Gemcitabine (DRUG); nab-paclitaxel (DRUG); Irinotecan (DRUG); Liposomal irinotecan (DRUG); 5-fluorouracil (DRUG); leucovorin (DRUG); Oxaliplatin (DRUG),135398658,PGA,Pancreatic Ductal Adenocarcinoma,Pancreas,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +955,NCT03950674,Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study,COMPLETED,PHASE3,Non-Small-Cell Lung Carcinoma,Pembrolizumab 200 mg (BIOLOGICAL); Cisplatin (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Folic acid 350-1000 μg (DIETARY_SUPPLEMENT); Vitamin B12 1000 μg (DIETARY_SUPPLEMENT); Dexamethasone 4 mg (DRUG); Saline solution (DRUG),135398658,PGA,Non-Small-Cell Lung Carcinoma,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +956,NCT00488774,An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis,TERMINATED,PHASE2,"Colitis, Ulcerative",Placebo (OTHER); Golimumab 1 mg per kg (DRUG); Golimumab 2 mg per kg (DRUG); Golimumab 4 mg per kg (DRUG),135398658,PGA,"Colitis, Ulcerative",Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +957,NCT03819465,A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Non-Small Cell Lung Cancer (NSCLC),Durvalumab (DRUG); Danvatirsen (DRUG); Oleclumab (DRUG); MEDI5752 (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG); Nab-paclitaxel (DRUG); AZD2936 (DRUG),135398658,PGA,Metastatic Non-Small Cell Lung Cancer (NSCLC),Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +958,NCT02966665,: Vascular Function in Health and Disease,RECRUITING,PHASE1,Chronic Obstructive Pulmonary Disease; Pulmonary Artery Hypertension; Heart Failure; Hypertension,"Maximum Exercise Tests (OTHER); BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate (DRUG); BQ-123 (DRUG); Fexofenadine, Ranitidine (DRUG); Angiotensin-II, Valsartan (OTHER); Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine (DRUG); BQ-123, MitoQ, BH4 (DRUG)",135398658,PGA,Chronic Obstructive Pulmonary Disease; Pulmonary Artery Hypertension; Heart Failure; Hypertension,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +959,NCT02589665,A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis,COMPLETED,PHASE2,Ulcerative Colitis,Mirikizumab (DRUG); Placebo (DRUG),135398658,PGA,Ulcerative Colitis,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +960,NCT01640782,Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach,COMPLETED,PHASE3,Adenocarcinoma of the Stomach; Adenocarcinoma of the Gastroesophageal Junction,"Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin (DRUG); Leucovorin, 5-Fluorouracil (DRUG)",135398658,PGA,Gastric Adenocarcinoma,Esophagus/Stomach,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +961,NCT00249782,"A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.",COMPLETED,PHASE2,Rosacea,"Vehicle control, 2x/day (DRUG); ACZONE (dapsone) Gel, 5%, 2x/day (DRUG); ACZONE (dapsone) Gel, 5%, 1x/day (DRUG); MetroGel® (metronidazole gel), 1.0% 1x/day (DRUG); ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM) (DRUG)",135398658,PGA,Rosacea,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +962,NCT06741020,Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma,RECRUITING,PHASE1,Hepatocellular Carcinoma (HCC),"Adebrelimab, Oxaliplatin, Fluorouracil,Leucovorin (DRUG)",135398658,PGA,Hepatocellular Carcinoma (HCC),Liver,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +963,NCT04421820,BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours,RECRUITING,PHASE1,Colorectal Cancer; Pancreatic Cancer; Gastric Cancers; Cholangiocarcinoma,BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion) (DRUG); BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation) (DRUG),135398658,PGA,Colorectal Cancer; Pancreatic Cancer; Gastric Cancers; Cholangiocarcinoma,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +964,NCT01420874,Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer),COMPLETED,PHASE1,Colorectal Cancer; Cancer of Pancreas; Pancreatic Neoplasm; Malignant Neoplasm of Large Intestine; Malignant Tumor of Colon; Colon Carcinoma; Cancer of Colon; Pancreatic Cancer,FOLFOX6 (DRUG); EGFRBi armed ATC Infusions (BIOLOGICAL),135398658,PGA,Colorectal Cancer; Cancer of Pancreas; Pancreatic Neoplasm; Malignant Neoplasm of Large Intestine; Malignant Tumor of Colon; Colon Carcinoma; Cancer of Colon; Pancreatic Cancer,Pancreas,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +965,NCT02573220,Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer,WITHDRAWN,PHASE1,Stage IVA Colorectal Cancer; Stage IVB Colorectal Cancer,Cetuximab (BIOLOGICAL); Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Leucovorin Calcium (DRUG),135398658,PGA,Stage IV Colorectal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +966,NCT00014274,Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium,COMPLETED,PHASE2,Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer,carboplatin (DRUG); gemcitabine hydrochloride (DRUG); methotrexate (DRUG); vinblastine sulfate (DRUG),135398658,PGA,Urinary Tract Cancers,Bladder/Urinary Tract,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +967,NCT02733874,A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris.,COMPLETED,PHASE4,Psoriasis,Compound Clobetasol Propionate Ointment (DRUG); Calcipotriol Betamethasone Ointment (DRUG),135398658,PGA,Psoriasis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +968,NCT02958865,"Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis",COMPLETED,PHASE2,Ulcerative Colitis,PF-06651600 or Placebo (DRUG); PF-06700841 or Placebo (DRUG); PF-06700841 (DRUG); PF-06651600 (DRUG),135398658,PGA,Ulcerative Colitis,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +969,NCT01712074,Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil,TERMINATED,PHASE2,Alzheimer's Disease,PF-05212377 (SAM-760) (DRUG); Placebo (OTHER),135398658,PGA,Alzheimer's Disease,CNS/Brain,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +970,NCT02576574,Avelumab in First-line NSCLC (JAVELIN Lung 100),COMPLETED,PHASE3,First Line Non-Small Cell Lung Cancer,Avelumab (DRUG); Pemetrexed (DRUG); Paclitaxel (DRUG); Gemcitabine (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Avelumab Weekly (DRUG),135398658,PGA,First Line Non-Small Cell Lung Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +971,NCT01936974,"(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma",TERMINATED,PHASE2,Ovarian Carcinoma; Fallopian Tube Carcinoma; Peritoneal Carcinoma,Gemcitabine (DRUG); Bevacizumab (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Oxaliplatin (DRUG),135398658,PGA,Ovarian and Related Carcinomas,Ovary/Fallopian Tube,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +972,NCT02529774,Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer,UNKNOWN,PHASE2,Resected Liver Metastases From Colorectal Cancer,"Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6) (DRUG); Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6) (DRUG)",135398658,PGA,Resected Liver Metastases From Colorectal Cancer,Liver,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +973,NCT00072865,Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Neoplasm Metastasis,Pemetrexed (DRUG); Carboplatin (DRUG),135398658,PGA,Breast Cancer; Neoplasm Metastasis,Breast,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +974,NCT00166465,Stage IV Colorectal CA ALIMTA,COMPLETED,PHASE1,Locally Advanced Unresectable or Stage IV Colorectal Cancer,ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen) (DRUG),135398658,PGA,Locally Advanced Unresectable or Stage IV Colorectal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +975,NCT06726265,Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004),RECRUITING,PHASE3,Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC),eftilagimod alfa (BIOLOGICAL); carboplatin plus paclitaxel (DRUG); cisplatin or carboplatin + pemetrexed (DRUG); Pembrolizumab (KEYTRUDA®) (BIOLOGICAL); Placebo (OTHER),135398658,PGA,Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC),Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +976,NCT02772965,Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy,COMPLETED,PHASE3,Pediatric Crohn's Disease,Methotrexate (DRUG); Sugar pill (placebo) (OTHER),135398658,PGA,Pediatric Crohn's Disease,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +977,NCT01219920,FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer,COMPLETED,PHASE3,Metastatic Colorectal Cancer,FOLFIRI (DRUG); FOLFOXIRI (DRUG),135398658,PGA,Metastatic Colorectal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +978,NCT01458574,"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis",COMPLETED,PHASE3,Ulcerative Colitis,"Placebo (DRUG); CP690,550 (DRUG); CP-690,550 (DRUG)",135398658,PGA,Ulcerative Colitis,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +979,NCT00936065,Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis,COMPLETED,PHASE4,Moderate to Severe Psoriasis,Etanercept (DRUG); Etanercept + Acitretin (DRUG); Acitretin (DRUG),135398658,PGA,Moderate to Severe Psoriasis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +980,NCT01017874,A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer,COMPLETED,PHASE3,Non Small Cell Lung Cancer,Pemetrexed (DRUG); Cisplatin (DRUG); Gefitinib (DRUG); Gefitinib (DRUG),135398658,PGA,Non Small Cell Lung Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +981,NCT03000374,Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery,COMPLETED,PHASE2,Rectal Cancer,Panitumumab (DRUG); 5Fluorouracil (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG),135398658,PGA,Rectal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +982,NCT02258074,The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE,COMPLETED,PHASE2,Chronic Kidney Disease,Nicotinamide (DRUG); Lanthanum Carbonate (DRUG); Placebo (for Nicotinamide) (DRUG); Placebo (for lanthanum carbonate) (DRUG),135398658,PGA,Chronic Kidney Disease,Kidney,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +983,NCT03310320,Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis,TERMINATED,PHASE1,Plaque Psoriasis Vulgaris,AZD0284 oral solution 2.5 mg/mL (DRUG); Placebo (DRUG),135398658,PGA,Plaque Psoriasis Vulgaris,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +984,NCT06704620,Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer,NOT_YET_RECRUITING,PHASE3,Advanced and Metastatic NSCLC,Diphenhydramine (DRUG); Tislelizumab (DRUG); Pemetrexed (DRUG); Albumin paclitaxel (DRUG); Carboplatin (DRUG); Cisplatin (DRUG),135398658,PGA,Non-small Cell Lung Cancer Stage IV,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +985,NCT03500874,Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM,TERMINATED,PHASE3,Colorectal Cancer; Liver Metastases; HAI,FUDR (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); 5FU (DRUG); Irinotecan (DRUG),135398658,PGA,Colorectal Cancer with Liver Metastases,Liver,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +986,NCT02039674,A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021),COMPLETED,PHASE1,Non-small Cell Lung Carcinoma,Pembrolizumab (BIOLOGICAL); Paclitaxel (DRUG); Carboplatin (DRUG); Bevacizumab (BIOLOGICAL); Pemetrexed (DRUG); Ipilimumab (BIOLOGICAL); Erlotinib (DRUG); Gefitinib (DRUG),135398658,PGA,Non-small Cell Lung Carcinoma,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +987,NCT02004574,Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris,COMPLETED,PHASE4,Psoriasis Vulgaris,Calcipotriol/betamethasone dipropionate gel (DRUG),135398658,PGA,Psoriasis Vulgaris,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +988,NCT05930665,Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma,RECRUITING,PHASE2,Pleural Mesothelioma,Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin (DRUG),135398658,PGA,Pleural Mesothelioma,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +989,NCT03654274,SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain,COMPLETED,PHASE3,Endometriosis,Relugolix (DRUG); Estradiol/norethindrone acetate (DRUG),135398658,PGA,Endometriosis,Uterus,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +990,NCT02120274,Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C,TERMINATED,PHASE4,"RNA Virus Infections; Flaviviridae Infections; Hepatitis C; Hepatitis C, Chronic",Vitamin D (DRUG); Vitamin B 12 (DRUG),135398658,PGA,"RNA Virus Infections; Flaviviridae Infections; Hepatitis C; Hepatitis C, Chronic",Liver,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +991,NCT06525974,Clinical Study to Evaluate the Possible Efficacy and Safety of Febuxostat in Patients With Ulcerative Colitis Treated With Mesalamine,NOT_YET_RECRUITING,EARLY_PHASE1,Ulcerative Colitis,Febuxostat (DRUG); Mesalamine (DRUG),135398658,PGA,Ulcerative Colitis,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +992,NCT02620865,BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer,COMPLETED,PHASE1,Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Aldesleukin (BIOLOGICAL); Antibody Therapy (BIOLOGICAL); Fluorouracil (DRUG); Gemcitabine Hydrochloride (DRUG); Irinotecan Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Leucovorin Calcium (DRUG); Oxaliplatin (DRUG); Paclitaxel Albumin-Stabilized Nanoparticle Formulation (DRUG); Sargramostim (BIOLOGICAL),135398658,PGA,Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +993,NCT01011920,Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma,COMPLETED,PHASE2,Central Nervous System Lymphoma,Methotrexate (DRUG); Ara-C (DRUG); Rituximab (DRUG); Thiotepa (DRUG); radiotherapy (RADIATION); BCNU (DRUG); APBSCT (OTHER),135398658,PGA,Central Nervous System Lymphoma,CNS/Brain,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +994,NCT02759120,CleanUP IPF for the Pulmonary Trials Cooperative,TERMINATED,PHASE3,Idiopathic Pulmonary Fibrosis,Antimicrobial therapy: Co-trimoxazole or Doxycycline (DRUG); No Intervention: Standard of Care (OTHER),135398658,PGA,Idiopathic Pulmonary Fibrosis,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +995,NCT00434174,Safety of Everolimus and Pemetrexed in Lung Cancer Patients,COMPLETED,PHASE1,Non Small Cell Lung Cancer,Everolimus (DRUG); Pemetrexed (DRUG),135398658,PGA,Non Small Cell Lung Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +996,NCT04180774,Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer,COMPLETED,PHASE1,Melanoma; Kidney Cancer,Tag-7 gene modified inactivated tumor cells (BIOLOGICAL),135398658,PGA,Melanoma; Kidney Cancer,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +997,NCT00066274,Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,FOLFIRI regimen (DRUG); FOLFOX regimen (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG),135398658,PGA,Colorectal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +998,NCT00391274,Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE3,Non-Small Cell Lung Cancer,pemetrexed (DRUG); docetaxel (DRUG),135398658,PGA,Advanced Non-Small Cell Lung Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +999,NCT00176774,"Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma",COMPLETED,PHASE2,Colorectal Carcinoma,Irinotecan (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG); Tetrathiomolybdate (DRUG),135398658,PGA,Colorectal Carcinoma,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1000,NCT03971474,Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial),COMPLETED,PHASE2,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Docetaxel (DRUG); Gemcitabine (DRUG); Gemcitabine Hydrochloride (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed (DRUG); Pemetrexed Disodium (DRUG); Ramucirumab (BIOLOGICAL),135398658,PGA,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1001,NCT00496665,ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer,COMPLETED,PHASE1,Metastatic Breast Cancer,Vandetanib (DRUG); Cyclophosphamide (DRUG); Methotrexate (DRUG),135398658,PGA,Metastatic Breast Cancer,Breast,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1002,NCT05579366,"Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)",RECRUITING,PHASE1,High Grade Epithelial Ovarian Cancer; High Grade Serous Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Endometrial Cancer; Non-small Cell Lung Cancer; Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC); Mesothelioma; Breast Adenocarcinoma; Triple Negative Breast Cancer; Hormone Receptor-positive/Her2 Negative Breast Cancer; Platinum-resistant Ovarian Cancer (PROC); Platinum Sensitive Ovarian Cancer (PSOC); Primary Refractory Ovarian Cancer; Uterine Cancer,Rina-S (DRUG); Carboplatin (DRUG); Bevacizumab (DRUG); Pembrolizumab (DRUG),135398658,PGA,High Grade Epithelial Ovarian Cancer; High Grade Serous Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Endometrial Cancer; Non-small Cell Lung Cancer; Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC); Mesothelioma; Breast Adenocarcinoma; Triple Negative Breast Cancer; Hormone Receptor-positive/Her2 Negative Breast Cancer; Platinum-resistant Ovarian Cancer (PROC); Platinum Sensitive Ovarian Cancer (PSOC); Primary Refractory Ovarian Cancer; Uterine Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1003,NCT06454266,"First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)",COMPLETED,PHASE2,Primary Central Nervous System Lymphoma,ORM regimen (DRUG),135398658,PGA,Primary Central Nervous System Lymphoma,CNS/Brain,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1004,NCT05171166,Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.,RECRUITING,PHASE2,Hepatocellular Carcinoma,HAIC (PROCEDURE); TACE (PROCEDURE); FOLFOX (DRUG); cTACE or DEB-TACE (DRUG); Donafenib (DRUG),135398658,PGA,Hepatocellular Carcinoma,Liver,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1005,NCT00402766,"Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma",COMPLETED,PHASE1,Mesothelioma,Cisplatin (DRUG); Imatinib Mesylate (DRUG); Pemetrexed (DRUG); Dexamethasone (DRUG),135398658,PGA,Mesothelioma,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1006,NCT01831466,Tofacitinib Ointment For Chronic Plaque Psoriasis,COMPLETED,PHASE2,Psoriasis Vulgaris; Psoriasis,tofacitinib ointment 20 mg/g (DRUG); tofacitinib ointment 10 mg/g (DRUG); placebo ointment (vehicle) (DRUG); tofacitinib ointment 20 mg/g (DRUG); tofacitinib ointment 10 mg/g (DRUG); placebo ointment (vehicle) (DRUG),135398658,PGA,Psoriasis Vulgaris; Psoriasis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1007,NCT02647866,Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis,COMPLETED,PHASE2,"Ulcerative Colitis; Digestive System Diseases; Colitis, Ulcerative; Colitis; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Intestinal Diseases; Colonic Diseases; Autoimmune Disease; Abdominal Pain",KHK4083 (DRUG); Placebo (DRUG),135398658,PGA,"Ulcerative Colitis; Digestive System Diseases; Colitis, Ulcerative; Colitis; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Intestinal Diseases; Colonic Diseases; Autoimmune Disease; Abdominal Pain",Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1008,NCT00383266,A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer,TERMINATED,PHASE2,Esophageal Neoplasms,Pemetrexed (DRUG); Carboplatin (DRUG),135398658,PGA,Esophageal Neoplasms,Esophagus/Stomach,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1009,NCT00513266,Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery,UNKNOWN,PHASE2,Colorectal Cancer; Metastatic Cancer,bevacizumab (BIOLOGICAL); cetuximab (BIOLOGICAL); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG); laboratory biomarker analysis (OTHER); adjuvant therapy (PROCEDURE); biopsy (PROCEDURE); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE),135398658,PGA,Colorectal Cancer; Metastatic Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1010,NCT05589766,N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease,ACTIVE_NOT_RECRUITING,PHASE2,Parkinson Disease,Nicotinamide Riboside (DIETARY_SUPPLEMENT); Placebo (OTHER),135398658,PGA,Parkinson Disease,CNS/Brain,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1011,NCT02156466,Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects,COMPLETED,PHASE1,Psoriasis,MSB0010841 (DRUG); MSB0010841 (DRUG); MSB0010841 (DRUG); MSB0010841 (DRUG); Placebo (DRUG),135398658,PGA,Psoriasis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1012,NCT05663866,Premedication to Reduce Amivantamab Associated Infusion Related Reactions,ACTIVE_NOT_RECRUITING,PHASE2,"Carcinoma, Non-Small-Cell Lung",Dexamethasone (DRUG); Montelukast (DRUG); Methotrexate (DRUG); Amivantamab (DRUG); Lazertinib (DRUG),135398658,PGA,"Carcinoma, Non-Small-Cell Lung",Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1013,NCT00000966,A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS,COMPLETED,PHASE1,"Toxoplasmosis, Cerebral; HIV Infections",Azithromycin (DRUG); Pyrimethamine (DRUG); Leucovorin calcium (DRUG),135398658,PGA,"Toxoplasmosis, Cerebral; HIV Infections",CNS/Brain,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1014,NCT06476366,Comparison of Efficacy of Methotrexate and Azathioprine in Patients With Chronic Actinic Dermatitis: A Randomized Controlled Trial,RECRUITING,EARLY_PHASE1,Chronic Actinic Dermatitis,Azathioprine (DRUG); Methotrexate (DRUG),135398658,PGA,Chronic Actinic Dermatitis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1015,NCT04683965,Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer,UNKNOWN,PHASE2,Colorectal Neoplasms,Pemetrexed (DRUG); TAS-102 (DRUG); Bevacizumab (DRUG),135398658,PGA,Colorectal Neoplasms,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1016,NCT02903966,GSK2982772 Study in Subjects With Ulcerative Colitis,COMPLETED,PHASE2,"Colitis, Ulcerative",GSK2982772 (DRUG); Placebo (DRUG),135398658,PGA,"Colitis, Ulcerative",Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1017,NCT03929666,"A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer",ACTIVE_NOT_RECRUITING,PHASE2,"HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer",ZW25 (Zanidatamab) (DRUG); Capecitabine (DRUG); Cisplatin (DRUG); Fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Bevacizumab (DRUG); Gemcitabine (DRUG),135398658,PGA,HER2-expressing Gastrointestinal Cancers,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1018,NCT04214665,"To Assess the Bioequivalence of Test Oral Formulation of Alpha Lipoic Acid 600 mg HR Film Coated Tablets of Ilko Ilac San. Ve Tic. A.S. Versus Reference Thioctacid (Alpha Lipoic Acid) 600 mg HR Film Coated Tablets of Meda Pharma GmbH& CO .KG, Germany.",COMPLETED,PHASE1,Peripheral (Sensorimotor) Diabetic Polyneuropathy,Alpha Lipoic acid 600 mg HR film coated tablets (DRUG),135398658,PGA,Peripheral (Sensorimotor) Diabetic Polyneuropathy,Peripheral Nervous System,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1019,NCT01689766,Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma,COMPLETED,PHASE2,Metastatic Renal Cell Carcinoma,Technetium Tc 99m EC20 (DRUG),135398658,PGA,Metastatic Renal Cell Carcinoma,Kidney,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1020,NCT01271166,Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer,TERMINATED,PHASE1,Advanced Colorectal Cancer,"Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab (DRUG)",135398658,PGA,Advanced Colorectal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1021,NCT01356966,Exercise Intolerance in Renal Failure,COMPLETED,PHASE2,"Kidney Failure, Chronic",Tetrahydrobiopterin (DRUG); Placebo (DRUG); Folate (DIETARY_SUPPLEMENT),135398658,PGA,"Kidney Failure, Chronic",Kidney,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1022,NCT00964366,Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications,COMPLETED,PHASE4,Acne Vulgaris,clindamycin and benzoyl peroxide (DRUG); Dapsone gel (DRUG),135398658,PGA,Acne Vulgaris,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1023,NCT01107626,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,COMPLETED,PHASE3,Lung Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Bevacizumab (BIOLOGICAL); Pemetrexed Disodium Heptahydrate (DRUG),135398658,PGA,Lung Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1024,NCT02399566,Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma,UNKNOWN,PHASE4,Lung Adenocarcinoma,"Erlotinib, Pemetrexed (DRUG)",135398658,PGA,Lung Adenocarcinoma,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1025,NCT05640726,The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy,NOT_YET_RECRUITING,PHASE2,Rectal Cancer,PD-1 (DRUG); SCRT (RADIATION); Bevacizumab (DRUG); Oxaliplatin (DRUG); Calcium folinate (DRUG); 5-fluorouracil (DRUG),135398658,PGA,Rectal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1026,NCT00998166,A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy,TERMINATED,PHASE2,Non-Small Cell Lung Cancer,Pemetrexed (DRUG); Cisplatin (DRUG); Bevacizumab (DRUG),135398658,PGA,Advanced Non-Small Cell Lung Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1027,NCT04233866,"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Fluorouracil (DRUG); Gemcitabine (DRUG); Gemcitabine Hydrochloride (DRUG); Leucovorin (DRUG); Leucovorin Calcium (DRUG); Liposomal Irinotecan (DRUG); Nab-paclitaxel (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),135398658,PGA,Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Pancreas,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1028,NCT02707666,A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma,TERMINATED,PHASE1,Pleural Mesothelioma,Pembrolizumab (DRUG); Cisplatin and Pemetrexed (DRUG),135398658,PGA,Pleural Mesothelioma,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1029,NCT00614965,Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV,COMPLETED,PHASE2,Non Small Cell Lung Cancer,Irinotecan (DRUG); Cisplatin (DRUG); Pemetrexed (DRUG),135398658,PGA,Non Small Cell Lung Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1030,NCT02044965,Can Probiotics be Used in the Prevention of Recurrent UTI in Paediatric Neurogenic Bladder,UNKNOWN,PHASE1,Urinary Tract Infection,Antibiotic (OTHER); Probiotic (DRUG),135398658,PGA,Urinary Tract Infection,Bladder/Urinary Tract,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1031,NCT00377520,A Trial for Patients With Advanced/Recurrent Endometrial Cancer,COMPLETED,PHASE2,"Neoplasms; Neoplasms by Site; Urogenital Neoplasms; Genital Neoplasms, Female; Uterine Neoplasms; Endometrial Neoplasms; Cancer of Endometrium; Endometrial Cancer; Cancer of the Endometrium; Endometrium Cancer; Neoplasms, Endometrial",pemetrexed (DRUG),135398658,PGA,"Neoplasms; Neoplasms by Site; Urogenital Neoplasms; Genital Neoplasms, Female; Uterine Neoplasms; Endometrial Neoplasms; Cancer of Endometrium; Endometrial Cancer; Cancer of the Endometrium; Endometrium Cancer; Neoplasms, Endometrial",Uterus,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1032,NCT02753127,A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer,COMPLETED,PHASE3,Colorectal Cancer,Napabucasin (DRUG); Fluorouracil (DRUG); Leucovorin (DRUG); Irinotecan (DRUG); Bevacizumab (DRUG),135398658,PGA,Colorectal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1033,NCT06935474,C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease,NOT_YET_RECRUITING,PHASE1,Lupus Nephritis (LN),C-CAR168 (BIOLOGICAL),135398658,PGA,Lupus Nephritis (LN),Kidney,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1034,NCT01031420,Dose Dense MVAC for Muscle Invasive Bladder Cancer,COMPLETED,PHASE2,Muscle Invasive Bladder Cancer; High Risk Urothelial Carcinoma of the Upper Urinary Tracts,single arm dose dense MVAC (DRUG),135398658,PGA,Muscle Invasive Bladder Cancer; High Risk Urothelial Carcinoma of the Upper Urinary Tracts,Bladder/Urinary Tract,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1035,NCT04470674,Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients,WITHDRAWN,PHASE2,Lung Cancer; Non-small Cell Lung Cancer; PD-L1 Gene Mutation; KRAS Activating Mutation,Durvalumab (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG),135398658,PGA,Lung Cancer; Non-small Cell Lung Cancer; PD-L1 Gene Mutation; KRAS Activating Mutation,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1036,NCT01928420,"A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease",COMPLETED,PHASE2,Alzheimer's Disease; Dementia,Drug: NIC5-15 (DRUG); Placebo (DRUG),135398658,PGA,Alzheimer's Disease; Dementia,CNS/Brain,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1037,NCT02737774,Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation,UNKNOWN,PHASE2,Lung Adenocarcinoma,Icotinib (DRUG); Pemetrexed/Carboplatin (DRUG),135398658,PGA,Lung Adenocarcinoma,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1038,NCT00083031,Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,bevacizumab (DRUG); cyclophosphamide (DRUG); methotrexate (DRUG),135398658,PGA,Breast Cancer,Breast,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1039,NCT03123120,A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy,COMPLETED,PHASE2,"Colitis, Ulcerative",Spesolimab (DRUG); Placebo (DRUG),135398658,PGA,"Colitis, Ulcerative",Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1040,NCT04215731,Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer,RECRUITING,PHASE3,Rectal Cancer,Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab (DRUG); Restaging (PROCEDURE); Concomitant Chemoradiotherapy (RADIATION); Surgery (PROCEDURE); Chemoradiotherapy (only when patients with MRF involved or ycT4a/b by restaging) (RADIATION); Induction chemotherpay with FOLFOX (DRUG),135398658,PGA,Rectal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1041,NCT00580931,Safety Study of Nicotinamide to Treat Alzheimer's Disease,COMPLETED,PHASE1,Alzheimer's Disease,Nicotinamide (DRUG); Enduramide placebo (DRUG),135398658,PGA,Alzheimer's Disease,CNS/Brain,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1042,NCT01225731,A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003),COMPLETED,PHASE2,Psoriasis,tildrakizumab (BIOLOGICAL); Placebo (DRUG),135398658,PGA,Psoriasis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1043,NCT00027573,Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer,COMPLETED,PHASE2,Kidney Cancer,filgrastim (BIOLOGICAL); therapeutic allogeneic lymphocytes (BIOLOGICAL); cyclophosphamide (DRUG); fludarabine phosphate (DRUG); methotrexate (DRUG); tacrolimus (DRUG); peripheral blood stem cell transplantation (PROCEDURE),135398658,PGA,Kidney Cancer,Kidney,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1044,NCT00490373,Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is Metastatic,COMPLETED,PHASE2,Pancreatic Cancer,pemetrexed (DRUG),135398658,PGA,Pancreatic Cancer,Pancreas,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1045,NCT01718873,Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer,COMPLETED,PHASE3,Colorectal Cancer,Bevacizumab (DRUG); Oxaliplatin (DRUG); levo-folinic acid (DRUG); 5-fluorouracil (DRUG); Capecitabine (DRUG),135398658,PGA,Colorectal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1046,NCT00923273,Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer,TERMINATED,PHASE1,"Carcinoma, Non-Small-Cell Lung",FDG-PET (DRUG); Pemetrexed (DRUG); Sirolimus (DRUG); Vitamin B12 (DIETARY_SUPPLEMENT); Folic acid tablets (DIETARY_SUPPLEMENT); Dexamethasone tablets (DRUG),135398658,PGA,"Carcinoma, Non-Small-Cell Lung",Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1047,NCT04054531,Study of KN046 With Chemotherapy in First Line Advanced NSCLC,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,KN046 (BIOLOGICAL); Paclitaxel (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),135398658,PGA,Non-small Cell Lung Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1048,NCT00703573,"A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis",COMPLETED,PHASE2,Atopic Dermatitis,S-777469 400 mg (DRUG); S-777469 800 mg (DRUG); Placebo (DRUG),135398658,PGA,Atopic Dermatitis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1049,NCT00193973,Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma,COMPLETED,PHASE2,Primary Central Nervous System Lymphoma,"Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C (DRUG); Radiation Therapy (RADIATION)",135398658,PGA,Primary Central Nervous System Lymphoma,CNS/Brain,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1050,NCT00737373,Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer,COMPLETED,PHASE2,Gastric Cancer; Adenocarcinoma of the Esophagogastric Junction,Docetaxel (DRUG); 5-Fluorouracil (DRUG); Oxaliplatin (DRUG); folinic acid (DRUG),135398658,PGA,Gastric Cancer; Adenocarcinoma of the Esophagogastric Junction,Esophagus/Stomach,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1051,NCT05870748,REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1,RECRUITING,PHASE2,Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Platinum-resistant Ovarian Cancer,Luveltamab tazevibulin (DRUG); Pegfilgrastim (DRUG); Gemcitabine (DRUG); Paclitaxel (DRUG); Pegylated liposomal doxorubicin (DRUG); Topotecan (DRUG),135398658,PGA,Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Platinum-resistant Ovarian Cancer,Ovary/Fallopian Tube,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1052,NCT05344248,"Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing",COMPLETED,PHASE1,Moderate to Severe Psoriasis,JS005 (recombinant humanized monoclonal antibody against IL-17A) (BIOLOGICAL); JS005 placebo (BIOLOGICAL),135398658,PGA,Moderate to Severe Psoriasis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1053,NCT06941857,NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer,NOT_YET_RECRUITING,PHASE2,Pancreatic Cancer,Oxaliplatin (DRUG); Irinotecan (DRUG); Folinic Acid (DRUG); 5-Fluorouracil (5-FU) (DRUG); NC410 (DRUG); Nivolumab (DRUG); Ipilimumab (DRUG),135398658,PGA,Pancreatic Cancer,Pancreas,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1054,NCT01383148,Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer,TERMINATED,PHASE2,Non-Small-Cell Lung Carcinoma,TG4010 (BIOLOGICAL); placebo (DRUG),135398658,PGA,Non-Small-Cell Lung Carcinoma,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1055,NCT04267848,"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial",RECRUITING,PHASE3,Lung Non-Small Cell Carcinoma; Lung Non-Small Cell Squamous Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Gemcitabine Hydrochloride (DRUG); Magnetic Resonance Imaging (PROCEDURE); Observation Activity (OTHER); Paclitaxel (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed Disodium (DRUG); Questionnaire Administration (OTHER),135398658,PGA,Lung Non-Small Cell Carcinoma; Lung Non-Small Cell Squamous Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1056,NCT02337530,Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Selumetinib (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG); Carboplatin (DRUG),135398658,PGA,Advanced Non-Small Cell Lung Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1057,NCT03358030,A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis,COMPLETED,PHASE2,End-stage Renal Disease (ESRD),ISIS 416858 (DRUG); Placebo (DRUG),135398658,PGA,End-stage Renal Disease (ESRD),Kidney,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1058,NCT05064748,Phase IV Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Psoriasis in Adults,UNKNOWN,PHASE4,Psoriasis,Benvitimod (DRUG),135398658,PGA,Psoriasis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1059,NCT05198830,"Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer",RECRUITING,PHASE2,Lung Adenocarcinoma; Lung Large Cell Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8,Carboplatin (DRUG); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Durvalumab (BIOLOGICAL); FDG-Positron Emission Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Methoxyamine (DRUG); Pemetrexed (DRUG); Radiation Therapy (RADIATION),135398658,PGA,Lung Adenocarcinoma; Lung Large Cell Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1060,NCT00203931,Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer,TERMINATED,PHASE2,Non-small Cell Lung Cancer,Cetuximab (DRUG); Pemetrexed (DRUG),135398658,PGA,Non-small Cell Lung Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1061,NCT00002582,"Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer",COMPLETED,PHASE3,Breast Cancer,CMF regimen (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); fluorouracil (DRUG); goserelin acetate (DRUG); leuprolide acetate (DRUG); methotrexate (DRUG); tamoxifen citrate (DRUG); oophorectomy (PROCEDURE); radiation therapy (RADIATION),135398658,PGA,Breast Cancer,Breast,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1062,NCT01271582,Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients,UNKNOWN,PHASE4,Stage IV Colorectal Cancer; Gastric Cancer,"Irinotecan, 5FU, leucovorin (DRUG)",135398658,PGA,Advanced Gastrointestinal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1063,NCT01951482,Pemetrexed/Cisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer,UNKNOWN,PHASE2,Non Squamous Non-small Cell Lung Cancer; Brain Metastases; Bevacizumab,Pemetrexed/cisplatin (DRUG); Bevacizumab and Pemetrexed/cisplatin (DRUG),135398658,PGA,Non Squamous Non-small Cell Lung Cancer; Brain Metastases; Bevacizumab,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1064,NCT05072782,"Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the POMEROL Trial. (POMEROL)",UNKNOWN,PHASE4,Crohn Disease,Infliximab CT-P13 (DRUG); Immunosuppressors (Thiopurines or Methotrexate) (DRUG),135398658,PGA,Crohn Disease,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1065,NCT02259582,"A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer",COMPLETED,PHASE2,Nonsquamous Nonsmall Cell Neoplasm of Lung,Pemetrexed (DRUG); Carboplatin (DRUG); demcizumab (DRUG),135398658,PGA,Nonsquamous Nonsmall Cell Neoplasm of Lung,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1066,NCT00098982,"Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer",COMPLETED,PHASE1,Colorectal Cancer,bortezomib (DRUG); fluorouracil (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG),135398658,PGA,Colorectal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1067,NCT05919082,A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis,COMPLETED,PHASE3,Stable Plaque Psoriasis,LEO 90100 (DRUG); Daivobet® ointment (DRUG),135398658,PGA,Stable Plaque Psoriasis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1068,NCT00560573,"Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer",COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung","CP-751,871 (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG); Pemetrexed (DRUG)",135398658,PGA,"Carcinoma, Non-Small-Cell Lung",Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1069,NCT00000973,A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients,COMPLETED,PHASE1,"Toxoplasmosis, Cerebral; HIV Infections",Pyrimethamine (DRUG); Leucovorin calcium (DRUG); Zidovudine (DRUG),135398658,PGA,"Toxoplasmosis, Cerebral; HIV Infections",CNS/Brain,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1070,NCT03059173,Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome,RECRUITING,PHASE3,Polycystic Ovary Syndrome; Reproductive Medicine,Myo-Inositol + Levomefolic acid (DIETARY_SUPPLEMENT); Clomiphene Citrate (DRUG); placebo (DIETARY_SUPPLEMENT),135398658,PGA,Polycystic Ovary Syndrome; Reproductive Medicine,Ovary/Fallopian Tube,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1071,NCT00739882,TRUST Study: Raptiva ® in Hand & Foot Psoriasis,TERMINATED,PHASE4,Chronic Plaque Psoriasis,Efalizumab - anti CD11a recombinant human monoclonal antibody (DRUG); Placebo (DRUG),135398658,PGA,Chronic Plaque Psoriasis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1072,NCT04061590,Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer,WITHDRAWN,PHASE2,Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8,Cisplatin (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed (DRUG); Pemetrexed Disodium (DRUG); Therapeutic Conventional Surgery (PROCEDURE),135398658,PGA,Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1073,NCT01531790,A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients,COMPLETED,PHASE1,Non-Small Cell Lung Cancer,Carboplatin (DRUG); Pemetrexed (DRUG); Endostar (DRUG); Centrum (DRUG),135398658,PGA,Advanced Non-Small Cell Lung Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1074,NCT01208090,ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis,COMPLETED,PHASE2,Psoriasis,ACT-128800 (DRUG); Placebo (DRUG),135398658,PGA,Psoriasis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1075,NCT02284490,High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases,UNKNOWN,PHASE2,Brain Metastases,pemetrexed (DRUG),135398658,PGA,Brain Metastases,CNS/Brain,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1076,NCT03792503,Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen,WITHDRAWN,PHASE4,Advanced Non-squamous Non-small-cell Lung Cancer,Apatinib (DRUG); Pemetrexed (DRUG),135398658,PGA,Advanced Non-Small Cell Lung Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1077,NCT00871403,Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer,COMPLETED,PHASE2,"Lung Cancer, Non-Small Cell",pazopanib and pemetrexed (DRUG); pemetrexed and cisplatin (DRUG),135398658,PGA,"Lung Cancer, Non-Small Cell",Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1078,NCT01133990,FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer,TERMINATED,PHASE1,Colorectal Cancer,FOLFIRI (DRUG); E7820 (DRUG); Bevacizumab (DRUG),135398658,PGA,Colorectal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1079,NCT03964090,"Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)",ACTIVE_NOT_RECRUITING,PHASE2,Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma,TEDD-R (DRUG); TEDDI-R (DRUG); Ibrutinib (DRUG); Cytarabine (DRUG); Isavuconazole (DRUG); Methotrexate (DRUG),135398658,PGA,Central Nervous System Lymphoma,CNS/Brain,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1080,NCT02185690,"A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung",COMPLETED,PHASE1,Lungcancer,Binimetinib (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),135398658,PGA,Lungcancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1081,NCT00798603,"Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",COMPLETED,PHASE2,Lung Cancer,bevacizumab (BIOLOGICAL); carboplatin (DRUG); pemetrexed disodium (DRUG),135398658,PGA,Lung Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1082,NCT03991403,Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC,UNKNOWN,PHASE3,Non-small Cell Lung Cancer,Atezolizumab(Tecentriq) (DRUG); Pemetrexed (DRUG); Bevacizumab (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Carboplatin or cisplatin (DRUG),135398658,PGA,Non-small Cell Lung Cancer,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1083,NCT05622890,"A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer",UNKNOWN,PHASE3,Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer,Mirvetuximab Soravtansine (DRUG),135398658,PGA,Epithelial Ovarian and Related Cancers,Ovary/Fallopian Tube,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1084,NCT04068103,Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery,ACTIVE_NOT_RECRUITING,PHASE2,Colon Adenocarcinoma; Stage IIA Colon Cancer AJCC v8,Capecitabine (DRUG); Fluorouracil (DRUG); Leucovorin (DRUG); Leucovorin Calcium (DRUG); Oxaliplatin (DRUG); Patient Observation (OTHER),135398658,PGA,Stage IIA Colon Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1085,NCT01105390,"AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma",WITHDRAWN,PHASE2,Advanced Malignant Mesothelioma; Epithelial Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma,rilotumumab (BIOLOGICAL); cisplatin (DRUG); pemetrexed disodium (DRUG); laboratory biomarker analysis (OTHER),135398658,PGA,Advanced Malignant Mesothelioma; Epithelial Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1086,NCT01426490,"The Effects of Vitamin B-6 Status on Homocysteine, Oxidative Stress, One-carbon Metabolism and Methylation: Cross-section, Case-control, Intervention and Follow-up Studies in Colorectal Cancer",UNKNOWN,PHASE2,Colorectal Cancer,Vitamin C (DIETARY_SUPPLEMENT); Vitamin B6 (DIETARY_SUPPLEMENT); Folic acid (DIETARY_SUPPLEMENT); Vitamin B6 plus folic acid (DIETARY_SUPPLEMENT),135398658,PGA,Colorectal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1087,NCT06700603,Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer,NOT_YET_RECRUITING,PHASE2,Pancreatic Cancer,Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate (DRUG),135398658,PGA,Pancreatic Cancer,Pancreas,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1088,NCT03193190,A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer),COMPLETED,PHASE1,Pancreatic Adenocarcinoma,Nab-Paclitaxel (DRUG); Gemcitabine (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); Fluorouracil (DRUG); Atezolizumab (DRUG); Cobimetinib (DRUG); PEGPH20 (DRUG); BL-8040 (DRUG); Selicrelumab (DRUG); Bevacizumab (DRUG); RO6874281 (DRUG); AB928 (DRUG); Tiragolumab (DRUG); Tocilizumab (DRUG),135398658,PGA,Pancreatic Adenocarcinoma,Pancreas,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1089,NCT01913964,Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin,COMPLETED,PHASE4,Work Productivity and Activity Impairment in Workers With Chronic C Hepatitis; Fatigue in Workers With Chronic C Hepatitis; Fatigue,Acetylcarnitine (DRUG); Placebo (DRUG),135398658,PGA,Work Productivity and Activity Impairment in Workers With Chronic C Hepatitis; Fatigue in Workers With Chronic C Hepatitis; Fatigue,Liver,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1090,NCT02978690,Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis,COMPLETED,PHASE1,Psoriasis,Spesolimab (DRUG),135398658,PGA,Psoriasis,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1091,NCT01862003,Phase I/II Trial of Antagonism of HER in GI Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer; Recurrent Colorectal Cancer,AZD8931 (DRUG); Irinotecan (DRUG); Folinic Acid (DRUG); Fluorouracil (DRUG); Fluorouracil (DRUG),135398658,PGA,Metastatic Colorectal Cancer; Recurrent Colorectal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1092,NCT03358290,Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis,TERMINATED,PHASE2,Plaque Psoriasis; Skin Diseases,JTE-051 (DRUG); Placebo (DRUG),135398658,PGA,Plaque Psoriasis; Skin Diseases,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1093,NCT01988103,Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis,COMPLETED,PHASE2,Psoriasis; Psoriatic Arthritis; Psoriasis Arthropatica,Apremilast (DRUG); Apremilast (DRUG); Placebo (DRUG),135398658,PGA,Psoriasis; Psoriatic Arthritis; Psoriasis Arthropatica,Skin,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1094,NCT06917079,BBO-11818 in Adult Subjects With KRAS Mutant Cancer,RECRUITING,PHASE1,"Non-Small Cell Lung Cancer; NSCLC; PDAC - Pancreatic Ductal Adenocarcinoma; CRC (Colorectal Cancer); Metastatic Non-Small Lung Cell Cancer; Metastatic Colorectal Cancer (CRC); KRAS G12A; KRAS G12C; KRAS G12D; KRAS G12S; KRAS G12V; Metastatic Pancreatic Ductal Adenocarcinoma; Advanced Lung Carcinoma; Solid Tumor, Adult",BBO-11818 (DRUG); Pembrolizumab (DRUG); Platinum chemotherapy (cisplatin or carboplatin) (DRUG); Pemetrexed (DRUG); Cetuximab (DRUG),135398658,PGA,"Non-Small Cell Lung Cancer; NSCLC; PDAC - Pancreatic Ductal Adenocarcinoma; CRC (Colorectal Cancer); Metastatic Non-Small Lung Cell Cancer; Metastatic Colorectal Cancer (CRC); KRAS G12A; KRAS G12C; KRAS G12D; KRAS G12S; KRAS G12V; Metastatic Pancreatic Ductal Adenocarcinoma; Advanced Lung Carcinoma; Solid Tumor, Adult",Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1095,NCT06928584,Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer,RECRUITING,PHASE2,Locally Recurrent Rectal Cancer,Conventional Radiotherapy (RADIATION); Capecitabine (DRUG); 5-fluorouracil (DRUG); folinic acid (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG); Cetuximab (DRUG); Bevacizumab (DRUG); Hypofractionated radiotherapy (RADIATION); PD-1 antibody (DRUG),135398658,PGA,Locally Recurrent Rectal Cancer,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1096,NCT01482884,"Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis",COMPLETED,PHASE2,Ulcerative Colitis,tralokinumab (DRUG); placebo (DRUG),135398658,PGA,Ulcerative Colitis,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1097,NCT01053390,New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma,COMPLETED,PHASE3,Gallbladder Neoplasms,"Somatostatin (DRUG); epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil） (DRUG)",135398658,PGA,Gallbladder Neoplasms,Bladder/Urinary Tract,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1098,NCT04955990,A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants,TERMINATED,PHASE4,Pulmonary Arterial Hypertension,PAH Therapies (OTHER),135398658,PGA,Pulmonary Arterial Hypertension,Lung,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1099,NCT01588990,A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer,COMPLETED,PHASE4,Colorectal Neoplasms,Oxaliplatin (DRUG); Capecitabine (DRUG); Bevacizumab (DRUG); Leucovorin (DRUG); 5-Fluouracil (DRUG); Irinotecan (DRUG),135398658,PGA,Colorectal Neoplasms,Bowel,Folic acid,,unclear,unclear,yes,yes,Widely used as a dietary supplement and in fortified foods.,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,1.46,134.0 +1100,NCT06433219,Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302),RECRUITING,PHASE2,Ovarian Cancer,Tuvusertib (M1774) (DRUG); Niraparib (DRUG); Lartesertib (M4076) (DRUG),445154,STL,Ovarian Cancer,Ovary/Fallopian Tube,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1101,NCT05683054,A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are Overtreated,COMPLETED,PHASE4,Psoriasis,Dose tapering of adalimumab in patients with supratheurapeutic serum trough levels (BIOLOGICAL); Venapuncture (PROCEDURE); Dermatology Life Quality Index (DLQI) (OTHER); EQ-5D-5L questionnaire (OTHER); Dried blood spot sampling (PROCEDURE),445154,STL,Psoriasis,Skin,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1102,NCT03563365,The Functional and Emotional Benefits of Replenix Power of Three With Resveratrol,TERMINATED,PHASE4,Acne Vulgaris,"Replenix Power of 3 Cream with resveratrol (OTHER); Adapalene and Benzoyl peroxide gel, 0.1%/2.5% (DRUG)",445154,STL,Acne Vulgaris,Skin,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1103,NCT00920803,"A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases",COMPLETED,PHASE1,"Neoplasms, Colorectal",Placebo (DRUG); SRT501 (DRUG),445154,STL,"Neoplasms, Colorectal",Bowel,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1104,NCT02475564,Resveratrol for Pain Due to Endometriosis,COMPLETED,PHASE4,Endometriosis,Placebo (DRUG); Resveratrol (DRUG),445154,STL,Endometriosis,Uterus,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1105,NCT00678431,Randomized Trial of a Nutritional Supplement in Alzheimer's Disease,COMPLETED,PHASE3,Alzheimer's Disease,"Resveratrol with Glucose, and Malate (DIETARY_SUPPLEMENT); Placebo (DIETARY_SUPPLEMENT)",445154,STL,Alzheimer's Disease,CNS/Brain,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1106,NCT02433925,Resveratrol's Effects on Inflammation and Oxidative Stress in Chronic Kidney Disease,COMPLETED,PHASE3,Chronic Renal Insufficiency,Resveratrol (DIETARY_SUPPLEMENT); Placebo (DIETARY_SUPPLEMENT),445154,STL,Chronic Renal Insufficiency,Kidney,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1107,NCT00433576,Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery,COMPLETED,PHASE1,Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Stage I Colon Cancer; Stage I Rectal Cancer; Stage II Colon Cancer; Stage II Rectal Cancer; Stage III Colon Cancer; Stage III Rectal Cancer,resveratrol (DRUG); pharmacological study (OTHER); laboratory biomarker analysis (OTHER),445154,STL,Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Stage I Colon Cancer; Stage I Rectal Cancer; Stage II Colon Cancer; Stage II Rectal Cancer; Stage III Colon Cancer; Stage III Rectal Cancer,Bowel,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1108,NCT02704494,Resveratrol's Effects in Diabetic Nephropathy,COMPLETED,EARLY_PHASE1,Diabetic Nephropathy,Resveratrol (DRUG); Placebo (DRUG); Losartan (DRUG),445154,STL,Diabetic Nephropathy,Kidney,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1109,NCT00578396,Phase I Biomarker Study of Dietary Grape-derived Low Dose Resveratrol for Colon Cancer Prevention,WITHDRAWN,PHASE1,Colon Cancer,grapes (DIETARY_SUPPLEMENT); grapes (DIETARY_SUPPLEMENT); grapes (DIETARY_SUPPLEMENT),445154,STL,Colon Cancer,Bowel,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1110,NCT05736224,Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen,COMPLETED,PHASE1,Skin Cancer,Sunscreen (DRUG); UV Light (OTHER),445154,STL,Skin Cancer,Skin,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1111,NCT02261844,Resveratrol and Human Hepatocyte Function in Cancer,WITHDRAWN,PHASE1,Liver Cancer,Resveratrol (DIETARY_SUPPLEMENT); Placebo (DRUG),445154,STL,Liver Cancer,Liver,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1112,NCT03093389,Tolerability and Steady-state Pharmacokinetics of BIA 6-512,COMPLETED,PHASE1,Parkinson Disease,BIA 6-512 (DRUG); Placebo (DRUG),445154,STL,Parkinson Disease,CNS/Brain,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1113,NCT04654689,Impact of the Combined Treatment of Liposomed Polyphenols With G04CB02 on the ALS Patients,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,Liposomed polyphenols resveratrol and curcumin (DIETARY_SUPPLEMENT); Placebo for liposomed resveratrol and curcumin (OTHER); Isocaloric Diet (DIETARY_SUPPLEMENT); G04CB02 (DRUG); Placebo microcrystalline methylcellulose (OTHER),445154,STL,Amyotrophic Lateral Sclerosis,CNS/Brain,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1114,NCT00256334,Resveratrol for Patients With Colon Cancer,COMPLETED,PHASE1,Colon Cancer; Cancer,Resveratrol (DRUG),445154,STL,Colon Cancer; Cancer,Bowel,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1115,NCT03095092,Effect of Food on BIA 6-512 (Trans-resveratrol),COMPLETED,PHASE1,Parkinson Disease,BIA 6-512 400 mg (DRUG),445154,STL,Parkinson Disease,CNS/Brain,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1116,NCT01489319,Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS),TERMINATED,PHASE1,Polycystic Ovary Syndrome,Salsalate (DRUG); Salsalate (DRUG),445154,STL,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1117,NCT00743743,Pilot Study of the Effects of Resveratrol Supplement in Mild-to-moderate Alzheimer's Disease,WITHDRAWN,PHASE3,Alzheimer Disease,Longevinex brand resveratrol supplement (DIETARY_SUPPLEMENT); placebo (DIETARY_SUPPLEMENT),445154,STL,Alzheimer Disease,CNS/Brain,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1118,NCT03091543,"Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics",COMPLETED,PHASE1,Parkinson Disease,Madopar® HBS 125 (DRUG); Placebo (DRUG); BIA 6-512 25 mg dose (DRUG); BIA 6-512 50 mg dose (DRUG); BIA 6-512 100 mg dose (DRUG); BIA 6-512 200 mg dose (DRUG),445154,STL,Parkinson Disease,CNS/Brain,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1119,NCT01107665,Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma,COMPLETED,PHASE2,Stage III Melanoma; Stage IV Melanoma; Unresectable Melanoma,Pazopanib and Paclitaxel (DRUG),445154,STL,Stage III Melanoma; Stage IV Melanoma; Unresectable Melanoma,Skin,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1120,NCT03819517,Improving Cardiovascular Health in Patients With Chronic Obstructive Pulmonary Disease,COMPLETED,EARLY_PHASE1,Chronic Obstructive Pulmonary Disease,Resveratrol (DRUG); Placebo (OTHER),445154,STL,Chronic Obstructive Pulmonary Disease,Lung,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1121,NCT06131918,Assessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With Neuropathy,COMPLETED,PHASE2,Peripheral Diabetic Neuropathy,"Resveratrol, Alpha lipoic acid, Super oxide dismutase (DRUG); Resveratrol (DRUG); Alpha lipoic acid (DRUG); Super Oxide Dismutase (DRUG)",445154,STL,Peripheral Diabetic Neuropathy,Peripheral Nervous System,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1122,NCT02947932,Oral Resveratrol to Prevent Post-ERCP Pancreatitis,UNKNOWN,PHASE4,"Pancreatitis, Acute; Gastrointestinal Disease",Resveratrol (DRUG); Indomethacin (DRUG),445154,STL,"Pancreatitis, Acute; Gastrointestinal Disease",Pancreas,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1123,NCT01716637,Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease,COMPLETED,PHASE1,Alzheimer's Disease,"Etanercept (BIOLOGICAL); Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr. (DIETARY_SUPPLEMENT)",445154,STL,Alzheimer's Disease,CNS/Brain,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1124,NCT01504854,Resveratrol for Alzheimer's Disease,COMPLETED,PHASE2,Alzheimer's Disease,Resveratrol (DRUG); Placebo (DRUG),445154,STL,Alzheimer's Disease,CNS/Brain,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1125,NCT02502253,BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM),COMPLETED,PHASE1,Mild Cognitive Impairment; Alzheimer's Disease,"grape seed polyphenolic extract, resveratrol (DRUG)",445154,STL,Mild Cognitive Impairment; Alzheimer's Disease,CNS/Brain,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1126,NCT02030977,The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis,COMPLETED,PHASE2,Non Alcoholic Fatty Liver,Resveratrol (DIETARY_SUPPLEMENT); placebo (OTHER),445154,STL,Non Alcoholic Fatty Liver,Liver,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1127,NCT03094156,Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics,COMPLETED,PHASE1,Parkinson Disease,Placebo (DRUG); BIA 6-512 (DRUG); Madopar® 250 (DRUG); Comtan® (DRUG),445154,STL,Parkinson Disease,CNS/Brain,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1128,NCT06470061,RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β,NOT_YET_RECRUITING,PHASE2,Alzheimer Disease; Mild Cognitive Impairment; Cognitive Decline,"Resveratrol, Quercetin, and Curcumin (RQC) (DRUG); Curcumin (DRUG)",445154,STL,Alzheimer Disease; Mild Cognitive Impairment; Cognitive Decline,CNS/Brain,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1129,NCT03097211,Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg,COMPLETED,PHASE1,Parkinson Disease,Placebo (DRUG); BIA 6-512 (DRUG); Madopar® 250 (DRUG); Nebicapone (DRUG),445154,STL,Parkinson Disease,CNS/Brain,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1130,NCT03095105,Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects,COMPLETED,PHASE1,Parkinson Disease,200 mg BIA 6-512 (DRUG),445154,STL,Parkinson Disease,CNS/Brain,Resveratrol,SIRT1,unclear,unclear,no,yes,"Studies showed promising results, but no approval for therapeutic use.",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,1.47,113.0 +1131,NCT05198830,"Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer",RECRUITING,PHASE2,Lung Adenocarcinoma; Lung Large Cell Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8,Carboplatin (DRUG); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Durvalumab (BIOLOGICAL); FDG-Positron Emission Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Methoxyamine (DRUG); Pemetrexed (DRUG); Radiation Therapy (RADIATION),135410875,LYA,Lung Adenocarcinoma; Lung Large Cell Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1132,NCT04372927,ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy,TERMINATED,PHASE2,Locally Advanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8,Cisplatin (DRUG); Durvalumab (BIOLOGICAL); Etoposide (DRUG); Hypofractionated Radiation Therapy (RADIATION); Pemetrexed (DRUG),135410875,LYA,Locally Advanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1133,NCT02535325,"Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer",COMPLETED,PHASE1,Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma; Stage III Lung Adenocarcinoma AJCC v7; Stage III Lung Large Cell Carcinoma AJCC v7; Stage III Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Adenocarcinoma AJCC v7; Stage IIIA Lung Large Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Adenocarcinoma AJCC v7; Stage IIIB Lung Large Cell Carcinoma AJCC v7; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IV Lung Adenocarcinoma AJCC v7; Stage IV Lung Large Cell Carcinoma AJCC v7; Stage IV Lung Non-Small Cell Cancer AJCC v7,3-Dimensional Conformal Radiation Therapy (RADIATION); Cisplatin (DRUG); Intensity-Modulated Radiation Therapy (RADIATION); Methoxyamine (DRUG); Methoxyamine Hydrochloride (DRUG); Pemetrexed (DRUG); Pemetrexed Disodium (DRUG),135410875,LYA,Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma; Stage III Lung Adenocarcinoma AJCC v7; Stage III Lung Large Cell Carcinoma AJCC v7; Stage III Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Adenocarcinoma AJCC v7; Stage IIIA Lung Large Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Adenocarcinoma AJCC v7; Stage IIIB Lung Large Cell Carcinoma AJCC v7; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IV Lung Adenocarcinoma AJCC v7; Stage IV Lung Large Cell Carcinoma AJCC v7; Stage IV Lung Non-Small Cell Cancer AJCC v7,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1134,NCT05948462,Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib,WITHDRAWN,PHASE2,Lung Cancer; Non-small Cell Lung Cancer,Lorlatinib (DRUG); Cisplatin or Carboplatin (DRUG); Pemetrexed (DRUG),135410875,LYA,Lung Cancer; Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1135,NCT05001880,Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma,RECRUITING,PHASE2,Peritoneal Malignant Mesothelioma,Atezolizumab (BIOLOGICAL); Bevacizumab (BIOLOGICAL); Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Computed Tomography (PROCEDURE); Cytoreductive Surgery (PROCEDURE); Hyperthermic Intraperitoneal Chemotherapy (DRUG); Pemetrexed (DRUG); Positron Emission Tomography (PROCEDURE),135410875,LYA,Peritoneal Malignant Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1136,NCT03737994,Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Alectinib (DRUG); Brigatinib (DRUG); Carboplatin (DRUG); Ceritinib (DRUG); Cisplatin (DRUG); Crizotinib (DRUG); Ensartinib (DRUG); Lorlatinib (DRUG); Pemetrexed (DRUG),135410875,LYA,Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1137,NCT05096663,Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial),ACTIVE_NOT_RECRUITING,PHASE2,Advanced Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Cobalamin (DIETARY_SUPPLEMENT); Dexamethasone (DRUG); Docetaxel (DRUG); Folic Acid (DIETARY_SUPPLEMENT); Gemcitabine (DRUG); Nogapendekin Alfa (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed (DRUG); Ramucirumab (BIOLOGICAL),135410875,LYA,Advanced Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1138,NCT06630416,Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors,RECRUITING,PHASE2,Metastatic Bladder Urothelial Carcinoma; Metastatic Malignant Solid Neoplasm; Stage IV Bladder Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Pemetrexed (DRUG),135410875,LYA,Metastatic Bladder Urothelial Carcinoma; Metastatic Malignant Solid Neoplasm; Stage IV Bladder Cancer AJCC v8,Bladder/Urinary Tract,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1139,NCT04837716,"Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Bevacizumab (BIOLOGICAL); Carboplatin (DRUG); Ensartinib (DRUG); Pemetrexed (DRUG),135410875,LYA,Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1140,NCT06096844,"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial",RECRUITING,PHASE3,Advanced Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8,Carboplatin (DRUG); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Nab-paclitaxel (DRUG); Paclitaxel (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed (DRUG); Positron Emission Tomography (PROCEDURE); Questionnaire Administration (OTHER),135410875,LYA,Advanced Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1141,NCT05715229,Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy,RECRUITING,PHASE2,"Carcinoma, Non-Small-Cell Lung",Nivolumab (DRUG); Ipilimumab (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Pemetrexed (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1142,NCT05624996,"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer",RECRUITING,PHASE3,Locally Advanced Lung Non-Small Cell Carcinoma; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8,Carboplatin (DRUG); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Durvalumab (BIOLOGICAL); Etoposide (DRUG); Image Guided Radiation Therapy (RADIATION); Nab-paclitaxel (DRUG); Paclitaxel (DRUG); Pemetrexed (DRUG); Positron Emission Tomography (PROCEDURE); Questionnaire Administration (OTHER); Stereotactic Body Radiation Therapy (RADIATION),135410875,LYA,Locally Advanced Lung Non-Small Cell Carcinoma; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1143,NCT05501665,Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer,RECRUITING,PHASE1,Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage III Lung Cancer,Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Computed Tomography (PROCEDURE); Fludeoxyglucose F-18 (OTHER); Nab-paclitaxel (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed (DRUG); Positron Emission Tomography (PROCEDURE); Radiation Therapy (RADIATION); [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan (OTHER); Ipilimumab (BIOLOGICAL); Nivolumab (BIOLOGICAL); Cemiplimab (BIOLOGICAL); Atezolizumab (BIOLOGICAL),135410875,LYA,Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage III Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1144,NCT05136846,Papaverine in Combination with Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer,RECRUITING,PHASE1,Locally Advanced Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC V8; Stage IIA Lung Cancer AJCC V8; Stage IIB Lung Cancer AJCC V8; Stage III Lung Cancer AJCC V8; Stage IIIA Lung Cancer AJCC V8; Stage IIIB Lung Cancer AJCC V8; Stage IIIC Lung Cancer AJCC V8; Unresectable Lung Non-Small Cell Carcinoma,Carboplatin (DRUG); Durvalumab (BIOLOGICAL); Paclitaxel (DRUG); Papaverine (DRUG); Radiation Therapy (RADIATION); Pemetrexed (DRUG),135410875,LYA,Locally Advanced Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC V8; Stage IIA Lung Cancer AJCC V8; Stage IIB Lung Cancer AJCC V8; Stage III Lung Cancer AJCC V8; Stage IIIA Lung Cancer AJCC V8; Stage IIIB Lung Cancer AJCC V8; Stage IIIC Lung Cancer AJCC V8; Unresectable Lung Non-Small Cell Carcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1145,NCT02419495,Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies,TERMINATED,PHASE1,Advanced Malignant Solid Neoplasm; Clinical Stage III Cutaneous Melanoma AJCC V8; Clinical Stage IV Cutaneous Melanoma AJCC V8; Fallopian Tube Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Renal Cell Carcinoma; Ovarian Carcinoma; Pathologic Stage III Cutaneous Melanoma AJCC V8; Pathologic Stage IIIA Cutaneous Melanoma AJCC V8; Pathologic Stage IIIB Cutaneous Melanoma AJCC V8; Pathologic Stage IIIC Cutaneous Melanoma AJCC V8; Pathologic Stage IIID Cutaneous Melanoma AJCC V8; Pathologic Stage IV Cutaneous Melanoma AJCC V8; Primary Peritoneal Carcinoma; Stage III Lung Cancer AJCC V8; Stage III Renal Cell Cancer AJCC V8; Stage IIIA Lung Cancer AJCC V8; Stage IIIB Lung Cancer AJCC V8; Stage IIIC Lung Cancer AJCC V8; Stage IV Lung Cancer AJCC V8; Stage IV Renal Cell Cancer AJCC V8; Stage IVA Lung Cancer AJCC V8; Stage IVB Lung Cancer AJCC V8; Triple-Negative Breast Carcinoma; Unresectable Lung Non-Small Cell Carcinoma; Unresectable Melanoma; Unresectable Renal Cell Carcinoma,Capecitabine (DRUG); Carboplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin (DRUG); Eribulin (DRUG); Fluorouracil (DRUG); Ipilimumab (BIOLOGICAL); Irinotecan Hydrochloride (DRUG); Leucovorin Calcium (DRUG); Nivolumab (BIOLOGICAL); Olaparib (DRUG); Oxaliplatin (DRUG); Paclitaxel (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed (DRUG); Selinexor (DRUG); Topotecan (DRUG),135410875,LYA,Advanced Malignant Solid Neoplasm; Clinical Stage III Cutaneous Melanoma AJCC V8; Clinical Stage IV Cutaneous Melanoma AJCC V8; Fallopian Tube Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Renal Cell Carcinoma; Ovarian Carcinoma; Pathologic Stage III Cutaneous Melanoma AJCC V8; Pathologic Stage IIIA Cutaneous Melanoma AJCC V8; Pathologic Stage IIIB Cutaneous Melanoma AJCC V8; Pathologic Stage IIIC Cutaneous Melanoma AJCC V8; Pathologic Stage IIID Cutaneous Melanoma AJCC V8; Pathologic Stage IV Cutaneous Melanoma AJCC V8; Primary Peritoneal Carcinoma; Stage III Lung Cancer AJCC V8; Stage III Renal Cell Cancer AJCC V8; Stage IIIA Lung Cancer AJCC V8; Stage IIIB Lung Cancer AJCC V8; Stage IIIC Lung Cancer AJCC V8; Stage IV Lung Cancer AJCC V8; Stage IV Renal Cell Cancer AJCC V8; Stage IVA Lung Cancer AJCC V8; Stage IVB Lung Cancer AJCC V8; Triple-Negative Breast Carcinoma; Unresectable Lung Non-Small Cell Carcinoma; Unresectable Melanoma; Unresectable Renal Cell Carcinoma,Kidney,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1146,NCT05746481,Tiragolumab and Atezolizumab in Patients with Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases,ACTIVE_NOT_RECRUITING,PHASE2,Non-small Cell Lung Cancer,Tiragolumab (DRUG); Atezolizumab (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1147,NCT03793179,Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Lung Non-Squamous Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Pembrolizumab (BIOLOGICAL); Pemetrexed (DRUG); Positron Emission Tomography (PROCEDURE),135410875,LYA,Lung Non-Squamous Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1148,NCT04966663,Using ctDNA to Determine Therapies for Lung Cancer,RECRUITING,PHASE2,Non Small Cell Lung Cancer; Complete Surgical Resection; Circulating Tumor DNA,Nivolumab (DRUG); Pemetrexed (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); ctDNA blood test (PROCEDURE),135410875,LYA,Non Small Cell Lung Cancer; Complete Surgical Resection; Circulating Tumor DNA,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1149,NCT04971187,Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer,TERMINATED,PHASE2,Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma; Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Unresectable Lung Non-Squamous Non-Small Cell Carcinoma,Bintrafusp Alfa (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG); Cisplatin (DRUG),135410875,LYA,Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma; Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Unresectable Lung Non-Squamous Non-Small Cell Carcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1150,NCT05555732,Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07),RECRUITING,PHASE3,Metastatic Non Small Cell Lung Cancer,Datopotamab Deruxtecan (DRUG); Pembrolizumab (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG); Cisplatin (DRUG),135410875,LYA,Metastatic Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1151,NCT05456256,A Study of LP-300 with Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma,RECRUITING,PHASE2,"Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung",LP-300 (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),135410875,LYA,"Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1152,NCT04892953,Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy,RECRUITING,PHASE2,Stage III Lung Cancer AJCC v8; Stage III Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Cancer AJCC v8; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Cancer AJCC v8; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IIIC Lung Cancer AJCC v8,Carboplatin (DRUG); Durvalumab (BIOLOGICAL); Gemcitabine (DRUG); Local Consolidation Therapy (PROCEDURE); Nab-paclitaxel (DRUG); Paclitaxel (DRUG); Pemetrexed (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),135410875,LYA,Stage III Lung Cancer AJCC v8; Stage III Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Cancer AJCC v8; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Cancer AJCC v8; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IIIC Lung Cancer AJCC v8,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1153,NCT05364645,Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer,WITHDRAWN,PHASE2,Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Carboplatin (DRUG); Pemetrexed (DRUG); Selpercatinib (DRUG),135410875,LYA,Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1154,NCT03132532,Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients with Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery,COMPLETED,PHASE2,Recurrent Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC V8; Stage III Lung Cancer AJCC V8; Unresectable Lung Non-Small Cell Carcinoma,Carboplatin (DRUG); Cisplatin (DRUG); Etoposide (DRUG); Paclitaxel (DRUG); Pemetrexed (DRUG); Proton Beam Radiation Therapy (RADIATION); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),135410875,LYA,Recurrent Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC V8; Stage III Lung Cancer AJCC V8; Unresectable Lung Non-Small Cell Carcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1155,NCT04989283,"Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer",WITHDRAWN,PHASE2,Lung Non-Small Cell Carcinoma; Stage IIB Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Superior Sulcus Lung Carcinoma,Atezolizumab (BIOLOGICAL); Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Etoposide (DRUG); External Beam Radiation Therapy (RADIATION); Magnetic Resonance Imaging (PROCEDURE); Paclitaxel (DRUG); Pemetrexed (DRUG); Positron Emission Tomography (PROCEDURE); Therapeutic Conventional Surgery (PROCEDURE),135410875,LYA,Lung Non-Small Cell Carcinoma; Stage IIB Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Superior Sulcus Lung Carcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1156,NCT01303926,Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer,UNKNOWN,PHASE3,Non-squamous Nonsmall Cell Neoplasm of Lung,cisplatin pemetrexed (DRUG); carboplatin paclitaxel bevacizumab (DRUG),135410875,LYA,Non-squamous Nonsmall Cell Neoplasm of Lung,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1157,NCT04198766,Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist),RECRUITING,PHASE1,Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer; Melanoma; Gastric Cancer; Renal Cell Carcinoma; Urothelial Carcinoma,INBRX-106 - Hexavalent OX40 agonist antibody (DRUG); pembrolizumab 200 mg (DRUG); pembrolizumab 400 mg (DRUG); Carboplatin AUC-5 (DRUG); Carboplatin AUC-6 (DRUG); Pemetrexed 500 mg/m2 (DRUG); Cisplatin 75mg/m2 (DRUG); Paclitaxel 200mg/m2 (DRUG); Nab paclitaxel 100mg/m2 (DRUG),135410875,LYA,Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer; Melanoma; Gastric Cancer; Renal Cell Carcinoma; Urothelial Carcinoma,Bladder/Urinary Tract,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1158,NCT00470548,Abraxane and Alimta in Advanced Solid Tumors,TERMINATED,PHASE1,"Breast Cancer; Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Abraxane (DRUG); Alimta (DRUG),135410875,LYA,Breast and Lung Cancer,Breast,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1159,NCT06652048,High-dose Furmonertinib or Combined with Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI,NOT_YET_RECRUITING,PHASE2,Non-Small Cell Lung Cancer,Furmonertinib 160mg QD (DRUG); Furmonertinib 240mg QD (DRUG); Furmonertinib 160mg QD plus Chemotherapy (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1160,NCT00475657,Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer,TERMINATED,PHASE2,Small Cell Lung Cancer,pemetrexed (DRUG); cisplatin (DRUG),135410875,LYA,Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1161,NCT04396457,Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901,UNKNOWN,PHASE2,"Non-squamous Non-small-cell Lung Cancer; Cancer, Lung",Pembrolizumab (DRUG); Pemetrexed (DRUG),135410875,LYA,"Non-squamous Non-small-cell Lung Cancer; Cancer, Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1162,NCT06334757,Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure,RECRUITING,PHASE2,Non-Squamous Non-Small Cell Lung Cancer,Serplulimab (DRUG); Bevacizumab Biosimilar HLX04 (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),135410875,LYA,Non-Squamous Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1163,NCT06758557,A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor,RECRUITING,PHASE1,Advanced NSCLC; Advanced Endometrial Cancer,HB0025 (DRUG); Pemetrexed (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1164,NCT01064648,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,ACTIVE_NOT_RECRUITING,PHASE1,Epithelioid Mesothelioma; Pleural Malignant Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Cediranib Maleate (DRUG); Cisplatin (DRUG); Laboratory Biomarker Analysis (OTHER); Pemetrexed Disodium (DRUG); Placebo Administration (OTHER),135410875,LYA,Epithelioid Mesothelioma; Pleural Malignant Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1165,NCT02308020,"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",COMPLETED,PHASE2,Breast Cancer; Non-small Cell Lung Cancer; Melanoma; Brain Metastases,Abemaciclib (DRUG),135410875,LYA,Breast Cancer; Non-small Cell Lung Cancer; Melanoma; Brain Metastases,CNS/Brain,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1166,NCT06277674,Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI,RECRUITING,PHASE2,Non-small Cell Lung Cancer,Cadonilimab plus Pemetrexed and Anlotinib (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1167,NCT06151574,Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment,RECRUITING,PHASE3,"Lung Cancer, Non-squamous, Non-small Cell",zongertinib (DRUG); pembrolizumab (DRUG); cisplatin (DRUG); carboplatin (DRUG); pemetrexed (DRUG),135410875,LYA,"Lung Cancer, Non-squamous, Non-small Cell",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1168,NCT06918782,Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma,NOT_YET_RECRUITING,PHASE2,Lung Cancer (NSCLC),Osimertinib plus platinum doublet chemotherapy (DRUG),135410875,LYA,Lung Cancer (NSCLC),Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1169,NCT04405674,Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,Tislelizumab (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Bevacizumab (DRUG); Nab paclitaxel (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1170,NCT05081674,Brazilian Lung Immunotherapy Study,COMPLETED,PHASE2,Lung Neoplasm,Alectinib (DRUG); Pembrolizumab (DRUG); Nivolumab (DRUG); Erlotinib (DRUG),135410875,LYA,Lung Neoplasm,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1171,NCT03950674,Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study,COMPLETED,PHASE3,Non-Small-Cell Lung Carcinoma,Pembrolizumab 200 mg (BIOLOGICAL); Cisplatin (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Folic acid 350-1000 μg (DIETARY_SUPPLEMENT); Vitamin B12 1000 μg (DIETARY_SUPPLEMENT); Dexamethasone 4 mg (DRUG); Saline solution (DRUG),135410875,LYA,Non-Small-Cell Lung Carcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1172,NCT03819465,A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Non-Small Cell Lung Cancer (NSCLC),Durvalumab (DRUG); Danvatirsen (DRUG); Oleclumab (DRUG); MEDI5752 (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG); Nab-paclitaxel (DRUG); AZD2936 (DRUG),135410875,LYA,Metastatic Non-Small Cell Lung Cancer (NSCLC),Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1173,NCT02576574,Avelumab in First-line NSCLC (JAVELIN Lung 100),COMPLETED,PHASE3,First Line Non-Small Cell Lung Cancer,Avelumab (DRUG); Pemetrexed (DRUG); Paclitaxel (DRUG); Gemcitabine (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Avelumab Weekly (DRUG),135410875,LYA,First Line Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1174,NCT00072865,Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Neoplasm Metastasis,Pemetrexed (DRUG); Carboplatin (DRUG),135410875,LYA,Breast Cancer; Neoplasm Metastasis,Breast,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1175,NCT00166465,Stage IV Colorectal CA ALIMTA,COMPLETED,PHASE1,Locally Advanced Unresectable or Stage IV Colorectal Cancer,ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen) (DRUG),135410875,LYA,Locally Advanced Unresectable or Stage IV Colorectal Cancer,Bowel,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1176,NCT06726265,Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004),RECRUITING,PHASE3,Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC),eftilagimod alfa (BIOLOGICAL); carboplatin plus paclitaxel (DRUG); cisplatin or carboplatin + pemetrexed (DRUG); Pembrolizumab (KEYTRUDA®) (BIOLOGICAL); Placebo (OTHER),135410875,LYA,Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC),Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1177,NCT04998474,FRAME-001 Personalized Vaccine in NSCLC,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,FRAME-001 personalized vaccine (BIOLOGICAL),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1178,NCT01017874,A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer,COMPLETED,PHASE3,Non Small Cell Lung Cancer,Pemetrexed (DRUG); Cisplatin (DRUG); Gefitinib (DRUG); Gefitinib (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1179,NCT06704620,Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer,NOT_YET_RECRUITING,PHASE3,Advanced and Metastatic NSCLC,Diphenhydramine (DRUG); Tislelizumab (DRUG); Pemetrexed (DRUG); Albumin paclitaxel (DRUG); Carboplatin (DRUG); Cisplatin (DRUG),135410875,LYA,Non-small Cell Lung Cancer Stage IV,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1180,NCT02705820,Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy,COMPLETED,PHASE2,Metastatic Non Small Cell Lung Cancer,Pembrolizumab (DRUG),135410875,LYA,Metastatic Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1181,NCT02039674,A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021),COMPLETED,PHASE1,Non-small Cell Lung Carcinoma,Pembrolizumab (BIOLOGICAL); Paclitaxel (DRUG); Carboplatin (DRUG); Bevacizumab (BIOLOGICAL); Pemetrexed (DRUG); Ipilimumab (BIOLOGICAL); Erlotinib (DRUG); Gefitinib (DRUG),135410875,LYA,Non-small Cell Lung Carcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1182,NCT05930665,Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma,RECRUITING,PHASE2,Pleural Mesothelioma,Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin (DRUG),135410875,LYA,Pleural Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1183,NCT00434174,Safety of Everolimus and Pemetrexed in Lung Cancer Patients,COMPLETED,PHASE1,Non Small Cell Lung Cancer,Everolimus (DRUG); Pemetrexed (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1184,NCT00391274,Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE3,Non-Small Cell Lung Cancer,pemetrexed (DRUG); docetaxel (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1185,NCT03971474,Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial),COMPLETED,PHASE2,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Docetaxel (DRUG); Gemcitabine (DRUG); Gemcitabine Hydrochloride (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed (DRUG); Pemetrexed Disodium (DRUG); Ramucirumab (BIOLOGICAL),135410875,LYA,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1186,NCT00402766,"Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma",COMPLETED,PHASE1,Mesothelioma,Cisplatin (DRUG); Imatinib Mesylate (DRUG); Pemetrexed (DRUG); Dexamethasone (DRUG),135410875,LYA,Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1187,NCT03663166,Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC),TERMINATED,PHASE1,"Carcinoma, Non-Small-Cell Lung",Thoracic Radiotherapy (RADIATION); Platinum Based Chemotherapy (DRUG); ipilimumab (DRUG); Nivolumab (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1188,NCT00383266,A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer,TERMINATED,PHASE2,Esophageal Neoplasms,Pemetrexed (DRUG); Carboplatin (DRUG),135410875,LYA,Esophageal Neoplasms,Esophagus/Stomach,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1189,NCT04683965,Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer,UNKNOWN,PHASE2,Colorectal Neoplasms,Pemetrexed (DRUG); TAS-102 (DRUG); Bevacizumab (DRUG),135410875,LYA,Colorectal Neoplasms,Bowel,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1190,NCT03322566,A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06),COMPLETED,PHASE2,Lung Cancer,Pembrolizumab (DRUG); Epacadostat (DRUG); Platinum-based chemotherapy (DRUG); Placebo (DRUG),135410875,LYA,Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1191,NCT01107626,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,COMPLETED,PHASE3,Lung Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Bevacizumab (BIOLOGICAL); Pemetrexed Disodium Heptahydrate (DRUG),135410875,LYA,Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1192,NCT02399566,Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma,UNKNOWN,PHASE4,Lung Adenocarcinoma,"Erlotinib, Pemetrexed (DRUG)",135410875,LYA,Lung Adenocarcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1193,NCT00998166,A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy,TERMINATED,PHASE2,Non-Small Cell Lung Cancer,Pemetrexed (DRUG); Cisplatin (DRUG); Bevacizumab (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1194,NCT02707666,A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma,TERMINATED,PHASE1,Pleural Mesothelioma,Pembrolizumab (DRUG); Cisplatin and Pemetrexed (DRUG),135410875,LYA,Pleural Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1195,NCT00614965,Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV,COMPLETED,PHASE2,Non Small Cell Lung Cancer,Irinotecan (DRUG); Cisplatin (DRUG); Pemetrexed (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1196,NCT00377520,A Trial for Patients With Advanced/Recurrent Endometrial Cancer,COMPLETED,PHASE2,"Neoplasms; Neoplasms by Site; Urogenital Neoplasms; Genital Neoplasms, Female; Uterine Neoplasms; Endometrial Neoplasms; Cancer of Endometrium; Endometrial Cancer; Cancer of the Endometrium; Endometrium Cancer; Neoplasms, Endometrial",pemetrexed (DRUG),135410875,LYA,"Neoplasms; Neoplasms by Site; Urogenital Neoplasms; Genital Neoplasms, Female; Uterine Neoplasms; Endometrial Neoplasms; Cancer of Endometrium; Endometrial Cancer; Cancer of the Endometrium; Endometrium Cancer; Neoplasms, Endometrial",Uterus,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1197,NCT04470674,Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients,WITHDRAWN,PHASE2,Lung Cancer; Non-small Cell Lung Cancer; PD-L1 Gene Mutation; KRAS Activating Mutation,Durvalumab (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG),135410875,LYA,Lung Cancer; Non-small Cell Lung Cancer; PD-L1 Gene Mutation; KRAS Activating Mutation,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1198,NCT02737774,Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation,UNKNOWN,PHASE2,Lung Adenocarcinoma,Icotinib (DRUG); Pemetrexed/Carboplatin (DRUG),135410875,LYA,Lung Adenocarcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1199,NCT00490373,Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is Metastatic,COMPLETED,PHASE2,Pancreatic Cancer,pemetrexed (DRUG),135410875,LYA,Pancreatic Cancer,Pancreas,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1200,NCT00923273,Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer,TERMINATED,PHASE1,"Carcinoma, Non-Small-Cell Lung",FDG-PET (DRUG); Pemetrexed (DRUG); Sirolimus (DRUG); Vitamin B12 (DIETARY_SUPPLEMENT); Folic acid tablets (DIETARY_SUPPLEMENT); Dexamethasone tablets (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1201,NCT04054531,Study of KN046 With Chemotherapy in First Line Advanced NSCLC,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,KN046 (BIOLOGICAL); Paclitaxel (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1202,NCT01383148,Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer,TERMINATED,PHASE2,Non-Small-Cell Lung Carcinoma,TG4010 (BIOLOGICAL); placebo (DRUG),135410875,LYA,Non-Small-Cell Lung Carcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1203,NCT04267848,"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial",RECRUITING,PHASE3,Lung Non-Small Cell Carcinoma; Lung Non-Small Cell Squamous Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Gemcitabine Hydrochloride (DRUG); Magnetic Resonance Imaging (PROCEDURE); Observation Activity (OTHER); Paclitaxel (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed Disodium (DRUG); Questionnaire Administration (OTHER),135410875,LYA,Lung Non-Small Cell Carcinoma; Lung Non-Small Cell Squamous Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1204,NCT02337530,Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Selumetinib (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG); Carboplatin (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1205,NCT06416930,Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma,NOT_YET_RECRUITING,PHASE2,Pleural Mesothelioma,Cadonilimab Combined with chemotherapy (DRUG),135410875,LYA,Pleural Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1206,NCT00203931,Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer,TERMINATED,PHASE2,Non-small Cell Lung Cancer,Cetuximab (DRUG); Pemetrexed (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1207,NCT01951482,Pemetrexed/Cisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer,UNKNOWN,PHASE2,Non Squamous Non-small Cell Lung Cancer; Brain Metastases; Bevacizumab,Pemetrexed/cisplatin (DRUG); Bevacizumab and Pemetrexed/cisplatin (DRUG),135410875,LYA,Non Squamous Non-small Cell Lung Cancer; Brain Metastases; Bevacizumab,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1208,NCT02259582,"A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer",COMPLETED,PHASE2,Nonsquamous Nonsmall Cell Neoplasm of Lung,Pemetrexed (DRUG); Carboplatin (DRUG); demcizumab (DRUG),135410875,LYA,Nonsquamous Nonsmall Cell Neoplasm of Lung,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1209,NCT00560573,"Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer",COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung","CP-751,871 (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG); Pemetrexed (DRUG)",135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1210,NCT00343720,Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,VELCADE (DRUG); Alimta (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1211,NCT04061590,Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer,WITHDRAWN,PHASE2,Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8,Cisplatin (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed (DRUG); Pemetrexed Disodium (DRUG); Therapeutic Conventional Surgery (PROCEDURE),135410875,LYA,Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1212,NCT01531790,A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients,COMPLETED,PHASE1,Non-Small Cell Lung Cancer,Carboplatin (DRUG); Pemetrexed (DRUG); Endostar (DRUG); Centrum (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1213,NCT02284490,High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases,UNKNOWN,PHASE2,Brain Metastases,pemetrexed (DRUG),135410875,LYA,Brain Metastases,CNS/Brain,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1214,NCT03792503,Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen,WITHDRAWN,PHASE4,Advanced Non-squamous Non-small-cell Lung Cancer,Apatinib (DRUG); Pemetrexed (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1215,NCT00871403,Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer,COMPLETED,PHASE2,"Lung Cancer, Non-Small Cell",pazopanib and pemetrexed (DRUG); pemetrexed and cisplatin (DRUG),135410875,LYA,"Lung Cancer, Non-Small Cell",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1216,NCT06896890,Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer,RECRUITING,PHASE1,NSCLC (advanced Non-small Cell Lung Cancer); Stage IV Lung Cancer,CIS-DPI (DRUG),135410875,LYA,NSCLC (advanced Non-small Cell Lung Cancer); Stage IV Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1217,NCT02185690,"A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung",COMPLETED,PHASE1,Lungcancer,Binimetinib (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),135410875,LYA,Lungcancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1218,NCT00798603,"Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",COMPLETED,PHASE2,Lung Cancer,bevacizumab (BIOLOGICAL); carboplatin (DRUG); pemetrexed disodium (DRUG),135410875,LYA,Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1219,NCT03991403,Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC,UNKNOWN,PHASE3,Non-small Cell Lung Cancer,Atezolizumab(Tecentriq) (DRUG); Pemetrexed (DRUG); Bevacizumab (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Carboplatin or cisplatin (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1220,NCT01105390,"AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma",WITHDRAWN,PHASE2,Advanced Malignant Mesothelioma; Epithelial Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma,rilotumumab (BIOLOGICAL); cisplatin (DRUG); pemetrexed disodium (DRUG); laboratory biomarker analysis (OTHER),135410875,LYA,Advanced Malignant Mesothelioma; Epithelial Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1221,NCT02029690,Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin,TERMINATED,PHASE1,Pleural Mesothelioma Malignant Advanced; Peritoneal Mesothelioma Malignant Advanced; Non-squamous Non-small Cell Lung Carcinoma; Uveal Melanoma; Hepatocellular Carcinoma; Glioma; Sarcomatoid Carcinoma,ADI-PEG 20 (DRUG),135410875,LYA,Pleural Mesothelioma Malignant Advanced; Peritoneal Mesothelioma Malignant Advanced; Non-squamous Non-small Cell Lung Carcinoma; Uveal Melanoma; Hepatocellular Carcinoma; Glioma; Sarcomatoid Carcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1222,NCT06917079,BBO-11818 in Adult Subjects With KRAS Mutant Cancer,RECRUITING,PHASE1,"Non-Small Cell Lung Cancer; NSCLC; PDAC - Pancreatic Ductal Adenocarcinoma; CRC (Colorectal Cancer); Metastatic Non-Small Lung Cell Cancer; Metastatic Colorectal Cancer (CRC); KRAS G12A; KRAS G12C; KRAS G12D; KRAS G12S; KRAS G12V; Metastatic Pancreatic Ductal Adenocarcinoma; Advanced Lung Carcinoma; Solid Tumor, Adult",BBO-11818 (DRUG); Pembrolizumab (DRUG); Platinum chemotherapy (cisplatin or carboplatin) (DRUG); Pemetrexed (DRUG); Cetuximab (DRUG),135410875,LYA,"Non-Small Cell Lung Cancer; NSCLC; PDAC - Pancreatic Ductal Adenocarcinoma; CRC (Colorectal Cancer); Metastatic Non-Small Lung Cell Cancer; Metastatic Colorectal Cancer (CRC); KRAS G12A; KRAS G12C; KRAS G12D; KRAS G12S; KRAS G12V; Metastatic Pancreatic Ductal Adenocarcinoma; Advanced Lung Carcinoma; Solid Tumor, Adult",Bowel,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1223,NCT04439890,A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer,UNKNOWN,PHASE3,Advanced Non-squamous Cell Non-small Cell Lung Cancer,Anlotinib hydrochloride capsule (DRUG); Carboplatin injection (DRUG); Pemetrexed disodium f Injection (DRUG); Placebo (DRUG),135410875,LYA,Advanced Non-squamous Cell Non-small Cell Lung Cancer,Skin,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1224,NCT04211090,"Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC",UNKNOWN,PHASE2,Non-squamous Non-small-cell Lung Cancer; Brain Metastases,Camrelizumab (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),135410875,LYA,Non-squamous Non-small-cell Lung Cancer; Brain Metastases,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1225,NCT01850303,Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer,COMPLETED,PHASE3,Non Small Cell Lung Cancer (Squamous or Non Squamous),Pemetrexed (DRUG); Gemcitabine (DRUG); Induction chemotherapy (DRUG),135410875,LYA,Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1226,NCT04194203,"A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)",COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung",Atezolizumab (DRUG); Placebo (DRUG); Bevacizumab (DRUG); Paclitaxel (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1227,NCT00295503,"Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma",COMPLETED,PHASE2,Mesothelioma,bevacizumab (DRUG); cisplatin (DRUG); pemetrexed (DRUG),135410875,LYA,Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1228,NCT04322890,Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation,RECRUITING,PHASE2,Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROS1 Gene Mutation; MET Gene Mutation,"Osimertinib (DRUG); Alectinib 150 MG (DRUG); Crizotinib 250 MG (DRUG); Savolitinib, Crizotinib. (DRUG); Chemotherapy (DRUG)",135410875,LYA,Non-Small Cell Lung Cancer with Gene Mutations,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1229,NCT00732303,Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer,TERMINATED,PHASE2,Non-Small Cell Lung Cancer,Pemetrexed (DRUG); Radiation Therapy (RADIATION),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1230,NCT03952403,A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC),ACTIVE_NOT_RECRUITING,PHASE3,Carcinoma; Non-Small-Cell Lung,"HLX10, an engineered anti-PD-1 antibody (DRUG); HLX04, a bevacizumab biosimilar (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG)",135410875,LYA,Carcinoma; Non-Small-Cell Lung,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1231,NCT00989690,Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer,UNKNOWN,PHASE3,Lung Cancer,docetaxel (DRUG); erlotinib hydrochloride (DRUG); pemetrexed disodium (DRUG); fluorescence in situ hybridization (GENETIC); mutation analysis (GENETIC); proteomic profiling (GENETIC); immunohistochemistry staining method (OTHER); laboratory biomarker analysis (OTHER); matrix-assisted laser desorption/ionization time of flight mass spectrometry (OTHER); breath test (PROCEDURE),135410875,LYA,Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1232,NCT04585490,Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC,RECRUITING,PHASE3,"Non Small Cell Lung Cancer; NSCLC, Stage III; Nsclc",Durvalumab (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Paclitaxel (DRUG); Cisplatin (DRUG); AVENIO ctDNA Surveillance Kit (DEVICE); Tremelimumab (DRUG),135410875,LYA,"Non Small Cell Lung Cancer; NSCLC, Stage III; Nsclc",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1233,NCT02922764,A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer,COMPLETED,PHASE1,Endometrial Cancer; Endometrial Cancer Recurrent; Lung Cancer Recurrent; Lung Cancer; Non-small Cell Lung Cancer Metastatic; Non-small Cell Carcinoma,RGX-104 (DRUG); Ipilimumab (DRUG); Docetaxel (DRUG); Pembrolizumab (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG),135410875,LYA,Endometrial Cancer; Endometrial Cancer Recurrent; Lung Cancer Recurrent; Lung Cancer; Non-small Cell Lung Cancer Metastatic; Non-small Cell Carcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1234,NCT02264990,Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers,COMPLETED,PHASE3,Non-squamous Non-small Cell Lung Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Veliparib (DRUG); Pemetrexed (DRUG),135410875,LYA,Non-squamous Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1235,NCT01510990,First Line Gefitinib by FDG-PET Metabolic Response,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,Gefitinib (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1236,NCT04538664,"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions",ACTIVE_NOT_RECRUITING,PHASE3,"Carcinoma, Non-Small-Cell Lung",Amivantamab (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1237,NCT02066038,Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation,UNKNOWN,PHASE2,"Lung, Carcinoma",Erlotinib (DRUG),135410875,LYA,Lung Carcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1238,NCT06788912,Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01),RECRUITING,PHASE2,Lung Neoplasm Malignant,Pembrolizumab (neoadjuvant) (BIOLOGICAL); Cisplatin (DRUG); Gemcitabine (DRUG); Pemetrexed (DRUG); Sacituzumab tirumotecan (DRUG); Antihistamine (DRUG); H2 receptor antagonist (DRUG); Acetaminophen (or equivalent) (DRUG); Dexamethasone (or equivalent) (DRUG); Carboplatin (DRUG); Pembrolizumab (adjuvant) (BIOLOGICAL); Paclitaxel (DRUG); Steroid mouthwash (dexamethasone or equivalent) (DRUG),135410875,LYA,Lung Neoplasm Malignant,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1239,NCT00859495,Trimodal Lung-Sparing Treatment of Pleural Mesothelioma,TERMINATED,PHASE2,Pleural Mesothelioma,Doxorubicin (DRUG); Cisplatin (DRUG); Pemetrexed (DRUG); Radiotherapy (RADIATION),135410875,LYA,Pleural Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1240,NCT06091943,Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Non-small Cell Lung Cancer,Tislelizumab IV (DRUG); Tislelizumab SC (DRUG); Histology-Based Chemotherapy Doublet (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1241,NCT06281964,Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.,NOT_YET_RECRUITING,PHASE3,Non-Small-Cell Lung Cancer,PLB1004 (DRUG); Pemetrexed+（carboplatin or Cisplatin）with or without Sintilimab (DRUG),135410875,LYA,Non-Small-Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1242,NCT05014464,ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma,RECRUITING,PHASE2,Non-small Cell Lung Cancer,Crizotinib (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1243,NCT05681195,Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas,RECRUITING,PHASE2,Primary Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma; Relapsed Cancer; Refractory Cancer,Pemetrexed (DRUG); Zanubrutinib (DRUG); Autologous Stem Cell Transplant (ASCT) (PROCEDURE); Whole Brain Radiation Therapy (WBRT) (RADIATION),135410875,LYA,Primary Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma; Relapsed Cancer; Refractory Cancer,CNS/Brain,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1244,NCT00410904,AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Recurrent Non-small Cell Lung Cancer,cediranib maleate (DRUG); pemetrexed disodium (DRUG),135410875,LYA,Recurrent Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1245,NCT03348904,Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer,TERMINATED,PHASE3,Lung Cancer,Nivolumab (DRUG); Epacadostat (DRUG); Placebo (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG); Paclitaxel (DRUG); Pemetrexed (DRUG),135410875,LYA,Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1246,NCT04262869,Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer,WITHDRAWN,PHASE2,Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Carboplatin (DRUG); Durvalumab (BIOLOGICAL); Paclitaxel (DRUG); Pemetrexed (DRUG),135410875,LYA,Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1247,NCT01189968,A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Non Small Cell Lung Cancer,Demcizumab (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1248,NCT02977169,To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer,UNKNOWN,PHASE2,Non-small Cell Lung Cancer Stage IIIA; Radiotherapy,PORT (RADIATION); Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen) (DRUG),135410875,LYA,Non-small Cell Lung Cancer Stage IIIA; Radiotherapy,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1249,NCT06687369,"A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)",RECRUITING,PHASE3,Non Squamous Non Small Cell Lung Cancer,MB12 (Proposed Pembrolizumab Biosimilar) (DRUG); EU-sourced Keytruda® (DRUG); US-sourced Keytruda® (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG); Cisplatin (DRUG),135410875,LYA,Non Squamous Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1250,NCT06543069,"Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM",RECRUITING,PHASE2,"Malignant Peritoneal Mesothelioma, Advanced","Sintilimab, Bevacizumab , Pemetrexed , Cisplatin (DRUG)",135410875,LYA,"Malignant Peritoneal Mesothelioma, Advanced",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1251,NCT00487669,Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,Advanced Non-small Cell Lung Cancer,"paclitaxel poliglumex, pemetrexed (DRUG)",135410875,LYA,Advanced Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1252,NCT06897046,Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC,NOT_YET_RECRUITING,PHASE2,Non-small Cell Lung Cancer (NSCLC); II-IIIB,QL1706 (DRUG); QL1706+Carboplatin+Paclitaxel（Albumin-bound ）/ Pemetrexed (DRUG),135410875,LYA,Non-small Cell Lung Cancer (NSCLC); II-IIIB,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1253,NCT06875076,Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma,RECRUITING,PHASE2,Pretreated Pleural Mesothelioma,Ivonescimab Combined With Chemotherapy (DRUG),135410875,LYA,Pretreated Pleural Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1254,NCT06667076,"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",RECRUITING,PHASE2,"Carcinoma, Non-Small-Cell Lung",Amivantamab (DRUG); Lazertinib (DRUG); Chemotherapy: Pemetrexed (DRUG); Chemotherapy: Carboplatin (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1255,NCT05298176,"Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors",COMPLETED,PHASE2,Non-Small Cell Lung Cancer,"Afatinib, Osimertinib, Carboplatin and Pemetrexed (DRUG)",135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1256,NCT04611776,"A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer",WITHDRAWN,PHASE2,"Carcinoma, Non-Small Cell Lung",Atezolizumab (DRUG); Placebo (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Pemetrexed (DRUG); Gemcitabine (DRUG); Paclitaxel (DRUG),135410875,LYA,"Carcinoma, Non-Small Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1257,NCT06632327,Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer,RECRUITING,PHASE3,Resectable Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8,Surgical Procedure (PROCEDURE); Cisplatin (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Gemcitabine (DRUG); Docetaxel (DRUG); Vinorelbine (DRUG); Nivolumab (DRUG); Pembrolizumab (DRUG); Atezolizumab (DRUG); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Positron Emission Tomography (PROCEDURE),135410875,LYA,Non-Small-Cell Lung Carcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1258,NCT04943627,Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA),WITHDRAWN,PHASE3,Advanced Cancer; Metastatic Cervical Cancer,Balstilimab (BAL) (DRUG); Topotecan (DRUG); Vinorelbine (DRUG); Gemcitabine (DRUG); Irinotecan (DRUG); Pemetrexed (DRUG),135410875,LYA,Advanced Cancer; Metastatic Cervical Cancer,Cervix,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1259,NCT01803282,Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors,COMPLETED,PHASE1,Pancreatic Cancer; Non-small Cell Lung Cancer; Esophagogastric Cancer; Colorectal Cancer; Breast Cancer,Andecaliximab (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); 5-FU (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG); Paclitaxel (DRUG),135410875,LYA,"Multiple Cancers (Pancreatic, Lung, Esophagogastric, Colorectal, Breast)",Breast,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1260,NCT06745882,Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC,RECRUITING,PHASE2,Non-small Cell Lung Cancer,Cisplatin (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Pembrolizumab (DRUG); Abraxane (DRUG); Paclitaxel (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1261,NCT01353482,"A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma",WITHDRAWN,PHASE1,Malignant Pleural Mesothelioma,Cisplatin (DRUG); Pemetrexed (DRUG); Vorinostat (DRUG); Placebo (DRUG),135410875,LYA,Malignant Pleural Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1262,NCT02919462,"Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression",TERMINATED,PHASE2,"Carcinoma, Non-Small-Cell Lung; Secondary; Advanced Stage IIIB; High Thymidylate Synthase Expression",Oral vinorelbine (DRUG); Cisplatin (DRUG); Maintenance with Metronomic Oral Vinorelbine (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG); Maintenance with Pemetrexed (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung; Secondary; Advanced Stage IIIB; High Thymidylate Synthase Expression",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1263,NCT00334594,Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma,COMPLETED,PHASE2,Malignant Mesothelioma,Cisplatin (DRUG); Pemetrexed (DRUG); Therapeutic conventional surgery (PROCEDURE); Radiotherapy (RADIATION),135410875,LYA,Malignant Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1264,NCT06522360,Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2),WITHDRAWN,PHASE2,Non-small Cell Lung Cancer,Brigatinib (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1265,NCT06514027,Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations,NOT_YET_RECRUITING,PHASE2,Non Small Cell Lung Cancer,BEBT-109 Capsules (DRUG); Pemetrexed Disodium for Injection (DRUG); Carboplatin Injection (DRUG); Cisplatin Injection (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1266,NCT00979576,BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC),TERMINATED,PHASE1,"Carcinoma, Non-Small-Cell Lung",BIBF 1120 M + Pemetrexed (DRUG); BIBF 1120 H + Pemetrexed (DRUG); BIBF 1120 RD + Pemetrexed (DRUG); BIBF 1120 L + Pemetrexed (DRUG); BIBF 1120 Placebo + Pemetrexed (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1267,NCT00103831,Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Non-small Cell Lung Cancer,Oral Taxane (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1268,NCT06890182,Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC,NOT_YET_RECRUITING,PHASE2,Non-small Cell Lung Cancer,Firmonertinib combined with Carboplatin/Cisplatin and Pemetrexed (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1269,NCT00738582,An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma,COMPLETED,PHASE2,Malignant Pleural Mesothelioma,MORAb-009 (Amatuximab) (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG),135410875,LYA,Malignant Pleural Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1270,NCT01102231,Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,Stage III Non-small Cell Lung Cancer,Chemotherapy (DRUG); ERBITUX (DRUG); Radiotherapy (RADIATION),135410875,LYA,Stage III Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1271,NCT01088620,Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer,SUSPENDED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Panitumumab (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1272,NCT06840782,First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.,NOT_YET_RECRUITING,PHASE3,Oligometastatic Non-small Cell Lung Cancer (NSCLC),Radical local treatment (RADIATION); SoC-based immunotherapy (+/- chemotherapy) (DRUG),135410875,LYA,Oligometastatic Non-small Cell Lung Cancer (NSCLC),Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1273,NCT05789082,"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation",RECRUITING,PHASE1,Non-Small Cell Lung Cancer,Divarasib (DRUG); Pembrolizumab (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Pemetrexed (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1274,NCT01263782,BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,Carboplatin (DRUG); Pemetrexed (DRUG); Bevacizumab (DRUG); Cixutumumab (DRUG),135410875,LYA,Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1275,NCT00541073,"Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery",COMPLETED,PHASE2,Malignant Mesothelioma,vitamin B12 (DIETARY_SUPPLEMENT); cisplatin (DRUG); pemetrexed disodium (DRUG); gene expression analysis (GENETIC); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),135410875,LYA,Malignant Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1276,NCT05805631,Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC,NOT_YET_RECRUITING,PHASE2,"Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor Receptor; Leptomeningeal Metastasis",Pemetrexed (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor Receptor; Leptomeningeal Metastasis",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1277,NCT04124731,Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE),UNKNOWN,PHASE2,Carcinoma; Non-small Cell Lung Cancer,sintilimab plus anlotinib (DRUG); Chemotherapy (DRUG),135410875,LYA,Carcinoma; Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1278,NCT00786331,Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC,UNKNOWN,PHASE2,Advanced Non-Small Cell Lung Cancer,Pemetrexed (DRUG); Pemetrexed plus carboplatin (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1279,NCT00383331,Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer,TERMINATED,PHASE2,Non-Small-Cell Lung Cancer,Pemetrexed (DRUG); Gemcitabine (DRUG),135410875,LYA,Non-Small-Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1280,NCT00520676,Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer,COMPLETED,PHASE3,Non-Small Cell Lung Cancer,pemetrexed (DRUG); docetaxel (DRUG); carboplatin (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1281,NCT01590160,"Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma",COMPLETED,PHASE1,Lung Cancer - Malignant Pleural Mesothelioma,Ganetespib (DRUG),135410875,LYA,Lung Cancer - Malignant Pleural Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1282,NCT02609776,"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Non-Small-Cell Lung Cancer,Amivantamab (DRUG); Amivantamab (DRUG); Lazertinib (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG),135410875,LYA,Non-Small-Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1283,NCT04964960,Pembro+Chemo in Brain Mets,TERMINATED,PHASE2,Lung Cancer; Lung Cancer Metastatic; Brain Cancer; Cancer,Pembrolizumab (DRUG); Nab paclitaxel (DRUG); Paclitaxel (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),135410875,LYA,Lung Cancer; Lung Cancer Metastatic; Brain Cancer; Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1284,NCT04022876,A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection),TERMINATED,PHASE1,Non Small Cell Lung Cancer; Small-cell Lung Cancer,ALRN-6924 (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Placebo (DRUG); ALRN-6924 (DRUG); Topotecan (DRUG),135410875,LYA,Non Small Cell Lung Cancer; Small-cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1285,NCT03456076,A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE3,"Carcinoma, Non-Small-Cell Lung",Alectnib (DRUG); Cisplatin (DRUG); Vinorelbine (DRUG); Gemcitabine (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1286,NCT04470076,Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation,UNKNOWN,PHASE2,Non Small Cell Lung Cancer; Surgery; EGFR Activating Mutation; Chemotherapy; EGFR TKI,"Neoadjuvant treatment: Afatinib, pemetrexed, gemcitabine, cisplatin, carboplatin (DRUG); Surgical treatment (PROCEDURE); Adjuvant treatment:afatinib (DRUG)",135410875,LYA,Non Small Cell Lung Cancer; Surgery; EGFR Activating Mutation; Chemotherapy; EGFR TKI,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1287,NCT01445392,SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma,TERMINATED,PHASE1,Mesothelioma,Multicycle SS1P (BIOLOGICAL); Pemetrexed (DRUG); Cisplatin (DRUG); Single cycle SS1P (BIOLOGICAL),135410875,LYA,Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1288,NCT01336192,Maintenance Gemcitabine in the Chinese Advanced Lung Cancer,UNKNOWN,PHASE4,Non Small Cell Lung Cancer,Gemcitabine (DRUG); Best supportive care (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1289,NCT02117167,SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients,COMPLETED,PHASE2,Non-small Cell Lung Cancer Metastatic,AZD2014 (DRUG); AZD4547 (DRUG); AZD5363 (DRUG); AZD8931 (DRUG); Selumetinib (DRUG); Vandetanib (DRUG); Standard maintenance for squamous NSCLC (DRUG); Pemetrexed (DRUG); Durvalumab (DRUG); savolitinib (DRUG); Olaparib (DRUG),135410875,LYA,Non-small Cell Lung Cancer Metastatic,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1290,NCT06275360,Repositioning Immunotherapy in VetArans With Lung Cancer,RECRUITING,PHASE2,Non-Small Cell Lung Cancer,Nivolumab (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1291,NCT05849246,The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC),TERMINATED,PHASE2,Non-squamous Non-small-cell Lung Cancer,Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed (DRUG); Sintilimab+Carboplatin or Cisplatin+Pemetrexed (DRUG); Tusamitamab ravtansine+Sintilimab (DRUG),135410875,LYA,Non-squamous Non-small-cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1292,NCT03944772,Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD),ACTIVE_NOT_RECRUITING,PHASE2,Non-Small Cell Lung Cancer,Osimertinib (DRUG); Savolitinib (DRUG); Gefitinib (DRUG); Necitumumab (DRUG); Durvalumab (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Alectinib (DRUG); Selpercatinib (DRUG); Selumetinib (DRUG); Etoposide (DRUG); Cisplatin (DRUG); Datopotamab deruxtecan (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1293,NCT01005680,A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer,COMPLETED,PHASE3,Non Small Cell Lung Cancer,Pemetrexed (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1294,NCT02639767,Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma,WITHDRAWN,PHASE1,Malignant Pleural Mesothelioma,Pemetrexed/Cisplatin (DRUG); Pleural Intensity Modulated Radiation Therapy (RADIATION); MRI (DEVICE),135410875,LYA,Malignant Pleural Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1295,NCT05633667,Study of Novel Treatment Combinations in Patients With Lung Cancer,RECRUITING,PHASE2,Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer; Resectable Non-Small-Cell Lung Cancer,Zimberelimab (ZIM) (DRUG); Domvanalimab (DOM) (DRUG); Sacituzumab govitecan-hziy (SG) (DRUG); Etrumadenant (ETRUMA) (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Pemetrexed (DRUG); Paclitaxel (DRUG); Nab-paclitaxel (DRUG); Docetaxel (DRUG); Nivolumab (DRUG),135410875,LYA,Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer; Resectable Non-Small-Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1296,NCT00415168,Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer,COMPLETED,PHASE2,Gastric Cancer,pemetrexed (DRUG); cisplatin (DRUG),135410875,LYA,Gastric Cancer,Esophagus/Stomach,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1297,NCT05241873,(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations,TERMINATED,PHASE1,"Lung Neoplasm Malignant; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Neoplasms; Neoplasms by Site; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; EGFR Exon 20 Mutation; EGFR Exon 20 Insertion Mutation; EGFR Activating Mutation; Antineoplastic Agents; Metastatic Lung Cancer; Brain Metastases; EGFR-mutated NSCLC; EGFR Atypical Mutations, Including G719X and L861Q",BLU-451 (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG),135410875,LYA,"Lung Neoplasm Malignant; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Neoplasms; Neoplasms by Site; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; EGFR Exon 20 Mutation; EGFR Exon 20 Insertion Mutation; EGFR Activating Mutation; Antineoplastic Agents; Metastatic Lung Cancer; Brain Metastases; EGFR-mutated NSCLC; EGFR Atypical Mutations, Including G719X and L861Q",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1298,NCT00789373,A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer,COMPLETED,PHASE3,Non-Small Cell Lung Cancer,Pemetrexed (DRUG); Cisplatin (DRUG); Placebo (DRUG); Pemetrexed (DRUG); Best Supportive Care (OTHER),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1299,NCT00550173,A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small-Cell Lung Cancer,pemetrexed (DRUG); erlotinib (DRUG),135410875,LYA,Non-Small-Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1300,NCT00280748,Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer,TERMINATED,PHASE2,Lung Cancer; Metastatic Cancer,pemetrexed disodium (DRUG); radiation therapy (RADIATION),135410875,LYA,Metastatic Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1301,NCT02124148,A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer,COMPLETED,PHASE1,Neoplasm Metastasis; Colorectal Neoplasms; Breast Cancer,Prexasertib (DRUG); Cisplatin (DRUG); Cetuximab (DRUG); G-CSF (DRUG); Pemetrexed (DRUG); Fluorouracil (DRUG); LY3023414 (DRUG); Leucovorin (DRUG),135410875,LYA,Neoplasm Metastasis; Colorectal Neoplasms; Breast Cancer,Bowel,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1302,NCT00701857,"Pemetrexed, Cisplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer",COMPLETED,PHASE1,Esophageal Cancer,cisplatin (DRUG); Pemetrexed (DRUG); radiation therapy (RADIATION),135410875,LYA,Esophageal Cancer,Esophagus/Stomach,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1303,NCT00906282,"Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer",COMPLETED,PHASE2,Non Small Cell Lung Cancer,Pemetrexed (DRUG); Carboplatin (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1304,NCT01241682,Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma,COMPLETED,PHASE1,Malignant (Pleural) Mesothelioma,DC + CTX (BIOLOGICAL),135410875,LYA,Malignant (Pleural) Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1305,NCT02453282,Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC),ACTIVE_NOT_RECRUITING,PHASE3,Non-Small-Cell Lung Carcinoma NSCLC,MEDI4736 (Durvalumab) (BIOLOGICAL); MEDI4736 (Durvalumab)+Tremelimumab (BIOLOGICAL); Paclitaxel + Carboplatin (DRUG); Gemcitabine + Cisplatin (DRUG); Gemcitabine + Carboplatin (DRUG); Pemetrexed + Cisplatin (DRUG); Pemetrexed + Carboplatin (DRUG); Tremelimumab (BIOLOGICAL),135410875,LYA,Non-Small-Cell Lung Carcinoma NSCLC,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1306,NCT04638582,Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC),RECRUITING,PHASE2,"Lung Cancer, Nonsmall Cell",Pembrolizumab (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Pemetrexed (DRUG),135410875,LYA,"Lung Cancer, Nonsmall Cell",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1307,NCT06899126,"Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer",NOT_YET_RECRUITING,PHASE3,Non-small Cell Lung Cancer,Trastuzumab Deruxtecan (DRUG); pembrolizumab (DRUG); Pemetrexed (DRUG); Chemotherapy (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1308,NCT02103257,Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma,UNKNOWN,PHASE4,EGFR Positive Non-small Cell Lung Cancer; Adenocarcinoma,Sequential Icotinib Plus Chemotherapy (DRUG); Icotinib (DRUG),135410875,LYA,EGFR Positive Non-small Cell Lung Cancer; Adenocarcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1309,NCT00545948,Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer,TERMINATED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Vinorelbine followed by Cisplatin (DRUG); Pemetrexed followed by Cisplatin (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1310,NCT00895648,Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma,TERMINATED,PHASE2,Mesothelioma; Pleural Mesothelioma,Pemetrexed (DRUG); Cisplatin (DRUG),135410875,LYA,Mesothelioma; Pleural Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1311,NCT04512430,Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients,TERMINATED,PHASE2,Non Small Cell Lung Cancer; EGFR Gene Mutation,Atezolizumab (DRUG); Bevacizumab (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG),135410875,LYA,Non Small Cell Lung Cancer; EGFR Gene Mutation,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1312,NCT05786430,Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib,NOT_YET_RECRUITING,PHASE2,Non-small Cell Lung Cancer,Lazertinib/Pemetrexed/Carboplatin (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1313,NCT03626922,Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients,UNKNOWN,PHASE1,Metastatic Colorectal Cancer,Pembrolizumab (DRUG); Pemetrexed (DRUG); Oxaliplatin (DRUG); Dexamethasone (DRUG); Folic Acid (DIETARY_SUPPLEMENT); Vitamin B-12 (DIETARY_SUPPLEMENT),135410875,LYA,Metastatic Colorectal Cancer,Bowel,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1314,NCT04989322,"Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC",UNKNOWN,PHASE2,Nsclc; EGFR Activating Mutation; EGF-R Positive Non-Small Cell Lung Cancer; ALK Gene Rearrangement Positive; ROS1 Gene Rearrangement; ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancer,Pembrolizumab (DRUG); Lenvatinib (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),135410875,LYA,Nsclc; EGFR Activating Mutation; EGF-R Positive Non-Small Cell Lung Cancer; ALK Gene Rearrangement Positive; ROS1 Gene Rearrangement; ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1315,NCT06194448,"To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations",RECRUITING,PHASE2,Lung Cancer,Osimertinib (DRUG); Cisplatin or Carboplatin; Pemetrexed or Paclitaxel (DRUG); Radiation (DRUG),135410875,LYA,Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1316,NCT03402048,The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial,UNKNOWN,PHASE3,"Stage IV, NSCLC; Lung Neoplasms; Bronchial Neoplasms; Carcinoma, Bronchogenic; Lung Diseases; Neoplasms; Respiratory Tract Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms",Carboplatin (DRUG); Gemcitabine (DRUG); Pemetrexed (DRUG); Docetaxel (DRUG); Vinorelbine (DRUG),135410875,LYA,"Stage IV, NSCLC; Lung Neoplasms; Bronchial Neoplasms; Carcinoma, Bronchogenic; Lung Diseases; Neoplasms; Respiratory Tract Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1317,NCT04364048,Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer,TERMINATED,PHASE2,Lung Cancer; Non-small Cell Carcinoma,Induction Durvalumab (DRUG); Chemotherapy (DRUG); Radiation (RADIATION); Consolidation durvalumab (DRUG),135410875,LYA,Lung Cancer; Non-small Cell Carcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1318,NCT05299125,"Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Non-small Cell Lung Cancers,Amivantamab (DRUG); Lazertinib (DRUG); Pemetrexed 500 mg (DRUG),135410875,LYA,Metastatic Non-small Cell Lung Cancers,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1319,NCT01655225,A Study of LY3023414 in Participants With Advanced Cancer,COMPLETED,PHASE1,Advanced Cancer; Metastatic Cancer; Non-Hodgkin's Lymphoma; Metastatic Breast Cancer; Malignant Mesothelioma; Non-small Cell Lung Cancer,LY3023414 (DRUG); Midazolam (DRUG); Fulvestrant (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG); Abemaciclib (DRUG); Letrozole (DRUG),135410875,LYA,Advanced Cancer; Metastatic Cancer; Non-Hodgkin's Lymphoma; Metastatic Breast Cancer; Malignant Mesothelioma; Non-small Cell Lung Cancer,Breast,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1320,NCT05329025,A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Non-small-cell Lung Cancer,QL1706 (DRUG),135410875,LYA,Non-small-cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1321,NCT06405230,Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC),NOT_YET_RECRUITING,PHASE1,"Lung Cancer, Non-Small Cell",Pembrolizumab (BIOLOGICAL); Dostarlimab (BIOLOGICAL); Pemetrexed+ (carboplatin or cisplatin) (DRUG),135410875,LYA,"Lung Cancer, Non-Small Cell",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1322,NCT00356525,Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor,TERMINATED,PHASE2,Lung Neoplasms,pemetrexed (DRUG); gemcitabine (DRUG); carboplatin (DRUG); Pemetrexed (DRUG),135410875,LYA,Lung Neoplasms,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1323,NCT04991025,Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery,RECRUITING,PHASE2,Lung Cancer; Lung Cancer Stage II; Lung Cancer Stage III,Cisplatin (DRUG); Pemetrexed (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG); Certolizumab (DRUG); Nivolumab (DRUG),135410875,LYA,Lung Cancer; Lung Cancer Stage II; Lung Cancer Stage III,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1324,NCT00509366,Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer,TERMINATED,PHASE2,Non Small Cell Lung Cancer,Cisplatin & Gemcitabine (DRUG); Cisplatin & Pemetrexed (DRUG); Docetaxel & Gemcitabine (DRUG); Pemetrexed & Gemcitabine (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1325,NCT04592666,Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer,UNKNOWN,PHASE2,"Lung Cancer, Non-small Cell; EGFR T790M; EGFR Gene Mutation",Almonertinib (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),135410875,LYA,"Lung Cancer, Non-small Cell; EGFR T790M; EGFR Gene Mutation",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1326,NCT05458726,Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC,UNKNOWN,PHASE2,EGFR T790M; Osimertinib; Non-small Cell Lung Cancer; ddPCR,Osimertinib (DRUG),135410875,LYA,EGFR T790M; Osimertinib; Non-small Cell Lung Cancer; ddPCR,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1327,NCT02407366,Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,Icotinib (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG); Thoracic radiotherapy(TRT) (RADIATION),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1328,NCT04517526,"Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study",UNKNOWN,PHASE2,Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT,pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT (DRUG),135410875,LYA,Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1329,NCT04083066,Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma,UNKNOWN,PHASE4,Primary Central Nervous System Lymphoma,"rituximab in combination with methotrexate, cytarabine and dexamethasone (DRUG)",135410875,LYA,Primary Central Nervous System Lymphoma,CNS/Brain,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1330,NCT03366766,"Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery",COMPLETED,PHASE2,Non-Squamous Non-Small Cell Lung Carcinoma; Stage I Non-Small Cell Lung Cancer; Stage IA Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage II Non-Small Cell Lung Cancer; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Nivolumab (BIOLOGICAL); Cisplatin (DRUG); Pemetrexed Disodium (DRUG); Gemcitabine Hydrochloride (DRUG),135410875,LYA,Non-Squamous Non-Small Cell Lung Carcinoma; Stage I Non-Small Cell Lung Cancer; Stage IA Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage II Non-Small Cell Lung Cancer; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1331,NCT06692166,A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer,RECRUITING,PHASE3,Cervical Cancer,9MW2821 (DRUG); Chemotherapy (DRUG),135410875,LYA,Cervical Cancer,Cervix,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1332,NCT04586465,Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC,UNKNOWN,PHASE2,Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage III; PET/CT,"pembrolizumab, pemetrexed, gemcitabine, cisplatin, carboplatin (DRUG)",135410875,LYA,Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage III; PET/CT,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1333,NCT06396065,Phase III Study of AK112 for NSCLC Patients,ACTIVE_NOT_RECRUITING,PHASE3,Non-Squamous Non-small Cell Lung Cancer,AK112 Injection (DRUG); Placebo Injection (DRUG),135410875,LYA,Non-Squamous Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1334,NCT06463665,Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer,RECRUITING,PHASE2,Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; Metastatic Non-squamous Non Small Cell Lung Cancer; Metastatic Squamous Non-Small Cell Lung Carcinoma; Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Stage III; Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Recurrent,"Olvimulogene nanivacirepvec (BIOLOGICAL); Platinum chemotherapy: carboplatin or cisplatin (DRUG); Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC (DRUG); Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab (DRUG); Docetaxel (DRUG)",135410875,LYA,Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; Metastatic Non-squamous Non Small Cell Lung Cancer; Metastatic Squamous Non-Small Cell Lung Carcinoma; Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Stage III; Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Recurrent,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1335,NCT04153565,A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17),COMPLETED,PHASE1,Mesothelioma,Pembrolizumab (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG),135410875,LYA,Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1336,NCT00942825,Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,Metastatic Non-squamous Non Small Cell Lung Cancer,CBP501 + Cisplatin + Pemetrexed (DRUG); Cisplatin + Pemetrexed (DRUG),135410875,LYA,Metastatic Non-squamous Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1337,NCT00281125,Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer,TERMINATED,PHASE1,Non-Small Cell Lung Cancer and Pleural Mesothelioma,PTK787 and Pemetrexed with or without Cisplatin (DRUG),135410875,LYA,Non-Small Cell Lung Cancer and Pleural Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1338,NCT01646125,"An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations",TERMINATED,PHASE2,Advanced Non Small Cell Lung Cancer (NSCLC),AUY922 (DRUG); Docetaxel (DRUG); Pemetrexed (DRUG),135410875,LYA,Advanced Non Small Cell Lung Cancer (NSCLC),Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1339,NCT06462222,Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors,RECRUITING,PHASE1,Leptomeningeal Metastasis,"Toripalimab, pemetrexed (DRUG)",135410875,LYA,Leptomeningeal Metastasis,CNS/Brain,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1340,NCT05059522,Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing,ACTIVE_NOT_RECRUITING,PHASE3,Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors,Avelumab (DRUG); Lorlatanib (DRUG); Talazoparib (DRUG); Pemetrexed (DRUG); Axitinib (DRUG); CMP 001 (DRUG); Utomilumab (DRUG); PF04518600 (DRUG),135410875,LYA,Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors,Ovary/Fallopian Tube,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1341,NCT00095225,A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer),COMPLETED,PHASE2,"Non-Small-Cell Lung Carcinoma; Neoplasm Recurrence, Local",Avastin (bevacizumab) (DRUG); Tarceva (erlotinib HCl) (DRUG),135410875,LYA,"Non-Small-Cell Lung Carcinoma; Neoplasm Recurrence, Local",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1342,NCT05284539,Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer,RECRUITING,PHASE2,Non Small Cell Lung Cancer,"Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab (DRUG)",135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1343,NCT03498222,"Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin",WITHDRAWN,PHASE1,"Carcinoma, Non-Small-Cell Lung",Atezolizumab (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG); ADI PEG20 (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1344,NCT00227539,"Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer",COMPLETED,PHASE2,Lung Cancer,cisplatin (DRUG); pemetrexed disodium (DRUG); adjuvant therapy (PROCEDURE); therapeutic conventional surgery (PROCEDURE); fludeoxyglucose F 18 (RADIATION),135410875,LYA,Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1345,NCT00387322,Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors,COMPLETED,PHASE1,"Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",erlotinib hydrochloride (DRUG); pemetrexed disodium (DRUG),135410875,LYA,"Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1346,NCT00614822,"Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer",COMPLETED,PHASE2,Non Small Cell Lung Cancer,"Carboplatin, Pemetrexed and Bevacizumab (DRUG)",135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1347,NCT03607539,Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC,COMPLETED,PHASE3,Lung Neoplasms,Sintilimab (DRUG); Pemetrexed (DRUG); Platinum (DRUG); Placebos (DRUG),135410875,LYA,Lung Neoplasms,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1348,NCT06318286,Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma,NOT_YET_RECRUITING,PHASE2,Malignant Pleural Mesothelioma,Lenvatinib (DRUG); Pemetrexed (DRUG); Cisplatin/Carboplatin (DRUG); Pembrolizumab (DRUG),135410875,LYA,Malignant Pleural Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1349,NCT06623422,A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009),RECRUITING,PHASE3,"Carcinoma, Non-Small-Cell Lung",Pembrolizumab (BIOLOGICAL); Cisplatin (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Gemcitabine (DRUG); Paclitaxel (DRUG); Intismeran autogene (BIOLOGICAL); Placebo (OTHER),135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1350,NCT00418886,Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients,COMPLETED,PHASE3,Non Small Cell Lung Cancer; Lung Cancer,Vandetanib (DRUG); Pemetrexed (DRUG),135410875,LYA,Non Small Cell Lung Cancer; Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1351,NCT00111839,Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer,COMPLETED,PHASE2,Lung Cancer; Non Small Cell Lung Carcinoma,Pemetrexed (DRUG); Matuzumab (DRUG),135410875,LYA,Lung Cancer; Non Small Cell Lung Carcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1352,NCT06809530,Intrathecal Double Checkpoint Inhibition in Combination with Pemetrexed,RECRUITING,PHASE1,Leptomeningeal Metastasis,QL1706 (bispecific antibody targeting PD-1 and CLTA-4) (DRUG); Pemetrexed (Alimta) (DRUG),135410875,LYA,Leptomeningeal Metastasis,CNS/Brain,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1353,NCT01257139,"Trial Involving Subjects Over 70 Years of Age With Non Small-cell Lung Cancer of Stage IV and Comparing a ""Classical"" Strategy of Treatment Allocation, With an""Optimized"" Strategy Allocating the Same Treatments",COMPLETED,PHASE3,Non Small-cell Lung Cancer,Dual-agent therapy or docetaxel alone or best supportive care (PROCEDURE),135410875,LYA,Non Small-cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1354,NCT00351039,"Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer",TERMINATED,PHASE1,Non-Small Cell Lung Cancer,Bevacizumab (DRUG); Erlotinib (DRUG); Pemetrexed (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1355,NCT03920839,INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105),WITHDRAWN,PHASE1,Advanced and/or Metastatic Solid Tumors; Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer; Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma,Retifanlimab (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG),135410875,LYA,Advanced and/or Metastatic Solid Tumors; Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer; Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1356,NCT06800339,"A Phase I, Single-Arm, Single-Institution Study Evaluating Neoadjuvant Chemoimmunotherapy with Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer",NOT_YET_RECRUITING,PHASE1,Non-Small Cell Lung Cancer,Nivolumab (DRUG); Chemotherapy (DRUG); SBRT (RADIATION); Surgical Resection (PROCEDURE),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1357,NCT03190239,Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients,WITHDRAWN,PHASE2,Advanced Non-squamous Non-small-cell Lung Cancer,Apatinib (DRUG); Pemetrexed (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1358,NCT04379739,Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Non Small Cell Lung Cancer,Camrelizumab (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1359,NCT04966676,Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Non Small Cell Lung Cancer,cfDNA blood test (DIAGNOSTIC_TEST); Nivolumab (DRUG); Ipilimumab (DRUG); Platinum-based Chemotherapy (COMBINATION_PRODUCT),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1360,NCT04530227,Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC,RECRUITING,PHASE2,Early Stage Non-small Cell Lung Cancer,Biological: Camrelizumab (DRUG); Pemetrexed (DRUG); Nab-paclitaxel (DRUG),135410875,LYA,Early Stage Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1361,NCT00807573,"Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment",COMPLETED,PHASE2,Lung Cancer,Paclitaxel (DRUG); Pemetrexed (DRUG); Bevacizumab (DRUG),135410875,LYA,Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1362,NCT01533727,CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC),WITHDRAWN,PHASE2,Non-small Cell Lung Cancer,Autologous CIK Transfusion plus Chemotherapy (DRUG); chemotherapy alone (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1363,NCT02477826,"An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)",COMPLETED,PHASE3,Non-Small Cell Lung Cancer,Nivolumab (DRUG); Ipilimumab (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG); Pemetrexed (DRUG); Paclitaxel (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1364,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,COMPLETED,PHASE3,Malignant Pleural Mesothelioma,NGR-hTNF plus Best Investigator's Choice (BIC) (DRUG); Placebo plus Best Investigator's Choice (BIC) (DRUG),135410875,LYA,Malignant Pleural Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1365,NCT05020457,SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.,RECRUITING,PHASE2,Non Small Cell Lung Cancer,SI-B001 (DRUG); AP or TP (DRUG); Docetaxel (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1366,NCT00059865,Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer,COMPLETED,PHASE1,Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer,gemcitabine hydrochloride (DRUG); pemetrexed disodium (DRUG),135410875,LYA,Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer,Liver,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1367,NCT06883630,A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC,RECRUITING,PHASE1,Non-Small Cell Lung Cancer,RC148 plus Carboplatin and Paclitaxel/pemetrexed (DRUG); RC148 (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1368,NCT01909830,Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patients,COMPLETED,PHASE2,Colorectal Cancer Metastatic,Arm A : Gemcitabine + Pemetrexed (DRUG),135410875,LYA,Colorectal Cancer Metastatic,Bowel,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1369,NCT01085630,Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy,COMPLETED,PHASE2,Malignant Mesothelioma,pemetrexed disodium (DRUG); clinical observation (OTHER),135410875,LYA,Malignant Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1370,NCT01192230,Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients,UNKNOWN,PHASE2,"Carcinoma, Non-Small-Cell Lung",Endostatins (DRUG); Docetaxel (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1371,NCT06561386,A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%,RECRUITING,PHASE3,Non-small Cell Lung Cancer,Nivolumab (DRUG); Relatlimab (DRUG); Pembrolizumab (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1372,NCT00391586,"Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung",TERMINATED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Erlotinib (DRUG); Platinum-based chemotherapy (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1373,NCT03061058,Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC,UNKNOWN,PHASE3,Stomach Neoplasms; Chemotherapy Effect; Chemotherapeutic Toxicity,Docetaxel (DRUG); Oxaliplatin (DRUG); Cisplatin (DRUG); Irinotecan (DRUG); Pemetrexed (DRUG); S1 (DRUG),135410875,LYA,Chemotherapy-Induced Gastric Toxicity,Esophagus/Stomach,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1374,NCT00988858,A Study of Advanced or Metastatic Non-small Cell Lung Cancer,COMPLETED,PHASE2,Non Small Cell Lung Cancer,LY2603618 (DRUG); Pemetrexed (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1375,NCT04861948,IBI188 Combination Therapy in Solid Tumors,TERMINATED,PHASE1,Solid Tumors; Lung Adenocarcinoma; Osteosarcoma,IBI188 (DRUG); GM-CSF (DRUG); Cisplatin/Carboplatin (DRUG); Bevacizumab (DRUG); Sintilimab (DRUG); Pemetrexed (DRUG),135410875,LYA,Solid Tumors; Lung Adenocarcinoma; Osteosarcoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1376,NCT00227630,Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma,COMPLETED,PHASE2,Malignant Mesothelioma,cisplatin (DRUG); pemetrexed disodium (DRUG); adjuvant therapy (PROCEDURE); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE); radiation therapy (RADIATION),135410875,LYA,Malignant Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1377,NCT00556322,"A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)",COMPLETED,PHASE3,Non-Small Cell Lung Cancer,Alimta or Taxotere (DRUG); erlotinib [Tarceva] (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1378,NCT01333696,Pemetrexed as Salvage Treatment in Squamous Cell Carcinoma of Head and Neck,UNKNOWN,PHASE2,Squamous Cell Carcinoma of Head and Neck,Pemetrexed (DRUG),135410875,LYA,Squamous Cell Carcinoma of Head and Neck,Skin,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1379,NCT00434135,Alimta and Gemcitabine in Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small Cell Lung Cancer; Stage IIIB or IV,"gemcitabine plus pemetrexed, paclitaxel plus gemcitabine (DRUG)",135410875,LYA,Non-Small Cell Lung Cancer; Stage IIIB or IV,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1380,NCT01323062,Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects,COMPLETED,PHASE1,Non Small Cell Lung Cancer (NSCLC),Bavituximab (DRUG),135410875,LYA,Non Small Cell Lung Cancer (NSCLC),Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1381,NCT02064491,Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC,COMPLETED,PHASE2,Non-small Cell Lung Cancer,Erlotinib (DRUG); Chemotherapy (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1382,NCT06447662,A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.,RECRUITING,PHASE1,"Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung",PF-07934040 (DRUG); Gemcitabine (COMBINATION_PRODUCT); Nab-paclitaxel (COMBINATION_PRODUCT); Cetuximab (COMBINATION_PRODUCT); Fluorouracil (COMBINATION_PRODUCT); Oxaliplatin (COMBINATION_PRODUCT); Leucovorin (COMBINATION_PRODUCT); Bevacizumab (COMBINATION_PRODUCT); Pembrolizumab (COMBINATION_PRODUCT); pemetrexed (COMBINATION_PRODUCT); Cisplatin (COMBINATION_PRODUCT); Paclitaxel (COMBINATION_PRODUCT); Carboplatin (COMBINATION_PRODUCT),135410875,LYA,"Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung",Bowel,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1383,NCT03003962,Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL),ACTIVE_NOT_RECRUITING,PHASE3,Non Small Cell Lung Carcinoma NSCLC,Durvalumab (MEDI4736) (DRUG); Paclitaxel + carboplatin (DRUG); Gemcitabine + cisplatin (DRUG); Gemcitabine + carboplatin (DRUG); Pemetrexed + cisplatin (DRUG); Pemetrexed + carboplatin (DRUG),135410875,LYA,Non Small Cell Lung Carcinoma NSCLC,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1384,NCT02980991,Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002),COMPLETED,PHASE2,Lung Adenocarcinoma,Pemetrexed (DRUG); Cisplatin (DRUG),135410875,LYA,Lung Adenocarcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1385,NCT05543629,A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer,TERMINATED,PHASE1,Advanced Solid Tumors; Non-small Cell Lung Cancer,BMS-986442 (BIOLOGICAL); Nivolumab (BIOLOGICAL); Docetaxel (DRUG); Carboplatin (DRUG); Pemexetred (DRUG); Paclitaxel (DRUG),135410875,LYA,Advanced Solid Tumors; Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1386,NCT02578680,Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189),COMPLETED,PHASE3,Non-Small-Cell Lung Carcinoma,Pembrolizumab 200 mg (BIOLOGICAL); Cisplatin (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Folic acid 350-1000 μg (DIETARY_SUPPLEMENT); Vitamin B12 1000 μg (DIETARY_SUPPLEMENT); Dexamethasone 4 mg (DRUG); Saline solution (DRUG),135410875,LYA,Non-Small-Cell Lung Carcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1387,NCT04524689,Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC,TERMINATED,PHASE2,Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC),SAR408701 (Tusamitamab ravtansine) (DRUG); Pembrolizumab (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG),135410875,LYA,Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC),Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1388,NCT06020989,Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy,NOT_YET_RECRUITING,PHASE2,Non Small Cell Lung Cancer,Lazertinib+Pemetrexed+Carboplatin (DRUG); Lazertinib (DRUG); Lazertinib (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1389,NCT02649829,Autologous Dendritic Cell Vaccination in Mesothelioma,COMPLETED,PHASE1,Malignant Pleural Mesothelioma,dendritic cell vaccination plus chemotherapy (BIOLOGICAL),135410875,LYA,Malignant Pleural Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1390,NCT06231680,Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP),RECRUITING,PHASE2,"Lung Cancer, Nonsmall Cell; Esophageal Carcinoma",Camrelizumab (DRUG); Thalidomide 50mg (DRUG); Thalidomide 100mg (DRUG); Thalidomide 200mg (DRUG); Chemotherapy (DRUG),135410875,LYA,"Lung Cancer, Nonsmall Cell; Esophageal Carcinoma",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1391,NCT05894889,Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC,RECRUITING,PHASE2,Stage IIIB(N2) Non-small Cell Lung Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIB Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer,Pembrolizumab 200 mg IV infusion (BIOLOGICAL),135410875,LYA,Stage IIIB(N2) Non-small Cell Lung Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIB Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1392,NCT00034489,A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.,COMPLETED,PHASE2,Breast Neoplasms,pemetrexed (DRUG); gemcitabine (DRUG),135410875,LYA,Breast Neoplasms,Breast,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1393,NCT06762080,Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis,RECRUITING,PHASE1,Leptomeningeal Metastasis,Cadonilimab (AK104) (DRUG); Pemetrexed (Alimta) (DRUG),135410875,LYA,Leptomeningeal Metastasis,CNS/Brain,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1394,NCT04943029,Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,Carrelizumab (DRUG); Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC) (DRUG); Carboplatin (DRUG); Surgery (PROCEDURE),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1395,NCT06459180,A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20),RECRUITING,PHASE3,Cervical Cancer,Sacituzumab Tirumotecan (BIOLOGICAL); Pemetrexed (DRUG); Tisotumab Vedotin (BIOLOGICAL); Topotecan (DRUG); Vinorelbine (DRUG); Gemcitabine (DRUG); Irinotecan (DRUG),135410875,LYA,Cervical Cancer,Cervix,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1396,NCT01000480,"A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer",COMPLETED,PHASE2,Non Small Cell Lung Cancer,Pemetrexed (DRUG); Cisplatin (DRUG); Thoracic Radiotherapy (RADIATION),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1397,NCT01707329,Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,Chemotherapy (DRUG); Icotinib+chemotherapy (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1398,NCT05775289,A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Non-small Cell Lung Cancer,Tobemstomig (DRUG); Pembrolizumab (DRUG); Paclitaxel (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1399,NCT00268489,Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,bevacizumab (BIOLOGICAL); pemetrexed disodium (DRUG),135410875,LYA,Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1400,NCT01564329,The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar,UNKNOWN,PHASE2,Advanced Primary Lung Adenocarcinoma,endostar (DRUG),135410875,LYA,Advanced Primary Lung Adenocarcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1401,NCT00297089,A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer; NSCLC; Non-Small-Cell Lung Cancer,ABT-751 (DRUG); pemetrexed (DRUG); placebo (DRUG),135410875,LYA,Lung Cancer; NSCLC; Non-Small-Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1402,NCT01837329,Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer,COMPLETED,PHASE1,Non-Small Cell Lung Cancer,Tetrathiomolybdate (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1403,NCT05500092,"An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer",RECRUITING,PHASE2,Resectable Stage IIA to IIIB Non-small Cell Lung Cancer,Nivolumab (DRUG); (8gy x 3) (RADIATION); Platinum Doublet (DRUG),135410875,LYA,Resectable Stage IIA to IIIB Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1404,NCT03138889,Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors,TERMINATED,PHASE1,Non-Small Cell Lung Cancer,NKTR-214 (DRUG); Pembrolizumab (DRUG); NKTR-214 (DRUG); NKTR-214 (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Nab paclitaxel (DRUG); Paclitaxel (DRUG); Pemetrexed (DRUG); Atezolizumab (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1405,NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,pemetrexed disodium (DRUG); sorafenib tosylate (DRUG),135410875,LYA,Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1406,NCT03164694,APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC,WITHDRAWN,PHASE2,Lung Cancer,Apatinib (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),135410875,LYA,Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1407,NCT06930794,A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET Amplification.,NOT_YET_RECRUITING,PHASE3,Non-Small Cell Lung Cancer,Vebreltinib combined with platinum-based doublet chemotherapy. (DRUG); platinum-based doublet chemotherapy. (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1408,NCT00191191,To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,Non-small Cell Lung Cancer,Pemetrexed 500 mg/m2 (DRUG); Pemetrexed 1000 mg/m2 (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1409,NCT06784791,Preoperative Amivantamab or Amivantamab and Carboplatin/pemetrexed Treatment in Patients with Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR),RECRUITING,PHASE2,Lung Cancer (NSCLC),Amivantamab Intravenous (DRUG); Carboplatin/Pemetrexed (DRUG),135410875,LYA,Lung Cancer (NSCLC),Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1410,NCT05116462,Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer,RECRUITING,PHASE3,Non-Small Cell Lung Cancer,Pemetrexed (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Sintilimab (DRUG); Cisplatin (DRUG); Nab paclitaxel (DRUG); Placebo (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1411,NCT03177291,Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC,COMPLETED,PHASE1,Lung Cancer; Non Small Cell Lung Cancer; Advanced Cancer; Metastatic Lung Cancer; Squamous Cell Lung Cancer; Non-Squamous Non-Small Cell Neoplasm of Lung,Pirfenidone (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Pemetrexed (DRUG),135410875,LYA,Lung Cancer; Non Small Cell Lung Cancer; Advanced Cancer; Metastatic Lung Cancer; Squamous Cell Lung Cancer; Non-Squamous Non-Small Cell Neoplasm of Lung,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1412,NCT02093962,Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer,TERMINATED,PHASE2,Non-small Cell Lung Cancer,TH-302 combination with pemetrexed (DRUG); Matched placebo in combination with pemetrexed (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1413,NCT05487391,A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.,RECRUITING,PHASE3,"Carcinoma, Non-Small-Cell Lung",QL1706 injection (DRUG); Vinorelbine Tartrate (DRUG); Paclitaxel (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Placebo (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1414,NCT02276560,Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC,TERMINATED,PHASE2,Stage IIIA Non-Small Cell Lung Cancer,"Neoadjuvant Cisplatin, nab-paclitaxel (DRUG); Adjuvant Cisplatin,nab-paclitaxel (DRUG); Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine (DRUG)",135410875,LYA,Stage IIIA Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1415,NCT02220894,Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042),COMPLETED,PHASE3,Non-small Cell Lung Cancer,pembrolizumab (BIOLOGICAL); carboplatin (DRUG); paclitaxel (DRUG); pemetrexed (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1416,NCT02488694,Maintaining ERBB Blockade in EGFR-mutated Lung Cancer,TERMINATED,PHASE2,Non-small-cell Lung Cancer With Somatic EGFR Mutations,Afatinib (DRUG); Pemetrexed (DRUG),135410875,LYA,Non-small-cell Lung Cancer With Somatic EGFR Mutations,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1417,NCT03656094,Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors,UNKNOWN,PHASE2,Non-small Cell Lung Cancer Metastatic,Pembrolizumab plus chemotherapy (DRUG); Placebo plus chemotherapy (DRUG),135410875,LYA,Non-small Cell Lung Cancer Metastatic,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1418,NCT04455594,Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC,NOT_YET_RECRUITING,PHASE2,Non-Small Cell Lung Cancer Stage IIIA,Almonertinib (DRUG); Erlotinib (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG),135410875,LYA,Non-Small Cell Lung Cancer Stage IIIA,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1419,NCT00190762,A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma,COMPLETED,PHASE3,Mesothelioma,Pemetrexed (DRUG),135410875,LYA,Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1420,NCT00712062,Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma,WITHDRAWN,PHASE2,Primary Central Nervous System Lymphoma,Pemetrexed (DRUG),135410875,LYA,Primary Central Nervous System Lymphoma,CNS/Brain,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1421,NCT00117962,"Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer",COMPLETED,PHASE2,Lung Cancer,cetuximab (BIOLOGICAL); carboplatin (DRUG); pemetrexed disodium (DRUG); radiation therapy (RADIATION),135410875,LYA,Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1422,NCT05891080,"Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial",NOT_YET_RECRUITING,PHASE2,Stage III Non-small Cell Lung Cancer,Toripalimab (DRUG); JS004 (DRUG); Pemetrexed (DRUG); Nab-paclitaxel (DRUG); Carboplatin (DRUG); Surgery (PROCEDURE),135410875,LYA,Stage III Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1423,NCT03374280,Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,pemetrexed/cisplatin intercalating gefitinib (DRUG); pemetrexed/cisplatin (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1424,NCT00533429,Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy,COMPLETED,PHASE2,Non-small Cell Lung Cancer,enzastaurin (DRUG); pemetrexed (DRUG); carboplatin (DRUG); bevacizumab (DRUG); Placebo (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1425,NCT03866980,A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer,TERMINATED,PHASE3,Lung Cancer Non-small Cell Stage IV,AK105 (BIOLOGICAL); carboplatin (DRUG); pemetrexed (DRUG); placebo (DRUG); Anlotinib (DRUG),135410875,LYA,Non-small Cell Lung Cancer Stage IV,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1426,NCT01951586,Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Denosumab (DRUG); Zoledronic acid (DRUG); Placebo to Denosumab (DRUG); Standard Chemotherapy (DRUG); Placebo to Zoledronic Acid (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1427,NCT01313663,A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population,TERMINATED,PHASE2,"Lung Cancer, Small Cell",pazopanib (DRUG); pemetrexed (DRUG),135410875,LYA,Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1428,NCT00035035,"A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.",COMPLETED,PHASE3,"Pancreatic Neoplasms; Metastases, Neoplasm",GEMZAR (DRUG); ALIMTA (DRUG),135410875,LYA,"Pancreatic Neoplasms; Metastases, Neoplasm",Pancreas,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1429,NCT04379635,Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC),ACTIVE_NOT_RECRUITING,PHASE3,Non Small Cell Lung Cancer,Tislelizumab (DRUG); Cisplatin injection (DRUG); Paclitaxel injection (DRUG); Pemetrexed Disodium (DRUG); Placebos (DRUG); Carboplatin (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1430,NCT04425135,Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC,UNKNOWN,PHASE2,Lung Neoplasms,Camrelizumab (DRUG); Apatinib (DRUG); Pemetrixed (DRUG); Carboplatin (DRUG),135410875,LYA,Lung Neoplasms,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1431,NCT00461786,A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer,COMPLETED,PHASE2,Ovarian Cancer; Peritoneal Cancer,pemetrexed (DRUG),135410875,LYA,Ovarian Cancer; Peritoneal Cancer,Ovary/Fallopian Tube,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1432,NCT06621563,Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors,RECRUITING,PHASE1,Solid Tumors; Non-Small Cell Lung Cancer; Colorectal Cancer,HS-20117 combined HS-20093 (DRUG); HS-20117 combined Platinum-containing chemotherapy (DRUG); HS-20117 combined HS-20093 and 5-FU (DRUG); HS-20117+CAPEOX (DRUG); HS-20117+FOLFIRI (DRUG); HS-20117+mFOLFOX6 (DRUG),135410875,LYA,Solid Tumors; Non-Small Cell Lung Cancer; Colorectal Cancer,Bowel,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1433,NCT02679963,Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,Olaparib (DRUG); Placebo (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1434,NCT03775486,Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION),ACTIVE_NOT_RECRUITING,PHASE2,Non-small Cell Lung Cancer NSCLC,Durvalumab (DRUG); Placebo for Olaparib (DRUG); Olaparib (DRUG); Nab-paclitaxel+carboplatin (DRUG); Gemcitabine+carboplatin (DRUG); Pemetrexed+carboplatin (DRUG); Gemcitabine+cisplatin (DRUG); Pemetrexed+cisplatin (DRUG),135410875,LYA,Non-small Cell Lung Cancer NSCLC,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1435,NCT01373463,Cisplatin and Pemetrexed With Radiation Followed by Lobectomy,TERMINATED,PHASE1,Nonsquamous Nonsmall Cell Neoplasm of Lung; Nonsmall Cell Lung Cancer Stage III,Pemetrexed (DRUG); Carboplatin (DRUG); Radiation Therapy (RADIATION); Pemetrexed (DRUG); Cisplatin (DRUG); Radiation Therapy (RADIATION); Lobectomy (PROCEDURE); Lobectomy (PROCEDURE),135410875,LYA,Nonsquamous Nonsmall Cell Neoplasm of Lung; Nonsmall Cell Lung Cancer Stage III,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1436,NCT03520686,QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.,ACTIVE_NOT_RECRUITING,PHASE3,Non Small Cell Lung Cancer,N-803 + Pembrolizumab (DRUG); N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab (DRUG); N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed (DRUG); Pembrolizumab (DRUG); Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab (DRUG); Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed (DRUG); N-803 + Carboplatin + Nab-paclitaxel + Ipilimumab + Nivolumab (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1437,NCT01473563,A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,Nonsquamous Non-Small Cell Neoplasm of Lung; Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer Stage IIIB,Pemetrexed (DRUG),135410875,LYA,Nonsquamous Non-Small Cell Neoplasm of Lung; Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer Stage IIIB,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1438,NCT06110663,A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy,NOT_YET_RECRUITING,PHASE3,Non-Small Cell Lung Cancer,HS-10241+ Almonertinib (DRUG); Pemetrexed + Cisplatin /Carboplatin (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1439,NCT02710396,Genetic Predictors of Benefit to Pembrolizumab,TERMINATED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Pembrolizumab (DRUG); Carboplatin (DRUG); Nab-paclitaxel (DRUG); Pemetrexed (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1440,NCT06382116,A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,RECRUITING,PHASE3,Non-small Cell Lung Cancer,BL-B01D1 (DRUG); Pemetrexed+Cisplatin or Carboplatin (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1441,NCT00660816,Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,erlotinib hydrochloride (DRUG); pemetrexed disodium (DRUG); docetaxel (DRUG),135410875,LYA,Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1442,NCT03164616,Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).,ACTIVE_NOT_RECRUITING,PHASE3,Non Small Cell Lung Cancer NSCLC,Durvalumab (DRUG); Tremelimumab (DRUG); Abraxane + carboplatin (DRUG); Gemcitabine + cisplatin (DRUG); Gemcitabine + carboplatin (DRUG); Pemetrexed + carboplatin (DRUG); Pemetrexed + cisplatin (DRUG),135410875,LYA,Non Small Cell Lung Cancer NSCLC,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1443,NCT03664024,"Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)",COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Pembrolizumab (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG); Cisplatin (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1444,NCT03319316,Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC),WITHDRAWN,PHASE2,Squamous Non-small Cell Lung Cancer; Non-Squamous Non-small Cell Lung Cancer,Durvalumab (DRUG); Tremelimumab (DRUG),135410875,LYA,Squamous Non-small Cell Lung Cancer; Non-Squamous Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1445,NCT00216216,Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer,TERMINATED,PHASE2,Small Cell Lung Cancer,Pemetrexed (DRUG),135410875,LYA,Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1446,NCT00109096,Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy,COMPLETED,PHASE2,Ovarian Neoplasms; Primary Peritoneal Cancer,Pemetrexed (DRUG),135410875,LYA,Ovarian Neoplasms; Primary Peritoneal Cancer,Ovary/Fallopian Tube,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1447,NCT03317496,Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies,TERMINATED,PHASE1,Non-small Cell Lung Cancer; Urothelial Cancer,Avelumab 800 mg in combination with pemetrexed / carboplatin (DRUG); Avelumab 800 mg in combination with gemcitabine / cisplatin. (DRUG); Avelumab 1200 mg in combination with pemetrexed/carboplatin (DRUG); Avelumab 1200 mg in combination with gemcitabine/cisplatin (DRUG),135410875,LYA,Non-small Cell Lung Cancer; Urothelial Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1448,NCT03267316,A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors,COMPLETED,PHASE1,Non Small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma; Triple Negative Breast Cancer; Colorectal Cancer,CAN04 (BIOLOGICAL); Cisplatin (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG),135410875,LYA,Non Small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma; Triple Negative Breast Cancer; Colorectal Cancer,Bowel,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1449,NCT04410796,Osimertinib Alone or with Chemotherapy for EGFR-Mutant Lung Cancers,RECRUITING,PHASE2,Metastatic Non-small Cell Lung Cancer,Osimertinib (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG),135410875,LYA,Metastatic Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1450,NCT05660616,Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma,COMPLETED,PHASE2,Malignant Pleural Mesothelioma,Gemcitabine (DRUG); supportive care (OTHER),135410875,LYA,Malignant Pleural Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1451,NCT06280196,"A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC",RECRUITING,PHASE3,"Carcinoma, Non-Small-Cell Lung",BAT3306 (DRUG); EU-Keytruda® (DRUG); US-Keytruda® (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1452,NCT00473486,Study in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus Sorafenib,TERMINATED,PHASE1,"Carcinoma, Non-Small-Cell Lung","pemetrexed, carboplatin, sorafenib (DRUG); pemetrexed, carboplatin, placebo (DRUG)",135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1453,NCT01020786,A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients,COMPLETED,PHASE4,Non Small Cell Lung Cancer,Pemetrexed (DRUG); Carboplatin (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1454,NCT01344824,"Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers",COMPLETED,PHASE2,Lung Cancer,bevacizumab (BIOLOGICAL); carboplatin (DRUG); erlotinib hydrochloride (DRUG); pemetrexed disodium (DRUG),135410875,LYA,Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1455,NCT06712316,"Safety, Effectiveness, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer",RECRUITING,PHASE2,Non-small Cell Lung Cancer,BNT327 (DRUG); Pembrolizumab (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Paclitaxel (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1456,NCT04905316,"A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Non-small Cell Lung Cancer,Canakinumab (DRUG); Durvalumab (DRUG); Radiation therapy (RADIATION); Chemotherapy (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1457,NCT04581824,Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC),TERMINATED,PHASE2,"Lung Cancer, Non-Small Cell",Dostarlimab (DRUG); Pembrolizumab (DRUG); Chemotherapy (DRUG),135410875,LYA,"Lung Cancer, Non-Small Cell",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1458,NCT00619424,A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors,COMPLETED,PHASE1,"Lung Cancer, Non-Small Cell",pazopanib (DRUG); erlotinib (DRUG); pemetrexed (DRUG),135410875,LYA,"Lung Cancer, Non-Small Cell",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1459,NCT02426658,Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3,COMPLETED,PHASE2,Stage IV Non-Small Cell Lung Cancer,Laboratory Biomarker Analysis (OTHER); Pemetrexed Disodium (DRUG); Quality-of-Life Assessment (OTHER),135410875,LYA,Stage IV Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1460,NCT02049060,Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin,COMPLETED,PHASE1,Malignant Pleural Mesothelioma; Nonsquamous Nonsmall Cell Neoplasm of Lung,Tivantinib (DRUG),135410875,LYA,Malignant Pleural Mesothelioma; Nonsquamous Nonsmall Cell Neoplasm of Lung,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1461,NCT02498860,Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung,COMPLETED,PHASE2,Adenocarcinoma; Lung Neoplasm,Pemebit (DRUG); Cisplatin (DRUG),135410875,LYA,Adenocarcinoma; Lung Neoplasm,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1462,NCT00078260,A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer,COMPLETED,PHASE3,Non-Small Cell Lung Cancer,pemetrexed (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1463,NCT01928160,Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib,WITHDRAWN,PHASE2,Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,pemetrexed disodium (DRUG); carboplatin (DRUG); cisplatin (DRUG); erlotinib hydrochloride (DRUG); laboratory biomarker analysis (OTHER),135410875,LYA,Non-small-cell Lung Carcinoma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1464,NCT06136910,Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer,RECRUITING,PHASE1,Untreated Advanced Non-small Cell Lung Cancer,Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy (DRUG),135410875,LYA,Untreated Advanced Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1465,NCT02535312,"Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin",ACTIVE_NOT_RECRUITING,PHASE1,Advanced Malignant Solid Neoplasm; Advanced Peritoneal Malignant Mesothelioma; Advanced Pleural Malignant Mesothelioma; Recurrent Peritoneal Malignant Mesothelioma; Recurrent Pleural Malignant Mesothelioma; Refractory Malignant Solid Neoplasm; Unresectable Solid Neoplasm,Cisplatin (DRUG); Methoxyamine (DRUG); Pemetrexed Disodium (DRUG),135410875,LYA,Advanced Malignant Solid Neoplasm; Advanced Peritoneal Malignant Mesothelioma; Advanced Pleural Malignant Mesothelioma; Recurrent Peritoneal Malignant Mesothelioma; Recurrent Pleural Malignant Mesothelioma; Refractory Malignant Solid Neoplasm; Unresectable Solid Neoplasm,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1466,NCT00921310,Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer,TERMINATED,PHASE1,"Carcinoma, Non-Small-Cell Lung",Pemetrexed (DRUG); Temsirolimus (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1467,NCT01993810,Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Stage II Non-Small Cell Lung Cancer AJCC v7; Stage IIA Non-Small Cell Lung Carcinoma AJCC v7; Stage IIB Non-Small Cell Lung Carcinoma AJCC v7; Stage III Non-Small Cell Lung Cancer AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7; Stage IIIB Non-Small Cell Lung Cancer AJCC v7,Carboplatin (DRUG); Cisplatin (DRUG); Durvalumab (BIOLOGICAL); Etoposide (DRUG); Paclitaxel (DRUG); Pemetrexed Disodium (DRUG); Photon Beam Radiation Therapy (RADIATION); Proton Beam Radiation Therapy (RADIATION); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),135410875,LYA,Stage II Non-Small Cell Lung Cancer AJCC v7; Stage IIA Non-Small Cell Lung Carcinoma AJCC v7; Stage IIB Non-Small Cell Lung Carcinoma AJCC v7; Stage III Non-Small Cell Lung Cancer AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7; Stage IIIB Non-Small Cell Lung Cancer AJCC v7,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1468,NCT02314481,Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity,ACTIVE_NOT_RECRUITING,PHASE2,Non-small Cell Lung Cancer,MPDL3280A (DRUG); Vemurafenib (DRUG); Alectinib (DRUG); Trastuzumab emtansine (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1469,NCT01160744,A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",IMC-1121B (ramucirumab) (BIOLOGICAL); Pemetrexed (DRUG); Carboplatin (AUC 6) (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG); Carboplatin (AUC 5) (DRUG),135410875,LYA,"Carcinoma, Non-Small-Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1470,NCT01401192,Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According to Thymidylate Synthase Expression,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,Gemcitabine plus cisplatin (DRUG); pemetrexed plus cisplatin (DRUG); pemetrexed plus cisplatin (DRUG); Gemcitabine plus cisplatin (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1471,NCT04422392,Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer,TERMINATED,PHASE2,Non Small Cell Lung Cancer,Carboplatin (DRUG); Pemetrexed or Nab-paclitaxel (DRUG); PD-1 antibody (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1472,NCT03507244,Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors,COMPLETED,PHASE1,Leptomeningeal Metastasis,Pemetrexed (DRUG); Dexamethasone (DRUG); Radiotherapy (RADIATION),135410875,LYA,Leptomeningeal Metastasis,CNS/Brain,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1473,NCT06378892,A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib,RECRUITING,PHASE2,Non Small Cell Lung Cancer Metastatic; ALK Gene Mutation,Lorlatinib (DRUG),135410875,LYA,Non Small Cell Lung Cancer Metastatic; ALK Gene Mutation,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1474,NCT03875144,Treatment of Malignant Peritoneal Mesothelioma (MESOTIP),ACTIVE_NOT_RECRUITING,PHASE2,Peritoneal Mesothelioma; Peritoneal Carcinomatosis,PIPAC (PROCEDURE); Cisplatin (DRUG); Pemetrexed (DRUG),135410875,LYA,Peritoneal Mesothelioma; Peritoneal Carcinomatosis,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1475,NCT00508144,Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,Alimta (DRUG),135410875,LYA,Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1476,NCT00190840,A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE2,"Carcinoma, Non-Small Cell Lung",pemetrexed (DRUG),135410875,LYA,"Carcinoma, Non-Small Cell Lung",Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1477,NCT05800340,Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC,RECRUITING,PHASE2,Non-Small Cell Lung Cancer; RET Driver Mutation; BRAF V600 Mutation; Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation; MET Amplification; MET Exon 14 Skipping Mutation,Toripalimab (BIOLOGICAL); Nab paclitaxel (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),135410875,LYA,Non-Small Cell Lung Cancer; RET Driver Mutation; BRAF V600 Mutation; Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation; MET Amplification; MET Exon 14 Skipping Mutation,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1478,NCT04647344,A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV,AK104 plus Carboplatin and Pemetrexed (DRUG); AK104 plus Carboplatin and paclitaxel (DRUG),135410875,LYA,Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1479,NCT06564844,"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features",RECRUITING,PHASE3,Non-small Cell Lung Cancer,Datopotamab Deruxtecan (DRUG); Rilvegostomig (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Etoposide (DRUG); Pemetrexed (DRUG); Vinorelbine (DRUG); UFT (DRUG),135410875,LYA,Non-small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1480,NCT00330044,"Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer",COMPLETED,PHASE1,Inoperable Non Small Cell Lung Cancer,Premetrexed (Alimta) (DRUG); Carboplatin (DRUG),135410875,LYA,Inoperable Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1481,NCT02716272,"Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients",COMPLETED,PHASE2,Mesothelioma,Nivolumab (DRUG); Nivolumab + Ipilimumab (DRUG),135410875,LYA,Mesothelioma,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1482,NCT06902272,CtDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer,NOT_YET_RECRUITING,PHASE2,Non Small Cell Lung Cancer,Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay (DIAGNOSTIC_TEST); Pembrolizumab (DRUG); Platinum Doublet Chemotherapy (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1483,NCT00190801,Phase 2 Study on Use of a Combination of Pemetrexed in Patients With Advanced Gastric Carcinoma,COMPLETED,PHASE2,Gastrointestinal Neoplasms,pemetrexed (DRUG); cisplatin (DRUG),135410875,LYA,Gastrointestinal Neoplasms,Bowel,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1484,NCT04500704,"Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC",UNKNOWN,PHASE3,Non Small Cell Lung Cancer,Almonertinib (DRUG); Almonertinib plus carboplatin and pemetrexed (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1485,NCT04547504,PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %,ACTIVE_NOT_RECRUITING,PHASE3,Non-small-cell Lung Cancer,Pembrolizumab (DRUG); Pembrolizumab and Chemotherapy drugs (DRUG),135410875,LYA,Non-small-cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1486,NCT00438204,"Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",TERMINATED,PHASE2,Lung Cancer,bevacizumab (BIOLOGICAL); gemcitabine hydrochloride (DRUG); pemetrexed disodium (DRUG),135410875,LYA,Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1487,NCT04031872,LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615),UNKNOWN,PHASE1,Colorectal Cancer Metastatic,LY3200882 (DRUG),135410875,LYA,Colorectal Cancer Metastatic,Bowel,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1488,NCT01639001,A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients,COMPLETED,PHASE3,NSCLC (Non-small Cell Lung Cancer),Crizotinib (DRUG); Pemetrexed/Cisplatin (DRUG); Pemetrexed/Carboplatin (DRUG),135410875,LYA,NSCLC (Non-small Cell Lung Cancer),Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1489,NCT05978401,"Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer",NOT_YET_RECRUITING,PHASE1,Advanced Non-Small Cell Lung Cancer,GLS-012+GLS-010 (DRUG); GLS-012+GLS-010 (DRUG); GLS-012+GLS-010+pemetrexed+carboplatin (DRUG); GLS-012+GLS-010+paclitaxel+carboplatin (DRUG),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1490,NCT00102804,Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE3,Non-Small Cell Lung Cancer,Pemetrexed (DRUG); Placebo (DRUG); Best Supportive Care (OTHER),135410875,LYA,Advanced Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1491,NCT03789604,A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Non Small Cell Lung Cancer,CS1001 monoclonal antibody (BIOLOGICAL); CS1001 placebo (BIOLOGICAL),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1492,NCT04181372,A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer,UNKNOWN,PHASE2,Stage III Non-small-cell Lung Cancer,Anlotinib hydrochloride (DRUG); platinum-based chemotherapy medicine (DRUG),135410875,LYA,Stage III Non-small-cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1493,NCT03802240,Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure,COMPLETED,PHASE3,Non-Squamous Non-Small Cell Lung Cancer,Sintilimab (DRUG); IBI305 (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG); Placebo1 (DRUG); Placebo2 (DRUG),135410875,LYA,Non-Squamous Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1494,NCT02045446,Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial,COMPLETED,PHASE2,Stage IV Non-Small Cell Lung Cancer,Stereotactic Body Radiation Therapy (RADIATION); Maintenance chemotherapy (DRUG),135410875,LYA,Stage IV Non-Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1495,NCT00863512,Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer,TERMINATED,PHASE3,Lung Cancer,cisplatin (DRUG); docetaxel (DRUG); gemcitabine hydrochloride (DRUG); pemetrexed disodium (DRUG); vinorelbine tartrate (DRUG); standard follow-up care (PROCEDURE),135410875,LYA,Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1496,NCT03970746,"Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC",ACTIVE_NOT_RECRUITING,PHASE1,Non Small Cell Lung Cancer,PDC*lung01 (BIOLOGICAL); Keytruda Injectable Product (DRUG); Alimta Injectable Product (DRUG),135410875,LYA,Non Small Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1497,NCT00691301,"Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer",COMPLETED,PHASE2,Cervical Cancer,cisplatin (DRUG); pemetrexed disodium (DRUG),135410875,LYA,Cervical Cancer,Cervix,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1498,NCT02031601,Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer,UNKNOWN,PHASE4,Non-Small-Cell Lung Cancer,Erlotinib (DRUG); Gefitinib (DRUG); Icotinib (DRUG); Docetaxel (DRUG); Pemetrexed (DRUG); Platinum (cisplatin or carboplatin) (DRUG); Erlotinib (DRUG); Gefitinib (DRUG); Icotinib (DRUG),135410875,LYA,Non-Small-Cell Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1499,NCT01588704,"Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma",COMPLETED,PHASE2,Lung Cancer,Neoadjuvant Bevacizumab (DRUG),135410875,LYA,Lung Cancer,Lung,Pemetrexed,"TYMS, DHFR, GART",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Chemotherapy drug for mesothelioma and non-small cell lung cancer.,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,1.0,312.0 +1500,NCT03151603,Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial,COMPLETED,PHASE4,Urinary Tract Infections,Arctuvan (DRUG); Fosfomycin (DRUG); Placebo to Arctuvan (DRUG); Placebo to Fosfomycin (DRUG),440936,Ursi,Urinary Tract Infections,Bladder/Urinary Tract,Arbutin,"MYC, KLF4",inhibitor/antagonist,unclear,no,yes,"Used in cosmetics, trials for skin-lightening, not approved as a drug.",C1=CC(=CC=C1O)OC2C(C(C(C(O2)CO)O)O)O,1.0,200.0 +1501,NCT03574402,Phase II Umbrella Study Directed by Next Generation Sequencing,UNKNOWN,PHASE2,"Carcinoma, Non-Small-Cell Lung",Avitinib Maleate (DRUG); Afatinib (DRUG); Crizotinib (DRUG); X-396 (DRUG); Chidamide (DRUG); Pyrotinib Maleate (DRUG); AZD3759 (DRUG); Pirotinib (DRUG); Nimotuzumab (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG); Sintilimab (DRUG); Gemcitabine (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG),12136798,Epidaza,"Carcinoma, Non-Small-Cell Lung",Lung,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1502,NCT05747313,Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer,UNKNOWN,PHASE1,Breast Cancer; Chemotherapy Effect,Chidamide (DRUG),12136798,Epidaza,Breast Cancer; Chemotherapy Effect,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1503,NCT02815007,Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer,UNKNOWN,PHASE2,Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer,Chidamide with EGFR-TKI (DRUG),12136798,Epidaza,Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer,Lung,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1504,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Tucidinostat (DRUG); Exemestane (DRUG); Ovarian function suppression (DRUG),12136798,Epidaza,Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1505,NCT05519865,A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC,ACTIVE_NOT_RECRUITING,PHASE2,Non Small Cell Lung Cancer,Tucidinostat (DRUG); Tislelizumab (DRUG),12136798,Epidaza,Non Small Cell Lung Cancer,Lung,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1506,NCT05068427,Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.,COMPLETED,PHASE2,Non Small Cell Lung Cancer,Chidamide (DRUG); Envafolimab (DRUG),12136798,Epidaza,Non Small Cell Lung Cancer,Lung,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1507,NCT02718066,"Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer",COMPLETED,PHASE1,Melanoma; Renal Cell Carcinoma; Non-Small Cell Lung Cancer,HBI-8000 in combination with nivolumab (DRUG),12136798,Epidaza,Melanoma; Renal Cell Carcinoma; Non-Small Cell Lung Cancer,Lung,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1508,NCT01836679,Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer,COMPLETED,PHASE2,Non-small-cell Lung Cancer,Chidamide (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Placebo (DRUG),12136798,Epidaza,Non-small-cell Lung Cancer,Lung,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1509,NCT02482753,Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Chidamide (DRUG); exemestane (DRUG); placebo (DRUG),12136798,Epidaza,Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1510,NCT05464173,Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib,RECRUITING,PHASE1,Breast Cancer,Chidamide (DRUG); Abemaciclib (DRUG); endocrinotherapy（doctor's choice） (DRUG),12136798,Epidaza,Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1511,NCT05335473,Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure,RECRUITING,PHASE1,HR Positive HER2 Negative Advanced Breast Cancer,Eribulin and Tucidinostat (DRUG),12136798,Epidaza,HR Positive HER2 Negative Advanced Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1512,NCT06858969,"Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer",NOT_YET_RECRUITING,PHASE2,Metastatic Colorectal Cancer,Treatment group (DRUG); Standard-of-care control group (DRUG),12136798,Epidaza,Metastatic Colorectal Cancer,Bowel,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1513,NCT06685276,Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer,RECRUITING,PHASE2,Colorectal Cancer Metastatic,Fruquintinib (DRUG); Sintilimab (DRUG); Chidamide (DRUG),12136798,Epidaza,Colorectal Cancer Metastatic,Bowel,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1514,NCT04651127,Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer,UNKNOWN,PHASE1,Cervical Cancer; Cervix Cancer; Cervix Neoplasm,Toripalimab + Chidamide (DRUG),12136798,Epidaza,Cervical Cancer; Cervix Cancer; Cervix Neoplasm,Cervix,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1515,NCT05770882,Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC),TERMINATED,PHASE1,Hepatocellular Carcinoma (HCC),Chidamide (DRUG); Regorafenib (DRUG),12136798,Epidaza,Hepatocellular Carcinoma (HCC),Liver,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1516,NCT05390476,"Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial",UNKNOWN,PHASE2,Triple Negative Breast Cancer,Capecitabine (DRUG); Tucidinostat (DRUG),12136798,Epidaza,Triple Negative Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1517,NCT06547476,Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed,NOT_YET_RECRUITING,PHASE2,Breast Cancer,"Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib (DRUG)",12136798,Epidaza,Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1518,NCT05808582,Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer,UNKNOWN,PHASE2,Hormone Receptor-positive Advanced Breast Cancer,chidamide，fulvestrant (DRUG),12136798,Epidaza,Hormone Receptor-positive Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1519,NCT06750848,"Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer",NOT_YET_RECRUITING,PHASE2,Advanced Breast Cancer,Chidamide，Fulvestrant，angiogenesis inhibitors (DRUG),12136798,Epidaza,Advanced Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1520,NCT05253066,Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer,UNKNOWN,PHASE2,Breast Neoplasms,Chidamide combined with exemestane (+/- goserelin) (DRUG); Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician) (DRUG),12136798,Epidaza,Breast Neoplasms,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1521,NCT06584227,Adebrelimab and Chidamide for Pancreatic Cancer,NOT_YET_RECRUITING,PHASE2,"Pancreatic Cancer, Adult",Adebrelimab and Chidamide Combined with Gemcitabine and S1 (DRUG),12136798,Epidaza,"Pancreatic Cancer, Adult",Pancreas,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1522,NCT05411380,"Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.",UNKNOWN,PHASE2,Breast Cancer,Tucidinostat (DRUG); Capecitabine (DRUG); Endocrine Therapy (DRUG),12136798,Epidaza,Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1523,NCT06556862,Exploration of Dalpiciclib + Tucidinostat in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor,NOT_YET_RECRUITING,PHASE2,HR+/HER2- Advanced Breast Cancer,Dalpiciclib (DRUG); Tucidinostat (DRUG),12136798,Epidaza,HR+/HER2- Advanced Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1524,NCT04724239,Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma,ACTIVE_NOT_RECRUITING,PHASE2,Advanced Microsatellite Stable Colorectal Cancer; Metastatic Microsatellite-stable Colorectal Cancer,Sintilimab (DRUG); Chidamide (DRUG); IBI305 (DRUG),12136798,Epidaza,Advanced Microsatellite Stable Colorectal Cancer; Metastatic Microsatellite-stable Colorectal Cancer,Bowel,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1525,NCT05281276,Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC),TERMINATED,PHASE1,Metastatic Colorectal Cancer,chidamide (DRUG); celecoxib (DRUG),12136798,Epidaza,Metastatic Colorectal Cancer,Bowel,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1526,NCT04999540,Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Tucidinostat (DRUG); Fulvestrant (DRUG),12136798,Epidaza,Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1527,NCT05586841,Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study,NOT_YET_RECRUITING,PHASE1,HR+/HER2- Advanced Breast Cancer,Dalpiciclib (DRUG); Chidamide (DRUG),12136798,Epidaza,HR+/HER2- Advanced Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1528,NCT05338541,Tucidinostat Plus Etoposide in the Treatment of Neuroblastoma in Childhood.,RECRUITING,PHASE1,Neuroblastoma in Children,Tucidinostat and etoposide (DRUG),12136798,Epidaza,Neuroblastoma in Children,CNS/Brain,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1529,NCT05633914,Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer,RECRUITING,PHASE2,HR+/HER2- Breast Cancer,Tucidinostat (DRUG); nab-paclitaxel (DRUG),12136798,Epidaza,HR+/HER2- Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1530,NCT04516655,"A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients",UNKNOWN,PHASE2,Central Nervous System Lymphoma,chidamide combined with rituximab and high-dose methotrexate (DRUG),12136798,Epidaza,Central Nervous System Lymphoma,CNS/Brain,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1531,NCT05191914,Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors,UNKNOWN,PHASE4,Breast Cancer,Chidamide+ Fulvestrant (DRUG),12136798,Epidaza,Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1532,NCT06408623,Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer,NOT_YET_RECRUITING,PHASE2,Liver Cancer,chidamide combined with Sintilimab and bevacizumab (DRUG),12136798,Epidaza,Liver Cancer,Liver,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1533,NCT05749575,"Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.",UNKNOWN,PHASE2,Breast Cancer,Chidamide Plus Toripalimab Plus Paclitaxel (DRUG),12136798,Epidaza,Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1534,NCT05438706,A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer,UNKNOWN,PHASE2,Triple-negative Breast Cancer,chidamide (DRUG); camrelizumab (DRUG); carboplatin (DRUG); capecitabine (DRUG),12136798,Epidaza,Triple-negative Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1535,NCT05768503,Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC,RECRUITING,PHASE3,Metastatic Microsatellite-stable Colorectal Cancer,Experimental drug (DRUG); Control Rx (DRUG),12136798,Epidaza,Metastatic Microsatellite-stable Colorectal Cancer,Bowel,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1536,NCT04192903,Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer,UNKNOWN,PHASE2,Triple-negative Breast Cancer,Chidamide combined with Cisplatin (DRUG),12136798,Epidaza,Triple-negative Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1537,NCT05141357,A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer,TERMINATED,PHASE2,Non Small Cell Lung Cancer,HBI-8000 in combination with pembrolizumab (DRUG),12136798,Epidaza,Non Small Cell Lung Cancer,Lung,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1538,NCT05632848,Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients,RECRUITING,PHASE2,Triple Negative Breast Cancer,Chidamide combined with Zimberelimab (DRUG),12136798,Epidaza,Triple Negative Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1539,NCT04984018,Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade,UNKNOWN,PHASE2,Esophageal Squamous Cell Carcinoma,chidamide + camrelizumab (DRUG),12136798,Epidaza,Esophageal Squamous Cell Carcinoma,Skin,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1540,NCT06930118,"The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.",RECRUITING,PHASE2,Advanced Colorectal Cancer in the Third-line Treatment and Beyond; pMMR/MSS Advanced Colorectal Cancer,"chidamide, regorafenib, and iparomlimab/tuvonralimab (DRUG)",12136798,Epidaza,Advanced Colorectal Cancer in the Third-line Treatment and Beyond; pMMR/MSS Advanced Colorectal Cancer,Bowel,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1541,NCT06497985,A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients,RECRUITING,PHASE3,Colorectal Cancer,Tucidinostat (DRUG); Sintilimab (DRUG); Bevacizumab (DRUG); Fruquintinib (DRUG),12136798,Epidaza,Colorectal Cancer,Bowel,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1542,NCT06709885,HDAC Inhibitor Combination with Chemoimmunotherapy in the Neoadjuvant Treatment of PMMR Locally Advanced Colon Cancer,RECRUITING,PHASE2,Colon Adenocarcinoma,Chidamide + Tislelizumab + chemotherapy (CapeOX ) (DRUG); CapeOX (DRUG),12136798,Epidaza,Colon Adenocarcinoma,Bowel,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1543,NCT05983107,Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer,RECRUITING,PHASE2,HR+/HER2- Advanced Breast Cancer; Targeted Therapy,Everolimus (DRUG); Chidamide (DRUG); Endocrine therapy (DRUG); Ovarian function suppression(OFS) (DRUG),12136798,Epidaza,HR+/HER2- Advanced Breast Cancer; Targeted Therapy,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1544,NCT06745193,"A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer",NOT_YET_RECRUITING,PHASE2,Advanced Esophageal Carcinoma,chidamide+Camrelizumab+Apatinib (DRUG); Irinotecan or Docetaxel or Paclitaxel (DRUG),12136798,Epidaza,Advanced Esophageal Carcinoma,Esophagus/Stomach,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1545,NCT04562311,Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma,ACTIVE_NOT_RECRUITING,PHASE2,Bladder Cancer Stage IV,Chidamide (DRUG),12136798,Epidaza,Bladder Cancer Stage IV,Bladder/Urinary Tract,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1546,NCT05163483,"Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer",RECRUITING,PHASE2,"Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma","Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab (DRUG)",12136798,Epidaza,"Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma",Esophagus/Stomach,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1547,NCT05186545,An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer,RECRUITING,PHASE2,Breast Cancer; Breast Cancer Female,surufatinib + fulvestrant + chidamide (DRUG),12136798,Epidaza,Breast Cancer; Breast Cancer Female,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1548,NCT06218888,A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases,NOT_YET_RECRUITING,PHASE2,Colo-rectal Cancer,Tislelizumab (DRUG); Fruquintinib (DRUG); Chidamide (DRUG),12136798,Epidaza,Colorectal Cancer,Bowel,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1549,NCT05400993,Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC,UNKNOWN,PHASE2,Breast Cancer,Chidamide (COMBINATION_PRODUCT),12136798,Epidaza,Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1550,NCT05085626,Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer,UNKNOWN,PHASE2,Advanced HER2 Negative Breast Carcinoma; HRD+Breast Cancer,fluzoparib+chidamide (DRUG); fluzoparib+camrelizumab (DRUG),12136798,Epidaza,Advanced HER2 Negative Breast Carcinoma; HRD+Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1551,NCT05806047,Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy,UNKNOWN,PHASE2,Hormone Receptor-positive Advanced Breast Cancer,chidamide combined with fulvestrant (DRUG),12136798,Epidaza,Hormone Receptor-positive Breast Cancer,Breast,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1552,NCT06951997,"QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer",NOT_YET_RECRUITING,PHASE2,Metastatic Pancreatic Cancer,QL1706 (DRUG); Chidamide (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG),12136798,Epidaza,Metastatic Pancreatic Cancer,Pancreas,Tucidinostat,"HDAC1, HDAC2, HDAC3, HDAC10, HDAC8, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for use in China for certain cancers.,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,1.0,2775.0 +1553,NCT04785365,Long-Term Follow-Up Study of Patients Receiving ATL001,TERMINATED,PHASE2,Melanoma; Advanced Non Small Cell Lung Cancer,Biological: ATL001 (OTHER),16760658,Clin,Melanoma; Advanced Non Small Cell Lung Cancer,Lung,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1554,NCT05869565,Best Solution Identification to Prevent Hyperchloremia Combinations of Sodium Chloride and Sodium Acetate IV Fluids Along With Standard of Care Treatment in Acute Stroke Patients,UNKNOWN,PHASE2,"Stroke, Acute","Sodium Chloride 0.9% infusion alone or in combination with Sodim acetate with normal saline in a ratio 1;1, 2;1 and 3;1 (DRUG)",16760658,Clin,Acute Stroke,CNS/Brain,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1555,NCT05080465,Long Term Follow up Mesenchymal Stem Cell Therapy for Patients Virus-related Liver Cirrhosis,ACTIVE_NOT_RECRUITING,PHASE3,Liver Cirrhosis,Autologous BM MSC (BIOLOGICAL),16760658,Clin,Liver Cirrhosis,Liver,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1556,NCT01187966,"Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease",COMPLETED,PHASE3,Parkinson's Disease,Safinamide (DRUG); Safinamide (DRUG); Placebo (DRUG),16760658,Clin,Parkinson's Disease,CNS/Brain,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1557,NCT03836066,Atezolizumab Plus Bevacizumab in First Line NSCLC Patients,COMPLETED,PHASE2,Non Small Cell Lung Cancer,Atezolizumab-Bevacizumab (DRUG),16760658,Clin,Non Small Cell Lung Cancer,Lung,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1558,NCT02135666,"Evaluation of the Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20 Years Earlier With GSK Biologicals' Combined Hepatitis A and B Vaccine, Twinrix® (SB208127) in Study HAB-084 (208127/084)",WITHDRAWN,PHASE4,Hepatitis B; Hepatitis A,Blood sampling (PROCEDURE),16760658,Clin,Hepatitis B; Hepatitis A,Liver,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1559,NCT01437566,Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy,COMPLETED,PHASE2,Breast Cancer,Fulvestrant (DRUG); GDC-0941 (DRUG); GDC-0941 Matching Placebo (DRUG); GDC-0980 (DRUG); GDC-0980 Matching Placebo (DRUG),16760658,Clin,Breast Cancer,Breast,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1560,NCT02693366,Stem Cell Therapy for Patients With Focal Segmental Glomerulosclerosis,COMPLETED,PHASE1,Focal Segmental Glomerulosclerosis; Chronic Kidney Diseases,Bone marrow stem cell (OTHER),16760658,Clin,Focal Segmental Glomerulosclerosis; Chronic Kidney Diseases,Kidney,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1561,NCT02134366,Clobazam Use in Epilepsia Partialis Continua - Pilot Study,TERMINATED,PHASE3,Epilepsia Partialis Continua; Kojewnikov's Epilepsy; Epilepsy,Clobazam (DRUG); Clonazepam (DRUG); Lorazepam (DRUG),16760658,Clin,Epilepsia Partialis Continua; Kojewnikov's Epilepsy; Epilepsy,CNS/Brain,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1562,NCT01849666,A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy,COMPLETED,PHASE1,"Malignant Melanoma, Neoplasms",phenprocoumon (DRUG); vemurafenib (DRUG),16760658,Clin,"Malignant Melanoma, Neoplasms",Skin,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1563,NCT05162066,"Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)",TERMINATED,PHASE2,Complement 3 Glomerulopathy; Immunoglobulin A Nephropathy; Membranous Nephropathy,BCX9930 (DRUG),16760658,Clin,Complement 3 Glomerulopathy; Immunoglobulin A Nephropathy; Membranous Nephropathy,Kidney,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1564,NCT06717126,A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma,RECRUITING,PHASE2,Uveal Melanoma; Ocular Melanoma,roginolisib (DRUG); Investigator choice of standard therapy (DRUG),16760658,Clin,Uveal Melanoma; Ocular Melanoma,Skin,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1565,NCT04929626,Different Doses of Nebulized Magnesium Sulphate in Status Asthmaticus,COMPLETED,PHASE1,Status Asthmaticus,Magnesium Sulfate 500 mg/ml+ ventolin (DRUG); Ventolin (DRUG),16760658,Clin,Status Asthmaticus,Lung,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1566,NCT04270526,Minimizing Pain During Office Intradetrussor Botox Injection,COMPLETED,PHASE4,Overactive Bladder; Overactive Detrusor; Overactive Bladder Syndrome; Overactivity; Behavior; Urge Incontinence,Bicarbonate protocol (DRUG); Standard protocol (DRUG),16760658,Clin,Overactive Bladder; Overactive Detrusor; Overactive Bladder Syndrome; Overactivity; Behavior; Urge Incontinence,Bladder/Urinary Tract,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1567,NCT02315326,"Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)",RECRUITING,PHASE1,Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL); Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL),Ibrutinib (DRUG); HD- Methotrexate (MTX) (DRUG); Rituximab + HD- Methotrexate (MTX) (DRUG); procarbazine (DRUG),16760658,Clin,Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL); Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL),CNS/Brain,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1568,NCT03399526,1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat,COMPLETED,PHASE1,Psoriasis,"Mapracorat (ZK 245186, BAY 86-5319) (DRUG); Prednicarbate 0.25% ointment (DRUG); Clobetasol 0.05% ointment (DRUG); Calcipotriene 0.005% ointment (DRUG); Calcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment (DRUG)",16760658,Clin,Psoriasis,Skin,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1569,NCT04842526,"Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study",UNKNOWN,PHASE2,Refractory or Recurrent Neuroblastoma in Children,Anlotinib and irinotecan combined with temozolomide (DRUG),16760658,Clin,Refractory or Recurrent Neuroblastoma in Children,CNS/Brain,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1570,NCT02295826,Dabigatran Following Transient Ischemic Attack and Minor Stroke,COMPLETED,PHASE2,Transient Ischemic Attack; Minor Ischemic Stroke,Dabigatran (DRUG); Acetylsalicylic acid (DRUG),16760658,Clin,Transient Ischemic Attack and Minor Ischemic Stroke,CNS/Brain,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1571,NCT02165826,"Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD",COMPLETED,PHASE3,Chronic Obstructive Pulmonary Disease (COPD),Roflumilast (DRUG); Roflumilast Placebo (DRUG); Standard of Care COPD Treatment (DRUG),16760658,Clin,Chronic Obstructive Pulmonary Disease (COPD),Lung,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1572,NCT05536726,A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants with Moderate-to-Severe Plaque Psoriasis,COMPLETED,PHASE3,Psoriasis,608 Q2W (DRUG); 608 Q4W (DRUG); Placebo (DRUG),16760658,Clin,Psoriasis,Skin,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1573,NCT06610526,A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease,RECRUITING,PHASE4,Chronic Kidney Disease,Dapagliflozin (DRUG),16760658,Clin,Chronic Kidney Disease,Kidney,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1574,NCT01786226,Mifepristone to Treat Uterine Fibroids,TERMINATED,PHASE2,Uterine Fibroids,Oral administration of mifepristone 2.5 mg daily for three months (DRUG); Oral administration of mifepristone 5 mg daily for three months (DRUG),16760658,Clin,Uterine Fibroids,Uterus,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1575,NCT00221026,Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease,COMPLETED,PHASE2,Crohn's Disease,Methoxsalen +ECP (DRUG); Extracorporeal Photopheresis (PROCEDURE),16760658,Clin,Crohn's Disease,Bowel,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1576,NCT06139926,Clinical Study of Dexmedetomidine Administered Intranasally to Relieve Perioperative Anxiety and Depression in Patients With Colorectal Tumors,RECRUITING,PHASE3,Colorectal Cancer,Dexmedetomidine administered intranasally (DRUG),16760658,Clin,Colorectal Cancer,Bowel,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1577,NCT02433626,Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies,UNKNOWN,PHASE1,Ovarian Cancer; Fallopian Tube Cancer; Endometrial Cancer; Cervical Cancer; Peritoneal Cancer; Head and Neck Cancer; HNSCC; Colorectal Cancer; Lung Cancer; Pancreatic Cancer,COTI2 (DRUG); Cisplatin (DRUG),16760658,Clin,Ovarian Cancer; Fallopian Tube Cancer; Endometrial Cancer; Cervical Cancer; Peritoneal Cancer; Head and Neck Cancer; HNSCC; Colorectal Cancer; Lung Cancer; Pancreatic Cancer,Bowel,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1578,NCT03894826,Voronistat in Pediatric Patients With Drug Resistant Epilepsy,UNKNOWN,PHASE2,Refractory Epilepsy,Vorinostat 100 MG (DRUG),16760658,Clin,Refractory Epilepsy,CNS/Brain,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1579,NCT02613026,Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer,COMPLETED,PHASE3,Breast Neoplasms,Pirarubicin (DRUG); Docetaxel (DRUG); Cyclophosphamide (DRUG),16760658,Clin,Breast Neoplasms,Breast,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1580,NCT05467826,Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis,UNKNOWN,PHASE4,Hepatitis C; Cirrhosis,Sofosbuvir/Velpatasvir + Ribavirin (DRUG); Sofosbuvir/Velpatasvir/Voxilaprevir (DRUG),16760658,Clin,Hepatitis C; Cirrhosis,Liver,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1581,NCT04225026,Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer,TERMINATED,PHASE2,Esophagitis,GC4419 (avasopasem manganese) (DRUG),16760658,Clin,Esophagitis,Esophagus/Stomach,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1582,NCT03377426,"LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)",WITHDRAWN,PHASE2,Complicated Urinary Tract Infections,LYS228 (DRUG); Standard of care therapy (DRUG),16760658,Clin,Complicated Urinary Tract Infections,Bladder/Urinary Tract,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1583,NCT04648826,"Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies",WITHDRAWN,PHASE1,Sarcomas; Melanomas; Germ Cell Tumors; Epithelial Malignancies (Excluding Lung and Renal Cell Carcinomas); Pulmonary Metastases,AeroEclipse II Breath Actuated Nebulizer (DEVICE); Bintrafusp alfa (DRUG); Azacytidine (DRUG),16760658,Clin,Sarcomas; Melanomas; Germ Cell Tumors; Epithelial Malignancies (Excluding Lung and Renal Cell Carcinomas); Pulmonary Metastases,Skin,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1584,NCT00240526,LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers,COMPLETED,PHASE4,Hepatitis B,Engerix™ -B (BIOLOGICAL); Hepatitis B immunoglobulin (HBIg) (BIOLOGICAL),16760658,Clin,Hepatitis B,Liver,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1585,NCT06831526,Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma,NOT_YET_RECRUITING,EARLY_PHASE1,Glioblastoma,Azeliragon (DRUG); Temozolomide (DRUG); Radiation therapy (RADIATION); Surgery or LITT (PROCEDURE),16760658,Clin,Glioblastoma,CNS/Brain,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1586,NCT01695226,Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms; Breast Cancer,celecoxib (DRUG); Placebo (DRUG),16760658,Clin,Breast Neoplasms; Breast Cancer,Breast,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1587,NCT04540926,Cyclosporine A Plus Low-steroid Treatment in COVID-19 Pneumonia,UNKNOWN,PHASE1,COVID 19 Pneumonia,Cyclosporin A (DRUG),16760658,Clin,COVID 19 Pneumonia,Lung,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1588,NCT00028626,Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer; Metastatic Cancer,embolization therapy (DRUG),16760658,Clin,Colorectal Cancer; Metastatic Cancer,Bowel,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1589,NCT04442126,A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors,TERMINATED,PHASE1,Advanced Solid Tumor; Non-small Cell Lung Cancer; Colorectal Cancer; Squamous Cell Carcinoma; Ovarian Carcinoma; Peritoneal Carcinoma; Fallopian Tube Cancer; Head and Neck Squamous Cell Carcinoma; Triple Negative Breast Cancer,NM21-1480 (BIOLOGICAL),16760658,Clin,Advanced Solid Tumor; Non-small Cell Lung Cancer; Colorectal Cancer; Squamous Cell Carcinoma; Ovarian Carcinoma; Peritoneal Carcinoma; Fallopian Tube Cancer; Head and Neck Squamous Cell Carcinoma; Triple Negative Breast Cancer,Bowel,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1590,NCT04470726,Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype,COMPLETED,PHASE1,Superficial Basal Cell Carcinoma; Nodular Basal Cell Carcinoma; Nonmelanoma Skin Cancers,AIV001 (DRUG); AIV001 suspension (DRUG),16760658,Clin,Superficial Basal Cell Carcinoma; Nodular Basal Cell Carcinoma; Nonmelanoma Skin Cancers,Skin,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1591,NCT05573126,Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer,RECRUITING,PHASE1,Hormone Receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Metastatic Breast Cancer,Vosilasarm (DRUG); Elacestrant (DRUG); Everolimus (DRUG),16760658,Clin,Hormone Receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Metastatic Breast Cancer,Breast,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1592,NCT03889626,The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer,UNKNOWN,PHASE3,Stomach Neoplasms; Gastrointestinal Neoplasms; Stomach Diseases; Digestive System Neoplasms; Capecitabine; Apatinib; Neoplasms; Molecular Mechanisms of Pharmacological Action,Apatinib (DRUG); Capecitabine (DRUG),16760658,Clin,Stomach Neoplasms; Gastrointestinal Neoplasms; Stomach Diseases; Digestive System Neoplasms; Capecitabine; Apatinib; Neoplasms; Molecular Mechanisms of Pharmacological Action,Bowel,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1593,NCT00005766,Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,Creatinine (DRUG),16760658,Clin,Amyotrophic Lateral Sclerosis,CNS/Brain,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1594,NCT03173066,Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography,COMPLETED,PHASE1,Pulmonary Embolism,Ferumoxytol (DRUG),16760658,Clin,Pulmonary Embolism,Lung,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1595,NCT01228266,Mesenchymal Stem Cell Transplantation in MS,TERMINATED,PHASE2,Multiple Sclerosis,autologous mesenchymal stem cells (BIOLOGICAL),16760658,Clin,Multiple Sclerosis,CNS/Brain,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1596,NCT01854866,Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion,UNKNOWN,PHASE2,"Malignant Pleural Effusion,; Malignant Ascites",Drug-packaging microparticles (OTHER),16760658,Clin,"Malignant Pleural Effusion,; Malignant Ascites",Lung,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1597,NCT02307266,Patient Education in Adherence on Acne (PEAce),COMPLETED,PHASE4,Acne,Standard of care + supplementary education (BEHAVIORAL); Standard of care + additional visits (BEHAVIORAL); Standard of care (BEHAVIORAL),16760658,Clin,Acne,Skin,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1598,NCT01889966,VasoREACTivity Testing With Intravenous SILdenafil in Patients With Precapillary Pulmonary Hypertension,COMPLETED,PHASE4,Pulmonary Hypertension Associated With Connective Tissue Disease,Sildenafil (DRUG),16760658,Clin,Pulmonary Hypertension Associated With Connective Tissue Disease,Lung,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1599,NCT04198766,Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist),RECRUITING,PHASE1,Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer; Melanoma; Gastric Cancer; Renal Cell Carcinoma; Urothelial Carcinoma,INBRX-106 - Hexavalent OX40 agonist antibody (DRUG); pembrolizumab 200 mg (DRUG); pembrolizumab 400 mg (DRUG); Carboplatin AUC-5 (DRUG); Carboplatin AUC-6 (DRUG); Pemetrexed 500 mg/m2 (DRUG); Cisplatin 75mg/m2 (DRUG); Paclitaxel 200mg/m2 (DRUG); Nab paclitaxel 100mg/m2 (DRUG),16760658,Clin,Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer; Melanoma; Gastric Cancer; Renal Cell Carcinoma; Urothelial Carcinoma,Bladder/Urinary Tract,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1600,NCT02395666,Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission,COMPLETED,PHASE2,Neuroblastoma,DFMO (DRUG),16760658,Clin,Neuroblastoma,CNS/Brain,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1601,NCT03560466,Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion),COMPLETED,PHASE3,Asthma,Dupilumab (SAR231893/REGN668) (DRUG); Asthma controller therapies (incl. prednisone/prednisolone) (DRUG); Asthma reliever therapies (DRUG),16760658,Clin,Asthma,Lung,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1602,NCT06878066,Thrombolysis in Factor Xa-inhibitors Trial,RECRUITING,PHASE3,Stroke; Stroke (in Patients With Atrial Fibrillation); Ischemic Stroke; Acute Ischemic Stroke; Anticoagulant Therapy; Factor Xa Inhibitor; Intracranial Hemorrhages; Hemorrhagic Transformation Due to Acute Stroke; Bleeding in the Brain,thrombolysis therapy (DRUG),16760658,Clin,Stroke; Stroke (in Patients With Atrial Fibrillation); Ischemic Stroke; Acute Ischemic Stroke; Anticoagulant Therapy; Factor Xa Inhibitor; Intracranial Hemorrhages; Hemorrhagic Transformation Due to Acute Stroke; Bleeding in the Brain,CNS/Brain,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1603,NCT03793166,"Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study",ACTIVE_NOT_RECRUITING,PHASE3,Clear Cell Renal Cell Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Lymph Nodes; Metastatic Malignant Neoplasm in the Soft Tissue; Metastatic Malignant Neoplasm in the Viscera; Rhabdoid Tumor of the Kidney; Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Cabozantinib (DRUG); Computed Tomography (PROCEDURE); Ipilimumab (BIOLOGICAL); Magnetic Resonance Imaging (PROCEDURE); Nivolumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),16760658,Clin,Renal Cell Carcinoma,Kidney,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1604,NCT04547166,A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC),RECRUITING,PHASE2,Metastatic Colorectal Cancer,HLX10 (DRUG); HLX04、 (DRUG),16760658,Clin,Metastatic Colorectal Cancer,Bowel,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1605,NCT02882126,An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension,WITHDRAWN,PHASE4,Pulmonary Arterial Hypertension,Subcutaneous Treprostinil (DRUG),16760658,Clin,Pulmonary Arterial Hypertension,Lung,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1606,NCT05696626,Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation,RECRUITING,PHASE3,Metastatic Breast Cancer,Lasofoxifene in combination with abemaciclib (DRUG); Fulvestrant in combination with abemaciclib (DRUG),16760658,Clin,Metastatic Breast Cancer,Breast,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1607,NCT00543426,Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis,COMPLETED,PHASE4,Posthepatitic Cirrhosis,Fuzheng Huayu Tablets (DRUG); sham Fuzheng Huayu Tablets (placebo) (DRUG),16760658,Clin,Posthepatitic Cirrhosis,Liver,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1608,NCT04106726,Bioequivalence Study of Ivermectin Cream 1% in Treatment of Moderate to Severe Facial Rosacea,COMPLETED,PHASE3,Facial Rosacea,Soolantra® Ivermectin cream 1% (DRUG); Ivermectin cream 1% (DRUG); Placebo for Ivermectin cream 1% (DRUG),16760658,Clin,Facial Rosacea,Skin,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1609,NCT06605326,Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm Retrospective Study,COMPLETED,PHASE4,Pulmonary Hypertension; Pulmonary Arterial Hypertension; Chronic Lung Disease-Associated Pulmonary Hypertension; Lung Transplantation; Heart Failure,Subcutaneous Treprostinil (DRUG),16760658,Clin,Pulmonary Hypertension; Pulmonary Arterial Hypertension; Chronic Lung Disease-Associated Pulmonary Hypertension; Lung Transplantation; Heart Failure,Lung,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1610,NCT05578326,Study of Trilaciclib and Lurbinectidin,RECRUITING,PHASE2,Lung Cancer; Small-cell Lung Cancer,Trilaciclib (DRUG); Lurbinectedin (DRUG),16760658,Clin,Lung Cancer; Small-cell Lung Cancer,Lung,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1611,NCT02282826,"A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis",COMPLETED,PHASE1,Progressive Multiple Sclerosis,GZ402668 (DRUG); placebo (DRUG); GZ402668 (DRUG); placebo (DRUG); acyclovir (DRUG),16760658,Clin,Progressive Multiple Sclerosis,CNS/Brain,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1612,NCT06284226,An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients,WITHDRAWN,EARLY_PHASE1,"Solid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer)",Allogeneic NK（CCT-ANK-11) (DRUG),16760658,Clin,"Solid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer)",Lung,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1613,NCT01385657,Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis,COMPLETED,PHASE1,Atopic Dermatitis,Placebo (DRUG); Dupilumab (DRUG); Background treatment (OTHER),16760658,Clin,Atopic Dermatitis,Skin,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1614,NCT00493857,Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer,TERMINATED,PHASE2,Colorectal Cancer,Nimotuzumab Humanized Monoclonal Antibody (DRUG); Nimotuzumab (DRUG),16760658,Clin,Colorectal Cancer,Bowel,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1615,NCT05610657,A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function,COMPLETED,PHASE1,Moderate Hepatic Impairment,Mitapivat (DRUG),16760658,Clin,Moderate Hepatic Impairment,Liver,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1616,NCT00837057,Early Continuous Renal Replacement Therapies (CRRT) in Patients With Severe Sepsis or Septic Shock With Acute Kidney Injury,UNKNOWN,PHASE4,Severe Sepsis; Septic Shock; Acute Kidney Injury,crrt (PROCEDURE),16760658,Clin,Severe Sepsis; Septic Shock; Acute Kidney Injury,Kidney,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1617,NCT01767857,A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer,TERMINATED,PHASE3,Metastatic Colorectal Cancer,Xilonix (DRUG); Placebo (DRUG),16760658,Clin,Metastatic Colorectal Cancer,Bowel,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1618,NCT03284957,Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer,TERMINATED,PHASE1,Breast Cancer,Amcenestrant (DRUG); Palbociclib (DRUG); Alpelisib (DRUG); Everolimus (DRUG); Abemaciclib (DRUG),16760658,Clin,Breast Cancer,Breast,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1619,NCT02892357,Efficacy of Traditional Chinese Medicine Combined With Omeprazole in Patients With Non-erosive Reflux Disease,UNKNOWN,PHASE1,Non-erosive Reflux Disease,Treatment group (DRUG); Control group (DRUG),16760658,Clin,Gastroesophageal Reflux Disease,Esophagus/Stomach,Sodium Salicylate,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,"Used in studies, NSAID-related research, not approved for standard human therapy.",C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],1.04,1260.0 +1620,NCT02524665,8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne,COMPLETED,PHASE4,Acne Vulgaris,MAXCLARITY II (2.5% BPO) Foam Cleanser (OTHER); MAXCLARITY II (2.5% BPO) Foam Treatment (OTHER); MAXCLARITY II (0.5% Salicylic Acid) Toner Foam (OTHER); MURAD Clarifying Cleanser (1.5% SA) (OTHER); Exfoliating Acne Treatment Gel (1% SA) (OTHER); Skin Perfecting Lotion (OTHER),338,SAX,Acne Vulgaris,Skin,Salicylic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used topically for acne and in aspirin synthesis.,C1=CC=C(C(=C1)C(=O)O)O,1.16,284.0 +1621,NCT01260766,Acne Treatment With Active Oplon's Patches - 15-18 Years Old,UNKNOWN,PHASE2,Acne Vulgaris,Oplon Active Patch (DEVICE); Placebo Patch (DEVICE),338,SAX,Acne Vulgaris,Skin,Salicylic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used topically for acne and in aspirin synthesis.,C1=CC=C(C(=C1)C(=O)O)O,1.16,284.0 +1622,NCT03859843,Efficacy and Antimicrobial Activity of Platelet Rich Plasma (PRP) in Acne Vulgaris,UNKNOWN,PHASE3,Platelet-Rich Plasma; Acne Vulgaris,PRP (COMBINATION_PRODUCT); Chemical peeling (Salycilic acid) (OTHER); Chemical peeling (Jessener's solution) (OTHER),338,SAX,Platelet-Rich Plasma; Acne Vulgaris,Skin,Salicylic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used topically for acne and in aspirin synthesis.,C1=CC=C(C(=C1)C(=O)O)O,1.16,284.0 +1623,NCT01914627,Parallel Group Trial to Evaluate the Efficacy and Safety of Loion® Compared to 10% Salicylic Acid in Patients With Chronic Psoriasis Capitis,COMPLETED,PHASE2,Scalp Psoriasis,Dimethicone (DRUG); Salicylic Acid (DRUG),338,SAX,Scalp Psoriasis,Skin,Salicylic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used topically for acne and in aspirin synthesis.,C1=CC=C(C(=C1)C(=O)O)O,1.16,284.0 +1624,NCT00361322,Efficacy and Safety of a Preparation Containing an Antibiotic and Anti-Inflammatory Agent in Acne Vulgaris,COMPLETED,PHASE1,Acne Vulgaris,clindamycin phosphate (DRUG); salicylic acid (DRUG),338,SAX,Acne Vulgaris,Skin,Salicylic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used topically for acne and in aspirin synthesis.,C1=CC=C(C(=C1)C(=O)O)O,1.16,284.0 +1625,NCT03277573,Salsalate in Patients Mild to Moderate Alzheimer's Disease,COMPLETED,PHASE1,Alzheimer Disease,Salsalate (DRUG); Placebo (DRUG),338,SAX,Alzheimer Disease,CNS/Brain,Salicylic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used topically for acne and in aspirin synthesis.,C1=CC=C(C(=C1)C(=O)O)O,1.16,284.0 +1626,NCT01225562,"Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin",COMPLETED,PHASE3,Myocardial Infarction; Cardiovascular Death; Atherothrombosis; Stroke,Ticagrelor 90 mg (DRUG); Ticagrelor 60 mg (DRUG); Ticagrelor Placebo (DRUG),338,SAX,Myocardial Infarction; Cardiovascular Death; Atherothrombosis; Stroke,CNS/Brain,Salicylic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used topically for acne and in aspirin synthesis.,C1=CC=C(C(=C1)C(=O)O)O,1.16,284.0 +1627,NCT01706263,"U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne",COMPLETED,PHASE4,Acne Vulgaris,MAXCLARITY II (2.5% BPO) Foam Cleanser (DRUG); MAXCLARITY II (2.5% BPO) Foam Treatment (DRUG); MAXCLARITY II (0.5% Salicylic Acid) Toner Foam (DRUG),338,SAX,Acne Vulgaris,Skin,Salicylic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used topically for acne and in aspirin synthesis.,C1=CC=C(C(=C1)C(=O)O)O,1.16,284.0 +1628,NCT05056896,ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,Colorectal Cancer,Aspirin (DRUG); Placebo (OTHER),338,SAX,Colorectal Cancer,Bowel,Salicylic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used topically for acne and in aspirin synthesis.,C1=CC=C(C(=C1)C(=O)O)O,1.16,284.0 +1629,NCT03450369,"A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne",COMPLETED,PHASE1,Acne Vulgaris,NB01 (BIOLOGICAL),338,SAX,Acne Vulgaris,Skin,Salicylic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used topically for acne and in aspirin synthesis.,C1=CC=C(C(=C1)C(=O)O)O,1.16,284.0 +1630,NCT05753267,Fenofibrate in Ulcerative Colitis,RECRUITING,PHASE2,Inflammatory Bowel Diseases,Mesalamine (DRUG); Fenofibrate 160mg (DRUG),338,SAX,Inflammatory Bowel Diseases,Bowel,Salicylic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used topically for acne and in aspirin synthesis.,C1=CC=C(C(=C1)C(=O)O)O,1.16,284.0 +1631,NCT04490967,Silymarin Cream Versus Salicylic Acid in Treatment of Acne Vulgaris,UNKNOWN,PHASE4,Acne Vulgaris,Silymarin (COMBINATION_PRODUCT); Salicylic acid (PROCEDURE),338,SAX,Acne Vulgaris,Skin,Salicylic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used topically for acne and in aspirin synthesis.,C1=CC=C(C(=C1)C(=O)O)O,1.16,284.0 +1632,NCT02289768,Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses,COMPLETED,PHASE3,Actinic Keratosis,5-fluorouracil/salicylic acid (DRUG); Vehicle (DRUG),338,SAX,Actinic Keratosis,Skin,Salicylic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used topically for acne and in aspirin synthesis.,C1=CC=C(C(=C1)C(=O)O)O,1.16,284.0 +1633,NCT06943118,Comparison of Efficacy of 35% Glycolic Acid vs 20% Salicylic Acid Peel in the Treatment of Post Acne Scars,NOT_YET_RECRUITING,PHASE4,Post Acne Scars,Chemical Peels (PROCEDURE),338,SAX,Post Acne Scars,Skin,Salicylic acid,,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used topically for acne and in aspirin synthesis.,C1=CC=C(C(=C1)C(=O)O)O,1.16,284.0 +1634,NCT04014530,Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study,UNKNOWN,PHASE1,Colorectal Cancer; Endometrium Cancer,Ataluren + Pembrolizumab (DRUG),11219835,JBF,Colorectal Cancer; Endometrium Cancer,Bowel,Ataluren,CFTR,inhibitor/antagonist,unclear,yes,yes,For Duchenne muscular dystrophy with specific genetic mutation.,C1=CC=C(C(=C1)C2=NC(=NO2)C3=CC(=CC=C3)C(=O)O)F,1.631578947368421,273.0 +1635,NCT02758626,Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome,COMPLETED,PHASE2,Epilepsy,ataluren (DRUG); Placebo (DRUG),11219835,JBF,Epilepsy,CNS/Brain,Ataluren,CFTR,inhibitor/antagonist,unclear,yes,yes,For Duchenne muscular dystrophy with specific genetic mutation.,C1=CC=C(C(=C1)C2=NC(=NO2)C3=CC(=CC=C3)C(=O)O)F,1.631578947368421,273.0 +1636,NCT06878066,Thrombolysis in Factor Xa-inhibitors Trial,RECRUITING,PHASE3,Stroke; Stroke (in Patients With Atrial Fibrillation); Ischemic Stroke; Acute Ischemic Stroke; Anticoagulant Therapy; Factor Xa Inhibitor; Intracranial Hemorrhages; Hemorrhagic Transformation Due to Acute Stroke; Bleeding in the Brain,thrombolysis therapy (DRUG),2812,CLOT,Stroke; Stroke (in Patients With Atrial Fibrillation); Ischemic Stroke; Acute Ischemic Stroke; Anticoagulant Therapy; Factor Xa Inhibitor; Intracranial Hemorrhages; Hemorrhagic Transformation Due to Acute Stroke; Bleeding in the Brain,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1637,NCT02472574,Dose-effect Relationship of Rt-PA on ICH Evacuation,UNKNOWN,PHASE2,Hypertensive Intracerebral Hemorrhage,YL-1 type of intracranial hematoma puncture needle (DEVICE); rt-PA (DRUG),2812,CLOT,Hypertensive Intracerebral Hemorrhage,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1638,NCT06483074,Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients,RECRUITING,PHASE2,End Stage Renal Disease on Dialysis; Peritoneal Dialysis Complication; Sodium-glucose Cotransporter-2 Inhibitor; Residual Kidney Function,Empagliflozin 10 MG (DRUG),2812,CLOT,End Stage Renal Disease on Dialysis; Peritoneal Dialysis Complication; Sodium-glucose Cotransporter-2 Inhibitor; Residual Kidney Function,Kidney,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1639,NCT05900674,Endovascular Stroke Treatment And Reteplase Protocol,WITHDRAWN,PHASE2,Ischemic Stroke,Reteplase Injection (DRUG),2812,CLOT,Ischemic Stroke,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1640,NCT01957774,THR-18's Pharmacokinetics and Pharmacodynamics in Subjects With Acute Ischemic Stroke Treated With tPA,COMPLETED,PHASE2,"Stroke, Acute",THR-18 (DRUG); Placebo (DRUG),2812,CLOT,Acute Stroke,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1641,NCT05948566,Strategy for Improving Stroke Treatment Response,RECRUITING,PHASE2,Ischemic Stroke,TS23 (BIOLOGICAL),2812,CLOT,Ischemic Stroke,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1642,NCT06819566,Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC,NOT_YET_RECRUITING,PHASE2,Hepatocellular Carcinoma; Esophageal Varix; Bleeding Esophageal Varices,Endoscopic variceal ligation (EVL) (PROCEDURE),2812,CLOT,Hepatocellular Carcinoma; Esophageal Varix; Bleeding Esophageal Varices,Liver,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1643,NCT05563766,A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer,RECRUITING,PHASE2,Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Carcinoma,Itraconazole (DRUG),2812,CLOT,Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Carcinoma,Skin,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1644,NCT05807074,Impact of Topical Tranexamic Acid in Breast Reconstruction,TERMINATED,PHASE4,Breast Cancer,Tranexamic Acid (DRUG); Saline (OTHER),2812,CLOT,Breast Cancer,Breast,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1645,NCT00061282,Clotrimazole Enemas for Pouchitis in Children and Adults,TERMINATED,PHASE1,Ulcerative Colitis; Pouchitis; Ileitis; Inflammatory Bowel Disease,Clotrimazole (DRUG),2812,CLOT,Ulcerative Colitis; Pouchitis; Ileitis; Inflammatory Bowel Disease,Bowel,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1646,NCT03964090,"Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)",ACTIVE_NOT_RECRUITING,PHASE2,Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma,TEDD-R (DRUG); TEDDI-R (DRUG); Ibrutinib (DRUG); Cytarabine (DRUG); Isavuconazole (DRUG); Methotrexate (DRUG),2812,CLOT,Central Nervous System Lymphoma,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1647,NCT00805090,"Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects",COMPLETED,PHASE1,"Renal Insufficiency, Chronic; Hepatic Insufficiency; Healthy",Sporanox (DRUG); Diclofenac Sodium (DRUG),2812,CLOT,"Renal Insufficiency, Chronic; Hepatic Insufficiency; Healthy",Liver,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1648,NCT00894803,Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke,COMPLETED,PHASE2,Ischemic Stroke; Stroke; Brain Infarction,Eptifibatide (DRUG); rt-PA (DRUG),2812,CLOT,Ischemic Stroke; Stroke; Brain Infarction,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1649,NCT05049590,Acute Normovolemic Hemodilution in Complex Cardiac Surgery,COMPLETED,PHASE3,Cardiac Surgery; Acute Kidney Injury; Congenital Heart Disease; Aortic Surgery,Acute normovolemic hemodilution (ANH) (BIOLOGICAL),2812,CLOT,Cardiac Surgery; Acute Kidney Injury; Congenital Heart Disease; Aortic Surgery,Kidney,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1650,NCT05119712,Terbinafine Treatment of Axial Spondyloarthropathy,WITHDRAWN,EARLY_PHASE1,Ankylosing Spondylitis; Axial Spondyloarthritis; Psoriatic Spondylitis; Spondylitis Secondary to Inflammatory Bowel Disease; Axial Spondyloarthopathy,Terbinafine Tablets (DRUG); Laboratory Testing (DIAGNOSTIC_TEST); Laboratory Testing (DIAGNOSTIC_TEST),2812,CLOT,Ankylosing Spondylitis; Axial Spondyloarthritis; Psoriatic Spondylitis; Spondylitis Secondary to Inflammatory Bowel Disease; Axial Spondyloarthopathy,Bowel,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1651,NCT01827046,Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III,COMPLETED,PHASE3,Intracerebral Hemorrhage,rt-PA (DRUG),2812,CLOT,Intracerebral Hemorrhage,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1652,NCT01428401,Astragalus Membranaceus for Brain Edema Induced by Hemorrhagic Stroke,COMPLETED,PHASE2,Stroke; Hemorrhagic Transformation Due to Acute Stroke,Chinese Herb Astragalus membranaceus (DRUG); Placebo (OTHER),2812,CLOT,Stroke; Hemorrhagic Transformation Due to Acute Stroke,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1653,NCT01221246,Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours,COMPLETED,PHASE2,Stroke,GM602 (DRUG); Placebo Comparator (DRUG),2812,CLOT,Stroke,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1654,NCT05227846,Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1),UNKNOWN,PHASE1,Decompensated Cirrhosis,Human Umbilical Cord-derived Mesenchymal Stem Cells (BIOLOGICAL),2812,CLOT,Decompensated Cirrhosis,Liver,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1655,NCT01990768,Prehospital Tranexamic Acid Use for Traumatic Brain Injury,COMPLETED,PHASE2,Traumatic Brain Injury,1 gram Tranexamic Acid (TXA) (DRUG); 2 grams TXA (DRUG); 0.9% Sodium Chloride injectable (DRUG),2812,CLOT,Traumatic Brain Injury,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1656,NCT06764927,Fibrinogen in Liver Transplant Subjects,NOT_YET_RECRUITING,EARLY_PHASE1,Liver Transplant Surgery,Cryoprecipitate Intercept Fibrinogen Complex (IFC) (BIOLOGICAL); Cryoprecipitate Antihemophilic Factor (AHF) (BIOLOGICAL),2812,CLOT,Liver Transplant Surgery,Liver,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1657,NCT00540527,Local Versus Systemic Thrombolysis for Acute Ischemic Stroke (SYNTHESIS),COMPLETED,PHASE3,Stroke; Cerebrovascular Accident,local interarterial recombinant tissue plasminogen activator (DRUG); intravenous (IV) rt-PA (DRUG),2812,CLOT,Stroke,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1658,NCT03181360,Tenecteplase in Wake-up Ischaemic Stroke Trial,UNKNOWN,PHASE3,"Ischemic Stroke; Stroke, Acute",Tenecteplase (DRUG); Control (OTHER),2812,CLOT,"Ischemic Stroke; Stroke, Acute",CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1659,NCT01519076,A Safety Evaluation of the Use of Magnetic-guided Iron Particles,TERMINATED,PHASE1,Ischemic Stroke,Pulse Therapeutics (PTI) Magnetically-Enhanced Diffusion (MED) (DEVICE),2812,CLOT,Ischemic Stroke,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1660,NCT03432260,"A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis",COMPLETED,PHASE2,Alcoholic Hepatitis,DUR-928 30 mg (DRUG); DUR-928 90 mg (DRUG); DUR-928 150 mg (DRUG),2812,CLOT,Alcoholic Hepatitis,Liver,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1661,NCT05948982,Safety of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Decompensated Hepatitis B Cirrhosis,NOT_YET_RECRUITING,PHASE1,Decompensated Liver Cirrhosis,Human Umbilical Cord Mesenchymal Stem Cells (BIOLOGICAL),2812,CLOT,Decompensated Liver Cirrhosis,Liver,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1662,NCT06689982,Tofacitinib in Patients With Amyotrophic Lateral Sclerosis,NOT_YET_RECRUITING,EARLY_PHASE1,Amyotrophic Lateral Sclerosis,Tofacitinib tablets (DRUG),2812,CLOT,Amyotrophic Lateral Sclerosis,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1663,NCT06696131,Tenecteplase (TNK) in the Treatment of Intracerebral Hemorrhage (ICH),NOT_YET_RECRUITING,PHASE1,Intracerebral Hemorrhage; Intracranial Hemorrhages; Hemorrhagic Strokes,TNK (DRUG),2812,CLOT,Intracerebral Hemorrhage; Intracranial Hemorrhages; Hemorrhagic Strokes,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1664,NCT02618031,The Capillary Index Score Trial,COMPLETED,PHASE1,Acute Stroke; Brain Ischemia; Ischemic Stroke,Endovascular Treatment (EVT) (PROCEDURE),2812,CLOT,Acute Stroke; Brain Ischemia; Ischemic Stroke,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1665,NCT02584660,A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department,COMPLETED,PHASE4,Pulmonary Embolism,Rivaroxaban (DRUG); Standard-of-care (DRUG),2812,CLOT,Pulmonary Embolism,Lung,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1666,NCT00827892,Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage,COMPLETED,PHASE2,Intracerebral Hemorrhage,Pioglitazone (DRUG); Placebo Control (DRUG),2812,CLOT,Intracerebral Hemorrhage,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1667,NCT06393868,Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism,NOT_YET_RECRUITING,PHASE3,Venous Thromboembolism; Gastro Intestinal Bleeding; Blood Clot,Omeprazole 20 mg Oral Tablet (DRUG); Placebo (OTHER),2812,CLOT,Venous Thromboembolism; Gastro Intestinal Bleeding; Blood Clot,Bowel,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1668,NCT00403767,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,COMPLETED,PHASE3,Atrial Fibrillation; Stroke; Embolism,Rivaroxaban (DRUG); Warfarin (DRUG); Matching placebo for Rivaroxaban arm (Warfarin placebo) (DRUG); Matching placebo for Warfarin arm (Rivaroxaban placebo) (DRUG),2812,CLOT,Atrial Fibrillation; Stroke; Embolism,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1669,NCT03419325,A Genomic Approach for Clopidogrel in Caribbean Hispanics,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,Cardiovascular Disease (CVD); Stroke; Acute Coronary Syndrome; Peripheral Arterial Disease; Coronary Artery Disease; Myocardial Infarction,CYP2C19 test (GENETIC); P2RY12 assay (DIAGNOSTIC_TEST),2812,CLOT,Cardiovascular Disease (CVD); Stroke; Acute Coronary Syndrome; Peripheral Arterial Disease; Coronary Artery Disease; Myocardial Infarction,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1670,NCT01492725,Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial,TERMINATED,PHASE2,Ischemic Stroke,Intra-arterial Clot Retrieval with Solitaire device (DEVICE); intravenous tissue plasminogen activator (tPA) (GENETIC),2812,CLOT,Ischemic Stroke,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1671,NCT01241539,Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis,COMPLETED,PHASE1,"Cardiovascular Diseases; Kidney Failure, Chronic",Dabigatran etexilate (DRUG); Dabigatran etexilate (DRUG); Dabigatran etexilate (DRUG),2812,CLOT,"Cardiovascular Diseases; Kidney Failure, Chronic",Kidney,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1672,NCT00061373,Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST),COMPLETED,PHASE2,Ischemic Stroke,Aspirin (DRUG); tinzaparin sodium (DRUG); eptifibatide (DRUG),2812,CLOT,Ischemic Stroke,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1673,NCT00629122,Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation,COMPLETED,PHASE4,"Kidney Failure, Chronic",Tacrolimus (Arm B) (DRUG); Clotrimazole Troche (DRUG); Tacrolimus (Arm A) (DRUG); Nystatin Suspension (DRUG),2812,CLOT,"Kidney Failure, Chronic",Kidney,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1674,NCT05630586,Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke,RECRUITING,PHASE2,Acute Ischemic Stroke,Semaglutide (DRUG); Standard care (OTHER),2812,CLOT,Acute Ischemic Stroke,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1675,NCT01949948,Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke,COMPLETED,PHASE3,Ischemic Stroke,Tenecteplase (DRUG); Alteplase (DRUG),2812,CLOT,Ischemic Stroke,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1676,NCT06267794,Prolonged Release Pirfenidone Versus Placebo in Compensated Cirrhosis.,COMPLETED,PHASE2,"Liver Fibrosis; Cirrhosis, Liver; Chronic Liver Disease",Pirfenidone 1200 mg (DRUG); Pirfenidone 1800 mg (DRUG); Placebo (DRUG),2812,CLOT,"Liver Fibrosis; Cirrhosis, Liver; Chronic Liver Disease",Liver,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1677,NCT00000991,A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients,COMPLETED,PHASE3,"Pneumonia, Pneumocystis Carinii; HIV Infections",Pentamidine isethionate (DRUG); Sulfamethoxazole-Trimethoprim (DRUG); Dapsone (DRUG); Zidovudine (DRUG),2812,CLOT,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1678,NCT04278729,A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome,COMPLETED,PHASE1,Nephrotic Syndrome; Membranous Nephropathy,Apixaban 5 MG (DRUG),2812,CLOT,Nephrotic Syndrome; Membranous Nephropathy,Kidney,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1679,NCT00377091,Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Traditional Therapy,WITHDRAWN,PHASE4,Pulmonary Embolism,Fondaparinux (DRUG),2812,CLOT,Pulmonary Embolism,Lung,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1680,NCT01108094,Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas,COMPLETED,PHASE2,Basal Cell Carcinoma (BCC); Skin Cancer,Itraconazole (DRUG),2812,CLOT,Basal Cell Carcinoma (BCC); Skin Cancer,Skin,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1681,NCT01455935,Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention,UNKNOWN,PHASE2,Stroke,Anti-platelets and statin (DRUG); alteplase (DRUG); intra arterial intervention (PROCEDURE),2812,CLOT,Stroke,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1682,NCT05419635,"A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver Function",COMPLETED,PHASE1,Prevention of Thromboembolic Events; Atrial Fibrillation; Acute Myocardial Infarction; Non-cardioembolic Ischemic Stroke; Hepatic Impairment,Asundexian (BAY2433334) (DRUG),2812,CLOT,Prevention of Thromboembolic Events; Atrial Fibrillation; Acute Myocardial Infarction; Non-cardioembolic Ischemic Stroke; Hepatic Impairment,CNS/Brain,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1683,NCT06886516,Apixaban in Thrombocytopenia,RECRUITING,EARLY_PHASE1,Deep Vein Thrombosis; Pulmonary Embolism and Thrombosis; Thrombocytopenia; Recurrent Venous Thromboembolism,Apixaban (DRUG),2812,CLOT,Deep Vein Thrombosis; Pulmonary Embolism and Thrombosis; Thrombocytopenia; Recurrent Venous Thromboembolism,Lung,Clotrimazole,"CYP2A6, CYP51A1",inhibitor/antagonist,unclear,yes,yes,Antifungal used in topical and oral preparations.,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,1.2,171.0 +1684,NCT00426673,An Open-Label Interaction Study to Look at the Effects of Brivaracetam on Phenytoin When Taken Together in 15 Adult Patients With Epilepsy.,COMPLETED,PHASE1,Epilepsy,Brivaracetam (ucb34714) (DRUG),23679632,Antisacer,Epilepsy,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1685,NCT04573803,Pharmacological Management of Seizures Post Traumatic Brain Injury,NOT_YET_RECRUITING,PHASE3,Traumatic Brain Injury; Post Traumatic Seizures,Phenytoin Sodium (DRUG); Levetiracetam (DRUG),23679632,Antisacer,Traumatic Brain Injury; Post Traumatic Seizures,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1686,NCT00612638,Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas,COMPLETED,PHASE1,Glioblastoma; Gliosarcoma,"Temodar, O6-BG, and Irinotecan (DRUG)",23679632,Antisacer,Glioblastoma,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1687,NCT00108069,Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors,COMPLETED,PHASE2,Glioma,Tamoxifen citrate (DRUG); Bortezomib (DRUG),23679632,Antisacer,Glioma,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1688,NCT02283827,Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.,COMPLETED,PHASE1,Epilepsy,BIA 2-093 (DRUG); Phenytoin (DRUG),23679632,Antisacer,Epilepsy,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1689,NCT02205931,Ketogenic Diet in Infants With Epilepsy (KIWE),UNKNOWN,PHASE4,Epilepsy,Ketogenic diet (OTHER); Antiepileptic drug therapy (DRUG),23679632,Antisacer,Epilepsy,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1690,NCT00210782,A Comparison of the Effectiveness and Safety of Topiramate and Phenytoin in Patients With New Onset Epilepsy Requiring Rapid Initiation of Antiepileptic Drug Treatment,COMPLETED,PHASE3,Epilepsy,"topiramate, phenytoin (DRUG)",23679632,Antisacer,Epilepsy,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1691,NCT00801931,Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders,TERMINATED,PHASE1,Leukemia; Lymphoma; Neuroblastoma; Immunodeficiencies; Anemia,Alemtuzumab (DRUG); Total Body Irradiation (RADIATION); Melphalan (DRUG); Busulfan (DRUG); Phenytoin (DRUG); Fludarabine (DRUG); Cyclophosphamide (DRUG); Horse Antithymocyte Globulin (DRUG); Rabbit Antithymocyte Globulin (DRUG); Thiotepa (DRUG),23679632,Antisacer,Leukemia; Lymphoma; Neuroblastoma; Immunodeficiencies; Anemia,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1692,NCT02088957,Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures,TERMINATED,PHASE2,Nonconvulsive Electrographic Seizures,Brivaracetam intravenous solution (DRUG); Brivaracetam oral tablets (DRUG); Phenytoin intravenous solution (DRUG); Phenytoin oral tablets (DRUG),23679632,Antisacer,Nonconvulsive Electrographic Seizures,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1693,NCT00826930,"Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma",TERMINATED,PHASE1,High Grade Glioma,Trans Sodium Crocetinate (TSC) (DRUG),23679632,Antisacer,Glioma,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1694,NCT03325439,"A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures",TERMINATED,PHASE3,Electroencephalographic Neonatal Seizures,Brivaracetam (BRV) intravenous (iv) (DRUG); Brivaracetam (BRV) oral (DRUG),23679632,Antisacer,Electroencephalographic Neonatal Seizures,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1695,NCT04967326,Role of Clinical Pharmacists in Epilepsy Management,COMPLETED,PHASE4,Epilepsy,"Optimizing therapy with antiepileptic drugs (carbamazepine, phenytoin, valproic acid) (DRUG)",23679632,Antisacer,Epilepsy,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1696,NCT05637086,Clinical Study Evaluating Safety of Pentoxifylline and Celecoxib in Patients With Grand-Mal Epilepsy Treated by Phenytoin Monotherapy,RECRUITING,PHASE2,Epilepsy,Phenytoin (DRUG); Pentoxifylline 400 MG (DRUG); Celecoxib 200mg (DRUG),23679632,Antisacer,Epilepsy,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1697,NCT02535091,Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures,COMPLETED,PHASE3,Partial Epilepsy,YKP3089 (DRUG),23679632,Antisacer,Partial Epilepsy,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1698,NCT01478035,Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old.,TERMINATED,PHASE4,Seizures; Pneumococcal Meningitis,Phenytoin (DRUG); placebo (DRUG),23679632,Antisacer,Seizures; Pneumococcal Meningitis,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1699,NCT00567424,GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures,WITHDRAWN,PHASE2,Epilepsy,GW273225 (DRUG),23679632,Antisacer,Epilepsy,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1700,NCT00903786,A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs),COMPLETED,PHASE2,Refractory Partial Seizures,perampanel (DRUG),23679632,Antisacer,Refractory Partial Seizures,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1701,NCT01870024,"Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus",COMPLETED,PHASE3,Status Epilepticus; Epilepsy,Clonazepam (DRUG); Fosphenytoin (DRUG); Placebo (DRUG); Lorazepam (DRUG),23679632,Antisacer,Status Epilepticus; Epilepsy,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1702,NCT00366067,Study of Efficacy of Phenytoin in Therapy of Children With Bronchial Asthma,COMPLETED,PHASE4,Bronchial Asthma,Phenytoin (DRUG),23679632,Antisacer,Bronchial Asthma,Lung,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1703,NCT04229004,A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer,COMPLETED,PHASE3,Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma,Gemcitabine combined with nab-paclitaxel (DRUG); Dose -mFOLFIRINOX (DRUG); Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel (DRUG); Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine (DRUG); Drug: Dose -SM-88 (DRUG),23679632,Antisacer,Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma,Pancreas,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1704,NCT02726867,"Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus",WITHDRAWN,PHASE3,Epilepsy; Status Epilepticus,levetiracetam (DRUG); lacosamide (DRUG); Ketamine (DRUG); Phenobarbital (DRUG),23679632,Antisacer,Epilepsy; Status Epilepticus,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1705,NCT01713946,A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures,COMPLETED,PHASE3,Tuberous Sclerosis Complex-associated Refractory Seizures,RAD001 (DRUG); Placebo (DRUG); Antiepileptic drug (1 to 3 only) (DRUG); open label RAD001 (only used for post-extension phase) (DRUG),23679632,Antisacer,Tuberous Sclerosis Complex-associated Refractory Seizures,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1706,NCT06942468,Phenytoin in Treatment of Atrophic Post Acne Scars.,NOT_YET_RECRUITING,PHASE4,Atrophic Acne Scar,Topical nano preparation of Phenytoin (DRUG); Fractional CO2 laser (DEVICE),23679632,Antisacer,Atrophic Acne Scar,Skin,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1707,NCT05833919,Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients,UNKNOWN,PHASE2,Metastatic Breast Cancer,Eribulin Mesylate (DRUG); Capecitabine (DRUG),23679632,Antisacer,Metastatic Breast Cancer,Breast,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1708,NCT00598923,Preventing Epilepsy After Traumatic Brain Injury With Topiramate,TERMINATED,EARLY_PHASE1,Traumatic Brain Injury; Epilepsy,topiramate (DRUG); topiramate (DRUG); phenytoin (DRUG),23679632,Antisacer,Traumatic Brain Injury; Epilepsy,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1709,NCT05697614,The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children,UNKNOWN,PHASE4,Drug Resistant Epilepsy,Valproic acid (DRUG); Carbamazepin (DRUG); Phenytoin (DRUG); Lamotrigine (DRUG); Clobazam (DRUG); Oxcarbazepine (DRUG),23679632,Antisacer,Drug Resistant Epilepsy,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1710,NCT04720664,Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer,TERMINATED,PHASE2,Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Positive Breast Carcinoma,SM-88 (DRUG),23679632,Antisacer,Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Positive Breast Carcinoma,Breast,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1711,NCT00618436,Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention,COMPLETED,PHASE4,Traumatic Brain Injury; Subarachnoid Hemorrhage,Levetiracetam (DRUG); Phenytoin (DRUG),23679632,Antisacer,Traumatic Brain Injury; Subarachnoid Hemorrhage,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1712,NCT00734864,Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma,WITHDRAWN,PHASE1,Glioblastoma Multiforme; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Glioma,enzyme-inducing anti-epileptic drugs (DRUG); enzyme-inducing anti-epileptic drugs (DRUG),23679632,Antisacer,Glioblastoma Multiforme; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Glioma,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1713,NCT00219479,Dilantin Levels With Continuous Delivery of Enteral Feedings - A Pilot Study,TERMINATED,PHASE4,Seizures,Phenytoin (Dilantin) levels during change in enteral feeding (DRUG),23679632,Antisacer,Seizures,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1714,NCT00404248,Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma,COMPLETED,PHASE1,Brain and Central Nervous System Tumors,terameprocol (DRUG); pharmacological study (OTHER),23679632,Antisacer,Brain and Central Nervous System Tumors,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1715,NCT02707965,Characterization of Epilepsy Patients BEEP 2b,COMPLETED,PHASE1,Epilepsy,Oxcarbazepine (brand name vs generic drugs) (DRUG); Divalproex Sodium (brand name vs generic drugs) (DRUG); Carbamazepine (brand name vs generic drugs) (DRUG); Lamotrigine (brand name vs generic drugs) (DRUG); levetiracetam (brand name vs generic drugs) (DRUG); Topiramate (brand name vs generic drugs) (DRUG); Zonisamide (brand name vs generic drugs) (DRUG); Phenytoin sodium (brand name vs generic drugs) (DRUG),23679632,Antisacer,Epilepsy,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1716,NCT01605734,TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma,UNKNOWN,PHASE2,"PHENYTOIN/SORAFENIB [VA Drug Interaction]; Carcinoma, Hepatocellular",TACE (PROCEDURE); sorafenib combined with TACE (DRUG),23679632,Antisacer,"PHENYTOIN/SORAFENIB [VA Drug Interaction]; Carcinoma, Hepatocellular",Liver,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1717,NCT00068770,Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT,TERMINATED,PHASE2,Brain and Central Nervous System Tumors,radiation therapy (RADIATION); Celecoxib (DRUG),23679632,Antisacer,Brain and Central Nervous System Tumors,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1718,NCT00627575,AED/Statin Interaction Study,COMPLETED,PHASE1,Epilepsy,lamotrigine (DRUG); atorvastatin (DRUG); phenytoin (DRUG),23679632,Antisacer,Epilepsy,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1719,NCT00610532,Evaluating the Transporter Protein Inhibitor Probenecid In Patients With Epilepsy,TERMINATED,PHASE4,Epilepsy,phenytoin (DRUG); phenytoin and probenecid (DRUG),23679632,Antisacer,Epilepsy,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1720,NCT00441142,Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors,COMPLETED,PHASE1,Glioblastoma Multiforme; Gliosarcoma,ZD6474 (DRUG); temozolomide (DRUG); Radiation Therapy (RADIATION),23679632,Antisacer,Glioblastoma Multiforme; Gliosarcoma,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1721,NCT00441285,Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ),COMPLETED,PHASE2,Neurocysticercosis; Epilepsy,Praziquantel (DRUG); Albendazole (DRUG); ABZ Placebo (DRUG); PZQ Placebo (DRUG),23679632,Antisacer,Neurocysticercosis; Epilepsy,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1722,NCT03512756,A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer,TERMINATED,PHASE2,Pancreatic Cancer,"SM-88 used with MPS (methoxsalen, phenytoin, sirolimus) (DRUG); Capecitabine, Gemcitabine, and 5-FU (DRUG)",23679632,Antisacer,Pancreatic Cancer,Pancreas,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1723,NCT01556815,Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma,UNKNOWN,PHASE2,"PHENYTOIN/SORAFENIB [VA Drug Interaction]; Liver Neoplasms; Carcinoma, Hepatocellular; Digestive System Neoplasms; Neoplasms by Site; Liver Diseases; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; DOXORUBICIN/TRASTUZUMAB [VA Drug Interaction]; HBV",Transarterial Chemoembolization (TACE) (PROCEDURE); Sorafenib in combination with TACE (OTHER),23679632,Antisacer,"PHENYTOIN/SORAFENIB [VA Drug Interaction]; Liver Neoplasms; Carcinoma, Hepatocellular; Digestive System Neoplasms; Neoplasms by Site; Liver Diseases; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; DOXORUBICIN/TRASTUZUMAB [VA Drug Interaction]; HBV",Liver,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1724,NCT02409433,Comparative Trial of IV Lacosamide Versus Phenytoin for Seizure Management,TERMINATED,PHASE4,Seizures,lacosamide (DRUG); Phenytoin (DRUG),23679632,Antisacer,Seizures,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1725,NCT00612651,PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas,COMPLETED,PHASE1,Gliosarcoma; Glioblastoma; Anaplastic Astrocytoma,Temodar and SCH 66336 (DRUG),23679632,Antisacer,Gliosarcoma; Glioblastoma; Anaplastic Astrocytoma,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1726,NCT01608451,Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer,TERMINATED,PHASE3,Locally Advanced Breast Cancer and Large Operable Breast Cancer,Cholecalciferol (DRUG); Inj. Progesterone (DRUG),23679632,Antisacer,Locally Advanced Breast Cancer and Large Operable Breast Cancer,Breast,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1727,NCT00908453,"The Study of NPC-06 - Investigation of Safety, Efficacy and Pharmacokinetics of Fosphenytoin",COMPLETED,PHASE3,Epilepsy,fosphenytoin (DRUG),23679632,Antisacer,Epilepsy,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1728,NCT02939937,Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis,COMPLETED,PHASE2,Optic Neuritis,Phenytoin (DRUG); placebo (DRUG),23679632,Antisacer,Optic Neuritis,Peripheral Nervous System,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1729,NCT01878578,The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients,TERMINATED,PHASE1,Epilepsy,Eslicarbazepine acetate (DRUG); phenytoin (DRUG); Placebo (DRUG),23679632,Antisacer,Epilepsy,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1730,NCT00327028,Study of Efficacy of Phenytoin in Therapy of Patients With Bronchial Asthma,COMPLETED,PHASE4,Bronchial Asthma,Diphenine (DRUG),23679632,Antisacer,Bronchial Asthma,Lung,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1731,NCT00552526,Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy,UNKNOWN,PHASE4,Epilepsy; Mental Retardation,Ketogenic diet (DIETARY_SUPPLEMENT); Antiepileptic drug (AED) (DRUG),23679632,Antisacer,Epilepsy; Mental Retardation,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1732,NCT01451593,Neuroprotection With Phenytoin in Optic Neuritis,COMPLETED,PHASE2,Optic Neuritis; Multiple Sclerosis,Phenytoin (DRUG); Placebo (DRUG),23679632,Antisacer,Optic Neuritis; Multiple Sclerosis,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1733,NCT00610571,Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas,COMPLETED,PHASE1,Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma,Oral Topotecan and Temodar (DRUG),23679632,Antisacer,Malignant Glioma,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1734,NCT01463033,Levetiracetam to Prevent Post-Traumatic Epilepsy,COMPLETED,PHASE2,Epilepsy; Post-traumatic Epilepsy,Levetiracetam (DRUG),23679632,Antisacer,Epilepsy; Post-traumatic Epilepsy,CNS/Brain,Phenytoin (sodium),,inhibitor/antagonist,unclear,yes,yes,Commonly used as an anti-seizure medication.,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],1.14,248.0 +1735,NCT00321594,Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery,COMPLETED,PHASE1,Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer,belinostat (DRUG),6918638,Beleodaq,Primary Hepatocellular Carcinoma,Liver,Belinostat,HDAC6,inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for relapsed/refractory peripheral T-cell lymphoma.,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,1.02,1895.0 +1736,NCT01090830,Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer,TERMINATED,PHASE1,Non-Small-Cell Lung Carcinoma,"Belinostat, carboplatin, paclitaxel and bevacizumab (DRUG)",6918638,Beleodaq,Non-Small-Cell Lung Carcinoma,Lung,Belinostat,HDAC6,inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for relapsed/refractory peripheral T-cell lymphoma.,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,1.02,1895.0 +1737,NCT05154994,Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma,RECRUITING,PHASE1,"Infiltrating Urothelial Carcinoma, Sarcomatoid Variant; Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma",Belinostat (DRUG); Durvalumab (BIOLOGICAL),6918638,Beleodaq,"Infiltrating Urothelial Carcinoma, Sarcomatoid Variant; Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma",Bladder/Urinary Tract,Belinostat,HDAC6,inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for relapsed/refractory peripheral T-cell lymphoma.,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,1.02,1895.0 +1738,NCT00993616,"Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin",COMPLETED,PHASE2,Brenner Tumor; Fallopian Tube Cancer; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Adenocarcinoma; Primary Peritoneal Cavity Cancer; Recurrent Ovarian Epithelial Cancer,belinostat (DRUG); carboplatin (DRUG),6918638,Beleodaq,Brenner Tumor; Fallopian Tube Cancer; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Adenocarcinoma; Primary Peritoneal Cavity Cancer; Recurrent Ovarian Epithelial Cancer,Ovary/Fallopian Tube,Belinostat,HDAC6,inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for relapsed/refractory peripheral T-cell lymphoma.,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,1.02,1895.0 +1739,NCT01310244,MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC,COMPLETED,PHASE1,Stage IV Non-small Cell Lung Cancer,"Belinostat, Carboplatin, Paclitaxel (DRUG)",6918638,Beleodaq,Stage IV Non-small Cell Lung Cancer,Lung,Belinostat,HDAC6,inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for relapsed/refractory peripheral T-cell lymphoma.,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,1.02,1895.0 +1740,NCT00421889,A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment,COMPLETED,PHASE1,Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Bladder Cancer,belinostat (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG),6918638,Beleodaq,Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Bladder Cancer,Ovary/Fallopian Tube,Belinostat,HDAC6,inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for relapsed/refractory peripheral T-cell lymphoma.,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,1.02,1895.0 +1741,NCT00926640,A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers,COMPLETED,PHASE1,Carcinoma Neuroendocrine; Small Cell Lung Carcinoma; Malignant Epithelial Neoplasms,Belinostat (DRUG); Cisplatin (DRUG); Etoposide (DRUG),6918638,Beleodaq,Carcinoma Neuroendocrine; Small Cell Lung Carcinoma; Malignant Epithelial Neoplasms,Lung,Belinostat,HDAC6,inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for relapsed/refractory peripheral T-cell lymphoma.,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,1.02,1895.0 +1742,NCT05170334,Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma,RECRUITING,PHASE2,Metastatic Uveal Melanoma,Binimetinib (DRUG); Belinostat (DRUG),6918638,Beleodaq,Metastatic Uveal Melanoma,Skin,Belinostat,HDAC6,inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for relapsed/refractory peripheral T-cell lymphoma.,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,1.02,1895.0 +1743,NCT03432741,"Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer",SUSPENDED,PHASE1,Breast Adenocarcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Recurrent Hodgkin Lymphoma; Recurrent Mycosis Fungoides; Recurrent Non-Hodgkin Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Breast Carcinoma; Refractory Hodgkin Lymphoma; Refractory Mycosis Fungoides; Refractory Nodal Marginal Zone Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Stage IV Breast Cancer AJCC v6 and v7,Belinostat (DRUG); Carfilzomib (DRUG); Copanlisib Hydrochloride (DRUG); Daratumumab (BIOLOGICAL); Fludeoxyglucose F-18 (DRUG); Gemcitabine Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Nivolumab (BIOLOGICAL); Obinutuzumab (BIOLOGICAL); Pembrolizumab (BIOLOGICAL); Positron Emission Tomography (PROCEDURE); Rituximab (BIOLOGICAL); Romidepsin (DRUG); Saline (OTHER); Trastuzumab (BIOLOGICAL),6918638,Beleodaq,Breast Adenocarcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Recurrent Hodgkin Lymphoma; Recurrent Mycosis Fungoides; Recurrent Non-Hodgkin Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Breast Carcinoma; Refractory Hodgkin Lymphoma; Refractory Mycosis Fungoides; Refractory Nodal Marginal Zone Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Stage IV Breast Cancer AJCC v6 and v7,Breast,Belinostat,HDAC6,inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for relapsed/refractory peripheral T-cell lymphoma.,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,1.02,1895.0 +1744,NCT02137759,MRSI to Predict Response to RT/TMZ ± Belinostat in GBM,UNKNOWN,PHASE2,Glioblastoma Multiforme of Brain,Standard Radiation Therapy (RADIATION); Standard Temozolomide (DRUG); Belinostat (DRUG),6918638,Beleodaq,Glioblastoma Multiforme of Brain,CNS/Brain,Belinostat,HDAC6,inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for relapsed/refractory peripheral T-cell lymphoma.,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,1.02,1895.0 +1745,NCT00301756,"Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors",COMPLETED,PHASE2,Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma; Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor; Recurrent Ovarian Carcinoma; Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor; Stage III Ovarian Cancer; Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor; Stage IV Ovarian Cancer,Belinostat (DRUG); Laboratory Biomarker Analysis (OTHER),6918638,Beleodaq,Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma; Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor; Recurrent Ovarian Carcinoma; Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor; Stage III Ovarian Cancer; Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor; Stage IV Ovarian Cancer,Ovary/Fallopian Tube,Belinostat,HDAC6,inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for relapsed/refractory peripheral T-cell lymphoma.,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,1.02,1895.0 +1746,NCT04315233,Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics,RECRUITING,PHASE1,Metastatic Breast Cancer; Recurrent Ovarian Carcinoma,Ribociclib (DRUG); Belinostat (DRUG),6918638,Beleodaq,Metastatic Breast Cancer; Recurrent Ovarian Carcinoma,Breast,Belinostat,HDAC6,inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for relapsed/refractory peripheral T-cell lymphoma.,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,1.02,1895.0 +1747,NCT00365053,PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery,COMPLETED,PHASE2,Advanced Malignant Mesothelioma; Epithelial Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma,belinostat (DRUG); laboratory biomarker analysis (OTHER),6918638,Beleodaq,Advanced Malignant Mesothelioma; Epithelial Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma,Lung,Belinostat,HDAC6,inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for relapsed/refractory peripheral T-cell lymphoma.,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,1.02,1895.0 +1748,NCT01188707,A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer,TERMINATED,PHASE1,Non Small Cell Lung Cancer,Belinostat and Erlotinib (DRUG),6918638,Beleodaq,Non Small Cell Lung Cancer,Lung,Belinostat,HDAC6,inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for relapsed/refractory peripheral T-cell lymphoma.,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,1.02,1895.0 +1749,NCT04703920,"Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer",COMPLETED,PHASE1,Metastatic Breast Cancer; Metastatic Castration-resistant Prostate Cancer; Metastatic Ovarian Carcinoma; Metastic or Unresectable Pancreatic Adenocarcinoma,Talazoparib (DRUG); Belinostat (DRUG),6918638,Beleodaq,Metastatic Breast Cancer; Metastatic Castration-resistant Prostate Cancer; Metastatic Ovarian Carcinoma; Metastic or Unresectable Pancreatic Adenocarcinoma,Pancreas,Belinostat,HDAC6,inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for relapsed/refractory peripheral T-cell lymphoma.,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,1.02,1895.0 +1750,NCT00175903,Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy,COMPLETED,PHASE3,Epilepsy,Levetiracetam (DRUG); Carbamazepine Controlled Release (CBZ-CR) (DRUG); Valproate Extended Release (DRUG),2554,CBZ,Epilepsy,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1751,NCT00612638,Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas,COMPLETED,PHASE1,Glioblastoma; Gliosarcoma,"Temodar, O6-BG, and Irinotecan (DRUG)",2554,CBZ,Glioblastoma,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1752,NCT01379469,Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency,TERMINATED,PHASE2,Alpha-1-antitrypsin Deficiency; Liver Cirrhosis,Drug-Carbamazepine (Tegretol XR) (DRUG); Carbamazepine (Tegretol XR) Placebo (DRUG),2554,CBZ,Alpha-1-antitrypsin Deficiency; Liver Cirrhosis,Liver,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1753,NCT00108069,Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors,COMPLETED,PHASE2,Glioma,Tamoxifen citrate (DRUG); Bortezomib (DRUG),2554,CBZ,Glioma,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1754,NCT01162460,Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures,COMPLETED,PHASE3,Epilepsy,Eslicarbazepine acetate (BIA 2-093) (DRUG),2554,CBZ,Epilepsy,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1755,NCT02705768,Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase and S100B in Focal Seizures,COMPLETED,PHASE4,"Seizures, Focal",Carbamazepine (DRUG); Oxcarbazepine (DRUG),2554,CBZ,"Seizures, Focal",CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1756,NCT00807989,The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy,COMPLETED,PHASE4,Epilepsy,Carbamazepine (DRUG); Lamotrigine/Valproate (DRUG),2554,CBZ,Epilepsy,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1757,NCT02429596,A Trial of Generic Substitution of Antiepileptic Drugs,UNKNOWN,PHASE4,Epilepsy,Experimental (DRUG),2554,CBZ,Epilepsy,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1758,NCT00567424,GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures,WITHDRAWN,PHASE2,Epilepsy,GW273225 (DRUG),2554,CBZ,Epilepsy,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1759,NCT00894010,Photosensitivity Proof of Concept Trial,COMPLETED,PHASE2,Photosensitive Epilepsy,carbamazepine 400mg (DRUG); levetiracetam 1000mg (DRUG),2554,CBZ,Photosensitive Epilepsy,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1760,NCT02208492,"The Effects on Cognitive Function of Levetiracetam (Keppra®) Compared to Carbamazepine (Tegretol®, Carmazepine®) as Monotherapy for Children With Partial Seizure; A Multicentric Randomized Controlled Study",COMPLETED,PHASE4,Focal Epilepsy,Levetiracetam (DRUG); Carabamazepine (DRUG),2554,CBZ,Focal Epilepsy,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1761,NCT05697614,The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children,UNKNOWN,PHASE4,Drug Resistant Epilepsy,Valproic acid (DRUG); Carbamazepin (DRUG); Phenytoin (DRUG); Lamotrigine (DRUG); Clobazam (DRUG); Oxcarbazepine (DRUG),2554,CBZ,Drug Resistant Epilepsy,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1762,NCT00848549,Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures,COMPLETED,PHASE3,Epilepsy,Zonisamide (DRUG); Carbamazepine (DRUG),2554,CBZ,Epilepsy,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1763,NCT05748236,The Efficacy and Safety of Lamotrigine Versus Carbamazepine in Focal Epilepsy,ENROLLING_BY_INVITATION,PHASE4,Focal Epilepsy,Lamotrigine tablet (DRUG); Carbamazepine-Containing Product in Oral Dose Form (DRUG),2554,CBZ,Focal Epilepsy,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1764,NCT01954121,"Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures",COMPLETED,PHASE3,Epilepsy; Partial Seizures,Levetiracetam (DRUG); Carbamazepine (DRUG),2554,CBZ,Epilepsy; Partial Seizures,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1765,NCT02912364,Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults,COMPLETED,PHASE4,Epilepsy,Eslicarbazepine (DRUG); Carbamazepine (DRUG),2554,CBZ,Epilepsy,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1766,NCT00734864,Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma,WITHDRAWN,PHASE1,Glioblastoma Multiforme; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Glioma,enzyme-inducing anti-epileptic drugs (DRUG); enzyme-inducing anti-epileptic drugs (DRUG),2554,CBZ,Glioblastoma Multiforme; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Glioma,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1767,NCT00542802,Levetiracetam Versus Carbamazepine in Post-Stroke Late Onset Crisis,UNKNOWN,PHASE3,Epileptic Seizures; Stroke,Levetiracetam (DRUG); Carbamazepine (DRUG),2554,CBZ,Epileptic Seizures; Stroke,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1768,NCT01128959,Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy,COMPLETED,PHASE3,Epilepsy,Intravenous Carbamazepine (IV CBZ) (DRUG),2554,CBZ,Epilepsy,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1769,NCT00441142,Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors,COMPLETED,PHASE1,Glioblastoma Multiforme; Gliosarcoma,ZD6474 (DRUG); temozolomide (DRUG); Radiation Therapy (RADIATION),2554,CBZ,Glioblastoma Multiforme; Gliosarcoma,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1770,NCT06849219,Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia,ACTIVE_NOT_RECRUITING,PHASE4,Trigeminal Neuralgia,Oxcarbazepine (DRUG); Carbamazepine (DRUG),2554,CBZ,Trigeminal Neuralgia,Peripheral Nervous System,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1771,NCT00896987,Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies,COMPLETED,PHASE4,Epilepsy,lamotrigine (Lamictal) (DRUG); Carbamazepine (Tegretol) (DRUG),2554,CBZ,Epilepsy,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1772,NCT01079351,A Study of the Pharmacokinetics (PK) and Safety of IV Carbamazepine Relative to Oral Carbamazepine in Adults With Epilepsy,COMPLETED,PHASE1,Epilepsy,Intravenous Carbamazepine (DRUG),2554,CBZ,Epilepsy,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1773,NCT02284854,Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine,COMPLETED,PHASE1,Epilepsy,BIA 2-093 (DRUG); Carbamazepine (DRUG),2554,CBZ,Epilepsy,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1774,NCT00438451,Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs,COMPLETED,PHASE4,Focal Epilepsy,Levetiracetam (DRUG); Carbamazepine (DRUG); Lamotrigine (DRUG),2554,CBZ,Focal Epilepsy,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1775,NCT01243177,Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older,COMPLETED,PHASE3,Epilepsy; Monotherapy,Lacosamide (DRUG); Carbamazepine-Controlled Release (DRUG),2554,CBZ,Epilepsy; Monotherapy,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1776,NCT06348888,A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants,COMPLETED,PHASE1,Advanced Non-small Cell Lung Cancer; EGFR Mutation; HER2 Mutation; Healthy Volunteers,BAY2927088 (DRUG); Itraconazole (DRUG); Carbamazepine (DRUG),2554,CBZ,Advanced Non-small Cell Lung Cancer; EGFR Mutation; HER2 Mutation; Healthy Volunteers,Lung,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1777,NCT00913107,Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia,COMPLETED,PHASE2,Trigeminal Neuralgia,Lamictal® (DRUG); Tegretol® (DRUG),2554,CBZ,Trigeminal Neuralgia,Peripheral Nervous System,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1778,NCT01465997,Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older,COMPLETED,PHASE3,Epilepsy; Monotherapy,Lacosamide (DRUG); Carbamazepine-Controlled Release (CBZ-CR) (DRUG),2554,CBZ,Epilepsy; Monotherapy,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1779,NCT00610571,Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas,COMPLETED,PHASE1,Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma,Oral Topotecan and Temodar (DRUG),2554,CBZ,Malignant Glioma,CNS/Brain,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1780,NCT02735707,"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",RECRUITING,PHASE3,"Community-acquired Pneumonia, Influenza, COVID-19",Ceftriaxone (DRUG); Moxifloxacin or Levofloxacin (DRUG); Piperacillin-tazobactam (DRUG); Ceftaroline (DRUG); Amoxicillin-clavulanate (DRUG); Standard course macrolide (DRUG); Extended course macrolide (DRUG); No systemic corticosteroid (OTHER); Fixed-duration Hydrocortisone (DRUG); Shock-dependent hydrocortisone (DRUG); Fixed-duration higher dose Hydrocortisone (DRUG); No antiviral agent for influenza (OTHER); Five-days oseltamivir (DRUG); Ten-days oseltamivir (DRUG); No antiviral agent for COVID-19 (OTHER); Lopinavir / Ritonavir (DRUG); Hydroxychloroquine (DRUG); Hydroxychloroquine + lopinavir/ritonavir (DRUG); Ivermectin (DRUG); No immune modulation for COVID-19 (OTHER); Interferon beta-1a (DRUG); Anakinra (DRUG); Tocilizumab (DRUG); Sarilumab (DRUG); Local standard venous thromboprophylaxis (DRUG); Therapeutic dose anticoagulation (DRUG); Conventional low dose thromboprophylaxis (DRUG); Intermediate dose thromboprophylaxis (DRUG); Continuation of therapeutic dose anticoagulation (DRUG); No immunoglobulin (OTHER); Convalescent plasma (BIOLOGICAL); Delayed administration of convalescent plasma (BIOLOGICAL); No vitamin C (OTHER); Vitamin C (DRUG); No antiplatelet (OTHER); Aspirin (DRUG); P2Y12 inhibitor (DRUG); No simvastatin (OTHER); Simvastatin (DRUG); Eritoran (DRUG); Apremilast (DRUG); Clinician-preferred mechanical ventilation strategy (PROCEDURE); Protocolised mechanical ventilation strategy (PROCEDURE); No renin-angiotensin system inhibitor (OTHER); Angiotensin converting enzyme inhibitor (DRUG); Angiotensin Receptor Blockers (DRUG); ARB + DMX-200 (DRUG); No cysteamine (OTHER); Cysteamine (DRUG); Fixed-duration dexamethasone (DRUG); Baloxavir Marboxil (DRUG); Five-days oseltamivir + baloxavir marboxil (DRUG); Ten-days oseltamivir + baloxavir marboxil (DRUG); No endothelial modulator (OTHER); Imatinib (DRUG); No Immune Modulator for Influenza (OTHER); Tocilizumab (DRUG); Baricitinib (DRUG); No antiviral agent for COVID-19 (OTHER); Nirmatrelvir/ritonavir (DRUG); Remdesivir (DRUG); Nirmatrelvir/ritonavir + remdesivir (DRUG),2554,CBZ,Community-acquired Respiratory Infections,Lung,Carbamazepine,,inhibitor/antagonist,HDAC inhibitor,yes,yes,Used for epilepsy and neuropathic pain.,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1.08,199.0 +1781,NCT03807973,Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.,RECRUITING,PHASE1,Fibromyalgia; Chronic Fatigue Syndrome; Multiple Sclerosis; Healthy,[Zr-89]Oxine-labeled leukocytes PET/MRI (DRUG),1923,HQY,Fibromyalgia; Chronic Fatigue Syndrome; Multiple Sclerosis; Healthy,CNS/Brain,8-Hydroxyquinoline,,unclear,unclear,no,yes,"Used in some clinical trial formulations, not approved as standalone drug.",C1=CC2=C(C(=C1)O)N=CC=C2,1.1428571428571428,54.0 +1782,NCT00243594,Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection,COMPLETED,PHASE1,Melanoma Stage III or IV,Peptide-pulsed dendritic cells (BIOLOGICAL),1923,HQY,Melanoma Stage III or IV,Skin,8-Hydroxyquinoline,,unclear,unclear,no,yes,"Used in some clinical trial formulations, not approved as standalone drug.",C1=CC2=C(C(=C1)O)N=CC=C2,1.1428571428571428,54.0 +1783,NCT02153541,Assessing the Efficacy of CREWS01 to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults,UNKNOWN,PHASE2,Asthma,Antipyrine-benzocaine otic solution (DRUG); Glycerin with Oxyquinoline Sulfate (OTHER),1923,HQY,Asthma,Lung,8-Hydroxyquinoline,,unclear,unclear,no,yes,"Used in some clinical trial formulations, not approved as standalone drug.",C1=CC2=C(C(=C1)O)N=CC=C2,1.1428571428571428,54.0 +1784,NCT03853187,Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer,COMPLETED,PHASE2,Non-small Cell Lung Cancer,Zr-89 labelled durvalumab PET/CT (RADIATION); Durvalumab (MEDI4736) (DRUG),1923,HQY,Non-small Cell Lung Cancer,Lung,8-Hydroxyquinoline,,unclear,unclear,no,yes,"Used in some clinical trial formulations, not approved as standalone drug.",C1=CC2=C(C(=C1)O)N=CC=C2,1.1428571428571428,54.0 +1785,NCT05508074,Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol),COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis; ALS,IFB-088 50mg/day (DRUG); Placebo (DRUG); Riluzole 100mg/day (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis; ALS,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1786,NCT00868166,Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS,COMPLETED,PHASE3,Amyotrophic Lateral Sclerosis,Olesoxime (DRUG); Placebo Comparator (DRUG); Riluzole (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1787,NCT02238626,Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS),COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,Placebo (for MN-166) (DRUG); MN-166 (DRUG); riluzole (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1788,NCT00501943,Neuroprotection With Riluzole Patients With Early Multiple Sclerosis,COMPLETED,PHASE2,Multiple Sclerosis,Avonex (Interferon beta 1a) (DRUG); Riluzole (DRUG); Placebo (DRUG),6419992,HB0548,Multiple Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1789,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,Ozanezumab (DRUG); Placebo (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1790,NCT03456882,The Effect of RNS60 on ALS Biomarkers,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,RNS60 (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1791,NCT01020331,Memantine Therapy in Amyotrophic Lateral Sclerosis,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,Memantine (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1792,NCT01378676,A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,Placebo (Part A) (DRUG); CK-2017357 (Part A) (DRUG); CK-2017357 (Part A) (DRUG); CK-2017357 (Part A) (DRUG); Riluzole 50 MG (Part B) (DRUG); Placebo (Part B) (DRUG); CK-2017357 (Part B) (DRUG); CK-2017357 (Part B) (DRUG); CK-2017357 (Part B) (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1793,NCT06552260,A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma,RECRUITING,EARLY_PHASE1,Glioblastoma; Recurrent Glioblastoma; Brain Tumor,Troriluzole (DRUG),6419992,HB0548,Glioblastoma; Recurrent Glioblastoma; Brain Tumor,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1794,NCT03127267,Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients,UNKNOWN,PHASE3,Amyotrophic Lateral Sclerosis,Masitinib (6.0) (DRUG); Riluzole (DRUG); Placebo (DRUG); Masitinib (4.5) (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1795,NCT03039673,MIROCALS: Modifying Immune Response and OutComes in ALS,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,Riluzole (DRUG); IL-2 (DRUG); 5% glucose water solution (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1796,NCT02463825,A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS,UNKNOWN,PHASE2,Amyotrophic Lateral Sclerosis (ALS),Pimozide 2 mg per day (DRUG); Pimozide 4 mg per day (DRUG); Placebo (Lactose tablet) (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis (ALS),CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1797,NCT00326625,Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS),COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,40 mg glatiramer acetate (DRUG); Placebo (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1798,NCT00353665,Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS),COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,Memantine (Ebixa) (DRUG); riluzole (DRUG); Placebo (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1799,NCT02118727,Therapy in Amyotrophic Lateral Sclerosis (TAME),COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis; Frontal Temporal Dementia,Memantine (DRUG); Placebo (for Memantine) (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis; Frontal Temporal Dementia,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1800,NCT03722680,Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.,SUSPENDED,PHASE2,Oxaliplatin-induced Peripheral Neuropathy,Riluzole (DRUG); Placebo Oral Tablet (DRUG),6419992,HB0548,Oxaliplatin-induced Peripheral Neuropathy,Peripheral Nervous System,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1801,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,COMPLETED,PHASE3,Amyotrophic Lateral Sclerosis,Dexpramipexole (DRUG); Placebo (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1802,NCT03500289,Ketamine for Treatment of MS Fatigue,COMPLETED,PHASE1,Multiple Sclerosis; Fatigue,Ketamine (DRUG); Midazolam (DRUG),6419992,HB0548,Multiple Sclerosis; Fatigue,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1803,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),TERMINATED,PHASE2,Amyotrophic Lateral Sclerosis,Lithium Carbonate (DRUG); Riluzole (DRUG); placebo (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1804,NCT00635960,Growth Hormone in Amyotrophic Lateral Sclerosis,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,Growth Hormone (Somatropin) (DRUG); Placebo (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1805,NCT02492516,Intravenous Injection of Adipose Derived Mesenchymal Stem Cell for ALS,COMPLETED,PHASE1,Amyotrophic Lateral Sclerosis,mesenchymal stem cells (BIOLOGICAL),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1806,NCT00013624,Riluzole to Treat Parkinson's Disease,COMPLETED,PHASE2,Parkinson's Disease,IV Levodopa (DRUG),6419992,HB0548,Parkinson's Disease,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1807,NCT01569958,Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis,UNKNOWN,PHASE2,Amyotrophic Lateral Sclerosis,transcranial direct current stimulation (OTHER); Sham stimulation (OTHER),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1808,NCT02166944,Tamoxifen Treatment in Patients With Motor Neuron Disease,COMPLETED,PHASE1,Amyotrophic Lateral Sclerosis; ALS Functional Ration Scale; TAR-DNA-binding Protein-43; Tamoxifen; mTOR,tamoxifen 40 mg daily for one year (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis; ALS Functional Ration Scale; TAR-DNA-binding Protein-43; Tamoxifen; mTOR,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1809,NCT00667901,Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery,TERMINATED,PHASE1,Melanoma (Skin),riluzole (DRUG); protein expression analysis (GENETIC); reverse transcriptase-polymerase chain reaction (GENETIC); western blotting (GENETIC); immunohistochemistry staining method (OTHER); laboratory biomarker analysis (OTHER); pharmacological study (OTHER); neoadjuvant therapy (PROCEDURE); therapeutic conventional surgery (PROCEDURE),6419992,HB0548,Melanoma (Skin),Skin,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1810,NCT00876772,Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS),COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis (ALS),Olanzapine (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis (ALS),CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1811,NCT00877604,Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,tauroursodeoxycholic acid (TUDCA) (DRUG); Placebo (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1812,NCT00866840,Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,COMPLETED,PHASE2,Melanoma (Skin),riluzole (DRUG),6419992,HB0548,Melanoma (Skin),Skin,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1813,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis (ALS),ONO-2506PO (DRUG); ONO-2506PO (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis (ALS),CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1814,NCT00231140,Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS),TERMINATED,PHASE2,Amyotrophic Lateral Sclerosis (ALS),Thalidomide (drug) (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis (ALS),CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1815,NCT01771640,Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS,COMPLETED,PHASE1,Amyotrophic Lateral Sclerosis,intrathecal injection (BIOLOGICAL),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1816,NCT03605667,Study of BHV-4157 in Alzheimer's Disease,COMPLETED,PHASE2,Alzheimer Disease,troriluzole (DRUG); Placebo oral capsule (DRUG),6419992,HB0548,Alzheimer Disease,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1817,NCT04454840,Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral Sclerosis,COMPLETED,EARLY_PHASE1,Amyotrophic Lateral Sclerosis,Plasma from healthy young people treatment + Riluzole (BIOLOGICAL); Riluzole (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1818,NCT03520517,"Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS",COMPLETED,PHASE1,"Amyotrophic Lateral Sclerosis; ALS; Lou Gehrig Disease; Lou Gehrig's Disease; Lou-Gehrigs Disease; Motor Neuron Disease, Amyotrophic Lateral Sclerosis",BHV-0223 (DRUG),6419992,HB0548,"Amyotrophic Lateral Sclerosis; ALS; Lou Gehrig Disease; Lou Gehrig's Disease; Lou-Gehrigs Disease; Motor Neuron Disease, Amyotrophic Lateral Sclerosis",CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1819,NCT01703117,Riluzole in Mild Alzheimer's Disease,COMPLETED,PHASE2,Alzheimer's Disease,Riluzole (DRUG); Placebo (DRUG),6419992,HB0548,Alzheimer's Disease,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1820,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis (ALS),ONO-2506PO (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis (ALS),CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1821,NCT01303341,Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma,ACTIVE_NOT_RECRUITING,PHASE1,Advanced Malignant Solid Neoplasm; Recurrent Melanoma; Refractory Malignant Solid Neoplasm; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7,Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Riluzole (DRUG); Sorafenib Tosylate (DRUG),6419992,HB0548,Advanced Malignant Solid Neoplasm; Recurrent Melanoma; Refractory Malignant Solid Neoplasm; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7,Skin,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1822,NCT01879241,Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,Rasagiline (DRUG); Placebo (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1823,NCT00690118,Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis,TERMINATED,PHASE2,Amyotrophic Lateral Sclerosis,pioglitazone (DRUG); placebo (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1824,NCT01486849,Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,CK-2017357 (DRUG); Placebo (DRUG); Riluzole 50 MG (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1825,NCT05357950,"A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS",ACTIVE_NOT_RECRUITING,PHASE2,Amyotrophic Lateral Sclerosis; ALS,PrimeC (DRUG); Placebo (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis; ALS,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1826,NCT04761614,Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE1,Metastatic Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Bevacizumab (BIOLOGICAL); Fluorouracil (DRUG); Leucovorin Calcium (DRUG); Oxaliplatin (DRUG); Riluzole (DRUG),6419992,HB0548,Metastatic Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Bowel,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1827,NCT00542412,CARE Canadian ALS Riluzole Evaluation,COMPLETED,PHASE4,Amyotrophic Lateral Sclerosis,Riluzole (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1828,NCT00397423,G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical Response,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,Granulocyte Colony Stimulating Factor (DRUG); NS (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1829,NCT00903214,"Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer",WITHDRAWN,PHASE1,Breast Cancer,riluzole (DRUG); polymorphism analysis (GENETIC); axillary lymph node biopsy (PROCEDURE); digital image analysis (PROCEDURE); needle biopsy (PROCEDURE); sentinel lymph node biopsy (PROCEDURE); therapeutic conventional surgery (PROCEDURE),6419992,HB0548,Breast Cancer,Breast,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1830,NCT06676423,Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS,COMPLETED,PHASE1,Amyotrophic Lateral Sclerosis,Lenzumestrocel (BIOLOGICAL); Riluzole (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1831,NCT00919555,Combination Therapy in Amyotrophic Lateral Sclerosis (ALS),COMPLETED,PHASE1,Amyotrophic Lateral Sclerosis,Pioglitazone and Tretinoin (DRUG); Tretinoin and Pioglitazone HCL (DRUG); Placebo (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1832,NCT03693781,Colchicine for Amyotrophic Lateral Sclerosis,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,Colchicine 1 MG Oral Tablet (DRUG); Colchicine 1 MG Oral Tablet (DRUG); Placebo Oral Tablet (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1833,NCT03359538,Rapamycin Treatment for ALS,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,Rapamycin (DRUG); Placebo Oral Tablet (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1834,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,CK-2017357 (DRUG); Placebo tablets (OTHER); Riluzole (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1835,NCT04745299,Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients with ALS,ACTIVE_NOT_RECRUITING,PHASE3,Amyotrophic Lateral Sclerosis,Lenzumestrocel (BIOLOGICAL); Riluzole (DRUG); Placebo Comparator (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1836,NCT00277602,Riluzole in Huntington's Disease,COMPLETED,PHASE3,Huntington Disease,Riluzole (DRUG),6419992,HB0548,Huntington Disease,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1837,NCT05237284,Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS),TERMINATED,PHASE2,Amyotrophic Lateral Sclerosis,SAR443820 (DRUG); Placebo (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1838,NCT06580002,Repurposing Riluzole for Cancer-Related Cognitive Impairment: a Pilot Trial,RECRUITING,PHASE2,Breast Cancer,Riluzole (DRUG); Placebo (DRUG),6419992,HB0548,Breast Cancer,Breast,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1839,NCT04944784,A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS),TERMINATED,PHASE3,Amyotrophic Lateral Sclerosis,Reldesemtiv (DRUG); Placebo (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1840,NCT01759784,Intraventricular Transplantation of Mesenchymal Stem Cell in Patients With ALS,WITHDRAWN,PHASE1,Amyotrophic Lateral Sclerosis,Intraventricular injection (BIOLOGICAL),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1841,NCT03679975,Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS),TERMINATED,PHASE2,Amyotrophic Lateral Sclerosis,Riluzole Oral Soluble film (ROSF) 50 mg (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1842,NCT02969759,Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis,UNKNOWN,EARLY_PHASE1,Sporadic Amyotrophic Lateral Sclerosis,Skin Biopsy (OTHER),6419992,HB0548,Sporadic Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1843,NCT02059759,Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,Placebo (DRUG); 1.0 MIU IL-2 per day (DRUG); 2.0 MIU IL-2 per day (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1844,NCT00560287,Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis,UNKNOWN,PHASE4,Amyotrophic Lateral Sclerosis; Chronic Respiratory Failure,Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers (DEVICE); Non invasive ventilation (DEVICE),6419992,HB0548,Amyotrophic Lateral Sclerosis; Chronic Respiratory Failure,Lung,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1845,NCT06126315,Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS,NOT_YET_RECRUITING,PHASE2,Amyotrophic Lateral Sclerosis,Acetyl-l-carnitine (DRUG); Placebo (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1846,NCT01910259,MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial,COMPLETED,PHASE2,Secondary Progressive Multiple Sclerosis,Amiloride (DRUG); Riluzole (DRUG); Fluoxetine (DRUG); Placebo (DRUG),6419992,HB0548,Secondary Progressive Multiple Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1847,NCT00925847,Effect of Lithium Carbonate in Patients With Amyotrophic Lateral Sclerosis,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,lithium (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1848,NCT04950933,The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules,UNKNOWN,PHASE2,Amyotrophic Lateral Sclerosis,Huolingshengji Granules (DRUG); Riluzole tablet (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1849,NCT02588677,Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS),COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis (ALS),Masitinib (4.5) (DRUG); Riluzole (DRUG); Placebo (DRUG); Masitinib (3.0) (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis (ALS),CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1850,NCT03457753,Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis,WITHDRAWN,PHASE2,ALS,Riluzole Oral Soluble Film (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis (ALS),CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1851,NCT01277315,Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis (ALS),Anakinra (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis (ALS),CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1852,NCT03377309,Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients,TERMINATED,PHASE2,Amyotrophic Lateral Sclerosis,Fycompa (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1853,NCT04326283,"Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)",TERMINATED,PHASE1,Amyotrophic Lateral Sclerosis,Trametinib (0.5 mg) (DRUG); Trametinib (1 mg) (DRUG); Riluzole (100 mg) (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1854,NCT00753571,Cistanche Total Glycosides for Amyotrophic Lateral Sclerosis: A Randomized Control Trial (RCT) Study Assessing Clinical Response,UNKNOWN,PHASE2,Amyotrophic Lateral Sclerosis,Cistanche Total Glycosides (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1855,NCT01285583,Safety Extension Study of TRO19622 in ALS,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,TRO19622 (DRUG),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1856,NCT01759797,Intravenous Transplantation of Mesenchymal Stem Cell in Patients With ALS,COMPLETED,PHASE1,Amyotrophic Lateral Sclerosis,intra venous injection of stem cell (BIOLOGICAL),6419992,HB0548,Amyotrophic Lateral Sclerosis,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1857,NCT00202397,Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia,COMPLETED,PHASE2,Hereditary Ataxia; Multiple Sclerosis; Cerebellar Ataxia,Riluzole (DRUG); placebo (OTHER),6419992,HB0548,Hereditary Ataxia; Multiple Sclerosis; Cerebellar Ataxia,CNS/Brain,Riluzole hydrochloride,,inhibitor/antagonist,unclear,yes,yes,Used in ALS treatment.,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N.Cl,, +1858,NCT03850873,A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics,UNKNOWN,PHASE1,Advanced Breast Cancer,TQB3616 (DRUG),60750,Zefei,Advanced Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1859,NCT05263869,A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients,UNKNOWN,PHASE2,Breast Cancer With Liver Metastases,MRG002 (DRUG),60750,Zefei,Breast Cancer With Liver Metastases,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1860,NCT01439191,"Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer",COMPLETED,PHASE2,Metastatic Breast Cancer,humanized anti-HER2 antibody (DRUG); Vinorelbine (DRUG),60750,Zefei,Metastatic Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1861,NCT06167694,Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer,RECRUITING,PHASE1,Unresectable or Metastatic Breast Cancer,HRS-8080; Dalpiciclib Isethionate Tablets (DRUG),60750,Zefei,Unresectable or Metastatic Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1862,NCT02072512,The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer,UNKNOWN,PHASE2,Metastatic Breast Cancer,Fulvestrant (DRUG); Goserelin (DRUG); Anastrozole (DRUG); Goserelin (DRUG),60750,Zefei,Metastatic Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1863,NCT03658213,To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.,WITHDRAWN,PHASE3,Breast Cancer,ZOLADEX 10.8 mg (DRUG); ZOLADEX 3.6mg (DRUG),60750,Zefei,Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1864,NCT04514419,Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel,UNKNOWN,PHASE3,Breast Cancer,HS627 (DRUG); Pertuzumab (DRUG),60750,Zefei,Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1865,NCT04138719,Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer,UNKNOWN,PHASE2,Breast Cancer; Triple-negative Breast Cancer; Nab-paclitaxel,Nab-paclitaxel + Carboplatin (DRUG); Nab-paclitaxel + Epirubicin (DRUG),60750,Zefei,Breast Cancer; Triple-negative Breast Cancer; Nab-paclitaxel,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1866,NCT02510781,A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs,UNKNOWN,PHASE2,Breast Neoplasms,Epirubicin (DRUG); Docetaxel (DRUG); Trastuzumab (DRUG); Carboplatin (DRUG),60750,Zefei,Breast Neoplasms,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1867,NCT02838823,Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer,COMPLETED,PHASE1,Breast Cancer,humanized anti-PD-1 monoclonal antibody toripalimab (BIOLOGICAL),60750,Zefei,Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1868,NCT04796623,A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer,UNKNOWN,PHASE2,"HR-positive, HER2-negative Advanced Breast Cancer",TQB3616 capsules (DRUG); Fulvestrant injection (DRUG),60750,Zefei,"HR-positive, HER2-negative Advanced Breast Cancer",Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1869,NCT04924699,A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer,UNKNOWN,PHASE2,Advanced Breast Cancer; Metastatic Breast Cancer,MRG002 (DRUG); Trastuzumab Emtansine for Injection (DRUG),60750,Zefei,Advanced Breast Cancer; Metastatic Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1870,NCT04159142,Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer,UNKNOWN,PHASE2,Triple Negative Breast Cancer; Nab-paclitaxel,Nab-paclitaxel + Carboplatin (DRUG); Nab-paclitaxel + Capecitabine (DRUG),60750,Zefei,Triple Negative Breast Cancer; Nab-paclitaxel,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1871,NCT03086785,"Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer",UNKNOWN,PHASE2,Breast Cancer Metastatic,Apatinib (DRUG),60750,Zefei,Breast Cancer Metastatic,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1872,NCT02119715,A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy,COMPLETED,PHASE2,Breast Cancer; Neutropenia; Febrile Neutropenia,Pegylated rhG-CSF 100μg/kg (DRUG); Pegylated rhG-CSF:150 μg/kg (DRUG); rhG-CSF 5 μg/kg/day (DRUG),60750,Zefei,Breast Cancer; Neutropenia; Febrile Neutropenia,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1873,NCT01300351,Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women,COMPLETED,PHASE3,Breast Cancer,Fulvestrant (DRUG); Placebo (DRUG),60750,Zefei,Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1874,NCT00717951,"A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer",UNKNOWN,PHASE2,Advanced Breast Cancer,"docetaxol, cisplatin, capecitabine (DRUG)",60750,Zefei,Advanced Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1875,NCT02482753,Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Chidamide (DRUG); exemestane (DRUG); placebo (DRUG),60750,Zefei,Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1876,NCT06635447,Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients,RECRUITING,PHASE3,Breast Cancer,Capivasertib (DRUG); Fulvestrant (DRUG),60750,Zefei,Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1877,NCT04742153,A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC),UNKNOWN,PHASE2,Advanced or Metastatic Breast Cancer,MRG002 (DRUG),60750,Zefei,Advanced or Metastatic Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1878,NCT06265428,A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer,RECRUITING,PHASE3,HER2-positive Breast Cancer,DB-1303/BNT323 (DRUG); T-DM1 (DRUG),60750,Zefei,HER2-positive Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1879,NCT05065957,Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer,RECRUITING,PHASE2,Biliary Tract Cancer,D07001-softgel capsules + Xeloda (or TS-1) (DRUG); mFOLFOX (DRUG),60750,Zefei,Biliary Tract Cancer,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1880,NCT00055757,"Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer",COMPLETED,PHASE2,Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,tipifarnib (DRUG); cisplatin (DRUG); gemcitabine hydrochloride (DRUG); laboratory biomarker analysis (OTHER),60750,Zefei,Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1881,NCT03662074,Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer,TERMINATED,PHASE2,Small Cell Lung Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Gemcitabine (DRUG); Nivolumab (BIOLOGICAL),60750,Zefei,Small Cell Lung Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1882,NCT03971474,Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial),COMPLETED,PHASE2,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Docetaxel (DRUG); Gemcitabine (DRUG); Gemcitabine Hydrochloride (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed (DRUG); Pemetrexed Disodium (DRUG); Ramucirumab (BIOLOGICAL),60750,Zefei,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1883,NCT02351765,ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers,COMPLETED,PHASE1,Biliary Tract Cancer; Gallbladder Cancer; Cholangiocarcinoma; Ampullary Cancer,Acelarin (DRUG); Cisplatin (DRUG),60750,Zefei,Biliary Tract Cancer; Gallbladder Cancer; Cholangiocarcinoma; Ampullary Cancer,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1884,NCT00095966,Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,sorafenib tosylate (DRUG); gemcitabine hydrochloride (DRUG),60750,Zefei,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1885,NCT03775265,Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Bladder Urothelial Carcinoma; Muscle Invasive Bladder Carcinoma; Stage II Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8,Atezolizumab (DRUG); Biopsy of Bladder (PROCEDURE); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Cystoscopy (PROCEDURE); Fluorouracil (DRUG); Gemcitabine (DRUG); Magnetic Resonance Imaging (PROCEDURE); Mitomycin (DRUG); Quality-of-Life Assessment (OTHER); Radiation Therapy (RADIATION); Survey Administration (OTHER); Transurethral Resection of Bladder Tumor (PROCEDURE),60750,Zefei,Muscle Invasive Bladder Cancer,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1886,NCT04233866,"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Fluorouracil (DRUG); Gemcitabine (DRUG); Gemcitabine Hydrochloride (DRUG); Leucovorin (DRUG); Leucovorin Calcium (DRUG); Liposomal Irinotecan (DRUG); Nab-paclitaxel (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),60750,Zefei,Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1887,NCT00091026,Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer,COMPLETED,PHASE2,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,cetuximab (BIOLOGICAL); gemcitabine hydrochloride (DRUG); bevacizumab (BIOLOGICAL); erlotinib hydrochloride (DRUG),60750,Zefei,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1888,NCT00039403,UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer,COMPLETED,PHASE1,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,7-hydroxystaurosporine (DRUG); gemcitabine hydrochloride (DRUG); pharmacological study (OTHER); laboratory biomarker analysis (OTHER),60750,Zefei,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1889,NCT00027703,Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma,COMPLETED,PHASE2,Advanced Malignant Mesothelioma; Epithelial Mesothelioma; Localized Malignant Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma,gemcitabine hydrochloride (DRUG); cisplatin (DRUG); bevacizumab (BIOLOGICAL); placebo (OTHER); laboratory biomarker analysis (OTHER),60750,Zefei,Advanced Malignant Mesothelioma; Epithelial Mesothelioma; Localized Malignant Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1890,NCT00096395,Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer,COMPLETED,PHASE2,Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer,gemcitabine hydrochloride (DRUG); sorafenib tosylate (DRUG); laboratory biomarker analysis (OTHER),60750,Zefei,Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1891,NCT02048943,"Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer",WITHDRAWN,PHASE1,"Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",dovitinib lactate (DRUG); gemcitabine hydrochloride (DRUG); paclitaxel albumin-stabilized nanoparticle formulation (DRUG); pharmacological study (OTHER); laboratory biomarker analysis (OTHER),60750,Zefei,"Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1892,NCT01068327,"Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer",COMPLETED,PHASE1,Adenocarcinoma of the Pancreas; Stage III Pancreatic Cancer,gemcitabine hydrochloride (DRUG); leucovorin calcium (DRUG); fluorouracil (DRUG); nelfinavir mesylate (DRUG); stereotactic body radiation therapy (RADIATION); hypofractionated radiation therapy (RADIATION); therapeutic conventional surgery (PROCEDURE),60750,Zefei,Adenocarcinoma of the Pancreas; Stage III Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1893,NCT00005831,Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer,COMPLETED,PHASE2,Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Bladder Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Squamous Cell Carcinoma of the Bladder; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder,trastuzumab (BIOLOGICAL); paclitaxel (DRUG); carboplatin (DRUG); gemcitabine hydrochloride (DRUG); laboratory biomarker analysis (OTHER),60750,Zefei,Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Bladder Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Squamous Cell Carcinoma of the Bladder; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder,Skin,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1894,NCT01924260,Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer,COMPLETED,PHASE1,"Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",alisertib (DRUG); gemcitabine (DRUG),60750,Zefei,"Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1895,NCT03533582,Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery,ACTIVE_NOT_RECRUITING,PHASE3,"Childhood Hepatocellular Carcinoma; Childhood Malignant Liver Neoplasm; Fibrolamellar Carcinoma; Hepatoblastoma; Hepatocellular Malignant Neoplasm, Not Otherwise Specified",Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Doxorubicin (DRUG); Etoposide (DRUG); Fluorouracil (DRUG); Gemcitabine (DRUG); Irinotecan (DRUG); Oxaliplatin (DRUG); Patient Observation (OTHER); Resection (PROCEDURE); Sorafenib (DRUG); Vincristine Sulfate (DRUG),60750,Zefei,Childhood Liver Malignancies,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1896,NCT06770582,"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, the PARRC Trial",RECRUITING,PHASE2,Non-Muscle Invasive Bladder Urothelial Carcinoma; Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma; Stage I Bladder Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Fluorouracil (DRUG); Gemcitabine (DRUG); Magnetic Resonance Imaging (PROCEDURE); Mitomycin (DRUG); Pembrolizumab (BIOLOGICAL); Questionnaire Administration (OTHER); Radiation Therapy (RADIATION),60750,Zefei,Non-Muscle Invasive Bladder Urothelial Carcinoma; Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma; Stage I Bladder Cancer AJCC v8,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1897,NCT02996825,"Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer",COMPLETED,PHASE1,Recurrent Breast Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Triple-Negative Breast Carcinoma,Gemcitabine (DRUG); Gemcitabine Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Mirvetuximab Soravtansine (BIOLOGICAL); Pharmacological Study (OTHER),60750,Zefei,Recurrent Breast Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Triple-Negative Breast Carcinoma,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1898,NCT06423326,"Gemcitabine, Cisplatin and Nab-Paclitaxel As Neoadjuvant Treatment for Patients with Resectable or Borderline Resectable Pancreatic Cancer",RECRUITING,PHASE2,Borderline Resectable Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Adenocarcinoma; Stage I Pancreatic Cancer AJCC V8; Stage II Pancreatic Cancer AJCC V8; Stage III Pancreatic Cancer AJCC V8,Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Gemcitabine (DRUG); Magnetic Resonance Imaging (PROCEDURE); Nab-paclitaxel (DRUG); Pancreatic Surgical Procedure (PROCEDURE),60750,Zefei,Borderline Resectable Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Adenocarcinoma; Stage I Pancreatic Cancer AJCC V8; Stage II Pancreatic Cancer AJCC V8; Stage III Pancreatic Cancer AJCC V8,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1899,NCT02479230,Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients,COMPLETED,PHASE1,Breast Cancer; Metastatic Breast Cancer,tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine (BIOLOGICAL); gemcitabine hydrochloride (DRUG),60750,Zefei,Breast Cancer; Metastatic Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1900,NCT01739439,Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery,TERMINATED,PHASE1,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer,gemcitabine hydrochloride (DRUG); hyperfractionated radiation therapy (RADIATION); intensity-modulated radiation therapy (RADIATION); radiosurgery (RADIATION); diffusion-weighted magnetic resonance imaging (PROCEDURE),60750,Zefei,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1901,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,COMPLETED,PHASE3,Primary Peritoneal Carcinoma; Stage III Ovarian Cancer; Stage IV Ovarian Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Gemcitabine Hydrochloride (DRUG); Pegylated Liposomal Doxorubicin Hydrochloride (DRUG); Topotecan Hydrochloride (DRUG); Therapeutic Conventional Surgery (PROCEDURE),60750,Zefei,Ovarian and Peritoneal Carcinoma,Ovary/Fallopian Tube,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1902,NCT02275039,p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer,COMPLETED,PHASE1,Recurrent Ovarian Epithelial Cancer; Recurrent Fallopian Tube Carcinoma; Recurrent Primary Peritoneal Carcinoma,modified vaccinia virus ankara vaccine expressing p53 (BIOLOGICAL); gemcitabine hydrochloride (DRUG); laboratory biomarker analysis (OTHER),60750,Zefei,Recurrent Ovarian Epithelial Cancer; Recurrent Fallopian Tube Carcinoma; Recurrent Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1903,NCT01611662,Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer,TERMINATED,PHASE2,Distal Urethral Cancer; Proximal Urethral Cancer; Squamous Cell Carcinoma of the Bladder; Stage II Bladder Cancer; Stage III Bladder Cancer; Urethral Cancer Associated With Invasive Bladder Cancer,gemcitabine hydrochloride (DRUG); cisplatin (DRUG); therapeutic conventional surgery (PROCEDURE); laboratory biomarker analysis (OTHER),60750,Zefei,Distal Urethral Cancer; Proximal Urethral Cancer; Squamous Cell Carcinoma of the Bladder; Stage II Bladder Cancer; Stage III Bladder Cancer; Urethral Cancer Associated With Invasive Bladder Cancer,Skin,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1904,NCT03587662,"Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients with Locally Advanced or Metastatic Kidney Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Kidney Medullary Carcinoma; Metastatic Renal Cell Carcinoma; SMARCB1 Negative; Stage III Renal Cell Cancer AJCC V8; Stage IV Renal Cell Cancer AJCC V8,Doxorubicin (DRUG); Doxorubicin Hydrochloride (DRUG); Gemcitabine (DRUG); Gemcitabine Hydrochloride (DRUG); Ixazomib (DRUG); Ixazomib Citrate (DRUG),60750,Zefei,Metastatic Kidney Medullary Carcinoma; Metastatic Renal Cell Carcinoma; SMARCB1 Negative; Stage III Renal Cell Cancer AJCC V8; Stage IV Renal Cell Cancer AJCC V8,Kidney,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1905,NCT00679029,Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer,TERMINATED,PHASE2,HER2-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,doxorubicin hydrochloride (DRUG); cyclophosphamide (DRUG); bevacizumab (BIOLOGICAL); paclitaxel (DRUG); gemcitabine hydrochloride (DRUG); laboratory biomarker analysis (OTHER); pegfilgrastim (BIOLOGICAL),60750,Zefei,HER2-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1906,NCT01652794,"Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer",COMPLETED,PHASE1,Leydig Cell Tumor; Ovarian Sarcoma; Ovarian Stromal Cancer; Pseudomyxoma Peritonei; Recurrent Cervical Cancer; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Primary Peritoneal Cavity Cancer; Recurrent Uterine Sarcoma; Recurrent Vaginal Cancer; Recurrent Vulvar Cancer,stereotactic body radiation therapy (RADIATION); carboplatin (DRUG); gemcitabine hydrochloride (DRUG); laboratory biomarker analysis (OTHER); pharmacogenomic studies (OTHER),60750,Zefei,Leydig Cell Tumor; Ovarian Sarcoma; Ovarian Stromal Cancer; Pseudomyxoma Peritonei; Recurrent Cervical Cancer; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Primary Peritoneal Cavity Cancer; Recurrent Uterine Sarcoma; Recurrent Vaginal Cancer; Recurrent Vulvar Cancer,Uterus,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1907,NCT00088894,Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,COMPLETED,PHASE3,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,gemcitabine hydrochloride (DRUG); bevacizumab (BIOLOGICAL); placebo (OTHER); laboratory biomarker analysis (OTHER); pharmacogenomic studies (OTHER); pharmacological study (OTHER),60750,Zefei,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1908,NCT01893294,Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer,COMPLETED,PHASE1,Duct Cell Adenocarcinoma of the Pancreas; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,gemcitabine hydrochloride (DRUG); fluorouracil (DRUG); radiation therapy (RADIATION); laboratory biomarker analysis (OTHER),60750,Zefei,Duct Cell Adenocarcinoma of the Pancreas; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1909,NCT06704191,"In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial",RECRUITING,PHASE1,Non-Muscle Invasive Bladder Carcinoma; Stage 0a Bladder Cancer AJCC v8; Stage I Bladder Cancer AJCC v8; Stage 0is Bladder Cancer AJCC v8,BCG Solution (BIOLOGICAL); Cystoscopy (PROCEDURE); Docetaxel (DRUG); Gemcitabine (DRUG); Home Health Encounter (OTHER); Mitomycin (DRUG); Questionnaire Administration (OTHER),60750,Zefei,Non-Muscle Invasive Bladder Carcinoma; Stage 0a Bladder Cancer AJCC v8; Stage I Bladder Cancer AJCC v8; Stage 0is Bladder Cancer AJCC v8,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1910,NCT04940286,"Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Borderline Resectable Pancreatic Adenocarcinoma; Resectable Pancreatic Adenocarcinoma; Stage IA Pancreatic Cancer AJCC v8; Stage IB Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8,Durvalumab (BIOLOGICAL); Gemcitabine (DRUG); Nab-paclitaxel (DRUG); Oleclumab (BIOLOGICAL),60750,Zefei,Borderline Resectable Pancreatic Adenocarcinoma; Resectable Pancreatic Adenocarcinoma; Stage IA Pancreatic Cancer AJCC v8; Stage IB Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1911,NCT01234935,Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery,COMPLETED,PHASE2,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer,dasatinib (DRUG); gemcitabine hydrochloride (DRUG); laboratory biomarker analysis (OTHER); mutation analysis (GENETIC); nucleic acid sequencing (GENETIC); immunohistochemistry staining method (OTHER),60750,Zefei,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1912,NCT05096663,Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial),ACTIVE_NOT_RECRUITING,PHASE2,Advanced Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Cobalamin (DIETARY_SUPPLEMENT); Dexamethasone (DRUG); Docetaxel (DRUG); Folic Acid (DIETARY_SUPPLEMENT); Gemcitabine (DRUG); Nogapendekin Alfa (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed (DRUG); Ramucirumab (BIOLOGICAL),60750,Zefei,Advanced Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1913,NCT01497392,"Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers",COMPLETED,PHASE1,"Adenocarcinoma of the Pancreas; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",dovitinib lactate (DRUG); gemcitabine hydrochloride (DRUG); capecitabine (DRUG); laboratory biomarker analysis (OTHER); enzyme-linked immunosorbent assay (OTHER); pharmacological study (OTHER),60750,Zefei,"Adenocarcinoma of the Pancreas; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1914,NCT00610740,"CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer",COMPLETED,PHASE2,Cervical Cancer; Endometrial Cancer; Ovarian Cancer,topical gemcitabine hydrochloride (DRUG); therapeutic conventional surgery (PROCEDURE),60750,Zefei,Cervical Cancer; Endometrial Cancer; Ovarian Cancer,Uterus,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1915,NCT01525069,"Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma",TERMINATED,PHASE1,Cholangiocarcinoma; Liver Neoplasms,Floxuridine (DRUG); Dexamethasone (DRUG); Gemcitabine (DRUG); Oxaliplatin (DRUG),60750,Zefei,Cholangiocarcinoma; Liver Neoplasms,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1916,NCT00026104,Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer,COMPLETED,PHASE2,Adenocarcinoma of the Pancreas; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer,gemcitabine hydrochloride (DRUG); paclitaxel (DRUG); tipifarnib (DRUG); radiation therapy (RADIATION),60750,Zefei,Pancreatic Adenocarcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1917,NCT04481204,"New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study",ACTIVE_NOT_RECRUITING,PHASE2,Borderline Resectable Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma,Cisplatin (DRUG); Fluorouracil (DRUG); Gemcitabine (DRUG); Irinotecan (DRUG); Leucovorin (DRUG); Nab-paclitaxel (DRUG); Oxaliplatin (DRUG); Radiation Therapy (RADIATION),60750,Zefei,Borderline Resectable Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1918,NCT02720367,Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer,COMPLETED,PHASE1,Urinary Bladder Cancer,Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 (DRUG),60750,Zefei,Urinary Bladder Cancer,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1919,NCT00114244,Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Stage IV Pancreatic Cancer,sorafenib tosylate (DRUG); gemcitabine hydrochloride (DRUG); laboratory biomarker analysis (OTHER),60750,Zefei,Stage IV Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1920,NCT00577889,Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer,COMPLETED,PHASE2,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer,gemcitabine hydrochloride (DRUG); tanespimycin (DRUG),60750,Zefei,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1921,NCT02595892,"Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Ovarian Serous Tumor; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Berzosertib (DRUG); Gemcitabine (DRUG); Gemcitabine Hydrochloride (DRUG),60750,Zefei,Ovarian Serous Tumor; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1922,NCT00476827,A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain,TERMINATED,PHASE2,Breast Cancer,Bevacizumab (DRUG); Docetaxel (DRUG); CPT-11 (DRUG); Paclitaxel (DRUG); Vinorelbine Tartrate (DRUG); Gemcitabine (DRUG),60750,Zefei,Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1923,NCT05285358,Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases,RECRUITING,PHASE1,Distal Bile Duct Adenocarcinoma; Gallbladder Carcinoma; Intrahepatic Cholangiocarcinoma; Metastatic Malignant Neoplasm in the Peritoneum; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVB Gallbladder Cancer AJCC v8,Cisplatin (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),60750,Zefei,Distal Bile Duct Adenocarcinoma; Gallbladder Carcinoma; Intrahepatic Cholangiocarcinoma; Metastatic Malignant Neoplasm in the Peritoneum; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVB Gallbladder Cancer AJCC v8,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1924,NCT00093496,Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer,COMPLETED,PHASE2,Primary Peritoneal Cavity Cancer; Recurrent Ovarian Epithelial Cancer; Stage III Ovarian Epithelial Cancer; Stage IV Ovarian Epithelial Cancer,gemcitabine hydrochloride (DRUG); tanespimycin (DRUG),60750,Zefei,Primary Peritoneal Cavity Cancer; Recurrent Ovarian Epithelial Cancer; Stage III Ovarian Epithelial Cancer; Stage IV Ovarian Epithelial Cancer,Ovary/Fallopian Tube,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1925,NCT01473940,Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery,COMPLETED,PHASE1,Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,ipilimumab (BIOLOGICAL); gemcitabine hydrochloride (DRUG); laboratory biomarker analysis (OTHER),60750,Zefei,Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1926,NCT02349867,Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer,COMPLETED,PHASE1,Pancreatic Adenocarcinoma; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer; Recurrent Pancreatic Carcinoma,Gemcitabine (DRUG); Sorafenib (DRUG); Vorinostat (DRUG); 3-Dimensional Conformal Radiation Therapy (RADIATION); Intensity-Modulated Radiation Therapy (RADIATION); RosetteSep (OTHER); DEPfff (OTHER),60750,Zefei,Pancreatic Adenocarcinoma; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer; Recurrent Pancreatic Carcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1927,NCT00066768,Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,suramin (DRUG); docetaxel (DRUG); gemcitabine hydrochloride (DRUG); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),60750,Zefei,Advanced Non-Small Cell Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1928,NCT00028834,Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer,COMPLETED,PHASE2,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,gemcitabine hydrochloride (DRUG); bevacizumab (BIOLOGICAL); laboratory biomarker analysis (OTHER),60750,Zefei,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1929,NCT04616534,"Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors",ACTIVE_NOT_RECRUITING,PHASE1,Advanced Fallopian Tube Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Adenocarcinoma; Advanced Primary Peritoneal Carcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Fallopian Tube Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Diagnostic Imaging Testing (PROCEDURE); Elimusertib (DRUG); Gemcitabine (DRUG),60750,Zefei,Advanced Fallopian Tube Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Adenocarcinoma; Advanced Primary Peritoneal Carcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Fallopian Tube Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1930,NCT00645710,"Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery",COMPLETED,PHASE1,Liver Metastases; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer,gemcitabine hydrochloride (DRUG); floxuridine (DRUG); proteomic profiling (GENETIC); matrix-assisted laser desorption/ionization time of flight mass spectrometry (OTHER); liquid chromatography (OTHER); yttrium Y 90 anti-CEA monoclonal antibody cT84.66 (RADIATION); laboratory biomarker analysis (OTHER); mass spectrometry (OTHER); pharmacological study (OTHER),60750,Zefei,Liver Metastases; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer,Bowel,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1931,NCT00617708,S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery,COMPLETED,PHASE1,Stage IV Pancreatic Cancer,cixutumumab (BIOLOGICAL); erlotinib hydrochloride (DRUG); gemcitabine hydrochloride (DRUG),60750,Zefei,Stage IV Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1932,NCT00100750,Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer,COMPLETED,PHASE1,Recurrent Breast Carcinoma; Stage IV Breast Cancer,Gemcitabine Hydrochloride (DRUG); Tipifarnib (DRUG); Laboratory Biomarker Analysis (OTHER),60750,Zefei,Recurrent Breast Carcinoma; Stage IV Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1933,NCT00077350,A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Recurrent Non-small Cell Lung Cancer,triapine (DRUG); gemcitabine hydrochloride (DRUG); laboratory biomarker analysis (OTHER),60750,Zefei,Recurrent Non-small Cell Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1934,NCT02722538,Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer,COMPLETED,PHASE1,Urinary Bladder Cancer,Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 (DRUG),60750,Zefei,Urinary Bladder Cancer,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1935,NCT01828736,Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma,COMPLETED,PHASE2,Recurrent Bladder Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder,Trastuzumab (BIOLOGICAL); Gemcitabine (DRUG); Carboplatin (DRUG); Cisplatin (DRUG),60750,Zefei,Recurrent Bladder Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1936,NCT00068549,Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer,COMPLETED,PHASE1,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Small Cell Carcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Gemcitabine Hydrochloride (DRUG); Cisplatin (DRUG); Radiation Therapy (RADIATION); Internal Radiation Therapy (RADIATION),60750,Zefei,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Small Cell Carcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Skin,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1937,NCT02178436,"Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer",COMPLETED,PHASE1,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Stage IV Pancreatic Cancer,gemcitabine hydrochloride (DRUG); Selinexor (DRUG); Pharmacological Study (OTHER); Laboratory Biomarker Analysis (OTHER); Nab paclitaxel (DRUG),60750,Zefei,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Stage IV Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1938,NCT00609336,Perioperative Therapy for Resectable Pancreatic Cancer,COMPLETED,PHASE2,Adenocarcinoma of the Pancreas; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,gemcitabine hydrochloride (DRUG); docetaxel (DRUG); capecitabine (DRUG); intensity-modulated radiation therapy (RADIATION); oxaliplatin (DRUG); pancreatic surgical procedure (PROCEDURE); therapeutic conventional surgery (PROCEDURE); laboratory biomarker analysis (OTHER),60750,Zefei,Adenocarcinoma of the Pancreas; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1939,NCT00949949,"Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy",COMPLETED,PHASE1,"Cholangiocarcinoma of the Gallbladder; Localized Gallbladder Cancer; Unresectable Gallbladder Cancer; Unspecified Adult Solid Tumor, Protocol Specific",everolimus (DRUG); gemcitabine hydrochloride (DRUG); cisplatin (DRUG),60750,Zefei,"Cholangiocarcinoma of the Gallbladder; Localized Gallbladder Cancer; Unresectable Gallbladder Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1940,NCT00096070,"Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer",COMPLETED,PHASE2,Adenocarcinoma of the Pancreas; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer,radiation therapy (RADIATION); oxaliplatin (DRUG); fluorouracil (DRUG); gemcitabine hydrochloride (DRUG),60750,Zefei,Pancreatic Adenocarcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1941,NCT04390399,Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Pancreatic Cancer,N-803 (BIOLOGICAL); Aldoxorubicin HCl (DRUG); PD-L1 t-haNK (BIOLOGICAL); Nab-paclitaxel (DRUG); Gemcitabine (DRUG); Cyclophosphamide (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG); SBRT (PROCEDURE); Irinotecan liposome (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1942,NCT00114179,"Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery",COMPLETED,PHASE2,Adenocarcinoma of the Pancreas; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer,capecitabine (DRUG); radiation therapy (RADIATION); bevacizumab (BIOLOGICAL); therapeutic conventional surgery (PROCEDURE); gemcitabine hydrochloride (DRUG),60750,Zefei,Pancreatic Adenocarcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1943,NCT02046421,"Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",COMPLETED,PHASE1,Male Breast Cancer; Recurrent Breast Cancer; Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,mifepristone (DRUG); carboplatin (DRUG); gemcitabine hydrochloride (DRUG); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),60750,Zefei,Male Breast Cancer; Recurrent Breast Cancer; Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1944,NCT01639521,"Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer",WITHDRAWN,PHASE2,Anterior Urethral Cancer; Localized Transitional Cell Cancer of the Renal Pelvis and Ureter; Posterior Urethral Cancer; Recurrent Bladder Cancer; Recurrent Urethral Cancer; Regional Transitional Cell Cancer of the Renal Pelvis and Ureter; Stage III Bladder Cancer; Transitional Cell Carcinoma of the Bladder; Ureter Cancer; Urethral Cancer Associated With Invasive Bladder Cancer,cisplatin (DRUG); gemcitabine hydrochloride (DRUG); methotrexate (DRUG); vinblastine (DRUG); doxorubicin hydrochloride (DRUG); pegfilgrastim (BIOLOGICAL); laboratory biomarker analysis (OTHER),60750,Zefei,Anterior Urethral Cancer; Localized Transitional Cell Cancer of the Renal Pelvis and Ureter; Posterior Urethral Cancer; Recurrent Bladder Cancer; Recurrent Urethral Cancer; Regional Transitional Cell Cancer of the Renal Pelvis and Ureter; Stage III Bladder Cancer; Transitional Cell Carcinoma of the Bladder; Ureter Cancer; Urethral Cancer Associated With Invasive Bladder Cancer,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1945,NCT04524702,Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Advanced Pancreatic Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Gemcitabine (DRUG); Hydroxychloroquine (DRUG); Nab-paclitaxel (DRUG); Paricalcitol (DRUG),60750,Zefei,Advanced Pancreatic Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1946,NCT00052338,Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Malignant Pleural Effusion; Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,gemcitabine hydrochloride (DRUG); carboplatin (DRUG); bortezomib (DRUG); laboratory biomarker analysis (OTHER),60750,Zefei,Malignant Pleural Effusion; Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1947,NCT06026657,"Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells with or Without Naxitamab (Danyelza) for the Treatment of Patients with Metastatic, GD2 Expressing, HER2 Negative Breast Cancer",RECRUITING,PHASE1,Anatomic Stage IV Breast Cancer AJCC V8; HER2-Negative Breast Carcinoma,Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Gemcitabine (DRUG); Magnetic Resonance Imaging (PROCEDURE); Naxitamab (BIOLOGICAL); Universal Donor Expanded TGF-beta-imprinted NK Cells (BIOLOGICAL),60750,Zefei,Anatomic Stage IV Breast Cancer AJCC V8; HER2-Negative Breast Carcinoma,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1948,NCT04158635,"Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer",RECRUITING,PHASE1,Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Carcinoma,Bosentan (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),60750,Zefei,Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Carcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1949,NCT04966663,Using ctDNA to Determine Therapies for Lung Cancer,RECRUITING,PHASE2,Non Small Cell Lung Cancer; Complete Surgical Resection; Circulating Tumor DNA,Nivolumab (DRUG); Pemetrexed (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); ctDNA blood test (PROCEDURE),60750,Zefei,Non Small Cell Lung Cancer; Complete Surgical Resection; Circulating Tumor DNA,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1950,NCT04115163,Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer,RECRUITING,PHASE2,Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC V8,Gemcitabine (DRUG); Nab-paclitaxel (DRUG),60750,Zefei,Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC V8,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1951,NCT06492759,High Dose Radiation Therapy with Pembrolizumab and Chemotherapy for the Treatment of Patients with PD-L1 Positive Metastatic Triple Negative Breast Cancer,NOT_YET_RECRUITING,PHASE2,Anatomic Stage IV Breast Cancer AJCC V8; Metastatic Triple-Negative Breast Carcinoma,Radiation Therapy (RADIATION); Pembrolizumab (BIOLOGICAL); Nab-paclitaxel (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Gemcitabine (DRUG); Biopsy (PROCEDURE); Computed Tomography (PROCEDURE); Bone Scan (PROCEDURE); Biospecimen Collection (PROCEDURE); Medical Chart Review (OTHER),60750,Zefei,Anatomic Stage IV Breast Cancer AJCC V8; Metastatic Triple-Negative Breast Carcinoma,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1952,NCT06050252,Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery,RECRUITING,PHASE2,Resectable Intrahepatic Cholangiocarcinoma,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Durvalumab (BIOLOGICAL); Gemcitabine (DRUG); Magnetic Resonance Imaging (PROCEDURE); Resection (PROCEDURE),60750,Zefei,Resectable Intrahepatic Cholangiocarcinoma,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1953,NCT01276613,Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas,TERMINATED,EARLY_PHASE1,Pancreatic Cancer,Gemcitabine (DRUG); Losartan (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1954,NCT01534637,Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer,COMPLETED,PHASE2,Extrahepatic Bile Duct Cancer; Nausea; Vomiting; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,aprepitant (DRUG); gemcitabine hydrochloride (DRUG); capecitabine (DRUG); fluorouracil (DRUG); radiation therapy (PROCEDURE); questionnaire administration (OTHER); quality-of-life assessment (PROCEDURE); nausea and vomiting therapy (PROCEDURE); management of therapy complications (PROCEDURE),60750,Zefei,Extrahepatic Bile Duct Cancer; Nausea; Vomiting; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1955,NCT01145456,Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors,COMPLETED,PHASE1,"Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",gamma-secretase/Notch signalling pathway inhibitor RO4929097 (DRUG); gemcitabine hydrochloride (DRUG); pharmacological study (OTHER); laboratory biomarker analysis (OTHER),60750,Zefei,"Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1956,NCT00564733,FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Malignant Pleural Effusion; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,carboplatin (DRUG); docetaxel (DRUG); gemcitabine hydrochloride (DRUG); paclitaxel (DRUG); computed tomography (PROCEDURE); positron emission tomography (PROCEDURE); fludeoxyglucose F 18 (RADIATION); imaging biomarker analysis (OTHER),60750,Zefei,Malignant Pleural Effusion; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1957,NCT01282333,"Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer",TERMINATED,PHASE1,Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Regional Transitional Cell Cancer of the Renal Pelvis and Ureter; Stage III Bladder Cancer; Stage III Pancreatic Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Bladder Cancer; Stage IV Non-small Cell Lung Cancer; Stage IV Pancreatic Cancer; Transitional Cell Carcinoma of the Bladder; Unresectable Extrahepatic Bile Duct Cancer; Unresectable Gallbladder Cancer,gemcitabine hydrochloride (DRUG); veliparib (DRUG); diagnostic laboratory biomarker analysis (OTHER); pharmacological study (OTHER); cisplatin (DRUG),60750,Zefei,Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Regional Transitional Cell Cancer of the Renal Pelvis and Ureter; Stage III Bladder Cancer; Stage III Pancreatic Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Bladder Cancer; Stage IV Non-small Cell Lung Cancer; Stage IV Pancreatic Cancer; Transitional Cell Carcinoma of the Bladder; Unresectable Extrahepatic Bile Duct Cancer; Unresectable Gallbladder Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1958,NCT00063947,"Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer",COMPLETED,PHASE1,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer,erlotinib hydrochloride (DRUG); gemcitabine hydrochloride (DRUG); radiation therapy (RADIATION); laboratory biomarker analysis (OTHER),60750,Zefei,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1959,NCT00305877,"Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery",COMPLETED,PHASE2,Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,cetuximab (BIOLOGICAL); gemcitabine hydrochloride (DRUG); capecitabine (DRUG); radiation therapy (RADIATION); bevacizumab (BIOLOGICAL); laboratory biomarker analysis (OTHER),60750,Zefei,Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1960,NCT00462553,Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors,COMPLETED,PHASE1,"Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",sunitinib malate (DRUG); gemcitabine hydrochloride (DRUG),60750,Zefei,"Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1961,NCT00075751,"Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer",COMPLETED,PHASE2,Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,gemcitabine hydrochloride (DRUG); carboplatin (DRUG); bortezomib (DRUG),60750,Zefei,Advanced Non-Small Cell Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1962,NCT04892953,Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy,RECRUITING,PHASE2,Stage III Lung Cancer AJCC v8; Stage III Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Cancer AJCC v8; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Cancer AJCC v8; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IIIC Lung Cancer AJCC v8,Carboplatin (DRUG); Durvalumab (BIOLOGICAL); Gemcitabine (DRUG); Local Consolidation Therapy (PROCEDURE); Nab-paclitaxel (DRUG); Paclitaxel (DRUG); Pemetrexed (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),60750,Zefei,Stage III Lung Cancer AJCC v8; Stage III Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Cancer AJCC v8; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Cancer AJCC v8; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IIIC Lung Cancer AJCC v8,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1963,NCT00095888,3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer,TERMINATED,PHASE2,Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer,triapine (DRUG); gemcitabine hydrochloride (DRUG); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),60750,Zefei,Metastatic Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1964,NCT00047307,"Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer",COMPLETED,PHASE1,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,alvocidib (DRUG); gemcitabine hydrochloride (DRUG); 3-dimensional conformal radiation therapy (RADIATION); laboratory biomarker analysis (OTHER),60750,Zefei,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1965,NCT04458909,Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer,TERMINATED,PHASE3,Metastatic Nasopharyngeal Carcinoma; Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Metastatic Nasopharyngeal Nonkeratinizing Carcinoma; Metastatic Nasopharyngeal Undifferentiated Carcinoma; Nasopharyngeal Nonkeratinizing Carcinoma; Recurrent Nasopharyngeal Carcinoma; Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Recurrent Nasopharyngeal Undifferentiated Carcinoma; Stage IV Nasopharyngeal Carcinoma AJCC v8; Stage IVA Nasopharyngeal Carcinoma AJCC v8; Stage IVB Nasopharyngeal Carcinoma AJCC v8,Carboplatin (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG); Nivolumab (BIOLOGICAL); Questionnaire Administration (OTHER),60750,Zefei,Metastatic Nasopharyngeal Carcinoma; Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Metastatic Nasopharyngeal Nonkeratinizing Carcinoma; Metastatic Nasopharyngeal Undifferentiated Carcinoma; Nasopharyngeal Nonkeratinizing Carcinoma; Recurrent Nasopharyngeal Carcinoma; Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Recurrent Nasopharyngeal Undifferentiated Carcinoma; Stage IV Nasopharyngeal Carcinoma AJCC v8; Stage IVA Nasopharyngeal Carcinoma AJCC v8; Stage IVB Nasopharyngeal Carcinoma AJCC v8,Skin,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1966,NCT00028756,Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium,COMPLETED,PHASE3,Stage III Bladder Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder,doxorubicin hydrochloride (DRUG); gemcitabine hydrochloride (DRUG); vinblastine sulfate (DRUG); methotrexate (DRUG); cisplatin (DRUG); filgrastim (BIOLOGICAL),60750,Zefei,Stage III Bladder Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1967,NCT04088188,Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma,TERMINATED,PHASE1,Advanced Cholangiocarcinoma; Metastatic Cholangiocarcinoma; Unresectable Cholangiocarcinoma,Cisplatin (DRUG); Gemcitabine (DRUG); Ivosidenib (DRUG); Pemigatinib (DRUG),60750,Zefei,Advanced Cholangiocarcinoma; Metastatic Cholangiocarcinoma; Unresectable Cholangiocarcinoma,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1968,NCT02383433,Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer,TERMINATED,PHASE2,Metastatic Pancreatic Adenocarcinoma,Regorafenib (DRUG); Gemcitabine Hydrochloride (DRUG),60750,Zefei,Metastatic Pancreatic Adenocarcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1969,NCT02336087,"Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery",ACTIVE_NOT_RECRUITING,PHASE1,Pancreatic Adenocarcinoma; Unresectable Pancreatic Carcinoma; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IV Pancreatic Cancer AJCC v6 and v7,Gemcitabine Hydrochloride (DRUG); Paclitaxel Albumin-Stabilized Nanoparticle Formulation (DRUG); Metformin Hydrochloride (DRUG); Therapeutic Dietary Intervention (DIETARY_SUPPLEMENT); Laboratory Biomarker Analysis (OTHER); Quality-of-Life Assessment (OTHER),60750,Zefei,Pancreatic Adenocarcinoma; Unresectable Pancreatic Carcinoma; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IV Pancreatic Cancer AJCC v6 and v7,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1970,NCT06454383,Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer,RECRUITING,PHASE1,Advanced Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma,Biospecimen Collection (PROCEDURE); Cholestyramine (DRUG); Computed Tomography (PROCEDURE); Diagnostic Imaging (PROCEDURE); Gemcitabine (DRUG); Leflunomide (DRUG); Magnetic Resonance Imaging (PROCEDURE),60750,Zefei,Advanced Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1971,NCT06398587,"Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma",WITHDRAWN,PHASE2,Locally Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma,Onvansertib (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG); Electrocardiography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Positron Emission Tomography (PROCEDURE); Biospecimen Collection (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE),60750,Zefei,Locally Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1972,NCT00478361,"Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function",COMPLETED,PHASE2,Distal Urethral Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Regional Transitional Cell Cancer of the Renal Pelvis and Ureter; Stage III Bladder Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder; Urethral Cancer Associated With Invasive Bladder Cancer,Gemcitabine hydrochloride (DRUG); Paclitaxel (DRUG); Doxorubicin hydrochloride (DRUG); Pegfilgrastim (DRUG),60750,Zefei,Distal Urethral Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Regional Transitional Cell Cancer of the Renal Pelvis and Ureter; Stage III Bladder Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder; Urethral Cancer Associated With Invasive Bladder Cancer,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1973,NCT03531320,Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase,COMPLETED,PHASE1,Gastrointestinal Cancer; Biliary Tract Cancer,D07001-softgel capsules (DRUG),60750,Zefei,Gastrointestinal Cancer; Biliary Tract Cancer,Bowel,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1974,NCT03137771,Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,3-Dimensional Conformal Radiation Therapy (3D-CRT) (RADIATION); Docetaxel (DRUG); Gemcitabine (DRUG); Intensity-Modulated Radiation Therapy (IMRT) (RADIATION); Pemetrexed Disodium (DRUG); Stereotactic Body Radiation Therapy (SBRT) (RADIATION); Erlotinib Hydrochloride (DRUG); Pembrolizumab (DRUG),60750,Zefei,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1975,NCT06958328,Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer,NOT_YET_RECRUITING,PHASE3,Pancreas Cancer,Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); leucovorin calcium (DRUG); Oxaliplatin (DRUG); Irinotecan Sucrosofate (DRUG); Gemcitabine (DRUG); Nab paclitaxel (DRUG); Radiation Therapy (RADIATION); Capecitabine (DRUG); Observation Activity (OTHER); Biospecimen Collection (PROCEDURE); Biopsy Procedure (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Questionnaire Administration (OTHER); Dose-escalated Radiation Therapy (RADIATION); Biospecimen Collection (PROCEDURE); Biopsy Procedure (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Questionnaire Administration (OTHER),60750,Zefei,Pancreas Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1976,NCT01016483,Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer,COMPLETED,PHASE1,Pancreatic Adenocarcinoma,Pimasertib (DRUG); Gemcitabine (DRUG); Placebo (DRUG),60750,Zefei,Pancreatic Adenocarcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1977,NCT01585805,Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Locally Advanced Pancreatic Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Gemcitabine (DRUG); Gemcitabine Hydrochloride (DRUG); Magnetic Resonance Imaging (PROCEDURE); Veliparib (DRUG),60750,Zefei,Locally Advanced Pancreatic Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1978,NCT00004066,"Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma",COMPLETED,PHASE2,Ovarian Cancer; Sarcoma; Small Intestine Cancer,filgrastim (BIOLOGICAL); docetaxel (DRUG); gemcitabine hydrochloride (DRUG),60750,Zefei,Ovarian Cancer and Related Malignancies,Ovary/Fallopian Tube,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1979,NCT06055348,SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer,NOT_YET_RECRUITING,PHASE1,Serous Ovarian Cancer; Advanced Ovarian Cancer,SC0191 (DRUG); Gemcitabine (DRUG); Paclitaxel (DRUG),60750,Zefei,Serous Ovarian Cancer; Advanced Ovarian Cancer,Ovary/Fallopian Tube,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1980,NCT02555657,Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119),COMPLETED,PHASE3,Metastatic Triple Negative Breast Cancer,pembrolizumab (BIOLOGICAL); capecitabine (DRUG); eribulin (DRUG); gemcitabine (DRUG); vinorelbine (DRUG),60750,Zefei,Metastatic Triple Negative Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1981,NCT00878657,Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer,TERMINATED,PHASE1,Pancreatic Cancer,gemcitabine hydrochloride (DRUG); intensity-modulated radiation therapy (RADIATION),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1982,NCT02308020,"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",COMPLETED,PHASE2,Breast Cancer; Non-small Cell Lung Cancer; Melanoma; Brain Metastases,Abemaciclib (DRUG),60750,Zefei,Breast Cancer; Non-small Cell Lung Cancer; Melanoma; Brain Metastases,CNS/Brain,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1983,NCT01394120,Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer,UNKNOWN,PHASE2,"Carcinoma, Pancreatic Ductal",Targeted Therapy Tailored Treatment (DRUG); Standard Chemotherapy (DRUG),60750,Zefei,Pancreatic Ductal Carcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1984,NCT04834674,DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma,RECRUITING,PHASE2,Intrahepatic Cholangiocarcinoma; Transarterial Chemoembolization; Apatinib; PD-1 Antibody,DEB-TACE combined with apatinib and PD-1 antibody (COMBINATION_PRODUCT),60750,Zefei,Intrahepatic Cholangiocarcinoma; Transarterial Chemoembolization; Apatinib; PD-1 Antibody,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1985,NCT03518320,Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer,TERMINATED,PHASE1,Bladder Cancer TNM Staging Primary Tumor (T) T2; Bladder Cancer TNM Staging Primary Tumor (T) T2A; Bladder Cancer TNM Staging Primary Tumor (T) T2B; Bladder Cancer TNM Staging Primary Tumor (T) T3; Bladder Cancer TNM Staging Primary Tumor (T) T3A; Bladder Cancer TNM Staging Primary Tumor (T) T3B; Bladder Cancer TNM Staging Regional Lymph Node (N) N0; Bladder Cancer TNM Staging Regional Lymph Node (N) N1; Bladder Cancer TNM Staging Distant Metastasis (M) M0,Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 (DRUG); Nivolumab Injection [Opdivo] (DRUG),60750,Zefei,Bladder Cancer TNM Staging Primary Tumor (T) T2; Bladder Cancer TNM Staging Primary Tumor (T) T2A; Bladder Cancer TNM Staging Primary Tumor (T) T2B; Bladder Cancer TNM Staging Primary Tumor (T) T3; Bladder Cancer TNM Staging Primary Tumor (T) T3A; Bladder Cancer TNM Staging Primary Tumor (T) T3B; Bladder Cancer TNM Staging Regional Lymph Node (N) N0; Bladder Cancer TNM Staging Regional Lymph Node (N) N1; Bladder Cancer TNM Staging Distant Metastasis (M) M0,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1986,NCT00020774,SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer,WITHDRAWN,PHASE2,Liver Cancer,gemcitabine hydrochloride (DRUG); lonafarnib (DRUG); conventional surgery (PROCEDURE),60750,Zefei,Liver Cancer,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1987,NCT01214720,A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer,COMPLETED,PHASE3,Pancreatic Cancer,bevacizumab [Avastin] (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1988,NCT00316420,Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer,COMPLETED,PHASE1,Pancreatic Cancer,Capecitabine (Xeloda) (DRUG); Gemcitabine (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1989,NCT04796220,Focused Ultrasound and Gemcitabine in Breast Cancer,RECRUITING,PHASE1,Breast Cancer; Breast Neoplasms,Gemcitabine (DRUG); Focused Ultrasound (DEVICE); Gemcitabine and Focused Ultrasound (OTHER),60750,Zefei,Breast Cancer; Breast Neoplasms,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1990,NCT02885974,"Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Bladder Cancer,Celecoxib (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG),60750,Zefei,Bladder Cancer,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1991,NCT06625320,Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),RECRUITING,PHASE3,Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma,RMC-6236 (DRUG); Gemcitabine (DRUG); nab-paclitaxel (DRUG); Irinotecan (DRUG); Liposomal irinotecan (DRUG); 5-fluorouracil (DRUG); leucovorin (DRUG); Oxaliplatin (DRUG),60750,Zefei,Pancreatic Ductal Adenocarcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1992,NCT03473574,Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients,COMPLETED,PHASE2,Cholangiocarcinoma; Gall Bladder Carcinoma; Cholangiocarcinoma Non-resectable; Gallbladder Carcinoma Non-Resectable,Durvalumab (BIOLOGICAL); Gemcitabine (DRUG); Cisplatin (DRUG); Tremelimumab (BIOLOGICAL),60750,Zefei,Cholangiocarcinoma; Gall Bladder Carcinoma; Cholangiocarcinoma Non-resectable; Gallbladder Carcinoma Non-Resectable,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1993,NCT00055965,Hospitalization Rates of Patients With Non-Small Cell Lung Cancer Treated With Gemcitabine and Either Cisplatin or Carboplatin,UNKNOWN,PHASE3,Lung Cancer,carboplatin (DRUG); cisplatin (DRUG); gemcitabine hydrochloride (DRUG),60750,Zefei,Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1994,NCT03819465,A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Non-Small Cell Lung Cancer (NSCLC),Durvalumab (DRUG); Danvatirsen (DRUG); Oleclumab (DRUG); MEDI5752 (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG); Nab-paclitaxel (DRUG); AZD2936 (DRUG),60750,Zefei,Metastatic Non-Small Cell Lung Cancer (NSCLC),Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1995,NCT04247165,"Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.",COMPLETED,PHASE1,"Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer",Gemcitabine (DRUG); Nab-paclitaxel (DRUG); Nivolumab (DRUG); Ipilimumab (DRUG); SBRT (RADIATION),60750,Zefei,"Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer",Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1996,NCT05795920,Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer,RECRUITING,PHASE2,Pancreatic Neoplasms,Utidelone injection in combination with gemcitabine (DRUG),60750,Zefei,Pancreatic Neoplasms,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1997,NCT01851174,Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer,TERMINATED,PHASE2,Pancreatic Carcinoma Non-resectable; Stage IV Pancreatic Cancer,Gemcitabine (DRUG); nab-Paclitaxel (DRUG),60750,Zefei,Pancreatic Carcinoma Non-resectable; Stage IV Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1998,NCT02030574,"Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin",TERMINATED,PHASE2,Invasive Bladder Cancer; Bladder Cancer,Gemcitabine and fractionated cisplatin (combination treatment) (DRUG),60750,Zefei,Invasive Bladder Cancer; Bladder Cancer,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +1999,NCT00410774,Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery,TERMINATED,PHASE1,Pancreatic Cancer,bevacizumab (BIOLOGICAL); gemcitabine hydrochloride (DRUG); adjuvant therapy (PROCEDURE),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2000,NCT00564720,"Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer",TERMINATED,PHASE2,Pancreatic Cancer,Gemcitabine (DRUG); Gemcitabine (DRUG); Erlotinib (DRUG); Oxaliplatin (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2001,NCT05585320,A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors,RECRUITING,PHASE1,Advanced Solid Tumor; Pancreatic Adenocarcinoma; Malignant Melanoma (Cutaneous); Non-small Cell Lung Cancer (NSCLC),IMM-1-104 Monotherapy (Treatment Group A) (DRUG); IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B) (DRUG); IMM-1-104 + modified FOLFIRINOX (Treatment Group C) (DRUG); IMM-1-104 + dabrafenib (Treatment Group D) (DRUG); IMM-1-104 + pembrolizumab (Treatment Group E) (DRUG),60750,Zefei,Advanced Solid Tumor; Pancreatic Adenocarcinoma; Malignant Melanoma (Cutaneous); Non-small Cell Lung Cancer (NSCLC),Skin,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2002,NCT00014274,Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium,COMPLETED,PHASE2,Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer,carboplatin (DRUG); gemcitabine hydrochloride (DRUG); methotrexate (DRUG); vinblastine sulfate (DRUG),60750,Zefei,Urinary Tract Cancers,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2003,NCT01266720,HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1),UNKNOWN,PHASE1,Pancreatic Cancer,"VEGFR1, VEGFR2 (BIOLOGICAL); Gemcitabine (DRUG)",60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2004,NCT02576574,Avelumab in First-line NSCLC (JAVELIN Lung 100),COMPLETED,PHASE3,First Line Non-Small Cell Lung Cancer,Avelumab (DRUG); Pemetrexed (DRUG); Paclitaxel (DRUG); Gemcitabine (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Avelumab Weekly (DRUG),60750,Zefei,First Line Non-Small Cell Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2005,NCT01936974,"(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma",TERMINATED,PHASE2,Ovarian Carcinoma; Fallopian Tube Carcinoma; Peritoneal Carcinoma,Gemcitabine (DRUG); Bevacizumab (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Oxaliplatin (DRUG),60750,Zefei,Ovarian and Related Carcinomas,Ovary/Fallopian Tube,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2006,NCT02559674,QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel,COMPLETED,PHASE1,Advanced Pancreatic Cancer,Gemcitabine (BIOLOGICAL); Nab-paclitaxel (BIOLOGICAL); ALT-803 (BIOLOGICAL),60750,Zefei,Advanced Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2007,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,COMPLETED,PHASE3,"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity",OLAPARIB (DRUG); Single agent chemotherapy (DRUG),60750,Zefei,"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity",Ovary/Fallopian Tube,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2008,NCT01652820,Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer,COMPLETED,PHASE2,Non Small-cell Lung Cancer,"Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation 2Gy/day (DRUG); Docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT 2Gy/d (DRUG)",60750,Zefei,Non Small-cell Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2009,NCT06111274,A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer,RECRUITING,PHASE2,Advanced Pancreatic Cancer,Pimicotinib (ABSK021) (DRUG),60750,Zefei,Advanced Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2010,NCT06888674,Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.,NOT_YET_RECRUITING,PHASE1,Pancreatic Cancer Resectable,individualized anti-tumor new antigen iNeo-Vac-R01 injection (BIOLOGICAL); Gemcitabine + Capecitabine (DRUG); Sintilimab injection (DRUG),60750,Zefei,Pancreatic Cancer Resectable,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2011,NCT00536874,Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery,COMPLETED,PHASE2,Pancreatic Cancer,gemcitabine hydrochloride (DRUG); oxaliplatin (DRUG); protein expression analysis (GENETIC); proteomic profiling (GENETIC); diagnostic laboratory biomarker analysis (OTHER); adjuvant therapy (PROCEDURE); neoadjuvant therapy (PROCEDURE); therapeutic conventional surgery (PROCEDURE),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2012,NCT02620865,BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer,COMPLETED,PHASE1,Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Aldesleukin (BIOLOGICAL); Antibody Therapy (BIOLOGICAL); Fluorouracil (DRUG); Gemcitabine Hydrochloride (DRUG); Irinotecan Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Leucovorin Calcium (DRUG); Oxaliplatin (DRUG); Paclitaxel Albumin-Stabilized Nanoparticle Formulation (DRUG); Sargramostim (BIOLOGICAL),60750,Zefei,Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2013,NCT06227065,Precise Neoadjuvant Chemoresection of Low Grade NMIBC,NOT_YET_RECRUITING,PHASE2,Bladder Cancer; Non-muscle Invasive Bladder Cancer; Low-risk,Epirubicin (DRUG); Mitomycin (DRUG); Gemcitabine (DRUG); Docetaxel (DRUG),60750,Zefei,Non-muscle Invasive Bladder Cancer,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2014,NCT03472274,Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO),COMPLETED,PHASE2,Bladder Cancer,Durvalumab (DRUG); Tremelimumab (DRUG); Cisplatin-based neoadjuvant chemotherapy (DRUG),60750,Zefei,Bladder Cancer,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2015,NCT00010166,Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas,COMPLETED,PHASE2,Pancreatic Cancer,gemcitabine hydrochloride (DRUG); adjuvant therapy (PROCEDURE); radiation therapy (RADIATION),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2016,NCT03251365,Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer,UNKNOWN,PHASE2,Resectable Pancreatic Adenocarcinoma,HIPEC-gemcitabine (DRUG),60750,Zefei,Pancreatic Ductal Adenocarcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2017,NCT06597565,A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC,RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma,Gemcitabine (DRUG); ACR-368 (DRUG),60750,Zefei,Head and Neck Squamous Cell Carcinoma,Skin,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2018,NCT00462865,Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse,TERMINATED,PHASE2,Breast Cancer,Gemcitabine and Capecitabine and Avastin (DRUG),60750,Zefei,Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2019,NCT00588666,"Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma",COMPLETED,PHASE2,Myeloproliferative Disorder; Urothelial Carcinoma; Cancer,Bevacizumab (DRUG); Carboplatin (DRUG); Gemcitabine (DRUG),60750,Zefei,Myeloproliferative Disorder; Urothelial Carcinoma; Cancer,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2020,NCT06199466,A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Pancreatic Cancer,Gemcitabine (DRUG); Nab-paclitaxel (DRUG); YL-13027 (DRUG),60750,Zefei,Metastatic Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2021,NCT03929666,"A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer",ACTIVE_NOT_RECRUITING,PHASE2,"HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer",ZW25 (Zanidatamab) (DRUG); Capecitabine (DRUG); Cisplatin (DRUG); Fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Bevacizumab (DRUG); Gemcitabine (DRUG),60750,Zefei,HER2-expressing Gastrointestinal Cancers,Bowel,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2022,NCT01090466,"Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium",COMPLETED,PHASE1,Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer,cisplatin (DRUG); gemcitabine hydrochloride (DRUG); temsirolimus (DRUG); pharmacological study (OTHER),60750,Zefei,Urinary Tract Cancers,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2023,NCT00652366,A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,"Erlotinib, escalating dose (DRUG); Erlotinib, standard dose (DRUG); Gemcitabine (DRUG)",60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2024,NCT06393166,Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer,RECRUITING,PHASE2,Non-Resectable Pancreas Carcinoma,Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection (DRUG),60750,Zefei,Non-Resectable Pancreas Carcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2025,NCT00442026,Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC,TERMINATED,PHASE3,Non-small-cell Lung Cancer,Docetaxel (DRUG); Gemcitabine (DRUG); Gemcitabine (DRUG),60750,Zefei,Non-small-cell Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2026,NCT00885066,"Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer",COMPLETED,PHASE1,Pancreatic Cancer,capecitabine (DRUG); erlotinib hydrochloride (DRUG); gemcitabine hydrochloride (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2027,NCT03101566,Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer,COMPLETED,PHASE2,Biliary Tract Neoplasms,Gemcitabine (DRUG); Cisplatin (DRUG); Ipilimumab (DRUG); Nivolumab (DRUG),60750,Zefei,Biliary Tract Neoplasms,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2028,NCT02365766,Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects,COMPLETED,PHASE1,Urothelial Carcinoma; Bladder Cancer,Pembrolizumab (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG); Consolidative Surgery (PROCEDURE),60750,Zefei,Urothelial Carcinoma,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2029,NCT02754726,Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma,COMPLETED,PHASE2,Untreated Metastatic Pancreatic Ductal Adenocarcinoma,Nivolumab (DRUG); Albumin-bound paclitaxel (DRUG); Paricalcitol (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG),60750,Zefei,Untreated Metastatic Pancreatic Ductal Adenocarcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2030,NCT02957266,"Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy",UNKNOWN,PHASE3,Cervical Cancer,Volumetric Arc Radiotherapy (RADIATION); Interstitial brachytherapy (RADIATION); Cisplatin (DRUG); Gemcitabine (DRUG); PIK3CA (GENETIC); KRAS (GENETIC); BRAF (GENETIC); RRM1 (GENETIC),60750,Zefei,Cervical Cancer,Cervix,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2031,NCT00907166,A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients,TERMINATED,PHASE1,Cancer; Pancreatic Cancer; Pancreatic Carcinoma,CPI-613 (DRUG); CPI-613 (DRUG); Gemcitabine (DRUG); Gemcitabine (DRUG); Gemcitabine (DRUG),60750,Zefei,Cancer; Pancreatic Cancer; Pancreatic Carcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2032,NCT05494866,A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma,TERMINATED,PHASE1,CYP3A Inhibitor; Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Pancreatic Adenocarcinoma; Pancreatic Neoplasm,Cobicistat Oral Tablet (DRUG); Gemcitabin (DRUG); Nab paclitaxel (DRUG),60750,Zefei,CYP3A Inhibitor; Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Pancreatic Adenocarcinoma; Pancreatic Neoplasm,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2033,NCT00191126,Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC,COMPLETED,PHASE3,Non-Small Cell Lung Cancer,gemcitabine (DRUG); Cisplatin (DRUG); surgery (PROCEDURE),60750,Zefei,Advanced Non-Small Cell Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2034,NCT02626520,Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla,TERMINATED,PHASE2,Ductal Adenocarcinoma of Pancreas; Adenocarcinoma of Ampulla,Gemcitabine and nanoparticle albumin bound paclitaxel (DRUG); 5-fluorouracil and irinotecan (DRUG); Preoperative chemoradiation (RADIATION); Definitive resection (PROCEDURE),60750,Zefei,Ductal Adenocarcinoma of Pancreas; Adenocarcinoma of Ampulla,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2035,NCT00012220,Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas,COMPLETED,PHASE2,Pancreatic Cancer,cisplatin (DRUG); docetaxel (DRUG); gemcitabine hydrochloride (DRUG); irinotecan hydrochloride (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2036,NCT00281827,"Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer",TERMINATED,PHASE2,Lung Cancer,carboplatin (DRUG); gemcitabine hydrochloride (DRUG); thalidomide (DRUG); conventional surgery (PROCEDURE),60750,Zefei,Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2037,NCT06319820,A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer,RECRUITING,PHASE3,Non-Muscle Invasive Bladder Cancer,TAR-210 (COMBINATION_PRODUCT); Gemcitabine (DRUG); MMC (DRUG),60750,Zefei,Non-Muscle Invasive Bladder Cancer,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2038,NCT04308174,Neoadjuvant Gemcitabine Plus Cisplatin with or Without Durvalumab in Resectable Biliary Tract Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Biliary Tract Neoplasms; Gallbladder Cancer; Cholangiocarcinoma,Durvalumab + Gem/Cis (DRUG); Gem/Cis (DRUG),60750,Zefei,Biliary Tract Neoplasms; Gallbladder Cancer; Cholangiocarcinoma,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2039,NCT05298020,Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer,UNKNOWN,PHASE2,Advanced Pancreatic Cancer,Envafolimab (DRUG); Endostar (DRUG); Nab paclitaxel (DRUG); Gemcitabine (DRUG),60750,Zefei,Advanced Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2040,NCT00246974,Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT,COMPLETED,PHASE2,Bladder Cancer,Gemcitabine (DRUG); Cisplatin (DRUG); Gefitinib (DRUG),60750,Zefei,Bladder Cancer,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2041,NCT03138720,Pre-operative Treatment for Patients With Untreated Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Resectable Pancreatic Cancer; Unresectable Pancreatic Cancer; Pancreatic Adenocarcinoma; Neoadjuvant Pancreatic Cancer,Paclitaxel Protein Bound (Abraxane) (DRUG),60750,Zefei,Resectable Pancreatic Cancer; Unresectable Pancreatic Cancer; Pancreatic Adenocarcinoma; Neoadjuvant Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2042,NCT02850874,HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma,WITHDRAWN,PHASE2,Pancreatic Neoplasms; Pancreatic Adenocarcinoma,Hyperthermic intraperitoneal chemotherapy (PROCEDURE); Open pancreaticoduodenectomy (PROCEDURE); Gemcitabine (DRUG),60750,Zefei,Pancreatic Neoplasms; Pancreatic Adenocarcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2043,NCT00050674,Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma,COMPLETED,PHASE2,Non-small Cell Lung Cancer,Filgrastim-SD/01 (DRUG),60750,Zefei,Non-small Cell Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2044,NCT06591520,AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer,NOT_YET_RECRUITING,PHASE3,Biliary Tract Cancer,"AK112, Gemcitabine, Cisplatin (DRUG); Durvalumab, Gemcitabine, Cisplatin (DRUG)",60750,Zefei,Biliary Tract Cancer,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2045,NCT04896320,"Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.",WITHDRAWN,PHASE1,Breast Cancer Stage IV,Tucatinib (DRUG),60750,Zefei,Breast Cancer Stage IV,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2046,NCT05684731,Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer,RECRUITING,PHASE1,Ovarian Cancer,KM1 (BIOLOGICAL); Chemotherapy (DRUG),60750,Zefei,Ovarian Cancer,Ovary/Fallopian Tube,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2047,NCT00490373,Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is Metastatic,COMPLETED,PHASE2,Pancreatic Cancer,pemetrexed (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2048,NCT03520231,Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases,COMPLETED,PHASE2,Urothelial Carcinoma; Kidney Cancer; Ureter Cancer; Bladder Cancer,Denosumab (DRUG); Denosumab Placebo (OTHER); Gemcitabine (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Calcium (DIETARY_SUPPLEMENT); Vitamin D (DIETARY_SUPPLEMENT),60750,Zefei,Urothelial Carcinoma; Kidney Cancer; Ureter Cancer; Bladder Cancer,Kidney,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2049,NCT03560973,"A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM",COMPLETED,PHASE2,Mesothelioma,Gemcitabine (DRUG); Ramucirumab (DRUG),60750,Zefei,Mesothelioma,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2050,NCT03547973,Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread,RECRUITING,PHASE2,Metastatic Urothelial Cancer,Sacituzumab Govitecan-hziy (DRUG); Pembrolizumab (DRUG); Cisplatin (DRUG); Avelumab (DRUG); Zimberelimab (DRUG); Carboplatin (DRUG); Gemcitabine (DRUG); Domvanalimab (DRUG); Enfortumab Vedotin (DRUG),60750,Zefei,Metastatic Urothelial Cancer,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2051,NCT06903273,"Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma",NOT_YET_RECRUITING,PHASE2,Cholangiocarcinoma; Biliary Tract Cancer (BTC),Tislelizumab (DRUG),60750,Zefei,Cholangiocarcinoma; Biliary Tract Cancer (BTC),Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2052,NCT05085548,ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies,RECRUITING,PHASE1,Advanced Pancreatic Cancer; Solid Tumor Malignancies,"ProAgio Dose Levels (DL) 1,2,3 (DRUG); ProAgio Dose Levels (DL) 4,5,6 (DRUG); ProAgio Dose Levels 4a,5a,6a (DRUG)",60750,Zefei,Advanced Pancreatic Cancer; Solid Tumor Malignancies,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2053,NCT02159248,"Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation",WITHDRAWN,PHASE1,Pancreatic Cancer,Tolfenamic acid + gemcitabine + radiation (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2054,NCT05870748,REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1,RECRUITING,PHASE2,Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Platinum-resistant Ovarian Cancer,Luveltamab tazevibulin (DRUG); Pegfilgrastim (DRUG); Gemcitabine (DRUG); Paclitaxel (DRUG); Pegylated liposomal doxorubicin (DRUG); Topotecan (DRUG),60750,Zefei,Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Platinum-resistant Ovarian Cancer,Ovary/Fallopian Tube,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2055,NCT00336648,Preop Chemoradiation Resectable Pancreas,COMPLETED,PHASE2,Pancreatic Neoplasms,Avastin (Bevacizumab) (DRUG); Gemcitabine (DRUG); Radiation Therapy (PROCEDURE),60750,Zefei,Pancreatic Neoplasms,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2056,NCT05149326,KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.,ACTIVE_NOT_RECRUITING,PHASE3,Advanced Pancreatic Ductal Adenocarcinoma,KN046 (DRUG); placebo (DRUG),60750,Zefei,Advanced Pancreatic Ductal Adenocarcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2057,NCT01383148,Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer,TERMINATED,PHASE2,Non-Small-Cell Lung Carcinoma,TG4010 (BIOLOGICAL); placebo (DRUG),60750,Zefei,Non-Small-Cell Lung Carcinoma,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2058,NCT01964430,"Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the ""Apact"" Study)",COMPLETED,PHASE3,"Pancreatic Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Digestive System Diseases; Endocrine System Diseases; Gemcitabine; Antimetabolites, Antineoplastic",nab-Paclitaxel (DRUG); Gemcitabine (DRUG),60750,Zefei,"Pancreatic Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Digestive System Diseases; Endocrine System Diseases; Gemcitabine; Antimetabolites, Antineoplastic",Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2059,NCT04267848,"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial",RECRUITING,PHASE3,Lung Non-Small Cell Carcinoma; Lung Non-Small Cell Squamous Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Gemcitabine Hydrochloride (DRUG); Magnetic Resonance Imaging (PROCEDURE); Observation Activity (OTHER); Paclitaxel (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed Disodium (DRUG); Questionnaire Administration (OTHER),60750,Zefei,Lung Non-Small Cell Carcinoma; Lung Non-Small Cell Squamous Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2060,NCT00006048,ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer,UNKNOWN,PHASE3,Lung Cancer,cisplatin (DRUG); gefitinib (DRUG); gemcitabine hydrochloride (DRUG),60750,Zefei,Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2061,NCT06343948,"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer",RECRUITING,PHASE3,HR+HER2- Breast Cancer,BL-B01D1 (DRUG); Eribulin (DRUG); Vinorelbine (DRUG); Gemcitabine (DRUG); Capecitabine (DRUG),60750,Zefei,HR+HER2- Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2062,NCT01080248,Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer,TERMINATED,PHASE2,Pancreatic Cancer,Gemcitabine (DRUG); Pazopanib (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2063,NCT00376948,"Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",COMPLETED,PHASE2,Pancreatic Cancer,genistein (DIETARY_SUPPLEMENT); erlotinib hydrochloride (DRUG); gemcitabine hydrochloride (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2064,NCT06678048,Arsenous Acid for Refractory Triple-Negative Breast Cancer,RECRUITING,PHASE2,Breast Cancer,Arsenous Acid plus Chemotherapy (DRUG),60750,Zefei,Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2065,NCT06416930,Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma,NOT_YET_RECRUITING,PHASE2,Pleural Mesothelioma,Cadonilimab Combined with chemotherapy (DRUG),60750,Zefei,Pleural Mesothelioma,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2066,NCT02393248,"Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)",TERMINATED,PHASE1,Lung Cancer; Solid Tumor; Gastric Cancer; Urothelial Cancer; Endometrial Cancer; Multiple Myeloma; Myeloproliferative Neoplasms; Breast Cancer; Cholangiocarcinoma; UC; MPN,Pemigatinib (DRUG); Gemcitabine (DRUG); Pembrolizumab (DRUG); Docetaxel (DRUG); Trastuzumab (DRUG); Retifanlimab (DRUG); Cisplatin (DRUG),60750,Zefei,Lung Cancer; Solid Tumor; Gastric Cancer; Urothelial Cancer; Endometrial Cancer; Multiple Myeloma; Myeloproliferative Neoplasms; Breast Cancer; Cholangiocarcinoma; UC; MPN,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2067,NCT00003382,Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer,TERMINATED,PHASE1,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,filgrastim (BIOLOGICAL); gemcitabine hydrochloride (DRUG); topotecan hydrochloride (DRUG),60750,Zefei,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2068,NCT04750382,A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer,UNKNOWN,PHASE1,Triple-negative Breast Cancer,HX008+Cisplatin+Gemcitabine (DRUG),60750,Zefei,Triple-negative Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2069,NCT00217282,Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,"oxaliplatin, gemcitabine, bevacizumab (DRUG)",60750,Zefei,Advanced Non-Small Cell Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2070,NCT00560573,"Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer",COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung","CP-751,871 (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG); Pemetrexed (DRUG)",60750,Zefei,"Carcinoma, Non-Small-Cell Lung",Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2071,NCT00006482,Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix,TERMINATED,PHASE2,Cervical Cancer,cisplatin (DRUG); gemcitabine hydrochloride (DRUG),60750,Zefei,Cervical Cancer,Cervix,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2072,NCT01852890,"Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I",ACTIVE_NOT_RECRUITING,PHASE1,Pancreatic Neoplasms,Ascorbate (DRUG); Gemcitabine (DRUG); Radiation therapy (RADIATION),60750,Zefei,Pancreatic Neoplasms,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2073,NCT02631590,Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma,COMPLETED,PHASE2,Biliary Carcinoma; Gall Bladder Carcinoma; Cholangiocarcinoma; Gastrointestinal Tumor,Cisplatin (DRUG); Gemcitabine (DRUG); Copanlisib (DRUG),60750,Zefei,Biliary Carcinoma; Gall Bladder Carcinoma; Cholangiocarcinoma; Gastrointestinal Tumor,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2074,NCT03193190,A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer),COMPLETED,PHASE1,Pancreatic Adenocarcinoma,Nab-Paclitaxel (DRUG); Gemcitabine (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); Fluorouracil (DRUG); Atezolizumab (DRUG); Cobimetinib (DRUG); PEGPH20 (DRUG); BL-8040 (DRUG); Selicrelumab (DRUG); Bevacizumab (DRUG); RO6874281 (DRUG); AB928 (DRUG); Tiragolumab (DRUG); Tocilizumab (DRUG),60750,Zefei,Pancreatic Adenocarcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2075,NCT04216290,"A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial",ACTIVE_NOT_RECRUITING,PHASE2,Bladder Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8,Biopsy of Bladder (PROCEDURE); Biospecimen Collection (PROCEDURE); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Cystoscopy (PROCEDURE); Durvalumab (BIOLOGICAL); Fluorouracil (DRUG); Gemcitabine Hydrochloride (DRUG); Magnetic Resonance Imaging (PROCEDURE); Mitomycin (DRUG); Patient Observation (OTHER); Radiation Therapy (RADIATION),60750,Zefei,Bladder Urothelial Carcinoma,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2076,NCT00226590,Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC,COMPLETED,PHASE2,Lung Cancer,Gemcitabine (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Radiation (PROCEDURE),60750,Zefei,Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2077,NCT02506803,Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer.,UNKNOWN,PHASE1,Pancreatic Cancer,NAC-GEMABR (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2078,NCT03520790,Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer,TERMINATED,PHASE1,Pancreatic Cancer,Gemcitabine (DRUG); Nab-paclitaxel (DRUG); Paricalcitol (DRUG); Placebo (OTHER),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2079,NCT00003202,Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer,cisplatin (DRUG); gemcitabine hydrochloride (DRUG); radiation therapy (RADIATION),60750,Zefei,Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2080,NCT02671890,Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer,TERMINATED,PHASE1,Metastatic Pancreatic Adenocarcinoma; Refractory Malignant Solid Neoplasm; Stage IV Pancreatic Cancer AJCC v8,Chemotherapy (DRUG); Disulfiram (DRUG); Gemcitabine Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER),60750,Zefei,Metastatic Pancreatic Adenocarcinoma; Refractory Malignant Solid Neoplasm; Stage IV Pancreatic Cancer AJCC v8,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2081,NCT00561990,Nimotuzumab in Adults With Pancreatic Cancer,COMPLETED,PHASE2,"Pancreatic Cancer, Advanced or Metastatic",Nimotuzumab (DRUG),60750,Zefei,"Pancreatic Cancer, Advanced or Metastatic",Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2082,NCT00003803,"Chemotherapy Plus Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed",TERMINATED,PHASE3,Lung Cancer,cisplatin (DRUG); gemcitabine hydrochloride (DRUG); radiation therapy (RADIATION),60750,Zefei,Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2083,NCT04659603,Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors,COMPLETED,PHASE2,Breast Cancer Metastatic; Pancreatic Carcinoma Metastatic,tusamitamab ravtansine (DRUG); Gemcitabine (DRUG),60750,Zefei,Breast Cancer Metastatic; Pancreatic Carcinoma Metastatic,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2084,NCT00242190,"Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer",COMPLETED,PHASE1,Pancreatic Neoplasms,oxaliplatin (DRUG); gemcitabine (DRUG); radiation therapy (PROCEDURE),60750,Zefei,Pancreatic Neoplasms,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2085,NCT04480190,Neoadjuvant Therapy in Biliary Adenocarcinoma,WITHDRAWN,PHASE1,Cholangiocarcinoma; Biliary Cancer,Gemcitabine (DRUG); Cisplatin (DRUG); Fluorouracil (DRUG); Short course ChemoRT (RADIATION),60750,Zefei,Cholangiocarcinoma; Biliary Cancer,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2086,NCT02132403,(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer,TERMINATED,PHASE1,Pancreatic Cancer,BTH1704 (DRUG); IMPRIME PGG (DRUG); Gemcitabine (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2087,NCT00191490,A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Gemcitabine (DRUG); docetaxel (DRUG); cisplatin (DRUG),60750,Zefei,"Carcinoma, Non-Small-Cell Lung",Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2088,NCT02423590,Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers,UNKNOWN,PHASE2,Squamous Cell Lung Cancer,Apatorsen (OGX-427) (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG),60750,Zefei,Squamous Cell Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2089,NCT01850303,Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer,COMPLETED,PHASE3,Non Small Cell Lung Cancer (Squamous or Non Squamous),Pemetrexed (DRUG); Gemcitabine (DRUG); Induction chemotherapy (DRUG),60750,Zefei,Non-Small Cell Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2090,NCT01530503,Second Line Therapy in Advanced Biliary Tract Cancer,COMPLETED,PHASE2,Biliary Tract Cancer,capecitabine and mitomycin (DRUG); Capecitabine (DRUG),60750,Zefei,Biliary Tract Cancer,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2091,NCT01825603,"ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer",COMPLETED,PHASE1,Ampulla of Vater Adenocarcinoma; Gallbladder Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma; Stage III Ampulla of Vater Cancer; Stage III Intrahepatic Cholangiocarcinoma; Stage III Pancreatic Cancer; Stage IIIA Gallbladder Cancer; Stage IIIA Hilar Cholangiocarcinoma; Stage IIIB Gallbladder Cancer; Stage IIIB Hilar Cholangiocarcinoma; Stage IV Ampulla of Vater Cancer; Stage IVA Gallbladder Cancer; Stage IVA Hilar Cholangiocarcinoma; Stage IVA Intrahepatic Cholangiocarcinoma; Stage IVA Pancreatic Cancer; Stage IVB Gallbladder Cancer; Stage IVB Hilar Cholangiocarcinoma; Stage IVB Intrahepatic Cholangiocarcinoma; Stage IVB Pancreatic Cancer,ADH-1 (DRUG); Cisplatin (DRUG); Gemcitabine Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER),60750,Zefei,Ampulla of Vater Adenocarcinoma; Gallbladder Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma; Stage III Ampulla of Vater Cancer; Stage III Intrahepatic Cholangiocarcinoma; Stage III Pancreatic Cancer; Stage IIIA Gallbladder Cancer; Stage IIIA Hilar Cholangiocarcinoma; Stage IIIB Gallbladder Cancer; Stage IIIB Hilar Cholangiocarcinoma; Stage IV Ampulla of Vater Cancer; Stage IVA Gallbladder Cancer; Stage IVA Hilar Cholangiocarcinoma; Stage IVA Intrahepatic Cholangiocarcinoma; Stage IVA Pancreatic Cancer; Stage IVB Gallbladder Cancer; Stage IVB Hilar Cholangiocarcinoma; Stage IVB Intrahepatic Cholangiocarcinoma; Stage IVB Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2092,NCT00004190,Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,gemcitabine hydrochloride (DRUG); oxaliplatin (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2093,NCT05422690,"The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer",RECRUITING,PHASE2,Intrahepatic Cholangiocarcinoma,Induction Chemotherapy Triplet Therapy (DRUG); Concurrent Y-90 treatment (RADIATION); Consolidation Doublet Therapy: (DRUG),60750,Zefei,Intrahepatic Cholangiocarcinoma,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2094,NCT02588443,Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma,COMPLETED,PHASE1,Pancreatic Cancer,RO70097890 (DRUG); nab-paclitaxel (DRUG); gemcitabine (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2095,NCT00004003,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery,COMPLETED,PHASE2,Pancreatic Cancer,cisplatin (DRUG); fluorouracil (DRUG); gemcitabine hydrochloride (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2096,NCT00400803,Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung","Gemcitabine, Carboplatin, Bevacizumab (DRUG)",60750,Zefei,"Carcinoma, Non-Small-Cell Lung",Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2097,NCT05451290,Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer,RECRUITING,PHASE2,Advanced Biliary Tract Carcinoma,"Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur (DRUG)",60750,Zefei,Advanced Biliary Tract Carcinoma,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2098,NCT03869190,Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC),ACTIVE_NOT_RECRUITING,PHASE1,Urothelial Carcinoma; Bladder Cancer,Atezolizumab (DRUG); Enfortumab Vedotin (DRUG); Niraparib (DRUG); Magrolimab (Hu5F9-G4) (DRUG); Tiragolumab (DRUG); Sacituzumab Govitecan (DRUG); Tocilizumab (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG),60750,Zefei,Urothelial Carcinoma,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2099,NCT02170090,Adjuvant Chemotherapy with Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Cholangiocarcinoma; Gall Bladder Carcinoma,Gemcitabine (DRUG); Cisplatin (DRUG); Capecitabine (DRUG),60750,Zefei,Cholangiocarcinoma; Gall Bladder Carcinoma,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2100,NCT01373164,A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer,COMPLETED,PHASE1,Neoplasms; Neoplasm Metastasis; Pancreatic Cancer,Galunisertib (DRUG); Gemcitabine (DRUG); Placebo (DRUG),60750,Zefei,Neoplasms; Neoplasm Metastasis; Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2101,NCT05487443,The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies,UNKNOWN,PHASE2,Gemcitabine; Biliary Tract Cancer; Immune Checkpoint Inhibitors,Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors (DRUG),60750,Zefei,Gemcitabine; Biliary Tract Cancer; Immune Checkpoint Inhibitors,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2102,NCT01808638,Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02),COMPLETED,PHASE1,"Carcinoma, Pancreatic Ductal",Atu027 & gemcitabine in lead in safety period (DRUG); Atu027 & gemcitabine in treatment arm 1 (DRUG); Atu027 & gemcitabine in treatment arm 2 (DRUG),60750,Zefei,Pancreatic Ductal Carcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2103,NCT05251038,Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer,WITHDRAWN,PHASE1,Pancreatic Cancer; Unresectable Pancreatic Cancer; Metastatic Pancreatic Cancer; KRAS P.G12C,Sotorasib (DRUG); Liposomal Irinotecan (nal-IRI) (DRUG); 5 Fluorouracil (5FU) (DRUG); Leucovorin (LV) (DRUG); Gemcitabine (GEM) (DRUG); Nab paclitaxel (DRUG),60750,Zefei,Pancreatic Cancer; Unresectable Pancreatic Cancer; Metastatic Pancreatic Cancer; KRAS P.G12C,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2104,NCT01905150,"Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer",COMPLETED,PHASE2,Pancreatic Cancer,G-FLIP (DRUG); G-FLIP-DM (DRUG); Vitamin C (DIETARY_SUPPLEMENT),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2105,NCT00655850,Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Paclitaxel (DRUG); Gemcitabine (DRUG); Avastin (BIOLOGICAL),60750,Zefei,Advanced Non-Small Cell Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2106,NCT06788912,Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01),RECRUITING,PHASE2,Lung Neoplasm Malignant,Pembrolizumab (neoadjuvant) (BIOLOGICAL); Cisplatin (DRUG); Gemcitabine (DRUG); Pemetrexed (DRUG); Sacituzumab tirumotecan (DRUG); Antihistamine (DRUG); H2 receptor antagonist (DRUG); Acetaminophen (or equivalent) (DRUG); Dexamethasone (or equivalent) (DRUG); Carboplatin (DRUG); Pembrolizumab (adjuvant) (BIOLOGICAL); Paclitaxel (DRUG); Steroid mouthwash (dexamethasone or equivalent) (DRUG),60750,Zefei,Lung Neoplasm Malignant,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2107,NCT02784795,A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,COMPLETED,PHASE1,Solid Tumor; Breast Cancer; Colon Cancer; Cholangiocarcinoma; Soft Tissue Sarcoma,LY3039478 (DRUG); Taladegib (DRUG); Abemaciclib (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG); LY3023414 (DRUG),60750,Zefei,Solid Tumor; Breast Cancer; Colon Cancer; Cholangiocarcinoma; Soft Tissue Sarcoma,Bowel,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2108,NCT02263495,Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Paclitaxel (DRUG); Eribulin (DRUG); Gemcitabine (DRUG),60750,Zefei,Metastatic Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2109,NCT05911295,Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2,RECRUITING,PHASE3,Urothelial Carcinoma,disitamab vedotin (DRUG); pembrolizumab (DRUG); gemcitabine (DRUG); cisplatin (DRUG); carboplatin (DRUG),60750,Zefei,Urothelial Carcinoma,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2110,NCT01470443,Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma,UNKNOWN,PHASE3,"Biliary Tract (Intrahepatic, Extrahepatic Cholangiocarcinoma, Gall Bladder) Cancer",Oxaliplatin (DRUG); Oxaliplatin (DRUG),60750,Zefei,"Biliary Tract (Intrahepatic, Extrahepatic Cholangiocarcinoma, Gall Bladder) Cancer",Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2111,NCT03251612,Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer Metastatic,Based on sensitivity analysis (DRUG),60750,Zefei,Colorectal Cancer Metastatic,Bowel,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2112,NCT01531712,Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable,TERMINATED,PHASE2,Pancreatic Cancer,Gemcitabine (DRUG); Radiotherapy (RADIATION); Tarceva (DRUG); Oxaliplatin (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2113,NCT02436668,"Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)",COMPLETED,PHASE3,Metastatic Pancreatic Adenocarcinoma,Ibrutinib (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG),60750,Zefei,Metastatic Pancreatic Adenocarcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2114,NCT00521404,Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,CS-1008 (humanized anti-DR5 antibody) (DRUG); gemcitabine (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2115,NCT03348904,Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer,TERMINATED,PHASE3,Lung Cancer,Nivolumab (DRUG); Epacadostat (DRUG); Placebo (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG); Paclitaxel (DRUG); Pemetrexed (DRUG),60750,Zefei,Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2116,NCT00003001,Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer,UNKNOWN,PHASE1,Colorectal Cancer,fluorouracil (DRUG); gemcitabine hydrochloride (DRUG); leucovorin calcium (DRUG),60750,Zefei,Colorectal Cancer,Bowel,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2117,NCT00038701,"Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas",TERMINATED,PHASE2,Pancreatic Neoplasms,TNP-470 (DRUG),60750,Zefei,Pancreatic Neoplasms,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2118,NCT01056601,Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy,TERMINATED,PHASE2,Pancreatic Cancer,Bortezomib (DRUG); Panobinostat (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2119,NCT06027268,"Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer",RECRUITING,PHASE2,Metastatic Triple-Negative Breast Cancer,Trilaciclib (DRUG); Pembrolizumab (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG),60750,Zefei,Metastatic Triple-Negative Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2120,NCT01396668,Fixed Dose Rate Gemcitabine and Cisplatin Followed by Chemoradiation for Locally Advanced Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,"gemcitabine, cisplatin, capecitabine (DRUG)",60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2121,NCT00112346,Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small-Cell Lung Carcinoma,Cetuximab + platinum + gemcitabine (DRUG); Platinum + Gemcitabine (DRUG),60750,Zefei,Non-Small-Cell Lung Carcinoma,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2122,NCT01596868,GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China,COMPLETED,PHASE2,Nasopharyngeal Squamous Cell Carcinoma; Toxicity Due to Radiotherapy,gemcitabine and cisplatin (DRUG); docetaxel and cisplatin (DRUG),60750,Zefei,Nasopharyngeal Squamous Cell Carcinoma; Toxicity Due to Radiotherapy,Skin,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2123,NCT03464968,mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line,COMPLETED,PHASE2,Biliary Cancer Metastatic,"Oxaliplatin,5FU, leucovorin (DRUG); irinotecan,5FU, leucovorin (DRUG)",60750,Zefei,Metastatic Biliary Cancer,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2124,NCT03086369,A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer,COMPLETED,PHASE1,Metastatic Pancreatic Cancer,Olaratumab (DRUG); Nab-paclitaxel (DRUG); Gemcitabine (DRUG); Placebo (DRUG),60750,Zefei,Metastatic Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2125,NCT01946646,Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer,TERMINATED,PHASE1,Metastatic Pancreatic Cancer,S-1-CCRT (DRUG),60750,Zefei,Metastatic Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2126,NCT06546969,Chemoimmunotherapy Combined with Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer,RECRUITING,PHASE1,Biliary Tract Cancer; Cholangiocarcinoma,Gemcitabine (DRUG); Cisplatin (DRUG); Durvalumab (DRUG); Spatially Fractionated RT (RADIATION); Deep Hyperthermia (DEVICE),60750,Zefei,Biliary Tract Cancer; Cholangiocarcinoma,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2127,NCT00212069,Serum Proteomics to Predict Gemcitabine Sensitivity in Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,"gemcitabine, carboplatin (DRUG)",60750,Zefei,Metastatic Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2128,NCT00191269,Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen,COMPLETED,PHASE2,Metastatic Breast Cancer,gemcitabine (DRUG); gemcitabine (DRUG),60750,Zefei,Metastatic Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2129,NCT00025168,Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,gemcitabine hydrochloride (DRUG); irinotecan hydrochloride (DRUG); radiation therapy (RADIATION),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2130,NCT06662669,YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer,NOT_YET_RECRUITING,PHASE1,Metastatic Pancreatic Cancer,YL-13027 (DRUG); HY-0102 (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG),60750,Zefei,Metastatic Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2131,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer",COMPLETED,PHASE2,Breast Cancer,Gemcitabine (DRUG); Carboplatin (DRUG); Trastuzumab (DRUG),60750,Zefei,Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2132,NCT01077427,Hyperthermia European Adjuvant Trial,UNKNOWN,PHASE3,Resected Pancreatic Adenocarcinoma,Gemcitabine + Cisplatin + regional hyperthermia (DEVICE); Gemcitabine + Capecitabine (DRUG),60750,Zefei,Resected Pancreatic Adenocarcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2133,NCT06875076,Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma,RECRUITING,PHASE2,Pretreated Pleural Mesothelioma,Ivonescimab Combined With Chemotherapy (DRUG),60750,Zefei,Pretreated Pleural Mesothelioma,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2134,NCT00601627,"Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery",COMPLETED,PHASE2,Pancreatic Cancer,panitumumab (BIOLOGICAL); capecitabine (DRUG); fluorouracil (DRUG); gemcitabine hydrochloride (DRUG); radiation therapy (RADIATION),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2135,NCT04241276,A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Pancreatic Cancer,ATRA (DRUG); Gemcitabine (DRUG); nab-paclitaxel (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2136,NCT04611776,"A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer",WITHDRAWN,PHASE2,"Carcinoma, Non-Small Cell Lung",Atezolizumab (DRUG); Placebo (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Pemetrexed (DRUG); Gemcitabine (DRUG); Paclitaxel (DRUG),60750,Zefei,"Carcinoma, Non-Small Cell Lung",Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2137,NCT06608927,Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma,RECRUITING,PHASE3,Metastatic Pancreatic Ductal Adenocarcinoma,Quemliclustat (DRUG); Placebo (DRUG); Nab-paclitaxel (DRUG); Gemcitabine (DRUG),60750,Zefei,Metastatic Pancreatic Ductal Adenocarcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2138,NCT01718327,A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma,COMPLETED,PHASE2,Unresectable and Advanced Cholangiocarcinoma,Sunitinib (DRUG),60750,Zefei,Unresectable and Advanced Cholangiocarcinoma,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2139,NCT06632327,Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer,RECRUITING,PHASE3,Resectable Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8,Surgical Procedure (PROCEDURE); Cisplatin (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Gemcitabine (DRUG); Docetaxel (DRUG); Vinorelbine (DRUG); Nivolumab (DRUG); Pembrolizumab (DRUG); Atezolizumab (DRUG); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Positron Emission Tomography (PROCEDURE),60750,Zefei,Non-Small-Cell Lung Carcinoma,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2140,NCT04943627,Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA),WITHDRAWN,PHASE3,Advanced Cancer; Metastatic Cervical Cancer,Balstilimab (BAL) (DRUG); Topotecan (DRUG); Vinorelbine (DRUG); Gemcitabine (DRUG); Irinotecan (DRUG); Pemetrexed (DRUG),60750,Zefei,Advanced Cancer; Metastatic Cervical Cancer,Cervix,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2141,NCT02651727,"Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects",TERMINATED,PHASE1,Pancreatic Cancer,"Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine (DRUG); Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine (DRUG); Part A- VS-4718, nab-paclitaxel, gemcitabine (DRUG)",60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2142,NCT00278460,Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,docetaxel (DRUG); gemcitabine hydrochloride (DRUG),60750,Zefei,Lung Cancer,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2143,NCT00846027,A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Bevacizumab (DRUG); Paclitaxel (DRUG); Gemcitabine (DRUG),60750,Zefei,Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2144,NCT03401827,The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer,UNKNOWN,PHASE4,Pancreatic Adenocarcinoma; Chemotherapy Effect,Chemotherapy (Gemcitabine + nab-paclitaxel) (DRUG),60750,Zefei,Pancreatic Adenocarcinoma; Chemotherapy Effect,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2145,NCT02550327,"Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer",COMPLETED,EARLY_PHASE1,Pancreatic Adenocarcinoma,Nab-paclitaxel (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG); Anakinra (DRUG),60750,Zefei,Pancreatic Adenocarcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2146,NCT02546531,Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer,COMPLETED,PHASE1,Advanced Solid Tumors; Solid Tumors; Pancreatic Cancer,Defactinib (BIOLOGICAL); Pembrolizumab (BIOLOGICAL); Gemcitabine (DRUG),60750,Zefei,Advanced Solid Tumors; Solid Tumors; Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2147,NCT06532331,"A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Pancreatic Cancer,ONO-7475 (DRUG); ONO-4538 (DRUG); Nab-paclitaxel (DRUG); Gemcitabine (DRUG),60750,Zefei,Metastatic Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2148,NCT05263882,Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer,UNKNOWN,PHASE2,HER2-negative Breast Cancer,Gemcitabine combined with eribulin (DRUG),60750,Zefei,HER2-negative Breast Cancer,Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2149,NCT02514031,ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer,TERMINATED,PHASE1,Pancreatic Cancer,ARQ-761 (DRUG); Gemcitabine (DRUG); nab-paclitaxel (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2150,NCT00001431,A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas,COMPLETED,PHASE1,Gastrointestinal Neoplasms; Pancreatic Neoplasms,gemcitabine (DRUG),60750,Zefei,Gastrointestinal Neoplasms; Pancreatic Neoplasms,Bowel,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2151,NCT00270582,A Study of Weekly Docetaxel Plus Cisplatin Followed by Gemcitabine vs. Gemcitabine Plus Cisplatin Followed by Weekly Docetaxel in the Treatment of Advanced Non-Small-Cell Lung Cancer,UNKNOWN,PHASE2,"Carcinoma, Non-Small-Cell Lung","Taxotere, Cisplatin, Gemcitabine (DRUG)",60750,Zefei,"Carcinoma, Non-Small-Cell Lung",Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2152,NCT05669482,Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer,RECRUITING,PHASE1,KRAS Activating Mutation; Metastatic Cancer; Pancreas Cancer; Neoplasms Pancreatic; Malignant Neoplasm of Pancreas,avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel (DRUG),60750,Zefei,KRAS Activating Mutation; Metastatic Cancer; Pancreas Cancer; Neoplasms Pancreatic; Malignant Neoplasm of Pancreas,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2153,NCT01803282,Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors,COMPLETED,PHASE1,Pancreatic Cancer; Non-small Cell Lung Cancer; Esophagogastric Cancer; Colorectal Cancer; Breast Cancer,Andecaliximab (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); 5-FU (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG); Paclitaxel (DRUG),60750,Zefei,"Multiple Cancers (Pancreatic, Lung, Esophagogastric, Colorectal, Breast)",Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2154,NCT02991482,PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma,COMPLETED,PHASE3,Pleural Mesothelioma Malignant Advanced,Pembrolizumab (DRUG); Gemcitabine (DRUG); Vinorelbine (DRUG),60750,Zefei,Pleural Mesothelioma Malignant Advanced,Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2155,NCT03451331,Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer,COMPLETED,PHASE2,Metastatic Urothelial Cancer,Nivolumab (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG); Oxaliplatin (DRUG),60750,Zefei,Metastatic Urothelial Cancer,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2156,NCT01025882,Margin-Intense Combo Therapy in Pts w/Potentially Resectable Pancreatic Cancer,TERMINATED,PHASE1,Pancreatic Cancer,gemcitabine hydrochloride (DRUG); stereotactic body radiation therapy (RADIATION),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2157,NCT02000531,Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population,COMPLETED,PHASE4,"Carcinoma, Non-Small-Cell Lung",Erlotinib (DRUG); Chemotherapy (DRUG),60750,Zefei,"Carcinoma, Non-Small-Cell Lung",Lung,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2158,NCT00044031,Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma,COMPLETED,PHASE3,Pancreatic Cancer,G17DT Immunogen (BIOLOGICAL),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2159,NCT06735131,The Optimal Radioimmunotherapy Combinations for Advanced TNBC,NOT_YET_RECRUITING,PHASE2,Triple-Negative Breast Cancer (TNBC),"radiotherapy 5 Gy × 5 fractions, once a day (RADIATION); radiotherapy 8 Gy × 5 fractions, once a day (RADIATION); radiotherapy 8 Gy × 3 fractions, once every other day (RADIATION); radiotherapy 10 Gy× 3 fractions, once every other day (RADIATION); radiotehrapy 0.5Gy twice-a-day × 2 days, repeat for 4 cycles (total 8Gy) (RADIATION); Toripalimab (DRUG); chemotherapy regimen selected by the investigator (DRUG)",60750,Zefei,Triple-Negative Breast Cancer (TNBC),Breast,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2160,NCT02993731,A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma,COMPLETED,PHASE3,"Carcinoma, Pancreatic Ductal",Napabucasin (DRUG); Nab-paclitaxel (DRUG); Gemcitabine (DRUG),60750,Zefei,Pancreatic Ductal Carcinoma,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2161,NCT00361231,"Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer",COMPLETED,PHASE2,Biliary Tract Cancer; Gallbladder Adenocarcinoma,Bevacizumab (DRUG); Gemcitabine (DRUG); Oxaliplatin (DRUG),60750,Zefei,Biliary Tract Cancer; Gallbladder Adenocarcinoma,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2162,NCT01019382,A Study of the Effect of Gemcitabine With Fish Oil in Patients With Advanced Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Neoplasms,Lipidem fish oil infusion + Gemcitabine chemotherapy (DRUG),60750,Zefei,Pancreatic Neoplasms,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2163,NCT02375880,Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder,COMPLETED,PHASE1,Carcinoma of Intrahepatic and Extra-hepatic Biliary System; Carcinoma of Gallbladder; Bile Duct Cancer; Cholangiocarcinoma,DKN-01 (DRUG); gemcitabine (DRUG); cisplatin (DRUG),60750,Zefei,Carcinoma of Intrahepatic and Extra-hepatic Biliary System; Carcinoma of Gallbladder; Bile Duct Cancer; Cholangiocarcinoma,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2164,NCT06037980,CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence,RECRUITING,PHASE2,Biliary Tract Cancer; Cholangiocarcinoma,Gemcitabine (DRUG); Nab paclitaxel (DRUG); Cisplatin (DRUG); Curative Surgery (PROCEDURE); Capecitabine (DRUG),60750,Zefei,Biliary Tract Cancer; Cholangiocarcinoma,Liver,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2165,NCT00486460,"Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer",UNKNOWN,PHASE3,Pancreatic Cancer,Gemcitabine (DRUG); Curcumin (DRUG); Celebrex (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2166,NCT01693276,"Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer",TERMINATED,PHASE1,Pancreatic Cancer,Gemcitabine (DRUG); Abraxane (DRUG); Radiation Therapy (RADIATION),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2167,NCT00424827,A Trial of Chemo & Radiation Therapy for Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,Gemcitabine/Fluorouracil with External Beam Radiation (DRUG),60750,Zefei,Pancreatic Cancer,Pancreas,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2168,NCT00821327,"Gemzar, Cisp, Sunitinib Urothelial Ca",COMPLETED,PHASE2,Urothelial Cancer,"Gemcitabine, Cisplatin, Sunitinib (DRUG)",60750,Zefei,Urothelial Cancer,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2169,NCT01622660,Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy,TERMINATED,PHASE2,Bladder Cancer,Gemcitabine (DRUG); Pazopanib (DRUG),60750,Zefei,Bladder Cancer,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2170,NCT01222676,"Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder",UNKNOWN,PHASE2,Bladder Cancer,cisplatin (DRUG); gemcitabine hydrochloride (DRUG); sorafenib tosylate (DRUG); imaging biomarker analysis (OTHER); laboratory biomarker analysis (OTHER); computed tomography (PROCEDURE); neoadjuvant therapy (PROCEDURE); fludeoxyglucose F 18 (RADIATION),60750,Zefei,Bladder Cancer,Bladder/Urinary Tract,Gemcitabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment like pancreatic and non-small cell lung cancer.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,1.0,319.0 +2171,NCT01011920,Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma,COMPLETED,PHASE2,Central Nervous System Lymphoma,Methotrexate (DRUG); Ara-C (DRUG); Rituximab (DRUG); Thiotepa (DRUG); radiotherapy (RADIATION); BCNU (DRUG); APBSCT (OTHER),6253,AraC,Central Nervous System Lymphoma,CNS/Brain,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2172,NCT05222269,[68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients,TERMINATED,PHASE2,CNS Lymphoma,68Ga-PTF (DRUG),6253,AraC,CNS Lymphoma,CNS/Brain,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2173,NCT00153530,Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL),COMPLETED,PHASE4,Central Nervous System Lymphoma,methotrexate (DRUG); radiotherapy (RADIATION),6253,AraC,Central Nervous System Lymphoma,CNS/Brain,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2174,NCT06830421,Adjusted High-dose Chemotherapy with Autologous Stem Cell Transplant Vs. Conventional Immunochemotherapy in Elderly PCNSL Patients,RECRUITING,PHASE3,Primary Central Nervous System Lymphoma,R-MP and Procarbazine maintenance (DRUG); R-MTX/AraC (MARTA) induction followed by consolidating HCT-ASCT (DRUG),6253,AraC,Primary Central Nervous System Lymphoma,CNS/Brain,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2175,NCT00716066,Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases,ACTIVE_NOT_RECRUITING,PHASE2,Autoimmune Disease; Neurologic Autoimmune Disease; Autologous Transplant Autoimmune; Multiple Sclerosis Transplant; MS Stem Cell Transplant; Multiple Sclerosis Stem Cell Transplant; Stiff Person Syndrome; HCT for Neurologic Autoimmune Disorders; CIDP Transplant; Myasthenia Gravis Transplant; Autoimmune Nervous System Disorder; Central Nervous System Vasculitis; Cerebellar Degeneration; Chronic Inflammatory Demyelinating Polyneuropathy; Lambert Eaton Myasthenic Syndrome; Myasthenia Gravis; Neuromyelitis Optica; Opsoclonus Myoclonus Syndrome; Rasmussen Subacute Encephalitis,Anti-Thymocyte Globulin (BIOLOGICAL); Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE); Carmustine (DRUG); Cytarabine (DRUG); Etoposide (DRUG); Laboratory Biomarker Analysis (OTHER); Melphalan (DRUG); Peripheral Blood Stem Cell Transplantation (PROCEDURE); Prednisone (DRUG); Syngeneic Bone Marrow Transplantation (PROCEDURE),6253,AraC,Autoimmune Disease; Neurologic Autoimmune Disease; Autologous Transplant Autoimmune; Multiple Sclerosis Transplant; MS Stem Cell Transplant; Multiple Sclerosis Stem Cell Transplant; Stiff Person Syndrome; HCT for Neurologic Autoimmune Disorders; CIDP Transplant; Myasthenia Gravis Transplant; Autoimmune Nervous System Disorder; Central Nervous System Vasculitis; Cerebellar Degeneration; Chronic Inflammatory Demyelinating Polyneuropathy; Lambert Eaton Myasthenic Syndrome; Myasthenia Gravis; Neuromyelitis Optica; Opsoclonus Myoclonus Syndrome; Rasmussen Subacute Encephalitis,CNS/Brain,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2176,NCT00193973,Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma,COMPLETED,PHASE2,Primary Central Nervous System Lymphoma,"Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C (DRUG); Radiation Therapy (RADIATION)",6253,AraC,Primary Central Nervous System Lymphoma,CNS/Brain,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2177,NCT03964090,"Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)",ACTIVE_NOT_RECRUITING,PHASE2,Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma,TEDD-R (DRUG); TEDDI-R (DRUG); Ibrutinib (DRUG); Cytarabine (DRUG); Isavuconazole (DRUG); Methotrexate (DRUG),6253,AraC,Central Nervous System Lymphoma,CNS/Brain,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2178,NCT01356290,"Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma and ATRT",RECRUITING,PHASE2,Medulloblastoma Recurrent; Ependymoma Recurrent; ATRT Recurrent,Bevacizumab (DRUG); Thalidomide (DRUG); Celecoxib (DRUG); Fenofibric acid (DRUG); Etoposide (DRUG); Cyclophosphamide (DRUG); Etoposide phosphate (DRUG); Cytarabine (DRUG),6253,AraC,Recurrent CNS Tumors,CNS/Brain,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2179,NCT04931368,OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma,RECRUITING,PHASE3,Primary Central Nervous System Lymphoma,"Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix (DRUG); Control intervention: four courses of MATRix (DRUG)",6253,AraC,Primary Central Nervous System Lymphoma,CNS/Brain,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2180,NCT04115631,A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma,ACTIVE_NOT_RECRUITING,PHASE2,Liver Lymphoma; Mantle Cell Lymphoma,Acalabrutinib (DRUG); Bendamustine (DRUG); Bendamustine Hydrochloride (DRUG); Cytarabine (DRUG); Rituximab (BIOLOGICAL),6253,AraC,Liver Lymphoma; Mantle Cell Lymphoma,Liver,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2181,NCT01960192,Treatment of Primary CNS Lymphoma,UNKNOWN,PHASE4,Primary CNS Lymphoma (PCNSL),HD-MTX-Ara-C regimen (DRUG); FVD regimen (DRUG),6253,AraC,Primary CNS Lymphoma,CNS/Brain,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2182,NCT00863460,Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients,ACTIVE_NOT_RECRUITING,PHASE2,Primary Central Nervous System Lymphoma,cranial radiotherapy (RADIATION); intensive chemotherapy and hematopoietic stem cell rescue (DRUG); MTX based chemotherapy (DRUG),6253,AraC,Primary Central Nervous System Lymphoma,CNS/Brain,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2183,NCT00669812,High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma,UNKNOWN,PHASE2,Lymphoma; Small Intestine Cancer,carmustine (DRUG); cyclophosphamide (DRUG); cytarabine (DRUG); doxorubicin hydrochloride (DRUG); epirubicin hydrochloride (DRUG); etoposide (DRUG); ifosfamide (DRUG); melphalan (DRUG); methotrexate (DRUG); prednisolone (DRUG); vincristine sulfate (DRUG); autologous hematopoietic stem cell transplantation (PROCEDURE); biopsy (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE),6253,AraC,Lymphoma and Small Intestine Cancer,Bowel,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2184,NCT00003073,"Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors",UNKNOWN,PHASE1,"Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific",liposomal cytarabine (DRUG),6253,AraC,"Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific",CNS/Brain,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2185,NCT04083066,Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma,UNKNOWN,PHASE4,Primary Central Nervous System Lymphoma,"rituximab in combination with methotrexate, cytarabine and dexamethasone (DRUG)",6253,AraC,Primary Central Nervous System Lymphoma,CNS/Brain,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2186,NCT01044966,A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma,TERMINATED,PHASE1,Glioblastoma Multiforme; Glioma; Astrocytoma; Brain Tumor,ITV DepoCyt + Temozolomide (DRUG),6253,AraC,Glioblastoma Multiforme; Glioma; Astrocytoma; Brain Tumor,CNS/Brain,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2187,NCT01458730,Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma,COMPLETED,PHASE2,Central Nervous System Lymphoma,Immunochemotherapy (DRUG),6253,AraC,Central Nervous System Lymphoma,CNS/Brain,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2188,NCT01645839,Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer,COMPLETED,PHASE3,Breast Cancer; Leptomeningeal Metastases,Liposomal Cytarabine (DRUG),6253,AraC,Breast Cancer; Leptomeningeal Metastases,Breast,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2189,NCT05274139,Treatment of Primary CNS Lymphoma ( FTD ),COMPLETED,PHASE2,Primary CNS Lymphoma (PCNSL),HD-MTX-Ara-C regimen (DRUG); FTD regimen (DRUG),6253,AraC,Primary CNS Lymphoma,CNS/Brain,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2190,NCT06942039,"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation",NOT_YET_RECRUITING,EARLY_PHASE1,"CNS Embryonal Tumor; CNS, Medulloblastoma; Atypical Teratoid Rhabdoid Tumor; Medulloblastoma, Childhood; Medulloblastoma, Group 3; Medulloblastoma, Group 4; Pineoblastoma; Neuroblastoma; Embryonal Tumor With Multilayered Rosettes; Embryonal Tumor With Abundant Neuropil and True Rosettes; Ependymoblastoma; Medulloepithelioma; CNS Embryonal Tumor With Rhabdoid Features; CNS Embryonal Tumor, Nos",Cytarabine IT (DRUG); hydrocortisone (DRUG); Cisplatin (DRUG); Vincristine (DRUG); Etoposide (DRUG); Cyclophosphamide (DRUG); Mesna (DRUG); Filgrastim (DRUG); carboplatin (DRUG); Thiotepa (DRUG); Topotecan IT (DRUG); Tamoxifen (DRUG); ISOtretinoin (DRUG); Celecoxib (DRUG); etoposide phosphate (DRUG); Temozolomide (DRUG),6253,AraC,CNS Embryonal Tumors,CNS/Brain,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2191,NCT00734773,Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL,WITHDRAWN,EARLY_PHASE1,Brain and Central Nervous System Tumors; Lymphoma; Neurotoxicity,Rituximab (BIOLOGICAL); Cytarabine (DRUG); Methotrexate (DRUG); Motexafin gadolinium (DRUG); Procarbazine hydrochloride (DRUG); Vincristine sulfate (DRUG); Radiation therapy (RADIATION),6253,AraC,Brain and Central Nervous System Conditions,CNS/Brain,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2192,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,COMPLETED,PHASE2,Relapsing-Remitting Multiple Sclerosis,"Granulocyte-colony stimulating factor (G-CSF) and prednisone (DRUG); Carmustine, etoposide, cytarabine, and melphalan (BEAM) (DRUG); Autologous hematopoietic stem cell transplant (PROCEDURE)",6253,AraC,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Cytarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and other cancers.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,1.0,309.0 +2193,NCT04115631,A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma,ACTIVE_NOT_RECRUITING,PHASE2,Liver Lymphoma; Mantle Cell Lymphoma,Acalabrutinib (DRUG); Bendamustine (DRUG); Bendamustine Hydrochloride (DRUG); Cytarabine (DRUG); Rituximab (BIOLOGICAL),6252,s5582,Liver Lymphoma; Mantle Cell Lymphoma,Liver,Cytarabine (hydrochloride),,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and lymphoma.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O.Cl,1.0,247.0 +2194,NCT00669812,High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma,UNKNOWN,PHASE2,Lymphoma; Small Intestine Cancer,carmustine (DRUG); cyclophosphamide (DRUG); cytarabine (DRUG); doxorubicin hydrochloride (DRUG); epirubicin hydrochloride (DRUG); etoposide (DRUG); ifosfamide (DRUG); melphalan (DRUG); methotrexate (DRUG); prednisolone (DRUG); vincristine sulfate (DRUG); autologous hematopoietic stem cell transplantation (PROCEDURE); biopsy (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE),6252,s5582,Lymphoma and Small Intestine Cancer,Bowel,Cytarabine (hydrochloride),,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and lymphoma.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O.Cl,1.0,247.0 +2195,NCT00734773,Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL,WITHDRAWN,EARLY_PHASE1,Brain and Central Nervous System Tumors; Lymphoma; Neurotoxicity,Rituximab (BIOLOGICAL); Cytarabine (DRUG); Methotrexate (DRUG); Motexafin gadolinium (DRUG); Procarbazine hydrochloride (DRUG); Vincristine sulfate (DRUG); Radiation therapy (RADIATION),6252,s5582,Brain and Central Nervous System Conditions,CNS/Brain,Cytarabine (hydrochloride),,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and lymphoma.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O.Cl,1.0,247.0 +2196,NCT00863512,Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer,TERMINATED,PHASE3,Lung Cancer,cisplatin (DRUG); docetaxel (DRUG); gemcitabine hydrochloride (DRUG); pemetrexed disodium (DRUG); vinorelbine tartrate (DRUG); standard follow-up care (PROCEDURE),6252,s5582,Lung Cancer,Lung,Cytarabine (hydrochloride),,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and lymphoma.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O.Cl,1.0,247.0 +2197,NCT02130869,A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,COMPLETED,PHASE1,Neuroblastoma; Lymphoma; High-risk Tumor,CD133+ selected autologous stem cell infusion (BIOLOGICAL); IL-2 (BIOLOGICAL); hu14.18K322A (BIOLOGICAL); Busulfan (DRUG); Melphalan (DRUG); GM-CSF (BIOLOGICAL); Bendamustine (DRUG); Etoposide (DRUG); Cytarabine (DRUG); Carboplatin (DRUG); Haploidentical natural killer cell infusion (DEVICE); G-CSF (BIOLOGICAL); Etoposide phosphate (DRUG); CliniMACS (DEVICE),6252,s5582,Neuroblastoma and Lymphoma,CNS/Brain,Cytarabine (hydrochloride),,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and lymphoma.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O.Cl,1.0,247.0 +2198,NCT05518383,B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021,RECRUITING,PHASE4,"Non-hodgkin Lymphoma,B Cell; Burkitt Lymphoma; Primary Mediastinal Lymphoma; Primary CNS Lymphoma; Diffuse Large B-cell Lymphoma","Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate (DRUG); Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine (DRUG); Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine (DRUG); Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin (DRUG)",6252,s5582,"Non-hodgkin Lymphoma,B Cell; Burkitt Lymphoma; Primary Mediastinal Lymphoma; Primary CNS Lymphoma; Diffuse Large B-cell Lymphoma",CNS/Brain,Cytarabine (hydrochloride),,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and lymphoma.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O.Cl,1.0,247.0 +2199,NCT00716066,Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases,ACTIVE_NOT_RECRUITING,PHASE2,Autoimmune Disease; Neurologic Autoimmune Disease; Autologous Transplant Autoimmune; Multiple Sclerosis Transplant; MS Stem Cell Transplant; Multiple Sclerosis Stem Cell Transplant; Stiff Person Syndrome; HCT for Neurologic Autoimmune Disorders; CIDP Transplant; Myasthenia Gravis Transplant; Autoimmune Nervous System Disorder; Central Nervous System Vasculitis; Cerebellar Degeneration; Chronic Inflammatory Demyelinating Polyneuropathy; Lambert Eaton Myasthenic Syndrome; Myasthenia Gravis; Neuromyelitis Optica; Opsoclonus Myoclonus Syndrome; Rasmussen Subacute Encephalitis,Anti-Thymocyte Globulin (BIOLOGICAL); Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE); Carmustine (DRUG); Cytarabine (DRUG); Etoposide (DRUG); Laboratory Biomarker Analysis (OTHER); Melphalan (DRUG); Peripheral Blood Stem Cell Transplantation (PROCEDURE); Prednisone (DRUG); Syngeneic Bone Marrow Transplantation (PROCEDURE),6252,s5582,Autoimmune Disease; Neurologic Autoimmune Disease; Autologous Transplant Autoimmune; Multiple Sclerosis Transplant; MS Stem Cell Transplant; Multiple Sclerosis Stem Cell Transplant; Stiff Person Syndrome; HCT for Neurologic Autoimmune Disorders; CIDP Transplant; Myasthenia Gravis Transplant; Autoimmune Nervous System Disorder; Central Nervous System Vasculitis; Cerebellar Degeneration; Chronic Inflammatory Demyelinating Polyneuropathy; Lambert Eaton Myasthenic Syndrome; Myasthenia Gravis; Neuromyelitis Optica; Opsoclonus Myoclonus Syndrome; Rasmussen Subacute Encephalitis,CNS/Brain,Cytarabine (hydrochloride),,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapy for leukemia and lymphoma.,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O.Cl,1.0,247.0 +2200,NCT02573220,Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer,WITHDRAWN,PHASE1,Stage IVA Colorectal Cancer; Stage IVB Colorectal Cancer,Cetuximab (BIOLOGICAL); Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Leucovorin Calcium (DRUG),6029,Urd,Stage IV Colorectal Cancer,Bowel,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2201,NCT02157974,Liver and Fat Regulation in Overweight Adolescent Girls,COMPLETED,PHASE2,Hepatic Steatosis; Polycystic Ovarian Syndrome; Obesity,Byetta 5Mcg Pen Injection (DRUG),6029,Urd,Hepatic Steatosis; Polycystic Ovarian Syndrome; Obesity,Ovary/Fallopian Tube,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2202,NCT00210080,A Study to Diagnose Lung Cancer by Sputum Cytology (01-312),COMPLETED,PHASE3,Lung Cancer,Uridine 5'-Triphosphate (UTP) Solution for Inhalation (DRUG),6029,Urd,Lung Cancer,Lung,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2203,NCT02497157,Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Oxaliplatin (L-OHP) (DRUG); Irinotecan hydrochloride hydrate (CPT-11) (DRUG); Continuous intravenous infusion of fluorouracil (CIV 5-FU) (DRUG); Levofolinate calcium (l-LV) (DRUG); Bevacizumab (Bmab) (DRUG),6029,Urd,Metastatic Colorectal Cancer,Bowel,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2204,NCT02273739,"Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation",COMPLETED,PHASE1,Solid Tumor; Glioma; Angioimmunoblastic T-cell Lymphoma; Intrahepatic Cholangiocarcinoma; Chondrosarcoma,Enasidenib (DRUG),6029,Urd,Solid Tumor; Glioma; Angioimmunoblastic T-cell Lymphoma; Intrahepatic Cholangiocarcinoma; Chondrosarcoma,CNS/Brain,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2205,NCT00730158,"A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer",COMPLETED,PHASE2,Colorectal Neoplasms,KD018 (DRUG); Irinotecan (DRUG); Placebo (DRUG),6029,Urd,Colorectal Neoplasms,Bowel,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2206,NCT01231529,GSK1349572 Hepatic Impairment Study,COMPLETED,PHASE1,"Healthy Subjects; Hepatic Impairment; Infection, Human Immunodeficiency Virus; HIV Infections",GSK1349572 (DRUG),6029,Urd,"Healthy Subjects; Hepatic Impairment; Infection, Human Immunodeficiency Virus; HIV Infections",Liver,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2207,NCT01977235,Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer,UNKNOWN,PHASE2,Small Cell Lung Carcinoma,Irinotecan (DRUG); Cisplatin (DRUG),6029,Urd,Small Cell Lung Carcinoma,Lung,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2208,NCT01826396,Standard and High Dose Irinotecan Based on UGT1A1 Genotype for First-line Treatment of Locally Advanced Colon Cancer,UNKNOWN,PHASE2,Colonic Neoplasms,Irinotecan (DRUG),6029,Urd,Colonic Neoplasms,Bowel,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2209,NCT03815916,31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease,COMPLETED,PHASE2,Parkinson's Disease,Gold Nanocrystals (DRUG),6029,Urd,Parkinson's Disease,CNS/Brain,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2210,NCT00842244,Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer,COMPLETED,PHASE1,Stomach Neoplasms; Advanced Gastric Cancer,axitinib (DRUG); capecitabine (DRUG); cisplatin (DRUG),6029,Urd,Stomach Neoplasms; Advanced Gastric Cancer,Esophagus/Stomach,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2211,NCT04879368,RegoNivo vs Standard of Care Chemotherapy in AGOC,ACTIVE_NOT_RECRUITING,PHASE3,Gastro-Oesophageal Cancer,Regorafenib (DRUG); Nivolumab (BIOLOGICAL); Docetaxel (DRUG); Paclitaxel (DRUG); Irinotecan (DRUG); Trifluridine/Tipracil (DRUG),6029,Urd,Gastric Cancer,Esophagus/Stomach,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2212,NCT00008255,INS316 in Diagnosing Lung Cancer in Patients With Untreated Lung Cancer,COMPLETED,PHASE2,Lung Cancer,INS316 (DRUG); sputum cytology (OTHER),6029,Urd,Lung Cancer,Lung,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2213,NCT03843710,31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS),WITHDRAWN,PHASE2,Amyotrophic Lateral Sclerosis,Gold Nanocrystals (DRUG),6029,Urd,Amyotrophic Lateral Sclerosis,CNS/Brain,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2214,NCT01643499,Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies,COMPLETED,PHASE1,Acinar Cell Adenocarcinoma of the Pancreas; Adenocarcinoma of the Gallbladder; Adenocarcinoma of Unknown Primary; Adult Primary Cholangiocellular Carcinoma; Advanced Adult Primary Liver Cancer; Cholangiocarcinoma of the Extrahepatic Bile Duct; Cholangiocarcinoma of the Gallbladder; Diffuse Adenocarcinoma of the Stomach; Duct Cell Adenocarcinoma of the Pancreas; Intestinal Adenocarcinoma of the Stomach; Localized Unresectable Adult Primary Liver Cancer; Metastatic Carcinoma of Unknown Primary; Metastatic Extrahepatic Bile Duct Cancer; Mixed Adenocarcinoma of the Stomach; Mucinous Adenocarcinoma of the Colon; Mucinous Adenocarcinoma of the Rectum; Newly Diagnosed Carcinoma of Unknown Primary; Signet Ring Adenocarcinoma of the Colon; Signet Ring Adenocarcinoma of the Rectum; Stage III Pancreatic Cancer; Stage IIIA Colon Cancer; Stage IIIA Gallbladder Cancer; Stage IIIA Gastric Cancer; Stage IIIA Rectal Cancer; Stage IIIB Colon Cancer; Stage IIIB Gallbladder Cancer; Stage IIIB Gastric Cancer; Stage IIIB Rectal Cancer; Stage IIIC Colon Cancer; Stage IIIC Gastric Cancer; Stage IIIC Rectal Cancer; Stage IV Gastric Cancer; Stage IV Pancreatic Cancer; Stage IVA Colon Cancer; Stage IVA Gallbladder Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Gallbladder Cancer; Stage IVB Rectal Cancer; Unresectable Extrahepatic Bile Duct Cancer,oxaliplatin (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); fluorouracil (DRUG); laboratory biomarker analysis (OTHER),6029,Urd,Acinar Cell Adenocarcinoma of the Pancreas; Adenocarcinoma of the Gallbladder; Adenocarcinoma of Unknown Primary; Adult Primary Cholangiocellular Carcinoma; Advanced Adult Primary Liver Cancer; Cholangiocarcinoma of the Extrahepatic Bile Duct; Cholangiocarcinoma of the Gallbladder; Diffuse Adenocarcinoma of the Stomach; Duct Cell Adenocarcinoma of the Pancreas; Intestinal Adenocarcinoma of the Stomach; Localized Unresectable Adult Primary Liver Cancer; Metastatic Carcinoma of Unknown Primary; Metastatic Extrahepatic Bile Duct Cancer; Mixed Adenocarcinoma of the Stomach; Mucinous Adenocarcinoma of the Colon; Mucinous Adenocarcinoma of the Rectum; Newly Diagnosed Carcinoma of Unknown Primary; Signet Ring Adenocarcinoma of the Colon; Signet Ring Adenocarcinoma of the Rectum; Stage III Pancreatic Cancer; Stage IIIA Colon Cancer; Stage IIIA Gallbladder Cancer; Stage IIIA Gastric Cancer; Stage IIIA Rectal Cancer; Stage IIIB Colon Cancer; Stage IIIB Gallbladder Cancer; Stage IIIB Gastric Cancer; Stage IIIB Rectal Cancer; Stage IIIC Colon Cancer; Stage IIIC Gastric Cancer; Stage IIIC Rectal Cancer; Stage IV Gastric Cancer; Stage IV Pancreatic Cancer; Stage IVA Colon Cancer; Stage IVA Gallbladder Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Gallbladder Cancer; Stage IVB Rectal Cancer; Unresectable Extrahepatic Bile Duct Cancer,Bowel,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2215,NCT00600821,A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.,COMPLETED,PHASE2,Non-Small-Cell Lung Carcinoma; Adenocarcinoma,Bevacizumab (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); AG-013736 (axitinib) (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG),6029,Urd,Non-Small-Cell Lung Carcinoma; Adenocarcinoma,Lung,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2216,NCT05920213,Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy,NOT_YET_RECRUITING,PHASE4,Hepatic Encephalopathy Stage 2; Hepatic Encephalopathy Stage 3; Hepatic Encephalopathy Stage 4,Polyethylene Glycols (DRUG); Lactulose oral solution (DRUG); L-ornithine L-aspartate (DRUG),6029,Urd,Hepatic Encephalopathy Stage 2; Hepatic Encephalopathy Stage 3; Hepatic Encephalopathy Stage 4,Liver,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2217,NCT01266252,Dexmedetomidine in Mechanically Ventilated Neonates With Single-Organ Respiratory Failure.,COMPLETED,PHASE3,Mechanically-ventilated Neonates With Single-organ Respiratory Failure,Dexmedetomidine (DRUG),6029,Urd,Mechanically-ventilated Neonates With Single-organ Respiratory Failure,Lung,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2218,NCT01740271,A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients,RECRUITING,PHASE2,Breast Neoplasms,Epirubicin (DRUG),6029,Urd,Breast Neoplasms,Breast,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2219,NCT03993171,31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.,ACTIVE_NOT_RECRUITING,PHASE2,Multiple Sclerosis,gold nanocrystals (DRUG),6029,Urd,Multiple Sclerosis,CNS/Brain,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2220,NCT06110598,CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X),WITHDRAWN,PHASE2,Pancreas Cancer; Pancreas Adenocarcinoma,Capecitabine (DRUG),6029,Urd,Pancreas Cancer; Pancreas Adenocarcinoma,Pancreas,Uridine,,unclear,unclear,no,yes,"Studied in trials; not approved as standalone drug, essential body metabolite.",C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,1.2604166666666667,1535.0 +2221,NCT05983276,Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer,RECRUITING,PHASE2,Ovarian Cancer,Decitabine (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Selinexor (DRUG),71481097,Xpovio,Ovarian Cancer,Ovary/Fallopian Tube,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2222,NCT02323880,Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas,COMPLETED,PHASE1,Malignant Glioma; Recurrent Brain Neoplasm; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Glioblastoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Primary Central Nervous System Neoplasm; WHO Grade 3 Glioma,Pharmacological Study (OTHER); Selinexor (DRUG),71481097,Xpovio,Malignant Glioma; Recurrent Brain Neoplasm; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Glioblastoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Primary Central Nervous System Neoplasm; WHO Grade 3 Glioma,CNS/Brain,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2223,NCT04856189,Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma,RECRUITING,PHASE1,Advanced Urothelial Carcinoma; Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Refractory Urothelial Carcinoma,Pembrolizumab (BIOLOGICAL); Selinexor (DRUG),71481097,Xpovio,Advanced Urothelial Carcinoma; Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Refractory Urothelial Carcinoma,Bladder/Urinary Tract,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2224,NCT04216329,Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma,ACTIVE_NOT_RECRUITING,PHASE1,Gliosarcoma; Newly Diagnosed; Glioblastoma,Selinexor (DRUG); Temozolomide (DRUG); Generic Radiation therapy (RT) (RADIATION); Selective serotonin receptor (5-HT3) antagonists (OTHER); Olanzapine (OTHER); Salt tablets (DIETARY_SUPPLEMENT); Anti-diarrheal (OTHER),71481097,Xpovio,Gliosarcoma; Newly Diagnosed; Glioblastoma,CNS/Brain,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2225,NCT05432804,"Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment",RECRUITING,PHASE1,"MGMT-Methylated Glioblastoma; Recurrent Glioblastoma, IDH-Wildtype; Recurrent MGMT-Methylated Glioblastoma",Biospecimen Collection (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Selinexor (DRUG); Temozolomide (DRUG),71481097,Xpovio,"MGMT-Methylated Glioblastoma; Recurrent Glioblastoma, IDH-Wildtype; Recurrent MGMT-Methylated Glioblastoma",CNS/Brain,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2226,NCT04854434,A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations,TERMINATED,PHASE2,Metastatic Colorectal Cancer,Selinexor (DRUG); Pembrolizumab (DRUG); Trifluridine (DRUG); Tipiracil (DRUG),71481097,Xpovio,Metastatic Colorectal Cancer,Bowel,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2227,NCT04768881,Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma,TERMINATED,PHASE2,Locally Advanced Unresectable or Metastatic Melanoma,Selinexor (DRUG); Pembrolizumab (DRUG),71481097,Xpovio,Locally Advanced Unresectable or Metastatic Melanoma,Skin,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2228,NCT02419495,Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies,TERMINATED,PHASE1,Advanced Malignant Solid Neoplasm; Clinical Stage III Cutaneous Melanoma AJCC V8; Clinical Stage IV Cutaneous Melanoma AJCC V8; Fallopian Tube Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Renal Cell Carcinoma; Ovarian Carcinoma; Pathologic Stage III Cutaneous Melanoma AJCC V8; Pathologic Stage IIIA Cutaneous Melanoma AJCC V8; Pathologic Stage IIIB Cutaneous Melanoma AJCC V8; Pathologic Stage IIIC Cutaneous Melanoma AJCC V8; Pathologic Stage IIID Cutaneous Melanoma AJCC V8; Pathologic Stage IV Cutaneous Melanoma AJCC V8; Primary Peritoneal Carcinoma; Stage III Lung Cancer AJCC V8; Stage III Renal Cell Cancer AJCC V8; Stage IIIA Lung Cancer AJCC V8; Stage IIIB Lung Cancer AJCC V8; Stage IIIC Lung Cancer AJCC V8; Stage IV Lung Cancer AJCC V8; Stage IV Renal Cell Cancer AJCC V8; Stage IVA Lung Cancer AJCC V8; Stage IVB Lung Cancer AJCC V8; Triple-Negative Breast Carcinoma; Unresectable Lung Non-Small Cell Carcinoma; Unresectable Melanoma; Unresectable Renal Cell Carcinoma,Capecitabine (DRUG); Carboplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin (DRUG); Eribulin (DRUG); Fluorouracil (DRUG); Ipilimumab (BIOLOGICAL); Irinotecan Hydrochloride (DRUG); Leucovorin Calcium (DRUG); Nivolumab (BIOLOGICAL); Olaparib (DRUG); Oxaliplatin (DRUG); Paclitaxel (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed (DRUG); Selinexor (DRUG); Topotecan (DRUG),71481097,Xpovio,Advanced Malignant Solid Neoplasm; Clinical Stage III Cutaneous Melanoma AJCC V8; Clinical Stage IV Cutaneous Melanoma AJCC V8; Fallopian Tube Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Renal Cell Carcinoma; Ovarian Carcinoma; Pathologic Stage III Cutaneous Melanoma AJCC V8; Pathologic Stage IIIA Cutaneous Melanoma AJCC V8; Pathologic Stage IIIB Cutaneous Melanoma AJCC V8; Pathologic Stage IIIC Cutaneous Melanoma AJCC V8; Pathologic Stage IIID Cutaneous Melanoma AJCC V8; Pathologic Stage IV Cutaneous Melanoma AJCC V8; Primary Peritoneal Carcinoma; Stage III Lung Cancer AJCC V8; Stage III Renal Cell Cancer AJCC V8; Stage IIIA Lung Cancer AJCC V8; Stage IIIB Lung Cancer AJCC V8; Stage IIIC Lung Cancer AJCC V8; Stage IV Lung Cancer AJCC V8; Stage IV Renal Cell Cancer AJCC V8; Stage IVA Lung Cancer AJCC V8; Stage IVB Lung Cancer AJCC V8; Triple-Negative Breast Carcinoma; Unresectable Lung Non-Small Cell Carcinoma; Unresectable Melanoma; Unresectable Renal Cell Carcinoma,Kidney,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2229,NCT02178436,"Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer",COMPLETED,PHASE1,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Stage IV Pancreatic Cancer,gemcitabine hydrochloride (DRUG); Selinexor (DRUG); Pharmacological Study (OTHER); Laboratory Biomarker Analysis (OTHER); Nab paclitaxel (DRUG),71481097,Xpovio,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Stage IV Pancreatic Cancer,Pancreas,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2230,NCT05099003,A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG),SUSPENDED,PHASE1,"Anaplastic Astrocytoma; Anaplastic Astrocytoma, Not Otherwise Specified; Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma, H3 K27M-Mutant; Glioblastoma; Glioblastoma, Not Otherwise Specified; Malignant Glioma",Biopsy Procedure (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Radiation Therapy (RADIATION); Selinexor (DRUG),71481097,Xpovio,"Anaplastic Astrocytoma; Anaplastic Astrocytoma, Not Otherwise Specified; Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma, H3 K27M-Mutant; Glioblastoma; Glioblastoma, Not Otherwise Specified; Malignant Glioma",CNS/Brain,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2231,NCT05093608,SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma,TERMINATED,PHASE1,Hepatocellular Carcinoma,Selinexor Pill (DRUG); Bevacizumab (DRUG); Atezolizumab (DRUG),71481097,Xpovio,Hepatocellular Carcinoma,Liver,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2232,NCT02025985,Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies,COMPLETED,PHASE2,Ovarian Carcinoma; Endometrial Carcinoma; Cervical Carcinoma,Selinexor (DRUG),71481097,Xpovio,Ovarian Carcinoma; Endometrial Carcinoma; Cervical Carcinoma,Uterus,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2233,NCT04256707,"Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment",COMPLETED,PHASE1,Non-Small Cell Lung Carcinoma (NSCLC); Colorectal Cancer (CRC); Other Solid Tumors,Selinexor 100 mg (DRUG); Docetaxel (DRUG); Pembrolizumab (DRUG); FOLFIRI (DRUG); Selinexor 40 mg (DRUG); Selinexor 80 mg (DRUG); Selinexor 60 mg (DRUG),71481097,Xpovio,Non-Small Cell Lung Carcinoma (NSCLC); Colorectal Cancer (CRC); Other Solid Tumors,Bowel,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2234,NCT04421378,A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma,TERMINATED,PHASE1,Glioblastoma Multiforme,Selinexor (DRUG); Temozolomide (TMZ) (DRUG); Lomustine (CCNU) (DRUG); Standard Fractionated Radiation therapy (RT) (RADIATION); Bevacizumab (DRUG); TTField (DEVICE); Carmustine (DRUG),71481097,Xpovio,Glioblastoma Multiforme,CNS/Brain,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2235,NCT05611931,"Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma",RECRUITING,PHASE3,Endometrial Cancer,Selinexor (DRUG); Matching Placebo for selinexor (DRUG),71481097,Xpovio,Endometrial Cancer,Uterus,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2236,NCT02120222,Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery,COMPLETED,PHASE1,Recurrent Melanoma,selinexor (DRUG); Correlative studies (OTHER),71481097,Xpovio,Recurrent Melanoma,Skin,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2237,NCT05975944,Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer,UNKNOWN,PHASE1,Extensive-stage Small Cell Lung Cancer,Selinexor，Olaparib (DRUG),71481097,Xpovio,Extensive-stage Small Cell Lung Cancer,Lung,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2238,NCT03095612,Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC),TERMINATED,PHASE1,Non-small Cell Lung Cancer,Selinexor (DRUG); Docetaxel (DRUG),71481097,Xpovio,Non-small Cell Lung Cancer,Lung,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2239,NCT02384850,Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer,TERMINATED,PHASE1,Colorectal Neoplasm,Selinexor (DRUG); Oxaliplatin (DRUG); 5-FU (DRUG); Folinic Acid (DRUG),71481097,Xpovio,Colorectal Neoplasm,Bowel,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2240,NCT02536495,Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer,WITHDRAWN,PHASE1,Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma,Docetaxel (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Selinexor (DRUG),71481097,Xpovio,Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma,Lung,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2241,NCT06556199,A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma,RECRUITING,PHASE1,Relapsed/Refractory Primary Central Nervous System Lymphoma,Selinexor (DRUG); Temozolomide (DRUG); Anti-PD-1 monoclonal antibody (DRUG),71481097,Xpovio,Relapsed/Refractory Primary Central Nervous System Lymphoma,CNS/Brain,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2242,NCT02402764,Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC),COMPLETED,PHASE2,Breast Cancer,Selinexor (DRUG),71481097,Xpovio,Breast Cancer,Breast,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2243,NCT06813079,Using Tumor Models to Determine Treatments,NOT_YET_RECRUITING,PHASE2,Pancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor,Cobimetinib (DRUG); Ponatinib (DRUG); Brigatinib (DRUG); Colchicine (DRUG); Selinexor (DRUG); Abemaciclib (DRUG); Neratinib (DRUG); Doxorubicin (DRUG); Etoposide (DRUG); Ceritinib (DRUG),71481097,Xpovio,Pancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor,Pancreas,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2244,NCT01986348,Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas,TERMINATED,PHASE2,Glioblastoma; Glioma,Selinexor (DRUG),71481097,Xpovio,Glioblastoma; Glioma,CNS/Brain,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2245,NCT02283359,Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus,TERMINATED,PHASE1,Esophageal Cancer; Gastric Cancer,Selinexor (DRUG); Irinotecan (DRUG),71481097,Xpovio,Esophageal and Gastric Cancer,Esophagus/Stomach,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2246,NCT05035745,Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START),RECRUITING,PHASE1,Advanced Refractory Solid Tumors; Advanced Triple Negative Breast Cancers; Metastatic Triple Negative Breast Cancers,Talazoparib (DRUG); Selinexor (DRUG),71481097,Xpovio,Advanced Refractory Solid Tumors; Advanced Triple Negative Breast Cancers; Metastatic Triple Negative Breast Cancers,Breast,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2247,NCT05698147,Selinexor in Combination With MTX+Ritu to Treat R/R CNSL,RECRUITING,PHASE1,Central Nervous System Lymphoma,Selinexor (DRUG); Rituximab (DRUG); Methotrexate (DRUG),71481097,Xpovio,Central Nervous System Lymphoma,CNS/Brain,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2248,NCT02137356,Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer,UNKNOWN,PHASE1,Rectal Neoplasms,standard dose pelvic radiation therapy (RADIATION); standard dose capecitabine (DRUG); dose-escalated selinexor treatment (DRUG),71481097,Xpovio,Rectal Neoplasms,Bowel,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2249,NCT02213133,Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas,TERMINATED,PHASE2,Squamous Cell Carcinoma,Selinexor (KPT-330) (DRUG),71481097,Xpovio,Squamous Cell Carcinoma,Skin,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2250,NCT03555422,Maintenance with Selinexor/Placebo After Combination Chemotherapy in Participants with Endometrial Cancer [SIENDO],ACTIVE_NOT_RECRUITING,PHASE3,Endometrial Cancer,Selinexor (DRUG); Matching placebo for selinexor (DRUG),71481097,Xpovio,Endometrial Cancer,Uterus,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2251,NCT02269293,"Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers",COMPLETED,PHASE1,Ovarian Cancer; Endometrial Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Selinexor (DRUG),71481097,Xpovio,Ovarian Cancer; Endometrial Cancer,Ovary/Fallopian Tube,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2252,NCT02351505,Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer,TERMINATED,PHASE2,Recurrent Small Cell Lung Carcinoma,Selinexor (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER),71481097,Xpovio,Recurrent Small Cell Lung Carcinoma,Lung,Selinexor,XPO1,inhibitor/antagonist,unclear,yes,yes,Approved for certain cancer treatments.,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1.01,480.0 +2253,NCT00393926,Robot-Assisted Motivating Rehabilitation,COMPLETED,PHASE1,Stroke; Cerebrovascular Accident,TheraDrive Assistive Device (DEVICE); Rote Therapy versus Fun Therapy (PROCEDURE),3440,FUN,Stroke,CNS/Brain,Furosemide,"SLC12A1, SLC12A2",inhibitor/antagonist,unclear,yes,yes,"Widely used diuretic, approved for various conditions like hypertension and edema.",C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,1.52,128.0 +2254,NCT05119712,Terbinafine Treatment of Axial Spondyloarthropathy,WITHDRAWN,EARLY_PHASE1,Ankylosing Spondylitis; Axial Spondyloarthritis; Psoriatic Spondylitis; Spondylitis Secondary to Inflammatory Bowel Disease; Axial Spondyloarthopathy,Terbinafine Tablets (DRUG); Laboratory Testing (DIAGNOSTIC_TEST); Laboratory Testing (DIAGNOSTIC_TEST),3440,FUN,Ankylosing Spondylitis; Axial Spondyloarthritis; Psoriatic Spondylitis; Spondylitis Secondary to Inflammatory Bowel Disease; Axial Spondyloarthopathy,Bowel,Furosemide,"SLC12A1, SLC12A2",inhibitor/antagonist,unclear,yes,yes,"Widely used diuretic, approved for various conditions like hypertension and edema.",C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,1.52,128.0 +2255,NCT04249869,The Efficacy of Traditional Chinese Herbal Medicine for Alzheimer's Disease,UNKNOWN,PHASE1,Alzheimer Disease,VGH-AD1 (DRUG),3440,FUN,Alzheimer Disease,CNS/Brain,Furosemide,"SLC12A1, SLC12A2",inhibitor/antagonist,unclear,yes,yes,"Widely used diuretic, approved for various conditions like hypertension and edema.",C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,1.52,128.0 +2256,NCT00038467,Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer,COMPLETED,PHASE3,Breast Neoplasms,Tamoxifen (DRUG); Exemestane (DRUG),3440,FUN,Breast Neoplasms,Breast,Furosemide,"SLC12A1, SLC12A2",inhibitor/antagonist,unclear,yes,yes,"Widely used diuretic, approved for various conditions like hypertension and edema.",C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,1.52,128.0 +2257,NCT02350127,Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia,COMPLETED,PHASE2,Dementia; Alzheimer's Disease,Preventing Loss of Independence through Exercise (PLIE) (BEHAVIORAL); Usual Care (BEHAVIORAL),3440,FUN,Dementia; Alzheimer's Disease,CNS/Brain,Furosemide,"SLC12A1, SLC12A2",inhibitor/antagonist,unclear,yes,yes,"Widely used diuretic, approved for various conditions like hypertension and edema.",C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,1.52,128.0 +2258,NCT04913480,SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma,UNKNOWN,PHASE2,Hepatocellular Carcinoma,Durvalumab (DRUG); Stereotactic body radiation therapy (RADIATION),3440,FUN,Hepatocellular Carcinoma,Liver,Furosemide,"SLC12A1, SLC12A2",inhibitor/antagonist,unclear,yes,yes,"Widely used diuretic, approved for various conditions like hypertension and edema.",C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,1.52,128.0 +2259,NCT05809869,Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma,RECRUITING,PHASE2,Hepatocellular Carcinoma,Durvalumab (DRUG); Tremelimumab (DRUG); Yttrium-90 radioembolisation (RADIATION),3440,FUN,Hepatocellular Carcinoma,Liver,Furosemide,"SLC12A1, SLC12A2",inhibitor/antagonist,unclear,yes,yes,"Widely used diuretic, approved for various conditions like hypertension and edema.",C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,1.52,128.0 +2260,NCT04418232,Feasibility of a Systems Approach for Alzheimer's Services Among Latinos Attending Primary Care Practices,COMPLETED,PHASE1,Dementia,Alianza Latina (COMBINATION_PRODUCT),3440,FUN,Dementia,CNS/Brain,Furosemide,"SLC12A1, SLC12A2",inhibitor/antagonist,unclear,yes,yes,"Widely used diuretic, approved for various conditions like hypertension and edema.",C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,1.52,128.0 +2261,NCT05071885,Computer Game-based Exercise Program Targeting Manual Dexterity for People With Spinal Cord Injury or Stroke.,UNKNOWN,EARLY_PHASE1,"Stroke, Spinal Cord Injury",games based exercise (OTHER),3440,FUN,"Stroke, Spinal Cord Injury",CNS/Brain,Furosemide,"SLC12A1, SLC12A2",inhibitor/antagonist,unclear,yes,yes,"Widely used diuretic, approved for various conditions like hypertension and edema.",C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,1.52,128.0 +2262,NCT06274554,Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease,RECRUITING,PHASE3,Crohn's Disease; Inflammatory Bowel Diseases,Fluconazole (DRUG); Placebo (DRUG); IL-23 Therapy (BIOLOGICAL),3440,FUN,Crohn's Disease; Inflammatory Bowel Diseases,Bowel,Furosemide,"SLC12A1, SLC12A2",inhibitor/antagonist,unclear,yes,yes,"Widely used diuretic, approved for various conditions like hypertension and edema.",C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,1.52,128.0 +2263,NCT01853748,T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Trastuzumab (DRUG); Paclitaxel (DRUG); Trastuzumab emtansine (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2264,NCT00951665,"A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer",COMPLETED,PHASE1,Metastatic Breast Cancer,paclitaxel (DRUG); pertuzumab [Perjeta] (DRUG); trastuzumab emtansine [Kadcyla] (DRUG); paclitaxel (DRUG); trastuzumab emtansine [Kadcyla] (DRUG),60961,Myocol,Metastatic Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2265,NCT00829166,A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Trastuzumab emtansine (DRUG); Lapatinib (DRUG); Capecitabine (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2266,NCT05429684,Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer,UNKNOWN,PHASE3,HER2+ Breast Cancer,Trastuzumab (DRUG); Pertuzumab (DRUG); Nab paclitaxel (DRUG); Pyrotinib (DRUG); Capecitabine (DRUG); T-DM1 (DRUG); Everolimus (DRUG); CDK4/6 inhibitor (DRUG); AI (DRUG); Anti-PD-1 monoclonal antibody (DRUG),60961,Myocol,HER2+ Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2267,NCT01904903,Cardiac Safety Study in Patients With HER2 + Breast Cancer,COMPLETED,PHASE2,HER2 Positive Breast Cancer; Left Ventricular Function Systolic Dysfunction,Trastuzumab (DRUG); Pertuzumab (DRUG); Ado Trastuzumab Emtansine (DRUG),60961,Myocol,HER2 Positive Breast Cancer; Left Ventricular Function Systolic Dysfunction,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2268,NCT02144012,A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer,TERMINATED,PHASE3,Metastatic Breast Cancer,Trastuzumab (DRUG); Trastuzumab Emtansine (DRUG); Docetaxel (DRUG),60961,Myocol,Metastatic Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2269,NCT00509769,A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Trastuzumab emtansine [Kadcyla] (DRUG),60961,Myocol,Metastatic Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2270,NCT02390427,Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer,COMPLETED,PHASE1,Metastatic Breast Cancer; Recurrent Breast Cancer,Taselisib (DRUG); Trastuzumab emtansine (DRUG); Pertuzumab (DRUG); Trastuzumab (DRUG); Paclitaxel (DRUG),60961,Myocol,Metastatic Breast Cancer; Recurrent Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2271,NCT00932373,A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen,COMPLETED,PHASE1,Metastatic Breast Cancer,trastuzumab-MCC-DM1 (DRUG),60961,Myocol,Metastatic Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2272,NCT05238831,SMMART Adaptive Clinical Treatment (ACT) Trial,WITHDRAWN,EARLY_PHASE1,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Alectinib (DRUG); Alpelisib (DRUG); Anastrozole (DRUG); Atezolizumab (BIOLOGICAL); Bevacizumab (BIOLOGICAL); Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Capecitabine (DRUG); Carboplatin (DRUG); Cobimetinib (DRUG); Entrectinib (DRUG); Eribulin (DRUG); Fulvestrant (DRUG); Hyaluronidase-zzxf/Pertuzumab/Trastuzumab (BIOLOGICAL); Irinotecan (DRUG); Letrozole (DRUG); Nab-paclitaxel (DRUG); Niraparib (DRUG); Olaparib (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Pertuzumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Trastuzumab (BIOLOGICAL); Trastuzumab Emtansine (BIOLOGICAL); Vemurafenib (DRUG); Vinorelbine (DRUG); Vismodegib (DRUG),60961,Myocol,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Ovary/Fallopian Tube,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2273,NCT03709082,Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer,TERMINATED,PHASE1,HER2-positive Breast Cancer; Breast Cancer Metastatic,Palbociclib 75mg (DRUG); Letrozole 2.5mg (DRUG); T-DM1 (DRUG); Palbociclib 100mg (DRUG); Palbociclib 125mg (DRUG); Palbociclib (DRUG),60961,Myocol,HER2-positive Breast Cancer; Breast Cancer Metastatic,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2274,NCT06324357,Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread,RECRUITING,PHASE1,Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma,Zongertinib (DRUG); Trastuzumab deruxtecan (DRUG); Trastuzumab emtansine (DRUG); Trastuzumab (DRUG); Capecitabine (DRUG),60961,Myocol,Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma,Esophagus/Stomach,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2275,NCT03364348,4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer,COMPLETED,PHASE1,HER2 Positive Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Utomilumab (DRUG); Trastuzumab (DRUG); Ado-Trastuzumab Emtansine (DRUG),60961,Myocol,HER2 Positive Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2276,NCT05755048,FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer,RECRUITING,PHASE3,Breast Cancer,"Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502) (BIOLOGICAL); Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) (BIOLOGICAL)",60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2277,NCT00928330,Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy,COMPLETED,PHASE1,Metastatic Breast Cancer,GDC-0941 (DRUG); Trastuzumab (DRUG); trastuzumab-MCC-DM1 (DRUG),60961,Myocol,Metastatic Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2278,NCT01641939,A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer,TERMINATED,PHASE2,Gastric Cancer,Taxane (DRUG); trastuzumab emtansine (DRUG); trastuzumab emtansine (DRUG),60961,Myocol,Gastric Cancer,Esophagus/Stomach,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2279,NCT06313086,DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer,RECRUITING,PHASE3,HER2-positive Breast Cancer,DP303c (DRUG); trastuzumab emtansine (DRUG),60961,Myocol,HER2-positive Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2280,NCT03084939,Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Trastuzumab Emtansine (BIOLOGICAL); Lapatinib (DRUG); Capecitabine (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2281,NCT04675827,De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade,TERMINATED,PHASE2,HER2-positive Breast Cancer; ER-Negative Breast Cancer; PR-Negative Breast Cancer; Node-negative Breast Cancer,Pertuzumab and tratuzumab fixed dose combination (DRUG); Trastuzumab emtansine (DRUG),60961,Myocol,HER2-positive Breast Cancer; ER-Negative Breast Cancer; PR-Negative Breast Cancer; Node-negative Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2282,NCT04873362,A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Atezolizumab (DRUG); Trastuzumab Emtansine (DRUG); Placebo (DRUG); Trastuzumab (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2283,NCT02675829,Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers,RECRUITING,PHASE2,Solid Tumor Cancers; Lung Cancer; Bladder Cancer; Urinary Tract Cancers,ado-trastuzumab emtansine (DRUG),60961,Myocol,Solid Tumor Cancers; Lung Cancer; Bladder Cancer; Urinary Tract Cancers,Lung,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2284,NCT01494662,HKI-272 for HER2-Positive Breast Cancer and Brain Metastases,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,HKI-272 (DRUG); Surgical Resection (PROCEDURE); Capecitabine (DRUG); HKI-272 (DRUG); Ado-Trastuzumab Emtansine (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2285,NCT05593094,A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors,RECRUITING,PHASE1,Advanced Solid Tumors; HER2-positive Breast Cancer,ZN-A-1041 50mg BID (DRUG); ZN-A-1041 100mg BID (DRUG); ZN-A-1041 200mg BID (DRUG); ZN-A-1041 400mg BID (DRUG); ZN-A-1041 600mg BID (DRUG); ZN-A-1041 800mg BID (DRUG); ZN-A-1041 1000mg BID (DRUG); ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b (DRUG); ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b (DRUG); ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b (DRUG); ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c (DRUG); ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c (DRUG); ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c (DRUG),60961,Myocol,Advanced Solid Tumors; HER2-positive Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2286,NCT03190967,T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery,TERMINATED,PHASE1,Breast Cancer; Brain Metastasis; Brain Cancer,T-DM1 (DRUG); TMZ (DRUG),60961,Myocol,Breast Cancer; Brain Metastasis; Brain Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2287,NCT06595563,HER2 Molecular Imaging with 89Zr-trastuzumab PET/CT As a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients with Advanced HER2-positive Breast Cancer,NOT_YET_RECRUITING,PHASE2,HER2-positive Metastatic Breast Cancer; HER2-positive Advanced Breast Cancer,Trastuzumab emtansine (DRUG),60961,Myocol,HER2-positive Metastatic Breast Cancer; HER2-positive Advanced Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2288,NCT04457596,"T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial",RECRUITING,PHASE3,Anatomic Stage IA Breast Cancer AJCC V8; Anatomic Stage II Breast Cancer AJCC V8; Anatomic Stage IIA Breast Cancer AJCC V8; Anatomic Stage IIB Breast Cancer AJCC V8; Anatomic Stage III Breast Cancer AJCC V8; Anatomic Stage IIIA Breast Cancer AJCC V8; Anatomic Stage IIIB Breast Cancer AJCC V8; Anatomic Stage IIIC Breast Cancer AJCC V8; HER2 Positive Breast Carcinoma; Invasive Breast Carcinoma; Multifocal Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC V8; Prognostic Stage IA Breast Cancer AJCC V8; Prognostic Stage IB Breast Cancer AJCC V8; Prognostic Stage II Breast Cancer AJCC V8; Prognostic Stage IIA Breast Cancer AJCC V8; Prognostic Stage IIB Breast Cancer AJCC V8; Prognostic Stage III Breast Cancer AJCC V8; Prognostic Stage IIIA Breast Cancer AJCC V8; Prognostic Stage IIIB Breast Cancer AJCC V8; Prognostic Stage IIIC Breast Cancer AJCC V8; Synchronous Bilateral Breast Carcinoma,Trastuzumab Emtansine (BIOLOGICAL); Placebo Administration (DRUG); Tucatinib (DRUG); Questionnaire Administration (OTHER); Quality-of-Life Assessment (OTHER),60961,Myocol,Anatomic Stage IA Breast Cancer AJCC V8; Anatomic Stage II Breast Cancer AJCC V8; Anatomic Stage IIA Breast Cancer AJCC V8; Anatomic Stage IIB Breast Cancer AJCC V8; Anatomic Stage III Breast Cancer AJCC V8; Anatomic Stage IIIA Breast Cancer AJCC V8; Anatomic Stage IIIB Breast Cancer AJCC V8; Anatomic Stage IIIC Breast Cancer AJCC V8; HER2 Positive Breast Carcinoma; Invasive Breast Carcinoma; Multifocal Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC V8; Prognostic Stage IA Breast Cancer AJCC V8; Prognostic Stage IB Breast Cancer AJCC V8; Prognostic Stage II Breast Cancer AJCC V8; Prognostic Stage IIA Breast Cancer AJCC V8; Prognostic Stage IIB Breast Cancer AJCC V8; Prognostic Stage III Breast Cancer AJCC V8; Prognostic Stage IIIA Breast Cancer AJCC V8; Prognostic Stage IIIB Breast Cancer AJCC V8; Prognostic Stage IIIC Breast Cancer AJCC V8; Synchronous Bilateral Breast Carcinoma,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2289,NCT02073916,T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer,COMPLETED,PHASE1,Metastatic Breast Cancer,T-DM1 (DRUG); Lapatinib (DRUG); Abraxane (DRUG),60961,Myocol,Metastatic Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2290,NCT03153163,Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer,COMPLETED,PHASE1,Breast Neoplasms,Trastuzumab Emtansine (DRUG),60961,Myocol,Breast Neoplasms,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2291,NCT04419181,Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer,SUSPENDED,PHASE2,HER2-positive Breast Cancer,Docetaxel (DRUG); Carboplatin (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); Trastuzumab emtansine (DRUG),60961,Myocol,HER2-positive Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2292,NCT02314481,Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity,ACTIVE_NOT_RECRUITING,PHASE2,Non-small Cell Lung Cancer,MPDL3280A (DRUG); Vemurafenib (DRUG); Alectinib (DRUG); Trastuzumab emtansine (DRUG),60961,Myocol,Non-small Cell Lung Cancer,Lung,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2293,NCT02038010,BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx,COMPLETED,PHASE1,HER2-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,PI3K inhibitor BYL719 (DRUG); ado-trastuzumab emtansine (BIOLOGICAL); pharmacological study (OTHER); laboratory biomarker analysis (OTHER),60961,Myocol,HER2-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2294,NCT01983501,A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer,COMPLETED,PHASE1,HER2 Positive Breast Cancers,Tucatinib (ONT-380) (DRUG); T-DM1 (DRUG),60961,Myocol,HER2 Positive Breast Cancers,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2295,NCT04042701,DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer; Non-small Cell Lung Carcinoma,Trastuzumab deruxtecan (DS-8201a) (DRUG); Trastuzumab deruxtecan (DS-8201a) (DRUG); Pembrolizumab (DRUG),60961,Myocol,Breast Cancer; Non-small Cell Lung Carcinoma,Lung,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2296,NCT02999672,A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors,COMPLETED,PHASE2,Bladder Cancer; Pancreas Cancer; Cholangiocellular Carcinoma,Trastuzumab Emtansine (DRUG),60961,Myocol,Bladder Cancer; Pancreas Cancer; Cholangiocellular Carcinoma,Pancreas,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2297,NCT06126640,"A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy",RECRUITING,PHASE3,HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy,SHR-A1811 (DRUG); Trastuzumab Emtansine (DRUG),60961,Myocol,HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2298,NCT02318901,Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer,TERMINATED,PHASE1,Advanced Cancer; Breast Cancer; Gastric Cancer; Esophageal Cancer; Colorectal Cancer,Pembrolizumab (DRUG); Trastuzumab (DRUG); ado-trastuzumab emtansine (DRUG); Cetuximab (DRUG),60961,Myocol,Advanced Cancer; Breast Cancer; Gastric Cancer; Esophageal Cancer; Colorectal Cancer,Bowel,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2299,NCT03429101,A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer,TERMINATED,PHASE1,Breast Cancer,Poziotinib (DRUG); T-DM1 (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2300,NCT02213744,MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients,TERMINATED,PHASE2,Breast Cancer; HER2 Positive Breast Cancer,MM-302 (DRUG); Gemcitabine (DRUG); Capecitabine (DRUG); Vinorelbine (DRUG); Trastuzumab (DRUG),60961,Myocol,Breast Cancer; HER2 Positive Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2301,NCT03418558,Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,Trastuzumab emtansine (DRUG),60961,Myocol,Metastatic Colorectal Cancer,Bowel,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2302,NCT01702558,A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC),TERMINATED,PHASE2,Breast Cancer; Gastric Cancer,Capecitabine (DRUG); Trastuzumab emtansine (T-DM1) (DRUG); Trastuzumab emtansine (T-DM1) (DRUG); Capecitabine (DRUG),60961,Myocol,Breast Cancer; Gastric Cancer,Esophagus/Stomach,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2303,NCT01772472,A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),COMPLETED,PHASE3,Breast Cancer,trastuzumab (DRUG); trastuzumab emtansine (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2304,NCT03587740,ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,T-DM1 (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2305,NCT03529110,"DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]",ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Trastuzumab deruxtecan (T-DXd) (DRUG); Ado-trastuzumab emtansine (T-DM1) (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2306,NCT01976169,Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1),COMPLETED,PHASE1,Advanced Breast Cancer,PD-0332991 and T-DM1 (DRUG),60961,Myocol,Advanced Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2307,NCT03523572,Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer,COMPLETED,PHASE1,Breast Cancer; Urothelial Carcinoma,Trastuzumab deruxtecan (DRUG); Nivolumab (DRUG),60961,Myocol,Breast Cancer; Urothelial Carcinoma,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2308,NCT06125834,Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy,RECRUITING,PHASE2,Advanced Breast Cancer; Objective Response Rate; Trastuzumab Emtansine,Trastuzumab Emtansine (T-DM1) (DRUG),60961,Myocol,Advanced Breast Cancer; Objective Response Rate; Trastuzumab Emtansine,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2309,NCT00679341,A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease,COMPLETED,PHASE2,Breast Cancer,Trastuzumab emtansine [Kadcyla] (DRUG); Trastuzumab (DRUG); Docetaxel (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2310,NCT02725541,Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer,WITHDRAWN,PHASE2,Breast Cancer,Trastuzumab emtansine (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2311,NCT06348134,Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery,NOT_YET_RECRUITING,PHASE2,Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; HER2-positive Breast Cancer; Breast Cancer,Trastuzumab emtansine (DRUG); Pertuzumab Injection (DRUG); Docetaxel (DRUG); Tamoxifen (DRUG); Letrozole (DRUG); Goserelin (DRUG),60961,Myocol,Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; HER2-positive Breast Cancer; Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2312,NCT02658734,A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane,COMPLETED,PHASE4,"HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer",Trastuzumab emtansine (DRUG),60961,Myocol,"HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer",Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2313,NCT04740918,A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC),TERMINATED,PHASE3,Metastatic Breast Cancer,Trastuzumab Emtansine (DRUG); Atezolizumab (DRUG); Placebo (OTHER),60961,Myocol,Metastatic Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2314,NCT04622319,A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05),ACTIVE_NOT_RECRUITING,PHASE3,HER2-Positive Primary Breast Cancer; Residual Invasive Breast Cancer,DS-8201a (DRUG); T-DM1 (DRUG),60961,Myocol,HER2-Positive Primary Breast Cancer; Residual Invasive Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2315,NCT01835236,Trastuzumab & Pertuzumab Followed by T-DM1 in MBC,COMPLETED,PHASE2,Metastatic Breast Cancer,Trastuzumab (DRUG); Pertuzumab (DRUG); Paclitaxel (DRUG); Vinorelbine (DRUG); T-DM1 (DRUG),60961,Myocol,Metastatic Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2316,NCT04266249,CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy,ACTIVE_NOT_RECRUITING,PHASE2,Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Invasive Breast Carcinoma; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8,Docetaxel (DRUG); Lumpectomy (PROCEDURE); Mastectomy (PROCEDURE); Nab-paclitaxel (DRUG); Paclitaxel (DRUG); Pertuzumab (BIOLOGICAL); Radiation Therapy (RADIATION); Trastuzumab (BIOLOGICAL); Trastuzumab Emtansine (BIOLOGICAL),60961,Myocol,Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Invasive Breast Carcinoma; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2317,NCT05323955,Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients with ADvanced Human Epidermal Growth Factor Receptor 2+ BrEast Cancer with the Addition of Tucatinib,RECRUITING,PHASE2,Brain Metastases; Human Epidermal Growth Factor 2 Positive Carcinoma of Breast; Advanced Breast Cancer,Trastuzumab (DRUG); Trastuzumab Emtansine (T-DM1) (DRUG); Pertuzumab (DRUG); Tucatinib (DRUG),60961,Myocol,Brain Metastases; Human Epidermal Growth Factor 2 Positive Carcinoma of Breast; Advanced Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2318,NCT05650879,ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer,RECRUITING,PHASE1,HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer; HER2 Gene Mutation; HER2 Amplification,ELVN-002 (DRUG); Fam-Trastuzumab Deruxtecan-Nxki (DRUG); Trastuzumab emtansine (DRUG),60961,Myocol,HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer; HER2 Gene Mutation; HER2 Amplification,Lung,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2319,NCT02131064,A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,COMPLETED,PHASE3,Breast Neoplasms,Carboplatin (DRUG); Docetaxel (DRUG); Pertuzumab (DRUG); Trastuzumab (DRUG); Trastuzumab Emtansine (DRUG),60961,Myocol,Breast Neoplasms,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2320,NCT02229149,"Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",TERMINATED,PHASE2,Breast Neoplasms; Malignant Tumor of the Breast,"Trastuzumab (DRUG); Pertuzumab (DRUG); Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine (DRUG)",60961,Myocol,Breast Neoplasms; Malignant Tumor of the Breast,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2321,NCT00943670,Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression,COMPLETED,PHASE2,Metastatic Breast Cancer,pertuzumab (BIOLOGICAL); Trastuzumab emtansine [Kadcyla] (BIOLOGICAL),60961,Myocol,Metastatic Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2322,NCT04931342,A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors,ACTIVE_NOT_RECRUITING,PHASE2,Ovarian Cancer,Ipatasertib (DRUG); Cobimetinib (DRUG); Trastuzumab Emtansine (DRUG); Atezolizumab (DRUG); Bevacizumab (DRUG); Paclitaxel (DRUG); Giredestrant (DRUG); Abemaciclib (DRUG); Inavolisib (DRUG); Palbociclib (DRUG); Letrozole (DRUG); Olaparib (DRUG); Luteinizing Hormone-Releasing Hormone (LHRH) Agonists (DRUG); Cyclophosphamide (DRUG); Inavolisib (DRUG),60961,Myocol,Ovarian Cancer,Ovary/Fallopian Tube,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2323,NCT03784599,T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC,TERMINATED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Trastuzumab emtansine (DRUG); Osimertinib (DRUG),60961,Myocol,"Carcinoma, Non-Small-Cell Lung",Lung,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2324,NCT04924699,A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer,UNKNOWN,PHASE2,Advanced Breast Cancer; Metastatic Breast Cancer,MRG002 (DRUG); Trastuzumab Emtansine for Injection (DRUG),60961,Myocol,Advanced Breast Cancer; Metastatic Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2325,NCT02658084,Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer,TERMINATED,PHASE1,Breast Cancer; Metastatic Breast Cancer,Vinorelbine (DRUG); Trastuzumab Emtansine (DRUG),60961,Myocol,Breast Cancer; Metastatic Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2326,NCT01120184,A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE),COMPLETED,PHASE3,Breast Cancer,docetaxel (DRUG); paclitaxel (DRUG); pertuzumab (DRUG); pertuzumab-placebo (DRUG); trastuzumab [Herceptin] (DRUG); trastuzumab emtansine (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2327,NCT03726879,A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Atezolizumab (DRUG); Placebo (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Paclitaxel (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); Trastuzumab Emtansine (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2328,NCT00875979,"A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab",COMPLETED,PHASE1,Metastatic Breast Cancer,Trastuzumab emtansine [Kadcyla] 3.0 mg/kg (DRUG); Trastuzumab emtansine [Kadcyla] 3.6 mg/kg (DRUG); Pertuzumab 420 mg (DRUG),60961,Myocol,Metastatic Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2329,NCT01042379,I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,RECRUITING,PHASE2,Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer,Standard Therapy (DRUG); AMG 386 with or without Trastuzumab (DRUG); AMG 479 (Ganitumab) plus Metformin (DRUG); MK-2206 with or without Trastuzumab (DRUG); AMG 386 and Trastuzumab (DRUG); T-DM1 and Pertuzumab (DRUG); Pertuzumab and Trastuzumab (DRUG); Ganetespib (DRUG); ABT-888 (DRUG); Neratinib (DRUG); PLX3397 (DRUG); Pembrolizumab - 4 cycle (DRUG); Talazoparib plus Irinotecan (DRUG); Patritumab and Trastuzumab (DRUG); Pembrolizumab - 8 cycle (DRUG); SGN-LIV1A (DRUG); Durvalumab plus Olaparib (DRUG); SD-101 + Pembrolizumab (DRUG); Tucatinib plus trastuzumab and pertuzumab (DRUG); Cemiplimab (DRUG); Cemiplimab plus REGN3767 (DRUG); Trilaciclib with or without trastuzumab + pertuzumab (DRUG); SYD985 ([vic-]trastuzumab duocarmazine) (DRUG); Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab (DRUG); Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab (DRUG); Amcenestrant (DRUG); Amcenestrant + Abemaciclib (DRUG); Amcenestrant + Letrozole (DRUG); ARX788 (DRUG); ARX788 + Cemiplimab (DRUG); VV1 + Cemiplimab (DRUG); Datopotamab deruxtecan (DRUG); Datopotamab deruxtecan + Durvalumab (DRUG); Zanidatamab (DRUG); Lasofoxifene (DRUG); Z-endoxifen (DRUG); ARV-471 (DRUG); ARV-471 + Letrozole (DRUG); ARV-471 + Abemaciclib (DRUG); Endoxifen + Abemaciclib (DRUG); Rilvegostomig + TDXd (DRUG); Dan222 + Niraparib (DRUG); Sarilumab + Cemiplimab + Paclitaxel (DRUG),60961,Myocol,Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2330,NCT04351230,T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer,WITHDRAWN,PHASE2,Anatomic Stage IV Breast Cancer AJCC v8; HER2 Positive Breast Carcinoma; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8,Abemaciclib (DRUG); Trastuzumab Emtansine (BIOLOGICAL),60961,Myocol,Anatomic Stage IV Breast Cancer AJCC v8; HER2 Positive Breast Carcinoma; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2331,NCT01816035,Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery,COMPLETED,PHASE1,HER2/Neu Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Trastuzumab Emtansine (BIOLOGICAL),60961,Myocol,HER2/Neu Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2332,NCT03203616,Kadcyla In pAtients With bRAin Metastasis,WITHDRAWN,PHASE2,Metastatic HER2-positive Breast Cancer With Brain Metastasis,KADCYLA 160 MG Injection (DRUG),60961,Myocol,Metastatic HER2-positive Breast Cancer With Brain Metastasis,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2333,NCT04733118,Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Early Breast Cancer,Trastuzumab and Pertuzumab (FDC SC) and T-DM1 (DRUG),60961,Myocol,Early Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2334,NCT04298918,A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer,TERMINATED,PHASE1,Breast Cancer,Placebo (DRUG); Venetoclax (DRUG); Trastuzumab emtansine (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2335,NCT01565200,HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1,COMPLETED,PHASE2,HER-2 Positive Breast Cancer,T-DM1 (DRUG); 89Zr-trastuzumab (PROCEDURE),60961,Myocol,HER-2 Positive Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2336,NCT01196052,"A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer",COMPLETED,PHASE2,Breast Cancer,Trastuzumab emtansine (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2337,NCT04802759,A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer,RECRUITING,PHASE1,"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer",Giredestrant (DRUG); Abemaciclib (DRUG); Ipatasertib (DRUG); Inavolisib (DRUG); Ribociclib (DRUG); Everolimus (DRUG); Samuraciclib (DRUG); PH FDC SC (DRUG); Palbociclib (DRUG); Atezolizumab (DRUG),60961,Myocol,"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer",Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2338,NCT04296942,"BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)",TERMINATED,PHASE1,Breast Cancer; Triple Negative Breast Cancer; HER2+ Breast Cancer; Hormone Receptor Negative Breast Cancer; Metastatic Breast Cancer,Brachyury-TRICOM (BIOLOGICAL); Entinostat (DRUG); M7824 (BIOLOGICAL); Ado-trastuzumab emtansine (BIOLOGICAL),60961,Myocol,Breast Cancer; Triple Negative Breast Cancer; HER2+ Breast Cancer; Hormone Receptor Negative Breast Cancer; Metastatic Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2339,NCT04680442,Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction,RECRUITING,PHASE2,Breast Cancer; Heart Failure,Trastuzumab (DRUG); Pertuzumab (DRUG); Trastuzumab emtansine (DRUG),60961,Myocol,Breast Cancer with Heart Failure,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2340,NCT03225937,Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,"Trastuzumab, Lapatinib (DRUG); Pertuzumab, trastuzumab-emtansine (DRUG)",60961,Myocol,Metastatic Colorectal Cancer,Bowel,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2341,NCT04486352,A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer,RECRUITING,PHASE1,Endometrial Cancer,Atezolizumab - 28 Day Cycle (DRUG); Bevacizumab (DRUG); Ipatasertib (DRUG); Talazoparib (DRUG); Trastuzumab emtansine (DRUG); Tiragolumab (DRUG); Atezolizumab - 21 Day Cycle (DRUG); Inavolisib (DRUG); Letrozole (DRUG); Giredestrant (DRUG); Abemaciclib (DRUG),60961,Myocol,Endometrial Cancer,Uterus,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2342,NCT00934856,"A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer",COMPLETED,PHASE1,Breast Cancer,Docetaxel (DRUG); Pertuzumab (DRUG); Trastuzumab emtansine (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2343,NCT05081609,A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies,RECRUITING,PHASE1,Advanced Solid Tumor; Locally Advanced Solid Tumor; Metastatic Solid Tumor; Platinum-resistant Ovarian Cancer; Post Anti-PD-1 Melanoma; 2L+ Cervical Cancer; Neoadjuvant Melanoma; Neoadjuvant Non-Small Cell Lung Cancer; Post Anti-PD-(L)1 Non-Small Cell Lung Cancer; Post Anti-PD-(L)1 Small Cell Lung Cancer; Third Line or Later (3L+) HER2+ Breast Cancer; Second or Third Line (2L/3L) Cervical Cancer; Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC),TransCon IL-2 β/γ (DRUG); Pembrolizumab (DRUG); Chemotherapy drug (DRUG); TransCon TLR7/8 Agonist (DRUG); Surgery (PROCEDURE); Trastuzumab (DRUG); Trastuzumab emtansine (T-DM1) (DRUG),60961,Myocol,Advanced Solid Tumor; Locally Advanced Solid Tumor; Metastatic Solid Tumor; Platinum-resistant Ovarian Cancer; Post Anti-PD-1 Melanoma; 2L+ Cervical Cancer; Neoadjuvant Melanoma; Neoadjuvant Non-Small Cell Lung Cancer; Post Anti-PD-(L)1 Non-Small Cell Lung Cancer; Post Anti-PD-(L)1 Small Cell Lung Cancer; Third Line or Later (3L+) HER2+ Breast Cancer; Second or Third Line (2L/3L) Cervical Cancer; Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC),Lung,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2344,NCT03975647,A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,HER2-positive Breast Cancer,tucatinib (DRUG); placebo (DRUG); T-DM1 (DRUG),60961,Myocol,HER2-positive Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2345,NCT03264547,A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab,UNKNOWN,PHASE3,Breast Cancer,Pertuzumab (DRUG); Trastuzumab (DRUG); Docetaxel (DRUG); Paclitaxel (DRUG); Eribulin (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2346,NCT02289833,"A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Trastuzumab Emtansine (DRUG),60961,Myocol,Advanced Non-Small Cell Lung Cancer,Lung,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2347,NCT04158947,A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone,UNKNOWN,PHASE2,HER2-positive Breast Cancer; Brain Metastases,Afatinib (DRUG); T-DM1 (DRUG),60961,Myocol,HER2-positive Breast Cancer with Brain Metastases,CNS/Brain,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2348,NCT02452554,"Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma",COMPLETED,PHASE2,Pleuropulmonary Blastoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Neuroblastoma; Recurrent Rhabdomyosarcoma; Recurrent Synovial Sarcoma; Wilms Tumor,Laboratory Biomarker Analysis (OTHER); Lorvotuzumab Mertansine (BIOLOGICAL); Pharmacological Study (OTHER),60961,Myocol,Pleuropulmonary Blastoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Neuroblastoma; Recurrent Rhabdomyosarcoma; Recurrent Synovial Sarcoma; Wilms Tumor,CNS/Brain,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2349,NCT04042051,Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer,TERMINATED,PHASE1,HER2-positive Breast Cancer; Metastatic Breast Cancer; Locally Advanced Breast Cancer; Unresectable Breast Cancer,Copanlisib (DRUG); Trastuzumab emtansine (DRUG),60961,Myocol,HER2-positive Breast Cancer; Metastatic Breast Cancer; Locally Advanced Breast Cancer; Unresectable Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2350,NCT05288777,Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer,RECRUITING,PHASE2,Breast Cancer; Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer Stage III,T-DM1 (DRUG); Capecitabine (DRUG); External Beam Radiation Therapy 0 (RADIATION); External Beam Radiation Therapy 1 (RADIATION),60961,Myocol,Breast Cancer; Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer Stage III,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2351,NCT05415215,A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants with Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Early Breast Cancer; Locally Advanced Breast Cancer; Inflammatory Breast Cancer,Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC) (DRUG); Pertuzumab IV (DRUG); Trastuzumab IV (DRUG); Trastuzumab Emtansine (DRUG); Investigator's Choice of Chemotherapy (DRUG); Surgery (PROCEDURE); Radiotherapy (RADIATION),60961,Myocol,Early Breast Cancer; Locally Advanced Breast Cancer; Inflammatory Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2352,NCT06846437,"JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer",RECRUITING,PHASE3,Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants,JSKN003 (DRUG); Trastuzumab emtansine (T-DM1) (DRUG),60961,Myocol,Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2353,NCT02605915,Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer,COMPLETED,PHASE1,HER2-Positive Metastatic Breast Cancer; HER2-Negative Metastatic Breast Cancer; Locally Advanced or Early Breast Cancer,Atezolizumab (DRUG); Carboplatin (DRUG); Docetaxel (DRUG); Pertuzumab (DRUG); Trastuzumab (DRUG); Trastuzumab emtansine (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG),60961,Myocol,HER2-Positive Metastatic Breast Cancer; HER2-Negative Metastatic Breast Cancer; Locally Advanced or Early Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2354,NCT03523585,DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02],ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Trastuzumab deruxtecan (DRUG); Capecitabine (DRUG); Lapatinib (DRUG); Trastuzumab (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2355,NCT03032107,A Study Of Pembrolizumab In Combination With Trastuzumab-DM1,COMPLETED,PHASE1,Breast Cancer,T-DM1 (DRUG); Pembrolizumab (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2356,NCT04893109,ATEMPT 2.0: Adjuvant T-DM1 Vs TH,RECRUITING,PHASE2,Breast Cancer; HER2-positive Breast Cancer,trastuzumab-emtansine (DRUG); Trastuzumab SC (DRUG); Paclitaxel (DRUG),60961,Myocol,Breast Cancer; HER2-positive Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2357,NCT03894007,Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer,TERMINATED,PHASE2,Early-stage Breast Cancer; HER2-positive Breast Cancer,Docetaxel (DRUG); Carboplatin (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Atezolizumab (DRUG); Trastuzumab emtansine (DRUG); Paclitaxel (DRUG),60961,Myocol,Early-stage Breast Cancer; HER2-positive Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2358,NCT04197687,"TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery",UNKNOWN,PHASE2,Breast Adenocarcinoma; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7,Multi-epitope HER2 Peptide Vaccine TPIV100 (BIOLOGICAL); Pertuzumab (BIOLOGICAL); Placebo Administration (OTHER); Sargramostim (BIOLOGICAL); Trastuzumab (BIOLOGICAL); Trastuzumab Emtansine (BIOLOGICAL),60961,Myocol,Breast Adenocarcinoma; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2359,NCT01803087,Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients,COMPLETED,PHASE2,Asthma,Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1 (DRUG); CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2). (DRUG); BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF) (DRUG); CHF 1535 100/6 pMDI (Foster®) (CTR) (DRUG),60961,Myocol,Asthma,Lung,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2360,NCT02073487,Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel,COMPLETED,PHASE2,Breast Cancer,T-DM1 (DRUG); Trastuzumab (DRUG); Lapatinib (DRUG); Abraxane (DRUG); Paclitaxel (DRUG); Pertuzumab (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2361,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Trastuzumab Emtansine (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); Paclitaxel (DRUG); Epirubicin (DRUG); Doxorubicin (DRUG); Docetaxel (DRUG); Cyclophosphamide (DRUG); 5-Fluorouracil (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2362,NCT00679211,A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Trastuzumab emtansine [Kadcyla] (DRUG),60961,Myocol,Metastatic Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2363,NCT01419197,A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy,COMPLETED,PHASE3,Breast Cancer,Trastuzumab emtansine (DRUG); Treatment of physician's choice (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2364,NCT01513083,A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function,COMPLETED,PHASE1,Breast Cancer,trastuzumab emtansine (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2365,NCT05673928,A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB),RECRUITING,PHASE2,Metastatic Solid Tumor; Brain Metastases,Trastuzumab emtansine (DRUG); Tucatinib (DRUG),60961,Myocol,Metastatic Solid Tumor; Brain Metastases,CNS/Brain,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2366,NCT03379428,Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Breast Neoplasms; Malignant Neoplasm of Breast,Trastuzumab (DRUG); Ibrutinib 560 mg (DRUG); Ibrutinib 840 mg (DRUG); Ibrutinib 420 mg (DRUG),60961,Myocol,Breast Neoplasms; Malignant Neoplasm of Breast,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2367,NCT02448420,Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Palbociclib (DRUG); Trastuzumab (DRUG); Endocrine therapy (DRUG); Chemotherapy (DRUG); Antibody-Drug Conjugates (DRUG),60961,Myocol,Metastatic Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2368,NCT01702571,A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment,COMPLETED,PHASE3,Breast Cancer,Trastuzumab Emtansine (DRUG),60961,Myocol,Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2369,NCT06439693,The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer,RECRUITING,PHASE2,Breast Cancer Female; Breast Cancer; Breast Cancer Metastatic; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Stage IV Breast Cancer,Nab-Paclitaxel (DRUG); Paclitaxel (DRUG); Docetaxel (DRUG); Phesgo (DRUG); T-DM1 (DRUG); Pertuzumab (DRUG); Trastuzumab Deruxtecan (DRUG); Trastuzumab Subcutaneous Subcutaneous (DRUG); Tucatinib (DRUG); Trastuzumab (DRUG),60961,Myocol,Breast Cancer Female; Breast Cancer; Breast Cancer Metastatic; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Stage IV Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2370,NCT02924883,A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy,COMPLETED,PHASE2,Metastatic Breast Cancer,Atezolizumab (DRUG); Trastuzumab emtansine (DRUG); Placebo (OTHER),60961,Myocol,Metastatic Breast Cancer,Breast,Adenosine,"ADORA1, ADORA2A, ADORA2B, ADORA3",unclear,unclear,yes,yes,Used for certain arrhythmias; approved as a drug.,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,1.14,257.0 +2371,NCT05209295,A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies,RECRUITING,PHASE1,Hepatic Insufficiency; Neoplasms,Onureg (DRUG),9444,Onureg,Hepatic Insufficiency; Neoplasms,Liver,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2372,NCT04648826,"Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies",WITHDRAWN,PHASE1,Sarcomas; Melanomas; Germ Cell Tumors; Epithelial Malignancies (Excluding Lung and Renal Cell Carcinomas); Pulmonary Metastases,AeroEclipse II Breath Actuated Nebulizer (DEVICE); Bintrafusp alfa (DRUG); Azacytidine (DRUG),9444,Onureg,Sarcomas; Melanomas; Germ Cell Tumors; Epithelial Malignancies (Excluding Lung and Renal Cell Carcinomas); Pulmonary Metastases,Skin,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2373,NCT05381038,Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI,NOT_YET_RECRUITING,PHASE1,Solid Tumor; Gastrointestinal Cancer; Breast Cancer,QPOP (DEVICE); CURATE.AI (DEVICE); Azacitidine + docetaxel (DRUG); Azacitidine + paclitaxel (DRUG); Azacitidine + irinotecan (DRUG),9444,Onureg,Solid Tumors and Gastrointestinal Cancer,Bowel,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2374,NCT01928576,Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.,COMPLETED,PHASE2,Non-Small Cell Lung Cancer; Epigenetic Therapy,Azacitidine (DRUG); Entinostat (DRUG); Nivolumab (DRUG); CC-486 300 (DRUG),9444,Onureg,Non-Small Cell Lung Cancer; Epigenetic Therapy,Lung,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2375,NCT00842582,Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer,WITHDRAWN,PHASE1,Ovarian Cancer,Azacitidine (DRUG); Azacitidine (DRUG); Azacitidine (DRUG),9444,Onureg,Ovarian Cancer,Ovary/Fallopian Tube,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2376,NCT02900560,Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer,TERMINATED,PHASE2,Epithelial Ovarian Cancer,CC-486 (DRUG); Pembrolizumab (BIOLOGICAL),9444,Onureg,Ovarian Cancer,Ovary/Fallopian Tube,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2377,NCT01886573,Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery,TERMINATED,PHASE1,Stage IA Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Azacitidine (DRUG); Entinostat (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Therapeutic Conventional Surgery (PROCEDURE),9444,Onureg,Stage IA Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Lung,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2378,NCT01207726,Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery,TERMINATED,PHASE2,Stage IA Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung Carcinoma,Azacitidine (DRUG); Entinostat (DRUG); Laboratory Biomarker Analysis (OTHER),9444,Onureg,Stage IA Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung Carcinoma,Lung,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2379,NCT00477386,Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer,COMPLETED,PHASE1,Ovarian Cancer,decitabine (DRUG),9444,Onureg,Ovarian Cancer,Ovary/Fallopian Tube,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2380,NCT02250326,"Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer",COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",nab-paclitaxel IV (DRUG); CC-486 (DRUG); Duravalumab (DRUG),9444,Onureg,"Carcinoma, Non-Small-Cell Lung",Lung,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2381,NCT03941496,Azacytidine During Anti-tuberculosis Therapy,WITHDRAWN,PHASE1,"Tuberculosis, Pulmonary",Azacitidine Injection (DRUG),9444,Onureg,Pulmonary Tuberculosis,Lung,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2382,NCT03182894,Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer,WITHDRAWN,PHASE1,Metastatic Colorectal Cancer,Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA) (DRUG),9444,Onureg,Metastatic Colorectal Cancer,Bowel,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2383,NCT03576963,Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer,WITHDRAWN,PHASE1,Colorectal Adenocarcinoma; CpG Island Methylator Phenotype; Metastatic Microsatellite Stable Colorectal Carcinoma; Refractory Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Guadecitabine (DRUG); Nivolumab (BIOLOGICAL),9444,Onureg,Colorectal Adenocarcinoma; CpG Island Methylator Phenotype; Metastatic Microsatellite Stable Colorectal Carcinoma; Refractory Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Bowel,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2384,NCT02546986,Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,"Carcinoma, Non-Small-Cell Lung",CC-486 (DRUG); Pembrolizumab (DRUG); Placebo (DRUG),9444,Onureg,"Carcinoma, Non-Small-Cell Lung",Lung,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2385,NCT00336063,Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma,ACTIVE_NOT_RECRUITING,PHASE1,Adult Nasal Type Extranodal NK/T-Cell Lymphoma; Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Recurrent Nasopharyngeal Undifferentiated Carcinoma; Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7; Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7,Azacitidine (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Vorinostat (DRUG),9444,Onureg,Adult Nasal Type Extranodal NK/T-Cell Lymphoma; Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Recurrent Nasopharyngeal Undifferentiated Carcinoma; Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7; Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7,Skin,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2386,NCT01167816,Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer,TERMINATED,PHASE1,Pancreatic Cancer,Vidaza (DRUG),9444,Onureg,Pancreatic Cancer,Pancreas,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2387,NCT00005639,Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment,COMPLETED,PHASE1,"Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Azacitidine Injection (DRUG); sodium phenylbutyrate (DRUG),9444,Onureg,"Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Bowel,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2388,NCT02260440,A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Pembrolizumab (DRUG); Azacitidine (DRUG),9444,Onureg,Metastatic Colorectal Cancer,Bowel,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2389,NCT00934440,A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma,TERMINATED,PHASE1,Renal Cell Carcinoma,Bevacizumab (DRUG); Azacitidine (DRUG),9444,Onureg,Renal Cell Carcinoma,Kidney,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2390,NCT04891068,BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer,RECRUITING,PHASE2,Breast Cancer Female; Breast Cancer Invasive,Azacitidine (DRUG),9444,Onureg,Breast Cancer Female; Breast Cancer Invasive,Breast,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2391,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,75 approved agents (DRUG); COXEN (OTHER),9444,Onureg,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,Bladder/Urinary Tract,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2392,NCT03264404,Azacitidine and Pembrolizumab in Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Pancreas Cancer,Pembrolizumab (DRUG); Azacitidine (DRUG),9444,Onureg,Pancreas Cancer,Pancreas,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2393,NCT00387465,Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Recurrent Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Azacitidine 30mg/m2 (DRUG); Entinostat (DRUG); Azacitidine 40mg/m2 (DRUG),9444,Onureg,Recurrent Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Lung,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2394,NCT02512172,A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,Oral CC-486 (DRUG); Romidepsin (DRUG); MK-3475 (DRUG),9444,Onureg,Colorectal Cancer,Bowel,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2395,NCT01386346,Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer,COMPLETED,PHASE1,Esophageal Cancer; Malignant Neoplasm of Cardio-esophageal Junction of Stomach,Azacitidine (DRUG); Oxaliplatin (DRUG); Epirubicin (DRUG); Capecitabine (DRUG),9444,Onureg,Esophageal Cancer; Malignant Neoplasm of Cardio-esophageal Junction of Stomach,Esophagus/Stomach,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2396,NCT00561912,Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma,TERMINATED,PHASE2,Renal Cell Carcinoma,Decitabine (DRUG); Interferon Alfa-2b (DRUG),9444,Onureg,Renal Cell Carcinoma,Kidney,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2397,NCT04250246,A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1,UNKNOWN,PHASE2,Melanoma; Non Small Cell Lung Cancer,Ipilimumab plus nivolumab plus guadecitabine (DRUG); Ipilimumab plus nivolumab (DRUG),9444,Onureg,Melanoma; Non Small Cell Lung Cancer,Lung,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2398,NCT02178072,"Window Trial 5-aza in HNSCC, T-tare",COMPLETED,PHASE1,Head and Neck Squamous Cell Carcinoma,5-Azacitadine (DRUG),9444,Onureg,Head and Neck Squamous Cell Carcinoma,Skin,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2399,NCT00075634,"Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma",COMPLETED,PHASE1,"Recurrent Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific",decitabine (DRUG); doxorubicin hydrochloride (DRUG); cyclophosphamide (DRUG); filgrastim (BIOLOGICAL); pegfilgrastim (BIOLOGICAL); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),9444,Onureg,"Recurrent Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific",CNS/Brain,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2400,NCT00006019,"Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer",COMPLETED,PHASE2,Leukemia; Lung Cancer; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Prostate Cancer,azacitidine (DRUG); sodium phenylbutyrate (DRUG),9444,Onureg,Leukemia; Lung Cancer; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Prostate Cancer,Lung,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2401,NCT06161818,Total Neoadjuvant Therapy for Adenocarcinoma of the OESophagus and Oesophagogastric Junction: TNT-OES-2 Trial,NOT_YET_RECRUITING,PHASE2,Esophageal Cancer; Adenocarcinoma of the Esophagus,FLOT-CROSS or CROSS-FLOT (DRUG),9444,Onureg,Esophageal Cancer; Adenocarcinoma of the Esophagus,Esophagus/Stomach,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2402,NCT02009436,Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer,COMPLETED,PHASE1,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Azacitidine (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER),9444,Onureg,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Lung,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2403,NCT00398450,Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma,COMPLETED,PHASE1,Melanoma (Skin),recombinant interferon alfa-2b (BIOLOGICAL); azacitidine (DRUG),9444,Onureg,Melanoma (Skin),Skin,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2404,NCT06896110,Intrathecal Azacitidine and Nivolumab in Patients with Recurrent High-grade Glioma,NOT_YET_RECRUITING,PHASE1,"Glioblastoma (GBM); Diffuse Midline Glioma (DMG); Astrocytoma, IDH-Mutant, Grade 4; Diffuse Hemispheric Glioma, H3 G34-Mutant; Gliosarcoma of Brain",Nivolumab (DRUG); Azacitidine (AZA) (DRUG); lumbar puncture (PROCEDURE); MRI Contrast (DIAGNOSTIC_TEST),9444,Onureg,"Glioblastoma (GBM); Diffuse Midline Glioma (DMG); Astrocytoma, IDH-Mutant, Grade 4; Diffuse Hemispheric Glioma, H3 G34-Mutant; Gliosarcoma of Brain",CNS/Brain,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2405,NCT00084981,Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,decitabine (DRUG); valproic acid (DRUG); pharmacological study (OTHER); laboratory biomarker analysis (OTHER),9444,Onureg,Non-small-cell Lung Carcinoma,Lung,5-Azacytidine,DNMT1,inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,"Approved for use in specific cancers, such as myelodysplastic syndromes.",C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,1.01,371.0 +2406,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,75 approved agents (DRUG); COXEN (OTHER),119182,CAFdA,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,Bladder/Urinary Tract,Clofarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for leukemia treatment in pediatric patients.,C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N,1.01,435.0 +2407,NCT04727151,TAC T-cells for the Treatment of HER2-positive Solid Tumors,TERMINATED,PHASE1,HER2 Positive Gastric Cancer; Metastatic HER2 Positive Gastroesophageal Junction Cancer,TAC01-HER2 (BIOLOGICAL); TAC01-HER2 plus pembrolizumab (BIOLOGICAL),119182,CAFdA,HER2 Positive Gastric Cancer; Metastatic HER2 Positive Gastroesophageal Junction Cancer,Esophagus/Stomach,Clofarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for leukemia treatment in pediatric patients.,C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N,1.01,435.0 +2408,NCT02925351,Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases,COMPLETED,EARLY_PHASE1,Autoimmune Disease; Crohn Disease; Inflammatory Disorder; Rheumatoid Arthritis; Systemic Lupus Erythematosus; Takayasu Arteritis,Computed Tomography (PROCEDURE); Fluorine F 18 Clofarabine (RADIATION); Positron Emission Tomography (PROCEDURE),119182,CAFdA,Autoimmune Disease; Crohn Disease; Inflammatory Disorder; Rheumatoid Arthritis; Systemic Lupus Erythematosus; Takayasu Arteritis,Bowel,Clofarabine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for leukemia treatment in pediatric patients.,C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N,1.01,435.0 +2409,NCT01025648,"Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.",TERMINATED,PHASE1,Asthma,"E004 (epinephrine inhalation aerosol), 90 mcg/actuation (DRUG); E004 Placebo (DRUG); E004 (epinephrine inhalation aerosol), 125 mcg (DRUG); E004 (epinephrine inhalation aerosol), 220 mcg (DRUG); epinephrine inhalation aerosol, CFC propelled (DRUG); E004 (epinephrine inhalation aerosol), 160 mcg (DRUG)",190,ADE,Asthma,Lung,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2410,NCT03295786,Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease,COMPLETED,PHASE1,Parkinson Disease; Movement Disorders; Neurodegenerative Diseases; Nervous System Diseases; Brain Diseases,Cerebral Dopamine Neurotrophic Factor (DRUG); Renishaw Drug Delivery System (DEVICE),190,ADE,Parkinson Disease; Movement Disorders; Neurodegenerative Diseases; Nervous System Diseases; Brain Diseases,CNS/Brain,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2411,NCT01189396,"Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006",COMPLETED,PHASE2,Asthma; Bronchospasm; Chronic Obstructive Pulmonary Disease (COPD),A006 (DRUG); Placebo DPI (DRUG); Proventil-HFA (DRUG),190,ADE,Asthma; Bronchospasm; Chronic Obstructive Pulmonary Disease (COPD),Lung,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2412,NCT04004910,A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients,UNKNOWN,PHASE1,Advanced Breast Cancer,"Plasma soluble TNF receptor pulldown (OTHER); Plasma soluble TNF receptor pulldown + chemotherapy (OTHER); Chemotherapy Drugs, Cancer (DRUG)",190,ADE,Advanced Breast Cancer,Breast,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2413,NCT02271334,Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers,COMPLETED,PHASE2,Asthma,A006 DPI (DRUG); A006 DPI (DRUG); Proventil® MDI (DRUG); Proventil® MDI (DRUG),190,ADE,Asthma,Lung,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2414,NCT06737913,"HAI or IV of Adebrelimab, Combined with Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma",RECRUITING,PHASE2,Advanced Hepatocellular Carcinoma (HCC),HAI Adebrelimab (PROCEDURE); intravenous infusion (IV) of Adebrelimab (ADE) (DRUG); intravenous infusion (IV) of Bevacizumab (Bev.) (DRUG); HAIC with FOLFOX regimen (PROCEDURE); Adebrelimab and bevacizumab maintainance treatment (DRUG),190,ADE,Advanced Hepatocellular Carcinoma (HCC),Liver,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2415,NCT06453213,Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy,RECRUITING,PHASE4,Focal Onset Seizure,Cenobamate (DRUG),190,ADE,Focal Onset Seizure,CNS/Brain,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2416,NCT04485949,A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma,ACTIVE_NOT_RECRUITING,PHASE2,Glioblastoma,IGV-001 Cell Immunotherapy (COMBINATION_PRODUCT); Placebo (COMBINATION_PRODUCT); Standard of Care (SOC): Radiation Therapy (PROCEDURE); SOC: Temozolomide (DRUG),190,ADE,Glioblastoma,CNS/Brain,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2417,NCT06464614,Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.,NOT_YET_RECRUITING,PHASE2,Esophageal Cancer,Adebrelimab (DRUG); Apatinib (DRUG); Investigator chosen chemotherapy (ICC) (DRUG); Radiotherapy (RADIATION),190,ADE,Esophageal Cancer,Esophagus/Stomach,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2418,NCT03481842,"Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis",WITHDRAWN,PHASE1,"Endometriosis; Endometriosis Ovary; Endometriosis Externa; Endometriosis, Rectum",Linifanib (BIOLOGICAL); BIBW2992 (DRUG); Axitinib (DRUG),190,ADE,"Endometriosis; Endometriosis Ovary; Endometriosis Externa; Endometriosis, Rectum",Uterus,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2419,NCT00513903,Expanding the Role of Pharmacists in Treating Persons With Cardiovascular or Lung Diseases,COMPLETED,PHASE3,Cardiovascular Diseases; Lung Diseases,Minimal intervention (BEHAVIORAL); Enhanced Intervention (BEHAVIORAL),190,ADE,Cardiovascular Diseases; Lung Diseases,Lung,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2420,NCT03775538,Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study,COMPLETED,PHASE1,Parkinson Disease; Movement Disorders; Neuro-Degenerative Disease; Nervous System Diseases; Brain Diseases,Cerebral Dopamine Neurotrophic Factor (DRUG); Renishaw Drug Delivery System (DEVICE),190,ADE,Parkinson Disease; Movement Disorders; Neuro-Degenerative Disease; Nervous System Diseases; Brain Diseases,CNS/Brain,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2421,NCT04690686,Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,LW-02 device immunopheresis combined with atezolizumab (DEVICE); LW-02 device immunopheresis combined with weekly paclitaxel (DEVICE); LW-02 device immunopheresis (DEVICE),190,ADE,Non Small Cell Lung Cancer,Lung,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2422,NCT06776770,A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer,RECRUITING,PHASE1,Gastric Cancer,Adebrelimab (DRUG),190,ADE,Gastric Cancer,Esophagus/Stomach,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2423,NCT05299385,"The Study for Evaluating the Clinical Effectiveness and Safety of Respiratory Rehabilitation Software 'Redpill Breath'(COPD, Asthma, Lung Cancer, Etc.)",UNKNOWN,PHASE3,Respiratory System Disease; Chronic Obstructive Pulmonary Disease; Asthma Copd; Lung Cancer; Lung Diseases; Pulmonary Rehabilitation; Respiratory Rehabilitation; Home Based Rehabilitation; Mobile Application; Rehabilitation,Conventional rehabilition treatment(e.g leaflet) educated by hospital (BEHAVIORAL); Digital treatment based on Respiratory Rehabilitation Software (DEVICE),190,ADE,Respiratory System Disease; Chronic Obstructive Pulmonary Disease; Asthma Copd; Lung Cancer; Lung Diseases; Pulmonary Rehabilitation; Respiratory Rehabilitation; Home Based Rehabilitation; Mobile Application; Rehabilitation,Lung,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2424,NCT06169371,Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI),RECRUITING,PHASE4,Breast Cancer,Abemaciclib (DRUG); Abemaciclib (DRUG); Abemaciclib (DRUG),190,ADE,Breast Cancer,Breast,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2425,NCT03357471,"Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease",COMPLETED,PHASE3,Moderate and Severe Active Rheumatoid Arthritis; Active Psoriatic Arthritis; Active Ankylosing Spondylitis; Moderately to Severely Active Crohn's Disease,e-Device (DRUG),190,ADE,Moderate and Severe Active Rheumatoid Arthritis; Active Psoriatic Arthritis; Active Ankylosing Spondylitis; Moderately to Severely Active Crohn's Disease,Bowel,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2426,NCT05220605,Nebulised BromAc in Healthy Volunteers,COMPLETED,PHASE1,COVID-19 Pneumonia; Bromelains Adverse Reaction; Acetylcysteine Adverse Reaction; Mucus; Plug; COVID-19 Acute Respiratory Distress Syndrome,BromAc (DRUG),190,ADE,COVID-19 Pneumonia; Bromelains Adverse Reaction; Acetylcysteine Adverse Reaction; Mucus; Plug; COVID-19 Acute Respiratory Distress Syndrome,Lung,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2427,NCT04228653,Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions,UNKNOWN,PHASE1,Parkinson Disease; Movement Disorders; Neuro-Degenerative Disease; Nervous System Diseases; Brain Diseases,Renishaw Drug Delivery System (DEVICE),190,ADE,Parkinson Disease; Movement Disorders; Neuro-Degenerative Disease; Nervous System Diseases; Brain Diseases,CNS/Brain,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2428,NCT02157974,Liver and Fat Regulation in Overweight Adolescent Girls,COMPLETED,PHASE2,Hepatic Steatosis; Polycystic Ovarian Syndrome; Obesity,Byetta 5Mcg Pen Injection (DRUG),190,ADE,Hepatic Steatosis; Polycystic Ovarian Syndrome; Obesity,Ovary/Fallopian Tube,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2429,NCT05589766,N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease,ACTIVE_NOT_RECRUITING,PHASE2,Parkinson Disease,Nicotinamide Riboside (DIETARY_SUPPLEMENT); Placebo (OTHER),190,ADE,Parkinson Disease,CNS/Brain,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2430,NCT03568968,A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease,ACTIVE_NOT_RECRUITING,PHASE3,Parkinson Disease,Nicotinamide Riboside (DIETARY_SUPPLEMENT); Placebo (OTHER),190,ADE,Parkinson Disease,CNS/Brain,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2431,NCT03865927,GKT137831 in IPF Patients with Idiopathic Pulmonary Fibrosis,COMPLETED,PHASE2,Idiopathic Pulmonary Fibrosis,Placebo Oral Tablet (OTHER); GKT137831 (DRUG),190,ADE,Idiopathic Pulmonary Fibrosis,Lung,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2432,NCT02622386,The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis,COMPLETED,PHASE2,Psoriasis,Riboflavin (DRUG); Placebo (OTHER),190,ADE,Psoriasis,Skin,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2433,NCT00001422,A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis,COMPLETED,PHASE2,"Arthritis, Psoriatic; Psoriasis",fludarabine (DRUG),190,ADE,"Arthritis, Psoriatic; Psoriasis",Skin,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2434,NCT06152991,Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy,ENROLLING_BY_INVITATION,PHASE3,Non-Alcoholic Fatty Liver Disease,GODEX (DRUG); Placebo (DRUG),190,ADE,Non-Alcoholic Fatty Liver Disease,Liver,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2435,NCT03815916,31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease,COMPLETED,PHASE2,Parkinson's Disease,Gold Nanocrystals (DRUG),190,ADE,Parkinson's Disease,CNS/Brain,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2436,NCT04818216,Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection,COMPLETED,PHASE2,SARS-CoV-2 Infection; Acute Kidney Injury,Placebo (DRUG); Nicotinamide riboside (DRUG),190,ADE,SARS-CoV-2 Infection; Acute Kidney Injury,Kidney,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2437,NCT00842244,Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer,COMPLETED,PHASE1,Stomach Neoplasms; Advanced Gastric Cancer,axitinib (DRUG); capecitabine (DRUG); cisplatin (DRUG),190,ADE,Stomach Neoplasms; Advanced Gastric Cancer,Esophagus/Stomach,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2438,NCT03843710,31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS),WITHDRAWN,PHASE2,Amyotrophic Lateral Sclerosis,Gold Nanocrystals (DRUG),190,ADE,Amyotrophic Lateral Sclerosis,CNS/Brain,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2439,NCT00580723,Effects of PRK 124 Lotion in Acne Rosacea,COMPLETED,PHASE1,Acne Rosacea,PRK 124 (OTHER),190,ADE,Acne Rosacea,Skin,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2440,NCT03517995,"Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention",WITHDRAWN,PHASE2,Bladder Cancer; Bladder Tumor; Urothelial Carcinoma,Sulforaphane Administration (DRUG); Placebo Administration (OTHER); Standard of Care Surgery (PROCEDURE),190,ADE,Bladder Cancer; Bladder Tumor; Urothelial Carcinoma,Bladder/Urinary Tract,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2441,NCT04287543,Melatonin on Clock Genes in Parkinson's Disease,WITHDRAWN,PHASE2,Parkinson Disease,Melatonin (DRUG); Placebos (DRUG),190,ADE,Parkinson Disease,CNS/Brain,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2442,NCT05325099,Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum,RECRUITING,PHASE1,Acute Kidney Disease,Azacitidine (DRUG); Placebo (DRUG),190,ADE,Acute Kidney Disease,Kidney,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2443,NCT05617508,N-DOSE AD: a Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease,ACTIVE_NOT_RECRUITING,PHASE2,Alzheimer Disease; Dementia,Placebo (OTHER); Nicotinamide Riboside supplementation 1000mg daily in total (DIETARY_SUPPLEMENT); Nicotinamide Riboside dose escalation (up to 3000 mg daily in total) (DIETARY_SUPPLEMENT),190,ADE,Alzheimer Disease and Dementia,CNS/Brain,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2444,NCT05410717,CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors,RECRUITING,PHASE1,"Stage IV Ovarian Cancer; Testis Cancer, Refractory; Endometrial Cancer Recurrent; CAR NK","Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells (BIOLOGICAL)",190,ADE,"Stage IV Ovarian Cancer; Testis Cancer, Refractory; Endometrial Cancer Recurrent; CAR NK",Uterus,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2445,NCT06078215,CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke,RECRUITING,PHASE4,Acute Ischemic Stroke,Cerebrolysin (COMBINATION_PRODUCT),190,ADE,Acute Ischemic Stroke,CNS/Brain,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2446,NCT05732051,Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients,RECRUITING,PHASE2,Breast Cancer; Metastatic Breast Cancer; Cancer Therapy-Related Cardiac Dysfunction; Cardiotoxicity; Heart Failure,Nicotinamide Riboside (DIETARY_SUPPLEMENT); Placebo (DIETARY_SUPPLEMENT),190,ADE,Breast Cancer; Metastatic Breast Cancer; Cancer Therapy-Related Cardiac Dysfunction; Cardiotoxicity; Heart Failure,Breast,Adenine,,unclear,unclear,no,no,Commonly found in supplements; not a drug approved by itself.,C1=NC2=NC=NC(=C2N1)N,1.12,417.0 +2447,NCT01407874,"A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency",COMPLETED,PHASE2,Gout; Hyperuricemia; Arthritis; Joint Disease; Renal Insufficiency,Placebo (DRUG); Ulodesine (BCX4208) 5 mg (DRUG); Ulodesine (BCX4208) 10 mg (DRUG),135401907,Gotax,Gout; Hyperuricemia; Arthritis; Joint Disease; Renal Insufficiency,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2448,NCT05511766,Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis,UNKNOWN,PHASE2,Cirrhosis; Hepatic Encephalopathy; Ascites; Varices; SBP - Spontaneous Bacterial Peritonitis,Allopurinol 300 MG (DRUG); Atorvastatin 20mg (DRUG); Placebo (DRUG),135401907,Gotax,Cirrhosis; Hepatic Encephalopathy; Ascites; Varices; SBP - Spontaneous Bacterial Peritonitis,Liver,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2449,NCT00849368,Azathioprine & Allopurinol in Inflammatory Bowel Disease Patients,COMPLETED,PHASE1,Inflammatory Bowel Disease,Azathioprine / Allopurinol (DRUG),135401907,Gotax,Inflammatory Bowel Disease,Bowel,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2450,NCT05474560,Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients,COMPLETED,PHASE4,Non-Alcoholic Fatty Liver Disease; Hyperuricemia,Allopurinol (100 mg/day) plus lifestyle intervention (DRUG); Febuxostat 40 mg plus lifestyle intervention (DRUG); Life style intervention (BEHAVIORAL),135401907,Gotax,Non-Alcoholic Fatty Liver Disease; Hyperuricemia,Liver,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2451,NCT04983160,"Crossover Clinical Trial, Randomized, Double Blind, Placebo Controlled Trial",COMPLETED,PHASE2,Chronic Kidney Disease,Allopurinol (DRUG); Placebo (DRUG),135401907,Gotax,Chronic Kidney Disease,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2452,NCT01320722,Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function,COMPLETED,PHASE3,Renal Function; Endothelial Function; Blood Pressure; Overweight; Obesity,Vitamin D ergocalciferol (DRUG); Probenecid (DRUG); Allopurinol (DRUG); Placebo (DRUG); Placebo (DRUG),135401907,Gotax,Renal Function; Endothelial Function; Blood Pressure; Overweight; Obesity,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2453,NCT03767322,Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI),UNKNOWN,PHASE2,Contrast-induced Nephropathy; Contrast-induced Acute Kidney Injury,Allopurinol (DRUG); Febuxostat (DRUG); Placebo (DRUG),135401907,Gotax,Contrast-induced Nephropathy; Contrast-induced Acute Kidney Injury,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2454,NCT00688480,Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?,COMPLETED,PHASE4,Kidney Disease; Left Ventricular Hypertrophy,Placebo (DRUG); Allopurinol (DRUG),135401907,Gotax,Kidney Disease; Left Ventricular Hypertrophy,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2455,NCT04256629,A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart,COMPLETED,PHASE1,Healthy Volunteers (Intended Indication: Chronic Kidney Disease),Verinurad (DRUG); Placebo (DRUG); Allopurinol (DRUG),135401907,Gotax,Healthy Volunteers (Intended Indication: Chronic Kidney Disease),Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2456,NCT03990363,A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia,COMPLETED,PHASE2,Chronic Kidney Disease,Verinurad (DRUG); Allopurinol (DRUG); Placebo for Verinurad (DRUG); Placebo for Allopurinol (DRUG),135401907,Gotax,Chronic Kidney Disease,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2457,NCT05049863,Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial),TERMINATED,PHASE1,Small-cell Lung Cancer; Small Cell Lung Carcinoma,Mycophenolate Mofetil (DRUG); Allopurinol (DRUG); Irinotecan (DRUG),135401907,Gotax,Small-cell Lung Cancer; Small Cell Lung Carcinoma,Lung,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2458,NCT01951404,Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study,COMPLETED,PHASE4,End Stage Renal Disease; Left Ventricular Hypertrophy,Allopurinol (DRUG); Placebo (for allopurinol) (DRUG),135401907,Gotax,End Stage Renal Disease; Left Ventricular Hypertrophy,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2459,NCT02579096,CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat,COMPLETED,PHASE4,Gout; Chronic Kidney Diseases,"allopurinol capsule, 100-800 mg by mouth once daily (DRUG); febuxostat tablet 40-120 mg by mouth once daily (DRUG); Placebo, vehicle control (febuxostat-shaped) (DRUG); Placebo, vehicle control (allopurinol-shaped) (DRUG)",135401907,Gotax,Gout; Chronic Kidney Diseases,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2460,NCT04550234,A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol,COMPLETED,PHASE1,Chronic Kidney Disease,Verinurad prolonged release HPMC capsule (DRUG); Allopurinol Tablet (DRUG); Verinurad/Allopurinol FDC Capsule (DRUG); Verinurad prolonged release gelatin Capsule (DRUG),135401907,Gotax,Chronic Kidney Disease,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2461,NCT04532918,Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers,COMPLETED,PHASE1,Chronic Kidney Disease,Verinurad (DRUG); Allopurinol (DRUG); Cyclosporine (DRUG); Rifampicin (DRUG),135401907,Gotax,Chronic Kidney Disease,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2462,NCT05828836,Allopurinol and Quality of Life in Liver Cirrhosis,COMPLETED,PHASE2,"Cirrhosis, Liver",Allopurinol Tablet (DRUG); Placebo (DRUG),135401907,Gotax,Liver Cirrhosis,Liver,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2463,NCT02122718,"XILO-FIST, the Effect of Allopurinol on the Brain Heart and Blood Pressure After Stroke",COMPLETED,PHASE4,Ischaemic Stroke,Allopurinol (DRUG); Placebo (DRUG),135401907,Gotax,Ischaemic Stroke,CNS/Brain,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2464,NCT05545670,Allopurinol to Prevent Cirrhosis Related Morbidities,COMPLETED,PHASE2,Cirrhosis,Placebo (DRUG); Allopurinol 300 MG (DRUG),135401907,Gotax,Cirrhosis,Liver,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2465,NCT03226899,A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment,TERMINATED,PHASE4,Gout; Chronic Kidney Disease (CKD),Lesinurad (DRUG); XOI (DRUG); Placebo (DRUG); colchicine (DRUG); corticosteroids (DRUG),135401907,Gotax,Gout; Chronic Kidney Disease (CKD),Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2466,NCT01332799,Xanthine Oxidase Inhibition in Renal Transplant Recipients,TERMINATED,PHASE4,Complications of Renal Transplant,allopurinol or placebo (DRUG); Placebo (OTHER),135401907,Gotax,Complications of Renal Transplant,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2467,NCT00652899,"Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer",TERMINATED,PHASE2,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,Allopurinol (BIOLOGICAL); Cyclophosphamide (DRUG); Fludarabine phosphate (DRUG); total-body irradiation (RADIATION); Allogeneic natural killer cells (BIOLOGICAL); Aldesleukin (BIOLOGICAL),135401907,Gotax,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2468,NCT05540184,Allopurinol and Trimetazidine as a Preventive of Acute Kidney Injury in PCI Patients,RECRUITING,PHASE4,AKI - Acute Kidney Injury,Trimetazidine 35 mg (DRUG); Allopurinol 300 MG (DRUG); Normal saline (DRUG),135401907,Gotax,AKI - Acute Kidney Injury,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2469,NCT03101800,Beneficial and Harmful Effects of Azathioprine and Allopurinol Versus Standard Azathioprine Therapy for Patients With Ulcerative Colitis,UNKNOWN,PHASE3,"Colitis, Ulcerative; Colitis Ulcerative Exacerbation",Azathioprine and Allopurinol (DRUG); Azathioprine (DRUG),135401907,Gotax,"Colitis, Ulcerative; Colitis Ulcerative Exacerbation",Bowel,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2470,NCT03836599,A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects,COMPLETED,PHASE1,Chronic Kidney Disease,Verinurad (DRUG); Allopurinol (DRUG); Placebo (DRUG),135401907,Gotax,Chronic Kidney Disease,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2471,NCT05365477,Empiric Versus Selective Prevention Strategies for Kidney Stone Disease,RECRUITING,PHASE4,Kidney Stones; Nephrolithiasis,Empiric Therapy: Diet (BEHAVIORAL); Empiric Therapy: Drug (DRUG); Selective Therapy: Diet (BEHAVIORAL); Selective Therapy: Drug (DRUG),135401907,Gotax,Kidney Stones; Nephrolithiasis,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2472,NCT02829177,Microalbuminuria and Allopurinol in Type 1 Diabetes,COMPLETED,PHASE4,Type 1 Diabetes; Diabetic Nephropathy,Allopurinol (DRUG); Placebo (DRUG),135401907,Gotax,Type 1 Diabetes; Diabetic Nephropathy,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2473,NCT03865407,Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease,TERMINATED,PHASE2,Hyperuricemia; Chronic Kidney Diseases,Allopurinol (DRUG),135401907,Gotax,Hyperuricemia; Chronic Kidney Diseases,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2474,NCT02477488,Optimal Administration of Allopurinol in Dialysis Patients,COMPLETED,PHASE4,Gout; Renal Insufficiency,Allopurinol (DRUG),135401907,Gotax,Gout; Renal Insufficiency,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2475,NCT00288171,Allopurinol for Renal Transplant Associated Hypertension in Children,WITHDRAWN,PHASE1,Hypertension; Renal Transplant,Placebo (DRUG); Allopurinol (DRUG),135401907,Gotax,Hypertension; Renal Transplant,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2476,NCT02017171,A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes,COMPLETED,PHASE3,Diabetic Nephropathies; Coronary Artery Disease,Allopurinol (DRUG); Placebo (DRUG),135401907,Gotax,Diabetic Nephropathies; Coronary Artery Disease,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2477,NCT03353298,Lowering Uric Acid in Live Kidney Donors,COMPLETED,PHASE2,Renal Transplant Donor of Left Kidney; Renal Transplant Donor of Right Kidney,Allopurinol 300 mg (DRUG); Placebo Oral Tablet (DRUG),135401907,Gotax,Renal Transplant Donor of Left Kidney; Renal Transplant Donor of Right Kidney,Kidney,Allopurinol,XDH,inhibitor/antagonist,unclear,yes,yes,"Approved for gout treatment, reduces uric acid levels.",C1=NNC2=C1C(=O)NC=N2,1.62,55.0 +2478,NCT03381274,Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study,ACTIVE_NOT_RECRUITING,PHASE1,"Carcinoma, Non-Small-Cell Lung",Oleclumab (BIOLOGICAL); Osimertinib (DRUG); AZD4635 (DRUG),6256,TFT,"Carcinoma, Non-Small-Cell Lung",Lung,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2479,NCT03616574,First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors,COMPLETED,PHASE1,Advanced or Metastatic Solid Tumors; Advanced or Metastatic Colorectal Cancer (mCRC),CA102N (DRUG); LONSURF (DRUG),6256,TFT,Advanced or Metastatic Solid Tumors; Advanced or Metastatic Colorectal Cancer (mCRC),Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2480,NCT01712074,Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil,TERMINATED,PHASE2,Alzheimer's Disease,PF-05212377 (SAM-760) (DRUG); Placebo (OTHER),6256,TFT,Alzheimer's Disease,CNS/Brain,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2481,NCT03844620,Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Refractory Colorectal Carcinoma; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Best Practice (OTHER); Laboratory Procedure (OTHER); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); Regorafenib (DRUG); Trifluridine and Tipiracil Hydrochloride (DRUG),6256,TFT,Refractory Colorectal Carcinoma; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2482,NCT05266820,Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,Thalidomide (DRUG); TAS-102 (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2483,NCT01024231,Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma,COMPLETED,PHASE1,Malignant Melanoma,BMS-936558 (MDX1106-04) (DRUG); Ipilimumab (DRUG),6256,TFT,Malignant Melanoma,Skin,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2484,NCT05223673,Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer,TERMINATED,PHASE3,Metastatic Colorectal Cancer,Futuximab/modotuximab (BIOLOGICAL); Trifluridine/Tipiracil (DRUG); Trifluridine/Tipiracil (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2485,NCT03274882,Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies,COMPLETED,PHASE2,Metastatic Colorectal Cancer,S95005 (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2486,NCT06850090,Neoadjuvant Radiotherapy for Rectal Adenocarcinoma with Capecitabine Versus TAS-102,NOT_YET_RECRUITING,PHASE3,Rectal Cancer; Rectal Cancer Patients,TAS-102 (COMBINATION_PRODUCT); Capecitabine (COMBINATION_PRODUCT),6256,TFT,Rectal Cancer; Rectal Cancer Patients,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2487,NCT03223779,Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer,UNKNOWN,PHASE1,Colorectal Cancer,TAS-102 (DRUG); Photon SBRT (RADIATION),6256,TFT,Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2488,NCT05247684,AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC,UNKNOWN,PHASE2,Resectable Non-small Cell Lung Cancer,AK112 (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Paclitaxel (DRUG),6256,TFT,Resectable Non-small Cell Lung Cancer,Lung,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2489,NCT01621490,PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma,COMPLETED,PHASE1,Advanced Melanoma; Metastatic Melanoma,Nivolumab (BIOLOGICAL); Ipilimumab (DRUG),6256,TFT,Advanced Melanoma; Metastatic Melanoma,Skin,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2490,NCT05919264,FOG-001 in Locally Advanced or Metastatic Solid Tumors,RECRUITING,PHASE1,Cancer; Colorectal Cancer; Solid Tumor; Locally Advanced Solid Tumor; Metastatic Cancer; WNT Pathway; β-catenin; Beta-catenin; Adenomatous Polyposis Coli; APC; HCC; Desmoid; Microsatellite Stable Colorectal Cancer; Metastatic Castration-resistant Prostate Cancer; FAP; Endometrial Carcinoma; Prostate Cancer; Microsatellite Instability-High Colorectal Cancer; CTNNB1; Adamantinomatous Craniopharyngioma,FOG-001 (DRUG); mFOLFOX-6 (DRUG); Nivolumab (DRUG); Trifluridine/tipiracil (DRUG); Bevacizumab (DRUG),6256,TFT,Cancer; Colorectal Cancer; Solid Tumor; Locally Advanced Solid Tumor; Metastatic Cancer; WNT Pathway; β-catenin; Beta-catenin; Adenomatous Polyposis Coli; APC; HCC; Desmoid; Microsatellite Stable Colorectal Cancer; Metastatic Castration-resistant Prostate Cancer; FAP; Endometrial Carcinoma; Prostate Cancer; Microsatellite Instability-High Colorectal Cancer; CTNNB1; Adamantinomatous Craniopharyngioma,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2491,NCT04868773,Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy,ACTIVE_NOT_RECRUITING,PHASE1,Colorectal Cancer; Colorectal Carcinoma; Metastatic Cancer; CRC,Cabozantinib (DRUG); TAS-102 (DRUG),6256,TFT,Colorectal Cancer; Colorectal Carcinoma; Metastatic Cancer; CRC,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2492,NCT05965531,Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy,RECRUITING,PHASE2,Rectal Cancer,Trifluridine/Tipiracil (DRUG); intensity-modulated radiotherapy (RADIATION),6256,TFT,Rectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2493,NCT04660760,Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer,RECRUITING,PHASE2,Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Gastric Cancer AJCC v8; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Locally Advanced Unresectable Gastric Adenocarcinoma; Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Pathologic Stage III Gastric Cancer AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Gastric Cancer AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Gastric Cancer AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIC Gastric Cancer AJCC v8; Pathologic Stage IV Gastric Cancer AJCC v8; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8,Paclitaxel (DRUG); Quality-of-Life Assessment (OTHER); Ramucirumab (BIOLOGICAL); Trifluridine and Tipiracil Hydrochloride (DRUG),6256,TFT,Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Gastric Cancer AJCC v8; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Locally Advanced Unresectable Gastric Adenocarcinoma; Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Pathologic Stage III Gastric Cancer AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Gastric Cancer AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Gastric Cancer AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIC Gastric Cancer AJCC v8; Pathologic Stage IV Gastric Cancer AJCC v8; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8,Esophagus/Stomach,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2494,NCT05130060,A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer,COMPLETED,PHASE1,Metastatic Colon Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Colorectal Carcinoma; Metastatic Microsatellite Stable Colon Carcinoma; Metastatic Microsatellite Stable Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Microsatellite Stable Rectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Colorectal Cancer Peptide Vaccine PolyPEPI1018 (BIOLOGICAL); Trifluridine and Tipiracil Hydrochloride (DRUG),6256,TFT,Metastatic Colon Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Colorectal Carcinoma; Metastatic Microsatellite Stable Colon Carcinoma; Metastatic Microsatellite Stable Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Microsatellite Stable Rectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2495,NCT05029882,Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab,ACTIVE_NOT_RECRUITING,PHASE1,Non-Small Cell Lung Cancer; Advanced Solid Tumors; Gastroesophageal Adenocarcinoma; Colorectal Cancer,ABBV-400 (DRUG); Trifluridine/Tipiracil (DRUG); Bevacizumab (DRUG),6256,TFT,Non-Small Cell Lung Cancer; Advanced Solid Tumors; Gastroesophageal Adenocarcinoma; Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2496,NCT05468892,Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial,COMPLETED,PHASE2,Metastatic Colon Cancer,Trifluridine Tipiracil (DRUG); Panitumumab 20 MG/1 ML Intravenous Solution [VECTIBIX] (DRUG),6256,TFT,Metastatic Colon Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2497,NCT05806931,Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer,RECRUITING,PHASE2,Colon Cancer; Rectal Cancer,"TAS-102, oxaliplatin, irinotecan with bevacizumab (DRUG)",6256,TFT,Colon Cancer; Rectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2498,NCT03799731,Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers,COMPLETED,PHASE2,Colorectal Cancer,GM102 (DRUG); Trifluridine/Tipiracil (DRUG); GM102 expansion (DRUG),6256,TFT,Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2499,NCT05927857,"Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .",NOT_YET_RECRUITING,PHASE1,Metastatic Gastric Adenocarcinoma; Second Line; Chemotherapy,nal-IRI /Experimental (DRUG); Ramucirumab /Experimental (DRUG); Trifluridine/Tipiracil /Experimental (DRUG),6256,TFT,Gastric and Gastroesophageal Junction Cancer,Esophagus/Stomach,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2500,NCT04776148,Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017),COMPLETED,PHASE3,Colorectal Neoplasms,pembrolizumab (DRUG); lenvatinib (DRUG); regorafenib (DRUG); TAS-102 (trifluridine and tipiracil) (DRUG),6256,TFT,Colorectal Neoplasms,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2501,NCT06222125,A Study of HB0025 Injection in Patients With Advanced Renal Cancer,RECRUITING,PHASE2,Renal Cancer,HB0025 (DRUG),6256,TFT,Renal Cancer,Kidney,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2502,NCT06197425,Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer,NOT_YET_RECRUITING,PHASE3,Colon or Upper Rectum Adenocarcinoma,"""FOLFIRI"" cures (DRUG); Trifluridine cures (DRUG); BIOLOGICAL ASSESSMENT (BIOLOGICAL); Questionnaires (OTHER); Thoracic-abdomino-pelvic scan or MRI (OTHER)",6256,TFT,Colon Adenocarcinoma,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2503,NCT04104139,TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Rectal Adenocarcinoma; Stage IIA Rectal Cancer AJCC v8; Stage IIB Rectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Rectal Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8,3-Dimensional Conformal Radiation Therapy (RADIATION); Intensity-Modulated Radiation Therapy (RADIATION); Trifluridine and Tipiracil Hydrochloride (DRUG),6256,TFT,Rectal Adenocarcinoma; Stage IIA Rectal Cancer AJCC v8; Stage IIB Rectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Rectal Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2504,NCT03168139,Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer,COMPLETED,PHASE1,Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer,Olaptesed pegol - Monotherapy (DRUG); Olaptesed pegol + Pembrolizumab - Combination Therapy (DRUG),6256,TFT,Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2505,NCT05077839,Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC,RECRUITING,PHASE2,First-line Treatment; Advanced Colorectal Cancer,Trifluridine/Tipiracil (DRUG),6256,TFT,First-line Treatment; Advanced Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2506,NCT06563986,"FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer",RECRUITING,PHASE2,Metastatic Colorectal Cancer,Systemic treatment (FTD-TPI and bevacizumab) (DRUG); Radioembolization with 166-Ho microspheres (DEVICE),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2507,NCT06680622,"Bemarituzumab in FGFR2b+ Patients with Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed At Least One Prior Line of Palliative Chemotherapy",RECRUITING,PHASE2,Metastatic Gastro-esophageal Adenocarcinoma,"bemarituzumab, paclitaxel, ramucirumab (DRUG); bemarituzumab, irinotecan (DRUG); bemarituzumab, trifluridine/tipiracil (DRUG)",6256,TFT,Metastatic Gastro-esophageal Adenocarcinoma,Esophagus/Stomach,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2508,NCT03470922,A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma,ACTIVE_NOT_RECRUITING,PHASE2,Melanoma,Relatlimab (BIOLOGICAL); Nivolumab (BIOLOGICAL),6256,TFT,Melanoma,Skin,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2509,NCT05476796,"Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer",RECRUITING,PHASE2,Gastric Adenocarcinoma; Esophagus Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma,Trifluridine/Tipiracil (DRUG); Oxaliplatin (DRUG); FOLFOX regimen (DRUG); Nivolumab (DRUG),6256,TFT,Gastric Adenocarcinoma; Esophagus Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2510,NCT04059562,Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma,COMPLETED,PHASE2,Cholangiocarcinoma,Combination of Lonsurf® and Irinotecan (COMBINATION_PRODUCT),6256,TFT,Cholangiocarcinoma,Liver,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2511,NCT06614192,A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer,RECRUITING,PHASE3,Metastatic Colorectal Cancer,ABBV-400 (DRUG); Trifluridine/Tipiracil (DRUG); Bevacizumab (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2512,NCT05062889,Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients,RECRUITING,PHASE2,Stage II Colon Cancer; Stage III Colon Cancer; HER2-positive Colon Cancer; RAS Wild-type Colon Cancer,5-Fluorouracil continuous infusion FOLFOXIRI schedule (DRUG); 5-Fluorouracil bolus FOLFOX schedule (DRUG); 5-Fluorouracil continuous infusion FOLFOX schedule (DRUG); Oxaliplatin FOLFOX and FOLFOXIRI schedule (DRUG); Oxaliplatin CAPOX schedule (DRUG); L-Leucovorin (DRUG); Capecitabine (DRUG); Irinotecan (DRUG); Trifluridine/Tipiracil (DRUG); Trastuzumab (DRUG); Tucatinib (DRUG),6256,TFT,Colon Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2513,NCT03306394,A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).,COMPLETED,PHASE3,Metastatic Colorectal Cancer,Trifluridine/Tipiracil hydrochloride (S95005) (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2514,NCT03195491,A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia,COMPLETED,PHASE3,Lung Cancer; Non-Small Cell Lung Cancer,Nivolumab (BIOLOGICAL),6256,TFT,Lung Cancer; Non-Small Cell Lung Cancer,Lung,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2515,NCT03974594,Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients,COMPLETED,PHASE1,Colorectal Cancer,Trifluridine and Tipiracil Tablets (DRUG); TAS-102 (DRUG),6256,TFT,Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2516,NCT04645160,Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers,RECRUITING,PHASE1,Cholangiocarcinoma; Bile Duct Neoplasm; Biliary Tract Malignancy,Tivozanib (DRUG),6256,TFT,Cholangiocarcinoma; Bile Duct Neoplasm; Biliary Tract Malignancy,Liver,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2517,NCT04808791,iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma,COMPLETED,PHASE2,Gastroesophageal Junction Adenocarcinoma; Advanced Gastric Carcinoma,Irinotecan (DRUG); Oxaliplatin (DRUG); TAS 102 (Trifluridine/Tipiracil) (DRUG),6256,TFT,Gastroesophageal Junction Adenocarcinoma; Advanced Gastric Carcinoma,Esophagus/Stomach,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2518,NCT03031691,A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer,COMPLETED,PHASE1,Metastatic Colorectal Cancer,brontictuzumab (DRUG); trifluridine/tipiracil (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2519,NCT06764680,"Oral Chemotherapy, Targeted Therapy and Immunotherapy With/without Radiotherapy As 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer",NOT_YET_RECRUITING,PHASE2,"Colorectal Cancer Metastatic; Chemotherapy; Targeted Therapy; Immunotherapy; Radiotherapy, Intensity-Modulated",Trifluorouracil tepidopyrimidine (DRUG); Bevacizumab (DRUG); Sindilizumab (DRUG); IMRT (RADIATION),6256,TFT,"Colorectal Cancer Metastatic; Chemotherapy; Targeted Therapy; Immunotherapy; Radiotherapy, Intensity-Modulated",Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2520,NCT06873763,Nelmastobart in Combination with Trifluridine/Tipiracil and Bevacizumab in Metastatic/Recurrent Colorectal Cancer,NOT_YET_RECRUITING,PHASE1,Metastatic Colorectal Cancer (CRC); Recurrent Colorectal Cancer,Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab (DRUG),6256,TFT,Metastatic Colorectal Cancer (CRC); Recurrent Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2521,NCT03368963,TAS102 in Combination With NAL-IRI in Advanced GI Cancers,ACTIVE_NOT_RECRUITING,PHASE1,Colorectal Adenocarcinoma; Gastric Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Non-Resectable Cholangiocarcinoma; Stage IV Colorectal Cancer; Stage IV Gastric Cancer; Stage IV Pancreatic Cancer; Stage IVA Colorectal Cancer; Stage IVB Colorectal Cancer; Stage III Colorectal Cancer; Stage III Gastric Cancer; Stage III Pancreatic Cancer; Unresectable Digestive System Adenocarcinoma; Unresectable Pancreatic Carcinoma,Nanoliposomal Irinotecan (DRUG); Trifluridine and Tipiracil Hydrochloride (DRUG),6256,TFT,Colorectal Adenocarcinoma; Gastric Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Non-Resectable Cholangiocarcinoma; Stage IV Colorectal Cancer; Stage IV Gastric Cancer; Stage IV Pancreatic Cancer; Stage IVA Colorectal Cancer; Stage IVB Colorectal Cancer; Stage III Colorectal Cancer; Stage III Gastric Cancer; Stage III Pancreatic Cancer; Unresectable Digestive System Adenocarcinoma; Unresectable Pancreatic Carcinoma,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2522,NCT03190616,Apatinib in Refractory Colorectal Cancer,COMPLETED,PHASE2,Colorectal Neoplasms,apatinib (DRUG),6256,TFT,Colorectal Neoplasms,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2523,NCT04511039,Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer,RECRUITING,PHASE1,Advanced Malignant Solid Neoplasm; Clinical Stage III Gastroesophageal Junction Adenocarcinoma; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A; Locally Advanced Colorectal Carcinoma; Locally Advanced Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Trifluridine and Tipiracil Hydrochloride (DRUG); Talazoparib Tosylate (DRUG),6256,TFT,Advanced Malignant Solid Neoplasm; Clinical Stage III Gastroesophageal Junction Adenocarcinoma; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A; Locally Advanced Colorectal Carcinoma; Locally Advanced Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2524,NCT04149444,A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer,WITHDRAWN,PHASE2,Metastatic Triple Negative Breast Cancer,Trifluridine/Tipiracil (DRUG),6256,TFT,Metastatic Triple Negative Breast Cancer,Breast,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2525,NCT03084640,Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma,COMPLETED,PHASE1,Malignant Melanoma,CMP-001 (DRUG); Pembrolizumab (DRUG); CMP-001 (DRUG),6256,TFT,Malignant Melanoma,Skin,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2526,NCT01297244,A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma,COMPLETED,PHASE2,Renal Cell Carcinoma,Tivozanib (DRUG),6256,TFT,Renal Cell Carcinoma,Kidney,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2527,NCT05608044,A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Colorectal Cancer,Botensilimab (DRUG); Balstilimab (DRUG); Standard of Care (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2528,NCT04166604,LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Colorectal Cancer,Trifluridine/Tipiracil (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2529,NCT04075604,A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Cancer,Nivolumab (BIOLOGICAL); Anastrozole (DRUG); Palbociclib (DRUG),6256,TFT,Breast Cancer; Cancer,Breast,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2530,NCT06202001,"Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients",RECRUITING,PHASE1,Metastatic Colorectal Cancer,"Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab (DRUG)",6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2531,NCT06607458,Evaluation of the Safety and Efficacy of Treatment W/High Dose Melphalan Given Directly Into the Liver Followed by Treatment W/approved Cancer Treatment or Approved Cancer Treatment Alone in Patients W/ Metastatic Colorectal Cancer W/liver Dominant Disease,NOT_YET_RECRUITING,PHASE2,Refractory Metastatic Colorectal Cancer,Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab (DRUG); Trifluridine-tipiracil plus Bevacizumab Alone (DRUG),6256,TFT,Refractory Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2532,NCT05155124,Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC,UNKNOWN,PHASE1,Colorectal Neoplasms Malignant,Cetuximab + trifluridin tipiracil (DRUG),6256,TFT,Colorectal Neoplasms Malignant,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2533,NCT03869892,Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.,ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Colorectal Cancer,Trifluridine/tipiracil hydrochloride (S95005) (DRUG); Capecitabine (DRUG); Bevacizumab experimental (BIOLOGICAL); Bevacizumab control (BIOLOGICAL),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2534,NCT02602327,Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases,COMPLETED,PHASE1,Colon Cancer; Rectal Cancer; Liver Metastases,Tas-102 (DRUG); SIR-Sphere (DEVICE),6256,TFT,Colon Cancer; Rectal Cancer; Liver Metastases,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2535,NCT04489173,"TAS102 in Patients with ER-positive, HER2-negative Advanced Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Breast Neoplasm; Chemotherapy Effect,trifluridine/tipiracil (DRUG),6256,TFT,Breast Neoplasm; Chemotherapy Effect,Breast,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2536,NCT02320058,"An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself",COMPLETED,PHASE2,Melanoma,Ipilimumab (DRUG); Nivolumab (DRUG),6256,TFT,Melanoma,Skin,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2537,NCT06060704,Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.,RECRUITING,PHASE2,Metastatic Colorectal Cancer,Envafolimab (DRUG); Trifluridine/Tipiracil (DRUG); Bevacizumab (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2538,NCT03349710,"Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer",COMPLETED,PHASE3,Squamous Cell Carcinoma of the Head and Neck,Nivolumab (BIOLOGICAL); Cetuximab (DRUG); Cisplatin (DRUG); Radiotherapy (RADIATION),6256,TFT,Squamous Cell Carcinoma of the Head and Neck,Skin,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2539,NCT06242067,Second-line Treatment of Metastatic Colorectal Cancer,RECRUITING,PHASE2,Metastatic Colorectal Cancer,Trifluridine/tipiracil (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2540,NCT02088112,MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).,COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung",Gefitinib (DRUG); MEDI4736 (DRUG),6256,TFT,"Carcinoma, Non-Small-Cell Lung",Lung,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2541,NCT04879368,RegoNivo vs Standard of Care Chemotherapy in AGOC,ACTIVE_NOT_RECRUITING,PHASE3,Gastro-Oesophageal Cancer,Regorafenib (DRUG); Nivolumab (BIOLOGICAL); Docetaxel (DRUG); Paclitaxel (DRUG); Irinotecan (DRUG); Trifluridine/Tipracil (DRUG),6256,TFT,Gastric Cancer,Esophagus/Stomach,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2542,NCT04109924,"TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study",ACTIVE_NOT_RECRUITING,PHASE2,Advanced Colorectal Carcinoma; Metastatic Colon Adenocarcinoma; Metastatic Rectal Adenocarcinoma; Recurrent Colon Adenocarcinoma; Recurrent Colorectal Adenocarcinoma; Recurrent Rectal Adenocarcinoma; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Colon Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Colon Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Rectal Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Rectal Cancer AJCC v8; Stage IVC Colon Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage IVC Rectal Cancer AJCC v8; Unresectable Colon Adenocarcinoma; Unresectable Colorectal Carcinoma; Unresectable Rectal Adenocarcinoma,Irinotecan (DRUG); Bevacizumab (BIOLOGICAL); Trifluridine and Tipiracil Hydrochloride (DRUG),6256,TFT,Advanced Colorectal Carcinoma; Metastatic Colon Adenocarcinoma; Metastatic Rectal Adenocarcinoma; Recurrent Colon Adenocarcinoma; Recurrent Colorectal Adenocarcinoma; Recurrent Rectal Adenocarcinoma; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Colon Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Colon Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Rectal Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Rectal Cancer AJCC v8; Stage IVC Colon Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage IVC Rectal Cancer AJCC v8; Unresectable Colon Adenocarcinoma; Unresectable Colorectal Carcinoma; Unresectable Rectal Adenocarcinoma,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2543,NCT03296917,Study Examining PrEP-001 in Subjects With Asthma,COMPLETED,PHASE2,Asthma,PrEP-001 (DRUG); G-004 (DRUG),6256,TFT,Asthma,Lung,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2544,NCT05343013,TAS-102 in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy,SUSPENDED,PHASE2,Colorectal Cancer,TAS-102 (DRUG),6256,TFT,Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2545,NCT06485713,Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC,RECRUITING,PHASE2,Metastatic Colorectal Cancer; Drug Therapy,trifluridine/tipiracil combined with fufuquitinib (DRUG); fufuquitinib (DRUG); Trifluridine/tipiracil (DRUG),6256,TFT,Metastatic Colorectal Cancer; Drug Therapy,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2546,NCT06522919,Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer,RECRUITING,PHASE2,Colorectal Cancer Metastatic; Microsatellite Stable Colorectal Carcinoma; Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer,Autologous Dendritic Cell (DC) Vaccine (BIOLOGICAL),6256,TFT,Colorectal Cancer Metastatic; Microsatellite Stable Colorectal Carcinoma; Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2547,NCT04854434,A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations,TERMINATED,PHASE2,Metastatic Colorectal Cancer,Selinexor (DRUG); Pembrolizumab (DRUG); Trifluridine (DRUG); Tipiracil (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2548,NCT02935634,A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer,COMPLETED,PHASE2,Advanced Gastric Cancer,Nivolumab (BIOLOGICAL); Ipilimumab (BIOLOGICAL); Relatlimab (BIOLOGICAL); BMS-986205 (BIOLOGICAL); Rucaparib (DRUG),6256,TFT,Advanced Gastric Cancer,Esophagus/Stomach,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2549,NCT05198934,Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation,ACTIVE_NOT_RECRUITING,PHASE3,Colorectal Cancer (CRC),Sotorasib (DRUG); Panitumumab (DRUG); Trifluridine and Tipiracil (DRUG); Regorafenib (DRUG),6256,TFT,Colorectal Cancer (CRC),Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2550,NCT05551741,A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD),ACTIVE_NOT_RECRUITING,PHASE1,Alzheimer's Disease,IBC-Ab002 (BIOLOGICAL); Placebo (OTHER),6256,TFT,Alzheimer's Disease,CNS/Brain,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2551,NCT03317119,"Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery",COMPLETED,PHASE1,Metastatic Colon Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Carcinoma; RAS Family Gene Mutation; Stage III Colon Cancer AJCC v7; Stage III Colorectal Cancer AJCC v7; Stage III Rectal Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIA Colorectal Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIB Colorectal Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7; Stage IIIC Colorectal Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Colon Cancer AJCC v7; Stage IV Colorectal Cancer AJCC v7; Stage IV Rectal Cancer AJCC v7; Stage IVA Colon Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Colon Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7,Laboratory Biomarker Analysis (OTHER); Trametinib (DRUG); Trifluridine and Tipiracil Hydrochloride (DRUG),6256,TFT,Metastatic Colon Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Carcinoma; RAS Family Gene Mutation; Stage III Colon Cancer AJCC v7; Stage III Colorectal Cancer AJCC v7; Stage III Rectal Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIA Colorectal Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIB Colorectal Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7; Stage IIIC Colorectal Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Colon Cancer AJCC v7; Stage IV Colorectal Cancer AJCC v7; Stage IV Rectal Cancer AJCC v7; Stage IVA Colon Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Colon Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2552,NCT06887218,5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer,NOT_YET_RECRUITING,PHASE2,Metastatic Colorectal Cancer (CRC),Regorafenib (BAY 73-4506) (DRUG); 5FU/LV (DRUG); Bevacizumab (DRUG); Trifluridine-tipiracil (DRUG),6256,TFT,Metastatic Colorectal Cancer (CRC),Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2553,NCT03297710,"TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery",COMPLETED,PHASE1,Rectal Adenocarcinoma; Recurrent Rectal Carcinoma; Stage IV Rectal Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7,Quality-of-Life Assessment (OTHER); Radiation Therapy (RADIATION); Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102 (DRUG),6256,TFT,Rectal Adenocarcinoma; Recurrent Rectal Carcinoma; Stage IV Rectal Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2554,NCT03717038,Sym004 Versus TAS-102 in Patients With mCRC,WITHDRAWN,PHASE3,Metastatic Colorectal Cancer; Colorectal Cancer Metastatic; Carcinoma,Sym004 (DRUG); TAS-102 (DRUG),6256,TFT,Metastatic Colorectal Cancer; Colorectal Cancer Metastatic; Carcinoma,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2555,NCT05328908,A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Colorectal Neoplasms,Nivolumab-relatlimab FDC (DRUG); Regorafenib (DRUG); TAS-102 (DRUG),6256,TFT,Colorectal Neoplasms,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2556,NCT04894123,Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients,TERMINATED,PHASE2,Colorectal Adenocarcinoma; Oesogastric,Trifluridine/Tipiracil (DRUG); Oxaliplatin (DRUG),6256,TFT,Colorectal Adenocarcinoma; Oesogastric,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2557,NCT06293014,TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer,RECRUITING,PHASE2,Colorectal Cancer,TAS-102+bevacizumab (DRUG); Standard chemotherapy+bevacizumab (DRUG),6256,TFT,Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2558,NCT03981614,Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Unresectable Carcinoma,Binimetinib (DRUG); Palbociclib (DRUG); Trifluridine and Tipiracil Hydrochloride (DRUG),6256,TFT,Metastatic Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Unresectable Carcinoma,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2559,NCT04074343,TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma,COMPLETED,PHASE1,Gastric Adenocarcinoma; GastroEsophageal Cancer,TAS-102 (DRUG); Irinotecan (DRUG),6256,TFT,Gastric Adenocarcinoma; GastroEsophageal Cancer,Esophagus/Stomach,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2560,NCT02848443,Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer,COMPLETED,PHASE1,Metastatic Colorectal Cancer,Trifluridine/tipiracil hydrochloride (S 95005) (DRUG); Oxaliplatin (DRUG); Bevacizumab (DRUG); Nivolumab (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2561,NCT03347838,Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers,ACTIVE_NOT_RECRUITING,PHASE2,Bronchial Dysplasia; Tobacco Smoking; History of Non-Small Cell Lung Cancer; History of Head and Neck Cancer,Nivolumab (DRUG),6256,TFT,Bronchial Dysplasia; Tobacco Smoking; History of Non-Small Cell Lung Cancer; History of Head and Neck Cancer,Lung,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2562,NCT04096638,Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors,COMPLETED,PHASE1,Melanoma; Head and Neck Squamous Cell Carcinoma; Solid Tumor,SB 11285 (DRUG); Atezolizumab (DRUG),6256,TFT,Melanoma; Head and Neck Squamous Cell Carcinoma; Solid Tumor,Skin,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2563,NCT04280536,Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA),UNKNOWN,PHASE1,Breast Cancer,Cohort A (DRUG); Cohort B (DRUG),6256,TFT,Breast Cancer,Breast,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2564,NCT06699836,A Phase 2 Study of Leronlimab in Combination with TAS-102 + Bevacizumab in Previously Treated Participants with MCRC,NOT_YET_RECRUITING,PHASE2,Metastatic Colorectal Cancer (mCRC),350 mg leronlimab (DRUG); 700 mg leronlimab (DRUG),6256,TFT,Metastatic Colorectal Cancer (mCRC),Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2565,NCT04450836,Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer,TERMINATED,PHASE2,Metastatic Colorectal Cancer,Regorafenib then Trifluridine/Tipiracil (DRUG); Trifluridine/Tipiracil then Regorafenib (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2566,NCT02014636,Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018),COMPLETED,PHASE1,"Carcinoma, Renal Cell",Pazopanib (DRUG); MK-3475 (DRUG),6256,TFT,"Carcinoma, Renal Cell",Kidney,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2567,NCT06872606,"Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer",NOT_YET_RECRUITING,PHASE2,Rectal Adenocarcinoma,Pucotenlimab (DRUG); Bevacizumab (DRUG); Oxaliplatin (DRUG); Trifluridine/Tipiracil Hydrochloride (DRUG); Short-course radiotherapy (RADIATION); intracavitary brachytherapy (RADIATION),6256,TFT,Rectal Adenocarcinoma,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2568,NCT06379399,Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC,RECRUITING,PHASE1,Colorectal Cancer Metastatic,Cetuximab (DRUG); Trifluridine/Tipiracil (DRUG),6256,TFT,Colorectal Cancer Metastatic,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2569,NCT03278106,TAS-102 in Treating Advanced Biliary Tract Cancers,COMPLETED,PHASE2,Cholangiocarcinoma; Stage III Gallbladder Cancer AJCC v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVB Gallbladder Cancer AJCC v7,Laboratory Biomarker Analysis (OTHER); Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102 (DRUG),6256,TFT,Cholangiocarcinoma; Stage III Gallbladder Cancer AJCC v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVB Gallbladder Cancer AJCC v7,Liver,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2570,NCT06039202,Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer,NOT_YET_RECRUITING,PHASE2,Metastatic Colorectal Cancer,CA102N (DRUG); TAS-102 (DRUG); Bevacizumab (BIOLOGICAL),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2571,NCT02511184,Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients,TERMINATED,PHASE1,ALK-positive Advanced NSCLC,Crizotinib (DRUG); Pembrolizumab (DRUG),6256,TFT,Non-small Cell Lung Cancer (NSCLC),Lung,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2572,NCT01668784,Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025),COMPLETED,PHASE3,Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma,Nivolumab (BIOLOGICAL); Everolimus (DRUG),6256,TFT,Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma,Kidney,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2573,NCT02743221,A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Trifluridine/tipiracil + bevacizumab (DRUG); Capecitabine + bevacizumab (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2574,NCT04177602,Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial,TERMINATED,PHASE1,Locally Advanced Rectal Cancer,Trifluridine/tipiracil chemoradiation (COMBINATION_PRODUCT); Capecitabine based chemoradiation (COMBINATION_PRODUCT),6256,TFT,Rectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2575,NCT04797702,Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer.,UNKNOWN,PHASE1,Relapsed or Metastatic Non-small Cell Lung Cancer,Glumetinib combined with Toripalimab (COMBINATION_PRODUCT),6256,TFT,Relapsed or Metastatic Non-small Cell Lung Cancer,Lung,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2576,NCT04294264,TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Colorectal Carcinoma; Recurrent Colon Carcinoma; Refractory Colorectal Carcinoma; Stage IV Colon Cancer AJCC v7; Stage IVA Colon Cancer AJCC v7; Stage IVB Colon Cancer AJCC v7,Oxaliplatin (DRUG); Trifluridine and Tipiracil Hydrochloride (DRUG),6256,TFT,Metastatic Colorectal Carcinoma; Recurrent Colon Carcinoma; Refractory Colorectal Carcinoma; Stage IV Colon Cancer AJCC v7; Stage IVA Colon Cancer AJCC v7; Stage IVB Colon Cancer AJCC v7,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2577,NCT02017717,A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients,COMPLETED,PHASE3,Recurrent Glioblastoma,Nivolumab (BIOLOGICAL); Bevacizumab (BIOLOGICAL); Ipilimumab (BIOLOGICAL),6256,TFT,Recurrent Glioblastoma,CNS/Brain,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2578,NCT00085917,Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients,COMPLETED,PHASE2,Hepatitis C; HIV Infections,Double dose pegylated interferon with weight based Ribavirin (DRUG); standard dose pegylated interferon alfa -2a and ribavirin (DRUG),6256,TFT,Hepatitis C; HIV Infections,Liver,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2579,NCT03336216,A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer,COMPLETED,PHASE2,Advanced Pancreatic Cancer,Cabiralizumab (BIOLOGICAL); Nab-paclitaxel (DRUG); Onivyde (DRUG); Nivolumab (BIOLOGICAL); Fluorouracil (DRUG); Gemcitabine (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); Irinotecan Hydrochloride (DRUG),6256,TFT,Advanced Pancreatic Cancer,Pancreas,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2580,NCT06343116,Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer,NOT_YET_RECRUITING,PHASE3,Refractory Metastatic Colorectal Cancer,Nimotuzumab injection (DRUG); Placebo (DRUG); Trifluridine/tipiracil (DRUG),6256,TFT,Refractory Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2581,NCT06930118,"The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.",RECRUITING,PHASE2,Advanced Colorectal Cancer in the Third-line Treatment and Beyond; pMMR/MSS Advanced Colorectal Cancer,"chidamide, regorafenib, and iparomlimab/tuvonralimab (DRUG)",6256,TFT,Advanced Colorectal Cancer in the Third-line Treatment and Beyond; pMMR/MSS Advanced Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2582,NCT03662659,An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers,COMPLETED,PHASE2,Gastric Cancer; Cancer of the Stomach; Esophagogastric Junction,BMS-986213 (BIOLOGICAL); Nivolumab (BIOLOGICAL); XELOX (DRUG); FOLFOX (DRUG); SOX (DRUG),6256,TFT,Gastric Cancer; Cancer of the Stomach; Esophagogastric Junction,Esophagus/Stomach,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2583,NCT05064059,A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007),COMPLETED,PHASE3,Colorectal Cancer,favezelimab/pembrolizumab (BIOLOGICAL); regorafenib (DRUG); TAS-102 (DRUG),6256,TFT,Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2584,NCT06730100,CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer,NOT_YET_RECRUITING,PHASE2,Metastatic Microsatellite Stable Colorectal Carcinoma; Refractory Microsatellite Stable Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); pH Low Insertion Peptide-exatecan Conjugate CBX-12 (DRUG); X-Ray Imaging (PROCEDURE),6256,TFT,Metastatic Microsatellite Stable Colorectal Carcinoma; Refractory Microsatellite Stable Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2585,NCT02659059,Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small-Cell Lung Cancer,Nivolumab (BIOLOGICAL); Ipilimumab (BIOLOGICAL); Platinum Doublet Chemotherapy (DRUG),6256,TFT,Non-Small-Cell Lung Cancer,Lung,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2586,NCT00887536,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",COMPLETED,PHASE3,Breast Cancer,bevacizumab (DRUG); docetaxel (DRUG); doxorubicin (DRUG); cyclophosphamide (DRUG); pegfilgrastim (DRUG),6256,TFT,Breast Cancer,Breast,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2587,NCT04920032,Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas,RECRUITING,PHASE1,Colon Adenocarcinoma; Colorectal Cancer,TAS-102 (DRUG); Irinotecan (DRUG); Standard Treatment (COMBINATION_PRODUCT); Signatera MRD ctDNA Assay (DIAGNOSTIC_TEST),6256,TFT,Colon Adenocarcinoma; Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2588,NCT00321932,Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant,COMPLETED,PHASE2,Leukemia; Lymphoma; Myelodysplastic Syndromes; Osteoporosis; Ovarian Cancer,calcium (DIETARY_SUPPLEMENT); cholecalciferol (DIETARY_SUPPLEMENT); zoledronic acid (DRUG),6256,TFT,Leukemia; Lymphoma; Myelodysplastic Syndromes; Osteoporosis; Ovarian Cancer,Ovary/Fallopian Tube,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2589,NCT04073615,A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC),TERMINATED,PHASE1,Metastatic Colorectal Cancer,Rivoceranib (DRUG); Trifluridine/Tipiracil (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2590,NCT04737187,Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients,COMPLETED,PHASE3,Refractory Metastatic Colorectal Cancer,Trifluridine/Tipiracil (DRUG); Bevacizumab (DRUG),6256,TFT,Refractory Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2591,NCT03992456,"Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Colon Adenocarcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Colon Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIA Rectal Cancer AJCC v8; Stage IIIB Colon Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Colon Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Stage IVA Colon Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Rectal Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Rectal Cancer AJCC v8; Stage IVC Colon Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage IVC Rectal Cancer AJCC v8; Unresectable Colon Adenocarcinoma; Unresectable Colorectal Carcinoma; Unresectable Rectal Adenocarcinoma,Panitumumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); Regorafenib (DRUG); Trifluridine and Tipiracil Hydrochloride (DRUG),6256,TFT,Metastatic Colon Adenocarcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Colon Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIA Rectal Cancer AJCC v8; Stage IIIB Colon Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Colon Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Stage IVA Colon Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Rectal Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Rectal Cancer AJCC v8; Stage IVC Colon Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage IVC Rectal Cancer AJCC v8; Unresectable Colon Adenocarcinoma; Unresectable Colorectal Carcinoma; Unresectable Rectal Adenocarcinoma,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2592,NCT01955837,Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia,COMPLETED,PHASE3,Colorectal Cancer,TAS-102 (DRUG); Placebo (DRUG),6256,TFT,Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2593,NCT05201352,"Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine",RECRUITING,PHASE1,Metastatic Colorectal Cancer,trifluridine/tipiracil + XB2001 (DRUG); trifluridine/tipiracil + placebo (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2594,NCT05007132,Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer,RECRUITING,PHASE2,Metastatic Colorectal Cancer,Panitumumab 20 milligram/ML (BIOLOGICAL); Bevacizumab (BIOLOGICAL); Trifluridine/Tipiracil Hydrochloride (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2595,NCT06856837,- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases,NOT_YET_RECRUITING,PHASE2,Metastatic Colorectal Cancer,Fruquintinib (DRUG); Tislelizumab (DRUG); Trifluridine/tipiracil (DRUG); Bevacizumab (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2596,NCT01896856,Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer,COMPLETED,PHASE1,Previously Treated Metastatic Colorectal Cancer,SGI-110 Dose Escalation (DRUG); Regorafenib (DRUG); TAS-102 (DRUG); SGI-110 (DRUG); Irinotecan (DRUG),6256,TFT,Previously Treated Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2597,NCT05600309,A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study,COMPLETED,PHASE3,Colorectal Cancer,favezelimab/pembrolizumab (BIOLOGICAL); regorafenib (DRUG); TAS-102 (DRUG),6256,TFT,Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2598,NCT01252251,RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma,COMPLETED,PHASE2,Uveal Melanoma,RAD001 (Everolimus) and Pasireotide (SOM230) LAR (DRUG),6256,TFT,Uveal Melanoma,Skin,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2599,NCT03271047,Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation,COMPLETED,PHASE2,MSS; RAS-mutant Colorectal Cancer,binimetinib (DRUG); nivolumab (DRUG); ipilimumab (DRUG),6256,TFT,MSS; RAS-mutant Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2600,NCT05278351,Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC,RECRUITING,PHASE2,Colorectal Neoplasms Malignant,Tislelizumab Combined With Cetuximab and Irinotecan (DRUG); Third-line regimens (DRUG),6256,TFT,Colorectal Neoplasms Malignant,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2601,NCT04567615,A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors,ACTIVE_NOT_RECRUITING,PHASE2,"Hepatocellular Carcinoma; Hepatoma; Liver Cancer, Adult; Liver Cell Carcinoma; Liver Cell Carcinoma, Adult",Nivolumab (BIOLOGICAL); Relatlimab (BIOLOGICAL),6256,TFT,"Hepatocellular Carcinoma; Hepatoma; Liver Cancer, Adult; Liver Cell Carcinoma; Liver Cell Carcinoma, Adult",Liver,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2602,NCT05508737,Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Gastric and Gastroesophageal Junction Adenocarcinoma,"Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®) (DRUG)",6256,TFT,Gastric and Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2603,NCT06882915,"Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study",NOT_YET_RECRUITING,PHASE1,Colorectal Cancer (CRC),Trifluridine/tipiracil (TAS-102) combined with bevacizumab and ptemizumab (DRUG),6256,TFT,Colorectal Cancer (CRC),Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2604,NCT06403709,"Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Colorectal Cancer,"Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab (DRUG)",6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2605,NCT00087607,Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).,COMPLETED,PHASE4,"Hepatitis C, Chronic",Ribavirin (DRUG); Peginterferon alfa-2b (PEG-Intron) (DRUG); Ribavirin (DRUG); Peginterferon alfa-2a [Pegasys] (DRUG),6256,TFT,Chronic Hepatitis C,Liver,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2606,NCT06245356,Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer,RECRUITING,PHASE2,Metastatic Colorectal Cancer; Metastatic Gastroesophageal Adenocarcinoma; DPD Deficiency,Lonsurf (DRUG); Oxaliplatin (DRUG); Panitumumab (DRUG); Bevacizumab (DRUG); Trastuzumab (DRUG); Nivolumab (DRUG),6256,TFT,Metastatic Colorectal Cancer; Metastatic Gastroesophageal Adenocarcinoma; DPD Deficiency,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2607,NCT01631097,A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function,COMPLETED,PHASE1,Hepatic Impairment,Tivozanib hydrochloride (DRUG),6256,TFT,Hepatic Impairment,Liver,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2608,NCT04076761,Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma,TERMINATED,PHASE2,Cholangiocarcinoma; Bile Duct Cancer,Trifluridine/Tipiracil (DRUG),6256,TFT,Cholangiocarcinoma; Bile Duct Cancer,Liver,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2609,NCT03414983,An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread,COMPLETED,PHASE2,Colorectal Cancer,Nivolumab (BIOLOGICAL); Oxaliplatin (DRUG); Leucovorin (DRUG); Fluorouracil (DRUG); Bevacizumab (DRUG),6256,TFT,Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2610,NCT06243393,Sacituzumab Govitecan in Metastatic Colorectal Cancer,RECRUITING,PHASE2,Metastatic Colorectal Cancer,Sacituzumab Govitecan (SG) (DRUG); Physicians Choice (PhC). (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2611,NCT06711471,"Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer",RECRUITING,PHASE2,Gastric Cancer Adenocarcinoma Metastatic,"trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab (DRUG)",6256,TFT,Gastric Cancer Adenocarcinoma Metastatic,Esophagus/Stomach,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2612,NCT04097028,Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma,COMPLETED,PHASE2,Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage III Esophageal Adenocarcinoma AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8,Trifluridine and Tipiracil Hydrochloride (DRUG); Oxaliplatin (DRUG),6256,TFT,Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage III Esophageal Adenocarcinoma AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8,Esophagus/Stomach,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2613,NCT00923845,Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer,COMPLETED,PHASE2,Renal Cell Carcinoma; Graft-Versus-Host Disease; Engraftment Syndrome,Pentostatin (DRUG); Sirolimus (DRUG); Cyclophosphamide (DRUG); Allogeneic Hematopoietic Stem Cell Transplant (HSCT) (PROCEDURE); Th2 rapa cells (PROCEDURE); Donor Lymphocyte Harvest (PROCEDURE); Induction Therapy (PROCEDURE); GVHD prophylaxis (PROCEDURE); Donor Hematopoietic Stem Cell Harvest (PROCEDURE),6256,TFT,Renal Cell Carcinoma; Graft-Versus-Host Disease; Engraftment Syndrome,Kidney,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2614,NCT03251378,"A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers",COMPLETED,PHASE1,Advanced Solid Tumors; Metastatic Colon Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Rectal Cancer,Fruquintinib (HMPL-013) (DRUG),6256,TFT,Advanced Solid Tumors; Metastatic Colon Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Rectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2615,NCT02288078,Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402),UNKNOWN,PHASE2,Rectal Cancer,General condition (OTHER); Blood pressure (OTHER); Patient Reported Outcome (OTHER); Clinical findings (OTHER); Hematology/blood chemistry (OTHER); Coagulation and fibrinolysis system (OTHER); Urinalysis (OTHER); Medication check (OTHER); Adverse event (OTHER); Thyroid function test (OTHER); Contrast-enhanced torso CT (OTHER); Brain MRI (OTHER); Dexamethasone (DRUG); Regorafenib (DRUG); Placebo (DRUG); Proton pump inhibitor (DRUG),6256,TFT,Rectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2616,NCT00787371,Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED),COMPLETED,PHASE2,"Hepatitis C, Chronic; Hepatitis C",PegIntron (peginterferon alfa-2b) (BIOLOGICAL); PegIntron (peginterferon alfa-2b) (BIOLOGICAL); PegIntron (peginterferon alfa-2b) (BIOLOGICAL),6256,TFT,"Hepatitis C, Chronic; Hepatitis C",Liver,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2617,NCT06218511,A Phase I Trial of IMA970A Plus Montanide in Combination with Durvalumab (anti-PD-L1),RECRUITING,PHASE1,Hepatocellular Carcinoma,Peptide-based hepatocellular carcinoma vaccine IMA970A (BIOLOGICAL); Durvalumab (COMBINATION_PRODUCT); Montanide (Adjuvant) (OTHER),6256,TFT,Hepatocellular Carcinoma,Liver,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2618,NCT03203005,"IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients",COMPLETED,PHASE1,Hepatocellular Carcinoma,IMA970A plus CV8102 and Cyclophosphamide (DRUG),6256,TFT,Hepatocellular Carcinoma,Liver,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2619,NCT05970705,Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC,RECRUITING,PHASE2,Metastatic Colorectal Cancer,Regorafenib (DRUG); Trifluridine/Tipiracil (DRUG),6256,TFT,Metastatic Colorectal Cancer,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2620,NCT04457297,Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection,UNKNOWN,PHASE3,Colorectal Neoplasms; Trifluridine and Tipiracil; Circulating Tumor DNA,trifluridine and tipiracil (DRUG); Placebo (DRUG),6256,TFT,Colorectal Neoplasms; Trifluridine and Tipiracil; Circulating Tumor DNA,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2621,NCT04564898,Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.,ACTIVE_NOT_RECRUITING,PHASE1,Colorectal Cancer Metastatic,Capecitabine (DRUG); Bevacizumab (DRUG); Trifluridine/Tipiracil (DRUG),6256,TFT,Colorectal Cancer Metastatic,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2622,NCT05356897,"Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study",WITHDRAWN,PHASE2,Metastatic Colon Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Rectal Adenocarcinoma; Stage IV Colon Cancer AJCC V8; Stage IV Colorectal Cancer AJCC V8; Stage IV Rectal Cancer AJCC V8,Trastuzumab (BIOLOGICAL); Trifluridine and Tipiracil Hydrochloride (DRUG); Tucatinib (DRUG),6256,TFT,Metastatic Colon Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Rectal Adenocarcinoma; Stage IV Colon Cancer AJCC V8; Stage IV Colorectal Cancer AJCC V8; Stage IV Rectal Cancer AJCC V8,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2623,NCT05312398,CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Colorectal Adenocarcinoma,Cetuximab (DRUG); FOLFIRI (DRUG); FOLFOX regimen (DRUG); Irinotecan (DRUG),6256,TFT,Metastatic Colorectal Adenocarcinoma,Bowel,Trifluridine,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used to treat viral infections and in cancer therapy (with tipiracil).,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,1.34,238.0 +2624,NCT04244474,Effect of Vitamin D Supplementation on Improvement of Pneumonic Children,UNKNOWN,PHASE1,"Child, Hospitalized; Vitamin D Deficiency; Pneumonia",A single one ml injection (DRUG),446727,BVD,"Child, Hospitalized; Vitamin D Deficiency; Pneumonia",Lung,Brivudine,,unclear,unclear,yes,yes,"Approved in Europe, not widely used in the US.",C1C(C(OC1N2C=C(C(=O)NC2=O)C=CBr)CO)O,1.01,1301.0 +2625,NCT06353269,Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections,RECRUITING,PHASE4,Recurrent Urinary Tract Infection; Hypoestrogenism,Estring Vaginal Product (DRUG); Vagifem (DRUG); Estrace 0.01% Vaginal Cream (DRUG),446727,BVD,Recurrent Urinary Tract Infection; Hypoestrogenism,Bladder/Urinary Tract,Brivudine,,unclear,unclear,yes,yes,"Approved in Europe, not widely used in the US.",C1C(C(OC1N2C=C(C(=O)NC2=O)C=CBr)CO)O,1.01,1301.0 +2626,NCT00031616,NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer,UNKNOWN,PHASE1,Colorectal Cancer,brivudine phosphoramidate (DRUG),446727,BVD,Colorectal Cancer,Bowel,Brivudine,,unclear,unclear,yes,yes,"Approved in Europe, not widely used in the US.",C1C(C(OC1N2C=C(C(=O)NC2=O)C=CBr)CO)O,1.01,1301.0 +2627,NCT01436357,Staged Phase I/II Hepatitis C Prophylactic Vaccine,COMPLETED,PHASE1,Hepatitis C,AdCh3NSmut1 (BIOLOGICAL); MVA-NSmut (BIOLOGICAL); Placebo (OTHER),5905,IDU,Hepatitis C,Liver,Idoxuridine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as topical antiviral in eye infections. Approved for human use.,C1C(C(OC1N2C=C(C(=O)NC2=O)I)CO)O,1.3,48.0 +2628,NCT01170741,Computer-Assisted Tailored Cue-card Health [CATCH] Study,COMPLETED,PHASE1,"Human Immunodeficiency Virus; STDs; Hepatitis, Viral, Human",Tailored Cue Cards (BEHAVIORAL),5905,IDU,"Human Immunodeficiency Virus; STDs; Hepatitis, Viral, Human",Liver,Idoxuridine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as topical antiviral in eye infections. Approved for human use.,C1C(C(OC1N2C=C(C(=O)NC2=O)I)CO)O,1.3,48.0 +2629,NCT00109785,PET Scans in Patients With Locally Advanced Breast Cancer,COMPLETED,PHASE1,Breast Cancer,positron emission tomography (PROCEDURE); fludeoxyglucose F 18 (RADIATION); iodine I 124 iododeoxyuridine (RADIATION),5905,IDU,Breast Cancer,Breast,Idoxuridine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as topical antiviral in eye infections. Approved for human use.,C1C(C(OC1N2C=C(C(=O)NC2=O)I)CO)O,1.3,48.0 +2630,NCT02347345,Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs,COMPLETED,PHASE4,Hepatitis C,Harvoni (Fixed dose combination ledipasvir/sofosbuvir) (DRUG),5905,IDU,Hepatitis C,Liver,Idoxuridine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as topical antiviral in eye infections. Approved for human use.,C1C(C(OC1N2C=C(C(=O)NC2=O)I)CO)O,1.3,48.0 +2631,NCT02381561,Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy,ACTIVE_NOT_RECRUITING,PHASE1,Advanced Bile Duct Carcinoma; Stage II Esophageal Cancer AJCC v7; Stage II Pancreatic Cancer AJCC v6 and v7; Stage IIA Esophageal Cancer AJCC v7; Stage IIA Pancreatic Cancer AJCC v6 and v7; Stage IIB Esophageal Cancer AJCC v7; Stage IIB Pancreatic Cancer AJCC v6 and v7; Stage III Colon Cancer AJCC v7; Stage III Esophageal Cancer AJCC v7; Stage III Gastric Cancer AJCC v7; Stage III Liver Cancer; Stage III Pancreatic Cancer AJCC v6 and v7; Stage III Rectal Cancer AJCC v7; Stage III Small Intestinal Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIA Esophageal Cancer AJCC v7; Stage IIIA Gastric Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIA Small Intestinal Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIB Esophageal Cancer AJCC v7; Stage IIIB Gastric Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIB Small Intestinal Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7; Stage IIIC Esophageal Cancer AJCC v7; Stage IIIC Gastric Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Colon Cancer AJCC v7; Stage IV Esophageal Cancer AJCC v7; Stage IV Gastric Cancer AJCC v7; Stage IV Liver Cancer; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IV Rectal Cancer AJCC v7; Stage IV Small Intestinal Cancer AJCC v7; Stage IVA Colon Cancer AJCC v7; Stage IVA Liver Cancer; Stage IVA Rectal Cancer AJCC v7; Stage IVB Colon Cancer AJCC v7; Stage IVB Liver Cancer; Stage IVB Rectal Cancer AJCC v7,Intensity-Modulated Radiation Therapy (RADIATION); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Ropidoxuridine (DRUG),5905,IDU,Advanced Bile Duct Carcinoma; Stage II Esophageal Cancer AJCC v7; Stage II Pancreatic Cancer AJCC v6 and v7; Stage IIA Esophageal Cancer AJCC v7; Stage IIA Pancreatic Cancer AJCC v6 and v7; Stage IIB Esophageal Cancer AJCC v7; Stage IIB Pancreatic Cancer AJCC v6 and v7; Stage III Colon Cancer AJCC v7; Stage III Esophageal Cancer AJCC v7; Stage III Gastric Cancer AJCC v7; Stage III Liver Cancer; Stage III Pancreatic Cancer AJCC v6 and v7; Stage III Rectal Cancer AJCC v7; Stage III Small Intestinal Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIA Esophageal Cancer AJCC v7; Stage IIIA Gastric Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIA Small Intestinal Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIB Esophageal Cancer AJCC v7; Stage IIIB Gastric Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIB Small Intestinal Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7; Stage IIIC Esophageal Cancer AJCC v7; Stage IIIC Gastric Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Colon Cancer AJCC v7; Stage IV Esophageal Cancer AJCC v7; Stage IV Gastric Cancer AJCC v7; Stage IV Liver Cancer; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IV Rectal Cancer AJCC v7; Stage IV Small Intestinal Cancer AJCC v7; Stage IVA Colon Cancer AJCC v7; Stage IVA Liver Cancer; Stage IVA Rectal Cancer AJCC v7; Stage IVB Colon Cancer AJCC v7; Stage IVB Liver Cancer; Stage IVB Rectal Cancer AJCC v7,Bowel,Idoxuridine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as topical antiviral in eye infections. Approved for human use.,C1C(C(OC1N2C=C(C(=O)NC2=O)I)CO)O,1.3,48.0 +2632,NCT03093415,Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care,COMPLETED,PHASE4,"Hepatitis C; Substance Use Disorders; Substance Abuse, Intravenous",elbasvir-grazoprevir (50 mg/100 mg) (DRUG),5905,IDU,"Hepatitis C; Substance Use Disorders; Substance Abuse, Intravenous",Liver,Idoxuridine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as topical antiviral in eye infections. Approved for human use.,C1C(C(OC1N2C=C(C(=O)NC2=O)I)CO)O,1.3,48.0 +2633,NCT02649790,"Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants with Relapsed/Refractory Cancer Indications",COMPLETED,PHASE1,Relapsed/Refractory Multiple Myeloma (RRMM); Metastatic Colorectal Cancer (mCRC); Metastatic Castration-Resistant Prostate Cancer (mCRPC); Higher-Risk Myelodysplastic Syndrome (HR-MDS); Acute Myeloid Leukemia (AML); Newly Diagnosed Intermediate/High-Risk MDS,KPT-8602 (DRUG); ASTX727 (DRUG); Dexamethasone (DRUG),451668,Dac,Relapsed/Refractory Multiple Myeloma (RRMM); Metastatic Colorectal Cancer (mCRC); Metastatic Castration-Resistant Prostate Cancer (mCRPC); Higher-Risk Myelodysplastic Syndrome (HR-MDS); Acute Myeloid Leukemia (AML); Newly Diagnosed Intermediate/High-Risk MDS,Bowel,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2634,NCT02998567,Combination Study of Guadecitabine/ASTX727 and Pembrolizumab,RECRUITING,PHASE1,Non Small Cell Lung Cancer,Guadecitabine (DRUG); Pembrolizumab (DRUG); ASTX727 (DRUG),451668,Dac,Non Small Cell Lung Cancer,Lung,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2635,NCT02957968,Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca,ACTIVE_NOT_RECRUITING,PHASE2,Breast Adenocarcinoma; Estrogen Receptor- Negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive Tumor; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Triple-negative Breast Carcinoma,Doxorubicin (DRUG); Cyclophosphamide (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Decitabine (DRUG); Pembrolizumab (DRUG),451668,Dac,Breast Cancer (Various Types and Stages),Breast,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2636,NCT05983276,Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer,RECRUITING,PHASE2,Ovarian Cancer,Decitabine (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Selinexor (DRUG),451668,Dac,Ovarian Cancer,Ovary/Fallopian Tube,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2637,NCT03017131,"Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Aldesleukin (BIOLOGICAL); Cyclophosphamide (DRUG); Decitabine (DRUG); Genetically Engineered NY-ESO-1-specific T Lymphocytes (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER),451668,Dac,Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2638,NCT01160731,"Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer",WITHDRAWN,PHASE1,Lung Cancer,cisplatin (DRUG); etoposide phosphate (DRUG); panobinostat (DRUG); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),451668,Dac,Lung Cancer,Lung,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2639,NCT05960773,"Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma",RECRUITING,PHASE2,Mesothelioma; Malignant Mesothelioma (MM); Early-stage Mesothelioma; Subclinical Mesothelioma; BRCA1-Associated Protein-1 (BAP1) Mutations; Early-stage BAP1-associated Malignancies,Decitabine/cedazuridine (DRUG),451668,Dac,Mesothelioma; Malignant Mesothelioma (MM); Early-stage Mesothelioma; Subclinical Mesothelioma; BRCA1-Associated Protein-1 (BAP1) Mutations; Early-stage BAP1-associated Malignancies,Lung,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2640,NCT01207726,Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery,TERMINATED,PHASE2,Stage IA Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung Carcinoma,Azacitidine (DRUG); Entinostat (DRUG); Laboratory Biomarker Analysis (OTHER),451668,Dac,Stage IA Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung Carcinoma,Lung,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2641,NCT00019825,Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura,COMPLETED,PHASE1,Esophageal Cancer; Lung Cancer; Malignant Mesothelioma; Metastatic Cancer,decitabine (DRUG),451668,Dac,Esophageal Cancer; Lung Cancer; Malignant Mesothelioma; Metastatic Cancer,Lung,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2642,NCT03282825,Clinical Study of Decitabine and Paclitaxel Combination Therapy,UNKNOWN,PHASE1,Advanced Breast Cancer,Decitabine (DRUG); Paclitaxel (DRUG),451668,Dac,Advanced Breast Cancer,Breast,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2643,NCT02838225,DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer,COMPLETED,PHASE2,Breast Cancer,"Docetaxel, Doxorubicin (DRUG); Docetaxel, Doxorubicin, Cyclophosphamide (DRUG)",451668,Dac,Breast Cancer,Breast,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2644,NCT00477386,Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer,COMPLETED,PHASE1,Ovarian Cancer,decitabine (DRUG),451668,Dac,Ovarian Cancer,Ovary/Fallopian Tube,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2645,NCT03686722,Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin,COMPLETED,PHASE1,"Diabetes Mellitus, Type 2; Hepatitis C; Drug Interactions",Metformin (DRUG); Daclatasvir (DRUG),451668,Dac,"Diabetes Mellitus, Type 2; Hepatitis C; Drug Interactions",Liver,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2646,NCT02650986,Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1,ACTIVE_NOT_RECRUITING,PHASE1,Advanced Fallopian Tube Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Melanoma; Advanced Ovarian Carcinoma; Advanced Primary Peritoneal Carcinoma; Advanced Synovial Sarcoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Fallopian Tube Carcinoma; Metastatic Melanoma; Metastatic Ovarian Carcinoma; Metastatic Primary Peritoneal Carcinoma; Metastatic Synovial Sarcoma; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage IIIA Fallopian Tube Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Primary Peritoneal Cancer AJCC v8; Stage IIIA1 Fallopian Tube Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Fallopian Tube Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Fallopian Tube Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Primary Peritoneal Cancer AJCC v8; Stage IIIC Fallopian Tube Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Primary Peritoneal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8; Unresectable Melanoma; Unresectable Ovarian Carcinoma; Unresectable Synovial Sarcoma,Cyclophosphamide (DRUG); Decitabine (DRUG); Laboratory Biomarker Analysis (OTHER); Leukapheresis (PROCEDURE); TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes (BIOLOGICAL),451668,Dac,Advanced Fallopian Tube Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Melanoma; Advanced Ovarian Carcinoma; Advanced Primary Peritoneal Carcinoma; Advanced Synovial Sarcoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Fallopian Tube Carcinoma; Metastatic Melanoma; Metastatic Ovarian Carcinoma; Metastatic Primary Peritoneal Carcinoma; Metastatic Synovial Sarcoma; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage IIIA Fallopian Tube Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Primary Peritoneal Cancer AJCC v8; Stage IIIA1 Fallopian Tube Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Fallopian Tube Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Fallopian Tube Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Primary Peritoneal Cancer AJCC v8; Stage IIIC Fallopian Tube Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Primary Peritoneal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8; Unresectable Melanoma; Unresectable Ovarian Carcinoma; Unresectable Synovial Sarcoma,Skin,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2647,NCT00748527,"Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",TERMINATED,PHASE2,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,carboplatin (DRUG); decitabine (DRUG),451668,Dac,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2648,NCT00040430,Study of 111In-DAC as a Medical Imaging Agent for the Detection of Breast Cancer,UNKNOWN,PHASE1,Breast Cancer,111In-DAC (DRUG); Diagnostic (PROCEDURE),451668,Dac,Breast Cancer,Breast,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2649,NCT04049344,Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma,UNKNOWN,PHASE2,Metastatic Renal Cell Carcinoma,Decitabine; Oxaliplatin (DRUG),451668,Dac,Metastatic Renal Cell Carcinoma,Kidney,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2650,NCT05265962,Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade,UNKNOWN,PHASE2,Esophageal Squamous Cell Carcinoma,Decitabine plus Penpulimab (DRUG),451668,Dac,Esophageal Squamous Cell Carcinoma,Skin,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2651,NCT02839694,Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy,WITHDRAWN,PHASE1,"Neoplasm Metastasis; Sarcoma; Neoplasms, Germ Cell and Embryonal; Melanoma",decitabine (DAC) (DRUG); Tetrahydrouridine (THU) (DRUG); Celecoxib (DRUG),451668,Dac,"Neoplasm Metastasis; Sarcoma; Neoplasms, Germ Cell and Embryonal; Melanoma",Skin,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2652,NCT01241162,Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma,COMPLETED,PHASE1,Neuroblastoma; Ewings Sarcoma; Osteogenic Sarcoma; Rhabdomyosarcoma; Synovial Sarcoma,Autologous dendritic cell vaccine with adjuvant (BIOLOGICAL),451668,Dac,Neuroblastoma; Ewings Sarcoma; Osteogenic Sarcoma; Rhabdomyosarcoma; Synovial Sarcoma,CNS/Brain,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2653,NCT06357858,ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck,WITHDRAWN,PHASE1,Recurrent Squamous Cell Carcinoma of the Head and Neck; Metastatic Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma,INQOVI (decitabine and cedazuridine) (DRUG); Nivolumab (DRUG),451668,Dac,Recurrent Squamous Cell Carcinoma of the Head and Neck; Metastatic Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma,Skin,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2654,NCT03233724,"Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas",TERMINATED,PHASE1,"Carcinoma, Non-Small-Cell Lung; Lung Cancer; Non-Small Cell Lung Cancer; Carcinoma, Esophageal; Malignant Pleural Mesotheliomas",Decitabine (DAC) (DRUG); Tetrahydrouridine (THU) (DRUG); Pembrolizumab (DRUG),451668,Dac,"Carcinoma, Non-Small-Cell Lung; Lung Cancer; Non-Small Cell Lung Cancer; Carcinoma, Esophageal; Malignant Pleural Mesotheliomas",Lung,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2655,NCT00040560,Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With Metastatic Lung Cancer,UNKNOWN,PHASE1,"Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Brain Neoplasms; Metastases, Neoplasm",111In-DAC (DRUG); Diagnostic (PROCEDURE),451668,Dac,"Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Brain Neoplasms; Metastases, Neoplasm",Lung,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2656,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,75 approved agents (DRUG); COXEN (OTHER),451668,Dac,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,Bladder/Urinary Tract,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2657,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,COMPLETED,PHASE2,Relapsing-Remitting Multiple Sclerosis,BIIB019 (Daclizumab High Yield Process) (BIOLOGICAL); Placebo (DRUG),451668,Dac,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2658,NCT02332889,Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs,TERMINATED,PHASE1,"Gliomas; Medulloblastoma; Neuroectodermal Tumors, Primitive",Vaccine (autologous dendritic cells) (BIOLOGICAL); Decitabine and Hiltonol (DRUG),451668,Dac,"Gliomas; Medulloblastoma; Neuroectodermal Tumors, Primitive",CNS/Brain,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2659,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,TERMINATED,PHASE3,Relapsing-Remitting Multiple Sclerosis; Multiple Sclerosis,BIIB019 (Daclizumab) (DRUG),451668,Dac,Relapsing-Remitting Multiple Sclerosis; Multiple Sclerosis,CNS/Brain,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2660,NCT00389467,Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy,COMPLETED,PHASE2,Stroke,Merci Retriever and Penumbra System (DEVICE),451668,Dac,Stroke,CNS/Brain,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2661,NCT05816746,Decitabine and Anti-PD-1 in R/R DLBCL,RECRUITING,PHASE2,Diffuse Large B Cell Lymphoma; Relapse/Recurrence; Extranodal Extension; Central Nervous System Lymphoma,Low-Dose Decitabine plus anti-PD-1 (DRUG),451668,Dac,Diffuse Large B Cell Lymphoma; Relapse/Recurrence; Extranodal Extension; Central Nervous System Lymphoma,CNS/Brain,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2662,NCT00561912,Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma,TERMINATED,PHASE2,Renal Cell Carcinoma,Decitabine (DRUG); Interferon Alfa-2b (DRUG),451668,Dac,Renal Cell Carcinoma,Kidney,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2663,NCT01258868,Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas,TERMINATED,PHASE1,Mesolthelioma; Esophageal Cancer; Lung Cancer; Thoracic Sarcomas; Thymoma,Celebrex (DRUG); Tumor cell vaccine (BIOLOGICAL),451668,Dac,Mesolthelioma; Esophageal Cancer; Lung Cancer; Thoracic Sarcomas; Thymoma,Lung,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2664,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,COMPLETED,PHASE3,Relapsing-Remitting Multiple Sclerosis,BIIB019 (Daclizumab High Yield Process) (BIOLOGICAL); Interferon beta-1a Placebo (DRUG); Interferon beta-1a (BIOLOGICAL); Daclizumab High Yield Process Placebo (DRUG),451668,Dac,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2665,NCT01143441,Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS),COMPLETED,PHASE1,"Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting",DAC-HYP (BIOLOGICAL),451668,Dac,Multiple Sclerosis,CNS/Brain,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2666,NCT00075634,"Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma",COMPLETED,PHASE1,"Recurrent Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific",decitabine (DRUG); doxorubicin hydrochloride (DRUG); cyclophosphamide (DRUG); filgrastim (BIOLOGICAL); pegfilgrastim (BIOLOGICAL); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),451668,Dac,"Recurrent Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific",CNS/Brain,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2667,NCT02795819,Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer,TERMINATED,PHASE1,Renal Cell Carcinoma; Soft Tissue Sarcoma; Metastatic Disease,AR-42 (DRUG); Pazopanib (DRUG),451668,Dac,Renal Cell Carcinoma; Soft Tissue Sarcoma; Metastatic Disease,Kidney,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2668,NCT01876641,Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib,TERMINATED,PHASE1,Metastatic Melanoma; Melanoma; BRAF-mutated Metastatic Melanoma; V600EBRAF-mutated Metastatic Melanoma,"Vemurafenib + Cobimetinib, Decitabine (DRUG)",451668,Dac,Metastatic Melanoma; Melanoma; BRAF-mutated Metastatic Melanoma; V600EBRAF-mutated Metastatic Melanoma,Skin,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2669,NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,COMPLETED,PHASE3,Relapsing-Remitting Multiple Sclerosis,Midazolam (DRUG); Caffeine (OTHER); S-warfarin (DRUG); Vitamin K (OTHER); Omeprazole (DRUG); Dextromethorphan (DRUG); BIIB019 (Daclizumab) (BIOLOGICAL),451668,Dac,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2670,NCT01222936,LBH Phase II in Small Cell Lung Cancer (SCLC),COMPLETED,PHASE2,Small Cell Lung Carcinoma,LBH581 (DRUG),451668,Dac,Small Cell Lung Carcinoma,Lung,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2671,NCT01194908,Re-expression of ER in Triple Negative Breast Cancers,TERMINATED,PHASE1,Breast Cancer; Breast Tumors; Breast Neoplasms,"Decitabine, LBH589, Tamoxifen (DRUG)",451668,Dac,Breast Cancer; Breast Tumors; Breast Neoplasms,Breast,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2672,NCT00084981,Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,decitabine (DRUG); valproic acid (DRUG); pharmacological study (OTHER); laboratory biomarker analysis (OTHER),451668,Dac,Non-small-cell Lung Carcinoma,Lung,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2673,NCT02664181,Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial,COMPLETED,PHASE2,Lung Cancer; Non-small Cell Lung Cancer,Nivolumab (DRUG); oral decitabine (DRUG); Tetrahydrouridine (DRUG),451668,Dac,Lung Cancer; Non-small Cell Lung Cancer,Lung,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2674,NCT02959164,Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma,COMPLETED,PHASE1,Pancreatic Ductal Adenocarcinoma; Sarcoma,Decitabine (DRUG); Gemcitabine (DRUG),451668,Dac,Pancreatic Ductal Adenocarcinoma; Sarcoma,Pancreas,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2675,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,COMPLETED,PHASE2,Relapsing-Remitting Multiple Sclerosis,BIIB019 (Daclizumab) (BIOLOGICAL); trivalent seasonal influenza vaccine (BIOLOGICAL),451668,Dac,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2676,NCT00390221,Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis,COMPLETED,PHASE2,Relapsing-Remitting Multiple Sclerosis,BIIB019 (Daclizumab High Yield Process) (BIOLOGICAL); Placebo (DRUG),451668,Dac,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2677,NCT05360264,tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr,TERMINATED,PHASE2,Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenocarcinoma Recurrent,Decitabine 50 MG [Dacogen] (DRUG),451668,Dac,Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenocarcinoma Recurrent,Pancreas,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2678,NCT04134884,Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer,COMPLETED,PHASE1,Metastatic Breast Cancer; Triple Negative Breast Cancer; Hormone Receptor Positive Tumor,Talazoparib (DRUG); ASTX727 (DRUG),451668,Dac,Metastatic Breast Cancer; Triple Negative Breast Cancer; Hormone Receptor Positive Tumor,Breast,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2679,NCT06454448,"Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer",RECRUITING,PHASE1,Adebrelimab (SHR-1316); Decitabine; Metastatic Pancreatic Cancer,Adebrelimab;decitabine; (DRUG),451668,Dac,Adebrelimab (SHR-1316); Decitabine; Metastatic Pancreatic Cancer,Pancreas,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2680,NCT05155657,Study of Decompensated Alcoholic Cirrhosis Treatment by Stem Cells,UNKNOWN,PHASE1,Alcoholic Cirrhosis,Conventional therapy plus low dose UCMSCs treatment (BIOLOGICAL); Conventional therapy plus medium dose UCMSCs treatment (BIOLOGICAL); Conventional therapy plus high dose UCMSCs treatment (BIOLOGICAL),451668,Dac,Alcoholic Cirrhosis,Liver,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2681,NCT01193517,Azacitidine and CAPOX in Metastatic Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,Azacitidine (DRUG); Capecitabine (DRUG); Oxaliplatin (DRUG); Azacitidine MTD (DRUG),451668,Dac,Colorectal Cancer,Bowel,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2682,NCT00037817,Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies,COMPLETED,PHASE1,Advanced Esophageal Cancers; Primary Small Cell Lung Cancers; Non-Small-Cell Lung Carcinoma; Pleural Mesotheliomas; Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura,Decitabine (DRUG); Depsipeptide (BIOLOGICAL); Celecoxib (DRUG),451668,Dac,Advanced Esophageal Cancers; Primary Small Cell Lung Cancers; Non-Small-Cell Lung Carcinoma; Pleural Mesotheliomas; Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura,Lung,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2683,NCT05089370,Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma,ACTIVE_NOT_RECRUITING,PHASE1,Malignant Melanoma,Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab (COMBINATION_PRODUCT),451668,Dac,Malignant Melanoma,Skin,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2684,NCT02847000,p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer,COMPLETED,EARLY_PHASE1,Metastatic Pancreatic Adenocarcinoma,Tetrahydrouridine (DRUG); Decitabine (DRUG),451668,Dac,Metastatic Pancreatic Adenocarcinoma,Pancreas,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2685,NCT01696032,SGI-110 in Combination With Carboplatin in Ovarian Cancer,COMPLETED,PHASE2,Ovarian Cancer,"SGI-110 (DRUG); Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine) (DRUG); Carboplatin (DRUG)",451668,Dac,Ovarian Cancer,Ovary/Fallopian Tube,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2686,NCT05673200,"Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer",RECRUITING,PHASE1,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma; Unresectable Triple-Negative Breast Carcinoma,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Decitabine and Cedazuridine (DRUG); Magnetic Resonance Imaging (PROCEDURE); Paclitaxel (DRUG); Pembrolizumab (BIOLOGICAL),451668,Dac,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma; Unresectable Triple-Negative Breast Carcinoma,Breast,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2687,NCT00879385,KRAS Wild-type Metastatic Colorectal Cancer Trial,COMPLETED,PHASE1,Colorectal Cancer,Dacogen™ (decitabine) (DRUG); Vectibix® (panitumumab) (DRUG),451668,Dac,Colorectal Cancer,Bowel,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2688,NCT03295552,Decitabine Plus Carboplatin in the Treatment of Metastatic TNBC,TERMINATED,PHASE2,Breast Neoplasm,Decitabine (DRUG); Carboplatin (DRUG),451668,Dac,Breast Neoplasm,Breast,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2689,NCT03480932,Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C],COMPLETED,PHASE2,"Hepatitis C, Chronic",Sofosbuvir (DRUG); Daclatasvir (DRUG); Pegylated Interferon alfa-2a (DRUG),451668,Dac,Chronic Hepatitis C,Liver,Decitabine,"DNMT1, DNMT3A, DNMT3B",inhibitor/antagonist,DNA methyltransferase inhibitor,yes,yes,Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,1.04,320.0 +2690,NCT01693549,Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes,COMPLETED,PHASE2,Breast Cancer,Cabazitaxel (DRUG),91885558,SMAP,Breast Cancer,Breast,DT-061,,activator/agonist,unclear,no,yes,"Investigated for oncology, no approval yet for human use.",C1CC(C(C(C1)N2C3=CC=CC=C3OC4=CC=CC=C42)O)NS(=O)(=O)C5=CC=C(C=C5)OC(F)(F)F,, +2691,NCT03213704,"Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)",ACTIVE_NOT_RECRUITING,PHASE2,Advanced Malignant Solid Neoplasm; Recurrent Ependymoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Kidney Wilms Tumor; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma,Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration and Biopsy (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Larotrectinib Sulfate (DRUG); Magnetic Resonance Imaging (PROCEDURE); Radionuclide Imaging (PROCEDURE); X-Ray Imaging (PROCEDURE),46188928,Vitrakvi,Advanced Malignant Solid Neoplasm; Recurrent Ependymoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Kidney Wilms Tumor; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma,CNS/Brain,Larotrectinib,"NTRK1, NTRK2, NTRK3",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved specifically as a cancer treatment for tumors with NTRK gene fusions.,C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F,1.05,1324.0 +2692,NCT04655404,A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma with NTRK Fusion,RECRUITING,EARLY_PHASE1,High Grade Glioma; Diffuse Intrinsic Pontine Glioma,Larotrectinib (DRUG); Larotrectinib surgical (PROCEDURE),46188928,Vitrakvi,High Grade Glioma; Diffuse Intrinsic Pontine Glioma,CNS/Brain,Larotrectinib,"NTRK1, NTRK2, NTRK3",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved specifically as a cancer treatment for tumors with NTRK gene fusions.,C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F,1.05,1324.0 +2693,NCT06563999,Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.,RECRUITING,PHASE2,Lung Cancer Stage III; Mutation,Sunvozertinib (DRUG); Crizotinib (DRUG); Pralsetinib (DRUG); Larotrectinib (DRUG); Savolitinib (DRUG); Pyrotinib (DRUG); Dabrafenib+Trametinib (DRUG); Glecirasib (DRUG); Ensartinib (DRUG),46188928,Vitrakvi,Lung Cancer Stage III with Mutation,Lung,Larotrectinib,"NTRK1, NTRK2, NTRK3",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved specifically as a cancer treatment for tumors with NTRK gene fusions.,C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F,1.05,1324.0 +2694,NCT05725200,Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer,RECRUITING,PHASE2,Metastatic Colorectal Cancer,Alectinib (DRUG); Cetuximab (DRUG); Crizotinib (DRUG); Dasatinib (DRUG); Everolimus (DRUG); Encorafenib (DRUG); Gemcitabine (DRUG); Idelalisib (DRUG); Larotrectinib (DRUG); Methotrexate (DRUG); Palbociclib (DRUG); Panobinostat (DRUG); Pembrolizumab (DRUG); Petrozumab (DRUG); Trastuzumab (DRUG); Talazoparib (DRUG); Venetoclax (DRUG),46188928,Vitrakvi,Metastatic Colorectal Cancer,Bowel,Larotrectinib,"NTRK1, NTRK2, NTRK3",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved specifically as a cancer treatment for tumors with NTRK gene fusions.,C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F,1.05,1324.0 +2695,NCT03213704,"Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)",ACTIVE_NOT_RECRUITING,PHASE2,Advanced Malignant Solid Neoplasm; Recurrent Ependymoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Kidney Wilms Tumor; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma,Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration and Biopsy (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Larotrectinib Sulfate (DRUG); Magnetic Resonance Imaging (PROCEDURE); Radionuclide Imaging (PROCEDURE); X-Ray Imaging (PROCEDURE),67330085,Vitrakvi,Advanced Malignant Solid Neoplasm; Recurrent Ependymoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Kidney Wilms Tumor; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma,CNS/Brain,Larotrectinib sulfate,"NTRK1, NTRK2, NTRK3",inhibitor/antagonist,Other TK inhibitor,yes,yes,Larotrectinib sulfate is approved to treat TRK fusion-positive cancers.,C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F.OS(=O)(=O)O,1.0,66.0 +2696,NCT04655404,A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma with NTRK Fusion,RECRUITING,EARLY_PHASE1,High Grade Glioma; Diffuse Intrinsic Pontine Glioma,Larotrectinib (DRUG); Larotrectinib surgical (PROCEDURE),67330085,Vitrakvi,High Grade Glioma; Diffuse Intrinsic Pontine Glioma,CNS/Brain,Larotrectinib sulfate,"NTRK1, NTRK2, NTRK3",inhibitor/antagonist,Other TK inhibitor,yes,yes,Larotrectinib sulfate is approved to treat TRK fusion-positive cancers.,C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F.OS(=O)(=O)O,1.0,66.0 +2697,NCT06563999,Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.,RECRUITING,PHASE2,Lung Cancer Stage III; Mutation,Sunvozertinib (DRUG); Crizotinib (DRUG); Pralsetinib (DRUG); Larotrectinib (DRUG); Savolitinib (DRUG); Pyrotinib (DRUG); Dabrafenib+Trametinib (DRUG); Glecirasib (DRUG); Ensartinib (DRUG),67330085,Vitrakvi,Lung Cancer Stage III with Mutation,Lung,Larotrectinib sulfate,"NTRK1, NTRK2, NTRK3",inhibitor/antagonist,Other TK inhibitor,yes,yes,Larotrectinib sulfate is approved to treat TRK fusion-positive cancers.,C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F.OS(=O)(=O)O,1.0,66.0 +2698,NCT05725200,Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer,RECRUITING,PHASE2,Metastatic Colorectal Cancer,Alectinib (DRUG); Cetuximab (DRUG); Crizotinib (DRUG); Dasatinib (DRUG); Everolimus (DRUG); Encorafenib (DRUG); Gemcitabine (DRUG); Idelalisib (DRUG); Larotrectinib (DRUG); Methotrexate (DRUG); Palbociclib (DRUG); Panobinostat (DRUG); Pembrolizumab (DRUG); Petrozumab (DRUG); Trastuzumab (DRUG); Talazoparib (DRUG); Venetoclax (DRUG),67330085,Vitrakvi,Metastatic Colorectal Cancer,Bowel,Larotrectinib sulfate,"NTRK1, NTRK2, NTRK3",inhibitor/antagonist,Other TK inhibitor,yes,yes,Larotrectinib sulfate is approved to treat TRK fusion-positive cancers.,C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F.OS(=O)(=O)O,1.0,66.0 +2699,NCT06727357,"Next Generation Sequencing-based ""Oncochip"" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP",ACTIVE_NOT_RECRUITING,PHASE2,"Breast Cancer, Metastatic Breast Cancer",Chemotherapy (DRUG),23725625,Olaparib,"Breast Cancer, Metastatic Breast Cancer",Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2700,NCT01116648,"Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Fallopian Tube Carcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Serous Surface Papillary Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Triple-Negative Breast Carcinoma,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Cediranib Maleate (DRUG); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Olaparib (DRUG),23725625,Olaparib,Fallopian Tube Carcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Serous Surface Papillary Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Triple-Negative Breast Carcinoma,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2701,NCT03212274,"Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations",ACTIVE_NOT_RECRUITING,PHASE2,Advanced Malignant Solid Neoplasm; Glioblastoma; Recurrent Cholangiocarcinoma; Recurrent Glioma; Recurrent Malignant Solid Neoplasm; WHO Grade 2 Glioma; WHO Grade 3 Glioma,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Olaparib (DRUG),23725625,Olaparib,Advanced Malignant Solid Neoplasm; Glioblastoma; Recurrent Cholangiocarcinoma; Recurrent Glioma; Recurrent Malignant Solid Neoplasm; WHO Grade 2 Glioma; WHO Grade 3 Glioma,CNS/Brain,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2702,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,COMPLETED,PHASE3,"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity",OLAPARIB (DRUG); Single agent chemotherapy (DRUG),23725625,Olaparib,"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity",Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2703,NCT05485766,Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer,RECRUITING,PHASE2,Triple Negative Breast Neoplasms; Triple Negative Breast Cancer; Breast Neoplasms; Breast Cancer; BRCA1 Mutation; BRCA2 Mutation; BRCA Mutation; BRCA-Associated Breast Carcinoma,Pembrolizumab (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Olaparib (DRUG); Definitive Surgery (PROCEDURE),23725625,Olaparib,Triple Negative Breast Neoplasms; Triple Negative Breast Cancer; Breast Neoplasms; Breast Cancer; BRCA1 Mutation; BRCA2 Mutation; BRCA Mutation; BRCA-Associated Breast Carcinoma,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2704,NCT05366166,Pembrolizumab Plus Olaparib in LA-HNSCC,RECRUITING,PHASE2,Squamous Cell Carcinoma of Head and Neck,Pembrolizumab (BIOLOGICAL); Olaparib (DRUG); Cisplatin (DRUG); IMRT (intensity modulated radiation therapy) (RADIATION),23725625,Olaparib,Squamous Cell Carcinoma of Head and Neck,Skin,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2705,NCT03660826,"Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone",ACTIVE_NOT_RECRUITING,PHASE2,Endometrial Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Endometrioid Adenocarcinoma; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8,Biospecimen Collection (PROCEDURE); Bone Marrow Aspirate (PROCEDURE); Bone Marrow Biopsy (PROCEDURE); Capivasertib (DRUG); Cediranib (DRUG); Cediranib Maleate (DRUG); Computed Tomography (PROCEDURE); Durvalumab (BIOLOGICAL); Echocardiography (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Olaparib (DRUG),23725625,Olaparib,Endometrial Cancer,Uterus,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2706,NCT03741426,WIRE - Novel Treatments in Renal Cell Cancer,RECRUITING,PHASE2,Renal Cell Cancer,Olaparib (DRUG); Cediranib (DRUG); Durvalumab (DRUG),23725625,Olaparib,Renal Cell Cancer,Kidney,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2707,NCT05482074,Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2,WITHDRAWN,PHASE2,Recurrent Metastatic Melanoma; Cutaneous Melanoma; Mucosal Melanoma; Uveal Melanoma,Olaparib (DRUG),23725625,Olaparib,Recurrent Metastatic Melanoma; Cutaneous Melanoma; Mucosal Melanoma; Uveal Melanoma,Skin,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2708,NCT02624973,PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Neoadjuvant tamoxifen + goserelin (premenopausal women) (DRUG); Neoadjuvant letrozole (postmenopausal women) (DRUG); Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone) (DRUG); Neoadjuvant docetaxel + cyclophosphamide (DRUG); Neoadjuvant docetaxel (DRUG); Neoadjuvant docetaxel + trastuzumab + pertuzumab (DRUG); Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab (DRUG); Neoadjuvant olaparib (DRUG); Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone) (DRUG); Breast conserving surgery or mastectomy + SNB/axillary dissection (PROCEDURE); Postoperative radiotherapy breast/chest wall + regional lymph nodes (RADIATION); Adjuvant trastuzumab (DRUG); Adjuvant letrozole (postmenopausal women) (DRUG); Adjuvant tamoxifen + goserelin (premenopausal women) (DRUG); Adjuvant palbociclib (if palbociclib given neoadjuvant) (DRUG); Adjuvant Epirubicin+ Cyclophosphamide (DRUG),23725625,Olaparib,Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2709,NCT02227082,Olaparib and Radiotherapy in Inoperable Breast Cancer,COMPLETED,PHASE1,Locally Advanced Malignant Neoplasm; Inflammatory Breast Carcinoma; Triple-Negative Invasive Breast Carcinoma,radiotherapy (RADIATION); olaparib (DRUG),23725625,Olaparib,Locally Advanced Malignant Neoplasm; Inflammatory Breast Carcinoma; Triple-Negative Invasive Breast Carcinoma,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2710,NCT04005690,Targeted Pathway Inhibition in Patients With Pancreatic Cancer,RECRUITING,EARLY_PHASE1,Locally Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma; Borderline Resectable Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma,Cobimetinib (DRUG); Olaparib (DRUG); Onvansertib (DRUG); Azenosertib (DRUG); Saruparib (DRUG); Tremelimumab (BIOLOGICAL),23725625,Olaparib,Locally Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma; Borderline Resectable Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2711,NCT02121990,"Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",COMPLETED,PHASE1,Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer,"Paclitaxel, (DRUG); Bevacizumab (DRUG); Cisplatin (DRUG); Olaparib (DRUG)",23725625,Olaparib,Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2712,NCT05252390,NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors,TERMINATED,PHASE1,Advanced Solid Tumor; Ovarian Cancer; Ovary Cancer; Cancer of Ovary; Cancer of the Ovary; Ovary Neoplasm; Pancreatic Cancer; Pancreas Cancer; Cancer of Pancreas; Cancer of the Pancreas; Pancreas Neoplasm; Prostate Cancer; Prostatic Cancer; Cancer of Prostate; Cancer of the Prostate; Prostate Neoplasm; Castrate Resistant Prostate Cancer; Castration Resistant Prostatic Cancer; Castration Resistant Prostatic Neoplasms; Triple-negative Breast Cancer; Triple Negative Breast Cancer; Triple Negative Breast Neoplasms; Breast Cancer; Breast Carcinoma; Cancer of Breast; Cancer of the Breast; Breast Tumor,NUV-868 (DRUG); Olaparib (DRUG); Enzalutamide (DRUG),23725625,Olaparib,Advanced Solid Tumor; Ovarian Cancer; Ovary Cancer; Cancer of Ovary; Cancer of the Ovary; Ovary Neoplasm; Pancreatic Cancer; Pancreas Cancer; Cancer of Pancreas; Cancer of the Pancreas; Pancreas Neoplasm; Prostate Cancer; Prostatic Cancer; Cancer of Prostate; Cancer of the Prostate; Prostate Neoplasm; Castrate Resistant Prostate Cancer; Castration Resistant Prostatic Cancer; Castration Resistant Prostatic Neoplasms; Triple-negative Breast Cancer; Triple Negative Breast Cancer; Triple Negative Breast Neoplasms; Breast Cancer; Breast Carcinoma; Cancer of Breast; Cancer of the Breast; Breast Tumor,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2713,NCT06175390,"Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer",RECRUITING,PHASE2,Triple Negative Breast Cancer,68Ga-FAPI-46 PET/CT (RADIATION); Tumor samples analysis (BIOLOGICAL); Blood samples analysis: Circulating Tumor DNA (BIOLOGICAL),23725625,Olaparib,Triple Negative Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2714,NCT05659914,Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Pancreatic Cancer,olaparib+durvalumab (DRUG),23725625,Olaparib,Metastatic Pancreatic Cancer,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2715,NCT05568212,Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab,UNKNOWN,PHASE2,Non-small-cell Lung Cancer Patients,Durvalumab (DRUG); Olaparib tablet (DRUG); Single-agent chemotherapy (DRUG); Platinum doublet chemotherapy (DRUG),23725625,Olaparib,Non-small-cell Lung Cancer Patients,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2716,NCT03251612,Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer Metastatic,Based on sensitivity analysis (DRUG),23725625,Olaparib,Colorectal Cancer Metastatic,Bowel,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2717,NCT06377267,Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial),RECRUITING,PHASE2,Ovarian Cancer,Bevacizumab (DRUG); Olaparib (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2718,NCT05700669,Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors,COMPLETED,PHASE1,Metastatic Castration-resistant Prostate Cancer; Recurrent Epithelial Ovarian Cancer; Breast Cancer,AsiDNA (DRUG); Olaparib (DRUG),23725625,Olaparib,Metastatic Castration-resistant Prostate Cancer; Recurrent Epithelial Ovarian Cancer; Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2719,NCT05200260,Surgery Combined with Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer,RECRUITING,PHASE2,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Primary debulking surgery (PROCEDURE); Neoadjuvant chemotherapy (PROCEDURE); PARP inhibitor (DRUG); Bevacizumab (DRUG),23725625,Olaparib,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2720,NCT01650376,Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer,UNKNOWN,PHASE1,Stage III Ovarian Cancer; Stage IV Ovarian Cancer; Uterine Cancer,Olaparib (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG),23725625,Olaparib,Stage III Ovarian Cancer; Stage IV Ovarian Cancer; Uterine Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2721,NCT02392676,Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations,WITHDRAWN,PHASE3,Platinum Sensitive Relapsed Ovarian Cancer,OLAPARIB (DRUG); PLACEBO (DRUG),23725625,Olaparib,Platinum Sensitive Relapsed Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2722,NCT03009682,"Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations",COMPLETED,PHASE2,Small Cell Lung Cancer,Olaparib (DRUG),23725625,Olaparib,Small Cell Lung Cancer,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2723,NCT05093231,Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer,NOT_YET_RECRUITING,PHASE2,Pancreatic Cancer,Pembrolizumab (DRUG); Olaparib (DRUG),23725625,Olaparib,Pancreatic Cancer,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2724,NCT02681562,"Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients",UNKNOWN,PHASE2,Breast Cancer; Triple Negative Breast Cancer,olaparib (DRUG),23725625,Olaparib,Breast Cancer; Triple Negative Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2725,NCT03150576,Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer,RECRUITING,PHASE2,Breast Cancer,Olaparib (DRUG); Paclitaxel and Carboplatin (DRUG),23725625,Olaparib,Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2726,NCT05233982,"MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer",RECRUITING,PHASE2,Ovarian Cancer,Olaparib Oral Product (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2727,NCT01758731,Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History,COMPLETED,PHASE1,Squamous Cell Carcinoma of the Head and Neck,Olaparib (DRUG); Cetuximab (DRUG); Radiation Therapy (RADIATION),23725625,Olaparib,Squamous Cell Carcinoma of the Head and Neck,Skin,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2728,NCT03685331,"HOPE: Olaparib, Palbociclib and Fulvestrant in Patients with BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Breast Cancer; Locally Advanced Breast Cancer; Advanced Breast Cancer; BRCA2 Mutation; BRCA1 Mutation,Palbociclib (DRUG); Olaparib (DRUG); Fulvestrant (DRUG),23725625,Olaparib,Metastatic Breast Cancer; Locally Advanced Breast Cancer; Advanced Breast Cancer; BRCA2 Mutation; BRCA1 Mutation,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2729,NCT05238831,SMMART Adaptive Clinical Treatment (ACT) Trial,WITHDRAWN,EARLY_PHASE1,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Alectinib (DRUG); Alpelisib (DRUG); Anastrozole (DRUG); Atezolizumab (BIOLOGICAL); Bevacizumab (BIOLOGICAL); Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Capecitabine (DRUG); Carboplatin (DRUG); Cobimetinib (DRUG); Entrectinib (DRUG); Eribulin (DRUG); Fulvestrant (DRUG); Hyaluronidase-zzxf/Pertuzumab/Trastuzumab (BIOLOGICAL); Irinotecan (DRUG); Letrozole (DRUG); Nab-paclitaxel (DRUG); Niraparib (DRUG); Olaparib (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Pertuzumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Trastuzumab (BIOLOGICAL); Trastuzumab Emtansine (BIOLOGICAL); Vemurafenib (DRUG); Vinorelbine (DRUG); Vismodegib (DRUG),23725625,Olaparib,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2730,NCT03205176,"AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas",COMPLETED,PHASE1,Malignant Solid Tumors; Lymphoma; Ovarian Cancer; Breast Cancer; Pancreatic Cancer; Prostate Cancer,AZD5153 (DRUG); Olaparib (DRUG),23725625,Olaparib,Malignant Solid Tumors; Lymphoma; Ovarian Cancer; Breast Cancer; Pancreatic Cancer; Prostate Cancer,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2731,NCT02117167,SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients,COMPLETED,PHASE2,Non-small Cell Lung Cancer Metastatic,AZD2014 (DRUG); AZD4547 (DRUG); AZD5363 (DRUG); AZD8931 (DRUG); Selumetinib (DRUG); Vandetanib (DRUG); Standard maintenance for squamous NSCLC (DRUG); Pemetrexed (DRUG); Durvalumab (DRUG); savolitinib (DRUG); Olaparib (DRUG),23725625,Olaparib,Non-small Cell Lung Cancer Metastatic,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2732,NCT05201612,Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,Olaparib (DRUG); Pembrolizumab (DRUG),23725625,Olaparib,Metastatic Colorectal Cancer,Bowel,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2733,NCT04090567,Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer,RECRUITING,PHASE2,Advanced Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Germline BRCA1 Gene Mutation; Germline BRCA2 Gene Mutation; HER2/Neu Negative; Metastatic Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8,Cediranib (DRUG); Ceralasertib (DRUG); Olaparib (DRUG),23725625,Olaparib,Advanced Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Germline BRCA1 Gene Mutation; Germline BRCA2 Gene Mutation; HER2/Neu Negative; Metastatic Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2734,NCT03943173,"Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery",ACTIVE_NOT_RECRUITING,EARLY_PHASE1,BRCA-Mutated Ovarian Carcinoma; BRCA1 Gene Mutation; BRCA2 Gene Mutation; High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage IIIA Fallopian Tube Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Primary Peritoneal Cancer AJCC v8; Stage IIIA1 Fallopian Tube Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Fallopian Tube Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Fallopian Tube Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Primary Peritoneal Cancer AJCC v8; Stage IIIC Fallopian Tube Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Primary Peritoneal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8,Chemotherapy (DRUG); Olaparib (DRUG); Therapeutic Conventional Surgery (PROCEDURE),23725625,Olaparib,BRCA-Mutated Ovarian Carcinoma; BRCA1 Gene Mutation; BRCA2 Gene Mutation; High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage IIIA Fallopian Tube Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Primary Peritoneal Cancer AJCC v8; Stage IIIA1 Fallopian Tube Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Fallopian Tube Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Fallopian Tube Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Primary Peritoneal Cancer AJCC v8; Stage IIIC Fallopian Tube Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Primary Peritoneal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2735,NCT00516373,A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP),COMPLETED,PHASE1,Ovarian Neoplasms; BRCA1 Protein; BRCA2 Protein,KU-0059436 (AZD2281)(PARP inhibitor) (DRUG),23725625,Olaparib,Ovarian Neoplasms; BRCA1 Protein; BRCA2 Protein,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2736,NCT02953457,"Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation",COMPLETED,PHASE2,BRCA1 Gene Mutation; BRCA2 Gene Mutation; Ovarian Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Durvalumab (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER); Olaparib (DRUG); Tremelimumab (BIOLOGICAL),23725625,Olaparib,BRCA1 Gene Mutation; BRCA2 Gene Mutation; Ovarian Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2737,NCT02822157,Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer,UNKNOWN,PHASE2,Ovarian Epithelial Cancer,Olaparib (DRUG); carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly (DRUG),23725625,Olaparib,Ovarian Epithelial Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2738,NCT06217757,Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC,RECRUITING,PHASE1,Lung Cancer; Extensive-stage Small-cell Lung Cancer,Low-dose radiotherapy (RADIATION); Etoposide (DRUG); Cisplatin (DRUG); Sugemalimab (DRUG); Olaparib (DRUG),23725625,Olaparib,Lung Cancer; Extensive-stage Small-cell Lung Cancer,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2739,NCT06686030,Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer,RECRUITING,PHASE2,Platinum-sensitive Ovarian Cancer,AK112 low dose (DRUG); Chemotherapy (DRUG); Olaparib (DRUG); AK112 high dose (DRUG),23725625,Olaparib,Platinum-sensitive Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2740,NCT03544125,Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer,COMPLETED,PHASE1,Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Prognostic Stage IV Breast Cancer AJCC v8; Triple-Negative Breast Carcinoma,Durvalumab (BIOLOGICAL); Olaparib (DRUG),23725625,Olaparib,Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Prognostic Stage IV Breast Cancer AJCC v8; Triple-Negative Breast Carcinoma,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2741,NCT06915025,"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer",NOT_YET_RECRUITING,PHASE3,Epithelial Ovarian Cancer; Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Olaparib (DRUG); Niraparib (DRUG),23725625,Olaparib,Epithelial Ovarian Cancer; Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2742,NCT00515866,Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer,COMPLETED,PHASE1,Pancreatic Neoplasms,KU-0059436 (AZD2281)(PARP inhibitor) (DRUG); Gemcitabine (DRUG),23725625,Olaparib,Pancreatic Neoplasms,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2743,NCT03344965,Olaparib in Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Cancer; Invasive Breast Cancer; Somatic Mutation Breast Cancer (BRCA1); Somatic Mutation Breast Cancer (BRCA2); CHEK2 Gene Mutation; ATM Gene Mutation; PALB2 Gene Mutation; RAD51 Gene Mutation; BRIP1 Gene Mutation; NBN Gene Mutation,Olaparib (DRUG),23725625,Olaparib,Metastatic Breast Cancer; Invasive Breast Cancer; Somatic Mutation Breast Cancer (BRCA1); Somatic Mutation Breast Cancer (BRCA2); CHEK2 Gene Mutation; ATM Gene Mutation; PALB2 Gene Mutation; RAD51 Gene Mutation; BRIP1 Gene Mutation; NBN Gene Mutation,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2744,NCT04728230,"Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial",RECRUITING,PHASE1,Extensive Stage Lung Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Carboplatin (DRUG); Durvalumab (BIOLOGICAL); Etoposide (DRUG); Olaparib (DRUG); Radiation Therapy (RADIATION),23725625,Olaparib,Extensive Stage Lung Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2745,NCT02571725,PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms,Olaparib (DRUG); Tremelimumab (DRUG),23725625,Olaparib,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2746,NCT01491139,Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck,WITHDRAWN,PHASE1,"Carcinoma, Squamous Cell",olaparib (DRUG); cisplatin (DRUG); Intensity Modulated Radiotherapy (RADIATION),23725625,Olaparib,Squamous Cell Carcinoma,Skin,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2747,NCT05358639,Combination of Olaparib and Navitoclax in Women with HGSC and TNBC,ACTIVE_NOT_RECRUITING,PHASE1,High Grade Serous Carcinoma; Triple Negative Breast Cancer; Ovarian Cancer,Olaparib tablet (DRUG); Navitoclax (DRUG),23725625,Olaparib,High Grade Serous Carcinoma; Triple Negative Breast Cancer; Ovarian Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2748,NCT01844986,Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.,ACTIVE_NOT_RECRUITING,PHASE3,Newly Diagnosed; Advanced Ovarian Cancer; FIGO Stage III-IV; BRCA Mutation; Complete Response; Partial Response; First Line Platinum Chemotherapy,Olaparib 300mg tablets (DRUG),23725625,Olaparib,Newly Diagnosed; Advanced Ovarian Cancer; FIGO Stage III-IV; BRCA Mutation; Complete Response; Partial Response; First Line Platinum Chemotherapy,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2749,NCT04209686,"Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma",RECRUITING,PHASE2,Advanced Gastric Adenocarcinoma,Paclitaxel (DRUG); Olaparib (DRUG); Pembrolizumab (DRUG),23725625,Olaparib,Advanced Gastric Adenocarcinoma,Esophagus/Stomach,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2750,NCT03162627,Selumetinib and Olaparib in Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,Malignant Neoplasm of Breast; Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Female Genital Organs; Malignant Neoplasms of Male Genital Organs; Malignant Neoplasms of Thyroid and Other Endocrine Glands,Selumetinib (DRUG); Olaparib (DRUG),23725625,Olaparib,Malignant Neoplasm of Breast; Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Female Genital Organs; Malignant Neoplasms of Male Genital Organs; Malignant Neoplasms of Thyroid and Other Endocrine Glands,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2751,NCT05320757,Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients,RECRUITING,EARLY_PHASE1,Endometrial Cancer,Olaparib (DRUG),23725625,Olaparib,Endometrial Cancer,Uterus,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2752,NCT05774886,Implantable Microdevice for TNBC - Pilot Study,WITHDRAWN,PHASE1,Triple Negative Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer; Early Stage Triple-Negative Breast Carcinoma; Breast Neoplasms; Breast Carcinoma,Implantable Microdevice (IMD) (COMBINATION_PRODUCT),23725625,Olaparib,Triple Negative Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2753,NCT02000622,Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer Metastatic; BRCA 1 Gene Mutation; BRCA 2 Gene Mutation,Olaparib (DRUG); Physician's choice chemotherapy (DRUG),23725625,Olaparib,Breast Cancer Metastatic; BRCA 1 Gene Mutation; BRCA 2 Gene Mutation,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2754,NCT04053322,"Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.",ACTIVE_NOT_RECRUITING,PHASE2,"ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer; a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status",Durvalumab (DRUG); Olaparib (DRUG); Fulvestrant (DRUG),23725625,Olaparib,"ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer; a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status",Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2755,NCT06797635,"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)",RECRUITING,PHASE2,Breast Neoplasms; Breast Cancer,Patritumab deruxtecan (BIOLOGICAL); Pembrolizumab (BIOLOGICAL); Paclitaxel (DRUG); Carboplatin (DRUG); Doxorubicin hydrochloride (DRUG); Epirubicin hydrochloride (DRUG); Cyclophosphamide (DRUG); Capecitabine (DRUG); Olaparib (DRUG),23725625,Olaparib,Breast Neoplasms; Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2756,NCT05463848,Surgical Pembro +/- Olaparib W TMZ for RGBM,RECRUITING,PHASE2,Glioblastoma; Recurrent Glioblastoma,Pembrolizumab (DRUG); Olaparib (DRUG); Temozolomide (DRUG),23725625,Olaparib,Glioblastoma; Recurrent Glioblastoma,CNS/Brain,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2757,NCT03786796,Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations,RECRUITING,PHASE2,Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Kidney Cancer; Renal Carcinoma; Kidney Cancer Metastatic,Olaparib (DRUG),23725625,Olaparib,Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Kidney Cancer; Renal Carcinoma; Kidney Cancer Metastatic,Kidney,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2758,NCT05629429,Olaparib Maintenance Therapy in Metastatic Breast Cancer,RECRUITING,PHASE2,Metastatic Breast Cancer,Olaparib (DRUG); Chemotherapy drug (DRUG),23725625,Olaparib,Metastatic Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2759,NCT05209529,Chemo-free BRCA-targeted Neoadjuvant Strategy,WITHDRAWN,PHASE2,TNBC - Triple-Negative Breast Cancer; BRCA1 Mutation; BRCA2 Mutation,olaparib (DRUG); Durvalumab (DRUG),23725625,Olaparib,TNBC - Triple-Negative Breast Cancer; BRCA1 Mutation; BRCA2 Mutation,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2760,NCT03109080,Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC),COMPLETED,PHASE1,"Breast Neoplasms, Triple-Negative; Breast Neoplasm Malignant Female; Radiotherapy Side Effect",Olaparib (DRUG); Radiation therapy (RADIATION),23725625,Olaparib,"Breast Neoplasms, Triple-Negative; Breast Neoplasm Malignant Female; Radiotherapy Side Effect",Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2761,NCT03367689,A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent,TERMINATED,PHASE2,Breast Cancer,Olaparib (DRUG),23725625,Olaparib,Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2762,NCT06245889,PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC,RECRUITING,PHASE2,Triple Negative Breast Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Pembrolizumab (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Olaparib (DRUG); Capecitabine (DRUG),23725625,Olaparib,Triple Negative Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2763,NCT05245994,"An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese",UNKNOWN,PHASE2,Lung Cancer; Small Cell Lung Cancer; Durvalumab,"Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib (DRUG)",23725625,Olaparib,Lung Cancer; Small Cell Lung Cancer; Durvalumab,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2764,NCT02769962,"Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Urothelial Carcinoma; Urothelial Cancer; Lung Neoplasms; Small Cell Lung Cancer; Prostate Cancer,EP0057 (DRUG); olaparib (DRUG),23725625,Olaparib,Urothelial Carcinoma; Urothelial Cancer; Lung Neoplasms; Small Cell Lung Cancer; Prostate Cancer,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2765,NCT05411094,Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer,RECRUITING,PHASE1,Locally Advanced Pancreatic Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Unresectable Pancreatic Carcinoma,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Durvalumab (BIOLOGICAL); Olaparib (DRUG); Radiation Therapy (RADIATION); Radiologic Examination (PROCEDURE),23725625,Olaparib,Locally Advanced Pancreatic Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Unresectable Pancreatic Carcinoma,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2766,NCT04884360,D9319C00001- 1L OC Mono Global RCT,ACTIVE_NOT_RECRUITING,PHASE3,Ovarian Cancer,Olaparib (DRUG); Matching placebo (OTHER),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2767,NCT04939662,Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects,COMPLETED,PHASE2,Lung Cancer,Olaparib+Bevacizumab to SCLC patients (DRUG),23725625,Olaparib,Lung Cancer,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2768,NCT03532880,A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer,COMPLETED,PHASE1,Small-cell Lung Cancer; Small Cell Lung Carcinoma,Olaparib Pill 50 mg (DRUG); Olaparib Pill 100 mg (DRUG); Olaparib Pill 150 mg (DRUG); Olaparib Pill 200 mg (DRUG); Olaparib Pill 250 mg (DRUG); Olaparib Pill 300 mg (DRUG); Radiotherapy (RADIATION),23725625,Olaparib,Small-cell Lung Cancer; Small Cell Lung Carcinoma,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2769,NCT04166435,TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,Temozolomide + Olaparib (DRUG),23725625,Olaparib,Colorectal Cancer,Bowel,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2770,NCT03025035,Pembrolizumab in Combination with Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Pembrolizumab (DRUG); Olaparib (DRUG),23725625,Olaparib,Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2771,NCT04586335,Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.,TERMINATED,PHASE1,Ovarian Cancer; Breast Cancer; Solid Tumor; Prostate Cancer; Endometrial Cancer,CYH33 (DRUG),23725625,Olaparib,Ovarian Cancer; Breast Cancer; Solid Tumor; Prostate Cancer; Endometrial Cancer,Uterus,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2772,NCT02679963,Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,Olaparib (DRUG); Placebo (DRUG),23725625,Olaparib,Non Small Cell Lung Cancer,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2773,NCT03775486,Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION),ACTIVE_NOT_RECRUITING,PHASE2,Non-small Cell Lung Cancer NSCLC,Durvalumab (DRUG); Placebo for Olaparib (DRUG); Olaparib (DRUG); Nab-paclitaxel+carboplatin (DRUG); Gemcitabine+carboplatin (DRUG); Pemetrexed+carboplatin (DRUG); Gemcitabine+cisplatin (DRUG); Pemetrexed+cisplatin (DRUG),23725625,Olaparib,Non-small Cell Lung Cancer NSCLC,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2774,NCT05967286,"Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial",WITHDRAWN,PHASE2,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Negative Breast Carcinoma; Unresectable HER2-Negative Breast Carcinoma,Alpelisib (DRUG); Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Olaparib (DRUG); Positron Emission Tomography (PROCEDURE),23725625,Olaparib,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Negative Breast Carcinoma; Unresectable HER2-Negative Breast Carcinoma,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2775,NCT03579316,"Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Adavosertib (DRUG); Olaparib (DRUG); Ceralasertib (DRUG),23725625,Olaparib,Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2776,NCT06746116,A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain,RECRUITING,PHASE3,Advanced or Recurrent Endometrial Cancer,Durvalumab + Chemotherapy phase (DRUG); Durvalumab + Olaparib phase (DRUG),23725625,Olaparib,Advanced or Recurrent Endometrial Cancer,Uterus,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2777,NCT04015739,Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse,UNKNOWN,PHASE2,Epithelial Ovarian Cancer; Relapse,"Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination (DRUG)",23725625,Olaparib,Epithelial Ovarian Cancer; Relapse,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2778,NCT05524935,Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma,RECRUITING,PHASE2,Uveal Melanoma; Ocular Melanoma,Pembrolizumab (DRUG); Olaparib (DRUG),23725625,Olaparib,Uveal Melanoma; Ocular Melanoma,Skin,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2779,NCT04421963,Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib,ENROLLING_BY_INVITATION,PHASE3,Ovarian Cancer; Breast Cancer,Olaparib (DRUG),23725625,Olaparib,Breast and Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2780,NCT04191135,Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009),ACTIVE_NOT_RECRUITING,PHASE2,Triple Negative Breast Neoplasms,Pembrolizumab (BIOLOGICAL); Olaparib (DRUG); Carboplatin (DRUG); Gemcitabine (DRUG),23725625,Olaparib,Triple Negative Breast Neoplasms,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2781,NCT00516724,Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel,COMPLETED,PHASE1,Triple Negative Metastatic Breast Cancer; Advanced Ovarian Cancer; Carboplatin; Paclitaxel,KU-0059436 (AZD2281)(PARP inhibitor) (DRUG); Carboplatin (DRUG); KU-0059436 (AZD2281)(PARP inhibitor) (DRUG); Paclitaxel (DRUG); KU-0059436 (AZD2281)(PARP inhibitor) (DRUG); Paclitaxel + Carboplatin (DRUG),23725625,Olaparib,Triple Negative Metastatic Breast Cancer; Advanced Ovarian Cancer; Carboplatin; Paclitaxel,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2782,NCT04711824,Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases,RECRUITING,PHASE1,"Breast Cancer; Brain Metastases, Adult",Olaparib (DRUG); Stereotactic Radiosurgery (RADIATION); Durvalumab (DRUG); Physicians Choice systemic chemotherapy (DRUG),23725625,Olaparib,"Breast Cancer; Brain Metastases, Adult",Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2783,NCT06607692,Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).,RECRUITING,PHASE2,Solid Tumor Cancer; Medulloblastoma; High Risk Neuroblastoma; High Grade Gliomas; Meningioma; Paraganglioma; Pheochromocytoma; Neuroendocrine Tumours (NET); Adrenal Tumours,Olaparib; 177Lu-DOTATATE (DRUG),23725625,Olaparib,Solid Tumor Cancer; Medulloblastoma; High Risk Neuroblastoma; High Grade Gliomas; Meningioma; Paraganglioma; Pheochromocytoma; Neuroendocrine Tumours (NET); Adrenal Tumours,CNS/Brain,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2784,NCT02755844,"Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients",COMPLETED,PHASE1,Recurrent Endometrial Cancer,Olaparib (DRUG); metformin (DRUG); metronomic cyclophosphamide (DRUG),23725625,Olaparib,Recurrent Endometrial Cancer,Uterus,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2785,NCT03233204,"Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)",COMPLETED,PHASE2,Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Low Grade Glioma; Malignant Glioma; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Refractory Childhood Malignant Germ Cell Tumor; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Rhabdoid Tumor; Wilms Tumor,Olaparib (DRUG),23725625,Olaparib,Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Low Grade Glioma; Malignant Glioma; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Refractory Childhood Malignant Germ Cell Tumor; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Rhabdoid Tumor; Wilms Tumor,CNS/Brain,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2786,NCT02446704,Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy,UNKNOWN,PHASE1,Small Cell Lung Cancer,Olaparib (DRUG); Temozolomide (DRUG),23725625,Olaparib,Small Cell Lung Cancer,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2787,NCT04091204,Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study,UNKNOWN,PHASE2,BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer,Olaparib tablets (DRUG),23725625,Olaparib,BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2788,NCT04550104,A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC,RECRUITING,PHASE1,Non Small Cell Lung Cancer,Radiotherapy (RADIATION); Olaparib Oral Tablet [Lynparza] (DRUG); AZD1390 (DRUG); Ceralasertib (DRUG); AZD5305 (DRUG); Durvalumab (DRUG),23725625,Olaparib,Non Small Cell Lung Cancer,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2789,NCT02484404,"Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...",ACTIVE_NOT_RECRUITING,PHASE1,Colorectal Neoplasms; Breast Neoplasms,Olaparib (DRUG); Cediranib (DRUG); Durvalumab (DRUG),23725625,Olaparib,Colorectal Neoplasms; Breast Neoplasms,Bowel,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2790,NCT02477644,"Platine, Avastin and OLAparib in 1st Line",COMPLETED,PHASE3,Ovarian Cancer,Olaparib (DRUG); Placebo (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2791,NCT04306367,Study of Pembrolizumab and Olaparib in Bile Duct Cancer,COMPLETED,PHASE2,Cholangiocarcinoma,Pembrolizumab (DRUG); Olaparib (DRUG),23725625,Olaparib,Cholangiocarcinoma,Liver,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2792,NCT03955640,Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences,UNKNOWN,PHASE1,Metastatic Malignant Neoplasm in the Chest Wall; Recurrent Breast Carcinoma,Olaparib (DRUG); Hyperthermia Treatment (PROCEDURE); Questionnaire Administration (OTHER); Quality-of-Life Assessment (OTHER),23725625,Olaparib,Metastatic Malignant Neoplasm in the Chest Wall; Recurrent Breast Carcinoma,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2793,NCT03314740,Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib,COMPLETED,PHASE2,Ovarian Neoplasms,Paclitaxel (DRUG); Cediranib (DRUG); Olaparib (DRUG),23725625,Olaparib,Ovarian Neoplasms,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2794,NCT04483544,Pembrolizumab and Olaparib in Cervical Cancer Patients,TERMINATED,PHASE2,Cervical Cancer; Cervical Carcinoma,pembrolizumab (DRUG); olaparib (DRUG),23725625,Olaparib,Cervical Cancer; Cervical Carcinoma,Cervix,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2795,NCT05975944,Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer,UNKNOWN,PHASE1,Extensive-stage Small Cell Lung Cancer,Selinexor，Olaparib (DRUG),23725625,Olaparib,Extensive-stage Small Cell Lung Cancer,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2796,NCT03459846,"A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)",ACTIVE_NOT_RECRUITING,PHASE2,Urinary Bladder Neoplasms,Durvalumab (DRUG); Olaparib (DRUG); Placebo (DRUG),23725625,Olaparib,Urinary Bladder Neoplasms,Bladder/Urinary Tract,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2797,NCT04624204,"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)",ACTIVE_NOT_RECRUITING,PHASE3,Small Cell Lung Cancer,"Pembrolizumab 200 mg (BIOLOGICAL); Pembrolizumab 400 mg (BIOLOGICAL); Pembrolizumab placebo (saline) (DRUG); Pembrolizumab placebo (saline) (DRUG); Olaparib 300 mg BID (DRUG); Olaparib matching placebo (DRUG); Etoposide 100 mg/m^2 (DRUG); Platinum, investigator's choice (DRUG); Standard Thoracic Radiotherapy (RADIATION); Prophylactic Cranial Irradiation (PCI) (RADIATION)",23725625,Olaparib,Small Cell Lung Cancer,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2798,NCT04375267,177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours,ACTIVE_NOT_RECRUITING,PHASE1,"Clinical Trial, Phase I; Neuroendocrine Tumors; Thymoma; Mesothelioma",177Lu-DOTA-TATE + olaparib (DRUG),23725625,Olaparib,"Clinical Trial, Phase I; Neuroendocrine Tumors; Thymoma; Mesothelioma",Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2799,NCT04644289,WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC,RECRUITING,PHASE2,Epithelial Ovarian Cancer,olaparib (DRUG); durvalumab (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2800,NCT03682289,Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors,RECRUITING,PHASE2,Clear Cell Renal Cell Carcinoma; Locally Advanced Pancreatic Cancer; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Metastatic Renal Cell Carcinoma; Metastatic Urothelial Carcinoma; Metastatic Pancreatic Cancer; Stage III Pancreatic Cancer; Stage III Renal Cell Cancer; Stage IV Pancreatic Cancer; Stage IV Renal Cell Cancer; Endometrial Cancer; Metastatic Castration-resistant Prostate Cancer,Ceralasertib (DRUG); Olaparib (DRUG); Durvalumab (DRUG),23725625,Olaparib,Clear Cell Renal Cell Carcinoma; Locally Advanced Pancreatic Cancer; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Metastatic Renal Cell Carcinoma; Metastatic Urothelial Carcinoma; Metastatic Pancreatic Cancer; Stage III Pancreatic Cancer; Stage III Renal Cell Cancer; Stage IV Pancreatic Cancer; Stage IV Renal Cell Cancer; Endometrial Cancer; Metastatic Castration-resistant Prostate Cancer,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2801,NCT02849496,Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Unresectable Breast Carcinoma; Metastatic Breast Carcinoma,Atezolizumab (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration (PROCEDURE); Bone Marrow Biopsy (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Olaparib (DRUG); Positron Emission Tomography (PROCEDURE); Questionnaire Administration (OTHER); X-Ray Imaging (PROCEDURE),23725625,Olaparib,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Unresectable Breast Carcinoma; Metastatic Breast Carcinoma,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2802,NCT03594396,Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Breast Neoplasms,Olaparib (DRUG); Durvalumab (DRUG),23725625,Olaparib,Breast Neoplasms,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2803,NCT03740165,Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036),ACTIVE_NOT_RECRUITING,PHASE3,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms,Pembrolizumab (BIOLOGICAL); Placebo for pembrolizumab (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Olaparib (DRUG); Placebo for olaparib (DRUG); Bevacizumab (BIOLOGICAL); Docetaxel (DRUG),23725625,Olaparib,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2804,NCT05128734,Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC),NOT_YET_RECRUITING,PHASE2,Breast Cancer Triple Negative,Temozolomide (DRUG); Olaparib (DRUG),23725625,Olaparib,Breast Cancer Triple Negative,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2805,NCT05949424,OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults,NOT_YET_RECRUITING,PHASE4,Renal Cell Carcinoma; Ovarian Carcinoma; Thyroid Carcinoma; Breast Carcinoma; Endometrium Carcinoma,Olaparib (DRUG); Lenvatinib (DRUG); Sunitinib (DRUG); Palbociclib (DRUG); Pazopanib (DRUG); Olaparib (DRUG); Lenvatinib (DRUG); Sunitinib (DRUG); Palbociclib (DRUG); Pazopanib (DRUG),23725625,Olaparib,Renal Cell Carcinoma; Ovarian Carcinoma; Thyroid Carcinoma; Breast Carcinoma; Endometrium Carcinoma,Kidney,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2806,NCT03534492,Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB),COMPLETED,PHASE2,Bladder Cancer,Durvalumab (DRUG); Olaparib (DRUG),23725625,Olaparib,Bladder Cancer,Bladder/Urinary Tract,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2807,NCT04417192,Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer,COMPLETED,PHASE2,Ovarian Cancer,Olaparib (DRUG); Pembrolizumab (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2808,NCT02418624,Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer,COMPLETED,PHASE1,Breast Cancer; Ovarian Cancer; Advanced Cancer,"carboplatin, olaparib (DRUG)",23725625,Olaparib,Breast Cancer; Ovarian Cancer; Advanced Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2809,NCT03402841,Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients,COMPLETED,PHASE3,Non-Germline BRCA Mutated Ovarian Cancer,Olaparib (DRUG),23725625,Olaparib,Non-Germline BRCA Mutated Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2810,NCT01661868,Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer,WITHDRAWN,PHASE2,Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer,Olaparib (DRUG),23725625,Olaparib,Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2811,NCT05379972,Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers,RECRUITING,PHASE2,Gastric Cancer; GastroEsophageal Cancer,Pembrolizumab (DRUG); Olaparib (DRUG); Stereotactic Body Radiation Therapy (RADIATION),23725625,Olaparib,Gastric Cancer; GastroEsophageal Cancer,Esophagus/Stomach,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2812,NCT06120972,Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency,WITHDRAWN,PHASE2,Ovarian Cancer,Olaparib tablet (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2813,NCT06712472,Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for P53abn Endometrial Cancer,RECRUITING,PHASE3,Endometrial Cancer; P53abn,Olaparib (300 mg BID) (DRUG),23725625,Olaparib,Endometrial Cancer; P53abn,Uterus,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2814,NCT02734004,A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.,ACTIVE_NOT_RECRUITING,PHASE1,Ovarian; Breast; SCLC; Gastric Cancers,Olaparib (DRUG); MEDI4736 (DRUG); Bevacizumab (DRUG),23725625,Olaparib,Ovarian; Breast; SCLC; Gastric Cancers,Esophagus/Stomach,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2815,NCT01237067,Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers,COMPLETED,PHASE1,Ovarian Cancer; Breast Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Endometrial Cancer,Carboplatin (DRUG); Olaparib (DRUG),23725625,Olaparib,Ovarian Cancer; Breast Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Endometrial Cancer,Uterus,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2816,NCT04330040,Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer,COMPLETED,PHASE4,Ovarian Cancer; Breast Cancer,Olaparib (DRUG),23725625,Olaparib,Breast and Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2817,NCT03531840,Olaparib in People With Malignant Mesothelioma,COMPLETED,PHASE2,Mesothelioma,Olaparib (DRUG); ClinOmics (DEVICE),23725625,Olaparib,Mesothelioma,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2818,NCT04666740,A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Pancreatic Ductal Adenocarcinoma; Homologous Recombination Deficiency (HRD),Pembrolizumab (DRUG); Olaparib (DRUG),23725625,Olaparib,Metastatic Pancreatic Ductal Adenocarcinoma; Homologous Recombination Deficiency (HRD),Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2819,NCT03801369,"Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma,Biopsy (PROCEDURE); Capivasertib (DRUG); Ceralasertib (DRUG); Durvalumab (BIOLOGICAL); Olaparib (DRUG); Quality-of-Life Assessment (OTHER); Selumetinib (DRUG),23725625,Olaparib,Metastatic Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2820,NCT02511795,AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors,COMPLETED,PHASE1,Refractory Solid Tumours; Relapsed Small Cell Lung Cancer (SCLC),AZD1775 (DRUG); Olaparib (DRUG),23725625,Olaparib,Refractory Solid Tumours; Relapsed Small Cell Lung Cancer (SCLC),Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2821,NCT02476968,To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer,COMPLETED,PHASE4,BRCA or HRR+ Mutated Ovarian Cancer Patients,Olaparib (DRUG),23725625,Olaparib,BRCA or HRR+ Mutated Ovarian Cancer Patients,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2822,NCT03251872,Olaparib for PAH: a Pilot Study,TERMINATED,EARLY_PHASE1,Pulmonary Arterial Hypertension,Olaparib (DRUG),23725625,Olaparib,Pulmonary Arterial Hypertension,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2823,NCT03182634,The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial,UNKNOWN,PHASE2,Advanced Breast Cancer,Fulvestrant (DRUG); Neratinib (DRUG); AZD5363 (DRUG); Olaparib (DRUG); AZD6738 (DRUG),23725625,Olaparib,Advanced Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2824,NCT04858334,"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation",RECRUITING,PHASE2,Pancreatic Acinar Cell Carcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Squamous Cell Carcinoma; Resectable Pancreatic Acinar Cell Carcinoma; Resectable Pancreatic Adenocarcinoma; Resectable Pancreatic Adenosquamous Carcinoma; Resectable Pancreatic Carcinoma,Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Olaparib (DRUG); Placebo Administration (DRUG),23725625,Olaparib,Pancreatic Acinar Cell Carcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Squamous Cell Carcinoma; Resectable Pancreatic Acinar Cell Carcinoma; Resectable Pancreatic Adenocarcinoma; Resectable Pancreatic Adenosquamous Carcinoma; Resectable Pancreatic Carcinoma,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2825,NCT06201234,Evaluating the Addition of Elacestrant (oral SERD) to Olaparib (PARP-inhibitor) in Patients with Advanced/metastatic HR+/HER2- Breast Cancer,RECRUITING,PHASE2,Hormone Receptor Positive HER-2 Negative Breast Cancer; Advanced or Metastatic Breast Cancer; BRCA1 Mutation; BRCA2 Mutation,Olaparib + Elacestrant (DRUG); Olaparib (DRUG),23725625,Olaparib,Hormone Receptor Positive HER-2 Negative Breast Cancer; Advanced or Metastatic Breast Cancer; BRCA1 Mutation; BRCA2 Mutation,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2826,NCT00494234,Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms,Olaparib (DRUG),23725625,Olaparib,Breast Neoplasms,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2827,NCT01063517,Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients,COMPLETED,PHASE2,Gastric Cancer,olaparib (DRUG); paclitaxel (DRUG); Placebo (DRUG),23725625,Olaparib,Gastric Cancer,Esophagus/Stomach,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2828,NCT02937818,"A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer",COMPLETED,PHASE2,Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma,Durvalumab and Tremelimumab (DRUG); AZD1775 and carboplatin (CBPT) (DRUG); AZD6738 and olaparib (DRUG),23725625,Olaparib,Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2829,NCT05340413,Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.,UNKNOWN,PHASE2,HER2-negative Breast Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer,Olaparib (DRUG),23725625,Olaparib,HER2-negative Breast Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2830,NCT04515836,Olaparib in Patients With HRD Malignant Mesothelioma,RECRUITING,PHASE2,Mesothelioma; Homologous Recombination Deficiency,Olaparib (DRUG),23725625,Olaparib,Mesothelioma; Homologous Recombination Deficiency,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2831,NCT03167619,Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA),COMPLETED,PHASE2,Triple Negative Breast Cancer,Olaparib Oral Product (DRUG); Olaparib Oral Product in combination with Durvalumab (DRUG),23725625,Olaparib,Triple Negative Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2832,NCT03448718,Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations,COMPLETED,PHASE2,Metastatic Urothelial Cancer,Olaparib (DRUG),23725625,Olaparib,Metastatic Urothelial Cancer,Bladder/Urinary Tract,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2833,NCT03782818,Olaparib for PAH: a Multicenter Clinical Trial,TERMINATED,PHASE1,Pulmonary Arterial Hypertension,Olaparib (DRUG),23725625,Olaparib,Pulmonary Arterial Hypertension,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2834,NCT02684318,Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors,UNKNOWN,PHASE1,Advanced Cancer; Ovarian Cancer; Endometrial Cancer; Breast Cancer,PM01183 + olaparib (DRUG),23725625,Olaparib,Advanced Cancer; Ovarian Cancer; Endometrial Cancer; Breast Cancer,Uterus,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2835,NCT01623349,Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer,COMPLETED,PHASE1,Ovarian Cancer; Breast Cancer,BKM120 and Olaparib (DRUG); BYL719 and Olaparib (DRUG),23725625,Olaparib,Breast and Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2836,NCT02511223,Efficacy and Safety of PARPi to Treat Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,OLAPARIB (DRUG),23725625,Olaparib,Pancreatic Cancer,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2837,NCT03851614,"Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors",ACTIVE_NOT_RECRUITING,PHASE2,Mismatch Repair Proficient Colorectal Cancer; Pancreatic Adenocarcinoma; Leiomyosarcoma,Durvalumab (BIOLOGICAL); Olaparib (DRUG); Cediranib (DRUG),23725625,Olaparib,Mismatch Repair Proficient Colorectal Cancer; Pancreatic Adenocarcinoma; Leiomyosarcoma,Bowel,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2838,NCT03641755,Olaparib + Sapacitabine in BRCA Mutant Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,Sapacitabine (DRUG); Olaparib (DRUG),23725625,Olaparib,Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2839,NCT05268510,"Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma",COMPLETED,PHASE2,Esophagogastric Adenocarcinoma,Pembrolizumab (DRUG); Olaparib (DRUG); mFOLFOX-6 (DRUG); CapOX (DRUG),23725625,Olaparib,Esophagogastric Adenocarcinoma,Esophagus/Stomach,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2840,NCT05188508,"Pembrolizumab, Olaparib, and Temozolomide for People with Glioma",RECRUITING,PHASE2,Glioma,Pembrolizumab (DRUG); Olaparib and Temozolomide (COMBINATION_PRODUCT),23725625,Olaparib,Glioma,CNS/Brain,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2841,NCT02686008,Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC,WITHDRAWN,PHASE1,Squamous Cell Carcinoma of the Head and Neck,Olaparib (DRUG),23725625,Olaparib,Squamous Cell Carcinoma of the Head and Neck,Skin,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2842,NCT02419495,Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies,TERMINATED,PHASE1,Advanced Malignant Solid Neoplasm; Clinical Stage III Cutaneous Melanoma AJCC V8; Clinical Stage IV Cutaneous Melanoma AJCC V8; Fallopian Tube Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Renal Cell Carcinoma; Ovarian Carcinoma; Pathologic Stage III Cutaneous Melanoma AJCC V8; Pathologic Stage IIIA Cutaneous Melanoma AJCC V8; Pathologic Stage IIIB Cutaneous Melanoma AJCC V8; Pathologic Stage IIIC Cutaneous Melanoma AJCC V8; Pathologic Stage IIID Cutaneous Melanoma AJCC V8; Pathologic Stage IV Cutaneous Melanoma AJCC V8; Primary Peritoneal Carcinoma; Stage III Lung Cancer AJCC V8; Stage III Renal Cell Cancer AJCC V8; Stage IIIA Lung Cancer AJCC V8; Stage IIIB Lung Cancer AJCC V8; Stage IIIC Lung Cancer AJCC V8; Stage IV Lung Cancer AJCC V8; Stage IV Renal Cell Cancer AJCC V8; Stage IVA Lung Cancer AJCC V8; Stage IVB Lung Cancer AJCC V8; Triple-Negative Breast Carcinoma; Unresectable Lung Non-Small Cell Carcinoma; Unresectable Melanoma; Unresectable Renal Cell Carcinoma,Capecitabine (DRUG); Carboplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin (DRUG); Eribulin (DRUG); Fluorouracil (DRUG); Ipilimumab (BIOLOGICAL); Irinotecan Hydrochloride (DRUG); Leucovorin Calcium (DRUG); Nivolumab (BIOLOGICAL); Olaparib (DRUG); Oxaliplatin (DRUG); Paclitaxel (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed (DRUG); Selinexor (DRUG); Topotecan (DRUG),23725625,Olaparib,Advanced Malignant Solid Neoplasm; Clinical Stage III Cutaneous Melanoma AJCC V8; Clinical Stage IV Cutaneous Melanoma AJCC V8; Fallopian Tube Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Renal Cell Carcinoma; Ovarian Carcinoma; Pathologic Stage III Cutaneous Melanoma AJCC V8; Pathologic Stage IIIA Cutaneous Melanoma AJCC V8; Pathologic Stage IIIB Cutaneous Melanoma AJCC V8; Pathologic Stage IIIC Cutaneous Melanoma AJCC V8; Pathologic Stage IIID Cutaneous Melanoma AJCC V8; Pathologic Stage IV Cutaneous Melanoma AJCC V8; Primary Peritoneal Carcinoma; Stage III Lung Cancer AJCC V8; Stage III Renal Cell Cancer AJCC V8; Stage IIIA Lung Cancer AJCC V8; Stage IIIB Lung Cancer AJCC V8; Stage IIIC Lung Cancer AJCC V8; Stage IV Lung Cancer AJCC V8; Stage IV Renal Cell Cancer AJCC V8; Stage IVA Lung Cancer AJCC V8; Stage IVB Lung Cancer AJCC V8; Triple-Negative Breast Carcinoma; Unresectable Lung Non-Small Cell Carcinoma; Unresectable Melanoma; Unresectable Renal Cell Carcinoma,Kidney,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2843,NCT02032823,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Olaparib (DRUG); Placebo (DRUG),23725625,Olaparib,Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2844,NCT06580314,"Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer",NOT_YET_RECRUITING,PHASE3,Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; FIGO Stage III Ovarian Cancer 2014; FIGO Stage IV Ovarian Cancer 2014; Ovarian Carcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma,Olaparib (DRUG); Bevacizumab (BIOLOGICAL); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE),23725625,Olaparib,Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; FIGO Stage III Ovarian Cancer 2014; FIGO Stage IV Ovarian Cancer 2014; Ovarian Carcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2845,NCT05498155,Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Neoadjuvant Olaparib monotherapy group (DRUG); Neoadjuvant combination therapy with olaparib plus durvalumab (COMBINATION_PRODUCT),23725625,Olaparib,Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2846,NCT03745950,UTOLA: UTerin OLAparib,COMPLETED,PHASE2,Endometrial Carcinoma,Olaparib Oral Capsule (DRUG); Placebo oral capsule (DRUG),23725625,Olaparib,Endometrial Carcinoma,Uterus,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2847,NCT03878095,Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors,ACTIVE_NOT_RECRUITING,PHASE2,Malignant Solid Neoplasm; Refractory Cholangiocarcinoma; Refractory Malignant Solid Neoplasm,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration (PROCEDURE); Bone Marrow Biopsy (PROCEDURE); Ceralasertib (DRUG); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Olaparib (DRUG),23725625,Olaparib,Malignant Solid Neoplasm; Refractory Cholangiocarcinoma; Refractory Malignant Solid Neoplasm,Liver,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2848,NCT05900895,Estradiol Plus Olaparib for Breast Cancer (PHOEBE),RECRUITING,PHASE1,Metastatic Breast Cancer,Olaparib (DRUG); 17b-estradiol (DRUG),23725625,Olaparib,Metastatic Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2849,NCT04239014,"A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.",WITHDRAWN,PHASE2,Ovarian Cancer,Olaparib (DRUG); Ceralasertib (DRUG); Placebo to match olaparib (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2850,NCT06135714,Metastasis-directed Therapy for Oligometastases of Breast Cancer,RECRUITING,PHASE3,Breast Cancer; Oligometastasis; Metastatic Breast Cancer,Systemic therapy for 12 weeks after primary registration (DRUG); Radiation therapy (SBRT/conventional RT) (PROCEDURE); Surgery (PROCEDURE); Same systemic therapy after secondary registration (DRUG),23725625,Olaparib,Breast Cancer; Oligometastasis; Metastatic Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2851,NCT04380636,Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012),ACTIVE_NOT_RECRUITING,PHASE3,"Lung Neoplasms; Carcinoma, Non-Small-Cell Lung",Pembrolizumab (BIOLOGICAL); Olaparib (DRUG); Placebo for olaparib (DRUG); Etoposide (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Paclitaxel (DRUG); Pemetrexed (DRUG); Thoracic Radiotherapy (RADIATION); Durvalumab (DRUG),23725625,Olaparib,"Lung Neoplasms; Carcinoma, Non-Small-Cell Lung",Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2852,NCT03699449,An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION),UNKNOWN,PHASE2,Platinum-resistant Recurrent Ovarian Cancer,olaparib+cediranib combination therapy (DRUG); durvalumab + olaparib combination therapy (DRUG); durvalumab + chemotherapy treatment (DRUG); durvalumab + tremelimumab + chemotherapy treatment (DRUG); durvalumab + tremelimumab + paclitaxel treatment (DRUG); durvalumab +chemotherapy treatment (DRUG),23725625,Olaparib,Platinum-resistant Recurrent Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2853,NCT04361370,Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer,ENROLLING_BY_INVITATION,PHASE2,Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer,Olaparib-Pembrolizumab-Bevacizumab (DRUG),23725625,Olaparib,Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2854,NCT02208375,mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian,ACTIVE_NOT_RECRUITING,PHASE1,BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Endometrial Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; High Grade Ovarian Serous Adenocarcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage III Uterine Corpus Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Uterine Corpus Cancer AJCC v7; Triple-Negative Breast Carcinoma,Capivasertib (DRUG); Laboratory Biomarker Analysis (OTHER); Olaparib (DRUG); Pharmacological Study (OTHER); Vistusertib (DRUG),23725625,Olaparib,BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Endometrial Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; High Grade Ovarian Serous Adenocarcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage III Uterine Corpus Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Uterine Corpus Cancer AJCC v7; Triple-Negative Breast Carcinoma,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2855,NCT04931342,A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors,ACTIVE_NOT_RECRUITING,PHASE2,Ovarian Cancer,Ipatasertib (DRUG); Cobimetinib (DRUG); Trastuzumab Emtansine (DRUG); Atezolizumab (DRUG); Bevacizumab (DRUG); Paclitaxel (DRUG); Giredestrant (DRUG); Abemaciclib (DRUG); Inavolisib (DRUG); Palbociclib (DRUG); Letrozole (DRUG); Olaparib (DRUG); Luteinizing Hormone-Releasing Hormone (LHRH) Agonists (DRUG); Cyclophosphamide (DRUG); Inavolisib (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2856,NCT06545942,Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors,RECRUITING,PHASE1,Advanced Solid Tumor; Metastatic Solid Tumor; Prostate Cancer; Pancreas Cancer; Breast Cancer; Ovarian Cancer; Homologous Recombination Deficiency,MOMA-313 (DRUG); Olaparib (DRUG),23725625,Olaparib,Advanced Solid Tumor; Metastatic Solid Tumor; Prostate Cancer; Pancreas Cancer; Breast Cancer; Ovarian Cancer; Homologous Recombination Deficiency,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2857,NCT03212742,Phase I/IIa Study of Concomitant Radiotherapy with Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients,ACTIVE_NOT_RECRUITING,PHASE1,Malignant Gliomas; Radiotherapy; PARP Inhibitor,Olaparib (DRUG); Temozolomide (TMZ) (DRUG); IMRT (Intensity Modulated Radiation Therapy) (RADIATION),23725625,Olaparib,Malignant Gliomas; Radiotherapy; PARP Inhibitor,CNS/Brain,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2858,NCT06856499,Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/homologous Recombination Deficiency Platinum Resistant Ovarian Cancer,NOT_YET_RECRUITING,PHASE1,Endometrioid Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer,Cirtuvivint (DRUG); Olaparib (DRUG),23725625,Olaparib,Endometrioid Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2859,NCT02983799,Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status,COMPLETED,PHASE2,"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity",OLAPARIB (DRUG),23725625,Olaparib,"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity",Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2860,NCT04456699,Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003),COMPLETED,PHASE3,Metastatic Colorectal Cancer,Olaparib (DRUG); 5-FU (DRUG); Bevacizumab (DRUG); Capecitabine (DRUG); Leucovorin/ levoleucovorin (DRUG),23725625,Olaparib,Metastatic Colorectal Cancer,Bowel,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2861,NCT02299999,SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Cancer,AZD2014 (DRUG); AZD4547 (DRUG); AZD5363 (DRUG); AZD8931 (DRUG); Selumetinib (DRUG); Vandetanib (DRUG); Bicalutamide (DRUG); Olaparib (DRUG); Anthracyclines (DRUG); Taxanes (DRUG); cyclophosphamide (DRUG); DNA intercalators (DRUG); Methotrexate (DRUG); vinca alkaloids (DRUG); Platinum based chemotherapies (DRUG); Bevacizumab (DRUG); Mitomycin C (DRUG); Eribulin (DRUG); MEDI4736 (DRUG),23725625,Olaparib,Metastatic Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2862,NCT02489006,"A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Ovarian Cancer; Fallopian Tube Cancer; Neoadjuvant Treatment; Debulking Surgical Procedures,Olaparib (DRUG); Platinum-based Chemotherapy (DRUG),23725625,Olaparib,Ovarian Cancer; Fallopian Tube Cancer; Neoadjuvant Treatment; Debulking Surgical Procedures,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2863,NCT05411679,EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer,WITHDRAWN,PHASE2,Gastric Cancer; Small-cell Lung Cancer,EP0057 (DRUG); Olaparib tablets (DRUG),23725625,Olaparib,Gastric Cancer; Small-cell Lung Cancer,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2864,NCT00516802,A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine,COMPLETED,PHASE1,Melanoma Neoplasms,KU-0059436 (AZD2281)(PARP inhibitor) (DRUG); dacarbazine (DRUG),23725625,Olaparib,Melanoma Neoplasms,Skin,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2865,NCT04678102,"Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)",RECRUITING,PHASE1,Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Carcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma,PHI-101 administration (DRUG),23725625,Olaparib,Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Carcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2866,NCT04669002,EP0057 in Combination With Olaparib in Advanced Ovarian Cancer,COMPLETED,PHASE2,Ovarian Cancer,EP0057 (DRUG); Olaparib tablets (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2867,NCT04633902,Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation,UNKNOWN,PHASE2,Metastatic Melanoma,Olaparib (DRUG); Pembrolizumab (DRUG),23725625,Olaparib,Metastatic Melanoma,Skin,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2868,NCT02974621,Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma,ACTIVE_NOT_RECRUITING,PHASE2,Recurrent Glioblastoma,Bevacizumab (BIOLOGICAL); Cediranib (DRUG); Cediranib Maleate (DRUG); Olaparib (DRUG),23725625,Olaparib,Recurrent Glioblastoma,CNS/Brain,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2869,NCT06419179,"Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)",ENROLLING_BY_INVITATION,PHASE2,Small Cell Lung Carcinoma,Durvalumab (DRUG); Olaparib (DRUG),23725625,Olaparib,Small Cell Lung Carcinoma,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2870,NCT04683679,A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer,RECRUITING,PHASE2,Triple Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer,Pembrolizumab (DRUG); Olaparib (DRUG); Radiation (RADIATION),23725625,Olaparib,Triple Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2871,NCT06298084,"Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd",RECRUITING,PHASE1,Breast Cancer Metastatic; HER2-positive Metastatic Breast Cancer; HER2 Low Breast Carcinoma; Advanced Breast Cancer,Patritumab deruxtecan (DRUG); Olaparib (DRUG),23725625,Olaparib,Breast Cancer Metastatic; HER2-positive Metastatic Breast Cancer; HER2 Low Breast Carcinoma; Advanced Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2872,NCT03579784,Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Advanced Gastric Cancer,Paclitaxel (DRUG); Olaparib (DRUG); Durvalumab (DRUG),23725625,Olaparib,Advanced Gastric Cancer,Esophagus/Stomach,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2873,NCT02810743,Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,ddAC-CP-Olaparib (DRUG); ddAC-mini CTC (DRUG),23725625,Olaparib,Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2874,NCT03737643,"Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients",ACTIVE_NOT_RECRUITING,PHASE3,Advanced Ovarian Cancer,Bevacizumab (DRUG); Durvalumab (DRUG); Olaparib (DRUG); Placebo olaparib (DRUG); Durvalumab placebo (DRUG); Carboplatin+Paclitaxel (DRUG),23725625,Olaparib,Advanced Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2875,NCT00912743,"Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status",COMPLETED,PHASE2,Colorectal Cancer,olaparib (DRUG),23725625,Olaparib,Colorectal Cancer,Bowel,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2876,NCT04753879,Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.,RECRUITING,PHASE2,Metastatic Pancreatic Cancer,Nab-paclitaxel (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG); Irinotecan (DRUG); Capecitabine (DRUG); Pembrolizumab (DRUG); Olaparib (DRUG),23725625,Olaparib,Metastatic Pancreatic Cancer,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2877,NCT04643379,Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma,ACTIVE_NOT_RECRUITING,PHASE2,Recurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma,Olaparib (DRUG); Pembrolizumab (DRUG); Carboplatin (DRUG); Peripheral blood draw (PROCEDURE),23725625,Olaparib,Metastatic Head and Neck Squamous Cell Carcinoma,Skin,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2878,NCT06112379,A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer,RECRUITING,PHASE3,Breast Cancer,Dato-DXd (DRUG); Durvalumab (DRUG); Pembrolizumab (DRUG); Doxorubicin (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Capecitabine (DRUG); Olaparib (DRUG),23725625,Olaparib,Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2879,NCT01042379,I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,RECRUITING,PHASE2,Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer,Standard Therapy (DRUG); AMG 386 with or without Trastuzumab (DRUG); AMG 479 (Ganitumab) plus Metformin (DRUG); MK-2206 with or without Trastuzumab (DRUG); AMG 386 and Trastuzumab (DRUG); T-DM1 and Pertuzumab (DRUG); Pertuzumab and Trastuzumab (DRUG); Ganetespib (DRUG); ABT-888 (DRUG); Neratinib (DRUG); PLX3397 (DRUG); Pembrolizumab - 4 cycle (DRUG); Talazoparib plus Irinotecan (DRUG); Patritumab and Trastuzumab (DRUG); Pembrolizumab - 8 cycle (DRUG); SGN-LIV1A (DRUG); Durvalumab plus Olaparib (DRUG); SD-101 + Pembrolizumab (DRUG); Tucatinib plus trastuzumab and pertuzumab (DRUG); Cemiplimab (DRUG); Cemiplimab plus REGN3767 (DRUG); Trilaciclib with or without trastuzumab + pertuzumab (DRUG); SYD985 ([vic-]trastuzumab duocarmazine) (DRUG); Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab (DRUG); Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab (DRUG); Amcenestrant (DRUG); Amcenestrant + Abemaciclib (DRUG); Amcenestrant + Letrozole (DRUG); ARX788 (DRUG); ARX788 + Cemiplimab (DRUG); VV1 + Cemiplimab (DRUG); Datopotamab deruxtecan (DRUG); Datopotamab deruxtecan + Durvalumab (DRUG); Zanidatamab (DRUG); Lasofoxifene (DRUG); Z-endoxifen (DRUG); ARV-471 (DRUG); ARV-471 + Letrozole (DRUG); ARV-471 + Abemaciclib (DRUG); Endoxifen + Abemaciclib (DRUG); Rilvegostomig + TDXd (DRUG); Dan222 + Niraparib (DRUG); Sarilumab + Cemiplimab + Paclitaxel (DRUG),23725625,Olaparib,Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2880,NCT02882308,Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.,COMPLETED,PHASE2,Squamous Cell Carcinoma of the Head and Neck,Olaparib (DRUG); Cisplatin (DRUG); Olaparib (DRUG); Durvalumab (DRUG),23725625,Olaparib,Squamous Cell Carcinoma of the Head and Neck,Skin,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2881,NCT02677038,Olaparib in Treating Patients With Stage IV Pancreatic Cancer,COMPLETED,PHASE2,Metastatic Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v6 and v7,Olaparib (DRUG),23725625,Olaparib,Metastatic Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v6 and v7,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2882,NCT04261465,NUVOLA TRIAL Open-label Multicentre Study,UNKNOWN,PHASE2,High Grade Serous Ovarian Cancer,Olaparib (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG),23725625,Olaparib,High Grade Serous Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2883,NCT01296763,Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer,COMPLETED,PHASE1,Pancreatic Cancer,Irinotecan (DRUG); Cisplatin (DRUG); Olaparib (for levels 1 and 5) (DRUG); Olaparib (for dose level 2) (DRUG); Mitomycin-C (DRUG),23725625,Olaparib,Pancreatic Cancer,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2884,NCT03278717,Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients,UNKNOWN,PHASE3,Ovarian Cancer,Olaparib (DRUG); Cediranib (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2885,NCT03334617,Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy,ACTIVE_NOT_RECRUITING,PHASE2,Non-Small Cell Lung Cancer,Durvalumab (DRUG); AZD9150 (DRUG); AZD6738 (DRUG); Vistusertib (DRUG); Olaparib (DRUG); Oleclumab (DRUG); trastuzumab deruxtecan (DRUG); cediranib (DRUG); AZD6738 (ceralasertib) (DRUG); AZD6738 (ceralasertib) (DRUG); AZD6738 (ceralasertib) (240 mg or 160 mg) (DRUG); AZD6738 (ceralasertib) 7 days monotherapy (DRUG),23725625,Olaparib,Advanced Non-Small Cell Lung Cancer,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2886,NCT01445418,AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer,COMPLETED,PHASE1,Breast Cancer; Ovarian Cancer,AZ2281 + Carboplatin (DRUG),23725625,Olaparib,Breast Cancer; Ovarian Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2887,NCT05432518,Pilot Trial for Treatment of Recurrent Glioblastoma,RECRUITING,EARLY_PHASE1,Glioblastoma; Recurrent Disease; Recurrent Glioblastoma,Afatinib (DRUG); Dasatinib (DRUG); Palbociclib (DRUG); Everolimus (DRUG); Olaparib (DRUG),23725625,Olaparib,Glioblastoma; Recurrent Disease; Recurrent Glioblastoma,CNS/Brain,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2888,NCT04742075,"Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer",RECRUITING,PHASE2,Ovarian Cancer,Olaparib + durvalumab + UV1 (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2889,NCT03561870,Olaparib in Recurrent IDH-mutant Glioma,COMPLETED,PHASE2,Recurrent IDH; Mutant High Grade Glioma,Olaparib 150 MG (DRUG),23725625,Olaparib,Recurrent IDH; Mutant High Grade Glioma,CNS/Brain,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2890,NCT06065059,Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors,TERMINATED,PHASE1,Breast Cancer; Ovarian Cancer; Pancreas Cancer; Prostate Cancer; BRCA1 Mutation; BRCA-Mutated Ovarian Carcinoma; BRCA-Associated Breast Carcinoma; HRD Positive Advanced Ovarian Cancer,TNG348 (DRUG); Olaparib (DRUG),23725625,Olaparib,Breast Cancer; Ovarian Cancer; Pancreas Cancer; Prostate Cancer; BRCA1 Mutation; BRCA-Mutated Ovarian Carcinoma; BRCA-Associated Breast Carcinoma; HRD Positive Advanced Ovarian Cancer,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2891,NCT03923270,Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Small Cell Lung Cancer Extensive Stage; Small-cell Lung Cancer,Durvalumab (DRUG); Tremelimumab (DRUG); Olaparib Pill (DRUG); Thoracic Radiotherapy (RADIATION); Tremelimumab (DRUG),23725625,Olaparib,Small Cell Lung Cancer Extensive Stage; Small-cell Lung Cancer,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2892,NCT02498613,A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE2,Advanced Malignant Solid Neoplasm; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Small Cell Carcinoma; Metastatic Pancreatic Adenocarcinoma; Metastatic Triple-Negative Breast Carcinoma; Pancreatic Ductal Adenocarcinoma; Stage III Breast Cancer AJCC v7; Stage III Lung Non-Small Cell Cancer AJCC v7; Stage III Lung Small Cell Carcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Small Cell Carcinoma AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Small Cell Carcinoma AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Lung Non-Small Cell Cancer AJCC v7; Stage IV Lung Small Cell Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma; Unresectable Lung Small Cell Carcinoma; Unresectable Pancreatic Adenocarcinoma; Unresectable Pancreatic Carcinoma; Unresectable Triple-Negative Breast Carcinoma,18F-Fluoromisonidazole (OTHER); Cediranib Maleate (DRUG); Laboratory Biomarker Analysis (OTHER); Olaparib (DRUG); Positron Emission Tomography (PROCEDURE),23725625,Olaparib,Advanced Malignant Solid Neoplasm; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Small Cell Carcinoma; Metastatic Pancreatic Adenocarcinoma; Metastatic Triple-Negative Breast Carcinoma; Pancreatic Ductal Adenocarcinoma; Stage III Breast Cancer AJCC v7; Stage III Lung Non-Small Cell Cancer AJCC v7; Stage III Lung Small Cell Carcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Small Cell Carcinoma AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Small Cell Carcinoma AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Lung Non-Small Cell Cancer AJCC v7; Stage IV Lung Small Cell Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma; Unresectable Lung Small Cell Carcinoma; Unresectable Pancreatic Adenocarcinoma; Unresectable Pancreatic Carcinoma; Unresectable Triple-Negative Breast Carcinoma,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2893,NCT03161132,"Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin",COMPLETED,PHASE2,Advanced Ovarian Cancer,Olaparib (DRUG); Pegylated Liposomal Doxorubicin (DRUG),23725625,Olaparib,Advanced Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2894,NCT03991832,Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors,RECRUITING,PHASE2,Glioma; Cholangiocarcinoma; Solid Tumor; IDH Mutation,Olaparib (DRUG); Durvalumab (DRUG),23725625,Olaparib,Glioma; Cholangiocarcinoma; Solid Tumor; IDH Mutation,CNS/Brain,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2895,NCT04487587,A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Cervical Cancer,"Cediranib, Olaparib (DRUG)",23725625,Olaparib,Cervical Cancer,Cervix,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2896,NCT03570437,"Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?",UNKNOWN,PHASE2,Carcinosarcoma; Endometrial Neoplasms,Paclitaxel (DRUG); Cediranib (DRUG); Olaparib (DRUG),23725625,Olaparib,Carcinosarcoma; Endometrial Neoplasms,Uterus,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2897,NCT02561832,"A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer",TERMINATED,PHASE1,Breast Cancer,Olaparib (DRUG); Carboplatin (DRUG); Anthracycline (DRUG); Cyclophosphamide (DRUG),23725625,Olaparib,Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2898,NCT01788332,Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN),UNKNOWN,PHASE2,Non-small Cell Lung Cancer,Olaparib (DRUG); Placebo (OTHER),23725625,Olaparib,Non-small Cell Lung Cancer,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2899,NCT03286842,To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.,COMPLETED,PHASE3,HER2-ve Metastatic Breast Cancer; Germline BRCA1/2 Mutations; Somatic BRCA1/2 Mutations,Olaparib (DRUG),23725625,Olaparib,HER2-ve Metastatic Breast Cancer; Germline BRCA1/2 Mutations; Somatic BRCA1/2 Mutations,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2900,NCT04269200,Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Endometrial Neoplasms,olaparib (DRUG); durvalumab (BIOLOGICAL); durvalumab placebo (DRUG); olaparib placebo (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG),23725625,Olaparib,Endometrial Neoplasms,Uterus,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2901,NCT04548752,"Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations",RECRUITING,PHASE2,Metastatic Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Olaparib (DRUG); Pembrolizumab (BIOLOGICAL),23725625,Olaparib,Metastatic Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2902,NCT04566952,Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer,UNKNOWN,PHASE2,"Ovarian Cancer; Ovarian and Fallopian Tube Cysts and Neoplasms; Neoplasms by Site; Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Carcinoma, Ovarian Epithelial; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Carcinoma; Anlotinib; PARP Inhibitors; BRCA1 Mutation; Angiogenesis; Antineoplastic Agents; BRCA2 Mutation",Anlotinib (DRUG); Olaparib (DRUG),23725625,Olaparib,"Ovarian Cancer; Ovarian and Fallopian Tube Cysts and Neoplasms; Neoplasms by Site; Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Carcinoma, Ovarian Epithelial; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Carcinoma; Anlotinib; PARP Inhibitors; BRCA1 Mutation; Angiogenesis; Antineoplastic Agents; BRCA2 Mutation",Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2903,NCT02889900,Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer,COMPLETED,PHASE2,Recurrent Platinum Resistant Ovarian Cancer,cediranib and olaparib (DRUG),23725625,Olaparib,Recurrent Platinum Resistant Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2904,NCT06643585,A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse,RECRUITING,PHASE3,Breast Cancer,Trastuzumab-Deruxtecan (DRUG); Physicians Choice (PhC). (OTHER),23725625,Olaparib,Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2905,NCT02789332,Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency,COMPLETED,PHASE2,Breast Cancer; Triple Negative Breast Neoplasms; HRpos Breast Neoplasms; BRCA 1 /2 and / or HRD,PwO (DRUG); PwCb (DRUG); EC (DRUG); Surgery after neoadjuvant Therapy (PROCEDURE); Stratification (OTHER),23725625,Olaparib,Breast Cancer; Triple Negative Breast Neoplasms; HRpos Breast Neoplasms; BRCA 1 /2 and / or HRD,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2906,NCT03951415,Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer,UNKNOWN,PHASE2,Endometrial Neoplasms; Uterine Neoplasms; Endometrium Cancer,PARP inhibitor and Anti-PD-L1 (DRUG),23725625,Olaparib,Endometrial Neoplasms; Uterine Neoplasms; Endometrium Cancer,Uterus,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2907,NCT06829199,A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003),RECRUITING,PHASE2,Early Triple Negative Breast Cancer,Pembrolizumab (BIOLOGICAL); Paclitaxel (DRUG); Carboplatin (DRUG); Doxorubicin (hydrochloride) (DRUG); Boserolimab (BIOLOGICAL); Epirubicin Hydrochloride (DRUG); Cyclophosphamide (DRUG); Capecitabine (DRUG); Olaparib (if approved/available locally) (DRUG),23725625,Olaparib,Early Triple Negative Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2908,NCT03085147,A Dye for the Detection of Cancer of the Tongue and Mouth,ACTIVE_NOT_RECRUITING,PHASE1,Oral Squamous Cell Carcinoma (OSCC),Olaparib (DRUG),23725625,Olaparib,Oral Squamous Cell Carcinoma (OSCC),Skin,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2909,NCT05258747,"A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer",COMPLETED,PHASE1,Ovarian Cancer; Breast Cancer,"Olaparib tablets, 150 mg (DRUG); Lynparza® (olaparib) tablets 150 mg (DRUG)",23725625,Olaparib,Breast and Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2910,NCT03829345,A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer,UNKNOWN,PHASE2,Oesophageal Cancer; Gastro-Oesophageal Junction Cancer; Gastric Cancer,Olaparib (DRUG),23725625,Olaparib,Oesophageal Cancer; Gastro-Oesophageal Junction Cancer; Gastric Cancer,Esophagus/Stomach,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2911,NCT06441747,Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP),RECRUITING,PHASE2,Cholangiocarcinoma,Durvalumab (DRUG); Olaparib (DRUG),23725625,Olaparib,Cholangiocarcinoma,Liver,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2912,NCT06078787,Olaparib in PALB2 Advanced Pancreatic Cancer,RECRUITING,PHASE2,Advanced Pancreatic Cancer; Metastatic Pancreatic Cancer,Olaparib 150 MG (DRUG),23725625,Olaparib,Advanced Pancreatic Cancer; Metastatic Pancreatic Cancer,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2913,NCT04024254,A Study of Serum Folate Levels in Patients Treated With Olaparib,ACTIVE_NOT_RECRUITING,PHASE2,Ovarian Cancer; Breast Cancer; Folic Acid Deficiency,Folic Acid Tablet (DRUG),23725625,Olaparib,Ovarian Cancer; Breast Cancer; Folic Acid Deficiency,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2914,NCT03117933,Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer,COMPLETED,PHASE2,Ovarian Cancer,Olaparib (DRUG); Cediranib (DRUG); Paclitaxel (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2915,NCT03330847,To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Triple Negative Breast Cancer,Olaparib Continuous (28-Day cycle) 300 mg BD. (DRUG); Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle). (DRUG); Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle). (DRUG),23725625,Olaparib,Metastatic Triple Negative Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2916,NCT05564377,"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial",RECRUITING,PHASE2,Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm,Alpelisib (DRUG); Binimetinib (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Fluorouracil (DRUG); Fulvestrant (DRUG); Ipatasertib (DRUG); Leucovorin (DRUG); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Mutation Carrier Screening (PROCEDURE); Neratinib Maleate (DRUG); Nilotinib Hydrochloride Monohydrate (DRUG); Olaparib (DRUG); Oxaliplatin (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Panitumumab (BIOLOGICAL); Positron Emission Tomography (PROCEDURE); Selumetinib Sulfate (DRUG); Sotorasib (DRUG),23725625,Olaparib,Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2917,NCT00628251,Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer,COMPLETED,PHASE2,Ovarian Neoplasms,AZD2281 (DRUG); Liposomal Doxorubicin (DRUG); AZD2281 (DRUG),23725625,Olaparib,Ovarian Neoplasms,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2918,NCT06130254,"Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers",RECRUITING,PHASE1,Advanced Solid Tumor; Non-small Cell Lung Cancers,Adagrasib (DRUG); Olaparib (DRUG),23725625,Olaparib,Advanced Solid Tumor; Non-small Cell Lung Cancers,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2919,NCT05255653,Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features,RECRUITING,PHASE2,Endometrial Cancer,Olaparib (DRUG); Pelvic external beam radiotherapy (RADIATION); Chemotherapy (DRUG); Durvalumab (DRUG); Medroxyprogesterone Acetate (DRUG); Megestrol Acetate (DRUG); Vaginal brachytherapy (RADIATION); Observation (OTHER),23725625,Olaparib,Endometrial Cancer,Uterus,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2920,NCT03931551,"Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer",TERMINATED,PHASE2,Advanced Breast Cancer,Olaparib [Lynparza®] plus Trastuzumab [Herceptin®] (DRUG),23725625,Olaparib,Advanced Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2921,NCT05952453,"Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/taxol/pembro, Maintenance Olaparib/pembro",RECRUITING,PHASE2,Ovarian Cancer,"Carboplatin (DRUG); olaparibp, embro (DRUG)",23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2922,NCT01081951,"Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Ovarian Cancer,olaparib (DRUG); paclitaxel (DRUG); carboplatin (DRUG); paclitaxel (DRUG); Drug: carboplatin (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2923,NCT01874353,Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy,ACTIVE_NOT_RECRUITING,PHASE3,Platinum Sensitive; BRCA Mutated; Relapsed Ovarian Cancer; Following Complete or Partial Response to Platinum Based Chemotherapy,Olaparib 300mg tablets (DRUG); Placebo to match olaparib 300mg (DRUG),23725625,Olaparib,Platinum Sensitive; BRCA Mutated; Relapsed Ovarian Cancer; Following Complete or Partial Response to Platinum Based Chemotherapy,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2924,NCT06437353,Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer,RECRUITING,PHASE2,Ovarian Cancer,Paclitaxel (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2925,NCT03534453,Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy,ACTIVE_NOT_RECRUITING,PHASE3,Relapsed Ovarian Cancer; Following Complete or Partial Response to Platinum Based Chemotherapy; Platinum Sensitive,Olaparib 300mg tablets (DRUG),23725625,Olaparib,Relapsed Ovarian Cancer; Following Complete or Partial Response to Platinum Based Chemotherapy; Platinum Sensitive,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2926,NCT00535353,AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,irinotecan hydrochloride (DRUG); olaparib (DRUG),23725625,Olaparib,Colorectal Cancer,Bowel,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2927,NCT04644432,Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma,UNKNOWN,PHASE2,Metastatic Renal Cell Carcinoma; Kidney Neoplasm; Urologic Neoplasms; Urogenital Neoplasms,Medication (A specification is listed under each arm) (DRUG); Patient reported outcomes measurement (OTHER),23725625,Olaparib,Metastatic Renal Cell Carcinoma,Kidney,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2928,NCT03568656,Study to Evaluate CCS1477 in Advanced Tumours,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Castration-Resistant Prostate Cancer; Metastatic Breast Cancer; Non-small Cell Lung Cancer; Advanced Solid Tumors,CCS1477 (DRUG); Abiraterone acetate (DRUG); Enzalutamide (DRUG); Darolutamide (DRUG); Olaparib (DRUG); Atezolizumab (DRUG),23725625,Olaparib,Metastatic Castration-Resistant Prostate Cancer; Metastatic Breast Cancer; Non-small Cell Lung Cancer; Advanced Solid Tumors,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2929,NCT00707707,Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer,COMPLETED,PHASE1,Breast Cancer; Triple Negative Breast Cancer; Metastatic Breast Cancer,AZD2281 (DRUG); Paclitaxel (DRUG),23725625,Olaparib,Breast Cancer; Triple Negative Breast Cancer; Metastatic Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2930,NCT02898207,"Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer",COMPLETED,PHASE1,Metastatic High Grade Fallopian Tube Serous Adenocarcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Primary Peritoneal Serous Adenocarcinoma; Metastatic Triple-Negative Breast Carcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Breast Carcinoma; Recurrent High Grade Fallopian Tube Serous Adenocarcinoma; Recurrent High Grade Ovarian Serous Adenocarcinoma; Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma; Recurrent Triple-Negative Breast Carcinoma; Refractory Fallopian Tube Serous Adenocarcinoma; Refractory Ovarian Serous Adenocarcinoma; Refractory Primary Peritoneal Serous Adenocarcinoma; Refractory Triple-Negative Breast Carcinoma; Unresectable High Grade Fallopian Tube Serous Adenocarcinoma; Unresectable Malignant Solid Neoplasm; Unresectable Primary Peritoneal Serous Adenocarcinoma,Olaparib (DRUG); Onalespib (DRUG),23725625,Olaparib,Metastatic High Grade Fallopian Tube Serous Adenocarcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Primary Peritoneal Serous Adenocarcinoma; Metastatic Triple-Negative Breast Carcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Breast Carcinoma; Recurrent High Grade Fallopian Tube Serous Adenocarcinoma; Recurrent High Grade Ovarian Serous Adenocarcinoma; Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma; Recurrent Triple-Negative Breast Carcinoma; Refractory Fallopian Tube Serous Adenocarcinoma; Refractory Ovarian Serous Adenocarcinoma; Refractory Primary Peritoneal Serous Adenocarcinoma; Refractory Triple-Negative Breast Carcinoma; Unresectable High Grade Fallopian Tube Serous Adenocarcinoma; Unresectable Malignant Solid Neoplasm; Unresectable Primary Peritoneal Serous Adenocarcinoma,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2931,NCT05033756,Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO,ACTIVE_NOT_RECRUITING,PHASE2,Malignant Neoplasm of Breast; Breast Cancer,Pembrolizumab Injection [Keytruda] (DRUG); Olaparib Oral Tablet [Lynparza] (DRUG),23725625,Olaparib,Malignant Neoplasm of Breast; Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2932,NCT04462809,Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma,UNKNOWN,PHASE2,Advanced Malignant Pleural or Peritoneal Mesothelioma,Talazoparib (DRUG),23725625,Olaparib,Advanced Malignant Pleural or Peritoneal Mesothelioma,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2933,NCT03008278,Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Esophageal Carcinoma; Metastatic Gastric Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Gastroesophageal Junction Adenocarcinoma; Stage III Esophageal Cancer AJCC v7; Stage III Gastric Cancer AJCC v7; Stage IV Esophageal Cancer AJCC v7; Stage IV Gastric Cancer AJCC v7; Unresectable Esophageal Carcinoma; Unresectable Gastric Carcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma,Olaparib (DRUG); Ramucirumab (BIOLOGICAL),23725625,Olaparib,Metastatic Esophageal Carcinoma; Metastatic Gastric Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Gastroesophageal Junction Adenocarcinoma; Stage III Esophageal Cancer AJCC v7; Stage III Gastric Cancer AJCC v7; Stage IV Esophageal Cancer AJCC v7; Stage IV Gastric Cancer AJCC v7; Unresectable Esophageal Carcinoma; Unresectable Gastric Carcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2934,NCT04614909,Study of Pamiparib in Newly Diagnosed and RGBM,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,"Glioblastoma; Glioblastoma Multiforme; Glioblastoma Multiforme, Adult",Pamiparib (DRUG); Olaparib (DRUG); Radiation therapy (RADIATION); Temozolomide (DRUG),23725625,Olaparib,"Glioblastoma; Glioblastoma Multiforme; Glioblastoma Multiforme, Adult",CNS/Brain,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2935,NCT05887609,An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib,RECRUITING,PHASE2,Ovary Cancer; Peritoneal Cancer; Fallopian Tube Cancer,Mirvetuximab Soravtansine (DRUG); Olaparib (DRUG),23725625,Olaparib,Ovary Cancer; Peritoneal Cancer; Fallopian Tube Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2936,NCT06482307,Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET,NOT_YET_RECRUITING,PHASE1,Head and Neck Squamous Cell Carcinoma (HNSCC),[18F]-olaparib PET scan (DIAGNOSTIC_TEST),23725625,Olaparib,Head and Neck Squamous Cell Carcinoma (HNSCC),Skin,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2937,NCT03375307,Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes,RECRUITING,PHASE2,Advanced Bladder Carcinoma; Advanced Genitourinary System Carcinoma; Metastatic Bladder Carcinoma; Metastatic Genitourinary System Carcinoma; Stage III Bladder Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Marrow Biopsy (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Olaparib (DRUG); Positron Emission Tomography (PROCEDURE),23725625,Olaparib,Advanced Bladder Carcinoma; Advanced Genitourinary System Carcinoma; Metastatic Bladder Carcinoma; Metastatic Genitourinary System Carcinoma; Stage III Bladder Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8,Bladder/Urinary Tract,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2938,NCT06650709,NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study,NOT_YET_RECRUITING,PHASE2,Ovarian Cancer Stage IV,Olaparib (DRUG); Bevacizumab (DRUG); Durvalumab (DRUG),23725625,Olaparib,Ovarian Cancer Stage IV,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2939,NCT03022409,A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).,COMPLETED,PHASE1,Head and Neck Squamous Cell Carcinoma,Ceralasertib (DRUG); Olaparib (DRUG),23725625,Olaparib,Head and Neck Squamous Cell Carcinoma,Skin,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2940,NCT01924533,Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.,COMPLETED,PHASE3,Gastric Cancer,Olaparib (DRUG); Paclitaxel (DRUG); Placebo (DRUG),23725625,Olaparib,Gastric Cancer,Esophagus/Stomach,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2941,NCT04729387,"Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected",ACTIVE_NOT_RECRUITING,PHASE3,Ovarian Cancer,Alpelisib (DRUG); Olaparib (DRUG); Paclitaxel (DRUG); Pegylated liposomal doxorubicin (PLD) (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2942,NCT04579133,Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy,TERMINATED,PHASE2,Bladder Cancer; Urothelial Carcinoma,Olaparib (DRUG); Durvalumab (DRUG),23725625,Olaparib,Bladder Cancer; Urothelial Carcinoma,Bladder/Urinary Tract,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2943,NCT04410887,Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC),UNKNOWN,PHASE1,Stomach Cancer; Gastric Cancer,PIPAC+SOX+OLAPARIB (DRUG),23725625,Olaparib,Stomach Cancer; Gastric Cancer,Esophagus/Stomach,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2944,NCT03106987,A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.,COMPLETED,PHASE3,Epithelial Ovarian Cancer,Active Comparator: Olaparib tablets (DRUG); Placebo (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2945,NCT03205761,Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer,COMPLETED,PHASE2,Advanced Breast Cancer,Olaparib (DRUG),23725625,Olaparib,Advanced Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2946,NCT05222971,Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy,RECRUITING,PHASE2,Biliary Tract Cancer; DNA Damage Repair Deficiency,Durvalumab (DRUG); Olaparib (DRUG),23725625,Olaparib,Biliary Tract Cancer; DNA Damage Repair Deficiency,Liver,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2947,NCT04592211,"Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer",RECRUITING,PHASE1,Gastric Cancer Stage IV,olaparib+pembrolizumab+paclitaxel (DRUG),23725625,Olaparib,Gastric Cancer Stage IV,Esophagus/Stomach,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2948,NCT05332561,Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE),RECRUITING,PHASE2,Early-stage Breast Cancer,Atezolizumab 1200 mg in 20 ML Injection (DRUG); Inavolisib (DRUG); Ipatasertib (DRUG); Olaparib (DRUG); Sacituzumab govitecan (DRUG); Trastuzumab/pertuzumab (DRUG),23725625,Olaparib,Early-stage Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2949,NCT04041128,PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer,COMPLETED,EARLY_PHASE1,Ovarian Cancer; Breast Cancer,Lynparza (DRUG),23725625,Olaparib,Breast and Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2950,NCT04641728,Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer,UNKNOWN,PHASE2,Cervical Cancer,Pembrolizumab (DRUG); Olaparib (DRUG),23725625,Olaparib,Cervical Cancer,Cervix,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2951,NCT02546661,"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Muscle Invasive Bladder Cancer,AZD4547 (DRUG); MEDI4736 (DRUG); Olaparib (DRUG); AZD1775 (DRUG); Vistusertib (DRUG); AZD9150 (DRUG); Selumetinib (DRUG),23725625,Olaparib,Muscle Invasive Bladder Cancer,Bladder/Urinary Tract,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2952,NCT05536128,Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor,RECRUITING,PHASE2,Advanced Breast Cancer,Olaparib (DRUG); Fulvestrant (DRUG),23725625,Olaparib,Advanced Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2953,NCT03378297,IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC,COMPLETED,EARLY_PHASE1,Ovarian Cancer,Metformin (DRUG); Acetylsalicylic acid (DRUG); Olaparib (DRUG); Letrozole (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2954,NCT04999605,A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer,TERMINATED,PHASE1,Ovarian Neoplasms; Recurrent Ovarian Carcinoma; Relapsed Ovarian Cancer; Ovarian Cancer,AK112 low dose (DRUG); AK112 medium dose (DRUG); AK112 high dose (DRUG),23725625,Olaparib,Ovarian Neoplasms; Recurrent Ovarian Carcinoma; Relapsed Ovarian Cancer; Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2955,NCT04348045,"Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status.",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Pancreatic Adenocarcinoma,Arm A - Olaparib (DRUG); ARM B - durvalumab plus selumetinib (DRUG); ARM C FOLFIRI (DRUG),23725625,Olaparib,Metastatic Pancreatic Adenocarcinoma,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2956,NCT00753545,Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer,COMPLETED,PHASE2,Ovarian Cancer,AZD2281 (DRUG); matching placebo (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2957,NCT04701645,"Microdevice in Ovarian, Fallopian Tube, and Peritoneal Cancer",RECRUITING,PHASE1,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Ovarian Cancer Stage III; Ovarian Cancer Stage IV; Fallopian Tube Cancer Stage IV; Fallopian Tube Cancer Stage III,Microdevice (COMBINATION_PRODUCT),23725625,Olaparib,Ovarian and Related Cancers,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2958,NCT05203445,A Study of Olaparib and Pembrolizumab in People with Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Olaparib (DRUG); Pembrolizumab (DRUG),23725625,Olaparib,Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2959,NCT02264678,Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents,ACTIVE_NOT_RECRUITING,PHASE1,"Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer",Administration of ceralasertib (DRUG); Administration of ceralasertib in combination with olaparib (DRUG); Administation of ceralasertib in combination with durvalumab (DRUG); Administration of ceralasertib monotherapy (DRUG); Administration of ceralasertib and olaparib (DRUG); Administration of ceralasertib and durvalumab (DRUG); Administration of ceralasertib in combination with AZD5305 (DRUG); Administration of ceralasertib in combination with carboplatin (DRUG),23725625,Olaparib,"Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer",Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2960,NCT06488378,Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer,RECRUITING,PHASE1,Breast Cancer; PALB2-Mutated Breast Carcinoma; HER2-negative Breast Cancer; BRCA1 Mutation; BRCA2 Mutation,Axatilimab (DRUG); Olaparib (DRUG),23725625,Olaparib,Breast Cancer; PALB2-Mutated Breast Carcinoma; HER2-negative Breast Cancer; BRCA1 Mutation; BRCA2 Mutation,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2961,NCT05174832,Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients,UNKNOWN,PHASE2,Triple Negative Breast Cancer,Cisplatin (DRUG); Nab-paclitaxel (DRUG); Pembrolizumab (DRUG); Olaparib (DRUG),23725625,Olaparib,Triple Negative Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2962,NCT05255471,MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.,RECRUITING,PHASE3,Ovarian Cancer,Olaparib (DRUG); Chemotherapy drug (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2963,NCT04538378,Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors,TERMINATED,PHASE2,EGFR-Mutated Non-Small-Cell Lung Carcinoma; Small Cell/Neuroendocrine,"Olaparib (DRUG); Durvalumab (DRUG); EKG (DIAGNOSTIC_TEST); Tumor biopsy (PROCEDURE); CT chest, abdomen and pelvis (DIAGNOSTIC_TEST); MRI chest, abdomen and pelvis (DIAGNOSTIC_TEST)",23725625,Olaparib,EGFR-Mutated Non-Small-Cell Lung Carcinoma; Small Cell/Neuroendocrine,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2964,NCT01513174,Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone,COMPLETED,PHASE1,Non Small Cell Lung Cancer,Gefitinib (DRUG); Olaparib (DRUG),23725625,Olaparib,Non Small Cell Lung Cancer,Lung,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2965,NCT05933265,Study of LP-184 in Patients with Advanced Solid Tumors,RECRUITING,PHASE1,Advanced Solid Tumor; Metastatic Solid Tumor; GBM; TNBC - Triple-Negative Breast Cancer; NSCLC; Pancreatic Adenocarcinoma; DDR Gene Mutation,LP-184 (DRUG); Spironolactone (DRUG); Olaparib (DRUG),23725625,Olaparib,Advanced Solid Tumor; Metastatic Solid Tumor; GBM; TNBC - Triple-Negative Breast Cancer; NSCLC; Pancreatic Adenocarcinoma; DDR Gene Mutation,Pancreas,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2966,NCT05807126,"Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations",WITHDRAWN,PHASE1,Anatomic Stage IV Breast Cancer AJCC v8; Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8,Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Magrolimab (BIOLOGICAL); Olaparib (DRUG),23725625,Olaparib,Anatomic Stage IV Breast Cancer AJCC v8; Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2967,NCT03740893,PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer,RECRUITING,PHASE2,Breast Neoplasm,AZD6738 (DRUG); Olaparib (DRUG); Durvalumab (DRUG),23725625,Olaparib,Breast Neoplasm,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2968,NCT01390571,Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma,COMPLETED,PHASE1,Brain and Central Nervous System Tumors,olaparib (DRUG); temozolomide (DRUG); gene expression analysis (GENETIC); protein expression analysis (GENETIC); laboratory biomarker analysis (OTHER); pharmacological study (OTHER); diffusion-weighted magnetic resonance imaging (PROCEDURE); dynamic contrast-enhanced magnetic resonance imaging (PROCEDURE); therapeutic conventional surgery (PROCEDURE),23725625,Olaparib,Brain and Central Nervous System Tumors,CNS/Brain,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2969,NCT02340611,A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib,COMPLETED,PHASE2,Ovarian Cancer,Olaparib (DRUG); Cediranib (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2970,NCT00679783,Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer,COMPLETED,PHASE2,Ovarian Carcinoma; Breast Cancer,AZD2281 (DRUG),23725625,Olaparib,Ovarian Carcinoma; Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2971,NCT03470805,Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma,COMPLETED,PHASE2,Ovarian Cancer,Olaparib (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2972,NCT03924245,"Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers",TERMINATED,PHASE1,Fallopian Tube Cancer; Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Ovarian Carcinosarcoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Endometrial Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Entinostat (DRUG); Olaparib (DRUG),23725625,Olaparib,Fallopian Tube Cancer; Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Ovarian Carcinosarcoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Endometrial Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Uterus,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2973,NCT03742245,Olaparib in Combination with Vorinostat in Patients with Relapsed/Refractory And/or Metastatic Breast Cancer,RECRUITING,PHASE1,Breast Cancer Metastatic; Breast Cancer,Olaparib (DRUG); Vorinostat (DRUG),23725625,Olaparib,Breast Cancer Metastatic; Breast Cancer,Breast,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2974,NCT02855697,Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer,COMPLETED,EARLY_PHASE1,Ovarian Cancer,Olaparib (DRUG); Cediranib (DRUG); Platinum-based Chemotherapy (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2975,NCT04826198,"Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months",TERMINATED,PHASE1,Ovarian Cancer,AsiDNA (DRUG); Niraparib (DRUG); Olaparib (DRUG); Rucaparib (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2976,NCT04377087,Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer,TERMINATED,PHASE2,Ovarian Cancer,Olaparib (DRUG),23725625,Olaparib,Ovarian Cancer,Ovary/Fallopian Tube,olaparib,"PARP1, PARP2",unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for BRCA-mutated cancers.,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,1.17,239.0 +2977,NCT06964113,A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice,NOT_YET_RECRUITING,PHASE4,Ulcerative Colitis,Filgotinib Maleate (DRUG),49831257,Jyseleca,Ulcerative Colitis,Bowel,Filgotinib,"JAK1, JAK2, TYK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved in Japan and EU for rheumatoid arthritis.,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,1.01,1563.0 +2978,NCT02914600,Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease,TERMINATED,PHASE3,Crohn's Disease,Filgotinib (DRUG); Placebo (DRUG),49831257,Jyseleca,Crohn's Disease,Bowel,Filgotinib,"JAK1, JAK2, TYK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved in Japan and EU for rheumatoid arthritis.,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,1.01,1563.0 +2979,NCT06604273,Unravelling Intestinal Fibrosis in Ulcerative Colitis,RECRUITING,PHASE2,Ulcerative Colitis (UC); Inflammatory Bowel Disease (IBD); Fibroblast Activation Protein Inhibitor,Fibroblast Activation Protein Inhibitor (DIAGNOSTIC_TEST),49831257,Jyseleca,Ulcerative Colitis (UC); Inflammatory Bowel Disease (IBD); Fibroblast Activation Protein Inhibitor,Bowel,Filgotinib,"JAK1, JAK2, TYK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved in Japan and EU for rheumatoid arthritis.,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,1.01,1563.0 +2980,NCT03077412,Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease,COMPLETED,PHASE2,Fistulizing Crohn's Disease,Filgotinib (DRUG); Placebo to match filgotinib (DRUG),49831257,Jyseleca,Fistulizing Crohn's Disease,Bowel,Filgotinib,"JAK1, JAK2, TYK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved in Japan and EU for rheumatoid arthritis.,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,1.01,1563.0 +2981,NCT02914522,Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis,COMPLETED,PHASE3,Ulcerative Colitis,Filgotinib (DRUG); PTM filgotinib (DRUG),49831257,Jyseleca,Ulcerative Colitis,Bowel,Filgotinib,"JAK1, JAK2, TYK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved in Japan and EU for rheumatoid arthritis.,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,1.01,1563.0 +2982,NCT05479058,A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission,TERMINATED,PHASE3,Ulcerative Colitis,Filgotinib (DRUG); Placebo (DRUG),49831257,Jyseleca,Ulcerative Colitis,Bowel,Filgotinib,"JAK1, JAK2, TYK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved in Japan and EU for rheumatoid arthritis.,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,1.01,1563.0 +2983,NCT06865417,A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis,NOT_YET_RECRUITING,PHASE3,Ulcerative Colitis,Filgotinib (DRUG),49831257,Jyseleca,Ulcerative Colitis,Bowel,Filgotinib,"JAK1, JAK2, TYK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved in Japan and EU for rheumatoid arthritis.,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,1.01,1563.0 +2984,NCT02084199,Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects,COMPLETED,PHASE1,Renal Impairment,GLPG0634 (DRUG),49831257,Jyseleca,Renal Impairment,Kidney,Filgotinib,"JAK1, JAK2, TYK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved in Japan and EU for rheumatoid arthritis.,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,1.01,1563.0 +2985,NCT02914535,Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis,ACTIVE_NOT_RECRUITING,PHASE3,Ulcerative Colitis,Filgotinib (DRUG); Placebo (DRUG),49831257,Jyseleca,Ulcerative Colitis,Bowel,Filgotinib,"JAK1, JAK2, TYK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved in Japan and EU for rheumatoid arthritis.,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,1.01,1563.0 +2986,NCT02048618,Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease,COMPLETED,PHASE2,Crohn's Disease,GLPG0634 (DRUG); Placebo (DRUG),49831257,Jyseleca,Crohn's Disease,Bowel,Filgotinib,"JAK1, JAK2, TYK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved in Japan and EU for rheumatoid arthritis.,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,1.01,1563.0 +2987,NCT03046056,Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD),COMPLETED,PHASE2,Small Bowel Crohn's Disease,Filgotinib (DRUG); Placebo to match filgotinib (DRUG),49831257,Jyseleca,Small Bowel Crohn's Disease,Bowel,Filgotinib,"JAK1, JAK2, TYK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved in Japan and EU for rheumatoid arthritis.,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,1.01,1563.0 +2988,NCT02914561,Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease,COMPLETED,PHASE3,Crohn's Disease,Filgotinib (DRUG); Placebo (OTHER),49831257,Jyseleca,Crohn's Disease,Bowel,Filgotinib,"JAK1, JAK2, TYK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved in Japan and EU for rheumatoid arthritis.,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,1.01,1563.0 +2989,NCT03201445,Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease,TERMINATED,PHASE2,Inflammatory Bowel Disease,Filgotinib (DRUG); Placebo (DRUG); Standard of Care (DRUG),49831257,Jyseleca,Inflammatory Bowel Disease,Bowel,Filgotinib,"JAK1, JAK2, TYK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved in Japan and EU for rheumatoid arthritis.,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,1.01,1563.0 +2990,NCT01490866,A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC),COMPLETED,PHASE2,Colorectal Cancer,Axitinib (DRUG); Bevacizumab (DRUG); 5-Fluorouracil (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +2991,NCT03563157,QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine,TERMINATED,PHASE1,Colorectal Cancer Metastatic; mCRC,Aldoxorubicin Hydrochloride (BIOLOGICAL); ALT-803 (BIOLOGICAL); ETBX-011 (BIOLOGICAL); ETBX-021 (BIOLOGICAL); ETBX-051 (BIOLOGICAL); ETBX-061 (BIOLOGICAL); GI-4000 (BIOLOGICAL); GI-6207 (BIOLOGICAL); GI-6301 (BIOLOGICAL); haNK (BIOLOGICAL); Avelumab (DRUG); Capecitabine (DRUG); Cetuximab (DRUG); Cyclophosphamide (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG); Nab-paclitaxel (DRUG); Oxaliplatin (DRUG); Regorafenib (DRUG); SBRT (PROCEDURE),9887053,CS-0992,Colorectal Cancer Metastatic; mCRC,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +2992,NCT00004257,Oxaliplatin and Fluorouracil Plus Radiation Therapy in Treating Patients With Primary Esophageal or Stomach Cancer,COMPLETED,PHASE1,Esophageal Cancer,fluorouracil (DRUG); oxaliplatin (DRUG); conventional surgery (PROCEDURE); radiation therapy (RADIATION),9887053,CS-0992,Esophageal Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +2993,NCT02624726,Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,5 Fluorouracil (DRUG); Leucovorin (DRUG); Irinotecan (DRUG); Aflibercept (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +2994,NCT06226857,Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer,RECRUITING,PHASE3,Colorectal Neoplasms; Chemotherapy Effect; Molecular Sequence Variation,Cetuximab (DRUG),9887053,CS-0992,Colorectal Neoplasms; Chemotherapy Effect; Molecular Sequence Variation,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +2995,NCT04617457,Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas,RECRUITING,PHASE2,Pancreatic Cancer; Metastasis; Surgery; Oligometastatic Disease,"nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA) (DRUG)",9887053,CS-0992,Pancreatic Cancer; Metastasis; Surgery; Oligometastatic Disease,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +2996,NCT05566457,HGWD Improve the Paclitaxel-related Neurotoxicity in Patients With BC,UNKNOWN,PHASE2,Breast Cancer,Huangqi Guizhi Wuwu decoction (HGWD) infusion packs (DRUG),9887053,CS-0992,Breast Cancer,Breast,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +2997,NCT03563248,Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Pancreatic Cancer,FOLFIRINOX (DRUG); Losartan (DRUG); Nivolumab (DRUG); SBRT (RADIATION); Surgery (PROCEDURE),9887053,CS-0992,Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +2998,NCT01394120,Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer,UNKNOWN,PHASE2,"Carcinoma, Pancreatic Ductal",Targeted Therapy Tailored Treatment (DRUG); Standard Chemotherapy (DRUG),9887053,CS-0992,Pancreatic Ductal Carcinoma,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +2999,NCT04834674,DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma,RECRUITING,PHASE2,Intrahepatic Cholangiocarcinoma; Transarterial Chemoembolization; Apatinib; PD-1 Antibody,DEB-TACE combined with apatinib and PD-1 antibody (COMBINATION_PRODUCT),9887053,CS-0992,Intrahepatic Cholangiocarcinoma; Transarterial Chemoembolization; Apatinib; PD-1 Antibody,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3000,NCT02047474,Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Stage I Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,oxaliplatin (DRUG); leucovorin calcium (DRUG); irinotecan hydrochloride (DRUG); fluorouracil (DRUG); therapeutic conventional surgery (PROCEDURE); laboratory biomarker analysis (OTHER),9887053,CS-0992,Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3001,NCT01262482,Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment,COMPLETED,PHASE2,Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment),Oxaliplatin (DRUG); Sorafenib (DRUG),9887053,CS-0992,Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment),Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3002,NCT05018182,FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer,UNKNOWN,PHASE2,High-risk Locally Advanced Colorectal Cancer; Neoadjuvant Chemotherapy; FOLFOXIRI Regimen,Oxaliplatin (DRUG); Irinotecan (DRUG); Folinic Acid (DRUG); 5FU (DRUG); Capecitabine (DRUG),9887053,CS-0992,High-risk Locally Advanced Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3003,NCT00079274,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,COMPLETED,PHASE3,Adenocarcinoma of the Colon; Stage III Colon Cancer,irinotecan hydrochloride (DRUG); oxaliplatin (DRUG); leucovorin calcium (DRUG); fluorouracil (DRUG); cetuximab (BIOLOGICAL); Locally Directed Therapy (DRUG),9887053,CS-0992,Colon Adenocarcinoma,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3004,NCT03161574,FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for Circumferential Radial Margin (CRM) Positive Rectal Cancer,WITHDRAWN,PHASE2,Rectal Cancer,FOLFOXIRI (DRUG),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3005,NCT05634720,Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer,RECRUITING,PHASE4,Pancreatic Ductal Adenocarcinoma,HA Chemotherapy (DRUG),9887053,CS-0992,Pancreatic Ductal Adenocarcinoma,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3006,NCT00555620,Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer,COMPLETED,PHASE1,Stomach Neoplasms,capecitabine (DRUG); oxaliplatin (DRUG); sunitinib malate (DRUG); capecitabine (DRUG); cisplatin (DRUG); sunitinib malate (DRUG),9887053,CS-0992,Stomach Neoplasms,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3007,NCT05103020,Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks (DRUG); IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3008,NCT00202774,Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer,COMPLETED,PHASE3,Colorectal Cancer,"(capecitabine, oxaliplatin, 5-fluorouracil) (DRUG)",9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3009,NCT03616574,First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors,COMPLETED,PHASE1,Advanced or Metastatic Solid Tumors; Advanced or Metastatic Colorectal Cancer (mCRC),CA102N (DRUG); LONSURF (DRUG),9887053,CS-0992,Advanced or Metastatic Solid Tumors; Advanced or Metastatic Colorectal Cancer (mCRC),Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3010,NCT06625320,Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),RECRUITING,PHASE3,Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma,RMC-6236 (DRUG); Gemcitabine (DRUG); nab-paclitaxel (DRUG); Irinotecan (DRUG); Liposomal irinotecan (DRUG); 5-fluorouracil (DRUG); leucovorin (DRUG); Oxaliplatin (DRUG),9887053,CS-0992,Pancreatic Ductal Adenocarcinoma,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3011,NCT01097265,Study of Micrometastases in Patients With Stage I or Stage II Localized Colon Cancer That Can Be Removed by Surgery,UNKNOWN,PHASE2,Colorectal Cancer,capecitabine (DRUG); oxaliplatin (DRUG); active surveillance (OTHER); laboratory biomarker analysis (OTHER); adjuvant therapy (PROCEDURE); lymph node mapping (PROCEDURE); sentinel lymph node biopsy (PROCEDURE),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3012,NCT01237665,"IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer",UNKNOWN,PHASE2,Rectal Cancer,IXO regimen (DRUG),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3013,NCT03788174,Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma,UNKNOWN,PHASE2,Gastric Adenocarcinoma,Apatinib (DRUG); POF (DRUG),9887053,CS-0992,Gastric Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3014,NCT05246982,HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer,UNKNOWN,PHASE2,Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ),HLX07+HLX10+oxaliplatin+capecitabine (DRUG); HLX07 (DRUG),9887053,CS-0992,Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ),Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3015,NCT01379482,Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer,COMPLETED,PHASE2,Peritoneal Carcinomatosis; Gastric Cancer,Multimodal treatment (DRUG),9887053,CS-0992,Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3016,NCT01362582,Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With Pancreatic Cancer,TERMINATED,PHASE3,Pancreatic Cancer,SMOF Kabiven (DRUG),9887053,CS-0992,Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3017,NCT06741020,Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma,RECRUITING,PHASE1,Hepatocellular Carcinoma (HCC),"Adebrelimab, Oxaliplatin, Fluorouracil,Leucovorin (DRUG)",9887053,CS-0992,Hepatocellular Carcinoma (HCC),Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3018,NCT04421820,BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours,RECRUITING,PHASE1,Colorectal Cancer; Pancreatic Cancer; Gastric Cancers; Cholangiocarcinoma,BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion) (DRUG); BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation) (DRUG),9887053,CS-0992,Colorectal Cancer; Pancreatic Cancer; Gastric Cancers; Cholangiocarcinoma,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3019,NCT01420874,Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer),COMPLETED,PHASE1,Colorectal Cancer; Cancer of Pancreas; Pancreatic Neoplasm; Malignant Neoplasm of Large Intestine; Malignant Tumor of Colon; Colon Carcinoma; Cancer of Colon; Pancreatic Cancer,FOLFOX6 (DRUG); EGFRBi armed ATC Infusions (BIOLOGICAL),9887053,CS-0992,Colorectal Cancer; Cancer of Pancreas; Pancreatic Neoplasm; Malignant Neoplasm of Large Intestine; Malignant Tumor of Colon; Colon Carcinoma; Cancer of Colon; Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3020,NCT05799820,QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC,RECRUITING,PHASE2,Colorectal Carcinoma,QL1706 (DRUG); Bevacizumab (DRUG); Oxaliplatin injection (DRUG); Capecitabine (DRUG),9887053,CS-0992,Colorectal Carcinoma,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3021,NCT00564720,"Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer",TERMINATED,PHASE2,Pancreatic Cancer,Gemcitabine (DRUG); Gemcitabine (DRUG); Erlotinib (DRUG); Oxaliplatin (DRUG),9887053,CS-0992,Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3022,NCT02079220,A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer,WITHDRAWN,PHASE2,Metastatic Colorectal Cancer,Arm A (DRUG); Arm B (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3023,NCT05585320,A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors,RECRUITING,PHASE1,Advanced Solid Tumor; Pancreatic Adenocarcinoma; Malignant Melanoma (Cutaneous); Non-small Cell Lung Cancer (NSCLC),IMM-1-104 Monotherapy (Treatment Group A) (DRUG); IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B) (DRUG); IMM-1-104 + modified FOLFIRINOX (Treatment Group C) (DRUG); IMM-1-104 + dabrafenib (Treatment Group D) (DRUG); IMM-1-104 + pembrolizumab (Treatment Group E) (DRUG),9887053,CS-0992,Advanced Solid Tumor; Pancreatic Adenocarcinoma; Malignant Melanoma (Cutaneous); Non-small Cell Lung Cancer (NSCLC),Skin,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3024,NCT00058474,Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer,UNKNOWN,PHASE3,Colorectal Cancer,capecitabine (DRUG); fluorouracil (DRUG); oxaliplatin (DRUG); radiation therapy (RADIATION),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3025,NCT01618474,Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer Patients,UNKNOWN,PHASE2,Stomach Cancer,DX (DRUG); XELOX (DRUG),9887053,CS-0992,Stomach Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3026,NCT06760520,Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer,NOT_YET_RECRUITING,PHASE2,Locally Advanced Rectal Cancer,Ivonescimab (SMT112 or AK112) Injection (DRUG),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3027,NCT01936974,"(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma",TERMINATED,PHASE2,Ovarian Carcinoma; Fallopian Tube Carcinoma; Peritoneal Carcinoma,Gemcitabine (DRUG); Bevacizumab (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Oxaliplatin (DRUG),9887053,CS-0992,Ovarian and Related Carcinomas,Ovary/Fallopian Tube,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3028,NCT01665274,Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer,TERMINATED,PHASE2,Gastric Cancer,Capecitabine (DRUG); Oxaliplatin (DRUG); D2 resection (PROCEDURE),9887053,CS-0992,Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3029,NCT02529774,Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer,UNKNOWN,PHASE2,Resected Liver Metastases From Colorectal Cancer,"Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6) (DRUG); Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6) (DRUG)",9887053,CS-0992,Resected Liver Metastases From Colorectal Cancer,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3030,NCT03472365,A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer,COMPLETED,PHASE2,Gastric Cancer; GastroEsophageal Cancer,SHR-1210 (BIOLOGICAL); Capecitabine (DRUG); Oxaliplatin (DRUG); Apatinib (DRUG),9887053,CS-0992,Gastric Cancer; GastroEsophageal Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3031,NCT00166465,Stage IV Colorectal CA ALIMTA,COMPLETED,PHASE1,Locally Advanced Unresectable or Stage IV Colorectal Cancer,ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen) (DRUG),9887053,CS-0992,Locally Advanced Unresectable or Stage IV Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3032,NCT01219920,FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer,COMPLETED,PHASE3,Metastatic Colorectal Cancer,FOLFIRI (DRUG); FOLFOXIRI (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3033,NCT05241574,Planned Non-operative Management for Rectal Cancer,UNKNOWN,PHASE2,Rectal Cancer,Radiotherapy boost (RADIATION); Additional consolidation chemotherapy (DRUG),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3034,NCT05524974,"Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes",NOT_YET_RECRUITING,PHASE2,Locally Advanced Gastric Cancer,Camrelizumab (DRUG); Oxaliplatin (DRUG); S1 (DRUG); Apatinib Mesylate (DRUG); Nab paclitaxel (DRUG),9887053,CS-0992,Metastatic Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3035,NCT05709574,Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer,RECRUITING,PHASE2,Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma,Tadalafil 20 MG (DRUG),9887053,CS-0992,Gastric and Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3036,NCT03000374,Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery,COMPLETED,PHASE2,Rectal Cancer,Panitumumab (DRUG); 5Fluorouracil (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3037,NCT00536874,Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery,COMPLETED,PHASE2,Pancreatic Cancer,gemcitabine hydrochloride (DRUG); oxaliplatin (DRUG); protein expression analysis (GENETIC); proteomic profiling (GENETIC); diagnostic laboratory biomarker analysis (OTHER); adjuvant therapy (PROCEDURE); neoadjuvant therapy (PROCEDURE); therapeutic conventional surgery (PROCEDURE),9887053,CS-0992,Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3038,NCT00115765,PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study,COMPLETED,PHASE3,Colorectal Cancer,Oxaliplatin Based Chemotherapy (DRUG); Panitumumab (DRUG); Irinotecan Based Chemotherapy (DRUG); Bevacizumab (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3039,NCT03500874,Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM,TERMINATED,PHASE3,Colorectal Cancer; Liver Metastases; HAI,FUDR (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); 5FU (DRUG); Irinotecan (DRUG),9887053,CS-0992,Colorectal Cancer with Liver Metastases,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3040,NCT02620865,BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer,COMPLETED,PHASE1,Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Aldesleukin (BIOLOGICAL); Antibody Therapy (BIOLOGICAL); Fluorouracil (DRUG); Gemcitabine Hydrochloride (DRUG); Irinotecan Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Leucovorin Calcium (DRUG); Oxaliplatin (DRUG); Paclitaxel Albumin-Stabilized Nanoparticle Formulation (DRUG); Sargramostim (BIOLOGICAL),9887053,CS-0992,Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3041,NCT03244774,Phase I Study of the Combination of Apatinib and POF,UNKNOWN,PHASE1,Gastric Adenocarcinoma,Apatinib (DRUG); POF (DRUG),9887053,CS-0992,Gastric Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3042,NCT05346874,Neoadjuvant TACiE in Locally Advanced Gastric Cancer,UNKNOWN,PHASE2,Gastric Cancer,Oxaliplatin (DRUG); Teysuno (DRUG); Transarterial chemoembolization (TACE) (PROCEDURE),9887053,CS-0992,Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3043,NCT00066274,Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,FOLFIRI regimen (DRUG); FOLFOX regimen (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3044,NCT04945720,Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma,UNKNOWN,PHASE2,Hepatocellular Carcinoma,Hepatic artery infusion chemotherapy（HAIC） (PROCEDURE); Durvalumab (DRUG),9887053,CS-0992,Hepatocellular Carcinoma,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3045,NCT05171166,Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.,RECRUITING,PHASE2,Hepatocellular Carcinoma,HAIC (PROCEDURE); TACE (PROCEDURE); FOLFOX (DRUG); cTACE or DEB-TACE (DRUG); Donafenib (DRUG),9887053,CS-0992,Hepatocellular Carcinoma,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3046,NCT06802666,Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer,RECRUITING,PHASE2,Locally Advanced Rectal Cancer; Neoadjuvant Therapy,short-course radiotherapy (RADIATION); Ivonescimab (DRUG); capecitabine (DRUG); oxaliplatin (DRUG); TME surgery (PROCEDURE),9887053,CS-0992,Locally Advanced Rectal Cancer; Neoadjuvant Therapy,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3047,NCT03186326,Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer,UNKNOWN,PHASE2,Metastatic Colorectal Cancer; MSI,FOLFOX regimen (DRUG); FOLFIRI Protocol (DRUG); Avelumab (DRUG); Panitumumab (DRUG); Cetuximab (DRUG); Bevacizumab (DRUG); Aflibercept (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer; MSI,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3048,NCT01505166,Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases,TERMINATED,PHASE2,Colon Cancer,Vigil™ Vaccine (BIOLOGICAL); Placebo (DRUG),9887053,CS-0992,Colon Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3049,NCT00513266,Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery,UNKNOWN,PHASE2,Colorectal Cancer; Metastatic Cancer,bevacizumab (BIOLOGICAL); cetuximab (BIOLOGICAL); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG); laboratory biomarker analysis (OTHER); adjuvant therapy (PROCEDURE); biopsy (PROCEDURE); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE),9887053,CS-0992,Colorectal Cancer; Metastatic Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3050,NCT04423965,A Trial of Neoadjuvant mFOLFOXIRI Versus CRT in the EMVI Positive LARC,UNKNOWN,PHASE2,Locally Advanced Rectal Cancer,mFOLFOXIRI (DRUG); Chemoradiotherapy (COMBINATION_PRODUCT),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3051,NCT04643366,Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer,RECRUITING,PHASE2,Rectal Cancer,Chemotherapy (DRUG); Radiation Therapy (RADIATION),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3052,NCT04908566,Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma,RECRUITING,PHASE2,Locally Advanced Gastric Adenocarcinoma,PD-1 antibody combined with FOLFIRINOX regimen (DRUG); PD-1 antibody combined with SOX program (DRUG),9887053,CS-0992,Locally Advanced Gastric Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3053,NCT03929666,"A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer",ACTIVE_NOT_RECRUITING,PHASE2,"HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer",ZW25 (Zanidatamab) (DRUG); Capecitabine (DRUG); Cisplatin (DRUG); Fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Bevacizumab (DRUG); Gemcitabine (DRUG),9887053,CS-0992,HER2-expressing Gastrointestinal Cancers,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3054,NCT06467565,NALIRIFOX as Induction Therapy in LAPC,RECRUITING,PHASE2,Pancreatic Ductal Adenocarcinoma,Liposomal irinotecan (DRUG),9887053,CS-0992,Pancreatic Ductal Adenocarcinoma,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3055,NCT01271166,Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer,TERMINATED,PHASE1,Advanced Colorectal Cancer,"Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab (DRUG)",9887053,CS-0992,Advanced Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3056,NCT00378066,"Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer",COMPLETED,PHASE2,Metastatic Colorectal Cancer,Bevacizumab (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3057,NCT05498766,Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients,NOT_YET_RECRUITING,PHASE4,Gastric Cancer,"Huaier granule (DRUG); Oxaliplatin (DRUG); Tegafur, Gimeracil and Oteracil Potassium (DRUG)",9887053,CS-0992,Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3058,NCT05640726,The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy,NOT_YET_RECRUITING,PHASE2,Rectal Cancer,PD-1 (DRUG); SCRT (RADIATION); Bevacizumab (DRUG); Oxaliplatin (DRUG); Calcium folinate (DRUG); 5-fluorouracil (DRUG),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3059,NCT05833126,Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation,RECRUITING,PHASE2,Recurrent Liver Cancer After Liver Transplantation,Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab (DRUG),9887053,CS-0992,Recurrent Liver Cancer After Liver Transplantation,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3060,NCT00686166,"S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer",COMPLETED,PHASE2,Colorectal Cancer,cetuximab (BIOLOGICAL); capecitabine (DRUG); oxaliplatin (DRUG); therapeutic surgical procedure (PROCEDURE); radiation therapy (RADIATION),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3061,NCT06393166,Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer,RECRUITING,PHASE2,Non-Resectable Pancreas Carcinoma,Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection (DRUG),9887053,CS-0992,Non-Resectable Pancreas Carcinoma,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3062,NCT02191566,S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy,TERMINATED,PHASE2,Stomach Cancer,S-1 (452500ACH) (DRUG); OXALIPLATIN (205803BIJ) (DRUG),9887053,CS-0992,Stomach Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3063,NCT05136326,"Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer",RECRUITING,PHASE2,Rectal Cancer,External-beam radiation (RADIATION); Capecitabine (DRUG); Temozolomide (DRUG),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3064,NCT05396326,A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer,NOT_YET_RECRUITING,PHASE1,Gastric Cancer,Oxaliplatin (DRUG); Teysuno (DRUG); Transarterial arterial chemoinfusion and embolism (TACiE) (PROCEDURE),9887053,CS-0992,Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3065,NCT06521866,"Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer",RECRUITING,PHASE2,Advanced Colorectal Carcinoma; Immunotherapy,Serplulimab (DRUG); Chemotherapy (DRUG); SABR (RADIATION); Targeted therapy (DRUG),9887053,CS-0992,Advanced Colorectal Carcinoma; Immunotherapy,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3066,NCT05111626,Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.,ACTIVE_NOT_RECRUITING,PHASE3,Gastric Cancer; Gastroesophageal Junction Adenocarcinoma,Bemarituzumab (DRUG); Nivolumab (DRUG); Chemotherapy (DRUG); Placebo (OTHER),9887053,CS-0992,Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3067,NCT03349866,A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction,UNKNOWN,PHASE2,Gastroesophageal Junction Adenocarcinoma,apatinib (DRUG); Capecitabine (DRUG); Oxaliplatin (DRUG); Radiotherapy (RADIATION),9887053,CS-0992,Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3068,NCT00094965,Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function,COMPLETED,PHASE2,Gastrointestinal Cancer,Oxaliplatin (SR96669) (DRUG),9887053,CS-0992,Gastrointestinal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3069,NCT05504720,"Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma",ACTIVE_NOT_RECRUITING,PHASE2,Esophagogastric Adenocarcinoma,Pembrolizumab (DRUG); Trastuzumab (DRUG); FLOT (DRUG),9887053,CS-0992,Esophagogastric Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3070,NCT01523574,Vitamin E for Oxaliplatin-induced Peripheral Neuropathy Prophylaxis,COMPLETED,PHASE2,Peripheral Neuropathy,Vitamin E (DRUG); Placebo (DRUG),9887053,CS-0992,Peripheral Neuropathy,Peripheral Nervous System,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3071,NCT03177382,Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors,UNKNOWN,PHASE3,Total Neoadjuvant Treatment; Chemoradiotherapy; Local Advanced Rectal Cancer; High Risk Factors,Total neoadjuvant treatment (RADIATION); concurrent chemoradiotherapy (RADIATION); TME (PROCEDURE); Adjuvant chemotherapy (DRUG),9887053,CS-0992,Total Neoadjuvant Treatment; Chemoradiotherapy; Local Advanced Rectal Cancer; High Risk Factors,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3072,NCT02314182,GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis,COMPLETED,PHASE3,Rectal Adenocarcinoma,"Primary tumor resection + chemotherapy (PROCEDURE); Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab (DRUG)",9887053,CS-0992,Rectal Adenocarcinoma,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3073,NCT00667420,"Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma",TERMINATED,PHASE1,Esophageal Adenocarcinoma; Gastric Adenocarcinoma,"panitumumab, epirubicin, oxaliplatin, xeloda (DRUG)",9887053,CS-0992,Esophageal Adenocarcinoma; Gastric Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3074,NCT00422773,Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer,COMPLETED,PHASE1,Metastatic Colorectal Cancer,Cetuximab (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3075,NCT04215731,Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer,RECRUITING,PHASE3,Rectal Cancer,Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab (DRUG); Restaging (PROCEDURE); Concomitant Chemoradiotherapy (RADIATION); Surgery (PROCEDURE); Chemoradiotherapy (only when patients with MRF involved or ycT4a/b by restaging) (RADIATION); Induction chemotherpay with FOLFOX (DRUG),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3076,NCT00833131,The Randomised Study of Preoperative Radiotherapy With Consolidating Chemotherapy for Unresectable Rectal Cancer,UNKNOWN,PHASE3,Rectal Cancer,Short course of radiotherapy (RADIATION); Radiochemotherapy (RADIATION),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3077,NCT00086931,"Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum",COMPLETED,PHASE1,Colorectal Cancer,capecitabine (DRUG); oxaliplatin (DRUG); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE); radiation therapy (RADIATION),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3078,NCT01718873,Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer,COMPLETED,PHASE3,Colorectal Cancer,Bevacizumab (DRUG); Oxaliplatin (DRUG); levo-folinic acid (DRUG); 5-fluorouracil (DRUG); Capecitabine (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3079,NCT06310473,Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial,NOT_YET_RECRUITING,PHASE2,Gastric Cancer; Esophagogastric Junction Cancer,Cadonilimab (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG),9887053,CS-0992,Gastric Cancer; Esophagogastric Junction Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3080,NCT06199973,"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan",RECRUITING,PHASE3,Advanced Colorectal Cancer,"SHR-A1811 (DRUG); TAS-102, Regorafenib , Fruquintinib (DRUG)",9887053,CS-0992,Advanced Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3081,NCT05223673,Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer,TERMINATED,PHASE3,Metastatic Colorectal Cancer,Futuximab/modotuximab (BIOLOGICAL); Trifluridine/Tipiracil (DRUG); Trifluridine/Tipiracil (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3082,NCT00625573,Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01),COMPLETED,PHASE2,Colorectal Cancer,Abraxane (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3083,NCT02494973,Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases,COMPLETED,PHASE2,Colorectal Cancer,Oxaliplatin HAI (DRUG); Oxaliplatin IV (DRUG); mFOLFOX6 (DRUG); LV5FU2 (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3084,NCT00737373,Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer,COMPLETED,PHASE2,Gastric Cancer; Adenocarcinoma of the Esophagogastric Junction,Docetaxel (DRUG); 5-Fluorouracil (DRUG); Oxaliplatin (DRUG); folinic acid (DRUG),9887053,CS-0992,Gastric Cancer; Adenocarcinoma of the Esophagogastric Junction,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3085,NCT02350530,FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,FOLFOXIRI + Bevacizumab (DRUG); FOLFOXIRI (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3086,NCT01321957,Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,"Oxaliplatin, 5FU/LV, Bevacizumab (DRUG); 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan (DRUG)",9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3087,NCT06941857,NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer,NOT_YET_RECRUITING,PHASE2,Pancreatic Cancer,Oxaliplatin (DRUG); Irinotecan (DRUG); Folinic Acid (DRUG); 5-Fluorouracil (5-FU) (DRUG); NC410 (DRUG); Nivolumab (DRUG); Ipilimumab (DRUG),9887053,CS-0992,Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3088,NCT01523457,Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer,COMPLETED,PHASE2,Metastatic Pancreatic Cancer; Pancreatic Cancer,Folfirinox (DRUG),9887053,CS-0992,Metastatic Pancreatic Cancer; Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3089,NCT03777657,"Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma",COMPLETED,PHASE3,"Gastric, or Gastroesophageal Junction Adenocarcinoma",Tislelizumab (DRUG); Placebo (DRUG); Cisplatin (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG); 5-Fluorouracil (DRUG),9887053,CS-0992,"Gastric, or Gastroesophageal Junction Adenocarcinoma",Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3090,NCT02856126,HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC,COMPLETED,PHASE3,Hepatocellular Carcinoma,Hepatic arterial infusion chemotherapy (PROCEDURE); Transarterial chemoembolization (PROCEDURE); TACE regimen (DRUG); HAIC Regimen (DRUG); Oral Sorafenib (DRUG),9887053,CS-0992,Hepatocellular Carcinoma,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3091,NCT01515748,Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer,COMPLETED,PHASE3,Gastric Cancer,"Docetaxel (XRP6976) (DRUG); Oxaliplatin (SR96669) (DRUG); S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil) (DRUG)",9887053,CS-0992,Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3092,NCT00244348,Hepatic Artery Infusion With Oxaliplatin,WITHDRAWN,PHASE1,Colorectal Cancer; Metastasis; Liver Cancer,Oxaliplatin (via HAI) (DRUG); 5 Fluorouracil (systemic) (DRUG),9887053,CS-0992,Colorectal Cancer with Liver Metastasis,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3093,NCT00891930,Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Panitumumab (BIOLOGICAL); Ganitumab (BIOLOGICAL); Irinotecan (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3094,NCT03164382,"Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma",COMPLETED,PHASE3,Liver Cancer; Hepatic Carcinoma,FOLFOX regimen (DRUG); Sorafenib 200Mg Tab (DRUG),9887053,CS-0992,Liver Cancer; Hepatic Carcinoma,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3095,NCT05353582,Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases,NOT_YET_RECRUITING,PHASE2,Colorectal Neoplasms; Colorectal Cancer; Colorectal Cancer Metastatic; Peritoneal Metastases; Peritoneal Cancer; Peritoneal Neoplasms; Chemotherapy Effect; Cytoreductive Surgery; Hyperthermic Intraperitoneal Chemotherapy,Preoperative systematic therapy (DRUG); CRS+HIPEC (PROCEDURE); Postoperative chemotherapy (DRUG); Postoperative chemotherapy (DRUG),9887053,CS-0992,Colorectal Neoplasms; Colorectal Cancer; Colorectal Cancer Metastatic; Peritoneal Metastases; Peritoneal Cancer; Peritoneal Neoplasms; Chemotherapy Effect; Cytoreductive Surgery; Hyperthermic Intraperitoneal Chemotherapy,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3096,NCT00934882,"Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI",COMPLETED,PHASE1,Colorectal Neoplasms,Regorafenib (BAY73-4506) (DRUG),9887053,CS-0992,Colorectal Neoplasms,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3097,NCT00098982,"Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer",COMPLETED,PHASE1,Colorectal Cancer,bortezomib (DRUG); fluorouracil (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3098,NCT05313282,A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification,RECRUITING,PHASE3,C-staged Hepatocellular Carcinoma in BCLC Classification,Hepatic Arterial Infusion combined with Apatinib and Camrelizumab (COMBINATION_PRODUCT); Apatinib combined with Camrelizumab (COMBINATION_PRODUCT),9887053,CS-0992,C-staged Hepatocellular Carcinoma in BCLC Classification,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3099,NCT00091182,Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment,COMPLETED,PHASE2,Childhood Central Nervous System Germ Cell Tumor; Childhood Extragonadal Germ Cell Tumor; Childhood Hepatoblastoma; Childhood Hepatocellular Carcinoma; Childhood High-grade Cerebral Astrocytoma; Childhood Low-grade Cerebral Astrocytoma; Childhood Malignant Ovarian Germ Cell Tumor; Childhood Malignant Testicular Germ Cell Tumor; Childhood Teratoma; Recurrent Adrenocortical Carcinoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Liver Cancer; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Childhood Visual Pathway and Hypothalamic Glioma; Recurrent Colon Cancer; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Nasopharyngeal Cancer; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer,oxaliplatin (DRUG),9887053,CS-0992,Childhood Central Nervous System Germ Cell Tumor; Childhood Extragonadal Germ Cell Tumor; Childhood Hepatoblastoma; Childhood Hepatocellular Carcinoma; Childhood High-grade Cerebral Astrocytoma; Childhood Low-grade Cerebral Astrocytoma; Childhood Malignant Ovarian Germ Cell Tumor; Childhood Malignant Testicular Germ Cell Tumor; Childhood Teratoma; Recurrent Adrenocortical Carcinoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Liver Cancer; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Childhood Visual Pathway and Hypothalamic Glioma; Recurrent Colon Cancer; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Nasopharyngeal Cancer; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3100,NCT00217282,Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,"oxaliplatin, gemcitabine, bevacizumab (DRUG)",9887053,CS-0992,Advanced Non-Small Cell Lung Cancer,Lung,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3101,NCT06329973,Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer,RECRUITING,PHASE1,Metastatic Gastroesophageal Junction Adenocarcinoma,Fruquintinib in combination with Sintilimab and CAPEOX (DRUG),9887053,CS-0992,Metastatic Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3102,NCT00950820,Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer,TERMINATED,PHASE2,Colorectal Neoplasms,"Oxaliplatin, Capecitabine, Panitumumab (DRUG); Oxaliplatin, Capecitabine (DRUG)",9887053,CS-0992,Colorectal Neoplasms,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3103,NCT00717990,"Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment",TERMINATED,PHASE2,Metastatic Colorectal Cancer,Capecitabine (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3104,NCT04135690,"HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial",RECRUITING,PHASE2,Hepatocellular Carcinoma,Hepatic arterial infusion chemotherapy (PROCEDURE); Toripalimab (DRUG); Sorafenib (DRUG); systemic treatment (DRUG),9887053,CS-0992,Hepatocellular Carcinoma,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3105,NCT00446290,"Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer",COMPLETED,PHASE1,Stomach Cancer,"Docetaxel, Capecitabine and Oxaliplatin (DRUG)",9887053,CS-0992,Stomach Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3106,NCT00642603,A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer,TERMINATED,PHASE2,Colorectal Cancer,capecitabine [Xeloda] (DRUG); capecitabine [Xeloda] (DRUG); bevacizumab [Avastin] (DRUG); oxaliplatin (DRUG); irinotecan (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3107,NCT02931890,Multicentric Randomised Trial for Resectable Gastric Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Gastric Cancer,Docetaxel (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG); gastrectomy (PROCEDURE); radiotherapy of gastric cancer (RADIATION); Paclitaxel (DRUG); Carboplatin (DRUG),9887053,CS-0992,Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3108,NCT04068103,Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery,ACTIVE_NOT_RECRUITING,PHASE2,Colon Adenocarcinoma; Stage IIA Colon Cancer AJCC v8,Capecitabine (DRUG); Fluorouracil (DRUG); Leucovorin (DRUG); Leucovorin Calcium (DRUG); Oxaliplatin (DRUG); Patient Observation (OTHER),9887053,CS-0992,Stage IIA Colon Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3109,NCT05074290,Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients,RECRUITING,PHASE1,Breast Cancer,Epidiferphane (DRUG); Taxane Chemotherapy (DRUG),9887053,CS-0992,Breast Cancer,Breast,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3110,NCT01703390,Biomarker Directed Treatment in Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,FOLFIRI + Cetuximab (DRUG); modifiedFOLFOX6 + Cetuximab (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3111,NCT03193190,A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer),COMPLETED,PHASE1,Pancreatic Adenocarcinoma,Nab-Paclitaxel (DRUG); Gemcitabine (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); Fluorouracil (DRUG); Atezolizumab (DRUG); Cobimetinib (DRUG); PEGPH20 (DRUG); BL-8040 (DRUG); Selicrelumab (DRUG); Bevacizumab (DRUG); RO6874281 (DRUG); AB928 (DRUG); Tiragolumab (DRUG); Tocilizumab (DRUG),9887053,CS-0992,Pancreatic Adenocarcinoma,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3112,NCT03714490,MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer,RECRUITING,PHASE2,Rectal Neoplasms,SCPRT (RADIATION); CRT (RADIATION); CAPOX (DRUG),9887053,CS-0992,Rectal Neoplasms,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3113,NCT06850090,Neoadjuvant Radiotherapy for Rectal Adenocarcinoma with Capecitabine Versus TAS-102,NOT_YET_RECRUITING,PHASE3,Rectal Cancer; Rectal Cancer Patients,TAS-102 (COMBINATION_PRODUCT); Capecitabine (COMBINATION_PRODUCT),9887053,CS-0992,Rectal Cancer; Rectal Cancer Patients,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3114,NCT06405490,NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC,RECRUITING,PHASE2,Nanoliposomal Irinotecan; Cadonilimab; Oxaliplatin; Capecitabine; First-Line; Advanced Cancer; Pancreatic Adenocarcinoma; Drug Use,Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab (DRUG),9887053,CS-0992,Pancreatic Adenocarcinoma Treatment,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3115,NCT06860490,HAIC Combined with Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03),RECRUITING,PHASE2,Hepatocellular Carcinoma (HCC),Sintilimab (DRUG); Bevacizumab Biosimilar (DRUG); HAIC (PROCEDURE),9887053,CS-0992,Hepatocellular Carcinoma (HCC),Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3116,NCT05634590,The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer,NOT_YET_RECRUITING,PHASE2,Metastatic Colorectal Cancer,Fruquintinib (DRUG); FOLFIRI (DRUG); mFOLFOX6 (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3117,NCT03026803,A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer,TERMINATED,PHASE2,Liver Cancer; Hepatocellular Cancer,Oxaliplatin (DRUG); Capecitabine (DRUG),9887053,CS-0992,Liver Cancer; Hepatocellular Cancer,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3118,NCT06841679,Utidelone Capsule Combined with Capecitabine and Oxaliplatin in First-line Treatment of PD-L1-negative Gastric or Gastroesophageal Junction Adenocarcinoma Patients,NOT_YET_RECRUITING,PHASE2,Gastric or Gastroesophageal Junction Adenocarcinoma,Utidelone Capsule (DRUG); Utidelone Capsule (DRUG); Utidelone Capsule (DRUG); Capecitabine (DRUG); Oxaliplatin (DRUG); Utidelone Capsule (DRUG),9887053,CS-0992,Gastric or Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3119,NCT06928584,Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer,RECRUITING,PHASE2,Locally Recurrent Rectal Cancer,Conventional Radiotherapy (RADIATION); Capecitabine (DRUG); 5-fluorouracil (DRUG); folinic acid (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG); Cetuximab (DRUG); Bevacizumab (DRUG); Hypofractionated radiotherapy (RADIATION); PD-1 antibody (DRUG),9887053,CS-0992,Locally Recurrent Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3120,NCT04224402,Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.,COMPLETED,PHASE2,Pancreatic Cancer Resectable,mFOLFORINOX (DRUG),9887053,CS-0992,Pancreatic Cancer Resectable,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3121,NCT01070290,A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen,WITHDRAWN,PHASE2,Gastric Cancer,"ARQ 197 (DRUG); Oxaliplatin, capecitabine or irinotecan (DRUG)",9887053,CS-0992,Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3122,NCT05322590,BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Colorectal Carcinoma; Neuropathy,BXQ-350 (DRUG); Placebo (OTHER),9887053,CS-0992,Metastatic Colorectal Carcinoma; Neuropathy,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3123,NCT01588990,A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer,COMPLETED,PHASE4,Colorectal Neoplasms,Oxaliplatin (DRUG); Capecitabine (DRUG); Bevacizumab (DRUG); Leucovorin (DRUG); 5-Fluouracil (DRUG); Irinotecan (DRUG),9887053,CS-0992,Colorectal Neoplasms,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3124,NCT05379790,Concomitant Intraperitoneal and Systemic Chemotherapy in Patients with Extensive Peritoneal Carcinomatosis of Gastric Origin,COMPLETED,PHASE1,Gastric Cancer; Peritoneal Metastases,Irinotecan (DRUG); CAPOX (DRUG),9887053,CS-0992,Gastric Cancer with Peritoneal Metastases,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3125,NCT03130790,Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line),COMPLETED,PHASE2,Gastric Cancer,Varlitinib (DRUG); mFOLFOX6 (DRUG); Placebo (DRUG); mFOLFOX6 (DRUG),9887053,CS-0992,Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3126,NCT01928290,"Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer",COMPLETED,PHASE2,Stomach Neoplasms; Esophageal Neoplasms,Irinotecan (DRUG); Trastuzumab (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); Fluorouracil (DRUG),9887053,CS-0992,Gastrointestinal Neoplasms,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3127,NCT00242190,"Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer",COMPLETED,PHASE1,Pancreatic Neoplasms,oxaliplatin (DRUG); gemcitabine (DRUG); radiation therapy (PROCEDURE),9887053,CS-0992,Pancreatic Neoplasms,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3128,NCT00940303,OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,5-FU (DRUG); bevacizumab [Avastin] (DRUG); irinotecan (DRUG); leucovorin (DRUG); oxaliplatin (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3129,NCT06850103,SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases,NOT_YET_RECRUITING,PHASE2,Colorectal Carcinoma; Oligometastases; pMMR; MSS; iTNT,short-course radiotherapy (RADIATION); CAPEOX/XELOX (DRUG); Serplulimab (DRUG); surgery (PROCEDURE),9887053,CS-0992,Colorectal Carcinoma; Oligometastases; pMMR; MSS; iTNT,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3130,NCT04282590,A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study),WITHDRAWN,PHASE2,Chemotherapy-induced Peripheral Neuropathy,TRK-750/Placebo (DRUG); Placebo/TRK-750 (DRUG),9887053,CS-0992,Chemotherapy-induced Peripheral Neuropathy,Peripheral Nervous System,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3131,NCT00004203,Oxaliplatin in Treating Patients With Metastatic Bladder Cancer,COMPLETED,PHASE2,Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter,oxaliplatin (DRUG),9887053,CS-0992,Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter,Bladder/Urinary Tract,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3132,NCT04380103,A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer,UNKNOWN,PHASE1,Metastatic Cancer; Colorectal Cancer; Colorectal Adenocarcinoma,XELOXIRI/Bevacizumab (DRUG),9887053,CS-0992,Metastatic Cancer; Colorectal Cancer; Colorectal Adenocarcinoma,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3133,NCT00515190,Study of Continuous or Intermittent S-1 Combined With Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma,UNKNOWN,PHASE2,Stomach Neoplasms,"S-1,oxaliplatin (DRUG)",9887053,CS-0992,Stomach Neoplasms,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3134,NCT02557490,Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases,UNKNOWN,PHASE4,Colon Cancer Liver Metastasis,oxaliplatin and raltitrexed (DRUG),9887053,CS-0992,Colon Cancer Liver Metastasis,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3135,NCT05815303,"XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer",RECRUITING,PHASE2,Rectal Cancer; MSS,Cadonilimab (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG),9887053,CS-0992,Rectal Cancer; MSS,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3136,NCT03990103,S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites,UNKNOWN,PHASE2,Metastatic Gastric Adenocarcinoma,S1 (DRUG); Paclitaxel (DRUG); Bevacizumab (DRUG); Oxaliplatin (DRUG),9887053,CS-0992,Metastatic Gastric Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3137,NCT00460603,Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE1,Colorectal Neoplasms,bevacizumab (DRUG); AG-013726 (DRUG); AG-013736 (axitinib) (DRUG),9887053,CS-0992,Colorectal Neoplasms,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3138,NCT00004190,Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,gemcitabine hydrochloride (DRUG); oxaliplatin (DRUG),9887053,CS-0992,Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3139,NCT02453490,Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis,TERMINATED,PHASE3,Colorectal Cancer; Liver Metastasis,Raltitrexed-based chemotherapy (DRUG); Raltitrexed-based chemotherapy (DRUG); 5-fluorouracil-based chemotherapy (DRUG); 5-fluorouracil-based chemotherapy (DRUG),9887053,CS-0992,Colorectal Cancer; Liver Metastasis,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3140,NCT03388190,METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin,ACTIVE_NOT_RECRUITING,PHASE2,Colorectal Cancer Metastatic,Nivolumab (DRUG); FLOX (DRUG),9887053,CS-0992,Colorectal Cancer Metastatic,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3141,NCT05677490,"mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma",RECRUITING,PHASE3,Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Metastatic Esophageal Adenocarcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Unresectable Esophageal Adenocarcinoma; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma,Fluorouracil (DRUG); Leucovorin Calcium (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG); Nivolumab (BIOLOGICAL); Magnetic Resonance Imaging (PROCEDURE); Computed Tomography (PROCEDURE); Biospecimen Collection (PROCEDURE); Questionnaire Administration (OTHER),9887053,CS-0992,Advanced Gastroesophageal Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3142,NCT01972490,Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases,COMPLETED,PHASE4,Colorectal Neoplasms,avastin (DRUG); mFOLFOX6 (DRUG),9887053,CS-0992,Colorectal Neoplasms,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3143,NCT05451290,Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer,RECRUITING,PHASE2,Advanced Biliary Tract Carcinoma,"Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur (DRUG)",9887053,CS-0992,Advanced Biliary Tract Carcinoma,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3144,NCT04510064,Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial,COMPLETED,PHASE2,Metastatic Gastric Cancer; Locally Advanced Gastric Adenocarcinoma; Gastric Cancer Adenocarcinoma Metastatic,Camrelizumab plus mFLOT regimen (DRUG); R0 surgery (PROCEDURE),9887053,CS-0992,Metastatic Gastric Cancer; Locally Advanced Gastric Adenocarcinoma; Gastric Cancer Adenocarcinoma Metastatic,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3145,NCT06123338,A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer,RECRUITING,PHASE2,Esophageal Cancer; Gastric Adenocarcinoma; HER2 Gene Mutation,Pembrolizumab (DRUG); Trastuzumab (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG); 5-Fluorouracil (DRUG); Docetaxel (DRUG),9887053,CS-0992,Gastroesophageal Cancer with HER2 Mutation,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3146,NCT06197438,Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer,NOT_YET_RECRUITING,PHASE2,Gastric Cancer,Tislelizumab (DRUG); Oxaliplatin (DRUG); Levo-Leucovorin (DRUG); 5-fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Paclitaxel (DRUG),9887053,CS-0992,Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3147,NCT00889343,Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer,TERMINATED,PHASE2,Colorectal Neoplasms,Sorafenib (DRUG); Placebo (DRUG); Oxaliplatin or Irinotecan (DRUG); Leucovorin (DRUG); 5-Fluorouracil (DRUG),9887053,CS-0992,Colorectal Neoplasms,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3148,NCT00711243,"Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor",COMPLETED,PHASE1,"Gastric Cancer; Unspecified Adult Solid Tumor, Protocol Specific",docetaxel (DRUG); fluorouracil (DRUG); oxaliplatin (DRUG),9887053,CS-0992,"Gastric Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3149,NCT02071043,Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis,COMPLETED,PHASE2,Advanced Gastric Cancer,Capecitabine (DRUG); Oxaliplatin (DRUG),9887053,CS-0992,Advanced Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3150,NCT06722950,Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy,NOT_YET_RECRUITING,PHASE2,Colorectal Adenoma,CAPEOX (DRUG); Placebo (DRUG); AC591 (DRUG),9887053,CS-0992,Colorectal Adenoma,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3151,NCT05794750,Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13）,NOT_YET_RECRUITING,PHASE2,Locally Advanced Rectal Cancer,AK104 injection (DRUG); TME surgery (PROCEDURE); Capecitabine (DRUG); Oxaliplatin (DRUG),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3152,NCT01905150,"Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer",COMPLETED,PHASE2,Pancreatic Cancer,G-FLIP (DRUG); G-FLIP-DM (DRUG); Vitamin C (DIETARY_SUPPLEMENT),9887053,CS-0992,Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3153,NCT00612495,Endometrial Cancer - LOHP Alone and With 5FU,COMPLETED,PHASE2,Endometrial Cancer,"oxaliplatin, 5 FU (DRUG)",9887053,CS-0992,Endometrial Cancer,Uterus,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3154,NCT03564912,Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC,COMPLETED,PHASE1,Colorectal Cancer,Capecitabine Oral Tablet [Xeloda] (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3155,NCT06652412,CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC,NOT_YET_RECRUITING,PHASE2,Colon Cancer; Rectal Cancer,Ultrafractionated RT and CGA Guided systemic treatment. (DRUG); data prospectively collected (OTHER); Ultrafractionated Radiotherapy (RADIATION); Sintilimab (DRUG); Fluorouracil (DRUG); Raltitrexed (DRUG); Oxaliplatin (DRUG); Irinotecan (CPT-11) (DRUG),9887053,CS-0992,Colon Cancer; Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3156,NCT03167112,A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer,UNKNOWN,PHASE2,Pancreatic Cancer,Oxaliplatin (DRUG); Irinotecan (DRUG); Leucovorin (DRUG); Fluorouracil (DRUG),9887053,CS-0992,Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3157,NCT05990543,Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer,NOT_YET_RECRUITING,PHASE1,Recurrent or Metastatic Colorectal Cancer,Nelmastobart and Capecitabine (DRUG),9887053,CS-0992,Recurrent or Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3158,NCT05919264,FOG-001 in Locally Advanced or Metastatic Solid Tumors,RECRUITING,PHASE1,Cancer; Colorectal Cancer; Solid Tumor; Locally Advanced Solid Tumor; Metastatic Cancer; WNT Pathway; β-catenin; Beta-catenin; Adenomatous Polyposis Coli; APC; HCC; Desmoid; Microsatellite Stable Colorectal Cancer; Metastatic Castration-resistant Prostate Cancer; FAP; Endometrial Carcinoma; Prostate Cancer; Microsatellite Instability-High Colorectal Cancer; CTNNB1; Adamantinomatous Craniopharyngioma,FOG-001 (DRUG); mFOLFOX-6 (DRUG); Nivolumab (DRUG); Trifluridine/tipiracil (DRUG); Bevacizumab (DRUG),9887053,CS-0992,Cancer; Colorectal Cancer; Solid Tumor; Locally Advanced Solid Tumor; Metastatic Cancer; WNT Pathway; β-catenin; Beta-catenin; Adenomatous Polyposis Coli; APC; HCC; Desmoid; Microsatellite Stable Colorectal Cancer; Metastatic Castration-resistant Prostate Cancer; FAP; Endometrial Carcinoma; Prostate Cancer; Microsatellite Instability-High Colorectal Cancer; CTNNB1; Adamantinomatous Craniopharyngioma,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3159,NCT04082364,"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer",COMPLETED,PHASE2,Gastric Cancer; Gastroesophageal Junction Cancer; HER2-positive Gastric Cancer,margetuximab (BIOLOGICAL); Retifanlimab (BIOLOGICAL); Tebotelimab (BIOLOGICAL); Trastuzumab (BIOLOGICAL); Chemotherapy (OTHER),9887053,CS-0992,Gastric Cancer; Gastroesophageal Junction Cancer; HER2-positive Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3160,NCT06225843,Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis,RECRUITING,PHASE2,Metastatic Colorectal Cancer,Sotevtamab (BIOLOGICAL); FOLFOX (COMBINATION_PRODUCT),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3161,NCT01470443,Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma,UNKNOWN,PHASE3,"Biliary Tract (Intrahepatic, Extrahepatic Cholangiocarcinoma, Gall Bladder) Cancer",Oxaliplatin (DRUG); Oxaliplatin (DRUG),9887053,CS-0992,"Biliary Tract (Intrahepatic, Extrahepatic Cholangiocarcinoma, Gall Bladder) Cancer",Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3162,NCT03251612,Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer Metastatic,Based on sensitivity analysis (DRUG),9887053,CS-0992,Colorectal Cancer Metastatic,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3163,NCT01531712,Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable,TERMINATED,PHASE2,Pancreatic Cancer,Gemcitabine (DRUG); Radiotherapy (RADIATION); Tarceva (DRUG); Oxaliplatin (DRUG),9887053,CS-0992,Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3164,NCT01662869,A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer,COMPLETED,PHASE3,Gastric Cancer,5-Fluoruracil (DRUG); Folinic acid (DRUG); Onartuzumab (DRUG); Oxaliplatin (DRUG); Placebo (DRUG),9887053,CS-0992,Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3165,NCT00868569,Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer,UNKNOWN,PHASE4,Liver Metastasis; Colorectal Cancer,TACE + folfox 4 (PROCEDURE); TAC + folfox4 (PROCEDURE),9887053,CS-0992,Liver Metastasis; Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3166,NCT03792269,Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC,UNKNOWN,PHASE2,Colorectal Cancer Metastatic; Chemotherapy Effect; Chemotherapeutic Toxicity,Irinotecan (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer with Chemotherapy Effects,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3167,NCT06858969,"Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer",NOT_YET_RECRUITING,PHASE2,Metastatic Colorectal Cancer,Treatment group (DRUG); Standard-of-care control group (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3168,NCT02017704,Chemoradiation or Brachytherapy for Rectal Cancer,COMPLETED,PHASE2,Rectal Cancer,Endo-HDR (if randomized to this arm) (RADIATION); capecitabine and IMRT (if randomized to this arm) (DRUG); IMRT (intensity modulated radiation therapy) (RADIATION); FOLFOX6 (DRUG); Surgery (PROCEDURE),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3169,NCT03991104,SOX-based CRT for Esophageal Cancer.,WITHDRAWN,PHASE1,Esophageal Cancer,Oxaliplatin (DRUG); S-1 capsule (DRUG); Intensity modulated radiotherapy (IMRT) (RADIATION),9887053,CS-0992,Esophageal Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3170,NCT01100801,A Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients,UNKNOWN,PHASE2,Recurrent Gastric Cancer,TS-1 with cisplatin (DRUG); TS-1 with oxaliplatin (DRUG),9887053,CS-0992,Recurrent Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3171,NCT01653301,"Preoperative Downstaging of Extraperitoneal T3 Rectal Cancer: XELOXRT Versus XELACRT. A Multicenter, Phase III Study",UNKNOWN,PHASE3,Rectal Cancer,XELAC RT (DRUG); XELOX RT (DRUG),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3172,NCT02347904,Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer,COMPLETED,PHASE1,Esophageal Cancer,S-1 and Oxaliplatin (DRUG),9887053,CS-0992,Esophageal Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3173,NCT05300269,SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer,RECRUITING,PHASE2,Locally Advanced Rectal Cancer,SHR-1701；Capecitabine；Oxaliplatin (DRUG),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3174,NCT06838546,"A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer",NOT_YET_RECRUITING,PHASE2,Advanced Colorectal Cancer,B1962 (DRUG),9887053,CS-0992,Advanced Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3175,NCT01962246,Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction,COMPLETED,PHASE2,Gastroesophageal Junction Adenocarcinoma,Oxaliplatin; Capecitabine (DRUG); Oxaliplatin; Capecitabine; concurrent radiotherapy (OTHER),9887053,CS-0992,Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3176,NCT01006369,"Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",COMPLETED,PHASE2,Colorectal Cancer,hydroxychloroquine (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3177,NCT02359968,PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer,COMPLETED,PHASE2,Esophageal Neoplasms; Gastro-esophageal Junction Cancer,FOLFOX (DRUG); CarboP-pacliT (DRUG),9887053,CS-0992,Esophageal Neoplasms; Gastro-esophageal Junction Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3178,NCT05699746,CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD,NOT_YET_RECRUITING,PHASE3,Colorectal Cancer,Capecitabine tablets (DRUG); Oxaliplatin (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3179,NCT05253846,Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29,ACTIVE_NOT_RECRUITING,PHASE2,Locally Advanced Rectal Cancer,Irinotecan (DRUG); Oxaliplatin (DRUG); Lederfolin (DRUG); 5-Fluorouracil (DRUG); Short-course radiotherapy (RADIATION); TME (PROCEDURE),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3180,NCT01608646,Study of DPD for Predicting Efficacy and Safety to S-1 Plus Oxaliplatin in Gastrointestinal Cancer,UNKNOWN,PHASE2,Gastrointestinal Cancer,S-1 plus oxaliplatin (DRUG),9887053,CS-0992,Gastrointestinal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3181,NCT03464968,mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line,COMPLETED,PHASE2,Biliary Cancer Metastatic,"Oxaliplatin,5FU, leucovorin (DRUG); irinotecan,5FU, leucovorin (DRUG)",9887053,CS-0992,Metastatic Biliary Cancer,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3182,NCT03647969,Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer,COMPLETED,PHASE2,Adenocarcinoma of the Stomach; GastroEsophageal Cancer,Nivolumab (DRUG); Ipilimumab (DRUG); mFOLFOX (DRUG); FLOT (DRUG),9887053,CS-0992,Adenocarcinoma of the Stomach; GastroEsophageal Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3183,NCT00114946,A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer,TERMINATED,PHASE4,Colorectal Cancer,Avastin (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3184,NCT02060669,Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer,TERMINATED,PHASE3,Metastatic Colorectal Cancer,Xeloda (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3185,NCT05427669,Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD),NOT_YET_RECRUITING,PHASE3,Colorectal Cancer,mFOLFOXIRI (DRUG); mFOLFOX6 (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3186,NCT00006468,Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer,UNKNOWN,PHASE3,Colorectal Cancer,FOLFOX regimen (DRUG); fluorouracil (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3187,NCT03693846,Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors,TERMINATED,PHASE2,Mucinous Adenocarcinoma of the Colon; Mucinous Adenocarcinoma of the Rectum,Nivolumab (DRUG); Ipilimumab (DRUG),9887053,CS-0992,Mucinous Adenocarcinoma of the Colon and Rectum,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3188,NCT00871169,"Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer",COMPLETED,PHASE2,Pancreatic Cancer,"Irinotecan, oxaliplatin, and cetuximab (DRUG)",9887053,CS-0992,Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3189,NCT06853769,Neoadjuvant Therapy for Locally Advanced Rectal Cancer,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,Colorectal Cancer,"Anlotinib hydrochloride,Penpulimab (DRUG)",9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3190,NCT00349076,Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy With 5-Fluorouracil and Oxaliplatin Versus 5-Fluorouracil Alone in Rectal Cancer,COMPLETED,PHASE3,Rectal Neoplasms,5-FU and oxaliplatin (DRUG); 5-FU (DRUG),9887053,CS-0992,Rectal Neoplasms,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3191,NCT06436976,The Effect of Probiotics ATG-F4 in Cancer Patients,RECRUITING,PHASE2,Pancreatic Cancer; Colon Cancer,LT-002 (Lactobacillus reuteri ATG-F4 (DRUG),9887053,CS-0992,Pancreatic Cancer; Colon Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3192,NCT04310176,Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer,UNKNOWN,PHASE2,Ras-mutated Metastatic Colorectal Cancer,Bevacizumab (DRUG); mFOLFOX6 regimen (DRUG); mOXXEL regimen (DRUG); Valproic acid (DRUG); Capecitabine (DRUG); 5-fluorouracil (DRUG),9887053,CS-0992,Ras-mutated Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3193,NCT02356276,Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2,UNKNOWN,PHASE3,Gastric Cancer,D2 lymphadenectomy (PROCEDURE); Hyperthermic Intraperitoneal Chemotherapy (PROCEDURE); Systemic chemotherapy (XELOX or SOX regimens) (DRUG),9887053,CS-0992,Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3194,NCT06599827,Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC,NOT_YET_RECRUITING,PHASE2,Rectal Cancer,moderately hypofractionated radiotherapy (RADIATION); chemotherapy (DRUG); immunotherapy (DRUG); Total mesorectal excision (TME) surgery (PROCEDURE),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3195,NCT01679327,Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer,UNKNOWN,PHASE2,Colorectal Cancer,Oxaliplatin (DRUG); Xeloda (DRUG); Calcium folinate (CF) (DRUG); 5-FU (DRUG); Bevacizumab (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3196,NCT03641976,"A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer",UNKNOWN,PHASE2,"Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy; Unresectable Metastatic Right-sided Colon Cancer, Stage IV",A-FOLFOXIRI (DRUG); Arm II (A-FOLFOX/A-FOLFIRI) (DRUG),9887053,CS-0992,Metastatic Colon Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3197,NCT01196260,Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III,UNKNOWN,PHASE2,Colorectal Cancer,Capecitabine and Oxaliplatin (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3198,NCT00954876,Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer,WITHDRAWN,PHASE2,Metastatic Colorectal Cancer,capecitabine and cetuximab (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3199,NCT01652976,"Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma",COMPLETED,PHASE2,Pancreatic Cancer Metastatic,Dasatinib (DRUG); mFOLFOX6 (DRUG),9887053,CS-0992,Pancreatic Cancer Metastatic,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3200,NCT05251727,Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients,TERMINATED,PHASE1,Chemotherapy-induced Peripheral Neuropathy,thrombomodulin alfa (DRUG); Placebo (DRUG),9887053,CS-0992,Chemotherapy-induced Peripheral Neuropathy,Peripheral Nervous System,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3201,NCT01918527,Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Colon Cancer,Capecitabine (DRUG); Oxaliplatin (DRUG),9887053,CS-0992,Colon Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3202,NCT04933227,"A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)",TERMINATED,PHASE2,Stomach Neoplasms; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma,Atezolizumab (DRUG); Tiragolumab (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG),9887053,CS-0992,Stomach Neoplasms; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3203,NCT06936527,XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation,NOT_YET_RECRUITING,PHASE1,Colorectal Cancer; Metastatic Colorectal Cancer With RAS Mutation,"Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI (BIOLOGICAL); Drug: XS-03 (BIOLOGICAL); Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI (BIOLOGICAL)",9887053,CS-0992,Colorectal Cancer; Metastatic Colorectal Cancer With RAS Mutation,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3204,NCT00114231,"Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer",COMPLETED,PHASE2,Colorectal Cancer,capecitabine (DRUG); oxaliplatin (DRUG); neoadjuvant therapy (PROCEDURE); radiation therapy (RADIATION),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3205,NCT05815082,ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer,RECRUITING,PHASE3,Colorectal Cancer; Liver Metastases; Circulating Tumor Cell; Chemotherapy Effect,Colorectal cancer resection combined with liver metastasis resection. (PROCEDURE); FOLFOX chemotherapy regimen (DRUG),9887053,CS-0992,Colorectal Cancer; Liver Metastases; Circulating Tumor Cell; Chemotherapy Effect,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3206,NCT05965531,Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy,RECRUITING,PHASE2,Rectal Cancer,Trifluridine/Tipiracil (DRUG); intensity-modulated radiotherapy (RADIATION),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3207,NCT00004931,Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer,COMPLETED,PHASE3,Stage II Colon Cancer; Stage III Colon Cancer,leucovorin calcium (DRUG); fluorouracil (DRUG); oxaliplatin (DRUG); laboratory biomarker analysis (OTHER),9887053,CS-0992,Stage II-III Colon Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3208,NCT01765582,Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer,TERMINATED,PHASE2,Colorectal Neoplasms,5-fluorouracil (DRUG); bevacizumab (DRUG); capecitabine (DRUG); irinotecan (DRUG); folinic acid (DRUG); oxaliplatin (DRUG),9887053,CS-0992,Colorectal Neoplasms,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3209,NCT05231382,Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma,UNKNOWN,PHASE3,Hepatocellular Carcinoma,"Raltitrexed, oxaliplatin (SALOX) treatment (PROCEDURE); Oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment (PROCEDURE)",9887053,CS-0992,Hepatocellular Carcinoma,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3210,NCT02380131,Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis,UNKNOWN,PHASE4,HER-2 Positive Gastric Cancer; Liver Metastasis,Oxaliplatin plus Capecitabine (DRUG); Herceptin (DRUG),9887053,CS-0992,HER-2 Positive Gastric Cancer; Liver Metastasis,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3211,NCT01803282,Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors,COMPLETED,PHASE1,Pancreatic Cancer; Non-small Cell Lung Cancer; Esophagogastric Cancer; Colorectal Cancer; Breast Cancer,Andecaliximab (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); 5-FU (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG); Paclitaxel (DRUG),9887053,CS-0992,"Multiple Cancers (Pancreatic, Lung, Esophagogastric, Colorectal, Breast)",Breast,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3212,NCT03451331,Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer,COMPLETED,PHASE2,Metastatic Urothelial Cancer,Nivolumab (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG); Oxaliplatin (DRUG),9887053,CS-0992,Metastatic Urothelial Cancer,Bladder/Urinary Tract,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3213,NCT01136031,Paclitaxel and Irinotecan in Advanced Gastric Cancer,COMPLETED,PHASE1,Advanced Gastric Cancer,Paclitaxel and irinotecan (DRUG),9887053,CS-0992,Advanced Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3214,NCT05052931,Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer,UNKNOWN,PHASE2,Gastric Cancer,Nab-paclitaxel combined with oxaliplatin and S-1 (DRUG),9887053,CS-0992,Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3215,NCT00361231,"Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer",COMPLETED,PHASE2,Biliary Tract Cancer; Gallbladder Adenocarcinoma,Bevacizumab (DRUG); Gemcitabine (DRUG); Oxaliplatin (DRUG),9887053,CS-0992,Biliary Tract Cancer; Gallbladder Adenocarcinoma,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3216,NCT01081262,Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Borderline Ovarian Mucinous Tumor; Ovarian Mucinous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Stage IA Fallopian Tube Cancer AJCC v6 and v7; Stage IA Ovarian Cancer AJCC v6 and v7; Stage IB Fallopian Tube Cancer AJCC v6 and v7; Stage IB Ovarian Cancer AJCC v6 and v7; Stage IC Fallopian Tube Cancer AJCC v6 and v7; Stage IC Ovarian Cancer AJCC v6 and v7; Stage IIA Fallopian Tube Cancer AJCC v6 and v7; Stage IIA Ovarian Cancer AJCC V6 and v7; Stage IIB Fallopian Tube Cancer AJCC v6 and v7; Stage IIB Ovarian Cancer AJCC v6 and v7; Stage IIC Fallopian Tube Cancer AJCC v6 and v7; Stage IIC Ovarian Cancer AJCC v6 and v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7,Bevacizumab (BIOLOGICAL); Capecitabine (DRUG); Carboplatin (DRUG); Laboratory Biomarker Analysis (OTHER); Oxaliplatin (DRUG); Paclitaxel (DRUG); Quality-of-Life Assessment (OTHER),9887053,CS-0992,Borderline Ovarian Mucinous Tumor; Ovarian Mucinous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Stage IA Fallopian Tube Cancer AJCC v6 and v7; Stage IA Ovarian Cancer AJCC v6 and v7; Stage IB Fallopian Tube Cancer AJCC v6 and v7; Stage IB Ovarian Cancer AJCC v6 and v7; Stage IC Fallopian Tube Cancer AJCC v6 and v7; Stage IC Ovarian Cancer AJCC v6 and v7; Stage IIA Fallopian Tube Cancer AJCC v6 and v7; Stage IIA Ovarian Cancer AJCC V6 and v7; Stage IIB Fallopian Tube Cancer AJCC v6 and v7; Stage IIB Ovarian Cancer AJCC v6 and v7; Stage IIC Fallopian Tube Cancer AJCC v6 and v7; Stage IIC Ovarian Cancer AJCC v6 and v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7,Ovary/Fallopian Tube,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3217,NCT00486460,"Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer",UNKNOWN,PHASE3,Pancreatic Cancer,Gemcitabine (DRUG); Curcumin (DRUG); Celebrex (DRUG),9887053,CS-0992,Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3218,NCT02368860,"OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma",COMPLETED,PHASE1,Pancreatic Cancer,"oxaliplatin, irinotecan, capecitabine (DRUG)",9887053,CS-0992,Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3219,NCT03645876,SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer,TERMINATED,PHASE2,Metastatic Colorectal Cancer,SHR-1210 (DRUG); BP102 (DRUG); oxaliplatin (DRUG); capecitabine (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3220,NCT05299476,CAPOX + Bevacizumab + Tislelizumab Treating PD-L1 CPS < 5 Locally Advanced or Metastatic GEA,COMPLETED,PHASE2,Advanced Gastroesophageal Adenocarcinoma; First-line Therapy; PDL1 CPS < 5,CAPOX combined with bevacizumab and Tislelizumab (DRUG),9887053,CS-0992,Advanced Gastroesophageal Adenocarcinoma; First-line Therapy; PDL1 CPS < 5,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3221,NCT02172976,Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma,COMPLETED,PHASE2,Resectable Prancreas Carcinoma,Gemcitabine (DRUG); Oxaliplatin (DRUG); 5-Fluorouracil (DRUG); Irinotecan (DRUG); Natriumfolinate (DRUG),9887053,CS-0992,Pancreatic Carcinoma,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3222,NCT00559676,Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer,COMPLETED,PHASE4,Colorectal Cancer,capecitabine (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3223,NCT04668976,A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma,UNKNOWN,PHASE2,Colorectal Cancer; Cholangiocarcinoma,Medtronic pump and Codman catheter (DEVICE); Floxuridine (FUDR) (DRUG); Gemcitabine (DRUG); Oxaliplatin (DRUG); Irinotecan (CPT-11) (DRUG); Fluorouracil (DRUG); Anti-EGFR (Panitumumab or Cetuximab) (DRUG),9887053,CS-0992,Colorectal Cancer; Cholangiocarcinoma,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3224,NCT01962376,Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis,UNKNOWN,PHASE4,Gastric Cancer; Liver Metastasis,Oxaliplatin;Capecitabine (DRUG); Oxaliplatin;Capecitabine;Bevacizumab (DRUG),9887053,CS-0992,Gastric Cancer; Liver Metastasis,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3225,NCT00300027,Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies,TERMINATED,PHASE1,Gastrointestinal Neoplasms,BMS-582664 (DRUG),9887053,CS-0992,Gastrointestinal Neoplasms,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3226,NCT03528876,FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma,TERMINATED,PHASE2,Metastatic Gastro-esophageal Adenocarcinoma,FOLFOX and FOLFIRI (DRUG),9887053,CS-0992,Metastatic Gastro-esophageal Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3227,NCT03485027,Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer; Chemotherapy Effect,the rechallenge regimen (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3228,NCT00384176,First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX,COMPLETED,PHASE2,Colorectal Cancer,Cediranib (DRUG); Bevacizumab (DRUG); 5-fluorouracil ( in FOLFOX) (DRUG); Leucovorin (in FOLFOX) (DRUG); Oxaliplatin (in FOLFOX) (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3229,NCT03751176,Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal,UNKNOWN,PHASE2,Colorectal Cancer Metastatic,Panitumumab (DRUG); Irinotecan (DRUG); Folinic acid (DRUG); 5-FU (DRUG),9887053,CS-0992,Colorectal Cancer Metastatic,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3230,NCT06901531,A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer,NOT_YET_RECRUITING,PHASE3,Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma,zolbetuximab (DRUG); Pembrolizumab (DRUG); Capecitabine (DRUG); Oxaliplatin (DRUG); Folinic acid (leucovorin or local equivalent) (DRUG); 5-fluorouracil (5-FU) (DRUG); Placebo (DRUG),9887053,CS-0992,Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3231,NCT03368131,"Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study",UNKNOWN,PHASE2,Gastroesophageal Junction Adenocarcinoma,Trastuzumab (DRUG); Capecitabine (DRUG); Oxaliplatin (DRUG); Radiotherapy (RADIATION),9887053,CS-0992,Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3232,NCT02904031,Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients,UNKNOWN,PHASE2,Elderly Metastatic Colorectal Cancer Patients,5-fluorouracil (DRUG); oxaliplatin (DRUG); l-leucovorin (DRUG); panitumumab (DRUG),9887053,CS-0992,Elderly Metastatic Colorectal Cancer Patients,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3233,NCT04065282,The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.,UNKNOWN,PHASE2,Gastric Cancer,Sintilimab (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG),9887053,CS-0992,Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3234,NCT00017082,Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,oxaliplatin (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3235,NCT04659382,"Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer",RECRUITING,PHASE2,Metastatic Colorectal Cancer; pMMR; MSS; Immune Checkpoint Inhibitor; Internal Radiotherapy,Atezolizumab (DRUG); Therasphere (DEVICE); XELOX (DRUG); Bevacizumab (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer; pMMR; MSS; Immune Checkpoint Inhibitor; Internal Radiotherapy,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3236,NCT02953782,Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer,COMPLETED,PHASE1,Solid Tumor; Colorectal Cancer,Magrolimab (DRUG); Cetuximab (DRUG),9887053,CS-0992,Solid Tumor; Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3237,NCT02607982,CCRT for Esophageal Cancer.,COMPLETED,PHASE2,Esophageal Cancer; Concurrent Chemoradiotherapy; Oxaliplatin; Paclitaxel,Paclitaxel (DRUG); Oxaliplatin (DRUG); Radiotherapy (RADIATION),9887053,CS-0992,Esophageal Cancer; Concurrent Chemoradiotherapy; Oxaliplatin; Paclitaxel,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3238,NCT00577031,OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.,COMPLETED,PHASE4,Colorectal Cancer,bevacizumab [Avastin] (DRUG); Oxaliplatin (DRUG); Xeloda (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3239,NCT01652482,Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC),COMPLETED,PHASE2,Colorectal Cancer,5-fluorouracil (DRUG); Cetuximab (DRUG); Irinotecan (DRUG); Leucovorin (DRUG); MEHD7945A (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3240,NCT04361331,"Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma",COMPLETED,PHASE2,"Cholangiocarcinoma, Intrahepatic",Lenvatinib combined with gemox (DRUG); Toripalimab combined with lenvatinib (DRUG),9887053,CS-0992,"Cholangiocarcinoma, Intrahepatic",Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3241,NCT06390982,Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study,NOT_YET_RECRUITING,PHASE2,RECTAL NEOPLASMS; Rectal Cancer,Radiotherapy (RADIATION); Tislelizumab (DRUG); Capecitabine (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG),9887053,CS-0992,RECTAL NEOPLASMS; Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3242,NCT00660582,FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Cetuximab (Erbitux) (DRUG); Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3243,NCT06190782,Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor,RECRUITING,PHASE3,Esophageal Squamous Cell Carcinoma; Oligometastatic Disease; Radiotherapy,PD-1 inhibitor+/- chemotherapy combined with local therapy (COMBINATION_PRODUCT); systemic therapy alone (DRUG),9887053,CS-0992,Esophageal Squamous Cell Carcinoma; Oligometastatic Disease; Radiotherapy,Skin,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3244,NCT04687631,Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases,RECRUITING,PHASE3,Colorectal Cancer; Liver Metastases,mFOLFOXIRI plus Cetuximab (DRUG); mFOLFOXIRI Plus Bevacizumab (DRUG),9887053,CS-0992,Colorectal Cancer; Liver Metastases,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3245,NCT04859582,Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension,WITHDRAWN,PHASE3,Stomach Neoplasms,Pembrolizumab (BIOLOGICAL); Cisplatin (DRUG); 5-fluorouracil (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG); Placebo for Pembrolizumab (DRUG),9887053,CS-0992,Stomach Neoplasms,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3246,NCT03505320,A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Pharmacokinetics of Zolbetuximab; Gastric Cancer; Gastro-esophageal Junction (GEJ) Cancer; Pharmacokinetics of Oxaliplatin; Pharmacokinetics of Fluorouracil Bolus (5-FU),zolbetuximab (DRUG); oxaliplatin (DRUG); leucovorin (DRUG); fluorouracil (DRUG); Pembrolizumab (DRUG); folinic acid (DRUG); nivolumab (DRUG); Docetaxel (DRUG),9887053,CS-0992,Gastric and Gastro-esophageal Junction Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3247,NCT01048320,Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer,COMPLETED,PHASE1,Advanced Pancreatic Cancer,Gemcitabine (DRUG); Oxaliplatin (DRUG); Imatinib (DRUG),9887053,CS-0992,Advanced Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3248,NCT00673673,FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer,COMPLETED,PHASE2,Gastroesophageal Cancer; Gastric Cancer,FOLFOX (DRUG); bevacizumab (DRUG),9887053,CS-0992,Gastroesophageal Cancer; Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3249,NCT03533582,Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery,ACTIVE_NOT_RECRUITING,PHASE3,"Childhood Hepatocellular Carcinoma; Childhood Malignant Liver Neoplasm; Fibrolamellar Carcinoma; Hepatoblastoma; Hepatocellular Malignant Neoplasm, Not Otherwise Specified",Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Doxorubicin (DRUG); Etoposide (DRUG); Fluorouracil (DRUG); Gemcitabine (DRUG); Irinotecan (DRUG); Oxaliplatin (DRUG); Patient Observation (OTHER); Resection (PROCEDURE); Sorafenib (DRUG); Vincristine Sulfate (DRUG),9887053,CS-0992,Childhood Liver Malignancies,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3250,NCT03206073,A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer; Colorectal Carcinoma; Colorectal Adenocarcinoma; Refractory Cancer; Colorectal Neoplasms,Durvalumab (DRUG); Tremelimumab (DRUG); Pexa-Vec (BIOLOGICAL); Pexa-Vec (BIOLOGICAL),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3251,NCT03979131,Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC),ACTIVE_NOT_RECRUITING,PHASE2,Gastroesophageal Junction Adenocarcinoma; Stomach Neoplasms,Avelumab addition to perioperative chemotherapy in GC and GEJC (COMBINATION_PRODUCT),9887053,CS-0992,Gastroesophageal Junction Adenocarcinoma; Stomach Neoplasms,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3252,NCT05340231,An Exploratory Study of Sequential Transarterial Chemoembolization With Lipiodol and Neoadjuvant Chemotherapy in the Treatment of Initial Unresectable Colorectal Cancer (CRC),NOT_YET_RECRUITING,PHASE2,Colorectal Cancer,TACE protocol (DRUG); Neoadjuvant Chemotherapy (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3253,NCT04089631,Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation,RECRUITING,PHASE3,Colon Cancer Stage II,Capecitabine (DRUG),9887053,CS-0992,Colon Cancer Stage II,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3254,NCT02782182,Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study,TERMINATED,PHASE1,Pancreatic Ductal Adenocarcinoma (PDAC),"FOLFIRINOX (oxaliplatin, leucovorin, irinotecan) (DRUG)",9887053,CS-0992,Pancreatic Ductal Adenocarcinoma (PDAC),Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3255,NCT01818973,"Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer",UNKNOWN,PHASE2,Rectal Cancer,Xeloda (DRUG); Oxaliplatin (DRUG); Bevacizumab (DRUG); Radiation (RADIATION); surgery (PROCEDURE),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3256,NCT03940131,Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,Panitumumab (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3257,NCT05715931,Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma,RECRUITING,PHASE2,Adenocarcinoma of the Stomach; Adenocarcinoma of Esophagogastric Junction; HER2-positive Gastric Cancer,"Toripalimab (DRUG); Trastuzumab (DRUG); 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT) (DRUG)",9887053,CS-0992,Gastric and Gastroesophageal Junction Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3258,NCT04479527,Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma,UNKNOWN,PHASE2,Hepatocellular Carcinoma,Camrelizumab (DRUG),9887053,CS-0992,Hepatocellular Carcinoma,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3259,NCT06730373,First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2),RECRUITING,PHASE2,HER2-positive Gastric Cancer; Metastatic Gastric Cancer; Unresectable Gastric Carcinoma,Disitamab Vedotin (DRUG); Sintilimab (DRUG); S-1 (DRUG); Trastuzumab (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG); 5-FU (DRUG); Cisplatin (DRUG),9887053,CS-0992,HER2-positive Gastric Cancer; Metastatic Gastric Cancer; Unresectable Gastric Carcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3260,NCT00448760,Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery,COMPLETED,PHASE2,Esophageal Cancer,Docetaxel (DRUG); Floxuridine (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Microarray analysis (GENETIC); reverse transcriptase-polymerase chain reaction (GENETIC); Conventional surgery (PROCEDURE),9887053,CS-0992,Esophageal Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3261,NCT06417476,Short-course Radiotherapy or Long-course Chemoradiation Followed by MFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer,RECRUITING,PHASE2,Rectal Neoplasms,Short-course radiotherapy (RADIATION); Irinotecan (DRUG); Oxaliplatin (DRUG); Calcium Formate (DRUG); Fluorouracil (DRUG); Long-course chemoradiation (RADIATION); Capecitabine (DRUG),9887053,CS-0992,Rectal Neoplasms,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3262,NCT04009876,A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer,COMPLETED,PHASE2,Locally Advanced Rectal Cancer (LARC),nal-IRI (DRUG); Surgical resection (PROCEDURE); Watch-and-wait (OTHER); 5-FU/LV (DRUG); Oxaliplatin (DRUG),9887053,CS-0992,Locally Advanced Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3263,NCT06493760,A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients,RECRUITING,PHASE2,Metastatic Colorectal Cancer,SSGJ-707 (DRUG); Bevacizumab (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG); Calcium Folinate (DRUG); 5-fluorouracil (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3264,NCT03801876,Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer,RECRUITING,PHASE3,Clinical Stage I Esophageal Adenocarcinoma AJCC v8; Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage I Esophageal Adenocarcinoma AJCC v8; Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage II Esophageal Adenocarcinoma AJCC v8; Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage III Esophageal Adenocarcinoma AJCC v8; Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Thoracic Esophagus Squamous Cell Carcinoma,Carboplatin (DRUG); Esophagectomy (PROCEDURE); Intensity-Modulated Radiation Therapy (RADIATION); Paclitaxel (DRUG); Proton Beam Radiation Therapy (RADIATION); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); FOLFOX regimen (DRUG); CAPOX regimen (DRUG); Docetaxel (DRUG); 5FU (DRUG),9887053,CS-0992,Esophageal and Gastroesophageal Junction Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3265,NCT00003260,Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer,UNKNOWN,PHASE3,Colorectal Cancer,FOLFIRI regimen (DRUG); FOLFOX regimen (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3266,NCT04483076,Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer,RECRUITING,PHASE3,Gastric Cancer; Chemotherapy Effect,Chemotherapy drug (DRUG); Gastrectomy (PROCEDURE); Laparoscopic exploration (PROCEDURE),9887053,CS-0992,Gastric Cancer; Chemotherapy Effect,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3267,NCT00204776,XELOX for Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Capecitabine and Oxaliplatin (DRUG),9887053,CS-0992,Metastatic Breast Cancer,Breast,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3268,NCT05193292,Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer,UNKNOWN,PHASE2,Colorectal Neoplasms; Intestinal Neoplasms,Camrelizumab (DRUG); Trastuzumab (DRUG); XELOX regimen (DRUG); mFOLFOX6 regimen (DRUG); FOLFIRI regimen (DRUG); mXELIRI regimen (DRUG); mIRIS regimen (DRUG),9887053,CS-0992,Intestinal Neoplasms,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3269,NCT00500292,A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer,COMPLETED,PHASE2,Colorectal; Cancer,"Vandetanib (DRUG); FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid (DRUG)",9887053,CS-0992,Colorectal; Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3270,NCT03085992,Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer,COMPLETED,PHASE2,Rectal Cancer,FOLFOXIRI plus Bevacizumab (DRUG); Chemoradiotherapy plus Bevacizumab (OTHER),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3271,NCT01867892,A Phase II Study of Locally Advanced Pancreatic Cancer,UNKNOWN,PHASE2,Pancreatic Cancer,"ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT (DRUG); ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT (DRUG)",9887053,CS-0992,Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3272,NCT00982592,Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer,COMPLETED,PHASE2,Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach; Recurrent Gastric Cancer; Stage IIIA Gastric Cancer; Stage IIIB Gastric Cancer; Stage IIIC Gastric Cancer; Stage IV Gastric Cancer,oxaliplatin (DRUG); leucovorin calcium (DRUG); fluorouracil (DRUG); placebo (OTHER); vismodegib (DRUG); laboratory biomarker analysis (OTHER),9887053,CS-0992,Gastric and Gastroesophageal Junction Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3273,NCT01063192,A Study of Locally Advanced Pancreatic Cancer,UNKNOWN,PHASE2,Locally Advanced Pancreatic Cancer,"Gemcitabine (DRUG); Gemcitabine, Oxaliplatin, 5-Fluorouracil, Leucovorin (GOFL) (DRUG)",9887053,CS-0992,Locally Advanced Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3274,NCT00394992,Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer,TERMINATED,PHASE3,Colorectal Cancer; Liver Metastases,oxaliplatin+capecitabine (DRUG); Oxaliplatin+capecitabine+bevacizumab (DRUG),9887053,CS-0992,Colorectal Cancer; Liver Metastases,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3275,NCT06594692,"Node-Sparing Short-Course Radiation with CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: a Randomized, Prospective, Multicenter Study",NOT_YET_RECRUITING,PHASE2,Microsatellite Stable (MSS) Colon Cancer; Locally Advanced Colon Cancer,Node-Sparing Short-Course Radiotherapy Combined with CAPOX and Sintilimab (DRUG); CAPOX Chemotherapy (DRUG),9887053,CS-0992,Microsatellite Stable (MSS) Colon Cancer; Locally Advanced Colon Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3276,NCT00374660,Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors,COMPLETED,PHASE1,Liver Cancer,Oxaliplatin (DRUG); Irofulven (DRUG),9887053,CS-0992,Liver Cancer,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3277,NCT00008060,Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer,COMPLETED,PHASE3,Colorectal Cancer,FOLFIRI regimen (DRUG); FOLFOX regimen (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3278,NCT06210360,Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX,NOT_YET_RECRUITING,PHASE2,Pancreatic Cancer,Irinotecan liposome injection (DRUG); Oxaliplatin (DRUG); 5-FU (DRUG); LV (DRUG),9887053,CS-0992,Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3279,NCT05171660,Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer,RECRUITING,PHASE3,Colorectal Cancer Stage IV,Sintilimab Injection (DRUG); Control Test (DRUG),9887053,CS-0992,Colorectal Cancer Stage IV,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3280,NCT01246960,"A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer",COMPLETED,PHASE2,Stomach Cancer; Esophageal Cancer,Ramucirumab (BIOLOGICAL); Placebo (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); 5-Fluorouracil (DRUG),9887053,CS-0992,Stomach Cancer; Esophageal Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3281,NCT00711412,"Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer",COMPLETED,PHASE2,Esophageal Cancer,Induction Therapy - Capecitabine (DRUG); Induction Therapy - Oxaliplatin (DRUG); Combination Therapy - Capecitabine (DRUG); Combination Therapy - Oxaliplatin (DRUG); Combination Therapy - Radiation (RADIATION); Evaluation for response and surgery (PROCEDURE),9887053,CS-0992,Esophageal Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3282,NCT05024812,Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma,UNKNOWN,PHASE1,Metastatic Gastric Cancer,fruquintinib＋toripalimab + SOX (DRUG),9887053,CS-0992,Metastatic Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3283,NCT04888312,Safety and Efficacy of Mitazalimab in Combination with Chemotherapy in Pancreatic Cancer Patients,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Pancreatic Ductal Adenocarcinoma,CD40 agonist mitazalimab in combination with chemotherapy (BIOLOGICAL),9887053,CS-0992,Metastatic Pancreatic Ductal Adenocarcinoma,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3284,NCT01821612,Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer,COMPLETED,EARLY_PHASE1,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer,oxaliplatin (DRUG); irinotecan (DRUG); leucovorin (DRUG); 5-fluorouracil (DRUG); capecitabine (DRUG); radiation (RADIATION); surgery (PROCEDURE); gemcitabine (DRUG),9887053,CS-0992,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3285,NCT06791512,mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC,RECRUITING,PHASE3,Colorectal Cancer (CRC); pMMR/MSS Adenocarcinoma of the Colon or Rectum,mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody (DRUG); mFOLFOX6 (DRUG),9887053,CS-0992,Colorectal Cancer (CRC); pMMR/MSS Adenocarcinoma of the Colon or Rectum,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3286,NCT03801668,Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma,UNKNOWN,PHASE3,Gastric Cancer,Albumin-bound Paclitaxel plus S-1 (DRUG); Oxaliplatin plus S-1 (DRUG),9887053,CS-0992,Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3287,NCT03891472,Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer,COMPLETED,PHASE2,Cancer of Pancreas; Unresectable Pancreatic Cancer; Chemotherapy Effect; SBRT,"Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy. (DRUG)",9887053,CS-0992,Cancer of Pancreas; Unresectable Pancreatic Cancer; Chemotherapy Effect; SBRT,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3288,NCT04607668,"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):",TERMINATED,PHASE3,Colorectal Cancer Metastatic; Myelosuppression-Adult; Chemotherapeutic Toxicity,Trilaciclib (DRUG); Placebo (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer with Chemotherapy Complications,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3289,NCT05866172,HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC,RECRUITING,PHASE3,Hepatocellular Carcinoma,HAIC (PROCEDURE); Zoledronic acid (DRUG),9887053,CS-0992,Hepatocellular Carcinoma,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3290,NCT00613080,Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,capecitabine (DRUG); oxaliplatin (DRUG); resection (PROCEDURE); radiation therapy (RADIATION); FOLFOX (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3291,NCT04927780,Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer,RECRUITING,PHASE3,Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Adenocarcinoma,Leucovorin Calcium (DRUG); Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Oxaliplatin (DRUG); Resection (PROCEDURE),9887053,CS-0992,Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Adenocarcinoma,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3292,NCT05771480,Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs),ACTIVE_NOT_RECRUITING,PHASE3,Biliary Tract Cancer,Durvalumab (BIOLOGICAL); Gemcitabine monotherapy (DRUG); Gemcitabine + cisplatin (DRUG); Gemcitabine + oxaliplatin (DRUG); Gemcitabine + carboplatin (DRUG); Gemcitabine + cisplatin + S-1 (DRUG); Gemcitabine + S-1 (DRUG); Gemcitabine + cisplatin + albumin-bound paclitaxel (DRUG),9887053,CS-0992,Biliary Tract Cancer,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3293,NCT00483080,Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC),COMPLETED,PHASE2,Colorectal Cancer (CRC),NGR-hTNF (DRUG),9887053,CS-0992,Colorectal Cancer (CRC),Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3294,NCT06502080,Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC),NOT_YET_RECRUITING,PHASE2,Biliary Tract Cancer,Consolidative radiotherapy (RADIATION); Standard-of-care systemic therapy: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab (DRUG),9887053,CS-0992,Biliary Tract Cancer,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3295,NCT05846867,A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer,RECRUITING,PHASE1,Colorectal Cancer,AK119 (DRUG); AK112 (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG); Calcium folinate (DRUG); Fluorouracil (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3296,NCT02856867,Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN),WITHDRAWN,PHASE2,Esophagogastric Adenocarcinoma; Metastatic Disease; No Previous Chemotherapy for Metastatic Esophagogastric Cancer,Nintedanib (DRUG); Fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Placebo (DRUG),9887053,CS-0992,Esophagogastric Adenocarcinoma; Metastatic Disease; No Previous Chemotherapy for Metastatic Esophagogastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3297,NCT06942767,"Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",NOT_YET_RECRUITING,PHASE2,Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma,QLS31905 for Injection (DRUG); QL2107 Injection (DRUG); Oxaliplatin Injection (DRUG); Capecitabine Tablets (DRUG),9887053,CS-0992,Gastric and Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3298,NCT06109467,Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer,RECRUITING,PHASE2,GastroEsophageal Cancer; Gastric Cancer,Neratinib (DRUG); Trastuzumab (DRUG); Oxaliplatin (DRUG); 5-Fluorouracil + leucovorin (DRUG); Pembrolizumab (DRUG),9887053,CS-0992,Esophageal and Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3299,NCT06238167,Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC,NOT_YET_RECRUITING,PHASE2,Gastric Cancer,Tislelizumab (DRUG); S-1 therapy (DRUG); low dose SOX therapy (DRUG),9887053,CS-0992,Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3300,NCT03488667,Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma,UNKNOWN,PHASE2,Gastro Esophageal Junction Cancer; Stomach Cancer; Adenocarcinoma,Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab (DRUG); Adjuvant Treatment - mFOLFOX & Pembrolizumab (DRUG),9887053,CS-0992,Gastro Esophageal Junction Cancer; Stomach Cancer; Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3301,NCT02591667,Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer,UNKNOWN,PHASE2,Colorectal Cancer; Peritoneal Metastasis,Upfront staging laparoscopy + peritoneal biopsy (PROCEDURE); Neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab (DRUG); Surgical re-exploration (PROCEDURE),9887053,CS-0992,Colorectal Cancer; Peritoneal Metastasis,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3302,NCT04351867,A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer,UNKNOWN,PHASE3,Stomach Neoplasms,docetaxel plus oxaliplatin and capecitabine (DRUG); oxaliplatin plus capecitabine (DRUG),9887053,CS-0992,Stomach Neoplasms,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3303,NCT00049101,Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,erlotinib hydrochloride (DRUG); fluorouracil (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3304,NCT03585673,Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma,UNKNOWN,PHASE2,Esophagus Squamous Cell Carcinoma (SCC); Metastatic Cancer,Docetaxel-PM (DRUG); Oxaliplatin (DRUG),9887053,CS-0992,Esophagus Squamous Cell Carcinoma (SCC); Metastatic Cancer,Skin,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3305,NCT04677673,Neoadjuvant Chemotherapy Plus Surgery Versus Surgery First For Elderly Gastric Cancer Patients,NOT_YET_RECRUITING,PHASE2,Gastric Cancer; Chemotherapy Effect; Elderly Patients; Surgery,Chemotherapy (DRUG); Curative gastrectomy (PROCEDURE),9887053,CS-0992,Gastric Cancer; Chemotherapy Effect; Elderly Patients; Surgery,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3306,NCT05029973,HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC,UNKNOWN,PHASE2,Hepatocellular Carcinoma,HAIC (DRUG); Sintilimab (DRUG); Bevacizumab Biosimilar (DRUG),9887053,CS-0992,Hepatocellular Carcinoma,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3307,NCT03468231,HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC,UNKNOWN,PHASE3,Hepatocellular Carcinoma,Sorafenib (DRUG); HAIC of FOLFOX (DRUG); HAIC of OXA (DRUG),9887053,CS-0992,Hepatocellular Carcinoma,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3308,NCT05228431,Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer,RECRUITING,PHASE2,Advanced Rectal Cancer,XELOX (DRUG); Capecitabine monotherapy (DRUG); Radiation (RADIATION),9887053,CS-0992,Advanced Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3309,NCT05806931,Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer,RECRUITING,PHASE2,Colon Cancer; Rectal Cancer,"TAS-102, oxaliplatin, irinotecan with bevacizumab (DRUG)",9887053,CS-0992,Colon Cancer; Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3310,NCT01896531,A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer,COMPLETED,PHASE2,Gastric Cancer,5-Fluorouracil (DRUG); Ipatasertib (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Placebo (DRUG),9887053,CS-0992,Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3311,NCT00215982,Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,capecitabine (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3312,NCT00448682,Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery,TERMINATED,PHASE2,Gastric Cancer,Docetaxel (DRUG); Floxuridine (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG),9887053,CS-0992,Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3313,NCT01726582,"Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery (""Personalized Medicine"")",COMPLETED,PHASE2,Pancreatic Adenocarcinoma,Milestone 1: Targeted chemotherapy prior to surgery (DRUG); Milestone 2: Chemoradiotherapy (cXRT) (RADIATION); Milestone 3: Targeted chemotherapy prior to surgery (DRUG); Milestone 3: Chemoradiotherapy (cXRT) (RADIATION); Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery (DRUG); Milestone 4: Chemoradiotherapy (cXRT) (RADIATION); Milestone 5: Targeted chemotherapy after surgery (DRUG); Milestone 5: Chemoradiotherapy (cXRT) (RADIATION); Milestone 6: Gemcitabine after surgery (DRUG); Milestone 6: Chemoradiotherapy (cXRT) (RADIATION); Milestone 7: Chemoradiotherapy (cXRT) (RADIATION); Milestone 8: Targeted chemotherapy after surgery (DRUG); Milestone 9: Gemcitabine after surgery (DRUG); Milestone 10: No additional therapy after surgery (OTHER),9887053,CS-0992,Pancreatic Adenocarcinoma,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3314,NCT03536182,"Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer",WITHDRAWN,PHASE3,Locally Advanced Pancreatic Adenocarcinoma,Carbon Ion Radiation Therapy (CIRT) (RADIATION); Intensity Modulated Radiation Therapy (IMRT) (RADIATION),9887053,CS-0992,Pancreatic Neoplasms,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3315,NCT05412082,SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer,RECRUITING,PHASE1,Locally Advanced Rectal Cancer,Intensity-modulated radiation therapy (RADIATION); 5-fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG); Accelerated Radiation Therapy (RADIATION); Irinotecan (DRUG),9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3316,NCT01198548,High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer,TERMINATED,PHASE2,Stage IV Colon Cancer; Stage IV Rectal Cancer,leucovorin calcium (DRUG); bevacizumab (BIOLOGICAL); cholecalciferol (DIETARY_SUPPLEMENT); fluorouracil (DRUG); oxaliplatin (DRUG); pharmacological study (OTHER),9887053,CS-0992,Stage IV Colon Cancer; Stage IV Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3317,NCT02497157,Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Oxaliplatin (L-OHP) (DRUG); Irinotecan hydrochloride hydrate (CPT-11) (DRUG); Continuous intravenous infusion of fluorouracil (CIV 5-FU) (DRUG); Levofolinate calcium (l-LV) (DRUG); Bevacizumab (Bmab) (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3318,NCT06501482,Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI,NOT_YET_RECRUITING,PHASE3,Colorectal Cancer; Colorectal Liver Metastases,Postoperative reintroduction of FOLFIRI based chemotherapy (DRUG),9887053,CS-0992,Colorectal Cancer; Colorectal Liver Metastases,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3319,NCT06475326,Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer,RECRUITING,PHASE2,Pancreatic Cancer,Adebrelimab (DRUG); Oxaliplatin 100 MG (DRUG); Irinotecan liposome (DRUG); Calcium Folinate (DRUG); Fluorouracil (DRUG),9887053,CS-0992,Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3320,NCT02468557,Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma,TERMINATED,PHASE1,Previously Untreated Pancreatic Ductal Adenocarcinoma; Relapsed/Refractory Pancreatic Ductal Adenocarcinoma,Idelalisib (DRUG); Nab-paclitaxel (DRUG); mFOLFOX6 (DRUG),9887053,CS-0992,Previously Untreated Pancreatic Ductal Adenocarcinoma; Relapsed/Refractory Pancreatic Ductal Adenocarcinoma,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3321,NCT00353457,"Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma",TERMINATED,PHASE2,Rectal Cancer,"Capecitabine, Oxaliplatin and Cetuximab (DRUG); Radiation (RADIATION)",9887053,CS-0992,Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3322,NCT05099848,A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma,ACTIVE_NOT_RECRUITING,PHASE2,Hepatocellular Carcinoma,Camrelizumab (DRUG),9887053,CS-0992,Hepatocellular Carcinoma,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3323,NCT02720926,Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer,TERMINATED,PHASE1,Colorectal Cancer; Gastric Cancer,"Xeloda, (DRUG); Oxaliplatin (DRUG); TKI258 (DRUG)",9887053,CS-0992,Colorectal Cancer; Gastric Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3324,NCT05218148,SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma,NOT_YET_RECRUITING,PHASE2,HER2-positive; Locally Advanced Solid Tumor; Immunotherapy; Sintilimab; S-1; Oxaliplatin; Gastric or Gastroesophageal Junction Adenocarcinoma,sintilimab (DRUG); Trastuzumab (DRUG); S-1 plus oxaliplatin (DRUG),9887053,CS-0992,HER2-positive; Locally Advanced Solid Tumor; Immunotherapy; Sintilimab; S-1; Oxaliplatin; Gastric or Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3325,NCT03798626,"Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers",COMPLETED,PHASE1,Colorectal Cancer; Gastroesophageal Cancer; Renal Cell Carcinoma,Gevokizumab (DRUG); Bevacizumab (DRUG); Modified FOLFOX6 (DRUG); FOLFIRI (DRUG); Ramucirumab (DRUG); Paclitaxel (DRUG); Cabozantinib (DRUG),9887053,CS-0992,Colorectal and Gastroesophageal Cancers,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3326,NCT01740648,"Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer",COMPLETED,PHASE1,Recurrent Rectal Cancer; Stage IIA Rectal Cancer; Stage IIB Rectal Cancer; Stage IIC Rectal Cancer; Stage IIIA Rectal Cancer; Stage IIIB Rectal Cancer; Stage IIIC Rectal Cancer,trametinib (DRUG); fluorouracil (DRUG); radiation therapy (RADIATION),9887053,CS-0992,Recurrent Rectal Cancer; Stage IIA Rectal Cancer; Stage IIB Rectal Cancer; Stage IIC Rectal Cancer; Stage IIIA Rectal Cancer; Stage IIIB Rectal Cancer; Stage IIIC Rectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3327,NCT01528826,Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective Trial,UNKNOWN,PHASE2,Breast Cancer,vinorelbine plus oxaliplatin (DRUG),9887053,CS-0992,Breast Cancer,Breast,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3328,NCT03409848,Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma,COMPLETED,PHASE2,Gastric Cancer; Esophageal Cancer; Adenocarcinoma Gastric; HER2 Positive Gastric Cancer; Metastatic Gastric Cancer; GastroEsophageal Cancer,Nivolumab (DRUG); Nivolumab (DRUG); Ipilimumab (DRUG),9887053,CS-0992,Gastric Cancer; Esophageal Cancer; Adenocarcinoma Gastric; HER2 Positive Gastric Cancer; Metastatic Gastric Cancer; GastroEsophageal Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3329,NCT03329248,QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,TERMINATED,PHASE1,Pancreatic Cancer,ALT-803 (BIOLOGICAL); ETBX-011 (BIOLOGICAL); GI-4000 (BIOLOGICAL); haNK for infusion (BIOLOGICAL); avelumab (BIOLOGICAL); bevacizumab (BIOLOGICAL); Capecitabine (DRUG); Cyclophosphamide (DRUG); Fluorouracil (DRUG); Leucovorin (DRUG); nab-Paclitaxel (DRUG); lovaza (DRUG); Oxaliplatin (DRUG); SBRT (PROCEDURE),9887053,CS-0992,Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3330,NCT04863430,Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach,WITHDRAWN,PHASE2,Gastric Cancer,Apatinib (DRUG); Oxaliplatin (DRUG); S1 (DRUG),9887053,CS-0992,Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3331,NCT00286130,Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,"Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan (DRUG); FOLFOX 6 (DRUG); FOLFIRI (DRUG)",9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3332,NCT06244225,HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma,RECRUITING,PHASE2,Hepatocellular Carcinoma,Donafenib； Sintilimab； HAIC (DRUG),9887053,CS-0992,Hepatocellular Carcinoma,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3333,NCT01149122,Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract Carcinoma,COMPLETED,PHASE3,"Unresectable, Metastatic Biliary Tract Carcinoma",Gemcitabine/Oxaliplatin (DRUG); Gemcitabine/Oxaliplatin with Erlotinib (Tarceva) (DRUG),9887053,CS-0992,"Unresectable, Metastatic Biliary Tract Carcinoma",Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3334,NCT03203525,"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer",RECRUITING,PHASE1,Advanced Malignant Neoplasm; Colorectal Carcinoma Metastatic in the Liver; Metastatic Malignant Neoplasm in the Liver; Refractory Malignant Neoplasm,Bevacizumab (BIOLOGICAL); Fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Pegylated Liposomal Doxorubicin Hydrochloride (DRUG); Temsirolimus (DRUG); Tumor Treating Fields Therapy (PROCEDURE),9887053,CS-0992,Advanced Malignant Neoplasm; Colorectal Carcinoma Metastatic in the Liver; Metastatic Malignant Neoplasm in the Liver; Refractory Malignant Neoplasm,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3335,NCT01167725,Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer,TERMINATED,PHASE3,Colorectal Cancer,bevacizumab (BIOLOGICAL); cetuximab (BIOLOGICAL); FOLFIRI regimen (DRUG); FOLFOX regimen (DRUG); capecitabine (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); mitomycin C (DRUG); oxaliplatin (DRUG); therapeutic conventional surgery (PROCEDURE),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3336,NCT03626922,Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients,UNKNOWN,PHASE1,Metastatic Colorectal Cancer,Pembrolizumab (DRUG); Pemetrexed (DRUG); Oxaliplatin (DRUG); Dexamethasone (DRUG); Folic Acid (DIETARY_SUPPLEMENT); Vitamin B-12 (DIETARY_SUPPLEMENT),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3337,NCT06888648,Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.,NOT_YET_RECRUITING,PHASE1,Pancreatic Cancer Metastatic; Pancreatic Cancer Non-resectable,individualized anti-tumor new antigen iNeo-Vac-R01 injection (BIOLOGICAL); mFOLFIRINOX Treatment Regimen (DRUG); Sintilimab injection (DRUG),9887053,CS-0992,Advanced Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3338,NCT04008030,"A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)",ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Colorectal Cancer,Ipilimumab (BIOLOGICAL); Oxaliplatin (DRUG); Leucovorin (DRUG); Fluorouracil (DRUG); Irinotecan (DRUG); Bevacizumab (DRUG); Cetuximab (DRUG); Nivolumab (BIOLOGICAL),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3339,NCT06758830,Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.,RECRUITING,PHASE2,Rectal Cancer; Total Neoadjuvant Treatment; Neoadjuvant Therapy; Radiotherapy; Chemotherapy; Organ Preservation; Radiotherapy Side Effect; Chemotherapy Side Effects; Chemoradiotherapy; Low Anterior Resection Syndrome; Quality of Life,Radiation Therapy (RADIATION); Chemoradiotherapy (DRUG); Consolidation Chemotherapy (DRUG); Surgery (PROCEDURE); Part two (OTHER); Adjuvant treatment (OTHER),9887053,CS-0992,Rectal Cancer; Total Neoadjuvant Treatment; Neoadjuvant Therapy; Radiotherapy; Chemotherapy; Organ Preservation; Radiotherapy Side Effect; Chemotherapy Side Effects; Chemoradiotherapy; Low Anterior Resection Syndrome; Quality of Life,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3340,NCT02128425,FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,FOLFOXIRI (DRUG); FOLFOX (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3341,NCT00425425,"Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer",UNKNOWN,PHASE1,Esophageal Cancer,cetuximab (BIOLOGICAL); fluorouracil (DRUG); oxaliplatin (DRUG); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE); radiation therapy (RADIATION),9887053,CS-0992,Esophageal Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3342,NCT01666730,Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer,metformin hydrochloride (DRUG); oxaliplatin (DRUG); leucovorin calcium (DRUG); fluorouracil (DRUG); laboratory biomarker analysis (OTHER),9887053,CS-0992,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3343,NCT02045030,Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer,TERMINATED,PHASE2,Metastatic Colorectal Cancer,aflibercept + FOLFIRI (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3344,NCT01374425,Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC),COMPLETED,PHASE2,Colorectal Cancer,5-Fluorouracil (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3345,NCT01489865,ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer,UNKNOWN,PHASE1,Metastatic Pancreatic Cancer,ABT-888 and mFOLFOX-6 (DRUG),9887053,CS-0992,Metastatic Pancreatic Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3346,NCT06848465,LDRT Combined With SCRT Plus Immunochemotherapy for Rectal Cancer With Liver Metastasis,RECRUITING,PHASE1,Rectal Cancer; Liver Metastasis,Low Dose Radiotherapy (RADIATION); Short course Radiotherapy (RADIATION); XELOX (DRUG); Tislelizumab (DRUG),9887053,CS-0992,Rectal Cancer; Liver Metastasis,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3347,NCT02716766,Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC),COMPLETED,PHASE2,"Carcinoma, Hepatocellular; Secondary",Sorafenib (DRUG); Capecitabine (DRUG); Oxaliplatin (DRUG),9887053,CS-0992,"Carcinoma, Hepatocellular; Secondary",Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3348,NCT04595266,Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease,RECRUITING,PHASE2,Colorectal Cancer Metastatic; Liver Metastasis Colon Cancer,FOLFOX regimen (DRUG); Anti-EGFR or Bevacizumab (BIOLOGICAL); LIVERPEARLS-Irinotecan (DRUG),9887053,CS-0992,Colorectal Cancer Metastatic; Liver Metastasis Colon Cancer,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3349,NCT02889666,A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer,RECRUITING,PHASE1,Recurrent Non-small Cell Lung Cancer,Cisplatin (DRUG); Carboplatin (DRUG); Docetaxel (DRUG); Gemcitabine/Carboplatin (DRUG); Gemcitabine/Cisplatin (DRUG); Docetaxel/Oxaliplatin (DRUG); Docetaxel/Carboplatin (DRUG); Placebo (DRUG),9887053,CS-0992,Recurrent Non-small Cell Lung Cancer,Lung,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3350,NCT05825066,Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma,RECRUITING,PHASE2,Pancreas Adenocarcinoma; Borderline Resectable Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Adenocarcinoma,Nab paclitaxel (DRUG); Gemcitabine (DRUG); Radiological Assessments (OTHER); mFOLFIRINOX (DRUG),9887053,CS-0992,Pancreas Adenocarcinoma; Borderline Resectable Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Adenocarcinoma,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3351,NCT00987766,"Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer",COMPLETED,PHASE1,Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer; Pancreatic Cancer; Periampullary Adenocarcinoma; Small Intestine Cancer,erlotinib hydrochloride (DRUG); gemcitabine hydrochloride (DRUG); oxaliplatin (DRUG); laboratory biomarker analysis (OTHER),9887053,CS-0992,Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer; Pancreatic Cancer; Periampullary Adenocarcinoma; Small Intestine Cancer,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3352,NCT06485466,TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma,RECRUITING,PHASE3,Unresectable Hepatocellular Carcinoma; Transarterial Chemoembolization; Camrelizumab; Apatinib,TACE plus camrelizumab and apatinib (COMBINATION_PRODUCT); Camrelizumab and apatinib (COMBINATION_PRODUCT),9887053,CS-0992,Unresectable Hepatocellular Carcinoma; Transarterial Chemoembolization; Camrelizumab; Apatinib,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3353,NCT03316326,"S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer",UNKNOWN,PHASE2,Pancreatic Ductal Adenocarcinoma,Tegafur-gimeracil-oteracil potassium (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG),9887053,CS-0992,Pancreatic Ductal Adenocarcinoma,Pancreas,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3354,NCT01479465,Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma,TERMINATED,PHASE2,Colorectal Cancer,Simtuzumab (BIOLOGICAL); Placebo to match SIM (DRUG); Leucovorin (DRUG); Irinotecan (DRUG); Fluorouracil (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3355,NCT06441565,Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer,RECRUITING,PHASE2,Colorectal Cancer,Fruquintinib (DRUG); Fluorouracil (DRUG); Oxaliplatin (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3356,NCT00403130,"Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer",COMPLETED,PHASE2,Breast Cancer; Metastatic Breast Cancer,Gemcitabine (DRUG); Paclitaxel (DRUG); Bevacizumab (DRUG),9887053,CS-0992,Breast Cancer; Metastatic Breast Cancer,Breast,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3357,NCT00205322,"Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer",COMPLETED,PHASE2,Metastatic Colorectal Cancer,"chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin) (DRUG)",9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3358,NCT00250822,"Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter",COMPLETED,PHASE2,Liver Cancer,Gemcitabine and Oxaliplatin (DRUG),9887053,CS-0992,Liver Cancer,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3359,NCT06363825,A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma,RECRUITING,PHASE2,Advanced Hepatocellular Carcinoma,camrelizumab (DRUG),9887053,CS-0992,Advanced Hepatocellular Carcinoma,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3360,NCT02142322,Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer,COMPLETED,PHASE2,Advanced Gastric Cancer,MODIFIED FOLFOX6 (DRUG),9887053,CS-0992,Advanced Gastric Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3361,NCT03231722,First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS,COMPLETED,PHASE3,Metastatic Colorectal Cancer,Panitumumab (DRUG); Irinotecan (DRUG); Oxaliplatin (DRUG); l-leucovorin (DRUG); 5-fluorouracil (DRUG),9887053,CS-0992,Metastatic Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3362,NCT00055822,Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,oblimersen sodium (BIOLOGICAL); fluorouracil (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG),9887053,CS-0992,Colorectal Cancer,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3363,NCT00785122,IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101),COMPLETED,PHASE1,Colorectal Carcinoma,"Endoxana, Leukine, IMA910 (DRUG); Endoxana, Leukine, IMA910, Aldara (DRUG)",9887053,CS-0992,Colorectal Carcinoma,Bowel,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3364,NCT03364530,Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma,RECRUITING,PHASE2,Cholangiocarcinoma Non-resectable; Non-metastatic,Gemcitabine-Oxaliplatin Regimen (DRUG); Hepatic intra arterial chemotherapy (PROCEDURE),9887053,CS-0992,Cholangiocarcinoma Non-resectable; Non-metastatic,Liver,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3365,NCT06093425,"Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma",NOT_YET_RECRUITING,PHASE3,Gastric Cancer; Gastroesophageal-junction Cancer; Advanced Cancer,"TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU) (DRUG); Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU) (DRUG)",9887053,CS-0992,Gastric Cancer; Gastroesophageal-junction Cancer; Advanced Cancer,Esophagus/Stomach,Oxaliplatin,,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for use in chemotherapy treatments.,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],1.03,240.0 +3366,NCT05836766,Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion,RECRUITING,PHASE2,Acute Ischemic Stroke; Reperfusion; Large Vessel Occlusion,Y-6 sublingual tablets (DRUG); Placebo tablets of Y-6 sublingual tablet (DRUG),2754,Pletal,Acute Ischemic Stroke; Reperfusion; Large Vessel Occlusion,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3367,NCT06591390,Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA,RECRUITING,PHASE3,Ischemic Stroke,Ticagrelor 90 MG (DRUG); Cilostazol 100 MG (DRUG),2754,Pletal,Ischemic Stroke,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3368,NCT01932203,Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease,UNKNOWN,PHASE4,Cerebral Small Vessel Disease,aspirin (DRUG); cilostazol (DRUG),2754,Pletal,Cerebral Small Vessel Disease,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3369,NCT06504576,Effect of Cilostazol in Promoting Hematoma Clearance After Intracerebral Hemorrhage,NOT_YET_RECRUITING,PHASE2,ICH - Intracerebral Hemorrhage,Cilostazol 50 MG Oral Tablet (DRUG); Conventional internal medicine treatment (PROCEDURE),2754,Pletal,ICH - Intracerebral Hemorrhage,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3370,NCT06591312,Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA,RECRUITING,PHASE3,Ischemic Stroke,Ticagrelor 90 MG (DRUG); Clopidogrel (DRUG),2754,Pletal,Ischemic Stroke,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3371,NCT00130039,Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II,COMPLETED,PHASE4,Cerebral Infarction; Atherosclerosis,clopidogrel (DRUG); Cilostazol (DRUG),2754,Pletal,Cerebral Infarction; Atherosclerosis,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3372,NCT03451591,LACunar Intervention (LACI-2) Trial-2,COMPLETED,PHASE2,"Cerebral Small Vessel Diseases; Stroke, Lacunar",Isosorbide Mononitrate XL (ISMN) (DRUG); Cilostazol (DRUG); ISMN XL and Cilostazol (DRUG); Neither ISMN nor cilostazol (OTHER),2754,Pletal,"Cerebral Small Vessel Diseases; Stroke, Lacunar",CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3373,NCT00847860,Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions,COMPLETED,PHASE4,Vascular Dementia; Stroke,Cilostazol (DRUG); Aspirin (DRUG),2754,Pletal,Vascular Dementia; Stroke,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3374,NCT06919835,CiLostAzol for pReventIon of Recurrent sTroke in Africa,NOT_YET_RECRUITING,PHASE3,Stroke,Cilostazol 100 mg (DRUG),2754,Pletal,Stroke,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3375,NCT00741286,Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler,COMPLETED,PHASE4,Cerebral Infarction,Aspirin (DRUG); cilostazol (DRUG),2754,Pletal,Cerebral Infarction,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3376,NCT05298696,Efficacy of Cilostazol in Prevention of Peripheral Neuropathy,COMPLETED,PHASE1,Peripheral Neuropathy; Breast Cancer,Cilostazol (DRUG); Placebo (DRUG),2754,Pletal,Peripheral Neuropathy; Breast Cancer,Breast,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3377,NCT01188824,The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study),COMPLETED,PHASE4,Ischemic Stroke,Cilostazol (DRUG); placebo (OTHER),2754,Pletal,Ischemic Stroke,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3378,NCT02253004,Induction of Migraine Aura With Cilostazol,COMPLETED,EARLY_PHASE1,Migraine With Aura; Stroke,Cilostazol (DRUG); Placebo (DRUG),2754,Pletal,Migraine With Aura; Stroke,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3379,NCT00234065,Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2),COMPLETED,PHASE4,Cerebral Infarction,Cilostazol (DRUG); Aspirin (DRUG),2754,Pletal,Cerebral Infarction,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3380,NCT00446641,Overcome Biochemical Aspirin Resistance Through Cilostazol Combination,COMPLETED,PHASE4,Cerebral Infarction,Cilostazol (DRUG); placebo (DRUG),2754,Pletal,Cerebral Infarction,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3381,NCT03471169,Individualized Antithrombotic Therapy for Patients With Ischemic Cerebrovascular Disease,UNKNOWN,PHASE1,Cerebrovascular Disease,Desirable TEG (DRUG); Undesirable TEG (DRUG),2754,Pletal,Cerebrovascular Disease,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3382,NCT06561867,Ticagrelor Versus Cilostazol in Ischemic Stroke,RECRUITING,PHASE3,Ischemic Stroke,Ticagrelor 90 MG (DRUG); Cilostazol 100 MG (DRUG),2754,Pletal,Ischemic Stroke,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3383,NCT03116269,The Effect of Cilostazol Compared to Aspirin on Endothelial Function in Acute Cerebral Ischemia Patients,COMPLETED,PHASE4,Ischemic Stroke; Endothelial Dysfunction,Cilostazol 100mg (DRUG); Aspirin (DRUG),2754,Pletal,Ischemic Stroke; Endothelial Dysfunction,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3384,NCT06138834,EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE),NOT_YET_RECRUITING,PHASE2,Acute Ischemic Stroke; Large Vessel Occlusion; Reperfusion,Low-dose Y-6 sublingual tablets (DRUG); High-dose Y-6 sublingual tablets (DRUG); Low-dose Cilostazol (DRUG); High-dose Cilostazol (DRUG); Placebo (DRUG),2754,Pletal,Acute Ischemic Stroke; Large Vessel Occlusion; Reperfusion,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3385,NCT03062319,Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis,TERMINATED,PHASE4,Ischemic Stroke; Atrial Fibrillation; Atherothrombosis,Oral Anticoagulant (DRUG); Antiplatelet Drug (DRUG),2754,Pletal,Ischemic Stroke; Atrial Fibrillation; Atherothrombosis,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3386,NCT02983214,Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?,COMPLETED,PHASE4,"Ischemic Stroke; Peripheral Artery Disease; Diabetes Mellitus, Type 2",Clopidogrel (DRUG); Cilostazol (DRUG),2754,Pletal,"Ischemic Stroke; Peripheral Artery Disease; Diabetes Mellitus, Type 2",CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3387,NCT06202755,Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke,RECRUITING,PHASE3,Ischemic Stroke,Ticagrelor 90 MG (DRUG); Cilostazol 100 MG (DRUG),2754,Pletal,Ischemic Stroke,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3388,NCT02481323,Lacunar Intervention Trial 1 (LACI-1),COMPLETED,PHASE2,Cerebral Small Vessel Diseases; Cognitive Impairment; Stroke,isosorbide mononitrate (DRUG); cilostazol (DRUG),2754,Pletal,Cerebral Small Vessel Diseases; Cognitive Impairment; Stroke,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3389,NCT01328470,Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease,COMPLETED,PHASE4,Chronic Kidney Disease; Stable Angina,"Clopidogrel, cilostazol (DRUG)",2754,Pletal,Chronic Kidney Disease; Stable Angina,Kidney,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3390,NCT01995370,Cilostazol Stroke Prevention Study for Antiplatelet Combination,COMPLETED,PHASE4,Noncardioembolic Cerebral Infarction,aspirin (DRUG); clopidogrel (DRUG); cilostazol (DRUG),2754,Pletal,Noncardioembolic Cerebral Infarction,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3391,NCT06591299,Combining Aspirin With Cilostazol or Clopidogrel in Minor Stroke or TIA,RECRUITING,PHASE3,Ischemic Stroke,Cilostazol 100 MG (DRUG); Clopidogrel 75mg (DRUG),2754,Pletal,Ischemic Stroke,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3392,NCT04522102,Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral HaemorrhaGe (ASPIRING)-Pilot Phase,COMPLETED,PHASE3,Intracerebral Hemorrhage,Start antiplatelet monotherapy (DRUG),2754,Pletal,Intracerebral Hemorrhage,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3393,NCT00333164,Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis,COMPLETED,PHASE3,Cerebrovascular Disease,"Asprin, Cilostazol (DRUG)",2754,Pletal,Cerebrovascular Disease,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3394,NCT01409564,Cilostazol Augmentation Study in Dementia,COMPLETED,PHASE4,Alzheimer's Dementia,Cilostazol (DRUG); Placebo (DRUG),2754,Pletal,Alzheimer's Dementia,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3395,NCT06757764,The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis,NOT_YET_RECRUITING,PHASE4,Cerebral Infarction; Stenosis Artery,Aspirin (DRUG); Clopidogrel (DRUG); Cilostazol (DRUG); Placebo (DRUG),2754,Pletal,Cerebral Infarction; Stenosis Artery,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3396,NCT06591338,Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA,RECRUITING,PHASE3,Ischemic Stroke,Ticagrelor 90 MG (DRUG); Clopidogrel (DRUG),2754,Pletal,Ischemic Stroke,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3397,NCT04761848,Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease,ACTIVE_NOT_RECRUITING,PHASE1,"Fatty Liver, Nonalcoholic",Cilostazol 50 MG (DRUG); Placebo (DRUG),2754,Pletal,"Fatty Liver, Nonalcoholic",Liver,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3398,NCT06522113,Cilostazol and Aspirin in Stroke and TIA,COMPLETED,PHASE4,Ischemic Stroke; TIA,Cilostazol (DRUG); Clopidogrel (DRUG),2754,Pletal,Ischemic Stroke; TIA,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3399,NCT04753970,Retina is a Marker for Cerebrovascular Heath,RECRUITING,PHASE1,Cerebral Small Vessel Diseases; Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy; Cerebral Microbleeding; Sporadic White Matter Disease,Cilostazol (DRUG),2754,Pletal,Cerebral Small Vessel Diseases; Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy; Cerebral Microbleeding; Sporadic White Matter Disease,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3400,NCT00823875,Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject,COMPLETED,PHASE4,Atherosclerosis Cerebral Infarction,Cilostazol group (DRUG); Probucol group (DRUG); Cilostazol + Probucol group (DRUG); control group (DRUG),2754,Pletal,Atherosclerosis Cerebral Infarction,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3401,NCT03855332,Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial,COMPLETED,PHASE2,Small Vessel Cerebrovascular Disease,Sildenafil (DRUG); Cilostazol (DRUG); Placebo (DRUG),2754,Pletal,Small Vessel Cerebrovascular Disease,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3402,NCT06530537,Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds,RECRUITING,PHASE3,Cerebral Microbleeds; Stroke,Cilostazol (DRUG); Aspirin (DRUG),2754,Pletal,Cerebral Microbleeds; Stroke,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3403,NCT06242132,Clopidogrel Versus Cilostazol in Ischemic Stroke,COMPLETED,PHASE3,Ischemic Stroke,Clopidogrel tablet (DRUG); Cilostazol 100 MG (DRUG),2754,Pletal,Ischemic Stroke,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3404,NCT01252056,A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy,COMPLETED,PHASE4,Diabetic Nephropathy,Probucol (DRUG); Probucol and Cilostazol (DRUG),2754,Pletal,Diabetic Nephropathy,Kidney,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3405,NCT06196047,Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA,RECRUITING,PHASE3,Ischemic Stroke,Ticagrelor 90 MG (DRUG); Cilostazol 100 MG (DRUG),2754,Pletal,Ischemic Stroke,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3406,NCT00272454,Cilostazol in Acute Ischemic Stroke Treatment (CAIST),COMPLETED,PHASE4,Cerebral Infarction,Cilostazol (DRUG); Aspirin (DRUG),2754,Pletal,Cerebral Infarction,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3407,NCT06591377,Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA,RECRUITING,PHASE3,Ischemic Stroke,Ticagrelor 90 MG (DRUG); Cilostazol 100 MG (DRUG); Aspirin 75mg (DRUG); Aspirin 75mg (DRUG),2754,Pletal,Ischemic Stroke,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3408,NCT00766545,Cilostazol Stroke Prevention Study : A Placebo-controlled Double-blind Trial for Secondary Prevention of Cerebral Infarction.,COMPLETED,PHASE3,Cerebral Infarction,cilostazol (DRUG); placebo of cilostazol (DRUG),2754,Pletal,Cerebral Infarction,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3409,NCT06242145,Clopidogrel Versus Cilostazol in Large-vessel Ischemic Stroke,COMPLETED,PHASE3,Ischemic Stroke,Clopidogrel tablet (DRUG); Cilostazol 100 MG (DRUG),2754,Pletal,Ischemic Stroke,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3410,NCT06612593,Cilostazol in Parkinson's Disease,NOT_YET_RECRUITING,PHASE2,Parkinson's Disease,Cilostazol (DRUG); Placebo (DRUG); Standard treatment (DRUG),2754,Pletal,Parkinson's Disease,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3411,NCT00202020,Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke,COMPLETED,PHASE3,Cerebral Infarction,Cilostazol 200mg/day Oral (DRUG); Aspirin 100mg/day Oral (DRUG),2754,Pletal,Cerebral Infarction,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3412,NCT06591351,Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA,RECRUITING,PHASE3,Ischemic Stroke,Cilostazol 100 MG (DRUG); Clopidogrel (DRUG),2754,Pletal,Ischemic Stroke,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3413,NCT01533116,Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide,COMPLETED,PHASE1,Parkinson Disease,BIA 9-1067 (DRUG); Placebo (DRUG); levodopa/carbidopa (DRUG); levodopa/benserazide (DRUG),2754,Pletal,Parkinson Disease,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3414,NCT05307939,A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC),RECRUITING,PHASE2,HPV; Oropharynx Cancer; HPV-Related Carcinoma; HPV-Related Malignancy; HPV Positive Oropharyngeal Squamous Cell Carcinoma,HPV ctDNA Assay (DIAGNOSTIC_TEST); MRI Studies (DIAGNOSTIC_TEST); EORTC QLQ H&N 35 and C30 (BEHAVIORAL); MDADI-HN (BEHAVIORAL); COST-FACIT (BEHAVIORAL); Intensity-Modulated Radiation Therapy (Arm A) (RADIATION); Chemoradiation (Arm B) (COMBINATION_PRODUCT),2754,Pletal,HPV; Oropharynx Cancer; HPV-Related Carcinoma; HPV-Related Malignancy; HPV Positive Oropharyngeal Squamous Cell Carcinoma,Skin,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3415,NCT03809624,Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer,TERMINATED,PHASE1,Metastatic Solid Tumors; Non-small Cell Lung Cancer; Melanoma; Head and Neck Squamous Cell Carcinoma; Gastric Adenocarcinoma; Renal Cell Carcinoma; Esophageal Adenocarcinoma; Nasopharyngeal Carcinoma; Oropharyngeal Carcinoma,INBRX-105 - PDL1x41BB antibody (DRUG); Pembrolizumab (DRUG),2754,Pletal,Metastatic Solid Tumors; Non-small Cell Lung Cancer; Melanoma; Head and Neck Squamous Cell Carcinoma; Gastric Adenocarcinoma; Renal Cell Carcinoma; Esophageal Adenocarcinoma; Nasopharyngeal Carcinoma; Oropharyngeal Carcinoma,Lung,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3416,NCT01568047,Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients,COMPLETED,PHASE2,Parkinson's Disease,Placebo (DRUG); BIA 9-1067 (DRUG); BIA 9-1067 (DRUG); BIA 9-1067 (DRUG); Levodopa/Carbidopa (DRUG); Levodopa/Benzerazide (DRUG),2754,Pletal,Parkinson's Disease,CNS/Brain,Cilostazol,PDE3A,inhibitor/antagonist,unclear,yes,yes,Used to treat intermittent claudication associated with peripheral artery disease.,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,1.19,249.0 +3417,NCT01632306,A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer,TERMINATED,PHASE1,Pancreatic Cancer,LY2090314 (DRUG); FOLFOX (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG),10029385,s7063,Pancreatic Cancer,Pancreas,LY2090314,"GSK3B, GSK3A",inhibitor/antagonist,GSK3 inhibitor,no,yes,Investigated for Alzheimer's; not approved for any condition.,C1CCN(CC1)C(=O)N2CCN3C=C(C4=CC(=CC(=C43)C2)F)C5=C(C(=O)NC5=O)C6=CN=C7N6C=CC=C7,1.0,6.0 +3418,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,COMPLETED,PHASE3,Multiple Sclerosis,Fingolimod 1.25 mg (DRUG); Fingolimod 0.5 mg (DRUG); Interferon β-1a 30 µg (DRUG),16222096,EUI,Multiple Sclerosis,CNS/Brain,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3419,NCT01431599,Short-course Preoperative Chemoradiotherapy for Rectal Cancer,UNKNOWN,PHASE2,Rectal Cancer,short-course radiation (RADIATION),16222096,EUI,Rectal Cancer,Bowel,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3420,NCT00501475,NAC in Preventing CIN in CRF Patients Who Need Enhanced CT Scan in ED,UNKNOWN,PHASE4,Chronic Renal Failure,NAC Bicarbonate (DRUG),16222096,EUI,Chronic Renal Failure,Kidney,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3421,NCT06388720,The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy,RECRUITING,PHASE2,Bladder Cancer,Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml (DRUG),16222096,EUI,Bladder Cancer,Bladder/Urinary Tract,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3422,NCT04005690,Targeted Pathway Inhibition in Patients With Pancreatic Cancer,RECRUITING,EARLY_PHASE1,Locally Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma; Borderline Resectable Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma,Cobimetinib (DRUG); Olaparib (DRUG); Onvansertib (DRUG); Azenosertib (DRUG); Saruparib (DRUG); Tremelimumab (BIOLOGICAL),16222096,EUI,Locally Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma; Borderline Resectable Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma,Pancreas,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3423,NCT03193190,A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer),COMPLETED,PHASE1,Pancreatic Adenocarcinoma,Nab-Paclitaxel (DRUG); Gemcitabine (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); Fluorouracil (DRUG); Atezolizumab (DRUG); Cobimetinib (DRUG); PEGPH20 (DRUG); BL-8040 (DRUG); Selicrelumab (DRUG); Bevacizumab (DRUG); RO6874281 (DRUG); AB928 (DRUG); Tiragolumab (DRUG); Tocilizumab (DRUG),16222096,EUI,Pancreatic Adenocarcinoma,Pancreas,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3424,NCT02414750,Vemurafenib Plus Cobimetinib in Metastatic Melanoma,TERMINATED,PHASE2,Metastatic Melanoma,Vemurafenib plus cobimetinib (DRUG); Positron Emission Tomography (DEVICE); Tissue sampling (PROCEDURE); Blood sampling (PROCEDURE),16222096,EUI,Metastatic Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3425,NCT05034627,Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer,RECRUITING,PHASE1,Locally Advanced Pancreatic Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Biopsy (PROCEDURE); Calaspargase Pegol-mknl (DRUG); Cobimetinib (DRUG),16222096,EUI,Locally Advanced Pancreatic Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Pancreas,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3426,NCT03108131,Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors,COMPLETED,PHASE2,Skin Squamous Cell Carcinoma; Appendix Adenocarcinoma; Rare Lesion; Locally Advanced Malignant Neoplasm; Locally Advanced Skin Squamous Cell Carcinoma; Metastatic Malignant Neoplasm; Metastatic Skin Squamous Cell Carcinoma; Metastatic Small Intestinal Adenocarcinoma; Rare Neoplastic Syndrome; Refractory Malignant Neoplasm; Stage IV Small Intestinal Adenocarcinoma AJCC v8; Unresectable Malignant Neoplasm,Atezolizumab (DRUG); Cobimetinib (DRUG),16222096,EUI,Skin Squamous Cell Carcinoma; Appendix Adenocarcinoma; Rare Lesion; Locally Advanced Malignant Neoplasm; Locally Advanced Skin Squamous Cell Carcinoma; Metastatic Malignant Neoplasm; Metastatic Skin Squamous Cell Carcinoma; Metastatic Small Intestinal Adenocarcinoma; Rare Neoplastic Syndrome; Refractory Malignant Neoplasm; Stage IV Small Intestinal Adenocarcinoma AJCC v8; Unresectable Malignant Neoplasm,Bowel,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3427,NCT05238831,SMMART Adaptive Clinical Treatment (ACT) Trial,WITHDRAWN,EARLY_PHASE1,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Alectinib (DRUG); Alpelisib (DRUG); Anastrozole (DRUG); Atezolizumab (BIOLOGICAL); Bevacizumab (BIOLOGICAL); Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Capecitabine (DRUG); Carboplatin (DRUG); Cobimetinib (DRUG); Entrectinib (DRUG); Eribulin (DRUG); Fulvestrant (DRUG); Hyaluronidase-zzxf/Pertuzumab/Trastuzumab (BIOLOGICAL); Irinotecan (DRUG); Letrozole (DRUG); Nab-paclitaxel (DRUG); Niraparib (DRUG); Olaparib (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Pertuzumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Trastuzumab (BIOLOGICAL); Trastuzumab Emtansine (BIOLOGICAL); Vemurafenib (DRUG); Vinorelbine (DRUG); Vismodegib (DRUG),16222096,EUI,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Ovary/Fallopian Tube,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3428,NCT02902029,Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma,COMPLETED,PHASE2,Malignant Melanoma,Vemurafenib (DRUG); Cobimetinib (DRUG); Atezolizumab (DRUG),16222096,EUI,Malignant Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3429,NCT02291289,A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC),COMPLETED,PHASE2,Colorectal Cancer,Cetuximab (DRUG); FOLFOX induction regimen (DRUG); Fluoropyrimidine (5-FU/LV or capecitabine) (DRUG); Atezolizumab (DRUG); Vemurafenib (DRUG); Bevacizumab (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); Cobimetinib (DRUG); 5-FU/LV (DRUG); Capecitabine (DRUG),16222096,EUI,Colorectal Cancer,Bowel,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3430,NCT02036086,Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases,UNKNOWN,PHASE2,Melanoma,Vemurafenib (DRUG); Cobimetinib (DRUG),16222096,EUI,Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3431,NCT03005639,ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma,WITHDRAWN,PHASE2,Stage IIIB-C Melanoma,Vemurafenib and Cobimetinib (DRUG),16222096,EUI,Stage IIIB-C Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3432,NCT02583516,Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma,COMPLETED,PHASE2,Melanoma,vemurafenib and cobimetinib (DRUG),16222096,EUI,Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3433,NCT02908672,A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma,COMPLETED,PHASE3,Melanoma,Atezolizumab (DRUG); Atezolizumab Placebo (DRUG); Cobimetinib (DRUG); Vemurafenib (DRUG); Vemurafenib Placebo (DRUG),16222096,EUI,Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3434,NCT03363867,BEACON - ABC in Recurrent Platinum Resistant HGSOC,ACTIVE_NOT_RECRUITING,PHASE2,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Atezolizumab (DRUG); Bevacizumab (DRUG); Cobimetinib (DRUG),16222096,EUI,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3435,NCT03281369,A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer),ACTIVE_NOT_RECRUITING,PHASE1,Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma,5-Fluorouracil (5-FU) (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Atezolizumab (DRUG); Cobimetinib (DRUG); Ramucirumab (BIOLOGICAL); Paclitaxel (DRUG); PEGylated recombinant human hyaluronidase (PEGPH20) (BIOLOGICAL); BL-8040 (DRUG); Linagliptin (DRUG); Atezolizumab (DRUG); Cobimetinib (DRUG); Cisplatin (DRUG); Tiragolumab (DRUG); 5-Fluorouracil (5-FU) (DRUG),16222096,EUI,Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma,Esophagus/Stomach,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3436,NCT02876224,Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors,COMPLETED,PHASE1,Colorectal Cancer,Atezolizumab (DRUG); Bevacizumab (DRUG); Cobimetinib (DRUG),16222096,EUI,Colorectal Cancer,Bowel,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3437,NCT03201458,Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer,COMPLETED,PHASE2,Gallbladder Carcinoma; Metastatic Cholangiocarcinoma; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Cholangiocarcinoma,Atezolizumab (DRUG); Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Cobimetinib (DRUG); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE),16222096,EUI,Gallbladder Carcinoma; Metastatic Cholangiocarcinoma; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Cholangiocarcinoma,Liver,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3438,NCT03340558,Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer,WITHDRAWN,PHASE2,Metastatic Colorectal Cancer,Atezolizumab (BIOLOGICAL); Cobimetinib (DRUG),16222096,EUI,Metastatic Colorectal Cancer,Bowel,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3439,NCT05691504,Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers,RECRUITING,PHASE1,Advanced Endometrial Carcinoma; Metastatic Endometrial Carcinoma; Metastatic Fallopian Tube Carcinoma; Metastatic Platinum-Resistant Ovarian Carcinoma; Metastatic Primary Peritoneal Carcinoma; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Cobimetinib (DRUG); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Pelcitoclax (DRUG),16222096,EUI,Advanced Endometrial Carcinoma; Metastatic Endometrial Carcinoma; Metastatic Fallopian Tube Carcinoma; Metastatic Platinum-Resistant Ovarian Carcinoma; Metastatic Primary Peritoneal Carcinoma; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8,Uterus,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3440,NCT03202940,A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC,ACTIVE_NOT_RECRUITING,PHASE1,Non-small Cell Lung Cancer,Alectinib (DRUG); Cobimetinib (DRUG),16222096,EUI,Non-small Cell Lung Cancer,Lung,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3441,NCT03600701,"Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Refractory Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Atezolizumab (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Cobimetinib (DRUG); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE),16222096,EUI,Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Refractory Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Lung,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3442,NCT03514901,To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.,UNKNOWN,PHASE2,Melanoma Metastatic; BRAF V600 Mutation,Experimental combination beyond Focal Progression (OTHER); Pembrolizumab or Nivolumab (DRUG),16222096,EUI,Melanoma Metastatic; BRAF V600 Mutation,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3443,NCT03026517,Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma,COMPLETED,PHASE1,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Phenformin (DRUG),16222096,EUI,Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3444,NCT01689519,A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma,COMPLETED,PHASE3,Malignant Melanoma,Placebo (DRUG); Vemurafenib (DRUG); Cobimetinib (DRUG),16222096,EUI,Malignant Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3445,NCT03625141,A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases,COMPLETED,PHASE2,Metastatic Melanoma,Cobimetinib (DRUG); Atezolizumab (DRUG); Vemurafenib (DRUG),16222096,EUI,Metastatic Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3446,NCT01876641,Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib,TERMINATED,PHASE1,Metastatic Melanoma; Melanoma; BRAF-mutated Metastatic Melanoma; V600EBRAF-mutated Metastatic Melanoma,"Vemurafenib + Cobimetinib, Decitabine (DRUG)",16222096,EUI,Metastatic Melanoma; Melanoma; BRAF-mutated Metastatic Melanoma; V600EBRAF-mutated Metastatic Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3447,NCT04214418,"Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies",TERMINATED,PHASE1,Gastrointestinal Cancer,Cobimetinib (DRUG); Hydroxychloroquine (DRUG); Atezolizumab (DRUG),16222096,EUI,Gastrointestinal Cancer,Bowel,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3448,NCT01843738,Radiation Use During Vemurafenib Treatment,WITHDRAWN,PHASE1,BRAFV600 Mutation; Stage IV Melanoma,Radiation therapy (RADIATION); Vemurafenib (DRUG),16222096,EUI,BRAFV600 Mutation; Stage IV Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3449,NCT02818023,Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma,TERMINATED,PHASE1,Melanoma,Pembrolizumab (DRUG); Vemurafenib (DRUG); Cobimetinib (DRUG),16222096,EUI,Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3450,NCT02322814,"A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread",TERMINATED,PHASE2,Breast Cancer,Cobimetinib (DRUG); Paclitaxel (DRUG); Placebo (DRUG); Atezolizumab (DRUG); Nab-Paclitaxel (DRUG),16222096,EUI,Breast Cancer,Breast,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3451,NCT01813214,The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma,TERMINATED,PHASE2,Melanoma,Vemurafenib (DRUG); Cobimetinib (DRUG),16222096,EUI,Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3452,NCT03224208,Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients,TERMINATED,PHASE2,Melanoma; Melanoma (Skin); Melanoma Stage,Vemurafenib (DRUG); Cobimetinib (DRUG),16222096,EUI,Melanoma; Melanoma (Skin); Melanoma Stage,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3453,NCT02382549,A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib,TERMINATED,EARLY_PHASE1,Melanoma,BRAF inhibitor (DRUG); 6MHP (BIOLOGICAL); MEK inhibitor (DRUG),16222096,EUI,Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3454,NCT01656642,A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma,COMPLETED,PHASE1,Malignant Melanoma,Atezolizumab (DRUG); Cobimetinib (DRUG); Vemurafenib (DRUG),16222096,EUI,Malignant Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3455,NCT04931342,A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors,ACTIVE_NOT_RECRUITING,PHASE2,Ovarian Cancer,Ipatasertib (DRUG); Cobimetinib (DRUG); Trastuzumab Emtansine (DRUG); Atezolizumab (DRUG); Bevacizumab (DRUG); Paclitaxel (DRUG); Giredestrant (DRUG); Abemaciclib (DRUG); Inavolisib (DRUG); Palbociclib (DRUG); Letrozole (DRUG); Olaparib (DRUG); Luteinizing Hormone-Releasing Hormone (LHRH) Agonists (DRUG); Cyclophosphamide (DRUG); Inavolisib (DRUG),16222096,EUI,Ovarian Cancer,Ovary/Fallopian Tube,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3456,NCT02230306,Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases,TERMINATED,PHASE2,Active Melanoma Brain Metastases,Cobimetinib (DRUG); Vemurafenib (DRUG),16222096,EUI,Active Melanoma Brain Metastases,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3457,NCT03395899,Pre-operative Immunotherapy Combination Strategies in Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Estrogen Receptor-positive Breast Cancer,Atezolizumab (DRUG); Cobimetinib (DRUG); Ipatasertib (DRUG); Bevacizumab (DRUG),16222096,EUI,Breast Cancer; Estrogen Receptor-positive Breast Cancer,Breast,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3458,NCT02788279,A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370),COMPLETED,PHASE3,Colorectal Cancer,"Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody (DRUG); Cobimetinib (DRUG); Regorafenib (DRUG)",16222096,EUI,Colorectal Cancer,Bowel,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3459,NCT01271803,A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma,COMPLETED,PHASE1,Malignant Melanoma,Cobimetinib (DRUG); vemurafenib (DRUG),16222096,EUI,Malignant Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3460,NCT02968303,Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy,UNKNOWN,PHASE2,"Melanoma, Malignant, of Soft Parts",Vemurafenib and Cobimetinib (DRUG),16222096,EUI,Malignant Melanoma of Soft Parts,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3461,NCT06813079,Using Tumor Models to Determine Treatments,NOT_YET_RECRUITING,PHASE2,Pancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor,Cobimetinib (DRUG); Ponatinib (DRUG); Brigatinib (DRUG); Colchicine (DRUG); Selinexor (DRUG); Abemaciclib (DRUG); Neratinib (DRUG); Doxorubicin (DRUG); Etoposide (DRUG); Ceritinib (DRUG),16222096,EUI,Pancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor,Pancreas,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3462,NCT04722575,"Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma",ACTIVE_NOT_RECRUITING,PHASE2,Melanoma,Cobimetinib 20 MG Oral Tablet (DRUG); Vemurafenib 240 Mg Oral Capsule (DRUG); Atezolizumab 1200 MG in 20 ML Injection (DRUG),16222096,EUI,Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3463,NCT03178552,A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC),ACTIVE_NOT_RECRUITING,PHASE2,Non-Small Cell Lung Cancer,Alectinib (DRUG); Atezolizumab (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Gemcitabine (DRUG); Entrectinib (DRUG); Cobimetinib (DRUG); Vemurafenib (DRUG); Bevacizumab (DRUG); Divarasib (DRUG); Docetaxel (DRUG),16222096,EUI,Advanced Non-Small Cell Lung Cancer,Lung,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3464,NCT04109456,IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Melanoma,IN10018 (DRUG); Cobimetinib (DRUG); Atezolizumab (BIOLOGICAL),16222096,EUI,Metastatic Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3465,NCT02721459,XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma,ACTIVE_NOT_RECRUITING,PHASE1,Melanoma; Skin Cancer,XL888 (DRUG); Vemurafenib (DRUG); Cobimetinib (DRUG),16222096,EUI,Melanoma; Skin Cancer,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3466,NCT02537600,Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis,COMPLETED,PHASE2,Malignant Melanoma,Cobimetinib + Vemurafenib combination treatment (DRUG),16222096,EUI,Malignant Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3467,NCT05756556,T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma,SUSPENDED,PHASE2,Melanoma; Malignant Melanoma,T3011 + Cobimetinib (COMBINATION_PRODUCT),16222096,EUI,Melanoma; Malignant Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3468,NCT03430947,Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases,TERMINATED,PHASE2,Malignant Melanoma Stage IV; BRAF V600 Mutation; Brain Metastases,Vemurafenib (DRUG); Cobimetinib (DRUG),16222096,EUI,Malignant Melanoma Stage IV; BRAF V600 Mutation; Brain Metastases,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3469,NCT03101254,LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma,COMPLETED,PHASE1,Melanoma,LY3022855 (DRUG); Vemurafenib (DRUG); Cobimetinib (DRUG),16222096,EUI,Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3470,NCT02303951,Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC,TERMINATED,PHASE2,Malignant Melanoma,Vemurafenib (DRUG); Cobimetinib (DRUG); Atezolizumab (DRUG),16222096,EUI,Malignant Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3471,NCT03273153,A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma,TERMINATED,PHASE3,Advanced BRAFV600 Wild-type Melanoma,Cobimetinib (DRUG); Atezolizumab (DRUG); Pembrolizumab (DRUG),16222096,EUI,Advanced BRAFV600 Wild-type Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3472,NCT01959633,Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation,COMPLETED,PHASE1,Melanoma,Vemurafenib (DRUG); Peg-interferon (DRUG); Cobimetinib (DRUG),16222096,EUI,Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3473,NCT03175432,Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases,ACTIVE_NOT_RECRUITING,PHASE2,BRAF V600 Wild Type; Clinical Stage IV Cutaneous Melanoma AJCC v8; Intracranial Melanoma; Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Refractory Melanoma,Atezolizumab (DRUG); Bevacizumab (BIOLOGICAL); Cobimetinib (DRUG); Quality-of-Life Assessment (PROCEDURE),16222096,EUI,BRAF V600 Wild Type; Clinical Stage IV Cutaneous Melanoma AJCC v8; Intracranial Melanoma; Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Refractory Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3474,NCT03566485,Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer,TERMINATED,PHASE1,Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Estrogen Receptor-positive; HER2/Neu Negative,Atezolizumab (DRUG); Cobimetinib (DRUG); Idasanutlin (DRUG),16222096,EUI,Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Estrogen Receptor-positive; HER2/Neu Negative,Breast,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3475,NCT02768207,A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma,COMPLETED,PHASE2,Metastatic Melanoma,Cobimetinib (DRUG); Vemurafenib (DRUG),16222096,EUI,Metastatic Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3476,NCT02060188,A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread,COMPLETED,PHASE2,Microsatellite Unstable Colorectal Cancer; Microsatellite Stable Colorectal Cancer; Mismatch Repair Proficient Colorectal Cancer; Mismatch Repair Deficient Colorectal Cancer,Ipilimumab (DRUG); Nivolumab (DRUG); Cobimetinib (DRUG); Daratumumab (DRUG); BMS-986016 (DRUG),16222096,EUI,Microsatellite Unstable Colorectal Cancer; Microsatellite Stable Colorectal Cancer; Mismatch Repair Proficient Colorectal Cancer; Mismatch Repair Deficient Colorectal Cancer,Bowel,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3477,NCT01495988,Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma,TERMINATED,PHASE2,Melanoma; Metastatic Melanoma,Vemurafenib (DRUG); Bevacizumab (DRUG); Cobimetinib (DRUG),16222096,EUI,Melanoma; Metastatic Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3478,NCT04941287,"Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Distal Bile Duct Adenocarcinoma; Metastatic Gallbladder Carcinoma; Metastatic Intrahepatic Cholangiocarcinoma; Recurrent Distal Bile Duct Adenocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Liver Carcinoma,Atezolizumab (BIOLOGICAL); Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Cobimetinib (DRUG); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Varlilumab (DRUG),16222096,EUI,Metastatic Distal Bile Duct Adenocarcinoma; Metastatic Gallbladder Carcinoma; Metastatic Intrahepatic Cholangiocarcinoma; Recurrent Distal Bile Duct Adenocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Liver Carcinoma,Liver,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3479,NCT05768178,DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.,RECRUITING,PHASE2,"Solid Tumor; Haematological Malignancy; Melanoma; Thyroid Cancer, Papillary; Ovarian Neoplasms; Colorectal Neoplasms; Laryngeal Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioma; Multiple Myeloma; Erdheim-Chester Disease; Thyroid Carcinoma, Anaplastic",Vemurafenib (DRUG); Cobimetinib (DRUG),16222096,EUI,"Solid Tumor; Haematological Malignancy; Melanoma; Thyroid Cancer, Papillary; Ovarian Neoplasms; Colorectal Neoplasms; Laryngeal Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioma; Multiple Myeloma; Erdheim-Chester Disease; Thyroid Carcinoma, Anaplastic",Bowel,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3480,NCT04302025,A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer,RECRUITING,PHASE2,Non-small Cell Lung Cancer,Alectinib (DRUG); Entrectinib (DRUG); Vemurafenib (Enrollment closed) (DRUG); Cobimetinib (Enrollment closed) (DRUG); Pralsetinib (Enrollment closed) (DRUG); Atezolizumab (DRUG); SBRT (DRUG); Resection (PROCEDURE); Chemotherapy (DRUG); Divarasib (DRUG),16222096,EUI,Non-small Cell Lung Cancer,Lung,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3481,NCT02427893,Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma,WITHDRAWN,PHASE3,Melanoma,Cobimetinib (DRUG); Vemurafenib (DRUG),16222096,EUI,Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3482,NCT02457793,"A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors",COMPLETED,PHASE1,"Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma",Cobimetinib (DRUG); GDC-0994 (DRUG),16222096,EUI,"Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma",Bowel,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3483,NCT03554083,"Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma",ACTIVE_NOT_RECRUITING,PHASE2,Clinical Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8,Atezolizumab (DRUG); Cobimetinib (DRUG); Tiragolumab (BIOLOGICAL); Vemurafenib (DRUG),16222096,EUI,Clinical Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3484,NCT03337698,A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer),ACTIVE_NOT_RECRUITING,PHASE1,"Carcinoma, Non-Small-Cell Lung",Atezolizumab (DRUG); Cobimetinib (DRUG); RO6958688 (DRUG); Docetaxel (DRUG); CPI-444 (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG); Gemcitabine (DRUG); Linagliptin (DRUG); Tocilizumab (DRUG); Ipatasertib (DRUG); Bevacizumab (DRUG); Sacituzumab Govitecan (DRUG); Radiation (OTHER); Evolocumab (DRUG); Tiragolumab (DRUG); XL092 (DRUG); Camonsertib (DRUG),16222096,EUI,"Carcinoma, Non-Small-Cell Lung",Lung,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3485,NCT04835805,A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.,ACTIVE_NOT_RECRUITING,PHASE1,Melanoma,Belvarafenib (DRUG); Cobimetinib (DRUG); Nivolumab (DRUG),16222096,EUI,Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3486,NCT03178851,Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma,COMPLETED,PHASE1,Malignant Melanoma,Atezolizumab (BIOLOGICAL); Cobimetinib (DRUG); Atezolizumab (BIOLOGICAL); Atezolizumab (BIOLOGICAL),16222096,EUI,Malignant Melanoma,Skin,Cobimetinib,MAP2K1,inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma in combination with vemurafenib.,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,1.01,280.0 +3487,NCT02857868,A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects,COMPLETED,PHASE1,Hepatic Impairment,ABL001 (DRUG),72165228,AY7,Hepatic Impairment,Liver,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3488,NCT04492033,A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients,TERMINATED,PHASE1,P1b: Advanced Solid Tumors; P2: Biliary Tract Cancer,CTX-009 (ABL001) (DRUG); Paclitaxel (DRUG); Irinotecan (DRUG),72165228,AY7,P1b: Advanced Solid Tumors; P2: Biliary Tract Cancer,Liver,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3489,NCT03605277,Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers,COMPLETED,PHASE1,Renal Impairment,Asciminib (DRUG),72165228,AY7,Renal Impairment,Kidney,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3490,NCT01957774,THR-18's Pharmacokinetics and Pharmacodynamics in Subjects With Acute Ischemic Stroke Treated With tPA,COMPLETED,PHASE2,"Stroke, Acute",THR-18 (DRUG); Placebo (DRUG),72165228,AY7,Acute Stroke,CNS/Brain,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3491,NCT02958865,"Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis",COMPLETED,PHASE2,Ulcerative Colitis,PF-06651600 or Placebo (DRUG); PF-06700841 or Placebo (DRUG); PF-06700841 (DRUG); PF-06651600 (DRUG),72165228,AY7,Ulcerative Colitis,Bowel,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3492,NCT04847674,A Study to Test if TEV-53275 is Effective in Relieving Asthma,TERMINATED,PHASE2,Asthma,TEV-53275 Dose A (DRUG); TEV-53275 Dose B (DRUG); Placebo (DRUG),72165228,AY7,Asthma,Lung,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3493,NCT03186326,Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer,UNKNOWN,PHASE2,Metastatic Colorectal Cancer; MSI,FOLFOX regimen (DRUG); FOLFIRI Protocol (DRUG); Avelumab (DRUG); Panitumumab (DRUG); Cetuximab (DRUG); Bevacizumab (DRUG); Aflibercept (DRUG),72165228,AY7,Metastatic Colorectal Cancer; MSI,Bowel,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3494,NCT04955990,A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants,TERMINATED,PHASE4,Pulmonary Arterial Hypertension,PAH Therapies (OTHER),72165228,AY7,Pulmonary Arterial Hypertension,Lung,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3495,NCT02219490,A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection,COMPLETED,PHASE3,Chronic Hepatitis C Virus (HCV) Infection Genotype 1,ABT-450/r/ABT-267 (DRUG); ABT-333 (DRUG); Ribavirin (RBV) (DRUG),72165228,AY7,Chronic Hepatitis C Virus (HCV) Infection Genotype 1,Liver,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3496,NCT03674112,A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer,COMPLETED,PHASE2,HER2-Positive Early Breast Cancer,Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC) (DRUG); Pertuzumab IV (DRUG); Trastuzumab IV (DRUG),72165228,AY7,HER2-Positive Early Breast Cancer,Breast,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3497,NCT02144012,A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer,TERMINATED,PHASE3,Metastatic Breast Cancer,Trastuzumab (DRUG); Trastuzumab Emtansine (DRUG); Docetaxel (DRUG),72165228,AY7,Metastatic Breast Cancer,Breast,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3498,NCT02513160,Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma,COMPLETED,PHASE3,Persistent Asthma,Beclomethasone Dipropionate 640 (DRUG); Placebo (DRUG); Beclomethasone dipropionate via 320 mcg BAI (DRUG); albuterol/salbutamol (DRUG); Beclomethasone dipropionate via 320 mcg MDI (DRUG),72165228,AY7,Persistent Asthma,Lung,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3499,NCT04876131,Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children,RECRUITING,PHASE4,Complicated Urinary Tract Infection; Infection; Pediatric Infectious Disease,Benzylpenicillin - single dose (DRUG); Benzylpenicillin - three days (DRUG); Gentamicin - single dose (DRUG); Gentamicin - three days (DRUG); Cefalexin - post single dose of IV antibiotics for the remaining two days (DRUG),72165228,AY7,Complicated Urinary Tract Infection; Infection; Pediatric Infectious Disease,Bladder/Urinary Tract,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3500,NCT04640194,A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19,COMPLETED,PHASE2,Acute Respiratory Distress Syndrome,Standard of care (PROCEDURE); Alteplase low dose (DRUG); Alteplase high dose (DRUG),72165228,AY7,Acute Respiratory Distress Syndrome,Lung,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3501,NCT05643573,"A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke",TERMINATED,PHASE3,Prevention of Stroke or Systemic Embolism; Atrial Fibrillation,Asundexian (BAY2433334) (DRUG); Apixaban (DRUG); Asundexian matching placebo (DRUG); Apixaban matching placebo (DRUG),72165228,AY7,Prevention of Stroke or Systemic Embolism; Atrial Fibrillation,CNS/Brain,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3502,NCT06770582,"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, the PARRC Trial",RECRUITING,PHASE2,Non-Muscle Invasive Bladder Urothelial Carcinoma; Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma; Stage I Bladder Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Fluorouracil (DRUG); Gemcitabine (DRUG); Magnetic Resonance Imaging (PROCEDURE); Mitomycin (DRUG); Pembrolizumab (BIOLOGICAL); Questionnaire Administration (OTHER); Radiation Therapy (RADIATION),72165228,AY7,Non-Muscle Invasive Bladder Urothelial Carcinoma; Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma; Stage I Bladder Cancer AJCC v8,Bladder/Urinary Tract,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3503,NCT02345330,Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC),TERMINATED,PHASE2,Head and Neck Squamous Cell Carcinoma,Tavokinogene Telseplasmid (tavo) (BIOLOGICAL); OncoSec Medical System (OMS) (DEVICE),72165228,AY7,Head and Neck Squamous Cell Carcinoma,Skin,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3504,NCT03890666,A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma,COMPLETED,PHASE4,Asthma,Albuterol eMDPI DS (DRUG); albuterol (DRUG),72165228,AY7,Asthma,Lung,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3505,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,COMPLETED,PHASE3,Breast Cancer,FEC Chemotherapy (DRUG); Surgery (PROCEDURE); Docetaxel (DRUG); Pertuzumab (DRUG); Placebo (DRUG); Trastuzumab (DRUG),72165228,AY7,Breast Cancer,Breast,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3506,NCT01639339,Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis,COMPLETED,PHASE3,Lupus Nephritis,Placebo plus standard therapy (BIOLOGICAL); Belimumab 10 mg/kg plus standard therapy (BIOLOGICAL); Standard therapy (DRUG),72165228,AY7,Lupus Nephritis,Kidney,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3507,NCT05749939,Acceptance Commitment Therapy for Caregivers of People with Memory Loss,COMPLETED,PHASE3,Caregiver Burden; Behavioral and Psychiatric Symptoms of Dementia; Depressive Symptoms; Quality of Life; Psychological Flexibility; Sleep Quality; Positive Aspects of Caregiving,Acceptance and Commitment Therapy (BEHAVIORAL),72165228,AY7,Caregiver Burden; Behavioral and Psychiatric Symptoms of Dementia; Depressive Symptoms; Quality of Life; Psychological Flexibility; Sleep Quality; Positive Aspects of Caregiving,CNS/Brain,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3508,NCT01319539,"MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer",TERMINATED,PHASE2,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Akt Inhibitor MK2206 (DRUG); Therapeutic Conventional Surgery (PROCEDURE); Pharmacological Study (OTHER); Laboratory Biomarker Analysis (OTHER),72165228,AY7,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Breast,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3509,NCT01276639,"A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis",COMPLETED,PHASE3,Psoriasis,"CP-690,550 (DRUG); CP-690,550 (DRUG); Placebo/CP-690,550 (DRUG); Placebo/CP-690,550 (DRUG)",72165228,AY7,Psoriasis,Skin,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3510,NCT01235962,A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC),COMPLETED,PHASE3,Renal Cell Carcinoma (RCC); Cancer,pazopanib (DRUG); placebo (DRUG); pazopanib (DRUG); placebo (DRUG),72165228,AY7,Renal Cell Carcinoma (RCC); Cancer,Kidney,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3511,NCT00796991,"Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine",COMPLETED,PHASE1,Advanced Melanoma,Ipilimumab (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Dacarbazine (DRUG),72165228,AY7,Advanced Melanoma,Skin,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3512,NCT03765229,An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma,COMPLETED,PHASE2,Melanoma,Entinostat (DRUG); Pembrolizumab (DRUG),72165228,AY7,Melanoma,Skin,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3513,NCT02293980,"A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)",ACTIVE_NOT_RECRUITING,PHASE1,ccRCC; RCC; Kidney Cancer; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma,MK-3795 (DRUG); Nivolumab (DRUG); Cabozantinib (DRUG); Bezlutifan (DRUG),72165228,AY7,ccRCC; RCC; Kidney Cancer; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma,Kidney,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3514,NCT01872689,A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF),COMPLETED,PHASE2,Idiopathic Pulmonary Fibrosis,Lebrikizumab (DRUG); Pirfenidone (DRUG); Placebo (DRUG),72165228,AY7,Idiopathic Pulmonary Fibrosis,Lung,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3515,NCT02934529,Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab,COMPLETED,PHASE3,Metastatic Colorectal Cancer,Irinotecan (DRUG); Folinic Acid (DRUG); 5-FU (DRUG); 5-FU (DRUG); Cetuximab (DRUG); Bevacizumab (DRUG); Capecitabine (DRUG); regorafenib (DRUG); Irinotecan 125mg (DRUG); Cetuximab wkly (DRUG),72165228,AY7,Metastatic Colorectal Cancer,Bowel,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3516,NCT03711162,A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care,TERMINATED,PHASE3,Idiopathic Pulmonary Fibrosis,GLPG1690 (DRUG); Placebo (DRUG),72165228,AY7,Idiopathic Pulmonary Fibrosis,Lung,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3517,NCT06933394,Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma,RECRUITING,PHASE2,Neuroblastoma,Arsenic trioxide (DRUG); MAPK inhibitors (DRUG); Chemotherapy (DRUG),72165228,AY7,Neuroblastoma,CNS/Brain,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3518,NCT03159416,A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7),COMPLETED,PHASE1,Renal Impairment,Inclisiran (DRUG),72165228,AY7,Renal Impairment,Kidney,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3519,NCT03337724,"A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer",COMPLETED,PHASE3,Breast Cancer,Ipatasertib (DRUG); Paclitaxel (DRUG); Placebo (DRUG),72165228,AY7,Breast Cancer,Breast,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3520,NCT03751124,Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids,COMPLETED,PHASE3,Uterine Leiomyoma; Uterine Fibroids,Relugolix (DRUG); Estradiol/norethindrone acetate (DRUG); Placebo for relugolix (DRUG); Placebo for E2/NETA (DRUG),72165228,AY7,Uterine Leiomyoma; Uterine Fibroids,Uterus,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3521,NCT04831281,ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial),TERMINATED,PHASE2,Parkinson Disease Dementia; Dementia With Lewy Bodies,ATH-1017 (DRUG); Placebo (DRUG),72165228,AY7,Parkinson Disease Dementia; Dementia With Lewy Bodies,CNS/Brain,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3522,NCT03267940,"Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma",TERMINATED,PHASE1,"Cholangiocarcinoma Non-resectable; Cholangiocarcinoma, Intrahepatic; Cholangiocarcinoma, Extrahepatic; Gallbladder Adenocarcinoma",PEGPH20 (DRUG); CIS (DRUG); GEM (DRUG); Atezolizumab (DRUG),72165228,AY7,"Cholangiocarcinoma Non-resectable; Cholangiocarcinoma, Intrahepatic; Cholangiocarcinoma, Extrahepatic; Gallbladder Adenocarcinoma",Liver,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3523,NCT02358044,"Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)",COMPLETED,PHASE3,Hepatitis C,Sofosbuvir (DRUG); PegIntron (BIOLOGICAL); Ribavirin (DRUG); Grazoprevir/Elbasvir (100 mg/50 mg) FDC (DRUG),72165228,AY7,Hepatitis C,Liver,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3524,NCT03535740,"A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib",COMPLETED,PHASE2,ALK-positive Advanced NSCLC,Brigatinib (DRUG),72165228,AY7,Non-small Cell Lung Cancer (NSCLC),Lung,Asciminib,ABL1,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for chronic myeloid leukemia (CML) treatment.,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,1.07,1653.0 +3525,NCT03660826,"Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone",ACTIVE_NOT_RECRUITING,PHASE2,Endometrial Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Endometrioid Adenocarcinoma; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8,Biospecimen Collection (PROCEDURE); Bone Marrow Aspirate (PROCEDURE); Bone Marrow Biopsy (PROCEDURE); Capivasertib (DRUG); Cediranib (DRUG); Cediranib Maleate (DRUG); Computed Tomography (PROCEDURE); Durvalumab (BIOLOGICAL); Echocardiography (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Olaparib (DRUG),25227436,Truqap,Endometrial Cancer,Uterus,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3526,NCT05563220,Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer,RECRUITING,PHASE1,Breast Cancer; Metastatic Breast Cancer,Elacestrant (DRUG); Alpelisib (DRUG); Everolimus (DRUG); Ribociclib (DRUG); Palbociclib (DRUG); Capivasertib (DRUG); Abemaciclib (DRUG),25227436,Truqap,Breast Cancer; Metastatic Breast Cancer,Breast,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3527,NCT04556773,A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Breast Cancer,Trastuzumab deruxtecan (DRUG); Durvalumab (DRUG); Paclitaxel (DRUG); Capivasertib (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG); Capecitabine (DRUG),25227436,Truqap,Metastatic Breast Cancer,Breast,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3528,NCT02117167,SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients,COMPLETED,PHASE2,Non-small Cell Lung Cancer Metastatic,AZD2014 (DRUG); AZD4547 (DRUG); AZD5363 (DRUG); AZD8931 (DRUG); Selumetinib (DRUG); Vandetanib (DRUG); Standard maintenance for squamous NSCLC (DRUG); Pemetrexed (DRUG); Durvalumab (DRUG); savolitinib (DRUG); Olaparib (DRUG),25227436,Truqap,Non-small Cell Lung Cancer Metastatic,Lung,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3529,NCT05720260,"Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC",RECRUITING,PHASE2,Premenopausal Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer,Goserelin (DRUG); Fulvestrant (DRUG); Capivasertib (DRUG); Durvalumab (DRUG),25227436,Truqap,Metastatic ER-Positive Breast Cancer,Breast,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3530,NCT01625286,"Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients",COMPLETED,PHASE1,Advanced or Metastatic Breast Cancer; ER+ve Advanced or Metastatic Breast Cancer,AZD5363 when combined with weekly paclitaxel. (DRUG); AZD5363 when combined with weekly paclitaxel. (DRUG); AZD5363when combined with weekly paclitaxel. (DRUG); A placebo in combination with weekly paclitaxel. (DRUG),25227436,Truqap,Advanced or Metastatic Breast Cancer; ER+ve Advanced or Metastatic Breast Cancer,Breast,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3531,NCT01226316,"Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules",COMPLETED,PHASE1,Advanced Solid Malignancy; Safety and Tolerability; Pharmacokinetics; Pharmacodynamics; Tumour Response; Advanced or Metastatic Breast Cancer; Ovarian Cancer; Cervical Cancer; Endometrial Cancer; PIK3CA; AKT1; PTEN; ER Positive; HER2 Positive,AZD5363 (DRUG); AZD5363 (DRUG); AZD5363 (DRUG); AZD5363 (DRUG),25227436,Truqap,Advanced Solid Malignancy; Safety and Tolerability; Pharmacokinetics; Pharmacodynamics; Tumour Response; Advanced or Metastatic Breast Cancer; Ovarian Cancer; Cervical Cancer; Endometrial Cancer; PIK3CA; AKT1; PTEN; ER Positive; HER2 Positive,Uterus,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3532,NCT05039801,IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors,RECRUITING,PHASE1,Advanced Endometrial Carcinoma; Advanced Head and Neck Squamous Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Melanoma; Advanced Ovarian Clear Cell Adenocarcinoma; Chondrosarcoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Recurrent Ovarian High Grade Serous Adenocarcinoma; Refractory Endometrial Carcinoma; Refractory Head and Neck Squamous Cell Carcinoma; Refractory Melanoma; Refractory Ovarian Clear Cell Adenocarcinoma; Refractory Ovarian High Grade Serous Adenocarcinoma; Stage III Ovarian Cancer AJCC v8; Stage III Uterine Corpus Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Uterine Corpus Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Uterine Corpus Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Uterine Corpus Cancer AJCC v8; Stage IIIC1 Uterine Corpus Cancer AJCC v8; Stage IIIC2 Uterine Corpus Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8,Bevacizumab (BIOLOGICAL); Glutaminase-1 Inhibitor IACS-6274 (DRUG); Paclitaxel (DRUG); Capivasertib (DRUG),25227436,Truqap,Advanced Endometrial Carcinoma; Advanced Head and Neck Squamous Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Melanoma; Advanced Ovarian Clear Cell Adenocarcinoma; Chondrosarcoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Recurrent Ovarian High Grade Serous Adenocarcinoma; Refractory Endometrial Carcinoma; Refractory Head and Neck Squamous Cell Carcinoma; Refractory Melanoma; Refractory Ovarian Clear Cell Adenocarcinoma; Refractory Ovarian High Grade Serous Adenocarcinoma; Stage III Ovarian Cancer AJCC v8; Stage III Uterine Corpus Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Uterine Corpus Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Uterine Corpus Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Uterine Corpus Cancer AJCC v8; Stage IIIC1 Uterine Corpus Cancer AJCC v8; Stage IIIC2 Uterine Corpus Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8,Skin,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3533,NCT03801369,"Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma,Biopsy (PROCEDURE); Capivasertib (DRUG); Ceralasertib (DRUG); Durvalumab (BIOLOGICAL); Olaparib (DRUG); Quality-of-Life Assessment (OTHER); Selumetinib (DRUG),25227436,Truqap,Metastatic Breast Cancer,Breast,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3534,NCT02077569,AKT Inhibitor in Oestrogen Positive Breast Cancer,COMPLETED,PHASE2,Invasive Breast Cancer,AZD5363 (DRUG),25227436,Truqap,Invasive Breast Cancer,Breast,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3535,NCT03182634,The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial,UNKNOWN,PHASE2,Advanced Breast Cancer,Fulvestrant (DRUG); Neratinib (DRUG); AZD5363 (DRUG); Olaparib (DRUG); AZD6738 (DRUG),25227436,Truqap,Advanced Breast Cancer,Breast,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3536,NCT03310541,AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations,COMPLETED,PHASE1,Breast Cancer; Prostate Cancer; Advanced Solid Tumors,AZD5363 (DRUG); Enzalutamide (DRUG); Fulvestrant (DRUG),25227436,Truqap,Breast Cancer; Prostate Cancer; Advanced Solid Tumors,Breast,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3537,NCT02449655,Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy,TERMINATED,PHASE2,Advanced Gastric Adenocarcinoma,AZD5363 (DRUG); paclitaxel (DRUG); AZD2014 (DRUG); paclitaxel (DRUG),25227436,Truqap,Advanced Gastric Adenocarcinoma,Esophagus/Stomach,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3538,NCT02523014,"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas",RECRUITING,PHASE2,Intracranial Meningioma; Recurrent Meningioma; NF2 Gene Mutation,Vismodegib (DRUG); FAK Inhibitor GSK2256098 (DRUG); Capivasertib (DRUG); Abemaciclib (DRUG),25227436,Truqap,Meningioma,CNS/Brain,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3539,NCT03997123,Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC,ACTIVE_NOT_RECRUITING,PHASE3,Triple Negative Breast Neoplasms,Capivasertib (DRUG); Paclitaxel (DRUG); Placebo (DRUG),25227436,Truqap,Triple Negative Breast Neoplasms,Breast,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3540,NCT02208375,mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian,ACTIVE_NOT_RECRUITING,PHASE1,BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Endometrial Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; High Grade Ovarian Serous Adenocarcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage III Uterine Corpus Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Uterine Corpus Cancer AJCC v7; Triple-Negative Breast Carcinoma,Capivasertib (DRUG); Laboratory Biomarker Analysis (OTHER); Olaparib (DRUG); Pharmacological Study (OTHER); Vistusertib (DRUG),25227436,Truqap,BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Endometrial Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; High Grade Ovarian Serous Adenocarcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage III Uterine Corpus Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Uterine Corpus Cancer AJCC v7; Triple-Negative Breast Carcinoma,Breast,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3541,NCT02299999,SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Cancer,AZD2014 (DRUG); AZD4547 (DRUG); AZD5363 (DRUG); AZD8931 (DRUG); Selumetinib (DRUG); Vandetanib (DRUG); Bicalutamide (DRUG); Olaparib (DRUG); Anthracyclines (DRUG); Taxanes (DRUG); cyclophosphamide (DRUG); DNA intercalators (DRUG); Methotrexate (DRUG); vinca alkaloids (DRUG); Platinum based chemotherapies (DRUG); Bevacizumab (DRUG); Mitomycin C (DRUG); Eribulin (DRUG); MEDI4736 (DRUG),25227436,Truqap,Metastatic Breast Cancer,Breast,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3542,NCT03742102,A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Triple Negative Breast Neoplasms,Durvalumab (DRUG); Capivasertib (DRUG); Oleclumab (DRUG); Paclitaxel (DRUG); Trastuzumab deruxtecan (DRUG); Datopotamab deruxtecan (DRUG),25227436,Truqap,Triple Negative Breast Neoplasms,Breast,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3543,NCT02423603,PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Paclitaxel (DRUG); AZD5363 (DRUG); Placebo (DRUG),25227436,Truqap,Metastatic Breast Cancer,Breast,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3544,NCT02664935,National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,"Non-Small Cell Lung Cancer; Carcinoma, Squamous Cell; Adenocarcinoma",AZD4547 (DRUG); Vistusertib (DRUG); Palbociclib (DRUG); Crizotinib (DRUG); Selumetinib (DRUG); Docetaxel (DRUG); AZD5363 (DRUG); Osimertinib (DRUG); Durvalumab (DRUG); Sitravatinib (DRUG); AZD6738 (DRUG),25227436,Truqap,"Non-Small Cell Lung Cancer; Carcinoma, Squamous Cell; Adenocarcinoma",Skin,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3545,NCT01992952,Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer,UNKNOWN,PHASE1,Estrogen Receptor Positive Breast Cancer,AZD5363 (DRUG); Placebo (DRUG); Fulvestrant (DRUG),25227436,Truqap,ER-Positive HER2-Negative Breast Cancer,Breast,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3546,NCT02451956,"Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy",COMPLETED,PHASE2,Advanced Gastric Cancer,AZD5363 (DRUG); paclitaxel (DRUG),25227436,Truqap,Advanced Gastric Cancer,Esophagus/Stomach,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3547,NCT06635447,Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients,RECRUITING,PHASE3,Breast Cancer,Capivasertib (DRUG); Fulvestrant (DRUG),25227436,Truqap,Breast Cancer,Breast,Capivasertib,"AKT1, AKT2, AKT3, RPS6KB1, PRKACA, ROCK2, ROCK1",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,In clinical trials for cancer. Not yet approved for human use.,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,1.13,2569.0 +3548,NCT00068757,"Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer",COMPLETED,PHASE1,Breast Cancer,trastuzumab (BIOLOGICAL); lonafarnib (DRUG); paclitaxel (DRUG); pharmacological study (OTHER),148195,Sarasar,Breast Cancer,Breast,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3549,NCT00102648,Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide,ACTIVE_NOT_RECRUITING,PHASE1,Malignant Supratentorial Neoplasm; Recurrent Glioblastoma; Recurrent Gliosarcoma,Lonafarnib (DRUG); Temozolomide (DRUG),148195,Sarasar,Malignant Supratentorial Neoplasm; Recurrent Glioblastoma; Recurrent Gliosarcoma,CNS/Brain,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3550,NCT00020774,SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer,WITHDRAWN,PHASE2,Liver Cancer,gemcitabine hydrochloride (DRUG); lonafarnib (DRUG); conventional surgery (PROCEDURE),148195,Sarasar,Liver Cancer,Liver,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3551,NCT00773474,Lonafarnib in Metastatic Breast Cancer,TERMINATED,PHASE2,Metastatic Breast Cancer,Lonafarnib (DRUG),148195,Sarasar,Metastatic Breast Cancer,Breast,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3552,NCT02511431,Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir,COMPLETED,PHASE2,Hepatitis D,Lonafarnib (DRUG); Ritonavir (DRUG); Placebo (OTHER),148195,Sarasar,Hepatitis D,Liver,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3553,NCT02430194,Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2),COMPLETED,PHASE2,Chronic Hepatitis D Infection,lonafarnib (DRUG); ritonavir (DRUG); Pegylated interferon-alfa-2a (DRUG),148195,Sarasar,Chronic Hepatitis D Infection,Liver,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3554,NCT05229991,Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection,UNKNOWN,PHASE3,"Hepatitis D, Chronic",Lonafarnib (DRUG); Ritonavir (DRUG),148195,Sarasar,Chronic Hepatitis D,Liver,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3555,NCT00083096,Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas,UNKNOWN,PHASE1,Brain and Central Nervous System Tumors,lonafarnib (DRUG); temozolomide (DRUG),148195,Sarasar,Brain and Central Nervous System Tumors,CNS/Brain,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3556,NCT00288444,Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer,TERMINATED,PHASE1,Lung Cancer; Soft Tissue Sarcoma; Colorectal Carcinoma; Breast Cancer; Prostate Cancer,Lonafarnib (DRUG); Docetaxel (DRUG),148195,Sarasar,Lung Cancer; Soft Tissue Sarcoma; Colorectal Carcinoma; Breast Cancer; Prostate Cancer,Bowel,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3557,NCT00539968,"A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)",TERMINATED,PHASE1,Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Gastric Cancer,Docetaxel plus lonafarnib (DRUG),148195,Sarasar,Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Gastric Cancer,Lung,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3558,NCT02968641,A Study of Lonafarnib With or Without Ritonavir in Patients With HDV,WITHDRAWN,PHASE2,Chronic Delta Hepatitis,Lonafarnib (DRUG); Ritonavir (DRUG),148195,Sarasar,Chronic Delta Hepatitis,Liver,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3559,NCT00081510,Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480),COMPLETED,PHASE2,Breast Cancer,Lonafarnib (DRUG); Placebo (DRUG); anastrozole (DRUG),148195,Sarasar,Breast Cancer,Breast,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3560,NCT02430181,Lonafarnib With and Without Ritonavir in HDV (LOWR-1),COMPLETED,PHASE2,Chronic Hepatitis D Infection,lonafarnib (DRUG); peginterferon alfa-2a (DRUG); ritonavir (DRUG),148195,Sarasar,Chronic Hepatitis D Infection,Liver,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3561,NCT03600714,"Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon",COMPLETED,PHASE2,Liver Disease; Hepatitis D,Peg-interferon lambda (DRUG); Lonafarnib (DRUG); Ritonavir (DRUG),148195,Sarasar,Liver Disease; Hepatitis D,Liver,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3562,NCT03719313,Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a,COMPLETED,PHASE3,Hepatitis Delta Virus,Lonafarnib (DRUG); Ritonavir (DRUG); PEG IFN-alfa-2a (DRUG); Placebo Lonafarnib (DRUG); Placebo Ritonavir (DRUG),148195,Sarasar,Hepatitis Delta Virus,Liver,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3563,NCT00281515,Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer,COMPLETED,PHASE2,Epithelial Ovarian Cancer,Lonafarnib (DRUG),148195,Sarasar,Ovarian Cancer,Ovary/Fallopian Tube,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3564,NCT00015899,SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors,COMPLETED,PHASE1,Brain and Central Nervous System Tumors,lonafarnib (DRUG),148195,Sarasar,Brain and Central Nervous System Tumors,CNS/Brain,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3565,NCT00612651,PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas,COMPLETED,PHASE1,Gliosarcoma; Glioblastoma; Anaplastic Astrocytoma,Temodar and SCH 66336 (DRUG),148195,Sarasar,Gliosarcoma; Glioblastoma; Anaplastic Astrocytoma,CNS/Brain,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3566,NCT00006351,SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract,COMPLETED,PHASE2,Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer,gemcitabine hydrochloride (DRUG); lonafarnib (DRUG),148195,Sarasar,Urinary Tract Cancers,Bladder/Urinary Tract,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3567,NCT01495585,Lonafarnib for Chronic Hepatitis D,COMPLETED,PHASE2,Hepatitis D,Lonafarnib (DRUG); Placebo (OTHER),148195,Sarasar,Hepatitis D,Liver,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3568,NCT02527707,Titrating-Dose of Lonafarnib in Combination With Ritonavir,COMPLETED,PHASE2,Chronic Delta Hepatitis,lonafarnib (DRUG); Ritonavir (DRUG),148195,Sarasar,Chronic Delta Hepatitis,Liver,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3569,NCT05953545,Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis,WITHDRAWN,PHASE2,Chronic Hepatitis Delta,Peginterferon Lambda (DRUG),148195,Sarasar,Chronic Hepatitis Delta,Liver,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3570,NCT00005030,SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver,WITHDRAWN,PHASE1,Colorectal Cancer; Metastatic Cancer,SCH 66336 (DRUG); conventional surgery (PROCEDURE),148195,Sarasar,Colorectal Cancer; Metastatic Cancer,Bowel,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3571,NCT00038493,Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme,COMPLETED,PHASE2,Glioblastoma Multiforme,Temozolomide and SCH66336 (DRUG),148195,Sarasar,Glioblastoma Multiforme,CNS/Brain,Lonafarnib,"HRAS, KRAS, NRAS",inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for progeria treatment in children.,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,1.03921568627451,341.0 +3572,NCT02463825,A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS,UNKNOWN,PHASE2,Amyotrophic Lateral Sclerosis (ALS),Pimozide 2 mg per day (DRUG); Pimozide 4 mg per day (DRUG); Placebo (Lactose tablet) (DRUG),16362,Orap,Amyotrophic Lateral Sclerosis (ALS),CNS/Brain,Pimozide,"DRD2, DRD3",inhibitor/antagonist,unclear,yes,yes,Approved antipsychotic used mainly for Tourette's syndrome and chronic schizophrenia.,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,1.08,303.0 +3573,NCT03272503,A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS),UNKNOWN,PHASE2,ALS; Amyotrophic Lateral Sclerosis,Pimozide 2mg/day (current) or 4 mg/day (study initiation) (DRUG); Placebo Oral Tablet (DRUG),16362,Orap,ALS; Amyotrophic Lateral Sclerosis,CNS/Brain,Pimozide,"DRD2, DRD3",inhibitor/antagonist,unclear,yes,yes,Approved antipsychotic used mainly for Tourette's syndrome and chronic schizophrenia.,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,1.08,303.0 +3574,NCT03989206,Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis,ACTIVE_NOT_RECRUITING,PHASE3,Moderate-to-Severe Atopic Dermatitis,Nemolizumab (DRUG),16362,Orap,Moderate-to-Severe Atopic Dermatitis,Skin,Pimozide,"DRD2, DRD3",inhibitor/antagonist,unclear,yes,yes,Approved antipsychotic used mainly for Tourette's syndrome and chronic schizophrenia.,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,1.08,303.0 +3575,NCT03989349,Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis,COMPLETED,PHASE3,Moderate-to-Severe Atopic Dermatitis,Placebo (DRUG); Nemolizumab (DRUG),16362,Orap,Moderate-to-Severe Atopic Dermatitis,Skin,Pimozide,"DRD2, DRD3",inhibitor/antagonist,unclear,yes,yes,Approved antipsychotic used mainly for Tourette's syndrome and chronic schizophrenia.,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,1.08,303.0 +3576,NCT00695565,Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy,COMPLETED,PHASE2,Painful Diabetic Neuropathy,Placebo Gel (DRUG); Clonidine Topical Gel (ARC-4558) (DRUG),20179,Kapvay,Painful Diabetic Neuropathy,Peripheral Nervous System,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3577,NCT01322048,DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury,COMPLETED,PHASE2,"Brain Injuries; Craniocerebral Trauma; Trauma, Nervous System; Traumatic Brain Injury",IV Propranolol and Per Tube Clonidine (DRUG); Placebo (DRUG),20179,Kapvay,"Brain Injuries; Craniocerebral Trauma; Trauma, Nervous System; Traumatic Brain Injury",CNS/Brain,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3578,NCT02068027,"Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy",COMPLETED,PHASE2,Painful Diabetic Neuropathy; Diabetic Neuropathy; Neuropathy,Clonidine Gel 0.1% (DRUG); Placebo (DRUG),20179,Kapvay,Painful Diabetic Neuropathy; Diabetic Neuropathy; Neuropathy,Peripheral Nervous System,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3579,NCT05560230,Intraoperative Clonidine for Postoperative Pain Management in Patients Undergoing Surgical Treatment for Endometriosis,COMPLETED,PHASE4,"Endometriosis; Postoperative Pain; Pain, Acute; Pain, Acute Postoperative",Clonidine (DRUG); Isotonic saline (DRUG),20179,Kapvay,"Endometriosis; Postoperative Pain; Pain, Acute; Pain, Acute Postoperative",Uterus,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3580,NCT00535925,Nephropathy In Type 2 Diabetes and Cardio-renal Events,COMPLETED,PHASE4,Diabetic Nephropathy,SoC therapy (DRUG); irbesartan (DRUG); ramipril (DRUG); hydrochlorothiazide (DRUG); furosemide (DRUG); amlodipine (DRUG); atenolol (DRUG); doxazosin (DRUG); clonidine (DRUG); insulin (DRUG); simvastatin (DRUG); fibrate (DRUG); erythropoietin (DRUG); aspirin (DRUG),20179,Kapvay,Diabetic Nephropathy,Kidney,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3581,NCT01530373,Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients,RECRUITING,PHASE2,Hot Flashes; Breast Cancer,solifenacin (DRUG); Clonidine (DRUG),20179,Kapvay,Hot Flashes; Breast Cancer,Breast,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3582,NCT02355158,"A Safety Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Painful Diabetic Neuropathy",COMPLETED,PHASE2,Painful Diabetic Neuropathy; Diabetes,"clonidine hydrochloride topical gel, 0.1% (DRUG)",20179,Kapvay,Painful Diabetic Neuropathy; Diabetes,Peripheral Nervous System,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3583,NCT05536362,Propofol With Clonidine and Ketamine Throughout Colon Cancer Surgery,COMPLETED,PHASE1,Colon Cancer; Post Operative Pain,TCI Propofol Injection (DRUG),20179,Kapvay,Colon Cancer; Post Operative Pain,Bowel,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3584,NCT00661063,Diabetic Neuropathy Topical Treatment,UNKNOWN,PHASE3,Diabetic Neuropathy; Pain,ketamine (DRUG); vehicle gel (DRUG); ketamine + clonidine (DRUG); clonidine gel 1% (DRUG),20179,Kapvay,Diabetic Neuropathy; Pain,Peripheral Nervous System,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3585,NCT01422616,Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED),COMPLETED,PHASE3,Ischemic Stroke; High Blood Pressure,Low-dose rtPA (DRUG); Standard-dose rtPA (DRUG); Intensive blood pressure (BP) lowering (OTHER); BP management policies (OTHER),20179,Kapvay,Ischemic Stroke; High Blood Pressure,CNS/Brain,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3586,NCT03552068,Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease:,COMPLETED,PHASE2,Parkinson's Disease; Mpulse Control Disorders,placebo (DRUG); Clonidine (DRUG),20179,Kapvay,Parkinson's Disease; Mpulse Control Disorders,CNS/Brain,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3587,NCT02030717,Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma,COMPLETED,PHASE2,Pre- and Postoperative Analgesia; Spinal Anesthesia; Renal Cell Carcinoma,klonidin (DRUG); epidural anesthesia (DRUG),20179,Kapvay,Pre- and Postoperative Analgesia; Spinal Anesthesia; Renal Cell Carcinoma,Kidney,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3588,NCT04833218,Propranolol Versus Propranolol and Clonidine in Sympathetic Hyperactivity After Moderate Traumatic Brain Injury,UNKNOWN,EARLY_PHASE1,Traumatic Brain Injury,Propranolol (DRUG),20179,Kapvay,Traumatic Brain Injury,CNS/Brain,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3589,NCT01405950,Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy,TERMINATED,PHASE1,Spasticity Due to Cerebral Palsy,Zanaflex Capsules (DRUG); Zanaflex Capsules (DRUG); Zanaflex Capsules (DRUG); Zanaflex Capsules (DRUG),20179,Kapvay,Spasticity Due to Cerebral Palsy,CNS/Brain,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3590,NCT03388814,Speeding Recovery From Pain and Opioid Use,WITHDRAWN,EARLY_PHASE1,"Pain, Postoperative; Breast Cancer; Opioid Use; Surgery",Local infiltration of bupivacaine (DRUG); Pectoralis Nerve block (DRUG),20179,Kapvay,"Pain, Postoperative; Breast Cancer; Opioid Use; Surgery",Breast,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3591,NCT01415895,Naltrexone and Clonidine Combination (ATNC05) in the Treatment of Chronic Back Pain,COMPLETED,PHASE2,Back Pain; Lower Back Pain; Cervical Pain,Naltrexone and Clonidine Combination (DRUG); placebo (DRUG),20179,Kapvay,Back Pain; Lower Back Pain; Cervical Pain,Cervix,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3592,NCT02643251,"The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy",COMPLETED,PHASE2,Painful Diabetic Neuropathy; Diabetic Neuropathy; Neuropathy,"Clonidine Hydrochloride Topical Gel, 0.1% (DRUG); Clonidine Hydrochloride Gel Comparator (DRUG)",20179,Kapvay,Painful Diabetic Neuropathy; Diabetic Neuropathy; Neuropathy,Peripheral Nervous System,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3593,NCT02126332,Epidural Analgesia for Pancreatitis (Epipan Study),COMPLETED,PHASE3,Severe Acute Pancreatitis,"ropivacaine and sufentanil (OTHER); acetaminophen, nefopam, tramadol, opidoids (OTHER)",20179,Kapvay,Severe Acute Pancreatitis,Pancreas,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3594,NCT04603911,RCT Comparing ESPB Solutions in Breast Surgery,COMPLETED,PHASE2,Breast Cancer,"Liposomal bupivacaine (DRUG); Bupivacaine, epinephrine, dexamethasone, and clonidine (DRUG)",20179,Kapvay,Breast Cancer,Breast,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3595,NCT05727098,Dexmedetomedine and Ketamine in Erector Spinae Block for Postoperative Analgesia Following Mastectomy.,COMPLETED,PHASE2,Breast Cancer,Bupivacaine Hydrochloride (DRUG); Bupivacaine Hydrochloride and dexmedetomedine (DRUG); Bupivacaine Hydrochloride and ketamine (DRUG),20179,Kapvay,Breast Cancer,Breast,Clonidine (hydrochloride),"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used for hypertension and ADHD among other conditions.,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,1.28,168.0 +3596,NCT02147691,Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study,COMPLETED,PHASE4,Acne Rosacea,Azelaic acid 15% (DRUG); Brimonidine 0.33% (DRUG),2435,Brimodine,Acne Rosacea,Skin,Brimonidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used in the form of brimonidine tartrate for glaucoma treatment.,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,1.95,6.0 +3597,NCT03048058,Internet Surveys and Their Impact on Adherence for Rosacea,COMPLETED,PHASE4,Rosacea,brimonidine topical gel 0.33% & survey (DRUG); brimonidine topical gel 0.33% & SOC (DRUG),2435,Brimodine,Rosacea,Skin,Brimonidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used in the form of brimonidine tartrate for glaucoma treatment.,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,1.95,6.0 +3598,NCT02385240,Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea,COMPLETED,PHASE3,Rosacea,"Brimonidine Topical Gel, 0.33 percent (Perrigo) (DRUG); Brimonidine Topical Gel, 0.33 percent (Reference) (DRUG); Placebo gel (DRUG)",2435,Brimodine,Rosacea,Skin,Brimonidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used in the form of brimonidine tartrate for glaucoma treatment.,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,1.95,6.0 +3599,NCT00697541,Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%,COMPLETED,PHASE2,Erythematous Rosacea,0.18% COL-118 facial gel (1.8 mg brimonidine) (DRUG); 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) (DRUG); Advanced Eye Relief (DRUG); COL-118 facial gel vehicle (DRUG),2435,Brimodine,Erythematous Rosacea,Skin,Brimonidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used in the form of brimonidine tartrate for glaucoma treatment.,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,1.95,6.0 +3600,NCT02616250,MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.,COMPLETED,PHASE4,Rosacea,Brimonidine 0.33% gel (Br) (DRUG); CD07805/47 (Br) placebo gel (OTHER); Ivermectin 1% cream (IVM) (DRUG); CD5024 (IVM) placebo cream (OTHER),2435,Brimodine,Rosacea,Skin,Brimonidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used in the form of brimonidine tartrate for glaucoma treatment.,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,1.95,6.0 +3601,NCT01885000,Patient-Reported Outcome Of Facial Erythema (PROOF),COMPLETED,PHASE3,Rosacea; Erythema,Brimonidine tartrate was applied cutaneously once daily for 8 days. (DRUG); Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days. (DRUG),2435,Brimodine,Rosacea; Erythema,Skin,Brimonidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used in the form of brimonidine tartrate for glaucoma treatment.,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,1.95,6.0 +3602,NCT06033352,Potassium-titanyl Phosphate (KTP) Laser vs KTP Laser and Ivermectin Cream for Facial Rosacea,COMPLETED,PHASE2,Rosacea,KTP laser (DEVICE); Ivermectin 1% cream (DRUG),2435,Brimodine,Rosacea,Skin,Brimonidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used in the form of brimonidine tartrate for glaucoma treatment.,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,1.95,6.0 +3603,NCT02289352,"Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea",COMPLETED,PHASE3,Rosacea,Brimonidine (DRUG); placebo (DRUG),2435,Brimodine,Rosacea,Skin,Brimonidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used in the form of brimonidine tartrate for glaucoma treatment.,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,1.95,6.0 +3604,NCT01659853,Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea,COMPLETED,PHASE3,Erythema; Rosacea,CD07805/47 gel 0.5%/CD07805/47 Vehicle (DRUG); azelaic acid gel 15% (DRUG),2435,Brimodine,Erythema; Rosacea,Skin,Brimonidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used in the form of brimonidine tartrate for glaucoma treatment.,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,1.95,6.0 +3605,NCT06365853,A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression,RECRUITING,PHASE2,Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive,Mirvetuximab Soravtansine (DRUG); Lubricating Eye Drops (DRUG); Prednisolone acetate ophthalmic suspension 1% eye drops (DRUG); Brimonidine tartrate ophthalmic solution eye drops (DRUG),2435,Brimodine,Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive,Ovary/Fallopian Tube,Brimonidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used in the form of brimonidine tartrate for glaucoma treatment.,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,1.95,6.0 +3606,NCT02568111,Brimonidine Tartrate for the Treatment of Injection Related Erythema,WITHDRAWN,PHASE4,Relapsing-Remitting Multiple Sclerosis (RRMS),peginterferon beta-1a (DRUG); brimonidine tartrate (DRUG); Vehicle Gel (DRUG),2435,Brimodine,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Brimonidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used in the form of brimonidine tartrate for glaucoma treatment.,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,1.95,6.0 +3607,NCT02249065,Mirvaso in Use Study,COMPLETED,PHASE4,Rosacea,Brimonidine (DRUG),2435,Brimodine,Rosacea,Skin,Brimonidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Used in the form of brimonidine tartrate for glaucoma treatment.,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,1.95,6.0 +3608,NCT00570986,A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis,COMPLETED,PHASE3,Plaque Psoriasis,Placebo (DRUG); ABT-874 (BIOLOGICAL); ABT-874 (BIOLOGICAL),11338033,LZE,Plaque Psoriasis,Skin,AT7519,"CDK2, CDK4, CDK5, CDK6, CDK9, CDK1, CDK7, GSK3B",inhibitor/antagonist,CDK inhibitor,no,yes,Tested in trials for cancer treatments.,C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl,, +3609,NCT06585787,A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4),RECRUITING,PHASE3,Alzheimer Disease,KarXT (DRUG); Placebo (DRUG),11338033,LZE,Alzheimer Disease,CNS/Brain,AT7519,"CDK2, CDK4, CDK5, CDK6, CDK9, CDK1, CDK7, GSK3B",inhibitor/antagonist,CDK inhibitor,no,yes,Tested in trials for cancer treatments.,C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl,, +3610,NCT05462236,MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer,RECRUITING,PHASE2,Metastatic Colorectal Cancer,Tinodasertib (DRUG); Pembrolizumab (DRUG); Irinotecan (DRUG),71766360,Tinodasertib,Metastatic Colorectal Cancer,Bowel,ETC-206,,inhibitor/antagonist,Protein synthesis inhibitor,no,yes,"Investigational drug for cancer, not yet approved for human use.",C1COCCN1C(=O)C2=CC=C(C=C2)C3=CN4C(=NC=C4C5=CC=C(C=C5)C#N)C=C3,, +3611,NCT06319794,Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis,RECRUITING,PHASE2,Actinic Keratosis,Bimiralisib (DRUG); Bimiralisib (DRUG),58507717,Bimiralisib,Actinic Keratosis,Skin,Bimiralisib,"PIK3CA, PIK3CB, MTOR",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,Investigational PI3K/mTOR inhibitor; not approved for human use as of 2023.,C1COCCN1C2=NC(=NC(=N2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4,1.0,38.0 +3612,NCT02669511,PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma,COMPLETED,PHASE2,Primary Central Nervous System Lymphoma,PQR309 (DRUG),58507717,Bimiralisib,Primary Central Nervous System Lymphoma,CNS/Brain,Bimiralisib,"PIK3CA, PIK3CB, MTOR",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,Investigational PI3K/mTOR inhibitor; not approved for human use as of 2023.,C1COCCN1C2=NC(=NC(=N2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4,1.0,38.0 +3613,NCT02850744,"Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients",TERMINATED,PHASE2,Glioblastoma Multiforme,PQR309 (DRUG),58507717,Bimiralisib,Glioblastoma Multiforme,CNS/Brain,Bimiralisib,"PIK3CA, PIK3CB, MTOR",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,Investigational PI3K/mTOR inhibitor; not approved for human use as of 2023.,C1COCCN1C2=NC(=NC(=N2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4,1.0,38.0 +3614,NCT03120000,PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma,WITHDRAWN,PHASE2,Primary Central Nervous System Lymphoma,PQR309 (DRUG),58507717,Bimiralisib,Primary Central Nervous System Lymphoma,CNS/Brain,Bimiralisib,"PIK3CA, PIK3CB, MTOR",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,Investigational PI3K/mTOR inhibitor; not approved for human use as of 2023.,C1COCCN1C2=NC(=NC(=N2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4,1.0,38.0 +3615,NCT02723877,PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO),COMPLETED,PHASE1,Metastatic Breast Cancer,PQR309 (DRUG); Eribulin (DRUG),58507717,Bimiralisib,Metastatic Breast Cancer,Breast,Bimiralisib,"PIK3CA, PIK3CB, MTOR",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,Investigational PI3K/mTOR inhibitor; not approved for human use as of 2023.,C1COCCN1C2=NC(=NC(=N2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4,1.0,38.0 +3616,NCT01630252,PGL5001 Proof of Concept Study in Inflammatory Endometriosis,COMPLETED,PHASE2,Endometriosis,PGL5001 (DRUG); Placebo (DRUG); PGL5001 (DRUG); Placebo (DRUG); PGL5001 (DRUG),10195250,Bentamapimod,Endometriosis,Uterus,Bentamapimod,"MAPK8, MAPK9, MAPK10",inhibitor/antagonist,Other MAPK inhibitor,no,yes,Investigated for ovarian cancer; not approved for human use.,C1COCCN1CC2=CC=C(C=C2)COC3=NC=CC(=N3)C(C#N)C4=NC5=CC=CC=C5S4,, +3617,NCT02966665,: Vascular Function in Health and Disease,RECRUITING,PHASE1,Chronic Obstructive Pulmonary Disease; Pulmonary Artery Hypertension; Heart Failure; Hypertension,"Maximum Exercise Tests (OTHER); BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate (DRUG); BQ-123 (DRUG); Fexofenadine, Ranitidine (DRUG); Angiotensin-II, Valsartan (OTHER); Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine (DRUG); BQ-123, MitoQ, BH4 (DRUG)",6112,Lipoec,Chronic Obstructive Pulmonary Disease; Pulmonary Artery Hypertension; Heart Failure; Hypertension,Lung,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3618,NCT04214665,"To Assess the Bioequivalence of Test Oral Formulation of Alpha Lipoic Acid 600 mg HR Film Coated Tablets of Ilko Ilac San. Ve Tic. A.S. Versus Reference Thioctacid (Alpha Lipoic Acid) 600 mg HR Film Coated Tablets of Meda Pharma GmbH& CO .KG, Germany.",COMPLETED,PHASE1,Peripheral (Sensorimotor) Diabetic Polyneuropathy,Alpha Lipoic acid 600 mg HR film coated tablets (DRUG),6112,Lipoec,Peripheral (Sensorimotor) Diabetic Polyneuropathy,Peripheral Nervous System,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3619,NCT06406127,Effect of Alpha Lipoic Acid on Chemotherapy Induced Neurological Changes in Breast Cancer Patients,RECRUITING,PHASE4,Breast Cancer; Alpha Lipoic Acid; Paclitaxel; Neurologic Disorder; Chemotherapy,Alpha Lipoic Acid 600 MG Oral Capsule (DRUG),6112,Lipoec,Breast Cancer; Alpha Lipoic Acid; Paclitaxel; Neurologic Disorder; Chemotherapy,Breast,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3620,NCT01294176,Lipoic Acid as a Treatment for Acute Optic Neuritis,COMPLETED,PHASE1,Optic Neuritis,Lipoic Acid (DRUG),6112,Lipoec,Optic Neuritis,Peripheral Nervous System,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3621,NCT03420976,Novel Supplement-based Therapy for the Treatment of Small Intestinal Bacterial Overgrowth,WITHDRAWN,EARLY_PHASE1,Small Intestinal Bacterial Overgrowth,Novel Supplement Based Therapy (DIETARY_SUPPLEMENT),6112,Lipoec,Small Intestinal Bacterial Overgrowth,Bowel,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3622,NCT04041167,Impact of Lipoic Acid Use on Stroke Outcome After Reperfusion Therapy in Patients With Diabetes (IMPORTANT),UNKNOWN,PHASE3,"Stroke, Ischemic",alpha lipoic acid (DRUG); Saline (DRUG),6112,Lipoec,"Stroke, Ischemic",CNS/Brain,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3623,NCT04308980,Safety and Tolerability of Novel Medical Nutrition Products for NAFLD Treatment,UNKNOWN,PHASE2,NAFLD; NASH - Nonalcoholic Steatohepatitis,Specialized product for medical nutrition (SPP-1) (DIETARY_SUPPLEMENT); individualized diet (BEHAVIORAL),6112,Lipoec,NAFLD; NASH - Nonalcoholic Steatohepatitis,Liver,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3624,NCT05231980,Efficacy of Pentoxifylline and Alpha Lipoic Acid in PCOS Resistant to Clomiphene Citrate,COMPLETED,PHASE2,Clomiphene Citrate; Resistant Ovary Syndrome; Polycystic Ovary Syndrome,Alpha lipoic acid (ALA) (DIETARY_SUPPLEMENT); Pentoxifylline (PTX) (DRUG); Clomiphene Citrate (DRUG),6112,Lipoec,Clomiphene Citrate; Resistant Ovary Syndrome; Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3625,NCT05266794,A Novel Role of Alpha Lipoic Acid in Comparison With Selenium in Mitochondrial Resuscitation and miRNA-126 Expression in Hemodialysis Patients,COMPLETED,PHASE4,Antioxidative Stress; End Stage Renal Disease on Dialysis,Alpha lipoic acid (DRUG); Selenium (DRUG),6112,Lipoec,Antioxidative Stress; End Stage Renal Disease on Dialysis,Kidney,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3626,NCT04475276,Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases,RECRUITING,PHASE4,Non-Alcoholic Fatty Liver Disease,Placebo (DRUG); Alphalipoic acid (DRUG),6112,Lipoec,Non-Alcoholic Fatty Liver Disease,Liver,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3627,NCT03914404,Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy,COMPLETED,PHASE4,Diabetic Neuropathy,γ-linoleic acid and placebo(Thioctic Acid) (DRUG); Thioctic Acid and placebo(γ-linoleic acid) (DRUG),6112,Lipoec,Diabetic Neuropathy,Peripheral Nervous System,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3628,NCT00328601,Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2),COMPLETED,PHASE3,Diabetic Polyneuropathy,Thioctic Acid (DRUG),6112,Lipoec,Diabetic Polyneuropathy,Peripheral Nervous System,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3629,NCT04557410,Open Label Study: Treatment of ALS Fatigue With PolyMVA,COMPLETED,PHASE1,Amyotrophic Lateral Sclerosis,PolyMVA (DRUG),6112,Lipoec,Amyotrophic Lateral Sclerosis,CNS/Brain,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3630,NCT04846673,Pregabalin and Alpha-lipoic Acid Combination Versus Each Monotherapy in Patients With Diabetic Peripheral Neuropathy,COMPLETED,PHASE4,Diabetic Peripheral Neuropathy,Pregabalin 150mg + Alpha-lipoic acid 480mg (DRUG); Pregabalin 150mg (DRUG); Alpha-Lipoic Acid 480mg (DRUG),6112,Lipoec,Diabetic Peripheral Neuropathy,Peripheral Nervous System,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3631,NCT01835041,CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer,COMPLETED,PHASE1,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer,"6,8-bis(benzylthio)octanoic acid (DRUG); oxaliplatin (DRUG); leucovorin calcium (DRUG); irinotecan hydrochloride (DRUG); fluorouracil (DRUG); laboratory biomarker analysis (OTHER)",6112,Lipoec,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3632,NCT02696512,A Study of IBRF Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Severe Disorders of Consciousness,UNKNOWN,PHASE1,Brain Injury,Polypharmacy using FDA-approved products (DRUG); Median Nerve Stimulation (MNS) (DEVICE); Nutraceutical Supplementation (DIETARY_SUPPLEMENT); Standard of Care (OTHER),6112,Lipoec,Traumatic Brain Injury,CNS/Brain,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3633,NCT01313117,Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy,COMPLETED,PHASE1,Peripheral Neuropathy,Alpha lipoic acid (DRUG),6112,Lipoec,Peripheral Neuropathy,Peripheral Nervous System,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3634,NCT00237718,Provision of Antioxidant Therapy in Hemodialysis (PATH) Study,COMPLETED,PHASE2,End-stage Renal Disease,"Alpha, gamma, beta, and delta (mixed) tocopherols (DRUG); Alpha lipoic acid (DRUG); Placebo (DRUG); Placebo (DRUG)",6112,Lipoec,End-stage Renal Disease,Kidney,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3635,NCT01058941,Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease,COMPLETED,PHASE1,Alzheimer's Disease,Lipoic acid and fish oil concentrate (DRUG); Placebo (DRUG),6112,Lipoec,Alzheimer's Disease,CNS/Brain,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3636,NCT03493841,Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis,COMPLETED,PHASE1,Multiple Sclerosis; Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Primary Progressive Multiple Sclerosis,Alpha Lipoic Acid (DRUG),6112,Lipoec,Multiple Sclerosis; Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Primary Progressive Multiple Sclerosis,CNS/Brain,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3637,NCT01766219,CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery,COMPLETED,PHASE1,Adult Primary Cholangiocellular Carcinoma; Advanced Adult Primary Liver Cancer; Cholangiocarcinoma of the Extrahepatic Bile Duct; Cholangiocarcinoma of the Gallbladder; Localized Unresectable Adult Primary Liver Cancer; Metastatic Extrahepatic Bile Duct Cancer; Recurrent Adult Primary Liver Cancer; Recurrent Extrahepatic Bile Duct Cancer; Unresectable Extrahepatic Bile Duct Cancer,"6,8-bis(benzylthio)octanoic acid (DRUG)",6112,Lipoec,Adult Primary Cholangiocellular Carcinoma; Advanced Adult Primary Liver Cancer; Cholangiocarcinoma of the Extrahepatic Bile Duct; Cholangiocarcinoma of the Gallbladder; Localized Unresectable Adult Primary Liver Cancer; Metastatic Extrahepatic Bile Duct Cancer; Recurrent Adult Primary Liver Cancer; Recurrent Extrahepatic Bile Duct Cancer; Unresectable Extrahepatic Bile Duct Cancer,Liver,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3638,NCT01650181,Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis,COMPLETED,PHASE4,Liver Disease,Metformin (DRUG); Siliphos+ Selenium - Methionine + Alpha Lipoic Acid (DIETARY_SUPPLEMENT); Siliphos+ Selenium - Methionine + Alpha Lipoic Acid (DIETARY_SUPPLEMENT); Metformin (DRUG),6112,Lipoec,Liver Disease,Liver,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3639,NCT01839981,CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,COMPLETED,PHASE1,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,"6,8-bis(benzylthio)octanoic acid (DRUG)",6112,Lipoec,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3640,NCT02439879,Alpha Lipoic Acid for Treatment of Diabetic Neuropathy,COMPLETED,PHASE4,Diabetic Neuropathy,Alpha lipoic acid (DRUG),6112,Lipoec,Diabetic Neuropathy,Peripheral Nervous System,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3641,NCT00090402,Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease,COMPLETED,PHASE1,Alzheimer's Disease; Oxidative Stress; Dementia; Hyperlipidemia; Inflammation,Fish Oil (DIETARY_SUPPLEMENT); Lipoic Acid (DIETARY_SUPPLEMENT); Fish Oil Placebo (OTHER); Lipoic Acid Placebo (OTHER),6112,Lipoec,Alzheimer's Disease; Oxidative Stress; Dementia; Hyperlipidemia; Inflammation,CNS/Brain,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3642,NCT02133664,Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis,COMPLETED,PHASE1,Multiple Sclerosis; Cognition,lipoic acid and omega-3 fatty acids (DRUG); Placebo (DRUG),6112,Lipoec,Multiple Sclerosis; Cognition,CNS/Brain,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3643,NCT06650384,Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid in Colistin-Induced Nephrotoxicity,RECRUITING,PHASE2,Nephrotoxicity,Addition of sachets of N-acetyl cysteine 1200 mg twice/day to the maintenance dose of colistin (DRUG); Addition of Alpha-lipoic acid 600mg twice daily to the maintenance dose of colistin (DRUG),6112,Lipoec,Nephrotoxicity,Kidney,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3644,NCT00117403,Anti-Oxidant Treatment of Alzheimer's Disease,COMPLETED,PHASE1,Alzheimer's Disease,"Vitamin E, Vitamin C, and Alpha-lipoic Acid (DRUG); Coenzyme Q (DRUG); Placebo capsules (DRUG); Placebo wafers (DRUG)",6112,Lipoec,Alzheimer's Disease,CNS/Brain,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3645,NCT00997438,Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis,COMPLETED,PHASE1,Multiple Sclerosis,Lipoic Acid (DIETARY_SUPPLEMENT),6112,Lipoec,Multiple Sclerosis,CNS/Brain,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3646,NCT06131918,Assessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With Neuropathy,COMPLETED,PHASE2,Peripheral Diabetic Neuropathy,"Resveratrol, Alpha lipoic acid, Super oxide dismutase (DRUG); Resveratrol (DRUG); Alpha lipoic acid (DRUG); Super Oxide Dismutase (DRUG)",6112,Lipoec,Peripheral Diabetic Neuropathy,Peripheral Nervous System,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3647,NCT05733000,CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors,RECRUITING,PHASE2,Advanced Biliary Tract Carcinoma; Advanced Colorectal Carcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Advanced Lung Adenocarcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Urothelial Carcinoma; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Metastatic Biliary Tract Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Lung Adenocarcinoma; Metastatic Ovarian Carcinoma; Metastatic Pancreatic Carcinoma; Metastatic Urothelial Carcinoma; Refractory Biliary Tract Carcinoma; Refractory Colorectal Carcinoma; Refractory Gastroesophageal Junction Adenocarcinoma; Refractory Lung Adenocarcinoma; Refractory Ovarian Carcinoma; Refractory Pancreatic Carcinoma; Refractory Urothelial Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Devimistat (DRUG); Fluorouracil (DRUG); Gemcitabine Hydrochloride (DRUG); Hydroxychloroquine (DRUG); Magnetic Resonance Imaging (PROCEDURE),6112,Lipoec,Advanced Biliary Tract Carcinoma; Advanced Colorectal Carcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Advanced Lung Adenocarcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Urothelial Carcinoma; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Metastatic Biliary Tract Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Lung Adenocarcinoma; Metastatic Ovarian Carcinoma; Metastatic Pancreatic Carcinoma; Metastatic Urothelial Carcinoma; Refractory Biliary Tract Carcinoma; Refractory Colorectal Carcinoma; Refractory Gastroesophageal Junction Adenocarcinoma; Refractory Lung Adenocarcinoma; Refractory Ovarian Carcinoma; Refractory Pancreatic Carcinoma; Refractory Urothelial Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Bowel,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3648,NCT03370159,CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer,WITHDRAWN,PHASE1,Stage IIIB Non-Small Cell Lung Cancer AJCC v7; Stage IV Non-Small Cell Lung Cancer AJCC v7,"6,8-Bis(benzylthio)octanoic Acid (DRUG); Docetaxel (DRUG); Pharmacological Study (OTHER)",6112,Lipoec,Stage IIIB Non-Small Cell Lung Cancer AJCC v7; Stage IV Non-Small Cell Lung Cancer AJCC v7,Lung,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3649,NCT00010842,Natural Antioxidants in the Treatment of Multiple Sclerosis,COMPLETED,PHASE1,Multiple Sclerosis,Ginkgo biloba (DRUG); Alpha-lipoic acid (DRUG); Vitamin E/Selenium (DRUG); Essential fatty acids (DRUG),6112,Lipoec,Multiple Sclerosis,CNS/Brain,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3650,NCT06568185,The Effect of Alpha Lipoid Acid and Vitamin B Preparation on Diabetic Polyneuropathy in Type 2 Diabetes Mellitus Patient,RECRUITING,PHASE2,Diabetic Polyneuropathy,Alpha-Lipoic Acid/Vitamin/Mineral Supplement PolyMVA (DRUG),6112,Lipoec,Diabetic Polyneuropathy,Peripheral Nervous System,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3651,NCT02232152,CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery,COMPLETED,PHASE1,Mucinous Adenocarcinoma of the Colon; Mucinous Adenocarcinoma of the Rectum; Recurrent Colon Cancer; Recurrent Rectal Cancer; Signet Ring Adenocarcinoma of the Colon; Signet Ring Adenocarcinoma of the Rectum; Stage IIIA Colon Cancer; Stage IIIA Rectal Cancer; Stage IIIB Colon Cancer; Stage IIIB Rectal Cancer; Stage IIIC Colon Cancer; Stage IIIC Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,"6,8-bis(benzylthio)octanoic acid (DRUG); fluorouracil (DRUG); pharmacological study (OTHER); laboratory biomarker analysis (OTHER)",6112,Lipoec,Mucinous Adenocarcinoma of the Colon; Mucinous Adenocarcinoma of the Rectum; Recurrent Colon Cancer; Recurrent Rectal Cancer; Signet Ring Adenocarcinoma of the Colon; Signet Ring Adenocarcinoma of the Rectum; Stage IIIA Colon Cancer; Stage IIIA Rectal Cancer; Stage IIIB Colon Cancer; Stage IIIB Rectal Cancer; Stage IIIC Colon Cancer; Stage IIIC Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,Bowel,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3652,NCT01381354,"Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)",COMPLETED,PHASE1,Multiple Sclerosis,Progressive exercise (OTHER); Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV (DEVICE); Modified paleolithic diet (OTHER); Omega 3 fatty acids (DIETARY_SUPPLEMENT); Full Spectrum vitamin (DIETARY_SUPPLEMENT); Essential - hydroxytyrosol (DIETARY_SUPPLEMENT); Maltodextrin fiber supplement (DIETARY_SUPPLEMENT); Mineral boost (magnesium) (DIETARY_SUPPLEMENT); Niacinamide (DIETARY_SUPPLEMENT); Methyl B12 (DIETARY_SUPPLEMENT); Taurine (DIETARY_SUPPLEMENT); creatine (DIETARY_SUPPLEMENT); thiamine (DIETARY_SUPPLEMENT); riboflavin (DIETARY_SUPPLEMENT); N acetylcysteine (DIETARY_SUPPLEMENT); alpha lipoic acid (DIETARY_SUPPLEMENT); L acetyl carnitine (DIETARY_SUPPLEMENT); methyl folate (DIETARY_SUPPLEMENT); coenzyme Q (DIETARY_SUPPLEMENT); meditation (BEHAVIORAL); self massage (BEHAVIORAL); learning (BEHAVIORAL); Coconut oil (DIETARY_SUPPLEMENT),6112,Lipoec,Multiple Sclerosis,CNS/Brain,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3653,NCT06418347,Effect of ALA Combined with Letrozole on Polycystic Ovary Syndrome Clinical Outcome in Infertile Females,RECRUITING,PHASE3,"Polycystic Ovary Syndrome; Infertility, Female",Alpha lipoic acid (DRUG); Letrozole (DRUG),6112,Lipoec,"Polycystic Ovary Syndrome; Infertility, Female",Ovary/Fallopian Tube,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3654,NCT00676156,A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis,COMPLETED,PHASE1,Multiple Sclerosis,oral lipoic acid (LA) (DRUG); lipoic acid (LA) with fish oil and LA without fish oil (DRUG); R lipoic acid (DRUG),6112,Lipoec,Multiple Sclerosis,CNS/Brain,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3655,NCT00079807,Painful HIV Neuropathy and Alpha-Lipoic Acid,COMPLETED,PHASE1,HIV; Peripheral Neuropathy,Alpha-Lipoic Acid (DRUG),6112,Lipoec,HIV; Peripheral Neuropathy,Peripheral Nervous System,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3656,NCT01188811,Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS),COMPLETED,PHASE2,"Multiple Sclerosis, Chronic Progressive",lipoic acid (DRUG); Placebo (DRUG),6112,Lipoec,"Multiple Sclerosis, Chronic Progressive",CNS/Brain,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3657,NCT03161028,Lipoic Acid for Progressive Multiple Sclerosis (MS),COMPLETED,PHASE2,Multiple Sclerosis,Lipoic acid (DRUG); Placebo (DRUG),6112,Lipoec,Multiple Sclerosis,CNS/Brain,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3658,NCT00308971,Tocopherols and Alpha Lipoic Acid Treatment Chronic Kidney Disease (TALAT),COMPLETED,PHASE2,Chronic Kidney Disease,"Alpha, gamma, beta, and delta (mixed) tocopherols (DRUG); alpha lipoic acid (DRUG); placebo (DRUG); placebo (DRUG)",6112,Lipoec,Chronic Kidney Disease,Kidney,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3659,NCT00977483,Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2),COMPLETED,PHASE3,Diabetic Polyneuropathy,Thioctic Acid (DRUG); Placebo (DRUG),6112,Lipoec,Diabetic Polyneuropathy,Peripheral Nervous System,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3660,NCT06201611,"Evaluating a Nitric Oxide Generator, Nebivolol As a Disease Modifier in Patients with Diabetic Neuropathy.",RECRUITING,PHASE2,Diabetic Neuropathy Peripheral,Nebivolol+ Standard care arm (DRUG); Epalrestat + Alpha Lipoic Acid +Standard care (DRUG); Standard care alone (DRUG),6112,Lipoec,Diabetic Neuropathy Peripheral,Peripheral Nervous System,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3661,NCT01931787,CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer,COMPLETED,PHASE1,Recurrent Small Cell Lung Cancer,"6,8-bis(benzylthio)octanoic acid (DRUG)",6112,Lipoec,Recurrent Small Cell Lung Cancer,Lung,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3662,NCT02774226,Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease,COMPLETED,PHASE2,Chronic Obstructive Pulmonary Disease (COPD),Tetrahydrobiopterin (BH4) (DRUG); Antioxidant Cocktail (DIETARY_SUPPLEMENT),6112,Lipoec,Chronic Obstructive Pulmonary Disease (COPD),Lung,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3663,NCT06703593,Prevention of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients,RECRUITING,PHASE2,Breast Cancer Female,Alpha lipoic acid (DRUG),6112,Lipoec,Breast Cancer Female,Breast,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3664,NCT06286098,Alpha Lipoic Acid in Pediatrics on Hemodialysis,ENROLLING_BY_INVITATION,PHASE3,Hemodialysis Complication; Pediatric Kidney Disease; Cardiovascular Complication,Alpha lipoic acid (DRUG); Placebo (OTHER),6112,Lipoec,Hemodialysis Complication; Pediatric Kidney Disease; Cardiovascular Complication,Kidney,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3665,NCT05507697,Treatment With Human Umbilical Cord Mesenchymal Stem Cells for Refractory Diabetic Peripheral Neuropathy,UNKNOWN,PHASE1,Diabetic Peripheral Neuropathy Type 2,HUC-MSCs (BIOLOGICAL); Lipoic Acid (BIOLOGICAL),6112,Lipoec,Diabetic Peripheral Neuropathy Type 2,Peripheral Nervous System,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3666,NCT01978405,Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes,UNKNOWN,PHASE4,Acute Kidney Injury; The Changes of Plasma Creatinine; The Changes of Plasma Free Radicals; The Changes of Endothelium-dependent Arterial Dilation,Alpha lipoic acid (DRUG),6112,Lipoec,Acute Kidney Injury; The Changes of Plasma Creatinine; The Changes of Plasma Free Radicals; The Changes of Endothelium-dependent Arterial Dilation,Kidney,Lipoic acid,,unclear,unclear,yes,yes,"Approved as dietary supplement, not as a drug for specific indications.",C1CSSC1CCCCC(=O)O,1.24,147.0 +3667,NCT04996667,Effect of INO in Patients with Submassive and Massive PE,WITHDRAWN,PHASE2,Pulmonary Embolism; Pulmonary Embolism Subacute Massive,inhaled nitric oxide (iNO) (DRUG),5823908,IQ1,Pulmonary Embolism; Pulmonary Embolism Subacute Massive,Lung,IQ 1,,unclear,unclear,no,yes,Investigational drug; not approved for human use yet.,CC(=O)C1=CC=C(C=C1)NN=C(C2=NC(CC3=CC=CC=C32)(C)C)C(=O)N,, +3668,NCT03475186,Testing Ramipril to Prevent Memory Loss in People With Glioblastoma,COMPLETED,PHASE2,Glioblastoma; Radiotherapy; Complications; Cognitive Decline; Chemoradiation,Ramipril (DRUG),5823908,IQ1,Glioblastoma; Radiotherapy; Complications; Cognitive Decline; Chemoradiation,CNS/Brain,IQ 1,,unclear,unclear,no,yes,Investigational drug; not approved for human use yet.,CC(=O)C1=CC=C(C=C1)NN=C(C2=NC(CC3=CC=CC=C32)(C)C)C(=O)N,, +3669,NCT01390948,A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma,COMPLETED,PHASE2,High Grade Glioma,Bevacizumab (DRUG); Radiotherapy (RADIATION); Temozolomide (TMZ) (DRUG),5823908,IQ1,Glioma,CNS/Brain,IQ 1,,unclear,unclear,no,yes,Investigational drug; not approved for human use yet.,CC(=O)C1=CC=C(C=C1)NN=C(C2=NC(CC3=CC=CC=C32)(C)C)C(=O)N,, +3670,NCT02723591,To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients,COMPLETED,PHASE4,Kidney Transplantation,Tacrolimus (DRUG); Tacrolimus immediate release (DRUG),5823908,IQ1,Kidney Transplantation,Kidney,IQ 1,,unclear,unclear,no,yes,Investigational drug; not approved for human use yet.,CC(=O)C1=CC=C(C=C1)NN=C(C2=NC(CC3=CC=CC=C32)(C)C)C(=O)N,, +3671,NCT01089504,Prophylactic Phenobarbital After Neonatal Seizures,TERMINATED,PHASE4,Neonatal Seizures,phenobarbital (DRUG); placebo (DRUG),5823908,IQ1,Neonatal Seizures,CNS/Brain,IQ 1,,unclear,unclear,no,yes,Investigational drug; not approved for human use yet.,CC(=O)C1=CC=C(C=C1)NN=C(C2=NC(CC3=CC=CC=C32)(C)C)C(=O)N,, +3672,NCT00602667,"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",ACTIVE_NOT_RECRUITING,PHASE2,Brain and Central Nervous System Tumors,Induction Chemotherapy (DRUG); Low-Risk Therapy (DRUG); High-Risk Therapy (DRUG); Intermediate-Risk Therapy (DRUG),5823908,IQ1,Brain and Central Nervous System Tumors,CNS/Brain,IQ 1,,unclear,unclear,no,yes,Investigational drug; not approved for human use yet.,CC(=O)C1=CC=C(C=C1)NN=C(C2=NC(CC3=CC=CC=C32)(C)C)C(=O)N,, +3673,NCT01127165,Low and High Dose Zonisamide in Children as Monotherapy,COMPLETED,PHASE4,Epilepsy,zonisamide low dose group (DRUG); zonisamide high dose group (DRUG),5823908,IQ1,Epilepsy,CNS/Brain,IQ 1,,unclear,unclear,no,yes,Investigational drug; not approved for human use yet.,CC(=O)C1=CC=C(C=C1)NN=C(C2=NC(CC3=CC=CC=C32)(C)C)C(=O)N,, +3674,NCT04400318,The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma,COMPLETED,PHASE4,Asthma,Dupilumab (DRUG); Placebo (DRUG),5823908,IQ1,Asthma,Lung,IQ 1,,unclear,unclear,no,yes,Investigational drug; not approved for human use yet.,CC(=O)C1=CC=C(C=C1)NN=C(C2=NC(CC3=CC=CC=C32)(C)C)C(=O)N,, +3675,NCT03345550,OPTIMA-TBI Pilot Study,TERMINATED,PHASE2,Mild Traumatic Brain Injury,Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules. (DRUG); Placebo - Cap (DRUG),5823908,IQ1,Mild Traumatic Brain Injury,CNS/Brain,IQ 1,,unclear,unclear,no,yes,Investigational drug; not approved for human use yet.,CC(=O)C1=CC=C(C=C1)NN=C(C2=NC(CC3=CC=CC=C32)(C)C)C(=O)N,, +3676,NCT03181399,Diet Treatment Glucose Transporter Type 1 Deficiency (G1D),COMPLETED,PHASE2,"GLUT1DS1; Epilepsy; Glut1 Deficiency Syndrome 1, Autosomal Recessive; Glucose Metabolism Disorders; Glucose Transport Defect; Glucose Transporter Type 1 Deficiency Syndrome; Glucose Transporter Protein Type 1 Deficiency Syndrome",Triheptanoin (DRUG),5823908,IQ1,"GLUT1DS1; Epilepsy; Glut1 Deficiency Syndrome 1, Autosomal Recessive; Glucose Metabolism Disorders; Glucose Transport Defect; Glucose Transporter Type 1 Deficiency Syndrome; Glucose Transporter Protein Type 1 Deficiency Syndrome",CNS/Brain,IQ 1,,unclear,unclear,no,yes,Investigational drug; not approved for human use yet.,CC(=O)C1=CC=C(C=C1)NN=C(C2=NC(CC3=CC=CC=C32)(C)C)C(=O)N,, +3677,NCT04623242,Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.,COMPLETED,PHASE2,"Alzheimers Disease; Dementia; Alzheimers Disease, Familial",Gantenerumab (DRUG); Solanezumab (DRUG); Matching Placebo (Gantenerumab) (DRUG); Matching Placebo (Solanezumab) (DRUG),5823908,IQ1,"Alzheimers Disease; Dementia; Alzheimers Disease, Familial",CNS/Brain,IQ 1,,unclear,unclear,no,yes,Investigational drug; not approved for human use yet.,CC(=O)C1=CC=C(C=C1)NN=C(C2=NC(CC3=CC=CC=C32)(C)C)C(=O)N,, +3678,NCT02017964,"Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma",COMPLETED,PHASE2,Desmoplastic/Nodular Medulloblastoma; Medulloblastoma; Medulloblastoma With Extensive Nodularity; Nevoid Basal Cell Carcinoma Syndrome,Carboplatin (DRUG); Cognitive Assessment (OTHER); Cyclophosphamide (DRUG); Etoposide (DRUG); Laboratory Biomarker Analysis (OTHER); Methotrexate (DRUG); Vincristine Sulfate (DRUG),5823908,IQ1,Desmoplastic/Nodular Medulloblastoma; Medulloblastoma; Medulloblastoma With Extensive Nodularity; Nevoid Basal Cell Carcinoma Syndrome,Skin,IQ 1,,unclear,unclear,no,yes,Investigational drug; not approved for human use yet.,CC(=O)C1=CC=C(C=C1)NN=C(C2=NC(CC3=CC=CC=C32)(C)C)C(=O)N,, +3679,NCT03633617,Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE),COMPLETED,PHASE3,Eosinophilic Esophagitis,Dupilumab (DRUG); Placebo (DRUG),5823908,IQ1,Eosinophilic Esophagitis,Esophagus/Stomach,IQ 1,,unclear,unclear,no,yes,Investigational drug; not approved for human use yet.,CC(=O)C1=CC=C(C=C1)NN=C(C2=NC(CC3=CC=CC=C32)(C)C)C(=O)N,, +3680,NCT03582137,A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease,COMPLETED,PHASE2,Parkinson Disease,Cannabidiol (DRUG); Placebo (OTHER),5823908,IQ1,Parkinson Disease,CNS/Brain,IQ 1,,unclear,unclear,no,yes,Investigational drug; not approved for human use yet.,CC(=O)C1=CC=C(C=C1)NN=C(C2=NC(CC3=CC=CC=C32)(C)C)C(=O)N,, +3681,NCT01668654,"Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS",TERMINATED,PHASE3,Epilepsy,retigabine/ezogabine (DRUG),5823908,IQ1,Epilepsy,CNS/Brain,IQ 1,,unclear,unclear,no,yes,Investigational drug; not approved for human use yet.,CC(=O)C1=CC=C(C=C1)NN=C(C2=NC(CC3=CC=CC=C32)(C)C)C(=O)N,, +3682,NCT01147653,A Randomized Study of Autologous Umbilical Cord Blood Reinfusion in Children With Cerebral Palsy,COMPLETED,PHASE2,Cerebral Palsy; CP; Spastic Cerebral Palsy,Autologous UCB Reinfusion (BIOLOGICAL); Placebo (OTHER),5823908,IQ1,Cerebral Palsy; CP; Spastic Cerebral Palsy,CNS/Brain,IQ 1,,unclear,unclear,no,yes,Investigational drug; not approved for human use yet.,CC(=O)C1=CC=C(C=C1)NN=C(C2=NC(CC3=CC=CC=C32)(C)C)C(=O)N,, +3683,NCT05255653,Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features,RECRUITING,PHASE2,Endometrial Cancer,Olaparib (DRUG); Pelvic external beam radiotherapy (RADIATION); Chemotherapy (DRUG); Durvalumab (DRUG); Medroxyprogesterone Acetate (DRUG); Megestrol Acetate (DRUG); Vaginal brachytherapy (RADIATION); Observation (OTHER),4740,PNX,Endometrial Cancer,Uterus,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3684,NCT05194293,Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer,RECRUITING,PHASE2,Stage IB Hepatocellular Carcinoma AJCC v8; Stage II Hepatocellular Carcinoma AJCC v8; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8,Durvalumab (BIOLOGICAL); Regorafenib (DRUG),4740,PNX,Stage IB Hepatocellular Carcinoma AJCC v8; Stage II Hepatocellular Carcinoma AJCC v8; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3685,NCT01214226,Double-blind Randomized Controlled Trial in Severe Alcoholic Hepatitis,COMPLETED,PHASE3,Alcoholic Hepatitis; Alcoholic Liver Disease,Pentoxifylline (DRUG); placebo (DRUG),4740,PNX,Alcoholic Hepatitis; Alcoholic Liver Disease,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3686,NCT05583266,Efficacy of Pentoxifylline on Cerebrovascular Function in Patients With Cerebral Small Vessel Disease(PERFORM),UNKNOWN,PHASE4,Cerebral Small Vessel Diseases,Pentoxifylline sustained-release tablets (DRUG); Pentoxifylline sustained-release tablets placebo (DRUG),4740,PNX,Cerebral Small Vessel Diseases,CNS/Brain,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3687,NCT05284448,Pentoxifylline in Treatment of Patients With Nonalcoholic Steatohepatitis,COMPLETED,PHASE3,NASH - Nonalcoholic Steatohepatitis,pentoxifylline (Trental SR®) (DRUG),4740,PNX,Nonalcoholic Steatohepatitis,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3688,NCT03916068,Acute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy,TERMINATED,PHASE2,Breast Cancer,Hyperbaric Oxygen Therapy (PROCEDURE); Trental Pill (DRUG); Vitamin E (DIETARY_SUPPLEMENT),4740,PNX,Breast Cancer,Breast,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3689,NCT00188669,The Use of Pentoxifylline and Vitamin E in the Treatment of Chronic Breast Pain,TERMINATED,PHASE2,Breast Neoplasms,pentoxifylline (DRUG); alpha-Tocopherol (DRUG),4740,PNX,Breast Neoplasms,Breast,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3690,NCT06956482,PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis,NOT_YET_RECRUITING,PHASE3,Alcoholic Hepatitis,N-Acetylcysteine (NAC) Treatment (DRUG); Prednisolone (DRUG); Placebo of N-acetylcysteine (DRUG); Placebo of Prednisolone (DRUG); Prednisolone (DRUG),4740,PNX,Alcoholic Hepatitis,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3691,NCT00354731,Efficacy of Pentoxifylline on Primary Nephrotic Syndrome,COMPLETED,PHASE3,Nephrotic Syndrome,pentoxifylline (DRUG); Corticosteroid (DRUG),4740,PNX,Nephrotic Syndrome,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3692,NCT02898376,Clinical Benefit of Spa Care on Severe Radiation-induced Fibrosis After Postoperative Radiotherapy for Breast Cancer,UNKNOWN,PHASE3,Breast Carcinoma; Fibrosis,skin-oriented spa care (OTHER); Pentoxifylline (DRUG); Tocopherol acetate (DRUG),4740,PNX,Breast Carcinoma; Fibrosis,Breast,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3693,NCT01542268,Effect of Pentoxifylline on Tight Junctions (TJs) of Intestinal Mucosa in Patients With Irritable Bowel Syndrome(IBS),UNKNOWN,PHASE4,Irritable Bowel Syndrome,pentoxifylline (DRUG); pentoxifylline placebo (DRUG),4740,PNX,Irritable Bowel Syndrome,Bowel,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3694,NCT02487225,Pentoxifylline Treatment in Acute Pancreatitis (AP),COMPLETED,PHASE3,Acute Pancreatitis (AP); Gallstone Pancreatitis; Alcoholic Pancreatitis; Trauma Acute Pancreatitis; Hypertriglyceridemia Acute Pancreatitis; Idiopathic (Unknown) Acute Pancreatitis; Medication Induced Acute Pancreatitis; Cancer Acute Pancreatitis; Miscellaneous (i.e. Acute on Chronic Pancreatitis),Pentoxifylline (DRUG); Placebo (DRUG),4740,PNX,Acute Pancreatitis (AP); Gallstone Pancreatitis; Alcoholic Pancreatitis; Trauma Acute Pancreatitis; Hypertriglyceridemia Acute Pancreatitis; Idiopathic (Unknown) Acute Pancreatitis; Medication Induced Acute Pancreatitis; Cancer Acute Pancreatitis; Miscellaneous (i.e. Acute on Chronic Pancreatitis),Pancreas,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3695,NCT06176339,"Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients""",ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer Female,Pentoxifylline Oral Tablet (DRUG); Placebo (DRUG),4740,PNX,Breast Cancer Female,Breast,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3696,NCT01269827,Pentoxifylline and Systemic Inflammation in Hemodialysis Patients,COMPLETED,PHASE4,Inflammation; End-stage Renal Disease; Hemodialysis,Pentoxifylline (DRUG); starch tablets (DRUG),4740,PNX,Inflammation; End-stage Renal Disease; Hemodialysis,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3697,NCT05637086,Clinical Study Evaluating Safety of Pentoxifylline and Celecoxib in Patients With Grand-Mal Epilepsy Treated by Phenytoin Monotherapy,RECRUITING,PHASE2,Epilepsy,Phenytoin (DRUG); Pentoxifylline 400 MG (DRUG); Celecoxib 200mg (DRUG),4740,PNX,Epilepsy,CNS/Brain,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3698,NCT00019058,Radiation Therapy in Treating Patients With Glioblastoma,COMPLETED,PHASE1,Brain and Central Nervous System Tumors,chemotherapy (DRUG); hydroxyurea (DRUG); pentoxifylline (DRUG); radiation therapy (RADIATION),4740,PNX,Brain and Central Nervous System Tumors,CNS/Brain,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3699,NCT05231980,Efficacy of Pentoxifylline and Alpha Lipoic Acid in PCOS Resistant to Clomiphene Citrate,COMPLETED,PHASE2,Clomiphene Citrate; Resistant Ovary Syndrome; Polycystic Ovary Syndrome,Alpha lipoic acid (ALA) (DIETARY_SUPPLEMENT); Pentoxifylline (PTX) (DRUG); Clomiphene Citrate (DRUG),4740,PNX,Clomiphene Citrate; Resistant Ovary Syndrome; Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3700,NCT06903689,Pentoxifylline for Vascular Calcification in Kidney Disease,NOT_YET_RECRUITING,PHASE1,"Chronic Kidney Disease; Vascular Calcification; Kidney Failure, Chronic",Pentoxifylline 400 MG Oral Tablet (DRUG); Conventional Medications for Chronic Kidney Disease (OTHER),4740,PNX,"Chronic Kidney Disease; Vascular Calcification; Kidney Failure, Chronic",Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3701,NCT00635960,Growth Hormone in Amyotrophic Lateral Sclerosis,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,Growth Hormone (Somatropin) (DRUG); Placebo (DRUG),4740,PNX,Amyotrophic Lateral Sclerosis,CNS/Brain,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3702,NCT05189535,"""Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients""",COMPLETED,PHASE2,Breast Cancer Female; Peripheral Neuropathy,Pentoxifylline (DRUG); Paclitaxel (DRUG); Placebo (DRUG),4740,PNX,Breast Cancer Female; Peripheral Neuropathy,Breast,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3703,NCT02283710,The Effect of Pentoxifylline on Liver Function Tests in Fatty Liver Disease,COMPLETED,PHASE2,Fatty Liver,Pentoxifylline (DRUG); Lifestyle modification (BEHAVIORAL),4740,PNX,Fatty Liver,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3704,NCT00155246,Efficacy of Pentoxifylline on Chronic Kidney Disease,COMPLETED,PHASE4,Chronic Kidney Disease,pentoxifylline (drug) (DRUG),4740,PNX,Chronic Kidney Disease,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3705,NCT00771446,Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency,COMPLETED,PHASE1,Acute Hepatitis; Chronic Hepatitis,ELAD plus standard of care treatment (BIOLOGICAL); Standard of care treatment (OTHER),4740,PNX,Acute Hepatitis; Chronic Hepatitis,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3706,NCT00022204,Vitamin E and Pentoxifylline in Treating Women With Lymphedema After Radiation Therapy for Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Lymphedema,vitamin E (DIETARY_SUPPLEMENT); pentoxifylline (DRUG); quality-of-life assessment (PROCEDURE),4740,PNX,Breast Cancer; Lymphedema,Breast,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3707,NCT01149304,"Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity",COMPLETED,PHASE2,Colorectal Cancer; Liver Metastases; Irradiation Damage; Radiation Induced Liver Disease,Pentoxifylline (DRUG); Ursodeoxycholic Acid (DRUG); Enoxaparin (DRUG),4740,PNX,Colorectal Cancer; Liver Metastases; Irradiation Damage; Radiation Induced Liver Disease,Bowel,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3708,NCT01673204,Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy,UNKNOWN,PHASE4,Diabetic Nephropathy,Calcitriol (DRUG); Placebo (DRUG),4740,PNX,Diabetic Nephropathy,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3709,NCT06265389,Pentoxifylline as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia; A New Perspective of an Old Drug,NOT_YET_RECRUITING,PHASE4,Pentoxifylline as an Adjunct Therapy in the Treatment of Pneumonia,Pentoxifylline Oral Tablet (DRUG),4740,PNX,Pentoxifylline as an Adjunct Therapy in the Treatment of Pneumonia,Lung,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3710,NCT01249092,Pentoxifylline for Primary Biliary Cirrhosis,COMPLETED,PHASE2,Primary Biliary Cirrhosis,Pentoxifylline (DRUG),4740,PNX,Primary Biliary Cirrhosis,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3711,NCT00593658,Pilot Study of Pentoxifylline for Hepatopulmonary Syndrome,TERMINATED,PHASE1,Hepatopulmonary Syndrome,pentoxifylline (DRUG),4740,PNX,Hepatopulmonary Syndrome,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3712,NCT05897372,Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study,TERMINATED,PHASE2,Diabetic Kidney Disease,"ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib (DRUG)",4740,PNX,Chronic Kidney Disease,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3713,NCT02473341,Efficacy Of Bovine Colostrum In The Treatment Of Severe Alcohol-Associated Hepatitis,ACTIVE_NOT_RECRUITING,PHASE3,Alcoholic Hepatitis,Bovine Colostrum (DRUG); Placebo (DRUG),4740,PNX,Alcoholic Hepatitis,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3714,NCT02687841,A Uremic Toxin Absorbent (AST-120) to Treat Hospital Acquired Acute Kidney Injury,UNKNOWN,PHASE3,Acute Kidney Injury,AST-120and pentoxyphylline (PTX) (DRUG); pentoxyphylline (PTX) (DRUG),4740,PNX,Acute Kidney Injury,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3715,NCT03731741,Does Oral Pentoxifylline Administration Improve Hemoglobin in Hemodialysis Patients?,COMPLETED,PHASE2,Anemia of Chronic Kidney Disease,Pentoxifylline (DRUG),4740,PNX,Anemia of Chronic Kidney Disease,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3716,NCT03664414,Pentoxifylline Effect in Patients With Diabetic Nephropathy.(PENFOSIDINE STUDY),UNKNOWN,PHASE4,Chronic Kidney Disease stage3 and 4; Type 2 Diabetes Mellitus,pentoxifylline (DRUG),4740,PNX,Chronic Kidney Disease stage3 and 4; Type 2 Diabetes Mellitus,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3717,NCT05487755,Investigational and Comparative Study in the Management of Diabetic Nephropathy,COMPLETED,PHASE3,Diabetic Nephropathy Type 2,Tadalafil 20Mg Oral Tablet (DRUG); Pentoxifylline 400 MG Oral Tablet (DRUG),4740,PNX,Diabetic Nephropathy Type 2,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3718,NCT00205049,Pentoxifylline for Acute Alcoholic Hepatitis (AAH),TERMINATED,PHASE1,"Hepatitis, Alcoholic",pentoxifylline (DRUG),4740,PNX,"Hepatitis, Alcoholic",Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3719,NCT00663949,Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy,COMPLETED,PHASE2,Diabetic Nephropathy,Captopril (DRUG); Captopril + Pentoxifylline (DRUG),4740,PNX,Diabetic Nephropathy,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3720,NCT03859570,Pentoxifylline in Lupus Nephritis,WITHDRAWN,PHASE4,Lupus Nephritis,Pentoxifylline (DRUG); Placebos (DRUG),4740,PNX,Lupus Nephritis,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3721,NCT00267670,Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH,COMPLETED,PHASE2,Nonalcoholic Steatohepatitis; Liver Diseases,Pentoxifylline (DRUG); Placebo (DRUG),4740,PNX,Nonalcoholic Steatohepatitis; Liver Diseases,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3722,NCT02951299,The Protective Effect of Pentoxifylline on Acute Kidney Injury,UNKNOWN,PHASE2,Pentoxifylline; Acute Kidney Injury,Pentoxifylline 400Mg Tablet (DRUG),4740,PNX,Pentoxifylline; Acute Kidney Injury,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3723,NCT02485106,Rifaximin Use in Severe Alcoholic Hepatitis,UNKNOWN,PHASE3,Severe Alcoholic Hepatitis,Rifaximin (DRUG); Corticosteroid or pentoxifylline (DRUG),4740,PNX,Severe Alcoholic Hepatitis,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3724,NCT01328821,"Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499",COMPLETED,PHASE1,Diabetic Nephropathy,CTP-499 (DRUG); CTP-499 (DRUG),4740,PNX,Diabetic Nephropathy,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3725,NCT03625648,Pentoxifylline in Diabetic Kidney Disease,RECRUITING,PHASE4,Diabetic Kidney Disease,Pentoxifylline (DRUG); Placebo (DRUG),4740,PNX,Chronic Kidney Disease,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3726,NCT00271336,Pentoxifylline in the Treatment of NEC in Premature Neonates,UNKNOWN,PHASE2,Necrotizing Enterocolitis,Pentoxifylline (DRUG),4740,PNX,Necrotizing Enterocolitis,Bowel,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3727,NCT02776059,Pegfilgrastim in Patients With Alcoholic Hepatitis,COMPLETED,PHASE2,Alcoholic Hepatitis,Standard of care + pegfiltrastim (DRUG); Standard of care (DRUG),4740,PNX,Alcoholic Hepatitis,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3728,NCT00973817,Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis,COMPLETED,PHASE2,Acute On Chronic Hepatitis,ELAD plus standard of care treatment (BIOLOGICAL); Standard of care (OTHER),4740,PNX,Acute On Chronic Hepatitis,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3729,NCT01102218,A Safety Study of Pentoxifylline for the Treatment of Anemia,TERMINATED,PHASE2,End Stage Renal Disease,Erythropoietin (DRUG); Erythropoietin (DRUG); Pentoxifylline (DRUG),4740,PNX,End Stage Renal Disease,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3730,NCT06186700,Effect of Pentoxifylline on Preventing Chemotherapy-induced Toxicities in Patients with Breast Cancer,COMPLETED,PHASE2,Breast Cancer Female; Breast Cancer Patients; Neoadjuvant Therapy; Doxorubicin; Taxane-induced Peripheral Neuropathy,Pentoxifylline 400mg plus chemotherapy (DRUG); Chemotherapy (DRUG),4740,PNX,Breast Cancer Female; Breast Cancer Patients; Neoadjuvant Therapy; Doxorubicin; Taxane-induced Peripheral Neuropathy,Breast,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3731,NCT00162552,Clinical Trial of Pentoxifylline in Patient With Cirrhosis,COMPLETED,PHASE3,Cirrhosis; Liver Failure,pentoxifylline (DRUG); PLACEBO (DRUG),4740,PNX,Cirrhosis; Liver Failure,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3732,NCT03006952,Add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on NT-PRO BNP in Type 2 Diabetics With Nephropathy,COMPLETED,PHASE4,Diabetic Nephropathies,Pentoxifylline (DRUG); Losartan (DRUG),4740,PNX,Diabetic Nephropathies,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3733,NCT06422000,Effect of Pentoxifylline Versus Probiotic on Preterm Neonates With Necrotizing Enterocolitis,COMPLETED,PHASE3,Necrotizing Enterocolitis,Pentoxifylline (DRUG); Probiotic Formula (DRUG),4740,PNX,Necrotizing Enterocolitis,Bowel,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3734,NCT06421870,Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients,RECRUITING,PHASE3,Chronic Kidney Diseases,Dapagliflozin 10mg Tab (DRUG); Pentoxifylline 400 MG (DRUG),4740,PNX,Chronic Kidney Diseases,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3735,NCT05387187,Evaluate the Effect and Safety of Pu Yang Wan Wu Tang and Western Medicine on Chronic Kidney Disease,ENROLLING_BY_INVITATION,PHASE2,Chronic Kidney Diseases,Pu Yang Wan Wu Tang plus Pentoxifylline (DRUG); Pentoxifylline (DRUG),4740,PNX,Chronic Kidney Diseases,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3736,NCT01774487,Pentoxifylline Therapy in Biliary Atresia,TERMINATED,PHASE2,Biliary Atresia,Pentoxifylline (DRUG),4740,PNX,Biliary Atresia,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3737,NCT05284656,Effect of Folic Acid and/or Pentoxifylline on Patients With Chronic Kidney Disease,UNKNOWN,PHASE3,Chronic Kidney Diseases,combination of Pentoxifylline 400 MG and Folic Acid (DRUG); folic acid (DRUG); Pentoxifylline 400 MG (DRUG),4740,PNX,Chronic Kidney Diseases,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3738,NCT02953275,Synergistic Effect of Vedolizumab and Pentoxifylline,COMPLETED,EARLY_PHASE1,Crohn Disease,vedolizumab (DRUG); Pentoxifylline (DRUG); placebo (DRUG),4740,PNX,Crohn Disease,Bowel,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3739,NCT01377285,Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD),UNKNOWN,PHASE4,Chronic Renal Failure,ARB (DRUG); Pentoxifylline (DRUG); Placebo (for Pentoxifylline) (DRUG),4740,PNX,Chronic Renal Failure,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3740,NCT06087237,The Efficacy of Using Pentoxifylline in Patients Undergoing Breast Cancer Surgery,RECRUITING,PHASE2,Post-Surgical Complication; Breast Cancer Surgery,Pentoxifylline (DRUG); Placebo (DRUG),4740,PNX,Post-Surgical Complication; Breast Cancer Surgery,Breast,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3741,NCT01455337,Short-term Survival in Patients With Severe Alcoholic Hepatitis Treated With Steroid Versus Pentoxifylline,UNKNOWN,PHASE3,Alcoholic Hepatitis,pentoxifylline (DRUG); Prednisolone (DRUG),4740,PNX,Alcoholic Hepatitis,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3742,NCT02971306,G-CSF Plus NAC In Severe Alcoholic Hepatitis,UNKNOWN,PHASE4,Alcoholic Hepatitis,standard medical therapy (DRUG); G-CSF (DRUG); n-Acetylcysteine (DRUG),4740,PNX,Alcoholic Hepatitis,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3743,NCT00001877,Treatment of Pulmonary Sarcoidosis With Pentoxifylline,COMPLETED,PHASE2,Pulmonary Sarcoidosis,Pentoxifylline (DRUG),4740,PNX,Pulmonary Sarcoidosis,Lung,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3744,NCT04217733,Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome,RECRUITING,PHASE3,IBS - Irritable Bowel Syndrome,pentoxyifylline (DRUG); Mebeverine (DRUG); ethosuximide (DRUG),4740,PNX,Irritable Bowel Syndrome,Bowel,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3745,NCT02161653,Metadoxine as a Therapy for Severe Alcoholic Hepatitis,COMPLETED,PHASE4,Severe Alcoholic Hepatitis,Prednisone plus Metadoxine (DRUG); Pentoxifylline plus Metadoxine (DRUG),4740,PNX,Severe Alcoholic Hepatitis,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3746,NCT01809132,"Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis",COMPLETED,PHASE2,Acute Alcoholic Hepatitis,Anakinra (DRUG); Pentoxifylline (DRUG); Zinc Sulfate (DRUG); Methylprednisolone (DRUG),4740,PNX,Acute Alcoholic Hepatitis,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3747,NCT06634056,Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation,NOT_YET_RECRUITING,PHASE2,Non-Small Cell Lung Cancer; Radiation Induced Lung Injury (RILI),Pentoxifylline (DRUG); Placebo (OTHER); α-Tocopherol (OTHER),4740,PNX,Non-Small Cell Lung Cancer; Radiation Induced Lung Injury (RILI),Lung,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3748,NCT04356209,"Improving Theempowerment in Patients With Severe Breast Fibrosis Radio-induced Treated by Pravastatin : Benefit of e-PROs (Electronic "" Patient Reported Outcome "") on Breast-related Quality of Life",RECRUITING,PHASE2,Breast Cancer,e-PRO Intervention (OTHER); Pravastatin (DRUG),4740,PNX,Breast Cancer,Breast,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3749,NCT00590161,Pentoxifylline in Patients With Nonalcoholic Steatohepatitis,COMPLETED,PHASE2,Nonalcoholic Steatohepatitis,pentoxifylline (PTX) (DRUG); placebo (DRUG),4740,PNX,Nonalcoholic Steatohepatitis,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3750,NCT05558761,Pentoxifylline as Adjunctive Therapy in Patients With Ulcerative Colitis,RECRUITING,PHASE2,Inflammatory Bowel Diseases,Pentoxifylline 400 MG (DRUG),4740,PNX,Inflammatory Bowel Diseases,Bowel,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3751,NCT01384578,Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis,WITHDRAWN,PHASE3,Non Alcoholic Steatohepatitis,pentoxiphylline and Vitamin E (DRUG); Vitamin E (DRUG),4740,PNX,Non-Alcoholic Steatohepatitis,Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3752,NCT00632697,Pentoxifylline and Endometriosis,COMPLETED,PHASE3,Endometriosis-Associated Infertility,pentoxifylline (DRUG); placebo (DRUG),4740,PNX,Endometriosis-Associated Infertility,Uterus,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3753,NCT00561093,Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients,COMPLETED,PHASE3,Hypoalbuminemia; Protein-energy Malnutrition; Inflammation; Oxidative Stress; Chronic Kidney Disease (CKD) Hemodialysis,pentoxiphylline (DRUG); Nepro (DIETARY_SUPPLEMENT); anti-inflammatory module (similar to Oxepa) (DIETARY_SUPPLEMENT); Placebo pill imitating pentoxiphylline (DRUG); Placebo to imitate Nepro (DIETARY_SUPPLEMENT); Placebo to imitate anti-inflammatory module (similar to Oxepa) (DIETARY_SUPPLEMENT),4740,PNX,Hypoalbuminemia; Protein-energy Malnutrition; Inflammation; Oxidative Stress; Chronic Kidney Disease (CKD) Hemodialysis,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3754,NCT01292005,Pentoxifylline Treatment of Acute Pancreatitis,COMPLETED,EARLY_PHASE1,Acute Pancreatitis,Pentoxifylline (DRUG); Placebo (DRUG),4740,PNX,Acute Pancreatitis,Pancreas,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3755,NCT06115174,Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer,NOT_YET_RECRUITING,PHASE4,Metastatic Colorectal Carcinoma,Pentoxifylline (DRUG); FOLFOX (RADIATION); XELOX (RADIATION); Monoclonal antibodies (target therapy) (DRUG),4740,PNX,Metastatic Colorectal Carcinoma,Bowel,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3756,NCT05962957,Role of Pentoxifylline and Celecoxib in Parkinsonism,RECRUITING,PHASE2,Parkinson Disease,carbidopa-levodopa (DRUG); Pentoxifylline 400 MG (DRUG); Celecoxib 200mg (DRUG),4740,PNX,Parkinson Disease,CNS/Brain,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3757,NCT02992678,Pentoxifylline for the Prevention of PEP,UNKNOWN,EARLY_PHASE1,Pancreatitis,Pentoxifylline (DRUG); Placebo (DRUG),4740,PNX,Pancreatitis,Pancreas,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3758,NCT04977661,"Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients",COMPLETED,PHASE4,Nonalcoholic Steatohepatitis (NASH),Vitamin E (DRUG); Ursodeoxycholic acid (DRUG); Pentoxifylline (DRUG),4740,PNX,Nonalcoholic Steatohepatitis (NASH),Liver,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3759,NCT05575505,"Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.",RECRUITING,PHASE2,Inflammatory Bowel Diseases,Pentoxifylline 400 MG (DRUG),4740,PNX,Inflammatory Bowel Diseases,Bowel,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3760,NCT00354198,Efficacy of Pentoxifylline on Rapidly Progressive Glomerulonephritis,TERMINATED,PHASE3,Glomerulonephritis,pentoxifylline (DRUG); corticosteroids (DRUG),4740,PNX,Glomerulonephritis,Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3761,NCT00285298,Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients,COMPLETED,PHASE3,"Kidney Failure, Chronic",Pentoxifylline (DRUG); Placebo (DRUG),4740,PNX,"Kidney Failure, Chronic",Kidney,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3762,NCT01871454,Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers,RECRUITING,PHASE2,Non-small Cell Lung Cancers,stereotactic ablative radiotherapy (SABR) (RADIATION); Pentoxifylline (DRUG),4740,PNX,Non-small Cell Lung Cancers,Lung,Pentoxifylline,,inhibitor/antagonist,unclear,yes,yes,Used to improve blood flow in peripheral artery disease.,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1.22,202.0 +3763,NCT02295826,Dabigatran Following Transient Ischemic Attack and Minor Stroke,COMPLETED,PHASE2,Transient Ischemic Attack; Minor Ischemic Stroke,Dabigatran (DRUG); Acetylsalicylic acid (DRUG),2244,ASA,Transient Ischemic Attack and Minor Ischemic Stroke,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3764,NCT05336266,A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,Pancreas Cancer; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer,Ketorolac Tromethamine (DRUG),2244,ASA,Pancreas Cancer; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer,Pancreas,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3765,NCT04224857,"SAD/MAD Study in Healthy Subjects and Adults With UC to Evaluate Safety, Tolerability, PK, PD of AMT-101",COMPLETED,PHASE1,Ulcerative Colitis,AMT-101 (DRUG); Placebos (DRUG),2244,ASA,Ulcerative Colitis,Bowel,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3766,NCT03070574,Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome,TERMINATED,PHASE2,Colorectal Cancer,mesalamine 2400 MG (5-ASA) (DRUG); mesalamine 1200 MG (DRUG); Placebo (OTHER),2244,ASA,Colorectal Cancer,Bowel,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3767,NCT01763320,China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis,COMPLETED,PHASE3,Ischemic Stroke,Intracranial stenting group (PROCEDURE); medical group (DRUG),2244,ASA,Ischemic Stroke,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3768,NCT01994720,[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES],COMPLETED,PHASE3,Acute Ischaemic Stroke; Transient Ischaemic Attack,ticagrelor (DRUG); Acetylsalicylic acid (ASA) (DRUG),2244,ASA,Acute Ischaemic Stroke; Transient Ischaemic Attack,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3769,NCT02774265,A Different Approach to Preventing Thrombosis,COMPLETED,PHASE3,Venous Thromboembolism; Pulmonary Embolism,VTE prophylaxis with Enoxaparin 30mg BID (DRUG); VTE prophylaxis with Aspirin 81mg BID (DRUG),2244,ASA,Venous Thromboembolism; Pulmonary Embolism,Lung,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3770,NCT04219774,NeuroCognition After Carotid Recanalization,COMPLETED,PHASE2,Cognition Disorder; Stroke; Occlusion Carotid,Endovascular intervention (PROCEDURE); Aspirin and Clopidogrel (maximal medical Therapy) (DRUG),2244,ASA,Cognition Disorder; Stroke; Occlusion Carotid,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3771,NCT00251966,ASTERIX: Low Dose ASA and Nexium,COMPLETED,PHASE3,Gastroesophageal Reflux,Esomeprazole (DRUG),2244,ASA,Gastroesophageal Reflux,Esophagus/Stomach,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3772,NCT00816166,VISSIT Intracranial Stent Study for Ischemic Therapy,TERMINATED,PHASE2,Ischemic Stroke; Transient Ischemic Attack,Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel) (DEVICE); Aspirin and Clopidogrel (Medical therapy) (DRUG),2244,ASA,Ischemic Stroke,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3773,NCT05700266,Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis,NOT_YET_RECRUITING,PHASE2,Ischemic Stroke; Intracranial Atherosclerosis; Stenosis,Rivaroxaban (DRUG); Clopidogrel (DRUG); Aspirin (DRUG); Risk Factor Management in both arms (OTHER),2244,ASA,Ischemic Stroke; Intracranial Atherosclerosis; Stenosis,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3774,NCT00000527,Recurrent Carotid Stenosis,COMPLETED,PHASE2,Cardiovascular Diseases; Carotid Stenosis; Cerebrovascular Disorders; Heart Diseases; Vascular Diseases,aspirin (DRUG); dipyridamole (DRUG),2244,ASA,Cardiovascular Diseases; Carotid Stenosis; Cerebrovascular Disorders; Heart Diseases; Vascular Diseases,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3775,NCT06102720,Efficacy of Colchicine in Preventing Recurrent Stroke in the Patients With Acute Atherothrombotic Ischemic Stroke During Hospitalization,RECRUITING,PHASE4,Ischemic Stroke,Colchicine (DRUG); Clopidogrel (DRUG),2244,ASA,Ischemic Stroke,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3776,NCT00408174,Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis,COMPLETED,PHASE3,Inflammatory Bowel Disease; Ulcerative Colitis,Balsalazide disodium (DRUG),2244,ASA,Inflammatory Bowel Disease; Ulcerative Colitis,Bowel,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3777,NCT02239120,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),COMPLETED,PHASE3,Stroke; Secondary Prevention,optional ASA as comedication (DRUG); placebo to ASA (DRUG); placebo to optional ASA as comedication (DRUG); placebo to dabigatran etexilate (DRUG); ASA 100 mg (DRUG); dabigatran etexilate (DRUG),2244,ASA,Stroke; Secondary Prevention,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3778,NCT02224131,Study of Antiplatelet Therapy for Intracranial Aneurysm Stent-assisted Coiling,UNKNOWN,PHASE4,Embolic Stroke,Aspirin and clopidogrel (DRUG); Aspirin and clopidogrel (DRUG),2244,ASA,Embolic Stroke,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3779,NCT00947531,A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia,COMPLETED,PHASE4,Vascular Dementia,Cerebrolysin (DRUG); 0.9% Saline Solution (DRUG),2244,ASA,Vascular Dementia,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3780,NCT02963831,A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies,COMPLETED,PHASE1,Colorectal Cancer; Ovarian Cancer; Appendiceal Cancer,ONCOS-102 (BIOLOGICAL); Durvalumab (DRUG); Cyclophosphamide (DRUG),2244,ASA,Colorectal Cancer; Ovarian Cancer; Appendiceal Cancer,Bowel,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3781,NCT06644573,Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia,NOT_YET_RECRUITING,PHASE1,"Chronic Insomnia; Sleep Deprivation; REM Behavior Disorder; REM Sleep Behavior Disorder; REM Sleep Measurement; Insomnia; Insomnia Related to Specified Disorder; Insomnia Due to Other Mental Disorder; Insomnia Comorbid to Psychiatric Disorder; Insomnia Due to Anxiety and Fear; Insomnia Related to Another Mental Condition; Insomnia Disorders; Idiopathic Hypersomnia; Sleep Disorders, Circadian Rhythm; Post Trauma Nightmares; PTSD - Post Traumatic Stress Disorder; Sleep Quality; Anesthesia; Anxiety; Depression; Mental Health; Alzheimer Disease or Associated Disorder; Parkinsons; Circadian Rhythm; Circadian Dysregulation; PTSD; Post-Traumatic; Post-Traumatic Stress Disorder Complex; Military Combat Stress Reaction; Sleep; Military Activity; Veterans; Shift Work Sleep Disorder; Menopause Related Conditions; Pain; Cancer Pain; Athletes","PROSOMNIA Sleep Therapy™ (PSTx) (PROCEDURE); Anesthesia-Induced Sleep Therapy (PROCEDURE); Diprivan (propofol), Astra-Zeneca (DRUG); Continuous EEG Monitoring (DEVICE)",2244,ASA,"Chronic Insomnia; Sleep Deprivation; REM Behavior Disorder; REM Sleep Behavior Disorder; REM Sleep Measurement; Insomnia; Insomnia Related to Specified Disorder; Insomnia Due to Other Mental Disorder; Insomnia Comorbid to Psychiatric Disorder; Insomnia Due to Anxiety and Fear; Insomnia Related to Another Mental Condition; Insomnia Disorders; Idiopathic Hypersomnia; Sleep Disorders, Circadian Rhythm; Post Trauma Nightmares; PTSD - Post Traumatic Stress Disorder; Sleep Quality; Anesthesia; Anxiety; Depression; Mental Health; Alzheimer Disease or Associated Disorder; Parkinsons; Circadian Rhythm; Circadian Dysregulation; PTSD; Post-Traumatic; Post-Traumatic Stress Disorder Complex; Military Combat Stress Reaction; Sleep; Military Activity; Veterans; Shift Work Sleep Disorder; Menopause Related Conditions; Pain; Cancer Pain; Athletes",CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3782,NCT04607057,Supplemental Parenteral Nutrition During Postgastrectomy in Nutritionally at Risk Patient,UNKNOWN,PHASE4,Gastric Cancer; Gastrectomy; Malnutrition,Parenteral Nutrition Solutions (DRUG),2244,ASA,Gastric Cancer; Gastrectomy; Malnutrition,Esophagus/Stomach,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3783,NCT01532648,Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA),COMPLETED,PHASE3,Ulcerative Colitis,Budesonide MMX® (DRUG); Placebo (DRUG); 5-ASA (DRUG),2244,ASA,Ulcerative Colitis,Bowel,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3784,NCT02467582,Adjuvant Aspirin Treatment for Colon Cancer Patients,COMPLETED,PHASE3,Colon Cancer,Aspirin (DRUG); Placebo (DRUG),2244,ASA,Colon Cancer,Bowel,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3785,NCT03804931,Fecal Microbiota Transplantation for Ulcerative Colitis,RECRUITING,PHASE2,Ulcerative Colitis; Fecal Microbiota Transplantation,Fecal microbiota transplantation (PROCEDURE); Infusion of Saline (PROCEDURE); 5-Aminosalicylic acid(5-ASA) and/or Prednisone (DRUG),2244,ASA,Ulcerative Colitis; Fecal Microbiota Transplantation,Bowel,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3786,NCT06016920,Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma,RECRUITING,PHASE1,HPV Positive Oropharyngeal Squamous Cell Carcinoma; HNSCC,VB10.16 (BIOLOGICAL); Pembrolizumab (DRUG),2244,ASA,HPV Positive Oropharyngeal Squamous Cell Carcinoma; HNSCC,Skin,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3787,NCT00357682,"A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia",COMPLETED,PHASE3,Esophageal Cancer; Precancerous Condition,Esomeprazole (DRUG); Esomeprazole (DRUG); Aspirin (DRUG),2244,ASA,Esophageal Cancer; Precancerous Condition,Esophagus/Stomach,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3788,NCT03813303,Comparison of Post Anesthetic Recovery Time in Sedated Patients for Colonoscopy,COMPLETED,PHASE4,Colonoscopy; Anesthesia,Midazolam (DRUG); Fentanyl (DRUG); Propofol (DRUG),2244,ASA,Colonoscopy; Anesthesia,Bowel,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3789,NCT06591390,Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA,RECRUITING,PHASE3,Ischemic Stroke,Ticagrelor 90 MG (DRUG); Cilostazol 100 MG (DRUG),2244,ASA,Ischemic Stroke,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3790,NCT01988103,Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis,COMPLETED,PHASE2,Psoriasis; Psoriatic Arthritis; Psoriasis Arthropatica,Apremilast (DRUG); Apremilast (DRUG); Placebo (DRUG),2244,ASA,Psoriasis; Psoriatic Arthritis; Psoriasis Arthropatica,Skin,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3791,NCT04214990,Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients,RECRUITING,PHASE3,Aspirin; Gastric Cancer,Aspirin 100mg (DRUG); Placebo oral tablet (DRUG),2244,ASA,Aspirin; Gastric Cancer,Esophagus/Stomach,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3792,NCT04950790,Study on the Effectiveness and Safety of Shuxinin Injection in the Treatment of Acute Ischemic Stroke,UNKNOWN,PHASE4,Acute Ischemic Stroke,Shuxinin injection (DRUG); Basic treatment (DRUG); Placebo (DRUG),2244,ASA,Acute Ischemic Stroke,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3793,NCT05205603,Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis,RECRUITING,PHASE4,"Ulcerative Colitis; Efficacy, Self; Biologics; Mesalazine",Infliximab (DRUG); Vedolizumab (DRUG); Mesalazine (DRUG),2244,ASA,"Ulcerative Colitis; Efficacy, Self; Biologics; Mesalazine",Bowel,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3794,NCT01932203,Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease,UNKNOWN,PHASE4,Cerebral Small Vessel Disease,aspirin (DRUG); cilostazol (DRUG),2244,ASA,Cerebral Small Vessel Disease,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3795,NCT00474903,Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus,COMPLETED,PHASE2,Barrett Esophagus; Esophageal Cancer,acetylsalicylic acid (DRUG); esomeprazole magnesium (DRUG); placebo (OTHER),2244,ASA,Barrett Esophagus; Esophageal Cancer,Esophagus/Stomach,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3796,NCT03329690,DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01],COMPLETED,PHASE2,"Neoplasm, Gastrointestinal",DS-8201a (DRUG); Physician's Choice (DRUG),2244,ASA,Gastrointestinal Neoplasm,Bowel,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3797,NCT04425590,The Benefit of Add On DLBS1033 for Ischemic Stroke Patient,UNKNOWN,PHASE2,Ischemic Stroke,DLBS1033 (DRUG); Aspirin (DRUG); Statin (DRUG); Vit B12 (DRUG),2244,ASA,Ischemic Stroke,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3798,NCT04259138,Determination of the Optimal Treatment Target in Ulcerative Colitis,ACTIVE_NOT_RECRUITING,PHASE4,"Colitis, Ulcerative",Treatment Algorithm A (BIOLOGICAL); Treatment Algorithm B (BIOLOGICAL); Treatment Algorithm C (BIOLOGICAL),2244,ASA,"Colitis, Ulcerative",Bowel,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3799,NCT06469138,A Study to Investigate 14C-bemcentinib in Healthy Male Subjects,COMPLETED,PHASE1,Non-Small Cell Lung Cancer; Metastatic Melanoma; Acute Myeloid Leukemia; Myelodysplastic Syndromes; Metastatic Pancreatic Cancer; Glioblastoma; Malignant Mesothelioma; COVID-19,Bemcentinib (DRUG),2244,ASA,Non-Small Cell Lung Cancer; Metastatic Melanoma; Acute Myeloid Leukemia; Myelodysplastic Syndromes; Metastatic Pancreatic Cancer; Glioblastoma; Malignant Mesothelioma; COVID-19,Lung,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3800,NCT00041938,Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial,COMPLETED,PHASE3,Heart Disease; Stroke; Ischemic Heart Disease; Myocardial Infarction,aspirin (DRUG); Warfarin (DRUG),2244,ASA,Heart Disease; Stroke; Ischemic Heart Disease; Myocardial Infarction,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3801,NCT02294643,Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' Study,COMPLETED,PHASE3,"Coronary Artery Disease; Diabetes Mellitus; Renal Insufficiency, Chronic",Sarpogrelate (DRUG); Aspirin (DRUG); Clopidogrel (DRUG); Placebo (for Sarpogrelate) (DRUG),2244,ASA,"Coronary Artery Disease; Diabetes Mellitus; Renal Insufficiency, Chronic",Kidney,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3802,NCT05604638,Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke,NOT_YET_RECRUITING,PHASE4,Acute Ischemic Stroke,Tenecteplase plus Tirofiban (DRUG); Tenecteplase plus Placebo (DRUG),2244,ASA,Acute Ischemic Stroke,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3803,NCT00957112,"Acupuncture or Self-Acupuncture in Managing Cancer-Related Fatigue in Women Who Have Received Chemotherapy for Stage I, Stage II, or Stage IIIA Breast Cancer",COMPLETED,PHASE3,Anxiety Disorder; Breast Cancer; Depression; Fatigue,acupuncture therapy (PROCEDURE); standard follow-up care (PROCEDURE),2244,ASA,Anxiety Disorder; Breast Cancer; Depression; Fatigue,Breast,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3804,NCT02350543,Peri-operative Aspirin Continuation Versus Discontinuation,TERMINATED,PHASE4,Hematuria; Urinary Bladder Neoplasms,Aspirin (DRUG),2244,ASA,Hematuria; Urinary Bladder Neoplasms,Bladder/Urinary Tract,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3805,NCT00533364,Effect of SBG in Patients With Breast Cancer,COMPLETED,PHASE1,Breast Cancer,SBG (Soluble beta-glucan) (DRUG),2244,ASA,Breast Cancer,Breast,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3806,NCT06210646,"Citicoline in Ischemic Stroke, a Randomized Trial",COMPLETED,PHASE3,Ischemic Stroke,Citicoline 2000 (DRUG); citocoline 1000 (DRUG),2244,ASA,Ischemic Stroke,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3807,NCT00000469,Asymptomatic Carotid Artery Plaque Study (ACAPS),COMPLETED,PHASE2,Cardiovascular Diseases; Carotid Stenosis; Cerebral Arteriosclerosis; Cerebrovascular Disorders; Heart Diseases; Vascular Diseases,aspirin (DRUG); lovastatin (DRUG),2244,ASA,Cardiovascular Diseases; Carotid Stenosis; Cerebral Arteriosclerosis; Cerebrovascular Disorders; Heart Diseases; Vascular Diseases,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3808,NCT06601127,Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).,RECRUITING,PHASE2,Ischemic Stroke,Tiprogrel (DRUG); Tiprogrel (DRUG); Clopidogrel (DRUG),2244,ASA,Ischemic Stroke,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3809,NCT00002527,Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed,COMPLETED,PHASE3,Colorectal Cancer,aspirin (DRUG); placebo (OTHER),2244,ASA,Colorectal Cancer,Bowel,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3810,NCT00004727,Antiplatelet Therapy to Prevent Stroke in African Americans,COMPLETED,PHASE4,Stroke; Cerebral Infarction,aspirin (DRUG); ticlopidine (DRUG),2244,ASA,Stroke; Cerebral Infarction,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3811,NCT03480776,ASA in Prevention of Ovarian Cancer (STICs and STONEs),ACTIVE_NOT_RECRUITING,PHASE2,Ovarian Cancer Prevention,Acetylsalicylic acid (DRUG); Placebo (OTHER),2244,ASA,Ovarian Cancer Prevention,Ovary/Fallopian Tube,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3812,NCT01381627,Safety Evaluation of Dexmedetomidine for EBUS-TBNA,UNKNOWN,PHASE4,Lung Cancer,Remifentanil (DRUG); Dexmedetomidine (DRUG),2244,ASA,Lung Cancer,Lung,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3813,NCT00109382,Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER),COMPLETED,PHASE2,Transient Ischemic Attack; Stroke,Aspirin (DRUG); Clopidogrel (DRUG); Simvastatin (DRUG),2244,ASA,Transient Ischemic Attack; Stroke,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3814,NCT02144831,The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack,WITHDRAWN,PHASE4,Transient Ischemic Attacks; Minor Stroke,anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg) (DRUG),2244,ASA,Transient Ischemic Attacks; Minor Stroke,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3815,NCT00073073,Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms,Exemestane (DRUG); Calcium carbonate (DIETARY_SUPPLEMENT); Vitamin D (DIETARY_SUPPLEMENT),2244,ASA,Breast Neoplasms,Breast,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3816,NCT01518231,Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke,UNKNOWN,PHASE1,Stroke,autologous hematopoiesis stem cell transplantation (PROCEDURE); Aspirin (DRUG); Warfarin (DRUG); Atorvastatin (DRUG); Edaravone (DRUG); Aspirin (DRUG); Warfarin (DRUG); Atorvastatin (DRUG); Edaravone (DRUG),2244,ASA,Stroke,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3817,NCT00441727,Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA),COMPLETED,PHASE3,Gastric Ulcer; Duodenal Ulcer,Esomeprazole 40 mg (DRUG); Esomeprazole 20 mg (DRUG); Placebo (DRUG),2244,ASA,Gastric Ulcer; Duodenal Ulcer,Esophagus/Stomach,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3818,NCT05565976,Dapagliflozin Effect in Cognitive Impairment in Stroke Trial,RECRUITING,PHASE2,"Stroke, Ischemic; Mild Cognitive Impairment; Dementia, Vascular; Metabolic Syndrome",Dapagliflozin 10mg Tab (DRUG); Statins (Cardiovascular Agents) (DRUG); Platelet Antiaggregant (DRUG); Antidiabetic (DRUG),2244,ASA,Cerebrovascular and Cognitive Disorders,CNS/Brain,Aspirin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used widely for pain relief and anti-inflammatory purposes.,CC(=O)OC1=CC=CC=C1C(=O)O,1.34,167.0 +3819,NCT01381874,A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy,COMPLETED,PHASE2,Metastatic ER+ Her2- Breast Cancer; Postmenopausal,Exemestane (DRUG); Abiraterone acetate + Prednisone/ Prednisolone + Exemestane (DRUG); Abiraterone acetate + Prednisone or Prednisolone (DRUG),9821849,Yonsa,Metastatic ER+ Her2- Breast Cancer; Postmenopausal,Breast,Abiraterone acetate,CYP17A1,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer treatment.,CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C,1.01,250.0 +3820,NCT03548246,Androgen Reduction in Congenital Adrenal Hyperplasia,WITHDRAWN,PHASE2,Congenital Adrenal Hyperplasia,Abiraterone acetate (DRUG); Placebo (DRUG); Hydrocortisone (DRUG); Fludrocortisone (DRUG),9821849,Yonsa,Congenital Adrenal Hyperplasia,Kidney,Abiraterone acetate,CYP17A1,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer treatment.,CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C,1.01,250.0 +3821,NCT01814865,Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer,WITHDRAWN,PHASE2,Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer,Abiraterone Acetate (DRUG); Prednisone (DRUG); Aromatase Inhibitor (DRUG),9821849,Yonsa,Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer,Breast,Abiraterone acetate,CYP17A1,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer treatment.,CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C,1.01,250.0 +3822,NCT05137262,A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder,RECRUITING,PHASE2,Urothelial Carcinoma; Bladder Cancer,Abiraterone acetate (OTHER); Durvalumab (DRUG); Methotrexate (DRUG); Vinblastine (DRUG); Doxorubicin Hydrochloride (DRUG); Cisplatin (DRUG),9821849,Yonsa,Urothelial Carcinoma,Bladder/Urinary Tract,Abiraterone acetate,CYP17A1,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer treatment.,CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C,1.01,250.0 +3823,NCT02574910,"Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1",SUSPENDED,PHASE1,Congenital Adrenal Hyperplasia,Abiraterone acetate (DRUG),9821849,Yonsa,Congenital Adrenal Hyperplasia,Kidney,Abiraterone acetate,CYP17A1,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer treatment.,CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C,1.01,250.0 +3824,NCT01517802,A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate,COMPLETED,PHASE3,Metastatic Castration-resistant Prostate Cancer; Metastatic Breast Cancer,Abiraterone acetate (DRUG); Prednisone (DRUG),9821849,Yonsa,Metastatic Castration-resistant Prostate Cancer; Metastatic Breast Cancer,Breast,Abiraterone acetate,CYP17A1,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer treatment.,CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C,1.01,250.0 +3825,NCT01842321,Abiraterone Acetate in Molecular Apocrine Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Abiraterone Acetate (DRUG),9821849,Yonsa,Breast Cancer,Breast,Abiraterone acetate,CYP17A1,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer treatment.,CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C,1.01,250.0 +3826,NCT01715259,A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function,COMPLETED,PHASE1,Renal Insufficiency,Abiraterone acetate: participants with end-stage renal disease (DRUG); Abiraterone acetate: matched control participants with normal renal function (DRUG),9821849,Yonsa,Renal Insufficiency,Kidney,Abiraterone acetate,CYP17A1,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer treatment.,CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C,1.01,250.0 +3827,NCT01884285,AZD8186 First Time In Patient Ascending Dose Study,COMPLETED,PHASE1,Advanced Castrate-resistant Prostate Cancer CRPC; Squamous Non-Small Cell Lung Cancer sqNSCLC; Triple Negative Breast Cancer TNBC,Part A: AZD8186 monotherapy (DRUG); Part B: AZD8186 monotherapy (DRUG); Part C1: Abiraterone acetate combination with AZD8186 (DRUG); Part D1: AZD2014 combination with AZD8186 (DRUG); Part D2 AZD2014 combination with AZD8186 (DRUG); Part C2: Abiraterone acetate combination with AZD8186 (DRUG),9821849,Yonsa,Advanced Castrate-resistant Prostate Cancer CRPC; Squamous Non-Small Cell Lung Cancer sqNSCLC; Triple Negative Breast Cancer TNBC,Lung,Abiraterone acetate,CYP17A1,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer treatment.,CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C,1.01,250.0 +3828,NCT02740985,A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies,COMPLETED,PHASE1,Advanced Solid Malignancies; Non-Small Cell Lung Cancer (NSCLC); Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC); Colorectal Carcinoma (CRC),AZD4635 (DRUG); Durvalumab (DRUG); Abiraterone Acetate (DRUG); Enzalutamide (DRUG); Oleclumab (DRUG); Docetaxel (DRUG),9821849,Yonsa,Advanced Solid Malignancies; Non-Small Cell Lung Cancer (NSCLC); Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC); Colorectal Carcinoma (CRC),Bowel,Abiraterone acetate,CYP17A1,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer treatment.,CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C,1.01,250.0 +3829,NCT01516047,A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function,COMPLETED,PHASE1,Hepatic Impairment,Cohort 1 (DRUG); Cohort 2 (DRUG),9821849,Yonsa,Hepatic Impairment,Liver,Abiraterone acetate,CYP17A1,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer treatment.,CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C,1.01,250.0 +3830,NCT03568656,Study to Evaluate CCS1477 in Advanced Tumours,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Castration-Resistant Prostate Cancer; Metastatic Breast Cancer; Non-small Cell Lung Cancer; Advanced Solid Tumors,CCS1477 (DRUG); Abiraterone acetate (DRUG); Enzalutamide (DRUG); Darolutamide (DRUG); Olaparib (DRUG); Atezolizumab (DRUG),9821849,Yonsa,Metastatic Castration-Resistant Prostate Cancer; Metastatic Breast Cancer; Non-small Cell Lung Cancer; Advanced Solid Tumors,Breast,Abiraterone acetate,CYP17A1,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer treatment.,CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C,1.01,250.0 +3831,NCT00755885,Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer,COMPLETED,PHASE1,Breast Cancer,abiraterone acetate (DRUG); laboratory biomarker analysis (OTHER); pharmacogenomic studies (OTHER),9821849,Yonsa,Breast Cancer,Breast,Abiraterone acetate,CYP17A1,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer treatment.,CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C,1.01,250.0 +3832,NCT04158635,"Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer",RECRUITING,PHASE1,Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Carcinoma,Bosentan (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),185462,s3051,Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Carcinoma,Pancreas,Bosentan (hydrate),"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for treating pulmonary arterial hypertension.,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC.O,1.0303030303030305,117.0 +3833,NCT05585320,A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors,RECRUITING,PHASE1,Advanced Solid Tumor; Pancreatic Adenocarcinoma; Malignant Melanoma (Cutaneous); Non-small Cell Lung Cancer (NSCLC),IMM-1-104 Monotherapy (Treatment Group A) (DRUG); IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B) (DRUG); IMM-1-104 + modified FOLFIRINOX (Treatment Group C) (DRUG); IMM-1-104 + dabrafenib (Treatment Group D) (DRUG); IMM-1-104 + pembrolizumab (Treatment Group E) (DRUG),44462760,Tafinlar,Advanced Solid Tumor; Pancreatic Adenocarcinoma; Malignant Melanoma (Cutaneous); Non-small Cell Lung Cancer (NSCLC),Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3834,NCT02915666,A Clinical Trial of Patients With Melanoma,WITHDRAWN,PHASE1,Melanoma,Digoxin Combination (DRUG); Dabrafenib (DRUG); Trametinib (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3835,NCT03428126,Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer,COMPLETED,PHASE2,Malignant Neoplasms of Digestive Organs; Colorectal Cancer; Colon Cancer,Durvalumab (DRUG); Trametinib (DRUG),44462760,Tafinlar,Malignant Neoplasms of Digestive Organs; Colorectal Cancer; Colon Cancer,Bowel,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3836,NCT02130466,A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022),COMPLETED,PHASE1,Melanoma; Solid Tumors,Pembrolizumab (BIOLOGICAL); Dabrafenib (DRUG); Trametinib (DRUG); Placebo (DRUG),44462760,Tafinlar,Melanoma and Solid Tumors,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3837,NCT01619774,An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor,COMPLETED,PHASE2,Melanoma,GSK2118436 (DRUG); GSK1120212 (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3838,NCT01902173,"Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer",COMPLETED,PHASE1,Hematopoietic and Lymphoid Cell Neoplasm; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Melanoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Malignant Solid Neoplasm; Unresectable Melanoma,Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Dabrafenib Mesylate (DRUG); Magnetic Resonance Imaging (PROCEDURE); Trametinib Dimethyl Sulfoxide (DRUG); Uprosertib (DRUG),44462760,Tafinlar,Hematopoietic and Lymphoid Cell Neoplasm; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Melanoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Malignant Solid Neoplasm; Unresectable Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3839,NCT03754179,Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma,UNKNOWN,PHASE1,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Hydroxychloroquine (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3840,NCT01721603,Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets,TERMINATED,PHASE2,BRAFV600E Melanoma Patients,Dabrafenib (DRUG); Gamma Knife Radiosurgery (PROCEDURE); Trametinib (DRUG),44462760,Tafinlar,BRAFV600E Melanoma Patients,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3841,NCT03391050,A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma,TERMINATED,PHASE1,Melanoma,APR-246 (DRUG); Dabrafenib (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3842,NCT02314143,Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib,TERMINATED,PHASE2,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3843,NCT03088176,Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma,UNKNOWN,PHASE1,Melanoma; BRAF Gene Mutation,"Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil (DRUG); Talimogene Laherparep 100 Mil Pfu/Ml 1Ml (DRUG); Dabrafenib (DRUG); Trametinib (DRUG)",44462760,Tafinlar,Melanoma; BRAF Gene Mutation,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3844,NCT03668431,Dabrafenib + Trametinib + PDR001 In Colorectal Cancer,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,Dabrafenib (DRUG); Trametinib (DRUG); PDR001 (DRUG),44462760,Tafinlar,Metastatic Colorectal Cancer,Bowel,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3845,NCT04294160,A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer,TERMINATED,PHASE1,BRAF V600 Colorectal Cancer,Dabrafenib (DRUG); LTT462 (DRUG); Trametinib (DRUG); LXH254 (DRUG); TNO155 (DRUG); Spartalizumab (BIOLOGICAL); Tislelizumab (BIOLOGICAL),44462760,Tafinlar,BRAF V600 Colorectal Cancer,Bowel,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3846,NCT01266967,A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain,COMPLETED,PHASE2,Melanoma and Brain Metastases,GSK2118436 (DRUG),44462760,Tafinlar,Melanoma with Brain Metastases,CNS/Brain,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3847,NCT03551626,Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes,COMPLETED,PHASE3,Malignant Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),44462760,Tafinlar,Malignant Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3848,NCT02097225,"Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",TERMINATED,PHASE1,BRAF V600E Mutation Present; BRAF V600K Mutation Present; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Solid Neoplasm,Dabrafenib (DRUG); Laboratory Biomarker Analysis (OTHER); Onalespib (DRUG); Pharmacological Study (OTHER); Trametinib (DRUG),44462760,Tafinlar,BRAF V600E Mutation Present; BRAF V600K Mutation Present; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Solid Neoplasm,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3849,NCT02852239,Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment,COMPLETED,PHASE1,Renal Impairment,dabrafenib (DRUG),44462760,Tafinlar,Renal Impairment,Kidney,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3850,NCT04201457,"A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration",ACTIVE_NOT_RECRUITING,PHASE1,Low Grade Glioma (LGG) of Brain With BRAF Aberration; High Grade Glioma (HGG) of the Brain With BRAF Aberration; Low Grade Glioma of Brain With Neurofibromatosis Type 1,Dabrafenib (DRUG); Trametinib (DRUG); Hydroxychloroquine (DRUG),44462760,Tafinlar,Low Grade Glioma (LGG) of Brain With BRAF Aberration; High Grade Glioma (HGG) of the Brain With BRAF Aberration; Low Grade Glioma of Brain With Neurofibromatosis Type 1,CNS/Brain,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3851,NCT02684058,Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors,COMPLETED,PHASE2,"Diffuse Astrocytoma; Anaplastic Astrocytoma; Astrocytoma; Oligodendroglioma, Childhood; Anaplastic Oligodendroglioma; Glioblastoma; Pilocytic Astrocytoma; Giant Cell Astrocytoma; Pleomorphic Xanthoastrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Angiocentric Glioma; Chordoid Glioma of Third Ventricle; Gangliocytoma; Ganglioglioma; Anaplastic Ganglioglioma; Dysplastic Gangliocytoma of Cerebrellum; Desmoplastic Infantile Astrocytoma and Ganglioglioma; Papillary Glioneuronal Tumor; Rosette-forming Glioneurona Tumor; Central Neurocytoma; Extraventricular Neurocytoma; Cerebellar Iponeurocytoma",Dabrafenib (DRUG); trametinib (DRUG); Carboplatin (DRUG); Vincristine (DRUG),44462760,Tafinlar,Gliomas and Neuronal Tumors,CNS/Brain,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3852,NCT02672358,Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC,WITHDRAWN,PHASE2,Non-Small-Cell Lung Cancer,Dabrafenib (DRUG); Trametinib (DRUG),44462760,Tafinlar,Non-Small-Cell Lung Cancer,Lung,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3853,NCT02200562,Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma,TERMINATED,PHASE1,Stage III or IV Melanoma,ipilimumab and dabrafenib (DRUG),44462760,Tafinlar,Stage III or IV Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3854,NCT03563729,Melanoma Metastasized to the Brain and Steroids,RECRUITING,PHASE2,Malignant Melanoma,Pembrolizumab Injection [Keytruda] (DRUG); Ipilimumab Injection [Yervoy] (DRUG); Nivolumab Injection [Opdivo] (DRUG); Encorafenib (DRUG); Binimetinib (DRUG); Dabrafenib (DRUG); Trametinib (DRUG),44462760,Tafinlar,Malignant Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3855,NCT03149029,Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Melanoma,Pembrolizumab (DRUG); Dabrafenib (DRUG); Trametinib (DRUG),44462760,Tafinlar,Metastatic Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3856,NCT03332589,E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS),TERMINATED,PHASE1,Malignant Melanoma; Brain Metastases,E6201 (DRUG); E6201 plus dabrafenib (DRUG),44462760,Tafinlar,Malignant Melanoma; Brain Metastases,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3857,NCT03975829,Pediatric Long-Term Follow-up and Rollover Study,ACTIVE_NOT_RECRUITING,PHASE4,"Diffuse Astrocytoma; Anaplastic Astrocytoma; Astrocytoma; Oligodendroglioma, Childhood; Anaplastic Oligodendroglioma; Glioblastoma; Pilocytic Astrocytoma; Giant Cell Astrocytoma; Pleomorphic Xanthoastrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Angiocentric Glioma; Chordoid Glioma of Third Ventricle; Gangliocytoma; Ganglioglioma; Anaplastic Ganglioglioma; Dysplastic Gangliocytoma of Cerebrellum; Desmoplastic Infantile Astrocytoma and Ganglioglioma; Papillary Glioneuronal Tumor; Rosette-forming Glioneuronal Tumor; Central Neurocytoma; Extraventricular Neurocytoma; Cerebellar Liponeurocytoma; Neurofibromatosis Type 1",dabrafenib (DRUG); trametinib (DRUG),44462760,Tafinlar,Gliomas and Neuroglial Tumors,CNS/Brain,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3858,NCT06054191,Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations,NOT_YET_RECRUITING,PHASE2,NSCLC; BRAF V600 Mutation; MET Exon 14 Mutation,Dabrafenib + Trametinib (DRUG); Capmatinib (DRUG),44462760,Tafinlar,Non-Small Cell Lung Cancer with Genetic Mutations,Lung,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3859,NCT05299580,"""Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)""",WITHDRAWN,PHASE2,Melanoma,dabrafenib (DRUG); Trametinib (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3860,NCT02410863,Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma,TERMINATED,PHASE2,Malignant Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),44462760,Tafinlar,Malignant Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3861,NCT01153763,A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma,COMPLETED,PHASE2,Melanoma,GSK2118436 (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3862,NCT02296996,Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients,COMPLETED,PHASE2,Malignant Melanoma,Dabrafenib + Trametinib (DRUG),44462760,Tafinlar,Malignant Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3863,NCT02447939,Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma,WITHDRAWN,PHASE1,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3864,NCT04059224,TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma,COMPLETED,PHASE2,Stage IV Melanoma; Stage III Melanoma,Trametinib (DRUG); Dabrafenib (DRUG),44462760,Tafinlar,Stage IV Melanoma; Stage III Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3865,NCT02196181,Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread,ACTIVE_NOT_RECRUITING,PHASE2,Stage III Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma,Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Dabrafenib Mesylate (DRUG); Echocardiography Test (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Positron Emission Tomography (PROCEDURE); Trametinib Dimethyl Sulfoxide (DRUG),44462760,Tafinlar,Stage III Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3866,NCT04675710,"Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Thyroid Gland Anaplastic Carcinoma; Thyroid Gland Squamous Cell Carcinoma,Conventional Surgery (PROCEDURE); Dabrafenib (DRUG); Intensity-Modulated Radiation Therapy (RADIATION); Pembrolizumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Trametinib (DRUG),44462760,Tafinlar,Thyroid Gland Anaplastic Carcinoma; Thyroid Gland Squamous Cell Carcinoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3867,NCT02967692,"A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",TERMINATED,PHASE3,Melanoma,Spartalizumab (BIOLOGICAL); Placebo (OTHER); Dabrafenib (DRUG); Trametinib (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3868,NCT02257424,"Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",COMPLETED,PHASE1,Advanced BRAF Mutant Melanoma,Trametinib 2 mg daily (DRUG); hydroxychloroquine (HCQ) (DRUG); dabrafenib 150 mg orally twice a day (DRUG),44462760,Tafinlar,Advanced BRAF Mutant Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3869,NCT01519427,Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib,TERMINATED,PHASE2,Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma,Akt inhibitor MK2206 (DRUG); selumetinib (DRUG); laboratory biomarker analysis (OTHER),44462760,Tafinlar,Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3870,NCT03972046,Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma,WITHDRAWN,PHASE2,Melanoma (Skin); Melanoma Stage IIIb-IVM1a; Metastasis Skin; Tumor Skin; BRAF Gene Mutation,Talimogene laherparepvec (T-Vec) (DRUG); Dabrafenib (BRAF Inhibitor) (DRUG); Trametinib (MEK Inhibitor) (DRUG),44462760,Tafinlar,Melanoma (Skin); Melanoma Stage IIIb-IVM1a; Metastasis Skin; Tumor Skin; BRAF Gene Mutation,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3871,NCT03026517,Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma,COMPLETED,PHASE1,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Phenformin (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3872,NCT03808441,CAcTUS - Circulating Tumour DNA Guided Switch,ACTIVE_NOT_RECRUITING,PHASE2,Melanoma,ctDNA analysis (OTHER),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3873,NCT04903119,Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma,RECRUITING,PHASE1,Metastatic Melanoma; BRAF Gene Mutation,Nilotinib 100mg (DRUG); Nilotinib 200mg (DRUG); Nilotinib 300mg (DRUG); Nilotinib 400mg (DRUG); Dabrafenib (DRUG); Trametinib (DRUG); Encorafenib (DRUG); Binimetinib (DRUG),44462760,Tafinlar,Advanced Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3874,NCT01726738,LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations,COMPLETED,PHASE2,Stage III Melanoma; Stage IV Melanoma; Unresectable Melanoma; BRAF Mutant Melanoma,BRAF inhibitor dabrafenib and MEK inhibitor trametinib (DRUG),44462760,Tafinlar,Stage III Melanoma; Stage IV Melanoma; Unresectable Melanoma; BRAF Mutant Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3875,NCT02110355,A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma,COMPLETED,PHASE1,Advanced Malignancy; Advanced Solid Tumors; Cancer; Oncology; Oncology Patients; Tumors; Melanoma,AMG 232 (DRUG); Trametinib (DRUG); Dabrafenib (DRUG),44462760,Tafinlar,Advanced Malignancy; Advanced Solid Tumors; Cancer; Oncology; Oncology Patients; Tumors; Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3876,NCT01597908,Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma,COMPLETED,PHASE3,Melanoma,Dabrafenib (DRUG); Vemurafenib (DRUG); Trametinib (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3877,NCT02143050,"Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",WITHDRAWN,PHASE1,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Metformin (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3878,NCT02873650,Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment,TERMINATED,PHASE1,Hepatic Impairment,dabrafenib (DRUG),44462760,Tafinlar,Hepatic Impairment,Liver,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3879,NCT02224781,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,ACTIVE_NOT_RECRUITING,PHASE3,Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma; Recurrent Melanoma; Unresectable Melanoma,Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Dabrafenib Mesylate (DRUG); Echocardiography Test (PROCEDURE); Ipilimumab (BIOLOGICAL); Multigated Acquisition Scan (PROCEDURE); Nivolumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Trametinib Dimethyl Sulfoxide (DRUG),44462760,Tafinlar,Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma; Recurrent Melanoma; Unresectable Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3880,NCT03455764,MCS110 With BRAF/MEK Inhibition in Patients With Melanoma,COMPLETED,PHASE1,Melanoma,MCS110 (DRUG); Dabrafenib (DRUG); Trametinib (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3881,NCT03272464,INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.,TERMINATED,PHASE1,Melanoma,Trametinib (DRUG); Dabrafenib (DRUG); INCB039110 (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3882,NCT03543306,Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation,UNKNOWN,PHASE2,Cancer; Lung Cancer Metastatic; BRAF V600E,daborafenib plus trametinib (DRUG),44462760,Tafinlar,Cancer; Lung Cancer Metastatic; BRAF V600E,Lung,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3883,NCT02382549,A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib,TERMINATED,EARLY_PHASE1,Melanoma,BRAF inhibitor (DRUG); 6MHP (BIOLOGICAL); MEK inhibitor (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3884,NCT04527549,Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma,TERMINATED,PHASE2,Clinical Stage IV Cutaneous Melanoma AJCC v8; Locally Advanced Melanoma; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Unresectable Melanoma,Dabrafenib mesylate (DRUG); Hydroxychloroquine (DRUG); Placebo Administration (DRUG); Trametinib dimethyl sulfoxide (DRUG),44462760,Tafinlar,Clinical Stage IV Cutaneous Melanoma AJCC v8; Locally Advanced Melanoma; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Unresectable Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3885,NCT06563999,Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.,RECRUITING,PHASE2,Lung Cancer Stage III; Mutation,Sunvozertinib (DRUG); Crizotinib (DRUG); Pralsetinib (DRUG); Larotrectinib (DRUG); Savolitinib (DRUG); Pyrotinib (DRUG); Dabrafenib+Trametinib (DRUG); Glecirasib (DRUG); Ensartinib (DRUG),44462760,Tafinlar,Lung Cancer Stage III with Mutation,Lung,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3886,NCT03340506,Dabrafenib and/or Trametinib Rollover Study,RECRUITING,PHASE4,Melanoma; Non Small Cell Lung Cancer; Solid Tumor; Rare Cancers; High Grade Glioma,dabrafenib (DRUG); trametinib (DRUG),44462760,Tafinlar,Melanoma; Non Small Cell Lung Cancer; Solid Tumor; Rare Cancers; High Grade Glioma,Lung,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3887,NCT01907802,Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction,TERMINATED,PHASE1,BRAF Gene Mutation; Hepatic Complication; Renal Failure; Solid Neoplasm,Dabrafenib (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacogenomic Study (OTHER); Pharmacological Study (OTHER),44462760,Tafinlar,BRAF Gene Mutation; Hepatic Complication; Renal Failure; Solid Neoplasm,Kidney,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3888,NCT02858921,"Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma",ACTIVE_NOT_RECRUITING,PHASE2,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Pembrolizumab (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3889,NCT02968303,Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy,UNKNOWN,PHASE2,"Melanoma, Malignant, of Soft Parts",Vemurafenib and Cobimetinib (DRUG),44462760,Tafinlar,Malignant Melanoma of Soft Parts,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3890,NCT02974803,Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases,TERMINATED,PHASE2,Melanoma; Brain Metastases,Dabrafenib (DRUG); Trametinib (DRUG),44462760,Tafinlar,Melanoma; Brain Metastases,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3891,NCT01584648,A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma,COMPLETED,PHASE3,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Trametinib placebo (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3892,NCT02231775,Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation,ACTIVE_NOT_RECRUITING,PHASE2,Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7,Dabrafenib (DRUG); Laboratory Biomarker Analysis (OTHER); Therapeutic Conventional Surgery (PROCEDURE); Trametinib (DRUG),44462760,Tafinlar,Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3893,NCT02872259,BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma,COMPLETED,PHASE1,Melanoma,BGB324+pembrolizumab (DRUG); BGB324+dabrafenib and trametinib (DRUG); pembrolizumab (DRUG); dabrafenib and trametinib (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3894,NCT01682213,Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation,COMPLETED,PHASE2,Melanoma,Dabrafenib (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3895,NCT06712875,MAPK Inhibition Combined with Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas,RECRUITING,PHASE1,Low Grade Glioma; High Grade Glioma,"Trametinib and Nivolumab (DRUG); Dabrafenib, trametinib, nivolumab (DRUG)",44462760,Tafinlar,Low Grade Glioma; High Grade Glioma,CNS/Brain,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3896,NCT02977052,Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab,ACTIVE_NOT_RECRUITING,PHASE2,Malignant Melanoma Stage III,Ipilimumab (DRUG); Nivolumab (DRUG); Surgery (PROCEDURE); Blood for PBMCs (PROCEDURE); Biopsies (PROCEDURE),44462760,Tafinlar,Malignant Melanoma Stage III,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3897,NCT01978236,"Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",TERMINATED,PHASE2,Melanoma and Brain Metastases,Dabrafenib 150 mg (DRUG); Trametinib 2.0 mg (DRUG),44462760,Tafinlar,Melanoma with Brain Metastases,CNS/Brain,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3898,NCT04949113,Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma,ACTIVE_NOT_RECRUITING,PHASE3,Malignant Melanoma Stage III,Neoadjuvant ipilimumab + nivolumab (DRUG); Adjuvant nivolumab (DRUG),44462760,Tafinlar,Malignant Melanoma Stage III,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3899,NCT02625337,Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients,UNKNOWN,PHASE2,Metastatic Melanoma,Pembrolizumab (DRUG); Dabrafenib (DRUG); Trametinib (DRUG); Biopsy (PROCEDURE); Blood taking (PROCEDURE),44462760,Tafinlar,Metastatic Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3900,NCT02910700,"Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma,Binimetinib (DRUG); Dabrafenib (DRUG); Encorafenib (DRUG); Laboratory Biomarker Analysis (OTHER); Nivolumab (BIOLOGICAL); Pharmacological Study (OTHER); Trametinib (DRUG),44462760,Tafinlar,Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma,CNS/Brain,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3901,NCT01989585,Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma,ACTIVE_NOT_RECRUITING,PHASE1,Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Malignant Solid Neoplasm; Metastatic Melanoma; Unresectable Melanoma,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Dabrafenib (DRUG); Echocardiography Test (PROCEDURE); Laboratory Biomarker Analysis (OTHER); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Navitoclax (BIOLOGICAL); Pharmacological Study (OTHER); Trametinib (DRUG),44462760,Tafinlar,Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Malignant Solid Neoplasm; Metastatic Melanoma; Unresectable Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3902,NCT01972347,Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma,ACTIVE_NOT_RECRUITING,PHASE2,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3903,NCT01512251,BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma,COMPLETED,PHASE1,BRAF Mutant Metastatic Melanoma,BKM120 Combined with Vemurafenib (PLX4032) (DRUG),44462760,Tafinlar,BRAF Mutant Metastatic Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3904,NCT05388877,E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases from BRAF V600 Mutated Metastatic Melanoma,ACTIVE_NOT_RECRUITING,PHASE1,Clinical Stage IV Cutaneous Melanoma AJCC V8; Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Neoplasm in the Central Nervous System; Metastatic Melanoma,Dabrafenib (DRUG); MEK-1/MEKK-1 Inhibitor E6201 (DRUG); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE),44462760,Tafinlar,Clinical Stage IV Cutaneous Melanoma AJCC V8; Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Neoplasm in the Central Nervous System; Metastatic Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3905,NCT04452877,A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Dabrafenib (DRUG); Trametinib (DRUG),44462760,Tafinlar,"Carcinoma, Non-Small-Cell Lung",Lung,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3906,NCT03949153,Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis,COMPLETED,PHASE1,Melanoma (Skin),Nivolumab 10 MG/ML Intravenous Solution [OPDIVO] (DRUG); Cryotherapy (PROCEDURE); Ipilimumab Injection (DRUG),44462760,Tafinlar,Melanoma (Skin),Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3907,NCT01701037,Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery,TERMINATED,PHASE2,"Recurrent Melanoma; Stage IIB Melanoma (Locally Advanced); Stage IIC Melanoma (Locally Advanced); Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma (Limited, Resectable)",dabrafenib (DRUG); trametinib (DRUG); laboratory biomarker analysis (OTHER),44462760,Tafinlar,"Recurrent Melanoma; Stage IIB Melanoma (Locally Advanced); Stage IIC Melanoma (Locally Advanced); Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma (Limited, Resectable)",Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3908,NCT04644432,Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma,UNKNOWN,PHASE2,Metastatic Renal Cell Carcinoma; Kidney Neoplasm; Urologic Neoplasms; Urogenital Neoplasms,Medication (A specification is listed under each arm) (DRUG); Patient reported outcomes measurement (OTHER),44462760,Tafinlar,Metastatic Renal Cell Carcinoma,Kidney,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3909,NCT02357732,Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib,WITHDRAWN,PHASE1,Metastatic Melanoma,Nivolumab (DRUG); Trametinib (DRUG); Dabrafenib (DRUG),44462760,Tafinlar,Metastatic Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3910,NCT04557956,"Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment",RECRUITING,PHASE1,Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma,Biopsy Procedure (PROCEDURE); Computed Tomography (PROCEDURE); Dabrafenib Mesylate (DRUG); Echocardiography Test (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Tazemetostat Hydrobromide (DRUG); Trametinib Dimethyl Sulfoxide (DRUG),44462760,Tafinlar,Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3911,NCT05370807,A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma,UNKNOWN,PHASE2,Melanoma Stage III; Melanoma Stage IV,Regorafenib 40 MG Oral Tablet (DRUG); Triplet therapy (DRUG),44462760,Tafinlar,Melanoma Stage III; Melanoma Stage IV,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3912,NCT01940809,"Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery",TERMINATED,PHASE1,BRAF V600E Mutation Present; BRAF V600K Mutation Present; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7,Dabrafenib (DRUG); Ipilimumab (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER); Nivolumab (BIOLOGICAL); Trametinib (DRUG),44462760,Tafinlar,BRAF V600E Mutation Present; BRAF V600K Mutation Present; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3913,NCT02027961,Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone,COMPLETED,PHASE1,Melanoma,Durvalumab (BIOLOGICAL); Dabrafenib (DRUG); Trametinib (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3914,NCT01682083,Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).,COMPLETED,PHASE3,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Placebos (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3915,NCT04310397,"Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma",TERMINATED,PHASE2,Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8,Dabrafenib (DRUG); Spartalizumab (BIOLOGICAL); Therapeutic Conventional Surgery (PROCEDURE); Trametinib (DRUG),44462760,Tafinlar,Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3916,NCT02392871,Radiotherapy & Combi in Metastatic Melanoma,COMPLETED,PHASE1,Metastatic Melanoma,Palliative radiotherapy (RADIATION); Dabrafenib and trametinib (combination) (DRUG),44462760,Tafinlar,Metastatic Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3917,NCT03919071,Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma,ACTIVE_NOT_RECRUITING,PHASE2,"Anaplastic Astrocytoma; Anaplastic Astrocytoma, Not Otherwise Specified; Anaplastic Ganglioglioma; Anaplastic Pleomorphic Xanthoastrocytoma; Glioblastoma; Malignant Glioma; WHO Grade 3 Glioma; WHO Grade 4 Glioma",Biospecimen Collection (PROCEDURE); Dabrafenib Mesylate (DRUG); Lumbar Puncture (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Radiation Therapy (RADIATION); Trametinib Dimethyl Sulfoxide (DRUG),44462760,Tafinlar,"Anaplastic Astrocytoma; Anaplastic Astrocytoma, Not Otherwise Specified; Anaplastic Ganglioglioma; Anaplastic Pleomorphic Xanthoastrocytoma; Glioblastoma; Malignant Glioma; WHO Grade 3 Glioma; WHO Grade 4 Glioma",CNS/Brain,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3918,NCT02052193,Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study,TERMINATED,PHASE2,Metastatic Melanoma (Carrying BRAF V600 Mutation),Dabrafenib (DRUG); Vemurafenib (DRUG),44462760,Tafinlar,Metastatic Melanoma (Carrying BRAF V600 Mutation),Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3919,NCT03352947,Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma,COMPLETED,PHASE2,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),44462760,Tafinlar,Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3920,NCT02039947,Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain,COMPLETED,PHASE2,Melanoma and Brain Metastases,Dabrafenib (DRUG); Trametinib (DRUG),44462760,Tafinlar,Melanoma with Brain Metastases,CNS/Brain,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3921,NCT02083354,Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma,COMPLETED,PHASE2,Cancer; Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),44462760,Tafinlar,Cancer; Melanoma,Skin,Dabrafenib,"BRAF, RAF1",inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for melanoma treatment.,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1.01,221.0 +3922,NCT01663857,A Study LY2228820 for Recurrent Ovarian Cancer,COMPLETED,PHASE1,Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer,LY2228820 (DRUG); Carboplatin (DRUG); Placebo (DRUG); Gemcitabine (DRUG),11570805,ZZ-84,Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer,Ovary/Fallopian Tube,Ralimetinib dimesylate,"MAPKAPK2, MAPK14, MAPK11",inhibitor/antagonist,Other MAPK inhibitor,no,yes,Investigated as cancer treatment; not approved for human use.,CC(C)(C)CN1C2=C(C=CC(=N2)C3=C(N=C(N3)C(C)(C)C)C4=CC=C(C=C4)F)N=C1N.CS(=O)(=O)O.CS(=O)(=O)O,, +3923,NCT02860780,A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer,COMPLETED,PHASE1,Advanced Cancer; Metastatic Cancer; Colorectal Cancer; Non-small Cell Lung Cancer,prexasertib (DRUG); ralimetinib (DRUG),11570805,ZZ-84,Advanced Cancer; Metastatic Cancer; Colorectal Cancer; Non-small Cell Lung Cancer,Bowel,Ralimetinib dimesylate,"MAPKAPK2, MAPK14, MAPK11",inhibitor/antagonist,Other MAPK inhibitor,no,yes,Investigated as cancer treatment; not approved for human use.,CC(C)(C)CN1C2=C(C=CC(=N2)C3=C(N=C(N3)C(C)(C)C)C4=CC=C(C=C4)F)N=C1N.CS(=O)(=O)O.CS(=O)(=O)O,, +3924,NCT02364206,Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma,COMPLETED,PHASE1,Adult Glioblastoma,LY2228820 (DRUG); Temozolomide (DRUG); radiotherapy (RADIATION),11570805,ZZ-84,Adult Glioblastoma,CNS/Brain,Ralimetinib dimesylate,"MAPKAPK2, MAPK14, MAPK11",inhibitor/antagonist,Other MAPK inhibitor,no,yes,Investigated as cancer treatment; not approved for human use.,CC(C)(C)CN1C2=C(C=CC(=N2)C3=C(N=C(N3)C(C)(C)C)C4=CC=C(C=C4)F)N=C1N.CS(=O)(=O)O.CS(=O)(=O)O,, +3925,NCT02322853,A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors,TERMINATED,PHASE2,Postmenopausal; Metastatic Breast Cancer,Tamoxifen (DRUG); Ralimetinib (LY2228820 dimesylate) (DRUG),11570805,ZZ-84,Postmenopausal; Metastatic Breast Cancer,Breast,Ralimetinib dimesylate,"MAPKAPK2, MAPK14, MAPK11",inhibitor/antagonist,Other MAPK inhibitor,no,yes,Investigated as cancer treatment; not approved for human use.,CC(C)(C)CN1C2=C(C=CC(=N2)C3=C(N=C(N3)C(C)(C)C)C4=CC=C(C=C4)F)N=C1N.CS(=O)(=O)O.CS(=O)(=O)O,, +3926,NCT05524974,"Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes",NOT_YET_RECRUITING,PHASE2,Locally Advanced Gastric Cancer,Camrelizumab (DRUG); Oxaliplatin (DRUG); S1 (DRUG); Apatinib Mesylate (DRUG); Nab paclitaxel (DRUG),441243,ROC,Metastatic Gastric Cancer,Esophagus/Stomach,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3927,NCT04871074,The Synapse Project,ACTIVE_NOT_RECRUITING,PHASE2,Alzheimer Disease,UCB-J (DRUG); MRI Scan (DEVICE); PET Scan (DEVICE),441243,ROC,Alzheimer Disease,CNS/Brain,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3928,NCT02020720,18F-DOPA-PET in Planning Surgery in Patients with Gliomas,COMPLETED,EARLY_PHASE1,Malignant Glioma; Recurrent Brain Neoplasm,Biopsy (PROCEDURE); Computed Tomography (PROCEDURE); Diffusion Weighted Imaging (PROCEDURE); Fluorine F 18 Fluorodopa (DRUG); Laboratory Biomarker Analysis (OTHER); Perfusion Magnetic Resonance Imaging (PROCEDURE); Positron Emission Tomography (PROCEDURE); Therapeutic Conventional Surgery (PROCEDURE),441243,ROC,Malignant Glioma; Recurrent Brain Neoplasm,CNS/Brain,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3929,NCT00715182,A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer,COMPLETED,PHASE1,Advanced/ Metastatic Renal Cell Cancer,TKI258 (DRUG),441243,ROC,Advanced/ Metastatic Renal Cell Cancer,Kidney,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3930,NCT02292550,Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.,COMPLETED,PHASE1,Non-small Cell Lung Cancer,Ribociclib (DRUG); Ceritinib (DRUG),441243,ROC,Non-small Cell Lung Cancer,Lung,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3931,NCT02714595,Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens,COMPLETED,PHASE3,Healthcare-associated Pneumonia (HCAP); Bloodstream Infections (BSI); Hospital Acquired Pneumonia (HAP); Complicated Urinary Tract Infection (cUTI); Sepsis; Ventilator Associated Pneumonia (VAP),Cefiderocol (DRUG); Best Available Therapy (DRUG),441243,ROC,Healthcare-associated Pneumonia (HCAP); Bloodstream Infections (BSI); Hospital Acquired Pneumonia (HAP); Complicated Urinary Tract Infection (cUTI); Sepsis; Ventilator Associated Pneumonia (VAP),Lung,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3932,NCT02085395,Clinical Study Assessment of SR-T100 Topical Gel Against Actinic Keratosis,COMPLETED,PHASE2,Actinic Keratosis; Bowen's Disease,SR-T100 ® Gel (DRUG),441243,ROC,Actinic Keratosis; Bowen's Disease,Skin,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3933,NCT01617668,"A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer",COMPLETED,PHASE2,Breast Cancer,LCL161 (DRUG); paclitaxel (DRUG),441243,ROC,Breast Cancer,Breast,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3934,NCT01183169,Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment,COMPLETED,PHASE2,Hepatitis C,Alisporivir (DRUG); Peginterferon alfa-2a (DRUG); Ribavirin (DRUG); Placebo (DRUG),441243,ROC,Hepatitis C,Liver,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3935,NCT01572727,"A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",COMPLETED,PHASE2,Breast Cancer,Paclitaxel (DRUG); BKM120 matching placebo (DRUG); BKM120 (DRUG),441243,ROC,Breast Cancer,Breast,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3936,NCT02398773,FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy,ACTIVE_NOT_RECRUITING,PHASE2,HER2/Neu Negative; Progesterone Receptor Negative; Progesterone Receptor Positive; Stage IV Breast Cancer AJCC v6 and v7,Computed Tomography (PROCEDURE); F-18 16 Alpha-Fluoroestradiol (DRUG); Laboratory Biomarker Analysis (OTHER); Positron Emission Tomography (PROCEDURE),441243,ROC,HER2/Neu Negative; Progesterone Receptor Negative; Progesterone Receptor Positive; Stage IV Breast Cancer AJCC v6 and v7,Breast,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3937,NCT03703492,Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS,COMPLETED,PHASE2,Breast Cancer; Ductal Carcinoma in Situ - Category,(18F)FES (DRUG); Gadobenate dimeglumine (DRUG),441243,ROC,Breast Cancer; Ductal Carcinoma in Situ - Category,Breast,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3938,NCT00983060,Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients,COMPLETED,PHASE2,Chronic Hepatitis C Genotype-1 Relapse,NIM811 (DRUG); Placebo BID + SOC (DRUG),441243,ROC,Chronic Hepatitis C Genotype-1 Relapse,Liver,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3939,NCT00273312,Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma,COMPLETED,PHASE2,Hepatocellular Carcinoma,Patupilone (DRUG),441243,ROC,Hepatocellular Carcinoma,Liver,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3940,NCT04193046,A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH),COMPLETED,EARLY_PHASE1,"Hypertension, Pulmonary",Blood Sample (OTHER),441243,ROC,Pulmonary Hypertension,Lung,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3941,NCT02563067,Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.,COMPLETED,PHASE3,Asthma,QAW039 (DRUG); QAW039 (DRUG); Placebo (DRUG),441243,ROC,Asthma,Lung,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3942,NCT02448225,18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules,COMPLETED,PHASE2,Lung Carcinoma; Solitary Pulmonary Nodule; Cigarette Smoking Behavior,Computed Tomography (PROCEDURE); Computed Tomography (PROCEDURE); fluorodeoxyglucose F-18 (RADIATION); Fluorine F 18 L-glutamate Derivative BAY94-9392 (DRUG); Laboratory Biomarker Analysis (OTHER); Positron Emission Tomography (PROCEDURE); Positron Emission Tomography (PET) (PROCEDURE),441243,ROC,Lung Carcinoma; Solitary Pulmonary Nodule; Cigarette Smoking Behavior,Lung,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3943,NCT01251666,"Comparison of Hemoccult, Magstream and OC-Sensor Faecal Occult Blood Tests in Colorectal Cancer Screening",COMPLETED,PHASE3,Colorectal Cancer,Colonoscopy (OTHER),441243,ROC,Colorectal Cancer,Bowel,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3944,NCT01084330,Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer,COMPLETED,PHASE2,Advanced Gastric Cancer; Gastro-esophageal Junction Cancer,AUY922 (DRUG); Docetaxel (DRUG); Irinotecan (DRUG),441243,ROC,Advanced Gastric and Gastro-esophageal Junction Cancer,Esophagus/Stomach,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3945,NCT01646125,"An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations",TERMINATED,PHASE2,Advanced Non Small Cell Lung Cancer (NSCLC),AUY922 (DRUG); Docetaxel (DRUG); Pemetrexed (DRUG),441243,ROC,Advanced Non Small Cell Lung Cancer (NSCLC),Lung,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3946,NCT02756130,"Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",WITHDRAWN,PHASE1,High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Birinapant (DRUG); Carboplatin (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER),441243,ROC,High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3947,NCT06695039,Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in ER-positive Breast Cancer,RECRUITING,PHASE2,Breast Cancer Invasive,Fluoroestradiol (18F) (DIAGNOSTIC_TEST),441243,ROC,Breast Cancer Invasive,Breast,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3948,NCT03517566,A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis,TERMINATED,PHASE2,Atopic Dermatitis,Placebo (DRUG); ZPL389 3mg (DRUG); ZPL389 10mg (DRUG); ZPL389 30mg (DRUG); ZPL389 50mg (DRUG),441243,ROC,Atopic Dermatitis,Skin,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3949,NCT00790426,Phase II Study of TKI258 in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Cancer,TKI258 (DRUG),441243,ROC,Urothelial Cancer,Bladder/Urinary Tract,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3950,NCT00436748,Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease,TERMINATED,PHASE3,Anemia; Chronic Kidney Disease; Kidney Disease,Darbepoetin Alfa (DRUG); Placebo (DRUG),441243,ROC,Anemia; Chronic Kidney Disease; Kidney Disease,Kidney,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3951,NCT06245889,PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC,RECRUITING,PHASE2,Triple Negative Breast Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Pembrolizumab (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Olaparib (DRUG); Capecitabine (DRUG),441243,ROC,Triple Negative Breast Cancer,Breast,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3952,NCT06074094,Probiotic Supplementation IN NAFLD Patients,COMPLETED,PHASE4,NAFLD,Control Test (DRUG),441243,ROC,Non-alcoholic Fatty Liver Disease,Liver,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3953,NCT04369560,Virtual Histology of the Bladder Wall for Bladder Cancer Staging,RECRUITING,EARLY_PHASE1,Urinary Bladder Neoplasms,Magnetic Resonance Imaging (DIAGNOSTIC_TEST); Gadobutrol intravesical administration (4mM) (DRUG); Ferumoxytol intravesical administration (5 mM) (DRUG),441243,ROC,Urinary Bladder Neoplasms,Bladder/Urinary Tract,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3954,NCT01297491,Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer,COMPLETED,PHASE2,Non-small Cell Lung Cancer,BKM120 (DRUG),441243,ROC,Non-small Cell Lung Cancer,Lung,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3955,NCT01801163,A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC),WITHDRAWN,PHASE1,Hepatocellular Carcinoma,Sorafenib (DRUG); Stereotactic radiotherapy (RADIATION),441243,ROC,Hepatocellular Carcinoma,Liver,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3956,NCT06381960,Clinical Study on the Prevention and Treatment of Postoperative Metastasis of Lung Cancer by Fuzheng Quxie Recipe,RECRUITING,PHASE2,Lung Cancer,Fuzheng Quxie Recipe (DRUG); Fuzhengquye Fang Recipe simulant (DRUG),441243,ROC,Lung Cancer,Lung,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3957,NCT06874140,Proteomic Study of Chuanhong Zhongfeng Capsule in the Treatment of ACI,COMPLETED,PHASE1,Acute Ischemic Stroke,Chuanhong Zhongfeng capsule (DRUG),441243,ROC,Acute Ischemic Stroke,CNS/Brain,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3958,NCT05685940,Therapeutic Drug Monitoring of Risankizumab in Psoriasis Patients (BIOLOPTIM-RIS),RECRUITING,PHASE4,Psoriasis Vulgaris,Venapuncture (PROCEDURE); Patient questionnaires (PROCEDURE),441243,ROC,Psoriasis Vulgaris,Skin,Saquinavir,,inhibitor/antagonist,unclear,yes,yes,Approved as part of antiretroviral therapy for HIV/AIDS.,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1.04,161.0 +3959,NCT00626262,"Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv",COMPLETED,PHASE4,Gastroesophageal Reflux Disease,Esomeprazole (DRUG),9853654,PETAVLON,Gastroesophageal Reflux Disease,Esophagus/Stomach,Pentagastrin,CCKBR,inhibitor/antagonist,unclear,yes,yes,Used mainly in diagnostic tests for gastric functions.,CC(C)(C)OC(=O)NCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(CC3=CC=CC=C3)C(=O)N,1.0,0.0 +3960,NCT00635414,"Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously",COMPLETED,PHASE4,GERD,Esomeprazole (DRUG); Esomeprazole (DRUG),9853654,PETAVLON,GERD,Esophagus/Stomach,Pentagastrin,CCKBR,inhibitor/antagonist,unclear,yes,yes,Used mainly in diagnostic tests for gastric functions.,CC(C)(C)OC(=O)NCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(CC3=CC=CC=C3)C(=O)N,1.0,0.0 +3961,NCT00625495,Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD),COMPLETED,PHASE4,Gastroesophageal Reflux Disease,Esomeprazole (DRUG); Esomeprazole (DRUG),9853654,PETAVLON,Gastroesophageal Reflux Disease,Esophagus/Stomach,Pentagastrin,CCKBR,inhibitor/antagonist,unclear,yes,yes,Used mainly in diagnostic tests for gastric functions.,CC(C)(C)OC(=O)NCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(CC3=CC=CC=C3)C(=O)N,1.0,0.0 +3962,NCT00629564,"An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)",COMPLETED,PHASE4,GERD,Esomeprazole (DRUG); Esomeprazole (DRUG),9853654,PETAVLON,GERD,Esophagus/Stomach,Pentagastrin,CCKBR,inhibitor/antagonist,unclear,yes,yes,Used mainly in diagnostic tests for gastric functions.,CC(C)(C)OC(=O)NCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(CC3=CC=CC=C3)C(=O)N,1.0,0.0 +3963,NCT00175045,Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis,COMPLETED,PHASE2,Esophagitis; Reflux,Lansoprazole (DRUG); Lansoprazole (DRUG),9853654,PETAVLON,Esophagitis; Reflux,Esophagus/Stomach,Pentagastrin,CCKBR,inhibitor/antagonist,unclear,yes,yes,Used mainly in diagnostic tests for gastric functions.,CC(C)(C)OC(=O)NCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(CC3=CC=CC=C3)C(=O)N,1.0,0.0 +3964,NCT05896566,A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer,RECRUITING,PHASE2,Breast Cancer,Giredestrant (DRUG); Triptorelin (DRUG); Anastrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3965,NCT00556374,Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy,COMPLETED,PHASE3,Breast Cancer,Placebo (DRUG); Denosumab (BIOLOGICAL); Non-steroidal aromatase inhibitor therapy (DRUG); Zoledronic Acid (DRUG); Standard of Care (OTHER),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3966,NCT03099174,This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer,COMPLETED,PHASE1,Neoplasms; Breast Neoplasms,Xentuzumab (DRUG); Abemaciclib (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG); Abemaciclib (DRUG),2187,Asiolex,Neoplasms; Breast Neoplasms,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3967,NCT01723774,PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Neoplasms,PD0332991 (DRUG); Anastrozole (DRUG); Goserelin (DRUG); Surgery (standard of care) (PROCEDURE); Tumor biopsy (PROCEDURE),2187,Asiolex,Breast Neoplasms,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3968,NCT01262274,Randomized Phase II Trial of Anastrozole Plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast Cancer,TERMINATED,PHASE2,Breast Neoplasms,Anastrozole (DRUG); Anastrozole plus tegafur-uracil (DRUG),2187,Asiolex,Breast Neoplasms,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3969,NCT04985266,A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer,RECRUITING,PHASE2,ER+ Breast Cancer; HER2-negative Breast Cancer,Palbociclib 125Mg Tab (DRUG); Fulvestrant injection (DRUG); Tamoxifen (DRUG); Letrozole (DRUG); Exemestane (DRUG); Anastrozole (DRUG),2187,Asiolex,Breast Cancer (ER+/HER2-),Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3970,NCT02763566,A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Abemaciclib (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Placebo (DRUG); Fulvestrant (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3971,NCT01381874,A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy,COMPLETED,PHASE2,Metastatic ER+ Her2- Breast Cancer; Postmenopausal,Exemestane (DRUG); Abiraterone acetate + Prednisone/ Prednisolone + Exemestane (DRUG); Abiraterone acetate + Prednisone or Prednisolone (DRUG),2187,Asiolex,Metastatic ER+ Her2- Breast Cancer; Postmenopausal,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3972,NCT04836520,SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.,COMPLETED,PHASE2,Breast Cancer,SHR6390+anatrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3973,NCT04886531,"Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers",RECRUITING,PHASE2,Breast Cancer; HER2-positive Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer,Neratinib (DRUG); Letrozole (L) or Anastrozole (A) (DRUG); Trastuzumab (DRUG),2187,Asiolex,Breast Cancer; HER2-positive Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3974,NCT00849030,"ATAC - Arimidex, Tamoxifen Alone or in Combination",COMPLETED,PHASE3,Breast Cancer,Anastozole (Arimidex) (DRUG); Tamoxifen (Nolvadex) (DRUG); Anastozole (Arimidex) placebo (DRUG); Tamoxifen (Nolvadex) placebo (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3975,NCT05952557,An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2),RECRUITING,PHASE3,"Breast Cancer, Early Breast Cancer",Camizestrant (DRUG); Tamoxifen (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Abemaciclib (DRUG),2187,Asiolex,Early Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3976,NCT03778931,Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Elacestrant (DRUG); Standard of Care (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3977,NCT06953882,"Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy",NOT_YET_RECRUITING,PHASE2,HER2 Negative Breast Cancer,Ribociclib 400mg (DRUG); Letrozole 2.5mg (DRUG); Anastrazole 1mg (DRUG); Goserelin 3.6 MG (DRUG); Adjuvant chemotherapy (RADIATION),2187,Asiolex,HER2 Negative Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3978,NCT01553903,Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not,COMPLETED,PHASE4,Breast Cancer,"Tamoxifen, (DRUG); Exemestane (DRUG); Anastrozole (DRUG); Letrozole (DRUG)",2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3979,NCT00143390,Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer,COMPLETED,PHASE3,Breast Neoplasms,exemestane (DRUG); anastrozole (DRUG),2187,Asiolex,Breast Neoplasms,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3980,NCT00259090,Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Fulvestrant (DRUG); Anastrazole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3981,NCT03184090,Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC,COMPLETED,PHASE2,Metastatic Breast Cancer,Palbociclib (DRUG); Endocrine therapy (non IMP) (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3982,NCT06016738,OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Negative Breast Carcinoma,Palazestrant (DRUG); Fulvestrant (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG),2187,Asiolex,Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Negative Breast Carcinoma,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3983,NCT01127295,Pharmacology of Adjuvant Hormonotherapy in Breast Cancer,COMPLETED,PHASE4,Hormono-depending Adjuvant Breast Cancer,"Tamoxifen, Letrozole, Anastrozole or Exemestane (DRUG)",2187,Asiolex,Hormono-depending Adjuvant Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3984,NCT00295646,"Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid",COMPLETED,PHASE3,Breast Cancer,tamoxifen (DRUG); anastrozole (DRUG); zoledronic acid (DRUG); goserelin (OTHER),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3985,NCT00274469,A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,fulvestrant (DRUG); anastrozole (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3986,NCT03948568,Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT),COMPLETED,PHASE4,Early-stage Breast Cancer,Endocrine Therapy and Radiotherapy (COMBINATION_PRODUCT),2187,Asiolex,Early-stage Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3987,NCT06585969,"A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer",NOT_YET_RECRUITING,PHASE3,Metastatic Breast Cancer; ER-positive Breast Cancer; Luminal B; Her2 Enriched; Basal Like,Trastuzumab deruxtecan (T-DXd) (DRUG); Ribociclib with ET (DRUG); Abemaciclib with ET (DRUG),2187,Asiolex,Metastatic Breast Cancer; ER-positive Breast Cancer; Luminal B; Her2 Enriched; Basal Like,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3988,NCT03219476,"Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer",COMPLETED,PHASE2,Breast Cancer; Invasive Breast Cancer,Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Tamoxifen (DRUG),2187,Asiolex,Breast Cancer; Invasive Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3989,NCT01216176,A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer,COMPLETED,PHASE1,Breast Cancer,Anastrozole (DRUG); AZD0530 (saracatinib) (DRUG); Placebo (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3990,NCT02203331,"Bay98-7196, Dose Finding / POC Study",COMPLETED,PHASE2,Endometriosis,Placebo (DRUG); Levonorgestrel (DRUG); Anastrozole (DRUG); Lupron / Leuprolide acetate (DRUG),2187,Asiolex,Endometriosis,Uterus,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3991,NCT01950182,Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Endocrine therapy combined with trastuzumab (DRUG); Chemotherapy combined with trastuzumab (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3992,NCT01344031,"MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer",COMPLETED,PHASE1,Estrogen Receptor Positive; Invasive Breast Carcinoma; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7,Akt Inhibitor MK2206 (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG); Laboratory Biomarker Analysis (OTHER),2187,Asiolex,Estrogen Receptor Positive; Invasive Breast Carcinoma; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3993,NCT04556773,A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Breast Cancer,Trastuzumab deruxtecan (DRUG); Durvalumab (DRUG); Paclitaxel (DRUG); Capivasertib (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG); Capecitabine (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3994,NCT00661531,Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy,TERMINATED,PHASE2,"Breast Cancer; Cancer of the Breast; Neoplasms, Breast",Estrace (DRUG); Anastrozole (DRUG),2187,Asiolex,"Breast Cancer; Cancer of the Breast; Neoplasms, Breast",Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3995,NCT04719273,Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Refractory Endometrial Adenocarcinoma; Refractory Endometrial Carcinoma; Refractory Endometrial Clear Cell Adenocarcinoma; Refractory Endometrial Endometrioid Adenocarcinoma; Refractory Endometrial Mixed Cell Adenocarcinoma; Refractory Endometrial Serous Adenocarcinoma; Refractory Endometrial Undifferentiated Carcinoma,Extended-release Onapristone (DRUG); Anastrozole (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive) (DIAGNOSTIC_TEST); Progesterone Receptor Positive ( PGR Positive; PR Positive) (DIAGNOSTIC_TEST),2187,Asiolex,Refractory Endometrial Adenocarcinoma; Refractory Endometrial Carcinoma; Refractory Endometrial Clear Cell Adenocarcinoma; Refractory Endometrial Endometrioid Adenocarcinoma; Refractory Endometrial Mixed Cell Adenocarcinoma; Refractory Endometrial Serous Adenocarcinoma; Refractory Endometrial Undifferentiated Carcinoma,Uterus,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3996,NCT05238831,SMMART Adaptive Clinical Treatment (ACT) Trial,WITHDRAWN,EARLY_PHASE1,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Alectinib (DRUG); Alpelisib (DRUG); Anastrozole (DRUG); Atezolizumab (BIOLOGICAL); Bevacizumab (BIOLOGICAL); Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Capecitabine (DRUG); Carboplatin (DRUG); Cobimetinib (DRUG); Entrectinib (DRUG); Eribulin (DRUG); Fulvestrant (DRUG); Hyaluronidase-zzxf/Pertuzumab/Trastuzumab (BIOLOGICAL); Irinotecan (DRUG); Letrozole (DRUG); Nab-paclitaxel (DRUG); Niraparib (DRUG); Olaparib (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Pertuzumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Trastuzumab (BIOLOGICAL); Trastuzumab Emtansine (BIOLOGICAL); Vemurafenib (DRUG); Vinorelbine (DRUG); Vismodegib (DRUG),2187,Asiolex,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Ovary/Fallopian Tube,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3997,NCT05257395,A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Advanced Breast Cancer,XZP-3287+ Letrozole/Anastrozole (DRUG); Placebo + Letrozole/Anastrozole (DRUG),2187,Asiolex,Advanced Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3998,NCT02441946,"A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",COMPLETED,PHASE2,Breast Cancer; Hormone Receptor Positive Tumor; Early-Stage Breast Carcinoma,Abemaciclib (DRUG); Loperamide (DRUG); Anastrozole (DRUG),2187,Asiolex,Breast Cancer; Hormone Receptor Positive Tumor; Early-Stage Breast Carcinoma,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +3999,NCT03211572,The EMPOwER Study Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers,UNKNOWN,PHASE2,Breast Cancer,Tamoxifen (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4000,NCT00310180,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),ACTIVE_NOT_RECRUITING,PHASE3,Breast Adenocarcinoma; Hormone Receptor Positive; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIB Breast Cancer AJCC v7,Anastrozole (DRUG); Exemestane (DRUG); Laboratory Biomarker Analysis (OTHER); Letrozole (DRUG); Quality-of-Life Assessment (OTHER); Radiation Therapy (RADIATION); Tamoxifen Citrate (DRUG),2187,Asiolex,Breast Adenocarcinoma; Hormone Receptor Positive; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIB Breast Cancer AJCC v7,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4001,NCT05780567,Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer,RECRUITING,PHASE3,Breast Cancer,"TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen (DRUG); Placebo capsules, Letrozole, Anastrozole, Tamoxifen (DRUG)",2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4002,NCT02344472,Detect V / CHEVENDO (Chemo vs. Endo),ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Breast Cancer,pertuzumab (DRUG); Trastuzumab (DRUG); Capecitabine (DRUG); Paclitaxel (DRUG); Vinorelbine (DRUG); Docetaxel (DRUG); Exemestane (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG); Ribociclib (DRUG); nab-Paclitaxel (DRUG); eribulin (DRUG); leuprorelin (DRUG); goserelin (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4003,NCT00077025,Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Gefitinib (DRUG); Anastrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4004,NCT00549822,Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Letrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4005,NCT02549430,To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy,COMPLETED,PHASE2,Breast Cancer,Palbociclib (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4006,NCT04294225,Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer,COMPLETED,PHASE2,Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Early-Stage Breast Carcinoma; Invasive Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8,Anastrozole (DRUG); Letrozole (DRUG),2187,Asiolex,Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Early-Stage Breast Carcinoma; Invasive Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4007,NCT01814865,Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer,WITHDRAWN,PHASE2,Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer,Abiraterone Acetate (DRUG); Prednisone (DRUG); Aromatase Inhibitor (DRUG),2187,Asiolex,Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4008,NCT06149130,Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer,RECRUITING,PHASE2,Breast Cancer,Adebrelimab (DRUG); dalpiciclib (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4009,NCT03874325,Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer,TERMINATED,PHASE2,Breast Cancer; Hormone Receptor Positive Tumor,Durvalumab (DRUG); Anastrozole 1mg (DRUG); Letrozole 2.5mg (DRUG); Exemestane 25 MG (DRUG),2187,Asiolex,Breast Cancer; Hormone Receptor Positive Tumor,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4010,NCT02511639,Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients,COMPLETED,PHASE3,Breast Cancer Metastatic,Everolimus (DRUG); Aromatase Inhibitors (DRUG),2187,Asiolex,Breast Cancer Metastatic,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4011,NCT00066339,Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy,COMPLETED,PHASE2,Breast Cancer,gefitinib (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4012,NCT00541086,"Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery",UNKNOWN,PHASE3,Breast Cancer,anastrozole (DRUG); exemestane (DRUG); letrozole (DRUG); tamoxifen citrate (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4013,NCT05894239,A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer,RECRUITING,PHASE3,Metastatic Breast Cancer,Inavolisib (DRUG); Phesgo (DRUG); Placebo (DRUG); Taxane-based Chemotherapy (DRUG); Optional Endocrine Therapy of Investigator's Choice (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4014,NCT04227327,"Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)",UNKNOWN,PHASE2,Advanced Breast Cancer,Abemaciclib (DRUG); Aromatase Inhibitors (DRUG),2187,Asiolex,Advanced Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4015,NCT00543127,Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole,TERMINATED,PHASE3,Breast Cancer,Fulvestrant (DRUG); Anastrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4016,NCT00066573,Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer,COMPLETED,PHASE3,Breast Cancer,anastrozole (DRUG); exemestane (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4017,NCT02040857,"Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer",COMPLETED,PHASE2,Breast Cancer,Palbociclib (DRUG); Aromatase Inhibitor (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4018,NCT00497458,Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced Side-Effects,UNKNOWN,PHASE2,Breast Cancer; Arthralgia; Osteoporosis,Testosterone (DRUG),2187,Asiolex,Breast Cancer; Arthralgia; Osteoporosis,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4019,NCT01626222,"4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer",COMPLETED,PHASE3,Metastatic Breast Cancer,Exemestane (DRUG); Everolimus (RAD001) (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4020,NCT00253422,Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer,UNKNOWN,PHASE3,Breast Cancer,anastrozole (DRUG); exemestane (DRUG); fulvestrant (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4021,NCT03820830,Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer Recurrent,Palbociclib 125mg (DRUG); Standard endocrine therapy (DRUG),2187,Asiolex,Recurrent Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4022,NCT00049062,Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,anastrozole (DRUG); gefitinib (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4023,NCT00887380,STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing),UNKNOWN,PHASE3,Breast Cancer,Pre-radiotherapy commencement of anastrozole (DRUG); Radiotherapy (RADIATION); Post radiotherapy commencement of anastrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4024,NCT00398489,"Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery",UNKNOWN,PHASE2,Breast Cancer,trastuzumab (BIOLOGICAL); anastrozole (DRUG); cyclophosphamide (DRUG); docetaxel (DRUG); epirubicin hydrochloride (DRUG); goserelin acetate (DRUG); tamoxifen citrate (DRUG); adjuvant therapy (PROCEDURE); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE); radiation therapy (RADIATION),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4025,NCT03024580,A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer,UNKNOWN,PHASE2,Breast Neoplasm,Megestrol Acetate 160Mg Tablet (DRUG); Anastrozole 1Mg Tablet (DRUG); Letrozole 2.5Mg Tablet (DRUG); Exemestane 25 MG (DRUG); Tamoxifen 20Mg Tablet (DRUG); Fulvestrant 50Mg Solution for Injection (DRUG),2187,Asiolex,Breast Neoplasm,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4026,NCT01989780,Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Paclitaxel (DRUG); Bevacizumab (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Goserelin (DRUG); leuprorelin (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4027,NCT05411380,"Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.",UNKNOWN,PHASE2,Breast Cancer,Tucidinostat (DRUG); Capecitabine (DRUG); Endocrine Therapy (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4028,NCT03304080,"Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast",ACTIVE_NOT_RECRUITING,PHASE1,Breast Neoplasms; Breast Diseases,Anastrozole (DRUG); Palbociclib (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG),2187,Asiolex,Breast Neoplasms; Breast Diseases,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4029,NCT02730091,"A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease",TERMINATED,PHASE3,Breast Cancer,Letrozole (DRUG); Anastrozole (DRUG); Vinorelbine (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4030,NCT05467891,"Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer",RECRUITING,PHASE2,Locoregional Recurrence; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer,Ribociclib (DRUG); Fulvestrant (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG),2187,Asiolex,Breast Cancer (ER+/HER2-),Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4031,NCT01352091,Adjuvant AI Combined With Zoladex,UNKNOWN,PHASE3,Breast Cancer,Zoladex+AI (DRUG); TAM (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4032,NCT06001762,TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer; Early-stage Breast Cancer; High Risk Breast Carcinoma,Abemaciclib (DRUG); Tamoxifen (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); LHRH Agonist (DRUG),2187,Asiolex,Breast Cancer; Early-stage Breast Cancer; High Risk Breast Carcinoma,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4033,NCT00688194,Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy,UNKNOWN,PHASE3,Breast Cancer,anastrozole (DRUG); exemestane (DRUG); fulvestrant (DRUG); lapatinib ditosylate (DRUG); letrozole (DRUG); placebo (OTHER),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4034,NCT05190094,"Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.",RECRUITING,PHASE2,"Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer",Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole) (DRUG),2187,Asiolex,"Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer",Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4035,NCT05362760,Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management,RECRUITING,PHASE4,Hormone Receptor-positive Metastatic Breast Cancer; HER2-negative Metastatic Breast Cancer,Abemaciclib + Aromatase Inhibitor (DRUG); Abemaciclib + Fulvestrant (DRUG),2187,Asiolex,Hormone Receptor-positive Metastatic Breast Cancer; HER2-negative Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4036,NCT00072462,Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ,COMPLETED,PHASE3,Breast Cancer,tamoxifen citrate (DRUG); Anastrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4037,NCT00784862,ATAC - Pharmacokinetics (PK) Sub-Protocol,COMPLETED,PHASE3,Breast Cancer,Anastrozole (DRUG); Tamoxifen (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4038,NCT01602380,A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.,ACTIVE_NOT_RECRUITING,PHASE3,Hormone Receptor Positive Breast Cancer,faslodex 500mg (DRUG); arimidex 1mg (DRUG); faslodex dummy (DRUG); arimidex dummy (DRUG),2187,Asiolex,Hormone Receptor Positive Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4039,NCT02476786,Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score,RECRUITING,PHASE2,Breast Cancer; Cancer of Breast; Breast Neoplasms; Cancer of the Breast,FACT-B (BEHAVIORAL); Goserelin (DRUG); Anastrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Tamoxifen (DRUG); Archived tissue collection (OTHER),2187,Asiolex,Breast Cancer; Cancer of Breast; Breast Neoplasms; Cancer of the Breast,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4040,NCT04113863,Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer,RECRUITING,PHASE2,Breast Neoplasm Female,all-trans retinoic acid (DRUG); Anastrozole 1mg (DRUG),2187,Asiolex,Female Breast Neoplasm,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4041,NCT01368263,Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer,TERMINATED,PHASE2,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,goserelin acetate (DRUG); letrozole (DRUG); anastrozole (DRUG); chemotherapy (DRUG); Surgery (PROCEDURE),2187,Asiolex,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4042,NCT00255463,Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study,COMPLETED,PHASE2,Breast Cancer,Anastrazole (DRUG); Gefitinib (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4043,NCT00508586,PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer,COMPLETED,PHASE1,Metastatic Breast Cancer,PTC299 (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4044,NCT04707196,A Study of Abemaciclib in Indian Women With Advanced Breast Cancer,COMPLETED,PHASE4,Breast Neoplasms; Neoplasm Metastasis,Abemaciclib (DRUG); Nonsteroidal Aromatase Inhibitor (NSAI) (DRUG); Fulvestrant (DRUG),2187,Asiolex,Breast Neoplasms with Metastasis,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4045,NCT04568616,Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI),RECRUITING,PHASE2,Breast Cancer; ER Positive Breast Cancer,Letrozole 2.5mg (DRUG),2187,Asiolex,Breast Cancer; ER Positive Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4046,NCT04539496,A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,Metastasis Solid Tumors; Advanced Breast Cancer,XZP-3287 (DRUG); XZP-3287;Letrozole;Anastrozole;Fulvestrant (DRUG); XZP-3287 (DRUG),2187,Asiolex,Metastasis Solid Tumors; Advanced Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4047,NCT00684216,Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer,TERMINATED,PHASE2,Breast Cancer,"capecitabine (DRUG); hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole) (DRUG)",2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4048,NCT02000596,1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.,TERMINATED,PHASE2,Metastatic Breast Cancer,Trastuzumab plus Pertuzumab (DRUG); Hormonal Therapy with Anastrozole and Fulvestrant (DRUG); Chemotherapy with Eribulin (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4049,NCT04961996,"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)",RECRUITING,PHASE3,Early Breast Cancer,Giredestrant (DRUG); Endocrine Therapy of Physician's Choice (DRUG); LHRH Agonist (DRUG); Abemaciclib (DRUG),2187,Asiolex,Early Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4050,NCT00629616,"Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer",COMPLETED,PHASE2,Breast Cancer,anastrozole (DRUG); fulvestrant (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4051,NCT06656624,Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel),RECRUITING,PHASE2,Advanced Breast Cancer,Ribociclib combined with AI±OFS (DRUG); physician's choice of chemotherapy sequential Ribociclib combined with AI±OFS (DRUG),2187,Asiolex,Advanced Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4052,NCT00126360,STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot),UNKNOWN,PHASE4,Breast Cancer,Timing of Anastrozole in respect to radiotherapy (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4053,NCT01769781,Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence,COMPLETED,PHASE4,Endometriosis,anastrazole (DRUG); GnRH analog alone (DRUG),2187,Asiolex,Endometriosis,Uterus,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4054,NCT05827081,Phase IIIb Study of Ribociclib + ET in Early Breast Cancer,NOT_YET_RECRUITING,PHASE3,Early Breast Cancer,Ribociclib (DRUG); Letrozole (DRUG); Ansastrozole (DRUG); Goserelin (DRUG); Leuprolide (DRUG); Exemestane (DRUG),2187,Asiolex,Early Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4055,NCT05594095,SNF Platform Study of HR+/ HER2-advanced Breast Cancer,RECRUITING,PHASE2,Breast Neoplasm; Breast Cancer; Hormone Receptor Positive Tumor; HER2-negative Breast Cancer; Advanced Breast Cancer,PIK3CA inhibitor (DRUG); AKT inhibitor (DRUG); Carrelizumab (DRUG); Famitinib (DRUG); Fluzoparib (DRUG); Dalpiciclib (DRUG); SHR-A1811 (DRUG); Everolimus (DRUG); Aromatase Inhibitors or Fulvestrant (DRUG); Goserelin (DRUG); TPC (DRUG); Sorafenib (DRUG); Apatinib (DRUG); SHR-A1921 (DRUG); SHR-A2102 (DRUG); SHR-A2009 (DRUG); SHR-1167 (DRUG); SHR-6209 (DRUG); bevacizumab (DRUG),2187,Asiolex,"Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4056,NCT03321981,MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.,COMPLETED,PHASE2,Breast Cancer Metastatic,Zenocutuzumab (DRUG); Trastuzumab (DRUG); Vinorelbine (DRUG); Endocrine therapy (DRUG),2187,Asiolex,Breast Cancer Metastatic,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4057,NCT05792410,A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.,UNKNOWN,PHASE1,HER2 Low Advanced or Metastatic Breast Cancer,SHR-A1811 & Dalpiciclib Isethionate Tablets (DRUG); SHR-A1811 & Fulvestrant (DRUG); SHR-A1811 & Bevacizumab injection (DRUG),2187,Asiolex,HER2 Low Advanced or Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4058,NCT05472792,Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN),RECRUITING,PHASE2,Breast Cancer; Quality of Life,"Accelerated Partial Breast Irradiation (APBI) (RADIATION); tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene (DRUG)",2187,Asiolex,Breast Cancer; Quality of Life,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4059,NCT01783444,A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.,COMPLETED,PHASE2,Breast Cancer,Capecitabine (DRUG); Exemestane (DRUG); Everolimus (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4060,NCT00002644,Tamoxifen for the Prevention of Breast Cancer in High-Risk Women,COMPLETED,PHASE3,Breast Cancer,Tamoxifen Citrate 20Mg Tab (DRUG); Placebo (OTHER),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4061,NCT04436744,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)",COMPLETED,PHASE2,Early Breast Cancer,Giredestrant (DRUG); Anastrozole (DRUG); Palbociclib (DRUG); Surgery (PROCEDURE),2187,Asiolex,Early Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4062,NCT00329940,Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Letrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4063,NCT00605267,Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment,COMPLETED,PHASE3,Breast Cancer,Tamoxifen (DRUG); Anastrazole (Arimidex) (DRUG); Goserelin acetate (Zoladex) (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4064,NCT04316169,"Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer",WITHDRAWN,PHASE1,Solid Tumor; Advanced Breast Cancer,Abemaciclib (DRUG); Hydroxychloroquine 200 mg (DRUG); Faslodex (DRUG); Anastrazole (DRUG); Letrozole (DRUG); Hydroxychloroquine 400 mg (DRUG); Hydroxychloroquine 600 mg (DRUG),2187,Asiolex,Advanced Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4065,NCT03179904,TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Advanced Breast Carcinoma; HER2-Positive Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; HER2-positive Breast Cancer,Anastrozole (DRUG); Denifanstat (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Echocardiography (PROCEDURE); Letrozole (DRUG); Paclitaxel (DRUG); Trastuzumab (BIOLOGICAL); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Biospecimen Collection (PROCEDURE); Biopsy (PROCEDURE),2187,Asiolex,Advanced Breast Carcinoma; HER2-Positive Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; HER2-positive Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4066,NCT02181101,"Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial",COMPLETED,PHASE3,Breast Neoplasms,FEC-DocGemzar adjuvant chemotherapy (DRUG); FEC-Doc adjuvant chemotherapy (DRUG); Zoledronic acid i.v. 2 years (DRUG); Zoledronic acid i.v. 5 years (DRUG),2187,Asiolex,Breast Neoplasms,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4067,NCT06086704,Study of 18F-FFNP Breast PET/MRI,RECRUITING,PHASE2,Breast Cancer,18F-fluorofuranylnorprogesterone (DRUG); Positron Emissions Tomography / Magnetic Resonance Imaging (DEVICE); Anastrozole (DRUG); Blood Sampling (OTHER); FDA-approved gadolinium-based intravenous contrast agent (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4068,NCT04075604,A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Cancer,Nivolumab (BIOLOGICAL); Anastrozole (DRUG); Palbociclib (DRUG),2187,Asiolex,Breast Cancer; Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4069,NCT05501704,ETHAN - ET for Male BC,RECRUITING,PHASE2,Male Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma,Tamoxifen (DRUG); Anastrozole (DRUG); Degarelix (DRUG); Abemaciclib (DRUG),2187,Asiolex,Male Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4070,NCT01466972,Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib,COMPLETED,PHASE2,Breast Cancer; Breast Neoplasm,Pazopanib (DRUG),2187,Asiolex,Breast Cancer; Breast Neoplasm,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4071,NCT06361940,Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients with Hormone Receptor-Positive HER2-negative Breast Cancer,RECRUITING,PHASE2,Breast Cancer,Aromatase inhibitors or tamoxifen (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4072,NCT02072512,The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer,UNKNOWN,PHASE2,Metastatic Breast Cancer,Fulvestrant (DRUG); Goserelin (DRUG); Anastrozole (DRUG); Goserelin (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4073,NCT00007904,Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes,COMPLETED,PHASE2,Breast Cancer,filgrastim (BIOLOGICAL); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); paclitaxel (DRUG); tamoxifen citrate (DRUG); adjuvant therapy (PROCEDURE); radiation therapy (RADIATION),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4074,NCT04272801,Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer Female,"tamoxifen, letrozole, anastrozole, or exemestane (DRUG); Patient reported outcomes (BEHAVIORAL)",2187,Asiolex,Breast Cancer Female,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4075,NCT01674140,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,anastrozole (DRUG); everolimus (DRUG); exemestane (DRUG); goserelin acetate (DRUG); letrozole (DRUG); leuprolide acetate (DRUG); tamoxifen citrate (DRUG); placebo (OTHER),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4076,NCT03554044,T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer,UNKNOWN,PHASE1,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Breast Carcinoma,Anastrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Paclitaxel (DRUG); Talimogene Laherparepvec (BIOLOGICAL); Tamoxifen (DRUG); Nab paclitaxel (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG),2187,Asiolex,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Breast Carcinoma,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4077,NCT04023292,Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer,RECRUITING,PHASE2,Breast Neoplasms,Endocrine therapy (DRUG); Endocrine therapy (DRUG),2187,Asiolex,Breast Neoplasms,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4078,NCT03944434,FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,"Ribociclib (DRUG); Aromatase Inhibitors, non steroideal (DRUG); LHRH agonist (DRUG)",2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4079,NCT00287534,Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.,COMPLETED,PHASE2,Breast Cancer,Anastrozole (DRUG); Tamoxifen (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4080,NCT04964934,Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6),ACTIVE_NOT_RECRUITING,PHASE3,ER-Positive HER2-Negative Breast Cancer,AZD9833 (DRUG); AZD9833 Placebo (DRUG); Anastrozole (DRUG); Anastrozole placebo (DRUG); Letrozole (DRUG); Letrozole placebo (DRUG); Palbociclib (DRUG); Abemaciclib (DRUG); Luteinizing hormone-releasing hormone (LHRH) agonist (DRUG); Ribociclib (DRUG),2187,Asiolex,ER-Positive HER2-Negative Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4081,NCT06176534,"Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial",RECRUITING,PHASE2,Advanced Breast Cancer; Treatment; HR Low/HER2 Negative,Experimental: chemotheyapy (DRUG); Active Comparator: endocrine therapy (DRUG),2187,Asiolex,Advanced Breast Cancer; Treatment; HR Low/HER2 Negative,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4082,NCT00871858,Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer,COMPLETED,PHASE2,Breast Cancer,anastrozole (DRUG); fulvestrant (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4083,NCT00935558,Dendritic Cell Based Therapy for Breast Cancer Patients,WITHDRAWN,PHASE2,Breast Cancer,DC vaccine (BIOLOGICAL); aromatase inhibitor (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4084,NCT00615524,Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer,WITHDRAWN,PHASE2,Hormone-receptor Positive Breast Cancer,exemestane and pazopanib (DRUG),2187,Asiolex,Hormone-receptor Positive Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4085,NCT02236572,"Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score",TERMINATED,PHASE2,Breast Cancer,Everolimus (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4086,NCT00022672,A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer,COMPLETED,PHASE3,Breast Cancer,trastuzumab (Herceptin®) (DRUG); anastrazole (Arimidex®) (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4087,NCT02995772,Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients,COMPLETED,PHASE3,Breast Cancer,Aromatase Inhibitors (Arimidex) (DRUG); Tamoxifen (DRUG); SOB (PROCEDURE); FAC (DRUG); Aromatase Inhibitors (Femara) (DRUG); Aromatase Inhibitors (Aromasin) (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4088,NCT00077168,Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole,UNKNOWN,PHASE2,Breast Cancer,anastrozole (DRUG); tamoxifen citrate (DRUG); adjuvant therapy (PROCEDURE); radiation therapy (RADIATION),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4089,NCT00327769,Faslodex Advanced Breast Cancer Local Chinese Study,COMPLETED,PHASE3,Advanced Breast Cancer,Fulvestrant (DRUG); Anastrozole (DRUG),2187,Asiolex,Advanced Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4090,NCT06671912,"Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial",RECRUITING,PHASE3,Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage 1 Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Estrogen Receptor-Positive Breast Carcinoma; HER2-Negative Breast Carcinoma,Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Tamoxifen (DRUG); Mammogram (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Dual X-ray Absorptiometry (BIOLOGICAL); Biospecimen Collection (PROCEDURE); Questionnaire Administration (OTHER),2187,Asiolex,Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage 1 Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Estrogen Receptor-Positive Breast Carcinoma; HER2-Negative Breast Carcinoma,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4091,NCT02338310,Trial of Perioperative Endocrine Therapy - Individualising Care,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Aromatase Inhibitors (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4092,NCT00354640,Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer,COMPLETED,PHASE2,Breast Cancer,anastrozole (DRUG); simvastatin (DRUG); pharmacological study (OTHER); adjuvant therapy (PROCEDURE),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4093,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",COMPLETED,PHASE2,Breast Cancer,Ribociclib (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Goserelin (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4094,NCT04256941,"Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study",TERMINATED,PHASE2,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8,Abemaciclib (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Palbociclib (DRUG); Ribociclib (DRUG),2187,Asiolex,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4095,NCT00286117,ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years,COMPLETED,PHASE3,Breast Cancer,Anastrozole (DRUG); Tamoxifen (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4096,NCT05949541,Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer,RECRUITING,PHASE2,Breast Cancer; Advanced Breast Cancer,Everolimus 10 mg (DRUG); CDK4/6 Inhibitor SHR6390 (DRUG); Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4097,NCT00635713,Second Line Breast Cancer Trial,COMPLETED,PHASE3,Advanced Breast Cancer,Fulvestrant (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG),2187,Asiolex,Advanced Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4098,NCT04714619,CB-103 Plus NSAI In Luminal Advanced Breast Cancer,TERMINATED,PHASE2,Advanced Breast Cancer,CB-103 (DRUG),2187,Asiolex,Advanced Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4099,NCT01484041,Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer,TERMINATED,PHASE1,Breast Cancer,Dovitinib (DRUG); Aromatase Inhibitors (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4100,NCT03081234,Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer,WITHDRAWN,PHASE3,Breast Cancer,Ribociclib (DRUG); Placebo (DRUG); Adjuvant endocrine therapy (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4101,NCT01266213,Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women,UNKNOWN,PHASE2,Metastatic Breast Cancer; Estrogen Receptor Positive Tumor; Breast Cancer Nos Premenopausal,Fulvestrant plus Goserelin (DRUG); Anastrozole plus Goserelin (DRUG); Goserelin (DRUG),2187,Asiolex,Metastatic Breast Cancer; Estrogen Receptor Positive Tumor; Breast Cancer Nos Premenopausal,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4102,NCT02291913,Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Everolimus (DRUG); Exemestane (DRUG); Tamoxifen (DRUG); Fulvestrant (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Toremifine (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4103,NCT00057941,Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer,COMPLETED,PHASE2,Estrogen Receptor-positive Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer,anastrozole (DRUG); gefitinib (DRUG); fulvestrant (DRUG); laboratory biomarker analysis (OTHER),2187,Asiolex,Estrogen Receptor-positive Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4104,NCT04012918,"Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study",UNKNOWN,PHASE2,Metastatic Breast Cancer,Capecitabine plus aromatase inhibitor (DRUG); A.I. (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4105,NCT00016549,Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Bevacizumab (BIOLOGICAL),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4106,NCT03988114,"A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer",WITHDRAWN,PHASE4,Metastatic Breast Cancer,Abemaciclib (DRUG); Nonsteroidal Aromatase Inhibitor (NSAI) (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4107,NCT00357110,Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Fulvestrant (DRUG); Anastrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4108,NCT00081510,Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480),COMPLETED,PHASE2,Breast Cancer,Lonafarnib (DRUG); Placebo (DRUG); anastrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4109,NCT04088110,Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer,UNKNOWN,PHASE2,Breast Cancer Female; HER2-positive Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast; Metastatic Breast Cancer; Breast Diseases; Hormone Receptor Positive Tumor,Pyrotinib (DRUG); Trastuzumab (DRUG); Aromatase Inhibitors (DRUG),2187,Asiolex,Breast Cancer Female; HER2-positive Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast; Metastatic Breast Cancer; Breast Diseases; Hormone Receptor Positive Tumor,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4110,NCT03910712,Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC,UNKNOWN,PHASE2,Breast Cancer Female; HER2-positive Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast; Metastatic Breast Cancer; Breast Diseases; Hormone Receptor Positive Tumor,Pyrotinib (DRUG); Trastuzumab (DRUG); Aromatase inhibitor (DRUG),2187,Asiolex,Breast Cancer Female; HER2-positive Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast; Metastatic Breast Cancer; Breast Diseases; Hormone Receptor Positive Tumor,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4111,NCT03839823,Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Docetaxel / Capecitabine (COMBINATION_PRODUCT); Capecitabine / Vinorelbine (COMBINATION_PRODUCT); Paclitaxel / Gemcitabine (COMBINATION_PRODUCT); Ribociclib (DRUG); Letrozole OR Anastrozole (DRUG); Goserelin (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4112,NCT04236310,"A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.",UNKNOWN,PHASE2,Breast Cancer; HER2-positive Breast Cancer; ER-positive Breast Cancer,SHR6390 (DRUG); Anastrozole (DRUG); Pyrotinib (DRUG); Trastuzumab (DRUG),2187,Asiolex,Breast Cancer; HER2-positive Breast Cancer; ER-positive Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4113,NCT06072781,A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer,RECRUITING,PHASE3,Low Grade Serous Ovarian Cancer,avutometinib (DRUG); Defactinib (DRUG); Pegylated liposomal doxorubicin (DRUG); Paclitaxel (DRUG); Letrozole (DRUG); Anastrozole (DRUG),2187,Asiolex,Low Grade Serous Ovarian Cancer,Ovary/Fallopian Tube,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4114,NCT02942355,Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Female Breast Carcinoma; Breast Cancer,anastrozole (DRUG); Palbociclib (DRUG),2187,Asiolex,Female Breast Carcinoma; Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4115,NCT02910050,Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Bicalutamide (DRUG); Aromatase Inhibitor (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4116,NCT06447623,Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer,RECRUITING,PHASE3,Advanced Breast Cancer; HR+/HER2- Breast Cancer,Apatinib (DRUG); CDK4/6 Inhibitor (DRUG); Aromatase inhibitor and Fulvestrant (DRUG),2187,Asiolex,Advanced HR+/HER2- Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4117,NCT03312738,"A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor",COMPLETED,PHASE2,Advanced Breast Cancer,Everolimus (DRUG); Exemestane (DRUG); Everolimus Placebo (DRUG),2187,Asiolex,Advanced Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4118,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Breast Neoplasm,Docetaxel - Dose A (DRUG); Anastrozole (DRUG); cyclophosphamide (DRUG); Docetaxel - Dose B (DRUG); Doxorubicin hydrochloride (DRUG); Tamoxifen Citrate (DRUG); Capecitabine - Dose B (DRUG); Capecitabine - Dose A (DRUG),2187,Asiolex,Breast Cancer; Breast Neoplasm,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4119,NCT01776008,Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer,TERMINATED,PHASE2,Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Akt Inhibitor MK2206 (DRUG); Anastrozole (DRUG); Goserelin Acetate (DRUG); Laboratory Biomarker Analysis (OTHER); Neoadjuvant Therapy (PROCEDURE); Pharmacological Study (OTHER); Therapeutic Conventional Surgery (PROCEDURE),2187,Asiolex,Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4120,NCT06044623,Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients,RECRUITING,PHASE3,Metastatic Breast Cancer; Advanced Breast Cancer; Quality of Life; Toxicity; Older Patients,CDK 4/6 inhibitors (DRUG); Endocrine therapy (DRUG),2187,Asiolex,Metastatic Breast Cancer; Advanced Breast Cancer; Quality of Life; Toxicity; Older Patients,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4121,NCT05837455,"NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer",RECRUITING,PHASE2,Breast Cancer; Cancer of the Breast,VENTANA MIB-1 Ki67 assay (DEVICE); Oncotype DX® Recurrence Score (DEVICE); PAM50-based Prosigna breast cancer gene signature assay (DEVICE); Anastrozole (DRUG); Combination anthracycline and/or taxane based treatment (DRUG),2187,Asiolex,Breast Cancer; Cancer of the Breast,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4122,NCT05161195,Roll-over Study to Allow Continued Access to Ribociclib,RECRUITING,PHASE4,Metastatic Breast Cancer,Ribociclib (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Goserelin (DRUG); Tamoxifen (DRUG); Fulvestrant (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4123,NCT04906395,Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer,RECRUITING,PHASE3,Breast Cancer,TOL2506 (DRUG); Tamoxifen (DRUG); Letrozole Tablets (DRUG); Anastrozole Tablets (DRUG); Exemestane Tablets (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4124,NCT02476955,Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole,TERMINATED,PHASE1,Solid Tumors; Ovarian Cancer; Endometrial Cancer,ARQ 092 + carboplatin + paclitaxel (Closed) (DRUG); ARQ 092 + paclitaxel (Closed) (DRUG); ARQ 092 + anastrozole (DRUG),2187,Asiolex,Solid Tumors; Ovarian Cancer; Endometrial Cancer,Uterus,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4125,NCT00324714,Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS,WITHDRAWN,PHASE3,Breast Cancer; Osteoporosis,risedronate sodium (DRUG); diagnostic laboratory biomarker analysis (OTHER),2187,Asiolex,Breast Cancer; Osteoporosis,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4126,NCT00206414,"Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer",TERMINATED,PHASE2,BREAST CANCER,Iressa Day 1 given with Arimidex and Faslodex (DRUG); Iressa Day 21 given with Arimidex and Faslodex (DRUG),2187,Asiolex,BREAST CANCER,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4127,NCT00573755,"Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer",TERMINATED,PHASE2,Breast Cancer,anastrozole (DRUG); exemestane (DRUG); letrozole (DRUG); sorafenib tosylate (DRUG); placebo (OTHER),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4128,NCT00863655,Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole,COMPLETED,PHASE3,Breast Cancer,Everolimus (DRUG); Exemestane (DRUG); Everolimus Placebo (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4129,NCT02188550,Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer,UNKNOWN,PHASE2,Ovarian Cancer; Endometrial Cancer,everolimus and letrozole (DRUG),2187,Asiolex,Ovarian Cancer; Endometrial Cancer,Ovary/Fallopian Tube,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4130,NCT02730923,Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA),ACTIVE_NOT_RECRUITING,PHASE1,Endometrial Carcinoma; Metastatic Carcinoma; Hormone Receptor Positive Tumor,AZD2014 (DRUG); Anastrozole (DRUG),2187,Asiolex,Endometrial Carcinoma; Metastatic Carcinoma; Hormone Receptor Positive Tumor,Uterus,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4131,NCT00570323,Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Arimidex (DRUG); Faslodex (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4132,NCT03238703,"Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer",WITHDRAWN,PHASE4,HER2/Neu Negative; Invasive Breast Carcinoma; Postmenopausal; Stage 0 Breast Cancer; Stage IA Breast Cancer,Anastrozole (DRUG); Exemestane (DRUG); Laboratory Biomarker Analysis (OTHER); Letrozole (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); Tamoxifen Citrate (DRUG); Toremifene Citrate (DRUG),2187,Asiolex,HER2/Neu Negative; Invasive Breast Carcinoma; Postmenopausal; Stage 0 Breast Cancer; Stage IA Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4133,NCT05826964,Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer,RECRUITING,PHASE2,Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer,AI+CDK4/6i (DRUG); SERD+CDK4/6i (DRUG); mTOR inhibitor + AI (DRUG); mTOR inhibitor + SERD (DRUG); mTOR inhibitor + Selective estrogen receptor modulator (DRUG); PI3K inhibitor + SERD (DRUG); PI3K inhibitor + AI (DRUG); Chemotherapy (DRUG); Oral SERD (DRUG),2187,Asiolex,Metastatic ER-positive/HER2-negative Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4134,NCT00075764,S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer,COMPLETED,PHASE3,Breast Cancer,anastrozole (DRUG); fulvestrant (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4135,NCT05512364,Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA),RECRUITING,PHASE3,ER-positive Breast Cancer; HER2-negative Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer,Elacestrant (DRUG); Tamoxifen (DRUG); Letrozole 2.5mg (DRUG); Anastrozole 1mg (DRUG); Exemestane 25 MG (DRUG),2187,Asiolex,ER-positive Breast Cancer; HER2-negative Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4136,NCT03384095,Trial of Oral Hyaluronic Acid for the Prevention of Aromatase Inhibitor-Associated Arthralgias,WITHDRAWN,PHASE2,Breast Neoplasm Female; Arthralgia,Hyaluronic Acid (HA) (DRUG); Placebo (OTHER),2187,Asiolex,Breast Neoplasm Female; Arthralgia,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4137,NCT00405938,Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Breast Neoplasms,Bevacizumab (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG),2187,Asiolex,Breast Cancer; Breast Neoplasms,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4138,NCT03425838,Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Neoplasm Female,CDK 4/6 inhibitor (DRUG); Non-Steroidal Aromatase Inhibitor (DRUG); Fulvestrant (DRUG),2187,Asiolex,Female Breast Neoplasm,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4139,NCT00004906,Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,filgrastim (BIOLOGICAL); anastrozole (DRUG); carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); docetaxel (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); pamidronate disodium (DRUG); thiotepa (DRUG); peripheral blood stem cell transplantation (PROCEDURE),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4140,NCT00728949,A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,IMC-A12 (cixutumumab) (BIOLOGICAL); tamoxifen (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4141,NCT05645536,"Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study",ENROLLING_BY_INVITATION,PHASE3,Breast Cancer,TOL2506 (DRUG); Tamoxifen (DRUG); Letrozole tablets (DRUG); Anastrozole Tablets (DRUG); Exemestane Tablets (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4142,NCT01545336,Anastrozole in Patients With Pulmonary Arterial Hypertension,COMPLETED,PHASE2,Pulmonary Arterial Hypertension,Anastrozole (DRUG); Placebo (DRUG),2187,Asiolex,Pulmonary Arterial Hypertension,Lung,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4143,NCT00248170,Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Letrozole (DRUG); Anastrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4144,NCT04553770,"Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer",RECRUITING,PHASE2,Early-stage Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Invasive Breast Cancer; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer,Anastrozole (DRUG); Therapeutic Conventional Surgery (PROCEDURE); Trastuzumab Deruxtecan (BIOLOGICAL),2187,Asiolex,Early-stage Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Invasive Breast Cancer; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4145,NCT02269670,Phase II Study of Everolimus Beyond Progression,TERMINATED,PHASE2,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,everolimus (DRUG); anastrozole (DRUG); letrozole (DRUG); tamoxifen citrate (DRUG); fulvestrant (DRUG); megestrol acetate (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4146,NCT05041842,Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Cancer With a Isolated Brain Progression,Tucatinib (DRUG); Pertuzumab (DRUG); Trastuzumab (DRUG); Hormone therapy (DRUG); Pertuzumab/ Trastuzumab (DRUG),2187,Asiolex,Metastatic Breast Cancer With a Isolated Brain Progression,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4147,NCT02213042,Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer,TERMINATED,PHASE2,"Neoplasms, Breast",Lapatinib (DRUG); Trastuzumab (BIOLOGICAL); Aromatase Inhibitors (AIs) (DRUG),2187,Asiolex,"Neoplasms, Breast",Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4148,NCT03229499,Pulmonary Hypertension and Anastrozole Trial,COMPLETED,PHASE2,Pulmonary Arterial Hypertension,Anastrozole (DRUG); Placebo Oral Tablet (DRUG),2187,Asiolex,Pulmonary Arterial Hypertension,Lung,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4149,NCT01573442,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,COMPLETED,PHASE3,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,testosterone (DRUG); placebo (OTHER),2187,Asiolex,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4150,NCT05439499,"This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.",UNKNOWN,PHASE3,Advanced Breast Cancer; Female Breast Cancer,"FCN-437c, Letrozole or anastrozole, Goserelin acetate (DRUG); Placebo, Letrozole or anastrozole, Goserelin acetate (DRUG)",2187,Asiolex,Advanced Breast Cancer; Female Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4151,NCT00217399,Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer,COMPLETED,PHASE1,Recurrent Breast Cancer; Stage IV Breast Cancer,sorafenib tosylate (DRUG); anastrozole (DRUG),2187,Asiolex,Recurrent Breast Cancer; Stage IV Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4152,NCT06253702,Brain Blood Flow Responses to Stress: Sex Differences,RECRUITING,PHASE4,Cerebrovascular Disorders,Indomethacin (DRUG); Placebo (DRUG); Orilissa (DRUG); Testosterone gel (DRUG); Anastrozole (DRUG); Estradiol (DRUG),2187,Asiolex,Cerebrovascular Disorders,CNS/Brain,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4153,NCT06957379,Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy,ACTIVE_NOT_RECRUITING,PHASE2,HR+/HER2- Advanced/Metastatic Breast Cancer,Letrozole (DRUG); Anastrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Sirolimus for Injection (Albumin-bound) (DRUG),2187,Asiolex,HR+/HER2- Advanced/Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4154,NCT05085002,A Study of Lerociclib in Participants With Advanced Breast Cancer,TERMINATED,PHASE2,Advanced Breast Cancer,Lerociclib + Letrozole or Fulvestrant (DRUG),2187,Asiolex,Advanced Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4155,NCT00354302,Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial,COMPLETED,PHASE3,Breast Cancer; Osteoporosis,calcium carbonate (DIETARY_SUPPLEMENT); calcium citrate (DIETARY_SUPPLEMENT); cholecalciferol (DIETARY_SUPPLEMENT); alendronate sodium (DRUG); calcium gluconate (DRUG); risedronate sodium (DRUG); laboratory biomarker analysis (OTHER); dual x-ray absorptometry (PROCEDURE),2187,Asiolex,Breast Cancer; Osteoporosis,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4156,NCT01972984,Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer Patients,COMPLETED,PHASE2,Breast Cancer,Anastrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4157,NCT02246621,A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Abemaciclib (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Placebo (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4158,NCT02689921,NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer,UNKNOWN,PHASE2,Breast Neoplasms,Exemestane (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Leuprolide Acetate (DRUG); Pertuzumab (DRUG); Trastuzumab (DRUG),2187,Asiolex,Breast Neoplasms,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4159,NCT01303679,1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer,TERMINATED,PHASE3,First Line Metastatic Breast Cancer,Paclitaxel (DRUG); Bevacizumab (DRUG); Exemestane (DRUG),2187,Asiolex,First Line Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4160,NCT04059484,Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer,TERMINATED,PHASE2,Breast Cancer Metastatic,Amcenestrant (DRUG); Fulvestrant (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Tamoxifen (DRUG),2187,Asiolex,Breast Cancer Metastatic,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4161,NCT02918084,CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Anastrozole or Letrozole or Exemestane (DRUG); Anastrozole or Letrozole or Exemestane (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4162,NCT05524584,"Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer",RECRUITING,PHASE2,Breast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer,Fulvestrant (DRUG); Anastrozole (DRUG); Abemaciclib (DRUG),2187,Asiolex,Breast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4163,NCT00186121,Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women,COMPLETED,PHASE2,Breast Cancer,Anastrozole (Arimidex) (DRUG); Goserelin (Zoladex) (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4164,NCT00323479,Arthralgia During Anastrozole Therapy for Breast Cancer,COMPLETED,PHASE4,Early Breast Cancer,Anastrozole (DRUG),2187,Asiolex,Early Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4165,NCT06179303,"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer",RECRUITING,PHASE2,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Unresectable HER2-Negative Breast Carcinoma; Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma,Abemaciclib (DRUG); Anastrozole (DRUG); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Diagnostic Imaging (PROCEDURE); Exemestane (DRUG); Fludeoxyglucose F-18 (OTHER); Fluorine F 18 Fluoro Furanyl Norprogesterone (DRUG); Fulvestrant (DRUG); Gonadotropin-releasing Hormone Analog (BIOLOGICAL); Letrozole (DRUG); Positron Emission Tomography (PROCEDURE); Tamoxifen (DRUG); Therapeutic Estradiol (DRUG),2187,Asiolex,"Advanced/Metastatic Breast Cancer, HER2-Negative",Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4166,NCT00588003,Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer,COMPLETED,PHASE1,Breast Cancer,anastrozole (DRUG); Placebo (OTHER),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4167,NCT00128843,Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients,COMPLETED,PHASE2,Breast Cancer,Exemestane (DRUG); Anastrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4168,NCT02206984,Endocrine Response in Women with Invasive Lobular Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Tamoxifen (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4169,NCT02603679,Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases,ACTIVE_NOT_RECRUITING,PHASE2,Early-Stage Breast Carcinoma; Estrogen Receptor Positive Tumor,Paclitaxel (DRUG); Tamoxifen + Palbociclib (DRUG); Aromatase Inhibitor + Palbociclib (DRUG); Goserelin + Aromatase Inhibitor + Palbociclib (DRUG),2187,Asiolex,Hormone-Receptor Positive Breast Carcinoma,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4170,NCT00300508,3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer,COMPLETED,PHASE3,Breast Neoplasms,Anastrozole (DRUG),2187,Asiolex,Breast Neoplasms,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4171,NCT04188548,A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; Endometrial Cancer,LY3484356 (DRUG); Abemaciclib (DRUG); Everolimus (DRUG); Alpelisib (DRUG); Trastuzumab (DRUG); Aromatase Inhibitor (AI) (DRUG); Pertuzumab (DRUG),2187,Asiolex,Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; Endometrial Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4172,NCT00687648,"Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer",UNKNOWN,PHASE2,Breast Cancer,anastrozole (DRUG); cyclophosphamide (DRUG); exemestane (DRUG); letrozole (DRUG); methotrexate (DRUG); prednisolone (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4173,NCT02000375,A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT),TERMINATED,PHASE2,Metastatic Breastcancer; Estrogen Receptor Positive Breast Cancer; Estrogen Receptor Negative Neoplasm; Progesterone Receptor Positive Tumor; Progesterone Receptor Negative Neoplasm; Androgen Receptor Gene Overexpression,DHEA (DRUG),2187,Asiolex,Metastatic Breastcancer; Estrogen Receptor Positive Breast Cancer; Estrogen Receptor Negative Neoplasm; Progesterone Receptor Positive Tumor; Progesterone Receptor Negative Neoplasm; Androgen Receptor Gene Overexpression,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4174,NCT02097459,Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer,UNKNOWN,PHASE3,Breast Cancer,Anastrozole (DRUG); Tamoxifen (DRUG); Toremifene (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4175,NCT00544986,"A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer",COMPLETED,PHASE4,Breast Cancer,Anastrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4176,NCT06492616,"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence",RECRUITING,PHASE3,Breast Cancer,Elacestrant (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Tamoxifen (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4177,NCT03204734,Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Capecitabine (DRUG); endocrine therapy (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4178,NCT05297617,Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk,RECRUITING,PHASE2,Breast Cancer,Anti-aromatase inhibitor (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4179,NCT06507618,Pre-Operative Window of ET to Inform RT Decisions (POWER II),RECRUITING,PHASE3,Breast Cancer Female,"Tamoxifen, Letrozole, Anastrozole, or Exemestane (DRUG)",2187,Asiolex,Breast Cancer Female,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4180,NCT04383275,Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS),RECRUITING,PHASE2,Breast Cancer,capecitabine and trastuzumab (DRUG); endocrine therapy and trastuzumab (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4181,NCT01231659,Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer,COMPLETED,PHASE2,Postmenopausal Women; Locally Advanced Metastatic Breast Cancer; Metastatic Breast Cancer,Everolimus (DRUG); Letrozole (DRUG),2187,Asiolex,Postmenopausal Women; Locally Advanced Metastatic Breast Cancer; Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4182,NCT01446159,Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer,COMPLETED,PHASE2,"Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer",MEDI-573 (DRUG); Aromatase Inhibitor (DRUG),2187,Asiolex,"Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer",Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4183,NCT00437359,Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer,TERMINATED,PHASE2,Breast Neoplasms,Toremifene citrate (DRUG); Anastrozole (DRUG),2187,Asiolex,Breast Neoplasms,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4184,NCT00004900,Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,filgrastim (BIOLOGICAL); anastrozole (DRUG); carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); etoposide (DRUG); thiotepa (DRUG); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4185,NCT02545452,"Effect of Concomitant Use of an Antimycotic, an Antibiotic, a Spermicide or Tampons on Pharmacokinetics of Anastrozole and Levonorgestrel Released From Intra-vaginal Ring",COMPLETED,PHASE1,Endometriosis,Anastrozole / Levonorgestrel (BAY98-7196) (DRUG); Gyno-Daktarin (DRUG); Sobelin vaginal creme (DRUG); Patentex oval (DRUG); Tampon (OTHER),2187,Asiolex,Endometriosis,Uterus,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4186,NCT03324932,Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Denosumab Injection (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4187,NCT04711252,A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease,ACTIVE_NOT_RECRUITING,PHASE3,ER-Positive HER2-Negative Breast Cancer,AZD9833 (DRUG); Anastrozole (DRUG); Anastrozole placebo (DRUG); AZD9833 placebo (DRUG); Palbociclib (DRUG); Luteinizing hormone-releasing hormone (LHRH) agonist (DRUG),2187,Asiolex,ER-Positive HER2-Negative Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4188,NCT00932152,Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer,TERMINATED,PHASE2,Non-small Cell Lung Cancer; Postmenopausal Women,fulvestrant (Faslodex) (DRUG); anastrozole (Arimidex) (DRUG); Bevacizumab (Avastin) (DRUG); Best supportive care (DRUG),2187,Asiolex,Non-small Cell Lung Cancer; Postmenopausal Women,Lung,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4189,NCT05150652,"Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer",RECRUITING,PHASE2,Breast Cancer; HER2-negative Breast Cancer; Node-negative Breast Cancer; Breast Carcinoma,Anastrozole 1mg (DRUG); Letrozole 2.5mg (DRUG); Exemestane 25 mg (DRUG); Tamoxifen (DRUG),2187,Asiolex,Breast Cancer; HER2-negative Breast Cancer; Node-negative Breast Cancer; Breast Carcinoma,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4190,NCT00217659,"S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer",WITHDRAWN,PHASE2,Breast Cancer,anastrozole (DRUG); goserelin acetate (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4191,NCT00291759,ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.,COMPLETED,PHASE3,Breast Cancer,Tamoxifen (DRUG); Anastrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4192,NCT00265759,"Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer",COMPLETED,PHASE3,Breast Cancer,anastrozole (DRUG); exemestane (DRUG); letrozole (DRUG); Therapeutic Conventional Surgery (PROCEDURE),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4193,NCT00244959,Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer,COMPLETED,PHASE2,Breast Cancer,anastrozole (DRUG); adjuvant therapy (PROCEDURE),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4194,NCT04852887,"De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)",RECRUITING,PHASE3,Stage I Breast Cancer,"Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane) (OTHER); Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane) (DRUG)",2187,Asiolex,Stage I Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4195,NCT00078832,Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer,COMPLETED,PHASE3,Breast Cancer,anastrozole (DRUG); placebo (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4196,NCT00263185,High Dose Vit D Musculoskeletal Symptoms & Bone Density in Anastrozole-Treated Breast Cancer With Marginal Vit D Status,COMPLETED,EARLY_PHASE1,Breast Neoplasms,Vitamin D (DIETARY_SUPPLEMENT); Calcium carbonate (DIETARY_SUPPLEMENT); Vitamin D (DRUG); Placebo (OTHER),2187,Asiolex,Breast Neoplasms,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4197,NCT01491737,A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Pertuzumab (DRUG); Trastuzumab (DRUG); Aromatase Inhibitor (DRUG); Induction Chemotherapy (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4198,NCT02137837,"S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",TERMINATED,PHASE3,Breast Cancer,Fulvestrant (DRUG); Anastrozole (DRUG); Everolimus (DRUG); Placebo - Anastrozole (DRUG); Placebo - Everolimus (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4199,NCT01234532,Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery,TERMINATED,PHASE2,Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Triple-negative Breast Cancer,entinostat (DRUG); anastrozole (DRUG); diagnostic laboratory biomarker analysis (OTHER); therapeutic conventional surgery (PROCEDURE),2187,Asiolex,Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Triple-negative Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4200,NCT00235937,Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex,COMPLETED,PHASE2,Breast Cancer,Anastrozole and goserelin (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4201,NCT03909152,A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone,COMPLETED,PHASE2,Granulosa Cell Ovarian Cancer; Low Grade Serous Ovarian/ Primary Peritoneal Cancer; Endometrioid Endometrial Cancer,Onapristone ER (DRUG); Onapristone ER + Anastrozole (DRUG),2187,Asiolex,Granulosa Cell Ovarian Cancer; Low Grade Serous Ovarian/ Primary Peritoneal Cancer; Endometrioid Endometrial Cancer,Uterus,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4202,NCT02532400,Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients,TERMINATED,PHASE3,Breast Cancer,Neoadjuvant endocrine therapy (DRUG); Neoadjuvant chemotherapy (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4203,NCT01791985,AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL),COMPLETED,PHASE1,Breast Cancer,AZD4547 / anastrozole or letrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4204,NCT01272037,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE3,Breast Ductal Carcinoma In Situ; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Anastrozole (DRUG); Exemestane (DRUG); Laboratory Biomarker Analysis (OTHER); Letrozole (DRUG); Quality-of-Life Assessment (OTHER); Systemic Chemotherapy (DRUG); Tamoxifen Citrate (DRUG),2187,Asiolex,Breast Ductal Carcinoma In Situ; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4205,NCT04088032,"Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer",WITHDRAWN,EARLY_PHASE1,Breast Cancer Female; Locally Advanced Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast,"Abemaciclib, durvalumab and aromatase inhibitor (DRUG)",2187,Asiolex,Breast Cancer Female; Locally Advanced Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4206,NCT02947685,"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE3,HER-2 Positive Breast Cancer; Estrogen Receptor Positive Breast Cancer,palbociclib (DRUG); trastuzumab (DRUG); pertuzumab (DRUG); letrozole (DRUG); Anastrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG),2187,Asiolex,HER-2 Positive Breast Cancer; Estrogen Receptor Positive Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4207,NCT01151215,Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer,TERMINATED,PHASE2,Neoplasms; Breast Neoplasms; Breast Cancer,AZD8931 (DRUG); anastrozole (DRUG); Placebo (DRUG),2187,Asiolex,Neoplasms; Breast Neoplasms; Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4208,NCT00303615,Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer,TERMINATED,PHASE2,Metastatic Breast Cancer,Fluoxymesterone 10 mg (DRUG); Anastrozole 1 mg (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4209,NCT00921115,Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.,COMPLETED,PHASE2,Invasive Breast Cancer,Fulvestrant (DRUG); Anastrazole (DRUG),2187,Asiolex,Invasive Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4210,NCT02648477,Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer,COMPLETED,PHASE2,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Negative; Progesterone Receptor Positive; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma,Anastrozole (DRUG); Doxorubicin Hydrochloride (DRUG); Exemestane (DRUG); Laboratory Biomarker Analysis (OTHER); Letrozole (DRUG); Pembrolizumab (BIOLOGICAL),2187,Asiolex,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Negative; Progesterone Receptor Positive; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4211,NCT00828854,Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing,COMPLETED,PHASE2,ER+ Breast Cancer,Entinostat (DRUG); Aromatase Inhibitor (AI) Therapy (DRUG),2187,Asiolex,ER+ Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4212,NCT03078751,Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Ribociclib (DRUG); Adjuvant endocrine therapy (DRUG); Placebo (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4213,NCT04569747,"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer",RECRUITING,PHASE2,HER2-positive Breast Cancer; Invasive Carcinoma of the Breast; Breast Cancer; Node Negative Breast Cancer; Micrometastasis Breast Cancer; Hormone Receptor Positive Breast Cancer,Pertuzumab+TRASTUZUMAB (COMBINATION_PRODUCT); ADJUVANT ENDOCRINE THERAPY (DRUG),2187,Asiolex,HER2-positive Breast Cancer; Invasive Carcinoma of the Breast; Breast Cancer; Node Negative Breast Cancer; Micrometastasis Breast Cancer; Hormone Receptor Positive Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4214,NCT02089854,Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer,UNKNOWN,PHASE4,Female Breast Cancer,Toremifene; Anastrozole (DRUG),2187,Asiolex,Female Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4215,NCT06380751,"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer",RECRUITING,PHASE3,Advanced Breast Cancer,Saruparib (AZD5305) (DRUG); Camizestrant (DRUG); Abemaciclib (DRUG); Ribociclib (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Exemestane (DRUG),2187,Asiolex,Advanced Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4216,NCT03272477,Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients,COMPLETED,PHASE2,Breast Neoplasms,Perjeta Injectable Product (DRUG); Herceptin (DRUG); Tamoxifen (DRUG); Paclitaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Leuprorelin acetate (DRUG); Goserelin (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Paclitaxel (DRUG); Tamoxifen (DRUG); Leuporelin acetate (DRUG); Goserelin (DRUG); Biopsy (DIAGNOSTIC_TEST); Surgery (PROCEDURE),2187,Asiolex,Breast Neoplasms,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4217,NCT03555877,Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer Metastatic,Ribociclib (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG),2187,Asiolex,Breast Cancer Metastatic,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4218,NCT05774951,A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy,RECRUITING,PHASE3,"Breast Cancer, Early Breast Cancer",Camizestrant (DRUG); Tamoxifen (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG),2187,Asiolex,Early Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4219,NCT00082277,Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer,COMPLETED,PHASE4,Breast Cancer,Anastrozole (DRUG); Risedronate Sodium (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4220,NCT04584853,PreOperative Endocrine Therapy for Individualised Care With Abemaciclib,RECRUITING,PHASE3,Breast Cancer Female,"Abemaciclib (DRUG); Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen) (DRUG)",2187,Asiolex,Breast Cancer Female,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4221,NCT04352777,Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Cancer; Locally Advanced Breast Cancer; Hormone Receptor Positive Tumor,Abemaciclib (DRUG); Fulvestrant (DRUG); Aromatase Inhibitors (DRUG),2187,Asiolex,"Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4222,NCT00738777,Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer,SUSPENDED,PHASE2,Breast Cancer,Anastrozole (DRUG); Anastrozole+Fulvestrant (DRUG); Tamoxifen (DRUG); Tamoxifen (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4223,NCT02140437,Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC,WITHDRAWN,PHASE2,Carcinoma Breast Stage IV,Fulvestrant (DRUG); Anastrozole (DRUG),2187,Asiolex,Carcinoma Breast Stage IV,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4224,NCT06369285,"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer",RECRUITING,PHASE2,Hormone Receptor Positive HER-2 Negative Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer,Alisertib (DRUG); Endocrine therapy (DRUG),2187,Asiolex,Hormone Receptor Positive HER-2 Negative Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4225,NCT02585388,Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.,TERMINATED,PHASE2,Breast Cancer,Vinorelbine (DRUG); Letrozole (DRUG); Anastrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4226,NCT05983107,Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer,RECRUITING,PHASE2,HR+/HER2- Advanced Breast Cancer; Targeted Therapy,Everolimus (DRUG); Chidamide (DRUG); Endocrine therapy (DRUG); Ovarian function suppression(OFS) (DRUG),2187,Asiolex,HR+/HER2- Advanced Breast Cancer; Targeted Therapy,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4227,NCT02028507,Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors,COMPLETED,PHASE3,Metastatic Breast Cancer,Palbociclib (DRUG); Capecitabine (DRUG); Exemestane (DRUG); Fulvestrant (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4228,NCT00688909,Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer,COMPLETED,PHASE4,Breast Cancer,letrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4229,NCT00122356,Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment,COMPLETED,PHASE3,Breast Cancer,Alendronate sodium (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4230,NCT03220178,Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy,TERMINATED,PHASE4,Breast Neoplasm,Palbociclib (DRUG); Fulvestrant (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG),2187,Asiolex,Breast Neoplasm,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4231,NCT00181688,Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer,COMPLETED,PHASE2,Ovarian Cancer; Peritoneal Carcinoma; Tubal Carcinoma,Iressa (ZD1839) (DRUG); Arimidex (Anastrozole) (DRUG),2187,Asiolex,Ovarian Cancer; Peritoneal Carcinoma; Tubal Carcinoma,Ovary/Fallopian Tube,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4232,NCT00066378,Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer,COMPLETED,PHASE2,Breast Cancer,anastrozole (DRUG); gefitinib (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4233,NCT06375707,Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer,RECRUITING,PHASE2,Advanced Breast Cancer,physician's choice of chemotherapy sequential Ribociclib combined with NSAI±OFS (DRUG); Ribociclib combined with NSAI±OFS (DRUG),2187,Asiolex,Advanced Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4234,NCT01953588,Fulvestrant And/or Anastrozole in Treating Postmenopausal Patients with Stage II-III Breast Cancer Undergoing Surgery,ACTIVE_NOT_RECRUITING,PHASE3,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,fulvestrant (DRUG); anastrozole (DRUG),2187,Asiolex,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4235,NCT05514054,A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer,RECRUITING,PHASE3,Breast Neoplasms,Imlunestrant (DRUG); Tamoxifen (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG),2187,Asiolex,Breast Neoplasms,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4236,NCT02057133,A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread,ACTIVE_NOT_RECRUITING,PHASE1,Breast Neoplasms,LY2835219 (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Tamoxifen (DRUG); Exemestane (DRUG); Everolimus (DRUG); Trastuzumab (DRUG); LY3023414 (DRUG); Fulvestrant (DRUG); Pertuzumab (DRUG); Loperamide (DRUG); Endocrine therapy (DRUG),2187,Asiolex,Breast Neoplasms,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4237,NCT03616587,Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.,ACTIVE_NOT_RECRUITING,PHASE1,ER+ HER2- Advanced Breast Cancer,AZD9833 (DRUG); AZD9833 (DRUG); AZD9833 with palbociclib (DRUG); AZD9833 with palbociclib (DRUG); AZD9833 with everolimus (DRUG); AZD9833 with everolimus (DRUG); AZD9833 with abemaciclib (DRUG); AZD9833 with abemaciclib (DRUG); AZD9833 with capivasertib (DRUG); AZD9833 with capivasertib (DRUG); AZD9833 with ribociclib (DRUG); AZD9833 with ribociclib (DRUG); AZD9833 with anastrozole (DRUG); AZD9833 with anastrozole (DRUG),2187,Asiolex,ER+ HER2- Advanced Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4238,NCT01394211,Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer,TERMINATED,PHASE2,Estrogen Receptor-positive Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Male Breast Cancer; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer,anastrozole (DRUG); pazopanib hydrochloride (DRUG); therapeutic conventional surgery (PROCEDURE),2187,Asiolex,Estrogen Receptor-positive Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Male Breast Cancer; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4239,NCT00537771,Liver Safety Under Upfront Arimidex vs Tamoxifen,COMPLETED,PHASE4,Breast Cancer,Anastrozole (DRUG); Tamoxifen (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4240,NCT02592083,Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors,ACTIVE_NOT_RECRUITING,PHASE2,Early-Stage Breast Carcinoma; Hormone Receptor Positive Tumor,Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin (DRUG); Palbociclib (DRUG),2187,Asiolex,Hormone Receptor-positive Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4241,NCT03846583,Tucatinib + Abemaciclib + Herceptin for HER2+ MBC,WITHDRAWN,PHASE1,Breast Cancer,Tucatinib (DRUG); Abemaciclib (DRUG); Trastuzumab (DRUG); Aromatase Inhibitor (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4242,NCT01402193,Study of Arimidex and Radiotherapy Sequencing,UNKNOWN,PHASE3,Breast Cancer,Pre-radiotherapy commencement of Arimidex (DRUG); Post radiotherapy commencement of Arimidex (DRUG); Radiotherapy (RADIATION); Radiotherapy (RADIATION),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4243,NCT01924078,Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Capecitabine (DRUG); aromatase Inhibitors (AIs) (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4244,NCT05861271,Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer,RECRUITING,PHASE2,Breast Cancer Stage I,Capecitabine，Pyrotinib (DRUG),2187,Asiolex,Breast Cancer Stage I,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4245,NCT01160211,"A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer",COMPLETED,PHASE3,"Neoplasms, Breast",Lapatinib (DRUG); Trastuzumab (DRUG); Aromatase Inhibitor (DRUG); Lapatinib (DRUG),2187,Asiolex,"Neoplasms, Breast",Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4246,NCT03079011,PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection,ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Breast Cancer,Palbociclib 125mg (DRUG); Aromatase Inhibitors (DRUG); Fulvestrant Injectable Product (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4247,NCT02188745,ER Reactivation Therapy for Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,17B-estradiol (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Exemestane (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4248,NCT00481845,Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Vandetanib (DRUG); Anastrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4249,NCT00555477,Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure,TERMINATED,PHASE2,Breast Cancer,anastrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4250,NCT00240071,Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.,COMPLETED,PHASE2,Metastatic Breast Cancer,Avastin (DRUG); Hormonal therapy (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4251,NCT05640778,Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER),RECRUITING,PHASE2,Luminal B/HER2-negative Breast Cancer,Dalpiciclib combined with aromatase inhibitors (DRUG),2187,Asiolex,Luminal B/HER2-negative Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4252,NCT03671330,"Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.",ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Ribociclib Placebo (DRUG); Ribociclib (DRUG); NSAI: Letrozole or Anastrazole (DRUG); Letrozole (DRUG); Goserelin (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4253,NCT02440230,Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients,COMPLETED,PHASE2,Breast Cancer,OFS + Anastrozole (DRUG); OFS + Exemestane (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4254,NCT00295620,Secondary Adjuvant Long Term Study With Arimidex,COMPLETED,PHASE3,Breast Cancer,Anastrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4255,NCT02448420,Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Palbociclib (DRUG); Trastuzumab (DRUG); Endocrine therapy (DRUG); Chemotherapy (DRUG); Antibody-Drug Conjugates (DRUG),2187,Asiolex,Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4256,NCT02278120,"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",COMPLETED,PHASE3,Advanced Metastatic Breast Cancer,Ribociclib (DRUG); Tamoxifen (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Goserelin (DRUG); Placebo (DRUG),2187,Asiolex,Advanced Metastatic Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4257,NCT00301457,Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Anastrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4258,NCT05861830,Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES),RECRUITING,PHASE3,Advanced Breast Cancer,The combination of Dalpiciclib with physician-selected endocrine therapy (DRUG); Chemotherapy selected by the physician (DRUG),2187,Asiolex,Advanced Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4259,NCT00814125,ATAC - Endometrial Sub-Protocol,COMPLETED,PHASE3,Breast Cancer,Anastrozole (Arimidex) (DRUG); Tamoxifen (Nolvadex) (DRUG); Nolvadex placebo (DRUG); Arimidex placebo (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4260,NCT05891093,Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01),RECRUITING,PHASE3,Breast Cancer,Fluzoparib (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Tamoxifen (DRUG); Toremifene (DRUG); Abemaciclib (DRUG); LHRH agonist (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4261,NCT03691493,"Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis",COMPLETED,PHASE2,Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Bone; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8,Anastrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Palbociclib (DRUG); Radiation Therapy (RADIATION); Tamoxifen (DRUG),2187,Asiolex,Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Bone; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4262,NCT01612871,Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer,COMPLETED,PHASE4,Breast Cancer,"Tamoxifen, Letrozole , Anastrozole, Exemestane (DRUG)",2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4263,NCT01619111,"DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs",COMPLETED,PHASE3,HER2-negative Metastatic Breast Cancer; HER2-positive Circulating Tumor Cells,standard chemo- or endocrine therapy (DRUG); standard chemo- or endocrine therapy + Lapatinib (DRUG),2187,Asiolex,HER2-negative Metastatic Breast Cancer; HER2-positive Circulating Tumor Cells,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4264,NCT00053911,Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer,TERMINATED,PHASE3,Breast Cancer,anastrozole (DRUG); cyclophosphamide (DRUG); docetaxel (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); goserelin acetate (DRUG); tamoxifen citrate (DRUG); adjuvant therapy (PROCEDURE),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4265,NCT01597193,Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer,COMPLETED,PHASE1,Breast Cancer,enzalutamide (DRUG); anastrozole (DRUG); exemestane (DRUG); fulvestrant (DRUG); enzalutamide (DRUG); exemestane (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4266,NCT06486883,Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype,NOT_YET_RECRUITING,PHASE2,Advanced Breast Cancer; Advanced Breast Carcinoma; Hormone Receptor Positive Breast Carcinoma,"Trastuzumab deruxtecan (T-DXd, DS-8201a) (DRUG); CDK4/6i plus ET (DRUG)",2187,Asiolex,Advanced Hormone Receptor Positive Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4267,NCT00893061,"Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer",COMPLETED,PHASE3,Breast Cancer,anastrozole (DRUG); exemestane (DRUG); letrozole (DRUG); tamoxifen citrate (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4268,NCT00232661,PROACT - Pre-Operative Arimidex Compared To Tamoxifen,COMPLETED,PHASE3,Breast Cancer,ARIMIDEX (anastrazole) (DRUG); NOLVADEX (tamoxifen) (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4269,NCT02767661,"Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Capecitabine (DRUG); Aromatase Inhibitor (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4270,NCT04134598,ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer,RECRUITING,PHASE3,Breast Cancer,"Breast irradiation (RT) (RADIATION); Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen (DRUG)",2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4271,NCT02894398,Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant,COMPLETED,PHASE2,Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast,Palbociclib (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG),2187,Asiolex,Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4272,NCT00256698,Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy,COMPLETED,PHASE3,Breast Cancer,Fulvestrant (DRUG); Anastrozole (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4273,NCT00053898,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,COMPLETED,PHASE3,Breast Cancer,anastrozole (DRUG); tamoxifen citrate (DRUG); Radiation Therapy (RADIATION),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4274,NCT03481998,A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer,COMPLETED,PHASE1,Advanced Breast Cancer,SHR6390 (DRUG); Letrozole or anastrozole or Fulvestrant (DRUG),2187,Asiolex,Advanced Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4275,NCT05549505,A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery,COMPLETED,PHASE2,Breast Cancer,ARV-471 (DRUG); Anastrozole (DRUG); Surgical resection of breast tumor (PROCEDURE),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4276,NCT05307705,A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,"LOXO-783 (DRUG); Fulvestrant (DRUG); Imlunestrant (DRUG); Abemaciclib (DRUG); Anastrozole, Exemestane, or Letrozole (DRUG); Paclitaxel (DRUG)",2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4277,NCT03966898,A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer,UNKNOWN,PHASE3,Advanced Breast Cancer,SHR6390 Tablets (DRUG); Placebo Tablets (DRUG); Letrozole or Anastrozole Tablets (DRUG),2187,Asiolex,Advanced Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4278,NCT06223698,Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer,NOT_YET_RECRUITING,PHASE3,Breast Cancer,Letrozole (DRUG); Anastrozole (DRUG); Exemestane (DRUG); Tamoxifen (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4279,NCT00286351,Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis,COMPLETED,PHASE4,Endometriosis,Combined treatment with Arimidex and Zoladex before IVF (DRUG),2187,Asiolex,Endometriosis,Uterus,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4280,NCT00902954,Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer,UNKNOWN,PHASE3,Breast Cancer,anastrozole (DRUG); letrozole (DRUG); exemestane (DRUG),2187,Asiolex,Breast Cancer,Breast,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4281,NCT02779751,A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Non Small Cell Lung Cancer; Breast Cancer,Abemaciclib (DRUG); Pembrolizumab (DRUG); Anastrozole (DRUG),2187,Asiolex,Non Small Cell Lung Cancer; Breast Cancer,Lung,Anastrozole,CYP19A1,inhibitor/antagonist,unclear,yes,yes,Used to treat breast cancer in postmenopausal women.,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,1.12,186.0 +4282,NCT01642082,Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer,COMPLETED,PHASE2,Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Mixed Adenocarcinoma; Endometrial Mucinous Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Squamous Cell Carcinoma; Endometrial Transitional Cell Carcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma,Dalantercept (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER),285033,HHT,Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Mixed Adenocarcinoma; Endometrial Mucinous Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Squamous Cell Carcinoma; Endometrial Transitional Cell Carcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma,Skin,Homoharringtonine,,inhibitor/antagonist,Protein synthesis inhibitor,yes,yes,"Used in leukemia treatment, also known as Omacetaxine.",CC(C)(CCCC(CC(=O)OC)(C(=O)OC1C2C3=CC4=C(C=C3CCN5C2(CCC5)C=C1OC)OCO4)O)O,1.0120481927710845,193.0 +4283,NCT01720173,"Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer",COMPLETED,PHASE2,Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Dalantercept (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER),285033,HHT,Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Homoharringtonine,,inhibitor/antagonist,Protein synthesis inhibitor,yes,yes,"Used in leukemia treatment, also known as Omacetaxine.",CC(C)(CCCC(CC(=O)OC)(C(=O)OC1C2C3=CC4=C(C=C3CCN5C2(CCC5)C=C1OC)OCO4)O)O,1.0120481927710845,193.0 +4284,NCT00588146,Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia,TERMINATED,PHASE2,Anemia; Liver Disease; Hypoxemia,Pegylated Interferon Alpha2b (DRUG); Standard care (OTHER),285033,HHT,Anemia; Liver Disease; Hypoxemia,Liver,Homoharringtonine,,inhibitor/antagonist,Protein synthesis inhibitor,yes,yes,"Used in leukemia treatment, also known as Omacetaxine.",CC(C)(CCCC(CC(=O)OC)(C(=O)OC1C2C3=CC4=C(C=C3CCN5C2(CCC5)C=C1OC)OCO4)O)O,1.0120481927710845,193.0 +4285,NCT06694350,Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCC,NOT_YET_RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma,Pembrolizumab+Flutamide (DRUG),3397,NFBA,Head and Neck Squamous Cell Carcinoma,Skin,Flutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Used to treat prostate cancer as an antiandrogen.,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F,1.17,228.0 +4286,NCT04597099,Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion,RECRUITING,EARLY_PHASE1,PCOS; Polycystic Ovary Syndrome,Micronized progesterone (DRUG); Placebo (DRUG); Flutamide (DRUG); Estradiol patch (DRUG),3397,NFBA,PCOS; Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Flutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Used to treat prostate cancer as an antiandrogen.,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F,1.17,228.0 +4287,NCT05899699,Effect of New Topical Preparation for Treatment of Acne Vulgaris,NOT_YET_RECRUITING,PHASE2,Acne Vulgaris,DAP-FLU ME (DRUG); Adapalene .1% gel (DRUG),3397,NFBA,Acne Vulgaris,Skin,Flutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Used to treat prostate cancer as an antiandrogen.,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F,1.17,228.0 +4288,NCT01889199,Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women,COMPLETED,PHASE2,Polycystic Ovary Syndrome (PCOS),Flutamide (DRUG); Placebo (OTHER),3397,NFBA,Polycystic Ovary Syndrome (PCOS),Ovary/Fallopian Tube,Flutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Used to treat prostate cancer as an antiandrogen.,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F,1.17,228.0 +4289,NCT00001521,Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia,COMPLETED,PHASE4,Congenital Adrenal Hyperplasia (CAH),Fludrocortisone (DRUG); Hydrocortisone (DRUG); Letrozole (DRUG); Flutamide (DRUG),3397,NFBA,Congenital Adrenal Hyperplasia (CAH),Kidney,Flutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Used to treat prostate cancer as an antiandrogen.,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F,1.17,228.0 +4290,NCT00699907,Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer,COMPLETED,PHASE2,Ovarian Cancer,flutamide (DRUG),3397,NFBA,Ovarian Cancer,Ovary/Fallopian Tube,Flutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Used to treat prostate cancer as an antiandrogen.,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F,1.17,228.0 +4291,NCT00930228,Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary Syndrome,ACTIVE_NOT_RECRUITING,PHASE1,Polycystic Ovary Syndrome,Flutamide (DRUG); Placebo (DRUG),3397,NFBA,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Flutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Used to treat prostate cancer as an antiandrogen.,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F,1.17,228.0 +4292,NCT00460681,Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma,UNKNOWN,PHASE3,Hepatocellular Carcinoma,Thymopentin (DRUG),451417,RKDVY,Hepatocellular Carcinoma,Liver,Thymopentin,,unclear,unclear,no,yes,In clinical trials for immune deficiency and autoimmune diseases.,CC(C)C(C(=O)NC(CC1=CC=C(C=C1)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCCCN)NC(=O)C(CCCN=C(N)N)N,1.027027027027027,630.0 +4293,NCT04430985,FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer,WITHDRAWN,PHASE2,Metastatic Colorectal Cancer,Oxaliplatin (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG); Nivolumab (DRUG); Ipilimumab (DEVICE),451417,RKDVY,Metastatic Colorectal Cancer,Bowel,Thymopentin,,unclear,unclear,no,yes,In clinical trials for immune deficiency and autoimmune diseases.,CC(C)C(C(=O)NC(CC1=CC=C(C=C1)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCCCN)NC(=O)C(CCCN=C(N)N)N,1.027027027027027,630.0 +4294,NCT01437943,Effect of Short Term Aliskiren Treatment in Kidney Transplant Patients,TERMINATED,PHASE4,"Kidney Disease; Kidney Failure, Chronic",Aliskiren (DRUG); Placebo (DRUG),5493444,Rasilez,"Kidney Disease; Kidney Failure, Chronic",Kidney,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4295,NCT01129557,"Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease",TERMINATED,PHASE4,"Proteinuric Kidney Disease; Diabetic Nephropathy; Hypertensive Nephrosclerosis; IgA Nephropathy; Focal Segmental Glomerulosclerosis; Glomerulopathy (Obesity-associated); Glomerulonephritis, Membranous",Aliskiren (DRUG); Valsartan (DRUG),5493444,Rasilez,"Proteinuric Kidney Disease; Diabetic Nephropathy; Hypertensive Nephrosclerosis; IgA Nephropathy; Focal Segmental Glomerulosclerosis; Glomerulopathy (Obesity-associated); Glomerulonephritis, Membranous",Kidney,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4296,NCT00719316,Aliskiren and Muscle Sympathetic Nerve Activity,UNKNOWN,PHASE4,Chronic Kidney Disease; Hypertension; Muscle Sympathetic Nerve Activity,Aliskiren (DRUG),5493444,Rasilez,Chronic Kidney Disease; Hypertension; Muscle Sympathetic Nerve Activity,Kidney,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4297,NCT04183101,"Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy",RECRUITING,PHASE2,C3 Glomerulopathy; Membranoproliferative Glomerulonephritis; Complement Abnormality; Dense Deposit Disease; C3 Glomerulonephritis,Aliskiren (DRUG); Enalapril (DRUG),5493444,Rasilez,C3 Glomerulopathy; Membranoproliferative Glomerulonephritis; Complement Abnormality; Dense Deposit Disease; C3 Glomerulonephritis,Kidney,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4298,NCT01150201,"Aliskiren Combined With Losartan in Proteinuric, Non-diabetic Chronic Kidney Disease",COMPLETED,PHASE4,Kidney Disease,Aliskiren (DRUG); Losartan (DRUG),5493444,Rasilez,Kidney Disease,Kidney,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4299,NCT01541267,The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria,COMPLETED,PHASE4,Chronic Kidney Disease; Proteinuria,"aliskiren, eplerenon, telmisartan (DRUG)",5493444,Rasilez,Chronic Kidney Disease; Proteinuria,Kidney,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4300,NCT01219413,Influence of Aliskiren on Proteinuria,COMPLETED,PHASE4,Chronic Kidney Disease; Proteinuria; Blood Pressure,"Aliskiren, Perindopril (DRUG)",5493444,Rasilez,Chronic Kidney Disease; Proteinuria; Blood Pressure,Kidney,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4301,NCT01284114,Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients,COMPLETED,PHASE4,Hypertension; Chronic Kidney Disease,Aliskiren (DRUG),5493444,Rasilez,Hypertension; Chronic Kidney Disease,Kidney,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4302,NCT00097955,"Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria",COMPLETED,PHASE2,Diabetic Nephropathy,aliskiren (DRUG),5493444,Rasilez,Diabetic Nephropathy,Kidney,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4303,NCT01217736,Direct Renin Inhibition and the Kidney,COMPLETED,PHASE1,Renal Function,aliskiren (DRUG); placebo (DRUG); VTP-27999 (DRUG),5493444,Rasilez,Renal Function,Kidney,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4304,NCT01184599,A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy,UNKNOWN,PHASE4,"Glomerulonephritis, IGA; Hypertension",aliskiren (DRUG),5493444,Rasilez,"Glomerulonephritis, IGA; Hypertension",Kidney,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4305,NCT01827202,RAS Quantification in Patients With Aliskiren or Candesartan,COMPLETED,PHASE4,Hypertension; Chronic Kidney Disease; Proteinuria,RAS blockade discontinuation (OTHER); Aliskiren (DRUG); Candesartan (DRUG),5493444,Rasilez,Hypertension; Chronic Kidney Disease; Proteinuria,Kidney,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4306,NCT01568775,"Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects",COMPLETED,PHASE1,End Stage Renal Disease,Aliskiren (DRUG),5493444,Rasilez,End Stage Renal Disease,Kidney,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4307,NCT00961207,Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients,TERMINATED,PHASE4,Microalbuminuria; Macroalbuminuric Diabetic Nephropathy; Diabetes; Proteinuria; Albuminuria,Aliskiren (DRUG); Aliskiren (DRUG),5493444,Rasilez,Microalbuminuria; Macroalbuminuric Diabetic Nephropathy; Diabetes; Proteinuria; Albuminuria,Kidney,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4308,NCT01635387,RAAS Inhibitor Drugs in Dialysis Patients,UNKNOWN,PHASE4,Hypertension; End Stage Renal Disease,aliskiren (DRUG),5493444,Rasilez,Hypertension; End Stage Renal Disease,Kidney,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4309,NCT00922311,Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade,COMPLETED,PHASE4,IgA Nephropathy,Aliskiren (DRUG),5493444,Rasilez,Kidney Diseases,Kidney,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4310,NCT00870493,Aliskiren for Immunoglobulin A (IgA) Nephropathy,COMPLETED,PHASE3,IgA Nephropathy,Aliskiren (DRUG); Placebo (DRUG),5493444,Rasilez,Kidney Diseases,Kidney,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4311,NCT06093191,Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis,RECRUITING,PHASE4,Bronchiectasis Adult; Pseudomonas Aeruginosa Infection,Tobramycin Inhalant Product (DRUG); Ciprofloxacin 750 MG (DRUG); Oral ciprofloxacin placebo (DRUG); Natural saline inhalation (DRUG),5493444,Rasilez,Bronchiectasis Adult; Pseudomonas Aeruginosa Infection,Lung,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4312,NCT01531179,Lactobacillus Reuteri for Prevention of Necrotizing Enterocolitis in Very Low-birth Weight Infants,COMPLETED,PHASE3,Necrotizing Enterocolitis; Very Low Birth Weight Infants,Lactobacillus reuteri (DRUG); Placebo (DRUG),5493444,Rasilez,Necrotizing Enterocolitis; Very Low Birth Weight Infants,Bowel,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4313,NCT00599053,Early Versus Expectant Treatment of Ureaplasma Infection in Very Low Birth Weight Neonates,TERMINATED,PHASE1,Bacteria Infection; Respiratory Tract Infections,Azithromycin (DRUG),5493444,Rasilez,Bacteria Infection; Respiratory Tract Infections,Lung,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4314,NCT03331445,Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections,TERMINATED,PHASE2,Respiratory Tract Infections; Corona Virus Infection,Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation (DRUG),5493444,Rasilez,Respiratory Tract Infections; Corona Virus Infection,Lung,Aliskiren,REN,inhibitor/antagonist,unclear,yes,yes,Renin inhibitor for hypertension. Approved in the US and EU.,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,1.01,310.0 +4315,NCT05299203,BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma),UNKNOWN,PHASE1,Head and Neck Squamous Cell Carcinoma,Sapropterin dihydrochloride tablets (DRUG),2520,Ansyr,Head and Neck Squamous Cell Carcinoma,Skin,Verapamil,"CYP3A4, ABCB1",inhibitor/antagonist,unclear,yes,yes,Used as a racemic mixture for hypertension and angina.,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,1.35,172.0 +4316,NCT03782662,A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants,COMPLETED,PHASE1,Respiratory Syncytial Virus Infections,Itraconazole (DRUG); Verapamil (DRUG); Rifampicin (DRUG); Midazolam (DRUG); Placebo for RV521 (DRUG); RV521 (DRUG),2520,Ansyr,Respiratory Syncytial Virus Infections,Lung,Verapamil,"CYP3A4, ABCB1",inhibitor/antagonist,unclear,yes,yes,Used as a racemic mixture for hypertension and angina.,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,1.35,172.0 +4317,NCT00435331,6R-BH4 Pulmonary Arterial Hypertension Study,COMPLETED,PHASE1,Pulmonary Arterial Hypertension,sapropterin dihydrochloride (6R-BH4) (DRUG),2520,Ansyr,Pulmonary Arterial Hypertension,Lung,Verapamil,"CYP3A4, ABCB1",inhibitor/antagonist,unclear,yes,yes,Used as a racemic mixture for hypertension and angina.,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,1.35,172.0 +4318,NCT00745576,Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered,COMPLETED,PHASE1,Alzheimer Disease,SAM-531 (DRUG),2520,Ansyr,Alzheimer Disease,CNS/Brain,Verapamil,"CYP3A4, ABCB1",inhibitor/antagonist,unclear,yes,yes,Used as a racemic mixture for hypertension and angina.,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,1.35,172.0 +4319,NCT03347786,Verapamil for Neuroprotection in Stroke,RECRUITING,PHASE1,Ischemic Stroke,10 mg Intra-arterial Verapamil (DRUG); 20 mg Intra-arterial Verapamil (DRUG),2520,Ansyr,Ischemic Stroke,CNS/Brain,Verapamil,"CYP3A4, ABCB1",inhibitor/antagonist,unclear,yes,yes,Used as a racemic mixture for hypertension and angina.,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,1.35,172.0 +4320,NCT01261286,Drug-Disease Interaction in Crohn's Disease,COMPLETED,PHASE1,Crohn's Disease,verapamil (DRUG),2520,Ansyr,Crohn's Disease,Bowel,Verapamil,"CYP3A4, ABCB1",inhibitor/antagonist,unclear,yes,yes,Used as a racemic mixture for hypertension and angina.,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,1.35,172.0 +4321,NCT02144792,Development and Clinical Application of [11C]Verapamil-PET,UNKNOWN,PHASE2,Epilepsy,[11C] -verapamil PET (DRUG),2520,Ansyr,Epilepsy,CNS/Brain,Verapamil,"CYP3A4, ABCB1",inhibitor/antagonist,unclear,yes,yes,Used as a racemic mixture for hypertension and angina.,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,1.35,172.0 +4322,NCT02912663,Magnesium And Verapamil After Recanalization in Ischemia of the Cerebrum: a Clinical and Translational Study.,COMPLETED,PHASE1,Ischemic Stroke,Verapamil and Magnesium Sulfate (DRUG); Placebo (OTHER),2520,Ansyr,Ischemic Stroke,CNS/Brain,Verapamil,"CYP3A4, ABCB1",inhibitor/antagonist,unclear,yes,yes,Used as a racemic mixture for hypertension and angina.,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,1.35,172.0 +4323,NCT02235558,Superselective Administration of VErapamil During Recanalization in Acute Ischemic Stroke,COMPLETED,PHASE1,Ischemic Stroke,Verapamil (DRUG),2520,Ansyr,Ischemic Stroke,CNS/Brain,Verapamil,"CYP3A4, ABCB1",inhibitor/antagonist,unclear,yes,yes,Used as a racemic mixture for hypertension and angina.,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,1.35,172.0 +4324,NCT00552565,Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D),COMPLETED,PHASE3,Irritable Bowel Syndrome With Diarrhea,Rezular 15mg (DRUG); Placebo (DRUG); Rezular (DRUG); Rezular (DRUG),2520,Ansyr,Irritable Bowel Syndrome With Diarrhea,Bowel,Verapamil,"CYP3A4, ABCB1",inhibitor/antagonist,unclear,yes,yes,Used as a racemic mixture for hypertension and angina.,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,1.35,172.0 +4325,NCT01128634,"Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually and Concurrently, With Verapamilin in Healthy Subjects",COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",GSK573719 (DRUG); GW573719/GW573719 (DRUG),2520,Ansyr,"Pulmonary Disease, Chronic Obstructive",Lung,Verapamil,"CYP3A4, ABCB1",inhibitor/antagonist,unclear,yes,yes,Used as a racemic mixture for hypertension and angina.,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,1.35,172.0 +4326,NCT00706810,Combination of Hydroxyurea and Verapamil for Refractory Meningiomas,COMPLETED,PHASE2,Cancer; Brain Cancer; Meningioma,Hydroxyurea (DRUG); Verapamil (DRUG),2520,Ansyr,Cancer; Brain Cancer; Meningioma,CNS/Brain,Verapamil,"CYP3A4, ABCB1",inhibitor/antagonist,unclear,yes,yes,Used as a racemic mixture for hypertension and angina.,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,1.35,172.0 +4327,NCT02823106,Superselective Citicoline and Verapamil for Ischemic Neuroprotection and Greater Effective Response,WITHDRAWN,PHASE1,Ischemic Stroke,Verapamil and Citicoline (DRUG); Placebo (OTHER),2520,Ansyr,Ischemic Stroke,CNS/Brain,Verapamil,"CYP3A4, ABCB1",inhibitor/antagonist,unclear,yes,yes,Used as a racemic mixture for hypertension and angina.,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,1.35,172.0 +4328,NCT06118684,Clinical Trial to Assess Effect of Verapamil on Systemic Exposure of EP395 and Effect of EP395 on Systemic Exposure of Midazolam and Digoxin,COMPLETED,PHASE1,Chronic Obstructive Pulmonary Disease Exacerbation; COPD,EP395 (Part A and B) (DRUG); Verapamil (Part A) (DRUG); Midazolam (Part B) (DRUG); Digoxin (Part B) (DRUG),2520,Ansyr,Chronic Obstructive Pulmonary Disease Exacerbation; COPD,Lung,Verapamil,"CYP3A4, ABCB1",inhibitor/antagonist,unclear,yes,yes,Used as a racemic mixture for hypertension and angina.,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,1.35,172.0 +4329,NCT00001302,A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833,COMPLETED,PHASE1,Breast Cancer; Kidney Neoplasm; Lymphoma; Neoplasm Metastasis; Ovarian Cancer,PSC 833 (DRUG),2520,Ansyr,Breast Cancer; Kidney Neoplasm; Lymphoma; Neoplasm Metastasis; Ovarian Cancer,Breast,Verapamil,"CYP3A4, ABCB1",inhibitor/antagonist,unclear,yes,yes,Used as a racemic mixture for hypertension and angina.,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,1.35,172.0 +4330,NCT06396637,PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC,RECRUITING,PHASE2,Pancreatic Adenocarcinoma Metastatic,Sapropterin Dihydrochloride (DRUG),2520,Ansyr,Metastatic Pancreatic Adenocarcinoma,Pancreas,Verapamil,"CYP3A4, ABCB1",inhibitor/antagonist,unclear,yes,yes,Used as a racemic mixture for hypertension and angina.,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,1.35,172.0 +4331,NCT05613478,Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma,RECRUITING,PHASE3,Hepatocellular Carcinoma; Immunotherapy; Preoperative,Camrelizumab (DRUG); Apatinib Mesylate (DRUG); Radical surgery (PROCEDURE); Preoperative TACE treatment (PROCEDURE); Camrelizumab (DRUG); Apatinib Mesylate (DRUG),2520,Ansyr,Hepatocellular Carcinoma; Immunotherapy; Preoperative,Liver,Verapamil,"CYP3A4, ABCB1",inhibitor/antagonist,unclear,yes,yes,Used as a racemic mixture for hypertension and angina.,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,1.35,172.0 +4332,NCT03832426,A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers,COMPLETED,PHASE1,Hepatic Impairment,Narlaprevir (DRUG); Ritonavir (DRUG),392622,RTV,Hepatic Impairment,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4333,NCT01685203,A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection,COMPLETED,PHASE2,"Hepatitis C, Chronic",ABT-450/r (DRUG); ABT-267 (DRUG); Ribavirin (RBV) (DRUG),392622,RTV,Chronic Hepatitis C,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4334,NCT02219503,A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis,COMPLETED,PHASE3,Chronic Hepatitis C Infection; Compensated Cirrhosis,Ombitasvir/Paritaprevir/Ritonavir (DRUG); Dasabuvir (DRUG),392622,RTV,Chronic Hepatitis C Infection; Compensated Cirrhosis,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4335,NCT02219490,A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection,COMPLETED,PHASE3,Chronic Hepatitis C Virus (HCV) Infection Genotype 1,ABT-450/r/ABT-267 (DRUG); ABT-333 (DRUG); Ribavirin (RBV) (DRUG),392622,RTV,Chronic Hepatitis C Virus (HCV) Infection Genotype 1,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4336,NCT06710990,Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer,RECRUITING,PHASE1,Advanced Breast Cancer,SHR-A1811 (DRUG); Ritonavir (DRUG); Itraconazole (DRUG),392622,RTV,Advanced Breast Cancer,Breast,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4337,NCT03003338,MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV,TERMINATED,PHASE4,"Hepatitis C, Chronic",OBV/PTV/r and DSV (DRUG); Placebo to match OBV/PTV/r and DSV (DRUG),392622,RTV,Chronic Hepatitis C,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4338,NCT03020095,Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan,COMPLETED,PHASE2,Chronic Hepatitis C,Ravidasvir (DRUG); Danoprevir (DRUG); Ritonavir (DRUG); Ribavirin (DRUG),392622,RTV,Chronic Hepatitis C,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4339,NCT01782495,A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients,COMPLETED,PHASE2,Chronic Hepatitis C Infection,ombitasvir/paritaprevir/ritonavir and dasabuvir (DRUG); ombitasvir/paritaprevir/ritonavir (DRUG); ribavirin (DRUG),392622,RTV,Chronic Hepatitis C Infection,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4340,NCT02247401,Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt,COMPLETED,PHASE3,HCV; Hepatitis C Infection; Genotype 4,2 DAA (DRUG); RBV (DRUG),392622,RTV,HCV; Hepatitis C Infection; Genotype 4,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4341,NCT03020082,Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III,COMPLETED,PHASE3,Chronic Hepatitis C,Danoprevir (DRUG); Ritonavir (DRUG); peginterferon alfa-2a (DRUG); RBV (DRUG),392622,RTV,Chronic Hepatitis C,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4342,NCT01464827,ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients,COMPLETED,PHASE2,Chronic Hepatitis C; Hepatitis C (HCV); Hepatitis C Genotype 1,ABT-450 (DRUG); ABT-333 (DRUG); ABT-267 (DRUG); Ribavirin (DRUG); Ritonavir (DRUG),392622,RTV,Chronic Hepatitis C; Hepatitis C (HCV); Hepatitis C Genotype 1,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4343,NCT02511431,Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir,COMPLETED,PHASE2,Hepatitis D,Lonafarnib (DRUG); Ritonavir (DRUG); Placebo (OTHER),392622,RTV,Hepatitis D,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4344,NCT03638076,"The Safety, Antiviral Activity, and Pharmacokinetics of Morphothiadine Mesilate Capsules",COMPLETED,PHASE2,Chronic Hepatitis B,GLS4 (DRUG); RTV (DRUG),392622,RTV,Chronic Hepatitis B,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4345,NCT01453192,Renal Transplantation and Raltegravir in HIV-Infected Patients,COMPLETED,PHASE3,HIV-1 Infection; Chronic Renal Insufficiency,Raltegravir (DRUG),392622,RTV,HIV-1 Infection; Chronic Renal Insufficiency,Kidney,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4346,NCT01251848,Drug Interaction Between Ritonavir And Sitaxsentan,WITHDRAWN,PHASE1,Pulmonary Arterial Hypertension,Sitaxentan (DRUG); Ritonavir (DRUG); Sitaxsentan (DRUG); Ritonavir (DRUG),392622,RTV,Pulmonary Arterial Hypertension,Lung,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4347,NCT01674725,A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C,COMPLETED,PHASE3,Chronic Hepatitis C Infection,"ABT-450/r/ABT-267, ABT-333 (DRUG); Ribavirin (DRUG)",392622,RTV,Chronic Hepatitis C Infection,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4348,NCT00775125,VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.,COMPLETED,PHASE1,Hepatitis C; Telaprevir; HIV,Telaprevir; Darunavir; Ritonavir; Fosamprenavir (DRUG),392622,RTV,Hepatitis C; Telaprevir; HIV,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4349,NCT03499639,Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease,COMPLETED,PHASE4,End-stage Renal Disease; HCV Coinfection,Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet (DRUG),392622,RTV,End-stage Renal Disease; HCV Coinfection,Kidney,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4350,NCT02874066,PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis,COMPLETED,PHASE4,Hepatitis Viruses,PTV/r/OBV/DSV (DRUG),392622,RTV,Hepatitis Viruses,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4351,NCT01323257,TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r),COMPLETED,PHASE1,Hepatitis C Virus,erythromycin (DRUG); Ritonavir (DRUG); TMC435 (DRUG); Darunavir (DRUG); TMC435 (DRUG); erythromycin (DRUG),392622,RTV,Hepatitis C Virus,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4352,NCT02216422,A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection,COMPLETED,PHASE3,Chronic Hepatitis C Virus (HCV) Infection,Ombitasvir/Paritaprevir/Ritonavir (DRUG); Dasabuvir (DRUG); Ribavirin (RBV) (DRUG),392622,RTV,Chronic Hepatitis C Virus (HCV) Infection,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4353,NCT02068222,A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection,COMPLETED,PHASE2,Chronic Hepatitis C; Hepatitis C Virus,ABT-450/ritonavir (r) (DRUG); ABT-530 (DRUG); Ribavirin (RBV) (DRUG),392622,RTV,Chronic Hepatitis C; Hepatitis C Virus,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4354,NCT01825980,Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients,COMPLETED,PHASE1,Hepatitis C,BZF961 (DRUG); Ritonavir (DRUG); Placebo (DRUG),392622,RTV,Hepatitis C,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4355,NCT02430194,Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2),COMPLETED,PHASE2,Chronic Hepatitis D Infection,lonafarnib (DRUG); ritonavir (DRUG); Pegylated interferon-alfa-2a (DRUG),392622,RTV,Chronic Hepatitis D Infection,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4356,NCT04366089,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,UNKNOWN,PHASE2,"COVID; SARS-CoV 2; Pneumonia, Viral; Coronavirus Infection","Oxygen-ozone therapy, probiotic supplementation and Standard of care (OTHER); SivoMixx (200 billion) (DIETARY_SUPPLEMENT); Azithromycin (DRUG); hydroxychloroquine (DRUG)",392622,RTV,"COVID; SARS-CoV 2; Pneumonia, Viral; Coronavirus Infection",Lung,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4357,NCT02806362,Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD),WITHDRAWN,PHASE3,Chronic Hepatitis C Virus,Ombitasvir/paritaprevir/ritonavir (DRUG),392622,RTV,Chronic Hepatitis C Virus,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4358,NCT02503462,Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals,TERMINATED,PHASE4,AIDS-related Dementia Complex,Darunavir (DRUG); ritonavir (DRUG); cobicistat (DRUG),392622,RTV,AIDS-related Dementia Complex,CNS/Brain,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4359,NCT05229991,Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection,UNKNOWN,PHASE3,"Hepatitis D, Chronic",Lonafarnib (DRUG); Ritonavir (DRUG),392622,RTV,Chronic Hepatitis D,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4360,NCT03833362,Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study),COMPLETED,PHASE3,Hepatitis C,Narlaprevir (DRUG); Ritonavir (DRUG); Placebo Narlaprevir (DRUG); Placebo Ritonavir (DRUG); Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b (DRUG); Ribavirin (DRUG),392622,RTV,Hepatitis C,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4361,NCT01628094,"ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment",COMPLETED,PHASE2,"Hepatitis C, Chronic",RO5024048 (DRUG); RO5190591 (DRUG); RO5466731 (DRUG); ribavirin [Copegus] (DRUG); ritonavir (DRUG),392622,RTV,Chronic Hepatitis C,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4362,NCT01185860,A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1,COMPLETED,PHASE1,"Hepatitis C, Chronic",danoprevir (DRUG); peginterferon alfa-2a [Pegasys] (DRUG); placebo (DRUG); ribavirin (DRUG); ritonavir (DRUG),392622,RTV,Chronic Hepatitis C,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4363,NCT01095094,Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma,TERMINATED,PHASE2,Brain Tumor; Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Oligodendroglioma; Brain Stem Glioma; Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Mixed Glioma,ritonavir (DRUG); lopinavir (DRUG),392622,RTV,Brain Tumor; Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Oligodendroglioma; Brain Stem Glioma; Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Mixed Glioma,CNS/Brain,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4364,NCT02356562,A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection,COMPLETED,PHASE2,Chronic Hepatitis C Infection,ombitasvir/paritaprevir/ritonavir and dasabuvir (DRUG); Sofosbuvir (DRUG); Ribavirin (DRUG),392622,RTV,Chronic Hepatitis C Infection,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4365,NCT05682586,UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients,UNKNOWN,PHASE3,Mesenchymal Stem Cell; COVID-19 Pneumonia,umbilical cord mesenchymal stem cells (BIOLOGICAL); paxlovid (DRUG),392622,RTV,Mesenchymal Stem Cell; COVID-19 Pneumonia,Lung,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4366,NCT01458535,"A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)",COMPLETED,PHASE2,Hepatitis C Virus,ABT-450 (DRUG); ABT-267 (DRUG); ribavirin (DRUG); ritonavir (DRUG),392622,RTV,Hepatitis C Virus,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4367,NCT01724086,"A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus",COMPLETED,PHASE2,Chronic Hepatitis C,TMC647055 (DRUG); TMC435 (DRUG); Ritonavir (DRUG); Ribavirin (DRUG); Pegylated interferon alpha-2a (PegIFN) (DRUG); GSK2336805 (DRUG),392622,RTV,Chronic Hepatitis C,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4368,NCT01125696,Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV,COMPLETED,PHASE2,HIV; Hepatitis B,Tenofovir/lamivudine/lopinavir-ritonavir (DRUG); Zidovudine/lamivudine/lopinavir-ritonavir (DRUG),392622,RTV,HIV; Hepatitis B,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4369,NCT01767116,A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection,COMPLETED,PHASE3,Chronic Hepatitis C Infection,"ABT-450/r/ABT-267, ABT-333 (DRUG); Ribavirin (DRUG); Placebo for ribavirin (DRUG)",392622,RTV,Chronic Hepatitis C Infection,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4370,NCT01500616,Telaprevir Open-Label Study in Co-Infected Patients,COMPLETED,PHASE3,"Hepatitis C, Chronic",Telaprevir (DRUG); Telaprevir (DRUG),392622,RTV,Chronic Hepatitis C,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4371,NCT01907724,"Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)",COMPLETED,PHASE1,"Hepatitis C, Chronic",IDX719 (DRUG); Simeprevir (DRUG); TMC647055 (DRUG); RTV (DRUG),392622,RTV,Chronic Hepatitis C,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4372,NCT00437476,Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy,UNKNOWN,PHASE3,HIV Infections; Hepatitis C,LPV/r (DRUG); Nucleoside Reverse Transcriptase Inhibitors (DRUG); PEG-IFNa 2a (DRUG); Ribavirin (DRUG),392622,RTV,HIV and Hepatitis C Coinfection,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4373,NCT05938140,Efficiency and Safety of Paxlovid for COVID-19 Patients With Severe Chronic Kidney Disease,RECRUITING,PHASE4,"COVID-19; Renal Insufficiency, Chronic",Nirmatrelvir/ritonavir (DRUG),392622,RTV,"COVID-19; Renal Insufficiency, Chronic",Kidney,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4374,NCT03020004,"Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II",COMPLETED,PHASE2,Chronic Hepatitis C,Danoprevir (DRUG); Ritonavir (DRUG); peginterferon alfa-2a (DRUG); Ribavirin (RBV) (DRUG),392622,RTV,Chronic Hepatitis C,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4375,NCT05731804,Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir,UNKNOWN,PHASE1,Renal Impairment; Hepatic Impairment,SIM0417 600 mg; Ritonavir100 mg (DRUG); SIM0417 375 mg; Ritonavir100 mg (DRUG); SIM0417 750 mg; Ritonavir100 mg (DRUG),392622,RTV,Renal Impairment; Hepatic Impairment,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4376,NCT01852604,Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005),COMPLETED,PHASE2,Chronic Hepatitis C Virus,Samatasvir (DRUG); Simeprevir (DRUG); Ribavirin (RBV) (DRUG); TMC647055 (DRUG); Ritonavir (RTV) (DRUG); Pegylated interferon (Peg-IFN) (BIOLOGICAL); Samatasvir matching placebo (OTHER),392622,RTV,Chronic Hepatitis C Virus,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4377,NCT00782301,Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients,WITHDRAWN,PHASE4,"Hepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic",maraviroc (DRUG); etravirine (DRUG),392622,RTV,"Hepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic",Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4378,NCT03890744,ModraDoc006/r in Patients With Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer; Recurrent Breast Cancer,ModraDoc006/r (DRUG),392622,RTV,Metastatic Breast Cancer; Recurrent Breast Cancer,Breast,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4379,NCT01565889,Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.,COMPLETED,PHASE1,Hepatitis C; HIV,SOF (DRUG); EFV/FTC/TDF (DRUG); EFV (DRUG); ZDV/3TC (DRUG); ATV (DRUG); Ritonavir (DRUG); FTC/TDF (DRUG); DRV (DRUG); RAL (DRUG); PEG (DRUG); RBV (DRUG),392622,RTV,Hepatitis C; HIV,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4380,NCT03133065,Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs,COMPLETED,PHASE4,Liver Transplantation,treatment of HCV with oral direct acting antiviral therapy (DRUG),392622,RTV,Liver Transplantation,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4381,NCT02734173,Pilot HCV Direct Acting Antiviral Therapy and Metabolism,COMPLETED,PHASE4,Hepatitis C,ABT450r-ABT267-ABT333 +/- Ribavirin (DRUG),392622,RTV,Hepatitis C,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4382,NCT01081158,"Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)",COMPLETED,PHASE1,"Hepatitis C, Chronic",Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron) (DRUG); Drug: SCH 900518 Biologic: Peginterferon alfa-2b (DRUG); Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron) (DRUG); Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron) (DRUG),392622,RTV,Chronic Hepatitis C,Liver,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4383,NCT04993872,Pharmacokinetics of Calcineurin & mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF,UNKNOWN,PHASE4,HIV-infected Patient Kidney Transplant Recipient,Biktarvy Tab (DRUG),392622,RTV,HIV-infected Patient Kidney Transplant Recipient,Kidney,Ritonavir,,inhibitor/antagonist,unclear,yes,yes,Used in combination HIV therapies.,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1.05,291.0 +4384,NCT03991520,Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms,UNKNOWN,EARLY_PHASE1,Endometriosis; Anakinra; Markers of Inflammation,Anakinra 100Mg/0.67Ml Inj Syringe (DRUG); Placebo (DRUG),16052011,ZDX,Endometriosis,Uterus,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4385,NCT01723774,PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Neoplasms,PD0332991 (DRUG); Anastrozole (DRUG); Goserelin (DRUG); Surgery (standard of care) (PROCEDURE); Tumor biopsy (PROCEDURE),16052011,ZDX,Breast Neoplasms,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4386,NCT04478266,Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer,TERMINATED,PHASE3,Breast Cancer,Amcenestrant-matching placebo (DRUG); SAR439859 (DRUG); Palbociclib (DRUG); Letrozole (DRUG); Goserelin (DRUG); Letrozole-matching placebo (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4387,NCT02624973,PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Neoadjuvant tamoxifen + goserelin (premenopausal women) (DRUG); Neoadjuvant letrozole (postmenopausal women) (DRUG); Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone) (DRUG); Neoadjuvant docetaxel + cyclophosphamide (DRUG); Neoadjuvant docetaxel (DRUG); Neoadjuvant docetaxel + trastuzumab + pertuzumab (DRUG); Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab (DRUG); Neoadjuvant olaparib (DRUG); Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone) (DRUG); Breast conserving surgery or mastectomy + SNB/axillary dissection (PROCEDURE); Postoperative radiotherapy breast/chest wall + regional lymph nodes (RADIATION); Adjuvant trastuzumab (DRUG); Adjuvant letrozole (postmenopausal women) (DRUG); Adjuvant tamoxifen + goserelin (premenopausal women) (DRUG); Adjuvant palbociclib (if palbociclib given neoadjuvant) (DRUG); Adjuvant Epirubicin+ Cyclophosphamide (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4388,NCT00002582,"Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer",COMPLETED,PHASE3,Breast Cancer,CMF regimen (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); fluorouracil (DRUG); goserelin acetate (DRUG); leuprolide acetate (DRUG); methotrexate (DRUG); tamoxifen citrate (DRUG); oophorectomy (PROCEDURE); radiation therapy (RADIATION),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4389,NCT06953882,"Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy",NOT_YET_RECRUITING,PHASE2,HER2 Negative Breast Cancer,Ribociclib 400mg (DRUG); Letrozole 2.5mg (DRUG); Anastrazole 1mg (DRUG); Goserelin 3.6 MG (DRUG); Adjuvant chemotherapy (RADIATION),16052011,ZDX,HER2 Negative Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4390,NCT00012090,"Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum",COMPLETED,PHASE2,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,bicalutamide (DRUG); goserelin acetate (DRUG),16052011,ZDX,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4391,NCT02132390,"Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea",UNKNOWN,PHASE3,Breast Cancer; Chemotherapy Induced Amenorrhea; Ovarian Function Suppression,Goserelin (DRUG); Toremifene (DRUG),16052011,ZDX,Breast Cancer; Chemotherapy Induced Amenorrhea; Ovarian Function Suppression,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4392,NCT00295646,"Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid",COMPLETED,PHASE3,Breast Cancer,tamoxifen (DRUG); anastrozole (DRUG); zoledronic acid (DRUG); goserelin (OTHER),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4393,NCT02592746,A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC,UNKNOWN,PHASE2,Metastatic Breast Cancer,Palbociclib (DRUG); Exemestane (DRUG); Leuprolide Acetate (DRUG); Capecitabine (DRUG),16052011,ZDX,Metastatic Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4394,NCT06009627,Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients,RECRUITING,PHASE2,Breast Cancer,Dalcelli、Exemestane、Gosserine (DRUG); Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4395,NCT02115282,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,ACTIVE_NOT_RECRUITING,PHASE3,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Breast Adenocarcinoma; HER2/Neu Negative; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma,Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Entinostat (DRUG); Exemestane (DRUG); Goserelin (DRUG); Goserelin Acetate (DRUG); Magnetic Resonance Imaging (PROCEDURE); Placebo Administration (OTHER); Quality-of-Life Assessment (OTHER),16052011,ZDX,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Breast Adenocarcinoma; HER2/Neu Negative; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4396,NCT00888082,Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy,WITHDRAWN,PHASE3,Breast Cancer; Ovarian Function,Goserelin acetate (DRUG),16052011,ZDX,Breast Cancer; Ovarian Function,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4397,NCT00002460,Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer,UNKNOWN,PHASE3,Breast Cancer,goserelin acetate (DRUG); tamoxifen citrate (DRUG); ablative endocrine surgery (PROCEDURE); oophorectomy (PROCEDURE),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4398,NCT00002580,"Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer",COMPLETED,PHASE3,Breast Cancer,cyclophosphamide (DRUG); fluorouracil (DRUG); goserelin acetate (DRUG); leuprolide acetate (DRUG); methotrexate (DRUG); tamoxifen citrate (DRUG); conventional surgery (PROCEDURE); laparoscopic surgery (PROCEDURE); oophorectomy (PROCEDURE); radiation therapy (RADIATION),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4399,NCT02483767,Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer,COMPLETED,PHASE3,Breast Cancer,goserelin (DRUG); standard chemotherapy (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4400,NCT04536467,Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients,ENROLLING_BY_INVITATION,PHASE2,Premature Ovarian Failure,Goserelin (DRUG); Chemotherapy (DRUG),16052011,ZDX,Premature Ovarian Failure,Ovary/Fallopian Tube,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4401,NCT02344472,Detect V / CHEVENDO (Chemo vs. Endo),ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Breast Cancer,pertuzumab (DRUG); Trastuzumab (DRUG); Capecitabine (DRUG); Paclitaxel (DRUG); Vinorelbine (DRUG); Docetaxel (DRUG); Exemestane (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG); Ribociclib (DRUG); nab-Paclitaxel (DRUG); eribulin (DRUG); leuprorelin (DRUG); goserelin (DRUG),16052011,ZDX,Metastatic Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4402,NCT00912548,Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women,UNKNOWN,PHASE3,Breast Cancer,goserelin (DRUG); tamoxifen (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4403,NCT03573648,"Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Avelumab (DRUG); Endocrine therapy (DRUG); Palbociclib (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4404,NCT05253066,Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer,UNKNOWN,PHASE2,Breast Neoplasms,Chidamide combined with exemestane (+/- goserelin) (DRUG); Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician) (DRUG),16052011,ZDX,Breast Neoplasms,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4405,NCT03628066,Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Letrozole (DRUG); Palbociclib (DRUG); Goserelin (DRUG); Oncotype DX Breast Recurrence Score (DIAGNOSTIC_TEST),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4406,NCT03444025,Neoadjuvant Goserelin for Triple Negative Breast Cancer,UNKNOWN,PHASE2,Breast Cancer Triple Negative,Goserelin (DRUG),16052011,ZDX,Breast Cancer Triple Negative,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4407,NCT05063786,Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET),ACTIVE_NOT_RECRUITING,PHASE3,Advanced Breast Cancer,Trastuzumab (BIOLOGICAL); Alpelisib (DRUG); Fulvestrant (DRUG); Vinorelbine (DRUG); Capecitabine (DRUG); Eribulin (DRUG),16052011,ZDX,Advanced Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4408,NCT00398489,"Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery",UNKNOWN,PHASE2,Breast Cancer,trastuzumab (BIOLOGICAL); anastrozole (DRUG); cyclophosphamide (DRUG); docetaxel (DRUG); epirubicin hydrochloride (DRUG); goserelin acetate (DRUG); tamoxifen citrate (DRUG); adjuvant therapy (PROCEDURE); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE); radiation therapy (RADIATION),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4409,NCT01989780,Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Paclitaxel (DRUG); Bevacizumab (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Goserelin (DRUG); leuprorelin (DRUG),16052011,ZDX,Metastatic Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4410,NCT02518191,Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity,COMPLETED,PHASE3,Breast Cancer,GnRHa (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4411,NCT01352091,Adjuvant AI Combined With Zoladex,UNKNOWN,PHASE3,Breast Cancer,Zoladex+AI (DRUG); TAM (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4412,NCT05720260,"Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC",RECRUITING,PHASE2,Premenopausal Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer,Goserelin (DRUG); Fulvestrant (DRUG); Capivasertib (DRUG); Durvalumab (DRUG),16052011,ZDX,Metastatic ER-Positive Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4413,NCT02476786,Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score,RECRUITING,PHASE2,Breast Cancer; Cancer of Breast; Breast Neoplasms; Cancer of the Breast,FACT-B (BEHAVIORAL); Goserelin (DRUG); Anastrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Tamoxifen (DRUG); Archived tissue collection (OTHER),16052011,ZDX,Breast Cancer; Cancer of Breast; Breast Neoplasms; Cancer of the Breast,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4414,NCT01368263,Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer,TERMINATED,PHASE2,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,goserelin acetate (DRUG); letrozole (DRUG); anastrozole (DRUG); chemotherapy (DRUG); Surgery (PROCEDURE),16052011,ZDX,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4415,NCT06656624,Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel),RECRUITING,PHASE2,Advanced Breast Cancer,Ribociclib combined with AI±OFS (DRUG); physician's choice of chemotherapy sequential Ribociclib combined with AI±OFS (DRUG),16052011,ZDX,Advanced Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4416,NCT01942135,Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3),COMPLETED,PHASE3,Metastatic Breast Cancer,Palbociclib (DRUG); Fulvestrant (DRUG); Placebo (DRUG); Fulvestrant (DRUG),16052011,ZDX,Metastatic Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4417,NCT05827081,Phase IIIb Study of Ribociclib + ET in Early Breast Cancer,NOT_YET_RECRUITING,PHASE3,Early Breast Cancer,Ribociclib (DRUG); Letrozole (DRUG); Ansastrozole (DRUG); Goserelin (DRUG); Leuprolide (DRUG); Exemestane (DRUG),16052011,ZDX,Early Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4418,NCT05594095,SNF Platform Study of HR+/ HER2-advanced Breast Cancer,RECRUITING,PHASE2,Breast Neoplasm; Breast Cancer; Hormone Receptor Positive Tumor; HER2-negative Breast Cancer; Advanced Breast Cancer,PIK3CA inhibitor (DRUG); AKT inhibitor (DRUG); Carrelizumab (DRUG); Famitinib (DRUG); Fluzoparib (DRUG); Dalpiciclib (DRUG); SHR-A1811 (DRUG); Everolimus (DRUG); Aromatase Inhibitors or Fulvestrant (DRUG); Goserelin (DRUG); TPC (DRUG); Sorafenib (DRUG); Apatinib (DRUG); SHR-A1921 (DRUG); SHR-A2102 (DRUG); SHR-A2009 (DRUG); SHR-1167 (DRUG); SHR-6209 (DRUG); bevacizumab (DRUG),16052011,ZDX,"Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4419,NCT05438810,"This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.",UNKNOWN,PHASE3,Advanced Breast Cancer; Female Breast Cancer,"FCN-437c,Fulvestrant,Goserelin acetate (DRUG); Placebo,Fulvestrant,Goserelin acetate (DRUG)",16052011,ZDX,Advanced Breast Cancer; Female Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4420,NCT00605267,Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment,COMPLETED,PHASE3,Breast Cancer,Tamoxifen (DRUG); Anastrazole (Arimidex) (DRUG); Goserelin acetate (Zoladex) (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4421,NCT00498901,Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer,TERMINATED,PHASE2,Breast Cancer,goserelin (DRUG); letrozole (DRUG); leuprolide acetate (DRUG); conventional surgery (PROCEDURE),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4422,NCT02181101,"Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial",COMPLETED,PHASE3,Breast Neoplasms,FEC-DocGemzar adjuvant chemotherapy (DRUG); FEC-Doc adjuvant chemotherapy (DRUG); Zoledronic acid i.v. 2 years (DRUG); Zoledronic acid i.v. 5 years (DRUG),16052011,ZDX,Breast Neoplasms,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4423,NCT05607004,(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer,RECRUITING,PHASE2,Breast Neoplasms; Invasive Breast Cancer; Estrogen-receptor-positive Breast Cancer; HER2-negative Breast Cancer,(Z)-endoxifen (DRUG); exemestane (DRUG); goserelin (DRUG),16052011,ZDX,Breast Neoplasms; Invasive Breast Cancer; Estrogen-receptor-positive Breast Cancer; HER2-negative Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4424,NCT00432172,Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients,COMPLETED,PHASE2,Breast Cancer,Epirubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG); Exemestane (DRUG); Goserelin (DRUG); Carboplatin (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4425,NCT02072512,The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer,UNKNOWN,PHASE2,Metastatic Breast Cancer,Fulvestrant (DRUG); Goserelin (DRUG); Anastrozole (DRUG); Goserelin (DRUG),16052011,ZDX,Metastatic Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4426,NCT00010010,Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,exemestane (DRUG); goserelin acetate (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4427,NCT00068601,S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer,COMPLETED,PHASE3,Breast Cancer; Infertility; Menopausal Symptoms,cyclophosphamide (DRUG); goserelin acetate (DRUG),16052011,ZDX,Breast Cancer; Infertility; Menopausal Symptoms,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4428,NCT06056804,Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Locally Advanced Rectal Cancer,capecitabine (DRUG); tislelizumab (DRUG); thymalfasin (DRUG); long-term radiotherapy (RADIATION),16052011,ZDX,Rectal Cancer,Bowel,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4429,NCT01674140,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,anastrozole (DRUG); everolimus (DRUG); exemestane (DRUG); goserelin acetate (DRUG); letrozole (DRUG); leuprolide acetate (DRUG); tamoxifen citrate (DRUG); placebo (OTHER),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4430,NCT02914158,Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women,RECRUITING,PHASE3,Breast Cancer,Goserelin (DRUG); Tamoxifen (DRUG); Aromatase Inhibitors (DRUG); Leuprolide (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4431,NCT03944434,FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,"Ribociclib (DRUG); Aromatase Inhibitors, non steroideal (DRUG); LHRH agonist (DRUG)",16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4432,NCT00303524,Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients,COMPLETED,PHASE2,Breast Cancer,Goserelin acetate (DRUG); Goserelin acetate (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4433,NCT00654524,Randomized Study of Gonadotropin-releasing-hormone Agonist (GnRH-a) or Expectant Management for Endometriosis,UNKNOWN,PHASE4,Endometriosis,gonadotropin-releasing-hormone agonist (GnRHa) - Goserelin (DRUG),16052011,ZDX,Endometriosis,Uterus,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4434,NCT00532272,Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC,COMPLETED,PHASE2,Metastatic Breast Cancer,"Letrozole ,Goserelin (DRUG)",16052011,ZDX,Metastatic Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4435,NCT00196846,Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO),COMPLETED,PHASE2,Breast Cancer,Goserelin (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4436,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",COMPLETED,PHASE2,Breast Cancer,Ribociclib (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Goserelin (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4437,NCT05949541,Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer,RECRUITING,PHASE2,Breast Cancer; Advanced Breast Cancer,Everolimus 10 mg (DRUG); CDK4/6 Inhibitor SHR6390 (DRUG); Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4438,NCT01240941,Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer,WITHDRAWN,PHASE2,Metastatic Breast Cancer,MK-2206 (DRUG); Exemestane (DRUG); Goserelin (DRUG),16052011,ZDX,Metastatic Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4439,NCT06348134,Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery,NOT_YET_RECRUITING,PHASE2,Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; HER2-positive Breast Cancer; Breast Cancer,Trastuzumab emtansine (DRUG); Pertuzumab Injection (DRUG); Docetaxel (DRUG); Tamoxifen (DRUG); Letrozole (DRUG); Goserelin (DRUG),16052011,ZDX,Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; HER2-positive Breast Cancer; Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4440,NCT01266213,Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women,UNKNOWN,PHASE2,Metastatic Breast Cancer; Estrogen Receptor Positive Tumor; Breast Cancer Nos Premenopausal,Fulvestrant plus Goserelin (DRUG); Anastrozole plus Goserelin (DRUG); Goserelin (DRUG),16052011,ZDX,Metastatic Breast Cancer; Estrogen Receptor Positive Tumor; Breast Cancer Nos Premenopausal,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4441,NCT03658213,To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.,WITHDRAWN,PHASE3,Breast Cancer,ZOLADEX 10.8 mg (DRUG); ZOLADEX 3.6mg (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4442,NCT02907918,Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer,TERMINATED,PHASE2,Breast Cancer; Cancer of Breast; Breast Carcinoma,Palbociclib (DRUG); Letrozole (DRUG); Trastuzumab (BIOLOGICAL); Goserelin (DRUG); Breast surgery (PROCEDURE); Research tumor biopsy (PROCEDURE); Research bone marrow (OPTIONAL) (PROCEDURE); Research blood sample (PROCEDURE); Research blood for germline DNA (GENETIC); Blood for detection of circulating tumor cells (PROCEDURE),16052011,ZDX,Breast Cancer; Cancer of Breast; Breast Carcinoma,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4443,NCT03373708,Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer,UNKNOWN,PHASE2,Breast Cancer; Chemotherapy; Endocrine Breast Diseases,Epirubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG); Goserelin acetate (DRUG); Tamoxifen (DRUG); Letrozole (DRUG),16052011,ZDX,Breast Cancer; Chemotherapy; Endocrine Breast Diseases,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4444,NCT03056755,"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments",COMPLETED,PHASE2,Breast Cancer,Alpelisib (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Goserelin (DRUG); Leuprolide (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4445,NCT05069038,Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy,RECRUITING,PHASE2,Breast Cancer,Palbociclib 125mg (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4446,NCT03839823,Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Docetaxel / Capecitabine (COMBINATION_PRODUCT); Capecitabine / Vinorelbine (COMBINATION_PRODUCT); Paclitaxel / Gemcitabine (COMBINATION_PRODUCT); Ribociclib (DRUG); Letrozole OR Anastrozole (DRUG); Goserelin (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4447,NCT04551495,Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE),ACTIVE_NOT_RECRUITING,PHASE2,Invasive Lobular Breast Carcinoma; ER+ Breast Cancer; HER2-negative Breast Cancer,Entrectinib (DRUG); Letrozole (DRUG); Goserelin (DRUG),16052011,ZDX,Invasive Lobular Breast Carcinoma; ER+ Breast Cancer; HER2-negative Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4448,NCT06447623,Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer,RECRUITING,PHASE3,Advanced Breast Cancer; HR+/HER2- Breast Cancer,Apatinib (DRUG); CDK4/6 Inhibitor (DRUG); Aromatase inhibitor and Fulvestrant (DRUG),16052011,ZDX,Advanced HR+/HER2- Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4449,NCT01776008,Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer,TERMINATED,PHASE2,Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Akt Inhibitor MK2206 (DRUG); Anastrozole (DRUG); Goserelin Acetate (DRUG); Laboratory Biomarker Analysis (OTHER); Neoadjuvant Therapy (PROCEDURE); Pharmacological Study (OTHER); Therapeutic Conventional Surgery (PROCEDURE),16052011,ZDX,Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4450,NCT05161195,Roll-over Study to Allow Continued Access to Ribociclib,RECRUITING,PHASE4,Metastatic Breast Cancer,Ribociclib (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Goserelin (DRUG); Tamoxifen (DRUG); Fulvestrant (DRUG),16052011,ZDX,Metastatic Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4451,NCT02058381,A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer,COMPLETED,PHASE1,Pre-menopausal Breast Cancer; PI3K Pathway Inhibition,alpelisib (BYL719) (DRUG); buparlisib (BKM120) (DRUG),16052011,ZDX,Pre-menopausal Breast Cancer; PI3K Pathway Inhibition,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4452,NCT04862143,Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant,TERMINATED,PHASE2,Advanced Breast Cancer,Alpelisib (DRUG); Fulvestrant (DRUG); Goserelin (DRUG),16052011,ZDX,Advanced Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4453,NCT03664895,"Density Lowering Effect of ""OFS Add on to TMX""(DELFINO Trial)",RECRUITING,PHASE3,Breast Cancer Invasive,Leuplin or zoladex (DRUG),16052011,ZDX,Breast Cancer Invasive,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4454,NCT06694350,Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCC,NOT_YET_RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma,Pembrolizumab+Flutamide (DRUG),16052011,ZDX,Head and Neck Squamous Cell Carcinoma,Skin,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4455,NCT03591549,Fulvestrant in Metastatic Breast Cancer,UNKNOWN,PHASE4,Metastatic Breast Cancer,Faslodex (DRUG); Zoladex (DRUG),16052011,ZDX,Metastatic Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4456,NCT05013242,Goserline Acetate VS Dienogest in Endometriosi,UNKNOWN,PHASE4,Endometriosis,Zoladex (DRUG); Visanne (DRUG),16052011,ZDX,Endometriosis,Uterus,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4457,NCT04931342,A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors,ACTIVE_NOT_RECRUITING,PHASE2,Ovarian Cancer,Ipatasertib (DRUG); Cobimetinib (DRUG); Trastuzumab Emtansine (DRUG); Atezolizumab (DRUG); Bevacizumab (DRUG); Paclitaxel (DRUG); Giredestrant (DRUG); Abemaciclib (DRUG); Inavolisib (DRUG); Palbociclib (DRUG); Letrozole (DRUG); Olaparib (DRUG); Luteinizing Hormone-Releasing Hormone (LHRH) Agonists (DRUG); Cyclophosphamide (DRUG); Inavolisib (DRUG),16052011,ZDX,Ovarian Cancer,Ovary/Fallopian Tube,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4458,NCT02333370,"A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",COMPLETED,PHASE1,"Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",LEE011 (DRUG); Letrozole (DRUG); Tamoxifen (DRUG); Fulvestrant (DRUG); goserelin (DRUG),16052011,ZDX,"Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4459,NCT03423199,"PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY",ACTIVE_NOT_RECRUITING,PHASE3,Breast Neoplasms,Palbociclib (DRUG); Placebo (DRUG); Tamoxifen (DRUG); Goserelin (DRUG),16052011,ZDX,Breast Neoplasms,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4460,NCT00047099,Combination Chemotherapy in Treating Women With Breast Cancer,COMPLETED,PHASE3,Breast Cancer,cyclophosphamide (DRUG); docetaxel (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); goserelin acetate (DRUG); tamoxifen citrate (DRUG); adjuvant therapy (PROCEDURE); radiation therapy (RADIATION),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4461,NCT02221999,Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients,ACTIVE_NOT_RECRUITING,PHASE2,Tubular Breast Cancer; Mucinous Breast Cancer; Invasive Ductal Breast Cancer; Inflammatory Breast Cancer,Paclitaxel (DRUG); Cisplatin (DRUG); Gonadotropin-releasing hormone agonist (DRUG); Letrozole (DRUG),16052011,ZDX,Tubular Breast Cancer; Mucinous Breast Cancer; Invasive Ductal Breast Cancer; Inflammatory Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4462,NCT05582499,Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy,RECRUITING,PHASE2,Breast Neoplasm; Breast Cancer; Breast Tumors; Triple-Negative Breast Cancer (TNBC); HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer,Dalpiciclib (DRUG); Pyrotinib (DRUG); SHR-A1811 (DRUG); SHR-1316 (DRUG); Camrelizumab (DRUG); SHR-A1921 (DRUG); Pertuzumab (DRUG); Trastuzumab (DRUG); Goserelin (DRUG); Letrozole (DRUG); Nab paclitaxel (DRUG); Carboplatin (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Fluzoparib (DRUG); Apatinib (DRUG); Famitinib (DRUG),16052011,ZDX,Breast Neoplasm; Breast Cancer; Breast Tumors; Triple-Negative Breast Cancer (TNBC); HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4463,NCT01682642,The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis.,COMPLETED,PHASE4,Infertility; Endometriosis,Zoladex (DRUG),16052011,ZDX,Infertility and Endometriosis,Uterus,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4464,NCT05439499,"This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.",UNKNOWN,PHASE3,Advanced Breast Cancer; Female Breast Cancer,"FCN-437c, Letrozole or anastrozole, Goserelin acetate (DRUG); Placebo, Letrozole or anastrozole, Goserelin acetate (DRUG)",16052011,ZDX,Advanced Breast Cancer; Female Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4465,NCT05004142,"Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin",UNKNOWN,PHASE2,Breast Neoplasms,FCN-437c+Fulvestrant (DRUG); FCN-437c+Letrozole+Goserelin (DRUG),16052011,ZDX,Breast Neoplasms,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4466,NCT01013506,"Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer",WITHDRAWN,PHASE2,Breast Cancer,IGF-1R inhibitor OSI-906 (DRUG); erlotinib hydrochloride (DRUG); goserelin (DRUG); letrozole (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4467,NCT05085002,A Study of Lerociclib in Participants With Advanced Breast Cancer,TERMINATED,PHASE2,Advanced Breast Cancer,Lerociclib + Letrozole or Fulvestrant (DRUG),16052011,ZDX,Advanced Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4468,NCT02535221,Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer,RECRUITING,PHASE3,Breast Cancer,Goserelin+TAM+AI (DRUG); Epirubicin+CTX+5-Fu (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4469,NCT03969121,"Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer",COMPLETED,PHASE3,Breast Cancer Female; Hormone Receptor Positive Malignant Neoplasm of Breast,Palbociclib (DRUG); Endocrine therapy (DRUG),16052011,ZDX,Breast Cancer Female; Hormone Receptor Positive Malignant Neoplasm of Breast,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4470,NCT06225284,Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients,RECRUITING,PHASE2,Triple Negative Breast Cancer; Premenopausal Breast Cancer,Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg (DRUG),16052011,ZDX,Triple Negative Breast Cancer; Premenopausal Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4471,NCT03007979,Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Breast Carcinoma; Cancer of Breast; Malignant Tumor of Breast,Palbociclib (DRUG); Letrozole (DRUG); Fulvestrant (DRUG); Optional research biopsy (PROCEDURE); Goserelin (DRUG); Research blood draw (PROCEDURE); Circulating tumor cell blood draw (PROCEDURE); Tumor biopsy (optional) (PROCEDURE),16052011,ZDX,Breast Cancer; Breast Carcinoma; Cancer of Breast; Malignant Tumor of Breast,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4472,NCT04428684,COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg,COMPLETED,PHASE1,Dysfunctional Uterine Bleeding,Pepti 3.6 mg (DRUG),16052011,ZDX,Dysfunctional Uterine Bleeding,Uterus,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4473,NCT06291064,Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer,NOT_YET_RECRUITING,PHASE2,Triple Negative Breast Cancer,Cyclophosphamide (DRUG); Epirubicin (DRUG); Docetaxel (DRUG); Carboplatin (DRUG); Breast Surgery (PROCEDURE); Capecitabine (DRUG),16052011,ZDX,Triple Negative Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4474,NCT00186121,Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women,COMPLETED,PHASE2,Breast Cancer,Anastrozole (Arimidex) (DRUG); Goserelin (Zoladex) (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4475,NCT00429403,Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer,TERMINATED,PHASE3,Breast Cancer,Goserelin (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4476,NCT05870579,"[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer",RECRUITING,PHASE1,Breast Cancer,[68Ga]Ga-NeoB (DRUG); [177Lu]Lu-NeoB (DRUG); Ribociclib (DRUG); Fulvestrant (DRUG); Goserelin (OTHER),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4477,NCT04657679,Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts,TERMINATED,PHASE4,Breast Cancer,Ribociclib (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4478,NCT02603679,Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases,ACTIVE_NOT_RECRUITING,PHASE2,Early-Stage Breast Carcinoma; Estrogen Receptor Positive Tumor,Paclitaxel (DRUG); Tamoxifen + Palbociclib (DRUG); Aromatase Inhibitor + Palbociclib (DRUG); Goserelin + Aromatase Inhibitor + Palbociclib (DRUG),16052011,ZDX,Hormone-Receptor Positive Breast Carcinoma,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4479,NCT01073865,Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer,COMPLETED,PHASE3,Breast Cancer,ZD9393 (Zoladex) 10.8 mg (DRUG); ZD9393 (Zoladex) 3.6 mg (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4480,NCT00322348,Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women,COMPLETED,PHASE2,Advanced Breast Cancer,Goserelin acetate (DRUG); Goserelin acetate (DRUG),16052011,ZDX,Advanced Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4481,NCT02586675,TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer,COMPLETED,PHASE1,Breast Cancer; Breast Cancer - Female; Breast Cancer - Male,Tamoxifen (DRUG); Ribociclib (DRUG); Goserelin (DRUG),16052011,ZDX,Breast Cancer; Breast Cancer - Female; Breast Cancer - Male,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4482,NCT06483386,Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer,NOT_YET_RECRUITING,PHASE2,Breast Cancer,Pyrotinib and Subcutaneous preparation of trastuzumab combined with capecitabine (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4483,NCT04130152,Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy,COMPLETED,EARLY_PHASE1,Breast Cancer,Palbociclib (DRUG); Letrozole (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4484,NCT00217659,"S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer",WITHDRAWN,PHASE2,Breast Cancer,anastrozole (DRUG); goserelin acetate (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4485,NCT05163106,Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole,COMPLETED,PHASE2,Breast Cancer; HER2-negative Breast Cancer; ER-positive Breast Cancer; Locally Advanced Breast Cancer; Luminal A Breast Cancer; Luminal B Breast Cancer,Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet (DRUG); Goserelin (DRUG),16052011,ZDX,Breast Cancer; HER2-negative Breast Cancer; ER-positive Breast Cancer; Locally Advanced Breast Cancer; Luminal A Breast Cancer; Luminal B Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4486,NCT01149356,RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer,TERMINATED,PHASE1,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Exemestane (DRUG); Gamma-Secretase Inhibitor RO4929097 (DRUG); Goserelin Acetate (DRUG),16052011,ZDX,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4487,NCT00235937,Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex,COMPLETED,PHASE2,Breast Cancer,Anastrozole and goserelin (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4488,NCT05110170,Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®,COMPLETED,PHASE3,Breast Cancer,LY01005 (DRUG); ZOLADEX® 3.6 mg (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4489,NCT03447132,Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant,COMPLETED,PHASE3,Breast Neoplasm Female,Fulvestrant 500mg (DRUG); Palbociclib 125mg (DRUG); Goserelin 3.6 MG (DRUG); Placebos (DRUG),16052011,ZDX,Female Breast Neoplasm,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4490,NCT02532400,Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients,TERMINATED,PHASE3,Breast Cancer,Neoadjuvant endocrine therapy (DRUG); Neoadjuvant chemotherapy (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4491,NCT03936933,Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer,TERMINATED,PHASE3,Breast Cancer,Goserelin acetate 3.6 mg Injection (DRUG); ZOLADEX® 3.6mg Injection (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4492,NCT02313051,Everolimus trIal for Advanced prememopausaL Breast Cancer Patients,UNKNOWN,PHASE2,Metastatic Breast Cancer,Everolimus (DRUG); Goserelin (DRUG); Letrozole (DRUG),16052011,ZDX,Metastatic Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4493,NCT00427245,"Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer",COMPLETED,PHASE3,Breast Cancer; Infertility; Menopausal Symptoms,cyclophosphamide (DRUG); goserelin acetate (DRUG); adjuvant therapy (PROCEDURE); fertility assessment and management (PROCEDURE); neoadjuvant therapy (PROCEDURE),16052011,ZDX,Breast Cancer; Infertility; Menopausal Symptoms,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4494,NCT01638247,Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients,COMPLETED,PHASE3,Male Breast Cancer,Tamoxifen (DRUG); Tamoxifen and GnRH analogue (DRUG); Exemestane and GnRH analogue (DRUG),16052011,ZDX,Male Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4495,NCT03272477,Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients,COMPLETED,PHASE2,Breast Neoplasms,Perjeta Injectable Product (DRUG); Herceptin (DRUG); Tamoxifen (DRUG); Paclitaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Leuprorelin acetate (DRUG); Goserelin (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Paclitaxel (DRUG); Tamoxifen (DRUG); Leuporelin acetate (DRUG); Goserelin (DRUG); Biopsy (DIAGNOSTIC_TEST); Surgery (PROCEDURE),16052011,ZDX,Breast Neoplasms,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4496,NCT01205685,Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer,TERMINATED,PHASE2,Hormone-sensitive Metastatic Breast Cancer,OSI-906 (DRUG); Erlotinib (DRUG); Letrozole (DRUG); Goserelin (DRUG),16052011,ZDX,Hormone-sensitive Metastatic Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4497,NCT01530607,"Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer",COMPLETED,PHASE3,Breast Cancer,Standard cyclophosphamide (DRUG); Goserelin (Zoladex) (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4498,NCT05983107,Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer,RECRUITING,PHASE2,HR+/HER2- Advanced Breast Cancer; Targeted Therapy,Everolimus (DRUG); Chidamide (DRUG); Endocrine therapy (DRUG); Ovarian function suppression(OFS) (DRUG),16052011,ZDX,HR+/HER2- Advanced Breast Cancer; Targeted Therapy,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4499,NCT02003209,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE3,HER2-Positive Breast Carcinoma; Hormone Receptor-Positive Breast Carcinoma; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7,Aromatase Inhibition Therapy (DRUG); Carboplatin (DRUG); Cytology Specimen Collection Procedure (OTHER); Docetaxel (DRUG); Goserelin Acetate (DRUG); Laboratory Biomarker Analysis (OTHER); Pertuzumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Therapeutic Conventional Surgery (PROCEDURE); Trastuzumab (BIOLOGICAL); Whole Breast Irradiation (RADIATION),16052011,ZDX,HER2-Positive Breast Carcinoma; Hormone Receptor-Positive Breast Carcinoma; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4500,NCT02626507,Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer,UNKNOWN,PHASE1,Breast Cancer,Gedatolisib (DRUG); Faslodex (DRUG); Palbociclib (DRUG); Zoladex (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4501,NCT05625087,Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib,RECRUITING,PHASE2,Breast Cancer Stage IV,Alpelisib (DRUG); Ribociclib (DRUG),16052011,ZDX,Breast Cancer Stage IV,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4502,NCT01240928,MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer,WITHDRAWN,PHASE1,Metastatic Breast Cancer,MSK-2206 (DRUG); Exemestane (DRUG); Goserelin (DRUG),16052011,ZDX,Metastatic Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4503,NCT02592083,Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors,ACTIVE_NOT_RECRUITING,PHASE2,Early-Stage Breast Carcinoma; Hormone Receptor Positive Tumor,Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin (DRUG); Palbociclib (DRUG),16052011,ZDX,Hormone Receptor-positive Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4504,NCT00309478,Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients,COMPLETED,PHASE3,Early-stage Breast Cancer,Cyclophosphamide (DRUG); Methotrexate (DRUG); Fluorouracil implant (DRUG); Goserelin (DRUG); Tamoxifen (DRUG),16052011,ZDX,Early-stage Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4505,NCT03332797,A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,GDC-9545 (DRUG); Palbociclib (DRUG); LHRH Agonist (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4506,NCT05333328,OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk,RECRUITING,PHASE4,Breast Cancer; Estrogen Receptor Positive Tumor; HER2-negative Breast Cancer; Premenopausal Breast Cancer; Node-positive Breast Cancer,Ovarian function suppression with endocrine treatments (DRUG),16052011,ZDX,Breast Cancer; Estrogen Receptor Positive Tumor; HER2-negative Breast Cancer; Premenopausal Breast Cancer; Node-positive Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4507,NCT03519178,A Study of PF-06873600 in People With Cancer,TERMINATED,PHASE1,"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer",PF-06873600 (DRUG); Endocrine Therapy 1 (DRUG); Endocrine Therapy 2 (DRUG),16052011,ZDX,"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer",Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4508,NCT02941926,Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC,COMPLETED,PHASE3,Breast Cancer,Ribociclib (DRUG); Letrozole (DRUG); Goserelin (DRUG); Leuprolide (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4509,NCT05879926,"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25",RECRUITING,PHASE3,Breast Cancer,Ovarian Function Suppression + Aromatase Inhibitor (DRUG); Adjuvant Chemotherapy + Ovarian Function Suppression (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4510,NCT06523530,Effect of a GnRH Analog on Hepatic Steatosis,RECRUITING,PHASE4,Metabolic Dysfunction-Associated Steatotic Liver Disease; Nonalcoholic Fatty Liver; Endometriosis,"Goserelin Acetate 3.6 mg inj, implant (DRUG)",16052011,ZDX,Metabolic Dysfunction-Associated Steatotic Liver Disease; Nonalcoholic Fatty Liver; Endometriosis,Uterus,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4511,NCT03671330,"Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.",ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Ribociclib Placebo (DRUG); Ribociclib (DRUG); NSAI: Letrozole or Anastrazole (DRUG); Letrozole (DRUG); Goserelin (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4512,NCT02440230,Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients,COMPLETED,PHASE2,Breast Cancer,OFS + Anastrozole (DRUG); OFS + Exemestane (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4513,NCT02278120,"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",COMPLETED,PHASE3,Advanced Metastatic Breast Cancer,Ribociclib (DRUG); Tamoxifen (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Goserelin (DRUG); Placebo (DRUG),16052011,ZDX,Advanced Metastatic Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4514,NCT05891093,Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01),RECRUITING,PHASE3,Breast Cancer,Fluzoparib (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Tamoxifen (DRUG); Toremifene (DRUG); Abemaciclib (DRUG); LHRH agonist (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4515,NCT00053911,Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer,TERMINATED,PHASE3,Breast Cancer,anastrozole (DRUG); cyclophosphamide (DRUG); docetaxel (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); goserelin acetate (DRUG); tamoxifen citrate (DRUG); adjuvant therapy (PROCEDURE),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4516,NCT04293393,Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients,ACTIVE_NOT_RECRUITING,PHASE2,Early Breast Cancer,Doxorubicin (DRUG); Cyclophosphamide (DRUG); Taxane (DRUG); Letrozole (DRUG); Abemaciclib (DRUG); LHRH Analogue (DRUG),16052011,ZDX,Early Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4517,NCT01712893,"Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer",COMPLETED,PHASE3,Breast Cancer,Zoladex (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4518,NCT02983071,"G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer",UNKNOWN,PHASE1,"Carcinoma, Ductal, Breast; Breast Cancer; Breast Neoplasm",G1T38 (DRUG); Fulvestrant (DRUG),16052011,ZDX,"Carcinoma, Ductal, Breast; Breast Cancer; Breast Neoplasm",Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4519,NCT01622361,"Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer",UNKNOWN,PHASE3,Breast Cancer,Adriamycin+Cyclophosphamide>Docetaxel (DRUG); GnRHa with Tamoxifen (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4520,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Tucidinostat (DRUG); Exemestane (DRUG); Ovarian function suppression (DRUG),16052011,ZDX,Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4521,NCT03096847,Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer,COMPLETED,PHASE3,Advanced Metastatic Breast Cancer,ribociclib (DRUG); letrozole (DRUG); goserelin (DRUG),16052011,ZDX,Advanced Metastatic Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4522,NCT02917005,PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer,UNKNOWN,PHASE2,Metastatic Breast Cancer,Palbociclib (DRUG); Exemestane (DRUG); Goserelin (DRUG),16052011,ZDX,Metastatic Breast Cancer,Breast,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4523,NCT06573398,Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC,NOT_YET_RECRUITING,PHASE2,"Carcinoma, Pancreatic Ductal",SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin (COMBINATION_PRODUCT),16052011,ZDX,Pancreatic Ductal Carcinoma,Pancreas,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4524,NCT00286351,Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis,COMPLETED,PHASE4,Endometriosis,Combined treatment with Arimidex and Zoladex before IVF (DRUG),16052011,ZDX,Endometriosis,Uterus,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4525,NCT03709849,Effectiveness and Safety of Bushen Culuan Decoction for Anovulatory Infertility,UNKNOWN,PHASE2,Anovulatory Infertility; Abnormal Uterine Bleeding-Ovulatory Disorders; Polycystic Ovarian Syndrome; Hyperprolactinemia; Luteinized Unruptured Follicle Syndrome; Corpus Luteum Insufficiency; Ovarian Insufficiency,experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo (DRUG); control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo (DRUG),16052011,ZDX,Anovulatory Infertility; Abnormal Uterine Bleeding-Ovulatory Disorders; Polycystic Ovarian Syndrome; Hyperprolactinemia; Luteinized Unruptured Follicle Syndrome; Corpus Luteum Insufficiency; Ovarian Insufficiency,Ovary/Fallopian Tube,Goserelin (acetate),GNRHR,activator/agonist,unclear,yes,yes,It's approved for prostate and breast cancer treatment.,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,1.06,309.0 +4526,NCT01944176,The Effects of Simvastatin on Th17 Cytokines and Th17 Polarizing Cytokine in COPD Patients,COMPLETED,PHASE3,COPD,"simvastatin, placebo (DRUG)",72172,Bestatin,COPD,Lung,Bestatin,ANPEP,inhibitor/antagonist,unclear,no,yes,Studied in trials; not approved for human therapeutic use.,CC(C)CC(C(=O)O)NC(=O)C(C(CC1=CC=CC=C1)N)O,1.2,151.0 +4527,NCT02664558,A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1),COMPLETED,PHASE2,Pulmonary Arterial Hypertension,ubenimex (DRUG); placebo (OTHER),72172,Bestatin,Pulmonary Arterial Hypertension,Lung,Bestatin,ANPEP,inhibitor/antagonist,unclear,no,yes,Studied in trials; not approved for human therapeutic use.,CC(C)CC(C(=O)O)NC(=O)C(C(CC1=CC=CC=C1)N)O,1.2,151.0 +4528,NCT03402204,Efficacy of High and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcome in Patients With AIS,COMPLETED,PHASE3,Ischemic Stroke,Simvastatin 10 mg (DRUG); Simvastatin 40 mg (DRUG),72172,Bestatin,Ischemic Stroke,CNS/Brain,Bestatin,ANPEP,inhibitor/antagonist,unclear,no,yes,Studied in trials; not approved for human therapeutic use.,CC(C)CC(C(=O)O)NC(=O)C(C(CC1=CC=CC=C1)N)O,1.2,151.0 +4529,NCT02736149,Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1),TERMINATED,PHASE2,Pulmonary Arterial Hypertension,ubenimex (DRUG),72172,Bestatin,Pulmonary Arterial Hypertension,Lung,Bestatin,ANPEP,inhibitor/antagonist,unclear,no,yes,Studied in trials; not approved for human therapeutic use.,CC(C)CC(C(=O)O)NC(=O)C(C(CC1=CC=CC=C1)N)O,1.2,151.0 +4530,NCT06640166,Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.,RECRUITING,PHASE2,Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumor; Colorectal Adenocarcinoma; Colorectal Cancer (CRC); Colorectal Cancer; Colon Cancer; Colon Adenocarcinoma; Colon Carcinoma; Colon Neoplasm,encorafenib + cetuximab + FOLFIRI (DRUG),50922675,Braftovi,Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumor; Colorectal Adenocarcinoma; Colorectal Cancer (CRC); Colorectal Cancer; Colon Cancer; Colon Adenocarcinoma; Colon Carcinoma; Colon Neoplasm,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4531,NCT04655157,Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma,TERMINATED,PHASE1,Melanoma,encorafenib (DRUG); nivolumab (DRUG); ipilimumab (DRUG); binimetinib (DRUG),50922675,Braftovi,Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4532,NCT02159066,"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",COMPLETED,PHASE2,Melanoma,LGX818 (DRUG); MEK162 (DRUG); LEE011 (DRUG); BGJ398 (DRUG); BKM120 (DRUG); INC280 (DRUG),50922675,Braftovi,Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4533,NCT05308446,Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Colon Adenocarcinoma; Metastatic Rectal Adenocarcinoma; Stage III Colon Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Unresectable Colon Adenocarcinoma; Unresectable Rectal Adenocarcinoma,Cetuximab (BIOLOGICAL); Encorafenib (DRUG); Nivolumab (BIOLOGICAL),50922675,Braftovi,Metastatic Colon Adenocarcinoma; Metastatic Rectal Adenocarcinoma; Stage III Colon Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Unresectable Colon Adenocarcinoma; Unresectable Rectal Adenocarcinoma,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4534,NCT05304546,Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma,NOT_YET_RECRUITING,PHASE2,Malignant Melanoma; Metastatic Melanoma; Immunotherapy; BRAF V600E; Malignant Melanoma Stage IV,Pembrolizumab (DRUG); Encorafenib (DRUG); Binimetinib (DRUG),50922675,Braftovi,Malignant Melanoma; Metastatic Melanoma; Immunotherapy; BRAF V600E; Malignant Melanoma Stage IV,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4535,NCT01777776,Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.,TERMINATED,PHASE1,Locally Advanced Metastatic BRAF Mutant Melanoma,LEE011 (DRUG); LGX818 (DRUG),50922675,Braftovi,Locally Advanced Metastatic BRAF Mutant Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4536,NCT04526782,ENCOrafenib With Binimetinib in bRAF NSCLC,ACTIVE_NOT_RECRUITING,PHASE2,Non Small Cell Lung Cancer; BRAF V600E,Encorafenib 75 MG (DRUG); Binimetinib 15 MG (DRUG),50922675,Braftovi,Non Small Cell Lung Cancer; BRAF V600E,Lung,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4537,NCT04044430,"Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer",TERMINATED,PHASE1,Metastatic Colon Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Microsatellite Stable Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Stage III Colon Cancer; Stage III Colorectal Cancer; Stage III Rectal Cancer; Stage IIIA Colon Cancer; Stage IIIA Colorectal Cancer; Stage IIIA Rectal Cancer; Stage IIIB Colon Cancer; Stage IIIB Colorectal Cancer; Stage IIIB Rectal Cancer; Stage IIIC Colon Cancer; Stage IIIC Colorectal Cancer; Stage IIIC Rectal Cancer; Stage IV Colon Cancer; Stage IV Colorectal Cancer; Stage IV Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Colorectal Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Colorectal Cancer; Stage IVB Rectal Cancer; Stage IVC Colon Cancer; Stage IVC Colorectal Cancer; Stage IVC Rectal Cancer,Binimetinib (DRUG); Encorafenib (DRUG); Nivolumab (BIOLOGICAL); Questionnaire Administration (OTHER),50922675,Braftovi,Metastatic Colon Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Microsatellite Stable Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Stage III Colon Cancer; Stage III Colorectal Cancer; Stage III Rectal Cancer; Stage IIIA Colon Cancer; Stage IIIA Colorectal Cancer; Stage IIIA Rectal Cancer; Stage IIIB Colon Cancer; Stage IIIB Colorectal Cancer; Stage IIIB Rectal Cancer; Stage IIIC Colon Cancer; Stage IIIC Colorectal Cancer; Stage IIIC Rectal Cancer; Stage IV Colon Cancer; Stage IV Colorectal Cancer; Stage IV Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Colorectal Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Colorectal Cancer; Stage IVB Rectal Cancer; Stage IVC Colon Cancer; Stage IVC Colorectal Cancer; Stage IVC Rectal Cancer,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4538,NCT05538130,A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors,RECRUITING,PHASE1,Melanoma; Glioma; Thyroid Cancer; Non-Small Cell Lung Cancer; Malignant Neoplasms; Brain Neoplasms; Colorectal Cancer,PF-07799544 (DRUG); PF-07799933 (DRUG); encorafenib (DRUG),50922675,Braftovi,Melanoma; Glioma; Thyroid Cancer; Non-Small Cell Lung Cancer; Malignant Neoplasms; Brain Neoplasms; Colorectal Cancer,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4539,NCT05003622,Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors,COMPLETED,PHASE1,BRAF V600E Unresectable or Metastatic Melanoma; BRAF V600E Metastatic NSCLC; Melanoma,Encorafenib (DRUG),50922675,Braftovi,BRAF V600E Unresectable or Metastatic Melanoma; BRAF V600E Metastatic NSCLC; Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4540,NCT03563729,Melanoma Metastasized to the Brain and Steroids,RECRUITING,PHASE2,Malignant Melanoma,Pembrolizumab Injection [Keytruda] (DRUG); Ipilimumab Injection [Yervoy] (DRUG); Nivolumab Injection [Opdivo] (DRUG); Encorafenib (DRUG); Binimetinib (DRUG); Dabrafenib (DRUG); Trametinib (DRUG),50922675,Braftovi,Malignant Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4541,NCT06470880,Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy,NOT_YET_RECRUITING,PHASE2,Melanoma,Adaptive Therapy (DRUG); Standard of Care (DRUG),50922675,Braftovi,Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4542,NCT01719380,"Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer",COMPLETED,PHASE2,Colorectal Cancer,LGX818 (DRUG); Cetuximab (DRUG); BYL719 (DRUG),50922675,Braftovi,Colorectal Cancer,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4543,NCT06194929,"Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma",RECRUITING,PHASE1,Melanoma,Defactinib (DRUG); Avutometinib (DRUG); Encorafenib (DRUG),50922675,Braftovi,Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4544,NCT05926960,"A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma",ACTIVE_NOT_RECRUITING,PHASE2,Melanoma,encorafenib (DRUG); binimetinib (DRUG); pembrolizumab (DRUG); ipilimumab (DRUG); nivolumab (DRUG),50922675,Braftovi,Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4545,NCT04657991,"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma",ACTIVE_NOT_RECRUITING,PHASE3,Melanoma,Encorafenib (DRUG); Binimetinib (DRUG); Pembrolizumab (DRUG),50922675,Braftovi,Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4546,NCT02928224,Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer,COMPLETED,PHASE3,BRAF V600E-mutant Metastatic Colorectal Cancer,Encorafenib (DRUG); Binimetinib (DRUG); Cetuximab (DRUG); Irinotecan (DRUG); Folinic Acid (DRUG); 5-Fluorouracil (DRUG),50922675,Braftovi,BRAF V600E-mutant Metastatic Colorectal Cancer,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4547,NCT05270044,Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.,ACTIVE_NOT_RECRUITING,PHASE3,Melanoma,Encorafenib and Binimetinib (DRUG); Placebo to match Encorafenib ; Placebo to match Binimetinib (DRUG),50922675,Braftovi,Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4548,NCT04759846,Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma,WITHDRAWN,PHASE1,BRAF V600 Mutation; Unresectable Melanoma; Metastatic Melanoma; Hepatic Impairment,Encorafenib + Binimetinib (DRUG); Encorafenib + Binimetinib (DRUG); Encorafenib + Binimetinib (DRUG),50922675,Braftovi,BRAF V600 Mutation; Unresectable Melanoma; Metastatic Melanoma; Hepatic Impairment,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4549,NCT01894672,"BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation",COMPLETED,PHASE2,Melanoma,LGX818 (DRUG),50922675,Braftovi,Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4550,NCT03543969,Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,Melanoma (Skin); Skin Cancer; Skin Melanoma; Skin Carcinoma,Encorafenib (DRUG); Binimetinib (DRUG); Nivolumab (DRUG),50922675,Braftovi,Melanoma (Skin); Skin Cancer; Skin Melanoma; Skin Carcinoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4551,NCT05217446,A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Colorectal Cancer,Encorafenib (DRUG); Cetuximab (BIOLOGICAL); Pembrolizumab (BIOLOGICAL),50922675,Braftovi,Metastatic Colorectal Cancer,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4552,NCT01519427,Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib,TERMINATED,PHASE2,Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma,Akt inhibitor MK2206 (DRUG); selumetinib (DRUG); laboratory biomarker analysis (OTHER),50922675,Braftovi,Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4553,NCT04074096,Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis,ACTIVE_NOT_RECRUITING,PHASE2,Malignant Melanoma; BRAF V600 Mutation; Brain Metastases,Stereotaxic radiosurgery (SRS) (RADIATION); Binimetinib Oral Tablet (DRUG); Encorafenib Oral Capsule (DRUG); Pembrolizumab (DRUG),50922675,Braftovi,Malignant Melanoma; BRAF V600 Mutation; Brain Metastases,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4554,NCT03878719,Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma,TERMINATED,PHASE1,Melanoma,binimetinib (DRUG); encorafenib (DRUG),50922675,Braftovi,Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4555,NCT03911869,"An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis",TERMINATED,PHASE2,Brain Metastases,encorafenib (DRUG); binimetinib (DRUG),50922675,Braftovi,Brain Metastases,CNS/Brain,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4556,NCT04720768,"Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE",RECRUITING,PHASE1,Melanoma; Metastasis,Binimetinib (DRUG); Encorafenib (DRUG); Palbociclib (DRUG),50922675,Braftovi,Metastatic Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4557,NCT05576896,Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory,RECRUITING,PHASE2,Stage IV Colorectal Cancer Positive for BRAF V600E Mutation; Colorectal Cancer; Colorectal Cancer Stage IV,Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab (DRUG),50922675,Braftovi,Stage IV Colorectal Cancer Positive for BRAF V600E Mutation; Colorectal Cancer; Colorectal Cancer Stage IV,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4558,NCT03026517,Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma,COMPLETED,PHASE1,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Phenformin (DRUG),50922675,Braftovi,Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4559,NCT05019534,"Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer",UNKNOWN,PHASE1,BRAF V600E-mutated /MSS Metastatic Colorectal Cancer; Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody,Vemurafenib Oral Tablet [Zelboraf] (DRUG); Cetuximab Injection [Erbitux] (DRUG); Camrelizumab (DRUG),50922675,Braftovi,BRAF V600E-mutated /MSS Metastatic Colorectal Cancer; Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4560,NCT03973918,Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG,TERMINATED,PHASE2,High Grade Glioma; BRAF V600E; BRAF V600K; Anaplastic Astrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Gliosarcoma; Glioblastoma,Encorafenib (DRUG); Binimetinib (DRUG); Research Bloods (BIOLOGICAL); Tumor Tissue (BIOLOGICAL),50922675,Braftovi,High Grade Glioma; BRAF V600E; BRAF V600K; Anaplastic Astrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Gliosarcoma; Glioblastoma,CNS/Brain,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4561,NCT05743036,ZN-c3 in Adult Participants With Metastatic Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Colorectal Cancer,ZN-c3 (DRUG); Encorafenib (DRUG); Cetuximab (DRUG),50922675,Braftovi,Metastatic Colorectal Cancer,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4562,NCT04903119,Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma,RECRUITING,PHASE1,Metastatic Melanoma; BRAF Gene Mutation,Nilotinib 100mg (DRUG); Nilotinib 200mg (DRUG); Nilotinib 300mg (DRUG); Nilotinib 400mg (DRUG); Dabrafenib (DRUG); Trametinib (DRUG); Encorafenib (DRUG); Binimetinib (DRUG),50922675,Braftovi,Advanced Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4563,NCT05615818,Personalized Medicine for Advanced Biliary Cancer Patients,RECRUITING,PHASE3,Biliary Tract Neoplasms,Futibatinib (DRUG); Ivosidenib (DRUG); Zanidatamab (DRUG); Trastuzumab (DRUG); Neratinib (DRUG); Encorafenib (DRUG); Binimetinib (DRUG); Niraparib (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG),50922675,Braftovi,Biliary Tract Neoplasms,Liver,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4564,NCT03898908,Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Melanoma; Brain Metastases,encorafenib (DRUG); binimetinib (DRUG); Whole brain radiation therapy (RADIATION); Radiosurgery/stereotactic radiosurgery (RADIATION),50922675,Braftovi,Metastatic Melanoma; Brain Metastases,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4565,NCT04221438,Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement,ACTIVE_NOT_RECRUITING,PHASE2,Melanoma of Unknown Primary; Metastatic Malignant Neoplasm in Lymph Node; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Recurrent Cutaneous Melanoma,Binimetinib (DRUG); Computed Tomography (PROCEDURE); Conventional Surgery (PROCEDURE); Encorafenib (DRUG); Fluorothymidine F-18 (OTHER); Positron Emission Tomography (PROCEDURE),50922675,Braftovi,Melanoma of Unknown Primary; Metastatic Malignant Neoplasm in Lymph Node; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Recurrent Cutaneous Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4566,NCT04017650,"Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer",ACTIVE_NOT_RECRUITING,PHASE1,BRAF NP_004324.2:p.V600E; Metastatic Colon Adenocarcinoma; Metastatic Microsatellite Stable Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Progressive Disease; Recurrent Colorectal Carcinoma; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Unresectable Colon Adenocarcinoma; Unresectable Rectal Adenocarcinoma,Cetuximab (BIOLOGICAL); Encorafenib (DRUG); Nivolumab (BIOLOGICAL),50922675,Braftovi,BRAF NP_004324.2:p.V600E; Metastatic Colon Adenocarcinoma; Metastatic Microsatellite Stable Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Progressive Disease; Recurrent Colorectal Carcinoma; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Unresectable Colon Adenocarcinoma; Unresectable Rectal Adenocarcinoma,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4567,NCT05004350,A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.,COMPLETED,PHASE2,BRAF V600E; Metastatic Colorectal Cancer,Encorafenib (DRUG); Cetuximab (DRUG); FOLFIRI (DRUG),50922675,Braftovi,BRAF V600E; Metastatic Colorectal Cancer,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4568,NCT05510895,"Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer",RECRUITING,PHASE2,Colorectal Cancer; Colon Cancer; BRAF V600E; BRAF V600 Mutation; Localized Cancer,Binimetinib (DRUG),50922675,Braftovi,Colorectal Cancer; Colon Cancer; BRAF V600E; BRAF V600 Mutation; Localized Cancer,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4569,NCT01820364,LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,TERMINATED,PHASE2,Melanoma,LGX818 (DRUG),50922675,Braftovi,Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4570,NCT02382549,A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib,TERMINATED,EARLY_PHASE1,Melanoma,BRAF inhibitor (DRUG); 6MHP (BIOLOGICAL); MEK inhibitor (DRUG),50922675,Braftovi,Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4571,NCT02902042,Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma,COMPLETED,PHASE1,Malignant Melanoma,Encorafenib (DRUG); Binimetinib (DRUG); Pembrolizumab (DRUG); Pembrolizumab alone (DRUG),50922675,Braftovi,Malignant Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4572,NCT03864042,Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors,COMPLETED,PHASE1,Advanced Solid Tumors; Metastatic Melanoma,losartan (DRUG); dextromethorphan (DRUG); caffeine (DRUG); omeprazole (DRUG); midazolam (DRUG); rosuvastatin (DRUG); bupropion immediate release (IR) (DRUG); encorafenib (DRUG); binimetinib (DRUG); modafinil (DRUG),50922675,Braftovi,Advanced Solid Tumors; Metastatic Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4573,NCT06102902,"Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer",RECRUITING,PHASE1,Metastatic Colorectal Adenocarcinoma; Recurrent Colorectal Adenocarcinoma; Refractory Colorectal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v8,BET Bromodomain Inhibitor ZEN-3694 (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Cetuximab (BIOLOGICAL); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Encorafenib (DRUG); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE),50922675,Braftovi,Metastatic Colorectal Adenocarcinoma; Recurrent Colorectal Adenocarcinoma; Refractory Colorectal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v8,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4574,NCT04390243,Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation,TERMINATED,PHASE2,Locally Advanced Pancreatic Carcinoma; Metastatic Pancreatic Carcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Binimetinib (DRUG); Encorafenib (DRUG),50922675,Braftovi,Locally Advanced Pancreatic Carcinoma; Metastatic Pancreatic Carcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Pancreas,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4575,NCT05706779,Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer,RECRUITING,PHASE2,Colorectal Cancer; BRAF V600E Mutation Positive,Encorafenib Oral Capsule + Cetuximab (DRUG),50922675,Braftovi,Colorectal Cancer; BRAF V600E Mutation Positive,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4576,NCT05767879,(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma,RECRUITING,PHASE2,Melanoma Stage III; In-Transit Metastasis of Cutaneous Melanoma,Encorafenib + Binimetinib (DRUG),50922675,Braftovi,Melanoma Stage III; In-Transit Metastasis of Cutaneous Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4577,NCT03693170,"Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer",COMPLETED,PHASE2,BRAF V600E-mutant Metastatic Colorectal Cancer,encorafenib (DRUG); Binimetinib (DRUG); Cetuximab (DRUG),50922675,Braftovi,BRAF V600E-mutant Metastatic Colorectal Cancer,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4578,NCT04511013,A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases,RECRUITING,PHASE2,Acral Lentiginous Melanoma; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Cutaneous Melanoma; Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Metastatic Mucosal Melanoma; Pathologic Stage IV Cutaneous Melanoma AJCC v8,Binimetinib (DRUG); Encorafenib (DRUG); Ipilimumab (BIOLOGICAL); Nivolumab (BIOLOGICAL),50922675,Braftovi,Acral Lentiginous Melanoma; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Cutaneous Melanoma; Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Metastatic Mucosal Melanoma; Pathologic Stage IV Cutaneous Melanoma AJCC v8,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4579,NCT06578559,Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC,RECRUITING,PHASE2,Colorectal Cancer,Cetuximab (DRUG); Encorafenib (DRUG),50922675,Braftovi,Colorectal Cancer,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4580,NCT05195632,Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients with Metastatic Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Non-Small Cell Lung Cancer,Encorafenib (DRUG); Binimetinib (DRUG),50922675,Braftovi,Advanced Non-Small Cell Lung Cancer,Lung,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4581,NCT06411600,Combination Therapy for BRAF-V600E Metastatic CRCm,RECRUITING,PHASE2,Metastatic Colorectal Cancer,Encorafenib (DRUG); Cetuximab (DRUG); Bevacizumab (DRUG),50922675,Braftovi,Metastatic Colorectal Cancer,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4582,NCT05710406,Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Colon Adenocarcinoma; Microsatellite Stable Colon Carcinoma; Stage IIB Colon Cancer AJCC V8; Stage IIC Colon Cancer AJCC V8; Stage III Colon Cancer AJCC V8,Encorafenib (DRUG); Cetuximab (BIOLOGICAL); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Patient Observation (OTHER),50922675,Braftovi,Colon Adenocarcinoma; Microsatellite Stable Colon Carcinoma; Stage IIB Colon Cancer AJCC V8; Stage IIC Colon Cancer AJCC V8; Stage III Colon Cancer AJCC V8,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4583,NCT05725200,Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer,RECRUITING,PHASE2,Metastatic Colorectal Cancer,Alectinib (DRUG); Cetuximab (DRUG); Crizotinib (DRUG); Dasatinib (DRUG); Everolimus (DRUG); Encorafenib (DRUG); Gemcitabine (DRUG); Idelalisib (DRUG); Larotrectinib (DRUG); Methotrexate (DRUG); Palbociclib (DRUG); Panobinostat (DRUG); Pembrolizumab (DRUG); Petrozumab (DRUG); Trastuzumab (DRUG); Talazoparib (DRUG); Venetoclax (DRUG),50922675,Braftovi,Metastatic Colorectal Cancer,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4584,NCT02910700,"Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma,Binimetinib (DRUG); Dabrafenib (DRUG); Encorafenib (DRUG); Laboratory Biomarker Analysis (OTHER); Nivolumab (BIOLOGICAL); Pharmacological Study (OTHER); Trametinib (DRUG),50922675,Braftovi,Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma,CNS/Brain,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4585,NCT01436656,A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma,COMPLETED,PHASE1,Melanoma and Metastatic Colorectal Cancer,LGX818 (DRUG),50922675,Braftovi,Melanoma and Metastatic Colorectal Cancer,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4586,NCT02631447,Sequential Combo Immuno and Target Therapy (SECOMBIT) Study,COMPLETED,PHASE2,Metastatic Melanoma,LGX818 (DRUG); MEK162 (DRUG); Nivolumab (DRUG); Ipilimumab (DRUG),50922675,Braftovi,Metastatic Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4587,NCT03915951,An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Non-small Cell Lung Cancer,encorafenib (DRUG); binimetinib (DRUG),50922675,Braftovi,Non-small Cell Lung Cancer,Lung,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4588,NCT05039177,A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Colorectal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma,ERAS-007 (DRUG); Encorafenib (DRUG); Cetuximab (DRUG); Palbociclib (DRUG),50922675,Braftovi,Metastatic Colorectal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4589,NCT02109653,Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC,WITHDRAWN,PHASE2,Non-Small Cell Lung Cancer,LGX818 (DRUG),50922675,Braftovi,Advanced Non-Small Cell Lung Cancer,Lung,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4590,NCT05985954,Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy,RECRUITING,PHASE1,Metastatic Colorectal Cancer,Cetuximab (DRUG); Ulixertinib (DRUG); Encorafenib (DRUG),50922675,Braftovi,Metastatic Colorectal Cancer,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4591,NCT03803553,Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer,RECRUITING,PHASE3,Metastatic Colon Cancer; Stage III Colon Cancer,FOLFIRI Protocol (DRUG); ACTIVE SURVEILLANCE (OTHER); Nivolumab Protocol (DRUG); Encorafenib/Binimetinib/Cetuximab Protocol (DRUG); Trastuzumab + Pertuzumab (DRUG),50922675,Braftovi,Metastatic Colon Cancer; Stage III Colon Cancer,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4592,NCT01909453,Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma,COMPLETED,PHASE3,Melanoma,LGX818 (DRUG); MEK162 (DRUG); vemurafenib (DRUG),50922675,Braftovi,Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4593,NCT06207656,Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer,RECRUITING,PHASE2,Colorectal Cancer,EBC (DRUG),50922675,Braftovi,Colorectal Cancer,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4594,NCT06887088,Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases,NOT_YET_RECRUITING,PHASE2,Melanoma BRAF V600E/K Mutated; Melanoma and Brain Metastases,Encorafenib + Binimetinib (DRUG); cemiplimab+fianlimab (DRUG),50922675,Braftovi,Melanoma BRAF V600E/K Mutated; Melanoma and Brain Metastases,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4595,NCT05370807,A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma,UNKNOWN,PHASE2,Melanoma Stage III; Melanoma Stage IV,Regorafenib 40 MG Oral Tablet (DRUG); Triplet therapy (DRUG),50922675,Braftovi,Melanoma Stage III; Melanoma Stage IV,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4596,NCT02278133,Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations,COMPLETED,PHASE1,Metastatic Colorectal Cancer,WNT974 (DRUG); LGX818 (DRUG); Cetuximab (BIOLOGICAL),50922675,Braftovi,Metastatic Colorectal Cancer,Bowel,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4597,NCT05097378,Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma,UNKNOWN,PHASE2,Melanoma; Cancer,Encorafenib + Binimetinib (DRUG); Standard Adjuvant Treatment (DRUG),50922675,Braftovi,Melanoma; Cancer,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4598,NCT05026983,Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases,RECRUITING,PHASE2,Clinical Stage IV Cutaneous Melanoma AJCC V8; Metastatic Melanoma; Pathologic Stage IV Cutaneous Melanoma AJCC V8,Binimetinib (DRUG); Encorafenib (DRUG); Questionnaire Administration (OTHER),50922675,Braftovi,Clinical Stage IV Cutaneous Melanoma AJCC V8; Metastatic Melanoma; Pathologic Stage IV Cutaneous Melanoma AJCC V8,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4599,NCT04741997,Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma,RECRUITING,EARLY_PHASE1,Melanoma Stage III; Melanoma Stage IV; BRAF V600 Mutation,Encorafenib Pill (DRUG); Binimetinib Pill (DRUG); Nivolumab (DRUG),50922675,Braftovi,Melanoma Stage III; Melanoma Stage IV; BRAF V600 Mutation,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4600,NCT03235245,Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib,ACTIVE_NOT_RECRUITING,PHASE2,Unresectable Stage III Melanoma; Stage IV Melanoma,Nivolumab + Ipilimumab (DRUG); Encorafenib + Binimetinib (DRUG),50922675,Braftovi,Unresectable Stage III Melanoma; Stage IV Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4601,NCT04585815,Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study),TERMINATED,PHASE1,"Carcinoma, Non-Small-Cell Lung",Sasanlimab Prefilled syringe (DRUG); Encorafenib (DRUG); Binimetinib (DRUG); Sasanlimab (DRUG); Axitinib (DRUG); SEA-TGT (DRUG),50922675,Braftovi,"Carcinoma, Non-Small-Cell Lung",Lung,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4602,NCT02263898,Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations,WITHDRAWN,PHASE2,Recurrent Melanoma; Stage IV Melanoma,Raf kinase inhibitor LGX818 (DRUG); binimetinib (DRUG); laboratory biomarker analysis (OTHER),50922675,Braftovi,Recurrent Melanoma; Stage IV Melanoma,Skin,Encorafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for use in BRAF-mutant melanoma.,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1.09,584.0 +4603,NCT04550104,A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC,RECRUITING,PHASE1,Non Small Cell Lung Cancer,Radiotherapy (RADIATION); Olaparib Oral Tablet [Lynparza] (DRUG); AZD1390 (DRUG); Ceralasertib (DRUG); AZD5305 (DRUG); Durvalumab (DRUG),126689157,s8680,Non Small Cell Lung Cancer,Lung,AZD1390,ATM,inhibitor/antagonist,unclear,no,yes,"Investigational ATM kinase inhibitor in clinical trials, not approved for human use.",CC(C)N1C2=C(C=NC3=CC(=C(C=C32)C4=CN=C(C=C4)OCCCN5CCCCC5)F)N(C1=O)C,, +4604,NCT06894979,"Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma",NOT_YET_RECRUITING,PHASE1,Childhood Astrocytoma; Childhood Diffuse Intrinsic Pontine Glioma; Childhood Diffuse Midline Glioma; Childhood Glioblastoma; Childhood Malignant Glioma,ATM Kinase Inhibitor AZD1390 (DRUG); Biospecimen Collection (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Radiation Therapy (RADIATION); Survey Administration (OTHER),126689157,s8680,Childhood Astrocytoma; Childhood Diffuse Intrinsic Pontine Glioma; Childhood Diffuse Midline Glioma; Childhood Glioblastoma; Childhood Malignant Glioma,CNS/Brain,AZD1390,ATM,inhibitor/antagonist,unclear,no,yes,"Investigational ATM kinase inhibitor in clinical trials, not approved for human use.",CC(C)N1C2=C(C=NC3=CC(=C(C=C32)C4=CN=C(C=C4)OCCCN5CCCCC5)F)N(C1=O)C,, +4605,NCT03423628,A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer,RECRUITING,PHASE1,"Recurrent Glioblastoma Multiforme; Primary Glioblastoma Multiforme; Brain Neoplasms, Malignant; Leptomeningeal Disease (LMD)",Radiation Therapy (RADIATION); AZD1390 (DRUG),126689157,s8680,"Recurrent Glioblastoma Multiforme; Primary Glioblastoma Multiforme; Brain Neoplasms, Malignant; Leptomeningeal Disease (LMD)",CNS/Brain,AZD1390,ATM,inhibitor/antagonist,unclear,no,yes,"Investigational ATM kinase inhibitor in clinical trials, not approved for human use.",CC(C)N1C2=C(C=NC3=CC(=C(C=C32)C4=CN=C(C=C4)OCCCN5CCCCC5)F)N(C1=O)C,, +4606,NCT05182905,AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients,RECRUITING,EARLY_PHASE1,"Glioblastoma; Glioma; Glioblastoma Multiforme; Glioma, Malignant",AZD1390 (DRUG),126689157,s8680,"Glioblastoma; Glioma; Glioblastoma Multiforme; Glioma, Malignant",CNS/Brain,AZD1390,ATM,inhibitor/antagonist,unclear,no,yes,"Investigational ATM kinase inhibitor in clinical trials, not approved for human use.",CC(C)N1C2=C(C=NC3=CC(=C(C=C32)C4=CN=C(C=C4)OCCCN5CCCCC5)F)N(C1=O)C,, +4607,NCT02049957,Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Sapanisertib (DRUG); Fulvestrant (DRUG); Exemestane (DRUG),45375953,Sapanisertib,Breast Cancer,Breast,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4608,NCT02142803,TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,Adult Glioblastoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Solid Neoplasm; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7,Bevacizumab (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Sapanisertib (DRUG),45375953,Sapanisertib,Adult Glioblastoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Solid Neoplasm; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7,Ovary/Fallopian Tube,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4609,NCT02417701,Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer,COMPLETED,PHASE2,Recurrent Lung Squamous Cell Carcinoma; Stage IV Lung Squamous Cell Carcinoma AJCC v7,Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Sapanisertib (DRUG),45375953,Sapanisertib,Recurrent Lung Squamous Cell Carcinoma; Stage IV Lung Squamous Cell Carcinoma AJCC v7,Skin,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4610,NCT02575339,MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma,TERMINATED,PHASE1,Hepatocellular Carcinoma; Liver Cancer; HCC,MLN0128 (DRUG); MLN0128 (RP2D) (DRUG); Sorafenib (DRUG),45375953,Sapanisertib,Hepatocellular Carcinoma; Liver Cancer; HCC,Liver,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4611,NCT05022394,"Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study",WITHDRAWN,PHASE1,Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Nivolumab (BIOLOGICAL); Sapanisertib (DRUG),45375953,Sapanisertib,Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4612,NCT06811116,"Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin",NOT_YET_RECRUITING,PHASE1,Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8,Biospecimen Collection (PROCEDURE); Cabozantinib S-malate (DRUG); Imaging Procedure (PROCEDURE); Sapanisertib (DRUG),45375953,Sapanisertib,Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8,Liver,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4613,NCT05275673,A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer,TERMINATED,PHASE2,Non-Small Cell Lung Cancer; Squamous Non-small-cell Lung Cancer; Squamous Non-Small Cell Neoplasm of Lung; NFE2L2 Gene Mutation,sapanisertib (DRUG),45375953,Sapanisertib,Non-Small Cell Lung Cancer; Squamous Non-small-cell Lung Cancer; Squamous Non-Small Cell Neoplasm of Lung; NFE2L2 Gene Mutation,Lung,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4614,NCT02725268,"A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer",COMPLETED,PHASE2,Endometrial Neoplasms,Paclitaxel (DRUG); Sapanisertib (DRUG); MLN1117 (DRUG),45375953,Sapanisertib,Endometrial Neoplasms,Uterus,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4615,NCT03047213,Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations,ACTIVE_NOT_RECRUITING,PHASE2,Locally Advanced Bladder Urothelial Carcinoma; Metastatic Transitional Cell Carcinoma; Metastatic Urothelial Carcinoma; Recurrent Bladder Carcinoma; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7; Stage IV Bladder Urothelial Carcinoma AJCC v7,Sapanisertib (DRUG),45375953,Sapanisertib,Locally Advanced Bladder Urothelial Carcinoma; Metastatic Transitional Cell Carcinoma; Metastatic Urothelial Carcinoma; Recurrent Bladder Carcinoma; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7; Stage IV Bladder Urothelial Carcinoma AJCC v7,Bladder/Urinary Tract,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4616,NCT04479306,Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Recurrent Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Alisertib (DRUG); Osimertinib (DRUG); Sapanisertib (DRUG),45375953,Sapanisertib,Recurrent Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4617,NCT02756364,Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy,COMPLETED,PHASE2,Breast Neoplasms,Fulvestrant (DRUG); Sapanisertib (DRUG),45375953,Sapanisertib,Breast Neoplasms,Breast,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4618,NCT04267913,"Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)",WITHDRAWN,PHASE2,Lung Squamous Cell Carcinoma; Recurrent Lung Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Dexamethasone (DRUG); Docetaxel (DRUG); Ramucirumab (BIOLOGICAL); Sapanisertib (DRUG),45375953,Sapanisertib,Lung Squamous Cell Carcinoma; Recurrent Lung Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4619,NCT06463028,Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With Diet in Patients With Advanced/Recurrent Endometrial Cancer,RECRUITING,PHASE2,Endometrial Cancer,Sapanisertib (DRUG); Serabelisib (DRUG); Paclitaxel (DRUG),45375953,Sapanisertib,Endometrial Cancer,Uterus,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4620,NCT04250545,Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Leptomeningeal Neoplasm; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Sapanisertib (DRUG); Telaglenastat Hydrochloride (DRUG),45375953,Sapanisertib,Leptomeningeal Neoplasm; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4621,NCT02133183,Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma,TERMINATED,PHASE1,Glioblastoma; Gliosarcoma,Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Sapanisertib (DRUG); Therapeutic Conventional Surgery (PROCEDURE),45375953,Sapanisertib,Glioblastoma,CNS/Brain,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4622,NCT02724020,MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma,COMPLETED,PHASE2,Clear-cell Metastatic Renal Cell Carcinoma,Everolimus (DRUG); MLN0128 (DRUG); MLN1117 (DRUG),45375953,Sapanisertib,Clear-cell Metastatic Renal Cell Carcinoma,Kidney,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4623,NCT02619669,Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer,WITHDRAWN,PHASE1,Breast Cancer,TAK-228 (DRUG); Letrozole (DRUG),45375953,Sapanisertib,Breast Cancer,Breast,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4624,NCT02988986,"TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer",COMPLETED,PHASE2,Estrogen Receptor Positive Breast Cancer,TAK-228 (DRUG); Tamoxifen (DRUG),45375953,Sapanisertib,ER-Positive HER2-Negative Breast Cancer,Breast,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4625,NCT03648489,"Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)",COMPLETED,PHASE2,Ovarian Cancer; Ovarian Neoplasms; Ovarian Carcinosarcoma; Ovarian Serous Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Fallopian Tube Cancer; Fallopian Tube Neoplasms; Primary Peritoneal Carcinoma; Primary Peritoneal Serous Adenocarcinoma,Paclitaxel (DRUG); TAK228 (DRUG),45375953,Sapanisertib,Ovarian Cancer; Ovarian Neoplasms; Ovarian Carcinosarcoma; Ovarian Serous Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Fallopian Tube Cancer; Fallopian Tube Neoplasms; Primary Peritoneal Carcinoma; Primary Peritoneal Serous Adenocarcinoma,Ovary/Fallopian Tube,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4626,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,COMPLETED,PHASE1,Metastatic Breast Cancer; Solid Tumors,Alisertib (DRUG); MLN0128 (DRUG),45375953,Sapanisertib,Metastatic Breast Cancer; Solid Tumors,Breast,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4627,NCT03193853,TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer,COMPLETED,PHASE2,Triple Negative Breast Cancer,Tak-228 & Tak-117 (DRUG); Cisplatin & Nab Paclitaxel (DRUG),45375953,Sapanisertib,Triple Negative Breast Cancer,Breast,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4628,NCT03097328,Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma,COMPLETED,PHASE2,Renal Cell Carcinoma,TAK-228 (DRUG),45375953,Sapanisertib,Renal Cell Carcinoma,Kidney,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4629,NCT03745911,Paclitaxel and TAK-228 in Urothelial Carcinoma,UNKNOWN,PHASE2,Metastatic Urothelial Cancer,Paclitaxel and TAK-228 (COMBINATION_PRODUCT),45375953,Sapanisertib,Metastatic Urothelial Cancer,Bladder/Urinary Tract,Sapanisertib,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,"Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.",CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,1.0,93.0 +4630,NCT00163319,Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101),COMPLETED,PHASE3,Asthma,Ciclesonide (DRUG),11950170,ICQ,Asthma,Lung,Belumosudil,"ROCK2, ROCK1",inhibitor/antagonist,unclear,yes,yes,Approved for chronic graft-versus-host disease in the US.,CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5,1.56,2846.0 +4631,NCT02169323,Step-down of Inhaled Corticosteroids (ICS) in Non-eosinophilic Asthmatics,COMPLETED,PHASE4,Asthma,Step-down (OTHER),11950170,ICQ,Asthma,Lung,Belumosudil,"ROCK2, ROCK1",inhibitor/antagonist,unclear,yes,yes,Approved for chronic graft-versus-host disease in the US.,CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5,1.56,2846.0 +4632,NCT06796855,Comparing Treatments for Refractory Overactive Bladder: Bladder Denervation Vs Botulinum Toxin Injections,COMPLETED,PHASE4,Overactive Bladder Syndrome; Refractory Overactive Bladder,Selective Bladder Denervation via Radiofrequency Ablation (DEVICE); Intravesical Onabotulinum Toxin A Injection (DRUG),11950170,ICQ,Overactive Bladder Syndrome; Refractory Overactive Bladder,Bladder/Urinary Tract,Belumosudil,"ROCK2, ROCK1",inhibitor/antagonist,unclear,yes,yes,Approved for chronic graft-versus-host disease in the US.,CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5,1.56,2846.0 +4633,NCT04610359,Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis,UNKNOWN,PHASE1,Interstitial Cystitis; Stem Cell Transplant; Mesenchymal Stem Cell,MR-MC-01 (DRUG),11950170,ICQ,Interstitial Cystitis; Stem Cell Transplant; Mesenchymal Stem Cell,Bladder/Urinary Tract,Belumosudil,"ROCK2, ROCK1",inhibitor/antagonist,unclear,yes,yes,Approved for chronic graft-versus-host disease in the US.,CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5,1.56,2846.0 +4634,NCT00235053,Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID,COMPLETED,PHASE4,"Asthma; Candidiasis, Oral; Voice Disorders",fluticasone/salmeterol DISKUS 250/50 (DRUG),11950170,ICQ,"Asthma; Candidiasis, Oral; Voice Disorders",Lung,Belumosudil,"ROCK2, ROCK1",inhibitor/antagonist,unclear,yes,yes,Approved for chronic graft-versus-host disease in the US.,CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5,1.56,2846.0 +4635,NCT02106195,A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris,COMPLETED,PHASE2,Psoriasis Vulgaris,Belumosudil (DRUG),11950170,ICQ,Psoriasis Vulgaris,Skin,Belumosudil,"ROCK2, ROCK1",inhibitor/antagonist,unclear,yes,yes,Approved for chronic graft-versus-host disease in the US.,CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5,1.56,2846.0 +4636,NCT02317627,"Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy",COMPLETED,PHASE2,Psoriasis Vulgaris,KD025 (DRUG),11950170,ICQ,Psoriasis Vulgaris,Skin,Belumosudil,"ROCK2, ROCK1",inhibitor/antagonist,unclear,yes,yes,Approved for chronic graft-versus-host disease in the US.,CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5,1.56,2846.0 +4637,NCT02688647,"A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis",COMPLETED,PHASE2,Idiopathic Pulmonary Fibrosis,Belumosudil (DRUG); BSC (OTHER),11950170,ICQ,Idiopathic Pulmonary Fibrosis,Lung,Belumosudil,"ROCK2, ROCK1",inhibitor/antagonist,unclear,yes,yes,Approved for chronic graft-versus-host disease in the US.,CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5,1.56,2846.0 +4638,NCT02106195,A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris,COMPLETED,PHASE2,Psoriasis Vulgaris,Belumosudil (DRUG),146681181,Rezurock,Psoriasis Vulgaris,Skin,Belumosudil (mesylate),"ROCK2, ROCK1",inhibitor/antagonist,unclear,yes,yes,Approved for chronic graft-versus-host disease.,CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5.CS(=O)(=O)O,1.02,2785.0 +4639,NCT02852967,"A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis",COMPLETED,PHASE2,Chronic Plaque Psoriasis,Belumosudil (DRUG); Placebo (DRUG),146681181,Rezurock,Chronic Plaque Psoriasis,Skin,Belumosudil (mesylate),"ROCK2, ROCK1",inhibitor/antagonist,unclear,yes,yes,Approved for chronic graft-versus-host disease.,CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5.CS(=O)(=O)O,1.02,2785.0 +4640,NCT06082037,A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction,RECRUITING,PHASE3,Lung Transplant Rejection,Belumosudil (DRUG); Azithromycin (DRUG); Placebo (DRUG),146681181,Rezurock,Lung Transplant Rejection,Lung,Belumosudil (mesylate),"ROCK2, ROCK1",inhibitor/antagonist,unclear,yes,yes,Approved for chronic graft-versus-host disease.,CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5.CS(=O)(=O)O,1.02,2785.0 +4641,NCT05922761,BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP),RECRUITING,PHASE2,Bronchiolitis Obliterans Syndrome; Bronchiolitis Obliterans; Lung Diseases; Chronic Graft Versus Host Disease,Belumosudil (DRUG); Fluticasone (DRUG); Azithromycin (DRUG); Prednisone (DRUG); Montelukast (DRUG),146681181,Rezurock,Bronchiolitis Obliterans Syndrome; Bronchiolitis Obliterans; Lung Diseases; Chronic Graft Versus Host Disease,Lung,Belumosudil (mesylate),"ROCK2, ROCK1",inhibitor/antagonist,unclear,yes,yes,Approved for chronic graft-versus-host disease.,CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5.CS(=O)(=O)O,1.02,2785.0 +4642,NCT05564416,"Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial",WITHDRAWN,PHASE2,Bladder Carcinoma; Bladder Urothelial Carcinoma; Muscle Invasive Bladder Carcinoma; Renal Pelvis and Ureter Urothelial Carcinoma; Stage II Bladder Cancer AJCC v8; Stage III Bladder Cancer AJCC v8; Stage IVA Bladder Cancer AJCC v8; Urothelial Carcinoma,Atezolizumab (BIOLOGICAL); Biospecimen Collection (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Cystoscopy (PROCEDURE); Erdafitinib (DRUG); Magnetic Resonance Imaging (PROCEDURE),67462786,Balversa,Bladder Carcinoma; Bladder Urothelial Carcinoma; Muscle Invasive Bladder Carcinoma; Renal Pelvis and Ureter Urothelial Carcinoma; Stage II Bladder Cancer AJCC v8; Stage III Bladder Cancer AJCC v8; Stage IVA Bladder Cancer AJCC v8; Urothelial Carcinoma,Bladder/Urinary Tract,Erdafitinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for bladder cancer treatment.,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,1.33,268.0 +4643,NCT03210714,"Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)",ACTIVE_NOT_RECRUITING,PHASE2,Advanced Malignant Solid Neoplasm; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Childhood Osteosarcoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Glioma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Primary Central Nervous System Neoplasm; Recurrent Rhabdoid Tumor; Refractory Childhood Malignant Germ Cell Tumor; Refractory Childhood Osteosarcoma; Refractory Childhood Rhabdomyosarcoma; Refractory Childhood Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdoid Tumor; Wilms Tumor,Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration and Biopsy (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Erdafitinib (DRUG); Laboratory Biomarker Analysis (OTHER); Magnetic Resonance Imaging (PROCEDURE); Pharmacological Study (OTHER); Positron Emission Tomography (PROCEDURE); Radionuclide Imaging (PROCEDURE); X-Ray Imaging (PROCEDURE),67462786,Balversa,Advanced Malignant Solid Neoplasm; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Childhood Osteosarcoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Glioma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Primary Central Nervous System Neoplasm; Recurrent Rhabdoid Tumor; Refractory Childhood Malignant Germ Cell Tumor; Refractory Childhood Osteosarcoma; Refractory Childhood Rhabdomyosarcoma; Refractory Childhood Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdoid Tumor; Wilms Tumor,CNS/Brain,Erdafitinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for bladder cancer treatment.,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,1.33,268.0 +4644,NCT05859334,Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment,RECRUITING,PHASE2,Recurrent Glioma; Recurrent WHO Grade 2 Glioma; Recurrent WHO Grade 3 Glioma; Recurrent WHO Grade 4 Glioma,Biospecimen Collection (PROCEDURE); Erdafitinib (DRUG); Magnetic Resonance Imaging (PROCEDURE); Optical Coherence Tomography (PROCEDURE),67462786,Balversa,Recurrent Glioma; Recurrent WHO Grade 2 Glioma; Recurrent WHO Grade 3 Glioma; Recurrent WHO Grade 4 Glioma,CNS/Brain,Erdafitinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for bladder cancer treatment.,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,1.33,268.0 +4645,NCT04963153,Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy,RECRUITING,PHASE1,Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis Urothelial Carcinoma; Locally Advanced Ureter Urothelial Carcinoma; Locally Advanced Urethral Urothelial Carcinoma; Locally Advanced Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma; Metastatic Urethral Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Recurrent Bladder Urothelial Carcinoma; Recurrent Renal Pelvis Urothelial Carcinoma; Recurrent Ureter Urothelial Carcinoma; Recurrent Urethral Urothelial Carcinoma; Recurrent Urothelial Carcinoma; Stage IIIB Bladder Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Renal Pelvis Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Enfortumab Vedotin (DRUG); Erdafitinib (DRUG); Multigated Acquisition Scan (PROCEDURE),67462786,Balversa,Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis Urothelial Carcinoma; Locally Advanced Ureter Urothelial Carcinoma; Locally Advanced Urethral Urothelial Carcinoma; Locally Advanced Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma; Metastatic Urethral Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Recurrent Bladder Urothelial Carcinoma; Recurrent Renal Pelvis Urothelial Carcinoma; Recurrent Ureter Urothelial Carcinoma; Recurrent Urethral Urothelial Carcinoma; Recurrent Urothelial Carcinoma; Stage IIIB Bladder Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Renal Pelvis Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8,Bladder/Urinary Tract,Erdafitinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for bladder cancer treatment.,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,1.33,268.0 +4646,NCT06319820,A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer,RECRUITING,PHASE3,Non-Muscle Invasive Bladder Cancer,TAR-210 (COMBINATION_PRODUCT); Gemcitabine (DRUG); MMC (DRUG),67462786,Balversa,Non-Muscle Invasive Bladder Cancer,Bladder/Urinary Tract,Erdafitinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for bladder cancer treatment.,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,1.33,268.0 +4647,NCT06511648,Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations,RECRUITING,PHASE2,Muscle-invasive Bladder Cancer,Erdafitinib monotherapy (DRUG); Cetrelimab and Erdafitinib combination (DRUG),67462786,Balversa,Muscle-invasive Bladder Cancer,Bladder/Urinary Tract,Erdafitinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for bladder cancer treatment.,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,1.33,268.0 +4648,NCT03587363,A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib,TERMINATED,PHASE1,Hepatic Impairment,Erdafitinib (DRUG),67462786,Balversa,Hepatic Impairment,Liver,Erdafitinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for bladder cancer treatment.,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,1.33,268.0 +4649,NCT03238196,"Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer",COMPLETED,PHASE1,Metastatic Breast Cancer,Erdafitinib (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG),67462786,Balversa,Metastatic Breast Cancer,Breast,Erdafitinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for bladder cancer treatment.,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,1.33,268.0 +4650,NCT03390504,A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations,ACTIVE_NOT_RECRUITING,PHASE3,Urothelial Cancer,Erdafitinib (DRUG); Vinflunine (DRUG); Docetaxel (DRUG); Pembrolizumab (DRUG); Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA) (DEVICE),67462786,Balversa,Urothelial Cancer,Bladder/Urinary Tract,Erdafitinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for bladder cancer treatment.,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,1.33,268.0 +4651,NCT05316155,Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer,RECRUITING,PHASE1,"Urinary Bladder Neoplasms; Receptors, Fibroblast Growth Factor",Erdafitinib Intravesical Delivery System (DRUG),67462786,Balversa,"Urinary Bladder Neoplasms; Receptors, Fibroblast Growth Factor",Bladder/Urinary Tract,Erdafitinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for bladder cancer treatment.,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,1.33,268.0 +4652,NCT06204614,Drug Screening Using IMD in Bladder Cancer,NOT_YET_RECRUITING,EARLY_PHASE1,Muscle Invasive Bladder Urothelial Carcinoma,Implantable Micro-Device (DEVICE); Methotrexate (DRUG); Carboplatin (DRUG); Avelumab (DRUG); Paclitaxel (DRUG); Vinblastine (DRUG); Gemcitabine/Cisplatin I (DRUG); Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab (DRUG); Gemcitabine/Cisplatin II (DRUG); Cisplatin (DRUG); Nivolumab (DRUG); Pembrolizumab (DRUG); Gemcitabine/Carboplatin (DRUG); Methotrexate/Vinblastine/Doxorubicin/Cisplatin (DRUG); Gemcitabine/Cisplatin/Nivolumab (DRUG); Erdafitinib (DRUG); Paclitaxel/Docetaxel/Ifosfamide (DRUG); Gemcitabine (DRUG); Gemcitabine/Carboplatin/Nivolumab (DRUG); Enfortumab (DRUG); Sacituzumab (DRUG),67462786,Balversa,Muscle Invasive Bladder Urothelial Carcinoma,Bladder/Urinary Tract,Erdafitinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for bladder cancer treatment.,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,1.33,268.0 +4653,NCT03827850,FGFR Inhibitor in FGFR Dysregulated Cancer,TERMINATED,PHASE2,Lung Cancer; NSCLC; Pulmonary Neoplasm; Squamous Cell Lung Cancer; NSCLC Stage IV,ERDAFITINIB (DRUG),67462786,Balversa,Lung Cancer; NSCLC; Pulmonary Neoplasm; Squamous Cell Lung Cancer; NSCLC Stage IV,Lung,Erdafitinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for bladder cancer treatment.,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,1.33,268.0 +4654,NCT03473743,A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Urothelial Carcinoma,Erdafitinib (DRUG); Cetrelimab (DRUG); Cisplatin (DRUG); Carboplatin (DRUG),67462786,Balversa,Urothelial Carcinoma,Bladder/Urinary Tract,Erdafitinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for bladder cancer treatment.,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,1.33,268.0 +4655,NCT04172675,A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC),COMPLETED,PHASE2,Urinary Bladder Neoplasms,Erdafitinib (DRUG); Investigator Choice (Gemcitabine) (DRUG); Investigator Choice (Mitomycin C) (DRUG),67462786,Balversa,Urinary Bladder Neoplasms,Bladder/Urinary Tract,Erdafitinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for bladder cancer treatment.,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,1.33,268.0 +4656,NCT02421185,"Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma",COMPLETED,PHASE1,"Carcinoma, Hepatocellular",JNJ-42756493 (erdafitinib) (DRUG),67462786,Balversa,"Carcinoma, Hepatocellular",Liver,Erdafitinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for bladder cancer treatment.,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,1.33,268.0 +4657,NCT05567185,A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer,ACTIVE_NOT_RECRUITING,PHASE1,"Urinary Bladder Neoplasms; Receptors, Fibroblast Growth Factor",Erdafitinib Intravesical Delivery System (DRUG),67462786,Balversa,"Urinary Bladder Neoplasms; Receptors, Fibroblast Growth Factor",Bladder/Urinary Tract,Erdafitinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for bladder cancer treatment.,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,1.33,268.0 +4658,NCT04917809,A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Bladder Cancer; Recurrent Bladder Cancer; FGFR3 Gene Mutation,Erdafitinib (DRUG),67462786,Balversa,Bladder Cancer; Recurrent Bladder Cancer; FGFR3 Gene Mutation,Bladder/Urinary Tract,Erdafitinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for bladder cancer treatment.,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,1.33,268.0 +4659,NCT02365597,An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Urothelial Cancer,Erdafitinib (DRUG); Midazolam (DRUG); Metformin (DRUG),67462786,Balversa,Urothelial Cancer,Bladder/Urinary Tract,Erdafitinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for bladder cancer treatment.,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,1.33,268.0 +4660,NCT03244774,Phase I Study of the Combination of Apatinib and POF,UNKNOWN,PHASE1,Gastric Adenocarcinoma,Apatinib (DRUG); POF (DRUG),3339,FNF,Gastric Adenocarcinoma,Esophagus/Stomach,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4661,NCT02823366,Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid,UNKNOWN,PHASE3,Primary Biliary Cirrhosis,Fenofibrate (DRUG); UDCA (DRUG),3339,FNF,Primary Biliary Cirrhosis,Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4662,NCT03869931,Effects of Fenofibrate Therapy in Diabetic Nephropathy,UNKNOWN,PHASE3,Diabetes Mellitus; Diabetic Nephropathies,Fenofibrate (DRUG),3339,FNF,Diabetes Mellitus; Diabetic Nephropathies,Kidney,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4663,NCT05537948,Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients,ACTIVE_NOT_RECRUITING,PHASE4,Dyslipidemias; Hyperlipidemias; Liver Transplant Disorder; Immunosuppression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Statins,Pitavastatin (DRUG); PCSK9 inhibitor (DRUG),3339,FNF,Dyslipidemias; Hyperlipidemias; Liver Transplant Disorder; Immunosuppression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Statins,Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4664,NCT01356290,"Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma and ATRT",RECRUITING,PHASE2,Medulloblastoma Recurrent; Ependymoma Recurrent; ATRT Recurrent,Bevacizumab (DRUG); Thalidomide (DRUG); Celecoxib (DRUG); Fenofibric acid (DRUG); Etoposide (DRUG); Cyclophosphamide (DRUG); Etoposide phosphate (DRUG); Cytarabine (DRUG),3339,FNF,Recurrent CNS Tumors,CNS/Brain,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4665,NCT06155331,Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients,RECRUITING,PHASE4,Breast Cancer Stage 2 and 3,Fenofibrate (DRUG); Placebo (OTHER); Doxorubicin (DRUG); Cyclophosphamide (DRUG),3339,FNF,Breast Cancer Stage 2 and 3,Breast,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4666,NCT02354976,A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.,COMPLETED,PHASE2,Non-alcoholic Fatty Liver Disease (NAFLD; Hypertriglyceridemia,Placebo (DRUG); Omega-3 carboxylic acid (DRUG); Fenofibrate 200mg (DRUG); Placebo (DRUG),3339,FNF,Non-alcoholic Fatty Liver Disease (NAFLD; Hypertriglyceridemia,Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4667,NCT03788226,A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer,UNKNOWN,PHASE3,Gastric Cancer Stage III,POF (DRUG); CAPOX/SOX/FOLFOX (DRUG),3339,FNF,Gastric Cancer Stage III,Esophagus/Stomach,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4668,NCT06796660,Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients,NOT_YET_RECRUITING,EARLY_PHASE1,"Renal Insufficiency, Chronic",Nephropathy Formula No. 1 (DRUG); integrated basic treatment for chronic kidney disease (DRUG),3339,FNF,Chronic Renal Insufficiency,Kidney,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4669,NCT01141296,Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis,WITHDRAWN,PHASE2,Primary Biliary Cirrhosis,fenofibrate (DRUG); placebo (DRUG),3339,FNF,Primary Biliary Cirrhosis,Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4670,NCT06623539,Efficacy and Safety of Pemafibrate for Nonalcoholic Fatty Liver Disease,ACTIVE_NOT_RECRUITING,PHASE2,Non Alcoholic Fatty Liver Disease,Pemafibrate high dose (DRUG); Pemafibrate low dose (DRUG); Fenofibrate (DRUG),3339,FNF,Non Alcoholic Fatty Liver Disease,Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4671,NCT06365424,Fenofibrate in Patients with Primary Biliary Cholangitis (PBC),RECRUITING,PHASE2,Primary Biliary Cholangitis,Fenofibrate (DRUG); UDCA (DRUG),3339,FNF,Primary Biliary Cholangitis,Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4672,NCT05751967,Fenofibrate Combined with Ursodeoxycholic Acid in Subjects with Primary Biliary Cholangitis,RECRUITING,PHASE3,Primary Biliary Cholangitis,Placebo Combined With Ursodeoxycholic Acid (DRUG); Fenofibrate Combined With Ursodeoxycholic Acid (DRUG),3339,FNF,Primary Biliary Cholangitis,Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4673,NCT03222089,Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC,WITHDRAWN,PHASE2,Metastatic Colorectal Cancer,Irinotecan (DRUG); Oxaliplatin (DRUG); Levoleucovorin (DRUG); 5-FU (DRUG); GM-CSF (DRUG); IL-2 (DRUG),3339,FNF,Metastatic Colorectal Cancer,Bowel,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4674,NCT05753267,Fenofibrate in Ulcerative Colitis,RECRUITING,PHASE2,Inflammatory Bowel Diseases,Mesalamine (DRUG); Fenofibrate 160mg (DRUG),3339,FNF,Inflammatory Bowel Diseases,Bowel,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4675,NCT05514119,A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation,COMPLETED,PHASE2,Liver Transplant,Fenofibrate (DRUG),3339,FNF,Liver Transplant,Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4676,NCT00842712,Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Cilengitide (DRUG); Cilengitide (DRUG); Cetuximab (DRUG); Cisplatin (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG); Vinorelbine (DRUG); Cilengitide (DRUG); Cilengitide (DRUG); Cetuximab (DRUG); Chemotherapy (DRUG),3339,FNF,"Carcinoma, Non-Small-Cell Lung",Lung,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4677,NCT06591455,A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis,ENROLLING_BY_INVITATION,EARLY_PHASE1,Primary Biliary Cholangitis (PBC),Fenofibrate (DRUG); UDCA (Ursodeoxycholic acid) (DRUG),3339,FNF,Primary Biliary Cholangitis (PBC),Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4678,NCT01142323,Pilot Study of Fenofibrate for PSC,TERMINATED,PHASE1,Primary Sclerosing Cholangitis,fenofibrate (DRUG),3339,FNF,Primary Sclerosing Cholangitis,Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4679,NCT03515213,Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease,COMPLETED,PHASE2,Huntington Disease,Fenofibrate (DRUG); Placebo (DRUG),3339,FNF,Huntington Disease,CNS/Brain,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4680,NCT00575042,Use of Fenofibrate for Primary Biliary Cirrhosis,COMPLETED,PHASE2,Primary Biliary Cirrhosis,Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) (DRUG),3339,FNF,Primary Biliary Cirrhosis,Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4681,NCT06174402,Fenofibrate in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis,RECRUITING,PHASE2,Primary Biliary Cholangitis,Fenofibrate (DRUG); Placebo (DRUG); UDCA (DRUG),3339,FNF,Primary Biliary Cholangitis,Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4682,NCT02781584,"Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)",COMPLETED,PHASE2,Nonalcoholic Steatohepatitis (NASH); Nonalcoholic Fatty Liver Disease (NAFLD),SEL (DRUG); FIR (DRUG); CILO (DRUG); FENO (DRUG); VAS (DRUG),3339,FNF,Nonalcoholic Steatohepatitis (NASH); Nonalcoholic Fatty Liver Disease (NAFLD),Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4683,NCT04929379,A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes,ACTIVE_NOT_RECRUITING,PHASE2,Diabetic Nephropathies,Fenofibrate (DRUG); Placebo (OTHER),3339,FNF,Diabetic Nephropathies,Kidney,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4684,NCT02891408,Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function,COMPLETED,PHASE1,Nonalcoholic Steatohepatitis (NASH),Firsocostat (DRUG); Fenofibrate (DRUG),3339,FNF,Nonalcoholic Steatohepatitis (NASH),Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4685,NCT06755541,Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study,RECRUITING,PHASE3,Primary Biliary Cholangitis (PBC),Fenofibrate in Combination With Ursodeoxycholic Acid (DRUG),3339,FNF,Primary Biliary Cholangitis (PBC),Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4686,NCT03708536,Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma,WITHDRAWN,PHASE3,Colorectal Adenocarcinoma,S-1 (DRUG); Bevacizumab (DRUG); Capecitabine (DRUG),3339,FNF,Colorectal Adenocarcinoma,Bowel,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4687,NCT00357500,"Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer",COMPLETED,PHASE2,"Central Nervous System Tumor, Pediatric; Leukemia; Lymphoma; Neuroblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific",celecoxib (DRUG); cyclophosphamide (DRUG); etoposide (DRUG); fenofibrate (DRUG); thalidomide (DRUG),3339,FNF,"Central Nervous System Tumor, Pediatric; Leukemia; Lymphoma; Neuroblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific",CNS/Brain,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4688,NCT06191133,Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma,RECRUITING,PHASE1,Cervical Intraepithelial Neoplasia; Invasive Cervical Cancer,Fenofibrate (DRUG); Cervical Conization (PROCEDURE); Hysterectomy (PROCEDURE); Chemoradiation (RADIATION),3339,FNF,Cervical Intraepithelial Neoplasia; Invasive Cervical Cancer,Cervix,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4689,NCT06905054,Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation,RECRUITING,PHASE2,"Primary Sclerosing Cholangitis; Liver Transplant, Complications; PSC; Biliary Strictures",Fenofibrate (drug) (DRUG); Blood draw for the laboratory assessment (DIAGNOSTIC_TEST); MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA) (DIAGNOSTIC_TEST),3339,FNF,"Primary Sclerosing Cholangitis; Liver Transplant, Complications; PSC; Biliary Strictures",Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4690,NCT06755151,Fenofibrate in Primary Biliary Cholangitis: a Real World Study,RECRUITING,PHASE3,Primary Biliary Cholangitis (PBC),Fenofibrate (DRUG),3339,FNF,Primary Biliary Cholangitis (PBC),Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4691,NCT02823353,Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis,COMPLETED,PHASE3,Primary Biliary Cirrhosis,Fenofibrate (DRUG); UDCA (DRUG),3339,FNF,Primary Biliary Cirrhosis,Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4692,NCT01320345,The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.,RECRUITING,PHASE3,Type 1 Diabetes Mellitus; Diabetic Retinopathy; Diabetic Nephropathies,Fenofibrate (DRUG); Inert lactose placebo (DRUG),3339,FNF,Type 1 Diabetes Mellitus; Diabetic Retinopathy; Diabetic Nephropathies,Kidney,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4693,NCT05749822,Fenofibrate for Compensated Cirrhosis Patients with Primary Biliary Cholangitis,RECRUITING,PHASE2,Primary Biliary Cholangitis,Fenofibrate 200mg (DRUG); Placebo (DRUG); UDCA (DRUG),3339,FNF,Primary Biliary Cholangitis,Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4694,NCT02965911,Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA,WITHDRAWN,PHASE1,Primary Biliary Cirrhosis,Fenofibrate (DRUG); UDCA (DRUG),3339,FNF,Primary Biliary Cirrhosis,Liver,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4695,NCT05781698,Repurposing Fenofibrate in Modulating mTOR/NLRP3 Inflammasome in Patients With Ulcerative Colitis,COMPLETED,PHASE2,Inflammatory Bowel Diseases,Mesalamine (DRUG); Fenofibrate (DRUG),3339,FNF,Inflammatory Bowel Diseases,Bowel,Fenofibrate,"CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP3A4, PPARA",unclear,unclear,yes,yes,Fenofibrate is approved for human use in treating hypercholesterolemia.,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,1.28,196.0 +4696,NCT02972034,Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013),TERMINATED,PHASE1,Neoplasms; Colorectal Cancer,MK-8353 (DRUG); Pembrolizumab (BIOLOGICAL),58282870,s8701,Neoplasms; Colorectal Cancer,Bowel,MK-8353,"MAPK3, MAPK1",inhibitor/antagonist,Other MAPK inhibitor,no,yes,Investigated for cancer treatment in clinical trials.,CC(C)OC1=NC=C(C=C1)C2=NNC3=C2C=C(C=C3)NC(=O)C4(CCN(C4)CC(=O)N5CCC(=CC5)C6=CC=C(C=C6)C7=NN(C=N7)C)SC,, +4697,NCT04186273,Clinical Safety and Scar Prevention Study of a Topical Antifibrotic Compound FS2.,UNKNOWN,PHASE2,Scar; Cicatrix; Hypertrophic Scar; Skin Graft Scar; Skin Graft Complications; Donor Site Complication; Keloid,Fibrosis-Inhibiting-Compound-FS2 (DRUG); Vehicle moisture balancing base (OTHER),11626560,VGH,Scar; Cicatrix; Hypertrophic Scar; Skin Graft Scar; Skin Graft Complications; Donor Site Complication; Keloid,Skin,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4698,NCT02704403,Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH),TERMINATED,PHASE3,Nonalcoholic Steatohepatitis (NASH) With Fibrosis,Elafibranor (DRUG); Placebo (DRUG),11626560,VGH,Nonalcoholic Steatohepatitis (NASH) With Fibrosis,Liver,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4699,NCT04249869,The Efficacy of Traditional Chinese Herbal Medicine for Alzheimer's Disease,UNKNOWN,PHASE1,Alzheimer Disease,VGH-AD1 (DRUG),11626560,VGH,Alzheimer Disease,CNS/Brain,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4700,NCT05651282,Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer,RECRUITING,PHASE4,Endometrium Cancer,Provera (DRUG),11626560,VGH,Endometrium Cancer,Uterus,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4701,NCT00990860,Study in Asia of the Combination of TACE With Sorafenib in HCC Patients,UNKNOWN,PHASE2,Hepatocellular Carcinoma,doxorubicin (DRUG); TACE (Transcatheter arterial chemoembolization) (PROCEDURE),11626560,VGH,Hepatocellular Carcinoma,Liver,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4702,NCT00359424,Interventional Management of Stroke (IMS) III Trial,TERMINATED,PHASE3,Stroke,IV rt-PA alone (DRUG); endovascular therapy (OTHER),11626560,VGH,Stroke,CNS/Brain,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4703,NCT04411472,(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI,TERMINATED,PHASE3,Acute Kidney Injury Due to Sepsis,Recombinant human alkaline phosphatase (BIOLOGICAL); Placebo (OTHER),11626560,VGH,Acute Kidney Injury Due to Sepsis,Kidney,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4704,NCT00152984,Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma,COMPLETED,PHASE4,"Pulmonary Disease, Chronic Obstructive; Asthma",Tiotropium inhalation capsules (DRUG); Placebo inhalation capsules (DRUG),11626560,VGH,"Pulmonary Disease, Chronic Obstructive; Asthma",Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4705,NCT00154635,Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease,UNKNOWN,PHASE2,"Dementia, Alzheimer Type",DCB-AD1 (DRUG),11626560,VGH,Alzheimer's Disease,CNS/Brain,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4706,NCT02669342,Sharklet Catheter Study,UNKNOWN,PHASE1,Urinary Catheter; Urinary Tract Infections,Radiance™ Clear Sharklet® Silicone Foley Catheter (DEVICE); Silicone Foley Catheter (DEVICE),11626560,VGH,Urinary Catheter; Urinary Tract Infections,Bladder/Urinary Tract,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4707,NCT02099656,A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma,COMPLETED,PHASE2,Asthma,Lebrikizumab (DRUG); Placebo (DRUG); Inhaled corticposteroids (ICS) (DRUG); Second Asthma Controller Medication (DRUG),11626560,VGH,Asthma,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4708,NCT00411385,Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3,COMPLETED,PHASE3,Chronic Hepatitis C,albumin interferon alfa-2b (DRUG); peginterferon alfa-2a (DRUG); Ribavirin (DRUG),11626560,VGH,Chronic Hepatitis C,Liver,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4709,NCT01442909,Pemetrexed Followed by Docetaxel or in Reverse Sequence,COMPLETED,PHASE4,Non-small-cell Lung Cancer,Docetaxel and pemetrexed (DRUG),11626560,VGH,Non-small-cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4710,NCT01037998,UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer,COMPLETED,PHASE2,Non-Small-Cell Lung Cancer,UFUR and Iressa (DRUG),11626560,VGH,Non-Small-Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4711,NCT02006030,Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma,COMPLETED,PHASE2,Unresectable Hepatocellular Carcinoma,ADI-PEG 20 (DRUG); Transarterial chemoembolization (DRUG),11626560,VGH,Unresectable Hepatocellular Carcinoma,Liver,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4712,NCT00686322,Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC),COMPLETED,PHASE4,Non-small-cell Lung Cancer,Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy) (DRUG),11626560,VGH,Non-small-cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4713,NCT03608878,Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype,TERMINATED,PHASE2,Hepatocellular Carcinoma,adagloxad simolenin/OBI-821 (BIOLOGICAL); TACE (PROCEDURE),11626560,VGH,Hepatocellular Carcinoma,Liver,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4714,NCT02761057,"Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed",COMPLETED,PHASE2,Locally Advanced Papillary Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma,Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Cabozantinib S-malate (DRUG); Computed Tomography (PROCEDURE); Crizotinib (DRUG); Savolitinib (DRUG); Sunitinib Malate (DRUG),11626560,VGH,Locally Advanced Papillary Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma,Kidney,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4715,NCT02838420,A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC),ACTIVE_NOT_RECRUITING,PHASE3,Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer,Alectinib (DRUG); Crizotinib (DRUG),11626560,VGH,Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4716,NCT06569420,Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC,ACTIVE_NOT_RECRUITING,PHASE3,Non-Small Cell Lung Cancer; ALK-positive; SAF-189s,Drug: Foritinib Succinate (OTHER); Drug: Crizotinib (OTHER),11626560,VGH,Non-Small Cell Lung Cancer; ALK-positive; SAF-189s,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4717,NCT01524926,CREATE: Cross-tumoral Phase 2 With Crizotinib,COMPLETED,PHASE2,Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma; Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor; Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1; Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma; Locally Advanced and/or Metastatic Clear Cell Sarcoma; Locally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma,Crizotinib (PF-02341066) (DRUG),11626560,VGH,Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma; Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor; Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1; Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma; Locally Advanced and/or Metastatic Clear Cell Sarcoma; Locally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma,Kidney,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4718,NCT00965731,"Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer",COMPLETED,PHASE1,Non-Small Cell Lung Cancer,Erlotinib (DRUG); Erlotinib (DRUG); PF-02341066 (DRUG),11626560,VGH,Advanced Non-Small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4719,NCT02314364,A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC,COMPLETED,PHASE2,"Non-small Cell Lung Cancer Metastatic; Targetable Oncogenes (EGFR, ALK, ROS1)",SBRT with protons or photons (RADIATION),11626560,VGH,"Non-small Cell Lung Cancer Metastatic; Targetable Oncogenes (EGFR, ALK, ROS1)",Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4720,NCT05297890,A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer,Lorlatinib (DRUG),11626560,VGH,Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4721,NCT04322890,Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation,RECRUITING,PHASE2,Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROS1 Gene Mutation; MET Gene Mutation,"Osimertinib (DRUG); Alectinib 150 MG (DRUG); Crizotinib 250 MG (DRUG); Savolitinib, Crizotinib. (DRUG); Chemotherapy (DRUG)",11626560,VGH,Non-Small Cell Lung Cancer with Gene Mutations,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4722,NCT01945021,"Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC",COMPLETED,PHASE2,Non Small Cell Lung Cancer; ROS1 Proto Oncogene; Crizotinib,Crizotinib (DRUG),11626560,VGH,Non Small Cell Lung Cancer; ROS1 Proto Oncogene; Crizotinib,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4723,NCT05014464,ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma,RECRUITING,PHASE2,Non-small Cell Lung Cancer,Crizotinib (DRUG),11626560,VGH,Non-small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4724,NCT02094573,"A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib",COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Brigatinib (DRUG),11626560,VGH,"Carcinoma, Non-Small-Cell Lung",Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4725,NCT01685060,LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,LDK378 (DRUG),11626560,VGH,Advanced Non-Small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4726,NCT01644773,Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG),COMPLETED,PHASE1,Diffuse Intrinsic Pontine Glioma; High-grade Glioma,Crizotinib (DRUG); Dasatinib (DRUG),11626560,VGH,Diffuse Intrinsic Pontine Glioma; High-grade Glioma,CNS/Brain,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4727,NCT03088930,Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer,COMPLETED,PHASE2,"Lung Cancer, Nonsmall Cell",Crizotinib (DRUG),11626560,VGH,"Lung Cancer, Nonsmall Cell",Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4728,NCT04211922,Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib,TERMINATED,PHASE2,ALK-positive Non-small Cell Lung Cancer,Alkotinib Capsules (DRUG),11626560,VGH,ALK-positive Non-small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4729,NCT01964157,"An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement",UNKNOWN,PHASE2,Non-small Cell Lung Cancer (NSCLC),LDK378 (DRUG),11626560,VGH,Non-small Cell Lung Cancer (NSCLC),Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4730,NCT02277457,"Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations",WITHDRAWN,EARLY_PHASE1,Non-Small Cell Lung Cancer,PET-Adaptive RT (RADIATION); Erlotinib (DRUG); Crizotinib (DRUG),11626560,VGH,Advanced Non-Small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4731,NCT01970865,A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,COMPLETED,PHASE1,ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC,PF-06463922 (DRUG); Crizotinib (DRUG),11626560,VGH,ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4732,NCT01822496,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,TERMINATED,PHASE2,Stage III Non-Small Cell Lung Cancer AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7; Stage IIIB Non-Small Cell Lung Cancer AJCC v7,Radiation Therapy (RADIATION); Carboplatin (DRUG); Cisplatin (DRUG); Crizotinib (DRUG); Erlotinib (DRUG); Etoposide (DRUG); Paclitaxel (DRUG),11626560,VGH,Stage III Non-Small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4733,NCT04030429,Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer,UNKNOWN,PHASE2,Endometrial Cancer Recurrent,Crizotinib 250 MG (DRUG),11626560,VGH,Endometrial Cancer Recurrent,Uterus,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4734,NCT02612194,LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer,TERMINATED,PHASE2,Urinary Bladder Neoplasms; Ureteral Neoplasms; Urethral Neoplasms,Crizotinib (DRUG),11626560,VGH,Urinary Bladder Neoplasms; Ureteral Neoplasms; Urethral Neoplasms,Bladder/Urinary Tract,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4735,NCT03737994,Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Alectinib (DRUG); Brigatinib (DRUG); Carboplatin (DRUG); Ceritinib (DRUG); Cisplatin (DRUG); Crizotinib (DRUG); Ensartinib (DRUG); Lorlatinib (DRUG); Pemetrexed (DRUG),11626560,VGH,Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4736,NCT01579994,Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers,COMPLETED,PHASE1,Advanced Lung Cancer,Ganetespib (STA-9090) and crizotinib (DRUG),11626560,VGH,Advanced Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4737,NCT01500824,A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer,WITHDRAWN,PHASE2,Non-Small Cell Lung Cancer,Crizotinib (DRUG),11626560,VGH,Advanced Non-Small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4738,NCT06082635,TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC),RECRUITING,PHASE3,Non Small Cell Lung Cancer,TGRX-326 (DRUG); Crizotinib (DRUG),11626560,VGH,Non Small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4739,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,75 approved agents (DRUG); COXEN (OTHER),11626560,VGH,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,Bladder/Urinary Tract,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4740,NCT02767804,eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients,ACTIVE_NOT_RECRUITING,PHASE3,Non-small Cell Lung Cancer,X-396 (ensartinib) (DRUG); crizotinib (DRUG),11626560,VGH,Non-small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4741,NCT02510001,MEK and MET Inhibition in Colorectal Cancer,COMPLETED,PHASE1,Solid Tumor; Colorectal Cancer,PF-02341066 (DRUG); PD-0325901 (DRUG); Binimetinib (DRUG),11626560,VGH,Solid Tumor; Colorectal Cancer,Bowel,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4742,NCT01639001,A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients,COMPLETED,PHASE3,NSCLC (Non-small Cell Lung Cancer),Crizotinib (DRUG); Pemetrexed/Cisplatin (DRUG); Pemetrexed/Carboplatin (DRUG),11626560,VGH,NSCLC (Non-small Cell Lung Cancer),Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4743,NCT02737501,ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants,COMPLETED,PHASE3,Non-small Cell Lung Cancer; Lung Cancer; Advanced Malignancies; Carcinoma,Brigatinib (DRUG); Crizotinib (DRUG),11626560,VGH,Non-small Cell Lung Cancer; Lung Cancer; Advanced Malignancies; Carcinoma,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4744,NCT02201992,Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial),RECRUITING,PHASE3,ALK Gene Rearrangement; ALK Gene Translocation; ALK Positive; Stage IB Non-Small Cell Lung Carcinoma AJCC v7; Stage II Non-Small Cell Lung Cancer AJCC v7; Stage IIA Non-Small Cell Lung Carcinoma AJCC v7; Stage IIB Non-Small Cell Lung Carcinoma AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7,Clinical Observation (OTHER); Crizotinib (DRUG); Laboratory Biomarker Analysis (OTHER),11626560,VGH,ALK Gene Rearrangement; ALK Gene Translocation; ALK Positive; Stage IB Non-Small Cell Lung Carcinoma AJCC v7; Stage II Non-Small Cell Lung Cancer AJCC v7; Stage IIA Non-Small Cell Lung Carcinoma AJCC v7; Stage IIB Non-Small Cell Lung Carcinoma AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4745,NCT04632758,Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients,ACTIVE_NOT_RECRUITING,PHASE3,Non-small Cell Lung Cancer,WX-0593 Tablets (DRUG); crizotinib (DRUG),11626560,VGH,Non-small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4746,NCT06564324,A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients,RECRUITING,PHASE3,Non Small Cell Lung Cancer,Taletrectinib (DRUG); Crizotinib (DRUG),11626560,VGH,Non Small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4747,NCT01154140,A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung,COMPLETED,PHASE3,Non Squamous Lung Cancer,treatment (DRUG); treatment (DRUG),11626560,VGH,Non Squamous Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4748,NCT02075840,A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants,COMPLETED,PHASE3,Non-Small Cell Lung Cancer,Alectinib (DRUG); Crizotinib (DRUG),11626560,VGH,Advanced Non-Small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4749,NCT02134912,S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,TERMINATED,PHASE2,Adenocarcinoma of the Lung; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,crizotinib (DRUG); pemetrexed disodium (DRUG); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),11626560,VGH,Adenocarcinoma of the Lung; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4750,NCT02568267,"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)",ACTIVE_NOT_RECRUITING,PHASE2,"Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Primary Brain Tumors; Renal Cell Carcinoma; Sarcomas; Salivary Gland Cancers; Adult Solid Tumor",Entrectinib (DRUG),11626560,VGH,"Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Primary Brain Tumors; Renal Cell Carcinoma; Sarcomas; Salivary Gland Cancers; Adult Solid Tumor",Bowel,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4751,NCT02584634,"Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)",TERMINATED,PHASE1,Non-Small Cell Lung Cancer,Avelumab (DRUG); PF-06463922 (DRUG); Crizotinib (DRUG),11626560,VGH,Advanced Non-Small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4752,NCT04084717,Study of Crizotinib for ROS1 and MET Activated Lung Cancer,RECRUITING,PHASE2,Non-squamous Non-small-cell Lung Cancer; Stage IV Non-small Cell Lung Cancer; ROS1 Gene Rearrangement; MET Activating Mutation; MET Amplification,Crizotinib (DRUG),11626560,VGH,Non-squamous Non-small-cell Lung Cancer; Stage IV Non-small Cell Lung Cancer; ROS1 Gene Rearrangement; MET Activating Mutation; MET Amplification,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4753,NCT05195619,Personalized DC Vaccines in Non Small Cell Lung Cancer,RECRUITING,PHASE1,Non-small Cell Lung Cancer,Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine) (BIOLOGICAL); Low dose cyclophosphamide (DRUG),11626560,VGH,Non-small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4754,NCT04292119,Lorlatinib Combinations in Lung Cancer,UNKNOWN,PHASE1,Lung Cancer; Anaplastic Lymphoma Kinase Gene Translocation; ROS1 Rearrangement; Relapsed Cancer; MET Amplification; Resistant Cancer; NSCLC,Lorlatinib (DRUG); Crizotinib (DRUG); Binimetinib (DRUG); TNO155 (DRUG),11626560,VGH,Lung Cancer; Anaplastic Lymphoma Kinase Gene Translocation; ROS1 Rearrangement; Relapsed Cancer; MET Amplification; Resistant Cancer; NSCLC,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4755,NCT02223819,Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy,COMPLETED,PHASE2,Uveal Melanoma,Crizotinib (DRUG),11626560,VGH,Uveal Melanoma,Skin,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4756,NCT01419041,A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function,COMPLETED,PHASE1,Renal Impairment,crizotinib (DRUG); crizotinib (DRUG),11626560,VGH,Renal Impairment,Kidney,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4757,NCT01828112,LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,COMPLETED,PHASE3,Non-Small Cell Lung Cancer,Ceritinib (DRUG); Pemetrexed (DRUG); Docetaxel (DRUG),11626560,VGH,Advanced Non-Small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4758,NCT02435108,A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy,COMPLETED,PHASE2,c-MET Positive Gastric Cancer,crizotinib (DRUG),11626560,VGH,c-MET Positive Gastric Cancer,Esophagus/Stomach,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4759,NCT06062810,Pharmacogenomics IND EXEMPT SNP Clinical Study - Crizotinib and Single Nucleotide Polymorphisms,NOT_YET_RECRUITING,PHASE2,Non-Small Cell Lung Cancer,Crizotinib - Usual (DRUG); Crizotinib - Study (DRUG),11626560,VGH,Advanced Non-Small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4760,NCT04634110,Brigatinib Before Brain Irradiation Trial (B3i Trial),TERMINATED,PHASE2,Brain Metastases; Lung Cancer,Brigatinib (DRUG),11626560,VGH,Brain Metastases; Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4761,NCT03052608,A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC,ACTIVE_NOT_RECRUITING,PHASE3,"Carcinoma, Non-Small-Cell Lung",Lorlatinib (DRUG); Crizotinib (DRUG),11626560,VGH,"Carcinoma, Non-Small-Cell Lung",Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4762,NCT01685138,LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,LDK378 (DRUG),11626560,VGH,Advanced Non-Small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4763,NCT02499614,Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS),UNKNOWN,PHASE2,"Carcinoma, Non-Small-Cell Lung",Crizotinib (DRUG),11626560,VGH,"Carcinoma, Non-Small-Cell Lung",Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4764,NCT02695550,"Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer",UNKNOWN,PHASE1,Non-small Cell Lung Cancer,CT-707 (DRUG),11626560,VGH,Non-small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4765,NCT00585195,"A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer",COMPLETED,PHASE1,Non-Small Cell Lung Cancer ALK-positive; Non-Small Cell Lung Cancer c-Met Dependent; Non-Small Cell Lung Cancer ROS Marker Positive; Systemic Anaplastic Large-Cell Lymphoma; Advanced Malignancies Except Leukemia,PF-02341066 (DRUG); Rifampin (DRUG); Itraconazole (DRUG),11626560,VGH,Non-Small Cell Lung Cancer ALK-positive; Non-Small Cell Lung Cancer c-Met Dependent; Non-Small Cell Lung Cancer ROS Marker Positive; Systemic Anaplastic Large-Cell Lymphoma; Advanced Malignancies Except Leukemia,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4766,NCT06563999,Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.,RECRUITING,PHASE2,Lung Cancer Stage III; Mutation,Sunvozertinib (DRUG); Crizotinib (DRUG); Pralsetinib (DRUG); Larotrectinib (DRUG); Savolitinib (DRUG); Pyrotinib (DRUG); Dabrafenib+Trametinib (DRUG); Glecirasib (DRUG); Ensartinib (DRUG),11626560,VGH,Lung Cancer Stage III with Mutation,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4767,NCT06254599,A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC,NOT_YET_RECRUITING,PHASE3,Non-small Cell Lung Cancer,SY-3505 Capsules (DRUG); Crizotinib Capsules (DRUG),11626560,VGH,Non-small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4768,NCT00939770,Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,COMPLETED,PHASE1,Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Refractory Anaplastic Large Cell Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma,Crizotinib (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Questionnaire Administration (OTHER),11626560,VGH,Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Refractory Anaplastic Large Cell Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma,CNS/Brain,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4769,NCT02604342,Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib,COMPLETED,PHASE3,Non-small Cell Lung Cancer,Alectinib (DRUG); Docetaxel (DRUG); Pemetrexed (DRUG),11626560,VGH,Non-small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4770,NCT02511184,Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients,TERMINATED,PHASE1,ALK-positive Advanced NSCLC,Crizotinib (DRUG); Pembrolizumab (DRUG),11626560,VGH,Non-small Cell Lung Cancer (NSCLC),Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4771,NCT03574402,Phase II Umbrella Study Directed by Next Generation Sequencing,UNKNOWN,PHASE2,"Carcinoma, Non-Small-Cell Lung",Avitinib Maleate (DRUG); Afatinib (DRUG); Crizotinib (DRUG); X-396 (DRUG); Chidamide (DRUG); Pyrotinib Maleate (DRUG); AZD3759 (DRUG); Pirotinib (DRUG); Nimotuzumab (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG); Sintilimab (DRUG); Gemcitabine (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG),11626560,VGH,"Carcinoma, Non-Small-Cell Lung",Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4772,NCT03620643,"Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours",ACTIVE_NOT_RECRUITING,PHASE2,Lobular Breast Carcinoma; Gastric Cancer; Triple Negative Breast Cancer; CDH1 Gene Mutation,Crizotinib Oral Capsule [Xalkori] (DRUG); Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic] (DRUG),11626560,VGH,Lobular Breast Carcinoma; Gastric Cancer; Triple Negative Breast Cancer; CDH1 Gene Mutation,Esophagus/Stomach,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4773,NCT01998126,Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer,COMPLETED,PHASE1,Non-small Cell Lung Cancer,Ipilimumab (DRUG); Erlotinib (DRUG); Crizotinib (DRUG); Nivolumab (DRUG),11626560,VGH,Non-small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4774,NCT03087448,Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC),TERMINATED,PHASE1,Non-small Cell Lung Cancer,Ceritinib (DRUG); Trametinib (DRUG),11626560,VGH,Non-small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4775,NCT01121575,A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer,COMPLETED,PHASE1,Non Small Cell Lung Cancer,PF-02341066 (DRUG); PF-00299804 (DRUG); PF-02341066 (DRUG); PF-00299804 (DRUG),11626560,VGH,Non Small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4776,NCT03768375,Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma,UNKNOWN,PHASE2,Cholangiocarcinoma of the Extrahepatic Bile Duct; Gallbladder Cancer,conventional chemotherapy(FORFIRINOX) combined with target agents (BIOLOGICAL); conventional chemotherapy(FORFIRINOX) (BIOLOGICAL),11626560,VGH,Biliary Tract Cancers,Liver,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4777,NCT02664935,National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,"Non-Small Cell Lung Cancer; Carcinoma, Squamous Cell; Adenocarcinoma",AZD4547 (DRUG); Vistusertib (DRUG); Palbociclib (DRUG); Crizotinib (DRUG); Selumetinib (DRUG); Docetaxel (DRUG); AZD5363 (DRUG); Osimertinib (DRUG); Durvalumab (DRUG); Sitravatinib (DRUG); AZD6738 (DRUG),11626560,VGH,"Non-Small Cell Lung Cancer; Carcinoma, Squamous Cell; Adenocarcinoma",Skin,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4778,NCT01712217,A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib,COMPLETED,PHASE1,Non-small Cell Lung Cancer(NSCLC),AT13387 (DRUG); Crizotinib (DRUG),11626560,VGH,Non-small Cell Lung Cancer(NSCLC),Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4779,NCT02270034,Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma,COMPLETED,PHASE1,Glioblastoma Multiforme (Grade IV) of Cerebellum,Crizotinib (DRUG),11626560,VGH,Glioblastoma Multiforme (Grade IV) of Cerebellum,CNS/Brain,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4780,NCT02183870,EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer,COMPLETED,PHASE2,Lung Cancer; Adenocarcinoma; NSCLC,Crizotinib (DRUG),11626560,VGH,Lung Cancer; Adenocarcinoma; NSCLC,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4781,NCT02946359,A+C in Metastatic Lung Adenocarcinoma Cancer,UNKNOWN,PHASE2,Lung Adenocarcinoma Metastatic,"Crizotinib, bevacizumab (DRUG)",11626560,VGH,Lung Adenocarcinoma Metastatic,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4782,NCT06140836,A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3),RECRUITING,PHASE3,"Carcinoma, Non-Small-Cell Lung",Repotrectinib (DRUG); Crizotinib (DRUG),11626560,VGH,"Carcinoma, Non-Small-Cell Lung",Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4783,NCT01752400,AUY922 for Advanced ALK-positive NSCLC,COMPLETED,PHASE2,Non Small Cell Lung Cancer,AUY922 (DRUG),11626560,VGH,Non Small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4784,NCT05725200,Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer,RECRUITING,PHASE2,Metastatic Colorectal Cancer,Alectinib (DRUG); Cetuximab (DRUG); Crizotinib (DRUG); Dasatinib (DRUG); Everolimus (DRUG); Encorafenib (DRUG); Gemcitabine (DRUG); Idelalisib (DRUG); Larotrectinib (DRUG); Methotrexate (DRUG); Palbociclib (DRUG); Panobinostat (DRUG); Pembrolizumab (DRUG); Petrozumab (DRUG); Trastuzumab (DRUG); Talazoparib (DRUG); Venetoclax (DRUG),11626560,VGH,Metastatic Colorectal Cancer,Bowel,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4785,NCT03947385,Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions,RECRUITING,PHASE1,Metastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumors,IDE196 (DRUG); Binimetinib (DRUG); Crizotinib (DRUG),11626560,VGH,Metastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumors,Bowel,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4786,NCT02040870,LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib,COMPLETED,PHASE1,Non-Small Cell Lung Cancer,LDK378 (DRUG),11626560,VGH,Advanced Non-Small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4787,NCT05987332,IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma,RECRUITING,PHASE2,Metastatic Uveal Melanoma,IDE196 (DRUG); Crizotinib (DRUG); Pembrolizumab (DRUG); Ipilimumab (DRUG); Nivolumab (DRUG); Dacarbazine (DRUG),11626560,VGH,Metastatic Uveal Melanoma,Skin,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4788,NCT03399487,A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement,UNKNOWN,PHASE2,Non-small Cell Lung Cancer Harboring ROS1 Rearrangement,LDK378(Ceritinib) (DRUG),11626560,VGH,Non-small Cell Lung Cancer Harboring ROS1 Rearrangement,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4789,NCT02836847,Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma,UNKNOWN,PHASE2,Cholangiocarcinoma of the Extrahepatic Bile Duct; Gallbladder Cancer,biological test (PROCEDURE); GEMOX (DRUG); Cetuximab (DRUG); Trastuzumab (DRUG); Gefitinib (DRUG); Lapatinib (DRUG); Everolimus (DRUG); Sorafenib (DRUG); Crizotinib (DRUG),11626560,VGH,Biliary Tract Cancers,Liver,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4790,NCT04641754,"A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer",UNKNOWN,PHASE2,Non-small Cell Lung Cancer,WX-0593 Tablets (DRUG),11626560,VGH,Non-small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4791,NCT00932451,"An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene",COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",PF-02341066 (DRUG),11626560,VGH,"Carcinoma, Non-Small-Cell Lung",Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4792,NCT02098954,Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers,RECRUITING,PHASE2,"Carcinoma, Non-Small Cell Lung; EGFR Gene Mutation",Gemcitabine platinum combined with erlotinib (DRUG),11626560,VGH,Non-Small Cell Lung Carcinoma with EGFR Mutation,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4793,NCT04644432,Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma,UNKNOWN,PHASE2,Metastatic Renal Cell Carcinoma; Kidney Neoplasm; Urologic Neoplasms; Urogenital Neoplasms,Medication (A specification is listed under each arm) (DRUG); Patient reported outcomes measurement (OTHER),11626560,VGH,Metastatic Renal Cell Carcinoma,Kidney,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4794,NCT03439215,PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer,UNKNOWN,PHASE2,"Carcinoma, Non-Small-Cell Lung",Lorlatinib (DRUG),11626560,VGH,"Carcinoma, Non-Small-Cell Lung",Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4795,NCT04621188,Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS),ACTIVE_NOT_RECRUITING,PHASE2,Non Small Cell Lung Cancer Metastatic,Lorlatinib (DRUG),11626560,VGH,Stage IV Non-small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4796,NCT04603807,A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases,RECRUITING,PHASE3,"Carcinoma, Non-Small-Cell Lung",Entrectinib (DRUG); Crizotinib (DRUG),11626560,VGH,"Carcinoma, Non-Small-Cell Lung",Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4797,NCT03155009,A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Alectinib (DRUG),11626560,VGH,"Carcinoma, Non-Small-Cell Lung",Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4798,NCT03607188,Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer,COMPLETED,PHASE1,Non-small Cell Lung Cancer,Alkotinib (DRUG),11626560,VGH,Non-small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4799,NCT02574078,A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE1,Non-Small Cell Lung Cancer,Nivolumab (DRUG); Bevacizumab (DRUG); Pemetrexed (DRUG); Best Supportive Care (OTHER); nab-Paclitaxel (DRUG); Paclitaxel (DRUG); Docetaxel (DRUG); Gemcitabine (DRUG); Erlotinib (DRUG); Crizotinib (DRUG); Carboplatin (DRUG),11626560,VGH,Advanced Non-Small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4800,NCT04193007,The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLC,UNKNOWN,PHASE2,Non Small Cell Lung Cancer; Brain Metastases,molecular targeted therapies (DRUG); Brain Radiotherapy (RADIATION),11626560,VGH,Non Small Cell Lung Cancer; Brain Metastases,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4801,NCT03107988,NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922),ACTIVE_NOT_RECRUITING,PHASE1,Neuroblastoma,Lorlatinib (DRUG); Cyclophosphamide (DRUG); Topotecan (DRUG); Filgrastim/pegfilgrastim (DRUG),11626560,VGH,Neuroblastoma,CNS/Brain,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4802,NCT05204628,A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib,NOT_YET_RECRUITING,PHASE3,Non-small Cell Lung Cancer,XZP-3621 (DRUG); Crizotinib (DRUG),11626560,VGH,Non-small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4803,NCT03215693,X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib,ACTIVE_NOT_RECRUITING,PHASE2,Non-Small Cell Lung Cancer,X-396 capsule (DRUG),11626560,VGH,Advanced Non-Small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4804,NCT01449461,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)",COMPLETED,PHASE1,"Lymphoma, Large-Cell, Anaplastic; Carcinoma, Non-Small-Cell Lung",Brigatinib (DRUG),11626560,VGH,"Lymphoma, Large-Cell, Anaplastic; Carcinoma, Non-Small-Cell Lung",Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4805,NCT06908993,Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated,NOT_YET_RECRUITING,PHASE3,Advanced Non Small Cell Lung Cancer; MET Exon 14 Mutation,Tepotinib (DRUG); Pemetrexed (Alimta) (DRUG); Vinorelbine (DRUG); Gemcitabine alone (DRUG); Docetaxel (DRUG); Paclitaxel (DRUG); Pembrolizumab (DRUG); Nivolumab (DRUG); Atezolizumab (DRUG),11626560,VGH,Advanced Non Small Cell Lung Cancer; MET Exon 14 Mutation,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4806,NCT01441128,-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer,TERMINATED,PHASE1,"Carcinoma, Non-Small Cell Lung; Adenocarcinoma; Carcinoma, Squamous Cell; Carcinoma, Large Cell",PF-02341066/PF-00299804 (DRUG); PF-02341066/PF-00299804 (DRUG),11626560,VGH,"Carcinoma, Non-Small Cell Lung; Adenocarcinoma; Carcinoma, Squamous Cell; Carcinoma, Large Cell",Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4807,NCT01441388,A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.,WITHDRAWN,PHASE1,"Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Hepatocellular",Crizotinib plus VEGF inhibitor combinations (DRUG); Crizotinib plus axitinib (DRUG); Crizotinib plus sunitinib (DRUG); Crizotinib plus axitinib (DRUG); Crizotinib plus sunitinib (DRUG); Crizotinib plus bevacizumab (DRUG); Crizotinib plus sorafenib (DRUG),11626560,VGH,"Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Hepatocellular",CNS/Brain,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4808,NCT04322578,Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC,RECRUITING,PHASE2,Non-small Cell Lung Cancer,Crizotinib (DRUG); Pemetrexed (DRUG),11626560,VGH,Non-small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4809,NCT02074878,CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer,TERMINATED,PHASE1,Breast Cancer,Crixotinib 200 mg and Sunitinib Cohort 1 (DRUG); Crixotinib 250 mg and Sunitinib Cohort 2 (DRUG); Crizotinib & Sunitinib 37.5 mg Cohort 3 (DRUG),11626560,VGH,Breast Cancer,Breast,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4810,NCT00932893,"An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene",COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung",PF-02341066 (DRUG); Pemetrexed (DRUG); Docetaxel (DRUG),11626560,VGH,"Carcinoma, Non-Small-Cell Lung",Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4811,NCT06214793,Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC),SUSPENDED,PHASE2,Breast Cancer; Metastatic Breast Cancer,Taletrectinib (DRUG),11626560,VGH,Breast Cancer; Metastatic Breast Cancer,Breast,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4812,NCT01801111,A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment,COMPLETED,PHASE1,Non-Small-Cell Lung Carcinoma,Erlotinib (DRUG); Alectinib (DRUG),11626560,VGH,Non-Small-Cell Lung Carcinoma,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4813,NCT04111705,Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer,COMPLETED,PHASE2,Non Small Cell Lung Cancer Metastatic,Lorlatinib (DRUG),11626560,VGH,Stage IV Non-small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4814,NCT01871805,A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE1,Non-Small Cell Lung Cancer,Alectinib (DRUG),11626560,VGH,Advanced Non-Small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4815,NCT02336451,A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges,COMPLETED,PHASE2,ALK-positive Non-small Cell Lung Cancer,Ceritinib (DRUG),11626560,VGH,ALK-positive Non-small Cell Lung Cancer,Lung,crizotinib,"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,1.12,333.0 +4816,NCT01467466,Prevention of Serious Adverse Events Following Angiography,COMPLETED,PHASE3,Acute Renal Failure; Kidney Disease; Coronary Artery Disease,IV isotonic saline (DRUG); IV isotonic bicarbonate (DRUG); N-acetylcysteine (DRUG); Placebo (DRUG),56671814,VHS,Acute Renal Failure; Kidney Disease; Coronary Artery Disease,Kidney,(S)-Crizotinib,NUDT1,inhibitor/antagonist,unclear,no,yes,"Racemic mixture Crizotinib is approved, not specific enantiomer.",CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,, +4817,NCT02144727,A Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer,UNKNOWN,PHASE3,Gastric Adenocarcinoma,D2 distal subtotal gastrectomy (PROCEDURE); D1+ distal subtotal gastrectomy (PROCEDURE),56671814,VHS,Gastric Adenocarcinoma,Esophagus/Stomach,(S)-Crizotinib,NUDT1,inhibitor/antagonist,unclear,no,yes,"Racemic mixture Crizotinib is approved, not specific enantiomer.",CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,, +4818,NCT06523725,Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy,WITHDRAWN,PHASE2,Post-traumatic Epilepsy,PO BRC-003 (High Cannabidiol Cannabis Extract) (DRUG); Placebo (DRUG),56671814,VHS,Post-traumatic Epilepsy,CNS/Brain,(S)-Crizotinib,NUDT1,inhibitor/antagonist,unclear,no,yes,"Racemic mixture Crizotinib is approved, not specific enantiomer.",CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,, +4819,NCT02871427,Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder,TERMINATED,PHASE2,Lewy Body Dementia; Dementia With Lewy Bodies; Parkinson's Disease Dementia; Visual Hallucinations; REM Sleep Behavior Disorder,Nelotanserin (DRUG),56671814,VHS,Lewy Body Dementia; Dementia With Lewy Bodies; Parkinson's Disease Dementia; Visual Hallucinations; REM Sleep Behavior Disorder,CNS/Brain,(S)-Crizotinib,NUDT1,inhibitor/antagonist,unclear,no,yes,"Racemic mixture Crizotinib is approved, not specific enantiomer.",CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,, +4820,NCT00805194,LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer,COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung",placebo plus docetaxel (DRUG); BIBF 1120 plus docetaxel (DRUG),56671814,VHS,"Carcinoma, Non-Small-Cell Lung",Lung,(S)-Crizotinib,NUDT1,inhibitor/antagonist,unclear,no,yes,"Racemic mixture Crizotinib is approved, not specific enantiomer.",CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,, +4821,NCT00555217,VA NEPHRON-D: Diabetes iN Nephropathy Study,TERMINATED,PHASE3,Kidney Disease; Nephropathy; Type 2 Diabetes,losartan (DRUG); lisinopril (DRUG),56671814,VHS,Kidney Disease; Nephropathy; Type 2 Diabetes,Kidney,(S)-Crizotinib,NUDT1,inhibitor/antagonist,unclear,no,yes,"Racemic mixture Crizotinib is approved, not specific enantiomer.",CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,, +4822,NCT00076219,Acute Renal Failure Trial Network (ATN) Study,COMPLETED,PHASE3,Acute Renal Failure,renal replacement therapy (PROCEDURE),56671814,VHS,Acute Renal Failure,Kidney,(S)-Crizotinib,NUDT1,inhibitor/antagonist,unclear,no,yes,"Racemic mixture Crizotinib is approved, not specific enantiomer.",CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,, +4823,NCT03296306,Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma,UNKNOWN,PHASE3,Bladder Cancer; Ureter Cancer; Urethral Cancer; Transitional Cell Carcinoma,Treatment duration of cisplatin based chemotherapy (DRUG),56671814,VHS,Bladder Cancer; Ureter Cancer; Urethral Cancer; Transitional Cell Carcinoma,Bladder/Urinary Tract,(S)-Crizotinib,NUDT1,inhibitor/antagonist,unclear,no,yes,"Racemic mixture Crizotinib is approved, not specific enantiomer.",CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,, +4824,NCT02248636,Cholinesterase Inhibitor Discontinuation,COMPLETED,PHASE2,Dementia,Cholinesterase inhibitor (DRUG); Sham discontinuation (DRUG),56671814,VHS,Dementia,CNS/Brain,(S)-Crizotinib,NUDT1,inhibitor/antagonist,unclear,no,yes,"Racemic mixture Crizotinib is approved, not specific enantiomer.",CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,, +4825,NCT02364999,A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,COMPLETED,PHASE3,Non-Small Cell Lung Cancer,Bevacizumab-Pfizer (DRUG); Bevacizumab-EU (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG),56671814,VHS,Advanced Non-Small Cell Lung Cancer,Lung,(S)-Crizotinib,NUDT1,inhibitor/antagonist,unclear,no,yes,"Racemic mixture Crizotinib is approved, not specific enantiomer.",CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,, +4826,NCT04211909,Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection,COMPLETED,PHASE3,Hepatitis C Virus Infection,SOF/VEL (DRUG); SOF/VEL/VOX (DRUG),56671814,VHS,Hepatitis C Virus Infection,Liver,(S)-Crizotinib,NUDT1,inhibitor/antagonist,unclear,no,yes,"Racemic mixture Crizotinib is approved, not specific enantiomer.",CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,, +4827,NCT01992809,Omega 3 Supplementation in Fatty Liver,COMPLETED,PHASE3,Fatty Liver,Omega 3 (DIETARY_SUPPLEMENT),56671814,VHS,Fatty Liver,Liver,(S)-Crizotinib,NUDT1,inhibitor/antagonist,unclear,no,yes,"Racemic mixture Crizotinib is approved, not specific enantiomer.",CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,, +4828,NCT03042611,A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer,COMPLETED,PHASE3,Gastric Cancer; Gastric Adenocarcinoma,Rivoceranib (DRUG); Placebo (DRUG),56671814,VHS,Gastric Cancer; Gastric Adenocarcinoma,Esophagus/Stomach,(S)-Crizotinib,NUDT1,inhibitor/antagonist,unclear,no,yes,"Racemic mixture Crizotinib is approved, not specific enantiomer.",CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,, +4829,NCT00007605,"Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm",COMPLETED,PHASE3,"Atrial Fibrillation; Cerebrovascular Accident; Death, Sudden",Amiodarone (DRUG); Sotalol (DRUG),56671814,VHS,"Atrial Fibrillation; Cerebrovascular Accident; Death, Sudden",CNS/Brain,(S)-Crizotinib,NUDT1,inhibitor/antagonist,unclear,no,yes,"Racemic mixture Crizotinib is approved, not specific enantiomer.",CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,, +4830,NCT00965731,"Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer",COMPLETED,PHASE1,Non-Small Cell Lung Cancer,Erlotinib (DRUG); Erlotinib (DRUG); PF-02341066 (DRUG),71576688,s5190,Advanced Non-Small Cell Lung Cancer,Lung,Crizotinib (hydrochloride),"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for ALK-positive NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N.Cl,, +4831,NCT02277457,"Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations",WITHDRAWN,EARLY_PHASE1,Non-Small Cell Lung Cancer,PET-Adaptive RT (RADIATION); Erlotinib (DRUG); Crizotinib (DRUG),71576688,s5190,Advanced Non-Small Cell Lung Cancer,Lung,Crizotinib (hydrochloride),"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for ALK-positive NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N.Cl,, +4832,NCT01822496,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,TERMINATED,PHASE2,Stage III Non-Small Cell Lung Cancer AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7; Stage IIIB Non-Small Cell Lung Cancer AJCC v7,Radiation Therapy (RADIATION); Carboplatin (DRUG); Cisplatin (DRUG); Crizotinib (DRUG); Erlotinib (DRUG); Etoposide (DRUG); Paclitaxel (DRUG),71576688,s5190,Stage III Non-Small Cell Lung Cancer,Lung,Crizotinib (hydrochloride),"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for ALK-positive NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N.Cl,, +4833,NCT01998126,Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer,COMPLETED,PHASE1,Non-small Cell Lung Cancer,Ipilimumab (DRUG); Erlotinib (DRUG); Crizotinib (DRUG); Nivolumab (DRUG),71576688,s5190,Non-small Cell Lung Cancer,Lung,Crizotinib (hydrochloride),"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for ALK-positive NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N.Cl,, +4834,NCT02098954,Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers,RECRUITING,PHASE2,"Carcinoma, Non-Small Cell Lung; EGFR Gene Mutation",Gemcitabine platinum combined with erlotinib (DRUG),71576688,s5190,Non-Small Cell Lung Carcinoma with EGFR Mutation,Lung,Crizotinib (hydrochloride),"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for ALK-positive NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N.Cl,, +4835,NCT06908993,Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated,NOT_YET_RECRUITING,PHASE3,Advanced Non Small Cell Lung Cancer; MET Exon 14 Mutation,Tepotinib (DRUG); Pemetrexed (Alimta) (DRUG); Vinorelbine (DRUG); Gemcitabine alone (DRUG); Docetaxel (DRUG); Paclitaxel (DRUG); Pembrolizumab (DRUG); Nivolumab (DRUG); Atezolizumab (DRUG),71576688,s5190,Advanced Non Small Cell Lung Cancer; MET Exon 14 Mutation,Lung,Crizotinib (hydrochloride),"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for ALK-positive NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N.Cl,, +4836,NCT01801111,A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment,COMPLETED,PHASE1,Non-Small-Cell Lung Carcinoma,Erlotinib (DRUG); Alectinib (DRUG),71576688,s5190,Non-Small-Cell Lung Carcinoma,Lung,Crizotinib (hydrochloride),"ALK, MET, ROS1",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for ALK-positive NSCLC treatment.,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N.Cl,, +4837,NCT01851369,TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas,COMPLETED,PHASE1,Lymphomas; Solid Tumors; NSCLC; Metastatic Colon Carcinoma; Granulosa Cell Ovarian Cancer,TRC102 (DRUG); CT scan (DIAGNOSTIC_TEST); Lomotil (OTHER); Prochlorperazine (OTHER); Metoclopramide (OTHER); 5-HT3 antagonist (OTHER); Aprepitant (OTHER); Biopsy (PROCEDURE),135413536,Emend,Lymphomas; Solid Tumors; NSCLC; Metastatic Colon Carcinoma; Granulosa Cell Ovarian Cancer,Ovary/Fallopian Tube,Aprepitant,TACR1,inhibitor/antagonist,unclear,yes,yes,Aprepitant is approved for preventing chemotherapy-induced nausea and vomiting.,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,1.01,320.0 +4838,NCT02161991,Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers,COMPLETED,PHASE3,"Carcinoma, Non-small Cell Lung",Aprepitant (DRUG); placebo (DRUG),135413536,Emend,"Carcinoma, Non-small Cell Lung",Lung,Aprepitant,TACR1,inhibitor/antagonist,unclear,yes,yes,Aprepitant is approved for preventing chemotherapy-induced nausea and vomiting.,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,1.01,320.0 +4839,NCT00381862,Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX,COMPLETED,PHASE2,Colorectal Cancer; Nausea and Vomiting,aprepitant (DRUG); dexamethasone (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG); palonosetron hydrochloride (DRUG); quality-of-life assessment (PROCEDURE),135413536,Emend,Colorectal Cancer; Nausea and Vomiting,Bowel,Aprepitant,TACR1,inhibitor/antagonist,unclear,yes,yes,Aprepitant is approved for preventing chemotherapy-induced nausea and vomiting.,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,1.01,320.0 +4840,NCT00092196,Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED),COMPLETED,PHASE3,Nausea; Vomiting; Breast Neoplasms,"MK0869, aprepitant / Duration of Treatment: 3 days (DRUG)",135413536,Emend,Nausea; Vomiting; Breast Neoplasms,Breast,Aprepitant,TACR1,inhibitor/antagonist,unclear,yes,yes,Aprepitant is approved for preventing chemotherapy-induced nausea and vomiting.,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,1.01,320.0 +4841,NCT01649258,Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy,TERMINATED,PHASE1,Breast Cancer; Nausea; Vomiting,granisetron transdermal system (DRUG); fosaprepitant dimeglumine (DRUG); laboratory biomarker analysis (OTHER),135413536,Emend,Breast Cancer; Nausea; Vomiting,Breast,Aprepitant,TACR1,inhibitor/antagonist,unclear,yes,yes,Aprepitant is approved for preventing chemotherapy-induced nausea and vomiting.,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,1.01,320.0 +4842,NCT02445872,Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy,UNKNOWN,PHASE2,Chemotherapy-Induced Nausea and Vomiting; Lung Cancer,Aprepitant (DRUG); Palonosetron (DRUG); Dexamethasone (DRUG),135413536,Emend,Chemotherapy-Induced Nausea and Vomiting; Lung Cancer,Lung,Aprepitant,TACR1,inhibitor/antagonist,unclear,yes,yes,Aprepitant is approved for preventing chemotherapy-induced nausea and vomiting.,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,1.01,320.0 +4843,NCT01534637,Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer,COMPLETED,PHASE2,Extrahepatic Bile Duct Cancer; Nausea; Vomiting; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,aprepitant (DRUG); gemcitabine hydrochloride (DRUG); capecitabine (DRUG); fluorouracil (DRUG); radiation therapy (PROCEDURE); questionnaire administration (OTHER); quality-of-life assessment (PROCEDURE); nausea and vomiting therapy (PROCEDURE); management of therapy complications (PROCEDURE),135413536,Emend,Extrahepatic Bile Duct Cancer; Nausea; Vomiting; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Aprepitant,TACR1,inhibitor/antagonist,unclear,yes,yes,Aprepitant is approved for preventing chemotherapy-induced nausea and vomiting.,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,1.01,320.0 +4844,NCT02407600,Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy,UNKNOWN,PHASE2,Non-small Cell Lung Cancer; Vomiting; Nausea; Emesis,FOSAPREPITANT (Emend) (DRUG); Placebo (DRUG),135413536,Emend,Non-small Cell Lung Cancer; Vomiting; Nausea; Emesis,Lung,Aprepitant,TACR1,inhibitor/antagonist,unclear,yes,yes,Aprepitant is approved for preventing chemotherapy-induced nausea and vomiting.,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,1.01,320.0 +4845,NCT01432015,Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting,COMPLETED,PHASE4,Ovarian Cancer; Uterine Cancer,fosaprepitant (DRUG); aprepitant (DRUG); Oral Placebo (OTHER); IV placebo (OTHER),135413536,Emend,Ovarian Cancer; Uterine Cancer,Ovary/Fallopian Tube,Aprepitant,TACR1,inhibitor/antagonist,unclear,yes,yes,Aprepitant is approved for preventing chemotherapy-induced nausea and vomiting.,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,1.01,320.0 +4846,NCT00092183,An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071),COMPLETED,PHASE4,Nausea; Vomiting; Breast Neoplasms,"MK0869, aprepitant / Duration of Treatment: 3 days (DRUG); Comparator: ondansetron / Duration of Treatment: 3 days (DRUG)",135413536,Emend,Nausea; Vomiting; Breast Neoplasms,Breast,Aprepitant,TACR1,inhibitor/antagonist,unclear,yes,yes,Aprepitant is approved for preventing chemotherapy-induced nausea and vomiting.,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,1.01,320.0 +4847,NCT00895245,"Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy",TERMINATED,PHASE2,Nausea and Vomiting; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx,fosaprepitant dimeglumine (DRUG); cisplatin (DRUG); palonosetron hydrochloride (DRUG); dexamethasone (DRUG); Functional Living Index-Emesis Questionnaire (OTHER); Emesis Diary (BEHAVIORAL); Radiotherapy (RADIATION),135413536,Emend,Nausea and Vomiting; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx,Skin,Aprepitant,TACR1,inhibitor/antagonist,unclear,yes,yes,Aprepitant is approved for preventing chemotherapy-induced nausea and vomiting.,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,1.01,320.0 +4848,NCT01450826,Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide,COMPLETED,PHASE2,Nausea; Vomiting; Glioma,aprepitant (DRUG); ondansetron (DRUG),135413536,Emend,Nausea; Vomiting; Glioma,CNS/Brain,Aprepitant,TACR1,inhibitor/antagonist,unclear,yes,yes,Aprepitant is approved for preventing chemotherapy-induced nausea and vomiting.,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,1.01,320.0 +4849,NCT00110890,A Research Study for Patients With End-Stage Renal Disease (ESRD),COMPLETED,PHASE4,End Stage Renal Disease,cinacalcet (DRUG); Standard of care (OTHER),156419,CNC,End Stage Renal Disease,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4850,NCT00132431,START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism,COMPLETED,PHASE4,Kidney Disease; Secondary Hyperparathyroidism; Chronic Kidney Disease,Sensipar (DRUG),156419,CNC,Kidney Disease; Secondary Hyperparathyroidism; Chronic Kidney Disease,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4851,NCT01439867,Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism,TERMINATED,PHASE2,"Chronic Kidney Disease; Hyperparathyroidism, Secondary",Cinacalcet hydrochloride (DRUG); Standard of Care (DRUG),156419,CNC,"Chronic Kidney Disease; Hyperparathyroidism, Secondary",Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4852,NCT05013892,NTS-WBRT in Brain Metastases,RECRUITING,PHASE2,Brain Metastases,NTS-WBRT (normal tissue sparing whole brain radiation therapy) (RADIATION); Memantine (DRUG),156419,CNC,Brain Metastases,CNS/Brain,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4853,NCT00345839,E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events,COMPLETED,PHASE3,Secondary Hyperparathyroidism; Chronic Kidney Disease,Cinacalcet (DRUG); Placebo (DRUG),156419,CNC,Secondary Hyperparathyroidism; Chronic Kidney Disease,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4854,NCT00110929,Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD),COMPLETED,PHASE2,End Stage Renal Disease,AMG 073 (DRUG),156419,CNC,End Stage Renal Disease,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4855,NCT01290029,Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease,COMPLETED,PHASE1,"Chronic Kidney Disease; Hyperparathyroidism, Secondary; Secondary Hyperparathyroidism",Cinacalcet (DRUG),156419,CNC,"Chronic Kidney Disease; Hyperparathyroidism, Secondary; Secondary Hyperparathyroidism",Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4856,NCT00977080,Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D,COMPLETED,PHASE4,Chronic Kidney Disease; Secondary Hyperparathyroidism; Hemodialysis,Paricalcitol (DRUG); Cinacalcet (DRUG),156419,CNC,Chronic Kidney Disease; Secondary Hyperparathyroidism; Hemodialysis,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4857,NCT00037635,A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients,COMPLETED,PHASE3,Secondary Hyperparathyroidism; End Stage Renal Disease,AMG 073 (DRUG); Placebo (DRUG),156419,CNC,Secondary Hyperparathyroidism in End Stage Renal Disease,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4858,NCT00113958,Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels,COMPLETED,PHASE2,End Stage Renal Disease,Cinacalcet (DRUG),156419,CNC,End Stage Renal Disease,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4859,NCT03299244,Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT),COMPLETED,PHASE3,Secondary Hyperparathyroidism; Chronic Kidney Disease,Etelcalcetide (DRUG); Cinacalcet (DRUG),156419,CNC,Secondary Hyperparathyroidism; Chronic Kidney Disease,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4860,NCT01277510,Pediatric Chronic Kidney Disease Safety and Efficacy,TERMINATED,PHASE3,"Chronic Kidney Disease; Hyperparathyroidism; Hyperparathyroidism, Secondary; Kidney Disease; Secondary Hyperparathyroidism",cinacalcet capsule (DRUG); placebo (DRUG); Standard of Care (DRUG),156419,CNC,"Chronic Kidney Disease; Hyperparathyroidism; Hyperparathyroidism, Secondary; Kidney Disease; Secondary Hyperparathyroidism",Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4861,NCT00803712,20070360 Incident Dialysis,COMPLETED,PHASE4,Chronic Kidney Disease; Secondary Hyperparathyroidism,Cinacalcet (DRUG); Vitamin D (DRUG),156419,CNC,Chronic Kidney Disease; Secondary Hyperparathyroidism,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4862,NCT01100723,Trial to Optimize Mineral Outcomes in Dialysis Patients,COMPLETED,PHASE4,Secondary Hyperparathyroidism; Chronic Kidney Disease,"Cinacalcet, active vitamin D analogue (OTHER)",156419,CNC,Secondary Hyperparathyroidism; Chronic Kidney Disease,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4863,NCT01011699,Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients,TERMINATED,PHASE3,Chronic Renal Failure; Hemodialysis,nicotinamide (DRUG); sevelamer (DRUG); cinacalcet (DRUG),156419,CNC,Chronic Renal Failure; Hemodialysis,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4864,NCT00094484,Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis,COMPLETED,PHASE3,Kidney Disease; Chronic Kidney Disease,Cinacalcet HCl (DRUG),156419,CNC,Kidney Disease; Chronic Kidney Disease,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4865,NCT02138838,Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis,TERMINATED,PHASE3,"Chronic Kidney Disease, Secondary Hyperparathyroidism",Cinacalcet HCl (DRUG); Standard of Care (DIETARY_SUPPLEMENT),156419,CNC,"Chronic Kidney Disease, Secondary Hyperparathyroidism",Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4866,NCT02341417,Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis,COMPLETED,PHASE3,"Secondary Hyperparathyroidism, Chronic Kidney Disease",Cinacalcet (DRUG),156419,CNC,"Secondary Hyperparathyroidism, Chronic Kidney Disease",Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4867,NCT00117052,SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism,COMPLETED,PHASE3,Secondary Hyperparathyroidism; End Stage Renal Disease,cinacalcet (DRUG),156419,CNC,Secondary Hyperparathyroidism in End Stage Renal Disease,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4868,NCT01896232,Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet,COMPLETED,PHASE3,Secondary Hyperparathyroidism; Chronic Kidney Disease,Etelcalcetide (DRUG); Cinacalcet (DRUG); Oral Placebo (DRUG); Intravenous Placebo (DRUG),156419,CNC,Secondary Hyperparathyroidism; Chronic Kidney Disease,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4869,NCT00975000,Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients,COMPLETED,PHASE3,Chronic Allograft Nephropathy; Chronic Kidney Disease; Chronic Renal Failure; Disordered Mineral Metabolism; End Stage Renal Disease; Hyperparathyroidism; Hypophosphatemia; Kidney Disease; Kidney Transplantation; Post Renal Transplantation,Cinacalcet (DRUG); Placebo (DRUG),156419,CNC,Chronic Allograft Nephropathy; Chronic Kidney Disease; Chronic Renal Failure; Disordered Mineral Metabolism; End Stage Renal Disease; Hyperparathyroidism; Hypophosphatemia; Kidney Disease; Kidney Transplantation; Post Renal Transplantation,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4870,NCT00042432,Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients,COMPLETED,PHASE2,Secondary Hyperparathyroidism; Chronic Renal Insufficiency,cinacalcet (AMG 073) (DRUG),156419,CNC,Secondary Hyperparathyroidism; Chronic Renal Insufficiency,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4871,NCT00656032,"Vitamin D, Insulin Resistance and Inflammation in ESRD",COMPLETED,PHASE2,End Stage Renal Disease,paricalcitol (OTHER); cinacalcet (OTHER),156419,CNC,End Stage Renal Disease,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4872,NCT00379899,ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis,COMPLETED,PHASE4,Chronic Kidney Disease; End Stage Renal Disease; Coronary Artery Calcification; Vascular Calcification; Calcification; Cardiovascular Disease; Chronic Renal Failure; Hyperparathyroidism; Kidney Disease; Nephrology; Secondary Hyperparathyroidism,cinacalcet (DRUG),156419,CNC,Chronic Kidney Disease; End Stage Renal Disease; Coronary Artery Calcification; Vascular Calcification; Calcification; Cardiovascular Disease; Chronic Renal Failure; Hyperparathyroidism; Kidney Disease; Nephrology; Secondary Hyperparathyroidism,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4873,NCT06288451,DePTH: De-emphasize PTH,RECRUITING,PHASE2,"Kidney Failure, Chronic; Chronic Kidney Disease-Mineral and Bone Disorder",Oral calcitriol with cinacalcet rescue (DRUG); IV activated vitamin D (DRUG),156419,CNC,"Kidney Failure, Chronic; Chronic Kidney Disease-Mineral and Bone Disorder",Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4874,NCT01902953,Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC),COMPLETED,PHASE2,Colon Cancer; Rectal Cancer,Lymphoseek and VBD Sln dissection (DRUG),156419,CNC,Colon Cancer; Rectal Cancer,Bowel,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4875,NCT00042653,A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis,COMPLETED,PHASE3,Secondary Hyperparathyroidism; End Stage Renal Disease,Placebo (DRUG); AMG 073 (DRUG),156419,CNC,Secondary Hyperparathyroidism in End Stage Renal Disease,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4876,NCT00994071,"A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors",COMPLETED,PHASE1,Medulloblastoma; Pontine Glioma; Ependymoma; Astrocytoma; PNET,Temozolomide (DRUG); ABT-888 (DRUG),156419,CNC,Medulloblastoma; Pontine Glioma; Ependymoma; Astrocytoma; PNET,CNS/Brain,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4877,NCT00761228,Efficacy Study of NH001 in Vegetative State & Minimally Conscious State Following a Traumatic Brain Injury,SUSPENDED,PHASE2,Brain Injury,Apomorphine (DRUG); Placebo (DRUG),156419,CNC,Traumatic Brain Injury,CNS/Brain,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4878,NCT00113945,Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD),COMPLETED,PHASE2,End Stage Renal Disease,Cinacalcet (DRUG),156419,CNC,End Stage Renal Disease,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4879,NCT01573520,Treatment Adhesion in Dialysis Patients Treated With Cinacalcet,COMPLETED,PHASE4,Hyperparathyroidism; Chronic Kidney Disease,Monitoring of drug adherence (OTHER),156419,CNC,Hyperparathyroidism; Chronic Kidney Disease,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4880,NCT01250405,Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in Hemodialysis Patients,COMPLETED,PHASE4,Chronic Kidney Disease,Cinacalcet (DRUG); Placebo (DRUG),156419,CNC,Chronic Kidney Disease,Kidney,Cinacalcet,CASR,activator/agonist,unclear,yes,yes,Used to treat secondary hyperparathyroidism and parathyroid carcinoma.,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,1.09,308.0 +4881,NCT05507203,ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1,RECRUITING,PHASE3,Ulcerative Colitis,ABX464 (DRUG); Placebo (DRUG),156391,Duk,Ulcerative Colitis,Bowel,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4882,NCT01157260,The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease,UNKNOWN,PHASE4,"Kidney Failure, Chronic",Kremezin (DRUG),156391,Duk,"Kidney Failure, Chronic",Kidney,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4883,NCT01282073,Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy,UNKNOWN,PHASE3,"Glomerulonephritis, Membranous","Mycophenolate mofetil, low dose steroid (DRUG); Cyclosporin, low dose steroid (DRUG)",156391,Duk,Membranous Glomerulonephritis,Kidney,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4884,NCT01111422,Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients,UNKNOWN,PHASE4,End-Stage Kidney Disease; Peritoneal Dialysis,N-acetylcysteine (DRUG),156391,Duk,End-Stage Kidney Disease; Peritoneal Dialysis,Kidney,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4885,NCT02338635,Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis,UNKNOWN,PHASE4,End-Stage Kidney Disease,Ursodeoxycholic Acid (DRUG),156391,Duk,End-Stage Kidney Disease,Kidney,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4886,NCT05535946,ABTECT - Maintenance,RECRUITING,PHASE3,Ulcerative Colitis,ABX464 (DRUG); Placebo (DRUG),156391,Duk,Ulcerative Colitis,Bowel,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4887,NCT01297218,The Safety and The Efficacy Evaluation of NEUROSTEM®-AD in Patients With Alzheimer's Disease,COMPLETED,PHASE1,Dementia of the Alzheimer's Type,Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells (BIOLOGICAL),156391,Duk,Dementia of the Alzheimer's Type,CNS/Brain,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4888,NCT01012336,"Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin",COMPLETED,PHASE2,Chemotherapy-Induced Nausea and Vomiting; Ovarian Cancer,Aprepitant/Ramosetron/Dexamethasone (DRUG),156391,Duk,Chemotherapy-Induced Nausea and Vomiting; Ovarian Cancer,Ovary/Fallopian Tube,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4889,NCT01553721,Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH),COMPLETED,PHASE2,Pulmonary Arterial Hypertension,udenafil (DRUG); placebo (DRUG),156391,Duk,Pulmonary Arterial Hypertension,Lung,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4890,NCT01466543,Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity,UNKNOWN,PHASE2,Vascular Dementia; Subcortical Vascular Dementia,Zydena (Udenafil) (DRUG); Placebo (DRUG),156391,Duk,Vascular Dementia; Subcortical Vascular Dementia,CNS/Brain,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4891,NCT01940952,Zydena on Cognitive Function of Alzheimer's Disease Patients,UNKNOWN,PHASE3,Alzheimer's Disease,Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg (DRUG); Placebo + Donepezil 5mg or 10mg (DRUG); Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg (DRUG),156391,Duk,Alzheimer's Disease,CNS/Brain,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4892,NCT06051253,TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease,RECRUITING,PHASE4,Crohn Disease; Infliximab; Perianal Fistula Due to Crohn's Disease; Therapeutic Drug Monitoring; Magnetic Resonance Novel Index for Fistula Imaging in Crohn's Disease Score,TDM-based infliximab intravenous therapy (DRUG); Standard infliximab intravenous therapy (DRUG),156391,Duk,Crohn Disease; Infliximab; Perianal Fistula Due to Crohn's Disease; Therapeutic Drug Monitoring; Magnetic Resonance Novel Index for Fistula Imaging in Crohn's Disease Score,Bowel,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4893,NCT02304198,Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH,COMPLETED,PHASE2,Pulmonary Arterial Hypertension,Udenafil (DRUG),156391,Duk,Pulmonary Arterial Hypertension,Lung,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4894,NCT03654326,A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034),COMPLETED,PHASE2,Endometriosis-related Pain,Gefapixant (DRUG); Placebo (DRUG); Naproxen (DRUG),156391,Duk,Endometriosis-related Pain,Uterus,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4895,NCT02128490,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment,COMPLETED,PHASE2,Gout; Moderate Renal Impairment,Febuxostat IR (DRUG); Febuxostat XR (DRUG); Febuxostat placebo (DRUG); Colchicine (DRUG); Naproxen (DRUG); Lansoprazole (DRUG),156391,Duk,Gout; Moderate Renal Impairment,Kidney,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4896,NCT04876131,Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children,RECRUITING,PHASE4,Complicated Urinary Tract Infection; Infection; Pediatric Infectious Disease,Benzylpenicillin - single dose (DRUG); Benzylpenicillin - three days (DRUG); Gentamicin - single dose (DRUG); Gentamicin - three days (DRUG); Cefalexin - post single dose of IV antibiotics for the remaining two days (DRUG),156391,Duk,Complicated Urinary Tract Infection; Infection; Pediatric Infectious Disease,Bladder/Urinary Tract,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4897,NCT00007189,Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT),COMPLETED,PHASE3,Alzheimer Disease,Naproxen Sodium (Aleve) (DRUG); Celecoxib (Celebrex) (DRUG),156391,Duk,Alzheimer Disease,CNS/Brain,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4898,NCT06693362,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses",RECRUITING,PHASE1,Severe Viral Pneumonia(Not Include COVID-19),Placebo (DRUG); Drug therapy (DRUG); Standard Treatment (OTHER),156391,Duk,Severe Viral Pneumonia(Not Include COVID-19),Lung,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4899,NCT00527904,"A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)",COMPLETED,PHASE3,Gastric Ulcer,PN400 (VIMOVO) (DRUG); PN 400 (VIMOVO) (DRUG),156391,Duk,Gastric Ulcer,Esophagus/Stomach,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4900,NCT03343067,A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain,TERMINATED,PHASE3,Endometriosis,elagolix (DRUG); estradiol/norethindrone acetate (E2/NETA) (DRUG),156391,Duk,Endometriosis,Uterus,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4901,NCT00543868,MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001),COMPLETED,PHASE2,Stomach Ulcer; Duodenal Ulcer,MK0782 (DRUG),156391,Duk,Stomach Ulcer; Duodenal Ulcer,Esophagus/Stomach,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4902,NCT05411718,"A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome",RECRUITING,PHASE2,T Cells; Colorectal Cancer; Lynch Syndrome,Naproxen (DRUG); Aspirin (DRUG),156391,Duk,T Cells; Colorectal Cancer; Lynch Syndrome,Bowel,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4903,NCT02702817,Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia,COMPLETED,PHASE2,Alzheimer Disease; Cognitive Decline Due to Alzheimer Disease; Mild Cognitive Impairment Due to Alzheimer Disease,Naproxen (DRUG); Placebo (DRUG),156391,Duk,Alzheimer Disease; Cognitive Decline Due to Alzheimer Disease; Mild Cognitive Impairment Due to Alzheimer Disease,CNS/Brain,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4904,NCT03084536,PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery,COMPLETED,PHASE2,Breast Cancer; Breast Cancer Female; Cancer of Breast,Bupivacaine (DRUG); Gabapentin (DRUG); Celecoxib (DRUG); Acetaminophen (DRUG); Midazolam (DRUG); Fentanyl (DRUG),156391,Duk,Breast Cancer; Breast Cancer Female; Cancer of Breast,Breast,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4905,NCT00621881,A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects,COMPLETED,PHASE1,Liver Disease,naproxcinod (DRUG),156391,Duk,Liver Disease,Liver,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4906,NCT01612975,The Effect of Non-Steroidal Anti-Inflammatory Drug Naproxen on Pleural Effusion Formation After Lung Resection,TERMINATED,PHASE2,Pleural Effusion; Pleural Effusion Malignant,Naproxen (DRUG); Placebo (DRUG),156391,Duk,Pleural Effusion; Pleural Effusion Malignant,Lung,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4907,NCT01939002,Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017),COMPLETED,PHASE3,Relapsing Multiple Sclerosis,BIIB017 (DRUG); naproxen (DRUG),156391,Duk,Relapsing Multiple Sclerosis,CNS/Brain,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4908,NCT02143713,Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain,COMPLETED,PHASE3,Endometriosis,Elagolix (DRUG),156391,Duk,Endometriosis,Uterus,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4909,NCT01931670,A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain,COMPLETED,PHASE3,Endometriosis,placebo (OTHER); Elagolix (DRUG),156391,Duk,Endometriosis,Uterus,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4910,NCT03291418,To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects,COMPLETED,PHASE1,Gastric Ulcer,ATB-346 OR Placebo (DRUG); Naproxen sodium (DRUG),156391,Duk,Gastric Ulcer,Esophagus/Stomach,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4911,NCT00594854,Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec,TERMINATED,PHASE3,Gastric Ulcer,PN400 (VIMOVO) (DRUG); Diclofenac/Misoprostol (DRUG),156391,Duk,Gastric Ulcer,Esophagus/Stomach,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4912,NCT01760954,Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain,COMPLETED,PHASE3,Endometriosis,Elagolix (DRUG),156391,Duk,Endometriosis,Uterus,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4913,NCT00674856,A Pharmacokinetics and Safety Study of Naproxcinod in Subjects With Impaired Renal Function,COMPLETED,PHASE1,Renal Failure,naproxcinod (DRUG),156391,Duk,Renal Failure,Kidney,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4914,NCT01712009,NOLAN: Naproxen or Loratadine and Neulasta,COMPLETED,PHASE2,Bone Pain in Stage I - III Breast Cancer,Naproxen (DRUG); Loratadine (DRUG); Pegfilgrastim (BIOLOGICAL); Chemotherapy (DRUG),156391,Duk,Bone Pain in Stage I - III Breast Cancer,Breast,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4915,NCT00527787,Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen,COMPLETED,PHASE3,Gastric Ulcer,PN400 (VIMOVO) (DRUG); Naproxen (DRUG),156391,Duk,Gastric Ulcer,Esophagus/Stomach,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4916,NCT01620528,A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain,COMPLETED,PHASE3,Endometriosis,elagolix (DRUG); placebo (OTHER),156391,Duk,Endometriosis,Uterus,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4917,NCT01129011,Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen,COMPLETED,PHASE3,Gastric Ulcer,PN400 (VIMOVO) (DRUG); Naproxen (DRUG),156391,Duk,Gastric Ulcer,Esophagus/Stomach,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4918,NCT00004845,A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study),COMPLETED,PHASE2,Alzheimer Disease,Rofecoxib (DRUG); Naproxen (DRUG),156391,Duk,Alzheimer Disease,CNS/Brain,Naproxen,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used as non-prescription NSAID in many countries.,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,1.17,206.0 +4919,NCT00493974,Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study),TERMINATED,PHASE3,"Pulmonary Disease, Chronic Obstructive",Zileuton (DRUG); Placebo (DRUG),60490,Zyflo,"Pulmonary Disease, Chronic Obstructive",Lung,Zileuton,ALOX5,inhibitor/antagonist,unclear,yes,yes,Approved for asthma treatment; 5-lipoxygenase inhibitor.,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,1.62,1066.0 +4920,NCT00299065,Safety Study of Zileuton Injection in Patients With Asthma,COMPLETED,PHASE1,Asthma,Zileuton injection (DRUG),60490,Zyflo,Asthma,Lung,Zileuton,ALOX5,inhibitor/antagonist,unclear,yes,yes,Approved for asthma treatment; 5-lipoxygenase inhibitor.,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,1.62,1066.0 +4921,NCT00486343,Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS,TERMINATED,PHASE4,Asthma,Zileuton CR (DRUG); Placebo (DRUG),60490,Zyflo,Asthma,Lung,Zileuton,ALOX5,inhibitor/antagonist,unclear,yes,yes,Approved for asthma treatment; 5-lipoxygenase inhibitor.,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,1.62,1066.0 +4922,NCT01805687,Single Dose Bronchodilatory Study in Asthma,COMPLETED,PHASE4,Asthma,Zileuton extended release (DRUG),60490,Zyflo,Asthma,Lung,Zileuton,ALOX5,inhibitor/antagonist,unclear,yes,yes,Approved for asthma treatment; 5-lipoxygenase inhibitor.,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,1.62,1066.0 +4923,NCT00575861,Zileuton and Exhaled Nitric Oxide in Asthmatics,COMPLETED,PHASE4,Asthma,zileuton (DRUG),60490,Zyflo,Asthma,Lung,Zileuton,ALOX5,inhibitor/antagonist,unclear,yes,yes,Approved for asthma treatment; 5-lipoxygenase inhibitor.,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,1.62,1066.0 +4924,NCT00534625,"Assessment of PFT, Safety, and PK of Zileuton Injection in Asthma Patients",COMPLETED,PHASE2,Asthma,zileuton (DRUG); placebo (DRUG); zileuton (DRUG),60490,Zyflo,Asthma,Lung,Zileuton,ALOX5,inhibitor/antagonist,unclear,yes,yes,Approved for asthma treatment; 5-lipoxygenase inhibitor.,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,1.62,1066.0 +4925,NCT00070486,Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,carboplatin (DRUG); celecoxib (DRUG); gemcitabine hydrochloride (DRUG); zileuton (DRUG),60490,Zyflo,Lung Cancer,Lung,Zileuton,ALOX5,inhibitor/antagonist,unclear,yes,yes,Approved for asthma treatment; 5-lipoxygenase inhibitor.,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,1.62,1066.0 +4926,NCT00056004,Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia,COMPLETED,PHASE2,Head and Neck Cancer; Lung Cancer,zileuton (DRUG),60490,Zyflo,Head and Neck Cancer; Lung Cancer,Lung,Zileuton,ALOX5,inhibitor/antagonist,unclear,yes,yes,Approved for asthma treatment; 5-lipoxygenase inhibitor.,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,1.62,1066.0 +4927,NCT00098358,Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris,UNKNOWN,PHASE2,Acne Vulgaris,Zileuton (DRUG),60490,Zyflo,Acne Vulgaris,Skin,Zileuton,ALOX5,inhibitor/antagonist,unclear,yes,yes,Approved for asthma treatment; 5-lipoxygenase inhibitor.,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,1.62,1066.0 +4928,NCT04996199,Comparision Efficacy of Carbamazepine & Oxcarbazepine in the Treatment of Trigeminal Neuralgia- a Randomised Clinical Trial,UNKNOWN,PHASE4,Trigeminal Neuralgia,Oxcarbazepine (DRUG); Carbamazepine (DRUG),60490,Zyflo,Trigeminal Neuralgia,Peripheral Nervous System,Zileuton,ALOX5,inhibitor/antagonist,unclear,yes,yes,Approved for asthma treatment; 5-lipoxygenase inhibitor.,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,1.62,1066.0 +4929,NCT00723021,PF-04191834 Single Dose Bronchodilatory Study In Asthma.,COMPLETED,PHASE2,Asthma,PF-04191834 (DRUG); PF-04191834 (DRUG); PF-04191834 (DRUG); zileuton (DRUG); Placebo (DRUG),60490,Zyflo,Asthma,Lung,Zileuton,ALOX5,inhibitor/antagonist,unclear,yes,yes,Approved for asthma treatment; 5-lipoxygenase inhibitor.,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,1.62,1066.0 +4930,NCT01125748,A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy,COMPLETED,PHASE4,Allergic Asthma,Omalizumab (DRUG); Placebo (DRUG); Asthma therapies (DRUG),60490,Zyflo,Allergic Asthma,Lung,Zileuton,ALOX5,inhibitor/antagonist,unclear,yes,yes,Approved for asthma treatment; 5-lipoxygenase inhibitor.,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,1.62,1066.0 +4931,NCT00262405,Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis,COMPLETED,PHASE2,Idiopathic Pulmonary Fibrosis,zileuton (DRUG); azathioprine/prednisone (DRUG),60490,Zyflo,Idiopathic Pulmonary Fibrosis,Lung,Zileuton,ALOX5,inhibitor/antagonist,unclear,yes,yes,Approved for asthma treatment; 5-lipoxygenase inhibitor.,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,1.62,1066.0 +4932,NCT02576366,Phenotypic Drug Probes as Predictors of Drug-drug Interactions With Tacrolimus,COMPLETED,PHASE4,Drug Interactions; Kidney Transplantation,Voriconazole (DRUG); Rifampin (DRUG),71616,VCZ,Drug Interactions; Kidney Transplantation,Kidney,Voriconazole,,inhibitor/antagonist,unclear,yes,yes,Approved for treating invasive fungal infections.,CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,1.08,320.0 +4933,NCT04229303,"Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects",COMPLETED,PHASE1,Allergic Bronchopulmonary Aspergillosis,Voriconazole inhaled (DRUG); oral voriconazole (DRUG),71616,VCZ,Allergic Bronchopulmonary Aspergillosis,Lung,Voriconazole,,inhibitor/antagonist,unclear,yes,yes,Approved for treating invasive fungal infections.,CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,1.08,320.0 +4934,NCT04576325,Pharmacokinetic Profile of Voriconazole Inhalation Powder in Adult Subjects With Asthma,COMPLETED,PHASE1,Asthma,Voriconazole Inhalation Powder (DRUG); Placebo (DRUG),71616,VCZ,Asthma,Lung,Voriconazole,,inhibitor/antagonist,unclear,yes,yes,Approved for treating invasive fungal infections.,CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,1.08,320.0 +4935,NCT02234739,Voriconazole for IPA in Chinese Patients With COPD,UNKNOWN,PHASE4,Invasive Pulmonary Aspergillosis; COPD,Voriconazole (DRUG),71616,VCZ,Invasive Pulmonary Aspergillosis; COPD,Lung,Voriconazole,,inhibitor/antagonist,unclear,yes,yes,Approved for treating invasive fungal infections.,CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,1.08,320.0 +4936,NCT06774144,Rezafungin Prophylaxis in Liver Transplant,NOT_YET_RECRUITING,PHASE3,Liver Transplant Infection; Fungal Infection,Rezafungin (DRUG); Standard of care antifungal prophylaxis (DRUG),71616,VCZ,Liver Transplant Infection; Fungal Infection,Liver,Voriconazole,,inhibitor/antagonist,unclear,yes,yes,Approved for treating invasive fungal infections.,CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,1.08,320.0 +4937,NCT01254708,Safety and Efficacy Study of Inhaled AmBisome for Prevention of Aspergillus Colonization in Lung Transplant Recipients,SUSPENDED,PHASE2,Lung Transplant Recipient,Ambisome ® (DRUG); Regular standard of care medication (DRUG),71616,VCZ,Lung Transplant Recipient,Lung,Voriconazole,,inhibitor/antagonist,unclear,yes,yes,Approved for treating invasive fungal infections.,CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,1.08,320.0 +4938,NCT00066599,Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy,COMPLETED,PHASE2,Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neuroblastoma; Neutropenia; Sarcoma,voriconazole (DRUG),71616,VCZ,Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neuroblastoma; Neutropenia; Sarcoma,CNS/Brain,Voriconazole,,inhibitor/antagonist,unclear,yes,yes,Approved for treating invasive fungal infections.,CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,1.08,320.0 +4939,NCT01621321,Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis,COMPLETED,PHASE2,Allergic Bronchopulmonary Aspergillosis,Prednisolone (DRUG); Voriconazole (DRUG),71616,VCZ,Allergic Bronchopulmonary Aspergillosis,Lung,Voriconazole,,inhibitor/antagonist,unclear,yes,yes,Approved for treating invasive fungal infections.,CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,1.08,320.0 +4940,NCT06160713,Compare Oral Itraconazole and Standard Care Versus Standard Care Alone in Patients With Non-cystic Fibrosis Related Bronchiectasis With Chronic Aspergillus Infection in Reducing Bronchiectasis Exacerbations,RECRUITING,PHASE3,Bronchiectasis; Bronchiectasis Adult,Itraconazole 65 MG (DRUG); Standard care (OTHER),71616,VCZ,Bronchiectasis; Bronchiectasis Adult,Lung,Voriconazole,,inhibitor/antagonist,unclear,yes,yes,Approved for treating invasive fungal infections.,CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,1.08,320.0 +4941,NCT00974974,A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).,COMPLETED,PHASE3,Parkinson's Disease,IPX066 (DRUG); IR CD-LD (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4942,NCT00134966,A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa,COMPLETED,PHASE3,Parkinson's Disease,"capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) (DRUG)",2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4943,NCT04750226,Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease,ACTIVE_NOT_RECRUITING,PHASE3,Parkinson's Disease (PD),ABBV-951 (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4944,NCT00143026,Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States,COMPLETED,PHASE4,Parkinson's Disease,"carbidopa, levodopa, entacapone (DRUG)",2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4945,NCT00199420,A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa,COMPLETED,PHASE3,Parkinson's Disease,Istradefylline (KW-6002) (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4946,NCT01568073,"Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With ""Wearing-off"" Phenomenon",COMPLETED,PHASE3,Parkinson's Disease,BIA 9-1067 (DRUG); Entacapone (DRUG); Placebo (DRUG); Levodopa (DRUG); Carbidopa (DRUG); Benserazide (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4947,NCT06236230,Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's Disease,RECRUITING,PHASE4,Parkinson Disease,levodopa/carbidopa/entacapone (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4948,NCT00880620,A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease,COMPLETED,PHASE3,Parkinson's Disease,Placebo (DRUG); IPX066 95 mg LD (DRUG); IPX066 145 mg LD (DRUG); IPX066 195 mg LD (DRUG); IPX066 245 mg LD (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4949,NCT02271503,A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease,COMPLETED,PHASE2,Parkinson's Disease,CD-LD IR (DRUG); IPX203 180 mg (DRUG); IPX203 270 mg (DRUG); Rytary 195 mg (DRUG); Rytary 145 mg (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4950,NCT06037590,A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops™ Relative to INBRIJA®,COMPLETED,PHASE1,Parkinson; Parkinson Disease; Parkinson's Disease and Parkinsonism,Levodopa Cyclops™ (COMBINATION_PRODUCT); INBRIJA® (COMBINATION_PRODUCT),2563,Lodosin,Parkinson; Parkinson Disease; Parkinson's Disease and Parkinsonism,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4951,NCT01484990,A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease,COMPLETED,PHASE1,Parkinson Disease,Levodopa-Carbidopa (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4952,NCT04325503,Neurobiological Drivers of Mobility Resilience: The Dopaminergic System,COMPLETED,PHASE1,Parkinsonian Signs in Older Persons,carbidopa (DRUG),2563,Lodosin,Parkinsonian Signs in Older Persons,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4953,NCT05512403,Evaluation of Diagnostic Performances of 18F-FDOPA PET KInetics,RECRUITING,PHASE3,Glioma,PET/CT with 18F-DOPA (DRUG),2563,Lodosin,Glioma,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4954,NCT04379050,Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease,ACTIVE_NOT_RECRUITING,PHASE3,Parkinson's Disease (PD),ABBV-951 (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4955,NCT00505843,A Study of MK0657 in Parkinson's Disease Patients (0657-006),COMPLETED,PHASE1,Parkinson's Disease,MK0657 (DRUG); Comparator: Placebo (unspecified) (DRUG); Comparator: levodopa (DRUG); Comparator: carbidopa (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4956,NCT00139867,"A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease",COMPLETED,PHASE3,Parkinson's Disease,PARCOPA (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4957,NCT06596876,A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations,RECRUITING,PHASE3,Parkinson's Disease,HRG2010; Sustained-release Carbidopa/Levodopa administered placebo (DRUG); Sustained-release Carbidopa/Levodopa; HRG2010 placebo (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4958,NCT01736176,A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease,COMPLETED,PHASE3,Advanced Parkinson's Disease,Levodopa-Carbidopa Intestinal Gel (DRUG); Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J) (PROCEDURE); Levodopa-carbidopa Immediate Release (LC-IR) Tablets (DRUG),2563,Lodosin,Advanced Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4959,NCT02549573,Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®,TERMINATED,PHASE4,Parkinson's Disease; Motor Symptoms,APOKYN (DRUG); Physical Therapy (BEHAVIORAL),2563,Lodosin,Parkinson's Disease; Motor Symptoms,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4960,NCT01968031,A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease,COMPLETED,PHASE3,Idiopathic Parkinson's Disease,Istradefylline 40 mg (DRUG); Istradefylline 20 mg (DRUG); Placebo (DRUG),2563,Lodosin,Idiopathic Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4961,NCT02610231,Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease,COMPLETED,PHASE3,Idiopathic Parkinson's Disease,Istradefylline 20 mg or 40 mg (DRUG),2563,Lodosin,Idiopathic Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4962,NCT00203060,"Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa",COMPLETED,PHASE3,Parkinson's Disease,Rasagiline Mesylate (DRUG); placebo (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4963,NCT05083260,NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa,COMPLETED,PHASE1,Parkinson Disease,NE3107 (DRUG); placebo (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4964,NCT01479127,"Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease",COMPLETED,PHASE2,Advanced Parkinson's Disease,ABT-SLV187 (DRUG); Oral Levodopa/Carbidopa (DRUG); Infusion Pump: CADD-Legacy® 1400 Pump (DEVICE); NJ-Tube: Silicon ED Tube (DEVICE); Adaptor: Hakko Adaptor (DEVICE),2563,Lodosin,Advanced Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4965,NCT03115827,Norepinephrine-targeted Therapy for Action Control in Parkinson Disease,COMPLETED,PHASE4,Parkinson Disease,Droxidopa (DRUG); Carbidopa (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4966,NCT02170376,The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics,COMPLETED,PHASE1,Parkinson's Disease (PD),BIA 9-1067 (DRUG); Entacapone (DRUG); Placebo (DRUG); Levodopa/carbidopa (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4967,NCT04778176,"Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson's Disease Patients",COMPLETED,PHASE2,Parkinson's Disease,continuous oral delivery of levodopa/carbidopa (COMBINATION_PRODUCT),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4968,NCT03091868,Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics,COMPLETED,PHASE1,Parkinson Disease,Placebo oral capsule (DRUG); Sinemet® 100/25 (DRUG); Comtan® (DRUG); BIA 6-512 25 mg (DRUG); BIA 6-512 100 mg (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4969,NCT00660673,Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease,COMPLETED,PHASE3,Advanced Parkinson's Disease,Levodopa-Carbidopa Intestinal Gel (LCIG) (DRUG); CADD-Legacy® 1400 ambulatory infusion pump (DEVICE); Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J) (DEVICE),2563,Lodosin,Advanced Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4970,NCT00590122,Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study,COMPLETED,PHASE4,Parkinson's Disease,Parcopa (DRUG); carbidopa-levodopa (Sinemet) (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4971,NCT02764125,Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC),COMPLETED,PHASE2,Parkinson's Disease,Stalevo (DRUG); levodopa MR (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4972,NCT00279825,"Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease",COMPLETED,PHASE2,Idiopathic Parkinson's Disease,IPX054 200 mg (DRUG); IPX054 250 mg (DRUG); CD-LD IR (DRUG); CD-LD CR (DRUG); IPX054 200 mg Placebo (DRUG); IPX054 250 mg Placebo (DRUG); CD-LD IR Placebo (DRUG); CD-LD CR Placebo (DRUG),2563,Lodosin,Idiopathic Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4973,NCT00174239,Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.,TERMINATED,PHASE4,Parkinson Disease,cabergoline (DRUG); controlled-release levodopa / carbidopa (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4974,NCT02763839,Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg),COMPLETED,PHASE1,Parkinson's Disease,BIA 3-202 (DRUG); Placebo (DRUG); Sinemet 25/100 (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4975,NCT01096186,An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease,COMPLETED,PHASE3,Parkinson's Disease,IPX066 95 mg (DRUG); IPX066 145 mg (DRUG); IPX066 195 mg (DRUG); IPX066 245 mg (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4976,NCT02615873,A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004,UNKNOWN,PHASE3,Parkinson's Disease,Accordion Pill™ Carbidopa/Levodopa (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4977,NCT00888186,Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics,COMPLETED,PHASE4,Parkinson Disease; Dyskinesias,levodopa/carbidopa (DRUG),2563,Lodosin,Parkinson Disease; Dyskinesias,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4978,NCT04244058,Changes in Glutamatergic Neurotransmission of Severe TBI Patients,SUSPENDED,EARLY_PHASE1,Disorder of Consciousness; Traumatic Brain Injury,Amantadine + L-DOPA (DRUG); NMDA blocker (DRUG),2563,Lodosin,Disorder of Consciousness; Traumatic Brain Injury,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4979,NCT02346630,Combining Robotic-Assisted Therapy and Pharmacotherapy in Post-Stroke Rehabilitation,WITHDRAWN,PHASE4,Stroke,Placebo (DRUG); Levodopa / Carbidopa (DRUG); Armeo (DEVICE),2563,Lodosin,Stroke,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4980,NCT00406029,Dyskinesia in Parkinson's Disease (Study P04501),COMPLETED,PHASE2,Parkinson Disease; Movement Disorders; Central Nervous System Diseases; Neurodegenerative Diseases; Brain Diseases,Preladenant (DRUG); Preladenant (DRUG); Preladenant (DRUG); Preladenant (DRUG); Placebo (DRUG); L-dopa (DRUG); Other Parkinson's Disease treatments (DRUG),2563,Lodosin,Parkinson Disease; Movement Disorders; Central Nervous System Diseases; Neurodegenerative Diseases; Brain Diseases,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4981,NCT00566462,Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT,TERMINATED,PHASE2,Parkinson's Disease,perampanel (DRUG); placebo (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4982,NCT00869791,A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa,COMPLETED,PHASE2,Parkinson's Disease,IPX066 (DRUG); IR CD-LD (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4983,NCT04952194,Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease,UNKNOWN,PHASE4,Parkinson Disease,Stalevo (DRUG); Carbidopa and Levodopa Controlled Release Tablets (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4984,NCT05885360,Istradefylline Effect Protocol on Parkinson's Disease Tremor,COMPLETED,PHASE4,Parkinson Disease; Tremor,Istradefylline Pill (DRUG),2563,Lodosin,Parkinson Disease; Tremor,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4985,NCT02812394,A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets,COMPLETED,PHASE1,Parkinson Disease,CVT-301 (Dose Level 1) (DRUG); CVT-301 (Dose Level 2) (DRUG); Sinemet® (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4986,NCT00086294,ACP-103 to Treat Parkinson's Disease,COMPLETED,PHASE2,Parkinson's Disease; Dyskinesias,Intravenous Levodopa (DRUG); ACP-103 (DRUG),2563,Lodosin,Parkinson's Disease; Dyskinesias,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4987,NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",COMPLETED,PHASE3,Advanced Parkinson's Disease,Levodopa carbidopa intestinal gel (LCIG) (DRUG); Placebo gel (DRUG); Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets (DRUG); Placebo (PBO) oral capsules (DRUG); CADD-Legacy® 1400 ambulatory infusion pump (DEVICE); PEG tube (DEVICE); J-tube (DEVICE),2563,Lodosin,Advanced Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4988,NCT00456794,"12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa",COMPLETED,PHASE2,Parkinson's Disease,Istradefylline (KW-6002) (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4989,NCT00139880,"A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease",COMPLETED,PHASE3,Parkinson's Disease,Parcopa (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4990,NCT01533116,Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide,COMPLETED,PHASE1,Parkinson Disease,BIA 9-1067 (DRUG); Placebo (DRUG); levodopa/carbidopa (DRUG); levodopa/benserazide (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4991,NCT00456586,"12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa",COMPLETED,PHASE2,Parkinson's Disease,KW-6002 (istradefylline) (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4992,NCT02726386,A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease,ACTIVE_NOT_RECRUITING,PHASE2,Parkinson's Disease,ND0612 (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4993,NCT04591535,PK Study of WD-1603 in Healthy Subjects,UNKNOWN,PHASE1,Parkinson Disease,WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4994,NCT01617135,"Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and ""Off"" Episodes",COMPLETED,PHASE2,Idiopathic Parkinson's Disease,CVT-301 (DRUG); Placebo (DRUG); Sinemet (carbidopa/levodopa) (DRUG); CVT-301 (DRUG),2563,Lodosin,Idiopathic Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4995,NCT01766258,Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations,COMPLETED,PHASE2,Parkinson's Disease,ODM-101 65mg Carbidopa (DRUG); ODM-101 105mg Carbidopa (DRUG); Stalevo (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4996,NCT04006210,"Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations",ACTIVE_NOT_RECRUITING,PHASE3,Parkinson's Disease,ND0612 Solution for SC infusion (COMBINATION_PRODUCT); Placebo for SC infusion (COMBINATION_PRODUCT); Oral IR-LD/CD (DRUG); Placebo for Oral IR-LD/CD (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4997,NCT04249544,Social Decision Making in Parkinson's Disease,COMPLETED,PHASE1,Parkinson Disease,Pramipexole (DRUG); Placebo (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4998,NCT04513340,WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects,UNKNOWN,PHASE1,Parkinson Disease,WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +4999,NCT00125567,Stalevo in Early Wearing-Off Patients,COMPLETED,PHASE4,Idiopathic Parkinson's Disease,Stalevo (levodopa/carbidopa/entacapone) (DRUG); Levodopa/carbidopa (DRUG),2563,Lodosin,Idiopathic Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5000,NCT02096601,"A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients",COMPLETED,PHASE1,Parkinson's Disease,LD/CD SC solution (DRUG); Entacapone (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5001,NCT02549092,A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD),COMPLETED,PHASE3,Advanced Parkinson's Disease,Optimized Medical Treatment (DRUG); Levodopa-Carbidopa Intestinal Gel (DRUG); Nasojejunal (NJ) tube (DEVICE); Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube (DEVICE),2563,Lodosin,Advanced Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5002,NCT03266965,Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach,COMPLETED,PHASE1,Multiple Sclerosis,Carbidopa (DRUG); L-Histidine (DIETARY_SUPPLEMENT),2563,Lodosin,Multiple Sclerosis,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5003,NCT05036473,A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease,UNKNOWN,PHASE2,Parkinson Disease,WD-1603 Carbidopa-Levodopa Extended-Release Tablets (DRUG); Placebo (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5004,NCT06113640,Montelukast in Parkinson Disease,RECRUITING,PHASE2,Parkinson Disease,levodopa-carbidopa (DRUG); Montelukast (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5005,NCT03000569,A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease,COMPLETED,PHASE2,Parkinson Disease,SAGE-217 (DRUG); Levodopa (DRUG); Antiparkinsonian Agent(s) (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5006,NCT02696512,A Study of IBRF Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Severe Disorders of Consciousness,UNKNOWN,PHASE1,Brain Injury,Polypharmacy using FDA-approved products (DRUG); Median Nerve Stimulation (MNS) (DEVICE); Nutraceutical Supplementation (DIETARY_SUPPLEMENT); Standard of Care (OTHER),2563,Lodosin,Traumatic Brain Injury,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5007,NCT03781167,A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD),COMPLETED,PHASE3,Parkinson's Disease (PD),ABBV-951 (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5008,NCT03575195,Microbiota Intervention to Change the Response of Parkinson's Disease,SUSPENDED,PHASE1,Parkinson Disease,Rifaximin (DRUG); Placebo (OTHER),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5009,NCT00099268,Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy,COMPLETED,PHASE3,Parkinson's Disease,Carbidopa/levodopa/entacapone (DRUG); Immediate release carbidopa/levodopa (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5010,NCT06765668,A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease,RECRUITING,PHASE4,Parkinson Disease,CREXONT ER (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5011,NCT00360568,Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects,COMPLETED,PHASE3,Dyskinesias; Parkinson's Disease; Severe Motor Fluctuations,Levodopa-carbidopa intestinal gel (DRUG); CADD-Legacy® 1400 ambulatory infusion pump (DEVICE); PEG tube (DEVICE); J-tube (DEVICE),2563,Lodosin,Dyskinesias; Parkinson's Disease; Severe Motor Fluctuations,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5012,NCT03929068,Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis,COMPLETED,PHASE1,Amyotrophic Lateral Sclerosis; Motor Neuron Disease,carbidopa-levodopa (DRUG); Placebo Oral Tablet (DRUG),2563,Lodosin,Amyotrophic Lateral Sclerosis; Motor Neuron Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5013,NCT03735901,Enhancement of Stroke Rehabilitation With Levodopa,ACTIVE_NOT_RECRUITING,PHASE3,Acute Stroke; Stroke Rehabilitation,IMP Levodopa 100mg/Carbidopa 25mg (DRUG); Matching placebo (DRUG),2563,Lodosin,Acute Stroke; Stroke Rehabilitation,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5014,NCT05204641,Effect of Fecal Microbiota Transfer on Progression of Parkinson Disease,COMPLETED,PHASE2,Parkinson Disease,Fecal Microbiota Transfer provided by Human Biome Institute (BIOLOGICAL),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5015,NCT02605434,A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients,UNKNOWN,PHASE3,Parkinson's Disease,Accordion Pill™ Carbidopa/Levodopa (DRUG); Sinemet® (DRUG); Placebo -AP-CD/LD (DRUG); Placebo- Sinemet (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5016,NCT00537017,Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175),COMPLETED,PHASE2,Parkinson Disease; Neurodegenerative Diseases; Central Nervous System Diseases; Movement Disorders; Brain Diseases,Preladenant (DRUG); L-dopa (DRUG); Other Parkinson's Disease treatments (DRUG),2563,Lodosin,Parkinson Disease; Neurodegenerative Diseases; Central Nervous System Diseases; Movement Disorders; Brain Diseases,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5017,NCT03374917,A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment,COMPLETED,PHASE1,Parkinson's Disease (PD),ABBV-951 (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5018,NCT00203034,Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations,COMPLETED,PHASE3,Parkinson's Disease,rasagiline mesylate (DRUG); 1.0 mg rasagiline mesylate (DRUG); Placebo (OTHER),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5019,NCT05103618,Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA,NOT_YET_RECRUITING,PHASE2,Parkinson Disease; Idiopathic Parkinson Disease,[F-18] Fluorodopa Positron Emission Tomography (DRUG); OM Meditation (BEHAVIORAL),2563,Lodosin,Parkinson Disease; Idiopathic Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5020,NCT02554734,Pharmacokinetic Study in Healthy Volunteers,COMPLETED,PHASE1,Parkinson's Disease,"levodopa, carbidopa, ODM-104 (DRUG); levodopa, carbidopa, entacapone (DRUG)",2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5021,NCT01568034,A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067,COMPLETED,PHASE2,Parkinson's Disease,BIA 9-1067 (DRUG); BIA 9-1067 (DRUG); BIA 9-1067 (DRUG); Placebo (DRUG); Levodopa/Carbidopa (DRUG); Levodopa/Benzerazide (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5022,NCT01646255,"Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients",COMPLETED,PHASE3,Idiopathic Parkinson's Disease,Rotigotine (DRUG); Placebo Patch (DRUG); L-dopa (DRUG),2563,Lodosin,Idiopathic Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5023,NCT02169414,Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics,COMPLETED,PHASE1,Parkinson's Disease (PD),BIA 9-1067 5 mg (DRUG); BIA 9-1067 25 mg (DRUG); levodopa/carbidopa 100/25 (DRUG); Placebo (DRUG); levodopa/benserazide 100/25 mg (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5024,NCT02799381,A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER),COMPLETED,PHASE3,Parkinson's Disease (PD),Optimized antiparkinsonian treatment (DRUG); Levodopa-Carbidopa Intestinal Gel (LCIG) (DRUG); CADD-Legacy ambulatory infusion pump (DEVICE); Percutaneous endoscopic gastrostomy tube (DEVICE); Jejunal extension tube (DEVICE),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5025,NCT01515410,Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations,COMPLETED,PHASE2,Parkinson's Disease; Motor Fluctuations,DM-1992 (DRUG); Sinemet IR (DRUG),2563,Lodosin,Parkinson's Disease; Motor Fluctuations,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5026,NCT03576638,Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients,UNKNOWN,PHASE2,Parkinson Disease,Accordion Pill Carbidopa/Levodopa (DRUG); Sinemet CR 25Mg-100Mg Extended-Release Tablet (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5027,NCT02604914,"A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects",COMPLETED,PHASE1,Parkinson's Disease,ND0612 (DRUG); LCIG (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5028,NCT01227655,Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.,COMPLETED,PHASE3,Parkinson's Disease,BIA 9-1067 (DRUG); Placebo (DRUG); Levodopa (DRUG); Carbidopa (DRUG); Benserazide (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5029,NCT05094050,Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease,COMPLETED,PHASE1,Parkinson's Disease,ABBV-951 (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5030,NCT02782481,"A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations",WITHDRAWN,PHASE3,Parkinson's Disease,ND0612 (DRUG); Placebo (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5031,NCT02448914,"A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients",COMPLETED,PHASE1,Parkinson's Disease,TRIGEL (DRUG); Duodopa (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5032,NCT02339064,Infusion of Apomorphine: Long-term Safety Study,ACTIVE_NOT_RECRUITING,PHASE3,Idiopathic Parkinson's Disease,apomorphine infusion (DRUG),2563,Lodosin,Idiopathic Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5033,NCT00239564,Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease,COMPLETED,PHASE1,Idiopathic Parkinson's Disease,IPX054 100 mg (DRUG); IPX054 150 mg (DRUG); IPX054 200 mg (DRUG); IPX054 250 mg (DRUG); IPX054 300 mg (DRUG),2563,Lodosin,Idiopathic Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5034,NCT02774564,Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa,COMPLETED,PHASE1,Parkinson's Disease,BIA 3-202 (DRUG); Placebo (DRUG); Sinemet® (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5035,NCT01296464,Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens,COMPLETED,PHASE2,Parkinson's Disease,Carbidopa (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5036,NCT02577523,"A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease",COMPLETED,PHASE2,Parkinson's Disease,ND0612 (Levodopa/Carbidopa solution) (DRUG); ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5037,NCT04147949,AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia,UNKNOWN,PHASE2,"Parkinson Disease; Dyskinesia, Medication-Induced; L-Dopa Causing Adverse Effects in Therapeutic Use",AV-101 (DRUG); Placebo (DRUG),2563,Lodosin,"Parkinson Disease; Dyskinesia, Medication-Induced; L-Dopa Causing Adverse Effects in Therapeutic Use",CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5038,NCT03419806,Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's Disease,COMPLETED,PHASE1,Parkinson Disease,Infudopa i.v. (DRUG); Infudopa s.c. (DRUG); LCIG (Duodopa) (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5039,NCT02082249,"An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications",COMPLETED,PHASE3,Advanced Parkinson's Disease,ABT-SLV187 (DRUG),2563,Lodosin,Advanced Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5040,NCT03103399,"Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With ""Wearingoff"" Phenomenon",COMPLETED,PHASE2,Parkinson Disease,Comtan® (DRUG); Nebicapone (DRUG); Levodopa/DDCI (DRUG); Placebo (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5041,NCT00253084,Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease,COMPLETED,PHASE2,Parkinson's Disease,IPX054 200 mg (DRUG); CD-LD IR (DRUG); IPX054 Placebo (DRUG); CD-LD IR Placebo (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5042,NCT01519284,Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic,COMPLETED,PHASE1,Parkinson Disease,BIA 9-1067 5 mg (DRUG); Entacapone (DRUG); Placebo (DRUG); levodopa/carbidopa (DRUG); BIA 9-1067 15 mg (DRUG); BIA 9-1067 30 mg (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5043,NCT00914602,An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects,COMPLETED,PHASE1,Parkinson's Disease,Sinemet 25-100 Oral Tablet (DRUG); XP21279 (DRUG); Carbidopa Pill (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5044,NCT01725802,"A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients",COMPLETED,PHASE1,Parkinson's Disease,Levodopa/carbidopa solution for SC administration (DRUG); Placebo (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5045,NCT04990284,eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.,COMPLETED,PHASE4,Parkinson Disease,Opicapone (DRUG); L-DOPA/DDCI (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5046,NCT00203164,Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients,COMPLETED,PHASE3,Parkinson's Disease,rasagiline mesylate (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5047,NCT00219284,Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease,COMPLETED,PHASE4,Parkinson's Disease With End of Dose Wearing Off,Carbidopa/levodopa/entacapone (DRUG),2563,Lodosin,Parkinson's Disease With End of Dose Wearing Off,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5048,NCT02169479,Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa,COMPLETED,PHASE1,Parkinson's Disease (PD),BIA 9-1067 (DRUG); Placebo (DRUG); Sinemet® 100/25 (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5049,NCT03887884,Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder),COMPLETED,PHASE1,Parkinson's Disease,CVT-301 (DRUG); Sinemet (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5050,NCT02480803,INfusion VErsus STimulation in Parkinson's Disease,COMPLETED,PHASE4,Parkinson's Disease,Continuous intrajejunal infusion of levodopa-carbidopa (DRUG); deep brain stimulation (DEVICE),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5051,NCT06115538,Comparison of Dopamin Level in Idiopathic Parkinson's Patients,ENROLLING_BY_INVITATION,PHASE4,Parkinson Disease; Treatment Adherence,Levodopa (OTHER),2563,Lodosin,Parkinson Disease; Treatment Adherence,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5052,NCT02225548,Sagene 2014 - Parkinson's Disease and Erectile Dysfunction,UNKNOWN,PHASE4,Parkinson's Disease; Erectile Dysfunction,Selegiline (DRUG); Tadalafil (DRUG),2563,Lodosin,Parkinson's Disease; Erectile Dysfunction,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5053,NCT02807675,A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder),COMPLETED,PHASE1,Parkinson's Disease,"CVT-301, LIP (DRUG); Placebo (OTHER)",2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5054,NCT00640159,Selegiline to Zelapar Switch Study in Parkinson Disease Patients,COMPLETED,PHASE4,Parkinson's Disease,Zelapar (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5055,NCT06587217,Neurobiological Drivers of Mobility Resilience: the Dopaminergic System - Supplemental Open-Label Arm,RECRUITING,PHASE1,Parkinsonian Signs in Older Persons,Carbidopa 25 mg (DRUG); Carbidopa-Levodopa 25/100 mg (DRUG),2563,Lodosin,Parkinsonian Signs in Older Persons,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5056,NCT00141518,Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact,COMPLETED,PHASE4,Advanced Idiopathic Parkinson's Disease,Levodopa-carbidopa intestinal gel (LCIG) (DRUG); CADD-Legacy® 1400 ambulatory infusion pump (DEVICE); percutaneous endoscopic gastrostomy tube (PEG tube) (DEVICE); jejunal extension tube (J-tube) (DEVICE),2563,Lodosin,Advanced Idiopathic Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5057,NCT05128175,Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions,UNKNOWN,PHASE1,Parkinson Disease,WD-1603 Carbidopa-Levodopa Extended-Release Tablets (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5058,NCT02386475,Effect of Serotonin and Levodopa in Ischemic Stroke,COMPLETED,PHASE4,Stroke,placebo (OTHER); citalopram (DRUG); sinemet plus (DRUG),2563,Lodosin,Stroke,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5059,NCT02312232,Pharmacokinetic Study in Healthy Males,COMPLETED,PHASE1,Parkinson's Disease,"levodopa, carbidopa, ODM-104 (DRUG)",2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5060,NCT06831500,Feasibility Study Assessing the Effect of Carbidopa/levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.,NOT_YET_RECRUITING,PHASE1,"Multi-system Atrophy - Parkinsonian Type; Orthostatic Hypotension, Dysautonomic; Parkinson Disease",Administration of Carbidopa/levodopa (DRUG),2563,Lodosin,"Multi-system Atrophy - Parkinsonian Type; Orthostatic Hypotension, Dysautonomic; Parkinson Disease",CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5061,NCT03496870,"A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.",COMPLETED,PHASE1,Parkinson Disease,Opicapone (DRUG); Carbidopa Levodopa (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5062,NCT01960842,"A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications",COMPLETED,PHASE3,Advanced Parkinson's Disease,Levodopa-carbidopa intestinal gel (DRUG); CADD-Legacy® 1400 ambulatory infusion pump (DEVICE); PEG tube (DEVICE); J-tube (DEVICE),2563,Lodosin,Advanced Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5063,NCT04380142,Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease,COMPLETED,PHASE3,Parkinson's Disease (PD),ABBV-951 (DRUG); Placebo for Levodopa/Carbidopa (LD/CD) (DRUG); Levodopa/Carbidopa (LD/CD) (DRUG); Placebo for ABBV-951 (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5064,NCT01171313,"A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects",COMPLETED,PHASE2,Parkinson's Disease,XP21279 and carbidopa (experimental) (DRUG); Sinemet (comparator) (DRUG); Placebo for XP21279 and carbidopa (DRUG); Placebo for Sinemet (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5065,NCT00845000,Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550),COMPLETED,PHASE1,Parkinson Disease,SCH 420814 10 mg (DRUG); SCH 420814 100 mg (DRUG); Placebo (DRUG); Levodopa (DRUG); Carbidopa (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5066,NCT02486432,A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa),COMPLETED,PHASE1,Parkinson's Disease,Levodopa/Carbidopa (Sinemet) (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5067,NCT03111485,Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease,COMPLETED,PHASE4,Parkinson's Disease; Obstructive Sleep Apnea,Sinemet CR (DRUG); Placebo oral capsule (DRUG),2563,Lodosin,Parkinson's Disease; Obstructive Sleep Apnea,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5068,NCT03541356,Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal,COMPLETED,PHASE2,Parkinson's Disease,Placebo (COMBINATION_PRODUCT); L-dopa 35 mg (COMBINATION_PRODUCT); L-dopa 70mg (COMBINATION_PRODUCT); L-dopa 140 mg (COMBINATION_PRODUCT); L-dopa 70mg/carbidopa 7mg (COMBINATION_PRODUCT),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5069,NCT01291537,Clinical and Economic Impact of Duodopa: Long-term Effectiveness Study in Advanced Parkinson's Disease Patients,COMPLETED,PHASE2,Parkinson's Disease,Duodopa (DRUG); best médical treatment (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5070,NCT00947037,"Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension Study",WITHDRAWN,PHASE2,Parkinson's Disease,AP-CD/LD (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5071,NCT01411137,Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study,COMPLETED,PHASE3,Parkinson's Disease,IPX066 (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5072,NCT03140956,Pharmacokinetic of Levodopa Study in Healthy Males,COMPLETED,PHASE1,Parkinson Disease,"Levodopa, carbidopa, ODM-104 (DRUG)",2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5073,NCT00642356,Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off,TERMINATED,PHASE4,Parkinson's Disease,Carbidopa/levodopa/entacapone (DRUG); Immediate release carbidopa/levodopa (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5074,NCT06013956,Personalized Real-Time DBS and PD Mechanisms,RECRUITING,PHASE4,Parkinson Disease,Neurostimulation (DEVICE); Carbidopa 25/Levodopa 100Mg Tab (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5075,NCT05471609,Sustained Release Oral Formulation for Treatment of Parkinson's Disease,SUSPENDED,EARLY_PHASE1,Idiopathic Parkinson Disease,levodopa/carbidopa oral formulation A (DRUG); levodopa/carbidopa oral formulation B (DRUG); levodopa/carbidopa oral formulation C (DRUG),2563,Lodosin,Idiopathic Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5076,NCT02812147,"Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease",UNKNOWN,PHASE2,Parkinson Disease,L-DOPS (DRUG); Placebo (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5077,NCT01568047,Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients,COMPLETED,PHASE2,Parkinson's Disease,Placebo (DRUG); BIA 9-1067 (DRUG); BIA 9-1067 (DRUG); BIA 9-1067 (DRUG); Levodopa/Carbidopa (DRUG); Levodopa/Benzerazide (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5078,NCT00200447,An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN),COMPLETED,PHASE2,Parkinson's Disease,carbidopa/l-dopa (DRUG); carbidopa/l-dopa/entacapone (DRUG); Stalevo (DRUG); [123I]-IBZM imaging (PROCEDURE),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5079,NCT03665454,PF 06412562 in Subjects With Advanced Stage Parkinson's Disease,COMPLETED,PHASE1,Parkinson Disease,PF-06412562 (DRUG); Standard of Care Placebo (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5080,NCT05369533,Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke,COMPLETED,PHASE1,Stroke,Telerehabilitation (DEVICE); Sinemet Pill (DRUG); Placebo (DRUG),2563,Lodosin,Stroke,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5081,NCT00203177,Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.,COMPLETED,PHASE3,Parkinson's Disease,rasagiline mesylate (DRUG); rasagiline mesylate 1.0 mg (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5082,NCT00918177,An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's Disease,COMPLETED,PHASE2,Parkinson's Disease,"AP09004 (DRUG); Carbidopa/Levodopa, immediate release (DRUG)",2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5083,NCT06614153,"Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations",COMPLETED,PHASE2,Parkinson's Disease,HRG2010(I) (DRUG); HRG2010(II) (DRUG); Sustained-release Carbidopa/Levodopa (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5084,NCT00335153,Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease,COMPLETED,PHASE3,Advanced Parkinson's Disease,Levodopa-carbidopa intestinal gel (DRUG); CADD-Legacy® 1400 ambulatory infusion pump (DEVICE); PEG tube (DEVICE); J-tube (DEVICE),2563,Lodosin,Advanced Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5085,NCT03670953,A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations,COMPLETED,PHASE3,Parkinson's Disease (Disorder),IR CD-LD (DRUG); IPX203 ER CD-LD (DRUG); Placebo Matching IPX203 (OTHER); Placebo Matching IR CD-LD (OTHER),2563,Lodosin,Parkinson's Disease (Disorder),CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5086,NCT01429077,Augmenting Language Therapy for Aphasia: Levodopa,COMPLETED,PHASE2,Nonfluent Aphasia; Stroke,levodopa/carbidopa (DRUG); Placebo comparator (DRUG),2563,Lodosin,Nonfluent Aphasia; Stroke,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5087,NCT02169453,Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa,COMPLETED,PHASE1,Parkinson's Disease (PD),BIA 9-1067 (DRUG); Placebo (DRUG); Sinemet® CR 100/25 (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5088,NCT01229332,"A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients",COMPLETED,PHASE1,Parkinson's Disease,Saline (DRUG); Carbidopa (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5089,NCT04246437,[18F]F-DOPA Imaging in Patients with Autonomic Failure,RECRUITING,PHASE1,Autonomic Failure; Pure Autonomic Failure; Parkinson Disease; Multiple System Atrophy; Dementia with Lewy Bodies,[18F]FDOPA (DRUG); Carbidopa 200mg oral dose (DRUG); Entacapone 400mg oral dose (DRUG),2563,Lodosin,Autonomic Failure; Pure Autonomic Failure; Parkinson Disease; Multiple System Atrophy; Dementia with Lewy Bodies,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5090,NCT06219915,Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm,COMPLETED,PHASE1,Parkinsonian Signs in Older Persons,Carbidopa 25 mg (DRUG); Carbidopa-Levodopa 25/100 mg (DRUG); Placebo 1 (DRUG); Placebo 2 (DRUG),2563,Lodosin,Parkinsonian Signs in Older Persons,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5091,NCT00558337,"Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease",COMPLETED,PHASE2,Parkinson's Disease,levodopa-carbidopa (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5092,NCT02763137,Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian Patients,COMPLETED,PHASE2,Parkinson Disease,Standard LD/CD (DRUG); Semi continuous intra-oral administration of LD/CD (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5093,NCT03205956,Measuring Parkinson's Disease Progression,COMPLETED,PHASE1,Parkinson's Disease,Levodopa (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5094,NCT00199407,A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa,COMPLETED,PHASE3,Parkinson's Disease,Istradefylline (KW-6002) (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5095,NCT00272688,Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit,COMPLETED,PHASE4,Parkinson Disease,"Levodopa (drug), intraduodenal administration (DRUG)",2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5096,NCT02633007,A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma,COMPLETED,PHASE1,Asthma,CVT-301 (levodopa inhalation powder) (DRUG); Carbidopa (DRUG); Placebo (OTHER),2563,Lodosin,Asthma,Lung,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5097,NCT03007888,A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease,COMPLETED,PHASE2,Advanced Parkinson's Disease,Sinemet (DRUG); IPX203 (DRUG),2563,Lodosin,Advanced Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5098,NCT02834507,"Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients",COMPLETED,PHASE2,Parkinson's Disease (PD),Placebo (DRUG); BIA 3-202 (DRUG); Comtan® (DRUG); Sinemet® (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5099,NCT00547911,Augmenting Effects of L-DOPS With Carbidopa and Entacapone,TERMINATED,PHASE1,Parkinson Disease; Multiple System Atrophy; Autonomic Nervous System Diseases,Droxidopa (DRUG); Carbidopa (DRUG); Entacapone (DRUG),2563,Lodosin,Parkinson Disease; Multiple System Atrophy; Autonomic Nervous System Diseases,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5100,NCT04928287,"Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)",COMPLETED,PHASE2,Parkinson Disease,HB-adMSCs (BIOLOGICAL); Placebo (OTHER),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5101,NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",COMPLETED,PHASE3,Advanced Parkinson's Disease,Levodopa carbidopa intestinal gel (LCIG) (DRUG); Placebo Gel (DRUG); Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets (DRUG); Placebo (PBO) oral capsules (DRUG); CADD-Legacy® 1400 ambulatory infusion pump (DEVICE); PEG tube (DEVICE); J-tube (DEVICE),2563,Lodosin,Advanced Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5102,NCT01486628,Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers,COMPLETED,PHASE1,Parkinson's Disease,ND0612 (DRUG); Placebo (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5103,NCT00601978,Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off,WITHDRAWN,PHASE4,Parkinson's Disease,carbidopa/levodopa (DRUG); Carbidopa/Levodopa/Entacapone (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5104,NCT04553978,"A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions",UNKNOWN,PHASE1,Parkinson Disease,WD-1603 (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5105,NCT04764383,Histaminergic Basis of Fatigue in Multiple Sclerosis,WITHDRAWN,PHASE2,Multiple Sclerosis,L-Histidine (DRUG); Placebo (DRUG); Lodosyn (DRUG),2563,Lodosin,Multiple Sclerosis,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5106,NCT01070628,Levodopa Concentration Profile With Stalevo 75/125 mg,COMPLETED,PHASE1,Parkinson's Disease,Stalevo (levodopa/ carbidopa/ entacapone) (DRUG); Sinemet (levodopa/carbidopa) (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5107,NCT05781711,Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease,RECRUITING,PHASE2,Parkinson Disease,levodopa-carbidopa (DRUG); Metformin (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5108,NCT01103011,"Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611",COMPLETED,PHASE1,Parkinson's Disease,ND0611 (DRUG); ND0611 (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5109,NCT00906828,Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors,COMPLETED,PHASE4,Parkinson Disease,levodopa/carbidopa (DRUG); entacapone (DRUG); tolcapone (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5110,NCT01026428,A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics,COMPLETED,PHASE1,Idiopathic Parkinson's Disease,Safinamide + Levodopa (DRUG); Placebo + Levodopa (OTHER),2563,Lodosin,Idiopathic Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5111,NCT01770145,Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT),COMPLETED,PHASE4,Parkinson's Disease; Motor Symptoms; Akinesia; Hypomobility; Delayed Levodopa Onset,APOKYN (DRUG); L-dopa (DRUG); Trimethobenzamide (DRUG),2563,Lodosin,Parkinson's Disease; Motor Symptoms; Akinesia; Hypomobility; Delayed Levodopa Onset,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5112,NCT00955045,"A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy",COMPLETED,PHASE2,Parkinson's Disease,istradefylline (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5113,NCT01533077,Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa,COMPLETED,PHASE1,Parkinson Disease,BIA 9-1067 (DRUG); Sinemet® 100/25 mg (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5114,NCT00507715,Study of the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk,COMPLETED,PHASE1,"Parkinson's Disease, Idiopathic",Plantago ovata husk (DRUG); hemicellulose crystalline (OTHER),2563,Lodosin,"Parkinson's Disease, Idiopathic",CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5115,NCT06612593,Cilostazol in Parkinson's Disease,NOT_YET_RECRUITING,PHASE2,Parkinson's Disease,Cilostazol (DRUG); Placebo (DRUG); Standard treatment (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5116,NCT05962957,Role of Pentoxifylline and Celecoxib in Parkinsonism,RECRUITING,PHASE2,Parkinson Disease,carbidopa-levodopa (DRUG); Pentoxifylline 400 MG (DRUG); Celecoxib 200mg (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5117,NCT01130493,A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066,COMPLETED,PHASE3,Parkinson's Disease,IPX066 (DRUG); CLE (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5118,NCT00432393,Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy,COMPLETED,PHASE4,Nonarteritic Anterior Ischemic Optic Neuropathy,levodopa-carbidopa (DRUG),2563,Lodosin,Nonarteritic Anterior Ischemic Optic Neuropathy,Peripheral Nervous System,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5119,NCT06785298,Fexofenadine As Adjuvant Therapy in Parkinson Disease,RECRUITING,PHASE2,Parkinson Disease,Levodopa/carbidopa (DRUG); Fexofenadine (DRUG),2563,Lodosin,Parkinson Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5120,NCT00491998,"PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets",COMPLETED,PHASE1,Parkinson's Disease,V1512 (DRUG); V1512 (DRUG); V1512 and Entacapone (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5121,NCT00391898,Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off,COMPLETED,PHASE4,Parkinson's Disease,Levodopa/carbidopa/entacapone (DRUG); Levodopa/carbidopa (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5122,NCT01883505,"A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612",COMPLETED,PHASE2,Parkinson's Disease,Levodopa and carbidopa (DRUG); Placebo (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5123,NCT01399905,High and Low Dose Carbidopa Treatment of Parkinson's Disease,COMPLETED,PHASE2,Parkinson's Disease,carbidopa (DRUG),2563,Lodosin,Parkinson's Disease,CNS/Brain,Carbidopa (monohydrate),AHR,inhibitor/antagonist,unclear,yes,yes,Used in combination with levodopa for Parkinson's treatment.,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,1.0434782608695652,396.0 +5124,NCT03383679,Study on Androgen Receptor and Triple Negative Breast Cancer,COMPLETED,PHASE2,Breast Cancer Female; Triple Negative and Androgen Receptor Positive,Darolutamide (DRUG); Capecitabine (DRUG),67171867,Nubeqa,Breast Cancer Female; Triple Negative and Androgen Receptor Positive,Breast,Darolutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved for treating non-metastatic castration-resistant prostate cancer.,CC(CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O,1.3,2187.0 +5125,NCT03004534,A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide,COMPLETED,EARLY_PHASE1,Breast Cancer Female,darolutamide (DRUG),67171867,Nubeqa,Breast Cancer Female,Breast,Darolutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved for treating non-metastatic castration-resistant prostate cancer.,CC(CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O,1.3,2187.0 +5126,NCT02894385,"Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)",COMPLETED,PHASE1,Pharmacokinetics; Hepatic Insufficiency; Renal Insufficiency,BAY1841788 (DRUG),67171867,Nubeqa,Pharmacokinetics; Hepatic Insufficiency; Renal Insufficiency,Liver,Darolutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved for treating non-metastatic castration-resistant prostate cancer.,CC(CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O,1.3,2187.0 +5127,NCT03568656,Study to Evaluate CCS1477 in Advanced Tumours,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Castration-Resistant Prostate Cancer; Metastatic Breast Cancer; Non-small Cell Lung Cancer; Advanced Solid Tumors,CCS1477 (DRUG); Abiraterone acetate (DRUG); Enzalutamide (DRUG); Darolutamide (DRUG); Olaparib (DRUG); Atezolizumab (DRUG),67171867,Nubeqa,Metastatic Castration-Resistant Prostate Cancer; Metastatic Breast Cancer; Non-small Cell Lung Cancer; Advanced Solid Tumors,Breast,Darolutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved for treating non-metastatic castration-resistant prostate cancer.,CC(CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O,1.3,2187.0 +5128,NCT06727357,"Next Generation Sequencing-based ""Oncochip"" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP",ACTIVE_NOT_RECRUITING,PHASE2,"Breast Cancer, Metastatic Breast Cancer",Chemotherapy (DRUG),2375,Bical,"Breast Cancer, Metastatic Breast Cancer",Breast,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5129,NCT03090165,Ribociclib and Bicalutamide in AR+ TNBC,RECRUITING,PHASE1,Triple Negative Breast Cancer,ribociclib (DRUG); ribociclib (DRUG); Bicalutamide (DRUG),2375,Bical,Triple Negative Breast Cancer,Breast,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5130,NCT04573231,Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer,RECRUITING,PHASE2,Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer,18F-DCFPyL (DRUG),2375,Bical,Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer,Breast,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5131,NCT00012090,"Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum",COMPLETED,PHASE2,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,bicalutamide (DRUG); goserelin acetate (DRUG),2375,Bical,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5132,NCT03650894,"Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients",ACTIVE_NOT_RECRUITING,PHASE2,Breast Neoplasm Female; Breast Cancer; Breast Carcinoma; Breast Tumor,Nivolumab (DRUG); Ipilimumab (DRUG); Bicalutamide (DRUG),2375,Bical,Breast Neoplasm Female; Breast Cancer; Breast Carcinoma; Breast Tumor,Breast,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5133,NCT06018116,A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.,WITHDRAWN,PHASE2,Metastatic Urothelial Carcinoma,Bicalutamide 150 mg (DRUG); Placebo (DRUG),2375,Bical,Metastatic Urothelial Carcinoma,Bladder/Urinary Tract,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5134,NCT02605486,Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC),ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Breast Cancer (MBC),Palbociclib (DRUG); Bicalutamide (DRUG),2375,Bical,Metastatic Breast Cancer (MBC),Breast,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5135,NCT03055312,Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer,TERMINATED,PHASE3,Metastatic Triple Negative Breast Cancer,TPC (DRUG); Bicalutamide 150 mg (DRUG),2375,Bical,Metastatic Triple Negative Breast Cancer,Breast,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5136,NCT02348281,Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients,TERMINATED,PHASE2,Breast Cancer,Bicalutamide (DRUG),2375,Bical,Breast Cancer,Breast,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5137,NCT02910050,Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Bicalutamide (DRUG); Aromatase Inhibitor (DRUG),2375,Bical,Breast Cancer,Breast,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5138,NCT02299999,SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Cancer,AZD2014 (DRUG); AZD4547 (DRUG); AZD5363 (DRUG); AZD8931 (DRUG); Selumetinib (DRUG); Vandetanib (DRUG); Bicalutamide (DRUG); Olaparib (DRUG); Anthracyclines (DRUG); Taxanes (DRUG); cyclophosphamide (DRUG); DNA intercalators (DRUG); Methotrexate (DRUG); vinca alkaloids (DRUG); Platinum based chemotherapies (DRUG); Bevacizumab (DRUG); Mitomycin C (DRUG); Eribulin (DRUG); MEDI4736 (DRUG),2375,Bical,Metastatic Breast Cancer,Breast,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5139,NCT03458221,Signal TrAnsduction Pathway Activity Analysis in OVarian cancER,RECRUITING,PHASE2,Recurrent Ovarian Cancer; Signal Transduction Pathway Deregulation; Therapy-Associated Cancer,Letrozole Oral Product (DRUG); Bicalutamide Oral Product (DRUG); Everolimus Oral Product (DRUG); Itraconazole Oral Product (DRUG),2375,Bical,Recurrent Ovarian Cancer; Signal Transduction Pathway Deregulation; Therapy-Associated Cancer,Ovary/Fallopian Tube,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5140,NCT00468715,Bicalutamide in Treating Patients With Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,bicalutamide (DRUG); diagnostic laboratory biomarker analysis (OTHER); immunohistochemistry staining method (OTHER),2375,Bical,Breast Cancer,Breast,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5141,NCT05327647,A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer,RECRUITING,PHASE2,Non-Muscle Invasive Bladder Cancer,Bicalutamide (DRUG); Control Arm (BIOLOGICAL),2375,Bical,Non-Muscle Invasive Bladder Cancer,Bladder/Urinary Tract,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5142,NCT00866554,Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy,COMPLETED,PHASE2,Prostate Cancer; Erectile Dysfunction; Lower Urinary Tract Symptoms,"administration of a LHRH agonist and Bicalutamide (DRUG); administration of Bicalutamide, Dutasteride and Tamoxifen (DRUG)",2375,Bical,Prostate Cancer; Erectile Dysfunction; Lower Urinary Tract Symptoms,Bladder/Urinary Tract,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5143,NCT05095207,"Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer",RECRUITING,PHASE1,Breast Cancer; Metastasis,Abemaciclib (DRUG); Bicalutamide (DRUG),2375,Bical,Breast Cancer; Metastasis,Breast,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5144,NCT06365788,Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer,RECRUITING,PHASE2,Triple Negative Breast Neoplasms,Abemaciclib (DRUG); Bicalutamide (DRUG),2375,Bical,Triple Negative Breast Neoplasms,Breast,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5145,NCT02353988,AR-inhibitor Bicalutamide in Treating Patients With TNBC,UNKNOWN,PHASE2,Breast Neoplasms,Bicalutamide (DRUG); Physician's Choice (OTHER),2375,Bical,Breast Neoplasms,Breast,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5146,NCT04284761,A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer,COMPLETED,PHASE1,Prostate Adenocarcinoma; Lower Urinary Tract Symptoms,Bicalutamide implant (COMBINATION_PRODUCT),2375,Bical,Prostate Adenocarcinoma; Lower Urinary Tract Symptoms,Bladder/Urinary Tract,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5147,NCT06501911,A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma,NOT_YET_RECRUITING,PHASE1,Recurrent Glioblastoma; Recurrent High-grade Glioma,Bicalutamide (DRUG); Intensity-modulated radiation therapy (IMRT) (RADIATION),2375,Bical,Recurrent Glioblastoma; Recurrent High-grade Glioma,CNS/Brain,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5148,NCT02697032,FDHT PET and Bicalutamide in Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Bicalutamide (DRUG); FDHT PET (PROCEDURE),2375,Bical,Breast Cancer,Breast,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5149,NCT06222593,Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC,RECRUITING,PHASE1,"Carcinoma, Renal Cell",Bicalutamide in combination with Sunitinib (DRUG),2375,Bical,"Carcinoma, Renal Cell",Kidney,Bicalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Approved as antiandrogen for prostate cancer treatment.,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,1.11,237.0 +5150,NCT06541665,"Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL",RECRUITING,PHASE1,Primary Central Nervous System Lymphoma,ONO-4059 (DRUG); Rituximab (DRUG); Methotrexate (DRUG); Procarbazine (DRUG); Vincristine (DRUG),54755438,Velexbru,Primary Central Nervous System Lymphoma,CNS/Brain,Tirabrutinib,BTK,inhibitor/antagonist,Other TK inhibitor,no,yes,"In clinical trials, not approved for human use yet.",CC#CC(=O)N1CCC(C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N,1.0208333333333333,776.0 +5151,NCT04947319,Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study),RECRUITING,PHASE2,Refractory Primary Central Nervous System Lymphoma; Primary CNS Lymphoma,Tirabrutinib (DRUG); Tirabrutinib (DRUG); Tirabrutinib (DRUG),54755438,Velexbru,Refractory Primary Central Nervous System Lymphoma; Primary CNS Lymphoma,CNS/Brain,Tirabrutinib,BTK,inhibitor/antagonist,Other TK inhibitor,no,yes,"In clinical trials, not approved for human use yet.",CC#CC(=O)N1CCC(C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N,1.0208333333333333,776.0 +5152,NCT06541665,"Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL",RECRUITING,PHASE1,Primary Central Nervous System Lymphoma,ONO-4059 (DRUG); Rituximab (DRUG); Methotrexate (DRUG); Procarbazine (DRUG); Vincristine (DRUG),71571562,s8166,Primary Central Nervous System Lymphoma,CNS/Brain,Tirabrutinib (hydrochloride),BTK,inhibitor/antagonist,Other TK inhibitor,no,yes,Not approved in US/EU; used investigationally in some regions.,CC#CC(=O)N1CCC(C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N.Cl,1.0,196.0 +5153,NCT00505739,Mifepristone for Patients With Endometrial Cancer and LGESS,COMPLETED,PHASE2,Endometrial Cancer,Mifepristone (DRUG),55245,Korlym,Endometrial Cancer,Uterus,Mifepristone,"NR3C1, PGR",inhibitor/antagonist,unclear,yes,yes,Approved for medical abortion and Cushing's syndrome treatment.,CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,1.68,85.0 +5154,NCT02642939,Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer,TERMINATED,PHASE2,Non-Small Cell Lung Cancer (NSCLC),Mifepristone (DRUG),55245,Korlym,Non-Small Cell Lung Cancer (NSCLC),Lung,Mifepristone,"NR3C1, PGR",inhibitor/antagonist,unclear,yes,yes,Approved for medical abortion and Cushing's syndrome treatment.,CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,1.68,85.0 +5155,NCT01493310,Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer,COMPLETED,PHASE1,Male Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,mifepristone (DRUG); placebo (DRUG); nab-paclitaxel (DRUG),55245,Korlym,Male Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Breast,Mifepristone,"NR3C1, PGR",inhibitor/antagonist,unclear,yes,yes,Approved for medical abortion and Cushing's syndrome treatment.,CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,1.68,85.0 +5156,NCT03015701,S9005 Mifepristone in Meningioma,COMPLETED,PHASE3,Meningioma,Mifepristone (DRUG); Placebo (OTHER),55245,Korlym,Meningioma,CNS/Brain,Mifepristone,"NR3C1, PGR",inhibitor/antagonist,unclear,yes,yes,Approved for medical abortion and Cushing's syndrome treatment.,CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,1.68,85.0 +5157,NCT02788981,"Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Mifepristone (DRUG); Placebo (OTHER); Nab-Paclitaxel (DRUG),55245,Korlym,Breast Cancer,Breast,Mifepristone,"NR3C1, PGR",inhibitor/antagonist,unclear,yes,yes,Approved for medical abortion and Cushing's syndrome treatment.,CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,1.68,85.0 +5158,NCT02046421,"Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",COMPLETED,PHASE1,Male Breast Cancer; Recurrent Breast Cancer; Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,mifepristone (DRUG); carboplatin (DRUG); gemcitabine hydrochloride (DRUG); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),55245,Korlym,Male Breast Cancer; Recurrent Breast Cancer; Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Breast,Mifepristone,"NR3C1, PGR",inhibitor/antagonist,unclear,yes,yes,Approved for medical abortion and Cushing's syndrome treatment.,CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,1.68,85.0 +5159,NCT03225547,Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Triple Negative Breast Neoplasms; Breast Cancer,Pembrolizumab (DRUG); Mifepristone (DRUG),55245,Korlym,Triple Negative Breast Neoplasms; Breast Cancer,Breast,Mifepristone,"NR3C1, PGR",inhibitor/antagonist,unclear,yes,yes,Approved for medical abortion and Cushing's syndrome treatment.,CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,1.68,85.0 +5160,NCT02014337,Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors,COMPLETED,PHASE1,"Breast Cancer; Ovarian Epithelial Cancer Recurrent; Sarcoma; Non-small Cell Lung Cancer; Carcinoma, Transitional Cell; Prostate Cancer; Prostatic Neoplasms",Mifepristone and Eribulin in combination (DRUG),55245,Korlym,"Breast Cancer; Ovarian Epithelial Cancer Recurrent; Sarcoma; Non-small Cell Lung Cancer; Carcinoma, Transitional Cell; Prostate Cancer; Prostatic Neoplasms",Lung,Mifepristone,"NR3C1, PGR",inhibitor/antagonist,unclear,yes,yes,Approved for medical abortion and Cushing's syndrome treatment.,CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,1.68,85.0 +5161,NCT04386057,LY3214996 +/- HCQ in Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer; Advanced Cancer,Hydroxychloroquine Sulfate (DRUG); LY3214996 (DRUG),121408882,Temuterkib,Pancreatic Cancer; Advanced Cancer,Pancreas,Temuterkib,,inhibitor/antagonist,Other MAPK inhibitor,no,yes,Temuterkib is in clinical trials for cancer treatment.,CC1(C2=C(C=C(S2)C3=NC(=NC=C3)NC4=CC=NN4C)C(=O)N1CCN5CCOCC5)C,1.0,27.0 +5162,NCT04916236,Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers,TERMINATED,PHASE1,Pancreatic Cancer; Colorectal Cancer; Non-small Cell Lung Cancer; KRAS Mutation-Related Tumors,RMC-4630 (DRUG); LY3214996 (DRUG),121408882,Temuterkib,Pancreatic Cancer; Colorectal Cancer; Non-small Cell Lung Cancer; KRAS Mutation-Related Tumors,Bowel,Temuterkib,,inhibitor/antagonist,Other MAPK inhibitor,no,yes,Temuterkib is in clinical trials for cancer treatment.,CC1(C2=C(C=C(S2)C3=NC(=NC=C3)NC4=CC=NN4C)C(=O)N1CCN5CCOCC5)C,1.0,27.0 +5163,NCT04391595,LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,Glioblastoma; GBM; Glioma,Abemaciclib (DRUG); LY3214996 (DRUG),121408882,Temuterkib,Glioblastoma; GBM; Glioma,CNS/Brain,Temuterkib,,inhibitor/antagonist,Other MAPK inhibitor,no,yes,Temuterkib is in clinical trials for cancer treatment.,CC1(C2=C(C=C(S2)C3=NC(=NC=C3)NC4=CC=NN4C)C(=O)N1CCN5CCOCC5)C,1.0,27.0 +5164,NCT04616183,LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Colon Adenocarcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Recurrent Colorectal Carcinoma; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Colon Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIA Rectal Cancer AJCC v8; Stage IIIB Colon Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Colon Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Stage IVA Colon Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Rectal Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Rectal Cancer AJCC v8; Stage IVC Colon Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage IVC Rectal Cancer AJCC v8; Unresectable Colon Adenocarcinoma; Unresectable Colorectal Carcinoma; Unresectable Rectal Adenocarcinoma,Abemaciclib (DRUG); Cetuximab (BIOLOGICAL); ERK1/2 Inhibitor LY3214996 (DRUG),121408882,Temuterkib,Metastatic Colon Adenocarcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Recurrent Colorectal Carcinoma; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Colon Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIA Rectal Cancer AJCC v8; Stage IIIB Colon Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Colon Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Stage IVA Colon Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Rectal Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Rectal Cancer AJCC v8; Stage IVC Colon Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage IVC Rectal Cancer AJCC v8; Unresectable Colon Adenocarcinoma; Unresectable Colorectal Carcinoma; Unresectable Rectal Adenocarcinoma,Bowel,Temuterkib,,inhibitor/antagonist,Other MAPK inhibitor,no,yes,Temuterkib is in clinical trials for cancer treatment.,CC1(C2=C(C=C(S2)C3=NC(=NC=C3)NC4=CC=NN4C)C(=O)N1CCN5CCOCC5)C,1.0,27.0 +5165,NCT01880515,Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib),COMPLETED,PHASE2,Skin Rash; Lung Cancer,Tetracycline (DRUG),54704426,Retet,Skin Rash with Lung Cancer,Skin,Tetracycline (hydrochloride),,unclear,unclear,yes,yes,Approved antibiotic often used as tetracycline hydrochloride.,CC1(C2CC3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.Cl,1.45,388.0 +5166,NCT05895773,Oro-nasal Decontamination to Prevent Ventilator-associated Pneumonia,COMPLETED,PHASE2,Ventilator Associated Pneumonia,Povidone-Iodine (DRUG); Saline spray (DRUG),656656,D02028,Ventilator Associated Pneumonia,Lung,Diammonium Glycyrrhizinate,,unclear,unclear,no,yes,Used in trials for hepatitis. Not approved for general human use.,CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C.N.N,1.0,688.0 +5167,NCT02473458,Efficacy of Whole Extract of Licorice in Neurological Improvement of Patients After Acute Ischemic Stroke,COMPLETED,PHASE1,Acute Stroke,Licorice whole extract (DRUG); Placebo (DRUG),656656,D02028,Acute Stroke,CNS/Brain,Diammonium Glycyrrhizinate,,unclear,unclear,no,yes,Used in trials for hepatitis. Not approved for general human use.,CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C.N.N,1.0,688.0 +5168,NCT03266146,36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent DILI,COMPLETED,PHASE1,"Drug-induced Liver Injury,Chronic",36 Weeks Methylprednisolone (DRUG); 48 weeks Methylprednisolone (DRUG),656656,D02028,Chronic Drug-induced Liver Injury,Liver,Diammonium Glycyrrhizinate,,unclear,unclear,no,yes,Used in trials for hepatitis. Not approved for general human use.,CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C.N.N,1.0,688.0 +5169,NCT02651350,Efficacy and Safety of Glucocorticosteroid Treatment in the Patients With Chronic Recurrent DILI,COMPLETED,PHASE1,"Drug-induced Liver Injury,Chronic",Methylprednisolone (DRUG); Standard Treatment (DRUG),656656,D02028,Chronic Drug-induced Liver Injury,Liver,Diammonium Glycyrrhizinate,,unclear,unclear,no,yes,Used in trials for hepatitis. Not approved for general human use.,CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C.N.N,1.0,688.0 +5170,NCT03349008,Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B,UNKNOWN,PHASE4,Chronic Hepatitis b; Liver Inflammation,Entecavir (DRUG); Magnesium Isoglycyrrhizinate (DRUG); Diammonium Glycyrrhizinate (DRUG); Magnesium Isoglycyrrhizinate Placebo (DRUG); Diammonium Glycyrrhizinate Placebo (DRUG),656656,D02028,Chronic Hepatitis b; Liver Inflammation,Liver,Diammonium Glycyrrhizinate,,unclear,unclear,no,yes,Used in trials for hepatitis. Not approved for general human use.,CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C.N.N,1.0,688.0 +5171,NCT00686881,Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773),TERMINATED,PHASE3,"Hepatitis C, Chronic",Peginterferon alfa-2b (PegIFN-2b) (BIOLOGICAL); Comparator: Stronger neo minophagen C (SNMC) (DRUG),656656,D02028,Chronic Hepatitis C,Liver,Diammonium Glycyrrhizinate,,unclear,unclear,no,yes,Used in trials for hepatitis. Not approved for general human use.,CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C.N.N,1.0,688.0 +5172,NCT01342185,Efficacy of Medical Ozone Therapy in Patients With Chronic Hepatitis B,UNKNOWN,PHASE3,Chronic Hepatitis B,medical ozone therapy with tianyi (DEVICE); medical ozone therapy with humares (DEVICE); Diammonium glycyrrhizinate Capsules (DRUG),656656,D02028,Chronic Hepatitis B,Liver,Diammonium Glycyrrhizinate,,unclear,unclear,no,yes,Used in trials for hepatitis. Not approved for general human use.,CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C.N.N,1.0,688.0 +5173,NCT04015245,SNMC (Stronger Neo-Minophagen C ) for Acute Hepatitis Post Transarterial Chemoembolization Therapy,COMPLETED,PHASE4,Hepatocellular Carcinoma,Stronger Neo-Minophagen C (DRUG),656656,D02028,Hepatocellular Carcinoma,Liver,Diammonium Glycyrrhizinate,,unclear,unclear,no,yes,Used in trials for hepatitis. Not approved for general human use.,CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C.N.N,1.0,688.0 +5174,NCT02449109,Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Carcinoma,COMPLETED,PHASE1,Liver Cancer,interventional therapy (PROCEDURE),656656,D02028,Liver Cancer,Liver,Diammonium Glycyrrhizinate,,unclear,unclear,no,yes,Used in trials for hepatitis. Not approved for general human use.,CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C.N.N,1.0,688.0 +5175,NCT02251678,Evaluate the Effect of Elimune Capsules,COMPLETED,PHASE1,Plaque Psoriasis,Elimune Capsules (DIETARY_SUPPLEMENT),656656,D02028,Plaque Psoriasis,Skin,Diammonium Glycyrrhizinate,,unclear,unclear,no,yes,Used in trials for hepatitis. Not approved for general human use.,CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C.N.N,1.0,688.0 +5176,NCT02449122,Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung Carcinoma,COMPLETED,PHASE1,Lung Cancer,interventional therapy (PROCEDURE),656656,D02028,Lung Cancer,Lung,Diammonium Glycyrrhizinate,,unclear,unclear,no,yes,Used in trials for hepatitis. Not approved for general human use.,CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C.N.N,1.0,688.0 +5177,NCT02331745,RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure,UNKNOWN,PHASE4,Liver Failure; Hepatitis B; Alcoholic Liver Disease,Granulocyte colony-stimulating factor (DRUG); standard treatment (DRUG),656656,D02028,Liver Failure; Hepatitis B; Alcoholic Liver Disease,Liver,Diammonium Glycyrrhizinate,,unclear,unclear,no,yes,Used in trials for hepatitis. Not approved for general human use.,CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C.N.N,1.0,688.0 +5178,NCT02391480,A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer,COMPLETED,PHASE1,Cancer; Breast Cancer; Non-Small Cell Lung Cancer; Acute Myeloid Leukemia (AML); Multiple Myeloma; Prostate Cancer; Small Cell Lung Cancer; Non-Hodgkins Lymphoma,ABBV-075 (DRUG); Venetoclax (DRUG),49846579,Venclexta,Cancer; Breast Cancer; Non-Small Cell Lung Cancer; Acute Myeloid Leukemia (AML); Multiple Myeloma; Prostate Cancer; Small Cell Lung Cancer; Non-Hodgkins Lymphoma,Lung,venetoclax,BCL2,inhibitor/antagonist,unclear,yes,yes,Approved for chronic lymphocytic leukemia and other cancers.,CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C,1.0,378.0 +5179,NCT05774886,Implantable Microdevice for TNBC - Pilot Study,WITHDRAWN,PHASE1,Triple Negative Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer; Early Stage Triple-Negative Breast Carcinoma; Breast Neoplasms; Breast Carcinoma,Implantable Microdevice (IMD) (COMBINATION_PRODUCT),49846579,Venclexta,Triple Negative Breast Cancer,Breast,venetoclax,BCL2,inhibitor/antagonist,unclear,yes,yes,Approved for chronic lymphocytic leukemia and other cancers.,CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C,1.0,378.0 +5180,NCT04543916,Venetoclax and Irinotecan in Relapsed/Refractory SCLC,WITHDRAWN,PHASE1,Relapsed Small Cell Lung Cancer; Refractory Small Cell Lung Carcinoma,Venetoclax 50 MG (DRUG); Venetoclax 100 MG (DRUG); Venetoclax 200 MG (DRUG); Venetoclax 400 (DRUG); Venetoclax 600 (DRUG); Irinotecan 60 mg/m2 (DRUG); Venetoclax (RP2D) (DRUG),49846579,Venclexta,Relapsed Small Cell Lung Cancer; Refractory Small Cell Lung Carcinoma,Lung,venetoclax,BCL2,inhibitor/antagonist,unclear,yes,yes,Approved for chronic lymphocytic leukemia and other cancers.,CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C,1.0,378.0 +5181,NCT05976217,Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis,COMPLETED,EARLY_PHASE1,Idiopathic Pulmonary Fibrosis,Venetoclax (DRUG),49846579,Venclexta,Idiopathic Pulmonary Fibrosis,Lung,venetoclax,BCL2,inhibitor/antagonist,unclear,yes,yes,Approved for chronic lymphocytic leukemia and other cancers.,CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C,1.0,378.0 +5182,NCT04422210,"A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).",TERMINATED,PHASE1,Small Cell Lung Cancer,Venetoclax (DRUG); Atezolizumab (DRUG); Carboplatin (DRUG); Etoposide (DRUG),49846579,Venclexta,Small Cell Lung Cancer,Lung,venetoclax,BCL2,inhibitor/antagonist,unclear,yes,yes,Approved for chronic lymphocytic leukemia and other cancers.,CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C,1.0,378.0 +5183,NCT03900884,"Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Breast Neoplasm Female,Venetoclax (DRUG); Palbociclib (DRUG); Letrozole (DRUG),49846579,Venclexta,Female Breast Neoplasm,Breast,venetoclax,BCL2,inhibitor/antagonist,unclear,yes,yes,Approved for chronic lymphocytic leukemia and other cancers.,CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C,1.0,378.0 +5184,NCT05926466,BTZ-043 Dose Evaluation in Combination and Selection,RECRUITING,PHASE2,"Tuberculosis, Pulmonary; Other Specified Pulmonary Tuberculosis",BTZ-043 (DRUG); Bedaquiline (DRUG); Delamanid (DRUG); Moxifloxacin (DRUG),6480466,Delamanid,"Tuberculosis, Pulmonary; Other Specified Pulmonary Tuberculosis",Lung,Delamanid,,inhibitor/antagonist,unclear,yes,yes,Approved for MDR-TB treatment.,CC1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F,1.0,441.0 +5185,NCT06649721,"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort",RECRUITING,PHASE3,Drug-resistant Tuberculosis; Pulmonary Tuberculosis; Rifampin-resistant Tuberculosis,bedaquiline (DRUG); delamanid (DRUG); linezolid (DRUG); Levofloxacin (DRUG); Clofazimine (DRUG),6480466,Delamanid,Drug-resistant Tuberculosis; Pulmonary Tuberculosis; Rifampin-resistant Tuberculosis,Lung,Delamanid,,inhibitor/antagonist,unclear,yes,yes,Approved for MDR-TB treatment.,CC1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F,1.0,441.0 +5186,NCT05388448,"EBA, Safety and Tolerability of Sanfetrinem Cilexetil",COMPLETED,PHASE2,"Tuberculosis, Pulmonary",Sanfetrinem Cilexetil (DRUG); Rifampicin (DRUG),6480466,Delamanid,Pulmonary Tuberculosis,Lung,Delamanid,,inhibitor/antagonist,unclear,yes,yes,Approved for MDR-TB treatment.,CC1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F,1.0,441.0 +5187,NCT03959566,PanACEA Sutezolid Dose-finding and Combination Evaluation,COMPLETED,PHASE2,Pulmonary Tuberculosis; Other Specified Pulmonary Tuberculosis,"Sutezolid (DRUG); Bedaquiline, Delamanid, Moxifloxacin (DRUG); Midazolam oral solution (DRUG)",6480466,Delamanid,Pulmonary Tuberculosis; Other Specified Pulmonary Tuberculosis,Lung,Delamanid,,inhibitor/antagonist,unclear,yes,yes,Approved for MDR-TB treatment.,CC1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F,1.0,441.0 +5188,NCT06476210,The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB),RECRUITING,PHASE4,Pulmonary Tuberculosis,BDL regimen (DRUG),6480466,Delamanid,Pulmonary Tuberculosis,Lung,Delamanid,,inhibitor/antagonist,unclear,yes,yes,Approved for MDR-TB treatment.,CC1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F,1.0,441.0 +5189,NCT05971602,Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis,TERMINATED,PHASE2,Pulmonary Tuberculosis,"Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS) (DRUG); Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS) (DRUG); Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) (DRUG); Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS) (DRUG); Isoniazid and Rifampicin (HR) (DRUG)",6480466,Delamanid,Pulmonary Tuberculosis,Lung,Delamanid,,inhibitor/antagonist,unclear,yes,yes,Approved for MDR-TB treatment.,CC1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F,1.0,441.0 +5190,NCT04550832,PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE),COMPLETED,PHASE2,Infections and Infestations; Pulmonary Tuberculosis,"Delpazolid (DRUG); Bedaquiline, Delamanid, Moxifloxacin (DRUG)",6480466,Delamanid,Infections and Infestations; Pulmonary Tuberculosis,Lung,Delamanid,,inhibitor/antagonist,unclear,yes,yes,Approved for MDR-TB treatment.,CC1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F,1.0,441.0 +5191,NCT06081361,"Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort",ACTIVE_NOT_RECRUITING,PHASE3,Pulmonary Tuberculosis; Rifampicin-resistant Tuberculosis,Bedaquiline (DRUG); Delamanid (DRUG); Contezolid (DRUG); Levofloxacin (DRUG); Moxifloxacin (DRUG); Clofazimine (DRUG); Linezolid (DRUG); Cycloserine (DRUG); Prothionamide (DRUG); Pyrazinamide (DRUG); Para-Aminosalicylic Acid (DRUG); Ethambutol (DRUG),6480466,Delamanid,Pulmonary Tuberculosis; Rifampicin-resistant Tuberculosis,Lung,Delamanid,,inhibitor/antagonist,unclear,yes,yes,Approved for MDR-TB treatment.,CC1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F,1.0,441.0 +5192,NCT06114628,Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB,RECRUITING,PHASE2,Pulmonary Tuberculosis,GSK3036656 (DRUG); BTZ-043 (DRUG); Bedaquiline (B) (DRUG); Delamanid (D) (DRUG); Pretomanid (Pa) (DRUG); Moxifloxacin (M) (DRUG); Linezolid (L) (DRUG); Pyrazinamide (Z) (DRUG); Rifampicin (R) (DRUG); Isoniazid (H) (DRUG); Ethambutol (E) (DRUG),6480466,Delamanid,Pulmonary Tuberculosis,Lung,Delamanid,,inhibitor/antagonist,unclear,yes,yes,Approved for MDR-TB treatment.,CC1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F,1.0,441.0 +5193,NCT00401271,"Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis",COMPLETED,PHASE2,Pulmonary Tuberculosis,OPC-67683 (DRUG); Rifafour e-275 (DRUG),6480466,Delamanid,Pulmonary Tuberculosis,Lung,Delamanid,,inhibitor/antagonist,unclear,yes,yes,Approved for MDR-TB treatment.,CC1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F,1.0,441.0 +5194,NCT06139926,Clinical Study of Dexmedetomidine Administered Intranasally to Relieve Perioperative Anxiety and Depression in Patients With Colorectal Tumors,RECRUITING,PHASE3,Colorectal Cancer,Dexmedetomidine administered intranasally (DRUG),5311068,DEXMEDETOMIDINE,Colorectal Cancer,Bowel,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5195,NCT06429657,Ketamine for Sedation in Severe Traumatic Brain Injury,SUSPENDED,PHASE4,"Severe Traumatic Brain Injury; Intracranial Hypertension; Intracranial Hemorrhage, Hypertensive","Ketamine with propofol (DRUG); Standard of Care propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam (OTHER)",5311068,DEXMEDETOMIDINE,"Severe Traumatic Brain Injury; Intracranial Hypertension; Intracranial Hemorrhage, Hypertensive",CNS/Brain,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5196,NCT04919174,A Randomized Single-blind Clinical Trial of the Efficacy and Safety of Remimazolam in Painless Bronchoscopy,UNKNOWN,PHASE4,Bronchoscopy; Sedation,Remimazolam (DRUG); Dexmedetomidine (DRUG),5311068,DEXMEDETOMIDINE,Bronchoscopy with Sedation,Lung,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5197,NCT01837290,Effects of Dexmedetomidine Premedication on Geriatric Patients With Chronic Renal Failure Undergoing Hip Surgery,COMPLETED,PHASE3,Chronic Renal Failure; Hip Fracture,dexmedetomidine infusion for premedication (DRUG); Midazolam (DRUG); saline infusion (DRUG); Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg (DRUG),5311068,DEXMEDETOMIDINE,Chronic Renal Failure; Hip Fracture,Kidney,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5198,NCT04346290,Effects of Dexmedetomidine on Microcirculation and Residual Kidney Function in Kidney Donors,UNKNOWN,PHASE4,Kidney Transplant; Microcirculation,Dexmedetomidine (DRUG),5311068,DEXMEDETOMIDINE,Kidney Transplant; Microcirculation,Kidney,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5199,NCT01072643,Sedation With Dexmedetomidine During Cardiac Catheterization,TERMINATED,PHASE2,Pulmonary Hypertension,Dexmedetomidine (DRUG),5311068,DEXMEDETOMIDINE,Pulmonary Hypertension,Lung,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5200,NCT06378827,Intraoperative Dexmedetomidine and Coronary Artery Bypass Graft Surgery,RECRUITING,PHASE2,Acute Kidney Injury,Dexmedetomidine (DRUG),5311068,DEXMEDETOMIDINE,Acute Kidney Injury,Kidney,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5201,NCT01381627,Safety Evaluation of Dexmedetomidine for EBUS-TBNA,UNKNOWN,PHASE4,Lung Cancer,Remifentanil (DRUG); Dexmedetomidine (DRUG),5311068,DEXMEDETOMIDINE,Lung Cancer,Lung,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5202,NCT00608231,Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation,WITHDRAWN,PHASE2,Parkinson's Disease; Essential Tremor; Dystonia,Dexmedetomidine Hydrochloride Infusion (DRUG); Normal Saline (DRUG),5311068,DEXMEDETOMIDINE,Parkinson's Disease; Essential Tremor; Dystonia,CNS/Brain,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5203,NCT03063073,Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block,UNKNOWN,PHASE3,Breast Cancer Female,Dexmedetomidine Injection [Precedex] (DRUG); Bupivacaine (DRUG),5311068,DEXMEDETOMIDINE,Breast Cancer Female,Breast,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5204,NCT01007773,Safety of Dexmedetomidine in Severe Traumatic Brain Injury,WITHDRAWN,PHASE2,Traumatic Brain Injury,Precedex (DRUG); Propofol (DRUG); Fentanyl (DRUG); Propofol (DRUG),5311068,DEXMEDETOMIDINE,Traumatic Brain Injury,CNS/Brain,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5205,NCT02164448,The Effects of Intraoperative Dexmedetomidine Infusion on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy,COMPLETED,PHASE4,Gastric Cancer Patients Undergoing Laparoscopic Gastrectomy,the dexmedetomidine group (DRUG); the control group (DRUG),5311068,DEXMEDETOMIDINE,Gastric Cancer Patients Undergoing Laparoscopic Gastrectomy,Esophagus/Stomach,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5206,NCT06947330,Comparison Between Erector Spinae Plane Block Versus Serratus Anterior Plane Block Regarding Analgesia Post Modified Radical Mastectomy,RECRUITING,PHASE3,Modified Radical Mastectomy; Breast Cancer,Unilateral Erector Spinae group (PROCEDURE); Unilateral Serratus Anterior group (PROCEDURE),5311068,DEXMEDETOMIDINE,Modified Radical Mastectomy; Breast Cancer,Breast,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5207,NCT03770130,Dexmedetomidine and Liver Transplantation,COMPLETED,EARLY_PHASE1,"Dexmedetomidine, Liver Transplantation, Allograft Function, Survival",Dexmedetomidine (DRUG); Saline (DRUG),5311068,DEXMEDETOMIDINE,"Dexmedetomidine, Liver Transplantation, Allograft Function, Survival",Liver,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5208,NCT05276830,"An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia",TERMINATED,PHASE2,Agitation; Dementia,BXCL501 (DRUG); BXCL501 (DRUG); Placebo film (DRUG),5311068,DEXMEDETOMIDINE,Agitation; Dementia,CNS/Brain,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5209,NCT04611425,REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19: REHSCU Study,COMPLETED,PHASE2,Acute Respiratory Failure; COVID-19; Trauma; Stroke; Sepsis; Shock,Remimazolam (DRUG),5311068,DEXMEDETOMIDINE,Acute Respiratory Failure; COVID-19; Trauma; Stroke; Sepsis; Shock,Lung,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5210,NCT03962725,Avoiding Neuromuscular Blockers to Reduce Complications,TERMINATED,PHASE4,Respiratory Failure; Respiratory Infection; Aspiration Pneumonia; Pneumonitis; Atelectasis; Bronchospasm,Neuromuscular Blocking Agents (DRUG); Anesthetic Adjuncts (DRUG),5311068,DEXMEDETOMIDINE,Respiratory Failure; Respiratory Infection; Aspiration Pneumonia; Pneumonitis; Atelectasis; Bronchospasm,Lung,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5211,NCT03170739,Effects of Dexmedetomidine and Dopamine on Renal Function After Major Surgery,UNKNOWN,PHASE4,Renal Function,Dexmedetomidine (DRUG); Dopamine (DRUG),5311068,DEXMEDETOMIDINE,Renal Function,Kidney,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5212,NCT04350086,Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection,WITHDRAWN,PHASE4,COVID-19 Infection; Sars-cov-2; Respiratory Failure; Palliative Situation,Treatment with Dexmedetomidine (DRUG),5311068,DEXMEDETOMIDINE,COVID-19 Infection; Sars-cov-2; Respiratory Failure; Palliative Situation,Lung,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5213,NCT04266665,Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome,COMPLETED,PHASE4,Brain Tumor; Metabolic Disturbance; Inflammatory Response; Oxygen Deficiency,Dexmedetomidine (DRUG); Normal saline (OTHER),5311068,DEXMEDETOMIDINE,Brain Tumor; Metabolic Disturbance; Inflammatory Response; Oxygen Deficiency,CNS/Brain,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5214,NCT05031026,Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation,ACTIVE_NOT_RECRUITING,PHASE4,Liver Transplant; Complications,Dexmedetomidine (DRUG); Normal Saline (DRUG),5311068,DEXMEDETOMIDINE,Liver Transplant; Complications,Liver,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5215,NCT05658692,Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome,UNKNOWN,PHASE4,Acute Respiratory Distress Syndrome,protective ventilation (DEVICE); prone position ventilation (BEHAVIORAL); glucocorticoid therapy (DRUG); restrictive fluid resuscitation (OTHER); Thymosin Alpha (BIOLOGICAL); Muscle relaxant therapy (DRUG); Integrated Chinese and Western Medicine Treatment (OTHER); statin therapy (DRUG); anti-infective treatment (COMBINATION_PRODUCT); Extracorporeal Membrane Oxygenation（ECMO） (DEVICE); stem cell therapy (GENETIC); Sedative analgesia/muscle relaxant therapy (DRUG); inotropes therapy (DRUG); Vasoactive drug therapy (DRUG),5311068,DEXMEDETOMIDINE,Acute Respiratory Distress Syndrome,Lung,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5216,NCT03404180,Peripheral Nerve Blocks for Above-the-knee Amputations,RECRUITING,PHASE4,"Peripheral Vascular Diseases; Hyperglycaemia (Diabetic); Hypertension; Coronary Artery Disease; Pulmonary Disease, Chronic Obstructive",Peripheral nerve block (PROCEDURE); Intravenous Sedatives (DRUG); Lateral femoral cutaneous nerve blocks (PROCEDURE); Obturator nerve blocks (PROCEDURE),5311068,DEXMEDETOMIDINE,"Peripheral Vascular Diseases; Hyperglycaemia (Diabetic); Hypertension; Coronary Artery Disease; Pulmonary Disease, Chronic Obstructive",Lung,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5217,NCT01070680,Dexmedetomidine Versus Placebo in Endoscopic Retrograde Cholangiopancreatography (ERCP) Sedation,COMPLETED,PHASE4,Pancreatitis,"Precedex (DRUG); sodium chlorid 0,9% (DRUG)",5311068,DEXMEDETOMIDINE,Pancreatitis,Pancreas,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5218,NCT02289391,Effect of Dexmedetomidine on Levels of Plasma Inflammatory Factor in Asthma Patients Undergoing General Anesthesia,UNKNOWN,PHASE4,Anesthesia; Asthma,Anesthesia induction (DRUG); Anesthesia maintenance (DRUG); Assisted anesthesia (DRUG),5311068,DEXMEDETOMIDINE,Anesthesia; Asthma,Lung,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5219,NCT01721460,Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus,COMPLETED,PHASE4,Parkinson's Disease; Deep Brain Stimulation Surgery,Dexmedetomidine (DRUG),5311068,DEXMEDETOMIDINE,Parkinson's Disease; Deep Brain Stimulation Surgery,CNS/Brain,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5220,NCT06252662,Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies,RECRUITING,PHASE4,Breast Cancer,Dexmedetomidine (DRUG); Liposomal bupivacaine (DRUG),5311068,DEXMEDETOMIDINE,Breast Cancer,Breast,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5221,NCT05903963,Evaluation of Renal Protection Of Dexmedetomidine Versus Midazolam As a Sedative For Septic Patients In Intensive Care Unit,RECRUITING,PHASE1,Renal Failure,Midazolam (DRUG); dexmedetomidine (DRUG),5311068,DEXMEDETOMIDINE,Renal Failure,Kidney,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5222,NCT01076816,Dexmedetomidine Pharmacokinetics-pharmacodynamics in Mechanically Ventilated Children With Single-organ Respiratory Failure,TERMINATED,PHASE3,Respiratory Failure,dexmedetomidine (DRUG); Vital signs (PROCEDURE); blood sampling (PROCEDURE),5311068,DEXMEDETOMIDINE,Respiratory Failure,Lung,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5223,NCT01195116,Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis,COMPLETED,PHASE4,Interstitial Cystitis,Dexmedetomidine (DRUG); Normal Saline (DRUG),5311068,DEXMEDETOMIDINE,Interstitial Cystitis,Bladder/Urinary Tract,Dexmedetomidine,"ADRA2A, ADRA2B, ADRA2C",activator/agonist,Adrenoceptor agonist,yes,yes,Approved as sedative and analgesic.,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,1.03,260.0 +5224,NCT01435174,Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients,COMPLETED,PHASE4,End-stage Renal Disease; Cardiovascular Disease,Ranolazine (DRUG); Pharmacokinetic Blood and Dialysate Sampling (PROCEDURE); QT Interval (PROCEDURE),56959,Ranexa,End-stage Renal Disease; Cardiovascular Disease,Kidney,Ranolazine,,inhibitor/antagonist,unclear,yes,yes,Approved for treating chronic angina.,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,1.01,211.0 +5225,NCT03472950,Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis,COMPLETED,PHASE2,ALS,Ranolazine 500 MG (DRUG); Ranolazine 1000 MG (DRUG),56959,Ranexa,Amyotrophic Lateral Sclerosis (ALS),CNS/Brain,Ranolazine,,inhibitor/antagonist,unclear,yes,yes,Approved for treating chronic angina.,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,1.01,211.0 +5226,NCT06570473,Feasibility Trial for a Right Ventricular Failure Platform Trial,RECRUITING,PHASE2,Pulmonary Hypertension; Right Ventricular Dysfunction; Right Heart Failure,Empagliflozin (DRUG); Ranolazine (DRUG),56959,Ranexa,Pulmonary Hypertension; Right Ventricular Dysfunction; Right Heart Failure,Lung,Ranolazine,,inhibitor/antagonist,unclear,yes,yes,Approved for treating chronic angina.,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,1.01,211.0 +5227,NCT01675973,"A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine",TERMINATED,PHASE1,Severe Renal Impairment,RANEXA (DRUG),56959,Ranexa,Severe Renal Impairment,Kidney,Ranolazine,,inhibitor/antagonist,unclear,yes,yes,Approved for treating chronic angina.,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,1.01,211.0 +5228,NCT06527222,A Study of Ranolazine in ALS,RECRUITING,PHASE2,Amyotrophic Lateral Sclerosis,Ranolazine (DRUG); Ranolazine (DRUG); Placebo (DRUG),56959,Ranexa,Amyotrophic Lateral Sclerosis,CNS/Brain,Ranolazine,,inhibitor/antagonist,unclear,yes,yes,Approved for treating chronic angina.,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,1.01,211.0 +5229,NCT02239926,Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D,TERMINATED,PHASE2,Diarrhea Predominant Irritable Bowel Syndrome,Ranolazine (DRUG); Placebo (DRUG),56959,Ranexa,Diarrhea Predominant Irritable Bowel Syndrome,Bowel,Ranolazine,,inhibitor/antagonist,unclear,yes,yes,Approved for treating chronic angina.,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,1.01,211.0 +5230,NCT01174173,Ranolazine and Pulmonary Hypertension,COMPLETED,PHASE3,Angina; Pulmonary Arterial Hypertension,Ranolazine (DRUG),56959,Ranexa,Angina; Pulmonary Arterial Hypertension,Lung,Ranolazine,,inhibitor/antagonist,unclear,yes,yes,Approved for treating chronic angina.,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,1.01,211.0 +5231,NCT04456517,Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy,TERMINATED,PHASE2,Crohn's Disease; Inflammatory Bowel Disease,Ranolazine (DRUG); Placebo (DRUG),56959,Ranexa,Crohn's Disease; Inflammatory Bowel Disease,Bowel,Ranolazine,,inhibitor/antagonist,unclear,yes,yes,Approved for treating chronic angina.,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,1.01,211.0 +5232,NCT02829034,Targeting Right Ventricle in Pulmonary Hypertension Gilead,COMPLETED,PHASE4,Pulmonary Hypertension,Ranolazine (DRUG); Placebo (DRUG),56959,Ranexa,Pulmonary Hypertension,Lung,Ranolazine,,inhibitor/antagonist,unclear,yes,yes,Approved for treating chronic angina.,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,1.01,211.0 +5233,NCT01839110,Targeting the Right Ventricle in Pulmonary Hypertension,COMPLETED,PHASE4,Pulmonary Hypertension,Ranolazine (DRUG); Placebo (DRUG),56959,Ranexa,Pulmonary Hypertension,Lung,Ranolazine,,inhibitor/antagonist,unclear,yes,yes,Approved for treating chronic angina.,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,1.01,211.0 +5234,NCT01757808,A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension,COMPLETED,PHASE1,Pulmonary Arterial Hypertension,Ranolazine (DRUG); Placebo (DRUG),56959,Ranexa,Pulmonary Arterial Hypertension,Lung,Ranolazine,,inhibitor/antagonist,unclear,yes,yes,Approved for treating chronic angina.,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,1.01,211.0 +5235,NCT01917136,11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension,COMPLETED,PHASE2,Pulmonary Hypertension,11C-acetate (DRUG); [18F]Fluoro-2-deoxy-2-D-glucose (DRUG); Cardiac MRI (OTHER),56959,Ranexa,Pulmonary Hypertension,Lung,Ranolazine,,inhibitor/antagonist,unclear,yes,yes,Approved for treating chronic angina.,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,1.01,211.0 +5236,NCT02133352,Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction,COMPLETED,PHASE4,Pulmonary Hypertension; Diastolic Left Ventricular Dysfunction,Ranolazine (DRUG),56959,Ranexa,Pulmonary Hypertension; Diastolic Left Ventricular Dysfunction,Lung,Ranolazine,,inhibitor/antagonist,unclear,yes,yes,Approved for treating chronic angina.,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,1.01,211.0 +5237,NCT01094158,Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis,COMPLETED,PHASE2,Non-Alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; Metabolic Syndrome,Aramchol (DRUG); Aramchol (DRUG); Placebo (DRUG),56959,Ranexa,Non-Alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; Metabolic Syndrome,Liver,Ranolazine,,inhibitor/antagonist,unclear,yes,yes,Approved for treating chronic angina.,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,1.01,211.0 +5238,NCT02294058,Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS),COMPLETED,PHASE3,Multiple Sclerosis,Ozanimod (DRUG); Interferon beta-1a (DRUG); Placebo to ozanimod (DRUG); Placebo to interferon beta-1a (DRUG),56959,Ranexa,Multiple Sclerosis,CNS/Brain,Ranolazine,,inhibitor/antagonist,unclear,yes,yes,Approved for treating chronic angina.,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,1.01,211.0 +5239,NCT06534892,An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study,RECRUITING,PHASE3,Respiratory Syncytial Virus Infections,RSVPreF3 OA vaccine (BIOLOGICAL),56959,Ranexa,Respiratory Syncytial Virus Infections,Lung,Ranolazine,,inhibitor/antagonist,unclear,yes,yes,Approved for treating chronic angina.,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,1.01,211.0 +5240,NCT06254950,A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis,RECRUITING,PHASE2,Ulcerative Colitis,TAK-279 (DRUG); Placebo (DRUG),56959,Ranexa,Ulcerative Colitis,Bowel,Ranolazine,,inhibitor/antagonist,unclear,yes,yes,Approved for treating chronic angina.,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,1.01,211.0 +5241,NCT06233461,A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease,RECRUITING,PHASE2,Crohn's Disease,TAK-279 (DRUG); Placebo (DRUG),56959,Ranexa,Crohn's Disease,Bowel,Ranolazine,,inhibitor/antagonist,unclear,yes,yes,Approved for treating chronic angina.,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,1.01,211.0 +5242,NCT02589405,Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris,COMPLETED,PHASE4,Acne Vulgaris,Benzoyl Peroxide (DRUG); Dermotivin® Soft Liquid cleanser (OTHER); Cetaphil® Dermacontrol Moisturizer SPF30 (OTHER),56959,Ranexa,Acne Vulgaris,Skin,Ranolazine,,inhibitor/antagonist,unclear,yes,yes,Approved for treating chronic angina.,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,1.01,211.0 +5243,NCT00437476,Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy,UNKNOWN,PHASE3,HIV Infections; Hepatitis C,LPV/r (DRUG); Nucleoside Reverse Transcriptase Inhibitors (DRUG); PEG-IFNa 2a (DRUG); Ribavirin (DRUG),92727,LPV,HIV and Hepatitis C Coinfection,Liver,Lopinavir,,inhibitor/antagonist,unclear,yes,yes,Combined with ritonavir for HIV treatment. Approved for human use.,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,1.02,236.0 +5244,NCT04466241,Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial,COMPLETED,PHASE2,COVID-19; COVID-19 Drug Treatment; Severe Acute Respiratory Syndrome Coronavirus 2,Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet (DRUG); Telmisartan 40Mg Oral Tablet (DRUG); Atorvastatin 20 Mg Oral Tablet (DRUG),92727,LPV,COVID-19; COVID-19 Drug Treatment; Severe Acute Respiratory Syndrome Coronavirus 2,Lung,Lopinavir,,inhibitor/antagonist,unclear,yes,yes,Combined with ritonavir for HIV treatment. Approved for human use.,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,1.02,236.0 +5245,NCT00936195,Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial,WITHDRAWN,PHASE3,HIV Infection; Pregnancy; Breastfeeding; HIV Infections,Efavirenz-Tenofovir-Emtricitabine (DRUG); Zidovudine-Lamivudine-Lopinavir/Ritonavir (DRUG),92727,LPV,HIV Infection; Pregnancy; Breastfeeding; HIV Infections,Breast,Lopinavir,,inhibitor/antagonist,unclear,yes,yes,Combined with ritonavir for HIV treatment. Approved for human use.,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,1.02,236.0 +5246,NCT00437684,Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy,UNKNOWN,PHASE3,HIV Infections; Hepatitis C,LPV/r (DRUG); PEG-IFNa 2a (DRUG); Ribavirin (DRUG); NUCS (DRUG),92727,LPV,HIV and Hepatitis C Coinfection,Liver,Lopinavir,,inhibitor/antagonist,unclear,yes,yes,Combined with ritonavir for HIV treatment. Approved for human use.,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,1.02,236.0 +5247,NCT00833378,Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.,COMPLETED,PHASE1,Hepatitis C,Eltrombopag (DRUG); Lopinavir/Ritonavir (DRUG); Eltrombopag and Lopinavir/Ritonavir (DRUG),92727,LPV,Hepatitis C,Liver,Lopinavir,,inhibitor/antagonist,unclear,yes,yes,Combined with ritonavir for HIV treatment. Approved for human use.,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,1.02,236.0 +5248,NCT02660905,HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection,COMPLETED,PHASE3,"Human Immunodeficiency Virus; Hepatitis C, Chronic",E/C/F/TAF; (DRUG); Ledipasvir-Sofosbuvir (DRUG),92727,LPV,"Human Immunodeficiency Virus; Hepatitis C, Chronic",Liver,Lopinavir,,inhibitor/antagonist,unclear,yes,yes,Combined with ritonavir for HIV treatment. Approved for human use.,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,1.02,236.0 +5249,NCT04366089,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,UNKNOWN,PHASE2,"COVID; SARS-CoV 2; Pneumonia, Viral; Coronavirus Infection","Oxygen-ozone therapy, probiotic supplementation and Standard of care (OTHER); SivoMixx (200 billion) (DIETARY_SUPPLEMENT); Azithromycin (DRUG); hydroxychloroquine (DRUG)",92727,LPV,"COVID; SARS-CoV 2; Pneumonia, Viral; Coronavirus Infection",Lung,Lopinavir,,inhibitor/antagonist,unclear,yes,yes,Combined with ritonavir for HIV treatment. Approved for human use.,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,1.02,236.0 +5250,NCT01095094,Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma,TERMINATED,PHASE2,Brain Tumor; Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Oligodendroglioma; Brain Stem Glioma; Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Mixed Glioma,ritonavir (DRUG); lopinavir (DRUG),92727,LPV,Brain Tumor; Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Oligodendroglioma; Brain Stem Glioma; Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Mixed Glioma,CNS/Brain,Lopinavir,,inhibitor/antagonist,unclear,yes,yes,Combined with ritonavir for HIV treatment. Approved for human use.,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,1.02,236.0 +5251,NCT01125696,Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV,COMPLETED,PHASE2,HIV; Hepatitis B,Tenofovir/lamivudine/lopinavir-ritonavir (DRUG); Zidovudine/lamivudine/lopinavir-ritonavir (DRUG),92727,LPV,HIV; Hepatitis B,Liver,Lopinavir,,inhibitor/antagonist,unclear,yes,yes,Combined with ritonavir for HIV treatment. Approved for human use.,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,1.02,236.0 +5252,NCT04358614,Baricitinib Therapy in COVID-19,COMPLETED,PHASE2,COVID; Pneumonia,Baricitinib 4 MG Oral Tablet (DRUG),92727,LPV,COVID; Pneumonia,Lung,Lopinavir,,inhibitor/antagonist,unclear,yes,yes,Combined with ritonavir for HIV treatment. Approved for human use.,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,1.02,236.0 +5253,NCT02295826,Dabigatran Following Transient Ischemic Attack and Minor Stroke,COMPLETED,PHASE2,Transient Ischemic Attack; Minor Ischemic Stroke,Dabigatran (DRUG); Acetylsalicylic acid (DRUG),119607,COX,Transient Ischemic Attack and Minor Ischemic Stroke,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5254,NCT01695226,Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms; Breast Cancer,celecoxib (DRUG); Placebo (DRUG),119607,COX,Breast Neoplasms; Breast Cancer,Breast,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5255,NCT05336266,A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,Pancreas Cancer; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer,Ketorolac Tromethamine (DRUG),119607,COX,Pancreas Cancer; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer,Pancreas,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5256,NCT03793166,"Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study",ACTIVE_NOT_RECRUITING,PHASE3,Clear Cell Renal Cell Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Lymph Nodes; Metastatic Malignant Neoplasm in the Soft Tissue; Metastatic Malignant Neoplasm in the Viscera; Rhabdoid Tumor of the Kidney; Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Cabozantinib (DRUG); Computed Tomography (PROCEDURE); Ipilimumab (BIOLOGICAL); Magnetic Resonance Imaging (PROCEDURE); Nivolumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),119607,COX,Renal Cell Carcinoma,Kidney,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5257,NCT05088057,Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer,UNKNOWN,PHASE2,Triple Negative Breast Cancer (TNBC),Camrelizumab (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG),119607,COX,Triple Negative Breast Cancer (TNBC),Breast,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5258,NCT02761057,"Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed",COMPLETED,PHASE2,Locally Advanced Papillary Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma,Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Cabozantinib S-malate (DRUG); Computed Tomography (PROCEDURE); Crizotinib (DRUG); Savolitinib (DRUG); Sunitinib Malate (DRUG),119607,COX,Locally Advanced Papillary Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma,Kidney,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5259,NCT00665457,Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery,TERMINATED,PHASE2,Breast Cancer,filgrastim (BIOLOGICAL); capecitabine (DRUG); celecoxib (DRUG); cyclophosphamide (DRUG); docetaxel (DRUG); doxorubicin hydrochloride (DRUG); gene expression analysis (GENETIC); polymorphism analysis (GENETIC); protein expression analysis (GENETIC); reverse transcriptase-polymerase chain reaction (GENETIC); imaging biomarker analysis (OTHER); immunohistochemistry staining method (OTHER); laboratory biomarker analysis (OTHER); pharmacogenomic studies (OTHER); dynamic contrast-enhanced magnetic resonance imaging (PROCEDURE); needle biopsy (PROCEDURE); neoadjuvant therapy (PROCEDURE); radiomammography (PROCEDURE); ultrasound imaging (PROCEDURE),119607,COX,Breast Cancer,Breast,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5260,NCT06662526,Lithium for Prevention of Cognitive Declining in Mood Illnesses,NOT_YET_RECRUITING,PHASE4,Dementia; Bipolar Disorder (BD); Depression - Major Depressive Disorder; Mild Cognitive Impairment (MCI),Trace lithium dose plus treatment as usual (DRUG); Placebo pill plus treatment as usual (DRUG),119607,COX,Dementia; Bipolar Disorder (BD); Depression - Major Depressive Disorder; Mild Cognitive Impairment (MCI),CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5261,NCT02971748,"Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy",ACTIVE_NOT_RECRUITING,PHASE2,Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Breast Inflammatory Carcinoma; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8,Pembrolizumab (BIOLOGICAL),119607,COX,Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Breast Inflammatory Carcinoma; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8,Breast,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5262,NCT00079274,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,COMPLETED,PHASE3,Adenocarcinoma of the Colon; Stage III Colon Cancer,irinotecan hydrochloride (DRUG); oxaliplatin (DRUG); leucovorin calcium (DRUG); fluorouracil (DRUG); cetuximab (BIOLOGICAL); Locally Directed Therapy (DRUG),119607,COX,Colon Adenocarcinoma,Bowel,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5263,NCT01994720,[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES],COMPLETED,PHASE3,Acute Ischaemic Stroke; Transient Ischaemic Attack,ticagrelor (DRUG); Acetylsalicylic acid (ASA) (DRUG),119607,COX,Acute Ischaemic Stroke; Transient Ischaemic Attack,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5264,NCT02885974,"Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Bladder Cancer,Celecoxib (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG),119607,COX,Bladder Cancer,Bladder/Urinary Tract,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5265,NCT02524665,8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne,COMPLETED,PHASE4,Acne Vulgaris,MAXCLARITY II (2.5% BPO) Foam Cleanser (OTHER); MAXCLARITY II (2.5% BPO) Foam Treatment (OTHER); MAXCLARITY II (0.5% Salicylic Acid) Toner Foam (OTHER); MURAD Clarifying Cleanser (1.5% SA) (OTHER); Exfoliating Acne Treatment Gel (1% SA) (OTHER); Skin Perfecting Lotion (OTHER),119607,COX,Acne Vulgaris,Skin,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5266,NCT00392665,Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck,TERMINATED,PHASE2,Squamous Cell Carcinoma of the Head and Neck (SCCHN),Bevacizumab (DRUG); erlotinib (DRUG); Sulindac (DRUG),119607,COX,Squamous Cell Carcinoma of the Head and Neck,Skin,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5267,NCT00000574,Ibuprofen in Sepsis Study,COMPLETED,PHASE3,"Acute Respiratory Distress Syndrome; Lung Diseases; Shock, Septic",ibuprofen (DRUG),119607,COX,"Acute Respiratory Distress Syndrome; Lung Diseases; Shock, Septic",Lung,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5268,NCT00304031,Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma,COMPLETED,PHASE3,Brain and Central Nervous System Tumors,Concurrent temozolomide (DRUG); Concurrent radiation therapy (RADIATION); 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle (DRUG); 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle (DRUG),119607,COX,Brain and Central Nervous System Tumors,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5269,NCT04340882,Phase 2 DoceRamPem for Patients with Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade,RECRUITING,PHASE2,Metastatic Non-Small Lung Cell Cancer; Recurrent Non-Small Lung Cell Cancer; Stage IV Lung Cancer AJCC V8; Stage IVA Lung Cancer AJCC V8; Stage IVB Lung Cancer AJCC V8,Docetaxel (DRUG); Pembrolizumab (BIOLOGICAL); Ramucirumab (BIOLOGICAL),119607,COX,Metastatic Non-Small Lung Cell Cancer; Recurrent Non-Small Lung Cell Cancer; Stage IV Lung Cancer AJCC V8; Stage IVA Lung Cancer AJCC V8; Stage IVB Lung Cancer AJCC V8,Lung,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5270,NCT02774265,A Different Approach to Preventing Thrombosis,COMPLETED,PHASE3,Venous Thromboembolism; Pulmonary Embolism,VTE prophylaxis with Enoxaparin 30mg BID (DRUG); VTE prophylaxis with Aspirin 81mg BID (DRUG),119607,COX,Venous Thromboembolism; Pulmonary Embolism,Lung,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5271,NCT04526665,Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC),ACTIVE_NOT_RECRUITING,PHASE3,Primary Biliary Cirrhosis,Elafibranor 80mg (DRUG); Placebo (DRUG),119607,COX,Primary Biliary Cirrhosis,Liver,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5272,NCT02954874,Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Invasive Breast Carcinoma; Stage 0 Breast Cancer AJCC v6 and v7; Stage I Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma,Biospecimen Collection (PROCEDURE); Laboratory Biomarker Analysis (OTHER); Patient Observation (OTHER); Pembrolizumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); Radiation Therapy (RADIATION),119607,COX,Invasive Breast Carcinoma; Stage 0 Breast Cancer AJCC v6 and v7; Stage I Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma,Breast,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5273,NCT01543165,Efficacy of Nefopam and Morphine in Balanced Analgesia for Acute Ureteric Colic,UNKNOWN,PHASE4,Renal Colic,Ketorolac and nefopam balanced analgesia (DRUG); Balanced analgesia using ketorolac and morphine (DRUG); Pain control with single analgesics (ketorolac) (DRUG),119607,COX,Renal Colic,Kidney,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5274,NCT04105374,"Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma",WITHDRAWN,PHASE2,Anaplastic Astrocytoma; Glioblastoma; Oligodendroglioma; Supratentorial Glioblastoma,Extended Release Flucytosine (DRUG); NovoTTF-100A Device (DEVICE); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); Radiation Therapy (RADIATION); Temozolomide (DRUG); Therapeutic Conventional Surgery (PROCEDURE); Vocimagene Amiretrorepvec (BIOLOGICAL),119607,COX,Anaplastic Astrocytoma; Glioblastoma; Oligodendroglioma; Supratentorial Glioblastoma,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5275,NCT00902174,Imatinib (QTI571) in Pulmonary Arterial Hypertension,COMPLETED,PHASE3,Pulmonary Arterial Hypertension,imatinib mesylate (DRUG); Placebo (DRUG),119607,COX,Pulmonary Arterial Hypertension,Lung,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5276,NCT05111574,Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery,RECRUITING,PHASE2,Anal Melanoma; Bladder Melanoma; Cervical Melanoma; Esophageal Melanoma; Gallbladder Melanoma; Head and Neck Mucosal Melanoma; Mucosal Melanoma; Nasopharyngeal Mucosal Melanoma; Oral Cavity Mucosal Melanoma; Penile Mucosal Melanoma; Rectal Melanoma; Recurrent Mucosal Melanoma; Sinonasal Mucosal Melanoma; Urethral Melanoma; Urinary System Mucosal Melanoma; Vaginal Melanoma; Vulvar Melanoma,Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Cabozantinib S-malate (DRUG); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Nivolumab (BIOLOGICAL); Placebo Administration (DRUG); Positron Emission Tomography (PROCEDURE),119607,COX,Anal Melanoma; Bladder Melanoma; Cervical Melanoma; Esophageal Melanoma; Gallbladder Melanoma; Head and Neck Mucosal Melanoma; Mucosal Melanoma; Nasopharyngeal Mucosal Melanoma; Oral Cavity Mucosal Melanoma; Penile Mucosal Melanoma; Rectal Melanoma; Recurrent Mucosal Melanoma; Sinonasal Mucosal Melanoma; Urethral Melanoma; Urinary System Mucosal Melanoma; Vaginal Melanoma; Vulvar Melanoma,Skin,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5277,NCT02105974,Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE3,"Pulmonary Disease, Chronic Obstructive",Fluticasone Furoate/Vilanterol (DRUG); Vilanterol (DRUG),119607,COX,"Pulmonary Disease, Chronic Obstructive",Lung,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5278,NCT03701074,Randomized Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus,TERMINATED,PHASE2,Patent Ductus Arteriosus; Preterm Infant; Bronchopulmonary Dysplasia,Ibuprofen and acetaminophen (DRUG); Ibuprofen and placebo (DRUG),119607,COX,Patent Ductus Arteriosus; Preterm Infant; Bronchopulmonary Dysplasia,Lung,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5279,NCT00954174,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",UNKNOWN,PHASE3,Mixed Mesodermal (Mullerian) Tumor; Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Stage I Ovarian Cancer AJCC v6 and v7; Stage IA Fallopian Tube Cancer AJCC v6 and v7; Stage IA Ovarian Cancer AJCC v6 and v7; Stage IA Uterine Sarcoma AJCC v7; Stage IB Fallopian Tube Cancer AJCC v6 and v7; Stage IB Ovarian Cancer AJCC v6 and v7; Stage IB Uterine Sarcoma AJCC v7; Stage IC Fallopian Tube Cancer AJCC v6 and v7; Stage IC Ovarian Cancer AJCC v6 and v7; Stage IC Uterine Sarcoma AJCC v7; Stage II Ovarian Cancer AJCC v6 and v7; Stage IIA Fallopian Tube Cancer AJCC v6 and v7; Stage IIA Ovarian Cancer AJCC V6 and v7; Stage IIA Uterine Sarcoma AJCC v7; Stage IIB Fallopian Tube Cancer AJCC v6 and v7; Stage IIB Ovarian Cancer AJCC v6 and v7; Stage IIB Uterine Sarcoma AJCC v7; Stage IIC Fallopian Tube Cancer AJCC v6 and v7; Stage IIC Ovarian Cancer AJCC v6 and v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIA Uterine Sarcoma AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIB Uterine Sarcoma AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IIIC Uterine Sarcoma AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7; Stage IVA Uterine Sarcoma AJCC v7; Stage IVB Uterine Sarcoma AJCC v7; Uterine Carcinosarcoma,Carboplatin (DRUG); Ifosfamide (DRUG); Paclitaxel (DRUG); Quality-of-Life Assessment (OTHER),119607,COX,Mixed Mesodermal (Mullerian) Tumor; Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Stage I Ovarian Cancer AJCC v6 and v7; Stage IA Fallopian Tube Cancer AJCC v6 and v7; Stage IA Ovarian Cancer AJCC v6 and v7; Stage IA Uterine Sarcoma AJCC v7; Stage IB Fallopian Tube Cancer AJCC v6 and v7; Stage IB Ovarian Cancer AJCC v6 and v7; Stage IB Uterine Sarcoma AJCC v7; Stage IC Fallopian Tube Cancer AJCC v6 and v7; Stage IC Ovarian Cancer AJCC v6 and v7; Stage IC Uterine Sarcoma AJCC v7; Stage II Ovarian Cancer AJCC v6 and v7; Stage IIA Fallopian Tube Cancer AJCC v6 and v7; Stage IIA Ovarian Cancer AJCC V6 and v7; Stage IIA Uterine Sarcoma AJCC v7; Stage IIB Fallopian Tube Cancer AJCC v6 and v7; Stage IIB Ovarian Cancer AJCC v6 and v7; Stage IIB Uterine Sarcoma AJCC v7; Stage IIC Fallopian Tube Cancer AJCC v6 and v7; Stage IIC Ovarian Cancer AJCC v6 and v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIA Uterine Sarcoma AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIB Uterine Sarcoma AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IIIC Uterine Sarcoma AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7; Stage IVA Uterine Sarcoma AJCC v7; Stage IVB Uterine Sarcoma AJCC v7; Uterine Carcinosarcoma,Ovary/Fallopian Tube,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5280,NCT00039520,Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer,COMPLETED,PHASE2,Breast Cancer,docetaxel (DRUG); sulindac (DRUG),119607,COX,Breast Cancer,Breast,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5281,NCT04219774,NeuroCognition After Carotid Recanalization,COMPLETED,PHASE2,Cognition Disorder; Stroke; Occlusion Carotid,Endovascular intervention (PROCEDURE); Aspirin and Clopidogrel (maximal medical Therapy) (DRUG),119607,COX,Cognition Disorder; Stroke; Occlusion Carotid,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5282,NCT01907165,Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide,COMPLETED,EARLY_PHASE1,Glioblastoma,Temozolomide (DRUG); Disulfiram (DRUG); Copper gluconate (DIETARY_SUPPLEMENT),119607,COX,Glioblastoma,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5283,NCT02115074,Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas,COMPLETED,PHASE1,Glioma,Fluvastatine (DRUG); Celebrex (DRUG),119607,COX,Glioma,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5284,NCT02615574,"A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer",WITHDRAWN,PHASE2,Metastatic Colorectal Cancer,αDC1 vaccine (BIOLOGICAL); CKM (DRUG),119607,COX,Metastatic Colorectal Cancer,Bowel,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5285,NCT05664074,Rectal Indomethacin vs Intravenous Ketorolac,RECRUITING,PHASE4,Post-ERCP Acute Pancreatitis,Rectal indomethacin (DRUG); IV ketorolac (DRUG),119607,COX,Post-ERCP Acute Pancreatitis,Pancreas,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5286,NCT02620865,BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer,COMPLETED,PHASE1,Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Aldesleukin (BIOLOGICAL); Antibody Therapy (BIOLOGICAL); Fluorouracil (DRUG); Gemcitabine Hydrochloride (DRUG); Irinotecan Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Leucovorin Calcium (DRUG); Oxaliplatin (DRUG); Paclitaxel Albumin-Stabilized Nanoparticle Formulation (DRUG); Sargramostim (BIOLOGICAL),119607,COX,Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5287,NCT03971474,Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial),COMPLETED,PHASE2,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Docetaxel (DRUG); Gemcitabine (DRUG); Gemcitabine Hydrochloride (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed (DRUG); Pemetrexed Disodium (DRUG); Ramucirumab (BIOLOGICAL),119607,COX,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5288,NCT04074265,Peri-operative Use of a Pain Injection in Pediatric Patients With Cerebral Palsy,COMPLETED,PHASE4,"Cerebral Palsy; Hip Dysplasia; Pain, Postoperative",Ropivacaine injection (DRUG); normal saline (DRUG),119607,COX,"Cerebral Palsy; Hip Dysplasia; Pain, Postoperative",CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5289,NCT00816166,VISSIT Intracranial Stent Study for Ischemic Therapy,TERMINATED,PHASE2,Ischemic Stroke; Transient Ischemic Attack,Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel) (DEVICE); Aspirin and Clopidogrel (Medical therapy) (DRUG),119607,COX,Ischemic Stroke,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5290,NCT04102566,Optimizing Pain Control in Transurethral Resection of the Prostate,RECRUITING,PHASE4,Pain; BPH With Urinary Obstruction; BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms,Ibuprofen 600 mg (DRUG); Education (BEHAVIORAL),119607,COX,Pain; BPH With Urinary Obstruction; BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms,Bladder/Urinary Tract,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5291,NCT02958566,Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery,UNKNOWN,PHASE4,"Colon Cancer; Colon Diverticulosis; Colonic Neoplasms; Colonic Diverticulitis; Pain, Postoperative; Ileus; Ileus Paralytic; Ileus; Mechanical; Constipation Drug Induced; Constipation; Rectum Cancer; Rectum Neoplasm",Acetaminophen (DRUG); Gabapentin (DRUG); Orphenadrine (DRUG); Lidocaine (DRUG); Marcaine (DRUG); Ketamine (DRUG); Methadone (DRUG); Tramadol (DRUG); Ketorolac (DRUG); Morphine Sulfate (DRUG); Fentanyl (DRUG); Dilaudid (DRUG); Hydrocodone-Acetaminophen Tab 5-325 MG (DRUG); Morphine Sulfate (DRUG); Fentanyl (DRUG); Dilaudid (DRUG); HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET (DRUG),119607,COX,"Colon Cancer; Colon Diverticulosis; Colonic Neoplasms; Colonic Diverticulitis; Pain, Postoperative; Ileus; Ileus Paralytic; Ileus; Mechanical; Constipation Drug Induced; Constipation; Rectum Cancer; Rectum Neoplasm",Bowel,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5292,NCT03775265,Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Bladder Urothelial Carcinoma; Muscle Invasive Bladder Carcinoma; Stage II Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8,Atezolizumab (DRUG); Biopsy of Bladder (PROCEDURE); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Cystoscopy (PROCEDURE); Fluorouracil (DRUG); Gemcitabine (DRUG); Magnetic Resonance Imaging (PROCEDURE); Mitomycin (DRUG); Quality-of-Life Assessment (OTHER); Radiation Therapy (RADIATION); Survey Administration (OTHER); Transurethral Resection of Bladder Tumor (PROCEDURE),119607,COX,Muscle Invasive Bladder Cancer,Bladder/Urinary Tract,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5293,NCT02359565,"Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma",ACTIVE_NOT_RECRUITING,PHASE1,Constitutional Mismatch Repair Deficiency Syndrome; Lynch Syndrome; Malignant Glioma; Recurrent Brain Neoplasm; Recurrent Childhood Ependymoma; Recurrent Diffuse Intrinsic Pontine Glioma; Recurrent Medulloblastoma; Refractory Brain Neoplasm; Refractory Diffuse Intrinsic Pontine Glioma; Refractory Ependymoma; Refractory Medulloblastoma,Biospecimen Collection (PROCEDURE); Conventional Magnetic Resonance Imaging (PROCEDURE); Diffusion Tensor Imaging (PROCEDURE); Diffusion Weighted Imaging (PROCEDURE); Dynamic Contrast-enhanced MR Perfusion (PROCEDURE); Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging (PROCEDURE); Magnetic Resonance Spectroscopic Imaging (PROCEDURE); Pembrolizumab (BIOLOGICAL),119607,COX,Constitutional Mismatch Repair Deficiency Syndrome; Lynch Syndrome; Malignant Glioma; Recurrent Brain Neoplasm; Recurrent Childhood Ependymoma; Recurrent Diffuse Intrinsic Pontine Glioma; Recurrent Medulloblastoma; Refractory Brain Neoplasm; Refractory Diffuse Intrinsic Pontine Glioma; Refractory Ependymoma; Refractory Medulloblastoma,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5294,NCT05493566,Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer,RECRUITING,EARLY_PHASE1,Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC V8; Stage IVA Lung Cancer AJCC V8; Stage IVB Lung Cancer AJCC V8,Aldesleukin (BIOLOGICAL); Pembrolizumab (BIOLOGICAL),119607,COX,Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC V8; Stage IVA Lung Cancer AJCC V8; Stage IVB Lung Cancer AJCC V8,Lung,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5295,NCT05924165,Narcotic-Free Percutaneous Nephrolithotomy,COMPLETED,PHASE4,Nephrolithiasis,"5mg Oxycodone, Q6 PRN (DRUG); 10mg Ketorolac, Q6 PRN (DRUG)",119607,COX,Nephrolithiasis,Kidney,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5296,NCT01067066,A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma,TERMINATED,PHASE1,Melanoma,TPI 287 (DRUG); Temodar (Temozolomide) (DRUG),119607,COX,Melanoma,Skin,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5297,NCT01107626,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,COMPLETED,PHASE3,Lung Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Bevacizumab (BIOLOGICAL); Pemetrexed Disodium Heptahydrate (DRUG),119607,COX,Lung Cancer,Lung,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5298,NCT02130466,A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022),COMPLETED,PHASE1,Melanoma; Solid Tumors,Pembrolizumab (BIOLOGICAL); Dabrafenib (DRUG); Trametinib (DRUG); Placebo (DRUG),119607,COX,Melanoma and Solid Tumors,Skin,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5299,NCT03660826,"Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone",ACTIVE_NOT_RECRUITING,PHASE2,Endometrial Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Endometrioid Adenocarcinoma; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8,Biospecimen Collection (PROCEDURE); Bone Marrow Aspirate (PROCEDURE); Bone Marrow Biopsy (PROCEDURE); Capivasertib (DRUG); Cediranib (DRUG); Cediranib Maleate (DRUG); Computed Tomography (PROCEDURE); Durvalumab (BIOLOGICAL); Echocardiography (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Olaparib (DRUG),119607,COX,Endometrial Cancer,Uterus,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5300,NCT00085826,A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients,COMPLETED,PHASE3,Non-Small Cell Lung Cancer,Exisulind (DRUG),119607,COX,Advanced Non-Small Cell Lung Cancer,Lung,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5301,NCT03654326,A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034),COMPLETED,PHASE2,Endometriosis-related Pain,Gefapixant (DRUG); Placebo (DRUG); Naproxen (DRUG),119607,COX,Endometriosis-related Pain,Uterus,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5302,NCT02750826,Breast Cancer WEight Loss Study (BWEL Study),ACTIVE_NOT_RECRUITING,PHASE3,Breast Carcinoma,Health Education Program (OTHER); Weight Loss Intervention (OTHER),119607,COX,Breast Carcinoma,Breast,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5303,NCT00073866,Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer,celecoxib (DRUG); docetaxel (DRUG); irinotecan hydrochloride (DRUG),119607,COX,Lung Cancer,Lung,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5304,NCT04539366,"Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial",SUSPENDED,PHASE1,Recurrent Childhood Neuroblastoma; Recurrent Childhood Osteosarcoma; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Refractory Childhood Neuroblastoma; Refractory Childhood Osteosarcoma; Refractory Neuroblastoma; Refractory Osteosarcoma,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration (PROCEDURE); Bone Marrow Biopsy (PROCEDURE); Cyclophosphamide (DRUG); Echocardiography Test (PROCEDURE); Fludarabine Phosphate (DRUG); GD2-CAR-expressing Autologous T-lymphocytes (BIOLOGICAL); Imaging Procedure (PROCEDURE); Magnetic Resonance Imaging of the Heart (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Questionnaire Administration (OTHER),119607,COX,Recurrent Childhood Neuroblastoma; Recurrent Childhood Osteosarcoma; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Refractory Childhood Neuroblastoma; Refractory Childhood Osteosarcoma; Refractory Neuroblastoma; Refractory Osteosarcoma,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5305,NCT04233866,"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Fluorouracil (DRUG); Gemcitabine (DRUG); Gemcitabine Hydrochloride (DRUG); Leucovorin (DRUG); Leucovorin Calcium (DRUG); Liposomal Irinotecan (DRUG); Nab-paclitaxel (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),119607,COX,Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Pancreas,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5306,NCT05700266,Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis,NOT_YET_RECRUITING,PHASE2,Ischemic Stroke; Intracranial Atherosclerosis; Stenosis,Rivaroxaban (DRUG); Clopidogrel (DRUG); Aspirin (DRUG); Risk Factor Management in both arms (OTHER),119607,COX,Ischemic Stroke; Intracranial Atherosclerosis; Stenosis,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5307,NCT00114166,"Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",COMPLETED,PHASE2,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,topotecan hydrochloride (DRUG),119607,COX,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5308,NCT00000527,Recurrent Carotid Stenosis,COMPLETED,PHASE2,Cardiovascular Diseases; Carotid Stenosis; Cerebrovascular Disorders; Heart Diseases; Vascular Diseases,aspirin (DRUG); dipyridamole (DRUG),119607,COX,Cardiovascular Diseases; Carotid Stenosis; Cerebrovascular Disorders; Heart Diseases; Vascular Diseases,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5309,NCT00030420,Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,Celecoxib (DRUG); Docetaxel (DRUG),119607,COX,Lung Cancer,Lung,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5310,NCT01555073,Preemptive Analgesia Following Uterine Artery Embolization,TERMINATED,PHASE4,Uterine Fibroids; Uterine Artery Embolization,pregabalin/celecoxib (DRUG); pregabalin/placebo (DRUG); celecoxib/placebo (DRUG); Placebo group (DRUG),119607,COX,Uterine Fibroids; Uterine Artery Embolization,Uterus,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5311,NCT00153673,Effect of Selective COX-2 Inhibition on Ulcer Healing,COMPLETED,PHASE3,Arthritis; Gastric Ulcer,celecoxib (DRUG); Dologesics (DRUG),119607,COX,Arthritis; Gastric Ulcer,Esophagus/Stomach,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5312,NCT00201773,"Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer",COMPLETED,PHASE2,Breast Cancer,Exemestane (DRUG); Celecoxib (DRUG); Correlative studies (OTHER),119607,COX,Breast Cancer,Breast,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5313,NCT00075673,Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer,TERMINATED,PHASE1,Breast Cancer,celecoxib (DRUG); vinorelbine ditartrate (DRUG),119607,COX,Breast Cancer,Breast,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5314,NCT03539731,[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers,TERMINATED,PHASE1,Healthy Subject; Intracranial Neoplasm; Glioblastoma,Fluorine F 18 DASA-23 (DRUG); Positron Emission Tomography (PROCEDURE),119607,COX,Healthy Subject; Intracranial Neoplasm; Glioblastoma,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5315,NCT02224131,Study of Antiplatelet Therapy for Intracranial Aneurysm Stent-assisted Coiling,UNKNOWN,PHASE4,Embolic Stroke,Aspirin and clopidogrel (DRUG); Aspirin and clopidogrel (DRUG),119607,COX,Embolic Stroke,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5316,NCT03584373,Pain Outcomes of Non-opioid vs. Opioid Analgesia for Kidney Stone Surgery.,COMPLETED,PHASE3,Nephrolithiasis,Ketorolac Oral Tablet [Toradol] (DRUG); Acetaminophen (DRUG); Oxycodone Acetaminophen (DRUG),119607,COX,Nephrolithiasis,Kidney,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5317,NCT00976573,"Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",COMPLETED,PHASE2,Melanoma (Skin),bevacizumab (BIOLOGICAL); carboplatin (DRUG); everolimus (DRUG); paclitaxel (DRUG),119607,COX,Melanoma (Skin),Skin,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5318,NCT02581930,Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Melanoma; Recurrent Cutaneous Melanoma; Stage IV Cutaneous Melanoma AJCC v6 and v7,Ibrutinib (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacogenomic Study (OTHER); Pharmacological Study (OTHER),119607,COX,Metastatic Melanoma; Recurrent Cutaneous Melanoma; Stage IV Cutaneous Melanoma AJCC v6 and v7,Skin,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5319,NCT04267848,"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial",RECRUITING,PHASE3,Lung Non-Small Cell Carcinoma; Lung Non-Small Cell Squamous Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Gemcitabine Hydrochloride (DRUG); Magnetic Resonance Imaging (PROCEDURE); Observation Activity (OTHER); Paclitaxel (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed Disodium (DRUG); Questionnaire Administration (OTHER),119607,COX,Lung Non-Small Cell Carcinoma; Lung Non-Small Cell Squamous Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8,Lung,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5320,NCT03007030,Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery,RECRUITING,PHASE2,CD30-Positive Neoplastic Cells Present; Malignant Mesothelioma,Brentuximab Vedotin (DRUG); Laboratory Biomarker Analysis (OTHER),119607,COX,CD30-Positive Neoplastic Cells Present; Malignant Mesothelioma,Lung,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5321,NCT02467582,Adjuvant Aspirin Treatment for Colon Cancer Patients,COMPLETED,PHASE3,Colon Cancer,Aspirin (DRUG); Placebo (DRUG),119607,COX,Colon Cancer,Bowel,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5322,NCT04092582,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MTPS9579A in Patients With Asthma Requiring Inhaled Corticosteroids and a Second Controller",COMPLETED,PHASE2,Asthma,MTPS9579A (DRUG); Placebo (DRUG),119607,COX,Asthma,Lung,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5323,NCT02661282,Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma,COMPLETED,PHASE1,Cytomegalovirus Positive; Glioblastoma; Gliosarcoma; Malignant Glioma; Recurrent Brain Neoplasm; Recurrent Glioblastoma,Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER); Temozolomide (DRUG); Therapeutic Conventional Surgery (PROCEDURE),119607,COX,Cytomegalovirus Positive; Glioblastoma; Gliosarcoma; Malignant Glioma; Recurrent Brain Neoplasm; Recurrent Glioblastoma,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5324,NCT00527982,Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer,TERMINATED,PHASE2,Head and Neck Cancer; Lung Cancer,Celecoxib (DRUG),119607,COX,Head and Neck Cancer; Lung Cancer,Lung,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5325,NCT01802073,Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects,COMPLETED,PHASE3,Primary Sclerosing Cholangitis,Oral Vancomycin (DRUG),119607,COX,Primary Sclerosing Cholangitis,Liver,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5326,NCT00357682,"A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia",COMPLETED,PHASE3,Esophageal Cancer; Precancerous Condition,Esomeprazole (DRUG); Esomeprazole (DRUG); Aspirin (DRUG),119607,COX,Esophageal Cancer; Precancerous Condition,Esophagus/Stomach,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5327,NCT02964403,COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis,UNKNOWN,PHASE4,"Pancreatitis, Acute",Cox-2 (DRUG); Indomethacin (DRUG),119607,COX,"Pancreatitis, Acute",Pancreas,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5328,NCT04068103,Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery,ACTIVE_NOT_RECRUITING,PHASE2,Colon Adenocarcinoma; Stage IIA Colon Cancer AJCC v8,Capecitabine (DRUG); Fluorouracil (DRUG); Leucovorin (DRUG); Leucovorin Calcium (DRUG); Oxaliplatin (DRUG); Patient Observation (OTHER),119607,COX,Stage IIA Colon Cancer,Bowel,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5329,NCT01950390,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,ACTIVE_NOT_RECRUITING,PHASE2,Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma,Bevacizumab (BIOLOGICAL); Ipilimumab (BIOLOGICAL),119607,COX,Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma,Skin,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5330,NCT04216290,"A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial",ACTIVE_NOT_RECRUITING,PHASE2,Bladder Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8,Biopsy of Bladder (PROCEDURE); Biospecimen Collection (PROCEDURE); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Cystoscopy (PROCEDURE); Durvalumab (BIOLOGICAL); Fluorouracil (DRUG); Gemcitabine Hydrochloride (DRUG); Magnetic Resonance Imaging (PROCEDURE); Mitomycin (DRUG); Patient Observation (OTHER); Radiation Therapy (RADIATION),119607,COX,Bladder Urothelial Carcinoma,Bladder/Urinary Tract,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5331,NCT00805090,"Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects",COMPLETED,PHASE1,"Renal Insufficiency, Chronic; Hepatic Insufficiency; Healthy",Sporanox (DRUG); Diclofenac Sodium (DRUG),119607,COX,"Renal Insufficiency, Chronic; Hepatic Insufficiency; Healthy",Liver,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5332,NCT00931203,Trial of Celecoxib With Preoperative Chemo- Radiation for Locally Advanced Rectal Cancer,COMPLETED,PHASE2,Locally Advanced Rectal Cancer,Celecoxib (DRUG),119607,COX,Rectal Cancer,Bowel,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5333,NCT01086384,Asthma Exacerbation Study,COMPLETED,PHASE3,Asthma,Fluticasone Furoate/GW642444 (DRUG); Fluticasone furoate (DRUG),119607,COX,Asthma,Lung,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5334,NCT03831464,Metformin as RenoProtector of Progressive Kidney Disease,ACTIVE_NOT_RECRUITING,PHASE3,Chronic Kidney Diseases,Metformin Hydrochloride (DRUG); Placebo Oral Tablet (DRUG),119607,COX,Chronic Kidney Diseases,Kidney,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5335,NCT04214990,Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients,RECRUITING,PHASE3,Aspirin; Gastric Cancer,Aspirin 100mg (DRUG); Placebo oral tablet (DRUG),119607,COX,Aspirin; Gastric Cancer,Esophagus/Stomach,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5336,NCT06327490,A Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer,RECRUITING,PHASE2,Breast Cancer,ICG-guided manual lymphatic drainage (PROCEDURE); Traditional manual lymphatic drainage (PROCEDURE); Indocyanine green (DRUG),119607,COX,Breast Cancer,Breast,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5337,NCT01356290,"Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma and ATRT",RECRUITING,PHASE2,Medulloblastoma Recurrent; Ependymoma Recurrent; ATRT Recurrent,Bevacizumab (DRUG); Thalidomide (DRUG); Celecoxib (DRUG); Fenofibric acid (DRUG); Etoposide (DRUG); Cyclophosphamide (DRUG); Etoposide phosphate (DRUG); Cytarabine (DRUG),119607,COX,Recurrent CNS Tumors,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5338,NCT00459290,"Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",COMPLETED,PHASE2,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,mifepristone (DRUG),119607,COX,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5339,NCT01251003,Safety Study of Umbilical Cord Blood To Treat Pediatric Traumatic Brain Injury,WITHDRAWN,PHASE1,Traumatic Brain Injury,Autologous cord blood (BIOLOGICAL),119607,COX,Traumatic Brain Injury,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5340,NCT02128490,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment,COMPLETED,PHASE2,Gout; Moderate Renal Impairment,Febuxostat IR (DRUG); Febuxostat XR (DRUG); Febuxostat placebo (DRUG); Colchicine (DRUG); Naproxen (DRUG); Lansoprazole (DRUG),119607,COX,Gout; Moderate Renal Impairment,Kidney,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5341,NCT00719303,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",UNKNOWN,PHASE3,Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer AJCC v6 and v7; Stage IIA Ovarian Cancer AJCC V6 and v7; Stage IIB Fallopian Tube Cancer AJCC v6 and v7; Stage IIB Ovarian Cancer AJCC v6 and v7; Stage IIC Fallopian Tube Cancer AJCC v6 and v7; Stage IIC Ovarian Cancer AJCC v6 and v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral Dietary Intervention (BEHAVIORAL); Compliance Monitoring (BEHAVIORAL); Counseling (OTHER); Educational Intervention (OTHER); Exercise Intervention (BEHAVIORAL); Laboratory Biomarker Analysis (OTHER); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),119607,COX,Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer AJCC v6 and v7; Stage IIA Ovarian Cancer AJCC V6 and v7; Stage IIB Fallopian Tube Cancer AJCC v6 and v7; Stage IIB Ovarian Cancer AJCC v6 and v7; Stage IIC Fallopian Tube Cancer AJCC v6 and v7; Stage IIC Ovarian Cancer AJCC v6 and v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Ovary/Fallopian Tube,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5342,NCT01932203,Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease,UNKNOWN,PHASE4,Cerebral Small Vessel Disease,aspirin (DRUG); cilostazol (DRUG),119607,COX,Cerebral Small Vessel Disease,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5343,NCT00038103,Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen,COMPLETED,PHASE2,Breast Neoplasms,Exemestane (DRUG); Celecoxib + Exemestane (DRUG),119607,COX,Breast Neoplasms,Breast,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5344,NCT00474903,Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus,COMPLETED,PHASE2,Barrett Esophagus; Esophageal Cancer,acetylsalicylic acid (DRUG); esomeprazole magnesium (DRUG); placebo (OTHER),119607,COX,Barrett Esophagus; Esophageal Cancer,Esophagus/Stomach,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5345,NCT05677490,"mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma",RECRUITING,PHASE3,Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Metastatic Esophageal Adenocarcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Unresectable Esophageal Adenocarcinoma; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma,Fluorouracil (DRUG); Leucovorin Calcium (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG); Nivolumab (BIOLOGICAL); Magnetic Resonance Imaging (PROCEDURE); Computed Tomography (PROCEDURE); Biospecimen Collection (PROCEDURE); Questionnaire Administration (OTHER),119607,COX,Advanced Gastroesophageal Adenocarcinoma,Esophagus/Stomach,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5346,NCT01196390,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",COMPLETED,PHASE3,Esophageal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Stage IB Esophageal Cancer AJCC v7; Stage IIA Esophageal Cancer AJCC v7; Stage IIB Esophageal Cancer AJCC v7; Stage IIIA Esophageal Cancer AJCC v7; Stage IIIB Esophageal Cancer AJCC v7,Carboplatin (DRUG); Laboratory Biomarker Analysis (OTHER); Paclitaxel (DRUG); Quality-of-Life Assessment (OTHER); Radiation Therapy (RADIATION); Therapeutic Conventional Surgery (PROCEDURE); Trastuzumab (BIOLOGICAL),119607,COX,Esophageal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Stage IB Esophageal Cancer AJCC v7; Stage IIA Esophageal Cancer AJCC v7; Stage IIB Esophageal Cancer AJCC v7; Stage IIIA Esophageal Cancer AJCC v7; Stage IIIB Esophageal Cancer AJCC v7,Esophagus/Stomach,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5347,NCT04425590,The Benefit of Add On DLBS1033 for Ischemic Stroke Patient,UNKNOWN,PHASE2,Ischemic Stroke,DLBS1033 (DRUG); Aspirin (DRUG); Statin (DRUG); Vit B12 (DRUG),119607,COX,Ischemic Stroke,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5348,NCT03831321,"The Effect of Preemptive Analgesia On The Comfort Of Patient and Doctor, in Cystoscopy",UNKNOWN,PHASE4,Bladder Cancer; Benign Prostate Hyperplasia; Hematuria; Pain; Lower Urinary Tract Symptoms,Diclofenac Sodium (DRUG); Cystoscopy (DEVICE); Lubricant Gel (DRUG),119607,COX,Bladder Cancer; Benign Prostate Hyperplasia; Hematuria; Pain; Lower Urinary Tract Symptoms,Bladder/Urinary Tract,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5349,NCT00070564,"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,pegfilgrastim (BIOLOGICAL); AC regimen (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); paclitaxel (DRUG),119607,COX,Breast Cancer,Breast,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5350,NCT01101438,A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer,COMPLETED,PHASE3,Breast Cancer,metformin hydrochloride (DRUG); placebo (OTHER),119607,COX,Breast Cancer,Breast,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5351,NCT00041938,Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial,COMPLETED,PHASE3,Heart Disease; Stroke; Ischemic Heart Disease; Myocardial Infarction,aspirin (DRUG); Warfarin (DRUG),119607,COX,Heart Disease; Stroke; Ischemic Heart Disease; Myocardial Infarction,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5352,NCT02294643,Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' Study,COMPLETED,PHASE3,"Coronary Artery Disease; Diabetes Mellitus; Renal Insufficiency, Chronic",Sarpogrelate (DRUG); Aspirin (DRUG); Clopidogrel (DRUG); Placebo (for Sarpogrelate) (DRUG),119607,COX,"Coronary Artery Disease; Diabetes Mellitus; Renal Insufficiency, Chronic",Kidney,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5353,NCT04165850,Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis; ALS,Fixed dose combination Ciprofloxacin/Celecoxib (DRUG),119607,COX,Amyotrophic Lateral Sclerosis; ALS,CNS/Brain,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5354,NCT02187614,Efficacy Study of Different Analgesic Options in Kidney Stone Pain Management,COMPLETED,PHASE4,Renal Colic; Urinary Calculi,Diclofenac (DRUG); Morphine (DRUG); Paracetamol (DRUG); Placebos (DRUG),119607,COX,Renal Colic; Urinary Calculi,Kidney,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5355,NCT02350543,Peri-operative Aspirin Continuation Versus Discontinuation,TERMINATED,PHASE4,Hematuria; Urinary Bladder Neoplasms,Aspirin (DRUG),119607,COX,Hematuria; Urinary Bladder Neoplasms,Bladder/Urinary Tract,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5356,NCT02241512,IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis,TERMINATED,PHASE2,Post-ERCP Acute Pancreatitis,Ibuprofen (DRUG); placebo (DRUG),119607,COX,Post-ERCP Acute Pancreatitis,Pancreas,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5357,NCT02636569,Topical Chemoprevention of Skin Cancer Biomarkers,ACTIVE_NOT_RECRUITING,PHASE2,Non-melanoma Skin Cancer,topical diclofenac daily (DRUG); placebo (DRUG),119607,COX,Non-melanoma Skin Cancer,Skin,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5358,NCT00026468,Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis,WITHDRAWN,PHASE2,Colorectal Cancer; Small Intestine Cancer,exisulind (DRUG),119607,COX,Colorectal Cancer; Small Intestine Cancer,Bowel,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5359,NCT03377101,"Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer",WITHDRAWN,PHASE2,Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Stage IV Breast Cancer AJCC v6 and v7,Copanlisib (DRUG); Fulvestrant (DRUG); Laboratory Biomarker Analysis (OTHER); Palbociclib (DRUG),119607,COX,Stage IV Hormone Receptor Positive HER2 Negative Breast Cancer,Breast,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5360,NCT02739204,Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma,UNKNOWN,PHASE2,Oral Squamous Cell Carcinoma,Celecoxib (DRUG),119607,COX,Oral Squamous Cell Carcinoma,Skin,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5361,NCT02488967,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Carboplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Paclitaxel (DRUG),119607,COX,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Breast,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5362,NCT01861301,Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma,TERMINATED,PHASE2,Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma; Stage II Pleural Mesothelioma; Stage III Pleural Mesothelioma; Stage IV Pleural Mesothelioma,Laboratory Biomarker Analysis (OTHER); Tivantinib (DRUG),119607,COX,Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma; Stage II Pleural Mesothelioma; Stage III Pleural Mesothelioma; Stage IV Pleural Mesothelioma,Lung,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5363,NCT05653401,Treatment of Renal Colic in the Emergency Department: Comparison Between Magnesium Sulfate and Lidocaine.,COMPLETED,PHASE2,Renal Colic,Magnesium sulfate and diclofenac (DRUG); Lidocain and diclofenac (DRUG); Placebo and diclofenac (DRUG),119607,COX,Renal Colic,Kidney,Valdecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn due to safety concerns related to cardiovascular risks.,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,1.21,335.0 +5364,NCT00857480,Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin,COMPLETED,PHASE1,Hepatic Cirrhosis,NRL972 (DRUG); NRL972 (DRUG); NRL972 (DRUG),23675320,Tegopen,Hepatic Cirrhosis,Liver,Cloxacillin (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved as a penicillinase-resistant antibiotic for human use.,CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)[O-].[Na+],1.08,1007.0 +5365,NCT01104662,Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment,TERMINATED,PHASE4,Complicated Skin and Skin Structure Infections; S. Aureus Bacteremia; Renal Impairment,Vancomycin (DRUG); Daptomycin (DRUG); Semi-Synthetic Penicillin (DRUG),23675320,Tegopen,Complicated Skin and Skin Structure Infections; S. Aureus Bacteremia; Renal Impairment,Kidney,Cloxacillin (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved as a penicillinase-resistant antibiotic for human use.,CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)[O-].[Na+],1.08,1007.0 +5366,NCT05599295,Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin,RECRUITING,PHASE2,Acute Bacterial Skin and Skin Structure Infection,Oritavancin (DRUG),23675320,Tegopen,Acute Bacterial Skin and Skin Structure Infection,Skin,Cloxacillin (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved as a penicillinase-resistant antibiotic for human use.,CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)[O-].[Na+],1.08,1007.0 +5367,NCT04173169,Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis,ACTIVE_NOT_RECRUITING,PHASE3,Infertility; Endometriosis,Elagolix 200 MG (DRUG); Placebo or SOC IVF (OTHER),24785956,Orlissa,Infertility and Endometriosis,Uterus,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5368,NCT06375811,Pre-IVF Treatment with a GnRH Antagonist in Women with Endometriosis_temp,RECRUITING,PHASE3,Infertility; Endometriosis,Elagolix 200 MG (DRUG); Placebo or SOC IVF (OTHER),24785956,Orlissa,Infertility and Endometriosis,Uterus,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5369,NCT00619866,An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis,COMPLETED,PHASE2,"Endometriosis, Pain",Elagolix (DRUG); placebo (DRUG),24785956,Orlissa,Endometriosis with Pain,Uterus,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5370,NCT03886220,A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women,COMPLETED,PHASE4,Uterine Fibroids,Elagolix (DRUG); Placebo (DRUG),24785956,Orlissa,Uterine Fibroids,Uterus,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5371,NCT03991520,Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms,UNKNOWN,EARLY_PHASE1,Endometriosis; Anakinra; Markers of Inflammation,Anakinra 100Mg/0.67Ml Inj Syringe (DRUG); Placebo (DRUG),24785956,Orlissa,Endometriosis,Uterus,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5372,NCT00973973,Efficacy and Safety Study of Elagolix in Women With Endometriosis,COMPLETED,PHASE2,"Endometriosis, Pain",Placebo (DRUG); Elagolix (DRUG),24785956,Orlissa,Endometriosis with Pain,Uterus,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5373,NCT01817530,Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF),COMPLETED,PHASE2,Heavy Uterine Bleeding; Uterine Fibroids,Elagolix placebo (OTHER); Elagolix (DRUG); 0.5 mg estradiol / 0.1 mg norethindrone acetate (DRUG); 1 mg estradiol / 0.5 mg norethindrone acetate (DRUG); E2/NETA placebo (DRUG),24785956,Orlissa,Heavy Uterine Bleeding; Uterine Fibroids,Uterus,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5374,NCT00797225,Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis,COMPLETED,PHASE2,Endometriosis,Leuprorelin Acetate Depot (DRUG); Elagolix (DRUG); Placebo to Elagolix (DRUG); Placebo to Leuprorelin Acetate (DRUG),24785956,Orlissa,Endometriosis,Uterus,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5375,NCT03213457,A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain,COMPLETED,PHASE3,Endometriosis,Estradiol/Norethindrone Acetate (DRUG); Placebo for Elagolix (DRUG); Elagolix (DRUG); Placebo for E2/NETA (DRUG),24785956,Orlissa,Endometriosis,Uterus,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5376,NCT01441635,Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids,COMPLETED,PHASE2,Heavy Uterine Bleeding; Uterine Fibroids,Elagolix (DRUG); Placebo (DRUG); Estradiol/Norethindrone acetate (E2/NETA) (DRUG); Estradiol (DRUG); Progesterone (DRUG),24785956,Orlissa,Heavy Uterine Bleeding; Uterine Fibroids,Uterus,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5377,NCT03271489,Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women,COMPLETED,PHASE3,Heavy Menstrual Bleeding; Uterine Fibroids,Elagolix Placebo (OTHER); E2/NETA (DRUG); E2/NETA Placebo (OTHER); Elagolix (DRUG),24785956,Orlissa,Heavy Menstrual Bleeding; Uterine Fibroids,Uterus,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5378,NCT00437658,Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis,COMPLETED,PHASE2,Endometriosis,Elagolix (DRUG); Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) (DRUG); Placebo to Elagolix (DRUG); Placebo to DMPA-SC (DRUG),24785956,Orlissa,Endometriosis,Uterus,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5379,NCT04333576,Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain,RECRUITING,PHASE3,Endometriosis,Elagolix (DRUG); Placebo (DRUG); Combined Oral Contraceptive (DRUG),24785956,Orlissa,Endometriosis,Uterus,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5380,NCT04039204,Elagolix for Fertility Enhancement Clinical Trial,COMPLETED,PHASE2,Endometriosis; Unexplained Infertility,Elagolix (DRUG); Ortho Cyclen (DRUG),24785956,Orlissa,Endometriosis; Unexplained Infertility,Uterus,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5381,NCT06253702,Brain Blood Flow Responses to Stress: Sex Differences,RECRUITING,PHASE4,Cerebrovascular Disorders,Indomethacin (DRUG); Placebo (DRUG); Orilissa (DRUG); Testosterone gel (DRUG); Anastrozole (DRUG); Estradiol (DRUG),24785956,Orlissa,Cerebrovascular Disorders,CNS/Brain,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5382,NCT02143713,Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain,COMPLETED,PHASE3,Endometriosis,Elagolix (DRUG),24785956,Orlissa,Endometriosis,Uterus,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5383,NCT01931670,A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain,COMPLETED,PHASE3,Endometriosis,placebo (OTHER); Elagolix (DRUG),24785956,Orlissa,Endometriosis,Uterus,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5384,NCT01760954,Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain,COMPLETED,PHASE3,Endometriosis,Elagolix (DRUG),24785956,Orlissa,Endometriosis,Uterus,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5385,NCT03951077,Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome,COMPLETED,PHASE2,Polycystic Ovary Syndrome,Elagolix (DRUG); Placebo (DRUG),24785956,Orlissa,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5386,NCT01620528,A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain,COMPLETED,PHASE3,Endometriosis,elagolix (DRUG); placebo (OTHER),24785956,Orlissa,Endometriosis,Uterus,Elagolix sodium,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for endometriosis pain in women.,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],1.8,1969.0 +5387,NCT05696626,Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation,RECRUITING,PHASE3,Metastatic Breast Cancer,Lasofoxifene in combination with abemaciclib (DRUG); Fulvestrant in combination with abemaciclib (DRUG),5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5388,NCT03284957,Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer,TERMINATED,PHASE1,Breast Cancer,Amcenestrant (DRUG); Palbociclib (DRUG); Alpelisib (DRUG); Everolimus (DRUG); Abemaciclib (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5389,NCT04567420,"DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)",RECRUITING,PHASE2,Breast Cancer,Palbociclib (DRUG); Fulvestrant (DRUG); Adjuvant Therapy (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5390,NCT01723774,PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Neoplasms,PD0332991 (DRUG); Anastrozole (DRUG); Goserelin (DRUG); Surgery (standard of care) (PROCEDURE); Tumor biopsy (PROCEDURE),5330286,LQQ,Breast Neoplasms,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5391,NCT02738866,Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Cancer,Palbociclib (DRUG); Fulvestrant (DRUG),5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5392,NCT04478266,Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer,TERMINATED,PHASE3,Breast Cancer,Amcenestrant-matching placebo (DRUG); SAR439859 (DRUG); Palbociclib (DRUG); Letrozole (DRUG); Goserelin (DRUG); Letrozole-matching placebo (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5393,NCT04985266,A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer,RECRUITING,PHASE2,ER+ Breast Cancer; HER2-negative Breast Cancer,Palbociclib 125Mg Tab (DRUG); Fulvestrant injection (DRUG); Tamoxifen (DRUG); Letrozole (DRUG); Exemestane (DRUG); Anastrozole (DRUG),5330286,LQQ,Breast Cancer (ER+/HER2-),Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5394,NCT05563220,Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer,RECRUITING,PHASE1,Breast Cancer; Metastatic Breast Cancer,Elacestrant (DRUG); Alpelisib (DRUG); Everolimus (DRUG); Ribociclib (DRUG); Palbociclib (DRUG); Capivasertib (DRUG); Abemaciclib (DRUG),5330286,LQQ,Breast Cancer; Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5395,NCT04498520,"Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer",WITHDRAWN,PHASE1,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Hormone Receptor Positive Breast Carcinoma; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Metastatic Endometrioid Adenocarcinoma; Metastatic Fallopian Tube Carcinoma; Metastatic HER2 Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Ovarian Carcinoma; Metastatic Primary Peritoneal Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Refractory Breast Carcinoma; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8,Abexinostat Tosylate (DRUG); Fulvestrant (DRUG); Palbociclib (DRUG),5330286,LQQ,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Hormone Receptor Positive Breast Carcinoma; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Metastatic Endometrioid Adenocarcinoma; Metastatic Fallopian Tube Carcinoma; Metastatic HER2 Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Ovarian Carcinoma; Metastatic Primary Peritoneal Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Refractory Breast Carcinoma; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5396,NCT03194373,Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,COMPLETED,PHASE2,Squamous Cell Carcinoma of the Head and Neck,Palbociclib (DRUG); Carboplatin (DRUG),5330286,LQQ,Squamous Cell Carcinoma of the Head and Neck,Skin,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5397,NCT05464173,Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib,RECRUITING,PHASE1,Breast Cancer,Chidamide (DRUG); Abemaciclib (DRUG); endocrinotherapy（doctor's choice） (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5398,NCT02624973,PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Neoadjuvant tamoxifen + goserelin (premenopausal women) (DRUG); Neoadjuvant letrozole (postmenopausal women) (DRUG); Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone) (DRUG); Neoadjuvant docetaxel + cyclophosphamide (DRUG); Neoadjuvant docetaxel (DRUG); Neoadjuvant docetaxel + trastuzumab + pertuzumab (DRUG); Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab (DRUG); Neoadjuvant olaparib (DRUG); Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone) (DRUG); Breast conserving surgery or mastectomy + SNB/axillary dissection (PROCEDURE); Postoperative radiotherapy breast/chest wall + regional lymph nodes (RADIATION); Adjuvant trastuzumab (DRUG); Adjuvant letrozole (postmenopausal women) (DRUG); Adjuvant tamoxifen + goserelin (premenopausal women) (DRUG); Adjuvant palbociclib (if palbociclib given neoadjuvant) (DRUG); Adjuvant Epirubicin+ Cyclophosphamide (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5399,NCT03355157,"A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).",COMPLETED,PHASE4,Metastatic Breast Cancer,"Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen) (DRUG)",5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5400,NCT02022982,PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors,COMPLETED,PHASE1,KRAS Mutant Non-Small Cell Lung Cancer; Solid Tumors,Palbociclib (DRUG); PD-0325901 (DRUG),5330286,LQQ,KRAS Mutant Non-Small Cell Lung Cancer; Solid Tumors,Lung,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5401,NCT03854903,"WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor",COMPLETED,PHASE1,Metastatic Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Hormone Receptor Positive Breast Cancer,Palbociclib (DRUG); Bosutinib (DRUG); Fulvestrant (DRUG),5330286,LQQ,Metastatic Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Hormone Receptor Positive Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5402,NCT05429684,Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer,UNKNOWN,PHASE3,HER2+ Breast Cancer,Trastuzumab (DRUG); Pertuzumab (DRUG); Nab paclitaxel (DRUG); Pyrotinib (DRUG); Capecitabine (DRUG); T-DM1 (DRUG); Everolimus (DRUG); CDK4/6 inhibitor (DRUG); AI (DRUG); Anti-PD-1 monoclonal antibody (DRUG),5330286,LQQ,HER2+ Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5403,NCT01037790,Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer,COMPLETED,PHASE2,Adult Solid Tumor; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Adult Central Nervous System Germ Cell Tumor; Adult Teratoma; Benign Teratoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Familial Testicular Germ Cell Tumor; HER2-negative Breast Cancer; HER2-positive Breast Cancer; Male Breast Cancer; Ovarian Immature Teratoma; Ovarian Mature Teratoma; Ovarian Monodermal and Highly Specialized Teratoma; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell Tumor; Recurrent Extragonadal Seminoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Melanoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Rectal Cancer; Stage III Extragonadal Non-seminomatous Germ Cell Tumor; Stage III Extragonadal Seminoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Ovarian Germ Cell Tumor; Stage IV Breast Cancer; Stage IV Colon Cancer; Stage IV Extragonadal Non-seminomatous Germ Cell Tumor; Stage IV Extragonadal Seminoma; Stage IV Melanoma; Stage IV Ovarian Germ Cell Tumor; Stage IV Rectal Cancer; Testicular Immature Teratoma; Testicular Mature Teratoma,PD-0332991 (DRUG),5330286,LQQ,Adult Solid Tumor; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Adult Central Nervous System Germ Cell Tumor; Adult Teratoma; Benign Teratoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Familial Testicular Germ Cell Tumor; HER2-negative Breast Cancer; HER2-positive Breast Cancer; Male Breast Cancer; Ovarian Immature Teratoma; Ovarian Mature Teratoma; Ovarian Monodermal and Highly Specialized Teratoma; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell Tumor; Recurrent Extragonadal Seminoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Melanoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Rectal Cancer; Stage III Extragonadal Non-seminomatous Germ Cell Tumor; Stage III Extragonadal Seminoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Ovarian Germ Cell Tumor; Stage IV Breast Cancer; Stage IV Colon Cancer; Stage IV Extragonadal Non-seminomatous Germ Cell Tumor; Stage IV Extragonadal Seminoma; Stage IV Melanoma; Stage IV Ovarian Germ Cell Tumor; Stage IV Rectal Cancer; Testicular Immature Teratoma; Testicular Mature Teratoma,Bowel,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5404,NCT03184090,Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC,COMPLETED,PHASE2,Metastatic Breast Cancer,Palbociclib (DRUG); Endocrine therapy (non IMP) (DRUG),5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5405,NCT05293964,"Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,SIM0270 (DRUG); Palbociclib (DRUG); everolimus (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5406,NCT06064812,A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC.,RECRUITING,PHASE1,Metastatic Breast Cancer; Locally Advanced Breast Cancer; Breast Cancer Stage I; ER+ Breast Cancer,FWD1802 (DRUG); palbocilib (DRUG),5330286,LQQ,Metastatic Breast Cancer; Locally Advanced Breast Cancer; Breast Cancer Stage I; ER+ Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5407,NCT03377101,"Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer",WITHDRAWN,PHASE2,Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Stage IV Breast Cancer AJCC v6 and v7,Copanlisib (DRUG); Fulvestrant (DRUG); Laboratory Biomarker Analysis (OTHER); Palbociclib (DRUG),5330286,LQQ,Stage IV Hormone Receptor Positive HER2 Negative Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5408,NCT02592746,A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC,UNKNOWN,PHASE2,Metastatic Breast Cancer,Palbociclib (DRUG); Exemestane (DRUG); Leuprolide Acetate (DRUG); Capecitabine (DRUG),5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5409,NCT02334527,Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy,TERMINATED,PHASE2,Metastatic Urothelial Carcinoma (UC),Palbociclib (DRUG),5330286,LQQ,Metastatic Urothelial Carcinoma (UC),Bladder/Urinary Tract,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5410,NCT06570031,ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer,ONO-4578 (DRUG); letrozole (DRUG); Palbociclib (DRUG); abemaciclib (DRUG),5330286,LQQ,Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5411,NCT02499120,Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer,COMPLETED,PHASE2,Squamous Cell Carcinoma of the Head and Neck (SCCHN),palbociclib (DRUG); Cetuximab (DRUG); Placebo (DRUG),5330286,LQQ,Squamous Cell Carcinoma of the Head and Neck,Skin,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5412,NCT03560531,A Study of ZN-c5 in Subjects With Breast Cancer,COMPLETED,PHASE1,Breast Cancer,ZN-c5 (DRUG); Palbociclib (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5413,NCT03633331,"Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer",UNKNOWN,PHASE2,Estrogen Receptor-positive Breast Cancer; HER2/Neu Negative; Stage IV Breast Cancer AJCC v6 and v7,Palbociclib (DRUG); Letrozole (DRUG); Fulvestrant (DRUG); Questionnaire Administration (OTHER); Quality-of-Life Assessment (OTHER),5330286,LQQ,Estrogen Receptor-positive Breast Cancer; HER2/Neu Negative; Stage IV Breast Cancer AJCC v6 and v7,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5414,NCT03685331,"HOPE: Olaparib, Palbociclib and Fulvestrant in Patients with BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Breast Cancer; Locally Advanced Breast Cancer; Advanced Breast Cancer; BRCA2 Mutation; BRCA1 Mutation,Palbociclib (DRUG); Olaparib (DRUG); Fulvestrant (DRUG),5330286,LQQ,Metastatic Breast Cancer; Locally Advanced Breast Cancer; Advanced Breast Cancer; BRCA2 Mutation; BRCA1 Mutation,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5415,NCT05238831,SMMART Adaptive Clinical Treatment (ACT) Trial,WITHDRAWN,EARLY_PHASE1,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Alectinib (DRUG); Alpelisib (DRUG); Anastrozole (DRUG); Atezolizumab (BIOLOGICAL); Bevacizumab (BIOLOGICAL); Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Capecitabine (DRUG); Carboplatin (DRUG); Cobimetinib (DRUG); Entrectinib (DRUG); Eribulin (DRUG); Fulvestrant (DRUG); Hyaluronidase-zzxf/Pertuzumab/Trastuzumab (BIOLOGICAL); Irinotecan (DRUG); Letrozole (DRUG); Nab-paclitaxel (DRUG); Niraparib (DRUG); Olaparib (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Pertuzumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Trastuzumab (BIOLOGICAL); Trastuzumab Emtansine (BIOLOGICAL); Vemurafenib (DRUG); Vinorelbine (DRUG); Vismodegib (DRUG),5330286,LQQ,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Ovary/Fallopian Tube,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5416,NCT04220476,CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer,WITHDRAWN,PHASE2,Breast Cancer,Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions) (RADIATION); Letrozole 2.5Mg Tab (DRUG); Palbociclib 125mg (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5417,NCT02499146,"Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Advanced Breast Cancer,Palbociclib (DRUG); Letrozole (DRUG),5330286,LQQ,Advanced Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5418,NCT03709082,Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer,TERMINATED,PHASE1,HER2-positive Breast Cancer; Breast Cancer Metastatic,Palbociclib 75mg (DRUG); Letrozole 2.5mg (DRUG); T-DM1 (DRUG); Palbociclib 100mg (DRUG); Palbociclib 125mg (DRUG); Palbociclib (DRUG),5330286,LQQ,HER2-positive Breast Cancer; Breast Cancer Metastatic,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5419,NCT05935748,Ph2 Study NKT2152 with Palbociclib & Sasanlimab in Subjects with Advanced Clear Cell Renal Cell Carcinoma (ccRcc),ACTIVE_NOT_RECRUITING,PHASE2,"CcRCC; Clear Cell Renal Cell Carcinoma; Kidney Cancer; Kidney Neoplasms; Renal Cancer; Renal Neoplasms; Recurrent Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Refractory Renal Cell Carcinoma; Advanced Renal Cell Carcinoma; Carcinoma; Neoplasms; Carcinoma, Renal Cell; Neoplasms, Glandular and Epithelial; Neoplasm by Histology; Adenocarcinoma; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Kidney Diseases; Urologic Diseases",NKT2152 (DRUG); palbociclib (DRUG); sasanlimab (OTHER),5330286,LQQ,"CcRCC; Clear Cell Renal Cell Carcinoma; Kidney Cancer; Kidney Neoplasms; Renal Cancer; Renal Neoplasms; Recurrent Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Refractory Renal Cell Carcinoma; Advanced Renal Cell Carcinoma; Carcinoma; Neoplasms; Carcinoma, Renal Cell; Neoplasms, Glandular and Epithelial; Neoplasm by Histology; Adenocarcinoma; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Kidney Diseases; Urologic Diseases",Kidney,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5420,NCT03573648,"Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Avelumab (DRUG); Endocrine therapy (DRUG); Palbociclib (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5421,NCT02549430,To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy,COMPLETED,PHASE2,Breast Cancer,Palbociclib (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5422,NCT02668666,Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer,COMPLETED,PHASE2,Hormone Receptor Positive Malignant Neoplasm of Breast; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Estrogen Receptor Positive Breast Cancer; Progesterone Receptor Positive Tumor; Metastatic Breast Cancer,Palbociclib (DRUG); Tamoxifen (DRUG),5330286,LQQ,Hormone Receptor Positive Malignant Neoplasm of Breast; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Estrogen Receptor Positive Breast Cancer; Progesterone Receptor Positive Tumor; Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5423,NCT03628066,Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Letrozole (DRUG); Palbociclib (DRUG); Goserelin (DRUG); Oncotype DX Breast Recurrence Score (DIAGNOSTIC_TEST),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5424,NCT02760030,Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients with Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery,ACTIVE_NOT_RECRUITING,PHASE2,Estrogen Receptor And/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Fulvestrant (DRUG); Laboratory Biomarker Analysis (OTHER); Palbociclib (DRUG); Questionnaire Administration (OTHER); Aromatase Inhibitors (DRUG),5330286,LQQ,Estrogen Receptor And/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5425,NCT02384239,A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer; Hormone Receptor Positive,Palbociclib (DRUG); Tamoxifen (DRUG); Fulvestrant (DRUG),5330286,LQQ,Metastatic Breast Cancer; Hormone Receptor Positive,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5426,NCT05768139,First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors,RECRUITING,PHASE1,"Breast Cancer; Gynecologic Cancer; HNSCC; Solid Tumors, Adult",STX-478 (DRUG); Fulvestrant (DRUG); Ribociclib (DRUG); Palbociclib (DRUG),5330286,LQQ,"Breast Cancer; Gynecologic Cancer; HNSCC; Solid Tumors, Adult",Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5427,NCT05501886,Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1),RECRUITING,PHASE3,Breast Cancer,Gedatolisib (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG); Alpelisib (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5428,NCT01740427,A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2),COMPLETED,PHASE3,Breast Neoplasms,PD-0332991 (DRUG); Letrozole (DRUG); Placebo (DRUG); Letrozole (DRUG),5330286,LQQ,Breast Neoplasms,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5429,NCT02040857,"Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer",COMPLETED,PHASE2,Breast Cancer,Palbociclib (DRUG); Aromatase Inhibitor (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5430,NCT05067530,"Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a ""Window of Opportunity"" Study",NOT_YET_RECRUITING,PHASE2,Triple Negative Breast Neoplasms,Palbociclib (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG),5330286,LQQ,Triple Negative Breast Neoplasms,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5431,NCT03644186,To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH),COMPLETED,PHASE2,Breast Cancer; Estrogen Receptor Positive Tumor; HER2-positive Breast Cancer,Paclitaxel (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); Palbociclib (DRUG); Letrozole (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG),5330286,LQQ,Breast Cancer; Estrogen Receptor Positive Tumor; HER2-positive Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5432,NCT01823835,A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer,TERMINATED,PHASE1,Breast Cancer,GDC-0810 (DRUG); LHRH Agonist (DRUG); Palbociclib (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5433,NCT06757335,A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer,NOT_YET_RECRUITING,PHASE1,Breast Cancer,HP568 (DRUG); HP568 in combination with palbociclib (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5434,NCT03820830,Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer Recurrent,Palbociclib 125mg (DRUG); Standard endocrine therapy (DRUG),5330286,LQQ,Recurrent Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5435,NCT06065748,"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)",RECRUITING,PHASE3,"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer",Giredestrant (DRUG); Fulvestrant (DRUG); Abemaciclib (DRUG); Palbociclib (DRUG); Ribociclib (DRUG); LHRH Agonist (DRUG); FoundationOne Liquid CDx Assay (F1LCDx) (DIAGNOSTIC_TEST),5330286,LQQ,"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer",Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5436,NCT04494958,Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer,COMPLETED,PHASE1,Triple Negative Breast Cancer,"Combination, Palbociclib + Binimetinib (DRUG)",5330286,LQQ,Triple Negative Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5437,NCT04060862,A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer,TERMINATED,PHASE1,Breast Cancer,Ipatasertib (DRUG); Placebo (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5438,NCT03065062,"Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors",RECRUITING,PHASE1,Lung Cancer Squamous Cell; Solid Tumors; Head & Neck Cancer; Pancreatic Cancer,Palbociclib (DRUG); Gedatolisib (DRUG),5330286,LQQ,Lung Cancer Squamous Cell; Solid Tumors; Head & Neck Cancer; Pancreatic Cancer,Lung,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5439,NCT02513394,PALbociclib CoLlaborative Adjuvant Study,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Palbociclib (DRUG); Standard Adjuvant Endocrine Therapy (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5440,NCT03386929,Survival Prolongation by Rationale Innovative Genomics,TERMINATED,PHASE1,Non-small Cell Lung Cancer Metastatic; Non-small Cell Lung Cancer Stage IIIB,Avelumab (DRUG); Axitinib (DRUG); Palbociclib (DRUG),5330286,LQQ,Non-small Cell Lung Cancer Metastatic; Non-small Cell Lung Cancer Stage IIIB,Lung,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5441,NCT02730429,Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer,COMPLETED,PHASE2,Endometrial Cancer,Palbociclib/placebo (DRUG); Letrozole (DRUG),5330286,LQQ,Endometrial Cancer,Uterus,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5442,NCT03304080,"Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast",ACTIVE_NOT_RECRUITING,PHASE1,Breast Neoplasms; Breast Diseases,Anastrozole (DRUG); Palbociclib (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG),5330286,LQQ,Breast Neoplasms; Breast Diseases,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5443,NCT04288089,A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,"Receptors, Estrogen; Genes, Erbb-2; Breast Neoplasms","Palbociclib (75, 100, 125 milligram [mg]) (DRUG); H3B-6545 (150, 300, 450 mg) (DRUG)",5330286,LQQ,"Receptors, Estrogen; Genes, Erbb-2; Breast Neoplasms",Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5444,NCT02871791,Palbociclib With Everolimus + Exemestane In BC,COMPLETED,PHASE1,Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Hormone Receptor (HR)-Positive Breast Cancer,Palbociclib (DRUG); Everolimus (DRUG); Exemestane (DRUG),5330286,LQQ,Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Hormone Receptor (HR)-Positive Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5445,NCT03959891,"AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)",ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,Ipatasertib (DRUG); Fulvestrant (DRUG); Aromatase Inhibitor (DRUG); Palbociclib (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5446,NCT03709680,Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE2,Ewing Sarcoma; Solid Tumors; Rhabdoid Tumor; Rhabdomyosarcoma; Neuroblastoma; Medulloblastoma; Diffuse Intrinsic Pontine Glioma,Palbociclib (DRUG); Temozolomide (DRUG); Irinotecan (DRUG); Topotecan (DRUG); Cyclophosphamide (DRUG),5330286,LQQ,Ewing Sarcoma; Solid Tumors; Rhabdoid Tumor; Rhabdomyosarcoma; Neuroblastoma; Medulloblastoma; Diffuse Intrinsic Pontine Glioma,CNS/Brain,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5447,NCT05190094,"Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.",RECRUITING,PHASE2,"Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer",Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole) (DRUG),5330286,LQQ,"Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer",Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5448,NCT02690480,Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer,UNKNOWN,PHASE2,Breast Neoplasms,PD-0332991 (Palbociclib) (DRUG); Fulvestrant (DRUG); Placebo (DRUG),5330286,LQQ,Breast Neoplasms,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5449,NCT03471663,A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer,COMPLETED,PHASE1,Breast Cancer,D-0502 (DRUG); palbociclib (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5450,NCT03454035,Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors,RECRUITING,PHASE1,"Tumor, Solid; Pancreatic Cancer; Melanoma",Ulixertinib (DRUG); Palbociclib (DRUG),5330286,LQQ,"Tumor, Solid; Pancreatic Cancer; Melanoma",Pancreas,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5451,NCT03054363,"Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer",COMPLETED,PHASE1,Breast Cancer,Tucatinib in Combination with Palbociclib and Letrozole (DRUG); Tucatinib in Combination with Palbociclib and Letrozole (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5452,NCT03238196,"Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer",COMPLETED,PHASE1,Metastatic Breast Cancer,Erdafitinib (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG),5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5453,NCT03530696,T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer,COMPLETED,PHASE2,HER2-positive Breast Cancer; Breast Cancer; Breast Cancer Stage; Recurrent Breast Cancer; Metastatic Breast Cancer; HER2 Positive Breast Carcinoma,Palbociclib (DRUG); T-DM1 (DRUG),5330286,LQQ,HER2-positive Breast Cancer; Breast Cancer; Breast Cancer Stage; Recurrent Breast Cancer; Metastatic Breast Cancer; HER2 Positive Breast Carcinoma,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5454,NCT02785939,Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer,COMPLETED,PHASE2,CCND1 Gene Amplification; CCND2 Gene Amplification; CCND3 Gene Amplification; CDK4 Gene Amplification; Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7,Docetaxel (DRUG); Laboratory Biomarker Analysis (OTHER); Palbociclib (DRUG),5330286,LQQ,CCND1 Gene Amplification; CCND2 Gene Amplification; CCND3 Gene Amplification; CDK4 Gene Amplification; Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7,Lung,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5455,NCT02605486,Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC),ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Breast Cancer (MBC),Palbociclib (DRUG); Bicalutamide (DRUG),5330286,LQQ,Metastatic Breast Cancer (MBC),Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5456,NCT03439735,Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC,RECRUITING,PHASE2,Breast Cancer,Endocrine Therapy and a CDK 4/6 inhibitor (DRUG); Endocrine Therapy and a CDK 4/6 inhibitor (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5457,NCT04585724,"Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases",WITHDRAWN,PHASE1,Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Prognostic Stage IV Breast Cancer AJCC v8,Abemaciclib (DRUG); Palbociclib (DRUG); Quality-of-Life Assessment (OTHER); Ribociclib (DRUG),5330286,LQQ,Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Prognostic Stage IV Breast Cancer AJCC v8,CNS/Brain,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5458,NCT01942135,Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3),COMPLETED,PHASE3,Metastatic Breast Cancer,Palbociclib (DRUG); Fulvestrant (DRUG); Placebo (DRUG); Fulvestrant (DRUG),5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5459,NCT03819010,"Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -",COMPLETED,PHASE2,Breast Cancer,Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib (DRUG); Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5460,NCT04436744,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)",COMPLETED,PHASE2,Early Breast Cancer,Giredestrant (DRUG); Anastrozole (DRUG); Palbociclib (DRUG); Surgery (PROCEDURE),5330286,LQQ,Early Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5461,NCT03006172,"To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer; Solid Tumor,Inavolisib (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Palbociclib (DRUG); Metformin (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG),5330286,LQQ,Breast Cancer; Solid Tumor,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5462,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,HER2+/HR+ Breast Cancer,ZW25 (Zanidatamab) (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG),5330286,LQQ,HER2+/HR+ Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5463,NCT04075604,A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Cancer,Nivolumab (BIOLOGICAL); Anastrozole (DRUG); Palbociclib (DRUG),5330286,LQQ,Breast Cancer; Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5464,NCT02296801,A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Breast Carcinoma; Breast Tumors,Letrozole (DRUG); palbociclib (DRUG),5330286,LQQ,Breast Cancer; Breast Carcinoma; Breast Tumors,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5465,NCT04137640,Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy,NOT_YET_RECRUITING,PHASE4,Breast Cancer,palbociclib combined with letrozole (DRUG); epirubicin combined with cyclophosphamide and sequential docetaxel (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5466,NCT05766410,"A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC",RECRUITING,PHASE2,Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Therapy,Palbociclib (DRUG); Ribociclib (DRUG); Abemaciclib (DRUG); Letrozole (DRUG),5330286,LQQ,Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Therapy,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5467,NCT02400567,"Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women",COMPLETED,PHASE2,Neoadjuvant Operable Breast Cancer,Fluorouracile (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Letrozole (DRUG); Palbociclib (DRUG),5330286,LQQ,Neoadjuvant Operable Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5468,NCT06065592,Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms,RECRUITING,PHASE1,Cancer; Solid Tumor; Thromboembolism; Cardiovascular Diseases; Immune System Diseases; Inflammatory Diseases; Colon Cancer; Breast Cancer; Prostate Cancer; Hepatocellular Carcinoma; Lung Cancer; Chemotherapy; Immunotherapy,Palbociclib (DRUG); Rivaroxaban (DRUG); SNP (GENETIC),5330286,LQQ,Cancer; Solid Tumor; Thromboembolism; Cardiovascular Diseases; Immune System Diseases; Inflammatory Diseases; Colon Cancer; Breast Cancer; Prostate Cancer; Hepatocellular Carcinoma; Lung Cancer; Chemotherapy; Immunotherapy,Bowel,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5469,NCT01320592,PD0332991/Paclitaxel in Advanced Breast Cancer,COMPLETED,PHASE1,Breast Cancer,PD0332991 (DRUG); Paclitaxel (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5470,NCT03158389,NCT Neuro Master Match - N²M² (NOA-20),COMPLETED,PHASE1,"Glioblastoma, Adult",APG101 (DRUG); Alectinib (DRUG); Idasanutlin (DRUG); Atezolizumab (DRUG); Vismodegib (DRUG); Temsirolimus (DRUG); Palbociclib (DRUG),5330286,LQQ,"Glioblastoma, Adult",CNS/Brain,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5471,NCT04047758,Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer,UNKNOWN,PHASE3,Breast Cancer,Palbociclib + Letrozole (DRUG); Letrozole (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5472,NCT02530424,"""Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment """,COMPLETED,PHASE2,Breast Neoplasms,Trastuzumab (DRUG); Pertuzumab (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG),5330286,LQQ,Breast Neoplasms,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5473,NCT04964934,Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6),ACTIVE_NOT_RECRUITING,PHASE3,ER-Positive HER2-Negative Breast Cancer,AZD9833 (DRUG); AZD9833 Placebo (DRUG); Anastrozole (DRUG); Anastrozole placebo (DRUG); Letrozole (DRUG); Letrozole placebo (DRUG); Palbociclib (DRUG); Abemaciclib (DRUG); Luteinizing hormone-releasing hormone (LHRH) agonist (DRUG); Ribociclib (DRUG),5330286,LQQ,ER-Positive HER2-Negative Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5474,NCT06176534,"Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial",RECRUITING,PHASE2,Advanced Breast Cancer; Treatment; HR Low/HER2 Negative,Experimental: chemotheyapy (DRUG); Active Comparator: endocrine therapy (DRUG),5330286,LQQ,Advanced Breast Cancer; Treatment; HR Low/HER2 Negative,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5475,NCT05949424,OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults,NOT_YET_RECRUITING,PHASE4,Renal Cell Carcinoma; Ovarian Carcinoma; Thyroid Carcinoma; Breast Carcinoma; Endometrium Carcinoma,Olaparib (DRUG); Lenvatinib (DRUG); Sunitinib (DRUG); Palbociclib (DRUG); Pazopanib (DRUG); Olaparib (DRUG); Lenvatinib (DRUG); Sunitinib (DRUG); Palbociclib (DRUG); Pazopanib (DRUG),5330286,LQQ,Renal Cell Carcinoma; Ovarian Carcinoma; Thyroid Carcinoma; Breast Carcinoma; Endometrium Carcinoma,Kidney,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5476,NCT04858516,"Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer",UNKNOWN,PHASE2,"Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer",palbociclib and exemestane plus trastuzumab and pyrotinib (DRUG),5330286,LQQ,"Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer",Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5477,NCT03774472,"Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer",COMPLETED,PHASE1,Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8,Hydroxychloroquine (DRUG); Letrozole (DRUG); Palbociclib (DRUG),5330286,LQQ,Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5478,NCT04606446,Study of PF-07248144 in Advanced or Metastatic Solid Tumors,RECRUITING,PHASE1,Locally Advanced or Metastatic ER+ HER2- Breast Cancer; Locally Advanced or Metastatic Castration-resistant Prostate Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer,PF-07248144 (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Palbociclib (DRUG); PF-07220060 (DRUG),5330286,LQQ,Locally Advanced or Metastatic ER+ HER2- Breast Cancer; Locally Advanced or Metastatic Castration-resistant Prostate Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer,Lung,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5479,NCT01864746,A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery,COMPLETED,PHASE3,Breast Cancer; Hormonreceptor Positive; Her2-normal; Postneoadjuvant Treatment With CDK 4/6 Inhibitor; CPS-EG Score,Palbociclib PD-0332991 (DRUG); Placebo (DRUG),5330286,LQQ,Breast Cancer; Hormonreceptor Positive; Her2-normal; Postneoadjuvant Treatment With CDK 4/6 Inhibitor; CPS-EG Score,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5480,NCT01976169,Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1),COMPLETED,PHASE1,Advanced Breast Cancer,PD-0332991 and T-DM1 (DRUG),5330286,LQQ,Advanced Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5481,NCT04720768,"Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE",RECRUITING,PHASE1,Melanoma; Metastasis,Binimetinib (DRUG); Encorafenib (DRUG); Palbociclib (DRUG),5330286,LQQ,Metastatic Melanoma,Skin,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5482,NCT05554367,"Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial",RECRUITING,PHASE2,Exocrine Pancreas Carcinoma; Malignant Solid Neoplasm; Ovarian Low Grade Serous Adenocarcinoma; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Binimetinib (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Palbociclib (DRUG),5330286,LQQ,Exocrine Pancreas Carcinoma; Malignant Solid Neoplasm; Ovarian Low Grade Serous Adenocarcinoma; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Pancreas,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5483,NCT04256941,"Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study",TERMINATED,PHASE2,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8,Abemaciclib (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Palbociclib (DRUG); Ribociclib (DRUG),5330286,LQQ,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5484,NCT03913234,"Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients",UNKNOWN,PHASE1,HER2-positive Breast Cancer; Postmenopausal; Metastatic Breast Cancer,"Ribociclib, Trastuzumab, Letrozole (DRUG)",5330286,LQQ,HER2-positive Breast Cancer; Postmenopausal; Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5485,NCT02008734,Randomized Phase II Study to Assess PD 0332991 in Breast Cancer,COMPLETED,PHASE2,Untreated Operable Early Breast Cancer,PD0332991 (DRUG),5330286,LQQ,Untreated Operable Early Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5486,NCT01291017,"Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.",COMPLETED,PHASE2,Non-small Cell Lung Cancer,PD0332991 (DRUG),5330286,LQQ,Non-small Cell Lung Cancer,Lung,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5487,NCT04870034,"Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer",WITHDRAWN,EARLY_PHASE1,Colorectal Carcinoma; Lung Adenocarcinoma; Malignant Solid Neoplasm; Pancreatic Carcinoma,Binimetinib (DRUG); Palbociclib (DRUG); Therapeutic Conventional Surgery (PROCEDURE),5330286,LQQ,Colorectal Carcinoma; Lung Adenocarcinoma; Malignant Solid Neoplasm; Pancreatic Carcinoma,Bowel,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5488,NCT04360941,PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer,RECRUITING,PHASE1,Triple Negative Breast Cancer; Locally Advanced Breast Cancer; Recurrent Breast Cancer; Metastatic Breast Cancer; ER+ Breast Cancer; HER2-positive Breast Cancer,Palbociclib (DRUG); Avelumab (DRUG),5330286,LQQ,Triple Negative Breast Cancer; Locally Advanced Breast Cancer; Recurrent Breast Cancer; Metastatic Breast Cancer; ER+ Breast Cancer; HER2-positive Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5489,NCT05384119,Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer,TERMINATED,PHASE1,Breast Cancer,TTI-101 (DRUG); Palbociclib (DRUG); Aromatase inhibitor (AI) (DRUG); fulvestrant (DRUG); ribociclib (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5490,NCT01227434,A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma,TERMINATED,PHASE2,Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma,PD 0332991 (pre-surgery) (DRUG); PD 0332991 (DRUG); Resection as clinical care (PROCEDURE),5330286,LQQ,Malignant Glioma,CNS/Brain,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5491,NCT03128619,"Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer",TERMINATED,PHASE1,Estrogen Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multifocal Breast Carcinoma; Postmenopausal; Progesterone Receptor Positive; Stage I Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Biopsy of Breast (PROCEDURE); Copanlisib (DRUG); Laboratory Biomarker Analysis (OTHER); Letrozole (DRUG); Palbociclib (DRUG); Pharmacological Study (OTHER),5330286,LQQ,Estrogen Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multifocal Breast Carcinoma; Postmenopausal; Progesterone Receptor Positive; Stage I Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5492,NCT03454919,Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations,UNKNOWN,PHASE2,Melanoma,Palbociclib (DRUG),5330286,LQQ,Melanoma,Skin,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5493,NCT02764541,Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS),ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Letrozole (DRUG); Tamoxifen (DRUG); Palbociclib (DRUG); Endocrine Therapy (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5494,NCT02907918,Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer,TERMINATED,PHASE2,Breast Cancer; Cancer of Breast; Breast Carcinoma,Palbociclib (DRUG); Letrozole (DRUG); Trastuzumab (BIOLOGICAL); Goserelin (DRUG); Breast surgery (PROCEDURE); Research tumor biopsy (PROCEDURE); Research bone marrow (OPTIONAL) (PROCEDURE); Research blood sample (PROCEDURE); Research blood for germline DNA (GENETIC); Blood for detection of circulating tumor cells (PROCEDURE),5330286,LQQ,Breast Cancer; Cancer of Breast; Breast Carcinoma,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5495,NCT04012918,"Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study",UNKNOWN,PHASE2,Metastatic Breast Cancer,Capecitabine plus aromatase inhibitor (DRUG); A.I. (DRUG),5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5496,NCT03526250,"Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)",COMPLETED,PHASE2,Advanced Malignant Solid Neoplasm; Recurrent Childhood Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Kidney Wilms Tumor; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma,Laboratory Biomarker Analysis (OTHER); Palbociclib (DRUG); Pharmacological Study (OTHER),5330286,LQQ,Advanced Malignant Solid Neoplasm; Recurrent Childhood Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Kidney Wilms Tumor; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma,CNS/Brain,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5497,NCT05933395,Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor,RECRUITING,PHASE2,Advanced Breast Cancer,Fulvestrant (DRUG); Neratinib (DRUG); Alpelisib (DRUG); Everolimus (DRUG); Abemaciclib (DRUG),5330286,LQQ,Advanced Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5498,NCT03284723,PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors,TERMINATED,PHASE1,Breast Neoplasms,PF-06804103 (DRUG); PF-06804103 + Palbociclib +Letrozole (DRUG),5330286,LQQ,Breast Neoplasms,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5499,NCT05069038,Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy,RECRUITING,PHASE2,Breast Cancer,Palbociclib 125mg (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5500,NCT04920708,"Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression",RECRUITING,PHASE2,Metastatic Breast Cancer; ER+ Breast Cancer; Advanced Breast Cancer,Ipatasertib 300mg (DRUG); Fulvestrant 500g (DRUG); Palbociclib 75mg-125mg (DRUG); CDK4/6 Inhibitor (DRUG),5330286,LQQ,Metastatic Breast Cancer; ER+ Breast Cancer; Advanced Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5501,NCT04966481,"Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor",RECRUITING,PHASE3,HPV-unrelated Head and Neck Squamous Cell Carcinoma,Palbociclib (DRUG); Cetuximab (DRUG),5330286,LQQ,HPV-unrelated Head and Neck Squamous Cell Carcinoma,Skin,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5502,NCT02774681,Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis,TERMINATED,PHASE2,Breast Carcinoma Metastatic in the Brain; Estrogen Receptor Negative; HER2/Neu Negative; HER2/Neu Positive; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Cognitive Assessment (PROCEDURE); Palbociclib (DRUG); Quality-of-Life Assessment (PROCEDURE); Trastuzumab (BIOLOGICAL),5330286,LQQ,Breast Carcinoma Metastatic in the Brain; Estrogen Receptor Negative; HER2/Neu Negative; HER2/Neu Positive; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5503,NCT02942355,Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Female Breast Carcinoma; Breast Cancer,anastrozole (DRUG); Palbociclib (DRUG),5330286,LQQ,Female Breast Carcinoma; Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5504,NCT02679755,"Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer",COMPLETED,PHASE4,Breast Cancer,Palbociclib (DRUG); Letrozole (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5505,NCT02692755,Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer,COMPLETED,PHASE2,Hormone Receptor Positive HER-2 Negative Breast Cancer,Palbociclib + Letrozole or Fulvestrant (DRUG),5330286,LQQ,Hormone Receptor Positive HER-2 Negative Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5506,NCT02806050,Palbociclib and FES PET,COMPLETED,PHASE2,Breast Cancer,Palbociclib (DRUG); FES PET (DEVICE); Letrozole (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5507,NCT02085538,Study Of Palbociclib (PD-0332991) In Renal Impairment,COMPLETED,PHASE1,Renal Impairment,palbociclib (DRUG); palbociclib (DRUG); palbociclib (DRUG); palbociclib (DRUG),5330286,LQQ,Renal Impairment,Kidney,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5508,NCT06044623,Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients,RECRUITING,PHASE3,Metastatic Breast Cancer; Advanced Breast Cancer; Quality of Life; Toxicity; Older Patients,CDK 4/6 inhibitors (DRUG); Endocrine therapy (DRUG),5330286,LQQ,Metastatic Breast Cancer; Advanced Breast Cancer; Quality of Life; Toxicity; Older Patients,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5509,NCT02599714,Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer,COMPLETED,PHASE1,Advanced and Metastatic Breast Cancer,AZD2014 (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG),5330286,LQQ,Advanced and Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5510,NCT05816655,"Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer",RECRUITING,PHASE2,Metastatic Breast Cancer,Fulvestrant plus AI plus ribociclib (DRUG); AI plus ribociclib (DRUG),5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5511,NCT03981614,Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Unresectable Carcinoma,Binimetinib (DRUG); Palbociclib (DRUG); Trifluridine and Tipiracil Hydrochloride (DRUG),5330286,LQQ,Metastatic Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Unresectable Carcinoma,Bowel,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5512,NCT02600923,Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate,COMPLETED,PHASE3,Advanced Breast Cancer Female,Palbociclib (DRUG); Letrozole (DRUG),5330286,LQQ,Advanced Breast Cancer Female,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5513,NCT04318223,Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy,UNKNOWN,PHASE2,Metastatic Breast Cancer; Locally Advanced Breast Cancer,Palbociclib (DRUG),5330286,LQQ,Metastatic Breast Cancer; Locally Advanced Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5514,NCT05826964,Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer,RECRUITING,PHASE2,Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer,AI+CDK4/6i (DRUG); SERD+CDK4/6i (DRUG); mTOR inhibitor + AI (DRUG); mTOR inhibitor + SERD (DRUG); mTOR inhibitor + Selective estrogen receptor modulator (DRUG); PI3K inhibitor + SERD (DRUG); PI3K inhibitor + AI (DRUG); Chemotherapy (DRUG); Oral SERD (DRUG),5330286,LQQ,Metastatic ER-positive/HER2-negative Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5515,NCT05076695,"Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer",UNKNOWN,PHASE2,Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer,Palbociclib (DRUG); trastuzumab (DRUG); pyrotinib (DRUG); fulvestrant (DRUG),5330286,LQQ,Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5516,NCT03425838,Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Neoplasm Female,CDK 4/6 inhibitor (DRUG); Non-Steroidal Aromatase Inhibitor (DRUG); Fulvestrant (DRUG),5330286,LQQ,Female Breast Neoplasm,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5517,NCT05759949,First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,"PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid Tumor; Hormone Receptor Positive Tumor",RLY-5836 (DRUG); Fulvestrant (DRUG); Palbociclib (DRUG); Ribociclib (DRUG); Abemaciclib (DRUG),5330286,LQQ,PIK3CA-Mutated Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5518,NCT06307249,Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA,RECRUITING,PHASE1,Cancer; Solid Tumor; Colorectal Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Targeted Therapy; Chemotherapy; Immunotherapy; Precision Therapy,SNP (GENETIC); Palbociclib 125mg (DRUG); Bevacizumab (DRUG),5330286,LQQ,Cancer; Solid Tumor; Colorectal Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Targeted Therapy; Chemotherapy; Immunotherapy; Precision Therapy,Bowel,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5519,NCT04191499,"A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Inavolisib (DRUG); Placebo (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5520,NCT02389842,PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib,COMPLETED,PHASE1,Advanced Solid Tumours; Breast Cancer,Palbociclib + Taselisib / Pictilisib (DRUG),5330286,LQQ,Advanced Solid Tumours; Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5521,NCT04931342,A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors,ACTIVE_NOT_RECRUITING,PHASE2,Ovarian Cancer,Ipatasertib (DRUG); Cobimetinib (DRUG); Trastuzumab Emtansine (DRUG); Atezolizumab (DRUG); Bevacizumab (DRUG); Paclitaxel (DRUG); Giredestrant (DRUG); Abemaciclib (DRUG); Inavolisib (DRUG); Palbociclib (DRUG); Letrozole (DRUG); Olaparib (DRUG); Luteinizing Hormone-Releasing Hormone (LHRH) Agonists (DRUG); Cyclophosphamide (DRUG); Inavolisib (DRUG),5330286,LQQ,Ovarian Cancer,Ovary/Fallopian Tube,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5522,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,COMPLETED,PHASE1,Solid Neoplasm; Stage III Pancreatic Cancer; Stage IIIA Breast Cancer; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Breast Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Non-Small Cell Lung Cancer; Stage IVA Pancreatic Cancer; Stage IVB Pancreatic Cancer; Sarcoma; Colorectal Cancer; Head and Neck Cancer; Cancer of Unknown Primary; Bladder Cancer; Ovarian Cancer,Carboplatin (DRUG); Cisplatin (DRUG); Palbociclib (DRUG),5330286,LQQ,Solid Neoplasm; Stage III Pancreatic Cancer; Stage IIIA Breast Cancer; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Breast Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Non-Small Cell Lung Cancer; Stage IVA Pancreatic Cancer; Stage IVB Pancreatic Cancer; Sarcoma; Colorectal Cancer; Head and Neck Cancer; Cancer of Unknown Primary; Bladder Cancer; Ovarian Cancer,Bowel,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5523,NCT03170206,Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Lung Cancer,Binimetinib (DRUG); Palbociclib (DRUG),5330286,LQQ,Lung Cancer,Lung,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5524,NCT03423199,"PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY",ACTIVE_NOT_RECRUITING,PHASE3,Breast Neoplasms,Palbociclib (DRUG); Placebo (DRUG); Tamoxifen (DRUG); Goserelin (DRUG),5330286,LQQ,Breast Neoplasms,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5525,NCT06941142,A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer,NOT_YET_RECRUITING,PHASE1,Advanced Breast Cancer,Sirolimus (albumin - bound) (DRUG); Palbociclib tablet (DRUG); Fulvestrant injection (DRUG),5330286,LQQ,Advanced Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5526,NCT02536742,Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Palbociclib (DRUG); Fulvestrant (DRUG),5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5527,NCT05969184,Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC,RECRUITING,PHASE2,Breast Neoplasm Female,"CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou) (DRUG)",5330286,LQQ,Female Breast Neoplasm,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5528,NCT03900884,"Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Breast Neoplasm Female,Venetoclax (DRUG); Palbociclib (DRUG); Letrozole (DRUG),5330286,LQQ,Female Breast Neoplasm,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5529,NCT03065621,Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA),COMPLETED,PHASE2,Breast Cancer Female,Palbociclib (DRUG),5330286,LQQ,Breast Cancer Female,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5530,NCT03969121,"Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer",COMPLETED,PHASE3,Breast Cancer Female; Hormone Receptor Positive Malignant Neoplasm of Breast,Palbociclib (DRUG); Endocrine therapy (DRUG),5330286,LQQ,Breast Cancer Female; Hormone Receptor Positive Malignant Neoplasm of Breast,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5531,NCT04946864,"A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer",SUSPENDED,PHASE1,"Breast Cancer; Solid Tumor, Adult",APG-2575 (DRUG); Palbociclib (DRUG),5330286,LQQ,"Breast Cancer; Solid Tumor, Adult",Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5532,NCT03007979,Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Breast Carcinoma; Cancer of Breast; Malignant Tumor of Breast,Palbociclib (DRUG); Letrozole (DRUG); Fulvestrant (DRUG); Optional research biopsy (PROCEDURE); Goserelin (DRUG); Research blood draw (PROCEDURE); Circulating tumor cell blood draw (PROCEDURE); Tumor biopsy (optional) (PROCEDURE),5330286,LQQ,Breast Cancer; Breast Carcinoma; Cancer of Breast; Malignant Tumor of Breast,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5533,NCT02501902,Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC,COMPLETED,PHASE1,Metastatic Pancreatic Ductal Adenocarcinoma,Palbociclib (DRUG); Nab-Paclitaxel (DRUG),5330286,LQQ,Metastatic Pancreatic Ductal Adenocarcinoma,Pancreas,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5534,NCT04819243,PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study,RECRUITING,PHASE2,Premenopausal HR+/HER2- Metastatic Breast Cancer,"Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, Atezolizumab (DRUG); Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, (DRUG)",5330286,LQQ,Premenopausal HR+/HER2- Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5535,NCT02297438,A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4],ACTIVE_NOT_RECRUITING,PHASE3,Breast Neoplasms,Palbociclib (DRUG); Letrozole (DRUG); Placebo (DRUG); Letrozole (DRUG),5330286,LQQ,Breast Neoplasms,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5536,NCT02603679,Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases,ACTIVE_NOT_RECRUITING,PHASE2,Early-Stage Breast Carcinoma; Estrogen Receptor Positive Tumor,Paclitaxel (DRUG); Tamoxifen + Palbociclib (DRUG); Aromatase Inhibitor + Palbociclib (DRUG); Goserelin + Aromatase Inhibitor + Palbociclib (DRUG),5330286,LQQ,Hormone-Receptor Positive Breast Carcinoma,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5537,NCT04872608,"A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer",WITHDRAWN,PHASE1,Metastatic Breast Cancer; Unresectable Breast Cancer,Letrozole (DRUG); Palbociclib (DRUG); Onapristone ER (DRUG),5330286,LQQ,Metastatic Breast Cancer; Unresectable Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5538,NCT03446157,Palbociclib and Cetuximab in Metastatic Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE2,"Cancer of the Colon; Colon Cancer; Colon Neoplasms; Colonic Cancer; Neoplasms, Colonic",Cetuximab (DRUG); Palbociclib (DRUG),5330286,LQQ,"Cancer of the Colon; Colon Cancer; Colon Neoplasms; Colonic Cancer; Neoplasms, Colonic",Bowel,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5539,NCT04841148,Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer,RECRUITING,PHASE2,Breast Cancer,HCQ (DRUG); Avelumab (DRUG); Palbociclib (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5540,NCT01709370,"Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women",UNKNOWN,PHASE2,"ER Positive, HER2 Negative Breast Cancer","Letrozole, PD 0332991 (DRUG)",5330286,LQQ,"ER Positive, HER2 Negative Breast Cancer",Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5541,NCT02664935,National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,"Non-Small Cell Lung Cancer; Carcinoma, Squamous Cell; Adenocarcinoma",AZD4547 (DRUG); Vistusertib (DRUG); Palbociclib (DRUG); Crizotinib (DRUG); Selumetinib (DRUG); Docetaxel (DRUG); AZD5363 (DRUG); Osimertinib (DRUG); Durvalumab (DRUG); Sitravatinib (DRUG); AZD6738 (DRUG),5330286,LQQ,"Non-Small Cell Lung Cancer; Carcinoma, Squamous Cell; Adenocarcinoma",Skin,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5542,NCT02896335,Palbociclib and Pembrolizumab in Central Nervous System Metastases,RECRUITING,PHASE2,Metastatic Malignant Neoplasm to Brain; Recurrent Brain Metastases; Progressive Brain Metastases,Palbociclib (DRUG); Pembrolizumab (DRUG),5330286,LQQ,Metastatic Malignant Neoplasm to Brain; Recurrent Brain Metastases; Progressive Brain Metastases,CNS/Brain,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5543,NCT03280563,A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,COMPLETED,PHASE1,Breast Neoplasms,"Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody (DRUG); Bevacizumab (DRUG); Entinostat (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Ipatasertib (DRUG); Tamoxifen (DRUG); Abemaciclib (DRUG)",5330286,LQQ,Breast Neoplasms,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5544,NCT04862663,Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292),RECRUITING,PHASE3,Locally Advanced (Inoperable) or Metastatic Breast Cancer,Capivasertib (DRUG); Fulvestrant (DRUG); Palbociclib (DRUG); Ribociclib (DRUG); Abemaciclib (DRUG),5330286,LQQ,Locally Advanced (Inoperable) or Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5545,NCT06757634,"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)",NOT_YET_RECRUITING,PHASE3,Breast Cancer,Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant (DRUG); Arm B: Palbociclib or Ribociclib + Fulvestrant (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5546,NCT06207734,"Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer",RECRUITING,PHASE2,Breast Cancer,Continuation of CDK4/6 inhibitor Palbociclib (DRUG); Discontinuation of CDK4/6 inhibitor Palbociclib (DRUG); Continuation of CDK4/6 inhibitor -Palbociclib (DRUG); Discontinuation of CDK4/6 inhibitor -Palbociclib (DRUG); Continuation of CDK4/6 inhibitor Abemaciclib (DRUG); Discontinuation of CDK4/6 inhibitor Abemaciclib (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5547,NCT02101034,PD 0332991 and Cetuximab in Patients With Incurable SCCHN,COMPLETED,PHASE1,"Carcinoma, Squamous Cell of Head and Neck",Cetuximab (BIOLOGICAL); PD 0332991 (DRUG),5330286,LQQ,Head and Neck Squamous Cell Carcinoma,Skin,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5548,NCT05432518,Pilot Trial for Treatment of Recurrent Glioblastoma,RECRUITING,EARLY_PHASE1,Glioblastoma; Recurrent Disease; Recurrent Glioblastoma,Afatinib (DRUG); Dasatinib (DRUG); Palbociclib (DRUG); Everolimus (DRUG); Olaparib (DRUG),5330286,LQQ,Glioblastoma; Recurrent Disease; Recurrent Glioblastoma,CNS/Brain,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5549,NCT03936270,Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer,COMPLETED,PHASE2,Ovarian Cancer,Palbociclib 125mg (DRUG); Letrozole 2.5mg (DRUG),5330286,LQQ,Ovarian Cancer,Ovary/Fallopian Tube,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5550,NCT03455270,"G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer",COMPLETED,PHASE1,"Carcinoma, Ductal, Breast; Breast Cancer Female; Breast Neoplasm; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Stage IV Breast Cancer",G1T48 (DRUG); Palbociclib (DRUG),5330286,LQQ,"Carcinoma, Ductal, Breast; Breast Cancer Female; Breast Neoplasm; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Stage IV Breast Cancer",Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5551,NCT03088059,Biomarker-based Study in R/M SCCHN,ACTIVE_NOT_RECRUITING,PHASE2,"Carcinoma, Squamous Cell of Head and Neck",Afatinib (DRUG); Palbociclib (DRUG); standard of care (DRUG); IPH2201 (DRUG); Durvalumab (DRUG); Niraparib (DRUG); INCAGN01876 (DRUG),5330286,LQQ,Head and Neck Squamous Cell Carcinoma,Skin,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5552,NCT04072952,A Phase 1/2 Trial of ARV-471 Alone and in Combination with Palbociclib (IBRANCE®) in Patients with ER+/HER2- Locally Advanced or Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,ARV-471 (DRUG); ARV-471 in combination with palbociclib (IBRANCE®) (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5553,NCT04130152,Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy,COMPLETED,EARLY_PHASE1,Breast Cancer,Palbociclib (DRUG); Letrozole (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5554,NCT04711252,A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease,ACTIVE_NOT_RECRUITING,PHASE3,ER-Positive HER2-Negative Breast Cancer,AZD9833 (DRUG); Anastrozole (DRUG); Anastrozole placebo (DRUG); AZD9833 placebo (DRUG); Palbociclib (DRUG); Luteinizing hormone-releasing hormone (LHRH) agonist (DRUG),5330286,LQQ,ER-Positive HER2-Negative Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5555,NCT06377852,The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study,RECRUITING,PHASE3,Metastatic Breast Cancer,Palbociclib 125mg (DRUG); Ribociclib 600mg (DRUG); Ribociclib (DRUG); Palbociclib (DRUG),5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5556,NCT04802759,A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer,RECRUITING,PHASE1,"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer",Giredestrant (DRUG); Abemaciclib (DRUG); Ipatasertib (DRUG); Inavolisib (DRUG); Ribociclib (DRUG); Everolimus (DRUG); Samuraciclib (DRUG); PH FDC SC (DRUG); Palbociclib (DRUG); Atezolizumab (DRUG),5330286,LQQ,"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer",Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5557,NCT02334800,A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib,COMPLETED,PHASE1,"Healthy, Hepatic Insufficiency",Palbociclib 75 mg Capsule (DRUG),5330286,LQQ,"Healthy, Hepatic Insufficiency",Liver,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5558,NCT05725200,Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer,RECRUITING,PHASE2,Metastatic Colorectal Cancer,Alectinib (DRUG); Cetuximab (DRUG); Crizotinib (DRUG); Dasatinib (DRUG); Everolimus (DRUG); Encorafenib (DRUG); Gemcitabine (DRUG); Idelalisib (DRUG); Larotrectinib (DRUG); Methotrexate (DRUG); Palbociclib (DRUG); Panobinostat (DRUG); Pembrolizumab (DRUG); Petrozumab (DRUG); Trastuzumab (DRUG); Talazoparib (DRUG); Venetoclax (DRUG),5330286,LQQ,Metastatic Colorectal Cancer,Bowel,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5559,NCT03147287,Palbociclib After CDK and Endocrine Therapy (PACE),ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Cancer,Palbociclib (DRUG); Fulvestrant (DRUG); Avelumab (DRUG),5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5560,NCT02202200,Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma,UNKNOWN,PHASE1,Melanoma BRAF V600E/K Mutated; CDNKN2A Loss Defined,PD- 0332991 (DRUG),5330286,LQQ,Melanoma BRAF V600E/K Mutated; CDNKN2A Loss Defined,Skin,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5561,NCT03447132,Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant,COMPLETED,PHASE3,Breast Neoplasm Female,Fulvestrant 500mg (DRUG); Palbociclib 125mg (DRUG); Goserelin 3.6 MG (DRUG); Placebos (DRUG),5330286,LQQ,Female Breast Neoplasm,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5562,NCT05216432,"First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer",RECRUITING,PHASE1,"PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid Tumor; Endometrial Cancer",RLY-2608 (DRUG); Fulvestrant (DRUG); Palbociclib 125mg (DRUG); Ribociclib 400mg (DRUG); Ribociclib 600mg (DRUG); PF-07220060 100mg (DRUG); PF-07220060 300 mg (DRUG),5330286,LQQ,"PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid Tumor; Endometrial Cancer",Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5563,NCT05865132,Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction,RECRUITING,PHASE2,Esophagus Squamous Cell Carcinoma,Palbociclib (DRUG); Afatinib (DRUG),5330286,LQQ,Esophagus Squamous Cell Carcinoma,Skin,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5564,NCT02778685,"Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7,Fulvestrant (DRUG); Laboratory Biomarker Analysis (OTHER); Letrozole (DRUG); Palbociclib (DRUG); Pembrolizumab (BIOLOGICAL),5330286,LQQ,Metastatic Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5565,NCT04818632,AZD9833 China PK Study,COMPLETED,PHASE1,"ER+, HER2-, Metastatic Breast Cancer",AZD9833 (DRUG); AZD9833 (DRUG); AZD9833 with palbociclib (DRUG); AZD9833 with everolimus (DRUG),5330286,LQQ,"ER+, HER2-, Metastatic Breast Cancer",Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5566,NCT03560856,"A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer",UNKNOWN,PHASE2,Breast Cancer; HR+/HER2-negative Breast Cancer; Metastasis,Fulvestrant + palbociclib (DRUG),5330286,LQQ,Breast Cancer; HR+/HER2-negative Breast Cancer; Metastasis,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5567,NCT02947685,"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE3,HER-2 Positive Breast Cancer; Estrogen Receptor Positive Breast Cancer,palbociclib (DRUG); trastuzumab (DRUG); pertuzumab (DRUG); letrozole (DRUG); Anastrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG),5330286,LQQ,HER-2 Positive Breast Cancer; Estrogen Receptor Positive Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5568,NCT06364956,Phase Ib/II Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma,RECRUITING,PHASE1,Bladder Cancer,Tislelizumab combined with two predefined dose groups of palbociclib (DRUG); RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial. (DRUG),5330286,LQQ,Bladder Cancer,Bladder/Urinary Tract,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5569,NCT03322215,HR+/HER2- Advanced Breast Cancer and Endocrine Resistance,TERMINATED,PHASE2,Breast Cancer Metastatic,Palbociclib (DRUG); Fulvestrant (DRUG); Capecitabine (DRUG),5330286,LQQ,Breast Cancer Metastatic,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5570,NCT00721409,Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer,COMPLETED,PHASE2,Breast Cancer,PD 0332991 (DRUG); letrozole (DRUG); letrozole (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5571,NCT03389477,"Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma",ACTIVE_NOT_RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma,Palbociclib (DRUG); Cetuximab (DRUG); Cisplatin (DRUG); Intensity-Modulated Radiation Therapy (RADIATION); Tumor biopsy (PROCEDURE); Peripheral blood draw (PROCEDURE),5330286,LQQ,Head and Neck Squamous Cell Carcinoma,Skin,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5572,NCT03609047,Adjuvant Palbociclib in Elderly Patients With Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer Stage II; Breast Cancer Stage III,Palbociclib (DRUG); Docetaxel / cyclophosphamide (DRUG); doxorubicin/cyclophosphamide (DRUG); epirubicin/cyclophosphamide (DRUG); paclitaxel (DRUG),5330286,LQQ,Breast Cancer Stage II; Breast Cancer Stage III,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5573,NCT05564377,"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial",RECRUITING,PHASE2,Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm,Alpelisib (DRUG); Binimetinib (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Fluorouracil (DRUG); Fulvestrant (DRUG); Ipatasertib (DRUG); Leucovorin (DRUG); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Mutation Carrier Screening (PROCEDURE); Neratinib Maleate (DRUG); Nilotinib Hydrochloride Monohydrate (DRUG); Olaparib (DRUG); Oxaliplatin (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Panitumumab (BIOLOGICAL); Positron Emission Tomography (PROCEDURE); Selumetinib Sulfate (DRUG); Sotorasib (DRUG),5330286,LQQ,Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm,Ovary/Fallopian Tube,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5574,NCT06380751,"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer",RECRUITING,PHASE3,Advanced Breast Cancer,Saruparib (AZD5305) (DRUG); Camizestrant (DRUG); Abemaciclib (DRUG); Ribociclib (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Exemestane (DRUG),5330286,LQQ,Advanced Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5575,NCT05039177,A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Colorectal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma,ERAS-007 (DRUG); Encorafenib (DRUG); Cetuximab (DRUG); Palbociclib (DRUG),5330286,LQQ,Metastatic Colorectal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma,Bowel,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5576,NCT05670054,Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients,UNKNOWN,PHASE3,Breast Cancer Stage IV,"comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival (DRUG)",5330286,LQQ,Breast Cancer Stage IV,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5577,NCT04247633,High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx),UNKNOWN,PHASE2,Breast Cancer,Palbociclib (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5578,NCT02684032,A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer,COMPLETED,PHASE1,Breast Cancer,Gedatolisib (DRUG); Palbociclib (DRUG); Letrozole (DRUG); Fulvestrant (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5579,NCT06760637,Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease,RECRUITING,PHASE3,Breast Cancer,PF-07220060 (DRUG); letrozole (DRUG); abemaciclib (DRUG); palbociclib (DRUG); ribociclib (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5580,NCT01684215,"A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer",COMPLETED,PHASE2,Neoplasms; Breast Neoplasms,PD-0332991 (DRUG); PD-0332991 (DRUG); letrozole (DRUG); PD-0332991 (DRUG); letrozole (DRUG),5330286,LQQ,Neoplasms; Breast Neoplasms,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5581,NCT04644432,Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma,UNKNOWN,PHASE2,Metastatic Renal Cell Carcinoma; Kidney Neoplasm; Urologic Neoplasms; Urogenital Neoplasms,Medication (A specification is listed under each arm) (DRUG); Patient reported outcomes measurement (OTHER),5330286,LQQ,Metastatic Renal Cell Carcinoma,Kidney,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5582,NCT03809988,PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA),COMPLETED,PHASE2,Breast Cancer; Advanced Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast,Palbociclib (DRUG); Endocrine therapy (DRUG),5330286,LQQ,Breast Cancer; Advanced Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5583,NCT01907607,Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib,COMPLETED,PHASE2,Advanced Gastrointestinal Stromal Tumors,PD 0332991 (DRUG),5330286,LQQ,Advanced Gastrointestinal Stromal Tumors,Bowel,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5584,NCT02028507,Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors,COMPLETED,PHASE3,Metastatic Breast Cancer,Palbociclib (DRUG); Capecitabine (DRUG); Exemestane (DRUG); Fulvestrant (DRUG),5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5585,NCT04546009,"A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)",ACTIVE_NOT_RECRUITING,PHASE3,"Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer",Giredestrant (DRUG); Giredestrant-matched Placebo (DRUG); Letrozole (DRUG); Letrozole-matched Placebo (DRUG); Palbociclib (DRUG); LHRH Agonist (DRUG),5330286,LQQ,"Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer",Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5586,NCT04563507,Combined Immunotherapies in Metastatic ER+ Breast Cancer,RECRUITING,PHASE2,Breast Cancer,Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions) (RADIATION); Letrozole 2.5Mg Tab (DRUG); Palbociclib 125mg (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5587,NCT05176288,"Avelumab, Palbociclib and Axitinib in Advanced RCC",WITHDRAWN,PHASE2,Advanced Clear Cell Renal Cell Carcinoma,Axitinib (DRUG); Palbociclib (DRUG); Avelumab (DRUG),5330286,LQQ,Advanced Clear Cell Renal Cell Carcinoma,Kidney,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5588,NCT03220178,Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy,TERMINATED,PHASE4,Breast Neoplasm,Palbociclib (DRUG); Fulvestrant (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG),5330286,LQQ,Breast Neoplasm,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5589,NCT05207709,Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype,ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Breast Cancer,Ribociclib + Letrozole OR Fulvestrant (DRUG); Palbociclib + Letrozole OR Fulvestrant (DRUG); Paclitaxel +/- Tislelizumab (DRUG),5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5590,NCT02626507,Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer,UNKNOWN,PHASE1,Breast Cancer,Gedatolisib (DRUG); Faslodex (DRUG); Palbociclib (DRUG); Zoladex (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5591,NCT04669587,ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study),UNKNOWN,PHASE1,Estrogen Receptor-Positive; HER2-Negative; Locally Advanced Breast Cancer; Metastatic Breast Cancer,ZB716 (DRUG); Palbociclib (DRUG),5330286,LQQ,Estrogen Receptor-Positive; HER2-Negative; Locally Advanced Breast Cancer; Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5592,NCT03616587,Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.,ACTIVE_NOT_RECRUITING,PHASE1,ER+ HER2- Advanced Breast Cancer,AZD9833 (DRUG); AZD9833 (DRUG); AZD9833 with palbociclib (DRUG); AZD9833 with palbociclib (DRUG); AZD9833 with everolimus (DRUG); AZD9833 with everolimus (DRUG); AZD9833 with abemaciclib (DRUG); AZD9833 with abemaciclib (DRUG); AZD9833 with capivasertib (DRUG); AZD9833 with capivasertib (DRUG); AZD9833 with ribociclib (DRUG); AZD9833 with ribociclib (DRUG); AZD9833 with anastrozole (DRUG); AZD9833 with anastrozole (DRUG),5330286,LQQ,ER+ HER2- Advanced Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5593,NCT02349633,Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M),TERMINATED,PHASE1,Non-Small Cell Lung Cancer,PF-06747775 (DRUG); Palbociclib (DRUG); Avelumab (DRUG),5330286,LQQ,Advanced Non-Small Cell Lung Cancer,Lung,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5594,NCT06790693,"A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer",NOT_YET_RECRUITING,PHASE3,Breast Cancer,Inavolisib (DRUG); Placebo (DRUG); CDK4/6i (DRUG); Letrozole (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5595,NCT05665361,Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC),RECRUITING,PHASE1,Advanced Clear Cell Renal Carcinoma (Ccrcc); Papillary Renal Cell Carcinoma (Prcc),Sasanlimab (DRUG); Palbocicilib (DRUG),5330286,LQQ,Advanced Clear Cell Renal Carcinoma (Ccrcc); Papillary Renal Cell Carcinoma (Prcc),Kidney,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5596,NCT02491983,"Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer",COMPLETED,PHASE2,Metastatic Breast Cancer,Palbociclib (DRUG); Fulvestrant (DRUG); Letrozole (DRUG),5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5597,NCT03227328,"CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO",COMPLETED,PHASE2,Hormone Receptor Positive Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Negative Breast Cancer,concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy (DRUG); chemotherapy plus endocrine therapy (administered either concomitantly or sequentially) (DRUG),5330286,LQQ,Hormone Receptor Positive Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Negative Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5598,NCT05065411,Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer,TERMINATED,PHASE3,Metastatic Breast Cancer,"Enobosarm & Abemaciclib Combo (DRUG); non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant (DRUG)",5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5599,NCT02592083,Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors,ACTIVE_NOT_RECRUITING,PHASE2,Early-Stage Breast Carcinoma; Hormone Receptor Positive Tumor,Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin (DRUG); Palbociclib (DRUG),5330286,LQQ,Hormone Receptor-positive Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5600,NCT02255461,"Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors",TERMINATED,PHASE1,Childhood Choroid Plexus Tumor; Childhood Ependymoblastoma; Childhood Grade III Meningioma; Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Childhood Medulloepithelioma; Recurrent Childhood Anaplastic Astrocytoma; Recurrent Childhood Anaplastic Oligoastrocytoma; Recurrent Childhood Anaplastic Oligodendroglioma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Giant Cell Glioblastoma; Recurrent Childhood Glioblastoma; Recurrent Childhood Gliomatosis Cerebri; Recurrent Childhood Gliosarcoma; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor,palbociclib isethionate (DRUG); pharmacological study (OTHER); laboratory biomarker analysis (OTHER),5330286,LQQ,Childhood Choroid Plexus Tumor; Childhood Ependymoblastoma; Childhood Grade III Meningioma; Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Childhood Medulloepithelioma; Recurrent Childhood Anaplastic Astrocytoma; Recurrent Childhood Anaplastic Oligoastrocytoma; Recurrent Childhood Anaplastic Oligodendroglioma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Giant Cell Glioblastoma; Recurrent Childhood Glioblastoma; Recurrent Childhood Gliomatosis Cerebri; Recurrent Childhood Gliosarcoma; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor,CNS/Brain,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5601,NCT05806671,"Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy",NOT_YET_RECRUITING,PHASE2,Breast Cancer,Dalpiciclib (DRUG); Pyrotinib (DRUG); Fulvestrant (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5602,NCT03498378,"Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",ACTIVE_NOT_RECRUITING,PHASE1,Head and Neck Squamous Cell Carcinoma,Avelumab (DRUG); Palbociclib (DRUG); Cetuximab (DRUG),5330286,LQQ,Head and Neck Squamous Cell Carcinoma,Skin,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5603,NCT05226871,Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies,RECRUITING,PHASE2,Breast Cancer; Head and Neck Cancer,Palbociclib (DRUG); Cetuximab (DRUG); Fulvestrant (DRUG); Letrozole (DRUG),5330286,LQQ,Breast Cancer; Head and Neck Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5604,NCT06654297,Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas,RECRUITING,PHASE1,Esophageal Squamous Cell Carcinoma,Camrelizumab (DRUG); Palbociclib(100mg) (DRUG); Palbociclib(125mg) (DRUG),5330286,LQQ,Esophageal Squamous Cell Carcinoma,Skin,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5605,NCT01356628,A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer,COMPLETED,PHASE2,Advanced Hepatocellular Carcinoma; HCC; Liver Cancer,PD-0332991 (DRUG),5330286,LQQ,Advanced Hepatocellular Carcinoma; HCC; Liver Cancer,Liver,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5606,NCT03332797,A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,GDC-9545 (DRUG); Palbociclib (DRUG); LHRH Agonist (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5607,NCT04858997,Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients,UNKNOWN,PHASE2,Breast Neoplasms,Palbociclib (DRUG); AI (DRUG),5330286,LQQ,Breast Neoplasms,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5608,NCT04483505,"Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.",COMPLETED,PHASE1,Breast Cancer Metastatic; Hormone Receptor Positive Malignant Neoplasm of Breast,"Combination, Rogaratinib + palbociclib + fulvestrant (DRUG)",5330286,LQQ,Breast Cancer Metastatic; Hormone Receptor Positive Malignant Neoplasm of Breast,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5609,NCT05266105,A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients,ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,Palazestrant (DRUG); Palbociclib (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5610,NCT03079011,PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection,ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Breast Cancer,Palbociclib 125mg (DRUG); Aromatase Inhibitors (DRUG); Fulvestrant Injectable Product (DRUG),5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5611,NCT02632045,Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer; Breast Carcinoma,LEE-011 (DRUG); Fulvestrant (DRUG); Placebo (DRUG),5330286,LQQ,Metastatic Breast Cancer; Breast Carcinoma,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5612,NCT02448771,A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer,COMPLETED,PHASE1,Breast Cancer Stage IV; Unresectable Locally Advanced Invasive Breast Cancer; Metastatic Invasive Breast Cancer,Palbociclib (DRUG); Bazedoxifene (DRUG),5330286,LQQ,Breast Cancer Stage IV; Unresectable Locally Advanced Invasive Breast Cancer; Metastatic Invasive Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5613,NCT04334330,"Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China",UNKNOWN,PHASE2,Breast Cancer; Brain Metastases,"Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant (DRUG)",5330286,LQQ,Breast Cancer with Brain Metastases,CNS/Brain,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5614,NCT02913430,Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib,COMPLETED,EARLY_PHASE1,Metastatic Breast Cancer,Fulvestrant (DRUG); Tamoxifen (DRUG); Palbociclib (DRUG),5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5615,NCT02448420,Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Palbociclib (DRUG); Trastuzumab (DRUG); Endocrine therapy (DRUG); Chemotherapy (DRUG); Antibody-Drug Conjugates (DRUG),5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5616,NCT06188520,"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors",RECRUITING,PHASE1,ER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC),AZD8421 (DRUG); Camizestrant (DRUG); Ribociclib (DRUG); Palbociclib (DRUG); Abemaciclib (DRUG),5330286,LQQ,Advanced Breast and Ovarian Cancer,Ovary/Fallopian Tube,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5617,NCT03691493,"Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis",COMPLETED,PHASE2,Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Bone; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8,Anastrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Palbociclib (DRUG); Radiation Therapy (RADIATION); Tamoxifen (DRUG),5330286,LQQ,Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Bone; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5618,NCT02630693,"Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer",COMPLETED,PHASE2,Breast Cancer,Palbociclib 100mg (DRUG); Palbociclib 125mg (DRUG); Fulvestrant or Tamoxifen or Aromatase Inhibitor (DRUG),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5619,NCT04856371,"Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer",UNKNOWN,PHASE1,Advanced Breast Cancer,CYH33 (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Palbociclib (DRUG),5330286,LQQ,Advanced Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5620,NCT06486883,Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype,NOT_YET_RECRUITING,PHASE2,Advanced Breast Cancer; Advanced Breast Carcinoma; Hormone Receptor Positive Breast Carcinoma,"Trastuzumab deruxtecan (T-DXd, DS-8201a) (DRUG); CDK4/6i plus ET (DRUG)",5330286,LQQ,Advanced Hormone Receptor Positive Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5621,NCT05468697,A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024),RECRUITING,PHASE1,Renal Cell Carcinoma,Belzutifan (DRUG); Palbociclib (DRUG),5330286,LQQ,Renal Cell Carcinoma,Kidney,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5622,NCT02894398,Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant,COMPLETED,PHASE2,Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast,Palbociclib (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG),5330286,LQQ,Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5623,NCT05655598,TAS-116 Plus Palbociclib in Breast and Rb-null Cancer,WITHDRAWN,PHASE1,Advanced Breast Cancer; Treatment-Refractory Solid Tumors; Retinoblastoma Deficiency; SCLC; Soft Tissue Sarcoma; Endometrial Cancer; Bladder Cancer,Palbociclib Oral Product (DRUG); TAS-116 (DRUG); TAS-116 (DRUG); TAS-116 (DRUG),5330286,LQQ,Advanced Breast Cancer; Treatment-Refractory Solid Tumors; Retinoblastoma Deficiency; SCLC; Soft Tissue Sarcoma; Endometrial Cancer; Bladder Cancer,Uterus,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5624,NCT05909397,"A Study of Vepdegestrant (ARV-471, PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,ARV-471 (PF-07850327) (DRUG); Palbociclib (COMBINATION_PRODUCT); Letrozole (DRUG); Palbociclib (COMBINATION_PRODUCT),5330286,LQQ,Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5625,NCT02917005,PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer,UNKNOWN,PHASE2,Metastatic Breast Cancer,Palbociclib (DRUG); Exemestane (DRUG); Goserelin (DRUG),5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5626,NCT06062498,Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer,NOT_YET_RECRUITING,PHASE2,Estrogen-receptor-positive Breast Cancer; HER2/Neu-Negative Breast Cancer; Advanced Breast Cancerv; Metastatic Breast Cancer,"elacestrant, palbociclib, abemaciclib, ribociclib (DRUG)",5330286,LQQ,Metastatic Breast Cancer,Breast,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5627,NCT04553133,PF-07104091 as a Single Agent and in Combination Therapy,ACTIVE_NOT_RECRUITING,PHASE1,Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer,PF-07104091 monotherapy dose escalation (DRUG); PF-07104091 + palbociclib + fulvestrant (DRUG); PF-07104091 + palbociclib + letrozole (DRUG); PF-07104091 monotherapy dose expansion (ovarian) (DRUG); PF-07104091 monotherapy dose expansion (SCLC) (DRUG); PF-07104091 + Fulvestrant (post CDK4/6) (DRUG); PF-0704091 + Fulvestrant (post CDK4/6) (DRUG),5330286,LQQ,Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer,Lung,palbociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use as a cancer treatment.,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,1.08,283.0 +5628,NCT01206348,Combination Treatment for Moderate to Severe Acne,COMPLETED,PHASE4,Acne,"Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide (DRUG)",444795,ATRA,Acne,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5629,NCT02850003,Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel,COMPLETED,PHASE1,Acne,IDP-120 Gel (DRUG),444795,ATRA,Acne,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5630,NCT04241276,A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Pancreatic Cancer,ATRA (DRUG); Gemcitabine (DRUG); nab-paclitaxel (DRUG),444795,ATRA,Pancreatic Cancer,Pancreas,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5631,NCT00841776,Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne,COMPLETED,PHASE4,Acne,Duac (DRUG); Ziana gel (DRUG),444795,ATRA,Acne,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5632,NCT02715960,Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules,UNKNOWN,PHASE2,Psoriasis Vulgaris,Acitretin Capsules (DRUG),444795,ATRA,Psoriasis Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5633,NCT00891982,A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash,COMPLETED,PHASE3,Acne Vulgaris,CTGel/ BPO Wash (DRUG); Soap Free Cleanser and CTGel (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5634,NCT02641782,NB2013-HR German (GPOH) / Dutch (DCOG) Trial,TERMINATED,PHASE2,Neuroblastoma,antibody ch14.18 (DRUG); GM-CSF (DRUG); IL-2 i.v. (DRUG); IL-2 s.c. (DRUG); Retinoic acid (DRUG),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5635,NCT04206631,Comedone Extraction and Oral Doxycycline In The First Line Treatment of Moderate Acne Vulgaris,COMPLETED,PHASE1,Acne Vulgaris,Doxycycline Capsule (DRUG); Comedone extraction (PROCEDURE),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5636,NCT02849860,Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris,COMPLETED,PHASE1,Acne,IDP-121 Lotion (DRUG),444795,ATRA,Acne,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5637,NCT05999812,"Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer",RECRUITING,PHASE2,Colorectal Cancer,all trans Retinoic Acid (DRUG); Atezolizumab (DRUG); Bevacizumab (DRUG),444795,ATRA,Colorectal Cancer,Bowel,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5638,NCT00838812,Safety and Efficacy Study of Association Between Tretinoin and Clindamycin on the Treatment of Acne Mild and Moderate,COMPLETED,PHASE3,Acne Vulgaris,application of the topic gel (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5639,NCT04940767,A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris,COMPLETED,PHASE4,Acne Vulgaris,Isotretinoin (DRUG); Amzeeq 4% Topical Foam (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5640,NCT00567567,Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma,COMPLETED,PHASE3,Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma; Regional Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma,Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin Hydrochloride (DRUG); Etoposide (DRUG); External Beam Radiation Therapy (RADIATION); Filgrastim (BIOLOGICAL); Isotretinoin (DRUG); Laboratory Biomarker Analysis (OTHER); Melphalan (DRUG); Peripheral Blood Stem Cell Transplantation (PROCEDURE); Pharmacological Study (OTHER); Thiotepa (DRUG); Topotecan Hydrochloride (DRUG); Vincristine Sulfate Liposome (DRUG),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5641,NCT04724473,A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris,COMPLETED,EARLY_PHASE1,Acne Vulgaris,Tretinoin Cream 0.025% (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5642,NCT00005825,Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer,UNKNOWN,PHASE2,Lung Cancer,cisplatin (DRUG); mitomycin C (DRUG); tretinoin (DRUG); vinorelbine tartrate (DRUG),444795,ATRA,Lung Cancer,Lung,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5643,NCT01404130,"A Pilot Study of the Effects of Isotretinoin on Cognition, Learning and Memory",COMPLETED,PHASE4,Acne Vulgaris,Isotretinoin (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5644,NCT01125930,Atralin Gel for the Treatment of Rosacea,TERMINATED,PHASE3,Rosacea,vehicle gel (DRUG); Atralin gel (DRUG),444795,ATRA,Rosacea,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5645,NCT00017225,Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma,filgrastim (BIOLOGICAL); carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); dacarbazine (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); ifosfamide (DRUG); melphalan (DRUG); tretinoin (DRUG); vincristine sulfate (DRUG); vindesine (DRUG); autologous bone marrow transplantation (PROCEDURE); conventional surgery (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5646,NCT00969722,A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients,TERMINATED,PHASE2,Primary Refractory Neuroblastoma,MAb-3F8 (BIOLOGICAL); Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) (BIOLOGICAL); 13-cis-Retinoic Acid (BIOLOGICAL),444795,ATRA,Primary Refractory Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5647,NCT06925386,The Relationship Between Microbioma Balance and Acne Vulgaris as a New Acne Treatment,NOT_YET_RECRUITING,PHASE2,Acne Vulgaris,Standard therapy (DRUG); HEXBIO (DIETARY_SUPPLEMENT); Secretome (BIOLOGICAL),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5648,NCT01705457,Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis,UNKNOWN,PHASE4,Relapsing Remitting Multiple Sclerosis,Dietary Supplement: vitamin A (DRUG); placebo (DRUG),444795,ATRA,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5649,NCT01915758,"W0265-104: A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers",COMPLETED,PHASE1,Acne Vulgaris,clindamycin1%/tretinoin 0.025% gel (DRUG); vehicle gel (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5650,NCT00135135,Therapy for Children With Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma,"Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid (DRUG); Radiation therapy, Surgery, Peripheral Stem cell transplant (PROCEDURE)",444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5651,NCT06787222,Effectiveness and Safety of Zingiber Officinale Transdermal Patch for Acne Vulgaris; Study of Interleukin 1 and Skin Microbiome,RECRUITING,PHASE2,Acne Vulgaris,tretinoin 0.025% + Z. officinale patch (DRUG); tretinoin 0.025% cream (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5652,NCT03042429,Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients,COMPLETED,PHASE3,Neuroblastoma,"Cycles N8, N5 and N6 (DRUG); Cycles N5 and N6 (DRUG)",444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5653,NCT03291080,Oral Liquid 13-cis-retinoic Acid (13-CRA),COMPLETED,PHASE1,Neuroblastoma,Liquid 13-Cis Retinoic Acid (DRUG); Extracted capsules 13-CRA (DRUG),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5654,NCT06447480,Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients,RECRUITING,PHASE3,Acne Vulgaris,ISOtretinoin 5 MG (DRUG); Topical cream (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5655,NCT01183429,3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma,3F8 and 13-cis-retinoic acid (DRUG),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5656,NCT01111994,Efficacy & Safety of Clindamycin and Tretinoin in Acne,UNKNOWN,PHASE4,Acne,Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel (DRUG),444795,ATRA,Acne,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5657,NCT00919191,Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face,COMPLETED,PHASE4,Acne Vulgaris,Tretinoin gel (DRUG); Adapalene and Benzoyl peroxide (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5658,NCT01048086,90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET),WITHDRAWN,PHASE2,Neuroblastoma; Neuroendocrine Tumor,Retinoic Acid (DRUG); Placebo (DRUG),444795,ATRA,Neuroblastoma; Neuroendocrine Tumor,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5659,NCT04113863,Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer,RECRUITING,PHASE2,Breast Neoplasm Female,all-trans retinoic acid (DRUG); Anastrozole 1mg (DRUG),444795,ATRA,Female Breast Neoplasm,Breast,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5660,NCT01704716,High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN),RECRUITING,PHASE3,Neuroblastoma,Vincristine (DRUG); Aldesleukin (DRUG); ch14.18/CHO (DRUG); Carboplatin (DRUG); Etoposide (DRUG); Cisplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin (DRUG); G-CSF (DRUG); Busulfan (DRUG); Melphalan (DRUG),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5661,NCT04118296,Decreasing Severity of Acne Vulgaris After the Use of a Combination of Anti-Acne Cream,COMPLETED,PHASE1,Acne Vulgaris,Anti-Acne Preparations for Topical Use (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5662,NCT00499616,Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma,COMPLETED,PHASE3,Neuroblastoma,carboplatin (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); topotecan hydrochloride (DRUG); Isotretinoin (DRUG); Surgery (PROCEDURE); Filgrastim (DRUG),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5663,NCT00687596,Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy,TERMINATED,PHASE2,Hepatocellular Carcinoma,TAC-101 (DRUG); Placebo (DRUG),444795,ATRA,Hepatocellular Carcinoma,Liver,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5664,NCT03126916,Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL),ACTIVE_NOT_RECRUITING,PHASE3,Ganglioneuroblastoma; Neuroblastoma,Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration and Biopsy (PROCEDURE); Busulfan (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Cyclophosphamide (DRUG); Dexrazoxane Hydrochloride (DRUG); Dinutuximab (BIOLOGICAL); Doxorubicin Hydrochloride (DRUG); Echocardiography (PROCEDURE); Etoposide Phosphate (DRUG); External Beam Radiation Therapy (RADIATION); Iobenguane I-123 (RADIATION); Iobenguane I-131 (RADIATION); Isotretinoin (DRUG); Lorlatinib (DRUG); Magnetic Resonance Imaging (PROCEDURE); Melphalan Hydrochloride (DRUG); Multigated Acquisition Scan (PROCEDURE); Positron Emission Tomography (PROCEDURE); Sargramostim (BIOLOGICAL); Therapeutic Conventional Surgery (PROCEDURE); Thiotepa (DRUG); Topotecan Hydrochloride (DRUG); Vincristine Sulfate (DRUG),444795,ATRA,Ganglioneuroblastoma; Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5665,NCT01183416,High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation,COMPLETED,PHASE2,Neuroblastoma,3F8 monoclonal antibody and 13-cis-Retinoic Acid (DRUG),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5666,NCT00002586,13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer,COMPLETED,PHASE2,Drug Toxicity; Lung Cancer,13-cis retinoic acid (DRUG); Tocopherol (DIETARY_SUPPLEMENT),444795,ATRA,Drug Toxicity; Lung Cancer,Lung,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5667,NCT00907335,A Study of Acne Treatment in Children Ages 9 to 11,COMPLETED,PHASE2,Acne Vulgaris,Retin-A Micro 0.04% facial acne treatment (DRUG); Vehicle control (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5668,NCT06636981,"All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial",RECRUITING,PHASE2,Triple Negative Breast Cancer (TNBC),Cohort2: ATRA+Toripalimab+TPC (DRUG); Cohort1: ATRA+Toripalimab+chemo (DRUG),444795,ATRA,Triple Negative Breast Cancer (TNBC),Breast,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5669,NCT06731140,Reverse Luminal Immune Resistant Breast Cancer,RECRUITING,PHASE2,Luminal Breast Cancer,Retinoic Acid (DRUG); anti-PD-1 antibody and chemotherapy (DRUG),444795,ATRA,Luminal Breast Cancer,Breast,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5670,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,75 approved agents (DRUG); COXEN (OTHER),444795,ATRA,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,Bladder/Urinary Tract,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5671,NCT00324740,Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer,TERMINATED,PHASE1,Recurrent Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,vorinostat (DRUG); isotretinoin (DRUG),444795,ATRA,Recurrent Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Kidney,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5672,NCT01135069,"Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo",COMPLETED,PHASE3,Acne,Tretinoin microsphere 0.1% (DRUG); Brand Retin-A Micro tretinoin microsphere gel 0.1% (DRUG); placebo microsphere gel (DRUG),444795,ATRA,Acne,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5673,NCT04303169,Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02),ACTIVE_NOT_RECRUITING,PHASE1,Melanoma,Pembrolizumab (BIOLOGICAL); Vibostolimab (BIOLOGICAL); Gebasaxturev (BIOLOGICAL); MK-4830 (BIOLOGICAL); Favezelimab + Pembrolizumab (BIOLOGICAL); ATRA (DRUG),444795,ATRA,Melanoma,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5674,NCT00533169,ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma,TERMINATED,PHASE1,Neuroblastoma,ZD6474 (DRUG); Retinoic Acid (DRUG),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5675,NCT03026946,Alitretinoin vs Cyclosporine in Severe Recurrent Vesicular Hand Eczema,UNKNOWN,PHASE3,Hand Eczema,Alitretinoin (DRUG); cyclosporin A (DRUG),444795,ATRA,Hand Eczema,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5676,NCT04080869,Retinyl Palmitate-loaded Ethosomes in Acne Vulgaris,COMPLETED,PHASE2,Facial Acne Vulgaris,retinyl palmitate (DRUG); Tretinoin (DRUG),444795,ATRA,Facial Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5677,NCT04919369,All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer,RECRUITING,PHASE1,Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC V8; Stage IVA Lung Cancer AJCC V8; Stage IVB Lung Cancer AJCC V8,Atezolizumab (BIOLOGICAL); Tretinoin (DRUG),444795,ATRA,Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC V8; Stage IVA Lung Cancer AJCC V8; Stage IVB Lung Cancer AJCC V8,Lung,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5678,NCT03761810,A Study of S6G5T3 in the Treatment of Acne Vulgaris,COMPLETED,PHASE3,Acne Vulgaris,S6G5T-3 (DRUG); S6G5T-8 (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5679,NCT00062010,"Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer",COMPLETED,PHASE2,Lung Cancer,interferon alpha (BIOLOGICAL); 13-cis-retinoic acid (DRUG); paclitaxel (DRUG),444795,ATRA,Lung Cancer,Lung,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5680,NCT00823901,Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea,COMPLETED,PHASE2,Rosacea,Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel (DRUG); Placebo gel (DRUG),444795,ATRA,Rosacea,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5681,NCT01047189,Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris,COMPLETED,PHASE4,Acne Vulgaris,clindamycin phosphate 1.2% and tretinoin 0.025% (DRUG); clindamycin 1% gel (DRUG); tretinoin 0.025% cream (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5682,NCT06172296,"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma",RECRUITING,PHASE3,"Ganglioneuroblastoma, Nodular; Neuroblastoma",Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration (PROCEDURE); Bone Marrow Biopsy (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Cyclophosphamide (DRUG); Dinutuximab (BIOLOGICAL); Doxorubicin (DRUG); Echocardiography Test (PROCEDURE); Etoposide (DRUG); FDG-Positron Emission Tomography and Computed Tomography Scan (PROCEDURE); Hematopoietic Cell Transplantation (PROCEDURE); Irinotecan (DRUG); Isotretinoin (DRUG); Leukapheresis (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Melphalan (DRUG); Multigated Acquisition Scan (PROCEDURE); Radiation Therapy (RADIATION); Radionuclide Imaging (PROCEDURE); Survey Administration (OTHER); Temozolomide (DRUG); Thiotepa (DRUG); Topotecan (DRUG); Tumor Resection (PROCEDURE); Vincristine (DRUG),444795,ATRA,"Ganglioneuroblastoma, Nodular; Neuroblastoma",CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5683,NCT00601796,"Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer",COMPLETED,PHASE2,Lung Cancer,Vaccine Treatment (BIOLOGICAL); Cyclophosphamide (DRUG); All-trans retinoic acid (ATRA) (DRUG),444795,ATRA,Lung Cancer,Lung,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5684,NCT00001504,A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients,COMPLETED,PHASE1,Breast Cancer; Breast Neoplasm,9-cis-Retinoic Acid (DRUG),444795,ATRA,Breast Cancer; Breast Neoplasm,Breast,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5685,NCT02249767,Bioequivalence Study of Tretinoin Gel 0.05% to Brand Tretinoin Gel,COMPLETED,PHASE3,Acne,Tretinoin (DRUG),444795,ATRA,Acne,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5686,NCT03004846,A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis,COMPLETED,PHASE1,Psoriasis,GSK2981278 ointment (DRUG); Vehicle ointment (DRUG),444795,ATRA,Psoriasis,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5687,NCT05373901,Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma,COMPLETED,PHASE1,High-risk Neuroblastoma,Dinutuximab Beta (DRUG); 13-cis-Retinoic Acid (DRUG),444795,ATRA,High-risk Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5688,NCT00003601,Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome,COMPLETED,PHASE2,Melanoma (Skin),fenretinide (DRUG); tretinoin (DRUG),444795,ATRA,Melanoma (Skin),Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5689,NCT00689117,A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel,COMPLETED,PHASE3,Acne Vulgaris; Acne,CT Gel (DRUG); Clindamycin Gel (clindamycin ) (DRUG); Tretinoin Gel (tretinoin) (DRUG); Vehicle Gel (DRUG),444795,ATRA,Acne Vulgaris; Acne,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5690,NCT01857934,Therapy for Children With Advanced Stage Neuroblastoma,ACTIVE_NOT_RECRUITING,PHASE2,Neuroblastoma,cyclophosphamide (DRUG); topotecan (DRUG); hu14.18K322A (BIOLOGICAL); peripheral blood stem cell harvest (PROCEDURE); surgical resection (PROCEDURE); cisplatin (DRUG); etoposide (DRUG); doxorubicin (DRUG); vincristine (DRUG); busulfan (DRUG); melphalan (DRUG); peripheral blood stem cell transplantation (BIOLOGICAL); natural killer cell infusion (BIOLOGICAL); radiation therapy (RADIATION); GM-CSF (BIOLOGICAL); G-CSF (BIOLOGICAL); mesna (DRUG); levetiracetam (DRUG); interleukin-2 (BIOLOGICAL); Isotretinoin (DRUG); CliniMACS (DEVICE),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5691,NCT00240513,Study Comparing Acne in Patients Taking Oral Minocycline to Patients Taking Minocycline Plus Topical Tretinoin,TERMINATED,PHASE4,Acne Vulgaris,Minocycline (DRUG); Minocycline plus tretinoin (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5692,NCT04305041,Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02),ACTIVE_NOT_RECRUITING,PHASE1,Melanoma,Pembrolizumab (BIOLOGICAL); Quavonlimab (BIOLOGICAL); Vibostolimab (BIOLOGICAL); Lenvatinib (DRUG); ATRA (DRUG),444795,ATRA,Melanoma,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5693,NCT02620813,De Novo Lipogenesis of Sebaceous Glands in Acne,COMPLETED,EARLY_PHASE1,Acne Vulgaris,Tretinoin (DRUG); Isotretinoin (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5694,NCT00621218,A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea,COMPLETED,PHASE2,Rosacea,tretinoin gel 0.05% (DRUG); vehicle (DRUG),444795,ATRA,Rosacea,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5695,NCT00217412,"Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia",COMPLETED,PHASE1,"Childhood Acute Promyelocytic Leukemia (M3); Childhood Atypical Teratoid/Rhabdoid Tumor; Childhood Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Juvenile Myelomonocytic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Medulloblastoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Recurrent Neuroblastoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Relapsing Chronic Myelogenous Leukemia; Unspecified Childhood Solid Tumor, Protocol Specific",vorinostat (DRUG); isotretinoin (DRUG),444795,ATRA,"Childhood Acute Promyelocytic Leukemia (M3); Childhood Atypical Teratoid/Rhabdoid Tumor; Childhood Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Juvenile Myelomonocytic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Medulloblastoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Recurrent Neuroblastoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Relapsing Chronic Myelogenous Leukemia; Unspecified Childhood Solid Tumor, Protocol Specific",CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5696,NCT00026312,"Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma",ACTIVE_NOT_RECRUITING,PHASE3,Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma; Regional Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma,Aldesleukin (BIOLOGICAL); Dinutuximab (BIOLOGICAL); Isotretinoin (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Quality-of-Life Assessment (OTHER); Sargramostim (BIOLOGICAL),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5697,NCT00714714,Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face.,COMPLETED,PHASE4,Acne Vulgaris,Adapalene Gel (DRUG); Tretinoin Gel (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5698,NCT00952523,Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face,COMPLETED,PHASE4,Acne Vulgaris,Tretinoin Facial Gel (DRUG); Adapalene/Benzoyl Peroxide Facial Gel (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5699,NCT00919555,Combination Therapy in Amyotrophic Lateral Sclerosis (ALS),COMPLETED,PHASE1,Amyotrophic Lateral Sclerosis,Pioglitazone and Tretinoin (DRUG); Tretinoin and Pioglitazone HCL (DRUG); Placebo (DRUG),444795,ATRA,Amyotrophic Lateral Sclerosis,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5700,NCT01261923,"Pharmacokinetics of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Hepatic Disease",COMPLETED,PHASE1,Hepatic Insufficiency,Alitretinoin (DRUG),444795,ATRA,Hepatic Insufficiency,Liver,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5701,NCT04059523,"MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3",COMPLETED,PHASE1,Acne Vulgaris,S6G5T-3 (DRUG); Retin-A® 0.1% Cream (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5702,NCT01243450,"Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo",COMPLETED,PHASE3,Acne,Tretinoin (DRUG); placebo (DRUG),444795,ATRA,Acne,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5703,NCT00003564,Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas,WITHDRAWN,PHASE3,Brain and Central Nervous System Tumors,Isotretinoin (DRUG); Procarbazine Hydrochloride (DRUG),444795,ATRA,Brain and Central Nervous System Tumors,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5704,NCT03327064,A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer,WITHDRAWN,PHASE1,Non-melanoma Skin Cancer,UAB30 (DRUG); Placebo (DRUG),444795,ATRA,Non-melanoma Skin Cancer,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5705,NCT01041638,"Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma",COMPLETED,PHASE3,High Risk Neuroblastoma,Aldesleukin (BIOLOGICAL); Diagnostic Laboratory Biomarker Analysis (OTHER); Dinutuximab (BIOLOGICAL); Isotretinoin (DRUG); Sargramostim (BIOLOGICAL),444795,ATRA,High Risk Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5706,NCT04883736,"A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris",COMPLETED,EARLY_PHASE1,Acne Vulgaris,"Tretinoin Gel Microsphere, 0.1% (DRUG); RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1% (DRUG); Placebo Control (DRUG)",444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5707,NCT05016349,"Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.",UNKNOWN,PHASE3,Breast Cancer Female,All trans-retinoic acid (DRUG); 13-Cis Retinoic Acid plus Tocopherol (DRUG); Mifepristone (DRUG); Cannabidiol (DRUG); 9 cis retinoic acid (DRUG); Tamoxifen (DRUG); Standard therapy (DRUG),444795,ATRA,Breast Cancer Female,Breast,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5708,NCT04548349,Profiling the Skin Microbiome in Response to Altreno in Acne Patients,COMPLETED,PHASE4,Acne; Healthy,Altreno (DRUG); Benzoyl peroxide (DRUG),444795,ATRA,Acne; Healthy,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5709,NCT00808899,Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma,TERMINATED,PHASE2,Neuroblastoma,Temsirolimus (DRUG); Irinotecan (DRUG); Surgical Resection of Primary Tumor (PROCEDURE); Cyclophosphamide (DRUG); Doxorubicin (DRUG); Etoposide (DRUG); Cisplatin (DRUG); Topotecan (DRUG); PBSC (PROCEDURE); Radiation Therapy (RADIATION); 13-cis-retinoic acid (DRUG),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5710,NCT00555399,"Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)",TERMINATED,PHASE1,Glioblastoma Multiforme; Anaplastic Glioma,Vorinostat (DRUG); Isotretinoin (DRUG); Surgical Resection (PROCEDURE); Temozolomide (DRUG),444795,ATRA,Glioblastoma Multiforme; Anaplastic Glioma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5711,NCT00002506,Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer,COMPLETED,PHASE2,Cervical Cancer; Esophageal Cancer; Head and Neck Cancer; Lung Cancer; Non-melanomatous Skin Cancer; Penile Cancer,recombinant interferon alfa (BIOLOGICAL); isotretinoin (DRUG),444795,ATRA,Cervical Cancer; Esophageal Cancer; Head and Neck Cancer; Lung Cancer; Non-melanomatous Skin Cancer; Penile Cancer,Lung,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5712,NCT04096742,Altreno for Chest Rejuvenation,UNKNOWN,PHASE4,Photodamaged Skin; Photoaging,tretinoin 0.05% lotion (Altreno) (DRUG); Vehicle (OTHER),444795,ATRA,Photodamaged Skin; Photoaging,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5713,NCT00100906,Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer,COMPLETED,PHASE2,Kidney Cancer,IL-2 (DRUG); ATRA (DRUG),444795,ATRA,Kidney Cancer,Kidney,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5714,NCT02932306,Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris,COMPLETED,PHASE3,Acne,IDP-121 Lotion (DRUG); IDP-121 Vehicle Lotion (DRUG),444795,ATRA,Acne,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5715,NCT00003599,Vitamin E in Preventing the Side Effects of Isotretinoin in Former and Current Smokers Who Are Receiving Isotretinoin to Prevent Lung Cancer,WITHDRAWN,PHASE3,Lung Cancer,Vitamin E (AT) (DIETARY_SUPPLEMENT); Isotretinoin (DRUG),444795,ATRA,Lung Cancer,Lung,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5716,NCT01404702,Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma,TERMINATED,PHASE1,Neuroblastoma,Zoledronic Acid (DRUG); Aldesleukin (BIOLOGICAL),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5717,NCT05345002,All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma,RECRUITING,PHASE2,Glioma; IDH Mutation; Astrocytoma; Oligodendroglioma,Retifanlimab (DRUG); All-trans retinoic acid (DRUG),444795,ATRA,Glioma; IDH Mutation; Astrocytoma; Oligodendroglioma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5718,NCT03761784,A Study of S6G5T-3 in the Treatment of Acne Vulgaris,COMPLETED,PHASE3,Acne Vulgaris,S6G5T-3 (DRUG); S6G5T-8 (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5719,NCT00000621,Feasibility of Retinoic Acid Treatment in Emphysema (FORTE),COMPLETED,PHASE2,"Emphysema; Lung Diseases; Lung Diseases, Obstructive; Chronic Obstructive Pulmonary Disease",all trans retinoic acid (DRUG); 13 cis retinoic acid (DRUG); placebo (DRUG),444795,ATRA,"Emphysema; Lung Diseases; Lung Diseases, Obstructive; Chronic Obstructive Pulmonary Disease",Lung,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5720,NCT05428202,Phase I Study of GN-037 Cream for Psoriasis,COMPLETED,PHASE1,Psoriasis,GN037 (DRUG); Placebo (DRUG),444795,ATRA,Psoriasis,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5721,NCT00112502,Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme,COMPLETED,PHASE2,Brain and Central Nervous System Tumors; Glioblastoma Multiforme,Celecoxib (DRUG); Isotretinoin (DRUG); Temozolomide (DRUG); Thalidomide (DRUG),444795,ATRA,Brain and Central Nervous System Tumors; Glioblastoma Multiforme,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5722,NCT01283464,Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles,COMPLETED,PHASE2,Photodamaged Skin; Wrinkles,Retinol (DRUG); Tretinoin (DRUG),444795,ATRA,Photodamaged Skin; Wrinkles,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5723,NCT01183884,3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma,TERMINATED,PHASE2,Neuroblastoma,3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid (BIOLOGICAL),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5724,NCT00201279,Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma,COMPLETED,PHASE3,Oral Cavity; Squamous Cell Carcinoma,13-cis Retino Acid (DRUG),444795,ATRA,Oral Cavity; Squamous Cell Carcinoma,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5725,NCT01701479,Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2),UNKNOWN,PHASE1,Neuroblastoma,ch14.18/CHO (DRUG); Aldesleukin (DRUG); Isotretinoin (DRUG),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5726,NCT00907257,A Study of Different Use Regimens Using Two Acne Treatments,COMPLETED,PHASE4,Acne Vulgaris,benzoyl peroxide wash (DRUG); Tretinoin gel (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5727,NCT03307148,Stromal TARgeting for PAncreatic Cancer (STAR_PAC),COMPLETED,PHASE1,Pancreatic Adenocarcinoma,ATRA (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG),444795,ATRA,Pancreatic Adenocarcinoma,Pancreas,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5728,NCT05316675,Impact of Isotretinoin in Different Doses on Quality of Life,UNKNOWN,PHASE4,Acne Vulgaris,Isotretinoin (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5729,NCT01103375,Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma,TERMINATED,PHASE1,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Diffuse Astrocytoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Oligodendroglioma; Recurrent Adult Brain Tumor,erlotinib hydrochloride (DRUG); isotretinoin (DRUG); laboratory biomarker analysis (OTHER); protein expression analysis (GENETIC),444795,ATRA,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Diffuse Astrocytoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Oligodendroglioma; Recurrent Adult Brain Tumor,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5730,NCT02548052,Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis,COMPLETED,PHASE1,Psoriasis,GSK2981278 0.03% (DRUG); GSK2981278 0.1% (DRUG); GSK2981278 0.8% (DRUG); GSK2981278 4% (DRUG); Vehicle (DRUG); Betamethasone valerate 0.1% (DRUG),444795,ATRA,Psoriasis,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5731,NCT01422785,A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne,UNKNOWN,PHASE4,Acne Vulgaris,clindamycin phosphate 1.2%/tretinoin 0.025% gel alone (DRUG); clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5732,NCT00003656,Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer,COMPLETED,PHASE2,Kidney Cancer,recombinant interferon alfa (BIOLOGICAL); tretinoin liposome (DRUG),444795,ATRA,Kidney Cancer,Kidney,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5733,NCT00002737,Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer,COMPLETED,PHASE3,Kidney Cancer,recombinant interferon alfa (BIOLOGICAL); chemotherapy (DRUG); isotretinoin (DRUG),444795,ATRA,Kidney Cancer,Kidney,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5734,NCT01175356,"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",ACTIVE_NOT_RECRUITING,PHASE1,Ganglioneuroblastoma; Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Regional Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma,3-Dimensional Conformal Radiation Therapy (RADIATION); Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE); Busulfan (DRUG); Cisplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin Hydrochloride (DRUG); Etoposide Phosphate (DRUG); External Beam Radiation Therapy (RADIATION); In Vitro-Treated Peripheral Blood Stem Cell Transplantation (PROCEDURE); Intensity-Modulated Radiation Therapy (RADIATION); Iobenguane I-131 (RADIATION); Isotretinoin (DRUG); Laboratory Biomarker Analysis (OTHER); Melphalan (DRUG); Pharmacological Study (OTHER); Questionnaire Administration (OTHER); Therapeutic Conventional Surgery (PROCEDURE); Topotecan Hydrochloride (DRUG); Vincristine Sulfate (DRUG),444795,ATRA,Ganglioneuroblastoma; Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Regional Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5735,NCT02965456,Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris,COMPLETED,PHASE3,Acne,IDP 121 Lotion (DRUG); IDP-121 Vehicle Lotion (DRUG),444795,ATRA,Acne,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5736,NCT01522456,Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel,COMPLETED,PHASE4,Acne Vulgaris,Epiduo Gel (DRUG); Retin-A Micro Microsphere 0.1% (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5737,NCT00617409,To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid,COMPLETED,PHASE2,Small Cell Lung Cancer,Paclitaxel (DRUG); Drug: Ad.p53-DC vaccines (BIOLOGICAL); All -trans Retinoic Acid (ATRA) (DRUG),444795,ATRA,Small Cell Lung Cancer,Lung,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5738,NCT06703047,Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma,NOT_YET_RECRUITING,PHASE2,Esophageal Squamous Cell Carcinoma,ATRA+pd-1+chemo (DRUG); placebo+PD-1+chemo (DRUG),444795,ATRA,Esophageal Squamous Cell Carcinoma,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5739,NCT04385277,"Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)",ACTIVE_NOT_RECRUITING,PHASE2,"Ganglioneuroblastoma, Nodular; Neuroblastoma",Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration (PROCEDURE); Bone Marrow Biopsy (PROCEDURE); Computed Tomography (PROCEDURE); Dinutuximab (BIOLOGICAL); FDG-Positron Emission Tomography (PROCEDURE); Iobenguane I-123 (RADIATION); Irinotecan (DRUG); Isotretinoin (DRUG); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Sargramostim (BIOLOGICAL); Temozolomide (DRUG),444795,ATRA,"Ganglioneuroblastoma, Nodular; Neuroblastoma",CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5740,NCT01592045,ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma,COMPLETED,PHASE1,Neuroblastoma,ch14.18 -NCI (BIOLOGICAL); ch14.18-UTC (BIOLOGICAL); Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) (BIOLOGICAL); Aldesleukin (IL-2) (BIOLOGICAL); Isotretinoin (DRUG),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5741,NCT01048645,Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small-Cell Lung Carcinoma,ATRA (DRUG); PLACEBO (OTHER),444795,ATRA,Non-Small-Cell Lung Carcinoma,Lung,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5742,NCT04305054,Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02),RECRUITING,PHASE1,Melanoma,Pembrolizumab (BIOLOGICAL); Vibostolimab (BIOLOGICAL); Pembrolizumab/Quavonlimab (BIOLOGICAL); Lenvatinib (DRUG); Favezelimab/Pembrolizumab (BIOLOGICAL); ATRA (DRUG),444795,ATRA,Melanoma,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5743,NCT03427554,"To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris",COMPLETED,EARLY_PHASE1,Acne Vulgaris,Tretinoin cream 0.1% (DRUG); RETIN-A® Cream (DRUG); Vehicle of the test product (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5744,NCT01448733,Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris,UNKNOWN,PHASE4,Acne Vulgaris,Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5745,NCT01711554,Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma,ACTIVE_NOT_RECRUITING,PHASE1,Recurrent Neuroblastoma; Refractory Neuroblastoma,Dinutuximab (BIOLOGICAL); Isotretinoin (DRUG); Laboratory Biomarker Analysis (OTHER); Lenalidomide (DRUG); Pharmacological Study (OTHER),444795,ATRA,Recurrent Neuroblastoma; Refractory Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5746,NCT00138151,"Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer",TERMINATED,PHASE2,Cervical Cancer,recombinant interferon alpha-2b (BIOLOGICAL); isotretinoin (DRUG); paclitaxel (DRUG),444795,ATRA,Cervical Cancer,Cervix,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5747,NCT01208454,Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma,COMPLETED,PHASE1,Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma; Regional Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma,Isotretinoin (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Vorinostat (DRUG),444795,ATRA,Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma; Regional Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5748,NCT03200847,Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma,COMPLETED,PHASE1,Stage IV Melanoma; Stage III Melanoma; Advanced Melanoma,Pembrolizumab with All-Trans Retinoic Acid (DRUG),444795,ATRA,Stage IV Melanoma; Stage III Melanoma; Advanced Melanoma,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5749,NCT06358677,Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Metastatic Colorectal Cancer,RECRUITING,PHASE2,Metastatic Colon Cancer; Metastatic Rectum Cancer,Topical Tretinoin (DRUG); Placebo (OTHER),444795,ATRA,Metastatic Colon Cancer; Metastatic Rectum Cancer,Bowel,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5750,NCT00528437,"Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors",COMPLETED,PHASE2,Brain Tumors,"temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid (DRUG)",444795,ATRA,Brain Tumors,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5751,NCT03026907,Alitretinoin vs Azathioprine in Severe Non-hyperkeratotic Hand Eczema,UNKNOWN,PHASE3,Hand Eczema,Alitretinoin (DRUG); Azathioprine (DRUG),444795,ATRA,Hand Eczema,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5752,NCT00001509,A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor,COMPLETED,PHASE2,Nephroblastoma; Neuroblastoma,IFN-alpha with retinoic acid (DRUG),444795,ATRA,Nephroblastoma; Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5753,NCT03061656,Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma,UNKNOWN,PHASE2,High Risk Neuroblastoma,Cyclophosphamide (DRUG); Carboplatin (DRUG); Etoposide (DRUG); 131I-MIBG (RADIATION); Thiotepa (DRUG); Melphalan (DRUG),444795,ATRA,High Risk Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5754,NCT03433378,"To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris",COMPLETED,EARLY_PHASE1,Acne Vulgaris,"Tretinoin cream, 0.05% (DRUG); RETIN-A® (tretinoin) cream, 0.05% (DRUG); Vehicle of the test product (DRUG)",444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5755,NCT02169609,Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma,COMPLETED,PHASE2,"Neuroblastoma; Neoplasm, Residual; Effects of Immunotherapy",Dinutuximab. Immunotherapy (DRUG),444795,ATRA,"Neuroblastoma; Neoplasm, Residual; Effects of Immunotherapy",CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5756,NCT06242288,"Correlation Between Depression Scores and Serum NF-ĸB/NLRP3 Axis, Biotinidase, and HMGB After Treatment With Isotretinoin in Patients With Acne Vulgaris",COMPLETED,PHASE3,Acne Vulgaris,ISOtretinoin 20 MG (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5757,NCT00078988,High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas,COMPLETED,PHASE3,Brain Tumor; Central Nervous System Tumor,filgrastim (BIOLOGICAL); carboplatin (DRUG); etoposide (DRUG); isotretinoin (DRUG); thiotepa (DRUG); autologous bone marrow transplantation (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE),444795,ATRA,Brain Tumor; Central Nervous System Tumor,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5758,NCT00939133,Proof of Concept Study to Investigate the Recurrence of Acne Post Isotretinoin,COMPLETED,PHASE4,Acne,tretinoin microsphere 0.04% gel (DRUG); vehicle gel (DRUG),444795,ATRA,Acne,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5759,NCT01041833,Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and Expression of RAR-alfa and RAR-beta as Response Biomarker,UNKNOWN,PHASE3,Non Small Cell Lung Cancer,atRA (DRUG); Placebo (DRUG),444795,ATRA,Non Small Cell Lung Cancer,Lung,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5760,NCT02278861,Oral Isotretinoin Versus Topical Tretinoin for Actinic Keratosis,COMPLETED,PHASE2,Actinic Keratosis,"Oral isotretinoin (DRUG); Tretinoin 0,05% cream (DRUG); Sunscreen FPS 60 (DRUG)",444795,ATRA,Actinic Keratosis,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5761,NCT00200161,Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma,COMPLETED,PHASE2,Glioblastoma; Gliomas,Temozolomide (DRUG); Temozolomide (DRUG),444795,ATRA,Glioblastoma; Gliomas,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5762,NCT01313728,A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products,COMPLETED,PHASE4,Acne Vulgaris,Dapsone plus Tretinoin Gel (DRUG); Tretinoin Gel (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5763,NCT00793845,Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma,Cyclophosphamide (DRUG); Etoposide (DRUG); Carboplatin (DRUG); Thiotepa (DRUG); Melphalan (DRUG); Total body irradiation (RADIATION),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5764,NCT02403778,Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma,COMPLETED,PHASE2,Melanoma,VESANOID (DRUG); Ipilimumab (DRUG),444795,ATRA,Melanoma,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5765,NCT00004188,Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma,COMPLETED,PHASE3,Neuroblastoma,filgrastim (BIOLOGICAL); carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); isotretinoin (DRUG); melphalan (DRUG); topotecan hydrochloride (DRUG); vincristine sulfate (DRUG); autologous bone marrow transplantation (PROCEDURE); bone marrow ablation with stem cell support (PROCEDURE); conventional surgery (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5766,NCT01276730,Advanced Cervical Cancer Trial in India,COMPLETED,PHASE2,Cervical Cancer,"Interferon, Retinoic Acid and radiation (DRUG); Cisplatin and radiation (DRUG)",444795,ATRA,Cervical Cancer,Cervix,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5767,NCT00514293,"Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer",UNKNOWN,PHASE2,Lung Cancer,bexarotene (DRUG); capecitabine (DRUG); carboplatin (DRUG); cisplatin (DRUG); docetaxel (DRUG); tretinoin (DRUG),444795,ATRA,Lung Cancer,Lung,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5768,NCT01929278,"W0265-103: A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, Phase 1 Clinical Trial Evaluating The Phototoxic Potential Of Topically Applied Clindamycin 1.0% - Tretinoin 0.025% Gel (Ct Gel) In Healthy Volunteers",COMPLETED,PHASE1,Acne Vulgaris,CT Gel (clindamycin 1% and tretinoin 0.025%) (DRUG); Vehicle gel patch (OTHER); Blank patch (OTHER),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5769,NCT03786783,"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma",ACTIVE_NOT_RECRUITING,PHASE2,Ganglioneuroblastoma; High Risk Neuroblastoma,Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Cyclophosphamide (DRUG); Dexrazoxane (DRUG); Dinutuximab (BIOLOGICAL); Doxorubicin (DRUG); Etoposide (DRUG); External Beam Radiation Therapy (RADIATION); Isotretinoin (DRUG); Melphalan (DRUG); Sargramostim (BIOLOGICAL); Thiotepa (DRUG); Topotecan (DRUG); Vincristine (DRUG),444795,ATRA,Ganglioneuroblastoma; High Risk Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5770,NCT00835198,Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris,COMPLETED,PHASE4,Acne Vulgaris,Dapsone; Tretinoin (DRUG); Tretinoin (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5771,NCT02731105,Pilot Study of Tolerability and Effectivity of Two Combination Topical Acne Products,COMPLETED,PHASE4,Acne Vulgaris,Acnatac® Gel left face (DRUG); Epiduo® Gel right face (DRUG); Acnatac® Gel right face (DRUG); Epiduo® Gel left face (DRUG),444795,ATRA,Acne Vulgaris,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5772,NCT01183897,3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow,COMPLETED,PHASE2,Neuroblastoma,3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic (BIOLOGICAL),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5773,NCT01916187,Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma,WITHDRAWN,PHASE1,Neuroblastoma,Imetelstat (DRUG),444795,ATRA,Neuroblastoma,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5774,NCT06224348,A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids,ACTIVE_NOT_RECRUITING,PHASE3,Dermatitis Atopic,Amlitelimab (DRUG); Placebo (DRUG); Topical corticosteroids (DRUG); Topical calcineurin inhibitors (DRUG),444795,ATRA,Dermatitis Atopic,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5775,NCT04152382,A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis,TERMINATED,PHASE1,Psoriasis,LY3462817 - IV (DRUG); LY3462817 - SC (DRUG); Placebo - IV (DRUG); Placebo - SC (DRUG); LY3509754 (DRUG); Placebo (DRUG),444795,ATRA,Psoriasis,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5776,NCT00170716,Safety and Effectiveness of Cortical Stimulation in the Treatment of Stroke Patients With Upper Extremity Hemiparesis,UNKNOWN,PHASE3,Stroke; Hemiparesis,Cortical Stimulation and rehabilitation (DEVICE); Rehabilitation (OTHER),444795,ATRA,Stroke; Hemiparesis,CNS/Brain,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5777,NCT01373567,"A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis",COMPLETED,PHASE4,Plaque Psoriasis,TINEFCON (DRUG),444795,ATRA,Plaque Psoriasis,Skin,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5778,NCT04273945,Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension,ACTIVE_NOT_RECRUITING,PHASE3,Pulmonary Arterial Hypertension,Macitentan 10 mg (DRUG); Macitentan 37.5 mg (DRUG); Macitentan 75 mg (DRUG); Placebo (DRUG),444795,ATRA,Pulmonary Arterial Hypertension,Lung,Retinoic acid,"RARB, RARG, RARA, PPARD",activator/agonist,Retinoic receptor agonist,yes,yes,Approved for acne and leukemia treatment.,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1.03,138.0 +5779,NCT00745732,Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC),TERMINATED,PHASE1,Non-Small Cell Lung Cancer,ZD6474 (ZACTIMA) (DRUG); Radiation Therapy (RADIATION),22049997,I45,Advanced Non-Small Cell Lung Cancer,Lung,PH-797804,MAPK14,inhibitor/antagonist,Other MAPK inhibitor,no,yes,"Investigated as an anti-inflammatory agent, not approved for human use.",CC1=C(C=C(C=C1)C(=O)NC)N2C(=CC(=C(C2=O)Br)OCC3=C(C=C(C=C3)F)F)C,1.0,9.0 +5780,NCT01321463,Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination,COMPLETED,PHASE2,"Pulmonary Disease, Chronic Obstructive",PH-797804 (DRUG); Placebo (DRUG),22049997,I45,"Pulmonary Disease, Chronic Obstructive",Lung,PH-797804,MAPK14,inhibitor/antagonist,Other MAPK inhibitor,no,yes,"Investigated as an anti-inflammatory agent, not approved for human use.",CC1=C(C=C(C=C1)C(=O)NC)N2C(=CC(=C(C2=O)Br)OCC3=C(C=C(C=C3)F)F)C,1.0,9.0 +5781,NCT00559910,"A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).",COMPLETED,PHASE2,Chronic Obstructive Pulmonary Disease,PH-797804 (DRUG); Placebo (DRUG),22049997,I45,Chronic Obstructive Pulmonary Disease,Lung,PH-797804,MAPK14,inhibitor/antagonist,Other MAPK inhibitor,no,yes,"Investigated as an anti-inflammatory agent, not approved for human use.",CC1=C(C=C(C=C1)C(=O)NC)N2C(=CC(=C(C2=O)Br)OCC3=C(C=C(C=C3)F)F)C,1.0,9.0 +5782,NCT01543919,Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide,COMPLETED,PHASE2,"Pulmonary Disease, Chronic Obstructive",PH-797804 (DRUG); PH-797804 (DRUG); PH-797804 (DRUG); PH-797804 (DRUG); PH-797804 (DRUG); Placebo (DRUG),22049997,I45,"Pulmonary Disease, Chronic Obstructive",Lung,PH-797804,MAPK14,inhibitor/antagonist,Other MAPK inhibitor,no,yes,"Investigated as an anti-inflammatory agent, not approved for human use.",CC1=C(C=C(C=C1)C(=O)NC)N2C(=CC(=C(C2=O)Br)OCC3=C(C=C(C=C3)F)F)C,1.0,9.0 +5783,NCT01314885,Single Dose Lipopolysaccharide (LPS) Study In Healthy Volunteers,COMPLETED,PHASE1,Chronic Obstructive Pulmonary Disease (COPD),PF-03715455 (DRUG); PH-797804 (DRUG); Placebo for PF-03715455 (DRUG); Placebo for PH-797804 (DRUG),22049997,I45,Chronic Obstructive Pulmonary Disease (COPD),Lung,PH-797804,MAPK14,inhibitor/antagonist,Other MAPK inhibitor,no,yes,"Investigated as an anti-inflammatory agent, not approved for human use.",CC1=C(C=C(C=C1)C(=O)NC)N2C(=CC(=C(C2=O)Br)OCC3=C(C=C(C=C3)F)F)C,1.0,9.0 +5784,NCT01935336,Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers,COMPLETED,PHASE2,Adenocarcinoma of the Lung; Extensive Stage Small Cell Lung Cancer; Limited Stage Small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Recurrent Small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Ponatinib (DRUG),24826799,PONATINIB,Adenocarcinoma of the Lung; Extensive Stage Small Cell Lung Cancer; Limited Stage Small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Recurrent Small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Lung,Ponatinib,"ABL1, PDGFRA, KDR, FGFR1, SRC, KIT",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for treatment of certain types of leukemia.,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5,1.07,309.0 +5785,NCT02478164,Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma,COMPLETED,PHASE2,Glioblastoma,Ponatinib (DRUG),24826799,PONATINIB,Glioblastoma,CNS/Brain,Ponatinib,"ABL1, PDGFRA, KDR, FGFR1, SRC, KIT",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for treatment of certain types of leukemia.,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5,1.07,309.0 +5786,NCT06813079,Using Tumor Models to Determine Treatments,NOT_YET_RECRUITING,PHASE2,Pancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor,Cobimetinib (DRUG); Ponatinib (DRUG); Brigatinib (DRUG); Colchicine (DRUG); Selinexor (DRUG); Abemaciclib (DRUG); Neratinib (DRUG); Doxorubicin (DRUG); Etoposide (DRUG); Ceritinib (DRUG),24826799,PONATINIB,Pancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor,Pancreas,Ponatinib,"ABL1, PDGFRA, KDR, FGFR1, SRC, KIT",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for treatment of certain types of leukemia.,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5,1.07,309.0 +5787,NCT01813734,Ponatinib in Advanced NSCLC w/ RET Translocations,COMPLETED,PHASE2,Non Small Cell Lung Cancer,Ponatinib (DRUG),24826799,PONATINIB,Non Small Cell Lung Cancer,Lung,Ponatinib,"ABL1, PDGFRA, KDR, FGFR1, SRC, KIT",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for treatment of certain types of leukemia.,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5,1.07,309.0 +5788,NCT01761747,Ponatinib for Squamous Cell Lung and Head and Neck Cancers,TERMINATED,PHASE2,"Non-Small Cell Lung Cancer, Head and Neck Cancer",ponatinib (DRUG),24826799,PONATINIB,"Non-Small Cell Lung Cancer, Head and Neck Cancer",Lung,Ponatinib,"ABL1, PDGFRA, KDR, FGFR1, SRC, KIT",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for treatment of certain types of leukemia.,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5,1.07,309.0 +5789,NCT03704688,Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Non Small Cell Lung Cancer; KRAS Gene Mutation,Trametinib 0.5 mg (DRUG); Trametinib 1 MG (DRUG); Trametinib 1.5 MG (DRUG); Trametinib 2 mg (DRUG); Ponatinib 15 MG (DRUG); Ponatinib 30 MG (DRUG),24826799,PONATINIB,Non Small Cell Lung Cancer; KRAS Gene Mutation,Lung,Ponatinib,"ABL1, PDGFRA, KDR, FGFR1, SRC, KIT",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for treatment of certain types of leukemia.,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5,1.07,309.0 +5790,NCT04691661,"Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease",RECRUITING,PHASE2,Parkinson Disease,Radotinib HCl 50 mg (DRUG); Placebo (DRUG),16063245,Radotinib,Parkinson Disease,CNS/Brain,Radotinib,ABL1,inhibitor/antagonist,Other TK inhibitor,no,yes,"Tested for chronic myeloid leukemia, not approved in major markets.",CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=NC=CN=C5,1.0,36.0 +5791,NCT01759576,"A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function",COMPLETED,PHASE1,Renal Insufficiency; Healthy,Canagliflozin (JNJ-28431754) (DRUG),24812758,Invokana,Renal Insufficiency; Healthy,Kidney,Canagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes treatment.,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,1.26,183.0 +5792,NCT04700839,SGLT2 Inhibitors in Patients With PCOS,COMPLETED,PHASE4,Polycystic Ovary Syndrome,SGLT2 inhibitors (DRUG); Metformin (DRUG),24812758,Invokana,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Canagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes treatment.,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,1.26,183.0 +5793,NCT02065791,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,COMPLETED,PHASE3,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Canagliflozin (DRUG); Placebo (DRUG),24812758,Invokana,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Kidney,Canagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes treatment.,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,1.26,183.0 +5794,NCT04073680,A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors,UNKNOWN,PHASE1,Breast Cancer; Endometrial Cancer; Lung Cancer; Colo-rectal Cancer; Head and Neck Cancer,Serabelisib (DRUG); Canagliflozin 300mg (DRUG),24812758,Invokana,Breast Cancer; Endometrial Cancer; Lung Cancer; Colo-rectal Cancer; Head and Neck Cancer,Lung,Canagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes treatment.,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,1.26,183.0 +5795,NCT06256289,Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome,NOT_YET_RECRUITING,PHASE4,Polycystic Ovary Syndrome; Non-Alcoholic Fatty Liver Disease,Canagliflozin 100mg Tab (DRUG); Metformin Hydrochloride (DRUG),24812758,Invokana,Polycystic Ovary Syndrome; Non-Alcoholic Fatty Liver Disease,Ovary/Fallopian Tube,Canagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes treatment.,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,1.26,183.0 +5796,NCT04973891,CANA/Met in Non-diabetic Women With PCOS,COMPLETED,PHASE1,Polycystic Ovary Syndrome,Canagliflozin combined with metformin (DRUG); metformin (DRUG),24812758,Invokana,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Canagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes treatment.,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,1.26,183.0 +5797,NCT05507892,Renal Mechanism of SGLT2 Inhibition,UNKNOWN,PHASE2,Type 2 Diabetes; Diabetic Kidney Disease,canagliflozin (DRUG); Aminohippurate Sodium Inj 20% (DRUG),24812758,Invokana,Type 2 Diabetes; Diabetic Kidney Disease,Kidney,Canagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes treatment.,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,1.26,183.0 +5798,NCT05090358,Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer; Breast Cancer Stage IV; Metastatic Breast Cancer,Ketogenic Diet (DIETARY_SUPPLEMENT); Low Carbohydrate Diet (DIETARY_SUPPLEMENT); Alpelisib (DRUG); Fulvestrant (DRUG); Canagliflozin (DRUG),24812758,Invokana,Breast Cancer; Breast Cancer Stage IV; Metastatic Breast Cancer,Breast,Canagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes treatment.,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,1.26,183.0 +5799,NCT01064414,"An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment",COMPLETED,PHASE3,"Diabetes Mellitus, Type 2; Renal Insufficiency",Canagliflozin (DRUG); Placebo (DRUG),24812758,Invokana,"Diabetes Mellitus, Type 2; Renal Insufficiency",Kidney,Canagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes treatment.,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,1.26,183.0 +5800,NCT04662723,Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.,RECRUITING,PHASE4,Glomerulonephritis; Immunoglobulin A Nephropathy,Corticosteroid (DRUG); Renin-angiotensin sytem blockers (DRUG); Sodium-glucose cotransporter 2 inhibitor (DRUG),24812758,Invokana,Glomerulonephritis,Kidney,Canagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes treatment.,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,1.26,183.0 +5801,NCT06291155,Mechanism of SGLT2 Inhibition in the Kidney,RECRUITING,PHASE4,Type 2 Diabetes; Diabetic Kidney Disease,SGLT2 inhibitor (DRUG),24812758,Invokana,Type 2 Diabetes; Diabetic Kidney Disease,Kidney,Canagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes treatment.,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,1.26,183.0 +5802,NCT06858436,SGLT2 Inhibitor Utilization Re-perfusion Therapy,NOT_YET_RECRUITING,PHASE4,Acute Ischemic Stroke From Large Vessel Occlusion,Canagliflozin 100mg (DRUG),24812758,Invokana,Acute Ischemic Stroke From Large Vessel Occlusion,CNS/Brain,Canagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes treatment.,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,1.26,183.0 +5803,NCT04127084,Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes,UNKNOWN,PHASE4,Type 2 Diabetes; Diabetic Nephropathy,SGLT2 Inhibition (DRUG),24812758,Invokana,Type 2 Diabetes with Diabetic Nephropathy,Kidney,Canagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes treatment.,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,1.26,183.0 +5804,NCT04419337,Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke,UNKNOWN,PHASE2,Diabetes Mellitus; Stroke,Metformin plus Pioglitazone plus an SGLT2 inhibitor (DRUG),24812758,Invokana,Diabetes Mellitus with Stroke,CNS/Brain,Canagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes treatment.,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,1.26,183.0 +5805,NCT01186588,A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function,COMPLETED,PHASE1,Healthy; Hepatic Insufficiency,Canagliflozin (DRUG),24812758,Invokana,Healthy; Hepatic Insufficiency,Liver,Canagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes treatment.,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,1.26,183.0 +5806,NCT03436693,Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy,COMPLETED,PHASE3,Diabetic Nephropathy,Canagliflozin (DRUG); Placebo (DRUG),24812758,Invokana,Diabetic Nephropathy,Kidney,Canagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes treatment.,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,1.26,183.0 +5807,NCT06528405,The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease,RECRUITING,PHASE2,Acute Kidney Injury,dapagliflozin (DRUG); Other anti-diabetic drug or no anti-diabetic drug (OTHER); empagliflozin (DRUG); canagliflozin (DRUG),24812758,Invokana,Acute Kidney Injury,Kidney,Canagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes treatment.,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,1.26,183.0 +5808,NCT06913647,Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis,NOT_YET_RECRUITING,PHASE2,ESRD; CKD (Chronic Kidney Disease) Stage 5D,Canagliflozin 300 MG (DRUG),24812758,Invokana,ESRD; CKD (Chronic Kidney Disease) Stage 5D,Kidney,Canagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes treatment.,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,1.26,183.0 +5809,NCT06074588,Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004),RECRUITING,PHASE3,Non-small Cell Lung Cancer (NSCLC),Sacituzumab tirumotecan (BIOLOGICAL); Docetaxel (DRUG); Pemetrexed (DRUG),45256689,s8803,Non-small Cell Lung Cancer (NSCLC),Lung,MK-3903,PRKAA1,activator/agonist,unclear,no,yes,"Investigated for NASH, not yet approved for human use.",CC1=C(C=C(C=C1)OC2=NC3=C(N2)C=C(C(=C3)C4=CC=C(C=C4)C5=CC=CC=C5)Cl)C(=O)O,, +5810,NCT05458674,Tucatinib+Trastuzumab+Eribulin in HER2+ MBC,RECRUITING,PHASE2,Breast Cancer; Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer,Tucatinib (DRUG); Eribulin (DRUG); Trastuzumab (DRUG),51039094,Tukysa,Breast Cancer; Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer,Breast,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5811,NCT05868226,PRE-I-SPY Phase I/Ib Oncology Platform Program,RECRUITING,PHASE1,"HER2-positive Breast Cancer; Metastatic Cancer; Metastatic Breast Cancer; Metastatic; HER2-positive Metastatic Breast Cancer; HER2 Mutation-Related Tumors; HER-2 Protein Overexpression; HER2-negative Breast Cancer; Triple Negative Breast Cancer; HR Positive; Hormone Receptor-positive Breast Cancer; Estrogen Receptor Positive Tumor; Progesterone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma; Solid Tumor; Solid Tumor, Adult; Solid Carcinoma; HER2 Low Breast Cancer; HER2 Low Breast Carcinoma; ER Positive Breast Cancer; PR-positive Breast Cancer",ALX148 (DRUG); Fam-Trastuzumab Deruxtecan-Nxki (DRUG); Zanidatamab (DRUG); Tucatinib (DRUG),51039094,Tukysa,"HER2-positive Breast Cancer; Metastatic Cancer; Metastatic Breast Cancer; Metastatic; HER2-positive Metastatic Breast Cancer; HER2 Mutation-Related Tumors; HER-2 Protein Overexpression; HER2-negative Breast Cancer; Triple Negative Breast Cancer; HR Positive; Hormone Receptor-positive Breast Cancer; Estrogen Receptor Positive Tumor; Progesterone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma; Solid Tumor; Solid Tumor, Adult; Solid Carcinoma; HER2 Low Breast Cancer; HER2 Low Breast Carcinoma; ER Positive Breast Cancer; PR-positive Breast Cancer",Breast,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5812,NCT06067776,"Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer",NOT_YET_RECRUITING,PHASE1,Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Cetuximab (BIOLOGICAL); Osimertinib (DRUG); Tucatinib (DRUG),51039094,Tukysa,Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Lung,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5813,NCT05132582,A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,HER2 Positive Breast Cancer,Tucatinib (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); Combination product: Trastuzumab + Pertuzumab (DRUG); Placebo (DRUG),51039094,Tukysa,HER2 Positive Breast Cancer,Breast,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5814,NCT05319873,"Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer",RECRUITING,PHASE1,Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Locally Advanced HER2-Positive Breast Carcinoma; Metastatic HER2-Positive Breast Carcinoma; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8,Carboplatin (DRUG); Docetaxel (DRUG); Fulvestrant (DRUG); Pertuzumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Ribociclib (DRUG); Trastuzumab (BIOLOGICAL); Tucatinib (DRUG),51039094,Tukysa,Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Locally Advanced HER2-Positive Breast Carcinoma; Metastatic HER2-Positive Breast Carcinoma; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8,Breast,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5815,NCT04789096,Tucatinib Together with Pembrolizumab and Trastuzumab,RECRUITING,PHASE2,Breast Cancer; HER2-positive Breast Cancer,Tucatinib (DRUG); Pembrolizumab (DRUG); Trastuzumab (DRUG); Capecitabine (DRUG),51039094,Tukysa,Breast Cancer; HER2-positive Breast Cancer,Breast,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5816,NCT05230810,Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.,RECRUITING,PHASE1,HER2-positive Metastatic Breast Cancer,Alpelisib (DRUG); Tucatinib (DRUG); Fulvestrant (DRUG),51039094,Tukysa,HER2-positive Metastatic Breast Cancer,Breast,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5817,NCT06157892,A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors,RECRUITING,PHASE2,Breast Neoplasms; Gastroesophageal Junction Adenocarcinoma; HER2 Low Breast Neoplasms; HER2 Positive Breast Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Metastatic Breast Cancer; Metastatic Gastric Cancer; Advanced Breast Cancer; Advanced Gastric Cancer,disitamab vedotin (DRUG); tucatinib (DRUG),51039094,Tukysa,Breast Neoplasms; Gastroesophageal Junction Adenocarcinoma; HER2 Low Breast Neoplasms; HER2 Positive Breast Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Metastatic Breast Cancer; Metastatic Gastric Cancer; Advanced Breast Cancer; Advanced Gastric Cancer,Esophagus/Stomach,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5818,NCT04499924,"Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer",COMPLETED,PHASE2,Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma,tucatinib (DRUG); trastuzumab (DRUG); ramucirumab (DRUG); paclitaxel (DRUG); tucatinib placebo (OTHER); trastuzumab placebo (OTHER),51039094,Tukysa,Gastrointestinal Adenocarcinoma,Bowel,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5819,NCT05583110,Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,HER2-positive Metastatic Breast Cancer; Locally Advanced HER2 Positive Breast Carcinoma,Tucatinib (DRUG); Trastuzumab (DRUG); Vinorelbine (DRUG),51039094,Tukysa,HER2-positive Metastatic Breast Cancer; Locally Advanced HER2 Positive Breast Carcinoma,Breast,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5820,NCT05323955,Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients with ADvanced Human Epidermal Growth Factor Receptor 2+ BrEast Cancer with the Addition of Tucatinib,RECRUITING,PHASE2,Brain Metastases; Human Epidermal Growth Factor 2 Positive Carcinoma of Breast; Advanced Breast Cancer,Trastuzumab (DRUG); Trastuzumab Emtansine (T-DM1) (DRUG); Pertuzumab (DRUG); Tucatinib (DRUG),51039094,Tukysa,Brain Metastases; Human Epidermal Growth Factor 2 Positive Carcinoma of Breast; Advanced Breast Cancer,Breast,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5821,NCT04430738,Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers,ACTIVE_NOT_RECRUITING,PHASE2,Colorectal Carcinoma; Gastric Adenocarcinoma; GEJ Adenocarcinoma; Esophageal Adenocarcinoma; Cholangiocarcinoma; Gallbladder Carcinoma,tucatinib (DRUG); trastuzumab (DRUG); oxaliplatin (DRUG); leucovorin (DRUG); fluorouracil (DRUG); capecitabine (DRUG); pembrolizumab (DRUG),51039094,Tukysa,Colorectal Carcinoma; Gastric Adenocarcinoma; GEJ Adenocarcinoma; Esophageal Adenocarcinoma; Cholangiocarcinoma; Gallbladder Carcinoma,Bowel,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5822,NCT04539938,A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,HER2 Positive Breast Cancer,tucatinib (DRUG); trastuzumab deruxtecan (DRUG),51039094,Tukysa,HER2 Positive Breast Cancer,Breast,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5823,NCT05748834,Study of Tucatinib and Doxil in Participants with Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer,RECRUITING,PHASE2,Breast Cancer,Tucatinib (DRUG); Doxil (DRUG),51039094,Tukysa,Breast Cancer,Breast,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5824,NCT03043313,Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Adenocarcinoma,Trastuzumab (DRUG); Tucatinib (DRUG),51039094,Tukysa,Metastatic Colorectal Adenocarcinoma,Bowel,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5825,NCT06162559,"Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study",RECRUITING,PHASE1,Breast Cancer,Tucatinib (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG),51039094,Tukysa,Breast Cancer,Breast,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5826,NCT06016387,Tucatinib With Brain and/or Spinal XRT in Patients With HER2+ Metastatic Breast Cancer and LMD,RECRUITING,PHASE2,HER2-positive Breast Cancer; LMD,Tucatinib 150 MG (DRUG); Trastuzumab (DRUG); Capecitabine (DRUG); Brain & Spinal Radiation (RADIATION),51039094,Tukysa,HER2-positive Breast Cancer; LMD,Breast,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5827,NCT05253651,A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer,RECRUITING,PHASE3,Colorectal Neoplasms,tucatinib (DRUG); trastuzumab (DRUG); bevacizumab (DRUG); cetuximab (DRUG); oxaliplatin (DRUG); leucovorin (DRUG); levoleucovorin (DRUG); fluorouracil (DRUG),51039094,Tukysa,Colorectal Neoplasms,Bowel,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5828,NCT04721977,A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001),ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Tucatinib (DRUG); Trastuzumab (BIOLOGICAL); Capecitabine (DRUG),51039094,Tukysa,Breast Cancer,Breast,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5829,NCT05091528,A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers,TERMINATED,PHASE1,HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2-positive Colorectal Cancer; HER2-expressing Non-small Cell Lung Cancer,SBT6050 (DRUG); trastuzumab deruxtecan (DRUG); tucatinib (DRUG); trastuzumab (DRUG); capecitabine (DRUG); trastuzumab deruxtecan (DRUG),51039094,Tukysa,HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2-positive Colorectal Cancer; HER2-expressing Non-small Cell Lung Cancer,Bowel,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5830,NCT04512261,TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases,WITHDRAWN,PHASE1,Breast Cancer; Brain Metastases; HER2-positive Breast Cancer; CNS Disease,Tucatinib (DRUG); Pembrolizumab (DRUG); Trastuzumab (DRUG),51039094,Tukysa,Breast Cancer; Brain Metastases; HER2-positive Breast Cancer; CNS Disease,Breast,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5831,NCT05356897,"Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study",WITHDRAWN,PHASE2,Metastatic Colon Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Rectal Adenocarcinoma; Stage IV Colon Cancer AJCC V8; Stage IV Colorectal Cancer AJCC V8; Stage IV Rectal Cancer AJCC V8,Trastuzumab (BIOLOGICAL); Trifluridine and Tipiracil Hydrochloride (DRUG); Tucatinib (DRUG),51039094,Tukysa,Metastatic Colon Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Rectal Adenocarcinoma; Stage IV Colon Cancer AJCC V8; Stage IV Colorectal Cancer AJCC V8; Stage IV Rectal Cancer AJCC V8,Bowel,Tucatinib,ERBB2,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use in advanced HER2-positive breast cancer.,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,1.07,641.0 +5832,NCT00002120,Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia,COMPLETED,PHASE1,"Pneumonia, Pneumocystis Carinii; HIV Infections",Trimetrexate glucuronate (DRUG); Trimethoprim (DRUG); Sulfamethoxazole (DRUG); Dapsone (DRUG); Leucovorin calcium (DRUG),5583,TMQ,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Trimetrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used with leucovorin for treating certain types of pneumonia.,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,1.0,6.0 +5833,NCT00003446,Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,fluorouracil (DRUG); leucovorin calcium (DRUG); trimetrexate glucuronate (DRUG),5583,TMQ,Colorectal Cancer,Bowel,Trimetrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used with leucovorin for treating certain types of pneumonia.,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,1.0,6.0 +5834,NCT00000730,Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients,TERMINATED,PHASE3,"Pneumonia, Pneumocystis Carinii; HIV Infections",Trimetrexate glucuronate (DRUG); Methylprednisolone (DRUG); Pentamidine isethionate (DRUG); Sulfamethoxazole-Trimethoprim (DRUG); Leucovorin calcium (DRUG),5583,TMQ,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Trimetrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used with leucovorin for treating certain types of pneumonia.,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,1.0,6.0 +5835,NCT00001016,A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies,COMPLETED,PHASE3,"Pneumonia, Pneumocystis Carinii; HIV Infections",Trimetrexate glucuronate (DRUG); Leucovorin calcium (DRUG),5583,TMQ,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Trimetrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used with leucovorin for treating certain types of pneumonia.,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,1.0,6.0 +5836,NCT00000724,A Study of Trimetrexate With Leucovorin Rescue for AIDS Patients Who Are Refractory to Standard Therapies for Pneumocystis Carinii Pneumonia,COMPLETED,PHASE3,"Pneumonia, Pneumocystis Carinii; HIV Infections",Trimetrexate glucuronate (DRUG); Leucovorin calcium (DRUG),5583,TMQ,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Trimetrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used with leucovorin for treating certain types of pneumonia.,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,1.0,6.0 +5837,NCT00002955,Combination Chemotherapy in Treating Patients With Advanced Cancer of the Pancreas,COMPLETED,PHASE2,Pancreatic Cancer,fluorouracil (DRUG); leucovorin calcium (DRUG); trimetrexate glucuronate (DRUG),5583,TMQ,Pancreatic Cancer,Pancreas,Trimetrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used with leucovorin for treating certain types of pneumonia.,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,1.0,6.0 +5838,NCT00000714,"An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies",COMPLETED,PHASE3,"Pneumonia, Pneumocystis Carinii; HIV Infections",Trimetrexate glucuronate (DRUG); Leucovorin calcium (DRUG),5583,TMQ,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Trimetrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used with leucovorin for treating certain types of pneumonia.,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,1.0,6.0 +5839,NCT00001014,Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS,COMPLETED,PHASE3,"Pneumonia, Pneumocystis Carinii; HIV Infections",Trimetrexate glucuronate (DRUG); Sulfamethoxazole-Trimethoprim (DRUG); Leucovorin calcium (DRUG),5583,TMQ,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Trimetrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used with leucovorin for treating certain types of pneumonia.,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,1.0,6.0 +5840,NCT00001013,Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS,COMPLETED,PHASE3,"Pneumonia, Pneumocystis Carinii; HIV Infections",Trimetrexate glucuronate (DRUG); Pentamidine isethionate (DRUG); Sulfamethoxazole-Trimethoprim (DRUG); Leucovorin calcium (DRUG),5583,TMQ,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Trimetrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used with leucovorin for treating certain types of pneumonia.,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,1.0,6.0 +5841,NCT00000998,A Study of Trimetrexate in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Not Previously Treated for PCP,COMPLETED,PHASE1,"Pneumonia, Pneumocystis Carinii; HIV Infections",Trimetrexate glucuronate (DRUG); Leucovorin calcium (DRUG),5583,TMQ,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Trimetrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used with leucovorin for treating certain types of pneumonia.,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,1.0,6.0 +5842,NCT01238965,Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy,TERMINATED,PHASE1,Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer,panobinostat (DRUG); fluorouracil (DRUG); leucovorin calcium (DRUG); biopsy (PROCEDURE); reverse transcriptase-polymerase chain reaction (GENETIC); western blotting (GENETIC); laboratory biomarker analysis (OTHER); gene expression analysis (GENETIC); RNA analysis (GENETIC); polymorphism analysis (GENETIC),6918837,Faridak,Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer,Bowel,Panobinostat,"HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, HDAC10, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for multiple myeloma treatment.,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO,1.29,230.0 +5843,NCT01324635,Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors,TERMINATED,PHASE1,Recurrent Glioma; High-grade Meningioma; Brain Metastasis,Panobinostat (DRUG); Stereotactic body radiation therapy (RADIATION); Quality-of-life assessment (PROCEDURE); Stereotactic radiosurgery (RADIATION),6918837,Faridak,Recurrent Glioma; High-grade Meningioma; Brain Metastasis,CNS/Brain,Panobinostat,"HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, HDAC10, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for multiple myeloma treatment.,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO,1.29,230.0 +5844,NCT01582009,Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,TERMINATED,PHASE1,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,panobinostat (DRUG); everolimus (DRUG); laboratory biomarker analysis (OTHER); pharmacological study (OTHER); liquid chromatography (OTHER); mass spectrometry (OTHER); enzyme-linked immunosorbent assay (OTHER); immunohistochemistry staining method (OTHER),6918837,Faridak,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Kidney,Panobinostat,"HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, HDAC10, HDAC11",inhibitor/antagonist,HDAC inhibitor,yes,yes,Approved for multiple myeloma treatment.,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO,1.29,230.0 +5845,NCT00577148,An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes,TERMINATED,PHASE3,Fatty Liver,Rimonabant (DRUG); Placebo (for Rimonabant) (DRUG),104850,Zimulti,Fatty Liver,Liver,Rimonabant,CNR1,inhibitor/antagonist,unclear,no,yes,Withdrawn due to psychiatric side effects.,CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl,1.0192307692307692,127.0 +5846,NCT00576667,An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes,TERMINATED,PHASE3,Fatty Liver,Rimonabant (DRUG); Placebo (for Rimonabant) (DRUG),104850,Zimulti,Fatty Liver,Liver,Rimonabant,CNR1,inhibitor/antagonist,unclear,no,yes,Withdrawn due to psychiatric side effects.,CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl,1.0192307692307692,127.0 +5847,NCT00525681,Interaction Between Rimonabant and Cyclosporine and Tacrolimus,COMPLETED,PHASE4,Renal Transplantation,cyclosporine A (DRUG); tacrolimus (DRUG),104850,Zimulti,Renal Transplantation,Kidney,Rimonabant,CNR1,inhibitor/antagonist,unclear,no,yes,Withdrawn due to psychiatric side effects.,CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl,1.0192307692307692,127.0 +5848,NCT01515774,Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID),UNKNOWN,PHASE4,Parkinson's Disease,Mirapex ER (DRUG),14296,TMPZ,Parkinson's Disease,CNS/Brain,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5849,NCT05948566,Strategy for Improving Stroke Treatment Response,RECRUITING,PHASE2,Ischemic Stroke,TS23 (BIOLOGICAL),14296,TMPZ,Ischemic Stroke,CNS/Brain,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5850,NCT04872166,A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer,RECRUITING,PHASE1,Advanced Solid Tumor; Metastatic Breast Cancer,BTX-A51 (DRUG),14296,TMPZ,Advanced Solid Tumor; Metastatic Breast Cancer,Breast,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5851,NCT06625073,Randomized Trial of SGLT2i in Heart Transplant Recipients,NOT_YET_RECRUITING,PHASE4,Heart Transplant; Cardiovascular Disease; Kidney Disease,Empagliflozin (DRUG); Placebo (DRUG),14296,TMPZ,Heart Transplant; Cardiovascular Disease; Kidney Disease,Kidney,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5852,NCT06764927,Fibrinogen in Liver Transplant Subjects,NOT_YET_RECRUITING,EARLY_PHASE1,Liver Transplant Surgery,Cryoprecipitate Intercept Fibrinogen Complex (IFC) (BIOLOGICAL); Cryoprecipitate Antihemophilic Factor (AHF) (BIOLOGICAL),14296,TMPZ,Liver Transplant Surgery,Liver,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5853,NCT01817972,Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease,UNKNOWN,PHASE3,Crohn's Disease,Certolizumab pegol (BIOLOGICAL); Azathioprine (DRUG),14296,TMPZ,Crohn's Disease,Bowel,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5854,NCT00403767,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,COMPLETED,PHASE3,Atrial Fibrillation; Stroke; Embolism,Rivaroxaban (DRUG); Warfarin (DRUG); Matching placebo for Rivaroxaban arm (Warfarin placebo) (DRUG); Matching placebo for Warfarin arm (Rivaroxaban placebo) (DRUG),14296,TMPZ,Atrial Fibrillation; Stroke; Embolism,CNS/Brain,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5855,NCT02414139,"Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)",COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Capmatinib (DRUG),14296,TMPZ,"Carcinoma, Non-Small-Cell Lung",Lung,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5856,NCT06579196,Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1,NOT_YET_RECRUITING,PHASE1,Non-small Cell Lung Cancer,Trabedersen (DRUG); Pembrolizumab (DRUG),14296,TMPZ,Non-small Cell Lung Cancer,Lung,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5857,NCT05097989,Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN),TERMINATED,PHASE2,Lupus Nephritis; Immunoglobulin A Nephropathy; IgAN; LN,ALXN2050 (DRUG); Placebo (DRUG),14296,TMPZ,Lupus Nephritis; Immunoglobulin A Nephropathy; IgAN; LN,Kidney,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5858,NCT00054691,ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin,COMPLETED,PHASE2,Skin Cancer,Iressa (DRUG),14296,TMPZ,Skin Cancer,Skin,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5859,NCT01633060,"A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi",TERMINATED,PHASE3,Metastatic Breast Cancer,Fulvestrant (DRUG); BKM120 (DRUG); BKM120 matching placebo (DRUG),14296,TMPZ,Metastatic Breast Cancer,Breast,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5860,NCT02249312,The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial Asthma,COMPLETED,PHASE2,Asthma,BIIL 284 BS (DRUG); Placebo (DRUG),14296,TMPZ,Asthma,Lung,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5861,NCT00676143,Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients,TERMINATED,PHASE3,Alzheimer Disease,bapineuzumab (DRUG); placebo (DRUG),14296,TMPZ,Alzheimer Disease,CNS/Brain,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5862,NCT01958021,Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer,COMPLETED,PHASE3,"Advanced, Metastatic Breast Cancer",Ribociclib (DRUG); Letrozole (DRUG); Placebo (DRUG),14296,TMPZ,"Advanced, Metastatic Breast Cancer",Breast,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5863,NCT06918964,TaVNS for Acute Intracerebral Hemorrhage,NOT_YET_RECRUITING,PHASE2,Intracerebral Hemorrhage,transcutaneous auricular vagus nerve stimulation device (DEVICE); Sham device (DEVICE),14296,TMPZ,Intracerebral Hemorrhage,CNS/Brain,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5864,NCT00423137,Effect of BIBW 2948 BS in COPD,COMPLETED,PHASE2,"Pulmonary Disease, Chronic Obstructive; Bronchitis, Chronic",BIBW 2948 BS (DRUG); Placebo (DRUG),14296,TMPZ,"Pulmonary Disease, Chronic Obstructive; Bronchitis, Chronic",Lung,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5865,NCT04585477,Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E),RECRUITING,PHASE2,Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Stage I; Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage III,AVENIO ctDNA Surveillance Kit (DEVICE); Durvalumab (DRUG); Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy (DRUG),14296,TMPZ,Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Stage I; Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage III,Lung,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5866,NCT00048087,Iressa/Docetaxel in Non-Small-Cell Lung Cancer,WITHDRAWN,PHASE2,Non-small Cell Lung Cancer,ZD1839 (DRUG); Docetaxel (DRUG),14296,TMPZ,Non-small Cell Lung Cancer,Lung,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5867,NCT03521154,A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA),ACTIVE_NOT_RECRUITING,PHASE3,Non Small Cell Lung Cancer (Stage III),Osimertinib 80mg/40mg (DRUG); Placebo Osimertinib 80mg/40mg (DRUG),14296,TMPZ,Non Small Cell Lung Cancer (Stage III),Lung,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5868,NCT02869347,Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects,COMPLETED,PHASE2,Acute Kidney Injury,Conestat alfa (DRUG); Sodium chloride 0.9% (DRUG),14296,TMPZ,Acute Kidney Injury,Kidney,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5869,NCT04546009,"A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)",ACTIVE_NOT_RECRUITING,PHASE3,"Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer",Giredestrant (DRUG); Giredestrant-matched Placebo (DRUG); Letrozole (DRUG); Letrozole-matched Placebo (DRUG); Palbociclib (DRUG); LHRH Agonist (DRUG),14296,TMPZ,"Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer",Breast,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5870,NCT03684278,"Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)",RECRUITING,PHASE2,Acute Pancreatitis,Infusion of 5 mg/kg Infliximab (DRUG); Infusion of 10 mg/kg Infliximab (DRUG); 0.9% Sodium Chloride (Placebo) (OTHER),14296,TMPZ,Acute Pancreatitis,Pancreas,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5871,NCT00845728,Exacerbation Study,COMPLETED,PHASE3,Chronic Obstructive Pulmonary Disease,Indacaterol 150 µg (DRUG); Tiotropium (DRUG),14296,TMPZ,Chronic Obstructive Pulmonary Disease,Lung,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5872,NCT04427293,Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC),RECRUITING,PHASE1,Triple Negative Breast Cancer,Lenvatinib (DRUG); Pembrolizumab (DRUG),14296,TMPZ,Triple Negative Breast Cancer,Breast,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5873,NCT03373461,Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation,COMPLETED,PHASE2,IgA Nephropathy,LNP023 (DRUG); Placebo (OTHER),14296,TMPZ,Kidney Diseases,Kidney,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5874,NCT06543797,A Pilot Clinical Trial Study to Determine the Safety of the Application of a Wearable Medical Electromagnetic Generator,NOT_YET_RECRUITING,EARLY_PHASE1,Stroke,wearable rTMS (DEVICE),14296,TMPZ,Stroke,CNS/Brain,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5875,NCT04258397,Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease,UNKNOWN,PHASE2,Chronic Kidney Disease,Pirfenidone (DRUG); matching placebo (DRUG),14296,TMPZ,Chronic Kidney Disease,Kidney,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5876,NCT01024647,Optimizing Cimzia in Crohn's Patients,UNKNOWN,PHASE4,Crohn's Disease,certolizumab pegol (BIOLOGICAL); certolizumab pegol (BIOLOGICAL); certolizumab pegol (BIOLOGICAL); certolizumab pegol (BIOLOGICAL),14296,TMPZ,Crohn's Disease,Bowel,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5877,NCT01059305,"Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin",TERMINATED,PHASE2,Skin Cancer,Erlotinib (DRUG),14296,TMPZ,Skin Cancer,Skin,Ligustrazine,,unclear,unclear,no,yes,"Mainly used in traditional Chinese medicine, limited human trials exist.",CC1=C(N=C(C(=N1)C)C)C,1.0,279.0 +5878,NCT03978559,Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP,UNKNOWN,PHASE4,Pneumocystis Pneumonia,caspofungin (DRUG); TMP/SMZ(trimethoprim/sulfisoxazole) (DRUG); Methylprednisolone (DRUG),5344,SOXO,Pneumocystis Pneumonia,Lung,Sulfisoxazole,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Discontinued in U.S.; previously used for bacterial infections.,CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N,1.1978021978021978,252.0 +5879,NCT03284957,Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer,TERMINATED,PHASE1,Breast Cancer,Amcenestrant (DRUG); Palbociclib (DRUG); Alpelisib (DRUG); Everolimus (DRUG); Abemaciclib (DRUG),56649450,Piqray,Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5880,NCT05563220,Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer,RECRUITING,PHASE1,Breast Cancer; Metastatic Breast Cancer,Elacestrant (DRUG); Alpelisib (DRUG); Everolimus (DRUG); Ribociclib (DRUG); Palbociclib (DRUG); Capivasertib (DRUG); Abemaciclib (DRUG),56649450,Piqray,Breast Cancer; Metastatic Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5881,NCT05238831,SMMART Adaptive Clinical Treatment (ACT) Trial,WITHDRAWN,EARLY_PHASE1,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Alectinib (DRUG); Alpelisib (DRUG); Anastrozole (DRUG); Atezolizumab (BIOLOGICAL); Bevacizumab (BIOLOGICAL); Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Capecitabine (DRUG); Carboplatin (DRUG); Cobimetinib (DRUG); Entrectinib (DRUG); Eribulin (DRUG); Fulvestrant (DRUG); Hyaluronidase-zzxf/Pertuzumab/Trastuzumab (BIOLOGICAL); Irinotecan (DRUG); Letrozole (DRUG); Nab-paclitaxel (DRUG); Niraparib (DRUG); Olaparib (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Pertuzumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Trastuzumab (BIOLOGICAL); Trastuzumab Emtansine (BIOLOGICAL); Vemurafenib (DRUG); Vinorelbine (DRUG); Vismodegib (DRUG),56649450,Piqray,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Ovary/Fallopian Tube,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5882,NCT05063786,Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET),ACTIVE_NOT_RECRUITING,PHASE3,Advanced Breast Cancer,Trastuzumab (BIOLOGICAL); Alpelisib (DRUG); Fulvestrant (DRUG); Vinorelbine (DRUG); Capecitabine (DRUG); Eribulin (DRUG),56649450,Piqray,Advanced Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5883,NCT05501886,Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1),RECRUITING,PHASE3,Breast Cancer,Gedatolisib (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG); Alpelisib (DRUG),56649450,Piqray,Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5884,NCT03207529,Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer,COMPLETED,PHASE1,Advanced Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Androgen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; PTEN Positive; Recurrent Breast Carcinoma; Refractory Breast Carcinoma; Triple-Negative Breast Carcinoma,Alpelisib (DRUG); Enzalutamide (DRUG),56649450,Piqray,Advanced Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Androgen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; PTEN Positive; Recurrent Breast Carcinoma; Refractory Breast Carcinoma; Triple-Negative Breast Carcinoma,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5885,NCT05143229,Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer,RECRUITING,PHASE1,Breast Cancer,Alpelisib (DRUG); Sacituzumab govitecan (DRUG),56649450,Piqray,Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5886,NCT05967286,"Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial",WITHDRAWN,PHASE2,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Negative Breast Carcinoma; Unresectable HER2-Negative Breast Carcinoma,Alpelisib (DRUG); Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Olaparib (DRUG); Positron Emission Tomography (PROCEDURE),56649450,Piqray,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Negative Breast Carcinoma; Unresectable HER2-Negative Breast Carcinoma,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5887,NCT05230810,Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.,RECRUITING,PHASE1,HER2-positive Metastatic Breast Cancer,Alpelisib (DRUG); Tucatinib (DRUG); Fulvestrant (DRUG),56649450,Piqray,HER2-positive Metastatic Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5888,NCT05090358,Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer; Breast Cancer Stage IV; Metastatic Breast Cancer,Ketogenic Diet (DIETARY_SUPPLEMENT); Low Carbohydrate Diet (DIETARY_SUPPLEMENT); Alpelisib (DRUG); Fulvestrant (DRUG); Canagliflozin (DRUG),56649450,Piqray,Breast Cancer; Breast Cancer Stage IV; Metastatic Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5889,NCT04216472,Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations,ACTIVE_NOT_RECRUITING,PHASE2,Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Refractory Breast Carcinoma; Triple-Negative Breast Carcinoma,Alpelisib (DRUG); Nab-paclitaxel (DRUG),56649450,Piqray,Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Refractory Breast Carcinoma; Triple-Negative Breast Carcinoma,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5890,NCT05508906,"Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus",RECRUITING,PHASE1,Metastatic Breast Cancer; Advanced Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; Breast Cancer,OP-1250 (DRUG); Ribociclib (DRUG); Alpelisib (DRUG); Everolimus (DRUG),56649450,Piqray,Metastatic Breast Cancer; Advanced Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5891,NCT05101564,"Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer; HER2-negative Breast Cancer; ER Positive Breast Cancer,Alpelisib (DRUG); Tamoxifen (DRUG); Zotatifin (DRUG); Fulvestrant (DRUG),56649450,Piqray,Breast Cancer; HER2-negative Breast Cancer; ER Positive Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5892,NCT05564377,"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial",RECRUITING,PHASE2,Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm,Alpelisib (DRUG); Binimetinib (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Fluorouracil (DRUG); Fulvestrant (DRUG); Ipatasertib (DRUG); Leucovorin (DRUG); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Mutation Carrier Screening (PROCEDURE); Neratinib Maleate (DRUG); Nilotinib Hydrochloride Monohydrate (DRUG); Olaparib (DRUG); Oxaliplatin (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Panitumumab (BIOLOGICAL); Positron Emission Tomography (PROCEDURE); Selumetinib Sulfate (DRUG); Sotorasib (DRUG),56649450,Piqray,Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm,Ovary/Fallopian Tube,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5893,NCT06354088,"Human Models of Selective Insulin Resistance: Alpelisib, Part I",RECRUITING,PHASE1,Insulin Resistance; Prediabetic State; Overweight and Obesity; Non-Alcoholic Fatty Liver Disease,"Alpelisib 300 mg (DRUG); Placebo (DRUG); [1-13C] sodium acetate (DRUG); [6,6-2H2] D-glucose (DRUG); Nestlé BOOST Plus (DIETARY_SUPPLEMENT)",56649450,Piqray,Insulin Resistance; Prediabetic State; Overweight and Obesity; Non-Alcoholic Fatty Liver Disease,Liver,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5894,NCT05154487,A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer,RECRUITING,PHASE2,Endometroid Endometrial Cancer,Alpelisib Pill (DRUG); Fulvestrant injection (DRUG),56649450,Piqray,Endometroid Endometrial Cancer,Uterus,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5895,NCT02379247,BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer,COMPLETED,PHASE1,Breast Cancer,BYL-719 (alpelisib) (DRUG); Nab-paclitaxel (DRUG),56649450,Piqray,Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5896,NCT02058381,A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer,COMPLETED,PHASE1,Pre-menopausal Breast Cancer; PI3K Pathway Inhibition,alpelisib (BYL719) (DRUG); buparlisib (BKM120) (DRUG),56649450,Piqray,Pre-menopausal Breast Cancer; PI3K Pathway Inhibition,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5897,NCT05472220,Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma,WITHDRAWN,PHASE1,"Solid Tumors, Adult; PIK3CA Mutation-Related Tumors; PIK3CA Mutation; Human Papillomavirus-Related Carcinoma; HPV-Related Squamous Cell Carcinoma; Human Papillomavirus-Related Squamous Cell Carcinoma; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm",Alpelisib (DRUG); Carboplatin (DRUG); Hyperpolarized Carbon-13 (13C) Pyruvate (DRUG); Continuous Glucose Monitor (CGM) (DEVICE),56649450,Piqray,"Solid Tumors, Adult; PIK3CA Mutation-Related Tumors; PIK3CA Mutation; Human Papillomavirus-Related Carcinoma; HPV-Related Squamous Cell Carcinoma; Human Papillomavirus-Related Squamous Cell Carcinoma; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm",Skin,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5898,NCT04300790,Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients,COMPLETED,PHASE2,Breast Cancer,Alpelisib (DRUG); Metformin (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Exemestane (DRUG); Vildagliptin (DRUG); Tamoxifen (DRUG),56649450,Piqray,Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5899,NCT02276027,"A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer",COMPLETED,PHASE2,Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma,BYL719 (DRUG); INC280 (DRUG); LDK378 (DRUG); MEK162 (DRUG),56649450,Piqray,Lung Adenocarcinoma and Squamous Cell Carcinoma,Skin,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5900,NCT06837792,Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer,RECRUITING,PHASE2,"Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)",Experimental treatment arm (DRUG); Control treatment arm (DRUG),56649450,Piqray,"Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)",Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5901,NCT01872260,"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,LEE011 (DRUG); Letrozole (DRUG); BYL719 (DRUG),56649450,Piqray,Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5902,NCT05627960,First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies,RECRUITING,PHASE1,Triple Negative Breast Cancer; Hormone-Resistant Breast Cancer; Non Small Cell Lung Cancer; Mesothelioma,AG-01 Compound (DRUG),56649450,Piqray,Triple Negative Breast Cancer; Hormone-Resistant Breast Cancer; Non Small Cell Lung Cancer; Mesothelioma,Lung,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5903,NCT02145312,"An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.",UNKNOWN,PHASE2,Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck,BYL719 (DRUG),56649450,Piqray,Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck,Skin,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5904,NCT02624557,Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.,COMPLETED,PHASE1,Hepatic Impairment,Alpelisib (DRUG),56649450,Piqray,Hepatic Impairment,Liver,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5905,NCT05768139,First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors,RECRUITING,PHASE1,"Breast Cancer; Gynecologic Cancer; HNSCC; Solid Tumors, Adult",STX-478 (DRUG); Fulvestrant (DRUG); Ribociclib (DRUG); Palbociclib (DRUG),56649450,Piqray,"Breast Cancer; Gynecologic Cancer; HNSCC; Solid Tumors, Adult",Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5906,NCT05753657,A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.,RECRUITING,EARLY_PHASE1,Metastatic Breast Cancer; Hyperinsulinism; Hyperglycemia Drug Induced,Pioglitazone (DRUG),56649450,Piqray,Metastatic Breast Cancer; Hyperinsulinism; Hyperglycemia Drug Induced,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5907,NCT03386162,SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer,TERMINATED,PHASE2,"Breast Cancer, PI3K, Alpelisib",Alpelisib (DRUG); Chemotherapy (DRUG),56649450,Piqray,"Breast Cancer, PI3K, Alpelisib",Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5908,NCT01719380,"Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer",COMPLETED,PHASE2,Colorectal Cancer,LGX818 (DRUG); Cetuximab (DRUG); BYL719 (DRUG),56649450,Piqray,Colorectal Cancer,Bowel,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5909,NCT01300962,Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer,COMPLETED,PHASE1,Metastatic Breast Cancer,BMK120 (DRUG); Capecitabine (DRUG); BYL719 (DRUG); Trastuzumab (DRUG); Lapatinib (DRUG),56649450,Piqray,Metastatic Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5910,NCT05646862,"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy",ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Inavolisib (DRUG); Fulvestrant (DRUG); Alpelisib (DRUG),56649450,Piqray,Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5911,NCT05038735,"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.",RECRUITING,PHASE3,Breast Cancer,Alpelisib (DRUG); Fulvestrant (DRUG); Alpelisib-matching placebo (DRUG),56649450,Piqray,Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5912,NCT05025735,"Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer",UNKNOWN,PHASE2,Metastatic Breast Cancer; HER2-negative Breast Cancer,Dapagliflozin 10Mg Tab (DRUG),56649450,Piqray,Metastatic HER2-negative Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5913,NCT02038010,BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx,COMPLETED,PHASE1,HER2-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,PI3K inhibitor BYL719 (DRUG); ado-trastuzumab emtansine (BIOLOGICAL); pharmacological study (OTHER); laboratory biomarker analysis (OTHER),56649450,Piqray,HER2-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5914,NCT04544189,Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Neoplasms,Alpelisib (DRUG); Fulvestrant (DRUG); Placebo (DRUG),56649450,Piqray,Breast Neoplasms,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5915,NCT01923168,"Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women",COMPLETED,PHASE2,Breast Cancer,alpelisib (DRUG); buparlisib (DRUG); Placebo (DRUG),56649450,Piqray,Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5916,NCT03439046,"Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant",COMPLETED,PHASE3,Breast Cancer,Ribociclib (DRUG); Letrozole (DRUG); Alpelisib (DRUG); Fulvestrant (DRUG),56649450,Piqray,Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5917,NCT05631795,"Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment",RECRUITING,PHASE4,Advanced Breast Cancer,Alpelisib (DRUG); Fulvestrant (DRUG),56649450,Piqray,Advanced Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5918,NCT02437318,Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.,COMPLETED,PHASE3,Breast Cancer,Fulvestrant (DRUG); Alpelisib (DRUG); Placebo (DRUG),56649450,Piqray,Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5919,NCT05455619,Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HR+/Her2- Breast Cancer,RECRUITING,PHASE1,HR+/HER2-negative Breast Cancer; Metastatic Breast Cancer,Evexomostat (DRUG),56649450,Piqray,HR+/HER2-negative Breast Cancer; Metastatic Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5920,NCT02273219,Trial of AEB071 in Combination With BYL719 in Patients With Melanoma,COMPLETED,PHASE1,Uveal Melanoma,AEB071 (DRUG); BYL719 (DRUG),56649450,Piqray,Uveal Melanoma,Skin,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5921,NCT01623349,Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer,COMPLETED,PHASE1,Ovarian Cancer; Breast Cancer,BKM120 and Olaparib (DRUG); BYL719 and Olaparib (DRUG),56649450,Piqray,Breast and Ovarian Cancer,Ovary/Fallopian Tube,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5922,NCT03056755,"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments",COMPLETED,PHASE2,Breast Cancer,Alpelisib (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Goserelin (DRUG); Leuprolide (DRUG),56649450,Piqray,Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5923,NCT05933395,Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor,RECRUITING,PHASE2,Advanced Breast Cancer,Fulvestrant (DRUG); Neratinib (DRUG); Alpelisib (DRUG); Everolimus (DRUG); Abemaciclib (DRUG),56649450,Piqray,Advanced Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5924,NCT01613950,PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer,COMPLETED,PHASE1,Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein,AUY922 (DRUG); BYL719 (DRUG),56649450,Piqray,Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein,Esophagus/Stomach,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5925,NCT02298595,"Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma",WITHDRAWN,PHASE1,"Carcinoma, Squamous; Squamous Cell Carcinoma; Oropharyngeal Neoplasms; Oropharyngeal Cancer",cisplatin (DRUG); Cetuximab (DRUG); BYL719 (DRUG),56649450,Piqray,"Carcinoma, Squamous; Squamous Cell Carcinoma; Oropharyngeal Neoplasms; Oropharyngeal Cancer",Skin,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5926,NCT02537223,Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer,COMPLETED,PHASE1,Squamous Cell Carcinoma of Head and Neck; Locoregionally Advanced,BYL719 (DRUG); Cisplatin (DRUG); Intensity modulated radiation therapy (IMRT) (RADIATION),56649450,Piqray,Squamous Cell Carcinoma of Head and Neck; Locoregionally Advanced,Skin,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5927,NCT05826964,Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer,RECRUITING,PHASE2,Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer,AI+CDK4/6i (DRUG); SERD+CDK4/6i (DRUG); mTOR inhibitor + AI (DRUG); mTOR inhibitor + SERD (DRUG); mTOR inhibitor + Selective estrogen receptor modulator (DRUG); PI3K inhibitor + SERD (DRUG); PI3K inhibitor + AI (DRUG); Chemotherapy (DRUG); Oral SERD (DRUG),56649450,Piqray,Metastatic ER-positive/HER2-negative Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5928,NCT04862143,Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant,TERMINATED,PHASE2,Advanced Breast Cancer,Alpelisib (DRUG); Fulvestrant (DRUG); Goserelin (DRUG),56649450,Piqray,Advanced Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5929,NCT02550743,"BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study",TERMINATED,PHASE1,Rectal Cancer,BYL719 (DRUG); Capecitabine (DRUG); Radiation (RADIATION),56649450,Piqray,Rectal Cancer,Bowel,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5930,NCT04899349,"Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant",TERMINATED,PHASE2,Breast Cancer,Alpelisib (DRUG); Fulvestrant (DRUG); Metformin XR (DRUG); Dapagliflozin + metformin XR (DRUG); Dapagliflozin (DRUG),56649450,Piqray,Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5931,NCT04762979,"Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer",RECRUITING,PHASE2,Hormone Receptor Positive Breast Carcinoma; HER2-negative Breast Cancer; PIK3CA Mutant Metastatic Breast Cancer,Alpelisib (DRUG); Fulvestrant (DRUG); Aromatase inhibitor (DRUG),56649450,Piqray,Hormone Receptor Positive Breast Carcinoma; HER2-negative Breast Cancer; PIK3CA Mutant Metastatic Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5932,NCT02088684,Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer,COMPLETED,PHASE1,Breast Cancer,LEE011 (DRUG); BYL719 (DRUG); fulvestrant (DRUG); BKM120 (DRUG),56649450,Piqray,Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5933,NCT04753203,Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Colorectal Cancer; PIK3CA Gene Mutation,Alpelisib plus Capecitabine combination (DRUG),56649450,Piqray,Metastatic Colorectal Cancer; PIK3CA Gene Mutation,Bowel,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5934,NCT05966584,A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Benralizumab (DRUG); fulvestrant or AIs) and PI3K inhibition (alpelisib) (DRUG),56649450,Piqray,Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5935,NCT04188548,A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; Endometrial Cancer,LY3484356 (DRUG); Abemaciclib (DRUG); Everolimus (DRUG); Alpelisib (DRUG); Trastuzumab (DRUG); Aromatase Inhibitor (AI) (DRUG); Pertuzumab (DRUG),56649450,Piqray,Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; Endometrial Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5936,NCT04526470,Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer,UNKNOWN,PHASE1,Solid Tumor; Stomach Cancer,Alpelisib (DRUG); Paclitaxel (DRUG),56649450,Piqray,Solid Tumor; Stomach Cancer,Esophagus/Stomach,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5937,NCT04524000,Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Advanced Breast Cancer,Alpelisib (DRUG); Fulvestrant (DRUG),56649450,Piqray,Advanced Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5938,NCT01822613,Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC),COMPLETED,PHASE1,Esophageal Squamous Cell Carcinoma,LJM716 (DRUG); BYL719 (DRUG); Paclitaxel (DRUG); Docetaxel (DRUG); Irinotecan (DRUG),56649450,Piqray,Esophageal Squamous Cell Carcinoma,Skin,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5939,NCT02734615,Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers,TERMINATED,PHASE1,Advanced or Metastatic ER+ Breast Cancer,LSZ102 (DRUG); LEE011 (DRUG); BYL719 (DRUG),56649450,Piqray,Advanced or Metastatic ER+ Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5940,NCT01219699,"A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene",COMPLETED,PHASE1,Advanced Solid Tumors With an Alteration of the PIK3CA Gene; Estrogen Receptor Positive Breast Cancer,BYL719 (DRUG); Fulvestrant (DRUG),56649450,Piqray,Advanced Solid Tumors With an Alteration of the PIK3CA Gene; Estrogen Receptor Positive Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5941,NCT04251533,Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss,ACTIVE_NOT_RECRUITING,PHASE3,Triple Negative Breast Neoplasms,alpelisib (DRUG); placebo (DRUG); nab-paclitaxel (DRUG),56649450,Piqray,Triple Negative Breast Neoplasms,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5942,NCT02051751,A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer,COMPLETED,PHASE1,"Neoplasms, Breast Neoplasms, Head and Neck Neoplasms",BYL719 (DRUG); Paclitaxel (DRUG),56649450,Piqray,"Neoplasms, Breast Neoplasms, Head and Neck Neoplasms",Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5943,NCT03631953,Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas,RECRUITING,PHASE1,Meningioma,Trametinib (DRUG); Alpelisib (DRUG); Blood sample (BIOLOGICAL); MRI (DEVICE),56649450,Piqray,Meningioma,CNS/Brain,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5944,NCT02167854,"Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer",COMPLETED,PHASE1,Breast Cancer,BYL719 (DRUG); LJM716 (DRUG); TRASTUZUMAB (DRUG),56649450,Piqray,Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5945,NCT01602315,A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,TERMINATED,PHASE1,Recurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma,BYL719 as film-coated (FC) whole tablets (DRUG); BYL719 as dispersible tablets (DT) (DRUG); cetuximab (BIOLOGICAL); BYL719 drink suspension (DRUG),56649450,Piqray,Metastatic Head and Neck Squamous Cell Carcinoma,Skin,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5946,NCT02506556,Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,BYl719 (DRUG),56649450,Piqray,Metastatic Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5947,NCT03601507,Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer,TERMINATED,PHASE2,CDKN2A-p16 Positive; HPV Positive Oropharyngeal Squamous Cell Carcinoma; Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7; Stage II Oropharyngeal Squamous Cell Carcinoma AJCC V7; Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7,Alpelisib (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacodynamic Study (OTHER); Therapeutic Conventional Surgery (PROCEDURE),56649450,Piqray,CDKN2A-p16 Positive; HPV Positive Oropharyngeal Squamous Cell Carcinoma; Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7; Stage II Oropharyngeal Squamous Cell Carcinoma AJCC V7; Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7,Skin,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5948,NCT02155088,BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer,COMPLETED,PHASE1,Pancreatic Cancer,BYL719 (DRUG); Gemcitabine (DRUG); (nab)-paclitaxel (DRUG),56649450,Piqray,Pancreatic Cancer,Pancreas,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5949,NCT04965688,Biology Guided Therapy for Breast Cancer for ER Positive,TERMINATED,PHASE2,Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer,Biopsy-Guided Therapy Selection (DRUG),56649450,Piqray,Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5950,NCT02077933,"Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors",COMPLETED,PHASE1,Neoplasms; Breast Neoplasms; Kidney Neoplasms; Pancreatic Neuroendocine Neoplasms (pNETs),alpelisib (DRUG); everolimus (DRUG); exemestane (DRUG),56649450,Piqray,Neoplasms; Breast Neoplasms; Kidney Neoplasms; Pancreatic Neuroendocine Neoplasms (pNETs),Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5951,NCT04729387,"Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected",ACTIVE_NOT_RECRUITING,PHASE3,Ovarian Cancer,Alpelisib (DRUG); Olaparib (DRUG); Paclitaxel (DRUG); Pegylated liposomal doxorubicin (PLD) (DRUG),56649450,Piqray,Ovarian Cancer,Ovary/Fallopian Tube,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5952,NCT05625087,Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib,RECRUITING,PHASE2,Breast Cancer Stage IV,Alpelisib (DRUG); Ribociclib (DRUG),56649450,Piqray,Breast Cancer Stage IV,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5953,NCT02282371,Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC),COMPLETED,PHASE1,Head and Neck Squamous Cell Cancer,Cetuximab (DRUG); BYL719 (DRUG); IMRT (Intensity-Modulated Radiation Therapy) (RADIATION),56649450,Piqray,Head and Neck Squamous Cell Cancer,Skin,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5954,NCT04208178,Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation,ACTIVE_NOT_RECRUITING,PHASE3,Advanced HER2+Breast Cancer,Alpelisib (DRUG); Alpelisib matching Placebo (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG),56649450,Piqray,Advanced HER2+Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5955,NCT01791478,BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer,PI3K inhibitor BYL719 (DRUG); letrozole (DRUG); laboratory biomarker analysis (OTHER); pharmacological studies (OTHER),56649450,Piqray,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5956,NCT05660083,Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC),RECRUITING,PHASE2,HER2-negative Breast Cancer; Metastatic Breast Cancer; Metaplastic Breast Carcinoma; TNBC - Triple-Negative Breast Cancer,L-NMMA (DRUG),56649450,Piqray,HER2-negative Breast Cancer; Metastatic Breast Cancer; Metaplastic Breast Carcinoma; TNBC - Triple-Negative Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5957,NCT01870505,BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer,COMPLETED,PHASE1,Metastatic or Locally-advanced Unresectable Breast Cancer,BYL719 (DRUG); Letrozole (DRUG); Exemestane (DRUG),56649450,Piqray,Metastatic or Locally-advanced Unresectable Breast Cancer,Breast,Alpelisib,PIK3CA,inhibitor/antagonist,PI3K/AKT inhibitor,yes,yes,Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1.42,341.0 +5958,NCT01749358,Dose Optimization for Stroke Evaluation,COMPLETED,PHASE1,Stroke; Cerebrovascular Disorders; Brain Ischemia; Infarction,Accelerated Skill Acquisition Program (ASAP) (BEHAVIORAL); Active Monitoring (BEHAVIORAL),11707110,QOM,Stroke; Cerebrovascular Disorders; Brain Ischemia; Infarction,CNS/Brain,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5959,NCT01749358,Dose Optimization for Stroke Evaluation,COMPLETED,PHASE1,Stroke; Cerebrovascular Disorders; Brain Ischemia; Infarction,Accelerated Skill Acquisition Program (ASAP) (BEHAVIORAL); Active Monitoring (BEHAVIORAL),11707110,QOM,Stroke; Cerebrovascular Disorders; Brain Ischemia; Infarction,CNS/Brain,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5960,NCT02166619,tDCS in Poststroke on Upper Limb Rehabilitation,UNKNOWN,PHASE2,Stroke,tDCS + physical therapy (DEVICE),11707110,QOM,Stroke,CNS/Brain,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5961,NCT02166619,tDCS in Poststroke on Upper Limb Rehabilitation,UNKNOWN,PHASE2,Stroke,tDCS + physical therapy (DEVICE),11707110,QOM,Stroke,CNS/Brain,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5962,NCT05227521,Feasibility of the Adapted H-GRASP Feedback Program in the Chronic Phase Post Stroke.,COMPLETED,PHASE1,Stroke,Adapted H-GRASP feedback program (BEHAVIORAL),11707110,QOM,Stroke,CNS/Brain,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5963,NCT05227521,Feasibility of the Adapted H-GRASP Feedback Program in the Chronic Phase Post Stroke.,COMPLETED,PHASE1,Stroke,Adapted H-GRASP feedback program (BEHAVIORAL),11707110,QOM,Stroke,CNS/Brain,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5964,NCT01268709,Effect of Doxepin and Nortriptyline on Irritable Bowel Syndrome,COMPLETED,PHASE2,Irritable Bowel Syndrome,Doxepin (DRUG); Nortriptyline (DRUG); placebo (DRUG),11707110,QOM,Irritable Bowel Syndrome,Bowel,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5965,NCT01268709,Effect of Doxepin and Nortriptyline on Irritable Bowel Syndrome,COMPLETED,PHASE2,Irritable Bowel Syndrome,Doxepin (DRUG); Nortriptyline (DRUG); placebo (DRUG),11707110,QOM,Irritable Bowel Syndrome,Bowel,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5966,NCT01879787,Effects of tDCS Combined With mCIMT or Mental Practice in Poststroke Patients,COMPLETED,PHASE2,Stroke,tDCS (OTHER),11707110,QOM,Stroke,CNS/Brain,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5967,NCT01879787,Effects of tDCS Combined With mCIMT or Mental Practice in Poststroke Patients,COMPLETED,PHASE2,Stroke,tDCS (OTHER),11707110,QOM,Stroke,CNS/Brain,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5968,NCT04294160,A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer,TERMINATED,PHASE1,BRAF V600 Colorectal Cancer,Dabrafenib (DRUG); LTT462 (DRUG); Trametinib (DRUG); LXH254 (DRUG); TNO155 (DRUG); Spartalizumab (BIOLOGICAL); Tislelizumab (BIOLOGICAL),11707110,QOM,BRAF V600 Colorectal Cancer,Bowel,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5969,NCT04294160,A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer,TERMINATED,PHASE1,BRAF V600 Colorectal Cancer,Dabrafenib (DRUG); LTT462 (DRUG); Trametinib (DRUG); LXH254 (DRUG); TNO155 (DRUG); Spartalizumab (BIOLOGICAL); Tislelizumab (BIOLOGICAL),11707110,QOM,BRAF V600 Colorectal Cancer,Bowel,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5970,NCT03551626,Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes,COMPLETED,PHASE3,Malignant Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Malignant Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5971,NCT03551626,Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes,COMPLETED,PHASE3,Malignant Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Malignant Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5972,NCT02684058,Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors,COMPLETED,PHASE2,"Diffuse Astrocytoma; Anaplastic Astrocytoma; Astrocytoma; Oligodendroglioma, Childhood; Anaplastic Oligodendroglioma; Glioblastoma; Pilocytic Astrocytoma; Giant Cell Astrocytoma; Pleomorphic Xanthoastrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Angiocentric Glioma; Chordoid Glioma of Third Ventricle; Gangliocytoma; Ganglioglioma; Anaplastic Ganglioglioma; Dysplastic Gangliocytoma of Cerebrellum; Desmoplastic Infantile Astrocytoma and Ganglioglioma; Papillary Glioneuronal Tumor; Rosette-forming Glioneurona Tumor; Central Neurocytoma; Extraventricular Neurocytoma; Cerebellar Iponeurocytoma",Dabrafenib (DRUG); trametinib (DRUG); Carboplatin (DRUG); Vincristine (DRUG),11707110,QOM,Gliomas and Neuronal Tumors,CNS/Brain,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5973,NCT02684058,Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors,COMPLETED,PHASE2,"Diffuse Astrocytoma; Anaplastic Astrocytoma; Astrocytoma; Oligodendroglioma, Childhood; Anaplastic Oligodendroglioma; Glioblastoma; Pilocytic Astrocytoma; Giant Cell Astrocytoma; Pleomorphic Xanthoastrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Angiocentric Glioma; Chordoid Glioma of Third Ventricle; Gangliocytoma; Ganglioglioma; Anaplastic Ganglioglioma; Dysplastic Gangliocytoma of Cerebrellum; Desmoplastic Infantile Astrocytoma and Ganglioglioma; Papillary Glioneuronal Tumor; Rosette-forming Glioneurona Tumor; Central Neurocytoma; Extraventricular Neurocytoma; Cerebellar Iponeurocytoma",Dabrafenib (DRUG); trametinib (DRUG); Carboplatin (DRUG); Vincristine (DRUG),11707110,QOM,Gliomas and Neuronal Tumors,CNS/Brain,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5974,NCT03434262,SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors,COMPLETED,PHASE1,"Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Ganglioglioma; Anaplastic Meningioma; Anaplastic Oligodendroglioma; Pleomorphic Xanthoastrocytoma, Anaplastic; Atypical Teratoid/Rhabdoid Tumor; Brain Cancer; Brain Tumor; Central Nervous System Neoplasms; Choroid Plexus Carcinoma; CNS Embryonal Tumor With Rhabdoid Features; Ganglioneuroblastoma of Central Nervous System; CNS Tumor; Embryonal Tumor of CNS; Ependymoma; Glioblastoma; Glioma; Glioma, Malignant; Medulloblastoma; Medulloblastoma; Unspecified Site; Medulloepithelioma; Neuroepithelial Tumor; Neoplasms; Neoplasms, Neuroepithelial; Papillary Tumor of the Pineal Region (High-grade Only); Pediatric Brain Tumor; Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only); Pineoblastoma; Primitive Neuroectodermal Tumor; Recurrent Medulloblastoma; Refractory Brain Tumor; Neuroblastoma. CNS; Glioblastoma, IDH-mutant; Glioblastoma, IDH-wildtype; Medulloblastoma, Group 3; Medulloblastoma, Group 4; Glioma, High Grade; Neuroepithelial Tumor, High Grade; Medulloblastoma, SHH-activated and TP53 Mutant; Medulloblastoma, SHH-activated and TP53 Wildtype; Medulloblastoma, Chromosome 9q Loss; Medulloblastoma, Non-WNT Non-SHH, NOS; Medulloblastoma, Non-WNT/Non-SHH; Medulloblastoma, PTCH1 Mutation; Medulloblastoma, WNT-activated; Ependymoma, Recurrent; Glioma, Recurrent High Grade; Glioma, Recurrent Malignant; Embryonal Tumor, NOS; Glioma, Diffuse Midline, H3K27M-mutant; Embryonal Tumor With Multilayered Rosettes (ETMR); Ependymoma, NOS, WHO Grade III; Ependymoma, NOS, WHO Grade II; Medulloblastoma, G3/G4; Ependymoma, RELA Fusion Positive",Gemcitabine (DRUG); ribociclib (DRUG); sonidegib (DRUG); trametinib (DRUG); filgrastim (BIOLOGICAL),11707110,QOM,CNS Tumors and Neoplasms,CNS/Brain,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5975,NCT03434262,SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors,COMPLETED,PHASE1,"Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Ganglioglioma; Anaplastic Meningioma; Anaplastic Oligodendroglioma; Pleomorphic Xanthoastrocytoma, Anaplastic; Atypical Teratoid/Rhabdoid Tumor; Brain Cancer; Brain Tumor; Central Nervous System Neoplasms; Choroid Plexus Carcinoma; CNS Embryonal Tumor With Rhabdoid Features; Ganglioneuroblastoma of Central Nervous System; CNS Tumor; Embryonal Tumor of CNS; Ependymoma; Glioblastoma; Glioma; Glioma, Malignant; Medulloblastoma; Medulloblastoma; Unspecified Site; Medulloepithelioma; Neuroepithelial Tumor; Neoplasms; Neoplasms, Neuroepithelial; Papillary Tumor of the Pineal Region (High-grade Only); Pediatric Brain Tumor; Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only); Pineoblastoma; Primitive Neuroectodermal Tumor; Recurrent Medulloblastoma; Refractory Brain Tumor; Neuroblastoma. CNS; Glioblastoma, IDH-mutant; Glioblastoma, IDH-wildtype; Medulloblastoma, Group 3; Medulloblastoma, Group 4; Glioma, High Grade; Neuroepithelial Tumor, High Grade; Medulloblastoma, SHH-activated and TP53 Mutant; Medulloblastoma, SHH-activated and TP53 Wildtype; Medulloblastoma, Chromosome 9q Loss; Medulloblastoma, Non-WNT Non-SHH, NOS; Medulloblastoma, Non-WNT/Non-SHH; Medulloblastoma, PTCH1 Mutation; Medulloblastoma, WNT-activated; Ependymoma, Recurrent; Glioma, Recurrent High Grade; Glioma, Recurrent Malignant; Embryonal Tumor, NOS; Glioma, Diffuse Midline, H3K27M-mutant; Embryonal Tumor With Multilayered Rosettes (ETMR); Ependymoma, NOS, WHO Grade III; Ependymoma, NOS, WHO Grade II; Medulloblastoma, G3/G4; Ependymoma, RELA Fusion Positive",Gemcitabine (DRUG); ribociclib (DRUG); sonidegib (DRUG); trametinib (DRUG); filgrastim (BIOLOGICAL),11707110,QOM,CNS Tumors and Neoplasms,CNS/Brain,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5976,NCT03975829,Pediatric Long-Term Follow-up and Rollover Study,ACTIVE_NOT_RECRUITING,PHASE4,"Diffuse Astrocytoma; Anaplastic Astrocytoma; Astrocytoma; Oligodendroglioma, Childhood; Anaplastic Oligodendroglioma; Glioblastoma; Pilocytic Astrocytoma; Giant Cell Astrocytoma; Pleomorphic Xanthoastrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Angiocentric Glioma; Chordoid Glioma of Third Ventricle; Gangliocytoma; Ganglioglioma; Anaplastic Ganglioglioma; Dysplastic Gangliocytoma of Cerebrellum; Desmoplastic Infantile Astrocytoma and Ganglioglioma; Papillary Glioneuronal Tumor; Rosette-forming Glioneuronal Tumor; Central Neurocytoma; Extraventricular Neurocytoma; Cerebellar Liponeurocytoma; Neurofibromatosis Type 1",dabrafenib (DRUG); trametinib (DRUG),11707110,QOM,Gliomas and Neuroglial Tumors,CNS/Brain,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5977,NCT03975829,Pediatric Long-Term Follow-up and Rollover Study,ACTIVE_NOT_RECRUITING,PHASE4,"Diffuse Astrocytoma; Anaplastic Astrocytoma; Astrocytoma; Oligodendroglioma, Childhood; Anaplastic Oligodendroglioma; Glioblastoma; Pilocytic Astrocytoma; Giant Cell Astrocytoma; Pleomorphic Xanthoastrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Angiocentric Glioma; Chordoid Glioma of Third Ventricle; Gangliocytoma; Ganglioglioma; Anaplastic Ganglioglioma; Dysplastic Gangliocytoma of Cerebrellum; Desmoplastic Infantile Astrocytoma and Ganglioglioma; Papillary Glioneuronal Tumor; Rosette-forming Glioneuronal Tumor; Central Neurocytoma; Extraventricular Neurocytoma; Cerebellar Liponeurocytoma; Neurofibromatosis Type 1",dabrafenib (DRUG); trametinib (DRUG),11707110,QOM,Gliomas and Neuroglial Tumors,CNS/Brain,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5978,NCT05435846,Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation,TERMINATED,PHASE1,Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer,Capmatinib (DRUG); Trametinib (DRUG),11707110,QOM,Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer,Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5979,NCT05435846,Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation,TERMINATED,PHASE1,Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer,Capmatinib (DRUG); Trametinib (DRUG),11707110,QOM,Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer,Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5980,NCT05358249,Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation,ACTIVE_NOT_RECRUITING,PHASE1,"KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma; Nonsmall Cell Lung Cancer; Colorectal Cancer; Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumors; Neoplasms, Colorectal",JDQ443 (DRUG); trametinib (DRUG); Ribociclib (DRUG); cetuximab (BIOLOGICAL),11707110,QOM,"KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma; Nonsmall Cell Lung Cancer; Colorectal Cancer; Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumors; Neoplasms, Colorectal",Bowel,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5981,NCT05358249,Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation,ACTIVE_NOT_RECRUITING,PHASE1,"KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma; Nonsmall Cell Lung Cancer; Colorectal Cancer; Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumors; Neoplasms, Colorectal",JDQ443 (DRUG); trametinib (DRUG); Ribociclib (DRUG); cetuximab (BIOLOGICAL),11707110,QOM,"KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma; Nonsmall Cell Lung Cancer; Colorectal Cancer; Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumors; Neoplasms, Colorectal",Bowel,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5982,NCT04527549,Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma,TERMINATED,PHASE2,Clinical Stage IV Cutaneous Melanoma AJCC v8; Locally Advanced Melanoma; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Unresectable Melanoma,Dabrafenib mesylate (DRUG); Hydroxychloroquine (DRUG); Placebo Administration (DRUG); Trametinib dimethyl sulfoxide (DRUG),11707110,QOM,Clinical Stage IV Cutaneous Melanoma AJCC v8; Locally Advanced Melanoma; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Unresectable Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5983,NCT04527549,Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma,TERMINATED,PHASE2,Clinical Stage IV Cutaneous Melanoma AJCC v8; Locally Advanced Melanoma; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Unresectable Melanoma,Dabrafenib mesylate (DRUG); Hydroxychloroquine (DRUG); Placebo Administration (DRUG); Trametinib dimethyl sulfoxide (DRUG),11707110,QOM,Clinical Stage IV Cutaneous Melanoma AJCC v8; Locally Advanced Melanoma; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Unresectable Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5984,NCT05440942,"Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma",ACTIVE_NOT_RECRUITING,PHASE1,Pancreatic Ductal Adenocarcinoma,Trametinib (DRUG); Ruxolitinib (DRUG); Retifanlimab (DRUG),11707110,QOM,Pancreatic Ductal Adenocarcinoma,Pancreas,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5985,NCT05440942,"Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma",ACTIVE_NOT_RECRUITING,PHASE1,Pancreatic Ductal Adenocarcinoma,Trametinib (DRUG); Ruxolitinib (DRUG); Retifanlimab (DRUG),11707110,QOM,Pancreatic Ductal Adenocarcinoma,Pancreas,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5986,NCT02900664,"A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)",COMPLETED,PHASE1,"Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma",PDR001 (BIOLOGICAL); ACZ885 (BIOLOGICAL); CJM112 (BIOLOGICAL); TMT212 (DRUG); EGF816 (DRUG),11707110,QOM,"Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma",Bowel,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5987,NCT02900664,"A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)",COMPLETED,PHASE1,"Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma",PDR001 (BIOLOGICAL); ACZ885 (BIOLOGICAL); CJM112 (BIOLOGICAL); TMT212 (DRUG); EGF816 (DRUG),11707110,QOM,"Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma",Bowel,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5988,NCT04452877,A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,"Carcinoma, Non-Small-Cell Lung",Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5989,NCT04452877,A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,"Carcinoma, Non-Small-Cell Lung",Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5990,NCT02703571,Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors,TERMINATED,PHASE1,Solid Tumors for Phase Ib; Pancreatic Cancer for Phase II; Colorectal Cancer for Phase II,ribociclib (DRUG); Trametinib (DRUG),11707110,QOM,Solid Tumors for Phase Ib; Pancreatic Cancer for Phase II; Colorectal Cancer for Phase II,Bowel,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5991,NCT02703571,Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors,TERMINATED,PHASE1,Solid Tumors for Phase Ib; Pancreatic Cancer for Phase II; Colorectal Cancer for Phase II,ribociclib (DRUG); Trametinib (DRUG),11707110,QOM,Solid Tumors for Phase Ib; Pancreatic Cancer for Phase II; Colorectal Cancer for Phase II,Bowel,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5992,NCT05275374,XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation,NOT_YET_RECRUITING,PHASE1,Cancer; BRAF V600 Mutation; Melanoma; Colorectal Cancer; Thyroid Cancer; Nonsmall Cell Lung Cancer,XP-102 (DRUG); Trametinib (DRUG),11707110,QOM,Cancer; BRAF V600 Mutation; Melanoma; Colorectal Cancer; Thyroid Cancer; Nonsmall Cell Lung Cancer,Bowel,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5993,NCT05275374,XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation,NOT_YET_RECRUITING,PHASE1,Cancer; BRAF V600 Mutation; Melanoma; Colorectal Cancer; Thyroid Cancer; Nonsmall Cell Lung Cancer,XP-102 (DRUG); Trametinib (DRUG),11707110,QOM,Cancer; BRAF V600 Mutation; Melanoma; Colorectal Cancer; Thyroid Cancer; Nonsmall Cell Lung Cancer,Bowel,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5994,NCT02915666,A Clinical Trial of Patients With Melanoma,WITHDRAWN,PHASE1,Melanoma,Digoxin Combination (DRUG); Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5995,NCT02915666,A Clinical Trial of Patients With Melanoma,WITHDRAWN,PHASE1,Melanoma,Digoxin Combination (DRUG); Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5996,NCT03428126,Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer,COMPLETED,PHASE2,Malignant Neoplasms of Digestive Organs; Colorectal Cancer; Colon Cancer,Durvalumab (DRUG); Trametinib (DRUG),11707110,QOM,Malignant Neoplasms of Digestive Organs; Colorectal Cancer; Colon Cancer,Bowel,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5997,NCT03428126,Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer,COMPLETED,PHASE2,Malignant Neoplasms of Digestive Organs; Colorectal Cancer; Colon Cancer,Durvalumab (DRUG); Trametinib (DRUG),11707110,QOM,Malignant Neoplasms of Digestive Organs; Colorectal Cancer; Colon Cancer,Bowel,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +5998,NCT02130466,A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022),COMPLETED,PHASE1,Melanoma; Solid Tumors,Pembrolizumab (BIOLOGICAL); Dabrafenib (DRUG); Trametinib (DRUG); Placebo (DRUG),11707110,QOM,Melanoma and Solid Tumors,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +5999,NCT02130466,A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022),COMPLETED,PHASE1,Melanoma; Solid Tumors,Pembrolizumab (BIOLOGICAL); Dabrafenib (DRUG); Trametinib (DRUG); Placebo (DRUG),11707110,QOM,Melanoma and Solid Tumors,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6000,NCT01619774,An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor,COMPLETED,PHASE2,Melanoma,GSK2118436 (DRUG); GSK1120212 (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6001,NCT01619774,An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor,COMPLETED,PHASE2,Melanoma,GSK2118436 (DRUG); GSK1120212 (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6002,NCT01902173,"Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer",COMPLETED,PHASE1,Hematopoietic and Lymphoid Cell Neoplasm; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Melanoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Malignant Solid Neoplasm; Unresectable Melanoma,Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Dabrafenib Mesylate (DRUG); Magnetic Resonance Imaging (PROCEDURE); Trametinib Dimethyl Sulfoxide (DRUG); Uprosertib (DRUG),11707110,QOM,Hematopoietic and Lymphoid Cell Neoplasm; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Melanoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Malignant Solid Neoplasm; Unresectable Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6003,NCT01902173,"Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer",COMPLETED,PHASE1,Hematopoietic and Lymphoid Cell Neoplasm; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Melanoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Malignant Solid Neoplasm; Unresectable Melanoma,Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Dabrafenib Mesylate (DRUG); Magnetic Resonance Imaging (PROCEDURE); Trametinib Dimethyl Sulfoxide (DRUG); Uprosertib (DRUG),11707110,QOM,Hematopoietic and Lymphoid Cell Neoplasm; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Melanoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Malignant Solid Neoplasm; Unresectable Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6004,NCT03754179,Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma,UNKNOWN,PHASE1,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Hydroxychloroquine (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6005,NCT03754179,Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma,UNKNOWN,PHASE1,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Hydroxychloroquine (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6006,NCT01721603,Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets,TERMINATED,PHASE2,BRAFV600E Melanoma Patients,Dabrafenib (DRUG); Gamma Knife Radiosurgery (PROCEDURE); Trametinib (DRUG),11707110,QOM,BRAFV600E Melanoma Patients,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6007,NCT01721603,Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets,TERMINATED,PHASE2,BRAFV600E Melanoma Patients,Dabrafenib (DRUG); Gamma Knife Radiosurgery (PROCEDURE); Trametinib (DRUG),11707110,QOM,BRAFV600E Melanoma Patients,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6008,NCT03391050,A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma,TERMINATED,PHASE1,Melanoma,APR-246 (DRUG); Dabrafenib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6009,NCT03391050,A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma,TERMINATED,PHASE1,Melanoma,APR-246 (DRUG); Dabrafenib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6010,NCT02314143,Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib,TERMINATED,PHASE2,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6011,NCT02314143,Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib,TERMINATED,PHASE2,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6012,NCT02042443,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,COMPLETED,PHASE2,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Capecitabine (DRUG); Fluorouracil (DRUG); Laboratory Biomarker Analysis (OTHER); Leucovorin Calcium (DRUG); Trametinib (DRUG),11707110,QOM,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Liver,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6013,NCT02042443,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,COMPLETED,PHASE2,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Capecitabine (DRUG); Fluorouracil (DRUG); Laboratory Biomarker Analysis (OTHER); Leucovorin Calcium (DRUG); Trametinib (DRUG),11707110,QOM,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Liver,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6014,NCT04454476,Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor,ACTIVE_NOT_RECRUITING,PHASE1,Gastric Cancer; Metaplasia; Stage I Gastric Cancer; Initial-onset Gastric Cancer,Trametinib treatment (DRUG); Endoscopy (PROCEDURE),11707110,QOM,Gastric Cancer; Metaplasia; Stage I Gastric Cancer; Initial-onset Gastric Cancer,Esophagus/Stomach,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6015,NCT04454476,Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor,ACTIVE_NOT_RECRUITING,PHASE1,Gastric Cancer; Metaplasia; Stage I Gastric Cancer; Initial-onset Gastric Cancer,Trametinib treatment (DRUG); Endoscopy (PROCEDURE),11707110,QOM,Gastric Cancer; Metaplasia; Stage I Gastric Cancer; Initial-onset Gastric Cancer,Esophagus/Stomach,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6016,NCT03088176,Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma,UNKNOWN,PHASE1,Melanoma; BRAF Gene Mutation,"Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil (DRUG); Talimogene Laherparep 100 Mil Pfu/Ml 1Ml (DRUG); Dabrafenib (DRUG); Trametinib (DRUG)",11707110,QOM,Melanoma; BRAF Gene Mutation,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6017,NCT03088176,Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma,UNKNOWN,PHASE1,Melanoma; BRAF Gene Mutation,"Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil (DRUG); Talimogene Laherparep 100 Mil Pfu/Ml 1Ml (DRUG); Dabrafenib (DRUG); Trametinib (DRUG)",11707110,QOM,Melanoma; BRAF Gene Mutation,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6018,NCT05677373,"Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma",WITHDRAWN,PHASE1,Advanced Uveal Melanoma; Metastatic Uveal Melanoma; Unresectable Uveal Melanoma,BRD4 Inhibitor PLX2853 (DRUG); Trametinib (DRUG); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Biospecimen collection (PROCEDURE); Biospecimen collection (PROCEDURE),11707110,QOM,Advanced Uveal Melanoma; Metastatic Uveal Melanoma; Unresectable Uveal Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6019,NCT05677373,"Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma",WITHDRAWN,PHASE1,Advanced Uveal Melanoma; Metastatic Uveal Melanoma; Unresectable Uveal Melanoma,BRD4 Inhibitor PLX2853 (DRUG); Trametinib (DRUG); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Biospecimen collection (PROCEDURE); Biospecimen collection (PROCEDURE),11707110,QOM,Advanced Uveal Melanoma; Metastatic Uveal Melanoma; Unresectable Uveal Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6020,NCT01941927,Trametinib With GSK2141795 in BRAF Wild-type Melanoma,COMPLETED,PHASE2,Melanoma,Trametinib (GSK1120212) (DRUG); GSK2141795 (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6021,NCT01941927,Trametinib With GSK2141795 in BRAF Wild-type Melanoma,COMPLETED,PHASE2,Melanoma,Trametinib (GSK1120212) (DRUG); GSK2141795 (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6022,NCT02538627,"Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib",TERMINATED,PHASE1,Colorectal Cancer; Non-small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck,MM-151 (DRUG); MM-121 (DRUG); MM-141 (DRUG); trametinib (DRUG),11707110,QOM,Colorectal Cancer; Non-small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck,Bowel,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6023,NCT02538627,"Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib",TERMINATED,PHASE1,Colorectal Cancer; Non-small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck,MM-151 (DRUG); MM-121 (DRUG); MM-141 (DRUG); trametinib (DRUG),11707110,QOM,Colorectal Cancer; Non-small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck,Bowel,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6024,NCT03580382,"Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma",TERMINATED,PHASE1,Melanoma,Trametinib daily Until PD (DRUG); CDX-3379 (ERBB3 antibody) (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6025,NCT03580382,"Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma",TERMINATED,PHASE1,Melanoma,Trametinib daily Until PD (DRUG); CDX-3379 (ERBB3 antibody) (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6026,NCT03668431,Dabrafenib + Trametinib + PDR001 In Colorectal Cancer,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,Dabrafenib (DRUG); Trametinib (DRUG); PDR001 (DRUG),11707110,QOM,Metastatic Colorectal Cancer,Bowel,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6027,NCT03668431,Dabrafenib + Trametinib + PDR001 In Colorectal Cancer,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,Dabrafenib (DRUG); Trametinib (DRUG); PDR001 (DRUG),11707110,QOM,Metastatic Colorectal Cancer,Bowel,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6028,NCT02292173,Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer,COMPLETED,PHASE1,Hepatocellular Cancer; Liver Cancer,Trametinib (DRUG); Sorafenib (DRUG),11707110,QOM,Hepatocellular Cancer; Liver Cancer,Liver,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6029,NCT02292173,Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer,COMPLETED,PHASE1,Hepatocellular Cancer; Liver Cancer,Trametinib (DRUG); Sorafenib (DRUG),11707110,QOM,Hepatocellular Cancer; Liver Cancer,Liver,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6030,NCT05783076,SBRT Plus vNKT for Pancreatic Cancer,RECRUITING,PHASE2,Pancreatic Cancer,Stereotactic body radiation therapy (DRUG); adoptive cell therapy with vNKT cells (DRUG),11707110,QOM,Pancreatic Cancer,Pancreas,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6031,NCT05783076,SBRT Plus vNKT for Pancreatic Cancer,RECRUITING,PHASE2,Pancreatic Cancer,Stereotactic body radiation therapy (DRUG); adoptive cell therapy with vNKT cells (DRUG),11707110,QOM,Pancreatic Cancer,Pancreas,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6032,NCT03232892,Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer,TERMINATED,PHASE2,Non-small Cell Lung Cancer,Trametinib (DRUG),11707110,QOM,Non-small Cell Lung Cancer,Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6033,NCT03232892,Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer,TERMINATED,PHASE2,Non-small Cell Lung Cancer,Trametinib (DRUG),11707110,QOM,Non-small Cell Lung Cancer,Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6034,NCT06346067,A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2),RECRUITING,PHASE3,Advanced or Metastatic NRAS-mutant Melanoma,Naporafenib (DRUG); Dacarbazine (DRUG); Temozolomide (DRUG); Trametinib (DRUG),11707110,QOM,Advanced or Metastatic NRAS-mutant Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6035,NCT06346067,A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2),RECRUITING,PHASE3,Advanced or Metastatic NRAS-mutant Melanoma,Naporafenib (DRUG); Dacarbazine (DRUG); Temozolomide (DRUG); Trametinib (DRUG),11707110,QOM,Advanced or Metastatic NRAS-mutant Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6036,NCT01740648,"Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer",COMPLETED,PHASE1,Recurrent Rectal Cancer; Stage IIA Rectal Cancer; Stage IIB Rectal Cancer; Stage IIC Rectal Cancer; Stage IIIA Rectal Cancer; Stage IIIB Rectal Cancer; Stage IIIC Rectal Cancer,trametinib (DRUG); fluorouracil (DRUG); radiation therapy (RADIATION),11707110,QOM,Recurrent Rectal Cancer; Stage IIA Rectal Cancer; Stage IIB Rectal Cancer; Stage IIC Rectal Cancer; Stage IIIA Rectal Cancer; Stage IIIB Rectal Cancer; Stage IIIC Rectal Cancer,Bowel,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6037,NCT01740648,"Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer",COMPLETED,PHASE1,Recurrent Rectal Cancer; Stage IIA Rectal Cancer; Stage IIB Rectal Cancer; Stage IIC Rectal Cancer; Stage IIIA Rectal Cancer; Stage IIIB Rectal Cancer; Stage IIIC Rectal Cancer,trametinib (DRUG); fluorouracil (DRUG); radiation therapy (RADIATION),11707110,QOM,Recurrent Rectal Cancer; Stage IIA Rectal Cancer; Stage IIB Rectal Cancer; Stage IIC Rectal Cancer; Stage IIIA Rectal Cancer; Stage IIIB Rectal Cancer; Stage IIIC Rectal Cancer,Bowel,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6038,NCT05180825,Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy,RECRUITING,PHASE2,Grade 1 Glioma; Mixed Glio-neuronal Tumors; Pleomorphic Xanthoastrocytoma,Trametinib (DRUG); Vinblastine (DRUG),11707110,QOM,Low-Grade Glioma,CNS/Brain,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6039,NCT05180825,Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy,RECRUITING,PHASE2,Grade 1 Glioma; Mixed Glio-neuronal Tumors; Pleomorphic Xanthoastrocytoma,Trametinib (DRUG); Vinblastine (DRUG),11707110,QOM,Low-Grade Glioma,CNS/Brain,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6040,NCT02097225,"Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",TERMINATED,PHASE1,BRAF V600E Mutation Present; BRAF V600K Mutation Present; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Solid Neoplasm,Dabrafenib (DRUG); Laboratory Biomarker Analysis (OTHER); Onalespib (DRUG); Pharmacological Study (OTHER); Trametinib (DRUG),11707110,QOM,BRAF V600E Mutation Present; BRAF V600K Mutation Present; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Solid Neoplasm,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6041,NCT02097225,"Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",TERMINATED,PHASE1,BRAF V600E Mutation Present; BRAF V600K Mutation Present; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Solid Neoplasm,Dabrafenib (DRUG); Laboratory Biomarker Analysis (OTHER); Onalespib (DRUG); Pharmacological Study (OTHER); Trametinib (DRUG),11707110,QOM,BRAF V600E Mutation Present; BRAF V600K Mutation Present; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Solid Neoplasm,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6042,NCT04201457,"A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration",ACTIVE_NOT_RECRUITING,PHASE1,Low Grade Glioma (LGG) of Brain With BRAF Aberration; High Grade Glioma (HGG) of the Brain With BRAF Aberration; Low Grade Glioma of Brain With Neurofibromatosis Type 1,Dabrafenib (DRUG); Trametinib (DRUG); Hydroxychloroquine (DRUG),11707110,QOM,Low Grade Glioma (LGG) of Brain With BRAF Aberration; High Grade Glioma (HGG) of the Brain With BRAF Aberration; Low Grade Glioma of Brain With Neurofibromatosis Type 1,CNS/Brain,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6043,NCT04201457,"A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration",ACTIVE_NOT_RECRUITING,PHASE1,Low Grade Glioma (LGG) of Brain With BRAF Aberration; High Grade Glioma (HGG) of the Brain With BRAF Aberration; Low Grade Glioma of Brain With Neurofibromatosis Type 1,Dabrafenib (DRUG); Trametinib (DRUG); Hydroxychloroquine (DRUG),11707110,QOM,Low Grade Glioma (LGG) of Brain With BRAF Aberration; High Grade Glioma (HGG) of the Brain With BRAF Aberration; Low Grade Glioma of Brain With Neurofibromatosis Type 1,CNS/Brain,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6044,NCT02300935,Study of Trametinib and Nab-paclitaxel in Patients With Melanoma,WITHDRAWN,PHASE1,Melanoma,trametinib (DRUG); nab-paclitaxel (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6045,NCT02300935,Study of Trametinib and Nab-paclitaxel in Patients With Melanoma,WITHDRAWN,PHASE1,Melanoma,trametinib (DRUG); nab-paclitaxel (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6046,NCT02672358,Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC,WITHDRAWN,PHASE2,Non-Small-Cell Lung Cancer,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Non-Small-Cell Lung Cancer,Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6047,NCT02672358,Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC,WITHDRAWN,PHASE2,Non-Small-Cell Lung Cancer,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Non-Small-Cell Lung Cancer,Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6048,NCT02138292,A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma,COMPLETED,PHASE1,Melanoma,Trametinib (2mg)/Digoxin (.25mg) (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6049,NCT02138292,A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma,COMPLETED,PHASE1,Melanoma,Trametinib (2mg)/Digoxin (.25mg) (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6050,NCT03563729,Melanoma Metastasized to the Brain and Steroids,RECRUITING,PHASE2,Malignant Melanoma,Pembrolizumab Injection [Keytruda] (DRUG); Ipilimumab Injection [Yervoy] (DRUG); Nivolumab Injection [Opdivo] (DRUG); Encorafenib (DRUG); Binimetinib (DRUG); Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Malignant Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6051,NCT03563729,Melanoma Metastasized to the Brain and Steroids,RECRUITING,PHASE2,Malignant Melanoma,Pembrolizumab Injection [Keytruda] (DRUG); Ipilimumab Injection [Yervoy] (DRUG); Nivolumab Injection [Opdivo] (DRUG); Encorafenib (DRUG); Binimetinib (DRUG); Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Malignant Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6052,NCT03149029,Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Melanoma,Pembrolizumab (DRUG); Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Metastatic Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6053,NCT03149029,Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Melanoma,Pembrolizumab (DRUG); Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Metastatic Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6054,NCT06933394,Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma,RECRUITING,PHASE2,Neuroblastoma,Arsenic trioxide (DRUG); MAPK inhibitors (DRUG); Chemotherapy (DRUG),11707110,QOM,Neuroblastoma,CNS/Brain,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6055,NCT06933394,Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma,RECRUITING,PHASE2,Neuroblastoma,Arsenic trioxide (DRUG); MAPK inhibitors (DRUG); Chemotherapy (DRUG),11707110,QOM,Neuroblastoma,CNS/Brain,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6056,NCT06054191,Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations,NOT_YET_RECRUITING,PHASE2,NSCLC; BRAF V600 Mutation; MET Exon 14 Mutation,Dabrafenib + Trametinib (DRUG); Capmatinib (DRUG),11707110,QOM,Non-Small Cell Lung Cancer with Genetic Mutations,Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6057,NCT06054191,Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations,NOT_YET_RECRUITING,PHASE2,NSCLC; BRAF V600 Mutation; MET Exon 14 Mutation,Dabrafenib + Trametinib (DRUG); Capmatinib (DRUG),11707110,QOM,Non-Small Cell Lung Cancer with Genetic Mutations,Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6058,NCT05299580,"""Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)""",WITHDRAWN,PHASE2,Melanoma,dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6059,NCT05299580,"""Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)""",WITHDRAWN,PHASE2,Melanoma,dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6060,NCT01245062,GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma,COMPLETED,PHASE3,Melanoma,GSK1120212 (DRUG); Chemotherapy (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6061,NCT01245062,GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma,COMPLETED,PHASE3,Melanoma,GSK1120212 (DRUG); Chemotherapy (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6062,NCT02410863,Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma,TERMINATED,PHASE2,Malignant Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Malignant Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6063,NCT02410863,Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma,TERMINATED,PHASE2,Malignant Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Malignant Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6064,NCT02296996,Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients,COMPLETED,PHASE2,Malignant Melanoma,Dabrafenib + Trametinib (DRUG),11707110,QOM,Malignant Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6065,NCT02296996,Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients,COMPLETED,PHASE2,Malignant Melanoma,Dabrafenib + Trametinib (DRUG),11707110,QOM,Malignant Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6066,NCT01362296,An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer,COMPLETED,PHASE2,"Lung Cancer, Non-Small Cell",GSK1120212 (DRUG); docetaxel (DRUG),11707110,QOM,"Lung Cancer, Non-Small Cell",Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6067,NCT01362296,An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer,COMPLETED,PHASE2,"Lung Cancer, Non-Small Cell",GSK1120212 (DRUG); docetaxel (DRUG),11707110,QOM,"Lung Cancer, Non-Small Cell",Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6068,NCT02447939,Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma,WITHDRAWN,PHASE1,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6069,NCT02447939,Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma,WITHDRAWN,PHASE1,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6070,NCT04059224,TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma,COMPLETED,PHASE2,Stage IV Melanoma; Stage III Melanoma,Trametinib (DRUG); Dabrafenib (DRUG),11707110,QOM,Stage IV Melanoma; Stage III Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6071,NCT04059224,TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma,COMPLETED,PHASE2,Stage IV Melanoma; Stage III Melanoma,Trametinib (DRUG); Dabrafenib (DRUG),11707110,QOM,Stage IV Melanoma; Stage III Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6072,NCT01964924,Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer,COMPLETED,PHASE2,Estrogen Receptor Negative; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma,Akt Inhibitor GSK2141795 (DRUG); Laboratory Biomarker Analysis (OTHER); Trametinib (DRUG),11707110,QOM,Estrogen Receptor Negative; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma,Breast,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6073,NCT01964924,Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer,COMPLETED,PHASE2,Estrogen Receptor Negative; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma,Akt Inhibitor GSK2141795 (DRUG); Laboratory Biomarker Analysis (OTHER); Trametinib (DRUG),11707110,QOM,Estrogen Receptor Negative; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma,Breast,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6074,NCT05518110,PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer,RECRUITING,PHASE2,Pancreatic Cancer,Trametinib (DRUG); Hydroxychloroquine (DRUG),11707110,QOM,Pancreatic Cancer,Pancreas,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6075,NCT05518110,PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer,RECRUITING,PHASE2,Pancreatic Cancer,Trametinib (DRUG); Hydroxychloroquine (DRUG),11707110,QOM,Pancreatic Cancer,Pancreas,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6076,NCT02196181,Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread,ACTIVE_NOT_RECRUITING,PHASE2,Stage III Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma,Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Dabrafenib Mesylate (DRUG); Echocardiography Test (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Positron Emission Tomography (PROCEDURE); Trametinib Dimethyl Sulfoxide (DRUG),11707110,QOM,Stage III Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6077,NCT02196181,Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread,ACTIVE_NOT_RECRUITING,PHASE2,Stage III Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma,Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Dabrafenib Mesylate (DRUG); Echocardiography Test (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Positron Emission Tomography (PROCEDURE); Trametinib Dimethyl Sulfoxide (DRUG),11707110,QOM,Stage III Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6078,NCT04675710,"Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Thyroid Gland Anaplastic Carcinoma; Thyroid Gland Squamous Cell Carcinoma,Conventional Surgery (PROCEDURE); Dabrafenib (DRUG); Intensity-Modulated Radiation Therapy (RADIATION); Pembrolizumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Trametinib (DRUG),11707110,QOM,Thyroid Gland Anaplastic Carcinoma; Thyroid Gland Squamous Cell Carcinoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6079,NCT04675710,"Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Thyroid Gland Anaplastic Carcinoma; Thyroid Gland Squamous Cell Carcinoma,Conventional Surgery (PROCEDURE); Dabrafenib (DRUG); Intensity-Modulated Radiation Therapy (RADIATION); Pembrolizumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Trametinib (DRUG),11707110,QOM,Thyroid Gland Anaplastic Carcinoma; Thyroid Gland Squamous Cell Carcinoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6080,NCT02967692,"A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",TERMINATED,PHASE3,Melanoma,Spartalizumab (BIOLOGICAL); Placebo (OTHER); Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6081,NCT02967692,"A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",TERMINATED,PHASE3,Melanoma,Spartalizumab (BIOLOGICAL); Placebo (OTHER); Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6082,NCT03825289,Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Pancreatic Carcinoma; Stage II Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unresectable Pancreatic Carcinoma,Hydroxychloroquine (DRUG); Trametinib (DRUG),11707110,QOM,Metastatic Pancreatic Carcinoma; Stage II Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unresectable Pancreatic Carcinoma,Pancreas,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6083,NCT03825289,Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Pancreatic Carcinoma; Stage II Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unresectable Pancreatic Carcinoma,Hydroxychloroquine (DRUG); Trametinib (DRUG),11707110,QOM,Metastatic Pancreatic Carcinoma; Stage II Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unresectable Pancreatic Carcinoma,Pancreas,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6084,NCT02257424,"Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",COMPLETED,PHASE1,Advanced BRAF Mutant Melanoma,Trametinib 2 mg daily (DRUG); hydroxychloroquine (HCQ) (DRUG); dabrafenib 150 mg orally twice a day (DRUG),11707110,QOM,Advanced BRAF Mutant Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6085,NCT02257424,"Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",COMPLETED,PHASE1,Advanced BRAF Mutant Melanoma,Trametinib 2 mg daily (DRUG); hydroxychloroquine (HCQ) (DRUG); dabrafenib 150 mg orally twice a day (DRUG),11707110,QOM,Advanced BRAF Mutant Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6086,NCT03714958,Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type,COMPLETED,PHASE1,Colorectal Cancer; Advanced Cancer; Metastatic Cancer,HDM201 (DRUG); Trametinib (DRUG),11707110,QOM,Colorectal Cancer; Advanced Cancer; Metastatic Cancer,Bowel,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6087,NCT03714958,Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type,COMPLETED,PHASE1,Colorectal Cancer; Advanced Cancer; Metastatic Cancer,HDM201 (DRUG); Trametinib (DRUG),11707110,QOM,Colorectal Cancer; Advanced Cancer; Metastatic Cancer,Bowel,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6088,NCT03972046,Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma,WITHDRAWN,PHASE2,Melanoma (Skin); Melanoma Stage IIIb-IVM1a; Metastasis Skin; Tumor Skin; BRAF Gene Mutation,Talimogene laherparepvec (T-Vec) (DRUG); Dabrafenib (BRAF Inhibitor) (DRUG); Trametinib (MEK Inhibitor) (DRUG),11707110,QOM,Melanoma (Skin); Melanoma Stage IIIb-IVM1a; Metastasis Skin; Tumor Skin; BRAF Gene Mutation,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6089,NCT03972046,Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma,WITHDRAWN,PHASE2,Melanoma (Skin); Melanoma Stage IIIb-IVM1a; Metastasis Skin; Tumor Skin; BRAF Gene Mutation,Talimogene laherparepvec (T-Vec) (DRUG); Dabrafenib (BRAF Inhibitor) (DRUG); Trametinib (MEK Inhibitor) (DRUG),11707110,QOM,Melanoma (Skin); Melanoma Stage IIIb-IVM1a; Metastasis Skin; Tumor Skin; BRAF Gene Mutation,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6090,NCT03501368,Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma,ACTIVE_NOT_RECRUITING,PHASE1,Melanoma; Unresectable Melanoma; Advanced Melanoma,Ceritinib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma; Unresectable Melanoma; Advanced Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6091,NCT03501368,Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma,ACTIVE_NOT_RECRUITING,PHASE1,Melanoma; Unresectable Melanoma; Advanced Melanoma,Ceritinib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma; Unresectable Melanoma; Advanced Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6092,NCT04892017,A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors,RECRUITING,PHASE1,Non-Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Solid Tumor,Inlexisertib (DRUG); Trametinib (DRUG); Binimetinib (DRUG); Sotorasib (DRUG),11707110,QOM,Non-Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Solid Tumor,Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6093,NCT04892017,A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors,RECRUITING,PHASE1,Non-Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Solid Tumor,Inlexisertib (DRUG); Trametinib (DRUG); Binimetinib (DRUG); Sotorasib (DRUG),11707110,QOM,Non-Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Solid Tumor,Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6094,NCT03026517,Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma,COMPLETED,PHASE1,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Phenformin (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6095,NCT03026517,Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma,COMPLETED,PHASE1,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Phenformin (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6096,NCT03363217,Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.,ACTIVE_NOT_RECRUITING,PHASE2,Low-grade Glioma; Plexiform Neurofibroma; Central Nervous System Glioma,Trametinib (DRUG),11707110,QOM,Low-grade Glioma; Plexiform Neurofibroma; Central Nervous System Glioma,CNS/Brain,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6097,NCT03363217,Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.,ACTIVE_NOT_RECRUITING,PHASE2,Low-grade Glioma; Plexiform Neurofibroma; Central Nervous System Glioma,Trametinib (DRUG),11707110,QOM,Low-grade Glioma; Plexiform Neurofibroma; Central Nervous System Glioma,CNS/Brain,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6098,NCT04803318,Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors,RECRUITING,PHASE2,"Solid Tumor, Adult; Hepatocellular Carcinoma","Combination of three inhibitors Trametinib, Everolimus and Lenvatinib (DRUG)",11707110,QOM,"Solid Tumor, Adult; Hepatocellular Carcinoma",Liver,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6099,NCT04803318,Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors,RECRUITING,PHASE2,"Solid Tumor, Adult; Hepatocellular Carcinoma","Combination of three inhibitors Trametinib, Everolimus and Lenvatinib (DRUG)",11707110,QOM,"Solid Tumor, Adult; Hepatocellular Carcinoma",Liver,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6100,NCT03808441,CAcTUS - Circulating Tumour DNA Guided Switch,ACTIVE_NOT_RECRUITING,PHASE2,Melanoma,ctDNA analysis (OTHER),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6101,NCT03808441,CAcTUS - Circulating Tumour DNA Guided Switch,ACTIVE_NOT_RECRUITING,PHASE2,Melanoma,ctDNA analysis (OTHER),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6102,NCT04903119,Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma,RECRUITING,PHASE1,Metastatic Melanoma; BRAF Gene Mutation,Nilotinib 100mg (DRUG); Nilotinib 200mg (DRUG); Nilotinib 300mg (DRUG); Nilotinib 400mg (DRUG); Dabrafenib (DRUG); Trametinib (DRUG); Encorafenib (DRUG); Binimetinib (DRUG),11707110,QOM,Advanced Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6103,NCT04903119,Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma,RECRUITING,PHASE1,Metastatic Melanoma; BRAF Gene Mutation,Nilotinib 100mg (DRUG); Nilotinib 200mg (DRUG); Nilotinib 300mg (DRUG); Nilotinib 400mg (DRUG); Dabrafenib (DRUG); Trametinib (DRUG); Encorafenib (DRUG); Binimetinib (DRUG),11707110,QOM,Advanced Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6104,NCT03317119,"Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery",COMPLETED,PHASE1,Metastatic Colon Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Carcinoma; RAS Family Gene Mutation; Stage III Colon Cancer AJCC v7; Stage III Colorectal Cancer AJCC v7; Stage III Rectal Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIA Colorectal Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIB Colorectal Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7; Stage IIIC Colorectal Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Colon Cancer AJCC v7; Stage IV Colorectal Cancer AJCC v7; Stage IV Rectal Cancer AJCC v7; Stage IVA Colon Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Colon Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7,Laboratory Biomarker Analysis (OTHER); Trametinib (DRUG); Trifluridine and Tipiracil Hydrochloride (DRUG),11707110,QOM,Metastatic Colon Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Carcinoma; RAS Family Gene Mutation; Stage III Colon Cancer AJCC v7; Stage III Colorectal Cancer AJCC v7; Stage III Rectal Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIA Colorectal Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIB Colorectal Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7; Stage IIIC Colorectal Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Colon Cancer AJCC v7; Stage IV Colorectal Cancer AJCC v7; Stage IV Rectal Cancer AJCC v7; Stage IVA Colon Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Colon Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7,Bowel,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6105,NCT03317119,"Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery",COMPLETED,PHASE1,Metastatic Colon Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Carcinoma; RAS Family Gene Mutation; Stage III Colon Cancer AJCC v7; Stage III Colorectal Cancer AJCC v7; Stage III Rectal Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIA Colorectal Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIB Colorectal Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7; Stage IIIC Colorectal Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Colon Cancer AJCC v7; Stage IV Colorectal Cancer AJCC v7; Stage IV Rectal Cancer AJCC v7; Stage IVA Colon Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Colon Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7,Laboratory Biomarker Analysis (OTHER); Trametinib (DRUG); Trifluridine and Tipiracil Hydrochloride (DRUG),11707110,QOM,Metastatic Colon Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Carcinoma; RAS Family Gene Mutation; Stage III Colon Cancer AJCC v7; Stage III Colorectal Cancer AJCC v7; Stage III Rectal Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIA Colorectal Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIB Colorectal Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7; Stage IIIC Colorectal Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Colon Cancer AJCC v7; Stage IV Colorectal Cancer AJCC v7; Stage IV Rectal Cancer AJCC v7; Stage IVA Colon Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Colon Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7,Bowel,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6106,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,COMPLETED,EARLY_PHASE1,Breast Cancer,GSK1120212 (DRUG),11707110,QOM,Breast Cancer,Breast,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6107,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,COMPLETED,EARLY_PHASE1,Breast Cancer,GSK1120212 (DRUG),11707110,QOM,Breast Cancer,Breast,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6108,NCT01958112,GSK1120212+GSK2141795 for Cervical Cancer,TERMINATED,PHASE2,Cervical Cancer,GSK1120212 (trametinib) (DRUG); GSK2141795 (DRUG),11707110,QOM,Cervical Cancer,Cervix,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6109,NCT01958112,GSK1120212+GSK2141795 for Cervical Cancer,TERMINATED,PHASE2,Cervical Cancer,GSK1120212 (trametinib) (DRUG); GSK2141795 (DRUG),11707110,QOM,Cervical Cancer,Cervix,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6110,NCT02296112,Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations,COMPLETED,PHASE2,Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma,trametinib (DRUG); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),11707110,QOM,Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6111,NCT02296112,Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations,COMPLETED,PHASE2,Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma,trametinib (DRUG); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),11707110,QOM,Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6112,NCT01979523,Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma,COMPLETED,PHASE2,Recurrent Uveal Melanoma; Stage IV Uveal Melanoma AJCC v7,Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Trametinib (DRUG); Uprosertib (DRUG),11707110,QOM,Recurrent Uveal Melanoma; Stage IV Uveal Melanoma AJCC v7,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6113,NCT01979523,Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma,COMPLETED,PHASE2,Recurrent Uveal Melanoma; Stage IV Uveal Melanoma AJCC v7,Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Trametinib (DRUG); Uprosertib (DRUG),11707110,QOM,Recurrent Uveal Melanoma; Stage IV Uveal Melanoma AJCC v7,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6114,NCT01726738,LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations,COMPLETED,PHASE2,Stage III Melanoma; Stage IV Melanoma; Unresectable Melanoma; BRAF Mutant Melanoma,BRAF inhibitor dabrafenib and MEK inhibitor trametinib (DRUG),11707110,QOM,Stage III Melanoma; Stage IV Melanoma; Unresectable Melanoma; BRAF Mutant Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6115,NCT01726738,LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations,COMPLETED,PHASE2,Stage III Melanoma; Stage IV Melanoma; Unresectable Melanoma; BRAF Mutant Melanoma,BRAF inhibitor dabrafenib and MEK inhibitor trametinib (DRUG),11707110,QOM,Stage III Melanoma; Stage IV Melanoma; Unresectable Melanoma; BRAF Mutant Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6116,NCT02110355,A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma,COMPLETED,PHASE1,Advanced Malignancy; Advanced Solid Tumors; Cancer; Oncology; Oncology Patients; Tumors; Melanoma,AMG 232 (DRUG); Trametinib (DRUG); Dabrafenib (DRUG),11707110,QOM,Advanced Malignancy; Advanced Solid Tumors; Cancer; Oncology; Oncology Patients; Tumors; Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6117,NCT02110355,A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma,COMPLETED,PHASE1,Advanced Malignancy; Advanced Solid Tumors; Cancer; Oncology; Oncology Patients; Tumors; Melanoma,AMG 232 (DRUG); Trametinib (DRUG); Dabrafenib (DRUG),11707110,QOM,Advanced Malignancy; Advanced Solid Tumors; Cancer; Oncology; Oncology Patients; Tumors; Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6118,NCT01597908,Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma,COMPLETED,PHASE3,Melanoma,Dabrafenib (DRUG); Vemurafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6119,NCT01597908,Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma,COMPLETED,PHASE3,Melanoma,Dabrafenib (DRUG); Vemurafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6120,NCT02580708,Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer,TERMINATED,PHASE1,Non-small Cell Lung Cancer,Rociletinib (DRUG); Trametinib (DRUG),11707110,QOM,Non-small Cell Lung Cancer,Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6121,NCT02580708,Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer,TERMINATED,PHASE1,Non-small Cell Lung Cancer,Rociletinib (DRUG); Trametinib (DRUG),11707110,QOM,Non-small Cell Lung Cancer,Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6122,NCT02143050,"Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",WITHDRAWN,PHASE1,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Metformin (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6123,NCT02143050,"Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",WITHDRAWN,PHASE1,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Metformin (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6124,NCT02224781,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,ACTIVE_NOT_RECRUITING,PHASE3,Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma; Recurrent Melanoma; Unresectable Melanoma,Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Dabrafenib Mesylate (DRUG); Echocardiography Test (PROCEDURE); Ipilimumab (BIOLOGICAL); Multigated Acquisition Scan (PROCEDURE); Nivolumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Trametinib Dimethyl Sulfoxide (DRUG),11707110,QOM,Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma; Recurrent Melanoma; Unresectable Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6125,NCT02224781,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,ACTIVE_NOT_RECRUITING,PHASE3,Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma; Recurrent Melanoma; Unresectable Melanoma,Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Dabrafenib Mesylate (DRUG); Echocardiography Test (PROCEDURE); Ipilimumab (BIOLOGICAL); Multigated Acquisition Scan (PROCEDURE); Nivolumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Trametinib Dimethyl Sulfoxide (DRUG),11707110,QOM,Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma; Recurrent Melanoma; Unresectable Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6126,NCT05874414,Combination of GNS561 and Trametinib in Patients with Advanced KRAS Mutated Cholangiocarcinoma,RECRUITING,PHASE1,Cholangiocarcinoma,GNS561 + Trametinib (DRUG),11707110,QOM,Cholangiocarcinoma,Liver,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6127,NCT05874414,Combination of GNS561 and Trametinib in Patients with Advanced KRAS Mutated Cholangiocarcinoma,RECRUITING,PHASE1,Cholangiocarcinoma,GNS561 + Trametinib (DRUG),11707110,QOM,Cholangiocarcinoma,Liver,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6128,NCT05616923,Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea,COMPLETED,PHASE1,"Rosacea, Erythematotelangiectatic",Trametinib (DRUG),11707110,QOM,"Rosacea, Erythematotelangiectatic",Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6129,NCT05616923,Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea,COMPLETED,PHASE1,"Rosacea, Erythematotelangiectatic",Trametinib (DRUG),11707110,QOM,"Rosacea, Erythematotelangiectatic",Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6130,NCT03455764,MCS110 With BRAF/MEK Inhibition in Patients With Melanoma,COMPLETED,PHASE1,Melanoma,MCS110 (DRUG); Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6131,NCT03455764,MCS110 With BRAF/MEK Inhibition in Patients With Melanoma,COMPLETED,PHASE1,Melanoma,MCS110 (DRUG); Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6132,NCT03272464,INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.,TERMINATED,PHASE1,Melanoma,Trametinib (DRUG); Dabrafenib (DRUG); INCB039110 (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6133,NCT03272464,INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.,TERMINATED,PHASE1,Melanoma,Trametinib (DRUG); Dabrafenib (DRUG); INCB039110 (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6134,NCT03543306,Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation,UNKNOWN,PHASE2,Cancer; Lung Cancer Metastatic; BRAF V600E,daborafenib plus trametinib (DRUG),11707110,QOM,Cancer; Lung Cancer Metastatic; BRAF V600E,Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6135,NCT03543306,Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation,UNKNOWN,PHASE2,Cancer; Lung Cancer Metastatic; BRAF V600E,daborafenib plus trametinib (DRUG),11707110,QOM,Cancer; Lung Cancer Metastatic; BRAF V600E,Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6136,NCT02382549,A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib,TERMINATED,EARLY_PHASE1,Melanoma,BRAF inhibitor (DRUG); 6MHP (BIOLOGICAL); MEK inhibitor (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6137,NCT02382549,A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib,TERMINATED,EARLY_PHASE1,Melanoma,BRAF inhibitor (DRUG); 6MHP (BIOLOGICAL); MEK inhibitor (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6138,NCT02645149,Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma,RECRUITING,PHASE2,Melanoma,Standard therapy or clinical trial (DRUG); Matched targeted therapy (DRUG); Trametinib and / or supportive care (DRUG); CDK4/6 and MEK inhibitor (DRUG); Compassionate Access Targeted Therapy (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6139,NCT02645149,Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma,RECRUITING,PHASE2,Melanoma,Standard therapy or clinical trial (DRUG); Matched targeted therapy (DRUG); Trametinib and / or supportive care (DRUG); CDK4/6 and MEK inhibitor (DRUG); Compassionate Access Targeted Therapy (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6140,NCT01328106,"Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma",WITHDRAWN,PHASE2,GNA11 Mutation-positive Metastatic Melanoma; GNAQ Mutation-positive Metastatic Melanoma; Cancer; Metastatic Uveal Melanoma,GSK1120212 (DRUG),11707110,QOM,GNA11 Mutation-positive Metastatic Melanoma; GNAQ Mutation-positive Metastatic Melanoma; Cancer; Metastatic Uveal Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6141,NCT01328106,"Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma",WITHDRAWN,PHASE2,GNA11 Mutation-positive Metastatic Melanoma; GNAQ Mutation-positive Metastatic Melanoma; Cancer; Metastatic Uveal Melanoma,GSK1120212 (DRUG),11707110,QOM,GNA11 Mutation-positive Metastatic Melanoma; GNAQ Mutation-positive Metastatic Melanoma; Cancer; Metastatic Uveal Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6142,NCT06563999,Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.,RECRUITING,PHASE2,Lung Cancer Stage III; Mutation,Sunvozertinib (DRUG); Crizotinib (DRUG); Pralsetinib (DRUG); Larotrectinib (DRUG); Savolitinib (DRUG); Pyrotinib (DRUG); Dabrafenib+Trametinib (DRUG); Glecirasib (DRUG); Ensartinib (DRUG),11707110,QOM,Lung Cancer Stage III with Mutation,Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6143,NCT06563999,Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.,RECRUITING,PHASE2,Lung Cancer Stage III; Mutation,Sunvozertinib (DRUG); Crizotinib (DRUG); Pralsetinib (DRUG); Larotrectinib (DRUG); Savolitinib (DRUG); Pyrotinib (DRUG); Dabrafenib+Trametinib (DRUG); Glecirasib (DRUG); Ensartinib (DRUG),11707110,QOM,Lung Cancer Stage III with Mutation,Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6144,NCT03340506,Dabrafenib and/or Trametinib Rollover Study,RECRUITING,PHASE4,Melanoma; Non Small Cell Lung Cancer; Solid Tumor; Rare Cancers; High Grade Glioma,dabrafenib (DRUG); trametinib (DRUG),11707110,QOM,Melanoma; Non Small Cell Lung Cancer; Solid Tumor; Rare Cancers; High Grade Glioma,Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6145,NCT03340506,Dabrafenib and/or Trametinib Rollover Study,RECRUITING,PHASE4,Melanoma; Non Small Cell Lung Cancer; Solid Tumor; Rare Cancers; High Grade Glioma,dabrafenib (DRUG); trametinib (DRUG),11707110,QOM,Melanoma; Non Small Cell Lung Cancer; Solid Tumor; Rare Cancers; High Grade Glioma,Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6146,NCT04417621,Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma,ACTIVE_NOT_RECRUITING,PHASE2,Melanoma,LXH254 (DRUG); LTT462 (DRUG); Trametinib (DRUG); Ribociclib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6147,NCT04417621,Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma,ACTIVE_NOT_RECRUITING,PHASE2,Melanoma,LXH254 (DRUG); LTT462 (DRUG); Trametinib (DRUG); Ribociclib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6148,NCT02858921,"Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma",ACTIVE_NOT_RECRUITING,PHASE2,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Pembrolizumab (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6149,NCT02858921,"Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma",ACTIVE_NOT_RECRUITING,PHASE2,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Pembrolizumab (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6150,NCT03076164,A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib,COMPLETED,PHASE1,Lung Adenocarcinoma; Lung Cancer; Lung Cancer Metastatic; Lung Cancer Stage IV; Recurrent Lung Adenocarcinoma; Recurrent Lung Cancer,Trametinib (DRUG); Erlotinib (DRUG),11707110,QOM,Lung Adenocarcinoma; Lung Cancer; Lung Cancer Metastatic; Lung Cancer Stage IV; Recurrent Lung Adenocarcinoma; Recurrent Lung Cancer,Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6151,NCT03076164,A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib,COMPLETED,PHASE1,Lung Adenocarcinoma; Lung Cancer; Lung Cancer Metastatic; Lung Cancer Stage IV; Recurrent Lung Adenocarcinoma; Recurrent Lung Cancer,Trametinib (DRUG); Erlotinib (DRUG),11707110,QOM,Lung Adenocarcinoma; Lung Cancer; Lung Cancer Metastatic; Lung Cancer Stage IV; Recurrent Lung Adenocarcinoma; Recurrent Lung Cancer,Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6152,NCT03225664,"Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced",ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Unresectable Lung Non-Small Cell Carcinoma,Pembrolizumab (BIOLOGICAL); Pharmacokinetic Study (OTHER); Trametinib (DRUG),11707110,QOM,Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Unresectable Lung Non-Small Cell Carcinoma,Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6153,NCT03225664,"Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced",ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Unresectable Lung Non-Small Cell Carcinoma,Pembrolizumab (BIOLOGICAL); Pharmacokinetic Study (OTHER); Trametinib (DRUG),11707110,QOM,Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Unresectable Lung Non-Small Cell Carcinoma,Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6154,NCT04967079,Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients,COMPLETED,PHASE1,Non Small Cell Lung Cancer,Trametinib (DRUG); Anlotinib (DRUG),11707110,QOM,Non Small Cell Lung Cancer,Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6155,NCT04967079,Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients,COMPLETED,PHASE1,Non Small Cell Lung Cancer,Trametinib (DRUG); Anlotinib (DRUG),11707110,QOM,Non Small Cell Lung Cancer,Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6156,NCT02968303,Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy,UNKNOWN,PHASE2,"Melanoma, Malignant, of Soft Parts",Vemurafenib and Cobimetinib (DRUG),11707110,QOM,Malignant Melanoma of Soft Parts,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6157,NCT02968303,Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy,UNKNOWN,PHASE2,"Melanoma, Malignant, of Soft Parts",Vemurafenib and Cobimetinib (DRUG),11707110,QOM,Malignant Melanoma of Soft Parts,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6158,NCT04303403,Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma,RECRUITING,PHASE1,Colorectal Cancer; Pancreatic Adenocarcinoma,Trametinib (DRUG); Ruxolitinib (DRUG),11707110,QOM,Colorectal Cancer; Pancreatic Adenocarcinoma,Bowel,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6159,NCT04303403,Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma,RECRUITING,PHASE1,Colorectal Cancer; Pancreatic Adenocarcinoma,Trametinib (DRUG); Ruxolitinib (DRUG),11707110,QOM,Colorectal Cancer; Pancreatic Adenocarcinoma,Bowel,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6160,NCT03333343,Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC,ACTIVE_NOT_RECRUITING,PHASE1,EGFR-mutant Non-small Cell Lung Cancer,EGF816 (DRUG); trametinib (DRUG); ribociclib (DRUG); LXH254 (DRUG); INC280 (DRUG); gefitinib (DRUG),11707110,QOM,EGFR-mutant Non-small Cell Lung Cancer,Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6161,NCT03333343,Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC,ACTIVE_NOT_RECRUITING,PHASE1,EGFR-mutant Non-small Cell Lung Cancer,EGF816 (DRUG); trametinib (DRUG); ribociclib (DRUG); LXH254 (DRUG); INC280 (DRUG); gefitinib (DRUG),11707110,QOM,EGFR-mutant Non-small Cell Lung Cancer,Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6162,NCT02399943,A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer; KRAS Wildtype; NRAS Wildtype; BRAF Wildtype,Trametinib (DRUG); Panitumumab (DRUG),11707110,QOM,Colorectal Cancer; KRAS Wildtype; NRAS Wildtype; BRAF Wildtype,Bowel,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6163,NCT02399943,A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer; KRAS Wildtype; NRAS Wildtype; BRAF Wildtype,Trametinib (DRUG); Panitumumab (DRUG),11707110,QOM,Colorectal Cancer; KRAS Wildtype; NRAS Wildtype; BRAF Wildtype,Bowel,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6164,NCT02974803,Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases,TERMINATED,PHASE2,Melanoma; Brain Metastases,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma; Brain Metastases,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6165,NCT02974803,Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases,TERMINATED,PHASE2,Melanoma; Brain Metastases,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma; Brain Metastases,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6166,NCT06456138,Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC,NOT_YET_RECRUITING,PHASE1,KRAS Mutation-Related Tumors; Advanced Lung Cancer; Refractory Tumor,Trametinib (DRUG); Anlotinib (DRUG); Tislelizumab (DRUG),11707110,QOM,KRAS Mutation-Related Tumors; Advanced Lung Cancer; Refractory Tumor,Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6167,NCT06456138,Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC,NOT_YET_RECRUITING,PHASE1,KRAS Mutation-Related Tumors; Advanced Lung Cancer; Refractory Tumor,Trametinib (DRUG); Anlotinib (DRUG); Tislelizumab (DRUG),11707110,QOM,KRAS Mutation-Related Tumors; Advanced Lung Cancer; Refractory Tumor,Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6168,NCT03087448,Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC),TERMINATED,PHASE1,Non-small Cell Lung Cancer,Ceritinib (DRUG); Trametinib (DRUG),11707110,QOM,Non-small Cell Lung Cancer,Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6169,NCT03087448,Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC),TERMINATED,PHASE1,Non-small Cell Lung Cancer,Ceritinib (DRUG); Trametinib (DRUG),11707110,QOM,Non-small Cell Lung Cancer,Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6170,NCT01584648,A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma,COMPLETED,PHASE3,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Trametinib placebo (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6171,NCT01584648,A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma,COMPLETED,PHASE3,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Trametinib placebo (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6172,NCT02231775,Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation,ACTIVE_NOT_RECRUITING,PHASE2,Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7,Dabrafenib (DRUG); Laboratory Biomarker Analysis (OTHER); Therapeutic Conventional Surgery (PROCEDURE); Trametinib (DRUG),11707110,QOM,Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6173,NCT02231775,Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation,ACTIVE_NOT_RECRUITING,PHASE2,Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7,Dabrafenib (DRUG); Laboratory Biomarker Analysis (OTHER); Therapeutic Conventional Surgery (PROCEDURE); Trametinib (DRUG),11707110,QOM,Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6174,NCT04485559,Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021),RECRUITING,PHASE1,Recurrent World Health Organization (WHO) Grade II Glioma; Low-grade Glioma; High Grade Glioma,Everolimus (DRUG); Trametinib (DRUG),11707110,QOM,Recurrent World Health Organization (WHO) Grade II Glioma; Low-grade Glioma; High Grade Glioma,CNS/Brain,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6175,NCT04485559,Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021),RECRUITING,PHASE1,Recurrent World Health Organization (WHO) Grade II Glioma; Low-grade Glioma; High Grade Glioma,Everolimus (DRUG); Trametinib (DRUG),11707110,QOM,Recurrent World Health Organization (WHO) Grade II Glioma; Low-grade Glioma; High Grade Glioma,CNS/Brain,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6176,NCT02872259,BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma,COMPLETED,PHASE1,Melanoma,BGB324+pembrolizumab (DRUG); BGB324+dabrafenib and trametinib (DRUG); pembrolizumab (DRUG); dabrafenib and trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6177,NCT02872259,BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma,COMPLETED,PHASE1,Melanoma,BGB324+pembrolizumab (DRUG); BGB324+dabrafenib and trametinib (DRUG); pembrolizumab (DRUG); dabrafenib and trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6178,NCT06712875,MAPK Inhibition Combined with Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas,RECRUITING,PHASE1,Low Grade Glioma; High Grade Glioma,"Trametinib and Nivolumab (DRUG); Dabrafenib, trametinib, nivolumab (DRUG)",11707110,QOM,Low Grade Glioma; High Grade Glioma,CNS/Brain,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6179,NCT06712875,MAPK Inhibition Combined with Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas,RECRUITING,PHASE1,Low Grade Glioma; High Grade Glioma,"Trametinib and Nivolumab (DRUG); Dabrafenib, trametinib, nivolumab (DRUG)",11707110,QOM,Low Grade Glioma; High Grade Glioma,CNS/Brain,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6180,NCT02342600,SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor),WITHDRAWN,PHASE2,Gastrointestinal Stromal Tumors,Pazopanib (DRUG); Trametinib (DRUG),11707110,QOM,Gastrointestinal Stromal Tumors,Bowel,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6181,NCT02342600,SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor),WITHDRAWN,PHASE2,Gastrointestinal Stromal Tumors,Pazopanib (DRUG); Trametinib (DRUG),11707110,QOM,Gastrointestinal Stromal Tumors,Bowel,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6182,NCT02977052,Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab,ACTIVE_NOT_RECRUITING,PHASE2,Malignant Melanoma Stage III,Ipilimumab (DRUG); Nivolumab (DRUG); Surgery (PROCEDURE); Blood for PBMCs (PROCEDURE); Biopsies (PROCEDURE),11707110,QOM,Malignant Melanoma Stage III,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6183,NCT02977052,Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab,ACTIVE_NOT_RECRUITING,PHASE2,Malignant Melanoma Stage III,Ipilimumab (DRUG); Nivolumab (DRUG); Surgery (PROCEDURE); Blood for PBMCs (PROCEDURE); Biopsies (PROCEDURE),11707110,QOM,Malignant Melanoma Stage III,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6184,NCT01978236,"Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",TERMINATED,PHASE2,Melanoma and Brain Metastases,Dabrafenib 150 mg (DRUG); Trametinib 2.0 mg (DRUG),11707110,QOM,Melanoma with Brain Metastases,CNS/Brain,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6185,NCT01978236,"Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",TERMINATED,PHASE2,Melanoma and Brain Metastases,Dabrafenib 150 mg (DRUG); Trametinib 2.0 mg (DRUG),11707110,QOM,Melanoma with Brain Metastases,CNS/Brain,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6186,NCT04949113,Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma,ACTIVE_NOT_RECRUITING,PHASE3,Malignant Melanoma Stage III,Neoadjuvant ipilimumab + nivolumab (DRUG); Adjuvant nivolumab (DRUG),11707110,QOM,Malignant Melanoma Stage III,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6187,NCT04949113,Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma,ACTIVE_NOT_RECRUITING,PHASE3,Malignant Melanoma Stage III,Neoadjuvant ipilimumab + nivolumab (DRUG); Adjuvant nivolumab (DRUG),11707110,QOM,Malignant Melanoma Stage III,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6188,NCT01938456,Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer,WITHDRAWN,PHASE1,"Lung Cancer, Non-Small Cell",Trametinib (DRUG); Docetaxel (DRUG); Filgrastim (DRUG),11707110,QOM,"Lung Cancer, Non-Small Cell",Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6189,NCT01938456,Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer,WITHDRAWN,PHASE1,"Lung Cancer, Non-Small Cell",Trametinib (DRUG); Docetaxel (DRUG); Filgrastim (DRUG),11707110,QOM,"Lung Cancer, Non-Small Cell",Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6190,NCT02625337,Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients,UNKNOWN,PHASE2,Metastatic Melanoma,Pembrolizumab (DRUG); Dabrafenib (DRUG); Trametinib (DRUG); Biopsy (PROCEDURE); Blood taking (PROCEDURE),11707110,QOM,Metastatic Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6191,NCT02625337,Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients,UNKNOWN,PHASE2,Metastatic Melanoma,Pembrolizumab (DRUG); Dabrafenib (DRUG); Trametinib (DRUG); Biopsy (PROCEDURE); Blood taking (PROCEDURE),11707110,QOM,Metastatic Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6192,NCT02428270,A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer; Adenocarcinoma,GSK2256098 (DRUG); Trametinib (DRUG),11707110,QOM,Pancreatic Cancer; Adenocarcinoma,Pancreas,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6193,NCT02428270,A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer; Adenocarcinoma,GSK2256098 (DRUG); Trametinib (DRUG),11707110,QOM,Pancreatic Cancer; Adenocarcinoma,Pancreas,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6194,NCT02910700,"Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma,Binimetinib (DRUG); Dabrafenib (DRUG); Encorafenib (DRUG); Laboratory Biomarker Analysis (OTHER); Nivolumab (BIOLOGICAL); Pharmacological Study (OTHER); Trametinib (DRUG),11707110,QOM,Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma,CNS/Brain,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6195,NCT02910700,"Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma,Binimetinib (DRUG); Dabrafenib (DRUG); Encorafenib (DRUG); Laboratory Biomarker Analysis (OTHER); Nivolumab (BIOLOGICAL); Pharmacological Study (OTHER); Trametinib (DRUG),11707110,QOM,Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma,CNS/Brain,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6196,NCT01989585,Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma,ACTIVE_NOT_RECRUITING,PHASE1,Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Malignant Solid Neoplasm; Metastatic Melanoma; Unresectable Melanoma,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Dabrafenib (DRUG); Echocardiography Test (PROCEDURE); Laboratory Biomarker Analysis (OTHER); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Navitoclax (BIOLOGICAL); Pharmacological Study (OTHER); Trametinib (DRUG),11707110,QOM,Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Malignant Solid Neoplasm; Metastatic Melanoma; Unresectable Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6197,NCT01989585,Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma,ACTIVE_NOT_RECRUITING,PHASE1,Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Malignant Solid Neoplasm; Metastatic Melanoma; Unresectable Melanoma,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Dabrafenib (DRUG); Echocardiography Test (PROCEDURE); Laboratory Biomarker Analysis (OTHER); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Navitoclax (BIOLOGICAL); Pharmacological Study (OTHER); Trametinib (DRUG),11707110,QOM,Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Malignant Solid Neoplasm; Metastatic Melanoma; Unresectable Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6198,NCT01972347,Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma,ACTIVE_NOT_RECRUITING,PHASE2,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6199,NCT01972347,Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma,ACTIVE_NOT_RECRUITING,PHASE2,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6200,NCT03631953,Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas,RECRUITING,PHASE1,Meningioma,Trametinib (DRUG); Alpelisib (DRUG); Blood sample (BIOLOGICAL); MRI (DEVICE),11707110,QOM,Meningioma,CNS/Brain,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6201,NCT03631953,Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas,RECRUITING,PHASE1,Meningioma,Trametinib (DRUG); Alpelisib (DRUG); Blood sample (BIOLOGICAL); MRI (DEVICE),11707110,QOM,Meningioma,CNS/Brain,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6202,NCT01438554,"Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma",COMPLETED,PHASE1,Solid Tumors; Thyroid Cancer; Soft-tissue Sarcoma; Cholangiocarcinoma,Pazopanib (DRUG); GSK1120212 (DRUG),11707110,QOM,Solid Tumors; Thyroid Cancer; Soft-tissue Sarcoma; Cholangiocarcinoma,Liver,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6203,NCT01438554,"Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma",COMPLETED,PHASE1,Solid Tumors; Thyroid Cancer; Soft-tissue Sarcoma; Cholangiocarcinoma,Pazopanib (DRUG); GSK1120212 (DRUG),11707110,QOM,Solid Tumors; Thyroid Cancer; Soft-tissue Sarcoma; Cholangiocarcinoma,Liver,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6204,NCT03932253,MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b),SUSPENDED,PHASE1,Melanoma,FCN-159 (OTHER),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6205,NCT03932253,MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b),SUSPENDED,PHASE1,Melanoma,FCN-159 (OTHER),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6206,NCT02230553,Lapatinib Plus Trametinib in KRAS Mutant NSCLC,UNKNOWN,PHASE1,Colorectal Cancer,Lapatinib (DRUG); trametinib (DRUG),11707110,QOM,Colorectal Cancer,Bowel,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6207,NCT02230553,Lapatinib Plus Trametinib in KRAS Mutant NSCLC,UNKNOWN,PHASE1,Colorectal Cancer,Lapatinib (DRUG); trametinib (DRUG),11707110,QOM,Colorectal Cancer,Bowel,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6208,NCT03949153,Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis,COMPLETED,PHASE1,Melanoma (Skin),Nivolumab 10 MG/ML Intravenous Solution [OPDIVO] (DRUG); Cryotherapy (PROCEDURE); Ipilimumab Injection (DRUG),11707110,QOM,Melanoma (Skin),Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6209,NCT03949153,Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis,COMPLETED,PHASE1,Melanoma (Skin),Nivolumab 10 MG/ML Intravenous Solution [OPDIVO] (DRUG); Cryotherapy (PROCEDURE); Ipilimumab Injection (DRUG),11707110,QOM,Melanoma (Skin),Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6210,NCT01701037,Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery,TERMINATED,PHASE2,"Recurrent Melanoma; Stage IIB Melanoma (Locally Advanced); Stage IIC Melanoma (Locally Advanced); Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma (Limited, Resectable)",dabrafenib (DRUG); trametinib (DRUG); laboratory biomarker analysis (OTHER),11707110,QOM,"Recurrent Melanoma; Stage IIB Melanoma (Locally Advanced); Stage IIC Melanoma (Locally Advanced); Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma (Limited, Resectable)",Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6211,NCT01701037,Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery,TERMINATED,PHASE2,"Recurrent Melanoma; Stage IIB Melanoma (Locally Advanced); Stage IIC Melanoma (Locally Advanced); Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma (Limited, Resectable)",dabrafenib (DRUG); trametinib (DRUG); laboratory biomarker analysis (OTHER),11707110,QOM,"Recurrent Melanoma; Stage IIB Melanoma (Locally Advanced); Stage IIC Melanoma (Locally Advanced); Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma (Limited, Resectable)",Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6212,NCT04644432,Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma,UNKNOWN,PHASE2,Metastatic Renal Cell Carcinoma; Kidney Neoplasm; Urologic Neoplasms; Urogenital Neoplasms,Medication (A specification is listed under each arm) (DRUG); Patient reported outcomes measurement (OTHER),11707110,QOM,Metastatic Renal Cell Carcinoma,Kidney,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6213,NCT04644432,Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma,UNKNOWN,PHASE2,Metastatic Renal Cell Carcinoma; Kidney Neoplasm; Urologic Neoplasms; Urogenital Neoplasms,Medication (A specification is listed under each arm) (DRUG); Patient reported outcomes measurement (OTHER),11707110,QOM,Metastatic Renal Cell Carcinoma,Kidney,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6214,NCT02357732,Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib,WITHDRAWN,PHASE1,Metastatic Melanoma,Nivolumab (DRUG); Trametinib (DRUG); Dabrafenib (DRUG),11707110,QOM,Metastatic Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6215,NCT02357732,Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib,WITHDRAWN,PHASE1,Metastatic Melanoma,Nivolumab (DRUG); Trametinib (DRUG); Dabrafenib (DRUG),11707110,QOM,Metastatic Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6216,NCT04557956,"Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment",RECRUITING,PHASE1,Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma,Biopsy Procedure (PROCEDURE); Computed Tomography (PROCEDURE); Dabrafenib Mesylate (DRUG); Echocardiography Test (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Tazemetostat Hydrobromide (DRUG); Trametinib Dimethyl Sulfoxide (DRUG),11707110,QOM,Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6217,NCT04557956,"Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment",RECRUITING,PHASE1,Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma,Biopsy Procedure (PROCEDURE); Computed Tomography (PROCEDURE); Dabrafenib Mesylate (DRUG); Echocardiography Test (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Tazemetostat Hydrobromide (DRUG); Trametinib Dimethyl Sulfoxide (DRUG),11707110,QOM,Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6218,NCT05370807,A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma,UNKNOWN,PHASE2,Melanoma Stage III; Melanoma Stage IV,Regorafenib 40 MG Oral Tablet (DRUG); Triplet therapy (DRUG),11707110,QOM,Melanoma Stage III; Melanoma Stage IV,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6219,NCT05370807,A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma,UNKNOWN,PHASE2,Melanoma Stage III; Melanoma Stage IV,Regorafenib 40 MG Oral Tablet (DRUG); Triplet therapy (DRUG),11707110,QOM,Melanoma Stage III; Melanoma Stage IV,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6220,NCT02258607,Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase,TERMINATED,PHASE1,Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer,Momelotinib (MMB) (DRUG); Trametinib (DRUG),11707110,QOM,Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer,Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6221,NCT02258607,Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase,TERMINATED,PHASE1,Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer,Momelotinib (MMB) (DRUG); Trametinib (DRUG),11707110,QOM,Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer,Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6222,NCT05668585,"A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 As Monotherapy and Combination Therapy in Subjects with BRAF V600 Mutant Solid Tumors",RECRUITING,PHASE1,Solid Tumors; Melanoma; NSCLC; CRC; ATC,CFT1946 (DRUG); Trametinib (DRUG); Cetuximab (DRUG),11707110,QOM,Solid Tumors; Melanoma; NSCLC; CRC; ATC,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6223,NCT05668585,"A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 As Monotherapy and Combination Therapy in Subjects with BRAF V600 Mutant Solid Tumors",RECRUITING,PHASE1,Solid Tumors; Melanoma; NSCLC; CRC; ATC,CFT1946 (DRUG); Trametinib (DRUG); Cetuximab (DRUG),11707110,QOM,Solid Tumors; Melanoma; NSCLC; CRC; ATC,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6224,NCT03299088,Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations,ACTIVE_NOT_RECRUITING,PHASE1,KRAS Gene Mutation; Metastatic Non-Squamous Non-Small Cell Lung Carcinoma; Recurrent Non-Squamous Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7,Pembrolizumab (BIOLOGICAL); Trametinib (DRUG),11707110,QOM,KRAS Gene Mutation; Metastatic Non-Squamous Non-Small Cell Lung Carcinoma; Recurrent Non-Squamous Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7,Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6225,NCT03299088,Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations,ACTIVE_NOT_RECRUITING,PHASE1,KRAS Gene Mutation; Metastatic Non-Squamous Non-Small Cell Lung Carcinoma; Recurrent Non-Squamous Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7,Pembrolizumab (BIOLOGICAL); Trametinib (DRUG),11707110,QOM,KRAS Gene Mutation; Metastatic Non-Squamous Non-Small Cell Lung Carcinoma; Recurrent Non-Squamous Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7,Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6226,NCT01940809,"Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery",TERMINATED,PHASE1,BRAF V600E Mutation Present; BRAF V600K Mutation Present; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7,Dabrafenib (DRUG); Ipilimumab (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER); Nivolumab (BIOLOGICAL); Trametinib (DRUG),11707110,QOM,BRAF V600E Mutation Present; BRAF V600K Mutation Present; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6227,NCT01940809,"Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery",TERMINATED,PHASE1,BRAF V600E Mutation Present; BRAF V600K Mutation Present; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7,Dabrafenib (DRUG); Ipilimumab (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER); Nivolumab (BIOLOGICAL); Trametinib (DRUG),11707110,QOM,BRAF V600E Mutation Present; BRAF V600K Mutation Present; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6228,NCT02704156,SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,Cyberknife plus Pembrolizumab and Trametinib (DEVICE); Cyberknife plus Gemcitabine (DEVICE),11707110,QOM,Pancreatic Cancer,Pancreas,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6229,NCT02704156,SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,Cyberknife plus Pembrolizumab and Trametinib (DEVICE); Cyberknife plus Gemcitabine (DEVICE),11707110,QOM,Pancreatic Cancer,Pancreas,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6230,NCT04566133,Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).,TERMINATED,PHASE2,Bile Duct Cancer; Biliary Cancer; Biliary Tract Neoplasms; Cholangiocarcinoma,Trametinib (DRUG); Hydroxychloroquine (DRUG),11707110,QOM,Bile Duct Cancer; Biliary Cancer; Biliary Tract Neoplasms; Cholangiocarcinoma,Liver,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6231,NCT04566133,Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).,TERMINATED,PHASE2,Bile Duct Cancer; Biliary Cancer; Biliary Tract Neoplasms; Cholangiocarcinoma,Trametinib (DRUG); Hydroxychloroquine (DRUG),11707110,QOM,Bile Duct Cancer; Biliary Cancer; Biliary Tract Neoplasms; Cholangiocarcinoma,Liver,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6232,NCT02027961,Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone,COMPLETED,PHASE1,Melanoma,Durvalumab (BIOLOGICAL); Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6233,NCT02027961,Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone,COMPLETED,PHASE1,Melanoma,Durvalumab (BIOLOGICAL); Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6234,NCT04326283,"Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)",TERMINATED,PHASE1,Amyotrophic Lateral Sclerosis,Trametinib (0.5 mg) (DRUG); Trametinib (1 mg) (DRUG); Riluzole (100 mg) (DRUG),11707110,QOM,Amyotrophic Lateral Sclerosis,CNS/Brain,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6235,NCT04326283,"Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)",TERMINATED,PHASE1,Amyotrophic Lateral Sclerosis,Trametinib (0.5 mg) (DRUG); Trametinib (1 mg) (DRUG); Riluzole (100 mg) (DRUG),11707110,QOM,Amyotrophic Lateral Sclerosis,CNS/Brain,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6236,NCT03087071,Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE2,EGFR NP_005219.2:p.S492R; KRAS Gene Mutation; MAP2K1 Gene Mutation; Metastatic Colorectal Adenocarcinoma; Refractory Colorectal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7,Laboratory Biomarker Analysis (OTHER); Panitumumab (BIOLOGICAL); Trametinib (DRUG),11707110,QOM,EGFR NP_005219.2:p.S492R; KRAS Gene Mutation; MAP2K1 Gene Mutation; Metastatic Colorectal Adenocarcinoma; Refractory Colorectal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7,Bowel,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6237,NCT03087071,Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE2,EGFR NP_005219.2:p.S492R; KRAS Gene Mutation; MAP2K1 Gene Mutation; Metastatic Colorectal Adenocarcinoma; Refractory Colorectal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7,Laboratory Biomarker Analysis (OTHER); Panitumumab (BIOLOGICAL); Trametinib (DRUG),11707110,QOM,EGFR NP_005219.2:p.S492R; KRAS Gene Mutation; MAP2K1 Gene Mutation; Metastatic Colorectal Adenocarcinoma; Refractory Colorectal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7,Bowel,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6238,NCT03704688,Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Non Small Cell Lung Cancer; KRAS Gene Mutation,Trametinib 0.5 mg (DRUG); Trametinib 1 MG (DRUG); Trametinib 1.5 MG (DRUG); Trametinib 2 mg (DRUG); Ponatinib 15 MG (DRUG); Ponatinib 30 MG (DRUG),11707110,QOM,Non Small Cell Lung Cancer; KRAS Gene Mutation,Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6239,NCT03704688,Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Non Small Cell Lung Cancer; KRAS Gene Mutation,Trametinib 0.5 mg (DRUG); Trametinib 1 MG (DRUG); Trametinib 1.5 MG (DRUG); Trametinib 2 mg (DRUG); Ponatinib 15 MG (DRUG); Ponatinib 30 MG (DRUG),11707110,QOM,Non Small Cell Lung Cancer; KRAS Gene Mutation,Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6240,NCT01682083,Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).,COMPLETED,PHASE3,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Placebos (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6241,NCT01682083,Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).,COMPLETED,PHASE3,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Placebos (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6242,NCT04310397,"Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma",TERMINATED,PHASE2,Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8,Dabrafenib (DRUG); Spartalizumab (BIOLOGICAL); Therapeutic Conventional Surgery (PROCEDURE); Trametinib (DRUG),11707110,QOM,Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6243,NCT04310397,"Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma",TERMINATED,PHASE2,Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8,Dabrafenib (DRUG); Spartalizumab (BIOLOGICAL); Therapeutic Conventional Surgery (PROCEDURE); Trametinib (DRUG),11707110,QOM,Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6244,NCT02392871,Radiotherapy & Combi in Metastatic Melanoma,COMPLETED,PHASE1,Metastatic Melanoma,Palliative radiotherapy (RADIATION); Dabrafenib and trametinib (combination) (DRUG),11707110,QOM,Metastatic Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6245,NCT02392871,Radiotherapy & Combi in Metastatic Melanoma,COMPLETED,PHASE1,Metastatic Melanoma,Palliative radiotherapy (RADIATION); Dabrafenib and trametinib (combination) (DRUG),11707110,QOM,Metastatic Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6246,NCT02974725,A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma,TERMINATED,PHASE1,Non-Small Cell Lung Cancer; Melanoma,LXH254 (DRUG); LTT462 (DRUG); Trametinib (DRUG); Ribociclib (DRUG),11707110,QOM,Non-Small Cell Lung Cancer; Melanoma,Lung,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6247,NCT02974725,A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma,TERMINATED,PHASE1,Non-Small Cell Lung Cancer; Melanoma,LXH254 (DRUG); LTT462 (DRUG); Trametinib (DRUG); Ribociclib (DRUG),11707110,QOM,Non-Small Cell Lung Cancer; Melanoma,Lung,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6248,NCT03919071,Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma,ACTIVE_NOT_RECRUITING,PHASE2,"Anaplastic Astrocytoma; Anaplastic Astrocytoma, Not Otherwise Specified; Anaplastic Ganglioglioma; Anaplastic Pleomorphic Xanthoastrocytoma; Glioblastoma; Malignant Glioma; WHO Grade 3 Glioma; WHO Grade 4 Glioma",Biospecimen Collection (PROCEDURE); Dabrafenib Mesylate (DRUG); Lumbar Puncture (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Radiation Therapy (RADIATION); Trametinib Dimethyl Sulfoxide (DRUG),11707110,QOM,"Anaplastic Astrocytoma; Anaplastic Astrocytoma, Not Otherwise Specified; Anaplastic Ganglioglioma; Anaplastic Pleomorphic Xanthoastrocytoma; Glioblastoma; Malignant Glioma; WHO Grade 3 Glioma; WHO Grade 4 Glioma",CNS/Brain,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6249,NCT03919071,Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma,ACTIVE_NOT_RECRUITING,PHASE2,"Anaplastic Astrocytoma; Anaplastic Astrocytoma, Not Otherwise Specified; Anaplastic Ganglioglioma; Anaplastic Pleomorphic Xanthoastrocytoma; Glioblastoma; Malignant Glioma; WHO Grade 3 Glioma; WHO Grade 4 Glioma",Biospecimen Collection (PROCEDURE); Dabrafenib Mesylate (DRUG); Lumbar Puncture (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Radiation Therapy (RADIATION); Trametinib Dimethyl Sulfoxide (DRUG),11707110,QOM,"Anaplastic Astrocytoma; Anaplastic Astrocytoma, Not Otherwise Specified; Anaplastic Ganglioglioma; Anaplastic Pleomorphic Xanthoastrocytoma; Glioblastoma; Malignant Glioma; WHO Grade 3 Glioma; WHO Grade 4 Glioma",CNS/Brain,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6250,NCT03377361,An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread,COMPLETED,PHASE1,Colorectal Cancer; Colorectal Tumors; Colorectal Carcinoma; Colorectal Neoplasm,Nivolumab (BIOLOGICAL); Trametinib (DRUG); Ipilimumab (BIOLOGICAL); Regorafenib (DRUG),11707110,QOM,Colorectal Cancer; Colorectal Tumors; Colorectal Carcinoma; Colorectal Neoplasm,Bowel,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6251,NCT03377361,An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread,COMPLETED,PHASE1,Colorectal Cancer; Colorectal Tumors; Colorectal Carcinoma; Colorectal Neoplasm,Nivolumab (BIOLOGICAL); Trametinib (DRUG); Ipilimumab (BIOLOGICAL); Regorafenib (DRUG),11707110,QOM,Colorectal Cancer; Colorectal Tumors; Colorectal Carcinoma; Colorectal Neoplasm,Bowel,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6252,NCT03352947,Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma,COMPLETED,PHASE2,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6253,NCT03352947,Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma,COMPLETED,PHASE2,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6254,NCT02039947,Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain,COMPLETED,PHASE2,Melanoma and Brain Metastases,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma with Brain Metastases,CNS/Brain,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6255,NCT02039947,Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain,COMPLETED,PHASE2,Melanoma and Brain Metastases,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Melanoma with Brain Metastases,CNS/Brain,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6256,NCT02083354,Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma,COMPLETED,PHASE2,Cancer; Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Cancer; Melanoma,Skin,Trametinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,Approved for melanoma treatment.,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1.0,291.0 +6257,NCT02083354,Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma,COMPLETED,PHASE2,Cancer; Melanoma,Dabrafenib (DRUG); Trametinib (DRUG),11707110,QOM,Cancer; Melanoma,Skin,Trametinib (DMSO_TF solvate),"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,yes,yes,"Approved for use in cancer treatment (e.g., melanoma).", CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 ,, +6258,NCT04504331,"Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer",TERMINATED,PHASE1,Breast Cancer; HER2-negative Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer,Infigratinib (DRUG); Tamoxifen (DRUG); Omnipaque 350 (DRUG); Iopamidol (DRUG); Computed tomography (CT) (DIAGNOSTIC_TEST),4463,NVP,Breast Cancer; HER2-negative Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer,Breast,Nevirapine,,inhibitor/antagonist,unclear,yes,yes,Antiretroviral for HIV treatment approved for human use.,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,1.01,277.0 +6259,NCT00144248,A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions,COMPLETED,PHASE4,HIV Infections; Hepatic Insufficiency,nevirapine (DRUG),4463,NVP,HIV Infections; Hepatic Insufficiency,Liver,Nevirapine,,inhibitor/antagonist,unclear,yes,yes,Antiretroviral for HIV treatment approved for human use.,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,1.01,277.0 +6260,NCT05544929,A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers,RECRUITING,PHASE1,"Carcinoma, Non-Small-Cell Lung; Cutaneous Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Nasopharyngeal Carcinoma; Carcinoma, Thymic; Anal Cancer; Mesothelioma; Esophagogastric Cancer; High Microsatellite Instability Colorectal Carcinoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms",KFA115 (DRUG); pembrolizumab (DRUG),4463,NVP,"Carcinoma, Non-Small-Cell Lung; Cutaneous Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Nasopharyngeal Carcinoma; Carcinoma, Thymic; Anal Cancer; Mesothelioma; Esophagogastric Cancer; High Microsatellite Instability Colorectal Carcinoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms",Bowel,Nevirapine,,inhibitor/antagonist,unclear,yes,yes,Antiretroviral for HIV treatment approved for human use.,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,1.01,277.0 +6261,NCT02184091,Study to Evaluate the Effects of Underlying Renal or Hepatic Dysfunction on the Pharmacokinetics of Nevirapine,COMPLETED,PHASE1,Renal Insufficiency; Hepatic Insufficiency,Nevirapine (DRUG),4463,NVP,Renal Insufficiency; Hepatic Insufficiency,Liver,Nevirapine,,inhibitor/antagonist,unclear,yes,yes,Antiretroviral for HIV treatment approved for human use.,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,1.01,277.0 +6262,NCT01550380,"BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers",WITHDRAWN,PHASE2,Endometrial Cancer,BKM120 (DRUG),4463,NVP,Endometrial Cancer,Uterus,Nevirapine,,inhibitor/antagonist,unclear,yes,yes,Antiretroviral for HIV treatment approved for human use.,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,1.01,277.0 +6263,NCT00986063,Genotype Based Personalized Prescription of Nevirapine,COMPLETED,PHASE4,Nevirapine Induced Rash; Nevirapine Induced Hepatitis; HIV; Adverse Side Effects; AIDS; HIV Infections,Genetic test for NVP induced rash (GENETIC); 3TC/D4T/NVP or 3TC/AZT/NVP (OTHER),4463,NVP,Nevirapine Induced Rash; Nevirapine Induced Hepatitis; HIV; Adverse Side Effects; AIDS; HIV Infections,Liver,Nevirapine,,inhibitor/antagonist,unclear,yes,yes,Antiretroviral for HIV treatment approved for human use.,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,1.01,277.0 +6264,NCT02430363,Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475,UNKNOWN,PHASE1,Glioblastoma,MK - 3475 (DRUG); Suppressor of the PI3K/Akt pathways (BIOLOGICAL),4463,NVP,Glioblastoma,CNS/Brain,Nevirapine,,inhibitor/antagonist,unclear,yes,yes,Antiretroviral for HIV treatment approved for human use.,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,1.01,277.0 +6265,NCT03537196,DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C),COMPLETED,PHASE4,Hepatitis C; Drug Use; Viral Hepatitis C,Sofosbuvir 400 mg and Daclatasvir 60 mg (DRUG); Sofosbuvir 400 mg and Daclatasvir 90 mg (DRUG); Ribavirin (DRUG); Sofosbuvir and Daclatasvir for 24 weeks (DRUG),4463,NVP,Hepatitis C; Drug Use; Viral Hepatitis C,Liver,Nevirapine,,inhibitor/antagonist,unclear,yes,yes,Antiretroviral for HIV treatment approved for human use.,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,1.01,277.0 +6266,NCT01694589,A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer,WITHDRAWN,EARLY_PHASE1,Resectable Pancreatic Cancer,LDE-225 (DRUG),4463,NVP,Resectable Pancreatic Cancer,Pancreas,Nevirapine,,inhibitor/antagonist,unclear,yes,yes,Antiretroviral for HIV treatment approved for human use.,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,1.01,277.0 +6267,NCT03435146,Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine and Isoniazid or Standard Isoniazid Preventive Therapy in HIV+ Patients (DOLPHIN & DOLPHIN TOO),COMPLETED,PHASE1,Respiratory Tract Infections; HIV Infections,3HP plus DTG +2NRTIs (COMBINATION_PRODUCT),4463,NVP,Respiratory Tract Infections; HIV Infections,Lung,Nevirapine,,inhibitor/antagonist,unclear,yes,yes,Antiretroviral for HIV treatment approved for human use.,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,1.01,277.0 +6268,NCT02273219,Trial of AEB071 in Combination With BYL719 in Patients With Melanoma,COMPLETED,PHASE1,Uveal Melanoma,AEB071 (DRUG); BYL719 (DRUG),4463,NVP,Uveal Melanoma,Skin,Nevirapine,,inhibitor/antagonist,unclear,yes,yes,Antiretroviral for HIV treatment approved for human use.,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,1.01,277.0 +6269,NCT01340950,Clinical Trial of Brain-Penetrating HIV Drugs to Prevent Cognitive Impairment in China,COMPLETED,PHASE4,HIV Infections; Central Nervous System Diseases; Dementia,zidovudine-lamivudine-nevirapine (DRUG); tenofovir-lamivudine-efavirenz (DRUG),4463,NVP,HIV Infections; Central Nervous System Diseases; Dementia,CNS/Brain,Nevirapine,,inhibitor/antagonist,unclear,yes,yes,Antiretroviral for HIV treatment approved for human use.,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,1.01,277.0 +6270,NCT01816984,PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,COMPLETED,PHASE1,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,PI3K inhibitor BKM120 (DRUG); cetuximab (BIOLOGICAL),4463,NVP,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Skin,Nevirapine,,inhibitor/antagonist,unclear,yes,yes,Antiretroviral for HIV treatment approved for human use.,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,1.01,277.0 +6271,NCT01602315,A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,TERMINATED,PHASE1,Recurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma,BYL719 as film-coated (FC) whole tablets (DRUG); BYL719 as dispersible tablets (DT) (DRUG); cetuximab (BIOLOGICAL); BYL719 drink suspension (DRUG),4463,NVP,Metastatic Head and Neck Squamous Cell Carcinoma,Skin,Nevirapine,,inhibitor/antagonist,unclear,yes,yes,Antiretroviral for HIV treatment approved for human use.,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,1.01,277.0 +6272,NCT01225705,Safety Study of Raltegravir in HIV/HCV Co-infected Patients,WITHDRAWN,PHASE4,HIV; Hepatitis C,raltegravir (DRUG); Atazanavir/ritonavir (DRUG),4463,NVP,HIV; Hepatitis C,Liver,Nevirapine,,inhibitor/antagonist,unclear,yes,yes,Antiretroviral for HIV treatment approved for human use.,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,1.01,277.0 +6273,NCT04261218,"Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer",COMPLETED,PHASE1,Breast Cancer,tomivosertib (DRUG); paclitaxel (DRUG),118598754,Tomivosertib,Breast Cancer,Breast,Tomivosertib,,inhibitor/antagonist,Protein synthesis inhibitor,no,yes,In clinical trials for cancer; not FDA approved for human use yet.,CC1=C2C(=O)NC3(N2C(=O)C(=C1)NC4=NC=NC(=C4)N)CCCCC3,1.0,0.0 +6274,NCT04622007,Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART),ACTIVE_NOT_RECRUITING,PHASE2,Non-small Cell Lung Cancer,Tomivosertib (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed (DRUG),118598754,Tomivosertib,Non-small Cell Lung Cancer,Lung,Tomivosertib,,inhibitor/antagonist,Protein synthesis inhibitor,no,yes,In clinical trials for cancer; not FDA approved for human use yet.,CC1=C2C(=O)NC3(N2C(=O)C(=C1)NC4=NC=NC(=C4)N)CCCCC3,1.0,0.0 +6275,NCT03318562,A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC,TERMINATED,PHASE2,Triple Negative Breast Cancer; Hepatocellular Carcinoma,eFT508 (DRUG),118598754,Tomivosertib,Triple Negative Breast Cancer; Hepatocellular Carcinoma,Breast,Tomivosertib,,inhibitor/antagonist,Protein synthesis inhibitor,no,yes,In clinical trials for cancer; not FDA approved for human use yet.,CC1=C2C(=O)NC3(N2C(=O)C(=C1)NC4=NC=NC(=C4)N)CCCCC3,1.0,0.0 +6276,NCT03258398,A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer,COMPLETED,PHASE2,Microsatellite Stable Relapsed or Refractory Colorectal Cancer,eFT508 (DRUG); Avelumab (DRUG),118598754,Tomivosertib,Microsatellite Stable Relapsed or Refractory Colorectal Cancer,Bowel,Tomivosertib,,inhibitor/antagonist,Protein synthesis inhibitor,no,yes,In clinical trials for cancer; not FDA approved for human use yet.,CC1=C2C(=O)NC3(N2C(=O)C(=C1)NC4=NC=NC(=C4)N)CCCCC3,1.0,0.0 +6277,NCT03175666,QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy,WITHDRAWN,PHASE1,Triple Negative Breast Cancer,avelumab (BIOLOGICAL); bevacizumab (BIOLOGICAL); capecitabine (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG); nab-paclitaxel (DRUG); Lovaza (DRUG); Stereotactic Body Radiation Therapy (RADIATION); ALT-803 (BIOLOGICAL); ETBX-011 (BIOLOGICAL); ETBX-051 (BIOLOGICAL); ETBX-061 (BIOLOGICAL); GI-4000 (BIOLOGICAL); GI-6207 (BIOLOGICAL); GI-6301 (BIOLOGICAL); haNK (BIOLOGICAL),36314,Zisu,Triple Negative Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6278,NCT01669226,First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer,COMPLETED,PHASE2,Bulky Stage IIIC and IV Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,PEip (weekly) and TCiv (DRUG); TCiv (DRUG),36314,Zisu,Bulky Stage IIIC and IV Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6279,NCT01303926,Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer,UNKNOWN,PHASE3,Non-squamous Nonsmall Cell Neoplasm of Lung,cisplatin pemetrexed (DRUG); carboplatin paclitaxel bevacizumab (DRUG),36314,Zisu,Non-squamous Nonsmall Cell Neoplasm of Lung,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6280,NCT04198766,Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist),RECRUITING,PHASE1,Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer; Melanoma; Gastric Cancer; Renal Cell Carcinoma; Urothelial Carcinoma,INBRX-106 - Hexavalent OX40 agonist antibody (DRUG); pembrolizumab 200 mg (DRUG); pembrolizumab 400 mg (DRUG); Carboplatin AUC-5 (DRUG); Carboplatin AUC-6 (DRUG); Pemetrexed 500 mg/m2 (DRUG); Cisplatin 75mg/m2 (DRUG); Paclitaxel 200mg/m2 (DRUG); Nab paclitaxel 100mg/m2 (DRUG),36314,Zisu,Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer; Melanoma; Gastric Cancer; Renal Cell Carcinoma; Urothelial Carcinoma,Bladder/Urinary Tract,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6281,NCT00470548,Abraxane and Alimta in Advanced Solid Tumors,TERMINATED,PHASE1,"Breast Cancer; Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Abraxane (DRUG); Alimta (DRUG),36314,Zisu,Breast and Lung Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6282,NCT01853748,T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Trastuzumab (DRUG); Paclitaxel (DRUG); Trastuzumab emtansine (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6283,NCT02525757,MPDL3280A With Chemoradiation for Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Lung Cancer; Non-Small Cell Lung Cancer,MPDL3280A (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Radiation Therapy (RADIATION),36314,Zisu,Lung Cancer; Non-Small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6284,NCT06055348,SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer,NOT_YET_RECRUITING,PHASE1,Serous Ovarian Cancer; Advanced Ovarian Cancer,SC0191 (DRUG); Gemcitabine (DRUG); Paclitaxel (DRUG),36314,Zisu,Serous Ovarian Cancer; Advanced Ovarian Cancer,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6285,NCT03563157,QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine,TERMINATED,PHASE1,Colorectal Cancer Metastatic; mCRC,Aldoxorubicin Hydrochloride (BIOLOGICAL); ALT-803 (BIOLOGICAL); ETBX-011 (BIOLOGICAL); ETBX-021 (BIOLOGICAL); ETBX-051 (BIOLOGICAL); ETBX-061 (BIOLOGICAL); GI-4000 (BIOLOGICAL); GI-6207 (BIOLOGICAL); GI-6301 (BIOLOGICAL); haNK (BIOLOGICAL); Avelumab (DRUG); Capecitabine (DRUG); Cetuximab (DRUG); Cyclophosphamide (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG); Nab-paclitaxel (DRUG); Oxaliplatin (DRUG); Regorafenib (DRUG); SBRT (PROCEDURE),36314,Zisu,Colorectal Cancer Metastatic; mCRC,Bowel,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6286,NCT00033657,Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer,COMPLETED,PHASE2,Esophageal Cancer; Gastric Cancer,cisplatin (DRUG); irinotecan hydrochloride (DRUG); paclitaxel (DRUG); conventional surgery (PROCEDURE); radiation therapy (RADIATION),36314,Zisu,Esophageal and Gastric Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6287,NCT00068757,"Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer",COMPLETED,PHASE1,Breast Cancer,trastuzumab (BIOLOGICAL); lonafarnib (DRUG); paclitaxel (DRUG); pharmacological study (OTHER),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6288,NCT05566457,HGWD Improve the Paclitaxel-related Neurotoxicity in Patients With BC,UNKNOWN,PHASE2,Breast Cancer,Huangqi Guizhi Wuwu decoction (HGWD) infusion packs (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6289,NCT06758557,A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor,RECRUITING,PHASE1,Advanced NSCLC; Advanced Endometrial Cancer,HB0025 (DRUG); Pemetrexed (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG),36314,Zisu,Advanced Non-Small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6290,NCT02489448,Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer,COMPLETED,PHASE1,Breast Neoplasms,MEDI4736 (DRUG),36314,Zisu,Breast Neoplasms,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6291,NCT06338657,FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer,RECRUITING,PHASE1,Head and Neck Squamous Cell Carcinoma,Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); PEOX-based Polymer Encapsulated Paclitaxel FID-007 (DRUG); Tumor Resection (PROCEDURE),36314,Zisu,Head and Neck Squamous Cell Carcinoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6292,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),COMPLETED,PHASE1,Triple Negative Breast Neoplasms,Pembrolizumab (BIOLOGICAL); Nab-paclitaxel (DRUG); Anthracycline (doxorubicin) (DRUG); Cyclophosphamide (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG),36314,Zisu,Triple Negative Breast Neoplasms,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6293,NCT00373620,A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients,UNKNOWN,PHASE2,Endometrial Cancer,paclitaxel (DRUG),36314,Zisu,Endometrial Cancer,Uterus,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6294,NCT05383482,Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1,ACTIVE_NOT_RECRUITING,PHASE1,Solid Tumor; NSCLC; Cervical Cancer; Endometrial Cancer; Esophageal Cancer; Gastric and Gastroesophageal Junction Adenocarcinoma,Afuresertib (DRUG); Nab paclitaxel (DRUG); Docetaxel (DRUG); Sintilimab (DRUG),36314,Zisu,Solid Tumor; NSCLC; Cervical Cancer; Endometrial Cancer; Esophageal Cancer; Gastric and Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6295,NCT06912074,Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma,RECRUITING,PHASE2,Esophageal Squamous Cell Carcinoma (ESCC),Induction chemoimmunotherapy (DRUG); Hypofractionated Radiation Therapy (RADIATION); Conventional Fractionated Radiation Therapy (RADIATION); Concurrent Chemotherapy (DRUG),36314,Zisu,Esophageal Squamous Cell Carcinoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6296,NCT02001974,Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC),COMPLETED,PHASE1,Metastatic Breast Cancer,Paclitaxel+Reparixin (DRUG),36314,Zisu,Metastatic Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6297,NCT02762474,Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer,UNKNOWN,PHASE1,Esophageal Cancer,nab-paclitaxel group (DRUG),36314,Zisu,Esophageal Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6298,NCT00003065,Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix,COMPLETED,PHASE2,Cervical Cancer,filgrastim (BIOLOGICAL); paclitaxel (DRUG); topotecan hydrochloride (DRUG),36314,Zisu,Cervical Cancer,Cervix,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6299,NCT01154920,"Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma",ACTIVE_NOT_RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma,Paclitaxel (DRUG); Carboplatin (DRUG); Cetuximab (DRUG); Docetaxel (DRUG); Cisplatin (DRUG); Fluorouracil (DRUG); Radiotherapy (RT) (RADIATION); Chemotherapy (OTHER),36314,Zisu,Head and Neck Squamous Cell Carcinoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6300,NCT00387374,"Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab",COMPLETED,PHASE2,Adenosquamous Cell Lung Cancer; Drug/Agent Toxicity by Tissue/Organ; Hemoptysis; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,bevacizumab (BIOLOGICAL); paclitaxel (DRUG); carboplatin (DRUG); radiation therapy (RADIATION),36314,Zisu,Adenosquamous Cell Lung Cancer; Drug/Agent Toxicity by Tissue/Organ; Hemoptysis; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6301,NCT00077220,"Paclitaxel, Carboplatin, and Radiation Therapy With or Without Adjuvant Paclitaxel and Carboplatin in Treating Patients With Stage II or Stage III Unresectable Non-Small Cell Lung Cancer",UNKNOWN,PHASE3,Lung Cancer,carboplatin (DRUG); paclitaxel (DRUG); adjuvant therapy (PROCEDURE); radiation therapy (RADIATION),36314,Zisu,Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6302,NCT03747120,Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP],ACTIVE_NOT_RECRUITING,PHASE2,HER2-positive Breast Cancer; Breast Cancer,Paclitaxel (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); Pembrolizumab (DRUG),36314,Zisu,HER2-positive Breast Cancer; Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6303,NCT04405674,Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,Tislelizumab (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Bevacizumab (DRUG); Nab paclitaxel (DRUG),36314,Zisu,Non Small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6304,NCT00006120,Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,docetaxel (DRUG); paclitaxel (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6305,NCT06625320,Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),RECRUITING,PHASE3,Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma,RMC-6236 (DRUG); Gemcitabine (DRUG); nab-paclitaxel (DRUG); Irinotecan (DRUG); Liposomal irinotecan (DRUG); 5-fluorouracil (DRUG); leucovorin (DRUG); Oxaliplatin (DRUG),36314,Zisu,Pancreatic Ductal Adenocarcinoma,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6306,NCT00004074,Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu,COMPLETED,PHASE1,Advanced Adult Primary Liver Cancer; Anaplastic Thyroid Cancer; Bone Metastases; Carcinoma of the Appendix; Distal Urethral Cancer; Fallopian Tube Cancer; Gastrinoma; Glucagonoma; Inflammatory Breast Cancer; Insulinoma; Liver Metastases; Localized Unresectable Adult Primary Liver Cancer; Lung Metastases; Male Breast Cancer; Malignant Pericardial Effusion; Malignant Pleural Effusion; Metastatic Gastrointestinal Carcinoid Tumor; Metastatic Parathyroid Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Newly Diagnosed Carcinoma of Unknown Primary; Occult Non-small Cell Lung Cancer; Pancreatic Polypeptide Tumor; Primary Peritoneal Cavity Cancer; Proximal Urethral Cancer; Pulmonary Carcinoid Tumor; Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Adrenocortical Carcinoma; Recurrent Adult Primary Liver Cancer; Recurrent Anal Cancer; Recurrent Bladder Cancer; Recurrent Breast Cancer; Recurrent Carcinoma of Unknown Primary; Recurrent Cervical Cancer; Recurrent Colon Cancer; Recurrent Endometrial Carcinoma; Recurrent Esophageal Cancer; Recurrent Extrahepatic Bile Duct Cancer; Recurrent Gallbladder Cancer; Recurrent Gastric Cancer; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Non-small Cell Lung Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Pancreatic Cancer; Recurrent Parathyroid Cancer; Recurrent Prostate Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Salivary Gland Cancer; Recurrent Small Intestine Cancer; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Thyroid Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Recurrent Vaginal Cancer; Recurrent Vulvar Cancer; Skin Metastases; Small Intestine Adenocarcinoma; Somatostatinoma; Stage III Adenoid Cystic Carcinoma of the Oral Cavity; Stage III Adrenocortical Carcinoma; Stage III Bladder Cancer; Stage III Cervical Cancer; Stage III Colon Cancer; Stage III Endometrial Carcinoma; Stage III Esophageal Cancer; Stage III Follicular Thyroid Cancer; Stage III Gastric Cancer; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mucoepidermoid Carcinoma of the Oral Cavity; Stage III Ovarian Epithelial Cancer; Stage III Pancreatic Cancer; Stage III Papillary Thyroid Cancer; Stage III Prostate Cancer; Stage III Rectal Cancer; Stage III Renal Cell Cancer; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Vaginal Cancer; Stage III Vulvar Cancer; Stage IIIA Anal Cancer; Stage IIIA Breast Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Anal Cancer; Stage IIIB Breast Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Adenoid Cystic Carcinoma of the Oral Cavity; Stage IV Adrenocortical Carcinoma; Stage IV Anal Cancer; Stage IV Bladder Cancer; Stage IV Breast Cancer; Stage IV Colon Cancer; Stage IV Endometrial Carcinoma; Stage IV Esophageal Cancer; Stage IV Follicular Thyroid Cancer; Stage IV Gastric Cancer; Stage IV Mucoepidermoid Carcinoma of the Oral Cavity; Stage IV Non-small Cell Lung Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Pancreatic Cancer; Stage IV Papillary Thyroid Cancer; Stage IV Prostate Cancer; Stage IV Rectal Cancer; Stage IV Renal Cell Cancer; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IVA Cervical Cancer; Stage IVA Vaginal Cancer; Stage IVB Cervical Cancer; Stage IVB Vaginal Cancer; Stage IVB Vulvar Cancer; Thyroid Gland Medullary Carcinoma; Unresectable Extrahepatic Bile Duct Cancer; Unresectable Gallbladder Cancer; Urethral Cancer Associated With Invasive Bladder Cancer; WDHA Syndrome,recombinant interleukin-12 (BIOLOGICAL); ABI-007/carboplatin/trastuzumab (BIOLOGICAL),36314,Zisu,Advanced Adult Primary Liver Cancer; Anaplastic Thyroid Cancer; Bone Metastases; Carcinoma of the Appendix; Distal Urethral Cancer; Fallopian Tube Cancer; Gastrinoma; Glucagonoma; Inflammatory Breast Cancer; Insulinoma; Liver Metastases; Localized Unresectable Adult Primary Liver Cancer; Lung Metastases; Male Breast Cancer; Malignant Pericardial Effusion; Malignant Pleural Effusion; Metastatic Gastrointestinal Carcinoid Tumor; Metastatic Parathyroid Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Newly Diagnosed Carcinoma of Unknown Primary; Occult Non-small Cell Lung Cancer; Pancreatic Polypeptide Tumor; Primary Peritoneal Cavity Cancer; Proximal Urethral Cancer; Pulmonary Carcinoid Tumor; Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Adrenocortical Carcinoma; Recurrent Adult Primary Liver Cancer; Recurrent Anal Cancer; Recurrent Bladder Cancer; Recurrent Breast Cancer; Recurrent Carcinoma of Unknown Primary; Recurrent Cervical Cancer; Recurrent Colon Cancer; Recurrent Endometrial Carcinoma; Recurrent Esophageal Cancer; Recurrent Extrahepatic Bile Duct Cancer; Recurrent Gallbladder Cancer; Recurrent Gastric Cancer; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Non-small Cell Lung Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Pancreatic Cancer; Recurrent Parathyroid Cancer; Recurrent Prostate Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Salivary Gland Cancer; Recurrent Small Intestine Cancer; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Thyroid Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Recurrent Vaginal Cancer; Recurrent Vulvar Cancer; Skin Metastases; Small Intestine Adenocarcinoma; Somatostatinoma; Stage III Adenoid Cystic Carcinoma of the Oral Cavity; Stage III Adrenocortical Carcinoma; Stage III Bladder Cancer; Stage III Cervical Cancer; Stage III Colon Cancer; Stage III Endometrial Carcinoma; Stage III Esophageal Cancer; Stage III Follicular Thyroid Cancer; Stage III Gastric Cancer; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mucoepidermoid Carcinoma of the Oral Cavity; Stage III Ovarian Epithelial Cancer; Stage III Pancreatic Cancer; Stage III Papillary Thyroid Cancer; Stage III Prostate Cancer; Stage III Rectal Cancer; Stage III Renal Cell Cancer; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Vaginal Cancer; Stage III Vulvar Cancer; Stage IIIA Anal Cancer; Stage IIIA Breast Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Anal Cancer; Stage IIIB Breast Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Adenoid Cystic Carcinoma of the Oral Cavity; Stage IV Adrenocortical Carcinoma; Stage IV Anal Cancer; Stage IV Bladder Cancer; Stage IV Breast Cancer; Stage IV Colon Cancer; Stage IV Endometrial Carcinoma; Stage IV Esophageal Cancer; Stage IV Follicular Thyroid Cancer; Stage IV Gastric Cancer; Stage IV Mucoepidermoid Carcinoma of the Oral Cavity; Stage IV Non-small Cell Lung Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Pancreatic Cancer; Stage IV Papillary Thyroid Cancer; Stage IV Prostate Cancer; Stage IV Rectal Cancer; Stage IV Renal Cell Cancer; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IVA Cervical Cancer; Stage IVA Vaginal Cancer; Stage IVB Cervical Cancer; Stage IVB Vaginal Cancer; Stage IVB Vulvar Cancer; Thyroid Gland Medullary Carcinoma; Unresectable Extrahepatic Bile Duct Cancer; Unresectable Gallbladder Cancer; Urethral Cancer Associated With Invasive Bladder Cancer; WDHA Syndrome,Bowel,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6307,NCT03819465,A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Non-Small Cell Lung Cancer (NSCLC),Durvalumab (DRUG); Danvatirsen (DRUG); Oleclumab (DRUG); MEDI5752 (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG); Nab-paclitaxel (DRUG); AZD2936 (DRUG),36314,Zisu,Metastatic Non-Small Cell Lung Cancer (NSCLC),Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6308,NCT00951665,"A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer",COMPLETED,PHASE1,Metastatic Breast Cancer,paclitaxel (DRUG); pertuzumab [Perjeta] (DRUG); trastuzumab emtansine [Kadcyla] (DRUG); paclitaxel (DRUG); trastuzumab emtansine [Kadcyla] (DRUG),36314,Zisu,Metastatic Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6309,NCT04247165,"Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.",COMPLETED,PHASE1,"Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer",Gemcitabine (DRUG); Nab-paclitaxel (DRUG); Nivolumab (DRUG); Ipilimumab (DRUG); SBRT (RADIATION),36314,Zisu,"Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer",Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6310,NCT04329065,"Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer",RECRUITING,PHASE2,Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8,pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine (BIOLOGICAL); Paclitaxel (DRUG); Trastuzumab (BIOLOGICAL); Pertuzumab (BIOLOGICAL),36314,Zisu,Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6311,NCT03788174,Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma,UNKNOWN,PHASE2,Gastric Adenocarcinoma,Apatinib (DRUG); POF (DRUG),36314,Zisu,Gastric Adenocarcinoma,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6312,NCT01379482,Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer,COMPLETED,PHASE2,Peritoneal Carcinomatosis; Gastric Cancer,Multimodal treatment (DRUG),36314,Zisu,Gastric Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6313,NCT00494182,Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Squamous Cell Carcinoma of the Hypopharynx; Metastatic Squamous Cell Carcinoma of the Larynx; Metastatic Squamous Cell Carcinoma of the Oral Cavity; Metastatic Squamous Cell Carcinoma of the Oropharynx; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Oral Cavity Squamous Cell Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma,Carboplatin (DRUG); Paclitaxel (DRUG); Sorafenib (DRUG),36314,Zisu,Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Squamous Cell Carcinoma of the Hypopharynx; Metastatic Squamous Cell Carcinoma of the Larynx; Metastatic Squamous Cell Carcinoma of the Oral Cavity; Metastatic Squamous Cell Carcinoma of the Oropharynx; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Oral Cavity Squamous Cell Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6314,NCT00394082,ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,ABI-007 (DRUG); Bevacizumab (DRUG),36314,Zisu,Metastatic Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6315,NCT01190982,Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,LEP-ETU (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6316,NCT00433420,Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,pegfilgrastim (BIOLOGICAL); cyclophosphamide (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); paclitaxel (DRUG); adjuvant therapy (PROCEDURE),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6317,NCT01851174,Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer,TERMINATED,PHASE2,Pancreatic Carcinoma Non-resectable; Stage IV Pancreatic Cancer,Gemcitabine (DRUG); nab-Paclitaxel (DRUG),36314,Zisu,Pancreatic Carcinoma Non-resectable; Stage IV Pancreatic Cancer,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6318,NCT04988074,"Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca",RECRUITING,PHASE2,HPV-Related Squamous Cell Carcinoma,Cemiplimab (DRUG),36314,Zisu,HPV-Related Squamous Cell Carcinoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6319,NCT00401674,MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer,COMPLETED,PHASE2,Ovarian Cancer,carboplatin (DRUG); paclitaxel (DRUG),36314,Zisu,Ovarian Cancer,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6320,NCT00021320,Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer,COMPLETED,PHASE2,Esophageal Cancer,cisplatin (DRUG); fluorouracil (DRUG); paclitaxel (DRUG); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE); radiation therapy (RADIATION),36314,Zisu,Esophageal Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6321,NCT05585320,A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors,RECRUITING,PHASE1,Advanced Solid Tumor; Pancreatic Adenocarcinoma; Malignant Melanoma (Cutaneous); Non-small Cell Lung Cancer (NSCLC),IMM-1-104 Monotherapy (Treatment Group A) (DRUG); IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B) (DRUG); IMM-1-104 + modified FOLFIRINOX (Treatment Group C) (DRUG); IMM-1-104 + dabrafenib (Treatment Group D) (DRUG); IMM-1-104 + pembrolizumab (Treatment Group E) (DRUG),36314,Zisu,Advanced Solid Tumor; Pancreatic Adenocarcinoma; Malignant Melanoma (Cutaneous); Non-small Cell Lung Cancer (NSCLC),Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6322,NCT00479674,"Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer",COMPLETED,PHASE2,Breast Cancer,Abraxane (DRUG); Bevacizumab (DRUG); Carboplatin (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6323,NCT02576574,Avelumab in First-line NSCLC (JAVELIN Lung 100),COMPLETED,PHASE3,First Line Non-Small Cell Lung Cancer,Avelumab (DRUG); Pemetrexed (DRUG); Paclitaxel (DRUG); Gemcitabine (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Avelumab Weekly (DRUG),36314,Zisu,First Line Non-Small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6324,NCT06964165,A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C),TERMINATED,PHASE2,Ovarian Neoplasms,Niraparib (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG),36314,Zisu,Ovarian Neoplasms,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6325,NCT06268665,Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy,RECRUITING,PHASE2,"Breast Cancer; Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer Stage IV; Invasive Breast Cancer; Ovarian Cancer; Ovarian Cancer Stage 1; Ovarian Cancer Stage II; Ovarian Cancer Stage III; Ovarian Cancer Stage IV; Ovarian Cancer Stage IA; Ovarian Cancer Stage IB; Ovarian Cancer Stage IC; Ovarian Cancer Stage 2; Ovarian Cancer Stage 3; Ovarian Cancer Stage IIIb; Ovarian Cancer Stage IIIC; Breast Cancer Stage IIIA; Breast Cancer Invasive; Breast Cancer, Stage IA; Breast Cancer, Stage IB; Breast Cancer Stage IIA; Breast Cancer Stage IIB; Breast Cancer Stage IIIB; Breast Cancer Stage IIIc; Cancer, Breast; Tumors, Breast; Mammary Cancer; Mammary Carcinoma; Breast Carcinoma; Breast Neoplasm; Malignant Breast Neoplasm; Malignant Tumor of Breast; Cancer of Ovary; Ovary Cancer; Ovary Neoplasm",Tart Cherry Juice (DRUG),36314,Zisu,"Breast Cancer; Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer Stage IV; Invasive Breast Cancer; Ovarian Cancer; Ovarian Cancer Stage 1; Ovarian Cancer Stage II; Ovarian Cancer Stage III; Ovarian Cancer Stage IV; Ovarian Cancer Stage IA; Ovarian Cancer Stage IB; Ovarian Cancer Stage IC; Ovarian Cancer Stage 2; Ovarian Cancer Stage 3; Ovarian Cancer Stage IIIb; Ovarian Cancer Stage IIIC; Breast Cancer Stage IIIA; Breast Cancer Invasive; Breast Cancer, Stage IA; Breast Cancer, Stage IB; Breast Cancer Stage IIA; Breast Cancer Stage IIB; Breast Cancer Stage IIIB; Breast Cancer Stage IIIc; Cancer, Breast; Tumors, Breast; Mammary Cancer; Mammary Carcinoma; Breast Carcinoma; Breast Neoplasm; Malignant Breast Neoplasm; Malignant Tumor of Breast; Cancer of Ovary; Ovary Cancer; Ovary Neoplasm",Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6326,NCT00933374,Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma,TERMINATED,PHASE2,Bladder Cancer,paclitaxel (DRUG); RAD001 (DRUG),36314,Zisu,Bladder Cancer,Bladder/Urinary Tract,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6327,NCT00570674,"Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck",TERMINATED,PHASE1,Squamous Cell Carcinoma of the Head and Neck; Basaloid Squamous Cell Carcinoma; Undifferentiated Carcinoma; Adenosquamous Cell Carcinoma,Abraxane (DRUG); Erbitux (DRUG); Carboplatin (DRUG); Intensity Modulated Radiation Therapy (RADIATION),36314,Zisu,Squamous Cell Carcinoma of the Head and Neck; Basaloid Squamous Cell Carcinoma; Undifferentiated Carcinoma; Adenosquamous Cell Carcinoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6328,NCT01936974,"(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma",TERMINATED,PHASE2,Ovarian Carcinoma; Fallopian Tube Carcinoma; Peritoneal Carcinoma,Gemcitabine (DRUG); Bevacizumab (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Oxaliplatin (DRUG),36314,Zisu,Ovarian and Related Carcinomas,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6329,NCT01665274,Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer,TERMINATED,PHASE2,Gastric Cancer,Capecitabine (DRUG); Oxaliplatin (DRUG); D2 resection (PROCEDURE),36314,Zisu,Gastric Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6330,NCT05476965,Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma,UNKNOWN,PHASE2,Head and Neck Squamous Cell Carcinoma; Radiotherapy; Immunotherapy; Surgery,induction therapy; surgery; radiotherapy (COMBINATION_PRODUCT),36314,Zisu,Head and Neck Squamous Cell Carcinoma; Radiotherapy; Immunotherapy; Surgery,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6331,NCT05582265,Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I),RECRUITING,PHASE3,Head and Neck Squamous Cell Carcinomas,Tislelizumab（neoadjuvant） (DRUG); Cisplatin （neoadjuvant） (DRUG); Nab-paclitaxel （neoadjuvant） (DRUG); Surgical resection (PROCEDURE); Cisplatin（adjuvant） (DRUG); Tislelizumab（adjuvant） (DRUG); Radiation (RADIATION); Carboplatin (neoadjuvant） (DRUG); Carboplatin (adjuvant） (DRUG),36314,Zisu,Head and Neck Squamous Cell Carcinomas,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6332,NCT06727565,Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma.,RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma,Domvanalimab (DRUG); Zimberelimab (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG),36314,Zisu,Head and Neck Squamous Cell Carcinoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6333,NCT06726265,Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004),RECRUITING,PHASE3,Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC),eftilagimod alfa (BIOLOGICAL); carboplatin plus paclitaxel (DRUG); cisplatin or carboplatin + pemetrexed (DRUG); Pembrolizumab (KEYTRUDA®) (BIOLOGICAL); Placebo (OTHER),36314,Zisu,Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC),Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6334,NCT02430974,Chemotherapy of NSCLC With or Without Icotinib,UNKNOWN,PHASE2,"Carcinoma, Non-Small-Cell Lung",Icotinib (DRUG),36314,Zisu,"Carcinoma, Non-Small-Cell Lung",Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6335,NCT02559674,QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel,COMPLETED,PHASE1,Advanced Pancreatic Cancer,Gemcitabine (BIOLOGICAL); Nab-paclitaxel (BIOLOGICAL); ALT-803 (BIOLOGICAL),36314,Zisu,Advanced Pancreatic Cancer,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6336,NCT05524974,"Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes",NOT_YET_RECRUITING,PHASE2,Locally Advanced Gastric Cancer,Camrelizumab (DRUG); Oxaliplatin (DRUG); S1 (DRUG); Apatinib Mesylate (DRUG); Nab paclitaxel (DRUG),36314,Zisu,Metastatic Gastric Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6337,NCT02207465,A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer,RECRUITING,PHASE1,Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy; Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy,Radiotherapy (RADIATION); Abraxane (DRUG),36314,Zisu,Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy; Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6338,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,COMPLETED,PHASE3,"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity",OLAPARIB (DRUG); Single agent chemotherapy (DRUG),36314,Zisu,"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity",Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6339,NCT04998474,FRAME-001 Personalized Vaccine in NSCLC,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,FRAME-001 personalized vaccine (BIOLOGICAL),36314,Zisu,Non Small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6340,NCT06304974,A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma,RECRUITING,PHASE3,Esophageal Squamous Cell Carcinoma,BL-B01D1 (DRUG); Irinotecan (DRUG); paclitaxel (DRUG); docetaxel (DRUG),36314,Zisu,Esophageal Squamous Cell Carcinoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6341,NCT00127920,"Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients",COMPLETED,PHASE2,Ovarian Neoplasms,Avastin (DRUG),36314,Zisu,Ovarian Neoplasms,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6342,NCT00003120,"S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission",COMPLETED,PHASE3,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,paclitaxel (DRUG),36314,Zisu,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6343,NCT00954174,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",UNKNOWN,PHASE3,Mixed Mesodermal (Mullerian) Tumor; Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Stage I Ovarian Cancer AJCC v6 and v7; Stage IA Fallopian Tube Cancer AJCC v6 and v7; Stage IA Ovarian Cancer AJCC v6 and v7; Stage IA Uterine Sarcoma AJCC v7; Stage IB Fallopian Tube Cancer AJCC v6 and v7; Stage IB Ovarian Cancer AJCC v6 and v7; Stage IB Uterine Sarcoma AJCC v7; Stage IC Fallopian Tube Cancer AJCC v6 and v7; Stage IC Ovarian Cancer AJCC v6 and v7; Stage IC Uterine Sarcoma AJCC v7; Stage II Ovarian Cancer AJCC v6 and v7; Stage IIA Fallopian Tube Cancer AJCC v6 and v7; Stage IIA Ovarian Cancer AJCC V6 and v7; Stage IIA Uterine Sarcoma AJCC v7; Stage IIB Fallopian Tube Cancer AJCC v6 and v7; Stage IIB Ovarian Cancer AJCC v6 and v7; Stage IIB Uterine Sarcoma AJCC v7; Stage IIC Fallopian Tube Cancer AJCC v6 and v7; Stage IIC Ovarian Cancer AJCC v6 and v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIA Uterine Sarcoma AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIB Uterine Sarcoma AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IIIC Uterine Sarcoma AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7; Stage IVA Uterine Sarcoma AJCC v7; Stage IVB Uterine Sarcoma AJCC v7; Uterine Carcinosarcoma,Carboplatin (DRUG); Ifosfamide (DRUG); Paclitaxel (DRUG); Quality-of-Life Assessment (OTHER),36314,Zisu,Mixed Mesodermal (Mullerian) Tumor; Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Stage I Ovarian Cancer AJCC v6 and v7; Stage IA Fallopian Tube Cancer AJCC v6 and v7; Stage IA Ovarian Cancer AJCC v6 and v7; Stage IA Uterine Sarcoma AJCC v7; Stage IB Fallopian Tube Cancer AJCC v6 and v7; Stage IB Ovarian Cancer AJCC v6 and v7; Stage IB Uterine Sarcoma AJCC v7; Stage IC Fallopian Tube Cancer AJCC v6 and v7; Stage IC Ovarian Cancer AJCC v6 and v7; Stage IC Uterine Sarcoma AJCC v7; Stage II Ovarian Cancer AJCC v6 and v7; Stage IIA Fallopian Tube Cancer AJCC v6 and v7; Stage IIA Ovarian Cancer AJCC V6 and v7; Stage IIA Uterine Sarcoma AJCC v7; Stage IIB Fallopian Tube Cancer AJCC v6 and v7; Stage IIB Ovarian Cancer AJCC v6 and v7; Stage IIB Uterine Sarcoma AJCC v7; Stage IIC Fallopian Tube Cancer AJCC v6 and v7; Stage IIC Ovarian Cancer AJCC v6 and v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIA Uterine Sarcoma AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIB Uterine Sarcoma AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IIIC Uterine Sarcoma AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7; Stage IVA Uterine Sarcoma AJCC v7; Stage IVB Uterine Sarcoma AJCC v7; Uterine Carcinosarcoma,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6344,NCT06870565,Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma,NOT_YET_RECRUITING,PHASE3,Gastric-type Endocervical Adenocarcinoma; Cervical Cancer,paclitaxel and platinum (DRUG); platinum (DRUG),36314,Zisu,Gastric-type Endocervical Adenocarcinoma; Cervical Cancer,Cervix,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6345,NCT02446574,Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma,COMPLETED,PHASE1,Esophageal Neoplasms,Paclitaxel (DRUG); Cisplatin (DRUG); Radiation (RADIATION),36314,Zisu,Esophageal Neoplasms,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6346,NCT04167774,A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC,UNKNOWN,PHASE2,Non-Small Cell Lung Cancer,Camrelizumab (DRUG); nb-Paclitaxel (DRUG),36314,Zisu,Advanced Non-Small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6347,NCT06704620,Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer,NOT_YET_RECRUITING,PHASE3,Advanced and Metastatic NSCLC,Diphenhydramine (DRUG); Tislelizumab (DRUG); Pemetrexed (DRUG); Albumin paclitaxel (DRUG); Carboplatin (DRUG); Cisplatin (DRUG),36314,Zisu,Non-small Cell Lung Cancer Stage IV,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6348,NCT06795074,Risk of Recurrent Urethral Stricture After Treatment With Paclitaxel-Coated Dilatation Balloon (Optilume) Compared With Non-coated Dilatation Balloon,NOT_YET_RECRUITING,PHASE4,Urethral Stricture,Optilume (COMBINATION_PRODUCT); UroMax Ultra (DEVICE),36314,Zisu,Urethral Stricture,Bladder/Urinary Tract,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6349,NCT03246074,Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer,COMPLETED,PHASE1,Ovarian Cancer,Fostamatinib 100 mg bid and Paclitaxel (DRUG); Fostamatinib 150 mg bid and Paclitaxel (DRUG); Fostamatinib 200 mg bid and Paclitaxel (DRUG),36314,Zisu,Ovarian Cancer,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6350,NCT02039674,A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021),COMPLETED,PHASE1,Non-small Cell Lung Carcinoma,Pembrolizumab (BIOLOGICAL); Paclitaxel (DRUG); Carboplatin (DRUG); Bevacizumab (BIOLOGICAL); Pemetrexed (DRUG); Ipilimumab (BIOLOGICAL); Erlotinib (DRUG); Gefitinib (DRUG),36314,Zisu,Non-small Cell Lung Carcinoma,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6351,NCT00006374,Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer,WITHDRAWN,PHASE2,Lung Cancer,filgrastim (BIOLOGICAL); cisplatin (DRUG); etoposide (DRUG); paclitaxel (DRUG); topotecan hydrochloride (DRUG),36314,Zisu,Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6352,NCT06123520,Laser Visual Internal Urethrotomy With Versus Without Paclitaxel Injection,COMPLETED,PHASE3,"Urethral Stricture, Male",Ho-YAG Laser Visual internal urethrotomy (PROCEDURE); Ho-YAG Laser Visual internal urethrotomy combined with intralesional submucosal injection of Paclitaxel (PROCEDURE),36314,Zisu,"Urethral Stricture, Male",Bladder/Urinary Tract,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6353,NCT02620865,BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer,COMPLETED,PHASE1,Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Aldesleukin (BIOLOGICAL); Antibody Therapy (BIOLOGICAL); Fluorouracil (DRUG); Gemcitabine Hydrochloride (DRUG); Irinotecan Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Leucovorin Calcium (DRUG); Oxaliplatin (DRUG); Paclitaxel Albumin-Stabilized Nanoparticle Formulation (DRUG); Sargramostim (BIOLOGICAL),36314,Zisu,Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6354,NCT05114720,Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer,RECRUITING,PHASE3,Breast Cancer,standard adjuvant chemotherapy plus moxifloxacin (DRUG); standard adjuvant chemotherapy plus placebo (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6355,NCT03244774,Phase I Study of the Combination of Apatinib and POF,UNKNOWN,PHASE1,Gastric Adenocarcinoma,Apatinib (DRUG); POF (DRUG),36314,Zisu,Gastric Adenocarcinoma,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6356,NCT01784120,A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer,UNKNOWN,PHASE2,Metastatic Breast Cancer,Doxorubicin/Genexol-PM (DRUG),36314,Zisu,Metastatic Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6357,NCT06811220,The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients,NOT_YET_RECRUITING,PHASE3,Breast Cancer,Hespiridin and Diosmin (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6358,NCT03472274,Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO),COMPLETED,PHASE2,Bladder Cancer,Durvalumab (DRUG); Tremelimumab (DRUG); Cisplatin-based neoadjuvant chemotherapy (DRUG),36314,Zisu,Bladder Cancer,Bladder/Urinary Tract,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6359,NCT00986674,Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,cixutumumab (BIOLOGICAL); carboplatin (DRUG); paclitaxel (DRUG); cetuximab (BIOLOGICAL),36314,Zisu,Advanced Non-Small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6360,NCT00669565,Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer,COMPLETED,PHASE2,Carcinoma Breast Stage IV,Bavituximab (DRUG),36314,Zisu,Carcinoma Breast Stage IV,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6361,NCT02432365,Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy,UNKNOWN,PHASE2,Cervical Cancer,paclitaxel (DRUG); cisplatin (DRUG); Radical hysterectomy and bilateral pelvic lymphadenectomy (PROCEDURE),36314,Zisu,Cervical Cancer,Cervix,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6362,NCT03663166,Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC),TERMINATED,PHASE1,"Carcinoma, Non-Small-Cell Lung",Thoracic Radiotherapy (RADIATION); Platinum Based Chemotherapy (DRUG); ipilimumab (DRUG); Nivolumab (DRUG),36314,Zisu,"Carcinoma, Non-Small-Cell Lung",Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6363,NCT05485766,Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer,RECRUITING,PHASE2,Triple Negative Breast Neoplasms; Triple Negative Breast Cancer; Breast Neoplasms; Breast Cancer; BRCA1 Mutation; BRCA2 Mutation; BRCA Mutation; BRCA-Associated Breast Carcinoma,Pembrolizumab (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Olaparib (DRUG); Definitive Surgery (PROCEDURE),36314,Zisu,Triple Negative Breast Neoplasms; Triple Negative Breast Cancer; Breast Neoplasms; Breast Cancer; BRCA1 Mutation; BRCA2 Mutation; BRCA Mutation; BRCA-Associated Breast Carcinoma,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6364,NCT01525966,Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Inflammatory Breast Cancer; Stage IIA Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer; Stage IIB Breast Cancer; Estrogen Receptor Negative; Progesterone Receptor Negative; HER2/Neu Negative,carboplatin (DRUG); paclitaxel albumin-stabilized nanoparticle formulation (DRUG); laboratory biomarker analysis (OTHER),36314,Zisu,Inflammatory Breast Cancer; Stage IIA Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer; Stage IIB Breast Cancer; Estrogen Receptor Negative; Progesterone Receptor Negative; HER2/Neu Negative,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6365,NCT00479765,A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma,TERMINATED,PHASE1,Glioblastoma Multiforme; Brain Neoplasms,OncoGel (ReGel/Paclitaxel) (DRUG),36314,Zisu,Glioblastoma Multiforme; Brain Neoplasms,CNS/Brain,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6366,NCT03833466,Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo),UNKNOWN,PHASE2,Esophageal Squamous Cell Carcinoma,metformin and chemotherapy (DRUG),36314,Zisu,Esophageal Squamous Cell Carcinoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6367,NCT06198465,Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma,NOT_YET_RECRUITING,PHASE2,Adebrelimab; Esophageal Cancer; Perioperative Period,"adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil (DRUG)",36314,Zisu,Adebrelimab; Esophageal Cancer; Perioperative Period,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6368,NCT00466466,Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients,COMPLETED,PHASE1,Small-Cell Lung Cancer,Everolimus (DRUG),36314,Zisu,Small-Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6369,NCT06199466,A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Pancreatic Cancer,Gemcitabine (DRUG); Nab-paclitaxel (DRUG); YL-13027 (DRUG),36314,Zisu,Metastatic Pancreatic Cancer,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6370,NCT03322566,A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06),COMPLETED,PHASE2,Lung Cancer,Pembrolizumab (DRUG); Epacadostat (DRUG); Platinum-based chemotherapy (DRUG); Placebo (DRUG),36314,Zisu,Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6371,NCT01107626,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,COMPLETED,PHASE3,Lung Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Bevacizumab (BIOLOGICAL); Pemetrexed Disodium Heptahydrate (DRUG),36314,Zisu,Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6372,NCT00003326,"Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus",UNKNOWN,PHASE2,Esophageal Cancer,paclitaxel (DRUG),36314,Zisu,Esophageal Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6373,NCT06393166,Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer,RECRUITING,PHASE2,Non-Resectable Pancreas Carcinoma,Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection (DRUG),36314,Zisu,Non-Resectable Pancreas Carcinoma,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6374,NCT00998166,A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy,TERMINATED,PHASE2,Non-Small Cell Lung Cancer,Pemetrexed (DRUG); Cisplatin (DRUG); Bevacizumab (DRUG),36314,Zisu,Advanced Non-Small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6375,NCT00096226,"Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer",COMPLETED,PHASE2,Lung Cancer,Induction Carboplatin (DRUG); Induction Paclitaxel (DRUG); Resection (PROCEDURE); Consolidation Carboplatin (DRUG); Radiation Therapy (RADIATION); Consolidation Paclitaxel (DRUG),36314,Zisu,Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6376,NCT00470366,Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors,COMPLETED,PHASE2,Brain and Central Nervous System Tumors; Extragonadal Germ Cell Tumor; Ovarian Cancer; Teratoma; Testicular Germ Cell Tumor,pegfilgrastim (BIOLOGICAL); cisplatin (DRUG); ifosfamide (DRUG); paclitaxel (DRUG),36314,Zisu,Brain and Central Nervous System Tumors; Extragonadal Germ Cell Tumor; Ovarian Cancer; Teratoma; Testicular Germ Cell Tumor,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6377,NCT00434226,"A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)",TERMINATED,PHASE2,Non-Small Cell Lung Cancer,bevacizumab (DRUG); sunitinib (DRUG); carboplatin (DRUG); paclitaxel (DRUG),36314,Zisu,Advanced Non-Small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6378,NCT02754726,Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma,COMPLETED,PHASE2,Untreated Metastatic Pancreatic Ductal Adenocarcinoma,Nivolumab (DRUG); Albumin-bound paclitaxel (DRUG); Paricalcitol (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG),36314,Zisu,Untreated Metastatic Pancreatic Ductal Adenocarcinoma,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6379,NCT04460066,A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.,UNKNOWN,PHASE1,Esophageal Cancer,anti-PD-L1 antibody (DRUG); albumin bound paclitaxel (DRUG); cisplatin (DRUG); placebo (DRUG); radical resection of esophageal carcinoma (PROCEDURE),36314,Zisu,Esophageal Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6380,NCT04233866,"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Fluorouracil (DRUG); Gemcitabine (DRUG); Gemcitabine Hydrochloride (DRUG); Leucovorin (DRUG); Leucovorin Calcium (DRUG); Liposomal Irinotecan (DRUG); Nab-paclitaxel (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),36314,Zisu,Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6381,NCT05249426,"A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Head and Neck Squamous Cell Carcinoma (HNSCC),BI 765063 (DRUG); Ezabenlimab (DRUG); BI 836880 (DRUG); Cetuximab (DRUG); Investigator´s Choice Chemotherapy (OTHER),36314,Zisu,Head and Neck Squamous Cell Carcinoma (HNSCC),Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6382,NCT05024266,Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma,UNKNOWN,PHASE2,Lung Squamous Cell Carcinoma; Neoadjuvant Therapy; Immunotherapy,Tislelizumab (DRUG),36314,Zisu,Lung Squamous Cell Carcinoma; Neoadjuvant Therapy; Immunotherapy,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6383,NCT05449366,Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma,RECRUITING,PHASE1,Peritoneal Malignant Mesothelioma,Intraperitoneal Paclitaxel Solution (Ml) (DRUG),36314,Zisu,Peritoneal Malignant Mesothelioma,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6384,NCT06714266,Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,NOT_YET_RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma (HNSCC),Trilaciclib (DRUG),36314,Zisu,Head and Neck Squamous Cell Carcinoma (HNSCC),Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6385,NCT05494866,A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma,TERMINATED,PHASE1,CYP3A Inhibitor; Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Pancreatic Adenocarcinoma; Pancreatic Neoplasm,Cobicistat Oral Tablet (DRUG); Gemcitabin (DRUG); Nab paclitaxel (DRUG),36314,Zisu,CYP3A Inhibitor; Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Pancreatic Adenocarcinoma; Pancreatic Neoplasm,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6386,NCT06786026,QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC,RECRUITING,PHASE2,"TNBC, Triple Negative Breast Cancer",bevacizumab (DRUG); QL1706 (DRUG); Nab paclitaxel (DRUG),36314,Zisu,"TNBC, Triple Negative Breast Cancer",Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6387,NCT05183126,Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer,RECRUITING,PHASE4,Breast Cancer; Metastatic Gastric Cancer; Esophageal Cancer,Paclitaxel (DRUG); Paclitaxel (DRUG),36314,Zisu,Breast Cancer; Metastatic Gastric Cancer; Esophageal Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6388,NCT02626520,Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla,TERMINATED,PHASE2,Ductal Adenocarcinoma of Pancreas; Adenocarcinoma of Ampulla,Gemcitabine and nanoparticle albumin bound paclitaxel (DRUG); 5-fluorouracil and irinotecan (DRUG); Preoperative chemoradiation (RADIATION); Definitive resection (PROCEDURE),36314,Zisu,Ductal Adenocarcinoma of Pancreas; Adenocarcinoma of Ampulla,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6389,NCT02413320,Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer,COMPLETED,PHASE2,Triple-negative Breast Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG),36314,Zisu,Triple-negative Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6390,NCT00238420,Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer,COMPLETED,PHASE1,Bladder Urothelial Carcinoma; Stage I Bladder Cancer AJCC v6 and v7; Stage II Bladder Cancer AJCC v6 and v7; Stage III Bladder Cancer AJCC v6 and v7,Paclitaxel (DRUG); Radiation Therapy (RADIATION); Trastuzumab (BIOLOGICAL),36314,Zisu,Bladder Urothelial Carcinoma; Stage I Bladder Cancer AJCC v6 and v7; Stage II Bladder Cancer AJCC v6 and v7; Stage III Bladder Cancer AJCC v6 and v7,Bladder/Urinary Tract,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6391,NCT01044420,mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial,UNKNOWN,PHASE2,Advanced Esophageal Carcinoma,mFOLFIRI (DRUG),36314,Zisu,Advanced Esophageal Carcinoma,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6392,NCT05444374,A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer,NOT_YET_RECRUITING,PHASE2,Cervical Cancer,Serplulimab (DRUG); Bevacizumab (DRUG),36314,Zisu,Cervical Cancer,Cervix,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6393,NCT00130520,Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer,COMPLETED,PHASE2,Ovarian Neoplasms,bevacizumab (DRUG); erlotinib (DRUG),36314,Zisu,Ovarian Neoplasms,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6394,NCT05298020,Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer,UNKNOWN,PHASE2,Advanced Pancreatic Cancer,Envafolimab (DRUG); Endostar (DRUG); Nab paclitaxel (DRUG); Gemcitabine (DRUG),36314,Zisu,Advanced Pancreatic Cancer,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6395,NCT03138720,Pre-operative Treatment for Patients With Untreated Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Resectable Pancreatic Cancer; Unresectable Pancreatic Cancer; Pancreatic Adenocarcinoma; Neoadjuvant Pancreatic Cancer,Paclitaxel Protein Bound (Abraxane) (DRUG),36314,Zisu,Resectable Pancreatic Cancer; Unresectable Pancreatic Cancer; Pancreatic Adenocarcinoma; Neoadjuvant Pancreatic Cancer,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6396,NCT00101920,ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,Non-small Cell Lung Cancer; Neoplasm Metastasis; Lung Cancer,ABX-EGF (DRUG),36314,Zisu,Non-small Cell Lung Cancer; Neoplasm Metastasis; Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6397,NCT03550482,Oncoxin® and Quality of Life in Cancer Patients,COMPLETED,PHASE4,Gastric Cancer Stage II; Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage III; Gastric Cancer Stage III,ONCOXIN® (DIETARY_SUPPLEMENT),36314,Zisu,Gastric Cancer Stage II; Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage III; Gastric Cancer Stage III,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6398,NCT04733820,Clinical Efficacy of Adjuvant Chemotherapy in Patients With Locally Advanced Cervical Cancer Who Did Not Meet the NCCN Guidelines for Adjuvant Treatment After NACT Combined With Surgery,RECRUITING,PHASE3,Uterine Cervical Neoplasms; Cervical Cancer,Adjuvant chemotherapy (DRUG),36314,Zisu,Uterine Cervical Neoplasms; Cervical Cancer,Cervix,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6399,NCT05684731,Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer,RECRUITING,PHASE1,Ovarian Cancer,KM1 (BIOLOGICAL); Chemotherapy (DRUG),36314,Zisu,Ovarian Cancer,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6400,NCT04807673,Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002),RECRUITING,PHASE3,Esophageal Squamous Cell Carcinoma,Pembrolizumab (BIOLOGICAL); Paclitaxel (DRUG); Cisplatin (DRUG); neoadjuvant chemoradiotherapy (RADIATION),36314,Zisu,Esophageal Squamous Cell Carcinoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6401,NCT06251973,"A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer",RECRUITING,PHASE2,Metastatic Esophageal Carcinoma; Advanced Unresectable Gastric Adenocarcinoma; Metastatic Gastric Cancer; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Esophageal Cancer; Metastatic Esophageal Adenocarcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastric Carcinoma; Unresectable Esophageal Cancer; Unresectable Esophageal Adenocarcinoma; Unresectable Gastric Carcinoma; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma,AgenT-797 (BIOLOGICAL); Botensilimab (BIOLOGICAL); Balstilimab (DRUG); Ramucirumab (DRUG); Paclitaxel (DRUG),36314,Zisu,Metastatic Esophageal Carcinoma; Advanced Unresectable Gastric Adenocarcinoma; Metastatic Gastric Cancer; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Esophageal Cancer; Metastatic Esophageal Adenocarcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastric Carcinoma; Unresectable Esophageal Cancer; Unresectable Esophageal Adenocarcinoma; Unresectable Gastric Carcinoma; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6402,NCT06358573,Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK,RECRUITING,PHASE2,Triple-negative Breast Cancer; TNBC - Triple-Negative Breast Cancer,INT230-6 (DRUG); neoadjuvant immuno-chemotherapy (OTHER),36314,Zisu,Triple-negative Breast Cancer; TNBC - Triple-Negative Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6403,NCT00014573,Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer,COMPLETED,PHASE2,Brain and Central Nervous System Tumors,aldesleukin (BIOLOGICAL); autologous tumor cell vaccine (BIOLOGICAL); filgrastim (BIOLOGICAL); sargramostim (BIOLOGICAL); therapeutic autologous lymphocytes (BIOLOGICAL); carmustine (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); paclitaxel (DRUG); autologous bone marrow transplantation (PROCEDURE); conventional surgery (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE),36314,Zisu,Brain and Central Nervous System Tumors,CNS/Brain,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6404,NCT04054531,Study of KN046 With Chemotherapy in First Line Advanced NSCLC,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,KN046 (BIOLOGICAL); Paclitaxel (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),36314,Zisu,Non-small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6405,NCT00976573,"Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",COMPLETED,PHASE2,Melanoma (Skin),bevacizumab (BIOLOGICAL); carboplatin (DRUG); everolimus (DRUG); paclitaxel (DRUG),36314,Zisu,Melanoma (Skin),Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6406,NCT00625573,Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01),COMPLETED,PHASE2,Colorectal Cancer,Abraxane (DRUG),36314,Zisu,Colorectal Cancer,Bowel,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6407,NCT04937673,The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma,UNKNOWN,PHASE2,Thoracic Esophageal Squamous Cell Carcinoma,Camrelizumab+Albumin bound paclitaxel+Cisplatin (DRUG); Camrelizumab+ Paclitaxel+ Cisplatin (DRUG),36314,Zisu,Thoracic Esophageal Squamous Cell Carcinoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6408,NCT05276973,Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Unresectable Fallopian Tube Endometrioid Adenocarcinoma; Unresectable Fallopian Tube High Grade Serous Adenocarcinoma; Unresectable Ovarian Endometrioid Adenocarcinoma; Unresectable Ovarian High Grade Serous Adenocarcinoma; Unresectable Primary Peritoneal Endometrioid Adenocarcinoma; Unresectable Primary Peritoneal High Grade Serous Adenocarcinoma,Biopsy (PROCEDURE); Carboplatin (DRUG); Ipatasertib (DRUG); Paclitaxel (DRUG),36314,Zisu,Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Unresectable Fallopian Tube Endometrioid Adenocarcinoma; Unresectable Fallopian Tube High Grade Serous Adenocarcinoma; Unresectable Ovarian Endometrioid Adenocarcinoma; Unresectable Ovarian High Grade Serous Adenocarcinoma; Unresectable Primary Peritoneal Endometrioid Adenocarcinoma; Unresectable Primary Peritoneal High Grade Serous Adenocarcinoma,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6409,NCT05870748,REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1,RECRUITING,PHASE2,Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Platinum-resistant Ovarian Cancer,Luveltamab tazevibulin (DRUG); Pegfilgrastim (DRUG); Gemcitabine (DRUG); Paclitaxel (DRUG); Pegylated liposomal doxorubicin (DRUG); Topotecan (DRUG),36314,Zisu,Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Platinum-resistant Ovarian Cancer,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6410,NCT04374630,Study with Afuresertib and Paclitaxel in Platinum Resistant Ovarian,COMPLETED,PHASE2,Platinum-resistant Ovarian Cancer,Paclitaxel (DRUG); Afuresertib (DRUG),36314,Zisu,Platinum-resistant Ovarian Cancer,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6411,NCT05149326,KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.,ACTIVE_NOT_RECRUITING,PHASE3,Advanced Pancreatic Ductal Adenocarcinoma,KN046 (DRUG); placebo (DRUG),36314,Zisu,Advanced Pancreatic Ductal Adenocarcinoma,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6412,NCT03355157,"A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).",COMPLETED,PHASE4,Metastatic Breast Cancer,"Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen) (DRUG)",36314,Zisu,Metastatic Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6413,NCT04196257,BP1001-A in Patients With Advanced or Recurrent Solid Tumors,RECRUITING,PHASE1,"Solid Tumor, Adult; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Endometrial Cancer; Peritoneal Cancer; Solid Tumor",BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) (DRUG); BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel (DRUG),36314,Zisu,"Solid Tumor, Adult; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Endometrial Cancer; Peritoneal Cancer; Solid Tumor",Uterus,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6414,NCT01583426,Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto),COMPLETED,PHASE3,Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer,nab-Paclitaxel (DRUG); Paclitaxel (DRUG),36314,Zisu,Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6415,NCT01383148,Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer,TERMINATED,PHASE2,Non-Small-Cell Lung Carcinoma,TG4010 (BIOLOGICAL); placebo (DRUG),36314,Zisu,Non-Small-Cell Lung Carcinoma,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6416,NCT03101748,Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Breast Inflammatory Carcinoma; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7,Cyclophosphamide (DRUG); Doxorubicin (DRUG); Laboratory Biomarker Analysis (OTHER); Neratinib (DRUG); Paclitaxel (DRUG); Pertuzumab (BIOLOGICAL); Trastuzumab (BIOLOGICAL),36314,Zisu,Breast Inflammatory Carcinoma; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6417,NCT01964430,"Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the ""Apact"" Study)",COMPLETED,PHASE3,"Pancreatic Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Digestive System Diseases; Endocrine System Diseases; Gemcitabine; Antimetabolites, Antineoplastic",nab-Paclitaxel (DRUG); Gemcitabine (DRUG),36314,Zisu,"Pancreatic Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Digestive System Diseases; Endocrine System Diseases; Gemcitabine; Antimetabolites, Antineoplastic",Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6418,NCT04267848,"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial",RECRUITING,PHASE3,Lung Non-Small Cell Carcinoma; Lung Non-Small Cell Squamous Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Gemcitabine Hydrochloride (DRUG); Magnetic Resonance Imaging (PROCEDURE); Observation Activity (OTHER); Paclitaxel (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed Disodium (DRUG); Questionnaire Administration (OTHER),36314,Zisu,Lung Non-Small Cell Carcinoma; Lung Non-Small Cell Squamous Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6419,NCT06837948,Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC,NOT_YET_RECRUITING,PHASE2,Locally Advanced Non-Small Cell Lung Cancer,PM8002 (DRUG); Sintilimab (DRUG); Nab-paclitaxel (DRUG); Carboplatin (DRUG); Surgery (PROCEDURE),36314,Zisu,Locally Advanced Non-Small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6420,NCT05420948,A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer,RECRUITING,PHASE2,Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Head and Neck Neoplasms; Head Cancer; Throat Carcinoma,Pembrolizumab (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG),36314,Zisu,Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Head and Neck Neoplasms; Head Cancer; Throat Carcinoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6421,NCT02615730,"PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma",COMPLETED,PHASE1,Advanced Gastric Adenocarcinoma,GSK2636771 (DRUG); Paclitaxel (DRUG),36314,Zisu,Advanced Gastric Adenocarcinoma,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6422,NCT00596830,"Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology",TERMINATED,PHASE3,"Carcinoma, Squamous Cell; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung","CP-751,871 (Figitumumab) (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG)",36314,Zisu,"Carcinoma, Squamous Cell; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung",Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6423,NCT02629848,Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer,TERMINATED,PHASE3,"Carcinoma, Non-Small-Cell Lung",Motesanib (DRUG); Placebo (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG),36314,Zisu,"Carcinoma, Non-Small-Cell Lung",Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6424,NCT00154882,Paclitaxel (Phyxol) and Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,"Paclitaxel (Phyxol) , Cisplatin (DRUG)",36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6425,NCT04192331,Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,nab-paclitaxel regimen1 (DRUG); nab-paclitaxel regimen2 (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6426,NCT05009082,Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer,RECRUITING,PHASE3,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer,Carboplatin (DRUG); Paclitaxel (DRUG); Bevacizumab (DRUG); Niraparib (DRUG),36314,Zisu,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6427,NCT02754882,A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer,COMPLETED,PHASE3,Lung Cancer; Non-small Cell Lung Cancer,Bevacizumab (DRUG); SB8 (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG),36314,Zisu,Lung Cancer; Non-small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6428,NCT05834582,Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer,RECRUITING,PHASE2,TNBC - Triple-Negative Breast Cancer,Fluzoparib+Paclitaxel (DRUG); Epirubicin+Cyclophosphamide (DRUG),36314,Zisu,TNBC - Triple-Negative Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6429,NCT04906382,Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer,TERMINATED,EARLY_PHASE1,Lynch Syndrome; Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Uterine Corpus Carcinosarcoma; Mismatch Repair Deficiency; Recurrent Endometrial Cancer; Metastatic Endometrial Cancer,Biopsy (PROCEDURE); Carboplatin (DRUG); Paclitaxel (DRUG); Tislelizumab (BIOLOGICAL),36314,Zisu,Lynch Syndrome; Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Uterine Corpus Carcinosarcoma; Mismatch Repair Deficiency; Recurrent Endometrial Cancer; Metastatic Endometrial Cancer,Uterus,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6430,NCT06908382,Neoadjuvant QL1706 Therapy for ESCC,RECRUITING,PHASE2,Locally Advanced Resectable Esophageal Squamous Cell Carcinoma,Iparomlimab and Tuvonralimab Injection (DRUG),36314,Zisu,Locally Advanced Resectable Esophageal Squamous Cell Carcinoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6431,NCT01839773,Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer,COMPLETED,PHASE3,Stage IV Gastric Cancer,Paclitaxel (DRUG); Paclitaxel (DRUG),36314,Zisu,Stage IV Gastric Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6432,NCT05488873,A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy,ACTIVE_NOT_RECRUITING,PHASE2,Chemotherapy-induced Peripheral Neuropathy,WST-057 Active (DRUG); Placebo (DRUG),36314,Zisu,Chemotherapy-induced Peripheral Neuropathy,Peripheral Nervous System,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6433,NCT02142790,Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer,UNKNOWN,PHASE4,Breast Cancer,paclitaxel liposome injection (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6434,NCT04840290,A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC,UNKNOWN,PHASE3,Non Small Cell Lung Cancer,Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin (DRUG),36314,Zisu,Non Small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6435,NCT00352690,"A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer",TERMINATED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Paclitaxel poliglumex (DRUG); Carboplatin (DRUG); External beam radiation therapy (RADIATION),36314,Zisu,"Carcinoma, Non-Small-Cell Lung",Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6436,NCT00017303,Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer,UNKNOWN,PHASE2,Ovarian Cancer; Primary Peritoneal Cavity Cancer,carboplatin (DRUG); oglufanide disodium (DRUG); paclitaxel (DRUG); conventional surgery (PROCEDURE),36314,Zisu,Ovarian Cancer,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6437,NCT06010303,A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma,ACTIVE_NOT_RECRUITING,PHASE2,Esophageal Cancer; Esophageal Squamous Cell Carcinoma; Esophageal Squamous Cell Carcinoma by AJCC V8 Stage,LBL-007 (DRUG); Tislelizumab (DRUG); Chemotherapy Doublet (DRUG),36314,Zisu,Esophageal Cancer; Esophageal Squamous Cell Carcinoma; Esophageal Squamous Cell Carcinoma by AJCC V8 Stage,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6438,NCT05465590,A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer,WITHDRAWN,EARLY_PHASE1,Advanced Solid Tumor; Breast Cancer; Non Small Cell Lung Cancer; Ovary Cancer; Pancreatic Neoplasms,MB1707 (DRUG),36314,Zisu,Advanced Solid Tumor; Breast Cancer; Non Small Cell Lung Cancer; Ovary Cancer; Pancreatic Neoplasms,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6439,NCT06896890,Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer,RECRUITING,PHASE1,NSCLC (advanced Non-small Cell Lung Cancer); Stage IV Lung Cancer,CIS-DPI (DRUG),36314,Zisu,NSCLC (advanced Non-small Cell Lung Cancer); Stage IV Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6440,NCT01620190,Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer,COMPLETED,PHASE2,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Laboratory Biomarker Analysis (OTHER); Paclitaxel Albumin-Stabilized Nanoparticle Formulation (DRUG),36314,Zisu,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6441,NCT01616303,A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer,COMPLETED,PHASE2,Ovarian Neoplasms,Carboplatin (DRUG); Paclitaxel (DRUG); oregovomab (BIOLOGICAL),36314,Zisu,Ovarian Neoplasms,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6442,NCT03991403,Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC,UNKNOWN,PHASE3,Non-small Cell Lung Cancer,Atezolizumab(Tecentriq) (DRUG); Pemetrexed (DRUG); Bevacizumab (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Carboplatin or cisplatin (DRUG),36314,Zisu,Non-small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6443,NCT02121990,"Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",COMPLETED,PHASE1,Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer,"Paclitaxel, (DRUG); Bevacizumab (DRUG); Cisplatin (DRUG); Olaparib (DRUG)",36314,Zisu,Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6444,NCT02931890,Multicentric Randomised Trial for Resectable Gastric Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Gastric Cancer,Docetaxel (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG); gastrectomy (PROCEDURE); radiotherapy of gastric cancer (RADIATION); Paclitaxel (DRUG); Carboplatin (DRUG),36314,Zisu,Gastric Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6445,NCT05074290,Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients,RECRUITING,PHASE1,Breast Cancer,Epidiferphane (DRUG); Taxane Chemotherapy (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6446,NCT04714190,A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression,RECRUITING,PHASE3,Gastric Cancer; HER2 Overexpressing Gastric Carcinoma,RC48-ADC (DRUG); Paclitaxel injection (DRUG); Irinotecan Hydrochloride Injection (DRUG); Apatinib Mesylate Tablets (DRUG),36314,Zisu,Gastric Cancer; HER2 Overexpressing Gastric Carcinoma,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6447,NCT03064490,"Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)",COMPLETED,PHASE2,Locally Advanced Esophageal and Gastric Cancers (EGC),Pembrolizumab (DRUG),36314,Zisu,Locally Advanced Esophageal and Gastric Cancers (EGC),Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6448,NCT03193190,A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer),COMPLETED,PHASE1,Pancreatic Adenocarcinoma,Nab-Paclitaxel (DRUG); Gemcitabine (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); Fluorouracil (DRUG); Atezolizumab (DRUG); Cobimetinib (DRUG); PEGPH20 (DRUG); BL-8040 (DRUG); Selicrelumab (DRUG); Bevacizumab (DRUG); RO6874281 (DRUG); AB928 (DRUG); Tiragolumab (DRUG); Tocilizumab (DRUG),36314,Zisu,Pancreatic Adenocarcinoma,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6449,NCT05889390,Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,HER2-negative Breast Cancer,Oncotherm EHY-2030 (DEVICE); Paclitaxel (DRUG); Carboplatin (DRUG); Cyclophosphamide/Doxorubicin (DRUG); Breast cancer removal surgery (PROCEDURE),36314,Zisu,HER2-negative Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6450,NCT00226590,Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC,COMPLETED,PHASE2,Lung Cancer,Gemcitabine (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Radiation (PROCEDURE),36314,Zisu,Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6451,NCT04666090,"Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma",ACTIVE_NOT_RECRUITING,PHASE2,Esophageal Squamous Cell Carcinoma; Neoadjuvant Therapy,Carillizumab (DRUG); Esophagectomy (PROCEDURE); Samples (OTHER),36314,Zisu,Esophageal Squamous Cell Carcinoma; Neoadjuvant Therapy,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6452,NCT04914390,A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer,RECRUITING,PHASE2,Triple-negative Breast Cancer,AT regimen (DRUG); Tislelizumab (DRUG); Anlotinib (DRUG),36314,Zisu,Triple-negative Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6453,NCT02506803,Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer.,UNKNOWN,PHASE1,Pancreatic Cancer,NAC-GEMABR (DRUG),36314,Zisu,Pancreatic Cancer,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6454,NCT04811703,Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer,RECRUITING,PHASE1,Metastatic Ovarian Carcinoma; Peritoneal Carcinomatosis; Stage III Ovarian Cancer; Stage IV Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Metastatic Malignant Neoplasm in the Peritoneum,Combined PIPAC / IV chemotherapy treatment (DRUG),36314,Zisu,Metastatic Ovarian Carcinoma; Peritoneal Carcinomatosis; Stage III Ovarian Cancer; Stage IV Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Metastatic Malignant Neoplasm in the Peritoneum,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6455,NCT01959490,Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer,COMPLETED,PHASE2,Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,trastuzumab (BIOLOGICAL); Pertuzumab (BIOLOGICAL); docetaxel (DRUG); carboplatin (DRUG); doxorubicin (DRUG); cyclophosphamide (DRUG); paclitaxel (DRUG); Bevacizumab (DRUG),36314,Zisu,Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6456,NCT03520790,Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer,TERMINATED,PHASE1,Pancreatic Cancer,Gemcitabine (DRUG); Nab-paclitaxel (DRUG); Paricalcitol (DRUG); Placebo (OTHER),36314,Zisu,Pancreatic Cancer,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6457,NCT00034190,Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma,COMPLETED,PHASE2,Colorectal Adenocarcinoma,S-8184 Paclitaxel Injectable Emulsion (DRUG),36314,Zisu,Colorectal Adenocarcinoma,Bowel,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6458,NCT00049790,Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",recombinant human Angiostatin protein (DRUG); paclitaxel (DRUG); carboplatin (DRUG),36314,Zisu,"Carcinoma, Non-Small-Cell Lung",Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6459,NCT06441890,BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer,RECRUITING,PHASE2,Breast Cancer; HER2-positive Breast Cancer,Paclitaxel (DRUG); Nab-paclitaxel (DRUG); Docetaxel (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG),36314,Zisu,Breast Cancer; HER2-positive Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6460,NCT05429684,Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer,UNKNOWN,PHASE3,HER2+ Breast Cancer,Trastuzumab (DRUG); Pertuzumab (DRUG); Nab paclitaxel (DRUG); Pyrotinib (DRUG); Capecitabine (DRUG); T-DM1 (DRUG); Everolimus (DRUG); CDK4/6 inhibitor (DRUG); AI (DRUG); Anti-PD-1 monoclonal antibody (DRUG),36314,Zisu,HER2+ Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6461,NCT05247684,AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC,UNKNOWN,PHASE2,Resectable Non-small Cell Lung Cancer,AK112 (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Paclitaxel (DRUG),36314,Zisu,Resectable Non-small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6462,NCT01486602,Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,COMPLETED,PHASE1,Lung Cancer,carboplatin (DRUG); paclitaxel (DRUG); radiation therapy (RADIATION),36314,Zisu,Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6463,NCT00028990,Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer,COMPLETED,PHASE3,Breast Cancer,bevacizumab (DRUG); Paclitaxel (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6464,NCT00078390,Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Non Small Cell Lung Cancer; Lung Cancer; Stage IIIA Non Small Cell Lung Cancer; Stage IIIB Non Small Cell Lung Cancer,S-3304 (DRUG); Chemo-irradiation (OTHER),36314,Zisu,Non Small Cell Lung Cancer; Lung Cancer; Stage IIIA Non Small Cell Lung Cancer; Stage IIIB Non Small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6465,NCT03957590,A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma,COMPLETED,PHASE3,Esophageal Squamous Cell Carcinoma (ESCC),Tislelizumab (DRUG); Placebo (DRUG); Paclitaxel (DRUG); Cisplatin (DRUG); Radiotherapy (RADIATION),36314,Zisu,Esophageal Squamous Cell Carcinoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6466,NCT04237090,Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel,COMPLETED,PHASE3,Breast Cancer; Lung Cancer; Ovarian Cancer; Oesophageal Cancer; Head Cancer Neck; Cervical Cancer; Endometrial Cancer,Diphenhydramine (DRUG); Cetirizine (DRUG); Lactose pill (DRUG); Sodium chloride 0.9% (DRUG),36314,Zisu,Breast Cancer; Lung Cancer; Ovarian Cancer; Oesophageal Cancer; Head Cancer Neck; Cervical Cancer; Endometrial Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6467,NCT05019690,Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer,RECRUITING,PHASE1,Advanced Triple Negative Breast Cancer,Apatinib Mesylate (DRUG); Albumin-Bound Paclitaxel (DRUG),36314,Zisu,Advanced Triple Negative Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6468,NCT02687490,Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Abraxane (DRUG),36314,Zisu,Metastatic Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6469,NCT00499603,Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Paclitaxel (DRUG); 5-Fluorouracil (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); RAD001 (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6470,NCT01962103,Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors,COMPLETED,PHASE1,"Neuroblastoma; Rhabdomyosarcoma; Ewing's Sarcoma; Ewing's Tumor; Sarcoma, Ewing's; Sarcomas, Epitheliod; Sarcoma, Soft Tissue; Sarcoma, Spindle Cell; Melanoma; Malignant Melanoma; Clinical Oncology; Oncology, Medical; Pediatrics, Osteosarcoma; Osteogenic Sarcoma; Osteosarcoma Tumor; Sarcoma, Osteogenic; Tumors; Cancer; Neoplasia; Neoplasm; Histiocytoma; Fibrosarcoma; Dermatofibrosarcoma",nab-paclitaxel (DRUG); nab-paclitaxel (DRUG),36314,Zisu,"Neuroblastoma; Rhabdomyosarcoma; Ewing's Sarcoma; Ewing's Tumor; Sarcoma, Ewing's; Sarcomas, Epitheliod; Sarcoma, Soft Tissue; Sarcoma, Spindle Cell; Melanoma; Malignant Melanoma; Clinical Oncology; Oncology, Medical; Pediatrics, Osteosarcoma; Osteogenic Sarcoma; Osteosarcoma Tumor; Sarcoma, Osteogenic; Tumors; Cancer; Neoplasia; Neoplasm; Histiocytoma; Fibrosarcoma; Dermatofibrosarcoma",Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6471,NCT01248403,"A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy",COMPLETED,PHASE3,Advanced Gastric Cancer; Esophagogastric Junction Cancer,Paclitaxel (DRUG); RAD001 (DRUG),36314,Zisu,Advanced Gastric Cancer; Esophagogastric Junction Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6472,NCT03112590,Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer,COMPLETED,PHASE1,"Breast Cancer; Breast Cancer, Male; Breast Cancer Female; HER2-positive Breast Cancer",Interferon-gamma (IFN-γ) (BIOLOGICAL); Paclitaxel (DRUG); Trastuzumab (DRUG); Pertuzumab (OTHER); Post Therapy Surgery (PROCEDURE),36314,Zisu,"Breast Cancer; Breast Cancer, Male; Breast Cancer Female; HER2-positive Breast Cancer",Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6473,NCT00542490,Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer,COMPLETED,PHASE2,Endometrial Cancer; Papillary Serous; Clear Cell Endometrial Cancer,Vaginal Cuff Brachytherapy (RADIATION),36314,Zisu,Endometrial Cancer; Papillary Serous; Clear Cell Endometrial Cancer,Uterus,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6474,NCT02861690,Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal Carcinoma,COMPLETED,PHASE2,Esophageal Carcinoma,Liposomal Paclitaxel (DRUG); Nedaplatin (DRUG),36314,Zisu,Esophageal Carcinoma,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6475,NCT04066790,Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Pyrotinib (DRUG); nab-Paclitaxel (DRUG); Trastuzumab (DRUG); EC chemotherapy (DRUG); Surgery (PROCEDURE),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6476,NCT01704690,Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer,TERMINATED,PHASE2,Esophageal Cancer,S-1 and Paclitaxel (DRUG); Paclitaxel and Cisplatin (DRUG); 5-FU and Cisplatin (DRUG),36314,Zisu,Esophageal Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6477,NCT00014690,"ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",COMPLETED,PHASE2,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,plevitrexed (DRUG); topotecan hydrochloride (DRUG),36314,Zisu,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6478,NCT01850303,Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer,COMPLETED,PHASE3,Non Small Cell Lung Cancer (Squamous or Non Squamous),Pemetrexed (DRUG); Gemcitabine (DRUG); Induction chemotherapy (DRUG),36314,Zisu,Non-Small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6479,NCT02688803,Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC),COMPLETED,PHASE4,Breast Cancer,Dose dense AC-P (DRUG); Dose dense AC (DRUG); FEC-D (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6480,NCT01966003,Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE3,Non-small Cell Lung Cancer Metastatic,Carboplatin (DRUG); Paclitaxel (DRUG); ABP 215 (DRUG); Bevacizumab (DRUG),36314,Zisu,Non-small Cell Lung Cancer Metastatic,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6481,NCT04194203,"A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)",COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung",Atezolizumab (DRUG); Placebo (DRUG); Bevacizumab (DRUG); Paclitaxel (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),36314,Zisu,"Carcinoma, Non-Small-Cell Lung",Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6482,NCT05596890,Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients,RECRUITING,PHASE2,Esophageal Squamous Cell Carcinoma; Patient-reported Outcomes; Immunotherapy,Paclitaxel-albumin (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Tislelizumab (DRUG); VMAT or IMRT (RADIATION); Esophagectomy (PROCEDURE),36314,Zisu,Esophageal Squamous Cell Carcinoma; Patient-reported Outcomes; Immunotherapy,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6483,NCT04222790,A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity,COMPLETED,PHASE2,Early Breast Cancer,monosialic gangliosides (DRUG); Placebo (OTHER),36314,Zisu,Early Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6484,NCT06422143,Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023],RECRUITING,PHASE3,Non-small Cell Lung Cancer; NSCLC,Pembrolizumab (BIOLOGICAL); sac-TMT (BIOLOGICAL); Carboplatin (DRUG); Paclitaxel (DRUG); Nab-paclitaxel (DRUG),36314,Zisu,Non-small Cell Lung Cancer; NSCLC,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6485,NCT06175390,"Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer",RECRUITING,PHASE2,Triple Negative Breast Cancer,68Ga-FAPI-46 PET/CT (RADIATION); Tumor samples analysis (BIOLOGICAL); Blood samples analysis: Circulating Tumor DNA (BIOLOGICAL),36314,Zisu,Triple Negative Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6486,NCT00526890,"Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery",TERMINATED,PHASE2,Lung Cancer,selenomethionine (DIETARY_SUPPLEMENT); carboplatin (DRUG); paclitaxel (DRUG); laboratory biomarker analysis (OTHER); radiation therapy (RADIATION),36314,Zisu,Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6487,NCT03990103,S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites,UNKNOWN,PHASE2,Metastatic Gastric Adenocarcinoma,S1 (DRUG); Paclitaxel (DRUG); Bevacizumab (DRUG); Oxaliplatin (DRUG),36314,Zisu,Metastatic Gastric Adenocarcinoma,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6488,NCT02590003,Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer,TERMINATED,PHASE2,"Carcinoma, Non-small Cell Lung",Carboplatin (DRUG); Nab-paclitaxel (DRUG),36314,Zisu,"Carcinoma, Non-small Cell Lung",Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6489,NCT00918203,A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Olaratumab (BIOLOGICAL); Paclitaxel (DRUG); Carboplatin (DRUG),36314,Zisu,Advanced Non-Small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6490,NCT04205903,Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients with Stage I-III Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Anatomic Stage I Breast Cancer AJCC V8; Anatomic Stage IA Breast Cancer AJCC V8; Anatomic Stage IB Breast Cancer AJCC V8; Anatomic Stage II Breast Cancer AJCC V8; Anatomic Stage IIA Breast Cancer AJCC V8; Anatomic Stage IIB Breast Cancer AJCC V8; Anatomic Stage III Breast Cancer AJCC V8; Anatomic Stage IIIA Breast Cancer AJCC V8; Anatomic Stage IIIB Breast Cancer AJCC V8; Anatomic Stage IIIC Breast Cancer AJCC V8; Prognostic Stage I Breast Cancer AJCC V8; Prognostic Stage IA Breast Cancer AJCC V8; Prognostic Stage IB Breast Cancer AJCC V8; Prognostic Stage II Breast Cancer AJCC V8; Prognostic Stage IIA Breast Cancer AJCC V8; Prognostic Stage IIB Breast Cancer AJCC V8; Prognostic Stage III Breast Cancer AJCC V8; Prognostic Stage IIIA Breast Cancer AJCC V8; Prognostic Stage IIIB Breast Cancer AJCC V8; Prognostic Stage IIIC Breast Cancer AJCC V8,Nilotinib (DRUG); Nilotinib Hydrochloride Monohydrate (DRUG); Paclitaxel (DRUG); Placebo (OTHER); Questionnaire Administration (OTHER),36314,Zisu,Anatomic Stage I Breast Cancer AJCC V8; Anatomic Stage IA Breast Cancer AJCC V8; Anatomic Stage IB Breast Cancer AJCC V8; Anatomic Stage II Breast Cancer AJCC V8; Anatomic Stage IIA Breast Cancer AJCC V8; Anatomic Stage IIB Breast Cancer AJCC V8; Anatomic Stage III Breast Cancer AJCC V8; Anatomic Stage IIIA Breast Cancer AJCC V8; Anatomic Stage IIIB Breast Cancer AJCC V8; Anatomic Stage IIIC Breast Cancer AJCC V8; Prognostic Stage I Breast Cancer AJCC V8; Prognostic Stage IA Breast Cancer AJCC V8; Prognostic Stage IB Breast Cancer AJCC V8; Prognostic Stage II Breast Cancer AJCC V8; Prognostic Stage IIA Breast Cancer AJCC V8; Prognostic Stage IIB Breast Cancer AJCC V8; Prognostic Stage III Breast Cancer AJCC V8; Prognostic Stage IIIA Breast Cancer AJCC V8; Prognostic Stage IIIB Breast Cancer AJCC V8; Prognostic Stage IIIC Breast Cancer AJCC V8,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6491,NCT02588443,Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma,COMPLETED,PHASE1,Pancreatic Cancer,RO70097890 (DRUG); nab-paclitaxel (DRUG); gemcitabine (DRUG),36314,Zisu,Pancreatic Cancer,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6492,NCT03642990,NR in Chemo-induced Peripheral Neuropathy,TERMINATED,PHASE2,Chemotherapy-induced Peripheral Neuropathy; Breast Cancer Metastatic; Platinum-resistant Recurrent Ovarian Cancer; Head and Neck Cancer Stage IV; Endometrial Cancer Stage IV,Nicotinamide Riboside (DRUG),36314,Zisu,Chemotherapy-induced Peripheral Neuropathy; Breast Cancer Metastatic; Platinum-resistant Recurrent Ovarian Cancer; Head and Neck Cancer Stage IV; Endometrial Cancer Stage IV,Uterus,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6493,NCT04585490,Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC,RECRUITING,PHASE3,"Non Small Cell Lung Cancer; NSCLC, Stage III; Nsclc",Durvalumab (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Paclitaxel (DRUG); Cisplatin (DRUG); AVENIO ctDNA Surveillance Kit (DEVICE); Tremelimumab (DRUG),36314,Zisu,"Non Small Cell Lung Cancer; NSCLC, Stage III; Nsclc",Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6494,NCT05281003,"Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)",RECRUITING,PHASE2,Esophageal Squamous Cell Carcinoma,Pembrolizumab (DRUG); Paclitaxel (DRUG); Cisplatin (DRUG),36314,Zisu,Esophageal Squamous Cell Carcinoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6495,NCT00524303,Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.,COMPLETED,PHASE2,"Neoplasms, Breast",Trastuzumab (DRUG); Paclitaxel (DRUG); FEC75 (DRUG); Lapatinib (DRUG),36314,Zisu,"Neoplasms, Breast",Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6496,NCT01462890,Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer,COMPLETED,PHASE3,"Genital Diseases, Female; Ovarian Diseases; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms",Bevacizumab (BIOLOGICAL); Paclitaxel (DRUG); Carboplatin (DRUG); specialized pathology review (Germany only) (OTHER),36314,Zisu,"Genital Diseases, Female; Ovarian Diseases; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms",Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6497,NCT02264990,Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers,COMPLETED,PHASE3,Non-squamous Non-small Cell Lung Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Veliparib (DRUG); Pemetrexed (DRUG),36314,Zisu,Non-squamous Non-small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6498,NCT01644890,A Phase III Study of NK105 in Patients With Breast Cancer,COMPLETED,PHASE3,Breast Cancer Nos Metastatic Recurrent,NK105 (DRUG); Paclitaxel (DRUG),36314,Zisu,Breast Cancer Nos Metastatic Recurrent,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6499,NCT03329690,DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01],COMPLETED,PHASE2,"Neoplasm, Gastrointestinal",DS-8201a (DRUG); Physician's Choice (DRUG),36314,Zisu,Gastrointestinal Neoplasm,Bowel,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6500,NCT01196390,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",COMPLETED,PHASE3,Esophageal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Stage IB Esophageal Cancer AJCC v7; Stage IIA Esophageal Cancer AJCC v7; Stage IIB Esophageal Cancer AJCC v7; Stage IIIA Esophageal Cancer AJCC v7; Stage IIIB Esophageal Cancer AJCC v7,Carboplatin (DRUG); Laboratory Biomarker Analysis (OTHER); Paclitaxel (DRUG); Quality-of-Life Assessment (OTHER); Radiation Therapy (RADIATION); Therapeutic Conventional Surgery (PROCEDURE); Trastuzumab (BIOLOGICAL),36314,Zisu,Esophageal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Stage IB Esophageal Cancer AJCC v7; Stage IIA Esophageal Cancer AJCC v7; Stage IIB Esophageal Cancer AJCC v7; Stage IIIA Esophageal Cancer AJCC v7; Stage IIIB Esophageal Cancer AJCC v7,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6501,NCT03691090,Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer,COMPLETED,PHASE3,Advanced Esophageal Cancer,SHR-1210 (DRUG); Placebo (DRUG); paclitaxel (DRUG); cisplatin (DRUG),36314,Zisu,Advanced Esophageal Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6502,NCT02734290,Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Triple Negative Breast Cancer,Pembrolizumab (DRUG); Paclitaxel (DRUG); Capecitabine (DRUG),36314,Zisu,Triple Negative Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6503,NCT04444921,EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients,ACTIVE_NOT_RECRUITING,PHASE3,Anal Basaloid Carcinoma; Anal Canal Cloacogenic Carcinoma; Metastatic Anal Squamous Cell Carcinoma; Recurrent Anal Squamous Cell Carcinoma; Stage III Anal Cancer AJCC v8; Stage IV Anal Cancer AJCC v8; Unresectable Anal Squamous Cell Carcinoma,Carboplatin (DRUG); Nivolumab (BIOLOGICAL); Paclitaxel (DRUG),36314,Zisu,Anal Basaloid Carcinoma; Anal Canal Cloacogenic Carcinoma; Metastatic Anal Squamous Cell Carcinoma; Recurrent Anal Squamous Cell Carcinoma; Stage III Anal Cancer AJCC v8; Stage IV Anal Cancer AJCC v8; Unresectable Anal Squamous Cell Carcinoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6504,NCT04510064,Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial,COMPLETED,PHASE2,Metastatic Gastric Cancer; Locally Advanced Gastric Adenocarcinoma; Gastric Cancer Adenocarcinoma Metastatic,Camrelizumab plus mFLOT regimen (DRUG); R0 surgery (PROCEDURE),36314,Zisu,Metastatic Gastric Cancer; Locally Advanced Gastric Adenocarcinoma; Gastric Cancer Adenocarcinoma Metastatic,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6505,NCT00070564,"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,pegfilgrastim (BIOLOGICAL); AC regimen (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); paclitaxel (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6506,NCT02859038,Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients with Advanced Ovarian Cancer (SUNNY),ACTIVE_NOT_RECRUITING,PHASE3,Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Upfront cytoreductive surgery (PROCEDURE); Interval debulking surgery (PROCEDURE),36314,Zisu,Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6507,NCT06197438,Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer,NOT_YET_RECRUITING,PHASE2,Gastric Cancer,Tislelizumab (DRUG); Oxaliplatin (DRUG); Levo-Leucovorin (DRUG); 5-fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Paclitaxel (DRUG),36314,Zisu,Gastric Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6508,NCT05381038,Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI,NOT_YET_RECRUITING,PHASE1,Solid Tumor; Gastrointestinal Cancer; Breast Cancer,QPOP (DEVICE); CURATE.AI (DEVICE); Azacitidine + docetaxel (DRUG); Azacitidine + paclitaxel (DRUG); Azacitidine + irinotecan (DRUG),36314,Zisu,Solid Tumors and Gastrointestinal Cancer,Bowel,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6509,NCT06093438,Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer,RECRUITING,PHASE1,Cervical Cancer; Induction Chemotherapy; Immunotherapy,Toripalimab (DRUG),36314,Zisu,Cervical Cancer; Induction Chemotherapy; Immunotherapy,Cervix,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6510,NCT05251038,Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer,WITHDRAWN,PHASE1,Pancreatic Cancer; Unresectable Pancreatic Cancer; Metastatic Pancreatic Cancer; KRAS P.G12C,Sotorasib (DRUG); Liposomal Irinotecan (nal-IRI) (DRUG); 5 Fluorouracil (5FU) (DRUG); Leucovorin (LV) (DRUG); Gemcitabine (GEM) (DRUG); Nab paclitaxel (DRUG),36314,Zisu,Pancreatic Cancer; Unresectable Pancreatic Cancer; Metastatic Pancreatic Cancer; KRAS P.G12C,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6511,NCT02041338,Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer,UNKNOWN,PHASE2,Breast Cancer; Neoadjuvant Chemotherapy,Paclitaxel and carboplatin (DRUG); Paclitaxel (DRUG); Epirubicin and Paclitaxel (DRUG),36314,Zisu,Breast Cancer; Neoadjuvant Chemotherapy,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6512,NCT02461043,Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma,UNKNOWN,PHASE3,Esophageal Cancer,paclitaxel; cisplatin (DRUG); radiation (RADIATION),36314,Zisu,Esophageal Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6513,NCT00503750,Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™),COMPLETED,PHASE2,Breast Cancer,Pre operativeTrastuzumab (DRUG); ABI-007 (Abraxane) (DRUG); Vinorelbine (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6514,NCT01281150,Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors,COMPLETED,PHASE1,Adult Solid Neoplasm; Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma,Carboplatin (DRUG); Laboratory Biomarker Analysis (OTHER); Paclitaxel (DRUG); Pharmacological Study (OTHER); Veliparib (DRUG),36314,Zisu,Adult Solid Neoplasm; Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6515,NCT00655850,Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Paclitaxel (DRUG); Gemcitabine (DRUG); Avastin (BIOLOGICAL),36314,Zisu,Advanced Non-Small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6516,NCT01792050,Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Docetaxel (DRUG); Placebo (OTHER); Indoximod (DRUG); Paclitaxel (DRUG),36314,Zisu,Metastatic Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6517,NCT06788912,Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01),RECRUITING,PHASE2,Lung Neoplasm Malignant,Pembrolizumab (neoadjuvant) (BIOLOGICAL); Cisplatin (DRUG); Gemcitabine (DRUG); Pemetrexed (DRUG); Sacituzumab tirumotecan (DRUG); Antihistamine (DRUG); H2 receptor antagonist (DRUG); Acetaminophen (or equivalent) (DRUG); Dexamethasone (or equivalent) (DRUG); Carboplatin (DRUG); Pembrolizumab (adjuvant) (BIOLOGICAL); Paclitaxel (DRUG); Steroid mouthwash (dexamethasone or equivalent) (DRUG),36314,Zisu,Lung Neoplasm Malignant,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6518,NCT02263495,Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Paclitaxel (DRUG); Eribulin (DRUG); Gemcitabine (DRUG),36314,Zisu,Metastatic Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6519,NCT05856695,Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC),RECRUITING,PHASE2,Small Cell Lung Cancer Extensive Stage,Carboplatin + Paclitaxel + Durvalumab (DRUG),36314,Zisu,Small Cell Lung Cancer Extensive Stage,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6520,NCT01146795,Neoadjuvant Therapy for Ovarian Cancer,COMPLETED,PHASE2,Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer,Carboplatin (DRUG); Paclitaxel (DRUG); Bevacizumab (DRUG),36314,Zisu,Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6521,NCT01024712,"Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer",UNKNOWN,PHASE2,Lung Cancer,carboplatin (DRUG); gefitinib (DRUG); paclitaxel (DRUG); quality-of-life assessment (PROCEDURE),36314,Zisu,Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6522,NCT02472964,"Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.",COMPLETED,PHASE3,Breast Cancer,Trastuzumab (BIOLOGICAL); MYL- 1401O (BIOLOGICAL); Paclitaxel (DRUG); Docetaxel (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6523,NCT06502743,"First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer",RECRUITING,PHASE2,Endometrial Cancer; Recurrent Endometrial Carcinoma; Endometrial Carcinoma; Gynecologycal Cancer; Endometrial Neoplasms,Nesuparib (DRUG); Pembrolizumab (DRUG),36314,Zisu,Endometrial Cancer; Recurrent Endometrial Carcinoma; Endometrial Carcinoma; Gynecologycal Cancer; Endometrial Neoplasms,Uterus,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6524,NCT06091943,Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Non-small Cell Lung Cancer,Tislelizumab IV (DRUG); Tislelizumab SC (DRUG); Histology-Based Chemotherapy Doublet (DRUG),36314,Zisu,Non-small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6525,NCT05014464,ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma,RECRUITING,PHASE2,Non-small Cell Lung Cancer,Crizotinib (DRUG),36314,Zisu,Non-small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6526,NCT01679743,GRN1005 for Brain Metastases From Breast or Lung Cancer,WITHDRAWN,PHASE2,Breast Cancer; Lung Neoplasms; Breast Neoplasms; Lung Cancer,Trastuzumab (DRUG); GRN 1005 (DRUG),36314,Zisu,Breast Cancer; Lung Neoplasms; Breast Neoplasms; Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6527,NCT02048943,"Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer",WITHDRAWN,PHASE1,"Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",dovitinib lactate (DRUG); gemcitabine hydrochloride (DRUG); paclitaxel albumin-stabilized nanoparticle formulation (DRUG); pharmacological study (OTHER); laboratory biomarker analysis (OTHER),36314,Zisu,"Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6528,NCT03008512,A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib,TERMINATED,PHASE2,"Carcinoma, Hepatocellular",Genexol-PM (DRUG),36314,Zisu,"Carcinoma, Hepatocellular",Liver,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6529,NCT03914612,Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Endometrial Clear Cell Adenocarcinoma; Endometrial Dedifferentiated Carcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Endometrial Adenocarcinoma; Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Dedifferentiated Carcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Endometrial Mixed Cell Adenocarcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Endometrial Undifferentiated Carcinoma; Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8,Carboplatin (DRUG); Computed Tomography (PROCEDURE); Paclitaxel (DRUG); Pembrolizumab (BIOLOGICAL); Placebo Administration (OTHER); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),36314,Zisu,Endometrial Clear Cell Adenocarcinoma; Endometrial Dedifferentiated Carcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Endometrial Adenocarcinoma; Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Dedifferentiated Carcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Endometrial Mixed Cell Adenocarcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Endometrial Undifferentiated Carcinoma; Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8,Uterus,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6530,NCT01364012,A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy,COMPLETED,PHASE3,Non-Small Cell Lung Cancer,Bevacizumab (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Placebo (DRUG),36314,Zisu,Advanced Non-Small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6531,NCT03126812,Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer,COMPLETED,PHASE1,Ovarian Cancer Stage IV; Peritoneal Cancer; Fallopian Tube Cancer,Carboplatin (DRUG); Paclitaxel (DRUG); Pembrolizumab (DRUG),36314,Zisu,Ovarian Cancer Stage IV; Peritoneal Cancer; Fallopian Tube Cancer,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6532,NCT03322969,Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy,UNKNOWN,PHASE2,Locally Advanced Gastric Cancer,Paclitaxel/DDP (DRUG); XELOX/SOX (DRUG),36314,Zisu,Metastatic Gastric Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6533,NCT06241469,"Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study",NOT_YET_RECRUITING,PHASE2,Gastric Cancer; GastroEsophageal Cancer; Adenocarcinoma,"Sintilimab,nab-paclitaxel and tegio (DRUG)",36314,Zisu,Gastric Cancer; GastroEsophageal Cancer; Adenocarcinoma,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6534,NCT02436668,"Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)",COMPLETED,PHASE3,Metastatic Pancreatic Adenocarcinoma,Ibrutinib (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG),36314,Zisu,Metastatic Pancreatic Adenocarcinoma,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6535,NCT03579004,Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer,UNKNOWN,PHASE2,Esophageal Neoplasms; Squamous Cell Carcinoma; Concurrent Chemoradiotherapy,Paclitaxel (DRUG); Cisplatin (DRUG); Fluorouracil (DRUG); chemoradiotherapy (RADIATION); Ivor Lewis esophagogastrectomy (PROCEDURE),36314,Zisu,Esophageal Neoplasms; Squamous Cell Carcinoma; Concurrent Chemoradiotherapy,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6536,NCT03348904,Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer,TERMINATED,PHASE3,Lung Cancer,Nivolumab (DRUG); Epacadostat (DRUG); Placebo (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG); Paclitaxel (DRUG); Pemetrexed (DRUG),36314,Zisu,Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6537,NCT02347904,Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer,COMPLETED,PHASE1,Esophageal Cancer,S-1 and Oxaliplatin (DRUG),36314,Zisu,Esophageal Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6538,NCT04762901,LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer,WITHDRAWN,PHASE1,Breast Cancer,Niraparib (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Paclitaxel (DRUG); Pegfilgrastim (DRUG); Carboplatin (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6539,NCT05169801,To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC,COMPLETED,PHASE3,Non-small Cell Lung Cancer(NSCLC),"BP102, paclitaxel, carboplatin (DRUG); Avastin®, paclitaxel, carboplatin (DRUG)",36314,Zisu,Non-small Cell Lung Cancer(NSCLC),Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6540,NCT00483301,"A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma",COMPLETED,PHASE2,Malignant Melanoma,Sorafenib (BAY 43-9006) (DRUG); ABI-007(Abraxane) (DRUG),36314,Zisu,Malignant Melanoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6541,NCT05371301,Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer,UNKNOWN,PHASE3,Ovarian Cancer,"Paclitaxel, Carboplatin (DRUG); debulking surgery (PROCEDURE)",36314,Zisu,Ovarian Cancer,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6542,NCT03884101,Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001),COMPLETED,PHASE3,Endometrial Neoplasms,Lenvatinib (DRUG); Pembrolizumab (BIOLOGICAL); Paclitaxel (DRUG); Carboplatin (DRUG),36314,Zisu,Endometrial Neoplasms,Uterus,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6543,NCT02488967,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Carboplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Paclitaxel (DRUG),36314,Zisu,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6544,NCT01160601,Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer,COMPLETED,PHASE2,Non-Squamous Non-Small Cell Lung Cancer,Paclitaxel / Carboplatin (DRUG); bavituximab (DRUG),36314,Zisu,Non-Squamous Non-Small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6545,NCT01097746,"First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",COMPLETED,PHASE2,Fallopian Tube Carcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; FIGO Stage III Ovarian Cancer; FIGO Stage IIIA Ovarian Cancer; FIGO Stage IIIA1 Ovarian Cancer; FIGO Stage IIIA1(i) Ovarian Cancer; FIGO Stage IIIA1(ii) Ovarian Cancer; FIGO Stage IIIA2 Ovarian Cancer; FIGO Stage IIIB Ovarian Cancer; FIGO Stage IIIC Ovarian Cancer; FIGO Stage IVA Ovarian Cancer; FIGO Stage IVB Ovarian Cancer; Malignant Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Carcinoma; Primary Peritoneal Serous Adenocarcinoma,Bevacizumab (BIOLOGICAL); Carboplatin (DRUG); Paclitaxel (DRUG),36314,Zisu,Fallopian Tube Carcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; FIGO Stage III Ovarian Cancer; FIGO Stage IIIA Ovarian Cancer; FIGO Stage IIIA1 Ovarian Cancer; FIGO Stage IIIA1(i) Ovarian Cancer; FIGO Stage IIIA1(ii) Ovarian Cancer; FIGO Stage IIIA2 Ovarian Cancer; FIGO Stage IIIB Ovarian Cancer; FIGO Stage IIIC Ovarian Cancer; FIGO Stage IVA Ovarian Cancer; FIGO Stage IVB Ovarian Cancer; Malignant Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Carcinoma; Primary Peritoneal Serous Adenocarcinoma,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6546,NCT04001569,AZD8186 and Paclitaxel in Advanced Gastric Cancer,UNKNOWN,PHASE1,Solid Tumor; Stomach Cancer,AZD8186 in combination with paclitaxel (DRUG),36314,Zisu,Solid Tumor; Stomach Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6547,NCT04262869,Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer,WITHDRAWN,PHASE2,Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Carboplatin (DRUG); Durvalumab (BIOLOGICAL); Paclitaxel (DRUG); Pemetrexed (DRUG),36314,Zisu,Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6548,NCT01654146,ICON8: Weekly Chemotherapy in Ovarian Cancer,UNKNOWN,PHASE3,Ovarian Cancer,Carboplatin (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Paclitaxel (DRUG),36314,Zisu,Ovarian Cancer,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6549,NCT06954246,A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer,NOT_YET_RECRUITING,PHASE3,Small Cell Lung Cancer Extensive Stage,MHB088C for Injection (DRUG); Topotecan (DRUG); Irinotecan (DRUG); Paclitaxel (DRUG),36314,Zisu,Small Cell Lung Cancer Extensive Stage,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6550,NCT05535569,"Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer",COMPLETED,PHASE1,Recurrent/Metastatic Gastric Cancer,"Nivolumab, Paclitaxel (DRUG)",36314,Zisu,Recurrent/Metastatic Gastric Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6551,NCT01276769,Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer,UNKNOWN,PHASE2,Triple Negative Breast Cancer,Paclitaxel plus carboplatin (DRUG); Paclitaxel and epirubicin (DRUG),36314,Zisu,Triple Negative Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6552,NCT02024568,Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia,UNKNOWN,PHASE2,Taxane; Drug-related Side Effects and Adverse Reactions; Pain; Breast Cancer,Pregabalin (DRUG); Placebo (DRUG),36314,Zisu,Taxane; Drug-related Side Effects and Adverse Reactions; Pain; Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6553,NCT01461746,Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer,UNKNOWN,PHASE2,Endometrial Cancer,Docetaxel (DRUG); Cisplatin (DRUG); Radiation therapy (RADIATION),36314,Zisu,Endometrial Cancer,Uterus,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6554,NCT01031446,"Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer",COMPLETED,PHASE1,Breast Cancer,cisplatin (DRUG); everolimus (DRUG); paclitaxel (DRUG); laboratory biomarker analysis (OTHER),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6555,NCT00006469,Combination Chemotherapy and Radiation Therapy Followed By Surgery in Treating Patients With Stage IIB or Stage IIIA Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,carboplatin (DRUG); paclitaxel (DRUG); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE); radiation therapy (RADIATION),36314,Zisu,Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6556,NCT01617668,"A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer",COMPLETED,PHASE2,Breast Cancer,LCL161 (DRUG); paclitaxel (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6557,NCT02359968,PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer,COMPLETED,PHASE2,Esophageal Neoplasms; Gastro-esophageal Junction Cancer,FOLFOX (DRUG); CarboP-pacliT (DRUG),36314,Zisu,Esophageal Neoplasms; Gastro-esophageal Junction Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6558,NCT04182568,Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer,UNKNOWN,PHASE4,Breast Cancer,nab-paclitaxel followed by anthracycline and cyclophosphamide (DRUG); Docetaxel followed by anthracycline and cyclophosphamide (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6559,NCT01722968,A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel,COMPLETED,PHASE2,Breast Cancer,Bevacizumab (DRUG); Paclitaxel (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6560,NCT04603846,A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma,UNKNOWN,PHASE1,Advanced Urothelial Carcinoma,anti-PD-L1 antibody (DRUG); albumin bound paclitaxel (DRUG),36314,Zisu,Advanced Urothelial Carcinoma,Bladder/Urinary Tract,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6561,NCT05033769,Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer,UNKNOWN,PHASE4,"Breast Cancer Female; Neoplasm, Breast; Breast Cancer Metastatic",Eribulin Injection [Halaven] (DRUG); Paclitaxel injection (DRUG),36314,Zisu,"Breast Cancer Female; Neoplasm, Breast; Breast Cancer Metastatic",Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6562,NCT00487669,Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,Advanced Non-small Cell Lung Cancer,"paclitaxel poliglumex, pemetrexed (DRUG)",36314,Zisu,Advanced Non-small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6563,NCT04251169,Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression,TERMINATED,PHASE2,Metastatic Breast Cancer,Pembrolizumab (DRUG); Paclitaxel (DRUG),36314,Zisu,Metastatic Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6564,NCT01057069,Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,"Carboplatin and Paclitaxel (DRUG); Doxorubicin, cyclophosphamide (DRUG); Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide (DRUG)",36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6565,NCT03086369,A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer,COMPLETED,PHASE1,Metastatic Pancreatic Cancer,Olaratumab (DRUG); Nab-paclitaxel (DRUG); Gemcitabine (DRUG); Placebo (DRUG),36314,Zisu,Metastatic Pancreatic Cancer,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6566,NCT05929768,Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer,RECRUITING,PHASE3,Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Early Stage Triple-Negative Breast Carcinoma,Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG); Doxorubicin (DRUG); Paclitaxel (DRUG); Pembrolizumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); Surgical Procedure (PROCEDURE),36314,Zisu,Early Stage Triple-Negative Breast Carcinoma,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6567,NCT00034346,ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,Non-Small Cell Lung Cancer; Neoplasm Metastasis; Lung Cancer,ABX-EGF (DRUG); paclitaxel (DRUG); carboplatin (DRUG),36314,Zisu,Non-Small Cell Lung Cancer; Neoplasm Metastasis; Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6568,NCT05357846,PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101),RECRUITING,PHASE3,Squamous Cell Esophageal Carcinoma; Esophageal Cancer; Oesophageal Cancer,Sintilimab (DRUG); Preoperative radiotherapy (RADIATION); Paclitaxel (DRUG); Cisplatin (DRUG); esophagectomy (PROCEDURE),36314,Zisu,Squamous Cell Esophageal Carcinoma; Esophageal Cancer; Oesophageal Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6569,NCT01721746,A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037),COMPLETED,PHASE3,Unresectable or Metastatic Melanoma,BMS-936558 (BIOLOGICAL); Dacarbazine (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG),36314,Zisu,Unresectable or Metastatic Melanoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6570,NCT04335669,"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC",RECRUITING,PHASE3,Breast Cancer; Triple Negative Breast Neoplasms,"epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab (DRUG); epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab (DRUG)",36314,Zisu,Breast Cancer; Triple Negative Breast Neoplasms,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6571,NCT04205968,Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers,RECRUITING,PHASE2,Metastatic Small Intestinal Adenocarcinoma; Stage III Small Intestinal Adenocarcinoma AJCC v8; Stage IIIA Small Intestinal Adenocarcinoma AJCC v8; Stage IIIB Small Intestinal Adenocarcinoma AJCC v8; Stage IV Small Intestinal Adenocarcinoma AJCC v8,Fluorouracil (DRUG); Irinotecan (DRUG); Irinotecan Hydrochloride (DRUG); Leucovorin (DRUG); Leucovorin Calcium (DRUG); Paclitaxel (DRUG); Ramucirumab (BIOLOGICAL),36314,Zisu,Small Intestinal Adenocarcinoma,Bowel,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6572,NCT02597946,Afatinib in NSCLC With HER2 Mutation,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",afatinib (DRUG); paclitaxel (DRUG),36314,Zisu,"Carcinoma, Non-Small-Cell Lung",Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6573,NCT06326346,GIST Oral Paclitaxel(Liporaxel),NOT_YET_RECRUITING,PHASE2,Gastrointestinal Stromal Tumors,Liporaxel (DRUG),36314,Zisu,Gastrointestinal Stromal Tumors,Bowel,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6574,NCT02172846,"Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer",COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung",Proton beam radiation therapy (PBT) (RADIATION); Paclitaxel (DRUG); Carboplatin (DRUG),36314,Zisu,"Carcinoma, Non-Small-Cell Lung",Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6575,NCT00077246,ABI-007 in Treating Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer,paclitaxel albumin-stabilized nanoparticle formulation (DRUG),36314,Zisu,Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6576,NCT05296746,Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer,RECRUITING,PHASE2,Breast Cancer Stage II,Ribociclib (neoadjuvant) (DRUG); Chemotherapy (adjuvant) (DRUG); Ribociclib (adjuvant) (DRUG),36314,Zisu,Early Stage Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6577,NCT06897046,Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC,NOT_YET_RECRUITING,PHASE2,Non-small Cell Lung Cancer (NSCLC); II-IIIB,QL1706 (DRUG); QL1706+Carboplatin+Paclitaxel（Albumin-bound ）/ Pemetrexed (DRUG),36314,Zisu,Non-small Cell Lung Cancer (NSCLC); II-IIIB,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6578,NCT00002568,Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer,COMPLETED,PHASE3,Ovarian Cancer,cisplatin (DRUG); paclitaxel (DRUG); conventional surgery (PROCEDURE),36314,Zisu,Ovarian Cancer,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6579,NCT05862168,"Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial",RECRUITING,PHASE2,Oral Squamous Cell Carcinoma,Tislelizumab (DRUG); Albumin paclitaxel (DRUG); Cisplatin (DRUG); 5-Fluorouracil (DRUG),36314,Zisu,Oral Squamous Cell Carcinoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6580,NCT02957968,Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca,ACTIVE_NOT_RECRUITING,PHASE2,Breast Adenocarcinoma; Estrogen Receptor- Negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive Tumor; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Triple-negative Breast Carcinoma,Doxorubicin (DRUG); Cyclophosphamide (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Decitabine (DRUG); Pembrolizumab (DRUG),36314,Zisu,Breast Cancer (Various Types and Stages),Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6581,NCT06662669,YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer,NOT_YET_RECRUITING,PHASE1,Metastatic Pancreatic Cancer,YL-13027 (DRUG); HY-0102 (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG),36314,Zisu,Metastatic Pancreatic Cancer,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6582,NCT02059876,Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,carboplatin and paclitaxel and or without trastuzumab (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6583,NCT04921527,Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer,RECRUITING,PHASE3,Ovarian Cancer; Relapsed or Refractory; Chiauranib; Paclitaxel,chiauranib (DRUG); Placebo (DRUG); Paclitaxel (DRUG),36314,Zisu,Ovarian Cancer; Relapsed or Refractory; Chiauranib; Paclitaxel,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6584,NCT00534027,A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Non-Small Cell Lung Cancer,AMG 655 (DRUG); AMG 655 placebo (OTHER),36314,Zisu,Advanced Non-Small Cell Lung Cancer,Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6585,NCT00129727,Carboplatin Taxol Avastin in Ovarian Cancer (OVCA),COMPLETED,PHASE2,Ovarian Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Bevacizumab (DRUG),36314,Zisu,Ovarian Cancer,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6586,NCT04946227,"Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')",UNKNOWN,PHASE2,Breast Cancer,Pembrolizumab 200mg +Paclitaxel 80mg/m2 (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6587,NCT02631876,"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer",COMPLETED,PHASE3,Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Ovarian Cancer,Mirvetuximab soravtansine (DRUG); Paclitaxel (DRUG); Pegylated liposomal doxorubicin (DRUG); Topotecan (DRUG),36314,Zisu,Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Ovarian Cancer,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6588,NCT00388076,"Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)",COMPLETED,PHASE1,"Neoplasms, Breast",Pazopanib (DRUG); Lapatinib (DRUG); paclitaxel (DRUG); carboplatin (DRUG),36314,Zisu,"Neoplasms, Breast",Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6589,NCT01663727,"Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer",COMPLETED,PHASE3,Metastatic Breast Cancer,Bevacizumab [Avastin] (DRUG); Paclitaxel (DRUG); Placebo (DRUG),36314,Zisu,Metastatic Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6590,NCT02390427,Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer,COMPLETED,PHASE1,Metastatic Breast Cancer; Recurrent Breast Cancer,Taselisib (DRUG); Trastuzumab emtansine (DRUG); Pertuzumab (DRUG); Trastuzumab (DRUG); Paclitaxel (DRUG),36314,Zisu,Metastatic Breast Cancer; Recurrent Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6591,NCT00006027,Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer,COMPLETED,PHASE3,Endometrial Cancer,cisplatin (DRUG); paclitaxel (DRUG); adjuvant therapy (PROCEDURE); radiation therapy (RADIATION),36314,Zisu,Endometrial Cancer,Uterus,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6592,NCT06421376,Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer,RECRUITING,PHASE2,Esophageal Cancer; Immunotherapy; Induction Therapy; Chemoradiotherapy; Surgery,Cardonilizumab (DRUG); Chemoradiotherapy ±immunotherapy (RADIATION); Radical surgery (PROCEDURE),36314,Zisu,Esophageal Cancer; Immunotherapy; Induction Therapy; Chemoradiotherapy; Surgery,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6593,NCT06406127,Effect of Alpha Lipoic Acid on Chemotherapy Induced Neurological Changes in Breast Cancer Patients,RECRUITING,PHASE4,Breast Cancer; Alpha Lipoic Acid; Paclitaxel; Neurologic Disorder; Chemotherapy,Alpha Lipoic Acid 600 MG Oral Capsule (DRUG),36314,Zisu,Breast Cancer; Alpha Lipoic Acid; Paclitaxel; Neurologic Disorder; Chemotherapy,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6594,NCT04241276,A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Pancreatic Cancer,ATRA (DRUG); Gemcitabine (DRUG); nab-paclitaxel (DRUG),36314,Zisu,Pancreatic Cancer,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6595,NCT05983276,Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer,RECRUITING,PHASE2,Ovarian Cancer,Decitabine (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Selinexor (DRUG),36314,Zisu,Ovarian Cancer,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6596,NCT02356276,Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2,UNKNOWN,PHASE3,Gastric Cancer,D2 lymphadenectomy (PROCEDURE); Hyperthermic Intraperitoneal Chemotherapy (PROCEDURE); Systemic chemotherapy (XELOX or SOX regimens) (DRUG),36314,Zisu,Gastric Cancer,Esophagus/Stomach,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6597,NCT01329627,Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer,TERMINATED,PHASE2,Locally Advanced HER2-negative Breast Cancer,Paclitaxel/doxorubicin/cyclophosphamide (DRUG); Paclitaxel/doxorubicin/cyclophosphamide (DRUG),36314,Zisu,Locally Advanced HER2-negative Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6598,NCT04611776,"A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer",WITHDRAWN,PHASE2,"Carcinoma, Non-Small Cell Lung",Atezolizumab (DRUG); Placebo (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Pemetrexed (DRUG); Gemcitabine (DRUG); Paclitaxel (DRUG),36314,Zisu,"Carcinoma, Non-Small Cell Lung",Lung,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6599,NCT05554276,Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer,RECRUITING,PHASE2,Neoadjuvant Chemotherapy; PD-1 Antibody; Radiotherapy; Cervical Cancer,neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy (COMBINATION_PRODUCT),36314,Zisu,Neoadjuvant Chemotherapy; PD-1 Antibody; Radiotherapy; Cervical Cancer,Cervix,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6600,NCT06608927,Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma,RECRUITING,PHASE3,Metastatic Pancreatic Ductal Adenocarcinoma,Quemliclustat (DRUG); Placebo (DRUG); Nab-paclitaxel (DRUG); Gemcitabine (DRUG),36314,Zisu,Metastatic Pancreatic Ductal Adenocarcinoma,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6601,NCT05200260,Surgery Combined with Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer,RECRUITING,PHASE2,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Primary debulking surgery (PROCEDURE); Neoadjuvant chemotherapy (PROCEDURE); PARP inhibitor (DRUG); Bevacizumab (DRUG),36314,Zisu,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6602,NCT03953976,INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy,COMPLETED,PHASE2,Head and Neck Squamous Cell Carcinoma,Intensity modulated radiation therapy (IMRT) (RADIATION),36314,Zisu,Head and Neck Squamous Cell Carcinoma,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6603,NCT01650376,Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer,UNKNOWN,PHASE1,Stage III Ovarian Cancer; Stage IV Ovarian Cancer; Uterine Cancer,Olaparib (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG),36314,Zisu,Stage III Ovarian Cancer; Stage IV Ovarian Cancer; Uterine Cancer,Ovary/Fallopian Tube,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6604,NCT06543576,External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer,NOT_YET_RECRUITING,PHASE1,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IVB Cervical Cancer American Joint Committee on Cancer (AJCC) v8,Bevacizumab (BIOLOGICAL); Biospecimen Collection (PROCEDURE); Brachytherapy (RADIATION); Cisplatin (DRUG); External Beam Radiation Therapy (RADIATION); Paclitaxel (DRUG); Pembrolizumab (BIOLOGICAL); Questionnaire Administration (OTHER),36314,Zisu,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IVB Cervical Cancer American Joint Committee on Cancer (AJCC) v8,Skin,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6605,NCT01572727,"A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",COMPLETED,PHASE2,Breast Cancer,Paclitaxel (DRUG); BKM120 matching placebo (DRUG); BKM120 (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6606,NCT02651727,"Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects",TERMINATED,PHASE1,Pancreatic Cancer,"Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine (DRUG); Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine (DRUG); Part A- VS-4718, nab-paclitaxel, gemcitabine (DRUG)",36314,Zisu,Pancreatic Cancer,Pancreas,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6607,NCT02689427,Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer,COMPLETED,PHASE2,Invasive Breast Carcinoma; Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma,Axillary Lymph Node Dissection (PROCEDURE); Enzalutamide (DRUG); Laboratory Biomarker Analysis (OTHER); Lymph Node Biopsy (PROCEDURE); Paclitaxel (DRUG); Therapeutic Conventional Surgery (PROCEDURE),36314,Zisu,Invasive Breast Carcinoma; Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6608,NCT00046527,Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer,COMPLETED,PHASE3,"Breast Neoplasms; Metastases, Neoplasm",ABI-007 (DRUG),36314,Zisu,"Breast Neoplasms; Metastases, Neoplasm",Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6609,NCT00003127,"S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer",COMPLETED,PHASE2,Endometrial Cancer,amifostine trihydrate (DRUG); carboplatin (DRUG); paclitaxel (DRUG),36314,Zisu,Endometrial Cancer,Uterus,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6610,NCT00846027,A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Bevacizumab (DRUG); Paclitaxel (DRUG); Gemcitabine (DRUG),36314,Zisu,Breast Cancer,Breast,Paclitaxel,,unclear,Microtubule inhibitor,yes,yes,Chemotherapy drug approved for cancer treatment.,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,1.02,268.0 +6611,NCT02915965,"A Trial of Neoadjuvant Chemotherapy for Stage II, III Esophageal Squamous Cell Carcinoma",UNKNOWN,PHASE2,Stage II and III Esophageal Squamous Cell Carcinoma,DCX (DRUG); surgery (PROCEDURE),148124,TXL,Stage II and III Esophageal Squamous Cell Carcinoma,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6612,NCT00003066,Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,docetaxel (DRUG); estramustine phosphate sodium (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6613,NCT02613026,Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer,COMPLETED,PHASE3,Breast Neoplasms,Pirarubicin (DRUG); Docetaxel (DRUG); Cyclophosphamide (DRUG),148124,TXL,Breast Neoplasms,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6614,NCT01669226,First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer,COMPLETED,PHASE2,Bulky Stage IIIC and IV Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,PEip (weekly) and TCiv (DRUG); TCiv (DRUG),148124,TXL,Bulky Stage IIIC and IV Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6615,NCT00004066,"Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma",COMPLETED,PHASE2,Ovarian Cancer; Sarcoma; Small Intestine Cancer,filgrastim (BIOLOGICAL); docetaxel (DRUG); gemcitabine hydrochloride (DRUG),148124,TXL,Ovarian Cancer and Related Malignancies,Ovary/Fallopian Tube,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6616,NCT05088057,Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer,UNKNOWN,PHASE2,Triple Negative Breast Cancer (TNBC),Camrelizumab (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG),148124,TXL,Triple Negative Breast Cancer (TNBC),Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6617,NCT01905657,Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010),COMPLETED,PHASE2,Non Small Cell Lung Cancer (NSCLC),Pembrolizumab (BIOLOGICAL); Docetaxel (DRUG),148124,TXL,Non Small Cell Lung Cancer (NSCLC),Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6618,NCT03117257,Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN,UNKNOWN,PHASE2,Locally Advanced Head and Neck Squamous Cell Carcinoma,Lobaplatin (DRUG); Cisplatin (DRUG),148124,TXL,Locally Advanced Head and Neck Squamous Cell Carcinoma,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6619,NCT00257348,Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer,COMPLETED,PHASE2,Cervical Cancer,Capecitabine (DRUG); Docetaxel (DRUG),148124,TXL,Cervical Cancer,Cervix,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6620,NCT00665457,Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery,TERMINATED,PHASE2,Breast Cancer,filgrastim (BIOLOGICAL); capecitabine (DRUG); celecoxib (DRUG); cyclophosphamide (DRUG); docetaxel (DRUG); doxorubicin hydrochloride (DRUG); gene expression analysis (GENETIC); polymorphism analysis (GENETIC); protein expression analysis (GENETIC); reverse transcriptase-polymerase chain reaction (GENETIC); imaging biomarker analysis (OTHER); immunohistochemistry staining method (OTHER); laboratory biomarker analysis (OTHER); pharmacogenomic studies (OTHER); dynamic contrast-enhanced magnetic resonance imaging (PROCEDURE); needle biopsy (PROCEDURE); neoadjuvant therapy (PROCEDURE); radiomammography (PROCEDURE); ultrasound imaging (PROCEDURE),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6621,NCT00911820,"Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer",COMPLETED,PHASE2,Esophageal Cancer; Gastric Cancer; Stomach Cancer,Bevacizumab (DRUG); Cisplatin (DRUG); Irinotecan (DRUG); Docetaxel (DEVICE),148124,TXL,Esophageal Cancer; Gastric Cancer; Stomach Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6622,NCT05383482,Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1,ACTIVE_NOT_RECRUITING,PHASE1,Solid Tumor; NSCLC; Cervical Cancer; Endometrial Cancer; Esophageal Cancer; Gastric and Gastroesophageal Junction Adenocarcinoma,Afuresertib (DRUG); Nab paclitaxel (DRUG); Docetaxel (DRUG); Sintilimab (DRUG),148124,TXL,Solid Tumor; NSCLC; Cervical Cancer; Endometrial Cancer; Esophageal Cancer; Gastric and Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6623,NCT00980382,A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma,COMPLETED,PHASE1,Stomach Neoplasms,"S-1, Docetaxel (DRUG)",148124,TXL,Stomach Neoplasms,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6624,NCT01836120,A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer,UNKNOWN,PHASE2,Gastric Cancer,Raltitrexed plus Docetaxel (DRUG); Docetaxel (DRUG),148124,TXL,Gastric Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6625,NCT00250874,"Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer",UNKNOWN,PHASE2,Metastatic Breast Cancer,"Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab (DRUG)",148124,TXL,Metastatic Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6626,NCT01154920,"Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma",ACTIVE_NOT_RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma,Paclitaxel (DRUG); Carboplatin (DRUG); Cetuximab (DRUG); Docetaxel (DRUG); Cisplatin (DRUG); Fluorouracil (DRUG); Radiotherapy (RT) (RADIATION); Chemotherapy (OTHER),148124,TXL,Head and Neck Squamous Cell Carcinoma,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6627,NCT05081674,Brazilian Lung Immunotherapy Study,COMPLETED,PHASE2,Lung Neoplasm,Alectinib (DRUG); Pembrolizumab (DRUG); Nivolumab (DRUG); Erlotinib (DRUG),148124,TXL,Lung Neoplasm,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6628,NCT00006120,Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,docetaxel (DRUG); paclitaxel (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6629,NCT00544765,"Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer",COMPLETED,PHASE3,Breast Cancer,TAC (DRUG); NX (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6630,NCT01640782,Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach,COMPLETED,PHASE3,Adenocarcinoma of the Stomach; Adenocarcinoma of the Gastroesophageal Junction,"Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin (DRUG); Leucovorin, 5-Fluorouracil (DRUG)",148124,TXL,Gastric Adenocarcinoma,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6631,NCT01379482,Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer,COMPLETED,PHASE2,Peritoneal Carcinomatosis; Gastric Cancer,Multimodal treatment (DRUG),148124,TXL,Gastric Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6632,NCT04340882,Phase 2 DoceRamPem for Patients with Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade,RECRUITING,PHASE2,Metastatic Non-Small Lung Cell Cancer; Recurrent Non-Small Lung Cell Cancer; Stage IV Lung Cancer AJCC V8; Stage IVA Lung Cancer AJCC V8; Stage IVB Lung Cancer AJCC V8,Docetaxel (DRUG); Pembrolizumab (BIOLOGICAL); Ramucirumab (BIOLOGICAL),148124,TXL,Metastatic Non-Small Lung Cell Cancer; Recurrent Non-Small Lung Cell Cancer; Stage IV Lung Cancer AJCC V8; Stage IVA Lung Cancer AJCC V8; Stage IVB Lung Cancer AJCC V8,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6633,NCT00256282,Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma,COMPLETED,PHASE2,Metastatic Melanoma,Vinorelbine (DRUG); Docetaxel (DRUG); Sargramostim (DRUG),148124,TXL,Metastatic Melanoma,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6634,NCT00051974,Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,VELCADE™ (bortezomib) for Injection (formerly PS-341) (DRUG),148124,TXL,Advanced Non-Small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6635,NCT01618474,Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer Patients,UNKNOWN,PHASE2,Stomach Cancer,DX (DRUG); XELOX (DRUG),148124,TXL,Stomach Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6636,NCT04009265,"Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma",RECRUITING,PHASE3,Esophageal Squamous Cell Carcinoma,adjuvant treatment (COMBINATION_PRODUCT),148124,TXL,Esophageal Squamous Cell Carcinoma,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6637,NCT05709574,Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer,RECRUITING,PHASE2,Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma,Tadalafil 20 MG (DRUG),148124,TXL,Gastric and Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6638,NCT01652820,Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer,COMPLETED,PHASE2,Non Small-cell Lung Cancer,"Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation 2Gy/day (DRUG); Docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT 2Gy/d (DRUG)",148124,TXL,Non Small-cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6639,NCT00075374,Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,docetaxel (DRUG),148124,TXL,Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6640,NCT06304974,A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma,RECRUITING,PHASE3,Esophageal Squamous Cell Carcinoma,BL-B01D1 (DRUG); Irinotecan (DRUG); paclitaxel (DRUG); docetaxel (DRUG),148124,TXL,Esophageal Squamous Cell Carcinoma,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6641,NCT02980965,"Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer",COMPLETED,PHASE3,Breast Cancer Female,"letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel (DRUG); fluorouracil, epirubicin, cyclophosphamide, docetaxel (DRUG)",148124,TXL,Breast Cancer Female,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6642,NCT00003120,"S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission",COMPLETED,PHASE3,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,paclitaxel (DRUG),148124,TXL,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6643,NCT00039520,Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer,COMPLETED,PHASE2,Breast Cancer,docetaxel (DRUG); sulindac (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6644,NCT02643420,SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE),COMPLETED,PHASE3,Neutropenia; Breast Cancer,SPI-2012 (DRUG); Pegfilgrastim (DRUG); Docetaxel (DRUG); Cyclophosphamide (DRUG),148124,TXL,Neutropenia; Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6645,NCT05114720,Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer,RECRUITING,PHASE3,Breast Cancer,standard adjuvant chemotherapy plus moxifloxacin (DRUG); standard adjuvant chemotherapy plus placebo (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6646,NCT00391274,Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE3,Non-Small Cell Lung Cancer,pemetrexed (DRUG); docetaxel (DRUG),148124,TXL,Advanced Non-Small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6647,NCT06227065,Precise Neoadjuvant Chemoresection of Low Grade NMIBC,NOT_YET_RECRUITING,PHASE2,Bladder Cancer; Non-muscle Invasive Bladder Cancer; Low-risk,Epirubicin (DRUG); Mitomycin (DRUG); Gemcitabine (DRUG); Docetaxel (DRUG),148124,TXL,Non-muscle Invasive Bladder Cancer,Bladder/Urinary Tract,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6648,NCT03971474,Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial),COMPLETED,PHASE2,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Docetaxel (DRUG); Gemcitabine (DRUG); Gemcitabine Hydrochloride (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed (DRUG); Pemetrexed Disodium (DRUG); Ramucirumab (BIOLOGICAL),148124,TXL,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6649,NCT00231465,Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,docetaxel (Taxotere®) (DRUG); ZD1839 (DRUG),148124,TXL,Advanced Non-Small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6650,NCT05838066,Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.,NOT_YET_RECRUITING,PHASE3,First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer,KN026 (DRUG); HB1801 (DRUG); Pertuzumab (DRUG); Trastuzumab (DRUG); Docetaxel (DRUG),148124,TXL,First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6651,NCT00290966,Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer,COMPLETED,PHASE2,Stomach Neoplasm,XRP6976 (DRUG),148124,TXL,Stomach Neoplasm,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6652,NCT00206466,Biologic Correlative Taxotere/AC,COMPLETED,PHASE2,Breast Cancer,Taxotere (DRUG); Adriamycin/cytoxan (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6653,NCT00404066,Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Metastatic Breast Cancer,Lapatinib (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG); Pegfilgrastim (DRUG); Filgrastim (DRUG); Dexamethasone (DRUG); Trastuzumab (DRUG),148124,TXL,Breast Cancer; Metastatic Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6654,NCT06141226,Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer,RECRUITING,PHASE2,Non-small-cell Lung Cancer,TQB2450 +Anlotinib+Docetaxel (DRUG); TQB2450 +Androtinib Placebo+Docetaxel (DRUG),148124,TXL,Non-small-cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6655,NCT01286766,Neoadjuvant Combination Chemotherapy of DCS and DCF in Patients With Locally Advanced Gastric Adenocarcinoma,COMPLETED,PHASE2,Gastric Cancer,DCS (docetaxel with cisplatin with TS-1) (DRUG); DCF (docetaxel with cisplatin with 5-FU) (DRUG),148124,TXL,Gastric Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6656,NCT04140526,"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC",RECRUITING,PHASE1,Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Colorectal Cancer; Sarcomas; Metastatic Prostate Cancer; Ovarian Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Pancreas Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Junction Adenocarcinoma; Cervical Cancer; Adenoid Cystic Carcinoma; Salivary Gland Cancer; Urothelial Carcinoma,ONC-392 (DRUG); Pembrolizumab (DRUG); Docetaxel (DRUG),148124,TXL,Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Colorectal Cancer; Sarcomas; Metastatic Prostate Cancer; Ovarian Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Pancreas Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Junction Adenocarcinoma; Cervical Cancer; Adenoid Cystic Carcinoma; Salivary Gland Cancer; Urothelial Carcinoma,Bowel,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6657,NCT00085826,A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients,COMPLETED,PHASE3,Non-Small Cell Lung Cancer,Exisulind (DRUG),148124,TXL,Advanced Non-Small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6658,NCT03218826,PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery,ACTIVE_NOT_RECRUITING,PHASE1,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Prostate Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Castration-Resistant Prostate Carcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Prostate Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Triple-Negative Breast Carcinoma; Unresectable Solid Neoplasm,Docetaxel (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); PI3Kbeta Inhibitor AZD8186 (DRUG),148124,TXL,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Prostate Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Castration-Resistant Prostate Carcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Prostate Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Triple-Negative Breast Carcinoma; Unresectable Solid Neoplasm,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6659,NCT00442026,Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC,TERMINATED,PHASE3,Non-small-cell Lung Cancer,Docetaxel (DRUG); Gemcitabine (DRUG); Gemcitabine (DRUG),148124,TXL,Non-small-cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6660,NCT00073866,Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer,celecoxib (DRUG); docetaxel (DRUG); irinotecan hydrochloride (DRUG),148124,TXL,Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6661,NCT03917966,The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC,UNKNOWN,PHASE2,Locally Advanced Esophageal Squamous Cell Carcinoma,SHR-1210+docetaxel+nedaplatin (DRUG); SHR-1210+Apatinib (DRUG),148124,TXL,Locally Advanced Esophageal Squamous Cell Carcinoma,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6662,NCT05249426,"A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Head and Neck Squamous Cell Carcinoma (HNSCC),BI 765063 (DRUG); Ezabenlimab (DRUG); BI 836880 (DRUG); Cetuximab (DRUG); Investigator´s Choice Chemotherapy (OTHER),148124,TXL,Head and Neck Squamous Cell Carcinoma (HNSCC),Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6663,NCT00080626,Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer,TERMINATED,PHASE2,Breast Cancer,pegfilgrastim (BIOLOGICAL); docetaxel (DRUG); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6664,NCT01485926,"A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.",COMPLETED,PHASE2,Breast Cancer,"Docetaxel, Carboplatin and Trastuzumab (DRUG); Docetaxel, Carboplatin, Trastuzumab and Lapatinib (DRUG)",148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6665,NCT06714266,Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,NOT_YET_RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma (HNSCC),Trilaciclib (DRUG),148124,TXL,Head and Neck Squamous Cell Carcinoma (HNSCC),Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6666,NCT00012220,Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas,COMPLETED,PHASE2,Pancreatic Cancer,cisplatin (DRUG); docetaxel (DRUG); gemcitabine hydrochloride (DRUG); irinotecan hydrochloride (DRUG),148124,TXL,Pancreatic Cancer,Pancreas,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6667,NCT02413320,Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer,COMPLETED,PHASE2,Triple-negative Breast Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG),148124,TXL,Triple-negative Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6668,NCT00449020,"Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer",COMPLETED,PHASE2,Lung Cancer,Carboplatin (DRUG); Docetaxel (DRUG); irinotecan hydrochloride (DRUG); radiation therapy (RADIATION),148124,TXL,Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6669,NCT05504720,"Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma",ACTIVE_NOT_RECRUITING,PHASE2,Esophagogastric Adenocarcinoma,Pembrolizumab (DRUG); Trastuzumab (DRUG); FLOT (DRUG),148124,TXL,Esophagogastric Adenocarcinoma,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6670,NCT00130520,Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer,COMPLETED,PHASE2,Ovarian Neoplasms,bevacizumab (DRUG); erlotinib (DRUG),148124,TXL,Ovarian Neoplasms,Ovary/Fallopian Tube,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6671,NCT00030420,Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,Celecoxib (DRUG); Docetaxel (DRUG),148124,TXL,Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6672,NCT01426620,Standard Chemotherapy With Blueberry Powder in Non-Small Cell Lung Cancer,TERMINATED,PHASE2,Non-small Cell Lung Cancer,Blueberry powder (DIETARY_SUPPLEMENT),148124,TXL,Non-small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6673,NCT00050674,Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma,COMPLETED,PHASE2,Non-small Cell Lung Cancer,Filgrastim-SD/01 (DRUG),148124,TXL,Non-small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6674,NCT00087620,A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer,TERMINATED,PHASE4,Breast Cancer,XELODA [capecitabine] (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6675,NCT00452920,"Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer",WITHDRAWN,PHASE1,Cervical Cancer,docetaxel (DRUG); cesium Cs 137 (RADIATION); radiation therapy (RADIATION),148124,TXL,Cervical Cancer,Cervix,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6676,NCT04733820,Clinical Efficacy of Adjuvant Chemotherapy in Patients With Locally Advanced Cervical Cancer Who Did Not Meet the NCCN Guidelines for Adjuvant Treatment After NACT Combined With Surgery,RECRUITING,PHASE3,Uterine Cervical Neoplasms; Cervical Cancer,Adjuvant chemotherapy (DRUG),148124,TXL,Uterine Cervical Neoplasms; Cervical Cancer,Cervix,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6677,NCT05684731,Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer,RECRUITING,PHASE1,Ovarian Cancer,KM1 (BIOLOGICAL); Chemotherapy (DRUG),148124,TXL,Ovarian Cancer,Ovary/Fallopian Tube,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6678,NCT02358473,Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer,COMPLETED,PHASE1,Non-Small Cell Lung Cancer,mogamulizumab (BIOLOGICAL); Docetaxel (DRUG),148124,TXL,Advanced Non-Small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6679,NCT06107673,Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）,RECRUITING,PHASE2,Breast Cancer,Dalpiciclib (DRUG); Aromatase inhibitor (DRUG); Docetaxel injection (DRUG); Epirubicin Hydrochloride Injection (DRUG); Cyclophosphamide injection (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6680,NCT04165031,A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation,TERMINATED,PHASE1,Advanced Solid Tumor; Non-Small Cell Lung Cancer; Colorectal Cancer,LY3499446 (DRUG); Abemaciclib (DRUG); Cetuximab (DRUG); Erlotinib (DRUG); Docetaxel (DRUG),148124,TXL,Advanced Solid Tumor; Non-Small Cell Lung Cancer; Colorectal Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6681,NCT02624973,PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Neoadjuvant tamoxifen + goserelin (premenopausal women) (DRUG); Neoadjuvant letrozole (postmenopausal women) (DRUG); Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone) (DRUG); Neoadjuvant docetaxel + cyclophosphamide (DRUG); Neoadjuvant docetaxel (DRUG); Neoadjuvant docetaxel + trastuzumab + pertuzumab (DRUG); Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab (DRUG); Neoadjuvant olaparib (DRUG); Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone) (DRUG); Breast conserving surgery or mastectomy + SNB/axillary dissection (PROCEDURE); Postoperative radiotherapy breast/chest wall + regional lymph nodes (RADIATION); Adjuvant trastuzumab (DRUG); Adjuvant letrozole (postmenopausal women) (DRUG); Adjuvant tamoxifen + goserelin (premenopausal women) (DRUG); Adjuvant palbociclib (if palbociclib given neoadjuvant) (DRUG); Adjuvant Epirubicin+ Cyclophosphamide (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6682,NCT00004873,Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer,COMPLETED,PHASE2,Gastric Cancer,cisplatin (DRUG); docetaxel (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG),148124,TXL,Gastric Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6683,NCT00737373,Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer,COMPLETED,PHASE2,Gastric Cancer; Adenocarcinoma of the Esophagogastric Junction,Docetaxel (DRUG); 5-Fluorouracil (DRUG); Oxaliplatin (DRUG); folinic acid (DRUG),148124,TXL,Gastric Cancer; Adenocarcinoma of the Esophagogastric Junction,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6684,NCT01583426,Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto),COMPLETED,PHASE3,Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer,nab-Paclitaxel (DRUG); Paclitaxel (DRUG),148124,TXL,Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6685,NCT03673657,Study of Early Nutritional Intervention During Concurrent Chemoradiotherapy for Local Advanced Non-small Cell Lung Cancer,COMPLETED,PHASE2,Local Advanced Non-small Cell Lung Cancer,Early Nutrition Intervention from the start of CCRT (DIETARY_SUPPLEMENT); Thoracic radiotherapy (RADIATION); Weekly DP chemotherapy concurrent with thoracic radiotherapy (DRUG),148124,TXL,Local Advanced Non-small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6686,NCT00086957,"Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer",COMPLETED,PHASE1,Breast Cancer,trastuzumab (BIOLOGICAL); docetaxel (DRUG); gefitinib (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6687,NCT01515748,Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer,COMPLETED,PHASE3,Gastric Cancer,"Docetaxel (XRP6976) (DRUG); Oxaliplatin (SR96669) (DRUG); S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil) (DRUG)",148124,TXL,Gastric Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6688,NCT04929548,Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP,NOT_YET_RECRUITING,PHASE4,Breast Cancer,Pyrotinib Maleate Tablets (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6689,NCT02393248,"Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)",TERMINATED,PHASE1,Lung Cancer; Solid Tumor; Gastric Cancer; Urothelial Cancer; Endometrial Cancer; Multiple Myeloma; Myeloproliferative Neoplasms; Breast Cancer; Cholangiocarcinoma; UC; MPN,Pemigatinib (DRUG); Gemcitabine (DRUG); Pembrolizumab (DRUG); Docetaxel (DRUG); Trastuzumab (DRUG); Retifanlimab (DRUG); Cisplatin (DRUG),148124,TXL,Lung Cancer; Solid Tumor; Gastric Cancer; Urothelial Cancer; Endometrial Cancer; Multiple Myeloma; Myeloproliferative Neoplasms; Breast Cancer; Cholangiocarcinoma; UC; MPN,Bladder/Urinary Tract,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6690,NCT00539630,TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN,COMPLETED,PHASE3,"Carcinoma, Squamous Cell",Docetaxel (DRUG),148124,TXL,Squamous Cell Carcinoma,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6691,NCT00331682,Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer,alvocidib (DRUG); docetaxel (DRUG),148124,TXL,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6692,NCT00065182,Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer,COMPLETED,PHASE2,"Lung Cancer, Non-Small Cell; Non-Small-Cell Lung Cancer",Topotecan/Docetaxel combination (DRUG); Docetaxel (DRUG),148124,TXL,"Lung Cancer, Non-Small Cell; Non-Small-Cell Lung Cancer",Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6693,NCT03099382,Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer,COMPLETED,PHASE3,Esophageal Carcinoma,camrelizumab (BIOLOGICAL); Docetaxel (DRUG); Irinotecan (DRUG),148124,TXL,Esophageal Carcinoma,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6694,NCT04367090,Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer,COMPLETED,PHASE1,Metastatic Breast Cancer,"Docetaxel, trastuzumab (DRUG); Pyrotinib (DRUG)",148124,TXL,Metastatic Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6695,NCT05673590,Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer,RECRUITING,PHASE3,Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Utidelone Injection (DRUG); Docetaxel Injection (DRUG),148124,TXL,Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6696,NCT05474690,A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer,WITHDRAWN,PHASE3,Breast Cancer; HER2-positive Breast Cancer,Docetaxel + Carboplatin + Trastuzumab + Pertuzumab (DRUG); (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab) (DRUG),148124,TXL,Breast Cancer; HER2-positive Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6697,NCT00446290,"Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer",COMPLETED,PHASE1,Stomach Cancer,"Docetaxel, Capecitabine and Oxaliplatin (DRUG)",148124,TXL,Stomach Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6698,NCT00567190,A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer,COMPLETED,PHASE3,Metastatic Breast Cancer,Pertuzumab (DRUG); Placebo (DRUG); Trastuzumab (DRUG); Docetaxel (DRUG),148124,TXL,Metastatic Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6699,NCT00821990,Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer,COMPLETED,PHASE3,Advanced Gastric Cancer,Chemotherapy (DRUG); Best supportive care (OTHER),148124,TXL,Advanced Gastric Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6700,NCT02931890,Multicentric Randomised Trial for Resectable Gastric Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Gastric Cancer,Docetaxel (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG); gastrectomy (PROCEDURE); radiotherapy of gastric cancer (RADIATION); Paclitaxel (DRUG); Carboplatin (DRUG),148124,TXL,Gastric Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6701,NCT02448290,"Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy",COMPLETED,PHASE2,Gastric Adenocarcinoma,docetaxel plus selumetinib (DRUG),148124,TXL,Gastric Adenocarcinoma,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6702,NCT05074290,Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients,RECRUITING,PHASE1,Breast Cancer,Epidiferphane (DRUG); Taxane Chemotherapy (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6703,NCT01959490,Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer,COMPLETED,PHASE2,Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,trastuzumab (BIOLOGICAL); Pertuzumab (BIOLOGICAL); docetaxel (DRUG); carboplatin (DRUG); doxorubicin (DRUG); cyclophosphamide (DRUG); paclitaxel (DRUG); Bevacizumab (DRUG),148124,TXL,Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6704,NCT06441890,BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer,RECRUITING,PHASE2,Breast Cancer; HER2-positive Breast Cancer,Paclitaxel (DRUG); Nab-paclitaxel (DRUG); Docetaxel (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG),148124,TXL,Breast Cancer; HER2-positive Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6705,NCT02134990,"Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer",UNKNOWN,PHASE2,"Carcinoma, Non-Small-Cell Lung",Oshadi D and Oshadi R (DRUG); Docetaxel (DRUG),148124,TXL,"Carcinoma, Non-Small-Cell Lung",Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6706,NCT01792479,A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-small Cell Lung Cancer,BIND-014 (DRUG),148124,TXL,Non-small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6707,NCT01070290,A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen,WITHDRAWN,PHASE2,Gastric Cancer,"ARQ 197 (DRUG); Oxaliplatin, capecitabine or irinotecan (DRUG)",148124,TXL,Gastric Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6708,NCT00084890,Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix,TERMINATED,PHASE1,Cervical Cancer,carboplatin (DRUG); docetaxel (DRUG),148124,TXL,Cervical Cancer,Cervix,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6709,NCT06409390,Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer,RECRUITING,EARLY_PHASE1,Metastatic Breast Cancer,Taxotere (DRUG); Cytoxan (DRUG); Trastuzumab deruxtecan (DRUG); Sacituzumab govitecan (DRUG); Xeloda (DRUG); Fulvestrant (DRUG); Ribociclib (DRUG); Abemaciclib (DRUG),148124,TXL,Metastatic Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6710,NCT00003103,Chemotherapy in Treating Patients With Solid Tumors,COMPLETED,PHASE1,"Bladder Cancer; Breast Cancer; Colorectal Cancer; Esophageal Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",oblimersen sodium (BIOLOGICAL); docetaxel (DRUG),148124,TXL,"Bladder Cancer; Breast Cancer; Colorectal Cancer; Esophageal Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Bowel,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6711,NCT01187290,Preoperative Chemoradiotherapy Versus Chemotherapy Alone in Nonsmall Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,neoadjuvant chemoradiotherapy (RADIATION),148124,TXL,Non-small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6712,NCT00191490,A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Gemcitabine (DRUG); docetaxel (DRUG); cisplatin (DRUG),148124,TXL,"Carcinoma, Non-Small-Cell Lung",Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6713,NCT02688803,Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC),COMPLETED,PHASE4,Breast Cancer,Dose dense AC-P (DRUG); Dose dense AC (DRUG); FEC-D (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6714,NCT00066443,"Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer",COMPLETED,PHASE1,Breast Cancer,pegfilgrastim (BIOLOGICAL); docetaxel (DRUG); epirubicin hydrochloride (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6715,NCT00209690,Phase I/II Study of TPF as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer.,COMPLETED,PHASE1,Esophageal Cancer,Taxotere (DRUG); 5-FU (DRUG); Briplatin (DRUG),148124,TXL,Esophageal Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6716,NCT00318903,Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer,COMPLETED,PHASE2,Esophageal Cancer; Cancer of the Esophagus; Esophagus Cancer; Esophageal Neoplasm; Cancer of Esophagus,Irinotecan (drug) (DRUG); Taxotere (drug) (DRUG); Radiotherapy (procedure) (PROCEDURE); Esophagectomy (procedure) (PROCEDURE),148124,TXL,Esophageal Cancer; Cancer of the Esophagus; Esophagus Cancer; Esophageal Neoplasm; Cancer of Esophagus,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6717,NCT01803503,"Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors",UNKNOWN,PHASE2,Solid Tumors; Breast Cancer; Non-small Cell Lung Cancer; Prostate Cancer; Gastric Cancer,Docetaxel (DRUG); Sunitinib (DRUG),148124,TXL,Solid Tumors; Breast Cancer; Non-small Cell Lung Cancer; Prostate Cancer; Gastric Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6718,NCT00989690,Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer,UNKNOWN,PHASE3,Lung Cancer,docetaxel (DRUG); erlotinib hydrochloride (DRUG); pemetrexed disodium (DRUG); fluorescence in situ hybridization (GENETIC); mutation analysis (GENETIC); proteomic profiling (GENETIC); immunohistochemistry staining method (OTHER); laboratory biomarker analysis (OTHER); matrix-assisted laser desorption/ionization time of flight mass spectrometry (OTHER); breath test (PROCEDURE),148124,TXL,Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6719,NCT00242203,Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms,Zometa (DRUG); Epirubicin (DRUG); Docetaxel (DRUG); Trastuzumab (DRUG); External beam radiation (RADIATION); Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection (PROCEDURE),148124,TXL,Breast Neoplasms,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6720,NCT02922764,A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer,COMPLETED,PHASE1,Endometrial Cancer; Endometrial Cancer Recurrent; Lung Cancer Recurrent; Lung Cancer; Non-small Cell Lung Cancer Metastatic; Non-small Cell Carcinoma,RGX-104 (DRUG); Ipilimumab (DRUG); Docetaxel (DRUG); Pembrolizumab (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG),148124,TXL,Endometrial Cancer; Endometrial Cancer Recurrent; Lung Cancer Recurrent; Lung Cancer; Non-small Cell Lung Cancer Metastatic; Non-small Cell Carcinoma,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6721,NCT00980603,Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer,UNKNOWN,PHASE2,Gastric Cancer,"docetaxel (DRUG); docetaxel, cisplatin (DRUG); docetaxel, S-1 (DRUG)",148124,TXL,Gastric Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6722,NCT06254690,The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study,RECRUITING,PHASE2,Breast Cancer,Pyrotinib dose escalation (DRUG); Pyrotinib dose normal (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6723,NCT00313690,Cancer Treatment Followed by Surgery for Early Stage Non-small Cell Lung Cancer,WITHDRAWN,PHASE1,Lung Cancer,"Bortezomib, Docetaxel and Cisplatin (DRUG)",148124,TXL,Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6724,NCT00004264,"Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer",UNKNOWN,PHASE1,Drug/Agent Toxicity by Tissue/Organ; Lung Cancer,amifostine trihydrate (DRUG); cisplatin (DRUG); docetaxel (DRUG),148124,TXL,Drug/Agent Toxicity by Tissue/Organ; Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6725,NCT02859038,Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients with Advanced Ovarian Cancer (SUNNY),ACTIVE_NOT_RECRUITING,PHASE3,Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Upfront cytoreductive surgery (PROCEDURE); Interval debulking surgery (PROCEDURE),148124,TXL,Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6726,NCT06123338,A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer,RECRUITING,PHASE2,Esophageal Cancer; Gastric Adenocarcinoma; HER2 Gene Mutation,Pembrolizumab (DRUG); Trastuzumab (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG); 5-Fluorouracil (DRUG); Docetaxel (DRUG),148124,TXL,Gastroesophageal Cancer with HER2 Mutation,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6727,NCT05381038,Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI,NOT_YET_RECRUITING,PHASE1,Solid Tumor; Gastrointestinal Cancer; Breast Cancer,QPOP (DEVICE); CURATE.AI (DEVICE); Azacitidine + docetaxel (DRUG); Azacitidine + paclitaxel (DRUG); Azacitidine + irinotecan (DRUG),148124,TXL,Solid Tumors and Gastrointestinal Cancer,Bowel,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6728,NCT03243838,Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer,COMPLETED,PHASE2,Triple-Negative Breast Cancer,Apatinib (DRUG),148124,TXL,Triple-Negative Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6729,NCT00711243,"Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor",COMPLETED,PHASE1,"Gastric Cancer; Unspecified Adult Solid Tumor, Protocol Specific",docetaxel (DRUG); fluorouracil (DRUG); oxaliplatin (DRUG),148124,TXL,"Gastric Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6730,NCT04085250,Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy,ACTIVE_NOT_RECRUITING,PHASE2,Stage III Non-small-cell Lung Cancer,Neoadjuvant therapy (OTHER); Chemotherapy concurrent with radiotherapy (OTHER); Radiotherapy (RADIATION); Nivolumab (DRUG); Observation (OTHER),148124,TXL,Stage III Non-small-cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6731,NCT01905150,"Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer",COMPLETED,PHASE2,Pancreatic Cancer,G-FLIP (DRUG); G-FLIP-DM (DRUG); Vitamin C (DIETARY_SUPPLEMENT),148124,TXL,Pancreatic Cancer,Pancreas,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6732,NCT01792050,Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Docetaxel (DRUG); Placebo (OTHER); Indoximod (DRUG); Paclitaxel (DRUG),148124,TXL,Metastatic Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6733,NCT03371550,A Phase II Trial of Cisplatin-Docetaxel Induction Plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy,COMPLETED,PHASE2,Locally Advanced Non-small Cell Lung Cancer,Docetaxel (DRUG); concomitant radiotherapy (RADIATION); Cisplatin (DRUG),148124,TXL,Locally Advanced Non-small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6734,NCT00364195,Tesmilifene in Combination With Docetaxel in the Treatment of Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Tesmilifene (YMB1002) (DRUG),148124,TXL,Metastatic Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6735,NCT02472964,"Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.",COMPLETED,PHASE3,Breast Cancer,Trastuzumab (BIOLOGICAL); MYL- 1401O (BIOLOGICAL); Paclitaxel (DRUG); Docetaxel (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6736,NCT00059943,"Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer",COMPLETED,PHASE2,Breast Cancer; Lung Cancer; Prostate Cancer,docetaxel (DRUG),148124,TXL,Breast Cancer; Lung Cancer; Prostate Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6737,NCT02144012,A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer,TERMINATED,PHASE3,Metastatic Breast Cancer,Trastuzumab (DRUG); Trastuzumab Emtansine (DRUG); Docetaxel (DRUG),148124,TXL,Metastatic Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6738,NCT06861712,Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer,NOT_YET_RECRUITING,PHASE2,Oral Squamous Cell Carcinoma (OSCC); Oropharyngeal Squamous Cell Carcinoma (SCC); Stereotactic Body Radiation Therapy (SBRT),"SBRT (RADIATION); Docetaxel, Cisplatin, Toripalimab (DRUG); Radical resection surgery (PROCEDURE); IMRT ± chemotherapy/toripalimab (RADIATION)",148124,TXL,Oral Squamous Cell Carcinoma (OSCC); Oropharyngeal Squamous Cell Carcinoma (SCC); Stereotactic Body Radiation Therapy (SBRT),Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6739,NCT00216112,"Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer",COMPLETED,PHASE2,Ovarian Cancer,Imatinib Mesylate (DRUG); Docetaxel (DRUG),148124,TXL,Ovarian Cancer,Ovary/Fallopian Tube,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6740,NCT00994968,"Doxorubicin Hydrochloride, Cyclophosphamide, Docetaxel, and S-1 Before Surgery in Treating Women With Stage II or Stage III Breast Cancer",UNKNOWN,PHASE2,Breast Cancer,cyclophosphamide (DRUG); docetaxel (DRUG); doxorubicin hydrochloride (DRUG); tegafur-gimeracil-oteracil potassium (DRUG); neoadjuvant therapy (PROCEDURE); therapeutic conventional surgery (PROCEDURE),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6741,NCT00964704,A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer,WITHDRAWN,PHASE2,Breast Cancer,bevacizumab [Avastin] (DRUG); capecitabine [Xeloda] (DRUG); docetaxel (DRUG); trastuzumab [Herceptin] (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6742,NCT01181401,InductionChemo-Radio-Antibody-Treatment,COMPLETED,PHASE2,Squamous Cell Carcinoma of the Head; Squamous Cell Carcinoma of the Neck,TPF induction chemotherapy (DRUG); TPF experimental (DRUG); Standard Radiochemotherapy (HART) (RADIATION),148124,TXL,Squamous Cell Carcinoma of the Head; Squamous Cell Carcinoma of the Neck,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6743,NCT03013504,"A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients",COMPLETED,PHASE3,HER2 Positive Breast Cancer,HD201 (DRUG); Herceptin (DRUG); Docetaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),148124,TXL,HER2 Positive Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6744,NCT00092001,Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Sunitinib (DRUG),148124,TXL,"Carcinoma, Non-Small-Cell Lung",Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6745,NCT02047201,Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC,COMPLETED,PHASE2,Head and Neck Squamous Cell Carcinoma,IMRT (RADIATION); PET/CT (RADIATION); Docetaxel (DRUG); Fluorouracil (DRUG); Cisplatin (DRUG),148124,TXL,Head and Neck Squamous Cell Carcinoma,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6746,NCT00086268,Non-small Cell Lung Cancer Study US75 (Z-PACT),COMPLETED,PHASE3,Non Small Cell Lung Carcinoma,zoledronic acid (DRUG); Taxotere (DRUG); Carboplatin (DRUG),148124,TXL,Non Small Cell Lung Carcinoma,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6747,NCT04629846,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.,COMPLETED,PHASE3,Breast Cancer,Trastuzumab (DRUG); QL1209 (DRUG); Pertuzumab (DRUG); Docetaxel (DRUG); surgery (PROCEDURE),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6748,NCT00490646,A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,ixabepilone (DRUG); docetaxel (DRUG); trastuzumab (DRUG),148124,TXL,Metastatic Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6749,NCT01461746,Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer,UNKNOWN,PHASE2,Endometrial Cancer,Docetaxel (DRUG); Cisplatin (DRUG); Radiation therapy (RADIATION),148124,TXL,Endometrial Cancer,Uterus,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6750,NCT01472146,ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Breast Disease; Neoplasms; Neoplasms by Site,Zo-Nantax (DRUG),148124,TXL,Breast Cancer; Breast Disease; Neoplasms; Neoplasms by Site,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6751,NCT01652469,Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.,COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung",Erlotinib (DRUG); Docetaxel (DRUG),148124,TXL,"Carcinoma, Non-Small-Cell Lung",Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6752,NCT00005868,Docetaxel and Cisplatin in Treating Patients With Untreated Stage IIIA Non-small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,cisplatin (DRUG); docetaxel (DRUG),148124,TXL,Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6753,NCT04182568,Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer,UNKNOWN,PHASE4,Breast Cancer,nab-paclitaxel followed by anthracycline and cyclophosphamide (DRUG); Docetaxel followed by anthracycline and cyclophosphamide (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6754,NCT01596868,GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China,COMPLETED,PHASE2,Nasopharyngeal Squamous Cell Carcinoma; Toxicity Due to Radiotherapy,gemcitabine and cisplatin (DRUG); docetaxel and cisplatin (DRUG),148124,TXL,Nasopharyngeal Squamous Cell Carcinoma; Toxicity Due to Radiotherapy,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6755,NCT01057069,Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,"Carboplatin and Paclitaxel (DRUG); Doxorubicin, cyclophosphamide (DRUG); Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide (DRUG)",148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6756,NCT05929768,Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer,RECRUITING,PHASE3,Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Early Stage Triple-Negative Breast Carcinoma,Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG); Doxorubicin (DRUG); Paclitaxel (DRUG); Pembrolizumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); Surgical Procedure (PROCEDURE),148124,TXL,Early Stage Triple-Negative Breast Carcinoma,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6757,NCT03647969,Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer,COMPLETED,PHASE2,Adenocarcinoma of the Stomach; GastroEsophageal Cancer,Nivolumab (DRUG); Ipilimumab (DRUG); mFOLFOX (DRUG); FLOT (DRUG),148124,TXL,Adenocarcinoma of the Stomach; GastroEsophageal Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6758,NCT05296746,Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer,RECRUITING,PHASE2,Breast Cancer Stage II,Ribociclib (neoadjuvant) (DRUG); Chemotherapy (adjuvant) (DRUG); Ribociclib (adjuvant) (DRUG),148124,TXL,Early Stage Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6759,NCT03196869,the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer,UNKNOWN,PHASE2,Locally Advanced Head and Neck Squamous Cell Carcinoma,Chrono-chemotherapy (DEVICE); Routine intravenous drip (DEVICE); induction Chrono-chemotherapy (DRUG); induction Routine-chemotherapy (DRUG); cisplatin chrono-chemotherapy (DRUG); cisplatin routine-chemotherapy (DRUG); intensity-modulated radiation therapy (RADIATION),148124,TXL,Locally Advanced Head and Neck Squamous Cell Carcinoma,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6760,NCT00139269,Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck,COMPLETED,PHASE1,Advanced Squamous Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; SSCHN,Docetaxel (DRUG); Cisplatin (DRUG); 5-Fluorouracil (DRUG),148124,TXL,Advanced Squamous Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; SSCHN,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6761,NCT00532727,Triple Negative Breast Cancer Trial,UNKNOWN,PHASE3,Breast Cancer,Carboplatin (DRUG); Docetaxel (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6762,NCT01921673,Dovitinib Plus Docetaxel in Gastric Cancer,COMPLETED,PHASE1,Gastric Cancer,Dovitinib and docetaxel (DRUG),148124,TXL,Gastric Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6763,NCT00003560,"Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",UNKNOWN,PHASE2,Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,carboplatin (DRUG); docetaxel (DRUG),148124,TXL,Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Uterus,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6764,NCT06632327,Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer,RECRUITING,PHASE3,Resectable Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8,Surgical Procedure (PROCEDURE); Cisplatin (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Gemcitabine (DRUG); Docetaxel (DRUG); Vinorelbine (DRUG); Nivolumab (DRUG); Pembrolizumab (DRUG); Atezolizumab (DRUG); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Positron Emission Tomography (PROCEDURE),148124,TXL,Non-Small-Cell Lung Carcinoma,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6765,NCT05200260,Surgery Combined with Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer,RECRUITING,PHASE2,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Primary debulking surgery (PROCEDURE); Neoadjuvant chemotherapy (PROCEDURE); PARP inhibitor (DRUG); Bevacizumab (DRUG),148124,TXL,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6766,NCT02035527,"Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",COMPLETED,PHASE1,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Oral Cavity Squamous Cell Carcinoma; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer; Untreated Metastatic Squamous Neck Cancer With Occult Primary,sorafenib tosylate (DRUG); cisplatin (DRUG); docetaxel (DRUG); Correlative Studies (OTHER),148124,TXL,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Oral Cavity Squamous Cell Carcinoma; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer; Untreated Metastatic Squamous Neck Cancer With Occult Primary,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6767,NCT03654027,Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,Anlotinib Plus Docetaxel (DRUG); Docetaxel (DRUG),148124,TXL,Non-small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6768,NCT06009627,Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients,RECRUITING,PHASE2,Breast Cancer,Dalcelli、Exemestane、Gosserine (DRUG); Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6769,NCT04649476,Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma,COMPLETED,PHASE2,Oral Squamous Cell Carcinoma,Camrelizumab (DRUG); Camrelizumanb plus TPF (DRUG),148124,TXL,Oral Squamous Cell Carcinoma,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6770,NCT01539876,Tumour Necrosis Factor Release in Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Docetaxel,WITHDRAWN,PHASE1,Breast Cancer,Fine needle aspiration assessing tumour TNFa levels (PROCEDURE),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6771,NCT00278460,Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,docetaxel (DRUG); gemcitabine hydrochloride (DRUG),148124,TXL,Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6772,NCT02307227,Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors,COMPLETED,PHASE2,Breast Neoplasms,Trastuzumab (DRUG); Paclitaxel (DRUG); Epirubicin (DRUG); Docetaxel (DRUG),148124,TXL,Breast Neoplasms,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6773,NCT00707473,"Docetaxel, Cisplatin and Fluorouracil in Treating Patients with Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma; Sinonasal Undifferentiated Carcinoma; Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC V8; Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC V8; Stage IVA Nasal Cavity and Paranasal Sinus Cancer AJCC V8; Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC V8,Carboplatin (DRUG); Chemoradiotherapy (OTHER); Cisplatin (DRUG); Definitive Surgical Resection (PROCEDURE); Docetaxel (DRUG); Fluorouracil (DRUG); Quality-of-Life Assessment (PROCEDURE); Radiation Therapy (RADIATION),148124,TXL,Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma; Sinonasal Undifferentiated Carcinoma; Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC V8; Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC V8; Stage IVA Nasal Cavity and Paranasal Sinus Cancer AJCC V8; Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC V8,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6774,NCT00190476,Elderly NSCLC/D vs DP (JCOG0207),TERMINATED,PHASE3,Non-small-cell Lung Cancer,Weekly docetaxel alone (DRUG); Weekly docetaxel + cisplatin combination (DRUG),148124,TXL,Non-small-cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6775,NCT04655976,Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy,ACTIVE_NOT_RECRUITING,PHASE3,"Lung Cancer, Non-Small Cell",Cobolimab (BIOLOGICAL); Dostarlimab (BIOLOGICAL); Docetaxel (DRUG),148124,TXL,"Lung Cancer, Non-Small Cell",Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6776,NCT00511576,Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors,TERMINATED,PHASE1,Breast Cancer; Lung Cancer; Pulmonary Cancer; Non-Small-Cell Lung Carcinoma; Prostate Cancer; Prostatic Cancer; Gastric Cancer; Stomach Cancer,MGCD0103 & Docetaxel (DRUG),148124,TXL,Breast Cancer; Lung Cancer; Pulmonary Cancer; Non-Small-Cell Lung Carcinoma; Prostate Cancer; Prostatic Cancer; Gastric Cancer; Stomach Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6777,NCT02008227,A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy,COMPLETED,PHASE3,Non-Squamous Non-Small Cell Lung Cancer,Atezolizumab (DRUG); Docetaxel (DRUG),148124,TXL,Non-Squamous Non-Small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6778,NCT01186731,Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,Liposome Entrapped Docetaxel (LE-DT) (DRUG),148124,TXL,Pancreatic Cancer,Pancreas,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6779,NCT06768931,Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer,RECRUITING,PHASE2,Breast Cancer; Triple Negative Breast Cancer (TNBC); Early Stage Breast Cancer; Immunotherapy; Probiotic,Biolosion (oral probiotic compound preparation) (OTHER),148124,TXL,Breast Cancer; Triple Negative Breast Cancer (TNBC); Early Stage Breast Cancer; Immunotherapy; Probiotic,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6780,NCT00270582,A Study of Weekly Docetaxel Plus Cisplatin Followed by Gemcitabine vs. Gemcitabine Plus Cisplatin Followed by Weekly Docetaxel in the Treatment of Advanced Non-Small-Cell Lung Cancer,UNKNOWN,PHASE2,"Carcinoma, Non-Small-Cell Lung","Taxotere, Cisplatin, Gemcitabine (DRUG)",148124,TXL,"Carcinoma, Non-Small-Cell Lung",Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6781,NCT03600831,Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma,COMPLETED,PHASE2,Esophageal Squamous Cell Carcinoma,Docetaxel plus cisplatin (DRUG); radiotherapy (RADIATION),148124,TXL,Esophageal Squamous Cell Carcinoma,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6782,NCT00118131,Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,TERMINATED,PHASE2,Lung Cancer,cisplatin (DRUG); docetaxel (DRUG),148124,TXL,Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6783,NCT03252431,Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,COMPLETED,PHASE3,Breast Cancer; Neutropenia,F-627 (DRUG); Neulasta (DRUG),148124,TXL,Breast Cancer with Neutropenia,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6784,NCT06523673,Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer,RECRUITING,PHASE3,Metastatic Non-Small Cell Lung Cancer; NSCLC Stage IV; OligoProgressive Metastatic Disease,Stereotactic Body Radiotherapy (RADIATION); second-line systemic therapy (DRUG),148124,TXL,Metastatic Non-Small Cell Lung Cancer; NSCLC Stage IV; OligoProgressive Metastatic Disease,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6785,NCT00434031,CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer,WITHDRAWN,PHASE2,Breast Cancer,docetaxel (DRUG); cyclophosphamide (DRUG); trastuzumab (DRUG); liposomal doxorubicin (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6786,NCT02087176,A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer,TERMINATED,PHASE2,Previously Treated Non Small Cell Lung Cancer,AZD1775 (DRUG); AZD1775 Placebo (DRUG); Antimitotic Agent (DRUG); pegfiligrastim (DRUG),148124,TXL,Previously Treated Non Small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6787,NCT03367676,"12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)",UNKNOWN,PHASE2,Breast Cancer,Trastuzumab (DRUG); Docetaxel (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6788,NCT06029127,A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,BGB-A445 (DRUG); Docetaxel (DRUG); Ramucirumab (DRUG); BGB-15025 (DRUG),148124,TXL,Advanced Non-Small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6789,NCT05910827,"Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers",RECRUITING,PHASE1,Advanced or Metastatic Squamous Non-Small Cell Lung Cancer; Advanced Head and Neck Squamous Cell Carcinoma; Advanced Esophageal Squamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Advanced Cutaneous Squamous Cell Carcinoma,HMBD-001 (DRUG); Docetaxel (DRUG); Cetuximab (DRUG),148124,TXL,Advanced or Metastatic Squamous Non-Small Cell Lung Cancer; Advanced Head and Neck Squamous Cell Carcinoma; Advanced Esophageal Squamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Advanced Cutaneous Squamous Cell Carcinoma,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6790,NCT02721576,A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC,TERMINATED,PHASE4,Esophageal Neoplasms,Sodium Glycididazole (DRUG),148124,TXL,Esophageal Neoplasms,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6791,NCT00426127,Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer,TERMINATED,PHASE2,Pancreatic Cancer,Docetaxel (DRUG); Liposomal Doxorubicin (DRUG); Enoxaparin (DRUG),148124,TXL,Pancreatic Cancer,Pancreas,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6792,NCT00406276,Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer,TERMINATED,PHASE1,Lung Cancer,RAD001 (DRUG); Docetaxel (DRUG),148124,TXL,Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6793,NCT00193427,"Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer",COMPLETED,PHASE2,Lung Cancer,Docetaxel (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG); Radiation (RADIATION),148124,TXL,Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6794,NCT00004082,"Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors",COMPLETED,PHASE1,Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,carboplatin (DRUG); docetaxel (DRUG); gemcitabine hydrochloride (DRUG),148124,TXL,Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Uterus,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6795,NCT04717531,Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Pyrotinib (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); Docetaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6796,NCT04144582,Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer,COMPLETED,PHASE2,Non-small Cell Lung Cancer,Sintilimab Combined With Docetaxel Monotherapy (DRUG),148124,TXL,Non-small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6797,NCT01588431,Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer,COMPLETED,PHASE2,"Carcinoma, Squamous Cell of Head and Neck","Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery (DRUG)",148124,TXL,Head and Neck Squamous Cell Carcinoma,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6798,NCT06732531,"Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer",RECRUITING,PHASE1,Bladder Cancer; Non Muscle Invasive,BH011 (DRUG),148124,TXL,Bladder Cancer; Non Muscle Invasive,Bladder/Urinary Tract,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6799,NCT00003231,Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,cisplatin (DRUG); docetaxel (DRUG); surgical procedure (PROCEDURE); radiation therapy (RADIATION),148124,TXL,Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6800,NCT05527782,Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck,ACTIVE_NOT_RECRUITING,PHASE2,Locally Advanced Head and Neck Squamous Cell Carcinoma,modified TPF (DRUG); Quality of life assessment (QoL) (OTHER),148124,TXL,Locally Advanced Head and Neck Squamous Cell Carcinoma,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6801,NCT06190782,Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor,RECRUITING,PHASE3,Esophageal Squamous Cell Carcinoma; Oligometastatic Disease; Radiotherapy,PD-1 inhibitor+/- chemotherapy combined with local therapy (COMBINATION_PRODUCT); systemic therapy alone (DRUG),148124,TXL,Esophageal Squamous Cell Carcinoma; Oligometastatic Disease; Radiotherapy,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6802,NCT00006682,Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,docetaxel (DRUG); vinorelbine ditartrate (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6803,NCT00212082,Gene Expression Profiles in Predicting Chemotherapy Response in Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,"doxorubicin, docetaxel (DRUG)",148124,TXL,Metastatic Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6804,NCT01639131,Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma,TERMINATED,PHASE2,Metastatic Colorectal Adenocarcinoma,Gemcitabine (DRUG); Docetaxel (DRUG); Filgrastim or Pegfilgrastim (DRUG),148124,TXL,Metastatic Colorectal Adenocarcinoma,Bowel,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6805,NCT00003782,"Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes",COMPLETED,PHASE3,Breast Cancer,cyclophosphamide (DRUG); docetaxel (DRUG); doxorubicin (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6806,NCT02969473,Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma,UNKNOWN,PHASE2,Esophageal Neoplasm; Chemoradiation,Docetaxel (DRUG); Fluorouracil (DRUG),148124,TXL,Esophageal Neoplasm,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6807,NCT04136782,Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer,RECRUITING,PHASE4,Breast Cancer,Albumin-bound paclitaxel combined with carboplatin (DRUG); Epirubicin combined with docetaxel (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6808,NCT06046482,Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma,TERMINATED,PHASE2,Head Neck; Squamous Cell Carcinoma of Head and Neck,Pembrolizumab (DRUG); Magrolimab (DRUG); cetuximab (DRUG); Docetaxel (DRUG),148124,TXL,Head Neck; Squamous Cell Carcinoma of Head and Neck,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6809,NCT03505320,A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Pharmacokinetics of Zolbetuximab; Gastric Cancer; Gastro-esophageal Junction (GEJ) Cancer; Pharmacokinetics of Oxaliplatin; Pharmacokinetics of Fluorouracil Bolus (5-FU),zolbetuximab (DRUG); oxaliplatin (DRUG); leucovorin (DRUG); fluorouracil (DRUG); Pembrolizumab (DRUG); folinic acid (DRUG); nivolumab (DRUG); Docetaxel (DRUG),148124,TXL,Gastric and Gastro-esophageal Junction Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6810,NCT06542731,"An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Non-small Cell Lung Cancer,ONO-4578 (DRUG); ONO-4538 (DRUG); Docetaxel (DRUG); Ramucirumab (DRUG),148124,TXL,Non-small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6811,NCT02061631,Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck,COMPLETED,PHASE2,Squamous Cell Carcinoma of Head and Neck,Cisplatin (DRUG); DOCETAXEL XRP6976 (DRUG); Dexamethasone (DRUG); Dexamethasone (DRUG),148124,TXL,Squamous Cell Carcinoma of Head and Neck,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6812,NCT03979131,Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC),ACTIVE_NOT_RECRUITING,PHASE2,Gastroesophageal Junction Adenocarcinoma; Stomach Neoplasms,Avelumab addition to perioperative chemotherapy in GC and GEJC (COMBINATION_PRODUCT),148124,TXL,Gastroesophageal Junction Adenocarcinoma; Stomach Neoplasms,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6813,NCT05676931,Study With Various Immunotherapy Treatments in Participants With Lung Cancer,RECRUITING,PHASE2,Advanced Non-Small Cell Lung Cancer,Domvanalimab (DRUG); Quemliclustat (DRUG); Zimberelimab (DRUG); Docetaxel (DRUG); Platinum-Based Doublet (DRUG),148124,TXL,Advanced Non-Small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6814,NCT04760431,TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN),NOT_YET_RECRUITING,PHASE2,HER2-positive Breast Cancer; Brain Metastases,Trastuzumab (DRUG); Taxanes (DRUG); Pertuzumab (DRUG); Tyrosine kinase inhibitor (DRUG),148124,TXL,HER2-positive Breast Cancer with Brain Metastases,CNS/Brain,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6815,NCT01542931,TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma,COMPLETED,PHASE2,Stage III Oral Cavity Squamous Cell Carcinoma; Stage IVA Oral Cavity Squamous Cell Carcinoma,TPF induction chemotherapy (DRUG),148124,TXL,Stage III Oral Cavity Squamous Cell Carcinoma; Stage IVA Oral Cavity Squamous Cell Carcinoma,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6816,NCT05319873,"Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer",RECRUITING,PHASE1,Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Locally Advanced HER2-Positive Breast Carcinoma; Metastatic HER2-Positive Breast Carcinoma; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8,Carboplatin (DRUG); Docetaxel (DRUG); Fulvestrant (DRUG); Pertuzumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Ribociclib (DRUG); Trastuzumab (BIOLOGICAL); Tucatinib (DRUG),148124,TXL,Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Locally Advanced HER2-Positive Breast Carcinoma; Metastatic HER2-Positive Breast Carcinoma; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6817,NCT01054482,Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung Cancer,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,Pre-operative chemotherapy (DRUG); Pre-operative concurrent chemoradiation therapy (OTHER),148124,TXL,Non-small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6818,NCT00028873,R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy,COMPLETED,PHASE2,Breast Cancer,docetaxel (DRUG); laniquidar (DRUG); paclitaxel (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6819,NCT00569673,"Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",COMPLETED,PHASE2,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,filgrastim (BIOLOGICAL); pegfilgrastim (BIOLOGICAL); docetaxel (DRUG); trabectedin (DRUG),148124,TXL,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6820,NCT05327231,IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma,COMPLETED,PHASE1,Gastric Cancer,IN10018 (DRUG); Docetaxel (DRUG),148124,TXL,Gastric Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6821,NCT05715931,Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma,RECRUITING,PHASE2,Adenocarcinoma of the Stomach; Adenocarcinoma of Esophagogastric Junction; HER2-positive Gastric Cancer,"Toripalimab (DRUG); Trastuzumab (DRUG); 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT) (DRUG)",148124,TXL,Gastric and Gastroesophageal Junction Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6822,NCT00876460,"BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I",COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung",BIBF 1120 M + docetaxel M (DRUG); BIBF 1120 M + docetaxel H (DRUG); BIBF 1120 H + docetaxel H (DRUG); BIBF 1120 L + docetaxel M (DRUG); BIBF 1120 H + docetaxel M (DRUG),148124,TXL,"Carcinoma, Non-Small-Cell Lung",Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6823,NCT00448760,Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery,COMPLETED,PHASE2,Esophageal Cancer,Docetaxel (DRUG); Floxuridine (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Microarray analysis (GENETIC); reverse transcriptase-polymerase chain reaction (GENETIC); Conventional surgery (PROCEDURE),148124,TXL,Esophageal Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6824,NCT02027376,Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients,COMPLETED,PHASE1,Advanced Breast Cancer,LDE225 (DRUG); Docetaxel (DRUG),148124,TXL,Advanced Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6825,NCT00520676,Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer,COMPLETED,PHASE3,Non-Small Cell Lung Cancer,pemetrexed (DRUG); docetaxel (DRUG); carboplatin (DRUG),148124,TXL,Advanced Non-Small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6826,NCT06577376,A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma,NOT_YET_RECRUITING,PHASE1,Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma; Expressing Human Epidermal Growth Factor Receptor-2 (HER-2); Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past,DP303c (DRUG); Simmitinib tablets (DRUG); Irinotecan liposomes (DRUG); Paclitaxel or docetaxel or irinotecan (DRUG),148124,TXL,HER-2 Positive Gastric or Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6827,NCT00256360,"Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer",COMPLETED,PHASE2,Breast Cancer,dose dense with neulasta (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6828,NCT03801876,Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer,RECRUITING,PHASE3,Clinical Stage I Esophageal Adenocarcinoma AJCC v8; Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage I Esophageal Adenocarcinoma AJCC v8; Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage II Esophageal Adenocarcinoma AJCC v8; Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage III Esophageal Adenocarcinoma AJCC v8; Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Thoracic Esophagus Squamous Cell Carcinoma,Carboplatin (DRUG); Esophagectomy (PROCEDURE); Intensity-Modulated Radiation Therapy (RADIATION); Paclitaxel (DRUG); Proton Beam Radiation Therapy (RADIATION); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); FOLFOX regimen (DRUG); CAPOX regimen (DRUG); Docetaxel (DRUG); 5FU (DRUG),148124,TXL,Esophageal and Gastroesophageal Junction Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6829,NCT00544960,A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-small Cell Lung Cancer,AT-101 and docetaxel (DRUG); placebo and docetaxel (DRUG),148124,TXL,Non-small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6830,NCT00129376,Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients,COMPLETED,PHASE2,Breast Cancer,Doxorubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6831,NCT00209092,Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Docetaxel (DRUG); Capecitabine (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6832,NCT00270894,Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients,COMPLETED,PHASE2,Breast Neoplasm,epirubicin (DRUG); cyclophosphamide (DRUG); docetaxel (DRUG); trastuzumab (DRUG),148124,TXL,Breast Neoplasm,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6833,NCT06123494,SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen,RECRUITING,PHASE3,HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma,SHR-A1811 (DRUG); Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan (DRUG),148124,TXL,HER2-positive Gastroesophageal Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6834,NCT00069160,"Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer",COMPLETED,PHASE2,Lung Neoplasms; Ovarian Neoplasms; Cervix Neoplasms; Renal Neoplasms,docetaxel (DRUG); tariquidar (DRUG); 99mTc-sestamibi imaging (OTHER),148124,TXL,Lung Neoplasms; Ovarian Neoplasms; Cervix Neoplasms; Renal Neoplasms,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6835,NCT00343512,Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer,TERMINATED,PHASE2,Breast Cancer,docetaxel (DRUG); protein expression analysis (GENETIC); laboratory biomarker analysis (OTHER); biopsy (PROCEDURE); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6836,NCT02816112,Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia,COMPLETED,PHASE4,Early Stage Breast Cancer,Ciprofloxacin (DRUG); Neupogen (DRUG),148124,TXL,Early Stage Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6837,NCT01711112,Salvage Docetaxel for Pretreated Urothelial Cancer,COMPLETED,PHASE2,Bladder Cancer,Docetaxel (DRUG),148124,TXL,Bladder Cancer,Bladder/Urinary Tract,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6838,NCT00813072,"Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma",COMPLETED,PHASE2,Stomach Neoplasms; Esophageal Neoplasms,PEP02 (DRUG); irinotecan (DRUG); docetaxel (DRUG),148124,TXL,Gastrointestinal Neoplasms,Bowel,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6839,NCT00820872,"Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer",COMPLETED,PHASE2,Breast Cancer,trastuzumab (BIOLOGICAL); carboplatin (DRUG); docetaxel (DRUG); lapatinib ditosylate (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6840,NCT00148668,Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Herceptin (DRUG); Navelbine (DRUG); Taxotere (DRUG); Carboplatin (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6841,NCT00217568,Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer,COMPLETED,PHASE2,Ovarian Cancer; Peritoneal Cavity Cancer,pegfilgrastim (BIOLOGICAL); carboplatin (DRUG); docetaxel (DRUG),148124,TXL,Ovarian and Peritoneal Cancer,Ovary/Fallopian Tube,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6842,NCT02447380,"Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment",COMPLETED,PHASE2,Advanced Gastric Adenocarcinoma,AZD6094 (DRUG); Docetaxel (DRUG),148124,TXL,Advanced Gastric Adenocarcinoma,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6843,NCT01208480,"Bevacizumab, Docetaxel, and Carboplatin in Treating Women With Stage II or Stage III Breast Cancer",COMPLETED,PHASE2,Breast Cancer,"Avastin, docetaxel, carboplatin (DRUG)",148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6844,NCT03661567,Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer,TERMINATED,PHASE2,Non-small Cell Lung Cancer,chest radiation (RADIATION); concurrent chemotherapy (DRUG); Methylprednisolone (DRUG),148124,TXL,Non-small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6845,NCT00262067,A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1),UNKNOWN,PHASE3,Metastatic Breast Cancer,Bevacizumab (DRUG); Placebo (DRUG); Chemotherapy (DRUG),148124,TXL,Metastatic Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6846,NCT04351867,A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer,UNKNOWN,PHASE3,Stomach Neoplasms,docetaxel plus oxaliplatin and capecitabine (DRUG); oxaliplatin plus capecitabine (DRUG),148124,TXL,Stomach Neoplasms,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6847,NCT00041067,"S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer",COMPLETED,PHASE2,Breast Cancer,filgrastim (BIOLOGICAL); trastuzumab (BIOLOGICAL); docetaxel (DRUG); vinorelbine (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6848,NCT00674167,"The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma",UNKNOWN,PHASE2,Gastric Cancer,Docetaxel (DRUG); Cisplatin (DRUG); Capecitabine (DRUG),148124,TXL,Gastric Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6849,NCT05633667,Study of Novel Treatment Combinations in Patients With Lung Cancer,RECRUITING,PHASE2,Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer; Resectable Non-Small-Cell Lung Cancer,Zimberelimab (ZIM) (DRUG); Domvanalimab (DOM) (DRUG); Sacituzumab govitecan-hziy (SG) (DRUG); Etrumadenant (ETRUMA) (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Pemetrexed (DRUG); Paclitaxel (DRUG); Nab-paclitaxel (DRUG); Docetaxel (DRUG); Nivolumab (DRUG),148124,TXL,Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer; Resectable Non-Small-Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6850,NCT01673867,Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC,COMPLETED,PHASE3,Non-Squamous Cell Non-small Cell Lung Cancer,Nivolumab (BIOLOGICAL); Docetaxel (DRUG),148124,TXL,Non-Squamous Cell Non-small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6851,NCT00617968,GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms,DOCETAXEL (DRUG),148124,TXL,Breast Neoplasms,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6852,NCT02344472,Detect V / CHEVENDO (Chemo vs. Endo),ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Breast Cancer,pertuzumab (DRUG); Trastuzumab (DRUG); Capecitabine (DRUG); Paclitaxel (DRUG); Vinorelbine (DRUG); Docetaxel (DRUG); Exemestane (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG); Ribociclib (DRUG); nab-Paclitaxel (DRUG); eribulin (DRUG); leuprorelin (DRUG); goserelin (DRUG),148124,TXL,Metastatic Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6853,NCT03646968,Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study,RECRUITING,PHASE2,Non-Squamous Non Small Cell Lung Cancer,Anlotinib and Docetaxel (DRUG),148124,TXL,Non-Squamous Non Small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6854,NCT03585673,Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma,UNKNOWN,PHASE2,Esophagus Squamous Cell Carcinoma (SCC); Metastatic Cancer,Docetaxel-PM (DRUG); Oxaliplatin (DRUG),148124,TXL,Esophagus Squamous Cell Carcinoma (SCC); Metastatic Cancer,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6855,NCT03904927,Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma,COMPLETED,PHASE2,Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma,"Radiation, Surgery or Radiofrequency ablation (OTHER); Systemic therapy (DRUG)",148124,TXL,Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6856,NCT00378573,"Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",TERMINATED,PHASE2,Non-small Cell Lung Cancer,docetaxel (DRUG); gemcitabine (DRUG); bevacizumab (DRUG),148124,TXL,Non-small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6857,NCT00669773,Validate Gene Expression and Proteomic Signatures Predictive of Treatment for Response for Breast Cancer Patient,UNKNOWN,PHASE2,Breast Cancer,Adriamycin (DRUG); Docetaxel (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6858,NCT01270373,NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After?,UNKNOWN,PHASE2,Breast Cancer,FAC x 3 followed by Docetaxel x 3 (DRUG); Docetaxel x 3 followed by FAC x 3 (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6859,NCT00362882,Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,docetaxel (DRUG); bortezomib (DRUG); laboratory biomarker analysis (OTHER); immunoenzyme technique (OTHER); immunohistochemistry staining method (OTHER); pharmacological study (OTHER),148124,TXL,Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6860,NCT00448682,Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery,TERMINATED,PHASE2,Gastric Cancer,Docetaxel (DRUG); Floxuridine (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG),148124,TXL,Gastric Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6861,NCT00865982,"Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer",UNKNOWN,PHASE2,Gastric Cancer; Esophageal Cancer,"Docetaxel, Cisplatin, Capecitabine (DRUG)",148124,TXL,Gastric Cancer; Esophageal Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6862,NCT04884282,Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED),RECRUITING,PHASE2,Metastatic Non Small Cell Lung Cancer,Tedopi (DRUG); Nivolumab (DRUG); Docetaxel (DRUG),148124,TXL,Metastatic Non Small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6863,NCT05171530,Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer,UNKNOWN,PHASE1,HER2-negative Advanced Gastric Cancer,Lenvatinib plus taxane drugs (DRUG),148124,TXL,HER2-negative Advanced Gastric Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6864,NCT03402048,The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial,UNKNOWN,PHASE3,"Stage IV, NSCLC; Lung Neoplasms; Bronchial Neoplasms; Carcinoma, Bronchogenic; Lung Diseases; Neoplasms; Respiratory Tract Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms",Carboplatin (DRUG); Gemcitabine (DRUG); Pemetrexed (DRUG); Docetaxel (DRUG); Vinorelbine (DRUG),148124,TXL,"Stage IV, NSCLC; Lung Neoplasms; Bronchial Neoplasms; Carcinoma, Bronchogenic; Lung Diseases; Neoplasms; Respiratory Tract Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms",Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6865,NCT00215748,Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Receiving Weekly Docetaxel,TERMINATED,PHASE2,Breast Cancer; Lung Cancer,Dexamethasone (DRUG),148124,TXL,Breast Cancer; Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6866,NCT03407430,Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain,TERMINATED,PHASE2,Breast Cancer; Lymphoma; Pain,Pregabalin (DRUG); Placebo (DRUG),148124,TXL,Breast Cancer; Lymphoma; Pain,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6867,NCT02426125,A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer,COMPLETED,PHASE3,Urothelial Carcinoma,Ramucirumab (DRUG); Docetaxel (DRUG); Placebo (DRUG),148124,TXL,Urothelial Carcinoma,Bladder/Urinary Tract,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6868,NCT00583622,"Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients",TERMINATED,PHASE2,Ovarian Cancer,Bevacizumab (DRUG); Carboplatin (DRUG); Docetaxel (DRUG); Gemcitabine (DRUG); Melphalan (DRUG); Stem Cell Transplant (PROCEDURE),148124,TXL,Ovarian Cancer,Ovary/Fallopian Tube,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6869,NCT05253066,Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer,UNKNOWN,PHASE2,Breast Neoplasms,Chidamide combined with exemestane (+/- goserelin) (DRUG); Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician) (DRUG),148124,TXL,Breast Neoplasms,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6870,NCT00509366,Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer,TERMINATED,PHASE2,Non Small Cell Lung Cancer,Cisplatin & Gemcitabine (DRUG); Cisplatin & Pemetrexed (DRUG); Docetaxel & Gemcitabine (DRUG); Pemetrexed & Gemcitabine (DRUG),148124,TXL,Non Small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6871,NCT00645866,"Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer",COMPLETED,PHASE2,Breast Cancer,capecitabine (DRUG); docetaxel (DRUG); epirubicin hydrochloride (DRUG); laboratory biomarker analysis (OTHER); pharmacogenomic studies (OTHER); biopsy (PROCEDURE); neoadjuvant therapy (PROCEDURE); therapeutic surgical procedure (PROCEDURE),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6872,NCT00002866,Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer,COMPLETED,PHASE1,Breast Cancer; Neutropenia,filgrastim (BIOLOGICAL); docetaxel (DRUG); epirubicin hydrochloride (DRUG),148124,TXL,Breast Cancer with Neutropenia,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6873,NCT03735966,Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.,COMPLETED,PHASE2,HER2 Positive Breast Cancer,Pyrotinib plus trastuzumab and docetaxel and carboplatin (DRUG),148124,TXL,HER2 Positive Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6874,NCT02889666,A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer,RECRUITING,PHASE1,Recurrent Non-small Cell Lung Cancer,Cisplatin (DRUG); Carboplatin (DRUG); Docetaxel (DRUG); Gemcitabine/Carboplatin (DRUG); Gemcitabine/Cisplatin (DRUG); Docetaxel/Oxaliplatin (DRUG); Docetaxel/Carboplatin (DRUG); Placebo (DRUG),148124,TXL,Recurrent Non-small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6875,NCT05251766,Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer,UNKNOWN,PHASE1,Breast Cancer; Chemotherapy Effect,Nab paclitaxel (DRUG); Docetaxel (DRUG),148124,TXL,Breast Cancer; Chemotherapy Effect,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6876,NCT02194166,A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration,COMPLETED,PHASE3,Breast Cancer,Trastuzumab (DRUG); Paclitaxel (DRUG); Docetaxel (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6877,NCT06463665,Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer,RECRUITING,PHASE2,Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; Metastatic Non-squamous Non Small Cell Lung Cancer; Metastatic Squamous Non-Small Cell Lung Carcinoma; Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Stage III; Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Recurrent,"Olvimulogene nanivacirepvec (BIOLOGICAL); Platinum chemotherapy: carboplatin or cisplatin (DRUG); Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC (DRUG); Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab (DRUG); Docetaxel (DRUG)",148124,TXL,Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; Metastatic Non-squamous Non Small Cell Lung Cancer; Metastatic Squamous Non-Small Cell Lung Carcinoma; Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Stage III; Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Recurrent,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6878,NCT01624025,A Comparative Study of Salvage Treatment With Combination of Docetaxel and Epirubicin,COMPLETED,PHASE2,Metastatic Advanced Gastric Cancer,"Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks (OTHER)",148124,TXL,Metastatic Advanced Gastric Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6879,NCT01690325,Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON),TERMINATED,PHASE2,Breast Cancer,Docetaxel (DRUG); Trastuzumab (DRUG); Bevacizumab (DRUG); Epirubicin (DRUG); Cyclophosphamid (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6880,NCT00022022,Docetaxel in Treating Patients With Non-Small Cell Lung Cancer,UNKNOWN,PHASE3,Lung Cancer,docetaxel (DRUG); quality-of-life assessment (PROCEDURE),148124,TXL,Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6881,NCT01084330,Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer,COMPLETED,PHASE2,Advanced Gastric Cancer; Gastro-esophageal Junction Cancer,AUY922 (DRUG); Docetaxel (DRUG); Irinotecan (DRUG),148124,TXL,Advanced Gastric and Gastro-esophageal Junction Cancer,Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6882,NCT05802225,Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer,RECRUITING,PHASE3,Breast Cancer,BCD-178 (DRUG); Perjeta (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6883,NCT00957125,A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early,UNKNOWN,PHASE2,Breast Cancer,Epirubicin (DRUG); Docetaxel (DRUG); Bevacizumab (DRUG),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6884,NCT00002825,Docetaxel in Treating Children With Recurrent Solid Tumors,COMPLETED,PHASE2,Brain and Central Nervous System Tumors; Neuroblastoma; Sarcoma,filgrastim (BIOLOGICAL); docetaxel (DRUG),148124,TXL,Brain and Central Nervous System Tumors; Neuroblastoma; Sarcoma,CNS/Brain,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6885,NCT03493425,Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery,RECRUITING,PHASE2,Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7,Carboplatin (DRUG); Cisplatin (DRUG); Docetaxel (DRUG); Image Guided Radiation Therapy (RADIATION); Intensity-Modulated Radiation Therapy (RADIATION); Laboratory Biomarker Analysis (OTHER); Questionnaire Administration (OTHER); Therapeutic Conventional Surgery (PROCEDURE),148124,TXL,Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6886,NCT05863325,A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC),RECRUITING,PHASE2,Locally Advanced or Metastatic Non-Small Cell Lung Cancer,HB1801 (DRUG); Taxotere (DRUG),148124,TXL,Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6887,NCT01646125,"An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations",TERMINATED,PHASE2,Advanced Non Small Cell Lung Cancer (NSCLC),AUY922 (DRUG); Docetaxel (DRUG); Pemetrexed (DRUG),148124,TXL,Advanced Non Small Cell Lung Cancer (NSCLC),Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6888,NCT00890825,AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients,COMPLETED,PHASE2,Non Small Cell Lung Cancer,AZD6244 (DRUG); docetaxel (DRUG); Placebo (DRUG),148124,TXL,Non Small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6889,NCT00004125,Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes,COMPLETED,PHASE3,Breast Cancer,cyclophosphamide (DRUG); docetaxel (DRUG); doxorubicin hydrochloride (DRUG); paclitaxel (DRUG); tamoxifen citrate (DRUG); radiation therapy (RADIATION),148124,TXL,Breast Cancer,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6890,NCT01049425,Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer,COMPLETED,PHASE3,Primary Breast Cancer; Her2 Non-overexpressing,Epirubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG),148124,TXL,Primary Breast Cancer; Her2 Non-overexpressing,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6891,NCT01911325,Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients,TERMINATED,PHASE1,Squamous Non-small Cell Lung Cancer,Buparlisib (DRUG); Buparlisib matching placebo (DRUG); Docetaxel (DRUG),148124,TXL,Squamous Non-small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6892,NCT05769725,A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer,RECRUITING,PHASE2,"Serplulimab,Gastric Cancer, Adjuvant Therapy",Serplulimab (DRUG); Docetaxel (DRUG); S1 (DRUG),148124,TXL,"Serplulimab,Gastric Cancer, Adjuvant Therapy",Esophagus/Stomach,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6893,NCT05301530,Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.,COMPLETED,PHASE1,Breast Cancer Metastatic; Breast Cancer Female; Breast Cancer Recurrent,Faceptor (DRUG); Herceptin (DRUG); Docetaxel (DRUG),148124,TXL,Breast Cancer Metastatic; Breast Cancer Female; Breast Cancer Recurrent,Breast,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6894,NCT06640725,Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N,RECRUITING,PHASE2,Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck,Avelumab administration at 10mg/kg (DRUG); Cetuximab (Erbitux) (DRUG),148124,TXL,Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck,Skin,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6895,NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,COMPLETED,PHASE3,Non-Small Cell Lung Cancer,Cisplatin (DRUG); Etoposide (DRUG); Radiation (RADIATION); Docetaxel (DRUG),148124,TXL,Advanced Non-Small Cell Lung Cancer,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6896,NCT00201825,A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients,COMPLETED,PHASE2,Lung Cancer; Non-Small-Cell Lung Carcinoma,Capecitabine (DRUG); Docetaxel (DRUG),148124,TXL,Lung Cancer; Non-Small-Cell Lung Carcinoma,Lung,Docetaxel,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Approved anticancer drug, often used in chemotherapy treatments.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,1.02,265.0 +6897,NCT00290966,Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer,COMPLETED,PHASE2,Stomach Neoplasm,XRP6976 (DRUG),148123,D02165,Stomach Neoplasm,Esophagus/Stomach,Docetaxel (Trihydrate),"TUBB1, TUBB3, TUBB4B, TUBB4A, TUBB2A, TUBB2B",unclear,Microtubule inhibitor,yes,yes,"Approved cancer treatment, commonly used in chemotherapy.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O.O.O.O,1.0,19.0 +6898,NCT01515748,Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer,COMPLETED,PHASE3,Gastric Cancer,"Docetaxel (XRP6976) (DRUG); Oxaliplatin (SR96669) (DRUG); S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil) (DRUG)",148123,D02165,Gastric Cancer,Esophagus/Stomach,Docetaxel (Trihydrate),"TUBB1, TUBB3, TUBB4B, TUBB4A, TUBB2A, TUBB2B",unclear,Microtubule inhibitor,yes,yes,"Approved cancer treatment, commonly used in chemotherapy.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O.O.O.O,1.0,19.0 +6899,NCT02061631,Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck,COMPLETED,PHASE2,Squamous Cell Carcinoma of Head and Neck,Cisplatin (DRUG); DOCETAXEL XRP6976 (DRUG); Dexamethasone (DRUG); Dexamethasone (DRUG),148123,D02165,Squamous Cell Carcinoma of Head and Neck,Skin,Docetaxel (Trihydrate),"TUBB1, TUBB3, TUBB4B, TUBB4A, TUBB2A, TUBB2B",unclear,Microtubule inhibitor,yes,yes,"Approved cancer treatment, commonly used in chemotherapy.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O.O.O.O,1.0,19.0 +6900,NCT00917748,Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF),COMPLETED,PHASE3,Prostatic Neoplasms; Breast Cancer,DOCETAXEL(XRP6976) + MODAFINIL (DRUG); Modafinil (DRUG); Placebo of Modafinil (DRUG),148123,D02165,Prostatic Neoplasms; Breast Cancer,Breast,Docetaxel (Trihydrate),"TUBB1, TUBB3, TUBB4B, TUBB4A, TUBB2A, TUBB2B",unclear,Microtubule inhibitor,yes,yes,"Approved cancer treatment, commonly used in chemotherapy.",CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O.O.O.O,1.0,19.0 +6901,NCT05970172,A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease,RECRUITING,PHASE3,Chronic Kidney Disease; Renal Anemia,Roxadustat (DRUG),11256664,Evrenzo,Chronic Kidney Disease; Renal Anemia,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6902,NCT05691257,Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia,UNKNOWN,PHASE4,Heart Failure; Chronic Kidney Diseases; Anemia,Roxadustat (DRUG); Recombinant human eythropoietin and/or Iron agents (DRUG),11256664,Evrenzo,Heart Failure; Chronic Kidney Diseases; Anemia,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6903,NCT02780726,A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia,COMPLETED,PHASE3,Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia,roxadustat (DRUG),11256664,Evrenzo,Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6904,NCT02988973,A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia,COMPLETED,PHASE3,Chronic Kidney Disease,roxadustat (DRUG); DA (DRUG),11256664,Evrenzo,Chronic Kidney Disease,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6905,NCT06917950,Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients,NOT_YET_RECRUITING,PHASE1,"Kidney Failure,Chronic; Anemia in End Stage Renal Disease; Depression Anxiety Disorder",Roxadustat (DRUG); Conventional Anemia Management (DRUG),11256664,Evrenzo,"Kidney Failure,Chronic; Anemia in End Stage Renal Disease; Depression Anxiety Disorder",Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6906,NCT04655027,A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD),COMPLETED,PHASE4,Anemia of Chronic Kidney Disease,Roxadustat (DRUG); rHuEPO (DRUG),11256664,Evrenzo,Anemia of Chronic Kidney Disease,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6907,NCT04621331,"Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD",WITHDRAWN,PHASE3,Anemia Associated With Chronic Kidney Disease,Roxadustat (DRUG),11256664,Evrenzo,Anemia Associated With Chronic Kidney Disease,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6908,NCT01147666,Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis,COMPLETED,PHASE2,End Stage Renal Disease; Anemia,Roxadustat (DRUG); Epoetin Alfa (DRUG); Placebo (OTHER),11256664,Evrenzo,End Stage Renal Disease; Anemia,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6909,NCT01244763,Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia,COMPLETED,PHASE2,Chronic Kidney Disease; Anemia,Roxadustat (DRUG),11256664,Evrenzo,Chronic Kidney Disease; Anemia,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6910,NCT02161224,A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function,COMPLETED,PHASE1,PK of FG-4592; Hepatic Insufficiency; Healthy Subjects,FG-4592 (DRUG),11256664,Evrenzo,PK of FG-4592; Hepatic Insufficiency; Healthy Subjects,Liver,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6911,NCT02965040,A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function,COMPLETED,PHASE1,Normal Renal Function; Impaired Renal Function,Roxadustat (DRUG),11256664,Evrenzo,Normal Renal Function; Impaired Renal Function,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6912,NCT02952092,A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia,COMPLETED,PHASE3,Hemodialysis Chronic Kidney Disease Patients With Anemia,roxadustat (DRUG); Darbepoetin alfa (DRUG),11256664,Evrenzo,Hemodialysis Chronic Kidney Disease Patients With Anemia,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6913,NCT01630889,Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease,COMPLETED,PHASE2,Chronic Kidney Disease; End Stage Renal Disease; Anemia,Roxadustat (DRUG),11256664,Evrenzo,Chronic Kidney Disease; End Stage Renal Disease; Anemia,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6914,NCT02780141,A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia,COMPLETED,PHASE3,ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia,roxadustat (DRUG),11256664,Evrenzo,ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6915,NCT02278341,Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis,COMPLETED,PHASE3,Anemia; End Stage Renal Disease (ESRD),Roxadustat (DRUG); Epoetin alfa (DRUG); Darbepoetin alfa (DRUG); Iron (DRUG),11256664,Evrenzo,Anemia; End Stage Renal Disease (ESRD),Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6916,NCT02021318,"Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa",COMPLETED,PHASE3,Anemia in Chronic Kidney Disease in Non-dialysis Patients,Roxadustat (DRUG); Darbepoetin alfa (DRUG),11256664,Evrenzo,Anemia in Chronic Kidney Disease in Non-dialysis Patients,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6917,NCT01596855,Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China,COMPLETED,PHASE2,Anemia in End Stage Renal Disease,FG-4592 (DRUG); Epoetin Alfa (DRUG),11256664,Evrenzo,Anemia in End Stage Renal Disease,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6918,NCT02964936,A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia,COMPLETED,PHASE3,Chronic Kidney Disease,roxadustat (DRUG),11256664,Evrenzo,Chronic Kidney Disease,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6919,NCT00761657,Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis,COMPLETED,PHASE2,Chronic Kidney Disease; Anemia,Roxadustat (DRUG); Placebo (DRUG),11256664,Evrenzo,Chronic Kidney Disease; Anemia,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6920,NCT04484857,Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants,COMPLETED,PHASE3,Anemia Associated With End Stage Renal Disease,Roxadustat (DRUG),11256664,Evrenzo,Anemia Associated With End Stage Renal Disease,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6921,NCT06903559,"Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients",NOT_YET_RECRUITING,PHASE1,"Kidney Failure, Chronic; Malnutrition-Inflammation Syndrome; Anemia in End Stage Renal Disease; Cardiovascular Diseases (CVD)",Roxadustat (DRUG); Conventional Anemia Management (DRUG),11256664,Evrenzo,"Kidney Failure, Chronic; Malnutrition-Inflammation Syndrome; Anemia in End Stage Renal Disease; Cardiovascular Diseases (CVD)",Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6922,NCT01887600,Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis,COMPLETED,PHASE3,Anemia in Chronic Kidney Disease in Non-dialysis Patients,Roxadustat (DRUG); Placebo (DRUG),11256664,Evrenzo,Anemia in Chronic Kidney Disease in Non-dialysis Patients,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6923,NCT01599507,Study of FG-4592 in Subjects With Chronic Kidney Disease in China,COMPLETED,PHASE2,Anemia in Chronic Kidney Disease,FG-4592 (DRUG); Placebo (DRUG),11256664,Evrenzo,Anemia in Chronic Kidney Disease,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6924,NCT01083888,ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis,COMPLETED,PHASE1,Anemia; Hemodialysis; Renal Impairment,roxadustat (DRUG),11256664,Evrenzo,Anemia; Hemodialysis; Renal Impairment,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6925,NCT04925011,Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD,UNKNOWN,PHASE3,Anemia Associated With Chronic Kidney Disease,Roxadustat (DRUG),11256664,Evrenzo,Anemia Associated With Chronic Kidney Disease,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6926,NCT01888445,A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug,COMPLETED,PHASE2,Renal Anemia Associated With Chronic Renal Failure (CRF),roxadustat (DRUG); darbepoetin alfa (DRUG),11256664,Evrenzo,Renal Anemia Associated With Chronic Renal Failure (CRF),Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6927,NCT04925661,HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia,UNKNOWN,PHASE1,Chronic Kidney Diseases; Renal Anemia,HEC53856 (DRUG); Roxadustat (DRUG); Placebo (DRUG),11256664,Evrenzo,Chronic Kidney Diseases; Renal Anemia,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6928,NCT04410198,Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants,COMPLETED,PHASE3,Anemia Associated With End Stage Renal Disease (ESRD),Roxadustat (DRUG),11256664,Evrenzo,Anemia Associated With End Stage Renal Disease (ESRD),Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6929,NCT01964196,ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-,COMPLETED,PHASE2,Anemia in Chronic Kidney Disease Patients Not on Dialysis,ASP1517 (DRUG); Placebo (DRUG),11256664,Evrenzo,Anemia in Chronic Kidney Disease Patients Not on Dialysis,Kidney,Roxadustat,,inhibitor/antagonist,unclear,yes,yes,"Approved for anemia treatment in some countries, e.g., China, Japan.",CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,1.03,2174.0 +6930,NCT04234113,Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors,TERMINATED,PHASE1,Thyroid Cancer; Renal Cell Carcinoma; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Bladder Cancer; Melanoma; Merkel Cell Carcinoma; Skin Squamous Cell Carcinoma; Microsatellite Instability High; Triple Negative Breast Cancer; Mesothelioma; Thymic Cancer; Cervical Cancer; Biliary Tract Cancer; Hepatocellular Carcinoma; Ovarian Cancer; Gastric Cancer; Head and Neck Squamous Cell Carcinoma; Anal Cancer,Nanrilkefusp alfa (DRUG); Pembrolizumab (DRUG),6989,IPMP,Thyroid Cancer; Renal Cell Carcinoma; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Bladder Cancer; Melanoma; Merkel Cell Carcinoma; Skin Squamous Cell Carcinoma; Microsatellite Instability High; Triple Negative Breast Cancer; Mesothelioma; Thymic Cancer; Cervical Cancer; Biliary Tract Cancer; Hepatocellular Carcinoma; Ovarian Cancer; Gastric Cancer; Head and Neck Squamous Cell Carcinoma; Anal Cancer,Lung,Thymol,TRPA1,activator/agonist,unclear,no,yes,Used in clinical trials as antiseptic and antifungal.,CC1=CC(=C(C=C1)C(C)C)O,1.14,1049.0 +6931,NCT04520308,"An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis",UNKNOWN,PHASE4,Atopic Dermatitis; AD; Eczema,Dupilumab Only Product (DRUG),6989,IPMP,Atopic Dermatitis; AD; Eczema,Skin,Thymol,TRPA1,activator/agonist,unclear,no,yes,Used in clinical trials as antiseptic and antifungal.,CC1=CC(=C(C=C1)C(C)C)O,1.14,1049.0 +6932,NCT06790706,IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers,NOT_YET_RECRUITING,PHASE2,Peritoneal Mesothelioma; Gestational Trophoblastic Tumor; Thymoma and Thymic Carcinoma; Anaplastic Thyroid Carcinomas; Gastroenteropancreatic Neuroendocrine Tumor; Carcinoid Tumor,DOMVANALIMAB + ZIMBERELIMAB (DRUG); DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4 (DRUG),6989,IPMP,Peritoneal Mesothelioma; Gestational Trophoblastic Tumor; Thymoma and Thymic Carcinoma; Anaplastic Thyroid Carcinomas; Gastroenteropancreatic Neuroendocrine Tumor; Carcinoid Tumor,Lung,Thymol,TRPA1,activator/agonist,unclear,no,yes,Used in clinical trials as antiseptic and antifungal.,CC1=CC(=C(C=C1)C(C)C)O,1.14,1049.0 +6933,NCT00004266,Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes,COMPLETED,PHASE3,Diabetic Nephropathy,Lisinopril (DRUG); Nifedipine (DRUG); Simvastatin (DRUG),3463,Gemd,Diabetic Nephropathy,Kidney,Gemfibrozil,"PPARA, CYP2C9, CYP2C19, CYP2C8, CYP1A2",unclear,unclear,yes,yes,Approved for dyslipidemia treatment.,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,1.34,156.0 +6934,NCT06064539,Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects,COMPLETED,PHASE1,Multiple Sclerosis,Tolebrutinib (DRUG); gemfibrozil (DRUG); rifampicin (DRUG),3463,Gemd,Multiple Sclerosis,CNS/Brain,Gemfibrozil,"PPARA, CYP2C9, CYP2C19, CYP2C8, CYP1A2",unclear,unclear,yes,yes,Approved for dyslipidemia treatment.,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,1.34,156.0 +6935,NCT05931484,"Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients.",NOT_YET_RECRUITING,PHASE2,Parkinson Disease,Gemfibrozil (DRUG); Placebo (DRUG),3463,Gemd,Parkinson Disease,CNS/Brain,Gemfibrozil,"PPARA, CYP2C9, CYP2C19, CYP2C8, CYP1A2",unclear,unclear,yes,yes,Approved for dyslipidemia treatment.,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,1.34,156.0 +6936,NCT02045056,Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease,COMPLETED,EARLY_PHASE1,Preclinical Alzheimer's Disease,Gemfibrozil (DRUG); Placebo (DRUG),3463,Gemd,Preclinical Alzheimer's Disease,CNS/Brain,Gemfibrozil,"PPARA, CYP2C9, CYP2C19, CYP2C8, CYP1A2",unclear,unclear,yes,yes,Approved for dyslipidemia treatment.,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,1.34,156.0 +6937,NCT02637466,"Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers",WITHDRAWN,PHASE4,"Unipolar Major Depression; Stage I, II or III Breast Cancer",Vortioxetine (DRUG),9966051,VTX,"Unipolar Major Depression; Stage I, II or III Breast Cancer",Breast,Vortioxetine,"SLC6A4, HTR3A, HTR7",unclear,unclear,yes,yes,Approved for major depressive disorder.,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,1.64,44.0 +6938,NCT01836029,Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,COMPLETED,PHASE2,"Carcinoma, Squamous Cell of Head and Neck",VTX-2337 (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); 5-fluorouracil (DRUG); Placebo (DRUG),9966051,VTX,Head and Neck Squamous Cell Carcinoma,Skin,Vortioxetine,"SLC6A4, HTR3A, HTR7",unclear,unclear,yes,yes,Approved for major depressive disorder.,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,1.64,44.0 +6939,NCT06563999,Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.,RECRUITING,PHASE2,Lung Cancer Stage III; Mutation,Sunvozertinib (DRUG); Crizotinib (DRUG); Pralsetinib (DRUG); Larotrectinib (DRUG); Savolitinib (DRUG); Pyrotinib (DRUG); Dabrafenib+Trametinib (DRUG); Glecirasib (DRUG); Ensartinib (DRUG),129073603,Gavreto,Lung Cancer Stage III with Mutation,Lung,Pralsetinib,RET,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for RET fusion-positive cancers.,CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)NC(C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC,1.01,1882.0 +6940,NCT04222972,A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE3,"RET-fusion Non Small Cell Lung Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Diseases; Head and Neck Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue",Pralsetinib (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Pemetrexed (DRUG); Pembrolizumab (DRUG); Gemcitabine (DRUG); Paclitaxel (DRUG); Nab-Paclitaxel (DRUG),129073603,Gavreto,"RET-fusion Non Small Cell Lung Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Diseases; Head and Neck Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue",Lung,Pralsetinib,RET,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for RET fusion-positive cancers.,CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)NC(C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC,1.01,1882.0 +6941,NCT03037385,"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors",COMPLETED,PHASE1,"RET-altered Non Small Cell Lung Cancer; Medullary Thyroid Cancer; RET-altered Papillary Thyroid Cancer; RET-altered Colon Cancer; RET-altered Solid Tumors; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Thyroid Diseases; Thyroid Neoplasm; Thyroid Cancer, Papillary; Carcinoma, Neuroendocrine; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Neoplasms; Endocrine System Diseases; Endocrine Gland Neoplasm; Head and Neck Neoplasms; Adenocarcinoma, Papillary; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Colonic Neoplasms; Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasm; Digestive System Disease; Gastrointestinal Disease; Colonic Diseases; Intestinal Disease",pralsetinib (BLU-667) (DRUG),129073603,Gavreto,"RET-altered Non Small Cell Lung Cancer; Medullary Thyroid Cancer; RET-altered Papillary Thyroid Cancer; RET-altered Colon Cancer; RET-altered Solid Tumors; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Thyroid Diseases; Thyroid Neoplasm; Thyroid Cancer, Papillary; Carcinoma, Neuroendocrine; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Neoplasms; Endocrine System Diseases; Endocrine Gland Neoplasm; Head and Neck Neoplasms; Adenocarcinoma, Papillary; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Colonic Neoplasms; Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasm; Digestive System Disease; Gastrointestinal Disease; Colonic Diseases; Intestinal Disease",Bowel,Pralsetinib,RET,inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for RET fusion-positive cancers.,CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)NC(C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC,1.01,1882.0 +6942,NCT04432220,AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study),RECRUITING,PHASE4,Atrial Fibrillation Patients With Moderate or High Stroke Risk Who Had Undergone Catheter Ablation of Atrial Fibrillation,Anticoagulation group(Apixaban group) (DRUG),4055,MNQ,Atrial Fibrillation Patients With Moderate or High Stroke Risk Who Had Undergone Catheter Ablation of Atrial Fibrillation,CNS/Brain,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6943,NCT03566303,Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis,TERMINATED,PHASE2,Prostheses and Implants; Stroke; Valve Heart Disease; Anticoagulants and Bleeding Disorders,Rivaroxaban 15 mg (DRUG); Warfarin (DRUG),4055,MNQ,Prostheses and Implants; Stroke; Valve Heart Disease; Anticoagulants and Bleeding Disorders,CNS/Brain,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6944,NCT02976246,Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients,COMPLETED,PHASE4,Vitamin K Supplementation; Endstage Renal Disease; Cardiovascular Disease; Bone Disease,Vitamin K2 (MK7) (DIETARY_SUPPLEMENT); Placebo (OTHER),4055,MNQ,Vitamin K Supplementation; Endstage Renal Disease; Cardiovascular Disease; Bone Disease,Kidney,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6945,NCT03091569,Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy,COMPLETED,PHASE4,Relapsing-Remitting Multiple Sclerosis,Vitamin K Cream (OTHER); Placebo Cream (OTHER),4055,MNQ,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6946,NCT02397382,Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis,COMPLETED,PHASE1,Psoriasis,Guselkumab (DRUG); Midazolam (DRUG); Warfarin (DRUG); Omeprazole (DRUG); Dextromethorphan (DRUG); Caffeine (DRUG),4055,MNQ,Psoriasis,Skin,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6947,NCT00500682,A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1),COMPLETED,PHASE3,Chronic Kidney Disease,Placebo (DRUG); AST-120 (DRUG),4055,MNQ,Chronic Kidney Disease,Kidney,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6948,NCT05948982,Safety of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Decompensated Hepatitis B Cirrhosis,NOT_YET_RECRUITING,PHASE1,Decompensated Liver Cirrhosis,Human Umbilical Cord Mesenchymal Stem Cells (BIOLOGICAL),4055,MNQ,Decompensated Liver Cirrhosis,Liver,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6949,NCT03702582,Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation,COMPLETED,PHASE3,Atrial Fibrillation; Stroke; Bleeding,Rivaroxaban (DRUG); Warfarin (DRUG),4055,MNQ,Atrial Fibrillation; Stroke; Bleeding,CNS/Brain,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6950,NCT04045665,Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG,RECRUITING,PHASE3,Atrial Fibrillation; Stroke; Bleeding,Antiplatelet-only strategy (DRUG); Oral Anticoagulant plus background antiplatelet therapy (DRUG),4055,MNQ,Atrial Fibrillation; Stroke; Bleeding,CNS/Brain,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6951,NCT04317248,"""Cocktail"" Therapy for Hepatitis B Related Hepatocellular Carcinoma",UNKNOWN,PHASE2,Hepatocellular Carcinoma,Cyclophosphamide (DRUG); Multiple Signals loaded Dendritic Cells Vaccine (BIOLOGICAL),4055,MNQ,Hepatocellular Carcinoma,Liver,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6952,NCT01235325,The Effect of Vitamin K Supplementation on Bone Health in Adult Crohn's Disease Patients,COMPLETED,PHASE4,Supplementation; Bone Health; Crohn's Disease,phylloquinone (vitamin K1) (DIETARY_SUPPLEMENT); placebo (DIETARY_SUPPLEMENT),4055,MNQ,Supplementation; Bone Health; Crohn's Disease,Bowel,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6953,NCT02324686,Vitamin K Supplementation in Patients on Hemodialysis,COMPLETED,PHASE2,End Stage Renal Failure on Dialysis; Atrial Fibrillation,vitamin K1 (DRUG),4055,MNQ,End Stage Renal Failure on Dialysis; Atrial Fibrillation,Kidney,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6954,NCT01761266,"A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma",COMPLETED,PHASE3,Hepatocellular Carcinoma (HCC),Lenvatinib (DRUG); Sorafenib (DRUG),4055,MNQ,Hepatocellular Carcinoma (HCC),Liver,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6955,NCT01345526,Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Reconval K1 Cream (DEVICE); Reconval Cream (DEVICE),4055,MNQ,Metastatic Colorectal Cancer,Bowel,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6956,NCT02886962,Oral Anticoagulation in Haemodialysis Patients,TERMINATED,PHASE4,"Kidney Failure, Chronic",No oral anticoagulation (BIOLOGICAL); Oral anticoagulation with vitamin K antagonists (DRUG),4055,MNQ,"Kidney Failure, Chronic",Kidney,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6957,NCT02066662,Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification,COMPLETED,PHASE4,"Atrial Fibrillation or Pulmonary Embolism; Need of Long Term Oral Anticoagulation Therapy (OAT); Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location",Rivaroxaban or Marcumar (DRUG),4055,MNQ,"Atrial Fibrillation or Pulmonary Embolism; Need of Long Term Oral Anticoagulation Therapy (OAT); Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location",Lung,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6958,NCT05304481,Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma,RECRUITING,PHASE2,Hepatocellular Carcinoma,ATL administration (BIOLOGICAL),4055,MNQ,Hepatocellular Carcinoma,Liver,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6959,NCT04718740,A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer,COMPLETED,PHASE1,Recurrent Ovarian Cancer,fluzoparib (DRUG),4055,MNQ,Recurrent Ovarian Cancer,Ovary/Fallopian Tube,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6960,NCT04145492,Effect of Vitamin K 2 on Vascular Calcification in Hemodialysis Patients,UNKNOWN,PHASE2,End Stage Renal Disease,Vitamin K2 (DRUG); Cholecalciferol (inactive vitamin D) (DRUG); Vitamin K2 and Cholecalciferol (DRUG),4055,MNQ,End Stage Renal Disease,Kidney,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6961,NCT00501046,A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2),COMPLETED,PHASE3,Chronic Kidney Disease,Placebo (DRUG); AST-120 (DRUG),4055,MNQ,Chronic Kidney Disease,Kidney,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6962,NCT04344717,Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition,RECRUITING,PHASE4,Short Bowel Syndrome; Anticoagulation,Apixaban single dose (DRUG); Apixaban steady-state (DRUG),4055,MNQ,Short Bowel Syndrome; Anticoagulation,Bowel,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6963,NCT05891119,Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis,COMPLETED,EARLY_PHASE1,Atopic Dermatitis,Caffeine (DIETARY_SUPPLEMENT); Metoprolol (DRUG); Midazolam (DRUG); Warfarin (DRUG); Vitamin K (DIETARY_SUPPLEMENT); Omeprazole (DRUG); Rocatinlimab (DRUG),4055,MNQ,Atopic Dermatitis,Skin,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6964,NCT04539418,Vitamin K2 Supplementation and Vascular Calcification,COMPLETED,PHASE4,Renal Disease,Vitamin K 2 (DRUG),4055,MNQ,Renal Disease,Kidney,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6965,NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,COMPLETED,PHASE3,Relapsing-Remitting Multiple Sclerosis,Midazolam (DRUG); Caffeine (OTHER); S-warfarin (DRUG); Vitamin K (OTHER); Omeprazole (DRUG); Dextromethorphan (DRUG); BIIB019 (Daclizumab) (BIOLOGICAL),4055,MNQ,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6966,NCT03129555,The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE),RECRUITING,PHASE4,Deep Vein Thrombosis; Pulmonary Embolism,Dabigatran Etexilate Oral Capsule (DRUG); Rivaroxaban Oral Tablet (DRUG); Edoxaban Oral Tablet (DRUG); Apixaban Oral Tablet (DRUG),4055,MNQ,Deep Vein Thrombosis; Pulmonary Embolism,Lung,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6967,NCT02664155,Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants,TERMINATED,PHASE3,Renal Insufficiency,Apixaban (DRUG); Rivaroxaban (DRUG); Heparin (DRUG); VKA (DRUG),4055,MNQ,Renal Insufficiency,Kidney,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6968,NCT02866838,Treatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist,COMPLETED,PHASE2,Intracerebral Hemorrhage,Tranexamic acid (DRUG); Saline 0.9% (DRUG),4055,MNQ,Intracerebral Hemorrhage,CNS/Brain,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6969,NCT03153150,Start or STop Anticoagulants Randomised Trial (SoSTART),COMPLETED,PHASE3,"Intracranial Hemorrhages; Intracranial Hemorrhage, Hypertensive; Subarachnoid Hemorrhage; Subdural Hematoma; Intraventricular Hemorrhage; Atrial Fibrillation; Atrial Flutter; Small Vessel Cerebrovascular Disease; Microhaemorrhage",Apixaban (DRUG); Rivaroxaban (DRUG); Edoxaban (DRUG); Dabigatran (DRUG); Acenocoumarol (DRUG); Phenindione (DRUG); Warfarin (DRUG),4055,MNQ,"Intracranial Hemorrhages; Intracranial Hemorrhage, Hypertensive; Subarachnoid Hemorrhage; Subdural Hematoma; Intraventricular Hemorrhage; Atrial Fibrillation; Atrial Flutter; Small Vessel Cerebrovascular Disease; Microhaemorrhage",CNS/Brain,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6970,NCT03358706,A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis,TERMINATED,PHASE1,Crohn Disease; Ulcerative Colitis,Ustekinumab IV Infusion (DRUG); Ustekinumab SC Injection (DRUG); Midazolam 2 mg (DRUG); Warfarin 10 mg (DRUG); Vitamin K 10 mg (DRUG); Omeprazole 20 mg (DRUG); Dextromethorphan 30 mg (DRUG); Caffeine 100 mg (DRUG),4055,MNQ,Crohn Disease; Ulcerative Colitis,Bowel,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6971,NCT01001299,A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma,COMPLETED,PHASE1,Malignant Melanoma,Drug cocktail (DRUG); RO5185426 (DRUG),4055,MNQ,Malignant Melanoma,Skin,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6972,NCT00676702,A Study of the Enzyme Activity and Safety of Pancrelipase in Patients With Severe Exocrine Pancreatic Insufficiency (EPI),COMPLETED,PHASE1,"Exocrine Pancreatic Insufficiency; Pancreatitis, Chronic; Steatorrhea; Pancreatitis",Ensure Plus (DIETARY_SUPPLEMENT); Pancrelipase in combination with Ensure Plus (DRUG),4055,MNQ,"Exocrine Pancreatic Insufficiency; Pancreatitis, Chronic; Steatorrhea; Pancreatitis",Pancreas,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6973,NCT03718884,A Study of Mirikizumab in Participants With Plaque Psoriasis,COMPLETED,PHASE1,Psoriasis,Drug Cocktail (DRUG); Mirikizumab (DRUG),4055,MNQ,Psoriasis,Skin,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6974,NCT03020602,BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab,COMPLETED,PHASE1,Gliosarcoma; Recurrent Glioblastoma; Astrocytoma of Brain; Glioblastoma,Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Ubidecarenone Injectable Nanosuspension (DRUG),4055,MNQ,Gliosarcoma; Recurrent Glioblastoma; Astrocytoma of Brain; Glioblastoma,CNS/Brain,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6975,NCT01036802,Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease,TERMINATED,PHASE2,Pulmonary Hypertension,Warfarin (DRUG); Placebo (DRUG),4055,MNQ,Pulmonary Hypertension,Lung,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6976,NCT00071279,SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis,COMPLETED,PHASE3,Pulmonary Embolism; Deep Vein Thrombosis,SR34006 (idraparinux sodium) Injection (DRUG),4055,MNQ,Pulmonary Embolism; Deep Vein Thrombosis,Lung,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6977,NCT00062803,SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism,COMPLETED,PHASE3,Pulmonary Embolism,SR34006 (DRUG); (LMW)heparin (DRUG); Warfarin VKA (DRUG); Acenocoumarol VKA (DRUG),4055,MNQ,Pulmonary Embolism,Lung,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6978,NCT04437303,Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI),COMPLETED,PHASE4,Aortic Valve Disease; Aortic Valve Stenosis; Stroke; Bleeding; Vascular Complications; Myocardial Infarction; Thrombosis Embolism,Continuation of oral anticoagulants (DRUG); Interruption of oral anticoagulants (DRUG),4055,MNQ,Aortic Valve Disease; Aortic Valve Stenosis; Stroke; Bleeding; Vascular Complications; Myocardial Infarction; Thrombosis Embolism,CNS/Brain,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6979,NCT00711308,Tinzaparin in the Treatment of the Acute Pulmonary Embolism,COMPLETED,PHASE4,Acute Pulmonary Embolism,tinzaparin (DRUG); acenocoumarol (DRUG),4055,MNQ,Acute Pulmonary Embolism,Lung,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6980,NCT02161965,Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation,COMPLETED,PHASE4,Permanent Atrial Fibrillation; Venous Thrombosis; Pulmonary Embolism; Anticoagulation Treatment at Least > or = to 12-month,Rivaroxaban (DRUG); Fluindione (DRUG); Warfarin (DRUG),4055,MNQ,Permanent Atrial Fibrillation; Venous Thrombosis; Pulmonary Embolism; Anticoagulation Treatment at Least > or = to 12-month,Lung,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6981,NCT03749057,Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation,RECRUITING,PHASE4,Cerebral Infarction; TIA,Rivaroxaban (DRUG),4055,MNQ,Cerebral Infarction; TIA,CNS/Brain,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6982,NCT03243175,Avoiding Anticoagulation After IntraCerebral Haemorrhage,RECRUITING,PHASE3,Intracerebral Hemorrhage; Atrial Fibrillation; Microhaemorrhage,Apixaban 5 MG (DRUG); left atrial appendage closure (DEVICE),4055,MNQ,Intracerebral Hemorrhage; Atrial Fibrillation; Microhaemorrhage,CNS/Brain,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6983,NCT05273775,A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers,COMPLETED,PHASE1,Chronic Hepatitis B,HRS5091 Tablets (DRUG); Midazolam Maleate Tablets (DRUG); Warfarin Sodium Tablets (DRUG); Omeprazole Enteric Capsules (DRUG); Vitamin K1 Tablets (DRUG); Digoxin Tablets (DRUG); Rosuvastatin Calcium Tablets (DRUG),4055,MNQ,Chronic Hepatitis B,Liver,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6984,NCT02970942,Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.,COMPLETED,PHASE2,Hepatobiliary Disorders; Non-alcoholic Steatohepatitis,Semaglutide (DRUG); Placebo (DRUG),4055,MNQ,Hepatobiliary Disorders; Non-alcoholic Steatohepatitis,Liver,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6985,NCT04752813,A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB),RECRUITING,PHASE2,Glioblastoma; Glioblastoma Multiforme,BPM31510 (DRUG); Vitamin K1 (OTHER); Temozolomide (TMZ) (DRUG); Radiation (RADIATION),4055,MNQ,Glioblastoma; Glioblastoma Multiforme,CNS/Brain,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6986,NCT05285787,A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD),COMPLETED,PHASE2,End-Stage Renal Disease (ESRD),EPN-701 (Oral) (DRUG),4055,MNQ,End-Stage Renal Disease (ESRD),Kidney,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6987,NCT01528800,Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients,COMPLETED,PHASE2,End-stage Kidney Disease,Vitamin K1 (DRUG); Microcrystalline Methylcellulose (DRUG),4055,MNQ,End-stage Kidney Disease,Kidney,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6988,NCT04098237,Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency,ACTIVE_NOT_RECRUITING,PHASE2,Pancreatic Adenocarcinoma,Pancrelipase (DRUG),4055,MNQ,Pancreatic Adenocarcinoma,Pancreas,Menadione,,unclear,unclear,no,yes,"Used in trials; a vitamin K analog, not fully approved for human use.",CC1=CC(=O)C2=CC=CC=C2C1=O,1.36,355.0 +6989,NCT06238674,Early Goal Nutrition Therapy Guided by Indirect Calorimetry and Nitrogen Balance Among Critically Ill Patients With Acute Kidney Injury (ENGINE Study),ACTIVE_NOT_RECRUITING,PHASE1,Critically Ill; Nutrition Disorders; Acute Kidney Injury,indirect calorimetry and nitrogen balance (OTHER); Indirect calorimetry (Standard care nutrition arm) (OTHER),667493,MTU,Critically Ill; Nutrition Disorders; Acute Kidney Injury,Kidney,Methylthiouracil,,unclear,unclear,no,yes,"Used in research, not approved for human therapeutic use.",CC1=CC(=O)NC(=S)N1,2.0,0.0 +6990,NCT03113448,0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy,COMPLETED,PHASE3,Peripheral Diabetic Neuropathy,0.075% Capsaicin Lotion (DRUG); placebo (DRUG),667493,MTU,Peripheral Diabetic Neuropathy,Peripheral Nervous System,Methylthiouracil,,unclear,unclear,no,yes,"Used in research, not approved for human therapeutic use.",CC1=CC(=O)NC(=S)N1,2.0,0.0 +6991,NCT00701480,Safety and Efficacy of Skin Cleanser Contained Roselle Extract in Acne,UNKNOWN,PHASE2,Acne,skin cleanser contained Hibiscus sabdariffa extract (OTHER); marketed skin cleanser (OTHER),667493,MTU,Acne,Skin,Methylthiouracil,,unclear,unclear,no,yes,"Used in research, not approved for human therapeutic use.",CC1=CC(=O)NC(=S)N1,2.0,0.0 +6992,NCT06346691,Effects of Oral Doxofylline and Procaterol on Chronic Obstructive Pulmonary Disease,COMPLETED,PHASE4,COPD,Doxofylline (DRUG); Procaterol (DRUG),667493,MTU,COPD,Lung,Methylthiouracil,,unclear,unclear,no,yes,"Used in research, not approved for human therapeutic use.",CC1=CC(=O)NC(=S)N1,2.0,0.0 +6993,NCT03402204,Efficacy of High and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcome in Patients With AIS,COMPLETED,PHASE3,Ischemic Stroke,Simvastatin 10 mg (DRUG); Simvastatin 40 mg (DRUG),667493,MTU,Ischemic Stroke,CNS/Brain,Methylthiouracil,,unclear,unclear,no,yes,"Used in research, not approved for human therapeutic use.",CC1=CC(=O)NC(=S)N1,2.0,0.0 +6994,NCT00993070,Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy,COMPLETED,PHASE2,Diabetic Polyneuropathy,Capsaicin (DRUG); placebo (DRUG),667493,MTU,Diabetic Polyneuropathy,Peripheral Nervous System,Methylthiouracil,,unclear,unclear,no,yes,"Used in research, not approved for human therapeutic use.",CC1=CC(=O)NC(=S)N1,2.0,0.0 +6995,NCT01066351,Efficacy of Erythropoietin to Prevent Acute Kidney Injury in Chronic Kidney Disease Patients Undergoing Cardiac Surgery,UNKNOWN,PHASE3,Acute Renal Failure,beta erythropoietin (DRUG); placebo (DRUG),667493,MTU,Acute Renal Failure,Kidney,Methylthiouracil,,unclear,unclear,no,yes,"Used in research, not approved for human therapeutic use.",CC1=CC(=O)NC(=S)N1,2.0,0.0 +6996,NCT06905483,Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study,RECRUITING,PHASE4,COPD; Chronic Obstructive Pulmonary Disease (COPD); Small Airway Disease; Triple Therapy; Lung Function,Budesonide/Glycopyrronium/Formoterol (BGF) (DRUG); Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) (DRUG),667493,MTU,COPD; Chronic Obstructive Pulmonary Disease (COPD); Small Airway Disease; Triple Therapy; Lung Function,Lung,Methylthiouracil,,unclear,unclear,no,yes,"Used in research, not approved for human therapeutic use.",CC1=CC(=O)NC(=S)N1,2.0,0.0 +6997,NCT03260556,Pirfenidone for Progressive Fibrotic Sarcoidosis,UNKNOWN,PHASE4,"Sarcoidosis, Pulmonary",Pirfenidone (DRUG); Placebos (DRUG),4659569,TCW,Pulmonary Sarcoidosis,Lung,Tolcapone,COMT,inhibitor/antagonist,unclear,yes,yes,"Used in Parkinson's treatment, subject to liver monitoring.",CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-],1.09,770.0 +6998,NCT02630043,Trial of Tolcapone With Oxaliplatin for Neuroblastoma,TERMINATED,PHASE1,Neuroblastoma,Tolcapone (DRUG); Oxaliplatin (DRUG),4659569,TCW,Neuroblastoma,CNS/Brain,Tolcapone,COMT,inhibitor/antagonist,unclear,yes,yes,"Used in Parkinson's treatment, subject to liver monitoring.",CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-],1.09,770.0 +6999,NCT00906828,Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors,COMPLETED,PHASE4,Parkinson Disease,levodopa/carbidopa (DRUG); entacapone (DRUG); tolcapone (DRUG),4659569,TCW,Parkinson Disease,CNS/Brain,Tolcapone,COMT,inhibitor/antagonist,unclear,yes,yes,"Used in Parkinson's treatment, subject to liver monitoring.",CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-],1.09,770.0 +7000,NCT05065671,Microbiome Derived Metabolism and Pharmacokinetics,RECRUITING,PHASE1,Microbial Colonization,Tolcapone 100 MG (DRUG); Duloxetine 20 MG (DRUG),4659569,TCW,Microbial Colonization,Bowel,Tolcapone,COMT,inhibitor/antagonist,unclear,yes,yes,"Used in Parkinson's treatment, subject to liver monitoring.",CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-],1.09,770.0 +7001,NCT01220739,Safety of Rt-PA + Transcranial Emission of Low-Energy Lasers for Acute Stroke Recovery,TERMINATED,PHASE2,Ischemic Stroke,Transcranial Laser Therapy (DEVICE),5509,TLT,Ischemic Stroke,CNS/Brain,Tolmetin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Approved NSAID for pain and inflammation.,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,1.59,464.0 +7002,NCT01120301,Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3),COMPLETED,PHASE3,Acute Ischemic Stroke,NeuroThera® Laser System (DEVICE),5509,TLT,Acute Ischemic Stroke,CNS/Brain,Tolmetin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Approved NSAID for pain and inflammation.,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,1.59,464.0 +7003,NCT01042041,Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer,COMPLETED,PHASE1,Hepatocellular Carcinoma; Liver Cancer; Localized Unresectable Liver Cancer,sorafenib tosylate (DRUG); doxorubicin hydrochloride (DRUG); cisplatin (DRUG); mitomycin C (DRUG); transarterial chemoembolization (PROCEDURE); hepatic artery embolization (PROCEDURE),5509,TLT,Hepatocellular Carcinoma; Liver Cancer; Localized Unresectable Liver Cancer,Liver,Tolmetin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Approved NSAID for pain and inflammation.,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,1.59,464.0 +7004,NCT05695521,Regulatory T Cells for Amyotrophic Lateral Sclerosis,ACTIVE_NOT_RECRUITING,PHASE1,Amyotrophic Lateral Sclerosis,CK0803 (BIOLOGICAL); Excipient (OTHER),5509,TLT,Amyotrophic Lateral Sclerosis,CNS/Brain,Tolmetin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Approved NSAID for pain and inflammation.,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,1.59,464.0 +7005,NCT05385705,A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020,RECRUITING,PHASE1,Breast Neoplasms,Cyclophosphamide (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); NK cells (BIOLOGICAL); Interleukin-2 (DRUG),5509,TLT,Breast Neoplasms,Breast,Tolmetin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Approved NSAID for pain and inflammation.,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,1.59,464.0 +7006,NCT01902771,Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors,TERMINATED,PHASE1,Glioma; Brain Cancer; Brain Tumor; Glioblastoma Multiforme; High Grade Glioma,Dendritic Cell Vaccine (BIOLOGICAL); Tumor Lysate (BIOLOGICAL); Imiquimod (OTHER); Leukapheresis (PROCEDURE),5509,TLT,Glioma; Brain Cancer; Brain Tumor; Glioblastoma Multiforme; High Grade Glioma,CNS/Brain,Tolmetin,"PTGS1, PTGS2",inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Approved NSAID for pain and inflammation.,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,1.59,464.0 +7007,NCT00538031,"Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",COMPLETED,PHASE2,Fallopian Tube Cancer; Peritoneal Cavity Cancer; Recurrent Ovarian Epithelial Cancer,cyclophosphamide (DRUG); celecoxib (DRUG),2662,ELYXYB,Fallopian Tube Cancer; Peritoneal Cavity Cancer; Recurrent Ovarian Epithelial Cancer,Ovary/Fallopian Tube,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7008,NCT05756166,"Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma; Unresectable Triple-Negative Breast Carcinoma,Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Celecoxib (DRUG); Computed Tomography (PROCEDURE); Interferon Alpha-2 (BIOLOGICAL); Magnetic Resonance Imaging (PROCEDURE); Pembrolizumab (BIOLOGICAL); Rintatolimod (DRUG),2662,ELYXYB,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma; Unresectable Triple-Negative Breast Carcinoma,Breast,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7009,NCT04081389,Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer,COMPLETED,PHASE1,Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Early-Stage Breast Carcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Prognostic Stage 0 Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Triple-Negative Breast Carcinoma,Celecoxib (DRUG); Cyclophosphamide (DRUG); Doxorubicin (DRUG); Doxorubicin Hydrochloride (DRUG); Paclitaxel (DRUG); Recombinant Interferon Alfa-2b (BIOLOGICAL); Rintatolimod (DRUG),2662,ELYXYB,Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Early-Stage Breast Carcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Prognostic Stage 0 Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Triple-Negative Breast Carcinoma,Breast,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7010,NCT00081263,Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia,COMPLETED,PHASE2,Cervical Carcinoma; Cervical Intraepithelial Neoplasia Grade 2/3; Stage 0 Cervical Cancer,Celecoxib (DRUG); Laboratory Biomarker Analysis (OTHER); Placebo (OTHER),2662,ELYXYB,Cervical Carcinoma; Cervical Intraepithelial Neoplasia Grade 2/3; Stage 0 Cervical Cancer,Cervix,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7011,NCT03403634,"Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver",COMPLETED,PHASE2,Metastatic Carcinoma in the Liver; Recurrent Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7,Celecoxib (DRUG); Laboratory Biomarker Analysis (OTHER); Recombinant Interferon Alfa-2b (BIOLOGICAL); Rintatolimod (DRUG),2662,ELYXYB,Metastatic Carcinoma in the Liver; Recurrent Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7012,NCT01158534,Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery,COMPLETED,PHASE2,Renal Cell Cancer; Stage IV Renal Cell Cancer,celecoxib (DRUG); recombinant interferon alfa-2b (BIOLOGICAL); polymerase chain reaction (OTHER); laboratory biomarker analysis (OTHER); reverse transcriptase-polymerase chain reaction (OTHER); immunologic technique (OTHER); immunohistochemistry staining method (OTHER); flow cytometry (OTHER),2662,ELYXYB,Renal Cell Cancer; Stage IV Renal Cell Cancer,Kidney,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7013,NCT01729923,A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer,TERMINATED,PHASE2,Recurrent Colon Carcinoma; Recurrent Rectal Carcinoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,Capecitabine (DRUG); Celecoxib (DRUG); Intensity-Modulated Radiation Therapy (RADIATION); Laboratory Biomarker Analysis (OTHER); Quality-of-Life Assessment (OTHER); Radiation Therapy (RADIATION); Stereotactic Radiosurgery (RADIATION); Therapeutic Conventional Surgery (PROCEDURE),2662,ELYXYB,Recurrent Colon Carcinoma; Recurrent Rectal Carcinoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7014,NCT00499655,Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,erlotinib hydrochloride (DRUG); celecoxib (DRUG); placebo (OTHER); laboratory biomarker analysis (OTHER); immunohistochemistry staining method (OTHER); fluorescence in situ hybridization (GENETIC); mutation analysis (GENETIC); protein expression analysis (GENETIC); gene expression analysis (GENETIC),2662,ELYXYB,Advanced Non-Small Cell Lung Cancer,Lung,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7015,NCT04093323,"Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma",RECRUITING,PHASE2,HLA-A2 Positive Cells Present; Refractory Melanoma,Alpha-type-1 Polarized Dendritic Cells (BIOLOGICAL); Celecoxib (DRUG); PD-1 Ligand Inhibitor (DRUG); PD1 Inhibitor (DRUG); Recombinant Interferon Alfa-2b (BIOLOGICAL); Rintatolimod (DRUG),2662,ELYXYB,HLA-A2 Positive Cells Present; Refractory Melanoma,Skin,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7016,NCT03599453,Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer,COMPLETED,EARLY_PHASE1,Triple -Negative Breast Cancer; Estrogen Receptor Negative; HER2/Neu Negative; Anatomic Stage IV Breast Cancer AJCC; Progesterone Receptor Negative,Biopsy (PROCEDURE); Chemokine Modulation Therapy (PROCEDURE); Celecoxib (DRUG); Recombinant Interferon Alfa-2b (BIOLOGICAL); Rintatolimod (DRUG); Pembrolizumab (BIOLOGICAL),2662,ELYXYB,Triple -Negative Breast Cancer; Estrogen Receptor Negative; HER2/Neu Negative; Anatomic Stage IV Breast Cancer AJCC; Progesterone Receptor Negative,Breast,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7017,NCT01695226,Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms; Breast Cancer,celecoxib (DRUG); Placebo (DRUG),2662,ELYXYB,Breast Neoplasms; Breast Cancer,Breast,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7018,NCT00665457,Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery,TERMINATED,PHASE2,Breast Cancer,filgrastim (BIOLOGICAL); capecitabine (DRUG); celecoxib (DRUG); cyclophosphamide (DRUG); docetaxel (DRUG); doxorubicin hydrochloride (DRUG); gene expression analysis (GENETIC); polymorphism analysis (GENETIC); protein expression analysis (GENETIC); reverse transcriptase-polymerase chain reaction (GENETIC); imaging biomarker analysis (OTHER); immunohistochemistry staining method (OTHER); laboratory biomarker analysis (OTHER); pharmacogenomic studies (OTHER); dynamic contrast-enhanced magnetic resonance imaging (PROCEDURE); needle biopsy (PROCEDURE); neoadjuvant therapy (PROCEDURE); radiomammography (PROCEDURE); ultrasound imaging (PROCEDURE),2662,ELYXYB,Breast Cancer,Breast,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7019,NCT02115074,Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas,COMPLETED,PHASE1,Glioma,Fluvastatine (DRUG); Celebrex (DRUG),2662,ELYXYB,Glioma,CNS/Brain,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7020,NCT02615574,"A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer",WITHDRAWN,PHASE2,Metastatic Colorectal Cancer,αDC1 vaccine (BIOLOGICAL); CKM (DRUG),2662,ELYXYB,Metastatic Colorectal Cancer,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7021,NCT00030420,Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,Celecoxib (DRUG); Docetaxel (DRUG),2662,ELYXYB,Lung Cancer,Lung,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7022,NCT01555073,Preemptive Analgesia Following Uterine Artery Embolization,TERMINATED,PHASE4,Uterine Fibroids; Uterine Artery Embolization,pregabalin/celecoxib (DRUG); pregabalin/placebo (DRUG); celecoxib/placebo (DRUG); Placebo group (DRUG),2662,ELYXYB,Uterine Fibroids; Uterine Artery Embolization,Uterus,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7023,NCT00201773,"Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer",COMPLETED,PHASE2,Breast Cancer,Exemestane (DRUG); Celecoxib (DRUG); Correlative studies (OTHER),2662,ELYXYB,Breast Cancer,Breast,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7024,NCT00075673,Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer,TERMINATED,PHASE1,Breast Cancer,celecoxib (DRUG); vinorelbine ditartrate (DRUG),2662,ELYXYB,Breast Cancer,Breast,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7025,NCT00527982,Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer,TERMINATED,PHASE2,Head and Neck Cancer; Lung Cancer,Celecoxib (DRUG),2662,ELYXYB,Head and Neck Cancer; Lung Cancer,Lung,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7026,NCT00038103,Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen,COMPLETED,PHASE2,Breast Neoplasms,Exemestane (DRUG); Celecoxib + Exemestane (DRUG),2662,ELYXYB,Breast Neoplasms,Breast,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7027,NCT02739204,Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma,UNKNOWN,PHASE2,Oral Squamous Cell Carcinoma,Celecoxib (DRUG),2662,ELYXYB,Oral Squamous Cell Carcinoma,Skin,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7028,NCT02429427,European Celecoxib Trial in Primary Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Celecoxib (DRUG); Placebo (OTHER),2662,ELYXYB,Breast Cancer,Breast,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7029,NCT00023660,"Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer",COMPLETED,PHASE1,Cervical Cancer,celecoxib (DRUG); cisplatin (DRUG); fluorouracil (DRUG); brachytherapy (RADIATION); radiation therapy (RADIATION),2662,ELYXYB,Cervical Cancer,Cervix,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7030,NCT00486460,"Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer",UNKNOWN,PHASE3,Pancreatic Cancer,Gemcitabine (DRUG); Curcumin (DRUG); Celebrex (DRUG),2662,ELYXYB,Pancreatic Cancer,Pancreas,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7031,NCT00056082,Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women,COMPLETED,PHASE2,Breast Cancer,celecoxib (DRUG),2662,ELYXYB,Breast Cancer,Breast,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7032,NCT01425476,Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors,COMPLETED,PHASE1,Breast Cancer,Celecoxib (DRUG); Placebo (DRUG); Cholecalciferol (DRUG),2662,ELYXYB,Breast Cancer,Breast,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7033,NCT00336960,"Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery",COMPLETED,PHASE2,Colorectal Cancer,celecoxib (DRUG); fluorouracil (DRUG); conventional surgery (PROCEDURE); radiation therapy (RADIATION); tumor biopsy (PROCEDURE); laboratory biomarker analysis (OTHER),2662,ELYXYB,Colorectal Cancer,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7034,NCT02151448,αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies,COMPLETED,PHASE1,Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface; Malignant Peritoneal Mesothelioma; Peritoneal Carcinomatosis,DC vaccine (BIOLOGICAL); Celecoxib (DRUG); Interferon Alfa-2b (DRUG); rintatolimod (BIOLOGICAL),2662,ELYXYB,Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface; Malignant Peritoneal Mesothelioma; Peritoneal Carcinomatosis,Lung,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7035,NCT00070057,Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer,COMPLETED,PHASE1,Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,celecoxib (DRUG); therapeutic conventional surgery (PROCEDURE); pharmacological study (OTHER); laboratory biomarker analysis (OTHER),2662,ELYXYB,Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Breast,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7036,NCT00177866,Safety of Celecoxib in Patients With Crohn's Disease,TERMINATED,PHASE4,Crohn's Disease,Celebrex (DRUG); placebo (DRUG),2662,ELYXYB,Crohn's Disease,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7037,NCT01769625,Changes in Biomarkers Using Prostaglandin Inhibitors,COMPLETED,PHASE1,Biomarker Change Linked to Breast Cancer,"placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU (DRUG)",2662,ELYXYB,Biomarker Change Linked to Breast Cancer,Breast,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7038,NCT00046839,Celecoxib and Radiation Therapy in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer,celecoxib (DRUG); radiation therapy (RADIATION),2662,ELYXYB,Lung Cancer,Lung,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7039,NCT01881048,Window of Opportunity Study Targeting the Inflammatory Milieu,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Omega-3 fatty acid (DIETARY_SUPPLEMENT); Celecoxib (DRUG),2662,ELYXYB,Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Breast,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7040,NCT00300729,Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy,UNKNOWN,PHASE3,Non-Small Cell Lung Cancer,Celecoxib (DRUG); Placebo (DRUG),2662,ELYXYB,Advanced Non-Small Cell Lung Cancer,Lung,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7041,NCT00007189,Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT),COMPLETED,PHASE3,Alzheimer Disease,Naproxen Sodium (Aleve) (DRUG); Celecoxib (Celebrex) (DRUG),2662,ELYXYB,Alzheimer Disease,CNS/Brain,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7042,NCT00005094,Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps,COMPLETED,PHASE3,Colon Cancer; Rectal Cancer,celecoxib (DRUG); placebo (OTHER),2662,ELYXYB,Colon Cancer; Rectal Cancer,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7043,NCT01111591,Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer,UNKNOWN,PHASE4,Bile Duct Cancer; Pancreatic Cancer,Cox2 inhibitor (Celecoxib) (DRUG),2662,ELYXYB,Bile Duct Cancer; Pancreatic Cancer,Pancreas,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7044,NCT00291694,Protocol for Women at Increased Risk of Developing Breast Cancer,COMPLETED,PHASE2,Breast Cancer,celecoxib (DRUG); placebo (OTHER),2662,ELYXYB,Breast Cancer,Breast,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7045,NCT00504660,"6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients",COMPLETED,PHASE2,Anaplastic Glioma of Brain; Glioblastoma Multiforme; Brain Cancer,Capecitabine (DRUG); Celecoxib (Celebrex) (DRUG); Temozolomide (DRUG); Lomustine (DRUG); 6-Thioguanine (DRUG),2662,ELYXYB,Anaplastic Glioma of Brain; Glioblastoma Multiforme; Brain Cancer,CNS/Brain,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7046,NCT00101062,Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer,TERMINATED,PHASE2,Breast Cancer,celecoxib (DRUG); letrozole (DRUG),2662,ELYXYB,Breast Cancer,Breast,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7047,NCT00250835,"Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer",TERMINATED,PHASE2,Rectal Cancer,"Chemotherapy, Celecoxib, and Radiation (OTHER)",2662,ELYXYB,Rectal Cancer,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7048,NCT00066716,"Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus",COMPLETED,PHASE2,Esophageal Cancer,carboplatin (DRUG); celecoxib (DRUG); paclitaxel (DRUG); adjuvant therapy (PROCEDURE); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE),2662,ELYXYB,Esophageal Cancer,Esophagus/Stomach,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7049,NCT03859024,Efficacy of Opioid-limiting Pain Management Protocol in Men Undergoing Urethroplasty,COMPLETED,PHASE4,"Pain, Postoperative; Urethral Stricture",Oxycodone (DRUG); Acetaminophen (DRUG); Gabapentin (DRUG); celebrex (DRUG); Bupivacaine (DRUG); Ibuprofen 800 mg (DRUG); Dexamethasone (DRUG),2662,ELYXYB,"Pain, Postoperative; Urethral Stricture",Bladder/Urinary Tract,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7050,NCT05281276,Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC),TERMINATED,PHASE1,Metastatic Colorectal Cancer,chidamide (DRUG); celecoxib (DRUG),2662,ELYXYB,Metastatic Colorectal Cancer,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7051,NCT02054104,"Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum",TERMINATED,PHASE1,Thoracic Sarcomas; Thorasic Cancers; Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura; Sarcoma; Melanoma,H1299 cell lysates (BIOLOGICAL); Cyclophosphamide (DRUG); Celecoxib (DRUG); Iscomatrix adjuvant (BIOLOGICAL),2662,ELYXYB,Thoracic Sarcomas; Thorasic Cancers; Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura; Sarcoma; Melanoma,Skin,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7052,NCT00062101,Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,erlotinib hydrochloride (DRUG); celecoxib (DRUG); laboratory biomarker analysis (OTHER),2662,ELYXYB,Advanced Non-Small Cell Lung Cancer,Lung,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7053,NCT05434065,Effects and Mechanisms of Celecoxib on Intracerebral Hemorrhage,RECRUITING,PHASE2,Intracerebral Hemorrhage,Celecoxib 200mg (DRUG),2662,ELYXYB,Intracerebral Hemorrhage,CNS/Brain,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7054,NCT00006124,Celecoxib in Treating Patients With Bladder Cancer,COMPLETED,PHASE2,Recurrent Bladder Cancer,celecoxib (DRUG); placebo (DRUG),2662,ELYXYB,Recurrent Bladder Cancer,Bladder/Urinary Tract,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7055,NCT00525096,Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer,COMPLETED,PHASE3,Metastatic Breast Cancer,placebo (DRUG); Celecoxib (DRUG); Exemestane (DRUG),2662,ELYXYB,Metastatic Breast Cancer,Breast,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7056,NCT00081224,Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum,TERMINATED,PHASE2,Colorectal Cancer,capecitabine (DRUG); celecoxib (DRUG); radiation therapy (RADIATION); surgery (PROCEDURE),2662,ELYXYB,Colorectal Cancer,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7057,NCT01545141,Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer,TERMINATED,PHASE1,"Colorectal Cancer; Colorectal Carcinoma; Colorectal Tumors; Neoplasms, Colorectal",Chemokin Modulatory Regimen (5 MU/m2) (DRUG); Chemokin Modulatory Regimen (10 MU/m2) (DRUG); Chemokin Modulatory Regimen (20 MU/m2) (DRUG),2662,ELYXYB,"Colorectal Cancer; Colorectal Carcinoma; Colorectal Tumors; Neoplasms, Colorectal",Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7058,NCT00346801,CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE1,Lung Cancer,Celecoxib (DRUG); Cisplatin (DRUG); CPT-11 (DRUG); Concurrent Thoracic Radiation Therapy (RADIATION),2662,ELYXYB,Lung Cancer,Lung,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7059,NCT01258868,Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas,TERMINATED,PHASE1,Mesolthelioma; Esophageal Cancer; Lung Cancer; Thoracic Sarcomas; Thymoma,Celebrex (DRUG); Tumor cell vaccine (BIOLOGICAL),2662,ELYXYB,Mesolthelioma; Esophageal Cancer; Lung Cancer; Thoracic Sarcomas; Thymoma,Lung,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7060,NCT02641314,Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma,COMPLETED,PHASE2,Recurrent Neuroblastoma,metronomic therapy (DRUG),2662,ELYXYB,Recurrent Neuroblastoma,CNS/Brain,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7061,NCT02030964,N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan,COMPLETED,PHASE1,Neuroblastoma,DFMO (DRUG); Celecoxib (DRUG); Cyclophosphamide (DRUG); Topotecan (DRUG),2662,ELYXYB,Neuroblastoma,CNS/Brain,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7062,NCT01280006,Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans,COMPLETED,PHASE1,Obstructive Sleep Apnea; Hypertension; Cardiovascular Diseases; Stroke,Intermittent hypoxia (OTHER); Indomethacin (DRUG); Celecoxib (DRUG); Placebo (DRUG),2662,ELYXYB,Obstructive Sleep Apnea; Hypertension; Cardiovascular Diseases; Stroke,CNS/Brain,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7063,NCT00159484,Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer,UNKNOWN,PHASE1,Colon Cancer; Colorectal Cancer,"EPO906, celecoxib (DRUG)",2662,ELYXYB,Colon Cancer; Colorectal Cancer,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7064,NCT00112502,Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme,COMPLETED,PHASE2,Brain and Central Nervous System Tumors; Glioblastoma Multiforme,Celecoxib (DRUG); Isotretinoin (DRUG); Temozolomide (DRUG); Thalidomide (DRUG),2662,ELYXYB,Brain and Central Nervous System Tumors; Glioblastoma Multiforme,CNS/Brain,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7065,NCT00305643,Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer,TERMINATED,PHASE3,Breast Cancer; Colorectal Cancer; Pain,Capecitabine (DRUG); Celecoxib (DRUG); Radiation Therapy (PROCEDURE); Placebo (DRUG),2662,ELYXYB,Breast Cancer; Colorectal Cancer; Pain,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7066,NCT00188565,Celebrex With Preoperative Chemoradiation - Rectal Cancer,COMPLETED,PHASE1,Colorectal Neoplasms,Celecoxib (DRUG),2662,ELYXYB,Colorectal Neoplasms,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7067,NCT00084448,Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer,TERMINATED,PHASE2,Ovarian Cancer; Primary Peritoneal Cavity Cancer,celecoxib (DRUG); paclitaxel (DRUG),2662,ELYXYB,Ovarian Cancer,Ovary/Fallopian Tube,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7068,NCT00088959,Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,erlotinib hydrochloride (DRUG); celecoxib (DRUG); laboratory biomarker analysis (OTHER),2662,ELYXYB,Advanced Non-Small Cell Lung Cancer,Lung,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7069,NCT00068432,Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,Celecoxib (DRUG); Gemcitabine Hydrochloride (DRUG),2662,ELYXYB,Pancreatic Cancer,Pancreas,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7070,NCT00087256,Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer,TERMINATED,PHASE3,Colorectal Cancer,Celecoxib (DRUG); placebo (OTHER),2662,ELYXYB,Colorectal Cancer,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7071,NCT00177853,"Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer",TERMINATED,PHASE1,Pancreatic Cancer,celecoxib (DRUG); irinotecan (DRUG); concurrent radiotherapy (PROCEDURE),2662,ELYXYB,Pancreatic Cancer,Pancreas,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7072,NCT00072553,"Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer",UNKNOWN,PHASE2,Colorectal Cancer,celecoxib (DRUG); fluorouracil (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG); adjuvant therapy (PROCEDURE); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE),2662,ELYXYB,Colorectal Cancer,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7073,NCT00068653,Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,Celecoxib (DRUG); ZD1839 (DRUG),2662,ELYXYB,Lung Cancer,Lung,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7074,NCT06076837,The Seven Trial: Exploiting the Unfolded Protein Response,RECRUITING,PHASE1,Pancreatic Cancer Metastatic; Pancreatic Adenocarcinoma Metastatic,Botensilimab (DRUG); Balstilimab (DRUG); Chloroquine Phosphate (DRUG); Celecoxib (DRUG); Nab paclitaxel (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG),2662,ELYXYB,Pancreatic Cancer Metastatic; Pancreatic Adenocarcinoma Metastatic,Pancreas,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7075,NCT00030407,Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,Celecoxib (DRUG); Docetaxel (DRUG),2662,ELYXYB,Lung Cancer,Lung,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7076,NCT00183807,"A Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer",TERMINATED,PHASE2,Esophageal Cancer,"irinotecan, cisplatin, celecoxib (DRUG)",2662,ELYXYB,Esophageal Cancer,Esophagus/Stomach,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7077,NCT00055978,Celecoxib in Preventing Lung Cancer in Former Heavy Smokers,COMPLETED,PHASE2,Lung Cancer,celecoxib (DRUG); placebo (OTHER),2662,ELYXYB,Lung Cancer,Lung,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7078,NCT00020878,Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers,COMPLETED,PHASE2,Lung Cancer,celecoxib (DRUG),2662,ELYXYB,Lung Cancer,Lung,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7079,NCT03185871,Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses,WITHDRAWN,PHASE2,Breast Carcinoma,Celecoxib (DRUG),2662,ELYXYB,Breast Carcinoma,Breast,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7080,NCT03638297,PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer,RECRUITING,PHASE2,Colorectal Cancer,PD-1 antibody + cox inhibitor (DRUG),2662,ELYXYB,Colorectal Cancer,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7081,NCT01503385,Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC),UNKNOWN,PHASE2,Lung Cancer,Celecoxib (DRUG),2662,ELYXYB,Lung Cancer,Lung,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7082,NCT03184493,Celebrex and Metformin for Postoperative Hepatocellular Carcinoma,UNKNOWN,PHASE3,Liver Cancer,Celebrex plus Metformin (DRUG); Celebrex (DRUG); Metformin (DRUG),2662,ELYXYB,Liver Cancer,Liver,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7083,NCT00001693,Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers,COMPLETED,PHASE1,Colorectal Neoplasm; Hereditary Nonpolyposis,Celecoxib (SC-58635) (DRUG),2662,ELYXYB,Colorectal Neoplasm; Hereditary Nonpolyposis,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7084,NCT00033371,Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis,COMPLETED,PHASE2,Colorectal Cancer; Familial Adenomatous Polyposis,Celecoxib (DRUG); Placebo (OTHER); eflornithine (DRUG); Laboratory biomarker analysis (OTHER); Questionnaire administration (OTHER),2662,ELYXYB,Colorectal Cancer; Familial Adenomatous Polyposis,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7085,NCT00141193,Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP),COMPLETED,PHASE3,Colorectal Adenoma,Celecoxib (DRUG),2662,ELYXYB,Colorectal Adenoma,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7086,NCT00466505,Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery,COMPLETED,PHASE2,Colorectal Cancer,cetuximab (BIOLOGICAL); celecoxib (DRUG); proteomic profiling (GENETIC); immunohistochemistry staining method (OTHER); laboratory biomarker analysis (OTHER); mass spectrometry (OTHER),2662,ELYXYB,Colorectal Cancer,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7087,NCT02961998,"Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail",COMPLETED,PHASE4,Hepatocellular Carcinoma,Celecoxib (DRUG); Sorafenib (DRUG),2662,ELYXYB,Hepatocellular Carcinoma,Liver,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7088,NCT02280694,Low Dose Metronomic Poly-chemotherapy for Metastatic CRC,COMPLETED,PHASE2,Colorectal Cancer,Capecitabine (DRUG); Cyclophosphamide (DRUG); Methotrexate (DRUG); Celecoxib (DRUG),2662,ELYXYB,Colorectal Cancer,Bowel,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7089,NCT01756989,ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors,COMPLETED,PHASE2,Brainstem Glioma,"Thalidomide, etoposide, celecoxib (DRUG)",2662,ELYXYB,Brainstem Glioma,CNS/Brain,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7090,NCT00197912,Dendritic Cell Based Therapy of Malignant Melanoma,COMPLETED,PHASE1,Advanced Melanoma,tumor antigen loaded autologous dendritic cells (BIOLOGICAL),2662,ELYXYB,Advanced Melanoma,Skin,Celecoxib,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,yes,yes,Used for arthritis pain and inflammation; approved NSAID.,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,1.13,255.0 +7091,NCT00508274,Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China,TERMINATED,PHASE3,"Neoplasms, Breast",lapatinib (DRUG); capecitabine (DRUG),11557040,Tyverb,"Neoplasms, Breast",Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7092,NCT00829166,A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Trastuzumab emtansine (DRUG); Lapatinib (DRUG); Capecitabine (DRUG),11557040,Tyverb,Breast Cancer,Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7093,NCT00437073,Brain Metastases In ErbB2-Positive Breast Cancer,TERMINATED,PHASE2,"Neoplasms, Breast",capecitabine (DRUG); topotecan (DRUG); lapatinib (DRUG),11557040,Tyverb,"Neoplasms, Breast",Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7094,NCT01426880,Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer,COMPLETED,PHASE2,Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer,Carboplatin (DRUG); background treatment (DRUG),11557040,Tyverb,Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer,Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7095,NCT00331630,"Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer",COMPLETED,EARLY_PHASE1,Breast Cancer,lapatinib ditosylate (DRUG); paclitaxel albumin-stabilized nanoparticle formulation (DRUG),11557040,Tyverb,Breast Cancer,Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7096,NCT00299286,Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Lapatinib (DRUG); Lapatinib-Placebo (DRUG),11557040,Tyverb,Breast Cancer,Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7097,NCT01238029,"Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer",TERMINATED,PHASE1,Metastatic Breast Cancer; HER2 Positive; First or Second Line Therapy; Failure or Contraindication of Trastuzumab Therapy,Lapatinib and Capecitabine and Vinorelbine (DRUG),11557040,Tyverb,Metastatic Breast Cancer; HER2 Positive; First or Second Line Therapy; Failure or Contraindication of Trastuzumab Therapy,Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7098,NCT01973660,PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Lapatinib (DRUG); Trastuzumab (DRUG); Endocrine Therapy (DRUG); Paclitaxel (DRUG),11557040,Tyverb,Breast Cancer,Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7099,NCT00444535,Lapatinib and Bevacizumab for Metastatic Breast Cancer,COMPLETED,PHASE2,"Neoplasms, Breast",lapatinib (DRUG); bevacizumab (DRUG),11557040,Tyverb,"Neoplasms, Breast",Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7100,NCT00447122,BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer,TERMINATED,PHASE1,Metastatic Pancreatic Cancer,Gemcitabine 1000mg/m2 30 minutes (DRUG); Lapatinib 1000mg/d (DRUG); Lapatinib 1500mg/d (DRUG); Gemcitabine 1000mg/m2 100minutes (DRUG); Oxaliplatin 100mg/m2 (DRUG),11557040,Tyverb,Metastatic Pancreatic Cancer,Pancreas,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7101,NCT01145404,Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer,TERMINATED,PHASE2,GastroEsophageal Cancer,Lapatinib (DRUG); Lapatinib plus capecitabine (DRUG),11557040,Tyverb,GastroEsophageal Cancer,Esophagus/Stomach,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7102,NCT01273610,Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Neoplasms; HER2/Neu Positive; Geriatric Health Services,Lapatinib (DRUG); Trastuzumab (DRUG); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),11557040,Tyverb,Breast Neoplasms; HER2/Neu Positive; Geriatric Health Services,Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7103,NCT00632489,LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients,COMPLETED,PHASE1,Breast Cancer,LBH589 (DRUG); Capecitabine (DRUG); Lapatinib (DRUG),11557040,Tyverb,Breast Cancer,Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7104,NCT00513058,Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer,COMPLETED,PHASE1,Breast Cancer,Lapatinib (DRUG); vinorelbine (DRUG),11557040,Tyverb,Breast Cancer,Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7105,NCT01808573,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,COMPLETED,PHASE3,HER2+ Metastatic Breast Cancer (MBC),neratinib (DRUG); capecitabine (DRUG); lapatinib (DRUG),11557040,Tyverb,HER2+ Metastatic Breast Cancer,Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7106,NCT01262469,Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer.,COMPLETED,PHASE2,Metastatic Breast Cancer; 70 Years Old Patients and Over; After One Line of Chemotherapy With Trastuzumab,lapatinib + capecitabine (DRUG),11557040,Tyverb,Metastatic Breast Cancer; 70 Years Old Patients and Over; After One Line of Chemotherapy With Trastuzumab,Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7107,NCT00777101,Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer,COMPLETED,PHASE2,Advanced Breast Cancer; Breast Cancer,Neratinib (DRUG); Lapatinib (DRUG); Capecitabine (DRUG),11557040,Tyverb,Advanced Breast Cancer; Breast Cancer,Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7108,NCT00949455,A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium,UNKNOWN,PHASE2,Bladder Cancer,lapatinib ditosylate (DRUG); Placebo (OTHER),11557040,Tyverb,Bladder Cancer,Bladder/Urinary Tract,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7109,NCT01534455,Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA),TERMINATED,PHASE2,Metastatic Breast Cancer,"Lapatinib + 1,23 mg Eribulin (DRUG); Lapatinib + 1,76 mg Eribulin (DRUG)",11557040,Tyverb,Metastatic Breast Cancer,Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7110,NCT00429299,"Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer",COMPLETED,PHASE2,"Neoplasms, Breast",lapatinib (DRUG); trastuzumab (BIOLOGICAL); paclitaxel (DRUG); fluorouracil (DRUG); epidoxorubicin (DRUG); cyclophosphamide (DRUG),11557040,Tyverb,"Neoplasms, Breast",Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7111,NCT01495884,"The Myocet/Lapatinib Study. ICORG 10-03, V5",TERMINATED,PHASE1,Her2 Positive Metastatic Breast Cancer,non-pegylated liposomal doxorubicon (Myocet™) (DRUG); Lapatinib (Tyverb™) (DRUG),11557040,Tyverb,Her2 Positive Metastatic Breast Cancer,Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7112,NCT00754702,Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Vinorelbine (DRUG); Lapatinib (DRUG),11557040,Tyverb,Breast Cancer,Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7113,NCT01205217,Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer,WITHDRAWN,PHASE2,"Neoplasms, Breast",Lapatinib (DRUG); Trastuzumab (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Paclitaxel (DRUG),11557040,Tyverb,"Neoplasms, Breast",Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7114,NCT00694252,Lapatinib and Circulating Tumor Cells in Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Lapatinib (DRUG),11557040,Tyverb,Metastatic Breast Cancer,Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7115,NCT00313599,Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors,COMPLETED,PHASE1,Bladder Cancer; Brain and Central Nervous System Tumors; Breast Cancer; Esophageal Cancer; Extragonadal Germ Cell Tumor; Gastric Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer,lapatinib (DRUG); paclitaxel (DRUG),11557040,Tyverb,Bladder Cancer; Brain and Central Nervous System Tumors; Breast Cancer; Esophageal Cancer; Extragonadal Germ Cell Tumor; Gastric Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer,Lung,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7116,NCT00320385,Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer,COMPLETED,PHASE3,"Neoplasms, Breast",Lapatinib (DRUG); Trastuzumab (BIOLOGICAL),11557040,Tyverb,"Neoplasms, Breast",Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7117,NCT00821054,A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients,COMPLETED,PHASE1,"Neoplasms, Breast",Lapatinib (DRUG),11557040,Tyverb,"Neoplasms, Breast",Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7118,NCT02238509,Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies,UNKNOWN,PHASE2,Metastatic Breast Cancer,Lapatinib (DRUG); Trastuzumab (DRUG),11557040,Tyverb,Metastatic Breast Cancer,Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7119,NCT01985893,Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer,WITHDRAWN,PHASE2,Metastatic Breast Cancer,Lapatinib plus trastuzumab (DRUG),11557040,Tyverb,Metastatic Breast Cancer,Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7120,NCT00356811,Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer,COMPLETED,PHASE2,"Neoplasms, Breast",Lapatinib oral tablets (DRUG); Paclitaxel infusion (DRUG),11557040,Tyverb,"Neoplasms, Breast",Breast,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7121,NCT00387205,Study To Assess Long Term Safety Of Pazopanib,COMPLETED,PHASE1,"Carcinoma, Renal Cell",Pazopanib (DRUG),11557040,Tyverb,"Carcinoma, Renal Cell",Kidney,Lapatinib ditosylate,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for use in breast cancer treatment.,CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O,1.03,614.0 +7122,NCT03494530,Lixiana Acute Stroke Evaluation Registry,COMPLETED,PHASE4,Ischemic Stroke; Atrial Fibrillation; Hemorrhagic Transformation Stroke,Edoxaban 60 MG (DRUG); Edoxaban 30 mg (DRUG),25022378,Lixiana,Ischemic Stroke; Atrial Fibrillation; Hemorrhagic Transformation Stroke,CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7123,NCT05869591,DOAC in Patients with Child a or B Liver Cirrhosis,RECRUITING,PHASE2,Liver Cirrhosis,Apixaban 5 MG [Eliquis] (DRUG); Edoxaban 60 MG [Lixiana] (DRUG),25022378,Lixiana,Liver Cirrhosis,Liver,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7124,NCT03433235,Early Administration of Edoxaban After Acute Ischemic Stroke in Patients With Non-valvular Atrial Fibrillation,COMPLETED,PHASE2,Acute Ischemic Stroke,Edoxaban (DRUG),25022378,Lixiana,Acute Ischemic Stroke,CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7125,NCT03996772,PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation,COMPLETED,PHASE3,Atrial Fibrillation; Intracerebral Hemorrhage,Apixaban Oral Tablet (DRUG); Dabigatran (DRUG); Edoxaban Tablets (DRUG); Rivaroxaban (DRUG),25022378,Lixiana,Atrial Fibrillation; Intracerebral Hemorrhage,CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7126,NCT03961334,MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention,RECRUITING,PHASE3,"Stroke, Ischemic",Dabigatran (DRUG); Apixaban (DRUG); Edoxaban (DRUG); Aspirin (DRUG); Clopidogrel (DRUG),25022378,Lixiana,"Stroke, Ischemic",CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7127,NCT03153150,Start or STop Anticoagulants Randomised Trial (SoSTART),COMPLETED,PHASE3,"Intracranial Hemorrhages; Intracranial Hemorrhage, Hypertensive; Subarachnoid Hemorrhage; Subdural Hematoma; Intraventricular Hemorrhage; Atrial Fibrillation; Atrial Flutter; Small Vessel Cerebrovascular Disease; Microhaemorrhage",Apixaban (DRUG); Rivaroxaban (DRUG); Edoxaban (DRUG); Dabigatran (DRUG); Acenocoumarol (DRUG); Phenindione (DRUG); Warfarin (DRUG),25022378,Lixiana,"Intracranial Hemorrhages; Intracranial Hemorrhage, Hypertensive; Subarachnoid Hemorrhage; Subdural Hematoma; Intraventricular Hemorrhage; Atrial Fibrillation; Atrial Flutter; Small Vessel Cerebrovascular Disease; Microhaemorrhage",CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7128,NCT02221102,Edoxaban for TIA and Acute Minor Stroke,UNKNOWN,PHASE2,Ischemia; Stroke; Cerebral Infarction,Aspirin (DRUG); edoxaban (DRUG); placebo (DRUG),25022378,Lixiana,Ischemia; Stroke; Cerebral Infarction,CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7129,NCT02073682,Cancer Venous Thromboembolism (VTE),COMPLETED,PHASE3,Venous Thromboembolism (VTE); Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Cancer,Edoxaban (DRUG); Dalteparin (DRUG); Low molecular weight heparin (DRUG),25022378,Lixiana,Venous Thromboembolism (VTE); Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Cancer,Lung,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7130,NCT01924065,Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation,COMPLETED,PHASE3,Atrial Fibrillation; Cardioversion; Cerebrovascular Stroke,Cardioversion (PROCEDURE); Oral Anticoagulant (DRUG),25022378,Lixiana,Atrial Fibrillation; Cardioversion; Cerebrovascular Stroke,CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7131,NCT03777631,STroke Secondary Prevention With Catheter ABLation and EDoxaban for Patients With Non-valvular Atrial Fibrillation: STABLED Study,ACTIVE_NOT_RECRUITING,PHASE3,Ischemic Stroke; Atrial Fibrillation Non-Rheumatic,Catheter ablation (PROCEDURE),25022378,Lixiana,Ischemic Stroke; Atrial Fibrillation Non-Rheumatic,CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7132,NCT04045665,Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG,RECRUITING,PHASE3,Atrial Fibrillation; Stroke; Bleeding,Antiplatelet-only strategy (DRUG); Oral Anticoagulant plus background antiplatelet therapy (DRUG),25022378,Lixiana,Atrial Fibrillation; Stroke; Bleeding,CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7133,NCT06900725,Low Dose Edoxaban in Elderly Patients With AF and a History of Stroke,NOT_YET_RECRUITING,PHASE2,Elderly; Atrial Fibrillation (AF); Ischemic Stroke,edoxaban (DRUG); Edoxaban 30 mg (DRUG),25022378,Lixiana,Elderly; Atrial Fibrillation (AF); Ischemic Stroke,CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7134,NCT00781391,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,COMPLETED,PHASE3,Stroke; Atrial Fibrillation; Embolism,warfarin tablets (DRUG); Edoxaban tablets (high dose regimen-60mg) (DRUG); Edoxaban tablets (low dose regimen-30mg) (DRUG); placebo warfarin (DRUG); placebo edoxaban (DRUG),25022378,Lixiana,Stroke; Atrial Fibrillation; Embolism,CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7135,NCT00806624,DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation,COMPLETED,PHASE2,Atrial Fibrillation; Stroke,DU-176b tablets (DRUG); DU-176b tablets (DRUG); Warfarin tablets (DRUG),25022378,Lixiana,Atrial Fibrillation and Stroke,CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7136,NCT03062319,Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis,TERMINATED,PHASE4,Ischemic Stroke; Atrial Fibrillation; Atherothrombosis,Oral Anticoagulant (DRUG); Antiplatelet Drug (DRUG),25022378,Lixiana,Ischemic Stroke; Atrial Fibrillation; Atherothrombosis,CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7137,NCT03129555,The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE),RECRUITING,PHASE4,Deep Vein Thrombosis; Pulmonary Embolism,Dabigatran Etexilate Oral Capsule (DRUG); Rivaroxaban Oral Tablet (DRUG); Edoxaban Oral Tablet (DRUG); Apixaban Oral Tablet (DRUG),25022378,Lixiana,Deep Vein Thrombosis; Pulmonary Embolism,Lung,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7138,NCT06571149,Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake,RECRUITING,PHASE4,Ischemic Stroke,Tenecteplase or Alteplase (DRUG),25022378,Lixiana,Ischemic Stroke,CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7139,NCT06749834,Intravenous Thrombolysis and NOAC,RECRUITING,PHASE3,Acute Ischemic Stroke,Intravenous thrombolysis (DRUG),25022378,Lixiana,Acute Ischemic Stroke,CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7140,NCT02666742,DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation,COMPLETED,PHASE4,Ventricular Tachycardia; Premature Ventricular Contraction; Stroke,DOAC (DRUG); Aspirin (DRUG),25022378,Lixiana,Ventricular Tachycardia; Premature Ventricular Contraction; Stroke,CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7141,NCT05540587,Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis,RECRUITING,PHASE2,Mitral Valve Stenosis; Atrial Fibrillation; Stroke; Systemic Embolism,Edoxaban (DRUG); Warfarin (DRUG),25022378,Lixiana,Mitral Valve Stenosis; Atrial Fibrillation; Stroke; Systemic Embolism,CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7142,NCT06402851,"Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)",RECRUITING,PHASE4,Atrium; Fibrillation; Chronic Kidney Diseases,Anticoagulant Oral (DRUG),25022378,Lixiana,Atrium; Fibrillation; Chronic Kidney Diseases,Kidney,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7143,NCT04436978,What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?,RECRUITING,PHASE4,Acute Coronary Syndrome; Myocardial Infarction; Atrial Fibrillation; Atrial Flutter; STEMI - ST Elevation Myocardial Infarction; NSTEMI - Non-ST Segment Elevation MI; Bleeding; Stroke; Stent Thrombosis; Embolism; Coronary Artery Disease,30-day DAPT (DRUG); Guideline-directed therapy (DRUG),25022378,Lixiana,Acute Coronary Syndrome; Myocardial Infarction; Atrial Fibrillation; Atrial Flutter; STEMI - ST Elevation Myocardial Infarction; NSTEMI - Non-ST Segment Elevation MI; Bleeding; Stroke; Stent Thrombosis; Embolism; Coronary Artery Disease,CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7144,NCT02798471,Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE),COMPLETED,PHASE3,Venous Thromboembolism (VTE); Pulmonary Embolism; Deep Vein Thrombosis (DVT),Edoxaban (DRUG); Standard of Care (DRUG),25022378,Lixiana,Venous Thromboembolism (VTE); Pulmonary Embolism; Deep Vein Thrombosis (DVT),Lung,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7145,NCT04191928,Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy,COMPLETED,PHASE1,Pancreas Cancer; DVT; Pulmonary Embolism,Apixaban (DRUG),25022378,Lixiana,Pancreas Cancer; DVT; Pulmonary Embolism,Lung,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7146,NCT03968393,Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery,RECRUITING,PHASE4,Stroke; Atrial Fibrillation,Non-vitamin K oral anticoagulant (NOAC) (DRUG),25022378,Lixiana,Stroke with Atrial Fibrillation,CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7147,NCT02998905,NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH,COMPLETED,PHASE2,Atrial Fibrillation; Intracerebral Hemorrhage,NOAC (DRUG); Acetylsalicylic Acid (DRUG),25022378,Lixiana,Atrial Fibrillation; Intracerebral Hemorrhage,CNS/Brain,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7148,NCT00986154,Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).,COMPLETED,PHASE3,Venous Thromboembolism; Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Thromboembolism; Venous Thrombosis,edoxaban tosylate(DU-176b) (DRUG); low molecular weight heparin/unfractionated heparin (DRUG); warfarin (DRUG),25022378,Lixiana,Venous Thromboembolism; Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Thromboembolism; Venous Thrombosis,Lung,Edoxaban (tosylate monohydrate),F10,inhibitor/antagonist,unclear,yes,yes,Approved as an anticoagulant for preventing stroke and blood clots.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O,1.0,30.0 +7149,NCT02078310,Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia,COMPLETED,PHASE1,Alzheimer's Disease,ITI-007 (DRUG); Placebo (DRUG); ITI-007 (DRUG); Placebo (DRUG),44241743,Caplyta,Alzheimer's Disease,CNS/Brain,Lumateperone (tosylate),"HTR2A, DRD2",unclear,unclear,yes,yes,Approved for schizophrenia; marketed as Caplyta.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCN2C3CCN(CC3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F,1.0,30.0 +7150,NCT02817906,"ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease",TERMINATED,PHASE3,"Agitation in Dementia, Including Alzheimer's Disease",ITI-007 (DRUG); Placebo (DRUG),44241743,Caplyta,"Agitation in Dementia, Including Alzheimer's Disease",CNS/Brain,Lumateperone (tosylate),"HTR2A, DRD2",unclear,unclear,yes,yes,Approved for schizophrenia; marketed as Caplyta.,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCN2C3CCN(CC3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F,1.0,30.0 +7151,NCT01808092,A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia,COMPLETED,PHASE3,Nosocomial Pneumonia (NP); Ventilator-associated Pneumonia (VAP),"ceftazidim-avibactam (CAZ-AVI, experimental product) (DRUG); meropenem (active comparator) (DRUG)",52920501,UKI,Nosocomial Pneumonia (NP); Ventilator-associated Pneumonia (VAP),Lung,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7152,NCT00392899,Tegafur-Uracil or Observation in Treating Patients With Stage II Colorectal Cancer That Has Been Completely Removed By Surgery,COMPLETED,PHASE3,Colorectal Cancer,UFT adjuvant chemotherapy (DRUG),52920501,UKI,Colorectal Cancer,Bowel,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7153,NCT05882630,Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer,NOT_YET_RECRUITING,PHASE1,Small Cell Lung Cancer,"Surufatinib,Serplulimab,Etoposide,Carboplatin (DRUG)",52920501,UKI,Small Cell Lung Cancer,Lung,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7154,NCT05627427,Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy,UNKNOWN,PHASE2,Neuroendocrine Tumor Grade 3; Neuroendocrine Carcinoma; Pancreatic Carcinoma,Surufatinib (DRUG); Sintilimab (DRUG),52920501,UKI,Neuroendocrine Tumor Grade 3; Neuroendocrine Carcinoma; Pancreatic Carcinoma,Pancreas,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7155,NCT05481476,Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer,RECRUITING,PHASE2,Pancreatic Neoplasms,Surufatinib (DRUG); Sintilimab (DRUG); AG (DRUG),52920501,UKI,Pancreatic Neoplasms,Pancreas,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7156,NCT06361030,Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer,NOT_YET_RECRUITING,PHASE2,"Pancreatic Cancer; Pancreatic Cancer Non-resectable; Pancreatic Ductal Adenocarcinoma, PDAC",surufatinib combined with gemcitabine plus nab-paclitaxel (DRUG),52920501,UKI,"Pancreatic Cancer; Pancreatic Cancer Non-resectable; Pancreatic Ductal Adenocarcinoma, PDAC",Pancreas,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7157,NCT05171439,Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples,UNKNOWN,PHASE2,Hepatocellular Carcinoma,Surufatinib (DRUG),52920501,UKI,Hepatocellular Carcinoma,Liver,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7158,NCT06255262,Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer,NOT_YET_RECRUITING,PHASE1,Biliary Tract Cancer,Surufatinib (DRUG); Durvalumab (DRUG),52920501,UKI,Biliary Tract Cancer,Liver,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7159,NCT06876844,Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC,RECRUITING,PHASE2,Head and Neck Cancer; Head and Neck Cancer Squamous Cell Carcinoma,combination of Surufatinib and Envolizumab (DRUG),52920501,UKI,Head and Neck Cancer; Head and Neck Cancer Squamous Cell Carcinoma,Skin,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7160,NCT05218889,Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer,RECRUITING,PHASE1,Pancreatic Cancer; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreas Cancer; Pancreatic Neoplasms,surufatinib + camrelizumab + nab-paclitaxel + S-1 (DRUG); nab-paclitaxel + gemcitabine (DRUG),52920501,UKI,Pancreatic Cancer; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreas Cancer; Pancreatic Neoplasms,Pancreas,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7161,NCT05595889,Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer,NOT_YET_RECRUITING,PHASE2,Small Cell Lung Cancer; Angiogenesis; Chemotherapy Effect,Surufatinib (DRUG); Irinotecan (DRUG),52920501,UKI,Small Cell Lung Cancer; Angiogenesis; Chemotherapy Effect,Lung,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7162,NCT05832892,Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer,RECRUITING,PHASE1,Unresectable Locally Advanced or Metastatic Pancreatic Cancer,surufatinib (DRUG); KN046 (DRUG); gemcitabine (DRUG); Nab paclitaxel (DRUG),52920501,UKI,Unresectable Locally Advanced or Metastatic Pancreatic Cancer,Pancreas,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7163,NCT04922658,Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer,RECRUITING,PHASE2,Advanced Non-Small Cell Lung Cancer,Surufatinib (DRUG); Surufatinib Plus Vinorelbine (DRUG),52920501,UKI,Advanced Non-Small Cell Lung Cancer,Lung,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7164,NCT05668767,Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC,NOT_YET_RECRUITING,PHASE2,Extensive-stage Small-cell Lung Cancer,Surufatinib Durvalizumab EP/EC (DRUG),52920501,UKI,Extensive-stage Small-cell Lung Cancer,Lung,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7165,NCT04734249,Second-line Surufatinib Combined With Chemotherapy in Advanced CRC,UNKNOWN,PHASE2,Advanced Colorectal Cancer,Surufatinib(HMPL-012) (DRUG),52920501,UKI,Advanced Colorectal Cancer,Bowel,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7166,NCT05235906,A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer,RECRUITING,PHASE2,Gastric Adenocarcinoma,Surufatinib+Sintilimab (DRUG),52920501,UKI,Gastric Adenocarcinoma,Esophagus/Stomach,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7167,NCT05236699,A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC,COMPLETED,PHASE2,Intrahepatic Cholangiocarcinoma,DEB-TACE combined with Surufatinib and Camrelizumab (COMBINATION_PRODUCT),52920501,UKI,Intrahepatic Cholangiocarcinoma,Liver,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7168,NCT06375642,"A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC",NOT_YET_RECRUITING,PHASE2,Intrahepatic Cholangiocarcinoma,Adebrelimab (DRUG),52920501,UKI,Intrahepatic Cholangiocarcinoma,Liver,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7169,NCT02966821,Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma,COMPLETED,PHASE2,Biliary Tract Cancer,Surufatinib (DRUG),52920501,UKI,Biliary Tract Cancer,Liver,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7170,NCT05527821,Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors,NOT_YET_RECRUITING,PHASE2,"Unresectable Advanced Solid Tumors; Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer",Surufatinib (DRUG); Sintilimab (DRUG); Short course radiotherapy (RADIATION),52920501,UKI,"Unresectable Advanced Solid Tumors; Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer",Lung,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7171,NCT04579757,Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors,TERMINATED,PHASE1,Metastatic Solid Tumor; Colorectal Cancer; Neuroendocrine Tumors; Small Cell Lung Cancer; Gastric Cancer; Soft Tissue Sarcoma; Anaplastic Thyroid Cancer,Surufatinib and Tislelizumab _ Part 1 (DRUG); Surufatinib and Tislelizumab _ Part 2 (DRUG),52920501,UKI,Metastatic Solid Tumor; Colorectal Cancer; Neuroendocrine Tumors; Small Cell Lung Cancer; Gastric Cancer; Soft Tissue Sarcoma; Anaplastic Thyroid Cancer,Bowel,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7172,NCT05481463,Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer,RECRUITING,PHASE2,Pancreatic Neoplasms,Surufatinib (DRUG); TAS-102 (DRUG),52920501,UKI,Pancreatic Neoplasms,Pancreas,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7173,NCT04755075,Surufatinib Hepatic Impairment Study,COMPLETED,PHASE1,Hepatic Impairment,Surufatinib (DRUG); Surufatinib (DRUG),52920501,UKI,Hepatic Impairment,Liver,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7174,NCT05003037,Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer,UNKNOWN,PHASE2,"Carcinoma, Non-Small-Cell Lung","Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin (DRUG)",52920501,UKI,"Carcinoma, Non-Small-Cell Lung",Lung,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7175,NCT04929652,Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer,UNKNOWN,PHASE1,Advanced Colorectal Cancer,"Surufatinib,Camrelizumab,Irinotecan,GM-CSF (DRUG)",52920501,UKI,Advanced Colorectal Cancer,Bowel,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7176,NCT04764006,Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study,UNKNOWN,PHASE2,Advanced Colorectal Cancer,Surufatinib (DRUG),52920501,UKI,Advanced Colorectal Cancer,Bowel,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7177,NCT05908747,Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer,RECRUITING,PHASE2,Pancreatic Cancer,surufatinib + gemcitabine + nab-paclitaxel (DRUG),52920501,UKI,Pancreatic Cancer,Pancreas,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7178,NCT06329947,A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD,NOT_YET_RECRUITING,PHASE2,Advanced Pancreatic Cancer,Surufatinib 250mg/d qd once daily (DRUG),52920501,UKI,Advanced Pancreatic Cancer,Pancreas,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7179,NCT03873532,A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients,UNKNOWN,PHASE2,Biliary Tract Cancer,Surufatinib (DRUG); Capecitabine (DRUG),52920501,UKI,Biliary Tract Cancer,Liver,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7180,NCT04755088,Surufatinib Renal Impairment Study,COMPLETED,PHASE1,Renal Impairment,Surufatinib (DRUG); Surufatinib (DRUG),52920501,UKI,Renal Impairment,Kidney,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7181,NCT05746728,Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer,NOT_YET_RECRUITING,PHASE1,Metastatic Triple-negative Breast Cancer,Surufatinib (DRUG); Tislelizumab (DRUG),52920501,UKI,Metastatic Triple-negative Breast Cancer,Breast,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7182,NCT05186545,An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer,RECRUITING,PHASE2,Breast Cancer; Breast Cancer Female,surufatinib + fulvestrant + chidamide (DRUG),52920501,UKI,Breast Cancer; Breast Cancer Female,Breast,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7183,NCT04996771,Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer,UNKNOWN,PHASE1,Small Cell Lung Carcinoma,"Surufatinib,Etoposide,Cisplatin,Toripalimab (DRUG); Surufatinib,Etoposide,Cisplatin (DRUG)",52920501,UKI,Small Cell Lung Carcinoma,Lung,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7184,NCT05652283,Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Ovarian Cancer,Pamiparib (DRUG); Surufatinib (DRUG),52920501,UKI,Ovarian Cancer,Ovary/Fallopian Tube,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7185,NCT06199882,SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma,SUSPENDED,PHASE2,Biliary Tract Carcinoma,SBRT Sequential Surufatinib Combined With Immunotherapy (DRUG),52920501,UKI,Biliary Tract Carcinoma,Liver,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7186,NCT06708858,Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer,RECRUITING,PHASE2,Advanced Biliary Tract Cancer,Surufatinib (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG); Durvalumab (DRUG); Pembrolizumab (DRUG),52920501,UKI,Advanced Biliary Tract Cancer,Liver,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7187,NCT05494580,Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer,RECRUITING,PHASE1,Ovarian Cancer; Ovarian Carcinoma; Platinum-resistant Ovarian Cancer; Fallopian Tube Carcinosarcoma; Primary Peritoneal Cancer,Pamiparib (DRUG); Surufatinib (DRUG),52920501,UKI,Ovarian Cancer; Ovarian Carcinoma; Platinum-resistant Ovarian Cancer; Fallopian Tube Carcinosarcoma; Primary Peritoneal Cancer,Ovary/Fallopian Tube,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7188,NCT04653480,"Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC",RECRUITING,PHASE2,Colorectal Cancer,Surufatinib (DRUG); Toripalimab (DRUG); chemotherapy (DRUG),52920501,UKI,Colorectal Cancer,Bowel,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7189,NCT06531291,Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation,NOT_YET_RECRUITING,PHASE2,ESCC; Biliary Tract Cancer; Gastric Cancer; Pancreas Cancer,Surufatinib (DRUG); Serplulimab (DRUG); standard chemotherapy (DRUG),52920501,UKI,ESCC; Biliary Tract Cancer; Gastric Cancer; Pancreas Cancer,Esophagus/Stomach,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7190,NCT05988372,Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE),NOT_YET_RECRUITING,PHASE2,Locally Advanced Pancreatic Cancer,Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine (DRUG); Albumin-paclitaxel + Gemcitabine (DRUG),52920501,UKI,Locally Advanced Pancreatic Cancer,Pancreas,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7191,NCT05451719,Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy,NOT_YET_RECRUITING,PHASE2,Colorectal Cancer; Colorectal Cancer Stage IV,Fruquintinib Plus Capecitabine (DRUG); Capecitabine (DRUG),52920501,UKI,Colorectal Cancer; Colorectal Cancer Stage IV,Bowel,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7192,NCT06447636,Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma,NOT_YET_RECRUITING,PHASE2,Gastric Cancer; Gastro Esophageal Junction Cancer,Surufatinib (DRUG); Sintilimab (DRUG); Oxaliplatin (DRUG); S1 (DRUG),52920501,UKI,Gastric Cancer; Gastro Esophageal Junction Cancer,Esophagus/Stomach,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7193,NCT05509699,Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer,UNKNOWN,PHASE2,Extensive-Stage Small Cell Lung Cancer,Surufatinib (DRUG); Anti-PD-1/L1 (DRUG),52920501,UKI,Extensive-Stage Small Cell Lung Cancer,Lung,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7194,NCT06719700,Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer,RECRUITING,PHASE2,Toripalimab; Surufatinib; Chemoradiotherapy; Limited-stage Small Cell Lung Cancer (LS-SCLC),Chemotherapy (DRUG); Immunotherapy (DRUG); Angio-immuno kinase inhibitor (DRUG); radiotherapy (RADIATION); Prophylactic Cranial Irradiation (RADIATION); Consolidation Therapy with Toripalimab and Surufatinib (DRUG),52920501,UKI,Toripalimab; Surufatinib; Chemoradiotherapy; Limited-stage Small Cell Lung Cancer (LS-SCLC),Lung,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7195,NCT06656559,Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma,NOT_YET_RECRUITING,PHASE2,Unresectable Biliary Tract Carcinoma,Envafolimab and Surufatinib (DRUG),52920501,UKI,Unresectable Biliary Tract Carcinoma,Liver,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7196,NCT06239532,HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma,ACTIVE_NOT_RECRUITING,PHASE2,Intrahepatic Cholangiocarcinoma,HAIC+TAE (DRUG); Tislelizumab (DRUG); Surufatinib (DRUG),52920501,UKI,Intrahepatic Cholangiocarcinoma,Liver,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7197,NCT05282433,Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma,UNKNOWN,PHASE2,Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival,Surufatinib (DRUG),52920501,UKI,Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival,Liver,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7198,NCT06654947,"A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.",NOT_YET_RECRUITING,PHASE2,Biliary Tract Cancer,Surufatinib+Toripalimab+GEMOX (DRUG),52920501,UKI,Biliary Tract Cancer,Liver,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7199,NCT06437353,Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer,RECRUITING,PHASE2,Ovarian Cancer,Paclitaxel (DRUG),52920501,UKI,Ovarian Cancer,Ovary/Fallopian Tube,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7200,NCT06361888,"A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer",RECRUITING,PHASE2,Metastatic Pancreatic Cancer,"Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine (DRUG); Nab-paclitaxel Plus Gemcitabine (DRUG); Surufatinib with Nab-paclitaxel, and Gemcitabine (DRUG)",52920501,UKI,Metastatic Pancreatic Cancer,Pancreas,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7201,NCT06134193,"Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer",NOT_YET_RECRUITING,PHASE2,"Carcinoma; Intrahepatic Cholangiocarcinoma; Gallbladder Cancer; Surufatinib; Angiogenesis Inhibitors; Tislelizumab; Antineoplastic Agents, Immunological; Immunotherapy",HAIC (DRUG); Surufatinib (DRUG); Tislelizumab (DRUG),52920501,UKI,"Carcinoma; Intrahepatic Cholangiocarcinoma; Gallbladder Cancer; Surufatinib; Angiogenesis Inhibitors; Tislelizumab; Antineoplastic Agents, Immunological; Immunotherapy",Liver,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7202,NCT05372198,Surufatinib With or Wothout Immunotherapy for Advanced Colorectal Cancer in Later Line,UNKNOWN,PHASE2,Colorectal Neoplasms,Chohort 1: Surufatinib (DRUG); Chohort 2: Immunotherapy (DRUG); Chohort 2: Surufatinib (DRUG),52920501,UKI,Colorectal Neoplasms,Bowel,Sulfatinib,"FLT1, KDR, FLT4, FGFR1, CSF1R",inhibitor/antagonist,Multi-TK inhibitor,no,yes,"Investigated in trials for neuroendocrine tumors, not yet approved for use.",CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,1.0,3.0 +7203,NCT05705492,"Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer",RECRUITING,PHASE2,Advanced Malignant Solid Neoplasm; Advanced Biliary Tract Carcinoma; Advanced Esophageal Carcinoma; Metastatic Esophageal Carcinoma; Locally Advanced Biliary Tract Carcinoma; Locally Advanced Colorectal Carcinoma; Locally Advanced Esophageal Carcinoma; Locally Advanced Gastric Carcinoma; Metastatic Colorectal Carcinoma (mCRC); Advanced Lung Carcinoma,Olanzapine (DRUG); Placebo Administration (DRUG); Questionnaire Administration (OTHER),135398745,Midax,Advanced Malignant Solid Neoplasm; Advanced Biliary Tract Carcinoma; Advanced Esophageal Carcinoma; Metastatic Esophageal Carcinoma; Locally Advanced Biliary Tract Carcinoma; Locally Advanced Colorectal Carcinoma; Locally Advanced Esophageal Carcinoma; Locally Advanced Gastric Carcinoma; Metastatic Colorectal Carcinoma (mCRC); Advanced Lung Carcinoma,Bowel,Olanzapine,"HTR2A, HTR2C, DRD2, DRD4, ADRA1A, ADRA1B, ADRA1D, HTR6, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",inhibitor/antagonist,unclear,yes,yes,Olanzapine is used in treatment of schizophrenia and bipolar disorder.,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,1.03,283.0 +7204,NCT03367572,Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer,COMPLETED,PHASE3,Breast Carcinoma,Dexamethasone (DRUG); Laboratory Biomarker Analysis (OTHER); Netupitant/Palonosetron Hydrochloride (DRUG); Olanzapine (DRUG); Placebo (OTHER); Prochlorperazine (DRUG); Quality-of-Life Assessment (OTHER),135398745,Midax,Breast Carcinoma,Breast,Olanzapine,"HTR2A, HTR2C, DRD2, DRD4, ADRA1A, ADRA1B, ADRA1D, HTR6, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",inhibitor/antagonist,unclear,yes,yes,Olanzapine is used in treatment of schizophrenia and bipolar disorder.,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,1.03,283.0 +7205,NCT03571126,Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer,UNKNOWN,PHASE4,Chemotherapy-induced Nausea and Vomiting; Lung Cancer,Olanzapine (DRUG); Placebos (DRUG),135398745,Midax,Chemotherapy-induced Nausea and Vomiting; Lung Cancer,Lung,Olanzapine,"HTR2A, HTR2C, DRD2, DRD4, ADRA1A, ADRA1B, ADRA1D, HTR6, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",inhibitor/antagonist,unclear,yes,yes,Olanzapine is used in treatment of schizophrenia and bipolar disorder.,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,1.03,283.0 +7206,NCT04216329,Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma,ACTIVE_NOT_RECRUITING,PHASE1,Gliosarcoma; Newly Diagnosed; Glioblastoma,Selinexor (DRUG); Temozolomide (DRUG); Generic Radiation therapy (RT) (RADIATION); Selective serotonin receptor (5-HT3) antagonists (OTHER); Olanzapine (OTHER); Salt tablets (DIETARY_SUPPLEMENT); Anti-diarrheal (OTHER),135398745,Midax,Gliosarcoma; Newly Diagnosed; Glioblastoma,CNS/Brain,Olanzapine,"HTR2A, HTR2C, DRD2, DRD4, ADRA1A, ADRA1B, ADRA1D, HTR6, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",inhibitor/antagonist,unclear,yes,yes,Olanzapine is used in treatment of schizophrenia and bipolar disorder.,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,1.03,283.0 +7207,NCT00876772,Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS),COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis (ALS),Olanzapine (DRUG),135398745,Midax,Amyotrophic Lateral Sclerosis (ALS),CNS/Brain,Olanzapine,"HTR2A, HTR2C, DRD2, DRD4, ADRA1A, ADRA1B, ADRA1D, HTR6, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",inhibitor/antagonist,unclear,yes,yes,Olanzapine is used in treatment of schizophrenia and bipolar disorder.,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,1.03,283.0 +7208,NCT00208819,A Comparison of Two Standard Therapies in the Management of Dementia With Agitation,COMPLETED,PHASE4,"Senile Dementia, Alzheimer Type; Dementia, Alzheimer Type; Alzheimer Disease; Dementia",risperidone (DRUG); quetiapine (DRUG); olanzapine (DRUG); divalproex (DRUG),135398745,Midax,"Senile Dementia, Alzheimer Type; Dementia, Alzheimer Type; Alzheimer Disease; Dementia",CNS/Brain,Olanzapine,"HTR2A, HTR2C, DRD2, DRD4, ADRA1A, ADRA1B, ADRA1D, HTR6, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",inhibitor/antagonist,unclear,yes,yes,Olanzapine is used in treatment of schizophrenia and bipolar disorder.,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,1.03,283.0 +7209,NCT06554613,Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC,NOT_YET_RECRUITING,PHASE2,Non-Small Cell Lung Cancer,Olanzapine (DRUG); Nivolumab (DRUG),135398745,Midax,Advanced Non-Small Cell Lung Cancer,Lung,Olanzapine,"HTR2A, HTR2C, DRD2, DRD4, ADRA1A, ADRA1B, ADRA1D, HTR6, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",inhibitor/antagonist,unclear,yes,yes,Olanzapine is used in treatment of schizophrenia and bipolar disorder.,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,1.03,283.0 +7210,NCT03079219,Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients,COMPLETED,PHASE3,Breast Cancer,Experimental drug: Aprepitant (DRUG); Experimental drug: Ondansetron (DRUG); Experimental drug: Dexamethasone (DRUG); Experimental drug: Olanzapine (DRUG); Standard: Aprepitant (DRUG); Standard: Ondansetron (DRUG); Standard: Dexamethasone (DRUG),135398745,Midax,Breast Cancer,Breast,Olanzapine,"HTR2A, HTR2C, DRD2, DRD4, ADRA1A, ADRA1B, ADRA1D, HTR6, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",inhibitor/antagonist,unclear,yes,yes,Olanzapine is used in treatment of schizophrenia and bipolar disorder.,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,1.03,283.0 +7211,NCT00245206,Side Effects of Newer Antipsychotics in Older Adults,COMPLETED,PHASE4,Schizophrenia; Alzheimer's Disease; Dementia,Aripiprazole (DRUG); Olanzapine (DRUG); Risperidone (DRUG),135398745,Midax,Schizophrenia; Alzheimer's Disease; Dementia,CNS/Brain,Olanzapine,"HTR2A, HTR2C, DRD2, DRD4, ADRA1A, ADRA1B, ADRA1D, HTR6, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",inhibitor/antagonist,unclear,yes,yes,Olanzapine is used in treatment of schizophrenia and bipolar disorder.,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,1.03,283.0 +7212,NCT00433121,Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD,COMPLETED,PHASE4,Dementia,Risperidone (DRUG); Olanzapine (DRUG); Haloperidole (DRUG); Quetiapin (DRUG); Escitalopram (DRUG); Citalopram (DRUG); Sertralin (DRUG),135398745,Midax,Dementia,CNS/Brain,Olanzapine,"HTR2A, HTR2C, DRD2, DRD4, ADRA1A, ADRA1B, ADRA1D, HTR6, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",inhibitor/antagonist,unclear,yes,yes,Olanzapine is used in treatment of schizophrenia and bipolar disorder.,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,1.03,283.0 +7213,NCT05202275,The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs,UNKNOWN,PHASE2,Nausea; Vomiting; Head and Neck Squamous Cell Carcinoma; Radiotherapy Side Effect,Olanzapine (DRUG),135398745,Midax,Nausea; Vomiting; Head and Neck Squamous Cell Carcinoma; Radiotherapy Side Effect,Skin,Olanzapine,"HTR2A, HTR2C, DRD2, DRD4, ADRA1A, ADRA1B, ADRA1D, HTR6, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",inhibitor/antagonist,unclear,yes,yes,Olanzapine is used in treatment of schizophrenia and bipolar disorder.,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,1.03,283.0 +7214,NCT02861859,Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study,COMPLETED,PHASE3,Breast Cancer,Olanzapine (DRUG); Olanzapine Placebo (DRUG),135398745,Midax,Breast Cancer,Breast,Olanzapine,"HTR2A, HTR2C, DRD2, DRD4, ADRA1A, ADRA1B, ADRA1D, HTR6, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",inhibitor/antagonist,unclear,yes,yes,Olanzapine is used in treatment of schizophrenia and bipolar disorder.,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,1.03,283.0 +7215,NCT03575637,Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer,UNKNOWN,PHASE2,Gastric Cancer,Olanzapine (DRUG),135398745,Midax,Gastric Cancer,Esophagus/Stomach,Olanzapine,"HTR2A, HTR2C, DRD2, DRD4, ADRA1A, ADRA1B, ADRA1D, HTR6, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",inhibitor/antagonist,unclear,yes,yes,Olanzapine is used in treatment of schizophrenia and bipolar disorder.,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,1.03,283.0 +7216,NCT00078403,Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV),COMPLETED,PHASE2,HIV Infections; Hepatitis C; Liver Disease,Peginterferon alfa-2a (DRUG); Ribavirin (DRUG),19090,Chronopil,HIV Infections; Hepatitis C; Liver Disease,Liver,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7217,NCT04491643,Megestrol Acetate Plus Rosuvastatin in Young Women with Early Endometrial Carcinoma,ACTIVE_NOT_RECRUITING,PHASE2,Endometrial Carcinoma Stage I,Megestrol Acetate (DRUG); Rosuvastatin (DRUG),19090,Chronopil,Endometrial Carcinoma Stage I,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7218,NCT04491682,Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia,COMPLETED,PHASE2,Atypical Endometrial Hyperplasia,Megestrol Acetate (DRUG); Rosuvastatin (DRUG),19090,Chronopil,Atypical Endometrial Hyperplasia,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7219,NCT05247268,Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer,RECRUITING,PHASE2,Endometrial Neoplasm Malignant Stage I,Megestrol Acetate 160 MG Oral Tablet (DRUG); Medroxyprogesterone Acetate 500 MG (DRUG); Triprorelin Acetate (DRUG); Letrozole 2.5mg (DRUG),19090,Chronopil,Stage I Endometrial Cancer,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7220,NCT00002680,Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,filgrastim (BIOLOGICAL); cyclophosphamide (DRUG); megestrol acetate (DRUG); melphalan (DRUG); tamoxifen citrate (DRUG); thiotepa (DRUG); conventional surgery (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),19090,Chronopil,Breast Cancer,Breast,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7221,NCT05316467,Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma,RECRUITING,PHASE2,Endometrial Carcinoma; Obese; Overweight; Fertility Issues,Intensive Lifestyle Intervention (ILI) (BEHAVIORAL); Megestrol Acetate 160 MG Oral Tablet (DRUG),19090,Chronopil,Endometrial Carcinoma; Obese; Overweight; Fertility Issues,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7222,NCT06828757,Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer,NOT_YET_RECRUITING,PHASE3,Non Small Cell Lung Cancer,nanocrystalline megestrol oral suspension + PD-1/L1 inhibitor combined with chemotherapy (DRUG); PD-1/L1 inhibitor combined with chemotherapy (DRUG),19090,Chronopil,Non Small Cell Lung Cancer,Lung,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7223,NCT06671548,Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids,NOT_YET_RECRUITING,PHASE3,Heavy Menstrual Bleeding; Uterine Fibroids,Relugolix (DRUG); Relugolix placebo (DRUG),19090,Chronopil,Heavy Menstrual Bleeding; Uterine Fibroids,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7224,NCT00739830,Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6),COMPLETED,PHASE2,Endometrial Cancer,ridaforolimus (DRUG); medroxyprogesterone acetate tablets OR megestrol acetate (DRUG); chemotherapy (DRUG),19090,Chronopil,Endometrial Cancer,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7225,NCT00483327,Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate,COMPLETED,PHASE2,Atypical Endometrial Hyperplasia; Endometrial Carcinoma,Megestrol Acetate (DRUG),19090,Chronopil,Atypical Endometrial Hyperplasia; Endometrial Carcinoma,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7226,NCT01237327,Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer,COMPLETED,PHASE3,Metastatic Breast Cancer,Megestrol acetate (DRUG); exemestane (Aromasin) (DRUG),19090,Chronopil,Metastatic Breast Cancer,Breast,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7227,NCT03024580,A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer,UNKNOWN,PHASE2,Breast Neoplasm,Megestrol Acetate 160Mg Tablet (DRUG); Anastrozole 1Mg Tablet (DRUG); Letrozole 2.5Mg Tablet (DRUG); Exemestane 25 MG (DRUG); Tamoxifen 20Mg Tablet (DRUG); Fulvestrant 50Mg Solution for Injection (DRUG),19090,Chronopil,Breast Neoplasm,Breast,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7228,NCT00910091,The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer,COMPLETED,PHASE2,Endometrial Cancer,BN83495 (DRUG); Megestrol Acetate (MA) (DRUG),19090,Chronopil,Endometrial Cancer,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7229,NCT00729586,"Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer",COMPLETED,PHASE2,Endometrial Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC1 Uterine Corpus Cancer; Stage IIIC2 Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Laboratory Biomarker Analysis (OTHER); Megestrol Acetate (DRUG); Tamoxifen Citrate (DRUG); Temsirolimus (DRUG),19090,Chronopil,Endometrial Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC1 Uterine Corpus Cancer; Stage IIIC2 Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7230,NCT00503516,Study to Evaluate the Effect of Megestrol Acetate in Weight Loss in Dementia Patients,TERMINATED,PHASE2,Dementia,Megestrol acetate (DRUG); Placebo (DRUG),19090,Chronopil,Dementia,CNS/Brain,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7231,NCT03306472,A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Megestrol Acetate 40 MG (DRUG); Megestrol Acetate 160 MG (DRUG); Letrozole (DRUG),19090,Chronopil,Breast Cancer,Breast,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7232,NCT04576104,Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer,RECRUITING,PHASE2,Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; Endometrial Carcinoma,Biopsy Procedure (PROCEDURE); Extended Release Metformin Hydrochloride (DRUG); Megestrol Acetate (DRUG); Questionnaire Administration (OTHER),19090,Chronopil,Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; Endometrial Carcinoma,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7233,NCT06961201,Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase,NOT_YET_RECRUITING,PHASE3,Extensive-stage Small Cell Lung Cancer (ES-SCLC); The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy,Nano-crystalline Megestrol Acetate Oral Suspension (DRUG); standard treatment (DRUG),19090,Chronopil,Extensive-stage Small Cell Lung Cancer (ES-SCLC); The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy,Lung,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7234,NCT01943058,Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer,WITHDRAWN,PHASE2,Atypical Endometrial Hyperplasia; Endometrial Adenocarcinoma; Recurrent Endometrial Carcinoma; Stage IA Endometrial Carcinoma; Stage IB Endometrial Carcinoma; Stage II Endometrial Carcinoma; Stage IIIA Endometrial Carcinoma; Stage IIIB Endometrial Carcinoma; Stage IIIC Endometrial Carcinoma; Stage IVA Endometrial Carcinoma; Stage IVB Endometrial Carcinoma,megestrol acetate (DRUG); levonorgestrel-releasing intrauterine system (DEVICE); laboratory biomarker analysis (OTHER); questionnaire administration (OTHER),19090,Chronopil,Atypical Endometrial Hyperplasia; Endometrial Adenocarcinoma; Recurrent Endometrial Carcinoma; Stage IA Endometrial Carcinoma; Stage IB Endometrial Carcinoma; Stage II Endometrial Carcinoma; Stage IIIA Endometrial Carcinoma; Stage IIIB Endometrial Carcinoma; Stage IIIC Endometrial Carcinoma; Stage IVA Endometrial Carcinoma; Stage IVB Endometrial Carcinoma,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7235,NCT00002465,"High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma",UNKNOWN,PHASE1,Breast Cancer; Endometrial Cancer; Malignant Mesothelioma,megestrol acetate (DRUG),19090,Chronopil,Breast Cancer; Endometrial Cancer; Malignant Mesothelioma,Lung,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7236,NCT04385667,LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia,COMPLETED,PHASE2,Atypical Endometrial Hyperplasia,levonorgestrel intrauterine system (LNG-IUD) (DEVICE); Oral Megesterol 160 mg daily (DRUG),19090,Chronopil,Atypical Endometrial Hyperplasia,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7237,NCT04897217,Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Management of Atypical Endometrial Hyperplasia,WITHDRAWN,PHASE3,Endometrial Hyperplasia,Megestrol Acetate (DRUG); Levonorgestrel Drug Implant (DRUG),19090,Chronopil,Endometrial Hyperplasia,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7238,NCT00016341,"Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer",TERMINATED,PHASE3,Endometrial Cancer,filgrastim (BIOLOGICAL); cisplatin (DRUG); doxorubicin hydrochloride (DRUG); megestrol acetate (DRUG); paclitaxel (DRUG); tamoxifen citrate (DRUG),19090,Chronopil,Endometrial Cancer,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7239,NCT02644408,Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy,COMPLETED,PHASE3,Stage III Esophageal Squamous Cell Carcinoma; Stage II Esophageal Squamous Cell Carcinoma,Megestrol（Yining） (DRUG); radiotherapy (RADIATION); chemotherapy (OTHER),19090,Chronopil,Stage III Esophageal Squamous Cell Carcinoma; Stage II Esophageal Squamous Cell Carcinoma,Skin,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7240,NCT03241914,Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer,COMPLETED,PHASE2,Endometrial Neoplasm Malignant Stage I,Megestrol Acetate (DRUG); Levonorgestrel-releasing Intrauterine System(LNG-IUS) (DEVICE),19090,Chronopil,Stage I Endometrial Cancer,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7241,NCT04907864,Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE),UNKNOWN,PHASE2,Gastric Cancer; Colorectal Cancer; Pancreatic Cancer; Biliary Tract Cancer; Lung Cancer; Precachexia; Cachexia,Multi-modal intervention (COMBINATION_PRODUCT),19090,Chronopil,Gastric Cancer; Colorectal Cancer; Pancreatic Cancer; Biliary Tract Cancer; Lung Cancer; Precachexia; Cachexia,Bowel,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7242,NCT00507949,Study to Evaluate the Effect of Megestrol Acetate in Severe Chronic Obstructive Pulmonary Disease With Loss of Weight,COMPLETED,PHASE2,Chronic Obstructive Pulmonary Disease,Megestrol acetate (DRUG); placebo (DRUG),19090,Chronopil,Chronic Obstructive Pulmonary Disease,Lung,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7243,NCT02269670,Phase II Study of Everolimus Beyond Progression,TERMINATED,PHASE2,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,everolimus (DRUG); anastrozole (DRUG); letrozole (DRUG); tamoxifen citrate (DRUG); fulvestrant (DRUG); megestrol acetate (DRUG),19090,Chronopil,Metastatic Breast Cancer,Breast,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7244,NCT00066248,Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment,COMPLETED,PHASE2,"Brain Tumor; Central Nervous System Tumors; Cachexia; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Unspecified Childhood Solid Tumor, Protocol Specific",cyproheptadine hydrochloride (DRUG); megestrol acetate (DRUG),19090,Chronopil,"Brain Tumor; Central Nervous System Tumors; Cachexia; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Unspecified Childhood Solid Tumor, Protocol Specific",CNS/Brain,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7245,NCT00041275,Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery,COMPLETED,PHASE3,Liver Cancer,megestrol acetate (DRUG),19090,Chronopil,Liver Cancer,Liver,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7246,NCT00005975,S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast Cancer,COMPLETED,PHASE3,Breast Cancer; Hot Flashes,Megestrol Acetate 20mg/day (DRUG); Megestrol Acetate 40 mg/day (DRUG); Megestrol Acetate Placebo 20 mg/day (DRUG); Megestrol Acetate Placebo 40 mg/day (DRUG),19090,Chronopil,Breast Cancer; Hot Flashes,Breast,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7247,NCT05492487,A Pilot Study on Fertility Conservative Treatment of Atypical Endometrial Hyperplasia in Singapore,UNKNOWN,PHASE2,Endometrial Hyperplasia; Fertility Issues; Disease Regression; Treatment Side Effects,Mirena (DRUG); Megace (DRUG),19090,Chronopil,Endometrial Hyperplasia; Fertility Issues; Disease Regression; Treatment Side Effects,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7248,NCT04607252,Metformin Plus Megestrol Acetate As a Fertility-sparing Treatment in Patients with Atypical Endometrial Hyperplasia,TERMINATED,PHASE2,Atypical Endometrial Hyperplasia,Metformin plus Megestrol acetate (DRUG); Megestrol Acetate (DRUG),19090,Chronopil,Atypical Endometrial Hyperplasia,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7249,NCT04046185,Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer,UNKNOWN,EARLY_PHASE1,Endometrial Cancer Stage I,PD-1 inhibitor combined progesterone (DRUG); progesterone (DRUG),19090,Chronopil,Endometrial Cancer Stage I,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7250,NCT05255653,Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features,RECRUITING,PHASE2,Endometrial Cancer,Olaparib (DRUG); Pelvic external beam radiotherapy (RADIATION); Chemotherapy (DRUG); Durvalumab (DRUG); Medroxyprogesterone Acetate (DRUG); Megestrol Acetate (DRUG); Vaginal brachytherapy (RADIATION); Observation (OTHER),19090,Chronopil,Endometrial Cancer,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7251,NCT04683237,Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia,WITHDRAWN,PHASE2,Atypical Endometrial Hyperplasia; Obese; Fertility Issues,Liraglutide Injection (DRUG); Megestrol Acetate 160 MG (DRUG),19090,Chronopil,Atypical Endometrial Hyperplasia; Obese; Fertility Issues,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7252,NCT00031785,Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer,COMPLETED,PHASE3,Anorexia; Cachexia; Lung Cancer,megestrol acetate (DRUG); radiation therapy (RADIATION),19090,Chronopil,Anorexia; Cachexia; Lung Cancer,Lung,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7253,NCT03241888,Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia,COMPLETED,PHASE2,Atypical Endometrial Hyperplasia,Megestrol Acetate (DRUG); Levonorgestrel-releasing Intrauterine System(LNG-IUS) (DEVICE),19090,Chronopil,Atypical Endometrial Hyperplasia,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7254,NCT06961188,Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis,NOT_YET_RECRUITING,PHASE3,Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity; Untreated With Systemic Therapy,Nano-crystalline Megestrol Acetate Oral Suspension (DRUG); Standard Therapy (OTHER),19090,Chronopil,Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity; Untreated With Systemic Therapy,Lung,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7255,NCT03671811,Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy,ACTIVE_NOT_RECRUITING,PHASE2,Atypical Endometrial Hyperplasia; Endometrial Carcinoma,Megestrol Acetate (DRUG); Pterostilbene (BIOLOGICAL),19090,Chronopil,Atypical Endometrial Hyperplasia; Endometrial Carcinoma,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7256,NCT06909383,"Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study",NOT_YET_RECRUITING,PHASE2,Extensive-stage Small Cell Lung Cancer (ES-SCLC); Cancer - Associated Anorexia - Cachexia Syndrome,Nanocrystalline megestrol acetate (DRUG),19090,Chronopil,Extensive-stage Small Cell Lung Cancer (ES-SCLC); Cancer - Associated Anorexia - Cachexia Syndrome,Lung,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7257,NCT06914297,TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC,RECRUITING,PHASE2,Endometrial Cancer,TQB2450 injection + oral progestin (DRUG),19090,Chronopil,Endometrial Cancer,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7258,NCT02990728,Mirena® ± Metformin as Fertility-preserving Treatment for Young Asian Women With Early Endometrial Cancer,UNKNOWN,PHASE2,Endometrial Cancer,Metformin (DRUG); Mirena® (DEVICE),19090,Chronopil,Endometrial Cancer,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7259,NCT06772428,Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery.,NOT_YET_RECRUITING,PHASE3,Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors,Nano-crystalline Megestrol Acetate Oral Suspension (DRUG); standard treatment (RADIATION),19090,Chronopil,Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors,Skin,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7260,NCT03077698,An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer,TERMINATED,PHASE2,Endometrial Cancer,Sodium Cridanimod (DRUG); progestin therapy (DRUG),19090,Chronopil,Endometrial Cancer,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7261,NCT02064725,Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA,UNKNOWN,PHASE2,Recurrent or Persistent Endometrial Carcinoma,Sodium cridanimod (DRUG),19090,Chronopil,Recurrent or Persistent Endometrial Carcinoma,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7262,NCT05316493,Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia,RECRUITING,PHASE2,Atypical Endometrial Hyperplasia; Fertility Issues; Overweight and Obesity,"Intensive Lifestyle Intervention (ILI) (BEHAVIORAL); Megestrol Acetate 160 MG Oral Tablet (DRUG); Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg (DRUG)",19090,Chronopil,Atypical Endometrial Hyperplasia; Fertility Issues; Overweight and Obesity,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7263,NCT05332483,Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer,TERMINATED,PHASE1,Endometrial Cancer,Megestrol Acetate (DRUG),19090,Chronopil,Endometrial Cancer,Uterus,Megestrol,,unclear,unclear,yes,yes,Used for appetite loss and weight gain in cancer/AIDS patients.,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,1.16,259.0 +7264,NCT02892357,Efficacy of Traditional Chinese Medicine Combined With Omeprazole in Patients With Non-erosive Reflux Disease,UNKNOWN,PHASE1,Non-erosive Reflux Disease,Treatment group (DRUG); Control group (DRUG),12108541,FO67914,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7265,NCT04028466,Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features,TERMINATED,PHASE4,GERD; Gastro Esophageal Reflux,Vonoprazan (DRUG); Omeprazole (DRUG),12108541,FO67914,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7266,NCT00564590,SThe Effects of Melatonin on GERD Symptoms,UNKNOWN,PHASE1,Gastroesophageal Reflux Disease,Melatonin (DRUG); omeprazole (OTHER); Placebo (DRUG),12108541,FO67914,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7267,NCT02140073,Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity,UNKNOWN,PHASE4,GERD,omeprazole+domperidone SR (DRUG); omeprazole (DRUG),12108541,FO67914,GERD,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7268,NCT02397382,Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis,COMPLETED,PHASE1,Psoriasis,Guselkumab (DRUG); Midazolam (DRUG); Warfarin (DRUG); Omeprazole (DRUG); Dextromethorphan (DRUG); Caffeine (DRUG),12108541,FO67914,Psoriasis,Skin,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7269,NCT00931073,A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers,COMPLETED,PHASE1,Alzheimer's Disease; Huntington's Disease,Dimebon alone (DRUG); Dimebon + Ketoconazole (DRUG); Dimebon + Omeprazole (DRUG),12108541,FO67914,Alzheimer's Disease; Huntington's Disease,CNS/Brain,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7270,NCT06393868,Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism,NOT_YET_RECRUITING,PHASE3,Venous Thromboembolism; Gastro Intestinal Bleeding; Blood Clot,Omeprazole 20 mg Oral Tablet (DRUG); Placebo (OTHER),12108541,FO67914,Venous Thromboembolism; Gastro Intestinal Bleeding; Blood Clot,Bowel,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7271,NCT02518373,Effect of G17DT in Patients With Stage II/III Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,G17DT (BIOLOGICAL); Omeprazole (DRUG),12108541,FO67914,Colorectal Cancer,Bowel,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7272,NCT01878526,Gastroesophageal Reflux Treatment in Scleroderma,COMPLETED,PHASE3,Gastroesophageal Reflux Disease; Systemic Sclerosis; Scleroderma,Alginic acid (DRUG); placebo (for domperidone) (DRUG); Domperidone (DRUG); placebo (of alginic acid) (DRUG),12108541,FO67914,Gastroesophageal Reflux Disease; Systemic Sclerosis; Scleroderma,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7273,NCT02637557,A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD),COMPLETED,PHASE2,Gastroesophageal Reflux Disease,IW-3718 (DRUG); Matching Placebo (DRUG); PPI (DRUG),12108541,FO67914,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7274,NCT02045966,Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects,COMPLETED,PHASE1,Hepatitis C,Cocktail (DRUG); DCV 3DAA FDC (DRUG); BMS-791325 (DRUG),12108541,FO67914,Hepatitis C,Liver,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7275,NCT02453022,"A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole",COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",Danirixin HBr 50 mg IR Tablet (DRUG); Danirixin FB 50 mg IR Tablet (DRUG); Prilosec (omeprazole) 40mg Delayed-Release capsule (DRUG),12108541,FO67914,"Pulmonary Disease, Chronic Obstructive",Lung,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7276,NCT06719622,Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn's Disease Located in the Esophagus And/or Stomach And/or Duodenum,ENROLLING_BY_INVITATION,PHASE2,Crohn Disease (CD),budesonide (DRUG); omeprazole (proton pump inhibitor) (DRUG),12108541,FO67914,Inflammatory Bowel Disease (IBD),Bowel,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7277,NCT06916130,A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A,NOT_YET_RECRUITING,PHASE1,Gastroesophageal Reflux Disease (GERD),AD-120A (DRUG); AD-120 (DRUG),12108541,FO67914,Gastroesophageal Reflux Disease (GERD),Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7278,NCT00693225,Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study,COMPLETED,PHASE4,Erosive Esophagitis,Omeprazole/sodium bicarbonate (DRUG),12108541,FO67914,Erosive Esophagitis,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7279,NCT02647086,"Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)",COMPLETED,PHASE1,Atopic Dermatitis,Dupilumab (DRUG); Midazolam (DRUG); Omeprazole (DRUG); Warfarin (DRUG); Caffeine (DRUG); Metoprolol (DRUG),12108541,FO67914,Atopic Dermatitis,Skin,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7280,NCT00492622,Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis,COMPLETED,PHASE4,Gastroparesis; Gastroesophageal Reflux Disease,Immediate-release omeprazole (DRUG); Delayed-release omeprazole (DRUG),12108541,FO67914,Gastroparesis; Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7281,NCT00161096,On-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive Medication,UNKNOWN,PHASE3,Chronic Use of Acid Suppressive Medication; GORD; GERD; Reflux; Peptic Ulcer,pantoprazole 20 mg (drug) (DRUG),12108541,FO67914,Chronic Use of Acid Suppressive Medication; GORD; GERD; Reflux; Peptic Ulcer,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7282,NCT02710994,Pharmacodynamics and Safety of CDFR0209,COMPLETED,PHASE1,Stomach Ulcer; Gastroesophageal Reflux,CDFR0209 (DRUG); Losec (DRUG),12108541,FO67914,Stomach Ulcer; Gastroesophageal Reflux,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7283,NCT04930991,High Dose Omeprazole in Patients With Pancreatic Cancer,RECRUITING,EARLY_PHASE1,Exocrine Pancreatic Cancer,Omeprazole (DRUG),12108541,FO67914,Exocrine Pancreatic Cancer,Pancreas,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7284,NCT01493089,Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease,COMPLETED,PHASE3,Gastroesophageal Reflux,Zegerid (DRUG); Losec (DRUG),12108541,FO67914,Gastroesophageal Reflux,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7285,NCT01150162,"Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation",COMPLETED,PHASE3,Gastric Ulcer,Rebamipide and Omeprazole (DRUG); Omeprazole (DRUG),12108541,FO67914,Gastric Ulcer,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7286,NCT03267680,IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3,TERMINATED,PHASE2,Cervical Squamous Cell Carcinoma In Situ; Vulvar High Grade Squamous Intraepithelial Lesion,Cyclophosphamide (DRUG); Indomethacin (DRUG); IRX-2 (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER); Multivitamin (DIETARY_SUPPLEMENT); Omeprazole (DRUG); Placebo (OTHER); Therapeutic Conventional Surgery (PROCEDURE),12108541,FO67914,Cervical Squamous Cell Carcinoma In Situ; Vulvar High Grade Squamous Intraepithelial Lesion,Skin,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7287,NCT06255886,Treatment of Gastroesophageal Reflux Disease in Infants,NOT_YET_RECRUITING,PHASE4,"Gastroesophageal Reflux; Infant, Newborn, Diseases",Protein pump inhibitor. Continuing nutrition containing cows' milk protein. (DRUG); Mother or infant diet (BEHAVIORAL); Placebo (DRUG),12108541,FO67914,"Gastroesophageal Reflux; Infant, Newborn, Diseases",Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7288,NCT02609386,"IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity",COMPLETED,PHASE2,Squamous Cell Carcinoma of the Oral Cavity,IRX-2 (BIOLOGICAL); Cyclophosphamide (DRUG); Indomethacin (DRUG); Zinc-containing multivitamin (DIETARY_SUPPLEMENT); Omeprazole (DRUG),12108541,FO67914,Squamous Cell Carcinoma of the Oral Cavity,Skin,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7289,NCT00978016,A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD),COMPLETED,PHASE2,Gastroesophageal Reflux Disease,arbaclofen placarbil-Cohort 1 (DRUG); Placebo-Cohort 5 (DRUG); arbaclofen placarbil-Cohort 2 (DRUG); arbaclofen placarbil-Cohort 3 (DRUG); arbaclofen placarbil-Cohort 4 (DRUG); PPI (DRUG),12108541,FO67914,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7290,NCT00915616,The Potential Therapeutic Effect of Melatonin in Gastro-Esophageal Reflux Disease,WITHDRAWN,PHASE3,Gastroesophageal Reflux Disease,Melatonin (DRUG),12108541,FO67914,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7291,NCT02860624,Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients,COMPLETED,PHASE3,Gastroesophageal Reflux Disease,10 mg ilaprazole (DRUG); 40mg esomeprazole (DRUG),12108541,FO67914,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7292,NCT04562116,A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis,COMPLETED,PHASE2,Atopic Dermatitis,Nemolizumab (DRUG); CYP 450 Substrates (DRUG),12108541,FO67914,Atopic Dermatitis,Skin,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7293,NCT01287195,Oral OKT3 for the Treatment of Active Ulcerative Colitis,COMPLETED,PHASE1,Ulcerative Colitis,Oral OKT3 (DRUG); Omeprazole (DRUG),12108541,FO67914,Ulcerative Colitis,Bowel,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7294,NCT00364481,Tongue Exercises and Reflux Therapy for Upper Airway Resistance Syndrome,WITHDRAWN,PHASE1,Obstructive Sleep Apnea; Upper Airway Resistance Syndrome; Gastroesophageal Reflux,omeprazole (DRUG); Tongue exercises (BEHAVIORAL),12108541,FO67914,Obstructive Sleep Apnea; Upper Airway Resistance Syndrome; Gastroesophageal Reflux,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7295,NCT00226044,Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.,COMPLETED,PHASE3,"Gastroesophageal Reflux; Esophageal Atresia; Hernia, Diaphragmatic",Omeprazole rectally 1mg/kg (DRUG),12108541,FO67914,"Gastroesophageal Reflux; Esophageal Atresia; Hernia, Diaphragmatic",Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7296,NCT00582972,Does Omeprazole Decrease Intestinal Calcium Absorption?,COMPLETED,PHASE4,Osteoporosis; Achlorhydria; GERD; Hip Fracture,Omeprazole (DRUG),12108541,FO67914,Osteoporosis; Achlorhydria; GERD; Hip Fracture,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7297,NCT02772601,This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis,COMPLETED,PHASE1,Psoriasis,Caffeine (DRUG); Warfarin (DRUG); Omeprazole (DRUG); Metoprolol (DRUG); Midazolam (DRUG); Risankizumab (DRUG),12108541,FO67914,Psoriasis,Skin,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7298,NCT01260844,"Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.",WITHDRAWN,PHASE1,Moderate to Severe Plaque Psoriasis,briakinumab (DRUG),12108541,FO67914,Moderate to Severe Plaque Psoriasis,Skin,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7299,NCT04718740,A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer,COMPLETED,PHASE1,Recurrent Ovarian Cancer,fluzoparib (DRUG),12108541,FO67914,Recurrent Ovarian Cancer,Ovary/Fallopian Tube,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7300,NCT00272467,Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy,COMPLETED,PHASE4,Stomach Ulcer,Rebamipide (DRUG); Omeprazole (DRUG),12108541,FO67914,Stomach Ulcer,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7301,NCT00861640,Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding,UNKNOWN,PHASE4,Nonvariceal Upper Gastrointestinal Bleeding,Intravenous Omeprazole (DRUG); Oral Rabeprazole (DRUG),12108541,FO67914,Nonvariceal Upper Gastrointestinal Bleeding,Bowel,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7302,NCT02794844,Implementation of PPI Medication PGX Testing,COMPLETED,PHASE4,Gastroesophageal Reflux,Genotype Guided PPI Dosing (DRUG),12108541,FO67914,Gastroesophageal Reflux,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7303,NCT05624229,Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding,NOT_YET_RECRUITING,PHASE4,Upper Gastrointestinal Hemorrhage,Proton Pump Inhibitors (DRUG); No Proton Pump Inhibitors (DRUG),12108541,FO67914,Upper Gastrointestinal Hemorrhage,Bowel,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7304,NCT03556592,Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4,COMPLETED,PHASE1,Atopic Dermatitis,Tralokinumab (DRUG); Caffeine (DRUG); Warfarin (DRUG); Omeprazole (DRUG); Metoprolol (DRUG); Midazolam Hydrochloride (DRUG),12108541,FO67914,Atopic Dermatitis,Skin,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7305,NCT02703896,Prophylaxis for Aspiration of Gastric Contents.,COMPLETED,PHASE4,Pulmonary Aspiration of Gastric Contents,Drug either PPIS or H2RA and prokinetics (DRUG); orogastric intubation (PROCEDURE),12108541,FO67914,Pulmonary Aspiration of Gastric Contents,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7306,NCT03238534,Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS,COMPLETED,PHASE4,GERD; EPS,Neobianacid® (DEVICE); Omeprazole 20mg (DRUG); Neobianacid® placebo (OTHER); Omeprazole placebo (OTHER),12108541,FO67914,GERD; EPS,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7307,NCT03457727,GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects,COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",Danirixin (DRUG); Omeprazole (DRUG),12108541,FO67914,"Pulmonary Disease, Chronic Obstructive",Lung,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7308,NCT03781596,EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone,UNKNOWN,PHASE4,Eosinophilic Esophagitis,Retrospective evaluation of endoscopy prior to study drug (DIAGNOSTIC_TEST); Symptom Survey (OTHER); Medication Compliance Phone Call (OTHER); Endoscopy while on study drug (DIAGNOSTIC_TEST); Symptom Survey (OTHER); Fluticasone (DRUG); Omeprazole (DRUG); Placebo oral capsule (DRUG),12108541,FO67914,Eosinophilic Esophagitis,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7309,NCT06949124,"A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects",NOT_YET_RECRUITING,PHASE1,Endometriosis; Uterine Fibroids; Assisted Reproduction,SHR7280 Tablets (DRUG),12108541,FO67914,Endometriosis; Uterine Fibroids; Assisted Reproduction,Uterus,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7310,NCT03980496,Effects of Different Omeprazole Dosing on Gastric pH in Non-variceal Upper Gastrointestinal Bleeding,COMPLETED,PHASE4,Non-variceal Upper Gastrointestinal Bleeding,Omeprazole (DRUG),12108541,FO67914,Non-variceal Upper Gastrointestinal Bleeding,Bowel,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7311,NCT01499368,"A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients",COMPLETED,PHASE3,Erosive Esophagitis,Lafutidine (DRUG); Famotidine (DRUG); Omeprazole (DRUG),12108541,FO67914,Erosive Esophagitis,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7312,NCT02125604,Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany,COMPLETED,PHASE4,Relapsing-Remitting Multiple Sclerosis,dimethyl fumarate (DRUG),12108541,FO67914,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7313,NCT00995410,Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers,COMPLETED,PHASE3,Aspirin-Associated Gastric Ulcers,PA32540 (DRUG),12108541,FO67914,Aspirin-Associated Gastric Ulcers,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7314,NCT01745510,Enteral Administration of Docosahexaenoic Acid to Prevent Necrotizing Enterocolitis in Preterm Neonates,COMPLETED,PHASE1,Necrotizing Enterocolitis,Docosahexaenoic acid (DHA) (DIETARY_SUPPLEMENT); Placebo (DIETARY_SUPPLEMENT),12108541,FO67914,Necrotizing Enterocolitis,Bowel,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7315,NCT00960869,Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers,COMPLETED,PHASE3,Gastric Ulcer,PA32540 (DRUG); EC-Aspirin 325 mg (DRUG),12108541,FO67914,Gastric Ulcer,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7316,NCT02272868,Fecal Microbial Transplant in Pediatric Crohn's Disease,TERMINATED,PHASE1,Crohn's Disease,Fecal Microbial transplant (BIOLOGICAL); Normal Saline (DRUG); rifaximin+omeprazole+miralax (DRUG),12108541,FO67914,Crohn's Disease,Bowel,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7317,NCT00374101,High Versus Standard Dose of Proton Pump Inhibitors (PPIs) in Peptic Ulcer Bleeding,COMPLETED,PHASE3,Peptic Ulcers; Upper Gastrointestinal Bleeding,omeprazole (DRUG); pantoprazole (DRUG),12108541,FO67914,Peptic Ulcers; Upper Gastrointestinal Bleeding,Bowel,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7318,NCT01136317,Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects,COMPLETED,PHASE2,Gastroesophageal Reflux,Omeprazole (DRUG); Rabeprazole (DRUG); Lactose (DRUG),12108541,FO67914,Gastroesophageal Reflux,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7319,NCT02407119,Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD,ACTIVE_NOT_RECRUITING,PHASE3,Helicobacter Pylori Infection; Early Gastric Cancer; Endoscopic Resection,"7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin (DRUG); Placebo, Omeprazole or Rabeprazole, Clarithromycin (DRUG)",12108541,FO67914,Helicobacter Pylori Infection; Early Gastric Cancer; Endoscopic Resection,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7320,NCT05891119,Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis,COMPLETED,EARLY_PHASE1,Atopic Dermatitis,Caffeine (DIETARY_SUPPLEMENT); Metoprolol (DRUG); Midazolam (DRUG); Warfarin (DRUG); Vitamin K (DIETARY_SUPPLEMENT); Omeprazole (DRUG); Rocatinlimab (DRUG),12108541,FO67914,Atopic Dermatitis,Skin,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7321,NCT06099119,Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.,NOT_YET_RECRUITING,PHASE4,Unresectable Pancreatic Cancer,creon 35.000 Ph.U (R) (DRUG); Best Standarard of Care (OTHER),12108541,FO67914,Unresectable Pancreatic Cancer,Pancreas,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7322,NCT01129713,Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.,UNKNOWN,PHASE1,Gastroesophageal Reflux Disease (GERD); Heartburn; Indigestion,Secretol (DRUG); Nexium (DRUG),12108541,FO67914,Gastroesophageal Reflux Disease (GERD); Heartburn; Indigestion,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7323,NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,COMPLETED,PHASE3,Relapsing-Remitting Multiple Sclerosis,Midazolam (DRUG); Caffeine (OTHER); S-warfarin (DRUG); Vitamin K (OTHER); Omeprazole (DRUG); Dextromethorphan (DRUG); BIIB019 (Daclizumab) (BIOLOGICAL),12108541,FO67914,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7324,NCT04660123,A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication,COMPLETED,PHASE4,Gastric Cancer; Helicobacter Pylori Infection; Bismuth,Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication (DRUG),12108541,FO67914,Gastric Cancer; Helicobacter Pylori Infection; Bismuth,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7325,NCT01265550,A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors,COMPLETED,PHASE3,GERD,Nissen fundoplication (DEVICE); baclofen (DRUG); Desipramine (DRUG),12108541,FO67914,GERD,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7326,NCT01876108,The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-alcoholic Fatty Liver Disease,COMPLETED,PHASE2,Fatty Liver; Liver Dysfunction; Insulin Resistance,"H.pylori eradication (Omeprazole, Amoxicillin, Bismuth subcitrate, Azithromycin) (DRUG)",12108541,FO67914,Fatty Liver; Liver Dysfunction; Insulin Resistance,Liver,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7327,NCT00692510,Drug Interaction Study Between AZD3480 and Cytochrome P450,COMPLETED,PHASE1,Metabolism; Alzheimer's Disease,"AZD3480 (DRUG); Placebo (DRUG); Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin) (DRUG)",12108541,FO67914,Metabolism; Alzheimer's Disease,CNS/Brain,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7328,NCT06664008,The Effect of Probiotic and Zinc Supplementation in Patients With Gastroesophageal Reflux Disease,NOT_YET_RECRUITING,PHASE4,Gastro-oesophageal Reflux Disease,PPI (proton pump inhibitor) (DRUG); Probiotic (DRUG); Zinc (DRUG),12108541,FO67914,Gastro-oesophageal Reflux Disease,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7329,NCT00634114,Reflux Esophagitis Phase III Study (Maintenance Treatment),COMPLETED,PHASE3,Reflux Esophagitis,Esomeprazole (DRUG); Esomeprazole (DRUG); Omeprazole (DRUG),12108541,FO67914,Reflux Esophagitis,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7330,NCT00961350,A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers,COMPLETED,PHASE3,Gastric Ulcer,PA32540 (DRUG); EC Aspirin 325 (DRUG),12108541,FO67914,Gastric Ulcer,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7331,NCT03367195,Efficacy and Safety of DLBS2411 in the Management of GERD,TERMINATED,PHASE3,Gastroesophageal Reflux Disease (GERD),Omeprazole (DRUG); DLBS2411 (DRUG); Placebo capsule of Omeprazole (DRUG); Placebo caplet of DLBS2411 (DRUG),12108541,FO67914,Gastroesophageal Reflux Disease (GERD),Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7332,NCT03291249,"Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM",WITHDRAWN,PHASE2,NASH - Nonalcoholic Steatohepatitis; NAFLD; T2DM (Type 2 Diabetes Mellitus),Foralumab (DRUG); placebo (OTHER); Omeprazole 20mg (DRUG),12108541,FO67914,NASH - Nonalcoholic Steatohepatitis; NAFLD; T2DM (Type 2 Diabetes Mellitus),Liver,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7333,NCT02685436,Role of Pepsin Assay in Wheezy Infants,COMPLETED,PHASE4,Gastroesophageal Reflux Disease,Omeprazole and domperidone (DRUG),12108541,FO67914,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7334,NCT01654549,Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis,COMPLETED,PHASE2,Non-alcoholic Fatty Liver Disease,H.pylori eradication (DRUG),12108541,FO67914,Non-alcoholic Fatty Liver Disease,Liver,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7335,NCT03358706,A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis,TERMINATED,PHASE1,Crohn Disease; Ulcerative Colitis,Ustekinumab IV Infusion (DRUG); Ustekinumab SC Injection (DRUG); Midazolam 2 mg (DRUG); Warfarin 10 mg (DRUG); Vitamin K 10 mg (DRUG); Omeprazole 20 mg (DRUG); Dextromethorphan 30 mg (DRUG); Caffeine 100 mg (DRUG),12108541,FO67914,Crohn Disease; Ulcerative Colitis,Bowel,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7336,NCT01001299,A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma,COMPLETED,PHASE1,Malignant Melanoma,Drug cocktail (DRUG); RO5185426 (DRUG),12108541,FO67914,Malignant Melanoma,Skin,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7337,NCT00210470,A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer,COMPLETED,PHASE2,Squamous Cell Carcinoma of the Head and Neck,IRX-2 (BIOLOGICAL); Cyclophosphamide (DRUG); Indomethacin (DRUG); Zinc (DRUG); Omeprazole (DRUG),12108541,FO67914,Squamous Cell Carcinoma of the Head and Neck,Skin,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7338,NCT00818870,Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH,COMPLETED,PHASE1,Gastroesophageal Reflux,Omeprazole (DRUG); Vecam (DRUG); Vecam (DRUG),12108541,FO67914,Gastroesophageal Reflux,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7339,NCT05680870,The Possible Protective Role of Omeprazole Against Oxaliplatin Induced Neuropathy in Cancer Patients,UNKNOWN,PHASE3,Chemotherapy Induced Peripheral Neuropathy,Omeprazole (DRUG),12108541,FO67914,Chemotherapy Induced Peripheral Neuropathy,Peripheral Nervous System,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7340,NCT01824199,CYP2C19 Genotype Predictor of Gastric Acid Suppression,WITHDRAWN,EARLY_PHASE1,Esophagitis,Omeprazole (DRUG),12108541,FO67914,Esophagitis,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7341,NCT03864042,Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors,COMPLETED,PHASE1,Advanced Solid Tumors; Metastatic Melanoma,losartan (DRUG); dextromethorphan (DRUG); caffeine (DRUG); omeprazole (DRUG); midazolam (DRUG); rosuvastatin (DRUG); bupropion immediate release (IR) (DRUG); encorafenib (DRUG); binimetinib (DRUG); modafinil (DRUG),12108541,FO67914,Advanced Solid Tumors; Metastatic Melanoma,Skin,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7342,NCT00765206,A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED),COMPLETED,PHASE3,Gastric Acid; Human Experimentation,Omeprazole/sodium bicarbonate (DRUG); omeprazole magnesium (20 mg equivalent) (DRUG),12108541,FO67914,Gastric Acid Studies,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7343,NCT02422706,Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori,UNKNOWN,PHASE3,Helicobacter-associated Gastritis,Nitazoxanide (DRUG); Metronidazole(MTZ) (DRUG); Omeprazole (DRUG); Clarithromycin (DRUG); Levofloxacin (DRUG); Doxicycline (DRUG),12108541,FO67914,Helicobacter-associated Gastritis,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7344,NCT05134584,Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders,UNKNOWN,PHASE4,Functional Dyspepsia; Constipation-predominant Irritable Bowel Syndrome,Linaclotide (DRUG); Lactulose (DRUG); Omeprazol (DRUG); Itopride (DRUG),12108541,FO67914,Functional Dyspepsia; Constipation-predominant Irritable Bowel Syndrome,Bowel,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7345,NCT00559364,Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea,COMPLETED,PHASE3,Exocrine Pancreatic Insufficiency; Chronic Pancreatitis; Pancreatectomy,Viokase® 16 (DRUG); Placebo (DRUG); Proton pump inhibitor (PPI) (DRUG); Omeprazole (DRUG),12108541,FO67914,Exocrine Pancreatic Insufficiency; Chronic Pancreatitis; Pancreatectomy,Pancreas,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7346,NCT03718884,A Study of Mirikizumab in Participants With Plaque Psoriasis,COMPLETED,PHASE1,Psoriasis,Drug Cocktail (DRUG); Mirikizumab (DRUG),12108541,FO67914,Psoriasis,Skin,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7347,NCT01489943,"A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects",COMPLETED,PHASE1,Crohn's Disease,GSK1605786 500 mg (DRUG); Midazolam 3 mg (DRUG); Pioglitazone 15 mg (DRUG); Omeprazole 40 mg (DRUG); Rosuvastatin 10 mg (DRUG),12108541,FO67914,Crohn's Disease,Bowel,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7348,NCT01002443,Efficacy Study of Helicobacter Pylori Eradication in Patients Undergoing Subtotal Gastrectomy for Gastric Cancer,COMPLETED,PHASE2,Gastric Cancer,Helicobacter pylori eradication (DRUG); placebo (DRUG),12108541,FO67914,Gastric Cancer,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7349,NCT00003617,Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach,UNKNOWN,PHASE3,Gastric Cancer,chlorambucil (DRUG); clarithromycin (DRUG); omeprazole (DRUG); tinidazole (DRUG),12108541,FO67914,Gastric Cancer,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7350,NCT02085018,Pilot Trial Of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF),COMPLETED,PHASE2,Idiopathic Pulmonary Fibrosis,Omeprazole (DRUG); Matched placebo (DRUG),12108541,FO67914,Idiopathic Pulmonary Fibrosis,Lung,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7351,NCT04149470,Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE),ACTIVE_NOT_RECRUITING,PHASE4,Eosinophilic Esophagitis,Omeprazole 20mg BID (DRUG),12108541,FO67914,Eosinophilic Esophagitis,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7352,NCT05273775,A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers,COMPLETED,PHASE1,Chronic Hepatitis B,HRS5091 Tablets (DRUG); Midazolam Maleate Tablets (DRUG); Warfarin Sodium Tablets (DRUG); Omeprazole Enteric Capsules (DRUG); Vitamin K1 Tablets (DRUG); Digoxin Tablets (DRUG); Rosuvastatin Calcium Tablets (DRUG),12108541,FO67914,Chronic Hepatitis B,Liver,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7353,NCT02950259,Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC),ACTIVE_NOT_RECRUITING,PHASE1,"Breast Neoplasm; Breast Neoplasm, Male; Triple Negative Breast Cancer",Cyclophosphamide (DRUG); Indomethacin (DRUG); Omeprazole (DRUG); Multivitamin (DIETARY_SUPPLEMENT),12108541,FO67914,"Breast Neoplasm; Breast Neoplasm, Male; Triple Negative Breast Cancer",Breast,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7354,NCT01205087,Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome,COMPLETED,PHASE2,Nonalcoholic Steatohepatitis,OKT3 (DRUG),12108541,FO67914,Nonalcoholic Steatohepatitis,Liver,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7355,NCT02299687,Influence of CYP2C19 Polymorphism on PK/PD of Omeprazole,COMPLETED,PHASE1,Stomach Ulcer,Omeprazole (DRUG),12108541,FO67914,Stomach Ulcer,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7356,NCT01822106,"Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD)",UNKNOWN,PHASE4,Gastroesophageal Reflux Disease,Placebo (OTHER),12108541,FO67914,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7357,NCT01459419,Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects,UNKNOWN,PHASE2,Chronic Hepatitis C,anti-CD3 monoclonal antibody (DRUG); Sodium Chloride placebo (DRUG),12108541,FO67914,Chronic Hepatitis C,Liver,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7358,NCT00633932,Reflux Esophagitis Phase III Study (Initial Treatment),COMPLETED,PHASE3,Reflux Esophagitis,Esomeprazole (DRUG); Esomeprazole (DRUG); Omeprazole (DRUG),12108541,FO67914,Reflux Esophagitis,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7359,NCT00045799,Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill,COMPLETED,PHASE3,Upper Gastrointestinal Bleeding,Omeprazole sodium bicarbonate immediate release PWD/FS (DRUG); Cimetidine IV (DRUG),12108541,FO67914,Upper Gastrointestinal Bleeding,Bowel,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7360,NCT01813552,To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006),COMPLETED,PHASE1,Chronic Hepatitis C Infection,Samatasvir (DRUG); Omeprazole (DRUG); Ritonavir (DRUG),12108541,FO67914,Chronic Hepatitis C Infection,Liver,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7361,NCT00256737,Sopran - Omeprazole Treatment Versus Surgery,COMPLETED,PHASE3,GERD,Omeprazole (DRUG),12108541,FO67914,GERD,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7362,NCT00674115,A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED),COMPLETED,PHASE3,Gastric Acid; Human Experimentation,Omeprazole/sodium bicarbonate (DRUG); omeprazole magnesium (DRUG); sodium bicarbonate (DRUG),12108541,FO67914,Gastric Acid Studies,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7363,NCT02922699,Efficacy and Saafety of Omez Iin Patients With H.Pylori Associated Diseases,COMPLETED,PHASE4,GERD,OMEZ 40 (DRUG); OMEZ 80 (DRUG),12108541,FO67914,GERD,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7364,NCT00664209,Treating H. Pylori in Parkinson's Patients With Motor Fluctuations,TERMINATED,PHASE3,Parkinson's Disease; Helicobacter Infections; Motor Fluctuations,"clartihromycin, amoxicillin, and omeprazole (DRUG); placebo (DRUG)",12108541,FO67914,Parkinson's Disease; Helicobacter Infections; Motor Fluctuations,CNS/Brain,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7365,NCT04118647,Effective Mechanisms of Wu-Chu-Yu Tang on Gastroesophageal Disorder,UNKNOWN,PHASE4,Wu-Chu-Yu Tang; Gastroesophageal Reflux Disorder; 24 Hours Esophageal PH and Multichannel Intraluminal Impedance Testing,Wu-Chu-Yu tang (DRUG),12108541,FO67914,Wu-Chu-Yu Tang; Gastroesophageal Reflux Disorder; 24 Hours Esophageal PH and Multichannel Intraluminal Impedance Testing,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7366,NCT01458054,Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults,COMPLETED,PHASE1,Hepatitis C,"Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose) (DRUG); Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose) (DRUG)",12108541,FO67914,Hepatitis C,Liver,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7367,NCT02584751,GERD and Anti-Reflux Therapy Between Able-bodied and SCI Individuals,UNKNOWN,PHASE1,Gastro Esophageal Reflux Disorder,Omeprazole (DRUG); 24 Hour pH Monitor (DEVICE); Pulmonary Function Examination (PROCEDURE); Exhaled Nitric Oxide (PROCEDURE); Exhaled Breath Concentrate (EBC) (PROCEDURE); Bernstein's Acid Clearance Test (PROCEDURE); Esophageal Motility (PROCEDURE),12108541,FO67914,Gastro Esophageal Reflux Disorder,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7368,NCT00259051,A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population,COMPLETED,PHASE3,Non-erosive Reflux Disease,Omeprazole (DRUG),12108541,FO67914,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole (sodium),,inhibitor/antagonist,unclear,yes,yes,Approved in salt form as acid reflux treatment.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+],1.15,232.0 +7369,NCT02892357,Efficacy of Traditional Chinese Medicine Combined With Omeprazole in Patients With Non-erosive Reflux Disease,UNKNOWN,PHASE1,Non-erosive Reflux Disease,Treatment group (DRUG); Control group (DRUG),4594,OMZ,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7370,NCT04028466,Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features,TERMINATED,PHASE4,GERD; Gastro Esophageal Reflux,Vonoprazan (DRUG); Omeprazole (DRUG),4594,OMZ,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7371,NCT00564590,SThe Effects of Melatonin on GERD Symptoms,UNKNOWN,PHASE1,Gastroesophageal Reflux Disease,Melatonin (DRUG); omeprazole (OTHER); Placebo (DRUG),4594,OMZ,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7372,NCT02140073,Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity,UNKNOWN,PHASE4,GERD,omeprazole+domperidone SR (DRUG); omeprazole (DRUG),4594,OMZ,GERD,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7373,NCT02397382,Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis,COMPLETED,PHASE1,Psoriasis,Guselkumab (DRUG); Midazolam (DRUG); Warfarin (DRUG); Omeprazole (DRUG); Dextromethorphan (DRUG); Caffeine (DRUG),4594,OMZ,Psoriasis,Skin,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7374,NCT00931073,A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers,COMPLETED,PHASE1,Alzheimer's Disease; Huntington's Disease,Dimebon alone (DRUG); Dimebon + Ketoconazole (DRUG); Dimebon + Omeprazole (DRUG),4594,OMZ,Alzheimer's Disease; Huntington's Disease,CNS/Brain,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7375,NCT06393868,Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism,NOT_YET_RECRUITING,PHASE3,Venous Thromboembolism; Gastro Intestinal Bleeding; Blood Clot,Omeprazole 20 mg Oral Tablet (DRUG); Placebo (OTHER),4594,OMZ,Venous Thromboembolism; Gastro Intestinal Bleeding; Blood Clot,Bowel,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7376,NCT02518373,Effect of G17DT in Patients With Stage II/III Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,G17DT (BIOLOGICAL); Omeprazole (DRUG),4594,OMZ,Colorectal Cancer,Bowel,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7377,NCT01878526,Gastroesophageal Reflux Treatment in Scleroderma,COMPLETED,PHASE3,Gastroesophageal Reflux Disease; Systemic Sclerosis; Scleroderma,Alginic acid (DRUG); placebo (for domperidone) (DRUG); Domperidone (DRUG); placebo (of alginic acid) (DRUG),4594,OMZ,Gastroesophageal Reflux Disease; Systemic Sclerosis; Scleroderma,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7378,NCT02637557,A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD),COMPLETED,PHASE2,Gastroesophageal Reflux Disease,IW-3718 (DRUG); Matching Placebo (DRUG); PPI (DRUG),4594,OMZ,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7379,NCT02045966,Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects,COMPLETED,PHASE1,Hepatitis C,Cocktail (DRUG); DCV 3DAA FDC (DRUG); BMS-791325 (DRUG),4594,OMZ,Hepatitis C,Liver,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7380,NCT02453022,"A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole",COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",Danirixin HBr 50 mg IR Tablet (DRUG); Danirixin FB 50 mg IR Tablet (DRUG); Prilosec (omeprazole) 40mg Delayed-Release capsule (DRUG),4594,OMZ,"Pulmonary Disease, Chronic Obstructive",Lung,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7381,NCT06719622,Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn's Disease Located in the Esophagus And/or Stomach And/or Duodenum,ENROLLING_BY_INVITATION,PHASE2,Crohn Disease (CD),budesonide (DRUG); omeprazole (proton pump inhibitor) (DRUG),4594,OMZ,Inflammatory Bowel Disease (IBD),Bowel,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7382,NCT06916130,A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A,NOT_YET_RECRUITING,PHASE1,Gastroesophageal Reflux Disease (GERD),AD-120A (DRUG); AD-120 (DRUG),4594,OMZ,Gastroesophageal Reflux Disease (GERD),Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7383,NCT00693225,Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study,COMPLETED,PHASE4,Erosive Esophagitis,Omeprazole/sodium bicarbonate (DRUG),4594,OMZ,Erosive Esophagitis,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7384,NCT02647086,"Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)",COMPLETED,PHASE1,Atopic Dermatitis,Dupilumab (DRUG); Midazolam (DRUG); Omeprazole (DRUG); Warfarin (DRUG); Caffeine (DRUG); Metoprolol (DRUG),4594,OMZ,Atopic Dermatitis,Skin,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7385,NCT00492622,Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis,COMPLETED,PHASE4,Gastroparesis; Gastroesophageal Reflux Disease,Immediate-release omeprazole (DRUG); Delayed-release omeprazole (DRUG),4594,OMZ,Gastroparesis; Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7386,NCT00161096,On-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive Medication,UNKNOWN,PHASE3,Chronic Use of Acid Suppressive Medication; GORD; GERD; Reflux; Peptic Ulcer,pantoprazole 20 mg (drug) (DRUG),4594,OMZ,Chronic Use of Acid Suppressive Medication; GORD; GERD; Reflux; Peptic Ulcer,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7387,NCT02710994,Pharmacodynamics and Safety of CDFR0209,COMPLETED,PHASE1,Stomach Ulcer; Gastroesophageal Reflux,CDFR0209 (DRUG); Losec (DRUG),4594,OMZ,Stomach Ulcer; Gastroesophageal Reflux,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7388,NCT04930991,High Dose Omeprazole in Patients With Pancreatic Cancer,RECRUITING,EARLY_PHASE1,Exocrine Pancreatic Cancer,Omeprazole (DRUG),4594,OMZ,Exocrine Pancreatic Cancer,Pancreas,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7389,NCT01493089,Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease,COMPLETED,PHASE3,Gastroesophageal Reflux,Zegerid (DRUG); Losec (DRUG),4594,OMZ,Gastroesophageal Reflux,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7390,NCT01150162,"Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation",COMPLETED,PHASE3,Gastric Ulcer,Rebamipide and Omeprazole (DRUG); Omeprazole (DRUG),4594,OMZ,Gastric Ulcer,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7391,NCT03267680,IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3,TERMINATED,PHASE2,Cervical Squamous Cell Carcinoma In Situ; Vulvar High Grade Squamous Intraepithelial Lesion,Cyclophosphamide (DRUG); Indomethacin (DRUG); IRX-2 (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER); Multivitamin (DIETARY_SUPPLEMENT); Omeprazole (DRUG); Placebo (OTHER); Therapeutic Conventional Surgery (PROCEDURE),4594,OMZ,Cervical Squamous Cell Carcinoma In Situ; Vulvar High Grade Squamous Intraepithelial Lesion,Skin,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7392,NCT06255886,Treatment of Gastroesophageal Reflux Disease in Infants,NOT_YET_RECRUITING,PHASE4,"Gastroesophageal Reflux; Infant, Newborn, Diseases",Protein pump inhibitor. Continuing nutrition containing cows' milk protein. (DRUG); Mother or infant diet (BEHAVIORAL); Placebo (DRUG),4594,OMZ,"Gastroesophageal Reflux; Infant, Newborn, Diseases",Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7393,NCT02609386,"IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity",COMPLETED,PHASE2,Squamous Cell Carcinoma of the Oral Cavity,IRX-2 (BIOLOGICAL); Cyclophosphamide (DRUG); Indomethacin (DRUG); Zinc-containing multivitamin (DIETARY_SUPPLEMENT); Omeprazole (DRUG),4594,OMZ,Squamous Cell Carcinoma of the Oral Cavity,Skin,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7394,NCT00978016,A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD),COMPLETED,PHASE2,Gastroesophageal Reflux Disease,arbaclofen placarbil-Cohort 1 (DRUG); Placebo-Cohort 5 (DRUG); arbaclofen placarbil-Cohort 2 (DRUG); arbaclofen placarbil-Cohort 3 (DRUG); arbaclofen placarbil-Cohort 4 (DRUG); PPI (DRUG),4594,OMZ,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7395,NCT00915616,The Potential Therapeutic Effect of Melatonin in Gastro-Esophageal Reflux Disease,WITHDRAWN,PHASE3,Gastroesophageal Reflux Disease,Melatonin (DRUG),4594,OMZ,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7396,NCT02860624,Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients,COMPLETED,PHASE3,Gastroesophageal Reflux Disease,10 mg ilaprazole (DRUG); 40mg esomeprazole (DRUG),4594,OMZ,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7397,NCT04562116,A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis,COMPLETED,PHASE2,Atopic Dermatitis,Nemolizumab (DRUG); CYP 450 Substrates (DRUG),4594,OMZ,Atopic Dermatitis,Skin,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7398,NCT01287195,Oral OKT3 for the Treatment of Active Ulcerative Colitis,COMPLETED,PHASE1,Ulcerative Colitis,Oral OKT3 (DRUG); Omeprazole (DRUG),4594,OMZ,Ulcerative Colitis,Bowel,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7399,NCT00364481,Tongue Exercises and Reflux Therapy for Upper Airway Resistance Syndrome,WITHDRAWN,PHASE1,Obstructive Sleep Apnea; Upper Airway Resistance Syndrome; Gastroesophageal Reflux,omeprazole (DRUG); Tongue exercises (BEHAVIORAL),4594,OMZ,Obstructive Sleep Apnea; Upper Airway Resistance Syndrome; Gastroesophageal Reflux,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7400,NCT00226044,Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.,COMPLETED,PHASE3,"Gastroesophageal Reflux; Esophageal Atresia; Hernia, Diaphragmatic",Omeprazole rectally 1mg/kg (DRUG),4594,OMZ,"Gastroesophageal Reflux; Esophageal Atresia; Hernia, Diaphragmatic",Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7401,NCT00582972,Does Omeprazole Decrease Intestinal Calcium Absorption?,COMPLETED,PHASE4,Osteoporosis; Achlorhydria; GERD; Hip Fracture,Omeprazole (DRUG),4594,OMZ,Osteoporosis; Achlorhydria; GERD; Hip Fracture,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7402,NCT02772601,This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis,COMPLETED,PHASE1,Psoriasis,Caffeine (DRUG); Warfarin (DRUG); Omeprazole (DRUG); Metoprolol (DRUG); Midazolam (DRUG); Risankizumab (DRUG),4594,OMZ,Psoriasis,Skin,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7403,NCT01260844,"Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.",WITHDRAWN,PHASE1,Moderate to Severe Plaque Psoriasis,briakinumab (DRUG),4594,OMZ,Moderate to Severe Plaque Psoriasis,Skin,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7404,NCT04718740,A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer,COMPLETED,PHASE1,Recurrent Ovarian Cancer,fluzoparib (DRUG),4594,OMZ,Recurrent Ovarian Cancer,Ovary/Fallopian Tube,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7405,NCT00272467,Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy,COMPLETED,PHASE4,Stomach Ulcer,Rebamipide (DRUG); Omeprazole (DRUG),4594,OMZ,Stomach Ulcer,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7406,NCT00861640,Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding,UNKNOWN,PHASE4,Nonvariceal Upper Gastrointestinal Bleeding,Intravenous Omeprazole (DRUG); Oral Rabeprazole (DRUG),4594,OMZ,Nonvariceal Upper Gastrointestinal Bleeding,Bowel,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7407,NCT02794844,Implementation of PPI Medication PGX Testing,COMPLETED,PHASE4,Gastroesophageal Reflux,Genotype Guided PPI Dosing (DRUG),4594,OMZ,Gastroesophageal Reflux,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7408,NCT05624229,Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding,NOT_YET_RECRUITING,PHASE4,Upper Gastrointestinal Hemorrhage,Proton Pump Inhibitors (DRUG); No Proton Pump Inhibitors (DRUG),4594,OMZ,Upper Gastrointestinal Hemorrhage,Bowel,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7409,NCT03556592,Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4,COMPLETED,PHASE1,Atopic Dermatitis,Tralokinumab (DRUG); Caffeine (DRUG); Warfarin (DRUG); Omeprazole (DRUG); Metoprolol (DRUG); Midazolam Hydrochloride (DRUG),4594,OMZ,Atopic Dermatitis,Skin,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7410,NCT02703896,Prophylaxis for Aspiration of Gastric Contents.,COMPLETED,PHASE4,Pulmonary Aspiration of Gastric Contents,Drug either PPIS or H2RA and prokinetics (DRUG); orogastric intubation (PROCEDURE),4594,OMZ,Pulmonary Aspiration of Gastric Contents,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7411,NCT03238534,Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS,COMPLETED,PHASE4,GERD; EPS,Neobianacid® (DEVICE); Omeprazole 20mg (DRUG); Neobianacid® placebo (OTHER); Omeprazole placebo (OTHER),4594,OMZ,GERD; EPS,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7412,NCT03457727,GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects,COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive",Danirixin (DRUG); Omeprazole (DRUG),4594,OMZ,"Pulmonary Disease, Chronic Obstructive",Lung,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7413,NCT03781596,EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone,UNKNOWN,PHASE4,Eosinophilic Esophagitis,Retrospective evaluation of endoscopy prior to study drug (DIAGNOSTIC_TEST); Symptom Survey (OTHER); Medication Compliance Phone Call (OTHER); Endoscopy while on study drug (DIAGNOSTIC_TEST); Symptom Survey (OTHER); Fluticasone (DRUG); Omeprazole (DRUG); Placebo oral capsule (DRUG),4594,OMZ,Eosinophilic Esophagitis,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7414,NCT06949124,"A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects",NOT_YET_RECRUITING,PHASE1,Endometriosis; Uterine Fibroids; Assisted Reproduction,SHR7280 Tablets (DRUG),4594,OMZ,Endometriosis; Uterine Fibroids; Assisted Reproduction,Uterus,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7415,NCT03980496,Effects of Different Omeprazole Dosing on Gastric pH in Non-variceal Upper Gastrointestinal Bleeding,COMPLETED,PHASE4,Non-variceal Upper Gastrointestinal Bleeding,Omeprazole (DRUG),4594,OMZ,Non-variceal Upper Gastrointestinal Bleeding,Bowel,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7416,NCT01499368,"A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients",COMPLETED,PHASE3,Erosive Esophagitis,Lafutidine (DRUG); Famotidine (DRUG); Omeprazole (DRUG),4594,OMZ,Erosive Esophagitis,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7417,NCT02125604,Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany,COMPLETED,PHASE4,Relapsing-Remitting Multiple Sclerosis,dimethyl fumarate (DRUG),4594,OMZ,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7418,NCT00995410,Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers,COMPLETED,PHASE3,Aspirin-Associated Gastric Ulcers,PA32540 (DRUG),4594,OMZ,Aspirin-Associated Gastric Ulcers,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7419,NCT01745510,Enteral Administration of Docosahexaenoic Acid to Prevent Necrotizing Enterocolitis in Preterm Neonates,COMPLETED,PHASE1,Necrotizing Enterocolitis,Docosahexaenoic acid (DHA) (DIETARY_SUPPLEMENT); Placebo (DIETARY_SUPPLEMENT),4594,OMZ,Necrotizing Enterocolitis,Bowel,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7420,NCT00960869,Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers,COMPLETED,PHASE3,Gastric Ulcer,PA32540 (DRUG); EC-Aspirin 325 mg (DRUG),4594,OMZ,Gastric Ulcer,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7421,NCT02272868,Fecal Microbial Transplant in Pediatric Crohn's Disease,TERMINATED,PHASE1,Crohn's Disease,Fecal Microbial transplant (BIOLOGICAL); Normal Saline (DRUG); rifaximin+omeprazole+miralax (DRUG),4594,OMZ,Crohn's Disease,Bowel,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7422,NCT00374101,High Versus Standard Dose of Proton Pump Inhibitors (PPIs) in Peptic Ulcer Bleeding,COMPLETED,PHASE3,Peptic Ulcers; Upper Gastrointestinal Bleeding,omeprazole (DRUG); pantoprazole (DRUG),4594,OMZ,Peptic Ulcers; Upper Gastrointestinal Bleeding,Bowel,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7423,NCT01136317,Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects,COMPLETED,PHASE2,Gastroesophageal Reflux,Omeprazole (DRUG); Rabeprazole (DRUG); Lactose (DRUG),4594,OMZ,Gastroesophageal Reflux,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7424,NCT02407119,Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD,ACTIVE_NOT_RECRUITING,PHASE3,Helicobacter Pylori Infection; Early Gastric Cancer; Endoscopic Resection,"7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin (DRUG); Placebo, Omeprazole or Rabeprazole, Clarithromycin (DRUG)",4594,OMZ,Helicobacter Pylori Infection; Early Gastric Cancer; Endoscopic Resection,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7425,NCT05891119,Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis,COMPLETED,EARLY_PHASE1,Atopic Dermatitis,Caffeine (DIETARY_SUPPLEMENT); Metoprolol (DRUG); Midazolam (DRUG); Warfarin (DRUG); Vitamin K (DIETARY_SUPPLEMENT); Omeprazole (DRUG); Rocatinlimab (DRUG),4594,OMZ,Atopic Dermatitis,Skin,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7426,NCT06099119,Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.,NOT_YET_RECRUITING,PHASE4,Unresectable Pancreatic Cancer,creon 35.000 Ph.U (R) (DRUG); Best Standarard of Care (OTHER),4594,OMZ,Unresectable Pancreatic Cancer,Pancreas,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7427,NCT01129713,Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.,UNKNOWN,PHASE1,Gastroesophageal Reflux Disease (GERD); Heartburn; Indigestion,Secretol (DRUG); Nexium (DRUG),4594,OMZ,Gastroesophageal Reflux Disease (GERD); Heartburn; Indigestion,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7428,NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,COMPLETED,PHASE3,Relapsing-Remitting Multiple Sclerosis,Midazolam (DRUG); Caffeine (OTHER); S-warfarin (DRUG); Vitamin K (OTHER); Omeprazole (DRUG); Dextromethorphan (DRUG); BIIB019 (Daclizumab) (BIOLOGICAL),4594,OMZ,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7429,NCT04660123,A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication,COMPLETED,PHASE4,Gastric Cancer; Helicobacter Pylori Infection; Bismuth,Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication (DRUG),4594,OMZ,Gastric Cancer; Helicobacter Pylori Infection; Bismuth,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7430,NCT01265550,A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors,COMPLETED,PHASE3,GERD,Nissen fundoplication (DEVICE); baclofen (DRUG); Desipramine (DRUG),4594,OMZ,GERD,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7431,NCT01876108,The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-alcoholic Fatty Liver Disease,COMPLETED,PHASE2,Fatty Liver; Liver Dysfunction; Insulin Resistance,"H.pylori eradication (Omeprazole, Amoxicillin, Bismuth subcitrate, Azithromycin) (DRUG)",4594,OMZ,Fatty Liver; Liver Dysfunction; Insulin Resistance,Liver,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7432,NCT00692510,Drug Interaction Study Between AZD3480 and Cytochrome P450,COMPLETED,PHASE1,Metabolism; Alzheimer's Disease,"AZD3480 (DRUG); Placebo (DRUG); Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin) (DRUG)",4594,OMZ,Metabolism; Alzheimer's Disease,CNS/Brain,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7433,NCT06664008,The Effect of Probiotic and Zinc Supplementation in Patients With Gastroesophageal Reflux Disease,NOT_YET_RECRUITING,PHASE4,Gastro-oesophageal Reflux Disease,PPI (proton pump inhibitor) (DRUG); Probiotic (DRUG); Zinc (DRUG),4594,OMZ,Gastro-oesophageal Reflux Disease,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7434,NCT00634114,Reflux Esophagitis Phase III Study (Maintenance Treatment),COMPLETED,PHASE3,Reflux Esophagitis,Esomeprazole (DRUG); Esomeprazole (DRUG); Omeprazole (DRUG),4594,OMZ,Reflux Esophagitis,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7435,NCT00961350,A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers,COMPLETED,PHASE3,Gastric Ulcer,PA32540 (DRUG); EC Aspirin 325 (DRUG),4594,OMZ,Gastric Ulcer,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7436,NCT03367195,Efficacy and Safety of DLBS2411 in the Management of GERD,TERMINATED,PHASE3,Gastroesophageal Reflux Disease (GERD),Omeprazole (DRUG); DLBS2411 (DRUG); Placebo capsule of Omeprazole (DRUG); Placebo caplet of DLBS2411 (DRUG),4594,OMZ,Gastroesophageal Reflux Disease (GERD),Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7437,NCT03291249,"Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM",WITHDRAWN,PHASE2,NASH - Nonalcoholic Steatohepatitis; NAFLD; T2DM (Type 2 Diabetes Mellitus),Foralumab (DRUG); placebo (OTHER); Omeprazole 20mg (DRUG),4594,OMZ,NASH - Nonalcoholic Steatohepatitis; NAFLD; T2DM (Type 2 Diabetes Mellitus),Liver,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7438,NCT02685436,Role of Pepsin Assay in Wheezy Infants,COMPLETED,PHASE4,Gastroesophageal Reflux Disease,Omeprazole and domperidone (DRUG),4594,OMZ,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7439,NCT01654549,Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis,COMPLETED,PHASE2,Non-alcoholic Fatty Liver Disease,H.pylori eradication (DRUG),4594,OMZ,Non-alcoholic Fatty Liver Disease,Liver,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7440,NCT03358706,A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis,TERMINATED,PHASE1,Crohn Disease; Ulcerative Colitis,Ustekinumab IV Infusion (DRUG); Ustekinumab SC Injection (DRUG); Midazolam 2 mg (DRUG); Warfarin 10 mg (DRUG); Vitamin K 10 mg (DRUG); Omeprazole 20 mg (DRUG); Dextromethorphan 30 mg (DRUG); Caffeine 100 mg (DRUG),4594,OMZ,Crohn Disease; Ulcerative Colitis,Bowel,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7441,NCT01001299,A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma,COMPLETED,PHASE1,Malignant Melanoma,Drug cocktail (DRUG); RO5185426 (DRUG),4594,OMZ,Malignant Melanoma,Skin,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7442,NCT00210470,A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer,COMPLETED,PHASE2,Squamous Cell Carcinoma of the Head and Neck,IRX-2 (BIOLOGICAL); Cyclophosphamide (DRUG); Indomethacin (DRUG); Zinc (DRUG); Omeprazole (DRUG),4594,OMZ,Squamous Cell Carcinoma of the Head and Neck,Skin,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7443,NCT00818870,Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH,COMPLETED,PHASE1,Gastroesophageal Reflux,Omeprazole (DRUG); Vecam (DRUG); Vecam (DRUG),4594,OMZ,Gastroesophageal Reflux,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7444,NCT05680870,The Possible Protective Role of Omeprazole Against Oxaliplatin Induced Neuropathy in Cancer Patients,UNKNOWN,PHASE3,Chemotherapy Induced Peripheral Neuropathy,Omeprazole (DRUG),4594,OMZ,Chemotherapy Induced Peripheral Neuropathy,Peripheral Nervous System,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7445,NCT01824199,CYP2C19 Genotype Predictor of Gastric Acid Suppression,WITHDRAWN,EARLY_PHASE1,Esophagitis,Omeprazole (DRUG),4594,OMZ,Esophagitis,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7446,NCT03864042,Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors,COMPLETED,PHASE1,Advanced Solid Tumors; Metastatic Melanoma,losartan (DRUG); dextromethorphan (DRUG); caffeine (DRUG); omeprazole (DRUG); midazolam (DRUG); rosuvastatin (DRUG); bupropion immediate release (IR) (DRUG); encorafenib (DRUG); binimetinib (DRUG); modafinil (DRUG),4594,OMZ,Advanced Solid Tumors; Metastatic Melanoma,Skin,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7447,NCT00765206,A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED),COMPLETED,PHASE3,Gastric Acid; Human Experimentation,Omeprazole/sodium bicarbonate (DRUG); omeprazole magnesium (20 mg equivalent) (DRUG),4594,OMZ,Gastric Acid Studies,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7448,NCT02422706,Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori,UNKNOWN,PHASE3,Helicobacter-associated Gastritis,Nitazoxanide (DRUG); Metronidazole(MTZ) (DRUG); Omeprazole (DRUG); Clarithromycin (DRUG); Levofloxacin (DRUG); Doxicycline (DRUG),4594,OMZ,Helicobacter-associated Gastritis,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7449,NCT05134584,Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders,UNKNOWN,PHASE4,Functional Dyspepsia; Constipation-predominant Irritable Bowel Syndrome,Linaclotide (DRUG); Lactulose (DRUG); Omeprazol (DRUG); Itopride (DRUG),4594,OMZ,Functional Dyspepsia; Constipation-predominant Irritable Bowel Syndrome,Bowel,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7450,NCT00559364,Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea,COMPLETED,PHASE3,Exocrine Pancreatic Insufficiency; Chronic Pancreatitis; Pancreatectomy,Viokase® 16 (DRUG); Placebo (DRUG); Proton pump inhibitor (PPI) (DRUG); Omeprazole (DRUG),4594,OMZ,Exocrine Pancreatic Insufficiency; Chronic Pancreatitis; Pancreatectomy,Pancreas,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7451,NCT03718884,A Study of Mirikizumab in Participants With Plaque Psoriasis,COMPLETED,PHASE1,Psoriasis,Drug Cocktail (DRUG); Mirikizumab (DRUG),4594,OMZ,Psoriasis,Skin,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7452,NCT01489943,"A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects",COMPLETED,PHASE1,Crohn's Disease,GSK1605786 500 mg (DRUG); Midazolam 3 mg (DRUG); Pioglitazone 15 mg (DRUG); Omeprazole 40 mg (DRUG); Rosuvastatin 10 mg (DRUG),4594,OMZ,Crohn's Disease,Bowel,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7453,NCT01002443,Efficacy Study of Helicobacter Pylori Eradication in Patients Undergoing Subtotal Gastrectomy for Gastric Cancer,COMPLETED,PHASE2,Gastric Cancer,Helicobacter pylori eradication (DRUG); placebo (DRUG),4594,OMZ,Gastric Cancer,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7454,NCT00003617,Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach,UNKNOWN,PHASE3,Gastric Cancer,chlorambucil (DRUG); clarithromycin (DRUG); omeprazole (DRUG); tinidazole (DRUG),4594,OMZ,Gastric Cancer,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7455,NCT02085018,Pilot Trial Of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF),COMPLETED,PHASE2,Idiopathic Pulmonary Fibrosis,Omeprazole (DRUG); Matched placebo (DRUG),4594,OMZ,Idiopathic Pulmonary Fibrosis,Lung,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7456,NCT04149470,Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE),ACTIVE_NOT_RECRUITING,PHASE4,Eosinophilic Esophagitis,Omeprazole 20mg BID (DRUG),4594,OMZ,Eosinophilic Esophagitis,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7457,NCT05273775,A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers,COMPLETED,PHASE1,Chronic Hepatitis B,HRS5091 Tablets (DRUG); Midazolam Maleate Tablets (DRUG); Warfarin Sodium Tablets (DRUG); Omeprazole Enteric Capsules (DRUG); Vitamin K1 Tablets (DRUG); Digoxin Tablets (DRUG); Rosuvastatin Calcium Tablets (DRUG),4594,OMZ,Chronic Hepatitis B,Liver,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7458,NCT02950259,Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC),ACTIVE_NOT_RECRUITING,PHASE1,"Breast Neoplasm; Breast Neoplasm, Male; Triple Negative Breast Cancer",Cyclophosphamide (DRUG); Indomethacin (DRUG); Omeprazole (DRUG); Multivitamin (DIETARY_SUPPLEMENT),4594,OMZ,"Breast Neoplasm; Breast Neoplasm, Male; Triple Negative Breast Cancer",Breast,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7459,NCT01205087,Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome,COMPLETED,PHASE2,Nonalcoholic Steatohepatitis,OKT3 (DRUG),4594,OMZ,Nonalcoholic Steatohepatitis,Liver,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7460,NCT02299687,Influence of CYP2C19 Polymorphism on PK/PD of Omeprazole,COMPLETED,PHASE1,Stomach Ulcer,Omeprazole (DRUG),4594,OMZ,Stomach Ulcer,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7461,NCT01822106,"Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD)",UNKNOWN,PHASE4,Gastroesophageal Reflux Disease,Placebo (OTHER),4594,OMZ,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7462,NCT01459419,Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects,UNKNOWN,PHASE2,Chronic Hepatitis C,anti-CD3 monoclonal antibody (DRUG); Sodium Chloride placebo (DRUG),4594,OMZ,Chronic Hepatitis C,Liver,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7463,NCT00633932,Reflux Esophagitis Phase III Study (Initial Treatment),COMPLETED,PHASE3,Reflux Esophagitis,Esomeprazole (DRUG); Esomeprazole (DRUG); Omeprazole (DRUG),4594,OMZ,Reflux Esophagitis,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7464,NCT00045799,Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill,COMPLETED,PHASE3,Upper Gastrointestinal Bleeding,Omeprazole sodium bicarbonate immediate release PWD/FS (DRUG); Cimetidine IV (DRUG),4594,OMZ,Upper Gastrointestinal Bleeding,Bowel,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7465,NCT01813552,To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006),COMPLETED,PHASE1,Chronic Hepatitis C Infection,Samatasvir (DRUG); Omeprazole (DRUG); Ritonavir (DRUG),4594,OMZ,Chronic Hepatitis C Infection,Liver,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7466,NCT00256737,Sopran - Omeprazole Treatment Versus Surgery,COMPLETED,PHASE3,GERD,Omeprazole (DRUG),4594,OMZ,GERD,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7467,NCT00674115,A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED),COMPLETED,PHASE3,Gastric Acid; Human Experimentation,Omeprazole/sodium bicarbonate (DRUG); omeprazole magnesium (DRUG); sodium bicarbonate (DRUG),4594,OMZ,Gastric Acid Studies,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7468,NCT02922699,Efficacy and Saafety of Omez Iin Patients With H.Pylori Associated Diseases,COMPLETED,PHASE4,GERD,OMEZ 40 (DRUG); OMEZ 80 (DRUG),4594,OMZ,GERD,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7469,NCT00664209,Treating H. Pylori in Parkinson's Patients With Motor Fluctuations,TERMINATED,PHASE3,Parkinson's Disease; Helicobacter Infections; Motor Fluctuations,"clartihromycin, amoxicillin, and omeprazole (DRUG); placebo (DRUG)",4594,OMZ,Parkinson's Disease; Helicobacter Infections; Motor Fluctuations,CNS/Brain,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7470,NCT04118647,Effective Mechanisms of Wu-Chu-Yu Tang on Gastroesophageal Disorder,UNKNOWN,PHASE4,Wu-Chu-Yu Tang; Gastroesophageal Reflux Disorder; 24 Hours Esophageal PH and Multichannel Intraluminal Impedance Testing,Wu-Chu-Yu tang (DRUG),4594,OMZ,Wu-Chu-Yu Tang; Gastroesophageal Reflux Disorder; 24 Hours Esophageal PH and Multichannel Intraluminal Impedance Testing,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7471,NCT01458054,Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults,COMPLETED,PHASE1,Hepatitis C,"Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose) (DRUG); Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose) (DRUG)",4594,OMZ,Hepatitis C,Liver,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7472,NCT02584751,GERD and Anti-Reflux Therapy Between Able-bodied and SCI Individuals,UNKNOWN,PHASE1,Gastro Esophageal Reflux Disorder,Omeprazole (DRUG); 24 Hour pH Monitor (DEVICE); Pulmonary Function Examination (PROCEDURE); Exhaled Nitric Oxide (PROCEDURE); Exhaled Breath Concentrate (EBC) (PROCEDURE); Bernstein's Acid Clearance Test (PROCEDURE); Esophageal Motility (PROCEDURE),4594,OMZ,Gastro Esophageal Reflux Disorder,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7473,NCT00259051,A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population,COMPLETED,PHASE3,Non-erosive Reflux Disease,Omeprazole (DRUG),4594,OMZ,Gastroesophageal Reflux Disease,Esophagus/Stomach,Omeprazole,,inhibitor/antagonist,unclear,yes,yes,Used as part of racemic mixture for acid-related conditions.,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,1.44,153.0 +7474,NCT05566457,HGWD Improve the Paclitaxel-related Neurotoxicity in Patients With BC,UNKNOWN,PHASE2,Breast Cancer,Huangqi Guizhi Wuwu decoction (HGWD) infusion packs (DRUG),1054,PN,Breast Cancer,Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7475,NCT01362582,Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With Pancreatic Cancer,TERMINATED,PHASE3,Pancreatic Cancer,SMOF Kabiven (DRUG),1054,PN,Pancreatic Cancer,Pancreas,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7476,NCT00826020,Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis,COMPLETED,PHASE2,Parenteral Nutrition Associated Liver Disease PNALD; Cholestasis,Omegaven™ (DRUG),1054,PN,Parenteral Nutrition Associated Liver Disease PNALD; Cholestasis,Liver,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7477,NCT06117774,Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC),RECRUITING,PHASE3,Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer,Tarlatamab (DRUG); Placebo (DRUG),1054,PN,Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer,Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7478,NCT01206166,Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP),TERMINATED,PHASE3,Critical Illness; Acute Respiratory Failure,Olimel (5.7%E / N9E) (DRUG),1054,PN,Critical Illness; Acute Respiratory Failure,Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7479,NCT01523574,Vitamin E for Oxaliplatin-induced Peripheral Neuropathy Prophylaxis,COMPLETED,PHASE2,Peripheral Neuropathy,Vitamin E (DRUG); Placebo (DRUG),1054,PN,Peripheral Neuropathy,Peripheral Nervous System,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7480,NCT04607057,Supplemental Parenteral Nutrition During Postgastrectomy in Nutritionally at Risk Patient,UNKNOWN,PHASE4,Gastric Cancer; Gastrectomy; Malnutrition,Parenteral Nutrition Solutions (DRUG),1054,PN,Gastric Cancer; Gastrectomy; Malnutrition,Esophagus/Stomach,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7481,NCT03319069,Post Mastectomy Hypofractionated Radiotherapy in High Risk Breast Cancer,UNKNOWN,PHASE3,Breast Cancer,Hypofractionated radiotherapy (RADIATION); Conventional fractionated radiotherapy (RADIATION),1054,PN,Breast Cancer,Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7482,NCT03663582,Study of Teduglutide in Japanese Participants With Short Bowel Syndrome,COMPLETED,PHASE3,Short Bowel Syndrome,Teduglutide (DRUG); Syringe (DEVICE); Needle (DEVICE); Vial Adapter for Device (DEVICE),1054,PN,Short Bowel Syndrome,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7483,NCT00788931,A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer,COMPLETED,PHASE1,HER-2 Positive Breast Cancer; Metastatic Breast Cancer,IV LBH589 (DRUG); Oral LBH589 (DRUG); trastuzumab (DRUG); paclitaxel (DRUG),1054,PN,HER-2 Positive Breast Cancer; Metastatic Breast Cancer,Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7484,NCT02448992,Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer,RECRUITING,PHASE2,Non-Small-Cell Lung Cancer (NSCLC); Brain Metastasis,hippocampal-sparing WBRT (RADIATION),1054,PN,Non-Small-Cell Lung Cancer (NSCLC); Brain Metastasis,Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7485,NCT03495960,Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System,COMPLETED,PHASE2,Primary Central Nervous System Lymphoma,Rituximab (DRUG); Methotrexate (DRUG); Procarbazine (DRUG); Lenalidomide (DRUG); Radiotherapy (RADIATION); Temozolomide (DRUG),1054,PN,Primary Central Nervous System Lymphoma,CNS/Brain,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7486,NCT02523768,Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment,TERMINATED,PHASE4,Glomerulonephritis; IgAN,ATG-F (DRUG); Simulect (DRUG),1054,PN,Glomerulonephritis; IgAN,Kidney,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7487,NCT00038467,Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer,COMPLETED,PHASE3,Breast Neoplasms,Tamoxifen (DRUG); Exemestane (DRUG),1054,PN,Breast Neoplasms,Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7488,NCT01000025,PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer,COMPLETED,PHASE3,Lung Cancer,PF-00299804 (DRUG); Placebo (DRUG),1054,PN,Lung Cancer,Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7489,NCT01853826,An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s),COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung",Afatinib (DRUG),1054,PN,"Carcinoma, Non-Small-Cell Lung",Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7490,NCT04627025,Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF,COMPLETED,PHASE3,Short Bowel Syndrome,apraglutide (DRUG),1054,PN,Short Bowel Syndrome,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7491,NCT02295930,Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient,COMPLETED,PHASE2,Metastatic Colorectal Cancer,folfoxiri+cetuximab+surgery+cetuximab (OTHER); folfoxiri+cetuximab+surgery+bevacizumab (OTHER),1054,PN,Metastatic Colorectal Cancer,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7492,NCT03874325,Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer,TERMINATED,PHASE2,Breast Cancer; Hormone Receptor Positive Tumor,Durvalumab (DRUG); Anastrozole 1mg (DRUG); Letrozole 2.5mg (DRUG); Exemestane 25 MG (DRUG),1054,PN,Breast Cancer; Hormone Receptor Positive Tumor,Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7493,NCT01834430,Effects of Delayed Enteral Nutrition on Inflammatory Responses and Immune Function Competence in Critically Ill Patients With Prolonged Fasting,COMPLETED,PHASE3,Severe Acute Pancreatitis Patients; Duodenal Fistula; Inflammatory Intestinal Obstruction,enteral nutrition (DIETARY_SUPPLEMENT),1054,PN,Severe Acute Pancreatitis Patients; Duodenal Fistula; Inflammatory Intestinal Obstruction,Pancreas,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7494,NCT02478086,Effects of High vs. Standard Protein Intake in Newborn Extreme Premature,COMPLETED,PHASE2,Abnormal Renal Function; Malnutrition,use amine acids parenteral 3.5g (DIETARY_SUPPLEMENT); use amine acids parenteral 4g (DIETARY_SUPPLEMENT),1054,PN,Abnormal Renal Function; Malnutrition,Kidney,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7495,NCT04475939,Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE3,"Lung Cancer, Non-Small Cell",Niraparib (DRUG); Pembrolizumab (BIOLOGICAL); Placebo (DRUG),1054,PN,"Lung Cancer, Non-Small Cell",Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7496,NCT03562130,"Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients",COMPLETED,PHASE4,Short Bowel Syndrome,Teduglutide (DRUG),1054,PN,Short Bowel Syndrome,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7497,NCT02273973,A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI),COMPLETED,PHASE2,Breast Cancer,Letrozole (DRUG); Placebo (OTHER); Taselisib (DRUG),1054,PN,Breast Cancer,Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7498,NCT01970865,A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,COMPLETED,PHASE1,ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC,PF-06463922 (DRUG); Crizotinib (DRUG),1054,PN,ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC,Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7499,NCT02323126,Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer,TERMINATED,PHASE2,Non Small Cell Lung Cancer,EGF816 (DRUG); INC280 (DRUG); Nivolumab (DRUG),1054,PN,Non Small Cell Lung Cancer,Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7500,NCT02865122,Safety and Efficacy Study in Infant With SBS,TERMINATED,PHASE2,Short Bowel Syndrome,NTRA-9620 (DRUG); Placebo (DRUG),1054,PN,Short Bowel Syndrome,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7501,NCT06065748,"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)",RECRUITING,PHASE3,"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer",Giredestrant (DRUG); Fulvestrant (DRUG); Abemaciclib (DRUG); Palbociclib (DRUG); Ribociclib (DRUG); LHRH Agonist (DRUG); FoundationOne Liquid CDx Assay (F1LCDx) (DIAGNOSTIC_TEST),1054,PN,"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer",Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7502,NCT01952080,"A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome",COMPLETED,PHASE3,Short Bowel Syndrome,teduglutide (DRUG),1054,PN,Short Bowel Syndrome,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7503,NCT06259929,"NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer",RECRUITING,PHASE2,Breast Cancer,Abemaciclib 150 MG + Giredestrant 30 MG (DRUG),1054,PN,Breast Cancer,Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7504,NCT05919680,A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).,RECRUITING,PHASE2,Intestinal Failure Associated Liver Disease,NST-6179 Part A (DRUG); NST-6179 Part B (DRUG); Matched Placebo (OTHER),1054,PN,Intestinal Failure Associated Liver Disease,Liver,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7505,NCT03770689,Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer,COMPLETED,PHASE1,Locally Advanced Rectal Cancer,Peposertib 50 mg (DRUG); Peposertib 100 mg (DRUG); Peposertib 150 mg (DRUG); Peposertib 250 mg (DRUG); Capecitabine (DRUG); Radiotherapy (RT) (RADIATION),1054,PN,Rectal Cancer,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7506,NCT03371862,Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS),WITHDRAWN,PHASE2,Short Bowel Syndrome,Liraglutide Pen Injector [Victoza] (DRUG),1054,PN,Short Bowel Syndrome,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7507,NCT00929162,ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer,TERMINATED,PHASE2,Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy,ZD4054 Zibotentan (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Placebo (DRUG),1054,PN,Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy,Ovary/Fallopian Tube,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7508,NCT06783491,Efficacy of the Use of Neoadjuvant With/without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer,NOT_YET_RECRUITING,PHASE3,Locally Advanced Colorectal Cancer,"Mitomycin (MM) (DRUG); FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) (DRUG); Cytoreductive surgery (PROCEDURE)",1054,PN,Locally Advanced Colorectal Cancer,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7509,NCT01633060,"A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi",TERMINATED,PHASE3,Metastatic Breast Cancer,Fulvestrant (DRUG); BKM120 (DRUG); BKM120 matching placebo (DRUG),1054,PN,Metastatic Breast Cancer,Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7510,NCT06726291,Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer,RECRUITING,PHASE4,Endometrial Cancer,NEPA (300mg netupitant/0.5mg palonosetron) (DRUG),1054,PN,Endometrial Cancer,Uterus,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7511,NCT00403429,MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer,COMPLETED,PHASE2,Ovarian Cancer,capecitabine (DRUG),1054,PN,Ovarian Cancer,Ovary/Fallopian Tube,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7512,NCT05038735,"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.",RECRUITING,PHASE3,Breast Cancer,Alpelisib (DRUG); Fulvestrant (DRUG); Alpelisib-matching placebo (DRUG),1054,PN,Breast Cancer,Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7513,NCT01368263,Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer,TERMINATED,PHASE2,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,goserelin acetate (DRUG); letrozole (DRUG); anastrozole (DRUG); chemotherapy (DRUG); Surgery (PROCEDURE),1054,PN,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7514,NCT01573286,Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure,TERMINATED,PHASE1,Intestinal Failure; Short Bowel Syndrome,Glucagon-Like Peptide 2 (DRUG); Glucagon like peptide-2 (DRUG),1054,PN,Intestinal Failure; Short Bowel Syndrome,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7515,NCT03571516,"Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome",COMPLETED,PHASE3,Short Bowel Syndrome,Teduglutide (DRUG); Standard Medical Therapy (OTHER); Syringe (DEVICE); Needle (DEVICE),1054,PN,Short Bowel Syndrome,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7516,NCT05526716,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)",COMPLETED,PHASE3,"Pneumonia, Pneumococcal",V116 (BIOLOGICAL); QIV (BIOLOGICAL); Matching Placebo for V116 (BIOLOGICAL),1054,PN,"Pneumonia, Pneumococcal",Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7517,NCT00051363,Apnea Positive Pressure Long-Term Efficacy Study,COMPLETED,PHASE3,Lung Diseases; Sleep Apnea Syndromes; Sleep,Active CPAP (DEVICE); Sham CPAP (DEVICE),1054,PN,Lung Diseases; Sleep Apnea Syndromes; Sleep,Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7518,NCT04581824,Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC),TERMINATED,PHASE2,"Lung Cancer, Non-Small Cell",Dostarlimab (DRUG); Pembrolizumab (DRUG); Chemotherapy (DRUG),1054,PN,"Lung Cancer, Non-Small Cell",Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7519,NCT02926196,Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab,ACTIVE_NOT_RECRUITING,PHASE3,Triple Negative Breast Neoplasms,MSB0010718C (DRUG),1054,PN,Triple Negative Breast Neoplasms,Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7520,NCT06903260,Robot-assisted Partial Nephrectomy With and Without Mixed Reality (REALITATEM Study),COMPLETED,PHASE3,Kidney Cancer,Mixed Reality (COMBINATION_PRODUCT),1054,PN,Kidney Cancer,Kidney,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7521,NCT02868580,Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,Triumeq (DRUG),1054,PN,Amyotrophic Lateral Sclerosis,CNS/Brain,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7522,NCT03916510,Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer,COMPLETED,PHASE1,Locally Advanced Rectal Cancer,Enadenotucirev (BIOLOGICAL); Capecitabine (DRUG); Radiotherapy (RADIATION),1054,PN,Rectal Cancer,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7523,NCT00809081,Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy,UNKNOWN,PHASE3,Pancreas Cancer; Bile Duct Cancer; Ampulla of Vater Cancer,Enteral Feeding and Total Parental Support (PROCEDURE),1054,PN,Pancreas Cancer; Bile Duct Cancer; Ampulla of Vater Cancer,Pancreas,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7524,NCT01633281,Acupuncture for Peripheral Neuropathy,TERMINATED,PHASE2,Peripheral Neuropathy Grade 2 or Greater,acupuncture (PROCEDURE),1054,PN,Peripheral Neuropathy Grade 2 or Greater,Peripheral Nervous System,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7525,NCT01444781,Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants,COMPLETED,PHASE3,Diphtheria; Tetanus; Whooping Cough; Hepatitis B; Poliomyelitis,DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide (BIOLOGICAL); DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide (BIOLOGICAL); DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine (BIOLOGICAL),1054,PN,Diphtheria; Tetanus; Whooping Cough; Hepatitis B; Poliomyelitis,Liver,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7526,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,COMPLETED,PHASE3,Kidney Neoplasms,Axitinib (AG-013736) (DRUG); Sorafenib (DRUG),1054,PN,Kidney Neoplasms,Kidney,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7527,NCT03294304,"BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy",COMPLETED,PHASE2,Muscle Invasive Bladder Cancer,Nivolumab (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG),1054,PN,Muscle Invasive Bladder Cancer,Bladder/Urinary Tract,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7528,NCT01697072,"First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma",TERMINATED,PHASE3,Gastric Cancer,Rilotumumab (DRUG); Placebo (OTHER); Epirubicin (DRUG); Cisplatin (DRUG); Capecitabine (DRUG),1054,PN,Gastric Cancer,Esophagus/Stomach,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7529,NCT00798967,Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects,COMPLETED,PHASE3,Short Bowel Syndrome,teduglutide (DRUG); placebo (DRUG),1054,PN,Short Bowel Syndrome,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7530,NCT00527904,"A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)",COMPLETED,PHASE3,Gastric Ulcer,PN400 (VIMOVO) (DRUG); PN 400 (VIMOVO) (DRUG),1054,PN,Gastric Ulcer,Esophagus/Stomach,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7531,NCT03300544,"Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer",TERMINATED,PHASE1,Locally Advanced Rectal Adenocarcinoma; Metastatic Rectal Adenocarcinoma; Rectal Adenocarcinoma; Stage III Rectal Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Rectal Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7,Capecitabine (DRUG); Fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Radiation Therapy (RADIATION); Talimogene Laherparepvec (BIOLOGICAL),1054,PN,Locally Advanced Rectal Adenocarcinoma; Metastatic Rectal Adenocarcinoma; Rectal Adenocarcinoma; Stage III Rectal Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Rectal Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7532,NCT00930644,Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS),COMPLETED,PHASE3,Short Bowel Syndrome,teduglutide (DRUG),1054,PN,Short Bowel Syndrome,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7533,NCT06023589,A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma,RECRUITING,PHASE3,Asthma,Tezepelumab (BIOLOGICAL); Placebo (OTHER),1054,PN,Asthma,Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7534,NCT00081458,Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome,COMPLETED,PHASE3,Short Bowel Syndrome,Placebo (DRUG); Teduglutide 0.05 mg/kg/d (DRUG); Teduglutide 0.1 mg/kg/d (DRUG),1054,PN,Short Bowel Syndrome,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7535,NCT00553358,Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study,COMPLETED,PHASE3,"Neoplasms, Breast",Lapatinib (DRUG); Trastuzumab (BIOLOGICAL); Paclitaxel (DRUG),1054,PN,"Neoplasms, Breast",Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7536,NCT02340819,"Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS)",COMPLETED,PHASE3,Short Bowel Syndrome,Teduglutide (DRUG),1054,PN,Short Bowel Syndrome,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7537,NCT00776919,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,COMPLETED,PHASE3,Acne Vulgaris,clindamycin / benzoyl peroxide gel (DRUG); clindamycin gel (DRUG); BPO gel (DRUG); vehicle gel (DRUG),1054,PN,Acne Vulgaris,Skin,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7538,NCT02176369,Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial,COMPLETED,PHASE2,Non-small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer Stage IV,Vinorelbine (DRUG),1054,PN,Non-small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer Stage IV,Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7539,NCT01923168,"Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women",COMPLETED,PHASE2,Breast Cancer,alpelisib (DRUG); buparlisib (DRUG); Placebo (DRUG),1054,PN,Breast Cancer,Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7540,NCT02236572,"Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score",TERMINATED,PHASE2,Breast Cancer,Everolimus (DRUG),1054,PN,Breast Cancer,Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7541,NCT06904872,Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC),NOT_YET_RECRUITING,PHASE2,Short Bowel Syndrome; Malabsorption Syndromes; Short Gut Syndrome; Post-Op Complication; Functional Gastrointestinal Disorders,Crofelemer Powder for Oral Solution (DRUG); Matched Placebo Powder for Oral Solution (DRUG),1054,PN,Short Bowel Syndrome; Malabsorption Syndromes; Short Gut Syndrome; Post-Op Complication; Functional Gastrointestinal Disorders,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7542,NCT01154140,A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung,COMPLETED,PHASE3,Non Squamous Lung Cancer,treatment (DRUG); treatment (DRUG),1054,PN,Non Squamous Lung Cancer,Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7543,NCT03447769,Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A,TERMINATED,PHASE3,Non-Small Cell Lung Cancer,Canakinumab (DRUG); Placebo (DRUG),1054,PN,Advanced Non-Small Cell Lung Cancer,Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7544,NCT03439046,"Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant",COMPLETED,PHASE3,Breast Cancer,Ribociclib (DRUG); Letrozole (DRUG); Alpelisib (DRUG); Fulvestrant (DRUG),1054,PN,Breast Cancer,Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7545,NCT04362072,Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer,COMPLETED,PHASE4,Carcinoma; Non-Small-Cell Lung,Lorlatinib (DRUG),1054,PN,Carcinoma; Non-Small-Cell Lung,Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7546,NCT05966441,Role of Curcumin in Paclitaxel Induced PN,NOT_YET_RECRUITING,PHASE2,Chemotherapy-induced Peripheral Neuropathy,Curcumin (DIETARY_SUPPLEMENT); Paclitaxel (DRUG),1054,PN,Chemotherapy-induced Peripheral Neuropathy,Peripheral Nervous System,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7547,NCT04139317,Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%,TERMINATED,PHASE2,Non-small Cell Lung Cancer (NSCLC),Capmatinib (DRUG); Pembrolizumab (BIOLOGICAL),1054,PN,Non-small Cell Lung Cancer (NSCLC),Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7548,NCT04344717,Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition,RECRUITING,PHASE4,Short Bowel Syndrome; Anticoagulation,Apixaban single dose (DRUG); Apixaban steady-state (DRUG),1054,PN,Short Bowel Syndrome; Anticoagulation,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7549,NCT03363217,Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.,ACTIVE_NOT_RECRUITING,PHASE2,Low-grade Glioma; Plexiform Neurofibroma; Central Nervous System Glioma,Trametinib (DRUG),1054,PN,Low-grade Glioma; Plexiform Neurofibroma; Central Nervous System Glioma,CNS/Brain,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7550,NCT02437318,Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.,COMPLETED,PHASE3,Breast Cancer,Fulvestrant (DRUG); Alpelisib (DRUG); Placebo (DRUG),1054,PN,Breast Cancer,Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7551,NCT01015118,LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer,COMPLETED,PHASE3,Ovarian Neoplasms; Peritoneal Neoplasms,Placebo (DRUG); Paclitaxel (DRUG); BIBF 1120 (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG),1054,PN,Ovarian Neoplasms; Peritoneal Neoplasms,Ovary/Fallopian Tube,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7552,NCT01289041,BKM120 as Second-line Therapy for Advanced Endometrial Cancer,COMPLETED,PHASE2,Advanced Endometrial Cancer,BKM120 (DRUG),1054,PN,Advanced Endometrial Cancer,Uterus,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7553,NCT04997941,Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients,ACTIVE_NOT_RECRUITING,PHASE2,Premenopausal Breast Cancer; Hormone Receptor-positive Breast Cancer,Tamoxifen Oral Product (DRUG); Assessment of Ki-67 (DIAGNOSTIC_TEST); Surgery (PROCEDURE),1054,PN,Premenopausal Breast Cancer; Hormone Receptor-positive Breast Cancer,Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7554,NCT04911517,Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.,UNKNOWN,PHASE2,Colorectal Neoplasms,long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations (COMBINATION_PRODUCT),1054,PN,Colorectal Neoplasms,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7555,NCT03701334,A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Early Breast Cancer,Ribociclib (DRUG); Endocrine Therapy (OTHER),1054,PN,Early Breast Cancer,Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7556,NCT01985334,Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen,COMPLETED,PHASE4,COPD,Glycopyrronium (DRUG); SABA (DRUG); LABA (DRUG); Indacaterol maleate and glycopyrronium bromide (DRUG); LAMA (DRUG); SAMA (DRUG); ICS (DRUG),1054,PN,COPD,Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7557,NCT00349219,TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer,COMPLETED,PHASE3,Advanced Non-Small Cell Lung Cancer,erlotinib (DRUG); cisplatin (DRUG); gemcitabine (DRUG); cisplatin (DRUG); gemcitabine (DRUG); erlotinib (DRUG),1054,PN,Advanced Non-Small Cell Lung Cancer,Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7558,NCT00075218,A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST),COMPLETED,PHASE3,Gastrointestinal Stromal Tumor,Placebo (DRUG); SU011248 (DRUG),1054,PN,Gastrointestinal Stromal Tumor,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7559,NCT00831636,A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer,COMPLETED,PHASE1,Ovarian Cancer,CP-4055 (DRUG); CP-4055 (DRUG),1054,PN,Ovarian Cancer,Ovary/Fallopian Tube,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7560,NCT01828112,LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,COMPLETED,PHASE3,Non-Small Cell Lung Cancer,Ceritinib (DRUG); Pemetrexed (DRUG); Docetaxel (DRUG),1054,PN,Advanced Non-Small Cell Lung Cancer,Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7561,NCT00247338,The Impact of Low Calorie and Low Nitrogen Parenteral Nutrition Support on the Clinical Outcome of Postoperative Patients,COMPLETED,PHASE4,Gastrointestinal Neoplasms; Postoperative Complications,"low calorie, low nitrogen parenteral nutrition for patient with NRS score 3 (DRUG)",1054,PN,Gastrointestinal Neoplasms; Postoperative Complications,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7562,NCT01306838,Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy,COMPLETED,EARLY_PHASE1,Short Bowel Syndrome; Necrotizing Enterocolitis; Small Intestine Perforation,MicroLipid and fish oil (DIETARY_SUPPLEMENT); Routine care (OTHER),1054,PN,Short Bowel Syndrome; Necrotizing Enterocolitis; Small Intestine Perforation,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7563,NCT01064310,Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer,COMPLETED,PHASE3,"Carcinoma, Renal Cell",pazopanib (DRUG); sunitinib (DRUG),1054,PN,"Carcinoma, Renal Cell",Kidney,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7564,NCT02682381,Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition,COMPLETED,PHASE3,Short Bowel Syndrome,Teduglutide 0.05mg/kg (DRUG); Teduglutide 0.025 mg/kg (DRUG); Standard of Care (OTHER),1054,PN,Short Bowel Syndrome,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7565,NCT03516708,Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer,RECRUITING,PHASE1,Rectal Cancer,Epacadostat (DRUG); Short-course radiation therapy (RADIATION); CAPOX chemotherapy (DRUG); FOLFOX chemotherapy (DRUG),1054,PN,Rectal Cancer,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7566,NCT03438708,Prior Axitinib as a Determinant of Outcome of Renal Surgery,UNKNOWN,PHASE2,Clear Cell Renal Cell Carcinoma,Axitinib Oral Tablet [Inlyta] (DRUG),1054,PN,Clear Cell Renal Cell Carcinoma,Kidney,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7567,NCT03052608,A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC,ACTIVE_NOT_RECRUITING,PHASE3,"Carcinoma, Non-Small-Cell Lung",Lorlatinib (DRUG); Crizotinib (DRUG),1054,PN,"Carcinoma, Non-Small-Cell Lung",Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7568,NCT00668408,LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure,UNKNOWN,PHASE4,"Lung Diseases, Obstructive; Chronic Heart Failure; Chronic Hypoxemia",LTOT (oxygen therapy) (OTHER); Pharmacological therapy of COPD and CHF (OTHER),1054,PN,"Lung Diseases, Obstructive; Chronic Heart Failure; Chronic Hypoxemia",Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7569,NCT01555138,Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.),COMPLETED,PHASE4,Chronic Obstructive Pulmonary Disease,Indacaterol (DRUG); Salmeterol (DRUG),1054,PN,Chronic Obstructive Pulmonary Disease,Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7570,NCT03596164,An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004,COMPLETED,PHASE3,Short Bowel Syndrome,Teduglutide (DRUG); Syringe (DEVICE); Needle (DEVICE); Vial Adapter for Device (DEVICE),1054,PN,Short Bowel Syndrome,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7571,NCT00119743,A Efficacy Against Otitis Media in Children With 11 Valent Pneumococcal Vaccine,TERMINATED,PHASE3,Hepatitis A,undecavalent pneumococcal-protein D conjugate vaccine (BIOLOGICAL),1054,PN,Hepatitis A,Liver,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7572,NCT02500043,Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer,COMPLETED,PHASE3,Refractory Metastatic Gastric Cancer,TAS-102 (DRUG); Placebo (DRUG),1054,PN,Refractory Metastatic Gastric Cancer,Esophagus/Stomach,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7573,NCT00793195,"Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants?",UNKNOWN,PHASE2,Short Bowel Syndrome; Intestinal Failure; Gastrointestinal Motility Disorder; Mucosal Enteropathy,Intralipid 20% (DRUG); SMOFlipid 20% (DRUG),1054,PN,Short Bowel Syndrome; Intestinal Failure; Gastrointestinal Motility Disorder; Mucosal Enteropathy,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7574,NCT04418895,Neoadjuvant Therapy for Localized Rectal Adenocarcinoma,WITHDRAWN,PHASE2,Rectal Adenocarcinoma,Chemoradiation (OTHER); short course radiation therapy (RADIATION); mFOLFOX6 (DRUG); CAPOX (DRUG); fluoropyrimidine +/- oxaliplatin (DRUG),1054,PN,Rectal Adenocarcinoma,Bowel,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7575,NCT05607550,Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT),ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; EGFR Exon 20 Mutations,"furmonertinib 240 mg oral, daily (DRUG); furmonertinib 160 mg oral, daily (DRUG); platinum-based chemotherapy (DRUG)",1054,PN,Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; EGFR Exon 20 Mutations,Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7576,NCT01085136,LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib,COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung",Investigator´s choice of chemotherapy (DRUG); BIBW 2992 (DRUG),1054,PN,"Carcinoma, Non-Small-Cell Lung",Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7577,NCT00796549,BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",BiBW 2992 (DRUG),1054,PN,"Carcinoma, Non-Small-Cell Lung",Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7578,NCT00673049,"Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer",TERMINATED,PHASE3,"Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Adenosquamous Cell","CP 751,871 (Figitumumab) (DRUG); Erlotinib (DRUG); Erlotinib (DRUG)",1054,PN,"Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Adenosquamous Cell",Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7579,NCT00248170,Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Letrozole (DRUG); Anastrozole (DRUG),1054,PN,Breast Cancer,Breast,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7580,NCT01828099,LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer,COMPLETED,PHASE3,Non-Small Cell Lung Cancer,Ceritinib (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG); Carboplatin (DRUG),1054,PN,Advanced Non-Small Cell Lung Cancer,Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7581,NCT00660842,Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer,UNKNOWN,PHASE3,Ovarian Cancer,carboplatin (PROCEDURE); paclitaxel (DRUG); carboplatin (DRUG); paclitaxel (DRUG),1054,PN,Ovarian Cancer,Ovary/Fallopian Tube,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7582,NCT02684006,A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101),COMPLETED,PHASE3,Renal Cell Cancer,Avelumab (MSB0010718C) (DRUG); Axitinib (AG-013736) (DRUG); Sunitinib (DRUG),1054,PN,Renal Cell Cancer,Kidney,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7583,NCT02376699,Safety Study of SEA-CD40 in Cancer Patients,TERMINATED,PHASE1,"Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Hodgkin Disease; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Melanoma; Neoplasm Metastasis; Neoplasms, Head and Neck; Neoplasms, Squamous Cell; Non-Small Cell Lung Cancer; Non-Small Cell Lung Cancer Metastatic; Non-small Cell Carcinoma; Squamous Cell Cancer; Squamous Cell Carcinoma; Squamous Cell Carcinoma of the Head and Neck; Squamous Cell Neoplasm; Lymphoma, Non-Hodgkin; Pancreatic Adenocarcinoma",Intravenous (IV) SEA-CD40 (DRUG); Pembrolizumab (DRUG); Subcutaneous (SC) SEA-CD40 (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG),1054,PN,"Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Hodgkin Disease; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Melanoma; Neoplasm Metastasis; Neoplasms, Head and Neck; Neoplasms, Squamous Cell; Non-Small Cell Lung Cancer; Non-Small Cell Lung Cancer Metastatic; Non-small Cell Carcinoma; Squamous Cell Cancer; Squamous Cell Carcinoma; Squamous Cell Carcinoma of the Head and Neck; Squamous Cell Neoplasm; Lymphoma, Non-Hodgkin; Pancreatic Adenocarcinoma",Lung,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7584,NCT04202679,"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)",COMPLETED,PHASE3,Neurodermatitis,Dupilumab SAR231893 (DRUG); Placebo (DRUG); Moisturizers (DRUG); Low to medium potent topical corticosteroids (DRUG); Topical calcineurin inhibitors (DRUG),1054,PN,Neurodermatitis,Skin,Pyridoxine,,unclear,unclear,yes,yes,Vitamin B6; essential nutrient approved for various health conditions.,CC1=NC=C(C(=C1O)CO)CO,1.13,342.0 +7585,NCT00609973,Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease,COMPLETED,PHASE2,Crohn's Disease,Ciprofloxacin (DRUG); Placebo (DRUG),28061,Tiberal,Crohn's Disease,Bowel,Ornidazole,,unclear,unclear,yes,yes,"Used for bacterial and protozoal infections, common in some countries.",CC1=NC=C(N1CC(CCl)O)[N+](=O)[O-],1.04,488.0 +7586,NCT03475680,Mechanical Bowel Preparation and Oral Antibiotics Before Colon Cancer Surgery,TERMINATED,PHASE3,Colon Cancer,Sennosides colonic preparation (DRUG); Oral Gentamycin (DRUG); Oral Ornidazole (DRUG); Oral placebo Gentamycin (DRUG); Oral placebo Ornidazole (DRUG),28061,Tiberal,Colon Cancer,Bowel,Ornidazole,,unclear,unclear,yes,yes,"Used for bacterial and protozoal infections, common in some countries.",CC1=NC=C(N1CC(CCl)O)[N+](=O)[O-],1.04,488.0 +7587,NCT03491540,Mechanical Bowel Preparation and Oral Antibiotics Before Rectal Cancer Surgery,COMPLETED,PHASE3,Rectal Cancer Surgery,Sennosides colonic preparation (DRUG); Oral Gentamycin (DRUG); Oral Ornidazole (DRUG); Oral Placebo Gentamycin (DRUG); Oral Placebo Ornidazole (DRUG),28061,Tiberal,Rectal Cancer Surgery,Bowel,Ornidazole,,unclear,unclear,yes,yes,"Used for bacterial and protozoal infections, common in some countries.",CC1=NC=C(N1CC(CCl)O)[N+](=O)[O-],1.04,488.0 +7588,NCT01836120,A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer,UNKNOWN,PHASE2,Gastric Cancer,Raltitrexed plus Docetaxel (DRUG); Docetaxel (DRUG),135400182,Tomudex,Gastric Cancer,Esophagus/Stomach,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7589,NCT03392103,Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection,UNKNOWN,PHASE2,Gastric Cancer,Raltitrexed (DRUG); postoperative radiotherapy (RADIATION),135400182,Tomudex,Gastric Cancer,Esophagus/Stomach,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7590,NCT02557490,Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases,UNKNOWN,PHASE4,Colon Cancer Liver Metastasis,oxaliplatin and raltitrexed (DRUG),135400182,Tomudex,Colon Cancer Liver Metastasis,Liver,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7591,NCT02453490,Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis,TERMINATED,PHASE3,Colorectal Cancer; Liver Metastasis,Raltitrexed-based chemotherapy (DRUG); Raltitrexed-based chemotherapy (DRUG); 5-fluorouracil-based chemotherapy (DRUG); 5-fluorouracil-based chemotherapy (DRUG),135400182,Tomudex,Colorectal Cancer; Liver Metastasis,Liver,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7592,NCT03196843,Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC.,UNKNOWN,PHASE4,Head and Neck Squamous Cell Carcinoma,Raltitrexed (DRUG); Intensity Modulated Radiotherapy (RADIATION),135400182,Tomudex,Head and Neck Squamous Cell Carcinoma,Skin,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7593,NCT06652412,CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC,NOT_YET_RECRUITING,PHASE2,Colon Cancer; Rectal Cancer,Ultrafractionated RT and CGA Guided systemic treatment. (DRUG); data prospectively collected (OTHER); Ultrafractionated Radiotherapy (RADIATION); Sintilimab (DRUG); Fluorouracil (DRUG); Raltitrexed (DRUG); Oxaliplatin (DRUG); Irinotecan (CPT-11) (DRUG),135400182,Tomudex,Colon Cancer; Rectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7594,NCT05231382,Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma,UNKNOWN,PHASE3,Hepatocellular Carcinoma,"Raltitrexed, oxaliplatin (SALOX) treatment (PROCEDURE); Oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment (PROCEDURE)",135400182,Tomudex,Hepatocellular Carcinoma,Liver,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7595,NCT04241731,A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer,UNKNOWN,PHASE2,Colorectal Cancer,Raltitrexed (DRUG); Cetuximab (DRUG),135400182,Tomudex,Colorectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7596,NCT04581876,The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer,UNKNOWN,PHASE2,Pancreatic Cancer; Chemotherapy Effect,raltitrexed for injection (DRUG); nab-paclitaxel (DRUG),135400182,Tomudex,Pancreatic Cancer; Chemotherapy Effect,Pancreas,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7597,NCT03485027,Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer; Chemotherapy Effect,the rechallenge regimen (DRUG),135400182,Tomudex,Metastatic Colorectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7598,NCT05340231,An Exploratory Study of Sequential Transarterial Chemoembolization With Lipiodol and Neoadjuvant Chemotherapy in the Treatment of Initial Unresectable Colorectal Cancer (CRC),NOT_YET_RECRUITING,PHASE2,Colorectal Cancer,TACE protocol (DRUG); Neoadjuvant Chemotherapy (DRUG),135400182,Tomudex,Colorectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7599,NCT03585530,Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus,UNKNOWN,PHASE2,Esophagus Squamous Cell Carcinoma,raltitrexed (DRUG),135400182,Tomudex,Esophagus Squamous Cell Carcinoma,Skin,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7600,NCT02965248,Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study),UNKNOWN,PHASE3,Locally Advanced Colorectal Cancer,Standard adjuvant systemic chemotherapy (DRUG); Hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed (PROCEDURE); Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin (PROCEDURE),135400182,Tomudex,Locally Advanced Colorectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7601,NCT06118762,Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer,RECRUITING,PHASE4,Metastatic Colorectal Cancer,Fruquintinib (DRUG),135400182,Tomudex,Metastatic Colorectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7602,NCT00234429,A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma,COMPLETED,PHASE2,Colorectal Cancer,"Gefitinib, raltitrexed (DRUG)",135400182,Tomudex,Colorectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7603,NCT01732380,A Phase-II Study Of Raltitrexed/Oxaliplatin Plus Radiotherapy Versus Radiotherapy In Subjects With Inoperable Esophageal Cancer,UNKNOWN,PHASE2,Inoperable Esophageal Cancer Stage I-III,Raltitrexed (DRUG); Oxaliplatin (DRUG); Radiotherapy (RADIATION),135400182,Tomudex,Inoperable Esophageal Cancer Stage I-III,Esophagus/Stomach,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7604,NCT02992886,Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly,COMPLETED,PHASE2,Rectal Neoplasms Malignant,Preoperative radiation (RADIATION); Raltitrexed (DRUG); Pelvic surgery (PROCEDURE),135400182,Tomudex,Rectal Neoplasms Malignant,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7605,NCT05160896,SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer,RECRUITING,PHASE2,Advanced Metastatic Colorectal Cancer,Raltitrexed (DRUG); Irinotecan (DRUG); Bevacizumab (DRUG); Cetuximab (DRUG),135400182,Tomudex,Advanced Metastatic Colorectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7606,NCT01348412,Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure,COMPLETED,PHASE2,Colorectal Cancer; Liver Metastases,oxaliplatin (DRUG); raltitrexed (DRUG); other intravenous chemotherapy drugs (DRUG),135400182,Tomudex,Colorectal Cancer; Liver Metastases,Liver,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7607,NCT01532804,2nd-line Treatment of Metastatic Colorectal Cancer,TERMINATED,PHASE2,Metastatic Colorectal Cancer,"bevacizumab, oxaliplatin and 5FU combination (DRUG); Bevacizumab, oxaliplatin and raltitrexed combination (DRUG)",135400182,Tomudex,Metastatic Colorectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7608,NCT03053167,Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients,UNKNOWN,PHASE2,ColoRectal Cancer,Irinotecan (DRUG); Raltitrexed (DRUG),135400182,Tomudex,ColoRectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7609,NCT00797719,Short Neoadjuvant Hemithoracic IMRT for MPM,ACTIVE_NOT_RECRUITING,PHASE1,Malignant Pleural Mesothelioma,Pre-op RT +/- chemotherapy (OTHER),135400182,Tomudex,Malignant Pleural Mesothelioma,Lung,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7610,NCT02072317,Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer,UNKNOWN,PHASE2,Advanced Gastric Cancer,taxel plus raltitrexed (DRUG); taxol (DRUG),135400182,Tomudex,Advanced Gastric Cancer,Esophagus/Stomach,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7611,NCT06441019,Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma,NOT_YET_RECRUITING,PHASE2,"Hepatocellular Carcinoma，Bispecific Antibodies, HAIC, Ramucirumab",HAIC（Oxaliplatin+ Raltitrexed）、TQB2868、Ramucirumab (DRUG),135400182,Tomudex,"Hepatocellular Carcinoma，Bispecific Antibodies, HAIC, Ramucirumab",Liver,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7612,NCT03813641,RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study),UNKNOWN,PHASE2,Colorectal Cancer,Raltitrexed (DRUG); Capecitabine (DRUG),135400182,Tomudex,Colorectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7613,NCT03083613,Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma,COMPLETED,PHASE2,Gastric Cancer; Gastroesophageal Junction Adenocarcinoma,Raltitrexed (DRUG); Paclitaxel (DRUG),135400182,Tomudex,Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7614,NCT05435313,Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy,ACTIVE_NOT_RECRUITING,PHASE2,Colorectal Cancer,HAIC (PROCEDURE); Fruquintinib (DRUG); Tislelizumab (DRUG); Raltitrexed (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG),135400182,Tomudex,Colorectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7615,NCT06285019,Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma,RECRUITING,PHASE2,Hepatocellular Carcinoma,TOMOX-HAIC (PROCEDURE); Sintilimab (DRUG); Bevacizumab (DRUG),135400182,Tomudex,Hepatocellular Carcinoma,Liver,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7616,NCT04582981,Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer,UNKNOWN,PHASE2,Advanced Colorectal Carcinoma,Fruquintinib and raltitrexed (DRUG); Fruquintinib (DRUG),135400182,Tomudex,Advanced Colorectal Carcinoma,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7617,NCT05628038,The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer,RECRUITING,PHASE2,Recurrent Rectal Cancer,PD-1 antibody (DRUG); Capecitabine (DRUG); 5FU (DRUG); folinic acid (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG); Raltitrexed (DRUG); Cetuximab (DRUG); Bevacizumab (DRUG); Radiation (RADIATION),135400182,Tomudex,Recurrent Rectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7618,NCT01703910,Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic,COMPLETED,PHASE2,Adenocarcinoma of Colon; Adenocarcinoma of Rectum; Metastatic Disease,Arm A chemotherapy (DRUG); arm B chemotherapy (DRUG),135400182,Tomudex,Adenocarcinoma of Colon; Adenocarcinoma of Rectum; Metastatic Disease,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7619,NCT03344614,A Study of Apatinib in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer,UNKNOWN,PHASE2,Colorectal Cancer,raltitrexed combined with apatinib (DRUG),135400182,Tomudex,Colorectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7620,NCT01869023,Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma,UNKNOWN,PHASE2,Advanced Malignant Pleural Mesothelioma,Gemcitabine (DRUG); Cisplatin (DRUG),135400182,Tomudex,Advanced Malignant Pleural Mesothelioma,Lung,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7621,NCT04597970,TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC,UNKNOWN,PHASE2,Transarterial Chemoembolization; Hepatocellular Carcinoma,cTACE-HAIC (DRUG),135400182,Tomudex,Transarterial Chemoembolization; Hepatocellular Carcinoma,Liver,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7622,NCT03179579,Efficacy of HIPEC Combined With Systemic Chemotherapy and CRS on Peritoneal Metastases From Gastric Cancer,UNKNOWN,PHASE3,Gastric Cancer; Peritoneal Carcinomatosis,HIPEC with neoadjuvant chemotherapy (PROCEDURE); Systemic chemotherapy (PROCEDURE),135400182,Tomudex,Gastric Cancer; Peritoneal Carcinomatosis,Esophagus/Stomach,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7623,NCT05420584,Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer,RECRUITING,PHASE2,Rectal Neoplasms,Arterial chemoembolization (PROCEDURE); Tislelizumab Injection (DRUG); XELOX (DRUG); Pelvic MRI (DIAGNOSTIC_TEST); Laparoscopic radical resection of rectal cancer (PROCEDURE),135400182,Tomudex,Rectal Neoplasms,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7624,NCT03823079,Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia,UNKNOWN,PHASE2,Recurrent Colorectal Carcinoma; Thrombopenia,rhTPO (DRUG); irinotecan (DRUG); Raltitrexed (DRUG); radiotherapy (RADIATION); rhIL-11 (DRUG),135400182,Tomudex,Recurrent Colorectal Carcinoma; Thrombopenia,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7625,NCT02485548,Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer,UNKNOWN,PHASE3,Head and Neck Squamous Cell Cancer,Raltitrexed (DRUG); 5-fluorouracil (DRUG); Cisplatin (DRUG); IMRT (RADIATION),135400182,Tomudex,Head and Neck Squamous Cell Cancer,Skin,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7626,NCT06397235,DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC,RECRUITING,PHASE2,Hepatocellular Carcinoma Non-resectable,DEB-TACE+HAIC (DRUG); DEB-TACE (DRUG),135400182,Tomudex,Hepatocellular Carcinoma Non-resectable,Liver,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7627,NCT04499586,A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer,UNKNOWN,PHASE2,Recurrent Colorectal Cancer,Radiotherapy Combined With Raltitrexed and Irinotecan (COMBINATION_PRODUCT),135400182,Tomudex,Recurrent Colorectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7628,NCT06841159,Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer,RECRUITING,PHASE2,Microsatellite Stable Metastatic Colorectal Cancer,Ultra-fractionated radiation therapy (RADIATION); Sintilimab (DRUG); Standard systemic therapy (DRUG),135400182,Tomudex,Microsatellite Stable Metastatic Colorectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7629,NCT02376452,Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients,UNKNOWN,PHASE2,Colorectal Carcinoma,Raltitrexed (DRUG); Irinotecan (DRUG); 5-fluorouracil (DRUG); Leucovorin (DRUG),135400182,Tomudex,Colorectal Carcinoma,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7630,NCT03811652,A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors,COMPLETED,PHASE1,Non Small Cell Lung Cancer Squamous (NSCLC-Sq); Head and Neck Squamous Cell Carcinoma (HNSCC); Small Cell Lung Cancer (SCLC); Pancreatic Ductal Adenocarcinoma (PDAC); Colorectal Cancer (CRC); Metastatic Castration-resistant Prostate Cancer (mCRPC),MEDI7247 (DRUG),135400182,Tomudex,Non Small Cell Lung Cancer Squamous (NSCLC-Sq); Head and Neck Squamous Cell Carcinoma (HNSCC); Small Cell Lung Cancer (SCLC); Pancreatic Ductal Adenocarcinoma (PDAC); Colorectal Cancer (CRC); Metastatic Castration-resistant Prostate Cancer (mCRPC),Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7631,NCT02821559,Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,TOMOX (DRUG); Bevacizumab (DRUG),135400182,Tomudex,Metastatic Colorectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7632,NCT05003700,Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma,COMPLETED,PHASE2,Hepatocellular Carcinoma,Hepatic arterial infusion chemotherapy (PROCEDURE); Lenvatinib (DRUG); Camrelizumab (DRUG),135400182,Tomudex,Hepatocellular Carcinoma,Liver,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7633,NCT05007587,Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC,UNKNOWN,EARLY_PHASE1,Hepatocellular Carcinoma Stage IIIa,Lenvatinib (DRUG); mFOLFOX regimen (DRUG); ROX regimen (DRUG),135400182,Tomudex,Hepatocellular Carcinoma Stage IIIa,Liver,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7634,NCT06239532,HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma,ACTIVE_NOT_RECRUITING,PHASE2,Intrahepatic Cholangiocarcinoma,HAIC+TAE (DRUG); Tislelizumab (DRUG); Surufatinib (DRUG),135400182,Tomudex,Intrahepatic Cholangiocarcinoma,Liver,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7635,NCT04761185,Raltitrexed in HIPEC,UNKNOWN,PHASE1,Colorectal Cancer; Raltitrexed; HIPEC,Raltitrexed (DRUG),135400182,Tomudex,Colorectal Cancer; Raltitrexed; HIPEC,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7636,NCT06423937,Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer,NOT_YET_RECRUITING,PHASE2,Colorectal Cancer,combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab (DRUG),135400182,Tomudex,Colorectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7637,NCT00004254,Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed,COMPLETED,PHASE2,Malignant Mesothelioma,raltitrexed (DRUG),135400182,Tomudex,Malignant Mesothelioma,Lung,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7638,NCT02723253,Concurrent Chemoradiation With Concomitant Boost In Locally Advanced Rectal Cancer,COMPLETED,PHASE2,Rectal Neoplasms,Radiotherapy (RADIATION); Tom-OX (DRUG),135400182,Tomudex,Rectal Neoplasms,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7639,NCT04093115,Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma,WITHDRAWN,PHASE2,Head and Neck Squamous Cell Carcinoma,CX1106 (DRUG),135400182,Tomudex,Head and Neck Squamous Cell Carcinoma,Skin,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7640,NCT02618356,Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer,UNKNOWN,PHASE2,Metastatic Colon Cancer,Raltitrexed and S-1 (DRUG),135400182,Tomudex,Metastatic Colon Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7641,NCT06475287,HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma,NOT_YET_RECRUITING,PHASE2,Hepatocellular Carcinoma,HAIC（Mitoxantrone+Raltitrexed）、anlotinib、TQB2450 (DRUG),135400182,Tomudex,Hepatocellular Carcinoma,Liver,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7642,NCT06665087,CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC,NOT_YET_RECRUITING,PHASE2,Colon Cancer; Rectal Cancer,Ultrafractionated RT and CGA Guided systemic treatment. (DRUG); Ultrafractionated Radiotherapy (RADIATION); PD-1 antibody (DRUG); Chemotherapy (Fluorouracil) (DRUG); Chemotherapy (Raltitrexed) (DRUG); Chemotherapy (Oxaliplatin) (DRUG); Chemotherapy (CPT-11) (DRUG); Targeted Therapy (anti-VEGF) (DRUG); Targeted Therapy (anti-EGFR) (DRUG),135400182,Tomudex,Colon Cancer; Rectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7643,NCT06525428,Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer,RECRUITING,PHASE2,Microsatellite Stable Metastatic Colorectal Cancer,standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab (DRUG),135400182,Tomudex,Microsatellite Stable Metastatic Colorectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7644,NCT03126071,Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer,UNKNOWN,PHASE2,Advanced Colorectal Cancer,Raltitrexed (DRUG); Irinotecan (DRUG); Oxaliplatin (DRUG); Bevacizumab (DRUG),135400182,Tomudex,Advanced Colorectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7645,NCT05361161,Transarterial Chemoembolization With Lipiodol in the Treatment of Initial Unresectable Gastric Cancer (GC),NOT_YET_RECRUITING,PHASE2,Gastric Cancer; Embolization,Transarterial Chemoembolization (DRUG),135400182,Tomudex,Gastric Cancer; Embolization,Esophagus/Stomach,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7646,NCT01959061,Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases,UNKNOWN,PHASE4,Colorectal Cancer Metastatic,Raltitrexed (DRUG); Oxaliplatin (DRUG); lipiodol (DRUG),135400182,Tomudex,Colorectal Cancer Metastatic,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7647,NCT00002828,Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,fluorouracil (DRUG); raltitrexed (DRUG),135400182,Tomudex,Colorectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7648,NCT05766605,Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial,RECRUITING,PHASE3,Hepatocellular Carcinoma Resectable,"Oxaliplatin (DRUG); Doxorubicin (DRUG); Lobaplatin (DRUG); Cisplatin (DRUG); Oxaliplatin, Leucovorin, fluorouracil (DRUG); Lobaplatin, Raltitrexed (DRUG)",135400182,Tomudex,Hepatocellular Carcinoma Resectable,Liver,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7649,NCT05426811,Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients,NOT_YET_RECRUITING,PHASE1,Regorafenib; Raltitrexed; Colorectal Neoplasms; Third-line Treatment,Regorafenib (DRUG); Raltitrexed (DRUG),135400182,Tomudex,Regorafenib; Raltitrexed; Colorectal Neoplasms; Third-line Treatment,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7650,NCT01481545,Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer,COMPLETED,PHASE2,Rectal Cancer,Radiation therapy (RADIATION); Oxaliplatin (DRUG); Raltitrexed (DRUG); levofolinic acid (DRUG); 5-fluorouracil (DRUG); Bevacizumab (DRUG),135400182,Tomudex,Rectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7651,NCT00590278,A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer,COMPLETED,PHASE2,Inoperable or Recurrent Rectal Cancer,Tomudex (DRUG); Radiotherapy (PROCEDURE); Haematology (PROCEDURE); Biochemistry (PROCEDURE),135400182,Tomudex,Inoperable or Recurrent Rectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7652,NCT00004920,Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura,COMPLETED,PHASE3,Malignant Mesothelioma,cisplatin (DRUG); raltitrexed (DRUG),135400182,Tomudex,Malignant Mesothelioma,Lung,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7653,NCT00002893,Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer,UNKNOWN,PHASE3,Colorectal Cancer,fluorouracil (DRUG); leucovorin calcium (DRUG); raltitrexed (DRUG),135400182,Tomudex,Colorectal Cancer,Bowel,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7654,NCT04103398,TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma,COMPLETED,PHASE3,Hepatocellular Carcinoma; Sorafenib; Transarterial Chemoembolization,TACE+sorafenib (COMBINATION_PRODUCT); TACE (PROCEDURE),135400182,Tomudex,Hepatocellular Carcinoma; Sorafenib; Transarterial Chemoembolization,Liver,Raltitrexed,TYMS,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as thymidylate synthase inhibitor.,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,1.01,220.0 +7655,NCT05658874,"A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain",ACTIVE_NOT_RECRUITING,PHASE3,Interstitial Cystitis,Multimodal Bundle Drugs (DRUG); Operative Cystoscopy (PROCEDURE); Behavioral health consultation/therapy (BEHAVIORAL); Pelvic floor physical therapy (OTHER); Usual Urogynecologic care (OTHER); Bladder Instillation (DRUG); Vaginal estrogen (DRUG); Methenamine (DRUG); Amitriptyline/Gabapentin (DRUG),31307,Volon,Interstitial Cystitis,Bladder/Urinary Tract,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7656,NCT00544765,"Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer",COMPLETED,PHASE3,Breast Cancer,TAC (DRUG); NX (DRUG),31307,Volon,Breast Cancer,Breast,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7657,NCT03164265,DCreg in Living Donor Liver Transplantation,COMPLETED,PHASE1,Living Donor Liver Transplantation,Regulatory Donor-Derived Dendritic Cell infusion (BIOLOGICAL),31307,Volon,Living Donor Liver Transplantation,Liver,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7658,NCT03105674,Multi-Drug Analgesia vs. Standard Solution for Anal Surgery,WITHDRAWN,PHASE4,Hemorrhoids; Fissure in Ano; Fistula;Rectal,Multi-drug local anesthetics (Combination) (DRUG); Standard local anesthetics (Combination) (DRUG),31307,Volon,Anorectal Disorders,Bowel,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7659,NCT00623766,Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases,COMPLETED,PHASE2,Melanoma,Ipilimumab (DRUG); Corticosteroid: Betamethasone (DRUG); Corticosteroid: Dexamethasone (DRUG); Corticosteroid: Fludrocortisone (DRUG); Corticosteroid: Hydrocortisone (DRUG); Corticosteroid: Meprednisone (DRUG); Corticosteroid: Methylprednisolone (DRUG); Corticosteroid: Prednisolone (DRUG); Corticosteroid: Prednisone (DRUG); Corticosteroid: Triamcinolone (DRUG),31307,Volon,Melanoma,Skin,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7660,NCT03577431,Liver Transplantation With Tregs at MGH,ACTIVE_NOT_RECRUITING,PHASE1,Liver Transplant,arTreg-CSB (BIOLOGICAL); leukapheresis (PROCEDURE); cyclophosphamide (DRUG); mesna (DRUG); everolimus (DRUG),31307,Volon,Liver Transplant,Liver,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7661,NCT01583426,Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto),COMPLETED,PHASE3,Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer,nab-Paclitaxel (DRUG); Paclitaxel (DRUG),31307,Volon,Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer,Breast,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7662,NCT04740190,Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd,UNKNOWN,PHASE2,Recurrent Glioma; Recurrent Glioblastoma; Poly ADP Ribose Polymerase (PARP) Inhibitor; PTEN Gene Inactivation; IDH Mutation,Talazoparib (DRUG),31307,Volon,Recurrent Glioma; Recurrent Glioblastoma; Poly ADP Ribose Polymerase (PARP) Inhibitor; PTEN Gene Inactivation; IDH Mutation,CNS/Brain,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7663,NCT02618603,Botulinum Toxin A for Shoulder Pain After Stroke,UNKNOWN,PHASE4,Stroke; Pain,Botulinum toxin A (DRUG); Triamcinolone Acetonide (DRUG),31307,Volon,Cerebrovascular Accident,CNS/Brain,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7664,NCT01318590,Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic Pancreatitis,TERMINATED,PHASE3,"Pancreatitis, Chronic",EUS procedure with drug injection (DRUG); EUS procedure (OTHER),31307,Volon,"Pancreatitis, Chronic",Pancreas,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7665,NCT00582738,Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection,TERMINATED,PHASE2,Recurrent Hepatitis C,CsA-TAC (standard Treatment) (DRUG); Everolimus (DRUG),31307,Volon,Recurrent Hepatitis C,Liver,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7666,NCT02576938,A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis,COMPLETED,PHASE2,Atopic Dermatitis,Baricitinib (DRUG); Placebo (DRUG); Triamcinolone (Optional) (DRUG),31307,Volon,Atopic Dermatitis,Skin,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7667,NCT00868569,Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer,UNKNOWN,PHASE4,Liver Metastasis; Colorectal Cancer,TACE + folfox 4 (PROCEDURE); TAC + folfox4 (PROCEDURE),31307,Volon,Liver Metastasis; Colorectal Cancer,Bowel,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7668,NCT06009627,Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients,RECRUITING,PHASE2,Breast Cancer,Dalcelli、Exemestane、Gosserine (DRUG); Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection (DRUG),31307,Volon,Breast Cancer,Breast,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7669,NCT02317276,A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal,TERMINATED,PHASE4,"Dermatitis, Atopic",Triamcinolone 0.1% (DRUG),31307,Volon,"Dermatitis, Atopic",Skin,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7670,NCT02129231,Statins for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy,COMPLETED,PHASE2,Oxidative Stress; Diabetic Polyneuropathy,calcined magnesia (DRUG); Ezetimibe/simvastatin (DRUG); Rosuvastatin (DRUG),31307,Volon,Oxidative Stress; Diabetic Polyneuropathy,Peripheral Nervous System,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7671,NCT02088931,Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation,COMPLETED,PHASE1,Late Complication From Kidney Transplant,Treg infusion (BIOLOGICAL),31307,Volon,Late Complication From Kidney Transplant,Kidney,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7672,NCT00021294,Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis,COMPLETED,PHASE2,Non-melanomatous Skin Cancer; Precancerous/Nonmalignant Condition,eflornithine (DRUG); triamcinolone (DRUG),31307,Volon,Non-melanomatous Skin Cancer; Precancerous/Nonmalignant Condition,Skin,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7673,NCT04234360,Eosinophil-driven Corticotherapy for Patients Hospitalized for COPD Exacerbation,RECRUITING,PHASE3,COPD Exacerbation,5 days of systemic corticotherapy (prednisone) (DRUG); 5 days of placebo (DRUG),31307,Volon,Acute Exacerbation of Chronic Obstructive Pulmonary Disease,Lung,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7674,NCT01551212,Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients,COMPLETED,PHASE4,Liver Transplantation,Everolimus (DRUG); Tacrolimus (DRUG); Corticosteroids (DRUG),31307,Volon,Liver Transplantation,Liver,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7675,NCT02483767,Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer,COMPLETED,PHASE3,Breast Cancer,goserelin (DRUG); standard chemotherapy (DRUG),31307,Volon,Breast Cancer,Breast,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7676,NCT00050648,To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris,COMPLETED,PHASE1,Psoriasis,Daclizumab (DRUG); Cyclosporine (DRUG); cyclosporine and Daclizumab (DRUG),31307,Volon,Psoriasis,Skin,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7677,NCT03382925,Does Low-does Cervical Epidural Lidocaine Cause Transient Weakness?,TERMINATED,PHASE4,Cervical Radiculopathy,cervical interlaminar with lidocaine (PROCEDURE); cervical interlaminar with normal saline (PROCEDURE); Lidocaine (DRUG); Triamcinolone Acetonide (DRUG); Normal saline (DRUG),31307,Volon,Cervical Radiculopathy,Cervix,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7678,NCT00446030,Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms,Docetaxel (DRUG); Doxorubicin (DRUG); Carboplatin (DRUG); Cyclophosphamide (DRUG); Trastuzumab (DRUG); Bevacizumab (DRUG),31307,Volon,Breast Neoplasms,Breast,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7679,NCT01962922,Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.,COMPLETED,PHASE3,Renal Failure,LCP-Tacro (DRUG); Tacrolimus -IR (DRUG),31307,Volon,Renal Failure,Kidney,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7680,NCT02137239,Regimen Optimization Study,COMPLETED,PHASE2,Kidney Transplantation,Thymoglobulin (DRUG); Belatacept (DRUG); mycophenolate mofetil(MMF) (DRUG); Corticosteroids (DRUG); Everolimus(EVL) (DRUG); Tacrolimus(TAC) (DRUG),31307,Volon,Kidney Transplantation,Kidney,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7681,NCT05917522,Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation,RECRUITING,PHASE2,Kidney Transplant,Abatacept (BIOLOGICAL); Standard of Care at US Transplant Centers (PROCEDURE),31307,Volon,Kidney Transplant,Kidney,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7682,NCT00106639,"A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients",COMPLETED,PHASE2,Kidney Transplantation,"CP-690,550 (DRUG); CP-690,550 (DRUG); tacrolimus (DRUG)",31307,Volon,Kidney Transplantation,Kidney,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7683,NCT01354522,TAC Versus TCX As Adjuvant Treatment for Node-Positive Her2-Negative Breast Cancer,COMPLETED,PHASE3,Breast Cancer,"Docetaxel, Doxorubicin, Cyclophosphamide (DRUG); Docetaxel, Cyclophosphamide, Capecitabine (DRUG)",31307,Volon,Breast Cancer,Breast,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7684,NCT03777891,Effect of Silicone Gel Versus Contractubex Phonophoresis for Post-burn Hypertrophic Scars,COMPLETED,PHASE4,Hypertrophic Scar,phonophoresis with different material (COMBINATION_PRODUCT),31307,Volon,Hypertrophic Scar,Skin,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7685,NCT04002362,Symptom Clusters in Children With Exacerbation-prone Asthma,RECRUITING,PHASE2,Asthma in Children,Triamcinolone Acetonide (DRUG),31307,Volon,Pediatric Asthma,Lung,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7686,NCT01544491,"Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients",COMPLETED,PHASE3,Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant,RAD001 (DRUG); MMF (DRUG),31307,Volon,Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant,Kidney,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7687,NCT04496492,Preoperative Use of Tocotrienol From Annatto Bixa Orellana L. in Breast Cancer Patients: a Prospective Clinical Trial.,COMPLETED,PHASE2,Breast Cancer,Tocotrienol (DRUG),31307,Volon,Breast Cancer,Breast,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7688,NCT04830592,A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck,COMPLETED,PHASE1,Squamous Cell Carcinoma of the Head and Neck,NG-641 (BIOLOGICAL); Pembrolizumab (BIOLOGICAL),31307,Volon,Squamous Cell Carcinoma of the Head and Neck,Skin,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7689,NCT01998789,Everolimus Post Orthotopic Liver Transplant,UNKNOWN,PHASE2,Orthotopic Liver Transplant,Everolimus (DRUG); Standard Tacrolimus (DRUG),31307,Volon,Orthotopic Liver Transplant,Liver,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7690,NCT01213394,Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients,TERMINATED,PHASE3,Kidney Transplantation; Cardiovascular Diseases,mycophenolate mofetil (DRUG); standard immunosuppression (OTHER),31307,Volon,Kidney Transplantation; Cardiovascular Diseases,Kidney,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7691,NCT03982862,Botulinum Toxins Intralesional Injection for Scar Pain,UNKNOWN,PHASE4,Scar Keloid; Hypertrophic Scar,Triamcinolone (DRUG); Lidocaine (DRUG); Botulinum toxin A (DRUG),31307,Volon,Scar Keloid; Hypertrophic Scar,Skin,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7692,NCT03663335,"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients",COMPLETED,PHASE2,Kidney Transplant Rejection,CFZ533 - MMF - CS (BIOLOGICAL); Tacrolimus - MMF - +/- corticosteroids (DRUG),31307,Volon,Kidney Transplant Rejection,Kidney,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7693,NCT02260986,Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis,COMPLETED,PHASE3,Atopic Dermatitis,Dupilumab (DRUG); Placebo (for Dupilumab) (DRUG); Topical Corticosteroid (TCS) (OTHER),31307,Volon,Atopic Dermatitis,Skin,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7694,NCT00687596,Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy,TERMINATED,PHASE2,Hepatocellular Carcinoma,TAC-101 (DRUG); Placebo (DRUG),31307,Volon,Hepatocellular Carcinoma,Liver,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7695,NCT05738616,Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study),RECRUITING,PHASE3,Advanced Hepatocellular Carcinoma,Lenvatinib combined with TACE and Camrelizumab (COMBINATION_PRODUCT),31307,Volon,Advanced Hepatocellular Carcinoma,Liver,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7696,NCT04126824,Effect of Addition of Steroids on Duration of Analgesia,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,Uterine Fibroids; Adenomyosis,Triamcinolone (DRUG); Bupivacaine (DRUG); Iohexol contrast (OTHER),31307,Volon,Uterine Fibroids; Adenomyosis,Uterus,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7697,NCT01166724,Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression-,TERMINATED,PHASE3,Kidney Transplant,Sirolimus (DRUG); Tacrolimus (DRUG),31307,Volon,Kidney Transplant,Kidney,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7698,NCT00296296,Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM),COMPLETED,PHASE4,"Kidney Transplant; Diabetes Mellitus, Type 2; Diabetic Nephropathy",Cyclosporin (DRUG); Tacrolimus (DRUG); 'Diabetes Education / Management' (BEHAVIORAL),31307,Volon,"Kidney Transplant; Diabetes Mellitus, Type 2; Diabetic Nephropathy",Kidney,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7699,NCT01330524,Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo,UNKNOWN,PHASE1,Acute Nonarteritic Anterior Ischemic Optic Neuropathy,Avastin and Triamcinolone (DRUG); placebo (OTHER),31307,Volon,Acute Nonarteritic Anterior Ischemic Optic Neuropathy,Peripheral Nervous System,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7700,NCT05916781,Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus,RECRUITING,PHASE4,Systemic Lupus Erythematosus; Lupus Nephritis,Mycophenolate Mofetil (DRUG); Tacrolimus (DRUG); Glucocorticoid (DRUG),31307,Volon,Systemic Lupus Erythematosus; Lupus Nephritis,Kidney,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7701,NCT05223244,Bladder Capacity as Objective Measure of Intravesical Treatment of Newly Diagnosed IC,COMPLETED,PHASE4,Interstitial Cystitis; Painful Bladder Syndrome,"bupivacaine, triamcinolone, and heparin (BTH) (DRUG); dimethyl sulfoxide (DMSO) (DRUG)",31307,Volon,Interstitial Cystitis; Painful Bladder Syndrome,Bladder/Urinary Tract,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7702,NCT00912444,"Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer",TERMINATED,PHASE3,Breast Cancer,"Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide (DRUG); Docetaxel, cyclophosphamide (DRUG)",31307,Volon,Breast Cancer,Breast,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7703,NCT01647672,Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Abraxane (DRUG),31307,Volon,Breast Cancer,Breast,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7704,NCT04678440,[18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients,ENROLLING_BY_INVITATION,EARLY_PHASE1,"Lung Cancer, Nonsmall Cell",[18F]F-AraG Imaging (DRUG),31307,Volon,"Lung Cancer, Nonsmall Cell",Lung,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7705,NCT04665310,"Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans with Kidney Transplant",ACTIVE_NOT_RECRUITING,PHASE4,"Kidney Disease, End-Stage; Donor Specific Antibodies; Acute Rejection of Renal Transplant",Envarsus XR (DRUG),31307,Volon,"Kidney Disease, End-Stage; Donor Specific Antibodies; Acute Rejection of Renal Transplant",Kidney,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7706,NCT02680301,Topical Steroid Formulation and Wet Wraps,COMPLETED,PHASE4,"Dermatitis, Atopic",0.1% triamcinolone CREAM (DRUG); 0.1% triamcinolone OINTMENT (DRUG),31307,Volon,"Dermatitis, Atopic",Skin,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7707,NCT00121992,"Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment",COMPLETED,PHASE3,Breast Neoplasms,Docetaxel (DRUG); 5-fluorouracil (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG),31307,Volon,Breast Neoplasms,Breast,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7708,NCT06832189,EVR and EPO for Liver Transplant Tolerance,NOT_YET_RECRUITING,PHASE1,Liver Transplant,Everolimus (DRUG); Epoetin alfa (DRUG),31307,Volon,Liver Transplant,Liver,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7709,NCT03011892,A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis,COMPLETED,PHASE2,Atopic Dermatitis,Ruxolitinib 0.15% Cream QD (DRUG); Ruxolitinib 0.5% Cream QD (DRUG); Ruxolitinib 1.5% Cream QD (DRUG); Ruxolitinib 1.5% Cream BID (DRUG); Triamcinolone 0.1% Cream BID (DRUG); Vehicle Cream BID (DRUG),31307,Volon,Atopic Dermatitis,Skin,Triamcinolone,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Approved corticosteroid for various inflammatory and allergic conditions.,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,1.34,129.0 +7710,NCT02515227,Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab,COMPLETED,PHASE1,Melanoma,6MHP (BIOLOGICAL); Pembrolizumab (DRUG),68873,DRSP,Melanoma,Skin,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7711,NCT01360996,Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism,COMPLETED,PHASE4,Polycystic Ovary Syndrome,3 mg DRSP/20 μg EE (DRUG),68873,DRSP,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7712,NCT00656981,Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne,COMPLETED,PHASE3,Acne Vulgaris,"YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300) (DRUG); Placebo (DRUG)",68873,DRSP,Acne Vulgaris,Skin,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7713,NCT00651469,Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.,COMPLETED,PHASE3,Acne Vulgaris,"YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300) (DRUG); Placebo (DRUG)",68873,DRSP,Acne Vulgaris,Skin,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7714,NCT00818519,GA YAZ ACNE in China Phase III,COMPLETED,PHASE3,Acne Vulgaris,"EE20/Drospirenone (YAZ, BAY86-5300) (DRUG); Placebo (DRUG)",68873,DRSP,Acne Vulgaris,Skin,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7715,NCT01581814,Effects of Drospirenone-ethinylestradiol and/or Metformin on Cardiovascular Risk in Hyperinsulinemic Women With Polycystic Ovary Syndrome,COMPLETED,PHASE3,Polycystic Ovary Syndrome,Metformin (DRUG); Yasmin; (DRUG); Metformin plus Yasmin (DRUG),68873,DRSP,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7716,NCT01668784,Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025),COMPLETED,PHASE3,Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma,Nivolumab (BIOLOGICAL); Everolimus (DRUG),68873,DRSP,Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma,Kidney,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7717,NCT01697111,Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis,COMPLETED,PHASE3,Endometriosis,EE20/DRSP(BAY86-5300) (DRUG); Placebo (DRUG); Dienogest (DRUG),68873,DRSP,Endometriosis,Uterus,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7718,NCT01511822,"Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance",COMPLETED,PHASE4,PCOS; Polycystic Ovary Syndrome,Drospirenone Ethinyl estradiol (DRUG); Drospirenone Ethinyl estradiol Myo-inositol (DRUG); placebo (DRUG),68873,DRSP,PCOS; Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7719,NCT00593294,Oral Contraceptive and Cardiovascular Risk in PCOS,COMPLETED,PHASE4,Polycystic Ovary Syndrome,"Physical exercise (BEHAVIORAL); OC - Drospirenone plus Ethynylestradiol (DRUG); Vitamin, polyvitamins tablets (DIETARY_SUPPLEMENT)",68873,DRSP,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7720,NCT06608186,Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?!,COMPLETED,PHASE1,PCOS (Polycystic Ovary Syndrome),Cetrorelix drug (DRUG); Drospirenone drug (DRUG),68873,DRSP,PCOS (Polycystic Ovary Syndrome),Ovary/Fallopian Tube,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7721,NCT04965116,Progestin-Only Pill Use and Breastfeeding Study,COMPLETED,PHASE4,Contraception; Breastfeeding,Progestin Only Contraceptive Pills (DRUG),68873,DRSP,Contraception; Breastfeeding,Breast,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7722,NCT00640224,"Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study",COMPLETED,PHASE4,Polycystic Ovary Syndrome,rosiglitazone (DRUG); drospirenone/ethinyl estradiol (DRUG),68873,DRSP,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7723,NCT03819140,Continuous Versus Cyclical OCP Use in PCOS,COMPLETED,PHASE4,Polycystic Ovary Syndrome,Yasmin (DRUG),68873,DRSP,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7724,NCT00283816,Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy,COMPLETED,PHASE3,Polycystic Ovary Syndrome,Metformin (DRUG); Oral Contraceptive Pill (DRUG); Lifestyle Management Program (BEHAVIORAL); Quality of Life Questionnaire (BEHAVIORAL); Oral Glucose Tolerance Test (PROCEDURE); Blood work (PROCEDURE); Abdominal Ultra Sound (PROCEDURE); Dual-energy x-ray absorptiometry (DEXA scan) (PROCEDURE); placebo (DRUG),68873,DRSP,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7725,NCT00948402,"PED/PEA-15 Protein, PCOS, Obesity, Insulin Sensitivity Indexes, Metformin, Oral Contraceptives",COMPLETED,PHASE3,Polycystic Ovarian Syndrome; Insulin Sensitivity,Metformin (DRUG); oral contraceptive (DRUG),68873,DRSP,Polycystic Ovarian Syndrome; Insulin Sensitivity,Ovary/Fallopian Tube,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7726,NCT05340634,Evaluation of Metionac for the Modulation of Metabolic and Endocrine Parameters in Patients With PCOS.,COMPLETED,PHASE4,Polycystic Ovary Syndrome,Metionac (DIETARY_SUPPLEMENT); Oral contraceptive (DRUG),68873,DRSP,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7727,NCT03843736,The Role of Dysbiosis of Gut Microbiota in the Pathogenesis of PCOS.,UNKNOWN,PHASE3,Polycystic Ovary Syndrome,Lifestyle intervention (BEHAVIORAL); Probiotic Agent (DRUG); Oral contraceptive (DRUG),68873,DRSP,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7728,NCT04256200,Efficacy of Dienogest Versus Oral Contraceptive Pills on Pain Associated With Endometriosis,UNKNOWN,PHASE2,Endometriosis,Dienogest 2 MG Oral Tablet (DRUG); Yasmin (DRUG),68873,DRSP,Endometriosis,Uterus,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7729,NCT02027337,"Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants",UNKNOWN,PHASE4,Polycystic Ovarian Syndrome; Hyperandrogenism; Menstrual Irregularities,20 mcg ethinylestradiol /3 mg drospirenone (DRUG); 20 mcg ethinylestradiol/3 mg drospirenone and Selmevit (DRUG); 30 mcg ethinylestradiol/3 mg drospirenone (DRUG); 30 mcg ethinylestradiol/3 mg drospirenone and Selmevit (DRUG); 35 mcg ethinylestradiol/2 mg cyproterone (DRUG); 35 mcg ethinylestradiol/2 mg cyproterone and Selmevit (DRUG),68873,DRSP,Polycystic Ovarian Syndrome; Hyperandrogenism; Menstrual Irregularities,Ovary/Fallopian Tube,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7730,NCT01603745,Effects of Drospirenone-ethinylestradiol and/or NOMAC-valerate Estradiol on Cardiovascular Risk in Women With Polycystic Ovary Syndrome,UNKNOWN,PHASE1,Polycystic Ovary Syndrome,Zoely (DRUG); Yasmin (DRUG),68873,DRSP,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7731,NCT00714233,Treatment of Adolescent Polycystic Ovary Syndrome (PCOS),COMPLETED,PHASE3,Polycystic Ovary Syndrome,Metformin (DRUG); Oral Contraceptive Pills (Yasmin) (DRUG); Lifestyle Modification (BEHAVIORAL); placebo (DRUG),68873,DRSP,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7732,NCT00722761,Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne,COMPLETED,PHASE3,Acne Vulgaris,drospirenone and ethinyl estradiol (DRUG); Placebo tablet (DRUG),68873,DRSP,Acne Vulgaris,Skin,Drospirenone,,unclear,unclear,yes,yes,"Found in birth control, often combined with ethinyl estradiol.",CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,1.26,148.0 +7733,NCT02055170,Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer,TERMINATED,PHASE2,Non-small Cell Lung Cancer,finasteride 5mg oral daily (DRUG),57363,Proscar,Non-small Cell Lung Cancer,Lung,Finasteride,SRD5A2,inhibitor/antagonist,unclear,yes,yes,Used for benign prostatic hyperplasia and male pattern baldness.,CC12CCC3C(C1CCC2C(=O)NC(C)(C)C)CCC4C3(C=CC(=O)N4)C,1.22,180.0 +7734,NCT01437566,Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy,COMPLETED,PHASE2,Breast Cancer,Fulvestrant (DRUG); GDC-0941 (DRUG); GDC-0941 Matching Placebo (DRUG); GDC-0980 (DRUG); GDC-0980 Matching Placebo (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7735,NCT05696626,Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation,RECRUITING,PHASE3,Metastatic Breast Cancer,Lasofoxifene in combination with abemaciclib (DRUG); Fulvestrant in combination with abemaciclib (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7736,NCT02049957,Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Sapanisertib (DRUG); Fulvestrant (DRUG); Exemestane (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7737,NCT01797120,"Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI",COMPLETED,PHASE2,Metastatic Breast Cancer,Fulvestrant (DRUG); Everolimus (DRUG); Placebo (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7738,NCT04355520,"A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer",UNKNOWN,PHASE1,"HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer",TQ-B3525 (DRUG); Fulvestrant injection (DRUG),104741,Faslodex,"HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7739,NCT03099174,This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer,COMPLETED,PHASE1,Neoplasms; Breast Neoplasms,Xentuzumab (DRUG); Abemaciclib (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG); Abemaciclib (DRUG),104741,Faslodex,Neoplasms; Breast Neoplasms,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7740,NCT00328120,Faslodex 500mg Multiple Dose Tolerability Study in BC Patients,COMPLETED,PHASE1,Advanced Breast Cancer,Fulvestrant (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7741,NCT04567420,"DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)",RECRUITING,PHASE2,Breast Cancer,Palbociclib (DRUG); Fulvestrant (DRUG); Adjuvant Therapy (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7742,NCT03236974,Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.,COMPLETED,PHASE1,Postmenopausal Women With ER+ HER2- Primary Breast Cancer,Standard Arm - Fulvestrant (DRUG); AZD9496 (DRUG),104741,Faslodex,Postmenopausal Women With ER+ HER2- Primary Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7743,NCT05054374,A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer,COMPLETED,PHASE1,Breast Cancer; Breast Cancer Stage IV; HER2-negative Breast Cancer; Solid Carcinoma; MEK1 Gene Mutation; MEK2 Gene Mutation; Metastatic Breast Cancer,Mirdametinib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer; Breast Cancer Stage IV; HER2-negative Breast Cancer; Solid Carcinoma; MEK1 Gene Mutation; MEK2 Gene Mutation; Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7744,NCT03430466,Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Durvalmab&Tremelimumab&Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7745,NCT02738866,Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Cancer,Palbociclib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7746,NCT04985266,A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer,RECRUITING,PHASE2,ER+ Breast Cancer; HER2-negative Breast Cancer,Palbociclib 125Mg Tab (DRUG); Fulvestrant injection (DRUG); Tamoxifen (DRUG); Letrozole (DRUG); Exemestane (DRUG); Anastrozole (DRUG),104741,Faslodex,Breast Cancer (ER+/HER2-),Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7747,NCT04872166,A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer,RECRUITING,PHASE1,Advanced Solid Tumor; Metastatic Breast Cancer,BTX-A51 (DRUG),104741,Faslodex,Advanced Solid Tumor; Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7748,NCT02763566,A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Abemaciclib (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Placebo (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7749,NCT04498520,"Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer",WITHDRAWN,PHASE1,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Hormone Receptor Positive Breast Carcinoma; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Metastatic Endometrioid Adenocarcinoma; Metastatic Fallopian Tube Carcinoma; Metastatic HER2 Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Ovarian Carcinoma; Metastatic Primary Peritoneal Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Refractory Breast Carcinoma; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8,Abexinostat Tosylate (DRUG); Fulvestrant (DRUG); Palbociclib (DRUG),104741,Faslodex,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Hormone Receptor Positive Breast Carcinoma; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Metastatic Endometrioid Adenocarcinoma; Metastatic Fallopian Tube Carcinoma; Metastatic HER2 Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Ovarian Carcinoma; Metastatic Primary Peritoneal Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Refractory Breast Carcinoma; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7750,NCT03355157,"A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).",COMPLETED,PHASE4,Metastatic Breast Cancer,"Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen) (DRUG)",104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7751,NCT06074757,"Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study",COMPLETED,PHASE1,Metastatic Breast Cancer,Fulvestrant injection (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7752,NCT03778931,Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Elacestrant (DRUG); Standard of Care (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7753,NCT02107703,A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Neoplasms,Abemaciclib (DRUG); Fulvestrant (DRUG); Placebo (DRUG),104741,Faslodex,Breast Neoplasms,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7754,NCT04300790,Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients,COMPLETED,PHASE2,Breast Cancer,Alpelisib (DRUG); Metformin (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Exemestane (DRUG); Vildagliptin (DRUG); Tamoxifen (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7755,NCT03854903,"WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor",COMPLETED,PHASE1,Metastatic Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Hormone Receptor Positive Breast Cancer,Palbociclib (DRUG); Bosutinib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Metastatic Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Hormone Receptor Positive Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7756,NCT00259090,Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Fulvestrant (DRUG); Anastrazole (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7757,NCT06409390,Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer,RECRUITING,EARLY_PHASE1,Metastatic Breast Cancer,Taxotere (DRUG); Cytoxan (DRUG); Trastuzumab deruxtecan (DRUG); Sacituzumab govitecan (DRUG); Xeloda (DRUG); Fulvestrant (DRUG); Ribociclib (DRUG); Abemaciclib (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7758,NCT00234403,A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,gefitinib and fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7759,NCT03184090,Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC,COMPLETED,PHASE2,Metastatic Breast Cancer,Palbociclib (DRUG); Endocrine therapy (non IMP) (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7760,NCT06016738,OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Negative Breast Carcinoma,Palazestrant (DRUG); Fulvestrant (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG),104741,Faslodex,Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Negative Breast Carcinoma,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7761,NCT02657343,"An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.",COMPLETED,PHASE1,Breast Cancer,Ribociclib (DRUG); T-DM1 (DRUG); Trastuzumab (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7762,NCT05654623,"A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE3,Advanced Breast Cancer,ARV-471 (DRUG); Fulvestrant (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7763,NCT03377101,"Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer",WITHDRAWN,PHASE2,Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Stage IV Breast Cancer AJCC v6 and v7,Copanlisib (DRUG); Fulvestrant (DRUG); Laboratory Biomarker Analysis (OTHER); Palbociclib (DRUG),104741,Faslodex,Stage IV Hormone Receptor Positive HER2 Negative Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7764,NCT05932667,"Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer",TERMINATED,PHASE2,Advanced or Metastatic Breast Cancer,Milademetan (DRUG); Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL) (BEHAVIORAL),104741,Faslodex,Advanced or Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7765,NCT00274469,A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,fulvestrant (DRUG); anastrozole (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7766,NCT06585969,"A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer",NOT_YET_RECRUITING,PHASE3,Metastatic Breast Cancer; ER-positive Breast Cancer; Luminal B; Her2 Enriched; Basal Like,Trastuzumab deruxtecan (T-DXd) (DRUG); Ribociclib with ET (DRUG); Abemaciclib with ET (DRUG),104741,Faslodex,Metastatic Breast Cancer; ER-positive Breast Cancer; Luminal B; Her2 Enriched; Basal Like,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7767,NCT05113368,Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer,RECRUITING,PHASE2,Ovarian Cancer; Serous Ovarian Cancer,Regorafenib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Ovarian Cancer; Serous Ovarian Cancer,Ovary/Fallopian Tube,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7768,NCT02384746,Phase I Study of the Combination of MLN9708 and Fulvestrant,TERMINATED,PHASE1,Breast Cancer,Fulvestrant (DRUG); MLN9708 (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7769,NCT02592746,A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC,UNKNOWN,PHASE2,Metastatic Breast Cancer,Palbociclib (DRUG); Exemestane (DRUG); Leuprolide Acetate (DRUG); Capecitabine (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7770,NCT02970682,SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Neoplasm,SFX-01 (DRUG); Fulvestrant (DRUG); Tamoxifen (DRUG); Aromatase Inhibitors (DRUG),104741,Faslodex,Breast Neoplasm,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7771,NCT04282031,A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer,RECRUITING,PHASE1,Advanced Solid Tumor; HR+/HER2- Breast Cancer,BPI-1178 (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); BPI-1178 (DRUG),104741,Faslodex,Advanced Solid Tumor; HR+/HER2- Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7772,NCT06341894,Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer,RECRUITING,PHASE2,Early Breast Cancer,Dalpiciclib (DRUG); Endocrine therapy (DRUG),104741,Faslodex,Early Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7773,NCT03633331,"Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer",UNKNOWN,PHASE2,Estrogen Receptor-positive Breast Cancer; HER2/Neu Negative; Stage IV Breast Cancer AJCC v6 and v7,Palbociclib (DRUG); Letrozole (DRUG); Fulvestrant (DRUG); Questionnaire Administration (OTHER); Quality-of-Life Assessment (OTHER),104741,Faslodex,Estrogen Receptor-positive Breast Cancer; HER2/Neu Negative; Stage IV Breast Cancer AJCC v6 and v7,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7774,NCT01344031,"MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer",COMPLETED,PHASE1,Estrogen Receptor Positive; Invasive Breast Carcinoma; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7,Akt Inhibitor MK2206 (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG); Laboratory Biomarker Analysis (OTHER),104741,Faslodex,Estrogen Receptor Positive; Invasive Breast Carcinoma; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7775,NCT04556773,A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Breast Cancer,Trastuzumab deruxtecan (DRUG); Durvalumab (DRUG); Paclitaxel (DRUG); Capivasertib (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG); Capecitabine (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7776,NCT02675231,"A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer",COMPLETED,PHASE2,Hormone Receptor Positive Breast Cancer; HER-2 Positive Breast Cancer,Abemaciclib (DRUG); Trastuzumab (DRUG); Fulvestrant (DRUG); Standard of Care Single Agent Chemotherapy (DRUG),104741,Faslodex,Hormone Receptor Positive Breast Cancer; HER-2 Positive Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7777,NCT05319873,"Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer",RECRUITING,PHASE1,Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Locally Advanced HER2-Positive Breast Carcinoma; Metastatic HER2-Positive Breast Carcinoma; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8,Carboplatin (DRUG); Docetaxel (DRUG); Fulvestrant (DRUG); Pertuzumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Ribociclib (DRUG); Trastuzumab (BIOLOGICAL); Tucatinib (DRUG),104741,Faslodex,Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Locally Advanced HER2-Positive Breast Carcinoma; Metastatic HER2-Positive Breast Carcinoma; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7778,NCT03685331,"HOPE: Olaparib, Palbociclib and Fulvestrant in Patients with BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Breast Cancer; Locally Advanced Breast Cancer; Advanced Breast Cancer; BRCA2 Mutation; BRCA1 Mutation,Palbociclib (DRUG); Olaparib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Metastatic Breast Cancer; Locally Advanced Breast Cancer; Advanced Breast Cancer; BRCA2 Mutation; BRCA1 Mutation,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7779,NCT05238831,SMMART Adaptive Clinical Treatment (ACT) Trial,WITHDRAWN,EARLY_PHASE1,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Alectinib (DRUG); Alpelisib (DRUG); Anastrozole (DRUG); Atezolizumab (BIOLOGICAL); Bevacizumab (BIOLOGICAL); Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Capecitabine (DRUG); Carboplatin (DRUG); Cobimetinib (DRUG); Entrectinib (DRUG); Eribulin (DRUG); Fulvestrant (DRUG); Hyaluronidase-zzxf/Pertuzumab/Trastuzumab (BIOLOGICAL); Irinotecan (DRUG); Letrozole (DRUG); Nab-paclitaxel (DRUG); Niraparib (DRUG); Olaparib (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Pertuzumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Trastuzumab (BIOLOGICAL); Trastuzumab Emtansine (BIOLOGICAL); Vemurafenib (DRUG); Vinorelbine (DRUG); Vismodegib (DRUG),104741,Faslodex,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Ovary/Fallopian Tube,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7780,NCT02953860,Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Fulvestrant with Enzalutamide (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7781,NCT06837792,Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer,RECRUITING,PHASE2,"Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)",Experimental treatment arm (DRUG); Control treatment arm (DRUG),104741,Faslodex,"Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7782,NCT05075512,The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer,RECRUITING,PHASE2,Breast Neoplasm Female,"anlotinib, fulvestrant (DRUG)",104741,Faslodex,Female Breast Neoplasm,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7783,NCT05735080,"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer",RECRUITING,PHASE1,Breast Cancer; Breast Cancer Metastatic; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Ovarian Cancer; CCNE1 Amplification; Solid Tumor; Advanced Cancer; Metastatic Cancer,INX-315 (DRUG); Fulvestrant (DRUG); Abemaciclib (DRUG),104741,Faslodex,Breast Cancer; Breast Cancer Metastatic; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Ovarian Cancer; CCNE1 Amplification; Solid Tumor; Advanced Cancer; Metastatic Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7784,NCT02569801,A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy,TERMINATED,PHASE2,Breast Cancer,Fulvestrant (DRUG); GDC-0810 (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7785,NCT02344472,Detect V / CHEVENDO (Chemo vs. Endo),ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Breast Cancer,pertuzumab (DRUG); Trastuzumab (DRUG); Capecitabine (DRUG); Paclitaxel (DRUG); Vinorelbine (DRUG); Docetaxel (DRUG); Exemestane (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG); Ribociclib (DRUG); nab-Paclitaxel (DRUG); eribulin (DRUG); leuprorelin (DRUG); goserelin (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7786,NCT05759572,Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer,RECRUITING,PHASE2,Breast Cancer Metastatic,Apatinib (DRUG); Dalpiciclib (DRUG); Fulvestrant/AI (DRUG),104741,Faslodex,Breast Cancer Metastatic,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7787,NCT06726148,Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors,RECRUITING,PHASE1,Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors,ECI830 (DRUG); ribociclib (DRUG); fulvestrant (DRUG),104741,Faslodex,Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7788,NCT05808582,Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer,UNKNOWN,PHASE2,Hormone Receptor-positive Advanced Breast Cancer,chidamide，fulvestrant (DRUG),104741,Faslodex,Hormone Receptor-positive Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7789,NCT00305448,"A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg",COMPLETED,PHASE2,Advanced Breast Cancer; Metastatic Breast Cancer,Fulvestrant (DRUG); Fulvestrant (DRUG),104741,Faslodex,Advanced Breast Cancer; Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7790,NCT02540330,A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant,TERMINATED,PHASE2,Female Breast Carcinoma; Female Ductal Carcinoma In Situ,Fulvestrant (DRUG),104741,Faslodex,Female Breast Carcinoma; Female Ductal Carcinoma In Situ,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7791,NCT05082025,"Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations",ACTIVE_NOT_RECRUITING,PHASE2,Endometrial Cancer; Ovarian Cancer,Copanlisib (DRUG); fulvestrant (DRUG),104741,Faslodex,Endometrial Cancer; Ovarian Cancer,Uterus,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7792,NCT06750848,"Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer",NOT_YET_RECRUITING,PHASE2,Advanced Breast Cancer,Chidamide，Fulvestrant，angiogenesis inhibitors (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7793,NCT02549430,To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy,COMPLETED,PHASE2,Breast Cancer,Palbociclib (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7794,NCT01655225,A Study of LY3023414 in Participants With Advanced Cancer,COMPLETED,PHASE1,Advanced Cancer; Metastatic Cancer; Non-Hodgkin's Lymphoma; Metastatic Breast Cancer; Malignant Mesothelioma; Non-small Cell Lung Cancer,LY3023414 (DRUG); Midazolam (DRUG); Fulvestrant (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG); Abemaciclib (DRUG); Letrozole (DRUG),104741,Faslodex,Advanced Cancer; Metastatic Cancer; Non-Hodgkin's Lymphoma; Metastatic Breast Cancer; Malignant Mesothelioma; Non-small Cell Lung Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7795,NCT05860465,Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer,RECRUITING,PHASE2,Locally Advanced or Metastatic Breast Cancer,SPH4336 Tablets (DRUG); SPH4336 Tablets Placebo (DRUG),104741,Faslodex,Locally Advanced or Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7796,NCT04247126,"A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors",COMPLETED,PHASE1,Advanced Solid Tumor; Breast Cancer; Small-cell Lung Cancer; Pancreatic Cancer,SY-5609 (DRUG); Fulvestrant (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG),104741,Faslodex,Advanced Solid Tumor; Breast Cancer; Small-cell Lung Cancer; Pancreatic Cancer,Lung,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7797,NCT00065325,The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer,COMPLETED,PHASE3,Locally Advanced Breast Cancer; Metastatic Breast Cancer,Fulvestrant (DRUG); Exemestane (DRUG),104741,Faslodex,Locally Advanced Breast Cancer; Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7798,NCT04460430,Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Neratinib + endocrine therapy (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7799,NCT06929325,Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors,NOT_YET_RECRUITING,PHASE3,HR+/HER2- Advanced/Metastatic Breast Cancer,Sirolimus for Injection (Albumin-bound) (DRUG); Fulvestrant Injection (DRUG); Placebo for Sirolimus for Injection (Albumin-bound) (DRUG),104741,Faslodex,HR+/HER2- Advanced/Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7800,NCT02366130,Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Ra-223 dichloride (DRUG); Denosumab (DRUG); Hormone Therapy (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7801,NCT00754325,Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor,COMPLETED,PHASE2,Advanced Breast Cancer,Dasatinib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7802,NCT00138125,Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Faslodex (DRUG); Herceptin (BIOLOGICAL),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7803,NCT00012025,ICI 182780 in Treating Women With Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7804,NCT06561022,Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping,NOT_YET_RECRUITING,PHASE2,Breast Cancer,Fluzoparib (DRUG); Everolimus (DRUG); Fulvestrant (DRUG); Abemaciclib (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7805,NCT06172322,A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer,RECRUITING,PHASE1,HR Positive/HER-2 Negative Breast Cancer,NTQ1062 with Fulvestrant (DRUG),104741,Faslodex,HR Positive/HER-2 Negative Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7806,NCT02760030,Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients with Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery,ACTIVE_NOT_RECRUITING,PHASE2,Estrogen Receptor And/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Fulvestrant (DRUG); Laboratory Biomarker Analysis (OTHER); Palbociclib (DRUG); Questionnaire Administration (OTHER); Aromatase Inhibitors (DRUG),104741,Faslodex,Estrogen Receptor And/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7807,NCT00752986,ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial,TERMINATED,PHASE2,Breast Cancer,ZD6474 (Vandetanib at the dose of 100 mg) (DRUG); Placebo to match ZD6474 (Vandetanib at the dose of 100 mg) (DRUG); Fulvestrant (DRUG); ZD6474 (Vandetanib at the dose of 300 mg) (DRUG); Placebo to match ZD6474 (Vandetanib at the dose of 300 mg) (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7808,NCT02384239,A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer; Hormone Receptor Positive,Palbociclib (DRUG); Tamoxifen (DRUG); Fulvestrant (DRUG),104741,Faslodex,Metastatic Breast Cancer; Hormone Receptor Positive,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7809,NCT06764186,A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain,RECRUITING,PHASE3,Locally Advanced or Metastatic Breast Cancer,Fulvestrant (DRUG); Capivasertib (DRUG),104741,Faslodex,Locally Advanced or Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7810,NCT05063786,Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET),ACTIVE_NOT_RECRUITING,PHASE3,Advanced Breast Cancer,Trastuzumab (BIOLOGICAL); Alpelisib (DRUG); Fulvestrant (DRUG); Vinorelbine (DRUG); Capecitabine (DRUG); Eribulin (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7811,NCT03289039,"Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer",TERMINATED,PHASE2,Breast Cancer,Neratinib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7812,NCT05768139,First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors,RECRUITING,PHASE1,"Breast Cancer; Gynecologic Cancer; HNSCC; Solid Tumors, Adult",STX-478 (DRUG); Fulvestrant (DRUG); Ribociclib (DRUG); Palbociclib (DRUG),104741,Faslodex,"Breast Cancer; Gynecologic Cancer; HNSCC; Solid Tumors, Adult",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7813,NCT05501886,Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1),RECRUITING,PHASE3,Breast Cancer,Gedatolisib (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG); Alpelisib (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7814,NCT05894239,A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer,RECRUITING,PHASE3,Metastatic Breast Cancer,Inavolisib (DRUG); Phesgo (DRUG); Placebo (DRUG); Taxane-based Chemotherapy (DRUG); Optional Endocrine Therapy of Investigator's Choice (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7815,NCT04227327,"Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)",UNKNOWN,PHASE2,Advanced Breast Cancer,Abemaciclib (DRUG); Aromatase Inhibitors (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7816,NCT00543127,Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole,TERMINATED,PHASE3,Breast Cancer,Fulvestrant (DRUG); Anastrozole (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7817,NCT02792465,A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,Advanced Solid Cancers; Breast Cancer,CFI-402257 (DRUG); Fulvestrant (DRUG),104741,Faslodex,Advanced Solid Cancers; Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7818,NCT06950086,Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors,RECRUITING,PHASE1,"HR-positive, HER2-negative Advanced Breast Cancer",TYK-00540 (DRUG),104741,Faslodex,"HR-positive, HER2-negative Advanced Breast Cancer",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7819,NCT01626222,"4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer",COMPLETED,PHASE3,Metastatic Breast Cancer,Exemestane (DRUG); Everolimus (RAD001) (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7820,NCT00253422,Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer,UNKNOWN,PHASE3,Breast Cancer,anastrozole (DRUG); exemestane (DRUG); fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7821,NCT04053322,"Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.",ACTIVE_NOT_RECRUITING,PHASE2,"ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer; a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status",Durvalumab (DRUG); Olaparib (DRUG); Fulvestrant (DRUG),104741,Faslodex,"ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer; a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7822,NCT01823835,A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer,TERMINATED,PHASE1,Breast Cancer,GDC-0810 (DRUG); LHRH Agonist (DRUG); Palbociclib (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7823,NCT02646735,Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients,UNKNOWN,PHASE2,Breast Cancer,Fulvestrant 500 mg (DRUG); Exemestane 25 mg (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7824,NCT03820830,Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer Recurrent,Palbociclib 125mg (DRUG); Standard endocrine therapy (DRUG),104741,Faslodex,Recurrent Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7825,NCT06065748,"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)",RECRUITING,PHASE3,"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer",Giredestrant (DRUG); Fulvestrant (DRUG); Abemaciclib (DRUG); Palbociclib (DRUG); Ribociclib (DRUG); LHRH Agonist (DRUG); FoundationOne Liquid CDx Assay (F1LCDx) (DIAGNOSTIC_TEST),104741,Faslodex,"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7826,NCT02383030,Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients,UNKNOWN,PHASE3,Metastatic Breast Cancer,Fulvestrant (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7827,NCT06428396,Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029),RECRUITING,PHASE2,Metastatic Breast Cancer,Belzutifan (DRUG); Fulvestrant (DRUG); Everolimus (DRUG); Exemestane (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7828,NCT04355858,Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer,UNKNOWN,PHASE2,Breast Cancer; Metastatic Cancer,SHR7390 (DRUG); Famitinib (DRUG); SHR3162 (DRUG); Pyrotinib (DRUG); Capecitabine (DRUG); SHR1210 (DRUG); Everolimus (DRUG); Nab paclitaxel (DRUG); SHR2554 (DRUG); SHR3680 (DRUG); SHR6390 (DRUG); SHR1701 (DRUG); SERD (DRUG); AI (DRUG); VEGFi (DRUG),104741,Faslodex,Breast Cancer; Metastatic Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7829,NCT03386162,SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer,TERMINATED,PHASE2,"Breast Cancer, PI3K, Alpelisib",Alpelisib (DRUG); Chemotherapy (DRUG),104741,Faslodex,"Breast Cancer, PI3K, Alpelisib",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7830,NCT04060862,A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer,TERMINATED,PHASE1,Breast Cancer,Ipatasertib (DRUG); Placebo (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7831,NCT05176080,"Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer",TERMINATED,PHASE1,Metastatic Breast Cancer,Famitinib (DRUG); SHR6390 (DRUG); Fulvestrant (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7832,NCT03024580,A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer,UNKNOWN,PHASE2,Breast Neoplasm,Megestrol Acetate 160Mg Tablet (DRUG); Anastrozole 1Mg Tablet (DRUG); Letrozole 2.5Mg Tablet (DRUG); Exemestane 25 MG (DRUG); Tamoxifen 20Mg Tablet (DRUG); Fulvestrant 50Mg Solution for Injection (DRUG),104741,Faslodex,Breast Neoplasm,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7833,NCT01989780,Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Paclitaxel (DRUG); Bevacizumab (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Goserelin (DRUG); leuprorelin (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7834,NCT05411380,"Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.",UNKNOWN,PHASE2,Breast Cancer,Tucidinostat (DRUG); Capecitabine (DRUG); Endocrine Therapy (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7835,NCT05433480,"A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,BPI-16350 (DRUG); placebo (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7836,NCT01556191,Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR,COMPLETED,PHASE2,Stage IV Lung Cancer,Gefitinib (DRUG); Fulvestrant (DRUG); Erlotinib (DRUG),104741,Faslodex,Stage IV Lung Cancer,Lung,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7837,NCT03959891,"AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)",ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,Ipatasertib (DRUG); Fulvestrant (DRUG); Aromatase Inhibitor (DRUG); Palbociclib (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7838,NCT05467891,"Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer",RECRUITING,PHASE2,Locoregional Recurrence; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer,Ribociclib (DRUG); Fulvestrant (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG),104741,Faslodex,Breast Cancer (ER+/HER2-),Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7839,NCT03202862,The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer,UNKNOWN,PHASE2,Breast Neoplasms,Fulvestrant (DRUG),104741,Faslodex,Breast Neoplasms,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7840,NCT03294694,Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer,TERMINATED,PHASE1,Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer; HER2-Negative Breast Cancer; Metastatic Epithelial Ovarian Cancer,Ribociclib (DRUG); PDR001 (DRUG); Fulvestrant (DRUG),104741,Faslodex,Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer; HER2-Negative Breast Cancer; Metastatic Epithelial Ovarian Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7841,NCT02115594,Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer,WITHDRAWN,PHASE2,Breast Cancer,Fulvestrant (DRUG); Entinostat (DRUG); Placebo (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7842,NCT00688194,Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy,UNKNOWN,PHASE3,Breast Cancer,anastrozole (DRUG); exemestane (DRUG); fulvestrant (DRUG); lapatinib ditosylate (DRUG); letrozole (DRUG); placebo (OTHER),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7843,NCT05079360,Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer,WITHDRAWN,PHASE2,Metastatic Breast Cancer,"Sabizabulin (DRUG); Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (DRUG)",104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7844,NCT05362760,Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management,RECRUITING,PHASE4,Hormone Receptor-positive Metastatic Breast Cancer; HER2-negative Metastatic Breast Cancer,Abemaciclib + Aromatase Inhibitor (DRUG); Abemaciclib + Fulvestrant (DRUG),104741,Faslodex,Hormone Receptor-positive Metastatic Breast Cancer; HER2-negative Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7845,NCT02955394,Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Enzalutamide (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7846,NCT05720260,"Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC",RECRUITING,PHASE2,Premenopausal Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer,Goserelin (DRUG); Fulvestrant (DRUG); Capivasertib (DRUG); Durvalumab (DRUG),104741,Faslodex,Metastatic ER-Positive Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7847,NCT01633060,"A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi",TERMINATED,PHASE3,Metastatic Breast Cancer,Fulvestrant (DRUG); BKM120 (DRUG); BKM120 matching placebo (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7848,NCT05646862,"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy",ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Inavolisib (DRUG); Fulvestrant (DRUG); Alpelisib (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7849,NCT01202591,Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients,COMPLETED,PHASE1,"FGFR Inhibition, Pharmacokinetics, Biomarkers; ER+ Breast Cancer",AZD4547 (DRUG); Exemestane (DRUG); Placebo (DRUG); Fulvestrant (DRUG),104741,Faslodex,"FGFR Inhibition, Pharmacokinetics, Biomarkers; ER+ Breast Cancer",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7850,NCT00784862,ATAC - Pharmacokinetics (PK) Sub-Protocol,COMPLETED,PHASE3,Breast Cancer,Anastrozole (DRUG); Tamoxifen (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7851,NCT02690480,Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer,UNKNOWN,PHASE2,Breast Neoplasms,PD-0332991 (Palbociclib) (DRUG); Fulvestrant (DRUG); Placebo (DRUG),104741,Faslodex,Breast Neoplasms,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7852,NCT01602380,A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.,ACTIVE_NOT_RECRUITING,PHASE3,Hormone Receptor Positive Breast Cancer,faslodex 500mg (DRUG); arimidex 1mg (DRUG); faslodex dummy (DRUG); arimidex dummy (DRUG),104741,Faslodex,Hormone Receptor Positive Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7853,NCT05038735,"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.",RECRUITING,PHASE3,Breast Cancer,Alpelisib (DRUG); Fulvestrant (DRUG); Alpelisib-matching placebo (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7854,NCT00183963,A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS),TERMINATED,PHASE2,Breast Carcinoma,Tamoxifen (DRUG); Fulvestrant (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Carcinoma,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7855,NCT02476786,Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score,RECRUITING,PHASE2,Breast Cancer; Cancer of Breast; Breast Neoplasms; Cancer of the Breast,FACT-B (BEHAVIORAL); Goserelin (DRUG); Anastrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Tamoxifen (DRUG); Archived tissue collection (OTHER),104741,Faslodex,Breast Cancer; Cancer of Breast; Breast Neoplasms; Cancer of the Breast,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7856,NCT02394496,Overcoming Endocrine Resistance in Metastatic Breast Cancer,UNKNOWN,PHASE3,Metastatic Breast Cancer,Fulvestrant (DRUG); Lapatinib (DRUG); Aromatase Inhibitors (DRUG); Placebo Lapatinib (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7857,NCT03238196,"Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer",COMPLETED,PHASE1,Metastatic Breast Cancer,Erdafitinib (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7858,NCT04707196,A Study of Abemaciclib in Indian Women With Advanced Breast Cancer,COMPLETED,PHASE4,Breast Neoplasms; Neoplasm Metastasis,Abemaciclib (DRUG); Nonsteroidal Aromatase Inhibitor (NSAI) (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Neoplasms with Metastasis,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7859,NCT01560416,Fulvestrant With or Without Ganetespib in HR+ Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Fulvestrant (DRUG); Ganetespib (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7860,NCT01226316,"Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules",COMPLETED,PHASE1,Advanced Solid Malignancy; Safety and Tolerability; Pharmacokinetics; Pharmacodynamics; Tumour Response; Advanced or Metastatic Breast Cancer; Ovarian Cancer; Cervical Cancer; Endometrial Cancer; PIK3CA; AKT1; PTEN; ER Positive; HER2 Positive,AZD5363 (DRUG); AZD5363 (DRUG); AZD5363 (DRUG); AZD5363 (DRUG),104741,Faslodex,Advanced Solid Malignancy; Safety and Tolerability; Pharmacokinetics; Pharmacodynamics; Tumour Response; Advanced or Metastatic Breast Cancer; Ovarian Cancer; Cervical Cancer; Endometrial Cancer; PIK3CA; AKT1; PTEN; ER Positive; HER2 Positive,Uterus,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7861,NCT01377324,Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites,COMPLETED,PHASE2,Metastatic Breast Cancer,Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol (OTHER),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7862,NCT03750396,Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer,RECRUITING,PHASE2,Breast Cancer; Recurrent Breast Cancer; Stereotactic Body Radiotherapy; Estrogen Receptor Positive Tumor; Her2-negative Tumor; Surgery,Surgical resection (PROCEDURE); Stereotactic body radiotherapy (RADIATION); Radiofrequency ablation (PROCEDURE),104741,Faslodex,Breast Cancer; Recurrent Breast Cancer; Stereotactic Body Radiotherapy; Estrogen Receptor Positive Tumor; Her2-negative Tumor; Surgery,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7863,NCT04539496,A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,Metastasis Solid Tumors; Advanced Breast Cancer,XZP-3287 (DRUG); XZP-3287;Letrozole;Anastrozole;Fulvestrant (DRUG); XZP-3287 (DRUG),104741,Faslodex,Metastasis Solid Tumors; Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7864,NCT05025735,"Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer",UNKNOWN,PHASE2,Metastatic Breast Cancer; HER2-negative Breast Cancer,Dapagliflozin 10Mg Tab (DRUG),104741,Faslodex,Metastatic HER2-negative Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7865,NCT02000596,1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.,TERMINATED,PHASE2,Metastatic Breast Cancer,Trastuzumab plus Pertuzumab (DRUG); Hormonal Therapy with Anastrozole and Fulvestrant (DRUG); Chemotherapy with Eribulin (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7866,NCT00629616,"Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer",COMPLETED,PHASE2,Breast Cancer,anastrozole (DRUG); fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7867,NCT00570258,"Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy",TERMINATED,PHASE2,Metastatic Breast Cancer,Fulvestrant (DRUG); erlotinib (DRUG); Fulvestrant (DRUG); Placebo (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7868,NCT01942135,Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3),COMPLETED,PHASE3,Metastatic Breast Cancer,Palbociclib (DRUG); Fulvestrant (DRUG); Placebo (DRUG); Fulvestrant (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7869,NCT05594095,SNF Platform Study of HR+/ HER2-advanced Breast Cancer,RECRUITING,PHASE2,Breast Neoplasm; Breast Cancer; Hormone Receptor Positive Tumor; HER2-negative Breast Cancer; Advanced Breast Cancer,PIK3CA inhibitor (DRUG); AKT inhibitor (DRUG); Carrelizumab (DRUG); Famitinib (DRUG); Fluzoparib (DRUG); Dalpiciclib (DRUG); SHR-A1811 (DRUG); Everolimus (DRUG); Aromatase Inhibitors or Fulvestrant (DRUG); Goserelin (DRUG); TPC (DRUG); Sorafenib (DRUG); Apatinib (DRUG); SHR-A1921 (DRUG); SHR-A2102 (DRUG); SHR-A2009 (DRUG); SHR-1167 (DRUG); SHR-6209 (DRUG); bevacizumab (DRUG),104741,Faslodex,"Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7870,NCT03321981,MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.,COMPLETED,PHASE2,Breast Cancer Metastatic,Zenocutuzumab (DRUG); Trastuzumab (DRUG); Vinorelbine (DRUG); Endocrine therapy (DRUG),104741,Faslodex,Breast Cancer Metastatic,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7871,NCT03241810,Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer,TERMINATED,PHASE2,Metastatic Breast Cancer,Seribantumab (DRUG); Fulvestrant (DRUG); Placebo (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7872,NCT05230810,Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.,RECRUITING,PHASE1,HER2-positive Metastatic Breast Cancer,Alpelisib (DRUG); Tucatinib (DRUG); Fulvestrant (DRUG),104741,Faslodex,HER2-positive Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7873,NCT05792410,A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.,UNKNOWN,PHASE1,HER2 Low Advanced or Metastatic Breast Cancer,SHR-A1811 & Dalpiciclib Isethionate Tablets (DRUG); SHR-A1811 & Fulvestrant (DRUG); SHR-A1811 & Bevacizumab injection (DRUG),104741,Faslodex,HER2 Low Advanced or Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7874,NCT05438810,"This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.",UNKNOWN,PHASE3,Advanced Breast Cancer; Female Breast Cancer,"FCN-437c,Fulvestrant,Goserelin acetate (DRUG); Placebo,Fulvestrant,Goserelin acetate (DRUG)",104741,Faslodex,Advanced Breast Cancer; Female Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7875,NCT04650581,Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Ipatasertib (DRUG); Fulvestrant (DRUG); Placebo (OTHER),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7876,NCT05306340,"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)",ACTIVE_NOT_RECRUITING,PHASE3,"Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer",Giredestrant (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Tamoxifen (DRUG); Everolimus (DRUG); LHRH Agonist (DRUG); Dexamethasone Mouth Rinse (DRUG),104741,Faslodex,"Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7877,NCT05472792,Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN),RECRUITING,PHASE2,Breast Cancer; Quality of Life,"Accelerated Partial Breast Irradiation (APBI) (RADIATION); tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene (DRUG)",104741,Faslodex,Breast Cancer; Quality of Life,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7878,NCT02911844,Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension,COMPLETED,PHASE2,Pulmonary Arterial Hypertension,Fulvestrant (DRUG),104741,Faslodex,Pulmonary Arterial Hypertension,Lung,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7879,NCT05463601,Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer,UNKNOWN,PHASE2,Metastatic Breast Cancer,"Mecapegfilgrastim (DRUG); dalpiciclib (DRUG); exemestane, fulvestrant, letrozole, tamoxifen (DRUG)",104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7880,NCT04316169,"Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer",WITHDRAWN,PHASE1,Solid Tumor; Advanced Breast Cancer,Abemaciclib (DRUG); Hydroxychloroquine 200 mg (DRUG); Faslodex (DRUG); Anastrazole (DRUG); Letrozole (DRUG); Hydroxychloroquine 400 mg (DRUG); Hydroxychloroquine 600 mg (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7881,NCT02345772,Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy,TERMINATED,PHASE1,HER2-positive Breast Cancer; ER-positive Breast Cancer,"fulvestrant 500 mg (DRUG); Docetaxel (DRUG); Trastuzumab (H, 8mg/kg (DRUG); Pertuzumab (P, 840 mg (DRUG)",104741,Faslodex,HER2-positive Breast Cancer; ER-positive Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7882,NCT03006172,"To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer; Solid Tumor,Inavolisib (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Palbociclib (DRUG); Metformin (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG),104741,Faslodex,Breast Cancer; Solid Tumor,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7883,NCT01142401,Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Carcinoma; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7,Bortezomib (DRUG); Fulvestrant (DRUG); Laboratory Biomarker Analysis (OTHER),104741,Faslodex,Metastatic Breast Carcinoma; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7884,NCT03179904,TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Advanced Breast Carcinoma; HER2-Positive Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; HER2-positive Breast Cancer,Anastrozole (DRUG); Denifanstat (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Echocardiography (PROCEDURE); Letrozole (DRUG); Paclitaxel (DRUG); Trastuzumab (BIOLOGICAL); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Biospecimen Collection (PROCEDURE); Biopsy (PROCEDURE),104741,Faslodex,Advanced Breast Carcinoma; HER2-Positive Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; HER2-positive Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7885,NCT00146601,Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7886,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,HER2+/HR+ Breast Cancer,ZW25 (Zanidatamab) (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG),104741,Faslodex,HER2+/HR+ Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7887,NCT04033172,Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant ),UNKNOWN,PHASE2,Breast Cancer; HER2-positive Breast Cancer,Pyrotinib Plus Fulvestrant (DRUG),104741,Faslodex,Breast Cancer; HER2-positive Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7888,NCT05169567,Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Neoplasm; Neoplasm Metastasis,Abemaciclib (DRUG); Fulvestrant (DRUG); Placebo (DRUG),104741,Faslodex,Breast Neoplasm; Neoplasm Metastasis,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7889,NCT00272740,SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms,Fulvestrant (DRUG),104741,Faslodex,Breast Neoplasms,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7890,NCT05328440,Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02),RECRUITING,PHASE2,Breast Neoplasms,Pyrotinib Maleate (DRUG); Dalpiciclib Isethionate Tablets (DRUG); Inetetamab (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Neoplasms,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7891,NCT04999540,Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Tucidinostat (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7892,NCT05759546,PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer,RECRUITING,PHASE2,Breast Cancer Metastatic,Fluzoparib (DRUG); Dalpiciclib (DRUG); Fulvestrant/AI (DRUG),104741,Faslodex,Breast Cancer Metastatic,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7893,NCT02072512,The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer,UNKNOWN,PHASE2,Metastatic Breast Cancer,Fulvestrant (DRUG); Goserelin (DRUG); Anastrozole (DRUG); Goserelin (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7894,NCT03308201,Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer,COMPLETED,PHASE1,Breast Cancer,Hemay022+exemestane (DRUG); Hemay022+letrozole (DRUG); Hemay022+ fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7895,NCT02983604,"GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer",TERMINATED,PHASE1,Advanced Estrogen Receptor Positive HER2- Breast Cancer,GS-5829 (DRUG); Exemestane (DRUG); Fulvestrant (DRUG),104741,Faslodex,Advanced Estrogen Receptor Positive HER2- Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7896,NCT03554044,T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer,UNKNOWN,PHASE1,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Breast Carcinoma,Anastrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Paclitaxel (DRUG); Talimogene Laherparepvec (BIOLOGICAL); Tamoxifen (DRUG); Nab paclitaxel (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG),104741,Faslodex,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Breast Carcinoma,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7897,NCT04034589,Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer,UNKNOWN,PHASE2,Metastatic Breast Cancer,Pyrotinib combined with fulvestrant (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7898,NCT02219789,Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,COMPLETED,PHASE1,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Alisertib (DRUG); Fulvestrant (DRUG); Laboratory Biomarker Analysis (OTHER),104741,Faslodex,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7899,NCT04544189,Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Neoplasms,Alpelisib (DRUG); Fulvestrant (DRUG); Placebo (DRUG),104741,Faslodex,Breast Neoplasms,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7900,NCT04738292,Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study),TERMINATED,PHASE2,ER-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Cancer,Onapristone (DRUG); Fulvestrant (DRUG),104741,Faslodex,ER-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7901,NCT04337658,"Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer",NOT_YET_RECRUITING,PHASE3,HER2-positive Breast Cancer,Pertuzumab (DRUG); Trastuzumab (DRUG); Fulvestrant (DRUG); Capecitabine (DRUG),104741,Faslodex,HER2-positive Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7902,NCT02530424,"""Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment """,COMPLETED,PHASE2,Breast Neoplasms,Trastuzumab (DRUG); Pertuzumab (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Neoplasms,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7903,NCT06176534,"Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial",RECRUITING,PHASE2,Advanced Breast Cancer; Treatment; HR Low/HER2 Negative,Experimental: chemotheyapy (DRUG); Active Comparator: endocrine therapy (DRUG),104741,Faslodex,Advanced Breast Cancer; Treatment; HR Low/HER2 Negative,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7904,NCT05090358,Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer; Breast Cancer Stage IV; Metastatic Breast Cancer,Ketogenic Diet (DIETARY_SUPPLEMENT); Low Carbohydrate Diet (DIETARY_SUPPLEMENT); Alpelisib (DRUG); Fulvestrant (DRUG); Canagliflozin (DRUG),104741,Faslodex,Breast Cancer; Breast Cancer Stage IV; Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7905,NCT00871858,Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer,COMPLETED,PHASE2,Breast Cancer,anastrozole (DRUG); fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7906,NCT04305496,Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Locally Advanced (Inoperable) or Metastatic Breast Cancer,Fulvestrant (DRUG); Capivasertib (DRUG); Placebo (DRUG),104741,Faslodex,Locally Advanced (Inoperable) or Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7907,NCT05252416,(VELA) Study of BLU-222 in Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,Advanced Solid Tumors; HR+ Breast Cancer; CCNE1 Amplification; HER2-negative Breast Cancer; Ovarian Cancer; Endometrial Cancer; Gastric Cancer; Esophageal Adenocarcinoma; Carcinosarcoma,BLU-222 (DRUG); Carboplatin (DRUG); Ribociclib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Advanced Solid Tumors; HR+ Breast Cancer; CCNE1 Amplification; HER2-negative Breast Cancer; Ovarian Cancer; Endometrial Cancer; Gastric Cancer; Esophageal Adenocarcinoma; Carcinosarcoma,Esophagus/Stomach,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7908,NCT05305924,"Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer",RECRUITING,PHASE2,ER-Positive Breast Cancer; HER2-negative Breast Cancer,Fulvestrant Run-In (DRUG),104741,Faslodex,ER-Positive Breast Cancer; HER2-negative Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7909,NCT00372996,"Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer",TERMINATED,PHASE2,Breast Neoplasms,"CP-751,871 (DRUG); exemestane (DRUG); exemestane (DRUG); Fulvestrant (DRUG)",104741,Faslodex,Breast Neoplasms,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7910,NCT06555068,"A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients",RECRUITING,PHASE1,Advanced Unresectable or Metastatic Breast Cancer,HRS-6209 in Combination with Fulvestrant (DRUG); HRS-6209 in Combination with HRS-1358 (DRUG); HRS-6209 in Combination with Letrozole (DRUG); HRS-6209 in Combination with HRS-8080 (DRUG); HRS-6209 in Combination with HRS-1358 (DRUG),104741,Faslodex,Advanced Unresectable or Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7911,NCT05191004,Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC,WITHDRAWN,PHASE1,Advanced Breast Cancer; Metastatic Breast Cancer; Breast Cancer; Breast Carcinoma; Cancer of the Breast; Cancer of Breast; Malignant Tumor of Breast; Breast Tumor,NUV-422 (DRUG); Fulvestrant (DRUG),104741,Faslodex,Advanced Breast Cancer; Metastatic Breast Cancer; Breast Cancer; Breast Carcinoma; Cancer of the Breast; Cancer of Breast; Malignant Tumor of Breast; Breast Tumor,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7912,NCT00722072,Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy,TERMINATED,PHASE2,Breast Cancer,fulvestrant (DRUG); sorafenib tosylate (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7913,NCT05601440,Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer,RECRUITING,PHASE2,Breast Cancer,RP-6306 (DRUG); Gemcitabine (DRUG); Observation (OTHER); Niraparib (DRUG); Fulvestrant (DRUG); RP-3500 (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7914,NCT00327769,Faslodex Advanced Breast Cancer Local Chinese Study,COMPLETED,PHASE3,Advanced Breast Cancer,Fulvestrant (DRUG); Anastrozole (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7915,NCT04606446,Study of PF-07248144 in Advanced or Metastatic Solid Tumors,RECRUITING,PHASE1,Locally Advanced or Metastatic ER+ HER2- Breast Cancer; Locally Advanced or Metastatic Castration-resistant Prostate Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer,PF-07248144 (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Palbociclib (DRUG); PF-07220060 (DRUG),104741,Faslodex,Locally Advanced or Metastatic ER+ HER2- Breast Cancer; Locally Advanced or Metastatic Castration-resistant Prostate Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer,Lung,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7916,NCT06239467,First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer,RECRUITING,PHASE1,Advanced Cancer; Breast Cancer,OKI-219 (DRUG); Fulvestrant (DRUG); Trastuzumab (DRUG),104741,Faslodex,Advanced Cancer; Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7917,NCT03439046,"Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant",COMPLETED,PHASE3,Breast Cancer,Ribociclib (DRUG); Letrozole (DRUG); Alpelisib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7918,NCT05631795,"Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment",RECRUITING,PHASE4,Advanced Breast Cancer,Alpelisib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7919,NCT05546268,Study of Oral MRT-2359 in Selected Cancer Patients,RECRUITING,PHASE1,"NSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC With High or Low L-MYC or N-MYC Expression; HR-positive, HER2-negative Breast Cancer; Prostate Cancer",Oral MRT-2359 (DRUG); Oral MRT-2359 (DRUG); Oral MRT-2359 (DRUG); Oral MRT-2359 (DRUG); Oral MRT-2359 (DRUG); Oral MRT-2359 (DRUG),104741,Faslodex,"NSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC With High or Low L-MYC or N-MYC Expression; HR-positive, HER2-negative Breast Cancer; Prostate Cancer",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7920,NCT00811369,"Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer",COMPLETED,PHASE2,Metastatic Breast Cancer,Fulvestrant + ZACTIMA (DRUG); Fulvestrant + Placebo (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7921,NCT04256941,"Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study",TERMINATED,PHASE2,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8,Abemaciclib (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Palbociclib (DRUG); Ribociclib (DRUG),104741,Faslodex,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7922,NCT03182634,The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial,UNKNOWN,PHASE2,Advanced Breast Cancer,Fulvestrant (DRUG); Neratinib (DRUG); AZD5363 (DRUG); Olaparib (DRUG); AZD6738 (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7923,NCT00534417,Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,capecitabine (DRUG); fulvestrant (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7924,NCT05949541,Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer,RECRUITING,PHASE2,Breast Cancer; Advanced Breast Cancer,Everolimus 10 mg (DRUG); CDK4/6 Inhibitor SHR6390 (DRUG); Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7925,NCT02437318,Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.,COMPLETED,PHASE3,Breast Cancer,Fulvestrant (DRUG); Alpelisib (DRUG); Placebo (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7926,NCT00635713,Second Line Breast Cancer Trial,COMPLETED,PHASE3,Advanced Breast Cancer,Fulvestrant (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7927,NCT03310541,AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations,COMPLETED,PHASE1,Breast Cancer; Prostate Cancer; Advanced Solid Tumors,AZD5363 (DRUG); Enzalutamide (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer; Prostate Cancer; Advanced Solid Tumors,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7928,NCT05384119,Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer,TERMINATED,PHASE1,Breast Cancer,TTI-101 (DRUG); Palbociclib (DRUG); Aromatase inhibitor (AI) (DRUG); fulvestrant (DRUG); ribociclib (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7929,NCT05905341,"Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.",WITHDRAWN,PHASE1,Breast Cancer; Ovarian Cancer; Liposarcoma; Non-small Cell Lung Cancer (NSCLC); Endometrial; Solid Tumors,PF-07224826 (DRUG); Fulvestrant (COMBINATION_PRODUCT); PF-07224826 (DRUG); Fulvestrant (COMBINATION_PRODUCT); PF-07224826 (DRUG); Fulvestrant (COMBINATION_PRODUCT); PF-07224826 (DRUG); Fulvestrant (COMBINATION_PRODUCT); PF-07224826 (DRUG); Fulvestrant (COMBINATION_PRODUCT); PF-07224826 (DRUG); Fulvestrant (COMBINATION_PRODUCT); PF-07224826 (DRUG); Fulvestrant (COMBINATION_PRODUCT),104741,Faslodex,Breast Cancer; Ovarian Cancer; Liposarcoma; Non-small Cell Lung Cancer (NSCLC); Endometrial; Solid Tumors,Lung,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7930,NCT01004419,Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer,WITHDRAWN,PHASE1,"Carcinoma, Non Small Cell Lung",ZD6474 (vandetanib) (DRUG); Faslodex (Fulvestrant) (DRUG),104741,Faslodex,Non-small Cell Lung Cancer (NSCLC),Lung,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7931,NCT05455619,Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HR+/Her2- Breast Cancer,RECRUITING,PHASE1,HR+/HER2-negative Breast Cancer; Metastatic Breast Cancer,Evexomostat (DRUG),104741,Faslodex,HR+/HER2-negative Breast Cancer; Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7932,NCT01266213,Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women,UNKNOWN,PHASE2,Metastatic Breast Cancer; Estrogen Receptor Positive Tumor; Breast Cancer Nos Premenopausal,Fulvestrant plus Goserelin (DRUG); Anastrozole plus Goserelin (DRUG); Goserelin (DRUG),104741,Faslodex,Metastatic Breast Cancer; Estrogen Receptor Positive Tumor; Breast Cancer Nos Premenopausal,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7933,NCT02291913,Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Everolimus (DRUG); Exemestane (DRUG); Tamoxifen (DRUG); Fulvestrant (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Toremifine (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7934,NCT00057941,Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer,COMPLETED,PHASE2,Estrogen Receptor-positive Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer,anastrozole (DRUG); gefitinib (DRUG); fulvestrant (DRUG); laboratory biomarker analysis (OTHER),104741,Faslodex,Estrogen Receptor-positive Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7935,NCT01160718,Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy,COMPLETED,PHASE2,Breast Cancer,fulvestrant (DRUG); selumetinib (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7936,NCT06702618,Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer,NOT_YET_RECRUITING,PHASE2,Breast Cancer,TQB3616 capsule+Fulvestrant Injection (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7937,NCT04305236,Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer,TERMINATED,PHASE2,Breast Neoplasm; Hormone Receptor Positive Breast Carcinoma,Abemaciclib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Neoplasm; Hormone Receptor Positive Breast Carcinoma,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7938,NCT03056755,"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments",COMPLETED,PHASE2,Breast Cancer,Alpelisib (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Goserelin (DRUG); Leuprolide (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7939,NCT00451555,Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer,COMPLETED,PHASE2,Breast Cancer,enzastaurin (DRUG); placebo (DRUG); fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7940,NCT06339281,A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer,NOT_YET_RECRUITING,PHASE2,Advanced Breast Cancer,apatinib mesylate+Capecitabine Tablets (DRUG); apatinib mesylate+Fulvestrant injection (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7941,NCT00357110,Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Fulvestrant (DRUG); Anastrozole (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7942,NCT04936295,Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation,RECRUITING,PHASE2,Breast Cancer,Fulvestrant plus Anlotinib (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7943,NCT05933395,Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor,RECRUITING,PHASE2,Advanced Breast Cancer,Fulvestrant (DRUG); Neratinib (DRUG); Alpelisib (DRUG); Everolimus (DRUG); Abemaciclib (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7944,NCT00082810,Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer,COMPLETED,PHASE2,Estrogen Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,fulvestrant (DRUG); tipifarnib (DRUG),104741,Faslodex,Estrogen Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7945,NCT03134638,A Study of SY-1365 in Adult Patients With Advanced Solid Tumors,TERMINATED,PHASE1,Advanced Solid Tumors; Ovarian Cancer; Breast Cancer,SY-1365 (Part 1) (DRUG); Carboplatin (DRUG); Fulvestrant (DRUG); SY-1365 (Cohort 2) (DRUG); SY-1365 (Cohort 5) (DRUG); SY-1365 (Part 2 Single Agent) (DRUG),104741,Faslodex,Advanced Solid Tumors; Ovarian Cancer; Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7946,NCT03169738,QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors,WITHDRAWN,PHASE1,Non-small Cell Lung Cancer,avelumab (BIOLOGICAL); Bevacizumab (BIOLOGICAL); Capecitabine (DRUG); Cisplatin (DRUG); cyclophosphamide (DRUG); 5-Fluorouracil (5-FU) (DRUG); fulvestrant (DRUG); leucovorin (DRUG); nab paclitaxel (DRUG); nivolumab (BIOLOGICAL); Lovaza (DRUG); Oxaliplatin (DRUG); Stereotactic Body Radiation Therapy (RADIATION); ALT-803 (BIOLOGICAL); ETBX-011 (BIOLOGICAL); ETBX-021 (BIOLOGICAL); ETBX-051 (BIOLOGICAL); ETBX-061 (BIOLOGICAL); GI-4000 (BIOLOGICAL); GI-6207 (BIOLOGICAL); GI-6301 (BIOLOGICAL); haNK (BIOLOGICAL),104741,Faslodex,Non-small Cell Lung Cancer,Lung,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7947,NCT04920708,"Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression",RECRUITING,PHASE2,Metastatic Breast Cancer; ER+ Breast Cancer; Advanced Breast Cancer,Ipatasertib 300mg (DRUG); Fulvestrant 500g (DRUG); Palbociclib 75mg-125mg (DRUG); CDK4/6 Inhibitor (DRUG),104741,Faslodex,Metastatic Breast Cancer; ER+ Breast Cancer; Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7948,NCT00334295,Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.,COMPLETED,PHASE2,Endometrial Carcinoma,Fulvestrant (DRUG),104741,Faslodex,Endometrial Carcinoma,Uterus,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7949,NCT02692755,Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer,COMPLETED,PHASE2,Hormone Receptor Positive HER-2 Negative Breast Cancer,Palbociclib + Letrozole or Fulvestrant (DRUG),104741,Faslodex,Hormone Receptor Positive HER-2 Negative Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7950,NCT06447623,Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer,RECRUITING,PHASE3,Advanced Breast Cancer; HR+/HER2- Breast Cancer,Apatinib (DRUG); CDK4/6 Inhibitor (DRUG); Aromatase inhibitor and Fulvestrant (DRUG),104741,Faslodex,Advanced HR+/HER2- Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7951,NCT04975308,"A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE3,Breast Neoplasms; Neoplasm Metastasis,Imlunestrant (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Abemaciclib (DRUG),104741,Faslodex,Breast Neoplasms with Metastasis,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7952,NCT06044623,Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients,RECRUITING,PHASE3,Metastatic Breast Cancer; Advanced Breast Cancer; Quality of Life; Toxicity; Older Patients,CDK 4/6 inhibitors (DRUG); Endocrine therapy (DRUG),104741,Faslodex,Metastatic Breast Cancer; Advanced Breast Cancer; Quality of Life; Toxicity; Older Patients,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7953,NCT02599714,Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer,COMPLETED,PHASE1,Advanced and Metastatic Breast Cancer,AZD2014 (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Advanced and Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7954,NCT05161195,Roll-over Study to Allow Continued Access to Ribociclib,RECRUITING,PHASE4,Metastatic Breast Cancer,Ribociclib (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Goserelin (DRUG); Tamoxifen (DRUG); Fulvestrant (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7955,NCT05816655,"Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer",RECRUITING,PHASE2,Metastatic Breast Cancer,Fulvestrant plus AI plus ribociclib (DRUG); AI plus ribociclib (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7956,NCT00390455,Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive,COMPLETED,PHASE3,Estrogen Receptor Positive; HER2 Positive Breast Carcinoma; HER2/Neu Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7,Fulvestrant (DRUG); Laboratory Biomarker Analysis (OTHER); Lapatinib Ditosylate (DRUG); Placebo Administration (OTHER),104741,Faslodex,Estrogen Receptor Positive; HER2 Positive Breast Carcinoma; HER2/Neu Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7957,NCT00206414,"Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer",TERMINATED,PHASE2,BREAST CANCER,Iressa Day 1 given with Arimidex and Faslodex (DRUG); Iressa Day 21 given with Arimidex and Faslodex (DRUG),104741,Faslodex,BREAST CANCER,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7958,NCT05191914,Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors,UNKNOWN,PHASE4,Breast Cancer,Chidamide+ Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7959,NCT05251714,"CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer",RECRUITING,PHASE1,Advanced Solid Tumor; Breast Cancer,CFI-402257 (DRUG); Fulvestrant (DRUG),104741,Faslodex,Advanced Solid Tumor; Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7960,NCT04576455,"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)",ACTIVE_NOT_RECRUITING,PHASE2,"Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer",Giredestrant (DRUG); Fulvestrant or an Aromatase Inhibitor (Physician Choice) (DRUG); LHRH Agonist (DRUG),104741,Faslodex,"Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7961,NCT05574881,"Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,Dalpiciclib (DRUG); Fulvestrant (DRUG); Pertuzumab (DRUG); Trastuzumab (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7962,NCT06253195,BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors,RECRUITING,PHASE1,Advanced Solid Tumor; Metastatic Solid Tumor; Hormone-receptor-positive Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast; HER2-negative Breast Cancer,BGB-43395 (DRUG); Fulvestrant (DRUG); Letrozole (DRUG),104741,Faslodex,Advanced Solid Tumor; Metastatic Solid Tumor; Hormone-receptor-positive Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast; HER2-negative Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7963,NCT06612814,PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer Metastatic,Fluzoparib (DRUG); Dalpiciclib (DRUG); Fulvestrant/AI (DRUG),104741,Faslodex,Breast Cancer Metastatic,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7964,NCT04796623,A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer,UNKNOWN,PHASE2,"HR-positive, HER2-negative Advanced Breast Cancer",TQB3616 capsules (DRUG); Fulvestrant injection (DRUG),104741,Faslodex,"HR-positive, HER2-negative Advanced Breast Cancer",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7965,NCT00570323,Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Arimidex (DRUG); Faslodex (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7966,NCT06257264,A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors,RECRUITING,PHASE1,Breast Cancer; Small Cell Lung Cancer; Ovarian Cancer; Gastric Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Advanced Solid Tumor; Endometrial Cancer; Prostate Cancer; TNBC - Triple-Negative Breast Cancer; GastroEsophageal Cancer; Bladder Cancer,BG-68501 (DRUG); Fulvestrant (DRUG); BGB-43395 (DRUG),104741,Faslodex,Breast Cancer; Small Cell Lung Cancer; Ovarian Cancer; Gastric Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Advanced Solid Tumor; Endometrial Cancer; Prostate Cancer; TNBC - Triple-Negative Breast Cancer; GastroEsophageal Cancer; Bladder Cancer,Lung,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7967,NCT05577923,Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower),NOT_YET_RECRUITING,PHASE2,Metastatic Breast Cancer,Trastuzumab (DRUG); pyrotinib (DRUG); Dalpiciclib (DRUG); fulvestrant (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7968,NCT04318223,Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy,UNKNOWN,PHASE2,Metastatic Breast Cancer; Locally Advanced Breast Cancer,Palbociclib (DRUG),104741,Faslodex,Metastatic Breast Cancer; Locally Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7969,NCT05826964,Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer,RECRUITING,PHASE2,Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer,AI+CDK4/6i (DRUG); SERD+CDK4/6i (DRUG); mTOR inhibitor + AI (DRUG); mTOR inhibitor + SERD (DRUG); mTOR inhibitor + Selective estrogen receptor modulator (DRUG); PI3K inhibitor + SERD (DRUG); PI3K inhibitor + AI (DRUG); Chemotherapy (DRUG); Oral SERD (DRUG),104741,Faslodex,Metastatic ER-positive/HER2-negative Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7970,NCT00075764,S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer,COMPLETED,PHASE3,Breast Cancer,anastrozole (DRUG); fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7971,NCT04862143,Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant,TERMINATED,PHASE2,Advanced Breast Cancer,Alpelisib (DRUG); Fulvestrant (DRUG); Goserelin (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7972,NCT06135714,Metastasis-directed Therapy for Oligometastases of Breast Cancer,RECRUITING,PHASE3,Breast Cancer; Oligometastasis; Metastatic Breast Cancer,Systemic therapy for 12 weeks after primary registration (DRUG); Radiation therapy (SBRT/conventional RT) (PROCEDURE); Surgery (PROCEDURE); Same systemic therapy after secondary registration (DRUG),104741,Faslodex,Breast Cancer; Oligometastasis; Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7973,NCT05076695,"Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer",UNKNOWN,PHASE2,Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer,Palbociclib (DRUG); trastuzumab (DRUG); pyrotinib (DRUG); fulvestrant (DRUG),104741,Faslodex,Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7974,NCT04572295,A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Breast Neoplasms,E7090 (DRUG); Fulvestrant (DRUG); Exemestane (DRUG),104741,Faslodex,Breast Neoplasms,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7975,NCT00405938,Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Breast Neoplasms,Bevacizumab (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer; Breast Neoplasms,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7976,NCT03425838,Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Neoplasm Female,CDK 4/6 inhibitor (DRUG); Non-Steroidal Aromatase Inhibitor (DRUG); Fulvestrant (DRUG),104741,Faslodex,Female Breast Neoplasm,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7977,NCT03591549,Fulvestrant in Metastatic Breast Cancer,UNKNOWN,PHASE4,Metastatic Breast Cancer,Faslodex (DRUG); Zoladex (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7978,NCT00728949,A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,IMC-A12 (cixutumumab) (BIOLOGICAL); tamoxifen (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7979,NCT03344536,A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer,COMPLETED,PHASE1,Breast Cancer,Fulvestrant (DRUG); Debio 1347 (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7980,NCT03926936,FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study,COMPLETED,PHASE2,Endometrial Stromal Sarcoma; Adenosarcoma of Uterus; Leiomyosarcoma Uterus; Endometrial Cancer; Sex Cord Stromal Tumor; Serous Ovarian Tumor,Fulvestrant (DRUG),104741,Faslodex,Endometrial Stromal Sarcoma; Adenosarcoma of Uterus; Leiomyosarcoma Uterus; Endometrial Cancer; Sex Cord Stromal Tumor; Serous Ovarian Tumor,Uterus,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7981,NCT04899349,"Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant",TERMINATED,PHASE2,Breast Cancer,Alpelisib (DRUG); Fulvestrant (DRUG); Metformin XR (DRUG); Dapagliflozin + metformin XR (DRUG); Dapagliflozin (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7982,NCT05077449,A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Advanced Breast Cancer,XZP-3287+Fulvestrant (DRUG); Placebo + Fulvestrant (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7983,NCT04024436,A Study of TAS-120 in Patients With Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer; FGFR 1 High Amplification; FGFR2 Amplification,Futibatinib (DRUG); Futibatinib plus Fulvestrant (DRUG),104741,Faslodex,Metastatic Breast Cancer; FGFR 1 High Amplification; FGFR2 Amplification,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7984,NCT05759949,First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,"PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid Tumor; Hormone Receptor Positive Tumor",RLY-5836 (DRUG); Fulvestrant (DRUG); Palbociclib (DRUG); Ribociclib (DRUG); Abemaciclib (DRUG),104741,Faslodex,PIK3CA-Mutated Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7985,NCT00241449,A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer,COMPLETED,PHASE3,Breast Cancer; Metastasis,Fulvestrant (DRUG); Tamoxifen (DRUG),104741,Faslodex,Breast Cancer; Metastasis,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7986,NCT04923542,Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases,RECRUITING,PHASE1,Brain Metastases; HR+ Metastatic Breast Cancer,Stereotactic Radiosurgery (SRS) (RADIATION); Abemaciclib (DRUG); Endocrine therapy (DRUG),104741,Faslodex,Brain Metastases; HR+ Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7987,NCT00626106,QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Breast Tumors; Metastatic Cancer,AMG 479 (DRUG); Placebo (DRUG),104741,Faslodex,Breast Cancer; Breast Tumors; Metastatic Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7988,NCT04191499,"A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Inavolisib (DRUG); Placebo (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7989,NCT02389842,PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib,COMPLETED,PHASE1,Advanced Solid Tumours; Breast Cancer,Palbociclib + Taselisib / Pictilisib (DRUG),104741,Faslodex,Advanced Solid Tumours; Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7990,NCT00313170,"A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg",COMPLETED,PHASE2,Advanced Breast Cancer; Metastatic Breast Cancer,Fulvestrant (DRUG),104741,Faslodex,Advanced Breast Cancer; Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7991,NCT02269670,Phase II Study of Everolimus Beyond Progression,TERMINATED,PHASE2,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,everolimus (DRUG); anastrozole (DRUG); letrozole (DRUG); tamoxifen citrate (DRUG); fulvestrant (DRUG); megestrol acetate (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7992,NCT02333370,"A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",COMPLETED,PHASE1,"Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",LEE011 (DRUG); Letrozole (DRUG); Tamoxifen (DRUG); Fulvestrant (DRUG); goserelin (DRUG),104741,Faslodex,"Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7993,NCT05041842,Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Cancer With a Isolated Brain Progression,Tucatinib (DRUG); Pertuzumab (DRUG); Trastuzumab (DRUG); Hormone therapy (DRUG); Pertuzumab/ Trastuzumab (DRUG),104741,Faslodex,Metastatic Breast Cancer With a Isolated Brain Progression,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7994,NCT04901299,Fulvestrant + Neratinib In Breast Cancer,WITHDRAWN,PHASE2,Stage IV (Metastatic) Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer; HER2-negative Breast Cancer; Invasive Breast Cancer,NERATINIB (DRUG); FULVESTRANT (DRUG),104741,Faslodex,Stage IV (Metastatic) Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer; HER2-negative Breast Cancer; Invasive Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7995,NCT00903006,"Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer",TERMINATED,PHASE1,Breast Cancer,Fulvestrant (DRUG); MK-0646 (DRUG); Dasatinib (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7996,NCT06941142,A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer,NOT_YET_RECRUITING,PHASE1,Advanced Breast Cancer,Sirolimus (albumin - bound) (DRUG); Palbociclib tablet (DRUG); Fulvestrant injection (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7997,NCT06851442,Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,NOT_YET_RECRUITING,PHASE1,Breast Cancer,TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7998,NCT02536742,Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Palbociclib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +7999,NCT05004142,"Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin",UNKNOWN,PHASE2,Breast Neoplasms,FCN-437c+Fulvestrant (DRUG); FCN-437c+Letrozole+Goserelin (DRUG),104741,Faslodex,Breast Neoplasms,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8000,NCT02936206,Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.,TERMINATED,PHASE1,Breast Cancer,Fulvestrant (DRUG); Tamoxifen (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8001,NCT04115306,Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer,RECRUITING,PHASE1,Metastatic Breast Cancer,PMD-026 (DRUG); fulvestrant (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8002,NCT06957379,Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy,ACTIVE_NOT_RECRUITING,PHASE2,HR+/HER2- Advanced/Metastatic Breast Cancer,Letrozole (DRUG); Anastrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Sirolimus for Injection (Albumin-bound) (DRUG),104741,Faslodex,HR+/HER2- Advanced/Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8003,NCT04791384,Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer,RECRUITING,PHASE1,Breast Cancer,Abemaciclib (DRUG); Elacestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8004,NCT04762979,"Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer",RECRUITING,PHASE2,Hormone Receptor Positive Breast Carcinoma; HER2-negative Breast Cancer; PIK3CA Mutant Metastatic Breast Cancer,Alpelisib (DRUG); Fulvestrant (DRUG); Aromatase inhibitor (DRUG),104741,Faslodex,Hormone Receptor Positive Breast Carcinoma; HER2-negative Breast Cancer; PIK3CA Mutant Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8005,NCT06047184,Phase I Study of BEBT-209 in Women With Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Advanced Breast Cancer,BEBT-209 capsules (DRUG); Letrozole tablets (DRUG); Fulvestrant (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8006,NCT01610284,Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor,COMPLETED,PHASE3,Breast Cancer,Fulvestrant (DRUG); BKM120 (DRUG); BKM120 matching placebo (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8007,NCT05085002,A Study of Lerociclib in Participants With Advanced Breast Cancer,TERMINATED,PHASE2,Advanced Breast Cancer,Lerociclib + Letrozole or Fulvestrant (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8008,NCT00570921,Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure,COMPLETED,PHASE2,Breast Cancer,Everolimus (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8009,NCT02756364,Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy,COMPLETED,PHASE2,Breast Neoplasms,Fulvestrant (DRUG); Sapanisertib (DRUG),104741,Faslodex,Breast Neoplasms,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8010,NCT00093002,Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8011,NCT03197584,QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy,WITHDRAWN,PHASE1,Ovarian Cancer,Avelumab (BIOLOGICAL); Bevacizumab (BIOLOGICAL); Capecitabine (DRUG); Cyclophosphamide (DRUG); 5-fluorouracil (DRUG); Fulvestrant (DRUG); Leucovorin (DRUG); Paclitaxel (DRUG); omega-3 acid ethyl esters (DRUG); Oxaliplatin (DRUG); Stereotactic Body Radiation Therapy (RADIATION); ALT-803 (BIOLOGICAL); ETBX-021 (BIOLOGICAL); ETBX-051 (BIOLOGICAL); ETBX-061 (BIOLOGICAL); GI-4000 (BIOLOGICAL); GI-6301 (BIOLOGICAL); haNK® (BIOLOGICAL),104741,Faslodex,Ovarian Cancer,Ovary/Fallopian Tube,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8012,NCT00201864,Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Exemestane (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8013,NCT02340221,A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy,TERMINATED,PHASE3,Breast Cancer,Taselisib (DRUG); Placebo (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8014,NCT06680921,A Study of SIM0270 Combined with Everolimus Vs. Treatment of Physician's Choice in Patients with ER+/HER2- Advanced Breast Cancer (SIMRISE),RECRUITING,PHASE3,Locally Advanced or Metastatic Breast Cancer,SIM0270 (DRUG); Everolimus (Afinitor®) (DRUG); Exemestane tablets (DRUG); Fulvestrant injection (DRUG),104741,Faslodex,Locally Advanced or Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8015,NCT05904964,"Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)",RECRUITING,PHASE3,HR Positive/HER2 Low Expression Metastatic Breast Cancer,Disitamab vedotin (DRUG); Endocrine therapy (OTHER),104741,Faslodex,HR Positive/HER2 Low Expression Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8016,NCT05101564,"Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer; HER2-negative Breast Cancer; ER Positive Breast Cancer,Alpelisib (DRUG); Tamoxifen (DRUG); Zotatifin (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer; HER2-negative Breast Cancer; ER Positive Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8017,NCT02088684,Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer,COMPLETED,PHASE1,Breast Cancer,LEE011 (DRUG); BYL719 (DRUG); fulvestrant (DRUG); BKM120 (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8018,NCT04059484,Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer,TERMINATED,PHASE2,Breast Cancer Metastatic,Amcenestrant (DRUG); Fulvestrant (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Tamoxifen (DRUG),104741,Faslodex,Breast Cancer Metastatic,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8019,NCT03007979,Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Breast Carcinoma; Cancer of Breast; Malignant Tumor of Breast,Palbociclib (DRUG); Letrozole (DRUG); Fulvestrant (DRUG); Optional research biopsy (PROCEDURE); Goserelin (DRUG); Research blood draw (PROCEDURE); Circulating tumor cell blood draw (PROCEDURE); Tumor biopsy (optional) (PROCEDURE),104741,Faslodex,Breast Cancer; Breast Carcinoma; Cancer of Breast; Malignant Tumor of Breast,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8020,NCT05524584,"Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer",RECRUITING,PHASE2,Breast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer,Fulvestrant (DRUG); Anastrozole (DRUG); Abemaciclib (DRUG),104741,Faslodex,Breast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8021,NCT06179303,"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer",RECRUITING,PHASE2,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Unresectable HER2-Negative Breast Carcinoma; Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma,Abemaciclib (DRUG); Anastrozole (DRUG); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Diagnostic Imaging (PROCEDURE); Exemestane (DRUG); Fludeoxyglucose F-18 (OTHER); Fluorine F 18 Fluoro Furanyl Norprogesterone (DRUG); Fulvestrant (DRUG); Gonadotropin-releasing Hormone Analog (BIOLOGICAL); Letrozole (DRUG); Positron Emission Tomography (PROCEDURE); Tamoxifen (DRUG); Therapeutic Estradiol (DRUG),104741,Faslodex,"Advanced/Metastatic Breast Cancer, HER2-Negative",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8022,NCT03620643,"Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours",ACTIVE_NOT_RECRUITING,PHASE2,Lobular Breast Carcinoma; Gastric Cancer; Triple Negative Breast Cancer; CDH1 Gene Mutation,Crizotinib Oral Capsule [Xalkori] (DRUG); Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic] (DRUG),104741,Faslodex,Lobular Breast Carcinoma; Gastric Cancer; Triple Negative Breast Cancer; CDH1 Gene Mutation,Esophagus/Stomach,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8023,NCT03169764,QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy,WITHDRAWN,PHASE1,Head and Neck Squamous Cell Carcinoma,Avelumab (BIOLOGICAL); Bevacizumab (BIOLOGICAL); Capecitabine (DRUG); Cetuximab (BIOLOGICAL); Cisplatin (DRUG); cyclophosphamide (DRUG); 5-Fluorouracil (5-FU) (DRUG); fulvestrant (DRUG); leucovorin (DRUG); nab-paclitaxel (DRUG); nivolumab (BIOLOGICAL); Lovaza (DRUG); Stereotactic Body Radiation Therapy (RADIATION); ALT-803 (BIOLOGICAL); ETBX-011 (BIOLOGICAL); ETBX-021 (BIOLOGICAL); ETBX-051 (BIOLOGICAL); ETBX-061 (BIOLOGICAL); GI-4000 (BIOLOGICAL); GI-6207 (BIOLOGICAL); GI-6301 (BIOLOGICAL); haNK (BIOLOGICAL),104741,Faslodex,Head and Neck Squamous Cell Carcinoma,Skin,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8024,NCT05870579,"[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer",RECRUITING,PHASE1,Breast Cancer,[68Ga]Ga-NeoB (DRUG); [177Lu]Lu-NeoB (DRUG); Ribociclib (DRUG); Fulvestrant (DRUG); Goserelin (OTHER),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8025,NCT04657679,Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts,TERMINATED,PHASE4,Breast Cancer,Ribociclib (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8026,NCT05963984,A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Cancer; Locally Advanced Breast Cancer; Breast Cancer,Samuraciclib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Metastatic Breast Cancer; Locally Advanced Breast Cancer; Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8027,NCT02206984,Endocrine Response in Women with Invasive Lobular Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Tamoxifen (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8028,NCT05966584,A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Benralizumab (DRUG); fulvestrant or AIs) and PI3K inhibition (alpelisib) (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8029,NCT03767335,MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer,COMPLETED,PHASE1,Advanced or Metastatic Breast Cancer,MEN1611 (DRUG); Trastuzumab (DRUG); Fulvestrant (DRUG),104741,Faslodex,Advanced or Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8030,NCT03781063,Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation,ACTIVE_NOT_RECRUITING,PHASE2,Locally Advanced or Metastatic Breast Cancer,Lasofoxifene (DRUG); Fulvestrant (DRUG),104741,Faslodex,Locally Advanced or Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8031,NCT02216786,A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer,COMPLETED,PHASE2,Estrogen Receptor Positive Breast Cancer,AZD2014 (DRUG); Everolimus (DRUG); Fulvestrant (DRUG),104741,Faslodex,ER-Positive HER2-Negative Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8032,NCT03280563,A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,COMPLETED,PHASE1,Breast Neoplasms,"Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody (DRUG); Bevacizumab (DRUG); Entinostat (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Ipatasertib (DRUG); Tamoxifen (DRUG); Abemaciclib (DRUG)",104741,Faslodex,Breast Neoplasms,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8033,NCT04862663,Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292),RECRUITING,PHASE3,Locally Advanced (Inoperable) or Metastatic Breast Cancer,Capivasertib (DRUG); Fulvestrant (DRUG); Palbociclib (DRUG); Ribociclib (DRUG); Abemaciclib (DRUG),104741,Faslodex,Locally Advanced (Inoperable) or Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8034,NCT00423917,Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,bevacizumab (BIOLOGICAL); fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8035,NCT06757634,"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)",NOT_YET_RECRUITING,PHASE3,Breast Cancer,Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant (DRUG); Arm B: Palbociclib or Ribociclib + Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8036,NCT03204734,Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Capecitabine (DRUG); endocrine therapy (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8037,NCT04851613,Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer,RECRUITING,PHASE3,Breast Cancer,Afuresertib (DRUG); Afuresertib/placebo (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8038,NCT06515470,"Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced And/or Metastatic Breast Cancer",RECRUITING,PHASE1,Breast Cancer,BTX-9341 (DRUG); Fulvestrant (DRUG); BTX-9341 (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8039,NCT04524000,Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Advanced Breast Cancer,Alpelisib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8040,NCT01231659,Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer,COMPLETED,PHASE2,Postmenopausal Women; Locally Advanced Metastatic Breast Cancer; Metastatic Breast Cancer,Everolimus (DRUG); Letrozole (DRUG),104741,Faslodex,Postmenopausal Women; Locally Advanced Metastatic Breast Cancer; Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8041,NCT02860000,"Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Estrogen Receptor Status; HER2/Neu Negative; Invasive Breast Carcinoma; Postmenopausal; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Alisertib (DRUG); Fulvestrant (DRUG); Laboratory Biomarker Analysis (OTHER),104741,Faslodex,Estrogen Receptor Status; HER2/Neu Negative; Invasive Breast Carcinoma; Postmenopausal; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8042,NCT05608252,VS-6766+Abema+Fulv in Met HR+/HER- BC,RECRUITING,PHASE1,Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer,VS-6766 (DRUG); Abemaciclib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8043,NCT02958852,A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Letrozole (DRUG); Letrozole and atorvastatin (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8044,NCT05205200,Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02,RECRUITING,PHASE2,Breast Cancer; Metastatic Cancer,SHR-1316 (DRUG); SHR6390 (DRUG); Nab paclitaxel (DRUG); SERD (DRUG); AI (DRUG),104741,Faslodex,Breast Cancer; Metastatic Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8045,NCT01992952,Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer,UNKNOWN,PHASE1,Estrogen Receptor Positive Breast Cancer,AZD5363 (DRUG); Placebo (DRUG); Fulvestrant (DRUG),104741,Faslodex,ER-Positive HER2-Negative Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8046,NCT06377852,The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study,RECRUITING,PHASE3,Metastatic Breast Cancer,Palbociclib 125mg (DRUG); Ribociclib 600mg (DRUG); Ribociclib (DRUG); Palbociclib (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8047,NCT00932152,Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer,TERMINATED,PHASE2,Non-small Cell Lung Cancer; Postmenopausal Women,fulvestrant (Faslodex) (DRUG); anastrozole (Arimidex) (DRUG); Bevacizumab (Avastin) (DRUG); Best supportive care (DRUG),104741,Faslodex,Non-small Cell Lung Cancer; Postmenopausal Women,Lung,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8048,NCT01339442,BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer,COMPLETED,PHASE1,Estrogen Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer,BKM120 (DRUG); Fulvestrant (DRUG); biopsy (PROCEDURE),104741,Faslodex,Estrogen Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8049,NCT05504213,A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer,RECRUITING,PHASE1,Breast Cancer,HS-10352 combined with fulvestrant (Stage 1) (DRUG); HS-10352 combined with fulvestrant (Stage 2) (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8050,NCT04646759,Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer,RECRUITING,PHASE3,Breast Cancer,Fulvestrant combined with Pyrotinib (DRUG); Capecitabine combined with Pyrotinib (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8051,NCT06105632,"A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment",ACTIVE_NOT_RECRUITING,PHASE2,Advanced or Metastatic Breast Cancer,PF-07220060 CDK4 inhibitor (DRUG); Fulvestrant (DRUG); Everolimus (DRUG); Exemestane (DRUG),104741,Faslodex,Advanced or Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8052,NCT03147287,Palbociclib After CDK and Endocrine Therapy (PACE),ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Cancer,Palbociclib (DRUG); Fulvestrant (DRUG); Avelumab (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8053,NCT06481956,T-DM1 Combined With CDK4/6 Inhibitor Ribociclib,ENROLLING_BY_INVITATION,PHASE2,HER2-positive Advanced Breast Cancer,Ribociclib Oral Tablet (DRUG),104741,Faslodex,HER2-positive Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8054,NCT02734615,Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers,TERMINATED,PHASE1,Advanced or Metastatic ER+ Breast Cancer,LSZ102 (DRUG); LEE011 (DRUG); BYL719 (DRUG),104741,Faslodex,Advanced or Metastatic ER+ Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8055,NCT02137837,"S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",TERMINATED,PHASE3,Breast Cancer,Fulvestrant (DRUG); Anastrozole (DRUG); Everolimus (DRUG); Placebo - Anastrozole (DRUG); Placebo - Everolimus (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8056,NCT00099437,Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8057,NCT06756932,BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer,RECRUITING,PHASE1,Hormone-receptor-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer,BGB-21447 (DRUG); Fulvestrant (DRUG); BGB-43395 (DRUG),104741,Faslodex,Hormone-receptor-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8058,NCT03447132,Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant,COMPLETED,PHASE3,Breast Neoplasm Female,Fulvestrant 500mg (DRUG); Palbociclib 125mg (DRUG); Goserelin 3.6 MG (DRUG); Placebos (DRUG),104741,Faslodex,Female Breast Neoplasm,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8059,NCT05216432,"First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer",RECRUITING,PHASE1,"PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid Tumor; Endometrial Cancer",RLY-2608 (DRUG); Fulvestrant (DRUG); Palbociclib 125mg (DRUG); Ribociclib 400mg (DRUG); Ribociclib 600mg (DRUG); PF-07220060 100mg (DRUG); PF-07220060 300 mg (DRUG),104741,Faslodex,"PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid Tumor; Endometrial Cancer",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8060,NCT04726332,Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101),TERMINATED,PHASE1,Neoplasm Malignant; Epithelial Ovarian Cancer; Triple Negative Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Metastatic Castration-resistant Prostate Cancer,XL102 (DRUG); Fulvestrant (DRUG); Abiraterone (DRUG); Prednisone (DRUG),104741,Faslodex,Neoplasm Malignant; Epithelial Ovarian Cancer; Triple Negative Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Metastatic Castration-resistant Prostate Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8061,NCT05262400,A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer; Solid Tumors,PF-07220060 + PF-07104091 combination dose escalation (DRUG); PF-07220060 + PF-07104091 combination dose escalation (DRUG); PF-07220060 + PF-07104091 combination dose escalation (DRUG); PF-07220060 + PF-07104091 combination dose escalation (DRUG); PF-07220060 + PF-07104091 combination dose escalation (DRUG); PF-07104091 + PF-07220060 + fulvestrant dose expansion (DRUG); PF-07104091 + PF-07220060 + fulvestrant dose expansion (DRUG); PF-07104091 + PF-07220060 + letrozole dose expansion (DRUG); PF-07220060 + PF-07104091 combination dose escalation (DRUG); PF-07220060 + PF-07104091 combination dose escalation (DRUG); PF-07220060 + PF-07104091 combination dose escalation (DRUG),104741,Faslodex,Breast Cancer; Solid Tumors,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8062,NCT04031885,"A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer",TERMINATED,PHASE4,Metastatic Breast Cancer,Abemaciclib (DRUG); Fulvestrant (DRUG); Standard Chemotherapy (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8063,NCT02778685,"Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7,Fulvestrant (DRUG); Laboratory Biomarker Analysis (OTHER); Letrozole (DRUG); Palbociclib (DRUG); Pembrolizumab (BIOLOGICAL),104741,Faslodex,Metastatic Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8064,NCT03927456,A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer,UNKNOWN,PHASE3,Advanced Breast Cancer,SHR6390 (DRUG); Placebo (DRUG); Fulvestrant (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8065,NCT03560856,"A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer",UNKNOWN,PHASE2,Breast Cancer; HR+/HER2-negative Breast Cancer; Metastasis,Fulvestrant + palbociclib (DRUG),104741,Faslodex,Breast Cancer; HR+/HER2-negative Breast Cancer; Metastasis,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8066,NCT02947685,"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE3,HER-2 Positive Breast Cancer; Estrogen Receptor Positive Breast Cancer,palbociclib (DRUG); trastuzumab (DRUG); pertuzumab (DRUG); letrozole (DRUG); Anastrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG),104741,Faslodex,HER-2 Positive Breast Cancer; Estrogen Receptor Positive Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8067,NCT00921115,Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.,COMPLETED,PHASE2,Invasive Breast Cancer,Fulvestrant (DRUG); Anastrazole (DRUG),104741,Faslodex,Invasive Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8068,NCT03322215,HR+/HER2- Advanced Breast Cancer and Endocrine Resistance,TERMINATED,PHASE2,Breast Cancer Metastatic,Palbociclib (DRUG); Fulvestrant (DRUG); Capecitabine (DRUG),104741,Faslodex,Breast Cancer Metastatic,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8069,NCT01219699,"A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene",COMPLETED,PHASE1,Advanced Solid Tumors With an Alteration of the PIK3CA Gene; Estrogen Receptor Positive Breast Cancer,BYL719 (DRUG); Fulvestrant (DRUG),104741,Faslodex,Advanced Solid Tumors With an Alteration of the PIK3CA Gene; Estrogen Receptor Positive Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8070,NCT02374099,Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant,TERMINATED,PHASE2,Breast Neoplasms,CC-486 (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Neoplasms,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8071,NCT04557449,Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors,RECRUITING,PHASE1,Liposarcoma; Prostate Cancer; Breast Neoplasms; Adenocarcinoma of Lung,PF-07220060 (DRUG); Letrozole (COMBINATION_PRODUCT); Fulvestrant (COMBINATION_PRODUCT); Midazolam (DRUG); Enzalutamide (COMBINATION_PRODUCT),104741,Faslodex,Liposarcoma; Prostate Cancer; Breast Neoplasms; Adenocarcinoma of Lung,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8072,NCT06849947,"Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer",NOT_YET_RECRUITING,PHASE2,Breast Cancer Metastatic,Ribociclib with fulvestrant (DRUG); Physician's choice treatments group (DRUG),104741,Faslodex,Breast Cancer Metastatic,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8073,NCT01441947,Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Cabozantinib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8074,NCT00100854,Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,erlotinib hydrochloride (DRUG); fulvestrant (DRUG),104741,Faslodex,Lung Cancer,Lung,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8075,NCT05054751,GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer,COMPLETED,PHASE3,Locally Advanced or Metastatic Breast Cancer,GB491+ Fulvestrant (DRUG); Placebo+Fulvestrant (DRUG),104741,Faslodex,Locally Advanced or Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8076,NCT04942054,A Study in Patients With Advanced Breast Cancer,TERMINATED,PHASE1,HER2-negative Breast Cancer; Advanced Breast Cancer; Hormone Receptor-positive Breast Cancer,Part 1 (DRUG); Part 2 (DRUG); Part 3 (DRUG),104741,Faslodex,HER2-negative Breast Cancer; Advanced Breast Cancer; Hormone Receptor-positive Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8077,NCT01300351,Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women,COMPLETED,PHASE3,Breast Cancer,Fulvestrant (DRUG); Placebo (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8078,NCT05554354,Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial),TERMINATED,PHASE2,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma,Binimetinib (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Fulvestrant (DRUG); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE),104741,Faslodex,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8079,NCT05872347,Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.,RECRUITING,PHASE2,Breast Cancer Brain Metastases,SPH4336 Tablets (DRUG),104741,Faslodex,Breast Cancer Brain Metastases,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8080,NCT01233947,Study of AFP464 +/- Faslodex in ER + Breast Cancer,TERMINATED,PHASE2,Breast Neoplasm,AFP464 (DRUG); AFP464 + Faslodex (DRUG),104741,Faslodex,Breast Neoplasm,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8081,NCT05564377,"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial",RECRUITING,PHASE2,Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm,Alpelisib (DRUG); Binimetinib (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Fluorouracil (DRUG); Fulvestrant (DRUG); Ipatasertib (DRUG); Leucovorin (DRUG); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Mutation Carrier Screening (PROCEDURE); Neratinib Maleate (DRUG); Nilotinib Hydrochloride Monohydrate (DRUG); Olaparib (DRUG); Oxaliplatin (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Panitumumab (BIOLOGICAL); Positron Emission Tomography (PROCEDURE); Selumetinib Sulfate (DRUG); Sotorasib (DRUG),104741,Faslodex,Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm,Ovary/Fallopian Tube,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8082,NCT02404051,Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer,UNKNOWN,PHASE3,Metastatic Breast Cancer; Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Locally Advanced Malignant Neoplasm,Everolimus (DRUG); Exemestane (DRUG); Fulvestrant (DRUG),104741,Faslodex,Metastatic Breast Cancer; Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Locally Advanced Malignant Neoplasm,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8083,NCT06380751,"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer",RECRUITING,PHASE3,Advanced Breast Cancer,Saruparib (AZD5305) (DRUG); Camizestrant (DRUG); Abemaciclib (DRUG); Ribociclib (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Exemestane (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8084,NCT03462251,Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line,COMPLETED,PHASE3,Breast Cancer; Hormone Receptor Positive Tumor; HER 2 Negative Breast Cancer,Ribociclib and aromatase inhibitor or fulvestrant (COMBINATION_PRODUCT); Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab (COMBINATION_PRODUCT),104741,Faslodex,Breast Cancer; Hormone Receptor Positive Tumor; HER 2 Negative Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8085,NCT02455453,Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography,COMPLETED,PHASE2,Breast Cancer,18F-FFNP (DRUG); CTI/Siemens Biograph 40 PET/CT Scanner (DEVICE); Estradiol (DRUG); 18F-FDG (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8086,NCT05181033,"Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor",RECRUITING,PHASE2,Breast Cancer,Lenvatinib + Letrozole (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8087,NCT05670054,Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients,UNKNOWN,PHASE3,Breast Cancer Stage IV,"comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival (DRUG)",104741,Faslodex,Breast Cancer Stage IV,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8088,NCT06635447,Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients,RECRUITING,PHASE3,Breast Cancer,Capivasertib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8089,NCT03555877,Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer Metastatic,Ribociclib (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer Metastatic,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8090,NCT03772353,"Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,Dalpiciclib (DRUG); Pyrotinib (DRUG); Letrozole (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8091,NCT03169777,QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC,WITHDRAWN,PHASE1,Colorectal Cancer,avelumab (BIOLOGICAL); bevacizumab (BIOLOGICAL); capecitabine (DRUG); cetuximab (BIOLOGICAL); Cyclophosphamide (DRUG); 5-Fluorouracil (5-FU) (DRUG); fulvestrant (DRUG); leucovorin (DRUG); nab paclitaxel (DRUG); nivolumab (BIOLOGICAL); Lovaza (DRUG); oxaliplatin (DRUG); Stereotactic Body Radiation Therapy (RADIATION); ALT-803 (BIOLOGICAL); ETBX-011 (BIOLOGICAL); ETBX-021 (BIOLOGICAL); ETBX-051 (BIOLOGICAL); ETBX-061 (BIOLOGICAL); GI-4000 (BIOLOGICAL); GI-6207 (BIOLOGICAL); GI-6301 (BIOLOGICAL); haNK (BIOLOGICAL),104741,Faslodex,Colorectal Cancer,Bowel,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8092,NCT00545077,Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women,COMPLETED,PHASE3,Breast Cancer,Letrozole (DRUG); Bevacizumab (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8093,NCT02322853,A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors,TERMINATED,PHASE2,Postmenopausal; Metastatic Breast Cancer,Tamoxifen (DRUG); Ralimetinib (LY2228820 dimesylate) (DRUG),104741,Faslodex,Postmenopausal; Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8094,NCT00010153,ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer,TERMINATED,PHASE3,Breast Cancer,fulvestrant (DRUG); conventional surgery (PROCEDURE),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8095,NCT04352777,Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Cancer; Locally Advanced Breast Cancer; Hormone Receptor Positive Tumor,Abemaciclib (DRUG); Fulvestrant (DRUG); Aromatase Inhibitors (DRUG),104741,Faslodex,"Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8096,NCT00738777,Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer,SUSPENDED,PHASE2,Breast Cancer,Anastrozole (DRUG); Anastrozole+Fulvestrant (DRUG); Tamoxifen (DRUG); Tamoxifen (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8097,NCT01670877,Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms,Neratinib (DRUG); Fulvestrant (DRUG); Trastuzumab (DRUG); Tumor biopsy (PROCEDURE); Research blood sample (PROCEDURE),104741,Faslodex,Breast Neoplasms,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8098,NCT02422615,Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.,COMPLETED,PHASE3,Advanced Breast Cancer,Ribociclib (DRUG); Fulvestrant (DRUG); Placebo (DRUG),104741,Faslodex,Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8099,NCT02684032,A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer,COMPLETED,PHASE1,Breast Cancer,Gedatolisib (DRUG); Palbociclib (DRUG); Letrozole (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8100,NCT02140437,Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC,WITHDRAWN,PHASE2,Carcinoma Breast Stage IV,Fulvestrant (DRUG); Anastrozole (DRUG),104741,Faslodex,Carcinoma Breast Stage IV,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8101,NCT06369285,"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer",RECRUITING,PHASE2,Hormone Receptor Positive HER-2 Negative Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer,Alisertib (DRUG); Endocrine therapy (DRUG),104741,Faslodex,Hormone Receptor Positive HER-2 Negative Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8102,NCT03809988,PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA),COMPLETED,PHASE2,Breast Cancer; Advanced Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast,Palbociclib (DRUG); Endocrine therapy (DRUG),104741,Faslodex,Breast Cancer; Advanced Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8103,NCT05983107,Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer,RECRUITING,PHASE2,HR+/HER2- Advanced Breast Cancer; Targeted Therapy,Everolimus (DRUG); Chidamide (DRUG); Endocrine therapy (DRUG); Ovarian function suppression(OFS) (DRUG),104741,Faslodex,HR+/HER2- Advanced Breast Cancer; Targeted Therapy,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8104,NCT02028507,Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors,COMPLETED,PHASE3,Metastatic Breast Cancer,Palbociclib (DRUG); Capecitabine (DRUG); Exemestane (DRUG); Fulvestrant (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8105,NCT00592007,Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer,TERMINATED,PHASE2,Non Small Cell Lung Carcinoma,Fulvestrant and Erlotinib (DRUG),104741,Faslodex,Non Small Cell Lung Carcinoma,Lung,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8106,NCT02238509,Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies,UNKNOWN,PHASE2,Metastatic Breast Cancer,Lapatinib (DRUG); Trastuzumab (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8107,NCT00617188,Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer,COMPLETED,PHASE2,Ovarian Cancer,Fulvestrant (DRUG),104741,Faslodex,Ovarian Cancer,Ovary/Fallopian Tube,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8108,NCT06133088,Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.,RECRUITING,PHASE2,Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed,dalpiciclib; fluvestrant; compound gossypol acetate tablets (DRUG),104741,Faslodex,Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8109,NCT03220178,Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy,TERMINATED,PHASE4,Breast Neoplasm,Palbociclib (DRUG); Fulvestrant (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG),104741,Faslodex,Breast Neoplasm,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8110,NCT05365178,"To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE3,"HR-positive, HER2-negative Breast Neoplasms",TQB3616 capsule (DRUG); Placebo (DRUG); Fulvestrant injection (DRUG),104741,Faslodex,"HR-positive, HER2-negative Breast Neoplasms",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8111,NCT00774878,Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer,TERMINATED,PHASE2,Breast Neoplasms,AVE1642 (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Neoplasms,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8112,NCT04214288,A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Advanced ER-Positive HER2-Negative Breast Cancer,AZD9833 (DRUG); Fulvestrant (DRUG),104741,Faslodex,Advanced ER-Positive HER2-Negative Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8113,NCT04965688,Biology Guided Therapy for Breast Cancer for ER Positive,TERMINATED,PHASE2,Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer,Biopsy-Guided Therapy Selection (DRUG),104741,Faslodex,Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8114,NCT05207709,Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype,ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Breast Cancer,Ribociclib + Letrozole OR Fulvestrant (DRUG); Palbociclib + Letrozole OR Fulvestrant (DRUG); Paclitaxel +/- Tislelizumab (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8115,NCT02626507,Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer,UNKNOWN,PHASE1,Breast Cancer,Gedatolisib (DRUG); Faslodex (DRUG); Palbociclib (DRUG); Zoladex (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8116,NCT03584009,"A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy",TERMINATED,PHASE2,Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer,Venetoclax (DRUG); Fulvestrant (DRUG),104741,Faslodex,Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8117,NCT01953588,Fulvestrant And/or Anastrozole in Treating Postmenopausal Patients with Stage II-III Breast Cancer Undergoing Surgery,ACTIVE_NOT_RECRUITING,PHASE3,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,fulvestrant (DRUG); anastrozole (DRUG),104741,Faslodex,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8118,NCT02057133,A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread,ACTIVE_NOT_RECRUITING,PHASE1,Breast Neoplasms,LY2835219 (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Tamoxifen (DRUG); Exemestane (DRUG); Everolimus (DRUG); Trastuzumab (DRUG); LY3023414 (DRUG); Fulvestrant (DRUG); Pertuzumab (DRUG); Loperamide (DRUG); Endocrine therapy (DRUG),104741,Faslodex,Breast Neoplasms,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8119,NCT04669587,ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study),UNKNOWN,PHASE1,Estrogen Receptor-Positive; HER2-Negative; Locally Advanced Breast Cancer; Metastatic Breast Cancer,ZB716 (DRUG); Palbociclib (DRUG),104741,Faslodex,Estrogen Receptor-Positive; HER2-Negative; Locally Advanced Breast Cancer; Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8120,NCT05154487,A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer,RECRUITING,PHASE2,Endometroid Endometrial Cancer,Alpelisib Pill (DRUG); Fulvestrant injection (DRUG),104741,Faslodex,Endometroid Endometrial Cancer,Uterus,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8121,NCT05625087,Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib,RECRUITING,PHASE2,Breast Cancer Stage IV,Alpelisib (DRUG); Ribociclib (DRUG),104741,Faslodex,Breast Cancer Stage IV,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8122,NCT06202261,A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer,RECRUITING,PHASE1,Metastatic Breast Cancer; Recurrent Breast Cancer; Advanced Malignancies,TQB2930 for injection (DRUG); Paclitaxel for injection (albumin-bound) (DRUG); TQB3616 capsule (DRUG); Fulvestrant injection (DRUG); Capecitabine tablets (DRUG); Vinorelbine tartrate injection (DRUG); Eribulin mesylate injection (DRUG); gemcitabine hydrochloride for injection (DRUG),104741,Faslodex,Metastatic Breast Cancer; Recurrent Breast Cancer; Advanced Malignancies,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8123,NCT05375461,TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail,ACTIVE_NOT_RECRUITING,PHASE3,"HR-positive,HER2-negative in Advanced Breast Cancer",TQB3616 capsules (DRUG); TQB3616-matching placebo (DRUG); Fluvestrin injection (DRUG),104741,Faslodex,"HR-positive,HER2-negative in Advanced Breast Cancer",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8124,NCT02260661,"Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours",COMPLETED,PHASE1,"Advanced Solid Malignancies; Breast Cancer - ER+, HER2 -; Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation",AZD8835 (DRUG); AZD8835 (DRUG); AZD8835 in combination with fulvestrant (DRUG); AZD8835 in combination with fulvestrant (DRUG),104741,Faslodex,"Advanced Solid Malignancies; Breast Cancer - ER+, HER2 -; Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation",Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8125,NCT02491983,"Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer",COMPLETED,PHASE2,Metastatic Breast Cancer,Palbociclib (DRUG); Fulvestrant (DRUG); Letrozole (DRUG),104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8126,NCT03227328,"CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO",COMPLETED,PHASE2,Hormone Receptor Positive Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Negative Breast Cancer,concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy (DRUG); chemotherapy plus endocrine therapy (administered either concomitantly or sequentially) (DRUG),104741,Faslodex,Hormone Receptor Positive Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Negative Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8127,NCT03803761,"A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer",WITHDRAWN,PHASE1,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Prognostic Stage IV Breast Cancer AJCC v8,Copanlisib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Prognostic Stage IV Breast Cancer AJCC v8,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8128,NCT05065411,Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer,TERMINATED,PHASE3,Metastatic Breast Cancer,"Enobosarm & Abemaciclib Combo (DRUG); non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant (DRUG)",104741,Faslodex,Metastatic Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8129,NCT03939871,A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer,UNKNOWN,PHASE2,Hormone Receptor Positive Advanced Breast Cancer,fluvestrant + oral vinorelbine (DRUG),104741,Faslodex,Hormone Receptor Positive Advanced Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8130,NCT06120283,BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors,RECRUITING,PHASE1,Advanced Solid Tumor; Advanced Breast Cancer; Metastatic Breast Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Hormone Receptor Positive Malignant Neoplasm of Breast; HER2-negative Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Non-small Cell Lung Cancer,BGB-43395 (DRUG); Fulvestrant (DRUG); Letrozole (DRUG),104741,Faslodex,Advanced Solid Tumor; Advanced Breast Cancer; Metastatic Breast Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Hormone Receptor Positive Malignant Neoplasm of Breast; HER2-negative Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Non-small Cell Lung Cancer,Lung,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8131,NCT05806671,"Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy",NOT_YET_RECRUITING,PHASE2,Breast Cancer,Dalpiciclib (DRUG); Pyrotinib (DRUG); Fulvestrant (DRUG),104741,Faslodex,Breast Cancer,Breast,Fulvestrant,ESR1,inhibitor/antagonist,unclear,yes,yes,Estrogen receptor antagonist used for hormone receptor-positive breast cancer.,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,1.07,253.0 +8132,NCT06430801,A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008),RECRUITING,PHASE3,Crohn's Disease,IV Tulisokibart (DRUG); SC Tulisokibart (DRUG); IV Placebo (OTHER); SC Placebo (OTHER),9415,Crotaline,Crohn's Disease,Bowel,Monocrotaline,"SLC22A1, SLC22A2",inhibitor/antagonist,unclear,no,no,"Toxic pyrrolizidine alkaloid, not approved for human use.",CC1C(=O)OC2CCN3C2C(=CC3)COC(=O)C(C1(C)O)(C)O,, +8133,NCT03989206,Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis,ACTIVE_NOT_RECRUITING,PHASE3,Moderate-to-Severe Atopic Dermatitis,Nemolizumab (DRUG),9415,Crotaline,Moderate-to-Severe Atopic Dermatitis,Skin,Monocrotaline,"SLC22A1, SLC22A2",inhibitor/antagonist,unclear,no,no,"Toxic pyrrolizidine alkaloid, not approved for human use.",CC1C(=O)OC2CCN3C2C(=CC3)COC(=O)C(C1(C)O)(C)O,, +8134,NCT03989349,Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis,COMPLETED,PHASE3,Moderate-to-Severe Atopic Dermatitis,Placebo (DRUG); Nemolizumab (DRUG),9415,Crotaline,Moderate-to-Severe Atopic Dermatitis,Skin,Monocrotaline,"SLC22A1, SLC22A2",inhibitor/antagonist,unclear,no,no,"Toxic pyrrolizidine alkaloid, not approved for human use.",CC1C(=O)OC2CCN3C2C(=CC3)COC(=O)C(C1(C)O)(C)O,, +8135,NCT05769777,"Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis",RECRUITING,PHASE2,Dermatitis Atopic,Amlitelimab (DRUG),9415,Crotaline,Dermatitis Atopic,Skin,Monocrotaline,"SLC22A1, SLC22A2",inhibitor/antagonist,unclear,no,no,"Toxic pyrrolizidine alkaloid, not approved for human use.",CC1C(=O)OC2CCN3C2C(=CC3)COC(=O)C(C1(C)O)(C)O,, +8136,NCT06811220,The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients,NOT_YET_RECRUITING,PHASE3,Breast Cancer,Hespiridin and Diosmin (DRUG),10621,Ciratin,Breast Cancer,Breast,Hesperidin,,unclear,unclear,no,yes,"Studied for various health benefits, but not approved as a drug.",CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=CC(=C4C(=O)CC(OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O,1.06,245.0 +8137,NCT05088057,Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer,UNKNOWN,PHASE2,Triple Negative Breast Cancer (TNBC),Camrelizumab (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG),443939,DOX,Triple Negative Breast Cancer (TNBC),Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8138,NCT00665457,Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery,TERMINATED,PHASE2,Breast Cancer,filgrastim (BIOLOGICAL); capecitabine (DRUG); celecoxib (DRUG); cyclophosphamide (DRUG); docetaxel (DRUG); doxorubicin hydrochloride (DRUG); gene expression analysis (GENETIC); polymorphism analysis (GENETIC); protein expression analysis (GENETIC); reverse transcriptase-polymerase chain reaction (GENETIC); imaging biomarker analysis (OTHER); immunohistochemistry staining method (OTHER); laboratory biomarker analysis (OTHER); pharmacogenomic studies (OTHER); dynamic contrast-enhanced magnetic resonance imaging (PROCEDURE); needle biopsy (PROCEDURE); neoadjuvant therapy (PROCEDURE); radiomammography (PROCEDURE); ultrasound imaging (PROCEDURE),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8139,NCT02489448,Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer,COMPLETED,PHASE1,Breast Neoplasms,MEDI4736 (DRUG),443939,DOX,Breast Neoplasms,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8140,NCT02200757,Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer,COMPLETED,PHASE2,Metastatic Small Cell Lung Cancer,Aldoxorubicin (DRUG); Topotecan (DRUG),443939,DOX,Metastatic Small Cell Lung Cancer,Lung,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8141,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),COMPLETED,PHASE1,Triple Negative Breast Neoplasms,Pembrolizumab (BIOLOGICAL); Nab-paclitaxel (DRUG); Anthracycline (doxorubicin) (DRUG); Cyclophosphamide (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG),443939,DOX,Triple Negative Breast Neoplasms,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8142,NCT00250874,"Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer",UNKNOWN,PHASE2,Metastatic Breast Cancer,"Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab (DRUG)",443939,DOX,Metastatic Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8143,NCT01485874,Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer,TERMINATED,PHASE1,Ovarian Cancer,Doxil (Pegylated Liposomal Doxorubicin) (DRUG); BIBF 1120 (DRUG),443939,DOX,Ovarian Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8144,NCT02076620,L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours,COMPLETED,PHASE1,"Advanced Solid Tumors Amenable to Anthracycline Therapy; Sarcoma, Breast Cancer, Lung Carcinomas, and Gynecological Cancer Amenable to Anthracycline Therapy",L19TNFα (DRUG); Doxorubicin (DRUG),443939,DOX,"Advanced Solid Tumors Amenable to Anthracycline Therapy; Sarcoma, Breast Cancer, Lung Carcinomas, and Gynecological Cancer Amenable to Anthracycline Therapy",Lung,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8145,NCT00544765,"Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer",COMPLETED,PHASE3,Breast Cancer,TAC (DRUG); NX (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8146,NCT01379482,Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer,COMPLETED,PHASE2,Peritoneal Carcinomatosis; Gastric Cancer,Multimodal treatment (DRUG),443939,DOX,Gastric Cancer,Esophagus/Stomach,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8147,NCT06741020,Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma,RECRUITING,PHASE1,Hepatocellular Carcinoma (HCC),"Adebrelimab, Oxaliplatin, Fluorouracil,Leucovorin (DRUG)",443939,DOX,Hepatocellular Carcinoma (HCC),Liver,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8148,NCT00478374,Sorafenib With TACE to Treat Hepatocellular Carcinoma,COMPLETED,PHASE1,Hepatocellular Carcinoma,Sorafenib (DRUG); Transarterial chemoembolisation with doxorubicin (PROCEDURE),443939,DOX,Hepatocellular Carcinoma,Liver,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8149,NCT03575520,Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients,COMPLETED,PHASE2,Breast Cancer,Pegfilgrastim (DRUG); Doxorubicin/Cyclophosphamide(AC) treatment (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8150,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,COMPLETED,PHASE3,"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity",OLAPARIB (DRUG); Single agent chemotherapy (DRUG),443939,DOX,"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity",Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8151,NCT05114720,Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer,RECRUITING,PHASE3,Breast Cancer,standard adjuvant chemotherapy plus moxifloxacin (DRUG); standard adjuvant chemotherapy plus placebo (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8152,NCT01784120,A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer,UNKNOWN,PHASE2,Metastatic Breast Cancer,Doxorubicin/Genexol-PM (DRUG),443939,DOX,Metastatic Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8153,NCT03472274,Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO),COMPLETED,PHASE2,Bladder Cancer,Durvalumab (DRUG); Tremelimumab (DRUG); Cisplatin-based neoadjuvant chemotherapy (DRUG),443939,DOX,Bladder Cancer,Bladder/Urinary Tract,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8154,NCT00448266,Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD,TERMINATED,PHASE2,Breast Cancer,"Intensified Cyclophophamide, Carboplatin and Thiotepa (DRUG); dose dense adriamycine and cyclophosphamide (DRUG)",443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8155,NCT00206466,Biologic Correlative Taxotere/AC,COMPLETED,PHASE2,Breast Cancer,Taxotere (DRUG); Adriamycin/cytoxan (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8156,NCT00002466,"Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer",COMPLETED,PHASE2,Kidney Cancer; Sarcoma,cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); ifosfamide (DRUG); vincristine sulfate (DRUG); conventional surgery (PROCEDURE); radiation therapy (RADIATION),443939,DOX,Kidney Cancer; Sarcoma,Kidney,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8157,NCT00404066,Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Metastatic Breast Cancer,Lapatinib (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG); Pegfilgrastim (DRUG); Filgrastim (DRUG); Dexamethasone (DRUG); Trastuzumab (DRUG),443939,DOX,Breast Cancer; Metastatic Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8158,NCT02758366,Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma,TERMINATED,PHASE2,"Glioblastoma (GBM); DIPG; Brainstem Glioma, Pediatric; Diffuse Spinal Glioma; Bilateral Thalamic Glioma; Gliomatosis Cerebri; Anaplastic Astrocytoma; Midline Diffuse Glioma",Doxorubicin (DRUG),443939,DOX,"Glioblastoma (GBM); DIPG; Brainstem Glioma, Pediatric; Diffuse Spinal Glioma; Bilateral Thalamic Glioma; Gliomatosis Cerebri; Anaplastic Astrocytoma; Midline Diffuse Glioma",CNS/Brain,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8159,NCT02413320,Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer,COMPLETED,PHASE2,Triple-negative Breast Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG),443939,DOX,Triple-negative Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8160,NCT00057720,TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer,COMPLETED,PHASE3,Ovarian Neoplasms,TLK286 HCl for injection (DRUG); topotecan hydrochloride for injection (DRUG); doxorubicin HCl liposome injection (DRUG),443939,DOX,Ovarian Neoplasms,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8161,NCT01031420,Dose Dense MVAC for Muscle Invasive Bladder Cancer,COMPLETED,PHASE2,Muscle Invasive Bladder Cancer; High Risk Urothelial Carcinoma of the Upper Urinary Tracts,single arm dose dense MVAC (DRUG),443939,DOX,Muscle Invasive Bladder Cancer; High Risk Urothelial Carcinoma of the Upper Urinary Tracts,Bladder/Urinary Tract,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8162,NCT02066220,International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma,ACTIVE_NOT_RECRUITING,PHASE2,Brain Tumors,Radiotherapy without Carboplatin (RADIATION); Reduced-intensity maintenance chemotherapy (DRUG); Radiotherapy with Carboplatin (RADIATION); Maintenance chemotherapy (DRUG); WNT-HR < 16 years (RADIATION); WNT-HR >= 16 years (RADIATION); Induction Chemotherapy (DRUG); SHH-TP53 M0 (RADIATION); SHH-TP53 M+ (germline) (RADIATION); SHH-TP53 (somatic) (RADIATION); Vinblastin Maintenance (DRUG),443939,DOX,Brain Tumors,CNS/Brain,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8163,NCT00861120,Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type,COMPLETED,PHASE2,Epithelial Ovarian Cancer,Pegylated liposomal doxorubicin (DRUG); Panitumumab (DRUG),443939,DOX,Ovarian Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8164,NCT05684731,Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer,RECRUITING,PHASE1,Ovarian Cancer,KM1 (BIOLOGICAL); Chemotherapy (DRUG),443939,DOX,Ovarian Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8165,NCT06358573,Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK,RECRUITING,PHASE2,Triple-negative Breast Cancer; TNBC - Triple-Negative Breast Cancer,INT230-6 (DRUG); neoadjuvant immuno-chemotherapy (OTHER),443939,DOX,Triple-negative Breast Cancer; TNBC - Triple-Negative Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8166,NCT00410631,"Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma",UNKNOWN,PHASE3,Neuroblastoma,filgrastim (BIOLOGICAL); carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); dacarbazine (DRUG); doxorubicin hydrochloride (DRUG); etoposide phosphate (DRUG); ifosfamide (DRUG); isotretinoin (DRUG); melphalan (DRUG); topotecan hydrochloride (DRUG); vincristine sulfate (DRUG); vindesine (DRUG); autologous hematopoietic stem cell transplantation (PROCEDURE); conventional surgery (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); iobenguane I 131 (RADIATION); radiation therapy (RADIATION),443939,DOX,Neuroblastoma,CNS/Brain,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8167,NCT00102973,TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer,COMPLETED,PHASE3,Ovarian Neoplasms,TLK286 in Combination with Carboplatin (DRUG); Doxorubicin HCl Liposome Injection (DRUG),443939,DOX,Ovarian Neoplasms,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8168,NCT05870748,REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1,RECRUITING,PHASE2,Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Platinum-resistant Ovarian Cancer,Luveltamab tazevibulin (DRUG); Pegfilgrastim (DRUG); Gemcitabine (DRUG); Paclitaxel (DRUG); Pegylated liposomal doxorubicin (DRUG); Topotecan (DRUG),443939,DOX,Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Platinum-resistant Ovarian Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8169,NCT00569257,Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors,COMPLETED,PHASE2,Ovarian Cancer; Endometrial Cancer,AEZS-108 (DRUG),443939,DOX,Ovarian Cancer; Endometrial Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8170,NCT02456857,"Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative",COMPLETED,PHASE2,Invasive Breast Carcinoma; Triple-Negative Breast Carcinoma,Bevacizumab (BIOLOGICAL); Everolimus (DRUG); Laboratory Biomarker Analysis (OTHER); Pegylated Liposomal Doxorubicin Hydrochloride (DRUG),443939,DOX,Triple-Negative Breast Carcinoma,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8171,NCT03101748,Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Breast Inflammatory Carcinoma; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7,Cyclophosphamide (DRUG); Doxorubicin (DRUG); Laboratory Biomarker Analysis (OTHER); Neratinib (DRUG); Paclitaxel (DRUG); Pertuzumab (BIOLOGICAL); Trastuzumab (BIOLOGICAL),443939,DOX,Breast Inflammatory Carcinoma; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8172,NCT00350948,Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer,TERMINATED,PHASE3,Ovarian Neoplasms,Telcyta (DRUG); Liposomal Doxorubicin (DRUG),443939,DOX,Ovarian Neoplasms,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8173,NCT06114082,TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma,RECRUITING,PHASE2,Hepatocellular Carcinoma; Liver Cancer,IDA-TACE (PROCEDURE); DOX-TACE (PROCEDURE),443939,DOX,Hepatocellular Carcinoma,Liver,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8174,NCT00002582,"Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer",COMPLETED,PHASE3,Breast Cancer,CMF regimen (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); fluorouracil (DRUG); goserelin acetate (DRUG); leuprolide acetate (DRUG); methotrexate (DRUG); tamoxifen citrate (DRUG); oophorectomy (PROCEDURE); radiation therapy (RADIATION),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8175,NCT03268382,"p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246",COMPLETED,PHASE2,High-grade Serous Ovarian Cancer,APR-246 (DRUG); Pegylated Liposomal Doxorubicin Hydrochloride (PLD) (DRUG),443939,DOX,High-grade Serous Ovarian Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8176,NCT00057382,"T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients",TERMINATED,PHASE2,Hepatocellular Carcinoma,T138067 intravenous (DRUG); doxorubicin intravenous (DRUG),443939,DOX,Hepatocellular Carcinoma,Liver,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8177,NCT03964090,"Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)",ACTIVE_NOT_RECRUITING,PHASE2,Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma,TEDD-R (DRUG); TEDDI-R (DRUG); Ibrutinib (DRUG); Cytarabine (DRUG); Isavuconazole (DRUG); Methotrexate (DRUG),443939,DOX,Central Nervous System Lymphoma,CNS/Brain,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8178,NCT03815890,Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO,RECRUITING,PHASE2,Breast Cancer,Nivolumab (DRUG); Ipilimumab (DRUG); Ipilimumab (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8179,NCT02237690,Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer,COMPLETED,PHASE1,Ovarian Cancer,Doxorubicin hydrochloride liposome (DRUG),443939,DOX,Ovarian Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8180,NCT01202890,Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer,TERMINATED,PHASE1,Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma,"Lenalidomide, Liposomal Doxorubicin, Bevacizumab (DRUG); Revlimid, Doxil, Avastin (DRUG)",443939,DOX,Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8181,NCT01205503,Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release,COMPLETED,PHASE2,Breast Cancer; Non-Hodgkin's Lymphoma,Mesna (DRUG); Saline (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG),443939,DOX,Breast Cancer; Non-Hodgkin's Lymphoma,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8182,NCT00262990,"Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer",COMPLETED,PHASE3,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms,EPO906 (Patupilone) (DRUG); doxorubicin (DRUG),443939,DOX,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8183,NCT05889390,Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,HER2-negative Breast Cancer,Oncotherm EHY-2030 (DEVICE); Paclitaxel (DRUG); Carboplatin (DRUG); Cyclophosphamide/Doxorubicin (DRUG); Breast cancer removal surgery (PROCEDURE),443939,DOX,HER2-negative Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8184,NCT04914390,A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer,RECRUITING,PHASE2,Triple-negative Breast Cancer,AT regimen (DRUG); Tislelizumab (DRUG); Anlotinib (DRUG),443939,DOX,Triple-negative Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8185,NCT00036790,Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer,COMPLETED,PHASE1,"Breast Cancer; Chronic Myeloproliferative Disorders; Colorectal Cancer; Head and Neck Cancer; Leukemia; Lung Cancer; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic/Myeloproliferative Diseases; Prostate Cancer; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific",doxorubicin hydrochloride (DRUG); motexafin gadolinium (DRUG),443939,DOX,"Breast Cancer; Chronic Myeloproliferative Disorders; Colorectal Cancer; Head and Neck Cancer; Leukemia; Lung Cancer; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic/Myeloproliferative Diseases; Prostate Cancer; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Bowel,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8186,NCT04811703,Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer,RECRUITING,PHASE1,Metastatic Ovarian Carcinoma; Peritoneal Carcinomatosis; Stage III Ovarian Cancer; Stage IV Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Metastatic Malignant Neoplasm in the Peritoneum,Combined PIPAC / IV chemotherapy treatment (DRUG),443939,DOX,Metastatic Ovarian Carcinoma; Peritoneal Carcinomatosis; Stage III Ovarian Cancer; Stage IV Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Metastatic Malignant Neoplasm in the Peritoneum,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8187,NCT03376503,Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients,COMPLETED,PHASE1,Breast Cancer,Pegfilgrastim (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8188,NCT01959490,Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer,COMPLETED,PHASE2,Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,trastuzumab (BIOLOGICAL); Pertuzumab (BIOLOGICAL); docetaxel (DRUG); carboplatin (DRUG); doxorubicin (DRUG); cyclophosphamide (DRUG); paclitaxel (DRUG); Bevacizumab (DRUG),443939,DOX,Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8189,NCT01111903,A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse,COMPLETED,PHASE1,Ovarian Cancer Recurrent,Lenalidomide (DRUG),443939,DOX,Ovarian Cancer Recurrent,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8190,NCT02688803,Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC),COMPLETED,PHASE4,Breast Cancer,Dose dense AC-P (DRUG); Dose dense AC (DRUG); FEC-D (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8191,NCT06175390,"Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer",RECRUITING,PHASE2,Triple Negative Breast Cancer,68Ga-FAPI-46 PET/CT (RADIATION); Tumor samples analysis (BIOLOGICAL); Blood samples analysis: Circulating Tumor DNA (BIOLOGICAL),443939,DOX,Triple Negative Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8192,NCT00955890,Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Dexrazoxane hydrochloride (DRUG); Dexrazoxane hydrochloride (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8193,NCT02098343,"p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246",COMPLETED,PHASE1,Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53,APR-246 (DRUG); Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) (DRUG),443939,DOX,Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8194,NCT05261490,Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer,TERMINATED,PHASE1,Ovarian Cancer; Ovarian Neoplasms; Ovarian Carcinoma; Fallopian Tube Cancer; Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma,maplirpacept (PF-07901801) (DRUG); Pegylated Liposomal Doxorubicin (PLD) (DRUG),443939,DOX,Ovarian Cancer; Ovarian Neoplasms; Ovarian Carcinoma; Fallopian Tube Cancer; Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8195,NCT00070564,"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,pegfilgrastim (BIOLOGICAL); AC regimen (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); paclitaxel (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8196,NCT03749850,Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer,UNKNOWN,PHASE1,Metastatic Breast Cancer; Breast Cancer; Breast Neoplasms; Stage IV Breast Cancer; Metastatic Cancer; Invasive Ductal Carcinoma of Female Breast; Invasive Ductal Breast Cancer; Adenocarcinoma Breast,LTLD (DRUG); MR-HIFU induced hyperthermia (PROCEDURE); Cyclophosphamide (DRUG),443939,DOX,Metastatic Breast Cancer; Breast Cancer; Breast Neoplasms; Stage IV Breast Cancer; Metastatic Cancer; Invasive Ductal Carcinoma of Female Breast; Invasive Ductal Breast Cancer; Adenocarcinoma Breast,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8197,NCT00859495,Trimodal Lung-Sparing Treatment of Pleural Mesothelioma,TERMINATED,PHASE2,Pleural Mesothelioma,Doxorubicin (DRUG); Cisplatin (DRUG); Pemetrexed (DRUG); Radiotherapy (RADIATION),443939,DOX,Pleural Mesothelioma,Lung,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8198,NCT00539643,Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma,COMPLETED,PHASE2,Hepatocellular Carcinoma; Liver Cancer; Hepatoma,Bead Block microspheres (DEVICE); Bead + Dox Arm (OTHER),443939,DOX,Hepatocellular Carcinoma; Liver Cancer; Hepatoma,Liver,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8199,NCT03055143,Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer,COMPLETED,PHASE1,Breast Cancer and Ovarian Cancer,SPARC-08-038 (DRUG); Ref-08-038 (DRUG),443939,DOX,Breast Cancer and Ovarian Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8200,NCT06787612,Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer,NOT_YET_RECRUITING,PHASE2,Ovarian Cancer,Ubamatamab (DRUG); Bevacizumab (DRUG); Cemiplimab (DRUG); Fianlimab (DRUG); PLD (DRUG); Sarilumab (DRUG),443939,DOX,Ovarian Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8201,NCT00994968,"Doxorubicin Hydrochloride, Cyclophosphamide, Docetaxel, and S-1 Before Surgery in Treating Women With Stage II or Stage III Breast Cancer",UNKNOWN,PHASE2,Breast Cancer,cyclophosphamide (DRUG); docetaxel (DRUG); doxorubicin hydrochloride (DRUG); tegafur-gimeracil-oteracil potassium (DRUG); neoadjuvant therapy (PROCEDURE); therapeutic conventional surgery (PROCEDURE),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8202,NCT01204801,Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors,UNKNOWN,PHASE3,Breast Cancer,Focused Microwave Thermotherapy (DEVICE); Chemotherapy (control) (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8203,NCT04762901,LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer,WITHDRAWN,PHASE1,Breast Cancer,Niraparib (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Paclitaxel (DRUG); Pegfilgrastim (DRUG); Carboplatin (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8204,NCT02488967,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Carboplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Paclitaxel (DRUG),443939,DOX,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8205,NCT01332669,Drug-eluting Bead in Hepatocellular Carcinoma,COMPLETED,PHASE4,Hepatocellular Carcinoma,DebDox TACE (PROCEDURE),443939,DOX,Hepatocellular Carcinoma,Liver,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8206,NCT01472146,ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Breast Disease; Neoplasms; Neoplasms by Site,Zo-Nantax (DRUG),443939,DOX,Breast Cancer; Breast Disease; Neoplasms; Neoplasms by Site,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8207,NCT00017368,Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma,filgrastim (BIOLOGICAL); sargramostim (BIOLOGICAL); carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); etoposide phosphate (DRUG); ifosfamide (DRUG); isotretinoin (DRUG); melphalan (DRUG); thiotepa (DRUG); vincristine sulfate (DRUG); conventional surgery (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),443939,DOX,Neuroblastoma,CNS/Brain,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8208,NCT01057069,Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,"Carboplatin and Paclitaxel (DRUG); Doxorubicin, cyclophosphamide (DRUG); Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide (DRUG)",443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8209,NCT05929768,Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer,RECRUITING,PHASE3,Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Early Stage Triple-Negative Breast Carcinoma,Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG); Doxorubicin (DRUG); Paclitaxel (DRUG); Pembrolizumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); Surgical Procedure (PROCEDURE),443939,DOX,Early Stage Triple-Negative Breast Carcinoma,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8210,NCT05296746,Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer,RECRUITING,PHASE2,Breast Cancer Stage II,Ribociclib (neoadjuvant) (DRUG); Chemotherapy (adjuvant) (DRUG); Ribociclib (adjuvant) (DRUG),443939,DOX,Early Stage Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8211,NCT03542669,Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer,UNKNOWN,PHASE1,Recurrent Ovarian Carcinoma; Platinum-resistant Ovarian Cancer,6B11-OCIK Injection (DRUG); Doxorubicin (DRUG),443939,DOX,Recurrent Ovarian Carcinoma; Platinum-resistant Ovarian Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8212,NCT00604968,Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059),TERMINATED,PHASE4,Breast Neoplasms,Caelyx (pegylated liposomal doxorubicin; SCH 200746) (DRUG),443939,DOX,Breast Neoplasms,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8213,NCT02957968,Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca,ACTIVE_NOT_RECRUITING,PHASE2,Breast Adenocarcinoma; Estrogen Receptor- Negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive Tumor; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Triple-negative Breast Carcinoma,Doxorubicin (DRUG); Cyclophosphamide (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Decitabine (DRUG); Pembrolizumab (DRUG),443939,DOX,Breast Cancer (Various Types and Stages),Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8214,NCT02631876,"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer",COMPLETED,PHASE3,Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Ovarian Cancer,Mirvetuximab soravtansine (DRUG); Paclitaxel (DRUG); Pegylated liposomal doxorubicin (DRUG); Topotecan (DRUG),443939,DOX,Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Ovarian Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8215,NCT01324076,Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery,UNKNOWN,PHASE3,Liver Cancer,doxorubicin-eluting beads (DRUG); sorafenib tosylate (DRUG); laboratory biomarker analysis (OTHER); pharmacogenomic studies (OTHER); pharmacological study (OTHER); quality-of-life assessment (PROCEDURE),443939,DOX,Liver Cancer,Liver,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8216,NCT01329627,Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer,TERMINATED,PHASE2,Locally Advanced HER2-negative Breast Cancer,Paclitaxel/doxorubicin/cyclophosphamide (DRUG); Paclitaxel/doxorubicin/cyclophosphamide (DRUG),443939,DOX,Locally Advanced HER2-negative Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8217,NCT00237627,Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer,COMPLETED,PHASE1,"Breast Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific",PS-341 (DRUG); Doxil (DRUG); Velcade (DRUG),443939,DOX,"Breast Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8218,NCT02215876,Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer,WITHDRAWN,PHASE2,Breast Cancer,Doxorubicin (DRUG); Cyclophosphamide (DRUG); Eribulin (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8219,NCT06768931,Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer,RECRUITING,PHASE2,Breast Cancer; Triple Negative Breast Cancer (TNBC); Early Stage Breast Cancer; Immunotherapy; Probiotic,Biolosion (oral probiotic compound preparation) (OTHER),443939,DOX,Breast Cancer; Triple Negative Breast Cancer (TNBC); Early Stage Breast Cancer; Immunotherapy; Probiotic,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8220,NCT00949182,Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery,COMPLETED,PHASE2,Liver Cancer,"sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C (DRUG); laboratory biomarker analysis (OTHER)",443939,DOX,Liver Cancer,Liver,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8221,NCT01750073,Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Invasive Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Stage IA Breast Cancer; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Cyclophosphamide (DRUG); Doxorubicin Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Paclitaxel (DRUG); Radiation Therapy (RADIATION); Therapeutic Conventional Surgery (PROCEDURE); Trastuzumab (BIOLOGICAL),443939,DOX,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Invasive Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Stage IA Breast Cancer; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8222,NCT00043082,S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer,COMPLETED,PHASE3,Ovarian Cancer; Peritoneal Cavity Cancer,carboplatin (DRUG); pegylated liposomal doxorubicin hydrochloride (DRUG),443939,DOX,Ovarian and Peritoneal Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8223,NCT04373031,"Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer; Breast Neoplasms,Pembrolizumab (DRUG); IRX 2 (DRUG),443939,DOX,Breast Cancer; Breast Neoplasms,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8224,NCT00434031,CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer,WITHDRAWN,PHASE2,Breast Cancer,docetaxel (DRUG); cyclophosphamide (DRUG); trastuzumab (DRUG); liposomal doxorubicin (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8225,NCT06155331,Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients,RECRUITING,PHASE4,Breast Cancer Stage 2 and 3,Fenofibrate (DRUG); Placebo (OTHER); Doxorubicin (DRUG); Cyclophosphamide (DRUG),443939,DOX,Breast Cancer Stage 2 and 3,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8226,NCT02525380,Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma,UNKNOWN,PHASE4,Hepatocellular Carcinoma,Device(DC Bead) (PROCEDURE),443939,DOX,Hepatocellular Carcinoma,Liver,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8227,NCT00426127,Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer,TERMINATED,PHASE2,Pancreatic Cancer,Docetaxel (DRUG); Liposomal Doxorubicin (DRUG); Enoxaparin (DRUG),443939,DOX,Pancreatic Cancer,Pancreas,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8228,NCT03248427,Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.,COMPLETED,PHASE2,Breast Cancer,Ribociclib (DRUG); Letrozole 2.5mg (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Paclitaxel (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8229,NCT00003376,Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium,COMPLETED,PHASE3,Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer,carboplatin (DRUG); cisplatin (DRUG); doxorubicin hydrochloride (DRUG); methotrexate (DRUG); paclitaxel (DRUG); vinblastine (DRUG),443939,DOX,Urinary Tract Cancers,Bladder/Urinary Tract,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8230,NCT00079027,Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer),UNKNOWN,PHASE3,Liver Cancer,doxorubicin hydrochloride (DRUG); hepatic artery embolization (PROCEDURE),443939,DOX,Liver Cancer,Liver,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8231,NCT00212082,Gene Expression Profiles in Predicting Chemotherapy Response in Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,"doxorubicin, docetaxel (DRUG)",443939,DOX,Metastatic Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8232,NCT00003782,"Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes",COMPLETED,PHASE3,Breast Cancer,cyclophosphamide (DRUG); docetaxel (DRUG); doxorubicin (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8233,NCT00982631,"A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer",UNKNOWN,PHASE1,Advanced/Recurrent Breast Cancer; Endometrial Cancer; Ovarian Cancer,Temsirolimus/PLD (DRUG),443939,DOX,Advanced/Recurrent Breast Cancer; Endometrial Cancer; Ovarian Cancer,Uterus,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8234,NCT03533582,Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery,ACTIVE_NOT_RECRUITING,PHASE3,"Childhood Hepatocellular Carcinoma; Childhood Malignant Liver Neoplasm; Fibrolamellar Carcinoma; Hepatoblastoma; Hepatocellular Malignant Neoplasm, Not Otherwise Specified",Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Doxorubicin (DRUG); Etoposide (DRUG); Fluorouracil (DRUG); Gemcitabine (DRUG); Irinotecan (DRUG); Oxaliplatin (DRUG); Patient Observation (OTHER); Resection (PROCEDURE); Sorafenib (DRUG); Vincristine Sulfate (DRUG),443939,DOX,Childhood Liver Malignancies,Liver,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8235,NCT00170573,Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer,COMPLETED,PHASE2,Ovarian Cancer,Caelyx (DRUG),443939,DOX,Ovarian Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8236,NCT00976131,Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer,COMPLETED,PHASE1,Breast Cancer,CoQ10 (DRUG); CoQ10 Placebo (OTHER); Doxorubicin (DRUG); Cyclophosphamide (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8237,NCT00441376,A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver,COMPLETED,PHASE1,Hepatocellular Carcinoma; Liver Neoplasms,ThermoDox (DRUG),443939,DOX,Hepatocellular Carcinoma; Liver Neoplasms,Liver,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8238,NCT03591276,Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer,UNKNOWN,PHASE1,Metastatic Breast Cancer,"Chemotherapy Drugs, Cancer (DRUG)",443939,DOX,Metastatic Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8239,NCT06312176,A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010),RECRUITING,PHASE3,Breast Neoplasms,Sacituzumab tirumotecan (DRUG); Pembrolizumab (BIOLOGICAL); Paclitaxel (DRUG); Nab-paclitaxel (DRUG); Capecitabine (DRUG); Liposomal doxorubicin (DRUG),443939,DOX,Breast Neoplasms,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8240,NCT05092360,Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7),ACTIVE_NOT_RECRUITING,PHASE3,Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer,Nemvaleukin and Pembrolizumab Combination (BIOLOGICAL); Pembrolizumab (BIOLOGICAL); Nemvaleukin (BIOLOGICAL); Pegylated Liposomal Doxorubicin (PLD) (DRUG); Paclitaxel (DRUG); Topotecan (DRUG); Gemcitabine (DRUG),443939,DOX,Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8241,NCT00980460,Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer,ACTIVE_NOT_RECRUITING,PHASE3,PRETEXT I Hepatoblastoma; PRETEXT II Hepatoblastoma; PRETEXT III Hepatoblastoma; PRETEXT IV Hepatoblastoma,Cisplatin (DRUG); Dexrazoxane (DRUG); Doxorubicin Hydrochloride (DRUG); Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Liver Transplantation (PROCEDURE); Temsirolimus (DRUG); Therapeutic Conventional Surgery (PROCEDURE); Vincristine Sulfate (DRUG),443939,DOX,Hepatoblastoma,Liver,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8242,NCT00442260,Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer,COMPLETED,PHASE1,Metastatic Breast Cancer,DOXIL (DRUG); Abraxane (DRUG),443939,DOX,Metastatic Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8243,NCT00129376,Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients,COMPLETED,PHASE2,Breast Cancer,Doxorubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8244,NCT00722592,"Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)",COMPLETED,PHASE2,Ovarian Cancer,Vintafolide (DRUG); pegylated liposomal doxorubicin (PLD) (DRUG); EC20 (OTHER),443939,DOX,Ovarian Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8245,NCT06394492,SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer,RECRUITING,PHASE3,Ovarian Cancer,SHR-A1921 (DRUG); Doxorubicin (DRUG); Paclitaxel (DRUG); Topotecan (DRUG),443939,DOX,Ovarian Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8246,NCT00159094,A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer,UNKNOWN,PHASE2,Metastatic Breast Cancer,Doxil and Vinorelbine (DRUG),443939,DOX,Metastatic Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8247,NCT00990860,Study in Asia of the Combination of TACE With Sorafenib in HCC Patients,UNKNOWN,PHASE2,Hepatocellular Carcinoma,doxorubicin (DRUG); TACE (Transcatheter arterial chemoembolization) (PROCEDURE),443939,DOX,Hepatocellular Carcinoma,Liver,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8248,NCT01798160,Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).,COMPLETED,PHASE4,Hepatocellular Carcinoma,DEB TACE (PROCEDURE); SIRT (PROCEDURE),443939,DOX,Hepatocellular Carcinoma,Liver,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8249,NCT04584112,"A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer",COMPLETED,PHASE1,Triple-Negative Breast Cancer,Tiragolumab (DRUG); Atezolizumab (DRUG); Nab-paclitaxel (DRUG); Tiragolumab (DRUG); Atezolizumab (DRUG); Nab-paclitaxel (DRUG); Carboplatin (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Granulocyte colony-stimulating factor (G-CSF) (DRUG); Granulocyte-macrophage colony-stimulating factor (GM-CSF) (DRUG),443939,DOX,Triple-Negative Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8250,NCT00669812,High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma,UNKNOWN,PHASE2,Lymphoma; Small Intestine Cancer,carmustine (DRUG); cyclophosphamide (DRUG); cytarabine (DRUG); doxorubicin hydrochloride (DRUG); epirubicin hydrochloride (DRUG); etoposide (DRUG); ifosfamide (DRUG); melphalan (DRUG); methotrexate (DRUG); prednisolone (DRUG); vincristine sulfate (DRUG); autologous hematopoietic stem cell transplantation (PROCEDURE); biopsy (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE),443939,DOX,Lymphoma and Small Intestine Cancer,Bowel,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8251,NCT00023868,Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655),TERMINATED,PHASE3,Colorectal Cancer; Metastatic Cancer,FOLFIRI regimen (DRUG); cisplatin (DRUG); doxorubicin hydrochloride (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); mitomycin C (DRUG),443939,DOX,Colorectal Cancer; Metastatic Cancer,Bowel,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8252,NCT01459380,"Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",COMPLETED,PHASE1,Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Ovarian Carcinoma,Bevacizumab (BIOLOGICAL); Carboplatin (DRUG); Laboratory Biomarker Analysis (OTHER); Pegylated Liposomal Doxorubicin Hydrochloride (DRUG); Veliparib (DRUG),443939,DOX,Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Ovarian Carcinoma,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8253,NCT00262067,A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1),UNKNOWN,PHASE3,Metastatic Breast Cancer,Bevacizumab (DRUG); Placebo (DRUG); Chemotherapy (DRUG),443939,DOX,Metastatic Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8254,NCT00567567,Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma,COMPLETED,PHASE3,Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma; Regional Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma,Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin Hydrochloride (DRUG); Etoposide (DRUG); External Beam Radiation Therapy (RADIATION); Filgrastim (BIOLOGICAL); Isotretinoin (DRUG); Laboratory Biomarker Analysis (OTHER); Melphalan (DRUG); Peripheral Blood Stem Cell Transplantation (PROCEDURE); Pharmacological Study (OTHER); Thiotepa (DRUG); Topotecan Hydrochloride (DRUG); Vincristine Sulfate Liposome (DRUG),443939,DOX,Neuroblastoma,CNS/Brain,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8255,NCT00944801,Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma,COMPLETED,PHASE1,Glioblastoma,Pegylated Liposomal Doxorubicine (DRUG),443939,DOX,Glioblastoma,CNS/Brain,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8256,NCT00004067,Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2,COMPLETED,PHASE3,Breast Cancer,herceptin (BIOLOGICAL); adriamycin (DRUG); cyclophosphamide (DRUG); taxol (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8257,NCT00470067,"Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer",TERMINATED,PHASE2,Endometrial Cancer,carboplatin (DRUG); pegylated liposomal doxorubicin hydrochloride (DRUG),443939,DOX,Endometrial Cancer,Uterus,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8258,NCT00040872,Multiple Therapies in Treating Patients With Advanced Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma,filgrastim (BIOLOGICAL); monoclonal antibody 3F8 (BIOLOGICAL); sargramostim (BIOLOGICAL); carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); isotretinoin (DRUG); thiotepa (DRUG); topotecan hydrochloride (DRUG); vincristine sulfate (DRUG); autologous bone marrow transplantation (PROCEDURE); bone marrow ablation with stem cell support (PROCEDURE); conventional surgery (PROCEDURE); drug resistance inhibition treatment (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); syngeneic bone marrow transplantation (PROCEDURE); radiation therapy (RADIATION),443939,DOX,Neuroblastoma,CNS/Brain,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8259,NCT00002967,"Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer",COMPLETED,PHASE3,Breast Cancer,cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); octreotide pamoate (DRUG); tamoxifen citrate (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8260,NCT00669773,Validate Gene Expression and Proteomic Signatures Predictive of Treatment for Response for Breast Cancer Patient,UNKNOWN,PHASE2,Breast Cancer,Adriamycin (DRUG); Docetaxel (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8261,NCT01270373,NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After?,UNKNOWN,PHASE2,Breast Cancer,FAC x 3 followed by Docetaxel x 3 (DRUG); Docetaxel x 3 followed by FAC x 3 (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8262,NCT05097248,Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy,UNKNOWN,PHASE2,Breast Cancer,Camrelizumab (DRUG); Liposomal Doxorubicin (DRUG); Losartan (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8263,NCT02789657,Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.,COMPLETED,PHASE2,Breast Cancer,paclitaxel (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); carboplatin (DRUG); Breast surgery (PROCEDURE); AC (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8264,NCT00436566,"Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery",COMPLETED,PHASE2,Breast Cancer; Cardiac Toxicity,trastuzumab (BIOLOGICAL); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); lapatinib ditosylate (DRUG); paclitaxel (DRUG); gene expression analysis (GENETIC); reverse transcriptase-polymerase chain reaction (GENETIC); fluorophotometry (OTHER); laboratory biomarker analysis (OTHER); mass spectrometry (OTHER); adjuvant therapy (PROCEDURE); quality-of-life assessment (PROCEDURE),443939,DOX,Breast Cancer; Cardiac Toxicity,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8265,NCT03719326,A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies,COMPLETED,PHASE1,TNBC - Triple-Negative Breast Cancer; Ovarian Cancer,Etrumadenant (DRUG); IPI-549 (DRUG); Pegylated liposomal doxorubicin (PLD) (DRUG); nanoparticle albumin-bound paclitaxel (NP) (DRUG),443939,DOX,TNBC - Triple-Negative Breast Cancer; Ovarian Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8266,NCT04443348,Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD),RECRUITING,PHASE2,"Triple Negative Breast Cancer; Hormone Receptor Positive (HR+), HER2-negative Breast Cancer; Biopsy-proven, Positive Lymph Node(s)",Radiation Therapy Boost (RADIATION); Pembrolizumab (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin (DRUG); Capecitabine (DRUG),443939,DOX,"Triple Negative Breast Cancer; Hormone Receptor Positive (HR+), HER2-negative Breast Cancer; Biopsy-proven, Positive Lymph Node(s)",Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8267,NCT02822157,Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer,UNKNOWN,PHASE2,Ovarian Epithelial Cancer,Olaparib (DRUG); carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly (DRUG),443939,DOX,Ovarian Epithelial Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8268,NCT03681548,A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.,COMPLETED,PHASE1,Ovarian Cancer Recurrent,Doxorubicin Hydrochloride Liposome Injection (DRUG),443939,DOX,Ovarian Cancer Recurrent,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8269,NCT00019630,Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors,COMPLETED,PHASE1,Childhood Soft Tissue Sarcoma; Childhood Liver Cancer; Bone Cancer; Brain Tumor; Kidney Tumor,doxorubicin HCl liposome (DRUG),443939,DOX,Childhood Soft Tissue Sarcoma; Childhood Liver Cancer; Bone Cancer; Brain Tumor; Kidney Tumor,CNS/Brain,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8270,NCT03203525,"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer",RECRUITING,PHASE1,Advanced Malignant Neoplasm; Colorectal Carcinoma Metastatic in the Liver; Metastatic Malignant Neoplasm in the Liver; Refractory Malignant Neoplasm,Bevacizumab (BIOLOGICAL); Fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Pegylated Liposomal Doxorubicin Hydrochloride (DRUG); Temsirolimus (DRUG); Tumor Treating Fields Therapy (PROCEDURE),443939,DOX,Advanced Malignant Neoplasm; Colorectal Carcinoma Metastatic in the Liver; Metastatic Malignant Neoplasm in the Liver; Refractory Malignant Neoplasm,Liver,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8271,NCT00723125,"Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer",COMPLETED,PHASE2,Breast Cancer,Abraxane (DRUG); Carboplatin (DRUG); Avastin (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8272,NCT02861222,Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma,COMPLETED,PHASE1,Malignant Glioma,Doxorubicin (DRUG),443939,DOX,Malignant Glioma,CNS/Brain,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8273,NCT03407430,Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain,TERMINATED,PHASE2,Breast Cancer; Lymphoma; Pain,Pregabalin (DRUG); Placebo (DRUG),443939,DOX,Breast Cancer; Lymphoma; Pain,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8274,NCT00739830,Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6),COMPLETED,PHASE2,Endometrial Cancer,ridaforolimus (DRUG); medroxyprogesterone acetate tablets OR megestrol acetate (DRUG); chemotherapy (DRUG),443939,DOX,Endometrial Cancer,Uterus,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8275,NCT01145430,"Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer",COMPLETED,PHASE1,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Stage IV Breast Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma,Laboratory Biomarker Analysis (OTHER); Pegylated Liposomal Doxorubicin Hydrochloride (DRUG); Pharmacological Study (OTHER); Veliparib (DRUG),443939,DOX,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Stage IV Breast Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8276,NCT01970722,"Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer",ACTIVE_NOT_RECRUITING,PHASE1,FIGO Stage IVA Ovarian Cancer; FIGO Stage IVB Ovarian Cancer; Platinum-Resistant Ovarian Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage III Fallopian Tube Cancer AJCC v7; Stage III Ovarian Cancer AJCC v6 and v7; Stage III Primary Peritoneal Cancer AJCC v7; Stage III Uterine Corpus Cancer AJCC v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIA Uterine Corpus Cancer AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIB Uterine Corpus Cancer AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IIIC Uterine Corpus Cancer AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7; Stage IV Uterine Corpus Cancer AJCC v7; Stage IVA Uterine Corpus Cancer AJCC v7; Stage IVB Uterine Corpus Cancer AJCC v7,Carboplatin (DRUG); Cisplatin (DRUG); Gemcitabine Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Paclitaxel (DRUG); Pegylated Liposomal Doxorubicin Hydrochloride (DRUG); Quality-of-Life Assessment (OTHER); Therapeutic Conventional Surgery (PROCEDURE),443939,DOX,FIGO Stage IVA Ovarian Cancer; FIGO Stage IVB Ovarian Cancer; Platinum-Resistant Ovarian Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage III Fallopian Tube Cancer AJCC v7; Stage III Ovarian Cancer AJCC v6 and v7; Stage III Primary Peritoneal Cancer AJCC v7; Stage III Uterine Corpus Cancer AJCC v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIA Uterine Corpus Cancer AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIB Uterine Corpus Cancer AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IIIC Uterine Corpus Cancer AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7; Stage IV Uterine Corpus Cancer AJCC v7; Stage IVA Uterine Corpus Cancer AJCC v7; Stage IVB Uterine Corpus Cancer AJCC v7,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8277,NCT00179725,"Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma",TERMINATED,PHASE1,Ovarian Cancer,CC-5013 (DRUG); liposomal doxorubicin (DRUG),443939,DOX,Ovarian Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8278,NCT00004925,"Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer",COMPLETED,PHASE1,Breast Cancer,trastuzumab (BIOLOGICAL); pegylated liposomal doxorubicin hydrochloride (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8279,NCT00002822,Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer,COMPLETED,PHASE3,Lung Cancer,carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); ifosfamide (DRUG); mesna (DRUG); vincristine sulfate (DRUG); radiation therapy (RADIATION),443939,DOX,Lung Cancer,Lung,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8280,NCT00006825,Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer,COMPLETED,PHASE1,Breast Cancer,trastuzumab (BIOLOGICAL); pegylated liposomal doxorubicin hydrochloride (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8281,NCT03804866,NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018),COMPLETED,PHASE2,Ovarian Cancer,NGR-hTNF (DRUG); Pegylated liposomal doxorubicin (DRUG); Doxorubicin (DRUG),443939,DOX,Ovarian Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8282,NCT00002526,Chemotherapy in Treating Patients With Advanced Sarcoma,COMPLETED,PHASE2,Ovarian Cancer; Sarcoma,filgrastim (BIOLOGICAL); doxorubicin hydrochloride (DRUG); ifosfamide (DRUG),443939,DOX,Ovarian Cancer; Sarcoma,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8283,NCT01093066,Prospective Multicentric Evaluation of a Bladder Preservation Strategy,TERMINATED,PHASE2,Urothelial Carcinoma,optimal TURB (DRUG),443939,DOX,Urothelial Carcinoma,Bladder/Urinary Tract,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8284,NCT00584766,Intensive Combo Chemo With Autologous BM Rescue for Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,High-dose chemotherapy (PROCEDURE),443939,DOX,Metastatic Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8285,NCT00635726,"Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer",TERMINATED,PHASE2,Bladder Cancer,Methotrexate (DRUG); Vinblastine (DRUG); Doxorubicin (DRUG); Cisplatin (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG),443939,DOX,Bladder Cancer,Bladder/Urinary Tract,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8286,NCT00052065,TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer,COMPLETED,PHASE1,Ovarian Neoplasms,TLK286 (DRUG),443939,DOX,Ovarian Neoplasms,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8287,NCT02728622,Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane,COMPLETED,PHASE3,Ovarian Cancer; Peritoneal Cancer; Cancer of the Fallopian Tube,Tamoxifen (DRUG); Chemotherapy (DRUG),443939,DOX,Ovarian Cancer; Peritoneal Cancer; Cancer of the Fallopian Tube,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8288,NCT04928222,Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II),ACTIVE_NOT_RECRUITING,PHASE1,Basal Cell Carcinoma,Doxorubicin-containing MNA (COMBINATION_PRODUCT); Placebo-containing MNA (DRUG),443939,DOX,Basal Cell Carcinoma,Skin,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8289,NCT00956930,Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery,COMPLETED,PHASE2,Liver Cancer,yttrium Y 90 glass microspheres (RADIATION); Doxorubicin (DRUG),443939,DOX,Liver Cancer,Liver,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8290,NCT00004125,Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes,COMPLETED,PHASE3,Breast Cancer,cyclophosphamide (DRUG); docetaxel (DRUG); doxorubicin hydrochloride (DRUG); paclitaxel (DRUG); tamoxifen citrate (DRUG); radiation therapy (RADIATION),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8291,NCT02818725,I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations,COMPLETED,PHASE3,Infiltrating Urothelial Carcinoma; KRAS Gene Mutation,Chemotherapy (DRUG); Panitumumab (DRUG),443939,DOX,Infiltrating Urothelial Carcinoma; KRAS Gene Mutation,Bladder/Urinary Tract,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8292,NCT00516425,Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer,UNKNOWN,PHASE3,Breast Cancer,pegfilgrastim (BIOLOGICAL); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); epirubicin hydrochloride (DRUG); proteomic profiling (GENETIC); diagnostic laboratory biomarker analysis (OTHER); matrix-assisted laser desorption/ionization time of flight mass spectrometry (OTHER); pharmacological study (OTHER); surface-enhanced laser desorption/ionization-time of flight mass spectrometry (OTHER); adjuvant therapy (PROCEDURE),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8293,NCT00017225,Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma,filgrastim (BIOLOGICAL); carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); dacarbazine (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); ifosfamide (DRUG); melphalan (DRUG); tretinoin (DRUG); vincristine sulfate (DRUG); vindesine (DRUG); autologous bone marrow transplantation (PROCEDURE); conventional surgery (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),443939,DOX,Neuroblastoma,CNS/Brain,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8294,NCT00903630,"Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",TERMINATED,PHASE1,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,Lenalidomide (DRUG); liposomal doxorubicin (DRUG),443939,DOX,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8295,NCT00004930,Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases,COMPLETED,PHASE1,Lung Cancer; Metastatic Cancer,doxorubicin hydrochloride (DRUG),443939,DOX,Metastatic Lung Cancer,Lung,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8296,NCT03444025,Neoadjuvant Goserelin for Triple Negative Breast Cancer,UNKNOWN,PHASE2,Breast Cancer Triple Negative,Goserelin (DRUG),443939,DOX,Breast Cancer Triple Negative,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8297,NCT06401330,A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT),RECRUITING,PHASE3,Stage I Kidney Wilms Tumor; Stage II Kidney Wilms Tumor; Stage III Kidney Wilms Tumor; Stage IV Kidney Wilms Tumor,Bone Scan (PROCEDURE); Carboplatin (DRUG); Computed Tomography (PROCEDURE); Cyclophosphamide (DRUG); Dactinomycin (BIOLOGICAL); Doxorubicin (DRUG); Etoposide (DRUG); Irinotecan (DRUG); Magnetic Resonance Imaging (PROCEDURE); Nephrectomy (PROCEDURE); Patient Observation (OTHER); Positron Emission Tomography (PROCEDURE); Ultrasound Imaging (PROCEDURE); Vincristine (DRUG); X-Ray Imaging (PROCEDURE),443939,DOX,Kidney Neoplasms,Kidney,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8298,NCT00446030,Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms,Docetaxel (DRUG); Doxorubicin (DRUG); Carboplatin (DRUG); Cyclophosphamide (DRUG); Trastuzumab (DRUG); Bevacizumab (DRUG),443939,DOX,Breast Neoplasms,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8299,NCT02838225,DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer,COMPLETED,PHASE2,Breast Cancer,"Docetaxel, Doxorubicin (DRUG); Docetaxel, Doxorubicin, Cyclophosphamide (DRUG)",443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8300,NCT00945139,Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA),COMPLETED,PHASE2,Ovarian Cancer,Doxil (DRUG); Avastin (DRUG),443939,DOX,Ovarian Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8301,NCT03071926,Metronomic PLD in Patients With Primary Endocrine Resistant ABC,UNKNOWN,PHASE2,Advanced Breast Cancer,Pegylated Liposomal Doxorubicin (DRUG),443939,DOX,Advanced Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8302,NCT00074139,"Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer",WITHDRAWN,PHASE1,Breast Cancer,cyclophosphamide (DRUG); docetaxel (DRUG); doxorubicin hydrochloride (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8303,NCT04301739,to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC),NOT_YET_RECRUITING,PHASE3,Triple Negative Breast Cancer,"HLX10 (DRUG); nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide (DRUG); Placebo (DRUG)",443939,DOX,Triple Negative Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8304,NCT03742986,Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC),COMPLETED,PHASE2,Breast Cancer,Nivolumab 360mg (DRUG); Paclitaxel 80mg/m^2 (DRUG); Doxorubicin 60mg/m^2 (DRUG); Cyclophosphamide 600mg/m^2 (DRUG); Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2 (DRUG); Trastuzumab 8mg/kg and 6 mg/kg (DRUG); Pertuzumab 840mg and 420mg (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8305,NCT06176339,"Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients""",ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer Female,Pentoxifylline Oral Tablet (DRUG); Placebo (DRUG),443939,DOX,Breast Cancer Female,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8306,NCT02641639,FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer,TERMINATED,PHASE2,Platinum Resistant Ovarian Cancer,Fosbretabulin tromethamine (DRUG); Placebo (DRUG),443939,DOX,Platinum Resistant Ovarian Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8307,NCT01669239,"Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer",COMPLETED,PHASE2,Breast Cancer,Liposomal Doxorubicin (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8308,NCT04065139,Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study,COMPLETED,PHASE2,Gastric Adenocarcinoma; Cancer Metastatic; Chemotherapy Effect,Pressurized intraperitoneal aerosol chemotherapy (PIPAC) (DRUG); Standard chemotherapy (DRUG),443939,DOX,Gastric Adenocarcinoma; Cancer Metastatic; Chemotherapy Effect,Esophagus/Stomach,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8309,NCT03755739,Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors,RECRUITING,PHASE2,Hepatocarcinoma; Lung Cancer; Melanoma; Renal Cancer; Head and Neck Cancer; Pancreas Cancer; Ovarian Cancer; Colo-rectal Cancer; Cervical Cancer; Breast Cancer,Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy (DRUG),443939,DOX,Hepatocarcinoma; Lung Cancer; Melanoma; Renal Cancer; Head and Neck Cancer; Pancreas Cancer; Ovarian Cancer; Colo-rectal Cancer; Cervical Cancer; Breast Cancer,Lung,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8310,NCT00780039,A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625),COMPLETED,PHASE2,Ovarian Neoplasms,Pegylated Liposomal Doxorubicin (DRUG); Carboplatin (DRUG),443939,DOX,Ovarian Neoplasms,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8311,NCT00165139,Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas,COMPLETED,PHASE2,Neuroblastoma; Ewings Sarcoma; Non-rhabdomyosarcoma Soft Tissue Sarcoma,Vincristine (DRUG); Cyclophosphamide (DRUG); Adriamycin (DRUG); Etoposide (VP-16) (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Melphalan (DRUG); Ifosfamide (DRUG); G-CSF (granulocyte-colony stimulating factor) (DRUG); Mesna (DRUG),443939,DOX,Neuroblastoma; Ewings Sarcoma; Non-rhabdomyosarcoma Soft Tissue Sarcoma,CNS/Brain,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8312,NCT00808639,Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma,COMPLETED,PHASE2,Bladder Cancer; Muscle-invasive Bladder Cancer,Methotrexate (DRUG); Doxorubicin (DRUG); vinblastine (DRUG); cisplatin (DRUG); Pegfilgrastim (DRUG),443939,DOX,Bladder Cancer; Muscle-invasive Bladder Cancer,Bladder/Urinary Tract,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8313,NCT01876927,Pre-Operative Or Peri-Operative Dox Regimen In Patients With Locally Advanced Resectable Gastric Cancer,COMPLETED,PHASE2,Gastric Cancer; Locally Advanced Malignant Neoplasm,DOX 4 cycles - Surgery (OTHER); DOX 2 cycles - Surgery - DOX 2 cycles (OTHER),443939,DOX,Gastric Cancer; Locally Advanced Malignant Neoplasm,Esophagus/Stomach,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8314,NCT00003927,"Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer",COMPLETED,PHASE1,Breast Cancer,filgrastim (BIOLOGICAL); amifostine trihydrate (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); paclitaxel (DRUG); peripheral blood stem cell transplantation (PROCEDURE),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8315,NCT02833766,Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer,TERMINATED,PHASE2,Breast Cancer,anti-EGFR-IL-dox (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8316,NCT06735326,Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer,RECRUITING,PHASE2,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer,Fluzoparib (DRUG); Bevacizumab (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG),443939,DOX,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8317,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,COMPLETED,PHASE3,Malignant Pleural Mesothelioma,NGR-hTNF plus Best Investigator's Choice (BIC) (DRUG); Placebo plus Best Investigator's Choice (BIC) (DRUG),443939,DOX,Malignant Pleural Mesothelioma,Lung,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8318,NCT01095926,Pharmacokinetic Study of Doxorubicin in Children With Cancer,COMPLETED,PHASE2,Wilms Tumor; Neuroblastoma; Soft Tissue Sarcoma; Acute Lymphoblastic Leukemia,doxorubicin (DRUG),443939,DOX,Wilms Tumor; Neuroblastoma; Soft Tissue Sarcoma; Acute Lymphoblastic Leukemia,CNS/Brain,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8319,NCT01113957,A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer,COMPLETED,PHASE2,Ovarian Cancer,ABT-888 (DRUG); pegylated liposomal doxorubicin (DRUG); temozolomide (DRUG),443939,DOX,Ovarian Cancer,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8320,NCT02685657,Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer,UNKNOWN,PHASE2,Triple Negative Breast Cancer,Drug: Selumetinib (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG),443939,DOX,Triple Negative Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8321,NCT00005822,SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer,COMPLETED,PHASE1,Breast Cancer,doxorubicin hydrochloride (DRUG); semaxanib (DRUG); conventional surgery (PROCEDURE); radiation therapy (RADIATION); tamoxifen (DRUG),443939,DOX,Breast Cancer,Breast,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8322,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,COMPLETED,PHASE3,Primary Peritoneal Carcinoma; Stage III Ovarian Cancer; Stage IV Ovarian Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Gemcitabine Hydrochloride (DRUG); Pegylated Liposomal Doxorubicin Hydrochloride (DRUG); Topotecan Hydrochloride (DRUG); Therapeutic Conventional Surgery (PROCEDURE),443939,DOX,Ovarian and Peritoneal Carcinoma,Ovary/Fallopian Tube,Doxorubicin (hydrochloride),"TOP2A, TOP2B, TOP1",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Commonly used chemotherapy drug for several cancers.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.02,280.0 +8323,NCT00322374,Phase I Combination w/ Epirubicin,COMPLETED,PHASE1,Metastatic Breast Cancer,Ixabepilone (DRUG); Epirubicin (DRUG),65348,Ellence,Metastatic Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8324,NCT00433420,Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,pegfilgrastim (BIOLOGICAL); cyclophosphamide (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); paclitaxel (DRUG); adjuvant therapy (PROCEDURE),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8325,NCT02980965,"Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer",COMPLETED,PHASE3,Breast Cancer Female,"letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel (DRUG); fluorouracil, epirubicin, cyclophosphamide, docetaxel (DRUG)",65348,Ellence,Breast Cancer Female,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8326,NCT03265574,PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?,COMPLETED,PHASE3,Breast Cancer; Non Hodgkin Lymphoma,Enalapril (DRUG),65348,Ellence,Breast Cancer; Non Hodgkin Lymphoma,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8327,NCT06227065,Precise Neoadjuvant Chemoresection of Low Grade NMIBC,NOT_YET_RECRUITING,PHASE2,Bladder Cancer; Non-muscle Invasive Bladder Cancer; Low-risk,Epirubicin (DRUG); Mitomycin (DRUG); Gemcitabine (DRUG); Docetaxel (DRUG),65348,Ellence,Non-muscle Invasive Bladder Cancer,Bladder/Urinary Tract,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8328,NCT06766266,Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment,RECRUITING,PHASE1,Non-Muscle Invasive Bladder Urothelial Carcinoma,Irinotecan liposome II combination therapy regimen (DRUG); Irinotecan liposome II combination therapy regimen (DRUG),65348,Ellence,Non-Muscle Invasive Bladder Urothelial Carcinoma,Bladder/Urinary Tract,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8329,NCT00667420,"Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma",TERMINATED,PHASE1,Esophageal Adenocarcinoma; Gastric Adenocarcinoma,"panitumumab, epirubicin, oxaliplatin, xeloda (DRUG)",65348,Ellence,Esophageal Adenocarcinoma; Gastric Adenocarcinoma,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8330,NCT06358573,Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK,RECRUITING,PHASE2,Triple-negative Breast Cancer; TNBC - Triple-Negative Breast Cancer,INT230-6 (DRUG); neoadjuvant immuno-chemotherapy (OTHER),65348,Ellence,Triple-negative Breast Cancer; TNBC - Triple-Negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8331,NCT01123473,"Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer",TERMINATED,PHASE2,Adenocarcinoma of the Gastroesophageal Junction; Gastric Cancer,capecitabine (DRUG); cisplatin (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); lapatinib ditosylate (DRUG),65348,Ellence,Adenocarcinoma of the Gastroesophageal Junction; Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8332,NCT06107673,Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）,RECRUITING,PHASE2,Breast Cancer,Dalpiciclib (DRUG); Aromatase inhibitor (DRUG); Docetaxel injection (DRUG); Epirubicin Hydrochloride Injection (DRUG); Cyclophosphamide injection (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8333,NCT02624973,PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Neoadjuvant tamoxifen + goserelin (premenopausal women) (DRUG); Neoadjuvant letrozole (postmenopausal women) (DRUG); Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone) (DRUG); Neoadjuvant docetaxel + cyclophosphamide (DRUG); Neoadjuvant docetaxel (DRUG); Neoadjuvant docetaxel + trastuzumab + pertuzumab (DRUG); Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab (DRUG); Neoadjuvant olaparib (DRUG); Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone) (DRUG); Breast conserving surgery or mastectomy + SNB/axillary dissection (PROCEDURE); Postoperative radiotherapy breast/chest wall + regional lymph nodes (RADIATION); Adjuvant trastuzumab (DRUG); Adjuvant letrozole (postmenopausal women) (DRUG); Adjuvant tamoxifen + goserelin (premenopausal women) (DRUG); Adjuvant palbociclib (if palbociclib given neoadjuvant) (DRUG); Adjuvant Epirubicin+ Cyclophosphamide (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8334,NCT00004873,Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer,COMPLETED,PHASE2,Gastric Cancer,cisplatin (DRUG); docetaxel (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG),65348,Ellence,Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8335,NCT03355157,"A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).",COMPLETED,PHASE4,Metastatic Breast Cancer,"Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen) (DRUG)",65348,Ellence,Metastatic Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8336,NCT01583426,Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto),COMPLETED,PHASE3,Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer,nab-Paclitaxel (DRUG); Paclitaxel (DRUG),65348,Ellence,Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8337,NCT04929548,Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP,NOT_YET_RECRUITING,PHASE4,Breast Cancer,Pyrotinib Maleate Tablets (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8338,NCT05834582,Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer,RECRUITING,PHASE2,TNBC - Triple-Negative Breast Cancer,Fluzoparib+Paclitaxel (DRUG); Epirubicin+Cyclophosphamide (DRUG),65348,Ellence,TNBC - Triple-Negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8339,NCT05474690,A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer,WITHDRAWN,PHASE3,Breast Cancer; HER2-positive Breast Cancer,Docetaxel + Carboplatin + Trastuzumab + Pertuzumab (DRUG); (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab) (DRUG),65348,Ellence,Breast Cancer; HER2-positive Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8340,NCT04914390,A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer,RECRUITING,PHASE2,Triple-negative Breast Cancer,AT regimen (DRUG); Tislelizumab (DRUG); Anlotinib (DRUG),65348,Ellence,Triple-negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8341,NCT01053390,New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma,COMPLETED,PHASE3,Gallbladder Neoplasms,"Somatostatin (DRUG); epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil） (DRUG)",65348,Ellence,Gallbladder Neoplasms,Bladder/Urinary Tract,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8342,NCT00499603,Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Paclitaxel (DRUG); 5-Fluorouracil (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); RAD001 (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8343,NCT04066790,Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Pyrotinib (DRUG); nab-Paclitaxel (DRUG); Trastuzumab (DRUG); EC chemotherapy (DRUG); Surgery (PROCEDURE),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8344,NCT02688803,Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC),COMPLETED,PHASE4,Breast Cancer,Dose dense AC-P (DRUG); Dose dense AC (DRUG); FEC-D (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8345,NCT00066443,"Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer",COMPLETED,PHASE1,Breast Cancer,pegfilgrastim (BIOLOGICAL); docetaxel (DRUG); epirubicin hydrochloride (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8346,NCT02557490,Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases,UNKNOWN,PHASE4,Colon Cancer Liver Metastasis,oxaliplatin and raltitrexed (DRUG),65348,Ellence,Colon Cancer Liver Metastasis,Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8347,NCT00242203,Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms,Zometa (DRUG); Epirubicin (DRUG); Docetaxel (DRUG); Trastuzumab (DRUG); External beam radiation (RADIATION); Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection (PROCEDURE),65348,Ellence,Breast Neoplasms,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8348,NCT00524303,Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.,COMPLETED,PHASE2,"Neoplasms, Breast",Trastuzumab (DRUG); Paclitaxel (DRUG); FEC75 (DRUG); Lapatinib (DRUG),65348,Ellence,"Neoplasms, Breast",Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8349,NCT03243838,Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer,COMPLETED,PHASE2,Triple-Negative Breast Cancer,Apatinib (DRUG),65348,Ellence,Triple-Negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8350,NCT02041338,Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer,UNKNOWN,PHASE2,Breast Cancer; Neoadjuvant Chemotherapy,Paclitaxel and carboplatin (DRUG); Paclitaxel (DRUG); Epirubicin and Paclitaxel (DRUG),65348,Ellence,Breast Cancer; Neoadjuvant Chemotherapy,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8351,NCT03251612,Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer Metastatic,Based on sensitivity analysis (DRUG),65348,Ellence,Colorectal Cancer Metastatic,Bowel,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8352,NCT01204801,Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors,UNKNOWN,PHASE3,Breast Cancer,Focused Microwave Thermotherapy (DEVICE); Chemotherapy (control) (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8353,NCT03013504,"A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients",COMPLETED,PHASE3,HER2 Positive Breast Cancer,HD201 (DRUG); Herceptin (DRUG); Docetaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),65348,Ellence,HER2 Positive Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8354,NCT01276769,Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer,UNKNOWN,PHASE2,Triple Negative Breast Cancer,Paclitaxel plus carboplatin (DRUG); Paclitaxel and epirubicin (DRUG),65348,Ellence,Triple Negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8355,NCT04335669,"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC",RECRUITING,PHASE3,Breast Cancer; Triple Negative Breast Neoplasms,"epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab (DRUG); epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab (DRUG)",65348,Ellence,Breast Cancer; Triple Negative Breast Neoplasms,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8356,NCT05296746,Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer,RECRUITING,PHASE2,Breast Cancer Stage II,Ribociclib (neoadjuvant) (DRUG); Chemotherapy (adjuvant) (DRUG); Ribociclib (adjuvant) (DRUG),65348,Ellence,Early Stage Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8357,NCT06009627,Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients,RECRUITING,PHASE2,Breast Cancer,Dalcelli、Exemestane、Gosserine (DRUG); Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8358,NCT00755976,Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma,COMPLETED,PHASE2,Melanoma (Skin),epirubicin hydrochloride (DRUG); sulindac (DRUG); immunologic technique (OTHER),65348,Ellence,Melanoma (Skin),Skin,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8359,NCT02307227,Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors,COMPLETED,PHASE2,Breast Neoplasms,Trastuzumab (DRUG); Paclitaxel (DRUG); Epirubicin (DRUG); Docetaxel (DRUG),65348,Ellence,Breast Neoplasms,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8360,NCT01964027,The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer,UNKNOWN,PHASE2,Stage IV Gastric Cancer With Metastasis,second line chemoregime for advanced gastric cancer (DRUG),65348,Ellence,Stage IV Gastric Cancer With Metastasis,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8361,NCT06768931,Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer,RECRUITING,PHASE2,Breast Cancer; Triple Negative Breast Cancer (TNBC); Early Stage Breast Cancer; Immunotherapy; Probiotic,Biolosion (oral probiotic compound preparation) (OTHER),65348,Ellence,Breast Cancer; Triple Negative Breast Cancer (TNBC); Early Stage Breast Cancer; Immunotherapy; Probiotic,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8362,NCT04717531,Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Pyrotinib (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); Docetaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8363,NCT04136782,Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer,RECRUITING,PHASE4,Breast Cancer,Albumin-bound paclitaxel combined with carboplatin (DRUG); Epirubicin combined with docetaxel (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8364,NCT04437160,Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy,RECRUITING,PHASE2,Triple Negative Breast Cancer,Epirubicin or Pirarubicin (DRUG); Cyclophosphamide (DRUG),65348,Ellence,Triple Negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8365,NCT00256360,"Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer",COMPLETED,PHASE2,Breast Cancer,dose dense with neulasta (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8366,NCT06631092,Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer,RECRUITING,PHASE1,Triple Negative Breast Cancer,Oral DNA Vaccine (BIOLOGICAL),65348,Ellence,Triple Negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8367,NCT00270894,Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients,COMPLETED,PHASE2,Breast Neoplasm,epirubicin (DRUG); cyclophosphamide (DRUG); docetaxel (DRUG); trastuzumab (DRUG),65348,Ellence,Breast Neoplasm,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8368,NCT05983094,Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer,NOT_YET_RECRUITING,PHASE2,Breast Cancer; Neoadjuvant Therapy,Utidelone (DRUG); Carboplatin (DRUG); Epirubicin (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG),65348,Ellence,Breast Cancer; Neoadjuvant Therapy,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8369,NCT06452394,NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline,NOT_YET_RECRUITING,PHASE2,Breast Cancer,Doxycyclin (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8370,NCT00669812,High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma,UNKNOWN,PHASE2,Lymphoma; Small Intestine Cancer,carmustine (DRUG); cyclophosphamide (DRUG); cytarabine (DRUG); doxorubicin hydrochloride (DRUG); epirubicin hydrochloride (DRUG); etoposide (DRUG); ifosfamide (DRUG); melphalan (DRUG); methotrexate (DRUG); prednisolone (DRUG); vincristine sulfate (DRUG); autologous hematopoietic stem cell transplantation (PROCEDURE); biopsy (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE),65348,Ellence,Lymphoma and Small Intestine Cancer,Bowel,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8371,NCT06908668,Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer,NOT_YET_RECRUITING,PHASE2,HER2-Negative Locally Advanced Breast Cancer,Neoadjuvant Chemotherapy Combined with Immunotherapy and Radiotherapy (DRUG); Neoadjuvant Chemotherapy Combined with Immunotherapy (DRUG),65348,Ellence,HER2-Negative Locally Advanced Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8372,NCT00262067,A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1),UNKNOWN,PHASE3,Metastatic Breast Cancer,Bevacizumab (DRUG); Placebo (DRUG); Chemotherapy (DRUG),65348,Ellence,Metastatic Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8373,NCT02638857,Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma,UNKNOWN,PHASE1,Recurrence Hepatocellular Carcinoma; Advanced Hepatocellular Carcinoma,TACE (PROCEDURE); Dendritic Cell (BIOLOGICAL); lipiodol (DRUG); Mitomycin (MMC) (DRUG); Epirubicin(EADM) (DRUG); Precision Multiple Antigen T Cell (BIOLOGICAL),65348,Ellence,Recurrence Hepatocellular Carcinoma; Advanced Hepatocellular Carcinoma,Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8374,NCT04224922,Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Paclitaxel (DRUG); Carboplatinum (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8375,NCT05253066,Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer,UNKNOWN,PHASE2,Breast Neoplasms,Chidamide combined with exemestane (+/- goserelin) (DRUG); Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician) (DRUG),65348,Ellence,Breast Neoplasms,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8376,NCT00645866,"Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer",COMPLETED,PHASE2,Breast Cancer,capecitabine (DRUG); docetaxel (DRUG); epirubicin hydrochloride (DRUG); laboratory biomarker analysis (OTHER); pharmacogenomic studies (OTHER); biopsy (PROCEDURE); neoadjuvant therapy (PROCEDURE); therapeutic surgical procedure (PROCEDURE),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8377,NCT00002866,Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer,COMPLETED,PHASE1,Breast Cancer; Neutropenia,filgrastim (BIOLOGICAL); docetaxel (DRUG); epirubicin hydrochloride (DRUG),65348,Ellence,Breast Cancer with Neutropenia,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8378,NCT05251766,Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer,UNKNOWN,PHASE1,Breast Cancer; Chemotherapy Effect,Nab paclitaxel (DRUG); Docetaxel (DRUG),65348,Ellence,Breast Cancer; Chemotherapy Effect,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8379,NCT01624025,A Comparative Study of Salvage Treatment With Combination of Docetaxel and Epirubicin,COMPLETED,PHASE2,Metastatic Advanced Gastric Cancer,"Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks (OTHER)",65348,Ellence,Metastatic Advanced Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8380,NCT01690325,Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON),TERMINATED,PHASE2,Breast Cancer,Docetaxel (DRUG); Trastuzumab (DRUG); Bevacizumab (DRUG); Epirubicin (DRUG); Cyclophosphamid (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8381,NCT00957125,A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early,UNKNOWN,PHASE2,Breast Cancer,Epirubicin (DRUG); Docetaxel (DRUG); Bevacizumab (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8382,NCT00516425,Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer,UNKNOWN,PHASE3,Breast Cancer,pegfilgrastim (BIOLOGICAL); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); epirubicin hydrochloride (DRUG); proteomic profiling (GENETIC); diagnostic laboratory biomarker analysis (OTHER); matrix-assisted laser desorption/ionization time of flight mass spectrometry (OTHER); pharmacological study (OTHER); surface-enhanced laser desorption/ionization-time of flight mass spectrometry (OTHER); adjuvant therapy (PROCEDURE),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8383,NCT01049425,Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer,COMPLETED,PHASE3,Primary Breast Cancer; Her2 Non-overexpressing,Epirubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG),65348,Ellence,Primary Breast Cancer; Her2 Non-overexpressing,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8384,NCT01340430,"Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer",COMPLETED,PHASE2,HER-2 Positive Breast Cancer,Trastuzumab (DRUG),65348,Ellence,HER-2 Positive Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8385,NCT00301925,Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery,UNKNOWN,PHASE3,Breast Cancer,pegfilgrastim (BIOLOGICAL); capecitabine (DRUG); cyclophosphamide (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); methotrexate (DRUG); adjuvant therapy (PROCEDURE),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8386,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,COMPLETED,PHASE3,Breast Cancer,FEC Chemotherapy (DRUG); Surgery (PROCEDURE); Docetaxel (DRUG); Pertuzumab (DRUG); Placebo (DRUG); Trastuzumab (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8387,NCT05165225,"Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial",ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer; HER2-low-expressing Breast Cancer; Hormone Receptor-positive Breast Cancer; Neoadjuvant Therapy,Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment (DRUG),65348,Ellence,Breast Cancer; HER2-low-expressing Breast Cancer; Hormone Receptor-positive Breast Cancer; Neoadjuvant Therapy,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8388,NCT02838225,DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer,COMPLETED,PHASE2,Breast Cancer,"Docetaxel, Doxorubicin (DRUG); Docetaxel, Doxorubicin, Cyclophosphamide (DRUG)",65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8389,NCT00017186,Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma,COMPLETED,PHASE2,Malignant Mesothelioma,epirubicin hydrochloride (DRUG); gemcitabine hydrochloride (DRUG),65348,Ellence,Malignant Mesothelioma,Lung,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8390,NCT04301739,to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC),NOT_YET_RECRUITING,PHASE3,Triple Negative Breast Cancer,"HLX10 (DRUG); nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide (DRUG); Placebo (DRUG)",65348,Ellence,Triple Negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8391,NCT05483439,A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer,UNKNOWN,PHASE2,Stage II-III Breast Cancer,"cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin) (DRUG); anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab) (DRUG); traditional herbal medicine (DRUG)",65348,Ellence,Stage II-III Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8392,NCT01031030,"Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)",UNKNOWN,PHASE3,Breast Cancer,cyclophosphamide (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); methotrexate (DRUG); laboratory biomarker analysis (OTHER); adjuvant therapy (PROCEDURE),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8393,NCT01833286,TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular Carcinoma,UNKNOWN,PHASE3,Hepatocellular Carcinoma; Surgery; Ablation,TACE+RFA (PROCEDURE); re-resection (PROCEDURE),65348,Ellence,Hepatocellular Carcinoma; Surgery; Ablation,Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8394,NCT06705127,"Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.",RECRUITING,PHASE2,"HR-positive,HER2-negative Breast Cancer",TORIPALIMAB INJECTION(JS001 ) (DRUG); Stereotactic Body Radiation Therapy (SBRT) (RADIATION),65348,Ellence,"HR-positive,HER2-negative Breast Cancer",Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8395,NCT01150630,"Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer",COMPLETED,PHASE2,Pancreatic Cancer,capecitabine (DRUG); cisplatin (DRUG); epirubicin (DRUG); gemcitabine (DRUG),65348,Ellence,Pancreatic Cancer,Pancreas,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8396,NCT00014222,Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer,COMPLETED,PHASE3,Breast Cancer,epoetin alfa (BIOLOGICAL); filgrastim (BIOLOGICAL); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); paclitaxel (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8397,NCT01354522,TAC Versus TCX As Adjuvant Treatment for Node-Positive Her2-Negative Breast Cancer,COMPLETED,PHASE3,Breast Cancer,"Docetaxel, Doxorubicin, Cyclophosphamide (DRUG); Docetaxel, Cyclophosphamide, Capecitabine (DRUG)",65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8398,NCT06797635,"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)",RECRUITING,PHASE2,Breast Neoplasms; Breast Cancer,Patritumab deruxtecan (BIOLOGICAL); Pembrolizumab (BIOLOGICAL); Paclitaxel (DRUG); Carboplatin (DRUG); Doxorubicin hydrochloride (DRUG); Epirubicin hydrochloride (DRUG); Cyclophosphamide (DRUG); Capecitabine (DRUG); Olaparib (DRUG),65348,Ellence,Breast Neoplasms; Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8399,NCT03876886,The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency,UNKNOWN,PHASE3,Triple Negative Breast Cancer,Epirubicin (DRUG); Cyclophosphamide (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG),65348,Ellence,Triple Negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8400,NCT02297230,Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics,TERMINATED,PHASE1,Breast Cancer,Radiation Therapy (RT) (RADIATION); Capecitabine (DRUG); Trastuzumab (DRUG); Paclitaxel (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8401,NCT03688958,Iodine Supplementation on Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Placebo (DRUG); iodine (DRUG); FEC/TE Placebo (DRUG); FEC/TE iodine (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8402,NCT04736394,A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients,RECRUITING,PHASE3,Non-muscle Invasive Bladder Cancer,APL-1202 (DRUG); Epirubicin Hydrochloride (DRUG),65348,Ellence,Non-muscle Invasive Bladder Cancer,Bladder/Urinary Tract,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8403,NCT06144944,Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer,RECRUITING,PHASE3,Breast Cancer Invasive; Hormone-receptor-positive Breast Cancer; HER2 Low Breast Carcinoma; Early-stage Breast Cancer,"Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel (DRUG); Epirubicin or doxorubicin, cyclophosphamide, paclitaxel (DRUG)",65348,Ellence,Breast Cancer Invasive; Hormone-receptor-positive Breast Cancer; HER2 Low Breast Carcinoma; Early-stage Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8404,NCT06860529,Serplulimab Combined with Chemotherapy for Early-stage HR+/HER2- Breast Cancer,NOT_YET_RECRUITING,PHASE2,HR+/HER2- Breast Cancer,Serplulimab (DRUG); Epirubicin (DRUG); Albumin Paclitaxel (DRUG),65348,Ellence,HR+/HER2- Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8405,NCT00398489,"Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery",UNKNOWN,PHASE2,Breast Cancer,trastuzumab (BIOLOGICAL); anastrozole (DRUG); cyclophosphamide (DRUG); docetaxel (DRUG); epirubicin hydrochloride (DRUG); goserelin acetate (DRUG); tamoxifen citrate (DRUG); adjuvant therapy (PROCEDURE); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE); radiation therapy (RADIATION),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8406,NCT02620280,Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1,COMPLETED,PHASE3,Invasive Ductal Breast Carcinoma,Carboplatin (DRUG); Abraxane (DRUG); MPDL3280A (DRUG); Surgery (PROCEDURE); Anthra (DRUG),65348,Ellence,Invasive Ductal Breast Carcinoma,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8407,NCT00963729,Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery,COMPLETED,PHASE3,Breast Cancer,cyclophosphamide (DRUG); docetaxel (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); letrozole (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8408,NCT00057980,Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma,COMPLETED,PHASE1,Liver Cancer,celecoxib (DRUG); epirubicin hydrochloride (DRUG),65348,Ellence,Liver Cancer,Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8409,NCT01849380,Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer,UNKNOWN,PHASE4,Breast Neoplasms; Neoadjuvant Therapy,S-1 (DRUG); 5-FU (DRUG),65348,Ellence,Breast Neoplasms; Neoadjuvant Therapy,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8410,NCT06491680,Cardiotoxicity in Breast Cancer Patients,RECRUITING,PHASE4,Breast Cancer,Dapagliflozin 10mg Tab (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8411,NCT00431080,Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Docetaxel (DRUG); Paclitaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); 5-fluoruracil (DRUG); Granulocyte-colony stimulating growth factor (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8412,NCT00002529,Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer,COMPLETED,PHASE3,Breast Cancer,cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); epirubicin hydrochloride (DRUG); tamoxifen citrate (DRUG); toremifene (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8413,NCT00936689,Traditional (Traditional Chemoembolization) TACE Versus Microsphere TACE,COMPLETED,PHASE4,"Carcinoma, Hepatocellular",Selective TACE via microsphere loaded with Doxorubicin (PROCEDURE); Selective traditional TACE (PROCEDURE),65348,Ellence,"Carcinoma, Hepatocellular",Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8414,NCT00976989,A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Pertuzumab (DRUG); Trastuzumab (DRUG); FEC (DRUG); Docetaxel (DRUG); TCH (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8415,NCT00779129,A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948),COMPLETED,PHASE2,Breast Neoplasm,Pegylated Lyposomal Doxorubicin (DRUG); Cyclophosphamide (DRUG),65348,Ellence,Breast Neoplasm,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8416,NCT01907529,A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer,UNKNOWN,PHASE2,Stage III Breast Cancer,"docetaxel, epirubicin and cyclophosphamide (DRUG); docetaxel, epirubicin and cyclophosphamide plus endostar (DRUG)",65348,Ellence,Stage III Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8417,NCT02076594,Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer,TERMINATED,PHASE3,Locally Advanced Unresectable Gastric Cancer; Metastatic Gastric Cancer,Docetaxel (DRUG); Epirubicin (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG),65348,Ellence,Locally Advanced Unresectable Gastric Cancer; Metastatic Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8418,NCT00336791,Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer,COMPLETED,PHASE3,Breast Cancer,5-Fluorouracil (DRUG); Cyclophosphamide (DRUG); Doxorubicin (DRUG); Paclitaxel (DRUG); Epirubicin (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8419,NCT00930891,Bevacizumab in Extensive Small Cell Lung Cancer,COMPLETED,PHASE2,Small Cell Lung Cancer,Standard Chemotherapy (PCDE or PE) (DRUG); Experimental Treatment (PCDE or PE + bevacizumab) (DRUG); Prerandomization Chemotherapy (PCDE or PE) (DRUG),65348,Ellence,Small Cell Lung Cancer,Lung,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8420,NCT00041262,Combination Chemotherapy in Treating Patients With Esophageal Cancer,UNKNOWN,PHASE3,Esophageal Cancer,cisplatin (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE),65348,Ellence,Esophageal Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8421,NCT04490694,TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma,UNKNOWN,PHASE2,Hepatocellular Carcinoma,Lenvatinib (DRUG); TACE (PROCEDURE),65348,Ellence,Hepatocellular Carcinoma,Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8422,NCT01870791,Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer,TERMINATED,PHASE2,Esophageal Neoplasm; Gastric Neoplasm,Omegaven (DRUG),65348,Ellence,Esophageal Neoplasm; Gastric Neoplasm,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8423,NCT05491694,To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer,UNKNOWN,PHASE2,Breast Cancer; TNBC - Triple-Negative Breast Cancer,Toripalimab (DRUG); Epirubicin (DRUG); High Intensity Focused Ultrasoun (PROCEDURE); Cyclophosphamide (DRUG); Carboplatin (DRUG); Nab-paclitaxel (DRUG),65348,Ellence,Breast Cancer; TNBC - Triple-Negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8424,NCT01433562,Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients,COMPLETED,PHASE2,Breast Cancer,DLBS1425 (DRUG); Placebo DLBS1425 (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8425,NCT02918162,Perioperative Chemo and Pembrolizumab in Gastric Cancer,COMPLETED,PHASE2,Gastric Cancer; Adenocarcinoma of the Gastroesophageal Junction,Pembrolizumab (DRUG); Standard of care chemotherapy regimen (DRUG),65348,Ellence,Gastric Cancer; Adenocarcinoma of the Gastroesophageal Junction,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8426,NCT00658580,Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer,COMPLETED,PHASE3,"Small Cell Lung Carcinoma, Extensive Disease",Cisplatin + etoposide (DRUG); Epirubicin + ifosfamide + etoposide (DRUG),65348,Ellence,"Small Cell Lung Carcinoma, Extensive Disease",Lung,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8427,NCT00604435,Neoadjuvant Endostatin and Chemotherapy for Breast Cancer,COMPLETED,PHASE2,Breast Cancer,docetaxel and epirubicin (DRUG); docetaxel and epirubicin plus endostatin (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8428,NCT00129935,EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Docetaxel (DRUG); Capecitabine (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8429,NCT00407186,Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS),ACTIVE_NOT_RECRUITING,PHASE3,Gastric Cancer,cisplatin+capecitabine (DRUG); radiotherapy (RADIATION); epirubicin+cisplatin+capecitabine (DRUG),65348,Ellence,Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8430,NCT06404463,QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer,NOT_YET_RECRUITING,PHASE2,Early Breast Cancer; Neoadjuvant Therapy; HR+HER2- Breast Cancer,QL1706 (bispecific antibody targeting PD-1 and CLTA-4) (DRUG); Albumin-bound paclitaxel (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Epirubicin (DRUG),65348,Ellence,Early Breast Cancer; Neoadjuvant Therapy; HR+HER2- Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8431,NCT06954116,Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence,NOT_YET_RECRUITING,PHASE2,Resectable Hepatocellular Carcinoma With High Risk of Recurrence,Iparomlimab and Tuvonralimab (QL1706) (DRUG); Partial hepatectomy (PROCEDURE); TACE (PROCEDURE),65348,Ellence,Resectable Hepatocellular Carcinoma With High Risk of Recurrence,Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8432,NCT00668616,Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes,COMPLETED,PHASE3,Breast Cancer,"Cyclophosphamide, Epirubicin, Paclitaxel (DRUG); Epirubicin, Paclitaxel, Filgrastim (DRUG)",65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8433,NCT03498716,A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer,TERMINATED,PHASE3,Triple Negative Breast Cancer,Atezolizumab (DRUG); Paclitaxel (DRUG); Dose-dense Doxorubicin or dose-dense Epirubicin (DRUG); Cyclophosphamide (DRUG),65348,Ellence,Triple Negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8434,NCT02315196,Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer,pegylated liposomal doxorubicin hydrochloride (DRUG); epirubicin hydrochloride (DRUG); carboplatin (DRUG); therapeutic conventional surgery (PROCEDURE); paclitaxel (DRUG); laboratory biomarker analysis (OTHER); quality-of-life assessment (OTHER),65348,Ellence,Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8435,NCT03510416,Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma,UNKNOWN,PHASE2,Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization,Apatinib (DRUG); TACE (RADIATION),65348,Ellence,Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization,Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8436,NCT02067416,PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer,WITHDRAWN,PHASE2,Breast Cancer,Anthracycline based chemotherapy (DRUG); taxane-based chemotherapy (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8437,NCT01985724,"Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer",COMPLETED,PHASE3,Breast Cancer,Docetaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); 5-fluoruracil (DRUG); Granulocyte-colony stimulating growth factor (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8438,NCT00114816,"Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer",COMPLETED,PHASE3,Breast Cancer,capecitabine (DRUG); docetaxel (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8439,NCT01872416,A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer,UNKNOWN,PHASE2,Small Cell Lung Cancer,Liposomal Doxorubicin Combined With ifosfamide (DEVICE),65348,Ellence,Small Cell Lung Cancer,Lung,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8440,NCT02694224,Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients,UNKNOWN,PHASE2,Breast Cancer,vismodegib (DRUG); Paclitaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8441,NCT05472896,TACE With Dicycloplatin(TP21) in Unresectable HCC,UNKNOWN,PHASE3,Hepatocellular Carcinoma,cTACE (PROCEDURE); Dicycloplatin (TP21) (DRUG); Epirubicin (DRUG),65348,Ellence,Hepatocellular Carcinoma,Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8442,NCT04094896,TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer,UNKNOWN,PHASE2,HER2-Positive Breast Cancer,TCHP (DRUG),65348,Ellence,HER2-Positive Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8443,NCT01787539,The Role of Postoperative Cycles in the Perioperative Chemotherapy for Gastric Cancer,UNKNOWN,PHASE2,Gastric Cancer,Postoperative Chemotherapy (DRUG),65348,Ellence,Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8444,NCT03058939,Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer,WITHDRAWN,PHASE2,Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III,Paclitaxel (DRUG); Perjeta (DRUG); Herceptin SC (DRUG); Tamoxifen (DRUG); Letrozole (DRUG); LHRH agonist (DRUG); FEC (DRUG); Carboplatin (DRUG),65348,Ellence,Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8445,NCT02468739,Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Ganglioside-monosialic acid (DRUG); placebo (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8446,NCT00154739,Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Gemcitabine (DRUG); Cisplatin (DRUG); Epirubicin (DRUG),65348,Ellence,Advanced Non-Small Cell Lung Cancer,Lung,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8447,NCT02568839,Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Early-Stage Breast Carcinoma; HER-2 Positive Breast Cancer,docetaxel + trastuzumab sc + pertuzumab (DRUG); trastuzumab emtansin (DRUG),65348,Ellence,Early-Stage Breast Carcinoma; HER-2 Positive Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8448,NCT01026116,A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old,COMPLETED,PHASE3,Breast Neoplasms,Epirubicin (DRUG); Cyclophosphamide (DRUG); Paclitaxel (DRUG),65348,Ellence,Breast Neoplasms,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8449,NCT01989858,ITACA-S2 (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach),TERMINATED,PHASE3,Gastric Adenocarcinoma,peri-operative cht (OTHER); post-operative CHT (OTHER); peri-operative cht + post-operative cht-rtx (OTHER); post-operative cht + post-operative cht-rtx (OTHER),65348,Ellence,Gastric Adenocarcinoma,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8450,NCT03356860,Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.,COMPLETED,PHASE1,Breast Cancer; Triple Negative Breast Cancer; Luminal B,Paclitaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Durvalumab (DRUG),65348,Ellence,Breast Cancer; Triple Negative Breast Cancer; Luminal B,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8451,NCT00773695,A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Aromatase Inhibitor (DRUG); Bevacizumab (DRUG); Epirubicine (DRUG); 5-Fluorouracil (5FU) (DRUG); Cyclophosphamide (DRUG); Paclitaxel (DRUG); Docetaxel (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8452,NCT00005581,Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer,UNKNOWN,PHASE3,Breast Cancer,cyclophosphamide (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); paclitaxel (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8453,NCT00851110,Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors,TERMINATED,PHASE2,High-Risk Breast Cancer,stem cell reinfusion (PROCEDURE); Chemotherapy (DRUG),65348,Ellence,High-Risk Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8454,NCT06914440,Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer,NOT_YET_RECRUITING,PHASE2,Breast Cancer,Stereotactic Body Radiation Therapy (SBRT) (RADIATION); Toripalimab (DRUG); Neoadjuvant Chemotherapy (DRUG); Surgery (PROCEDURE); Adjuvant Chemotherapy (DRUG); Adjuvant Radiotherapy (RADIATION); Endocrine therapy (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8455,NCT00450892,Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer,COMPLETED,PHASE1,Breast Cancer,docetaxel+lapatinib (DRUG); docetaxel + trastuzumab (DRUG); docetaxel + trastuzumab + lapatinib (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8456,NCT01216644,"5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer",COMPLETED,PHASE2,Gastric Cancer,5-Fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Docetaxel (DRUG); Epirubicin (DRUG); Cisplatin (DRUG); 5-fluorouracil (DRUG),65348,Ellence,Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8457,NCT00002544,Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer,COMPLETED,PHASE3,Breast Cancer,docetaxel (DRUG); mitoxantrone hydrochloride (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8458,NCT00513292,Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery,COMPLETED,PHASE3,HER2/Neu Positive; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer,Cyclophosphamide (DRUG); Epirubicin Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Paclitaxel (DRUG); Therapeutic Conventional Surgery (PROCEDURE); Trastuzumab (BIOLOGICAL),65348,Ellence,HER2/Neu Positive; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8459,NCT00847444,"Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as Well as Life Style Intervention",UNKNOWN,PHASE3,Breast Cancer,Drug-based intervention (DRUG); Lifestyle-based Intervention (BEHAVIORAL),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8460,NCT00912444,"Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer",TERMINATED,PHASE3,Breast Cancer,"Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide (DRUG); Docetaxel, cyclophosphamide (DRUG)",65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8461,NCT02125344,"A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)",COMPLETED,PHASE3,Tubular Breast Cancer Stage II; Tubular Breast Cancer Stage III; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; HER2 Positive Breast Cancer; Inflammatory Breast Cancer,non-pegylated liposomal doxorubicin (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Pertuzumab (DRUG); Trastuzumab (DRUG); Ferric carboxymaltose (DRUG),65348,Ellence,Tubular Breast Cancer Stage II; Tubular Breast Cancer Stage III; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; HER2 Positive Breast Cancer; Inflammatory Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8462,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,75 approved agents (DRUG); COXEN (OTHER),65348,Ellence,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,Bladder/Urinary Tract,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8463,NCT02181101,"Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial",COMPLETED,PHASE3,Breast Neoplasms,FEC-DocGemzar adjuvant chemotherapy (DRUG); FEC-Doc adjuvant chemotherapy (DRUG); Zoledronic acid i.v. 2 years (DRUG); Zoledronic acid i.v. 5 years (DRUG),65348,Ellence,Breast Neoplasms,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8464,NCT03696004,Outcome of Neo-adjuvant Chemotherapy Followed by Breast Conservative Surgery in Breast Cancer in Upper Egypt,UNKNOWN,PHASE2,Breast Cancer,FEC-100 (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8465,NCT03785704,Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer,UNKNOWN,PHASE2,Breast Neoplasms; Cardiac Event; Chemotherapeutic Toxicity,Xinmailong Injection (DRUG),65348,Ellence,Breast Neoplasms; Cardiac Event; Chemotherapeutic Toxicity,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8466,NCT02115204,"4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF",COMPLETED,PHASE3,Breast Cancer,Epirubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG); Methotrexate (DRUG); 5-fluorouracil (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8467,NCT00432172,Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients,COMPLETED,PHASE2,Breast Cancer,Epirubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG); Exemestane (DRUG); Goserelin (DRUG); Carboplatin (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8468,NCT01697072,"First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma",TERMINATED,PHASE3,Gastric Cancer,Rilotumumab (DRUG); Placebo (OTHER); Epirubicin (DRUG); Cisplatin (DRUG); Capecitabine (DRUG),65348,Ellence,Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8469,NCT00010140,Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer,UNKNOWN,PHASE3,Breast Cancer,docetaxel (DRUG); epirubicin hydrochloride (DRUG); tamoxifen citrate (DRUG); adjuvant therapy (PROCEDURE),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8470,NCT04137640,Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy,NOT_YET_RECRUITING,PHASE4,Breast Cancer,palbociclib combined with letrozole (DRUG); epirubicin combined with cyclophosphamide and sequential docetaxel (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8471,NCT01301040,Early Cardiac Toxicity of Adjuvant CT in Elderly BC.,TERMINATED,PHASE2,Breast Cancer,"epirubicin, cyclophosphamide, docetaxel (DRUG)",65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8472,NCT00830544,Study of Neoadjuvant Chemotherapy of Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Neoadjuvant chemotherapy (DRUG); Chemotherapy (DRUG); Neoadjuvant chemotherapy (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8473,NCT00050167,Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer,COMPLETED,PHASE1,Breast Cancer,Paclitaxel (DRUG); Docetaxel (DRUG); Capecitabine (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8474,NCT00003012,Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer,COMPLETED,PHASE3,Breast Cancer,CMF regimen (DRUG); cyclophosphamide (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); methotrexate (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8475,NCT00162812,Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin,TERMINATED,PHASE2,Breast Cancer,Epirubicin (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8476,NCT00039546,Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery,UNKNOWN,PHASE3,Breast Cancer,cyclophosphamide (DRUG); epirubicin hydrochloride (DRUG); gemcitabine hydrochloride (DRUG); paclitaxel (DRUG); adjuvant therapy (PROCEDURE),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8477,NCT01996267,"Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2",ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer; HER2 Positive,PTC+Pertuzumab (DRUG); FEC-T+Pertuzumab (DRUG),65348,Ellence,Breast Cancer; HER2 Positive,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8478,NCT02400567,"Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women",COMPLETED,PHASE2,Neoadjuvant Operable Breast Cancer,Fluorouracile (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Letrozole (DRUG); Palbociclib (DRUG),65348,Ellence,Neoadjuvant Operable Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8479,NCT00215644,"Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer",COMPLETED,PHASE2,Esophageal Cancer; Gastric Cancer,Matuzumab (DRUG); Epirubicin (DRUG); Cisplatin (DRUG); Capecitabine (DRUG),65348,Ellence,Esophageal and Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8480,NCT05763992,Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial,RECRUITING,PHASE2,Breast Cancer; Triple Negative Breast Cancer; Dietary Exposure; Fasting,"Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B) (DIETARY_SUPPLEMENT)",65348,Ellence,Breast Cancer; Triple Negative Breast Cancer; Dietary Exposure; Fasting,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8481,NCT03556358,"Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer",COMPLETED,PHASE3,Breast Cancer; Breast Neoplasms; HER2-positive Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer,TX05 (trastuzumab) (BIOLOGICAL); Herceptin® (BIOLOGICAL); Paclitaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),65348,Ellence,Breast Cancer; Breast Neoplasms; HER2-positive Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8482,NCT02450058,Adjuvant FEC Versus EP in Breast Cancer (MIG5),COMPLETED,PHASE3,"Breast Cancer; Chemotherapy, Adjuvant",5-fluorouracil (DRUG); epirubicin (DRUG); cyclophosphamide (DRUG); epirubicin (DRUG); paclitaxel (DRUG),65348,Ellence,"Breast Cancer; Chemotherapy, Adjuvant",Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8483,NCT02949258,Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric Cancer,UNKNOWN,PHASE2,Stomach Neoplasms; Gastric Cancer,oxaliplatin (DRUG); etoposide (DRUG); epirubicin (DRUG); S1 (DRUG),65348,Ellence,Stomach Neoplasms; Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8484,NCT00553358,Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study,COMPLETED,PHASE3,"Neoplasms, Breast",Lapatinib (DRUG); Trastuzumab (BIOLOGICAL); Paclitaxel (DRUG),65348,Ellence,"Neoplasms, Breast",Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8485,NCT00075465,Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach,UNKNOWN,PHASE2,Gastric Cancer,docetaxel (DRUG); epirubicin hydrochloride (DRUG),65348,Ellence,Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8486,NCT03507465,Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Letrozole Plus Low-Dose Metronomic Capecitabine (DRUG); EC-T (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8487,NCT01234324,ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction,COMPLETED,PHASE2,Stomach Neoplasms; Gastroesophageal Junction Neoplasms,"Epirubicin, Cisplatin, Capecitabine, Panitumumab (DRUG); Epirubicin, Cisplatin, Capecitabine (DRUG)",65348,Ellence,Stomach Neoplasms; Gastroesophageal Junction Neoplasms,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8488,NCT00189644,6 FEC 100 Vs 4 FEC 100 Followed by 4 Taxol in N+ Breast Cancer,UNKNOWN,PHASE3,Breast Cancer,6 FEC 100 (PROCEDURE); 4 FEC 100 followed by 4 Taxol (PROCEDURE),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8489,NCT04220944,Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.,ACTIVE_NOT_RECRUITING,PHASE1,Hepatic Carcinoma,Sintilimab (DRUG); Microwave Ablation (PROCEDURE); TACE (PROCEDURE),65348,Ellence,Hepatic Carcinoma,Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8490,NCT01830244,IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Nab-Paclitaxel (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8491,NCT03192644,"The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.",UNKNOWN,PHASE3,Hepatocellular Carcinoma,"TAI (PROCEDURE); TACE (PROCEDURE); epidoxorubicin and cisplatin and lipiodol (DRUG); mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU) (DRUG)",65348,Ellence,Hepatocellular Carcinoma,Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8492,NCT00531973,A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging,UNKNOWN,PHASE4,Breast Cancer,liposomal doxorubicin (DRUG); epirubicin (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8493,NCT01431196,Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer,COMPLETED,PHASE2,Stage II Breast Cancer; Stage III Breast Cancer,Autologous dendritic cell vaccination (BIOLOGICAL),65348,Ellence,Stage II Breast Cancer; Stage III Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8494,NCT00193024,Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Docetaxel (DRUG); Epirubicin (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8495,NCT00772824,Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients,COMPLETED,PHASE4,Breast Cancer,Glutamine (DIETARY_SUPPLEMENT); IV Glutamine (DIETARY_SUPPLEMENT),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8496,NCT00776724,Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm,COMPLETED,PHASE3,Breast Cancer; Chemotherapy,"Taxotere , Epirubicin (DRUG); E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP (DRUG)",65348,Ellence,Breast Cancer; Chemotherapy,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8497,NCT00309569,Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients,COMPLETED,PHASE3,Early Stage Breast Cancer,Cyclophosphamide (DRUG); Methotrexate (DRUG); Fluorouracil (DRUG); Epirubicin (DRUG); Surgery (OTHER),65348,Ellence,Early Stage Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8498,NCT00196872,A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN),COMPLETED,PHASE3,Breast Cancer,Epirubicine (DRUG); Cyclophosphamide (DRUG); Taxol (DRUG); Xeloda (DRUG); Ibandronat (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8499,NCT04770272,Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy with Atezolizumab - CTX Therapy,COMPLETED,PHASE2,Triple-negative Breast Cancer,Atezolizumab 840 MG in 14 ML Injection (DRUG); Atezolizumab 1200 MG in 20 ML Injection (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Biopsy Arm A (PROCEDURE); Biopsy Arm B (PROCEDURE); Surgery (PROCEDURE),65348,Ellence,Triple-negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8500,NCT06639672,Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer,NOT_YET_RECRUITING,PHASE2,HR+HER2- Breast Cancer,Chemotherapy+PD-1 inhibitor+8Gy x 3f (DRUG); Chemotherapy+PD-1 inhibitor+16Gy x 1f (DRUG); Chemotherapy+PD-1 inhibitor+2.67Gy x 15f (DRUG); Chemotherapy+PD-1 inhibitor+0.5Gy x 12-18f (DRUG),65348,Ellence,HR+HER2- Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8501,NCT02395640,The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer,COMPLETED,PHASE3,Gastric Cancer,Epirubicin (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG),65348,Ellence,Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8502,NCT05420467,A Study for the Adjuvant Treatment of Breast Cancer,RECRUITING,PHASE4,Breast Cancer,Docetaxel (DRUG); Carboplatin (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); Nab paclitaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Nab paclitaxel (DRUG); Cyclophosphamide (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8503,NCT00464646,"Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer",COMPLETED,PHASE2,Breast Cancer,Epirubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG); Trastuzumab (DRUG); Bevacizumab (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8504,NCT01386346,Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer,COMPLETED,PHASE1,Esophageal Cancer; Malignant Neoplasm of Cardio-esophageal Junction of Stomach,Azacitidine (DRUG); Oxaliplatin (DRUG); Epirubicin (DRUG); Capecitabine (DRUG),65348,Ellence,Esophageal Cancer; Malignant Neoplasm of Cardio-esophageal Junction of Stomach,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8505,NCT02527746,Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,COMPLETED,PHASE1,Neutropenia; Breast Cancer,F-627 (DRUG); EC regimen (DRUG),65348,Ellence,Neutropenia; Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8506,NCT06627712,SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC,NOT_YET_RECRUITING,PHASE3,TNBC - Triple-Negative Breast Cancer,SBRT+PD-1 Inhibitor + Chemotherapy (DRUG); PD-1 Inhibitor + Chemotherapy (DRUG),65348,Ellence,TNBC - Triple-Negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8507,NCT06682195,Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02),RECRUITING,PHASE2,"TNBC, Triple Negative Breast Cancer",Neoadjuvant chemotherapy combined with Toripalimab (DRUG),65348,Ellence,"TNBC, Triple Negative Breast Cancer",Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8508,NCT02185768,Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II,COMPLETED,PHASE2,Liver Cancer,idarubicin (DRUG); Dc- Beads 300-500µm (DEVICE),65348,Ellence,Liver Cancer,Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8509,NCT03085368,A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin,UNKNOWN,PHASE2,HER2-positive Breast Cancer,lapatinib/herceptin (DRUG),65348,Ellence,HER2-positive Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8510,NCT00751868,FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC,COMPLETED,PHASE2,Breast Cancer,Ixabepilone (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8511,NCT00595972,Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer,COMPLETED,PHASE2,Gastric Cancer,ECF-endostar (DRUG),65348,Ellence,Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8512,NCT01210768,A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients,UNKNOWN,PHASE2,Breast Cancer,Epirubicin+Cyclophosphamide (DRUG); liposomal-doxorubicin+Cyclophosphamide (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8513,NCT00025441,Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors,COMPLETED,PHASE2,Ovarian Cancer; Sarcoma; Small Intestine Cancer,dactinomycin (BIOLOGICAL); filgrastim (BIOLOGICAL); carboplatin (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); epirubicin hydrochloride (DRUG); etoposide (DRUG); ifosfamide (DRUG); vincristine sulfate (DRUG); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),65348,Ellence,Ovarian Cancer and Related Malignancies,Ovary/Fallopian Tube,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8514,NCT06227117,"Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer",RECRUITING,PHASE2,Breast Cancer,Disitamab Vedotin Injection （18 weeks） (DRUG); Toripalimab （18weeks） (DRUG); Carboplatin (DRUG); Disitamab Vedotin Injection （12 weeks） (DRUG); Sequential Epirubicin (DRUG); Sequential CTX (DRUG); Toripalimab （12weeks） (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8515,NCT00843934,Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma,UNKNOWN,PHASE2,"Carcinoma, Hepatocellular",epirubicin (DRUG); Cisplatin (DRUG),65348,Ellence,"Carcinoma, Hepatocellular",Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8516,NCT04499118,AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer,UNKNOWN,PHASE2,HER2-negative Breast Cancer,AT regimen (DRUG); TP regimen (DRUG),65348,Ellence,HER2-negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8517,NCT01924819,Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma,ACTIVE_NOT_RECRUITING,PHASE2,Gastric Cancer,Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel (DRUG); Preoperative chemoradiotherapy (RADIATION); Gastric resection (PROCEDURE),65348,Ellence,Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8518,NCT02338518,Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients,ACTIVE_NOT_RECRUITING,PHASE3,Stomach Neoplasms; Gastric Cancer,oxaliplatin (DRUG); etoposide (DRUG); pharmorubicin (DRUG); S-1 (DRUG),65348,Ellence,Stomach Neoplasms; Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8519,NCT05871918,"A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer",UNKNOWN,PHASE3,HER-2 Positive Breast Cancer,TCbHP VS ddEC-THP (DRUG),65348,Ellence,HER-2 Positive Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8520,NCT01985841,Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Bevacizumb (DRUG); 5-Fluorouracil (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8521,NCT02455141,Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer,UNKNOWN,PHASE3,Breast Neoplasm,Epirubicin plus Cyclophosphamide (DRUG); Taxanes (DRUG); Taxanes plus Carboplatin (DRUG),65348,Ellence,Breast Neoplasm,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8522,NCT00072319,"Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer",COMPLETED,PHASE2,Breast Cancer,filgrastim (BIOLOGICAL); cyclophosphamide (DRUG); epirubicin hydrochloride (DRUG); paclitaxel (DRUG); adjuvant therapy (PROCEDURE); neoadjuvant therapy (PROCEDURE),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8523,NCT03289819,Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC,COMPLETED,PHASE2,Malignant Neoplasm of Breast,Pembrolizumab (DRUG); nab-paclitaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),65348,Ellence,Malignant Neoplasm of Breast,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8524,NCT00008034,Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer,COMPLETED,PHASE1,Breast Cancer,capecitabine (DRUG); cyclophosphamide (DRUG); epirubicin hydrochloride (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8525,NCT05024734,Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids,RECRUITING,PHASE2,Bladder Cancer; Non-muscle Invasive,Epirubicin (DRUG); Mitomycin (DRUG); Gemcitabine (DRUG); Docetaxel (DRUG),65348,Ellence,Bladder Cancer; Non-muscle Invasive,Bladder/Urinary Tract,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8526,NCT01624441,Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer,COMPLETED,PHASE1,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma,Dinaciclib (DRUG); Epirubicin Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER),65348,Ellence,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8527,NCT01675219,Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9),UNKNOWN,PHASE3,Bladder Cancer,white light TUR-BT (PROCEDURE); blue light TUR-BT (PROCEDURE); optimized MMC (DRUG); single immediate chemotherapy instillation (DRUG),65348,Ellence,Bladder Cancer,Bladder/Urinary Tract,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8528,NCT00286819,Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer,COMPLETED,PHASE2,Breast Cancer,the FEC75 and 95 regimen (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8529,NCT00123318,A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer,COMPLETED,PHASE3,Gastric Cancer,epirubicin (DRUG); cisplatin (DRUG); 5-fluorouracil (DRUG); Radiotherapy (RADIATION),65348,Ellence,Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8530,NCT06611813,Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01),RECRUITING,PHASE2,HR+/HER2- Breast Cancer,Neoadjuvant Chemotherapy in Combination with Toripalimab (DRUG); HR+ HER2 breast cancer (DRUG),65348,Ellence,HR+/HER2- Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8531,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,COMPLETED,PHASE2,Breast Cancer,EC-T (DRUG); TP (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8532,NCT02879513,Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy,UNKNOWN,PHASE3,Invasive Ductal Breast Cancer; Tubular Breast Cancer; Mucinous Breast Cancer; Inflammatory Breast Cancer,Paclitaxel (DRUG); Cisplatin (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); 5-fluoruracil (DRUG),65348,Ellence,Invasive Ductal Breast Cancer; Tubular Breast Cancer; Mucinous Breast Cancer; Inflammatory Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8533,NCT04138719,Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer,UNKNOWN,PHASE2,Breast Cancer; Triple-negative Breast Cancer; Nab-paclitaxel,Nab-paclitaxel + Carboplatin (DRUG); Nab-paclitaxel + Epirubicin (DRUG),65348,Ellence,Breast Cancer; Triple-negative Breast Cancer; Nab-paclitaxel,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8534,NCT04127019,Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER),COMPLETED,PHASE3,Primary Breast Cancer,Paclitaxel (DRUG); Docetaxel (DRUG); Cyclophosphamide (DRUG); Epirubicin (DRUG); 5-fluorouracil (DRUG),65348,Ellence,Primary Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8535,NCT04358341,Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer,UNKNOWN,PHASE2,Gastric Cancer,Irinotecan (DRUG); DOXOrubicin Liposome Injection (DRUG); 5fluorouracil (DRUG),65348,Ellence,Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8536,NCT03433313,Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer,COMPLETED,PHASE3,Breast Cancer,EG12014 (DRUG); Herceptin (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8537,NCT03373708,Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer,UNKNOWN,PHASE2,Breast Cancer; Chemotherapy; Endocrine Breast Diseases,Epirubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG); Goserelin acetate (DRUG); Tamoxifen (DRUG); Letrozole (DRUG),65348,Ellence,Breast Cancer; Chemotherapy; Endocrine Breast Diseases,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8538,NCT00215514,Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma,COMPLETED,EARLY_PHASE1,Stomach Cancer; Gastric Cancer; Gastro-esophageal Junction Cancer,Epirubicin (DRUG); Cisplatin (DRUG); 5-Fluorouracil (5-FU) (DRUG); Radiation (PROCEDURE),65348,Ellence,Stomach Cancer; Gastric Cancer; Gastro-esophageal Junction Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8539,NCT00867750,SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma,COMPLETED,PHASE2,Hepatocellular Carcinoma,Radioembolisation (SIR-Spheres® microspheres) (DEVICE); Transarterial Chemoembolisation (DRUG),65348,Ellence,Hepatocellular Carcinoma,Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8540,NCT01822314,Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Abraxane (DRUG); Paclitaxel (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8541,NCT04398914,"Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer Invasive,Pyrotinib (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); Nab-paclitaxel (DRUG); EC chemotherapy (DRUG); Physician's choice (DRUG); T-DM1 (DRUG); Surgery (PROCEDURE),65348,Ellence,Breast Cancer Invasive,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8542,NCT02510781,A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs,UNKNOWN,PHASE2,Breast Neoplasms,Epirubicin (DRUG); Docetaxel (DRUG); Trastuzumab (DRUG); Carboplatin (DRUG),65348,Ellence,Breast Neoplasms,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8543,NCT06441110,Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer,RECRUITING,PHASE3,"Urinary Bladder Neoplasms; BCG Vaccine; Immunotherapy, Active; Multicenter Study; Treatment Outcome; Neoplasm Recurrence, Local",Tislelizumab in Combination with Bacillus Calmette-Guérin (DRUG),65348,Ellence,"Urinary Bladder Neoplasms; BCG Vaccine; Immunotherapy, Active; Multicenter Study; Treatment Outcome; Neoplasm Recurrence, Local",Bladder/Urinary Tract,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8544,NCT06500208,Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC,NOT_YET_RECRUITING,PHASE2,Breast Cancer,"Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide (DRUG)",65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8545,NCT00052910,Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer,COMPLETED,PHASE3,Esophageal Cancer; Gastric Cancer,cisplatin (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); leucovorin calcium (DRUG); radiation therapy (RADIATION),65348,Ellence,Esophageal and Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8546,NCT04174781,Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC,UNKNOWN,PHASE2,Hepatocellular Carcinoma,Sintilimab (DRUG); DEB-TACE (DRUG),65348,Ellence,Hepatocellular Carcinoma,Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8547,NCT05862610,The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC,NOT_YET_RECRUITING,PHASE2,Breast Neoplasm,Trilaciclib plus chemotherapy (DRUG); Chemotherapy (DRUG),65348,Ellence,Breast Neoplasm,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8548,NCT00099281,DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer,TERMINATED,PHASE3,Breast Cancer; Metastases,YMB 1002 (DRUG),65348,Ellence,Breast Cancer; Metastases,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8549,NCT06085755,Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer,RECRUITING,PHASE1,Stomach Neoplasm,Trastuzumab deruxtecan (DRUG); Afatinib (DRUG),65348,Ellence,Stomach Neoplasm,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8550,NCT01779050,Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,TERMINATED,PHASE2,Breast Neoplasms,Doxorubicin (DRUG); Trastuzumab (BIOLOGICAL); Cyclophosphamide (DRUG); Paclitaxel (DRUG); Epirubicin (DRUG); Docetaxel (DRUG); Carboplatin (DRUG); Fluorouracil (DRUG),65348,Ellence,Breast Neoplasms,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8551,NCT02897050,Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer,SUSPENDED,PHASE2,Breast Cancer,Docetaxel (DRUG); Capecitabine (DRUG); Cyclophosphamide (tablet) (DRUG); Fluorouracil (DRUG); Epirubicin (DRUG); Cyclophosphamide (injection) (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8552,NCT06831955,LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients with Triple Negative Breast Cancer,NOT_YET_RECRUITING,PHASE2,"Triple Negative Breast Cancer (TNBC), Early Setting",Exercise Therapy (OTHER); Fasting-Mimicking Diet (DIETARY_SUPPLEMENT); SOC (DRUG),65348,Ellence,"Triple Negative Breast Cancer (TNBC), Early Setting",Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8553,NCT01167738,Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer,TERMINATED,PHASE2,Pancreatic Cancer,capecitabine (DRUG); cisplatin (DRUG); epirubicin (DRUG); gemcitabine (DRUG); metformin (DRUG),65348,Ellence,Pancreatic Cancer,Pancreas,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8554,NCT03273595,Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer,UNKNOWN,PHASE2,"Neoplasms, Breast",Lapatinib (DRUG); Trastuzumab (BIOLOGICAL); Paclitaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),65348,Ellence,"Neoplasms, Breast",Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8555,NCT00017095,Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer,COMPLETED,PHASE3,Breast Cancer,filgrastim (BIOLOGICAL); cyclophosphamide (DRUG); docetaxel (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); microarray analysis (GENETIC); immunohistochemistry staining method (OTHER); laboratory biomarker analysis (OTHER); biopsy (PROCEDURE); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE); radiation therapy (RADIATION),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8556,NCT03006614,PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer,UNKNOWN,PHASE3,Breast Cancer Model; Effects of Chemotherapy; Breast Cancer,NVB (DRUG); EPI (DRUG); DDP (DRUG); CAP (DRUG); GEM (DRUG); H (DRUG); CTX (DRUG); T (DRUG),65348,Ellence,Breast Cancer Model; Effects of Chemotherapy; Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8557,NCT05981014,Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer,RECRUITING,PHASE1,Breast Neoplasms,Sentinel Lymph Node Biopsy (SLNB) (PROCEDURE); Doxorubicin (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Cyclophosphamide (DRUG); Fludarabine (DRUG); Tumor-draining lymph node-derived lymphocyte (LNL) (BIOLOGICAL); Interleukin-2 (BIOLOGICAL); Nab-paclitaxel (DRUG),65348,Ellence,Breast Neoplasms,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8558,NCT01433614,"Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer",COMPLETED,PHASE3,Metastatic Breast Cancer,Epirubicin (DRUG); Paclitaxel (DRUG); Capecitabine (DRUG),65348,Ellence,Metastatic Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8559,NCT01428414,Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer,UNKNOWN,PHASE2,HER-2 Positive Breast Cancer,Trastuzumab (DRUG); Paclitaxel (DRUG); Epirubicin (DRUG); Carboplatin (DRUG),65348,Ellence,HER-2 Positive Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8560,NCT02547350,Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas,UNKNOWN,PHASE2,Upper Tract Urothelial Carcinoma; Bladder Recurrence,pharmorubicin or pirarubicin (DRUG),65348,Ellence,Upper Tract Urothelial Carcinoma; Bladder Recurrence,Bladder/Urinary Tract,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8561,NCT03839550,Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection,UNKNOWN,PHASE2,Hepatocellular Carcinoma,Apatinib Mesylate +SHR-1210 (COMBINATION_PRODUCT); Hepatic Arterial Infusion(HAI) (PROCEDURE),65348,Ellence,Hepatocellular Carcinoma,Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8562,NCT00193050,"Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer",COMPLETED,PHASE2,Breast Cancer,Gemcitabine (DRUG); Epirubicin (DRUG); Docetaxel (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8563,NCT00113581,"Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer",COMPLETED,PHASE1,Esophageal Cancer; Gastric Cancer,EMD 72000 (matuzumab) + ECX (DRUG),65348,Ellence,Esophageal and Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8564,NCT01134523,Regimens Comparison for Breast Cancers of Positive Lymph Nodes,UNKNOWN,PHASE3,Breast Cancer,"Epirubicin, CTX, Paclitaxel (DRUG); Epirubicin, Paclitaxel (DRUG)",65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8565,NCT05862064,PD-1 Combined With Adjuvant Chemotherapy and Antivascular Therapy Versus Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer,RECRUITING,PHASE3,TNBC - Triple-Negative Breast Cancer,"epirubicin,cyclophosphamide,paclitaxel,Carrelizumab (DRUG); epirubicin,cyclophosphamide,paclitaxel (DRUG)",65348,Ellence,TNBC - Triple-Negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8566,NCT06513364,Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer,NOT_YET_RECRUITING,PHASE1,Breast Cancer,WH002 (DRUG); paclitaxel injection (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8567,NCT04576143,Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer,RECRUITING,PHASE2,HER2-negative Breast Cancer; Neoadjuvant Chemotherapy,Epirubicin (DRUG); Cyclophosphamid (DRUG); Docetaxel (DRUG); Paclitaxel (DRUG),65348,Ellence,HER2-negative Breast Cancer; Neoadjuvant Chemotherapy,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8568,NCT00719550,AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer,COMPLETED,PHASE1,Esophagogastric Junction Adenocarcinoma; Gastric Cancer; Esophageal Cancer,Capecitabine (DRUG); Epirubicin (DRUG); AMG 102 (DRUG); Cisplatin (DRUG); Placebo (DRUG),65348,Ellence,Esophagogastric Junction Adenocarcinoma; Gastric Cancer; Esophageal Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8569,NCT01094964,"Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer",UNKNOWN,PHASE3,Bladder Cancer,BCG solution (BIOLOGICAL); recombinant interferon alfa (BIOLOGICAL); epirubicin hydrochloride (DRUG); mitomycin C (DRUG); laboratory biomarker analysis (OTHER); hyperthermia treatment (PROCEDURE); quality-of-life assessment (PROCEDURE),65348,Ellence,Bladder Cancer,Bladder/Urinary Tract,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8570,NCT00496795,Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Stage III Breast Cancer AJCC V7,epirubicin/docetaxel sequential (OTHER),65348,Ellence,Stage III Breast Cancer AJCC V7,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8571,NCT00110695,"Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer",COMPLETED,PHASE2,Breast Neoplasms,Nanoparticle albumin bound paclitaxel followed by FEC (DRUG),65348,Ellence,Breast Neoplasms,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8572,NCT00431795,Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Pegylated liposomal doxorubicin (Caelyx) (DRUG); Epirubicin (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8573,NCT00737438,Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma,COMPLETED,PHASE2,Esophageal Cancer; Gastric Cancer,"epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan (DRUG)",65348,Ellence,Esophageal and Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8574,NCT02132949,"A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer",COMPLETED,PHASE2,Breast Cancer,5-Fluorouracil (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG); Doxorubicin (DRUG); Epirubicin (DRUG); Paclitaxel (DRUG); Pertuzumab (DRUG); Trastuzumab (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8575,NCT03154749,DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer,COMPLETED,PHASE2,Triple-Negative Breast Cancer,DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe) (DRUG),65348,Ellence,Triple-Negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8576,NCT00003606,Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer,COMPLETED,PHASE3,Lung Cancer,cisplatin (DRUG); cyclophosphamide (DRUG); epirubicin hydrochloride (DRUG); etoposide (DRUG); radiation therapy (RADIATION),65348,Ellence,Lung Cancer,Lung,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8577,NCT00311636,"Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery",COMPLETED,PHASE3,Breast Cancer,cyclophosphamide (DRUG); docetaxel (DRUG); doxorubicin hydrochloride (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); methotrexate (DRUG); paclitaxel (DRUG); triptorelin (DRUG); adjuvant therapy (PROCEDURE),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8578,NCT00454636,A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.,COMPLETED,PHASE2,Gastric Cancer,Cisplatin (DRUG); Capecitabine (DRUG); Epirubicin (DRUG); Cisplatin (DRUG); Capecitabine (DRUG); Oxaliplatin (DRUG); Docetaxel (DRUG); Capecitabine (DRUG),65348,Ellence,Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8579,NCT01479036,"Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer",UNKNOWN,PHASE3,Breast Cancer,docetaxel and epirubicin (DRUG); docetaxel and epirubicin plus endostatin (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8580,NCT00130936,"Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates",TERMINATED,PHASE1,Gastric Cancer; Esophageal Cancer; Tumors,Epirubicin (DRUG); Carboplatin (DRUG); Capecitabine (DRUG),65348,Ellence,Gastric Cancer; Esophageal Cancer; Tumors,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8581,NCT00527449,Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel,COMPLETED,PHASE2,Primary Breast Cancer,"Epirubicin, Carboplatin, Docetaxel (DRUG)",65348,Ellence,Primary Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8582,NCT01779206,ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Epirubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG); Paclitaxel (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8583,NCT00525642,"Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer",UNKNOWN,PHASE2,Breast Neoplasms; Adjuvant; Chemotherapy,"Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide (DRUG); Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide (DRUG)",65348,Ellence,Breast Neoplasms; Adjuvant; Chemotherapy,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8584,NCT02842099,Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,TA or TAC (DRUG); X (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8585,NCT01641406,"""Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer""",UNKNOWN,PHASE2,Infiltrating Duct and Lobular Carcinoma In Situ; Invasive Lobular Breast Carcinoma; Inflammatory Breast Carcinoma,"Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab (DRUG); Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab (DRUG); Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab (DRUG)",65348,Ellence,Infiltrating Duct and Lobular Carcinoma In Situ; Invasive Lobular Breast Carcinoma; Inflammatory Breast Carcinoma,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8586,NCT00756470,Phase II Neoadjuvant in Inflammatory Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Lapatinib (DRUG); Paclitaxel (DRUG); 5-Fluorouracil (5-FU) (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8587,NCT01830270,"Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer",TERMINATED,PHASE2,Stomach Neoplasms; Oesophageal Junction Cancer; Lower Oesophagus Cancer,Epirubicin (DRUG); Cisplatin (DRUG); Paclitaxel (DRUG); gastric surgery (PROCEDURE),65348,Ellence,Stomach Neoplasms; Oesophageal Junction Cancer; Lower Oesophagus Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8588,NCT02387099,Dose EScalation Induction of EvERolimus,COMPLETED,PHASE2,Breast Cancer; Hormone Receptor Positive Tumor,3 weeks Dose Induction of Everolimus (DRUG); 3 weeks Conventional Everolimus Dosing (DRUG); Open Label Phase with conventional 10mg Everolimus Dosing week 4-24 (DRUG); Standard Care after 24 weeks (DRUG),65348,Ellence,Breast Cancer; Hormone Receptor Positive Tumor,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8589,NCT02631499,Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation,UNKNOWN,PHASE4,"Carcinoma, Hepatocellular; Neoplastic Cells, Circulating",TACE (PROCEDURE); Epirubicin (DRUG); lipiodol (DRUG),65348,Ellence,"Carcinoma, Hepatocellular; Neoplastic Cells, Circulating",Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8590,NCT00002870,High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer,COMPLETED,PHASE3,Breast Cancer,filgrastim (BIOLOGICAL); cyclophosphamide (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); thiotepa (DRUG); peripheral blood stem cell transplantation (PROCEDURE),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8591,NCT00002542,Tamoxifen in Treating Women With High-Risk Breast Cancer,COMPLETED,PHASE3,Breast Cancer,CMF regimen (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); methotrexate (DRUG); tamoxifen citrate (DRUG); radiation therapy (RADIATION),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8592,NCT00798070,Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,dtEC→dtT (DRUG); FEC→T (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8593,NCT02692742,Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia,COMPLETED,PHASE2,Chemotherapy-Induced Neutropenia; Myelosuppression; Breast Cancer,Myelo001 (DRUG); Placebo (DRUG),65348,Ellence,Chemotherapy-Induced Neutropenia; Myelosuppression; Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8594,NCT00193206,"Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer",COMPLETED,PHASE2,Breast Cancer,Gemcitabine (DRUG); Epirubicin (DRUG); Albumin-bound Paclitaxel (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8595,NCT00548899,Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Nexavar (Sorafenib) (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8596,NCT00966706,"Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer",COMPLETED,PHASE2,Pancreatic Cancer,capecitabine (DRUG); cisplatin (DRUG); docetaxel (DRUG); epirubicin hydrochloride (DRUG); gemcitabine hydrochloride (DRUG),65348,Ellence,Pancreatic Cancer,Pancreas,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8597,NCT06389006,"To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer",RECRUITING,PHASE2,Breast Cancer,Disitamab Vedotin for Injection (DRUG); Toripalimab (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8598,NCT00429299,"Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer",COMPLETED,PHASE2,"Neoplasms, Breast",lapatinib (DRUG); trastuzumab (BIOLOGICAL); paclitaxel (DRUG); fluorouracil (DRUG); epidoxorubicin (DRUG); cyclophosphamide (DRUG),65348,Ellence,"Neoplasms, Breast",Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8599,NCT00378313,"A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer",COMPLETED,PHASE2,Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IV Breast Cancer; Breast Cancer; Locally Advanced,"gemcitabine, epirubicin, paclitaxel (DRUG)",65348,Ellence,Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IV Breast Cancer; Breast Cancer; Locally Advanced,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8600,NCT00381706,Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer,COMPLETED,PHASE2,Esophageal Cancer,cetuximab (BIOLOGICAL); ECF (DRUG); IC (DRUG); FOLFOX (DRUG),65348,Ellence,Esophageal Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8601,NCT00424606,Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients,COMPLETED,PHASE3,Breast Cancer,Docetaxel (DRUG); Epirubicin (DRUG); Epirubicin (DRUG); Docetaxel (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8602,NCT00047099,Combination Chemotherapy in Treating Women With Breast Cancer,COMPLETED,PHASE3,Breast Cancer,cyclophosphamide (DRUG); docetaxel (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); goserelin acetate (DRUG); tamoxifen citrate (DRUG); adjuvant therapy (PROCEDURE); radiation therapy (RADIATION),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8603,NCT00375999,Docetaxel and Epirubicin in Advanced Gastric Cancer,COMPLETED,PHASE2,Stomach Neoplasms,Docetaxel and epirubicin (DRUG),65348,Ellence,Stomach Neoplasms,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8604,NCT05582499,Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy,RECRUITING,PHASE2,Breast Neoplasm; Breast Cancer; Breast Tumors; Triple-Negative Breast Cancer (TNBC); HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer,Dalpiciclib (DRUG); Pyrotinib (DRUG); SHR-A1811 (DRUG); SHR-1316 (DRUG); Camrelizumab (DRUG); SHR-A1921 (DRUG); Pertuzumab (DRUG); Trastuzumab (DRUG); Goserelin (DRUG); Letrozole (DRUG); Nab paclitaxel (DRUG); Carboplatin (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Fluzoparib (DRUG); Apatinib (DRUG); Famitinib (DRUG),65348,Ellence,Breast Neoplasm; Breast Cancer; Breast Tumors; Triple-Negative Breast Cancer (TNBC); HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8605,NCT00795899,Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO),COMPLETED,PHASE2,Breast Cancer,"Epirubicin / Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab (DRUG)",65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8606,NCT02299999,SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Cancer,AZD2014 (DRUG); AZD4547 (DRUG); AZD5363 (DRUG); AZD8931 (DRUG); Selumetinib (DRUG); Vandetanib (DRUG); Bicalutamide (DRUG); Olaparib (DRUG); Anthracyclines (DRUG); Taxanes (DRUG); cyclophosphamide (DRUG); DNA intercalators (DRUG); Methotrexate (DRUG); vinca alkaloids (DRUG); Platinum based chemotherapies (DRUG); Bevacizumab (DRUG); Mitomycin C (DRUG); Eribulin (DRUG); MEDI4736 (DRUG),65348,Ellence,Metastatic Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8607,NCT05900206,Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer,RECRUITING,PHASE2,Breast Cancer,Trastuzumab deruxtecan (DRUG); Docetaxel (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); Ribociclib (DRUG); Letrozole (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8608,NCT02001506,Neoadjuvant Chemotherapy of 6 Cycles vs 8 Cycles in Node Positve Breast Cancer,COMPLETED,PHASE3,Breast Cancer,FEC3-D3 (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8609,NCT05447702,Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC),RECRUITING,PHASE2,Triple Negative Breast Cancer,Camrelizumab (DRUG); Apatinib (DRUG); Nab-paclitaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),65348,Ellence,Triple Negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8610,NCT01690702,Study of Nab-Paclitaxel in High Risk Early Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Epirubicin (DRUG); nab-Paclitaxel (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8611,NCT00011921,Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer,UNKNOWN,PHASE3,Lung Cancer,filgrastim (BIOLOGICAL); carboplatin (DRUG); epirubicin hydrochloride (DRUG); etoposide (DRUG); etoposide phosphate (DRUG); ifosfamide (DRUG); paclitaxel (DRUG); autologous bone marrow transplantation (PROCEDURE); bone marrow ablation with stem cell support (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),65348,Ellence,Lung Cancer,Lung,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8612,NCT04877821,The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC,RECRUITING,PHASE2,Triple Negative Breast Cancer,Sintilimab (DRUG); Anlotinib (DRUG); Nab paclitaxel (DRUG); Carboplatin (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),65348,Ellence,Triple Negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8613,NCT00615602,Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Docetaxel (DRUG); Trastuzumab (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); 5-fluoruracil (DRUG); Granulocyte-colony stimulating growth factor (DRUG); Trastuzumab (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8614,NCT00038402,Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Herceptin (DRUG); Taxol (DRUG); Fluorouracil (DRUG); Cytoxan (DRUG); Epirubicin (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8615,NCT00288002,"Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer",COMPLETED,PHASE3,Breast Cancer,trastuzumab (BIOLOGICAL); capecitabine (DRUG); cyclophosphamide (DRUG); docetaxel (DRUG); epirubicin hydrochloride (DRUG); adjuvant therapy (PROCEDURE); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8616,NCT02535221,Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer,RECRUITING,PHASE3,Breast Cancer,Goserelin+TAM+AI (DRUG); Epirubicin+CTX+5-Fu (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8617,NCT00002784,High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer,COMPLETED,PHASE3,Breast Cancer,filgrastim (BIOLOGICAL); CMF regimen (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); mesna (DRUG); methotrexate (DRUG); tamoxifen citrate (DRUG); peripheral blood stem cell transplantation (PROCEDURE); low-LET electron therapy (RADIATION); low-LET photon therapy (RADIATION),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8618,NCT04809779,PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC,UNKNOWN,PHASE2,Triple Negative Breast Cancer,Sintilimab (DRUG),65348,Ellence,Triple Negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8619,NCT03799679,Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer,UNKNOWN,PHASE4,Triple Negative Breast Cancer,Chemotherapeutic Agent (DRUG),65348,Ellence,Triple Negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8620,NCT00055679,Combination Chemotherapy in Treating Women With Stage I Breast Cancer,COMPLETED,PHASE3,Breast Cancer,cyclophosphamide (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8621,NCT00960284,"Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer",COMPLETED,PHASE2,Pancreatic Cancer,capecitabine (DRUG); cisplatin (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); gemcitabine hydrochloride (DRUG),65348,Ellence,Pancreatic Cancer,Pancreas,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8622,NCT00743964,"Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)",COMPLETED,PHASE2,Advanced Gastric Cancer,"Epirubicin (DRUG); Cisplatin, capecitabine (DRUG)",65348,Ellence,Advanced Gastric Cancer,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8623,NCT01327521,Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma,WITHDRAWN,PHASE3,"Carcinoma, Hepatocellular",CyberKnife (DEVICE); TACE (PROCEDURE); CT Contrast (DRUG); doxorubicin (DRUG); Epirubicin (DRUG); 5-fluorouracil (DRUG); Mitomycin C (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG); SMANCS (DEVICE),65348,Ellence,"Carcinoma, Hepatocellular",Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8624,NCT06291064,Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer,NOT_YET_RECRUITING,PHASE2,Triple Negative Breast Cancer,Cyclophosphamide (DRUG); Epirubicin (DRUG); Docetaxel (DRUG); Carboplatin (DRUG); Breast Surgery (PROCEDURE); Capecitabine (DRUG),65348,Ellence,Triple Negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8625,NCT00248703,Secondary Adjuvant Treatment for Patients With Isolated Tumor Cells in Bone Marrow,COMPLETED,PHASE2,Breast Cancer,Docetaxel (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8626,NCT06795503,Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients,NOT_YET_RECRUITING,PHASE3,Triple-negative Breast Cancer,"Docetaxel plus cyclophosphamide (DRUG); Epirubicin, cyclophosphamide plus paclitaxel (DRUG)",65348,Ellence,Triple-negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8627,NCT00239343,Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer,COMPLETED,PHASE2,Breast Cancer,gefitinib (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8628,NCT01554943,Late Cardiac Evaluation of the Three Arm Belgian Trial Involving Node-positive Early Breast Cancer Patients,COMPLETED,PHASE2,Breast Cancer,cardiac MRI (OTHER),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8629,NCT04031703,Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN),COMPLETED,PHASE3,Breast Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); 5-fluorouracil (DRUG); Docetaxel (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8630,NCT02128243,Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer,COMPLETED,PHASE2,"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction; Gastric Neoplasm; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma; Gastric Adenocarcinoma; Esophageal Neoplasms",S-1 de-escalation (DRUG); Chemotherapy by Investigator's choice (DRUG),65348,Ellence,"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction; Gastric Neoplasm; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma; Gastric Adenocarcinoma; Esophageal Neoplasms",Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8631,NCT02603679,Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases,ACTIVE_NOT_RECRUITING,PHASE2,Early-Stage Breast Carcinoma; Estrogen Receptor Positive Tumor,Paclitaxel (DRUG); Tamoxifen + Palbociclib (DRUG); Aromatase Inhibitor + Palbociclib (DRUG); Goserelin + Aromatase Inhibitor + Palbociclib (DRUG),65348,Ellence,Hormone-Receptor Positive Breast Carcinoma,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8632,NCT06112379,A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer,RECRUITING,PHASE3,Breast Cancer,Dato-DXd (DRUG); Durvalumab (DRUG); Pembrolizumab (DRUG); Doxorubicin (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Capecitabine (DRUG); Olaparib (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8633,NCT00142038,Docetaxel and Capecitabine in Advanced Gastric Cancer,COMPLETED,PHASE2,Stomach Neoplasm; Neoplasm Metastasis,Docetaxel (DRUG); Capecitabine (DRUG),65348,Ellence,Stomach Neoplasm; Neoplasm Metastasis,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8634,NCT01351038,"Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma",TERMINATED,PHASE2,KRAS Wild Type; Resectable Type II Gastric Adenocarcinoma,"Epirubicine, Oxaliplatin, Capecitabine, Panitumumab (DRUG)",65348,Ellence,KRAS Wild Type; Resectable Type II Gastric Adenocarcinoma,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8635,NCT02630108,TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma,UNKNOWN,PHASE3,"Carcinoma, Hepatocellular",Thermal Ablation (PROCEDURE); EADM (DRUG); Ultra-fluid lipiodol (DRUG); Gelatin sponge articles (OTHER),65348,Ellence,"Carcinoma, Hepatocellular",Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8636,NCT05978648,Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy,RECRUITING,PHASE2,Breast Neoplasms,Trilaciclib (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Paclitaxel (DRUG); Docetaxel (DRUG); Carboplatin (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG),65348,Ellence,Breast Neoplasms,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8637,NCT04152057,Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer,UNKNOWN,PHASE1,Breast Cancer; HER2 Positive; Combination Chemotherapy,Pyrotinib Maleate Tablets (DRUG); Albumin Paclitaxel (DRUG); Trastuzumab (DRUG),65348,Ellence,Breast Cancer; HER2 Positive; Combination Chemotherapy,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8638,NCT06802757,Posaconazole Plus Pembrolizumab and Chemotherapy Vs Pembrolizumab and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer,RECRUITING,PHASE2,Breast Cancer,Posaconazole (DRUG); Nab-paclitaxel (DRUG); Carboplatin (DRUG); Anthracycline (DRUG); Cyclophosphamide (DRUG); Pembrolizumab (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8639,NCT00301548,Perioperative Chemotherapy After Primary Chemotherapy for Locally Advanced Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms; Carcinoma,perioperative chemotherapy (DRUG),65348,Ellence,Breast Neoplasms; Carcinoma,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8640,NCT02627248,Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery,RECRUITING,PHASE4,Breast Cancer,Huaier Granule (DRUG); Epirubicin (DRUG); Docetaxel (DRUG); Cyclophosphamide (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8641,NCT02685059,Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer,COMPLETED,PHASE2,Breast Cancer,MEDI4736 (Anti PD-L1) (DRUG); Placebo (DRUG); nab-Paclitaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8642,NCT04193059,Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer,UNKNOWN,PHASE3,Breast Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); Docetaxel (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8643,NCT04296175,Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE),ACTIVE_NOT_RECRUITING,PHASE3,Triple-negative Breast Cancer,Epirubicin (DRUG); CTX (DRUG); Paclitaxel (DRUG); ddEpirubicin (DRUG); ddCTX (DRUG); Paclitaxel(with carbo) (DRUG); Carboplatin (DRUG),65348,Ellence,Triple-negative Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8644,NCT01093235,Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer,UNKNOWN,PHASE3,Breast Cancer; Cardiac Toxicity; Perioperative/Postoperative Complications,bevacizumab (BIOLOGICAL); cyclophosphamide (DRUG); docetaxel (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); assessment of therapy complications (PROCEDURE); neoadjuvant therapy (PROCEDURE); quality-of-life assessment (PROCEDURE); therapeutic conventional surgery (PROCEDURE),65348,Ellence,Breast Cancer; Cardiac Toxicity; Perioperative/Postoperative Complications,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8645,NCT00004934,"Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer",COMPLETED,PHASE3,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,carboplatin (DRUG); epirubicin hydrochloride (DRUG); paclitaxel (DRUG); conventional surgery (PROCEDURE),65348,Ellence,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8646,NCT01205217,Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer,WITHDRAWN,PHASE2,"Neoplasms, Breast",Lapatinib (DRUG); Trastuzumab (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Paclitaxel (DRUG),65348,Ellence,"Neoplasms, Breast",Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8647,NCT02539017,The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer,WITHDRAWN,PHASE2,Triple Negative Breast Neoplasms,Chemo (DRUG); Immunotherapy (BIOLOGICAL),65348,Ellence,Triple Negative Breast Neoplasms,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8648,NCT03123770,Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients,UNKNOWN,PHASE4,Breast Cancer,Pegylated liposomal doxorubicin (DRUG); Cyclophosphamide (DRUG); Epirubicin (DRUG); Docetaxel (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8649,NCT04172259,ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer; Neoadjuvant Chemotherapy,Doxorubicin liposome (DRUG); Cyclophosphamide (DRUG); Trastuzumab (DRUG); Docetaxel (DRUG); Epirubicin (DRUG); Pertuzumab (DRUG); Paclitaxel (DRUG); Paclitaxel-albumin (DRUG),65348,Ellence,Breast Cancer; Neoadjuvant Chemotherapy,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8650,NCT04947059,Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline),RECRUITING,PHASE3,Bladder Cancer,Gemcitabine Hydrochloride combined with continuous saline irrigation (DRUG); Epirubicin Hydrochloride combined with continuous saline irrigation (DRUG),65348,Ellence,Bladder Cancer,Bladder/Urinary Tract,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8651,NCT03725059,"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)",ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Pembrolizumab (K) (BIOLOGICAL); Placebo (P) (DRUG); Paclitaxel (X) (DRUG); Doxorubicin (A) (DRUG); Epirubicin (E) (DRUG); Cyclophosphamide (C) (DRUG); Endocrine therapy (DRUG); Radiation therapy (RADIATION); Surgery (PROCEDURE),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8652,NCT00253500,"Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer",COMPLETED,PHASE2,Breast Cancer,pegfilgrastim (BIOLOGICAL); epirubicin hydrochloride (DRUG); conventional surgery (PROCEDURE),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8653,NCT01222052,6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients,UNKNOWN,PHASE3,Breast Cancer,"5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel (DRUG)",65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8654,NCT04518852,"TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC",COMPLETED,PHASE2,Hepatocellular Carcinoma; Liver Neoplasms; Digestive System Neoplasms; Sorafenib; Molecular Mechanisms of Pharmacological Action; Liver Diseases; Antineoplastic Agents; Protein Kinase Inhibitors,TACE combined with sorafenib and PD-1 mAb (COMBINATION_PRODUCT),65348,Ellence,Hepatocellular Carcinoma; Liver Neoplasms; Digestive System Neoplasms; Sorafenib; Molecular Mechanisms of Pharmacological Action; Liver Diseases; Antineoplastic Agents; Protein Kinase Inhibitors,Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8655,NCT01196052,"A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer",COMPLETED,PHASE2,Breast Cancer,Trastuzumab emtansine (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8656,NCT02115152,Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer,UNKNOWN,PHASE2,Stage II Breast Cancer; Stage III Breast Cancer,fluorouracil (DRUG); capecitabine (DRUG); cyclophosphamide (DRUG); Epirubicin (DRUG),65348,Ellence,Stage II Breast Cancer; Stage III Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8657,NCT02225652,"A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.",COMPLETED,PHASE2,Women With Primary Breast Cancer,"FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel (DRUG)",65348,Ellence,Women With Primary Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8658,NCT00003852,Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors,TERMINATED,PHASE2,Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer; Testicular Germ Cell Tumor,filgrastim (BIOLOGICAL); carboplatin (DRUG); cyclophosphamide (DRUG); epirubicin hydrochloride (DRUG); etoposide (DRUG); ifosfamide (DRUG); paclitaxel (DRUG); thiotepa (DRUG); bone marrow ablation with stem cell support (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE),65348,Ellence,Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer; Testicular Germ Cell Tumor,Ovary/Fallopian Tube,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8659,NCT00525759,Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer,COMPLETED,PHASE2,Breast Cancer,"5-FU, Epirubicin, Cyclophosphamide, Docetaxel (DRUG); 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid (DRUG)",65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8660,NCT00054587,Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Trastuzumab (BIOLOGICAL); Cyclophosphamide (DRUG); docetaxel (DRUG); Epirubicin (DRUG); Fluorouracil (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8661,NCT06121570,Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer,RECRUITING,PHASE1,Breast Neoplasms,Sentinel Lymph Node Biopsy (SLNB) (PROCEDURE); Doxorubicin (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); Cyclophosphamide (DRUG); Fludarabine (DRUG); Tumor-draining lymph node-derived lymphocyte (LNL) (BIOLOGICAL); Interleukin-2 (BIOLOGICAL); Nab-paclitaxel (DRUG),65348,Ellence,Breast Neoplasms,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8662,NCT01537536,Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer,COMPLETED,PHASE2,Breast Cancer,EndoTAG-1 (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8663,NCT02628613,Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations,COMPLETED,PHASE2,Breast Cancer,Vinorelbine plus Epirubicin (DRUG); Paclitaxel plus Epirubicin (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8664,NCT02897700,A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast,RECRUITING,PHASE1,Breast Cancer,"Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (DRUG); cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) (DRUG); Placebo (DRUG)",65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8665,NCT00620100,To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent,TERMINATED,PHASE2,Breast Neoplasms,Docetaxel (DRUG),65348,Ellence,Breast Neoplasms,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8666,NCT00058487,Epirubicin and Thalidomide in Treating Patients With Liver Cancer,COMPLETED,PHASE2,Liver Cancer,epirubicin hydrochloride (DRUG); thalidomide (DRUG),65348,Ellence,Liver Cancer,Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8667,NCT04836156,Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients,RECRUITING,PHASE1,HER2-negative Early Breast Cancer,neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer (DRUG); neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer (DRUG),65348,Ellence,HER2-negative Early Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8668,NCT01880385,Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer,UNKNOWN,PHASE1,Inflammatory Breast Cancer,Bevacizumab (BIOLOGICAL); Cyclophosphamide (DRUG); epirubicin hydrochloride (DRUG); fluorouracil (DRUG); Docetaxel (DRUG); Trastuzumab (BIOLOGICAL),65348,Ellence,Inflammatory Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8669,NCT01204437,Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast,COMPLETED,PHASE2,Breast Cancer,"Epirubicin, Cyclophosphamide (DRUG); Cyclophosphamide, Methotrexate, 5 FU (DRUG); Capecitabine, Nab-Paclitaxel (DRUG)",65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8670,NCT00950300,A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer,COMPLETED,PHASE3,Breast Cancer,5-Fluorouracil (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG); Epirubicin (DRUG); Herceptin IV [trastuzumab] (DRUG); Herceptin SC [trastuzumab] (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8671,NCT04273100,"PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC",UNKNOWN,PHASE2,Hepatocellular Carcinoma Non-resectable,PD-1 mAb combined with TACE and lenvatinib (COMBINATION_PRODUCT),65348,Ellence,Hepatocellular Carcinoma Non-resectable,Liver,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8672,NCT05883852,EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer,RECRUITING,PHASE3,HER2 Positive Early Breast Cancer,Docetaxel (DRUG); carboplatin (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); Epirubicin (DRUG); cyclophosphamide (DRUG),65348,Ellence,HER2 Positive Early Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8673,NCT02177552,Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma,UNKNOWN,PHASE2,Esophageal Neoplasms; Stomach Neoplasms,Carboplatin (DRUG); Docetaxel (DRUG); Capecitabine (DRUG); Epirubicin (DRUG); Oxaliplatin (DRUG),65348,Ellence,Esophageal Neoplasms; Stomach Neoplasms,Esophagus/Stomach,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8674,NCT02532400,Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients,TERMINATED,PHASE3,Breast Cancer,Neoadjuvant endocrine therapy (DRUG); Neoadjuvant chemotherapy (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8675,NCT00540800,BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer,COMPLETED,PHASE3,Breast Cancer,docetaxel (DRUG); epirubicin (DRUG); capecitabine (DRUG),65348,Ellence,Breast Cancer,Breast,Epirubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in chemotherapies as single agent or in combination treatments.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,1.01,273.0 +8676,NCT06741020,Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma,RECRUITING,PHASE1,Hepatocellular Carcinoma (HCC),"Adebrelimab, Oxaliplatin, Fluorouracil,Leucovorin (DRUG)",636362,DMDR,Hepatocellular Carcinoma (HCC),Liver,Idarubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in acute myeloid leukemia treatment.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl,1.03,309.0 +8677,NCT00193973,Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma,COMPLETED,PHASE2,Primary Central Nervous System Lymphoma,"Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C (DRUG); Radiation Therapy (RADIATION)",636362,DMDR,Primary Central Nervous System Lymphoma,CNS/Brain,Idarubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in acute myeloid leukemia treatment.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl,1.03,309.0 +8678,NCT06114082,TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma,RECRUITING,PHASE2,Hepatocellular Carcinoma; Liver Cancer,IDA-TACE (PROCEDURE); DOX-TACE (PROCEDURE),636362,DMDR,Hepatocellular Carcinoma,Liver,Idarubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in acute myeloid leukemia treatment.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl,1.03,309.0 +8679,NCT06482801,Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT,RECRUITING,PHASE2,Liver Cancer; Antibody,"ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab (DRUG)",636362,DMDR,Liver Cancer; Antibody,Liver,Idarubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in acute myeloid leukemia treatment.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl,1.03,309.0 +8680,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,75 approved agents (DRUG); COXEN (OTHER),636362,DMDR,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,Bladder/Urinary Tract,Idarubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in acute myeloid leukemia treatment.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl,1.03,309.0 +8681,NCT02836158,Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL,RECRUITING,PHASE2,Primary Central Nervous System Lymphoma,R-IDARAM plus intrathecal chemotherapy (DRUG),636362,DMDR,Primary Central Nervous System Lymphoma,CNS/Brain,Idarubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in acute myeloid leukemia treatment.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl,1.03,309.0 +8682,NCT05280444,Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma,UNKNOWN,PHASE2,Hepatocellular Carcinoma,Idarubicin Hydrochloride for Injection (DRUG),636362,DMDR,Hepatocellular Carcinoma,Liver,Idarubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in acute myeloid leukemia treatment.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl,1.03,309.0 +8683,NCT02185768,Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II,COMPLETED,PHASE2,Liver Cancer,idarubicin (DRUG); Dc- Beads 300-500µm (DEVICE),636362,DMDR,Liver Cancer,Liver,Idarubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in acute myeloid leukemia treatment.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl,1.03,309.0 +8684,NCT02870010,Chemoembolization of Non-resectable Non-metastatic Hepatocellular Carcinoma Using Embolization Microspheres,COMPLETED,PHASE1,Localized Non-Resectable Adult Hepatocellular Carcinoma,blood samples (5 ml) will be taken (BIOLOGICAL); Chemoembolization (RADIATION),636362,DMDR,Localized Non-Resectable Adult Hepatocellular Carcinoma,Liver,Idarubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in acute myeloid leukemia treatment.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl,1.03,309.0 +8685,NCT06492421,Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.,RECRUITING,PHASE2,Lung Cancer; Surgery; Non-small Cell Lung Cancer,"ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab (DRUG)",636362,DMDR,Lung Cancer; Surgery; Non-small Cell Lung Cancer,Lung,Idarubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in acute myeloid leukemia treatment.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl,1.03,309.0 +8686,NCT02028949,Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study,COMPLETED,PHASE1,Unresectable Non-metastatic Hepatocellular Carcinoma; Child A/B7 Cirrhosis,Zavedos® (DRUG); Blood samples (OTHER),636362,DMDR,Unresectable Non-metastatic Hepatocellular Carcinoma; Child A/B7 Cirrhosis,Liver,Idarubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in acute myeloid leukemia treatment.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl,1.03,309.0 +8687,NCT04178642,The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol,WITHDRAWN,PHASE2,Hepatocellular Carcinoma,percutaneous destruction of the tumor + Idarubicin-Lipiodol treatment (DRUG); Percutaneous destruction of the tumor (PROCEDURE),636362,DMDR,Hepatocellular Carcinoma,Liver,Idarubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in acute myeloid leukemia treatment.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl,1.03,309.0 +8688,NCT01040559,"Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas",COMPLETED,PHASE1,"Carcinoma, Hepatocellular",idarubicin (DRUG),636362,DMDR,"Carcinoma, Hepatocellular",Liver,Idarubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in acute myeloid leukemia treatment.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl,1.03,309.0 +8689,NCT06483347,Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT,RECRUITING,PHASE2,Lung Cancer; Inoperable Disease,"ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab (DRUG)",636362,DMDR,Lung Cancer; Inoperable Disease,Lung,Idarubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in acute myeloid leukemia treatment.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl,1.03,309.0 +8690,NCT02657785,Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy,RECRUITING,PHASE2,Primary Central Nervous System Lymphoma,R-IDARAM plus intrathecal chemotherapy (DRUG),636362,DMDR,Primary Central Nervous System Lymphoma,CNS/Brain,Idarubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in acute myeloid leukemia treatment.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl,1.03,309.0 +8691,NCT03727633,Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion,RECRUITING,PHASE2,"Carcinoma, Hepatocellular",Idarubicin and Lipiodol (DRUG),636362,DMDR,"Carcinoma, Hepatocellular",Liver,Idarubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in acute myeloid leukemia treatment.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl,1.03,309.0 +8692,NCT05518383,B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021,RECRUITING,PHASE4,"Non-hodgkin Lymphoma,B Cell; Burkitt Lymphoma; Primary Mediastinal Lymphoma; Primary CNS Lymphoma; Diffuse Large B-cell Lymphoma","Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate (DRUG); Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine (DRUG); Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine (DRUG); Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin (DRUG)",636362,DMDR,"Non-hodgkin Lymphoma,B Cell; Burkitt Lymphoma; Primary Mediastinal Lymphoma; Primary CNS Lymphoma; Diffuse Large B-cell Lymphoma",CNS/Brain,Idarubicin (hydrochloride),TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in acute myeloid leukemia treatment.,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl,1.03,309.0 +8693,NCT01624090,"Mithramycin for Lung, Esophagus, and Other Chest Cancers",TERMINATED,PHASE2,Lung Cancer; Esophageal Cancer; Mesothelioma; Gastrointestinal Neoplasms; Breast Cancer,Mithramycin (DRUG),163659,Mithracin,Lung Cancer; Esophageal Cancer; Mesothelioma; Gastrointestinal Neoplasms; Breast Cancer,Bowel,Plicamycin,"SP1, GSTM2",inhibitor/antagonist,unclear,yes,yes,Plicamycin is used to treat testicular cancer and hypercalcemia.,CC1C(C(CC(O1)OC2CC(OC(C2O)C)OC3=CC4=CC5=C(C(=O)C(C(C5)C(C(=O)C(C(C)O)O)OC)OC6CC(C(C(O6)C)O)OC7CC(C(C(O7)C)O)OC8CC(C(C(O8)C)O)(C)O)C(=C4C(=C3C)O)O)O)O,, +8694,NCT02859415,"Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases",TERMINATED,PHASE1,"Esophageal Neoplasms; Lung Neoplasms; Mesothelioma; Thymus Neoplasms; Neoplasms, Germ Cell and Embryonal",Mithramycin (DRUG),163659,Mithracin,"Esophageal Neoplasms; Lung Neoplasms; Mesothelioma; Thymus Neoplasms; Neoplasms, Germ Cell and Embryonal",Lung,Plicamycin,"SP1, GSTM2",inhibitor/antagonist,unclear,yes,yes,Plicamycin is used to treat testicular cancer and hypercalcemia.,CC1C(C(CC(O1)OC2CC(OC(C2O)C)OC3=CC4=CC5=C(C(=O)C(C(C5)C(C(=O)C(C(C)O)O)OC)OC6CC(C(C(O6)C)O)OC7CC(C(C(O7)C)O)OC8CC(C(C(O8)C)O)(C)O)C(=C4C(=C3C)O)O)O)O,, +8695,NCT02016196,Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS,COMPLETED,PHASE3,Cirrhosis,Rifaximin (DRUG); placebo (DRUG),6436173,Normix,Cirrhosis,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8696,NCT01355575,Rifaximin in Fatty Liver Disease,TERMINATED,PHASE4,Nonalcoholic Fatty Liver Disease; NAFLD; Nonalcoholic Steatohepatitis,Rifaximin (DRUG),6436173,Normix,Nonalcoholic Fatty Liver Disease; NAFLD; Nonalcoholic Steatohepatitis,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8697,NCT01897051,Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients,UNKNOWN,PHASE2,Liver Cirrhosis; Portal Hypertension,Rifaximin + propranolol (DRUG); Propranolol + Placebo (DRUG),6436173,Normix,Liver Cirrhosis; Portal Hypertension,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8698,NCT03439982,Fecal Transplant for Hepatic Encephalopathy,COMPLETED,PHASE1,Hepatic Encephalopathy,FMT (BIOLOGICAL),6436173,Normix,Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8699,NCT02158182,"Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding",COMPLETED,PHASE4,Hepatic Encephalopathy,Lactulose (DRUG); L-ornithine L-aspartate (DRUG); Rifaximin (DRUG); Placebo (DRUG),6436173,Normix,Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8700,NCT01695174,A Pilot Study of Xifaxan to Treat Patients With PSC,COMPLETED,PHASE1,Primary Sclerosing Cholangitis (PSC),Xifaxan (DRUG),6436173,Normix,Primary Sclerosing Cholangitis (PSC),Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8701,NCT00686920,Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy,COMPLETED,PHASE3,Hepatic Encephalopathy,Rifaximin (DRUG),6436173,Normix,Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8702,NCT00528073,"Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease",COMPLETED,PHASE2,Crohn's Disease,Rifaximin-EIR (DRUG),6436173,Normix,Crohn's Disease,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8703,NCT03537157,A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention,TERMINATED,PHASE2,Crohn Disease,Rifaximin delayed release tablets (DRUG); Placebo (OTHER),6436173,Normix,Crohn Disease,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8704,NCT04073290,Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose,RECRUITING,PHASE4,"Hepatic Encephalopathy; Cirrhosis, Liver; Portal Hypertension; Liver Diseases; Pathological Processes",Rifaximin 550 milligram Oral Tablet [XIFAXAN] (DRUG); Placebo oral tablet (DRUG); Lactulose 667 milligram/milliliter Oral Solution (DRUG),6436173,Normix,"Hepatic Encephalopathy; Cirrhosis, Liver; Portal Hypertension; Liver Diseases; Pathological Processes",Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8705,NCT00269412,Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome,COMPLETED,PHASE2,Irritable Bowel Syndrome,Rifaximin (DRUG),6436173,Normix,Irritable Bowel Syndrome,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8706,NCT03069131,Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites,COMPLETED,PHASE3,Cirrhosis; Ascites; Peritonitis,Rifaximin (DRUG); Placebo (OTHER),6436173,Normix,Cirrhosis; Ascites; Peritonitis,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8707,NCT02086825,A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure,WITHDRAWN,PHASE3,Hepatic Encephalopathy,Rifaximin (DRUG); Lactulose (DRUG),6436173,Normix,Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8708,NCT00724126,Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS),COMPLETED,PHASE3,Non-Constipation Irritable Bowel Syndrome,Rifaximin (DRUG); Placebo (DRUG),6436173,Normix,Non-Constipation Irritable Bowel Syndrome,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8709,NCT03462966,Rifaximin on Visceral Hypersensitivity,TERMINATED,PHASE2,Visceral Hypersensitivity; Irritable Bowel Syndrome,Rifaximin (DRUG),6436173,Normix,Visceral Hypersensitivity; Irritable Bowel Syndrome,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8710,NCT06718686,Rifaximin SSD in Dementia Trial,RECRUITING,PHASE1,Dementia Alzheimer Type; Dementia Associated With Cerebrovascular Disease,Rifaximin SSD 40 mg IR tablet (DRUG); Placebo (DRUG),6436173,Normix,Dementia Alzheimer Type; Dementia Associated With Cerebrovascular Disease,CNS/Brain,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8711,NCT06727422,Efficacy of Rifaximin with NAC in IBS-D,NOT_YET_RECRUITING,PHASE2,IBS (Irritable Bowel Syndrome); IBS-D (diarrhea-predominant),rifaximin 66mg + N-acetylcysteine 560mg three times daily (DRUG); RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily (DRUG); Placebo (DRUG),6436173,Normix,IBS (Irritable Bowel Syndrome); IBS-D (diarrhea-predominant),Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8712,NCT04128462,MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function,WITHDRAWN,PHASE3,Hepatic Encephalopathy,MNK-6105 (DRUG); Placebo (DRUG); Standard of Care (DRUG),6436173,Normix,Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8713,NCT02074280,Rifaximin Predicts the Complications of Decompensated Cirrhosis,UNKNOWN,PHASE4,Cirrhosis,rifaximin (DRUG),6436173,Normix,Cirrhosis,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8714,NCT04841980,Rifaximin Therapy vs Low FODMAP Diet In IBS,UNKNOWN,PHASE4,Irritable Bowel Syndrome; Small Intestinal Bacterial Overgrowth,Rifaximin (DRUG); Low FODMAP diet (OTHER),6436173,Normix,Irritable Bowel Syndrome with SIBO,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8715,NCT02470780,Treating Bacterial Overgrowth in Parkinson's Disease,COMPLETED,PHASE2,Parkinson's Disease; Small Intestinal Bacterial Overgrowth,Rifaximin (DRUG); Placebo (DRUG),6436173,Normix,Parkinson's Disease; Small Intestinal Bacterial Overgrowth,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8716,NCT04775329,Primary Prophylaxis for Spontaneous Bacterial Peritonitis,TERMINATED,PHASE2,Decompensated Cirrhosis; Small Bowel Bacterial Overgrowth Syndrome,Rifaximin (DRUG),6436173,Normix,Decompensated Cirrhosis; Small Bowel Bacterial Overgrowth Syndrome,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8717,NCT01662791,Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth,COMPLETED,PHASE3,Parkinson's Disease,Rifaximin (DRUG),6436173,Normix,Parkinson's Disease,CNS/Brain,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8718,NCT03712280,MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy),COMPLETED,PHASE2,Hepatic Cirrhosis; Hepatic Encephalopathy (HE),MNK6106 (DRUG); Rifaximin (DRUG),6436173,Normix,Hepatic Cirrhosis; Hepatic Encephalopathy (HE),Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8719,NCT05071716,Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis,ACTIVE_NOT_RECRUITING,PHASE3,Hepatic Encephalopathy,Rifaximin SSD (DRUG); Placebo (DRUG),6436173,Normix,Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8720,NCT00603616,Induction of Clinical Response Using Rifaximin in Crohn's Disease,COMPLETED,PHASE2,Crohn's Disease,Placebo Comparator (DRUG); Rifaximin (DRUG),6436173,Normix,Crohn's Disease,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8721,NCT01654939,Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease,WITHDRAWN,PHASE4,HIV; Hepatitis C,Rifaximin (DRUG),6436173,Normix,HIV; Hepatitis C,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8722,NCT02342639,Rifaximin Therapy in Chronic Kidney Disease,COMPLETED,PHASE4,Chronic Kidney Disease,Rifaximin (DRUG); Placebo (DRUG),6436173,Normix,Chronic Kidney Disease,Kidney,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8723,NCT05754996,Efficacy and Safety of Nifuroxazide in the Treatment of Hepatic Encephalopathy in Egyptian Patients With Liver Cirrhosis,RECRUITING,PHASE3,Hepatic Encephalopathy,Nifuroxazide (DRUG); Lactulose (DRUG); Rifaximin 550Mg Tab (DRUG),6436173,Normix,Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8724,NCT05453916,Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation,RECRUITING,PHASE1,Irritable Bowel Syndrome With Diarrhea,Nitazoxanide 500Mg Oral Tablet (DRUG); Rifaximin 550Mg Tab (DRUG),6436173,Normix,Irritable Bowel Syndrome With Diarrhea,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8725,NCT03420144,Growth Hormone Therapy in Liver Cirrhosis,COMPLETED,PHASE2,"Cirrhosis, Liver",Standard Medical Therapy (DRUG); Growth Hormone (DRUG),6436173,Normix,Liver Cirrhosis,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8726,NCT03515044,Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE),COMPLETED,PHASE2,Overt Hepatic Encephalopathy,40 mg Rifaximin SSD once daily (DRUG); 40 mg Rifaximin SSD twice daily (DRUG); 80 mg Rifaximin SSD once daily (DRUG); 80 mg Rifaximin SSD twice daily (DRUG); Placebo (DRUG),6436173,Normix,Overt Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8727,NCT00748904,Rifaximin Versus Lactulose in Renal Failure,WITHDRAWN,PHASE4,Liver Cirrhosis; Renal Failure,Rifaximin (DRUG); Lactulose (DRUG),6436173,Normix,Liver Cirrhosis; Renal Failure,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8728,NCT06630572,Rifaximin in Cirrhosis: Effects on Endotoxin and Haemostatic Indexes,TERMINATED,PHASE4,Liver Cirrhosis; Coagulation Disorder; Platelet Disorder; Endotoxemia,Rifaximin (DRUG); Placebo (DRUG),6436173,Normix,Liver Cirrhosis; Coagulation Disorder; Platelet Disorder; Endotoxemia,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8729,NCT02651740,Gut Microbiota Reconstruction in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea,UNKNOWN,PHASE2,Irritable Bowel Syndrome,Rifaximin (DRUG); Fecal microbiota transplantation (PROCEDURE),6436173,Normix,Irritable Bowel Syndrome,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8730,NCT01769040,Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis,COMPLETED,PHASE4,Liver Cirrhosis; Ascites,Rifaximin (DRUG); placebo (DRUG),6436173,Normix,Liver Cirrhosis; Ascites,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8731,NCT00364689,"RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial",TERMINATED,PHASE3,Hepatic Encephalopathy,Rifaximin (DRUG); Lactulose (DRUG); Placebo (OTHER),6436173,Normix,Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8732,NCT03185624,Effectiveness of Rifaximin on Preventing Postoperative Recurrence in Crohn's Disease,UNKNOWN,PHASE3,Crohn Disease,Rifaximin (DRUG),6436173,Normix,Crohn Disease,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8733,NCT03077217,Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy,COMPLETED,PHASE4,Covert Hepatic Encephalopathy,Rifaximin (DRUG),6436173,Normix,Covert Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8734,NCT03818672,Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects,TERMINATED,PHASE4,Severe Hepatic Impairment,Rifaximin (DRUG),6436173,Normix,Severe Hepatic Impairment,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8735,NCT03575195,Microbiota Intervention to Change the Response of Parkinson's Disease,SUSPENDED,PHASE1,Parkinson Disease,Rifaximin (DRUG); Placebo (OTHER),6436173,Normix,Parkinson Disease,CNS/Brain,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8736,NCT02272868,Fecal Microbial Transplant in Pediatric Crohn's Disease,TERMINATED,PHASE1,Crohn's Disease,Fecal Microbial transplant (BIOLOGICAL); Normal Saline (DRUG); rifaximin+omeprazole+miralax (DRUG),6436173,Normix,Crohn's Disease,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8737,NCT05204641,Effect of Fecal Microbiota Transfer on Progression of Parkinson Disease,COMPLETED,PHASE2,Parkinson Disease,Fecal Microbiota Transfer provided by Human Biome Institute (BIOLOGICAL),6436173,Normix,Parkinson Disease,CNS/Brain,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8738,NCT04254549,Rifaximin in Patients With Diabetic Gastroparesis,SUSPENDED,PHASE2,Crohn Disease; Diabetic Gastroparesis,Rifaximin (DRUG); Placebo (DRUG),6436173,Normix,Crohn Disease; Diabetic Gastroparesis,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8739,NCT00298038,"A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy",COMPLETED,PHASE3,Hepatic Encephalopathy,Rifaximin (DRUG); Placebo (DRUG),6436173,Normix,Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8740,NCT03958708,Modulation of Gut Microbiota by Rifaximin in PD Patients,UNKNOWN,PHASE1,Parkinson Disease; Inflammation,Rifaximin 550 MG (DRUG),6436173,Normix,Parkinson Disease; Inflammation,CNS/Brain,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8741,NCT01603108,Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant,UNKNOWN,PHASE2,Hepatitis C,Rifaximin (DRUG); Placebo (DRUG),6436173,Normix,Hepatitis C,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8742,NCT06368895,Fecal Microbiota Transplantation by Oral Capsules for Hepatic Encephalopathy Treatment,RECRUITING,PHASE1,Hepatic Encephalopathy; Dysbiosis,Fecal microbiota transplantation delivery through colonoscopy (PROCEDURE); Fecal microbiota transplantation delivery through oral capsules (DRUG),6436173,Normix,Hepatic Encephalopathy; Dysbiosis,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8743,NCT00259155,Rifaximin for the Treatment of Irritable Bowel Syndrome,COMPLETED,PHASE2,Irritable Bowel Syndrome,Rifaximin (DRUG),6436173,Normix,Irritable Bowel Syndrome,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8744,NCT05867550,To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea,COMPLETED,PHASE4,Irritable Bowel Syndrome With Diarrhea,Rifaximin 550 MG (DRUG); Mebeverine 135 MG (DRUG); Psyllium Husk (DRUG); Amitriptyline Hydrochloride 25 MG (DRUG),6436173,Normix,Irritable Bowel Syndrome With Diarrhea,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8745,NCT01842581,The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy,COMPLETED,PHASE4,Hepatic Encephalopathy; Cirrhosis,Rifaximin (DRUG); Lactulose (DRUG),6436173,Normix,Hepatic Encephalopathy; Cirrhosis,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8746,NCT02508623,Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices,UNKNOWN,PHASE3,Liver Cirrhosis; Portal Hypertension,Rifaximin (DRUG); Placebo (DRUG),6436173,Normix,Liver Cirrhosis; Portal Hypertension,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8747,NCT01345175,Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer,COMPLETED,PHASE3,Rectal Cancer,Rifaximin (DRUG); Placebo (DRUG),6436173,Normix,Rectal Cancer,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8748,NCT02485106,Rifaximin Use in Severe Alcoholic Hepatitis,UNKNOWN,PHASE3,Severe Alcoholic Hepatitis,Rifaximin (DRUG); Corticosteroid or pentoxifylline (DRUG),6436173,Normix,Severe Alcoholic Hepatitis,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8749,NCT05502913,Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer,RECRUITING,PHASE2,Metastatic Lung Cancer,Antibiotics (DRUG); FMT (Fecal Microbiota Transplantation) (OTHER),6436173,Normix,Metastatic Lung Cancer,Lung,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8750,NCT01842113,Quality of Life and Nutritional Improvements in Cirrhotic Patients,TERMINATED,PHASE4,Liver Cirrhosis; Hepatic Encephalopathy; Portal Hypertension,Rifaximin (DRUG); Lactulose (DRUG); Lactulose Placebo (DRUG); Rifaximin Placebo (DRUG),6436173,Normix,Liver Cirrhosis; Hepatic Encephalopathy; Portal Hypertension,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8751,NCT00731679,Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS),COMPLETED,PHASE3,Non-Constipation Irritable Bowel Syndrome,Rifaximin (DRUG); Placebo (DRUG),6436173,Normix,Non-Constipation Irritable Bowel Syndrome,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8752,NCT04074421,Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D,UNKNOWN,PHASE4,IBS - Irritable Bowel Syndrome; Gut Microbiota,Rifaximin (DRUG); Probiotic Formula (DRUG); Placebo oral tablet (DRUG),6436173,Normix,IBS - Irritable Bowel Syndrome; Gut Microbiota,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8753,NCT02240121,One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease,TERMINATED,PHASE3,Crohn's Disease,Rifaximin EIR (DRUG); Placebo (DRUG),6436173,Normix,Crohn's Disease,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8754,NCT00281502,The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy,UNKNOWN,PHASE2,Hepatic Encephalopathy; Hepatitis C; Liver Cirrhosis,Rifaximin (drug) (DRUG),6436173,Normix,Hepatic Encephalopathy; Hepatitis C; Liver Cirrhosis,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8755,NCT02019784,Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy,COMPLETED,PHASE4,"Liver Cirrhosis; Hepatoencephalopathy, Early Fatal Progressive",Rifaximin-α (DRUG); Placebo Oral Tablet (DRUG),6436173,Normix,"Liver Cirrhosis; Hepatoencephalopathy, Early Fatal Progressive",Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8756,NCT02240108,One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease,TERMINATED,PHASE3,Crohn's Disease,Rifaximin EIR (DRUG); Placebo (DRUG),6436173,Normix,Crohn's Disease,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8757,NCT02190357,Rifaximin Reduces the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial,UNKNOWN,PHASE4,Cirrhosis,Rifaximin (DRUG),6436173,Normix,Cirrhosis,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8758,NCT03585257,HEAL STUDY (Hepatic Encephalopathy and Albumin Study),COMPLETED,PHASE2,Cirrhosis; Hepatic Encephalopathy; Minimal Hepatic Encephalopathy; Covert Hepatic Encephalopathy,25% IV albumin (BIOLOGICAL); Placebo (OTHER),6436173,Normix,Cirrhosis; Hepatic Encephalopathy; Minimal Hepatic Encephalopathy; Covert Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8759,NCT05297448,Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis,ACTIVE_NOT_RECRUITING,PHASE3,Hepatic Encephalopathy,Rifaximin SSD (DRUG); Placebo (DRUG),6436173,Normix,Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8760,NCT04154735,Autologous Transplant Targeted Against Crohn's,WITHDRAWN,PHASE2,Crohn's Disease,Fludarabine (DRUG); Cyclophosphamide (DRUG); Mesna (DRUG); Alemtuzumab (DRUG); G-CSF (DRUG); Rifaximin (DRUG); Tacrolimus (DRUG),6436173,Normix,Crohn's Disease,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8761,NCT02334163,The Effects of Nitazoxanide in Hepatic Encephalopathy,UNKNOWN,PHASE2,Hepatic Encephalopathy,Nitazoxanide (DRUG); Oral lactulose (DRUG); Metronidazole (DRUG); Rifaximine (DRUG),6436173,Normix,Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8762,NCT01846663,"Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy",TERMINATED,PHASE4,Hepatic Encephalopathy,Placebo (DRUG); Rifaximin (DRUG),6436173,Normix,Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8763,NCT02255617,Fecal Microbiota Transplantation (FMT) in the Management of Hepatic Encephalopathy (HE): a Pilot Study,COMPLETED,PHASE1,Hepatic Encephalopathy,Fecal Microbiota Transplant (BIOLOGICAL),6436173,Normix,Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8764,NCT02120196,Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis,UNKNOWN,PHASE3,Spontaneous Bacterial Peritonitis; Ascites; Liver Cirrhosis,Rifaximin (DRUG); Norfloxacin (DRUG),6436173,Normix,Spontaneous Bacterial Peritonitis; Ascites; Liver Cirrhosis,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8765,NCT05786859,The Efficacy and Safety of Rifaximin Treatment,RECRUITING,EARLY_PHASE1,"Liver Failure, Acute on Chronic; Hepatic Encephalopathy; HBV; Hepatitis B; Rifaximin; Effect of Drug",Rifaximin 200 mg (DRUG); Standard Treatment without Rifaximin (OTHER),6436173,Normix,"Liver Failure, Acute on Chronic; Hepatic Encephalopathy; HBV; Hepatitis B; Rifaximin; Effect of Drug",Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8766,NCT03856359,Trial of Rifaximin in Probable Alzheimer's Disease,COMPLETED,PHASE2,Alzheimer's Disease,Rifaximin 550 milligrams (MG) (DRUG),6436173,Normix,Alzheimer's Disease,CNS/Brain,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8767,NCT03945487,Mesenchymal Stem Cells Treatment for Decompensated Liver Cirrhosis,UNKNOWN,PHASE2,Decompensated Liver Cirrhosis,umbilical cord-derived mesenchymal stem cell (BIOLOGICAL); Comprehensive treatment (OTHER),6436173,Normix,Decompensated Liver Cirrhosis,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8768,NCT04736836,Microbial Resistance of Rifaximin in Hepatic Encephalopathy,COMPLETED,PHASE4,Hepatic Encephalopathy,Rifaximin (DRUG),6436173,Normix,Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8769,NCT01904409,Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis,COMPLETED,PHASE2,Liver Cirrhosis,Placebo (DRUG); Rifaximin SSD 40 mg IR tablet (DRUG); Rifaximin SSD 80 mg IR tablet (DRUG); Rifaximin SSD 40 mg SER tablet (DRUG); Rifaximin SSD 80 mg SER tablet (DRUG); Rifaximin SSD 80mgIR/80mgSER tablet (DRUG),6436173,Normix,Liver Cirrhosis,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8770,NCT01069133,Study of Rifaximin in Minimal Hepatic Encephalopathy,COMPLETED,PHASE1,Minimal Hepatic Encephalopathy,Rifaximin (DRUG); rifaximin (DRUG),6436173,Normix,Minimal Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8771,NCT04244877,Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility,WITHDRAWN,PHASE3,"Cirrhosis, Liver; Minimal Hepatic Encephalopathy; Small Intestinal Bacterial Overgrowth; Gastrointestinal Motility Disorder",Rifaximin (DRUG),6436173,Normix,"Cirrhosis, Liver; Minimal Hepatic Encephalopathy; Small Intestinal Bacterial Overgrowth; Gastrointestinal Motility Disorder",Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8772,NCT04161053,Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy,RECRUITING,PHASE3,Hepatic Encephalopathy,Rifaximin (DRUG); Nitazoxanide (DRUG),6436173,Normix,Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8773,NCT06783153,Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients,NOT_YET_RECRUITING,PHASE1,"Radiotherapy Induced Diarrhea; Acute Radiation Enteritis; Prostate Cancer; Cervical Adenocarcinoma; Bladder (Urothelial, Transitional Cell) Cancer; Rectal Adenocarcinoma; Pelvic Radiotherapy; Rifaximin",Rifaximin 550 MG (DRUG); Standard Care Chemoradiation (DRUG),6436173,Normix,"Radiotherapy Induced Diarrhea; Acute Radiation Enteritis; Prostate Cancer; Cervical Adenocarcinoma; Bladder (Urothelial, Transitional Cell) Cancer; Rectal Adenocarcinoma; Pelvic Radiotherapy; Rifaximin",Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8774,NCT03911037,GCSF Therapy in Decompensated Cirrhosis - A Double Blinded RCT,UNKNOWN,PHASE2,Decompensated Cirrhosis of Liver,G-CSF (DRUG); Placebo (DRUG),6436173,Normix,Decompensated Cirrhosis of Liver,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8775,NCT04557215,Efficacy and Safety of Rifaximin With NAC in IBS-D,COMPLETED,PHASE1,Irritable Bowel Syndrome With Diarrhea,Rifaximin (DRUG); N-acetylcysteine (DRUG); Placebo (DRUG),6436173,Normix,Irritable Bowel Syndrome With Diarrhea,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8776,NCT02116556,Effects of Rifaximin in Patients With Acute Alcoholic Hepatitis,UNKNOWN,PHASE2,Alcoholic Hepatitis,Prednisone (DRUG); Rifaximin (DRUG),6436173,Normix,Alcoholic Hepatitis,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8777,NCT01722578,L-ornithine L-aspartate in Overt Hepatic Encephalopathy,COMPLETED,PHASE4,Cirrhosis of Liver; Hepatic Encephalopathy,L-ornithine L-aspartate (DRUG); Placebo (DRUG),6436173,Normix,Cirrhosis of Liver; Hepatic Encephalopathy,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8778,NCT06298409,Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®,RECRUITING,PHASE1,Small Intestinal Bacterial Overgrowth,CapScan collection capsule (DEVICE),6436173,Normix,Small Intestinal Bacterial Overgrowth,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8779,NCT03557788,Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome,COMPLETED,PHASE4,Irritable Bowel Syndrome With Diarrhea,Rifaximin Oral Tablet (DRUG),6436173,Normix,Irritable Bowel Syndrome With Diarrhea,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8780,NCT02620007,Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease,TERMINATED,PHASE2,Crohn Disease; Adherent-invasive E. Coli,Ciprofloxacin (DRUG); Rifaximin (DRUG); Ciprofloxacin Placebo (DRUG); Rifaximin Placebo (DRUG),6436173,Normix,Crohn Disease; Adherent-invasive E. Coli,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8781,NCT05253287,Growth Hormone in Decompensated Liver Cirrhosis,UNKNOWN,PHASE2,Liver Cirrhosis; Fibrosis; End Stage Liver Disease; Digestive System Disease; Physiological Effect of Drugs; Growth Hormone Treatment; Sarcopenia,Growth Hormone (DRUG),6436173,Normix,Liver Cirrhosis; Fibrosis; End Stage Liver Disease; Digestive System Disease; Physiological Effect of Drugs; Growth Hormone Treatment; Sarcopenia,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8782,NCT05150587,"Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea",COMPLETED,PHASE2,Papulopustular Rosacea,Rifaximin (DRUG); Placebo (DRUG),6436173,Normix,Papulopustular Rosacea,Skin,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8783,NCT03219528,A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing,COMPLETED,PHASE4,Irritable Bowel Syndrome,Rifaximin 550 MG (DRUG); Low FODMAP Diet (OTHER),6436173,Normix,Irritable Bowel Syndrome,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8784,NCT01359228,Rifaximin Treatment of Papulopustular Rosacea,WITHDRAWN,PHASE2,Rosacea,Rifaximin (XIFAXAN) (DRUG); Placebo (DRUG),6436173,Normix,Rosacea,Skin,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8785,NCT04043897,Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis,RECRUITING,PHASE2,Microscopic Colitis,Rifaximin 550mg (DRUG),6436173,Normix,Microscopic Colitis,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8786,NCT03185611,Effectiveness of Rifaximin Combined With Thiopurine on Preventing Postoperative Recurrence in Crohn's Disease,UNKNOWN,PHASE3,Crohn Disease,Rifaximin (DRUG); Azathioprine (DRUG),6436173,Normix,Crohn Disease,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8787,NCT03613545,Fecal Microbiota Transplantation for Irritable Bowel Syndrome,RECRUITING,PHASE2,Irritable Bowel Syndrome; Fecal Microbiota Transplantation,"fecal microbiota transplantation (PROCEDURE); Infusion of sham (PROCEDURE); probiotics, antibiotics or antidepressants (DRUG)",6436173,Normix,Irritable Bowel Syndrome; Fecal Microbiota Transplantation,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8788,NCT04730245,Microbiota Modification for the Treatment of Motor Complication of Parkinson´s Disease,COMPLETED,PHASE1,Parkinson's Disease Aggravated,"sodium phosphate enema, oral rifaximin and polyethylene glycol (DRUG)",6436173,Normix,Parkinson's Disease Aggravated,CNS/Brain,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8789,NCT01543178,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,COMPLETED,PHASE3,Irritable Bowel Syndrome With Diarrhea,open-label rifaximin (DRUG); double-blind placebo (DRUG); double-blind rifaximin (DRUG),6436173,Normix,Irritable Bowel Syndrome With Diarrhea,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8790,NCT03864978,Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test,UNKNOWN,PHASE2,Papulopustular Rosacea,Rifaximin delayed release 400 mg tablet (DRUG); Placebo (DRUG),6436173,Normix,Papulopustular Rosacea,Skin,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8791,NCT04249622,Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients with Stage I-III HER2 Positive Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Anatomic Stage I Breast Cancer AJCC V8; Anatomic Stage IA Breast Cancer AJCC V8; Anatomic Stage IB Breast Cancer AJCC V8; Anatomic Stage II Breast Cancer AJCC V8; Anatomic Stage IIA Breast Cancer AJCC V8; Anatomic Stage IIB Breast Cancer AJCC V8; Anatomic Stage III Breast Cancer AJCC V8; Anatomic Stage IIIA Breast Cancer AJCC V8; Anatomic Stage IIIB Breast Cancer AJCC V8; Anatomic Stage IIIC Breast Cancer AJCC V8; HER2 Positive Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC V8; Prognostic Stage IA Breast Cancer AJCC V8; Prognostic Stage IB Breast Cancer AJCC V8; Prognostic Stage II Breast Cancer AJCC V8; Prognostic Stage IIA Breast Cancer AJCC V8; Prognostic Stage IIB Breast Cancer AJCC V8; Prognostic Stage III Breast Cancer AJCC V8; Prognostic Stage IIIA Breast Cancer AJCC V8; Prognostic Stage IIIB Breast Cancer AJCC V8; Prognostic Stage IIIC Breast Cancer AJCC V8,Best Practice (OTHER); Questionnaire Administration (OTHER); Rifaximin (DRUG),6436173,Normix,Anatomic Stage I Breast Cancer AJCC V8; Anatomic Stage IA Breast Cancer AJCC V8; Anatomic Stage IB Breast Cancer AJCC V8; Anatomic Stage II Breast Cancer AJCC V8; Anatomic Stage IIA Breast Cancer AJCC V8; Anatomic Stage IIB Breast Cancer AJCC V8; Anatomic Stage III Breast Cancer AJCC V8; Anatomic Stage IIIA Breast Cancer AJCC V8; Anatomic Stage IIIB Breast Cancer AJCC V8; Anatomic Stage IIIC Breast Cancer AJCC V8; HER2 Positive Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC V8; Prognostic Stage IA Breast Cancer AJCC V8; Prognostic Stage IB Breast Cancer AJCC V8; Prognostic Stage II Breast Cancer AJCC V8; Prognostic Stage IIA Breast Cancer AJCC V8; Prognostic Stage IIB Breast Cancer AJCC V8; Prognostic Stage III Breast Cancer AJCC V8; Prognostic Stage IIIA Breast Cancer AJCC V8; Prognostic Stage IIIB Breast Cancer AJCC V8; Prognostic Stage IIIC Breast Cancer AJCC V8,Breast,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8792,NCT03529825,Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation,COMPLETED,EARLY_PHASE1,Microbial Colonization,Rifaximin (DRUG),6436173,Normix,Microbial Colonization,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8793,NCT03987893,PEG3350 in ACLF With Hepatic Encephalopathy,UNKNOWN,PHASE4,Hepatic Encephalopathy; Acute-On-Chronic Liver Failure,PEG-3350 with Electolytes (DRUG); Lactulose (DRUG),6436173,Normix,Hepatic Encephalopathy; Acute-On-Chronic Liver Failure,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8794,NCT02555293,Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection,TERMINATED,PHASE2,Malignant Liver Disease; Major Liver Resection,XIFAXAN® (Rifaximin) (DRUG),6436173,Normix,Malignant Liver Disease; Major Liver Resection,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8795,NCT03729271,Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea,RECRUITING,PHASE4,Irritable Bowel Syndrome; Irritable Bowel Syndrome With Diarrhea,Rifaximin (DRUG); Glucose and lactulose hydrogen breath testing (DEVICE),6436173,Normix,Irritable Bowel Syndrome; Irritable Bowel Syndrome With Diarrhea,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8796,NCT03658993,Rifaximin-treatment of Collagenous Colitis,UNKNOWN,PHASE3,Collagenous Colitis,Rifaximin 550 MG (DRUG),6436173,Normix,Collagenous Colitis,Bowel,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8797,NCT03415698,G-CSF in Decompensated Cirrhosis: an Open Label Trial,UNKNOWN,PHASE2,"Cirrhosis, Liver",G-CSF (DRUG); Standard Medical Therapy (DRUG),6436173,Normix,Liver Cirrhosis,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8798,NCT03695705,Rifaximin and Norfloxacin for Prevention of SBP in Adults With Decompensated Cirrhosis,COMPLETED,PHASE3,"Cirrhosis, Liver",Rifaximin 550 mg twice a day and Norfloxacin 400 mg once a day (DRUG),6436173,Normix,Liver Cirrhosis,Liver,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8799,NCT02738905,Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease,WITHDRAWN,EARLY_PHASE1,End Stage Renal Disease,Rifaximin (DRUG),6436173,Normix,End Stage Renal Disease,Kidney,Rifaximin,,unclear,unclear,yes,yes,Approved for treatment of IBS and hepatic encephalopathy.,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,1.01,395.0 +8800,NCT02759120,CleanUP IPF for the Pulmonary Trials Cooperative,TERMINATED,PHASE3,Idiopathic Pulmonary Fibrosis,Antimicrobial therapy: Co-trimoxazole or Doxycycline (DRUG); No Intervention: Standard of Care (OTHER),54684461,Adoxa,Idiopathic Pulmonary Fibrosis,Lung,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8801,NCT00439166,Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid,COMPLETED,PHASE3,Alzheimer's Disease,doxycycline (DRUG); rifampicin (DRUG); Placebo matched to doxycycline (DRUG); Placebo matched to Rifampin (DRUG),54684461,Adoxa,Alzheimer's Disease,CNS/Brain,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8802,NCT02753426,A Trial of Doxycycline in Renal Disease,COMPLETED,PHASE1,Chronic Kidney Disease; Cardiorenal Syndrome,Doxycycline (DRUG); Placebo (for Doxycycline) (DRUG),54684461,Adoxa,Chronic Kidney Disease; Cardiorenal Syndrome,Kidney,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8803,NCT03334682,Randomized Double-blind Study on the Benefit of Spironolactone for Treating Acne of Adult Woman.,COMPLETED,PHASE3,Acne Vulgaris,spironolactone (DRUG); Doxycycline (DRUG),54684461,Adoxa,Acne Vulgaris,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8804,NCT01590082,"Doxycycline, Temozolomide and Ipilimumab in Melanoma",TERMINATED,PHASE1,Melanoma,Doxycycline (DRUG); Ipilimumab (DRUG); Temozolomide (DRUG),54684461,Adoxa,Melanoma,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8805,NCT05399290,Subantimicrobial Doxycycline in Acne,COMPLETED,PHASE4,Acne Vulgaris; Pediatrics,Doxycycline Hyclate (DRUG),54684461,Adoxa,Acne Vulgaris; Pediatrics,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8806,NCT01474590,Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne,COMPLETED,PHASE3,Acne,Epiduo/Tactuo (DRUG); vehicle gel (OTHER); doxycycline 200mg (DRUG); Isotretinoin (DRUG),54684461,Adoxa,Acne,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8807,NCT01931150,Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT,COMPLETED,PHASE3,Cetuximab-induced Papulopustular (Acneiform) Rash Who Have; Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma,Topical Dapsone 5% Gel (DRUG); Moisturizer (OTHER); oral antibiotics (DRUG),54684461,Adoxa,Cetuximab-induced Papulopustular (Acneiform) Rash Who Have; Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma,Bowel,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8808,NCT05001750,Prophylactic Antibiotics Useful With Antibiotic Impregnated External Ventricular Drains (EVDs)?,RECRUITING,PHASE1,"Subarachnoid Hemorrhage; Intracerebral Hemorrhage; Ventriculitis, Cerebral; Hydrocephalus",long term prophylactic antibiotics (Nafcillin or Doxycycline) (DRUG),54684461,Adoxa,"Subarachnoid Hemorrhage; Intracerebral Hemorrhage; Ventriculitis, Cerebral; Hydrocephalus",CNS/Brain,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8809,NCT00612573,Treatment of Moderate to Severe Facial Acne Vulgaris,COMPLETED,PHASE2,Acne Vulgaris,Doxycycline 0.6 mg/kg/day (DRUG); Doxycycline 1.2 mg/kg/day (DRUG); Doxycycline 2.4 mg/kg/day (DRUG); Placebo (DRUG),54684461,Adoxa,Acne Vulgaris,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8810,NCT04206631,Comedone Extraction and Oral Doxycycline In The First Line Treatment of Moderate Acne Vulgaris,COMPLETED,PHASE1,Acne Vulgaris,Doxycycline Capsule (DRUG); Comedone extraction (PROCEDURE),54684461,Adoxa,Acne Vulgaris,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8811,NCT04297592,Antibiotic Prophylaxis in High-Risk Arthroplasty Patients,ENROLLING_BY_INVITATION,PHASE4,Infections Joint Prosthetic; Overweight or Obesity; MSSA Colonization; MRSA; Chronic Kidney Diseases; Diabetes; Autoimmune Diseases; Inflammatory Disease; Tobacco Use,Cephalexin (DRUG); Doxycycline (DRUG); Cefadroxil (DRUG),54684461,Adoxa,Infections Joint Prosthetic; Overweight or Obesity; MSSA Colonization; MRSA; Chronic Kidney Diseases; Diabetes; Autoimmune Diseases; Inflammatory Disease; Tobacco Use,Kidney,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8812,NCT06452394,NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline,NOT_YET_RECRUITING,PHASE2,Breast Cancer,Doxycyclin (DRUG),54684461,Adoxa,Breast Cancer,Breast,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8813,NCT01874860,Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients,COMPLETED,PHASE2,Colorectal Cancer; Head and Neck Cancer,Doxycycline (DRUG); Hydrocortisone 1% cream (DRUG); Sunscreen (OTHER); Moisturizer (OTHER); Clindamycin (DRUG); Medrol-dose pack (Steroid) (DRUG),54684461,Adoxa,Colorectal Cancer; Head and Neck Cancer,Bowel,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8814,NCT04447625,Intrauterine Antibiotic Infusion in Treating Chronic Endometritis and Restoring Reproductive Dynamics,COMPLETED,PHASE2,Chronic Endometritis,Oral antibiotic administration (DRUG); Intrauterine antibiotic infusion (DRUG),54684461,Adoxa,Chronic Endometritis,Uterus,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8815,NCT00170222,Placebo Versus Antibiotics in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE4,Chronic Obstructive Pulmonary Disease,doxycycline (DRUG),54684461,Adoxa,Chronic Obstructive Pulmonary Disease,Lung,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8816,NCT02874430,Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer,UNKNOWN,PHASE2,Breast Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Uterine Corpus Cancer; Uterine Corpus Carcinosarcoma,Metformin Hydrochloride (DRUG); Doxycycline (DRUG),54684461,Adoxa,Breast Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Uterine Corpus Cancer; Uterine Corpus Carcinosarcoma,Breast,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8817,NCT01345526,Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Reconval K1 Cream (DEVICE); Reconval Cream (DEVICE),54684461,Adoxa,Metastatic Colorectal Cancer,Bowel,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8818,NCT00715858,A Pilot Study of Inflammatory Markers in Alzheimer's Disease,UNKNOWN,PHASE3,Alzheimer's Disease,doxycycline (DRUG); rifampin (DRUG); placebo (DRUG),54684461,Adoxa,Alzheimer's Disease,CNS/Brain,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8819,NCT06120140,Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib,RECRUITING,PHASE2,"Carcinoma, Non-Small-Cell Lung",Amivantamab IV (DRUG); Amivantamab SC (DRUG); Lazertinib (DRUG); Doxycycline (DRUG); Minocycline (DRUG); Clindamycin (DRUG); Chlorhexidine (DRUG); Noncomedogenic skin moisturizer (OTHER); Ruxolitinib (OTHER); Tacrolimus (OTHER),54684461,Adoxa,"Carcinoma, Non-Small-Cell Lung",Lung,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8820,NCT06447480,Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients,RECRUITING,PHASE3,Acne Vulgaris,ISOtretinoin 5 MG (DRUG); Topical cream (DRUG),54684461,Adoxa,Acne Vulgaris,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8821,NCT05296629,"A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.",COMPLETED,PHASE3,Papulopustular Rosacea,DFD-29 (DRUG); Doxycycline (DRUG); Placebo (DRUG),54684461,Adoxa,Papulopustular Rosacea,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8822,NCT03075891,Oracea Soolantra Association in Participants With Severe Rosacea,COMPLETED,PHASE4,Rosacea,Ivermectin 1% cream (DRUG); Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules (DRUG); Oral placebo capsules (OTHER),54684461,Adoxa,Rosacea,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8823,NCT06693362,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses",RECRUITING,PHASE1,Severe Viral Pneumonia(Not Include COVID-19),Placebo (DRUG); Drug therapy (DRUG); Standard Treatment (OTHER),54684461,Adoxa,Severe Viral Pneumonia(Not Include COVID-19),Lung,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8824,NCT06252194,Comparative Study of Metformin Versus Doxycycline in Moderate to Severe Adult Acne Vulgaris Patients.,RECRUITING,PHASE2,Acne Vulgaris,Metformin and doxycycline (DRUG),54684461,Adoxa,Acne Vulgaris,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8825,NCT03986996,Antimicrobial Therapy for Ulcerative Colitis (UC),TERMINATED,PHASE2,Ulcerative Colitis,"amoxicillin, metronidazole and doxycycline (DRUG); amoxicillin and doxycyclin (DRUG)",54684461,Adoxa,Ulcerative Colitis,Bowel,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8826,NCT00332163,Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy,COMPLETED,PHASE2,Metastatic Colorectal Cancer; Skin Rash; Skin Toxicities; Colon Cancer; Colorectal Cancer,Panitumumab (BIOLOGICAL); Irinotecan (DRUG); FOLFIRI (DRUG); Pre-emptive Skin Treatment (DRUG); Reactive Skin Treatment (DRUG),54684461,Adoxa,Metastatic Colorectal Cancer; Skin Rash; Skin Toxicities; Colon Cancer; Colorectal Cancer,Bowel,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8827,NCT00246324,Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis,COMPLETED,PHASE4,Multiple Sclerosis,"Interferon beta 1a, oral doxycycline (DRUG)",54684461,Adoxa,Multiple Sclerosis,CNS/Brain,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8828,NCT03263273,Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea,COMPLETED,PHASE2,Rosacea; Papulopustular Rosacea,1% Topical Minocycline Gel (DRUG); 3% Topical Minocycline Gel (DRUG); Topical Vehicle Gel (OTHER),54684461,Adoxa,Rosacea; Papulopustular Rosacea,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8829,NCT01398072,Development of an Optimal Antibiotic Regime for Long-term Therapy in Stable Chronic Obstructive Pulmonary Disease (COPD),UNKNOWN,PHASE3,Chronic Obstructive Pulmonary Disease (COPD).,Moxifloxacin (DRUG); Azithromycin (DRUG); Doxycycline (DRUG); Placebo (DRUG),54684461,Adoxa,Chronic Obstructive Pulmonary Disease (COPD).,Lung,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8830,NCT02305940,Effects of Long Term Antibiotic Therapy on Exacerbation Rate in Stable COPD Patients,COMPLETED,PHASE3,Chronic Obstructive Pulmonary Disease (COPD),Doxycycline (DRUG); Placebo (DRUG),54684461,Adoxa,Chronic Obstructive Pulmonary Disease (COPD),Lung,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8831,NCT01245946,Photodynamic Therapy Compared to Adapalene 0.1% Gel Plus Doxycycline in the Treatment of Acne Vulgaris,COMPLETED,PHASE2,Acne,Photodynamic therapy (PROCEDURE); Conventional therapy (DRUG),54684461,Adoxa,Acne,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8832,NCT01426269,"Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo",COMPLETED,PHASE4,Rosacea,Doxycycline (DRUG); Metronidazole (DRUG); Placebo (DRUG),54684461,Adoxa,Rosacea,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8833,NCT01631617,Effects of Treatments on Atopic Dermatitis,RECRUITING,PHASE2,"Eczema; Dermatitis; Skin Diseases, Genetic; Dermatitis, Atopic; Skin Diseases",Trimethoprim/sulfamethoxazole (TMP/SMZ) (DRUG); Cephalexin (DRUG); Doxycycline (DRUG); Sodium hypochlorite (OTHER); Placebo capsules (OTHER); Placebo Sodium hypochlorite (OTHER),54684461,Adoxa,"Eczema; Dermatitis; Skin Diseases, Genetic; Dermatitis, Atopic; Skin Diseases",Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8834,NCT00531934,A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Doxycline (DRUG); erlotinib [Tarceva] (DRUG),54684461,Adoxa,Advanced Non-Small Cell Lung Cancer,Lung,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8835,NCT02913118,Adjunctive Therapy of Andrographolid Sulfonatein Community Acquired Pneumonia,UNKNOWN,PHASE4,Community Acquired Pneumonia,"Andrographolid Sulfonate Injection (AS Injection) (DRUG); Cephalosporin (DRUG); Azithromycin, Minocycline or Doxycycline (DRUG); Amoxicillin-clavulantic acid (DRUG); Fluoroquinolones (DRUG); Placebo (DRUG)",54684461,Adoxa,Community Acquired Pneumonia,Lung,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8836,NCT05492019,Effect of Doxycycline in Levodopa Treated Parkinson's Disease Patients,UNKNOWN,PHASE2,Parkinson Disease,Doxycycline (DRUG); Placebo (DRUG),54684461,Adoxa,Parkinson Disease,CNS/Brain,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8837,NCT01308619,Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo,COMPLETED,PHASE4,Rosacea,Doxycycline (DRUG); Placebo (OTHER),54684461,Adoxa,Rosacea,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8838,NCT03478436,Pharmacokinetics of Doxycycline in Skin of Healthy Volunteers,COMPLETED,PHASE1,Rosacea,Doxycycline (DRUG),54684461,Adoxa,Rosacea,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8839,NCT05343455,"A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)",COMPLETED,PHASE3,Papulopustular Rosacea,DFD-29 (DRUG); Doxycycline (DRUG); Placebo (DRUG),54684461,Adoxa,Papulopustular Rosacea,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8840,NCT03618108,Anti-chlamydophila Antibiotic Combination Therapy in the Treatment of Patients With Coronary Heart Disease,TERMINATED,PHASE2,Coronary Heart Disease; Chlamydophila Pneumoniae Infections,Doxycycline Capsule (DRUG); Azithromycin Capsule (DRUG); Rifabutin Oral Capsule (DRUG); Placebo oral capsule (DRUG); Placebo Oral Tablet (DRUG); Placebo oral capsule (DRUG),54684461,Adoxa,Coronary Heart Disease; Chlamydophila Pneumoniae Infections,Lung,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8841,NCT01885910,Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel,COMPLETED,PHASE4,Acne Vulgaris,Doxycycline 100mg (DRUG); Aczone 5% gel (DRUG),54684461,Adoxa,Acne Vulgaris,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8842,NCT04239755,Doxycycline in Acute Traumatic Brain Injury,COMPLETED,PHASE4,Traumatic Brain Injury,Doxycycline 100 MG Oral Tablet (DRUG); placebo (OTHER),54684461,Adoxa,Traumatic Brain Injury,CNS/Brain,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8843,NCT00687908,Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance,COMPLETED,PHASE3,Acne,Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel (DRUG); Vehicle Gel (DRUG),54684461,Adoxa,Acne,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8844,NCT00892281,ORCA - Oracea® for Rosacea: A Community-based Assessment,COMPLETED,PHASE4,Rosacea,doxycycline (Oracea®) 40 mg modified release as monotherapy (DRUG); doxycycline (Oracea®) 40 mg modified release as add-on therapy (DRUG),54684461,Adoxa,Rosacea,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8845,NCT01605864,Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia,COMPLETED,PHASE3,Community Acquired Bacterial Pneumonia,Efficacy of ceftaroline (DRUG),54684461,Adoxa,Community Acquired Bacterial Pneumonia,Lung,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8846,NCT00688064,Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris,COMPLETED,PHASE3,Severe Acne Vulgaris,Adapalene BPO Gel associated with Doxycyline Hyclate (DRUG); Vehicle Gel associated with Doxycycline Hyclate (DRUG),54684461,Adoxa,Severe Acne Vulgaris,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8847,NCT00857038,Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD),UNKNOWN,PHASE4,Chronic Obstructive Pulmonary Disease; Inflammation; Pulmonary Emphysema,Doxycycline (DRUG); Placebo (DRUG),54684461,Adoxa,Chronic Obstructive Pulmonary Disease; Inflammation; Pulmonary Emphysema,Lung,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8848,NCT02775695,Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer,COMPLETED,PHASE2,Resectable Pancreatic Cancer,Doxycycline (DRUG),54684461,Adoxa,Resectable Pancreatic Cancer,Pancreas,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8849,NCT00855595,Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea,COMPLETED,PHASE4,Papulopustular Rosacea,"Azelaic acid (Finacea, BAY39-6251) (DRUG); Metronidazole (Metrogel) (DRUG); Doxycycline (Oracea) (DRUG)",54684461,Adoxa,Papulopustular Rosacea,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8850,NCT02060149,The Effect of Nebulization of Alkaline Solution on Treating XDRAB Pneumonia With C/S Plus Minocycline,UNKNOWN,PHASE1,Pneumonia,C/S plus minocycline. (DRUG); nebulization with pH 7.4 solution (DRUG); nebulization with pH 7.8 solution (DRUG); No nebulization (DRUG),54684461,Adoxa,Pneumonia,Lung,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8851,NCT01418742,SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment,TERMINATED,PHASE2,Colorectal Carcinoma,"Panitumumab, Doxycycline/Placebo (DRUG); Panitumumab (DRUG)",54684461,Adoxa,Colorectal Carcinoma,Bowel,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8852,NCT01783106,Antibiotics and Hydroxychloroquine in Crohn's,COMPLETED,PHASE2,Crohn's Disease,Ciprofloxacin (DRUG); Doxycycline (DRUG); Hydroxychloroquine (DRUG); Budesonide (DRUG),54684461,Adoxa,Crohn's Disease,Bowel,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8853,NCT02422706,Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori,UNKNOWN,PHASE3,Helicobacter-associated Gastritis,Nitazoxanide (DRUG); Metronidazole(MTZ) (DRUG); Omeprazole (DRUG); Clarithromycin (DRUG); Levofloxacin (DRUG); Doxicycline (DRUG),54684461,Adoxa,Helicobacter-associated Gastritis,Esophagus/Stomach,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8854,NCT01465802,Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO,COMPLETED,PHASE2,Non Small Cell Lung Cancer (NSCLC),Dacomitinib (DRUG); Dacomitinib (DRUG); Doxycycline (DRUG); Probiotic (DRUG); Alclometasone cream (DRUG),54684461,Adoxa,Non Small Cell Lung Cancer (NSCLC),Lung,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8855,NCT01411202,Effectiveness of Doxycycline for Treating Pleural Effusions Related to Cancer in an Outpatient Population,UNKNOWN,PHASE2,Malignant Pleural Effusion,Doxycycline (DRUG); normal saline (OTHER),54684461,Adoxa,Malignant Pleural Effusion,Lung,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8856,NCT00419848,the Comparison Efficacy of Azithromycin With Doxycycline in the Treatment of Acne Vulgaris,UNKNOWN,PHASE2,Acne,Doxycycline (DRUG); Azithromycin (DRUG),54684461,Adoxa,Acne,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8857,NCT04864717,Doxycycline vs Isotretinoin for Acneiform Eruptions of TKI,UNKNOWN,PHASE4,"Acneiform Eruptions; Cancer, Treatment-Related",Doxycycline 100mg po once daily x 6 months (DRUG); Isotretinoin 40 mg po once daily x 6 months (DRUG),54684461,Adoxa,"Acneiform Eruptions; Cancer, Treatment-Related",Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8858,NCT00495313,Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens,COMPLETED,PHASE4,Rosacea,doxycycline (DRUG); doxycycline (DRUG),54684461,Adoxa,Rosacea,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8859,NCT00883818,Microorganism in Overactive Bladder Patients,COMPLETED,PHASE4,Overactive Bladder,"azithromycin, doxycycline (DRUG)",54684461,Adoxa,Overactive Bladder,Bladder/Urinary Tract,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8860,NCT02850913,Doxycycline for the Treatment of Nodding Syndrome,UNKNOWN,PHASE2,Seizures,Doxycycline (DRUG); Placebo (OTHER),54684461,Adoxa,Seizures,CNS/Brain,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8861,NCT00837213,Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne,COMPLETED,PHASE4,Acne,Benzoyl peroxide with clindamycin (DRUG); Benzoyl peroxide with clindamycin and doxycycline (DRUG),54684461,Adoxa,Acne,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8862,NCT06225570,Weekly Isotretinoin vs Tetracycline for Moderate Acne,RECRUITING,EARLY_PHASE1,Acne Vulgaris,Isotretinoin (DRUG); Tetracycline (DRUG),54684461,Adoxa,Acne Vulgaris,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8863,NCT02623959,Indwelling Pleural Catheter With Either Doxycycline or Saline at Day 7 for Pleurodesis,TERMINATED,PHASE4,Advanced Cancers; Malignant Pleural Effusions,Questionnaires (BEHAVIORAL); Fentanyl Patch (DRUG); Fentanyl (IV) (DRUG); Saline (OTHER); Doxycycline (DRUG); Phone Calls (BEHAVIORAL),54684461,Adoxa,Advanced Cancers; Malignant Pleural Effusions,Lung,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8864,NCT03457636,The Use of Oracea and Epiduo Forte in Severe Acne Patients,COMPLETED,PHASE4,Acne,Doxycycline Anhydrous 40 MG (DRUG); Adapalene/Benzoyl Peroxide Gel 0.3-2.5% (DRUG),54684461,Adoxa,Acne,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8865,NCT01872715,Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea,COMPLETED,PHASE4,Papulopustular Rosacea,Oracea (DRUG),54684461,Adoxa,Papulopustular Rosacea,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8866,NCT02345733,Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis,COMPLETED,PHASE4,Ulcerative Colitis (UC),Ulcerative Colitis Diet (OTHER); Antibiotic cocktail (DRUG),54684461,Adoxa,Ulcerative Colitis,Bowel,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8867,NCT05296837,Ocular Rosacea Biome Study,RECRUITING,PHASE4,Ocular Rosacea; Antimicrobial Resistance,Doxycycline 40 MG ( 20mg twice daily) (DRUG); Doxycycline 200 MG ( 100 mg twice daily) (DRUG); Placebo (DRUG),54684461,Adoxa,Ocular Rosacea; Antimicrobial Resistance,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8868,NCT02899000,A Treatment for Severe Inflammatory Acne Subjects,COMPLETED,PHASE4,Acne Vulgaris,Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel (DRUG); Oral doxycycline hyclate (DRUG),54684461,Adoxa,Acne Vulgaris,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8869,NCT03435952,Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT,ACTIVE_NOT_RECRUITING,PHASE1,Malignant Neoplasm of Breast; Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System; Malignant Neoplasms of Female Genital Organs; Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites; Malignant Neoplasms of Independent (Primary) Multiple Sites; Malignant Neoplasms of Lip Oral Cavity and Pharynx; Malignant Neoplasms of Male Genital Organs; Malignant Neoplasms of Mesothelial and Soft Tissue; Malignant Neoplasms of Respiratory and Intrathoracic Organs; Malignant Neoplasms of Thyroid and Other Endocrine Glands; Malignant Neoplasms of Urinary Tract,Pembrolizumab (DRUG); Clostridium Novyi-NT (BIOLOGICAL); Doxycycline (DRUG),54684461,Adoxa,Malignant Neoplasm of Breast; Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System; Malignant Neoplasms of Female Genital Organs; Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites; Malignant Neoplasms of Independent (Primary) Multiple Sites; Malignant Neoplasms of Lip Oral Cavity and Pharynx; Malignant Neoplasms of Male Genital Organs; Malignant Neoplasms of Mesothelial and Soft Tissue; Malignant Neoplasms of Respiratory and Intrathoracic Organs; Malignant Neoplasms of Thyroid and Other Endocrine Glands; Malignant Neoplasms of Urinary Tract,Breast,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8870,NCT06477185,"Characterization of Tuberculosis Associated Lung Fibrosis and Respiratory Impairment, and Prevention Using Doxycycline",RECRUITING,PHASE2,"Tuberculosis, Pulmonary",Doxycycline (DRUG); Placebo (DRUG),54684461,Adoxa,Pulmonary Tuberculosis,Lung,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8871,NCT00126399,A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea,COMPLETED,PHASE3,Rosacea,doxycycline (DRUG),54684461,Adoxa,Rosacea,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8872,NCT01320033,Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris,COMPLETED,PHASE2,Acne Vulgaris,CD2475/101 40 mg (DRUG); Doxycycline 100 mg (DRUG); Placebo (DRUG),54684461,Adoxa,Acne Vulgaris,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8873,NCT05894954,Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment,ACTIVE_NOT_RECRUITING,PHASE3,"Mild Cognitive Impairment; Dementia, Mild","Precision Medicine Approach (DIETARY_SUPPLEMENT); Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises (COMBINATION_PRODUCT); Standard-of-Care (BEHAVIORAL); Lifestyle including diet, exercise, stress management (BEHAVIORAL)",54684461,Adoxa,"Mild Cognitive Impairment; Dementia, Mild",CNS/Brain,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8874,NCT01880515,Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib),COMPLETED,PHASE2,Skin Rash; Lung Cancer,Tetracycline (DRUG),54684461,Adoxa,Skin Rash with Lung Cancer,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8875,NCT01788215,"Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome",COMPLETED,PHASE3,Polycystic Ovarian Syndrome (PCOS); Irregular Menstrual Cycles; Androgen Excess,doxycycline (DRUG); Sugar Pill (OTHER),54684461,Adoxa,Polycystic Ovarian Syndrome (PCOS); Irregular Menstrual Cycles; Androgen Excess,Ovary/Fallopian Tube,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8876,NCT02713607,Lipidome and Microbiome Profile of Acne,ACTIVE_NOT_RECRUITING,PHASE1,Acne Vulgaris,Doxycycline (DRUG),54684461,Adoxa,Acne Vulgaris,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8877,NCT00388778,The Effect of Doxycycline 100mg and Doxycycline 20mg in Treatment of Mild and Moderate Acne,UNKNOWN,PHASE2,Acne; Inflammation,Doxycycline (DRUG),54684461,Adoxa,Acne; Inflammation,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8878,NCT00635609,Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate,COMPLETED,PHASE4,Acne Vulgaris,Doxycycline hyclate (Doryx) (DRUG); Doxycycline hyclate (DRUG),54684461,Adoxa,Acne Vulgaris,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8879,NCT02554383,Efficacy of Antibiotics in Children With Acute Sinusitis: Which Subgroups Benefit?,COMPLETED,PHASE3,Sinusitis; Respiratory Tract Infections,Amoxicillin-clavulanate (DRUG); Placebo (DRUG),54684461,Adoxa,Sinusitis; Respiratory Tract Infections,Lung,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8880,NCT03340961,"A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules",COMPLETED,PHASE2,Rosacea,DFD-29 Extended Release Capsules (40 mg) (DRUG); DFD-29 Extended Release Capsules (20 mg) (DRUG); Oraycea® (doxycycline) Capsules (DRUG); Placebo Capsules (DRUG),54684461,Adoxa,Rosacea,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8881,NCT05205993,Εffectiveness of Intrauterine Antibiotic Administration for Treatment of Chronic Endometritis,UNKNOWN,PHASE2,Chronic Endometritis,Intrauterine infusion (DRUG); Oral administration (DRUG),54684461,Adoxa,Chronic Endometritis,Uterus,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8882,NCT04108897,Analysis of the Microbiome in Rosacea,RECRUITING,EARLY_PHASE1,Rosacea,Doxycycline (DRUG); Ivermectin Topical (DRUG),54684461,Adoxa,Rosacea,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8883,NCT06201793,Minocyclin in Ulcerative Colitis as Added on Therapy,RECRUITING,PHASE2,Inflammatory Bowel Diseases,Mesalazine (DRUG); Minocycline (DRUG),54684461,Adoxa,Inflammatory Bowel Diseases,Bowel,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8884,NCT01668498,Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer,COMPLETED,PHASE2,Ras-wildtype Colorectal Cancer,Erythromycin (DRUG); Doxycycline (DRUG),54684461,Adoxa,Ras-wildtype Colorectal Cancer,Bowel,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8885,NCT00041977,Determine the Effect of Administering Periostat(R) Twice Daily on Patients With Acne Rosacea,COMPLETED,PHASE3,Acne Rosacea,doxycycline hyclate 20 mg twice daily (DRUG),54684461,Adoxa,Acne Rosacea,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8886,NCT02606032,Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative Colitis,COMPLETED,PHASE2,Ulcerative Colitis,Metronidazole (DRUG); Doxycycline (DRUG); Terbinafine (DRUG); Placebo (DRUG),54684461,Adoxa,Ulcerative Colitis,Bowel,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8887,NCT04451330,A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV),COMPLETED,PHASE4,Acne Vulgaris,Trifarotene cream (DRUG); Doxycycline hyclate (DRUG); Trifarotene Vehicle (DRUG); Doxycycline Placebo (DRUG),54684461,Adoxa,Acne Vulgaris,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8888,NCT02910011,Topical NanoDox® for Atopic Dermatitis,COMPLETED,PHASE2,"Dermatitis, Atopic",Nanodox 1% (doxycycline monohydrate hydrogel) (DRUG),54684461,Adoxa,"Dermatitis, Atopic",Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8889,NCT04582383,Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne,RECRUITING,PHASE4,Acne,Spironolactone (DRUG); Doxycycline Hyclate (DRUG),54684461,Adoxa,Acne,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8890,NCT00952861,Antibiotics in Chronic Obstructive Pulmonary Disease (COPD),WITHDRAWN,PHASE4,"Pulmonary Disease, Chronic Obstructive",Doxycycline (DRUG); Placebo (matching) (DRUG),54684461,Adoxa,"Pulmonary Disease, Chronic Obstructive",Lung,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8891,NCT03655197,Lipidome and Microbiome Profile of the Eye in Rosacea,COMPLETED,EARLY_PHASE1,Rosacea; Ocular Rosacea; Cutaneous Rosacea,Doxycycline (DRUG),54684461,Adoxa,Rosacea; Ocular Rosacea; Cutaneous Rosacea,Skin,Doxycycline (monohydrate),"MMP7, MMP8, MMP9, MMP13, MMP14",inhibitor/antagonist,unclear,yes,yes,Approved antibiotic for bacterial infections.,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,1.2,128.0 +8892,NCT02570490,Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections,COMPLETED,PHASE3,Acute Bacterial Skin and Skin Structure Infections,sodium fusidate (DRUG); linezolid (DRUG),3000226,Taksta,Acute Bacterial Skin and Skin Structure Infections,Skin,Fusidic acid,,inhibitor/antagonist,unclear,yes,yes,Used topically and orally for bacterial infections.,CC1C2CCC3(C(C2(CCC1O)C)C(CC4C3(CC(C4=C(CCC=C(C)C)C(=O)O)OC(=O)C)C)O)C,1.02,156.0 +8893,NCT01113125,Scars After Central Venous Catheters,UNKNOWN,PHASE3,Hypertrophic Scars; Keloids,Betamethason-17-valerate and fusidic acid (DRUG); Fusidic Acid (DRUG),3000226,Taksta,Hypertrophic Scars; Keloids,Skin,Fusidic acid,,inhibitor/antagonist,unclear,yes,yes,Used topically and orally for bacterial infections.,CC1C2CCC3(C(C2(CCC1O)C)C(CC4C3(CC(C4=C(CCC=C(C)C)C(=O)O)OC(=O)C)C)O)C,1.02,156.0 +8894,NCT03395132,Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema,TERMINATED,PHASE3,Infected Atopic Dermatitis/Eczema,Fucicort® Lipid cream (DRUG); Fucidin® cream (DRUG); Fucicort® Lipid cream vehicle (DRUG); betamethasone (Lianbang Beisong®) cream (DRUG),3000226,Taksta,Infected Atopic Dermatitis/Eczema,Skin,Fusidic acid,,inhibitor/antagonist,unclear,yes,yes,Used topically and orally for bacterial infections.,CC1C2CCC3(C(C2(CCC1O)C)C(CC4C3(CC(C4=C(CCC=C(C)C)C(=O)O)OC(=O)C)C)O)C,1.02,156.0 +8895,NCT00718315,"A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.",COMPLETED,PHASE3,Non-Small Cell Lung Cancer,erlotinib [Tarceva] (DRUG); fusidic acid [Verutex] (DRUG); erythromycin [Eritex] (DRUG); Fisiogel (DRUG),3000226,Taksta,Advanced Non-Small Cell Lung Cancer,Lung,Fusidic acid,,inhibitor/antagonist,unclear,yes,yes,Used topically and orally for bacterial infections.,CC1C2CCC3(C(C2(CCC1O)C)C(CC4C3(CC(C4=C(CCC=C(C)C)C(=O)O)OC(=O)C)C)O)C,1.02,156.0 +8896,NCT05276973,Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Unresectable Fallopian Tube Endometrioid Adenocarcinoma; Unresectable Fallopian Tube High Grade Serous Adenocarcinoma; Unresectable Ovarian Endometrioid Adenocarcinoma; Unresectable Ovarian High Grade Serous Adenocarcinoma; Unresectable Primary Peritoneal Endometrioid Adenocarcinoma; Unresectable Primary Peritoneal High Grade Serous Adenocarcinoma,Biopsy (PROCEDURE); Carboplatin (DRUG); Ipatasertib (DRUG); Paclitaxel (DRUG),24788740,Ipatasertib,Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Unresectable Fallopian Tube Endometrioid Adenocarcinoma; Unresectable Fallopian Tube High Grade Serous Adenocarcinoma; Unresectable Ovarian Endometrioid Adenocarcinoma; Unresectable Ovarian High Grade Serous Adenocarcinoma; Unresectable Primary Peritoneal Endometrioid Adenocarcinoma; Unresectable Primary Peritoneal High Grade Serous Adenocarcinoma,Ovary/Fallopian Tube,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8897,NCT01896531,A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer,COMPLETED,PHASE2,Gastric Cancer,5-Fluorouracil (DRUG); Ipatasertib (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Placebo (DRUG),24788740,Ipatasertib,Gastric Cancer,Esophagus/Stomach,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8898,NCT04060862,A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer,TERMINATED,PHASE1,Breast Cancer,Ipatasertib (DRUG); Placebo (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG),24788740,Ipatasertib,Breast Cancer,Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8899,NCT03959891,"AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)",ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,Ipatasertib (DRUG); Fulvestrant (DRUG); Aromatase Inhibitor (DRUG); Palbociclib (DRUG),24788740,Ipatasertib,Breast Cancer,Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8900,NCT02430363,Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475,UNKNOWN,PHASE1,Glioblastoma,MK - 3475 (DRUG); Suppressor of the PI3K/Akt pathways (BIOLOGICAL),24788740,Ipatasertib,Glioblastoma,CNS/Brain,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8901,NCT03337724,"A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer",COMPLETED,PHASE3,Breast Cancer,Ipatasertib (DRUG); Paclitaxel (DRUG); Placebo (DRUG),24788740,Ipatasertib,Breast Cancer,Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8902,NCT05498896,Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC,ACTIVE_NOT_RECRUITING,PHASE2,Triple Negative Breast Cancer,Atezolizumab (DRUG); Ipatasertib (DRUG); Paclitaxel (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG),24788740,Ipatasertib,Triple Negative Breast Cancer,Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8903,NCT05172258,"Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck",ACTIVE_NOT_RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Hypopharyngeal Squamous Cell Carcinoma; Metastatic Laryngeal Squamous Cell Carcinoma; Metastatic Oral Cavity Squamous Cell Carcinoma; Metastatic Oropharyngeal Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Oral Cavity Squamous Cell Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Stage IV Hypopharyngeal Carcinoma AJCC v8; Stage IV Laryngeal Cancer AJCC v8; Stage IV Lip and Oral Cavity Cancer AJCC v8; Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Ipatasertib (DRUG); Pembrolizumab (BIOLOGICAL),24788740,Ipatasertib,Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Hypopharyngeal Squamous Cell Carcinoma; Metastatic Laryngeal Squamous Cell Carcinoma; Metastatic Oral Cavity Squamous Cell Carcinoma; Metastatic Oropharyngeal Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Oral Cavity Squamous Cell Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Stage IV Hypopharyngeal Carcinoma AJCC v8; Stage IV Laryngeal Cancer AJCC v8; Stage IV Lip and Oral Cavity Cancer AJCC v8; Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8,Skin,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8904,NCT04650581,Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Ipatasertib (DRUG); Fulvestrant (DRUG); Placebo (OTHER),24788740,Ipatasertib,Breast Cancer,Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8905,NCT04434040,Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA),ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer; Triple Negative Breast Cancer; Residual Cancer; Circulating Tumor DNA,Atezolizumab (DRUG); Sacituzumab govitecan (DRUG),24788740,Ipatasertib,Breast Cancer; Triple Negative Breast Cancer; Residual Cancer; Circulating Tumor DNA,Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8906,NCT04920708,"Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression",RECRUITING,PHASE2,Metastatic Breast Cancer; ER+ Breast Cancer; Advanced Breast Cancer,Ipatasertib 300mg (DRUG); Fulvestrant 500g (DRUG); Palbociclib 75mg-125mg (DRUG); CDK4/6 Inhibitor (DRUG),24788740,Ipatasertib,Metastatic Breast Cancer; ER+ Breast Cancer; Advanced Breast Cancer,Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8907,NCT04177108,A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer,COMPLETED,PHASE3,Triple-Negative Breast Cancer,Atezolizumab (DRUG); Ipatasertib (DRUG); Paclitaxel (DRUG); Placebo for Atezolizumab (DRUG); Placebo for Ipatasertib (DRUG),24788740,Ipatasertib,Triple-Negative Breast Cancer,Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8908,NCT05180006,Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy,RECRUITING,PHASE2,Breast Cancer,Atezolizumab Injection (DRUG); Bevacizumab (DRUG); Pertuzumab (DRUG); Trastuzumab (DRUG),24788740,Ipatasertib,Breast Cancer,Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8909,NCT04931342,A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors,ACTIVE_NOT_RECRUITING,PHASE2,Ovarian Cancer,Ipatasertib (DRUG); Cobimetinib (DRUG); Trastuzumab Emtansine (DRUG); Atezolizumab (DRUG); Bevacizumab (DRUG); Paclitaxel (DRUG); Giredestrant (DRUG); Abemaciclib (DRUG); Inavolisib (DRUG); Palbociclib (DRUG); Letrozole (DRUG); Olaparib (DRUG); Luteinizing Hormone-Releasing Hormone (LHRH) Agonists (DRUG); Cyclophosphamide (DRUG); Inavolisib (DRUG),24788740,Ipatasertib,Ovarian Cancer,Ovary/Fallopian Tube,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8910,NCT03395899,Pre-operative Immunotherapy Combination Strategies in Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Estrogen Receptor-positive Breast Cancer,Atezolizumab (DRUG); Cobimetinib (DRUG); Ipatasertib (DRUG); Bevacizumab (DRUG),24788740,Ipatasertib,Breast Cancer; Estrogen Receptor-positive Breast Cancer,Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8911,NCT04739202,Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST),UNKNOWN,PHASE2,Gastric Adenocarcinoma; Metastatic Gastric Cancer; Metastatic Adenocarcinoma; Advanced Gastric Carcinoma,Atezolizumab + Ipatasertib (DRUG); Atezolizumab + Bevacizumab (DRUG),24788740,Ipatasertib,Gastric Adenocarcinoma; Metastatic Gastric Cancer; Metastatic Adenocarcinoma; Advanced Gastric Carcinoma,Esophagus/Stomach,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8912,NCT03341884,"A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants",COMPLETED,PHASE1,Hepatic Insufficiency,Ipatasertib (DRUG),24788740,Ipatasertib,Hepatic Insufficiency,Liver,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8913,NCT03280563,A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,COMPLETED,PHASE1,Breast Neoplasms,"Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody (DRUG); Bevacizumab (DRUG); Entinostat (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Ipatasertib (DRUG); Tamoxifen (DRUG); Abemaciclib (DRUG)",24788740,Ipatasertib,Breast Neoplasms,Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8914,NCT04561817,To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer,WITHDRAWN,PHASE2,Ovarian Neoplasms,Ipatasertib (DRUG); Paclitaxel (DRUG),24788740,Ipatasertib,Ovarian Neoplasms,Ovary/Fallopian Tube,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8915,NCT04802759,A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer,RECRUITING,PHASE1,"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer",Giredestrant (DRUG); Abemaciclib (DRUG); Ipatasertib (DRUG); Inavolisib (DRUG); Ribociclib (DRUG); Everolimus (DRUG); Samuraciclib (DRUG); PH FDC SC (DRUG); Palbociclib (DRUG); Atezolizumab (DRUG),24788740,Ipatasertib,"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer",Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8916,NCT03800836,A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer,COMPLETED,PHASE1,Breast Cancer,Ipatasertib (DRUG); Paclitaxel (DRUG); Atezolizumab (DRUG); Nab-Paclitaxel (DRUG); AC (DRUG),24788740,Ipatasertib,Breast Cancer,Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8917,NCT02162719,"A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors",COMPLETED,PHASE2,Breast Neoplasms,Ipatasertib (DRUG); Paclitaxel (DRUG); Placebo (DRUG),24788740,Ipatasertib,Breast Neoplasms,Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8918,NCT03840200,"A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.",COMPLETED,PHASE1,Breast Cancer; Prostate Cancer; Ovarian Cancer,Ipatasertib (DRUG); Rucaparib (DRUG),24788740,Ipatasertib,"Breast, Prostate, and Ovarian Cancers",Ovary/Fallopian Tube,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8919,NCT04486352,A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer,RECRUITING,PHASE1,Endometrial Cancer,Atezolizumab - 28 Day Cycle (DRUG); Bevacizumab (DRUG); Ipatasertib (DRUG); Talazoparib (DRUG); Trastuzumab emtansine (DRUG); Tiragolumab (DRUG); Atezolizumab - 21 Day Cycle (DRUG); Inavolisib (DRUG); Letrozole (DRUG); Giredestrant (DRUG); Abemaciclib (DRUG),24788740,Ipatasertib,Endometrial Cancer,Uterus,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8920,NCT05564377,"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial",RECRUITING,PHASE2,Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm,Alpelisib (DRUG); Binimetinib (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Fluorouracil (DRUG); Fulvestrant (DRUG); Ipatasertib (DRUG); Leucovorin (DRUG); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Mutation Carrier Screening (PROCEDURE); Neratinib Maleate (DRUG); Nilotinib Hydrochloride Monohydrate (DRUG); Olaparib (DRUG); Oxaliplatin (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Panitumumab (BIOLOGICAL); Positron Emission Tomography (PROCEDURE); Selumetinib Sulfate (DRUG); Sotorasib (DRUG),24788740,Ipatasertib,Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm,Ovary/Fallopian Tube,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8921,NCT02301988,A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Ipatasertib (DRUG); Paclitaxel (DRUG); Placebo (DRUG),24788740,Ipatasertib,Breast Cancer,Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8922,NCT03853707,"Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer",COMPLETED,PHASE1,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8,Atezolizumab (DRUG); Capecitabine (DRUG); Carboplatin (DRUG); Ipatasertib (DRUG); Paclitaxel (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),24788740,Ipatasertib,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8,Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8923,NCT03673787,A Trial of Ipatasertib in Combination With Atezolizumab,UNKNOWN,PHASE1,Solid Tumor; Glioblastoma Multiforme; Prostate Cancer Metastatic,ipatasertib (DRUG); Atezolizumab (DRUG),24788740,Ipatasertib,Solid Tumor; Glioblastoma Multiforme; Prostate Cancer Metastatic,CNS/Brain,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8924,NCT04253561,Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients,RECRUITING,PHASE1,Metastatic Breast Cancer,Ipatasertib (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG),24788740,Ipatasertib,Metastatic Breast Cancer,Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8925,NCT05332561,Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE),RECRUITING,PHASE2,Early-stage Breast Cancer,Atezolizumab 1200 mg in 20 ML Injection (DRUG); Inavolisib (DRUG); Ipatasertib (DRUG); Olaparib (DRUG); Sacituzumab govitecan (DRUG); Trastuzumab/pertuzumab (DRUG),24788740,Ipatasertib,Early-stage Breast Cancer,Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8926,NCT05172245,Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer,RECRUITING,PHASE1,Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Head and Neck Carcinoma of Unknown Primary; Locally Advanced Head and Neck Squamous Cell Carcinoma; Locally Advanced Hypopharyngeal Squamous Cell Carcinoma; Locally Advanced Laryngeal Squamous Cell Carcinoma; Locally Advanced Nasal Cavity Squamous Cell Carcinoma; Locally Advanced Oral Cavity Squamous Cell Carcinoma; Locally Advanced Oropharyngeal Squamous Cell Carcinoma; Locally Advanced Paranasal Sinus Squamous Cell Carcinoma; Locally Advanced Sinonasal Squamous Cell Carcinoma; Maxillary Sinus Squamous Cell Carcinoma; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage III Sinonasal Cancer AJCC v8; Stage IVA Hypopharyngeal Carcinoma AJCC v8; Stage IVA Laryngeal Cancer AJCC v8; Stage IVA Lip and Oral Cavity Cancer AJCC v8; Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVA Sinonasal Cancer AJCC v8; Stage IVB Hypopharyngeal Carcinoma AJCC v8; Stage IVB Laryngeal Cancer AJCC v8; Stage IVB Lip and Oral Cavity Cancer AJCC v8; Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVB Sinonasal Cancer AJCC v8,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Ipatasertib (DRUG); Magnetic Resonance Imaging (PROCEDURE); Positron Emission Tomography (PROCEDURE); Radiation Therapy (RADIATION),24788740,Ipatasertib,Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Head and Neck Carcinoma of Unknown Primary; Locally Advanced Head and Neck Squamous Cell Carcinoma; Locally Advanced Hypopharyngeal Squamous Cell Carcinoma; Locally Advanced Laryngeal Squamous Cell Carcinoma; Locally Advanced Nasal Cavity Squamous Cell Carcinoma; Locally Advanced Oral Cavity Squamous Cell Carcinoma; Locally Advanced Oropharyngeal Squamous Cell Carcinoma; Locally Advanced Paranasal Sinus Squamous Cell Carcinoma; Locally Advanced Sinonasal Squamous Cell Carcinoma; Maxillary Sinus Squamous Cell Carcinoma; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage III Sinonasal Cancer AJCC v8; Stage IVA Hypopharyngeal Carcinoma AJCC v8; Stage IVA Laryngeal Cancer AJCC v8; Stage IVA Lip and Oral Cavity Cancer AJCC v8; Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVA Sinonasal Cancer AJCC v8; Stage IVB Hypopharyngeal Carcinoma AJCC v8; Stage IVB Laryngeal Cancer AJCC v8; Stage IVB Lip and Oral Cavity Cancer AJCC v8; Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVB Sinonasal Cancer AJCC v8,Skin,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8927,NCT04464174,Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer,COMPLETED,PHASE2,Triple Negative Breast Cancer,Ipatasertib (DRUG); Capecitabine (DRUG); Eribulin (DRUG); Carboplatin (DRUG); Gemcitabine (DRUG),24788740,Ipatasertib,Triple Negative Breast Cancer,Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8928,NCT03337698,A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer),ACTIVE_NOT_RECRUITING,PHASE1,"Carcinoma, Non-Small-Cell Lung",Atezolizumab (DRUG); Cobimetinib (DRUG); RO6958688 (DRUG); Docetaxel (DRUG); CPI-444 (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG); Gemcitabine (DRUG); Linagliptin (DRUG); Tocilizumab (DRUG); Ipatasertib (DRUG); Bevacizumab (DRUG); Sacituzumab Govitecan (DRUG); Radiation (OTHER); Evolocumab (DRUG); Tiragolumab (DRUG); XL092 (DRUG); Camonsertib (DRUG),24788740,Ipatasertib,"Carcinoma, Non-Small-Cell Lung",Lung,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8929,NCT03424005,A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer,RECRUITING,PHASE1,Metastatic Breast Cancer,Capecitabine (DRUG); Atezolizumab (DRUG); Ipatasertib (DRUG); SGN-LIV1A (DRUG); Bevacizumab (DRUG); Chemotherapy (Gemcitabine + Carboplatin or Eribulin) (DRUG); Selicrelumab (DRUG); Tocilizumab (DRUG); Nab-Paclitaxel (DRUG); Sacituzumab Govitecan (DRUG); Abemaciclib (DRUG); Fulvestrant (DRUG); Ribociclib (dose #1) (DRUG); Inavolisib (dose #2) (DRUG); Trastuzumab Deruxtecan (DRUG); Ribociclib (dose #2) (DRUG); Letrozole (DRUG); Inavolisib (dose #1) (DRUG); Inavolisib (DRUG),24788740,Ipatasertib,Metastatic Breast Cancer,Breast,Ipatasertib,"AKT1, AKT2, AKT3",inhibitor/antagonist,PI3K/AKT inhibitor,no,yes,"Investigational cancer drug, not approved for human use.",CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,1.02,1090.0 +8930,NCT00002920,"S9630, Medroxyprogesterone in Treating Women With Breast Cancer",COMPLETED,PHASE3,Breast Cancer; Endometrial Cancer,medroxyprogesterone (DRUG); tamoxifen citrate (DRUG); adjuvant therapy (PROCEDURE),6279,Amen,Breast Cancer; Endometrial Cancer,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8931,NCT01148420,DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding,COMPLETED,PHASE4,Dysfunctional Uterine Bleeding,Medroxyprogesterone 17-Acetate (DRUG); medroxyprogesterone acetate (DRUG),6279,Amen,Dysfunctional Uterine Bleeding,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8932,NCT03991520,Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms,UNKNOWN,EARLY_PHASE1,Endometriosis; Anakinra; Markers of Inflammation,Anakinra 100Mg/0.67Ml Inj Syringe (DRUG); Placebo (DRUG),6279,Amen,Endometriosis,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8933,NCT06904274,A Study to Learn How Well Mirena Works as Compared to Oral Progestin in Nonatypical Endometrial Hyperplasia in Women Who Have Started Their Periods,NOT_YET_RECRUITING,PHASE3,Endometrial Hyperplasia,BAY865028 (COMBINATION_PRODUCT); Medroxyprogesterone acetate (DRUG),6279,Amen,Endometrial Hyperplasia,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8934,NCT00291369,Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis,COMPLETED,PHASE3,Metastatic Renal Cell Carcinoma,Interleukin-2 (DRUG); Interferon alfa (DRUG); medroxyprogesterone acetate (DRUG),6279,Amen,Metastatic Renal Cell Carcinoma,Kidney,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8935,NCT05651282,Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer,RECRUITING,PHASE4,Endometrium Cancer,Provera (DRUG),6279,Amen,Endometrium Cancer,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8936,NCT05247268,Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer,RECRUITING,PHASE2,Endometrial Neoplasm Malignant Stage I,Megestrol Acetate 160 MG Oral Tablet (DRUG); Medroxyprogesterone Acetate 500 MG (DRUG); Triprorelin Acetate (DRUG); Letrozole 2.5mg (DRUG),6279,Amen,Stage I Endometrial Cancer,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8937,NCT00066157,Alzheimer's Disease: Therapeutic Potential of Estrogen,COMPLETED,PHASE2,Alzheimer Disease,Transdermal estradiol (DRUG); Medroxyprogesterone (DRUG); Placebo Patch (DRUG); Placebo (DRUG),6279,Amen,Alzheimer Disease,CNS/Brain,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8938,NCT06671548,Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids,NOT_YET_RECRUITING,PHASE3,Heavy Menstrual Bleeding; Uterine Fibroids,Relugolix (DRUG); Relugolix placebo (DRUG),6279,Amen,Heavy Menstrual Bleeding; Uterine Fibroids,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8939,NCT00739830,Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6),COMPLETED,PHASE2,Endometrial Cancer,ridaforolimus (DRUG); medroxyprogesterone acetate tablets OR megestrol acetate (DRUG); chemotherapy (DRUG),6279,Amen,Endometrial Cancer,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8940,NCT03675139,MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia,COMPLETED,PHASE3,Endometrial Hyperplasia Without Atypia,Medroxyprogesterone Acetate (DRUG); Dydrogesterone 10 MG (DRUG),6279,Amen,Endometrial Hyperplasia Without Atypia,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8941,NCT00026286,Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer,COMPLETED,PHASE3,Breast Cancer; Hot Flashes; Menopausal Symptoms,conjugated estrogens (DRUG); medroxyprogesterone (DRUG),6279,Amen,Breast Cancer; Hot Flashes; Menopausal Symptoms,Breast,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8942,NCT00577122,Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer,COMPLETED,PHASE2,Estrogen Receptor-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer,Medroxyprogesterone progesterone acetate (MPA) (DRUG); Medroxyprogesterone with Cyclophosphamide + Methotrexate (DRUG),6279,Amen,Estrogen Receptor-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer,Breast,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8943,NCT02922348,Hormone Replacement for Premature Ovarian Insufficiency,WITHDRAWN,PHASE3,Primary Ovarian Insufficiency,Hormone Replacement Therapy (DRUG); Combined Oral Contraceptives (DRUG),6279,Amen,Primary Ovarian Insufficiency,Ovary/Fallopian Tube,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8944,NCT00416429,Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer,COMPLETED,PHASE3,Kidney Cancer,aldesleukin (BIOLOGICAL); recombinant interferon alpha-2a (BIOLOGICAL); medroxyprogesterone (DRUG),6279,Amen,Kidney Cancer,Kidney,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8945,NCT06102863,Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia,RECRUITING,PHASE2,Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I,statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day); (DRUG),6279,Amen,Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8946,NCT00033358,Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer,COMPLETED,PHASE2,Endometrial Cancer,medroxyprogesterone (DRUG); ethinyl estradiol (DRUG); norgestrel (DRUG); laboratory biomarker analysis (OTHER),6279,Amen,Endometrial Cancer,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8947,NCT00437658,Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis,COMPLETED,PHASE2,Endometriosis,Elagolix (DRUG); Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) (DRUG); Placebo to Elagolix (DRUG); Placebo to DMPA-SC (DRUG),6279,Amen,Endometriosis,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8948,NCT01074892,A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia,COMPLETED,PHASE4,Endometrial Hyperplasia,Provera (medroxyprogesterone/progestin) (DRUG); Provera (medroxyprogesterone) (DRUG); Mirena (levonorgestrel) (DEVICE),6279,Amen,Endometrial Hyperplasia,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8949,NCT05138367,Effects of UCA-PSCs in Women With POF,COMPLETED,PHASE1,Premature Ovarian Failure,transplantation of human UCA-PSCs or WJ-MSCs into ovaries of POF patients (PROCEDURE),6279,Amen,Premature Ovarian Failure,Ovary/Fallopian Tube,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8950,NCT02872818,Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia,COMPLETED,PHASE4,Apoptotic Signal Pathways in Endometrial Hyperplasia,17β estradiol hemihydrate (DRUG); Metformin (DRUG); medroxyprogesterone acetate (DRUG),6279,Amen,Apoptotic Signal Pathways in Endometrial Hyperplasia,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8951,NCT00370019,Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure,WITHDRAWN,PHASE2,Premature Ovarian Failure,Estradiol/Medroxyprogesterone acetate (DRUG),6279,Amen,Premature Ovarian Failure,Ovary/Fallopian Tube,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8952,NCT02228681,Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer,COMPLETED,PHASE2,"Advanced, Persistent, or Recurrent Endometrial Cancer",Everolimus (DRUG); Tamoxifen (DRUG); Letrozole (DRUG); Medroxyprogesterone Acetate (DRUG),6279,Amen,"Advanced, Persistent, or Recurrent Endometrial Cancer",Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8953,NCT03567655,Fertility-sparing Management Using High-dose Oral Progestin in Young Women With Endometrial Cancer,UNKNOWN,PHASE2,Endometrial Cancer,Farlutal tab. 500mg/ Pfizer (DRUG),6279,Amen,Endometrial Cancer,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8954,NCT04792749,Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial Cancer,UNKNOWN,PHASE3,Endometrial Cancer Stage I,Metformin (DRUG),6279,Amen,Endometrial Cancer Stage I,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8955,NCT01056042,Efficacy of Injectable Contraceptive and Oral Contraceptive Administered After Surgical Treatment of Endometriosis With Pain,COMPLETED,PHASE4,Endometriosis,"intramuscular depot medroxyprogesterone acetate (DRUG); ethinyl estradiol 30 micrograms, gestodene 75 micrograms (DRUG)",6279,Amen,Endometriosis,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8956,NCT01594879,Treatment With Medroxyprogesterone Acetate Plus LNG-IUS in Young Women With Early Stage Endometrial Cancer,UNKNOWN,PHASE2,Endometrial Cancer,"MIrena(LNG-IUS), oral MPA (DEVICE)",6279,Amen,Endometrial Cancer,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8957,NCT00003179,Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer,TERMINATED,PHASE2,Endometrial Cancer,medroxyprogesterone (DRUG),6279,Amen,Endometrial Cancer,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8958,NCT02103764,Efficacy of Cyclic DSG Compared With Cyclic MPA for the Treatment of Anovulatory DUB,UNKNOWN,PHASE3,Dysfunctional Uterine Bleeding,Desogestrel (DRUG); Medroxyprogesterone acetate (DRUG),6279,Amen,Dysfunctional Uterine Bleeding,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8959,NCT02335203,The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy,UNKNOWN,PHASE2,Grade 1 Endometrial Endometrioid Adenocarcinoma; Grade 2 Endometrial Endometrioid Adenocarcinoma; Complex Atypical Endometrial Hyperplasia,Depot medroxyprogesterone acetate (DRUG); Placebo (OTHER),6279,Amen,Grade 1 Endometrial Endometrioid Adenocarcinoma; Grade 2 Endometrial Endometrioid Adenocarcinoma; Complex Atypical Endometrial Hyperplasia,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8960,NCT01698164,Multi-centre Clinical Trial on Hormone Replacement Treatment in China,UNKNOWN,PHASE4,Menopausal Syndrome; Cardiovascular Disease; Osteoporosis; Breast Cancer,estradiol plus MPA (DRUG); Ximingting Tablet (DRUG); estradiol plus progesterone (DRUG),6279,Amen,Menopausal Syndrome; Cardiovascular Disease; Osteoporosis; Breast Cancer,Breast,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8961,NCT01776203,Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist,TERMINATED,PHASE4,Dysfunctional Uterine Bleeding,Medroxyprogesterone 17-Acetate (DRUG),6279,Amen,Dysfunctional Uterine Bleeding,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8962,NCT06145438,Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery,COMPLETED,PHASE3,Endometriosis Ovary,"Dienogest (DRUG); Depo Medroxyprogesterone acetate (DRUG); Leuprolide (as Leuprolide Acetate) (DRUG); Levonogestrel + etinilestradiol (30 mcg, brand name Mycrogynon) (DRUG)",6279,Amen,Endometriosis Ovary,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8963,NCT00123175,Treatment of Endometrial Hyperplasia With an Intrauterine Device (IUD),WITHDRAWN,PHASE1,Endometrial Hyperplasia,Intrauterine Device (DEVICE),6279,Amen,Endometrial Hyperplasia,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8964,NCT01791413,Effect of Pre-operative Depo Medroxyprogesterone Acetate on Serum Anti-mullerian Hormone Level After Laparoscopic Ovarian Cystectomy of Endometriomas,COMPLETED,PHASE1,Endometriosis,depot medroxyprogesterone acetate (DRUG),6279,Amen,Endometriosis,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8965,NCT01966575,Effect of Progestin-Induced Withdrawal Bleed on Ovulation Induction Cycles With Clomiphene Citrate,WITHDRAWN,PHASE4,Polycystic Ovary Syndrome; Infertility,Progestin (DRUG),6279,Amen,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8966,NCT05675787,Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia,RECRUITING,PHASE2,Atypical Endometrial Hyperplasia; Endometrial Carcinoma Stage I,Medroxyprogesterone acetate + Atorvastatin (DRUG),6279,Amen,Atypical Endometrial Hyperplasia; Endometrial Carcinoma Stage I,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8967,NCT05326087,Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A,NOT_YET_RECRUITING,PHASE3,Preimplantation Genetic Testing; Progestin-primed Ovarian Stimulation; Polycystic Ovarian Syndrome; GnRH Antagonist,GnRH antagonist (DRUG); MPA (DRUG),6279,Amen,Preimplantation Genetic Testing; Progestin-primed Ovarian Stimulation; Polycystic Ovarian Syndrome; GnRH Antagonist,Ovary/Fallopian Tube,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8968,NCT03463252,Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC,RECRUITING,PHASE2,Endometrial Cancer; Atypical Endometrial Hyperplasia,Progesterone (DRUG); Mirena® (DEVICE); GnRH agonist (DRUG),6279,Amen,Endometrial Cancer; Atypical Endometrial Hyperplasia,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8969,NCT01630252,PGL5001 Proof of Concept Study in Inflammatory Endometriosis,COMPLETED,PHASE2,Endometriosis,PGL5001 (DRUG); Placebo (DRUG); PGL5001 (DRUG); Placebo (DRUG); PGL5001 (DRUG),6279,Amen,Endometriosis,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8970,NCT05255653,Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features,RECRUITING,PHASE2,Endometrial Cancer,Olaparib (DRUG); Pelvic external beam radiotherapy (RADIATION); Chemotherapy (DRUG); Durvalumab (DRUG); Medroxyprogesterone Acetate (DRUG); Megestrol Acetate (DRUG); Vaginal brachytherapy (RADIATION); Observation (OTHER),6279,Amen,Endometrial Cancer,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8971,NCT06961188,Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis,NOT_YET_RECRUITING,PHASE3,Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity; Untreated With Systemic Therapy,Nano-crystalline Megestrol Acetate Oral Suspension (DRUG); Standard Therapy (OTHER),6279,Amen,Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity; Untreated With Systemic Therapy,Lung,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8972,NCT02534688,Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients,COMPLETED,PHASE4,Endometriosis,LNG-IUS (DRUG); DMPA (DRUG),6279,Amen,Endometriosis,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8973,NCT06914297,TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC,RECRUITING,PHASE2,Endometrial Cancer,TQB2450 injection + oral progestin (DRUG),6279,Amen,Endometrial Cancer,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8974,NCT02990728,Mirena® ± Metformin as Fertility-preserving Treatment for Young Asian Women With Early Endometrial Cancer,UNKNOWN,PHASE2,Endometrial Cancer,Metformin (DRUG); Mirena® (DEVICE),6279,Amen,Endometrial Cancer,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8975,NCT06942377,Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy,NOT_YET_RECRUITING,PHASE2,Endometrial Cancer; Atypical Endometrial Hyperplasia,Amlodipine (DRUG),6279,Amen,Endometrial Cancer; Atypical Endometrial Hyperplasia,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8976,NCT02064725,Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA,UNKNOWN,PHASE2,Recurrent or Persistent Endometrial Carcinoma,Sodium cridanimod (DRUG),6279,Amen,Recurrent or Persistent Endometrial Carcinoma,Uterus,Medroxyprogesterone acetate,PGR,unclear,unclear,yes,yes,Approved as a contraceptive and for hormone therapy.,CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,1.31,142.0 +8977,NCT03667157,Liver Function After Intravenous Methylprednisolone Administration,COMPLETED,PHASE4,"Graves Disease; Graves Ophthalmopathy; Liver Diseases; Liver Failure; Liver Injury; Liver Dysfunction; Liver Insufficiency; Acute Liver Failure; Acute Liver Injury; Acute Liver Injury, Drug Induced; Methylprednisolone Adverse Reaction; Glucocorticoids Toxicity; Dysthyroid Orbitopathy; Dysthyroid Ophthalmopathy",every week IVMP therapy (DRUG); very high doses IVMP therapy (DRUG),16923,s6588,"Graves Disease; Graves Ophthalmopathy; Liver Diseases; Liver Failure; Liver Injury; Liver Dysfunction; Liver Insufficiency; Acute Liver Failure; Acute Liver Injury; Acute Liver Injury, Drug Induced; Methylprednisolone Adverse Reaction; Glucocorticoids Toxicity; Dysthyroid Orbitopathy; Dysthyroid Ophthalmopathy",Liver,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8978,NCT00410657,Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant,COMPLETED,PHASE2,Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor,alemtuzumab (BIOLOGICAL); methylprednisolone (DRUG); prednisone (DRUG); flow cytometry (OTHER); immunologic technique (OTHER); pharmacological study (OTHER),16923,s6588,Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor,Breast,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8979,NCT06635720,REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE),RECRUITING,PHASE3,"Nephrotic Syndrome in Children; Nephrotic Syndrome, Minimal Change; Nephrotic Syndrome; Nephrotic Syndrome，idiopathic",Prednisone (DRUG),16923,s6588,"Nephrotic Syndrome in Children; Nephrotic Syndrome, Minimal Change; Nephrotic Syndrome; Nephrotic Syndrome，idiopathic",Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8980,NCT06223074,Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration,ENROLLING_BY_INVITATION,PHASE2,Multiple Sclerosis Relapsing Remitting; Treatment,IV Methylprednisolone administration (OTHER); Nasal Methylprednisolone (MT) (DRUG),16923,s6588,Multiple Sclerosis Relapsing Remitting; Treatment,CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8981,NCT01838174,A Trial of Neuroprotection With ACTH in Acute Optic Neuritis,TERMINATED,PHASE4,Multiple Sclerosis,ACTHAR Gel (ACTH) (DRUG); IV methylprednisolone (steroids) (DRUG),16923,s6588,Multiple Sclerosis,CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8982,NCT00421174,Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403),COMPLETED,PHASE3,Pneumonia; Idiopathic Pneumonia Syndrome,Etanercept (DRUG); Placebo plus corticosteroid (DRUG),16923,s6588,Pneumonia; Idiopathic Pneumonia Syndrome,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8983,NCT02772965,Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy,COMPLETED,PHASE3,Pediatric Crohn's Disease,Methotrexate (DRUG); Sugar pill (placebo) (OTHER),16923,s6588,Pediatric Crohn's Disease,Bowel,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8984,NCT04847674,A Study to Test if TEV-53275 is Effective in Relieving Asthma,TERMINATED,PHASE2,Asthma,TEV-53275 Dose A (DRUG); TEV-53275 Dose B (DRUG); Placebo (DRUG),16923,s6588,Asthma,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8985,NCT00413920,"Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant Recipients",COMPLETED,PHASE3,Renal Transplantation,Enteric-coated mycophenolate sodium (EC-MPS) (DRUG); Prednisone (DRUG),16923,s6588,Renal Transplantation,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8986,NCT02645565,Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis,COMPLETED,PHASE4,Lupus Nephritis,Cyclophosphamide (DRUG); Azathioprine (DRUG); Methylprednisolone (DRUG),16923,s6588,Lupus Nephritis,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8987,NCT00492466,Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies,COMPLETED,PHASE4,Relapsing-Remitting Multiple Sclerosis,Interferon-beta-1a (DRUG); methylprednisolone (DRUG),16923,s6588,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8988,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,COMPLETED,PHASE4,Relapsing-remitting Multiple Sclerosis,Interferon-beta-1a (Avonex) plus methylprednisolone (DRUG),16923,s6588,Relapsing-remitting Multiple Sclerosis,CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8989,NCT00623766,Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases,COMPLETED,PHASE2,Melanoma,Ipilimumab (DRUG); Corticosteroid: Betamethasone (DRUG); Corticosteroid: Dexamethasone (DRUG); Corticosteroid: Fludrocortisone (DRUG); Corticosteroid: Hydrocortisone (DRUG); Corticosteroid: Meprednisone (DRUG); Corticosteroid: Methylprednisolone (DRUG); Corticosteroid: Prednisolone (DRUG); Corticosteroid: Prednisone (DRUG); Corticosteroid: Triamcinolone (DRUG),16923,s6588,Melanoma,Skin,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8990,NCT01381874,A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy,COMPLETED,PHASE2,Metastatic ER+ Her2- Breast Cancer; Postmenopausal,Exemestane (DRUG); Abiraterone acetate + Prednisone/ Prednisolone + Exemestane (DRUG); Abiraterone acetate + Prednisone or Prednisolone (DRUG),16923,s6588,Metastatic ER+ Her2- Breast Cancer; Postmenopausal,Breast,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8991,NCT01529320,Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers,COMPLETED,PHASE1,Allergic Contact Eczema,"Adventan® (methylprednisolone aceponate 0,1%) (DRUG)",16923,s6588,Allergic Contact Eczema,Skin,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8992,NCT03828682,Veloxis de Novo Kidney Transplant ECSWD,UNKNOWN,PHASE4,Kidney Transplantation; Immunosuppression,Tacrolimus Extended Release Oral Tablet [Envarsus] (DRUG); Mycophenolate Mofetil (DRUG); Mycophenolic Acid Oral Product (DRUG); Tacrolimus (DRUG); Methylprednisolone (DRUG); Prednisone (DRUG); Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin] (DRUG),16923,s6588,Kidney Transplantation; Immunosuppression,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8993,NCT01856257,"Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen",TERMINATED,PHASE2,Primary Renal Allograft Candidate; Kidney Transplantation,Anti-thymocyte Globulin (Rabbit) (BIOLOGICAL); belatacept (BIOLOGICAL); methylprednisolone (DRUG); basiliximab (BIOLOGICAL); mycophenolate mofetil (DRUG); tacrolimus (DRUG),16923,s6588,Primary Renal Allograft Candidate; Kidney Transplantation,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8994,NCT01039103,Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS),TERMINATED,PHASE2,Acute Exacerbation of Remitting Relapsing Multiple Sclerosis; Clinically Isolated Syndrome,PEG-liposomal prednisolone sodium phosphate (DRUG); Methylprednisolone (DRUG),16923,s6588,Acute Exacerbation of Remitting Relapsing Multiple Sclerosis; Clinically Isolated Syndrome,CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8995,NCT01752790,Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease,WITHDRAWN,PHASE4,Pediatric Crohn's Disease,Top-down (DRUG); Step-up (DRUG),16923,s6588,Pediatric Crohn's Disease,Bowel,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8996,NCT05824390,"A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy",UNKNOWN,PHASE4,IgA Nephropathy,rituximab group (DRUG),16923,s6588,Kidney Diseases,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8997,NCT01430403,Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations,COMPLETED,PHASE4,Asthma,Omalizumab (BIOLOGICAL); Inhaled Corticosteroid Boost Therapy (ICS) (DRUG); Placebo omalizumab (BIOLOGICAL); Placebo fluticasone (BIOLOGICAL),16923,s6588,Asthma,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8998,NCT01742338,Dose of Corticosteroids in COPD,TERMINATED,PHASE4,COPD,Low Dose Corticosteroids (DRUG); High Dose Corticosteroids (DRUG),16923,s6588,COPD,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +8999,NCT01105650,"Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer",COMPLETED,PHASE2,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Breast Cancer,Fludarabine (DRUG); Cyclophosphamide (DRUG); Cyclosporine (DRUG); Natural killer cells (BIOLOGICAL); IL-2 (DRUG); Methylprednisolone (DRUG); Methylprednisolone (DRUG); Interleukin-2 (DRUG),16923,s6588,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Breast Cancer,Breast,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9000,NCT04420195,Envarsus XR in Lung Transplant,COMPLETED,PHASE2,Lung Transplant,Extended-Release Tacrolimus (DRUG); Immediate-Release Tacrolimus (DRUG),16923,s6588,Lung Transplant,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9001,NCT05401812,Glucocorticoid Therapy for Acute Respiratory Distress Syndrome,WITHDRAWN,PHASE2,Acute Respiratory Distress Syndrome,Intravenous glucocorticoid therapy (DRUG),16923,s6588,Acute Respiratory Distress Syndrome,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9002,NCT00000146,Optic Neuritis Treatment Trial (ONTT),UNKNOWN,PHASE3,Multiple Sclerosis; Optic Neuritis,Methylprednisolone (DRUG); Prednisone (DRUG),16923,s6588,Multiple Sclerosis; Optic Neuritis,CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9003,NCT05843968,Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome,RECRUITING,PHASE2,Nephrotic Syndrome in Children,Rituximab (DRUG); Mycophenolate Mofetil (DRUG),16923,s6588,Nephrotic Syndrome in Children,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9004,NCT01524068,"A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations",WITHDRAWN,PHASE2,Idiopathic Pulmonary Fibrosis,"Standard Steroid Treatment (DRUG); The Standard Steroid Treatment, Plasma Exchange and rituximab (DRUG)",16923,s6588,Idiopathic Pulmonary Fibrosis,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9005,NCT02351427,Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney Transplantation,UNKNOWN,PHASE3,Kidney Transplantation,Bortezomib (DRUG); Steroid (DRUG),16923,s6588,Kidney Transplantation,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9006,NCT06956482,PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis,NOT_YET_RECRUITING,PHASE3,Alcoholic Hepatitis,N-Acetylcysteine (NAC) Treatment (DRUG); Prednisolone (DRUG); Placebo of N-acetylcysteine (DRUG); Placebo of Prednisolone (DRUG); Prednisolone (DRUG),16923,s6588,Alcoholic Hepatitis,Liver,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9007,NCT04988282,Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung Disease,COMPLETED,PHASE4,Covid19; COVID-19 Pneumonia; Interstitial Lung Disease,Methylprednisolone Tablet (DRUG),16923,s6588,Covid19; COVID-19 Pneumonia; Interstitial Lung Disease,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9008,NCT04146220,Efficacy of Lower Dose Prednisolone in the Induction of Remission of Lupus Nephritis,COMPLETED,PHASE4,Lupus Nephritis,Prednisolone (DRUG),16923,s6588,Lupus Nephritis,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9009,NCT00627731,Oral Glucocorticosteroid in the Treatment of Severe Asthma Exacerbation in Hospitalized Patients,COMPLETED,PHASE4,Asthma,methylprednisolone sodium succinate (mPSL) (DRUG); prednisolone (PSL) (DRUG),16923,s6588,Asthma,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9010,NCT00933231,Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts,COMPLETED,PHASE3,Kidney Transplantation,tacrolimus (DRUG); tacrolimus (DRUG); Simulect (BIOLOGICAL); Cellcept (DRUG); Corticosteroids (DRUG); Ramipril (DRUG); Irbesartan (DRUG),16923,s6588,Kidney Transplantation,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9011,NCT04977960,Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19,UNKNOWN,PHASE2,COVID-19 Acute Respiratory Distress Syndrome,Potassium Canrenoate (DRUG),16923,s6588,COVID-19 Acute Respiratory Distress Syndrome,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9012,NCT01274260,Trial of Steroids in Pediatric Acute Lung Injury/ARDS,UNKNOWN,PHASE2,Acute Respiratory Distress Syndrome (ARDS); Acute Lung Injury (ALI),methylprednisolone (DRUG); Normal Saline (0.9%) (DRUG),16923,s6588,Acute Respiratory Distress Syndrome (ARDS); Acute Lung Injury (ALI),Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9013,NCT04467892,Low Versus High Corticosteroid Use in Ventilator Associated Pneumonia,COMPLETED,PHASE2,Ventilator Associated Pneumonia,methylprednisolone (DRUG); Methyl Prednisolonate (DRUG); ventilators (DEVICE),16923,s6588,Ventilator Associated Pneumonia,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9014,NCT03794492,Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome,COMPLETED,PHASE4,Kidney Transplant,Mycophenolate mofetil 500mg Tab. or 250mg Cap. (DRUG); Tacrolimus (DRUG); Methylprednisolone/prednisolone (DRUG); Basiliximab (DRUG),16923,s6588,Kidney Transplant,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9015,NCT01874860,Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients,COMPLETED,PHASE2,Colorectal Cancer; Head and Neck Cancer,Doxycycline (DRUG); Hydrocortisone 1% cream (DRUG); Sunscreen (OTHER); Moisturizer (OTHER); Clindamycin (DRUG); Medrol-dose pack (Steroid) (DRUG),16923,s6588,Colorectal Cancer; Head and Neck Cancer,Bowel,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9016,NCT00404794,A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis,COMPLETED,PHASE3,"Lupus Nephritis; Glomerulonephritis, Membranous",prednisolone and mycophenolate mofetil (DRUG); prednisolone and tacrolimus (DRUG),16923,s6588,"Lupus Nephritis; Glomerulonephritis, Membranous",Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9017,NCT00001212,Drug Therapy in Lupus Nephropathy,COMPLETED,PHASE2,Nephrotic Syndrome; Systemic Lupus Erythematosus,prednisone (DRUG); cyclophosphamide (DRUG); cyclosporin A (DRUG),16923,s6588,Nephrotic Syndrome; Systemic Lupus Erythematosus,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9018,NCT02523768,Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment,TERMINATED,PHASE4,Glomerulonephritis; IgAN,ATG-F (DRUG); Simulect (DRUG),16923,s6588,Glomerulonephritis; IgAN,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9019,NCT03661567,Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer,TERMINATED,PHASE2,Non-small Cell Lung Cancer,chest radiation (RADIATION); concurrent chemotherapy (DRUG); Methylprednisolone (DRUG),16923,s6588,Non-small Cell Lung Cancer,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9020,NCT00393367,Budesonide Inhalation Suspension for Acute Asthma in Children,COMPLETED,PHASE4,Asthma; Acute Asthma; Reactive Airway Exacerbation,"Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg (DRUG); Prednisolone, prednisone, or methylprednisolone (DRUG); Albuterol, ipratropium bromide (DRUG); Ipratropium bromide (DRUG)",16923,s6588,Asthma; Acute Asthma; Reactive Airway Exacerbation,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9021,NCT05587673,High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD),COMPLETED,PHASE1,Inflammatory Bowel Diseases; Crohn Disease; Ulcerative Colitis; Indeterminate Colitis,Methylprednisolone (DRUG),16923,s6588,Inflammatory Bowel Diseases; Crohn Disease; Ulcerative Colitis; Indeterminate Colitis,Bowel,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9022,NCT06870448,Methylprednisolone With Endovascular Thrombectomy for Large Ischemic Stroke,NOT_YET_RECRUITING,PHASE3,Acute Ischemic Stroke,Methyprednisolone sodium succinate (DRUG); Placebo (DRUG),16923,s6588,Acute Ischemic Stroke,CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9023,NCT04629248,A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy,ACTIVE_NOT_RECRUITING,PHASE3,Primary Membranous Nephropathy,Obinutuzumab (DRUG); Tacrolimus (DRUG); Methylprednisolone (DRUG); Acetaminophen (DRUG); Diphenhydramine (DRUG),16923,s6588,Primary Membranous Nephropathy,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9024,NCT04900948,Prevention of Development of Transcutaneous Sensitization in Children With Atopic Dermatitis During Their First Year of Life,COMPLETED,PHASE4,Atopic Dermatitis,Pimecrolimus cream 1% (DRUG); cream 0.1% methylprednisolone aceponate (DRUG),16923,s6588,Atopic Dermatitis,Skin,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9025,NCT05807048,Daratumumab in STK11 Mutated NSCLC,RECRUITING,PHASE2,Non-small Cell Lung Cancer With STK11/LKB1 Mutation,Daratumumab and Hyaluronidase-fihj (DRUG); Pre-Intervention Medication (DRUG); Post-Intervention Medication (DRUG),16923,s6588,Non-small Cell Lung Cancer With STK11/LKB1 Mutation,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9026,NCT01817322,Kidney Graft Function Under the Immunosuppression Strategies,COMPLETED,PHASE4,Chronic Renal Disease,Standard Dose of Myfortic and Reduced Dose of Myfortic (DRUG); Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group (DRUG); Basiliximab injected both control group and experimental group (DRUG),16923,s6588,Chronic Renal Disease,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9027,NCT04016025,A Clinical Study of Adherence to Methylprednisolone Aceponate in Different Carriers,COMPLETED,PHASE4,"Adherence, Patient; Chronic Eczema",Adherence to topical standard therapy assessed (BEHAVIORAL),16923,s6588,"Adherence, Patient; Chronic Eczema",Skin,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9028,NCT04408625,Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN),RECRUITING,PHASE1,Frontotemporal Dementia,LY3884963 (BIOLOGICAL); Methylprednisolone (DRUG); Optional Sirolimus (DRUG); Optional Prednisone (DRUG),16923,s6588,Frontotemporal Dementia,CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9029,NCT05232825,"A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis",ACTIVE_NOT_RECRUITING,PHASE3,Relapsing Multiple Sclerosis; Primary Progressive Multiple Sclerosis,Ocrelizumab IV (DRUG); Ocrelizumab SC (DRUG); Methylprednisolone IV (DRUG); Diphenhydramine IV (DRUG); Dexamethasone given orally (DRUG); Desloratadine given orally (DRUG),16923,s6588,Relapsing Multiple Sclerosis; Primary Progressive Multiple Sclerosis,CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9030,NCT03698630,Single Dose Oral Dexamethasone Versus Multi-dose Prednisolone in the Treatment of Acute Exacerbations of Asthma in Children,COMPLETED,PHASE4,Asthma; Acute Asthma,Prednisolone Sodium Phosphate (DRUG); Dexamethasone (DRUG),16923,s6588,Asthma,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9031,NCT00000730,Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients,TERMINATED,PHASE3,"Pneumonia, Pneumocystis Carinii; HIV Infections",Trimetrexate glucuronate (DRUG); Methylprednisolone (DRUG); Pentamidine isethionate (DRUG); Sulfamethoxazole-Trimethoprim (DRUG); Leucovorin calcium (DRUG),16923,s6588,"Pneumonia, Pneumocystis Carinii; HIV Infections",Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9032,NCT00446030,Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms,Docetaxel (DRUG); Doxorubicin (DRUG); Carboplatin (DRUG); Cyclophosphamide (DRUG); Trastuzumab (DRUG); Bevacizumab (DRUG),16923,s6588,Breast Neoplasms,Breast,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9033,NCT01639339,Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis,COMPLETED,PHASE3,Lupus Nephritis,Placebo plus standard therapy (BIOLOGICAL); Belimumab 10 mg/kg plus standard therapy (BIOLOGICAL); Standard therapy (DRUG),16923,s6588,Lupus Nephritis,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9034,NCT00600639,Non-Invasive Mechanical Ventilation in Elderly Patients,TERMINATED,PHASE4,Acute Respiratory Failure,"Non-invasive mechanical ventilation using a BiPAP Vision or any other ICU ventilators with NIV option (DEVICE); standard medical therapy plus oxygen that includes salbutamol, prednisolone and antibiotics as needed (DRUG); standard medical therapy that includes salbutamol, prednisolone and antibiotics as needed (DRUG)",16923,s6588,Acute Respiratory Failure,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9035,NCT02137239,Regimen Optimization Study,COMPLETED,PHASE2,Kidney Transplantation,Thymoglobulin (DRUG); Belatacept (DRUG); mycophenolate mofetil(MMF) (DRUG); Corticosteroids (DRUG); Everolimus(EVL) (DRUG); Tacrolimus(TAC) (DRUG),16923,s6588,Kidney Transplantation,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9036,NCT05627557,A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome,ACTIVE_NOT_RECRUITING,PHASE3,Childhood Idiopathic Nephrotic Syndrome,Obinutuzumab (DRUG); MMF (DRUG); Prednisone (DRUG); Methylprednisolone (DRUG); Acetaminophen/ Paracetamol (DRUG); Diphenhydramine Hydrochloride (DRUG),16923,s6588,Childhood Idiopathic Nephrotic Syndrome,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9037,NCT05969522,Stratified Therapy on Pediatric AAGN,RECRUITING,PHASE4,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; ANCA-Associated Glomerulonephritis,GlucoCorticoid (DRUG),16923,s6588,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; ANCA-Associated Glomerulonephritis,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9038,NCT02048358,"Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients",TERMINATED,PHASE1,Healthy Volunteers; Multiple Sclerosis,2B3-201 (DRUG); Placebo (DRUG); Methylprednisolone hemisuccinate (DRUG),16923,s6588,Healthy Volunteers; Multiple Sclerosis,CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9039,NCT03099122,A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant,COMPLETED,PHASE4,End-stage Renal Disease,Rabbit Anti-thymocyte Immunoglobulin (BIOLOGICAL); Tacrolimus (DRUG); Methylprednisolone (DRUG); Mycophenolate mofetil (DRUG); Mycophenolate Na (DRUG); prednisone (DRUG),16923,s6588,End-stage Renal Disease,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9040,NCT02909335,"De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study",WITHDRAWN,PHASE3,Liver Transplantation,"Tacrolimus (DRUG); Everolimus (DRUG); Mycophenolate mofetil (DRUG); Prednisolone, Prednisone or Methylprednisolone (DRUG)",16923,s6588,Liver Transplantation,Liver,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9041,NCT01281748,Evaluation Of The Efficacy Of Corticosteroids In Patients With An Acute Exacerbation Of Chronic Obstructive Pulmonary Disease Receiving Ventilator Support,TERMINATED,PHASE4,COPD,intravenous methylprednisolone (DRUG); intravenous normal saline solution (OTHER),16923,s6588,COPD,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9042,NCT00000596,Diffuse Fibrotic Lung Disease,COMPLETED,PHASE2,Lung Diseases; Pulmonary Fibrosis; Sarcoidosis,prednisone (DRUG); cyclophosphamide (DRUG); dapsone (DRUG),16923,s6588,Lung Diseases; Pulmonary Fibrosis; Sarcoidosis,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9043,NCT04343729,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,COMPLETED,PHASE2,SARS-CoV Infection; Severe Acute Respiratory Syndrome (SARS) Pneumonia,Methylprednisolone Sodium Succinate (DRUG); Placebo solution (DRUG),16923,s6588,SARS-CoV Infection; Severe Acute Respiratory Syndrome (SARS) Pneumonia,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9044,NCT05658692,Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome,UNKNOWN,PHASE4,Acute Respiratory Distress Syndrome,protective ventilation (DEVICE); prone position ventilation (BEHAVIORAL); glucocorticoid therapy (DRUG); restrictive fluid resuscitation (OTHER); Thymosin Alpha (BIOLOGICAL); Muscle relaxant therapy (DRUG); Integrated Chinese and Western Medicine Treatment (OTHER); statin therapy (DRUG); anti-infective treatment (COMBINATION_PRODUCT); Extracorporeal Membrane Oxygenation（ECMO） (DEVICE); stem cell therapy (GENETIC); Sedative analgesia/muscle relaxant therapy (DRUG); inotropes therapy (DRUG); Vasoactive drug therapy (DRUG),16923,s6588,Acute Respiratory Distress Syndrome,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9045,NCT02442180,Efficacy and Safety of G-CSF in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid,TERMINATED,PHASE3,Alcoholic Hepatitis,G-CSF (Filgrastim injection) (DRUG); steroid (DRUG); placebo (DRUG),16923,s6588,Alcoholic Hepatitis,Liver,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9046,NCT04438980,Glucocorticoids in COVID-19 (CORTIVID),COMPLETED,PHASE3,Covid-19 Pneumonia,Methylprednisolone (DRUG); Placebo (OTHER),16923,s6588,Covid-19 Pneumonia,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9047,NCT02444429,3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation,ACTIVE_NOT_RECRUITING,PHASE3,Renal Transplantation,Corticosteroid boluses Methylprednisolone (DRUG); No therapeutic modification (OTHER); Stop maintenance corticotherapy (OTHER),16923,s6588,Renal Transplantation,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9048,NCT02769689,Methylprednisolone During the Switch Between Natalizumab and Fingolimod,UNKNOWN,PHASE4,Multiple Sclerosis,Methylprednisolone (DRUG); Placebo (DRUG); natalizumab (NTZ) (DRUG); fingolimob (FTY) (DRUG),16923,s6588,Multiple Sclerosis,CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9049,NCT02583594,A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis,COMPLETED,PHASE1,Progressive Multiple Sclerosis,Acyclovir (DRUG); Methylprednisolone (DRUG); alemtuzumab GZ402673 (DRUG); alemtuzumab GZ402673 (DRUG); Paracetamol (DRUG); Loratadine (DRUG); Ceterizine (DRUG); Dexchlorpheniramine (DRUG),16923,s6588,Progressive Multiple Sclerosis,CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9050,NCT02005562,OPERA Study: A Study of Two Dosing Regimens of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.,COMPLETED,PHASE3,Kidney Transplantation,mycophenolate mofetil (DRUG); mycophenolate mofetil (DRUG); anti-IL-2R (DRUG); methylprednisolone (DRUG); cyclosporine (DRUG),16923,s6588,Kidney Transplantation,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9051,NCT01435291,AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation,COMPLETED,PHASE4,Renal Transplantation,Advagraf Capsule (DRUG); Prograf Capsule (DRUG),16923,s6588,Renal Transplantation,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9052,NCT05674994,Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis,RECRUITING,PHASE3,Acute Exacerbation of Idiopathic Pulmonary Fibrosis,Methylprednisone/Prednisone (DRUG); Placebo (OTHER),16923,s6588,Acute Exacerbation of Idiopathic Pulmonary Fibrosis,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9053,NCT02331862,To Study the Effect of Adjunctive Oral Methylprednisolone Therapy in Pediatric Urinary Tract Infection,UNKNOWN,PHASE3,Urinary Tract Infection,Methylprednisolone (DRUG),16923,s6588,Urinary Tract Infection,Bladder/Urinary Tract,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9054,NCT01729494,Belatacept Early Steroid Withdrawal Trial,COMPLETED,PHASE4,Renal Transplantation,Alemtuzumab (DRUG); rabbit antithymocyte globulin (DRUG); Belatacept (DRUG); Tacrolimus (DRUG); Mycophenolate mofetil (DRUG); early cessation of steroids (DRUG),16923,s6588,Renal Transplantation,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9055,NCT00240994,Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients,COMPLETED,PHASE2,"Kidney Failure, Chronic; Kidney Transplantation; Immunosuppression",Alemtuzumab (DRUG); Tacrolimus (DRUG); Mycophenolate mofetil (DRUG); Sirolimus (DRUG),16923,s6588,Chronic Kidney Failure and Transplantation,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9056,NCT00149994,Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients,COMPLETED,PHASE4,Liver Transplant,Cyclosporine A (DRUG); Tacrolimus (DRUG); Basiliximab (DRUG); Methylprednisolone (DRUG); Prednisone (DRUG),16923,s6588,Liver Transplant,Liver,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9057,NCT02578394,Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study,COMPLETED,PHASE2,Gout; Chronic Kidney Diseases,Anakinra 100mg and Placebo Depo-Medrone (DRUG); Depo-Medrone 120mg and Placebo (Anakinra) (DRUG),16923,s6588,Gout; Chronic Kidney Diseases,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9058,NCT05867329,Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis,RECRUITING,PHASE4,Ulcerative Colitis Acute,Cyclosporine Injection (IV) (DRUG); Cyclosporine Oral Product (DRUG); Upadacitinib Extended Release Oral Tablet (DRUG); Intravenous Methylprednisolone (DRUG); Prednisone Oral Product (DRUG),16923,s6588,Ulcerative Colitis Acute,Bowel,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9059,NCT04540380,Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH,RECRUITING,PHASE1,Renal Failure,"Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab (DRUG); Combined bone marrow and kidney transplant (PROCEDURE)",16923,s6588,Renal Failure,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9060,NCT00455286,a Phase II Study in Primary Central Nervous System Lymphoma,UNKNOWN,PHASE2,Primary Central Nervous System Lymphoma,Methotrexate (DRUG); Methylprednisolone (DRUG); Temozolomide (DRUG),16923,s6588,Primary Central Nervous System Lymphoma,CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9061,NCT01272635,Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids.,COMPLETED,PHASE3,Asthma; Wheezing,Azithromycin (DRUG); Prednisolone (DRUG); Placebo Azithromycin (OTHER); Placebo Prednisolone (DRUG),16923,s6588,Asthma; Wheezing,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9062,NCT02392286,Corticosteroid Dosage for Crohn's Disease Flare,TERMINATED,PHASE4,Crohn's Disease; Inflammatory Bowel Disease,Corticosteroid (DRUG),16923,s6588,Crohn's Disease; Inflammatory Bowel Disease,Bowel,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9063,NCT00493116,Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta,COMPLETED,PHASE4,Relapsing-Remitting Multiple Sclerosis,Interferon-beta-1a (DRUG); methylprednisolone (DRUG),16923,s6588,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9064,NCT06921616,Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Lobar Intracerebral Hemorrhage at the Early Stage.,NOT_YET_RECRUITING,PHASE4,Stroke; Intracerebral Hemorrhage Lobar; Methylprednisolone; Surgery,Simple neuroendoscopic hematoma evacuation (PROCEDURE); Neuroendoscopic hematoma evacuation combined with sodium methylprednisolone succinate (COMBINATION_PRODUCT),16923,s6588,Stroke; Intracerebral Hemorrhage Lobar; Methylprednisolone; Surgery,CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9065,NCT01773616,Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis,TERMINATED,PHASE3,"Systemic Lupus Erythematosus, Lupus Nephritis",Oral prednisolone (DRUG); Rituximab (DRUG); Mycophenolate mofetil (DRUG); Methyl prednisolone (DRUG),16923,s6588,"Systemic Lupus Erythematosus, Lupus Nephritis",Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9066,NCT04527016,Airway Microbiota Based Treatment of Asthma in Preschool Children,COMPLETED,PHASE4,Asthma in Children,Microbiota and eosinophils based therapy (PROCEDURE); Clinical guidelines based therapy (DRUG),16923,s6588,Pediatric Asthma,Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9067,NCT03018535,Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy,UNKNOWN,PHASE3,"Glomerulonephritis, Membranous",Rituximab (DRUG); Methylprednisolone (DRUG); Cyclophosphamide (DRUG),16923,s6588,Membranous Glomerulonephritis,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9068,NCT00084695,Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,UNKNOWN,PHASE2,"Childhood Langerhans Cell Histiocytosis; Fanconi Anemia; Leukemia; Lymphoma; Myelodysplastic Syndromes; Neuroblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific",anti-thymocyte globulin (BIOLOGICAL); busulfan (DRUG); cyclophosphamide (DRUG); fludarabine phosphate (DRUG); melphalan (DRUG); methylprednisolone (DRUG); radiation therapy (RADIATION),16923,s6588,"Childhood Langerhans Cell Histiocytosis; Fanconi Anemia; Leukemia; Lymphoma; Myelodysplastic Syndromes; Neuroblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific",CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9069,NCT06892210,Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD),NOT_YET_RECRUITING,PHASE4,Chronic Obstructive Pulmonary Disease (COPD),Methylprednisolone (drug) (DRUG); Hydrocortisone (DRUG),16923,s6588,Chronic Obstructive Pulmonary Disease (COPD),Lung,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9070,NCT00296244,Steroid Free Immunosuppression in Liver Transplantation,COMPLETED,PHASE4,Liver Cirrhosis; Liver Transplant Disorder,Steroids (DRUG); Basiliximab (DRUG); Tacrolimus (DRUG); Enteric-coated Mycophenolic acid (EC-MPA) (DRUG),16923,s6588,Liver Cirrhosis; Liver Transplant Disorder,Liver,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9071,NCT04933292,A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome,UNKNOWN,PHASE4,Autoimmune Hepatitis; Primary Biliary Cirrhosis,Methylprednisolone and Mycophenolate mofetil (DRUG); Methylprednisolone and azathioprine (DRUG),16923,s6588,Autoimmune Hepatitis; Primary Biliary Cirrhosis,Liver,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9072,NCT00617604,A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients,COMPLETED,PHASE2,De Novo Kidney Transplantation,Alefacept (DRUG); placebo (DRUG); Tacrolimus (DRUG); Mycophenolate Mofetil (DRUG); Steroids (DRUG),16923,s6588,De Novo Kidney Transplantation,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9073,NCT01560572,Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen,COMPLETED,PHASE4,Renal Insufficiency; Kidney Transplantation,"tacrolimus OD, mycophenolic acid, prednisolone (DRUG)",16923,s6588,Renal Insufficiency; Kidney Transplantation,Kidney,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9074,NCT01490840,Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis,TERMINATED,PHASE4,Fatigue in Multiple Sclerosis,Physical exercise (OTHER),16923,s6588,Fatigue in Multiple Sclerosis,CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9075,NCT03249844,Paediatric Arteriopathy Steroid Aspirin Project,WITHDRAWN,PHASE3,Arterial Ischemic Stroke,Methylprednisolone + prednisolone (DRUG),16923,s6588,Arterial Ischemic Stroke,CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9076,NCT01639040,Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD),COMPLETED,PHASE2,Atopic Dermatitis,Dupilumab (DRUG); Placebo (for Dupilumab) (DRUG); Topical Corticosteroid (TCS) (OTHER),16923,s6588,Atopic Dermatitis,Skin,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9077,NCT03266146,36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent DILI,COMPLETED,PHASE1,"Drug-induced Liver Injury,Chronic",36 Weeks Methylprednisolone (DRUG); 48 weeks Methylprednisolone (DRUG),16923,s6588,Chronic Drug-induced Liver Injury,Liver,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9078,NCT03387046,A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS),TERMINATED,PHASE2,"Multiple Sclerosis, Relapsing-Remitting",D-aspartate (DIETARY_SUPPLEMENT); Placebo (DRUG); IFN beta-1a (BIOLOGICAL); Methylprednisolone (DRUG),16923,s6588,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9079,NCT02784210,Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques,RECRUITING,PHASE2,Multiple Sclerosis,Methylprednisolone (DRUG); Prednisone (DRUG),16923,s6588,Multiple Sclerosis,CNS/Brain,Methylprednisolone succinate,NR3C1,unclear,Glucocorticoid receptor agonist,yes,yes,Corticosteroid; approved for reducing inflammation in various conditions.,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,1.0810810810810811,146.0 +9080,NCT01088763,"Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia",TERMINATED,PHASE1,"Childhood Atypical Teratoid/Rhabdoid Tumor; Childhood Central Nervous System Choriocarcinoma; Childhood Central Nervous System Germinoma; Childhood Central Nervous System Mixed Germ Cell Tumor; Childhood Central Nervous System Teratoma; Childhood Central Nervous System Yolk Sac Tumor; Childhood Choroid Plexus Tumor; Childhood Craniopharyngioma; Childhood Ependymoblastoma; Childhood Grade I Meningioma; Childhood Grade II Meningioma; Childhood Grade III Meningioma; Childhood Infratentorial Ependymoma; Childhood Medulloepithelioma; Childhood Mixed Glioma; Childhood Oligodendroglioma; Childhood Supratentorial Ependymoma; Gonadotroph Adenoma; Pituitary Basophilic Adenoma; Pituitary Chromophobe Adenoma; Pituitary Eosinophilic Adenoma; Prolactin Secreting Adenoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Central Nervous System Embryonal Tumor; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Childhood Spinal Cord Neoplasm; Recurrent Childhood Subependymal Giant Cell Astrocytoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Recurrent Childhood Visual Pathway and Hypothalamic Glioma; Recurrent Childhood Visual Pathway Glioma; Recurrent Pituitary Tumor; Recurrent/Refractory Childhood Hodgkin Lymphoma; T-cell Childhood Acute Lymphoblastic Leukemia; T-cell Large Granular Lymphocyte Leukemia; TSH Secreting Adenoma; Unspecified Childhood Solid Tumor, Protocol Specific",gamma-secretase/Notch signalling pathway inhibitor RO4929097 (DRUG); diagnostic laboratory biomarker analysis (OTHER); pharmacological study (OTHER); dexamethasone (DRUG),5743,Dxms,"Childhood Atypical Teratoid/Rhabdoid Tumor; Childhood Central Nervous System Choriocarcinoma; Childhood Central Nervous System Germinoma; Childhood Central Nervous System Mixed Germ Cell Tumor; Childhood Central Nervous System Teratoma; Childhood Central Nervous System Yolk Sac Tumor; Childhood Choroid Plexus Tumor; Childhood Craniopharyngioma; Childhood Ependymoblastoma; Childhood Grade I Meningioma; Childhood Grade II Meningioma; Childhood Grade III Meningioma; Childhood Infratentorial Ependymoma; Childhood Medulloepithelioma; Childhood Mixed Glioma; Childhood Oligodendroglioma; Childhood Supratentorial Ependymoma; Gonadotroph Adenoma; Pituitary Basophilic Adenoma; Pituitary Chromophobe Adenoma; Pituitary Eosinophilic Adenoma; Prolactin Secreting Adenoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Central Nervous System Embryonal Tumor; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Childhood Spinal Cord Neoplasm; Recurrent Childhood Subependymal Giant Cell Astrocytoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Recurrent Childhood Visual Pathway and Hypothalamic Glioma; Recurrent Childhood Visual Pathway Glioma; Recurrent Pituitary Tumor; Recurrent/Refractory Childhood Hodgkin Lymphoma; T-cell Childhood Acute Lymphoblastic Leukemia; T-cell Large Granular Lymphocyte Leukemia; TSH Secreting Adenoma; Unspecified Childhood Solid Tumor, Protocol Specific",CNS/Brain,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9081,NCT01525069,"Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma",TERMINATED,PHASE1,Cholangiocarcinoma; Liver Neoplasms,Floxuridine (DRUG); Dexamethasone (DRUG); Gemcitabine (DRUG); Oxaliplatin (DRUG),5743,Dxms,Cholangiocarcinoma; Liver Neoplasms,Liver,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9082,NCT00026234,Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver,COMPLETED,PHASE2,Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Liver Metastases; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer,floxuridine (DRUG); dexamethasone (DRUG); oxaliplatin (DRUG); capecitabine (DRUG),5743,Dxms,Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Liver Metastases; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer,Bowel,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9083,NCT02031965,Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery,TERMINATED,PHASE1,Recurrent Childhood Anaplastic Astrocytoma; Recurrent Childhood Anaplastic Oligoastrocytoma; Recurrent Childhood Anaplastic Oligodendroglioma; Recurrent Childhood Giant Cell Glioblastoma; Recurrent Childhood Glioblastoma; Recurrent Childhood Gliomatosis Cerebri; Recurrent Childhood Gliosarcoma,oncolytic HSV-1716 (BIOLOGICAL); dexamethasone (DRUG); therapeutic conventional surgery (PROCEDURE); laboratory biomarker analysis (OTHER),5743,Dxms,Recurrent Childhood Anaplastic Astrocytoma; Recurrent Childhood Anaplastic Oligoastrocytoma; Recurrent Childhood Anaplastic Oligodendroglioma; Recurrent Childhood Giant Cell Glioblastoma; Recurrent Childhood Glioblastoma; Recurrent Childhood Gliomatosis Cerebri; Recurrent Childhood Gliosarcoma,CNS/Brain,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9084,NCT00895245,"Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy",TERMINATED,PHASE2,Nausea and Vomiting; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx,fosaprepitant dimeglumine (DRUG); cisplatin (DRUG); palonosetron hydrochloride (DRUG); dexamethasone (DRUG); Functional Living Index-Emesis Questionnaire (OTHER); Emesis Diary (BEHAVIORAL); Radiotherapy (RADIATION),5743,Dxms,Nausea and Vomiting; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx,Skin,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9085,NCT00402766,"Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma",COMPLETED,PHASE1,Mesothelioma,Cisplatin (DRUG); Imatinib Mesylate (DRUG); Pemetrexed (DRUG); Dexamethasone (DRUG),5743,Dxms,Mesothelioma,Lung,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9086,NCT00088166,XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors,COMPLETED,PHASE3,Brain Edema; Brain Tumor,hCRF (DRUG); placebo hCRF (DRUG),5743,Dxms,Brain Edema; Brain Tumor,CNS/Brain,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9087,NCT04303065,Dexamethasone for the Treatment of Vasogenic Pericontusional Edema.,UNKNOWN,PHASE3,Traumatic Brain Injury; Cerebral Edema,Dexamethasone Oral (DRUG); Placebo oral tablet (DRUG),5743,Dxms,Traumatic Brain Injury; Cerebral Edema,CNS/Brain,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9088,NCT04452565,"NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection",UNKNOWN,PHASE2,Coronavirus Infection; Severe Acute Respiratory Infection; Severe Acute Respiratory Syndrome Coronavirus 2,Drug: NA-831 (DRUG); NA-831 and Atazanavir (COMBINATION_PRODUCT); NA-831and Dexamethasone (COMBINATION_PRODUCT); Atazanavir and Dexamethasone (COMBINATION_PRODUCT),5743,Dxms,Coronavirus Infection; Severe Acute Respiratory Infection; Severe Acute Respiratory Syndrome Coronavirus 2,Lung,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9089,NCT02234466,Preoperative Oral Dexamethasone to Improve Recovery After Surgery,UNKNOWN,PHASE2,Breast Cancer,Oral dexamethasone (DRUG); Ondansetron (DRUG); Gelatin capsule (OTHER),5743,Dxms,Breast Cancer,Breast,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9090,NCT00404066,Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer,COMPLETED,PHASE2,Breast Cancer; Metastatic Breast Cancer,Lapatinib (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Docetaxel (DRUG); Pegfilgrastim (DRUG); Filgrastim (DRUG); Dexamethasone (DRUG); Trastuzumab (DRUG),5743,Dxms,Breast Cancer; Metastatic Breast Cancer,Breast,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9091,NCT00923273,Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer,TERMINATED,PHASE1,"Carcinoma, Non-Small-Cell Lung",FDG-PET (DRUG); Pemetrexed (DRUG); Sirolimus (DRUG); Vitamin B12 (DIETARY_SUPPLEMENT); Folic acid tablets (DIETARY_SUPPLEMENT); Dexamethasone tablets (DRUG),5743,Dxms,"Carcinoma, Non-Small-Cell Lung",Lung,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9092,NCT03705273,Comparison of Dexamethasone Oral Preparations to Assess Taste and Acceptance in Children With Asthma and Croup,TERMINATED,PHASE4,Asthma; Croup,Dexamethasone IV for PO (DRUG); Dexamethasone crushed tablets (DRUG),5743,Dxms,Asthma; Croup,Lung,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9093,NCT03554473,M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers,COMPLETED,PHASE1,"Carcinoma, Small Cell; Lung Cancer; Small Cell Lung Cancer",M7824 (DRUG); Topotecan (DRUG); Temozolomide (DRUG); EKG (DIAGNOSTIC_TEST); CT scan (DIAGNOSTIC_TEST); PET scan (DIAGNOSTIC_TEST); Acetaminophen (DRUG); Antihistamines (DRUG); Diphenhydramine (DRUG); Dexamethasone (DRUG); Epinephrine (DRUG),5743,Dxms,"Carcinoma, Small Cell; Lung Cancer; Small Cell Lung Cancer",Lung,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9094,NCT06788912,Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01),RECRUITING,PHASE2,Lung Neoplasm Malignant,Pembrolizumab (neoadjuvant) (BIOLOGICAL); Cisplatin (DRUG); Gemcitabine (DRUG); Pemetrexed (DRUG); Sacituzumab tirumotecan (DRUG); Antihistamine (DRUG); H2 receptor antagonist (DRUG); Acetaminophen (or equivalent) (DRUG); Dexamethasone (or equivalent) (DRUG); Carboplatin (DRUG); Pembrolizumab (adjuvant) (BIOLOGICAL); Paclitaxel (DRUG); Steroid mouthwash (dexamethasone or equivalent) (DRUG),5743,Dxms,Lung Neoplasm Malignant,Lung,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9095,NCT05773664,Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma,WITHDRAWN,PHASE1,Glioblastoma; Malignant Glioma,Azeliragon (DRUG); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Dexamethasone (DRUG); Magnetic Resonance Imaging of the Brain with and without Contrast (PROCEDURE),5743,Dxms,Glioblastoma; Malignant Glioma,CNS/Brain,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9096,NCT02192827,Use of Dexamethasone in Pediatric Asthma Exacerbations,COMPLETED,PHASE3,Asthma,Dexamethasone Sodium Phosphate Injection (DRUG),5743,Dxms,Asthma,Lung,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9097,NCT02061631,Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck,COMPLETED,PHASE2,Squamous Cell Carcinoma of Head and Neck,Cisplatin (DRUG); DOCETAXEL XRP6976 (DRUG); Dexamethasone (DRUG); Dexamethasone (DRUG),5743,Dxms,Squamous Cell Carcinoma of Head and Neck,Skin,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9098,NCT03367572,Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer,COMPLETED,PHASE3,Breast Carcinoma,Dexamethasone (DRUG); Laboratory Biomarker Analysis (OTHER); Netupitant/Palonosetron Hydrochloride (DRUG); Olanzapine (DRUG); Placebo (OTHER); Prochlorperazine (DRUG); Quality-of-Life Assessment (OTHER),5743,Dxms,Breast Carcinoma,Breast,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9099,NCT04836780,DEXamethasone EARLY Administration in Hospitalized Patients With Covid-19 Pneumonia,UNKNOWN,PHASE3,"COVID-19; Acute Respiratory Distress Syndrome; Pneumonia, Viral",Dexamethasone (DRUG),5743,Dxms,"COVID-19; Acute Respiratory Distress Syndrome; Pneumonia, Viral",Lung,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9100,NCT03626922,Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients,UNKNOWN,PHASE1,Metastatic Colorectal Cancer,Pembrolizumab (DRUG); Pemetrexed (DRUG); Oxaliplatin (DRUG); Dexamethasone (DRUG); Folic Acid (DIETARY_SUPPLEMENT); Vitamin B-12 (DIETARY_SUPPLEMENT),5743,Dxms,Metastatic Colorectal Cancer,Bowel,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9101,NCT00003625,Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma,COMPLETED,PHASE1,Brain Tumors; Central Nervous System Tumors,cyclosporine (DRUG); etoposide (DRUG); vincristine sulfate (DRUG); radiation therapy (RADIATION),5743,Dxms,Brain Tumors; Central Nervous System Tumors,CNS/Brain,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9102,NCT03165825,Cervical Interlaminar Versus Transforaminal Epidural Steroid Injection,WITHDRAWN,PHASE4,Cervical Radiculopathy,Transforaminal Epidural Steroid Injection with Dexamethasone (DRUG); Interlaminar Epidural Steroid Injection with Betamethasone (DRUG),5743,Dxms,Cervical Radiculopathy,Cervix,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9103,NCT00967330,A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma,COMPLETED,PHASE2,Glioblastoma Multiforme,bevacizumab [Avastin] (DRUG); irinotecan (DRUG); temozolomide (DRUG),5743,Dxms,Glioblastoma Multiforme,CNS/Brain,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9104,NCT01332630,TPI 287 in Breast Cancer Metastatic to the Brain,COMPLETED,PHASE2,Breast Cancer,TPI 287 (DRUG); Dexamethasone (DRUG); Benadryl (DRUG); Ranitidine (DRUG),5743,Dxms,Breast Cancer,Breast,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9105,NCT05319730,A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B),RECRUITING,PHASE1,Esophageal Squamous Cell Carcinoma,Paclitaxel (DRUG); Irinotecan (DRUG); Pembrolizumab (BIOLOGICAL); MK-4830 (BIOLOGICAL); Lenvatinib (DRUG); Sacituzumab tirumotecan (BIOLOGICAL); Antihistamine (DRUG); H2 Receptor Antagonist (DRUG); Acetaminophen (or equivalent) (DRUG); Dexamethasone (or equivalent) (DRUG); Steroid Mouthwash (dexamethasone or equivalent) (DRUG); Supportive care measures (DRUG),5743,Dxms,Esophageal Squamous Cell Carcinoma,Skin,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9106,NCT03436225,Steroid Therapy in Acute Bronchiolitis A New Old Line of Therapy.,UNKNOWN,PHASE1,Bronchiolitis; Respiratory Syncytial Virus,Dexamethasone orally. (DRUG); Dexamethasone parenteral. (DRUG); Inhaled nebulized Budesonide. (DRUG); Inhaled nebulized salbutamol. (DRUG),5743,Dxms,Bronchiolitis; Respiratory Syncytial Virus,Lung,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9107,NCT02581839,Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate,COMPLETED,PHASE2,Metastatic Breast Cancer; Brain Metastases,Eribulin Mesylate (DRUG); MRI (DEVICE); Pre-Medication: Zofran (DRUG); Pre-Medication: Decadron (DRUG),5743,Dxms,Metastatic Breast Cancer; Brain Metastases,Breast,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9108,NCT02297230,Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics,TERMINATED,PHASE1,Breast Cancer,Radiation Therapy (RT) (RADIATION); Capecitabine (DRUG); Trastuzumab (DRUG); Paclitaxel (DRUG),5743,Dxms,Breast Cancer,Breast,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9109,NCT03348696,Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for TAPS in Breast Cancer Patients,COMPLETED,PHASE4,Early-stage Breast Cancer; Pain Syndrome,Dexamethasone tapering dose (DRUG); Dexamethasone physician choice (DRUG),5743,Dxms,Early-stage Breast Cancer; Pain Syndrome,Breast,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9110,NCT04082962,Dexamethasone Implant for Retinal Detachment in Uveal Melanoma,UNKNOWN,PHASE1,Exudative Retinal Detachment and Uveal Melanoma,Dexamethasone intravitreal implant (DRUG),5743,Dxms,Exudative Retinal Detachment and Uveal Melanoma,Skin,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9111,NCT01455389,TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer,TERMINATED,PHASE1,Lung Cancer,DOTAP:Chol-TUSC2 (DRUG); Erlotinib (DRUG); Dexamethasone (DRUG); Diphenhydramine (DRUG),5743,Dxms,Lung Cancer,Lung,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9112,NCT00011362,Dexamethasone Therapy in VLBW Infants at Risk of CLD,COMPLETED,PHASE3,"Infant, Newborn; Infant, Low Birth Weight; Infant, Small for Gestational Age; Infant, Premature; Bronchopulmonary Dysplasia",Dexamethasone Early (DRUG); Dexamethasone Late (DRUG),5743,Dxms,"Infant, Newborn; Infant, Low Birth Weight; Infant, Small for Gestational Age; Infant, Premature; Bronchopulmonary Dysplasia",Lung,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9113,NCT05096663,Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial),ACTIVE_NOT_RECRUITING,PHASE2,Advanced Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Cobalamin (DIETARY_SUPPLEMENT); Dexamethasone (DRUG); Docetaxel (DRUG); Folic Acid (DIETARY_SUPPLEMENT); Gemcitabine (DRUG); Nogapendekin Alfa (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed (DRUG); Ramucirumab (BIOLOGICAL),5743,Dxms,Advanced Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9114,NCT03859024,Efficacy of Opioid-limiting Pain Management Protocol in Men Undergoing Urethroplasty,COMPLETED,PHASE4,"Pain, Postoperative; Urethral Stricture",Oxycodone (DRUG); Acetaminophen (DRUG); Gabapentin (DRUG); celebrex (DRUG); Bupivacaine (DRUG); Ibuprofen 800 mg (DRUG); Dexamethasone (DRUG),5743,Dxms,"Pain, Postoperative; Urethral Stricture",Bladder/Urinary Tract,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9115,NCT01217060,Trimodality Management of T1b Esophageal Cancers,COMPLETED,PHASE1,Esophageal Cancer,Docetaxel (DRUG); 5-FU (DRUG); Radiotherapy (RADIATION); Esophagectomy (PROCEDURE); Dexamethasone (DRUG),5743,Dxms,Esophageal Cancer,Esophagus/Stomach,Dexamethasone,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,Commonly used glucocorticoid for inflammation and immune response regulation.,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,1.04,304.0 +9116,NCT05465135,The Effect of Dihydroartemisinin in PCOS,COMPLETED,PHASE4,Polycystic Ovary Syndrome,Dihydroartemisinin (DRUG),3000518,Alaxin,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Dihydroartemisinin,,unclear,unclear,yes,yes,"Active metabolite of artemisinin, approved for malaria treatment.",CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)O)C,1.0,30.0 +9117,NCT06842524,Dihydroartemisinin for the Treatment of Polycystic Ovary Syndrome,RECRUITING,PHASE2,Polycystic Ovary Syndrome (PCOS),Dihydroartemisinin (DRUG); Placebo (DRUG),3000518,Alaxin,Polycystic Ovary Syndrome (PCOS),Ovary/Fallopian Tube,Dihydroartemisinin,,unclear,unclear,yes,yes,"Active metabolite of artemisinin, approved for malaria treatment.",CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)O)C,1.0,30.0 +9118,NCT06417099,Efficacy of Dihydroartemisinin for Treating PCOS,COMPLETED,PHASE2,Polycystic Ovary Syndrome,Dihydroartemisinin (DRUG),3000518,Alaxin,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Dihydroartemisinin,,unclear,unclear,yes,yes,"Active metabolite of artemisinin, approved for malaria treatment.",CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)O)C,1.0,30.0 +9119,NCT03093129,Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer (NeoART-V),UNKNOWN,PHASE2,Colorectal Cancer,artesunate (DRUG); placebo (OTHER),6917864,Asumax,Colorectal Cancer,Bowel,Artesunate,,inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,"Used for severe malaria, often partnered with other antimalarial drugs.",CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)OC(=O)CCC(=O)O)C,1.01,289.0 +9120,NCT04000360,Pragmatic Cyclical Lower Extremity Exercise Trial for Parkinson's Disease,COMPLETED,PHASE2,Parkinson Disease,High-Intensity Aerobic Exercise (OTHER),5284616,RPM,Parkinson Disease,CNS/Brain,Rapamycin,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved mainly for organ transplantation and cancer treatment.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC,1.11,253.0 +9121,NCT04984226,Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD,RECRUITING,PHASE2,Chronic Kidney Diseases; Metabolic Acidosis; Fatigue; Physical Endurance; Insulin Resistance; Mitochondrial Energetics; Diabetes,Sodium bicarbonate (DRUG); placebo (DRUG),5284616,RPM,Chronic Kidney Diseases; Metabolic Acidosis; Fatigue; Physical Endurance; Insulin Resistance; Mitochondrial Energetics; Diabetes,Kidney,Rapamycin,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved mainly for organ transplantation and cancer treatment.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC,1.11,253.0 +9122,NCT04134416,Brain Correlates of Multimodal Rehabilitation in Chronic Post-stroke Aphasia,COMPLETED,PHASE3,Aphasia; Stroke,Donepezil (DRUG); Intensive-Language Action Therapy (BEHAVIORAL); Transcranial direct current stimulation (DEVICE),5284616,RPM,Aphasia; Stroke,CNS/Brain,Rapamycin,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved mainly for organ transplantation and cancer treatment.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC,1.11,253.0 +9123,NCT06227481,Combined Procedures in the Treatment of Severe Acne Scars,NOT_YET_RECRUITING,PHASE2,Atrophic Acne Scar,Scar subcision (PROCEDURE); Platelet rich plasma injection (PROCEDURE); Polydioxanone mono threads insertion (PROCEDURE); Fractional carbon dioxide laser (DEVICE),5284616,RPM,Atrophic Acne Scar,Skin,Rapamycin,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved mainly for organ transplantation and cancer treatment.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC,1.11,253.0 +9124,NCT01626001,Imaging Study Compare 4DCT Image,COMPLETED,PHASE1,Esophagus Cancer; Lung Cancer,4D CT scans (PROCEDURE),5284616,RPM,Esophagus Cancer; Lung Cancer,Lung,Rapamycin,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved mainly for organ transplantation and cancer treatment.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC,1.11,253.0 +9125,NCT00169104,"Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function",TERMINATED,PHASE2,Metastatic Breast Cancer,G-CSF (DRUG); trastuzumab (DRUG); vinorelbine (DRUG); G-CSF (DRUG); saline placebo (DRUG),5284616,RPM,Metastatic Breast Cancer,Breast,Rapamycin,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved mainly for organ transplantation and cancer treatment.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC,1.11,253.0 +9126,NCT02002819,Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability,COMPLETED,PHASE2,Alzheimer's Disease,levetiracetam (DRUG),5284616,RPM,Alzheimer's Disease,CNS/Brain,Rapamycin,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved mainly for organ transplantation and cancer treatment.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC,1.11,253.0 +9127,NCT01034514,4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy,TERMINATED,EARLY_PHASE1,Lung Cancer,Real-time Position Management system (DEVICE); Discovery ST multislice PET/CT scanner (DEVICE); Infinia Hawkeye SPECT/CT gamma camera (DEVICE); Pinnacle3 treatment planning system (DEVICE); SKYLight nuclear camera (DEVICE); DTPA (DRUG); TECHNETIUM TC 99M MAA (DRUG),5284616,RPM,Lung Cancer,Lung,Rapamycin,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved mainly for organ transplantation and cancer treatment.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC,1.11,253.0 +9128,NCT02711826,Treg Therapy in Subclinical Inflammation in Kidney Transplantation,COMPLETED,PHASE1,Kidney Transplant; Adult Living Donor Kidney Transplant Recipients; Renal Transplant; Living Kidney Donor,"Polyclonal Regulatory T Cells (BIOLOGICAL); Everolimus (DRUG); Tacrolimus (DRUG); Mycophenolate mofetil (DRUG); Mycophenolic acid (DRUG); Acetaminophen (DRUG); Diphenhydramine (DRUG); Biopsy, Kidney (PROCEDURE); Blood Draw (PROCEDURE); Leukapheresis (PROCEDURE); IS regimen conversion (PROCEDURE)",6918289,Torisel,Kidney Transplant; Adult Living Donor Kidney Transplant Recipients; Renal Transplant; Living Kidney Donor,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9129,NCT05573126,Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer,RECRUITING,PHASE1,Hormone Receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Metastatic Breast Cancer,Vosilasarm (DRUG); Elacestrant (DRUG); Everolimus (DRUG),6918289,Torisel,Hormone Receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Metastatic Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9130,NCT03284957,Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer,TERMINATED,PHASE1,Breast Cancer,Amcenestrant (DRUG); Palbociclib (DRUG); Alpelisib (DRUG); Everolimus (DRUG); Abemaciclib (DRUG),6918289,Torisel,Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9131,NCT06727357,"Next Generation Sequencing-based ""Oncochip"" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP",ACTIVE_NOT_RECRUITING,PHASE2,"Breast Cancer, Metastatic Breast Cancer",Chemotherapy (DRUG),6918289,Torisel,"Breast Cancer, Metastatic Breast Cancer",Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9132,NCT01051557,Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma,COMPLETED,PHASE1,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Diffuse Astrocytoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Oligodendroglioma; Recurrent Adult Brain Neoplasm,Laboratory Biomarker Analysis (OTHER); Perifosine (DRUG); Temsirolimus (DRUG); Therapeutic Conventional Surgery (PROCEDURE),6918289,Torisel,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Diffuse Astrocytoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Oligodendroglioma; Recurrent Adult Brain Neoplasm,CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9133,NCT00187174,Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors,COMPLETED,PHASE1,"Tumors; Brain Tumors; Rhabdomyosarcoma; Sarcoma, Soft Tissue",Everolimus (DRUG),6918289,Torisel,"Tumors; Brain Tumors; Rhabdomyosarcoma; Sarcoma, Soft Tissue",CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9134,NCT01797120,"Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI",COMPLETED,PHASE2,Metastatic Breast Cancer,Fulvestrant (DRUG); Everolimus (DRUG); Placebo (DRUG),6918289,Torisel,Metastatic Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9135,NCT01925274,A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer,TERMINATED,PHASE2,Metastatic Colorectal Cancer,PF-05212384 (DRUG); irinotecan (DRUG); Cetuximab (DRUG); Irinotecan (DRUG),6918289,Torisel,Metastatic Colorectal Cancer,Bowel,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9136,NCT00317720,Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer,COMPLETED,PHASE1,Breast Cancer; Neoplasm Metastasis,Trastuzumab (DRUG); RAD001 (DRUG),6918289,Torisel,Breast Cancer; Neoplasm Metastasis,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9137,NCT00634920,Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients,COMPLETED,PHASE4,Renal Function,everolimus (DRUG); cyclosporine A (DRUG); Enteric Coated Mycophenolate Sodium (EC-MPS) (DRUG); corticosteroids (DRUG); Basiliximab (DRUG),6918289,Torisel,Renal Function,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9138,NCT03190174,Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers,COMPLETED,PHASE1,Ewing Sarcoma; PEComa; Epithelioid Sarcoma; Desmoid Tumor; Chordoma; Non Small Cell Lung Cancer; Urothelial Carcinoma; Melanoma; Renal Cell Carcinoma; Squamous Cell Carcinoma; Hepatocellular Carcinoma; Classical Hodgkin Lymphoma; Colorectal Cancer; MTOR Activating Mutation,Nab-Rapamycin (DRUG); Nivolumab (BIOLOGICAL),6918289,Torisel,Ewing Sarcoma; PEComa; Epithelioid Sarcoma; Desmoid Tumor; Chordoma; Non Small Cell Lung Cancer; Urothelial Carcinoma; Melanoma; Renal Cell Carcinoma; Squamous Cell Carcinoma; Hepatocellular Carcinoma; Classical Hodgkin Lymphoma; Colorectal Cancer; MTOR Activating Mutation,Bowel,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9139,NCT00933374,Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma,TERMINATED,PHASE2,Bladder Cancer,paclitaxel (DRUG); RAD001 (DRUG),6918289,Torisel,Bladder Cancer,Bladder/Urinary Tract,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9140,NCT00516165,RAD001 in Advanced Hepatocellular Carcinoma,COMPLETED,PHASE1,Hepatocellular Carcinoma,RAD001 (DRUG),6918289,Torisel,Hepatocellular Carcinoma,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9141,NCT01522820,Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors,COMPLETED,PHASE1,Anaplastic Astrocytoma; Anaplastic Oligoastrocytoma; Anaplastic Oligodendroglioma; Estrogen Receptor Negative; Estrogen Receptor Positive; Glioblastoma; Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma; Metastatic Renal Cell Cancer; Recurrent Adult Brain Neoplasm; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Lung Carcinoma; Recurrent Melanoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Recurrent Renal Cell Carcinoma; Recurrent Uterine Corpus Carcinoma; Resectable Hepatocellular Carcinoma; Sarcoma; Stage IA Breast Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Corpus Cancer; Stage IB Breast Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Corpus Cancer; Stage IC Ovarian Cancer; Stage II Uterine Corpus Cancer; Stage IIA Breast Cancer; Stage IIA Lung Carcinoma; Stage IIA Ovarian Cancer; Stage IIB Breast Cancer; Stage IIB Esophageal Cancer; Stage IIB Lung Carcinoma; Stage IIB Ovarian Cancer; Stage IIB Skin Melanoma; Stage IIC Ovarian Cancer; Stage IIC Skin Melanoma; Stage IIIA Breast Cancer; Stage IIIA Esophageal Cancer; Stage IIIA Lung Carcinoma; Stage IIIA Ovarian Cancer; Stage IIIA Skin Melanoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Breast Cancer; Stage IIIB Esophageal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Skin Melanoma; Stage IIIB Uterine Corpus Cancer; Stage IIIC Breast Cancer; Stage IIIC Esophageal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Skin Melanoma; Stage IIIC Uterine Corpus Cancer; Stage IV Bladder Urothelial Carcinoma; Stage IV Esophageal Cancer; Stage IV Ovarian Cancer; Stage IV Prostate Cancer; Stage IV Skin Melanoma; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,DEC-205/NY-ESO-1 Fusion Protein CDX-1401 (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Sirolimus (DRUG),6918289,Torisel,Anaplastic Astrocytoma; Anaplastic Oligoastrocytoma; Anaplastic Oligodendroglioma; Estrogen Receptor Negative; Estrogen Receptor Positive; Glioblastoma; Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma; Metastatic Renal Cell Cancer; Recurrent Adult Brain Neoplasm; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Lung Carcinoma; Recurrent Melanoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Recurrent Renal Cell Carcinoma; Recurrent Uterine Corpus Carcinoma; Resectable Hepatocellular Carcinoma; Sarcoma; Stage IA Breast Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Corpus Cancer; Stage IB Breast Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Corpus Cancer; Stage IC Ovarian Cancer; Stage II Uterine Corpus Cancer; Stage IIA Breast Cancer; Stage IIA Lung Carcinoma; Stage IIA Ovarian Cancer; Stage IIB Breast Cancer; Stage IIB Esophageal Cancer; Stage IIB Lung Carcinoma; Stage IIB Ovarian Cancer; Stage IIB Skin Melanoma; Stage IIC Ovarian Cancer; Stage IIC Skin Melanoma; Stage IIIA Breast Cancer; Stage IIIA Esophageal Cancer; Stage IIIA Lung Carcinoma; Stage IIIA Ovarian Cancer; Stage IIIA Skin Melanoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Breast Cancer; Stage IIIB Esophageal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Skin Melanoma; Stage IIIB Uterine Corpus Cancer; Stage IIIC Breast Cancer; Stage IIIC Esophageal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Skin Melanoma; Stage IIIC Uterine Corpus Cancer; Stage IV Bladder Urothelial Carcinoma; Stage IV Esophageal Cancer; Stage IV Ovarian Cancer; Stage IV Prostate Cancer; Stage IV Skin Melanoma; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Bowel,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9142,NCT00770120,S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery,COMPLETED,PHASE2,Malignant Mesothelioma,everolimus (DRUG),6918289,Torisel,Malignant Mesothelioma,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9143,NCT00434174,Safety of Everolimus and Pemetrexed in Lung Cancer Patients,COMPLETED,PHASE1,Non Small Cell Lung Cancer,Everolimus (DRUG); Pemetrexed (DRUG),6918289,Torisel,Non Small Cell Lung Cancer,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9144,NCT02724020,MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma,COMPLETED,PHASE2,Clear-cell Metastatic Renal Cell Carcinoma,Everolimus (DRUG); MLN0128 (DRUG); MLN1117 (DRUG),6918289,Torisel,Clear-cell Metastatic Renal Cell Carcinoma,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9145,NCT00522665,Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,Irinotecan (DRUG); Cetuximab (BIOLOGICAL); RAD001 (BIOLOGICAL),6918289,Torisel,Colorectal Cancer,Bowel,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9146,NCT00574366,Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer,COMPLETED,PHASE1,Breast Cancer,erlotinib (DRUG); RAD001 (DRUG),6918289,Torisel,Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9147,NCT02333565,Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas,COMPLETED,PHASE2,Recurrent Meningiomas; Resistant Meningiomas,Everolimus (DRUG); Octreotide (DRUG),6918289,Torisel,Recurrent Meningiomas; Resistant Meningiomas,CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9148,NCT05613166,Adjunctive Everolimus Treatment of Refractory Epilepsy,UNKNOWN,PHASE2,Epilepsy,Everolimus (DRUG); Placebo (DRUG),6918289,Torisel,Epilepsy,CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9149,NCT03463265,Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma,COMPLETED,PHASE2,High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma,nab-sirolimus (DRUG); nab-sirolimus + temozolomide (DRUG); nab-sirolimus + bevacizumab (DRUG); nab-sirolimus + lomustine (DRUG); nab-sirolimus + marizomib (MRZ) (DRUG); nab-sirolimus + temozolomide + radiotherapy (DRUG),6918289,Torisel,High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma,CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9150,NCT06018766,LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.,RECRUITING,PHASE2,Bronchiolitis Obliterans Syndrome; Chronic Lung Allograft Dysfunction; Lung Transplantation,LAM-001 (DRUG); Placebo (DRUG),6918289,Torisel,Bronchiolitis Obliterans Syndrome; Chronic Lung Allograft Dysfunction; Lung Transplantation,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9151,NCT00466466,Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients,COMPLETED,PHASE1,Small-Cell Lung Cancer,Everolimus (DRUG),6918289,Torisel,Small-Cell Lung Cancer,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9152,NCT01185366,Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma,TERMINATED,PHASE2,Kidney Cancer,Everolimus (DRUG); Sunitinib (DRUG),6918289,Torisel,Kidney Cancer,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9153,NCT01090466,"Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium",COMPLETED,PHASE1,Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer,cisplatin (DRUG); gemcitabine hydrochloride (DRUG); temsirolimus (DRUG); pharmacological study (OTHER),6918289,Torisel,Urinary Tract Cancers,Bladder/Urinary Tract,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9154,NCT01636466,The Everolimus-Transplant Exit Strategy Trial (E-TEST),TERMINATED,PHASE3,"Kidney Failure, Chronic",Everolimus (DRUG),6918289,Torisel,"Kidney Failure, Chronic",Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9155,NCT01166126,Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV,TERMINATED,PHASE2,Mucosal Melanoma; Recurrent Melanoma; Stage IV Melanoma,temsirolimus (DRUG); selumetinib (DRUG); laboratory biomarker analysis (OTHER),6918289,Torisel,Mucosal Melanoma; Recurrent Melanoma; Stage IV Melanoma,Skin,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9156,NCT00979966,Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib,COMPLETED,PHASE2,Non-clear Cell Renal Cell Cancer,Temsirolimus (DRUG); Sunitinib (DRUG),6918289,Torisel,Non-clear Cell Renal Cell Cancer,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9157,NCT05563220,Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer,RECRUITING,PHASE1,Breast Cancer; Metastatic Breast Cancer,Elacestrant (DRUG); Alpelisib (DRUG); Everolimus (DRUG); Ribociclib (DRUG); Palbociclib (DRUG); Capivasertib (DRUG); Abemaciclib (DRUG),6918289,Torisel,Breast Cancer; Metastatic Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9158,NCT01335074,Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC),WITHDRAWN,PHASE1,Hepatocellular Carcinoma,Temsirolimus + Sorafenib (DRUG),6918289,Torisel,Hepatocellular Carcinoma,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9159,NCT00044720,Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients,COMPLETED,PHASE4,Chronic Kidney Failure; Graft vs Host Disease; Kidney Transplantation,Rapamune (DRUG),6918289,Torisel,Chronic Kidney Failure; Graft vs Host Disease; Kidney Transplantation,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9160,NCT00170820,Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen,COMPLETED,PHASE4,Renal Transplantation,Everolimus (DRUG),6918289,Torisel,Renal Transplantation,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9161,NCT00775073,Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001,COMPLETED,PHASE2,Hepatocellular Carcinoma,"Everolimus, Bevacizumab (DRUG)",6918289,Torisel,Hepatocellular Carcinoma,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9162,NCT03577431,Liver Transplantation With Tregs at MGH,ACTIVE_NOT_RECRUITING,PHASE1,Liver Transplant,arTreg-CSB (BIOLOGICAL); leukapheresis (PROCEDURE); cyclophosphamide (DRUG); mesna (DRUG); everolimus (DRUG),6918289,Torisel,Liver Transplant,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9163,NCT00923273,Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer,TERMINATED,PHASE1,"Carcinoma, Non-Small-Cell Lung",FDG-PET (DRUG); Pemetrexed (DRUG); Sirolimus (DRUG); Vitamin B12 (DIETARY_SUPPLEMENT); Folic acid tablets (DIETARY_SUPPLEMENT); Dexamethasone tablets (DRUG),6918289,Torisel,"Carcinoma, Non-Small-Cell Lung",Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9164,NCT01034631,BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma,COMPLETED,PHASE1,Renal Cell Carcinoma,Everolimus (DRUG); BNC105P (DRUG),6918289,Torisel,Renal Cell Carcinoma,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9165,NCT00976573,"Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",COMPLETED,PHASE2,Melanoma (Skin),bevacizumab (BIOLOGICAL); carboplatin (DRUG); everolimus (DRUG); paclitaxel (DRUG),6918289,Torisel,Melanoma (Skin),Skin,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9166,NCT02456857,"Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative",COMPLETED,PHASE2,Invasive Breast Carcinoma; Triple-Negative Breast Carcinoma,Bevacizumab (BIOLOGICAL); Everolimus (DRUG); Laboratory Biomarker Analysis (OTHER); Pegylated Liposomal Doxorubicin Hydrochloride (DRUG),6918289,Torisel,Triple-Negative Breast Carcinoma,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9167,NCT01514448,Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib,COMPLETED,PHASE4,Metastatic Renal Cell Carcinoma (mRCC),Everolimus (RAD001) (DRUG),6918289,Torisel,Metastatic Renal Cell Carcinoma (mRCC),Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9168,NCT00397982,Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma,COMPLETED,PHASE2,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Bevacizumab (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER); Temsirolimus (DRUG); Therapeutic Conventional Surgery (PROCEDURE),6918289,Torisel,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Skin,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9169,NCT00047073,Sirolimus in Treating Patients With Glioblastoma Multiforme,COMPLETED,PHASE1,Brain and Central Nervous System Tumors,Rapamycin (DRUG); Surgery (PROCEDURE); Supportive Care (PROCEDURE),6918289,Torisel,Brain and Central Nervous System Tumors,CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9170,NCT06326190,177Lu-DOTATATE for Recurrent Meningioma,RECRUITING,PHASE2,Recurrent Meningioma,Local standard of Care (DRUG); 177Lu-DOTATATE (DRUG),6918289,Torisel,Recurrent Meningioma,CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9171,NCT01677390,A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma,TERMINATED,PHASE1,Renal Cell Carcinoma,SGN-75 (DRUG); everolimus (DRUG),6918289,Torisel,Renal Cell Carcinoma,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9172,NCT00378703,"Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer",COMPLETED,PHASE2,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v7,Bevacizumab (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Sorafenib Tosylate (DRUG); Temsirolimus (DRUG),6918289,Torisel,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v7,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9173,NCT01442090,Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy,COMPLETED,PHASE2,Renal Cell Carcinoma,Everolimus (DRUG); GDC-0980 (DRUG),6918289,Torisel,Renal Cell Carcinoma,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9174,NCT01958190,Study Comparing in Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus&Sirolimus,COMPLETED,PHASE4,Liver Disease,Tacrolimus and Sirolimus (DRUG); Tacrolimus (DRUG),6918289,Torisel,Liver Disease,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9175,NCT02142803,TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,Adult Glioblastoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Solid Neoplasm; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7,Bevacizumab (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Sapanisertib (DRUG),6918289,Torisel,Adult Glioblastoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Solid Neoplasm; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7,Ovary/Fallopian Tube,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9176,NCT05429684,Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer,UNKNOWN,PHASE3,HER2+ Breast Cancer,Trastuzumab (DRUG); Pertuzumab (DRUG); Nab paclitaxel (DRUG); Pyrotinib (DRUG); Capecitabine (DRUG); T-DM1 (DRUG); Everolimus (DRUG); CDK4/6 inhibitor (DRUG); AI (DRUG); Anti-PD-1 monoclonal antibody (DRUG),6918289,Torisel,HER2+ Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9177,NCT02479490,PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI,TERMINATED,PHASE2,Metastatic Renal Cancer,Prednisone + Everolimus (DRUG),6918289,Torisel,Metastatic Renal Cancer,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9178,NCT00499603,Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Paclitaxel (DRUG); 5-Fluorouracil (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG); RAD001 (DRUG),6918289,Torisel,Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9179,NCT01248403,"A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy",COMPLETED,PHASE3,Advanced Gastric Cancer; Esophagogastric Junction Cancer,Paclitaxel (DRUG); RAD001 (DRUG),6918289,Torisel,Advanced Gastric Cancer; Esophagogastric Junction Cancer,Esophagus/Stomach,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9180,NCT02513303,Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes,COMPLETED,PHASE3,Complication of Renal Dialysis; End Stage Renal Disease; End Stage Kidney Disease; ESRD; Chronic Kidney Failure; Complication of Hemodialysis; Vascular Access Complication; Arteriovenous Fistula,Sirolimus (DRUG); AV Fistula Surgery (PROCEDURE); Sirolimus-eluting Collagen Implant (SeCI) (DEVICE),6918289,Torisel,Complication of Renal Dialysis; End Stage Renal Disease; End Stage Kidney Disease; ESRD; Chronic Kidney Failure; Complication of Hemodialysis; Vascular Access Complication; Arteriovenous Fistula,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9181,NCT03373903,Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly,ACTIVE_NOT_RECRUITING,PHASE2,Respiratory Tract Infections,Placebo (OTHER); BEZ235 (DRUG); BEZ235 plus everolimus (RAD001) (DRUG),6918289,Torisel,Respiratory Tract Infections,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9182,NCT04948203,Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis,RECRUITING,PHASE2,Pulmonary Fibrosis; COVID-19 Pneumonia; Long COVID,Sirolimus (DRUG),6918289,Torisel,Pulmonary Fibrosis; COVID-19 Pneumonia; Long COVID,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9183,NCT01520103,Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer,COMPLETED,PHASE2,Her2-negative Metastatic Breast Cancer; Her2-negative Locally Advanced Breast Cancer,"Vinorebine, Everolimus (DRUG); Vinorelbine (DRUG)",6918289,Torisel,Her2-negative Metastatic Breast Cancer; Her2-negative Locally Advanced Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9184,NCT06211790,Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma,RECRUITING,PHASE2,Kidney Cancer; Renal Cell Carcinoma; Renal Clear Cell Carcinoma,"Anlotinib, Everolimus and Tislelizumab (DRUG)",6918289,Torisel,Kidney Cancer; Renal Cell Carcinoma; Renal Clear Cell Carcinoma,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9185,NCT05293964,"Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,SIM0270 (DRUG); Palbociclib (DRUG); everolimus (DRUG),6918289,Torisel,Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9186,NCT00582738,Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection,TERMINATED,PHASE2,Recurrent Hepatitis C,CsA-TAC (standard Treatment) (DRUG); Everolimus (DRUG),6918289,Torisel,Recurrent Hepatitis C,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9187,NCT01680250,Sirolimus for Massive Polycystic Liver,UNKNOWN,PHASE2,Polycystic Kidney Diseases,Sirolimus (DRUG),6918289,Torisel,Polycystic Kidney Diseases,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9188,NCT04892212,Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis,UNKNOWN,PHASE2,Lupus Nephritis; Immunosuppression; Effect of Drug,Sirolimus (DRUG),6918289,Torisel,Lupus Nephritis; Immunosuppression; Effect of Drug,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9189,NCT05501769,"ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,ARV-471 in combination with Everolimus (DRUG),6918289,Torisel,Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9190,NCT01561404,Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise,TERMINATED,PHASE4,"Disorder Related to Renal Transplantation; Exercise, Aerobic; Muscle Strength",Everolimus (DRUG),6918289,Torisel,"Disorder Related to Renal Transplantation; Exercise, Aerobic; Muscle Strength",Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9191,NCT01354301,Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate,COMPLETED,PHASE4,"Cytomegalovirus Infection; Renal Transplant Failure; Transplant; Complication, Rejection",Thymoglobulin (DRUG); Everolimus (DRUG); Basiliximabe (DRUG); mycophenolate sodium (DRUG); Tacrolimus (DRUG); Tacrolimus (DRUG); Tacrolimus (DRUG),6918289,Torisel,"Cytomegalovirus Infection; Renal Transplant Failure; Transplant; Complication, Rejection",Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9192,NCT00384969,Sorafenib and RAD001 Renal Cell Carcinoma,COMPLETED,PHASE1,Renal Cell Carcinoma,RAD001 and Sorafenib (DRUG),6918289,Torisel,Renal Cell Carcinoma,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9193,NCT06022068,Evaluating Rapamycin Treatment in Alzheimer's Disease Using Positron Emission Tomography,ENROLLING_BY_INVITATION,PHASE1,Alzheimer Disease,Sirolimus (DRUG),6918289,Torisel,Alzheimer Disease,CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9194,NCT01031446,"Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer",COMPLETED,PHASE1,Breast Cancer,cisplatin (DRUG); everolimus (DRUG); paclitaxel (DRUG); laboratory biomarker analysis (OTHER),6918289,Torisel,Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9195,NCT01024946,Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity,COMPLETED,PHASE2,Malignant Pleural Mesothelioma,everolimus (DRUG),6918289,Torisel,Malignant Pleural Mesothelioma,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9196,NCT03217669,Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy,ACTIVE_NOT_RECRUITING,PHASE1,Advanced Solid Tumor; Non-small Cell Lung Cancer (NSCLC),Epacadostat (DRUG); sirolimus (DRUG),6918289,Torisel,Advanced Solid Tumor; Non-small Cell Lung Cancer (NSCLC),Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9197,NCT01172769,Efficacy Study of Temsirolimus to Treat Head and Neck Cancer,COMPLETED,PHASE2,Head and Neck Squamous Cell Carcinoma,Temsirolimus (BIOLOGICAL),6918289,Torisel,Head and Neck Squamous Cell Carcinoma,Skin,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9198,NCT02890069,"A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",COMPLETED,PHASE1,"Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma",PDR001 (BIOLOGICAL); LCL161 (DRUG); Everolimus (DRUG); Panobinostat (DRUG); QBM076 (DRUG); HDM201 (DRUG),6918289,Torisel,"Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma",Bowel,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9199,NCT00659568,Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma,COMPLETED,PHASE1,"Breast Cancer; Endometrial Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific",metformin hydrochloride (DRUG); temsirolimus (DRUG),6918289,Torisel,"Breast Cancer; Endometrial Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific",Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9200,NCT00622869,Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients,COMPLETED,PHASE3,Liver Transplantation,Tacrolimus (reduced tacrolimus) (DRUG); Tacrolimus (tacrolimus elimination) (DRUG); Tacrolimus (tacrolimus control) (DRUG); Everolimus (reduced tacrolimus) (DRUG); Everolimus (tacrolimus elimination) (DRUG); Corticosteroids (DRUG),6918289,Torisel,Liver Transplantation,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9201,NCT01383668,Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer,WITHDRAWN,PHASE1,"Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",sirolimus (DRUG); gold sodium thiomalate (DRUG); pharmacological study (OTHER); RNA analysis (GENETIC); polymerase chain reaction (GENETIC),6918289,Torisel,"Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9202,NCT00086346,Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients,TERMINATED,PHASE3,Liver Transplantation,Sirolimus (Rapamune) (DRUG); Cyclosporine or Tacrolimus (DRUG),6918289,Torisel,Liver Transplantation,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9203,NCT00290069,Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA),UNKNOWN,PHASE4,Kidney Diseases; Graft Rejection,Tacrolimus (DRUG); Rapamycin (DRUG),6918289,Torisel,Kidney Diseases; Graft Rejection,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9204,NCT00619268,Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma,COMPLETED,PHASE2,Metastatic Renal Cell Carcinoma,Temsirolimus (DRUG); Bevacizumab (DRUG); Sunitinib (DRUG); Interferon alpha-2a (DRUG),6918289,Torisel,Metastatic Renal Cell Carcinoma,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9205,NCT02619669,Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer,WITHDRAWN,PHASE1,Breast Cancer,TAK-228 (DRUG); Letrozole (DRUG),6918289,Torisel,Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9206,NCT00112476,Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors,COMPLETED,PHASE1,"Recurrent Melanoma; Recurrent Renal Cell Cancer; Stage IV Melanoma; Stage IV Renal Cell Cancer; Unspecified Adult Solid Tumor, Protocol Specific",bryostatin 1 (DRUG); temsirolimus (DRUG),6918289,Torisel,"Recurrent Melanoma; Recurrent Renal Cell Cancer; Stage IV Melanoma; Stage IV Renal Cell Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Skin,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9207,NCT06881927,Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure,NOT_YET_RECRUITING,PHASE4,Sepsis and Septic Shock; Acute Respiratory Failure; Kidney Transplant Recipients; Immunosuppressive Agents,Hydrocortisone Hemisuccinate: 200 mg per day. (DRUG); reduction of the level of immunosuppression (OTHER),6918289,Torisel,Sepsis and Septic Shock; Acute Respiratory Failure; Kidney Transplant Recipients; Immunosuppressive Agents,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9208,NCT00788060,A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma,COMPLETED,PHASE1,Renal Cell Carcinoma,Everolimus (RAD001) (DRUG); Sunitinib (Sutent) (DRUG),6918289,Torisel,Renal Cell Carcinoma,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9209,NCT02126527,Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer,WITHDRAWN,PHASE1,"Recurrent Non-small Cell Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",auranofin (DRUG); sirolimus (DRUG); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),6918289,Torisel,"Recurrent Non-small Cell Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9210,NCT04415476,"Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS)",WITHDRAWN,PHASE2,Disorder Related to Lung Transplantation; Chronic Rejection of Lung Transplant; Decreased Immunologic Activity,Assigned Interventions (DRUG),6918289,Torisel,Disorder Related to Lung Transplantation; Chronic Rejection of Lung Transplant; Decreased Immunologic Activity,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9211,NCT00123331,Rapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation,COMPLETED,PHASE4,Heart Transplantation; Renal Failure,Cyclosporine discontinuation (DRUG); Rapamycin medication (DRUG),6918289,Torisel,Heart Transplantation; Renal Failure,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9212,NCT05522231,Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2),ACTIVE_NOT_RECRUITING,PHASE2,Advanced Renal Cell Carcinoma,fruquintinib+sintilimab (DRUG); axitinib / everolimus (DRUG); fruquintinib (DRUG),6918289,Torisel,Advanced Renal Cell Carcinoma,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9213,NCT05124431,Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma,UNKNOWN,PHASE2,Renal Cell Carcinoma,Anlotinib hydrochloride (DRUG); everolimus (DRUG),6918289,Torisel,Renal Cell Carcinoma,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9214,NCT00729482,RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment,COMPLETED,PHASE2,Stomach Neoplasm,RAD001 (DRUG),6918289,Torisel,Stomach Neoplasm,Esophagus/Stomach,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9215,NCT01042782,Phase I Study of Daily RAD001 in Combination With Mitomycin C in Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction,COMPLETED,PHASE1,Advanced Gastric Cancer; Advanced Cancer of the Esophagogastric Junction,RAD001 and MitomycinC (DRUG),6918289,Torisel,Advanced Gastric Cancer; Advanced Cancer of the Esophagogastric Junction,Esophagus/Stomach,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9216,NCT00593060,"Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer",COMPLETED,PHASE1,Colorectal Cancer; Colorectal Adenocarcinoma,Temsirolimus (DRUG); Cetuximab (DRUG),6918289,Torisel,Colorectal Cancer; Colorectal Adenocarcinoma,Bowel,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9217,NCT01773460,Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane,TERMINATED,PHASE3,Metastatic Breast Cancer,Everolimus (DRUG); Everolimus-placebo (DRUG),6918289,Torisel,Metastatic Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9218,NCT00072176,Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer,COMPLETED,PHASE2,Endometrial Adenocarcinoma; Endometrial Adenosquamous Cell Carcinoma; Endometrial Clear Cell Carcinoma; Endometrial Papillary Serous Carcinoma; Recurrent Endometrial Carcinoma; Stage IIIA Endometrial Carcinoma; Stage IIIB Endometrial Carcinoma; Stage IIIC Endometrial Carcinoma; Stage IVA Endometrial Carcinoma; Stage IVB Endometrial Carcinoma,temsirolimus (DRUG); laboratory biomarker analysis (OTHER),6918289,Torisel,Endometrial Adenocarcinoma; Endometrial Adenosquamous Cell Carcinoma; Endometrial Clear Cell Carcinoma; Endometrial Papillary Serous Carcinoma; Recurrent Endometrial Carcinoma; Stage IIIA Endometrial Carcinoma; Stage IIIB Endometrial Carcinoma; Stage IIIC Endometrial Carcinoma; Stage IVA Endometrial Carcinoma; Stage IVB Endometrial Carcinoma,Uterus,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9219,NCT01658176,Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer,WITHDRAWN,PHASE2,Breast Neoplasms,PF-04691502 (DRUG); Exemestane (DRUG); Exemestane (DRUG),6918289,Torisel,Breast Neoplasms,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9220,NCT03352427,Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations,TERMINATED,PHASE2,Glioma; High Grade Glioma; Pontine Tumors,Dasatinib (DRUG); Everolimus (DRUG),6918289,Torisel,Glioma; High Grade Glioma; Pontine Tumors,CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9221,NCT02372227,"A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma",TERMINATED,PHASE1,Relapsed Malignant Mesothelioma,VS-5584 and VS-6063 (DRUG),6918289,Torisel,Relapsed Malignant Mesothelioma,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9222,NCT00406276,Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer,TERMINATED,PHASE1,Lung Cancer,RAD001 (DRUG); Docetaxel (DRUG),6918289,Torisel,Lung Cancer,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9223,NCT00651482,Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus),TERMINATED,PHASE2,Kidney Neoplasms; Kidney (Renal Cell) Cancer,Everolimus (DRUG); Bevacizumab (DRUG),6918289,Torisel,Kidney Neoplasms; Kidney (Renal Cell) Cancer,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9224,NCT01217931,Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial,ACTIVE_NOT_RECRUITING,PHASE2,Kidney Cancer,Pazopanib (DRUG); Bevacizumab (DRUG); Everolimus (DRUG),6918289,Torisel,Kidney Cancer,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9225,NCT01548482,Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,COMPLETED,PHASE1,Adult Solid Neoplasm; Lung Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Recurrent Renal Cell Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage III Renal Cell Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Uterine Sarcoma; Stage IV Renal Cell Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma,Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Temsirolimus (DRUG); Trebananib (BIOLOGICAL),6918289,Torisel,Adult Solid Neoplasm; Lung Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Recurrent Renal Cell Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage III Renal Cell Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Uterine Sarcoma; Stage IV Renal Cell Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9226,NCT00999882,"Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients",COMPLETED,PHASE1,Cancer; Advanced Hepatocellular Carcinoma,AZD8055 (DRUG),6918289,Torisel,Cancer; Advanced Hepatocellular Carcinoma,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9227,NCT00982631,"A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer",UNKNOWN,PHASE1,Advanced/Recurrent Breast Cancer; Endometrial Cancer; Ovarian Cancer,Temsirolimus/PLD (DRUG),6918289,Torisel,Advanced/Recurrent Breast Cancer; Endometrial Cancer; Ovarian Cancer,Uterus,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9228,NCT01687673,Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma,COMPLETED,PHASE2,Hepatocellular Carcinoma,Temsirolimus (DRUG); Sorafenib: (DRUG),6918289,Torisel,Hepatocellular Carcinoma,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9229,NCT00980460,Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer,ACTIVE_NOT_RECRUITING,PHASE3,PRETEXT I Hepatoblastoma; PRETEXT II Hepatoblastoma; PRETEXT III Hepatoblastoma; PRETEXT IV Hepatoblastoma,Cisplatin (DRUG); Dexrazoxane (DRUG); Doxorubicin Hydrochloride (DRUG); Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Liver Transplantation (PROCEDURE); Temsirolimus (DRUG); Therapeutic Conventional Surgery (PROCEDURE); Vincristine Sulfate (DRUG),6918289,Torisel,Hepatoblastoma,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9230,NCT01499160,Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer,TERMINATED,PHASE2,Breast Neoplasms; Endocrine Breast Diseases; Neoplasm Metastasis,letrozole (DRUG); lapatinib (DRUG); everolimus (DRUG),6918289,Torisel,Breast Neoplasms; Endocrine Breast Diseases; Neoplasm Metastasis,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9231,NCT01240460,Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection,COMPLETED,PHASE1,"Glioblastoma; Astrocytoma, Grade IV",XL765 (SAR245409) (DRUG); XL147 (SAR245408) (DRUG),6918289,Torisel,"Glioblastoma; Astrocytoma, Grade IV",CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9232,NCT05627960,First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies,RECRUITING,PHASE1,Triple Negative Breast Cancer; Hormone-Resistant Breast Cancer; Non Small Cell Lung Cancer; Mesothelioma,AG-01 Compound (DRUG),6918289,Torisel,Triple Negative Breast Cancer; Hormone-Resistant Breast Cancer; Non Small Cell Lung Cancer; Mesothelioma,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9233,NCT03355794,A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG),COMPLETED,PHASE1,Diffuse Intrinsic Pontine Glioma; Malignant Glioma of Brain; High Grade Glioma; Bithalamic High Grade Glioma; Brainstem Glioma; Glioblastoma; Anaplastic Astrocytoma,ribociclib (DRUG); Everolimus (DRUG),6918289,Torisel,Diffuse Intrinsic Pontine Glioma; Malignant Glioma of Brain; High Grade Glioma; Bithalamic High Grade Glioma; Brainstem Glioma; Glioblastoma; Anaplastic Astrocytoma,CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9234,NCT01948960,Influence of Exceptional Patient Characteristics on Everolimus Exposure,COMPLETED,PHASE4,Breast Neoplasms,everolimus dose escalation (DRUG),6918289,Torisel,Breast Neoplasms,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9235,NCT01551212,Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients,COMPLETED,PHASE4,Liver Transplantation,Everolimus (DRUG); Tacrolimus (DRUG); Corticosteroids (DRUG),6918289,Torisel,Liver Transplantation,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9236,NCT01734512,PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children,COMPLETED,PHASE2,Pediatric Recurrent Progressive Low-grade Gliomas; Pediatric Progressive Low-grade Gliomas,Everolimus (DRUG),6918289,Torisel,Pediatric Recurrent Progressive Low-grade Gliomas; Pediatric Progressive Low-grade Gliomas,CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9237,NCT04482712,Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS,WITHDRAWN,PHASE1,Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS); Respiratory Failure; Sars-CoV2,Rapamycin (DRUG); Placebo (DRUG),6918289,Torisel,Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS); Respiratory Failure; Sars-CoV2,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9238,NCT00632268,Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric Cancer,COMPLETED,PHASE2,Metastatic Gastric Cancer,RAD001; Cisplatin; 5-FU; Leucovorin (DRUG),6918289,Torisel,Metastatic Gastric Cancer,Esophagus/Stomach,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9239,NCT00124280,Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,Non-small-cell Lung Carcinoma,RAD001 (DRUG),6918289,Torisel,Non-small-cell Lung Carcinoma,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9240,NCT01827267,Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer,COMPLETED,PHASE2,HER2-mutant Non-Small Cell Lung Cancer,neratinib (DRUG); temsirolimus (DRUG),6918289,Torisel,HER2-mutant Non-Small Cell Lung Cancer,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9241,NCT01938573,"Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer",COMPLETED,PHASE1,Recurrent Bladder Carcinoma; Stage II Bladder Cancer; Stage III Bladder Cancer; Stage IV Bladder Cancer,Cisplatin (DRUG); Gemcitabine Hydrochloride (DRUG); Sirolimus (DRUG); Cystectomy (PROCEDURE),6918289,Torisel,Recurrent Bladder Carcinoma; Stage II Bladder Cancer; Stage III Bladder Cancer; Stage IV Bladder Cancer,Bladder/Urinary Tract,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9242,NCT03324373,Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC),COMPLETED,PHASE1,Renal Cell Carcinoma,Lenvatinib (DRUG); Everolimus (DRUG); Partial or Radical Cytoreductive Nephrectomy (PROCEDURE),6918289,Torisel,Renal Cell Carcinoma,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9243,NCT01099527,A Trial of RAD001/Capecitabine in Refractory Gastric Cancer,COMPLETED,PHASE1,Metastatic Gastric Cancer,Everolimus (RAD001) (DRUG); Capecitabine (DRUG),6918289,Torisel,Metastatic Gastric Cancer,Esophagus/Stomach,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9244,NCT01334073,Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors,COMPLETED,PHASE1,"Malignant Advanced Solid Tumors; Carcinoma, Renal Cell",Axitinib plus everolimus (DRUG),6918289,Torisel,"Malignant Advanced Solid Tumors; Carcinoma, Renal Cell",Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9245,NCT04895748,DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies,ACTIVE_NOT_RECRUITING,PHASE1,"Carcinoma, Renal Cell",DFF332 (DRUG); RAD001 (DRUG); PDR001 (DRUG); NIR178 (DRUG),6918289,Torisel,"Carcinoma, Renal Cell",Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9246,NCT00949026,Assessment of Systemically Administered Torisel Delivery to Brain Tumors by Intratumoral Microdialysis,WITHDRAWN,PHASE1,Brain Neoplasms,Temsirolimus (Torisel) (DRUG),6918289,Torisel,Brain Neoplasms,CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9247,NCT01184326,Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer,COMPLETED,PHASE1,Solid Tumor; Kidney Cancer,pazopanib (DRUG); everolimus (DRUG),6918289,Torisel,Solid Tumor; Kidney Cancer,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9248,NCT03008148,Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM,UNKNOWN,PHASE2,Glioblastoma,CCRT (RADIATION); Temozolomide (DRUG); Siroquine (DRUG),6918289,Torisel,Glioblastoma,CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9249,NCT03203525,"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer",RECRUITING,PHASE1,Advanced Malignant Neoplasm; Colorectal Carcinoma Metastatic in the Liver; Metastatic Malignant Neoplasm in the Liver; Refractory Malignant Neoplasm,Bevacizumab (BIOLOGICAL); Fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Pegylated Liposomal Doxorubicin Hydrochloride (DRUG); Temsirolimus (DRUG); Tumor Treating Fields Therapy (PROCEDURE),6918289,Torisel,Advanced Malignant Neoplasm; Colorectal Carcinoma Metastatic in the Liver; Metastatic Malignant Neoplasm in the Liver; Refractory Malignant Neoplasm,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9250,NCT00183248,Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients,COMPLETED,PHASE1,Kidney Transplantation; Kidney Disease; Kidney Failure,Alemtuzumab (DRUG); Mycophenolate mofetil (DRUG); Sirolimus (DRUG); Tacrolimus (DRUG); Donor bone marrow stem cell infusion (PROCEDURE); Kidney transplant (PROCEDURE),6918289,Torisel,Kidney Transplantation; Kidney Disease; Kidney Failure,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9251,NCT01567930,Temsirolimus as Second-line Therapy in HCC,UNKNOWN,PHASE2,Unresectable or Metastatic Hepatocellular Carcinoma,Temsirolimus (DRUG),6918289,Torisel,Unresectable or Metastatic Hepatocellular Carcinoma,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9252,NCT00325325,Pharmacokinetic Study on the Combination of Everolimus-Tacrolimus,UNKNOWN,PHASE2,Kidney Diseases,everolimus and tacrolimus (DRUG),6918289,Torisel,Kidney Diseases,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9253,NCT02985125,LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy,UNKNOWN,PHASE1,Metastatic Pancreatic Adenocarcinoma,LEE011 (DRUG); Everolimus (DRUG),6918289,Torisel,Metastatic Pancreatic Adenocarcinoma,Pancreas,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9254,NCT02970630,Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical Study,COMPLETED,PHASE2,Kidney Transplantation,Tacrolimus (DRUG); Everolimus (DRUG),6918289,Torisel,Kidney Transplantation,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9255,NCT00498966,Ph II Study of Perifosine for Patients With Carcinoma of the Kidney,COMPLETED,PHASE2,Kidney Cancer,Perifosine (DRUG),6918289,Torisel,Kidney Cancer,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9256,NCT00085566,Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer,COMPLETED,PHASE1,Brain and Central Nervous System Tumors; Prostate Cancer,everolimus (DRUG); gefitinib (DRUG),6918289,Torisel,Brain and Central Nervous System Tumors; Prostate Cancer,CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9257,NCT01275222,Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors,COMPLETED,PHASE1,Gastrointestinal Stromal Tumors,RAD001 (DRUG); Imatinib 600mg/day (Glevec is the brand name for imatinib) (DRUG); Imatinib 800mg/day (Glevec is the brand name for imatinib) (DRUG),6918289,Torisel,Gastrointestinal Stromal Tumors,Bowel,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9258,NCT01111825,Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer,COMPLETED,PHASE1,Breast Cancer,Temsirolimus (DRUG); Neratinib (DRUG),6918289,Torisel,Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9259,NCT00426530,"Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer",COMPLETED,PHASE1,Breast Neoplasms; Neoplasm Metastasis,everolimus (RAD001) (DRUG),6918289,Torisel,Breast Neoplasms with Metastasis,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9260,NCT06929325,Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors,NOT_YET_RECRUITING,PHASE3,HR+/HER2- Advanced/Metastatic Breast Cancer,Sirolimus for Injection (Albumin-bound) (DRUG); Fulvestrant Injection (DRUG); Placebo for Sirolimus for Injection (Albumin-bound) (DRUG),6918289,Torisel,HR+/HER2- Advanced/Metastatic Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9261,NCT01404325,Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients,COMPLETED,PHASE3,Lung Transplantation,standard therapy (DRUG); Everolimus (DRUG),6918289,Torisel,Lung Transplantation,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9262,NCT02587325,Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension,COMPLETED,PHASE1,Pulmonary Hypertension,nab-sirolimus (DRUG),6918289,Torisel,Pulmonary Hypertension,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9263,NCT01353625,"Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",COMPLETED,PHASE1,Glioblastoma Multiforme; Squamous Cell Carcinoma of Head and Neck; Prostate Cancer; Ewing's Osteosarcoma; Chronic Lymphocytic Leukemia; Neoplasm Metastasis,CC-115 (DRUG),6918289,Torisel,Glioblastoma Multiforme; Squamous Cell Carcinoma of Head and Neck; Prostate Cancer; Ewing's Osteosarcoma; Chronic Lymphocytic Leukemia; Neoplasm Metastasis,Skin,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9264,NCT06561022,Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping,NOT_YET_RECRUITING,PHASE2,Breast Cancer,Fluzoparib (DRUG); Everolimus (DRUG); Fulvestrant (DRUG); Abemaciclib (DRUG),6918289,Torisel,Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9265,NCT00332839,Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.,TERMINATED,PHASE4,Renal Transplantation,Everolimus (DRUG); Cyclosporin A (CsA) (DRUG); Tacrolimus (DRUG); Enteric Coated - Mycophenolate Sodium (EC-MPS) (DRUG); Corticosteroids (DRUG),6918289,Torisel,Renal Transplantation,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9266,NCT02511639,Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients,COMPLETED,PHASE3,Breast Cancer Metastatic,Everolimus (DRUG); Aromatase Inhibitors (DRUG),6918289,Torisel,Breast Cancer Metastatic,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9267,NCT00323739,Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma,COMPLETED,PHASE2,Kidney Cancer,bevacizumab (DRUG); RAD001 (DRUG),6918289,Torisel,Kidney Cancer,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9268,NCT01167530,Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer,UNKNOWN,PHASE1,Non-small Cell Lung Cancer; Locally Advanced Disease,Everolimus (DRUG),6918289,Torisel,Non-small Cell Lung Cancer; Locally Advanced Disease,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9269,NCT02974686,Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation,TERMINATED,PHASE4,"Kidney Transplant Rejection; Gastrointestinal Disorder, Functional",Everolimus (DRUG); Mycophenolic Acid (DRUG),6918289,Torisel,"Kidney Transplant Rejection; Gastrointestinal Disorder, Functional",Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9270,NCT01079286,Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers,COMPLETED,PHASE1,Renal Cell Cancer; Cancer,Nelfinavir and temsirolimus (DRUG),6918289,Torisel,Renal Cell Cancer; Cancer,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9271,NCT05476939,Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0,RECRUITING,PHASE3,"Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma, H3 K27M-Mutant",Everolimus (DRUG); ONC201 (DRUG); Radiotherapy (RADIATION),6918289,Torisel,"Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma, H3 K27M-Mutant",CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9272,NCT02137239,Regimen Optimization Study,COMPLETED,PHASE2,Kidney Transplantation,Thymoglobulin (DRUG); Belatacept (DRUG); mycophenolate mofetil(MMF) (DRUG); Corticosteroids (DRUG); Everolimus(EVL) (DRUG); Tacrolimus(TAC) (DRUG),6918289,Torisel,Kidney Transplantation,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9273,NCT01467986,Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma Recurrent,Dasatinib (DRUG); Rapamycin (DRUG); Irinotecan (DRUG); Temozolomide (DRUG); Irinotecan (DRUG); Temozolomide (DRUG),6918289,Torisel,Neuroblastoma Recurrent,CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9274,NCT03386539,Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score,ACTIVE_NOT_RECRUITING,PHASE3,Pediatric Heart Transplantation; Immunosuppression; Chronic Kidney Diseases; Cardiac Allograft Vasculopathy; Heart Transplant Failure and Rejection; Post-transplant Lymphoproliferative Disorder; Heart Transplant Infection,Everolimus (DRUG); Tacrolimus (DRUG); Mycophenolate Mofetil (DRUG),6918289,Torisel,Pediatric Heart Transplantation; Immunosuppression; Chronic Kidney Diseases; Cardiac Allograft Vasculopathy; Heart Transplant Failure and Rejection; Post-transplant Lymphoproliferative Disorder; Heart Transplant Infection,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9275,NCT05896839,Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer,RECRUITING,PHASE1,Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8; Metastatic Basal Cell Carcinoma; Metastatic Carcinoma in the Skin; Metastatic Melanoma; Metastatic Merkel Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma; Unresectable Basal Cell Carcinoma; Unresectable Melanoma; Unresectable Merkel Cell Carcinoma; Unresectable Skin Squamous Cell Carcinoma,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Ipilimumab (BIOLOGICAL); Kidney Biopsy (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Nivolumab (BIOLOGICAL); Prednisone (DRUG); Sirolimus (DRUG),6918289,Torisel,Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8; Metastatic Basal Cell Carcinoma; Metastatic Carcinoma in the Skin; Metastatic Melanoma; Metastatic Merkel Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma; Unresectable Basal Cell Carcinoma; Unresectable Melanoma; Unresectable Merkel Cell Carcinoma; Unresectable Skin Squamous Cell Carcinoma,Skin,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9276,NCT06301386,Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients,NOT_YET_RECRUITING,PHASE2,Colon Cancer,Everolimus (DRUG); PD-1 (DRUG),6918289,Torisel,Colon Cancer,Bowel,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9277,NCT06584773,Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients,RECRUITING,PHASE4,Disorder Related to Renal Transplantation,Everolimus (DRUG); standard maintenance immunosuppression (DRUG),6918289,Torisel,Disorder Related to Renal Transplantation,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9278,NCT05773326,Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG,RECRUITING,EARLY_PHASE1,"High Grade Glioma; Glioma; Glioma, Malignant; Glioblastoma",Temsirolimus (DRUG),6918289,Torisel,"High Grade Glioma; Glioma; Glioma, Malignant; Glioblastoma",CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9279,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,COMPLETED,PHASE2,Recurrent Melanoma; Stage IV Melanoma,sorafenib tosylate (DRUG); tipifarnib (DRUG); temsirolimus (DRUG),6918289,Torisel,Recurrent Melanoma; Stage IV Melanoma,Skin,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9280,NCT00604357,CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment,COMPLETED,PHASE3,End Stage Liver Disease; Impaired Renal Function,"anti-CD 25 mAb, Sirolimus, MMF (DRUG)",6918289,Torisel,End Stage Liver Disease; Impaired Renal Function,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9281,NCT01714765,Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer,COMPLETED,PHASE1,Metastatic Clear Cell Renal Cancer,Dovitinib (DRUG); Everolimus (DRUG),6918289,Torisel,Metastatic Clear Cell Renal Cancer,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9282,NCT00782626,Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas,COMPLETED,PHASE2,Glioma; Low-grade Glioma; Astrocytoma,everolimus (DRUG),6918289,Torisel,Glioma; Low-grade Glioma; Astrocytoma,CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9283,NCT00499486,Sirolimus in Treating Patients With Advanced Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,sirolimus (DRUG),6918289,Torisel,Pancreatic Cancer,Pancreas,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9284,NCT01626222,"4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer",COMPLETED,PHASE3,Metastatic Breast Cancer,Exemestane (DRUG); Everolimus (RAD001) (DRUG),6918289,Torisel,Metastatic Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9285,NCT01715935,Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus,COMPLETED,PHASE2,Clear-cell Renal Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma,Everolimus (DRUG),6918289,Torisel,Clear-cell Renal Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9286,NCT02909335,"De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study",WITHDRAWN,PHASE3,Liver Transplantation,"Tacrolimus (DRUG); Everolimus (DRUG); Mycophenolate mofetil (DRUG); Prednisolone, Prednisone or Methylprednisolone (DRUG)",6918289,Torisel,Liver Transplantation,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9287,NCT00275535,The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients,COMPLETED,PHASE4,Kidney Diseases,Anti-thymocyte globulin (DRUG); Mycophenolate mofetil (DRUG); Prednisone (DRUG); Tacrolimus (DRUG); Sirolimus (DRUG),6918289,Torisel,Kidney Diseases,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9288,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,COMPLETED,PHASE3,Renal Cell Carcinoma,Sorafenib (DRUG); temsirolimus (Torisel) (DRUG),6918289,Torisel,Renal Cell Carcinoma,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9289,NCT00096486,Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer,everolimus (DRUG); gefitinib (DRUG),6918289,Torisel,Lung Cancer,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9290,NCT01266148,SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance,COMPLETED,PHASE4,Renal Function and Chronic Allograft Vasculopathy,Cyclosporine (DRUG); Mycophenolate mofetil (DRUG); Corticosteroids (DRUG); Everolimus (DRUG); Anti Thymocyte Globulin (DRUG),6918289,Torisel,Renal Function and Chronic Allograft Vasculopathy,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9291,NCT03685448,ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB),UNKNOWN,PHASE2,Renal Cell Carcinoma; Papillary Renal Cell Carcinoma Type 1; Papillary Renal Cell Carcinoma Type 2; Chromophobe Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Xp11.2 Translocation-Related Renal Cell Carcinoma,Cabozantinib (DRUG),6918289,Torisel,Renal Cell Carcinoma; Papillary Renal Cell Carcinoma Type 1; Papillary Renal Cell Carcinoma Type 2; Chromophobe Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Xp11.2 Translocation-Related Renal Cell Carcinoma,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9292,NCT00930930,Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer,COMPLETED,PHASE2,Breast Cancer,cisplatin (DRUG); everolimus (DRUG); paclitaxel (DRUG); placebo (OTHER); Venous blood draw (PROCEDURE),6918289,Torisel,Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9293,NCT06428396,Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029),RECRUITING,PHASE2,Metastatic Breast Cancer,Belzutifan (DRUG); Fulvestrant (DRUG); Everolimus (DRUG); Exemestane (DRUG),6918289,Torisel,Metastatic Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9294,NCT04355858,Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer,UNKNOWN,PHASE2,Breast Cancer; Metastatic Cancer,SHR7390 (DRUG); Famitinib (DRUG); SHR3162 (DRUG); Pyrotinib (DRUG); Capecitabine (DRUG); SHR1210 (DRUG); Everolimus (DRUG); Nab paclitaxel (DRUG); SHR2554 (DRUG); SHR3680 (DRUG); SHR6390 (DRUG); SHR1701 (DRUG); SERD (DRUG); AI (DRUG); VEGFi (DRUG),6918289,Torisel,Breast Cancer; Metastatic Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9295,NCT01155258,Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors,COMPLETED,PHASE1,Extensive Stage Small Cell Lung Cancer; Hereditary Paraganglioma; Male Breast Cancer; Malignant Paraganglioma; Metastatic Gastrointestinal Carcinoid Tumor; Metastatic Pheochromocytoma; Pancreatic Polypeptide Tumor; Recurrent Breast Cancer; Recurrent Cervical Cancer; Recurrent Endometrial Carcinoma; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Recurrent Neuroendocrine Carcinoma of the Skin; Recurrent Non-small Cell Lung Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Pheochromocytoma; Recurrent Prostate Cancer; Recurrent Renal Cell Cancer; Recurrent Small Cell Lung Cancer; Recurrent Uterine Sarcoma; Regional Gastrointestinal Carcinoid Tumor; Regional Pheochromocytoma; Stage III Cervical Cancer; Stage III Endometrial Carcinoma; Stage III Neuroendocrine Carcinoma of the Skin; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Prostate Cancer; Stage III Renal Cell Cancer; Stage III Uterine Sarcoma; Stage IIIA Breast Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Breast Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Endometrial Carcinoma; Stage IV Neuroendocrine Carcinoma of the Skin; Stage IV Non-small Cell Lung Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Uterine Sarcoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer; Thyroid Gland Medullary Carcinoma,temsirolimus (DRUG); vinorelbine ditartrate (DRUG),6918289,Torisel,Extensive Stage Small Cell Lung Cancer; Hereditary Paraganglioma; Male Breast Cancer; Malignant Paraganglioma; Metastatic Gastrointestinal Carcinoid Tumor; Metastatic Pheochromocytoma; Pancreatic Polypeptide Tumor; Recurrent Breast Cancer; Recurrent Cervical Cancer; Recurrent Endometrial Carcinoma; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Recurrent Neuroendocrine Carcinoma of the Skin; Recurrent Non-small Cell Lung Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Pheochromocytoma; Recurrent Prostate Cancer; Recurrent Renal Cell Cancer; Recurrent Small Cell Lung Cancer; Recurrent Uterine Sarcoma; Regional Gastrointestinal Carcinoid Tumor; Regional Pheochromocytoma; Stage III Cervical Cancer; Stage III Endometrial Carcinoma; Stage III Neuroendocrine Carcinoma of the Skin; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Prostate Cancer; Stage III Renal Cell Cancer; Stage III Uterine Sarcoma; Stage IIIA Breast Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Breast Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Endometrial Carcinoma; Stage IV Neuroendocrine Carcinoma of the Skin; Stage IV Non-small Cell Lung Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Uterine Sarcoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer; Thyroid Gland Medullary Carcinoma,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9296,NCT00968591,Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency,COMPLETED,PHASE1,Hepatic Insufficiency,Everolimus (DRUG),6918289,Torisel,Hepatic Insufficiency,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9297,NCT01637194,Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer,COMPLETED,PHASE1,Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Basal Cell Carcinoma of the Lip; Recurrent Colon Cancer; Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage IV Adenoid Cystic Carcinoma of the Oral Cavity; Stage IV Basal Cell Carcinoma of the Lip; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Lymphoepithelioma of the Oropharynx; Stage IV Mucoepidermoid Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Stage IVA Colon Cancer; Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Colon Cancer; Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Tongue Cancer,everolimus (DRUG); cetuximab (BIOLOGICAL); pharmacological study (OTHER); laboratory biomarker analysis (OTHER),6918289,Torisel,Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Basal Cell Carcinoma of the Lip; Recurrent Colon Cancer; Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage IV Adenoid Cystic Carcinoma of the Oral Cavity; Stage IV Basal Cell Carcinoma of the Lip; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Lymphoepithelioma of the Oropharynx; Stage IV Mucoepidermoid Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Stage IVA Colon Cancer; Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Colon Cancer; Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Tongue Cancer,Bowel,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9298,NCT03065062,"Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors",RECRUITING,PHASE1,Lung Cancer Squamous Cell; Solid Tumors; Head & Neck Cancer; Pancreatic Cancer,Palbociclib (DRUG); Gedatolisib (DRUG),6918289,Torisel,Lung Cancer Squamous Cell; Solid Tumors; Head & Neck Cancer; Pancreatic Cancer,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9299,NCT00402662,A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma,TERMINATED,PHASE2,Metastatic Melanoma,everolimus (DRUG); Imatinib (DRUG),6918289,Torisel,Metastatic Melanoma,Skin,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9300,NCT04339062,Cemiplimab in AlloSCT/SOT Recipients With CSCC,COMPLETED,PHASE1,Cutaneous Squamous Cell Carcinoma; Advanced Cancer,Cemiplimab (DRUG); Everolimus (DRUG); Sirolimus (DRUG); Prednisone (DRUG),6918289,Torisel,Cutaneous Squamous Cell Carcinoma; Advanced Cancer,Skin,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9301,NCT01051791,Phase II Study of RAD001 Head and Neck Cancer,TERMINATED,PHASE2,Squamous Cell Carcinoma of the Head and Neck,Everolimus 10mg daily (DRUG),6918289,Torisel,Squamous Cell Carcinoma of the Head and Neck,Skin,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9302,NCT00699491,Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer,COMPLETED,PHASE1,Male Breast Carcinoma; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7,Cixutumumab (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Temsirolimus (DRUG),6918289,Torisel,Male Breast Carcinoma; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9303,NCT01596062,"Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)",COMPLETED,PHASE2,Renal Transplantation,Simulect® (DRUG); Neoral® (DRUG); Certican® (DRUG); Myfortic® (DRUG); Corticosteroids (DRUG),6918289,Torisel,Renal Transplantation,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9304,NCT01544491,"Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients",COMPLETED,PHASE3,Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant,RAD001 (DRUG); MMF (DRUG),6918289,Torisel,Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9305,NCT03834740,A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection,COMPLETED,EARLY_PHASE1,Glioblastoma Multiforme; Glioma of Brain,Ribociclib (DRUG); Everolimus (DRUG),6918289,Torisel,Glioblastoma Multiforme; Glioma of Brain,CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9306,NCT01387880,"Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer",COMPLETED,PHASE2,Metastatic Colorectal Cancer,Everolimus (DRUG); Everolimus (DRUG),6918289,Torisel,Metastatic Colorectal Cancer,Bowel,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9307,NCT00831480,Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal,TERMINATED,PHASE2,Kidney Cancer,everolimus (DRUG),6918289,Torisel,Kidney Cancer,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9308,NCT01960829,Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study,UNKNOWN,PHASE2,Melanoma; TOR Serine-Threonine Kinases; Neoplasm Metastasis,Everolimus (DRUG),6918289,Torisel,Melanoma; TOR Serine-Threonine Kinases; Neoplasm Metastasis,Skin,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9309,NCT01283789,Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer,UNKNOWN,PHASE2,Metastatic Breast Cancer,Lapatinib and RAD-001 (DRUG),6918289,Torisel,Metastatic Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9310,NCT00768729,Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation,COMPLETED,PHASE1,"Kidney Failure, Chronic; Kidney Transplantation; Immunosuppression",Sirolimus (DRUG); MMF or Azathioprine (DRUG),6918289,Torisel,Chronic Kidney Failure and Transplantation,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9311,NCT00805129,Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium,COMPLETED,PHASE2,Bladder Cancer; Metastatic Transitional Cell Carcinoma,Everolimus (DRUG),6918289,Torisel,Bladder Cancer; Metastatic Transitional Cell Carcinoma,Bladder/Urinary Tract,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9312,NCT01114529,"Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients",COMPLETED,PHASE3,Kidney Transplantation,Everolimus (DRUG); Prograf or Neoral (DRUG),6918289,Torisel,Kidney Transplantation,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9313,NCT01998789,Everolimus Post Orthotopic Liver Transplant,UNKNOWN,PHASE2,Orthotopic Liver Transplant,Everolimus (DRUG); Standard Tacrolimus (DRUG),6918289,Torisel,Orthotopic Liver Transplant,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9314,NCT00095329,"Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor",TERMINATED,PHASE1,Multiple Sclerosis (MS) - Relapsing-remitting,sirolimus (BIOLOGICAL),6918289,Torisel,Multiple Sclerosis (MS) - Relapsing-remitting,CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9315,NCT02138929,LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma,COMPLETED,PHASE1,Esophageal Cancer,Everolimus (DRUG); LDE 225 (DRUG),6918289,Torisel,Esophageal Cancer,Esophagus/Stomach,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9316,NCT02871791,Palbociclib With Everolimus + Exemestane In BC,COMPLETED,PHASE1,Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Hormone Receptor (HR)-Positive Breast Cancer,Palbociclib (DRUG); Everolimus (DRUG); Exemestane (DRUG),6918289,Torisel,Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Hormone Receptor (HR)-Positive Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9317,NCT06719791,Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE),RECRUITING,EARLY_PHASE1,"Epilepsy, Drug Resistant",Sirolimus (DRUG),6918289,Torisel,"Epilepsy, Drug Resistant",CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9318,NCT02683291,Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients,COMPLETED,PHASE4,Disorder Related to Renal Transplantation; Cytomegalovirus Infections,sirolimus (DRUG); tacrolimus (DRUG); mycophenolate (DRUG); Prednisone (DRUG); Basiliximab (DRUG); Thymoglobulin (DRUG),6918289,Torisel,Disorder Related to Renal Transplantation; Cytomegalovirus Infections,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9319,NCT00965094,Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients,COMPLETED,PHASE4,Chronic Renal Failure,Everolimus (DRUG); Tacrolimus (FK506) (DRUG); Basiliximab (DRUG); Enteric Coated Mycophenolate Sodium (EC-MPS) (DRUG); Corticosteroids (DRUG),6918289,Torisel,Chronic Renal Failure,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9320,NCT00886691,"Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",COMPLETED,PHASE2,Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Bevacizumab (BIOLOGICAL); Everolimus (DRUG); Laboratory Biomarker Analysis (OTHER); Placebo (OTHER),6918289,Torisel,Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9321,NCT03439462,Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer Metastatic,nab-sirolimus (DRUG),6918289,Torisel,Colorectal Cancer Metastatic,Bowel,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9322,NCT00467194,Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,COMPLETED,PHASE1,Liver Cancer,Rapamycin (DRUG); Bevacizumab (DRUG),6918289,Torisel,Liver Cancer,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9323,NCT01743560,"An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis",COMPLETED,PHASE4,Oestrogen Receptor Positive Advanced Breast Cancer,RAD001 (DRUG); Exemestane (DRUG),6918289,Torisel,Oestrogen Receptor Positive Advanced Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9324,NCT03333694,"Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)",TERMINATED,PHASE1,Cutaneous Squamous Cell Carcinoma in Situ (CSCCis),Cutaneous Cream application (DRUG); Placebo Cutaneous Cream application (DRUG),6918289,Torisel,Cutaneous Squamous Cell Carcinoma in Situ (CSCCis),Skin,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9325,NCT05079360,Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer,WITHDRAWN,PHASE2,Metastatic Breast Cancer,"Sabizabulin (DRUG); Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (DRUG)",6918289,Torisel,Metastatic Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9326,NCT01767194,Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma,COMPLETED,PHASE2,Ganglioneuroblastoma; Recurrent Neuroblastoma,Dinutuximab (BIOLOGICAL); Irinotecan Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Sargramostim (BIOLOGICAL); Temozolomide (DRUG); Temsirolimus (DRUG),6918289,Torisel,Ganglioneuroblastoma; Recurrent Neuroblastoma,CNS/Brain,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9327,NCT00494091,"Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma",COMPLETED,PHASE2,Advanced Renal Cell Carcinoma,Temsirolimus (CCI-779) (DRUG); Temsirolimus (CCI-779) (DRUG),6918289,Torisel,Advanced Renal Cell Carcinoma,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9328,NCT00240994,Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients,COMPLETED,PHASE2,"Kidney Failure, Chronic; Kidney Transplantation; Immunosuppression",Alemtuzumab (DRUG); Tacrolimus (DRUG); Mycophenolate mofetil (DRUG); Sirolimus (DRUG),6918289,Torisel,Chronic Kidney Failure and Transplantation,Kidney,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9329,NCT00828594,Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma,TERMINATED,PHASE1,Hepatocellular Carcinoma,"RAD001 (DRUG); RAD001, sorafenib (DRUG)",6918289,Torisel,Hepatocellular Carcinoma,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9330,NCT01248494,PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer,COMPLETED,PHASE1,Metastatic Breast Cancer,BEZ235 (DRUG); BKM 120 (DRUG); Letrozole (DRUG); BKM120 (DRUG),6918289,Torisel,Metastatic Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9331,NCT01633060,"A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi",TERMINATED,PHASE3,Metastatic Breast Cancer,Fulvestrant (DRUG); BKM120 (DRUG); BKM120 matching placebo (DRUG),6918289,Torisel,Metastatic Breast Cancer,Breast,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9332,NCT05445791,Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations,RECRUITING,PHASE3,Non Small Cell Lung Cancer,Metformin Hydrochloride (DRUG); Placebo (OTHER),6918289,Torisel,Non Small Cell Lung Cancer,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9333,NCT00098462,Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer,WITHDRAWN,PHASE1,Lung Cancer,gefitinib (DRUG); sirolimus (DRUG),6918289,Torisel,Lung Cancer,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9334,NCT01065662,AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies,COMPLETED,PHASE1,Endometrial Cancer; Ovarian Cancer; Cervical Cancer; Fallopian Tube Cancer; Peritoneal Cancer,temsirolimus (DRUG); cediranib (DRUG),6918289,Torisel,Endometrial Cancer; Ovarian Cancer; Cervical Cancer; Fallopian Tube Cancer; Peritoneal Cancer,Uterus,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9335,NCT00355862,Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma,COMPLETED,PHASE3,Hepatocellular Carcinoma,"CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free) (DRUG); Sirolimus (DRUG)",6918289,Torisel,Hepatocellular Carcinoma,Liver,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9336,NCT00981162,Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride,COMPLETED,PHASE1,"Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",sorafenib tosylate (DRUG); everolimus (DRUG); laboratory biomarker analysis (OTHER); pharmacogenomic studies (OTHER); pharmacological study (OTHER),6918289,Torisel,"Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Pancreas,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9337,NCT01196429,"Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer",COMPLETED,PHASE2,Ovarian Clear Cell Cystadenocarcinoma; Stage III Ovarian Cancer; Stage IV Ovarian Cancer,Carboplatin (DRUG); Docetaxel (DRUG); Laboratory Biomarker Analysis (OTHER); Paclitaxel (DRUG); Temsirolimus (DRUG),6918289,Torisel,Ovarian Clear Cell Cystadenocarcinoma; Stage III Ovarian Cancer; Stage IV Ovarian Cancer,Ovary/Fallopian Tube,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9338,NCT01259063,RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder,COMPLETED,PHASE1,Bladder Cancer,Everolimus and Intravesical Gemcitabine (DRUG),6918289,Torisel,Bladder Cancer,Bladder/Urinary Tract,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9339,NCT00079235,CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,temsirolimus (DRUG); laboratory biomarker analysis (OTHER),6918289,Torisel,Advanced Non-Small Cell Lung Cancer,Lung,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9340,NCT00729586,"Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer",COMPLETED,PHASE2,Endometrial Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC1 Uterine Corpus Cancer; Stage IIIC2 Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Laboratory Biomarker Analysis (OTHER); Megestrol Acetate (DRUG); Tamoxifen Citrate (DRUG); Temsirolimus (DRUG),6918289,Torisel,Endometrial Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC1 Uterine Corpus Cancer; Stage IIIC2 Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Uterus,Temsirolimus,MTOR,inhibitor/antagonist,MTOR inhibitor,yes,yes,Approved for treating renal cell carcinoma.,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1.04,303.0 +9341,NCT00619866,An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis,COMPLETED,PHASE2,"Endometriosis, Pain",Elagolix (DRUG); placebo (DRUG),6442177,RAD,Endometriosis with Pain,Uterus,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9342,NCT01767857,A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer,TERMINATED,PHASE3,Metastatic Colorectal Cancer,Xilonix (DRUG); Placebo (DRUG),6442177,RAD,Metastatic Colorectal Cancer,Bowel,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9343,NCT01853748,T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Trastuzumab (DRUG); Paclitaxel (DRUG); Trastuzumab emtansine (DRUG),6442177,RAD,Breast Cancer,Breast,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9344,NCT03011320,An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery,COMPLETED,PHASE1,Ovary Cancer,EC1456 (DRUG); 99mTc-Etarfolatide (DRUG),6442177,RAD,Ovary Cancer,Ovary/Fallopian Tube,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9345,NCT00467974,Transarterial Ethanol Ablation (TEA) Versus Transcatheter Arterial Chemoembolisation (TACE) for Hepatocellular Carcinoma,COMPLETED,PHASE3,Hepatocellular Carcinoma,TEA with LEM (PROCEDURE); TACE (PROCEDURE),6442177,RAD,Hepatocellular Carcinoma,Liver,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9346,NCT02296320,Study of the Efficacy and Safety of MEDI4893,COMPLETED,PHASE2,Staphylococcus Aureus Pneumonia,MEDI4893 (DRUG); Placebo (OTHER),6442177,RAD,Staphylococcus Aureus Pneumonia,Lung,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9347,NCT00556374,Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy,COMPLETED,PHASE3,Breast Cancer,Placebo (DRUG); Denosumab (BIOLOGICAL); Non-steroidal aromatase inhibitor therapy (DRUG); Zoledronic Acid (DRUG); Standard of Care (OTHER),6442177,RAD,Breast Cancer,Breast,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9348,NCT00798720,Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer,COMPLETED,PHASE2,"Carcinoma, Non Small Cell Lung",vorinostat (DRUG); bortezomib (DRUG),6442177,RAD,Non-small Cell Lung Cancer (NSCLC),Lung,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9349,NCT02077920,Methods of Chlorhexidine Cleansing to Prevent Ventilator-Associated Pneumonia (VAP),COMPLETED,PHASE2,Ventilator-associated Pneumonia,Chlorhexidine (DRUG); 0.9% sodium chloride injection (DRUG); Endotracheal tube (DEVICE); Fiber bronchoscope (DEVICE),6442177,RAD,Ventilator-associated Pneumonia,Lung,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9350,NCT03618420,Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function,COMPLETED,PHASE1,"Diabetes Mellitus, Type 1; Nephropathy; Diabetic Nephropathies; Juvenile Diabetes; Diabetes Mellitus Complication; Autoimmune Diabetes; Type 1 Diabetes Mellitus",Aminohippurate Sodium Inj 20% (DRUG); Iohexol Inj 300 mg/mL (DRUG),6442177,RAD,"Diabetes Mellitus, Type 1; Nephropathy; Diabetic Nephropathies; Juvenile Diabetes; Diabetes Mellitus Complication; Autoimmune Diabetes; Type 1 Diabetes Mellitus",Kidney,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9351,NCT00264420,Safety and Efficacy Study of Concomitant Radiotherapy and Zoledronic Acid for Bone Metastases Palliation,COMPLETED,PHASE1,Bone Metastases; Breast Cancer; Lung Cancer; Prostate Cancer,zoledronic acid (DRUG),6442177,RAD,Bone Metastases; Breast Cancer; Lung Cancer; Prostate Cancer,Lung,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9352,NCT04526665,Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC),ACTIVE_NOT_RECRUITING,PHASE3,Primary Biliary Cirrhosis,Elafibranor 80mg (DRUG); Placebo (DRUG),6442177,RAD,Primary Biliary Cirrhosis,Liver,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9353,NCT05582265,Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I),RECRUITING,PHASE3,Head and Neck Squamous Cell Carcinomas,Tislelizumab（neoadjuvant） (DRUG); Cisplatin （neoadjuvant） (DRUG); Nab-paclitaxel （neoadjuvant） (DRUG); Surgical resection (PROCEDURE); Cisplatin（adjuvant） (DRUG); Tislelizumab（adjuvant） (DRUG); Radiation (RADIATION); Carboplatin (neoadjuvant） (DRUG); Carboplatin (adjuvant） (DRUG),6442177,RAD,Head and Neck Squamous Cell Carcinomas,Skin,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9354,NCT03068065,Antidiabetic Effects on Intrahepatic Fat,COMPLETED,PHASE4,Non-Alcoholic Fatty Liver Disease; Type2 Diabetes,Liraglutide (DRUG); Metformin (DRUG); Gliclazide (DRUG),6442177,RAD,Non-Alcoholic Fatty Liver Disease; Type2 Diabetes,Liver,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9355,NCT01939665,PANFIRE Study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma,COMPLETED,PHASE1,Locally Advanced Pancreatic Carcinoma (LAPC); Non-metastasized Unresectable Pancreatic Carcinoma; Pancreatic Cancer,"NanoKnife ""Irreversible electroporation (IRE)"" (DEVICE)",6442177,RAD,Locally Advanced Pancreatic Carcinoma (LAPC); Non-metastasized Unresectable Pancreatic Carcinoma; Pancreatic Cancer,Pancreas,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9356,NCT01638520,Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis,UNKNOWN,PHASE2,"Tuberculosis, Pulmonary",Pascolizumab (DRUG); Placebo (DRUG),6442177,RAD,Pulmonary Tuberculosis,Lung,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9357,NCT01388920,Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting,TERMINATED,PHASE2,Chronic Obstructive Pulmonary Disease (COPD),Tesamorelin (DRUG); Placebo (DRUG),6442177,RAD,Chronic Obstructive Pulmonary Disease (COPD),Lung,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9358,NCT00427674,Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients,TERMINATED,PHASE1,Parkinson Disease,[123I] mZINT injection and serial dynamic SPECT imaging (DRUG),6442177,RAD,Parkinson Disease,CNS/Brain,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9359,NCT01446874,Prevention of Post-operative Pneumonia (POPP),TERMINATED,PHASE2,Post-operative Pneumonia; Lung Cancer; Esophageal Cancer,0.12% chlorhexidine solution (DRUG),6442177,RAD,Post-operative Pneumonia; Lung Cancer; Esophageal Cancer,Lung,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9360,NCT03199274,Perflutren Protein-Type a Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients with Liver Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Hepatocellular Carcinoma,Yttrium-90 Microsphere Radioembolization (PROCEDURE); Perflutren Protein-Type A Microspheres (DRUG); Dynamic Contrast-Enhanced Ultrasound Imaging (PROCEDURE),6442177,RAD,Hepatocellular Carcinoma,Liver,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9361,NCT05868174,Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors,RECRUITING,PHASE1,"Solid Tumor, Adult; Advanced Solid Tumor; Advanced Renal Cell Carcinoma",89Zr-TLX250 (DIAGNOSTIC_TEST); 177Lu-TLX250 and Peposertib (COMBINATION_PRODUCT),6442177,RAD,"Solid Tumor, Adult; Advanced Solid Tumor; Advanced Renal Cell Carcinoma",Kidney,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9362,NCT03654274,SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain,COMPLETED,PHASE3,Endometriosis,Relugolix (DRUG); Estradiol/norethindrone acetate (DRUG),6442177,RAD,Endometriosis,Uterus,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9363,NCT02024074,Evaluation of Magnetic Resonance Imaging (MRI) vs Molecular Breast Imaging (Tc-MBI) in Breast Cancer Patients,TERMINATED,PHASE1,Breast Cancer,Sestamibi (Tc-MBI) scan of the breast (OTHER),6442177,RAD,Breast Cancer,Breast,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9364,NCT01147874,Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice,COMPLETED,PHASE4,Psoriasis; Psoriatic Arthritis,lab draws and imaging (PROCEDURE),6442177,RAD,Psoriasis; Psoriatic Arthritis,Skin,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9365,NCT03743766,"Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting",COMPLETED,PHASE2,Melanoma,Relatlimab (DRUG); Nivolumab (DRUG); Relatlimab + Nivolumab (DRUG),6442177,RAD,Melanoma,Skin,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9366,NCT02908165,Randomized Phase II Trial of Chemoembolization and Sorafenib,WITHDRAWN,PHASE2,Hepatocellular Carcinoma,"conventional TACE in combination with sorafenib, administered on a continuous schedule (DRUG); conventional TACE in combination with sorafenib, administered on a sequential schedule (DRUG)",6442177,RAD,Hepatocellular Carcinoma,Liver,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9367,NCT06476366,Comparison of Efficacy of Methotrexate and Azathioprine in Patients With Chronic Actinic Dermatitis: A Randomized Controlled Trial,RECRUITING,EARLY_PHASE1,Chronic Actinic Dermatitis,Azathioprine (DRUG); Methotrexate (DRUG),6442177,RAD,Chronic Actinic Dermatitis,Skin,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9368,NCT00466466,Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients,COMPLETED,PHASE1,Small-Cell Lung Cancer,Everolimus (DRUG),6442177,RAD,Small-Cell Lung Cancer,Lung,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9369,NCT05718466,Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy,COMPLETED,PHASE3,Recurrent or Progressive Glioblastoma,Bevacizumab (DRUG); Chemotherapy (DRUG); Fractionated radiosurgery (RADIATION),6442177,RAD,Recurrent or Progressive Glioblastoma,CNS/Brain,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9370,NCT00075166,Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors,COMPLETED,PHASE4,Brain Neoplasms; Neoplasm Metastasis,Stereotactic surgery (SRS) (PROCEDURE); Craniotomy (PROCEDURE),6442177,RAD,Brain Neoplasms; Neoplasm Metastasis,CNS/Brain,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9371,NCT02589366,Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium,TERMINATED,PHASE1,Endometrial Cancer,Lymphoseek plus Vital Blue Dye (DRUG),6442177,RAD,Endometrial Cancer,Uterus,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9372,NCT03026166,A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer,TERMINATED,PHASE1,Small Cell Lung Cancer,Ipilimumab (DRUG); Nivolumab (DRUG); Rovalpituzumab tesirine (DRUG),6442177,RAD,Small Cell Lung Cancer,Lung,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9373,NCT03997266,NICU Antibiotics and Outcomes Trial,RECRUITING,PHASE4,Microbial Colonization; Extreme Prematurity; Early-Onset Neonatal Sepsis; Late-Onset Neonatal Sepsis; Necrotizing Enterocolitis of Newborn; Death; Neonatal,Ampicillin (DRUG); Gentamycin (DRUG); Normal saline (DRUG),6442177,RAD,Microbial Colonization; Extreme Prematurity; Early-Onset Neonatal Sepsis; Late-Onset Neonatal Sepsis; Necrotizing Enterocolitis of Newborn; Death; Neonatal,Bowel,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9374,NCT04332666,"Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial",UNKNOWN,PHASE2,Coronavirus; Respiratory Failure; Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere; SARS-CoV-2,Angiotensin 1-7 (DRUG); Placebos (DRUG),6442177,RAD,Coronavirus; Respiratory Failure; Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere; SARS-CoV-2,Lung,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9375,NCT02044965,Can Probiotics be Used in the Prevention of Recurrent UTI in Paediatric Neurogenic Bladder,UNKNOWN,PHASE1,Urinary Tract Infection,Antibiotic (OTHER); Probiotic (DRUG),6442177,RAD,Urinary Tract Infection,Bladder/Urinary Tract,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9376,NCT06721520,Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy,RECRUITING,PHASE2,Esophageal Cancer Surgery; Esophagectomy; Delayed Gastric Emptying Following Procedure; Esophageal Diseases; Esophageal Achalasia; Pylorus Dysfunction; Esophageal Dysmotility,Botulinum Toxin A (Botox ) (BIOLOGICAL); Pyloromyotomy (PROCEDURE),6442177,RAD,Esophageal Cancer Surgery; Esophagectomy; Delayed Gastric Emptying Following Procedure; Esophageal Diseases; Esophageal Achalasia; Pylorus Dysfunction; Esophageal Dysmotility,Esophagus/Stomach,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9377,NCT00923520,"A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies",COMPLETED,PHASE1,Renal Cell Carcinoma; Breast Cancer; Colon Cancer; Lung Cancer; Non-Hodgkin Lymphoma,DMS 612 (DRUG),6442177,RAD,Renal Cell Carcinoma; Breast Cancer; Colon Cancer; Lung Cancer; Non-Hodgkin Lymphoma,Bowel,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9378,NCT06642220,Ablative Radioembolization of Renal Cell Carcinoma Trial,NOT_YET_RECRUITING,PHASE2,Renal Cell Carcinoma (RCC); Radioembolization,Y-90 Selective Internal Radiation Therapy (SIRT) (DEVICE),6442177,RAD,Renal Cell Carcinoma (RCC); Radioembolization,Kidney,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9379,NCT03799874,Safety and Efficacy Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS),ACTIVE_NOT_RECRUITING,PHASE2,Acute Respiratory Distress Syndrome,Inhaled Carbon Monoxide at 200 ppm (DRUG); Inhaled Medical air (OTHER),6442177,RAD,Acute Respiratory Distress Syndrome,Lung,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9380,NCT04573231,Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer,RECRUITING,PHASE2,Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer,18F-DCFPyL (DRUG),6442177,RAD,Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer,Breast,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9381,NCT00018031,Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients,COMPLETED,PHASE2,Hepatitis C; HIV Infections,Peginterferon alfa-2b (DRUG); Ribavirin (DRUG),6442177,RAD,Hepatitis C; HIV Infections,Liver,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9382,NCT05678673,Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma,RECRUITING,PHASE3,Non-Clear Cell Renal Cell Carcinoma,XL092 (DRUG); Nivolumab (DRUG); Sunitinib Malate (DRUG),6442177,RAD,Non-Clear Cell Renal Cell Carcinoma,Kidney,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9383,NCT02177773,GA-68 DOTA-TOC of Somatostatin Positive Malignancies,TERMINATED,PHASE1,Neuroendocrine Tumor; Paraganglioma; Carcinoid Tumors; Neuroblastoma,Computed Tomography (CT) (PROCEDURE); Gallium Ga 68-Edotreotide (DRUG); Magnetic Resonance Imaging (MRI) (PROCEDURE); Positron Emission Tomography (PET) (PROCEDURE),6442177,RAD,Neuroendocrine Tumor; Paraganglioma; Carcinoid Tumors; Neuroblastoma,CNS/Brain,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9384,NCT06833073,A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011),RECRUITING,PHASE2,Urinary Bladder Neoplasms; Non-Muscle Invasive Bladder Neoplasms; Carcinoma in Situ,Intismeran autogene (BIOLOGICAL); BCG (BIOLOGICAL),6442177,RAD,Urinary Bladder Neoplasms; Non-Muscle Invasive Bladder Neoplasms; Carcinoma in Situ,Bladder/Urinary Tract,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9385,NCT03863457,[18F] F-GLN by PET/CT in Breast Cancer,RECRUITING,PHASE1,Breast Cancer,Fluoroglutamine [18F]F-GLN (DRUG),6442177,RAD,Breast Cancer,Breast,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9386,NCT01523457,Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer,COMPLETED,PHASE2,Metastatic Pancreatic Cancer; Pancreatic Cancer,Folfirinox (DRUG),6442177,RAD,Metastatic Pancreatic Cancer; Pancreatic Cancer,Pancreas,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9387,NCT02458157,Forced Fluid Removal in High Risk Acute Kidney Injury,TERMINATED,PHASE4,Acute Kidney Injury; Fluid Overload; Critical Illness,Furosemide (Furix) (DRUG); Continuous renal replacement therapy (CRRT) (OTHER); Resuscitation (OTHER); Usual Care (OTHER),6442177,RAD,Acute Kidney Injury; Fluid Overload; Critical Illness,Kidney,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9388,NCT02456857,"Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative",COMPLETED,PHASE2,Invasive Breast Carcinoma; Triple-Negative Breast Carcinoma,Bevacizumab (BIOLOGICAL); Everolimus (DRUG); Laboratory Biomarker Analysis (OTHER); Pegylated Liposomal Doxorubicin Hydrochloride (DRUG),6442177,RAD,Triple-Negative Breast Carcinoma,Breast,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9389,NCT00376948,"Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",COMPLETED,PHASE2,Pancreatic Cancer,genistein (DIETARY_SUPPLEMENT); erlotinib hydrochloride (DRUG); gemcitabine hydrochloride (DRUG),6442177,RAD,Pancreatic Cancer,Pancreas,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9390,NCT00244348,Hepatic Artery Infusion With Oxaliplatin,WITHDRAWN,PHASE1,Colorectal Cancer; Metastasis; Liver Cancer,Oxaliplatin (via HAI) (DRUG); 5 Fluorouracil (systemic) (DRUG),6442177,RAD,Colorectal Cancer with Liver Metastasis,Liver,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9391,NCT06114082,TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma,RECRUITING,PHASE2,Hepatocellular Carcinoma; Liver Cancer,IDA-TACE (PROCEDURE); DOX-TACE (PROCEDURE),6442177,RAD,Hepatocellular Carcinoma,Liver,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9392,NCT00994682,University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial),COMPLETED,PHASE4,Nonalcoholic Steatohepatitis; Nonalcoholic Fatty Liver Disease; Type 2 Diabetes Mellitus,Pioglitazone study drug (DRUG); Placebo (DRUG); Pioglitazone Open Label (DRUG),6442177,RAD,Nonalcoholic Steatohepatitis; Nonalcoholic Fatty Liver Disease; Type 2 Diabetes Mellitus,Liver,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9393,NCT03423082,Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.,TERMINATED,PHASE4,Cervical Cancer; Uterine Cancer,18F fluciclovine (DRUG); 18F fluciclovine PET (DEVICE),6442177,RAD,Cervical Cancer; Uterine Cancer,Cervix,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9394,NCT05488873,A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy,ACTIVE_NOT_RECRUITING,PHASE2,Chemotherapy-induced Peripheral Neuropathy,WST-057 Active (DRUG); Placebo (DRUG),6442177,RAD,Chemotherapy-induced Peripheral Neuropathy,Peripheral Nervous System,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9395,NCT05521373,Ultrasound-guided Versus Combined Ultrasound and Fluoroscopy-guided Cervical Selective Nerve Root Block for Lower Cervical Radiculopathy: Non-inferiority Randomized Controlled Study,UNKNOWN,PHASE2,Cervical Pain,ultrasound cervical selective nerve root block (DEVICE); ultrasound and fluoroscopy-guided cervical selective nerve root block (DEVICE),6442177,RAD,Cervical Pain,Cervix,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9396,NCT03221582,Impact of Hepatitis C Therapy and Bone Health,TERMINATED,PHASE4,Human Immunodeficiency Virus; Hepatitis C,EBR/GZR (DRUG),6442177,RAD,Human Immunodeficiency Virus; Hepatitis C,Liver,Everolimus,"MTOR, FKBP1A",inhibitor/antagonist,MTOR inhibitor,yes,yes,"Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.",CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,1.05,315.0 +9397,NCT01458574,"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis",COMPLETED,PHASE3,Ulcerative Colitis,"Placebo (DRUG); CP690,550 (DRUG); CP-690,550 (DRUG)",9926791,Tofacitinib,Ulcerative Colitis,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9398,NCT01831466,Tofacitinib Ointment For Chronic Plaque Psoriasis,COMPLETED,PHASE2,Psoriasis Vulgaris; Psoriasis,tofacitinib ointment 20 mg/g (DRUG); tofacitinib ointment 10 mg/g (DRUG); placebo ointment (vehicle) (DRUG); tofacitinib ointment 20 mg/g (DRUG); tofacitinib ointment 10 mg/g (DRUG); placebo ointment (vehicle) (DRUG),9926791,Tofacitinib,Psoriasis Vulgaris; Psoriasis,Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9399,NCT01710020,"Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease",COMPLETED,PHASE1,End-Stage Renal Disease; Hemodialysis,"CP-690,550 (DRUG)",9926791,Tofacitinib,End-Stage Renal Disease,Kidney,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9400,NCT05313620,"Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events",RECRUITING,PHASE4,Ulcerative Colitis; Thromboembolism,Tofacitinib (DRUG); Infliximab Adalimumab y Golimumab (DRUG),9926791,Tofacitinib,Ulcerative Colitis; Thromboembolism,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9401,NCT04259138,Determination of the Optimal Treatment Target in Ulcerative Colitis,ACTIVE_NOT_RECRUITING,PHASE4,"Colitis, Ulcerative",Treatment Algorithm A (BIOLOGICAL); Treatment Algorithm B (BIOLOGICAL); Treatment Algorithm C (BIOLOGICAL),9926791,Tofacitinib,"Colitis, Ulcerative",Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9402,NCT01710046,"Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis",COMPLETED,PHASE2,Plaque Psoriasis,"(CP-6890,550) Tofacitinib (DRUG); Placebo (DRUG); (CP-690,550) Tofacitinib (DRUG); Placebo (DRUG)",9926791,Tofacitinib,Plaque Psoriasis,Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9403,NCT06689982,Tofacitinib in Patients With Amyotrophic Lateral Sclerosis,NOT_YET_RECRUITING,EARLY_PHASE1,Amyotrophic Lateral Sclerosis,Tofacitinib tablets (DRUG),9926791,Tofacitinib,Amyotrophic Lateral Sclerosis,CNS/Brain,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9404,NCT03103412,TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC),COMPLETED,PHASE1,"Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects",TD-3504 (DRUG); 15N2-tofacitinib (DRUG); Placebo (DRUG),9926791,Tofacitinib,"Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects",Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9405,NCT04624230,Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis,RECRUITING,PHASE3,Ulcerative Colitis,tofacitinib (DRUG),9926791,Tofacitinib,Ulcerative Colitis,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9406,NCT00106639,"A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients",COMPLETED,PHASE2,Kidney Transplantation,"CP-690,550 (DRUG); CP-690,550 (DRUG); tacrolimus (DRUG)",9926791,Tofacitinib,Kidney Transplantation,Kidney,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9407,NCT01276639,"A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis",COMPLETED,PHASE3,Psoriasis,"CP-690,550 (DRUG); CP-690,550 (DRUG); Placebo/CP-690,550 (DRUG); Placebo/CP-690,550 (DRUG)",9926791,Tofacitinib,Psoriasis,Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9408,NCT04925973,Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management,ACTIVE_NOT_RECRUITING,PHASE2,Ulcerative Colitis Acute,Tofacitinib 10 MG [Xeljanz] (DRUG),9926791,Tofacitinib,Ulcerative Colitis Acute,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9409,NCT01740362,"Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function",COMPLETED,PHASE1,Renal Impairment,"CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG)",9926791,Tofacitinib,Renal Impairment,Kidney,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9410,NCT01241591,"A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis",COMPLETED,PHASE3,Psoriasis,"CP 690,550 5 mg (DRUG); CP 690,550 10 mg (DRUG); Etanercept 50 mg (BIOLOGICAL); Placebo (OTHER)",9926791,Tofacitinib,Psoriasis,Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9411,NCT05487963,"Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis",COMPLETED,PHASE1,Atopic Dermatitis,Tofacitinib Citrate (DRUG); placebo ointment (OTHER),9926791,Tofacitinib,Atopic Dermatitis,Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9412,NCT03518086,An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1),COMPLETED,PHASE3,Ulcerative Colitis,Mirikizumab (DRUG); Placebo (DRUG),9926791,Tofacitinib,Ulcerative Colitis,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9413,NCT01736696,Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis,COMPLETED,PHASE1,Psoriasis; Immunomodulation,tofacitinib (DRUG); tofacitinib (DRUG); tofacitinib (DRUG); tofacitinib (DRUG); tofacitinib (DRUG); tofacitinib (DRUG),9926791,Tofacitinib,Psoriasis; Immunomodulation,Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9414,NCT01815424,"A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis",COMPLETED,PHASE3,Psoriasis,"placebo (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG)",9926791,Tofacitinib,Psoriasis,Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9415,NCT03281304,A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission,TERMINATED,PHASE4,Ulcerative Colitis,"CP-690,500 5 mg (DRUG); CP-690,550 10 mg (DRUG)",9926791,Tofacitinib,Ulcerative Colitis,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9416,NCT01519089,"A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis",COMPLETED,PHASE3,Psoriasis,"CP-690,550 (DRUG); CP-690, 550 (DRUG)",9926791,Tofacitinib,Psoriasis,Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9417,NCT01186744,"A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis",COMPLETED,PHASE3,Psoriasis,"CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG)",9926791,Tofacitinib,Psoriasis,Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9418,NCT03524092,A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis,COMPLETED,PHASE3,Ulcerative Colitis,Mirikizumab SC (DRUG); Mirikizumab IV (DRUG); Placebo SC (DRUG),9926791,Tofacitinib,Ulcerative Colitis,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9419,NCT04246372,Tofacitinib for Immune Skin Conditions in Down Syndrome,COMPLETED,PHASE2,Down Syndrome; Alopecia Areata; Atopic Dermatitis / Eczema; Hidradenitis Suppurativa; Vitiligo; Psoriasis,Tofacitinib (DRUG),9926791,Tofacitinib,Down Syndrome; Alopecia Areata; Atopic Dermatitis / Eczema; Hidradenitis Suppurativa; Vitiligo; Psoriasis,Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9420,NCT00678210,"Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis",COMPLETED,PHASE2,Psoriasis,"CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG); Placebo (DRUG)",9926791,Tofacitinib,Psoriasis,Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9421,NCT01470612,"Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis",COMPLETED,PHASE3,Ulcerative Colitis,"CP-690,550 (DRUG); CP-690,550 (DRUG)",9926791,Tofacitinib,Ulcerative Colitis,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9422,NCT04505410,Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis,COMPLETED,PHASE3,Ulcerative Colitis,"A plant based high fiber diet that mimics fasting (""FMD"") plus advanced therapy (OTHER); Advanced therapy only without dietary intervention (DRUG)",9926791,Tofacitinib,Ulcerative Colitis,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9423,NCT03885713,Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease,COMPLETED,PHASE4,Inflammatory Bowel Diseases; Crohn Disease; Ulcerative Colitis,Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib (BIOLOGICAL),9926791,Tofacitinib,Inflammatory Bowel Diseases; Crohn Disease; Ulcerative Colitis,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9424,NCT04034238,"Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors",COMPLETED,PHASE1,"Neoplasms With Mesothelin Expression; Epithelioid Mesothelioma; Cholangiocarcinoma, Extrahepatic; Adenocarcinoma, Pancreatic",LMB-100 (DRUG); Tofacitinib (DRUG); Mesothelin Expression (DEVICE),9926791,Tofacitinib,"Neoplasms With Mesothelin Expression; Epithelioid Mesothelioma; Cholangiocarcinoma, Extrahepatic; Adenocarcinoma, Pancreatic",Lung,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9425,NCT02001181,Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema),COMPLETED,PHASE2,"Dermatitis, Atopic",Tofacitinib ointment 20mg/g (DRUG); Placebo ointment (Vehicle) (DRUG),9926791,Tofacitinib,"Dermatitis, Atopic",Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9426,NCT06055023,Phase I Clinical Study of ZL-82 Tablets,COMPLETED,PHASE1,Rheumatoid Arthritis (RA); Inflammatory Bowel Disease - IBD1,ZL-82 12.5mg (DRUG); ZL-82 25mg (DRUG); ZL-82 50mg (DRUG); ZL-82 100mg (DRUG); ZL-82 200mg (DRUG); ZL-82 300mg (DRUG); ZL-82 450mg (DRUG); ZL-82 600mg (DRUG); zL-82 placebo 12.5mg (DRUG); ZL-82 placebo 25mg (DRUG); ZL-82 placebo 50mg (DRUG); ZL-82 placebo 100mg (DRUG); ZL-82 placebo 200mg (DRUG); ZL-82 placebo 300mg (DRUG); ZL-82 placebo 450mg (DRUG); ZL-82 placebo 600mg (DRUG),9926791,Tofacitinib,Rheumatoid Arthritis and Inflammatory Bowel Disease,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9427,NCT06625450,TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS,NOT_YET_RECRUITING,PHASE4,Ulcerative Colitis,Tofacitinib (DRUG); Tofacitinib plus mesalamine (DRUG),9926791,Tofacitinib,Ulcerative Colitis,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9428,NCT06810050,Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis,RECRUITING,PHASE2,Atopic Dermatitis (AD),CGB-500 with 0.5% tofacitinib (DRUG); CGB-500 Ointment with 1% tofacitinib (DRUG); Vehicle (placebo) (DRUG),9926791,Tofacitinib,Atopic Dermatitis (AD),Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9429,NCT02740049,In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma,COMPLETED,EARLY_PHASE1,Asthma,VR588 (DRUG),9926791,Tofacitinib,Asthma,Lung,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9430,NCT00615199,"A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease",COMPLETED,PHASE2,Crohn's Disease,"CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG); Placebo (DRUG)",9926791,Tofacitinib,Crohn's Disease,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9431,NCT03591770,Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib,TERMINATED,PHASE4,Inflammatory Bowel Diseases,SHINGRIX (BIOLOGICAL),9926791,Tofacitinib,Inflammatory Bowel Diseases,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9432,NCT01470599,"A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease",COMPLETED,PHASE2,Crohn's Disease,"CP-690,550 (DRUG); CP-690,550 (DRUG)",9926791,Tofacitinib,Crohn's Disease,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9433,NCT01393899,"The Safety And Efficacy Of Maintenance Therapy With CP-690,550",COMPLETED,PHASE2,Crohn's Disease,"Placebo (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG)",9926791,Tofacitinib,Crohn's Disease,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9434,NCT05326464,Tofacitinib in Recurrent GBM Patients,RECRUITING,PHASE3,Glioblastoma,Tofacitinib 10mg (DRUG),9926791,Tofacitinib,Glioblastoma,CNS/Brain,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9435,NCT01465763,"A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis",COMPLETED,PHASE3,Ulcerative Colitis,tofacitinib (DRUG); Placebo (DRUG),9926791,Tofacitinib,Ulcerative Colitis,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9436,NCT00969813,"A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function",COMPLETED,PHASE1,Hepatic Insufficiency,"CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG)",9926791,Tofacitinib,Hepatic Insufficiency,Liver,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9437,NCT00658359,Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients,COMPLETED,PHASE2,Kidney Transplantation,"Cyclosporine (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG)",9926791,Tofacitinib,Kidney Transplantation,Kidney,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9438,NCT04332042,TOFAcitinib in SARS-CoV2 Pneumonia,UNKNOWN,PHASE2,SARS-COv2 Related Interstitial Pneumonia,Tofacitinib (DRUG),9926791,Tofacitinib,SARS-COv2 Related Interstitial Pneumonia,Lung,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9439,NCT06465732,Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients,NOT_YET_RECRUITING,PHASE4,Atopic Dermatitis,Dupilumab (DRUG); Tofacitinib (DRUG),9926791,Tofacitinib,Atopic Dermatitis,Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9440,NCT00483756,Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients,COMPLETED,PHASE2,Kidney Transplantation,"Cyclosporine (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG)",9926791,Tofacitinib,Kidney Transplantation,Kidney,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9441,NCT01458951,"A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis",COMPLETED,PHASE3,Ulcerative Colitis,tofacitinib (DRUG); Placebo (DRUG),9926791,Tofacitinib,Ulcerative Colitis,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9442,NCT01163253,"A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis",TERMINATED,PHASE3,Psoriasis,"CP-690,550 (DRUG); CP-690,550 (DRUG)",9926791,Tofacitinib,Psoriasis,Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9443,NCT01309737,"A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis",COMPLETED,PHASE3,Psoriasis,"CP-690,550 (DRUG); CP-690,550 (DRUG); Placebo/CP-690,550 (DRUG); Placebo/CP-690,550 (DRUG)",9926791,Tofacitinib,Psoriasis,Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9444,NCT02193815,A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis,COMPLETED,PHASE1,Psoriasis Vulgaris,PF06263276 (DRUG); Vehicle (OTHER); 2%Tofacitinib Ointment (DRUG); Vehicle (OTHER); Daivonex (DRUG); Daivonex Ointment (DRUG),9926791,Tofacitinib,Psoriasis Vulgaris,Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9445,NCT01710033,"A Study Of CP-690,550 In Stable Kidney Transplant Patients",COMPLETED,PHASE1,Kidney Transplant,"Placebo (DRUG); CP-690,550 5 mg BID (DRUG); CP-690,550 15 mg BID (DRUG); CP-690,550 30 mg BID (DRUG)",9926791,Tofacitinib,Kidney Transplant,Kidney,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9446,NCT04415151,Tofacitinib for Treatment of Moderate COVID-19,TERMINATED,PHASE2,COVID-19 Pneumonia,Tofacitinib 10 mg (DRUG); Placebo (DRUG),9926791,Tofacitinib,COVID-19 Pneumonia,Lung,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9447,NCT00263328,Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient,COMPLETED,PHASE2,Kidney Transplantation,"Tacrolimus (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG)",9926791,Tofacitinib,Kidney Transplantation,Kidney,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9448,NCT01246583,CP-690-550 Ointment For Chronic Plaque Psoriasis,COMPLETED,PHASE2,Psoriasis,"CP-690,550 Ointment 1 (DRUG); Vehicle 1 (DRUG); CP-690,550 Ointment 2 (DRUG); Vehicle 2 (DRUG)",9926791,Tofacitinib,Psoriasis,Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9449,NCT00678561,"Topical CP-690,550 For Chronic Plaque Psoriasis",COMPLETED,PHASE2,Psoriasis,"CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG); Placebo Vehicle (DRUG); Placebo Vehicle (DRUG)",9926791,Tofacitinib,Psoriasis,Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9450,NCT06095128,A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC),RECRUITING,PHASE4,Ulcerative Colitis,Vedolizumab (DRUG); Tofacitinib (DRUG),9926791,Tofacitinib,Ulcerative Colitis,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9451,NCT06923228,"A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis",NOT_YET_RECRUITING,PHASE2,Atopic Dermatitis (AD),CGB-500 Ointment with 1% tofacitinib (DRUG); Ruxolitinib 1.5% Cream QD (DRUG),9926791,Tofacitinib,Atopic Dermatitis (AD),Skin,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9452,NCT01393626,"A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease",COMPLETED,PHASE2,Crohn's Disease,"Placebo (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG)",9926791,Tofacitinib,Crohn's Disease,Bowel,Tofacitinib,"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.02,347.0 +9453,NCT01458574,"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis",COMPLETED,PHASE3,Ulcerative Colitis,"Placebo (DRUG); CP690,550 (DRUG); CP-690,550 (DRUG)",10174505,Xeljanz,Ulcerative Colitis,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9454,NCT01831466,Tofacitinib Ointment For Chronic Plaque Psoriasis,COMPLETED,PHASE2,Psoriasis Vulgaris; Psoriasis,tofacitinib ointment 20 mg/g (DRUG); tofacitinib ointment 10 mg/g (DRUG); placebo ointment (vehicle) (DRUG); tofacitinib ointment 20 mg/g (DRUG); tofacitinib ointment 10 mg/g (DRUG); placebo ointment (vehicle) (DRUG),10174505,Xeljanz,Psoriasis Vulgaris; Psoriasis,Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9455,NCT01710020,"Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease",COMPLETED,PHASE1,End-Stage Renal Disease; Hemodialysis,"CP-690,550 (DRUG)",10174505,Xeljanz,End-Stage Renal Disease,Kidney,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9456,NCT05313620,"Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events",RECRUITING,PHASE4,Ulcerative Colitis; Thromboembolism,Tofacitinib (DRUG); Infliximab Adalimumab y Golimumab (DRUG),10174505,Xeljanz,Ulcerative Colitis; Thromboembolism,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9457,NCT04259138,Determination of the Optimal Treatment Target in Ulcerative Colitis,ACTIVE_NOT_RECRUITING,PHASE4,"Colitis, Ulcerative",Treatment Algorithm A (BIOLOGICAL); Treatment Algorithm B (BIOLOGICAL); Treatment Algorithm C (BIOLOGICAL),10174505,Xeljanz,"Colitis, Ulcerative",Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9458,NCT01710046,"Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis",COMPLETED,PHASE2,Plaque Psoriasis,"(CP-6890,550) Tofacitinib (DRUG); Placebo (DRUG); (CP-690,550) Tofacitinib (DRUG); Placebo (DRUG)",10174505,Xeljanz,Plaque Psoriasis,Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9459,NCT06689982,Tofacitinib in Patients With Amyotrophic Lateral Sclerosis,NOT_YET_RECRUITING,EARLY_PHASE1,Amyotrophic Lateral Sclerosis,Tofacitinib tablets (DRUG),10174505,Xeljanz,Amyotrophic Lateral Sclerosis,CNS/Brain,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9460,NCT03103412,TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC),COMPLETED,PHASE1,"Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects",TD-3504 (DRUG); 15N2-tofacitinib (DRUG); Placebo (DRUG),10174505,Xeljanz,"Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects",Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9461,NCT04624230,Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis,RECRUITING,PHASE3,Ulcerative Colitis,tofacitinib (DRUG),10174505,Xeljanz,Ulcerative Colitis,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9462,NCT00106639,"A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients",COMPLETED,PHASE2,Kidney Transplantation,"CP-690,550 (DRUG); CP-690,550 (DRUG); tacrolimus (DRUG)",10174505,Xeljanz,Kidney Transplantation,Kidney,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9463,NCT01276639,"A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis",COMPLETED,PHASE3,Psoriasis,"CP-690,550 (DRUG); CP-690,550 (DRUG); Placebo/CP-690,550 (DRUG); Placebo/CP-690,550 (DRUG)",10174505,Xeljanz,Psoriasis,Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9464,NCT04925973,Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management,ACTIVE_NOT_RECRUITING,PHASE2,Ulcerative Colitis Acute,Tofacitinib 10 MG [Xeljanz] (DRUG),10174505,Xeljanz,Ulcerative Colitis Acute,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9465,NCT01740362,"Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function",COMPLETED,PHASE1,Renal Impairment,"CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG)",10174505,Xeljanz,Renal Impairment,Kidney,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9466,NCT01241591,"A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis",COMPLETED,PHASE3,Psoriasis,"CP 690,550 5 mg (DRUG); CP 690,550 10 mg (DRUG); Etanercept 50 mg (BIOLOGICAL); Placebo (OTHER)",10174505,Xeljanz,Psoriasis,Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9467,NCT05487963,"Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis",COMPLETED,PHASE1,Atopic Dermatitis,Tofacitinib Citrate (DRUG); placebo ointment (OTHER),10174505,Xeljanz,Atopic Dermatitis,Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9468,NCT03518086,An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1),COMPLETED,PHASE3,Ulcerative Colitis,Mirikizumab (DRUG); Placebo (DRUG),10174505,Xeljanz,Ulcerative Colitis,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9469,NCT01736696,Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis,COMPLETED,PHASE1,Psoriasis; Immunomodulation,tofacitinib (DRUG); tofacitinib (DRUG); tofacitinib (DRUG); tofacitinib (DRUG); tofacitinib (DRUG); tofacitinib (DRUG),10174505,Xeljanz,Psoriasis; Immunomodulation,Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9470,NCT01815424,"A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis",COMPLETED,PHASE3,Psoriasis,"placebo (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG)",10174505,Xeljanz,Psoriasis,Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9471,NCT03281304,A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission,TERMINATED,PHASE4,Ulcerative Colitis,"CP-690,500 5 mg (DRUG); CP-690,550 10 mg (DRUG)",10174505,Xeljanz,Ulcerative Colitis,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9472,NCT01519089,"A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis",COMPLETED,PHASE3,Psoriasis,"CP-690,550 (DRUG); CP-690, 550 (DRUG)",10174505,Xeljanz,Psoriasis,Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9473,NCT01186744,"A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis",COMPLETED,PHASE3,Psoriasis,"CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG)",10174505,Xeljanz,Psoriasis,Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9474,NCT03524092,A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis,COMPLETED,PHASE3,Ulcerative Colitis,Mirikizumab SC (DRUG); Mirikizumab IV (DRUG); Placebo SC (DRUG),10174505,Xeljanz,Ulcerative Colitis,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9475,NCT04246372,Tofacitinib for Immune Skin Conditions in Down Syndrome,COMPLETED,PHASE2,Down Syndrome; Alopecia Areata; Atopic Dermatitis / Eczema; Hidradenitis Suppurativa; Vitiligo; Psoriasis,Tofacitinib (DRUG),10174505,Xeljanz,Down Syndrome; Alopecia Areata; Atopic Dermatitis / Eczema; Hidradenitis Suppurativa; Vitiligo; Psoriasis,Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9476,NCT00678210,"Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis",COMPLETED,PHASE2,Psoriasis,"CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG); Placebo (DRUG)",10174505,Xeljanz,Psoriasis,Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9477,NCT01470612,"Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis",COMPLETED,PHASE3,Ulcerative Colitis,"CP-690,550 (DRUG); CP-690,550 (DRUG)",10174505,Xeljanz,Ulcerative Colitis,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9478,NCT04505410,Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis,COMPLETED,PHASE3,Ulcerative Colitis,"A plant based high fiber diet that mimics fasting (""FMD"") plus advanced therapy (OTHER); Advanced therapy only without dietary intervention (DRUG)",10174505,Xeljanz,Ulcerative Colitis,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9479,NCT03885713,Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease,COMPLETED,PHASE4,Inflammatory Bowel Diseases; Crohn Disease; Ulcerative Colitis,Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib (BIOLOGICAL),10174505,Xeljanz,Inflammatory Bowel Diseases; Crohn Disease; Ulcerative Colitis,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9480,NCT04034238,"Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors",COMPLETED,PHASE1,"Neoplasms With Mesothelin Expression; Epithelioid Mesothelioma; Cholangiocarcinoma, Extrahepatic; Adenocarcinoma, Pancreatic",LMB-100 (DRUG); Tofacitinib (DRUG); Mesothelin Expression (DEVICE),10174505,Xeljanz,"Neoplasms With Mesothelin Expression; Epithelioid Mesothelioma; Cholangiocarcinoma, Extrahepatic; Adenocarcinoma, Pancreatic",Lung,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9481,NCT02001181,Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema),COMPLETED,PHASE2,"Dermatitis, Atopic",Tofacitinib ointment 20mg/g (DRUG); Placebo ointment (Vehicle) (DRUG),10174505,Xeljanz,"Dermatitis, Atopic",Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9482,NCT06055023,Phase I Clinical Study of ZL-82 Tablets,COMPLETED,PHASE1,Rheumatoid Arthritis (RA); Inflammatory Bowel Disease - IBD1,ZL-82 12.5mg (DRUG); ZL-82 25mg (DRUG); ZL-82 50mg (DRUG); ZL-82 100mg (DRUG); ZL-82 200mg (DRUG); ZL-82 300mg (DRUG); ZL-82 450mg (DRUG); ZL-82 600mg (DRUG); zL-82 placebo 12.5mg (DRUG); ZL-82 placebo 25mg (DRUG); ZL-82 placebo 50mg (DRUG); ZL-82 placebo 100mg (DRUG); ZL-82 placebo 200mg (DRUG); ZL-82 placebo 300mg (DRUG); ZL-82 placebo 450mg (DRUG); ZL-82 placebo 600mg (DRUG),10174505,Xeljanz,Rheumatoid Arthritis and Inflammatory Bowel Disease,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9483,NCT06625450,TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS,NOT_YET_RECRUITING,PHASE4,Ulcerative Colitis,Tofacitinib (DRUG); Tofacitinib plus mesalamine (DRUG),10174505,Xeljanz,Ulcerative Colitis,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9484,NCT06810050,Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis,RECRUITING,PHASE2,Atopic Dermatitis (AD),CGB-500 with 0.5% tofacitinib (DRUG); CGB-500 Ointment with 1% tofacitinib (DRUG); Vehicle (placebo) (DRUG),10174505,Xeljanz,Atopic Dermatitis (AD),Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9485,NCT02740049,In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma,COMPLETED,EARLY_PHASE1,Asthma,VR588 (DRUG),10174505,Xeljanz,Asthma,Lung,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9486,NCT00615199,"A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease",COMPLETED,PHASE2,Crohn's Disease,"CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG); Placebo (DRUG)",10174505,Xeljanz,Crohn's Disease,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9487,NCT03591770,Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib,TERMINATED,PHASE4,Inflammatory Bowel Diseases,SHINGRIX (BIOLOGICAL),10174505,Xeljanz,Inflammatory Bowel Diseases,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9488,NCT01470599,"A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease",COMPLETED,PHASE2,Crohn's Disease,"CP-690,550 (DRUG); CP-690,550 (DRUG)",10174505,Xeljanz,Crohn's Disease,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9489,NCT01393899,"The Safety And Efficacy Of Maintenance Therapy With CP-690,550",COMPLETED,PHASE2,Crohn's Disease,"Placebo (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG)",10174505,Xeljanz,Crohn's Disease,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9490,NCT05326464,Tofacitinib in Recurrent GBM Patients,RECRUITING,PHASE3,Glioblastoma,Tofacitinib 10mg (DRUG),10174505,Xeljanz,Glioblastoma,CNS/Brain,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9491,NCT01465763,"A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis",COMPLETED,PHASE3,Ulcerative Colitis,tofacitinib (DRUG); Placebo (DRUG),10174505,Xeljanz,Ulcerative Colitis,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9492,NCT00969813,"A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function",COMPLETED,PHASE1,Hepatic Insufficiency,"CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG)",10174505,Xeljanz,Hepatic Insufficiency,Liver,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9493,NCT00658359,Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients,COMPLETED,PHASE2,Kidney Transplantation,"Cyclosporine (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG)",10174505,Xeljanz,Kidney Transplantation,Kidney,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9494,NCT04332042,TOFAcitinib in SARS-CoV2 Pneumonia,UNKNOWN,PHASE2,SARS-COv2 Related Interstitial Pneumonia,Tofacitinib (DRUG),10174505,Xeljanz,SARS-COv2 Related Interstitial Pneumonia,Lung,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9495,NCT06465732,Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients,NOT_YET_RECRUITING,PHASE4,Atopic Dermatitis,Dupilumab (DRUG); Tofacitinib (DRUG),10174505,Xeljanz,Atopic Dermatitis,Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9496,NCT00483756,Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients,COMPLETED,PHASE2,Kidney Transplantation,"Cyclosporine (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG)",10174505,Xeljanz,Kidney Transplantation,Kidney,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9497,NCT01458951,"A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis",COMPLETED,PHASE3,Ulcerative Colitis,tofacitinib (DRUG); Placebo (DRUG),10174505,Xeljanz,Ulcerative Colitis,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9498,NCT01163253,"A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis",TERMINATED,PHASE3,Psoriasis,"CP-690,550 (DRUG); CP-690,550 (DRUG)",10174505,Xeljanz,Psoriasis,Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9499,NCT01309737,"A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis",COMPLETED,PHASE3,Psoriasis,"CP-690,550 (DRUG); CP-690,550 (DRUG); Placebo/CP-690,550 (DRUG); Placebo/CP-690,550 (DRUG)",10174505,Xeljanz,Psoriasis,Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9500,NCT02193815,A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis,COMPLETED,PHASE1,Psoriasis Vulgaris,PF06263276 (DRUG); Vehicle (OTHER); 2%Tofacitinib Ointment (DRUG); Vehicle (OTHER); Daivonex (DRUG); Daivonex Ointment (DRUG),10174505,Xeljanz,Psoriasis Vulgaris,Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9501,NCT01710033,"A Study Of CP-690,550 In Stable Kidney Transplant Patients",COMPLETED,PHASE1,Kidney Transplant,"Placebo (DRUG); CP-690,550 5 mg BID (DRUG); CP-690,550 15 mg BID (DRUG); CP-690,550 30 mg BID (DRUG)",10174505,Xeljanz,Kidney Transplant,Kidney,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9502,NCT04415151,Tofacitinib for Treatment of Moderate COVID-19,TERMINATED,PHASE2,COVID-19 Pneumonia,Tofacitinib 10 mg (DRUG); Placebo (DRUG),10174505,Xeljanz,COVID-19 Pneumonia,Lung,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9503,NCT00263328,Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient,COMPLETED,PHASE2,Kidney Transplantation,"Tacrolimus (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG)",10174505,Xeljanz,Kidney Transplantation,Kidney,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9504,NCT01246583,CP-690-550 Ointment For Chronic Plaque Psoriasis,COMPLETED,PHASE2,Psoriasis,"CP-690,550 Ointment 1 (DRUG); Vehicle 1 (DRUG); CP-690,550 Ointment 2 (DRUG); Vehicle 2 (DRUG)",10174505,Xeljanz,Psoriasis,Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9505,NCT00678561,"Topical CP-690,550 For Chronic Plaque Psoriasis",COMPLETED,PHASE2,Psoriasis,"CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG); Placebo Vehicle (DRUG); Placebo Vehicle (DRUG)",10174505,Xeljanz,Psoriasis,Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9506,NCT06095128,A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC),RECRUITING,PHASE4,Ulcerative Colitis,Vedolizumab (DRUG); Tofacitinib (DRUG),10174505,Xeljanz,Ulcerative Colitis,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9507,NCT06923228,"A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis",NOT_YET_RECRUITING,PHASE2,Atopic Dermatitis (AD),CGB-500 Ointment with 1% tofacitinib (DRUG); Ruxolitinib 1.5% Cream QD (DRUG),10174505,Xeljanz,Atopic Dermatitis (AD),Skin,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9508,NCT01393626,"A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease",COMPLETED,PHASE2,Crohn's Disease,"Placebo (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG)",10174505,Xeljanz,Crohn's Disease,Bowel,Tofacitinib (citrate),"JAK1, JAK2, JAK3",inhibitor/antagonist,JAK/STAT inhibitor,yes,yes,Approved for rheumatoid arthritis and other conditions.,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,1.02,371.0 +9509,NCT01576666,"Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",COMPLETED,PHASE1,"Dose Escalation; Safety; Preliminary Efficacy; Advanced Solid Tumors; Metastatic Breast Cancer; Advanced Pancreatic Adenocarcinoma; Metastatic Colorectal Cancer; Recurrent Glioblastoma Multiforme; Gastric Cancer; Gastroesophageal Junction Cancer; Triple Negative Metastatic Breast Cancer; Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer",LDE225 (DRUG); BKM120 (DRUG),24775005,Odomzo,"Dose Escalation; Safety; Preliminary Efficacy; Advanced Solid Tumors; Metastatic Breast Cancer; Advanced Pancreatic Adenocarcinoma; Metastatic Colorectal Cancer; Recurrent Glioblastoma Multiforme; Gastric Cancer; Gastroesophageal Junction Cancer; Triple Negative Metastatic Breast Cancer; Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer",Bowel,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9510,NCT06623201,Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas,NOT_YET_RECRUITING,PHASE1,Basal Cell Carcinoma (BCC),aminolevulinic acid HCL (ALA) (DRUG); BLU-U device model 4170E (DEVICE),24775005,Odomzo,Basal Cell Carcinoma (BCC),Skin,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9511,NCT04806646,Tailored Sonidegib Schedule After Complete Response in BCC,RECRUITING,PHASE2,Locally Advanced Basal Cell Carcinoma,Sonidegib (DRUG),24775005,Odomzo,Locally Advanced Basal Cell Carcinoma,Skin,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9512,NCT02195973,Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer,COMPLETED,PHASE1,Recurrent Ovarian Cancer,LDE225 (DRUG),24775005,Odomzo,Recurrent Ovarian Cancer,Ovary/Fallopian Tube,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9513,NCT01757327,LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer,WITHDRAWN,PHASE2,Breast Neoplasms,Erismodegib (DRUG); Placebo (DRUG),24775005,Odomzo,Breast Neoplasms,Breast,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9514,NCT01208831,An East Asian Study of LDE225,COMPLETED,PHASE1,Advanced Solid Tumor Cancers; Medulloblastoma; Basal Cell Carcinoma,LDE225 (DRUG),24775005,Odomzo,Advanced Solid Tumor Cancers; Medulloblastoma; Basal Cell Carcinoma,Skin,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9515,NCT02027376,Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients,COMPLETED,PHASE1,Advanced Breast Cancer,LDE225 (DRUG); Docetaxel (DRUG),24775005,Odomzo,Advanced Breast Cancer,Breast,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9516,NCT05669339,AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma,RECRUITING,PHASE2,Hepatocellular Carcinoma,Irinotecan (DRUG); Sonidegib (DRUG); Sorafenib (DRUG),24775005,Odomzo,Hepatocellular Carcinoma,Liver,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9517,NCT03434262,SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors,COMPLETED,PHASE1,"Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Ganglioglioma; Anaplastic Meningioma; Anaplastic Oligodendroglioma; Pleomorphic Xanthoastrocytoma, Anaplastic; Atypical Teratoid/Rhabdoid Tumor; Brain Cancer; Brain Tumor; Central Nervous System Neoplasms; Choroid Plexus Carcinoma; CNS Embryonal Tumor With Rhabdoid Features; Ganglioneuroblastoma of Central Nervous System; CNS Tumor; Embryonal Tumor of CNS; Ependymoma; Glioblastoma; Glioma; Glioma, Malignant; Medulloblastoma; Medulloblastoma; Unspecified Site; Medulloepithelioma; Neuroepithelial Tumor; Neoplasms; Neoplasms, Neuroepithelial; Papillary Tumor of the Pineal Region (High-grade Only); Pediatric Brain Tumor; Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only); Pineoblastoma; Primitive Neuroectodermal Tumor; Recurrent Medulloblastoma; Refractory Brain Tumor; Neuroblastoma. CNS; Glioblastoma, IDH-mutant; Glioblastoma, IDH-wildtype; Medulloblastoma, Group 3; Medulloblastoma, Group 4; Glioma, High Grade; Neuroepithelial Tumor, High Grade; Medulloblastoma, SHH-activated and TP53 Mutant; Medulloblastoma, SHH-activated and TP53 Wildtype; Medulloblastoma, Chromosome 9q Loss; Medulloblastoma, Non-WNT Non-SHH, NOS; Medulloblastoma, Non-WNT/Non-SHH; Medulloblastoma, PTCH1 Mutation; Medulloblastoma, WNT-activated; Ependymoma, Recurrent; Glioma, Recurrent High Grade; Glioma, Recurrent Malignant; Embryonal Tumor, NOS; Glioma, Diffuse Midline, H3K27M-mutant; Embryonal Tumor With Multilayered Rosettes (ETMR); Ependymoma, NOS, WHO Grade III; Ependymoma, NOS, WHO Grade II; Medulloblastoma, G3/G4; Ependymoma, RELA Fusion Positive",Gemcitabine (DRUG); ribociclib (DRUG); sonidegib (DRUG); trametinib (DRUG); filgrastim (BIOLOGICAL),24775005,Odomzo,CNS Tumors and Neoplasms,CNS/Brain,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9518,NCT01579929,"Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)",COMPLETED,PHASE1,Lung Cancer,"LDE225, Etoposide and Cisplatin (DRUG)",24775005,Odomzo,Lung Cancer,Lung,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9519,NCT02138929,LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma,COMPLETED,PHASE1,Esophageal Cancer,Everolimus (DRUG); LDE 225 (DRUG),24775005,Odomzo,Esophageal Cancer,Esophagus/Stomach,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9520,NCT03070691,"Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)",WITHDRAWN,PHASE2,Basal Cell Carcinoma,LDE225B (DRUG); Vehicle (DRUG),24775005,Odomzo,Basal Cell Carcinoma,Skin,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9521,NCT04679480,Anti-PD1-antibody and Pulsed HHI for Advanced BCC,ACTIVE_NOT_RECRUITING,PHASE2,Basal Cell Carcinoma,Cemiplimab Injection [Libtayo] (DRUG),24775005,Odomzo,Basal Cell Carcinoma,Skin,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9522,NCT01431794,Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma,TERMINATED,PHASE1,Pancreatic Ductal Adenocarcinoma,LDE225-600mg (DRUG); Gemcitabine (DRUG); nab-paclitaxel (DRUG); LDE225-400mg (DRUG); LDE225-800mg (DRUG),24775005,Odomzo,Pancreatic Ductal Adenocarcinoma,Pancreas,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9523,NCT00961896,"A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients",COMPLETED,PHASE2,Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients,Vehicle (DRUG); LDE225 0.25% (DRUG); LDE225 0.75% (DRUG),24775005,Odomzo,Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients,Skin,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9524,NCT04007744,Sonidegib and Pembrolizumab in Treating Patients with Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,Clinical Stage III Cutaneous Melanoma AJCC V8; Clinical Stage III Gastric Cancer AJCC V8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC V8; Clinical Stage IV Cutaneous Melanoma AJCC V8; Clinical Stage IV Gastric Cancer AJCC V8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC V8; Locally Advanced Gastric Adenocarcinoma; Locally Advanced Gastroesophageal Junction Adenocarcinoma; Locally Advanced Urothelial Carcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Urothelial Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Refractory Lung Non-Small Cell Carcinoma; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC V8; Stage IV Lung Cancer AJCC V8; Unresectable Malignant Solid Neoplasm; Unresectable Melanoma,Pembrolizumab (BIOLOGICAL); Sonidegib (DRUG),24775005,Odomzo,Clinical Stage III Cutaneous Melanoma AJCC V8; Clinical Stage III Gastric Cancer AJCC V8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC V8; Clinical Stage IV Cutaneous Melanoma AJCC V8; Clinical Stage IV Gastric Cancer AJCC V8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC V8; Locally Advanced Gastric Adenocarcinoma; Locally Advanced Gastroesophageal Junction Adenocarcinoma; Locally Advanced Urothelial Carcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Urothelial Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Refractory Lung Non-Small Cell Carcinoma; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC V8; Stage IV Lung Cancer AJCC V8; Unresectable Malignant Solid Neoplasm; Unresectable Melanoma,Lung,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9525,NCT01485744,"LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer",COMPLETED,PHASE1,Pancreatic Cancer,LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan (DRUG),24775005,Odomzo,Pancreatic Cancer,Pancreas,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9526,NCT01694589,A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer,WITHDRAWN,EARLY_PHASE1,Resectable Pancreatic Cancer,LDE-225 (DRUG),24775005,Odomzo,Resectable Pancreatic Cancer,Pancreas,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9527,NCT02303041,Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma,TERMINATED,PHASE2,"Carcinoma, Basal Cell; Recurrent Skin Cancer; Skin Neoplasms; Basal Cell Nevus Syndrome",Buparlisib (DRUG); Sonidegib (DRUG),24775005,Odomzo,"Carcinoma, Basal Cell; Recurrent Skin Cancer; Skin Neoplasms; Basal Cell Nevus Syndrome",Skin,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9528,NCT01033019,"To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)",TERMINATED,PHASE2,Sporadic Superficial and Nodular Skin Basal Cell Carcinomas,LDE225 0.75% (DRUG); Vehicle (DRUG),24775005,Odomzo,Sporadic Superficial and Nodular Skin Basal Cell Carcinomas,Skin,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9529,NCT00880308,Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors,COMPLETED,PHASE1,Advanced Solid Tumor Cancers; Medulloblastoma; Basal Cell Carcinoma,LDE225 (DRUG),24775005,Odomzo,Advanced Solid Tumor Cancers; Medulloblastoma; Basal Cell Carcinoma,Skin,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9530,NCT01954355,LDE225 and Paclitaxel in Solid Tumors,COMPLETED,PHASE1,Solid Tumor; Ovarian Cancer,LDE225 (DRUG); Paclitaxel (DRUG),24775005,Odomzo,Solid Tumor; Ovarian Cancer,Ovary/Fallopian Tube,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9531,NCT02151864,LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis,COMPLETED,PHASE1,Hepatocellular Carcinoma; Cirrhosis,LDE225 (DRUG),24775005,Odomzo,Hepatocellular Carcinoma; Cirrhosis,Liver,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9532,NCT05561634,Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma,NOT_YET_RECRUITING,PHASE2,Basal Cell Carcinoma; Radiotherapy; Complications,Radiotherapy (RADIATION); Observation (OTHER); Vismodegib (DRUG),24775005,Odomzo,Basal Cell Carcinoma; Radiotherapy; Complications,Skin,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9533,NCT01125800,A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB,COMPLETED,PHASE1,Medulloblastoma; Rhabdomyosarcoma; Neuroblastoma; Hepatoblastoma; Glioma; Astrocytoma,LDE225 (DRUG),24775005,Odomzo,Medulloblastoma; Rhabdomyosarcoma; Neuroblastoma; Hepatoblastoma; Glioma; Astrocytoma,CNS/Brain,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9534,NCT01487785,"Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients",COMPLETED,PHASE1,Pancreatic Cancer,LDE225+gemcitabine (DRUG),24775005,Odomzo,Pancreatic Cancer,Pancreas,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9535,NCT03534947,A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma,RECRUITING,PHASE2,"Basal Cell Carcinoma; Basal Cell Carcinoma of Skin, Site Unspecified; Skin Cancer; Invasive Carcinoma",Sonidegib (DRUG); Imiquimod (DRUG); Surgery (PROCEDURE); Best supportive care (OTHER),24775005,Odomzo,"Basal Cell Carcinoma; Basal Cell Carcinoma of Skin, Site Unspecified; Skin Cancer; Invasive Carcinoma",Skin,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9536,NCT01327053,A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma,COMPLETED,PHASE2,Basal Cell Carcinoma,LDE225 (DRUG),24775005,Odomzo,Basal Cell Carcinoma,Skin,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9537,NCT01350115,"Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)",COMPLETED,PHASE2,Basal Cell Carcinoma; Gorlin Syndrome; Nevoid Basal Cell Carcinoma Syndrome,LDE225 (DRUG); Placebo (DRUG),24775005,Odomzo,Basal Cell Carcinoma; Gorlin Syndrome; Nevoid Basal Cell Carcinoma Syndrome,Skin,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9538,NCT02358161,Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer,COMPLETED,PHASE1,Pancreatic Cancer,gemcitabine and nab paclitaxel (DRUG),24775005,Odomzo,Pancreatic Cancer,Pancreas,Sonidegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for basal cell carcinoma treatment.,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,1.07,373.0 +9539,NCT00999882,"Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients",COMPLETED,PHASE1,Cancer; Advanced Hepatocellular Carcinoma,AZD8055 (DRUG),25262965,s1555,Cancer; Advanced Hepatocellular Carcinoma,Liver,AZD-8055,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,Investigational drug; explored in trials mainly for cancer treatment.,CC1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=C(C=C4)OC)CO)N5CCOCC5C,, +9540,NCT01316809,AZD8055 for Adults With Recurrent Gliomas,COMPLETED,PHASE1,Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Malignant Glioma; Brainstem Glioma,AZD8055 (DRUG),25262965,s1555,Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Malignant Glioma; Brainstem Glioma,CNS/Brain,AZD-8055,MTOR,inhibitor/antagonist,MTOR inhibitor,no,yes,Investigational drug; explored in trials mainly for cancer treatment.,CC1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=C(C=C4)OC)CO)N5CCOCC5C,, +9541,NCT04267939,ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer,TERMINATED,PHASE1,Advanced Solid Tumors (Excluding Prostate Cancer); Ovarian Cancer,Elimusertib (BAY1895344) (DRUG); Niraparib (DRUG),118869362,s9864,Advanced Solid Tumors (Excluding Prostate Cancer); Ovarian Cancer,Ovary/Fallopian Tube,Elimusertib hydrochloride,ATR,inhibitor/antagonist,unclear,no,yes,Tested in trials for cancer but not approved for human use.,CC1COCCN1C2=NC3=C(C=CN=C3C4=CC=NN4)C(=C2)C5=CC=NN5C,, +9542,NCT04576091,"Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Oral Cavity Squamous Cell Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Paranasal Sinus Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Major Salivary Gland Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage III Sinonasal Cancer AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Hypopharyngeal Carcinoma AJCC v8; Stage IV Laryngeal Cancer AJCC v8; Stage IV Lip and Oral Cavity Cancer AJCC v8; Stage IV Major Salivary Gland Cancer AJCC v8; Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IV Sinonasal Cancer AJCC v8; Unresectable Cutaneous Squamous Cell Carcinoma of the Head and Neck; Unresectable Head and Neck Squamous Cell Carcinoma; Unresectable Hypopharyngeal Squamous Cell Carcinoma; Unresectable Laryngeal Squamous Cell Carcinoma; Unresectable Oral Cavity Squamous Cell Carcinoma; Unresectable Oropharyngeal Squamous Cell Carcinoma; Unresectable Paranasal Sinus Squamous Cell Carcinoma; Unresectable Salivary Gland Squamous Cell Carcinoma,Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Elimusertib (DRUG); Pembrolizumab (BIOLOGICAL); Positron Emission Tomography (PROCEDURE); Quality-of-Life Assessment (OTHER); Stereotactic Body Radiation Therapy (RADIATION),118869362,s9864,Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Oral Cavity Squamous Cell Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Paranasal Sinus Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Major Salivary Gland Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage III Sinonasal Cancer AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Hypopharyngeal Carcinoma AJCC v8; Stage IV Laryngeal Cancer AJCC v8; Stage IV Lip and Oral Cavity Cancer AJCC v8; Stage IV Major Salivary Gland Cancer AJCC v8; Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IV Sinonasal Cancer AJCC v8; Unresectable Cutaneous Squamous Cell Carcinoma of the Head and Neck; Unresectable Head and Neck Squamous Cell Carcinoma; Unresectable Hypopharyngeal Squamous Cell Carcinoma; Unresectable Laryngeal Squamous Cell Carcinoma; Unresectable Oral Cavity Squamous Cell Carcinoma; Unresectable Oropharyngeal Squamous Cell Carcinoma; Unresectable Paranasal Sinus Squamous Cell Carcinoma; Unresectable Salivary Gland Squamous Cell Carcinoma,Skin,Elimusertib hydrochloride,ATR,inhibitor/antagonist,unclear,no,yes,Tested in trials for cancer but not approved for human use.,CC1COCCN1C2=NC3=C(C=CN=C3C4=CC=NN4)C(=C2)C5=CC=NN5C,, +9543,NCT04535401,"Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines",ACTIVE_NOT_RECRUITING,PHASE1,Advanced Colorectal Carcinoma; Advanced Digestive System Carcinoma; Advanced Gastric Carcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Metastatic Colorectal Carcinoma; Metastatic Digestive System Carcinoma; Metastatic Gastric Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Stage III Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8,Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Diagnostic Imaging (PROCEDURE); Elimusertib (DRUG); Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Leucovorin Calcium (DRUG),118869362,s9864,Advanced Colorectal Carcinoma; Advanced Digestive System Carcinoma; Advanced Gastric Carcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Metastatic Colorectal Carcinoma; Metastatic Digestive System Carcinoma; Metastatic Gastric Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Stage III Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8,Bowel,Elimusertib hydrochloride,ATR,inhibitor/antagonist,unclear,no,yes,Tested in trials for cancer but not approved for human use.,CC1COCCN1C2=NC3=C(C=CN=C3C4=CC=NN4)C(=C2)C5=CC=NN5C,, +9544,NCT04616534,"Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors",ACTIVE_NOT_RECRUITING,PHASE1,Advanced Fallopian Tube Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Adenocarcinoma; Advanced Primary Peritoneal Carcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Fallopian Tube Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Diagnostic Imaging Testing (PROCEDURE); Elimusertib (DRUG); Gemcitabine (DRUG),118869362,s9864,Advanced Fallopian Tube Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Adenocarcinoma; Advanced Primary Peritoneal Carcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Fallopian Tube Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma,Pancreas,Elimusertib hydrochloride,ATR,inhibitor/antagonist,unclear,no,yes,Tested in trials for cancer but not approved for human use.,CC1COCCN1C2=NC3=C(C=CN=C3C4=CC=NN4)C(=C2)C5=CC=NN5C,, +9545,NCT04491942,"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Advanced Bile Duct Carcinoma; Advanced Breast Carcinoma; Advanced Cervical Carcinoma; Advanced Endometrial Carcinoma; Advanced Esophageal Carcinoma; Advanced Gastric Carcinoma; Advanced Head and Neck Carcinoma; Advanced Lung Non-Small Cell Carcinoma; Advanced Lung Small Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Penile Carcinoma; Advanced Pleural Malignant Mesothelioma; Advanced Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Stage III Cervical Cancer AJCC v8; Stage III Distal Bile Duct Cancer AJCC v8; Stage III Intrahepatic Bile Duct Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Penile Cancer AJCC v8; Stage III Pleural Malignant Mesothelioma AJCC v8; Stage IV Cervical Cancer AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Bile Duct Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Pleural Malignant Mesothelioma AJCC v8; Triple-Negative Breast Carcinoma; Unresectable Urothelial Carcinoma,Cisplatin (DRUG); Elimusertib (DRUG); Gemcitabine Hydrochloride (DRUG),118869362,s9864,Advanced Bile Duct Carcinoma; Advanced Breast Carcinoma; Advanced Cervical Carcinoma; Advanced Endometrial Carcinoma; Advanced Esophageal Carcinoma; Advanced Gastric Carcinoma; Advanced Head and Neck Carcinoma; Advanced Lung Non-Small Cell Carcinoma; Advanced Lung Small Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Penile Carcinoma; Advanced Pleural Malignant Mesothelioma; Advanced Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Stage III Cervical Cancer AJCC v8; Stage III Distal Bile Duct Cancer AJCC v8; Stage III Intrahepatic Bile Duct Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Penile Cancer AJCC v8; Stage III Pleural Malignant Mesothelioma AJCC v8; Stage IV Cervical Cancer AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Bile Duct Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Pleural Malignant Mesothelioma AJCC v8; Triple-Negative Breast Carcinoma; Unresectable Urothelial Carcinoma,Lung,Elimusertib hydrochloride,ATR,inhibitor/antagonist,unclear,no,yes,Tested in trials for cancer but not approved for human use.,CC1COCCN1C2=NC3=C(C=CN=C3C4=CC=NN4)C(=C2)C5=CC=NN5C,, +9546,NCT04514497,"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Lung Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Neuroendocrine Carcinoma; Metastatic Pancreatic Adenocarcinoma; Stage III Lung Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Lung Small Cell Carcinoma; Unresectable Malignant Solid Neoplasm; Unresectable Neuroendocrine Carcinoma; Unresectable Pancreatic Adenocarcinoma,Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Elimusertib (DRUG); Irinotecan Hydrochloride (DRUG); Magnetic Resonance Imaging (PROCEDURE); Topotecan Hydrochloride (DRUG),118869362,s9864,Metastatic Lung Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Neuroendocrine Carcinoma; Metastatic Pancreatic Adenocarcinoma; Stage III Lung Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Lung Small Cell Carcinoma; Unresectable Malignant Solid Neoplasm; Unresectable Neuroendocrine Carcinoma; Unresectable Pancreatic Adenocarcinoma,Lung,Elimusertib hydrochloride,ATR,inhibitor/antagonist,unclear,no,yes,Tested in trials for cancer but not approved for human use.,CC1COCCN1C2=NC3=C(C=CN=C3C4=CC=NN4)C(=C2)C5=CC=NN5C,, +9547,NCT03399526,1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat,COMPLETED,PHASE1,Psoriasis,"Mapracorat (ZK 245186, BAY 86-5319) (DRUG); Prednicarbate 0.25% ointment (DRUG); Clobetasol 0.05% ointment (DRUG); Calcipotriene 0.005% ointment (DRUG); Calcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment (DRUG)",21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9548,NCT03025282,Safety and Efficacy of CD10367 in Psoriasis Vulgaris,COMPLETED,PHASE2,Psoriasis Vulgaris,CD10367 3% Solution - Non-desquamated zone (DRUG); CD10367 1% Solution - Non-desquamated zone (DRUG); CD10367 solution placebo - Non-desquamated zone (DRUG); Betneval ointment - Non-desquamated zone (DRUG); CD10367 3% Solution - Desquamated zone (DRUG); CD10367 solution placebo - Desquamated zone (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9549,NCT02004574,Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris,COMPLETED,PHASE4,Psoriasis Vulgaris,Calcipotriol/betamethasone dipropionate gel (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9550,NCT02605057,Dermatopharmacokinetic Trial of LEO 80185 Gel,COMPLETED,PHASE1,Psoriasis Vulgaris,LEO 80185 gel (DRUG); Dovobet(r) Ointment (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9551,NCT03806790,Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris,COMPLETED,PHASE3,Psoriasis Vulgaris,LEO 90100 foam (DRUG); Dovobet® ointment (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9552,NCT02527421,DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis,TERMINATED,PHASE3,Plaque Psoriasis,DFD01 Spray (DRUG),21800,Psorion,Plaque Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9553,NCT03707795,Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study,COMPLETED,EARLY_PHASE1,Familial Amyotrophic Lateral Sclerosis,"Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days (DRUG)",21800,Psorion,Familial Amyotrophic Lateral Sclerosis,CNS/Brain,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9554,NCT02973776,Vasoconstriction Trial With LEO 90100 Aerosol Foam,COMPLETED,PHASE1,Psoriasis Vulgaris,LEO 90100 aerosol foam (DRUG); Dermoval®/Dermovate® (DRUG); Diprosone (DRUG); Elocon (DRUG); Locoid (DRUG); LEO 90100 foam vehicle (OTHER),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9555,NCT00910676,Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors,COMPLETED,PHASE2,Metastatic Colorectal Cancer; Non-Small-Cell Lung Carcinoma,Diprosone (DRUG),21800,Psorion,Metastatic Colorectal Cancer; Non-Small-Cell Lung Carcinoma,Bowel,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9556,NCT00216827,Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis,COMPLETED,PHASE3,Psoriasis of Scalp,Calcipotriol plus betamethasone dipropionate (LEO80185 gel) (DRUG),21800,Psorion,Psoriasis of Scalp,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9557,NCT01837576,An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris,COMPLETED,PHASE1,Psoriasis Vulgaris,Calcipotriol plus BDP gel in different doses (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9558,NCT03584360,Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin,COMPLETED,PHASE2,Psoriasis Vulgaris,Betamethasone-Calcipotriene Topical (DRUG); Betamethasone-Calcipotriene Topical (DRUG); Betamethasone-Calcipotriene Topical (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9559,NCT03827876,Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis,RECRUITING,PHASE4,Psoriasis,Enstilar 0.005%-0.064% Topical Foam (DRUG),21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9560,NCT01646567,SHP-141C in Plaque Type Psoriasis,COMPLETED,PHASE1,Plaque Type Psoriasis,SHP-141C (DRUG); Placebo to SHP-141C (DRUG); Betamethasone Valerate (DRUG); Calcipotriol (DRUG),21800,Psorion,Plaque Type Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9561,NCT03880357,To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis,COMPLETED,PHASE1,Scalp Psoriasis,Betamethasone Scalp Suspension 0.064%;0.0005% (DRUG); Taclonex® (DRUG); Placebo topical suspension (DRUG),21800,Psorion,Scalp Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9562,NCT05260125,Comparison of the Efficacy of Ultrasound Guided vs Non-guided Suprascapular Nerve Block Treatment in Stroke Patients,RECRUITING,PHASE4,Hemiplegia; Stroke,Ultrasound-guided Suprascapular Nerve Block (DRUG); Anatomical Landmark-guided Suprascapular Nerve Block (DRUG),21800,Psorion,Hemiplegia; Stroke,CNS/Brain,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9563,NCT03004339,Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test,COMPLETED,PHASE1,Plaque Psoriasis,SOR007 Ointment 2.0% (DRUG); SOR007 Ointment 1.0% (DRUG); SOR007 Ointment 0.3% (DRUG); SOR007 Ointment 0.15% (DRUG); SOR007 Ointment Placebo (DRUG); Taclonex® Ointment (DRUG),21800,Psorion,Plaque Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9564,NCT01946386,A Vasoconstriction Study With LEO 90100,COMPLETED,PHASE1,Psoriasis Vulgaris,"LEO 90100 Aerosol, foam (DRUG); Betamethasone dipropionate in LEO 90100 Aerosol, foam, vehicle (DRUG); LEO 90100 Aerosol, foam, vehicle (DRUG); Daivobet® ointment (DRUG); Dermovate® cream (DRUG); Synalar® ointment (DRUG)",21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9565,NCT03462927,A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream,COMPLETED,PHASE2,Psoriasis Vulgaris,MC2-01 Cream (DRUG); CAL/BDP combination (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9566,NCT01536886,"LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris",COMPLETED,PHASE2,Psoriasis Vulgaris,LEO 90100 (DRUG); Betamethasone plus calcipotriol (DRUG); Ointment vehicle (DRUG); LEO 90100 vehicle (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9567,NCT03731091,"To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).",COMPLETED,PHASE3,Psoriasis Vulgaris,"Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064% (DRUG); Enstilar® foam (LEO Pharma Inc.) (DRUG); Placebo of Calcipotriene/ betamethasone dipropionate topical foam (OTHER)",21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9568,NCT00279162,Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis,COMPLETED,PHASE3,Psoriasis,Calcipotriene/betamethasone gel and ointment (DRUG),21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9569,NCT00216892,Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris,COMPLETED,PHASE4,Psoriasis Vulgaris,"Calcipotriol, (calcipotriol + betamethasone) (DRUG)",21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9570,NCT02355639,A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin,COMPLETED,PHASE1,Skin and Connective Tissue Diseases,Clobetasol propionate 0.05 % ointment (DRUG); Betamethasone dipropionate 0.064 % ointment (DRUG); Petrolatum ointment (DRUG),21800,Psorion,Skin and Connective Tissue Diseases,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9571,NCT01083758,Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis,COMPLETED,PHASE2,Scalp Psoriasis,LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) (DRUG),21800,Psorion,Scalp Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9572,NCT00762658,A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test,COMPLETED,PHASE1,Psoriasis,"AN2728 Ointment, 5% (DRUG); AN2728 Ointment, 2% (DRUG); AN2728 Ointment, 0.5% (DRUG); AN2728 Ointment Vehicle (DRUG); Betnesol®-V Creme, 0.1% (DRUG); Protopic® Ointment, 0.1 % (DRUG)",21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9573,NCT05249972,A Phase III Study in Subjects With Mild to Moderate Psoriasis.,UNKNOWN,PHASE3,Mild to Moderate Psoriasis,AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO) (DRUG); Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g) (DRUG); Placebo (OTHER),21800,Psorion,Mild to Moderate Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9574,NCT00763204,A Phase I Study to Assess Novel Cream in a Psoriasis Plaque Test,COMPLETED,PHASE1,Psoriasis,"AN2728 Cream, 2% (DRUG); AN2728 Cream, 1% (DRUG); AN2728 Cream, 0.3% (DRUG); AN2728 Cream Vehicle (DRUG); Betnesol®-V Creme, 0.1% (DRUG)",21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9575,NCT00216840,Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis,COMPLETED,PHASE3,Psoriasis of Scalp,Calcipotriol plus betamethasone dipropionate (LEO80185 gel) (DRUG),21800,Psorion,Psoriasis of Scalp,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9576,NCT01639040,Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD),COMPLETED,PHASE2,Atopic Dermatitis,Dupilumab (DRUG); Placebo (for Dupilumab) (DRUG); Topical Corticosteroid (TCS) (OTHER),21800,Psorion,Atopic Dermatitis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9577,NCT03802344,"This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream",COMPLETED,PHASE3,Psoriasis Vulgaris,MC2-01 cream (DRUG); Cal/BDP combination (DRUG); Vehicle (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9578,NCT03441789,Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis,COMPLETED,PHASE4,Plaque Psoriasis,Enstilar (DRUG); Vehicle (DRUG); Otezla (DRUG),21800,Psorion,Plaque Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9579,NCT02668692,LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis,COMPLETED,PHASE3,Psoriasis Vulgaris,LEO 80185 gel (DRUG); Dovobet ® ointment (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9580,NCT02070965,DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis,COMPLETED,PHASE2,Plaque Psoriasis,DFD01 Spray (DRUG); Comp01 Lotion (DRUG),21800,Psorion,Plaque Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9581,NCT02416258,A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123),COMPLETED,PHASE2,Skin and Connective Tissue Diseases,LP0113 aerosol spray (DRUG); Aerosol spray vehicle (DRUG); LEO 90100 aerosol foam (DRUG); Betamethasone dipropionate aerosol spray (DRUG); Calcipotriol aerosol spray (DRUG); Daivobet® gel (DRUG),21800,Psorion,Skin and Connective Tissue Diseases,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9582,NCT00437619,A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.,COMPLETED,PHASE4,Psoriasis,calcipotriol hydrate [Daivonex] (DRUG),21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9583,NCT03442244,Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects,COMPLETED,PHASE1,Psoriasis Vulgaris,LEO 90100 foam (DRUG); Vehicle of LEO 90100 foam (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9584,NCT02432040,Efficacy of Atorvastatin as Adjunctive Treatment for Chronic Plaque Type Psoriasis,COMPLETED,PHASE2,Psoriasis,Atorvastatin (DRUG); Placebo (DRUG),21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9585,NCT02038569,"An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects",COMPLETED,PHASE2,Psoriasis Vulgaris,LEO 80185 gel (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9586,NCT00670241,Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris,COMPLETED,PHASE3,Psoriasis Vulgaris,calcipotriol and betamethasone (LEO 80185 gel) (DRUG); LEO 80185 vehicle (DRUG); Tacalcitol ointment (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9587,NCT01761019,A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy,COMPLETED,PHASE4,Psoriasis,Taclonex Topical Suspension (DRUG),21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9588,NCT00817219,Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris,COMPLETED,PHASE2,Psoriasis Vulgaris,Calcipotriene plus betamethasone dipropionate ointment (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9589,NCT02132936,LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris,COMPLETED,PHASE3,Psoriasis Vulgaris,LEO 90100 aerosol foam (DRUG); Aerosol foam vehicle (DRUG); Calcipotriol BDP gel (DRUG); Gel vehicle (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9590,NCT00263718,Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris,COMPLETED,PHASE2,Psoriasis Vulgaris,Calcipotriol plus betamethasone dipropionate (LEO 80185) gel (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9591,NCT03819218,A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects,TERMINATED,PHASE2,Psoriasis Vulgaris,MC2-01 cream (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9592,NCT05981118,Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant),ENROLLING_BY_INVITATION,PHASE2,ICD10 Code L40.9 for Psoriasis,Betamethasone dipropionate 0.05% (DRUG); Tapinarof (DRUG),21800,Psorion,ICD10 Code L40.9 for Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9593,NCT00437255,"Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis",COMPLETED,PHASE4,Plaque Psoriasis,"Clobetasol Propionate, 0.05% (DRUG); Calcipotriene and betamethasone dipropionate ointment (DRUG)",21800,Psorion,Plaque Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9594,NCT00576238,Skin Tolerance Study of Betamethasone Creams in Atopic Eczema and the Preventative Properties of a Moisturiser,COMPLETED,PHASE3,Atopic Eczema,betamethasone valerate (DRUG); betamethasone valerate (DRUG); urea (DRUG),21800,Psorion,Atopic Eczema,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9595,NCT01536938,LEO 90100 in the Treatment of Psoriasis Vulgaris,COMPLETED,PHASE2,Psoriasis Vulgaris,LEO 90100 (DRUG); Calcipotriol (DRUG); Betamethasone (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9596,NCT00820950,A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis,COMPLETED,PHASE2,Psoriasis,Ruxolitinib phosphate cream (DRUG); Dovonex® calcipotriene 0.005% (DRUG); Diprolene® AF betamethasone dipropionate 0.05% cream. (DRUG); Placebo cream (DRUG); Ruxolitinib phosphate cream (DRUG); Ruxolitinib phosphate cream (DRUG),21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9597,NCT06125808,Efficacy and Safety Study of HRO350 in Patients with Mild-to-moderate Psoriasis (the 'HeROPA' Study).,COMPLETED,PHASE2,Psoriasis,HRO350 (DRUG); Placebo (DRUG),21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9598,NCT01347255,"A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris",COMPLETED,PHASE2,Psoriasis Vulgaris,"LEO90100 cutaneous spray, ointment (DRUG); LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate (DRUG); LEO 90100 cutaneous spray, ointment, vehicle (DRUG); Daivobet® ointment (DRUG)",21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9599,NCT04194814,Skin bioMARkers for Atopic Eczema Therapy Evaluation,COMPLETED,PHASE2,Atopic Eczema/Dermatitis (Non-Specific),crisaborole (2%) ointment (DRUG); betamethasone valerate 0.1% cream (DRUG),21800,Psorion,Atopic Eczema/Dermatitis (Non-Specific),Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9600,NCT01313221,Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis,COMPLETED,PHASE3,Psoriasis,etanercept (BIOLOGICAL); Topical agents (DRUG),21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9601,NCT00576550,A Randomised Trial of a Moisturising Cream in Preventing Recurrence of Hand Eczema,COMPLETED,PHASE4,Hand Eczema,Urea (DRUG); betamethasone valerate (DRUG); betamethasone valerate (DRUG),21800,Psorion,Hand Eczema,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9602,NCT03331523,"To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis",COMPLETED,PHASE3,Scalp Psoriasis,Calcipotriene/Betamethasone Dipropionate (DRUG); Taclonex® (DRUG); Placebo (DRUG),21800,Psorion,Scalp Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9603,NCT01120223,Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis,COMPLETED,PHASE2,Scalp Psoriasis,LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension) (DRUG),21800,Psorion,Scalp Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9604,NCT02376049,A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD),COMPLETED,PHASE1,Atopic Dermatitis,Pimecrolimus cream (DRUG); Betamethasone dipropionate cream (DRUG); Clobetasol propionate cream (DRUG); Glaxal Base cream vehicle (DRUG),21800,Psorion,Atopic Dermatitis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9605,NCT03308799,A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream,COMPLETED,PHASE3,Psoriasis Vulgaris,MC2-01 cream (DRUG); Cal/BDP combination (DRUG); Cream vehicle (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9606,NCT02749799,Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis,COMPLETED,PHASE4,Plaque Psoriasis,"DFD-01 (betamethasone dipropionate) Spray, 0.05% (DRUG)",21800,Psorion,Plaque Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9607,NCT04071106,Turmeric Based Therapy in the Treatment of Psoriasis: A Clinical Trial,UNKNOWN,PHASE2,Psoriasis,Turmeric Extract (DRUG); Turmeric Extract in Olive oil (DRUG); Petrolatum (DRUG); NB-UVB (DEVICE); calcipotriol/ Betamethasone (DRUG),21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9608,NCT04221906,Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test,COMPLETED,PHASE1,Chronic Plaque Psoriasis,BOS-475 (DRUG); Active ingredient-free vehicle cream (DRUG); Daivonex cream (calcipotriol 0.005%) (DRUG); Betnesol-V cream (betamethasone 0.1%) (DRUG),21800,Psorion,Chronic Plaque Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9609,NCT00216879,Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis,COMPLETED,PHASE3,Psoriasis of Scalp,Calcipotriol plus betamethasone dipropionate gel (LEO 80185) (DRUG),21800,Psorion,Psoriasis of Scalp,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9610,NCT00358384,Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034,COMPLETED,PHASE1,Psoriasis,Pazopanib (DRUG); Pazopanib vehicle (DRUG); Betamethasone valerate (DRUG); Calcipotriol (DRUG),21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9611,NCT00243464,Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis,COMPLETED,PHASE3,Psoriasis of Scalp,Calcipotriol plus betamethasone dipropionate (LEO80185 gel) (DRUG),21800,Psorion,Psoriasis of Scalp,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9612,NCT01011621,Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis,UNKNOWN,PHASE3,"Dermatitis, Atopic; Dermatitis, Contact; Dermatitis, Seborrheic; Psoriasis",0.5% prednisolone acetate cream (DRUG); 0.1% betamethasone valerate cream (DRUG),21800,Psorion,"Dermatitis, Atopic; Dermatitis, Contact; Dermatitis, Seborrheic; Psoriasis",Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9613,NCT01707043,Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris,COMPLETED,PHASE4,Plaque Psoriasis,Taclonex (DRUG),21800,Psorion,Plaque Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9614,NCT03669757,"Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis",COMPLETED,PHASE1,Psoriasis Vulgaris,LEO 134310 (DRUG); LEO 134310 (DRUG); LEO 134310 (DRUG); LEO 134310 (DRUG); LEO 134310 vehicle (DRUG); 0.1% betamethasone valerate ointment (class III steroid) (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9615,NCT02518048,A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris,COMPLETED,PHASE2,Skin and Connective Tissue Diseases,LEO 90100 Aerosol foam (DRUG); Betesil® 2.25 mg (DRUG),21800,Psorion,Skin and Connective Tissue Diseases,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9616,NCT01422434,LEO 90105 Ointment in Japanese Subjects With Psoriasis,COMPLETED,PHASE3,Psoriasis,LEO 90105 = calcipotriol + betamethasone dipropionate (DRUG); Dovonex® = calcipotriol (DRUG); Rinderon® - DP = betamethasone dipropionate (DRUG),21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9617,NCT01768013,The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris,COMPLETED,PHASE1,Psoriasis Vulgaris,LEO 90105 (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9618,NCT00578370,Efficacy and Tolerability Study of Topical Ciclosporin in a Psoriasis Plaque Test,COMPLETED,PHASE1,Psoriasis,Ciclosporin 0.5% (Formulation 01B) (DRUG); Ciclosporin 1.5% (Formulation 02B) (DRUG); 0.1% betamethasone (DRUG); 0.005% calcipotriol (DRUG); Formulation 00B (DRUG),21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9619,NCT02548052,Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis,COMPLETED,PHASE1,Psoriasis,GSK2981278 0.03% (DRUG); GSK2981278 0.1% (DRUG); GSK2981278 0.8% (DRUG); GSK2981278 4% (DRUG); Vehicle (DRUG); Betamethasone valerate 0.1% (DRUG),21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9620,NCT03080545,Enstilar in Combination With Biologic Agents,COMPLETED,PHASE4,Psoriasis,Enstilar 0.005%-0.064% Topical Foam (DRUG),21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9621,NCT04372277,Taltz in Combination With Enstilar for Psoriasis,RECRUITING,PHASE4,Psoriasis,Enstilar (DRUG),21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9622,NCT03506477,Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color,COMPLETED,PHASE4,Plaque Psoriasis; Psoriasis,Enstilar® foam (DRUG); Vehicle foam (DRUG),21800,Psorion,Plaque Psoriasis; Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9623,NCT03122353,BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis,COMPLETED,PHASE1,Scalp Psoriasis,Calcipotriene and betamethasone suspension (DRUG); Taclonex (DRUG); Placebo (DRUG),21800,Psorion,Scalp Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9624,NCT00875277,A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products,COMPLETED,PHASE2,Psoriasis Vulgaris,LEO 29102 cream (DRUG); LEO 29102 Cream Vehicle (DRUG); Betamethasone Dipropionate Cream (DRUG); LEO 29102 Plus Calcipotriol Cream (DRUG); LEO 29102 Plus Betamethasone Dipropionate (DRUG); Daivobet® Ointment (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9625,NCT04580537,Assessing the Efficacy of Image-guided Laser-assisted Enstilar® Delivery for Treatment of Psoriatic Nails,COMPLETED,PHASE2,Nail Psoriasis,Enstilar (DRUG); Ablative fractional laser (DEVICE),21800,Psorion,Nail Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9626,NCT04227288,A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis,COMPLETED,PHASE4,Nail Psoriasis,Enstilar Foam (DRUG),21800,Psorion,Nail Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9627,NCT04555707,The Maintenance Effect of Enstilar Foam in Combination With Otezla,UNKNOWN,PHASE4,Psoriasis,Apremilast 30mg (DRUG); calcipotriene and betamethasone dipropionate (DRUG),21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9628,NCT00248456,Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Ointment in Patients With Psoriasis Vulgaris,COMPLETED,PHASE4,Psoriasis Vulgaris,Calcipotriol plus betamethasone dipropionate ointment (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9629,NCT02586961,Nebulized Adrenalin and Oral Betamethasone in Children With Bronchiolitis Attending Pediatric Emergencies.,TERMINATED,PHASE2,Children; Bronchiolitis,0.9% saline solution (DRUG); oral betamethasone placebo (DRUG); adrenaline (DRUG); oral betamethasone (DRUG),21800,Psorion,Children; Bronchiolitis,Lung,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9630,NCT03898583,"Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.",COMPLETED,PHASE1,Psoriasis Vulgaris,Microarray patch A (DRUG); Microarray patch B (DRUG); Placebo (DRUG); Daivobet (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9631,NCT02379793,Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects,COMPLETED,PHASE1,Skin and Connective Tissue Diseases,"LEO 80185 gel, vehicle, liquid paraffin (DRUG)",21800,Psorion,Skin and Connective Tissue Diseases,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9632,NCT04114097,The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover,COMPLETED,PHASE4,Atopic Dermatitis; Atopic Eczema,"Betnovate, betamethasone dipropionate ointment 0.1% and placebo (DRUG); Protopic, tacrolimus ointment 0.1% (DRUG)",21800,Psorion,Atopic Dermatitis; Atopic Eczema,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9633,NCT01188928,LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs),COMPLETED,PHASE3,Psoriasis Vulgaris,"Calcipotriol plus betamethasone (DRUG); Betamethasone-17,21-dipropionate (DRUG); Calcipotriene (DRUG); Topical suspension vehicle (DRUG)",21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9634,NCT00671528,Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4),TERMINATED,PHASE4,"Dermatitis, Atopic; Eczema, Atopic; Skin Diseases, Eczematous","Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate) (DRUG); Cream (betamethasone diproprionate and gentamicin) (DRUG); Cream (betamethasone diproprionate) (DRUG)",21800,Psorion,"Dermatitis, Atopic; Eczema, Atopic; Skin Diseases, Eczematous",Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9635,NCT01466478,"An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris",COMPLETED,PHASE1,Psoriasis Vulgaris,Ointment A: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment (DRUG); Ointment B: LEO 29102 2.5 mg/g ointment (DRUG); Ointment C: Calcipotriol 50 µg/g ointment (DRUG); Ointment D: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment (DRUG); Ointment G: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment (DRUG); Daivonex® ointment (DRUG); Diprosone® ointment (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9636,NCT03848871,The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients,COMPLETED,PHASE4,Plaque Psoriasis,Enstilar (DRUG),21800,Psorion,Plaque Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9637,NCT05555797,Excimer Laser With Topical Agents in Psoriasis Vulgaris,UNKNOWN,PHASE4,Psoriasis,308nm Excimer laser (DEVICE); Tazarotene Topical Gel (DRUG); Betamethasone Valerate (DRUG),21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9638,NCT01229098,Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris,COMPLETED,PHASE2,Psoriasis Vulgaris,LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension) (DRUG),21800,Psorion,Psoriasis Vulgaris,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9639,NCT02432027,Trial to Evaluate Topical C-82 in a Psoriasis Plaque Test,COMPLETED,PHASE1,Psoriasis,"C-82 Topical Gel, Placebo (DRUG); C-82 Topical Gel, 1% (DRUG); Daivonex cream (DRUG); Diprosis gel (DRUG)",21800,Psorion,Psoriasis,Skin,Betamethasone dipropionate,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,A corticosteroid approved and used in topical formulations for inflammation.,CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC,1.39,171.0 +9640,NCT00240526,LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers,COMPLETED,PHASE4,Hepatitis B,Engerix™ -B (BIOLOGICAL); Hepatitis B immunoglobulin (HBIg) (BIOLOGICAL),468595,POS,Hepatitis B,Liver,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9641,NCT02161757,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,COMPLETED,PHASE3,Uncontrolled Asthma,Tralokinumab (BIOLOGICAL); Placebo (OTHER),468595,POS,Uncontrolled Asthma,Lung,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9642,NCT01710657,A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures,COMPLETED,PHASE3,Epilepsy; Partial Onset Seizures,Lacosamide 50 mg (DRUG); Lacosamide 100 mg (DRUG); Placebo (DRUG),468595,POS,Epilepsy; Partial Onset Seizures,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9643,NCT01394120,Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer,UNKNOWN,PHASE2,"Carcinoma, Pancreatic Ductal",Targeted Therapy Tailored Treatment (DRUG); Standard Chemotherapy (DRUG),468595,POS,Pancreatic Ductal Carcinoma,Pancreas,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9644,NCT02560220,MIC Cell Therapy for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients,COMPLETED,PHASE1,"Kidney Failure, Chronic",Mitomycin C-induced peripheral blood mononuclear cells (MICs) (BIOLOGICAL),468595,POS,"Kidney Failure, Chronic",Kidney,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9645,NCT06597565,A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC,RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma,Gemcitabine (DRUG); ACR-368 (DRUG),468595,POS,Head and Neck Squamous Cell Carcinoma,Skin,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9646,NCT02849626,Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures,COMPLETED,PHASE3,Partial-Onset or Primary Generalized Tonic-Clonic Seizures,Perampanel (DRUG),468595,POS,Partial-Onset or Primary Generalized Tonic-Clonic Seizures,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9647,NCT03754582,A Study of Intravenous Perampanel in Japanese Participants With Epilepsy,COMPLETED,PHASE2,Epilepsy; Seizures,Perampanel (DRUG); Perampanel (DRUG),468595,POS,Epilepsy; Seizures,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9648,NCT06788990,"FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC",RECRUITING,PHASE2,Metastatic Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma,Ficerafusp alfa (DRUG); Pembrolizumab (KEYTRUDA®) (DRUG); Placebo (DRUG),468595,POS,Metastatic Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma,Skin,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9649,NCT02625090,An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy,TERMINATED,PHASE2,Highly Drug-resistant Focal Epilepsy,UCB0942 (DRUG),468595,POS,Highly Drug-resistant Focal Epilepsy,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9650,NCT00464269,"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures",COMPLETED,PHASE3,Epilepsy,Placebo (OTHER); Brivaracetam 2.5 mg (DRUG); Brivaracetam 10 mg (DRUG); Brivaracetam 25 mg (DRUG),468595,POS,Epilepsy,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9651,NCT01648101,Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures,TERMINATED,PHASE3,Epilepsy,Retigabine 900mg/day (DRUG); Retigabine 600mg/day (DRUG); Placebo (OTHER),468595,POS,Epilepsy,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9652,NCT00368069,A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR,COMPLETED,PHASE3,Epilepsy,Keppra® extended release formulation - XR (DRUG); Placebo (DRUG),468595,POS,Epilepsy,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9653,NCT01607346,An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures,TERMINATED,PHASE4,Epilepsy,ezogabine/retigabine (DRUG),468595,POS,Epilepsy,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9654,NCT00152373,"Double-blind, Placebo-controlled Study of Levetiracetam in Adults With POS",COMPLETED,PHASE3,"Epilepsy, Partial",Levetiracetam (DRUG),468595,POS,"Epilepsy, Partial",CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9655,NCT01426880,Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer,COMPLETED,PHASE2,Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer,Carboplatin (DRUG); background treatment (DRUG),468595,POS,Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer,Breast,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9656,NCT01036022,Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis,COMPLETED,PHASE2,"Colitis, Ulcerative",GSK1399686 (DRUG),468595,POS,"Colitis, Ulcerative",Bowel,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9657,NCT02477839,Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures,COMPLETED,PHASE3,Epilepsy With Partial-onset Seizures,Lacosamide (DRUG); Placebo (OTHER),468595,POS,Epilepsy With Partial-onset Seizures,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9658,NCT01777139,"A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures",COMPLETED,PHASE3,Epilepsy,Retigabine IR (DRUG),468595,POS,Epilepsy,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9659,NCT01653262,Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV),COMPLETED,PHASE3,Epilepsy,Brivaracetam (DRUG),468595,POS,Epilepsy,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9660,NCT02558894,Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma,COMPLETED,PHASE2,Metastatic Pancreatic Ductal Adenocarcinoma,MEDI4736 monotherapy (DRUG); tremelimumab+MEDI4736 (DRUG),468595,POS,Metastatic Pancreatic Ductal Adenocarcinoma,Pancreas,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9661,NCT01650480,"HELPing Older People With Very Severe Chronic Obstructive Pulmonary Disease Towards the End of Their Lives: Developing, Piloting and Refining a Practical Intervention (HELP-COPD)",COMPLETED,EARLY_PHASE1,Chronic Obstructive Pulmonary Disease (COPD),HELP-COPD action plan (OTHER),468595,POS,Chronic Obstructive Pulmonary Disease (COPD),Lung,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9662,NCT00175916,Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy,COMPLETED,PHASE3,Epilepsy,Brivaracetam (ucb 34714) (DRUG),468595,POS,Epilepsy,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9663,NCT00504881,Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy,COMPLETED,PHASE3,Epilepsy,Placebo (DRUG); Brivaracetam (DRUG),468595,POS,Epilepsy,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9664,NCT02404844,"Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer",COMPLETED,PHASE2,Breast Cancer,BKM120 (DRUG); Tamoxifen (DRUG),468595,POS,Breast Cancer,Breast,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9665,NCT02236572,"Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score",TERMINATED,PHASE2,Breast Cancer,Everolimus (DRUG),468595,POS,Breast Cancer,Breast,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9666,NCT00233012,"A Study of the Pharmacokinetics, Safety and Tolerability of Topiramate in Infants (Age 1-24 Months) With Refractory Partial-onset Seizures",COMPLETED,PHASE1,Seizures,Topiramate (DRUG),468595,POS,Seizures,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9667,NCT04015141,A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy,RECRUITING,PHASE2,Pediatric Epileptic Syndrome; Partial-onset Seizures,Perampanel Oral Suspension (DRUG); Perampanel Tablet (DRUG),468595,POS,Pediatric Epileptic Syndrome; Partial-onset Seizures,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9668,NCT06453213,Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy,RECRUITING,PHASE4,Focal Onset Seizure,Cenobamate (DRUG),468595,POS,Focal Onset Seizure,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9669,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,COMPLETED,PHASE3,Relapsing Multiple Sclerosis,peginterferon beta-1a (DRUG),468595,POS,Relapsing Multiple Sclerosis,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9670,NCT03607955,"Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy",WITHDRAWN,PHASE1,Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer,AVB-S6-500 (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Tissue from Diagnostic Laparoscopy (PROCEDURE); Tissue from Core biopsy (PROCEDURE); Interval Debulking (PROCEDURE); Peripheral blood (PROCEDURE); Ascites collection (PROCEDURE),468595,POS,Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer,Ovary/Fallopian Tube,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9671,NCT01292408,Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients,UNKNOWN,PHASE2,Breast Cancer,Hydrochloroquine (DRUG),468595,POS,Breast Cancer,Breast,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9672,NCT02865395,Timing of B and O Suppositories to Help Relieve Post-operative Bladder Spasms,TERMINATED,PHASE4,Overactive Bladder,Belladonna and Opium Suppository (DRUG); Rectal Exam (PROCEDURE),468595,POS,Overactive Bladder,Bladder/Urinary Tract,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9673,NCT01954121,"Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures",COMPLETED,PHASE3,Epilepsy; Partial Seizures,Levetiracetam (DRUG); Carbamazepine (DRUG),468595,POS,Epilepsy; Partial Seizures,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9674,NCT01227902,Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures,COMPLETED,PHASE3,Epilepsy,Retigabine IR (DRUG),468595,POS,Epilepsy,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9675,NCT01336621,Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS),COMPLETED,PHASE3,Epilepsy,Retigabine IR (DRUG),468595,POS,Epilepsy,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9676,NCT01250379,A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA),COMPLETED,PHASE3,Breast Cancer,bevacizumab [Avastin] (DRUG); Chemotherapy (DRUG),468595,POS,Breast Cancer,Breast,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9677,NCT06802757,Posaconazole Plus Pembrolizumab and Chemotherapy Vs Pembrolizumab and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer,RECRUITING,PHASE2,Breast Cancer,Posaconazole (DRUG); Nab-paclitaxel (DRUG); Carboplatin (DRUG); Anthracycline (DRUG); Cyclophosphamide (DRUG); Pembrolizumab (DRUG),468595,POS,Breast Cancer,Breast,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9678,NCT01339559,Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy,COMPLETED,PHASE3,Epilepsy,Brivaracetam (DRUG),468595,POS,Epilepsy,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9679,NCT01229735,Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures,COMPLETED,PHASE4,Epilepsy,Levetiracetam (DRUG); Topiramate (DRUG),468595,POS,Epilepsy,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9680,NCT03212963,Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%,TERMINATED,PHASE4,Plaque Psoriasis,Halobetasol Topical Lotion (DRUG),468595,POS,Plaque Psoriasis,Skin,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9681,NCT00465517,"A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures",COMPLETED,PHASE2,Partial Epilepsy; Catamenial Epilepsy,Ganaxolone (DRUG); Placebo (OTHER),468595,POS,Partial Epilepsy; Catamenial Epilepsy,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9682,NCT01721317,"Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures",TERMINATED,PHASE4,Seizures,Ezogabine/Retigabine IR (DRUG); Placebo (DRUG),468595,POS,Seizures,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9683,NCT00139113,Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children,COMPLETED,PHASE4,Hepatitis A,hepatitis A vaccine (BIOLOGICAL),468595,POS,Hepatitis A,Liver,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9684,NCT03201900,Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study),COMPLETED,PHASE3,Partial Onset Seizures,E2007 (DRUG),468595,POS,Partial Onset Seizures,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9685,NCT02977052,Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab,ACTIVE_NOT_RECRUITING,PHASE2,Malignant Melanoma Stage III,Ipilimumab (DRUG); Nivolumab (DRUG); Surgery (PROCEDURE); Blood for PBMCs (PROCEDURE); Biopsies (PROCEDURE),468595,POS,Malignant Melanoma Stage III,Skin,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9686,NCT00150800,"This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment",COMPLETED,PHASE3,Epilepsy,Brivaracetam (DRUG),468595,POS,Epilepsy,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9687,NCT00658359,Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients,COMPLETED,PHASE2,Kidney Transplantation,"Cyclosporine (DRUG); CP-690,550 (DRUG); CP-690,550 (DRUG)",468595,POS,Kidney Transplantation,Kidney,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9688,NCT02194699,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,COMPLETED,PHASE3,Uncontrolled Asthma,Experimental: Tralokinumab (BIOLOGICAL); Placebo (OTHER),468595,POS,Uncontrolled Asthma,Lung,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9689,NCT01911156,Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues,UNKNOWN,PHASE4,Chronic Hepatitis B,Continue NA treatment (DRUG); Discontinue NA Treatment (DRUG),468595,POS,Chronic Hepatitis B,Liver,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9690,NCT00113815,Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures,COMPLETED,PHASE3,Partial Seizure Disorder; Epilepsy; Seizures,topiramate (DRUG); topiramate (DRUG); topiramate (DRUG); placebo (DRUG),468595,POS,Partial Seizure Disorder; Epilepsy; Seizures,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9691,NCT01668654,"Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS",TERMINATED,PHASE3,Epilepsy,retigabine/ezogabine (DRUG),468595,POS,Epilepsy,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9692,NCT05275647,Efficacy and Safety of Low Energy Shock Wave Plus BotulinumToxin A in Treating Patients With Interstitial Cystitis,UNKNOWN,PHASE2,Interstitial Cystitis,BOTOX 100U in normal saline (DRUG); Normal saline (DRUG),468595,POS,Interstitial Cystitis,Bladder/Urinary Tract,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9693,NCT00714233,Treatment of Adolescent Polycystic Ovary Syndrome (PCOS),COMPLETED,PHASE3,Polycystic Ovary Syndrome,Metformin (DRUG); Oral Contraceptive Pills (Yasmin) (DRUG); Lifestyle Modification (BEHAVIORAL); placebo (DRUG),468595,POS,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9694,NCT01728077,"Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy",COMPLETED,PHASE3,Epilepsy,Brivaracetam (DRUG),468595,POS,Epilepsy,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9695,NCT04791553,Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment,COMPLETED,PHASE1,Hepatic Impairment,Cenobamate (DRUG),468595,POS,Hepatic Impairment,Liver,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9696,NCT04907032,Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study),COMPLETED,PHASE4,Overactive Bladder,Mirabegron 50 MG (DRUG); Posterior Tibial Nerve Stimulation (PTNS) (DEVICE),468595,POS,Overactive Bladder,Bladder/Urinary Tract,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9697,NCT00567554,"Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer",COMPLETED,PHASE3,Breast Cancer,epirubicin - cyclophosphamide / docetaxel (DRUG); epirubicin - cyclophosphamide / docetaxel + bevacizumab (DRUG); paclitaxel (DRUG); paclitaxel + everolimus (RAD001) (DRUG); epirubicin - cyclophosphamide / docetaxel + trastuzumab (DRUG); epirubicin - cyclophosphamide / docetaxel + lapatinib (DRUG),468595,POS,Breast Cancer,Breast,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9698,NCT01364597,Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy,COMPLETED,PHASE3,Epilepsy,Brivaracetam (BRV) (DRUG),468595,POS,Epilepsy,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9699,NCT03116828,A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures,COMPLETED,PHASE4,Epilepsy With Partial On-set Seizures,Eslicarbazepine acetate (DRUG); Eslicarbazepine Acetate (DRUG),468595,POS,Epilepsy With Partial On-set Seizures,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9700,NCT02692378,Effects of Oral Sodium Bicarbonate Supplementation in Haemodialysis Patients (BicHD),COMPLETED,PHASE4,End-stage Renal Disease,sodium bicarbonate 500mg capsules (DRUG),468595,POS,End-stage Renal Disease,Kidney,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9701,NCT03968393,Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery,RECRUITING,PHASE4,Stroke; Atrial Fibrillation,Non-vitamin K oral anticoagulant (NOAC) (DRUG),468595,POS,Stroke with Atrial Fibrillation,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9702,NCT01367028,A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer,COMPLETED,PHASE2,Breast Cancer,"Trastuzumab, Docetaxel (DRUG); Trastuzumab, Docetaxel, Bevacizumab (DRUG); Trastuzumab+Docetaxel+NPLD (DRUG); Trastuzumab+Docetaxel+NPLD+Bevacizumab (DRUG)",468595,POS,Breast Cancer,Breast,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9703,NCT01484197,A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device,COMPLETED,PHASE2,Asthma,75 µg indacaterol maleate (LB) (DRUG); 75 µg indacaterol maleate (PoS) (DRUG); 37.5 µg indacaterol maleate (PoS) (DRUG); placebo to indacaterol (LB) (DRUG); placebo to indacaterol (PoS) (DRUG),468595,POS,Asthma,Lung,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9704,NCT01921205,Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures,COMPLETED,PHASE3,Epilepsy,Lacosamide (DRUG); Placebo (OTHER),468595,POS,Epilepsy,CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9705,NCT03763396,Azoles Targeting Recurrent High Grade Gliomas,NOT_YET_RECRUITING,EARLY_PHASE1,"Brain Tumor, Recurrent; Cancer, Advanced; Glioma of Brain",Ketoconazole (KCZ) (DRUG); Posaconazole (PCZ) (DRUG),468595,POS,"Brain Tumor, Recurrent; Cancer, Advanced; Glioma of Brain",CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9706,NCT04825275,Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: a Phase 0 Clinical Trial,TERMINATED,EARLY_PHASE1,"Glioblastoma; Glioblastoma Multiforme; Glioblastoma Multiforme of Brain; Glioblastoma Multiforme, Adult",Posaconazole Pill (DRUG),468595,POS,"Glioblastoma; Glioblastoma Multiforme; Glioblastoma Multiforme of Brain; Glioblastoma Multiforme, Adult",CNS/Brain,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9707,NCT04966585,Pilot Study of Posaconazole in Crohn's Disease,TERMINATED,PHASE4,Crohn Disease; CARD9 S12N Risk Allele,Posaconazole Delayed Release Oral Tablet (DRUG); Matching Placebo Tablet (DRUG),468595,POS,Crohn Disease; CARD9 S12N Risk Allele,Bowel,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9708,NCT04056611,Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV),TERMINATED,PHASE2,Respiratory Syncytial Virus Infections,JNJ-53718678 250 mg (DRUG); Placebo (DRUG); JNJ-53718678 125 mg (DRUG),468595,POS,Respiratory Syncytial Virus Infections,Lung,Posaconazole,,unclear,unclear,yes,yes,Broad-spectrum antifungal approved for human use.,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,1.04,393.0 +9709,NCT03070574,Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome,TERMINATED,PHASE2,Colorectal Cancer,mesalamine 2400 MG (5-ASA) (DRUG); mesalamine 1200 MG (DRUG); Placebo (OTHER),16759173,Vasen,Colorectal Cancer,Bowel,Pravastatin (sodium),HMGCR,inhibitor/antagonist,unclear,yes,yes,Approved as a cholesterol-lowering agent.,CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)[O-])O)O)O.[Na+],1.36,162.0 +9710,NCT03773263,New Application of Sequential in Vitro Muturation System for Infertility Patients With Polycystic Ovary Syndrome,UNKNOWN,PHASE3,Polycystic Ovary Syndrome; Infertility,sequential IVM system (DRUG); intracytoplasmic sperm injection (ICSI) (PROCEDURE); Thawed embryo transfer (TET) (PROCEDURE); traditional IVM system (DRUG),6321424,IVM,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9711,NCT03297489,"Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer",COMPLETED,EARLY_PHASE1,Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma; Stage I Ovarian Cancer; Stage IA Ovarian Cancer; Stage IB Ovarian Cancer; Stage IC Ovarian Cancer; Stage II Ovarian Cancer; Stage IIA Ovarian Cancer; Stage IIB Ovarian Cancer; Stage IIC Ovarian Cancer; Stage III Ovarian Cancer; Stage IIIA Ovarian Cancer; Stage IIIB Ovarian Cancer; Stage IIIC Ovarian Cancer; Stage IV Ovarian Cancer,Diagnostic Microscopy (PROCEDURE); Fluorescein Sodium Injection (DRUG); Laboratory Biomarker Analysis (OTHER),6321424,IVM,Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma; Stage I Ovarian Cancer; Stage IA Ovarian Cancer; Stage IB Ovarian Cancer; Stage IC Ovarian Cancer; Stage II Ovarian Cancer; Stage IIA Ovarian Cancer; Stage IIB Ovarian Cancer; Stage IIC Ovarian Cancer; Stage III Ovarian Cancer; Stage IIIA Ovarian Cancer; Stage IIIB Ovarian Cancer; Stage IIIC Ovarian Cancer; Stage IV Ovarian Cancer,Ovary/Fallopian Tube,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9712,NCT03344172,Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer,TERMINATED,PHASE2,Pancreatic Cancer Resectable,"Gemcitabine, Nab-Paclitaxel, hydroxychloroquine and Avelumab (DRUG); Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine (DRUG)",6321424,IVM,Pancreatic Cancer Resectable,Pancreas,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9713,NCT02616250,MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.,COMPLETED,PHASE4,Rosacea,Brimonidine 0.33% gel (Br) (DRUG); CD07805/47 (Br) placebo gel (OTHER); Ivermectin 1% cream (IVM) (DRUG); CD5024 (IVM) placebo cream (OTHER),6321424,IVM,Rosacea,Skin,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9714,NCT01012154,In Vivo Confocal Microscopy Tumor Atlas Study,UNKNOWN,PHASE1,Brain Neoplasms,Endomicroscope (DEVICE),6321424,IVM,Brain Neoplasms,CNS/Brain,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9715,NCT02178709,A Phase II Study of Neoadjuvant FOLFIRINOX,COMPLETED,PHASE2,Resectable Pancreatic Ductal Adenocarcinoma,FOLFIRINOX (DRUG),6321424,IVM,Resectable Pancreatic Ductal Adenocarcinoma,Pancreas,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9716,NCT03197077,Optimisation of Follicular Recruitment in IVM Cycles,COMPLETED,PHASE3,"Infertility, Female; Polycystic Ovary Syndrome",blood sampling (PROCEDURE); transvaginal ultrasound scanning (PROCEDURE); oocyte retrieval for IVM (PROCEDURE); Corifollitropin Alfa (DRUG); Follitropin beta (DRUG); oral contraceptive pill pretreatment (Marvelon) (DRUG),6321424,IVM,"Infertility, Female; Polycystic Ovary Syndrome",Ovary/Fallopian Tube,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9717,NCT04106726,Bioequivalence Study of Ivermectin Cream 1% in Treatment of Moderate to Severe Facial Rosacea,COMPLETED,PHASE3,Facial Rosacea,Soolantra® Ivermectin cream 1% (DRUG); Ivermectin cream 1% (DRUG); Placebo for Ivermectin cream 1% (DRUG),6321424,IVM,Facial Rosacea,Skin,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9718,NCT03852303,Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy,COMPLETED,PHASE4,Epilepsy,ivermectin (DRUG),6321424,IVM,Epilepsy,CNS/Brain,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9719,NCT03075891,Oracea Soolantra Association in Participants With Severe Rosacea,COMPLETED,PHASE4,Rosacea,Ivermectin 1% cream (DRUG); Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules (DRUG); Oral placebo capsules (OTHER),6321424,IVM,Rosacea,Skin,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9720,NCT04886362,Ivermectina Colombia (IVERCOL),UNKNOWN,PHASE2,COVID-19 Pneumonia,Ivermectin (DRUG); Placebo (DRUG),6321424,IVM,COVID-19 Pneumonia,Lung,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9721,NCT04959786,MANS-NRIZ Trial for COVID-19 Treatment : Extension Study,UNKNOWN,PHASE2,COVID-19 Pneumonia,"Ivermectin,ribavirin ,nitazoxanide and zinc (DRUG)",6321424,IVM,COVID-19 Pneumonia,Lung,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9722,NCT04784481,Ivermectin Reproposing for Mild Stage COVID-19 Outpatients,COMPLETED,PHASE1,Covid19; SARS (Severe Acute Respiratory Syndrome),Ivermectin (DRUG),6321424,IVM,Covid19; SARS (Severe Acute Respiratory Syndrome),Lung,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9723,NCT05318469,Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer,RECRUITING,PHASE1,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma,Ivermectin (DRUG); Balstilmab (DRUG); Pembrolizumab (DRUG),6321424,IVM,Metastatic Breast Cancer,Breast,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9724,NCT02036229,Topical 0.5% Ivermectin Cream for Treatment of Demodicidosis,UNKNOWN,PHASE3,Demodicidosis; Rosacea,ivermectin cream 0.5% (DRUG),6321424,IVM,Demodicidosis; Rosacea,Skin,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9725,NCT03250624,Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis,COMPLETED,PHASE2,Atopic Dermatitis,CD5024 0.3% cream (DRUG); Placebo (DRUG),6321424,IVM,Atopic Dermatitis,Skin,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9726,NCT02795117,Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea,COMPLETED,PHASE3,Rosacea,Ivermectin (DRUG); Ivermectin (reference) (DRUG); Placebo (DRUG),6321424,IVM,Rosacea,Skin,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9727,NCT04701710,Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan,COMPLETED,PHASE1,Covid19; SARS (Severe Acute Respiratory Syndrome),Ivermectin / Iota-Carrageenan (DRUG),6321424,IVM,Covid19; SARS (Severe Acute Respiratory Syndrome),Lung,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9728,NCT02806414,Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.,COMPLETED,PHASE1,Rosacea,Ivermectin (DRUG),6321424,IVM,Rosacea,Skin,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9729,NCT04275999,Rosacea and Ivermectin,ACTIVE_NOT_RECRUITING,PHASE2,Rosacea,ivermectin (DRUG); digital interaction (BEHAVIORAL); GPSkin (DEVICE),6321424,IVM,Rosacea,Skin,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9730,NCT06557603,Bioequivalence Study of Ivermectin 1% Cream and Soolantra (Ivermectin) 10 mg/g Cream,COMPLETED,PHASE1,Rosacea,Ivermectin cream (DRUG); Soolantra ® (Ivermectin) cream (DRUG),6321424,IVM,Rosacea,Skin,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9731,NCT06033352,Potassium-titanyl Phosphate (KTP) Laser vs KTP Laser and Ivermectin Cream for Facial Rosacea,COMPLETED,PHASE2,Rosacea,KTP laser (DEVICE); Ivermectin 1% cream (DRUG),6321424,IVM,Rosacea,Skin,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9732,NCT03553615,Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis,WITHDRAWN,PHASE2,Atopic Dermatitis,Ivermectin Pill (DRUG),6321424,IVM,Atopic Dermatitis,Skin,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9733,NCT01493947,CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study,COMPLETED,PHASE3,Papulopustular Rosacea,Ivermectin 1% cream (DRUG); Metronidazole 0.75% cream (DRUG),6321424,IVM,Papulopustular Rosacea,Skin,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9734,NCT04779047,Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.,UNKNOWN,PHASE4,Covid19; Pneumonia,Remdesivir (DRUG); Hydroxychloroquine (DRUG); Tocilizumab (DRUG); Lopinavir/ Ritonavir (DRUG); Ivermectin (DRUG),6321424,IVM,Covid19; Pneumonia,Lung,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9735,NCT04602507,Ivermectin in Adults With Severe COVID-19.,TERMINATED,PHASE2,Covid19; Severe Acute Respiratory Syndrome,Ivermectin (DRUG); Placebo (OTHER),6321424,IVM,Covid19; Severe Acute Respiratory Syndrome,Lung,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9736,NCT02735707,"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",RECRUITING,PHASE3,"Community-acquired Pneumonia, Influenza, COVID-19",Ceftriaxone (DRUG); Moxifloxacin or Levofloxacin (DRUG); Piperacillin-tazobactam (DRUG); Ceftaroline (DRUG); Amoxicillin-clavulanate (DRUG); Standard course macrolide (DRUG); Extended course macrolide (DRUG); No systemic corticosteroid (OTHER); Fixed-duration Hydrocortisone (DRUG); Shock-dependent hydrocortisone (DRUG); Fixed-duration higher dose Hydrocortisone (DRUG); No antiviral agent for influenza (OTHER); Five-days oseltamivir (DRUG); Ten-days oseltamivir (DRUG); No antiviral agent for COVID-19 (OTHER); Lopinavir / Ritonavir (DRUG); Hydroxychloroquine (DRUG); Hydroxychloroquine + lopinavir/ritonavir (DRUG); Ivermectin (DRUG); No immune modulation for COVID-19 (OTHER); Interferon beta-1a (DRUG); Anakinra (DRUG); Tocilizumab (DRUG); Sarilumab (DRUG); Local standard venous thromboprophylaxis (DRUG); Therapeutic dose anticoagulation (DRUG); Conventional low dose thromboprophylaxis (DRUG); Intermediate dose thromboprophylaxis (DRUG); Continuation of therapeutic dose anticoagulation (DRUG); No immunoglobulin (OTHER); Convalescent plasma (BIOLOGICAL); Delayed administration of convalescent plasma (BIOLOGICAL); No vitamin C (OTHER); Vitamin C (DRUG); No antiplatelet (OTHER); Aspirin (DRUG); P2Y12 inhibitor (DRUG); No simvastatin (OTHER); Simvastatin (DRUG); Eritoran (DRUG); Apremilast (DRUG); Clinician-preferred mechanical ventilation strategy (PROCEDURE); Protocolised mechanical ventilation strategy (PROCEDURE); No renin-angiotensin system inhibitor (OTHER); Angiotensin converting enzyme inhibitor (DRUG); Angiotensin Receptor Blockers (DRUG); ARB + DMX-200 (DRUG); No cysteamine (OTHER); Cysteamine (DRUG); Fixed-duration dexamethasone (DRUG); Baloxavir Marboxil (DRUG); Five-days oseltamivir + baloxavir marboxil (DRUG); Ten-days oseltamivir + baloxavir marboxil (DRUG); No endothelial modulator (OTHER); Imatinib (DRUG); No Immune Modulator for Influenza (OTHER); Tocilizumab (DRUG); Baricitinib (DRUG); No antiviral agent for COVID-19 (OTHER); Nirmatrelvir/ritonavir (DRUG); Remdesivir (DRUG); Nirmatrelvir/ritonavir + remdesivir (DRUG),6321424,IVM,Community-acquired Respiratory Infections,Lung,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9737,NCT02840461,Clinical Endpoint Study of Ivermectin 1% Cream,COMPLETED,PHASE3,Moderate to Severe Papulopustular Rosacea,"Ivermectin Cream, 1% (DRUG); Placebo/Vehicle cream (DRUG)",6321424,IVM,Moderate to Severe Papulopustular Rosacea,Skin,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9738,NCT04108897,Analysis of the Microbiome in Rosacea,RECRUITING,EARLY_PHASE1,Rosacea,Doxycycline (DRUG); Ivermectin Topical (DRUG),6321424,IVM,Rosacea,Skin,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9739,NCT03052998,Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy,COMPLETED,PHASE4,Ivermectin; Onchocerciasis; Epilepsy,Ivermectin (DRUG),6321424,IVM,Ivermectin; Onchocerciasis; Epilepsy,CNS/Brain,Ivermectin,,unclear,unclear,yes,yes,Approved for infections in humans and animals.,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,1.17,332.0 +9740,NCT03126916,Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL),ACTIVE_NOT_RECRUITING,PHASE3,Ganglioneuroblastoma; Neuroblastoma,Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration and Biopsy (PROCEDURE); Busulfan (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Cyclophosphamide (DRUG); Dexrazoxane Hydrochloride (DRUG); Dinutuximab (BIOLOGICAL); Doxorubicin Hydrochloride (DRUG); Echocardiography (PROCEDURE); Etoposide Phosphate (DRUG); External Beam Radiation Therapy (RADIATION); Iobenguane I-123 (RADIATION); Iobenguane I-131 (RADIATION); Isotretinoin (DRUG); Lorlatinib (DRUG); Magnetic Resonance Imaging (PROCEDURE); Melphalan Hydrochloride (DRUG); Multigated Acquisition Scan (PROCEDURE); Positron Emission Tomography (PROCEDURE); Sargramostim (BIOLOGICAL); Therapeutic Conventional Surgery (PROCEDURE); Thiotepa (DRUG); Topotecan Hydrochloride (DRUG); Vincristine Sulfate (DRUG),60699,Evotopin,Ganglioneuroblastoma; Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9741,NCT01798004,"Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma",COMPLETED,PHASE1,Ganglioneuroblastoma; Stage 1 Neuroblastoma; Stage 2 Neuroblastoma; Stage 2A Neuroblastoma; Stage 2B Neuroblastoma; Stage 3 Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma,Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE); Busulfan (DRUG); Cisplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin Hydrochloride (DRUG); Etoposide (DRUG); External Beam Radiation Therapy (RADIATION); Filgrastim (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER); Melphalan (DRUG); Mesna (DRUG); Peripheral Blood Stem Cell Transplantation (PROCEDURE); Pharmacological Study (OTHER); Topotecan Hydrochloride (DRUG); Vincristine Sulfate (DRUG),60699,Evotopin,Ganglioneuroblastoma; Stage 1 Neuroblastoma; Stage 2 Neuroblastoma; Stage 2A Neuroblastoma; Stage 2B Neuroblastoma; Stage 3 Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9742,NCT01012817,"Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Malignant Solid Neoplasm; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable Solid Neoplasm,Laboratory Biomarker Analysis (OTHER); Pharmacogenomic Study (OTHER); Pharmacological Study (OTHER); Topotecan Hydrochloride (DRUG); Veliparib (DRUG),60699,Evotopin,Metastatic Malignant Solid Neoplasm; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable Solid Neoplasm,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9743,NCT01175356,"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",ACTIVE_NOT_RECRUITING,PHASE1,Ganglioneuroblastoma; Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Regional Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma,3-Dimensional Conformal Radiation Therapy (RADIATION); Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE); Busulfan (DRUG); Cisplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin Hydrochloride (DRUG); Etoposide Phosphate (DRUG); External Beam Radiation Therapy (RADIATION); In Vitro-Treated Peripheral Blood Stem Cell Transplantation (PROCEDURE); Intensity-Modulated Radiation Therapy (RADIATION); Iobenguane I-131 (RADIATION); Isotretinoin (DRUG); Laboratory Biomarker Analysis (OTHER); Melphalan (DRUG); Pharmacological Study (OTHER); Questionnaire Administration (OTHER); Therapeutic Conventional Surgery (PROCEDURE); Topotecan Hydrochloride (DRUG); Vincristine Sulfate (DRUG),60699,Evotopin,Ganglioneuroblastoma; Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Regional Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9744,NCT04514497,"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Lung Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Neuroendocrine Carcinoma; Metastatic Pancreatic Adenocarcinoma; Stage III Lung Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Lung Small Cell Carcinoma; Unresectable Malignant Solid Neoplasm; Unresectable Neuroendocrine Carcinoma; Unresectable Pancreatic Adenocarcinoma,Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Elimusertib (DRUG); Irinotecan Hydrochloride (DRUG); Magnetic Resonance Imaging (PROCEDURE); Topotecan Hydrochloride (DRUG),60699,Evotopin,Metastatic Lung Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Neuroendocrine Carcinoma; Metastatic Pancreatic Adenocarcinoma; Stage III Lung Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Lung Small Cell Carcinoma; Unresectable Malignant Solid Neoplasm; Unresectable Neuroendocrine Carcinoma; Unresectable Pancreatic Adenocarcinoma,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9745,NCT05092360,Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7),ACTIVE_NOT_RECRUITING,PHASE3,Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer,Nemvaleukin and Pembrolizumab Combination (BIOLOGICAL); Pembrolizumab (BIOLOGICAL); Nemvaleukin (BIOLOGICAL); Pegylated Liposomal Doxorubicin (PLD) (DRUG); Paclitaxel (DRUG); Topotecan (DRUG); Gemcitabine (DRUG),60699,Evotopin,Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9746,NCT05578326,Study of Trilaciclib and Lurbinectidin,RECRUITING,PHASE2,Lung Cancer; Small-cell Lung Cancer,Trilaciclib (DRUG); Lurbinectedin (DRUG),60699,Evotopin,Lung Cancer; Small-cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9747,NCT02200757,Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer,COMPLETED,PHASE2,Metastatic Small Cell Lung Cancer,Aldoxorubicin (DRUG); Topotecan (DRUG),60699,Evotopin,Metastatic Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9748,NCT00003065,Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix,COMPLETED,PHASE2,Cervical Cancer,filgrastim (BIOLOGICAL); paclitaxel (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Cervical Cancer,Cervix,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9749,NCT03927274,Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma,TERMINATED,EARLY_PHASE1,Glioma of Brain,Topotecan (DRUG),60699,Evotopin,Glioma of Brain,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9750,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,COMPLETED,PHASE3,"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity",OLAPARIB (DRUG); Single agent chemotherapy (DRUG),60699,Evotopin,"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity",Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9751,NCT00006374,Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer,WITHDRAWN,PHASE2,Lung Cancer,filgrastim (BIOLOGICAL); cisplatin (DRUG); etoposide (DRUG); paclitaxel (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9752,NCT00918320,Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours,COMPLETED,PHASE2,Neuroblastoma; Brain Tumors; Solid Tumors,Temozolomide/Hycamtin (Topotecan) (DRUG),60699,Evotopin,Neuroblastoma; Brain Tumors; Solid Tumors,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9753,NCT01004874,Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma,COMPLETED,PHASE2,Malignant Glioma; Glioblastoma; Gliosarcoma,Bevacizumab (DRUG); Temozolomide (DRUG); Radiation Therapy (XRT) (RADIATION); Topotecan (DRUG),60699,Evotopin,Malignant Glioma; Glioblastoma; Gliosarcoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9754,NCT00812266,Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED),TERMINATED,PHASE3,Extensive Disease; First-Line; Small Cell Lung Cancer,topotecan + cisplatin (DRUG); Etoposide + carboplatin (DRUG),60699,Evotopin,Extensive Disease; First-Line; Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9755,NCT00114166,"Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",COMPLETED,PHASE2,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,topotecan hydrochloride (DRUG),60699,Evotopin,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9756,NCT00308165,Safety Study of Intracerebral Topotecan for Recurrent Brain Tumors,UNKNOWN,PHASE1,"Brain Neoplasms, Primary Malignant",Convection-Enhanced Delivery (PROCEDURE); Topotecan (DRUG),60699,Evotopin,"Brain Neoplasms, Primary Malignant",CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9757,NCT01500720,Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer,COMPLETED,PHASE2,Small Cell Lung Cancer,Cabazitaxel (DRUG); Topotecan (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9758,NCT00057720,TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer,COMPLETED,PHASE3,Ovarian Neoplasms,TLK286 HCl for injection (DRUG); topotecan hydrochloride for injection (DRUG); doxorubicin HCl liposome injection (DRUG),60699,Evotopin,Ovarian Neoplasms,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9759,NCT00437073,Brain Metastases In ErbB2-Positive Breast Cancer,TERMINATED,PHASE2,"Neoplasms, Breast",capecitabine (DRUG); topotecan (DRUG); lapatinib (DRUG),60699,Evotopin,"Neoplasms, Breast",Breast,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9760,NCT00410631,"Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma",UNKNOWN,PHASE3,Neuroblastoma,filgrastim (BIOLOGICAL); carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); dacarbazine (DRUG); doxorubicin hydrochloride (DRUG); etoposide phosphate (DRUG); ifosfamide (DRUG); isotretinoin (DRUG); melphalan (DRUG); topotecan hydrochloride (DRUG); vincristine sulfate (DRUG); vindesine (DRUG); autologous hematopoietic stem cell transplantation (PROCEDURE); conventional surgery (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); iobenguane I 131 (RADIATION); radiation therapy (RADIATION),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9761,NCT00765973,"Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors",COMPLETED,PHASE1,Small Cell Lung Cancer; Ovarian Cancer; Solid Tumors,Topotecan Liposomes Injection (TLI) (DRUG); Topotecan Liposomes Injection (TLI) (DRUG),60699,Evotopin,Small Cell Lung Cancer; Ovarian Cancer; Solid Tumors,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9762,NCT05870748,REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1,RECRUITING,PHASE2,Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Platinum-resistant Ovarian Cancer,Luveltamab tazevibulin (DRUG); Pegfilgrastim (DRUG); Gemcitabine (DRUG); Paclitaxel (DRUG); Pegylated liposomal doxorubicin (DRUG); Topotecan (DRUG),60699,Evotopin,Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Platinum-resistant Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9763,NCT02298348,Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,ACTIVE_NOT_RECRUITING,PHASE1,Neuroblastoma,Sorafenib (DRUG); Cyclophosphamide (DRUG); Topotecan (DRUG),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9764,NCT00003382,Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer,TERMINATED,PHASE1,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,filgrastim (BIOLOGICAL); gemcitabine hydrochloride (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9765,NCT00065182,Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer,COMPLETED,PHASE2,"Lung Cancer, Non-Small Cell; Non-Small-Cell Lung Cancer",Topotecan/Docetaxel combination (DRUG); Docetaxel (DRUG),60699,Evotopin,"Lung Cancer, Non-Small Cell; Non-Small-Cell Lung Cancer",Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9766,NCT03554473,M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers,COMPLETED,PHASE1,"Carcinoma, Small Cell; Lung Cancer; Small Cell Lung Cancer",M7824 (DRUG); Topotecan (DRUG); Temozolomide (DRUG); EKG (DIAGNOSTIC_TEST); CT scan (DIAGNOSTIC_TEST); PET scan (DIAGNOSTIC_TEST); Acetaminophen (DRUG); Antihistamines (DRUG); Diphenhydramine (DRUG); Dexamethasone (DRUG); Epinephrine (DRUG),60699,Evotopin,"Carcinoma, Small Cell; Lung Cancer; Small Cell Lung Cancer",Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9767,NCT02963090,Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer,TERMINATED,PHASE2,Small Cell Lung Cancer,Topotecan (DRUG); Pembrolizumab (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9768,NCT00294190,Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer,COMPLETED,PHASE2,"Small Cell Lung Cancer; Carcinoma, Small Cell",Topotecan (DRUG),60699,Evotopin,"Small Cell Lung Cancer; Carcinoma, Small Cell",Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9769,NCT00014690,"ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",COMPLETED,PHASE2,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,plevitrexed (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9770,NCT01003938,Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer,TERMINATED,PHASE2,Ovarian Cancer,Topotecan (DRUG); Erlotinib (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9771,NCT00179712,Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma,COMPLETED,PHASE1,Ovarian Cancer,CC-5013 (DRUG); topotecan (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9772,NCT02390843,Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors,COMPLETED,PHASE1,Retinoblastoma; Clear Cell Sarcoma; Renal Cell Carcinoma; Rhabdoid Tumor; Wilms Tumor; Hepatoblastoma; Neuroblastoma; Germ Cell Tumors; Ewings Sarcoma; Non-rhabdomyosarcoma Soft Tissue Sarcoma; Osteosarcoma; Rhabdomyosarcoma,Simvastatin (DRUG); Cyclophosphamide (DRUG); Topotecan (DRUG); Myeloid growth factor (DRUG),60699,Evotopin,Retinoblastoma; Clear Cell Sarcoma; Renal Cell Carcinoma; Rhabdoid Tumor; Wilms Tumor; Hepatoblastoma; Neuroblastoma; Germ Cell Tumors; Ewings Sarcoma; Non-rhabdomyosarcoma Soft Tissue Sarcoma; Osteosarcoma; Rhabdomyosarcoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9773,NCT06666712,Chronic CED of TPT for Recurrent Malignant Glioma,NOT_YET_RECRUITING,PHASE1,"Brain Tumor, Recurrent; Malignant Glioma (WHO Grade III or IV); IDH1/IDH2 Mutation",Topotecan (DRUG),60699,Evotopin,"Brain Tumor, Recurrent; Malignant Glioma (WHO Grade III or IV); IDH1/IDH2 Mutation",CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9774,NCT06954246,A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer,NOT_YET_RECRUITING,PHASE3,Small Cell Lung Cancer Extensive Stage,MHB088C for Injection (DRUG); Topotecan (DRUG); Irinotecan (DRUG); Paclitaxel (DRUG),60699,Evotopin,Small Cell Lung Cancer Extensive Stage,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9775,NCT02738346,SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013,UNKNOWN,PHASE3,Small Cell Lung Cancer,Carboplatin (DRUG); Etoposide (DRUG); Topotecan (DRUG); CT scans (DEVICE),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9776,NCT00319969,Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.,COMPLETED,PHASE2,Small Cell Lung Cancer,Amrubicin (DRUG); Topotecan (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9777,NCT02631876,"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer",COMPLETED,PHASE3,Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Ovarian Cancer,Mirvetuximab soravtansine (DRUG); Paclitaxel (DRUG); Pegylated liposomal doxorubicin (DRUG); Topotecan (DRUG),60699,Evotopin,Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9778,NCT04943627,Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA),WITHDRAWN,PHASE3,Advanced Cancer; Metastatic Cervical Cancer,Balstilimab (BAL) (DRUG); Topotecan (DRUG); Vinorelbine (DRUG); Gemcitabine (DRUG); Irinotecan (DRUG); Pemetrexed (DRUG),60699,Evotopin,Advanced Cancer; Metastatic Cervical Cancer,Cervix,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9779,NCT00697476,Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC,TERMINATED,PHASE1,Small Cell Lung Cancer,"topotecan, vorinostat (DRUG)",60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9780,NCT00043927,Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults,COMPLETED,PHASE3,Small Cell Lung Cancer,topotecan/cisplatin (DRUG); etoposide/cisplatin (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9781,NCT02649673,LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies,TERMINATED,PHASE1,Small Cell Lung Cancer; Ovarian Cancer,LCL161 (DRUG); Topotecan (DRUG); Pegylated GCSF (PEG-GCSF) (DRUG),60699,Evotopin,Small Cell Lung Cancer; Ovarian Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9782,NCT00316173,Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer,COMPLETED,PHASE2,"Ovarian Cancer; Neoplasms, Ovarian",topotecan (DRUG); CARBOPLATIN (DRUG),60699,Evotopin,"Ovarian Cancer; Neoplasms, Ovarian",Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9783,NCT00276276,Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer,COMPLETED,PHASE3,"Lung Cancer, Small Cell",topotecan (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9784,NCT01159327,Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy,TERMINATED,PHASE2,Small Cell Lung Cancer,Sorafenib (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9785,NCT00477282,Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer,COMPLETED,PHASE3,Ovarian Cancer,Karenitecin (DRUG); Topotecan (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9786,NCT04022876,A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection),TERMINATED,PHASE1,Non Small Cell Lung Cancer; Small-cell Lung Cancer,ALRN-6924 (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Placebo (DRUG); ALRN-6924 (DRUG); Topotecan (DRUG),60699,Evotopin,Non Small Cell Lung Cancer; Small-cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9787,NCT00004060,"Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer",COMPLETED,PHASE2,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,exatecan mesylate (DRUG),60699,Evotopin,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9788,NCT01576692,"Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma",COMPLETED,PHASE1,Neuroblastoma,Humanized anti-GD2 antibody (BIOLOGICAL); Chemotherapy (DRUG); Cytokines (OTHER); Natural killer cells (BIOLOGICAL); CliniMACS (DEVICE),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9789,NCT06394492,SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer,RECRUITING,PHASE3,Ovarian Cancer,SHR-A1921 (DRUG); Doxorubicin (DRUG); Paclitaxel (DRUG); Topotecan (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9790,NCT03061812,Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE),COMPLETED,PHASE3,Small Cell Lung Cancer,Rovalpituzumab tesirine (DRUG); Topotecan (DRUG); Dexamethasone (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9791,NCT00006012,Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer,COMPLETED,PHASE1,Drug/Agent Toxicity by Tissue/Organ; Lung Cancer; Radiation Toxicity,filgrastim (BIOLOGICAL); amifostine trihydrate (DRUG); cisplatin (DRUG); etoposide (DRUG); paclitaxel (DRUG); topotecan hydrochloride (DRUG); radiation therapy (RADIATION),60699,Evotopin,Drug/Agent Toxicity by Tissue/Organ; Lung Cancer; Radiation Toxicity,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9792,NCT06581380,JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer,NOT_YET_RECRUITING,PHASE3,Small Cell Lung Cancer,JK-1201I (DRUG); Topotecan (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9793,NCT00567567,Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma,COMPLETED,PHASE3,Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma; Regional Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma,Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin Hydrochloride (DRUG); Etoposide (DRUG); External Beam Radiation Therapy (RADIATION); Filgrastim (BIOLOGICAL); Isotretinoin (DRUG); Laboratory Biomarker Analysis (OTHER); Melphalan (DRUG); Peripheral Blood Stem Cell Transplantation (PROCEDURE); Pharmacological Study (OTHER); Thiotepa (DRUG); Topotecan Hydrochloride (DRUG); Vincristine Sulfate Liposome (DRUG),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9794,NCT00040872,Multiple Therapies in Treating Patients With Advanced Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma,filgrastim (BIOLOGICAL); monoclonal antibody 3F8 (BIOLOGICAL); sargramostim (BIOLOGICAL); carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); isotretinoin (DRUG); thiotepa (DRUG); topotecan hydrochloride (DRUG); vincristine sulfate (DRUG); autologous bone marrow transplantation (PROCEDURE); bone marrow ablation with stem cell support (PROCEDURE); conventional surgery (PROCEDURE); drug resistance inhibition treatment (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); syngeneic bone marrow transplantation (PROCEDURE); radiation therapy (RADIATION),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9795,NCT05874401,Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan,RECRUITING,PHASE4,Extensive-stage Small-cell Lung Cancer,Trilaciclib (DRUG); Placebo (DRUG); Topotecan (DRUG),60699,Evotopin,Extensive-stage Small-cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9796,NCT06406673,A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer,RECRUITING,PHASE2,Extensive Small Cell Lung Cancer,Cadonilimab+EC/ET+RT (DRUG); Cadonilimab+vorolanib (DRUG),60699,Evotopin,Extensive Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9797,NCT02569957,"Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",TERMINATED,PHASE2,Malignant Ovarian Endometrioid Tumor; Malignant Ovarian Serous Tumor; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Topotecan Hydrochloride (DRUG); Topotecan Hydrochloride (DRUG); Acetylcysteine (DRUG),60699,Evotopin,Malignant Ovarian Endometrioid Tumor; Malignant Ovarian Serous Tumor; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9798,NCT00005026,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer,COMPLETED,PHASE1,Ovarian Cancer; Primary Peritoneal Cavity Cancer,carboplatin (DRUG); paclitaxel (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9799,NCT02822157,Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer,UNKNOWN,PHASE2,Ovarian Epithelial Cancer,Olaparib (DRUG); carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly (DRUG),60699,Evotopin,Ovarian Epithelial Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9800,NCT06496048,Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC,RECRUITING,PHASE3,Relapsed Small Cell Lung Cancer,Lurbinectedin (DRUG); Irinotecan (DRUG); Lurbinectedin (DRUG); Topotecan (DRUG),60699,Evotopin,Relapsed Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9801,NCT00739830,Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6),COMPLETED,PHASE2,Endometrial Cancer,ridaforolimus (DRUG); medroxyprogesterone acetate tablets OR megestrol acetate (DRUG); chemotherapy (DRUG),60699,Evotopin,Endometrial Cancer,Uterus,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9802,NCT02481830,Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer,COMPLETED,PHASE3,Lung Cancer,Nivolumab (DRUG); Topotecan (DRUG); Amrubicin (DRUG),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9803,NCT00002625,Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma,COMPLETED,PHASE1,Esophageal Cancer; Lung Cancer; Lymphoma,topotecan hydrochloride (DRUG); low-LET electron therapy (RADIATION); low-LET photon therapy (RADIATION),60699,Evotopin,Esophageal Cancer; Lung Cancer; Lymphoma,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9804,NCT00583622,"Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients",TERMINATED,PHASE2,Ovarian Cancer,Bevacizumab (DRUG); Carboplatin (DRUG); Docetaxel (DRUG); Gemcitabine (DRUG); Melphalan (DRUG); Stem Cell Transplant (PROCEDURE),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9805,NCT01757626,Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma,ACTIVE_NOT_RECRUITING,PHASE1,Neuroblastoma,Hu3F8 With GM-CSF (BIOLOGICAL); Hu3F8 With GM-CSF (BIOLOGICAL),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9806,NCT00389766,"High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma",WITHDRAWN,PHASE2,Neuroblastoma,iodine I 131 metaiodobenzylguanidine (DRUG); topotecan hydrochloride (DRUG); chemotherapy (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); radioisotope therapy (PROCEDURE); radionuclide imaging (PROCEDURE); radiosensitization (PROCEDURE); total-body irradiation (PROCEDURE),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9807,NCT00189566,Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse,COMPLETED,PHASE2,Ovarian Cancer; Fallopian Tube Cancer; Malignant Tumor of Peritoneum,Paclitaxel (DRUG); Topotecan (DRUG); Carboplatin (DRUG),60699,Evotopin,Ovarian Cancer; Fallopian Tube Cancer; Malignant Tumor of Peritoneum,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9808,NCT06692166,A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer,RECRUITING,PHASE3,Cervical Cancer,9MW2821 (DRUG); Chemotherapy (DRUG),60699,Evotopin,Cervical Cancer,Cervix,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9809,NCT00170625,Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer,COMPLETED,PHASE1,Ovarian Cancer,Hycamtin (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9810,NCT00028925,Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,filgrastim (BIOLOGICAL); carboplatin (DRUG); topotecan hydrochloride (DRUG); WBRT (RADIATION),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9811,NCT06942039,"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation",NOT_YET_RECRUITING,EARLY_PHASE1,"CNS Embryonal Tumor; CNS, Medulloblastoma; Atypical Teratoid Rhabdoid Tumor; Medulloblastoma, Childhood; Medulloblastoma, Group 3; Medulloblastoma, Group 4; Pineoblastoma; Neuroblastoma; Embryonal Tumor With Multilayered Rosettes; Embryonal Tumor With Abundant Neuropil and True Rosettes; Ependymoblastoma; Medulloepithelioma; CNS Embryonal Tumor With Rhabdoid Features; CNS Embryonal Tumor, Nos",Cytarabine IT (DRUG); hydrocortisone (DRUG); Cisplatin (DRUG); Vincristine (DRUG); Etoposide (DRUG); Cyclophosphamide (DRUG); Mesna (DRUG); Filgrastim (DRUG); carboplatin (DRUG); Thiotepa (DRUG); Topotecan IT (DRUG); Tamoxifen (DRUG); ISOtretinoin (DRUG); Celecoxib (DRUG); etoposide phosphate (DRUG); Temozolomide (DRUG),60699,Evotopin,CNS Embryonal Tumors,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9812,NCT00004186,Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer,carboplatin (DRUG); etoposide (DRUG); ifosfamide (DRUG); topotecan hydrochloride (DRUG); radiation therapy (RADIATION),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9813,NCT00960739,Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma,Topotecan hydrochloride (DRUG); Autologous hematopoietic stem cell transplantation (PROCEDURE); iobenguane I 131 (RADIATION); total-body irradiation (RADIATION),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9814,NCT01600573,Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ),UNKNOWN,PHASE1,Ovarian Cancer,pazopanib in combination with weekly topotecan (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9815,NCT01492673,"Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma",COMPLETED,PHASE2,Neuroblastoma; Sarcoma,"Cyclophosphamide, Topotecan, and Bevacizumab (DRUG)",60699,Evotopin,Neuroblastoma; Sarcoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9816,NCT05740566,Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Small Cell Lung Cancer (SCLC),Tarlatamab (DRUG); Lurbinectedin (DRUG); Topotecan (DRUG); Amrubicin (DRUG),60699,Evotopin,Small Cell Lung Cancer (SCLC),Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9817,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,COMPLETED,PHASE3,Primary Peritoneal Carcinoma; Stage III Ovarian Cancer; Stage IV Ovarian Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Gemcitabine Hydrochloride (DRUG); Pegylated Liposomal Doxorubicin Hydrochloride (DRUG); Topotecan Hydrochloride (DRUG); Therapeutic Conventional Surgery (PROCEDURE),60699,Evotopin,Ovarian and Peritoneal Carcinoma,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9818,NCT00316186,First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin,COMPLETED,PHASE2,"Lung Cancer, Small Cell",topotecan (DRUG); carboplatin (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9819,NCT00158886,Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer,TERMINATED,PHASE1,"Carcinoma, Renal Cell",Topotecan (DRUG); Radiation therapy (RADIATION),60699,Evotopin,"Carcinoma, Renal Cell",Kidney,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9820,NCT00135135,Therapy for Children With Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma,"Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid (DRUG); Radiation therapy, Surgery, Peripheral Stem cell transplant (PROCEDURE)",60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9821,NCT00194935,Weekly Topotecan Therapy in Patients With Ovarian Cancer,TERMINATED,PHASE2,Ovarian Cancer,Topotecan (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9822,NCT00276796,"Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer",COMPLETED,PHASE2,Cervical Cancer,cisplatin (DRUG); paclitaxel (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Cervical Cancer,Cervix,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9823,NCT05153239,Clinical Trial of Lurbinectedin As Single-agent or in Combination with Irinotecan Versus Topotecan or Irinotecan in Patients with Relapsed Small-cell Lung Cancer (LAGOON),ACTIVE_NOT_RECRUITING,PHASE3,Relapsed Small Cell Lung Cancer,Irinotecan (DRUG); Lurbinectedin (DRUG); Irinotecan (DRUG); Topotecan (DRUG); Lurbinectedin (DRUG),60699,Evotopin,Relapsed Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9824,NCT00033696,Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,filgrastim (BIOLOGICAL); carboplatin (DRUG); etoposide (DRUG); paclitaxel (DRUG); topotecan hydrochloride (DRUG); radiation therapy (RADIATION),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9825,NCT01405235,Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma,UNKNOWN,PHASE3,"Recurrent, Persistent or Metastasized Cervical Cancer",Paclitaxel (DRUG); Cisplatin/Paclitaxel (DRUG),60699,Evotopin,"Recurrent, Persistent or Metastasized Cervical Cancer",Cervix,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9826,NCT01047891,Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer,COMPLETED,PHASE2,Ovarian Cancer,Sorafenib (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9827,NCT03042429,Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients,COMPLETED,PHASE3,Neuroblastoma,"Cycles N8, N5 and N6 (DRUG); Cycles N5 and N6 (DRUG)",60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9828,NCT01756989,ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors,COMPLETED,PHASE2,Brainstem Glioma,"Thalidomide, etoposide, celecoxib (DRUG)",60699,Evotopin,Brainstem Glioma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9829,NCT06459180,A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20),RECRUITING,PHASE3,Cervical Cancer,Sacituzumab Tirumotecan (BIOLOGICAL); Pemetrexed (DRUG); Tisotumab Vedotin (BIOLOGICAL); Topotecan (DRUG); Vinorelbine (DRUG); Gemcitabine (DRUG); Irinotecan (DRUG),60699,Evotopin,Cervical Cancer,Cervix,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9830,NCT00252889,Doxil Topotecan Doublet Cancer Study,COMPLETED,PHASE1,Small Cell Lung Cancer; Pancreatic Cancer; Head and Neck Cancer; Gastric Cancer; Esophageal Cancer,Topotecan and pegylated doxorubicin (DRUG),60699,Evotopin,Small Cell Lung Cancer; Pancreatic Cancer; Head and Neck Cancer; Gastric Cancer; Esophageal Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9831,NCT00005029,Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer,TERMINATED,PHASE2,Ovarian Cancer; Primary Peritoneal Cavity Cancer,topotecan hydrochloride (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9832,NCT00652691,"Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer",COMPLETED,PHASE1,Ovarian Cancer; Peritoneal Cavity Cancer,filgrastim (BIOLOGICAL); carboplatin (DRUG); cyclophosphamide (DRUG); topotecan hydrochloride (DRUG); autologous hematopoietic stem cell transplantation (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE),60699,Evotopin,Ovarian and Peritoneal Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9833,NCT06933394,Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma,RECRUITING,PHASE2,Neuroblastoma,Arsenic trioxide (DRUG); MAPK inhibitors (DRUG); Chemotherapy (DRUG),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9834,NCT03709680,Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE2,Ewing Sarcoma; Solid Tumors; Rhabdoid Tumor; Rhabdomyosarcoma; Neuroblastoma; Medulloblastoma; Diffuse Intrinsic Pontine Glioma,Palbociclib (DRUG); Temozolomide (DRUG); Irinotecan (DRUG); Topotecan (DRUG); Cyclophosphamide (DRUG),60699,Evotopin,Ewing Sarcoma; Solid Tumors; Rhabdoid Tumor; Rhabdomyosarcoma; Neuroblastoma; Medulloblastoma; Diffuse Intrinsic Pontine Glioma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9835,NCT00043862,The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC),COMPLETED,PHASE2,"Lung Cancer, Small Cell; Small Cell Lung Cancer",topotecan (DRUG),60699,Evotopin,"Lung Cancer, Small Cell; Small Cell Lung Cancer",Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9836,NCT00826891,Study of Cisplatin in Cervical Cancer Stage IVB,UNKNOWN,PHASE2,Cervical Cancer,Cisplatin Combined With Topotecan (DRUG),60699,Evotopin,Cervical Cancer,Cervix,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9837,NCT00250094,Clinical Benefit of Topoisomerase Downregulation,COMPLETED,PHASE1,Ovarian Cancer,Topotecan and VP16 (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9838,NCT00502762,Topotecan for Irinotecan-Refractory SCLC,UNKNOWN,PHASE2,Lung Cancer; Refractory to Chemotherapy,topotecan (DRUG),60699,Evotopin,Lung Cancer; Refractory to Chemotherapy,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9839,NCT00006391,"Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",COMPLETED,PHASE1,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,oxaliplatin (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9840,NCT00803062,"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",COMPLETED,PHASE3,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Bevacizumab (BIOLOGICAL); Cisplatin (DRUG); Laboratory Biomarker Analysis (OTHER); Paclitaxel (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); Topotecan Hydrochloride (DRUG),60699,Evotopin,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Skin,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9841,NCT06548763,Oral Topotecan With Toripalimab for Patients With Endometrial Cancer,NOT_YET_RECRUITING,PHASE2,Endometrial Cancer,Topotecan (DRUG); Toripalimab (DRUG),60699,Evotopin,Endometrial Cancer,Uterus,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9842,NCT00287963,Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer,COMPLETED,PHASE1,Lung Cancer,topotecan hydrochloride (DRUG); vinorelbine tartrate (DRUG),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9843,NCT01704716,High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN),RECRUITING,PHASE3,Neuroblastoma,Vincristine (DRUG); Aldesleukin (DRUG); ch14.18/CHO (DRUG); Carboplatin (DRUG); Etoposide (DRUG); Cisplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin (DRUG); G-CSF (DRUG); Busulfan (DRUG); Melphalan (DRUG),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9844,NCT00499616,Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma,COMPLETED,PHASE3,Neuroblastoma,carboplatin (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); topotecan hydrochloride (DRUG); Isotretinoin (DRUG); Surgery (PROCEDURE); Filgrastim (DRUG),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9845,NCT03227016,Study in Patients With SCLC of Veliparib in Combination With Topotecan,UNKNOWN,PHASE1,Small Cell Lung Cancer SCLC,veliparib (DRUG); Topotecan (DRUG),60699,Evotopin,Small Cell Lung Cancer SCLC,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9846,NCT06528496,N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma,RECRUITING,PHASE2,High-risk Neuroblastoma; Neuroblastoma; Childhood Neuroblastoma,DANYELZA (BIOLOGICAL); Sargramostim (BIOLOGICAL); Cytoxan (DRUG); Topotecan (DRUG); Vincristine (DRUG); Doxorubicin (DRUG); Ifosfamide (DRUG); Etoposide (DRUG); Carboplatin (DRUG); Irinotecan (DRUG); Temozolomide (DRUG),60699,Evotopin,High-risk Neuroblastoma; Neuroblastoma; Childhood Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9847,NCT01872416,A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer,UNKNOWN,PHASE2,Small Cell Lung Cancer,Liposomal Doxorubicin Combined With ifosfamide (DEVICE),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9848,NCT04768296,Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250),COMPLETED,PHASE2,Small-cell Lung Cancer,Berzosertib (DRUG); Berzosertib (DRUG); Topotecan (DRUG),60699,Evotopin,Small-cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9849,NCT00828139,S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer,COMPLETED,PHASE2,Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer,ziv-aflibercept (BIOLOGICAL); topotecan hydrochloride (DRUG),60699,Evotopin,Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9850,NCT00002986,Chemotherapy in Treating Patients With Recurrent Malignant Glioma,COMPLETED,PHASE1,Brain and Central Nervous System Tumors,carmustine (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Brain and Central Nervous System Tumors,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9851,NCT00259935,A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors,COMPLETED,PHASE1,"Lung Cancer, Small Cell",topotecan (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9852,NCT00001335,"New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma",COMPLETED,PHASE2,Ewing's Sarcoma; Neuroblastoma; Rhabdomyosarcoma,ADR-529 (DRUG); Topotecan (DRUG); G-CSF (DRUG),60699,Evotopin,Ewing's Sarcoma; Neuroblastoma; Rhabdomyosarcoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9853,NCT00257816,Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma,COMPLETED,PHASE2,Cervical Cancer,Topotecan (DRUG); Cisplatin (DRUG),60699,Evotopin,Cervical Cancer,Cervix,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9854,NCT03154996,Chronic Convection Enhanced Delivery of Topotecan,COMPLETED,PHASE1,Gliomas,Topotecan (DRUG); Gadolinium (DRUG); Synchromed II infusion pumps (DEVICE),60699,Evotopin,Gliomas,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9855,NCT06203210,A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer,RECRUITING,PHASE3,Small Cell Lung Cancer,Ifinatamab deruxtecan (DRUG); Topotecan (DRUG); Amrubicin (DRUG); Lurbinectedin (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9856,NCT00436644,Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin,COMPLETED,PHASE2,Ovarian Cancer; Peritoneal Cavity Cancer,Lapatinib (DRUG); Topotecan (DRUG),60699,Evotopin,Ovarian and Peritoneal Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9857,NCT00343044,Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers,COMPLETED,PHASE2,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer,Topotecan (DRUG); Bevacizumab (DRUG),60699,Evotopin,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9858,NCT00521144,Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors,COMPLETED,PHASE1,"Recurrent Small Cell Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",obatoclax mesylate (DRUG); topotecan hydrochloride (DRUG); laboratory biomarker analysis (OTHER),60699,Evotopin,"Recurrent Small Cell Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9859,NCT00054444,Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer,COMPLETED,PHASE1,Cervical Adenocarcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Topotecan Hydrochloride Liposomes (DRUG); 3-Dimensional Conformal Radiation Therapy (RADIATION); Cisplatin (DRUG),60699,Evotopin,Cervical Adenocarcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Skin,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9860,NCT04947501,A Study of N9 Chemotherapy in Children With Neuroblastoma,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,Neuroblastoma; Pediatric Cancer,Cyclophosphamide (DRUG); Topotecan (DRUG); Vincristine (DRUG); Doxorubicin (DRUG); Ifosfamide (DRUG); Etoposide (DRUG); Carboplatin (DRUG); Mesna (DRUG),60699,Evotopin,Neuroblastoma; Pediatric Cancer,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9861,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,75 approved agents (DRUG); COXEN (OTHER),60699,Evotopin,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,Bladder/Urinary Tract,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9862,NCT00193401,Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,Topotecan (DRUG),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9863,NCT00003372,Topotecan in Treating Patients With Recurrent Brain Tumors,COMPLETED,PHASE2,Brain and Central Nervous System Tumors,topotecan hydrochloride (DRUG),60699,Evotopin,Brain and Central Nervous System Tumors,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9864,NCT00317772,"Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer",COMPLETED,PHASE1,Ovarian Cancer; Peritoneal Neoplasms; Fallopian Tube Cancer,Topotecan (DRUG); Gefitinib (DRUG),60699,Evotopin,Ovarian Cancer; Peritoneal Neoplasms; Fallopian Tube Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9865,NCT00392340,"Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma",UNKNOWN,PHASE2,Neuroblastoma,filgrastim (BIOLOGICAL); doxorubicin hydrochloride (DRUG); topotecan hydrochloride (DRUG); vincristine sulfate (DRUG),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9866,NCT03059667,Immunotherapy as Second-line in Patient With Small Cell Lung Cancer,COMPLETED,PHASE2,Small Cell Lung Cancer; Small Cell Lung Cancer Limited Stage; Small Cell Lung Cancer Extensive Stage,Atezolizumab (DRUG); Topotecan (DRUG); Carboplatin (DRUG); Etoposide (DRUG),60699,Evotopin,Small Cell Lung Cancer; Small Cell Lung Cancer Limited Stage; Small Cell Lung Cancer Extensive Stage,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9867,NCT06855069,HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer,NOT_YET_RECRUITING,PHASE3,Ovarian Cancer,HS-20089 (DRUG); Paclitaxel (DRUG); Doxorubicin (DRUG); Topotecan (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9868,NCT01803269,Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer,TERMINATED,PHASE2,Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer,topotecan hydrochloride (DRUG); cyclodextrin-based polymer-camptothecin CRLX101 (DRUG),60699,Evotopin,Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9869,NCT00602667,"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",ACTIVE_NOT_RECRUITING,PHASE2,Brain and Central Nervous System Tumors,Induction Chemotherapy (DRUG); Low-Risk Therapy (DRUG); High-Risk Therapy (DRUG); Intermediate-Risk Therapy (DRUG),60699,Evotopin,Brain and Central Nervous System Tumors,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9870,NCT02903004,"Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients",COMPLETED,PHASE3,Ovarian Neoplasms,Trabectedin (DRUG); Pegylated Liposomal Doxorubicin (DRUG); Topotecan (DRUG); Gemcitabine (DRUG); Weekly Paclitaxel (DRUG); Carboplatin (DRUG),60699,Evotopin,Ovarian Neoplasms,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9871,NCT00003967,"Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer",COMPLETED,PHASE1,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,etoposide (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9872,NCT03257267,Study of Cemiplimab in Adults With Cervical Cancer,COMPLETED,PHASE3,"Squamous Cell Carcinoma (SCC); Recurrent or Metastatic, Platinum-refractory Cervical Cancer",Cemiplimab (DRUG); Investigator Choice (IC) Chemotherapy (DRUG),60699,Evotopin,"Squamous Cell Carcinoma (SCC); Recurrent or Metastatic, Platinum-refractory Cervical Cancer",Skin,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9873,NCT01177501,Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma,TERMINATED,PHASE1,Ovarian Cancer; Relapses,Topotecan (DRUG),60699,Evotopin,Ovarian Cancer; Relapses,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9874,NCT00003944,"Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",COMPLETED,PHASE2,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,filgrastim (BIOLOGICAL); carboplatin (DRUG); cyclophosphamide (DRUG); paclitaxel (DRUG); topotecan hydrochloride (DRUG); peripheral blood stem cell transplantation (PROCEDURE),60699,Evotopin,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9875,NCT04239092,9-ING-41 in Pediatric Patients with Refractory Malignancies.,RECRUITING,PHASE1,Refractory Cancer; Refractory Neoplasm; Cancer Pediatric; Refractory Tumor; Pediatric Cancer; Pediatric Brain Tumor; Neuroblastoma; Neuroblastoma Recurrent; Pediatric Lymphoma; Pediatric Meningioma; Diffuse Intrinsic Pontine Glioma,9-ING-41 (DRUG); Irinotecan (DRUG); Temozolomide (DRUG); Cyclophosphamide (DRUG); Topotecan (DRUG),60699,Evotopin,Refractory Cancer; Refractory Neoplasm; Cancer Pediatric; Refractory Tumor; Pediatric Cancer; Pediatric Brain Tumor; Neuroblastoma; Neuroblastoma Recurrent; Pediatric Lymphoma; Pediatric Meningioma; Diffuse Intrinsic Pontine Glioma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9876,NCT00388089,Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors,COMPLETED,PHASE1,"Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",bortezomib (DRUG); topotecan hydrochloride (DRUG); flow cytometry (OTHER); immunoenzyme technique (OTHER); immunohistochemistry staining method (OTHER); laboratory biomarker analysis (OTHER),60699,Evotopin,"Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9877,NCT00113789,Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer,COMPLETED,PHASE2,Ovarian Cancer,PI Discretion (OTHER),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9878,NCT03165292,Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction,TERMINATED,PHASE2,Very High Risk Neuroblastoma,mIBG (RADIATION); Topotecan (DRUG); Thiotepa (DRUG); Autologous stem cell transplant (PROCEDURE),60699,Evotopin,Very High Risk Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9879,NCT01849874,"A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer",TERMINATED,PHASE3,Low-grade Serous Ovarian Cancer; Low-grade Serous Fallopian Tube Cancer; Low-grade Serous Peritoneal Cancer,"MEK162, MEK inhibitor; oral (DRUG); Physician's choice chemotherapy (DRUG)",60699,Evotopin,Low-grade Serous Ovarian Cancer; Low-grade Serous Fallopian Tube Cancer; Low-grade Serous Peritoneal Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9880,NCT05303727,Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma,NOT_YET_RECRUITING,PHASE2,Neuroblastoma,Anti Thymocyte Globulin (DRUG); Fludarabine (DRUG); Cyclophosphamide injection (DRUG); Topotecan (DRUG); Melphalan (DRUG); Thiotepa (DRUG); Busulfan (DRUG); Cyclosporine (DRUG); Tacrolimus (DRUG); Mycophenolate Mofetil (DRUG); Methotrexate (DRUG),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9881,NCT02308527,Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children,ACTIVE_NOT_RECRUITING,PHASE2,Neuroblastoma,Bevacizumab (DRUG); Temozolomide (DRUG); Temozolomide (DRUG); Irinotecan (DRUG); Bevacizumab (DRUG); Topotecan (DRUG); Temozolomide (DRUG); Dinutuximab Beta (DRUG); Cyclophosphamide (DRUG),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9882,NCT01497873,A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer,COMPLETED,PHASE2,Small Cell Lung Cancer,Topotecan (DRUG); Belotecan (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9883,NCT06172296,"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma",RECRUITING,PHASE3,"Ganglioneuroblastoma, Nodular; Neuroblastoma",Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration (PROCEDURE); Bone Marrow Biopsy (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Cyclophosphamide (DRUG); Dinutuximab (BIOLOGICAL); Doxorubicin (DRUG); Echocardiography Test (PROCEDURE); Etoposide (DRUG); FDG-Positron Emission Tomography and Computed Tomography Scan (PROCEDURE); Hematopoietic Cell Transplantation (PROCEDURE); Irinotecan (DRUG); Isotretinoin (DRUG); Leukapheresis (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Melphalan (DRUG); Multigated Acquisition Scan (PROCEDURE); Radiation Therapy (RADIATION); Radionuclide Imaging (PROCEDURE); Survey Administration (OTHER); Temozolomide (DRUG); Thiotepa (DRUG); Topotecan (DRUG); Tumor Resection (PROCEDURE); Vincristine (DRUG),60699,Evotopin,"Ganglioneuroblastoma, Nodular; Neuroblastoma",CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9884,NCT00698516,Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer,COMPLETED,PHASE2,"Recurrent Small-cell Lung Cancer (SCLC); Lung Cancer, Small Cell",Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab) (DRUG),60699,Evotopin,"Recurrent Small-cell Lung Cancer (SCLC); Lung Cancer, Small Cell",Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9885,NCT00097019,A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed,COMPLETED,PHASE2,Ovarian Cancer,bevacizumab (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9886,NCT04106219,A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma,ACTIVE_NOT_RECRUITING,PHASE1,Neuroblastoma,LY3295668 Erbumine (DRUG); Topotecan (DRUG); Cyclophosphamide (DRUG),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9887,NCT00025272,Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,carboplatin (DRUG); etoposide (DRUG); topotecan hydrochloride (DRUG); radiation therapy (RADIATION),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9888,NCT02278510,Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma,COMPLETED,EARLY_PHASE1,Malignant Glioma; WHO Grade III or IV Recurrent Glioma,Topotecan (DRUG); Gadolinium DTPA (DRUG); Cleveland Multiport Catheter (DEVICE),60699,Evotopin,Malignant Glioma; WHO Grade III or IV Recurrent Glioma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9889,NCT00072267,"UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",COMPLETED,PHASE2,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,7-hydroxystaurosporine (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9890,NCT00193167,Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colon Cancer,Topotecan (DRUG),60699,Evotopin,Colon Cancer,Bowel,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9891,NCT00313612,Oxaliplatin and Topotecan in Advance Ovarian Cancer,TERMINATED,PHASE2,Recurrent Ovarian Epithelial Cancer,oxaliplatin (DRUG); topotecan (DRUG),60699,Evotopin,Recurrent Ovarian Epithelial Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9892,NCT00003917,Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer,COMPLETED,PHASE3,Lung Cancer,topotecan hydrochloride (DRUG),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9893,NCT00002734,"Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer",COMPLETED,PHASE1,Ovarian Cancer; Primary Peritoneal Cavity Cancer,recombinant interferon alfa (BIOLOGICAL); chemotherapy (DRUG); paclitaxel (DRUG); topotecan hydrochloride (DRUG); lutetium Lu 177 monoclonal antibody CC49 (RADIATION); yttrium Y 90 monoclonal antibody CC49 (RADIATION),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9894,NCT01857934,Therapy for Children With Advanced Stage Neuroblastoma,ACTIVE_NOT_RECRUITING,PHASE2,Neuroblastoma,cyclophosphamide (DRUG); topotecan (DRUG); hu14.18K322A (BIOLOGICAL); peripheral blood stem cell harvest (PROCEDURE); surgical resection (PROCEDURE); cisplatin (DRUG); etoposide (DRUG); doxorubicin (DRUG); vincristine (DRUG); busulfan (DRUG); melphalan (DRUG); peripheral blood stem cell transplantation (BIOLOGICAL); natural killer cell infusion (BIOLOGICAL); radiation therapy (RADIATION); GM-CSF (BIOLOGICAL); G-CSF (BIOLOGICAL); mesna (DRUG); levetiracetam (DRUG); interleukin-2 (BIOLOGICAL); Isotretinoin (DRUG); CliniMACS (DEVICE),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9895,NCT00112619,"Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors",TERMINATED,PHASE1,"Brain and Central Nervous System Tumors; Carcinoma of Unknown Primary; Leukemia; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific",topotecan hydrochloride (DRUG),60699,Evotopin,"Brain and Central Nervous System Tumors; Carcinoma of Unknown Primary; Leukemia; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific",CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9896,NCT00532818,Hydralazine Valproate for Cervical Cancer,UNKNOWN,PHASE3,Metastatic Cervical Cancer,Hydralazine and magnesium valproate (DRUG); Placebo (DRUG),60699,Evotopin,Metastatic Cervical Cancer,Cervix,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9897,NCT01630018,"Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial",COMPLETED,PHASE2,Epithelial Ovarian Cancer,Topotecan (DRUG); Belotecan (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9898,NCT00548418,"Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer",COMPLETED,PHASE2,Cervical Cancer,Topotecan (DRUG); Cisplatin (DRUG); Bevacizumab (DRUG),60699,Evotopin,Cervical Cancer,Cervix,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9899,NCT01222936,LBH Phase II in Small Cell Lung Cancer (SCLC),COMPLETED,PHASE2,Small Cell Lung Carcinoma,LBH581 (DRUG),60699,Evotopin,Small Cell Lung Carcinoma,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9900,NCT03763123,A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.,UNKNOWN,PHASE1,Ovarian Cancer,Sevacizumab (DRUG); Paclitaxel (DRUG); Topotecan (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9901,NCT06930755,Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer,NOT_YET_RECRUITING,PHASE1,Ovarian Cancer,NMS-03305293 (DRUG); Topotecan (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9902,NCT00003812,Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,filgrastim (BIOLOGICAL); carboplatin (DRUG); etoposide (DRUG); paclitaxel (DRUG); topotecan hydrochloride (DRUG); radiation therapy (RADIATION),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9903,NCT00005612,Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer,TERMINATED,PHASE1,Ovarian Cancer,filgrastim (BIOLOGICAL); carboplatin (DRUG); cyclophosphamide (DRUG); etoposide (DRUG); paclitaxel (DRUG); topotecan hydrochloride (DRUG); peripheral blood stem cell transplantation (PROCEDURE),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9904,NCT04055038,Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC),UNKNOWN,PHASE2,Ovarian Cancer; Ovarian Neoplasms; Serous Adenocarcinoma; BRCA1 Mutation; BRCA2 Mutation; Chemotherapy,Platinum-Based Drug (DRUG); Conventional chemotherapy (DRUG),60699,Evotopin,Ovarian Cancer; Ovarian Neoplasms; Serous Adenocarcinoma; BRCA1 Mutation; BRCA2 Mutation; Chemotherapy,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9905,NCT00877110,Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma,COMPLETED,PHASE1,"Neuroblastoma; Bone Marrow, Sympathetic Nervous System","cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8 (DRUG)",60699,Evotopin,"Neuroblastoma; Bone Marrow, Sympathetic Nervous System",CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9906,NCT01703910,Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic,COMPLETED,PHASE2,Adenocarcinoma of Colon; Adenocarcinoma of Rectum; Metastatic Disease,Arm A chemotherapy (DRUG); arm B chemotherapy (DRUG),60699,Evotopin,Adenocarcinoma of Colon; Adenocarcinoma of Rectum; Metastatic Disease,Bowel,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9907,NCT00003281,Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,paclitaxel (DRUG); topotecan hydrochloride (DRUG); radiation therapy (RADIATION),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9908,NCT02419495,Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies,TERMINATED,PHASE1,Advanced Malignant Solid Neoplasm; Clinical Stage III Cutaneous Melanoma AJCC V8; Clinical Stage IV Cutaneous Melanoma AJCC V8; Fallopian Tube Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Renal Cell Carcinoma; Ovarian Carcinoma; Pathologic Stage III Cutaneous Melanoma AJCC V8; Pathologic Stage IIIA Cutaneous Melanoma AJCC V8; Pathologic Stage IIIB Cutaneous Melanoma AJCC V8; Pathologic Stage IIIC Cutaneous Melanoma AJCC V8; Pathologic Stage IIID Cutaneous Melanoma AJCC V8; Pathologic Stage IV Cutaneous Melanoma AJCC V8; Primary Peritoneal Carcinoma; Stage III Lung Cancer AJCC V8; Stage III Renal Cell Cancer AJCC V8; Stage IIIA Lung Cancer AJCC V8; Stage IIIB Lung Cancer AJCC V8; Stage IIIC Lung Cancer AJCC V8; Stage IV Lung Cancer AJCC V8; Stage IV Renal Cell Cancer AJCC V8; Stage IVA Lung Cancer AJCC V8; Stage IVB Lung Cancer AJCC V8; Triple-Negative Breast Carcinoma; Unresectable Lung Non-Small Cell Carcinoma; Unresectable Melanoma; Unresectable Renal Cell Carcinoma,Capecitabine (DRUG); Carboplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin (DRUG); Eribulin (DRUG); Fluorouracil (DRUG); Ipilimumab (BIOLOGICAL); Irinotecan Hydrochloride (DRUG); Leucovorin Calcium (DRUG); Nivolumab (BIOLOGICAL); Olaparib (DRUG); Oxaliplatin (DRUG); Paclitaxel (DRUG); Pembrolizumab (BIOLOGICAL); Pemetrexed (DRUG); Selinexor (DRUG); Topotecan (DRUG),60699,Evotopin,Advanced Malignant Solid Neoplasm; Clinical Stage III Cutaneous Melanoma AJCC V8; Clinical Stage IV Cutaneous Melanoma AJCC V8; Fallopian Tube Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Renal Cell Carcinoma; Ovarian Carcinoma; Pathologic Stage III Cutaneous Melanoma AJCC V8; Pathologic Stage IIIA Cutaneous Melanoma AJCC V8; Pathologic Stage IIIB Cutaneous Melanoma AJCC V8; Pathologic Stage IIIC Cutaneous Melanoma AJCC V8; Pathologic Stage IIID Cutaneous Melanoma AJCC V8; Pathologic Stage IV Cutaneous Melanoma AJCC V8; Primary Peritoneal Carcinoma; Stage III Lung Cancer AJCC V8; Stage III Renal Cell Cancer AJCC V8; Stage IIIA Lung Cancer AJCC V8; Stage IIIB Lung Cancer AJCC V8; Stage IIIC Lung Cancer AJCC V8; Stage IV Lung Cancer AJCC V8; Stage IV Renal Cell Cancer AJCC V8; Stage IVA Lung Cancer AJCC V8; Stage IVB Lung Cancer AJCC V8; Triple-Negative Breast Carcinoma; Unresectable Lung Non-Small Cell Carcinoma; Unresectable Melanoma; Unresectable Renal Cell Carcinoma,Kidney,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9909,NCT00004055,"Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer",COMPLETED,PHASE2,Lung Cancer,filgrastim (BIOLOGICAL); paclitaxel (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9910,NCT00061308,"Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer",COMPLETED,PHASE2,"Peritoneal Cancer; Ovarian Cancer; Neoplasms, Ovarian; Fallopian Tube Cancer",Topotecan (DRUG); Gemcitabine (DRUG),60699,Evotopin,"Peritoneal Cancer; Ovarian Cancer; Neoplasms, Ovarian; Fallopian Tube Cancer",Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9911,NCT05990738,DAREONTM-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy,RECRUITING,PHASE1,Small Cell Lung Carcinoma (SCLC),BI 764532 (DRUG); Topotecan (DRUG); Single agent chemotherapy (DRUG),60699,Evotopin,Small Cell Lung Carcinoma (SCLC),Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9912,NCT00055614,"Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",COMPLETED,PHASE1,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,topotecan hydrochloride (DRUG); adjuvant therapy (PROCEDURE),60699,Evotopin,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9913,NCT00231855,Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers,COMPLETED,PHASE2,Ovarian Neoplasms; Uterine Neoplasms,Topotecan and Taxotere (DRUG),60699,Evotopin,Ovarian Neoplasms; Uterine Neoplasms,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9914,NCT04209855,"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression",COMPLETED,PHASE3,Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer,Mirvetuximab Soravtansine (DRUG); Paclitaxel (DRUG); Topotecan (DRUG); Pegylated liposomal doxorubicin (DRUG),60699,Evotopin,Epithelial Ovarian and Related Cancers,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9915,NCT00217555,"Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",COMPLETED,PHASE2,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,gemcitabine hydrochloride (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9916,NCT01533181,Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer,COMPLETED,PHASE2,Recurrent Small Cell Lung Carcinoma,Laboratory Biomarker Analysis (OTHER); Linsitinib (DRUG); Pharmacological Study (OTHER); Topotecan Hydrochloride (DRUG),60699,Evotopin,Recurrent Small Cell Lung Carcinoma,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9917,NCT00002814,Combination Chemotherapy for Patients With Brain Cancer,COMPLETED,PHASE2,Brain and Central Nervous System Tumors,filgrastim (BIOLOGICAL); paclitaxel (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Brain and Central Nervous System Tumors,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9918,NCT00003943,Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.,COMPLETED,PHASE2,Carcinoma of Unknown Primary; Lung Cancer,filgrastim (BIOLOGICAL); carboplatin (DRUG); cyclophosphamide (DRUG); paclitaxel (DRUG); topotecan hydrochloride (DRUG); peripheral blood stem cell transplantation (PROCEDURE),60699,Evotopin,Carcinoma of Unknown Primary; Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9919,NCT02030964,N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan,COMPLETED,PHASE1,Neuroblastoma,DFMO (DRUG); Celecoxib (DRUG); Cyclophosphamide (DRUG); Topotecan (DRUG),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9920,NCT00014443,Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma,TERMINATED,PHASE2,Brain and Central Nervous System Tumors,thalidomide (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Brain and Central Nervous System Tumors,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9921,NCT02487095,"Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers",COMPLETED,PHASE1,"Carcinoma, Non-Small -Cell Lung; Ovarian Neoplasms; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Neuroendocrine; Extrapulmonary Small Cell Cancer",Topotecan (DRUG); VX-970 (M6620) (DRUG),60699,Evotopin,"Carcinoma, Non-Small -Cell Lung; Ovarian Neoplasms; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Neuroendocrine; Extrapulmonary Small Cell Cancer",Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9922,NCT04073550,Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer,UNKNOWN,PHASE3,Small Cell Lung Cancer,Anlotinib (DRUG); Placebos (DRUG); Topotecan (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9923,NCT01840943,"A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy",TERMINATED,PHASE3,Epithelial Ovarian Cancer,CAELYX (DRUG); Topotecan HCl (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9924,NCT02866006,Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer,COMPLETED,PHASE1,Uterine Cervical Neoplasms,BVAC-C (DRUG); Topotecan (DRUG),60699,Evotopin,Uterine Cervical Neoplasms,Cervix,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9925,NCT06619236,Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer,RECRUITING,PHASE3,Platinum-resistant Ovarian Cancer,Rina-S (DRUG); Paclitaxel (DRUG); Topotecan (DRUG); Pegylated liposomal doxorubicin (PLD) (DRUG); Gemcitabine (DRUG),60699,Evotopin,Platinum-resistant Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9926,NCT00770536,AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR,COMPLETED,PHASE1,Cancer; Carcinoma; Fallopian Tube Cancer; Gynecological Malignancies; Metastases; Oncology; Ovarian Cancer; Solid Tumors; Tumors,A1: AMG 386 10 mg/kg + Liposomal doxorubicin (DRUG); A3: AMG 386 15mg/kg + Liposomal doxorubicin (DRUG); B1: AMG 386 10 mg/kg + Topotecan (DRUG); B3: AMG 386 15mg/kg + Topotecan (DRUG),60699,Evotopin,Cancer; Carcinoma; Fallopian Tube Cancer; Gynecological Malignancies; Metastases; Oncology; Ovarian Cancer; Solid Tumors; Tumors,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9927,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,COMPLETED,PHASE2,Ovarian Neoplasms,Paclitaxel (DRUG); Gemcitabine (DRUG); Topotecan (DRUG); Pegylated liposomal doxorubicin (PLD) (DRUG); BI 6727 (DRUG),60699,Evotopin,Ovarian Neoplasms,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9928,NCT00186849,Therapy for Children With Advanced Stage High Risk Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma,"Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin (DRUG); Peripheral Blood Stem Cell Transplant (PROCEDURE)",60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9929,NCT00808899,Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma,TERMINATED,PHASE2,Neuroblastoma,Temsirolimus (DRUG); Irinotecan (DRUG); Surgical Resection of Primary Tumor (PROCEDURE); Cyclophosphamide (DRUG); Doxorubicin (DRUG); Etoposide (DRUG); Cisplatin (DRUG); Topotecan (DRUG); PBSC (PROCEDURE); Radiation Therapy (RADIATION); 13-cis-retinoic acid (DRUG),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9930,NCT03699449,An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION),UNKNOWN,PHASE2,Platinum-resistant Recurrent Ovarian Cancer,olaparib+cediranib combination therapy (DRUG); durvalumab + olaparib combination therapy (DRUG); durvalumab + chemotherapy treatment (DRUG); durvalumab + tremelimumab + chemotherapy treatment (DRUG); durvalumab + tremelimumab + paclitaxel treatment (DRUG); durvalumab +chemotherapy treatment (DRUG),60699,Evotopin,Platinum-resistant Recurrent Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9931,NCT05429502,Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors,RECRUITING,PHASE1,Neuroblastoma,Topotecan (DRUG); Temozolomide (DRUG); Ribociclib (DRUG),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9932,NCT04678102,"Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)",RECRUITING,PHASE1,Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Carcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma,PHI-101 administration (DRUG),60699,Evotopin,Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Carcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9933,NCT00005021,Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma,COMPLETED,PHASE1,"Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific",filgrastim (BIOLOGICAL); carboplatin (DRUG); paclitaxel (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,"Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Bowel,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9934,NCT00486564,Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma,COMPLETED,PHASE1,Neuroblastoma,Nifurtimox (DRUG),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9935,NCT00004221,Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer,TERMINATED,PHASE2,Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Primary Peritoneal Carcinoma; Stage III Ovarian Cancer; Undifferentiated Ovarian Carcinoma,Carboplatin (DRUG); Cyclophosphamide (DRUG); Filgrastim (BIOLOGICAL); Paclitaxel (DRUG); Peripheral Blood Stem Cell Transplantation (PROCEDURE); Topotecan Hydrochloride (DRUG),60699,Evotopin,Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Primary Peritoneal Carcinoma; Stage III Ovarian Cancer; Undifferentiated Ovarian Carcinoma,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9936,NCT00003064,"Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer",UNKNOWN,PHASE1,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,filgrastim (BIOLOGICAL); carboplatin (DRUG); etoposide phosphate (DRUG); paclitaxel (DRUG); thiotepa (DRUG); topotecan hydrochloride (DRUG); peripheral blood stem cell transplantation (PROCEDURE),60699,Evotopin,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9937,NCT02030184,Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas,WITHDRAWN,PHASE1,Small Cell Lung Cancer (SCLC); Neuroendocrine (NE) Tumors; Large Cell Neuroendocrine (NE) Tumors,Rhenium Re 188-P2045 (DRUG),60699,Evotopin,Small Cell Lung Cancer (SCLC); Neuroendocrine (NE) Tumors; Large Cell Neuroendocrine (NE) Tumors,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9938,NCT00550784,"Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",COMPLETED,PHASE1,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,filgrastim (BIOLOGICAL); cisplatin (DRUG); cyclophosphamide (DRUG); melphalan (DRUG); paclitaxel (DRUG); topotecan hydrochloride (DRUG); TdT-mediated dUTP nick end labeling assay (GENETIC); gene expression analysis (GENETIC); immunohistochemistry staining method (OTHER); pharmacological study (OTHER); peripheral blood stem cell transplantation (PROCEDURE),60699,Evotopin,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9939,NCT05521984,Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i),RECRUITING,PHASE1,Pediatric Brain Tumor; Pediatric Solid Tumor,Dapagliflozin (DRUG); Carmustine (DRUG); Topotecan (DRUG); Cyclophosphamide (DRUG),60699,Evotopin,Pediatric Brain Tumor; Pediatric Solid Tumor,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9940,NCT06498479,ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer,RECRUITING,PHASE3,Small Cell Lung Cancer,HS-20093 (DRUG); Topotecan (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9941,NCT01652079,CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer,COMPLETED,PHASE2,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer,CRLX101 (DRUG),60699,Evotopin,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9942,NCT04679064,"Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment",UNKNOWN,PHASE3,Ovarian Cancer,Niraparib (DRUG); Dostarlimab (DRUG); Pegylated liposomal doxorubicin (DRUG); Paclitaxel (DRUG); Gemcitabine (DRUG); Topotecan (DRUG); Bevacizumab (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9943,NCT00028743,"Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",COMPLETED,PHASE3,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,carboplatin (DRUG); cisplatin (DRUG); paclitaxel (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9944,NCT05071703,"Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study",COMPLETED,PHASE4,Extensive-stage Small-cell Lung Cancer,Trilaciclib (DRUG),60699,Evotopin,Extensive-stage Small-cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9945,NCT00601003,Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma,COMPLETED,PHASE2,Neuroblastoma; Medulloblastoma,Nifurtimox (DRUG); Cyclophosphamide (DRUG); Topotecan (DRUG),60699,Evotopin,Neuroblastoma; Medulloblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9946,NCT00807079,Carboplatin and Topotecan in Treating Patients With Relapsed or Metastatic Cervical Cancer,COMPLETED,PHASE1,Cervical Cancer,carboplatin (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Cervical Cancer,Cervix,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9947,NCT00541138,"Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors",COMPLETED,PHASE2,"Brain and Central Nervous System Tumors; Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",carboplatin (DRUG); tamoxifen citrate (DRUG); topotecan hydrochloride (DRUG); pharmacological study (OTHER),60699,Evotopin,"Brain and Central Nervous System Tumors; Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9948,NCT01107665,Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma,COMPLETED,PHASE2,Stage III Melanoma; Stage IV Melanoma; Unresectable Melanoma,Pazopanib and Paclitaxel (DRUG),60699,Evotopin,Stage III Melanoma; Stage IV Melanoma; Unresectable Melanoma,Skin,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9949,NCT03098030,Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer,COMPLETED,PHASE2,Small Cell Lung Cancer,Dinutuximab (BIOLOGICAL); Irinotecan (DRUG); Topotecan (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9950,NCT00087048,Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer,TERMINATED,PHASE2,Lung Cancer,topotecan hydrochloride (DRUG),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9951,NCT00287859,"Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer",TERMINATED,PHASE1,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,topotecan hydrochloride (DRUG),60699,Evotopin,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9952,NCT00102375,"Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer",COMPLETED,PHASE3,Ovarian Cancer,Topotecan (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9953,NCT03193463,Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy,WITHDRAWN,EARLY_PHASE1,Glioma,Topotecan (<=8cc) (DRUG); Topotecan (>8cc) (DRUG); Cleveland Multiport Catheter (DEVICE); Magnetic Resonance Imaging (MRI) (DIAGNOSTIC_TEST); Lower Does Topotecan (DRUG),60699,Evotopin,Glioma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9954,NCT06801834,Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer,RECRUITING,PHASE3,Extensive Stage Small Cell Lung Cancer (ES-SCLC),Sacituzumab Govitecan (SG) (DRUG); Topotecan (DRUG); Amrubicin (Japan only) (DRUG),60699,Evotopin,Extensive Stage Small Cell Lung Cancer (ES-SCLC),Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9955,NCT00002913,"Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer",COMPLETED,PHASE1,Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Adenocarcinoma; Stage III Ovarian Epithelial Cancer; Stage IV Ovarian Epithelial Cancer,paclitaxel (DRUG); cisplatin (DRUG); topotecan hydrochloride (DRUG); filgrastim (BIOLOGICAL),60699,Evotopin,Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Adenocarcinoma; Stage III Ovarian Epithelial Cancer; Stage IV Ovarian Epithelial Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9956,NCT02364713,"MV-NIS or Investigator's Choice Chemotherapy in Treating Patients with Ovarian, Fallopian, or Peritoneal Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian Carcinosarcoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal Clear Cell Adenocarcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Primary Peritoneal Transitional Cell Carcinoma; Primary Peritoneal Undifferentiated Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Bevacizumab (BIOLOGICAL); Gemcitabine Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter (BIOLOGICAL); Paclitaxel (DRUG); Pegylated Liposomal Doxorubicin Hydrochloride (DRUG); Quality-of-Life Assessment (OTHER); Topotecan Hydrochloride (DRUG),60699,Evotopin,Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian Carcinosarcoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal Clear Cell Adenocarcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Primary Peritoneal Transitional Cell Carcinoma; Primary Peritoneal Undifferentiated Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9957,NCT03088813,Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer,COMPLETED,PHASE3,Small Cell Lung Cancer,Irinotecan liposome injection (DRUG); Topotecan (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9958,NCT00045175,"UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer",COMPLETED,PHASE1,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,7-hydroxystaurosporine (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9959,NCT00429559,Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma,COMPLETED,PHASE1,Ovarian Cancer,Hycamptin (DRUG); Gemcitabine (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9960,NCT00320359,Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer,COMPLETED,PHASE3,"Lung Cancer, Small Cell",Intravenous topotecan/cisplatin (DRUG); Intravenous etoposide/cisplatin (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9961,NCT02500459,Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection,TERMINATED,EARLY_PHASE1,Brain Tumor; High Grade Glioma,topotecan (DRUG); Cleveland Multiport Catheter (DEVICE),60699,Evotopin,Brain Tumor; High Grade Glioma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9962,NCT00046800,Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer,COMPLETED,PHASE2,Ovarian Neoplasms,OSI-211 (Liposomal Lurtotecan) (DRUG),60699,Evotopin,Ovarian Neoplasms,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9963,NCT02267213,Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma,TERMINATED,PHASE2,Hepatocellular Carcinoma,Lipotecan (DRUG),60699,Evotopin,Hepatocellular Carcinoma,Liver,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9964,NCT01696032,SGI-110 in Combination With Carboplatin in Ovarian Cancer,COMPLETED,PHASE2,Ovarian Cancer,"SGI-110 (DRUG); Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine) (DRUG); Carboplatin (DRUG)",60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9965,NCT01076400,A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008),TERMINATED,PHASE1,Cervical Cancer,adavosertib (DRUG); Topotecan (DRUG); Cisplatin (DRUG); Placebo to adavosertib (DRUG),60699,Evotopin,Cervical Cancer,Cervix,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9966,NCT00070200,Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma,COMPLETED,PHASE1,Neuroblastoma,filgrastim (BIOLOGICAL); cisplatin (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); isotretinoin (DRUG); melphalan (DRUG); topotecan hydrochloride (DRUG); vincristine sulfate (DRUG); conventional surgery (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9967,NCT01736800,Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors,WITHDRAWN,PHASE2,Central Nervous System (CNS) Metastases; Brain Metastases,Topotecan (DRUG); Temozolomide (DRUG),60699,Evotopin,Central Nervous System (CNS) Metastases; Brain Metastases,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9968,NCT04908787,"A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer",ACTIVE_NOT_RECRUITING,PHASE3,Ovarian Cancer,BD0801 (DRUG); Paclitaxel (DRUG); Placebo (DRUG); Topotecan (DRUG); doxorubicin liposome (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9969,NCT05800587,Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer,RECRUITING,PHASE2,Lung Cancer; Small-cell Lung Cancer; Non Small Cell Lung Cancer,Carboplatin (DRUG); Pemetrexed (DRUG); Paclitaxel (DRUG); Nab paclitaxel (DRUG); Docetaxel (DRUG); Gemcitabine (DRUG); Etoposide (DRUG); Irinotecan (DRUG); Topotecan (DRUG); Lurbinectedin (DRUG),60699,Evotopin,Lung Cancer; Small-cell Lung Cancer; Non Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9970,NCT00098956,7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer,COMPLETED,PHASE2,Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer,topotecan hydrochloride (DRUG); 7-hydroxystaurosporine (DRUG),60699,Evotopin,Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9971,NCT06751485,"JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer",NOT_YET_RECRUITING,PHASE3,Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancers,JSKN003 (DRUG); Doxorubicin (DRUG); Paclitaxel (DRUG); Topotecan (DRUG),60699,Evotopin,Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancers,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9972,NCT00856037,Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer,COMPLETED,PHASE1,Recurrent Small Cell Lung Carcinoma,Doxorubicin Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Quality-of-Life Assessment (OTHER); Topotecan Hydrochloride (DRUG),60699,Evotopin,Recurrent Small Cell Lung Carcinoma,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9973,NCT00006032,Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer,TERMINATED,PHASE2,Breast Cancer,etoposide (DRUG); ifosfamide (DRUG); topotecan hydrochloride (DRUG); peripheral blood stem cell transplantation (PROCEDURE),60699,Evotopin,Breast Cancer,Breast,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9974,NCT00004137,S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,filgrastim (BIOLOGICAL); carboplatin (DRUG); paclitaxel (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9975,NCT00002537,Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer,topotecan hydrochloride (DRUG); radiation therapy (RADIATION),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9976,NCT04213937,Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer,UNKNOWN,PHASE2,Extensive Stage Small Cell Lung Cancer,nab-paclitaxel (DRUG); Topotecan (DRUG),60699,Evotopin,Extensive Stage Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9977,NCT00003732,"Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer",COMPLETED,PHASE2,Ovarian Cancer,carboplatin (DRUG); paclitaxel (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9978,NCT05736952,Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer,WITHDRAWN,PHASE2,Platinum-resistant Ovarian Cancer,Oral Topotecan Combined With Anlotinib (DRUG),60699,Evotopin,Platinum-resistant Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9979,NCT02945852,Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.,COMPLETED,PHASE2,Small Cell Lung Cancer,apatinib (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9980,NCT00842452,Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery,COMPLETED,PHASE1,Cervical Cancer; Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Sarcoma; Vaginal Cancer; Vulvar Cancer,topotecan hydrochloride (DRUG); pharmacological study (OTHER),60699,Evotopin,Cervical Cancer; Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Sarcoma; Vaginal Cancer; Vulvar Cancer,Uterus,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9981,NCT00057837,Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer,COMPLETED,PHASE2,Extensive Stage Small Cell Lung Cancer,G-CSF (BIOLOGICAL); Cisplatin (DRUG); Etoposide (DRUG); Irinotecan (DRUG); Topotecan (DRUG),60699,Evotopin,Extensive Stage Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9982,NCT00466232,Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer,COMPLETED,PHASE1,Small Cell Carcinoma; Lung Cancer,Topotecan (DRUG); Sorafenib (DRUG),60699,Evotopin,Small Cell Carcinoma; Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9983,NCT04902885,"Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients",COMPLETED,PHASE3,Extensive-stage Small-cell Lung Cancer,"Trilaciclib, carboplatin, etoposide，or Topotecan (DRUG); placebo, carboplatin, etoposide，or Topotecan (DRUG)",60699,Evotopin,Extensive-stage Small-cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9984,NCT00041015,Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer,COMPLETED,PHASE3,Lung Cancer,cisplatin (DRUG); etoposide (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9985,NCT00002515,Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer,COMPLETED,PHASE2,Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Head and Neck Cancer; Kidney Cancer; Liver Cancer; Lymphoma; Neuroblastoma; Ovarian Cancer; Retinoblastoma; Sarcoma; Testicular Germ Cell Tumor,filgrastim (BIOLOGICAL); carboplatin (DRUG); thiotepa (DRUG); topotecan hydrochloride (DRUG); autologous bone marrow transplantation (PROCEDURE); bone marrow ablation with stem cell support (PROCEDURE); in vitro-treated bone marrow transplantation (PROCEDURE),60699,Evotopin,Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Head and Neck Cancer; Kidney Cancer; Liver Cancer; Lymphoma; Neuroblastoma; Ovarian Cancer; Retinoblastoma; Sarcoma; Testicular Germ Cell Tumor,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9986,NCT00533299,Hydralazine Valproate for Ovarian Cancer,UNKNOWN,PHASE3,Ovarian Cancer,Hydralazine and magnesium valproate (DRUG); Placebo (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9987,NCT01417806,Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer,UNKNOWN,PHASE2,Small Cell Lung Cancer,Topotecan and Pasireotide (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9988,NCT00390806,Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer,COMPLETED,PHASE3,"Lung Cancer, Non-Small Cell","HYCAMTIN, oral capsules (DRUG); Radiation (RADIATION)",60699,Evotopin,"Lung Cancer, Non-Small Cell",Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9989,NCT00526799,Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer,TERMINATED,PHASE1,Ovarian Cancer,Sorafenib (DRUG); Topotecan (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9990,NCT06449209,"Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy",ACTIVE_NOT_RECRUITING,PHASE2,Extensive-stage Small-cell Lung Cancer; Small-cell Lung Cancer,BNT327 Dose Level 1 (DL1) (DRUG); BNT327 Dose Level 2 (DL2) (DRUG); Etoposide (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); Topotecan (DRUG),60699,Evotopin,Extensive-stage Small-cell Lung Cancer; Small-cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9991,NCT02312245,"Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",COMPLETED,PHASE2,Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Bevacizumab (BIOLOGICAL); Gemcitabine Hydrochloride (DRUG); Paclitaxel (DRUG); Pegylated Liposomal Doxorubicin Hydrochloride (DRUG); Topotecan Hydrochloride (DRUG),60699,Evotopin,Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9992,NCT01266447,"Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer",COMPLETED,PHASE2,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Small Cell Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage III Cervical Cancer; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Filgrastim (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER); Pegfilgrastim (BIOLOGICAL); Topotecan Hydrochloride (DRUG); Veliparib (DRUG),60699,Evotopin,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Small Cell Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage III Cervical Cancer; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Skin,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9993,NCT00547651,AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy,COMPLETED,PHASE3,Small Cell Lung Cancer,Amrubicin (DRUG); Topotecan (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9994,NCT00793351,Reduced Intensity Stem Cell Transplantation in Children With Relapsed Neuroblastoma After Autologous Transplantation,COMPLETED,PHASE2,Neuroblastoma,Reduced-intensity allogeneic hematopoietic stem cell transplantation (PROCEDURE),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9995,NCT00365547,Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy,COMPLETED,PHASE2,Lung Cancer,bevacizumab (BIOLOGICAL); topotecan hydrochloride (DRUG),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9996,NCT00322751,Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer,Topotecan (DRUG),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9997,NCT06828354,A Study of SHR-A1811 in Subjects With Ovarian Cancer,RECRUITING,PHASE3,Ovarian Cancer,SHR-A1811 (DRUG); Paclitaxel Injection (DRUG); Doxorubicin Hydrochloride Liposome Injection (DRUG); Gemcitabine Hydrochloride for Injection (DRUG); Topotecan Hydrochloride for Injection (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9998,NCT06612151,A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer,RECRUITING,PHASE3,Small Cell Lung Cancer,YL201 (DRUG); topotecan hydrochloride for injection (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +9999,NCT00003733,"Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer",UNKNOWN,PHASE2,Ovarian Cancer,carboplatin (DRUG); paclitaxel (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10000,NCT00006454,"Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer",COMPLETED,PHASE3,Fallopian Tube Cancer; Ovarian Cancer,carboplatin (DRUG); paclitaxel (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Fallopian Tube Cancer; Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10001,NCT02514447,Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy,TERMINATED,PHASE1,Small Cell Lung Cancer,Trilaciclib (DRUG); Placebo (DRUG); Topotecan (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10002,NCT01904253,A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy,TERMINATED,PHASE2,Small Cell Lung Cancer (SCLC),TAS-102 (DRUG); Amrubicin (Japan) (DRUG); Topotecan (Japan/Europe) (DRUG),60699,Evotopin,Small Cell Lung Cancer (SCLC),Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10003,NCT06128837,Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer,RECRUITING,PHASE3,Relapsed Small Cell Lung Cancer,Irinotecan hydrochloride liposome Injection (DRUG); Topotecan (DRUG),60699,Evotopin,Relapsed Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10004,NCT01342237,Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors,UNKNOWN,PHASE2,Brain Tumors,"HDCT 1(TTC), HDCT2(MEC) (DRUG)",60699,Evotopin,Brain Tumors,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10005,NCT00312988,Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy,COMPLETED,PHASE3,Ovarian Cancer,Hycamtin (DRUG); Gemcitabine (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10006,NCT00193388,Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,Topotecan (DRUG),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10007,NCT00437307,Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse,COMPLETED,PHASE3,Ovarian Cancer,Topotecan (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10008,NCT00703807,Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers,COMPLETED,PHASE1,Endometrial Cancer,Topotecan (DRUG); RAD001 (DRUG),60699,Evotopin,Endometrial Cancer,Uterus,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10009,NCT02421588,Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients,COMPLETED,PHASE3,Ovarian Cancer,Lurbinectedin (PM01183) (DRUG); Pegylated liposomal doxorubicin (PLD) (DRUG); Topotecan (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10010,NCT00215956,A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma,COMPLETED,PHASE1,Rectal Neoplasms,topotecan (DRUG); radiation (PROCEDURE); surgery (PROCEDURE),60699,Evotopin,Rectal Neoplasms,Bowel,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10011,NCT02980809,Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer,UNKNOWN,PHASE2,Small Cell Lung Cancer,Apatinib (DRUG); Topotecan (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10012,NCT00267488,Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer,COMPLETED,PHASE2,"Neoplasms, Endometrial; Endometrial Cancer",topotecan (DRUG),60699,Evotopin,"Neoplasms, Endometrial; Endometrial Cancer",Uterus,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10013,NCT03107988,NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922),ACTIVE_NOT_RECRUITING,PHASE1,Neuroblastoma,Lorlatinib (DRUG); Cyclophosphamide (DRUG); Topotecan (DRUG); Filgrastim/pegfilgrastim (DRUG),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10014,NCT00397293,Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer,COMPLETED,PHASE1,Small Cell Lung Cancer,AT-101 (DRUG); topotecan (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10015,NCT00253461,11C Topotecan PET Imaging,TERMINATED,EARLY_PHASE1,"Lung Cancer; Metastatic Cancer; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific",computed tomography (PROCEDURE); positron emission tomography (PROCEDURE); 11C topotecan (RADIATION); fludeoxyglucose F 18 (RADIATION),60699,Evotopin,"Lung Cancer; Metastatic Cancer; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10016,NCT00315861,Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies,COMPLETED,PHASE1,Ovarian Cancer; Endometrial Cancer; Cervical Cancer; Lung Cancer,pemetrexed (DRUG); topotecan (DRUG),60699,Evotopin,Ovarian Cancer; Endometrial Cancer; Cervical Cancer; Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10017,NCT04697628,Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Cervical Cancer,tisotumab vedotin (DRUG); topotecan (DRUG); vinorelbine (DRUG); gemcitabine (DRUG); irinotecan (DRUG); pemetrexed (DRUG),60699,Evotopin,Cervical Cancer,Cervix,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10018,NCT00046111,A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors,COMPLETED,PHASE1,"Lung Cancer, Small Cell; Solid Tumor Cancer",topotecan (DRUG),60699,Evotopin,"Lung Cancer, Small Cell; Solid Tumor Cancer",Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10019,NCT00657878,Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval,UNKNOWN,PHASE3,Ovarian Cancer,stealth liposomal doxorubicin (DRUG); carboplatin (DRUG); paclitaxel (DRUG); Topotecan (DRUG); Gemcitabine (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10020,NCT01684878,Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE),COMPLETED,PHASE3,Ovarian Cancer,Gemcitabine (Chemotherapy) (DRUG); Paclitaxel (Chemotherapy) (DRUG); Pertuzumab (DRUG); Placebo (DRUG); Topotecan (Chemotherapy) (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10021,NCT05272371,Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease,RECRUITING,PHASE1,High-Risk Neuroblastoma,Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy) (COMBINATION_PRODUCT),60699,Evotopin,High-Risk Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10022,NCT03949283,Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Recurrent Ovarian Carcinoma; Platinum-resistant Ovarian Cancer,ChemoID Assay (DIAGNOSTIC_TEST); Standard Chemotherapy (DRUG),60699,Evotopin,Recurrent Ovarian Carcinoma; Platinum-resistant Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10023,NCT00193297,Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma,COMPLETED,PHASE2,Ovary Cancer,Topotecan (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG),60699,Evotopin,Ovary Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10024,NCT04701645,"Microdevice in Ovarian, Fallopian Tube, and Peritoneal Cancer",RECRUITING,PHASE1,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Ovarian Cancer Stage III; Ovarian Cancer Stage IV; Fallopian Tube Cancer Stage IV; Fallopian Tube Cancer Stage III,Microdevice (COMBINATION_PRODUCT),60699,Evotopin,Ovarian and Related Cancers,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10025,NCT00193245,Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,Topotecan (DRUG); Docetaxel (DRUG),60699,Evotopin,Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10026,NCT00003945,"Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",COMPLETED,PHASE3,Cervical Cancer,cisplatin (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Cervical Cancer,Cervix,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10027,NCT00170677,Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer,COMPLETED,PHASE2,Ovarian Cancer,Topotecan (DRUG); Topotecan (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10028,NCT00064077,"Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix",COMPLETED,PHASE3,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Cisplatin (DRUG); Gemcitabine Hydrochloride (DRUG); Paclitaxel (DRUG); Quality-of-Life Assessment (OTHER); Topotecan Hydrochloride (DRUG); Vinorelbine Tartrate (DRUG),60699,Evotopin,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Skin,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10029,NCT04029688,"A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors",TERMINATED,PHASE1,Acute Myeloid Leukemia (AML); Acute Lymphoblastic Leukemia (ALL); Neuroblastoma; Solid Tumors,Idasanutlin (DRUG); Venetoclax (DRUG); Cyclophosphamide (DRUG); Topotecan (DRUG); Fludarabine (DRUG); Cytarabine (DRUG); Intrathecal Chemotherapy (DRUG),60699,Evotopin,Acute Myeloid Leukemia (AML); Acute Lymphoblastic Leukemia (ALL); Neuroblastoma; Solid Tumors,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10030,NCT00004188,Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma,COMPLETED,PHASE3,Neuroblastoma,filgrastim (BIOLOGICAL); carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); isotretinoin (DRUG); melphalan (DRUG); topotecan hydrochloride (DRUG); vincristine sulfate (DRUG); autologous bone marrow transplantation (PROCEDURE); bone marrow ablation with stem cell support (PROCEDURE); conventional surgery (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10031,NCT00087126,Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer,COMPLETED,PHASE2,Cervical Cancer,topotecan hydrochloride (DRUG),60699,Evotopin,Cervical Cancer,Cervix,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10032,NCT06500026,A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer,RECRUITING,PHASE3,Small Cell Lung Cancer,BL-B01D1 (DRUG); Topotecan (DRUG),60699,Evotopin,Small Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10033,NCT00107471,"Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma",TERMINATED,PHASE1,Brain Tumors; Central Nervous System Tumors,filgrastim (BIOLOGICAL); topotecan hydrochloride (DRUG); radiation therapy (RADIATION),60699,Evotopin,Brain Tumors; Central Nervous System Tumors,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10034,NCT00005811,Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment,COMPLETED,PHASE2,"AIDS-related Diffuse Large Cell Lymphoma; AIDS-related Diffuse Mixed Cell Lymphoma; AIDS-related Diffuse Small Cleaved Cell Lymphoma; AIDS-related Immunoblastic Large Cell Lymphoma; AIDS-related Lymphoblastic Lymphoma; AIDS-related Peripheral/Systemic Lymphoma; AIDS-related Primary CNS Lymphoma; AIDS-related Small Noncleaved Cell Lymphoma; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; HIV-associated Hodgkin Lymphoma; Leptomeningeal Metastases; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Medulloblastoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific",topotecan hydrochloride (DRUG); laboratory biomarker analysis (OTHER),60699,Evotopin,"AIDS-related Diffuse Large Cell Lymphoma; AIDS-related Diffuse Mixed Cell Lymphoma; AIDS-related Diffuse Small Cleaved Cell Lymphoma; AIDS-related Immunoblastic Large Cell Lymphoma; AIDS-related Lymphoblastic Lymphoma; AIDS-related Peripheral/Systemic Lymphoma; AIDS-related Primary CNS Lymphoma; AIDS-related Small Noncleaved Cell Lymphoma; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; HIV-associated Hodgkin Lymphoma; Leptomeningeal Metastases; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Medulloblastoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific",CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10035,NCT00976911,AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer,COMPLETED,PHASE3,Ovarian Cancer,Bevacizumab (DRUG); liposomal doxorubicin (DRUG); paclitaxel (DRUG); topotecan (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10036,NCT00287911,"Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer",COMPLETED,PHASE1,Cervical Cancer,cisplatin (DRUG); topotecan hydrochloride (DRUG); brachytherapy (RADIATION); radiation therapy (RADIATION),60699,Evotopin,Cervical Cancer,Cervix,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10037,NCT00003211,"Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor",COMPLETED,PHASE2,Brain and Central Nervous System Tumors,filgrastim (BIOLOGICAL); amifostine trihydrate (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); vincristine sulfate (DRUG); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),60699,Evotopin,Brain and Central Nervous System Tumors,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10038,NCT00610571,Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas,COMPLETED,PHASE1,Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma,Oral Topotecan and Temodar (DRUG),60699,Evotopin,Malignant Glioma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10039,NCT00025311,"Topotecan in Treating Patients With Recurrent, Progressive, or Refractory Cancer That is Metastatic to the Lining Around the Brain",COMPLETED,PHASE1,Brain and Central Nervous System Tumors,topotecan hydrochloride (DRUG),60699,Evotopin,Brain and Central Nervous System Tumors,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10040,NCT02566993,Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer,COMPLETED,PHASE3,Small-cell Lung Cancer,Lurbinectedin (PM01183) (DRUG); Doxorubicin (DOX) (DRUG); Cyclophosphamide (CTX) (DRUG); Vincristine (VCR) (DRUG); Topotecan (DRUG),60699,Evotopin,Small-cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10041,NCT02584478,"Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)",ACTIVE_NOT_RECRUITING,PHASE3,Endometrial Carcinoma; Ovarian Carcinoma; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma; Cervical Carcinoma,AL3818 (DRUG); Paclitaxel (DRUG); Pegylated Liposomal Doxorubicin (PLD) (DRUG); Topotecan (DRUG); Topotecan (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); AL3818 (DRUG),60699,Evotopin,Endometrial Carcinoma; Ovarian Carcinoma; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma; Cervical Carcinoma,Uterus,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10042,NCT00314678,Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer,COMPLETED,PHASE2,Epithelial Ovarian Cancer; Primary Peritoneal Cancer,Topotecan (DRUG); Cisplatin (DRUG); Paclitaxel (DRUG),60699,Evotopin,Epithelial Ovarian Cancer; Primary Peritoneal Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10043,NCT03786783,"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma",ACTIVE_NOT_RECRUITING,PHASE2,Ganglioneuroblastoma; High Risk Neuroblastoma,Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Cyclophosphamide (DRUG); Dexrazoxane (DRUG); Dinutuximab (BIOLOGICAL); Doxorubicin (DRUG); Etoposide (DRUG); External Beam Radiation Therapy (RADIATION); Isotretinoin (DRUG); Melphalan (DRUG); Sargramostim (BIOLOGICAL); Thiotepa (DRUG); Topotecan (DRUG); Vincristine (DRUG),60699,Evotopin,Ganglioneuroblastoma; High Risk Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10044,NCT00320983,Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer,COMPLETED,PHASE1,Cervical Cancer,Topotecan (DRUG); Cisplatin (DRUG),60699,Evotopin,Cervical Cancer,Cervix,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10045,NCT03632798,Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer,WITHDRAWN,PHASE3,Recurrent Ovarian Cancer,ChemoID assay (DIAGNOSTIC_TEST); Chemotherapy (DRUG),60699,Evotopin,Recurrent Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10046,NCT00638898,"Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor",COMPLETED,PHASE1,"Solid Tumor; Adult Central Nervous System Germ Cell Tumor; Adult Rhabdomyosarcoma; Childhood Central Nervous System Germ Cell Tumor; Childhood Soft Tissue Sarcoma; Ewing Sarcoma; Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Ovarian Mixed Germ Cell Tumor; Previously Untreated Childhood Rhabdomyosarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Recurrent Childhood Visual Pathway and Hypothalamic Glioma; Recurrent Childhood Visual Pathway Glioma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell Tumor; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Neuroblastoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Wilms Tumor and Other Childhood Kidney Tumors; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific",busulfan (DRUG); melphalan (DRUG); topotecan hydrochloride (DRUG); laboratory biomarker analysis (OTHER); filgrastim (BIOLOGICAL); autologous hematopoietic stem cell transplantation (PROCEDURE); pharmacological study (OTHER); autologous bone marrow transplantation (PROCEDURE),60699,Evotopin,"Solid Tumor; Adult Central Nervous System Germ Cell Tumor; Adult Rhabdomyosarcoma; Childhood Central Nervous System Germ Cell Tumor; Childhood Soft Tissue Sarcoma; Ewing Sarcoma; Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Ovarian Mixed Germ Cell Tumor; Previously Untreated Childhood Rhabdomyosarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Recurrent Childhood Visual Pathway and Hypothalamic Glioma; Recurrent Childhood Visual Pathway Glioma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell Tumor; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Neuroblastoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Wilms Tumor and Other Childhood Kidney Tumors; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific",CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10047,NCT05421897,Rapid Administration Pilot for Infusing Dinutuximab,SUSPENDED,PHASE4,Neuroblastoma,Dinutuximab with Chemotherapy (DRUG),60699,Evotopin,Neuroblastoma,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10048,NCT01931098,Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab,COMPLETED,PHASE2,Glioblastoma; Glioblastoma Multiforme; Gliosarcoma; Brain Neoplasms; Central Nervous System Neoplasms,topotecan (DRUG); pazopanib (DRUG),60699,Evotopin,Glioblastoma; Glioblastoma Multiforme; Gliosarcoma; Brain Neoplasms; Central Nervous System Neoplasms,CNS/Brain,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10049,NCT00003297,Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer,COMPLETED,PHASE1,Ovarian Cancer,mitoxantrone hydrochloride (DRUG); thiotepa (DRUG); topotecan hydrochloride (DRUG); peripheral blood stem cell transplantation (PROCEDURE),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10050,NCT00772798,A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer,UNKNOWN,PHASE2,Ovarian Cancer,"Paclitaxel, Carboplatin and Vorinostat (DRUG)",60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10051,NCT00049998,"Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer",COMPLETED,PHASE3,Non-Small-Cell Lung Cancer,topotecan (DRUG),60699,Evotopin,Non-Small-Cell Lung Cancer,Lung,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10052,NCT04421547,Efficacy of Letrozole in Recurrent Ovarian Cancer,TERMINATED,PHASE3,Epithelial Ovarian Cancer,Letrozole 2.5mg (DRUG); Standard single agent chemotherapy (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10053,NCT02348398,Phase II Study of Pazopanib and Topotecan in Cervical Cancer,WITHDRAWN,PHASE2,Cervical Cancer,Pazopanib (DRUG); Topotecan (DRUG); Phone Call (BEHAVIORAL),60699,Evotopin,Cervical Cancer,Cervix,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10054,NCT01690598,Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status,COMPLETED,PHASE1,Ovarian Cancer,Veliparib (DRUG); Topotecan (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10055,NCT00005051,Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer,COMPLETED,PHASE2,Ovarian Cancer,carboplatin (DRUG); cisplatin (DRUG); paclitaxel (DRUG); topotecan hydrochloride (DRUG),60699,Evotopin,Ovarian Cancer,Ovary/Fallopian Tube,Topotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Approved for treating ovarian, small cell lung, and cervical cancer.",CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl,1.01,300.0 +10056,NCT00014274,Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium,COMPLETED,PHASE2,Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer,carboplatin (DRUG); gemcitabine hydrochloride (DRUG); methotrexate (DRUG); vinblastine sulfate (DRUG),5388983,EXAL,Urinary Tract Cancers,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10057,NCT03472274,Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO),COMPLETED,PHASE2,Bladder Cancer,Durvalumab (DRUG); Tremelimumab (DRUG); Cisplatin-based neoadjuvant chemotherapy (DRUG),5388983,EXAL,Bladder Cancer,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10058,NCT01031420,Dose Dense MVAC for Muscle Invasive Bladder Cancer,COMPLETED,PHASE2,Muscle Invasive Bladder Cancer; High Risk Urothelial Carcinoma of the Upper Urinary Tracts,single arm dose dense MVAC (DRUG),5388983,EXAL,Muscle Invasive Bladder Cancer; High Risk Urothelial Carcinoma of the Upper Urinary Tracts,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10059,NCT02066220,International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma,ACTIVE_NOT_RECRUITING,PHASE2,Brain Tumors,Radiotherapy without Carboplatin (RADIATION); Reduced-intensity maintenance chemotherapy (DRUG); Radiotherapy with Carboplatin (RADIATION); Maintenance chemotherapy (DRUG); WNT-HR < 16 years (RADIATION); WNT-HR >= 16 years (RADIATION); Induction Chemotherapy (DRUG); SHH-TP53 M0 (RADIATION); SHH-TP53 M+ (germline) (RADIATION); SHH-TP53 (somatic) (RADIATION); Vinblastin Maintenance (DRUG),5388983,EXAL,Brain Tumors,CNS/Brain,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10060,NCT06358573,Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK,RECRUITING,PHASE2,Triple-negative Breast Cancer; TNBC - Triple-Negative Breast Cancer,INT230-6 (DRUG); neoadjuvant immuno-chemotherapy (OTHER),5388983,EXAL,Triple-negative Breast Cancer; TNBC - Triple-Negative Breast Cancer,Breast,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10061,NCT06666348,Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK,NOT_YET_RECRUITING,PHASE1,Pediatric Low-grade Glioma,Mirdametinib (DRUG),5388983,EXAL,Pediatric Low-grade Glioma,CNS/Brain,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10062,NCT00520403,A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.,COMPLETED,PHASE2,Renal Cell Cancer,bevacizumab [Avastin] (DRUG); Interferon alfa-2a (DRUG); Vinblastine (DRUG),5388983,EXAL,Renal Cell Cancer,Kidney,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10063,NCT00003027,Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma,COMPLETED,PHASE3,Melanoma (Skin),aldesleukin (BIOLOGICAL); filgrastim (BIOLOGICAL); recombinant interferon alfa (BIOLOGICAL); cisplatin (DRUG); dacarbazine (DRUG); vinblastine (DRUG),5388983,EXAL,Melanoma (Skin),Skin,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10064,NCT00002882,Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma,COMPLETED,PHASE3,Melanoma; Skin Cancer,Aldesleukin (IL-2) (BIOLOGICAL); Recombinant Interferon Alfa (IFN-A) (BIOLOGICAL); Cisplatin (DRUG); Dacarbazine (DRUG); Vinblastine (DRUG); Adjuvant Therapy (PROCEDURE),5388983,EXAL,Melanoma; Skin Cancer,Skin,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10065,NCT00003376,Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium,COMPLETED,PHASE3,Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer,carboplatin (DRUG); cisplatin (DRUG); doxorubicin hydrochloride (DRUG); methotrexate (DRUG); paclitaxel (DRUG); vinblastine (DRUG),5388983,EXAL,Urinary Tract Cancers,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10066,NCT05180825,Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy,RECRUITING,PHASE2,Grade 1 Glioma; Mixed Glio-neuronal Tumors; Pleomorphic Xanthoastrocytoma,Trametinib (DRUG); Vinblastine (DRUG),5388983,EXAL,Low-Grade Glioma,CNS/Brain,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10067,NCT01093066,Prospective Multicentric Evaluation of a Bladder Preservation Strategy,TERMINATED,PHASE2,Urothelial Carcinoma,optimal TURB (DRUG),5388983,EXAL,Urothelial Carcinoma,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10068,NCT00635726,"Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer",TERMINATED,PHASE2,Bladder Cancer,Methotrexate (DRUG); Vinblastine (DRUG); Doxorubicin (DRUG); Cisplatin (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG),5388983,EXAL,Bladder Cancer,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10069,NCT02818725,I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations,COMPLETED,PHASE3,Infiltrating Urothelial Carcinoma; KRAS Gene Mutation,Chemotherapy (DRUG); Panitumumab (DRUG),5388983,EXAL,Infiltrating Urothelial Carcinoma; KRAS Gene Mutation,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10070,NCT04781725,INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,INT230-6 (DRUG); Saline injection (OTHER),5388983,EXAL,Breast Cancer,Breast,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10071,NCT00412425,Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting,COMPLETED,PHASE1,Melanoma,Palonosetron (DRUG),5388983,EXAL,Melanoma,Skin,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10072,NCT01884922,"Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults",COMPLETED,PHASE1,Refractory Low-grade Gliomas; Recurrent Low-grade Gliomas,Nilotinib (DRUG); Vinblastine (DRUG),5388983,EXAL,Refractory Low-grade Gliomas; Recurrent Low-grade Gliomas,CNS/Brain,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10073,NCT00808639,Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma,COMPLETED,PHASE2,Bladder Cancer; Muscle-invasive Bladder Cancer,Methotrexate (DRUG); Doxorubicin (DRUG); vinblastine (DRUG); cisplatin (DRUG); Pegfilgrastim (DRUG),5388983,EXAL,Bladder Cancer; Muscle-invasive Bladder Cancer,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10074,NCT01887522,"Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults",TERMINATED,PHASE2,Refractory Low-grade Gliomas; Recurrent Low-grade Gliomas,Vinblastine + Nilotinib (DRUG); Vinblastine (DRUG),5388983,EXAL,Refractory Low-grade Gliomas; Recurrent Low-grade Gliomas,CNS/Brain,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10075,NCT00575796,Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs),UNKNOWN,PHASE2,Glioma,Vinblastine Sulphate (DRUG),5388983,EXAL,Glioma,CNS/Brain,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10076,NCT05137262,A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder,RECRUITING,PHASE2,Urothelial Carcinoma; Bladder Cancer,Abiraterone acetate (OTHER); Durvalumab (DRUG); Methotrexate (DRUG); Vinblastine (DRUG); Doxorubicin Hydrochloride (DRUG); Cisplatin (DRUG),5388983,EXAL,Urothelial Carcinoma,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10077,NCT00505635,Biochemotherapy With Temozolomide for Metastatic Melanoma,TERMINATED,PHASE2,Melanoma,Temozolomide (DRUG); Velban (DRUG); Cisplatin (DRUG); Interleukin-2 (DRUG); Intron-A (DRUG); Thalidomide (DRUG),5388983,EXAL,Melanoma,Skin,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10078,NCT03092986,Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer,COMPLETED,PHASE4,"Carcinoma, Non-Small-Cell Lung",Paclitaxel (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Vinblastine Sulfate (DRUG); three dimensional conformal radiotherapy (RADIATION),5388983,EXAL,"Carcinoma, Non-Small-Cell Lung",Lung,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10079,NCT01196416,"Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma",COMPLETED,PHASE1,Recurrent Melanoma; Stage IV Skin Melanoma,Cisplatin (DRUG); Gamma-Secretase Inhibitor RO4929097 (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Temozolomide (DRUG); Vinblastine Sulfate (DRUG),5388983,EXAL,Recurrent Melanoma; Stage IV Skin Melanoma,Skin,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10080,NCT01494558,"Study of Etoposide, Cisplatin, and Radiotherapy Versus Paclitaxel, Carboplatin and Radiotherapy to Treat Non-Small Cell Lung Cancer",COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Chemoradiotherapy Regimen between PC and PE (OTHER),5388983,EXAL,Advanced Non-Small Cell Lung Cancer,Lung,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10081,NCT00352495,Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma,COMPLETED,PHASE1,Brain and Central Nervous System Tumors; Neurofibromatosis Type 1,carboplatin (DRUG); vinblastine sulfate (DRUG),5388983,EXAL,Brain and Central Nervous System Tumors; Neurofibromatosis Type 1,CNS/Brain,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10082,NCT02177695,"S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",COMPLETED,PHASE2,Bladder Cancer,Gemcitabine (DRUG); Cisplatin (DRUG); Methotrexate (DRUG); Vinblastine (DRUG); Doxorubicin (DRUG); Filgrastim (DRUG),5388983,EXAL,Bladder Cancer,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10083,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,75 approved agents (DRUG); COXEN (OTHER),5388983,EXAL,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10084,NCT00003701,Combination Chemotherapy in Treating Patients With Bladder Cancer,COMPLETED,PHASE3,Bladder Cancer; Urethral Cancer,carboplatin (DRUG); cisplatin (DRUG); doxorubicin hydrochloride (DRUG); methotrexate (DRUG); paclitaxel (DRUG); vinblastine sulfate (DRUG),5388983,EXAL,Bladder Cancer; Urethral Cancer,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10085,NCT00003240,Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer,UNKNOWN,PHASE3,Lung Cancer,cisplatin (DRUG); ifosfamide (DRUG); mitomycin C (DRUG); vinblastine sulfate (DRUG); vindesine (DRUG); vinorelbine tartrate (DRUG); conventional surgery (PROCEDURE); radiation therapy (RADIATION),5388983,EXAL,Lung Cancer,Lung,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10086,NCT00003640,Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer,TERMINATED,PHASE2,Bladder Cancer,filgrastim (BIOLOGICAL); cisplatin (DRUG); doxorubicin hydrochloride (DRUG); methotrexate (DRUG); vinblastine sulfate (DRUG); surgical procedure (PROCEDURE); radiation therapy (RADIATION),5388983,EXAL,Bladder Cancer,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10087,NCT00602667,"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",ACTIVE_NOT_RECRUITING,PHASE2,Brain and Central Nervous System Tumors,Induction Chemotherapy (DRUG); Low-Risk Therapy (DRUG); High-Risk Therapy (DRUG); Intermediate-Risk Therapy (DRUG),5388983,EXAL,Brain and Central Nervous System Tumors,CNS/Brain,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10088,NCT03058289,A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6,COMPLETED,PHASE1,Breast Cancer; Head and Neck Cancer; Squamous Cell Carcinoma; Lymphoma; Pancreatic Cancer; Liver Cancer; Colon Cancer; Lung Cancer; Bile Duct Cancer; Chordoma of Sacrum; Sarcoma,INT230-6 (DRUG); anti-PD-1 antibody (BIOLOGICAL); anti-CTLA-4 antibody (BIOLOGICAL),5388983,EXAL,Breast Cancer; Head and Neck Cancer; Squamous Cell Carcinoma; Lymphoma; Pancreatic Cancer; Liver Cancer; Colon Cancer; Lung Cancer; Bile Duct Cancer; Chordoma of Sacrum; Sarcoma,Bowel,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10089,NCT03674424,Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial),COMPLETED,PHASE2,Non-metastatic Muscle Invasive Bladder Cancer,Avelumab (DRUG); cystectomy (PROCEDURE); CG (COMBINATION_PRODUCT); DD-MVAC (COMBINATION_PRODUCT); PG (COMBINATION_PRODUCT),5388983,EXAL,Non-metastatic Muscle Invasive Bladder Cancer,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10090,NCT01265940,Pazopanib and Vinflunine in Urothelial Cancer of the Bladder,COMPLETED,PHASE1,Advanced Urothelial Cancer of Bladder After Failure of Platinum-containing Therapy.,Pazopanib as add-on to vinflunine (DRUG),5388983,EXAL,Advanced Urothelial Cancer of Bladder After Failure of Platinum-containing Therapy.,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10091,NCT01812369,Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer,UNKNOWN,PHASE3,Bladder Cancer,GEMCITABINE CISPLATINE (DRUG); METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF (DRUG),5388983,EXAL,Bladder Cancer,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10092,NCT04628767,Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer,RECRUITING,PHASE2,Renal Pelvis and Ureter Urothelial Carcinoma,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Doxorubicin Hydrochloride (DRUG); Durvalumab (BIOLOGICAL); Gemcitabine Hydrochloride (DRUG); Magnetic Resonance Imaging (PROCEDURE); Methotrexate (DRUG); Pegfilgrastim (BIOLOGICAL); Therapeutic Conventional Surgery (PROCEDURE); Vinblastine Sulfate (DRUG),5388983,EXAL,Renal Pelvis and Ureter Urothelial Carcinoma,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10093,NCT04576117,A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma,RECRUITING,PHASE3,Recurrent Low Grade Astrocytoma; Recurrent WHO Grade 2 Glioma; Refractory Low Grade Astrocytoma; Refractory Low Grade Glioma; Refractory WHO Grade 1 Glioma,Biospecimen Collection (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); Selumetinib Sulfate (DRUG); Vinblastine Sulfate (DRUG),5388983,EXAL,Recurrent Low Grade Astrocytoma; Recurrent WHO Grade 2 Glioma; Refractory Low Grade Astrocytoma; Refractory Low Grade Glioma; Refractory WHO Grade 1 Glioma,CNS/Brain,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10094,NCT03912818,Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer,TERMINATED,PHASE2,"Bladder Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Squamous Cell Carcinoma; Bladder Urothelial Carcinoma; Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant; Infiltrating Bladder Urothelial Carcinoma With Giant Cells; Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation; Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation; Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant; Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant; Infiltrating Bladder Urothelial Carcinoma, Nested Variant; Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant",Carboplatin (DRUG); Cisplatin (DRUG); Cystectomy (PROCEDURE); Doxorubicin (DRUG); Durvalumab (BIOLOGICAL); Gemcitabine (DRUG); Methotrexate (DRUG); Vinblastine (DRUG),5388983,EXAL,"Bladder Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Squamous Cell Carcinoma; Bladder Urothelial Carcinoma; Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant; Infiltrating Bladder Urothelial Carcinoma With Giant Cells; Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation; Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation; Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant; Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant; Infiltrating Bladder Urothelial Carcinoma, Nested Variant; Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant",Skin,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10095,NCT00002919,Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer,COMPLETED,PHASE2,Bladder Cancer,filgrastim (BIOLOGICAL); cisplatin (DRUG); doxorubicin hydrochloride (DRUG); methotrexate (DRUG); vinblastine sulfate (DRUG); conventional surgery (PROCEDURE),5388983,EXAL,Bladder Cancer,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10096,NCT02710734,Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN),ACTIVE_NOT_RECRUITING,PHASE2,Urothelial Carcinoma of the Bladder,Methotrexate (DRUG); Vinblastine (DRUG); Doxorubicin (DRUG); Cisplatin (DRUG); Intensity modulated radiation therapy (IMRT) (RADIATION); Transurethral Resection of Bladder tumor (PROCEDURE); 5-FU (DRUG); Mitomycin C (DRUG),5388983,EXAL,Urothelial Carcinoma of the Bladder,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10097,NCT00885534,"Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma",COMPLETED,PHASE2,Melanoma; Skin Cancer,"Cisplatin, Vinblastine, Temozolomide (DRUG)",5388983,EXAL,Melanoma; Skin Cancer,Skin,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10098,NCT00006212,Phosphorus-32 Plus Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer,UNKNOWN,PHASE1,Lung Cancer,cisplatin (DRUG); vinblastine sulfate (DRUG); phosphorus P32 (RADIATION); radiation therapy (RADIATION),5388983,EXAL,Lung Cancer,Lung,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10099,NCT00003181,"Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer",UNKNOWN,PHASE2,Kidney Cancer,aldesleukin (BIOLOGICAL); sargramostim (BIOLOGICAL); vinblastine sulfate (DRUG),5388983,EXAL,Kidney Cancer,Kidney,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10100,NCT00506155,"Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer",COMPLETED,PHASE2,Bladder Cancer,Avastin (DRUG); Cisplatin (DRUG); Doxorubicin (DRUG); Methotrexate (DRUG); Vinblastine Sulfate (DRUG),5388983,EXAL,Bladder Cancer,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10101,NCT06204614,Drug Screening Using IMD in Bladder Cancer,NOT_YET_RECRUITING,EARLY_PHASE1,Muscle Invasive Bladder Urothelial Carcinoma,Implantable Micro-Device (DEVICE); Methotrexate (DRUG); Carboplatin (DRUG); Avelumab (DRUG); Paclitaxel (DRUG); Vinblastine (DRUG); Gemcitabine/Cisplatin I (DRUG); Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab (DRUG); Gemcitabine/Cisplatin II (DRUG); Cisplatin (DRUG); Nivolumab (DRUG); Pembrolizumab (DRUG); Gemcitabine/Carboplatin (DRUG); Methotrexate/Vinblastine/Doxorubicin/Cisplatin (DRUG); Gemcitabine/Cisplatin/Nivolumab (DRUG); Erdafitinib (DRUG); Paclitaxel/Docetaxel/Ifosfamide (DRUG); Gemcitabine (DRUG); Gemcitabine/Carboplatin/Nivolumab (DRUG); Enfortumab (DRUG); Sacituzumab (DRUG),5388983,EXAL,Muscle Invasive Bladder Urothelial Carcinoma,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10102,NCT01542255,Metronomic Therapy in Patients With Metastatic Melanoma,TERMINATED,PHASE2,Metastatic Melanoma,vinblastine (DRUG); Cyclophosphamide (DRUG); dacarbazine (DRUG),5388983,EXAL,Metastatic Melanoma,Skin,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10103,NCT02641314,Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma,COMPLETED,PHASE2,Recurrent Neuroblastoma,metronomic therapy (DRUG),5388983,EXAL,Recurrent Neuroblastoma,CNS/Brain,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10104,NCT00002823,Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer,COMPLETED,PHASE3,Lung Cancer,cisplatin (DRUG); etoposide (DRUG); vinblastine sulfate (DRUG); vindesine (DRUG); vinorelbine tartrate (DRUG); radiation therapy (RADIATION),5388983,EXAL,Lung Cancer,Lung,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10105,NCT04383743,Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Stage II Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8; Muscle Invasive Bladder Carcinoma,Cisplatin (DRUG); Doxorubicin (DRUG); Methotrexate (DRUG); Pegfilgrastim (BIOLOGICAL); Pembrolizumab (BIOLOGICAL); Radical Cystectomy (PROCEDURE); Vinblastine Sulfate (DRUG),5388983,EXAL,Stage II Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8; Muscle Invasive Bladder Carcinoma,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10106,NCT00516750,"Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin",TERMINATED,PHASE2,Bladder Cancer,cisplatin (DRUG); doxorubicin hydrochloride (DRUG); methotrexate (DRUG); vinblastine (DRUG); gene expression profiling (GENETIC); neoadjuvant therapy (PROCEDURE),5388983,EXAL,Bladder Cancer,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10107,NCT00274950,Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors,UNKNOWN,PHASE3,Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer,bleomycin sulfate (BIOLOGICAL); carboplatin (DRUG); cisplatin (DRUG); etoposide (DRUG); ifosfamide (DRUG); vinblastine sulfate (DRUG); adjuvant therapy (PROCEDURE); conventional surgery (PROCEDURE),5388983,EXAL,Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer,Ovary/Fallopian Tube,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10108,NCT00498979,"Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers",COMPLETED,PHASE1,Stage IV Melanoma,recombinant interferon alfa-2b (BIOLOGICAL); cisplatin (DRUG); sodium stibogluconate (DRUG); dacarbazine (DRUG); vinblastine (DRUG),5388983,EXAL,Stage IV Melanoma,Skin,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10109,NCT03296306,Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma,UNKNOWN,PHASE3,Bladder Cancer; Ureter Cancer; Urethral Cancer; Transitional Cell Carcinoma,Treatment duration of cisplatin based chemotherapy (DRUG),5388983,EXAL,Bladder Cancer; Ureter Cancer; Urethral Cancer; Transitional Cell Carcinoma,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10110,NCT00001570,A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer,COMPLETED,PHASE1,Kidney Neoplasms; Neoplasm Metastasis,PSC 833 (DRUG); vinblastine (DRUG),5388983,EXAL,Kidney Neoplasms; Neoplasm Metastasis,Kidney,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10111,NCT02412670,Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,COMPLETED,PHASE2,High Grade Upper Tract Urothelial Carcinoma,Methotrexate (DRUG); Vinblastine (DRUG); Doxorubicin (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG); Pegfilgrastim (DRUG); Nephroureterectomy (PROCEDURE),5388983,EXAL,High Grade Upper Tract Urothelial Carcinoma,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10112,NCT06424899,A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC,RECRUITING,PHASE2,Non Small Cell Lung Cancer,Adebrelimab (DRUG); radical chemoradiotherapy (RADIATION); Platinum based chemotherapy (DRUG),5388983,EXAL,Non Small Cell Lung Cancer,Lung,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10113,NCT02299999,SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Cancer,AZD2014 (DRUG); AZD4547 (DRUG); AZD5363 (DRUG); AZD8931 (DRUG); Selumetinib (DRUG); Vandetanib (DRUG); Bicalutamide (DRUG); Olaparib (DRUG); Anthracyclines (DRUG); Taxanes (DRUG); cyclophosphamide (DRUG); DNA intercalators (DRUG); Methotrexate (DRUG); vinca alkaloids (DRUG); Platinum based chemotherapies (DRUG); Bevacizumab (DRUG); Mitomycin C (DRUG); Eribulin (DRUG); MEDI4736 (DRUG),5388983,EXAL,Metastatic Breast Cancer,Breast,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10114,NCT00001302,A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833,COMPLETED,PHASE1,Breast Cancer; Kidney Neoplasm; Lymphoma; Neoplasm Metastasis; Ovarian Cancer,PSC 833 (DRUG),5388983,EXAL,Breast Cancer; Kidney Neoplasm; Lymphoma; Neoplasm Metastasis; Ovarian Cancer,Breast,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10115,NCT01639521,"Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer",WITHDRAWN,PHASE2,Anterior Urethral Cancer; Localized Transitional Cell Cancer of the Renal Pelvis and Ureter; Posterior Urethral Cancer; Recurrent Bladder Cancer; Recurrent Urethral Cancer; Regional Transitional Cell Cancer of the Renal Pelvis and Ureter; Stage III Bladder Cancer; Transitional Cell Carcinoma of the Bladder; Ureter Cancer; Urethral Cancer Associated With Invasive Bladder Cancer,cisplatin (DRUG); gemcitabine hydrochloride (DRUG); methotrexate (DRUG); vinblastine (DRUG); doxorubicin hydrochloride (DRUG); pegfilgrastim (BIOLOGICAL); laboratory biomarker analysis (OTHER),5388983,EXAL,Anterior Urethral Cancer; Localized Transitional Cell Cancer of the Renal Pelvis and Ureter; Posterior Urethral Cancer; Recurrent Bladder Cancer; Recurrent Urethral Cancer; Regional Transitional Cell Cancer of the Renal Pelvis and Ureter; Stage III Bladder Cancer; Transitional Cell Carcinoma of the Bladder; Ureter Cancer; Urethral Cancer Associated With Invasive Bladder Cancer,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10116,NCT01743157,Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma,COMPLETED,PHASE1,Metastatic Melanoma,Biochemo + bevacizumab then ipilimumab (DRUG),5388983,EXAL,Metastatic Melanoma,Skin,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10117,NCT06381570,Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas,RECRUITING,EARLY_PHASE1,Low-grade Glioma,Tovorafenib (DRUG),5388983,EXAL,Low-grade Glioma,CNS/Brain,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10118,NCT00003159,Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer,COMPLETED,PHASE3,Lung Cancer,carboplatin (DRUG); cisplatin (DRUG); docetaxel (DRUG); gemcitabine hydrochloride (DRUG); ifosfamide (DRUG); mitomycin C (DRUG); paclitaxel (DRUG); vinblastine sulfate (DRUG); vinorelbine tartrate (DRUG); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE),5388983,EXAL,Lung Cancer,Lung,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10119,NCT00030459,Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma,UNKNOWN,PHASE2,Malignant Mesothelioma,cisplatin (DRUG); mitomycin C (DRUG); vinblastine sulfate (DRUG); vinorelbine tartrate (DRUG),5388983,EXAL,Malignant Mesothelioma,Lung,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10120,NCT01490437,Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma,Pemetrexed (DRUG); Cisplatin (DRUG); Dexamethasone (DRUG); Vitamins (DRUG),5388983,EXAL,Urothelial Carcinoma,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10121,NCT01487915,Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma,UNKNOWN,PHASE2,Advanced Urothelial Carcinoma,GCb (DRUG); GemOx (DRUG),5388983,EXAL,Advanced Urothelial Carcinoma,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10122,NCT02840409,Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG),ACTIVE_NOT_RECRUITING,PHASE2,Low Grade Glioma,Vinblastine (DRUG); Bevacizumab (DRUG),5388983,EXAL,Low Grade Glioma,CNS/Brain,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10123,NCT00005047,"4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer",TERMINATED,PHASE3,Bladder Cancer,cisplatin (DRUG); doxorubicin hydrochloride (DRUG); methotrexate (DRUG); vinblastine (DRUG),5388983,EXAL,Bladder Cancer,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10124,NCT06960577,Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2),NOT_YET_RECRUITING,PHASE3,Urinary Bladder Neoplasms; Immune Checkpoint Inhibitors; Methotrexate; Vinblastine; Doxorubicin; Cisplatin; Gemcitabine,Durvalumab (DRUG); Methotrexate (DRUG); Vinblastine (DRUG); Doxorubicin (DRUG); Cisplatin (DRUG); Durvalumab (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG),5388983,EXAL,Urinary Bladder Neoplasms; Immune Checkpoint Inhibitors; Methotrexate; Vinblastine; Doxorubicin; Cisplatin; Gemcitabine,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10125,NCT00006237,S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma,COMPLETED,PHASE3,Melanoma (Skin),interleukin-2 (BIOLOGICAL); filgrastim (BIOLOGICAL); interferon alfa (BIOLOGICAL); cisplatin (DRUG); dacarbazine (DRUG); vinblastine (DRUG),5388983,EXAL,Melanoma (Skin),Skin,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10126,NCT03549715,NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma,ACTIVE_NOT_RECRUITING,PHASE1,Infiltrating Bladder Urothelial Carcinoma,Durvalumab (DRUG); Tremelimumab (DRUG); MVAC Protocol (DRUG),5388983,EXAL,Infiltrating Bladder Urothelial Carcinoma,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10127,NCT00003209,Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer,COMPLETED,PHASE3,Cervical Cancer,bleomycin sulfate (BIOLOGICAL); cisplatin (DRUG); fluorouracil (DRUG); ifosfamide (DRUG); methotrexate (DRUG); mitomycin C (DRUG); vinblastine sulfate (DRUG); vindesine (DRUG); radiation therapy (RADIATION),5388983,EXAL,Cervical Cancer,Cervix,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10128,NCT00004209,Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer,UNKNOWN,PHASE3,Lung Cancer,cisplatin (DRUG); mitomycin C (DRUG); vinblastine sulfate (DRUG),5388983,EXAL,Lung Cancer,Lung,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10129,NCT00028756,Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium,COMPLETED,PHASE3,Stage III Bladder Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder,doxorubicin hydrochloride (DRUG); gemcitabine hydrochloride (DRUG); vinblastine sulfate (DRUG); methotrexate (DRUG); cisplatin (DRUG); filgrastim (BIOLOGICAL),5388983,EXAL,Stage III Bladder Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10130,NCT00004887,Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery,UNKNOWN,PHASE3,Lung Cancer,carboplatin (DRUG); cisplatin (DRUG); ifosfamide (DRUG); mitomycin C (DRUG); paclitaxel (DRUG); vinblastine sulfate (DRUG),5388983,EXAL,Lung Cancer,Lung,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10131,NCT00002887,Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer,UNKNOWN,PHASE1,Lung Cancer,cisplatin (DRUG); etoposide (DRUG); hydroxyurea (DRUG); vinblastine sulfate (DRUG); vindesine (DRUG); vinorelbine tartrate (DRUG); drug resistance inhibition treatment (PROCEDURE),5388983,EXAL,Lung Cancer,Lung,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10132,NCT02969083,Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma,RECRUITING,PHASE2,Upper Tract Urothelial Carcinoma,RNU (PROCEDURE); Gemcitabine/Cisplatin (DRUG); M-VAC Protocol (DRUG),5388983,EXAL,Upper Tract Urothelial Carcinoma,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10133,NCT00083083,Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer,UNKNOWN,PHASE2,Lung Cancer,carboplatin (DRUG); cisplatin (DRUG); docetaxel (DRUG); etoposide (DRUG); paclitaxel (DRUG); vinblastine sulfate (DRUG); vinorelbine tartrate (DRUG); gene expression analysis (GENETIC); positron emission tomography (PROCEDURE); fludeoxyglucose F 18 (RADIATION); radiation therapy (RADIATION),5388983,EXAL,Lung Cancer,Lung,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10134,NCT00673361,"Pilot Trial of ""Chemo-Switch"" Regimen to Treat Advanced Melanoma",TERMINATED,PHASE2,Melanoma,Concurrent decrescendo biochemotherapy regimen (DRUG); Low-dose Temozolomide plus Sorafenib (DRUG),5388983,EXAL,Melanoma,Skin,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10135,NCT00213278,Phase 2 Study of Vinblastine in Children With Recurrent or Refractory Low Grade Glioma,COMPLETED,PHASE2,Glioma,vinblastine sulphate injection (DRUG),5388983,EXAL,Glioma,CNS/Brain,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10136,NCT04047693,Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma,UNKNOWN,PHASE2,Muscle Invasive Bladder Cancer; Urothelial Carcinoma; Neoadjuvant Chemotherapy,dose dense MVAC with pegylated GCSF (DRUG),5388983,EXAL,Muscle Invasive Bladder Cancer; Urothelial Carcinoma; Neoadjuvant Chemotherapy,Bladder/Urinary Tract,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10137,NCT01134861,Radiation Therapy Plus Chemotherapy in Treating Patients With Non-small Cell Lung Cancer,COMPLETED,PHASE3,Lung Cancer,cisplatin (DRUG); Etoposide (DRUG); Vinblastine (DRUG); Radiation therapy (RADIATION); Cisplatin (DRUG); Radiation therapy (RADIATION); Radiation therapy (RADIATION),5388983,EXAL,Lung Cancer,Lung,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10138,NCT00001498,"A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer",COMPLETED,PHASE2,Breast Cancer; Breast Neoplasms,methotrexate (DRUG); leucovorin (DRUG); 5-fluorouracil (DRUG); cyclophosphamide (DRUG); peripheral blood progenitor cell (PROCEDURE); paclitaxel (DRUG); doxorubicin (DRUG),5388983,EXAL,Breast Cancer; Breast Neoplasms,Breast,Vinblastine (sulfate),,inhibitor/antagonist,Microtubule inhibitor,yes,yes,"Used in cancer treatment, notably Hodgkin's lymphoma.",CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.06,290.0 +10139,NCT02315326,"Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)",RECRUITING,PHASE1,Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL); Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL),Ibrutinib (DRUG); HD- Methotrexate (MTX) (DRUG); Rituximab + HD- Methotrexate (MTX) (DRUG); procarbazine (DRUG),249332,Vincrex,Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL); Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL),CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10140,NCT00276666,Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Metastatic Medulloblastoma Who Have Undergone Surgery,UNKNOWN,PHASE2,Brain and Central Nervous System Tumors,cisplatin (DRUG); lomustine (DRUG); vincristine sulfate (DRUG); adjuvant therapy (PROCEDURE); radiation therapy (RADIATION),249332,Vincrex,Brain and Central Nervous System Tumors,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10141,NCT00002466,"Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer",COMPLETED,PHASE2,Kidney Cancer; Sarcoma,cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); ifosfamide (DRUG); vincristine sulfate (DRUG); conventional surgery (PROCEDURE); radiation therapy (RADIATION),249332,Vincrex,Kidney Cancer; Sarcoma,Kidney,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10142,NCT02066220,International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma,ACTIVE_NOT_RECRUITING,PHASE2,Brain Tumors,Radiotherapy without Carboplatin (RADIATION); Reduced-intensity maintenance chemotherapy (DRUG); Radiotherapy with Carboplatin (RADIATION); Maintenance chemotherapy (DRUG); WNT-HR < 16 years (RADIATION); WNT-HR >= 16 years (RADIATION); Induction Chemotherapy (DRUG); SHH-TP53 M0 (RADIATION); SHH-TP53 M+ (germline) (RADIATION); SHH-TP53 (somatic) (RADIATION); Vinblastin Maintenance (DRUG),249332,Vincrex,Brain Tumors,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10143,NCT00410631,"Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma",UNKNOWN,PHASE3,Neuroblastoma,filgrastim (BIOLOGICAL); carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); dacarbazine (DRUG); doxorubicin hydrochloride (DRUG); etoposide phosphate (DRUG); ifosfamide (DRUG); isotretinoin (DRUG); melphalan (DRUG); topotecan hydrochloride (DRUG); vincristine sulfate (DRUG); vindesine (DRUG); autologous hematopoietic stem cell transplantation (PROCEDURE); conventional surgery (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); iobenguane I 131 (RADIATION); radiation therapy (RADIATION),249332,Vincrex,Neuroblastoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10144,NCT00031590,Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma,TERMINATED,PHASE2,Brain Tumors; Central Nervous System Tumors; Medulloblastoma,Cisplatin (DRUG); Cyclophosphamide (DRUG); Etoposide (DRUG); Lomustine (DRUG); Vincristine (DRUG); Craniospinal Radiation (RADIATION),249332,Vincrex,Brain Tumors; Central Nervous System Tumors; Medulloblastoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10145,NCT04659421,Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas,COMPLETED,PHASE2,Low-grade Glioma; Pediatric Brain Tumor,combined therapy with rh-ES and CV (DRUG),249332,Vincrex,Pediatric Low-grade Glioma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10146,NCT00003846,"Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors",COMPLETED,PHASE2,Brain and Central Nervous System Tumors; Neuroblastoma,filgrastim (BIOLOGICAL); carboplatin (DRUG); cyclophosphamide (DRUG); thiotepa (DRUG); vincristine sulfate (DRUG); bone marrow ablation with stem cell support (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),249332,Vincrex,Brain and Central Nervous System Tumors; Neuroblastoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10147,NCT03925246,Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas,COMPLETED,PHASE2,High Grade Glioma; Brain Cancer,Nivolumab (DRUG),249332,Vincrex,High Grade Glioma; Brain Cancer,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10148,NCT00017368,Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma,filgrastim (BIOLOGICAL); sargramostim (BIOLOGICAL); carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); etoposide phosphate (DRUG); ifosfamide (DRUG); isotretinoin (DRUG); melphalan (DRUG); thiotepa (DRUG); vincristine sulfate (DRUG); conventional surgery (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),249332,Vincrex,Neuroblastoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10149,NCT00365768,"Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors",COMPLETED,PHASE2,Kidney Cancer; Leukemia; Lymphoma; Neurotoxicity; Peripheral Neuropathy; Sarcoma,Glutamine (DRUG); Placebo (OTHER),249332,Vincrex,Kidney Cancer; Leukemia; Lymphoma; Neurotoxicity; Peripheral Neuropathy; Sarcoma,Kidney,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10150,NCT03533582,Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery,ACTIVE_NOT_RECRUITING,PHASE3,"Childhood Hepatocellular Carcinoma; Childhood Malignant Liver Neoplasm; Fibrolamellar Carcinoma; Hepatoblastoma; Hepatocellular Malignant Neoplasm, Not Otherwise Specified",Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Doxorubicin (DRUG); Etoposide (DRUG); Fluorouracil (DRUG); Gemcitabine (DRUG); Irinotecan (DRUG); Oxaliplatin (DRUG); Patient Observation (OTHER); Resection (PROCEDURE); Sorafenib (DRUG); Vincristine Sulfate (DRUG),249332,Vincrex,Childhood Liver Malignancies,Liver,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10151,NCT00003573,Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma,COMPLETED,PHASE2,Brain Tumors; Central Nervous System Tumors,filgrastim (BIOLOGICAL); cisplatin (DRUG); cyclophosphamide (DRUG); etoposide (DRUG); vincristine sulfate (DRUG); radiation therapy (RADIATION),249332,Vincrex,Brain Tumors; Central Nervous System Tumors,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10152,NCT00276731,Combination Chemotherapy Followed By Surgery With or Without Radiation Therapy in Treating Young Patients With Stage II or Stage III Neuroblastoma,UNKNOWN,PHASE3,Neuroblastoma,carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); etoposide (DRUG); vincristine sulfate (DRUG); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE); radiation therapy (RADIATION),249332,Vincrex,Neuroblastoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10153,NCT00416676,Combination Chemotherapy and Surgery With or Without Radiation Therapy in Treating Patients With Stage 2 or Stage 3 Neuroblastoma,UNKNOWN,PHASE3,Neuroblastoma,carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); etoposide (DRUG); vincristine sulfate (DRUG); adjuvant therapy (PROCEDURE); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE); radiation therapy (RADIATION),249332,Vincrex,Neuroblastoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10154,NCT00980460,Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer,ACTIVE_NOT_RECRUITING,PHASE3,PRETEXT I Hepatoblastoma; PRETEXT II Hepatoblastoma; PRETEXT III Hepatoblastoma; PRETEXT IV Hepatoblastoma,Cisplatin (DRUG); Dexrazoxane (DRUG); Doxorubicin Hydrochloride (DRUG); Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Liver Transplantation (PROCEDURE); Temsirolimus (DRUG); Therapeutic Conventional Surgery (PROCEDURE); Vincristine Sulfate (DRUG),249332,Vincrex,Hepatoblastoma,Liver,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10155,NCT00669812,High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma,UNKNOWN,PHASE2,Lymphoma; Small Intestine Cancer,carmustine (DRUG); cyclophosphamide (DRUG); cytarabine (DRUG); doxorubicin hydrochloride (DRUG); epirubicin hydrochloride (DRUG); etoposide (DRUG); ifosfamide (DRUG); melphalan (DRUG); methotrexate (DRUG); prednisolone (DRUG); vincristine sulfate (DRUG); autologous hematopoietic stem cell transplantation (PROCEDURE); biopsy (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE),249332,Vincrex,Lymphoma and Small Intestine Cancer,Bowel,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10156,NCT00567567,Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma,COMPLETED,PHASE3,Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma; Regional Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma,Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin Hydrochloride (DRUG); Etoposide (DRUG); External Beam Radiation Therapy (RADIATION); Filgrastim (BIOLOGICAL); Isotretinoin (DRUG); Laboratory Biomarker Analysis (OTHER); Melphalan (DRUG); Peripheral Blood Stem Cell Transplantation (PROCEDURE); Pharmacological Study (OTHER); Thiotepa (DRUG); Topotecan Hydrochloride (DRUG); Vincristine Sulfate Liposome (DRUG),249332,Vincrex,Neuroblastoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10157,NCT00040872,Multiple Therapies in Treating Patients With Advanced Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma,filgrastim (BIOLOGICAL); monoclonal antibody 3F8 (BIOLOGICAL); sargramostim (BIOLOGICAL); carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); isotretinoin (DRUG); thiotepa (DRUG); topotecan hydrochloride (DRUG); vincristine sulfate (DRUG); autologous bone marrow transplantation (PROCEDURE); bone marrow ablation with stem cell support (PROCEDURE); conventional surgery (PROCEDURE); drug resistance inhibition treatment (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); syngeneic bone marrow transplantation (PROCEDURE); radiation therapy (RADIATION),249332,Vincrex,Neuroblastoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10158,NCT05180825,Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy,RECRUITING,PHASE2,Grade 1 Glioma; Mixed Glio-neuronal Tumors; Pleomorphic Xanthoastrocytoma,Trametinib (DRUG); Vinblastine (DRUG),249332,Vincrex,Low-Grade Glioma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10159,NCT00002822,Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer,COMPLETED,PHASE3,Lung Cancer,carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); ifosfamide (DRUG); mesna (DRUG); vincristine sulfate (DRUG); radiation therapy (RADIATION),249332,Vincrex,Lung Cancer,Lung,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10160,NCT00003625,Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma,COMPLETED,PHASE1,Brain Tumors; Central Nervous System Tumors,cyclosporine (DRUG); etoposide (DRUG); vincristine sulfate (DRUG); radiation therapy (RADIATION),249332,Vincrex,Brain Tumors; Central Nervous System Tumors,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10161,NCT00017225,Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma,filgrastim (BIOLOGICAL); carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); dacarbazine (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); ifosfamide (DRUG); melphalan (DRUG); tretinoin (DRUG); vincristine sulfate (DRUG); vindesine (DRUG); autologous bone marrow transplantation (PROCEDURE); conventional surgery (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),249332,Vincrex,Neuroblastoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10162,NCT06401330,A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT),RECRUITING,PHASE3,Stage I Kidney Wilms Tumor; Stage II Kidney Wilms Tumor; Stage III Kidney Wilms Tumor; Stage IV Kidney Wilms Tumor,Bone Scan (PROCEDURE); Carboplatin (DRUG); Computed Tomography (PROCEDURE); Cyclophosphamide (DRUG); Dactinomycin (BIOLOGICAL); Doxorubicin (DRUG); Etoposide (DRUG); Irinotecan (DRUG); Magnetic Resonance Imaging (PROCEDURE); Nephrectomy (PROCEDURE); Patient Observation (OTHER); Positron Emission Tomography (PROCEDURE); Ultrasound Imaging (PROCEDURE); Vincristine (DRUG); X-Ray Imaging (PROCEDURE),249332,Vincrex,Kidney Neoplasms,Kidney,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10163,NCT01458730,Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma,COMPLETED,PHASE2,Central Nervous System Lymphoma,Immunochemotherapy (DRUG),249332,Vincrex,Central Nervous System Lymphoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10164,NCT06942039,"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation",NOT_YET_RECRUITING,EARLY_PHASE1,"CNS Embryonal Tumor; CNS, Medulloblastoma; Atypical Teratoid Rhabdoid Tumor; Medulloblastoma, Childhood; Medulloblastoma, Group 3; Medulloblastoma, Group 4; Pineoblastoma; Neuroblastoma; Embryonal Tumor With Multilayered Rosettes; Embryonal Tumor With Abundant Neuropil and True Rosettes; Ependymoblastoma; Medulloepithelioma; CNS Embryonal Tumor With Rhabdoid Features; CNS Embryonal Tumor, Nos",Cytarabine IT (DRUG); hydrocortisone (DRUG); Cisplatin (DRUG); Vincristine (DRUG); Etoposide (DRUG); Cyclophosphamide (DRUG); Mesna (DRUG); Filgrastim (DRUG); carboplatin (DRUG); Thiotepa (DRUG); Topotecan IT (DRUG); Tamoxifen (DRUG); ISOtretinoin (DRUG); Celecoxib (DRUG); etoposide phosphate (DRUG); Temozolomide (DRUG),249332,Vincrex,CNS Embryonal Tumors,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10165,NCT00165139,Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas,COMPLETED,PHASE2,Neuroblastoma; Ewings Sarcoma; Non-rhabdomyosarcoma Soft Tissue Sarcoma,Vincristine (DRUG); Cyclophosphamide (DRUG); Adriamycin (DRUG); Etoposide (VP-16) (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Melphalan (DRUG); Ifosfamide (DRUG); G-CSF (granulocyte-colony stimulating factor) (DRUG); Mesna (DRUG),249332,Vincrex,Neuroblastoma; Ewings Sarcoma; Non-rhabdomyosarcoma Soft Tissue Sarcoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10166,NCT00003273,Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor,WITHDRAWN,PHASE2,Brain and Central Nervous System Tumors; Neuroblastoma; Retinoblastoma; Sarcoma,filgrastim (BIOLOGICAL); carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); etoposide (DRUG); leucovorin calcium (DRUG); methotrexate (DRUG); temozolomide (DRUG); thiotepa (DRUG); vincristine sulfate (DRUG); autologous bone marrow transplantation (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),249332,Vincrex,Brain and Central Nervous System Tumors; Neuroblastoma; Retinoblastoma; Sarcoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10167,NCT00734773,Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL,WITHDRAWN,EARLY_PHASE1,Brain and Central Nervous System Tumors; Lymphoma; Neurotoxicity,Rituximab (BIOLOGICAL); Cytarabine (DRUG); Methotrexate (DRUG); Motexafin gadolinium (DRUG); Procarbazine hydrochloride (DRUG); Vincristine sulfate (DRUG); Radiation therapy (RADIATION),249332,Vincrex,Brain and Central Nervous System Conditions,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10168,NCT02684058,Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors,COMPLETED,PHASE2,"Diffuse Astrocytoma; Anaplastic Astrocytoma; Astrocytoma; Oligodendroglioma, Childhood; Anaplastic Oligodendroglioma; Glioblastoma; Pilocytic Astrocytoma; Giant Cell Astrocytoma; Pleomorphic Xanthoastrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Angiocentric Glioma; Chordoid Glioma of Third Ventricle; Gangliocytoma; Ganglioglioma; Anaplastic Ganglioglioma; Dysplastic Gangliocytoma of Cerebrellum; Desmoplastic Infantile Astrocytoma and Ganglioglioma; Papillary Glioneuronal Tumor; Rosette-forming Glioneurona Tumor; Central Neurocytoma; Extraventricular Neurocytoma; Cerebellar Iponeurocytoma",Dabrafenib (DRUG); trametinib (DRUG); Carboplatin (DRUG); Vincristine (DRUG),249332,Vincrex,Gliomas and Neuronal Tumors,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10169,NCT00005796,Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors,COMPLETED,PHASE1,Bone Marrow Suppression; Brain and Central Nervous System Tumors; Drug/Agent Toxicity by Tissue/Organ,filgrastim (PROCEDURE); gene therapy (BIOLOGICAL); lomustine (DRUG); procarbazine hydrochloride (DRUG); vincristine sulfate (DRUG); in vitro-treated peripheral blood stem cell transplantation (PROCEDURE),249332,Vincrex,Bone Marrow Suppression; Brain and Central Nervous System Tumors; Drug/Agent Toxicity by Tissue/Organ,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10170,NCT04316039,Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery,RECRUITING,PHASE2,Low-grade Glioma,Temozolomide (DRUG); intensity modulated radiation therapy (RADIATION),249332,Vincrex,Low-grade Glioma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10171,NCT03042429,Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients,COMPLETED,PHASE3,Neuroblastoma,"Cycles N8, N5 and N6 (DRUG); Cycles N5 and N6 (DRUG)",249332,Vincrex,Neuroblastoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10172,NCT01222780,"To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer",COMPLETED,PHASE1,Sarcoma; Neuroblastoma; Wilms Tumor; Leukemia; Lymphoma; Brain Tumors,Marqibo (DRUG),249332,Vincrex,Sarcoma; Neuroblastoma; Wilms Tumor; Leukemia; Lymphoma; Brain Tumors,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10173,NCT06933394,Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma,RECRUITING,PHASE2,Neuroblastoma,Arsenic trioxide (DRUG); MAPK inhibitors (DRUG); Chemotherapy (DRUG),249332,Vincrex,Neuroblastoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10174,NCT06541262,Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors,RECRUITING,PHASE1,Neuroblastoma Recurrent; Ewing's Sarcoma Recurrent; Osteosarcoma Recurrent; Rhabdomyosarcoma Recurrent; Liposarcoma Recurrent,Silmitasertib (DRUG); Irinotecan (DRUG); Temozolomide (DRUG); Vincristine (DRUG),249332,Vincrex,Neuroblastoma Recurrent; Ewing's Sarcoma Recurrent; Osteosarcoma Recurrent; Rhabdomyosarcoma Recurrent; Liposarcoma Recurrent,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10175,NCT00003994,Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer,COMPLETED,PHASE3,Childhood Hepatoblastoma; Recurrent Childhood Liver Cancer; Stage I Childhood Liver Cancer,therapeutic conventional surgery (PROCEDURE); cisplatin (DRUG); vincristine sulfate (DRUG); fluorouracil (DRUG); amifostine trihydrate (DRUG); carboplatin (DRUG),249332,Vincrex,Childhood Hepatoblastoma; Recurrent Childhood Liver Cancer; Stage I Childhood Liver Cancer,Liver,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10176,NCT01837862,A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas,COMPLETED,PHASE1,"Pilomyxoid Astrocytoma; Pilocytic Astrocytoma; Glioma, Astrocytic; Optic Nerve Glioma; Pleomorphic Xanthoastrocytoma; Glioblastoma Multiforme; Anaplastic Astrocytoma; Gliosarcoma; Diffuse Intrinsic Pontine Glioma; DIPG; Low-grade Glioma; Brainstem Glioma",Mebendazole (DRUG); Vincristine (DRUG); Carboplatin (DRUG); Temozolomide (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG),249332,Vincrex,"Pilomyxoid Astrocytoma; Pilocytic Astrocytoma; Glioma, Astrocytic; Optic Nerve Glioma; Pleomorphic Xanthoastrocytoma; Glioblastoma Multiforme; Anaplastic Astrocytoma; Gliosarcoma; Diffuse Intrinsic Pontine Glioma; DIPG; Low-grade Glioma; Brainstem Glioma",CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10177,NCT03684980,LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma,RECRUITING,EARLY_PHASE1,Central Nervous System Lymphoma,Methotrexate (DRUG); Rituximab (DRUG); leucovorin (DRUG); Glucarpidase (DRUG),249332,Vincrex,Central Nervous System Lymphoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10178,NCT03632135,Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma,COMPLETED,PHASE3,Recurrent Glioblastoma,ChemoID assay (DIAGNOSTIC_TEST); Chemotherapy (DRUG),249332,Vincrex,Recurrent Glioblastoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10179,NCT01704716,High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN),RECRUITING,PHASE3,Neuroblastoma,Vincristine (DRUG); Aldesleukin (DRUG); ch14.18/CHO (DRUG); Carboplatin (DRUG); Etoposide (DRUG); Cisplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin (DRUG); G-CSF (DRUG); Busulfan (DRUG); Melphalan (DRUG),249332,Vincrex,Neuroblastoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10180,NCT03126916,Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL),ACTIVE_NOT_RECRUITING,PHASE3,Ganglioneuroblastoma; Neuroblastoma,Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration and Biopsy (PROCEDURE); Busulfan (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Cyclophosphamide (DRUG); Dexrazoxane Hydrochloride (DRUG); Dinutuximab (BIOLOGICAL); Doxorubicin Hydrochloride (DRUG); Echocardiography (PROCEDURE); Etoposide Phosphate (DRUG); External Beam Radiation Therapy (RADIATION); Iobenguane I-123 (RADIATION); Iobenguane I-131 (RADIATION); Isotretinoin (DRUG); Lorlatinib (DRUG); Magnetic Resonance Imaging (PROCEDURE); Melphalan Hydrochloride (DRUG); Multigated Acquisition Scan (PROCEDURE); Positron Emission Tomography (PROCEDURE); Sargramostim (BIOLOGICAL); Therapeutic Conventional Surgery (PROCEDURE); Thiotepa (DRUG); Topotecan Hydrochloride (DRUG); Vincristine Sulfate (DRUG),249332,Vincrex,Ganglioneuroblastoma; Neuroblastoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10181,NCT06528496,N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma,RECRUITING,PHASE2,High-risk Neuroblastoma; Neuroblastoma; Childhood Neuroblastoma,DANYELZA (BIOLOGICAL); Sargramostim (BIOLOGICAL); Cytoxan (DRUG); Topotecan (DRUG); Vincristine (DRUG); Doxorubicin (DRUG); Ifosfamide (DRUG); Etoposide (DRUG); Carboplatin (DRUG); Irinotecan (DRUG); Temozolomide (DRUG),249332,Vincrex,High-risk Neuroblastoma; Neuroblastoma; Childhood Neuroblastoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10182,NCT00392886,Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors,UNKNOWN,PHASE3,Brain and Central Nervous System Tumors,carboplatin (DRUG); cisplatin (DRUG); cyclophosphamide (DRUG); etoposide (DRUG); methotrexate (DRUG); temozolomide (DRUG); thiotepa (DRUG); vincristine sulfate (DRUG); autologous bone marrow transplantation (PROCEDURE); autologous hematopoietic stem cell transplantation (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),249332,Vincrex,Brain and Central Nervous System Tumors,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10183,NCT00003935,Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma,COMPLETED,PHASE1,Brain Tumors; Central Nervous System Tumors,etoposide (DRUG); vincristine sulfate (DRUG); radiation therapy (RADIATION),249332,Vincrex,Brain Tumors; Central Nervous System Tumors,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10184,NCT00001335,"New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma",COMPLETED,PHASE2,Ewing's Sarcoma; Neuroblastoma; Rhabdomyosarcoma,ADR-529 (DRUG); Topotecan (DRUG); G-CSF (DRUG),249332,Vincrex,Ewing's Sarcoma; Neuroblastoma; Rhabdomyosarcoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10185,NCT04221035,High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN),RECRUITING,PHASE3,High-Risk Neuroblastoma; Patient With Insufficient Response Chemoimmunotherapy,Vincristine (DRUG); Carboplatin (DRUG); Etoposide (DRUG); Vindesine (DRUG); Dacarbazine (DRUG); Ifosfamide (DRUG); Doxorubicin (DRUG); Busulfan (DRUG); Melphalan (DRUG); Thiotepa (DRUG); Radiotherapy (RADIATION); Dinutuximab Beta (DRUG); Cisplatin (DRUG); Temozolomide 100 MG (DRUG); Irinotecan (DRUG); Cyclophosphamid (DRUG),249332,Vincrex,High-Risk Neuroblastoma; Patient With Insufficient Response Chemoimmunotherapy,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10186,NCT00960063,"A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)",TERMINATED,PHASE1,Neoplasms; Solid Tumors; Bone Cancer; Kidney Tumor; Neuroblastoma,Temozolomide (DRUG); Vincristine (DRUG); Ifosfamide (DRUG); Irinotecan (DRUG); Robatumumab (BIOLOGICAL); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Etoposide (DRUG),249332,Vincrex,Neoplasms; Solid Tumors; Bone Cancer; Kidney Tumor; Neuroblastoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10187,NCT00138216,"Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors",COMPLETED,PHASE1,"Brain and Central Nervous System Tumors; Unspecified Childhood Solid Tumor, Protocol Specific",irinotecan hydrochloride (DRUG); temozolomide (DRUG); vincristine sulfate (DRUG),249332,Vincrex,"Brain and Central Nervous System Tumors; Unspecified Childhood Solid Tumor, Protocol Specific",CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10188,NCT00004224,Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma,COMPLETED,PHASE2,Brain and Central Nervous System Tumors,cyclophosphamide (DRUG); etoposide (DRUG); vincristine sulfate (DRUG); adjuvant therapy (PROCEDURE); conventional surgery (PROCEDURE); radiation therapy (RADIATION),249332,Vincrex,Brain and Central Nervous System Tumors,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10189,NCT00006258,"Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma",COMPLETED,PHASE2,Brain and Central Nervous System Tumors,filgrastim (BIOLOGICAL); cisplatin (DRUG); cyclophosphamide (DRUG); etoposide (DRUG); methotrexate (DRUG); vincristine sulfate (DRUG); adjuvant therapy (PROCEDURE); radiation therapy (RADIATION),249332,Vincrex,Brain and Central Nervous System Tumors,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10190,NCT04947501,A Study of N9 Chemotherapy in Children With Neuroblastoma,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,Neuroblastoma; Pediatric Cancer,Cyclophosphamide (DRUG); Topotecan (DRUG); Vincristine (DRUG); Doxorubicin (DRUG); Ifosfamide (DRUG); Etoposide (DRUG); Carboplatin (DRUG); Mesna (DRUG),249332,Vincrex,Neuroblastoma; Pediatric Cancer,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10191,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,75 approved agents (DRUG); COXEN (OTHER),249332,Vincrex,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,Bladder/Urinary Tract,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10192,NCT00053872,Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma,UNKNOWN,PHASE3,Brain and Central Nervous System Tumors,cisplatin (DRUG); lomustine (DRUG); vincristine sulfate (DRUG); adjuvant therapy (PROCEDURE); radiation therapy (RADIATION),249332,Vincrex,Brain and Central Nervous System Tumors,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10193,NCT00002840,Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma,COMPLETED,PHASE3,Brain and Central Nervous System Tumors,lomustine (DRUG); procarbazine hydrochloride (DRUG); vincristine sulfate (DRUG); radiation therapy (RADIATION),249332,Vincrex,Brain and Central Nervous System Tumors,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10194,NCT00002740,Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma,COMPLETED,PHASE1,Neuroblastoma,filgrastim (BIOLOGICAL); carboplatin (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); mesna (DRUG); vincristine sulfate (DRUG); conventional surgery (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); low-LET cobalt-60 gamma ray therapy (RADIATION); low-LET photon therapy (RADIATION),249332,Vincrex,Neuroblastoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10195,NCT00392340,"Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma",UNKNOWN,PHASE2,Neuroblastoma,filgrastim (BIOLOGICAL); doxorubicin hydrochloride (DRUG); topotecan hydrochloride (DRUG); vincristine sulfate (DRUG),249332,Vincrex,Neuroblastoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10196,NCT01528046,Metformin in Children With Relapsed or Refractory Solid Tumors,COMPLETED,PHASE1,Solid Tumors; Primary Brain Tumors,Vincristine (DRUG); Irinotecan (DRUG); Temozolomide (DRUG); Metformin (DRUG),249332,Vincrex,Solid Tumors; Primary Brain Tumors,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10197,NCT00025610,Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma,carboplatin (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); vincristine sulfate (DRUG),249332,Vincrex,Neuroblastoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10198,NCT00602667,"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",ACTIVE_NOT_RECRUITING,PHASE2,Brain and Central Nervous System Tumors,Induction Chemotherapy (DRUG); Low-Risk Therapy (DRUG); High-Risk Therapy (DRUG); Intermediate-Risk Therapy (DRUG),249332,Vincrex,Brain and Central Nervous System Tumors,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10199,NCT00003804,Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor,UNKNOWN,PHASE3,Kidney Cancer,dactinomycin (BIOLOGICAL); vincristine sulfate (DRUG); conventional surgery (PROCEDURE),249332,Vincrex,Kidney Cancer,Kidney,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10200,NCT04478292,A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy,RECRUITING,PHASE3,Hepatoblastoma,"Sodium Thiosulfate Injection (DRUG); Primary surgery resection (PROCEDURE); mono CDDP-Group A2 (DRUG); Cisplatin, 5-Fluorouracil, Vincristine, Doxorubicin-Group C (DRUG); Biopsy (PROCEDURE); Resection or transplant (PROCEDURE); Resection of pulmonary nodules (PROCEDURE); mono CDDP- Group B (DRUG); Block 1 to 3 (Cisplatin, Doxorubicin) Group D (DRUG); Consolidation (Carboplatin, Doxorubicin) -Group D1 (DRUG); Consolidation (Carboplatin +Doxorubicin/Vincristine + Irinotecan)-Group D2 (DRUG)",249332,Vincrex,Hepatoblastoma,Liver,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10201,NCT00002944,Combination Chemotherapy in Treating Children With Progressive Brain Tumors,COMPLETED,PHASE3,Brain Tumors; Central Nervous System Tumors,carboplatin (DRUG); lomustine (DRUG); procarbazine hydrochloride (DRUG); thioguanine (DRUG); vincristine sulfate (DRUG),249332,Vincrex,Brain Tumors; Central Nervous System Tumors,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10202,NCT06721689,"PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors",RECRUITING,PHASE1,Refractory Solid Tumors; Relapsed Solid Tumors; Relapsed Neuroblastoma; Refractory Neuroblastoma; Relapsed Rhabdomyosarcoma; Refractory Rhabdomyosarcoma,PEEL-224 (DRUG); Vincristine (DRUG); Temozolomide (TMZ) (DRUG),249332,Vincrex,Refractory Solid Tumors; Relapsed Solid Tumors; Relapsed Neuroblastoma; Refractory Neuroblastoma; Relapsed Rhabdomyosarcoma; Refractory Rhabdomyosarcoma,CNS/Brain,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10203,NCT00002489,Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors,COMPLETED,PHASE2,Extragonadal Germ Cell Tumor; Ovarian Cancer,dactinomycin (BIOLOGICAL); filgrastim (BIOLOGICAL); carboplatin (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); leucovorin calcium (DRUG); methotrexate (DRUG); vincristine sulfate (DRUG); conventional surgery (PROCEDURE),249332,Vincrex,Extragonadal Germ Cell Tumor; Ovarian Cancer,Ovary/Fallopian Tube,vincristine,,inhibitor/antagonist,Microtubule inhibitor,yes,yes,Used in chemotherapy for various cancers.,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,1.01,262.0 +10204,NCT05245968,A Study of Pimitespib in Combination with Imatinib in Patients with GIST (CHAPTER-GIST-101),RECRUITING,PHASE1,Gastrointestinal Stromal Tumors,Pimitespib (DRUG); Imatinib (DRUG); Sunitinib (DRUG),67501411,Jeselhy,Gastrointestinal Stromal Tumors,Bowel,Pimitespib,"HSP90AA1, HSP90AB1",inhibitor/antagonist,unclear,no,yes,Investigated in trials for cancer; not approved for human use yet.,CCC1=C(C=CC(=C1)C(=O)N)N2C3=NC=CC(=C3C(=N2)C(C)C)N4C=C(N=C4)C5=CN(N=C5)C,1.0,27.0 +10205,NCT04999761,AB122 Platform Study,RECRUITING,PHASE1,Advanced or Metastatic Solid Tumor; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Non-small Cell Lung Cancer; Gastric Cancer; Alveolar Soft Part Sarcoma; Esophageal Cancer; Head and Neck Cancer; Biliary Tract Cancer,AB122 (DRUG); AB122 (DRUG); TAS-116 (DRUG); AB122 (DRUG); TAS-116 (DRUG); AB122 (DRUG); TAS-116 (DRUG); AB122 (DRUG); TAS-120 (DRUG); AB122 (DRUG); TAS-115 (DRUG); AB122 (DRUG); TAS-115 (DRUG); AB122 (DRUG); TAS-102 (DRUG); Ramucirumab (DRUG); AB122 (DRUG); TAS-102 (DRUG); Bevacizumab (DRUG); AB122 (DRUG); AB122 (DRUG); TAS-120 (DRUG); Fluorouracil (DRUG); Cisplatin (DRUG); AB122 (DRUG); TAS-120 (DRUG); AB154 (DRUG); AB122 (DRUG); TAS-120 (DRUG); Fluorouracil (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); AB122 (DRUG); TAS-120 (DRUG); AB154 (DRUG); AB122 (DRUG); TAS-120 (DRUG); Carboplatin (DRUG); nab-Paclitaxel (DRUG); AB122 (DRUG); TAS-120 (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG); AB122 (DRUG); TAS-120 (DRUG); nab-Paclitaxel (DRUG); Gemcitabine (DRUG),67501411,Jeselhy,Advanced or Metastatic Solid Tumor; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Non-small Cell Lung Cancer; Gastric Cancer; Alveolar Soft Part Sarcoma; Esophageal Cancer; Head and Neck Cancer; Biliary Tract Cancer,Bowel,Pimitespib,"HSP90AA1, HSP90AB1",inhibitor/antagonist,unclear,no,yes,Investigated in trials for cancer; not approved for human use yet.,CCC1=C(C=CC(=C1)C(=O)N)N2C3=NC=CC(=C3C(=N2)C(C)C)N4C=C(N=C4)C5=CN(N=C5)C,1.0,27.0 +10206,NCT05655598,TAS-116 Plus Palbociclib in Breast and Rb-null Cancer,WITHDRAWN,PHASE1,Advanced Breast Cancer; Treatment-Refractory Solid Tumors; Retinoblastoma Deficiency; SCLC; Soft Tissue Sarcoma; Endometrial Cancer; Bladder Cancer,Palbociclib Oral Product (DRUG); TAS-116 (DRUG); TAS-116 (DRUG); TAS-116 (DRUG),67501411,Jeselhy,Advanced Breast Cancer; Treatment-Refractory Solid Tumors; Retinoblastoma Deficiency; SCLC; Soft Tissue Sarcoma; Endometrial Cancer; Bladder Cancer,Uterus,Pimitespib,"HSP90AA1, HSP90AB1",inhibitor/antagonist,unclear,no,yes,Investigated in trials for cancer; not approved for human use yet.,CCC1=C(C=CC(=C1)C(=O)N)N2C3=NC=CC(=C3C(=N2)C(C)C)N4C=C(N=C4)C5=CN(N=C5)C,1.0,27.0 +10207,NCT06640166,Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.,RECRUITING,PHASE2,Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumor; Colorectal Adenocarcinoma; Colorectal Cancer (CRC); Colorectal Cancer; Colon Cancer; Colon Adenocarcinoma; Colon Carcinoma; Colon Neoplasm,encorafenib + cetuximab + FOLFIRI (DRUG),60838,Biotecan,Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumor; Colorectal Adenocarcinoma; Colorectal Cancer (CRC); Colorectal Cancer; Colon Cancer; Colon Adenocarcinoma; Colon Carcinoma; Colon Neoplasm,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10208,NCT04842526,"Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study",UNKNOWN,PHASE2,Refractory or Recurrent Neuroblastoma in Children,Anlotinib and irinotecan combined with temozolomide (DRUG),60838,Biotecan,Refractory or Recurrent Neuroblastoma in Children,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10209,NCT00493857,Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer,TERMINATED,PHASE2,Colorectal Cancer,Nimotuzumab Humanized Monoclonal Antibody (DRUG); Nimotuzumab (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10210,NCT00033657,Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer,COMPLETED,PHASE2,Esophageal Cancer; Gastric Cancer,cisplatin (DRUG); irinotecan hydrochloride (DRUG); paclitaxel (DRUG); conventional surgery (PROCEDURE); radiation therapy (RADIATION),60838,Biotecan,Esophageal and Gastric Cancer,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10211,NCT06208657,Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer,RECRUITING,PHASE1,Childhood Cancer; Childhood Solid Tumor; Childhood Brain Tumor; Recurrent Cancer; Refractory Cancer,"Paxalisib, Irinotecan, Temozolomide (DRUG)",60838,Biotecan,Childhood Cancer; Childhood Solid Tumor; Childhood Brain Tumor; Recurrent Cancer; Refractory Cancer,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10212,NCT02624726,Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,5 Fluorouracil (DRUG); Leucovorin (DRUG); Irinotecan (DRUG); Aflibercept (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10213,NCT04617457,Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas,RECRUITING,PHASE2,Pancreatic Cancer; Metastasis; Surgery; Oligometastatic Disease,"nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA) (DRUG)",60838,Biotecan,Pancreatic Cancer; Metastasis; Surgery; Oligometastatic Disease,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10214,NCT03563248,Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Pancreatic Cancer,FOLFIRINOX (DRUG); Losartan (DRUG); Nivolumab (DRUG); SBRT (RADIATION); Surgery (PROCEDURE),60838,Biotecan,Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10215,NCT01312857,"Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer",COMPLETED,PHASE2,Metastatic Colorectal Cancer,panitumumab (DRUG); Randomization to No Panitumumab (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10216,NCT01394120,Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer,UNKNOWN,PHASE2,"Carcinoma, Pancreatic Ductal",Targeted Therapy Tailored Treatment (DRUG); Standard Chemotherapy (DRUG),60838,Biotecan,Pancreatic Ductal Carcinoma,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10217,NCT02047474,Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Stage I Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,oxaliplatin (DRUG); leucovorin calcium (DRUG); irinotecan hydrochloride (DRUG); fluorouracil (DRUG); therapeutic conventional surgery (PROCEDURE); laboratory biomarker analysis (OTHER),60838,Biotecan,Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10218,NCT00911820,"Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer",COMPLETED,PHASE2,Esophageal Cancer; Gastric Cancer; Stomach Cancer,Bevacizumab (DRUG); Cisplatin (DRUG); Irinotecan (DRUG); Docetaxel (DEVICE),60838,Biotecan,Esophageal Cancer; Gastric Cancer; Stomach Cancer,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10219,NCT05018182,FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer,UNKNOWN,PHASE2,High-risk Locally Advanced Colorectal Cancer; Neoadjuvant Chemotherapy; FOLFOXIRI Regimen,Oxaliplatin (DRUG); Irinotecan (DRUG); Folinic Acid (DRUG); 5FU (DRUG); Capecitabine (DRUG),60838,Biotecan,High-risk Locally Advanced Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10220,NCT01963182,Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer,COMPLETED,PHASE2,First Line Metastatic Colorectal Cancer,Irinotecan (DRUG),60838,Biotecan,First Line Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10221,NCT00079274,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,COMPLETED,PHASE3,Adenocarcinoma of the Colon; Stage III Colon Cancer,irinotecan hydrochloride (DRUG); oxaliplatin (DRUG); leucovorin calcium (DRUG); fluorouracil (DRUG); cetuximab (BIOLOGICAL); Locally Directed Therapy (DRUG),60838,Biotecan,Colon Adenocarcinoma,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10222,NCT03161574,FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for Circumferential Radial Margin (CRM) Positive Rectal Cancer,WITHDRAWN,PHASE2,Rectal Cancer,FOLFOXIRI (DRUG),60838,Biotecan,Rectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10223,NCT05103020,Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks (DRUG); IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10224,NCT01925274,A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer,TERMINATED,PHASE2,Metastatic Colorectal Cancer,PF-05212384 (DRUG); irinotecan (DRUG); Cetuximab (DRUG); Irinotecan (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10225,NCT03616574,First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors,COMPLETED,PHASE1,Advanced or Metastatic Solid Tumors; Advanced or Metastatic Colorectal Cancer (mCRC),CA102N (DRUG); LONSURF (DRUG),60838,Biotecan,Advanced or Metastatic Solid Tumors; Advanced or Metastatic Colorectal Cancer (mCRC),Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10226,NCT00320320,Irinotecan Discontinuation and Reintroduction for Advanced Colorectal Cancer,TERMINATED,PHASE2,Colorectal Neoplasms; Metastases,Irinotecan (DRUG),60838,Biotecan,Colorectal Neoplasms; Metastases,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10227,NCT06625320,Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),RECRUITING,PHASE3,Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma,RMC-6236 (DRUG); Gemcitabine (DRUG); nab-paclitaxel (DRUG); Irinotecan (DRUG); Liposomal irinotecan (DRUG); 5-fluorouracil (DRUG); leucovorin (DRUG); Oxaliplatin (DRUG),60838,Biotecan,Pancreatic Ductal Adenocarcinoma,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10228,NCT01237665,"IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer",UNKNOWN,PHASE2,Rectal Cancer,IXO regimen (DRUG),60838,Biotecan,Rectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10229,NCT01640782,Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach,COMPLETED,PHASE3,Adenocarcinoma of the Stomach; Adenocarcinoma of the Gastroesophageal Junction,"Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin (DRUG); Leucovorin, 5-Fluorouracil (DRUG)",60838,Biotecan,Gastric Adenocarcinoma,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10230,NCT01379482,Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer,COMPLETED,PHASE2,Peritoneal Carcinomatosis; Gastric Cancer,Multimodal treatment (DRUG),60838,Biotecan,Gastric Cancer,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10231,NCT00766220,Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver,WITHDRAWN,PHASE2,Colon Cancer; Colorectal Cancer,SIR-spheres Agent Administration (DRUG); Cetuximab (DRUG); Irinotecan (DRUG),60838,Biotecan,Colon Cancer; Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10232,NCT02573220,Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer,WITHDRAWN,PHASE1,Stage IVA Colorectal Cancer; Stage IVB Colorectal Cancer,Cetuximab (BIOLOGICAL); Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Leucovorin Calcium (DRUG),60838,Biotecan,Stage IV Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10233,NCT05585320,A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors,RECRUITING,PHASE1,Advanced Solid Tumor; Pancreatic Adenocarcinoma; Malignant Melanoma (Cutaneous); Non-small Cell Lung Cancer (NSCLC),IMM-1-104 Monotherapy (Treatment Group A) (DRUG); IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B) (DRUG); IMM-1-104 + modified FOLFIRINOX (Treatment Group C) (DRUG); IMM-1-104 + dabrafenib (Treatment Group D) (DRUG); IMM-1-104 + pembrolizumab (Treatment Group E) (DRUG),60838,Biotecan,Advanced Solid Tumor; Pancreatic Adenocarcinoma; Malignant Melanoma (Cutaneous); Non-small Cell Lung Cancer (NSCLC),Skin,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10234,NCT01219920,FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer,COMPLETED,PHASE3,Metastatic Colorectal Cancer,FOLFIRI (DRUG); FOLFOXIRI (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10235,NCT06304974,A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma,RECRUITING,PHASE3,Esophageal Squamous Cell Carcinoma,BL-B01D1 (DRUG); Irinotecan (DRUG); paclitaxel (DRUG); docetaxel (DRUG),60838,Biotecan,Esophageal Squamous Cell Carcinoma,Skin,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10236,NCT00115765,PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study,COMPLETED,PHASE3,Colorectal Cancer,Oxaliplatin Based Chemotherapy (DRUG); Panitumumab (DRUG); Irinotecan Based Chemotherapy (DRUG); Bevacizumab (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10237,NCT03500874,Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM,TERMINATED,PHASE3,Colorectal Cancer; Liver Metastases; HAI,FUDR (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); 5FU (DRUG); Irinotecan (DRUG),60838,Biotecan,Colorectal Cancer with Liver Metastases,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10238,NCT00062374,Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction,COMPLETED,PHASE2,Gastric Adenocarcinoma; Stage II Gastric Cancer; Stage III Gastric Cancer; Stage IV Gastric Cancer,Cisplatin (DRUG); Computed Tomography (PROCEDURE); Fludeoxyglucose F-18 (RADIATION); Fluorothymidine F-18 (OTHER); Irinotecan Hydrochloride (DRUG); Positron Emission Tomography (PROCEDURE); Therapeutic Conventional Surgery (PROCEDURE),60838,Biotecan,Gastric Adenocarcinoma; Stage II Gastric Cancer; Stage III Gastric Cancer; Stage IV Gastric Cancer,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10239,NCT02620865,BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer,COMPLETED,PHASE1,Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Aldesleukin (BIOLOGICAL); Antibody Therapy (BIOLOGICAL); Fluorouracil (DRUG); Gemcitabine Hydrochloride (DRUG); Irinotecan Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Leucovorin Calcium (DRUG); Oxaliplatin (DRUG); Paclitaxel Albumin-Stabilized Nanoparticle Formulation (DRUG); Sargramostim (BIOLOGICAL),60838,Biotecan,Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10240,NCT00066274,Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,FOLFIRI regimen (DRUG); FOLFOX regimen (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10241,NCT00176774,"Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma",COMPLETED,PHASE2,Colorectal Carcinoma,Irinotecan (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG); Tetrathiomolybdate (DRUG),60838,Biotecan,Colorectal Carcinoma,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10242,NCT00522665,Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,Irinotecan (DRUG); Cetuximab (BIOLOGICAL); RAD001 (BIOLOGICAL),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10243,NCT03186326,Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer,UNKNOWN,PHASE2,Metastatic Colorectal Cancer; MSI,FOLFOX regimen (DRUG); FOLFIRI Protocol (DRUG); Avelumab (DRUG); Panitumumab (DRUG); Cetuximab (DRUG); Bevacizumab (DRUG); Aflibercept (DRUG),60838,Biotecan,Metastatic Colorectal Cancer; MSI,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10244,NCT00513266,Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery,UNKNOWN,PHASE2,Colorectal Cancer; Metastatic Cancer,bevacizumab (BIOLOGICAL); cetuximab (BIOLOGICAL); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG); laboratory biomarker analysis (OTHER); adjuvant therapy (PROCEDURE); biopsy (PROCEDURE); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE),60838,Biotecan,Colorectal Cancer; Metastatic Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10245,NCT04423965,A Trial of Neoadjuvant mFOLFOXIRI Versus CRT in the EMVI Positive LARC,UNKNOWN,PHASE2,Locally Advanced Rectal Cancer,mFOLFOXIRI (DRUG); Chemoradiotherapy (COMBINATION_PRODUCT),60838,Biotecan,Rectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10246,NCT04908566,Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma,RECRUITING,PHASE2,Locally Advanced Gastric Adenocarcinoma,PD-1 antibody combined with FOLFIRINOX regimen (DRUG); PD-1 antibody combined with SOX program (DRUG),60838,Biotecan,Locally Advanced Gastric Adenocarcinoma,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10247,NCT04560166,Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma,TERMINATED,PHASE2,Neuroblastoma Recurrent,Naxitamab and GM-CSF in combination with irinotecan and temozolomide (DRUG),60838,Biotecan,Neuroblastoma Recurrent,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10248,NCT05718466,Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy,COMPLETED,PHASE3,Recurrent or Progressive Glioblastoma,Bevacizumab (DRUG); Chemotherapy (DRUG); Fractionated radiosurgery (RADIATION),60838,Biotecan,Recurrent or Progressive Glioblastoma,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10249,NCT05277766,Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis from Gastrointestinal Cancer,RECRUITING,PHASE1,Peritoneal Carcinomatosis; Peritoneal Metastases; Colorectal Cancer; Small Bowel Cancer; Appendix Cancer; Gastric Cancer; Pancreatic Cancer; Bile Duct Cancer,PIPAC with Nal-IRI (DRUG),60838,Biotecan,Peritoneal Carcinomatosis; Peritoneal Metastases; Colorectal Cancer; Small Bowel Cancer; Appendix Cancer; Gastric Cancer; Pancreatic Cancer; Bile Duct Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10250,NCT06467565,NALIRIFOX as Induction Therapy in LAPC,RECRUITING,PHASE2,Pancreatic Ductal Adenocarcinoma,Liposomal irinotecan (DRUG),60838,Biotecan,Pancreatic Ductal Adenocarcinoma,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10251,NCT05255666,Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM),WITHDRAWN,PHASE2,Triple Negative Breast Cancer; Brain Metastases,Pembrolizumab (DRUG); Liposomal Irinotecan (DRUG),60838,Biotecan,Triple Negative Breast Cancer; Brain Metastases,Breast,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10252,NCT06586866,JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases,NOT_YET_RECRUITING,PHASE2,Triple Negative Breast Cancer (TNBC); Brain Metastasases,JK-1201I (DRUG),60838,Biotecan,Triple Negative Breast Cancer (TNBC); Brain Metastasases,Breast,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10253,NCT00073866,Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer,celecoxib (DRUG); docetaxel (DRUG); irinotecan hydrochloride (DRUG),60838,Biotecan,Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10254,NCT04233866,"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Fluorouracil (DRUG); Gemcitabine (DRUG); Gemcitabine Hydrochloride (DRUG); Leucovorin (DRUG); Leucovorin Calcium (DRUG); Liposomal Irinotecan (DRUG); Nab-paclitaxel (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),60838,Biotecan,Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10255,NCT06766266,Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment,RECRUITING,PHASE1,Non-Muscle Invasive Bladder Urothelial Carcinoma,Irinotecan liposome II combination therapy regimen (DRUG); Irinotecan liposome II combination therapy regimen (DRUG),60838,Biotecan,Non-Muscle Invasive Bladder Urothelial Carcinoma,Bladder/Urinary Tract,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10256,NCT00614965,Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV,COMPLETED,PHASE2,Non Small Cell Lung Cancer,Irinotecan (DRUG); Cisplatin (DRUG); Pemetrexed (DRUG),60838,Biotecan,Non Small Cell Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10257,NCT02626520,Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla,TERMINATED,PHASE2,Ductal Adenocarcinoma of Pancreas; Adenocarcinoma of Ampulla,Gemcitabine and nanoparticle albumin bound paclitaxel (DRUG); 5-fluorouracil and irinotecan (DRUG); Preoperative chemoradiation (RADIATION); Definitive resection (PROCEDURE),60838,Biotecan,Ductal Adenocarcinoma of Pancreas; Adenocarcinoma of Ampulla,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10258,NCT00012220,Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas,COMPLETED,PHASE2,Pancreatic Cancer,cisplatin (DRUG); docetaxel (DRUG); gemcitabine hydrochloride (DRUG); irinotecan hydrochloride (DRUG),60838,Biotecan,Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10259,NCT02753127,A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer,COMPLETED,PHASE3,Colorectal Cancer,Napabucasin (DRUG); Fluorouracil (DRUG); Leucovorin (DRUG); Irinotecan (DRUG); Bevacizumab (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10260,NCT01044420,mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial,UNKNOWN,PHASE2,Advanced Esophageal Carcinoma,mFOLFIRI (DRUG),60838,Biotecan,Advanced Esophageal Carcinoma,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10261,NCT00449020,"Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer",COMPLETED,PHASE2,Lung Cancer,Carboplatin (DRUG); Docetaxel (DRUG); irinotecan hydrochloride (DRUG); radiation therapy (RADIATION),60838,Biotecan,Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10262,NCT03454620,"A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy",COMPLETED,PHASE1,Metastatic Colorectal Cancer; Solid Tumor,irinotecan (DRUG); FOLFIRI (DRUG),60838,Biotecan,Metastatic Colorectal Cancer; Solid Tumor,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10263,NCT02314182,GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis,COMPLETED,PHASE3,Rectal Adenocarcinoma,"Primary tumor resection + chemotherapy (PROCEDURE); Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab (DRUG)",60838,Biotecan,Rectal Adenocarcinoma,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10264,NCT00422773,Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer,COMPLETED,PHASE1,Metastatic Colorectal Cancer,Cetuximab (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10265,NCT04215731,Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer,RECRUITING,PHASE3,Rectal Cancer,Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab (DRUG); Restaging (PROCEDURE); Concomitant Chemoradiotherapy (RADIATION); Surgery (PROCEDURE); Chemoradiotherapy (only when patients with MRF involved or ycT4a/b by restaging) (RADIATION); Induction chemotherpay with FOLFOX (DRUG),60838,Biotecan,Rectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10266,NCT00590031,Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.,COMPLETED,PHASE2,Esophageal Carcinoma,Cisplatin (DRUG); Irinotecan (DRUG); External Beam Radiation Therapy (RADIATION),60838,Biotecan,Esophageal Carcinoma,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10267,NCT06199973,"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan",RECRUITING,PHASE3,Advanced Colorectal Cancer,"SHR-A1811 (DRUG); TAS-102, Regorafenib , Fruquintinib (DRUG)",60838,Biotecan,Advanced Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10268,NCT05223673,Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer,TERMINATED,PHASE3,Metastatic Colorectal Cancer,Futuximab/modotuximab (BIOLOGICAL); Trifluridine/Tipiracil (DRUG); Trifluridine/Tipiracil (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10269,NCT00625573,Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01),COMPLETED,PHASE2,Colorectal Cancer,Abraxane (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10270,NCT04790448,Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer Metastatic,Cetuximab (DRUG); Irinotecan (DRUG); Vemurafenib (DRUG),60838,Biotecan,Colorectal Cancer Metastatic,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10271,NCT02350530,FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,FOLFOXIRI + Bevacizumab (DRUG); FOLFOXIRI (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10272,NCT01321957,Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,"Oxaliplatin, 5FU/LV, Bevacizumab (DRUG); 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan (DRUG)",60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10273,NCT06941857,NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer,NOT_YET_RECRUITING,PHASE2,Pancreatic Cancer,Oxaliplatin (DRUG); Irinotecan (DRUG); Folinic Acid (DRUG); 5-Fluorouracil (5-FU) (DRUG); NC410 (DRUG); Nivolumab (DRUG); Ipilimumab (DRUG),60838,Biotecan,Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10274,NCT01523457,Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer,COMPLETED,PHASE2,Metastatic Pancreatic Cancer; Pancreatic Cancer,Folfirinox (DRUG),60838,Biotecan,Metastatic Pancreatic Cancer; Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10275,NCT00891930,Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Panitumumab (BIOLOGICAL); Ganitumab (BIOLOGICAL); Irinotecan (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10276,NCT01271582,Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients,UNKNOWN,PHASE4,Stage IV Colorectal Cancer; Gastric Cancer,"Irinotecan, 5FU, leucovorin (DRUG)",60838,Biotecan,Advanced Gastrointestinal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10277,NCT05818982,To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC,RECRUITING,PHASE2,Advanced Esophageal Squamous Cell Carcinoma,Afatinib (DRUG); Irinotecan (DRUG),60838,Biotecan,Advanced Esophageal Squamous Cell Carcinoma,Skin,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10278,NCT00087282,Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer,COMPLETED,PHASE2,Liver Cancer,alvocidib (DRUG); irinotecan hydrochloride (DRUG),60838,Biotecan,Liver Cancer,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10279,NCT00934882,"Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI",COMPLETED,PHASE1,Colorectal Neoplasms,Regorafenib (BAY73-4506) (DRUG),60838,Biotecan,Colorectal Neoplasms,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10280,NCT03099382,Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer,COMPLETED,PHASE3,Esophageal Carcinoma,camrelizumab (BIOLOGICAL); Docetaxel (DRUG); Irinotecan (DRUG),60838,Biotecan,Esophageal Carcinoma,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10281,NCT00463073,"Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas",COMPLETED,PHASE2,Malignant Gliomas,Cetuximab (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG),60838,Biotecan,Malignant Gliomas,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10282,NCT00950820,Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer,TERMINATED,PHASE2,Colorectal Neoplasms,"Oxaliplatin, Capecitabine, Panitumumab (DRUG); Oxaliplatin, Capecitabine (DRUG)",60838,Biotecan,Colorectal Neoplasms,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10283,NCT00717990,"Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment",TERMINATED,PHASE2,Metastatic Colorectal Cancer,Capecitabine (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10284,NCT01133990,FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer,TERMINATED,PHASE1,Colorectal Cancer,FOLFIRI (DRUG); E7820 (DRUG); Bevacizumab (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10285,NCT00642603,A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer,TERMINATED,PHASE2,Colorectal Cancer,capecitabine [Xeloda] (DRUG); capecitabine [Xeloda] (DRUG); bevacizumab [Avastin] (DRUG); oxaliplatin (DRUG); irinotecan (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10286,NCT00821990,Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer,COMPLETED,PHASE3,Advanced Gastric Cancer,Chemotherapy (DRUG); Best supportive care (OTHER),60838,Biotecan,Advanced Gastric Cancer,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10287,NCT01703390,Biomarker Directed Treatment in Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,FOLFIRI + Cetuximab (DRUG); modifiedFOLFOX6 + Cetuximab (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10288,NCT06700603,Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer,NOT_YET_RECRUITING,PHASE2,Pancreatic Cancer,Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate (DRUG),60838,Biotecan,Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10289,NCT04714190,A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression,RECRUITING,PHASE3,Gastric Cancer; HER2 Overexpressing Gastric Carcinoma,RC48-ADC (DRUG); Paclitaxel injection (DRUG); Irinotecan Hydrochloride Injection (DRUG); Apatinib Mesylate Tablets (DRUG),60838,Biotecan,Gastric Cancer; HER2 Overexpressing Gastric Carcinoma,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10290,NCT02173990,Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).,TERMINATED,PHASE2,Metastatic Colorectal Cancer,Aflibercept-FOLFIRI (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10291,NCT01862003,Phase I/II Trial of Antagonism of HER in GI Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer; Recurrent Colorectal Cancer,AZD8931 (DRUG); Irinotecan (DRUG); Folinic Acid (DRUG); Fluorouracil (DRUG); Fluorouracil (DRUG),60838,Biotecan,Metastatic Colorectal Cancer; Recurrent Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10292,NCT03562390,Irinotecan for Advanced and Metastatic Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Irinotecan (DRUG),60838,Biotecan,Breast Cancer,Breast,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10293,NCT06405490,NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC,RECRUITING,PHASE2,Nanoliposomal Irinotecan; Cadonilimab; Oxaliplatin; Capecitabine; First-Line; Advanced Cancer; Pancreatic Adenocarcinoma; Drug Use,Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab (DRUG),60838,Biotecan,Pancreatic Adenocarcinoma Treatment,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10294,NCT05634590,The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer,NOT_YET_RECRUITING,PHASE2,Metastatic Colorectal Cancer,Fruquintinib (DRUG); FOLFIRI (DRUG); mFOLFOX6 (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10295,NCT06928584,Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer,RECRUITING,PHASE2,Locally Recurrent Rectal Cancer,Conventional Radiotherapy (RADIATION); Capecitabine (DRUG); 5-fluorouracil (DRUG); folinic acid (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG); Cetuximab (DRUG); Bevacizumab (DRUG); Hypofractionated radiotherapy (RADIATION); PD-1 antibody (DRUG),60838,Biotecan,Locally Recurrent Rectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10296,NCT04224402,Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.,COMPLETED,PHASE2,Pancreatic Cancer Resectable,mFOLFORINOX (DRUG),60838,Biotecan,Pancreatic Cancer Resectable,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10297,NCT01070290,A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen,WITHDRAWN,PHASE2,Gastric Cancer,"ARQ 197 (DRUG); Oxaliplatin, capecitabine or irinotecan (DRUG)",60838,Biotecan,Gastric Cancer,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10298,NCT01588990,A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer,COMPLETED,PHASE4,Colorectal Neoplasms,Oxaliplatin (DRUG); Capecitabine (DRUG); Bevacizumab (DRUG); Leucovorin (DRUG); 5-Fluouracil (DRUG); Irinotecan (DRUG),60838,Biotecan,Colorectal Neoplasms,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10299,NCT05379790,Concomitant Intraperitoneal and Systemic Chemotherapy in Patients with Extensive Peritoneal Carcinomatosis of Gastric Origin,COMPLETED,PHASE1,Gastric Cancer; Peritoneal Metastases,Irinotecan (DRUG); CAPOX (DRUG),60838,Biotecan,Gastric Cancer with Peritoneal Metastases,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10300,NCT01928290,"Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer",COMPLETED,PHASE2,Stomach Neoplasms; Esophageal Neoplasms,Irinotecan (DRUG); Trastuzumab (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); Fluorouracil (DRUG),60838,Biotecan,Gastrointestinal Neoplasms,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10301,NCT00569790,"Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer",COMPLETED,PHASE2,Colorectal Cancer,"S-1, Irinotecan, Bevacizumab (DRUG)",60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10302,NCT00463203,Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy,COMPLETED,PHASE2,Brain Neoplasms; Glioma,Bevacizumab (DRUG); Irinotecan (DRUG),60838,Biotecan,Brain Neoplasms; Glioma,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10303,NCT00940303,OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,5-FU (DRUG); bevacizumab [Avastin] (DRUG); irinotecan (DRUG); leucovorin (DRUG); oxaliplatin (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10304,NCT04380103,A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer,UNKNOWN,PHASE1,Metastatic Cancer; Colorectal Cancer; Colorectal Adenocarcinoma,XELOXIRI/Bevacizumab (DRUG),60838,Biotecan,Metastatic Cancer; Colorectal Cancer; Colorectal Adenocarcinoma,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10305,NCT05400603,Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma,RECRUITING,PHASE1,Neuroblastoma; Refractory Neuroblastoma; Relapsed Neuroblastoma; Relapsed Osteosarcoma; Refractory Osteosarcoma,"Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate (COMBINATION_PRODUCT)",60838,Biotecan,Neuroblastoma; Refractory Neuroblastoma; Relapsed Neuroblastoma; Relapsed Osteosarcoma; Refractory Osteosarcoma,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10306,NCT05229003,Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC,RECRUITING,PHASE2,Metastatic Colorectal Cancer,Anlotinib (DRUG); Penpulimab (DRUG); Irinotecan (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10307,NCT00460603,Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE1,Colorectal Neoplasms,bevacizumab (DRUG); AG-013726 (DRUG); AG-013736 (axitinib) (DRUG),60838,Biotecan,Colorectal Neoplasms,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10308,NCT00006103,Combination Chemotherapy in Treating Patients With Colorectal Cancer,COMPLETED,PHASE3,Colorectal Cancer,fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10309,NCT00318903,Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer,COMPLETED,PHASE2,Esophageal Cancer; Cancer of the Esophagus; Esophagus Cancer; Esophageal Neoplasm; Cancer of Esophagus,Irinotecan (drug) (DRUG); Taxotere (drug) (DRUG); Radiotherapy (procedure) (PROCEDURE); Esophagectomy (procedure) (PROCEDURE),60838,Biotecan,Esophageal Cancer; Cancer of the Esophagus; Esophagus Cancer; Esophageal Neoplasm; Cancer of Esophagus,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10310,NCT06434090,Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer,NOT_YET_RECRUITING,PHASE1,Colorectal Cancer,Liposomal irinotecan (DRUG); Bevacizumab (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10311,NCT02453490,Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis,TERMINATED,PHASE3,Colorectal Cancer; Liver Metastasis,Raltitrexed-based chemotherapy (DRUG); Raltitrexed-based chemotherapy (DRUG); 5-fluorouracil-based chemotherapy (DRUG); 5-fluorouracil-based chemotherapy (DRUG),60838,Biotecan,Colorectal Cancer; Liver Metastasis,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10312,NCT01704703,"Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques",COMPLETED,PHASE2,Stage IV Colorectal Cancer,panitumumab (DRUG); FOLFIRI (DRUG),60838,Biotecan,Stage IV Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10313,NCT01383343,"Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer",COMPLETED,PHASE1,Recurrent Colon Carcinoma; Recurrent Rectal Carcinoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,Bevacizumab (BIOLOGICAL); Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Leucovorin Calcium (DRUG); Sorafenib Tosylate (DRUG),60838,Biotecan,Recurrent Colon Carcinoma; Recurrent Rectal Carcinoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10314,NCT00165490,"Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer",COMPLETED,PHASE2,Adenocarcinoma of Esophagus; Squamous Cell Carcinoma of Esophagus,Cetuximab (DRUG); Cisplatin (DRUG); Irinotecan (DRUG); Radiation therapy (DEVICE); Surgery (PROCEDURE),60838,Biotecan,Adenocarcinoma of Esophagus; Squamous Cell Carcinoma of Esophagus,Skin,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10315,NCT05677490,"mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma",RECRUITING,PHASE3,Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Metastatic Esophageal Adenocarcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Unresectable Esophageal Adenocarcinoma; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma,Fluorouracil (DRUG); Leucovorin Calcium (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG); Nivolumab (BIOLOGICAL); Magnetic Resonance Imaging (PROCEDURE); Computed Tomography (PROCEDURE); Biospecimen Collection (PROCEDURE); Questionnaire Administration (OTHER),60838,Biotecan,Advanced Gastroesophageal Adenocarcinoma,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10316,NCT01315990,FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema,UNKNOWN,PHASE4,Colorectal Cancer Metastatic,FOLFIRI + Cetuximab (DRUG),60838,Biotecan,Colorectal Cancer Metastatic,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10317,NCT03329690,DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01],COMPLETED,PHASE2,"Neoplasm, Gastrointestinal",DS-8201a (DRUG); Physician's Choice (DRUG),60838,Biotecan,Gastrointestinal Neoplasm,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10318,NCT05750290,CKD-702 Plus Irinotecan in Gastric Cancer,RECRUITING,PHASE2,Gastric Cancer,CKD-702 in combination with irinotecan (DRUG),60838,Biotecan,Gastric Cancer,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10319,NCT04659421,Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas,COMPLETED,PHASE2,Low-grade Glioma; Pediatric Brain Tumor,combined therapy with rh-ES and CV (DRUG),60838,Biotecan,Pediatric Low-grade Glioma,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10320,NCT00953121,Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG),COMPLETED,PHASE2,Malignant Glioma,bevacizumab and CPT-11 and Carboplatin (DRUG),60838,Biotecan,Malignant Glioma,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10321,NCT06197438,Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer,NOT_YET_RECRUITING,PHASE2,Gastric Cancer,Tislelizumab (DRUG); Oxaliplatin (DRUG); Levo-Leucovorin (DRUG); 5-fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Paclitaxel (DRUG),60838,Biotecan,Gastric Cancer,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10322,NCT05381038,Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI,NOT_YET_RECRUITING,PHASE1,Solid Tumor; Gastrointestinal Cancer; Breast Cancer,QPOP (DEVICE); CURATE.AI (DEVICE); Azacitidine + docetaxel (DRUG); Azacitidine + paclitaxel (DRUG); Azacitidine + irinotecan (DRUG),60838,Biotecan,Solid Tumors and Gastrointestinal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10323,NCT00889343,Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer,TERMINATED,PHASE2,Colorectal Neoplasms,Sorafenib (DRUG); Placebo (DRUG); Oxaliplatin or Irinotecan (DRUG); Leucovorin (DRUG); 5-Fluorouracil (DRUG),60838,Biotecan,Colorectal Neoplasms,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10324,NCT05251038,Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer,WITHDRAWN,PHASE1,Pancreatic Cancer; Unresectable Pancreatic Cancer; Metastatic Pancreatic Cancer; KRAS P.G12C,Sotorasib (DRUG); Liposomal Irinotecan (nal-IRI) (DRUG); 5 Fluorouracil (5FU) (DRUG); Leucovorin (LV) (DRUG); Gemcitabine (GEM) (DRUG); Nab paclitaxel (DRUG),60838,Biotecan,Pancreatic Cancer; Unresectable Pancreatic Cancer; Metastatic Pancreatic Cancer; KRAS P.G12C,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10325,NCT00612638,Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas,COMPLETED,PHASE1,Glioblastoma; Gliosarcoma,"Temodar, O6-BG, and Irinotecan (DRUG)",60838,Biotecan,Glioblastoma,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10326,NCT01905150,"Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer",COMPLETED,PHASE2,Pancreatic Cancer,G-FLIP (DRUG); G-FLIP-DM (DRUG); Vitamin C (DIETARY_SUPPLEMENT),60838,Biotecan,Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10327,NCT00003950,"Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer",COMPLETED,PHASE2,Colorectal Cancer,cyclosporine (DRUG); CPT-11 (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10328,NCT06652412,CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC,NOT_YET_RECRUITING,PHASE2,Colon Cancer; Rectal Cancer,Ultrafractionated RT and CGA Guided systemic treatment. (DRUG); data prospectively collected (OTHER); Ultrafractionated Radiotherapy (RADIATION); Sintilimab (DRUG); Fluorouracil (DRUG); Raltitrexed (DRUG); Oxaliplatin (DRUG); Irinotecan (CPT-11) (DRUG),60838,Biotecan,Colon Cancer; Rectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10329,NCT03167112,A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer,UNKNOWN,PHASE2,Pancreatic Cancer,Oxaliplatin (DRUG); Irinotecan (DRUG); Leucovorin (DRUG); Fluorouracil (DRUG),60838,Biotecan,Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10330,NCT05990543,Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer,NOT_YET_RECRUITING,PHASE1,Recurrent or Metastatic Colorectal Cancer,Nelmastobart and Capecitabine (DRUG),60838,Biotecan,Recurrent or Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10331,NCT00540943,"Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer",COMPLETED,PHASE1,"Neoplasms, Colorectal",Pazopanib (DRUG); Cetuximab (DRUG); Irinotecan (DRUG),60838,Biotecan,"Neoplasms, Colorectal",Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10332,NCT03251612,Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer Metastatic,Based on sensitivity analysis (DRUG),60838,Biotecan,Colorectal Cancer Metastatic,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10333,NCT00027612,Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme,COMPLETED,PHASE1,Brain and Central Nervous System Tumors,carmustine (DRUG); irinotecan hydrochloride (DRUG); radiation therapy (RADIATION),60838,Biotecan,Brain and Central Nervous System Tumors,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10334,NCT03792269,Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC,UNKNOWN,PHASE2,Colorectal Cancer Metastatic; Chemotherapy Effect; Chemotherapeutic Toxicity,Irinotecan (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG),60838,Biotecan,Metastatic Colorectal Cancer with Chemotherapy Effects,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10335,NCT00003301,Irinotecan in Treating Patients With Recurrent Malignant Glioma,COMPLETED,PHASE1,Brain and Central Nervous System Tumors,irinotecan hydrochloride (DRUG),60838,Biotecan,Brain and Central Nervous System Tumors,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10336,NCT04985201,Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy,UNKNOWN,PHASE2,Small Cell Lung Cancer,Irinotecan (DRUG); Simvastatin (DRUG),60838,Biotecan,Small Cell Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10337,NCT06954246,A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer,NOT_YET_RECRUITING,PHASE3,Small Cell Lung Cancer Extensive Stage,MHB088C for Injection (DRUG); Topotecan (DRUG); Irinotecan (DRUG); Paclitaxel (DRUG),60838,Biotecan,Small Cell Lung Cancer Extensive Stage,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10338,NCT06838546,"A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer",NOT_YET_RECRUITING,PHASE2,Advanced Colorectal Cancer,B1962 (DRUG),60838,Biotecan,Advanced Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10339,NCT00039468,Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy,COMPLETED,PHASE2,Brain and Central Nervous System Tumors,irinotecan hydrochloride (DRUG); thalidomide (DRUG),60838,Biotecan,Brain and Central Nervous System Tumors,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10340,NCT05253846,Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29,ACTIVE_NOT_RECRUITING,PHASE2,Locally Advanced Rectal Cancer,Irinotecan (DRUG); Oxaliplatin (DRUG); Lederfolin (DRUG); 5-Fluorouracil (DRUG); Short-course radiotherapy (RADIATION); TME (PROCEDURE),60838,Biotecan,Rectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10341,NCT00499369,Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy,TERMINATED,PHASE3,Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); fluorouracil (DRUG); cetuximab (BIOLOGICAL); bevacizumab (BIOLOGICAL),60838,Biotecan,Advanced Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10342,NCT03464968,mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line,COMPLETED,PHASE2,Biliary Cancer Metastatic,"Oxaliplatin,5FU, leucovorin (DRUG); irinotecan,5FU, leucovorin (DRUG)",60838,Biotecan,Metastatic Biliary Cancer,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10343,NCT00780169,Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer,COMPLETED,PHASE1,Metastatic Colorectal Cancer,sorafenib + FOLFIRI (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10344,NCT04205968,Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers,RECRUITING,PHASE2,Metastatic Small Intestinal Adenocarcinoma; Stage III Small Intestinal Adenocarcinoma AJCC v8; Stage IIIA Small Intestinal Adenocarcinoma AJCC v8; Stage IIIB Small Intestinal Adenocarcinoma AJCC v8; Stage IV Small Intestinal Adenocarcinoma AJCC v8,Fluorouracil (DRUG); Irinotecan (DRUG); Irinotecan Hydrochloride (DRUG); Leucovorin (DRUG); Leucovorin Calcium (DRUG); Paclitaxel (DRUG); Ramucirumab (BIOLOGICAL),60838,Biotecan,Small Intestinal Adenocarcinoma,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10345,NCT00114946,A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer,TERMINATED,PHASE4,Colorectal Cancer,Avastin (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10346,NCT02060669,Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer,TERMINATED,PHASE3,Metastatic Colorectal Cancer,Xeloda (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10347,NCT05427669,Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD),NOT_YET_RECRUITING,PHASE3,Colorectal Cancer,mFOLFOXIRI (DRUG); mFOLFOX6 (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10348,NCT00025168,Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,gemcitabine hydrochloride (DRUG); irinotecan hydrochloride (DRUG); radiation therapy (RADIATION),60838,Biotecan,Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10349,NCT03693846,Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors,TERMINATED,PHASE2,Mucinous Adenocarcinoma of the Colon; Mucinous Adenocarcinoma of the Rectum,Nivolumab (DRUG); Ipilimumab (DRUG),60838,Biotecan,Mucinous Adenocarcinoma of the Colon and Rectum,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10350,NCT00620269,Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III,UNKNOWN,PHASE2,Lung Cancer; NSCLC,Erlotinib (DRUG); Induction or consolidation IP chemotherapy (DRUG); CCRT with IP chemotherapy (Irinotecan + Cisplatin) (DRUG); CCRT (RADIATION),60838,Biotecan,Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10351,NCT00871169,"Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer",COMPLETED,PHASE2,Pancreatic Cancer,"Irinotecan, oxaliplatin, and cetuximab (DRUG)",60838,Biotecan,Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10352,NCT06430827,Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma,NOT_YET_RECRUITING,PHASE2,Biliary Tract Carcinoma,irinotecan hydrochloride liposome injection (DRUG); Capecitabine (DRUG),60838,Biotecan,Biliary Tract Carcinoma,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10353,NCT00639327,Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer,COMPLETED,PHASE2,Gastric Cancer,S-1 + irinotecan (DRUG); irinotecan (DRUG),60838,Biotecan,Gastric Cancer,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10354,NCT04943627,Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA),WITHDRAWN,PHASE3,Advanced Cancer; Metastatic Cervical Cancer,Balstilimab (BAL) (DRUG); Topotecan (DRUG); Vinorelbine (DRUG); Gemcitabine (DRUG); Irinotecan (DRUG); Pemetrexed (DRUG),60838,Biotecan,Advanced Cancer; Metastatic Cervical Cancer,Cervix,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10355,NCT00287976,Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma,UNKNOWN,PHASE2,Liver Cancer,irinotecan hydrochloride (DRUG),60838,Biotecan,Liver Cancer,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10356,NCT05722327,Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Colon Cancer; Colorectal Cancer,MRTX849 (DRUG); Irinotecan (DRUG); Cetuximab (DRUG),60838,Biotecan,Colon Cancer; Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10357,NCT03641976,"A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer",UNKNOWN,PHASE2,"Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy; Unresectable Metastatic Right-sided Colon Cancer, Stage IV",A-FOLFOXIRI (DRUG); Arm II (A-FOLFOX/A-FOLFIRI) (DRUG),60838,Biotecan,Metastatic Colon Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10358,NCT00954876,Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer,WITHDRAWN,PHASE2,Metastatic Colorectal Cancer,capecitabine and cetuximab (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10359,NCT00681876,Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer,TERMINATED,PHASE2,Colorectal Cancer,Irinotecan (DRUG); Avastin (DRUG); Erbitux (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10360,NCT01964027,The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer,UNKNOWN,PHASE2,Stage IV Gastric Cancer With Metastasis,second line chemoregime for advanced gastric cancer (DRUG),60838,Biotecan,Stage IV Gastric Cancer With Metastasis,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10361,NCT06936527,XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation,NOT_YET_RECRUITING,PHASE1,Colorectal Cancer; Metastatic Colorectal Cancer With RAS Mutation,"Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI (BIOLOGICAL); Drug: XS-03 (BIOLOGICAL); Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI (BIOLOGICAL)",60838,Biotecan,Colorectal Cancer; Metastatic Colorectal Cancer With RAS Mutation,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10362,NCT01609231,A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025),TERMINATED,PHASE2,Rectal Neoplasms,Dalotuzumab (DRUG); Irinotecan (DRUG); Cetuximab (DRUG),60838,Biotecan,Rectal Neoplasms,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10363,NCT05770531,Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy,RECRUITING,PHASE2,Metastatic HER2-Negative Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma,Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Biospecimen Collection (PROCEDURE); Sacituzumab Govitecan (BIOLOGICAL),60838,Biotecan,Metastatic HER2-Negative Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma,Breast,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10364,NCT01765582,Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer,TERMINATED,PHASE2,Colorectal Neoplasms,5-fluorouracil (DRUG); bevacizumab (DRUG); capecitabine (DRUG); irinotecan (DRUG); folinic acid (DRUG); oxaliplatin (DRUG),60838,Biotecan,Colorectal Neoplasms,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10365,NCT02595931,M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Colorectal Carcinoma; Metastatic Lung Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Carcinoma; Refractory Colorectal Carcinoma; Refractory Lung Small Cell Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Pancreatic Carcinoma; Stage III Colorectal Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Colorectal Carcinoma; Unresectable Lung Small Cell Carcinoma; Unresectable Malignant Solid Neoplasm; Unresectable Pancreatic Carcinoma,Berzosertib (DRUG); Biopsy Specimen (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Irinotecan Hydrochloride (DRUG),60838,Biotecan,Metastatic Colorectal Carcinoma; Metastatic Lung Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Carcinoma; Refractory Colorectal Carcinoma; Refractory Lung Small Cell Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Pancreatic Carcinoma; Stage III Colorectal Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Colorectal Carcinoma; Unresectable Lung Small Cell Carcinoma; Unresectable Malignant Solid Neoplasm; Unresectable Pancreatic Carcinoma,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10366,NCT01803282,Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors,COMPLETED,PHASE1,Pancreatic Cancer; Non-small Cell Lung Cancer; Esophagogastric Cancer; Colorectal Cancer; Breast Cancer,Andecaliximab (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); 5-FU (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG); Paclitaxel (DRUG),60838,Biotecan,"Multiple Cancers (Pancreatic, Lung, Esophagogastric, Colorectal, Breast)",Breast,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10367,NCT01136031,Paclitaxel and Irinotecan in Advanced Gastric Cancer,COMPLETED,PHASE1,Advanced Gastric Cancer,Paclitaxel and irinotecan (DRUG),60838,Biotecan,Advanced Gastric Cancer,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10368,NCT03829462,Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients,ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Colorectal Cancer (mCRC),Regorafenib (DRUG); Irinotecan (DRUG),60838,Biotecan,Metastatic Colorectal Cancer (mCRC),Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10369,NCT00106262,"Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer",TERMINATED,PHASE2,Cervical Cancer,Velcade (bortezomib) (DRUG); Irinotecan (DRUG),60838,Biotecan,Cervical Cancer,Cervix,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10370,NCT00486460,"Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer",UNKNOWN,PHASE3,Pancreatic Cancer,Gemcitabine (DRUG); Curcumin (DRUG); Celebrex (DRUG),60838,Biotecan,Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10371,NCT02368860,"OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma",COMPLETED,PHASE1,Pancreatic Cancer,"oxaliplatin, irinotecan, capecitabine (DRUG)",60838,Biotecan,Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10372,NCT06603376,"Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer",RECRUITING,PHASE2,Colorectal Carcinoma,FOLFIRI + Vemurafenib + Cetuximab (DRUG); FOLFIRI ± Bevacizumab (DRUG),60838,Biotecan,Colorectal Carcinoma,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10373,NCT00072527,"Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer",COMPLETED,PHASE2,Lung Cancer,carboplatin (DRUG); cisplatin (DRUG); etoposide (DRUG); irinotecan hydrochloride (DRUG); radiation therapy (RADIATION),60838,Biotecan,Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10374,NCT02172976,Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma,COMPLETED,PHASE2,Resectable Prancreas Carcinoma,Gemcitabine (DRUG); Oxaliplatin (DRUG); 5-Fluorouracil (DRUG); Irinotecan (DRUG); Natriumfolinate (DRUG),60838,Biotecan,Pancreatic Carcinoma,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10375,NCT00559676,Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer,COMPLETED,PHASE4,Colorectal Cancer,capecitabine (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10376,NCT04668976,A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma,UNKNOWN,PHASE2,Colorectal Cancer; Cholangiocarcinoma,Medtronic pump and Codman catheter (DEVICE); Floxuridine (FUDR) (DRUG); Gemcitabine (DRUG); Oxaliplatin (DRUG); Irinotecan (CPT-11) (DRUG); Fluorouracil (DRUG); Anti-EGFR (Panitumumab or Cetuximab) (DRUG),60838,Biotecan,Colorectal Cancer; Cholangiocarcinoma,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10377,NCT01123876,Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor,COMPLETED,PHASE1,Gastric Cancer,Veliparib (DRUG),60838,Biotecan,Gastric Cancer,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10378,NCT02279576,Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG),TERMINATED,PHASE2,Penile Squamous Cell Carcinoma Stage IV,Pazopanib (DRUG); Paclitaxel (DRUG),60838,Biotecan,Penile Squamous Cell Carcinoma Stage IV,Skin,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10379,NCT00300027,Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies,TERMINATED,PHASE1,Gastrointestinal Neoplasms,BMS-582664 (DRUG),60838,Biotecan,Gastrointestinal Neoplasms,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10380,NCT03528876,FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma,TERMINATED,PHASE2,Metastatic Gastro-esophageal Adenocarcinoma,FOLFOX and FOLFIRI (DRUG),60838,Biotecan,Metastatic Gastro-esophageal Adenocarcinoma,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10381,NCT03485027,Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer; Chemotherapy Effect,the rechallenge regimen (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10382,NCT03751176,Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal,UNKNOWN,PHASE2,Colorectal Cancer Metastatic,Panitumumab (DRUG); Irinotecan (DRUG); Folinic acid (DRUG); 5-FU (DRUG),60838,Biotecan,Colorectal Cancer Metastatic,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10383,NCT01085331,MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC),TERMINATED,PHASE1,Metastatic Colorectal Cancer,Pimasertib (DRUG); Placebo (DRUG); FOLFIRI (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10384,NCT02953782,Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer,COMPLETED,PHASE1,Solid Tumor; Colorectal Cancer,Magrolimab (DRUG); Cetuximab (DRUG),60838,Biotecan,Solid Tumor; Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10385,NCT01523431,Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Irinotecan Injection [Camptosar] (DRUG); 5-fluorouracil (DRUG); Leucovorin (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10386,NCT01652482,Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC),COMPLETED,PHASE2,Colorectal Cancer,5-fluorouracil (DRUG); Cetuximab (DRUG); Irinotecan (DRUG); Leucovorin (DRUG); MEHD7945A (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10387,NCT06190782,Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor,RECRUITING,PHASE3,Esophageal Squamous Cell Carcinoma; Oligometastatic Disease; Radiotherapy,PD-1 inhibitor+/- chemotherapy combined with local therapy (COMBINATION_PRODUCT); systemic therapy alone (DRUG),60838,Biotecan,Esophageal Squamous Cell Carcinoma; Oligometastatic Disease; Radiotherapy,Skin,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10388,NCT04581473,"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection",RECRUITING,PHASE1,Gastric Adenocarcinoma; Pancreatic Cancer; Gastroesophageal Junction Adenocarcinoma,CT041 autologous CAR T-cell injection (DRUG); Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody） (DRUG),60838,Biotecan,Gastric and Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10389,NCT04687631,Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases,RECRUITING,PHASE3,Colorectal Cancer; Liver Metastases,mFOLFOXIRI plus Cetuximab (DRUG); mFOLFOXIRI Plus Bevacizumab (DRUG),60838,Biotecan,Colorectal Cancer; Liver Metastases,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10390,NCT00004182,Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer,COMPLETED,PHASE2,Breast Cancer,irinotecan hydrochloride (DRUG),60838,Biotecan,Breast Cancer,Breast,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10391,NCT03533582,Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery,ACTIVE_NOT_RECRUITING,PHASE3,"Childhood Hepatocellular Carcinoma; Childhood Malignant Liver Neoplasm; Fibrolamellar Carcinoma; Hepatoblastoma; Hepatocellular Malignant Neoplasm, Not Otherwise Specified",Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Doxorubicin (DRUG); Etoposide (DRUG); Fluorouracil (DRUG); Gemcitabine (DRUG); Irinotecan (DRUG); Oxaliplatin (DRUG); Patient Observation (OTHER); Resection (PROCEDURE); Sorafenib (DRUG); Vincristine Sulfate (DRUG),60838,Biotecan,Childhood Liver Malignancies,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10392,NCT03206073,A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer; Colorectal Carcinoma; Colorectal Adenocarcinoma; Refractory Cancer; Colorectal Neoplasms,Durvalumab (DRUG); Tremelimumab (DRUG); Pexa-Vec (BIOLOGICAL); Pexa-Vec (BIOLOGICAL),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10393,NCT00734682,A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas,COMPLETED,PHASE1,Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma,Nanoliposomal CPT-11 (DRUG),60838,Biotecan,Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10394,NCT02782182,Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study,TERMINATED,PHASE1,Pancreatic Ductal Adenocarcinoma (PDAC),"FOLFIRINOX (oxaliplatin, leucovorin, irinotecan) (DRUG)",60838,Biotecan,Pancreatic Ductal Adenocarcinoma (PDAC),Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10395,NCT03940131,Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,Panitumumab (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10396,NCT02641873,A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE1,Metastatic Colorectal Cancer,BBI608 (DRUG); 5-FU (DRUG); Irinotecan (DRUG); Levofolinate (DRUG); Bevacizumab (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10397,NCT05238831,SMMART Adaptive Clinical Treatment (ACT) Trial,WITHDRAWN,EARLY_PHASE1,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Alectinib (DRUG); Alpelisib (DRUG); Anastrozole (DRUG); Atezolizumab (BIOLOGICAL); Bevacizumab (BIOLOGICAL); Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Capecitabine (DRUG); Carboplatin (DRUG); Cobimetinib (DRUG); Entrectinib (DRUG); Eribulin (DRUG); Fulvestrant (DRUG); Hyaluronidase-zzxf/Pertuzumab/Trastuzumab (BIOLOGICAL); Irinotecan (DRUG); Letrozole (DRUG); Nab-paclitaxel (DRUG); Niraparib (DRUG); Olaparib (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Pertuzumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Trastuzumab (BIOLOGICAL); Trastuzumab Emtansine (BIOLOGICAL); Vemurafenib (DRUG); Vinorelbine (DRUG); Vismodegib (DRUG),60838,Biotecan,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Ovary/Fallopian Tube,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10398,NCT06417476,Short-course Radiotherapy or Long-course Chemoradiation Followed by MFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer,RECRUITING,PHASE2,Rectal Neoplasms,Short-course radiotherapy (RADIATION); Irinotecan (DRUG); Oxaliplatin (DRUG); Calcium Formate (DRUG); Fluorouracil (DRUG); Long-course chemoradiation (RADIATION); Capecitabine (DRUG),60838,Biotecan,Rectal Neoplasms,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10399,NCT04009876,A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer,COMPLETED,PHASE2,Locally Advanced Rectal Cancer (LARC),nal-IRI (DRUG); Surgical resection (PROCEDURE); Watch-and-wait (OTHER); 5-FU/LV (DRUG); Oxaliplatin (DRUG),60838,Biotecan,Locally Advanced Rectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10400,NCT00387660,Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,carboplatin (DRUG); irinotecan (DRUG),60838,Biotecan,Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10401,NCT06577376,A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma,NOT_YET_RECRUITING,PHASE1,Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma; Expressing Human Epidermal Growth Factor Receptor-2 (HER-2); Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past,DP303c (DRUG); Simmitinib tablets (DRUG); Irinotecan liposomes (DRUG); Paclitaxel or docetaxel or irinotecan (DRUG),60838,Biotecan,HER-2 Positive Gastric or Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10402,NCT00003260,Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer,UNKNOWN,PHASE3,Colorectal Cancer,FOLFIRI regimen (DRUG); FOLFOX regimen (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10403,NCT00980460,Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer,ACTIVE_NOT_RECRUITING,PHASE3,PRETEXT I Hepatoblastoma; PRETEXT II Hepatoblastoma; PRETEXT III Hepatoblastoma; PRETEXT IV Hepatoblastoma,Cisplatin (DRUG); Dexrazoxane (DRUG); Doxorubicin Hydrochloride (DRUG); Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Liver Transplantation (PROCEDURE); Temsirolimus (DRUG); Therapeutic Conventional Surgery (PROCEDURE); Vincristine Sulfate (DRUG),60838,Biotecan,Hepatoblastoma,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10404,NCT00005076,Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,cetuximab (BIOLOGICAL); irinotecan hydrochloride (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10405,NCT05193292,Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer,UNKNOWN,PHASE2,Colorectal Neoplasms; Intestinal Neoplasms,Camrelizumab (DRUG); Trastuzumab (DRUG); XELOX regimen (DRUG); mFOLFOX6 regimen (DRUG); FOLFIRI regimen (DRUG); mXELIRI regimen (DRUG); mIRIS regimen (DRUG),60838,Biotecan,Intestinal Neoplasms,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10406,NCT00500292,A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer,COMPLETED,PHASE2,Colorectal; Cancer,"Vandetanib (DRUG); FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid (DRUG)",60838,Biotecan,Colorectal; Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10407,NCT03085992,Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer,COMPLETED,PHASE2,Rectal Cancer,FOLFOXIRI plus Bevacizumab (DRUG); Chemoradiotherapy plus Bevacizumab (OTHER),60838,Biotecan,Rectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10408,NCT01576692,"Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma",COMPLETED,PHASE1,Neuroblastoma,Humanized anti-GD2 antibody (BIOLOGICAL); Chemotherapy (DRUG); Cytokines (OTHER); Natural killer cells (BIOLOGICAL); CliniMACS (DEVICE),60838,Biotecan,Neuroblastoma,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10409,NCT01867892,A Phase II Study of Locally Advanced Pancreatic Cancer,UNKNOWN,PHASE2,Pancreatic Cancer,"ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT (DRUG); ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT (DRUG)",60838,Biotecan,Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10410,NCT00349492,A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer,COMPLETED,PHASE3,Small Cell Lung Cancer,IP (DRUG),60838,Biotecan,Small Cell Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10411,NCT03606967,Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer,RECRUITING,PHASE2,Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Computed Tomography (PROCEDURE); Durvalumab (BIOLOGICAL); Gemcitabine Hydrochloride (DRUG); Magnetic Resonance Imaging (PROCEDURE); Nab-paclitaxel (DRUG); Personalized Synthetic Long Peptide Vaccine (BIOLOGICAL); Poly ICLC (DRUG); Sacituzumab Govitecan (BIOLOGICAL); Tremelimumab (BIOLOGICAL),60838,Biotecan,Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma,Breast,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10412,NCT01183494,A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients,COMPLETED,PHASE1,Metastatic Colorectal Cancer,"FOLFIRI, Avastin, Irinotecan (DRUG)",60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10413,NCT06123494,SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen,RECRUITING,PHASE3,HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma,SHR-A1811 (DRUG); Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan (DRUG),60838,Biotecan,HER2-positive Gastroesophageal Cancer,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10414,NCT00008060,Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer,COMPLETED,PHASE3,Colorectal Cancer,FOLFIRI regimen (DRUG); FOLFOX regimen (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10415,NCT06750094,A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy,RECRUITING,PHASE3,Colorectal Neoplasms,Amivantamab (BIOLOGICAL); Cetuximab (BIOLOGICAL); Bevacizumab (BIOLOGICAL); 5-fluorouracil (DRUG); Leucovorin calcium/Levoleucovorin (DRUG); Irinotecan (DRUG),60838,Biotecan,Colorectal Neoplasms,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10416,NCT06210360,Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX,NOT_YET_RECRUITING,PHASE2,Pancreatic Cancer,Irinotecan liposome injection (DRUG); Oxaliplatin (DRUG); 5-FU (DRUG); LV (DRUG),60838,Biotecan,Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10417,NCT04888312,Safety and Efficacy of Mitazalimab in Combination with Chemotherapy in Pancreatic Cancer Patients,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Pancreatic Ductal Adenocarcinoma,CD40 agonist mitazalimab in combination with chemotherapy (BIOLOGICAL),60838,Biotecan,Metastatic Pancreatic Ductal Adenocarcinoma,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10418,NCT00003995,Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2,COMPLETED,PHASE2,Colorectal Cancer,trastuzumab (BIOLOGICAL); irinotecan hydrochloride (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10419,NCT01821612,Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer,COMPLETED,EARLY_PHASE1,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer,oxaliplatin (DRUG); irinotecan (DRUG); leucovorin (DRUG); 5-fluorouracil (DRUG); capecitabine (DRUG); radiation (RADIATION); surgery (PROCEDURE); gemcitabine (DRUG),60838,Biotecan,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10420,NCT00066612,"S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy",COMPLETED,PHASE2,Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer,irinotecan hydrochloride (DRUG),60838,Biotecan,Urinary Tract Cancers,Bladder/Urinary Tract,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10421,NCT01663012,Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma,COMPLETED,PHASE2,Anaplastic Astrocytomas; Anaplastic Oligodendrogliomas; Glioblastomas (GBM),Etirinotecan pegol (DRUG),60838,Biotecan,Anaplastic Astrocytomas; Anaplastic Oligodendrogliomas; Glioblastomas (GBM),CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10422,NCT00813072,"Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma",COMPLETED,PHASE2,Stomach Neoplasms; Esophageal Neoplasms,PEP02 (DRUG); irinotecan (DRUG); docetaxel (DRUG),60838,Biotecan,Gastrointestinal Neoplasms,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10423,NCT03891472,Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer,COMPLETED,PHASE2,Cancer of Pancreas; Unresectable Pancreatic Cancer; Chemotherapy Effect; SBRT,"Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy. (DRUG)",60838,Biotecan,Cancer of Pancreas; Unresectable Pancreatic Cancer; Chemotherapy Effect; SBRT,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10424,NCT04607668,"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):",TERMINATED,PHASE3,Colorectal Cancer Metastatic; Myelosuppression-Adult; Chemotherapeutic Toxicity,Trilaciclib (DRUG); Placebo (DRUG),60838,Biotecan,Metastatic Colorectal Cancer with Chemotherapy Complications,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10425,NCT00021268,Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer,UNKNOWN,PHASE1,Colorectal Cancer,tocladesine (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10426,NCT00023868,Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655),TERMINATED,PHASE3,Colorectal Cancer; Metastatic Cancer,FOLFIRI regimen (DRUG); cisplatin (DRUG); doxorubicin hydrochloride (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); mitomycin C (DRUG),60838,Biotecan,Colorectal Cancer; Metastatic Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10427,NCT00037180,For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy,TERMINATED,PHASE2,Neoplasm Metastasis; Colorectal Neoplasms,Celecoxib (DRUG); Irinotecan (DRUG); 5-fluorouracil (DRUG); Leucovorin (DRUG),60838,Biotecan,Metastatic Colorectal Neoplasms,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10428,NCT04927780,Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer,RECRUITING,PHASE3,Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Adenocarcinoma,Leucovorin Calcium (DRUG); Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Oxaliplatin (DRUG); Resection (PROCEDURE),60838,Biotecan,Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Adenocarcinoma,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10429,NCT06581380,JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer,NOT_YET_RECRUITING,PHASE3,Small Cell Lung Cancer,JK-1201I (DRUG); Topotecan (DRUG),60838,Biotecan,Small Cell Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10430,NCT00483080,Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC),COMPLETED,PHASE2,Colorectal Cancer (CRC),NGR-hTNF (DRUG),60838,Biotecan,Colorectal Cancer (CRC),Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10431,NCT05846867,A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer,RECRUITING,PHASE1,Colorectal Cancer,AK119 (DRUG); AK112 (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG); Calcium folinate (DRUG); Fluorouracil (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10432,NCT05148767,UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer,RECRUITING,PHASE4,Rectal Cancer Stage III,Neoadjuvant chemoradiotherapy based on irinotecan (DRUG),60838,Biotecan,Rectal Cancer Stage III,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10433,NCT02591667,Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer,UNKNOWN,PHASE2,Colorectal Cancer; Peritoneal Metastasis,Upfront staging laparoscopy + peritoneal biopsy (PROCEDURE); Neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab (DRUG); Surgical re-exploration (PROCEDURE),60838,Biotecan,Colorectal Cancer; Peritoneal Metastasis,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10434,NCT00921167,A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas,COMPLETED,PHASE2,Glioblastoma; Astrocytoma,Bevacizumab/Irinotecan (DRUG),60838,Biotecan,Glioblastoma; Astrocytoma,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10435,NCT00020501,Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver,COMPLETED,PHASE3,Colorectal Cancer; Metastatic Cancer,FOLFIRI regimen (DRUG); floxuridine (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); melphalan (DRUG); hyperthermia treatment (PROCEDURE),60838,Biotecan,Colorectal Cancer; Metastatic Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10436,NCT02720601,Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers,WITHDRAWN,PHASE2,Biliary Tract Cancer,Irinotecan & Capecitabine (DRUG),60838,Biotecan,Biliary Tract Cancer,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10437,NCT02827201,FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine,COMPLETED,PHASE2,Metastatic Pancreatic Cancer,FOLFIRI.3 (DRUG); nab-paclitaxel+ gemcitabine (DRUG),60838,Biotecan,Metastatic Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10438,NCT03904927,Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma,COMPLETED,PHASE2,Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma,"Radiation, Surgery or Radiofrequency ablation (OTHER); Systemic therapy (DRUG)",60838,Biotecan,Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma,Skin,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10439,NCT05806931,Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer,RECRUITING,PHASE2,Colon Cancer; Rectal Cancer,"TAS-102, oxaliplatin, irinotecan with bevacizumab (DRUG)",60838,Biotecan,Colon Cancer; Rectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10440,NCT00215982,Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,capecitabine (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10441,NCT01726582,"Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery (""Personalized Medicine"")",COMPLETED,PHASE2,Pancreatic Adenocarcinoma,Milestone 1: Targeted chemotherapy prior to surgery (DRUG); Milestone 2: Chemoradiotherapy (cXRT) (RADIATION); Milestone 3: Targeted chemotherapy prior to surgery (DRUG); Milestone 3: Chemoradiotherapy (cXRT) (RADIATION); Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery (DRUG); Milestone 4: Chemoradiotherapy (cXRT) (RADIATION); Milestone 5: Targeted chemotherapy after surgery (DRUG); Milestone 5: Chemoradiotherapy (cXRT) (RADIATION); Milestone 6: Gemcitabine after surgery (DRUG); Milestone 6: Chemoradiotherapy (cXRT) (RADIATION); Milestone 7: Chemoradiotherapy (cXRT) (RADIATION); Milestone 8: Targeted chemotherapy after surgery (DRUG); Milestone 9: Gemcitabine after surgery (DRUG); Milestone 10: No additional therapy after surgery (OTHER),60838,Biotecan,Pancreatic Adenocarcinoma,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10442,NCT00248482,Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,Cisplatin (DRUG); Gleevec™ (DRUG); irinotecan (DRUG),60838,Biotecan,Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10443,NCT03365882,"S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",ACTIVE_NOT_RECRUITING,PHASE2,Colon Adenocarcinoma; ERBB2 Gene Amplification; Rectal Adenocarcinoma; Recurrent Colon Carcinoma; Recurrent Rectal Carcinoma; Stage III Colon Cancer AJCC v7; Stage III Rectal Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Colon Cancer AJCC v7; Stage IV Rectal Cancer AJCC v7; Stage IVA Colon Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Colon Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7,Cetuximab (BIOLOGICAL); Irinotecan Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Pertuzumab (BIOLOGICAL); Trastuzumab (BIOLOGICAL); HER-2 testing (DEVICE),60838,Biotecan,Colon Adenocarcinoma; ERBB2 Gene Amplification; Rectal Adenocarcinoma; Recurrent Colon Carcinoma; Recurrent Rectal Carcinoma; Stage III Colon Cancer AJCC v7; Stage III Rectal Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Colon Cancer AJCC v7; Stage IV Rectal Cancer AJCC v7; Stage IVA Colon Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Colon Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10444,NCT03536182,"Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer",WITHDRAWN,PHASE3,Locally Advanced Pancreatic Adenocarcinoma,Carbon Ion Radiation Therapy (CIRT) (RADIATION); Intensity Modulated Radiation Therapy (IMRT) (RADIATION),60838,Biotecan,Pancreatic Neoplasms,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10445,NCT05412082,SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer,RECRUITING,PHASE1,Locally Advanced Rectal Cancer,Intensity-modulated radiation therapy (RADIATION); 5-fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG); Accelerated Radiation Therapy (RADIATION); Irinotecan (DRUG),60838,Biotecan,Rectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10446,NCT01639326,Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,Irinotecan high doses (DRUG); Irinotecan standard doses (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10447,NCT00048126,A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,Irinotecan (DRUG); capecitabine [Xeloda] (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10448,NCT02497157,Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Oxaliplatin (L-OHP) (DRUG); Irinotecan hydrochloride hydrate (CPT-11) (DRUG); Continuous intravenous infusion of fluorouracil (CIV 5-FU) (DRUG); Levofolinate calcium (l-LV) (DRUG); Bevacizumab (Bmab) (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10449,NCT06501482,Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI,NOT_YET_RECRUITING,PHASE3,Colorectal Cancer; Colorectal Liver Metastases,Postoperative reintroduction of FOLFIRI based chemotherapy (DRUG),60838,Biotecan,Colorectal Cancer; Colorectal Liver Metastases,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10450,NCT05927857,"Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .",NOT_YET_RECRUITING,PHASE1,Metastatic Gastric Adenocarcinoma; Second Line; Chemotherapy,nal-IRI /Experimental (DRUG); Ramucirumab /Experimental (DRUG); Trifluridine/Tipiracil /Experimental (DRUG),60838,Biotecan,Gastric and Gastroesophageal Junction Cancer,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10451,NCT02129257,Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,AFLIBERCEPT (DRUG); Irinotecan (DRUG); 5-Fluorouracil (DRUG); Folinic Acid (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10452,NCT06475326,Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer,RECRUITING,PHASE2,Pancreatic Cancer,Adebrelimab (DRUG); Oxaliplatin 100 MG (DRUG); Irinotecan liposome (DRUG); Calcium Folinate (DRUG); Fluorouracil (DRUG),60838,Biotecan,Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10453,NCT06698757,"Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer",RECRUITING,PHASE2,Colorectal Cancer,Sintilimab (BIOLOGICAL),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10454,NCT00083148,Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer,COMPLETED,PHASE1,Breast Cancer,capecitabine (DRUG); irinotecan hydrochloride (DRUG),60838,Biotecan,Breast Cancer,Breast,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10455,NCT00003748,Irinotecan in Treating Patients With Esophageal or Stomach Cancer,COMPLETED,PHASE2,Esophageal Cancer; Gastric Cancer,irinotecan hydrochloride (DRUG),60838,Biotecan,Esophageal and Gastric Cancer,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10456,NCT03798626,"Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers",COMPLETED,PHASE1,Colorectal Cancer; Gastroesophageal Cancer; Renal Cell Carcinoma,Gevokizumab (DRUG); Bevacizumab (DRUG); Modified FOLFOX6 (DRUG); FOLFIRI (DRUG); Ramucirumab (DRUG); Paclitaxel (DRUG); Cabozantinib (DRUG),60838,Biotecan,Colorectal and Gastroesophageal Cancers,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10457,NCT06622057,D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer,NOT_YET_RECRUITING,PHASE3,Biliary Tract Cancer (BTC),D07001-Softgel Capsules (DRUG); Placebo (DRUG); Capecitabine (COMBINATION_PRODUCT),60838,Biotecan,Biliary Tract Cancer (BTC),Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10458,NCT06538857,CEB-01 in Locally Resectable Pancreatic Cancer,RECRUITING,PHASE2,Pancreatic Carcinoma,Standard surgery (PROCEDURE); CEB-01 (DRUG),60838,Biotecan,Pancreatic Carcinoma,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10459,NCT00286130,Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,"Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan (DRUG); FOLFOX 6 (DRUG); FOLFIRI (DRUG)",60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10460,NCT00003225,Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,amifostine trihydrate (DRUG); irinotecan hydrochloride (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10461,NCT05842525,Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer,UNKNOWN,PHASE2,Colorectal Cancer,intensive treatment (DRUG); Maintenance treatment (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10462,NCT01167725,Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer,TERMINATED,PHASE3,Colorectal Cancer,bevacizumab (BIOLOGICAL); cetuximab (BIOLOGICAL); FOLFIRI regimen (DRUG); FOLFOX regimen (DRUG); capecitabine (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); mitomycin C (DRUG); oxaliplatin (DRUG); therapeutic conventional surgery (PROCEDURE),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10463,NCT06888648,Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.,NOT_YET_RECRUITING,PHASE1,Pancreatic Cancer Metastatic; Pancreatic Cancer Non-resectable,individualized anti-tumor new antigen iNeo-Vac-R01 injection (BIOLOGICAL); mFOLFIRINOX Treatment Regimen (DRUG); Sintilimab injection (DRUG),60838,Biotecan,Advanced Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10464,NCT06496048,Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC,RECRUITING,PHASE3,Relapsed Small Cell Lung Cancer,Lurbinectedin (DRUG); Irinotecan (DRUG); Lurbinectedin (DRUG); Topotecan (DRUG),60838,Biotecan,Relapsed Small Cell Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10465,NCT04008030,"A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)",ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Colorectal Cancer,Ipilimumab (BIOLOGICAL); Oxaliplatin (DRUG); Leucovorin (DRUG); Fluorouracil (DRUG); Irinotecan (DRUG); Bevacizumab (DRUG); Cetuximab (DRUG); Nivolumab (BIOLOGICAL),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10466,NCT02128425,FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,FOLFOXIRI (DRUG); FOLFOX (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10467,NCT03866525,OH2 Oncolytic Viral Therapy in Solid Tumors,RECRUITING,PHASE1,Solid Tumor; Gastrointestinal Cancer,"OH2 injection, with or without irinotecan or HX008 (BIOLOGICAL)",60838,Biotecan,Solid Tumor; Gastrointestinal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10468,NCT01374425,Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC),COMPLETED,PHASE2,Colorectal Cancer,5-Fluorouracil (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10469,NCT01757626,Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma,ACTIVE_NOT_RECRUITING,PHASE1,Neuroblastoma,Hu3F8 With GM-CSF (BIOLOGICAL); Hu3F8 With GM-CSF (BIOLOGICAL),60838,Biotecan,Neuroblastoma,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10470,NCT06697366,Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer,NOT_YET_RECRUITING,PHASE2,Gastric Cancer,Irinotecan liposome injection Ⅱ (DRUG); Sintilimab (DRUG),60838,Biotecan,Gastric Cancer,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10471,NCT06540326,Clinical Study of Second-line Treatment in Advanced Colorectal Cancer with Chemotherapy with Bevacizumab or Cetuximab,RECRUITING,PHASE2,Colorectal Cancer Metastatic,irinotecan liposome (II) (DRUG); fluorouracil (DRUG); cetuximab (DRUG); bevacizumab (DRUG),60838,Biotecan,Colorectal Cancer Metastatic,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10472,NCT04595266,Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease,RECRUITING,PHASE2,Colorectal Cancer Metastatic; Liver Metastasis Colon Cancer,FOLFOX regimen (DRUG); Anti-EGFR or Bevacizumab (BIOLOGICAL); LIVERPEARLS-Irinotecan (DRUG),60838,Biotecan,Colorectal Cancer Metastatic; Liver Metastasis Colon Cancer,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10473,NCT05825066,Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma,RECRUITING,PHASE2,Pancreas Adenocarcinoma; Borderline Resectable Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Adenocarcinoma,Nab paclitaxel (DRUG); Gemcitabine (DRUG); Radiological Assessments (OTHER); mFOLFIRINOX (DRUG),60838,Biotecan,Pancreas Adenocarcinoma; Borderline Resectable Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Adenocarcinoma,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10474,NCT00006366,Radiation Therapy Plus Chemotherapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum,COMPLETED,PHASE2,Colorectal Cancer,fluorouracil (DRUG); irinotecan hydrochloride (DRUG); conventional surgery (PROCEDURE); radiation therapy (RADIATION),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10475,NCT03316326,"S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer",UNKNOWN,PHASE2,Pancreatic Ductal Adenocarcinoma,Tegafur-gimeracil-oteracil potassium (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG),60838,Biotecan,Pancreatic Ductal Adenocarcinoma,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10476,NCT01479465,Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma,TERMINATED,PHASE2,Colorectal Cancer,Simtuzumab (BIOLOGICAL); Placebo to match SIM (DRUG); Leucovorin (DRUG); Irinotecan (DRUG); Fluorouracil (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10477,NCT01084330,Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer,COMPLETED,PHASE2,Advanced Gastric Cancer; Gastro-esophageal Junction Cancer,AUY922 (DRUG); Docetaxel (DRUG); Irinotecan (DRUG),60838,Biotecan,Advanced Gastric and Gastro-esophageal Junction Cancer,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10478,NCT06438822,Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma,RECRUITING,PHASE2,Cholangiocarcinoma,Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil (COMBINATION_PRODUCT),60838,Biotecan,Cholangiocarcinoma,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10479,NCT03231722,First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS,COMPLETED,PHASE3,Metastatic Colorectal Cancer,Panitumumab (DRUG); Irinotecan (DRUG); Oxaliplatin (DRUG); l-leucovorin (DRUG); 5-fluorouracil (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10480,NCT00020930,Cetuximab in Treating Patients With Stage IV Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,cetuximab (BIOLOGICAL),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10481,NCT00006025,Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma,COMPLETED,PHASE1,Brain and Central Nervous System Tumors,irinotecan hydrochloride (DRUG); temozolomide (DRUG),60838,Biotecan,Brain and Central Nervous System Tumors,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10482,NCT00541125,G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,bevacizumab (BIOLOGICAL); filgrastim (BIOLOGICAL); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10483,NCT00967330,A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma,COMPLETED,PHASE2,Glioblastoma Multiforme,bevacizumab [Avastin] (DRUG); irinotecan (DRUG); temozolomide (DRUG),60838,Biotecan,Glioblastoma Multiforme,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10484,NCT05453825,A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors,UNKNOWN,PHASE2,Colorectal Cancer; Triple Negative Breast Cancer; Gastric Cancer; Ovarian Cancer,navicixizumab+paclitaxel (BIOLOGICAL); navicixizumab+irinotecan (BIOLOGICAL); navicixizumab monotherapy (BIOLOGICAL),60838,Biotecan,Colorectal Cancer; Triple Negative Breast Cancer; Gastric Cancer; Ovarian Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10485,NCT04173325,Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer,TERMINATED,PHASE1,Small-cell Lung Cancer; Small Cell Lung Carcinoma,Nivolumab 10 MG/ML Intravenous Solution [OPDIVO] (DRUG); Irinotecan Injection [Camptosar] (DRUG),60838,Biotecan,Small-cell Lung Cancer; Small Cell Lung Carcinoma,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10486,NCT00778830,Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study),COMPLETED,PHASE1,Metastatic Colorectal Cancer,Cetuximab (DRUG); FOLFIRI (DRUG); FOLFOX (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10487,NCT06648525,"Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC",NOT_YET_RECRUITING,PHASE2,Intrahepatic Cholangiocarcinoma (Icc),Adebrelimab (DRUG); Irinotecan liposomes (DRUG); Lenvatinib (DRUG); 5-Fluorouracil (5-FU) (DRUG); Calcium Folinate (DRUG),60838,Biotecan,Intrahepatic Cholangiocarcinoma,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10488,NCT01075048,ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE1,Metastatic Colorectal Cancer,Tivantinib (DRUG); Placebo (DRUG); Cetuximab (DRUG); Irinotecan (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10489,NCT05319730,A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B),RECRUITING,PHASE1,Esophageal Squamous Cell Carcinoma,Paclitaxel (DRUG); Irinotecan (DRUG); Pembrolizumab (BIOLOGICAL); MK-4830 (BIOLOGICAL); Lenvatinib (DRUG); Sacituzumab tirumotecan (BIOLOGICAL); Antihistamine (DRUG); H2 Receptor Antagonist (DRUG); Acetaminophen (or equivalent) (DRUG); Dexamethasone (or equivalent) (DRUG); Steroid Mouthwash (dexamethasone or equivalent) (DRUG); Supportive care measures (DRUG),60838,Biotecan,Esophageal Squamous Cell Carcinoma,Skin,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10490,NCT00099125,"Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",COMPLETED,PHASE2,Brain and Central Nervous System Tumors,irinotecan hydrochloride (DRUG); temozolomide (DRUG); adjuvant therapy (PROCEDURE); radiation therapy (RADIATION),60838,Biotecan,Brain and Central Nervous System Tumors,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10491,NCT02295930,Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient,COMPLETED,PHASE2,Metastatic Colorectal Cancer,folfoxiri+cetuximab+surgery+cetuximab (OTHER); folfoxiri+cetuximab+surgery+bevacizumab (OTHER),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10492,NCT06197425,Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer,NOT_YET_RECRUITING,PHASE3,Colon or Upper Rectum Adenocarcinoma,"""FOLFIRI"" cures (DRUG); Trifluridine cures (DRUG); BIOLOGICAL ASSESSMENT (BIOLOGICAL); Questionnaires (OTHER); Thoracic-abdomino-pelvic scan or MRI (OTHER)",60838,Biotecan,Colon Adenocarcinoma,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10493,NCT02171325,Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment,UNKNOWN,PHASE2,Small Cell Lung Cancer,irinotecan (DRUG),60838,Biotecan,Small Cell Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10494,NCT06401330,A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT),RECRUITING,PHASE3,Stage I Kidney Wilms Tumor; Stage II Kidney Wilms Tumor; Stage III Kidney Wilms Tumor; Stage IV Kidney Wilms Tumor,Bone Scan (PROCEDURE); Carboplatin (DRUG); Computed Tomography (PROCEDURE); Cyclophosphamide (DRUG); Dactinomycin (BIOLOGICAL); Doxorubicin (DRUG); Etoposide (DRUG); Irinotecan (DRUG); Magnetic Resonance Imaging (PROCEDURE); Nephrectomy (PROCEDURE); Patient Observation (OTHER); Positron Emission Tomography (PROCEDURE); Ultrasound Imaging (PROCEDURE); Vincristine (DRUG); X-Ray Imaging (PROCEDURE),60838,Biotecan,Kidney Neoplasms,Kidney,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10495,NCT03797625,Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas,UNKNOWN,PHASE2,Esophageal Squamous Cell Carcinoma,Irinotecan (DRUG); DDP (DRUG); Endostar (DRUG),60838,Biotecan,Esophageal Squamous Cell Carcinoma,Skin,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10496,NCT04986930,MFOLFIRINOX with or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma,ACTIVE_NOT_RECRUITING,PHASE2,Pancreatic Adenocarcinoma; Pancreatic Cancer Non-resectable,SBRT+mFOLFIRINOX (RADIATION); mFOLFIRINOX (DRUG),60838,Biotecan,Pancreatic Adenocarcinoma; Pancreatic Cancer Non-resectable,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10497,NCT00209625,Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,irinotecan (DRUG); leucovorin (DRUG); fluorouracil (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10498,NCT00062322,Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer,cisplatin (DRUG); irinotecan hydrochloride (DRUG); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE); radiation therapy (RADIATION),60838,Biotecan,Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10499,NCT00980239,"HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver",COMPLETED,PHASE1,Liver Cancer; Advanced Cancer,Irinotecan (DRUG); Bevacizumab (DRUG); Oxaliplatin (DRUG); Cetuximab (DRUG),60838,Biotecan,Liver Cancer; Advanced Cancer,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10500,NCT00042939,Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,cetuximab (BIOLOGICAL); docetaxel (DRUG); irinotecan hydrochloride (DRUG),60838,Biotecan,Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10501,NCT04005339,"NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer",RECRUITING,PHASE2,Advanced Biliary Tract Cancer,Nanoliposomal Irinotecan (DRUG); Leucovorin (DRUG); Fluorouracil (DRUG),60838,Biotecan,Advanced Biliary Tract Cancer,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10502,NCT00546130,Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer,UNKNOWN,PHASE2,Small Cell Lung Cancer,Irinotecan hydrochloride (DRUG); Cisplatin (DRUG); Krestin (DRUG),60838,Biotecan,Small Cell Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10503,NCT04170530,Neoadjuvant mFOLFOXIRI Chemotherapy Alone for Extramural Vascular Invasion Positive Locally Advanced Rectal Cancer,UNKNOWN,PHASE2,Locally Advanced Rectal Cancer,mFOLFOXIRI (DRUG),60838,Biotecan,Rectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10504,NCT00006786,Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,bevacizumab (BIOLOGICAL); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10505,NCT04425239,Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer Stage IV,Panitumumab (DRUG); Panitumumab (DRUG),60838,Biotecan,Colorectal Cancer Stage IV,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10506,NCT01394939,"Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma",COMPLETED,PHASE1,Colorectal Carcinoma; CRC,JX-594 (BIOLOGICAL); Irinotecan (DRUG),60838,Biotecan,Colorectal Carcinoma; CRC,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10507,NCT02654639,Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer,TERMINATED,PHASE2,Metastatic Colorectal Cancer,TAS-102 (DRUG); Bevacizumab (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10508,NCT00048139,A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,Irinotecan (DRUG); capecitabine [Xeloda] (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10509,NCT01467986,Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma Recurrent,Dasatinib (DRUG); Rapamycin (DRUG); Irinotecan (DRUG); Temozolomide (DRUG); Irinotecan (DRUG); Temozolomide (DRUG),60838,Biotecan,Neuroblastoma Recurrent,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10510,NCT06680622,"Bemarituzumab in FGFR2b+ Patients with Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed At Least One Prior Line of Palliative Chemotherapy",RECRUITING,PHASE2,Metastatic Gastro-esophageal Adenocarcinoma,"bemarituzumab, paclitaxel, ramucirumab (DRUG); bemarituzumab, irinotecan (DRUG); bemarituzumab, trifluridine/tipiracil (DRUG)",60838,Biotecan,Metastatic Gastro-esophageal Adenocarcinoma,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10511,NCT00004139,Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,docetaxel (DRUG); gemcitabine hydrochloride (DRUG); irinotecan hydrochloride (DRUG),60838,Biotecan,Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10512,NCT00612586,Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer,COMPLETED,PHASE2,Colorectal Cancer,Enzastaurin (DRUG); Placebo (DRUG); Leucovorin (LV) (DRUG); 5-fluorouracil (5-FU) (DRUG); Bevacizumab (Bev) (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10513,NCT05848739,A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors,RECRUITING,PHASE1,Colon Cancer; Metastatic Colon Cancer,ST316 (DRUG); FOLFIRI regimen & bevacizumab (DRUG); Fruquintinib (DRUG); Lonsurf & bevacizumab (DRUG),60838,Biotecan,Colon Cancer; Metastatic Colon Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10514,NCT00617539,Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases,COMPLETED,PHASE2,Breast Cancer; Metastatic Cancer,irinotecan hydrochloride (DRUG); temozolomide (DRUG),60838,Biotecan,Breast Cancer; Metastatic Cancer,Breast,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10515,NCT05669339,AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma,RECRUITING,PHASE2,Hepatocellular Carcinoma,Irinotecan (DRUG); Sonidegib (DRUG); Sorafenib (DRUG),60838,Biotecan,Hepatocellular Carcinoma,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10516,NCT00890786,A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas,COMPLETED,EARLY_PHASE1,Newly Diagnosed High-Grade Gliomas; Diffuse Intrinsic Pontine Glioma,Temozolomide (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG),60838,Biotecan,Newly Diagnosed High-Grade Gliomas; Diffuse Intrinsic Pontine Glioma,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10517,NCT00845039,A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab,TERMINATED,PHASE2,Colon Cancer; Rectal Cancer,Cetuximab (BIOLOGICAL); Irinotecan (DRUG); IMC-A12 (cixutumumab) (BIOLOGICAL),60838,Biotecan,Colon Cancer; Rectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10518,NCT06662786,A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer,RECRUITING,PHASE3,Colorectal Neoplasms,Amivantamab (BIOLOGICAL); Cetuximab (BIOLOGICAL); 5-fluorouracil (DRUG); Leucovorin calcium/Levoleucovorin (DRUG); Oxaliplatin (DRUG); Irinotecan Hydrochloride (DRUG),60838,Biotecan,Colorectal Neoplasms,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10519,NCT05027386,"Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.",RECRUITING,PHASE1,Neuroblastoma,"Apatinib, Irinotecan, Temozolomide (DRUG)",60838,Biotecan,Neuroblastoma,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10520,NCT00433927,"5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)",UNKNOWN,PHASE3,Neoplasm Metastasis; Colorectal Cancer,5-FU (DRUG); folinic acid (DRUG); irinotecan (DRUG); cetuximab (DRUG); bevacizumab (DRUG),60838,Biotecan,Neoplasm Metastasis; Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10521,NCT00003427,Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer,COMPLETED,PHASE1,Anal Cancer; Colorectal Cancer; Esophageal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Gastrointestinal Carcinoid Tumor; Liver Cancer; Pancreatic Cancer; Small Intestine Cancer,irinotecan hydrochloride (DRUG); oxaliplatin (DRUG),60838,Biotecan,Anal Cancer; Colorectal Cancer; Esophageal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Gastrointestinal Carcinoid Tumor; Liver Cancer; Pancreatic Cancer; Small Intestine Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10522,NCT00510627,Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases,WITHDRAWN,PHASE4,Metastatic Liver Cancer; Secondary Liver Cancer; Liver Neoplasm,Radiofrequency Ablation (RFA) (DEVICE); Chemotherapy (DRUG),60838,Biotecan,Metastatic Liver Cancer; Secondary Liver Cancer; Liver Neoplasm,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10523,NCT05160727,Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer,UNKNOWN,PHASE2,Mismatch Repair-proficient; Colorectal Cancer Metastatic; Microsatellite Stable,Tislelizumab (DRUG); Irinotecan (DRUG); radiotherapy (RADIATION),60838,Biotecan,Mismatch Repair-proficient; Colorectal Cancer Metastatic; Microsatellite Stable,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10524,NCT06575127,Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study,RECRUITING,PHASE2,Neoplasm Malignant; Colon Cancer Stage 4,FOLFOXIRI Protocol (DRUG),60838,Biotecan,Neoplasm Malignant; Colon Cancer Stage 4,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10525,NCT03785873,Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer,COMPLETED,PHASE1,Biliary Tract Cancer,Nivolumab (DRUG); Nanoliposomal-Irinotecan (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG),60838,Biotecan,Biliary Tract Cancer,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10526,NCT03874026,Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients,RECRUITING,PHASE2,Colorectal Cancer; ADCC,Folfiri/Cetuximab (DRUG),60838,Biotecan,Colorectal Cancer; ADCC,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10527,NCT06509126,Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer,RECRUITING,PHASE3,Colorectal Cancer Stage IV,Panitumumab (DRUG); Irinotecan (DRUG); 5-fluorouracil (DRUG); L-folinic acid (DRUG),60838,Biotecan,Colorectal Cancer Stage IV,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10528,NCT04482257,Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.,UNKNOWN,PHASE1,Advanced Pancreatic Cancer,Irinotecan Liposome Injection combined with 5-FU/LV (DRUG),60838,Biotecan,Advanced Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10529,NCT00972465,Study of Nimotuzumab to Treat Colorectal Cancer,UNKNOWN,PHASE2,Advanced Colorectal Cancer,Nimotuzumab and chemotherapy (DRUG),60838,Biotecan,Advanced Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10530,NCT05201430,Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer,RECRUITING,PHASE3,Rectal Cancer,FOLFOXIRI (DRUG); CapeOX (DRUG),60838,Biotecan,Rectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10531,NCT00156286,Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC,COMPLETED,PHASE2,Small Cell Lung Cancer,Gleevec (DRUG),60838,Biotecan,Small Cell Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10532,NCT06595186,JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM),RECRUITING,PHASE2,Glioblastoma Multiforme (GBM),JK-1201I (DRUG); Temozolomide (TMZ) (DRUG),60838,Biotecan,Glioblastoma Multiforme (GBM),CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10533,NCT00213486,Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial,COMPLETED,PHASE2,Esophageal Neoplasms,irinotecan (DRUG),60838,Biotecan,Esophageal Neoplasms,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10534,NCT00524186,"Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer",TERMINATED,PHASE1,Esophageal Cancer; Gastric Cancer,fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); sunitinib malate (DRUG); flow cytometry (OTHER); pharmacological study (OTHER),60838,Biotecan,Esophageal and Gastric Cancer,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10535,NCT00216086,Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer,TERMINATED,PHASE2,Rectal Cancer,Capecitabine (DRUG); Irinotecan (DRUG); EUS (PROCEDURE); Neoadjuvant Chemotherapy (DRUG); Preoperative Radiation (PROCEDURE); Surgery (PROCEDURE); Adjuvant Chemotherapy (PROCEDURE),60838,Biotecan,Rectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10536,NCT00958386,Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA),COMPLETED,PHASE2,Metastatic Colorectal Cancer,Panitumumab+irinotecan (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10537,NCT00391586,"Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung",TERMINATED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Erlotinib (DRUG); Platinum-based chemotherapy (DRUG),60838,Biotecan,"Carcinoma, Non-Small-Cell Lung",Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10538,NCT00730158,"A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer",COMPLETED,PHASE2,Colorectal Neoplasms,KD018 (DRUG); Irinotecan (DRUG); Placebo (DRUG),60838,Biotecan,Colorectal Neoplasms,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10539,NCT03061058,Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC,UNKNOWN,PHASE3,Stomach Neoplasms; Chemotherapy Effect; Chemotherapeutic Toxicity,Docetaxel (DRUG); Oxaliplatin (DRUG); Cisplatin (DRUG); Irinotecan (DRUG); Pemetrexed (DRUG); S1 (DRUG),60838,Biotecan,Chemotherapy-Induced Gastric Toxicity,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10540,NCT04861558,Efficacy of Hyperthermic Intraperitoneal Chemotherapy,RECRUITING,PHASE3,Colorectal Cancer; Peritoneal Metastases,5Fluorouracil (DRUG); Irinotecan (DRUG); Oxaliplatin (DRUG),60838,Biotecan,Colorectal Cancer; Peritoneal Metastases,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10541,NCT04912258,Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis,UNKNOWN,PHASE3,Colorectal Cancer; Liver Metastases,Trans arterial chemoembolization with Irinotecan Drug-eluting Beads (DRUG),60838,Biotecan,Colorectal Cancer; Liver Metastases,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10542,NCT01205022,"Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",COMPLETED,PHASE1,Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer,irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); fluorouracil (DRUG); bevacizumab (BIOLOGICAL); yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A (RADIATION); laboratory biomarker analysis (OTHER),60838,Biotecan,Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10543,NCT01878422,Sequential Treatment Strategy for Metastatic Colorectal Cancer,COMPLETED,PHASE3,Metastatic Colorectal Cancer,Arm A: FOLFIRI or FOLFOX + Bevacizumab (DRUG); Arm B: FOLFIRI or FOLFOX (DRUG); Arm D: FOLFIRI or FOLFOX plus CETUXIMAB (DRUG); Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10544,NCT00135135,Therapy for Children With Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma,"Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid (DRUG); Radiation therapy, Surgery, Peripheral Stem cell transplant (PROCEDURE)",60838,Biotecan,Neuroblastoma,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10545,NCT00118235,"Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer",COMPLETED,PHASE2,Extensive Stage Small Cell Lung Cancer,cisplatin (DRUG); irinotecan hydrochloride (DRUG); bevacizumab (BIOLOGICAL); laboratory biomarker analysis (OTHER),60838,Biotecan,Extensive Stage Small Cell Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10546,NCT00004235,Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach,COMPLETED,PHASE2,Esophageal Cancer; Gastric Cancer,docetaxel (DRUG); irinotecan hydrochloride (DRUG),60838,Biotecan,Esophageal and Gastric Cancer,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10547,NCT03126435,EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX,COMPLETED,PHASE3,Metastatic Pancreas Cancer; Locally Advanced Pancreatic Cancer; Pancreatic Adenocarcinoma,EndoTAG-1 (DRUG); Gemcitabine (DRUG),60838,Biotecan,Metastatic Pancreas Cancer; Locally Advanced Pancreatic Cancer; Pancreatic Adenocarcinoma,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10548,NCT01601535,Study of MLN8237 in Combination With Irinotecan and Temozolomide,COMPLETED,PHASE1,Neuroblastoma,MLN8237 (DRUG); Irinotecan (DRUG); Temozolomide (DRUG),60838,Biotecan,Neuroblastoma,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10549,NCT04389086,Induction Chemotherapy for Locally Recurrent Rectal Cancer,RECRUITING,PHASE3,Recurrent Rectal Cancer,Combination drug (DRUG); Chemoradiotherapy (RADIATION); Surgery locally recurrent rectal cancer (PROCEDURE),60838,Biotecan,Recurrent Rectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10550,NCT03688230,Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.,WITHDRAWN,PHASE2,Metastatic Colorectal Cancer,abituzumab (DRUG); Placebo + Cetuximab + FOLFIRI (COMBINATION_PRODUCT),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10551,NCT06801730,Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma,RECRUITING,PHASE2,Glioma,Irinotecan liposome combined with bevacizumab (DRUG),60838,Biotecan,Glioma,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10552,NCT02055196,Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas,WITHDRAWN,PHASE1,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor,carboxylesterase-expressing allogeneic neural stem cells (BIOLOGICAL); irinotecan hydrochloride (DRUG); laboratory biomarker analysis (OTHER),60838,Biotecan,Adult Malignant Gliomas,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10553,NCT04084496,mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients,RECRUITING,PHASE2,Pancreatic Cancer,Folfirinox (DRUG),60838,Biotecan,Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10554,NCT02021422,"A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy",UNKNOWN,PHASE1,Pancreas Cancer,anakinra (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG); fluorouracil (DRUG),60838,Biotecan,Pancreas Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10555,NCT06867822,Trial of ProAgio in Advanced/Metastatic Colorectal Cancer,NOT_YET_RECRUITING,PHASE1,Advanced Colorectal Cancer; Metastatic Colorectal Cancer,ProAgio (DRUG); FOLFIRI (DRUG); Bevacizumab (DRUG),60838,Biotecan,Advanced Colorectal Cancer; Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10556,NCT05153239,Clinical Trial of Lurbinectedin As Single-agent or in Combination with Irinotecan Versus Topotecan or Irinotecan in Patients with Relapsed Small-cell Lung Cancer (LAGOON),ACTIVE_NOT_RECRUITING,PHASE3,Relapsed Small Cell Lung Cancer,Irinotecan (DRUG); Lurbinectedin (DRUG); Irinotecan (DRUG); Topotecan (DRUG); Lurbinectedin (DRUG),60838,Biotecan,Relapsed Small Cell Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10557,NCT02316496,Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study,TERMINATED,PHASE2,Colorectal Cancer Metastatic,cetuximab (DRUG); Irinotecan (DRUG),60838,Biotecan,Colorectal Cancer Metastatic,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10558,NCT04838496,Induction Chemotherapy for Locally Advanced Rectal Cancer,NOT_YET_RECRUITING,PHASE2,Rectal Cancer,FOLFOXIRI Protocol (DRUG),60838,Biotecan,Rectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10559,NCT03428958,"A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment",COMPLETED,PHASE1,"Colorectal Cancer; Colorectal Neoplasms; Colorectal Carcinoma; Colorectal Tumors; Neoplasms, Colorectal",NUC-3373 + leucovorin (DRUG); NUC-3373 (DRUG); NUFOX (DRUG); NUFOX + VEGF pathway inhibitor (DRUG); NUFOX + EGFR inhibitor (DRUG); NUFIRI (DRUG); NUFIRI + VEGF pathway inhibitor (DRUG); NUFIRI + EGFR inhibitor (DRUG); NUC-3373 + bevacizumab (DRUG),60838,Biotecan,"Colorectal Cancer; Colorectal Neoplasms; Colorectal Carcinoma; Colorectal Tumors; Neoplasms, Colorectal",Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10560,NCT01183780,A Study in Second Line Metastatic Colorectal Cancer,COMPLETED,PHASE3,Colorectal Cancer,Ramucirumab (BIOLOGICAL); Placebo (BIOLOGICAL); Irinotecan (DRUG); Folinic Acid (DRUG); 5-Fluorouracil (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10561,NCT00030862,Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus,COMPLETED,PHASE2,Esophageal Cancer,cisplatin (DRUG); irinotecan hydrochloride (DRUG),60838,Biotecan,Esophageal Cancer,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10562,NCT00047762,"Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer",COMPLETED,PHASE1,Colorectal Cancer,Erlotinib (aka Tarceva or OSI-774) (DRUG); Bevacizumab (aka Avastin or Rhu MAb VEGF) (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10563,NCT04059562,Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma,COMPLETED,PHASE2,Cholangiocarcinoma,Combination of Lonsurf® and Irinotecan (COMBINATION_PRODUCT),60838,Biotecan,Cholangiocarcinoma,Liver,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10564,NCT06118762,Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer,RECRUITING,PHASE4,Metastatic Colorectal Cancer,Fruquintinib (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10565,NCT02551991,"Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma",COMPLETED,PHASE2,Pancreatic Cancer,nal-IRI (DRUG); 5 fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG),60838,Biotecan,Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10566,NCT00045162,S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer,COMPLETED,PHASE3,Lung Cancer,cisplatin (DRUG); etoposide (DRUG); irinotecan hydrochloride (DRUG),60838,Biotecan,Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10567,NCT00040391,A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer,TERMINATED,PHASE2,Colorectal Neoplasms; Diarrhea,Investigational drug (DRUG); Irinotecan (DRUG); 5-fluorouracil (DRUG); Leucovorin (DRUG),60838,Biotecan,Colorectal Neoplasms; Diarrhea,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10568,NCT06749691,Liposomal Irinotecan and Apatinib in ES-SCLC,RECRUITING,PHASE2,Small Cell Lung Cancer Extensive Stage,Liposomal Irinotecan and Apatinib (DRUG),60838,Biotecan,Small Cell Lung Cancer Extensive Stage,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10569,NCT04931394,Organoid-Guided Adjuvant Chemotherapy for Pancreatic Cancer,RECRUITING,PHASE3,Pancreatic Cancer,Adjuvant chemotherapy guided by organoid drug sensitivity test (OTHER),60838,Biotecan,Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10570,NCT00320294,ILF With/Without Cisplatin for Advanced Gastric Cancer,UNKNOWN,PHASE2,Stomach Neoplasm,irinotecan (DRUG); cisplatin (DRUG),60838,Biotecan,Stomach Neoplasm,Esophagus/Stomach,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10571,NCT06077591,Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients with Advanced/ Inoperable Solid Tumors,RECRUITING,PHASE3,Hepatocellular Carcinoma; Colorectal Cancer,Patient-Derived Tumor Organoids (OTHER),60838,Biotecan,Hepatocellular Carcinoma; Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10572,NCT04446091,A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC),UNKNOWN,PHASE1,Colorectal Cancer,"Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.) (DRUG); Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan (DRUG)",60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10573,NCT02022644,"Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma",COMPLETED,PHASE1,High Grade Glioma,nanoliposomal irinotecan (DRUG),60838,Biotecan,Glioma,CNS/Brain,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10574,NCT06763029,Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer,RECRUITING,PHASE2,Colorectal Cancer Metastatic,Irinotecan liposomes combined with cetuximab + vermofenib (DRUG),60838,Biotecan,Colorectal Cancer Metastatic,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10575,NCT06166589,Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer,NOT_YET_RECRUITING,PHASE2,Previously AG Chemotherapy Treated Pancreatic Cancer,Zimberelimab (DRUG); Oxaliplatin (DRUG); S-1 (DRUG); Irinotecan (DRUG),60838,Biotecan,Previously AG Chemotherapy Treated Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10576,NCT05062889,Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients,RECRUITING,PHASE2,Stage II Colon Cancer; Stage III Colon Cancer; HER2-positive Colon Cancer; RAS Wild-type Colon Cancer,5-Fluorouracil continuous infusion FOLFOXIRI schedule (DRUG); 5-Fluorouracil bolus FOLFOX schedule (DRUG); 5-Fluorouracil continuous infusion FOLFOX schedule (DRUG); Oxaliplatin FOLFOX and FOLFOXIRI schedule (DRUG); Oxaliplatin CAPOX schedule (DRUG); L-Leucovorin (DRUG); Capecitabine (DRUG); Irinotecan (DRUG); Trifluridine/Tipiracil (DRUG); Trastuzumab (DRUG); Tucatinib (DRUG),60838,Biotecan,Colon Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10577,NCT01387880,"Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer",COMPLETED,PHASE2,Metastatic Colorectal Cancer,Everolimus (DRUG); Everolimus (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10578,NCT00255229,Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Glutamine (DRUG); Placebo (OTHER),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10579,NCT03263429,Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer; Metastatic Colorectal Cancer; RAS Wild Type Colorectal Cancer; Refractory Colorectal Cancer,Glutaminase Inhibitor CB-839 (DRUG); Panitumumab (BIOLOGICAL); Irinotecan Hydrochloride (phase I only) (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans (DEVICE),60838,Biotecan,Colorectal Cancer; Metastatic Colorectal Cancer; RAS Wild Type Colorectal Cancer; Refractory Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10580,NCT00027729,Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,etaracizumab (BIOLOGICAL),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10581,NCT00144989,A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC,COMPLETED,PHASE3,Small-Cell-Lung Cancer,Etoposide and cisplatin after chemoradiotherapy (DRUG); Irinotecan and cisplatin after chemoradiotherapy (DRUG),60838,Biotecan,Small-Cell-Lung Cancer,Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10582,NCT04101929,"Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen",UNKNOWN,PHASE2,Metastatic Pancreatic Cancer,Apatinib (DRUG); S-1 capsule (DRUG); Irinotecan (DRUG),60838,Biotecan,Metastatic Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10583,NCT00081289,Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,Radiation Therapy (RADIATION); Capecitabine 1650 mg/m^2/day (DRUG); Capecitabine 1200 mg/m^2/day (DRUG); Irinotecan (DRUG); Oxaliplatin (DRUG); Surgery (PROCEDURE); Folinic Acid (DRUG); Fluorouracil (DRUG); Oxaliplatin (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10584,NCT04653480,"Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC",RECRUITING,PHASE2,Colorectal Cancer,Surufatinib (DRUG); Toripalimab (DRUG); chemotherapy (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10585,NCT01454180,Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets,COMPLETED,PHASE2,Advanced Pancreatic Carcinoma,"gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI. (DRUG); Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI (DRUG)",60838,Biotecan,Advanced Pancreatic Carcinoma,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10586,NCT05330429,Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC),TERMINATED,PHASE2,Metastatic Colorectal Cancer,Magrolimab (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG); Fluorouracil (DRUG); Leucovorin (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10587,NCT02063529,FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,FOLFOXIRI + Cetuximab (DRUG); FOLFOXIRI (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10588,NCT06459180,A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20),RECRUITING,PHASE3,Cervical Cancer,Sacituzumab Tirumotecan (BIOLOGICAL); Pemetrexed (DRUG); Tisotumab Vedotin (BIOLOGICAL); Topotecan (DRUG); Vinorelbine (DRUG); Gemcitabine (DRUG); Irinotecan (DRUG),60838,Biotecan,Cervical Cancer,Cervix,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10589,NCT03692429,alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells,RECRUITING,PHASE1,Unresectable Metastatic Colorectal Cancer,CYAD-101 (DRUG); FOLFOX (DRUG); FOLFIRI (DRUG),60838,Biotecan,Unresectable Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10590,NCT03279289,"Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen",COMPLETED,PHASE2,Metastatic Colorectal Cancer,Aflibercept (DRUG); Irinotecan (DRUG); folinic acid (dl racemic) (DRUG); 5Fluorouracil (DRUG); 5-FU (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10591,NCT00308529,"Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer",COMPLETED,PHASE2,"Carcinoma, Small Cell Lung; Lung Cancer",irinotecan (DRUG); carboplatin (DRUG); bevacizumab (DRUG); Radiation Therapy (PROCEDURE),60838,Biotecan,"Carcinoma, Small Cell Lung; Lung Cancer",Lung,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10592,NCT00012389,Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE3,Colorectal Cancer,irinotecan hydrochloride (DRUG); oxaliplatin (DRUG),60838,Biotecan,Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10593,NCT01821729,Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer,UNKNOWN,PHASE2,Pancreatic Cancer,FOLFIRINOX (DRUG); Losartan (DRUG); Proton Beam Radiation (RADIATION),60838,Biotecan,Pancreatic Cancer,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10594,NCT05732129,The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.,UNKNOWN,PHASE2,Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer,Fluzoparib (DRUG); Irinotecan (DRUG),60838,Biotecan,Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10595,NCT05074589,Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer,COMPLETED,PHASE3,Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy,Irinotecan liposome、5-Fluorouracil、Leucovorin (DRUG); Placebo、5-Fluorouracil、Leucovorin (DRUG),60838,Biotecan,Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10596,NCT00303992,Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,trastuzumab (BIOLOGICAL); irinotecan hydrochloride (DRUG),60838,Biotecan,Breast Cancer,Breast,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10597,NCT06149689,mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer,RECRUITING,PHASE2,Pancreatic Adenocarcinoma,mFOLFIRINOX plus radiotherapy (COMBINATION_PRODUCT),60838,Biotecan,Pancreatic Adenocarcinoma,Pancreas,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10598,NCT02934529,Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab,COMPLETED,PHASE3,Metastatic Colorectal Cancer,Irinotecan (DRUG); Folinic Acid (DRUG); 5-FU (DRUG); 5-FU (DRUG); Cetuximab (DRUG); Bevacizumab (DRUG); Capecitabine (DRUG); regorafenib (DRUG); Irinotecan 125mg (DRUG); Cetuximab wkly (DRUG),60838,Biotecan,Metastatic Colorectal Cancer,Bowel,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10599,NCT05143229,Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer,RECRUITING,PHASE1,Breast Cancer,Alpelisib (DRUG); Sacituzumab govitecan (DRUG),60838,Biotecan,Breast Cancer,Breast,Irinotecan,TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,"Used in cancer treatment, especially for colorectal cancer.",CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,1.24,173.0 +10600,NCT06640166,Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.,RECRUITING,PHASE2,Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumor; Colorectal Adenocarcinoma; Colorectal Cancer (CRC); Colorectal Cancer; Colon Cancer; Colon Adenocarcinoma; Colon Carcinoma; Colon Neoplasm,encorafenib + cetuximab + FOLFIRI (DRUG),74990,Campto,Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumor; Colorectal Adenocarcinoma; Colorectal Cancer (CRC); Colorectal Cancer; Colon Cancer; Colon Adenocarcinoma; Colon Carcinoma; Colon Neoplasm,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10601,NCT04842526,"Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study",UNKNOWN,PHASE2,Refractory or Recurrent Neuroblastoma in Children,Anlotinib and irinotecan combined with temozolomide (DRUG),74990,Campto,Refractory or Recurrent Neuroblastoma in Children,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10602,NCT00493857,Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer,TERMINATED,PHASE2,Colorectal Cancer,Nimotuzumab Humanized Monoclonal Antibody (DRUG); Nimotuzumab (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10603,NCT00033657,Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer,COMPLETED,PHASE2,Esophageal Cancer; Gastric Cancer,cisplatin (DRUG); irinotecan hydrochloride (DRUG); paclitaxel (DRUG); conventional surgery (PROCEDURE); radiation therapy (RADIATION),74990,Campto,Esophageal and Gastric Cancer,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10604,NCT06208657,Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer,RECRUITING,PHASE1,Childhood Cancer; Childhood Solid Tumor; Childhood Brain Tumor; Recurrent Cancer; Refractory Cancer,"Paxalisib, Irinotecan, Temozolomide (DRUG)",74990,Campto,Childhood Cancer; Childhood Solid Tumor; Childhood Brain Tumor; Recurrent Cancer; Refractory Cancer,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10605,NCT02624726,Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,5 Fluorouracil (DRUG); Leucovorin (DRUG); Irinotecan (DRUG); Aflibercept (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10606,NCT04617457,Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas,RECRUITING,PHASE2,Pancreatic Cancer; Metastasis; Surgery; Oligometastatic Disease,"nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA) (DRUG)",74990,Campto,Pancreatic Cancer; Metastasis; Surgery; Oligometastatic Disease,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10607,NCT03563248,Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Pancreatic Cancer,FOLFIRINOX (DRUG); Losartan (DRUG); Nivolumab (DRUG); SBRT (RADIATION); Surgery (PROCEDURE),74990,Campto,Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10608,NCT01312857,"Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer",COMPLETED,PHASE2,Metastatic Colorectal Cancer,panitumumab (DRUG); Randomization to No Panitumumab (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10609,NCT01394120,Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer,UNKNOWN,PHASE2,"Carcinoma, Pancreatic Ductal",Targeted Therapy Tailored Treatment (DRUG); Standard Chemotherapy (DRUG),74990,Campto,Pancreatic Ductal Carcinoma,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10610,NCT02047474,Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Stage I Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,oxaliplatin (DRUG); leucovorin calcium (DRUG); irinotecan hydrochloride (DRUG); fluorouracil (DRUG); therapeutic conventional surgery (PROCEDURE); laboratory biomarker analysis (OTHER),74990,Campto,Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10611,NCT00911820,"Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer",COMPLETED,PHASE2,Esophageal Cancer; Gastric Cancer; Stomach Cancer,Bevacizumab (DRUG); Cisplatin (DRUG); Irinotecan (DRUG); Docetaxel (DEVICE),74990,Campto,Esophageal Cancer; Gastric Cancer; Stomach Cancer,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10612,NCT05018182,FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer,UNKNOWN,PHASE2,High-risk Locally Advanced Colorectal Cancer; Neoadjuvant Chemotherapy; FOLFOXIRI Regimen,Oxaliplatin (DRUG); Irinotecan (DRUG); Folinic Acid (DRUG); 5FU (DRUG); Capecitabine (DRUG),74990,Campto,High-risk Locally Advanced Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10613,NCT01963182,Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer,COMPLETED,PHASE2,First Line Metastatic Colorectal Cancer,Irinotecan (DRUG),74990,Campto,First Line Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10614,NCT00079274,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,COMPLETED,PHASE3,Adenocarcinoma of the Colon; Stage III Colon Cancer,irinotecan hydrochloride (DRUG); oxaliplatin (DRUG); leucovorin calcium (DRUG); fluorouracil (DRUG); cetuximab (BIOLOGICAL); Locally Directed Therapy (DRUG),74990,Campto,Colon Adenocarcinoma,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10615,NCT03161574,FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for Circumferential Radial Margin (CRM) Positive Rectal Cancer,WITHDRAWN,PHASE2,Rectal Cancer,FOLFOXIRI (DRUG),74990,Campto,Rectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10616,NCT05103020,Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks (DRUG); IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10617,NCT01925274,A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer,TERMINATED,PHASE2,Metastatic Colorectal Cancer,PF-05212384 (DRUG); irinotecan (DRUG); Cetuximab (DRUG); Irinotecan (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10618,NCT03616574,First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors,COMPLETED,PHASE1,Advanced or Metastatic Solid Tumors; Advanced or Metastatic Colorectal Cancer (mCRC),CA102N (DRUG); LONSURF (DRUG),74990,Campto,Advanced or Metastatic Solid Tumors; Advanced or Metastatic Colorectal Cancer (mCRC),Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10619,NCT00320320,Irinotecan Discontinuation and Reintroduction for Advanced Colorectal Cancer,TERMINATED,PHASE2,Colorectal Neoplasms; Metastases,Irinotecan (DRUG),74990,Campto,Colorectal Neoplasms; Metastases,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10620,NCT06625320,Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),RECRUITING,PHASE3,Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma,RMC-6236 (DRUG); Gemcitabine (DRUG); nab-paclitaxel (DRUG); Irinotecan (DRUG); Liposomal irinotecan (DRUG); 5-fluorouracil (DRUG); leucovorin (DRUG); Oxaliplatin (DRUG),74990,Campto,Pancreatic Ductal Adenocarcinoma,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10621,NCT01237665,"IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer",UNKNOWN,PHASE2,Rectal Cancer,IXO regimen (DRUG),74990,Campto,Rectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10622,NCT01640782,Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach,COMPLETED,PHASE3,Adenocarcinoma of the Stomach; Adenocarcinoma of the Gastroesophageal Junction,"Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin (DRUG); Leucovorin, 5-Fluorouracil (DRUG)",74990,Campto,Gastric Adenocarcinoma,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10623,NCT01379482,Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer,COMPLETED,PHASE2,Peritoneal Carcinomatosis; Gastric Cancer,Multimodal treatment (DRUG),74990,Campto,Gastric Cancer,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10624,NCT00766220,Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver,WITHDRAWN,PHASE2,Colon Cancer; Colorectal Cancer,SIR-spheres Agent Administration (DRUG); Cetuximab (DRUG); Irinotecan (DRUG),74990,Campto,Colon Cancer; Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10625,NCT02573220,Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer,WITHDRAWN,PHASE1,Stage IVA Colorectal Cancer; Stage IVB Colorectal Cancer,Cetuximab (BIOLOGICAL); Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Leucovorin Calcium (DRUG),74990,Campto,Stage IV Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10626,NCT05585320,A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors,RECRUITING,PHASE1,Advanced Solid Tumor; Pancreatic Adenocarcinoma; Malignant Melanoma (Cutaneous); Non-small Cell Lung Cancer (NSCLC),IMM-1-104 Monotherapy (Treatment Group A) (DRUG); IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B) (DRUG); IMM-1-104 + modified FOLFIRINOX (Treatment Group C) (DRUG); IMM-1-104 + dabrafenib (Treatment Group D) (DRUG); IMM-1-104 + pembrolizumab (Treatment Group E) (DRUG),74990,Campto,Advanced Solid Tumor; Pancreatic Adenocarcinoma; Malignant Melanoma (Cutaneous); Non-small Cell Lung Cancer (NSCLC),Skin,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10627,NCT01219920,FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer,COMPLETED,PHASE3,Metastatic Colorectal Cancer,FOLFIRI (DRUG); FOLFOXIRI (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10628,NCT06304974,A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma,RECRUITING,PHASE3,Esophageal Squamous Cell Carcinoma,BL-B01D1 (DRUG); Irinotecan (DRUG); paclitaxel (DRUG); docetaxel (DRUG),74990,Campto,Esophageal Squamous Cell Carcinoma,Skin,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10629,NCT00115765,PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study,COMPLETED,PHASE3,Colorectal Cancer,Oxaliplatin Based Chemotherapy (DRUG); Panitumumab (DRUG); Irinotecan Based Chemotherapy (DRUG); Bevacizumab (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10630,NCT03500874,Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM,TERMINATED,PHASE3,Colorectal Cancer; Liver Metastases; HAI,FUDR (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); 5FU (DRUG); Irinotecan (DRUG),74990,Campto,Colorectal Cancer with Liver Metastases,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10631,NCT00062374,Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction,COMPLETED,PHASE2,Gastric Adenocarcinoma; Stage II Gastric Cancer; Stage III Gastric Cancer; Stage IV Gastric Cancer,Cisplatin (DRUG); Computed Tomography (PROCEDURE); Fludeoxyglucose F-18 (RADIATION); Fluorothymidine F-18 (OTHER); Irinotecan Hydrochloride (DRUG); Positron Emission Tomography (PROCEDURE); Therapeutic Conventional Surgery (PROCEDURE),74990,Campto,Gastric Adenocarcinoma; Stage II Gastric Cancer; Stage III Gastric Cancer; Stage IV Gastric Cancer,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10632,NCT02620865,BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer,COMPLETED,PHASE1,Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Aldesleukin (BIOLOGICAL); Antibody Therapy (BIOLOGICAL); Fluorouracil (DRUG); Gemcitabine Hydrochloride (DRUG); Irinotecan Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Leucovorin Calcium (DRUG); Oxaliplatin (DRUG); Paclitaxel Albumin-Stabilized Nanoparticle Formulation (DRUG); Sargramostim (BIOLOGICAL),74990,Campto,Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10633,NCT00066274,Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,FOLFIRI regimen (DRUG); FOLFOX regimen (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10634,NCT00176774,"Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma",COMPLETED,PHASE2,Colorectal Carcinoma,Irinotecan (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG); Tetrathiomolybdate (DRUG),74990,Campto,Colorectal Carcinoma,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10635,NCT00522665,Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,Irinotecan (DRUG); Cetuximab (BIOLOGICAL); RAD001 (BIOLOGICAL),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10636,NCT03186326,Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer,UNKNOWN,PHASE2,Metastatic Colorectal Cancer; MSI,FOLFOX regimen (DRUG); FOLFIRI Protocol (DRUG); Avelumab (DRUG); Panitumumab (DRUG); Cetuximab (DRUG); Bevacizumab (DRUG); Aflibercept (DRUG),74990,Campto,Metastatic Colorectal Cancer; MSI,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10637,NCT00513266,Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery,UNKNOWN,PHASE2,Colorectal Cancer; Metastatic Cancer,bevacizumab (BIOLOGICAL); cetuximab (BIOLOGICAL); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG); laboratory biomarker analysis (OTHER); adjuvant therapy (PROCEDURE); biopsy (PROCEDURE); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE),74990,Campto,Colorectal Cancer; Metastatic Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10638,NCT04423965,A Trial of Neoadjuvant mFOLFOXIRI Versus CRT in the EMVI Positive LARC,UNKNOWN,PHASE2,Locally Advanced Rectal Cancer,mFOLFOXIRI (DRUG); Chemoradiotherapy (COMBINATION_PRODUCT),74990,Campto,Rectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10639,NCT04908566,Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma,RECRUITING,PHASE2,Locally Advanced Gastric Adenocarcinoma,PD-1 antibody combined with FOLFIRINOX regimen (DRUG); PD-1 antibody combined with SOX program (DRUG),74990,Campto,Locally Advanced Gastric Adenocarcinoma,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10640,NCT04560166,Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma,TERMINATED,PHASE2,Neuroblastoma Recurrent,Naxitamab and GM-CSF in combination with irinotecan and temozolomide (DRUG),74990,Campto,Neuroblastoma Recurrent,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10641,NCT05718466,Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy,COMPLETED,PHASE3,Recurrent or Progressive Glioblastoma,Bevacizumab (DRUG); Chemotherapy (DRUG); Fractionated radiosurgery (RADIATION),74990,Campto,Recurrent or Progressive Glioblastoma,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10642,NCT05277766,Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis from Gastrointestinal Cancer,RECRUITING,PHASE1,Peritoneal Carcinomatosis; Peritoneal Metastases; Colorectal Cancer; Small Bowel Cancer; Appendix Cancer; Gastric Cancer; Pancreatic Cancer; Bile Duct Cancer,PIPAC with Nal-IRI (DRUG),74990,Campto,Peritoneal Carcinomatosis; Peritoneal Metastases; Colorectal Cancer; Small Bowel Cancer; Appendix Cancer; Gastric Cancer; Pancreatic Cancer; Bile Duct Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10643,NCT06467565,NALIRIFOX as Induction Therapy in LAPC,RECRUITING,PHASE2,Pancreatic Ductal Adenocarcinoma,Liposomal irinotecan (DRUG),74990,Campto,Pancreatic Ductal Adenocarcinoma,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10644,NCT05255666,Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM),WITHDRAWN,PHASE2,Triple Negative Breast Cancer; Brain Metastases,Pembrolizumab (DRUG); Liposomal Irinotecan (DRUG),74990,Campto,Triple Negative Breast Cancer; Brain Metastases,Breast,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10645,NCT06586866,JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases,NOT_YET_RECRUITING,PHASE2,Triple Negative Breast Cancer (TNBC); Brain Metastasases,JK-1201I (DRUG),74990,Campto,Triple Negative Breast Cancer (TNBC); Brain Metastasases,Breast,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10646,NCT00073866,Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer,celecoxib (DRUG); docetaxel (DRUG); irinotecan hydrochloride (DRUG),74990,Campto,Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10647,NCT04233866,"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Fluorouracil (DRUG); Gemcitabine (DRUG); Gemcitabine Hydrochloride (DRUG); Leucovorin (DRUG); Leucovorin Calcium (DRUG); Liposomal Irinotecan (DRUG); Nab-paclitaxel (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),74990,Campto,Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10648,NCT06766266,Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment,RECRUITING,PHASE1,Non-Muscle Invasive Bladder Urothelial Carcinoma,Irinotecan liposome II combination therapy regimen (DRUG); Irinotecan liposome II combination therapy regimen (DRUG),74990,Campto,Non-Muscle Invasive Bladder Urothelial Carcinoma,Bladder/Urinary Tract,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10649,NCT00614965,Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV,COMPLETED,PHASE2,Non Small Cell Lung Cancer,Irinotecan (DRUG); Cisplatin (DRUG); Pemetrexed (DRUG),74990,Campto,Non Small Cell Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10650,NCT02626520,Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla,TERMINATED,PHASE2,Ductal Adenocarcinoma of Pancreas; Adenocarcinoma of Ampulla,Gemcitabine and nanoparticle albumin bound paclitaxel (DRUG); 5-fluorouracil and irinotecan (DRUG); Preoperative chemoradiation (RADIATION); Definitive resection (PROCEDURE),74990,Campto,Ductal Adenocarcinoma of Pancreas; Adenocarcinoma of Ampulla,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10651,NCT00012220,Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas,COMPLETED,PHASE2,Pancreatic Cancer,cisplatin (DRUG); docetaxel (DRUG); gemcitabine hydrochloride (DRUG); irinotecan hydrochloride (DRUG),74990,Campto,Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10652,NCT02753127,A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer,COMPLETED,PHASE3,Colorectal Cancer,Napabucasin (DRUG); Fluorouracil (DRUG); Leucovorin (DRUG); Irinotecan (DRUG); Bevacizumab (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10653,NCT01044420,mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial,UNKNOWN,PHASE2,Advanced Esophageal Carcinoma,mFOLFIRI (DRUG),74990,Campto,Advanced Esophageal Carcinoma,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10654,NCT00449020,"Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer",COMPLETED,PHASE2,Lung Cancer,Carboplatin (DRUG); Docetaxel (DRUG); irinotecan hydrochloride (DRUG); radiation therapy (RADIATION),74990,Campto,Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10655,NCT03454620,"A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy",COMPLETED,PHASE1,Metastatic Colorectal Cancer; Solid Tumor,irinotecan (DRUG); FOLFIRI (DRUG),74990,Campto,Metastatic Colorectal Cancer; Solid Tumor,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10656,NCT02314182,GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis,COMPLETED,PHASE3,Rectal Adenocarcinoma,"Primary tumor resection + chemotherapy (PROCEDURE); Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab (DRUG)",74990,Campto,Rectal Adenocarcinoma,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10657,NCT00422773,Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer,COMPLETED,PHASE1,Metastatic Colorectal Cancer,Cetuximab (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10658,NCT04215731,Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer,RECRUITING,PHASE3,Rectal Cancer,Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab (DRUG); Restaging (PROCEDURE); Concomitant Chemoradiotherapy (RADIATION); Surgery (PROCEDURE); Chemoradiotherapy (only when patients with MRF involved or ycT4a/b by restaging) (RADIATION); Induction chemotherpay with FOLFOX (DRUG),74990,Campto,Rectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10659,NCT00590031,Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.,COMPLETED,PHASE2,Esophageal Carcinoma,Cisplatin (DRUG); Irinotecan (DRUG); External Beam Radiation Therapy (RADIATION),74990,Campto,Esophageal Carcinoma,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10660,NCT06199973,"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan",RECRUITING,PHASE3,Advanced Colorectal Cancer,"SHR-A1811 (DRUG); TAS-102, Regorafenib , Fruquintinib (DRUG)",74990,Campto,Advanced Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10661,NCT05223673,Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer,TERMINATED,PHASE3,Metastatic Colorectal Cancer,Futuximab/modotuximab (BIOLOGICAL); Trifluridine/Tipiracil (DRUG); Trifluridine/Tipiracil (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10662,NCT00625573,Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01),COMPLETED,PHASE2,Colorectal Cancer,Abraxane (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10663,NCT04790448,Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer Metastatic,Cetuximab (DRUG); Irinotecan (DRUG); Vemurafenib (DRUG),74990,Campto,Colorectal Cancer Metastatic,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10664,NCT02350530,FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,FOLFOXIRI + Bevacizumab (DRUG); FOLFOXIRI (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10665,NCT01321957,Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,"Oxaliplatin, 5FU/LV, Bevacizumab (DRUG); 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan (DRUG)",74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10666,NCT06941857,NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer,NOT_YET_RECRUITING,PHASE2,Pancreatic Cancer,Oxaliplatin (DRUG); Irinotecan (DRUG); Folinic Acid (DRUG); 5-Fluorouracil (5-FU) (DRUG); NC410 (DRUG); Nivolumab (DRUG); Ipilimumab (DRUG),74990,Campto,Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10667,NCT01523457,Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer,COMPLETED,PHASE2,Metastatic Pancreatic Cancer; Pancreatic Cancer,Folfirinox (DRUG),74990,Campto,Metastatic Pancreatic Cancer; Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10668,NCT00891930,Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Panitumumab (BIOLOGICAL); Ganitumab (BIOLOGICAL); Irinotecan (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10669,NCT01271582,Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients,UNKNOWN,PHASE4,Stage IV Colorectal Cancer; Gastric Cancer,"Irinotecan, 5FU, leucovorin (DRUG)",74990,Campto,Advanced Gastrointestinal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10670,NCT05818982,To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC,RECRUITING,PHASE2,Advanced Esophageal Squamous Cell Carcinoma,Afatinib (DRUG); Irinotecan (DRUG),74990,Campto,Advanced Esophageal Squamous Cell Carcinoma,Skin,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10671,NCT00087282,Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer,COMPLETED,PHASE2,Liver Cancer,alvocidib (DRUG); irinotecan hydrochloride (DRUG),74990,Campto,Liver Cancer,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10672,NCT00934882,"Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI",COMPLETED,PHASE1,Colorectal Neoplasms,Regorafenib (BAY73-4506) (DRUG),74990,Campto,Colorectal Neoplasms,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10673,NCT03099382,Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer,COMPLETED,PHASE3,Esophageal Carcinoma,camrelizumab (BIOLOGICAL); Docetaxel (DRUG); Irinotecan (DRUG),74990,Campto,Esophageal Carcinoma,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10674,NCT00463073,"Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas",COMPLETED,PHASE2,Malignant Gliomas,Cetuximab (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG),74990,Campto,Malignant Gliomas,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10675,NCT00950820,Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer,TERMINATED,PHASE2,Colorectal Neoplasms,"Oxaliplatin, Capecitabine, Panitumumab (DRUG); Oxaliplatin, Capecitabine (DRUG)",74990,Campto,Colorectal Neoplasms,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10676,NCT00717990,"Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment",TERMINATED,PHASE2,Metastatic Colorectal Cancer,Capecitabine (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10677,NCT01133990,FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer,TERMINATED,PHASE1,Colorectal Cancer,FOLFIRI (DRUG); E7820 (DRUG); Bevacizumab (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10678,NCT00642603,A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer,TERMINATED,PHASE2,Colorectal Cancer,capecitabine [Xeloda] (DRUG); capecitabine [Xeloda] (DRUG); bevacizumab [Avastin] (DRUG); oxaliplatin (DRUG); irinotecan (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10679,NCT00821990,Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer,COMPLETED,PHASE3,Advanced Gastric Cancer,Chemotherapy (DRUG); Best supportive care (OTHER),74990,Campto,Advanced Gastric Cancer,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10680,NCT01703390,Biomarker Directed Treatment in Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,FOLFIRI + Cetuximab (DRUG); modifiedFOLFOX6 + Cetuximab (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10681,NCT06700603,Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer,NOT_YET_RECRUITING,PHASE2,Pancreatic Cancer,Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate (DRUG),74990,Campto,Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10682,NCT04714190,A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression,RECRUITING,PHASE3,Gastric Cancer; HER2 Overexpressing Gastric Carcinoma,RC48-ADC (DRUG); Paclitaxel injection (DRUG); Irinotecan Hydrochloride Injection (DRUG); Apatinib Mesylate Tablets (DRUG),74990,Campto,Gastric Cancer; HER2 Overexpressing Gastric Carcinoma,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10683,NCT02173990,Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).,TERMINATED,PHASE2,Metastatic Colorectal Cancer,Aflibercept-FOLFIRI (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10684,NCT01862003,Phase I/II Trial of Antagonism of HER in GI Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer; Recurrent Colorectal Cancer,AZD8931 (DRUG); Irinotecan (DRUG); Folinic Acid (DRUG); Fluorouracil (DRUG); Fluorouracil (DRUG),74990,Campto,Metastatic Colorectal Cancer; Recurrent Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10685,NCT03562390,Irinotecan for Advanced and Metastatic Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Irinotecan (DRUG),74990,Campto,Breast Cancer,Breast,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10686,NCT06405490,NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC,RECRUITING,PHASE2,Nanoliposomal Irinotecan; Cadonilimab; Oxaliplatin; Capecitabine; First-Line; Advanced Cancer; Pancreatic Adenocarcinoma; Drug Use,Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab (DRUG),74990,Campto,Pancreatic Adenocarcinoma Treatment,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10687,NCT05634590,The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer,NOT_YET_RECRUITING,PHASE2,Metastatic Colorectal Cancer,Fruquintinib (DRUG); FOLFIRI (DRUG); mFOLFOX6 (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10688,NCT06928584,Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer,RECRUITING,PHASE2,Locally Recurrent Rectal Cancer,Conventional Radiotherapy (RADIATION); Capecitabine (DRUG); 5-fluorouracil (DRUG); folinic acid (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG); Cetuximab (DRUG); Bevacizumab (DRUG); Hypofractionated radiotherapy (RADIATION); PD-1 antibody (DRUG),74990,Campto,Locally Recurrent Rectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10689,NCT04224402,Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.,COMPLETED,PHASE2,Pancreatic Cancer Resectable,mFOLFORINOX (DRUG),74990,Campto,Pancreatic Cancer Resectable,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10690,NCT01070290,A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen,WITHDRAWN,PHASE2,Gastric Cancer,"ARQ 197 (DRUG); Oxaliplatin, capecitabine or irinotecan (DRUG)",74990,Campto,Gastric Cancer,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10691,NCT01588990,A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer,COMPLETED,PHASE4,Colorectal Neoplasms,Oxaliplatin (DRUG); Capecitabine (DRUG); Bevacizumab (DRUG); Leucovorin (DRUG); 5-Fluouracil (DRUG); Irinotecan (DRUG),74990,Campto,Colorectal Neoplasms,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10692,NCT05379790,Concomitant Intraperitoneal and Systemic Chemotherapy in Patients with Extensive Peritoneal Carcinomatosis of Gastric Origin,COMPLETED,PHASE1,Gastric Cancer; Peritoneal Metastases,Irinotecan (DRUG); CAPOX (DRUG),74990,Campto,Gastric Cancer with Peritoneal Metastases,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10693,NCT01928290,"Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer",COMPLETED,PHASE2,Stomach Neoplasms; Esophageal Neoplasms,Irinotecan (DRUG); Trastuzumab (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); Fluorouracil (DRUG),74990,Campto,Gastrointestinal Neoplasms,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10694,NCT00569790,"Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer",COMPLETED,PHASE2,Colorectal Cancer,"S-1, Irinotecan, Bevacizumab (DRUG)",74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10695,NCT00463203,Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy,COMPLETED,PHASE2,Brain Neoplasms; Glioma,Bevacizumab (DRUG); Irinotecan (DRUG),74990,Campto,Brain Neoplasms; Glioma,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10696,NCT00940303,OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,5-FU (DRUG); bevacizumab [Avastin] (DRUG); irinotecan (DRUG); leucovorin (DRUG); oxaliplatin (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10697,NCT04380103,A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer,UNKNOWN,PHASE1,Metastatic Cancer; Colorectal Cancer; Colorectal Adenocarcinoma,XELOXIRI/Bevacizumab (DRUG),74990,Campto,Metastatic Cancer; Colorectal Cancer; Colorectal Adenocarcinoma,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10698,NCT05400603,Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma,RECRUITING,PHASE1,Neuroblastoma; Refractory Neuroblastoma; Relapsed Neuroblastoma; Relapsed Osteosarcoma; Refractory Osteosarcoma,"Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate (COMBINATION_PRODUCT)",74990,Campto,Neuroblastoma; Refractory Neuroblastoma; Relapsed Neuroblastoma; Relapsed Osteosarcoma; Refractory Osteosarcoma,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10699,NCT05229003,Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC,RECRUITING,PHASE2,Metastatic Colorectal Cancer,Anlotinib (DRUG); Penpulimab (DRUG); Irinotecan (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10700,NCT00460603,Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE1,Colorectal Neoplasms,bevacizumab (DRUG); AG-013726 (DRUG); AG-013736 (axitinib) (DRUG),74990,Campto,Colorectal Neoplasms,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10701,NCT00006103,Combination Chemotherapy in Treating Patients With Colorectal Cancer,COMPLETED,PHASE3,Colorectal Cancer,fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10702,NCT00318903,Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer,COMPLETED,PHASE2,Esophageal Cancer; Cancer of the Esophagus; Esophagus Cancer; Esophageal Neoplasm; Cancer of Esophagus,Irinotecan (drug) (DRUG); Taxotere (drug) (DRUG); Radiotherapy (procedure) (PROCEDURE); Esophagectomy (procedure) (PROCEDURE),74990,Campto,Esophageal Cancer; Cancer of the Esophagus; Esophagus Cancer; Esophageal Neoplasm; Cancer of Esophagus,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10703,NCT06434090,Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer,NOT_YET_RECRUITING,PHASE1,Colorectal Cancer,Liposomal irinotecan (DRUG); Bevacizumab (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10704,NCT02453490,Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis,TERMINATED,PHASE3,Colorectal Cancer; Liver Metastasis,Raltitrexed-based chemotherapy (DRUG); Raltitrexed-based chemotherapy (DRUG); 5-fluorouracil-based chemotherapy (DRUG); 5-fluorouracil-based chemotherapy (DRUG),74990,Campto,Colorectal Cancer; Liver Metastasis,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10705,NCT01704703,"Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques",COMPLETED,PHASE2,Stage IV Colorectal Cancer,panitumumab (DRUG); FOLFIRI (DRUG),74990,Campto,Stage IV Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10706,NCT01383343,"Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer",COMPLETED,PHASE1,Recurrent Colon Carcinoma; Recurrent Rectal Carcinoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,Bevacizumab (BIOLOGICAL); Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Leucovorin Calcium (DRUG); Sorafenib Tosylate (DRUG),74990,Campto,Recurrent Colon Carcinoma; Recurrent Rectal Carcinoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10707,NCT00165490,"Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer",COMPLETED,PHASE2,Adenocarcinoma of Esophagus; Squamous Cell Carcinoma of Esophagus,Cetuximab (DRUG); Cisplatin (DRUG); Irinotecan (DRUG); Radiation therapy (DEVICE); Surgery (PROCEDURE),74990,Campto,Adenocarcinoma of Esophagus; Squamous Cell Carcinoma of Esophagus,Skin,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10708,NCT05677490,"mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma",RECRUITING,PHASE3,Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Metastatic Esophageal Adenocarcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Unresectable Esophageal Adenocarcinoma; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma,Fluorouracil (DRUG); Leucovorin Calcium (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG); Nivolumab (BIOLOGICAL); Magnetic Resonance Imaging (PROCEDURE); Computed Tomography (PROCEDURE); Biospecimen Collection (PROCEDURE); Questionnaire Administration (OTHER),74990,Campto,Advanced Gastroesophageal Adenocarcinoma,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10709,NCT01315990,FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema,UNKNOWN,PHASE4,Colorectal Cancer Metastatic,FOLFIRI + Cetuximab (DRUG),74990,Campto,Colorectal Cancer Metastatic,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10710,NCT03329690,DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01],COMPLETED,PHASE2,"Neoplasm, Gastrointestinal",DS-8201a (DRUG); Physician's Choice (DRUG),74990,Campto,Gastrointestinal Neoplasm,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10711,NCT05750290,CKD-702 Plus Irinotecan in Gastric Cancer,RECRUITING,PHASE2,Gastric Cancer,CKD-702 in combination with irinotecan (DRUG),74990,Campto,Gastric Cancer,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10712,NCT04659421,Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas,COMPLETED,PHASE2,Low-grade Glioma; Pediatric Brain Tumor,combined therapy with rh-ES and CV (DRUG),74990,Campto,Pediatric Low-grade Glioma,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10713,NCT00953121,Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG),COMPLETED,PHASE2,Malignant Glioma,bevacizumab and CPT-11 and Carboplatin (DRUG),74990,Campto,Malignant Glioma,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10714,NCT06197438,Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer,NOT_YET_RECRUITING,PHASE2,Gastric Cancer,Tislelizumab (DRUG); Oxaliplatin (DRUG); Levo-Leucovorin (DRUG); 5-fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Paclitaxel (DRUG),74990,Campto,Gastric Cancer,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10715,NCT05381038,Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI,NOT_YET_RECRUITING,PHASE1,Solid Tumor; Gastrointestinal Cancer; Breast Cancer,QPOP (DEVICE); CURATE.AI (DEVICE); Azacitidine + docetaxel (DRUG); Azacitidine + paclitaxel (DRUG); Azacitidine + irinotecan (DRUG),74990,Campto,Solid Tumors and Gastrointestinal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10716,NCT00889343,Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer,TERMINATED,PHASE2,Colorectal Neoplasms,Sorafenib (DRUG); Placebo (DRUG); Oxaliplatin or Irinotecan (DRUG); Leucovorin (DRUG); 5-Fluorouracil (DRUG),74990,Campto,Colorectal Neoplasms,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10717,NCT05251038,Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer,WITHDRAWN,PHASE1,Pancreatic Cancer; Unresectable Pancreatic Cancer; Metastatic Pancreatic Cancer; KRAS P.G12C,Sotorasib (DRUG); Liposomal Irinotecan (nal-IRI) (DRUG); 5 Fluorouracil (5FU) (DRUG); Leucovorin (LV) (DRUG); Gemcitabine (GEM) (DRUG); Nab paclitaxel (DRUG),74990,Campto,Pancreatic Cancer; Unresectable Pancreatic Cancer; Metastatic Pancreatic Cancer; KRAS P.G12C,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10718,NCT00612638,Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas,COMPLETED,PHASE1,Glioblastoma; Gliosarcoma,"Temodar, O6-BG, and Irinotecan (DRUG)",74990,Campto,Glioblastoma,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10719,NCT01905150,"Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer",COMPLETED,PHASE2,Pancreatic Cancer,G-FLIP (DRUG); G-FLIP-DM (DRUG); Vitamin C (DIETARY_SUPPLEMENT),74990,Campto,Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10720,NCT00003950,"Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer",COMPLETED,PHASE2,Colorectal Cancer,cyclosporine (DRUG); CPT-11 (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10721,NCT06652412,CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC,NOT_YET_RECRUITING,PHASE2,Colon Cancer; Rectal Cancer,Ultrafractionated RT and CGA Guided systemic treatment. (DRUG); data prospectively collected (OTHER); Ultrafractionated Radiotherapy (RADIATION); Sintilimab (DRUG); Fluorouracil (DRUG); Raltitrexed (DRUG); Oxaliplatin (DRUG); Irinotecan (CPT-11) (DRUG),74990,Campto,Colon Cancer; Rectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10722,NCT03167112,A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer,UNKNOWN,PHASE2,Pancreatic Cancer,Oxaliplatin (DRUG); Irinotecan (DRUG); Leucovorin (DRUG); Fluorouracil (DRUG),74990,Campto,Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10723,NCT05990543,Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer,NOT_YET_RECRUITING,PHASE1,Recurrent or Metastatic Colorectal Cancer,Nelmastobart and Capecitabine (DRUG),74990,Campto,Recurrent or Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10724,NCT00540943,"Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer",COMPLETED,PHASE1,"Neoplasms, Colorectal",Pazopanib (DRUG); Cetuximab (DRUG); Irinotecan (DRUG),74990,Campto,"Neoplasms, Colorectal",Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10725,NCT03251612,Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer Metastatic,Based on sensitivity analysis (DRUG),74990,Campto,Colorectal Cancer Metastatic,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10726,NCT00027612,Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme,COMPLETED,PHASE1,Brain and Central Nervous System Tumors,carmustine (DRUG); irinotecan hydrochloride (DRUG); radiation therapy (RADIATION),74990,Campto,Brain and Central Nervous System Tumors,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10727,NCT03792269,Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC,UNKNOWN,PHASE2,Colorectal Cancer Metastatic; Chemotherapy Effect; Chemotherapeutic Toxicity,Irinotecan (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG),74990,Campto,Metastatic Colorectal Cancer with Chemotherapy Effects,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10728,NCT00003301,Irinotecan in Treating Patients With Recurrent Malignant Glioma,COMPLETED,PHASE1,Brain and Central Nervous System Tumors,irinotecan hydrochloride (DRUG),74990,Campto,Brain and Central Nervous System Tumors,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10729,NCT04985201,Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy,UNKNOWN,PHASE2,Small Cell Lung Cancer,Irinotecan (DRUG); Simvastatin (DRUG),74990,Campto,Small Cell Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10730,NCT06954246,A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer,NOT_YET_RECRUITING,PHASE3,Small Cell Lung Cancer Extensive Stage,MHB088C for Injection (DRUG); Topotecan (DRUG); Irinotecan (DRUG); Paclitaxel (DRUG),74990,Campto,Small Cell Lung Cancer Extensive Stage,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10731,NCT06838546,"A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer",NOT_YET_RECRUITING,PHASE2,Advanced Colorectal Cancer,B1962 (DRUG),74990,Campto,Advanced Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10732,NCT00039468,Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy,COMPLETED,PHASE2,Brain and Central Nervous System Tumors,irinotecan hydrochloride (DRUG); thalidomide (DRUG),74990,Campto,Brain and Central Nervous System Tumors,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10733,NCT05253846,Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29,ACTIVE_NOT_RECRUITING,PHASE2,Locally Advanced Rectal Cancer,Irinotecan (DRUG); Oxaliplatin (DRUG); Lederfolin (DRUG); 5-Fluorouracil (DRUG); Short-course radiotherapy (RADIATION); TME (PROCEDURE),74990,Campto,Rectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10734,NCT00499369,Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy,TERMINATED,PHASE3,Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); fluorouracil (DRUG); cetuximab (BIOLOGICAL); bevacizumab (BIOLOGICAL),74990,Campto,Advanced Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10735,NCT03464968,mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line,COMPLETED,PHASE2,Biliary Cancer Metastatic,"Oxaliplatin,5FU, leucovorin (DRUG); irinotecan,5FU, leucovorin (DRUG)",74990,Campto,Metastatic Biliary Cancer,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10736,NCT00780169,Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer,COMPLETED,PHASE1,Metastatic Colorectal Cancer,sorafenib + FOLFIRI (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10737,NCT04205968,Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers,RECRUITING,PHASE2,Metastatic Small Intestinal Adenocarcinoma; Stage III Small Intestinal Adenocarcinoma AJCC v8; Stage IIIA Small Intestinal Adenocarcinoma AJCC v8; Stage IIIB Small Intestinal Adenocarcinoma AJCC v8; Stage IV Small Intestinal Adenocarcinoma AJCC v8,Fluorouracil (DRUG); Irinotecan (DRUG); Irinotecan Hydrochloride (DRUG); Leucovorin (DRUG); Leucovorin Calcium (DRUG); Paclitaxel (DRUG); Ramucirumab (BIOLOGICAL),74990,Campto,Small Intestinal Adenocarcinoma,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10738,NCT00114946,A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer,TERMINATED,PHASE4,Colorectal Cancer,Avastin (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10739,NCT02060669,Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer,TERMINATED,PHASE3,Metastatic Colorectal Cancer,Xeloda (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10740,NCT05427669,Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD),NOT_YET_RECRUITING,PHASE3,Colorectal Cancer,mFOLFOXIRI (DRUG); mFOLFOX6 (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10741,NCT00025168,Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,gemcitabine hydrochloride (DRUG); irinotecan hydrochloride (DRUG); radiation therapy (RADIATION),74990,Campto,Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10742,NCT03693846,Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors,TERMINATED,PHASE2,Mucinous Adenocarcinoma of the Colon; Mucinous Adenocarcinoma of the Rectum,Nivolumab (DRUG); Ipilimumab (DRUG),74990,Campto,Mucinous Adenocarcinoma of the Colon and Rectum,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10743,NCT00620269,Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III,UNKNOWN,PHASE2,Lung Cancer; NSCLC,Erlotinib (DRUG); Induction or consolidation IP chemotherapy (DRUG); CCRT with IP chemotherapy (Irinotecan + Cisplatin) (DRUG); CCRT (RADIATION),74990,Campto,Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10744,NCT00871169,"Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer",COMPLETED,PHASE2,Pancreatic Cancer,"Irinotecan, oxaliplatin, and cetuximab (DRUG)",74990,Campto,Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10745,NCT06430827,Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma,NOT_YET_RECRUITING,PHASE2,Biliary Tract Carcinoma,irinotecan hydrochloride liposome injection (DRUG); Capecitabine (DRUG),74990,Campto,Biliary Tract Carcinoma,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10746,NCT00639327,Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer,COMPLETED,PHASE2,Gastric Cancer,S-1 + irinotecan (DRUG); irinotecan (DRUG),74990,Campto,Gastric Cancer,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10747,NCT04943627,Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA),WITHDRAWN,PHASE3,Advanced Cancer; Metastatic Cervical Cancer,Balstilimab (BAL) (DRUG); Topotecan (DRUG); Vinorelbine (DRUG); Gemcitabine (DRUG); Irinotecan (DRUG); Pemetrexed (DRUG),74990,Campto,Advanced Cancer; Metastatic Cervical Cancer,Cervix,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10748,NCT00287976,Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma,UNKNOWN,PHASE2,Liver Cancer,irinotecan hydrochloride (DRUG),74990,Campto,Liver Cancer,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10749,NCT05722327,Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Colon Cancer; Colorectal Cancer,MRTX849 (DRUG); Irinotecan (DRUG); Cetuximab (DRUG),74990,Campto,Colon Cancer; Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10750,NCT03641976,"A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer",UNKNOWN,PHASE2,"Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy; Unresectable Metastatic Right-sided Colon Cancer, Stage IV",A-FOLFOXIRI (DRUG); Arm II (A-FOLFOX/A-FOLFIRI) (DRUG),74990,Campto,Metastatic Colon Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10751,NCT00954876,Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer,WITHDRAWN,PHASE2,Metastatic Colorectal Cancer,capecitabine and cetuximab (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10752,NCT00681876,Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer,TERMINATED,PHASE2,Colorectal Cancer,Irinotecan (DRUG); Avastin (DRUG); Erbitux (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10753,NCT01964027,The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer,UNKNOWN,PHASE2,Stage IV Gastric Cancer With Metastasis,second line chemoregime for advanced gastric cancer (DRUG),74990,Campto,Stage IV Gastric Cancer With Metastasis,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10754,NCT06936527,XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation,NOT_YET_RECRUITING,PHASE1,Colorectal Cancer; Metastatic Colorectal Cancer With RAS Mutation,"Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI (BIOLOGICAL); Drug: XS-03 (BIOLOGICAL); Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI (BIOLOGICAL)",74990,Campto,Colorectal Cancer; Metastatic Colorectal Cancer With RAS Mutation,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10755,NCT01609231,A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025),TERMINATED,PHASE2,Rectal Neoplasms,Dalotuzumab (DRUG); Irinotecan (DRUG); Cetuximab (DRUG),74990,Campto,Rectal Neoplasms,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10756,NCT05770531,Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy,RECRUITING,PHASE2,Metastatic HER2-Negative Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma,Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Biospecimen Collection (PROCEDURE); Sacituzumab Govitecan (BIOLOGICAL),74990,Campto,Metastatic HER2-Negative Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma,Breast,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10757,NCT01765582,Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer,TERMINATED,PHASE2,Colorectal Neoplasms,5-fluorouracil (DRUG); bevacizumab (DRUG); capecitabine (DRUG); irinotecan (DRUG); folinic acid (DRUG); oxaliplatin (DRUG),74990,Campto,Colorectal Neoplasms,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10758,NCT02595931,M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Colorectal Carcinoma; Metastatic Lung Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Carcinoma; Refractory Colorectal Carcinoma; Refractory Lung Small Cell Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Pancreatic Carcinoma; Stage III Colorectal Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Colorectal Carcinoma; Unresectable Lung Small Cell Carcinoma; Unresectable Malignant Solid Neoplasm; Unresectable Pancreatic Carcinoma,Berzosertib (DRUG); Biopsy Specimen (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Irinotecan Hydrochloride (DRUG),74990,Campto,Metastatic Colorectal Carcinoma; Metastatic Lung Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Carcinoma; Refractory Colorectal Carcinoma; Refractory Lung Small Cell Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Pancreatic Carcinoma; Stage III Colorectal Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Colorectal Carcinoma; Unresectable Lung Small Cell Carcinoma; Unresectable Malignant Solid Neoplasm; Unresectable Pancreatic Carcinoma,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10759,NCT01803282,Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors,COMPLETED,PHASE1,Pancreatic Cancer; Non-small Cell Lung Cancer; Esophagogastric Cancer; Colorectal Cancer; Breast Cancer,Andecaliximab (DRUG); Gemcitabine (DRUG); Nab-paclitaxel (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); 5-FU (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG); Paclitaxel (DRUG),74990,Campto,"Multiple Cancers (Pancreatic, Lung, Esophagogastric, Colorectal, Breast)",Breast,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10760,NCT01136031,Paclitaxel and Irinotecan in Advanced Gastric Cancer,COMPLETED,PHASE1,Advanced Gastric Cancer,Paclitaxel and irinotecan (DRUG),74990,Campto,Advanced Gastric Cancer,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10761,NCT03829462,Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients,ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Colorectal Cancer (mCRC),Regorafenib (DRUG); Irinotecan (DRUG),74990,Campto,Metastatic Colorectal Cancer (mCRC),Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10762,NCT00106262,"Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer",TERMINATED,PHASE2,Cervical Cancer,Velcade (bortezomib) (DRUG); Irinotecan (DRUG),74990,Campto,Cervical Cancer,Cervix,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10763,NCT00486460,"Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer",UNKNOWN,PHASE3,Pancreatic Cancer,Gemcitabine (DRUG); Curcumin (DRUG); Celebrex (DRUG),74990,Campto,Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10764,NCT02368860,"OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma",COMPLETED,PHASE1,Pancreatic Cancer,"oxaliplatin, irinotecan, capecitabine (DRUG)",74990,Campto,Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10765,NCT06603376,"Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer",RECRUITING,PHASE2,Colorectal Carcinoma,FOLFIRI + Vemurafenib + Cetuximab (DRUG); FOLFIRI ± Bevacizumab (DRUG),74990,Campto,Colorectal Carcinoma,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10766,NCT00072527,"Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer",COMPLETED,PHASE2,Lung Cancer,carboplatin (DRUG); cisplatin (DRUG); etoposide (DRUG); irinotecan hydrochloride (DRUG); radiation therapy (RADIATION),74990,Campto,Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10767,NCT02172976,Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma,COMPLETED,PHASE2,Resectable Prancreas Carcinoma,Gemcitabine (DRUG); Oxaliplatin (DRUG); 5-Fluorouracil (DRUG); Irinotecan (DRUG); Natriumfolinate (DRUG),74990,Campto,Pancreatic Carcinoma,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10768,NCT00559676,Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer,COMPLETED,PHASE4,Colorectal Cancer,capecitabine (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10769,NCT04668976,A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma,UNKNOWN,PHASE2,Colorectal Cancer; Cholangiocarcinoma,Medtronic pump and Codman catheter (DEVICE); Floxuridine (FUDR) (DRUG); Gemcitabine (DRUG); Oxaliplatin (DRUG); Irinotecan (CPT-11) (DRUG); Fluorouracil (DRUG); Anti-EGFR (Panitumumab or Cetuximab) (DRUG),74990,Campto,Colorectal Cancer; Cholangiocarcinoma,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10770,NCT01123876,Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor,COMPLETED,PHASE1,Gastric Cancer,Veliparib (DRUG),74990,Campto,Gastric Cancer,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10771,NCT02279576,Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG),TERMINATED,PHASE2,Penile Squamous Cell Carcinoma Stage IV,Pazopanib (DRUG); Paclitaxel (DRUG),74990,Campto,Penile Squamous Cell Carcinoma Stage IV,Skin,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10772,NCT00300027,Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies,TERMINATED,PHASE1,Gastrointestinal Neoplasms,BMS-582664 (DRUG),74990,Campto,Gastrointestinal Neoplasms,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10773,NCT03528876,FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma,TERMINATED,PHASE2,Metastatic Gastro-esophageal Adenocarcinoma,FOLFOX and FOLFIRI (DRUG),74990,Campto,Metastatic Gastro-esophageal Adenocarcinoma,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10774,NCT03485027,Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer; Chemotherapy Effect,the rechallenge regimen (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10775,NCT03751176,Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal,UNKNOWN,PHASE2,Colorectal Cancer Metastatic,Panitumumab (DRUG); Irinotecan (DRUG); Folinic acid (DRUG); 5-FU (DRUG),74990,Campto,Colorectal Cancer Metastatic,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10776,NCT01085331,MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC),TERMINATED,PHASE1,Metastatic Colorectal Cancer,Pimasertib (DRUG); Placebo (DRUG); FOLFIRI (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10777,NCT02953782,Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer,COMPLETED,PHASE1,Solid Tumor; Colorectal Cancer,Magrolimab (DRUG); Cetuximab (DRUG),74990,Campto,Solid Tumor; Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10778,NCT01523431,Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Irinotecan Injection [Camptosar] (DRUG); 5-fluorouracil (DRUG); Leucovorin (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10779,NCT01652482,Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC),COMPLETED,PHASE2,Colorectal Cancer,5-fluorouracil (DRUG); Cetuximab (DRUG); Irinotecan (DRUG); Leucovorin (DRUG); MEHD7945A (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10780,NCT06190782,Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor,RECRUITING,PHASE3,Esophageal Squamous Cell Carcinoma; Oligometastatic Disease; Radiotherapy,PD-1 inhibitor+/- chemotherapy combined with local therapy (COMBINATION_PRODUCT); systemic therapy alone (DRUG),74990,Campto,Esophageal Squamous Cell Carcinoma; Oligometastatic Disease; Radiotherapy,Skin,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10781,NCT04581473,"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection",RECRUITING,PHASE1,Gastric Adenocarcinoma; Pancreatic Cancer; Gastroesophageal Junction Adenocarcinoma,CT041 autologous CAR T-cell injection (DRUG); Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody） (DRUG),74990,Campto,Gastric and Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10782,NCT04687631,Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases,RECRUITING,PHASE3,Colorectal Cancer; Liver Metastases,mFOLFOXIRI plus Cetuximab (DRUG); mFOLFOXIRI Plus Bevacizumab (DRUG),74990,Campto,Colorectal Cancer; Liver Metastases,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10783,NCT00004182,Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer,COMPLETED,PHASE2,Breast Cancer,irinotecan hydrochloride (DRUG),74990,Campto,Breast Cancer,Breast,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10784,NCT03533582,Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery,ACTIVE_NOT_RECRUITING,PHASE3,"Childhood Hepatocellular Carcinoma; Childhood Malignant Liver Neoplasm; Fibrolamellar Carcinoma; Hepatoblastoma; Hepatocellular Malignant Neoplasm, Not Otherwise Specified",Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Cisplatin (DRUG); Doxorubicin (DRUG); Etoposide (DRUG); Fluorouracil (DRUG); Gemcitabine (DRUG); Irinotecan (DRUG); Oxaliplatin (DRUG); Patient Observation (OTHER); Resection (PROCEDURE); Sorafenib (DRUG); Vincristine Sulfate (DRUG),74990,Campto,Childhood Liver Malignancies,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10785,NCT03206073,A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer; Colorectal Carcinoma; Colorectal Adenocarcinoma; Refractory Cancer; Colorectal Neoplasms,Durvalumab (DRUG); Tremelimumab (DRUG); Pexa-Vec (BIOLOGICAL); Pexa-Vec (BIOLOGICAL),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10786,NCT00734682,A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas,COMPLETED,PHASE1,Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma,Nanoliposomal CPT-11 (DRUG),74990,Campto,Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10787,NCT02782182,Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study,TERMINATED,PHASE1,Pancreatic Ductal Adenocarcinoma (PDAC),"FOLFIRINOX (oxaliplatin, leucovorin, irinotecan) (DRUG)",74990,Campto,Pancreatic Ductal Adenocarcinoma (PDAC),Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10788,NCT03940131,Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,Panitumumab (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10789,NCT02641873,A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE1,Metastatic Colorectal Cancer,BBI608 (DRUG); 5-FU (DRUG); Irinotecan (DRUG); Levofolinate (DRUG); Bevacizumab (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10790,NCT05238831,SMMART Adaptive Clinical Treatment (ACT) Trial,WITHDRAWN,EARLY_PHASE1,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Alectinib (DRUG); Alpelisib (DRUG); Anastrozole (DRUG); Atezolizumab (BIOLOGICAL); Bevacizumab (BIOLOGICAL); Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Capecitabine (DRUG); Carboplatin (DRUG); Cobimetinib (DRUG); Entrectinib (DRUG); Eribulin (DRUG); Fulvestrant (DRUG); Hyaluronidase-zzxf/Pertuzumab/Trastuzumab (BIOLOGICAL); Irinotecan (DRUG); Letrozole (DRUG); Nab-paclitaxel (DRUG); Niraparib (DRUG); Olaparib (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Pertuzumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Trastuzumab (BIOLOGICAL); Trastuzumab Emtansine (BIOLOGICAL); Vemurafenib (DRUG); Vinorelbine (DRUG); Vismodegib (DRUG),74990,Campto,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Ovary/Fallopian Tube,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10791,NCT06417476,Short-course Radiotherapy or Long-course Chemoradiation Followed by MFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer,RECRUITING,PHASE2,Rectal Neoplasms,Short-course radiotherapy (RADIATION); Irinotecan (DRUG); Oxaliplatin (DRUG); Calcium Formate (DRUG); Fluorouracil (DRUG); Long-course chemoradiation (RADIATION); Capecitabine (DRUG),74990,Campto,Rectal Neoplasms,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10792,NCT04009876,A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer,COMPLETED,PHASE2,Locally Advanced Rectal Cancer (LARC),nal-IRI (DRUG); Surgical resection (PROCEDURE); Watch-and-wait (OTHER); 5-FU/LV (DRUG); Oxaliplatin (DRUG),74990,Campto,Locally Advanced Rectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10793,NCT00387660,Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,carboplatin (DRUG); irinotecan (DRUG),74990,Campto,Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10794,NCT06577376,A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma,NOT_YET_RECRUITING,PHASE1,Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma; Expressing Human Epidermal Growth Factor Receptor-2 (HER-2); Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past,DP303c (DRUG); Simmitinib tablets (DRUG); Irinotecan liposomes (DRUG); Paclitaxel or docetaxel or irinotecan (DRUG),74990,Campto,HER-2 Positive Gastric or Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10795,NCT00003260,Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer,UNKNOWN,PHASE3,Colorectal Cancer,FOLFIRI regimen (DRUG); FOLFOX regimen (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10796,NCT00980460,Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer,ACTIVE_NOT_RECRUITING,PHASE3,PRETEXT I Hepatoblastoma; PRETEXT II Hepatoblastoma; PRETEXT III Hepatoblastoma; PRETEXT IV Hepatoblastoma,Cisplatin (DRUG); Dexrazoxane (DRUG); Doxorubicin Hydrochloride (DRUG); Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Liver Transplantation (PROCEDURE); Temsirolimus (DRUG); Therapeutic Conventional Surgery (PROCEDURE); Vincristine Sulfate (DRUG),74990,Campto,Hepatoblastoma,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10797,NCT00005076,Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,cetuximab (BIOLOGICAL); irinotecan hydrochloride (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10798,NCT05193292,Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer,UNKNOWN,PHASE2,Colorectal Neoplasms; Intestinal Neoplasms,Camrelizumab (DRUG); Trastuzumab (DRUG); XELOX regimen (DRUG); mFOLFOX6 regimen (DRUG); FOLFIRI regimen (DRUG); mXELIRI regimen (DRUG); mIRIS regimen (DRUG),74990,Campto,Intestinal Neoplasms,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10799,NCT00500292,A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer,COMPLETED,PHASE2,Colorectal; Cancer,"Vandetanib (DRUG); FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid (DRUG)",74990,Campto,Colorectal; Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10800,NCT03085992,Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer,COMPLETED,PHASE2,Rectal Cancer,FOLFOXIRI plus Bevacizumab (DRUG); Chemoradiotherapy plus Bevacizumab (OTHER),74990,Campto,Rectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10801,NCT01576692,"Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma",COMPLETED,PHASE1,Neuroblastoma,Humanized anti-GD2 antibody (BIOLOGICAL); Chemotherapy (DRUG); Cytokines (OTHER); Natural killer cells (BIOLOGICAL); CliniMACS (DEVICE),74990,Campto,Neuroblastoma,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10802,NCT01867892,A Phase II Study of Locally Advanced Pancreatic Cancer,UNKNOWN,PHASE2,Pancreatic Cancer,"ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT (DRUG); ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT (DRUG)",74990,Campto,Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10803,NCT00349492,A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer,COMPLETED,PHASE3,Small Cell Lung Cancer,IP (DRUG),74990,Campto,Small Cell Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10804,NCT03606967,Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer,RECRUITING,PHASE2,Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Computed Tomography (PROCEDURE); Durvalumab (BIOLOGICAL); Gemcitabine Hydrochloride (DRUG); Magnetic Resonance Imaging (PROCEDURE); Nab-paclitaxel (DRUG); Personalized Synthetic Long Peptide Vaccine (BIOLOGICAL); Poly ICLC (DRUG); Sacituzumab Govitecan (BIOLOGICAL); Tremelimumab (BIOLOGICAL),74990,Campto,Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma,Breast,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10805,NCT01183494,A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients,COMPLETED,PHASE1,Metastatic Colorectal Cancer,"FOLFIRI, Avastin, Irinotecan (DRUG)",74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10806,NCT06123494,SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen,RECRUITING,PHASE3,HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma,SHR-A1811 (DRUG); Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan (DRUG),74990,Campto,HER2-positive Gastroesophageal Cancer,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10807,NCT00008060,Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer,COMPLETED,PHASE3,Colorectal Cancer,FOLFIRI regimen (DRUG); FOLFOX regimen (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10808,NCT06750094,A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy,RECRUITING,PHASE3,Colorectal Neoplasms,Amivantamab (BIOLOGICAL); Cetuximab (BIOLOGICAL); Bevacizumab (BIOLOGICAL); 5-fluorouracil (DRUG); Leucovorin calcium/Levoleucovorin (DRUG); Irinotecan (DRUG),74990,Campto,Colorectal Neoplasms,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10809,NCT06210360,Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX,NOT_YET_RECRUITING,PHASE2,Pancreatic Cancer,Irinotecan liposome injection (DRUG); Oxaliplatin (DRUG); 5-FU (DRUG); LV (DRUG),74990,Campto,Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10810,NCT04888312,Safety and Efficacy of Mitazalimab in Combination with Chemotherapy in Pancreatic Cancer Patients,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Pancreatic Ductal Adenocarcinoma,CD40 agonist mitazalimab in combination with chemotherapy (BIOLOGICAL),74990,Campto,Metastatic Pancreatic Ductal Adenocarcinoma,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10811,NCT00003995,Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2,COMPLETED,PHASE2,Colorectal Cancer,trastuzumab (BIOLOGICAL); irinotecan hydrochloride (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10812,NCT01821612,Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer,COMPLETED,EARLY_PHASE1,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer,oxaliplatin (DRUG); irinotecan (DRUG); leucovorin (DRUG); 5-fluorouracil (DRUG); capecitabine (DRUG); radiation (RADIATION); surgery (PROCEDURE); gemcitabine (DRUG),74990,Campto,Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10813,NCT00066612,"S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy",COMPLETED,PHASE2,Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer,irinotecan hydrochloride (DRUG),74990,Campto,Urinary Tract Cancers,Bladder/Urinary Tract,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10814,NCT01663012,Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma,COMPLETED,PHASE2,Anaplastic Astrocytomas; Anaplastic Oligodendrogliomas; Glioblastomas (GBM),Etirinotecan pegol (DRUG),74990,Campto,Anaplastic Astrocytomas; Anaplastic Oligodendrogliomas; Glioblastomas (GBM),CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10815,NCT00813072,"Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma",COMPLETED,PHASE2,Stomach Neoplasms; Esophageal Neoplasms,PEP02 (DRUG); irinotecan (DRUG); docetaxel (DRUG),74990,Campto,Gastrointestinal Neoplasms,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10816,NCT03891472,Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer,COMPLETED,PHASE2,Cancer of Pancreas; Unresectable Pancreatic Cancer; Chemotherapy Effect; SBRT,"Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy. (DRUG)",74990,Campto,Cancer of Pancreas; Unresectable Pancreatic Cancer; Chemotherapy Effect; SBRT,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10817,NCT04607668,"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):",TERMINATED,PHASE3,Colorectal Cancer Metastatic; Myelosuppression-Adult; Chemotherapeutic Toxicity,Trilaciclib (DRUG); Placebo (DRUG),74990,Campto,Metastatic Colorectal Cancer with Chemotherapy Complications,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10818,NCT00021268,Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer,UNKNOWN,PHASE1,Colorectal Cancer,tocladesine (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10819,NCT00023868,Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655),TERMINATED,PHASE3,Colorectal Cancer; Metastatic Cancer,FOLFIRI regimen (DRUG); cisplatin (DRUG); doxorubicin hydrochloride (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); mitomycin C (DRUG),74990,Campto,Colorectal Cancer; Metastatic Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10820,NCT00037180,For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy,TERMINATED,PHASE2,Neoplasm Metastasis; Colorectal Neoplasms,Celecoxib (DRUG); Irinotecan (DRUG); 5-fluorouracil (DRUG); Leucovorin (DRUG),74990,Campto,Metastatic Colorectal Neoplasms,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10821,NCT04927780,Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer,RECRUITING,PHASE3,Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Adenocarcinoma,Leucovorin Calcium (DRUG); Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Oxaliplatin (DRUG); Resection (PROCEDURE),74990,Campto,Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Adenocarcinoma,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10822,NCT06581380,JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer,NOT_YET_RECRUITING,PHASE3,Small Cell Lung Cancer,JK-1201I (DRUG); Topotecan (DRUG),74990,Campto,Small Cell Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10823,NCT00483080,Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC),COMPLETED,PHASE2,Colorectal Cancer (CRC),NGR-hTNF (DRUG),74990,Campto,Colorectal Cancer (CRC),Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10824,NCT05846867,A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer,RECRUITING,PHASE1,Colorectal Cancer,AK119 (DRUG); AK112 (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG); Calcium folinate (DRUG); Fluorouracil (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10825,NCT05148767,UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer,RECRUITING,PHASE4,Rectal Cancer Stage III,Neoadjuvant chemoradiotherapy based on irinotecan (DRUG),74990,Campto,Rectal Cancer Stage III,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10826,NCT02591667,Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer,UNKNOWN,PHASE2,Colorectal Cancer; Peritoneal Metastasis,Upfront staging laparoscopy + peritoneal biopsy (PROCEDURE); Neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab (DRUG); Surgical re-exploration (PROCEDURE),74990,Campto,Colorectal Cancer; Peritoneal Metastasis,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10827,NCT00921167,A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas,COMPLETED,PHASE2,Glioblastoma; Astrocytoma,Bevacizumab/Irinotecan (DRUG),74990,Campto,Glioblastoma; Astrocytoma,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10828,NCT00020501,Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver,COMPLETED,PHASE3,Colorectal Cancer; Metastatic Cancer,FOLFIRI regimen (DRUG); floxuridine (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); melphalan (DRUG); hyperthermia treatment (PROCEDURE),74990,Campto,Colorectal Cancer; Metastatic Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10829,NCT02720601,Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers,WITHDRAWN,PHASE2,Biliary Tract Cancer,Irinotecan & Capecitabine (DRUG),74990,Campto,Biliary Tract Cancer,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10830,NCT02827201,FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine,COMPLETED,PHASE2,Metastatic Pancreatic Cancer,FOLFIRI.3 (DRUG); nab-paclitaxel+ gemcitabine (DRUG),74990,Campto,Metastatic Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10831,NCT03904927,Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma,COMPLETED,PHASE2,Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma,"Radiation, Surgery or Radiofrequency ablation (OTHER); Systemic therapy (DRUG)",74990,Campto,Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma,Skin,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10832,NCT05806931,Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer,RECRUITING,PHASE2,Colon Cancer; Rectal Cancer,"TAS-102, oxaliplatin, irinotecan with bevacizumab (DRUG)",74990,Campto,Colon Cancer; Rectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10833,NCT00215982,Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,capecitabine (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10834,NCT01726582,"Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery (""Personalized Medicine"")",COMPLETED,PHASE2,Pancreatic Adenocarcinoma,Milestone 1: Targeted chemotherapy prior to surgery (DRUG); Milestone 2: Chemoradiotherapy (cXRT) (RADIATION); Milestone 3: Targeted chemotherapy prior to surgery (DRUG); Milestone 3: Chemoradiotherapy (cXRT) (RADIATION); Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery (DRUG); Milestone 4: Chemoradiotherapy (cXRT) (RADIATION); Milestone 5: Targeted chemotherapy after surgery (DRUG); Milestone 5: Chemoradiotherapy (cXRT) (RADIATION); Milestone 6: Gemcitabine after surgery (DRUG); Milestone 6: Chemoradiotherapy (cXRT) (RADIATION); Milestone 7: Chemoradiotherapy (cXRT) (RADIATION); Milestone 8: Targeted chemotherapy after surgery (DRUG); Milestone 9: Gemcitabine after surgery (DRUG); Milestone 10: No additional therapy after surgery (OTHER),74990,Campto,Pancreatic Adenocarcinoma,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10835,NCT00248482,Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,Cisplatin (DRUG); Gleevec™ (DRUG); irinotecan (DRUG),74990,Campto,Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10836,NCT03365882,"S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",ACTIVE_NOT_RECRUITING,PHASE2,Colon Adenocarcinoma; ERBB2 Gene Amplification; Rectal Adenocarcinoma; Recurrent Colon Carcinoma; Recurrent Rectal Carcinoma; Stage III Colon Cancer AJCC v7; Stage III Rectal Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Colon Cancer AJCC v7; Stage IV Rectal Cancer AJCC v7; Stage IVA Colon Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Colon Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7,Cetuximab (BIOLOGICAL); Irinotecan Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Pertuzumab (BIOLOGICAL); Trastuzumab (BIOLOGICAL); HER-2 testing (DEVICE),74990,Campto,Colon Adenocarcinoma; ERBB2 Gene Amplification; Rectal Adenocarcinoma; Recurrent Colon Carcinoma; Recurrent Rectal Carcinoma; Stage III Colon Cancer AJCC v7; Stage III Rectal Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Colon Cancer AJCC v7; Stage IV Rectal Cancer AJCC v7; Stage IVA Colon Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Colon Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10837,NCT03536182,"Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer",WITHDRAWN,PHASE3,Locally Advanced Pancreatic Adenocarcinoma,Carbon Ion Radiation Therapy (CIRT) (RADIATION); Intensity Modulated Radiation Therapy (IMRT) (RADIATION),74990,Campto,Pancreatic Neoplasms,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10838,NCT05412082,SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer,RECRUITING,PHASE1,Locally Advanced Rectal Cancer,Intensity-modulated radiation therapy (RADIATION); 5-fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG); Accelerated Radiation Therapy (RADIATION); Irinotecan (DRUG),74990,Campto,Rectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10839,NCT01639326,Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,Irinotecan high doses (DRUG); Irinotecan standard doses (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10840,NCT00048126,A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,Irinotecan (DRUG); capecitabine [Xeloda] (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10841,NCT02497157,Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Oxaliplatin (L-OHP) (DRUG); Irinotecan hydrochloride hydrate (CPT-11) (DRUG); Continuous intravenous infusion of fluorouracil (CIV 5-FU) (DRUG); Levofolinate calcium (l-LV) (DRUG); Bevacizumab (Bmab) (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10842,NCT06501482,Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI,NOT_YET_RECRUITING,PHASE3,Colorectal Cancer; Colorectal Liver Metastases,Postoperative reintroduction of FOLFIRI based chemotherapy (DRUG),74990,Campto,Colorectal Cancer; Colorectal Liver Metastases,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10843,NCT05927857,"Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .",NOT_YET_RECRUITING,PHASE1,Metastatic Gastric Adenocarcinoma; Second Line; Chemotherapy,nal-IRI /Experimental (DRUG); Ramucirumab /Experimental (DRUG); Trifluridine/Tipiracil /Experimental (DRUG),74990,Campto,Gastric and Gastroesophageal Junction Cancer,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10844,NCT02129257,Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,AFLIBERCEPT (DRUG); Irinotecan (DRUG); 5-Fluorouracil (DRUG); Folinic Acid (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10845,NCT06475326,Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer,RECRUITING,PHASE2,Pancreatic Cancer,Adebrelimab (DRUG); Oxaliplatin 100 MG (DRUG); Irinotecan liposome (DRUG); Calcium Folinate (DRUG); Fluorouracil (DRUG),74990,Campto,Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10846,NCT06698757,"Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer",RECRUITING,PHASE2,Colorectal Cancer,Sintilimab (BIOLOGICAL),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10847,NCT00083148,Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer,COMPLETED,PHASE1,Breast Cancer,capecitabine (DRUG); irinotecan hydrochloride (DRUG),74990,Campto,Breast Cancer,Breast,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10848,NCT00003748,Irinotecan in Treating Patients With Esophageal or Stomach Cancer,COMPLETED,PHASE2,Esophageal Cancer; Gastric Cancer,irinotecan hydrochloride (DRUG),74990,Campto,Esophageal and Gastric Cancer,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10849,NCT03798626,"Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers",COMPLETED,PHASE1,Colorectal Cancer; Gastroesophageal Cancer; Renal Cell Carcinoma,Gevokizumab (DRUG); Bevacizumab (DRUG); Modified FOLFOX6 (DRUG); FOLFIRI (DRUG); Ramucirumab (DRUG); Paclitaxel (DRUG); Cabozantinib (DRUG),74990,Campto,Colorectal and Gastroesophageal Cancers,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10850,NCT06622057,D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer,NOT_YET_RECRUITING,PHASE3,Biliary Tract Cancer (BTC),D07001-Softgel Capsules (DRUG); Placebo (DRUG); Capecitabine (COMBINATION_PRODUCT),74990,Campto,Biliary Tract Cancer (BTC),Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10851,NCT06538857,CEB-01 in Locally Resectable Pancreatic Cancer,RECRUITING,PHASE2,Pancreatic Carcinoma,Standard surgery (PROCEDURE); CEB-01 (DRUG),74990,Campto,Pancreatic Carcinoma,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10852,NCT00286130,Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,"Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan (DRUG); FOLFOX 6 (DRUG); FOLFIRI (DRUG)",74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10853,NCT00003225,Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,amifostine trihydrate (DRUG); irinotecan hydrochloride (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10854,NCT05842525,Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer,UNKNOWN,PHASE2,Colorectal Cancer,intensive treatment (DRUG); Maintenance treatment (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10855,NCT01167725,Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer,TERMINATED,PHASE3,Colorectal Cancer,bevacizumab (BIOLOGICAL); cetuximab (BIOLOGICAL); FOLFIRI regimen (DRUG); FOLFOX regimen (DRUG); capecitabine (DRUG); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); mitomycin C (DRUG); oxaliplatin (DRUG); therapeutic conventional surgery (PROCEDURE),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10856,NCT06888648,Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.,NOT_YET_RECRUITING,PHASE1,Pancreatic Cancer Metastatic; Pancreatic Cancer Non-resectable,individualized anti-tumor new antigen iNeo-Vac-R01 injection (BIOLOGICAL); mFOLFIRINOX Treatment Regimen (DRUG); Sintilimab injection (DRUG),74990,Campto,Advanced Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10857,NCT06496048,Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC,RECRUITING,PHASE3,Relapsed Small Cell Lung Cancer,Lurbinectedin (DRUG); Irinotecan (DRUG); Lurbinectedin (DRUG); Topotecan (DRUG),74990,Campto,Relapsed Small Cell Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10858,NCT04008030,"A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)",ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Colorectal Cancer,Ipilimumab (BIOLOGICAL); Oxaliplatin (DRUG); Leucovorin (DRUG); Fluorouracil (DRUG); Irinotecan (DRUG); Bevacizumab (DRUG); Cetuximab (DRUG); Nivolumab (BIOLOGICAL),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10859,NCT02128425,FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,FOLFOXIRI (DRUG); FOLFOX (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10860,NCT03866525,OH2 Oncolytic Viral Therapy in Solid Tumors,RECRUITING,PHASE1,Solid Tumor; Gastrointestinal Cancer,"OH2 injection, with or without irinotecan or HX008 (BIOLOGICAL)",74990,Campto,Solid Tumor; Gastrointestinal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10861,NCT01374425,Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC),COMPLETED,PHASE2,Colorectal Cancer,5-Fluorouracil (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10862,NCT01757626,Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma,ACTIVE_NOT_RECRUITING,PHASE1,Neuroblastoma,Hu3F8 With GM-CSF (BIOLOGICAL); Hu3F8 With GM-CSF (BIOLOGICAL),74990,Campto,Neuroblastoma,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10863,NCT06697366,Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer,NOT_YET_RECRUITING,PHASE2,Gastric Cancer,Irinotecan liposome injection Ⅱ (DRUG); Sintilimab (DRUG),74990,Campto,Gastric Cancer,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10864,NCT06540326,Clinical Study of Second-line Treatment in Advanced Colorectal Cancer with Chemotherapy with Bevacizumab or Cetuximab,RECRUITING,PHASE2,Colorectal Cancer Metastatic,irinotecan liposome (II) (DRUG); fluorouracil (DRUG); cetuximab (DRUG); bevacizumab (DRUG),74990,Campto,Colorectal Cancer Metastatic,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10865,NCT04595266,Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease,RECRUITING,PHASE2,Colorectal Cancer Metastatic; Liver Metastasis Colon Cancer,FOLFOX regimen (DRUG); Anti-EGFR or Bevacizumab (BIOLOGICAL); LIVERPEARLS-Irinotecan (DRUG),74990,Campto,Colorectal Cancer Metastatic; Liver Metastasis Colon Cancer,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10866,NCT05825066,Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma,RECRUITING,PHASE2,Pancreas Adenocarcinoma; Borderline Resectable Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Adenocarcinoma,Nab paclitaxel (DRUG); Gemcitabine (DRUG); Radiological Assessments (OTHER); mFOLFIRINOX (DRUG),74990,Campto,Pancreas Adenocarcinoma; Borderline Resectable Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Adenocarcinoma,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10867,NCT00006366,Radiation Therapy Plus Chemotherapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum,COMPLETED,PHASE2,Colorectal Cancer,fluorouracil (DRUG); irinotecan hydrochloride (DRUG); conventional surgery (PROCEDURE); radiation therapy (RADIATION),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10868,NCT03316326,"S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer",UNKNOWN,PHASE2,Pancreatic Ductal Adenocarcinoma,Tegafur-gimeracil-oteracil potassium (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG),74990,Campto,Pancreatic Ductal Adenocarcinoma,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10869,NCT01479465,Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma,TERMINATED,PHASE2,Colorectal Cancer,Simtuzumab (BIOLOGICAL); Placebo to match SIM (DRUG); Leucovorin (DRUG); Irinotecan (DRUG); Fluorouracil (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10870,NCT01084330,Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer,COMPLETED,PHASE2,Advanced Gastric Cancer; Gastro-esophageal Junction Cancer,AUY922 (DRUG); Docetaxel (DRUG); Irinotecan (DRUG),74990,Campto,Advanced Gastric and Gastro-esophageal Junction Cancer,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10871,NCT06438822,Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma,RECRUITING,PHASE2,Cholangiocarcinoma,Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil (COMBINATION_PRODUCT),74990,Campto,Cholangiocarcinoma,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10872,NCT03231722,First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS,COMPLETED,PHASE3,Metastatic Colorectal Cancer,Panitumumab (DRUG); Irinotecan (DRUG); Oxaliplatin (DRUG); l-leucovorin (DRUG); 5-fluorouracil (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10873,NCT00020930,Cetuximab in Treating Patients With Stage IV Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,cetuximab (BIOLOGICAL),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10874,NCT00006025,Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma,COMPLETED,PHASE1,Brain and Central Nervous System Tumors,irinotecan hydrochloride (DRUG); temozolomide (DRUG),74990,Campto,Brain and Central Nervous System Tumors,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10875,NCT00541125,G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,bevacizumab (BIOLOGICAL); filgrastim (BIOLOGICAL); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10876,NCT00967330,A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma,COMPLETED,PHASE2,Glioblastoma Multiforme,bevacizumab [Avastin] (DRUG); irinotecan (DRUG); temozolomide (DRUG),74990,Campto,Glioblastoma Multiforme,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10877,NCT05453825,A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors,UNKNOWN,PHASE2,Colorectal Cancer; Triple Negative Breast Cancer; Gastric Cancer; Ovarian Cancer,navicixizumab+paclitaxel (BIOLOGICAL); navicixizumab+irinotecan (BIOLOGICAL); navicixizumab monotherapy (BIOLOGICAL),74990,Campto,Colorectal Cancer; Triple Negative Breast Cancer; Gastric Cancer; Ovarian Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10878,NCT04173325,Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer,TERMINATED,PHASE1,Small-cell Lung Cancer; Small Cell Lung Carcinoma,Nivolumab 10 MG/ML Intravenous Solution [OPDIVO] (DRUG); Irinotecan Injection [Camptosar] (DRUG),74990,Campto,Small-cell Lung Cancer; Small Cell Lung Carcinoma,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10879,NCT00778830,Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study),COMPLETED,PHASE1,Metastatic Colorectal Cancer,Cetuximab (DRUG); FOLFIRI (DRUG); FOLFOX (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10880,NCT06648525,"Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC",NOT_YET_RECRUITING,PHASE2,Intrahepatic Cholangiocarcinoma (Icc),Adebrelimab (DRUG); Irinotecan liposomes (DRUG); Lenvatinib (DRUG); 5-Fluorouracil (5-FU) (DRUG); Calcium Folinate (DRUG),74990,Campto,Intrahepatic Cholangiocarcinoma,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10881,NCT01075048,ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE1,Metastatic Colorectal Cancer,Tivantinib (DRUG); Placebo (DRUG); Cetuximab (DRUG); Irinotecan (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10882,NCT05319730,A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B),RECRUITING,PHASE1,Esophageal Squamous Cell Carcinoma,Paclitaxel (DRUG); Irinotecan (DRUG); Pembrolizumab (BIOLOGICAL); MK-4830 (BIOLOGICAL); Lenvatinib (DRUG); Sacituzumab tirumotecan (BIOLOGICAL); Antihistamine (DRUG); H2 Receptor Antagonist (DRUG); Acetaminophen (or equivalent) (DRUG); Dexamethasone (or equivalent) (DRUG); Steroid Mouthwash (dexamethasone or equivalent) (DRUG); Supportive care measures (DRUG),74990,Campto,Esophageal Squamous Cell Carcinoma,Skin,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10883,NCT00099125,"Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",COMPLETED,PHASE2,Brain and Central Nervous System Tumors,irinotecan hydrochloride (DRUG); temozolomide (DRUG); adjuvant therapy (PROCEDURE); radiation therapy (RADIATION),74990,Campto,Brain and Central Nervous System Tumors,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10884,NCT02295930,Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient,COMPLETED,PHASE2,Metastatic Colorectal Cancer,folfoxiri+cetuximab+surgery+cetuximab (OTHER); folfoxiri+cetuximab+surgery+bevacizumab (OTHER),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10885,NCT06197425,Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer,NOT_YET_RECRUITING,PHASE3,Colon or Upper Rectum Adenocarcinoma,"""FOLFIRI"" cures (DRUG); Trifluridine cures (DRUG); BIOLOGICAL ASSESSMENT (BIOLOGICAL); Questionnaires (OTHER); Thoracic-abdomino-pelvic scan or MRI (OTHER)",74990,Campto,Colon Adenocarcinoma,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10886,NCT02171325,Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment,UNKNOWN,PHASE2,Small Cell Lung Cancer,irinotecan (DRUG),74990,Campto,Small Cell Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10887,NCT06401330,A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT),RECRUITING,PHASE3,Stage I Kidney Wilms Tumor; Stage II Kidney Wilms Tumor; Stage III Kidney Wilms Tumor; Stage IV Kidney Wilms Tumor,Bone Scan (PROCEDURE); Carboplatin (DRUG); Computed Tomography (PROCEDURE); Cyclophosphamide (DRUG); Dactinomycin (BIOLOGICAL); Doxorubicin (DRUG); Etoposide (DRUG); Irinotecan (DRUG); Magnetic Resonance Imaging (PROCEDURE); Nephrectomy (PROCEDURE); Patient Observation (OTHER); Positron Emission Tomography (PROCEDURE); Ultrasound Imaging (PROCEDURE); Vincristine (DRUG); X-Ray Imaging (PROCEDURE),74990,Campto,Kidney Neoplasms,Kidney,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10888,NCT03797625,Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas,UNKNOWN,PHASE2,Esophageal Squamous Cell Carcinoma,Irinotecan (DRUG); DDP (DRUG); Endostar (DRUG),74990,Campto,Esophageal Squamous Cell Carcinoma,Skin,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10889,NCT04986930,MFOLFIRINOX with or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma,ACTIVE_NOT_RECRUITING,PHASE2,Pancreatic Adenocarcinoma; Pancreatic Cancer Non-resectable,SBRT+mFOLFIRINOX (RADIATION); mFOLFIRINOX (DRUG),74990,Campto,Pancreatic Adenocarcinoma; Pancreatic Cancer Non-resectable,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10890,NCT00209625,Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,irinotecan (DRUG); leucovorin (DRUG); fluorouracil (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10891,NCT00062322,Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer,cisplatin (DRUG); irinotecan hydrochloride (DRUG); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE); radiation therapy (RADIATION),74990,Campto,Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10892,NCT00980239,"HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver",COMPLETED,PHASE1,Liver Cancer; Advanced Cancer,Irinotecan (DRUG); Bevacizumab (DRUG); Oxaliplatin (DRUG); Cetuximab (DRUG),74990,Campto,Liver Cancer; Advanced Cancer,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10893,NCT00042939,Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,cetuximab (BIOLOGICAL); docetaxel (DRUG); irinotecan hydrochloride (DRUG),74990,Campto,Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10894,NCT04005339,"NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer",RECRUITING,PHASE2,Advanced Biliary Tract Cancer,Nanoliposomal Irinotecan (DRUG); Leucovorin (DRUG); Fluorouracil (DRUG),74990,Campto,Advanced Biliary Tract Cancer,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10895,NCT00546130,Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer,UNKNOWN,PHASE2,Small Cell Lung Cancer,Irinotecan hydrochloride (DRUG); Cisplatin (DRUG); Krestin (DRUG),74990,Campto,Small Cell Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10896,NCT04170530,Neoadjuvant mFOLFOXIRI Chemotherapy Alone for Extramural Vascular Invasion Positive Locally Advanced Rectal Cancer,UNKNOWN,PHASE2,Locally Advanced Rectal Cancer,mFOLFOXIRI (DRUG),74990,Campto,Rectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10897,NCT00006786,Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,bevacizumab (BIOLOGICAL); fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10898,NCT04425239,Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer Stage IV,Panitumumab (DRUG); Panitumumab (DRUG),74990,Campto,Colorectal Cancer Stage IV,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10899,NCT01394939,"Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma",COMPLETED,PHASE1,Colorectal Carcinoma; CRC,JX-594 (BIOLOGICAL); Irinotecan (DRUG),74990,Campto,Colorectal Carcinoma; CRC,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10900,NCT02654639,Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer,TERMINATED,PHASE2,Metastatic Colorectal Cancer,TAS-102 (DRUG); Bevacizumab (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10901,NCT00048139,A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,Irinotecan (DRUG); capecitabine [Xeloda] (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10902,NCT01467986,Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma Recurrent,Dasatinib (DRUG); Rapamycin (DRUG); Irinotecan (DRUG); Temozolomide (DRUG); Irinotecan (DRUG); Temozolomide (DRUG),74990,Campto,Neuroblastoma Recurrent,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10903,NCT06680622,"Bemarituzumab in FGFR2b+ Patients with Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed At Least One Prior Line of Palliative Chemotherapy",RECRUITING,PHASE2,Metastatic Gastro-esophageal Adenocarcinoma,"bemarituzumab, paclitaxel, ramucirumab (DRUG); bemarituzumab, irinotecan (DRUG); bemarituzumab, trifluridine/tipiracil (DRUG)",74990,Campto,Metastatic Gastro-esophageal Adenocarcinoma,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10904,NCT00004139,Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,docetaxel (DRUG); gemcitabine hydrochloride (DRUG); irinotecan hydrochloride (DRUG),74990,Campto,Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10905,NCT00612586,Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer,COMPLETED,PHASE2,Colorectal Cancer,Enzastaurin (DRUG); Placebo (DRUG); Leucovorin (LV) (DRUG); 5-fluorouracil (5-FU) (DRUG); Bevacizumab (Bev) (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10906,NCT05848739,A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors,RECRUITING,PHASE1,Colon Cancer; Metastatic Colon Cancer,ST316 (DRUG); FOLFIRI regimen & bevacizumab (DRUG); Fruquintinib (DRUG); Lonsurf & bevacizumab (DRUG),74990,Campto,Colon Cancer; Metastatic Colon Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10907,NCT00617539,Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases,COMPLETED,PHASE2,Breast Cancer; Metastatic Cancer,irinotecan hydrochloride (DRUG); temozolomide (DRUG),74990,Campto,Breast Cancer; Metastatic Cancer,Breast,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10908,NCT05669339,AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma,RECRUITING,PHASE2,Hepatocellular Carcinoma,Irinotecan (DRUG); Sonidegib (DRUG); Sorafenib (DRUG),74990,Campto,Hepatocellular Carcinoma,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10909,NCT00890786,A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas,COMPLETED,EARLY_PHASE1,Newly Diagnosed High-Grade Gliomas; Diffuse Intrinsic Pontine Glioma,Temozolomide (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG),74990,Campto,Newly Diagnosed High-Grade Gliomas; Diffuse Intrinsic Pontine Glioma,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10910,NCT00845039,A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab,TERMINATED,PHASE2,Colon Cancer; Rectal Cancer,Cetuximab (BIOLOGICAL); Irinotecan (DRUG); IMC-A12 (cixutumumab) (BIOLOGICAL),74990,Campto,Colon Cancer; Rectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10911,NCT06662786,A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer,RECRUITING,PHASE3,Colorectal Neoplasms,Amivantamab (BIOLOGICAL); Cetuximab (BIOLOGICAL); 5-fluorouracil (DRUG); Leucovorin calcium/Levoleucovorin (DRUG); Oxaliplatin (DRUG); Irinotecan Hydrochloride (DRUG),74990,Campto,Colorectal Neoplasms,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10912,NCT05027386,"Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.",RECRUITING,PHASE1,Neuroblastoma,"Apatinib, Irinotecan, Temozolomide (DRUG)",74990,Campto,Neuroblastoma,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10913,NCT00433927,"5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)",UNKNOWN,PHASE3,Neoplasm Metastasis; Colorectal Cancer,5-FU (DRUG); folinic acid (DRUG); irinotecan (DRUG); cetuximab (DRUG); bevacizumab (DRUG),74990,Campto,Neoplasm Metastasis; Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10914,NCT00003427,Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer,COMPLETED,PHASE1,Anal Cancer; Colorectal Cancer; Esophageal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Gastrointestinal Carcinoid Tumor; Liver Cancer; Pancreatic Cancer; Small Intestine Cancer,irinotecan hydrochloride (DRUG); oxaliplatin (DRUG),74990,Campto,Anal Cancer; Colorectal Cancer; Esophageal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Gastrointestinal Carcinoid Tumor; Liver Cancer; Pancreatic Cancer; Small Intestine Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10915,NCT00510627,Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases,WITHDRAWN,PHASE4,Metastatic Liver Cancer; Secondary Liver Cancer; Liver Neoplasm,Radiofrequency Ablation (RFA) (DEVICE); Chemotherapy (DRUG),74990,Campto,Metastatic Liver Cancer; Secondary Liver Cancer; Liver Neoplasm,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10916,NCT05160727,Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer,UNKNOWN,PHASE2,Mismatch Repair-proficient; Colorectal Cancer Metastatic; Microsatellite Stable,Tislelizumab (DRUG); Irinotecan (DRUG); radiotherapy (RADIATION),74990,Campto,Mismatch Repair-proficient; Colorectal Cancer Metastatic; Microsatellite Stable,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10917,NCT06575127,Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study,RECRUITING,PHASE2,Neoplasm Malignant; Colon Cancer Stage 4,FOLFOXIRI Protocol (DRUG),74990,Campto,Neoplasm Malignant; Colon Cancer Stage 4,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10918,NCT03785873,Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer,COMPLETED,PHASE1,Biliary Tract Cancer,Nivolumab (DRUG); Nanoliposomal-Irinotecan (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG),74990,Campto,Biliary Tract Cancer,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10919,NCT03874026,Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients,RECRUITING,PHASE2,Colorectal Cancer; ADCC,Folfiri/Cetuximab (DRUG),74990,Campto,Colorectal Cancer; ADCC,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10920,NCT06509126,Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer,RECRUITING,PHASE3,Colorectal Cancer Stage IV,Panitumumab (DRUG); Irinotecan (DRUG); 5-fluorouracil (DRUG); L-folinic acid (DRUG),74990,Campto,Colorectal Cancer Stage IV,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10921,NCT04482257,Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.,UNKNOWN,PHASE1,Advanced Pancreatic Cancer,Irinotecan Liposome Injection combined with 5-FU/LV (DRUG),74990,Campto,Advanced Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10922,NCT00972465,Study of Nimotuzumab to Treat Colorectal Cancer,UNKNOWN,PHASE2,Advanced Colorectal Cancer,Nimotuzumab and chemotherapy (DRUG),74990,Campto,Advanced Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10923,NCT05201430,Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer,RECRUITING,PHASE3,Rectal Cancer,FOLFOXIRI (DRUG); CapeOX (DRUG),74990,Campto,Rectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10924,NCT00156286,Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC,COMPLETED,PHASE2,Small Cell Lung Cancer,Gleevec (DRUG),74990,Campto,Small Cell Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10925,NCT06595186,JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM),RECRUITING,PHASE2,Glioblastoma Multiforme (GBM),JK-1201I (DRUG); Temozolomide (TMZ) (DRUG),74990,Campto,Glioblastoma Multiforme (GBM),CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10926,NCT00213486,Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial,COMPLETED,PHASE2,Esophageal Neoplasms,irinotecan (DRUG),74990,Campto,Esophageal Neoplasms,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10927,NCT00524186,"Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer",TERMINATED,PHASE1,Esophageal Cancer; Gastric Cancer,fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); sunitinib malate (DRUG); flow cytometry (OTHER); pharmacological study (OTHER),74990,Campto,Esophageal and Gastric Cancer,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10928,NCT00216086,Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer,TERMINATED,PHASE2,Rectal Cancer,Capecitabine (DRUG); Irinotecan (DRUG); EUS (PROCEDURE); Neoadjuvant Chemotherapy (DRUG); Preoperative Radiation (PROCEDURE); Surgery (PROCEDURE); Adjuvant Chemotherapy (PROCEDURE),74990,Campto,Rectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10929,NCT00958386,Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA),COMPLETED,PHASE2,Metastatic Colorectal Cancer,Panitumumab+irinotecan (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10930,NCT00391586,"Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung",TERMINATED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Erlotinib (DRUG); Platinum-based chemotherapy (DRUG),74990,Campto,"Carcinoma, Non-Small-Cell Lung",Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10931,NCT00730158,"A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer",COMPLETED,PHASE2,Colorectal Neoplasms,KD018 (DRUG); Irinotecan (DRUG); Placebo (DRUG),74990,Campto,Colorectal Neoplasms,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10932,NCT03061058,Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC,UNKNOWN,PHASE3,Stomach Neoplasms; Chemotherapy Effect; Chemotherapeutic Toxicity,Docetaxel (DRUG); Oxaliplatin (DRUG); Cisplatin (DRUG); Irinotecan (DRUG); Pemetrexed (DRUG); S1 (DRUG),74990,Campto,Chemotherapy-Induced Gastric Toxicity,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10933,NCT04861558,Efficacy of Hyperthermic Intraperitoneal Chemotherapy,RECRUITING,PHASE3,Colorectal Cancer; Peritoneal Metastases,5Fluorouracil (DRUG); Irinotecan (DRUG); Oxaliplatin (DRUG),74990,Campto,Colorectal Cancer; Peritoneal Metastases,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10934,NCT04912258,Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis,UNKNOWN,PHASE3,Colorectal Cancer; Liver Metastases,Trans arterial chemoembolization with Irinotecan Drug-eluting Beads (DRUG),74990,Campto,Colorectal Cancer; Liver Metastases,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10935,NCT01205022,"Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",COMPLETED,PHASE1,Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer,irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); fluorouracil (DRUG); bevacizumab (BIOLOGICAL); yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A (RADIATION); laboratory biomarker analysis (OTHER),74990,Campto,Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10936,NCT01878422,Sequential Treatment Strategy for Metastatic Colorectal Cancer,COMPLETED,PHASE3,Metastatic Colorectal Cancer,Arm A: FOLFIRI or FOLFOX + Bevacizumab (DRUG); Arm B: FOLFIRI or FOLFOX (DRUG); Arm D: FOLFIRI or FOLFOX plus CETUXIMAB (DRUG); Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10937,NCT00135135,Therapy for Children With Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma,"Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid (DRUG); Radiation therapy, Surgery, Peripheral Stem cell transplant (PROCEDURE)",74990,Campto,Neuroblastoma,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10938,NCT00118235,"Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer",COMPLETED,PHASE2,Extensive Stage Small Cell Lung Cancer,cisplatin (DRUG); irinotecan hydrochloride (DRUG); bevacizumab (BIOLOGICAL); laboratory biomarker analysis (OTHER),74990,Campto,Extensive Stage Small Cell Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10939,NCT00004235,Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach,COMPLETED,PHASE2,Esophageal Cancer; Gastric Cancer,docetaxel (DRUG); irinotecan hydrochloride (DRUG),74990,Campto,Esophageal and Gastric Cancer,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10940,NCT03126435,EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX,COMPLETED,PHASE3,Metastatic Pancreas Cancer; Locally Advanced Pancreatic Cancer; Pancreatic Adenocarcinoma,EndoTAG-1 (DRUG); Gemcitabine (DRUG),74990,Campto,Metastatic Pancreas Cancer; Locally Advanced Pancreatic Cancer; Pancreatic Adenocarcinoma,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10941,NCT01601535,Study of MLN8237 in Combination With Irinotecan and Temozolomide,COMPLETED,PHASE1,Neuroblastoma,MLN8237 (DRUG); Irinotecan (DRUG); Temozolomide (DRUG),74990,Campto,Neuroblastoma,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10942,NCT04389086,Induction Chemotherapy for Locally Recurrent Rectal Cancer,RECRUITING,PHASE3,Recurrent Rectal Cancer,Combination drug (DRUG); Chemoradiotherapy (RADIATION); Surgery locally recurrent rectal cancer (PROCEDURE),74990,Campto,Recurrent Rectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10943,NCT03688230,Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.,WITHDRAWN,PHASE2,Metastatic Colorectal Cancer,abituzumab (DRUG); Placebo + Cetuximab + FOLFIRI (COMBINATION_PRODUCT),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10944,NCT06801730,Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma,RECRUITING,PHASE2,Glioma,Irinotecan liposome combined with bevacizumab (DRUG),74990,Campto,Glioma,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10945,NCT02055196,Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas,WITHDRAWN,PHASE1,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor,carboxylesterase-expressing allogeneic neural stem cells (BIOLOGICAL); irinotecan hydrochloride (DRUG); laboratory biomarker analysis (OTHER),74990,Campto,Adult Malignant Gliomas,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10946,NCT04084496,mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients,RECRUITING,PHASE2,Pancreatic Cancer,Folfirinox (DRUG),74990,Campto,Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10947,NCT02021422,"A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy",UNKNOWN,PHASE1,Pancreas Cancer,anakinra (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG); fluorouracil (DRUG),74990,Campto,Pancreas Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10948,NCT06867822,Trial of ProAgio in Advanced/Metastatic Colorectal Cancer,NOT_YET_RECRUITING,PHASE1,Advanced Colorectal Cancer; Metastatic Colorectal Cancer,ProAgio (DRUG); FOLFIRI (DRUG); Bevacizumab (DRUG),74990,Campto,Advanced Colorectal Cancer; Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10949,NCT05153239,Clinical Trial of Lurbinectedin As Single-agent or in Combination with Irinotecan Versus Topotecan or Irinotecan in Patients with Relapsed Small-cell Lung Cancer (LAGOON),ACTIVE_NOT_RECRUITING,PHASE3,Relapsed Small Cell Lung Cancer,Irinotecan (DRUG); Lurbinectedin (DRUG); Irinotecan (DRUG); Topotecan (DRUG); Lurbinectedin (DRUG),74990,Campto,Relapsed Small Cell Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10950,NCT02316496,Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study,TERMINATED,PHASE2,Colorectal Cancer Metastatic,cetuximab (DRUG); Irinotecan (DRUG),74990,Campto,Colorectal Cancer Metastatic,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10951,NCT04838496,Induction Chemotherapy for Locally Advanced Rectal Cancer,NOT_YET_RECRUITING,PHASE2,Rectal Cancer,FOLFOXIRI Protocol (DRUG),74990,Campto,Rectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10952,NCT03428958,"A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment",COMPLETED,PHASE1,"Colorectal Cancer; Colorectal Neoplasms; Colorectal Carcinoma; Colorectal Tumors; Neoplasms, Colorectal",NUC-3373 + leucovorin (DRUG); NUC-3373 (DRUG); NUFOX (DRUG); NUFOX + VEGF pathway inhibitor (DRUG); NUFOX + EGFR inhibitor (DRUG); NUFIRI (DRUG); NUFIRI + VEGF pathway inhibitor (DRUG); NUFIRI + EGFR inhibitor (DRUG); NUC-3373 + bevacizumab (DRUG),74990,Campto,"Colorectal Cancer; Colorectal Neoplasms; Colorectal Carcinoma; Colorectal Tumors; Neoplasms, Colorectal",Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10953,NCT01183780,A Study in Second Line Metastatic Colorectal Cancer,COMPLETED,PHASE3,Colorectal Cancer,Ramucirumab (BIOLOGICAL); Placebo (BIOLOGICAL); Irinotecan (DRUG); Folinic Acid (DRUG); 5-Fluorouracil (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10954,NCT00030862,Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus,COMPLETED,PHASE2,Esophageal Cancer,cisplatin (DRUG); irinotecan hydrochloride (DRUG),74990,Campto,Esophageal Cancer,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10955,NCT00047762,"Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer",COMPLETED,PHASE1,Colorectal Cancer,Erlotinib (aka Tarceva or OSI-774) (DRUG); Bevacizumab (aka Avastin or Rhu MAb VEGF) (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10956,NCT04059562,Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma,COMPLETED,PHASE2,Cholangiocarcinoma,Combination of Lonsurf® and Irinotecan (COMBINATION_PRODUCT),74990,Campto,Cholangiocarcinoma,Liver,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10957,NCT06118762,Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer,RECRUITING,PHASE4,Metastatic Colorectal Cancer,Fruquintinib (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10958,NCT02551991,"Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma",COMPLETED,PHASE2,Pancreatic Cancer,nal-IRI (DRUG); 5 fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG),74990,Campto,Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10959,NCT00045162,S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer,COMPLETED,PHASE3,Lung Cancer,cisplatin (DRUG); etoposide (DRUG); irinotecan hydrochloride (DRUG),74990,Campto,Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10960,NCT00040391,A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer,TERMINATED,PHASE2,Colorectal Neoplasms; Diarrhea,Investigational drug (DRUG); Irinotecan (DRUG); 5-fluorouracil (DRUG); Leucovorin (DRUG),74990,Campto,Colorectal Neoplasms; Diarrhea,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10961,NCT06749691,Liposomal Irinotecan and Apatinib in ES-SCLC,RECRUITING,PHASE2,Small Cell Lung Cancer Extensive Stage,Liposomal Irinotecan and Apatinib (DRUG),74990,Campto,Small Cell Lung Cancer Extensive Stage,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10962,NCT04931394,Organoid-Guided Adjuvant Chemotherapy for Pancreatic Cancer,RECRUITING,PHASE3,Pancreatic Cancer,Adjuvant chemotherapy guided by organoid drug sensitivity test (OTHER),74990,Campto,Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10963,NCT00320294,ILF With/Without Cisplatin for Advanced Gastric Cancer,UNKNOWN,PHASE2,Stomach Neoplasm,irinotecan (DRUG); cisplatin (DRUG),74990,Campto,Stomach Neoplasm,Esophagus/Stomach,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10964,NCT06077591,Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients with Advanced/ Inoperable Solid Tumors,RECRUITING,PHASE3,Hepatocellular Carcinoma; Colorectal Cancer,Patient-Derived Tumor Organoids (OTHER),74990,Campto,Hepatocellular Carcinoma; Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10965,NCT04446091,A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC),UNKNOWN,PHASE1,Colorectal Cancer,"Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.) (DRUG); Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan (DRUG)",74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10966,NCT02022644,"Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma",COMPLETED,PHASE1,High Grade Glioma,nanoliposomal irinotecan (DRUG),74990,Campto,Glioma,CNS/Brain,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10967,NCT06763029,Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer,RECRUITING,PHASE2,Colorectal Cancer Metastatic,Irinotecan liposomes combined with cetuximab + vermofenib (DRUG),74990,Campto,Colorectal Cancer Metastatic,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10968,NCT06166589,Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer,NOT_YET_RECRUITING,PHASE2,Previously AG Chemotherapy Treated Pancreatic Cancer,Zimberelimab (DRUG); Oxaliplatin (DRUG); S-1 (DRUG); Irinotecan (DRUG),74990,Campto,Previously AG Chemotherapy Treated Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10969,NCT05062889,Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients,RECRUITING,PHASE2,Stage II Colon Cancer; Stage III Colon Cancer; HER2-positive Colon Cancer; RAS Wild-type Colon Cancer,5-Fluorouracil continuous infusion FOLFOXIRI schedule (DRUG); 5-Fluorouracil bolus FOLFOX schedule (DRUG); 5-Fluorouracil continuous infusion FOLFOX schedule (DRUG); Oxaliplatin FOLFOX and FOLFOXIRI schedule (DRUG); Oxaliplatin CAPOX schedule (DRUG); L-Leucovorin (DRUG); Capecitabine (DRUG); Irinotecan (DRUG); Trifluridine/Tipiracil (DRUG); Trastuzumab (DRUG); Tucatinib (DRUG),74990,Campto,Colon Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10970,NCT01387880,"Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer",COMPLETED,PHASE2,Metastatic Colorectal Cancer,Everolimus (DRUG); Everolimus (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10971,NCT00255229,Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Glutamine (DRUG); Placebo (OTHER),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10972,NCT03263429,Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer; Metastatic Colorectal Cancer; RAS Wild Type Colorectal Cancer; Refractory Colorectal Cancer,Glutaminase Inhibitor CB-839 (DRUG); Panitumumab (BIOLOGICAL); Irinotecan Hydrochloride (phase I only) (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans (DEVICE),74990,Campto,Colorectal Cancer; Metastatic Colorectal Cancer; RAS Wild Type Colorectal Cancer; Refractory Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10973,NCT00027729,Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,etaracizumab (BIOLOGICAL),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10974,NCT00144989,A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC,COMPLETED,PHASE3,Small-Cell-Lung Cancer,Etoposide and cisplatin after chemoradiotherapy (DRUG); Irinotecan and cisplatin after chemoradiotherapy (DRUG),74990,Campto,Small-Cell-Lung Cancer,Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10975,NCT04101929,"Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen",UNKNOWN,PHASE2,Metastatic Pancreatic Cancer,Apatinib (DRUG); S-1 capsule (DRUG); Irinotecan (DRUG),74990,Campto,Metastatic Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10976,NCT00081289,Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,Radiation Therapy (RADIATION); Capecitabine 1650 mg/m^2/day (DRUG); Capecitabine 1200 mg/m^2/day (DRUG); Irinotecan (DRUG); Oxaliplatin (DRUG); Surgery (PROCEDURE); Folinic Acid (DRUG); Fluorouracil (DRUG); Oxaliplatin (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10977,NCT04653480,"Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC",RECRUITING,PHASE2,Colorectal Cancer,Surufatinib (DRUG); Toripalimab (DRUG); chemotherapy (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10978,NCT01454180,Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets,COMPLETED,PHASE2,Advanced Pancreatic Carcinoma,"gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI. (DRUG); Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI (DRUG)",74990,Campto,Advanced Pancreatic Carcinoma,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10979,NCT05330429,Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC),TERMINATED,PHASE2,Metastatic Colorectal Cancer,Magrolimab (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG); Fluorouracil (DRUG); Leucovorin (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10980,NCT02063529,FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,FOLFOXIRI + Cetuximab (DRUG); FOLFOXIRI (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10981,NCT06459180,A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20),RECRUITING,PHASE3,Cervical Cancer,Sacituzumab Tirumotecan (BIOLOGICAL); Pemetrexed (DRUG); Tisotumab Vedotin (BIOLOGICAL); Topotecan (DRUG); Vinorelbine (DRUG); Gemcitabine (DRUG); Irinotecan (DRUG),74990,Campto,Cervical Cancer,Cervix,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10982,NCT03692429,alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells,RECRUITING,PHASE1,Unresectable Metastatic Colorectal Cancer,CYAD-101 (DRUG); FOLFOX (DRUG); FOLFIRI (DRUG),74990,Campto,Unresectable Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10983,NCT03279289,"Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen",COMPLETED,PHASE2,Metastatic Colorectal Cancer,Aflibercept (DRUG); Irinotecan (DRUG); folinic acid (dl racemic) (DRUG); 5Fluorouracil (DRUG); 5-FU (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10984,NCT00308529,"Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer",COMPLETED,PHASE2,"Carcinoma, Small Cell Lung; Lung Cancer",irinotecan (DRUG); carboplatin (DRUG); bevacizumab (DRUG); Radiation Therapy (PROCEDURE),74990,Campto,"Carcinoma, Small Cell Lung; Lung Cancer",Lung,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10985,NCT00012389,Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE3,Colorectal Cancer,irinotecan hydrochloride (DRUG); oxaliplatin (DRUG),74990,Campto,Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10986,NCT01821729,Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer,UNKNOWN,PHASE2,Pancreatic Cancer,FOLFIRINOX (DRUG); Losartan (DRUG); Proton Beam Radiation (RADIATION),74990,Campto,Pancreatic Cancer,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10987,NCT05732129,The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.,UNKNOWN,PHASE2,Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer,Fluzoparib (DRUG); Irinotecan (DRUG),74990,Campto,Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10988,NCT05074589,Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer,COMPLETED,PHASE3,Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy,Irinotecan liposome、5-Fluorouracil、Leucovorin (DRUG); Placebo、5-Fluorouracil、Leucovorin (DRUG),74990,Campto,Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10989,NCT00303992,Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,trastuzumab (BIOLOGICAL); irinotecan hydrochloride (DRUG),74990,Campto,Breast Cancer,Breast,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10990,NCT06149689,mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer,RECRUITING,PHASE2,Pancreatic Adenocarcinoma,mFOLFIRINOX plus radiotherapy (COMBINATION_PRODUCT),74990,Campto,Pancreatic Adenocarcinoma,Pancreas,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10991,NCT02934529,Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab,COMPLETED,PHASE3,Metastatic Colorectal Cancer,Irinotecan (DRUG); Folinic Acid (DRUG); 5-FU (DRUG); 5-FU (DRUG); Cetuximab (DRUG); Bevacizumab (DRUG); Capecitabine (DRUG); regorafenib (DRUG); Irinotecan 125mg (DRUG); Cetuximab wkly (DRUG),74990,Campto,Metastatic Colorectal Cancer,Bowel,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10992,NCT05143229,Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer,RECRUITING,PHASE1,Breast Cancer,Alpelisib (DRUG); Sacituzumab govitecan (DRUG),74990,Campto,Breast Cancer,Breast,Irinotecan (hydrochloride),TOP1,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved for cancer treatment as a topoisomerase inhibitor.,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,1.01,263.0 +10993,NCT01026324,Dinaciclib in Treating Patients With Stage III-IV Melanoma,TERMINATED,PHASE1,Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma,dinaciclib (DRUG); pharmacological study (OTHER); laboratory biomarker analysis (OTHER),46926350,Dinaciclib,Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma,Skin,Dinaciclib,"CDK1, CDK2, CDK5, CDK9",inhibitor/antagonist,CDK inhibitor,no,yes,Investigated in trials; not yet approved for human use.,CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCCC4CCO,1.0,128.0 +10994,NCT00732810,SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716),COMPLETED,PHASE2,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung",SCH 727965 (DRUG); Capecitabine (DRUG); Erlotinib (DRUG),46926350,Dinaciclib,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung",Lung,Dinaciclib,"CDK1, CDK2, CDK5, CDK9",inhibitor/antagonist,CDK inhibitor,no,yes,Investigated in trials; not yet approved for human use.,CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCCC4CCO,1.0,128.0 +10995,NCT01624441,Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer,COMPLETED,PHASE1,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma,Dinaciclib (DRUG); Epirubicin Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER),46926350,Dinaciclib,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma,Breast,Dinaciclib,"CDK1, CDK2, CDK5, CDK9",inhibitor/antagonist,CDK inhibitor,no,yes,Investigated in trials; not yet approved for human use.,CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCCC4CCO,1.0,128.0 +10996,NCT00937937,Dinaciclib in Treating Patients With Stage IV Melanoma,ACTIVE_NOT_RECRUITING,PHASE2,Acral Lentiginous Melanoma; Cutaneous Nodular Melanoma; Lentigo Maligna Melanoma; Low-CSD Melanoma; Mucosal Melanoma; Recurrent Melanoma; Stage IV Cutaneous Melanoma AJCC v6 and v7,Dinaciclib (DRUG),46926350,Dinaciclib,Acral Lentiginous Melanoma; Cutaneous Nodular Melanoma; Lentigo Maligna Melanoma; Low-CSD Melanoma; Mucosal Melanoma; Recurrent Melanoma; Stage IV Cutaneous Melanoma AJCC v6 and v7,Skin,Dinaciclib,"CDK1, CDK2, CDK5, CDK9",inhibitor/antagonist,CDK inhibitor,no,yes,Investigated in trials; not yet approved for human use.,CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCCC4CCO,1.0,128.0 +10997,NCT01676753,Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer,COMPLETED,PHASE1,Advanced or Metastatic Breast Cancer; Triple Negative Breast Cancer,Dinaciclib (DRUG); Pembrolizumab (DRUG),46926350,Dinaciclib,Advanced or Metastatic Breast Cancer; Triple Negative Breast Cancer,Breast,Dinaciclib,"CDK1, CDK2, CDK5, CDK9",inhibitor/antagonist,CDK inhibitor,no,yes,Investigated in trials; not yet approved for human use.,CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCCC4CCO,1.0,128.0 +10998,NCT01783171,Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery,COMPLETED,PHASE1,Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Unresectable Pancreatic Carcinoma,Akt Inhibitor MK2206 (DRUG); Dinaciclib (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER),46926350,Dinaciclib,Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Unresectable Pancreatic Carcinoma,Pancreas,Dinaciclib,"CDK1, CDK2, CDK5, CDK9",inhibitor/antagonist,CDK inhibitor,no,yes,Investigated in trials; not yet approved for human use.,CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCCC4CCO,1.0,128.0 +10999,NCT01025765,The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin,UNKNOWN,PHASE4,Chronic Hepatitis C,Pioglitazone (DRUG); Acarbose (DRUG); Metformin (DRUG),4829,Actos,Chronic Hepatitis C,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11000,NCT00825266,Insulin Resistance in Pulmonary Arterial Hypertension,TERMINATED,PHASE2,"Hypertension, Pulmonary",bosentan (DRUG); Pioglitazone (DRUG),4829,Actos,Pulmonary Hypertension,Lung,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11001,NCT01931566,Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset,TERMINATED,PHASE3,Mild Cognitive Impairment Due to Alzheimer's Disease,Pioglitazone (DRUG); Pioglitazone placebo (DRUG),4829,Actos,Mild Cognitive Impairment Due to Alzheimer's Disease,CNS/Brain,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11002,NCT02683226,Comparison of Alogliptin Versus Alogliptin and Pioglitazone on Insulin Resistance of Metformin Treated Women With PCOS,COMPLETED,PHASE4,Polycystic Ovary Syndrome; Insulin Resistance,Vipdomet (DRUG); Incresync (DRUG),4829,Actos,Polycystic Ovary Syndrome; Insulin Resistance,Ovary/Fallopian Tube,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11003,NCT00994682,University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial),COMPLETED,PHASE4,Nonalcoholic Steatohepatitis; Nonalcoholic Fatty Liver Disease; Type 2 Diabetes Mellitus,Pioglitazone study drug (DRUG); Placebo (DRUG); Pioglitazone Open Label (DRUG),4829,Actos,Nonalcoholic Steatohepatitis; Nonalcoholic Fatty Liver Disease; Type 2 Diabetes Mellitus,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11004,NCT00633282,Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease,COMPLETED,PHASE2,Nonalcoholic Fatty Liver Disease,Life style intervention (BEHAVIORAL); pioglitazone (DRUG); berberine (DRUG),4829,Actos,Nonalcoholic Fatty Liver Disease,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11005,NCT02341703,Ovulation Induction in Clomiphene Citrate Resistant PCO Women,COMPLETED,EARLY_PHASE1,Polycystic Ovary Syndrome; Infertility,letrozole-metformin (DRUG); letrozole-metformin-pioglitazone (DRUG); transvaginal ultrasound (RADIATION); laboratory investigations (OTHER),4829,Actos,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11006,NCT00927290,Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance,TERMINATED,PHASE3,Chronic Hepatitis C; Insulin Resistance,Pioglitazone (DRUG); Placebo (DRUG),4829,Actos,Chronic Hepatitis C; Insulin Resistance,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11007,NCT00433069,Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone,COMPLETED,PHASE2,Chronic Hepatitis C,Pioglitazone (DRUG); Interferon Alfa-2a (DRUG); Ribavirin (DRUG),4829,Actos,Chronic Hepatitis C,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11008,NCT02265276,"A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease",UNKNOWN,PHASE3,Fatty Liver,Saroglitazar (DRUG); Pioglitazone (DRUG),4829,Actos,Fatty Liver,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11009,NCT05705492,"Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer",RECRUITING,PHASE2,Advanced Malignant Solid Neoplasm; Advanced Biliary Tract Carcinoma; Advanced Esophageal Carcinoma; Metastatic Esophageal Carcinoma; Locally Advanced Biliary Tract Carcinoma; Locally Advanced Colorectal Carcinoma; Locally Advanced Esophageal Carcinoma; Locally Advanced Gastric Carcinoma; Metastatic Colorectal Carcinoma (mCRC); Advanced Lung Carcinoma,Olanzapine (DRUG); Placebo Administration (DRUG); Questionnaire Administration (OTHER),4829,Actos,Advanced Malignant Solid Neoplasm; Advanced Biliary Tract Carcinoma; Advanced Esophageal Carcinoma; Metastatic Esophageal Carcinoma; Locally Advanced Biliary Tract Carcinoma; Locally Advanced Colorectal Carcinoma; Locally Advanced Esophageal Carcinoma; Locally Advanced Gastric Carcinoma; Metastatic Colorectal Carcinoma (mCRC); Advanced Lung Carcinoma,Bowel,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11010,NCT00827892,Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage,COMPLETED,PHASE2,Intracerebral Hemorrhage,Pioglitazone (DRUG); Placebo Control (DRUG),4829,Actos,Intracerebral Hemorrhage,CNS/Brain,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11011,NCT03646292,Antidiabetic Drugs for Steatotic Liver Disease,COMPLETED,PHASE4,MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease; Type 2 Diabetes; Digestive System Disease; Liver Diseases; Fatty Liver; Metabolic Dysfunction-Associated Steatotic Liver Disease; Non-Alcoholic Fatty Liver Disease; Hypoglycemic Agents; Physiological Effects of Drugs; Sodium-Glucose Cotransporter 2 Inhibitors; Pioglitazone; Molecular Mechanisms of Pharmacological Action; Empagliflozin; Thiazolidinediones,Pioglitazone (DRUG); Empagliflozin (DRUG); Combination of pioglitazone and empagliflozin (DRUG),4829,Actos,MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease; Type 2 Diabetes; Digestive System Disease; Liver Diseases; Fatty Liver; Metabolic Dysfunction-Associated Steatotic Liver Disease; Non-Alcoholic Fatty Liver Disease; Hypoglycemic Agents; Physiological Effects of Drugs; Sodium-Glucose Cotransporter 2 Inhibitors; Pioglitazone; Molecular Mechanisms of Pharmacological Action; Empagliflozin; Thiazolidinediones,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11012,NCT00745225,Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients,COMPLETED,PHASE4,End-stage Renal Disease,Pioglitazone (DRUG); placebo comparator (DRUG),4829,Actos,End-stage Renal Disease,Kidney,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11013,NCT00570622,Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis,COMPLETED,PHASE4,Cirrhosis; Ascites; Portal Hypertension,Pioglitazone (DRUG); Placebo (DRUG),4829,Actos,Cirrhosis; Ascites; Portal Hypertension,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11014,NCT05753657,A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.,RECRUITING,EARLY_PHASE1,Metastatic Breast Cancer; Hyperinsulinism; Hyperglycemia Drug Induced,Pioglitazone (DRUG),4829,Actos,Metastatic Breast Cancer; Hyperinsulinism; Hyperglycemia Drug Induced,Breast,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11015,NCT00063622,Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS),COMPLETED,PHASE3,Liver Diseases,Pioglitazone (DRUG); Vitamin E (DIETARY_SUPPLEMENT); Matching placebo (DRUG),4829,Actos,Liver Diseases,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11016,NCT05605158,Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis,UNKNOWN,PHASE3,Non Alcoholic Steatohepatitis,Pioglitazone 30mg (DRUG); Empagliflozin 10 MG (DRUG),4829,Actos,Non-Alcoholic Steatohepatitis,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11017,NCT05254626,Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic Steatohepatitis,COMPLETED,PHASE2,Non-alcoholic Steatohepatitis,Dapagliflozin 10Mg Tab (DRUG); Pioglitazone 30 mg (DRUG),4829,Actos,Non-alcoholic Steatohepatitis,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11018,NCT00507494,Influence of Pioglitazone for Renal Transplant Function in Diabetics,COMPLETED,PHASE3,Diabetes Mellitus; Kidney Transplantation; Proteinuria,pioglitazone (DRUG),4829,Actos,Diabetes Mellitus; Kidney Transplantation; Proteinuria,Kidney,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11019,NCT01068444,The Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis,COMPLETED,PHASE2,Hepatitis,Pioglitazone (DRUG); placebo (DRUG),4829,Actos,Hepatitis,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11020,NCT02917629,ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment,TERMINATED,PHASE2,Oral Cavity Neoplasm; Oropharyngeal Neoplasm; Stage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7; Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7; Stage I Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7; Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7; Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7,Laboratory Biomarker Analysis (OTHER); Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet (DRUG); Pharmacological Study (OTHER); Placebo (OTHER),4829,Actos,Oral Cavity Neoplasm; Oropharyngeal Neoplasm; Stage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7; Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7; Stage I Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7; Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7; Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7,Skin,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11021,NCT02195791,Neuroprotection of Pioglitazone in Acute Ischemic Stroke,TERMINATED,PHASE2,Stroke,Pioglitazone (DRUG); Placebo (DRUG),4829,Actos,Stroke,CNS/Brain,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11022,NCT00189163,Pioglitazone in Hepatitis C,COMPLETED,PHASE4,Chronic Hepatitis C,Pioglitazone (DRUG); Placebo Oral Tablet (DRUG),4829,Actos,Chronic Hepatitis C,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11023,NCT00203996,Polycystic Ovary Syndrome (PCOS) and Sleep Apnea,TERMINATED,PHASE4,Polycystic Ovary Syndrome; Obstructive Sleep Apnea,continuous positive airway pressure (CPAP) (DEVICE); depot leuprolide plus estrogen/progestin replacement (DRUG); pioglitazone (DRUG); REM frag (PROCEDURE); SWS supp (PROCEDURE),4829,Actos,Polycystic Ovary Syndrome; Obstructive Sleep Apnea,Ovary/Fallopian Tube,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11024,NCT06729996,Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus,RECRUITING,PHASE2,"Pancreatitis, Chronic; Pancreatitis, Acute; Diabetes Mellitus",Pioglitazone (PIO) (DRUG); Empagliflozin (EMPA) (DRUG),4829,Actos,"Pancreatitis, Chronic; Pancreatitis, Acute; Diabetes Mellitus",Pancreas,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11025,NCT01134835,PPAR-gamma: a Novel Therapeutic Target for Asthma?,TERMINATED,PHASE4,Asthma,placebo (OTHER); IMP Pioglitozone (DRUG),4829,Actos,Asthma,Lung,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11026,NCT04475276,Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases,RECRUITING,PHASE4,Non-Alcoholic Fatty Liver Disease,Placebo (DRUG); Alphalipoic acid (DRUG),4829,Actos,Non-Alcoholic Fatty Liver Disease,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11027,NCT00145340,Pioglitazone Treatment in Polycystic Ovary Syndrome,COMPLETED,PHASE4,Polycystic Ovary Syndrome,pioglitazone (DRUG),4829,Actos,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11028,NCT00787644,Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma),TERMINATED,PHASE2,Asthma; Obesity,Pioglitazone (DRUG); Placebo (DRUG),4829,Actos,Asthma with Obesity,Lung,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11029,NCT01614301,"Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma",UNKNOWN,PHASE1,Advanced Melanoma,"dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus (DRUG)",4829,Actos,Advanced Melanoma,Skin,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11030,NCT04123067,Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke,TERMINATED,PHASE1,"Stroke, Acute; Hyperglycemia; Diabetes",Pioglitazone 45 mg (DRUG); Placebo oral tablet (DRUG),4829,Actos,"Stroke, Acute; Hyperglycemia; Diabetes",CNS/Brain,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11031,NCT01184144,Endometriosis: Immunomodulation,WITHDRAWN,PHASE2,Endometriosis,Pioglitazone (DRUG),4829,Actos,Endometriosis,Uterus,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11032,NCT00368017,Metabolic Effects of Thiazolidinediones in Chronic Kidney Disease,TERMINATED,PHASE2,Chronic Kidney Disease,pioglitazone (DRUG); placebo (DRUG),4829,Actos,Chronic Kidney Disease,Kidney,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11033,NCT03117517,Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome,COMPLETED,EARLY_PHASE1,Polycystic Ovarian Syndrome,"Metformin (DRUG); Metformin, Pioglitazone (DRUG)",4829,Actos,Polycystic Ovarian Syndrome,Ovary/Fallopian Tube,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11034,NCT00780234,Pioglitazone for Lung Cancer Chemoprevention,COMPLETED,PHASE2,Lung Cancer; Endobronchial Dysplasia,fluorescence bronchoscopy (PROCEDURE); quantitative high resolution CT scan (PROCEDURE); PIOGLITAZONE VS. PLACEBO 30 mg (DRUG),4829,Actos,Lung Cancer; Endobronchial Dysplasia,Lung,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11035,NCT00395941,Efficacy and Safety of Acitretin Plus Pioglitazone in Patients With Psoriasis,COMPLETED,PHASE2,Psoriasis,Pioglitazone (DRUG); Acitretin (DRUG),4829,Actos,Psoriasis,Skin,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11036,NCT00690118,Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis,TERMINATED,PHASE2,Amyotrophic Lateral Sclerosis,pioglitazone (DRUG); placebo (DRUG),4829,Actos,Amyotrophic Lateral Sclerosis,CNS/Brain,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11037,NCT00227110,Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH),COMPLETED,PHASE4,Nonalcoholic Steatohepatitis,Pioglitazone (DRUG); Placebo (DRUG),4829,Actos,Nonalcoholic Steatohepatitis,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11038,NCT01280123,Pioglitazone in Early Parkinson's Disease,COMPLETED,PHASE2,Parkinson's Disease,Pioglitazone (DRUG); placebo (DRUG),4829,Actos,Parkinson's Disease,CNS/Brain,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11039,NCT00919555,Combination Therapy in Amyotrophic Lateral Sclerosis (ALS),COMPLETED,PHASE1,Amyotrophic Lateral Sclerosis,Pioglitazone and Tretinoin (DRUG); Tretinoin and Pioglitazone HCL (DRUG); Placebo (DRUG),4829,Actos,Amyotrophic Lateral Sclerosis,CNS/Brain,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11040,NCT00782795,"Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality",COMPLETED,PHASE2,Chronic Pancreatitis; Insulin Resistance; Normal or Mildly Abnormal Stool Fat Levels,Pioglitazone (DRUG); Placebo (DRUG),4829,Actos,Chronic Pancreatitis; Insulin Resistance; Normal or Mildly Abnormal Stool Fat Levels,Pancreas,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11041,NCT00926614,Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba,COMPLETED,PHASE4,Hepatitis c,pioglitazone (Actos) (DRUG); atorvastatin (Lipitor) (DRUG),4829,Actos,Hepatitis c,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11042,NCT05013255,Pioglitazone Therapy Targeting Fatigue in Breast Cancer,RECRUITING,PHASE2,Breast Cancer; Muscle Fatigue,Pioglitazone 15mg (DRUG); Pioglitazone 30 mg (DRUG),4829,Actos,Breast Cancer; Muscle Fatigue,Breast,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11043,NCT00091949,Insulin Resistance Intervention After Stroke Trial,COMPLETED,PHASE3,Stroke; Myocardial Infarction; Diabetes,pioglitazone (DRUG); placebo (DRUG),4829,Actos,Stroke; Myocardial Infarction; Diabetes,CNS/Brain,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11044,NCT02284906,AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease,TERMINATED,PHASE3,Mild Cognitive Impairment Due to Alzheimer's Disease,Pioglitazone (DRUG); Placebo (DRUG),4829,Actos,Mild Cognitive Impairment Due to Alzheimer's Disease,CNS/Brain,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11045,NCT01454336,Transplantation of Autologous Mesenchymal Stem Cell in Decompensate Cirrhotic Patients With Pioglitazone,COMPLETED,PHASE1,Liver Fibrosis,Cell injection (BIOLOGICAL),4829,Actos,Liver Fibrosis,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11046,NCT00923949,Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer,TERMINATED,PHASE2,Non-Small-Cell Lung Cancer,Pioglitazone (DRUG),4829,Actos,Non-Small-Cell Lung Cancer,Lung,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11047,NCT04501406,Low-Dose Pioglitazone in Patients With NASH (AIM 2),RECRUITING,PHASE2,Type 2 Diabetes Mellitus (T2DM); Nonalcoholic Steatohepatitis,Pioglitazone (DRUG); Placebo (OTHER),4829,Actos,Type 2 Diabetes Mellitus (T2DM); Nonalcoholic Steatohepatitis,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11048,NCT05813249,Semaglutide in Nonalcoholic Fatty Liver Disease,COMPLETED,PHASE4,Non-alcoholic Fatty Liver Disease,Rybelsus Oral Product (DRUG); Ozempic Injectable Product (DRUG); Tocopherol and/or Actos (DRUG),4829,Actos,Non-alcoholic Fatty Liver Disease,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11049,NCT01151670,Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors,COMPLETED,PHASE1,"Brain Neoplasms, Malignant; Brain Neoplasms, Benign; Malignant Meningioma; Glioblastoma Multiforme; Anaplastic Astrocytoma",pioglitazone (DRUG); Pioglitazone (DRUG),4829,Actos,"Brain Neoplasms, Malignant; Brain Neoplasms, Benign; Malignant Meningioma; Glioblastoma Multiforme; Anaplastic Astrocytoma",CNS/Brain,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11050,NCT05394142,"A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)",RECRUITING,PHASE2,Polycystic Ovary Syndrome (PCOS),Placebo (DRUG); Pioglitazone (DRUG); Spironolactone (DRUG); Metformin (DRUG),4829,Actos,Polycystic Ovary Syndrome (PCOS),Ovary/Fallopian Tube,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11051,NCT05473806,Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes,UNKNOWN,PHASE4,"Hepatitis B, Chronic; Fibrosis, Liver; Diabetes Mellitus, Type 2",Pioglitazone 15 Mg Oral Tablet (DRUG); Evogliptin 5mg (DRUG),4829,Actos,"Hepatitis B, Chronic; Fibrosis, Liver; Diabetes Mellitus, Type 2",Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11052,NCT04584242,Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes,UNKNOWN,PHASE4,Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes,gluconon tab 15mg (DRUG); suganon tab 5mg (DRUG),4829,Actos,Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11053,NCT01431521,Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008),COMPLETED,PHASE1,Non-alcoholic Fatty Liver Disease,MK-4074 200 mg (DRUG); Placebo for MK-4074 (DRUG); Pioglitazone hydrochloride 30 mg (DRUG); Placebo for pioglitazone hydrochloride (DRUG),4829,Actos,Non-alcoholic Fatty Liver Disease,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11054,NCT00982202,Pioglitazone in Alzheimer Disease,COMPLETED,PHASE2,Alzheimer Disease,pioglitazone (DRUG); Placebo (DRUG),4829,Actos,Alzheimer Disease,CNS/Brain,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11055,NCT02875821,Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone,COMPLETED,PHASE4,Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD),Ipragliflozin (DRUG); metformin with pioglitazone (DRUG),4829,Actos,Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD),Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11056,NCT05946564,A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial,RECRUITING,PHASE3,ANCA Associated Vasculitis; Rapidly Progressive Glomerulonephritis; Crescentic Glomerulonephritis,Pioglitazone (ACTOS®) (DRUG); Placebo of Pioglitazone (DRUG),4829,Actos,ANCA Associated Vasculitis; Rapidly Progressive Glomerulonephritis; Crescentic Glomerulonephritis,Kidney,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11057,NCT00062764,Treating Nonalcoholic Steatohepatitis With Pioglitazone,COMPLETED,PHASE2,Hepatitis,Actos (Pioglitazone) (DRUG),4829,Actos,Hepatitis,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11058,NCT01489943,"A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects",COMPLETED,PHASE1,Crohn's Disease,GSK1605786 500 mg (DRUG); Midazolam 3 mg (DRUG); Pioglitazone 15 mg (DRUG); Omeprazole 40 mg (DRUG); Rosuvastatin 10 mg (DRUG),4829,Actos,Crohn's Disease,Bowel,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11059,NCT02689843,"Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS",COMPLETED,EARLY_PHASE1,Polycystic Ovary Syndrome,Cyproterone compound + Spironolactone (DRUG); Metformin (DRUG); Pioglitazone (DRUG),4829,Actos,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11060,NCT00634036,Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics,COMPLETED,PHASE2,Asthma,pioglitazone (DRUG); placebo (DRUG),4829,Actos,Asthma,Lung,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11061,NCT05942963,Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD,NOT_YET_RECRUITING,PHASE4,Non-Alcoholic Fatty Liver Disease; Type2diabetes,Empagliflozin 10 MG (DRUG); Pioglitazone 15mg (DRUG); Metformin (DRUG),4829,Actos,Non-Alcoholic Fatty Liver Disease; Type2diabetes,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11062,NCT01909141,Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS,COMPLETED,EARLY_PHASE1,Polycystic Ovary Syndrome; Infertility,"induction of ovulation using letrozole-pioglitazone-metformin (DRUG); induction of ovulation using clomiphene citrate-pioglitazone-metformin (DRUG); transvaginal ultrasound (RADIATION); body mass index (BMI) calculation (OTHER); day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone (OTHER); pretreatment blood urea and serum creatinine (OTHER); serum estradiol (E2) on day 12 (OTHER); serum progesterone on day 21 (OTHER); blood urea and serum creatinine every month (OTHER)",4829,Actos,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11063,NCT02697617,Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease,COMPLETED,PHASE2,Polycystic Kidney Disease,Pioglitazone (DRUG); Placebo (DRUG),4829,Actos,Polycystic Kidney Disease,Kidney,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11064,NCT03471117,Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients,RECRUITING,PHASE4,Chronic Kidney Diseases,Pioglitazone (DRUG); Placebo (OTHER),4829,Actos,Chronic Kidney Diseases,Kidney,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11065,NCT02347813,Preventing Squamous Cell Skin Cancer,COMPLETED,PHASE2,Squamous Cell Carcinoma of the Skin,Pioglitazone (DRUG),4829,Actos,Squamous Cell Carcinoma of the Skin,Skin,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11066,NCT05519813,Effects of Pioglitazone Combined With Metformin on Gonadal and Metabolic Profiles in Chinese Nonobese PCOS Patients.,UNKNOWN,PHASE4,Polycystic Ovary Syndrome,Metformin (DRUG); Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets (DRUG),4829,Actos,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11067,NCT00994175,"A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma",COMPLETED,PHASE2,"Severe, Refractory Asthma; Airway Inflammation; Airflow Obstruction",Pioglitazone (DRUG); Placebo (DRUG),4829,Actos,"Severe, Refractory Asthma; Airway Inflammation; Airflow Obstruction",Lung,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11068,NCT03796975,Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease,COMPLETED,PHASE4,Type 2 Diabetes Mellitus; Non-alcoholic Fatty Liver Disease; Efficacy,Combination of Pioglitazone and Metformin Tablets (DRUG); Metformin Hydrochloride Tablets (DRUG),4829,Actos,Type 2 Diabetes Mellitus; Non-alcoholic Fatty Liver Disease; Efficacy,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11069,NCT01342770,Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung Cancer,TERMINATED,PHASE2,Stage IA Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Laboratory Biomarker Analysis (OTHER); Pioglitazone Hydrochloride (DRUG); Quality-of-Life Assessment (OTHER),4829,Actos,Stage IA Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Lung,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11070,NCT05305287,Quantifying Hepatic Mitochondrial Fluxes in Humans,RECRUITING,PHASE4,Non-Alcoholic Fatty Liver Disease; Type 2 Diabetes; Mitochondrial Metabolism Disorders,Pioglitazone (DRUG); Placebo (OTHER),4829,Actos,Non-Alcoholic Fatty Liver Disease; Type 2 Diabetes; Mitochondrial Metabolism Disorders,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11071,NCT01157975,Study the Relationship Between Obesity and Hepatitis C Replication,WITHDRAWN,PHASE2,Hepatitis C,Pioglitazone (DRUG); Prednisone (DRUG),4829,Actos,Hepatitis C,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11072,NCT04419337,Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke,UNKNOWN,PHASE2,Diabetes Mellitus; Stroke,Metformin plus Pioglitazone plus an SGLT2 inhibitor (DRUG),4829,Actos,Diabetes Mellitus with Stroke,CNS/Brain,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11073,NCT05919147,The Neuroendocrine Effects of Pioglitazone in Patients with Cancer and Cachexia,ACTIVE_NOT_RECRUITING,PHASE2,Lung Cancer,Pioglitazone 45 mg (DRUG); Placebo (DRUG),4829,Actos,Lung Cancer,Lung,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11074,NCT00665353,Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance,COMPLETED,PHASE2,HIV-1 and Hepatitis C Co-Infection,pioglitazone (DRUG); peginterferon (DRUG); ribavirin (DRUG),4829,Actos,HIV-1 and Hepatitis C Co-Infection,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11075,NCT02365233,Fatty Liver Study in Patients With Type II Diabetes,TERMINATED,PHASE4,Type II Diabetes; Nonalcoholic Fatty Liver,DPP4 inhibitor (DRUG); Pioglitazone (DRUG); Lantus insulin (DRUG),4829,Actos,Type II Diabetes; Nonalcoholic Fatty Liver,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11076,NCT05521633,Comparison of the Effects of Metformin and Pioglitazone on Liver Enzymes and Ultrasound Changes in Non-Diabetic Non-Alcoholic Fatty Liver,COMPLETED,PHASE3,NAFLD,Metformin and Pioglitazone (DRUG),4829,Actos,Non-alcoholic Fatty Liver Disease,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11077,NCT00545233,A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.,COMPLETED,PHASE4,"Hepatitis C, Chronic",peginterferon alfa-2a [Pegasys] (DRUG); ribavirin [Copegus] (DRUG); Pioglitazone (DRUG),4829,Actos,Chronic Hepatitis C,Liver,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11078,NCT00242177,Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability,COMPLETED,PHASE1,"Multiple Sclerosis, Relapsing-Remitting",ACTOS (Pioglitazone) (DRUG),4829,Actos,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Pioglitazone,PPARG,activator/agonist,unclear,yes,yes,Approved for type 2 diabetes treatment.,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,1.19,290.0 +11079,NCT04958473,A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer,NOT_YET_RECRUITING,PHASE2,Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma,Sintilimab (DRUG); Axitinib (DRUG),10461508,IBI,Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma,Kidney,Volasertib,"PLK1, PLK2, PLK3",inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,1.0,53.0 +11080,NCT06089382,A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection,NOT_YET_RECRUITING,PHASE3,Hepatocellular Carcinoma,Sintilimab (DRUG); Lenvatinib (DRUG); Transarterial Chemoembolization (TACE) (PROCEDURE),10461508,IBI,Hepatocellular Carcinoma,Liver,Volasertib,"PLK1, PLK2, PLK3",inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,1.0,53.0 +11081,NCT00072462,Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ,COMPLETED,PHASE3,Breast Cancer,tamoxifen citrate (DRUG); Anastrozole (DRUG),10461508,IBI,Breast Cancer,Breast,Volasertib,"PLK1, PLK2, PLK3",inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,1.0,53.0 +11082,NCT00002644,Tamoxifen for the Prevention of Breast Cancer in High-Risk Women,COMPLETED,PHASE3,Breast Cancer,Tamoxifen Citrate 20Mg Tab (DRUG); Placebo (OTHER),10461508,IBI,Breast Cancer,Breast,Volasertib,"PLK1, PLK2, PLK3",inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,1.0,53.0 +11083,NCT06089369,Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion,NOT_YET_RECRUITING,PHASE3,Hepatocellular Carcinoma,Sintilimab (9 cycles) (DRUG); Sintilimab (18 cycles) (DRUG); Active surveillance (OTHER),10461508,IBI,Hepatocellular Carcinoma,Liver,Volasertib,"PLK1, PLK2, PLK3",inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,1.0,53.0 +11084,NCT00287768,Phase III Study of Docetaxel + S-1 vs. S-1 for Advanced Gastric Cancer,COMPLETED,PHASE3,Gastric Cancer,docetaxel + S-1 (DRUG); S-1 (DRUG),10461508,IBI,Gastric Cancer,Esophagus/Stomach,Volasertib,"PLK1, PLK2, PLK3",inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,1.0,53.0 +11085,NCT04478734,Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease,RECRUITING,PHASE2,Huntington Disease,Moderate doses of Thiamine y Biotin (DRUG); High doses of Thiamine y Biotin (DRUG),10461508,IBI,Huntington Disease,CNS/Brain,Volasertib,"PLK1, PLK2, PLK3",inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,1.0,53.0 +11086,NCT00324714,Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS,WITHDRAWN,PHASE3,Breast Cancer; Osteoporosis,risedronate sodium (DRUG); diagnostic laboratory biomarker analysis (OTHER),10461508,IBI,Breast Cancer; Osteoporosis,Breast,Volasertib,"PLK1, PLK2, PLK3",inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,1.0,53.0 +11087,NCT03585595,Intensive Blood Pressure Intervention in Stroke (IBIS) Trial,WITHDRAWN,PHASE3,Ischemic Stroke,Blood pressure lowering strategy (OTHER),10461508,IBI,Ischemic Stroke,CNS/Brain,Volasertib,"PLK1, PLK2, PLK3",inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,1.0,53.0 +11088,NCT03765775,Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative,UNKNOWN,PHASE2,Carcinoma; Non-small Cell Lung Cancer; Lung Neoplasm,Sintilimab (BIOLOGICAL); Anlotinib Hydrochloride (DRUG),10461508,IBI,Carcinoma; Non-small Cell Lung Cancer; Lung Neoplasm,Lung,Volasertib,"PLK1, PLK2, PLK3",inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,1.0,53.0 +11089,NCT00078832,Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer,COMPLETED,PHASE3,Breast Cancer,anastrozole (DRUG); placebo (DRUG),10461508,IBI,Breast Cancer,Breast,Volasertib,"PLK1, PLK2, PLK3",inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,1.0,53.0 +11090,NCT01818856,Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir,COMPLETED,PHASE1,"Hepatitis C, Chronic; HIV Infection","Ritonavir withdrawal, atazanavir 200 mg/12h (DRUG); Telaprevir interactions (DRUG)",10461508,IBI,"Hepatitis C, Chronic; HIV Infection",Liver,Volasertib,"PLK1, PLK2, PLK3",inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,1.0,53.0 +11091,NCT01603654,Sodium Picosulphate/Magnesium Citrate and Low-volume PEG -Ascorbic Acid as Preparation for Colonoscopy,COMPLETED,PHASE4,Colon Cleansing for Colonoscopy,sodium picosulphate magnesium citrate (DRUG); low-volume PEG -ascorbic acid (DRUG),10461508,IBI,Colon Cleansing for Colonoscopy,Bowel,Volasertib,"PLK1, PLK2, PLK3",inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,1.0,53.0 +11092,NCT04486287,Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer,UNKNOWN,PHASE2,Oligometastasis; Lung Neoplasms,Sintilimab (DRUG),10461508,IBI,Oligometastasis; Lung Neoplasms,Lung,Volasertib,"PLK1, PLK2, PLK3",inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,1.0,53.0 +11093,NCT02517593,Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake,COMPLETED,PHASE1,Breast Cancer,Polygenic Risk Score (GENETIC),10461508,IBI,Breast Cancer,Breast,Volasertib,"PLK1, PLK2, PLK3",inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,1.0,53.0 +11094,NCT02539615,A Trial of the ForeCYTE Breast Aspirator for Cytological Testing of Nipple Aspirate Fluid in Women 30-55 Years Old,WITHDRAWN,PHASE3,"Breast Cancer, Preneoplastic Conditions, BRCA",ForeCYTE Breast Aspirator (DEVICE),10461508,IBI,"Breast Cancer, Preneoplastic Conditions, BRCA",Breast,Volasertib,"PLK1, PLK2, PLK3",inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,1.0,53.0 +11095,NCT00824408,Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",pemetrexed (DRUG); pemetrexed (DRUG); BI 6727 (DRUG),10461508,IBI,"Carcinoma, Non-Small-Cell Lung",Lung,Volasertib,"PLK1, PLK2, PLK3",inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,1.0,53.0 +11096,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,COMPLETED,PHASE2,Ovarian Neoplasms,Paclitaxel (DRUG); Gemcitabine (DRUG); Topotecan (DRUG); Pegylated liposomal doxorubicin (PLD) (DRUG); BI 6727 (DRUG),10461508,IBI,Ovarian Neoplasms,Ovary/Fallopian Tube,Volasertib,"PLK1, PLK2, PLK3",inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,1.0,53.0 +11097,NCT04540926,Cyclosporine A Plus Low-steroid Treatment in COVID-19 Pneumonia,UNKNOWN,PHASE1,COVID 19 Pneumonia,Cyclosporin A (DRUG),5284373,CSA,COVID 19 Pneumonia,Lung,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11098,NCT02144857,Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis,UNKNOWN,PHASE4,Psoriasis,etanercept (DRUG); ustekinumab (DRUG); cyclosporine (DRUG); Secukinumab (DRUG); Apremilast (DRUG),5284373,CSA,Psoriasis,Skin,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11099,NCT00150020,Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI Intolerance,COMPLETED,PHASE4,Renal Transplantation,Enteric-coated mycophenolate sodium (EC-MPS) (DRUG),5284373,CSA,Renal Transplantation,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11100,NCT00003920,Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer,UNKNOWN,PHASE1,Breast Cancer,filgrastim (BIOLOGICAL); cyclosporine (DRUG); peripheral blood stem cell transplantation (PROCEDURE); indium In 111 monoclonal antibody m170 (RADIATION); yttrium Y 90 monoclonal antibody m170 (RADIATION),5284373,CSA,Breast Cancer,Breast,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11101,NCT00634920,Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients,COMPLETED,PHASE4,Renal Function,everolimus (DRUG); cyclosporine A (DRUG); Enteric Coated Mycophenolate Sodium (EC-MPS) (DRUG); corticosteroids (DRUG); Basiliximab (DRUG),5284373,CSA,Renal Function,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11102,NCT00413920,"Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant Recipients",COMPLETED,PHASE3,Renal Transplantation,Enteric-coated mycophenolate sodium (EC-MPS) (DRUG); Prednisone (DRUG),5284373,CSA,Renal Transplantation,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11103,NCT00027820,Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer,COMPLETED,PHASE1,Adult Acute Myeloid Leukemia in Remission; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Myelodysplastic Syndrome; Childhood Renal Cell Carcinoma; Chronic Myelomonocytic Leukemia; Clear Cell Renal Cell Carcinoma; de Novo Myelodysplastic Syndrome; Metastatic Renal Cell Cancer; Previously Treated Myelodysplastic Syndrome; Progression of Multiple Myeloma or Plasma Cell Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult Non-Hodgkin Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Non-Hodgkin Lymphoma; Refractory Anemia; Refractory Anemia With Ringed Sideroblasts; Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Renal Medullary Carcinoma; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Fludarabine Phosphate (DRUG); Total-Body Irradiation (RADIATION); Peripheral Blood Stem Cell Transplantation (PROCEDURE); Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation (PROCEDURE); Cyclosporine (DRUG); Mycophenolate Mofetil (DRUG),5284373,CSA,Adult Acute Myeloid Leukemia in Remission; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Myelodysplastic Syndrome; Childhood Renal Cell Carcinoma; Chronic Myelomonocytic Leukemia; Clear Cell Renal Cell Carcinoma; de Novo Myelodysplastic Syndrome; Metastatic Renal Cell Cancer; Previously Treated Myelodysplastic Syndrome; Progression of Multiple Myeloma or Plasma Cell Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult Non-Hodgkin Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Non-Hodgkin Lymphoma; Refractory Anemia; Refractory Anemia With Ringed Sideroblasts; Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Renal Medullary Carcinoma; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11104,NCT00214266,A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation,COMPLETED,PHASE2,Renal Transplantation,"Campath 1H®, Rituximab, mycophenolate mofetil (DRUG)",5284373,CSA,Renal Transplantation,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11105,NCT03794765,Antibiotics as an Adjuvant in Patients With Acute Severe Ulcerative Colitis,COMPLETED,PHASE2,Ulcerative Colitis; Inflammatory Bowel Diseases; Acute Severe Colitis,Ceftriaxone (DRUG); Metronidazole (DRUG); Placebo infusion (OTHER),5284373,CSA,Ulcerative Colitis; Inflammatory Bowel Diseases; Acute Severe Colitis,Bowel,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11106,NCT01953120,Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309),COMPLETED,PHASE4,Renal Transplant Rejection,Belatacept (DRUG),5284373,CSA,Renal Transplant Rejection,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11107,NCT00254982,Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED),COMPLETED,PHASE3,Psoriasis,Infliximab (BIOLOGICAL),5284373,CSA,Psoriasis,Skin,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11108,NCT00362531,Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome,COMPLETED,PHASE2,Idiopathic Membranous Nephropathy; Nephrotic Syndrome,tacrolimus combined with prednisone (DRUG),5284373,CSA,Idiopathic Membranous Nephropathy; Nephrotic Syndrome,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11109,NCT00739882,TRUST Study: Raptiva ® in Hand & Foot Psoriasis,TERMINATED,PHASE4,Chronic Plaque Psoriasis,Efalizumab - anti CD11a recombinant human monoclonal antibody (DRUG); Placebo (DRUG),5284373,CSA,Chronic Plaque Psoriasis,Skin,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11110,NCT00149890,"Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids",COMPLETED,PHASE3,Liver Transplantation; Infection,Basiliximab (DRUG); Cyclosporine/cyclosporine microemulsion (DRUG); Steroid (DRUG),5284373,CSA,Liver Transplantation; Infection,Liver,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11111,NCT02963103,A Study to Assess the Safety and Efficacy of a Tacrolimus Based Immunosuppressive Regimen in Stable Kidney Transplant Recipients Converted From Cyclosporine Based Immunosuppressive Regimen,TERMINATED,PHASE4,Kidney Transplantation,Tacrolimus (DRUG),5284373,CSA,Kidney Transplantation,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11112,NCT00213590,Renal Function Evaluation After Reduction of Cyclosporine A Dose in Renal Transplant Patients,COMPLETED,PHASE3,Kidney Transplantation; Primary Prevention; Kidney Failure,cyclosporine A (DRUG),5284373,CSA,Kidney Transplantation; Primary Prevention; Kidney Failure,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11113,NCT00434590,"Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients",TERMINATED,PHASE4,Kidney Transplantation,Enteric coated mycophenolate sodium (Myfortic®) (DRUG),5284373,CSA,Kidney Transplantation,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11114,NCT00004990,Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis,COMPLETED,PHASE2,Glomerulonephritis; Nephrotic Syndrome,Dexamethasone (DRUG),5284373,CSA,Glomerulonephritis; Nephrotic Syndrome,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11115,NCT01053221,Mycophenolic Acid Monotherapy in Recipients of HLA-identical Living-Related Transplantation,TERMINATED,PHASE2,Kidney Transplantation,Mycophenolic Acid (DRUG); Standard of Care: CNI and MPA (DRUG),5284373,CSA,Kidney Transplantation,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11116,NCT00582738,Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection,TERMINATED,PHASE2,Recurrent Hepatitis C,CsA-TAC (standard Treatment) (DRUG); Everolimus (DRUG),5284373,CSA,Recurrent Hepatitis C,Liver,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11117,NCT00312143,Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients,COMPLETED,PHASE4,De Novo Kidney Transplant Recipients,Enteric-coated Mycophenolate sodium (EC-MPS) (DRUG),5284373,CSA,De Novo Kidney Transplant Recipients,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11118,NCT01105650,"Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer",COMPLETED,PHASE2,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Breast Cancer,Fludarabine (DRUG); Cyclophosphamide (DRUG); Cyclosporine (DRUG); Natural killer cells (BIOLOGICAL); IL-2 (DRUG); Methylprednisolone (DRUG); Methylprednisolone (DRUG); Interleukin-2 (DRUG),5284373,CSA,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Breast Cancer,Breast,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11119,NCT03170323,Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy,UNKNOWN,PHASE4,Idiopathic Membranous Nephropathy,Mycophenolate Mofetil (DRUG); Cyclosporins (DRUG),5284373,CSA,Idiopathic Membranous Nephropathy,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11120,NCT00003950,"Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer",COMPLETED,PHASE2,Colorectal Cancer,cyclosporine (DRUG); CPT-11 (DRUG),5284373,CSA,Colorectal Cancer,Bowel,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11121,NCT00056095,Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer,COMPLETED,PHASE2,Kidney Cancer,therapeutic allogeneic lymphocytes (BIOLOGICAL); cyclophosphamide (DRUG); cyclosporine (DRUG); fludarabine phosphate (DRUG); allogeneic bone marrow transplantation (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE),5284373,CSA,Kidney Cancer,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11122,NCT00972543,Raptiva in Palm and Sole Psoriasis,TERMINATED,PHASE4,Chronic Plaque Psoriasis,Efalizumab (Raptiva) (BIOLOGICAL); Placebo (BIOLOGICAL),5284373,CSA,Chronic Plaque Psoriasis,Skin,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11123,NCT01561404,Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise,TERMINATED,PHASE4,"Disorder Related to Renal Transplantation; Exercise, Aerobic; Muscle Strength",Everolimus (DRUG),5284373,CSA,"Disorder Related to Renal Transplantation; Exercise, Aerobic; Muscle Strength",Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11124,NCT01824368,Extracorporeal Photopheresis in Liver Transplantation. Phase II Clinical Trial in Safety and Efficacy in Patients With Gradual Decrease of Immunosuppression.,COMPLETED,PHASE1,Liver Transplantation; Immunosuppression,Extracorporeal Photopheresis Procedure (FEC) (PROCEDURE),5284373,CSA,Liver Transplantation; Immunosuppression,Liver,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11125,NCT00086346,Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients,TERMINATED,PHASE3,Liver Transplantation,Sirolimus (Rapamune) (DRUG); Cyclosporine or Tacrolimus (DRUG),5284373,CSA,Liver Transplantation,Liver,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11126,NCT00020176,Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer,COMPLETED,PHASE2,Breast Cancer,filgrastim (BIOLOGICAL); therapeutic allogeneic lymphocytes (BIOLOGICAL); cyclophosphamide (DRUG); cyclosporine (DRUG); fludarabine phosphate (DRUG); peripheral blood stem cell transplantation (PROCEDURE),5284373,CSA,Breast Cancer,Breast,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11127,NCT00239876,Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients,COMPLETED,PHASE3,Renal Transplantation,FTY720 (DRUG),5284373,CSA,Renal Transplantation,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11128,NCT00232076,Verification Study of Ciclosporin for Atopic Dermatitis,COMPLETED,PHASE3,Severe Atopic Dermatitis,ciclosporin (DRUG),5284373,CSA,Eczema,Skin,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11129,NCT00123331,Rapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation,COMPLETED,PHASE4,Heart Transplantation; Renal Failure,Cyclosporine discontinuation (DRUG); Rapamycin medication (DRUG),5284373,CSA,Heart Transplantation; Renal Failure,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11130,NCT00003060,Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma,TERMINATED,PHASE1,Melanoma (Skin),filgrastim (BIOLOGICAL); busulfan (DRUG); cyclophosphamide (DRUG); cyclosporine (DRUG); methotrexate (DRUG); allogeneic bone marrow transplantation (PROCEDURE),5284373,CSA,Melanoma (Skin),Skin,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11131,NCT00239031,Study of Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Reduced-dose Cyclosporine Microemulsion (CsA-ME) Compared to EC-MPS Plus Standard Dose CsA-ME in Eldery de Novo Renal Transplant Recipients Treated With Basiliximab and Short-term Steroids,COMPLETED,PHASE3,Denovo Renal Transplantation,Enteric-Coated Mycophenolate Sodium (DRUG),5284373,CSA,Denovo Renal Transplantation,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11132,NCT05702931,Semaglutide Treatment for Hyperglycaemia After Renal Transplantation,RECRUITING,PHASE4,Hyperglycemia; Renal Transplant Complication Primary Non-Function; Diabetes,Semaglutide 14 MG [Rybelsus] (DRUG); Placebo (DRUG),5284373,CSA,Hyperglycemia; Renal Transplant Complication Primary Non-Function; Diabetes,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11133,NCT01699360,The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients,UNKNOWN,PHASE4,Kidney Transplantation,"Cyclosporine A, Tacrolimus, Sirolimus (DRUG)",5284373,CSA,Kidney Transplantation,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11134,NCT00206076,Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation,COMPLETED,PHASE4,Liver Disease,mycophenolate mofetil (DRUG); mycophenolate mofetil (DRUG),5284373,CSA,Liver Disease,Liver,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11135,NCT01268995,Improving Secretion of Insulin in New Onset Diabetes After Renal Transplantation,TERMINATED,PHASE2,New Onset Diabetes Mellitus After Renal Transplantation,Cyclosporine A (DRUG); Tacrolimus (DRUG),5284373,CSA,New Onset Diabetes Mellitus After Renal Transplantation,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11136,NCT00001212,Drug Therapy in Lupus Nephropathy,COMPLETED,PHASE2,Nephrotic Syndrome; Systemic Lupus Erythematosus,prednisone (DRUG); cyclophosphamide (DRUG); cyclosporin A (DRUG),5284373,CSA,Nephrotic Syndrome; Systemic Lupus Erythematosus,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11137,NCT00754468,"Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus.",COMPLETED,PHASE4,Barrett's Esophagus; Esophageal Cancer,Cryo Spray Ablation (DEVICE); Cryo Spray Ablation (DEVICE),5284373,CSA,Barrett's Esophagus; Esophageal Cancer,Esophagus/Stomach,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11138,NCT00402168,A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids,COMPLETED,PHASE2,Renal Transplant,Belatacept (DRUG); Cyclosporine A (DRUG); Tacrolimus (DRUG),5284373,CSA,Renal Transplant,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11139,NCT01038167,A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults,COMPLETED,PHASE1,Hepatitis C,telaprevir (DRUG); telaprevir (DRUG); cyclosporine (DRUG); cyclosporine (DRUG); tacrolimus (DRUG); tacrolimus (DRUG),5284373,CSA,Hepatitis C,Liver,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11140,NCT02268201,A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule,TERMINATED,PHASE4,Kidney Transplant Recipients,Advagraf (DRUG); Prograf (DRUG),5284373,CSA,Kidney Transplant Recipients,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11141,NCT00747773,Cryospray Ablation of Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung,COMPLETED,PHASE4,Lung Cancer,CryoSpray Ablation System (DEVICE),5284373,CSA,Lung Cancer,Lung,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11142,NCT00050648,To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris,COMPLETED,PHASE1,Psoriasis,Daclizumab (DRUG); Cyclosporine (DRUG); cyclosporine and Daclizumab (DRUG),5284373,CSA,Psoriasis,Skin,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11143,NCT00079625,Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer,COMPLETED,PHASE1,Breast Neoplasms,Th2/Tc2 Cells (DRUG),5284373,CSA,Breast Neoplasms,Breast,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11144,NCT01817322,Kidney Graft Function Under the Immunosuppression Strategies,COMPLETED,PHASE4,Chronic Renal Disease,Standard Dose of Myfortic and Reduced Dose of Myfortic (DRUG); Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group (DRUG); Basiliximab injected both control group and experimental group (DRUG),5284373,CSA,Chronic Renal Disease,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11145,NCT00377325,The Effectiveness of Lower Cyclosporine Doses for Psoriasis,WITHDRAWN,PHASE2,Psoriasis,Cyclosporine (DRUG),5284373,CSA,Psoriasis,Skin,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11146,NCT05041426,Letermovir for CMV Prevention After Lung Transplantation,ACTIVE_NOT_RECRUITING,PHASE2,Lung Transplant; CMV,Letermovir (DRUG); Valganciclovir (DRUG),5284373,CSA,Lung Transplant; CMV,Lung,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11147,NCT00003625,Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma,COMPLETED,PHASE1,Brain Tumors; Central Nervous System Tumors,cyclosporine (DRUG); etoposide (DRUG); vincristine sulfate (DRUG); radiation therapy (RADIATION),5284373,CSA,Brain Tumors; Central Nervous System Tumors,CNS/Brain,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11148,NCT00308425,Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) Plus Valsartan in Patients With Kidney Transplants (MYTHOS,COMPLETED,PHASE3,De Novo Renal Transplantation,"Enteric-coated Mycophenolate sodium (EC-MPS), valsartan (DRUG)",5284373,CSA,De Novo Renal Transplantation,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11149,NCT00295425,CYA Versus MMF for Treatment of Moderate-Severe Psoriasis.,UNKNOWN,PHASE2,Psoriasis,Cyclosporine A versus mycophenolate mofetil for psoriasis (DRUG),5284373,CSA,Psoriasis,Skin,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11150,NCT00461825,Maintenance Neoral Monotherapy Compared to Bitherapy in Renal Transplantation,COMPLETED,PHASE3,Kidney Transplantation,Cyclosporin A: C0: 75-125ng/ml-dose adapted in the 3 groups (DRUG); Group A: CsA + Azathioprine(1 to 2 mg/kg/day) (DRUG); Group B: CsA + CellCept(500 mg x 2/day) (DRUG); Group C: CsAm (DRUG),5284373,CSA,Kidney Transplantation,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11151,NCT00038948,Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients,COMPLETED,PHASE3,Renal Transplantation,Sirolimus (DRUG); tacrolimus (DRUG); Cyclosporine A (DRUG),5284373,CSA,Renal Transplantation,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11152,NCT01938625,"A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation",COMPLETED,PHASE2,"Hepatitis C, Chronic",Simeprevir (DRUG); Daclatasvir (DRUG); Ribavirin (DRUG); Cyclosporine (DRUG); Tacrolimus (DRUG),5284373,CSA,Chronic Hepatitis C,Liver,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11153,NCT01404325,Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients,COMPLETED,PHASE3,Lung Transplantation,standard therapy (DRUG); Everolimus (DRUG),5284373,CSA,Lung Transplantation,Lung,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11154,NCT05539625,Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis,SUSPENDED,PHASE2,Ulcerative Colitis,MitoQ (DIETARY_SUPPLEMENT); Placebo (OTHER),5284373,CSA,Ulcerative Colitis,Bowel,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11155,NCT00332839,Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.,TERMINATED,PHASE4,Renal Transplantation,Everolimus (DRUG); Cyclosporin A (CsA) (DRUG); Tacrolimus (DRUG); Enteric Coated - Mycophenolate Sodium (EC-MPS) (DRUG); Corticosteroids (DRUG),5284373,CSA,Renal Transplantation,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11156,NCT01299922,Clinical Trial Treatment in Lupus Nephritis,WITHDRAWN,PHASE3,Lupus Nephritis,cyclosporine +mycophenolic acid+prednison (DRUG); Mycophenolic Acid + prednison (DRUG),5284373,CSA,Lupus Nephritis,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11157,NCT01282073,Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy,UNKNOWN,PHASE3,"Glomerulonephritis, Membranous","Mycophenolate mofetil, low dose steroid (DRUG); Cyclosporin, low dose steroid (DRUG)",5284373,CSA,Membranous Glomerulonephritis,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11158,NCT00419926,Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant Patients,COMPLETED,PHASE4,Kidney Transplantation,Enteric-coated mycophenolate sodium (Myfortic) (DRUG); Cyclosporine (Neoral) (DRUG); Prednisone (DRUG),5284373,CSA,Kidney Transplantation,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11159,NCT00343226,"An Open, Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in ""de Novo"" Liver Transplantation.",COMPLETED,PHASE4,Liver Transplantation,Basiliximab (DRUG),5284373,CSA,Liver Transplantation,Liver,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11160,NCT01439958,Long-term Safety Follow-up Study in the Prevention of Bronchiolitis Obliterans Syndrome (BOS),TERMINATED,PHASE3,Bronchiolitis Obliterans,Inhalation (DRUG),5284373,CSA,Bronchiolitis Obliterans,Lung,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11161,NCT01266148,SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance,COMPLETED,PHASE4,Renal Function and Chronic Allograft Vasculopathy,Cyclosporine (DRUG); Mycophenolate mofetil (DRUG); Corticosteroids (DRUG); Everolimus (DRUG); Anti Thymocyte Globulin (DRUG),5284373,CSA,Renal Function and Chronic Allograft Vasculopathy,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11162,NCT00171496,Evaluation of Cyclosporine Microemulsion and Tacrolimus on the Rate of New Onset Diabetes Mellitus in Kidney Transplantation Recipients,COMPLETED,PHASE4,Kidney Transplant,Cyclosporine microemulsion (DRUG); Tacrolimus (DRUG),5284373,CSA,Kidney Transplant,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11163,NCT06676696,Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure,RECRUITING,PHASE4,"Renal Failure , Chronic; Graft Failure; Graft Rejection; Allograft; Renal Failure Chronic Requiring Dialysis",Continue low dose calcineurin inhibitor (CNI) (DRUG); Calcineurin inhibitor withdrawal at 6 months (DRUG),5284373,CSA,"Renal Failure , Chronic; Graft Failure; Graft Rejection; Allograft; Renal Failure Chronic Requiring Dialysis",Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11164,NCT01596062,"Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)",COMPLETED,PHASE2,Renal Transplantation,Simulect® (DRUG); Neoral® (DRUG); Certican® (DRUG); Myfortic® (DRUG); Corticosteroids (DRUG),5284373,CSA,Renal Transplantation,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11165,NCT00509444,Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial,COMPLETED,PHASE3,Breast Cancer; Colon Cancer; Rectum Cancer; Cervix Cancer; Prostate Cancer; Lung Cancer,"Educational materials (BEHAVIORAL); educational materials, plus patient navigation (BEHAVIORAL)",5284373,CSA,Breast Cancer; Colon Cancer; Rectum Cancer; Cervix Cancer; Prostate Cancer; Lung Cancer,Bowel,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11166,NCT01552629,A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients,COMPLETED,PHASE2,Atopic Dermatitis,QGE031 (DRUG); Placebo (DRUG); Cyclosporine A (DRUG),5284373,CSA,Atopic Dermatitis,Skin,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11167,NCT01114529,"Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients",COMPLETED,PHASE3,Kidney Transplantation,Everolimus (DRUG); Prograf or Neoral (DRUG),5284373,CSA,Kidney Transplantation,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11168,NCT01921829,Protocolized Diuretic Strategy in Cardiorenal Failure,TERMINATED,PHASE4,Cardiac Failure; Renal Failure; Kidney Failure,Protocolized Diuretic Strategy (DRUG),5284373,CSA,Cardiac Failure; Renal Failure; Kidney Failure,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11169,NCT02144792,Development and Clinical Application of [11C]Verapamil-PET,UNKNOWN,PHASE2,Epilepsy,[11C] -verapamil PET (DRUG),5284373,CSA,Epilepsy,CNS/Brain,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11170,NCT02005562,OPERA Study: A Study of Two Dosing Regimens of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.,COMPLETED,PHASE3,Kidney Transplantation,mycophenolate mofetil (DRUG); mycophenolate mofetil (DRUG); anti-IL-2R (DRUG); methylprednisolone (DRUG); cyclosporine (DRUG),5284373,CSA,Kidney Transplantation,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11171,NCT06470191,A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.,RECRUITING,PHASE2,Primary Membranous Nephropathy,B007 (DRUG); Cyclosporin Capsules (DRUG),5284373,CSA,Primary Membranous Nephropathy,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11172,NCT00493194,Fibrosis in Renal Allografts,UNKNOWN,PHASE4,"Kidney Failure, Chronic; Transplantation; Immunosuppression; Interstitial Fibrosis",sirolimus (DRUG); cyclosporine (DRUG); daclizumab (DRUG),5284373,CSA,"Kidney Failure, Chronic; Transplantation; Immunosuppression; Interstitial Fibrosis",Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11173,NCT00204191,Comparison of the Two Immunosuppressive Regimens Based on Tacrolimus and Cyclosporine Following Kidney Transplantation,UNKNOWN,PHASE4,Kidney Transplantation,tacrolimus (DRUG),5284373,CSA,Kidney Transplantation,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11174,NCT00135694,Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant,COMPLETED,PHASE2,"Hepatitis C; Hepatitis C, Chronic; Nonimmune Nonviral Causes of Liver Failure",calcineurin inhibitor-based immunosuppression (DRUG); liver transplant (PROCEDURE); corticosteroids (DRUG); immunosuppression withdrawal (OTHER),5284373,CSA,"Hepatitis C; Hepatitis C, Chronic; Nonimmune Nonviral Causes of Liver Failure",Liver,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11175,NCT01895894,Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome,COMPLETED,PHASE4,Nephrotic Syndrome,Mycophenolate mofetil (DRUG),5284373,CSA,Nephrotic Syndrome,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11176,NCT00438360,Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis,COMPLETED,PHASE3,Chronic Plaque Psoriasis,Cyclosporine A microemulsion (DRUG); Placebo (DRUG),5284373,CSA,Chronic Plaque Psoriasis,Skin,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11177,NCT00149994,Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients,COMPLETED,PHASE4,Liver Transplant,Cyclosporine A (DRUG); Tacrolimus (DRUG); Basiliximab (DRUG); Methylprednisolone (DRUG); Prednisone (DRUG),5284373,CSA,Liver Transplant,Liver,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11178,NCT01213394,Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients,TERMINATED,PHASE3,Kidney Transplantation; Cardiovascular Diseases,mycophenolate mofetil (DRUG); standard immunosuppression (OTHER),5284373,CSA,Kidney Transplantation; Cardiovascular Diseases,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11179,NCT01092962,Cyclophosphamide Versus Mycophenolate Mofetil for the Treatment of Steroid-dependent Nephrotic Syndrome in Children,COMPLETED,PHASE3,Idiopathic Nephrotic Syndrome,Cyclophosphamide (DRUG); Mycophenolate mofetil (DRUG),5284373,CSA,Idiopathic Nephrotic Syndrome,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11180,NCT01806662,Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis,COMPLETED,PHASE2,Atopic Dermatitis,Ustekinumab (DRUG); Placebo (OTHER),5284373,CSA,Atopic Dermatitis,Skin,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11181,NCT00537862,Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients,COMPLETED,PHASE4,Kidney Transplant,Enteric-Coated Mycophenolate Sodium (EC-MPS) (DRUG),5284373,CSA,Kidney Transplant,Kidney,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11182,NCT00355862,Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma,COMPLETED,PHASE3,Hepatocellular Carcinoma,"CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free) (DRUG); Sirolimus (DRUG)",5284373,CSA,Hepatocellular Carcinoma,Liver,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11183,NCT00332462,A Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine in de Novo Liver Transplant Recipients,COMPLETED,PHASE4,Liver Transplantation,Cyclosporine (Sandimmun® i.v.) (DRUG); Cyclosporine (Sandimmun® Optoral) (DRUG),5284373,CSA,Liver Transplantation,Liver,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11184,NCT05867329,Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis,RECRUITING,PHASE4,Ulcerative Colitis Acute,Cyclosporine Injection (IV) (DRUG); Cyclosporine Oral Product (DRUG); Upadacitinib Extended Release Oral Tablet (DRUG); Intravenous Methylprednisolone (DRUG); Prednisone Oral Product (DRUG),5284373,CSA,Ulcerative Colitis Acute,Bowel,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11185,NCT01536535,Predicting Response to Standardized Pediatric Colitis Therapy,COMPLETED,PHASE4,Ulcerative Colitis,Mesalazine (DRUG); IV Corticosteroid (DRUG); Oral Corticosteroids (DRUG); Additional Therapies (OTHER); Colectomy (PROCEDURE),5284373,CSA,Ulcerative Colitis,Bowel,Cyclosporin A,"PPP3CA, PPP3CB, PPP3CC",inhibitor/antagonist,unclear,yes,yes,Immunosuppressant approved for organ transplant patients.,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,1.0,260.0 +11186,NCT04526665,Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC),ACTIVE_NOT_RECRUITING,PHASE3,Primary Biliary Cirrhosis,Elafibranor 80mg (DRUG); Placebo (DRUG),12560,ERY,Primary Biliary Cirrhosis,Liver,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11187,NCT00259220,HDUPE 2004: Gastro-Oesophageal Haemorrhage in Emergency : Gastric Préparation to Endoscopy,COMPLETED,PHASE3,Upper Gastrointestinal Bleeding,erythomycin (DRUG); gastric lavage alone (PROCEDURE); erythromycine and gastric lavage (PROCEDURE),12560,ERY,Upper Gastrointestinal Bleeding,Bowel,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11188,NCT04668066,Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis,COMPLETED,PHASE1,Atopic Dermatitis,PF-07242813 (DRUG); Placebo (DRUG),12560,ERY,Atopic Dermatitis,Skin,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11189,NCT00648726,"An Open, Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Intravenous Followed by Oral Azithromycin Versus Cefuroxime Alone or With Oral Erythromycin for the Treatment of Chinese Patients Who Were Hospitalized for Pneumonia",COMPLETED,PHASE3,Pneumonia,cefuroxime plus erythromycin (DRUG); azithromycin (Zithromax) (DRUG); cefuroxime (DRUG),12560,ERY,Pneumonia,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11190,NCT00059943,"Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer",COMPLETED,PHASE2,Breast Cancer; Lung Cancer; Prostate Cancer,docetaxel (DRUG),12560,ERY,Breast Cancer; Lung Cancer; Prostate Cancer,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11191,NCT00841776,Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne,COMPLETED,PHASE4,Acne,Duac (DRUG); Ziana gel (DRUG),12560,ERY,Acne,Skin,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11192,NCT04321031,Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA),COMPLETED,PHASE2,Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis With Liver Fibrosis,Placebo (DRUG); PF-06865571 (DRUG); PF-05221304 (DRUG),12560,ERY,Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis With Liver Fibrosis,Liver,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11193,NCT03840057,"Metoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy",UNKNOWN,PHASE2,Gastro Intestinal Bleeding; Upper Gastrointestinal Bleeding,Azithromycin Injection (DRUG); Metoclopramide Injectable Solution (DRUG); Sodium chloride 0.9% (DRUG),12560,ERY,Gastro Intestinal Bleeding; Upper Gastrointestinal Bleeding,Bowel,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11194,NCT05283330,Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors,RECRUITING,PHASE1,Cervical Cancer; Prostate Cancer Metastatic; Breast Cancer; Colon Cancer; NSCLC; Cutaneous Melanoma,²¹²Pb-DOTAM-GRPR1 (DRUG),12560,ERY,Cervical Cancer; Prostate Cancer Metastatic; Breast Cancer; Colon Cancer; NSCLC; Cutaneous Melanoma,Bowel,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11195,NCT01830322,Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer,WITHDRAWN,PHASE2,Metastatic Pancreatic Adenocarcinoma,CPI-613 (DRUG); Gemcitabine (DRUG); Any non-gemcitabine chemotherapies or best supportive care (DRUG),12560,ERY,Metastatic Pancreatic Adenocarcinoma,Pancreas,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11196,NCT02605122,Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia,TERMINATED,PHASE2,Community-acquired Bacterial Pneumonia,Solithromycin (DRUG); Standard of Care (DRUG),12560,ERY,Community-acquired Bacterial Pneumonia,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11197,NCT06961786,TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma,RECRUITING,PHASE1,Metastatic Melanoma,TILT-123 (BIOLOGICAL); TIL (BIOLOGICAL); Cyclophosphamide (DRUG); Fludarabine (DRUG),12560,ERY,Metastatic Melanoma,Skin,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11198,NCT03545373,Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis (ACT-TB Study),COMPLETED,PHASE3,Tuberculosis; Respiratory Tract Infections; Pneumonia,Azithromycin (DRUG); Amoxicillin (DRUG),12560,ERY,Tuberculosis; Respiratory Tract Infections; Pneumonia,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11199,NCT01323257,TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r),COMPLETED,PHASE1,Hepatitis C Virus,erythromycin (DRUG); Ritonavir (DRUG); TMC435 (DRUG); Darunavir (DRUG); TMC435 (DRUG); erythromycin (DRUG),12560,ERY,Hepatitis C Virus,Liver,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11200,NCT02171429,A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors,COMPLETED,PHASE3,Ulcerative Colitis,Adalimumab (DRUG); Adalimumab Placebo (OTHER); Etrolizumab (DRUG); Etrolizumab Placebo (OTHER),12560,ERY,Ulcerative Colitis,Bowel,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11201,NCT01007591,"A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas",COMPLETED,PHASE3,Psoriasis Vulgaris,LEO 80190 (DRUG); Hydrocortisone (DRUG),12560,ERY,Psoriasis Vulgaris,Skin,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11202,NCT04583280,A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV),TERMINATED,PHASE3,Respiratory Tract Infections,Rilematovir (DRUG); Rilematovir X mg/kg (DRUG); Placebo (DRUG),12560,ERY,Respiratory Tract Infections,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11203,NCT06504160,Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2),RECRUITING,PHASE1,Atopic Dermatitis,ShA9 Topical Gel (DRUG); Hydrocortisone Ointment (DRUG); Clobetasol Ointment (DRUG); Fluocinonide Ointment (DRUG); Placebo (Vehicle) Topical Gel (DRUG),12560,ERY,Atopic Dermatitis,Skin,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11204,NCT00147667,Effects of Long Term Macrolide Antibiotic Therapy in Patients With COPD,UNKNOWN,PHASE2,COPD,Erythromycin (DRUG),12560,ERY,COPD,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11205,NCT03034967,Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE2,"Pulmonary Disease, Chronic Obstructive",Danirixin (DRUG); Danirixin matching placebo (DRUG); Standard of care (DRUG); Rescue medication (DRUG),12560,ERY,"Pulmonary Disease, Chronic Obstructive",Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11206,NCT01277289,Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease,TERMINATED,PHASE3,Crohn's Disease,Dexamethasone (DRUG),12560,ERY,Crohn's Disease,Bowel,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11207,NCT02703896,Prophylaxis for Aspiration of Gastric Contents.,COMPLETED,PHASE4,Pulmonary Aspiration of Gastric Contents,Drug either PPIS or H2RA and prokinetics (DRUG); orogastric intubation (PROCEDURE),12560,ERY,Pulmonary Aspiration of Gastric Contents,Esophagus/Stomach,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11208,NCT04604496,STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT,COMPLETED,PHASE1,Hepatic Impairment; Healthy Volunteers,PF-06882961 20MG (DRUG),12560,ERY,Hepatic Impairment; Healthy Volunteers,Liver,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11209,NCT03893565,"Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis",TERMINATED,PHASE2,"Colitis, Ulcerative",GSK2831781 - Double Blind Phase (DRUG); Placebo (DRUG); GSK2831781 - Open Label phase (DRUG),12560,ERY,"Colitis, Ulcerative",Bowel,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11210,NCT02377427,Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children,COMPLETED,PHASE2,Asthma,Mepolizumab (DRUG),12560,ERY,Asthma,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11211,NCT03895372,A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis,COMPLETED,PHASE2,Psoriasis,PF-06826647 or Placebo (DRUG); PF-06826647 (DRUG),12560,ERY,Psoriasis,Skin,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11212,NCT03883269,Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients,RECRUITING,PHASE4,Acne Vulgaris,Erythromycin 4% topical gel formulation (DRUG); Clindamycin 1% topical lotion formulation (DRUG); 70% topical ethanol solution (DRUG),12560,ERY,Acne Vulgaris,Skin,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11213,NCT00367419,Use of Erythromycin in Mustard-Induced Bronchiolitis,COMPLETED,PHASE4,Bronchiolitis Obliterans; Acute Obliterating Bronchiolitis,Erythromycin (DRUG),12560,ERY,Bronchiolitis Obliterans; Acute Obliterating Bronchiolitis,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11214,NCT04126213,"Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants",COMPLETED,PHASE2,Respiratory Syncytial Virus Infections,RSV MAT 60 µg (BIOLOGICAL); RSV MAT 120 µg (BIOLOGICAL); Placebo (DRUG),12560,ERY,Respiratory Syncytial Virus Infections,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11215,NCT01659619,"Effect of Erythromycin Before Endoscopy of Patients With Subtotal Gastrectomy (STG), High Risk of Gastric Stasis",COMPLETED,PHASE2,Subtotal Gastrectomy; Stomach Cancer,Erythromycin (DRUG),12560,ERY,Subtotal Gastrectomy; Stomach Cancer,Esophagus/Stomach,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11216,NCT01087749,Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers,COMPLETED,PHASE1,Kidney Disease,Propranolol (DRUG); Losartan (DRUG); Eprosartan (DRUG),12560,ERY,Kidney Disease,Kidney,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11217,NCT01866410,Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7,Cabozantinib S-malate (DRUG); Erlotinib Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER),12560,ERY,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11218,NCT06395610,"Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers",COMPLETED,PHASE1,Chronic Obstructive Pulmonary Disease,CHF6001 DPI (DRUG); Erythromycin (DRUG),12560,ERY,Chronic Obstructive Pulmonary Disease,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11219,NCT01116895,A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris,COMPLETED,PHASE2,Psoriasis Vulgaris,LEO 22811 (DRUG); Placebo (DRUG),12560,ERY,Psoriasis Vulgaris,Skin,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11220,NCT05375955,A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.,COMPLETED,PHASE2,Atopic Dermatitis; Plaque Psoriasis,PF-07038124 ointment 0.01% (DRUG); Vehicle ointment (DRUG); PF-07038124 ointment 0.03% (DRUG); PF-07038124 ointment 0.06% (DRUG),12560,ERY,Atopic Dermatitis; Plaque Psoriasis,Skin,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11221,NCT01309438,A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function,COMPLETED,PHASE1,Healthy; Renal Insufficiency,Rivaroxaban (normal renal function) (DRUG); Rivaroxaban (mild and moderate renal impairment) (DRUG); Erythromycin (normal renal function) (DRUG); Erythromycin (mild and moderate renal function) (DRUG),12560,ERY,Healthy; Renal Insufficiency,Kidney,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11222,NCT02196714,PK Study of PT003 and PT001 in Japanese Healthy Subjects,COMPLETED,PHASE1,COPD,Glycopyrronium and Formoterol Fumarate (GFF) Dose 1 (DRUG); Glycopyrronium and Formoterol Fumarate (GFF) Dose 2 (DRUG); Glycopyrronium (GP) Dose 1 (DRUG); Glycopyrronium (GP) Dose 2 (DRUG),12560,ERY,COPD,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11223,NCT03469336,"Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis",COMPLETED,PHASE1,Psoriasis,PF-06763809 (DRUG); Vehicle (OTHER); Calcipotriene/calcipotriol (DRUG); Betamethasone (DRUG),12560,ERY,Psoriasis,Skin,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11224,NCT00146042,UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer,COMPLETED,PHASE2,HER-2 Positive Metastatic Breast Cancer,Docetaxel (DRUG); Trastuzumab (DRUG); Erythromycin Breath Test (ERMBT) (PROCEDURE),12560,ERY,HER-2 Positive Metastatic Breast Cancer,Breast,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11225,NCT02342899,Cost Effectiveness of Outpatient Set-up of Automated NIV in Obese Patients With Chronic Respiratory Failure,COMPLETED,PHASE3,Obesity Hypoventilation Syndrome; Chronic Respiratory Failure,Outpatient NIV Set Up using AVAPS AE (Manufactured by Philips-Respironics) (DEVICE); Inpatient NIV Set Up using spontaneous/timed (S/T) mode pressure support ventilation (Manufactured by Philips-Respironics) (DEVICE),12560,ERY,Obesity Hypoventilation Syndrome; Chronic Respiratory Failure,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11226,NCT03393806,Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD),TERMINATED,PHASE2,Asthma,GSK3772847 (DRUG); Placebo (DRUG),12560,ERY,Asthma,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11227,NCT03395184,Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease,COMPLETED,PHASE2,Crohn's Disease,PF-06651600 Placebo (DRUG); PF-06651600 (DRUG); Placebo PF-06700841 (DRUG); PF-06700841 (DRUG),12560,ERY,Crohn's Disease,Bowel,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11228,NCT03692403,Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain,COMPLETED,PHASE2,Endometriosis-related Pain,Quinagolide 360 µg (DRUG); Quinagolide 720 µg (DRUG); Quinagolide 1080 µg (DRUG); Placebo (DRUG),12560,ERY,Endometriosis-related Pain,Uterus,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11229,NCT04299048,Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.,COMPLETED,PHASE1,Cachexia; Non-Small-Cell Lung Cancer; Pancreatic Cancer; Colorectal Cancer,PF-06946860 (DRUG),12560,ERY,Cachexia; Non-Small-Cell Lung Cancer; Pancreatic Cancer; Colorectal Cancer,Bowel,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11230,NCT05716048,Combinatory Rehabilitation Used for Substantially Helping Individuals With Traumatic Brain Injury,RECRUITING,PHASE1,Traumatic Brain Injury,KF-mSMT Plus Aerobic Exercise Training (BEHAVIORAL); KF-mSMT Plus Stretching Exercise Training (BEHAVIORAL),12560,ERY,Traumatic Brain Injury,CNS/Brain,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11231,NCT06640517,"Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children with Moderate to Severe Plaque Psoriasis",RECRUITING,PHASE3,Plaque Psoriasis,Netakimab (DRUG); Placebo (DRUG); Adalimumab (DRUG),12560,ERY,Plaque Psoriasis,Skin,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11232,NCT01422434,LEO 90105 Ointment in Japanese Subjects With Psoriasis,COMPLETED,PHASE3,Psoriasis,LEO 90105 = calcipotriol + betamethasone dipropionate (DRUG); Dovonex® = calcipotriol (DRUG); Rinderon® - DP = betamethasone dipropionate (DRUG),12560,ERY,Psoriasis,Skin,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11233,NCT00148070,Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Docetaxel (DRUG); Erythromycin Breath Test (ERMBT) (PROCEDURE),12560,ERY,Metastatic Breast Cancer,Breast,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11234,NCT02163759,A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors,COMPLETED,PHASE3,Ulcerative Colitis,Adalimumab (DRUG); Adalimumab Placebo (OTHER); Etrolizumab (DRUG); Etrolizumab Placebo (OTHER),12560,ERY,Ulcerative Colitis,Bowel,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11235,NCT00368342,Chronic Bronchiolitis or Resistant Asthma?,COMPLETED,PHASE4,Asthma,"Erythromycin, Azithromycin , Clarithromycin (DRUG)",12560,ERY,Asthma,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11236,NCT03942042,A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis,COMPLETED,PHASE4,Generalized Pustular Psoriasis; Erythrodermic Psoriasis,Ixekizumab (DRUG),12560,ERY,Generalized Pustular Psoriasis; Erythrodermic Psoriasis,Skin,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11237,NCT00034736,A Study to Compare the Efficacy and Safety of Levofloxacin in the Treatment of Children With Community-acquired Pneumonia in the Hospital or Outpatient Setting,COMPLETED,PHASE3,Pneumonia,Levofloxacin (DRUG),12560,ERY,Pneumonia,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11238,NCT00999232,Assess the Effect of Erythromycin on the Rate of Success in Placement of a Self-propelled Feeding Tube,COMPLETED,PHASE4,Pancreatitis,Erythromycin (DRUG); Placebo (DRUG),12560,ERY,Pancreatitis,Pancreas,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11239,NCT05540587,Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis,RECRUITING,PHASE2,Mitral Valve Stenosis; Atrial Fibrillation; Stroke; Systemic Embolism,Edoxaban (DRUG); Warfarin (DRUG),12560,ERY,Mitral Valve Stenosis; Atrial Fibrillation; Stroke; Systemic Embolism,CNS/Brain,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11240,NCT03073200,Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis,COMPLETED,PHASE3,Plaque Psoriasis,Ixekizumab (DRUG); Placebo (DRUG); Etanercept (DRUG),12560,ERY,Plaque Psoriasis,Skin,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11241,NCT01166256,Comparison Between High-flow Nasal Cannula System and Non-invasive Ventilation in Acute Hypoxemic Respiratory Failure,UNKNOWN,PHASE2,Acute Hypoxemic Respiratory Failure,Non-invasive ventilation (DEVICE); High flow nasal cannula system (DEVICE),12560,ERY,Acute Hypoxemic Respiratory Failure,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11242,NCT03847909,A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2,COMPLETED,PHASE2,Primary Hyperoxaluria Type 1 (PH1); Primary Hyperoxaluria Type 2 (PH2); Kidney Diseases; Urologic Diseases; Genetic Disease,DCR-PHXC (DRUG); Sterile Normal Saline (0.9% NaCl) (DRUG),12560,ERY,Primary Hyperoxaluria Type 1 (PH1); Primary Hyperoxaluria Type 2 (PH2); Kidney Diseases; Urologic Diseases; Genetic Disease,Kidney,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11243,NCT00764751,Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris,COMPLETED,PHASE2,Psoriasis Vulgaris,LEO 19123 Cream (calcipotriol plus LEO 80122) (DRUG); Dovonex® cream (DRUG); Cream vehicle (DRUG),12560,ERY,Psoriasis Vulgaris,Skin,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11244,NCT05797753,A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B),COMPLETED,PHASE1,Amyotrophic Lateral Sclerosis; Healthy Volunteer,SAR443820 (DRUG); SAR443820 (DRUG); Erythromycin ethyl succinate (DRUG); Itraconazole (DRUG),12560,ERY,Amyotrophic Lateral Sclerosis; Healthy Volunteer,CNS/Brain,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11245,NCT00718315,"A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.",COMPLETED,PHASE3,Non-Small Cell Lung Cancer,erlotinib [Tarceva] (DRUG); fusidic acid [Verutex] (DRUG); erythromycin [Eritex] (DRUG); Fisiogel (DRUG),12560,ERY,Advanced Non-Small Cell Lung Cancer,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11246,NCT03749109,Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis,COMPLETED,PHASE2,Endometriosis,Quinagolide 1080 µg (DRUG); Placebo (DRUG),12560,ERY,Endometriosis,Uterus,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11247,NCT05035407,"T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers",RECRUITING,PHASE1,"Kita-kyushu Lung Cancer Antigen 1, Human",IL-2 (Aldesleukin) (DRUG); Cyclophosphamide (DRUG); KK-LC-1 TCR (BIOLOGICAL); Fludarabine (DRUG),12560,ERY,"Kita-kyushu Lung Cancer Antigen 1, Human",Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11248,NCT06918288,Post-extubation Nasal Humidified High-flow Oxygen Versus Non-invasive Positive Pressure Ventilation,ACTIVE_NOT_RECRUITING,PHASE2,Respiratory Failure With Hypercapnia,High flow nasal canula (DEVICE); Non-invasive positive pressure mechanical ventilation (DEVICE),12560,ERY,Respiratory Failure With Hypercapnia,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11249,NCT00305461,Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101),COMPLETED,PHASE3,Asthma,Ciclesonide (DRUG),12560,ERY,Asthma,Lung,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11250,NCT06885697,Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma,NOT_YET_RECRUITING,PHASE1,Mesothelioma; Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Ovarian Neoplasms; Lung Neoplasms; Thymus Neoplasms; Colonic Neoplasms,mesothelin expression testing (DEVICE); TNhYP217 CAR T Cells (BIOLOGICAL); fludarabine (DRUG); cyclophosphamide (DRUG),12560,ERY,Mesothelioma; Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Ovarian Neoplasms; Lung Neoplasms; Thymus Neoplasms; Colonic Neoplasms,Bowel,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11251,NCT05732428,"A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China",COMPLETED,PHASE1,Breast Cancer,ARV-471 (DRUG),12560,ERY,Breast Cancer,Breast,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11252,NCT01668498,Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer,COMPLETED,PHASE2,Ras-wildtype Colorectal Cancer,Erythromycin (DRUG); Doxycycline (DRUG),12560,ERY,Ras-wildtype Colorectal Cancer,Bowel,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11253,NCT03256526,6-week Safety and PD Study in Adults With NAFLD,COMPLETED,PHASE2,Non-alcoholic Fatty Liver Disease,Placebo (DRUG); PF-06835919 Low Dose (DRUG); PF-06835919 High Dose (DRUG),12560,ERY,Non-alcoholic Fatty Liver Disease,Liver,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11254,NCT03903822,"Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis",COMPLETED,PHASE2,Atopic Dermatitis,PF-06700841 (DRUG); Vehicle (Placebo) (DRUG),12560,ERY,Atopic Dermatitis,Skin,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11255,NCT00580593,Trial of Early Noninvasive Ventilation for Amyotrophic Lateral Sclerosis (ALS),COMPLETED,PHASE1,Amyotrophic Lateral Sclerosis,BiPAP® S/T System (DEVICE); sham-NIPPV (OTHER),12560,ERY,Amyotrophic Lateral Sclerosis,CNS/Brain,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11256,NCT03199911,Topical Antibiotic Prophylaxis for Eyelids,COMPLETED,PHASE4,"Antibiotic Side Effect; Eyelid; Wound; Eyelid Diseases; Surgical Wound Infection; Surgical Wound, Recent; Surgical Incision; Skin Cancer Face; Antibiotic Allergy; Surgical Site Infection",Topical Antibiotic Product (DRUG); Topical Non-Antibiotic Ointment (DRUG),12560,ERY,"Antibiotic Side Effect; Eyelid; Wound; Eyelid Diseases; Surgical Wound Infection; Surgical Wound, Recent; Surgical Incision; Skin Cancer Face; Antibiotic Allergy; Surgical Site Infection",Skin,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11257,NCT03210961,"A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis",COMPLETED,PHASE1,Plaque Psoriasis,PF-06826647 tablet (DRUG); PF-06826647 oral suspension (DRUG); Placebo oral solution/suspension (OTHER); Placebo tablet (OTHER),12560,ERY,Plaque Psoriasis,Skin,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11258,NCT05074498,"Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease",COMPLETED,PHASE1,Alzheimer's Disease,TB006 (DRUG); Placebo (DRUG),12560,ERY,Alzheimer's Disease,CNS/Brain,Erythromycin,,inhibitor/antagonist,unclear,yes,yes,Antibiotic used to treat infections; approved for human use.,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1.39,134.0 +11259,NCT03502031,Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy,UNKNOWN,PHASE4,"Renal Insufficiency, Chronic; Diabetic Nephropathy Type 2",Renin-Angiotensin (RAAS) alone (DRUG); Renin-Angiotensin (RAAS) blockers in combination with Spironolactone (DRUG),441313,ACEON,"Renal Insufficiency, Chronic; Diabetic Nephropathy Type 2",Kidney,Perindopril (erbumine),"STAT3, ACE",inhibitor/antagonist,unclear,yes,yes,Approved ACE inhibitor for hypertension and heart failure.,CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O.CC(C)(C)N,1.02,217.0 +11260,NCT04588935,Prevention of Cardiovascular Diseases Caused by Complex Treatment of Patients With Primary Operated Breast Cancer,COMPLETED,PHASE2,Women With Breast Cancer,Bisoprolol; Perindopril; (DRUG),441313,ACEON,Women With Breast Cancer,Breast,Perindopril (erbumine),"STAT3, ACE",inhibitor/antagonist,unclear,yes,yes,Approved ACE inhibitor for hypertension and heart failure.,CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O.CC(C)(C)N,1.02,217.0 +11261,NCT04980716,Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients,RECRUITING,PHASE3,Non-small Cell Lung Cancer; Cardiovascular Complication,"Multiple cardiovascular drugs related to ""Golden Triangle"" (DRUG)",441313,ACEON,Non-small Cell Lung Cancer; Cardiovascular Complication,Lung,Perindopril (erbumine),"STAT3, ACE",inhibitor/antagonist,unclear,yes,yes,Approved ACE inhibitor for hypertension and heart failure.,CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O.CC(C)(C)N,1.02,217.0 +11262,NCT02299310,Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease,UNKNOWN,PHASE4,Chronic Kidney Disease,Valsartan (DRUG); Perindopril (DRUG),441313,ACEON,Chronic Kidney Disease,Kidney,Perindopril (erbumine),"STAT3, ACE",inhibitor/antagonist,unclear,yes,yes,Approved ACE inhibitor for hypertension and heart failure.,CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O.CC(C)(C)N,1.02,217.0 +11263,NCT04647292,European Blood Pressure Intensive Control After Stroke,RECRUITING,PHASE2,Ischemic Stroke; Transient Ischemic Attack,"anti-hypertensive, home blood pressure measurement, telemonitoring and medication titration (OTHER); Standard of Care Blood Pressure Management with Antihypertensives (OTHER)",441313,ACEON,Ischemic Stroke,CNS/Brain,Perindopril (erbumine),"STAT3, ACE",inhibitor/antagonist,unclear,yes,yes,Approved ACE inhibitor for hypertension and heart failure.,CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O.CC(C)(C)N,1.02,217.0 +11264,NCT02085265,Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients,TERMINATED,PHASE2,Alzheimer's Disease,Perindopril (DRUG); Telmisartan (DRUG),441313,ACEON,Alzheimer's Disease,CNS/Brain,Perindopril (erbumine),"STAT3, ACE",inhibitor/antagonist,unclear,yes,yes,Approved ACE inhibitor for hypertension and heart failure.,CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O.CC(C)(C)N,1.02,217.0 +11265,NCT02213224,Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease,UNKNOWN,PHASE4,Nonalcoholic Fatty Liver Disease (NAFLD),Perindopril (DRUG); Telmisartan (DRUG); Amlodipine (DRUG),441313,ACEON,Nonalcoholic Fatty Liver Disease (NAFLD),Liver,Perindopril (erbumine),"STAT3, ACE",inhibitor/antagonist,unclear,yes,yes,Approved ACE inhibitor for hypertension and heart failure.,CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O.CC(C)(C)N,1.02,217.0 +11266,NCT01819441,Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients,UNKNOWN,PHASE4,Cerebral Small Vessel Diseases,Azelnidipine (DRUG); Perindopril (DRUG); hydrochlorothiazide (DRUG),441313,ACEON,Cerebral Small Vessel Diseases,CNS/Brain,Perindopril (erbumine),"STAT3, ACE",inhibitor/antagonist,unclear,yes,yes,Approved ACE inhibitor for hypertension and heart failure.,CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O.CC(C)(C)N,1.02,217.0 +11267,NCT01219413,Influence of Aliskiren on Proteinuria,COMPLETED,PHASE4,Chronic Kidney Disease; Proteinuria; Blood Pressure,"Aliskiren, Perindopril (DRUG)",441313,ACEON,Chronic Kidney Disease; Proteinuria; Blood Pressure,Kidney,Perindopril (erbumine),"STAT3, ACE",inhibitor/antagonist,unclear,yes,yes,Approved ACE inhibitor for hypertension and heart failure.,CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O.CC(C)(C)N,1.02,217.0 +11268,NCT01016886,Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research,UNKNOWN,PHASE1,Breast Cancer; Heart Failure,perindopril OR bisoprolol OR placebo (DRUG),441313,ACEON,Breast Cancer with Heart Failure,Breast,Perindopril (erbumine),"STAT3, ACE",inhibitor/antagonist,unclear,yes,yes,Approved ACE inhibitor for hypertension and heart failure.,CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O.CC(C)(C)N,1.02,217.0 +11269,NCT02651415,Phase II Study of Perindopril and Regorafenib in mCRC,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Regorafenib (DRUG); Perindopril (DRUG),441313,ACEON,Metastatic Colorectal Cancer,Bowel,Perindopril (erbumine),"STAT3, ACE",inhibitor/antagonist,unclear,yes,yes,Approved ACE inhibitor for hypertension and heart failure.,CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O.CC(C)(C)N,1.02,217.0 +11270,NCT02735707,"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",RECRUITING,PHASE3,"Community-acquired Pneumonia, Influenza, COVID-19",Ceftriaxone (DRUG); Moxifloxacin or Levofloxacin (DRUG); Piperacillin-tazobactam (DRUG); Ceftaroline (DRUG); Amoxicillin-clavulanate (DRUG); Standard course macrolide (DRUG); Extended course macrolide (DRUG); No systemic corticosteroid (OTHER); Fixed-duration Hydrocortisone (DRUG); Shock-dependent hydrocortisone (DRUG); Fixed-duration higher dose Hydrocortisone (DRUG); No antiviral agent for influenza (OTHER); Five-days oseltamivir (DRUG); Ten-days oseltamivir (DRUG); No antiviral agent for COVID-19 (OTHER); Lopinavir / Ritonavir (DRUG); Hydroxychloroquine (DRUG); Hydroxychloroquine + lopinavir/ritonavir (DRUG); Ivermectin (DRUG); No immune modulation for COVID-19 (OTHER); Interferon beta-1a (DRUG); Anakinra (DRUG); Tocilizumab (DRUG); Sarilumab (DRUG); Local standard venous thromboprophylaxis (DRUG); Therapeutic dose anticoagulation (DRUG); Conventional low dose thromboprophylaxis (DRUG); Intermediate dose thromboprophylaxis (DRUG); Continuation of therapeutic dose anticoagulation (DRUG); No immunoglobulin (OTHER); Convalescent plasma (BIOLOGICAL); Delayed administration of convalescent plasma (BIOLOGICAL); No vitamin C (OTHER); Vitamin C (DRUG); No antiplatelet (OTHER); Aspirin (DRUG); P2Y12 inhibitor (DRUG); No simvastatin (OTHER); Simvastatin (DRUG); Eritoran (DRUG); Apremilast (DRUG); Clinician-preferred mechanical ventilation strategy (PROCEDURE); Protocolised mechanical ventilation strategy (PROCEDURE); No renin-angiotensin system inhibitor (OTHER); Angiotensin converting enzyme inhibitor (DRUG); Angiotensin Receptor Blockers (DRUG); ARB + DMX-200 (DRUG); No cysteamine (OTHER); Cysteamine (DRUG); Fixed-duration dexamethasone (DRUG); Baloxavir Marboxil (DRUG); Five-days oseltamivir + baloxavir marboxil (DRUG); Ten-days oseltamivir + baloxavir marboxil (DRUG); No endothelial modulator (OTHER); Imatinib (DRUG); No Immune Modulator for Influenza (OTHER); Tocilizumab (DRUG); Baricitinib (DRUG); No antiviral agent for COVID-19 (OTHER); Nirmatrelvir/ritonavir (DRUG); Remdesivir (DRUG); Nirmatrelvir/ritonavir + remdesivir (DRUG),441313,ACEON,Community-acquired Respiratory Infections,Lung,Perindopril (erbumine),"STAT3, ACE",inhibitor/antagonist,unclear,yes,yes,Approved ACE inhibitor for hypertension and heart failure.,CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O.CC(C)(C)N,1.02,217.0 +11271,NCT01889966,VasoREACTivity Testing With Intravenous SILdenafil in Patients With Precapillary Pulmonary Hypertension,COMPLETED,PHASE4,Pulmonary Hypertension Associated With Connective Tissue Disease,Sildenafil (DRUG),135398744,Patrex,Pulmonary Hypertension Associated With Connective Tissue Disease,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11272,NCT04908657,Sildenafil for Liver Fibrosis in Adolescents and Adults After Fontan Operation,UNKNOWN,PHASE4,Liver Fibrosis,Sildenafil 20 MG (DRUG),135398744,Patrex,Liver Fibrosis,Liver,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11273,NCT00159874,A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children,COMPLETED,PHASE3,Pulmonary Arterial Hypertension,Sildenafil citrate (DRUG); Sildenafil citrate (DRUG); Sildenafil citrate (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11274,NCT00483626,Hemodynamic Response After Six Months of Sildenafil,UNKNOWN,PHASE4,Pulmonary Arterial Hypertension,oral sildenafil (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11275,NCT01244620,"A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses",TERMINATED,PHASE1,Pulmonary Arterial Hypertension,sitaxentan (DRUG); tadalafil (DRUG); sitaxsentan (DRUG); tadalafil (DRUG); sitaxsentan (DRUG); sildenafil (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11276,NCT04003857,Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial,ACTIVE_NOT_RECRUITING,PHASE2,Bronchopulmonary Dysplasia; BPD,PNEUMOSTEM® (BIOLOGICAL); normal saline (BIOLOGICAL),135398744,Patrex,Bronchopulmonary Dysplasia; BPD,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11277,NCT00452582,Sildenafil (Viagra) Treatment of Subacute Ischemic Stroke,TERMINATED,PHASE1,Ischemic Stroke,Sildenafil (Viagra) (DRUG); Usual care (OTHER),135398744,Patrex,Ischemic Stroke,CNS/Brain,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11278,NCT00491803,Sildenafil Effects on Pulmonary Haemodynamics and Gas Exchange in Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE4,Chronic Obstructive Pulmonary Disease; Pulmonary Hypertension,Sildenafil (DRUG); Sildenafil (DRUG),135398744,Patrex,Chronic Obstructive Pulmonary Disease; Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11279,NCT00334490,Does Oral Sildenafil (Viagra) Decrease Mean Pulmonary Artery Pressure After Cardiac Surgery?,COMPLETED,PHASE2,Pulmonary Hypertension,Sildenafil (DRUG); Sildenafil (DRUG); Placebo (DRUG),135398744,Patrex,Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11280,NCT00145938,Sildenafil and Pulmonary Artery Pressure,TERMINATED,PHASE2,Pulmonary Hypertension,sildenafil (DRUG),135398744,Patrex,Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11281,NCT02891850,Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy,COMPLETED,PHASE4,Pulmonary Arterial Hypertension,"Riociguat (Adempas, BAY63-2521) (DRUG); Sildenafil (DRUG); Tadalafil (DRUG)",135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11282,NCT05061368,"Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD",RECRUITING,PHASE2,Chronic Obstructive Pulmonary Disease,Sildenafil Citrate (DRUG); Placebo (OTHER),135398744,Patrex,Chronic Obstructive Pulmonary Disease,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11283,NCT01392469,Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants,COMPLETED,PHASE3,Pulmonary Arterial Hypertension,Imatinib (DRUG); Sildenafil (DRUG); Bosentan (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11284,NCT04538976,Copd Exacerbation and Pulmonary Hypertension Trial,COMPLETED,PHASE4,Acute Exacerbation of COPD,Sildenafil (DRUG),135398744,Patrex,Acute Exacerbation of COPD,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11285,NCT04994860,Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil,COMPLETED,PHASE1,Pulmonary Arterial Hypertension,BIA 5-1058 (DRUG); Sildenafil (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11286,NCT01757782,Oral Sildenafil in Persistent Pulmonary Hypertension Secondary to Meconium Aspiration Syndrome in Newborns,COMPLETED,PHASE4,Meconium Aspiration Syndrome; Persistent Pulmonary Hypertension of Newborn,Oral Sildenafil (DRUG); Placebo (distilled water) (DRUG),135398744,Patrex,Meconium Aspiration Syndrome; Persistent Pulmonary Hypertension of Newborn,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11287,NCT03154476,Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study,COMPLETED,PHASE3,Cirrhosis; Congenital Heart Disease,Sildenafil (DRUG); Placebo (DRUG),135398744,Patrex,Cirrhosis; Congenital Heart Disease,Liver,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11288,NCT01409031,Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension,TERMINATED,PHASE2,Persistent Pulmonary Hypertension; Respiratory Failure,Intravenous Sildenafil (DRUG); Placebo (OTHER),135398744,Patrex,Persistent Pulmonary Hypertension; Respiratory Failure,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11289,NCT00492531,Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease,TERMINATED,PHASE2,Sickle Cell Disease; Pulmonary Hypertension,Sildenafil (DRUG); Placebo (DRUG),135398744,Patrex,Sickle Cell Disease; Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11290,NCT02442492,Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction,TERMINATED,PHASE2,Intrauterine Growth Restriction (IUGR); Fetal Growth Restriction (FGR),Sildenafil (DRUG); Placebo (DRUG),135398744,Patrex,Intrauterine Growth Restriction (IUGR); Fetal Growth Restriction (FGR),Uterus,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11291,NCT06715280,Sildenafil Switching to Riociguat,RECRUITING,PHASE4,Chronic Thromboembolic Pulmonary Hypertension; Balloon Pulmonary Angioplasty,Riociguat (Adempas) (DRUG),135398744,Patrex,Chronic Thromboembolic Pulmonary Hypertension; Balloon Pulmonary Angioplasty,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11292,NCT00800592,Sildenafil IV Bolus Study,COMPLETED,PHASE1,"Hypertension, Pulmonary",sildenafil (DRUG),135398744,Patrex,Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11293,NCT01409122,"Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects",COMPLETED,PHASE1,Pulmonary Hypertension; Pulmonary Arterial Hypertension,15 mg sodium nitrite inhalation solution (DRUG); 90 mg sodium nitrite inhalation solution (DRUG); 45 mg sodium nitrite inhalation solution (DRUG); 120 mg sodium nitrite inhalation solution (DRUG); 25% MTD sodium nitrite inhalation solution (DRUG),135398744,Patrex,Pulmonary Hypertension; Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11294,NCT00796666,Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil,TERMINATED,PHASE3,Pulmonary Arterial Hypertension; Pulmonary Hypertension,Sitaxsentan (DRUG); Sitaxsentan and Sildenafil (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension; Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11295,NCT00352430,Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension,COMPLETED,PHASE1,Pulmonary Hypertension,Nitric Oxide/INP Pulse Delivery (DRUG); Nitric Oxide/INO Pulse Delivery (DRUG),135398744,Patrex,Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11296,NCT00795639,Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS),TERMINATED,PHASE3,Pulmonary Arterial Hypertension; Pulmonary Hypertension,Sitaxsentan (DRUG); Placebo (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension; Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11297,NCT02028429,Efficacy of Sildenafil in the Improvement of Cognition and Quality of Life in Patients With Cirrhosis of Liver. A Proof of Concept Study.,UNKNOWN,PHASE1,Hepatic Encephalopathy.,Sildenafil. (DRUG),135398744,Patrex,Hepatic Encephalopathy.,Liver,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11298,NCT02951429,"Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension",COMPLETED,PHASE2,Idiopathic Pulmonary Fibrosis,Pirfenidone (DRUG); Placebo (DRUG); Sildenafil (DRUG),135398744,Patrex,Idiopathic Pulmonary Fibrosis,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11299,NCT02136329,"A Study to Determine the Pharmacokinetic Profile, Safety and Tolerability of Sildenafil (REVATIO®) in Cardiac Surgery",COMPLETED,PHASE1,Acute Kidney Injury,Sildenafil (DRUG),135398744,Patrex,Acute Kidney Injury,Kidney,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11300,NCT02007629,Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor,COMPLETED,PHASE3,"Hypertension, Pulmonary","Riociguat (Adempas, BAY63-2521) (DRUG)",135398744,Patrex,Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11301,NCT00433329,Combination Therapy in Pulmonary Arterial Hypertension,COMPLETED,PHASE4,Pulmonary Arterial Hypertension,Bosentan (DRUG); Sildenafil (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11302,NCT00586794,Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger Patients,TERMINATED,PHASE3,Pulmonary Arterial Hypertension (PAH),Sildenafil (DRUG); Placebo (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension (PAH),Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11303,NCT00430716,To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.,TERMINATED,PHASE4,Pulmonary Arterial Hypertension,Sildenafil citrate (DRUG); Sildenafil citrate (DRUG); Sildenafil citrate (DRUG); Sildenafil citrate (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11304,NCT01954524,"A Phase 1, Open-Label Study of Intravenous Sildenafil in Patients With Cirrhosis",TERMINATED,PHASE1,Cirrhosis,IV bolus injection of Sildenafil (DRUG),135398744,Patrex,Cirrhosis,Liver,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11305,NCT03053739,To Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis,UNKNOWN,PHASE4,Associated Pulmonary Arterial Hypertension,Sildenafil 20mg and Bosentan 62.5mg (DRUG); Sildenafil 20mg and Placebo (DRUG),135398744,Patrex,Associated Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11306,NCT01720524,A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn,COMPLETED,PHASE3,"Pulmonary Hypertension, Familial Persistent, of the Newborn",placebo (DRUG); iv sildenafil (DRUG),135398744,Patrex,"Pulmonary Hypertension, Familial Persistent, of the Newborn",Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11307,NCT01616381,Sildenafil Versus Placebo in Chronic Heart Failure,UNKNOWN,PHASE3,Heart Failure; Pulmonary Hypertension,Sildenafil (DRUG); Placebo (DRUG),135398744,Patrex,Heart Failure with Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11308,NCT05201144,A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH),RECRUITING,PHASE2,Congenital Diaphragmatic Hernia; Pulmonary Hypertension,Sildenafil Oral Suspension (DRUG); Placebo (OTHER),135398744,Patrex,Congenital Diaphragmatic Hernia; Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11309,NCT05782244,Sildenafil for Microvasculopathy in Chronic TBI,RECRUITING,PHASE2,Traumatic Brain Injury,Sildenafil Citrate low dose (DRUG); Placebo (DRUG); Sildenafil medium dose (DRUG); Sildenafil high dose (DRUG),135398744,Patrex,Traumatic Brain Injury,CNS/Brain,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11310,NCT02946944,Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism,UNKNOWN,PHASE1,Pulmonary Embolism; Intermediate-high Risk; Combination of Oral Anticoagulation Therapy and Sildenafil,Sildenafil/apixaban (DRUG); apixaban (DRUG),135398744,Patrex,Pulmonary Embolism; Intermediate-high Risk; Combination of Oral Anticoagulation Therapy and Sildenafil,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11311,NCT01091012,"Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension",UNKNOWN,PHASE3,Pulmonary Hypertension,Sildenafil 20mg oral vs Sildenafil 10mg intravenous (DRUG),135398744,Patrex,Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11312,NCT03417492,Cerebrovascular Reactivity in American Football Players,TERMINATED,PHASE1,Traumatic Brain Injury; Mild Traumatic Brain Injury; Post-Concussion Syndrome,Sildenafil Citrate (DRUG),135398744,Patrex,Traumatic Brain Injury; Mild Traumatic Brain Injury; Post-Concussion Syndrome,CNS/Brain,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11313,NCT04447989,Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia,COMPLETED,PHASE2,Bronchopulmonary Dysplasia of Newborn,Sildenafil (DRUG); Placebo (DRUG),135398744,Patrex,Bronchopulmonary Dysplasia of Newborn,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11314,NCT00380068,Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension,COMPLETED,PHASE3,Pulmonary Hypertension,Ambrisentan (DRUG),135398744,Patrex,Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11315,NCT03142568,Safety of Sildenafil in Premature Infants,COMPLETED,PHASE2,Bronchopulmonary Dysplasia,Sildenafil (DRUG); Placebo (OTHER),135398744,Patrex,Bronchopulmonary Dysplasia,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11316,NCT04283240,Sildenafil in Acute Pulmonary Embolism,COMPLETED,EARLY_PHASE1,Pulmonary Embolism,Sildenafil (DRUG); Placebo (DRUG),135398744,Patrex,Pulmonary Embolism,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11317,NCT00730067,Sildenafil for Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension,WITHDRAWN,PHASE4,COPD; Pulmonary Hypertension,sildenafil (DRUG); placebo (DRUG),135398744,Patrex,COPD with Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11318,NCT01382368,"Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients",UNKNOWN,PHASE4,Chronic Obstructive Pulmonary Disease; Idiopathic Pulmonary Fibrosis,Sildenafil (DRUG),135398744,Patrex,Chronic Obstructive Pulmonary Disease; Idiopathic Pulmonary Fibrosis,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11319,NCT01441934,SPHERIC-1. Sildenafil and Pulmonary HypERtension In COPD,UNKNOWN,PHASE3,Pulmonary Hypertension; COPD,Sildenafil citrate (DRUG); Sugar pills (DRUG),135398744,Patrex,Pulmonary Hypertension; COPD,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11320,NCT02595541,Oral Sildenafil and Intravenous Milrinone on Postoperative Pulmonary Hypertension,COMPLETED,PHASE1,Pulmonary Hypertension,milrinone (DRUG); Sildenafil (DRUG),135398744,Patrex,Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11321,NCT01179334,Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.,COMPLETED,PHASE2,Pulmonary Hypertension,"Riociguat (Adempas, BAY63-2521) (DRUG); Placebo (DRUG); Sildenafil (DRUG)",135398744,Patrex,Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11322,NCT00159913,"A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.",COMPLETED,PHASE3,"Pulmonary Arterial Hypertension, Children",Sildenafil citrate (DRUG); Sildenafil citrate (DRUG); Placebo (DRUG); Sildenafil citrate (DRUG),135398744,Patrex,"Pulmonary Arterial Hypertension, Children",Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11323,NCT00431418,The Effect of Sildenafil in Preterm Infants With Evolving Chronic Lung Disease,COMPLETED,PHASE3,Lung Diseases,Sildenafil (DRUG); Placebo (DRUG),135398744,Patrex,Lung Diseases,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11324,NCT00452218,Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH),COMPLETED,PHASE1,Pulmonary Arterial Hypertension,Sorafenib (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11325,NCT01156636,Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure,COMPLETED,PHASE2,Pulmonary Hypertension; Diastolic Heart Failure,Sildenafil (DRUG); Placebo (DRUG),135398744,Patrex,Pulmonary Hypertension; Diastolic Heart Failure,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11326,NCT01726049,Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH,COMPLETED,PHASE3,"Heart Failure, Diastolic; Pulmonary Hypertension",Sildenafil (DRUG); Placebo (DRUG),135398744,Patrex,"Heart Failure, Diastolic; Pulmonary Hypertension",Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11327,NCT04898114,Nebulized Magnesium Sulfate and Sildenafil for Persistent Pulmonary Hypertension of Newborn,RECRUITING,PHASE1,Persistent Pulmonary Hypertension of Newborn,Magnesium sulfate (DRUG); Sildenafil Citrate (DRUG); Isotonic saline (OTHER),135398744,Patrex,Persistent Pulmonary Hypertension of Newborn,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11328,NCT00853112,A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension,TERMINATED,PHASE2,"Hypertension, Pulmonary",PF-00489791 (DRUG); PF-00489791 (DRUG); PF-00489791 (DRUG); PF-00489791 (DRUG); PF-00489791 (DRUG); placebo (DRUG); sildenafil (DRUG),135398744,Patrex,Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11329,NCT00796510,Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety,TERMINATED,PHASE3,Pulmonary Arterial Hypertension; Pulmonary Hypertension,Sitaxsentan (DRUG); Sitaxsentan and Sildenafil (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension; Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11330,NCT01757808,A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension,COMPLETED,PHASE1,Pulmonary Arterial Hypertension,Ranolazine (DRUG); Placebo (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11331,NCT01481350,Sildenafil for Post-capillary Pulmonary Hypertension in Patients Undergoing Cardiac Surgery,COMPLETED,PHASE2,Pulmonary Hypertension,sildenafil (DRUG),135398744,Patrex,Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11332,NCT01670136,Pharmacokinetics of Sildenafil in Premature Infants,COMPLETED,PHASE1,Persistent Pulmonary Hypertension of the Newborn,1 dose of sildenafil (DRUG),135398744,Patrex,Persistent Pulmonary Hypertension of the Newborn,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11333,NCT02378649,PDEI Following Mitral Valve Surgery in Patients With Pulmonary Hypertension,COMPLETED,PHASE4,Pulmonary Hypertension; Mitral Valve Surgery,Sildenafil (DRUG); Placebo (DRUG),135398744,Patrex,Pulmonary Hypertension; Mitral Valve Surgery,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11334,NCT03431649,Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Children,COMPLETED,PHASE4,Pediatric Pulmonary Hypertension,Beraprost Sodium (DRUG); Sildenafil Citrate (DRUG),135398744,Patrex,Pediatric Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11335,NCT01375699,"Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers",COMPLETED,PHASE1,Breast Cancer; Gastrointestinal Cancer; Genitourinary Cancer; Sarcoma; Gynecologic Cancer,Doxorubicin (DRUG); Sildenafil (DRUG),135398744,Patrex,Breast Cancer; Gastrointestinal Cancer; Genitourinary Cancer; Sarcoma; Gynecologic Cancer,Bowel,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11336,NCT00625079,Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil,WITHDRAWN,PHASE4,Pulmonary Arterial Hypertension; Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease; Pulmonary Hypertension,sildenafil (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension; Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease; Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11337,NCT01966302,Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH),COMPLETED,PHASE2,Pulmonary Arterial Hypertension,BPS-314d-MR (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11338,NCT00424021,Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension,COMPLETED,PHASE2,Pulmonary Hypertension,ambrisentan (DRUG),135398744,Patrex,Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11339,NCT04039464,Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension,RECRUITING,PHASE3,Pediatric Pulmonary Hypertension,Mono-Therapy with Sildenafil (DRUG); Duo-Therapy with Sildenafil + Bosentan (DRUG),135398744,Patrex,Pediatric Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11340,NCT02678221,Sildenafil Citrate for the Management of Asymmetrical Intrauterine Growth Restriction,UNKNOWN,PHASE2,Intrauterine Growth Restriction,Sildenafil citrate (DRUG); Aspirin (DRUG),135398744,Patrex,Intrauterine Growth Restriction,Uterus,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11341,NCT00862043,Sildenafil for Secondary Pulmonary Hypertension Due to Valvular Disease,COMPLETED,PHASE4,Pulmonary Hypertension; Valvular Heart Disease,Sildenafil Citrate (DRUG); Placebo (DRUG),135398744,Patrex,Pulmonary Hypertension; Valvular Heart Disease,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11342,NCT02162979,Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease,TERMINATED,PHASE2,Parkinson's Disease,sildenafil (DRUG); Placebo (DRUG),135398744,Patrex,Parkinson's Disease,CNS/Brain,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11343,NCT01637675,Efficacy and Safety Study of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension,UNKNOWN,PHASE2,Pulmonary Hypertension; Pulmonary Arterial Hypertension; Cardiovascular Diseases; Lung Diseases; Tanshinone IIA Sulfonate,"20 mg sildenafil citrate by mouth (DRUG); sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth (DRUG)",135398744,Patrex,Pulmonary Hypertension; Pulmonary Arterial Hypertension; Cardiovascular Diseases; Lung Diseases; Tanshinone IIA Sulfonate,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11344,NCT03236818,Goal Oriented Strategy to Preserve Ejection Fraction Trial,UNKNOWN,PHASE4,Pulmonary Arterial Hypertension,"ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan) (DRUG)",135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11345,NCT03460470,Sildenafil in US Heart Failure Patients (SilHF-US),UNKNOWN,PHASE3,Heart Failure; Pulmonary Hypertension,Sildenafil (DRUG); Placebo oral capsule (DRUG),135398744,Patrex,Heart Failure with Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11346,NCT02114775,Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI),COMPLETED,PHASE1,Traumatic Brain Injury,Growth Hormone (DRUG); Sildenafil (DRUG); Placebo (DRUG),135398744,Patrex,Traumatic Brain Injury,CNS/Brain,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11347,NCT00303459,Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH),COMPLETED,PHASE4,Pulmonary Arterial Hypertension,bosentan (DRUG); placebo (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11348,NCT04058132,Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military,TERMINATED,PHASE2,Traumatic Brain Injury,Sildenafil Citrate 50Mg Tab (DRUG); functional Near-infrared Spectroscopy (fNIRS) (DEVICE); Carbon Dioxide (CO2) 5% (OTHER); Neuropsychological Assessments (OTHER); Gadolinium contrast infusion (DRUG); Blood sample collection for research purposes (PROCEDURE); Structural brain Magnetic Resonance Imaging (MRI (OTHER),135398744,Patrex,Traumatic Brain Injury,CNS/Brain,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11349,NCT06123156,Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer,NOT_YET_RECRUITING,PHASE3,Rectal Cancer,Sildenafil (DRUG); Placebo (OTHER),135398744,Patrex,Rectal Cancer,Bowel,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11350,NCT03855332,Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial,COMPLETED,PHASE2,Small Vessel Cerebrovascular Disease,Sildenafil (DRUG); Cilostazol (DRUG); Placebo (DRUG),135398744,Patrex,Small Vessel Cerebrovascular Disease,CNS/Brain,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11351,NCT01762475,Sildenafil for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury.,COMPLETED,PHASE2,Traumatic Brain Injury; Post-concussive Syndrome,Sildenafil (DRUG),135398744,Patrex,Traumatic Brain Injury; Post-concussive Syndrome,CNS/Brain,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11352,NCT00104637,Sildenafil for Chronic Obstructive Pulmonary Disease,COMPLETED,PHASE2,"Pulmonary Disease, Chronic Obstructive; Emphysema",sildenafil citrate (DRUG); Placebo (DRUG),135398744,Patrex,"Pulmonary Disease, Chronic Obstructive; Emphysema",Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11353,NCT02284737,A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH,TERMINATED,PHASE4,Pulmonary Arterial Hypertension,PADN (PROCEDURE); sham PADN (PROCEDURE); Sildenafil (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11354,NCT01913847,Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension,UNKNOWN,PHASE3,Pulmonary Hypertension; Systolic Dysfunction,Sildenafil (DRUG); Placebo (DRUG),135398744,Patrex,Pulmonary Hypertension; Systolic Dysfunction,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11355,NCT00981747,Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis,TERMINATED,PHASE2,Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis,Sildenafil (DRUG); Losartan (DRUG); Sildenafil and Losartan (DRUG); Placebo Oral Tablet (DRUG),135398744,Patrex,Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11356,NCT01449253,Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia,UNKNOWN,PHASE4,Pulmonary Hypertension Secondary to Lung Disease and/or Hypoxia,Sildenafil (DRUG); Bosentan (DRUG),135398744,Patrex,Pulmonary Hypertension Secondary to Lung Disease and/or Hypoxia,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11357,NCT02422277,Role of Low-intensity Shock Wave Therapy in Penile Rehabilitation Post Nerve Sparing Radical Cysto-prostatectomy,UNKNOWN,PHASE2,Bladder Cancer,LI-ESWT group (DEVICE); PDE-5 inhibitors group (DRUG),135398744,Patrex,Bladder Cancer,Bladder/Urinary Tract,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11358,NCT00752115,Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer,COMPLETED,PHASE2,Non-small Cell Lung Cancer,sildenafil (DRUG); placebo (DRUG); paclitaxel (taxol) (DRUG); carboplatin (palaplatin) (DRUG),135398744,Patrex,Non-small Cell Lung Cancer,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11359,NCT00454207,Open Label Study of Sildenafil in Patients With Pulmonary Arterial Hypertension,COMPLETED,PHASE3,Pulmonary Hypertension,"sildenafil citrate (UK-92,480) (DRUG)",135398744,Patrex,Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11360,NCT02546609,The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease,COMPLETED,PHASE2,NAFLD,Leu-Met-Sil 0.5 (DRUG); Leu-Met-Sil 1.0 (DRUG); Placebo (DRUG),135398744,Patrex,Non-alcoholic Fatty Liver Disease,Liver,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11361,NCT00709956,Iloprost Power 15 in Pulmonary Arterial Hypertension,COMPLETED,PHASE3,Pulmonary Arterial Hypertension,iloprost (5 µg) (DRUG); placebo (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11362,NCT04391478,Efficacy and Safety of Milrinone Versus Sildenafil in the Treatment of Neonates With Persistent Pulmonary Hypertension,COMPLETED,PHASE1,Persistent Pulmonary Hypertension,Milrinone (DRUG); Sildenafil (DRUG),135398744,Patrex,Persistent Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11363,NCT00705588,Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.,UNKNOWN,PHASE4,Pulmonary Arterial Hypertension,Tadalafil (DRUG); Vardenafil (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11364,NCT00194909,"An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus)",COMPLETED,PHASE4,Diabetic Neuropathy,sildenafil (Viagra) (DRUG),135398744,Patrex,Diabetic Neuropathy,Peripheral Nervous System,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11365,NCT01642407,Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension,COMPLETED,PHASE4,"Pulmonary Arterial Hypertension; Hypertension, Pulmonary",Sildenafil (DRUG),135398744,Patrex,"Pulmonary Arterial Hypertension; Hypertension, Pulmonary",Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11366,NCT02060487,Effects of Oral Sildenafil on Mortality in Adults With PAH,TERMINATED,PHASE4,Pulmonary Arterial Hypertension,sildenafil citrate (DRUG); sildenafil citrate (DRUG); sildenafil citrate (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11367,NCT00159887,Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension,COMPLETED,PHASE3,Pulmonary Hypertension,Sildenafil citrate (DRUG),135398744,Patrex,Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11368,NCT02349633,Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M),TERMINATED,PHASE1,Non-Small Cell Lung Cancer,PF-06747775 (DRUG); Palbociclib (DRUG); Avelumab (DRUG),135398744,Patrex,Advanced Non-Small Cell Lung Cancer,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11369,NCT00159861,The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH,COMPLETED,PHASE3,Pulmonary Hypertension,Sildenafil citrate (DRUG),135398744,Patrex,Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11370,NCT01712997,Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients,UNKNOWN,PHASE3,Pulmonary Arterial Hypertension,Iloprost (DRUG); Bosentan (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11371,NCT00780728,Study Evaluating the Addition of Sildenafil to Bosentan Therapy in Pulmonary Arterial Hypertension,WITHDRAWN,PHASE3,"Hypertension, Pulmonary",Sildenafil (DRUG),135398744,Patrex,Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11372,NCT03997097,Efficacy of Phosphodiesterase-type 5 Inhibitors in Patients With Univentricular Congenital Heart Disease,WITHDRAWN,PHASE3,Single-ventricle; Pulmonary Hypertension; Univentricular Heart,Sildenafil (DRUG); Placebos (DRUG),135398744,Patrex,Single-ventricle; Pulmonary Hypertension; Univentricular Heart,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11373,NCT00644605,"A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension",COMPLETED,PHASE3,"Hypertension, Pulmonary",sildenafil (DRUG); sildenafil (DRUG); placebo (DRUG); sildenafil (DRUG),135398744,Patrex,Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11374,NCT00709098,Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension,COMPLETED,PHASE3,Pulmonary Arterial Hypertension,iloprost (DRUG); iloprost (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11375,NCT02802345,Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment,COMPLETED,PHASE3,Idiopathic Pulmonary Fibrosis,Nintedanib (DRUG); Placebo (DRUG); Sildenafil (DRUG),135398744,Patrex,Idiopathic Pulmonary Fibrosis,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11376,NCT00302211,"The ""VISION"" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension",TERMINATED,PHASE3,Pulmonary Hypertension,Inhaled Iloprost (5 μg) (DRUG); Inhaled Placebo (DRUG); Sildenafil (DRUG); Bosentan (DRUG),135398744,Patrex,Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11377,NCT01360671,IV Sildenafil Persistent Pulmonary Hypertension Of The Newborn,WITHDRAWN,PHASE2,Persistent Pulmonary Hypertension of the Newborn,Sildenafil (DRUG),135398744,Patrex,Persistent Pulmonary Hypertension of the Newborn,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11378,NCT02106871,Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer,WITHDRAWN,PHASE1,Pancreatic Cancer; Cholangiocarcinoma,Sildenafil (DRUG),135398744,Patrex,Pancreatic Cancer; Cholangiocarcinoma,Pancreas,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11379,NCT01069861,Study To Investigate Safety And Efficacy Of Sildenafil In The Newborns With Persistent Pulmonary Hypertension (PPHN),TERMINATED,PHASE2,PPHN; Persistent Pulmonary Hypertension of the Newborn; Hypoxic Respiratory Failure,sildanefil (DRUG),135398744,Patrex,PPHN; Persistent Pulmonary Hypertension of the Newborn; Hypoxic Respiratory Failure,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11380,NCT02304705,Sildenafil in Heart Failure With Reactive Pulmonary Hypertension,TERMINATED,PHASE4,Heart Failure With Reactive Pulmonary Hypertension,Sildenafil (DRUG); Placebo (DRUG),135398744,Patrex,Heart Failure With Reactive Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11381,NCT01055405,Study of Sildenafil Effects in Combination With Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Associated Pulmonary Hypertension,COMPLETED,PHASE4,COPD; Pulmonary Hypertension,Sildenafil (DRUG); Placebo (OTHER),135398744,Patrex,COPD with Pulmonary Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11382,NCT00617305,Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1),COMPLETED,PHASE4,Pulmonary Arterial Hypertension,Ambrisentan (DRUG); Placebo (DRUG); Sildenafil (DRUG); Tadalafil (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11383,NCT06317805,Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients,RECRUITING,PHASE4,Pulmonary Arterial Hypertension,Generic treprostinil sodium + Standard of Care (Double Oral) (DRUG); Standard of Care - Double Oral (DRUG),135398744,Patrex,Pulmonary Arterial Hypertension,Lung,Sildenafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Approved for erectile dysfunction and pulmonary arterial hypertension.,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,1.33,258.0 +11384,NCT02165826,"Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD",COMPLETED,PHASE3,Chronic Obstructive Pulmonary Disease (COPD),Roflumilast (DRUG); Roflumilast Placebo (DRUG); Standard of Care COPD Treatment (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease (COPD),Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11385,NCT02224157,A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma,COMPLETED,PHASE3,Asthma,budesonide/formoterol 'as needed' + budesonide placebo bid (DRUG); budesonode bid + terbutaline 'as needed' (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11386,NCT00522782,Effect of Budesonide on Exhaled Nitric Oxide in Asthmatic Children,COMPLETED,PHASE4,Asthma,Nebulized Budesonide (DRUG); Nitric Oxide Analyzer (DEVICE),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11387,NCT02772965,Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy,COMPLETED,PHASE3,Pediatric Crohn's Disease,Methotrexate (DRUG); Sugar pill (placebo) (OTHER),5281004,Noex,Pediatric Crohn's Disease,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11388,NCT03643965,Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy,COMPLETED,PHASE3,Primary IgA Nephropathy,Nefecon (DRUG); Placebo oral capsule (DRUG),5281004,Noex,Primary IgA Nephropathy,Kidney,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11389,NCT05562466,A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma,RECRUITING,PHASE3,Asthma,QMF149 (DRUG); Budesonide (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11390,NCT00259766,SHARE - Symbicort and Health Economics in a Real Life Evaluation,COMPLETED,PHASE3,Asthma,Budesonide (DRUG); Formoterol (DRUG); Terbutaline (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11391,NCT06502366,A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma,RECRUITING,PHASE3,Asthma,BDA MDI HFO 160/180 μg (DRUG); BDA MDI HFA 160/180 μg (DRUG); Placebo MDI HFA (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11392,NCT06283966,"A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease",RECRUITING,PHASE3,COPD (Chronic Obstructive Pulmonary Disease),BGF MDI 320/14.4/9.6 μg (DRUG); GFF MDI 14.4/9.6 μg (DRUG),5281004,Noex,COPD (Chronic Obstructive Pulmonary Disease),Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11393,NCT03219866,Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD),TERMINATED,PHASE4,COPD; COPD Exacerbation,Nebulizers (DEVICE); Dry Powder Inhaler (DEVICE); Brovana (DRUG); Pulmicort (DRUG); Atrovent (DRUG); Advair Diskus (DRUG); Spiriva HandiHaler (DRUG),5281004,Noex,COPD; COPD Exacerbation,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11394,NCT04016220,Nebulized Budesonide Combined With Systemic Corticosteroid in Acute Severe Asthma,UNKNOWN,PHASE1,Acute Asthma,Budesonide (DRUG); normal saline (DRUG),5281004,Noex,Acute Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11395,NCT00232674,Efficacy Study of the Effect of Budesonide on Emphysema,COMPLETED,PHASE4,Chronic Obstructive Pulmonary Disease,Pulmicort (budesonide) Turbuhaler (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11396,NCT00733473,Nebulized Budesonide for Children Who Are Hospitalized for Acute Wheezing,COMPLETED,PHASE4,Asthma; Acute Asthma,Budesonide 0.5 mg/ml nebules (DRUG); % 0.9 Saline solution (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11397,NCT00661973,Inhaled Corticosteroids on Airway Smooth Muscle in Asthma,WITHDRAWN,PHASE4,Asthma,budesonide (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11398,NCT06471257,A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma,RECRUITING,PHASE3,Asthma,"Budesonide/Albuterol metered dose inhaler, MDI (COMBINATION_PRODUCT); Albuterol sulfate metered dose inhaler, MDI (COMBINATION_PRODUCT)",5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11399,NCT04215848,As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period,COMPLETED,PHASE3,Asthma,Budesonide/Formoterol Fumarate 160 MCG-4.5 MCG Inhalation Powder (DRUG); Budesonide 200Mcg Inhalation Powder (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11400,NCT01532648,Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA),COMPLETED,PHASE3,Ulcerative Colitis,Budesonide MMX® (DRUG); Placebo (DRUG); 5-ASA (DRUG),5281004,Noex,Ulcerative Colitis,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11401,NCT00117182,Aridol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD,COMPLETED,PHASE2,"Lung Diseases, Obstructive",Dry powder mannitol (DRUG); Budesonide 400mcg administered via turbuhaler (DRUG); Ipratropium bromide 80mcg (DRUG); Salbutamol 400mcg (DRUG),5281004,Noex,"Lung Diseases, Obstructive",Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11402,NCT04233190,"A Multicenter, Randomized, Parallel, Two-period, Non-inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment",COMPLETED,PHASE3,Asthma Copd,Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg (DRUG),5281004,Noex,Asthma Copd,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11403,NCT03879590,Efficacy Of Doxophylline As A Sparing Treatment For Inhaled Corticosteroids In Mexican Children With Asthma,UNKNOWN,PHASE3,Asthma Chronic; Asthma in Children,Doxophylline (DRUG); Budesonide (DRUG),5281004,Noex,Asthma Chronic; Asthma in Children,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11404,NCT01035190,Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia,COMPLETED,PHASE3,Bronchopulmonary Dysplasia,Budesonide (DRUG),5281004,Noex,Bronchopulmonary Dysplasia,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11405,NCT05555290,PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction,COMPLETED,PHASE3,Asthma,PT027 (COMBINATION_PRODUCT); PT007 (COMBINATION_PRODUCT),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11406,NCT03769090,A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma,COMPLETED,PHASE3,Asthma,Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg (COMBINATION_PRODUCT); Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg (COMBINATION_PRODUCT); Albuterol sulfate metered-dose inhaler 180 μg (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11407,NCT03468790,Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.,COMPLETED,PHASE3,"Asthma, Allergic",CMAB007 (DRUG); Symbicort (DRUG); Seretide (DRUG); Ventolin (DRUG); placebo (DRUG),5281004,Noex,"Asthma, Allergic",Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11408,NCT06110403,"Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness",RECRUITING,PHASE1,Copd,TRIXEO AEROSPHERE (DRUG),5281004,Noex,Copd,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11409,NCT01397890,Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE4,Chronic Obstructive Pulmonary Disease (COPD),Budesonide/formoterol (Symbicort® Turbuhaler®) (DRUG); Tiotropium (SpirivaTM) (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease (COPD),Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11410,NCT00234390,PreAsthmaControl (PAC),COMPLETED,PHASE4,Asthma,Pulmicort (budesonide) pMDI (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11411,NCT00849095,Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma,COMPLETED,PHASE3,Asthma,budesonide/formoterol combination (PRN) (DRUG); budesonide/formoterol combination (DRUG); placebo (DRUG); terbutaline (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11412,NCT02504801,Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD,UNKNOWN,PHASE4,"Post Operative Complication, Pulmonary; Lung Cancer; COPD",Budesonide (DRUG),5281004,Noex,"Post Operative Complication, Pulmonary; Lung Cancer; COPD",Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11413,NCT06297668,"A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C).",COMPLETED,PHASE1,Chronic Obstructive Pulmonary Disease,Treatment A: BGF MDI HFA (DRUG); Treatment B: BGF MDI HFO (DRUG); Treatment C: BGF MDI HFO (DRUG); AeroChamber Plus Flow-Vu spacer (DEVICE),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11414,NCT01329276,Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients.,COMPLETED,PHASE4,Chronic Obstructive Pulmonary Disease,Symbicort® forte Turbohaler® (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11415,NCT02972476,Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial,COMPLETED,PHASE4,Chronic Obstructive Pulmonary Disease,Budesonide & formoterol fumarate and Aclidinium bromide (DRUG); Fluticasone 500 & salmeterol and Aclidinium bromide (DRUG); Fluticasone 250 & salmeterol and Aclidinium bromide (DRUG); Aclidinium bromide & formoterol fumarate (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11416,NCT00536731,Symbicort Rapihaler Therapeutic Equivalence Study,COMPLETED,PHASE3,Bronchial Asthma,Symbicort Turbuhaler (DRUG); Symbicort pMDI (DRUG); Pulmicort Turbuhaler (DRUG),5281004,Noex,Bronchial Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11417,NCT03250182,A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose,COMPLETED,PHASE1,Chronic Obstructive Pulmonary Disease,PT010 (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11418,NCT03412682,To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis,COMPLETED,PHASE3,"Colitis, Ulcerative","Budesonide (6 mg) (DRUG); Budesonide (9 mg) (DRUG); Mesalazine (3,600 mg) (DRUG)",5281004,Noex,"Colitis, Ulcerative",Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11419,NCT01278082,SOIBD Collagenous Colitis Maintenance Study,COMPLETED,PHASE3,Induction and Maintaining Remission of Collagenous Colitis,Budesonide (DRUG); Placebo (DRUG),5281004,Noex,Induction and Maintaining Remission of Collagenous Colitis,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11420,NCT01136382,A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo,COMPLETED,PHASE2,Asthma,budesonide (DRUG); placebo (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11421,NCT05735431,"Non-Inferiority,Combination Formoterol/FluticasonexAlenia®Formoterol/Budesonide for Asthma in Brazil",NOT_YET_RECRUITING,PHASE3,Moderate Asthma,Administration of investigation drug (DRUG); Administration of comparator (DRUG),5281004,Noex,Moderate Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11422,NCT03888131,Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient,COMPLETED,PHASE3,Chronic Obstructive Pulmonary Disease,CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo (DRUG); Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11423,NCT02400476,An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide,COMPLETED,PHASE2,Early Stage HER2+ Breast Cancer,Neratinib (DRUG); Loperamide (DRUG); Colestipol (DRUG); Budesonide (DRUG),5281004,Noex,Early Stage HER2+ Breast Cancer,Breast,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11424,NCT00462592,Comparison of Combination Therapy: Montelukast and Inhaled Steroid on Exercise Induced Bronchoconstriction,COMPLETED,PHASE3,Asthma,budesonide (DRUG); montelukast (DRUG); placebo (OTHER),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11425,NCT00092092,Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254),COMPLETED,PHASE4,"Asthma, Bronchial",Montelukast chewable tablets (DRUG); Budesonide inhaler (DRUG); Placebo to montelukast chewable tablets (DRUG); Placebo to budesonide inhaler (DRUG),5281004,Noex,"Asthma, Bronchial",Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11426,NCT00667992,Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma,COMPLETED,PHASE3,Asthma,Budesonide HFA (DRUG); Budesonide CFC (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11427,NCT00641446,Varicella Vaccination With Pulmicort,COMPLETED,PHASE4,Asthma,budesonide (DRUG); varicella zoster virus (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11428,NCT00651768,Titratable Dosing in Moderate to Severe Asthmatics,COMPLETED,PHASE3,Asthma,budesonide/formoterol (DRUG); Symbicort pMDI + budesonide HFA pMDI (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11429,NCT01266772,Effect of Montelukast in Asthma in Children,UNKNOWN,PHASE3,Bronchial Asthma,Montelukast sodium. (DRUG); Placebo tablet and budesonide (DRUG),5281004,Noex,Bronchial Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11430,NCT00679380,(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis,COMPLETED,PHASE3,Ulcerative Colitis,"Blood sampling, endoscopy (PROCEDURE); Budesonide MMX® 6 mg (DRUG); Budesonide MMX® 9 mg (DRUG); Entocort EC® 3 mg (DRUG); Placebo (DRUG)",5281004,Noex,Ulcerative Colitis,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11431,NCT01432080,"Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant",TERMINATED,PHASE2,"Respiratory Tract Infections; Bronchiolitis Obliterans; Cryptogenic Organizing Pneumonia; Lung Diseases, Interstitial",Prednisone (DRUG); Azithromycin (DRUG); Montelukast (DRUG); Symbicort (DRUG),5281004,Noex,"Respiratory Tract Infections; Bronchiolitis Obliterans; Cryptogenic Organizing Pneumonia; Lung Diseases, Interstitial",Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11432,NCT00393367,Budesonide Inhalation Suspension for Acute Asthma in Children,COMPLETED,PHASE4,Asthma; Acute Asthma; Reactive Airway Exacerbation,"Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg (DRUG); Prednisolone, prednisone, or methylprednisolone (DRUG); Albuterol, ipratropium bromide (DRUG); Ipratropium bromide (DRUG)",5281004,Noex,Asthma; Acute Asthma; Reactive Airway Exacerbation,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11433,NCT00837967,Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients,COMPLETED,PHASE3,Asthma,Symbicort Turbuhaler (DRUG); Terbutaline Turbuhaler (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11434,NCT00449501,A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects,COMPLETED,PHASE3,Asthma,Budesonide/formoterol pMDI (DRUG); Budesonide HFA pMDI (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11435,NCT02465567,Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos),COMPLETED,PHASE3,COPD,BGF MDI 320/14.4/9.6 μg (DRUG); GFF MDI 14.4/9.6 μg (DRUG); BGF MDI 160/14.4/9.6 μg (DRUG); BFF MDI 320/9.6 μg (DRUG),5281004,Noex,COPD,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11436,NCT00449527,A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects,COMPLETED,PHASE3,Asthma,Budesonide/formoterol pMDI (DRUG); Budesonide HFA pMDI (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11437,NCT01253473,Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE4,"Pulmonary Disease, Chronic Obstructive",Budesonide (DRUG); budesonide/formoterol (DRUG); Ipratropium/albuterol (DRUG),5281004,Noex,"Pulmonary Disease, Chronic Obstructive",Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11438,NCT00109473,Trial of Growth Hormone Therapy in Pediatric Crohn's Disease,COMPLETED,PHASE2,Crohn's Disease,growth hormone (DRUG); cortecosteroid (DRUG),5281004,Noex,Crohn's Disease,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11439,NCT03073057,Pharmacokinetic Study to Compare Absorption of Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler,COMPLETED,PHASE1,Asthma,Budesonide/formoterol (DRUG); Charcoal (OTHER); Symbicort Turbuhaler (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11440,NCT04078126,Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.,COMPLETED,PHASE3,Chronic Obstructive Pulmonary Disease (COPD),BFF (COMBINATION_PRODUCT); Symbicort Turbuhaler (COMBINATION_PRODUCT),5281004,Noex,Chronic Obstructive Pulmonary Disease (COPD),Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11441,NCT00232648,Long Term Safety & Efficacy of Budesonide Inhalation Suspension in Japanese Children With Bronchial Asthma,COMPLETED,PHASE3,Asthma,Pulmicort (budesonide) Respules (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11442,NCT00702325,Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans,COMPLETED,PHASE4,Asthma,Budesonide / formoterol fumarate (SYMBICORT) (DRUG); Budesonide (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11443,NCT05831566,Expertise Asthma COPD Program with Digital Support,RECRUITING,PHASE3,Asthma,Budesonide/Formoterol fumarate dihydrate (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11444,NCT01593826,Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler,COMPLETED,PHASE1,Asthma,Charcoal and Budesonide/formoterol Easyhaler 320/9 microg (DRUG); Charcoal and Symbicort Turbuhaler (DRUG); Budesonide/formoterol Easyhaler 320/9 microg (DRUG); Symbicort Turbuhaler forte (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11445,NCT00463866,Local Phase 4 Pan-European SMART Study,COMPLETED,PHASE4,Asthma,Budesonide/formoterol (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11446,NCT04545866,The Budesonide in Babies (BiB) Trial,ACTIVE_NOT_RECRUITING,PHASE3,Bronchopulmonary Dysplasia (BPD); Respiratory Distress Syndrome; Prematurity; Extreme; Neonatal,budesonide (Pulmicort nebulizing suspension). (DRUG); surfactant (poractant alfa;Curosurf) (DRUG),5281004,Noex,Bronchopulmonary Dysplasia (BPD); Respiratory Distress Syndrome; Prematurity; Extreme; Neonatal,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11447,NCT05084222,Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing,COMPLETED,PHASE4,Asthma,Buventol® Easyhaler® 200 µg/inhalation dmDPI (DRUG); Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI (DRUG); Ventoline® Evohaler® 100 µg/inhalation pMDI (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11448,NCT06719622,Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn's Disease Located in the Esophagus And/or Stomach And/or Duodenum,ENROLLING_BY_INVITATION,PHASE2,Crohn Disease (CD),budesonide (DRUG); omeprazole (proton pump inhibitor) (DRUG),5281004,Noex,Inflammatory Bowel Disease (IBD),Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11449,NCT01099722,"Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma",COMPLETED,PHASE3,Asthma,Flutiform (DRUG); Symbicort Turbohaler (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11450,NCT03436225,Steroid Therapy in Acute Bronchiolitis A New Old Line of Therapy.,UNKNOWN,PHASE1,Bronchiolitis; Respiratory Syncytial Virus,Dexamethasone orally. (DRUG); Dexamethasone parenteral. (DRUG); Inhaled nebulized Budesonide. (DRUG); Inhaled nebulized salbutamol. (DRUG),5281004,Noex,Bronchiolitis; Respiratory Syncytial Virus,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11451,NCT00642122,Adults With Moderate to Severe Asthma,COMPLETED,PHASE3,Asthma,Budesonide (DRUG); Budesonide (DRUG); Budesonide (DRUG); Budesonide (DRUG); Budesonide (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11452,NCT01089322,Risk Factors Associated to Difficult-to-control Asthma,COMPLETED,PHASE4,ASTHMA,inhaled corticosteroid plus LABA plus oral corticosteroid (DRUG),5281004,Noex,ASTHMA,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11453,NCT00395239,Asthma/Steroid Withdrawal Study,TERMINATED,PHASE4,Asthma,inhaled corticosteroid (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11454,NCT00479739,CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.,COMPLETED,PHASE4,Asthma,Salmeterol/fluticasone propionate or formoterol/budesonide (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11455,NCT00746486,Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC),TERMINATED,PHASE3,Primary Biliary Cirrhosis,budesonide (DRUG); budesonide placebo (DRUG),5281004,Noex,Primary Biliary Cirrhosis,Liver,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11456,NCT03311373,"A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010",COMPLETED,PHASE1,Chronic Obstructive Pulmonary Disease,Regimen A (DRUG); Regimen B (DRUG); Regimen C (DRUG); Regimen D (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11457,NCT03740373,"A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate",COMPLETED,PHASE1,"Pulmonary Disease, Chronic Obstructive","BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold (DRUG); BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold (DRUG)",5281004,Noex,"Pulmonary Disease, Chronic Obstructive",Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11458,NCT04705727,Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation,TERMINATED,PHASE3,Asthma in Children,Budesonide Formoterol Drug Combination (DRUG); nebulisation of terbutaline (DRUG),5281004,Noex,Pediatric Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11459,NCT00487773,Effect of Different Doses of Budesonide on Markers of Bone Metabolism in Children With Asthma,COMPLETED,PHASE4,Asthma,budesonide (DRUG); D3 vitamin (DRUG); montelukast sodium (DRUG); salbutamol (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11460,NCT00419757,"An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma",COMPLETED,PHASE3,Asthma,Budesonide/formoterol (SYMBICORT) pMDI (DRUG); Budesonide HFA pMDI (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11461,NCT01444430,A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents,COMPLETED,PHASE3,Asthma,Symbicort pMDI (DRUG); budesonide pMDI (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11462,NCT03421730,"A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma",COMPLETED,PHASE1,Wheezing; Reactive Airway Disease; Mild Asthma,VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (COMBINATION_PRODUCT); 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (COMBINATION_PRODUCT),5281004,Noex,Wheezing; Reactive Airway Disease; Mild Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11463,NCT03952286,ED-Initiated School-based Asthma Medication Supervision,COMPLETED,PHASE4,Asthma; Asthma in Children,ED-Dispensing home and school supervision (DRUG),5281004,Noex,Asthma; Asthma in Children,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11464,NCT00421122,Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD,COMPLETED,PHASE3,Chronic Obstructive Pulmonary Disease,budesonide/formoterol (Symbicort) (DRUG); budesonide (Pulmicort) (DRUG); terbutaline sulfate (Bricasol) (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11465,NCT01386996,Comparison of Budesonide and Formoterol Absorption From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler,COMPLETED,PHASE1,Asthma,Budesonide/formoterol Easyhaler 320/9 microg (DRUG); Symbicort Turbuhaler forte (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11466,NCT05111262,Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers,RECRUITING,PHASE1,"Asthma; Nonadherence, Medication",Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA (DRUG),5281004,Noex,"Asthma; Nonadherence, Medication",Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11467,NCT04848662,To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.,COMPLETED,PHASE1,Asthma,BDA MDI (PT027) 160/180 μg (DRUG); Pulmicort Respules 0.5 MG/ML Inhalation Suspension (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11468,NCT00624429,A Pilot Study Involving an Asthma Management Program for Inner-city Early Head Start Children,UNKNOWN,PHASE4,Asthma,Budesonide respules (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11469,NCT01170429,Efficacy and Safety Study of Procaterol Hydrochloride to Treat Patients With Cough Variant Asthma (CVA),UNKNOWN,PHASE4,Cough Variant Asthma,Procaterol hydrochloride (DRUG); Meptin placebo (DRUG),5281004,Noex,Cough Variant Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11470,NCT01560689,Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation,COMPLETED,PHASE2,Bronchiolitis Obliterans; Allogeneic Stem Cell Transplantation,Budesonide/formoterol (DRUG); Placebo (DRUG),5281004,Noex,Bronchiolitis Obliterans; Allogeneic Stem Cell Transplantation,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11471,NCT02833480,A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota,UNKNOWN,PHASE2,Chronic Obstructive Pulmonary Disease,Fluticasone group (DRUG); Budesonide group (DRUG); Formoterol group (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11472,NCT00646529,Long-Term Safety of Symbicort in Asthmatic Children - SAPLING,COMPLETED,PHASE3,Asthma,budesonide/formoterol (Symbicort) (DRUG); budesonide (Pulmicort) (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11473,NCT06482294,"CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma",ACTIVE_NOT_RECRUITING,PHASE2,Asthma,Salbutamol (DRUG); Fluticason either Beclometasone or Budesonide (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11474,NCT00504062,"Open-label, Safety and Efficacy Study of Pulmicort® Turbuhaler® in Japanese Children With Bronchial Asthma",COMPLETED,PHASE3,Asthma,budesonide (DRUG); fluticasone (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11475,NCT05202262,A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS),COMPLETED,PHASE3,Asthma,BFF MDI 320/9.6 μg (DRUG); BFF MDI 160/9.6 μg (DRUG); BD MDI 320 μg (DRUG); Open-label Symbicort TBH 320/9 μg (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11476,NCT02227394,Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients,COMPLETED,PHASE2,Asthma; Asthma Chronic; Asthma Bronchial; Asthmatic,Z7200 (DRUG); Symbicort® Turbohaler® (DRUG),5281004,Noex,Asthma; Asthma Chronic; Asthma Bronchial; Asthmatic,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11477,NCT00646594,Atlantis Symbicort,COMPLETED,PHASE3,Asthma,budesonide/formoterol (Symbicort) (DRUG); fluticasone/salmeterol (Advair) (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11478,NCT01846962,Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis,COMPLETED,PHASE4,Eosinophilic Esophagitis,Budesonide (DRUG); Fluticasone (DRUG); six-foods elimination diet (BEHAVIORAL); Oral Viscous Budesonide (OVB) (DRUG),5281004,Noex,Eosinophilic Esophagitis,Esophagus/Stomach,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11479,NCT04171180,The Efficacy of Budesonide/Formoterol in Cough Variant Asthma,UNKNOWN,PHASE4,Cough Variant Asthma,budesonide/formoterol (DRUG),5281004,Noex,Cough Variant Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11480,NCT00542880,Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®,COMPLETED,PHASE4,Chronic Obstructive Pulmonary Disease (COPD),Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg (DRUG); Seretide Diskus (salmeterol/fluticasone) 50/500 μg (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease (COPD),Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11481,NCT01794780,"A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator",COMPLETED,PHASE4,COPD,LABA based treatment: indacaterol (DRUG); LAMA based treatment: tiotropium (DRUG); LABA/ICS based treatment: salmeterol/fluticasone (DRUG); LABA/ICS based treatment: budesonide/formoterol (DRUG); theophylline based treatment (DRUG); Other treatment (DRUG),5281004,Noex,COPD,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11482,NCT00716963,Does Fluticasone Propionate Reduce the Late Allergic Reaction When the Drug is Given Post-allergen?,COMPLETED,PHASE4,Mild Intermittent Asthma,Fluticasone propionate (Flovent Diskus) 250 mcg (DRUG); budesonide 400 mcg (DRUG); Placebo (OTHER),5281004,Noex,Mild Intermittent Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11483,NCT02181335,Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy,COMPLETED,PHASE3,Asthma,Respimat® Budesonide low dose (DRUG); Respimat® Budesonide high dose (DRUG); Turbohaler® Budesonide (DRUG); Placebo (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11484,NCT02091986,"A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg",COMPLETED,PHASE3,Asthma,Symbicort pMDI (DRUG); Symbicort pMDI (DRUG); Budesonide pMDI (OTHER),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11485,NCT00826163,Innate Immune Responses in Chronic Obstructive Pulmonary Disease (COPD) Patients,COMPLETED,PHASE3,Chronic Obstructive Pulmonary Disease,Budesonide (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11486,NCT00450086,Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis,COMPLETED,PHASE3,Collagenous Colitis,Budesonide (DRUG); Mesalazine (DRUG); Placebo (DRUG),5281004,Noex,Collagenous Colitis,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11487,NCT04589663,Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ≥ 6 to < 12 Years Old With Asthma,COMPLETED,PHASE2,Asthma,Mometasone furoate (DRUG); QMF149 (DRUG); Standard of Care (Soc) (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11488,NCT00646516,Gemini Symbicort pMDI,COMPLETED,PHASE3,Mild or Moderate Asthma,budesonide/formoterol (Symbicort) (DRUG),5281004,Noex,Mild or Moderate Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11489,NCT03478696,"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",COMPLETED,PHASE4,"Pulmonary Disease, Chronic Obstructive",budesonide/formoterol (DRUG); albuterol/salbutamol (DRUG); FF/UMEC/VI (DRUG); Placebo to match budesonide/formoterol (DRUG); tiotropium (DRUG); Placebo to match FF/UMEC/VI (DRUG); placebo to match tiotropium (DRUG); ELLIPTA (DEVICE); MDI (DEVICE); HandiHaler (DEVICE),5281004,Noex,"Pulmonary Disease, Chronic Obstructive",Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11490,NCT00576316,Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia,COMPLETED,PHASE4,Asthma,Symbicort Turbuhaler 160/4.5 (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11491,NCT06372496,Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma,ACTIVE_NOT_RECRUITING,PHASE4,Asthma,Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (DRUG); Inhaled corticosteroids/long-acting beta-2 agonists (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11492,NCT03847896,A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma,COMPLETED,PHASE3,Asthma,Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose) (COMBINATION_PRODUCT); Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose) (COMBINATION_PRODUCT); Budesonide metered dose inhaler / BD MDI 160 µg (DRUG); Albuterol sulfate metered dose inhaler / AS MDI 180 μg (DRUG); Placebo metered-dose inhaler / Placebo MDI (OTHER),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11493,NCT04527016,Airway Microbiota Based Treatment of Asthma in Preschool Children,COMPLETED,PHASE4,Asthma in Children,Microbiota and eosinophils based therapy (PROCEDURE); Clinical guidelines based therapy (DRUG),5281004,Noex,Pediatric Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11494,NCT02280616,Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis,COMPLETED,PHASE2,Eosinophilic Esophagitis,low dose budesonide tablet (DRUG); high dose budesonide tablet (DRUG); high dose budesonide suspension (DRUG); Placebo (DRUG),5281004,Noex,Eosinophilic Esophagitis,Esophagus/Stomach,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11495,NCT00964535,Bioequivalence Study of Budesonide/Formoterol Easyhaler and Symbicort Turbohaler in Asthmatics,COMPLETED,PHASE1,Asthma,budesonide and formoterol 200/6 microg (DRUG); budesonide and formoterol 200/6 microg (DRUG); budesonide and formoterol 200/6 microg (DRUG); budesonide and formoterol 200/6 microg (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11496,NCT00252863,DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults,COMPLETED,PHASE3,Asthma,"Symbicort, used twice daily (b.i.d) and as needed (prn) (DRUG); Budesonide Turbuhaler 200 µg (DRUG); Fluticasone Discus 250 µg (DRUG); Formoterol Turbuhaler 4.5 µg (DRUG); Terbutaline Turbuhaler 0.5 mg (DRUG); Salbutamol pressurized metered dose inhaler (pMDI) 100 µg (DRUG); Salmeterol Discus 50 µg (DRUG); Budesonide/Formoterol Turbuhaler 160/4.5 µg (DRUG); Fluticasone/Salmeterol Discus 250/50 µg (DRUG); Fluticasone/Salmeterol Discus 500/50 µg (DRUG); Theophylline 200 mg (DRUG); Theophylline 300 mg (DRUG); Singulair 10 mg (DRUG)",5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11497,NCT01181063,Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers,COMPLETED,PHASE1,Asthma,Budesonide/formoterol 320/9 μg and 400/12 μg inhalers (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11498,NCT00094458,Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC,COMPLETED,PHASE3,Crohn Disease,infliximab infusion; AZA placebo caps (BIOLOGICAL); infliximab (IFX) infusion; azathioprine (AZA) caps (OTHER); infliximab (IFX) placebo infusion; azathioprine (AZA) caps (DRUG),5281004,Noex,Crohn Disease,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11499,NCT01023516,Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol,COMPLETED,PHASE2,Chronic Obstructive Pulmonary Disease (COPD),AZD9668 (DRUG); Placebo (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease (COPD),Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11500,NCT02493335,Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis,COMPLETED,PHASE3,Eosinophilic Esophagitis,Budesonide 0.5mg orodispersible tablet twice daily (DRUG); Budesonide 1mg orodispersible tablet twice daily (DRUG); Placebo orodispersible tablet twice daily (DRUG),5281004,Noex,Eosinophilic Esophagitis,Esophagus/Stomach,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11501,NCT01028560,Allergy Immunotherapy for the Reduction of Asthma,COMPLETED,PHASE1,Wheezing; Asthma; Allergy,Allergen extracts (subcutaneous injections) (BIOLOGICAL); Standard of care (OTHER),5281004,Noex,Wheezing; Asthma; Allergy,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11502,NCT00005880,Budesonide in Treating Former and Current Smokers With Bronchial Dysplasia,COMPLETED,PHASE2,Lung Cancer,budesonide (DRUG),5281004,Noex,Lung Cancer,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11503,NCT00180076,Budesonide for Maintenance Treatment of Collagenous Colitis,COMPLETED,PHASE3,Collagenous Colitis,Budesonide (DRUG),5281004,Noex,Collagenous Colitis,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11504,NCT05813860,HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's Disease,NOT_YET_RECRUITING,PHASE4,Crohn Disease; Infliximab,Azathioprine (DRUG); Infliximab (DRUG),5281004,Noex,Crohn Disease; Infliximab,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11505,NCT06895460,A Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets),NOT_YET_RECRUITING,PHASE3,Bronchial Asthma,Budesonide Formoterol (DRUG); Placebo (DRUG); Immune Modulators (Staphylococcus and Neisseria Tablets) (DRUG),5281004,Noex,Bronchial Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11506,NCT00747110,Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC),COMPLETED,PHASE3,"Colitis, Ulcerative",budesonide (DRUG); mesalazine (DRUG),5281004,Noex,"Colitis, Ulcerative",Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11507,NCT00419744,A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD,COMPLETED,PHASE3,Chronic Obstructive Pulmonary Disease,Budesonide/formoterol (SYMBICORT) pMDI (DRUG); Formoterol Turbuhaler (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11508,NCT00377572,Inner-City Anti-IgE Therapy for Asthma,COMPLETED,PHASE4,Asthma,omalizumab (BIOLOGICAL); omalizumab placebo (BIOLOGICAL),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11509,NCT05915104,Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis,NOT_YET_RECRUITING,PHASE2,Microscopic Colitis,Budesonide MMX® (DRUG); Budesonide controlled ileal release (CR) capsules (DRUG),5281004,Noex,Microscopic Colitis,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11510,NCT04609904,Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS),COMPLETED,PHASE3,Asthma,BGF MDI 320/28.8/9.6 μg (DRUG); BGF MDI 320/14.4/9.6 μg (DRUG); BFF MDI 320/9.6 μg (DRUG); BFF pMDI 320/9 μg (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11511,NCT00697801,Study of MAP0010 in Asthmatic Children and Adolescents,COMPLETED,PHASE2,Asthma,MAP0010 low dose (DRUG); MAP0010 high dose (DRUG); Placebo (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11512,NCT00995904,Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma,COMPLETED,PHASE2,Asthma,84ug MAP0020 (DRUG); 42ug MAP0020 (DRUG); 21ug MAP0020 (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11513,NCT00206167,A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD,COMPLETED,PHASE3,Chronic Obstructive Pulmonary Disease,Budesonide/formoterol pMDI (DRUG); Formoterol Turbuhaler (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11514,NCT01453946,Safety and Maintenance Study of Entocort for Children With Crohn's Disease,COMPLETED,PHASE3,Crohn's Disease,Entocort (DRUG),5281004,Noex,Crohn's Disease,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11515,NCT00140946,A Study to Assess the Effect of Montelukast Sodium With Concomitant Administration of Inhaled Budesonide in Asthmatic Patients (0476-075),COMPLETED,PHASE4,Asthma,MK0476; montelukast sodium/Duration of Treatment: 16 weeks (DRUG); Comparator: placebo / Duration of Treatment: 16 weeks (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11516,NCT03563001,Differences of Small Airways Function Between Chronic Obstructive Pulmonary Disease(COPD) and Asthma-copd Overlap(ACO),UNKNOWN,PHASE4,"Pulmonary Disease, Chronic Obstructive; Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome; Small Airway Disease; Quality of Life",Budesonide(160ug) and Formoterol(4.5ug) bid (DRUG),5281004,Noex,"Pulmonary Disease, Chronic Obstructive; Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome; Small Airway Disease; Quality of Life",Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11517,NCT02497001,"A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)",COMPLETED,PHASE3,COPD,BGF MDI 320/14.4/9.6 μg (DRUG); GFF MDI (PT003) 14.4/9.6 μg (DRUG); BFF MDI (PT009) 320/9.6 μg (DRUG); Symbicort® Turbuhaler® (TBH) Inhalation Powder (DRUG),5281004,Noex,COPD,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11518,NCT00569192,A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children,COMPLETED,PHASE3,Asthma,0.135mg MAP0010 (DRUG); 0.25mg MAP0010 (DRUG); Placebo (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11519,NCT01069289,Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients,COMPLETED,PHASE3,Chronic Obstructive Pulmonary Disease,Budesonide/formoterol (Symbicort Turbuhaler) (DRUG); Formoterol (Oxis Turbuhaler) (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11520,NCT04607629,An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma,COMPLETED,PHASE3,Bronchial Asthma,Genolar® + Symbicort® (BIOLOGICAL); Xolair® + Symbicort® (BIOLOGICAL),5281004,Noex,Bronchial Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11521,NCT02434029,Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis,COMPLETED,PHASE3,Eosinophilic Esophagitis,Budesonide 1mg orodispersible tablet twice daily (DRUG); Placebo orodispersible tablet twice daily (DRUG),5281004,Noex,Eosinophilic Esophagitis,Esophagus/Stomach,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11522,NCT00202189,Effects of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE4,Chronic Obstructive Pulmonary Disease,Budesonide (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11523,NCT01351792,A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR),TERMINATED,PHASE3,Chronic Obstructive Pulmonary Disease,Foster® 100/6 µg/unit dose (DRUG); Symbicort® Turbohaler® 200/6 μg/actuation (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11524,NCT00259792,SYMPHONIE - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults,COMPLETED,PHASE3,Asthma,Budesonide/formoterol Turbuhaler (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11525,NCT01444092,Safety Study of Entocort for Children With Crohn's Disease,COMPLETED,PHASE3,Crohn's Disease,Entocort (DRUG),5281004,Noex,Crohn's Disease,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11526,NCT06422689,Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care,RECRUITING,PHASE4,Asthma,Albuterol and budesonide inhalation aerosol (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11527,NCT00652392,Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM,COMPLETED,PHASE3,Asthma,budesonide/formoterol (DRUG); budesonide and placebo (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11528,NCT02019758,Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis,COMPLETED,PHASE4,Eosinophilic Esophagitis,Oral Viscous Budesonide (DRUG); Fluticasone MDI (DRUG); Placebo slurry (DRUG); Placebo inhaler (DRUG),5281004,Noex,Eosinophilic Esophagitis,Esophagus/Stomach,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11529,NCT00628758,A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma,COMPLETED,PHASE3,Asthma,"Symbicort TBH - Turbuhaler (DRUG); beta-II-agonist, inhale steroid (DRUG)",5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11530,NCT00139165,Long-Term Treatment of Collagenous Colitis With Budesonide,UNKNOWN,PHASE3,Collagenous Colitis,Budesonide (DRUG); sigmoidoscopy (PROCEDURE),5281004,Noex,Collagenous Colitis,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11531,NCT00762073,Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis,COMPLETED,PHASE2,Eosinophilic Esophagitis (EoE),budesonide (DRUG); placebo (DRUG),5281004,Noex,Eosinophilic Esophagitis (EoE),Esophagus/Stomach,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11532,NCT01627158,Pharmacokinetic Study Comparing Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler Forte,COMPLETED,PHASE1,Asthma,Budesonide/formoterol Easyhaler (DRUG); Symbicort Turbuhaler (DRUG); Charcoal and Budesonide/formoterol Easyhaler (DRUG); Charcoal and Symbicort Turbuhaler (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11533,NCT01070524,Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma,COMPLETED,PHASE2,Asthma,CHF 5188 pMDI (DRUG); Budesonide extrafine pMDI (DRUG); Seretide(r) Evohaler(r) (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11534,NCT03141424,Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma,COMPLETED,PHASE4,Asthma,Tapering of inhaled corticosteroid (ICS) treatment (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11535,NCT03992469,"Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease",RECRUITING,PHASE1,Crohn's Disease,EBFAHF-2 (DRUG); Placebo (DRUG),5281004,Noex,Crohn's Disease,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11536,NCT01912872,Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma,TERMINATED,PHASE4,Severe IgE-mediated Asthma,Omalizumab (DRUG); Budesonide (DRUG); Formoterol (DRUG); Budesonide (DRUG); Formoterol (DRUG),5281004,Noex,Severe IgE-mediated Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11537,NCT00641472,"Pulmicort Respules(Budesonide Inhalation Suspension) vs Singulair, Children",COMPLETED,PHASE4,Asthma,Budesonide inhalation suspension (DRUG); Montelukast Sodium (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11538,NCT02189304,Pharmacokinetics and Safety Study of PT010 in Healthy Subjects,COMPLETED,PHASE1,COPD,PT010 (DRUG); PT009 (DRUG); Symbicort Turbohaler (DRUG),5281004,Noex,COPD,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11539,NCT01760304,Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo,TERMINATED,PHASE4,Chronic Obstructive Pulmonary Disease (COPD),Budesonide / Formoterol (DRUG); Placebo (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease (COPD),Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11540,NCT03245840,Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE),TERMINATED,PHASE3,Eosinophilic Esophagitis (EoE),Budesonide oral suspension (DRUG),5281004,Noex,Eosinophilic Esophagitis (EoE),Esophagus/Stomach,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11541,NCT01647646,Real Life Effectiveness in Patients With Not Optimally Controlled Asthma,COMPLETED,PHASE4,Asthma,Seretide (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11542,NCT00504946,Pharmacological Modulations of Allergen-Specific Immunotherapy,COMPLETED,PHASE3,Asthma,"prednisone, lactose (DRUG); prednisone, colecalciferol, lactose (DRUG); lactose (DRUG); montelukast sodium (DRUG); lactose (DRUG)",5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11543,NCT02165046,"Bioavailability Study of SYN006, Pulmicort pMDI and Meptin Air in Healthy Adult.",COMPLETED,PHASE1,Asthma; Chronic Obstructive Pulmonary Disease (COPD),Budesonide (DRUG); Procaterol (DRUG),5281004,Noex,Asthma; Chronic Obstructive Pulmonary Disease (COPD),Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11544,NCT00569712,Studying Genes in Blood and Lung Fluid Samples From Patients With Chronic Obstructive Pulmonary Disease With or Without a Previous Diagnosis of Lung Cancer or With Asthma Treated With Budesonide and Formoterol,COMPLETED,PHASE1,Lung Cancer; Precancerous Condition,budesonide/formoterol fumarate dihydrate inhalation aerosol (DRUG); DNA methylation analysis (GENETIC); comparative genomic hybridization (GENETIC); microarray analysis (GENETIC); bronchoalveolar lavage (OTHER); immunoenzyme technique (OTHER); laboratory biomarker analysis (OTHER); bronchoscopy (PROCEDURE),5281004,Noex,Lung Cancer; Precancerous Condition,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11545,NCT02105012,Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma,COMPLETED,PHASE2,Asthma,BD MDI 320 µg (DRUG); BD MDI 160 µg (DRUG); BD MDI 80 µg (DRUG); BD MDI 40 µg (DRUG); Placebo MDI (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11546,NCT03075267,Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects,COMPLETED,PHASE1,Chronic Obstructive Pulmonary Disease,PT010 (BGF MDI) 320/14.4/9.6 µg (DRUG); PT010 (BGF MDI) 160/14.4/9.6 µg (DRUG); PT003 (GFF MDI) 14.4/9.6 µg (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11547,NCT00397267,Treatment of Acute Asthma in ER With Combination of Systemic Steroids and Inhaled Steroids,UNKNOWN,PHASE4,Asthma Exacerbation,inhalation of corticosteroids (DRUG),5281004,Noex,Asthma Exacerbation,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11548,NCT05341401,Budesonide Multimatrix(MMX) Versus Prednisolone in Management of Mild to Moderate Ulcerative Colitis,UNKNOWN,PHASE2,Ulcerative Colitis Chronic,Budesonide MMX (DRUG); Prednisolone (DRUG),5281004,Noex,Ulcerative Colitis Chronic,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11549,NCT03028701,Assessment of Bronchodilator Efficacy of Formoterol/Budesonide 12/400 mcg Via Discair in COPD,COMPLETED,PHASE4,Copd,Formoterol/Budesonide 12/400 mcg Discair (DRUG),5281004,Noex,Copd,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11550,NCT02113267,Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study.,TERMINATED,PHASE2,Eosinophilic Esophagitis,Mometasone furoate (DRUG); Placebo (DRUG),5281004,Noex,Eosinophilic Esophagitis,Esophagus/Stomach,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11551,NCT05660746,Precise Infliximab Exposure and Pharmacodynamic Control,RECRUITING,PHASE2,Crohn Disease,RoadMAB (DEVICE); Infliximab (DRUG),5281004,Noex,Crohn Disease,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11552,NCT02495168,"Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants",COMPLETED,PHASE3,Asthma,Generic Budesonide/Formoterol Fumarate Dihydrate (DRUG); Symbicort® (Budesonide/Formoterol Fumarate Dihydrate) (DRUG); Placebo (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11553,NCT01293734,Research on Traditional Chinese Medicine (TCM) Clinical Treatment of the Acute Episode of Bronchial Asthma.,COMPLETED,PHASE2,Bronchial Asthma,warming lung and relieving asthmatic granule and Securing origin and warming lung emplastrum (OTHER); clearing lung and relieving asthmatic granule and securing origin and clearing lung emplastrum (OTHER); securing origin and relieving asthmatic granule and securing origin and nourishing lung emplastrum (OTHER); Theophylline Sustained-release Tablets and budesonide suspension (DRUG),5281004,Noex,Bronchial Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11554,NCT00442117,A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880),COMPLETED,PHASE3,Asthma,mometasone furoate dry powder inhaler (DRUG); Budesonide DPI (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11555,NCT02771717,Low Exhaled NO and ICS in Suspected Asthma,UNKNOWN,PHASE4,Asthma,Budesonide (Pulmicort) (DRUG); Placebo - dummy inhaler (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11556,NCT00252824,STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma,COMPLETED,PHASE3,Asthma,Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11557,NCT02142634,Budesonide for Induction of Remission in Incomplete Microscopic Colitis,COMPLETED,PHASE3,Incomplete Microscopic Colitis,Budesonide granules 9 mg (DRUG); Placebo granules (DRUG),5281004,Noex,Incomplete Microscopic Colitis,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11558,NCT00733317,Budesonide for Emergency Treatment of Acute Wheezing in Children,COMPLETED,PHASE4,Asthma; Acute Asthma,0.5 mg/ml budesonide nebules (DRUG); Saline (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11559,NCT02631941,Clinical Study to Evaluate Z7200 Pharmacokinetics Profile,COMPLETED,PHASE1,Asthma,Z7200 without oral activated charcoal (DRUG); Symbicort Turbohaler without oral activated charcoal (DRUG); Z7200 with oral activated charcoal (DRUG); Symbicort Turbohaler with oral activated charcoal (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11560,NCT01340118,Improvement of FeNO and FEF25-75 After Inhaled Corticosteroid Treatment of Asthma,COMPLETED,PHASE4,Asthma,Budesonide (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11561,NCT02550418,Budesonide 9 mg Capsules in Active UC,COMPLETED,PHASE2,"Colitis, Ulcerative",Budesonide (DRUG),5281004,Noex,"Colitis, Ulcerative",Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11562,NCT04159519,A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab,COMPLETED,PHASE4,Asthma; Severe Eosinophilic Asthma,Symbicort® (DRUG); Fasenra® (DRUG); Ventolin® (DRUG),5281004,Noex,Asthma; Severe Eosinophilic Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11563,NCT00939341,Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia,COMPLETED,PHASE4,Asthma,Symbicort (Budesonide/Formoterol) (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11564,NCT04191434,Efficacy and Safety of Flamboyant 125/12 Association in the Treatment of Adults With Moderate Asthma,UNKNOWN,PHASE3,Asthma,Flamboyant 125/12 (DRUG); Budesonide/formoterol 200/6 (DRUG); Flamboyant 125/12 Placebo (OTHER); Budesonide/formoterol 200/6 placebo (OTHER),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11565,NCT05505734,A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma,COMPLETED,PHASE3,Asthma,BDA MDI (DRUG); AS MDI (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11566,NCT00634413,Effect of ADC4022 Co-Administered With Budesonide on Pulmonary Inflammation in Subjects With Moderate to Severe COPD,COMPLETED,PHASE2,Chronic Obstructive Pulmonary Disease,Theophylline - ADC4022 (DRUG); Placebo (DRUG); Budesonide (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11567,NCT06676319,Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma,RECRUITING,PHASE2,Asthma,Lunsekimig (DRUG); Short-Acting Beta Agonists (SABA) (DRUG); Placebo (DRUG); Fluticasone/salmeterol (DRUG); Budesonide/formoterol (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11568,NCT03197818,Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD),COMPLETED,PHASE3,COPD (Chronic Obstructive Pulmonary Disease),CHF 5993 100/6/12.5 µg (DRUG); 160 µg budesonide + 4.5 µg formoterol fumarate (DRUG),5281004,Noex,COPD (Chronic Obstructive Pulmonary Disease),Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11569,NCT02446418,A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma,COMPLETED,PHASE3,Asthma,Fluticasone Furoate (DRUG); Vilanterol (DRUG); Fluticasone propionate (DRUG); Salmeterol (DRUG); Budesonide (DRUG); Formoterol Fumarate (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11570,NCT00584636,Pulmicort Respules on Relapse Rates After Treatment in the ED,WITHDRAWN,PHASE4,Asthma,pulmicort respules (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11571,NCT01225549,The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen,COMPLETED,PHASE2,Asthma,AZD5423 (DRUG); Budesonide 200 microgram (DRUG); Placebo (DRUG); Placebo (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11572,NCT00641914,Inhaled Steroid Treatment as Regular Therapy in Early Asthma,COMPLETED,PHASE4,Asthma,budesonide (DRUG); Placebo (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11573,NCT01642212,"OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension",COMPLETED,PHASE2,Eosinophilic Esophagitis (EoE),Oral Budesonide Suspension (MB-9) (DRUG); Placebo (DRUG),5281004,Noex,Eosinophilic Esophagitis (EoE),Esophagus/Stomach,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11574,NCT01100112,(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets,COMPLETED,PHASE3,"Colitis, Ulcerative",Budesonide (DRUG),5281004,Noex,"Colitis, Ulcerative",Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11575,NCT00554710,Top Down Versus Step Up Strategies in Crohn's Disease,COMPLETED,PHASE4,Crohn's Disease,infliximab+azathioprine (DRUG); methylprednisolone or budesonide (DRUG),5281004,Noex,Crohn's Disease,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11576,NCT01147510,Asthma Control in Elderly Patients With Montelukast,COMPLETED,PHASE4,Persistent Asthma; Elderly,Combination of low ICS and montelukast (DRUG); Monotherapy of medium dose ICS (DRUG),5281004,Noex,Persistent Asthma; Elderly,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11577,NCT01167010,"A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma",COMPLETED,PHASE3,Asthma,Formoterol/Budesonide (DRUG); Foraseq (DRUG); Alenia (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11578,NCT03262012,"Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®",COMPLETED,PHASE3,COPD,BGF MDI (PT010) (DRUG); GFF MDI (PT003) (DRUG); BFF MDI (PT009) (DRUG); Symbicort® Turbohaler® Inhalation Powder (DRUG),5281004,Noex,COPD,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11579,NCT04655508,Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation,TERMINATED,PHASE3,Stem Cell Transplant Complications; Respiratory Disease; Bronchiolitis Obliterans,Seretide (DRUG); Placebo (DRUG),5281004,Noex,Stem Cell Transplant Complications; Respiratory Disease; Bronchiolitis Obliterans,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11580,NCT05477108,"Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA",COMPLETED,PHASE1,Chronic Obstructive Pulmonary Disease,Treatment A (BGF MDI HFO with oral activated charcoal) (DRUG); Treatment B (BGF MDI HFA with oral activated charcoal) (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11581,NCT02237508,A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers,COMPLETED,PHASE1,Asthma,Z7200 without oral activated charcoal (DRUG); Symbicort Turbohaler without oral activated charcoal (DRUG); Z7200 with oral activated charcoal (DRUG); Symbicort Turbohaler with oral activated charcoal (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11582,NCT02536508,"Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease",COMPLETED,PHASE3,COPD,BGF MDI 320/14.4/9.6 μg (DRUG); GFF MDI 14.4/9.6 μg (DRUG); BFF MDI 320/9.6 μg (DRUG),5281004,Noex,COPD,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11583,NCT00728481,The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis,COMPLETED,PHASE2,Eosinophilic Esophagitis; Gastroesophageal Reflux Disease; EE; GERD,Esomeprazole (DRUG); Budesonide (DRUG),5281004,Noex,Eosinophilic Esophagitis; Gastroesophageal Reflux Disease; EE; GERD,Esophagus/Stomach,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11584,NCT04208581,Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure,UNKNOWN,PHASE3,Chronic Obstructive Pulmonary Disease; Chronic Respiratory Failure,Yiqi Huoxue Huatan granule (DRUG); Placebo Yiqi Huoxue Huatan granule (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease; Chronic Respiratory Failure,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11585,NCT00291408,Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD,WITHDRAWN,PHASE4,Chronic Obstructive Pulmonary Disease (COPD); Age Matched Healthy Volunteers (Non-smokers),Skin Prick Test (PROCEDURE); Impulse Oscillometry (PROCEDURE); Exhaled Nitric Oxide (PROCEDURE); Spirometry (PROCEDURE); Reversibility (PROCEDURE); Exhaled Breath Condensate (PROCEDURE); Sputum Induction (PROCEDURE),5281004,Noex,Chronic Obstructive Pulmonary Disease (COPD); Age Matched Healthy Volunteers (Non-smokers),Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11586,NCT05542355,EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease,TERMINATED,PHASE1,Crohn Disease,EXL01 (DRUG); Placebo (DRUG); SoC corticosteroid - Induction Period (OTHER); SoC corticosteroid - Tapering (OTHER),5281004,Noex,Crohn Disease,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11587,NCT00658255,Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler,COMPLETED,PHASE2,Stable Asthma,budesonide/formoterol (DRUG); formoterol (DRUG),5281004,Noex,Stable Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11588,NCT00135408,A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide,COMPLETED,PHASE2,Malignant Melanoma,Ipilimumab+ Placebo (DRUG); Ipilimumab+ Budesonide (DRUG),5281004,Noex,Malignant Melanoma,Skin,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11589,NCT01976208,Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma,COMPLETED,PHASE2,Allergic Asthma,Omalizumab (DRUG); placebo (DRUG),5281004,Noex,Allergic Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11590,NCT04920838,Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection,UNKNOWN,PHASE2,Covid19; Covid19 Drug Treatment; Severe Acute Respiratory Syndrome Coronavirus 2; SARS-CoV2 Infection,Nitazoxanide and Ciclésonide (DRUG); Telmisartan 20Mg Oral Tablet (DRUG); Paracetamol (DRUG); Fluoxétine and Budésonide (DRUG),5281004,Noex,Covid19; Covid19 Drug Treatment; Severe Acute Respiratory Syndrome Coronavirus 2; SARS-CoV2 Infection,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11591,NCT00860938,Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD,COMPLETED,PHASE4,COPD,Budesonide (DRUG),5281004,Noex,COPD,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11592,NCT00668408,LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure,UNKNOWN,PHASE4,"Lung Diseases, Obstructive; Chronic Heart Failure; Chronic Hypoxemia",LTOT (oxygen therapy) (OTHER); Pharmacological therapy of COPD and CHF (OTHER),5281004,Noex,"Lung Diseases, Obstructive; Chronic Heart Failure; Chronic Hypoxemia",Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11593,NCT00244608,A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®,COMPLETED,PHASE3,Asthma,Budesonide/Formoterol Turbuhaler (DRUG); Budesonide Turbuhaler (Pulmicort) (DRUG); Terbutaline Turbuhaler (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11594,NCT01803555,Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®,COMPLETED,PHASE3,Asthma,Budesonide/Formoterol SPIROMAX® (DRUG); SYMBICORT® TURBOHALER® (DRUG); SYMBICORT placebo (DRUG); SPIROMAX Placebo (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11595,NCT01136655,A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy,COMPLETED,PHASE2,Asthma,80/2.25 μg Symbicort pMDI (DRUG); 80/4.5 μg Symbicort pMDI (DRUG); Foradil Aerolizer 12 μg (DRUG); 40 μg budesonide HFA pMDI (DRUG); placebo HFA pMDI (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11596,NCT00838214,Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis,COMPLETED,PHASE2,Autoimmune Hepatitis,budesonide (DRUG); prednisone (DRUG),5281004,Noex,Autoimmune Hepatitis,Liver,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11597,NCT00255255,"Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma",COMPLETED,PHASE3,Asthma,Budesonide/Formoterol (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11598,NCT05152355,Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients,COMPLETED,PHASE4,Asthma,"Budesonide 200 microgram/Puff, HFA MDI (DRUG); Budesonide 100 microgram/Actuation Powder for Inhalation (DRUG)",5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11599,NCT06075095,"A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD",RECRUITING,PHASE3,COPD (Chronic Obstructive Pulmonary Disease),BGF MDI HFO 320/14.4/9.6μg (DRUG); BGF MDI HFA 320/14.4/9.6 μg (DRUG); Placebo MDI HFA (DRUG),5281004,Noex,COPD (Chronic Obstructive Pulmonary Disease),Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11600,NCT01200108,AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects With Asthma,COMPLETED,PHASE2,Asthma,Budesonide (DRUG); Budesonide (DRUG); Budesonide (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11601,NCT05573464,A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,COMPLETED,PHASE3,Chronic Obstructive Pulmonary Disease (COPD),BGF MDI HFO 320/14.4/9.6 μg (DRUG); BGF MDI HFA 320/14.4/9.6 μg (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease (COPD),Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11602,NCT01001364,A Comparative Study Between Foraseq and Formoterol/Budesonide Inhalation Capsules in Patients with Asthma,COMPLETED,PHASE3,ASTHMA,Formoterol/Budesonide (DRUG); Foraseq (DRUG),5281004,Noex,ASTHMA,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11603,NCT05444543,Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis),COMPLETED,PHASE4,Eosinophilic Esophagitis,Fluticasone Propionate (DRUG); Budesonide (DRUG),5281004,Noex,Eosinophilic Esophagitis,Esophagus/Stomach,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11604,NCT00180050,Budesonide Treatment for Lymphocytic Colitis,COMPLETED,PHASE3,Microscopic Colitis,Budesonide (DRUG),5281004,Noex,Microscopic Colitis,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11605,NCT00259779,Comparison Between Symbicort® and Prednisolone in COPD,COMPLETED,PHASE3,Chronic Obstructive Pulmonary Disease,budesonide/formoterol (DRUG); Prednisolone (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11606,NCT00483743,"Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled Budesonide in COPD Patients",COMPLETED,PHASE2,Copd Bronchitis,TPI 1020 (DRUG); Budesonide (DRUG); Placebo (DRUG),5281004,Noex,Copd Bronchitis,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11607,NCT02093195,Study of Bosentan in the Treatment of Stable Severe Chronic Obstructive Pulmonary Disease Patients,UNKNOWN,PHASE2,Chronic Obstructive Pulmonary Disease (COPD),Bosentan (DRUG); Symbicort turbuhaler (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease (COPD),Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11608,NCT03788395,The Use of an Innovative Device for Therapeutic Adherence in Pediatric Asthma,COMPLETED,PHASE4,Asthma,Symbicort Turbohaler plus Turbo+ (DEVICE); Symbicort Turbohaler without Turbo+ (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11609,NCT00801723,(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.,COMPLETED,PHASE3,Ulcerative Colitis,Budesonide MMX 6 mg Tablet (DRUG); Placebo Tablet (DRUG),5281004,Noex,Ulcerative Colitis,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11610,NCT00271349,Budesonide for Eosinophilic Esophagitis,COMPLETED,PHASE2,Eosinophilic Esophagitis,Budesonide (DRUG),5281004,Noex,Eosinophilic Esophagitis,Esophagus/Stomach,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11611,NCT00189436,Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Children,COMPLETED,PHASE4,Asthma,Nebulized Budesonide (DRUG); Usual care (albuterol with or without oral steroid) (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11612,NCT01555099,Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol,COMPLETED,PHASE2,Chronic Obstructive Pulmonary Disease (COPD),AZD5423 (DRUG); Budesonide (DRUG); Placebo (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease (COPD),Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11613,NCT06429475,Anti-Inflammatory Reliever South Africa,ENROLLING_BY_INVITATION,PHASE3,Asthma,Budesonide/formoterol (DRUG); standard of care (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11614,NCT00496470,Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.,COMPLETED,PHASE4,"Chronic Obstructive Pulmonary Disease, COPD",Symbicort (budesonide/formoterol turbuhaler 320/9ug) (DRUG); Spiriva (tiotropium bromide 18ug) (DRUG),5281004,Noex,"Chronic Obstructive Pulmonary Disease, COPD",Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11615,NCT00242775,"Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg",COMPLETED,PHASE3,Asthma,Budesonide/formoterol Turbuhaler (DRUG); Salmeterol/fluticasone Diskus (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11616,NCT00554970,A Study of 2 Doses of MAP0010 in Adult Asthmatics,COMPLETED,PHASE2,Asthma,MAP0010 low dose (DRUG); MAP0010 high dose (DRUG); Budesonide inhalation suspension 0.25mg (DRUG); Budesonide inhalation suspension 0.5mg (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11617,NCT02149199,A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.,COMPLETED,PHASE3,Asthma,budesonide/formoterol 'as needed' + budesonide placebo bid (DRUG); terbutaline 'as needed' + placebo budesonide bid (DRUG); budesonide bid + terbutaline 'as needed' (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11618,NCT02725242,Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down Asthma,COMPLETED,PHASE3,Asthma,Budesonide/formoterol (160/4.5 μg/d) (DRUG); Budesonide (400μg/d) (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11619,NCT05214599,"Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults' Subjects of Both Genders With Eosinophilic Esophagitis (EoE)",WITHDRAWN,PHASE2,Eosinophilic Esophagitis,Budesonide Gel (DRUG),5281004,Noex,Eosinophilic Esophagitis,Esophagus/Stomach,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11620,NCT00004842,Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis,COMPLETED,PHASE1,"Cholangitis, Sclerosing; Liver Cirrhosis, Biliary",budesonide (DRUG),5281004,Noex,"Cholangitis, Sclerosing; Liver Cirrhosis, Biliary",Liver,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11621,NCT04019106,Budesonide With Intratracheal Surfactants in Extremely Preterm Infants,UNKNOWN,PHASE1,Bronchopulmonary Dysplasia; Respiratory Distress Syndrome in Premature Infant,Budesonide in bovine lipid extract surfactant (BLES) (DRUG),5281004,Noex,Bronchopulmonary Dysplasia; Respiratory Distress Syndrome in Premature Infant,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11622,NCT01783106,Antibiotics and Hydroxychloroquine in Crohn's,COMPLETED,PHASE2,Crohn's Disease,Ciprofloxacin (DRUG); Doxycycline (DRUG); Hydroxychloroquine (DRUG); Budesonide (DRUG),5281004,Noex,Crohn's Disease,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11623,NCT02407236,A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis,COMPLETED,PHASE3,"Colitis, Ulcerative; Inflammatory Bowel Diseases",Placebo IV (DRUG); Placebo SC (DRUG); Ustekinumab IV (DRUG); Ustekinumab SC (DRUG),5281004,Noex,"Colitis, Ulcerative; Inflammatory Bowel Diseases",Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11624,NCT01404013,Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma,UNKNOWN,PHASE4,Asthma,ICS/LABA (DRUG); Montelukast (DRUG); ICS/LABA and Montelukast (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11625,NCT05755906,A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS),COMPLETED,PHASE3,Asthma,BFF MDI 160/9.6 μg BID (320/19.2μg/day) (DRUG); BD MDI 160 μg BID (320 μg/day) (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11626,NCT00476099,Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD,COMPLETED,PHASE3,Chronic Obstructive Pulmonary Disease,Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI (DRUG); Budesonide 200 µg plus formoterol 6 µg DPI (DRUG); Formoterol 12 µg DPI (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11627,NCT06571942,Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure,RECRUITING,PHASE4,COPD Bronchitis; Pollution Related Respiratory Disorder,Vilanterol / Umeclidinium (25/62.5 mcg) (DRUG); Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg) (DRUG); Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg (DRUG); Budesonide / Formoterol / Glycopyrronyum 160/4.8/7.2 mcg (DRUG),5281004,Noex,COPD Bronchitis; Pollution Related Respiratory Disorder,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11628,NCT00588406,Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.,COMPLETED,PHASE3,Asthma,Budesonide (DRUG); albuterol (DRUG); Ipratropium bromide (DRUG); Prednisone (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11629,NCT02850484,A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block,COMPLETED,PHASE1,Asthma; Chronic Obstructive Pulmonary Disease (COPD),Budesonide (DRUG); Formoterol (DRUG),5281004,Noex,Asthma; Chronic Obstructive Pulmonary Disease (COPD),Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11630,NCT06473779,Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.,RECRUITING,PHASE3,Severe Asthma,Tezepelumab (COMBINATION_PRODUCT); Budesonide/formoterol (COMBINATION_PRODUCT); Albuterol/budesonide (AIRSUPRA®) (COMBINATION_PRODUCT); Mannitol (COMBINATION_PRODUCT); Salbutamol (COMBINATION_PRODUCT),5281004,Noex,Severe Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11631,NCT01511302,Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma,COMPLETED,PHASE1,Asthma,RNS60 (DRUG); Normal Saline (DRUG); Budesonide (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11632,NCT06563102,"Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma",RECRUITING,PHASE4,Mild Asthma,Albuterol/Budesonide (COMBINATION_PRODUCT); Albuterol (COMBINATION_PRODUCT),5281004,Noex,Mild Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11633,NCT02986321,A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD,COMPLETED,PHASE2,Chronic Obstructive Pulmonary Disease,CHF6001 (DRUG); Budesonide (DRUG); Placebo (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11634,NCT02422121,Effect of RNS60 on the Late Phase Asthmatic Response to Allergen Challenge,COMPLETED,PHASE2,Asthma,RNS60 (DRUG); Placebo (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11635,NCT05596721,Azithromycin Treatment for Non-eosinophilic Chest Tightness Variant Asthma,UNKNOWN,PHASE4,Asthma; Chest Syndrome; Azithromycin; Effect of Drug,Azithromycin (DRUG); ICS/LABA (DRUG),5281004,Noex,Asthma; Chest Syndrome; Azithromycin; Effect of Drug,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11636,NCT05569421,"A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA",COMPLETED,PHASE1,Chronic Obstructive Pulmonary Disease,Treatment A: BGF MDI HFO (DRUG); Treatment B: BGF MDI HFA (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11637,NCT04494321,A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block,COMPLETED,PHASE1,Asthma; COPD,Budesonide (DRUG); Formoterol (DRUG),5281004,Noex,Asthma; COPD,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11638,NCT01783821,LIPS-B: Lung Injury Prevention Study With Budesonide and Beta,COMPLETED,PHASE2,Acute Respiratory Distress Syndrome (ARDS),Budesonide (DRUG); Placebo (DRUG); Formoterol (DRUG),5281004,Noex,Acute Respiratory Distress Syndrome (ARDS),Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11639,NCT00652002,Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5,COMPLETED,PHASE3,Asthma,budesonide/formoterol (DRUG); budesonide (DRUG); formoterol (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11640,NCT05976802,"Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis",NOT_YET_RECRUITING,PHASE4,Ulcerative Colitis,High dose budesonide rectal foam (DRUG); Low dose budesonide rectal foam (DRUG); Matching placebo rectal foam (DRUG),5281004,Noex,Ulcerative Colitis,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11641,NCT06676384,Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate At Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?,NOT_YET_RECRUITING,PHASE4,"IgA Nephropathy; Renal Insufficiency, Chronic; IgA Vasculitis; IGA Glomerulonephritis",Oral prednisolone and SoC (DRUG); Gut-directed budesonide and SoC (DRUG); Mycophenolate mofetil (MMF) and SoC (DRUG); Hydroxychloroquine and SoC (DRUG); Non-steroidal mineralocorticoid receptor antagonist and SoC (DRUG); SoC defined as maximal labelled or tolerated dose of angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker (ACEi/ARB) & steady dose of sodium-glucose cotransporter-2 inhibitor (SGLT2i) (DRUG),5281004,Noex,"IgA Nephropathy; Renal Insufficiency, Chronic; IgA Vasculitis; IGA Glomerulonephritis",Kidney,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11642,NCT00380484,Short- and Long Term Growth in Children With Asthma,COMPLETED,PHASE4,Asthma,Budesonide (DRUG); Montelukast (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11643,NCT01360021,New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day,COMPLETED,PHASE3,Asthma,Symbicort (DRUG); Symbicort (DRUG); Budesonide (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11644,NCT01668121,Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers,COMPLETED,PHASE1,Asthma,Symbicort Turbohaler (DRUG); Budesonide/formoterol Easyhaler (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11645,NCT00646321,Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT,COMPLETED,PHASE3,Asthma,budesonide/formoterol (Symbicort) (DRUG); budesonide (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11646,NCT04064684,Inhaled Steroids for the Treatment of Early Pediatric Acute Respiratory Distress Syndrome,TERMINATED,PHASE2,Acute Respiratory Distress Syndrome,Budesonide (DRUG); Placebo (DRUG); Nebulizer (DEVICE),5281004,Noex,Acute Respiratory Distress Syndrome,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11647,NCT01857479,A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis,COMPLETED,PHASE2,Allergic Bronchopulmonary Aspergillosis,Inhaled budesonide (DRUG); Inhaled amphotericin (DRUG),5281004,Noex,Allergic Bronchopulmonary Aspergillosis,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11648,NCT00627679,Safety and Blood Level Study of Unit Dose Budesonide,COMPLETED,PHASE1,Asthma,Budesonide Inhalation Suspension (DRUG); MAP0010 low dose (DRUG); MAP0010 intermediate dose (DRUG); MAP0010 high dose (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11649,NCT02162784,Efficacy Study of SYN006 HFA MDI in Asthma Patients,COMPLETED,PHASE2,Asthma,"Budesonide/Procaterol, 180/10mcg X1 (DRUG); Budesonide/procaterol 180/10 mcg X 2 (DRUG); Albuterol HFA MDI 100mcg X2 (DRUG)",5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11650,NCT01070784,A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan,COMPLETED,PHASE3,Chronic Obstructive Pulmonary Disease,Symbicort Turbuhaler (Budesonide/formoterol) (DRUG); Drug: any available COPD treatment; investigator to decide (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11651,NCT00290264,SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent Asthma,COMPLETED,PHASE3,Asthma,Budesonide/formoterol (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11652,NCT00675584,CARE Network Maintenance Versus Intermittent Inhaled Steroids in Wheezing Toddlers (MIST),COMPLETED,PHASE3,Asthma,Budesonide (DRUG); Placebo Budesonide (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11653,NCT02233803,"A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma",COMPLETED,PHASE4,Asthma,NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler (DRUG); SYMBICORT forte (BFF 320/9mcg) TURBUHALER inhaler (DRUG); NEUMOTEX 400 (Budesonide 400 mcg) (DRUG); Salbutamol 100 mcg pMDI (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11654,NCT00113503,Imuran Dosing in Crohn's Disease Study,TERMINATED,PHASE2,Crohn's Disease,Azathioprine weight-based dose (DRUG); Azathioprine individualised dose (DRUG),5281004,Noex,Crohn's Disease,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11655,NCT03917303,Control Crohn Safe Trial,RECRUITING,PHASE4,Crohn Disease; Inflammatory Bowel Diseases,Adalimumab (DRUG); standard step-up care (DRUG),5281004,Noex,Crohn Disease; Inflammatory Bowel Diseases,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11656,NCT00490243,Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma,COMPLETED,PHASE4,Asthma,budesonide and montelukast (DRUG); budesonide and formoterol (DRUG); montelukast (DRUG); budesonide (DRUG); placebo (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11657,NCT03319043,Observation of Cough Variant Asthma Treated in Combination of Chanqin Granules.,UNKNOWN,PHASE1,Cough Variant Asthma,Chanqin granules (DRUG),5281004,Noex,Cough Variant Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11658,NCT00163384,Effectiveness of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-136),COMPLETED,PHASE3,Asthma,Ciclesonide (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11659,NCT00238784,SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults,COMPLETED,PHASE3,Asthma,Budesonide/formoterol Turbuhaler (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11660,NCT00288379,SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma,COMPLETED,PHASE3,Asthma,formoterol (DRUG); budesonide/formoterol (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11661,NCT00915538,Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus),COMPLETED,PHASE4,Asthma,pMDI budesonide/formotrol 160/4.5 is in group 1 (DRUG); Symbicort 160/4.5 plus Aerochamber Plus included in group 2 (DEVICE),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11662,NCT00327808,Inhaled TPI-1020 Versus Inhaled Budesonide in Smokers With Mild Reversible Asthma,COMPLETED,PHASE2,Asthma,TPI-1020 (DRUG); budesonide (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11663,NCT01257048,Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler,COMPLETED,EARLY_PHASE1,COPD Method Evaluation; Chronic Obstructive Pulmonary Disease Method Evaluation,Formoterol Turbuhaler (DRUG); Budesonide/Formoterol Turbuhaler (DRUG); Formoterol Turbuhaler (DRUG),5281004,Noex,COPD Method Evaluation; Chronic Obstructive Pulmonary Disease Method Evaluation,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11664,NCT02991859,"Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects",COMPLETED,PHASE2,Asthma,Fluticasone furoate (FF) Dry Powder Inhaler (DRUG); Fluticasone propionate (FP) Dry Powder Inhaler (DRUG); Budesonide (BUD) Turbuhaler (DRUG); Placebo (ELLIPTA or DISKUS) (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11665,NCT04314375,"Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis",RECRUITING,PHASE4,Ulcerative Colitis,Low Dose Budesonide (DRUG); High Dose Budesonide (DRUG); Placebo (DRUG),5281004,Noex,Ulcerative Colitis,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11666,NCT02197975,"Randomized, Crossover Safety and Pharmacokinetics Study of PT010",COMPLETED,PHASE1,COPD,PT010 Dose 1 (DRUG); PT010 Dose 2 (DRUG); Placebo MDI (DRUG),5281004,Noex,COPD,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11667,NCT03521063,Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia.,UNKNOWN,PHASE4,"Bronchopulmonary Dysplasia; Infant,Premature; Respiratory Distress Syndrome",Budesonide (DRUG); Poractant Alfa (DRUG); Saline (DRUG),5281004,Noex,"Bronchopulmonary Dysplasia; Infant,Premature; Respiratory Distress Syndrome",Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11668,NCT01738035,The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease,COMPLETED,PHASE2,Primary IgA Nephropathy,NEFECON (DRUG); Placebo (OTHER),5281004,Noex,Primary IgA Nephropathy,Kidney,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11669,NCT02157935,Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease,COMPLETED,PHASE3,COPD Patients,Symbicort (DRUG); Formoterol turbohaler (DRUG); Placebo for Symbicort pMDI (OTHER); Placebo for Formoterol Turbohaler (OTHER),5281004,Noex,COPD Patients,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11670,NCT00672763,Adjuvant Vitamin D With Corticosteroids in Active Crohn's Disease,WITHDRAWN,PHASE4,Crohn's Disease,Colecalciferol D3 (Vigantol Oil) (DRUG); Medium chain triglycerides (DRUG),5281004,Noex,Crohn's Disease,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11671,NCT02062463,Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma,COMPLETED,PHASE3,Asthma,Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX (DRUG); SYMBICORT TURBOHALER budesonide and formoterol fumarate (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11672,NCT03924635,"An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients",COMPLETED,PHASE4,Airway Inflammation; Asthma,SYMBICORT and salbutamol (COMBINATION_PRODUCT),5281004,Noex,Airway Inflammation; Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11673,NCT05970263,IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US,WITHDRAWN,PHASE4,COPD,"Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily. (DRUG); External Comparator (OTHER)",5281004,Noex,COPD,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11674,NCT04032834,A Comparison of VR647 and Conventionally Nebulized Budesonide in Healthy Volunteers and Adult Asthma Subjects,COMPLETED,PHASE1,Asthma,VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece (COMBINATION_PRODUCT); VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask (COMBINATION_PRODUCT); 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece (COMBINATION_PRODUCT); 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask (COMBINATION_PRODUCT); 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece (COMBINATION_PRODUCT); 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask (COMBINATION_PRODUCT),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11675,NCT00300118,Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD),COMPLETED,PHASE3,Crohn's Disease,budesonide (DRUG); mesalazine (DRUG),5281004,Noex,Crohn's Disease,Bowel,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11676,NCT01225913,Mechanism(s) of Airflow Limitation During Exacerbation of Asthma,RECRUITING,PHASE4,Asthma,fluticasone/salmeterol in all asthmatics (DRUG); budesonide/formoterol or fluticasone/salmeterol in all asthmatics (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11677,NCT00536913,"Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma",COMPLETED,PHASE3,Asthma,Budesonide/formoterol pMDI 40/2.25ug + spacer (DRUG); Budesonide/formoterol pMDI 40/2.25 ug (DRUG),5281004,Noex,Asthma,Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11678,NCT01415518,Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients,COMPLETED,PHASE4,Chronic Obstructive Pulmonary Disease (COPD),Drug: Budesonide/formoterol (Symbicort Turbuhaler (DRUG); Drug: ipratropium (AtroventTM) (DRUG); theophylline SR (DRUG),5281004,Noex,Chronic Obstructive Pulmonary Disease (COPD),Lung,Budesonide,NR3C1,activator/agonist,Glucocorticoid receptor agonist,yes,yes,"Used for asthma, Crohn's disease, ulcerative colitis.",CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,1.03,250.0 +11679,NCT05168163,"Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer",RECRUITING,PHASE2,Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Unresectable Hepatocellular Carcinoma,Atezolizumab (BIOLOGICAL); Cabozantinib (DRUG); Lenvatinib (DRUG),3610,Oxana,Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Unresectable Hepatocellular Carcinoma,Liver,Hexylresorcinol,,inhibitor/antagonist,unclear,yes,yes,Used in throat lozenges and skin creams for antiseptic purposes.,CCCCCCC1=C(C=C(C=C1)O)O,1.5555555555555556,148.0 +11680,NCT03890120,Study of Cilofexor in Adults With Primary Sclerosing Cholangitis,TERMINATED,PHASE3,Primary Sclerosing Cholangitis,Cilofexor (DRUG); Placebo (DRUG),445639,Ole,Primary Sclerosing Cholangitis,Liver,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11681,NCT05032066,"A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis",TERMINATED,PHASE2,Idiopathic Pulmonary Fibrosis,HZN-825 (DRUG); Placebo (DRUG),445639,Ole,Idiopathic Pulmonary Fibrosis,Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11682,NCT03443973,Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD),TERMINATED,PHASE3,Alzheimer Disease,Gantenerumab (DRUG); Placebo (DRUG),445639,Ole,Alzheimer Disease,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11683,NCT05006573,Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis,TERMINATED,PHASE3,Non-cystic Fibrosis Bronchiectasis,Benralizumab (BIOLOGICAL); Placebo to Benralizumab (BIOLOGICAL),445639,Ole,Non-cystic Fibrosis Bronchiectasis,Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11684,NCT03841448,A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN),TERMINATED,PHASE2,"IgA Nephropathy (IgAN); Berger Disease; Glomerulonephritis, IgA",Placebo (DRUG); Cemdisiran (DRUG),445639,Ole,"IgA Nephropathy (IgAN); Berger Disease; Glomerulonephritis, IgA",Kidney,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11685,NCT05649748,An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH),ACTIVE_NOT_RECRUITING,PHASE2,Pulmonary Arterial Hypertension,Treprostinil Palmitil (DRUG); Placebo (DRUG),445639,Ole,Pulmonary Arterial Hypertension,Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11686,NCT06384573,DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease,RECRUITING,PHASE3,"Alzheimer's Disease; Dementia; Alzheimer's Disease, Familial",lecanemab (DRUG),445639,Ole,"Alzheimer's Disease; Dementia; Alzheimer's Disease, Familial",CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11687,NCT04524390,Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai,COMPLETED,PHASE2,Biliary Atresia,Maralixibat (DRUG); Placebo (OTHER),445639,Ole,Biliary Atresia,Liver,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11688,NCT03536884,A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis,COMPLETED,PHASE3,Chronic Plaque Psoriasis; Moderate to Severe Chronic Plaque Psoriasis,Bimekizumab (DRUG); Secukinumab (DRUG); Placebo (OTHER),445639,Ole,Chronic Plaque Psoriasis; Moderate to Severe Chronic Plaque Psoriasis,Skin,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11689,NCT02224690,A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults,COMPLETED,PHASE3,Epilepsy; Lennox-Gastaut Syndrome,GWP42003-P 20 mg/kg/day Dose (DRUG); Placebo (DRUG),445639,Ole,Epilepsy; Lennox-Gastaut Syndrome,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11690,NCT04538664,"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions",ACTIVE_NOT_RECRUITING,PHASE3,"Carcinoma, Non-Small-Cell Lung",Amivantamab (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG),445639,Ole,"Carcinoma, Non-Small-Cell Lung",Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11691,NCT01648101,Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures,TERMINATED,PHASE3,Epilepsy,Retigabine 900mg/day (DRUG); Retigabine 600mg/day (DRUG); Placebo (OTHER),445639,Ole,Epilepsy,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11692,NCT02943460,"Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis",COMPLETED,PHASE2,Primary Sclerosing Cholangitis,Cilofexor (DRUG); Placebo to match cilofexor (DRUG),445639,Ole,Primary Sclerosing Cholangitis,Liver,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11693,NCT04678882,Dupilumab in Japanese Patients With Atopic Dermatitis,COMPLETED,PHASE3,Atopic Dermatitis,Placebo (DRUG); Dupilumab SAR231893 (DRUG),445639,Ole,Atopic Dermatitis,Skin,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11694,NCT05299931,An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients with Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study,ACTIVE_NOT_RECRUITING,PHASE3,Crohn Disease,Ustekinumab (DRUG),445639,Ole,Crohn Disease,Bowel,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11695,NCT04096573,Efficacy and Safety of LC51-0255 in Subjects With Ulcerative Colitis,WITHDRAWN,PHASE2,Ulcerative Colitis,LC51-0255 (DRUG); Placebo (DRUG),445639,Ole,Ulcerative Colitis,Bowel,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11696,NCT03782792,Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis,COMPLETED,PHASE2,Generalized Pustular Psoriasis,Spesolimab (DRUG); Placebo (DRUG),445639,Ole,Generalized Pustular Psoriasis,Skin,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11697,NCT04617860,Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease,TERMINATED,PHASE1,Huntington Disease,WVE-120102 (DRUG),445639,Ole,Huntington Disease,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11698,NCT04711148,A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis,ACTIVE_NOT_RECRUITING,PHASE2,Relapsing Remitting Multiple Sclerosis,placebo (OTHER); orelabrutinib (DRUG),445639,Ole,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11699,NCT00436826,A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD),COMPLETED,PHASE2,Multiple Sclerosis,Cladribine (DRUG); Placebo (DRUG); Interferon-beta (IFN-beta) (DRUG),445639,Ole,Multiple Sclerosis,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11700,NCT00488839,IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis,COMPLETED,PHASE3,Multiple Sclerosis,IPX056 20 mg (DRUG); IPX056 40 mg (DRUG); Encapsulated Baclofen 20 mg (DRUG); Placebo Baclofen Tablet (DRUG); IPX056 10 mg (DRUG); IPX056 30 mg (DRUG); IPX056 35 mg (DRUG); Placebo IPX056 20 mg (DRUG); Placebo IPX056 40 mg (DRUG),445639,Ole,Multiple Sclerosis,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11701,NCT03551522,A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH),TERMINATED,PHASE2,NASH - Nonalcoholic Steatohepatitis,Seladelpar (DRUG); Placebos (DRUG),445639,Ole,Nonalcoholic Steatohepatitis,Liver,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11702,NCT01777139,"A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures",COMPLETED,PHASE3,Epilepsy,Retigabine IR (DRUG),445639,Ole,Epilepsy,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11703,NCT06903286,Extension Study of Participants From SPG302-ALS-001,NOT_YET_RECRUITING,PHASE2,Amyotrophic Lateral Sclerosis (ALS),SPG302 (DRUG),445639,Ole,Amyotrophic Lateral Sclerosis (ALS),CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11704,NCT03683186,A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension,ENROLLING_BY_INVITATION,PHASE3,"PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tissue Diseases; Familial Primary Pulmonary Hypertension; Vascular Diseases; Cardiovascular Diseases; Hypertension, Pulmonary; Lung Diseases; Respiratory Tract Disease",Ralinepag (DRUG),445639,Ole,"PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tissue Diseases; Familial Primary Pulmonary Hypertension; Vascular Diseases; Cardiovascular Diseases; Hypertension, Pulmonary; Lung Diseases; Respiratory Tract Disease",Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11705,NCT02615873,A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004,UNKNOWN,PHASE3,Parkinson's Disease,Accordion Pill™ Carbidopa/Levodopa (DRUG),445639,Ole,Parkinson's Disease,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11706,NCT06668727,Safety and Antiviral Activity of a Monoclonal Hepatitis B Antibody (The SAMBA Study),RECRUITING,PHASE1,Hepatitis B,HepB mAb19 (DRUG),445639,Ole,Hepatitis B,Liver,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11707,NCT06335173,A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants with Early Alzheimer's Disease (ALTITUDE-AD),ACTIVE_NOT_RECRUITING,PHASE2,Alzheimer Disease,sabirnetug (DRUG); Placebo (DRUG),445639,Ole,Alzheimer Disease,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11708,NCT02647086,"Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)",COMPLETED,PHASE1,Atopic Dermatitis,Dupilumab (DRUG); Midazolam (DRUG); Omeprazole (DRUG); Warfarin (DRUG); Caffeine (DRUG); Metoprolol (DRUG),445639,Ole,Atopic Dermatitis,Skin,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11709,NCT05649722,An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD),ACTIVE_NOT_RECRUITING,PHASE2,Pulmonary Hypertension; Interstitial Lung Disease,Treprostinil Palmitil Inhalation Powder (DRUG); Placebo (DRUG),445639,Ole,Pulmonary Hypertension; Interstitial Lung Disease,Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11710,NCT04338022,Study of Evobrutinib in Participants With RMS (evolutionRMS 1),TERMINATED,PHASE3,Relapsing Multiple Sclerosis,Evobrutinib (DRUG); Placebo (match to Teriflunomide) (DRUG); Teriflunomide (DRUG); Placebo (match to Evobrutinib) (DRUG),445639,Ole,Relapsing Multiple Sclerosis,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11711,NCT05739435,Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis,ACTIVE_NOT_RECRUITING,PHASE2,Plaque Psoriasis,ESK-001 (DRUG),445639,Ole,Plaque Psoriasis,Skin,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11712,NCT04578548,A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD),TERMINATED,PHASE2,Autosomal Dominant Polycystic Kidney Disease,GLPG2737 (DRUG); Placebo (DRUG),445639,Ole,Autosomal Dominant Polycystic Kidney Disease,Kidney,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11713,NCT02607891,A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy,COMPLETED,PHASE2,Epilepsy,GWP42003-P (DRUG); Placebo (DRUG),445639,Ole,Epilepsy,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11714,NCT05097989,Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN),TERMINATED,PHASE2,Lupus Nephritis; Immunoglobulin A Nephropathy; IgAN; LN,ALXN2050 (DRUG); Placebo (DRUG),445639,Ole,Lupus Nephritis; Immunoglobulin A Nephropathy; IgAN; LN,Kidney,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11715,NCT03796962,A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy,ACTIVE_NOT_RECRUITING,PHASE2,Focal Epilepsy,XEN1101 (DRUG),445639,Ole,Focal Epilepsy,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11716,NCT02224560,Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults,COMPLETED,PHASE3,Epilepsy; Lennox Gastaut Syndrome,GWP42003-P (DRUG); Placebo control (DRUG),445639,Ole,Epilepsy; Lennox Gastaut Syndrome,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11717,NCT03341962,Phase 2 Dose-finding IMU-838 for Ulcerative Colitis,TERMINATED,PHASE2,Ulcerative Colitis,IMU-838 (DRUG); Placebo (DRUG),445639,Ole,Ulcerative Colitis,Bowel,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11718,NCT05692180,"A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)",RECRUITING,PHASE3,Asthma,Benralizumab (DRUG); Placebo (DRUG),445639,Ole,Asthma,Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11719,NCT02782663,"A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease",ACTIVE_NOT_RECRUITING,PHASE2,Crohn's Disease (CD),ABT-494 (DRUG),445639,Ole,Crohn's Disease (CD),Bowel,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11720,NCT02544763,"A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)",COMPLETED,PHASE3,Tuberous Sclerosis Complex; Seizures,GWP42003-P (DRUG); Placebo (DRUG),445639,Ole,Tuberous Sclerosis Complex; Seizures,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11721,NCT05321524,Obeticholic Acid in Pediatric Subjects With Biliary Atresia,TERMINATED,PHASE2,Biliary Atresia,OCA 0.1mg (DRUG); OCA 1.5mg (DRUG); OCA 5mg (DRUG),445639,Ole,Biliary Atresia,Liver,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11722,NCT04718896,"A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis",COMPLETED,PHASE2,Moderate to Severe Plaque Psoriasis,bimekizumab (DRUG),445639,Ole,Moderate to Severe Plaque Psoriasis,Skin,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11723,NCT02956486,A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease,TERMINATED,PHASE3,Alzheimer's Disease,Elenbecestat (DRUG); Placebo (DRUG),445639,Ole,Alzheimer's Disease,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11724,NCT05163886,"Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis",ACTIVE_NOT_RECRUITING,PHASE2,Amyotrophic Lateral Sclerosis; ALS,LAM-002A (DRUG); Placebo (OTHER),445639,Ole,Amyotrophic Lateral Sclerosis; ALS,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11725,NCT05785624,A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease,RECRUITING,PHASE2,Idiopathic Pulmonary Fibrosis; Systemic Sclerosis With Lung Involvement,Vixarelimab (DRUG); Placebo (DRUG),445639,Ole,Idiopathic Pulmonary Fibrosis; Systemic Sclerosis With Lung Involvement,Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11726,NCT06550076,A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis,RECRUITING,PHASE3,Plaque Psoriasis,TAK-279 (DRUG),445639,Ole,Plaque Psoriasis,Skin,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11727,NCT05469360,"Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants",RECRUITING,PHASE1,Alzheimer Disease; Mild Cognitive Impairment,NIO752 (DRUG); NIO752 (DRUG); Matching placebo (DRUG); NIO752 (DRUG); NIO752 (DRUG); NIO752 (DRUG); Matching placebo (DRUG),445639,Ole,Alzheimer Disease; Mild Cognitive Impairment,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11728,NCT00368472,4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures,COMPLETED,PHASE2,Epilepsy,Perampanel (DRUG),445639,Ole,Epilepsy,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11729,NCT04162769,A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis,COMPLETED,PHASE2,Atopic Dermatitis,Etrasimod 1 mg (DRUG); Etrasimod 2 mg (DRUG); Etrasimod matching placebo (DRUG),445639,Ole,Atopic Dermatitis,Skin,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11730,NCT03955146,Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF),TERMINATED,PHASE3,Idiopathic Pulmonary Fibrosis,Pamrevlumab (DRUG); Placebo (DRUG),445639,Ole,Idiopathic Pulmonary Fibrosis,Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11731,NCT06473701,Reducing Breathlessness With Dronabinol in COPD Patients,RECRUITING,PHASE3,COPD; Breathlessness; Cannabis,Dronabinol 2.5mg Capsule (DRUG); Placebo (DRUG),445639,Ole,COPD; Breathlessness; Cannabis,Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11732,NCT00139165,Long-Term Treatment of Collagenous Colitis With Budesonide,UNKNOWN,PHASE3,Collagenous Colitis,Budesonide (DRUG); sigmoidoscopy (PROCEDURE),445639,Ole,Collagenous Colitis,Bowel,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11733,NCT05299658,An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS,ACTIVE_NOT_RECRUITING,PHASE2,Amyotrophic Lateral Sclerosis,CNMAu8 (DRUG),445639,Ole,Amyotrophic Lateral Sclerosis,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11734,NCT03488524,Open Label Extension Study of AMX0035 in Patients With ALS,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis; ALS,AMX0035 (DRUG),445639,Ole,Amyotrophic Lateral Sclerosis; ALS,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11735,NCT04951219,"A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)",RECRUITING,PHASE3,Non-Alcoholic Fatty Liver Disease,Resmetirom (DRUG),445639,Ole,Non-Alcoholic Fatty Liver Disease,Liver,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11736,NCT02326272,A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO),COMPLETED,PHASE3,Psoriasis; Plaque Psoriasis,Certolizumab Pegol (BIOLOGICAL); Placebo (OTHER),445639,Ole,Psoriasis; Plaque Psoriasis,Skin,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11737,NCT05269004,A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis,ACTIVE_NOT_RECRUITING,PHASE3,Multiple Sclerosis,Ocrelizumab (DRUG),445639,Ole,Multiple Sclerosis,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11738,NCT03605667,Study of BHV-4157 in Alzheimer's Disease,COMPLETED,PHASE2,Alzheimer Disease,troriluzole (DRUG); Placebo oral capsule (DRUG),445639,Ole,Alzheimer Disease,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11739,NCT04033367,"SAR231893-LPS15497- ""Dupilumab Effect on Sleep in AD Patients""",COMPLETED,PHASE4,Atopic Dermatitis,Dupilumab (DRUG); Placebo (DRUG),445639,Ole,Atopic Dermatitis,Skin,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11740,NCT04520412,A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease,SUSPENDED,PHASE3,Alzheimer Disease,GV-971 (DRUG); Placebo (DRUG),445639,Ole,Alzheimer Disease,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11741,NCT00730067,Sildenafil for Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension,WITHDRAWN,PHASE4,COPD; Pulmonary Hypertension,sildenafil (DRUG); placebo (DRUG),445639,Ole,COPD with Pulmonary Hypertension,Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11742,NCT04277546,Open-label Extension Study of Brazikumab in Ulcerative Colitis,TERMINATED,PHASE2,Ulcerative Colitis,Brazikumab Maintenance Dose (DRUG); Brazikumab Induction Dose (DRUG),445639,Ole,Ulcerative Colitis,Bowel,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11743,NCT05119569,A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS),ACTIVE_NOT_RECRUITING,PHASE2,Relapsing Multiple Sclerosis,Fenebrutinib (DRUG); Placebo (DRUG),445639,Ole,Relapsing Multiple Sclerosis,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11744,NCT03566667,Beta-blockers to Patients With Chronic Obstructive Pulmonary Disease,ACTIVE_NOT_RECRUITING,PHASE4,Chronic Obstructive Pulmonary Disease,Metoprolol (DRUG); Standard care (DRUG),445639,Ole,Chronic Obstructive Pulmonary Disease,Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11745,NCT05718817,An Open-label Study of XEN1101 in Epilepsy,ENROLLING_BY_INVITATION,PHASE3,Focal Epilepsy; Tonic-Clonic Seizures,XEN1101 (DRUG),445639,Ole,Focal Epilepsy; Tonic-Clonic Seizures,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11746,NCT05314517,A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis,TERMINATED,PHASE2,"Sarcoidosis, Pulmonary",Namilumab (DRUG); Placebo (DRUG),445639,Ole,Pulmonary Sarcoidosis,Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11747,NCT06832618,A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis,NOT_YET_RECRUITING,PHASE3,Atopic Dermatitis,Ruxolitinib (DRUG); Vehicle Cream (DRUG),445639,Ole,Atopic Dermatitis,Skin,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11748,NCT05439941,A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials,TERMINATED,PHASE2,Atopic Dermatitis,EDP1815 (DRUG),445639,Ole,Atopic Dermatitis,Skin,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11749,NCT02979613,Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed,COMPLETED,PHASE3,Chronic Hepatitis B,TAF (DRUG); TDF (DRUG); TAF Placebo (DRUG); TDF Placebo (DRUG),445639,Ole,Chronic Hepatitis B,Liver,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11750,NCT02755649,A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable,COMPLETED,PHASE3,Atopic Dermatitis,Dupilumab (DRUG); Matching Placebo (DRUG),445639,Ole,Atopic Dermatitis,Skin,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11751,NCT01691508,Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma,COMPLETED,PHASE3,Asthma,Mepolizumab (DRUG); Placebo (DRUG); OCS (prednisone/prednisolone) (DRUG),445639,Ole,Asthma,Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11752,NCT05357950,"A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS",ACTIVE_NOT_RECRUITING,PHASE2,Amyotrophic Lateral Sclerosis; ALS,PrimeC (DRUG); Placebo (DRUG),445639,Ole,Amyotrophic Lateral Sclerosis; ALS,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11753,NCT05028114,Tricaprilin Liquid Formulation PK Study,TERMINATED,PHASE1,Alzheimer Disease,AC-1202 (DRUG); AC-OLE-01 (DRUG); AC-OLE-02 (DRUG); AC-OLE-03 (DRUG); AC-OLE-04 (DRUG); AC-OLE-05 (DRUG); AC-OLE-06 (DRUG); AC-OLE-07 (DRUG); AC-OLE-08 (DRUG); AC-OLE-09 (DRUG); AC-OLE-010 (DRUG); AC-OLE-P (DRUG),445639,Ole,Alzheimer Disease,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11754,NCT03491150,An Open-Label Crenezumab Study in Participants With Alzheimer's Disease,TERMINATED,PHASE3,Alzheimer's Disease,Crenezumab (DRUG),445639,Ole,Alzheimer's Disease,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11755,NCT02544750,"An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)",COMPLETED,PHASE3,Tuberous Sclerosis Complex; Seizures,GWP42003-P (DRUG),445639,Ole,Tuberous Sclerosis Complex; Seizures,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11756,NCT04639310,XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy,TERMINATED,PHASE3,Epilepsy; Epilepsy in Children; Epilepsy; Seizure; Disease; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Epileptic Syndromes,XEN496 (DRUG); Placebo (DRUG),445639,Ole,Epilepsy; Epilepsy in Children; Epilepsy; Seizure; Disease; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Epileptic Syndromes,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11757,NCT05083312,Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial,COMPLETED,PHASE3,Eosinophilic Esophagitis,APT-1011 (DRUG); Placebo oral tablet (DRUG),445639,Ole,Eosinophilic Esophagitis,Esophagus/Stomach,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11758,NCT06714123,Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease,NOT_YET_RECRUITING,PHASE2,"Pulmonary Fibrosis, Interstitial Lung Disease; Idiopathic Pulmonary Fibrosis",Senicapoc (DRUG); Placebo (DRUG),445639,Ole,"Pulmonary Fibrosis, Interstitial Lung Disease; Idiopathic Pulmonary Fibrosis",Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11759,NCT04322708,A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis,COMPLETED,PHASE2,Eosinophilic Esophagitis,Placebo (OTHER); lirentelimab (AK002) (DRUG),445639,Ole,Eosinophilic Esophagitis,Esophagus/Stomach,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11760,NCT03877510,Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations,COMPLETED,PHASE3,Parkinson Disease,IPX203 (DRUG),445639,Ole,Parkinson Disease,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11761,NCT06833281,Extension Study of Participants From SPG302-ALZ-101,ENROLLING_BY_INVITATION,PHASE2,Alzheimer's Disease,SPG302 (DRUG),445639,Ole,Alzheimer's Disease,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11762,NCT06643481,A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS),RECRUITING,PHASE2,Amyotrophic Lateral Sclerosis (ALS),VHB937 (BIOLOGICAL); Placebo (OTHER),445639,Ole,Amyotrophic Lateral Sclerosis (ALS),CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11763,NCT02831608,Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis,COMPLETED,PHASE4,"Myocardial Infarction; Influenza, Human; Influenza Vaccines; Heart Failure; Stroke",Influenza vaccine (BIOLOGICAL); Placebo (BIOLOGICAL),445639,Ole,"Myocardial Infarction; Influenza, Human; Influenza Vaccines; Heart Failure; Stroke",CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11764,NCT04281108,Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2),COMPLETED,PHASE3,Eosinophilic Esophagitis,APT-1011 (DRUG); Placebo oral tablet (DRUG); Esophagogastroduodenoscopy (PROCEDURE),445639,Ole,Eosinophilic Esophagitis,Esophagus/Stomach,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11765,NCT03267108,A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension,TERMINATED,PHASE3,Pulmonary Fibrosis; Pulmonary Hypertension,INOpulse® (COMBINATION_PRODUCT); Placebo (COMBINATION_PRODUCT); Open Label Extension (COMBINATION_PRODUCT),445639,Ole,Pulmonary Fibrosis; Pulmonary Hypertension,Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11766,NCT06101823,Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis,ACTIVE_NOT_RECRUITING,PHASE2,Atopic Dermatitis,OpSCF (BIOLOGICAL); Placebo (BIOLOGICAL); OpSCF (Open Label Extension) (BIOLOGICAL),445639,Ole,Atopic Dermatitis,Skin,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11767,NCT03657095,A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension,TERMINATED,PHASE3,Pulmonary Arterial Hypertension,Esuberaprost (DRUG); Placebo (DRUG),445639,Ole,Pulmonary Arterial Hypertension,Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11768,NCT03762850,A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy,ACTIVE_NOT_RECRUITING,PHASE3,Immunoglobulin A Nephropathy,sparsentan (DRUG); irbesartan (DRUG); Dapagliflozin (DRUG),445639,Ole,Immunoglobulin A Nephropathy,Kidney,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11769,NCT03861143,Efficacy and Safety of Oral BT-11 in Ulcerative Colitis,COMPLETED,PHASE2,Ulcerative Colitis,BT-11 (440 mg) (DRUG); BT-11 (880 mg) (DRUG); Placebo (DRUG),445639,Ole,Ulcerative Colitis,Bowel,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11770,NCT02358538,Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies,COMPLETED,PHASE2,Epilepsy,Ganaxolone (DRUG),445639,Ole,Epilepsy,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11771,NCT04988295,A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure,ACTIVE_NOT_RECRUITING,PHASE3,"Carcinoma, Non-Small-Cell Lung",Lazertinib (DRUG); Amivantamab (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),445639,Ole,"Carcinoma, Non-Small-Cell Lung",Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11772,NCT05262023,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)",RECRUITING,PHASE1,Frontotemporal Dementia,DNL593 (DRUG); Placebo (DRUG),445639,Ole,Frontotemporal Dementia,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11773,NCT02403323,Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144,TERMINATED,PHASE3,Crohn Disease,Etrolizumab (DRUG),445639,Ole,Crohn Disease,Bowel,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11774,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",ACTIVE_NOT_RECRUITING,PHASE3,Multiple Sclerosis,Ocrelizumab (DRUG); Ocrelizumab (DRUG); Antihistamine (DRUG); Methylprednisolone (DRUG),445639,Ole,Multiple Sclerosis,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11775,NCT04544449,A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis,ACTIVE_NOT_RECRUITING,PHASE3,"Multiple Sclerosis, Primary Progressive",Fenebrutinib (DRUG); Ocrelizumab (DRUG); Placebo matched to ocrelizumab (DRUG); Placebo matched to fenebrutinib (DRUG),445639,Ole,"Multiple Sclerosis, Primary Progressive",CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11776,NCT06425549,A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis,RECRUITING,PHASE3,Moderate to Severe Plaque Psoriasis,bimekizumab (DRUG); ustekinumab (DRUG); placebo (DRUG),445639,Ole,Moderate to Severe Plaque Psoriasis,Skin,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11777,NCT05980949,Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3),RECRUITING,PHASE3,Psychosis Associated With Alzheimer's Disease,KarXT (DRUG),445639,Ole,Psychosis Associated With Alzheimer's Disease,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11778,NCT04920149,Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome,RECRUITING,PHASE2,Lynch Syndrome; Colon Cancer; Colon Neoplasm,Mesalamine (DRUG); Placebo (DRUG),445639,Ole,Lynch Syndrome; Colon Cancer; Colon Neoplasm,Bowel,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11779,NCT01224106,A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease,COMPLETED,PHASE3,Alzheimer's Disease,Gantenerumab (DRUG); Placebo (DRUG),445639,Ole,Alzheimer's Disease,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11780,NCT03444870,Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD),TERMINATED,PHASE3,Alzheimer Disease,Gantenerumab (DRUG); Placebo (DRUG),445639,Ole,Alzheimer Disease,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11781,NCT00236106,Short Term Growth in Children With Atopic Dermatitis,COMPLETED,PHASE4,Atopic Dermatitis,tacrolimus ointment 0.1% (DRUG); mometasone furoate 0.1% (DRUG),445639,Ole,Atopic Dermatitis,Skin,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11782,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",ACTIVE_NOT_RECRUITING,PHASE3,Multiple Sclerosis,Ocrelizumab (DRUG); Ocrelizumab (DRUG); Antihistamine (DRUG); Methylprednisolone (DRUG),445639,Ole,Multiple Sclerosis,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11783,NCT03395184,Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease,COMPLETED,PHASE2,Crohn's Disease,PF-06651600 Placebo (DRUG); PF-06651600 (DRUG); Placebo PF-06700841 (DRUG); PF-06700841 (DRUG),445639,Ole,Crohn's Disease,Bowel,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11784,NCT00451984,Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2,UNKNOWN,PHASE3,HIV Infections; Hepatitis A; Hepatitis B,Twinrix (BIOLOGICAL); interleukin-2 (BIOLOGICAL),445639,Ole,HIV Infections; Hepatitis A; Hepatitis B,Liver,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11785,NCT01691521,Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma,COMPLETED,PHASE3,Asthma,Mepolizumab IV (DRUG); Mepolizumab SC (DRUG); IV Placebo (DRUG); SC Placebo (DRUG),445639,Ole,Asthma,Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11786,NCT04835402,Electroporation Potentiated Immunotherapy in Cancer,ACTIVE_NOT_RECRUITING,PHASE2,"Pancreas Cancer, Metastatic",Pembrolizumab (DRUG); Irreversible electroporation (DEVICE),445639,Ole,"Pancreas Cancer, Metastatic",Pancreas,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11787,NCT00380484,Short- and Long Term Growth in Children With Asthma,COMPLETED,PHASE4,Asthma,Budesonide (DRUG); Montelukast (DRUG),445639,Ole,Asthma,Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11788,NCT04759664,LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC,RECRUITING,PHASE2,EGFRI Induced Acneiform Lesions,LUT014 Gel (Dose 1) (DRUG); LUT014 Gel (Dose 2) (DRUG); Placebo (DRUG),445639,Ole,EGFRI Induced Acneiform Lesions,Skin,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11789,NCT01336621,Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS),COMPLETED,PHASE3,Epilepsy,Retigabine IR (DRUG),445639,Ole,Epilepsy,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11790,NCT02118584,Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies,TERMINATED,PHASE3,Ulcerative Colitis,Etrolizumab (DRUG),445639,Ole,Ulcerative Colitis,Bowel,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11791,NCT04541043,Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE),COMPLETED,PHASE3,Primary IgA Nephropathy,Nefecon 16mg daily (DRUG),445639,Ole,Primary IgA Nephropathy,Kidney,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11792,NCT02565108,A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol,COMPLETED,PHASE2,Epilepsy,GWP42003-P 20 mg/kg/Day Dose (DRUG); Placebo (DRUG); Clobazam (DRUG),445639,Ole,Epilepsy,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11793,NCT02051608,A Study of Gantenerumab in Participants With Mild Alzheimer Disease,COMPLETED,PHASE3,Alzheimer's Disease,Placebo (DRUG); Gantenerumab (DRUG),445639,Ole,Alzheimer's Disease,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11794,NCT02503657,Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF),COMPLETED,PHASE2,Idiopathic Pulmonary Fibrosis; IPF,tipelukast (DRUG); Placebo (DRUG),445639,Ole,Idiopathic Pulmonary Fibrosis; IPF,Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11795,NCT03320070,Acthar Gel in Participants With Pulmonary Sarcoidosis,COMPLETED,PHASE4,"Sarcoidosis, Pulmonary",Acthar Gel (DRUG); Placebo (DRUG),445639,Ole,Pulmonary Sarcoidosis,Lung,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11796,NCT02091375,Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1),COMPLETED,PHASE3,Epilepsy; Dravet Syndrome,GWP42003-P 20 mg/kg/day Dose (DRUG); Placebo control (DRUG),445639,Ole,Epilepsy; Dravet Syndrome,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11797,NCT05569759,A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA),ACTIVE_NOT_RECRUITING,PHASE2,Autoimmune Hepatitis,zetomipzomib (DRUG); placebo (DRUG); zetomipzomib in open-label extension (DRUG),445639,Ole,Autoimmune Hepatitis,Liver,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11798,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,COMPLETED,PHASE3,"Multiple Sclerosis, Primary Progressive",Ocrelizumab (DRUG); Placebo (OTHER),445639,Ole,"Multiple Sclerosis, Primary Progressive",CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11799,NCT05177835,Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis,ACTIVE_NOT_RECRUITING,PHASE2,Ulcerative Colitis,ABX464 (DRUG),445639,Ole,Ulcerative Colitis,Bowel,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11800,NCT01461317,Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis,COMPLETED,PHASE2,Ulcerative Colitis,Etrolizumab (DRUG),445639,Ole,Ulcerative Colitis,Bowel,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11801,NCT04314934,OLE of Phase 2b/3 Study ANAVEX2-73-AD-004,COMPLETED,PHASE2,Alzheimer Disease,ANAVEX2-73 (DRUG),445639,Ole,Alzheimer Disease,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11802,NCT04339413,A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD),TERMINATED,PHASE3,Alzheimer Disease,Gantenerumab (DRUG),445639,Ole,Alzheimer Disease,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11803,NCT05668013,A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease,ACTIVE_NOT_RECRUITING,PHASE2,"Crohn Disease; Colitis, Ulcerative",TEV-48574 Dose Regimen A (DRUG); TEV-48574 Dose Regiment B (DRUG),445639,Ole,"Crohn Disease; Colitis, Ulcerative",Bowel,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11804,NCT04435600,A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms,COMPLETED,PHASE3,Psoriasis,Risankizumab (DRUG); Ustekinumab (DRUG),445639,Ole,Psoriasis,Skin,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11805,NCT06425159,A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures,RECRUITING,PHASE2,Generalized Epilepsy,BHV-7000 (DRUG); Placebo (DRUG),445639,Ole,Generalized Epilepsy,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11806,NCT00310375,Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial,COMPLETED,PHASE3,Epilepsy,Ezogabine: USAN Retigabine (International Nonproprietary Name) (DRUG),445639,Ole,Epilepsy,CNS/Brain,Oleic acid,,activator/agonist,unclear,yes,yes,"Used in food, cosmetics, and as an excipient in pharmaceuticals.",CCCCCCCCC=CCCCCCCCC(=O)O,1.5357142857142858,176.0 +11807,NCT01786174,Gilenya in Amyotrophic Lateral Sclerosis (ALS),COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis,Gilenya (DRUG); Placebo (OTHER),107969,Gilenia,Amyotrophic Lateral Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11808,NCT01310166,Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,COMPLETED,PHASE4,Relapsing-remitting Multiple Sclerosis,Fingolimod (DRUG),107969,Gilenia,Relapsing-remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11809,NCT02002390,Efficacy and Safety of FTY720 for Acute Stroke,COMPLETED,PHASE2,"Stroke; Vascular Accident; Cerebral Stroke; Ischemic Cerebrovascular Accident; Stroke, Acute",Fingolimod (DRUG),107969,Gilenia,"Stroke; Vascular Accident; Cerebral Stroke; Ischemic Cerebrovascular Accident; Stroke, Acute",CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11810,NCT01709812,Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS,WITHDRAWN,PHASE4,Relapsing-remitting Multiple Sclerosis,individualized patient support program (OTHER); Standard care (OTHER),107969,Gilenia,Relapsing-remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11811,NCT00099801,Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant,COMPLETED,PHASE3,Kidney Transplantation,FTY720 (DRUG),107969,Gilenia,Kidney Transplantation,Kidney,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11812,NCT00239876,Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients,COMPLETED,PHASE3,Renal Transplantation,FTY720 (DRUG),107969,Gilenia,Renal Transplantation,Kidney,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11813,NCT01534182,Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC),COMPLETED,PHASE4,Relapsing Remitting Multiple Sclerosis,Fingolimod (DRUG); Interferon beta - 1a (IFN) (DRUG); Glatiramer acetate (GA) (DRUG),107969,Gilenia,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11814,NCT00537082,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS),COMPLETED,PHASE2,Multiple Sclerosis,FTY720 (DRUG); Placebo (DRUG),107969,Gilenia,Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11815,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",TERMINATED,PHASE3,Primary Progressive Multiple Sclerosis,FTY720 (DRUG); Placebo (DRUG),107969,Gilenia,Primary Progressive Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11816,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab,COMPLETED,PHASE3,Relapsing Multiple Sclerosis,Ofatumumab (BIOLOGICAL),107969,Gilenia,Relapsing Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11817,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,TERMINATED,PHASE3,Relapsing Remitting Multiple Sclerosis (RRMS),Fingolimod (DRUG); Placebo (DRUG),107969,Gilenia,Relapsing Remitting Multiple Sclerosis (RRMS),CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11818,NCT06087965,Fingolimod in Minimal Invasive Treatment of Intracerebral Hemorrhage,NOT_YET_RECRUITING,PHASE1,Intracerebral Hemorrhage,Fingolimod (DRUG),107969,Gilenia,Intracerebral Hemorrhage,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11819,NCT02490930,A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma,COMPLETED,EARLY_PHASE1,Glioblastoma; Anaplastic Astrocytoma,Fingolimod (DRUG),107969,Gilenia,Glioblastoma; Anaplastic Astrocytoma,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11820,NCT01578330,"A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720",COMPLETED,PHASE4,Multiple Sclerosis; Relapsing-Remitting,Fingolimod (DRUG),107969,Gilenia,Multiple Sclerosis; Relapsing-Remitting,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11821,NCT03257358,A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod,COMPLETED,PHASE4,Relapsing Multiple Sclerosis,Fingolimod (DRUG),107969,Gilenia,Relapsing Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11822,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,ACTIVE_NOT_RECRUITING,PHASE3,Multiple Sclerosis,Interferon beta-1a (DRUG); Fingolimod (DRUG); Placebo capsule (DRUG); Placebo i.m. injection (DRUG),107969,Gilenia,Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11823,NCT04675762,Combinating Fingolimod With Alteplase Bridging With Thrombectomy in Acute Ischemic Stroke,RECRUITING,PHASE2,Stroke; Inflammation,Fingolimod (DRUG); Placebo (OTHER),107969,Gilenia,Stroke; Inflammation,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11824,NCT01647880,MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study),TERMINATED,PHASE2,Multiple Sclerosis,Verum arm receiving Gilenya® (DRUG); Active Comparator receiving Extavia® (DRUG),107969,Gilenia,Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11825,NCT02769689,Methylprednisolone During the Switch Between Natalizumab and Fingolimod,UNKNOWN,PHASE4,Multiple Sclerosis,Methylprednisolone (DRUG); Placebo (DRUG); natalizumab (NTZ) (DRUG); fingolimob (FTY) (DRUG),107969,Gilenia,Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11826,NCT01757691,Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON),TERMINATED,PHASE2,Acute Demylelinating Optic Neuritis,Fingolimod 0.5mg/daily (DRUG); Placebo (DRUG),107969,Gilenia,Acute Demylelinating Optic Neuritis,Peripheral Nervous System,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11827,NCT01497262,Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,COMPLETED,PHASE3,Multiple Sclerosis,Fingolimod (DRUG),107969,Gilenia,Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11828,NCT00239863,"Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplant Recipients",COMPLETED,PHASE3,Renal Transplantation,FTY720 (DRUG),107969,Gilenia,Renal Transplantation,Kidney,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11829,NCT01623596,Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.,COMPLETED,PHASE4,Relapsing Remitting Multiple Sclerosis,Fingolimod (DRUG); Disease Modifying therapy (DRUG),107969,Gilenia,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11830,NCT01216072,"A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis",COMPLETED,PHASE4,Relapsing Forms of Multiple Sclerosis,Fingolimod (DRUG); Standard MS DMTs (DRUG),107969,Gilenia,Relapsing Forms of Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11831,NCT01333501,Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms,COMPLETED,PHASE4,Multiple Sclerosis,Fingolimod (DRUG); Interferon beta 1b (DRUG),107969,Gilenia,Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11832,NCT01317004,Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change,COMPLETED,PHASE4,Relapsing Remitting Multiple Sclerosis,Fingolimod (DRUG); Standard MS DMT (DRUG),107969,Gilenia,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11833,NCT04629872,Fingolimod in Endovascular Treatment of Ischemic Stroke,UNKNOWN,PHASE2,Stroke Inflammation,Fingolimod (DRUG),107969,Gilenia,Stroke Inflammation,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11834,NCT01490840,Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis,TERMINATED,PHASE4,Fatigue in Multiple Sclerosis,Physical exercise (OTHER),107969,Gilenia,Fatigue in Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11835,NCT01621269,ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon,WITHDRAWN,PHASE4,Multiple Sclerosis,Fingolimod (DRUG),107969,Gilenia,Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11836,NCT01633112,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,TERMINATED,PHASE3,Relapsing-remitting Multiple Sclerosis (RRMS),fingolimod (DRUG); glatiramer acetate (DRUG),107969,Gilenia,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11837,NCT01941004,Safety and Efficacy of Fingolimod in MS Patients in China,WITHDRAWN,PHASE3,Multiple Sclerosis (Relapsing Remitting),fingolimod (DRUG); Placebo (6mos) + open label fingolimod (6 mos) (DRUG),107969,Gilenia,Multiple Sclerosis (Relapsing Remitting),CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11838,NCT06424067,Phase 2 Study of Fingolimod in Lung Cancers,NOT_YET_RECRUITING,PHASE2,Non Small Cell Lung Cancer; Small-cell Lung Cancer,Fingolimod 0.5 milligram (mg) [Gilenya] (DRUG),107969,Gilenia,Non Small Cell Lung Cancer; Small-cell Lung Cancer,Lung,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11839,NCT03345940,Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis,TERMINATED,PHASE4,Relapsing Remitting Multiple Sclerosis,Fingolimod (DRUG); Dimethyl Fumarate (DRUG),107969,Gilenia,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11840,NCT02048072,Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS,COMPLETED,PHASE4,Multiple Sclerosis; Autonomic Nervous System Dysfunction,Gilenya (DRUG),107969,Gilenia,Multiple Sclerosis; Autonomic Nervous System Dysfunction,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11841,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,TERMINATED,PHASE4,Relapsing-Remitting Multiple Sclerosis,natalizumab (DRUG); fingolimod (DRUG),107969,Gilenia,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11842,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,COMPLETED,PHASE4,Multiple Sclerosis,Several diagnostic procedures (PROCEDURE),107969,Gilenia,Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11843,NCT02325440,Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya,UNKNOWN,PHASE4,Relapsing Remitting Multiple Sclerosis,Fingolimod (DRUG); Natalizumab (DRUG),107969,Gilenia,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11844,NCT00355134,Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,COMPLETED,PHASE3,Multiple Sclerosis,Fingolimod (DRUG); Placebo (DRUG),107969,Gilenia,Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11845,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,COMPLETED,PHASE3,Multiple Sclerosis,Fingolimod 1.25 mg (DRUG); Fingolimod 0.5 mg (DRUG); Interferon β-1a 30 µg (DRUG),107969,Gilenia,Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11846,NCT02193217,A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303,COMPLETED,PHASE1,Relapsing-remitting Multiple Sclerosis,MT-1303-Low (DRUG); MT-1303-High (DRUG); Fingolimod (DRUG); Placebo (DRUG),107969,Gilenia,Relapsing-remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11847,NCT00731523,Pharmacokinetics (PK) and Metabolism of FTY720 in Patients With Severe Renal Impairment and Healthy Matched Subjects.,COMPLETED,PHASE1,Renal Insufficiency,fingolimod (FTY720) (DRUG),107969,Gilenia,Renal Insufficiency,Kidney,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11848,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,COMPLETED,PHASE3,Relapsing Multiple Sclerosis,FTY720 (DRUG),107969,Gilenia,Relapsing Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11849,NCT01420055,Fingolimod -Response According to Coping - Evaluation,COMPLETED,PHASE4,"Multiple Sclerosis, Relapsing-Remitting",fingolimod (DRUG),107969,Gilenia,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11850,NCT03623243,"Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients",COMPLETED,PHASE3,Multiple Sclerosis; Relapsing Multiple Sclerosis; Advancing Multiple Sclerosis,Siponimod (DRUG),107969,Gilenia,Multiple Sclerosis; Relapsing Multiple Sclerosis; Advancing Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11851,NCT00333138,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis,COMPLETED,PHASE2,Multiple Sclerosis,FTY720 (DRUG); Placebo (DRUG),107969,Gilenia,Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11852,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,COMPLETED,PHASE4,"Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis",Assessments arm (OTHER),107969,Gilenia,"Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis",CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11853,NCT03941743,Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer,COMPLETED,PHASE1,Breast Carcinoma,Fingolimod (DRUG); Fingolimod Hydrochloride (DRUG); Questionnaire Administration (OTHER),107969,Gilenia,Breast Carcinoma,Breast,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11854,NCT04667949,Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients,COMPLETED,PHASE4,Relapsing Multiple Sclerosis (RMS),Fingolimod 0.5mg (DRUG),107969,Gilenia,Relapsing Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11855,NCT00099736,Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant,COMPLETED,PHASE3,Kidney Transplantation,FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids (DRUG); FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids (DRUG); MMF 2 g + full-dose Neoral (FDN) + corticosteroids (DRUG),107969,Gilenia,Kidney Transplantation,Kidney,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11856,NCT00670449,An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis,COMPLETED,PHASE2,Multiple Sclerosis,Fingolimod (DRUG),107969,Gilenia,Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11857,NCT00099749,Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant,COMPLETED,PHASE2,Kidney Transplantation,FTY 720 (DRUG),107969,Gilenia,Kidney Transplantation,Kidney,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11858,NCT01705236,A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®,COMPLETED,PHASE4,Relapsing Remitting Multiple Sclerosis RRMS,Fingolimod (DRUG),107969,Gilenia,Relapsing Remitting Multiple Sclerosis RRMS,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11859,NCT00273364,Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study,COMPLETED,PHASE2,Multiple Sclerosis,Hematopoietic Stem Cell Therapy (PROCEDURE); Standard treatment with a conventional drug (DRUG),107969,Gilenia,Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11860,NCT00239902,Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients,COMPLETED,PHASE2,Renal Transplantation,FTY720 (DRUG),107969,Gilenia,Renal Transplantation,Kidney,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11861,NCT05123703,A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS),ACTIVE_NOT_RECRUITING,PHASE3,Relapsing-Remitting Multiple Sclerosis,Ocrelizumab (DRUG); Ocrelizumab Placebo (OTHER); Fingolimod (DRUG); Fingolimod Placebo (OTHER),107969,Gilenia,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11862,NCT01436643,Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression,TERMINATED,PHASE4,Depression; Relapsing-remitting Multiple Sclerosis,Venlafaxine (DRUG); Fluoxetine (DRUG); Citalopram (DRUG); Fingolimod (DRUG),107969,Gilenia,Depression; Relapsing-remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11863,NCT02939079,Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients,COMPLETED,PHASE2,Multiple Sclerosis,Fingolimod (DRUG); Fish Oil (DIETARY_SUPPLEMENT); Placebo (for Fish Oil) (DRUG),107969,Gilenia,Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11864,NCT04088630,Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage,COMPLETED,EARLY_PHASE1,"Intracerebral Hemorrhage; Cerebral Edema; Stroke Hemorrhagic; Intracerebral Hemorrhage, Hypertensive; Intracerebral Hemorrhage Intraparenchymal",Fingolimod (DRUG); Placebo (DRUG); Open-label Fingolimod (DRUG),107969,Gilenia,"Intracerebral Hemorrhage; Cerebral Edema; Stroke Hemorrhagic; Intracerebral Hemorrhage, Hypertensive; Intracerebral Hemorrhage Intraparenchymal",CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11865,NCT06408259,Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis,RECRUITING,PHASE3,"Multiple Sclerosis, Relapsing-Remitting",Ozanimod (DRUG); Fingolimod (DRUG); Placebo (OTHER),107969,Gilenia,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11866,NCT00098735,Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation,COMPLETED,PHASE3,Kidney Transplantation,FTY720 (DRUG),107969,Gilenia,Kidney Transplantation,Kidney,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11867,NCT04926818,Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis,ACTIVE_NOT_RECRUITING,PHASE3,Multiple Sclerosis (MS),Fingolimod (DRUG); Ofatumumab (DRUG); Siponimod (DRUG); Fingolimod placebo (OTHER); Siponimod placebo (OTHER); Ofatumumab placebo (OTHER),107969,Gilenia,Multiple Sclerosis (MS),CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11868,NCT01498887,Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy,COMPLETED,PHASE4,Relapsing Remitting Multiple Sclerosis,Fingolimod (FTY720) (DRUG),107969,Gilenia,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11869,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,COMPLETED,PHASE3,Relapsing Forms of Multiple Sclerosis,Fingolimod (DRUG),107969,Gilenia,Relapsing Forms of Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11870,NCT02956200,Combinating Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic Stroke,WITHDRAWN,PHASE2,Stroke; Inflammation,Fingolimod (DRUG),107969,Gilenia,Stroke; Inflammation,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11871,NCT02241785,Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies,TERMINATED,PHASE4,Relapsing Multiple Sclerosis,natalizumab (DRUG),107969,Gilenia,Relapsing Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11872,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,COMPLETED,PHASE3,Multiple Sclerosis,Fingolimod 0.5 mg (DRUG); Fingolimod 1.25 mg (DRUG),107969,Gilenia,Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11873,NCT04480853,Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis,RECRUITING,PHASE4,Multiple Sclerosis,Fingolimod (DRUG),107969,Gilenia,Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11874,NCT00239785,Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients,COMPLETED,PHASE3,Renal Transplantation,FTY720 (DRUG),107969,Gilenia,Renal Transplantation,Kidney,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11875,NCT02720107,Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01),COMPLETED,PHASE4,Relapsing-remitting Multiple Sclerosis,fingolimod (DRUG),107969,Gilenia,Relapsing-remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11876,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,COMPLETED,PHASE3,Relapsing-remitting Multiple Sclerosis,Fingolimod 1.25 mg (DRUG); Fingolimod 0.5 mg (DRUG); Placebo (DRUG),107969,Gilenia,Relapsing-remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11877,NCT05285878,Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation,ENROLLING_BY_INVITATION,PHASE2,"Interstitial Fibrosis; Kidney Transplant; Complications; Kidney Transplant Rejection; Kidney Transplant Failure and Rejection; Kidney Transplant Failure; Kidney Failure, Chronic; Graft Rejection",Fingolimod (DRUG); Placebo (DRUG),107969,Gilenia,"Interstitial Fibrosis; Kidney Transplant; Complications; Kidney Transplant Rejection; Kidney Transplant Failure and Rejection; Kidney Transplant Failure; Kidney Failure, Chronic; Graft Rejection",Kidney,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11878,NCT02232061,"Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks",COMPLETED,PHASE4,Multiple Sclerosis,Fingolimod (DRUG),107969,Gilenia,Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11879,NCT00239811,Long Term Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients,COMPLETED,PHASE3,Renal Transplantation,FTY720 (DRUG),107969,Gilenia,Renal Transplantation,Kidney,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11880,NCT00785083,A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma,COMPLETED,PHASE2,Asthma,FTY720 (DRUG); Placebo (DRUG),107969,Gilenia,Asthma,Lung,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11881,NCT01199861,Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS),COMPLETED,PHASE3,Relapsing Multiple Sclerosis,Fingolimod (DRUG); Placebo (DRUG); Seasonal influenza vaccine (BIOLOGICAL); Tetanus toxoid vaccine (BIOLOGICAL),107969,Gilenia,Relapsing Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11882,NCT01585298,STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START),COMPLETED,PHASE4,Multiple Sclerosis,FTY720 (DRUG),107969,Gilenia,Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11883,NCT01755871,Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis,TERMINATED,PHASE4,Relapsing Remitting Multiple Sclerosis,Fingolimod (DRUG),107969,Gilenia,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11884,NCT03535298,Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS,ACTIVE_NOT_RECRUITING,PHASE4,"Multiple Sclerosis, Relapsing-Remitting",Early Highly Effective Therapies Group (DRUG); Escalation Therapies Group (DRUG),107969,Gilenia,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11885,NCT02373098,Fingolimod Effect on Cytokine and Chemokine Levels,COMPLETED,PHASE4,Relapsing Remitting Multiple Sclerosis,Fingolimod 0.5 mg (DRUG),107969,Gilenia,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11886,NCT00239798,Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients,COMPLETED,PHASE2,Renal Transplantation,FTY720 (DRUG),107969,Gilenia,Renal Transplantation,Kidney,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11887,NCT03943498,Fingolimod in Treating Patients With Chemotherapy-Induced Neuropathy,COMPLETED,EARLY_PHASE1,Chemotherapy-Induced Peripheral Neuropathy; Numbness; Pain; Tingling,Fingolimod (DRUG); Fingolimod Hydrochloride (DRUG); Questionnaire Administration (OTHER),107969,Gilenia,Chemotherapy-Induced Peripheral Neuropathy; Numbness; Pain; Tingling,Peripheral Nervous System,Fingolimod (hydrochloride),PAK1,unclear,unclear,yes,yes,Approved for multiple sclerosis treatment.,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,1.02,684.0 +11888,NCT00538694,Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia,COMPLETED,PHASE3,"Pneumonia, Bacterial",daptomycin (DRUG),21585658,Dapcin,Bacterial Pneumonia,Lung,Daptomycin,,unclear,unclear,yes,yes,Approved as an antibiotic for skin infections.,CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C,1.08,369.0 +11889,NCT00540072,Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae,COMPLETED,PHASE3,"Pneumonia, Bacterial",daptomycin (DRUG),21585658,Dapcin,Bacterial Pneumonia,Lung,Daptomycin,,unclear,unclear,yes,yes,Approved as an antibiotic for skin infections.,CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C,1.08,369.0 +11890,NCT00882557,Study to Evaluate Daptomycin Given During Dialysis and After Dialysis,COMPLETED,PHASE1,End-stage Renal Disease; Renal Failure Chronic Requiring Hemodialysis,daptomycin (DRUG); daptomycin (DRUG),21585658,Dapcin,End-stage Renal Disease; Renal Failure Chronic Requiring Hemodialysis,Kidney,Daptomycin,,unclear,unclear,yes,yes,Approved as an antibiotic for skin infections.,CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C,1.08,369.0 +11891,NCT01104662,Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment,TERMINATED,PHASE4,Complicated Skin and Skin Structure Infections; S. Aureus Bacteremia; Renal Impairment,Vancomycin (DRUG); Daptomycin (DRUG); Semi-Synthetic Penicillin (DRUG),21585658,Dapcin,Complicated Skin and Skin Structure Infections; S. Aureus Bacteremia; Renal Impairment,Kidney,Daptomycin,,unclear,unclear,yes,yes,Approved as an antibiotic for skin infections.,CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C,1.08,369.0 +11892,NCT01734694,Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients,TERMINATED,PHASE4,Health Care Associated Pneumonia; Osteomyelitis/Septic Arthritis; Endocarditis; Bacteremia; Acute Bacterial Skin and Skin Structure Infections,Vancomycin (DRUG); Ceftaroline (DRUG); Daptomycin (DRUG); Linezolid (DRUG),21585658,Dapcin,Health Care Associated Pneumonia; Osteomyelitis/Septic Arthritis; Endocarditis; Bacteremia; Acute Bacterial Skin and Skin Structure Infections,Lung,Daptomycin,,unclear,unclear,yes,yes,Approved as an antibiotic for skin infections.,CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C,1.08,369.0 +11893,NCT01455246,Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis,TERMINATED,PHASE2,Cirrhosis; Ascites; Nosocomial Spontaneous Bacterial Peritonitis,Daptomycin + Meropenem (DRUG); Ceftazidime (DRUG),21585658,Dapcin,Cirrhosis; Ascites; Nosocomial Spontaneous Bacterial Peritonitis,Liver,Daptomycin,,unclear,unclear,yes,yes,Approved as an antibiotic for skin infections.,CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C,1.08,369.0 +11894,NCT05599295,Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin,RECRUITING,PHASE2,Acute Bacterial Skin and Skin Structure Infection,Oritavancin (DRUG),21585658,Dapcin,Acute Bacterial Skin and Skin Structure Infection,Skin,Daptomycin,,unclear,unclear,yes,yes,Approved as an antibiotic for skin infections.,CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C,1.08,369.0 +11895,NCT02142075,"Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure",COMPLETED,PHASE3,Renal Failure; Critical Care; Gram Positive Bacteria,Daptomycin (DRUG),21585658,Dapcin,Renal Failure; Critical Care; Gram Positive Bacteria,Kidney,Daptomycin,,unclear,unclear,yes,yes,Approved as an antibiotic for skin infections.,CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C,1.08,369.0 +11896,NCT00490737,Safety Study to Evaluate Daptomycin in Non-infected Adults Who Are Either on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis (MK-3009-021),COMPLETED,PHASE1,End-Stage Renal Disease,daptomycin (DRUG),21585658,Dapcin,End-Stage Renal Disease,Kidney,Daptomycin,,unclear,unclear,yes,yes,Approved as an antibiotic for skin infections.,CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C,1.08,369.0 +11897,NCT06478953,Impact of Rapid Pathogen Detection in ICU Patients With Suspected Pneumonia on Antimicrobial Therapy,RECRUITING,PHASE2,Pneumonia; Critically Ill,FA Pneumonia Panel (DIAGNOSTIC_TEST),21585658,Dapcin,Pneumonia; Critically Ill,Lung,Daptomycin,,unclear,unclear,yes,yes,Approved as an antibiotic for skin infections.,CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C,1.08,369.0 +11898,NCT00976365,Evaluation of the Safety and Efficacy of THL-P in Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,THL-P (DIETARY_SUPPLEMENT),3034010,THL,Metastatic Breast Cancer,Breast,Orlistat,,inhibitor/antagonist,unclear,yes,yes,Used to treat obesity by preventing fat absorption.,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,1.04,179.0 +11899,NCT00861380,Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease,COMPLETED,PHASE3,"Infections, Streptococcal; Streptococcus Pneumoniae",Pneumococcal conjugate vaccine GSK1024850A (BIOLOGICAL); GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine) (BIOLOGICAL); GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine) (BIOLOGICAL),3034010,THL,"Infections, Streptococcal; Streptococcus Pneumoniae",Lung,Orlistat,,inhibitor/antagonist,unclear,yes,yes,Used to treat obesity by preventing fat absorption.,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,1.04,179.0 +11900,NCT01827163,Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer,COMPLETED,PHASE2,HER2-Positive Early Stage Breast Cancer,Paclitaxel (DRUG); Trastuzumab (DRUG); Lapatinib (DRUG); Pegfilgrastim (DRUG),3034010,THL,HER2-Positive Early Stage Breast Cancer,Breast,Orlistat,,inhibitor/antagonist,unclear,yes,yes,Used to treat obesity by preventing fat absorption.,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,1.04,179.0 +11901,NCT01547689,Safety and Efficiency of Umbilical Cord-derived Mesenchymal Stem Cells(UC-MSC) in Patients With Alzheimer's Disease,UNKNOWN,PHASE1,Alzheimer's Disease,Human Umbilical Cord Derived MSC (BIOLOGICAL),3034010,THL,Alzheimer's Disease,CNS/Brain,Orlistat,,inhibitor/antagonist,unclear,yes,yes,Used to treat obesity by preventing fat absorption.,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,1.04,179.0 +11902,NCT00231140,Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS),TERMINATED,PHASE2,Amyotrophic Lateral Sclerosis (ALS),Thalidomide (drug) (DRUG),3034010,THL,Amyotrophic Lateral Sclerosis (ALS),CNS/Brain,Orlistat,,inhibitor/antagonist,unclear,yes,yes,Used to treat obesity by preventing fat absorption.,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,1.04,179.0 +11903,NCT01526369,A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer,COMPLETED,PHASE3,Metastatic Breast Cancer,Trastuzumab (DRUG); Paclitaxel (DRUG); Lapatinib (DRUG),3034010,THL,Metastatic Breast Cancer,Breast,Orlistat,,inhibitor/antagonist,unclear,yes,yes,Used to treat obesity by preventing fat absorption.,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,1.04,179.0 +11904,NCT05109169,METformin and FINGER Intervention to Prevent Cognitive Impairment and Disability in Older Adults at Risk for Dementia,RECRUITING,PHASE2,Cognitive Decline; Cognitive Impairment; Dementia,FINGER 2.0 multidomain lifestyle-based intervention (COMBINATION_PRODUCT); Self-guided multidomain lifestyle intervention (OTHER),3034010,THL,Cognitive Decline; Cognitive Impairment; Dementia,CNS/Brain,Orlistat,,inhibitor/antagonist,unclear,yes,yes,Used to treat obesity by preventing fat absorption.,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,1.04,179.0 +11905,NCT00839254,"Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A",COMPLETED,PHASE3,"Infections, Streptococcal; Streptococcus Pneumoniae",Pneumococcal conjugate vaccine Synflorix (GSK1024850A) (BIOLOGICAL); GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine) (BIOLOGICAL); GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine) (BIOLOGICAL),3034010,THL,"Infections, Streptococcal; Streptococcus Pneumoniae",Lung,Orlistat,,inhibitor/antagonist,unclear,yes,yes,Used to treat obesity by preventing fat absorption.,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,1.04,179.0 +11906,NCT00770809,Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery,ACTIVE_NOT_RECRUITING,PHASE3,Male Breast Carcinoma; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7,Laboratory Biomarker Analysis (OTHER); Lapatinib Ditosylate (DRUG); Paclitaxel (DRUG); Trastuzumab (BIOLOGICAL),3034010,THL,Male Breast Carcinoma; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7,Breast,Orlistat,,inhibitor/antagonist,unclear,yes,yes,Used to treat obesity by preventing fat absorption.,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,1.04,179.0 +11907,NCT06501326,Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease,RECRUITING,PHASE4,Non-alcoholic Fatty Liver Disease; Obesity,Liraglutide (DRUG); Orlistat (DRUG),3034010,THL,Non-alcoholic Fatty Liver Disease; Obesity,Liver,Orlistat,,inhibitor/antagonist,unclear,yes,yes,Used to treat obesity by preventing fat absorption.,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,1.04,179.0 +11908,NCT00704912,Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women,COMPLETED,PHASE2,Polycystic Ovary Syndrome,Orlistat/Meal Replacement/Lifestyle Modification (DRUG); Loestrin 1/20 (DRUG); Combination of treatments (DRUG),3034010,THL,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Orlistat,,inhibitor/antagonist,unclear,yes,yes,Used to treat obesity by preventing fat absorption.,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,1.04,179.0 +11909,NCT06818955,Orlistat Overcoming Third-generation EGFR-TKI Resistance,NOT_YET_RECRUITING,PHASE2,Lung Adenocarcinoma; Osimertinib,Orlistat 120 mg (DRUG),3034010,THL,Lung Adenocarcinoma; Osimertinib,Lung,Orlistat,,inhibitor/antagonist,unclear,yes,yes,Used to treat obesity by preventing fat absorption.,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,1.04,179.0 +11910,NCT01047657,Effects of Weight Loss in Obese Difficult-to-treat Asthmatics,COMPLETED,PHASE3,Asthma; Obesity; Weight Loss,Low caloric diet plus orlistat and sibutramine (BEHAVIORAL),3034010,THL,Asthma; Obesity; Weight Loss,Lung,Orlistat,,inhibitor/antagonist,unclear,yes,yes,Used to treat obesity by preventing fat absorption.,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,1.04,179.0 +11911,NCT00160407,Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH),COMPLETED,PHASE4,Fatty Liver; Hepatitis,Orlistat (Xenical) (DRUG); 1400 kcal diet (30% fat) (BEHAVIORAL),3034010,THL,Fatty Liver; Hepatitis,Liver,Orlistat,,inhibitor/antagonist,unclear,yes,yes,Used to treat obesity by preventing fat absorption.,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,1.04,179.0 +11912,NCT00207311,Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus,COMPLETED,PHASE4,Fatty Liver; Hepatitis C,"Xenical, Pegasys, Copegus (DRUG); Xenicare Program (BEHAVIORAL)",3034010,THL,Fatty Liver; Hepatitis C,Liver,Orlistat,,inhibitor/antagonist,unclear,yes,yes,Used to treat obesity by preventing fat absorption.,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,1.04,179.0 +11913,NCT05760677,Study on the Efficacy and Safety of Chiglitazar Sodium in PCOS With T2DM,UNKNOWN,PHASE1,PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries; T2D,pioglitazone group: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone (DRUG); the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar (DRUG),3034010,THL,PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries; T2D,Ovary/Fallopian Tube,Orlistat,,inhibitor/antagonist,unclear,yes,yes,Used to treat obesity by preventing fat absorption.,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,1.04,179.0 +11914,NCT04152473,Safety and Tolerability of Oral Proglumide for NASH,COMPLETED,PHASE1,Nonalcoholic Steatohepatitis,Proglumide (DRUG),4922,Xyde,Nonalcoholic Steatohepatitis,Liver,Proglumide,"CCKBR, CCKAR",inhibitor/antagonist,unclear,no,yes,"Proglumide investigated for gastrointestinal use, not widely approved for humans.",CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1,1.25,33.0 +11915,NCT06017323,Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma,WITHDRAWN,PHASE1,Metastatic Pancreatic Cancer,Gemcitabine (DRUG); Nab paclitaxel (DRUG); Proglumide Dose level 1 (DRUG); Proglumide Dose level 2 (DRUG),4922,Xyde,Metastatic Pancreatic Cancer,Pancreas,Proglumide,"CCKBR, CCKAR",inhibitor/antagonist,unclear,no,yes,"Proglumide investigated for gastrointestinal use, not widely approved for humans.",CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1,1.25,33.0 +11916,NCT05827055,Proglumide and Chemotherapy for Metastatic Pancreatic Cancer,RECRUITING,PHASE2,Metastatic Pancreatic Cancer,Gemcitabine (DRUG); Nab paclitaxel (DRUG); Proglumide (DRUG); Placebo (DRUG),4922,Xyde,Metastatic Pancreatic Cancer,Pancreas,Proglumide,"CCKBR, CCKAR",inhibitor/antagonist,unclear,no,yes,"Proglumide investigated for gastrointestinal use, not widely approved for humans.",CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1,1.25,33.0 +11917,NCT04814602,Single-dose PK Assessment of Oral Proglumide in Those With Hepatic Impairment,COMPLETED,EARLY_PHASE1,"Cirrhosis, Liver",Proglumide (DRUG),4922,Xyde,Liver Cirrhosis,Liver,Proglumide,"CCKBR, CCKAR",inhibitor/antagonist,unclear,no,yes,"Proglumide investigated for gastrointestinal use, not widely approved for humans.",CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1,1.25,33.0 +11918,NCT03105674,Multi-Drug Analgesia vs. Standard Solution for Anal Surgery,WITHDRAWN,PHASE4,Hemorrhoids; Fissure in Ano; Fistula;Rectal,Multi-drug local anesthetics (Combination) (DRUG); Standard local anesthetics (Combination) (DRUG),6918111,Naropin,Anorectal Disorders,Bowel,Ropivacaine (hydrochloride monohydrate),,inhibitor/antagonist,unclear,yes,yes,A local anesthetic used in surgeries and pain management.,CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.O.Cl,1.0,60.0 +11919,NCT04074265,Peri-operative Use of a Pain Injection in Pediatric Patients With Cerebral Palsy,COMPLETED,PHASE4,"Cerebral Palsy; Hip Dysplasia; Pain, Postoperative",Ropivacaine injection (DRUG); normal saline (DRUG),6918111,Naropin,"Cerebral Palsy; Hip Dysplasia; Pain, Postoperative",CNS/Brain,Ropivacaine (hydrochloride monohydrate),,inhibitor/antagonist,unclear,yes,yes,A local anesthetic used in surgeries and pain management.,CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.O.Cl,1.0,60.0 +11920,NCT04021264,The Impact of an Epidural Anesthetic on the Consumption of Sevoflurane in Major Abdominal Surgery,WITHDRAWN,PHASE2,Bowel Disease; Liver Diseases; Pancreas Disease; Anesthesia; Functional,Ropivacaine-Sufentanil (DRUG); Dextrose 5 (DRUG),6918111,Naropin,Bowel Disease; Liver Diseases; Pancreas Disease; Anesthesia; Functional,Liver,Ropivacaine (hydrochloride monohydrate),,inhibitor/antagonist,unclear,yes,yes,A local anesthetic used in surgeries and pain management.,CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.O.Cl,1.0,60.0 +11921,NCT00964639,Postoperative Pain in Children With Cerebral Palsy After Pelvic and Femoral Osteotomies,COMPLETED,PHASE4,Postoperative Pain; Cerebral Palsy,Ropivacaine (DRUG); Saline (DRUG),6918111,Naropin,Postoperative Pain; Cerebral Palsy,CNS/Brain,Ropivacaine (hydrochloride monohydrate),,inhibitor/antagonist,unclear,yes,yes,A local anesthetic used in surgeries and pain management.,CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.O.Cl,1.0,60.0 +11922,NCT03152929,Paravertebral Block (PVC) Versus Pectoral Nerve Block (PEC),TERMINATED,PHASE3,Breast Cancer,Paravertebral Block (DRUG); Pectoral Nerve Block (DRUG),6918111,Naropin,Breast Cancer,Breast,Ropivacaine (hydrochloride monohydrate),,inhibitor/antagonist,unclear,yes,yes,A local anesthetic used in surgeries and pain management.,CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.O.Cl,1.0,60.0 +11923,NCT06760429,"Comparative Evaluation of Pectoral Nerve Block Type II Versus Rhomboid Intercostal and Subserratus Plane Block in Breast Cancer Mastectomy for Postoperative Analgesia: a Randomized, Controlled Trial",COMPLETED,EARLY_PHASE1,Breast Cancer,Pectoral Nerve Block Type II (PROCEDURE); Subserratus Plane Block (PROCEDURE),6918111,Naropin,Breast Cancer,Breast,Ropivacaine (hydrochloride monohydrate),,inhibitor/antagonist,unclear,yes,yes,A local anesthetic used in surgeries and pain management.,CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.O.Cl,1.0,60.0 +11924,NCT05044429,Postoperative Pain Control Following Renal Transplant,TERMINATED,PHASE4,"Kidney Transplant; Complications; Pain, Postoperative",Intravenous Lidocaine (DRUG); Transversus abdominis plane (TAP) block (DRUG); Quadratus Lumborum (QL) Block (DRUG),6918111,Naropin,"Kidney Transplant; Complications; Pain, Postoperative",Kidney,Ropivacaine (hydrochloride monohydrate),,inhibitor/antagonist,unclear,yes,yes,A local anesthetic used in surgeries and pain management.,CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.O.Cl,1.0,60.0 +11925,NCT04327063,MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery,COMPLETED,PHASE3,Malignant Neoplasm of Breast,Saline (DRUG); Ropivacaine (DRUG),6918111,Naropin,Malignant Neoplasm of Breast,Breast,Ropivacaine (hydrochloride monohydrate),,inhibitor/antagonist,unclear,yes,yes,A local anesthetic used in surgeries and pain management.,CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.O.Cl,1.0,60.0 +11926,NCT00903331,Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study,COMPLETED,PHASE2,Idiopathic Pulmonary Fibrosis,ACT-064992 (macitentan) (DRUG); Placebo (DRUG),16004692,Opsumit,Idiopathic Pulmonary Fibrosis,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11927,NCT02893176,Macitentan in the Treatment of Organ Rejection After Lung Transplantation,WITHDRAWN,PHASE4,Lung Transplant Rejection,macitentan (DRUG); placebo (for macitentan) (DRUG),16004692,Opsumit,Lung Transplant Rejection,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11928,NCT02310672,REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension,COMPLETED,PHASE4,Pulmonary Arterial Hypertension,Macitentan (DRUG),16004692,Opsumit,Pulmonary Arterial Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11929,NCT05167825,A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension,COMPLETED,PHASE3,Pulmonary Arterial Hypertension,Macitentan (DRUG),16004692,Opsumit,Pulmonary Arterial Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11930,NCT01841762,Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument,COMPLETED,PHASE3,Pulmonary Arterial Hypertension,Macitentan (DRUG),16004692,Opsumit,Pulmonary Arterial Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11931,NCT02070991,Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction,COMPLETED,PHASE2,Pulmonary Hypertension,Macitentan (DRUG); Placebo (DRUG),16004692,Opsumit,Pulmonary Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11932,NCT02932410,A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH),ACTIVE_NOT_RECRUITING,PHASE3,Pulmonary Arterial Hypertension,Macitentan (DRUG); Standard-of-care (OTHER),16004692,Opsumit,Pulmonary Arterial Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11933,NCT01743001,Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome,COMPLETED,PHASE3,Pulmonary Arterial Hypertension,Macitentan 10 mg (DRUG); Placebo (DRUG),16004692,Opsumit,Pulmonary Arterial Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11934,NCT02021292,"Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension",COMPLETED,PHASE2,Chronic Thromboembolic Pulmonary Hypertension,Macitentan (DRUG); Placebo (DRUG),16004692,Opsumit,Chronic Thromboembolic Pulmonary Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11935,NCT02651272,Macitentan in Pulmonary Hypertension of Sickle Cell Disease,TERMINATED,PHASE2,Pulmonary Hypertension; Sickle Cell Disease,macitentan (DRUG),16004692,Opsumit,Pulmonary Hypertension; Sickle Cell Disease,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11936,NCT02885012,Crossover Study From Macitentan or Bosentan Over to Ambrisentan,TERMINATED,PHASE4,Pulmonary Arterial Hypertension,Ambrisentan (DRUG),16004692,Opsumit,Pulmonary Arterial Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11937,NCT01847014,Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument,TERMINATED,PHASE3,Pulmonary Arterial Hypertension,Macitentan (DRUG),16004692,Opsumit,Pulmonary Arterial Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11938,NCT03809650,A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).,TERMINATED,PHASE3,Chronic Thromboembolic Pulmonary Hypertension (CTEPH),macitentan 10 mg (DRUG),16004692,Opsumit,Chronic Thromboembolic Pulmonary Hypertension (CTEPH),Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11939,NCT00667823,Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension,COMPLETED,PHASE3,Pulmonary Arterial Hypertension,Macitentan (DRUG),16004692,Opsumit,Pulmonary Arterial Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11940,NCT02060721,"Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension",COMPLETED,PHASE2,Chronic Thromboembolic Pulmonary Hypertension,Macitentan (DRUG),16004692,Opsumit,Chronic Thromboembolic Pulmonary Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11941,NCT00660179,Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension,COMPLETED,PHASE3,Pulmonary Arterial Hypertension,macitentan (ACT-064992) (DRUG); macitentan (ACT-064992) (DRUG); placebo (DRUG),16004692,Opsumit,Pulmonary Arterial Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11942,NCT04271475,A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension,TERMINATED,PHASE3,Chronic Thromboembolic Pulmonary Hypertension,Macitentan (DRUG); Placebo (DRUG),16004692,Opsumit,Chronic Thromboembolic Pulmonary Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11943,NCT01739400,"Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome",TERMINATED,PHASE3,Pulmonary Arterial Hypertension,"Macitentan 10 mg tablet, once daily. (DRUG)",16004692,Opsumit,Pulmonary Arterial Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11944,NCT02112487,Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH,COMPLETED,PHASE3,Pulmonary Arterial Hypertension,Macitentan (DRUG),16004692,Opsumit,Pulmonary Arterial Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11945,NCT03422328,A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.,COMPLETED,PHASE3,Pulmonary Arterial Hypertension; Chronic Thromboembolic Pulmonary Hypertension,macitentan (DRUG),16004692,Opsumit,Pulmonary Arterial Hypertension; Chronic Thromboembolic Pulmonary Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11946,NCT03904693,Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH),COMPLETED,PHASE3,Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH),FDC macitentan/tadalafil (DRUG); Macitentan 10 mg (DRUG); Tadalafil 40 mg (DRUG); Placebo FDC (DRUG); Placebo macitentan (DRUG); Placebo tadalafil (DRUG),16004692,Opsumit,Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH),Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11947,NCT03726398,CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH,WITHDRAWN,PHASE2,Interstitial Lung Disease; Scleroderma; Pulmonary Hypertension,Opsumit 10 Mg Tablet (DRUG),16004692,Opsumit,Interstitial Lung Disease; Scleroderma; Pulmonary Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11948,NCT02081690,"A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain",TERMINATED,PHASE3,Pulmonary Arterial Hypertension,Macitentan (DRUG),16004692,Opsumit,Pulmonary Arterial Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11949,NCT01824290,A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH),COMPLETED,PHASE3,"Hypertension, Pulmonary",Tadalafil (DRUG); Placebo (DRUG); ERA as specific PAH treatment (DRUG),16004692,Opsumit,Pulmonary Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11950,NCT04955990,A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants,TERMINATED,PHASE4,Pulmonary Arterial Hypertension,PAH Therapies (OTHER),16004692,Opsumit,Pulmonary Arterial Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11951,NCT05179876,A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option,RECRUITING,PHASE3,"Hypertension, Pulmonary",Macitentan (DRUG); Selexipag (DRUG); Macitentan/Tadalafil FDC (DRUG),16004692,Opsumit,Pulmonary Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11952,NCT02558231,The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension,COMPLETED,PHASE3,Pulmonary Arterial Hypertension,Macitentan (DRUG); Tadalafil (DRUG); Selexipag (DRUG),16004692,Opsumit,Pulmonary Arterial Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11953,NCT02968901,Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA),TERMINATED,PHASE4,Pulmonary Arterial Hypertension,macitentan (DRUG); tadalafil (DRUG),16004692,Opsumit,Pulmonary Arterial Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11954,NCT02554903,Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation,COMPLETED,PHASE2,Pulmonary Hypertension,Macitentan 10mg (DRUG); Placebo sugar pill (DRUG),16004692,Opsumit,Pulmonary Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11955,NCT03236818,Goal Oriented Strategy to Preserve Ejection Fraction Trial,UNKNOWN,PHASE4,Pulmonary Arterial Hypertension,"ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan) (DRUG)",16004692,Opsumit,Pulmonary Arterial Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11956,NCT04780932,Initial Dual Oral Combination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension,ACTIVE_NOT_RECRUITING,PHASE2,Thromboembolic Pulmonary Hypertension; Chronic Disease; Inoperable Disease,Macitentan 10mg (DRUG); Placebo (DRUG),16004692,Opsumit,Thromboembolic Pulmonary Hypertension; Chronic Disease; Inoperable Disease,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11957,NCT03362047,(RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment),COMPLETED,PHASE2,Pulmonary Arterial Hypertension (PAH),Riciguat Group (DRUG); Macitentan Group (DRUG),16004692,Opsumit,Pulmonary Arterial Hypertension (PAH),Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11958,NCT01499251,Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma,TERMINATED,PHASE1,Glioblastoma,Phase 1 Dose Escalation (DRUG); Phase 1b (DRUG); Ancillary Study (DRUG),16004692,Opsumit,Glioblastoma,CNS/Brain,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11959,NCT05946811,Macitentan to Prevent PRVO,WITHDRAWN,PHASE3,Pulmonary Embolism,Macitentan 10mg (DRUG),16004692,Opsumit,Pulmonary Embolism,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11960,NCT04273945,Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension,ACTIVE_NOT_RECRUITING,PHASE3,Pulmonary Arterial Hypertension,Macitentan 10 mg (DRUG); Macitentan 37.5 mg (DRUG); Macitentan 75 mg (DRUG); Placebo (DRUG),16004692,Opsumit,Pulmonary Arterial Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11961,NCT01346930,Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis,WITHDRAWN,PHASE2,Idiopathic Pulmonary Fibrosis,Macitentan (DRUG),16004692,Opsumit,Idiopathic Pulmonary Fibrosis,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11962,NCT06317805,Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients,RECRUITING,PHASE4,Pulmonary Arterial Hypertension,Generic treprostinil sodium + Standard of Care (Double Oral) (DRUG); Standard of Care - Double Oral (DRUG),16004692,Opsumit,Pulmonary Arterial Hypertension,Lung,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11963,NCT02254954,"Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma",TERMINATED,PHASE1,Glioblastoma,Macitentan in combination with RT and TMZ (DRUG),16004692,Opsumit,Glioblastoma,CNS/Brain,Macitentan,"EDNRA, EDNRB",inhibitor/antagonist,unclear,yes,yes,Approved for pulmonary arterial hypertension treatment.,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,1.05,341.0 +11964,NCT02441465,Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies,COMPLETED,PHASE1,"Malignant Melanoma, Cancer",Vemurafenib (DRUG); 14C-Labeled Vemurafenib (DRUG),42611257,Zelboraf,"Malignant Melanoma, Cancer",Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11965,NCT02038348,Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study,COMPLETED,PHASE2,Metastatic Melanoma,PET with 18F-FDOPA (DEVICE),42611257,Zelboraf,Metastatic Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11966,NCT04790448,Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer Metastatic,Cetuximab (DRUG); Irinotecan (DRUG); Vemurafenib (DRUG),42611257,Zelboraf,Colorectal Cancer Metastatic,Bowel,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11967,NCT02354690,Vemurafenib and TIL Therapy for Metastatic Melanoma,COMPLETED,PHASE1,Metastatic Melanoma,Vemurafenib (DRUG); Lymphodepleting chemotherapy (DRUG); TIL infusion (DRUG); Interleukin-2 (DRUG),42611257,Zelboraf,Metastatic Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11968,NCT02414750,Vemurafenib Plus Cobimetinib in Metastatic Melanoma,TERMINATED,PHASE2,Metastatic Melanoma,Vemurafenib plus cobimetinib (DRUG); Positron Emission Tomography (DEVICE); Tissue sampling (PROCEDURE); Blood sampling (PROCEDURE),42611257,Zelboraf,Metastatic Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11969,NCT01586195,"Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E",TERMINATED,PHASE2,Malignant Melanoma,Vemurafenib (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11970,NCT01754376,Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma,TERMINATED,PHASE2,Melanoma,Aldesleukin (DRUG); Vemurafenib (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11971,NCT05238831,SMMART Adaptive Clinical Treatment (ACT) Trial,WITHDRAWN,EARLY_PHASE1,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Alectinib (DRUG); Alpelisib (DRUG); Anastrozole (DRUG); Atezolizumab (BIOLOGICAL); Bevacizumab (BIOLOGICAL); Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Capecitabine (DRUG); Carboplatin (DRUG); Cobimetinib (DRUG); Entrectinib (DRUG); Eribulin (DRUG); Fulvestrant (DRUG); Hyaluronidase-zzxf/Pertuzumab/Trastuzumab (BIOLOGICAL); Irinotecan (DRUG); Letrozole (DRUG); Nab-paclitaxel (DRUG); Niraparib (DRUG); Olaparib (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Pertuzumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Trastuzumab (BIOLOGICAL); Trastuzumab Emtansine (BIOLOGICAL); Vemurafenib (DRUG); Vinorelbine (DRUG); Vismodegib (DRUG),42611257,Zelboraf,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Ovary/Fallopian Tube,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11972,NCT01638676,A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients,RECRUITING,PHASE1,Melanoma,Vemurafenib (DRUG); Metformin (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11973,NCT01603212,"Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor",COMPLETED,PHASE1,Melanoma,Vemurafenib (DRUG); IL-2 (DRUG); Interferon Alpha-2b (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11974,NCT01826448,"A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma",TERMINATED,PHASE1,V600-mutated BRAF Unresectable Melanoma; V600-mutated BRAF Metastatic Melanoma; Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor,PLX3397 (DRUG); vemurafenib (DRUG),42611257,Zelboraf,V600-mutated BRAF Unresectable Melanoma; V600-mutated BRAF Metastatic Melanoma; Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11975,NCT01943422,Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma,COMPLETED,PHASE1,Melanoma,High-dose Interferon alfa-2b (DRUG); Vemurafenib (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11976,NCT01164891,A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma,COMPLETED,PHASE1,Malignant Melanoma,RO5185426 (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11977,NCT01006980,A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3),COMPLETED,PHASE3,Malignant Melanoma,Vemurafenib (DRUG); Dacarbazine (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11978,NCT01657591,Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma,COMPLETED,PHASE1,Melanoma,XL888 (DRUG); Vemurafenib (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11979,NCT03727763,Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT),UNKNOWN,PHASE2,Colorectal Cancer,Vemurafenib (DRUG); Cetuximab (DRUG),42611257,Zelboraf,Colorectal Cancer,Bowel,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11980,NCT03220035,"Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)",COMPLETED,PHASE2,Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Ependymoma; Ewing Sarcoma; Hepatoblastoma; Langerhans Cell Histiocytosis; Malignant Germ Cell Tumor; Malignant Glioma; Osteosarcoma; Peripheral Primitive Neuroectodermal Tumor; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Central Nervous System Neoplasm; Rhabdoid Tumor; Rhabdomyosarcoma; Soft Tissue Sarcoma; Wilms Tumor,Laboratory Biomarker Analysis (OTHER); Vemurafenib (DRUG),42611257,Zelboraf,Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Ependymoma; Ewing Sarcoma; Hepatoblastoma; Langerhans Cell Histiocytosis; Malignant Germ Cell Tumor; Malignant Glioma; Osteosarcoma; Peripheral Primitive Neuroectodermal Tumor; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Central Nervous System Neoplasm; Rhabdoid Tumor; Rhabdomyosarcoma; Soft Tissue Sarcoma; Wilms Tumor,CNS/Brain,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11981,NCT02164916,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,cetuximab (BIOLOGICAL); irinotecan hydrochloride (DRUG); vemurafenib (DRUG),42611257,Zelboraf,Colorectal Cancer,Bowel,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11982,NCT02036086,Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases,UNKNOWN,PHASE2,Melanoma,Vemurafenib (DRUG); Cobimetinib (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11983,NCT03005639,ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma,WITHDRAWN,PHASE2,Stage IIIB-C Melanoma,Vemurafenib and Cobimetinib (DRUG),42611257,Zelboraf,Stage IIIB-C Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11984,NCT02314481,Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity,ACTIVE_NOT_RECRUITING,PHASE2,Non-small Cell Lung Cancer,MPDL3280A (DRUG); Vemurafenib (DRUG); Alectinib (DRUG); Trastuzumab emtansine (DRUG),42611257,Zelboraf,Non-small Cell Lung Cancer,Lung,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11985,NCT02145910,Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases,WITHDRAWN,PHASE1,Recurrent Melanoma; Stage IV Melanoma; Tumors Metastatic to Brain,Vemurafenib (DRUG); Whole-brain radiation therapy (WBRT) (RADIATION); Radiosurgery (SRS) (RADIATION),42611257,Zelboraf,Recurrent Melanoma; Stage IV Melanoma; Tumors Metastatic to Brain,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11986,NCT01983124,Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib,COMPLETED,PHASE2,Malignant Melanoma Stage IV,Fotemustine + Vemurafenib (DRUG),42611257,Zelboraf,Malignant Melanoma Stage IV,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11987,NCT01851824,A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy,COMPLETED,PHASE1,"Malignant Melanoma, Neoplasms",acenocoumarol (DRUG); vemurafenib (DRUG),42611257,Zelboraf,"Malignant Melanoma, Neoplasms",Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11988,NCT01667419,A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma,COMPLETED,PHASE3,Melanoma,Vemurafenib (DRUG); Placebo (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11989,NCT01689519,A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma,COMPLETED,PHASE3,Malignant Melanoma,Placebo (DRUG); Vemurafenib (DRUG); Cobimetinib (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11990,NCT05019534,"Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer",UNKNOWN,PHASE1,BRAF V600E-mutated /MSS Metastatic Colorectal Cancer; Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody,Vemurafenib Oral Tablet [Zelboraf] (DRUG); Cetuximab Injection [Erbitux] (DRUG); Camrelizumab (DRUG),42611257,Zelboraf,BRAF V600E-mutated /MSS Metastatic Colorectal Cancer; Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody,Bowel,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11991,NCT03625141,A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases,COMPLETED,PHASE2,Metastatic Melanoma,Cobimetinib (DRUG); Atezolizumab (DRUG); Vemurafenib (DRUG),42611257,Zelboraf,Metastatic Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11992,NCT01248936,A Study of RO5185426 in Patients With Metastatic Melanoma,COMPLETED,PHASE2,Malignant Melanoma,RO5185426 (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11993,NCT01876641,Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib,TERMINATED,PHASE1,Metastatic Melanoma; Melanoma; BRAF-mutated Metastatic Melanoma; V600EBRAF-mutated Metastatic Melanoma,"Vemurafenib + Cobimetinib, Decitabine (DRUG)",42611257,Zelboraf,Metastatic Melanoma; Melanoma; BRAF-mutated Metastatic Melanoma; V600EBRAF-mutated Metastatic Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11994,NCT01107418,A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma,COMPLETED,PHASE1,Malignant Melanoma,RO5185426 (DRUG); RO5185426 (DRUG); RO5185426 (DRUG); RO5185426 (DRUG); RO5185426 (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11995,NCT01748149,Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas,Vemurafenib (DRUG),42611257,Zelboraf,Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas,CNS/Brain,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11996,NCT01910181,A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma,COMPLETED,PHASE1,Malignant Melanoma,Vemurafenib (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11997,NCT01813214,The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma,TERMINATED,PHASE2,Melanoma,Vemurafenib (DRUG); Cobimetinib (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11998,NCT01519323,BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations,TERMINATED,PHASE1,Malignant Melanoma,vemurafenib (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +11999,NCT01656642,A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma,COMPLETED,PHASE1,Malignant Melanoma,Atezolizumab (DRUG); Cobimetinib (DRUG); Vemurafenib (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12000,NCT01001299,A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma,COMPLETED,PHASE1,Malignant Melanoma,Drug cocktail (DRUG); RO5185426 (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12001,NCT02230306,Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases,TERMINATED,PHASE2,Active Melanoma Brain Metastases,Cobimetinib (DRUG); Vemurafenib (DRUG),42611257,Zelboraf,Active Melanoma Brain Metastases,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12002,NCT02050321,A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma,TERMINATED,PHASE2,Malignant Melanoma,Acitretin (DRUG); Vemurafenib (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12003,NCT00949702,A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma,COMPLETED,PHASE2,Malignant Melanoma,vemurafenib (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12004,NCT01835184,Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery,TERMINATED,PHASE1,"Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma; Unspecified Adult Solid Tumor, Protocol Specific",cabozantinib-s-malate (DRUG); vemurafenib (DRUG); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),42611257,Zelboraf,"Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma; Unspecified Adult Solid Tumor, Protocol Specific",Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12005,NCT01765543,A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf),COMPLETED,PHASE1,"Malignant Melanoma, Neoplasms",Rifampin (DRUG); Vemurafenib (DRUG),42611257,Zelboraf,"Malignant Melanoma, Neoplasms",Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12006,NCT04722575,"Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma",ACTIVE_NOT_RECRUITING,PHASE2,Melanoma,Cobimetinib 20 MG Oral Tablet (DRUG); Vemurafenib 240 Mg Oral Capsule (DRUG); Atezolizumab 1200 MG in 20 ML Injection (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12007,NCT01841463,Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation,SUSPENDED,PHASE1,Advanced or Inoperable Malignant Melanoma With BRAF Mutation,P1446A-05 (DRUG); Vemurafenib (Zelboraf®) (DRUG),42611257,Zelboraf,Advanced or Inoperable Malignant Melanoma With BRAF Mutation,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12008,NCT02721459,XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma,ACTIVE_NOT_RECRUITING,PHASE1,Melanoma; Skin Cancer,XL888 (DRUG); Vemurafenib (DRUG); Cobimetinib (DRUG),42611257,Zelboraf,Melanoma; Skin Cancer,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12009,NCT01787500,"Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery",ACTIVE_NOT_RECRUITING,PHASE1,BRAF NP_004324.2:p.V600X; KRAS wt Allele; Metastatic Malignant Solid Neoplasm; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7; Unresectable Solid Neoplasm,Cetuximab (BIOLOGICAL); Irinotecan Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Vemurafenib (DRUG),42611257,Zelboraf,BRAF NP_004324.2:p.V600X; KRAS wt Allele; Metastatic Malignant Solid Neoplasm; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7; Unresectable Solid Neoplasm,Bowel,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12010,NCT02537600,Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis,COMPLETED,PHASE2,Malignant Melanoma,Cobimetinib + Vemurafenib combination treatment (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12011,NCT03430947,Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases,TERMINATED,PHASE2,Malignant Melanoma Stage IV; BRAF V600 Mutation; Brain Metastases,Vemurafenib (DRUG); Cobimetinib (DRUG),42611257,Zelboraf,Malignant Melanoma Stage IV; BRAF V600 Mutation; Brain Metastases,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12012,NCT00405587,Safety Study of PLX4032 in Patients With Solid Tumors,COMPLETED,PHASE1,Malignant Melanoma; Colorectal Carcinoma,PLX4032 (DRUG),42611257,Zelboraf,Malignant Melanoma; Colorectal Carcinoma,Bowel,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12013,NCT03101254,LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma,COMPLETED,PHASE1,Melanoma,LY3022855 (DRUG); Vemurafenib (DRUG); Cobimetinib (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12014,NCT01474551,Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation,TERMINATED,PHASE2,Melanoma,vemurafenib (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12015,NCT02303951,Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC,TERMINATED,PHASE2,Malignant Melanoma,Vemurafenib (DRUG); Cobimetinib (DRUG); Atezolizumab (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12016,NCT01512251,BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma,COMPLETED,PHASE1,BRAF Mutant Metastatic Melanoma,BKM120 Combined with Vemurafenib (PLX4032) (DRUG),42611257,Zelboraf,BRAF Mutant Metastatic Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12017,NCT01659151,Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Melanoma,High Dose Interleukin-2 (IL-2) (DRUG); ACT with TIL Infusion (PROCEDURE); Vemurafenib (DRUG); Lymphodepletion (DRUG),42611257,Zelboraf,Metastatic Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12018,NCT01959633,Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation,COMPLETED,PHASE1,Melanoma,Vemurafenib (DRUG); Peg-interferon (DRUG); Cobimetinib (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12019,NCT01673854,Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma,COMPLETED,PHASE2,Melanoma,Ipilimumab (DRUG); Vemurafenib (BIOLOGICAL),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12020,NCT01909453,Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma,COMPLETED,PHASE3,Melanoma,LGX818 (DRUG); MEK162 (DRUG); vemurafenib (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12021,NCT01898585,An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma,COMPLETED,PHASE4,Malignant Melanoma,Zelboraf (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12022,NCT01683188,HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma,TERMINATED,PHASE4,Metastatic Melanoma,vemurafenib + HD IL-2 (DRUG),42611257,Zelboraf,Metastatic Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12023,NCT01495988,Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma,TERMINATED,PHASE2,Melanoma; Metastatic Melanoma,Vemurafenib (DRUG); Bevacizumab (DRUG); Cobimetinib (DRUG),42611257,Zelboraf,Melanoma; Metastatic Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12024,NCT05768178,DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.,RECRUITING,PHASE2,"Solid Tumor; Haematological Malignancy; Melanoma; Thyroid Cancer, Papillary; Ovarian Neoplasms; Colorectal Neoplasms; Laryngeal Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioma; Multiple Myeloma; Erdheim-Chester Disease; Thyroid Carcinoma, Anaplastic",Vemurafenib (DRUG); Cobimetinib (DRUG),42611257,Zelboraf,"Solid Tumor; Haematological Malignancy; Melanoma; Thyroid Cancer, Papillary; Ovarian Neoplasms; Colorectal Neoplasms; Laryngeal Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioma; Multiple Myeloma; Erdheim-Chester Disease; Thyroid Carcinoma, Anaplastic",Bowel,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12025,NCT01781026,Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases,COMPLETED,PHASE2,Melanoma,Vemurafenib (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12026,NCT02427893,Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma,WITHDRAWN,PHASE3,Melanoma,Cobimetinib (DRUG); Vemurafenib (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12027,NCT03554083,"Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma",ACTIVE_NOT_RECRUITING,PHASE2,Clinical Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8,Atezolizumab (DRUG); Cobimetinib (DRUG); Tiragolumab (BIOLOGICAL); Vemurafenib (DRUG),42611257,Zelboraf,Clinical Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12028,NCT01307397,A Study of Vemurafenib in Participants With Metastatic Melanoma,COMPLETED,PHASE3,Malignant Melanoma,Vemurafenib (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12029,NCT01264380,A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma,COMPLETED,PHASE1,Malignant Melanoma,RO5185426 (DRUG); RO5185426 (DRUG); RO5185426 (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12030,NCT02291289,A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC),COMPLETED,PHASE2,Colorectal Cancer,Cetuximab (DRUG); FOLFOX induction regimen (DRUG); Fluoropyrimidine (5-FU/LV or capecitabine) (DRUG); Atezolizumab (DRUG); Vemurafenib (DRUG); Bevacizumab (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); Cobimetinib (DRUG); 5-FU/LV (DRUG); Capecitabine (DRUG),42611257,Zelboraf,Colorectal Cancer,Bowel,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12031,NCT01253564,A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases,COMPLETED,PHASE2,Malignant Melanoma,RO5185426 (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12032,NCT03178552,A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC),ACTIVE_NOT_RECRUITING,PHASE2,Non-Small Cell Lung Cancer,Alectinib (DRUG); Atezolizumab (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Gemcitabine (DRUG); Entrectinib (DRUG); Cobimetinib (DRUG); Vemurafenib (DRUG); Bevacizumab (DRUG); Divarasib (DRUG); Docetaxel (DRUG),42611257,Zelboraf,Advanced Non-Small Cell Lung Cancer,Lung,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12033,NCT02768207,A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma,COMPLETED,PHASE2,Metastatic Melanoma,Cobimetinib (DRUG); Vemurafenib (DRUG),42611257,Zelboraf,Metastatic Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12034,NCT01849666,A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy,COMPLETED,PHASE1,"Malignant Melanoma, Neoplasms",phenprocoumon (DRUG); vemurafenib (DRUG),42611257,Zelboraf,"Malignant Melanoma, Neoplasms",Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12035,NCT01844674,A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies,COMPLETED,PHASE1,"Malignant Melanoma, Neoplasms",Tizanidine (DRUG); Vemurafenib (DRUG),42611257,Zelboraf,"Malignant Melanoma, Neoplasms",Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12036,NCT01765569,A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma,COMPLETED,PHASE1,"Malignant Melanoma, Neoplasms",Digoxin (DRUG); Vemurafenib (DRUG),42611257,Zelboraf,"Malignant Melanoma, Neoplasms",Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12037,NCT06603376,"Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer",RECRUITING,PHASE2,Colorectal Carcinoma,FOLFIRI + Vemurafenib + Cetuximab (DRUG); FOLFIRI ± Bevacizumab (DRUG),42611257,Zelboraf,Colorectal Carcinoma,Bowel,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12038,NCT01973322,"Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized ""Proof-of-principle"" Phase II Study",COMPLETED,PHASE2,Malignant Melanoma of Skin Stage III; Malignant Melanoma of Skin Stage IV,arm 1: DC Vaccine + RT (OTHER); arm 2: DC Vaccine + IFN-alfa (OTHER); arm 3: both arm 1 and 2 + RT (OTHER); arm 4: DC Vaccine (BIOLOGICAL),42611257,Zelboraf,Malignant Melanoma of Skin Stage III; Malignant Melanoma of Skin Stage IV,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12039,NCT02902029,Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma,COMPLETED,PHASE2,Malignant Melanoma,Vemurafenib (DRUG); Cobimetinib (DRUG); Atezolizumab (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12040,NCT02296996,Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients,COMPLETED,PHASE2,Malignant Melanoma,Dabrafenib + Trametinib (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12041,NCT01897116,A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma,COMPLETED,PHASE1,Melanoma,Hydroxychloroquine (HCQ) (DRUG); Vemurafenib (VEM) (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12042,NCT02583516,Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma,COMPLETED,PHASE2,Melanoma,vemurafenib and cobimetinib (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12043,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,75 approved agents (DRUG); COXEN (OTHER),42611257,Zelboraf,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,Bladder/Urinary Tract,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12044,NCT02908672,A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma,COMPLETED,PHASE3,Melanoma,Atezolizumab (DRUG); Atezolizumab Placebo (DRUG); Cobimetinib (DRUG); Vemurafenib (DRUG); Vemurafenib Placebo (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12045,NCT02608034,A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State,COMPLETED,PHASE1,"Metastatic Melanoma, BRAF V600 Mutation Positive",Itraconazole (DRUG); Rifampin (DRUG); Vemurafenib (DRUG),42611257,Zelboraf,"Metastatic Melanoma, BRAF V600 Mutation Positive",Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12046,NCT01519427,Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib,TERMINATED,PHASE2,Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma,Akt inhibitor MK2206 (DRUG); selumetinib (DRUG); laboratory biomarker analysis (OTHER),42611257,Zelboraf,Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12047,NCT03514901,To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.,UNKNOWN,PHASE2,Melanoma Metastatic; BRAF V600 Mutation,Experimental combination beyond Focal Progression (OTHER); Pembrolizumab or Nivolumab (DRUG),42611257,Zelboraf,Melanoma Metastatic; BRAF V600 Mutation,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12048,NCT03026517,Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma,COMPLETED,PHASE1,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Phenformin (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12049,NCT06008119,Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer,RECRUITING,PHASE3,Colorectal Cancer Metastatic,Tunlametinib plus Vemurafenib (DRUG); Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab (DRUG),42611257,Zelboraf,Colorectal Cancer Metastatic,Bowel,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12050,NCT05900219,Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study,NOT_YET_RECRUITING,PHASE2,Non-small-cell Lung Cancer,HL-085+Vemurafenib (DRUG),42611257,Zelboraf,Non-small-cell Lung Cancer,Lung,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12051,NCT01843738,Radiation Use During Vemurafenib Treatment,WITHDRAWN,PHASE1,BRAFV600 Mutation; Stage IV Melanoma,Radiation therapy (RADIATION); Vemurafenib (DRUG),42611257,Zelboraf,BRAFV600 Mutation; Stage IV Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12052,NCT02818023,Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma,TERMINATED,PHASE1,Melanoma,Pembrolizumab (DRUG); Vemurafenib (DRUG); Cobimetinib (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12053,NCT01597908,Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma,COMPLETED,PHASE3,Melanoma,Dabrafenib (DRUG); Vemurafenib (DRUG); Trametinib (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12054,NCT02077114,Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma,COMPLETED,PHASE1,Malignant Melanoma With Metastasis,Vaccine consisting of a peptide derived from the protein IDO (BIOLOGICAL),42611257,Zelboraf,Malignant Melanoma With Metastasis,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12055,NCT03224208,Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients,TERMINATED,PHASE2,Melanoma; Melanoma (Skin); Melanoma Stage,Vemurafenib (DRUG); Cobimetinib (DRUG),42611257,Zelboraf,Melanoma; Melanoma (Skin); Melanoma Stage,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12056,NCT02382549,A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib,TERMINATED,EARLY_PHASE1,Melanoma,BRAF inhibitor (DRUG); 6MHP (BIOLOGICAL); MEK inhibitor (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12057,NCT01271803,A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma,COMPLETED,PHASE1,Malignant Melanoma,Cobimetinib (DRUG); vemurafenib (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12058,NCT02968303,Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy,UNKNOWN,PHASE2,"Melanoma, Malignant, of Soft Parts",Vemurafenib and Cobimetinib (DRUG),42611257,Zelboraf,Malignant Melanoma of Soft Parts,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12059,NCT02068079,A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma,WITHDRAWN,PHASE1,Melanoma,Vemurafenib and Trientine (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12060,NCT01611675,Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma,TERMINATED,PHASE1,Melanoma,Vemurafenib (DRUG); Leflunomide (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12061,NCT01378975,A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases,COMPLETED,PHASE2,Malignant Melanoma,Vemurafenib (DRUG),42611257,Zelboraf,Malignant Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12062,NCT02202200,Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma,UNKNOWN,PHASE1,Melanoma BRAF V600E/K Mutated; CDNKN2A Loss Defined,PD- 0332991 (DRUG),42611257,Zelboraf,Melanoma BRAF V600E/K Mutated; CDNKN2A Loss Defined,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12063,NCT05068752,Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Pancreas Cancer,Vemurafenib (DRUG); Sorafenib (DRUG),42611257,Zelboraf,Pancreas Cancer,Pancreas,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12064,NCT01400451,Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF),TERMINATED,PHASE1,Melanoma,Ipilimumab (BMS-734016) (DRUG); Vemurafenib (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12065,NCT05263453,HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation,UNKNOWN,PHASE2,Melanoma,HL-085 (DRUG); Vemurafenib (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12066,NCT05540951,VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer,UNKNOWN,PHASE3,Colorectal Cancer,VIC (DRUG); Bevacizumab Plus Chemotherapy (DRUG),42611257,Zelboraf,Colorectal Cancer,Bowel,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12067,NCT01585415,Vemurafenib and White Blood Cell Therapy for Advanced Melanoma,TERMINATED,PHASE1,Metastatic Cancer; Melanoma,Vemurafenib (DRUG); Young TIL (BIOLOGICAL); Cyclophosphamide (DRUG); Fludarabine (DRUG); Aldesleukin (DRUG),42611257,Zelboraf,Metastatic Cancer; Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12068,NCT01765556,A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma,WITHDRAWN,PHASE1,"Malignant Melanoma, Neoplasms",ketoconazole (DRUG); vemurafenib (DRUG),42611257,Zelboraf,"Malignant Melanoma, Neoplasms",Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12069,NCT01791309,Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer,COMPLETED,PHASE1,Metastatic Colorectal Cancer,combination panitumumab and vemurafenib (DRUG),42611257,Zelboraf,Metastatic Colorectal Cancer,Bowel,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12070,NCT04302025,A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer,RECRUITING,PHASE2,Non-small Cell Lung Cancer,Alectinib (DRUG); Entrectinib (DRUG); Vemurafenib (Enrollment closed) (DRUG); Cobimetinib (Enrollment closed) (DRUG); Pralsetinib (Enrollment closed) (DRUG); Atezolizumab (DRUG); SBRT (DRUG); Resection (PROCEDURE); Chemotherapy (DRUG); Divarasib (DRUG),42611257,Zelboraf,Non-small Cell Lung Cancer,Lung,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12071,NCT01942993,The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma,TERMINATED,PHASE2,Melanoma,Vemurafenib (DRUG),42611257,Zelboraf,Melanoma,Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12072,NCT02052193,Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study,TERMINATED,PHASE2,Metastatic Melanoma (Carrying BRAF V600 Mutation),Dabrafenib (DRUG); Vemurafenib (DRUG),42611257,Zelboraf,Metastatic Melanoma (Carrying BRAF V600 Mutation),Skin,Vemurafenib,BRAF,inhibitor/antagonist,RAF inhibitor,yes,yes,Approved for treating BRAF V600E mutation-positive melanoma.,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,1.06,173.0 +12073,NCT04270526,Minimizing Pain During Office Intradetrussor Botox Injection,COMPLETED,PHASE4,Overactive Bladder; Overactive Detrusor; Overactive Bladder Syndrome; Overactivity; Behavior; Urge Incontinence,Bicarbonate protocol (DRUG); Standard protocol (DRUG),6314,Glydo,Overactive Bladder; Overactive Detrusor; Overactive Bladder Syndrome; Overactivity; Behavior; Urge Incontinence,Bladder/Urinary Tract,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12074,NCT02597257,Efficacy and Safety of Lidocaine Infusion Treatment in Management of Neuropathic Pain,UNKNOWN,PHASE2,Postherpetic Neuralgia; Diabetic Polyneuropathy; Peripheral Neuropathy,Lidocaine HCl (DRUG); Normal saline (DRUG),6314,Glydo,Postherpetic Neuralgia; Diabetic Polyneuropathy; Peripheral Neuropathy,Peripheral Nervous System,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12075,NCT05658874,"A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain",ACTIVE_NOT_RECRUITING,PHASE3,Interstitial Cystitis,Multimodal Bundle Drugs (DRUG); Operative Cystoscopy (PROCEDURE); Behavioral health consultation/therapy (BEHAVIORAL); Pelvic floor physical therapy (OTHER); Usual Urogynecologic care (OTHER); Bladder Instillation (DRUG); Vaginal estrogen (DRUG); Methenamine (DRUG); Amitriptyline/Gabapentin (DRUG),6314,Glydo,Interstitial Cystitis,Bladder/Urinary Tract,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12076,NCT03105674,Multi-Drug Analgesia vs. Standard Solution for Anal Surgery,WITHDRAWN,PHASE4,Hemorrhoids; Fissure in Ano; Fistula;Rectal,Multi-drug local anesthetics (Combination) (DRUG); Standard local anesthetics (Combination) (DRUG),6314,Glydo,Anorectal Disorders,Bowel,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12077,NCT02401074,Airway Temperature,WITHDRAWN,PHASE1,Asthma,Segmental Bronchoprovocation with Allergen (SBP-Ag) (BIOLOGICAL),6314,Glydo,Asthma,Lung,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12078,NCT04609865,Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia,TERMINATED,PHASE3,Acute Respiratory Distress Syndrome (ARDS); COVID-19; Corona Virus Infection,Lidocaine 2% (DRUG); Control (DRUG),6314,Glydo,Acute Respiratory Distress Syndrome (ARDS); COVID-19; Corona Virus Infection,Lung,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12079,NCT04102566,Optimizing Pain Control in Transurethral Resection of the Prostate,RECRUITING,PHASE4,Pain; BPH With Urinary Obstruction; BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms,Ibuprofen 600 mg (DRUG); Education (BEHAVIORAL),6314,Glydo,Pain; BPH With Urinary Obstruction; BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms,Bladder/Urinary Tract,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12080,NCT05415865,The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder,UNKNOWN,PHASE3,"Urge Incontinence; Overactive Bladder; Anesthesia, Local; Pain, Procedural; Urinary Tract Infections; Hematuria",Alkalinized Lidocaine (COMBINATION_PRODUCT); Placebo Sodium Chloride 0.9% Inj (DRUG),6314,Glydo,"Urge Incontinence; Overactive Bladder; Anesthesia, Local; Pain, Procedural; Urinary Tract Infections; Hematuria",Bladder/Urinary Tract,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12081,NCT02958566,Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery,UNKNOWN,PHASE4,"Colon Cancer; Colon Diverticulosis; Colonic Neoplasms; Colonic Diverticulitis; Pain, Postoperative; Ileus; Ileus Paralytic; Ileus; Mechanical; Constipation Drug Induced; Constipation; Rectum Cancer; Rectum Neoplasm",Acetaminophen (DRUG); Gabapentin (DRUG); Orphenadrine (DRUG); Lidocaine (DRUG); Marcaine (DRUG); Ketamine (DRUG); Methadone (DRUG); Tramadol (DRUG); Ketorolac (DRUG); Morphine Sulfate (DRUG); Fentanyl (DRUG); Dilaudid (DRUG); Hydrocodone-Acetaminophen Tab 5-325 MG (DRUG); Morphine Sulfate (DRUG); Fentanyl (DRUG); Dilaudid (DRUG); HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET (DRUG),6314,Glydo,"Colon Cancer; Colon Diverticulosis; Colonic Neoplasms; Colonic Diverticulitis; Pain, Postoperative; Ileus; Ileus Paralytic; Ileus; Mechanical; Constipation Drug Induced; Constipation; Rectum Cancer; Rectum Neoplasm",Bowel,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12082,NCT00904020,"A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain",COMPLETED,PHASE4,Postherpetic Neuralgia; Diabetic Neuropathy; Low Back Pain,Lidoderm (DRUG),6314,Glydo,Postherpetic Neuralgia; Diabetic Neuropathy; Low Back Pain,Peripheral Nervous System,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12083,NCT00540982,Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction,COMPLETED,PHASE1,"Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",indocyanine green (DRUG); lidocaine (DRUG); vinorelbine ditartrate (DRUG); high performance liquid chromatography (OTHER); intracellular fluorescence polarization analysis (OTHER); liquid chromatography (OTHER); mass spectrometry (OTHER); pharmacological study (OTHER),6314,Glydo,"Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Lung,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12084,NCT05521373,Ultrasound-guided Versus Combined Ultrasound and Fluoroscopy-guided Cervical Selective Nerve Root Block for Lower Cervical Radiculopathy: Non-inferiority Randomized Controlled Study,UNKNOWN,PHASE2,Cervical Pain,ultrasound cervical selective nerve root block (DEVICE); ultrasound and fluoroscopy-guided cervical selective nerve root block (DEVICE),6314,Glydo,Cervical Pain,Cervix,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12085,NCT00521703,Evaluation of Topical Lidocaine Spray as Adjuvant to Upper Gastrointestinal Endoscopy in Children,COMPLETED,PHASE3,Dyspepsia; Malabsorption Syndrome; Gastroesophageal Reflux Disease; Abdominal Pain,Lidocaine (DRUG); Tannic acid (DRUG),6314,Glydo,Dyspepsia; Malabsorption Syndrome; Gastroesophageal Reflux Disease; Abdominal Pain,Esophagus/Stomach,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12086,NCT01824303,"Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis",TERMINATED,PHASE2,Interstitial Cystitis,LiRIS 400 mg (DRUG); LiRIS Placebo (OTHER),6314,Glydo,Interstitial Cystitis,Bladder/Urinary Tract,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12087,NCT02618603,Botulinum Toxin A for Shoulder Pain After Stroke,UNKNOWN,PHASE4,Stroke; Pain,Botulinum toxin A (DRUG); Triamcinolone Acetonide (DRUG),6314,Glydo,Cerebrovascular Accident,CNS/Brain,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12088,NCT06747390,Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery,RECRUITING,PHASE1,Oropharyngeal Squamous Cell Carcinoma (OPSCCA); Oropharyngeal Cancer; Human Papilloma Virus; Squamous Cell Carcinoma,Lidocaine 1% Injectable Solution (DRUG),6314,Glydo,Oropharyngeal Squamous Cell Carcinoma (OPSCCA); Oropharyngeal Cancer; Human Papilloma Virus; Squamous Cell Carcinoma,Skin,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12089,NCT03390790,Lidocaine for Pain After Urodynamic Testing,COMPLETED,PHASE4,Voiding Disorders; Overactive Bladder; Urinary Incontinence,Lidocaine gel 2% (DRUG); Standard lubricant gel (OTHER),6314,Glydo,Voiding Disorders; Overactive Bladder; Urinary Incontinence,Bladder/Urinary Tract,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12090,NCT03831321,"The Effect of Preemptive Analgesia On The Comfort Of Patient and Doctor, in Cystoscopy",UNKNOWN,PHASE4,Bladder Cancer; Benign Prostate Hyperplasia; Hematuria; Pain; Lower Urinary Tract Symptoms,Diclofenac Sodium (DRUG); Cystoscopy (DEVICE); Lubricant Gel (DRUG),6314,Glydo,Bladder Cancer; Benign Prostate Hyperplasia; Hematuria; Pain; Lower Urinary Tract Symptoms,Bladder/Urinary Tract,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12091,NCT06250543,Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA in Women With Overactive Bladder,COMPLETED,PHASE4,Overactive Bladder,AbobotulinumtoxinA 300 UNT (DRUG); IncobotulinumtoxinA 100 UNT (DRUG); Lidocain (DRUG); placebo (OTHER),6314,Glydo,Overactive Bladder,Bladder/Urinary Tract,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12092,NCT02839668,The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer (TIVA/TCI-BC),COMPLETED,PHASE2,Breast Cancer,Lidocaine (DRUG); Sevoflurane (DRUG); TIVA-TCI (DRUG); Acetaminophen (DRUG); Tramadol (DRUG); Neostigmine (DRUG); Atropine (DRUG); BIS (DEVICE),6314,Glydo,Breast Cancer,Breast,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12093,NCT05653401,Treatment of Renal Colic in the Emergency Department: Comparison Between Magnesium Sulfate and Lidocaine.,COMPLETED,PHASE2,Renal Colic,Magnesium sulfate and diclofenac (DRUG); Lidocain and diclofenac (DRUG); Placebo and diclofenac (DRUG),6314,Glydo,Renal Colic,Kidney,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12094,NCT05044468,EXPAREL or Lidocane as Local Anesthetic in Patients Undergoing Pleuroscopy With Pleural Biopsy and Indwelling Pleural Catheter Placement,RECRUITING,PHASE2,Malignant Pleural Neoplasm,Lidocaine (DRUG); Liposomal Bupivacaine (DRUG); Questionnaire Administration (OTHER),6314,Glydo,Malignant Pleural Neoplasm,Lung,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12095,NCT00108446,Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome,COMPLETED,PHASE2,Irritable Bowel Syndrome,dextromethorphan (DRUG); naloxone (DRUG); fentanyl (DRUG); lidocaine (DRUG),6314,Glydo,Irritable Bowel Syndrome,Bowel,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12096,NCT02784860,Effects of Intravenous Lidocaine During Sedation for Colonoscopy.,COMPLETED,PHASE4,Colonoscopy,Lidocaine (DRUG); normal saline (DRUG),6314,Glydo,Colonoscopy,Bowel,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12097,NCT01381627,Safety Evaluation of Dexmedetomidine for EBUS-TBNA,UNKNOWN,PHASE4,Lung Cancer,Remifentanil (DRUG); Dexmedetomidine (DRUG),6314,Glydo,Lung Cancer,Lung,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12098,NCT04401176,Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome,COMPLETED,PHASE2,Interstitial Cystitis; Bladder Pain Syndrome,Heparin & Alkalinized Lidocaine Bladder Instillation (DRUG); Onabotulinum Toxin A (DRUG),6314,Glydo,Interstitial Cystitis; Bladder Pain Syndrome,Bladder/Urinary Tract,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12099,NCT05340231,An Exploratory Study of Sequential Transarterial Chemoembolization With Lipiodol and Neoadjuvant Chemotherapy in the Treatment of Initial Unresectable Colorectal Cancer (CRC),NOT_YET_RECRUITING,PHASE2,Colorectal Cancer,TACE protocol (DRUG); Neoadjuvant Chemotherapy (DRUG),6314,Glydo,Colorectal Cancer,Bowel,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12100,NCT00440960,Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic,COMPLETED,PHASE4,Lung Cancer,propofol (DRUG); midazolam (DRUG); alfentanil (DRUG); lidocaine (DRUG),6314,Glydo,Lung Cancer,Lung,Lidocaine (hydrochloride),"MAP2K1, MAPK1, NFKB1",unclear,unclear,yes,yes,Lidocaine hydrochloride is approved as a local anesthetic.,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl,1.09,216.0 +12101,NCT02555748,Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma,COMPLETED,PHASE4,Metastatic Renal Cell Cancer,Pazopanib (DRUG); Sunitinib (DRUG),5329102,Sutent,Metastatic Renal Cell Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12102,NCT02761057,"Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed",COMPLETED,PHASE2,Locally Advanced Papillary Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma,Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Cabozantinib S-malate (DRUG); Computed Tomography (PROCEDURE); Crizotinib (DRUG); Savolitinib (DRUG); Sunitinib Malate (DRUG),5329102,Sutent,Locally Advanced Papillary Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12103,NCT00389974,"Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery",COMPLETED,PHASE2,Cervical Adenocarcinoma; Cervical Adenosquamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Cancer; Stage IVB Cervical Cancer,sunitinib malate (DRUG),5329102,Sutent,Cervical Adenocarcinoma; Cervical Adenosquamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Cancer; Stage IVB Cervical Cancer,Skin,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12104,NCT00555620,Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer,COMPLETED,PHASE1,Stomach Neoplasms,capecitabine (DRUG); oxaliplatin (DRUG); sunitinib malate (DRUG); capecitabine (DRUG); cisplatin (DRUG); sunitinib malate (DRUG),5329102,Sutent,Stomach Neoplasms,Esophagus/Stomach,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12105,NCT01215565,Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma,TERMINATED,PHASE2,Hepatocellular Carcinoma; Fibrolamellar Hepatocellular Carcinoma,Sutent (DRUG),5329102,Sutent,Hepatocellular Carcinoma; Fibrolamellar Hepatocellular Carcinoma,Liver,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12106,NCT00699374,Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer,TERMINATED,PHASE3,"Carcinoma, Hepatocellular",sunitinib malate (DRUG); sorafenib (DRUG),5329102,Sutent,"Carcinoma, Hepatocellular",Liver,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12107,NCT00077974,A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.,COMPLETED,PHASE2,"Carcinoma, Renal Cell",SU011248 (DRUG),5329102,Sutent,"Carcinoma, Renal Cell",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12108,NCT00375674,A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer,COMPLETED,PHASE3,Kidney Neoplasms,Sunitinib malate (DRUG); Placebo (OTHER),5329102,Sutent,Kidney Neoplasms,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12109,NCT01185366,Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma,TERMINATED,PHASE2,Kidney Cancer,Everolimus (DRUG); Sunitinib (DRUG),5329102,Sutent,Kidney Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12110,NCT00434226,"A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)",TERMINATED,PHASE2,Non-Small Cell Lung Cancer,bevacizumab (DRUG); sunitinib (DRUG); carboplatin (DRUG); paclitaxel (DRUG),5329102,Sutent,Advanced Non-Small Cell Lung Cancer,Lung,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12111,NCT00979966,Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib,COMPLETED,PHASE2,Non-clear Cell Renal Cell Cancer,Temsirolimus (DRUG); Sunitinib (DRUG),5329102,Sutent,Non-clear Cell Renal Cell Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12112,NCT01024920,Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.,COMPLETED,PHASE2,"Carcinoma, Renal Cell",BIBF 1120 (DRUG); sunitinib (DRUG),5329102,Sutent,"Carcinoma, Renal Cell",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12113,NCT02853331,Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426),ACTIVE_NOT_RECRUITING,PHASE3,Renal Cell Carcinoma,Pembrolizumab (BIOLOGICAL); Axitinib (DRUG); Sunitinib (DRUG),5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12114,NCT05678673,Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma,RECRUITING,PHASE3,Non-Clear Cell Renal Cell Carcinoma,XL092 (DRUG); Nivolumab (DRUG); Sunitinib Malate (DRUG),5329102,Sutent,Non-Clear Cell Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12115,NCT00267748,Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC),COMPLETED,PHASE2,"Carcinoma, Renal Cell",Sunitinib Malate Continuous Daily Dosing (DRUG); Sunitinib Malate Schedule 4/2 (DRUG),5329102,Sutent,"Carcinoma, Renal Cell",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12116,NCT01514448,Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib,COMPLETED,PHASE4,Metastatic Renal Cell Carcinoma (mRCC),Everolimus (RAD001) (DRUG),5329102,Sutent,Metastatic Renal Cell Carcinoma (mRCC),Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12117,NCT01396148,A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor,COMPLETED,PHASE2,Gastrointestinal Stromal Tumors,sunitinib malate dose escalation (DRUG); sunitinib malate (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12118,NCT00715182,A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer,COMPLETED,PHASE1,Advanced/ Metastatic Renal Cell Cancer,TKI258 (DRUG),5329102,Sutent,Advanced/ Metastatic Renal Cell Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12119,NCT00577382,SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma,COMPLETED,PHASE2,Mucosal Lentiginous Melanoma; Acral Lentiginous Malignant Melanoma,Sunitinib (DRUG),5329102,Sutent,Mucosal Lentiginous Melanoma; Acral Lentiginous Malignant Melanoma,Skin,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12120,NCT06326190,177Lu-DOTATATE for Recurrent Meningioma,RECRUITING,PHASE2,Recurrent Meningioma,Local standard of Care (DRUG); 177Lu-DOTATATE (DRUG),5329102,Sutent,Recurrent Meningioma,CNS/Brain,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12121,NCT00243503,Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms,SU011248/Trastuzumab (DRUG),5329102,Sutent,Breast Neoplasms,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12122,NCT00459979,Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery,COMPLETED,PHASE2,Kidney Cancer,sunitinib malate (DRUG); conventional surgery (PROCEDURE),5329102,Sutent,Kidney Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12123,NCT05043090,"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC",ACTIVE_NOT_RECRUITING,PHASE3,Papillary Renal Cell Carcinoma,savolitinib (DRUG); durvalumab (DRUG); sunitinib (DRUG),5329102,Sutent,Papillary Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12124,NCT00967603,Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,sunitinib (DRUG),5329102,Sutent,Pancreatic Cancer,Pancreas,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12125,NCT01803503,"Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors",UNKNOWN,PHASE2,Solid Tumors; Breast Cancer; Non-small Cell Lung Cancer; Prostate Cancer; Gastric Cancer,Docetaxel (DRUG); Sunitinib (DRUG),5329102,Sutent,Solid Tumors; Breast Cancer; Non-small Cell Lung Cancer; Prostate Cancer; Gastric Cancer,Lung,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12126,NCT00981890,Stereotactic Radiosurgery With Sunitinib for Brain Metastases,COMPLETED,PHASE1,Brain Metastases,Sunitinib (DRUG),5329102,Sutent,Brain Metastases,CNS/Brain,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12127,NCT00421512,A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients,COMPLETED,PHASE1,Metastatic Renal Cell Carcinoma; Kidney Cancer,Bevacizumab and Sunitinib (DRUG),5329102,Sutent,Metastatic Renal Cell Carcinoma; Kidney Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12128,NCT00092001,Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Sunitinib (DRUG),5329102,Sutent,"Carcinoma, Non-Small-Cell Lung",Lung,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12129,NCT01265901,IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma,COMPLETED,PHASE3,Metastatic Renal Cell Carcinoma,Sunitinib (DRUG); GM-CSF (BIOLOGICAL); Cyclophosphamide (DRUG); IMA901 (DRUG),5329102,Sutent,Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12130,NCT03013946,Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy,TERMINATED,PHASE3,"Renal Cell Carcinoma, Metastatic; Renal Cell Cancer, Recurrent",Concomitant coaching (BEHAVIORAL),5329102,Sutent,"Renal Cell Carcinoma, Metastatic; Renal Cell Cancer, Recurrent",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12131,NCT04006769,Entacapone Combination With Imatinib for Treatment of GIST,COMPLETED,EARLY_PHASE1,"Gastrointestinal Stromal Tumor, Malignant",Entacapone (DRUG); Imatinib Mesylate (DRUG),5329102,Sutent,"Gastrointestinal Stromal Tumor, Malignant",Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12132,NCT06326346,GIST Oral Paclitaxel(Liporaxel),NOT_YET_RECRUITING,PHASE2,Gastrointestinal Stromal Tumors,Liporaxel (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12133,NCT00619268,Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma,COMPLETED,PHASE2,Metastatic Renal Cell Carcinoma,Temsirolimus (DRUG); Bevacizumab (DRUG); Sunitinib (DRUG); Interferon alpha-2a (DRUG),5329102,Sutent,Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12134,NCT00471276,Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms,sunitinib (DRUG),5329102,Sutent,Breast Neoplasms,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12135,NCT00788060,A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma,COMPLETED,PHASE1,Renal Cell Carcinoma,Everolimus (RAD001) (DRUG); Sunitinib (Sutent) (DRUG),5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12136,NCT01718327,A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma,COMPLETED,PHASE2,Unresectable and Advanced Cholangiocarcinoma,Sunitinib (DRUG),5329102,Sutent,Unresectable and Advanced Cholangiocarcinoma,Liver,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12137,NCT00821327,"Gemzar, Cisp, Sunitinib Urothelial Ca",COMPLETED,PHASE2,Urothelial Cancer,"Gemcitabine, Cisplatin, Sunitinib (DRUG)",5329102,Sutent,Urothelial Cancer,Bladder/Urinary Tract,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12138,NCT00247676,An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer,COMPLETED,PHASE2,Liver Neoplasms; Unresectable Hepatocellular Carcinoma,Sunitinib (SU011248) (DRUG),5329102,Sutent,Liver Neoplasms; Unresectable Hepatocellular Carcinoma,Liver,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12139,NCT00570882,Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC),COMPLETED,PHASE2,Metastatic Renal Cell Carcinoma,Sunitinib 2/1 (DRUG); Sunitinib 4/2 (DRUG),5329102,Sutent,Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12140,NCT00462982,Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma,COMPLETED,PHASE2,Kidney Cancer; Melanoma (Skin); Metastatic Cancer,sunitinib malate (DRUG),5329102,Sutent,Kidney Cancer; Melanoma (Skin); Metastatic Cancer,Skin,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12141,NCT01664182,"Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",COMPLETED,PHASE2,Advanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7,Bevacizumab (BIOLOGICAL); Pazopanib Hydrochloride (DRUG); Sorafenib Tosylate (DRUG); Sunitinib Malate (DRUG); Trebananib (BIOLOGICAL),5329102,Sutent,Advanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12142,NCT00906360,"Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck",TERMINATED,PHASE1,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Tongue Cancer; Untreated Metastatic Squamous Neck Cancer With Occult Primary,sunitinib malate (DRUG); pharmacological study (OTHER); 3-dimensional conformal radiation therapy (RADIATION); cetuximab (BIOLOGICAL),5329102,Sutent,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Tongue Cancer; Untreated Metastatic Squamous Neck Cancer With Occult Primary,Skin,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12143,NCT03091192,Savolitinib vs. Sunitinib in MET-driven PRCC.,ACTIVE_NOT_RECRUITING,PHASE3,"Carcinoma; Carcinoma, Renal Cell; Kidney Neoplasms; Urologic Neoplasms; Kidney Diseases; Neoplasms by Site; Enzyme Inhibitors; Protein Kinase Inhibitors",Savolitinib (DRUG); Sunitinib (DRUG),5329102,Sutent,"Carcinoma; Carcinoma, Renal Cell; Kidney Neoplasms; Urologic Neoplasms; Kidney Diseases; Neoplasms by Site; Enzyme Inhibitors; Protein Kinase Inhibitors",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12144,NCT01649180,NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma,TERMINATED,PHASE2,Renal Cell Carcinoma,Axitinib (DRUG),5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12145,NCT02689167,Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma,UNKNOWN,PHASE2,Kidney Neoplasms; Metastatic Renal Cell Cancer,Sunitinib (DRUG),5329102,Sutent,Kidney Neoplasms; Metastatic Renal Cell Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12146,NCT00555672,Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer,COMPLETED,PHASE1,Stomach Neoplasms,5-fluorouracil (DRUG); cisplatin (DRUG); sunitinib malate (DRUG),5329102,Sutent,Stomach Neoplasms,Esophagus/Stomach,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12147,NCT00499473,Sunitinib in Treating Patients With Recurrent Malignant Gliomas,COMPLETED,PHASE2,Adult Anaplastic Astrocytoma; Adult Diffuse Astrocytoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Oligodendroglioma; Adult Pineal Gland Astrocytoma,sunitinib malate (DRUG); pharmacological study (OTHER),5329102,Sutent,Adult Anaplastic Astrocytoma; Adult Diffuse Astrocytoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Oligodendroglioma; Adult Pineal Gland Astrocytoma,CNS/Brain,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12148,NCT01216657,Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma,TERMINATED,PHASE2,Chemo-refractory Melanoma,Sunitinib (DRUG),5329102,Sutent,Chemo-refractory Melanoma,Skin,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12149,NCT01258348,A Phase 1b Trial in Patients With Renal Cell Cancer,COMPLETED,PHASE1,Metastatic Renal Cell Cancer,Drug: LY573636-sodium (DRUG); Sunitinib (DRUG),5329102,Sutent,Metastatic Renal Cell Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12150,NCT00853125,Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer,TERMINATED,PHASE2,Kidney Cancer,therapeutic allogeneic lymphocytes (BIOLOGICAL); sunitinib malate (DRUG),5329102,Sutent,Kidney Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12151,NCT00688766,Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib,TERMINATED,PHASE3,Gastrointestinal Stromal Tumors,retaspimycin hydrochloride (IPI-504) (DRUG); placebo (DRUG); Best supportive care (OTHER),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12152,NCT00578526,SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial,COMPLETED,PHASE2,Urothelial Cancer; Bladder Cancer; Adult,SU011248 (DRUG); Placebo (DRUG),5329102,Sutent,Urothelial Cancer; Bladder Cancer; Adult,Bladder/Urinary Tract,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12153,NCT00498966,Ph II Study of Perifosine for Patients With Carcinoma of the Kidney,COMPLETED,PHASE2,Kidney Cancer,Perifosine (DRUG),5329102,Sutent,Kidney Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12154,NCT00792025,Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer,COMPLETED,PHASE2,Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter,sunitinib malate (DRUG),5329102,Sutent,Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter,Bladder/Urinary Tract,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12155,NCT03035630,Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma,WITHDRAWN,PHASE2,Clear-cell Renal Cell Carcinoma; RCC; Kidney Cancer; Clear-cell Kidney Carcinoma,Avelumab (DRUG); Sunitinib (DRUG),5329102,Sutent,Clear-cell Renal Cell Carcinoma; RCC; Kidney Cancer; Clear-cell Kidney Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12156,NCT01391130,A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma,TERMINATED,PHASE2,Metastatic Clear Cell Renal Cell Carcinoma,LY2510924 (DRUG); Sunitinib (DRUG),5329102,Sutent,Metastatic Clear Cell Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12157,NCT01381822,"Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors",UNKNOWN,PHASE1,Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Pancreatic Neuroendocrine Tumors,TH-302 (DRUG),5329102,Sutent,Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Pancreatic Neuroendocrine Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12158,NCT00495625,Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC),TERMINATED,PHASE2,Liver Cancer,Sunitinib Malate (DRUG),5329102,Sutent,Liver Cancer,Liver,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12159,NCT01118039,"Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer",UNKNOWN,PHASE2,Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer,sunitinib malate (DRUG); immunohistochemistry staining method (OTHER); laboratory biomarker analysis (OTHER); pharmacological study (OTHER); quality-of-life assessment (PROCEDURE),5329102,Sutent,Urinary Tract Cancers,Bladder/Urinary Tract,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12160,NCT00393939,Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer,COMPLETED,PHASE3,Breast Neoplasms,Sunitinib malate (DRUG); Taxotere (DRUG),5329102,Sutent,Breast Neoplasms,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12161,NCT01070186,Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma,WITHDRAWN,PHASE2,Renal Cell Carcinoma,Sunitinib (DRUG); Tumor biopsy (OTHER); Nephrectomy (PROCEDURE); Biomarkers (OTHER),5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12162,NCT01342627,Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma,TERMINATED,PHASE2,Metastatic Renal Cell Carcinoma,Sorafenib (DRUG),5329102,Sutent,Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12163,NCT01714765,Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer,COMPLETED,PHASE1,Metastatic Clear Cell Renal Cancer,Dovitinib (DRUG); Everolimus (DRUG),5329102,Sutent,Metastatic Clear Cell Renal Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12164,NCT01158222,Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer,COMPLETED,PHASE2,Clear Cell Renal Cell Carcinoma; Stage IV Renal Cell Cancer,sunitinib malate (DRUG),5329102,Sutent,Clear Cell Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12165,NCT01147822,Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma,COMPLETED,PHASE2,"Carcinoma, Renal Cell",Pazopanib (DRUG); Sunitinib (DRUG),5329102,Sutent,"Carcinoma, Renal Cell",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12166,NCT00524186,"Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer",TERMINATED,PHASE1,Esophageal Cancer; Gastric Cancer,fluorouracil (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG); sunitinib malate (DRUG); flow cytometry (OTHER); pharmacological study (OTHER),5329102,Sutent,Esophageal and Gastric Cancer,Esophagus/Stomach,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12167,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,COMPLETED,PHASE3,Renal Cell Carcinoma,Sorafenib (DRUG); temsirolimus (Torisel) (DRUG),5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12168,NCT00923130,Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer,COMPLETED,PHASE2,Renal Cell Carcinoma,Bevacizumab (DRUG); Ixabepilone (DRUG),5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12169,NCT00694096,Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response,COMPLETED,PHASE1,Renal Cell Cancer,Sunitinib (DRUG),5329102,Sutent,Renal Cell Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12170,NCT00616122,"Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer",TERMINATED,PHASE1,Breast Cancer,cyclophosphamide (DRUG); methotrexate (DRUG); sunitinib malate (DRUG); laboratory biomarker analysis (OTHER),5329102,Sutent,Breast Cancer,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12171,NCT04633122,A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib,COMPLETED,PHASE2,Gastrointestinal Stromal Tumor(GIST),Ripretinib (DRUG); Sunitinib (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumor(GIST),Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12172,NCT02402062,A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours,COMPLETED,PHASE2,Neuroendocrine Tumors; Pancreatic Neoplasms,TH-302 + Sunitinib (DRUG),5329102,Sutent,Neuroendocrine Tumors; Pancreatic Neoplasms,Pancreas,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12173,NCT00581789,Erlotinib and Sunitinib in NSCLC,COMPLETED,PHASE1,Non Small Cell Lung Cancer,"erlotinib, sunitinib (DRUG)",5329102,Sutent,Non Small Cell Lung Cancer,Lung,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12174,NCT00113529,Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma,COMPLETED,PHASE1,"Carcinoma, Renal Cell",Gefitinib + Sunitinib (DRUG),5329102,Sutent,"Carcinoma, Renal Cell",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12175,NCT03905889,A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma,TERMINATED,PHASE1,Renal Cell Carcinoma Metastatic,Abemaciclib (DRUG); Sunitinib (DRUG),5329102,Sutent,Renal Cell Carcinoma Metastatic,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12176,NCT00457691,Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE3,Metastatic Colorectal Cancer,5 fluorouracil (DRUG); irinotecan (DRUG); levo- leucovorin (DRUG); sunitinib (DRUG); 5 fluorouracil (DRUG); irinotecan (DRUG); levo- leucovorin (DRUG); placebo (DRUG),5329102,Sutent,Metastatic Colorectal Cancer,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12177,NCT00474994,"Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas",COMPLETED,PHASE2,Adult Malignant Fibrous Histiocytoma of Bone; Desmoid Tumor; Endometrial Cancer; Ovarian Cancer; Sarcoma; Small Intestine Cancer,sunitinib malate (DRUG),5329102,Sutent,Adult Malignant Fibrous Histiocytoma of Bone; Desmoid Tumor; Endometrial Cancer; Ovarian Cancer; Sarcoma; Small Intestine Cancer,Uterus,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12178,NCT03260894,Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302),ACTIVE_NOT_RECRUITING,PHASE3,Renal Cell Carcinoma (RCC),Pembrolizumab (DRUG); Epacadostat (DRUG); Sunitinib (DRUG); Pazopanib (DRUG),5329102,Sutent,Renal Cell Carcinoma (RCC),Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12179,NCT00718562,Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib,COMPLETED,PHASE2,Gastrointestinal Stromal Tumors,AMN107 (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12180,NCT02790580,Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients,UNKNOWN,PHASE2,Breast Cancer,Dose-dense doxorubicin/cyclophosphamide + sunitinib (DRUG); Dose-dense doxorubicin/cyclophosphamide (DRUG),5329102,Sutent,Breast Cancer,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12181,NCT03170180,Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer,COMPLETED,PHASE2,Stomach Neoplasms,Sunitinib (DRUG); Gefitinib (DRUG); Imatinib (DRUG),5329102,Sutent,Stomach Neoplasms,Esophagus/Stomach,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12182,NCT00748163,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer,WITHDRAWN,PHASE2,Lung Cancer,paclitaxel albumin-stabilized nanoparticle formulation (DRUG); sunitinib malate (DRUG),5329102,Sutent,Lung Cancer,Lung,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12183,NCT00387335,Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer,COMPLETED,PHASE2,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity,sunitinib malate (DRUG),5329102,Sutent,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity,Skin,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12184,NCT03598816,PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma,WITHDRAWN,PHASE2,Renal Cell Carcinoma,Durvalumab (DRUG); Tremelimumab (DRUG); TDS-IM v1.0 System (DEVICE); Neoantigen DNA Vaccine (BIOLOGICAL); Research blood draw (PROCEDURE),5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12185,NCT00113516,A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-small Cell Lung Cancer,carboplatin (DRUG); paclitaxel (DRUG); sunitinib (DRUG),5329102,Sutent,Non-small Cell Lung Cancer,Lung,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12186,NCT00410124,RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib,COMPLETED,PHASE3,Metastatic Renal Cell Carcinoma,RAD001 (DRUG); Placebo (DRUG),5329102,Sutent,Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12187,NCT00618124,A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together,COMPLETED,PHASE1,Solid Tumors; Breast Cancer; Neoplasms,SU011248; Capecitabine (DRUG),5329102,Sutent,Solid Tumors; Breast Cancer; Neoplasms,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12188,NCT00393796,Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma,TERMINATED,PHASE2,Bladder Cancer,SUTENT (DRUG); Placebo (OTHER),5329102,Sutent,Bladder Cancer,Bladder/Urinary Tract,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12189,NCT03909724,Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC),UNKNOWN,PHASE2,Colorectal Cancer; Metastasis,Sunitinib Malate (DRUG); TAS 102 (DRUG),5329102,Sutent,Colorectal Cancer; Metastasis,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12190,NCT00553696,Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer,COMPLETED,PHASE1,Stomach Neoplasms,Cisplatin (DRUG); S-1 (DRUG); Sunitinib (DRUG),5329102,Sutent,Stomach Neoplasms,Esophagus/Stomach,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12191,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,TERMINATED,PHASE2,Liver Cancer,doxorubicin hydrochloride (DRUG); sunitinib malate (DRUG); laboratory biomarker analysis (OTHER); hepatic artery embolization (PROCEDURE); quality-of-life assessment (PROCEDURE),5329102,Sutent,Liver Cancer,Liver,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12192,NCT05366816,ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST,RECRUITING,PHASE2,Gastrointestinal Stromal Tumors,Sunitinib (DRUG); Regorafenib (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12193,NCT01673386,A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC,TERMINATED,PHASE2,Metastatic Renal Cell Carcinoma,Tivozanib (DRUG); Sunitinib (DRUG),5329102,Sutent,Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12194,NCT00609622,Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer,TERMINATED,PHASE2,Colorectal Neoplasms,sunitinib (DRUG); mFOLFOX6 (DRUG); bevacizumab (DRUG); mFOLFOX6 (DRUG),5329102,Sutent,Colorectal Neoplasms,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12195,NCT02068586,Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma,ACTIVE_NOT_RECRUITING,PHASE2,"Ciliary Body and Choroid Melanoma, Medium/Large Size; Ciliary Body and Choroid Melanoma, Small Size; Iris Melanoma; Stage I Intraocular Melanoma; Stage IIA Intraocular Melanoma; Stage IIB Intraocular Melanoma; Stage IIIA Intraocular Melanoma; Stage IIIB Intraocular Melanoma; Stage IIIC Intraocular Melanoma; Stage I Uveal Melanoma AJCC V7; Stage II Uveal Melanoma AJCC V7; Stage III Uveal Melanoma AJCC V7",Sunitinib (DRUG); Valproic Acid (DRUG); Sunitinib Malate (DRUG); Sunitinib Malate + Valproic Acid (DRUG),5329102,Sutent,"Ciliary Body and Choroid Melanoma, Medium/Large Size; Ciliary Body and Choroid Melanoma, Small Size; Iris Melanoma; Stage I Intraocular Melanoma; Stage IIA Intraocular Melanoma; Stage IIB Intraocular Melanoma; Stage IIIA Intraocular Melanoma; Stage IIIB Intraocular Melanoma; Stage IIIC Intraocular Melanoma; Stage I Uveal Melanoma AJCC V7; Stage II Uveal Melanoma AJCC V7; Stage III Uveal Melanoma AJCC V7",Skin,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12196,NCT00570635,A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib,COMPLETED,PHASE2,Gastrointestinal Stromal Tumors; Gastrointestinal Neoplasms,XL820 (DRUG); XL820 (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors; Gastrointestinal Neoplasms,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12197,NCT03275558,Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma,WITHDRAWN,PHASE1,Recurrent Glioblastoma; Gliosarcoma; Anaplastic Gliomas,Axitinib 1 MG (DRUG); Sunitinib 5 MG (DRUG); Pazopanib 5 MG (DRUG),5329102,Sutent,Recurrent Glioblastoma; Gliosarcoma; Anaplastic Gliomas,CNS/Brain,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12198,NCT01498458,Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer,COMPLETED,PHASE1,Metastatic Breast Cancer,Pazopanib plus capecitabine (DRUG),5329102,Sutent,Metastatic Breast Cancer,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12199,NCT00499135,Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors,COMPLETED,PHASE1,Adult Solid Neoplasm; Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Computed Tomography (OTHER); Fluorothymidine F-18 (OTHER); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Positron Emission Tomography (OTHER); Sunitinib Malate (DRUG),5329102,Sutent,Adult Solid Neoplasm; Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12200,NCT02019576,Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib,COMPLETED,PHASE2,Clear Cell Metastatic Renal Cell Carcinoma,Stereotactic radiotherapy (RADIATION),5329102,Sutent,Clear Cell Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12201,NCT00890110,Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib,UNKNOWN,PHASE1,Renal Cell Cancer,Autologous renal cell vaccine based on DNP modified cells (BIOLOGICAL),5329102,Sutent,Renal Cell Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12202,NCT01462695,"Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma",COMPLETED,PHASE2,Childhood Cerebellar Anaplastic Astrocytoma; Childhood Cerebral Anaplastic Astrocytoma; Childhood Cerebral Astrocytoma; Childhood Infratentorial Ependymoma; Childhood Mixed Glioma; Childhood Oligodendroglioma; Childhood Supratentorial Ependymoma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Subependymal Giant Cell Astrocytoma,Diagnostic Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Sunitinib Malate (DRUG),5329102,Sutent,Childhood Cerebellar Anaplastic Astrocytoma; Childhood Cerebral Anaplastic Astrocytoma; Childhood Cerebral Astrocytoma; Childhood Infratentorial Ependymoma; Childhood Mixed Glioma; Childhood Oligodendroglioma; Childhood Supratentorial Ependymoma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Subependymal Giant Cell Astrocytoma,CNS/Brain,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12203,NCT00631410,Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer,COMPLETED,PHASE1,Colorectal Neoplasms,sunitinib + mFOLFOX6 (DRUG); sunitinib + mFOLFOX6 (DRUG),5329102,Sutent,Colorectal Neoplasms,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12204,NCT00693992,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,COMPLETED,PHASE3,Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IV Non-Small Cell Lung Cancer AJCC v7,Laboratory Biomarker Analysis (OTHER); Placebo (OTHER); Quality-of-Life Assessment (OTHER); Sunitinib Malate (DRUG),5329102,Sutent,Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IV Non-Small Cell Lung Cancer AJCC v7,Lung,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12205,NCT00489944,"Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma",UNKNOWN,PHASE2,Intraocular Melanoma,cisplatin (DRUG); sunitinib malate (DRUG); tamoxifen citrate (DRUG); adjuvant therapy (PROCEDURE),5329102,Sutent,Intraocular Melanoma,Skin,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12206,NCT00673504,First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,Gemcitabine + Sunitinib (DRUG); Gemcitabine (DRUG),5329102,Sutent,Pancreatic Cancer,Pancreas,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12207,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,75 approved agents (DRUG); COXEN (OTHER),5329102,Sutent,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,Bladder/Urinary Tract,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12208,NCT00712504,Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer,COMPLETED,PHASE1,Advanced Solid Tumors; Non Small Cell Lung Cancer,sunitinib (DRUG); docetaxel (DRUG),5329102,Sutent,Advanced Solid Tumors; Non Small Cell Lung Cancer,Lung,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12209,NCT01491672,Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma,COMPLETED,PHASE2,Metastatic Renal Cell Carcinoma,RAD001 (DRUG),5329102,Sutent,Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12210,NCT00573404,Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors,TERMINATED,PHASE1,Gastrointestinal Stromal Tumor,imatinib mesylate (DRUG); sunitinib malate (DRUG); pharmacological study (OTHER),5329102,Sutent,Gastrointestinal Stromal Tumor,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12211,NCT02164240,Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST,COMPLETED,PHASE1,Gastrointestinal Stromal Tumor,Sunitinib (DRUG); Regorafenib (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumor,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12212,NCT06955169,"Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment",NOT_YET_RECRUITING,PHASE2,Intracranial Meningioma,[177Lu]Lu-DOTATATE (DRUG); Standard of Care treatments (OTHER),5329102,Sutent,Intracranial Meningioma,CNS/Brain,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12213,NCT03456401,Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study),TERMINATED,PHASE2,Renal Cancer Cell,Sorafenib or Sunitinib (DRUG),5329102,Sutent,Renal Cancer Cell,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12214,NCT03673501,A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib,ACTIVE_NOT_RECRUITING,PHASE3,Gastrointestinal Stromal Tumors,Ripretinib (DRUG); Sunitinib (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12215,NCT00422344,A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma,COMPLETED,PHASE1,Renal Cell Carcinoma; Kidney Cancer,"RAD001, Sunitinib (DRUG)",5329102,Sutent,Renal Cell Carcinoma; Kidney Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12216,NCT00361244,SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer,TERMINATED,PHASE1,Colorectal Carcinoma,SU011248 (DRUG); Irinotecan (DRUG); Cetuximab (DRUG),5329102,Sutent,Colorectal Carcinoma,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12217,NCT00392444,Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma,COMPLETED,PHASE2,Advanced Malignant Mesothelioma; Recurrent Malignant Mesothelioma,sunitinib malate (DRUG),5329102,Sutent,Advanced Malignant Mesothelioma; Recurrent Malignant Mesothelioma,Lung,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12218,NCT00768144,"Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma",COMPLETED,PHASE2,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer,Sunitinib (DRUG),5329102,Sutent,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12219,NCT00457392,A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone,COMPLETED,PHASE3,"Carcinoma, Non-Small Cell Lung",erlotinib (DRUG); sunitinib (DRUG); erlotinib (DRUG); placebo (DRUG),5329102,Sutent,"Carcinoma, Non-Small Cell Lung",Lung,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12220,NCT02570789,Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy,TERMINATED,PHASE4,Clear-cell Metastatic Renal Cell Carcinoma,patients with sunitinib or pazopanib (DRUG),5329102,Sutent,Clear-cell Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12221,NCT01402089,Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients,COMPLETED,PHASE4,Non Small-cell Lung Cancer; Renal-cell Cancer; Gastrointestinal Stroma Tumor,Sunitinib (DRUG); Erlotinib (DRUG); Midazolam (DRUG); Caffeine (DRUG),5329102,Sutent,Non Small-cell Lung Cancer; Renal-cell Cancer; Gastrointestinal Stroma Tumor,Lung,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12222,NCT00083889,SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma,COMPLETED,PHASE3,"Carcinoma, Renal Cell",Interferon-alfa (DRUG); SU011248 (DRUG),5329102,Sutent,"Carcinoma, Renal Cell",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12223,NCT00695292,"Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer",COMPLETED,PHASE2,Small Cell Lung Cancer,irinotecan (DRUG); Carboplatin (DRUG); sunitinib (DRUG),5329102,Sutent,Small Cell Lung Cancer,Lung,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12224,NCT01835158,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,COMPLETED,PHASE2,Clear Cell Renal Cell Carcinoma; Metastatic Kidney Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7,Cabozantinib S-malate (DRUG); Laboratory Biomarker Analysis (OTHER); Sunitinib Malate (DRUG),5329102,Sutent,Clear Cell Renal Cell Carcinoma; Metastatic Kidney Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12225,NCT01731158,Sequential Therapy in Metastatic Renal Cell Carinoma,COMPLETED,PHASE2,Metastatic Renal Cell Carcinoma,"Avastin in combination with Roferon-A (DRUG); Afinitor (DRUG); TKI: Sutent, Nexavar or Votrient (DRUG)",5329102,Sutent,Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12226,NCT04106024,"Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial",UNKNOWN,PHASE2,Gastrointestinal Stromal Tumors,Anlotinib (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12227,NCT05949424,OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults,NOT_YET_RECRUITING,PHASE4,Renal Cell Carcinoma; Ovarian Carcinoma; Thyroid Carcinoma; Breast Carcinoma; Endometrium Carcinoma,Olaparib (DRUG); Lenvatinib (DRUG); Sunitinib (DRUG); Palbociclib (DRUG); Pazopanib (DRUG); Olaparib (DRUG); Lenvatinib (DRUG); Sunitinib (DRUG); Palbociclib (DRUG); Pazopanib (DRUG),5329102,Sutent,Renal Cell Carcinoma; Ovarian Carcinoma; Thyroid Carcinoma; Breast Carcinoma; Endometrium Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12228,NCT00372424,Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive,COMPLETED,PHASE1,Breast Cancer,Herceptin (DRUG); Sunitinib (DRUG); Taxotere (DRUG),5329102,Sutent,Breast Cancer,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12229,NCT00599924,Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors,COMPLETED,PHASE1,Colorectal Neoplasms; Neoplasms,sunitinib + FOLFOX (DRUG); sunitinib + FOLFOX (DRUG); sunitinib + FOLFOX (DRUG); sunitinib + FOLFOX (DRUG); sunitinib + FOLFOX (DRUG); sunitinib + FOLFOX (DRUG); sunitinib + FOLFOX (DRUG),5329102,Sutent,Colorectal Neoplasms; Neoplasms,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12230,NCT03609424,PDR001 Plus Imatinib for Metastatic or Unresectable GIST,COMPLETED,PHASE1,Gastrointestinal Stromal Tumors,"PDR001, Imatinib (DRUG)",5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12231,NCT01039519,A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST),COMPLETED,PHASE2,Gastrointestinal Stromal Tumor,Ganetespib (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumor,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12232,NCT06275919,Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial),RECRUITING,PHASE2,"Meningioma, Malignant",Regorafenib 40 MG Oral Tablet (DRUG); Local Standard of Care (DRUG),5329102,Sutent,"Meningioma, Malignant",CNS/Brain,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12233,NCT05245968,A Study of Pimitespib in Combination with Imatinib in Patients with GIST (CHAPTER-GIST-101),RECRUITING,PHASE1,Gastrointestinal Stromal Tumors,Pimitespib (DRUG); Imatinib (DRUG); Sunitinib (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12234,NCT02700568,Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors,COMPLETED,PHASE2,"Carcinoma, Renal Cell; Clear Cell Renal Cell Carcinoma",axitinib (DRUG),5329102,Sutent,"Carcinoma, Renal Cell; Clear Cell Renal Cell Carcinoma",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12235,NCT04523272,A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Advanced Renal Cancer,TQB2450 (DRUG); Anlotinib (DRUG); Sunitinib (DRUG),5329102,Sutent,Advanced Renal Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12236,NCT01582672,Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma,TERMINATED,PHASE3,Advanced Renal Cell Carcinoma; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma,Standard Treatment (DRUG); AGS-003 (BIOLOGICAL),5329102,Sutent,Advanced Renal Cell Carcinoma; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12237,NCT03944304,"Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.",RECRUITING,PHASE2,Gastrointestinal Stromal Tumors,Paclitaxel (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12238,NCT05152472,"A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined with Atezolizumab Versus Imatinib Resumption Alone in Patients with Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments",RECRUITING,PHASE2,Unresectable Gastrointestinal Stromal Tumor (GIST); Locally Advanced Gastrointestinal Stromal Tumor (GIST); Metastatic Gastrointestinal Stromal Tumor,Atezolizumab 1200 mg (DRUG); Imatinib 400 MG (DRUG),5329102,Sutent,Unresectable Gastrointestinal Stromal Tumor (GIST); Locally Advanced Gastrointestinal Stromal Tumor (GIST); Metastatic Gastrointestinal Stromal Tumor,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12239,NCT00853372,AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib,COMPLETED,PHASE2,Advanced Renal Cell Carcinoma,Sunitinib (DRUG); Trebananib (DRUG),5329102,Sutent,Advanced Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12240,NCT00254540,Study of SU011248 in Patients With Advanced Kidney Cancer,COMPLETED,PHASE2,"Carcinoma, Renal Cell",SU011248 capsule (DRUG),5329102,Sutent,"Carcinoma, Renal Cell",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12241,NCT02432846,Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC),COMPLETED,PHASE2,"Renal Cell Carcinoma, Metastatic",Intuvax (INN: ilixadencel) (BIOLOGICAL); Sunitinib (DRUG),5329102,Sutent,"Renal Cell Carcinoma, Metastatic",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12242,NCT01798446,A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus,COMPLETED,PHASE2,Renal Cell Carcinoma; Nonclear Cell; Temsirolimus Resistance,Axitinib (DRUG),5329102,Sutent,Renal Cell Carcinoma; Nonclear Cell; Temsirolimus Resistance,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12243,NCT01265810,Caphosol in Oral Mucositis Due to Targeted Therapy,COMPLETED,PHASE3,Oral Complaints; Renal Cell Carcinoma; Hepatocellular Carcinoma; Gastrointestinal Stromal Tumors,supersaturated calcium-phosphate (OTHER); sodium chloride 0.9 % (OTHER),5329102,Sutent,Oral Complaints; Renal Cell Carcinoma; Hepatocellular Carcinoma; Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12244,NCT00372567,Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors,TERMINATED,PHASE3,Gastrointestinal Stromal Tumor,sunitinib malate (DRUG); imatinib mesylate (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumor,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12245,NCT01271712,Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST),COMPLETED,PHASE3,Gastrointestinal Stromal Tumors,"Regorafenib (Stivarga, BAY73-4506) (DRUG); Placebo (DRUG); Best supportive care (DRUG)",5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12246,NCT05160168,A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST),TERMINATED,PHASE1,"Gastrointestinal Stromal Tumors (GIST); Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasm; Digestive System Disease; Gastrointestinal Diseases",THE-630 (DRUG),5329102,Sutent,"Gastrointestinal Stromal Tumors (GIST); Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasm; Digestive System Disease; Gastrointestinal Diseases",Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12247,NCT01068769,Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor,COMPLETED,PHASE2,Gastrointestinal Stromal Tumor,regorafenib (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumor,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12248,NCT01005472,Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma,COMPLETED,PHASE1,Metastatic Melanoma,sunitinib malate (DRUG); temozolomide (DRUG),5329102,Sutent,Metastatic Melanoma,Skin,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12249,NCT01246817,Temsirolimus-RCC-imaging,UNKNOWN,PHASE2,Renal Cell Cancer,Temsirolimus (DRUG),5329102,Sutent,Renal Cell Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12250,NCT00782834,Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST),TERMINATED,PHASE2,Gastrointestinal Stromal Tumors,Nilotinib (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12251,NCT00265317,A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",erlotinib (DRUG); sunitinib (DRUG); erlotinib (DRUG); placebo (DRUG),5329102,Sutent,"Carcinoma, Non-Small-Cell Lung",Lung,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12252,NCT00720941,Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma,COMPLETED,PHASE3,"Carcinoma, Renal Cell",Pazopanib (DRUG); Sunitinib (DRUG),5329102,Sutent,"Carcinoma, Renal Cell",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12253,NCT01829217,Sunitinib in Never-Smokers With Lung Adenocarcinoma,COMPLETED,PHASE2,Lung Cancer,Sunitinib (DRUG),5329102,Sutent,Lung Cancer,Lung,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12254,NCT00923117,Sunitinib to Treat Recurrent Brain Cancer,TERMINATED,PHASE2,Glioblastoma Multiforme; Malignant Gliomas; Anaplastic Gliomas,Sutent (sunitinib) (DRUG),5329102,Sutent,Glioblastoma Multiforme; Malignant Gliomas; Anaplastic Gliomas,CNS/Brain,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12255,NCT01829841,A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer,COMPLETED,PHASE2,Renal Cell Cancer; Metastatic Renal Cell Cancer,Famitinib (DRUG); Sunitinib (DRUG),5329102,Sutent,Renal Cell Cancer; Metastatic Renal Cell Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12256,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,COMPLETED,PHASE1,Breast Neoplasms,SU011248 (DRUG); Paclitaxel (DRUG),5329102,Sutent,Breast Neoplasms,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12257,NCT01200134,HYPONCO - Hypoxia in Brain Tumors,COMPLETED,PHASE2,Anaplastic Glioma,18F-FMISO PET-scanning (OTHER),5329102,Sutent,Anaplastic Glioma,CNS/Brain,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12258,NCT02071641,Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma,TERMINATED,PHASE2,Metastatic Renal Cell Carcinoma,Sunitinib (DRUG),5329102,Sutent,Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12259,NCT00373113,A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine,TERMINATED,PHASE3,Breast Neoplasms,Capecitabine (DRUG); Sunitinib malate (DRUG),5329102,Sutent,Breast Neoplasms,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12260,NCT00678119,Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment,COMPLETED,PHASE2,Renal Cell Carcinoma,AGS-003 (BIOLOGICAL); Sunitinib (DRUG),5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12261,NCT00075218,A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST),COMPLETED,PHASE3,Gastrointestinal Stromal Tumor,Placebo (DRUG); SU011248 (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumor,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12262,NCT01506336,Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib,COMPLETED,PHASE2,Gastro Intestinal Stromal Tumor,masitinib (DRUG); sunitinib (DRUG),5329102,Sutent,Gastro Intestinal Stromal Tumor,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12263,NCT00543049,"Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor",COMPLETED,PHASE2,Platinum Refractory Epithelial Ovarian Cancer; Primary Cancer of the Peritoneum; Cancer of the Fallopian Tube,Sunitinib (DRUG); SUNITINIB (DRUG),5329102,Sutent,Platinum Refractory Epithelial Ovarian Cancer; Primary Cancer of the Peritoneum; Cancer of the Fallopian Tube,Ovary/Fallopian Tube,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12264,NCT00931450,Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer,UNKNOWN,PHASE1,Breast Cancer,exemestane (DRUG); sunitinib malate (DRUG); placebo (OTHER),5329102,Sutent,Breast Cancer,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12265,NCT00818350,Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer,UNKNOWN,PHASE1,Urinary Bladder Neoplasms,SUNITINIB (DRUG),5329102,Sutent,Urinary Bladder Neoplasms,Bladder/Urinary Tract,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12266,NCT02712112,A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs,COMPLETED,PHASE2,Gastrointestinal Stromal Tumors (GISTs),Imatinib Mesylate (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors (GISTs),Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12267,NCT03379012,Testosterone in Metastatic Renal Cell Carcinoma Patients,COMPLETED,PHASE2,Metastatic Renal Cell Carcinoma,Testosterone undecanoate and sunitinib or pazopanib (DRUG),5329102,Sutent,Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12268,NCT02560012,Personalized Targeted Inhibitors Treatment in Renal Cell Cancer,TERMINATED,PHASE2,"Carcinoma, Renal Cell",Sunitinib (DRUG); Temsirolimus (DRUG); Sorafenib (DRUG); Pazopanib (DRUG); Everolimus (DRUG); Axitinib (DRUG),5329102,Sutent,"Carcinoma, Renal Cell",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12269,NCT00570908,Brain Mets - Capecitabine Plus Sunitinib and WBRT,TERMINATED,PHASE2,Breast Cancer,sunitinib (DRUG); capecitabine (DRUG); WBRT (RADIATION),5329102,Sutent,Breast Cancer,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12270,NCT04409223,Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib,TERMINATED,PHASE3,Gastrointestinal Stromal Tumors,Famitinib capsules (DRUG); Sunitinib Capsules (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12271,NCT00824538,"Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow",TERMINATED,PHASE2,Breast Cancer,sunitinib malate (DRUG); flow cytometry (OTHER); immunohistochemistry staining method (OTHER); laboratory biomarker analysis (OTHER),5329102,Sutent,Breast Cancer,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12272,NCT01472081,"Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)",COMPLETED,PHASE1,Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma,Nivolumab (BIOLOGICAL); Pazopanib (BIOLOGICAL); Sunitinib (DRUG); Ipilimumab (BIOLOGICAL),5329102,Sutent,Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12273,NCT03323710,Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma,WITHDRAWN,PHASE2,Renal Cell Carcinoma,Propranolol (DRUG); Sunitinib (DRUG),5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12274,NCT01064310,Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer,COMPLETED,PHASE3,"Carcinoma, Renal Cell",pazopanib (DRUG); sunitinib (DRUG),5329102,Sutent,"Carcinoma, Renal Cell",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12275,NCT00453310,Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment,COMPLETED,PHASE2,Extragonadal Germ Cell Tumor; Ovarian Cancer; Teratoma; Testicular Germ Cell Tumor,sunitinib malate (DRUG),5329102,Sutent,Extragonadal Germ Cell Tumor; Ovarian Cancer; Teratoma; Testicular Germ Cell Tumor,Ovary/Fallopian Tube,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12276,NCT00482755,Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery,COMPLETED,PHASE2,Breast Cancer,sunitinib malate (DRUG); immunohistochemistry staining method (OTHER); laboratory biomarker analysis (OTHER); pharmacological study (OTHER); needle biopsy (PROCEDURE); neoadjuvant therapy (PROCEDURE),5329102,Sutent,Breast Cancer,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12277,NCT00400114,"Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer",COMPLETED,PHASE2,Esophageal Cancer,Irinotecan (DRUG); Cisplatin (DRUG); Radiation (PROCEDURE); Surgery (PROCEDURE); sunitinib (Sutent) (DRUG),5329102,Sutent,Esophageal Cancer,Esophagus/Stomach,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12278,NCT00496223,A Phase I/II Study of Sunitinib and Dacarbazine,TERMINATED,PHASE1,Melanoma,Sunitinib (DRUG); Dacarbazine (DRUG),5329102,Sutent,Melanoma,Skin,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12279,NCT00486538,Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib,COMPLETED,PHASE2,Advanced Renal Cell Carcinoma,ABT-869 (DRUG),5329102,Sutent,Advanced Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12280,NCT00606008,A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma,COMPLETED,PHASE2,Anaplastic Astrocytoma; Glioblastoma,Sunitinib Malate (DRUG),5329102,Sutent,Anaplastic Astrocytoma; Glioblastoma,CNS/Brain,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12281,NCT03387514,Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies,TERMINATED,PHASE2,Renal Cell Carcinoma,PSMA-based 18F-DCFPyL PET tracer for PET/CT exams (DRUG),5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12282,NCT05024214,Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors,RECRUITING,PHASE1,Solid Tumors; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma,Lenvatinib + Envafolimab (DRUG); Sunitinib (DRUG),5329102,Sutent,Solid Tumors; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma,Lung,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12283,NCT00513695,"Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer",COMPLETED,PHASE2,Inflammatory Breast Cancer; Male Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,sunitinib malate (DRUG); paclitaxel (DRUG); doxorubicin hydrochloride (DRUG); cyclophosphamide (DRUG); filgrastim (BIOLOGICAL); therapeutic conventional surgery (PROCEDURE); laboratory biomarker analysis (OTHER); flow cytometry (OTHER),5329102,Sutent,Inflammatory Breast Cancer; Male Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12284,NCT00444314,Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma,COMPLETED,PHASE2,Metastatic Renal Cell Carcinoma,Panzem® NCD (DRUG); Sunitinib Malate (DRUG),5329102,Sutent,Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12285,NCT01238055,Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer,COMPLETED,PHASE2,Advanced Gastric Cancer,Docetaxel + Sunitinib (DRUG); Docetaxel only (DRUG),5329102,Sutent,Advanced Gastric Cancer,Esophagus/Stomach,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12286,NCT02446795,Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial,UNKNOWN,PHASE1,Renal Cell Carcinoma; Kidney Cancer,Sunitinib (DRUG); Isoquercetin (DRUG); Placebo (DRUG),5329102,Sutent,Renal Cell Carcinoma; Kidney Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12287,NCT01042795,Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy,TERMINATED,PHASE2,Urothelial Carcinoma; Bladder Cancer,Sunitinib (DRUG),5329102,Sutent,Urothelial Carcinoma,Bladder/Urinary Tract,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12288,NCT00732914,Sequential Study to Treat Renal Cell Carcinoma,COMPLETED,PHASE3,Renal Cell Carcinoma,Sunitinib (Sutent) (DRUG); Sorafenib (Nexavar) (DRUG),5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12289,NCT00137423,Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer,COMPLETED,PHASE2,"Carcinoma, Renal Cell Metastasis",SU011248 (sunitinib) (DRUG),5329102,Sutent,"Carcinoma, Renal Cell Metastasis",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12290,NCT00457743,A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST),COMPLETED,PHASE1,Gastrointestinal Stromal Tumors,Sunitinib malate (SU011248) (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12291,NCT00794950,Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma,COMPLETED,PHASE2,Urinary Tract Urothelial Carcinoma,Sunitinib (DRUG),5329102,Sutent,Urinary Tract Urothelial Carcinoma,Bladder/Urinary Tract,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12292,NCT01538238,"pazopanib_NCRCC,Ph2 STUDY",COMPLETED,PHASE2,Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma,pazopanib (DRUG),5329102,Sutent,Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12293,NCT00633295,Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor,COMPLETED,PHASE2,Gastrointestinal Stromal Tumors (GIST),AMN107- NILOTINIB (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors (GIST),Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12294,NCT00709995,A Study for Participants With Metastatic Renal Cell Carcinoma,COMPLETED,PHASE2,Metastatic Renal Cell Carcinoma,Enzastaurin (DRUG); Sunitinib (DRUG); Placebo (DRUG),5329102,Sutent,Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12295,NCT01099423,Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer,UNKNOWN,PHASE3,Kidney Cancer,timing of surgery (PROCEDURE); gene expression analysis (GENETIC); biologic sample preservation procedure (OTHER); laboratory biomarker analysis (OTHER); therapeutic conventional surgery (PROCEDURE),5329102,Sutent,Kidney Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12296,NCT01482949,A Rollover Protocol for Subjects Previously Treated With AGS-003,TERMINATED,PHASE2,Renal Cell Carcinoma,AGS-003 (DRUG),5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12297,NCT00556049,Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma,COMPLETED,PHASE2,Renal Cell Carcinoma; Neoplasm Metastases,Gemcitabine (DRUG); Sunitinib (DRUG),5329102,Sutent,Renal Cell Carcinoma; Neoplasm Metastases,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12298,NCT00137449,Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor,COMPLETED,PHASE2,Gastrointestinal Stromal Tumors,SU011248 (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12299,NCT00522249,"Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC",TERMINATED,PHASE1,"Carcinoma, Renal Cell",Pegylated Alfa Interferon (DRUG); sunitinib (DRUG); erlotinib (DRUG),5329102,Sutent,"Carcinoma, Renal Cell",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12300,NCT02231749,Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214),ACTIVE_NOT_RECRUITING,PHASE3,Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma,Nivolumab (BIOLOGICAL); Ipilimumab (BIOLOGICAL); Sunitinib (DRUG),5329102,Sutent,Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12301,NCT01070706,"Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib",COMPLETED,PHASE1,Breast Cancer,"Paclitaxel,Gemcitabine,Sunitinib (DRUG)",5329102,Sutent,Breast Cancer,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12302,NCT00706706,Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma,COMPLETED,PHASE4,"Carcinoma, Renal Cell",Sunitinib Malate (SU011248) (DRUG),5329102,Sutent,"Carcinoma, Renal Cell",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12303,NCT01481870,Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma,UNKNOWN,PHASE3,Metastatic Renal Cell Carcinoma,Sorafenib-sunitinib (DRUG); Sunitinib-sorafenib (DRUG),5329102,Sutent,Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12304,NCT00459875,Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer,COMPLETED,PHASE2,Kidney Cancer,sunitinib malate (DRUG),5329102,Sutent,Kidney Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12305,NCT01069770,Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC),UNKNOWN,PHASE2,Clear Cell Renal Cell Carcinoma; Metastasis,Sunitinib (DRUG),5329102,Sutent,Clear Cell Renal Cell Carcinoma; Metastasis,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12306,NCT00715442,Pre-Surgical Sutent in Renal Cell Carcinoma (RCC),ACTIVE_NOT_RECRUITING,PHASE2,Renal Cell Carcinoma,Sunitinib (DRUG); Nephrectomy (PROCEDURE),5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12307,NCT01984242,A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma,COMPLETED,PHASE2,Renal Cell Carcinoma,"Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody (DRUG); Bevacizumab (DRUG); Sunitinib (DRUG)",5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12308,NCT02684006,A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101),COMPLETED,PHASE3,Renal Cell Cancer,Avelumab (MSB0010718C) (DRUG); Axitinib (AG-013736) (DRUG); Sunitinib (DRUG),5329102,Sutent,Renal Cell Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12309,NCT02960906,A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer,COMPLETED,PHASE2,Clear Cell Metastatic Renal Cell Carcinoma,Nivolumab (DRUG); Ipilimumab (DRUG); Pazopanib (DRUG); Sunitinib (DRUG),5329102,Sutent,Clear Cell Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12310,NCT05800106,A Bioequivalence Study of Sunitinib Malate Capsules.,COMPLETED,PHASE1,Gastrointestinal Stromal Tumors; Renal Cell Carcinoma; Pancreatic Neuroendocrine Tumor,Sunitinib malate capsules generic product (DRUG); Sunitinib malate capsules reference product (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors; Renal Cell Carcinoma; Pancreatic Neuroendocrine Tumor,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12311,NCT00975806,Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma,TERMINATED,PHASE1,Renal Cell Carcinoma,Lenalidomide (DRUG); Sunitinib (DRUG),5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12312,NCT03592199,Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib,UNKNOWN,PHASE2,Clear Cell Renal Cell Carcinoma,Sunitinib (DRUG),5329102,Sutent,Clear Cell Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12313,NCT00702884,Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer,COMPLETED,PHASE2,Esophageal Cancer,sunitinib malate (DRUG),5329102,Sutent,Esophageal Cancer,Esophagus/Stomach,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12314,NCT00338884,Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer,COMPLETED,PHASE2,"Carcinoma, Renal Cell",Sunitinib malate (DRUG),5329102,Sutent,"Carcinoma, Renal Cell",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12315,NCT01164202,Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer,COMPLETED,PHASE2,Liver Cancer,sunitinib malate (DRUG); Placebo (DRUG); transarterial chemoembolization (PROCEDURE),5329102,Sutent,Liver Cancer,Liver,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12316,NCT02599779,A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients,COMPLETED,PHASE2,Stage IV Renal Cell Cancer AJCC V7,Pembrolizumab (DRUG); Stereotactic Body Radiation Therapy (RADIATION),5329102,Sutent,Stage IV Renal Cell Cancer AJCC V7,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12317,NCT03541902,Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma,ACTIVE_NOT_RECRUITING,PHASE2,Malignant Neoplasms of Urinary Tract; Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions; Sarcomatoid Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8; Unclassified Renal Cell Carcinoma,Cabozantinib (DRUG); Sunitinib Malate (DRUG),5329102,Sutent,Malignant Neoplasms of Urinary Tract; Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions; Sarcomatoid Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8; Unclassified Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12318,NCT00448721,A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer,COMPLETED,PHASE2,Renal Cell Carcinoma,Perifosine (DRUG),5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12319,NCT00814021,Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain,COMPLETED,PHASE2,Kidney Cancer; Metastatic Cancer,sunitinib malate (DRUG),5329102,Sutent,Kidney Cancer; Metastatic Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12320,NCT00905021,Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer,TERMINATED,PHASE1,Metastatic Breast Cancer,Exemestane (DRUG); Sutent (DRUG),5329102,Sutent,Metastatic Breast Cancer,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12321,NCT02187302,CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC),COMPLETED,PHASE2,Metastatic Renal Cell Carcinoma,CRLX101 (DRUG); Bevacizumab (DRUG); Standard of Care (Investigator Choice) (DRUG),5329102,Sutent,Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12322,NCT00589784,Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma,COMPLETED,PHASE2,CNS Cancer; Meningioma; Intracranial Hemangiopericytoma; Hemangioblastoma; Neurofibromatosis,Sunitinib (DRUG),5329102,Sutent,CNS Cancer; Meningioma; Intracranial Hemangiopericytoma; Hemangioblastoma; Neurofibromatosis,CNS/Brain,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12323,NCT02420821,A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC),COMPLETED,PHASE3,Renal Cell Carcinoma,"Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody (DRUG); Bevacizumab (DRUG); Sunitinib (DRUG)",5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12324,NCT00330564,Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow,TERMINATED,PHASE2,Von Hippel-Lindau Syndrome; Renal Cell Carcinoma; Hemangioblastoma,SU011248 (DRUG),5329102,Sutent,Von Hippel-Lindau Syndrome; Renal Cell Carcinoma; Hemangioblastoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12325,NCT06726421,Systemic Therapy Alone or with Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study),RECRUITING,PHASE3,Renal Cell Carcinoma (Kidney Cancer); Kidney Cancer Metastatic; Renal Cell Carcinoma Metastatic,"Stereotactic body radiotherapy (SBRT) (RADIATION); axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib (DRUG)",5329102,Sutent,Renal Cell Carcinoma (Kidney Cancer); Kidney Cancer Metastatic; Renal Cell Carcinoma Metastatic,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12326,NCT00465179,Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer,COMPLETED,PHASE2,Renal Cell Cancer; Kidney Cancer,Sunitinib Malate (DRUG),5329102,Sutent,Renal Cell Cancer; Kidney Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12327,NCT03556384,Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST),ACTIVE_NOT_RECRUITING,PHASE2,Gastrointestinal Stromal Tumors; Sdh; GIST; Cancer,Temozolomide (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors; Sdh; GIST; Cancer,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12328,NCT00535379,"SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme",UNKNOWN,PHASE2,Glioblastoma Multiforme,Sunitinib (DRUG),5329102,Sutent,Glioblastoma Multiforme,CNS/Brain,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12329,NCT00864721,Sunitinib Non Small Cell Lung Cancer Patients Over 70,COMPLETED,PHASE2,Non Small Cell Lung Cancer,Sutent (DRUG),5329102,Sutent,Non Small Cell Lung Cancer,Lung,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12330,NCT01499121,Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule,COMPLETED,PHASE2,"Clear Cell, Metastatic Renal Cell Carcinoma",Sunitinib (DRUG),5329102,Sutent,"Clear Cell, Metastatic Renal Cell Carcinoma",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12331,NCT00864864,Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma,COMPLETED,EARLY_PHASE1,Glioblastoma; Brain Tumor,Sunitinib (DRUG),5329102,Sutent,Glioblastoma; Brain Tumor,CNS/Brain,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12332,NCT01517243,Phase II Study of Alternating Sunitinib and Temsirolimus,COMPLETED,PHASE2,Metastatic Renal Cell Carcinoma,Sunitinib (DRUG); Temsirolimus (DRUG),5329102,Sutent,Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12333,NCT02324803,Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients,UNKNOWN,PHASE2,"Self Efficacy; Adverse Drug Event; Carcinoma, Renal Cell",pazopanib (DRUG),5329102,Sutent,"Self Efficacy; Adverse Drug Event; Carcinoma, Renal Cell",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12334,NCT00491738,A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R),TERMINATED,PHASE2,Renal Cell Carcinoma,bevacizumab (DRUG); sunitinib (DRUG); placebo (DRUG),5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12335,NCT00541008,Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer,COMPLETED,PHASE2,Kidney Cancer,sunitinib malate (DRUG),5329102,Sutent,Kidney Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12336,NCT06208748,SARC044: a Phase II Trial of Bezuclastinib in Combination with Sunitinib in Patients with GIST,RECRUITING,PHASE2,Gastrointestinal Stromal Tumors; GIST,Bezuclastinib in combination with sunitinib (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors; GIST,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12337,NCT00089648,SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma,COMPLETED,PHASE2,"Carcinoma, Renal Cell",Sunitinib (DRUG),5329102,Sutent,"Carcinoma, Renal Cell",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12338,NCT01524848,Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib,COMPLETED,PHASE2,Gastrointestinal Stromal Tumors,Pazopanib (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12339,NCT00903175,Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma,COMPLETED,PHASE2,Renal Cell Carcinoma,everolimus (DRUG); sunitinib (DRUG),5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12340,NCT00054886,"Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer",COMPLETED,PHASE2,Kidney Neoplasms,"SU-011,248 (DRUG)",5329102,Sutent,Kidney Neoplasms,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12341,NCT00668863,Study Of Sunitinib With FOLFIRI In Colorectal Cancer,COMPLETED,PHASE2,Unresectable or Metastatic Colorectal Cancer,"FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil) (DRUG); Sunitinib (DRUG)",5329102,Sutent,Unresectable or Metastatic Colorectal Cancer,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12342,NCT00806663,FOLFIRI and Sunitinib in Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer; Liver Metastases,sunitinib added to FOLFIRI (DRUG),5329102,Sutent,Metastatic Colorectal Cancer; Liver Metastases,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12343,NCT00480935,A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma,TERMINATED,PHASE2,Renal Cell Carcinoma,Sunitinib Malate (Sutent) (DRUG),5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12344,NCT00425386,Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer,COMPLETED,PHASE2,Kidney Cancer,erlotinib hydrochloride (DRUG); sunitinib malate (DRUG); biopsy (PROCEDURE),5329102,Sutent,Kidney Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12345,NCT02268435,Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors,WITHDRAWN,PHASE1,Gastrointestinal Stromal Tumors,dovitinib plus imatinib (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12346,NCT00270413,SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,SU11248 (DRUG),5329102,Sutent,Metastatic Breast Cancer,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12347,NCT00631618,Clinical Trial of Sutent to Treat Metastatic Melanoma,COMPLETED,PHASE2,Metastatic Melanoma,Sutent (sunitinib) (DRUG),5329102,Sutent,Metastatic Melanoma,Skin,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12348,NCT02338570,Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE),TERMINATED,PHASE4,Renal Cell Carcinoma,Everolimus (DRUG),5329102,Sutent,Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12349,NCT00891475,Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients,COMPLETED,PHASE1,"Carcinoma, Renal Cell",Radiofrequency ablation; Interferon-alpha (PROCEDURE); Radiofrequency ablation; Sunitinib maleate (PROCEDURE); Sunitinib maleate (DRUG),5329102,Sutent,"Carcinoma, Renal Cell",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12350,NCT00782275,Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma,COMPLETED,PHASE2,Renal Cell Carcinoma; Kidney Cancer,bevacizumab (DRUG); temsirolimus (DRUG),5329102,Sutent,Renal Cell Carcinoma; Kidney Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12351,NCT00372775,Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Sunitinib (DRUG),5329102,Sutent,Advanced Non-Small Cell Lung Cancer,Lung,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12352,NCT02060370,Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC),COMPLETED,PHASE2,Genitourinary Cancer; Kidney Cancer,Sunitinib (DRUG); Questionnaire (BEHAVIORAL),5329102,Sutent,Genitourinary Cancer; Kidney Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12353,NCT02928575,"Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma",UNKNOWN,PHASE2,Glioblastoma Multiforme,Sunitinib (DRUG); Temozolomide (DRUG); Radiation Therapy (RADIATION),5329102,Sutent,Glioblastoma Multiforme,CNS/Brain,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12354,NCT04394975,Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1,Biological : Toripalimab Drug: Axitinib (COMBINATION_PRODUCT); sunitinib (DRUG),5329102,Sutent,Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12355,NCT01551459,A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma,COMPLETED,PHASE2,Metastatic Uveal Melanoma,Dacarbazine (DRUG); Sunitinib (DRUG),5329102,Sutent,Metastatic Uveal Melanoma,Skin,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12356,NCT00953459,Sunitinib Malate in Treating Patients With Small Cell Lung Cancer,TERMINATED,PHASE2,Lung Cancer,sunitinib malate (DRUG); laboratory biomarker analysis (OTHER); fludeoxyglucose F 18 (RADIATION),5329102,Sutent,Lung Cancer,Lung,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12357,NCT02342600,SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor),WITHDRAWN,PHASE2,Gastrointestinal Stromal Tumors,Pazopanib (DRUG); Trametinib (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12358,NCT01151852,Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT,COMPLETED,PHASE3,Gastrointestinal Stromal Tumors,Imatinib (DRUG); Placebo (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12359,NCT00399152,Perifosine + Sunitinib Malate for Patients With Advanced Cancers,COMPLETED,PHASE1,Renal Cancer; GIST,Perifosine (DRUG); Sunitinib Malate (DRUG),5329102,Sutent,Renal Cancer; GIST,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12360,NCT01243359,Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies,COMPLETED,PHASE1,"Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer; Unspecified Adult Solid Tumor, Protocol Specific",sunitinib malate (DRUG); bevacizumab (BIOLOGICAL); pharmacological study (OTHER); laboratory biomarker analysis (OTHER); fluorine F 18 fluorothymidine (OTHER); positron emission tomography (PROCEDURE); computed tomography (PROCEDURE),5329102,Sutent,"Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12361,NCT00304200,Temodar and Sutent as Therapy for Melanoma,TERMINATED,PHASE1,Metastatic Malignant Melanoma,Temozolomide and SU11248 (DRUG),5329102,Sutent,Metastatic Malignant Melanoma,Skin,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12362,NCT00787787,Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer,TERMINATED,PHASE2,Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer,sunitinib malate (DRUG); capecitabine (DRUG),5329102,Sutent,Primary Hepatocellular Carcinoma,Liver,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12363,NCT02607332,Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib,COMPLETED,PHASE2,Gastrointestinal Stromal Tumors,Paclitaxel (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12364,NCT00078000,A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.,COMPLETED,PHASE2,Breast Neoplasms,SU011248 (DRUG),5329102,Sutent,Breast Neoplasms,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12365,NCT05905887,Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor,RECRUITING,PHASE2,Gastrointestinal Stromal Tumors,"Rivoceranib Mesylate, Paclitaxel (DRUG)",5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12366,NCT02056587,Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment,COMPLETED,PHASE4,Metastatic Renal Cell Carcinoma,Everolimus (DRUG),5329102,Sutent,Metastatic Renal Cell Carcinoma,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12367,NCT04258956,A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy,UNKNOWN,PHASE2,Gastrointestinal Stromal Tumors,Axitinib (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12368,NCT02400385,A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma,WITHDRAWN,PHASE2,Melanoma,sunitinib (DRUG); nivolumab (DRUG),5329102,Sutent,Melanoma,Skin,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12369,NCT03024437,Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma,TERMINATED,PHASE1,Metastatic Cancer; Renal Cancer,Atezolizumab (DRUG); Bevacizumab (DRUG); Entinostat (DRUG),5329102,Sutent,Metastatic Cancer; Renal Cancer,Kidney,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12370,NCT00388037,"Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",COMPLETED,PHASE2,Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Primary Peritoneal Cavity Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Primary Peritoneal Cavity Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Primary Peritoneal Cavity Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Primary Peritoneal Cavity Cancer,sunitinib malate (DRUG); laboratory biomarker analysis (OTHER),5329102,Sutent,Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Primary Peritoneal Cavity Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Primary Peritoneal Cavity Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Primary Peritoneal Cavity Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12371,NCT01176799,Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor,UNKNOWN,PHASE2,Breast Cancer,Arm A (DRUG); Arm B (DRUG),5329102,Sutent,Breast Cancer,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12372,NCT00887575,Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer,COMPLETED,PHASE1,Breast Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Sunitinib (DRUG),5329102,Sutent,Breast Cancer,Breast,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12373,NCT01440959,Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258,COMPLETED,PHASE2,Gastrointestinal Stromal Tumors,dovitinib (DRUG),5329102,Sutent,Gastrointestinal Stromal Tumors,Bowel,Sunitinib,"KDR, PDGFRB",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,1.16,268.0 +12374,NCT01587144,Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM),TERMINATED,PHASE2,Glioblastoma Multiforme,Lucanthone (DRUG); Temozolomide (TMZ) (DRUG); Radiation (RADIATION); Placebo (DRUG),10180,Lucanthon,Glioblastoma Multiforme,CNS/Brain,Lucanthone,,inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCN(CC)CCNC1=C2C(=C(C=C1)C)SC3=CC=CC=C3C2=O,, +12375,NCT02014545,Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer,WITHDRAWN,PHASE2,Brain Metastases; Non-small Cell Lung Cancer,Lucanthone (DRUG); Placebo (OTHER),10180,Lucanthon,Brain Metastases; Non-small Cell Lung Cancer,Lung,Lucanthone,,inhibitor/antagonist,unclear,no,yes,"Investigated for cancer treatment, not approved for human use.",CCN(CC)CCNC1=C2C(=C(C=C1)C)SC3=CC=CC=C3C2=O,, +12376,NCT06625320,Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),RECRUITING,PHASE3,Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma,RMC-6236 (DRUG); Gemcitabine (DRUG); nab-paclitaxel (DRUG); Irinotecan (DRUG); Liposomal irinotecan (DRUG); 5-fluorouracil (DRUG); leucovorin (DRUG); Oxaliplatin (DRUG),164726578,Daraxonrasib,Pancreatic Ductal Adenocarcinoma,Pancreas,RMC-6236,KRAS,inhibitor/antagonist,RAS inhibitor,no,yes,"Investigated as a potential cancer treatment, but not approved for human use.",CCN1C2=C3C=C(C=C2)C4=CSC(=N4)CC(C(=O)N5CCCC(N5)C(=O)OCC(CC3=C1C6=C(N=CC(=C6)N7CCN(CC7)C)C(C)OC)(C)C)NC(=O)C8CC8C,, +12377,NCT06881784,Study of Daraxonrasib (RMC-6236) in Previously Treated Patients With RAS Mutated NSCLC (RASolve 301),RECRUITING,PHASE3,NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer; NSCLC; NSCLC (Non-small Cell Lung Carcinoma); NSCLC (Advanced Non-small Cell Lung Cancer),daraxonrasib (DRUG); docetaxel (DRUG),164726578,Daraxonrasib,NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer; NSCLC; NSCLC (Non-small Cell Lung Carcinoma); NSCLC (Advanced Non-small Cell Lung Cancer),Lung,RMC-6236,KRAS,inhibitor/antagonist,RAS inhibitor,no,yes,"Investigated as a potential cancer treatment, but not approved for human use.",CCN1C2=C3C=C(C=C2)C4=CSC(=N4)CC(C(=O)N5CCCC(N5)C(=O)OCC(CC3=C1C6=C(N=CC(=C6)N7CCN(CC7)C)C(C)OC)(C)C)NC(=O)C8CC8C,, +12378,NCT06445062,Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors,RECRUITING,PHASE1,Colorectal Cancer; CRC; Pancreatic Ductal Adenocarcinoma; PDAC; Gastrointestinal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma,RMC-6236 (DRUG); mFOLFOX6 regimen (DRUG); bevacizumab (DRUG); mFOLFIRINOX regimen (DRUG); cetuximab (DRUG); gemcitabine (DRUG); nab-paclitaxel (DRUG); RMC-9805 (DRUG),164726578,Daraxonrasib,Colorectal Cancer; CRC; Pancreatic Ductal Adenocarcinoma; PDAC; Gastrointestinal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma,Bowel,RMC-6236,KRAS,inhibitor/antagonist,RAS inhibitor,no,yes,"Investigated as a potential cancer treatment, but not approved for human use.",CCN1C2=C3C=C(C=C2)C4=CSC(=N4)CC(C(=O)N5CCCC(N5)C(=O)OCC(CC3=C1C6=C(N=CC(=C6)N7CCN(CC7)C)C(C)OC)(C)C)NC(=O)C8CC8C,, +12379,NCT06922591,"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients",NOT_YET_RECRUITING,PHASE1,PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; NSCLC; RAS Mutation; MTAP Deletion; Lung Cancer; Pancreatic Cancer Metastatic; Thoracic Cancer,TNG462 (DRUG); RMC-9805 (DRUG); RMC-6236 (DRUG),164726578,Daraxonrasib,PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; NSCLC; RAS Mutation; MTAP Deletion; Lung Cancer; Pancreatic Cancer Metastatic; Thoracic Cancer,Lung,RMC-6236,KRAS,inhibitor/antagonist,RAS inhibitor,no,yes,"Investigated as a potential cancer treatment, but not approved for human use.",CCN1C2=C3C=C(C=C2)C4=CSC(=N4)CC(C(=O)N5CCCC(N5)C(=O)OCC(CC3=C1C6=C(N=CC(=C6)N7CCN(CC7)C)C(C)OC)(C)C)NC(=O)C8CC8C,, +12380,NCT06040541,Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors,RECRUITING,PHASE1,Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Advanced Solid Tumors,RMC-9805 (DRUG); RMC-6236 (DRUG),164726578,Daraxonrasib,Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Advanced Solid Tumors,Bowel,RMC-6236,KRAS,inhibitor/antagonist,RAS inhibitor,no,yes,"Investigated as a potential cancer treatment, but not approved for human use.",CCN1C2=C3C=C(C=C2)C4=CSC(=N4)CC(C(=O)N5CCCC(N5)C(=O)OCC(CC3=C1C6=C(N=CC(=C6)N7CCN(CC7)C)C(C)OC)(C)C)NC(=O)C8CC8C,, +12381,NCT06162221,Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC,RECRUITING,PHASE1,"Non-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; RAS G12D-mutated NSCLC",RMC-6291 (DRUG); RMC-6236 (DRUG); Pembrolizumab (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); RMC-9805 (DRUG),164726578,Daraxonrasib,"Non-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; RAS G12D-mutated NSCLC",Lung,RMC-6236,KRAS,inhibitor/antagonist,RAS inhibitor,no,yes,"Investigated as a potential cancer treatment, but not approved for human use.",CCN1C2=C3C=C(C=C2)C4=CSC(=N4)CC(C(=O)N5CCCC(N5)C(=O)OCC(CC3=C1C6=C(N=CC(=C6)N7CCN(CC7)C)C(C)OC)(C)C)NC(=O)C8CC8C,, +12382,NCT06128551,Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors,RECRUITING,PHASE1,Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer; Pancreatic Ductal Adenocarcinoma,Assigned interventions (DRUG),164726578,Daraxonrasib,Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer; Pancreatic Ductal Adenocarcinoma,Bowel,RMC-6236,KRAS,inhibitor/antagonist,RAS inhibitor,no,yes,"Investigated as a potential cancer treatment, but not approved for human use.",CCN1C2=C3C=C(C=C2)C4=CSC(=N4)CC(C(=O)N5CCCC(N5)C(=O)OCC(CC3=C1C6=C(N=CC(=C6)N7CCN(CC7)C)C(C)OC)(C)C)NC(=O)C8CC8C,, +12383,NCT05379985,Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS,RECRUITING,PHASE1,Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Advanced Solid Tumors,RMC-6236 (DRUG),164726578,Daraxonrasib,Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Advanced Solid Tumors,Bowel,RMC-6236,KRAS,inhibitor/antagonist,RAS inhibitor,no,yes,"Investigated as a potential cancer treatment, but not approved for human use.",CCN1C2=C3C=C(C=C2)C4=CSC(=N4)CC(C(=O)N5CCCC(N5)C(=O)OCC(CC3=C1C6=C(N=CC(=C6)N7CCN(CC7)C)C(C)OC)(C)C)NC(=O)C8CC8C,, +12384,NCT05216120,Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas,WITHDRAWN,PHASE2,Pancreas Cancer,Pemigatinib 4.5 MG (DRUG),86705695,Pemazyre,Pancreas Cancer,Pancreas,Pemigatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for treating cholangiocarcinoma.,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1.75,2744.0 +12385,NCT06302621,Pemigatinib + Afatinib in Advanced Refractory Solid Tumors,RECRUITING,PHASE1,Advanced Solid Tumor; Unresectable Solid Tumor; Metastatic Solid Tumor; Cholangiocarcinoma,Afatinib (DRUG); Pemigatinib (DRUG),86705695,Pemazyre,Advanced Solid Tumor; Unresectable Solid Tumor; Metastatic Solid Tumor; Cholangiocarcinoma,Liver,Pemigatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for treating cholangiocarcinoma.,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1.75,2744.0 +12386,NCT05287386,A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy,UNKNOWN,PHASE2,Advanced Non-Small Cell Lung Cancer,Pemigatinib (DRUG),86705695,Pemazyre,Advanced Non-Small Cell Lung Cancer,Lung,Pemigatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for treating cholangiocarcinoma.,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1.75,2744.0 +12387,NCT05565794,Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements,TERMINATED,PHASE2,Intrahepatic Cholangiocarcinoma; FGFR2 Gene Mutation; FGFR2 Gene Rearrangement; FGFR2 Gene Translocation,Pemigatinib (DRUG),86705695,Pemazyre,Intrahepatic Cholangiocarcinoma; FGFR2 Gene Mutation; FGFR2 Gene Rearrangement; FGFR2 Gene Translocation,Liver,Pemigatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for treating cholangiocarcinoma.,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1.75,2744.0 +12388,NCT05651672,Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations,RECRUITING,PHASE2,Gastrointestinal Cancer,Pemigatinib (DRUG),86705695,Pemazyre,Gastrointestinal Cancer,Bowel,Pemigatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for treating cholangiocarcinoma.,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1.75,2744.0 +12389,NCT05560334,"A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations",RECRUITING,PHASE2,Breast Cancer,Pemigatinib Pill (DRUG),86705695,Pemazyre,Breast Cancer,Breast,Pemigatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for treating cholangiocarcinoma.,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1.75,2744.0 +12390,NCT06728410,A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement,NOT_YET_RECRUITING,PHASE2,Intrahepatic Cholangiocarcinoma; FGFR2 Gene Rearrangement; FGFR2 Gene Mutation,Pemigatinib (DRUG); Durvalumab (DRUG),86705695,Pemazyre,Intrahepatic Cholangiocarcinoma; FGFR2 Gene Rearrangement; FGFR2 Gene Mutation,Liver,Pemigatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for treating cholangiocarcinoma.,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1.75,2744.0 +12391,NCT05559775,A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard Therapy,RECRUITING,PHASE2,Gastrointestinal Cancer,Pemigatinib Pill (DRUG),86705695,Pemazyre,Gastrointestinal Cancer,Bowel,Pemigatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for treating cholangiocarcinoma.,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1.75,2744.0 +12392,NCT04088188,Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma,TERMINATED,PHASE1,Advanced Cholangiocarcinoma; Metastatic Cholangiocarcinoma; Unresectable Cholangiocarcinoma,Cisplatin (DRUG); Gemcitabine (DRUG); Ivosidenib (DRUG); Pemigatinib (DRUG),86705695,Pemazyre,Advanced Cholangiocarcinoma; Metastatic Cholangiocarcinoma; Unresectable Cholangiocarcinoma,Liver,Pemigatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for treating cholangiocarcinoma.,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1.75,2744.0 +12393,NCT05913661,Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma,UNKNOWN,PHASE2,Carcinoma; Intrahepatic Cholangiocarcinoma; Digestive System Neoplasms; PD-1 Inhibitor; First-line Treatment,Pemigatinib (DRUG); PD-1 Inhibitors (DRUG),86705695,Pemazyre,Carcinoma; Intrahepatic Cholangiocarcinoma; Digestive System Neoplasms; PD-1 Inhibitor; First-line Treatment,Liver,Pemigatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for treating cholangiocarcinoma.,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1.75,2744.0 +12394,NCT02393248,"Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)",TERMINATED,PHASE1,Lung Cancer; Solid Tumor; Gastric Cancer; Urothelial Cancer; Endometrial Cancer; Multiple Myeloma; Myeloproliferative Neoplasms; Breast Cancer; Cholangiocarcinoma; UC; MPN,Pemigatinib (DRUG); Gemcitabine (DRUG); Pembrolizumab (DRUG); Docetaxel (DRUG); Trastuzumab (DRUG); Retifanlimab (DRUG); Cisplatin (DRUG),86705695,Pemazyre,Lung Cancer; Solid Tumor; Gastric Cancer; Urothelial Cancer; Endometrial Cancer; Multiple Myeloma; Myeloproliferative Neoplasms; Breast Cancer; Cholangiocarcinoma; UC; MPN,Bladder/Urinary Tract,Pemigatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for treating cholangiocarcinoma.,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1.75,2744.0 +12395,NCT02872714,A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201),COMPLETED,PHASE2,UC (Urothelial Cancer),pemigatinib (DRUG); pemigatinib (DRUG),86705695,Pemazyre,UC (Urothelial Cancer),Bladder/Urinary Tract,Pemigatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for treating cholangiocarcinoma.,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1.75,2744.0 +12396,NCT02924376,Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202),COMPLETED,PHASE2,Cholangiocarcinoma,Pemigatinib (DRUG),86705695,Pemazyre,Cholangiocarcinoma,Liver,Pemigatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for treating cholangiocarcinoma.,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1.75,2744.0 +12397,NCT05529667,Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.,COMPLETED,PHASE1,"Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel","INCB054828, Paclitaxel (DRUG)",86705695,Pemazyre,"Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel",Esophagus/Stomach,Pemigatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for treating cholangiocarcinoma.,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1.75,2744.0 +12398,NCT03656536,A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma,ACTIVE_NOT_RECRUITING,PHASE3,Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma,Pemigatinib (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG),86705695,Pemazyre,Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma,Liver,Pemigatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for treating cholangiocarcinoma.,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1.75,2744.0 +12399,NCT04003610,Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205),TERMINATED,PHASE2,Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma,Pemigatinib (DRUG); Pembrolizumab (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG),86705695,Pemazyre,Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma,Bladder/Urinary Tract,Pemigatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for treating cholangiocarcinoma.,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1.75,2744.0 +12400,NCT05267106,Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations,COMPLETED,PHASE2,Glioblastoma; Adult-type Diffuse Gliomas,Pemigatinib (DRUG),86705695,Pemazyre,Glioblastoma; Adult-type Diffuse Gliomas,CNS/Brain,Pemigatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for treating cholangiocarcinoma.,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1.75,2744.0 +12401,NCT05253807,Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration,COMPLETED,PHASE2,Non-Small Cell Lung Cancer (NSCLC),Pemigatinib (DRUG),86705695,Pemazyre,Non-Small Cell Lung Cancer (NSCLC),Lung,Pemigatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for treating cholangiocarcinoma.,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1.75,2744.0 +12402,NCT05222165,Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations,WITHDRAWN,PHASE1,Advanced Solid Tumor; CNS Tumor; Recurrent WHO Grade II Glioma,Infigratinib (DRUG),53235510,Infigratinib,Advanced Solid Tumor; CNS Tumor; Recurrent WHO Grade II Glioma,CNS/Brain,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12403,NCT02159066,"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",COMPLETED,PHASE2,Melanoma,LGX818 (DRUG); MEK162 (DRUG); LEE011 (DRUG); BGJ398 (DRUG); BKM120 (DRUG); INC280 (DRUG),53235510,Infigratinib,Melanoma,Skin,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12404,NCT04424966,Infigratinib in Recurrent High-Grade Glioma Patients,TERMINATED,EARLY_PHASE1,Glioma; Glioblastoma; GBM,Infigratinib (DRUG),53235510,Infigratinib,Glioma; Glioblastoma; GBM,CNS/Brain,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12405,NCT05510427,Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification,WITHDRAWN,PHASE1,Cholangiocarcinoma; Liver Cancer,Infigratinib (DRUG); Atezolizumab (DRUG); Bevacizumab (DRUG),53235510,Infigratinib,Cholangiocarcinoma; Liver Cancer,Liver,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12406,NCT04504331,"Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer",TERMINATED,PHASE1,Breast Cancer; HER2-negative Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer,Infigratinib (DRUG); Tamoxifen (DRUG); Omnipaque 350 (DRUG); Iopamidol (DRUG); Computed tomography (CT) (DIAGNOSTIC_TEST),53235510,Infigratinib,Breast Cancer; HER2-negative Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer,Breast,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12407,NCT02706691,BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer,TERMINATED,PHASE2,FGFR Gene Amplification; FGFR1 Gene Amplification; FGFR2 Gene Amplification; FGFR2 Gene Mutation; FGFR3 Gene Mutation; Head and Neck Squamous Cell Carcinoma; Human Papillomavirus Infection; Recurrent Head and Neck Carcinoma; Recurrent Nasopharynx Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma,BGJ398 (DRUG),53235510,Infigratinib,FGFR Gene Amplification; FGFR1 Gene Amplification; FGFR2 Gene Amplification; FGFR2 Gene Mutation; FGFR3 Gene Mutation; Head and Neck Squamous Cell Carcinoma; Human Papillomavirus Infection; Recurrent Head and Neck Carcinoma; Recurrent Nasopharynx Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma,Skin,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12408,NCT05019794,Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations,UNKNOWN,PHASE2,Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Solid Tumor,Infigratinib (DRUG),53235510,Infigratinib,Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Solid Tumor,Esophagus/Stomach,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12409,NCT02150967,"A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma",TERMINATED,PHASE2,Advanced Cholangiocarcinoma; FGFR2 Gene Mutation,BGJ398 (infigratinib) (DRUG),53235510,Infigratinib,Advanced Cholangiocarcinoma; FGFR2 Gene Mutation,Liver,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12410,NCT01975701,A Phase 2 Study of BGJ398 in Patients With Recurrent GBM,COMPLETED,PHASE2,Recurrent Glioblastoma or Other Glioma Subtypes,BGJ398 (DRUG),53235510,Infigratinib,Recurrent Glioblastoma or Other Glioma Subtypes,CNS/Brain,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12411,NCT01004224,A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies,COMPLETED,PHASE1,"Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3; Squamous Lung Cancer With FGFR1 Amplification; Bladder Cancer With FGFR3 Mutation or Fusion; Advanced Solid Tumors With FGFR1 Amplication; Advanced Solid Tumors With FGFR2 Amplication; Advanced Solid Tumors With FGFR3 Mutation",BGJ398 (DRUG),53235510,Infigratinib,"Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3; Squamous Lung Cancer With FGFR1 Amplification; Bladder Cancer With FGFR3 Mutation or Fusion; Advanced Solid Tumors With FGFR1 Amplication; Advanced Solid Tumors With FGFR2 Amplication; Advanced Solid Tumors With FGFR3 Mutation",Lung,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12412,NCT04233567,Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations,ACTIVE_NOT_RECRUITING,PHASE2,Advanced Malignant Solid Neoplasm; Cholangiocarcinoma; Metastatic Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm,Infigratinib (DRUG),53235510,Infigratinib,Advanced Malignant Solid Neoplasm; Cholangiocarcinoma; Metastatic Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm,Liver,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12413,NCT02257541,BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST),COMPLETED,PHASE1,Advanced Gastrointestinal Stromal Tumor (GIST),BGJ398 (DRUG); Imatinib Mesylate (DRUG),53235510,Infigratinib,Advanced Gastrointestinal Stromal Tumor (GIST),Bowel,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12414,NCT05514912,"Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial",WITHDRAWN,PHASE2,Resectable Intrahepatic Cholangiocarcinoma; Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8; Stage I Intrahepatic Cholangiocarcinoma AJCC v8; Stage II Intrahepatic Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8,Cisplatin (DRUG); Gemcitabine Hydrochloride (DRUG); Infigratinib Phosphate (DRUG); Nab-paclitaxel (DRUG),53235510,Infigratinib,Resectable Intrahepatic Cholangiocarcinoma; Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8; Stage I Intrahepatic Cholangiocarcinoma AJCC v8; Stage II Intrahepatic Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8,Liver,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12415,NCT02575508,Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer,WITHDRAWN,PHASE1,Colon Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Rectal Adenocarcinoma; Stage III Pancreatic Cancer; Stage IIIA Colon Cancer; Stage IIIA Rectal Cancer; Stage IIIB Colon Cancer; Stage IIIB Rectal Cancer; Stage IIIC Colon Cancer; Stage IIIC Rectal Cancer; Stage IV Pancreatic Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,Fluorouracil (DRUG); Irinotecan Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Oxaliplatin (DRUG); pan FGFR Kinase Inhibitor BGJ398 (DRUG); Pharmacological Study (OTHER),53235510,Infigratinib,Colon Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Rectal Adenocarcinoma; Stage III Pancreatic Cancer; Stage IIIA Colon Cancer; Stage IIIA Rectal Cancer; Stage IIIB Colon Cancer; Stage IIIB Rectal Cancer; Stage IIIC Colon Cancer; Stage IIIC Rectal Cancer; Stage IV Pancreatic Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,Bowel,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12416,NCT04228042,Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer,TERMINATED,PHASE1,Renal Pelvis and Ureter Urothelial Carcinoma,Infigratinib (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); Surgical Procedure (PROCEDURE),53235510,Infigratinib,Renal Pelvis and Ureter Urothelial Carcinoma,Bladder/Urinary Tract,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12417,NCT03773302,Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations,TERMINATED,PHASE3,Advanced Cholangiocarcinoma; FGFR2 Gene Mutation,BGJ398 (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG),53235510,Infigratinib,Advanced Cholangiocarcinoma; FGFR2 Gene Mutation,Liver,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12418,NCT04197986,Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations,TERMINATED,PHASE3,Upper Tract Urothelial Carcinomas; Urothelial Bladder Cancer,Infigratinib (DRUG); Placebo (DRUG),53235510,Infigratinib,Upper Tract Urothelial Carcinomas; Urothelial Bladder Cancer,Bladder/Urinary Tract,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12419,NCT04972253,Phase I BLASST-3 Trial,WITHDRAWN,PHASE1,Bladder Transitional Cell Carcinoma; Bladder Cancer; Fibroblast Growth Factor Receptor,Infigratinib (DRUG),53235510,Infigratinib,Bladder Transitional Cell Carcinoma; Bladder Cancer; Fibroblast Growth Factor Receptor,Bladder/Urinary Tract,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12420,NCT06206278,Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma,TERMINATED,PHASE2,Gastric Cancer; Gastroesophageal Junction Adenocarcinoma,Infigratinib (DRUG),53235510,Infigratinib,Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12421,NCT01820364,LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,TERMINATED,PHASE2,Melanoma,LGX818 (DRUG),53235510,Infigratinib,Melanoma,Skin,Infigratinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for bile duct cancer treatment.,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,1.0952380952380951,474.0 +12422,NCT06817525,Nab-P+Cb+PD1 Inhibitors Combined/not Combined with Bevacizumab As Neoadjuvant Therapy for Early TNBC,RECRUITING,PHASE2,Triple-negative Breast Cancer,"6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1) (DRUG); 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1) (DRUG); 6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1) (DRUG); 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1) (DRUG)",53340664,NG2,Triple-negative Breast Cancer,Breast,NG25,"MAP4K2, MAP3K7, LYN, ABL1, ABL2, FER, SRC, EPHA2, EPHB2, EPHB4, ZAK, ZKSCAN1, RAF1",inhibitor/antagonist,Other MAPK inhibitor,no,yes,"NG25 is in preclinical stages, not approved for humans.",CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)C3=CC(=C(C=C3)C)OC4=C5C=CNC5=NC=C4)C(F)(F)F,, +12423,NCT05127824,Autologous Dendritic Cell Vaccine in Kidney Cancer,RECRUITING,PHASE2,"Carcinoma, Renal Cell",Autologous alpha-DC1/TBVA vaccine (BIOLOGICAL); Cabozantinib (DRUG),53340664,NG2,"Carcinoma, Renal Cell",Kidney,NG25,"MAP4K2, MAP3K7, LYN, ABL1, ABL2, FER, SRC, EPHA2, EPHB2, EPHB4, ZAK, ZKSCAN1, RAF1",inhibitor/antagonist,Other MAPK inhibitor,no,yes,"NG25 is in preclinical stages, not approved for humans.",CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)C3=CC(=C(C=C3)C)OC4=C5C=CNC5=NC=C4)C(F)(F)F,, +12424,NCT06925243,Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma,RECRUITING,PHASE3,"Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]); Neoadjuvant Therapy; Adjuvant Chemotherapy; pCR Rate; MPR; ORR,OS,PFS",Neoadjuvant apatinib combined with sintilimab and perioperative SOX (DRUG); Neoadjuvant sintilimab combined with perioperative SOX (DRUG),53340664,NG2,"Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]); Neoadjuvant Therapy; Adjuvant Chemotherapy; pCR Rate; MPR; ORR,OS,PFS",Esophagus/Stomach,NG25,"MAP4K2, MAP3K7, LYN, ABL1, ABL2, FER, SRC, EPHA2, EPHB2, EPHB4, ZAK, ZKSCAN1, RAF1",inhibitor/antagonist,Other MAPK inhibitor,no,yes,"NG25 is in preclinical stages, not approved for humans.",CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)C3=CC(=C(C=C3)C)OC4=C5C=CNC5=NC=C4)C(F)(F)F,, +12425,NCT05696626,Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation,RECRUITING,PHASE3,Metastatic Breast Cancer,Lasofoxifene in combination with abemaciclib (DRUG); Fulvestrant in combination with abemaciclib (DRUG),46220502,Verzenio,Metastatic Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12426,NCT03284957,Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer,TERMINATED,PHASE1,Breast Cancer,Amcenestrant (DRUG); Palbociclib (DRUG); Alpelisib (DRUG); Everolimus (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12427,NCT02308020,"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",COMPLETED,PHASE2,Breast Cancer; Non-small Cell Lung Cancer; Melanoma; Brain Metastases,Abemaciclib (DRUG),46220502,Verzenio,Breast Cancer; Non-small Cell Lung Cancer; Melanoma; Brain Metastases,CNS/Brain,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12428,NCT03099174,This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer,COMPLETED,PHASE1,Neoplasms; Breast Neoplasms,Xentuzumab (DRUG); Abemaciclib (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Neoplasms; Breast Neoplasms,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12429,NCT03703466,A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Abemaciclib (DRUG),46220502,Verzenio,Metastatic Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12430,NCT02763566,A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Abemaciclib (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Placebo (DRUG); Fulvestrant (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12431,NCT05563220,Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer,RECRUITING,PHASE1,Breast Cancer; Metastatic Breast Cancer,Elacestrant (DRUG); Alpelisib (DRUG); Everolimus (DRUG); Ribociclib (DRUG); Palbociclib (DRUG); Capivasertib (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Breast Cancer; Metastatic Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12432,NCT05464173,Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib,RECRUITING,PHASE1,Breast Cancer,Chidamide (DRUG); Abemaciclib (DRUG); endocrinotherapy（doctor's choice） (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12433,NCT04165031,A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation,TERMINATED,PHASE1,Advanced Solid Tumor; Non-Small Cell Lung Cancer; Colorectal Cancer,LY3499446 (DRUG); Abemaciclib (DRUG); Cetuximab (DRUG); Erlotinib (DRUG); Docetaxel (DRUG),46220502,Verzenio,Advanced Solid Tumor; Non-Small Cell Lung Cancer; Colorectal Cancer,Lung,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12434,NCT04523857,ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer,RECRUITING,PHASE2,Breast Cancer,Abemaciclib (DRUG); Hydroxychloroquine (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12435,NCT05952557,An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2),RECRUITING,PHASE3,"Breast Cancer, Early Breast Cancer",Camizestrant (DRUG); Tamoxifen (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Early Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12436,NCT02107703,A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Neoplasms,Abemaciclib (DRUG); Fulvestrant (DRUG); Placebo (DRUG),46220502,Verzenio,Breast Neoplasms,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12437,NCT02102490,A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread,COMPLETED,PHASE2,Metastatic Breast Cancer,Abemaciclib (DRUG),46220502,Verzenio,Metastatic Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12438,NCT06409390,Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer,RECRUITING,EARLY_PHASE1,Metastatic Breast Cancer,Taxotere (DRUG); Cytoxan (DRUG); Trastuzumab deruxtecan (DRUG); Sacituzumab govitecan (DRUG); Xeloda (DRUG); Fulvestrant (DRUG); Ribociclib (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Metastatic Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12439,NCT02784795,A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,COMPLETED,PHASE1,Solid Tumor; Breast Cancer; Colon Cancer; Cholangiocarcinoma; Soft Tissue Sarcoma,LY3039478 (DRUG); Taladegib (DRUG); Abemaciclib (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG); LY3023414 (DRUG),46220502,Verzenio,Solid Tumor; Breast Cancer; Colon Cancer; Cholangiocarcinoma; Soft Tissue Sarcoma,Bowel,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12440,NCT06585969,"A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer",NOT_YET_RECRUITING,PHASE3,Metastatic Breast Cancer; ER-positive Breast Cancer; Luminal B; Her2 Enriched; Basal Like,Trastuzumab deruxtecan (T-DXd) (DRUG); Ribociclib with ET (DRUG); Abemaciclib with ET (DRUG),46220502,Verzenio,Metastatic Breast Cancer; ER-positive Breast Cancer; Luminal B; Her2 Enriched; Basal Like,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12441,NCT02152631,A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Non Small Cell Lung Cancer,Abemaciclib (DRUG); Erlotinib (DRUG),46220502,Verzenio,Non Small Cell Lung Cancer,Lung,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12442,NCT06570031,ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer,ONO-4578 (DRUG); letrozole (DRUG); Palbociclib (DRUG); abemaciclib (DRUG),46220502,Verzenio,Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12443,NCT02675231,"A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer",COMPLETED,PHASE2,Hormone Receptor Positive Breast Cancer; HER-2 Positive Breast Cancer,Abemaciclib (DRUG); Trastuzumab (DRUG); Fulvestrant (DRUG); Standard of Care Single Agent Chemotherapy (DRUG),46220502,Verzenio,Hormone Receptor Positive Breast Cancer; HER-2 Positive Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12444,NCT03781960,Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma,TERMINATED,PHASE2,Hepatocellular Carcinoma,Abemaciclib (DRUG); Nivolumab (DRUG),46220502,Verzenio,Hepatocellular Carcinoma,Liver,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12445,NCT02441946,"A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",COMPLETED,PHASE2,Breast Cancer; Hormone Receptor Positive Tumor; Early-Stage Breast Carcinoma,Abemaciclib (DRUG); Loperamide (DRUG); Anastrozole (DRUG),46220502,Verzenio,Breast Cancer; Hormone Receptor Positive Tumor; Early-Stage Breast Carcinoma,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12446,NCT05735080,"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer",RECRUITING,PHASE1,Breast Cancer; Breast Cancer Metastatic; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Ovarian Cancer; CCNE1 Amplification; Solid Tumor; Advanced Cancer; Metastatic Cancer,INX-315 (DRUG); Fulvestrant (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Breast Cancer; Breast Cancer Metastatic; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Ovarian Cancer; CCNE1 Amplification; Solid Tumor; Advanced Cancer; Metastatic Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12447,NCT02977780,INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT),RECRUITING,PHASE2,Glioblastoma,Temozolomide (DRUG); Neratinib (DRUG); QBS10072S (DRUG),46220502,Verzenio,Glioblastoma,CNS/Brain,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12448,NCT01655225,A Study of LY3023414 in Participants With Advanced Cancer,COMPLETED,PHASE1,Advanced Cancer; Metastatic Cancer; Non-Hodgkin's Lymphoma; Metastatic Breast Cancer; Malignant Mesothelioma; Non-small Cell Lung Cancer,LY3023414 (DRUG); Midazolam (DRUG); Fulvestrant (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG); Abemaciclib (DRUG); Letrozole (DRUG),46220502,Verzenio,Advanced Cancer; Metastatic Cancer; Non-Hodgkin's Lymphoma; Metastatic Breast Cancer; Malignant Mesothelioma; Non-small Cell Lung Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12449,NCT06561022,Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping,NOT_YET_RECRUITING,PHASE2,Breast Cancer,Fluzoparib (DRUG); Everolimus (DRUG); Fulvestrant (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12450,NCT02450539,A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small Cell Lung Cancer Stage IV,Abemaciclib (DRUG); Docetaxel (DRUG),46220502,Verzenio,Non-Small Cell Lung Cancer Stage IV,Lung,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12451,NCT04227327,"Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)",UNKNOWN,PHASE2,Advanced Breast Cancer,Abemaciclib (DRUG); Aromatase Inhibitors (DRUG),46220502,Verzenio,Advanced Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12452,NCT04010357,"Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC",RECRUITING,PHASE2,Small-cell Lung Cancer; Large Cell Neuroendocrine Carcinoma of the Lung; Extrapulmonary Small Cell Carcinoma,"Abemaciclib, (DRUG)",46220502,Verzenio,Small-cell Lung Cancer; Large Cell Neuroendocrine Carcinoma of the Lung; Extrapulmonary Small Cell Carcinoma,Lung,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12453,NCT05774886,Implantable Microdevice for TNBC - Pilot Study,WITHDRAWN,PHASE1,Triple Negative Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer; Early Stage Triple-Negative Breast Carcinoma; Breast Neoplasms; Breast Carcinoma,Implantable Microdevice (IMD) (COMBINATION_PRODUCT),46220502,Verzenio,Triple Negative Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12454,NCT06065748,"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)",RECRUITING,PHASE3,"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer",Giredestrant (DRUG); Fulvestrant (DRUG); Abemaciclib (DRUG); Palbociclib (DRUG); Ribociclib (DRUG); LHRH Agonist (DRUG); FoundationOne Liquid CDx Assay (F1LCDx) (DIAGNOSTIC_TEST),46220502,Verzenio,"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer",Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12455,NCT02831530,Randomized Short-term Pre-surgical Study to Assess the Effects of Abemaciclib (LY2835219) in Early Breast Cancer Patients,COMPLETED,PHASE2,Breast Cancer,Abemaciclib (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12456,NCT02411591,A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis",Necitumumab (DRUG); Abemaciclib (DRUG),46220502,Verzenio,"Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis",Lung,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12457,NCT04614194,Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib,RECRUITING,PHASE2,Breast Cancer,Letrozole (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12458,NCT06259929,"NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer",RECRUITING,PHASE2,Breast Cancer,Abemaciclib 150 MG + Giredestrant 30 MG (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12459,NCT03905889,A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma,TERMINATED,PHASE1,Renal Cell Carcinoma Metastatic,Abemaciclib (DRUG); Sunitinib (DRUG),46220502,Verzenio,Renal Cell Carcinoma Metastatic,Kidney,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12460,NCT06001762,TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer; Early-stage Breast Cancer; High Risk Breast Carcinoma,Abemaciclib (DRUG); Tamoxifen (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); LHRH Agonist (DRUG),46220502,Verzenio,Breast Cancer; Early-stage Breast Cancer; High Risk Breast Carcinoma,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12461,NCT05362760,Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management,RECRUITING,PHASE4,Hormone Receptor-positive Metastatic Breast Cancer; HER2-negative Metastatic Breast Cancer,Abemaciclib + Aromatase Inhibitor (DRUG); Abemaciclib + Fulvestrant (DRUG),46220502,Verzenio,Hormone Receptor-positive Metastatic Breast Cancer; HER2-negative Metastatic Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12462,NCT05708235,A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Giredestrant (DRUG); Abemaciclib (DRUG); Inavolisib (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12463,NCT04707196,A Study of Abemaciclib in Indian Women With Advanced Breast Cancer,COMPLETED,PHASE4,Breast Neoplasms; Neoplasm Metastasis,Abemaciclib (DRUG); Nonsteroidal Aromatase Inhibitor (NSAI) (DRUG); Fulvestrant (DRUG),46220502,Verzenio,Breast Neoplasms with Metastasis,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12464,NCT03130439,"Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer",TERMINATED,PHASE2,Breast Cancer,Abemaciclib (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12465,NCT04961996,"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)",RECRUITING,PHASE3,Early Breast Cancer,Giredestrant (DRUG); Endocrine Therapy of Physician's Choice (DRUG); LHRH Agonist (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Early Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12466,NCT04585724,"Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases",WITHDRAWN,PHASE1,Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Prognostic Stage IV Breast Cancer AJCC v8,Abemaciclib (DRUG); Palbociclib (DRUG); Quality-of-Life Assessment (OTHER); Ribociclib (DRUG),46220502,Verzenio,Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Prognostic Stage IV Breast Cancer AJCC v8,CNS/Brain,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12467,NCT02644460,Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors,COMPLETED,PHASE1,"Diffuse Intrinsic Pontine Glioma; Brain Tumor, Recurrent; Solid Tumor, Recurrent; Neuroblastoma, Recurrent, Refractory; Ewing Sarcoma, Recurrent, Refractory; Rhabdomyosarcoma, Recurrent, Refractory; Osteosarcoma, Recurrent, Refractory; Rhabdoid Tumor, Recurrent, Refractory",Abemaciclib (DRUG),46220502,Verzenio,"Diffuse Intrinsic Pontine Glioma; Brain Tumor, Recurrent; Solid Tumor, Recurrent; Neuroblastoma, Recurrent, Refractory; Ewing Sarcoma, Recurrent, Refractory; Rhabdomyosarcoma, Recurrent, Refractory; Osteosarcoma, Recurrent, Refractory; Rhabdoid Tumor, Recurrent, Refractory",CNS/Brain,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12468,NCT03655444,Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy,TERMINATED,PHASE1,Head and Neck Squamous Cell Carcinoma,Abemaciclib (DRUG); Nivolumab (DRUG); Tumor biopsy (PROCEDURE); Peripheral blood (PROCEDURE); EORTC QLQ-30 (OTHER),46220502,Verzenio,Head and Neck Squamous Cell Carcinoma,Skin,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12469,NCT03220646,Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors,ACTIVE_NOT_RECRUITING,PHASE2,Brain Tumor,abemaciclib (DRUG); abemaciclib (DRUG),46220502,Verzenio,Brain Tumor,CNS/Brain,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12470,NCT04316169,"Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer",WITHDRAWN,PHASE1,Solid Tumor; Advanced Breast Cancer,Abemaciclib (DRUG); Hydroxychloroquine 200 mg (DRUG); Faslodex (DRUG); Anastrazole (DRUG); Letrozole (DRUG); Hydroxychloroquine 400 mg (DRUG); Hydroxychloroquine 600 mg (DRUG),46220502,Verzenio,Advanced Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12471,NCT02747004,A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Cancer,Abemaciclib (DRUG); Tamoxifen (DRUG); Prophylactic Loperamide (DRUG),46220502,Verzenio,Metastatic Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12472,NCT04921904,Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca,UNKNOWN,PHASE1,Metastatic Esophageal Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma,Abemaciclib (DRUG); Ramucirumab (DRUG),46220502,Verzenio,Metastatic Esophageal Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12473,NCT05501704,ETHAN - ET for Male BC,RECRUITING,PHASE2,Male Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma,Tamoxifen (DRUG); Anastrozole (DRUG); Degarelix (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Male Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12474,NCT06835972,A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC),RECRUITING,PHASE1,Metastatic Renal Cell Carcinoma,Abemaciclib (DRUG); Cabozantinib (DRUG),46220502,Verzenio,Metastatic Renal Cell Carcinoma,Kidney,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12475,NCT05169567,Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Neoplasm; Neoplasm Metastasis,Abemaciclib (DRUG); Fulvestrant (DRUG); Placebo (DRUG),46220502,Verzenio,Breast Neoplasm; Neoplasm Metastasis,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12476,NCT05766410,"A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC",RECRUITING,PHASE2,Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Therapy,Palbociclib (DRUG); Ribociclib (DRUG); Abemaciclib (DRUG); Letrozole (DRUG),46220502,Verzenio,Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Therapy,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12477,NCT04220892,Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma,WITHDRAWN,EARLY_PHASE1,High Grade Glioma,Pembrolizumab (DRUG); Pemetrexed (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Glioma,CNS/Brain,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12478,NCT06810544,Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss,RECRUITING,PHASE1,"Non Small Cell Lung Cancer; Glioma Glioblastoma Multiforme; Glioma, Malignant; Solid Tumor; Non-Small Cell Adenocarcinoma; Lung Cancer; Brain Tumor",TNG456 (DRUG); abemaciclib (DRUG),46220502,Verzenio,"Non Small Cell Lung Cancer; Glioma Glioblastoma Multiforme; Glioma, Malignant; Solid Tumor; Non-Small Cell Adenocarcinoma; Lung Cancer; Brain Tumor",Lung,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12479,NCT04964934,Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6),ACTIVE_NOT_RECRUITING,PHASE3,ER-Positive HER2-Negative Breast Cancer,AZD9833 (DRUG); AZD9833 Placebo (DRUG); Anastrozole (DRUG); Anastrozole placebo (DRUG); Letrozole (DRUG); Letrozole placebo (DRUG); Palbociclib (DRUG); Abemaciclib (DRUG); Luteinizing hormone-releasing hormone (LHRH) agonist (DRUG); Ribociclib (DRUG),46220502,Verzenio,ER-Positive HER2-Negative Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12480,NCT05548127,TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A),ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,ARV-471 (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12481,NCT05305924,"Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer",RECRUITING,PHASE2,ER-Positive Breast Cancer; HER2-negative Breast Cancer,Fulvestrant Run-In (DRUG),46220502,Verzenio,ER-Positive Breast Cancer; HER2-negative Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12482,NCT04003896,A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma,TERMINATED,PHASE2,Biliary Tract Carcinoma,Abemaciclib (DRUG),46220502,Verzenio,Biliary Tract Carcinoma,Liver,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12483,NCT05413304,Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis,RECRUITING,PHASE1,Glioma,pre-operative abemaciclib (DRUG); Device for Cerebral Fluid Dialysate Collection (DEVICE); Ashion Analytics GEM ExTra (DEVICE); abemaciclib + temozolomide (DRUG),46220502,Verzenio,Glioma,CNS/Brain,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12484,NCT05372640,"Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors",RECRUITING,PHASE1,Breast Carcinoma; Malignant Solid Neoplasm,Abemaciclib (DRUG); BET Bromodomain Inhibitor ZEN-3694 (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Diagnostic Imaging Testing (PROCEDURE),46220502,Verzenio,Breast Carcinoma; Malignant Solid Neoplasm,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12485,NCT02745769,A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents,COMPLETED,PHASE1,Advanced Cancer; Colorectal Cancer; Mantle Cell Lymphoma,Ramucirumab (DRUG); Merestinib (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Advanced Cancer; Colorectal Cancer; Mantle Cell Lymphoma,Bowel,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12486,NCT02981940,A Study of Abemaciclib in Recurrent Glioblastoma,ACTIVE_NOT_RECRUITING,PHASE2,Glioblastoma,Abemaciclib (DRUG); Surgery (PROCEDURE),46220502,Verzenio,Glioblastoma,CNS/Brain,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12487,NCT06678269,A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer,RECRUITING,PHASE1,Metastatic Breast Cancer; Stage IV Breast Cancer; Breast Cancer; Breast Cancer Stage IV; Breast Cancer Metastatic; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; Hormone-receptor-positive Breast Cancer,Abemaciclib (DRUG),46220502,Verzenio,Metastatic Breast Cancer; Stage IV Breast Cancer; Breast Cancer; Breast Cancer Stage IV; Breast Cancer Metastatic; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; Hormone-receptor-positive Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12488,NCT04256941,"Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study",TERMINATED,PHASE2,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8,Abemaciclib (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Palbociclib (DRUG); Ribociclib (DRUG),46220502,Verzenio,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12489,NCT03913234,"Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients",UNKNOWN,PHASE1,HER2-positive Breast Cancer; Postmenopausal; Metastatic Breast Cancer,"Ribociclib, Trastuzumab, Letrozole (DRUG)",46220502,Verzenio,HER2-positive Breast Cancer; Postmenopausal; Metastatic Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12490,NCT02791334,A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors,COMPLETED,PHASE1,Solid Tumor; Microsatellite Instability-High (MSI-H) Solid Tumors; Cutaneous Melanoma; Pancreatic Cancer; Breast Cancer (HR+HER2-),LY3300054 (DRUG); Ramucirumab (DRUG); Abemaciclib (DRUG); Merestinib (DRUG); LY3321367 (DRUG),46220502,Verzenio,Solid Tumor; Microsatellite Instability-High (MSI-H) Solid Tumors; Cutaneous Melanoma; Pancreatic Cancer; Breast Cancer (HR+HER2-),Pancreas,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12491,NCT04305834,Abemaciclib and Endocrine Therapy in Older Patients with Breast Cancer.,RECRUITING,PHASE2,Anatomic Stage IV Breast Cancer AJCC V8; Hormone Receptor Positive Breast Carcinoma; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC V8,Abemaciclib (DRUG); Questionnaire Administration (OTHER),46220502,Verzenio,Anatomic Stage IV Breast Cancer AJCC V8; Hormone Receptor Positive Breast Carcinoma; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC V8,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12492,NCT04305236,Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer,TERMINATED,PHASE2,Breast Neoplasm; Hormone Receptor Positive Breast Carcinoma,Abemaciclib (DRUG); Fulvestrant (DRUG),46220502,Verzenio,Breast Neoplasm; Hormone Receptor Positive Breast Carcinoma,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12493,NCT03979508,"Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer",RECRUITING,PHASE2,Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Breast Ductal Carcinoma In Situ; Breast Fibrocystic Change; Breast Lobular Carcinoma In Situ; Invasive Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Triple-Negative Breast Carcinoma,Abemaciclib (DRUG); Therapeutic Conventional Surgery (PROCEDURE),46220502,Verzenio,Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Breast Ductal Carcinoma In Situ; Breast Fibrocystic Change; Breast Lobular Carcinoma In Situ; Invasive Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Triple-Negative Breast Carcinoma,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12494,NCT03988114,"A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer",WITHDRAWN,PHASE4,Metastatic Breast Cancer,Abemaciclib (DRUG); Nonsteroidal Aromatase Inhibitor (NSAI) (DRUG),46220502,Verzenio,Metastatic Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12495,NCT02523014,"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas",RECRUITING,PHASE2,Intracranial Meningioma; Recurrent Meningioma; NF2 Gene Mutation,Vismodegib (DRUG); FAK Inhibitor GSK2256098 (DRUG); Capivasertib (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Meningioma,CNS/Brain,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12496,NCT05933395,Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor,RECRUITING,PHASE2,Advanced Breast Cancer,Fulvestrant (DRUG); Neratinib (DRUG); Alpelisib (DRUG); Everolimus (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Advanced Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12497,NCT04545710,Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance,ACTIVE_NOT_RECRUITING,PHASE2,Lung Cancer,Abemaciclib (DRUG); Osimertinib (DRUG),46220502,Verzenio,Lung Cancer,Lung,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12498,NCT04920708,"Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression",RECRUITING,PHASE2,Metastatic Breast Cancer; ER+ Breast Cancer; Advanced Breast Cancer,Ipatasertib 300mg (DRUG); Fulvestrant 500g (DRUG); Palbociclib 75mg-125mg (DRUG); CDK4/6 Inhibitor (DRUG),46220502,Verzenio,Metastatic Breast Cancer; ER+ Breast Cancer; Advanced Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12499,NCT04975308,"A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE3,Breast Neoplasms; Neoplasm Metastasis,Imlunestrant (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Breast Neoplasms with Metastasis,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12500,NCT06044623,Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients,RECRUITING,PHASE3,Metastatic Breast Cancer; Advanced Breast Cancer; Quality of Life; Toxicity; Older Patients,CDK 4/6 inhibitors (DRUG); Endocrine therapy (DRUG),46220502,Verzenio,Metastatic Breast Cancer; Advanced Breast Cancer; Quality of Life; Toxicity; Older Patients,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12501,NCT05386108,Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer,RECRUITING,PHASE1,Breast Neoplasms; Brain Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Central Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases,Elacestrant (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Breast Neoplasms; Brain Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Central Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12502,NCT05816655,"Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer",RECRUITING,PHASE2,Metastatic Breast Cancer,Fulvestrant plus AI plus ribociclib (DRUG); AI plus ribociclib (DRUG),46220502,Verzenio,Metastatic Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12503,NCT04391595,LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,Glioblastoma; GBM; Glioma,Abemaciclib (DRUG); LY3214996 (DRUG),46220502,Verzenio,Glioblastoma; GBM; Glioma,CNS/Brain,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12504,NCT02387814,A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment,COMPLETED,PHASE1,Hepatic Insufficiency,Abemaciclib (DRUG),46220502,Verzenio,Hepatic Insufficiency,Liver,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12505,NCT05826964,Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer,RECRUITING,PHASE2,Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer,AI+CDK4/6i (DRUG); SERD+CDK4/6i (DRUG); mTOR inhibitor + AI (DRUG); mTOR inhibitor + SERD (DRUG); mTOR inhibitor + Selective estrogen receptor modulator (DRUG); PI3K inhibitor + SERD (DRUG); PI3K inhibitor + AI (DRUG); Chemotherapy (DRUG); Oral SERD (DRUG),46220502,Verzenio,Metastatic ER-positive/HER2-negative Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12506,NCT03425838,Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Neoplasm Female,CDK 4/6 inhibitor (DRUG); Non-Steroidal Aromatase Inhibitor (DRUG); Fulvestrant (DRUG),46220502,Verzenio,Female Breast Neoplasm,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12507,NCT02079636,A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC),COMPLETED,PHASE1,"Carcinoma, Non-small Cell Lung",Abemaciclib (DRUG); Pemetrexed (DRUG); Gemcitabine (DRUG); Ramucirumab (DRUG); LY3023414 (DRUG); Pembrolizumab (DRUG),46220502,Verzenio,"Carcinoma, Non-small Cell Lung",Lung,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12508,NCT05759949,First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,"PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid Tumor; Hormone Receptor Positive Tumor",RLY-5836 (DRUG); Fulvestrant (DRUG); Palbociclib (DRUG); Ribociclib (DRUG); Abemaciclib (DRUG),46220502,Verzenio,PIK3CA-Mutated Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12509,NCT04923542,Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases,RECRUITING,PHASE1,Brain Metastases; HR+ Metastatic Breast Cancer,Stereotactic Radiosurgery (SRS) (RADIATION); Abemaciclib (DRUG); Endocrine therapy (DRUG),46220502,Verzenio,Brain Metastases; HR+ Metastatic Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12510,NCT04931342,A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors,ACTIVE_NOT_RECRUITING,PHASE2,Ovarian Cancer,Ipatasertib (DRUG); Cobimetinib (DRUG); Trastuzumab Emtansine (DRUG); Atezolizumab (DRUG); Bevacizumab (DRUG); Paclitaxel (DRUG); Giredestrant (DRUG); Abemaciclib (DRUG); Inavolisib (DRUG); Palbociclib (DRUG); Letrozole (DRUG); Olaparib (DRUG); Luteinizing Hormone-Releasing Hormone (LHRH) Agonists (DRUG); Cyclophosphamide (DRUG); Inavolisib (DRUG),46220502,Verzenio,Ovarian Cancer,Ovary/Fallopian Tube,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12511,NCT06413706,A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy,RECRUITING,PHASE2,Glioma,Abemaciclib (DRUG); Temozolomide (DRUG),46220502,Verzenio,Glioma,CNS/Brain,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12512,NCT04791384,Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer,RECRUITING,PHASE1,Breast Cancer,Abemaciclib (DRUG); Elacestrant (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12513,NCT03837821,(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,Bladder Cancer,Abemaciclib (DRUG),46220502,Verzenio,Bladder Cancer,Bladder/Urinary Tract,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12514,NCT06341621,Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib,RECRUITING,PHASE3,Breast Cancer,3-year abemaciclib without chemo (DRUG); treatment of physician's choice (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12515,NCT02246621,A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Abemaciclib (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Placebo (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12516,NCT05524584,"Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer",RECRUITING,PHASE2,Breast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer,Fulvestrant (DRUG); Anastrozole (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Breast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12517,NCT06179303,"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer",RECRUITING,PHASE2,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Unresectable HER2-Negative Breast Carcinoma; Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma,Abemaciclib (DRUG); Anastrozole (DRUG); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Diagnostic Imaging (PROCEDURE); Exemestane (DRUG); Fludeoxyglucose F-18 (OTHER); Fluorine F 18 Fluoro Furanyl Norprogesterone (DRUG); Fulvestrant (DRUG); Gonadotropin-releasing Hormone Analog (BIOLOGICAL); Letrozole (DRUG); Positron Emission Tomography (PROCEDURE); Tamoxifen (DRUG); Therapeutic Estradiol (DRUG),46220502,Verzenio,"Advanced/Metastatic Breast Cancer, HER2-Negative",Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12518,NCT04627064,ABEMA Alone or in COMBO With MK-6482,COMPLETED,PHASE1,Clear Cell Renal Cell Carcinoma,Abemaciclib (DRUG); MK-6482 (DRUG),46220502,Verzenio,Clear Cell Renal Cell Carcinoma,Kidney,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12519,NCT03339843,Multiorgan Metabolic Imaging Response Assessment of Abemaciclib,COMPLETED,PHASE2,"Esophageal Adenocarcinoma; Esophagus SCC; Cholangiocarcinoma; Urothelial/Bladder Cancer, Nos; Endometrial Cancer",Abemaciclib (DRUG),46220502,Verzenio,"Esophageal Adenocarcinoma; Esophagus SCC; Cholangiocarcinoma; Urothelial/Bladder Cancer, Nos; Endometrial Cancer",Uterus,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12520,NCT06594679,A Study of Niraparib in Combination with Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL),RECRUITING,PHASE1,Ovarian Cancer,Niraparib Tosylate Monohydrate (DRUG),46220502,Verzenio,Ovarian Cancer,Ovary/Fallopian Tube,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12521,NCT06813079,Using Tumor Models to Determine Treatments,NOT_YET_RECRUITING,PHASE2,Pancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor,Cobimetinib (DRUG); Ponatinib (DRUG); Brigatinib (DRUG); Colchicine (DRUG); Selinexor (DRUG); Abemaciclib (DRUG); Neratinib (DRUG); Doxorubicin (DRUG); Etoposide (DRUG); Ceritinib (DRUG),46220502,Verzenio,Pancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor,Pancreas,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12522,NCT01042379,I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,RECRUITING,PHASE2,Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer,Standard Therapy (DRUG); AMG 386 with or without Trastuzumab (DRUG); AMG 479 (Ganitumab) plus Metformin (DRUG); MK-2206 with or without Trastuzumab (DRUG); AMG 386 and Trastuzumab (DRUG); T-DM1 and Pertuzumab (DRUG); Pertuzumab and Trastuzumab (DRUG); Ganetespib (DRUG); ABT-888 (DRUG); Neratinib (DRUG); PLX3397 (DRUG); Pembrolizumab - 4 cycle (DRUG); Talazoparib plus Irinotecan (DRUG); Patritumab and Trastuzumab (DRUG); Pembrolizumab - 8 cycle (DRUG); SGN-LIV1A (DRUG); Durvalumab plus Olaparib (DRUG); SD-101 + Pembrolizumab (DRUG); Tucatinib plus trastuzumab and pertuzumab (DRUG); Cemiplimab (DRUG); Cemiplimab plus REGN3767 (DRUG); Trilaciclib with or without trastuzumab + pertuzumab (DRUG); SYD985 ([vic-]trastuzumab duocarmazine) (DRUG); Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab (DRUG); Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab (DRUG); Amcenestrant (DRUG); Amcenestrant + Abemaciclib (DRUG); Amcenestrant + Letrozole (DRUG); ARX788 (DRUG); ARX788 + Cemiplimab (DRUG); VV1 + Cemiplimab (DRUG); Datopotamab deruxtecan (DRUG); Datopotamab deruxtecan + Durvalumab (DRUG); Zanidatamab (DRUG); Lasofoxifene (DRUG); Z-endoxifen (DRUG); ARV-471 (DRUG); ARV-471 + Letrozole (DRUG); ARV-471 + Abemaciclib (DRUG); Endoxifen + Abemaciclib (DRUG); Rilvegostomig + TDXd (DRUG); Dan222 + Niraparib (DRUG); Sarilumab + Cemiplimab + Paclitaxel (DRUG),46220502,Verzenio,Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12523,NCT04188548,A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; Endometrial Cancer,LY3484356 (DRUG); Abemaciclib (DRUG); Everolimus (DRUG); Alpelisib (DRUG); Trastuzumab (DRUG); Aromatase Inhibitor (AI) (DRUG); Pertuzumab (DRUG),46220502,Verzenio,Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; Endometrial Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12524,NCT04351230,T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer,WITHDRAWN,PHASE2,Anatomic Stage IV Breast Cancer AJCC v8; HER2 Positive Breast Carcinoma; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8,Abemaciclib (DRUG); Trastuzumab Emtansine (BIOLOGICAL),46220502,Verzenio,Anatomic Stage IV Breast Cancer AJCC v8; HER2 Positive Breast Carcinoma; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12525,NCT03280563,A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,COMPLETED,PHASE1,Breast Neoplasms,"Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody (DRUG); Bevacizumab (DRUG); Entinostat (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Ipatasertib (DRUG); Tamoxifen (DRUG); Abemaciclib (DRUG)",46220502,Verzenio,Breast Neoplasms,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12526,NCT04862663,Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292),RECRUITING,PHASE3,Locally Advanced (Inoperable) or Metastatic Breast Cancer,Capivasertib (DRUG); Fulvestrant (DRUG); Palbociclib (DRUG); Ribociclib (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Locally Advanced (Inoperable) or Metastatic Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12527,NCT06207734,"Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer",RECRUITING,PHASE2,Breast Cancer,Continuation of CDK4/6 inhibitor Palbociclib (DRUG); Discontinuation of CDK4/6 inhibitor Palbociclib (DRUG); Continuation of CDK4/6 inhibitor -Palbociclib (DRUG); Discontinuation of CDK4/6 inhibitor -Palbociclib (DRUG); Continuation of CDK4/6 inhibitor Abemaciclib (DRUG); Discontinuation of CDK4/6 inhibitor Abemaciclib (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12528,NCT05189717,A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults,ENROLLING_BY_INVITATION,PHASE1,Metastatic or Local Advanced Breast Cancer of Patients,HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus (DRUG),46220502,Verzenio,Metastatic or Local Advanced Breast Cancer of Patients,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12529,NCT04481113,Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; HER2 Negative Breast Adenocarcinoma; Hormone Receptor Positive Breast Adenocarcinoma; Invasive Breast Carcinoma; Multifocal Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Unilateral Breast Carcinoma,Abemaciclib (DRUG); Niraparib Tosylate Monohydrate (DRUG),46220502,Verzenio,Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; HER2 Negative Breast Adenocarcinoma; Hormone Receptor Positive Breast Adenocarcinoma; Invasive Breast Carcinoma; Multifocal Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Unilateral Breast Carcinoma,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12530,NCT04514159,A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer,COMPLETED,PHASE1,Breast Cancer,ZN-c5 (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12531,NCT05608252,VS-6766+Abema+Fulv in Met HR+/HER- BC,RECRUITING,PHASE1,Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer,VS-6766 (DRUG); Abemaciclib (DRUG); Fulvestrant (DRUG),46220502,Verzenio,Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12532,NCT04802759,A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer,RECRUITING,PHASE1,"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer",Giredestrant (DRUG); Abemaciclib (DRUG); Ipatasertib (DRUG); Inavolisib (DRUG); Ribociclib (DRUG); Everolimus (DRUG); Samuraciclib (DRUG); PH FDC SC (DRUG); Palbociclib (DRUG); Atezolizumab (DRUG),46220502,Verzenio,"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer",Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12533,NCT02981342,A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma,COMPLETED,PHASE2,Pancreatic Ductal Adenocarcinoma,Abemaciclib (DRUG); LY3023414 (DRUG); Gemcitabine (DRUG); Capecitabine (DRUG),46220502,Verzenio,Pancreatic Ductal Adenocarcinoma,Pancreas,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12534,NCT04118036,Abemaciclib + Pembrolizumab In Glioblastoma,WITHDRAWN,PHASE2,Glioblastoma,Pembrolizumab (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Glioblastoma,CNS/Brain,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12535,NCT04074785,Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,"GBM; Glioblastoma; Brain Tumor; Brain Tumor, Recurrent",Abemaciclib (DRUG); Bevacizumab (DRUG),46220502,Verzenio,"GBM; Glioblastoma; Brain Tumor; Brain Tumor, Recurrent",CNS/Brain,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12536,NCT06654037,"Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer",RECRUITING,PHASE1,Metastatic Microsatellite Stable Colorectal Carcinoma; Refractory Microsatellite Stable Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8,Abemaciclib (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Fluorouracil (DRUG); Radiologic Imaging Procedure (PROCEDURE),46220502,Verzenio,Metastatic Microsatellite Stable Colorectal Carcinoma; Refractory Microsatellite Stable Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8,Bowel,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12537,NCT04486352,A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer,RECRUITING,PHASE1,Endometrial Cancer,Atezolizumab - 28 Day Cycle (DRUG); Bevacizumab (DRUG); Ipatasertib (DRUG); Talazoparib (DRUG); Trastuzumab emtansine (DRUG); Tiragolumab (DRUG); Atezolizumab - 21 Day Cycle (DRUG); Inavolisib (DRUG); Letrozole (DRUG); Giredestrant (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Endometrial Cancer,Uterus,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12538,NCT04031885,"A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer",TERMINATED,PHASE4,Metastatic Breast Cancer,Abemaciclib (DRUG); Fulvestrant (DRUG); Standard Chemotherapy (DRUG),46220502,Verzenio,Metastatic Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12539,NCT04393285,Abemaciclib and Letrozole to Treat Endometrial Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Endometrial Cancer,Abemaciclib (DRUG); Letrozole (DRUG),46220502,Verzenio,Endometrial Cancer,Uterus,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12540,NCT04088032,"Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer",WITHDRAWN,EARLY_PHASE1,Breast Cancer Female; Locally Advanced Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast,"Abemaciclib, durvalumab and aromatase inhibitor (DRUG)",46220502,Verzenio,Breast Cancer Female; Locally Advanced Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12541,NCT03654833,Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma,UNKNOWN,PHASE2,"Mesothelioma, Malignant",Rucaparib (DRUG); Abemaciclib (DRUG); pembrolizumab & bemcentinib (DRUG); Atezolizumab & Bevacizumab (DRUG); Dostarlimab and Niraparib (DRUG),46220502,Verzenio,Malignant Mesothelioma,Lung,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12542,NCT04432454,Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation,COMPLETED,PHASE2,Metastatic Breast Cancer,Lasofoxifene and abemaciclib (VERZENIO (R)). (DRUG),46220502,Verzenio,Metastatic Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12543,NCT04565054,"Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC",RECRUITING,PHASE3,Breast Cancer Female,Abemaciclib 50 MG; 150mg 1-0-1 per os (DRUG),46220502,Verzenio,Breast Cancer Female,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12544,NCT06380751,"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer",RECRUITING,PHASE3,Advanced Breast Cancer,Saruparib (AZD5305) (DRUG); Camizestrant (DRUG); Abemaciclib (DRUG); Ribociclib (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Exemestane (DRUG),46220502,Verzenio,Advanced Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12545,NCT05670054,Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients,UNKNOWN,PHASE3,Breast Cancer Stage IV,"comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival (DRUG)",46220502,Verzenio,Breast Cancer Stage IV,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12546,NCT06366347,ALPINE: Maintenance Letrozole/Abemaciclib Vs Pembrolizumab,RECRUITING,PHASE2,Endometrial Cancer; Recurrent Endometrial Cancer; TP53,Abemaciclib (DRUG); Letrozole (DRUG); Pembrolizumab (DRUG),46220502,Verzenio,Endometrial Cancer; Recurrent Endometrial Cancer; TP53,Uterus,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12547,NCT04584853,PreOperative Endocrine Therapy for Individualised Care With Abemaciclib,RECRUITING,PHASE3,Breast Cancer Female,"Abemaciclib (DRUG); Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen) (DRUG)",46220502,Verzenio,Breast Cancer Female,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12548,NCT04352777,Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Cancer; Locally Advanced Breast Cancer; Hormone Receptor Positive Tumor,Abemaciclib (DRUG); Fulvestrant (DRUG); Aromatase Inhibitors (DRUG),46220502,Verzenio,"Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12549,NCT04752332,A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer,TERMINATED,PHASE3,Breast Neoplasms,Abemaciclib (DRUG); Standard Adjuvant ET (DRUG); Placebo (DRUG),46220502,Verzenio,Breast Neoplasms,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12550,NCT06760637,Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease,RECRUITING,PHASE3,Breast Cancer,PF-07220060 (DRUG); letrozole (DRUG); abemaciclib (DRUG); palbociclib (DRUG); ribociclib (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12551,NCT05095207,"Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer",RECRUITING,PHASE1,Breast Cancer; Metastasis,Abemaciclib (DRUG); Bicalutamide (DRUG),46220502,Verzenio,Breast Cancer; Metastasis,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12552,NCT06365788,Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer,RECRUITING,PHASE2,Triple Negative Breast Neoplasms,Abemaciclib (DRUG); Bicalutamide (DRUG),46220502,Verzenio,Triple Negative Breast Neoplasms,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12553,NCT02057133,A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread,ACTIVE_NOT_RECRUITING,PHASE1,Breast Neoplasms,LY2835219 (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Tamoxifen (DRUG); Exemestane (DRUG); Everolimus (DRUG); Trastuzumab (DRUG); LY3023414 (DRUG); Fulvestrant (DRUG); Pertuzumab (DRUG); Loperamide (DRUG); Endocrine therapy (DRUG),46220502,Verzenio,Breast Neoplasms,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12554,NCT03616587,Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.,ACTIVE_NOT_RECRUITING,PHASE1,ER+ HER2- Advanced Breast Cancer,AZD9833 (DRUG); AZD9833 (DRUG); AZD9833 with palbociclib (DRUG); AZD9833 with palbociclib (DRUG); AZD9833 with everolimus (DRUG); AZD9833 with everolimus (DRUG); AZD9833 with abemaciclib (DRUG); AZD9833 with abemaciclib (DRUG); AZD9833 with capivasertib (DRUG); AZD9833 with capivasertib (DRUG); AZD9833 with ribociclib (DRUG); AZD9833 with ribociclib (DRUG); AZD9833 with anastrozole (DRUG); AZD9833 with anastrozole (DRUG),46220502,Verzenio,ER+ HER2- Advanced Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12555,NCT03283761,"FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma",COMPLETED,PHASE2,Gastro-Esophageal Junction Adenocarcinoma; Gastric Cancer,Nab-paclitaxel 150 mg/m^2 (DRUG); Oxaliplatin 85 mg/m^2 (DRUG); 5-FU 1200 mg/m^2 x 2 D (DRUG); Leucovorin 400 mg/m^2 (DRUG),46220502,Verzenio,Gastro-Esophageal Junction Adenocarcinoma; Gastric Cancer,Esophagus/Stomach,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12556,NCT03227328,"CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO",COMPLETED,PHASE2,Hormone Receptor Positive Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Negative Breast Cancer,concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy (DRUG); chemotherapy plus endocrine therapy (administered either concomitantly or sequentially) (DRUG),46220502,Verzenio,Hormone Receptor Positive Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Negative Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12557,NCT05700461,Drug Screening Using Novel IMD in Renal Cell Carcinoma,RECRUITING,PHASE1,Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Kidney Cancer,Implantable Microdevice (IMD) (COMBINATION_PRODUCT),46220502,Verzenio,Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Kidney Cancer,Kidney,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12558,NCT05940493,Abemaciclib in Newly Diagnosed Meningioma Patients,RECRUITING,PHASE2,Meningioma,Abemaciclib (DRUG); Placebo (DRUG),46220502,Verzenio,Meningioma,CNS/Brain,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12559,NCT05065411,Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer,TERMINATED,PHASE3,Metastatic Breast Cancer,"Enobosarm & Abemaciclib Combo (DRUG); non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant (DRUG)",46220502,Verzenio,Metastatic Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12560,NCT03846583,Tucatinib + Abemaciclib + Herceptin for HER2+ MBC,WITHDRAWN,PHASE1,Breast Cancer,Tucatinib (DRUG); Abemaciclib (DRUG); Trastuzumab (DRUG); Aromatase Inhibitor (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12561,NCT05806671,"Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy",NOT_YET_RECRUITING,PHASE2,Breast Cancer,Dalpiciclib (DRUG); Pyrotinib (DRUG); Fulvestrant (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12562,NCT06152471,Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer,RECRUITING,PHASE3,Early-stage Breast Cancer; Diarrhea; Adverse Drug Event,SPC-flakes (DRUG); Salovum (DRUG); Placebo (DRUG),46220502,Verzenio,Early-stage Breast Cancer; Diarrhea; Adverse Drug Event,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12563,NCT06169371,Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI),RECRUITING,PHASE4,Breast Cancer,Abemaciclib (DRUG); Abemaciclib (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12564,NCT04616183,LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Colon Adenocarcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Recurrent Colorectal Carcinoma; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Colon Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIA Rectal Cancer AJCC v8; Stage IIIB Colon Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Colon Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Stage IVA Colon Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Rectal Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Rectal Cancer AJCC v8; Stage IVC Colon Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage IVC Rectal Cancer AJCC v8; Unresectable Colon Adenocarcinoma; Unresectable Colorectal Carcinoma; Unresectable Rectal Adenocarcinoma,Abemaciclib (DRUG); Cetuximab (BIOLOGICAL); ERK1/2 Inhibitor LY3214996 (DRUG),46220502,Verzenio,Metastatic Colon Adenocarcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Recurrent Colorectal Carcinoma; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Colon Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIA Rectal Cancer AJCC v8; Stage IIIB Colon Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Colon Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Stage IVA Colon Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Rectal Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Rectal Cancer AJCC v8; Stage IVC Colon Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage IVC Rectal Cancer AJCC v8; Unresectable Colon Adenocarcinoma; Unresectable Colorectal Carcinoma; Unresectable Rectal Adenocarcinoma,Bowel,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12565,NCT04483505,"Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.",COMPLETED,PHASE1,Breast Cancer Metastatic; Hormone Receptor Positive Malignant Neoplasm of Breast,"Combination, Rogaratinib + palbociclib + fulvestrant (DRUG)",46220502,Verzenio,Breast Cancer Metastatic; Hormone Receptor Positive Malignant Neoplasm of Breast,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12566,NCT06139107,RADIANT: Pre-op Radiation With Abemaciclib and Letrozole,RECRUITING,PHASE1,Breast Cancer,Abemaciclib (DRUG); Letrozole (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12567,NCT06188520,"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors",RECRUITING,PHASE1,ER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC),AZD8421 (DRUG); Camizestrant (DRUG); Ribociclib (DRUG); Palbociclib (DRUG); Abemaciclib (DRUG),46220502,Verzenio,Advanced Breast and Ovarian Cancer,Ovary/Fallopian Tube,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12568,NCT05891093,Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01),RECRUITING,PHASE3,Breast Cancer,Fluzoparib (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Tamoxifen (DRUG); Toremifene (DRUG); Abemaciclib (DRUG); LHRH agonist (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12569,NCT03675893,RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Endometrial Cancer; Ovarian Cancer,Letrozole (DRUG); Abemaciclib (DRUG); LY3023414 (DRUG); Metformin (DRUG); Zotatifin (DRUG),46220502,Verzenio,Endometrial Cancer; Ovarian Cancer,Uterus,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12570,NCT04293393,Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients,ACTIVE_NOT_RECRUITING,PHASE2,Early Breast Cancer,Doxorubicin (DRUG); Cyclophosphamide (DRUG); Taxane (DRUG); Letrozole (DRUG); Abemaciclib (DRUG); LHRH Analogue (DRUG),46220502,Verzenio,Early Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12571,NCT06486883,Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype,NOT_YET_RECRUITING,PHASE2,Advanced Breast Cancer; Advanced Breast Carcinoma; Hormone Receptor Positive Breast Carcinoma,"Trastuzumab deruxtecan (T-DXd, DS-8201a) (DRUG); CDK4/6i plus ET (DRUG)",46220502,Verzenio,Advanced Hormone Receptor Positive Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12572,NCT04603183,"ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL",ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer Metastatic,Abemaciclib (DRUG); Paclitaxel (DRUG); Letrozole (DRUG); Fulvestrant (DRUG),46220502,Verzenio,Breast Cancer Metastatic,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12573,NCT03424005,A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer,RECRUITING,PHASE1,Metastatic Breast Cancer,Capecitabine (DRUG); Atezolizumab (DRUG); Ipatasertib (DRUG); SGN-LIV1A (DRUG); Bevacizumab (DRUG); Chemotherapy (Gemcitabine + Carboplatin or Eribulin) (DRUG); Selicrelumab (DRUG); Tocilizumab (DRUG); Nab-Paclitaxel (DRUG); Sacituzumab Govitecan (DRUG); Abemaciclib (DRUG); Fulvestrant (DRUG); Ribociclib (dose #1) (DRUG); Inavolisib (dose #2) (DRUG); Trastuzumab Deruxtecan (DRUG); Ribociclib (dose #2) (DRUG); Letrozole (DRUG); Inavolisib (dose #1) (DRUG); Inavolisib (DRUG),46220502,Verzenio,Metastatic Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12574,NCT03939897,Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer,COMPLETED,PHASE1,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma; Recurrent Breast Carcinoma,Abemaciclib (DRUG); Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Copanlisib Hydrochloride (DRUG); Diagnostic Imaging (PROCEDURE); Echocardiography (PROCEDURE); Fulvestrant (DRUG); Multigated Acquisition Scan (PROCEDURE),46220502,Verzenio,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma; Recurrent Breast Carcinoma,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12575,NCT03155997,Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Abemaciclib (DRUG); Standard Adjuvant Endocrine Therapy (DRUG),46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12576,NCT05307705,A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,"LOXO-783 (DRUG); Fulvestrant (DRUG); Imlunestrant (DRUG); Abemaciclib (DRUG); Anastrozole, Exemestane, or Letrozole (DRUG); Paclitaxel (DRUG)",46220502,Verzenio,Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12577,NCT06062498,Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer,NOT_YET_RECRUITING,PHASE2,Estrogen-receptor-positive Breast Cancer; HER2/Neu-Negative Breast Cancer; Advanced Breast Cancerv; Metastatic Breast Cancer,"elacestrant, palbociclib, abemaciclib, ribociclib (DRUG)",46220502,Verzenio,Metastatic Breast Cancer,Breast,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12578,NCT02779751,A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Non Small Cell Lung Cancer; Breast Cancer,Abemaciclib (DRUG); Pembrolizumab (DRUG); Anastrozole (DRUG),46220502,Verzenio,Non Small Cell Lung Cancer; Breast Cancer,Lung,Abemaciclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,"FDA approved for HR-positive, HER2-negative breast cancer.",CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1.34,275.0 +12579,NCT06074588,Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004),RECRUITING,PHASE3,Non-small Cell Lung Cancer (NSCLC),Sacituzumab tirumotecan (BIOLOGICAL); Docetaxel (DRUG); Pemetrexed (DRUG),6918132,Cosopt,Non-small Cell Lung Cancer (NSCLC),Lung,Dorzolamide (hydrochloride),CA2,inhibitor/antagonist,unclear,yes,yes,Approved for glaucoma treatment.,CCNC1CC(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C.Cl,1.4,93.0 +12580,NCT01262417,Resorbable Barrier for the Prevention of Abdominal and Peri-hepatic Adhesion Formation,COMPLETED,PHASE2,Colorectal Cancer,- use of resorbable membrane Seprafilm (PROCEDURE); without resorbable barrier (seprafilm) (PROCEDURE),5381,Zora,Colorectal Cancer,Bowel,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12581,NCT00409071,Placebo-controlled Evaluation of Cocculine® Efficacy in the Management of Nausea After Chemotherapy in Breast Cancer.,COMPLETED,PHASE3,Breast Cancer,Cocculine® (DRUG); placebo (DRUG),5381,Zora,Breast Cancer,Breast,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12582,NCT02160665,"Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis",COMPLETED,PHASE3,Plaque Psoriasis,"Tazarotene Cream, 0.05% (DRUG); Vehicle (DRUG); Reference: Tazorac Cream, 0.05% (DRUG)",5381,Zora,Plaque Psoriasis,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12583,NCT01019603,"A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris",COMPLETED,PHASE1,Acne Vulgaris,Tazarotene (DRUG); Tazaroc Gel (DRUG),5381,Zora,Acne Vulgaris,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12584,NCT02849873,Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream,COMPLETED,PHASE1,Acne,IDP-123 Lotion (DRUG); Tazorac Cream (DRUG),5381,Zora,Acne,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12585,NCT02267746,A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris,COMPLETED,PHASE3,Acne Vulgaris,Tazarotene (Fabior™) (DRUG); Tazarotene (Actavis) (DRUG); Vehicle foam (DRUG),5381,Zora,Acne Vulgaris,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12586,NCT02525822,Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris,UNKNOWN,PHASE2,Acne Vulgaris,"IDP-123 Lotion (DRUG); Tazorac Cream, 0.1%, (DRUG); Vehicle Cream (DRUG); Vehicle Lotion (DRUG)",5381,Zora,Acne Vulgaris,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12587,NCT00940862,Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis,COMPLETED,PHASE4,Psoriasis; Vascular Inflammation; Coronary Atherosclerosis,adalimumab (BIOLOGICAL); UVB Phototherapy (DEVICE); Topical treatment (OTHER),5381,Zora,Psoriasis; Vascular Inflammation; Coronary Atherosclerosis,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12588,NCT02938494,"Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris",COMPLETED,PHASE2,Acne Vulgaris,IDP-123 Lotion (DRUG); Tazorac Cream (DRUG); Vehicle Lotion (DRUG); Vehicle Cream (DRUG),5381,Zora,Acne Vulgaris,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12589,NCT03058744,Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis,COMPLETED,PHASE1,Psoriasis,IDP-118 Lotion (DRUG); HP Monad Lotion (DRUG); Ultravate Cream (DRUG); Tazorac Cream (DRUG),5381,Zora,Psoriasis,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12590,NCT03341910,"A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris",COMPLETED,PHASE2,Acne Vulgaris,"DFD-03 Lotion, 0.1% (DRUG); Tazorac Cream, 0.1% (DRUG); DFD-03 Vehicle Lotion 0% (DRUG); Tazorac Vehicle Cream 0% (DRUG)",5381,Zora,Acne Vulgaris,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12591,NCT00834210,Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris,COMPLETED,PHASE4,Acne Vulgaris,Dapsone (DRUG); Tazarotene (DRUG),5381,Zora,Acne Vulgaris,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12592,NCT00469755,Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne,COMPLETED,PHASE4,Acne Vulgaris,"Adapalene Gel, 0.1% (DRUG); Tazarotene Cream, 0.1% (DRUG); Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% (DRUG)",5381,Zora,Acne Vulgaris,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12593,NCT02411955,A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris,COMPLETED,PHASE1,Acne Vulgaris,Tazarotene Cream 0.1% (DRUG); Tazorac® (DRUG); Placebo (DRUG),5381,Zora,Acne Vulgaris,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12594,NCT00145106,Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Acne Vulgaris,COMPLETED,PHASE4,Acne Vulgaris,"Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule) (DRUG)",5381,Zora,Acne Vulgaris,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12595,NCT00829049,Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris,TERMINATED,PHASE4,Acne Vulgaris,Tazarotene Cream 0.1% (DRUG); Adapalene (DRUG),5381,Zora,Acne Vulgaris,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12596,NCT02886702,A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis,COMPLETED,PHASE3,Plaque Psoriasis,Tazarotene Cream 0.05% (DRUG); TAZORAC® (tazarotene) Cream 0.05% (DRUG); Placebo (DRUG),5381,Zora,Plaque Psoriasis,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12597,NCT02218034,"Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris",COMPLETED,PHASE1,Acne Vulgaris,AGN-190168 Formulation 1 (DRUG); AGN-190168 Formulation 2 (DRUG); tazarotene gel 0.1% (DRUG); tazarotene cream 0.1% (DRUG),5381,Zora,Acne Vulgaris,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12598,NCT02785159,Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis,COMPLETED,PHASE2,Psoriasis,IDP-118 Lotion (DRUG); Tazorac Cream (DRUG); IDP-118 Vehicle Lotion (DRUG); IDP-118 Vehicle Cream (DRUG),5381,Zora,Psoriasis,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12599,NCT02886715,A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris,COMPLETED,PHASE3,Acne Vulgaris,Tazarotene Cream 0.1% (DRUG); Tazorac® (DRUG); Placebo (DRUG),5381,Zora,Acne Vulgaris,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12600,NCT01016977,"A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris",COMPLETED,PHASE4,Acne Vulgaris,Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene (DRUG); clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene (DRUG),5381,Zora,Acne Vulgaris,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12601,NCT02160678,"Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris",COMPLETED,PHASE3,Acne Vulgaris,"Vehicle (DRUG); Tazarotene Cream, 0.1 % (DRUG); Tazorac Cream, 0.1% (DRUG)",5381,Zora,Acne Vulgaris,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12602,NCT03599193,A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris,COMPLETED,PHASE2,Acne Vulgaris,"Tazarotene Lotion, 0.1% (DRUG); Tazarotene Cream, 0.1% (DRUG)",5381,Zora,Acne Vulgaris,Skin,Tazarotene,"RARA, RARB, RARG",activator/agonist,Retinoic receptor agonist,yes,yes,Topical retinoid approved for psoriasis and acne treatment.,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,1.76,131.0 +12603,NCT04886531,"Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers",RECRUITING,PHASE2,Breast Cancer; HER2-positive Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer,Neratinib (DRUG); Letrozole (L) or Anastrozole (A) (DRUG); Trastuzumab (DRUG),9915743,Neratinib,Breast Cancer; HER2-positive Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12604,NCT03101748,Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Breast Inflammatory Carcinoma; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7,Cyclophosphamide (DRUG); Doxorubicin (DRUG); Laboratory Biomarker Analysis (OTHER); Neratinib (DRUG); Paclitaxel (DRUG); Pertuzumab (BIOLOGICAL); Trastuzumab (BIOLOGICAL),9915743,Neratinib,Breast Inflammatory Carcinoma; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12605,NCT05512182,"Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression",WITHDRAWN,PHASE2,Recurrent/Advanced Gastric Cancer,Chemotherapy (DRUG),9915743,Neratinib,Recurrent/Advanced Gastric Cancer,Esophagus/Stomach,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12606,NCT04760431,TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN),NOT_YET_RECRUITING,PHASE2,HER2-positive Breast Cancer; Brain Metastases,Trastuzumab (DRUG); Taxanes (DRUG); Pertuzumab (DRUG); Tyrosine kinase inhibitor (DRUG),9915743,Neratinib,HER2-positive Breast Cancer with Brain Metastases,CNS/Brain,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12607,NCT02400476,An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide,COMPLETED,PHASE2,Early Stage HER2+ Breast Cancer,Neratinib (DRUG); Loperamide (DRUG); Colestipol (DRUG); Budesonide (DRUG),9915743,Neratinib,Early Stage HER2+ Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12608,NCT02977780,INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT),RECRUITING,PHASE2,Glioblastoma,Temozolomide (DRUG); Neratinib (DRUG); QBS10072S (DRUG),9915743,Neratinib,Glioblastoma,CNS/Brain,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12609,NCT06109467,Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer,RECRUITING,PHASE2,GastroEsophageal Cancer; Gastric Cancer,Neratinib (DRUG); Trastuzumab (DRUG); Oxaliplatin (DRUG); 5-Fluorouracil + leucovorin (DRUG); Pembrolizumab (DRUG),9915743,Neratinib,Esophageal and Gastric Cancer,Esophagus/Stomach,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12610,NCT01827267,Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer,COMPLETED,PHASE2,HER2-mutant Non-Small Cell Lung Cancer,neratinib (DRUG); temsirolimus (DRUG),9915743,Neratinib,HER2-mutant Non-Small Cell Lung Cancer,Lung,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12611,NCT05274048,Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients,RECRUITING,PHASE1,Gastric Cancer; Gastrointestinal Cancer; HER2 Gene Mutation,Neratinib Pill (DRUG); Fam-Trastuzumab Deruxtecan-Nxki (TDxD) (DRUG),9915743,Neratinib,Gastric Cancer; Gastrointestinal Cancer; HER2 Gene Mutation,Bowel,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12612,NCT00706030,Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer,COMPLETED,PHASE1,Breast Cancer; Advanced Malignant Solid Tumors,neratinib (DRUG); vinorelbine (DRUG),9915743,Neratinib,Breast Cancer; Advanced Malignant Solid Tumors,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12613,NCT01111825,Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer,COMPLETED,PHASE1,Breast Cancer,Temsirolimus (DRUG); Neratinib (DRUG),9915743,Neratinib,Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12614,NCT04460430,Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Neratinib + endocrine therapy (DRUG),9915743,Neratinib,Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12615,NCT03289039,"Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer",TERMINATED,PHASE2,Breast Cancer,Neratinib (DRUG); Fulvestrant (DRUG),9915743,Neratinib,Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12616,NCT05154396,Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer,UNKNOWN,PHASE2,HER2-positive Breast Cancer,Neratinib (DRUG),9915743,Neratinib,HER2-positive Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12617,NCT00445458,A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer,COMPLETED,PHASE1,Advanced Breast Cancer; Advanced Malignant Solid Tumors; Breast Neoplasms,HKI-272 (DRUG); Paclitaxel (DRUG),9915743,Neratinib,Advanced Breast Cancer; Advanced Malignant Solid Tumors; Breast Neoplasms,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12618,NCT01494662,HKI-272 for HER2-Positive Breast Cancer and Brain Metastases,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,HKI-272 (DRUG); Surgical Resection (PROCEDURE); Capecitabine (DRUG); HKI-272 (DRUG); Ado-Trastuzumab Emtansine (DRUG),9915743,Neratinib,Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12619,NCT00741260,Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer,COMPLETED,PHASE1,Breast Cancer,Neratinib (DRUG); Capecitabine (DRUG),9915743,Neratinib,Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12620,NCT00146172,Study Evaluating HKI-272 in Tumors,COMPLETED,PHASE1,Breast Neoplasms,neratinib (DRUG),9915743,Neratinib,Breast Neoplasms,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12621,NCT01808573,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,COMPLETED,PHASE3,HER2+ Metastatic Breast Cancer (MBC),neratinib (DRUG); capecitabine (DRUG); lapatinib (DRUG),9915743,Neratinib,HER2+ Metastatic Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12622,NCT03457896,Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,Trastuzumab (DRUG); Cetuximab (DRUG); Neratinib (DRUG); Guardant360 Diagnostic Test (DIAGNOSTIC_TEST),9915743,Neratinib,Metastatic Colorectal Cancer,Bowel,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12623,NCT00777101,Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer,COMPLETED,PHASE2,Advanced Breast Cancer; Breast Cancer,Neratinib (DRUG); Lapatinib (DRUG); Capecitabine (DRUG),9915743,Neratinib,Advanced Breast Cancer; Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12624,NCT00398567,A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer,COMPLETED,PHASE1,Advanced Breast Cancer,HKI-272 (DRUG); trastuzumab (DRUG),9915743,Neratinib,Advanced Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12625,NCT03182634,The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial,UNKNOWN,PHASE2,Advanced Breast Cancer,Fulvestrant (DRUG); Neratinib (DRUG); AZD5363 (DRUG); Olaparib (DRUG); AZD6738 (DRUG),9915743,Neratinib,Advanced Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12626,NCT05243641,Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test,TERMINATED,PHASE1,Metastatic Breast Cancer; Breast Cancer,Neratinib (DRUG); Capmatinib (DRUG),9915743,Neratinib,Metastatic Breast Cancer; Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12627,NCT05615818,Personalized Medicine for Advanced Biliary Cancer Patients,RECRUITING,PHASE3,Biliary Tract Neoplasms,Futibatinib (DRUG); Ivosidenib (DRUG); Zanidatamab (DRUG); Trastuzumab (DRUG); Neratinib (DRUG); Encorafenib (DRUG); Binimetinib (DRUG); Niraparib (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG),9915743,Neratinib,Biliary Tract Neoplasms,Liver,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12628,NCT02396108,"Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer",UNKNOWN,PHASE1,Breast Cancer,Paclitaxel + Carboplatin + ASLAN001 (DRUG),9915743,Neratinib,Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12629,NCT05933395,Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor,RECRUITING,PHASE2,Advanced Breast Cancer,Fulvestrant (DRUG); Neratinib (DRUG); Alpelisib (DRUG); Everolimus (DRUG); Abemaciclib (DRUG),9915743,Neratinib,Advanced Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12630,NCT05760612,A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment with Trastuzumab Combined with Parezumab,RECRUITING,PHASE3,Early-stage Breast Cancer; HER2-positive Breast Cancer; Adjuvant Treatment After Trastuzumab; RCB Classification 1-2; Neratini,Trastuzumab and nelatinib (DRUG); Trastuzumab and Parstuzumab (DRUG),9915743,Neratinib,Early-stage Breast Cancer; HER2-positive Breast Cancer; Adjuvant Treatment After Trastuzumab; RCB Classification 1-2; Neratini,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12631,NCT00300781,Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms; Neoplasms,neratinib (DRUG),9915743,Neratinib,Breast Neoplasms; Neoplasms,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12632,NCT01423123,Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer,COMPLETED,PHASE1,Breast Cancer,Paclitaxel (DRUG); trastuzumab (BIOLOGICAL); Neratinib (DRUG),9915743,Neratinib,Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12633,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Paclitaxel (DRUG); Trastuzumab (DRUG); Neratinib (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG),9915743,Neratinib,Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12634,NCT01960023,Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer,WITHDRAWN,PHASE1,Colorectal Cancer,Cetuximab (DRUG); Neratinib (DRUG),9915743,Neratinib,Colorectal Cancer,Bowel,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12635,NCT05834764,Pyrotinib in Women With High-risk in Early Stage Breast Cancer,RECRUITING,PHASE2,HER2-positive Breast Cancer,Pyrotinib (DRUG),9915743,Neratinib,HER2-positive Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12636,NCT04965064,Trial of Neratinib Plus Capecitabine in Subjects with HER2-Negative Metastatic Breast Cancer with Brain Metastases and Abnormally Active HER2 Signaling,RECRUITING,PHASE2,Breast Cancer,Capecitabine and Neratinib. (DRUG),9915743,Neratinib,Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12637,NCT05388149,Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease,RECRUITING,PHASE2,Breast Cancer; HER2-positive Breast Cancer,Neratinib (DRUG),9915743,Neratinib,Breast Cancer; HER2-positive Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12638,NCT06008275,Neratinib in Combination With Ruxolitinib in Patients With mTNBC,RECRUITING,EARLY_PHASE1,Metastatic Triple-Negative Breast Carcinoma; Breast Cancer,Neratinib Oral Tablet (DRUG); Ruxolitinib Oral Tablet (DRUG),9915743,Neratinib,Metastatic Triple-Negative Breast Carcinoma; Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12639,NCT04901299,Fulvestrant + Neratinib In Breast Cancer,WITHDRAWN,PHASE2,Stage IV (Metastatic) Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer; HER2-negative Breast Cancer; Invasive Breast Cancer,NERATINIB (DRUG); FULVESTRANT (DRUG),9915743,Neratinib,Stage IV (Metastatic) Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer; HER2-negative Breast Cancer; Invasive Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12640,NCT04502602,Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Advanced Solid Tumor; Ovarian Cancer,Neratinib 160 mg (DRUG); Neratinib 200 mg (DRUG); Neratinib 240 mg (DRUG); Niraparib 100 mg (DRUG); Niraparib 200 mg (DRUG); Niraparib 300 mg (DRUG); Niraparib at RP2D (DRUG); Neratinib at RP2D (DRUG),9915743,Neratinib,Advanced Solid Tumor; Ovarian Cancer,Ovary/Fallopian Tube,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12641,NCT00708903,Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization),COMPLETED,PHASE1,Breast Cancer,neratinib (DRUG); Placebo (OTHER); Moxifloxacin (DRUG),9915743,Neratinib,Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12642,NCT06813079,Using Tumor Models to Determine Treatments,NOT_YET_RECRUITING,PHASE2,Pancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor,Cobimetinib (DRUG); Ponatinib (DRUG); Brigatinib (DRUG); Colchicine (DRUG); Selinexor (DRUG); Abemaciclib (DRUG); Neratinib (DRUG); Doxorubicin (DRUG); Etoposide (DRUG); Ceritinib (DRUG),9915743,Neratinib,Pancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor,Pancreas,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12643,NCT01042379,I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,RECRUITING,PHASE2,Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer,Standard Therapy (DRUG); AMG 386 with or without Trastuzumab (DRUG); AMG 479 (Ganitumab) plus Metformin (DRUG); MK-2206 with or without Trastuzumab (DRUG); AMG 386 and Trastuzumab (DRUG); T-DM1 and Pertuzumab (DRUG); Pertuzumab and Trastuzumab (DRUG); Ganetespib (DRUG); ABT-888 (DRUG); Neratinib (DRUG); PLX3397 (DRUG); Pembrolizumab - 4 cycle (DRUG); Talazoparib plus Irinotecan (DRUG); Patritumab and Trastuzumab (DRUG); Pembrolizumab - 8 cycle (DRUG); SGN-LIV1A (DRUG); Durvalumab plus Olaparib (DRUG); SD-101 + Pembrolizumab (DRUG); Tucatinib plus trastuzumab and pertuzumab (DRUG); Cemiplimab (DRUG); Cemiplimab plus REGN3767 (DRUG); Trilaciclib with or without trastuzumab + pertuzumab (DRUG); SYD985 ([vic-]trastuzumab duocarmazine) (DRUG); Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab (DRUG); Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab (DRUG); Amcenestrant (DRUG); Amcenestrant + Abemaciclib (DRUG); Amcenestrant + Letrozole (DRUG); ARX788 (DRUG); ARX788 + Cemiplimab (DRUG); VV1 + Cemiplimab (DRUG); Datopotamab deruxtecan (DRUG); Datopotamab deruxtecan + Durvalumab (DRUG); Zanidatamab (DRUG); Lasofoxifene (DRUG); Z-endoxifen (DRUG); ARV-471 (DRUG); ARV-471 + Letrozole (DRUG); ARV-471 + Abemaciclib (DRUG); Endoxifen + Abemaciclib (DRUG); Rilvegostomig + TDXd (DRUG); Dan222 + Niraparib (DRUG); Sarilumab + Cemiplimab + Paclitaxel (DRUG),9915743,Neratinib,Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12644,NCT05919108,Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers,RECRUITING,PHASE2,Anatomic Stage I Breast Cancer; Anatomic Stage II Breast Cancer; Anatomic Stage III Breast Cancer; Invasive Breast Lobular Carcinoma,Endocrine Therapy (PROCEDURE); Biopsy of breast (PROCEDURE); Neratinib (DRUG); Biospecimen Collection (PROCEDURE); Mammogram (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Breast Surgery (PROCEDURE); Ultrasound (PROCEDURE),9915743,Neratinib,Anatomic Stage I Breast Cancer; Anatomic Stage II Breast Cancer; Anatomic Stage III Breast Cancer; Invasive Breast Lobular Carcinoma,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12645,NCT04856475,Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer,WITHDRAWN,PHASE2,Breast Cancer; Brain Metastases,Neratinib (DRUG),9915743,Neratinib,Breast Cancer with Brain Metastases,CNS/Brain,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12646,NCT00915018,Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Neratinib (DRUG); Trastuzumab (DRUG); Paclitaxel (DRUG),9915743,Neratinib,Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12647,NCT04366713,A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib,COMPLETED,PHASE2,HER2 Amplified Breast Cancer,Neratinib (DRUG); Capecitabine (DRUG); Loperamide (DRUG),9915743,Neratinib,HER2 Amplified Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12648,NCT04802759,A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer,RECRUITING,PHASE1,"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer",Giredestrant (DRUG); Abemaciclib (DRUG); Ipatasertib (DRUG); Inavolisib (DRUG); Ribociclib (DRUG); Everolimus (DRUG); Samuraciclib (DRUG); PH FDC SC (DRUG); Palbociclib (DRUG); Atezolizumab (DRUG),9915743,Neratinib,"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer",Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12649,NCT02236000,A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer,COMPLETED,PHASE1,Breast Cancer,Neratinib (DRUG); T-DM1 (DRUG),9915743,Neratinib,Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12650,NCT03094052,Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib,COMPLETED,PHASE2,HER2-positive Breast Cancer; Breast Adenocarcinoma; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7,Neratinib (DRUG); Trastuzumab (BIOLOGICAL); Loperamide (DRUG); Diphenoxylate Hydrochloride/Atropine Sulfate (DRUG),9915743,Neratinib,HER2-positive Breast Cancer; Breast Adenocarcinoma; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12651,NCT06643585,A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse,RECRUITING,PHASE3,Breast Cancer,Trastuzumab-Deruxtecan (DRUG); Physicians Choice (PhC). (OTHER),9915743,Neratinib,Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12652,NCT00266877,Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung; Lung Neoplasms",HKI-272 (DRUG),9915743,Neratinib,"Carcinoma, Non-Small-Cell Lung; Lung Neoplasms",Lung,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12653,NCT05564377,"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial",RECRUITING,PHASE2,Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm,Alpelisib (DRUG); Binimetinib (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Fluorouracil (DRUG); Fulvestrant (DRUG); Ipatasertib (DRUG); Leucovorin (DRUG); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Mutation Carrier Screening (PROCEDURE); Neratinib Maleate (DRUG); Nilotinib Hydrochloride Monohydrate (DRUG); Olaparib (DRUG); Oxaliplatin (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Panitumumab (BIOLOGICAL); Positron Emission Tomography (PROCEDURE); Selumetinib Sulfate (DRUG); Sotorasib (DRUG),9915743,Neratinib,Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm,Ovary/Fallopian Tube,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12654,NCT01670877,Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms,Neratinib (DRUG); Fulvestrant (DRUG); Trastuzumab (DRUG); Tumor biopsy (PROCEDURE); Research blood sample (PROCEDURE),9915743,Neratinib,Breast Neoplasms,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12655,NCT06374888,Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases,NOT_YET_RECRUITING,PHASE2,Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis,Neratinib maleate in combination with capecitabine (DRUG),9915743,Neratinib,Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis,Esophagus/Stomach,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12656,NCT00878709,Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,COMPLETED,PHASE3,Breast Cancer,neratinib (DRUG); placebo (OTHER),9915743,Neratinib,Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12657,NCT03377387,Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,"Capecitabine (DRUG); Neratinib (DRUG); EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30 (BEHAVIORAL)",9915743,Neratinib,Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12658,NCT05252988,Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib,ACTIVE_NOT_RECRUITING,PHASE2,Early-stage Breast Cancer; HER2 Positive Breast Cancer; Hormone Receptor Positive,Neratinib (DRUG); Loperamide (DRUG); Colesevelam (DRUG),9915743,Neratinib,Early-stage Breast Cancer; HER2 Positive Breast Cancer; Hormone Receptor Positive,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12659,NCT00781430,Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease,COMPLETED,PHASE1,Hepatic Insufficiency,Neratinib (HKI-272) (DRUG),9915743,Neratinib,Hepatic Insufficiency,Liver,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12660,NCT03812393,Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast,ACTIVE_NOT_RECRUITING,PHASE2,Triple Negative Breast Cancer; Early-stage Breast Cancer; HER2-positive Breast Cancer,Neratinib (DRUG),9915743,Neratinib,Triple Negative Breast Cancer; Early-stage Breast Cancer; HER2-positive Breast Cancer,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12661,NCT02673398,Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer,COMPLETED,PHASE2,HER2 Positive Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7,Comprehensive Geriatric Assessment (OTHER); Laboratory Biomarker Analysis (OTHER); Neratinib (DRUG); Pharmacological Study (OTHER),9915743,Neratinib,HER2 Positive Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7,Breast,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12662,NCT04374305,Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2),ACTIVE_NOT_RECRUITING,PHASE2,Neurofibromatosis Type 2; Vestibular Schwannoma; Non-vestibular Schwannoma; Meningioma; Ependymoma,Brigatinib (DRUG); Neratinib (DRUG),9915743,Neratinib,Neurofibromatosis Type 2; Vestibular Schwannoma; Non-vestibular Schwannoma; Meningioma; Ependymoma,CNS/Brain,Neratinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,1.13,917.0 +12663,NCT04886531,"Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers",RECRUITING,PHASE2,Breast Cancer; HER2-positive Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer,Neratinib (DRUG); Letrozole (L) or Anastrozole (A) (DRUG); Trastuzumab (DRUG),67307512,Nerlynx,Breast Cancer; HER2-positive Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12664,NCT03101748,Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Breast Inflammatory Carcinoma; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7,Cyclophosphamide (DRUG); Doxorubicin (DRUG); Laboratory Biomarker Analysis (OTHER); Neratinib (DRUG); Paclitaxel (DRUG); Pertuzumab (BIOLOGICAL); Trastuzumab (BIOLOGICAL),67307512,Nerlynx,Breast Inflammatory Carcinoma; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12665,NCT05512182,"Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression",WITHDRAWN,PHASE2,Recurrent/Advanced Gastric Cancer,Chemotherapy (DRUG),67307512,Nerlynx,Recurrent/Advanced Gastric Cancer,Esophagus/Stomach,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12666,NCT04760431,TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN),NOT_YET_RECRUITING,PHASE2,HER2-positive Breast Cancer; Brain Metastases,Trastuzumab (DRUG); Taxanes (DRUG); Pertuzumab (DRUG); Tyrosine kinase inhibitor (DRUG),67307512,Nerlynx,HER2-positive Breast Cancer with Brain Metastases,CNS/Brain,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12667,NCT02400476,An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide,COMPLETED,PHASE2,Early Stage HER2+ Breast Cancer,Neratinib (DRUG); Loperamide (DRUG); Colestipol (DRUG); Budesonide (DRUG),67307512,Nerlynx,Early Stage HER2+ Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12668,NCT02977780,INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT),RECRUITING,PHASE2,Glioblastoma,Temozolomide (DRUG); Neratinib (DRUG); QBS10072S (DRUG),67307512,Nerlynx,Glioblastoma,CNS/Brain,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12669,NCT06109467,Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer,RECRUITING,PHASE2,GastroEsophageal Cancer; Gastric Cancer,Neratinib (DRUG); Trastuzumab (DRUG); Oxaliplatin (DRUG); 5-Fluorouracil + leucovorin (DRUG); Pembrolizumab (DRUG),67307512,Nerlynx,Esophageal and Gastric Cancer,Esophagus/Stomach,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12670,NCT01827267,Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer,COMPLETED,PHASE2,HER2-mutant Non-Small Cell Lung Cancer,neratinib (DRUG); temsirolimus (DRUG),67307512,Nerlynx,HER2-mutant Non-Small Cell Lung Cancer,Lung,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12671,NCT05274048,Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients,RECRUITING,PHASE1,Gastric Cancer; Gastrointestinal Cancer; HER2 Gene Mutation,Neratinib Pill (DRUG); Fam-Trastuzumab Deruxtecan-Nxki (TDxD) (DRUG),67307512,Nerlynx,Gastric Cancer; Gastrointestinal Cancer; HER2 Gene Mutation,Bowel,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12672,NCT00706030,Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer,COMPLETED,PHASE1,Breast Cancer; Advanced Malignant Solid Tumors,neratinib (DRUG); vinorelbine (DRUG),67307512,Nerlynx,Breast Cancer; Advanced Malignant Solid Tumors,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12673,NCT01111825,Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer,COMPLETED,PHASE1,Breast Cancer,Temsirolimus (DRUG); Neratinib (DRUG),67307512,Nerlynx,Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12674,NCT04460430,Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Neratinib + endocrine therapy (DRUG),67307512,Nerlynx,Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12675,NCT03289039,"Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer",TERMINATED,PHASE2,Breast Cancer,Neratinib (DRUG); Fulvestrant (DRUG),67307512,Nerlynx,Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12676,NCT05154396,Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer,UNKNOWN,PHASE2,HER2-positive Breast Cancer,Neratinib (DRUG),67307512,Nerlynx,HER2-positive Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12677,NCT00445458,A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer,COMPLETED,PHASE1,Advanced Breast Cancer; Advanced Malignant Solid Tumors; Breast Neoplasms,HKI-272 (DRUG); Paclitaxel (DRUG),67307512,Nerlynx,Advanced Breast Cancer; Advanced Malignant Solid Tumors; Breast Neoplasms,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12678,NCT01494662,HKI-272 for HER2-Positive Breast Cancer and Brain Metastases,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,HKI-272 (DRUG); Surgical Resection (PROCEDURE); Capecitabine (DRUG); HKI-272 (DRUG); Ado-Trastuzumab Emtansine (DRUG),67307512,Nerlynx,Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12679,NCT00741260,Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer,COMPLETED,PHASE1,Breast Cancer,Neratinib (DRUG); Capecitabine (DRUG),67307512,Nerlynx,Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12680,NCT00146172,Study Evaluating HKI-272 in Tumors,COMPLETED,PHASE1,Breast Neoplasms,neratinib (DRUG),67307512,Nerlynx,Breast Neoplasms,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12681,NCT01808573,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,COMPLETED,PHASE3,HER2+ Metastatic Breast Cancer (MBC),neratinib (DRUG); capecitabine (DRUG); lapatinib (DRUG),67307512,Nerlynx,HER2+ Metastatic Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12682,NCT03457896,Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,Trastuzumab (DRUG); Cetuximab (DRUG); Neratinib (DRUG); Guardant360 Diagnostic Test (DIAGNOSTIC_TEST),67307512,Nerlynx,Metastatic Colorectal Cancer,Bowel,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12683,NCT00777101,Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer,COMPLETED,PHASE2,Advanced Breast Cancer; Breast Cancer,Neratinib (DRUG); Lapatinib (DRUG); Capecitabine (DRUG),67307512,Nerlynx,Advanced Breast Cancer; Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12684,NCT00398567,A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer,COMPLETED,PHASE1,Advanced Breast Cancer,HKI-272 (DRUG); trastuzumab (DRUG),67307512,Nerlynx,Advanced Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12685,NCT03182634,The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial,UNKNOWN,PHASE2,Advanced Breast Cancer,Fulvestrant (DRUG); Neratinib (DRUG); AZD5363 (DRUG); Olaparib (DRUG); AZD6738 (DRUG),67307512,Nerlynx,Advanced Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12686,NCT05243641,Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test,TERMINATED,PHASE1,Metastatic Breast Cancer; Breast Cancer,Neratinib (DRUG); Capmatinib (DRUG),67307512,Nerlynx,Metastatic Breast Cancer; Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12687,NCT05615818,Personalized Medicine for Advanced Biliary Cancer Patients,RECRUITING,PHASE3,Biliary Tract Neoplasms,Futibatinib (DRUG); Ivosidenib (DRUG); Zanidatamab (DRUG); Trastuzumab (DRUG); Neratinib (DRUG); Encorafenib (DRUG); Binimetinib (DRUG); Niraparib (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG),67307512,Nerlynx,Biliary Tract Neoplasms,Liver,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12688,NCT02396108,"Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer",UNKNOWN,PHASE1,Breast Cancer,Paclitaxel + Carboplatin + ASLAN001 (DRUG),67307512,Nerlynx,Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12689,NCT05933395,Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor,RECRUITING,PHASE2,Advanced Breast Cancer,Fulvestrant (DRUG); Neratinib (DRUG); Alpelisib (DRUG); Everolimus (DRUG); Abemaciclib (DRUG),67307512,Nerlynx,Advanced Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12690,NCT05760612,A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment with Trastuzumab Combined with Parezumab,RECRUITING,PHASE3,Early-stage Breast Cancer; HER2-positive Breast Cancer; Adjuvant Treatment After Trastuzumab; RCB Classification 1-2; Neratini,Trastuzumab and nelatinib (DRUG); Trastuzumab and Parstuzumab (DRUG),67307512,Nerlynx,Early-stage Breast Cancer; HER2-positive Breast Cancer; Adjuvant Treatment After Trastuzumab; RCB Classification 1-2; Neratini,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12691,NCT00300781,Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms; Neoplasms,neratinib (DRUG),67307512,Nerlynx,Breast Neoplasms; Neoplasms,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12692,NCT01423123,Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer,COMPLETED,PHASE1,Breast Cancer,Paclitaxel (DRUG); trastuzumab (BIOLOGICAL); Neratinib (DRUG),67307512,Nerlynx,Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12693,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Paclitaxel (DRUG); Trastuzumab (DRUG); Neratinib (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG),67307512,Nerlynx,Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12694,NCT01960023,Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer,WITHDRAWN,PHASE1,Colorectal Cancer,Cetuximab (DRUG); Neratinib (DRUG),67307512,Nerlynx,Colorectal Cancer,Bowel,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12695,NCT05834764,Pyrotinib in Women With High-risk in Early Stage Breast Cancer,RECRUITING,PHASE2,HER2-positive Breast Cancer,Pyrotinib (DRUG),67307512,Nerlynx,HER2-positive Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12696,NCT04965064,Trial of Neratinib Plus Capecitabine in Subjects with HER2-Negative Metastatic Breast Cancer with Brain Metastases and Abnormally Active HER2 Signaling,RECRUITING,PHASE2,Breast Cancer,Capecitabine and Neratinib. (DRUG),67307512,Nerlynx,Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12697,NCT05388149,Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease,RECRUITING,PHASE2,Breast Cancer; HER2-positive Breast Cancer,Neratinib (DRUG),67307512,Nerlynx,Breast Cancer; HER2-positive Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12698,NCT06008275,Neratinib in Combination With Ruxolitinib in Patients With mTNBC,RECRUITING,EARLY_PHASE1,Metastatic Triple-Negative Breast Carcinoma; Breast Cancer,Neratinib Oral Tablet (DRUG); Ruxolitinib Oral Tablet (DRUG),67307512,Nerlynx,Metastatic Triple-Negative Breast Carcinoma; Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12699,NCT04901299,Fulvestrant + Neratinib In Breast Cancer,WITHDRAWN,PHASE2,Stage IV (Metastatic) Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer; HER2-negative Breast Cancer; Invasive Breast Cancer,NERATINIB (DRUG); FULVESTRANT (DRUG),67307512,Nerlynx,Stage IV (Metastatic) Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer; HER2-negative Breast Cancer; Invasive Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12700,NCT04502602,Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Advanced Solid Tumor; Ovarian Cancer,Neratinib 160 mg (DRUG); Neratinib 200 mg (DRUG); Neratinib 240 mg (DRUG); Niraparib 100 mg (DRUG); Niraparib 200 mg (DRUG); Niraparib 300 mg (DRUG); Niraparib at RP2D (DRUG); Neratinib at RP2D (DRUG),67307512,Nerlynx,Advanced Solid Tumor; Ovarian Cancer,Ovary/Fallopian Tube,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12701,NCT00708903,Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization),COMPLETED,PHASE1,Breast Cancer,neratinib (DRUG); Placebo (OTHER); Moxifloxacin (DRUG),67307512,Nerlynx,Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12702,NCT06813079,Using Tumor Models to Determine Treatments,NOT_YET_RECRUITING,PHASE2,Pancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor,Cobimetinib (DRUG); Ponatinib (DRUG); Brigatinib (DRUG); Colchicine (DRUG); Selinexor (DRUG); Abemaciclib (DRUG); Neratinib (DRUG); Doxorubicin (DRUG); Etoposide (DRUG); Ceritinib (DRUG),67307512,Nerlynx,Pancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor,Pancreas,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12703,NCT01042379,I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,RECRUITING,PHASE2,Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer,Standard Therapy (DRUG); AMG 386 with or without Trastuzumab (DRUG); AMG 479 (Ganitumab) plus Metformin (DRUG); MK-2206 with or without Trastuzumab (DRUG); AMG 386 and Trastuzumab (DRUG); T-DM1 and Pertuzumab (DRUG); Pertuzumab and Trastuzumab (DRUG); Ganetespib (DRUG); ABT-888 (DRUG); Neratinib (DRUG); PLX3397 (DRUG); Pembrolizumab - 4 cycle (DRUG); Talazoparib plus Irinotecan (DRUG); Patritumab and Trastuzumab (DRUG); Pembrolizumab - 8 cycle (DRUG); SGN-LIV1A (DRUG); Durvalumab plus Olaparib (DRUG); SD-101 + Pembrolizumab (DRUG); Tucatinib plus trastuzumab and pertuzumab (DRUG); Cemiplimab (DRUG); Cemiplimab plus REGN3767 (DRUG); Trilaciclib with or without trastuzumab + pertuzumab (DRUG); SYD985 ([vic-]trastuzumab duocarmazine) (DRUG); Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab (DRUG); Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab (DRUG); Amcenestrant (DRUG); Amcenestrant + Abemaciclib (DRUG); Amcenestrant + Letrozole (DRUG); ARX788 (DRUG); ARX788 + Cemiplimab (DRUG); VV1 + Cemiplimab (DRUG); Datopotamab deruxtecan (DRUG); Datopotamab deruxtecan + Durvalumab (DRUG); Zanidatamab (DRUG); Lasofoxifene (DRUG); Z-endoxifen (DRUG); ARV-471 (DRUG); ARV-471 + Letrozole (DRUG); ARV-471 + Abemaciclib (DRUG); Endoxifen + Abemaciclib (DRUG); Rilvegostomig + TDXd (DRUG); Dan222 + Niraparib (DRUG); Sarilumab + Cemiplimab + Paclitaxel (DRUG),67307512,Nerlynx,Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12704,NCT05919108,Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers,RECRUITING,PHASE2,Anatomic Stage I Breast Cancer; Anatomic Stage II Breast Cancer; Anatomic Stage III Breast Cancer; Invasive Breast Lobular Carcinoma,Endocrine Therapy (PROCEDURE); Biopsy of breast (PROCEDURE); Neratinib (DRUG); Biospecimen Collection (PROCEDURE); Mammogram (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Breast Surgery (PROCEDURE); Ultrasound (PROCEDURE),67307512,Nerlynx,Anatomic Stage I Breast Cancer; Anatomic Stage II Breast Cancer; Anatomic Stage III Breast Cancer; Invasive Breast Lobular Carcinoma,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12705,NCT04856475,Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer,WITHDRAWN,PHASE2,Breast Cancer; Brain Metastases,Neratinib (DRUG),67307512,Nerlynx,Breast Cancer with Brain Metastases,CNS/Brain,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12706,NCT00915018,Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Neratinib (DRUG); Trastuzumab (DRUG); Paclitaxel (DRUG),67307512,Nerlynx,Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12707,NCT04366713,A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib,COMPLETED,PHASE2,HER2 Amplified Breast Cancer,Neratinib (DRUG); Capecitabine (DRUG); Loperamide (DRUG),67307512,Nerlynx,HER2 Amplified Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12708,NCT04802759,A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer,RECRUITING,PHASE1,"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer",Giredestrant (DRUG); Abemaciclib (DRUG); Ipatasertib (DRUG); Inavolisib (DRUG); Ribociclib (DRUG); Everolimus (DRUG); Samuraciclib (DRUG); PH FDC SC (DRUG); Palbociclib (DRUG); Atezolizumab (DRUG),67307512,Nerlynx,"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer",Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12709,NCT02236000,A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer,COMPLETED,PHASE1,Breast Cancer,Neratinib (DRUG); T-DM1 (DRUG),67307512,Nerlynx,Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12710,NCT03094052,Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib,COMPLETED,PHASE2,HER2-positive Breast Cancer; Breast Adenocarcinoma; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7,Neratinib (DRUG); Trastuzumab (BIOLOGICAL); Loperamide (DRUG); Diphenoxylate Hydrochloride/Atropine Sulfate (DRUG),67307512,Nerlynx,HER2-positive Breast Cancer; Breast Adenocarcinoma; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12711,NCT06643585,A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse,RECRUITING,PHASE3,Breast Cancer,Trastuzumab-Deruxtecan (DRUG); Physicians Choice (PhC). (OTHER),67307512,Nerlynx,Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12712,NCT00266877,Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung; Lung Neoplasms",HKI-272 (DRUG),67307512,Nerlynx,"Carcinoma, Non-Small-Cell Lung; Lung Neoplasms",Lung,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12713,NCT05564377,"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial",RECRUITING,PHASE2,Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm,Alpelisib (DRUG); Binimetinib (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Fluorouracil (DRUG); Fulvestrant (DRUG); Ipatasertib (DRUG); Leucovorin (DRUG); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Mutation Carrier Screening (PROCEDURE); Neratinib Maleate (DRUG); Nilotinib Hydrochloride Monohydrate (DRUG); Olaparib (DRUG); Oxaliplatin (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Panitumumab (BIOLOGICAL); Positron Emission Tomography (PROCEDURE); Selumetinib Sulfate (DRUG); Sotorasib (DRUG),67307512,Nerlynx,Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm,Ovary/Fallopian Tube,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12714,NCT01670877,Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms,Neratinib (DRUG); Fulvestrant (DRUG); Trastuzumab (DRUG); Tumor biopsy (PROCEDURE); Research blood sample (PROCEDURE),67307512,Nerlynx,Breast Neoplasms,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12715,NCT06374888,Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases,NOT_YET_RECRUITING,PHASE2,Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis,Neratinib maleate in combination with capecitabine (DRUG),67307512,Nerlynx,Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis,Esophagus/Stomach,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12716,NCT00878709,Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,COMPLETED,PHASE3,Breast Cancer,neratinib (DRUG); placebo (OTHER),67307512,Nerlynx,Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12717,NCT03377387,Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,"Capecitabine (DRUG); Neratinib (DRUG); EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30 (BEHAVIORAL)",67307512,Nerlynx,Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12718,NCT05252988,Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib,ACTIVE_NOT_RECRUITING,PHASE2,Early-stage Breast Cancer; HER2 Positive Breast Cancer; Hormone Receptor Positive,Neratinib (DRUG); Loperamide (DRUG); Colesevelam (DRUG),67307512,Nerlynx,Early-stage Breast Cancer; HER2 Positive Breast Cancer; Hormone Receptor Positive,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12719,NCT00781430,Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease,COMPLETED,PHASE1,Hepatic Insufficiency,Neratinib (HKI-272) (DRUG),67307512,Nerlynx,Hepatic Insufficiency,Liver,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12720,NCT03812393,Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast,ACTIVE_NOT_RECRUITING,PHASE2,Triple Negative Breast Cancer; Early-stage Breast Cancer; HER2-positive Breast Cancer,Neratinib (DRUG),67307512,Nerlynx,Triple Negative Breast Cancer; Early-stage Breast Cancer; HER2-positive Breast Cancer,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12721,NCT02673398,Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer,COMPLETED,PHASE2,HER2 Positive Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7,Comprehensive Geriatric Assessment (OTHER); Laboratory Biomarker Analysis (OTHER); Neratinib (DRUG); Pharmacological Study (OTHER),67307512,Nerlynx,HER2 Positive Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7,Breast,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12722,NCT04374305,Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2),ACTIVE_NOT_RECRUITING,PHASE2,Neurofibromatosis Type 2; Vestibular Schwannoma; Non-vestibular Schwannoma; Meningioma; Ependymoma,Brigatinib (DRUG); Neratinib (DRUG),67307512,Nerlynx,Neurofibromatosis Type 2; Vestibular Schwannoma; Non-vestibular Schwannoma; Meningioma; Ependymoma,CNS/Brain,Neratinib (maleate),"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for HER2-positive breast cancer treatment.,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C.C(=CC(=O)O)C(=O)O,1.3333333333333333,87.0 +12723,NCT05884866,"A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.",RECRUITING,PHASE2,Chronic Renal Failure; Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis; Chronic Kidney Disease Stage 3; Electrolyte and Fluid Balance Conditions,Dapagliflozin 10mg Tab (DRUG); Balcinrenone 50mg Capsule (DRUG); Balcinrenone 100mg Capsule (DRUG); Dapagliflozin matching Placebo (DRUG); Balcinrenone 50mg matching Placebo (DRUG); Balcinrenone 100mg matching Placebo (DRUG),9887712,Forxiga,Chronic Renal Failure; Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis; Chronic Kidney Disease Stage 3; Electrolyte and Fluid Balance Conditions,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12724,NCT06417320,Effect of Sodium-glucose Cotransporter-2 Inhibitors (SGLT-2i) on Proteinuria in Nephrotic Children Older Than 10 Years,RECRUITING,PHASE4,Nephrotic Syndrome in Children,"ACEI, SGLT-2i (DRUG)",9887712,Forxiga,Nephrotic Syndrome in Children,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12725,NCT06155604,SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease,RECRUITING,PHASE2,Lupus Nephritis; Chronic Kidney Diseases,Dapagliflozin 10mg Tab (DRUG); Standard maintenance therapy (DRUG),9887712,Forxiga,Lupus Nephritis; Chronic Kidney Diseases,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12726,NCT05565976,Dapagliflozin Effect in Cognitive Impairment in Stroke Trial,RECRUITING,PHASE2,"Stroke, Ischemic; Mild Cognitive Impairment; Dementia, Vascular; Metabolic Syndrome",Dapagliflozin 10mg Tab (DRUG); Statins (Cardiovascular Agents) (DRUG); Platelet Antiaggregant (DRUG); Antidiabetic (DRUG),9887712,Forxiga,Cerebrovascular and Cognitive Disorders,CNS/Brain,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12727,NCT05179668,SGLT2 Inhibition in Hemodialysis,RECRUITING,PHASE2,"Kidney Failure; Hemodialysis; Diabetes Mellitus, Type 2; Chronic Kidney Disease; Left Ventricular Hypertrophy",Dapagliflozin 10 MG (DRUG); Placebo (DRUG),9887712,Forxiga,"Kidney Failure; Hemodialysis; Diabetes Mellitus, Type 2; Chronic Kidney Disease; Left Ventricular Hypertrophy",Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12728,NCT06304857,CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL,RECRUITING,PHASE3,Breast Cancer; Heart Failure,Dapagliflozin (DRUG); Placebo (DRUG),9887712,Forxiga,Breast Cancer with Heart Failure,Breast,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12729,NCT05374291,The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD,ENROLLING_BY_INVITATION,PHASE3,"Kidney Disease, Chronic; Renal Transplant Failure; Heart Failure; Kidney Failure; Death",Dapagliflozin 10 mg/day (oral) (DRUG); Placebo (DRUG),9887712,Forxiga,"Kidney Disease, Chronic; Renal Transplant Failure; Heart Failure; Kidney Failure; Death",Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12730,NCT06054035,SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes,RECRUITING,PHASE4,Type2diabetes; PreDiabetes; Renal Failure,Dapagliflozin (Forxiga®) (DRUG); Placebo matching Dapaglifolzin (DRUG); Lifestyle Intervention (BEHAVIORAL),9887712,Forxiga,Type2diabetes; PreDiabetes; Renal Failure,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12731,NCT02682563,Renoprotective Effects of Dapagliflozin in Type 2 Diabetes,COMPLETED,PHASE4,"Diabetes Mellitus, Type 2; Diabetic Nephropathies",Dapagliflozin 10mg QD (DRUG); Gliclazide 30mg QD (DRUG),9887712,Forxiga,"Diabetes Mellitus, Type 2; Diabetic Nephropathies",Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12732,NCT06750458,Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients,NOT_YET_RECRUITING,PHASE3,Glioma; Dapagliflozin (Forxiga); Dexamethasone,Dapagliflozin placebo (DRUG); Placebo (DRUG); DexamethasoneGroup III (n=25) (Dexamethasone group) (DRUG),9887712,Forxiga,Glioma; Dapagliflozin (Forxiga); Dexamethasone,CNS/Brain,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12733,NCT05782972,Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study,ACTIVE_NOT_RECRUITING,PHASE4,Metabolic Associated Fatty Liver Disease,dapagliflozin (Forxiga) (DRUG),9887712,Forxiga,Metabolic Associated Fatty Liver Disease,Liver,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12734,NCT03036150,A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease,COMPLETED,PHASE3,Chronic Kidney Disease,Dapagliflozin (DRUG); Placebo (DRUG),9887712,Forxiga,Chronic Kidney Disease,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12735,NCT06341842,Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity,RECRUITING,PHASE2,Breast Cancer,Dapagliflozin 10mg Tab (DRUG),9887712,Forxiga,Breast Cancer,Breast,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12736,NCT06374043,Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.,COMPLETED,PHASE4,"Diabetes Mellitus, Type 2; Diabetes Mellitus Type 2 With Proteinuria; Diabetes Mellitus; Diabetes; Diabetes Complications; Albuminuria; Chronic Kidney Diseases; Chronic Kidney Disease Due to Type 2 Diabetes Mellitus; CKD; Proteinuria",Dapagliflozin 10mg Tab (DRUG); Placebo (DRUG); Withings BPM Connect (DEVICE); Withings Body+ (DEVICE); Hem-Col Capillary Blood Collection Device (DIAGNOSTIC_TEST); MEMS (Medication Electronic Monitoring System) Cap (DEVICE); Questionnaire: participants' perspectives toward remote data collection (BEHAVIORAL),9887712,Forxiga,"Diabetes Mellitus, Type 2; Diabetes Mellitus Type 2 With Proteinuria; Diabetes Mellitus; Diabetes; Diabetes Complications; Albuminuria; Chronic Kidney Diseases; Chronic Kidney Disease Due to Type 2 Diabetes Mellitus; CKD; Proteinuria",Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12737,NCT06612086,Dapagliflozin in Mangement of Pulmonary Hypertension Patients,NOT_YET_RECRUITING,PHASE1,Pulmonary Hypertension,Dapagliflozin (Forxiga) (DRUG),9887712,Forxiga,Pulmonary Hypertension,Lung,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12738,NCT06576375,Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome,RECRUITING,PHASE3,Polycystic Ovary Syndrome,Dapagliflozin (DRUG); Metformin (DRUG),9887712,Forxiga,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12739,NCT05196347,Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease,COMPLETED,PHASE3,Chronic Kidney Diseases,Dapagliflozin (DRUG),9887712,Forxiga,Chronic Kidney Diseases,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12740,NCT06610526,A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease,RECRUITING,PHASE4,Chronic Kidney Disease,Dapagliflozin (DRUG),9887712,Forxiga,Chronic Kidney Disease,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12741,NCT06263673,Anti-Diabetic Medications to Fight PD and LBD,ACTIVE_NOT_RECRUITING,PHASE4,Lewy Body Dementia; Parkinson Disease,Sitagliptin (DRUG); Dapagliflozin (DRUG); Placebo (DRUG),9887712,Forxiga,Lewy Body Dementia; Parkinson Disease,CNS/Brain,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12742,NCT05162690,Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy,UNKNOWN,PHASE2,Diabetic Peripheral Neuropathy,Dapagliflozin 10 milligram (DRUG); Placebo (OTHER),9887712,Forxiga,Diabetic Peripheral Neuropathy,Peripheral Nervous System,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12743,NCT04620590,Dapagliflozin Treatment in Type 2 Diabetes,COMPLETED,PHASE4,"Diabetes Mellitus, Type 2; Impaired Renal Function",Dapagliflozin 10 MG [Farxiga] (DRUG),9887712,Forxiga,"Diabetes Mellitus, Type 2; Impaired Renal Function",Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12744,NCT06954090,Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study,NOT_YET_RECRUITING,PHASE4,Type 2 DM; Type 2 DM /Diabetic Nephropathy; Albuminuria,"Semaglutide, 1.34 mg/mL (DRUG); Finerenone Oral Tablet (DRUG); Dapagliflozin (DAPA) (DRUG)",9887712,Forxiga,Type 2 DM; Type 2 DM /Diabetic Nephropathy; Albuminuria,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12745,NCT05468203,PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care,RECRUITING,PHASE3,Acute Kidney Injury,Dapagliflozin 10mg Tab (DRUG); Placebo (DRUG),9887712,Forxiga,Acute Kidney Injury,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12746,NCT04170543,A Phase 2b Diabetic Kidney Disease Study,COMPLETED,PHASE2,Diabetic Kidney Disease,MEDI3506 (DRUG); Placebo (DRUG); Dapagliflozin (DRUG),9887712,Forxiga,Chronic Kidney Disease,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12747,NCT05788276,Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?,RECRUITING,PHASE4,Kidney Transplant; Complications; Kidney Transplant Failure; Renal Failure,Dapagliflozin 10mg Tab (DRUG); Placebo (DRUG),9887712,Forxiga,Kidney Transplant; Complications; Kidney Transplant Failure; Renal Failure,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12748,NCT06532682,Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes,ACTIVE_NOT_RECRUITING,PHASE4,Diabetic Kidney Disease; Type 1 Diabetes,dapagliflozin (DRUG); ACE inhibitor (DRUG),9887712,Forxiga,Diabetic Kidney Disease; Type 1 Diabetes,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12749,NCT06268873,A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.,RECRUITING,PHASE3,Chronic Kidney Disease and Hypertension,Baxdrostat/dapagliflozin (DRUG); Dapagliflozin in combination with placebo (DRUG),9887712,Forxiga,Chronic Kidney Disease and Hypertension,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12750,NCT05014594,Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT,UNKNOWN,PHASE2,Cirrhosis; Ascites Hepatic,Dapagliflozin (10Mg Tab) along with standard medical therapy (DRUG); Placebo of dapaglifozin along with standard medical therapy (DRUG),9887712,Forxiga,Cirrhosis; Ascites Hepatic,Liver,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12751,NCT05938712,"The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients",RECRUITING,PHASE2,Kidney Transplant Recipients,"Dapagliflozin 10 MG (DRUG); Semaglutide, 1.0 mg/mL (DRUG)",9887712,Forxiga,Kidney Transplant Recipients,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12752,NCT05748925,Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients,COMPLETED,PHASE4,SLE; Lupus Nephritis; SGLT2 Inhibitors,dapagliflozin (DRUG); placebo (DRUG),9887712,Forxiga,SLE; Lupus Nephritis; SGLT2 Inhibitors,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12753,NCT06364930,SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus,RECRUITING,PHASE4,Chronic Hepatitis B,Dapagliflozin 10mg Tab (DRUG); Placebo 10mg Tab (DRUG),9887712,Forxiga,Chronic Hepatitis B,Liver,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12754,NCT05737186,SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency,TERMINATED,PHASE4,"Heart Failure With Reduced Ejection Fraction; Renal Insufficiency, Chronic",SGLT-2 inhibitor (DRUG),9887712,Forxiga,"Heart Failure With Reduced Ejection Fraction; Renal Insufficiency, Chronic",Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12755,NCT04492722,A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease,TERMINATED,PHASE2,Chronic Kidney Disease,AZD5718 (DRUG); Dapagliflozin 10 mg (DRUG); Placebo (DRUG),9887712,Forxiga,Chronic Kidney Disease,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12756,NCT05254626,Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic Steatohepatitis,COMPLETED,PHASE2,Non-alcoholic Steatohepatitis,Dapagliflozin 10Mg Tab (DRUG); Pioglitazone 30 mg (DRUG),9887712,Forxiga,Non-alcoholic Steatohepatitis,Liver,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12757,NCT06087835,"Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)",ACTIVE_NOT_RECRUITING,PHASE3,Chronic Kidney Disease With High Proteinuria,Zibotentan/Dapagliflozin (DRUG); Dapagliflozin (DRUG),9887712,Forxiga,Chronic Kidney Disease With High Proteinuria,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12758,NCT05435235,Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury,SUSPENDED,PHASE4,Acute Kidney Injury; Percutaneous Coronary Intervention,Dapagliflozin 10mg Tab (DRUG),9887712,Forxiga,Acute Kidney Injury; Percutaneous Coronary Intervention,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12759,NCT06491680,Cardiotoxicity in Breast Cancer Patients,RECRUITING,PHASE4,Breast Cancer,Dapagliflozin 10mg Tab (DRUG),9887712,Forxiga,Breast Cancer,Breast,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12760,NCT04542291,Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition,COMPLETED,PHASE1,Pancreas Cancer; Pancreatic Cancer; Cancer of the Pancreas,Dapagliflozin (DRUG); BIOSENSE meters (DEVICE),9887712,Forxiga,Pancreas Cancer; Pancreatic Cancer; Cancer of the Pancreas,Pancreas,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12761,NCT05685394,DApagliflozin Cardiovascular Effects on Patients at End-stage REnal Disease,RECRUITING,PHASE4,End-stage Kidney Disease,Dapagliflozin (DRUG),9887712,Forxiga,End-stage Kidney Disease,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12762,NCT02914691,Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes,COMPLETED,PHASE4,Type 2 Diabetes; Diabetic Nephropathy,Dapagliflozine 10 mg once daily tablet treatment (DRUG); Placebo identical once daily tablet treatment (DRUG),9887712,Forxiga,Type 2 Diabetes with Diabetic Nephropathy,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12763,NCT03190694,Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria,COMPLETED,PHASE2,Chronic Kidney Diseases; Proteinuria,Dapagliflozin 10mg (DRUG),9887712,Forxiga,Chronic Kidney Diseases; Proteinuria,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12764,NCT05359263,Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD,RECRUITING,PHASE2,Chronic Kidney Diseases,Dapagliflozin 10 mg (DRUG); Placebo (DRUG),9887712,Forxiga,Chronic Kidney Diseases,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12765,NCT05944016,Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients,RECRUITING,PHASE3,Chronic Kidney Failure in Children and Young Adults,Dapagliflozin (DRUG); Placebo (DRUG),9887712,Forxiga,Chronic Kidney Failure in Children and Young Adults,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12766,NCT05025735,"Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer",UNKNOWN,PHASE2,Metastatic Breast Cancer; HER2-negative Breast Cancer,Dapagliflozin 10Mg Tab (DRUG),9887712,Forxiga,Metastatic HER2-negative Breast Cancer,Breast,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12767,NCT04965935,"Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients",COMPLETED,PHASE3,Kidney Transplant Recipients; Post-transplant Diabetes Mellitus; Type 2 Diabetes,Dapagliflozin 10 MG Oral Tablet (DRUG); Placebo Matching Dapagliflozin Oral Tablet (DRUG),9887712,Forxiga,Kidney Transplant Recipients; Post-transplant Diabetes Mellitus; Type 2 Diabetes,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12768,NCT05308160,"A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease",UNKNOWN,PHASE3,Fatty Liver,Dapagliflozin 10Mg Tab (DRUG); Placebo (DRUG),9887712,Forxiga,Fatty Liver,Liver,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12769,NCT05459701,Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD),COMPLETED,PHASE4,Nonalcoholic Fatty Liver Disease; Type 2 Diabetes,Dapagliflozin 10mg Tab (DRUG); Placebo (OTHER),9887712,Forxiga,Nonalcoholic Fatty Liver Disease; Type 2 Diabetes,Liver,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12770,NCT06820567,Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients with Type 2 Diabetes and CKD,NOT_YET_RECRUITING,PHASE3,Chronic Kidney Diseases; Diabetes Type 2,Dapagliflozin (DAPA) (DRUG); Placebo (DRUG),9887712,Forxiga,Chronic Kidney Diseases; Diabetes Type 2,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12771,NCT04242758,Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy,UNKNOWN,PHASE4,Renal Function Disorder; Glucose Metabolism Disorders,Dapagliflozin 10 MG (DRUG); Hydrochlorothiazide 12.5mg (DRUG),9887712,Forxiga,Renal Function Disorder; Glucose Metabolism Disorders,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12772,NCT06642272,A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record,RECRUITING,PHASE4,"Diabetes Mellitus, Type 2; Heart Failure; Chronic Kidney Diseases",Empagliflozin 10 MG (DRUG); Dapagliflozin 10 MG (DRUG),9887712,Forxiga,"Diabetes Mellitus, Type 2; Heart Failure; Chronic Kidney Diseases",Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12773,NCT06560801,Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation,RECRUITING,PHASE4,Chronic Kidney Diseases,Dapagliflozin 10mg Tab (DRUG),9887712,Forxiga,Chronic Kidney Diseases,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12774,NCT06929169,Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study,RECRUITING,PHASE2,Chronic Kidney Disease Requiring Hemodialysis,iSGLT2 (DRUG),9887712,Forxiga,Chronic Kidney Disease Requiring Hemodialysis,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12775,NCT02696941,SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis,COMPLETED,PHASE1,Non-alcoholic Fatty Liver Disease,Metformin (DRUG); SGLT2 inhibitor (DRUG),9887712,Forxiga,Non-alcoholic Fatty Liver Disease,Liver,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12776,NCT04794517,Dapagliflozin in Non-diabetic Stage IV CKD,COMPLETED,PHASE2,Chronic Kidney Diseases,Dapagliflozin 10Mg Tab (DRUG); Placebo (OTHER),9887712,Forxiga,Chronic Kidney Diseases,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12777,NCT06326034,Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients,COMPLETED,PHASE4,Diabetic Nephropathy Type 2,Dapagliflozin (DRUG),9887712,Forxiga,Diabetic Nephropathy Type 2,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12778,NCT05966818,Effect of Dapagliflozin in Non-Diabetic Patients With Nephrotic Syndrome.,NOT_YET_RECRUITING,PHASE4,Nephrotic Syndrome,Dapagliflozin and Standard therapy (ACEI or ARB). (DRUG); Standard Therapy (ACEI or ARB). (DRUG),9887712,Forxiga,Nephrotic Syndrome,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12779,NCT06942910,A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria,NOT_YET_RECRUITING,PHASE2,Chronic Kidney Disease With High Proteinuria,Zibotentan/Dapagliflozin (DRUG); Dapagliflozin (DRUG),9887712,Forxiga,Chronic Kidney Disease With High Proteinuria,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12780,NCT06350123,"Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease",ACTIVE_NOT_RECRUITING,PHASE2,Chronic Kidney Disease,Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg (DRUG); Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg (DRUG); Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin (DRUG),9887712,Forxiga,Chronic Kidney Disease,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12781,NCT05719714,Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease,RECRUITING,PHASE1,Chronic Kidney Diseases; Heart Failure with Preserved Ejection Fraction; Kidney Diseases; Heart Failure,Dapagliflozin 10 MG [Farxiga] (DRUG),9887712,Forxiga,Chronic Kidney Diseases; Heart Failure with Preserved Ejection Fraction; Kidney Diseases; Heart Failure,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12782,NCT04662723,Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.,RECRUITING,PHASE4,Glomerulonephritis; Immunoglobulin A Nephropathy,Corticosteroid (DRUG); Renin-angiotensin sytem blockers (DRUG); Sodium-glucose cotransporter 2 inhibitor (DRUG),9887712,Forxiga,Glomerulonephritis,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12783,NCT03762850,A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy,ACTIVE_NOT_RECRUITING,PHASE3,Immunoglobulin A Nephropathy,sparsentan (DRUG); irbesartan (DRUG); Dapagliflozin (DRUG),9887712,Forxiga,Immunoglobulin A Nephropathy,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12784,NCT06642623,A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients,RECRUITING,PHASE4,"Diabetes Mellitus, Type 2; Cardiovascular Diseases; Kidney Diseases",Enavogliflozin (DRUG); Dapagliflozin or Empagliflozin (DRUG),9887712,Forxiga,"Diabetes Mellitus, Type 2; Cardiovascular Diseases; Kidney Diseases",Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12785,NCT06373523,MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin,NOT_YET_RECRUITING,EARLY_PHASE1,Hepatic Steato-Fibrosis; Non-Alcoholic Fatty Liver Disease,Dapagliflozin 10mg Tab (DRUG); Placebo (DRUG); Levothyroxine Replacement daily (DRUG),9887712,Forxiga,Hepatic Steato-Fibrosis; Non-Alcoholic Fatty Liver Disease,Liver,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12786,NCT06742723,A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure,RECRUITING,PHASE3,Chronic Kidney Disease and Hypertension,Baxdrostat/dapagliflozin (DRUG); Placebo/dapagliflozin (DRUG),9887712,Forxiga,Chronic Kidney Disease and Hypertension,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12787,NCT04930549,Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC),UNKNOWN,PHASE2,"Renal Insufficiency, Chronic",Dapagliflozin 10Mg Tab (DRUG); Placebo (DRUG); impedance cardiography (PROCEDURE); Applanation tonometry (PROCEDURE); post-ischemic hyperemia of forearm (PROCEDURE); haemodynamics parameters (PROCEDURE),9887712,Forxiga,Chronic Renal Insufficiency,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12788,NCT04899349,"Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant",TERMINATED,PHASE2,Breast Cancer,Alpelisib (DRUG); Fulvestrant (DRUG); Metformin XR (DRUG); Dapagliflozin + metformin XR (DRUG); Dapagliflozin (DRUG),9887712,Forxiga,Breast Cancer,Breast,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12789,NCT06281899,Effect of Low Protein Diet on Top of Dapagliflozin on Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus,RECRUITING,PHASE4,Chronic Kidney Diseases; Type 2 Diabetes Mellitus,Dapagliflozin 10 mg Tab (DRUG); Low protein diet (BEHAVIORAL),9887712,Forxiga,Chronic Kidney Diseases; Type 2 Diabetes Mellitus,Kidney,Dapagliflozin,SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for diabetes treatment.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,1.08,264.0 +12790,NCT06610526,A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease,RECRUITING,PHASE4,Chronic Kidney Disease,Dapagliflozin (DRUG),24906252,s5566,Chronic Kidney Disease,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12791,NCT05884866,"A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.",RECRUITING,PHASE2,Chronic Renal Failure; Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis; Chronic Kidney Disease Stage 3; Electrolyte and Fluid Balance Conditions,Dapagliflozin 10mg Tab (DRUG); Balcinrenone 50mg Capsule (DRUG); Balcinrenone 100mg Capsule (DRUG); Dapagliflozin matching Placebo (DRUG); Balcinrenone 50mg matching Placebo (DRUG); Balcinrenone 100mg matching Placebo (DRUG),24906252,s5566,Chronic Renal Failure; Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis; Chronic Kidney Disease Stage 3; Electrolyte and Fluid Balance Conditions,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12792,NCT06263673,Anti-Diabetic Medications to Fight PD and LBD,ACTIVE_NOT_RECRUITING,PHASE4,Lewy Body Dementia; Parkinson Disease,Sitagliptin (DRUG); Dapagliflozin (DRUG); Placebo (DRUG),24906252,s5566,Lewy Body Dementia; Parkinson Disease,CNS/Brain,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12793,NCT05162690,Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy,UNKNOWN,PHASE2,Diabetic Peripheral Neuropathy,Dapagliflozin 10 milligram (DRUG); Placebo (OTHER),24906252,s5566,Diabetic Peripheral Neuropathy,Peripheral Nervous System,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12794,NCT04620590,Dapagliflozin Treatment in Type 2 Diabetes,COMPLETED,PHASE4,"Diabetes Mellitus, Type 2; Impaired Renal Function",Dapagliflozin 10 MG [Farxiga] (DRUG),24906252,s5566,"Diabetes Mellitus, Type 2; Impaired Renal Function",Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12795,NCT06954090,Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study,NOT_YET_RECRUITING,PHASE4,Type 2 DM; Type 2 DM /Diabetic Nephropathy; Albuminuria,"Semaglutide, 1.34 mg/mL (DRUG); Finerenone Oral Tablet (DRUG); Dapagliflozin (DAPA) (DRUG)",24906252,s5566,Type 2 DM; Type 2 DM /Diabetic Nephropathy; Albuminuria,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12796,NCT05468203,PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care,RECRUITING,PHASE3,Acute Kidney Injury,Dapagliflozin 10mg Tab (DRUG); Placebo (DRUG),24906252,s5566,Acute Kidney Injury,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12797,NCT04170543,A Phase 2b Diabetic Kidney Disease Study,COMPLETED,PHASE2,Diabetic Kidney Disease,MEDI3506 (DRUG); Placebo (DRUG); Dapagliflozin (DRUG),24906252,s5566,Chronic Kidney Disease,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12798,NCT06155604,SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease,RECRUITING,PHASE2,Lupus Nephritis; Chronic Kidney Diseases,Dapagliflozin 10mg Tab (DRUG); Standard maintenance therapy (DRUG),24906252,s5566,Lupus Nephritis; Chronic Kidney Diseases,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12799,NCT05788276,Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?,RECRUITING,PHASE4,Kidney Transplant; Complications; Kidney Transplant Failure; Renal Failure,Dapagliflozin 10mg Tab (DRUG); Placebo (DRUG),24906252,s5566,Kidney Transplant; Complications; Kidney Transplant Failure; Renal Failure,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12800,NCT06532682,Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes,ACTIVE_NOT_RECRUITING,PHASE4,Diabetic Kidney Disease; Type 1 Diabetes,dapagliflozin (DRUG); ACE inhibitor (DRUG),24906252,s5566,Diabetic Kidney Disease; Type 1 Diabetes,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12801,NCT06268873,A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.,RECRUITING,PHASE3,Chronic Kidney Disease and Hypertension,Baxdrostat/dapagliflozin (DRUG); Dapagliflozin in combination with placebo (DRUG),24906252,s5566,Chronic Kidney Disease and Hypertension,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12802,NCT05565976,Dapagliflozin Effect in Cognitive Impairment in Stroke Trial,RECRUITING,PHASE2,"Stroke, Ischemic; Mild Cognitive Impairment; Dementia, Vascular; Metabolic Syndrome",Dapagliflozin 10mg Tab (DRUG); Statins (Cardiovascular Agents) (DRUG); Platelet Antiaggregant (DRUG); Antidiabetic (DRUG),24906252,s5566,Cerebrovascular and Cognitive Disorders,CNS/Brain,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12803,NCT05014594,Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT,UNKNOWN,PHASE2,Cirrhosis; Ascites Hepatic,Dapagliflozin (10Mg Tab) along with standard medical therapy (DRUG); Placebo of dapaglifozin along with standard medical therapy (DRUG),24906252,s5566,Cirrhosis; Ascites Hepatic,Liver,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12804,NCT05938712,"The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients",RECRUITING,PHASE2,Kidney Transplant Recipients,"Dapagliflozin 10 MG (DRUG); Semaglutide, 1.0 mg/mL (DRUG)",24906252,s5566,Kidney Transplant Recipients,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12805,NCT05179668,SGLT2 Inhibition in Hemodialysis,RECRUITING,PHASE2,"Kidney Failure; Hemodialysis; Diabetes Mellitus, Type 2; Chronic Kidney Disease; Left Ventricular Hypertrophy",Dapagliflozin 10 MG (DRUG); Placebo (DRUG),24906252,s5566,"Kidney Failure; Hemodialysis; Diabetes Mellitus, Type 2; Chronic Kidney Disease; Left Ventricular Hypertrophy",Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12806,NCT06304857,CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL,RECRUITING,PHASE3,Breast Cancer; Heart Failure,Dapagliflozin (DRUG); Placebo (DRUG),24906252,s5566,Breast Cancer with Heart Failure,Breast,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12807,NCT05748925,Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients,COMPLETED,PHASE4,SLE; Lupus Nephritis; SGLT2 Inhibitors,dapagliflozin (DRUG); placebo (DRUG),24906252,s5566,SLE; Lupus Nephritis; SGLT2 Inhibitors,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12808,NCT06364930,SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus,RECRUITING,PHASE4,Chronic Hepatitis B,Dapagliflozin 10mg Tab (DRUG); Placebo 10mg Tab (DRUG),24906252,s5566,Chronic Hepatitis B,Liver,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12809,NCT05737186,SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency,TERMINATED,PHASE4,"Heart Failure With Reduced Ejection Fraction; Renal Insufficiency, Chronic",SGLT-2 inhibitor (DRUG),24906252,s5566,"Heart Failure With Reduced Ejection Fraction; Renal Insufficiency, Chronic",Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12810,NCT04492722,A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease,TERMINATED,PHASE2,Chronic Kidney Disease,AZD5718 (DRUG); Dapagliflozin 10 mg (DRUG); Placebo (DRUG),24906252,s5566,Chronic Kidney Disease,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12811,NCT05254626,Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic Steatohepatitis,COMPLETED,PHASE2,Non-alcoholic Steatohepatitis,Dapagliflozin 10Mg Tab (DRUG); Pioglitazone 30 mg (DRUG),24906252,s5566,Non-alcoholic Steatohepatitis,Liver,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12812,NCT06087835,"Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)",ACTIVE_NOT_RECRUITING,PHASE3,Chronic Kidney Disease With High Proteinuria,Zibotentan/Dapagliflozin (DRUG); Dapagliflozin (DRUG),24906252,s5566,Chronic Kidney Disease With High Proteinuria,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12813,NCT05435235,Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury,SUSPENDED,PHASE4,Acute Kidney Injury; Percutaneous Coronary Intervention,Dapagliflozin 10mg Tab (DRUG),24906252,s5566,Acute Kidney Injury; Percutaneous Coronary Intervention,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12814,NCT06491680,Cardiotoxicity in Breast Cancer Patients,RECRUITING,PHASE4,Breast Cancer,Dapagliflozin 10mg Tab (DRUG),24906252,s5566,Breast Cancer,Breast,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12815,NCT04542291,Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition,COMPLETED,PHASE1,Pancreas Cancer; Pancreatic Cancer; Cancer of the Pancreas,Dapagliflozin (DRUG); BIOSENSE meters (DEVICE),24906252,s5566,Pancreas Cancer; Pancreatic Cancer; Cancer of the Pancreas,Pancreas,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12816,NCT05374291,The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD,ENROLLING_BY_INVITATION,PHASE3,"Kidney Disease, Chronic; Renal Transplant Failure; Heart Failure; Kidney Failure; Death",Dapagliflozin 10 mg/day (oral) (DRUG); Placebo (DRUG),24906252,s5566,"Kidney Disease, Chronic; Renal Transplant Failure; Heart Failure; Kidney Failure; Death",Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12817,NCT05685394,DApagliflozin Cardiovascular Effects on Patients at End-stage REnal Disease,RECRUITING,PHASE4,End-stage Kidney Disease,Dapagliflozin (DRUG),24906252,s5566,End-stage Kidney Disease,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12818,NCT02914691,Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes,COMPLETED,PHASE4,Type 2 Diabetes; Diabetic Nephropathy,Dapagliflozine 10 mg once daily tablet treatment (DRUG); Placebo identical once daily tablet treatment (DRUG),24906252,s5566,Type 2 Diabetes with Diabetic Nephropathy,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12819,NCT03190694,Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria,COMPLETED,PHASE2,Chronic Kidney Diseases; Proteinuria,Dapagliflozin 10mg (DRUG),24906252,s5566,Chronic Kidney Diseases; Proteinuria,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12820,NCT06054035,SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes,RECRUITING,PHASE4,Type2diabetes; PreDiabetes; Renal Failure,Dapagliflozin (Forxiga®) (DRUG); Placebo matching Dapaglifolzin (DRUG); Lifestyle Intervention (BEHAVIORAL),24906252,s5566,Type2diabetes; PreDiabetes; Renal Failure,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12821,NCT05359263,Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD,RECRUITING,PHASE2,Chronic Kidney Diseases,Dapagliflozin 10 mg (DRUG); Placebo (DRUG),24906252,s5566,Chronic Kidney Diseases,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12822,NCT02682563,Renoprotective Effects of Dapagliflozin in Type 2 Diabetes,COMPLETED,PHASE4,"Diabetes Mellitus, Type 2; Diabetic Nephropathies",Dapagliflozin 10mg QD (DRUG); Gliclazide 30mg QD (DRUG),24906252,s5566,"Diabetes Mellitus, Type 2; Diabetic Nephropathies",Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12823,NCT05944016,Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients,RECRUITING,PHASE3,Chronic Kidney Failure in Children and Young Adults,Dapagliflozin (DRUG); Placebo (DRUG),24906252,s5566,Chronic Kidney Failure in Children and Young Adults,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12824,NCT05025735,"Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer",UNKNOWN,PHASE2,Metastatic Breast Cancer; HER2-negative Breast Cancer,Dapagliflozin 10Mg Tab (DRUG),24906252,s5566,Metastatic HER2-negative Breast Cancer,Breast,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12825,NCT04965935,"Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients",COMPLETED,PHASE3,Kidney Transplant Recipients; Post-transplant Diabetes Mellitus; Type 2 Diabetes,Dapagliflozin 10 MG Oral Tablet (DRUG); Placebo Matching Dapagliflozin Oral Tablet (DRUG),24906252,s5566,Kidney Transplant Recipients; Post-transplant Diabetes Mellitus; Type 2 Diabetes,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12826,NCT06750458,Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients,NOT_YET_RECRUITING,PHASE3,Glioma; Dapagliflozin (Forxiga); Dexamethasone,Dapagliflozin placebo (DRUG); Placebo (DRUG); DexamethasoneGroup III (n=25) (Dexamethasone group) (DRUG),24906252,s5566,Glioma; Dapagliflozin (Forxiga); Dexamethasone,CNS/Brain,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12827,NCT05308160,"A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease",UNKNOWN,PHASE3,Fatty Liver,Dapagliflozin 10Mg Tab (DRUG); Placebo (DRUG),24906252,s5566,Fatty Liver,Liver,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12828,NCT05459701,Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD),COMPLETED,PHASE4,Nonalcoholic Fatty Liver Disease; Type 2 Diabetes,Dapagliflozin 10mg Tab (DRUG); Placebo (OTHER),24906252,s5566,Nonalcoholic Fatty Liver Disease; Type 2 Diabetes,Liver,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12829,NCT06820567,Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients with Type 2 Diabetes and CKD,NOT_YET_RECRUITING,PHASE3,Chronic Kidney Diseases; Diabetes Type 2,Dapagliflozin (DAPA) (DRUG); Placebo (DRUG),24906252,s5566,Chronic Kidney Diseases; Diabetes Type 2,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12830,NCT04242758,Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy,UNKNOWN,PHASE4,Renal Function Disorder; Glucose Metabolism Disorders,Dapagliflozin 10 MG (DRUG); Hydrochlorothiazide 12.5mg (DRUG),24906252,s5566,Renal Function Disorder; Glucose Metabolism Disorders,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12831,NCT06642272,A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record,RECRUITING,PHASE4,"Diabetes Mellitus, Type 2; Heart Failure; Chronic Kidney Diseases",Empagliflozin 10 MG (DRUG); Dapagliflozin 10 MG (DRUG),24906252,s5566,"Diabetes Mellitus, Type 2; Heart Failure; Chronic Kidney Diseases",Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12832,NCT06560801,Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation,RECRUITING,PHASE4,Chronic Kidney Diseases,Dapagliflozin 10mg Tab (DRUG),24906252,s5566,Chronic Kidney Diseases,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12833,NCT06929169,Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study,RECRUITING,PHASE2,Chronic Kidney Disease Requiring Hemodialysis,iSGLT2 (DRUG),24906252,s5566,Chronic Kidney Disease Requiring Hemodialysis,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12834,NCT05782972,Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study,ACTIVE_NOT_RECRUITING,PHASE4,Metabolic Associated Fatty Liver Disease,dapagliflozin (Forxiga) (DRUG),24906252,s5566,Metabolic Associated Fatty Liver Disease,Liver,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12835,NCT02696941,SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis,COMPLETED,PHASE1,Non-alcoholic Fatty Liver Disease,Metformin (DRUG); SGLT2 inhibitor (DRUG),24906252,s5566,Non-alcoholic Fatty Liver Disease,Liver,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12836,NCT04794517,Dapagliflozin in Non-diabetic Stage IV CKD,COMPLETED,PHASE2,Chronic Kidney Diseases,Dapagliflozin 10Mg Tab (DRUG); Placebo (OTHER),24906252,s5566,Chronic Kidney Diseases,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12837,NCT06326034,Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients,COMPLETED,PHASE4,Diabetic Nephropathy Type 2,Dapagliflozin (DRUG),24906252,s5566,Diabetic Nephropathy Type 2,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12838,NCT05966818,Effect of Dapagliflozin in Non-Diabetic Patients With Nephrotic Syndrome.,NOT_YET_RECRUITING,PHASE4,Nephrotic Syndrome,Dapagliflozin and Standard therapy (ACEI or ARB). (DRUG); Standard Therapy (ACEI or ARB). (DRUG),24906252,s5566,Nephrotic Syndrome,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12839,NCT06942910,A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria,NOT_YET_RECRUITING,PHASE2,Chronic Kidney Disease With High Proteinuria,Zibotentan/Dapagliflozin (DRUG); Dapagliflozin (DRUG),24906252,s5566,Chronic Kidney Disease With High Proteinuria,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12840,NCT06350123,"Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease",ACTIVE_NOT_RECRUITING,PHASE2,Chronic Kidney Disease,Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg (DRUG); Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg (DRUG); Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin (DRUG),24906252,s5566,Chronic Kidney Disease,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12841,NCT05719714,Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease,RECRUITING,PHASE1,Chronic Kidney Diseases; Heart Failure with Preserved Ejection Fraction; Kidney Diseases; Heart Failure,Dapagliflozin 10 MG [Farxiga] (DRUG),24906252,s5566,Chronic Kidney Diseases; Heart Failure with Preserved Ejection Fraction; Kidney Diseases; Heart Failure,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12842,NCT04662723,Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.,RECRUITING,PHASE4,Glomerulonephritis; Immunoglobulin A Nephropathy,Corticosteroid (DRUG); Renin-angiotensin sytem blockers (DRUG); Sodium-glucose cotransporter 2 inhibitor (DRUG),24906252,s5566,Glomerulonephritis,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12843,NCT03762850,A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy,ACTIVE_NOT_RECRUITING,PHASE3,Immunoglobulin A Nephropathy,sparsentan (DRUG); irbesartan (DRUG); Dapagliflozin (DRUG),24906252,s5566,Immunoglobulin A Nephropathy,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12844,NCT03036150,A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease,COMPLETED,PHASE3,Chronic Kidney Disease,Dapagliflozin (DRUG); Placebo (DRUG),24906252,s5566,Chronic Kidney Disease,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12845,NCT06642623,A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients,RECRUITING,PHASE4,"Diabetes Mellitus, Type 2; Cardiovascular Diseases; Kidney Diseases",Enavogliflozin (DRUG); Dapagliflozin or Empagliflozin (DRUG),24906252,s5566,"Diabetes Mellitus, Type 2; Cardiovascular Diseases; Kidney Diseases",Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12846,NCT06373523,MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin,NOT_YET_RECRUITING,EARLY_PHASE1,Hepatic Steato-Fibrosis; Non-Alcoholic Fatty Liver Disease,Dapagliflozin 10mg Tab (DRUG); Placebo (DRUG); Levothyroxine Replacement daily (DRUG),24906252,s5566,Hepatic Steato-Fibrosis; Non-Alcoholic Fatty Liver Disease,Liver,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12847,NCT06742723,A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure,RECRUITING,PHASE3,Chronic Kidney Disease and Hypertension,Baxdrostat/dapagliflozin (DRUG); Placebo/dapagliflozin (DRUG),24906252,s5566,Chronic Kidney Disease and Hypertension,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12848,NCT04930549,Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC),UNKNOWN,PHASE2,"Renal Insufficiency, Chronic",Dapagliflozin 10Mg Tab (DRUG); Placebo (DRUG); impedance cardiography (PROCEDURE); Applanation tonometry (PROCEDURE); post-ischemic hyperemia of forearm (PROCEDURE); haemodynamics parameters (PROCEDURE),24906252,s5566,Chronic Renal Insufficiency,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12849,NCT04899349,"Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant",TERMINATED,PHASE2,Breast Cancer,Alpelisib (DRUG); Fulvestrant (DRUG); Metformin XR (DRUG); Dapagliflozin + metformin XR (DRUG); Dapagliflozin (DRUG),24906252,s5566,Breast Cancer,Breast,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12850,NCT06281899,Effect of Low Protein Diet on Top of Dapagliflozin on Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus,RECRUITING,PHASE4,Chronic Kidney Diseases; Type 2 Diabetes Mellitus,Dapagliflozin 10 mg Tab (DRUG); Low protein diet (BEHAVIORAL),24906252,s5566,Chronic Kidney Diseases; Type 2 Diabetes Mellitus,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12851,NCT03801642,Dapagliflozin In Alzheimer's Disease,COMPLETED,PHASE1,Alzheimer Disease,Dapagliflozin (DRUG); Placebo (OTHER),24906252,s5566,Alzheimer Disease,CNS/Brain,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12852,NCT06341842,Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity,RECRUITING,PHASE2,Breast Cancer,Dapagliflozin 10mg Tab (DRUG),24906252,s5566,Breast Cancer,Breast,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12853,NCT06676384,Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate At Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?,NOT_YET_RECRUITING,PHASE4,"IgA Nephropathy; Renal Insufficiency, Chronic; IgA Vasculitis; IGA Glomerulonephritis",Oral prednisolone and SoC (DRUG); Gut-directed budesonide and SoC (DRUG); Mycophenolate mofetil (MMF) and SoC (DRUG); Hydroxychloroquine and SoC (DRUG); Non-steroidal mineralocorticoid receptor antagonist and SoC (DRUG); SoC defined as maximal labelled or tolerated dose of angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker (ACEi/ARB) & steady dose of sodium-glucose cotransporter-2 inhibitor (SGLT2i) (DRUG),24906252,s5566,"IgA Nephropathy; Renal Insufficiency, Chronic; IgA Vasculitis; IGA Glomerulonephritis",Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12854,NCT05521984,Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i),RECRUITING,PHASE1,Pediatric Brain Tumor; Pediatric Solid Tumor,Dapagliflozin (DRUG); Carmustine (DRUG); Topotecan (DRUG); Cyclophosphamide (DRUG),24906252,s5566,Pediatric Brain Tumor; Pediatric Solid Tumor,CNS/Brain,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12855,NCT05590143,proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2,RECRUITING,PHASE4,Acute Kidney Injury; Cardiac Surgery; Sodium-Glucose Transporter 2 Inhibitor,Dapagliflozin 10 MG Oral Tablet [Farxiga] (DRUG); Placebo (DRUG),24906252,s5566,Acute Kidney Injury; Cardiac Surgery; Sodium-Glucose Transporter 2 Inhibitor,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12856,NCT06890143,The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children,NOT_YET_RECRUITING,PHASE3,Pediatric Hereditary Kidney Diseases,"Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks (DRUG); Standard Treatment alone for 12 weeks ,washout period for 4 weeks ,then Dapagliflozin+Standard Treatment for 12 weeks (DRUG)",24906252,s5566,Pediatric Hereditary Kidney Diseases,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12857,NCT06374043,Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.,COMPLETED,PHASE4,"Diabetes Mellitus, Type 2; Diabetes Mellitus Type 2 With Proteinuria; Diabetes Mellitus; Diabetes; Diabetes Complications; Albuminuria; Chronic Kidney Diseases; Chronic Kidney Disease Due to Type 2 Diabetes Mellitus; CKD; Proteinuria",Dapagliflozin 10mg Tab (DRUG); Placebo (DRUG); Withings BPM Connect (DEVICE); Withings Body+ (DEVICE); Hem-Col Capillary Blood Collection Device (DIAGNOSTIC_TEST); MEMS (Medication Electronic Monitoring System) Cap (DEVICE); Questionnaire: participants' perspectives toward remote data collection (BEHAVIORAL),24906252,s5566,"Diabetes Mellitus, Type 2; Diabetes Mellitus Type 2 With Proteinuria; Diabetes Mellitus; Diabetes; Diabetes Complications; Albuminuria; Chronic Kidney Diseases; Chronic Kidney Disease Due to Type 2 Diabetes Mellitus; CKD; Proteinuria",Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12858,NCT06269484,A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK,COMPLETED,PHASE2,Liver Cirrhosis,Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) (DRUG); Zibotentan + placebo (placebo matching dapagliflozin tablet) (DRUG); Zibotentan + dapagliflozin (DRUG),24906252,s5566,Liver Cirrhosis,Liver,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12859,NCT02635386,"EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)",COMPLETED,PHASE3,Polycystic Ovary Syndrome; Obesity,Exenatide once weekly (EQW ) (DRUG); Dapagliflozin (DAPA) (DRUG); EQW plus DAPA (DRUG); Dapagliflozin plus Glucophage (MET ER) (DRUG); Phentermine /Topiramate (PHEN/ TPM) ER (DRUG),24906252,s5566,Polycystic Ovary Syndrome; Obesity,Ovary/Fallopian Tube,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12860,NCT06612086,Dapagliflozin in Mangement of Pulmonary Hypertension Patients,NOT_YET_RECRUITING,PHASE1,Pulmonary Hypertension,Dapagliflozin (Forxiga) (DRUG),24906252,s5566,Pulmonary Hypertension,Lung,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12861,NCT04595370,"Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease",COMPLETED,PHASE2,Heart Failure; Chronic Kidney Disease,AZD9977 (DRUG); Dapagliflozin (DRUG),24906252,s5566,Heart Failure; Chronic Kidney Disease,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12862,NCT06576375,Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome,RECRUITING,PHASE3,Polycystic Ovary Syndrome,Dapagliflozin (DRUG); Metformin (DRUG),24906252,s5566,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12863,NCT06113900,Assessment of Safety and Efficacy of SGLT2is Among LN Patients,NOT_YET_RECRUITING,PHASE1,Lupus Nephritis,Dapagliflozin 10mg Tab orally once daily (DRUG),24906252,s5566,Lupus Nephritis,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12864,NCT03723252,Dapagliflozin Efficacy and Action in NASH,COMPLETED,PHASE3,Nonalcoholic Steatohepatitis,Dapagliflozin (DRUG); Placebo (DRUG),24906252,s5566,Nonalcoholic Steatohepatitis,Liver,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12865,NCT06421870,Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients,RECRUITING,PHASE3,Chronic Kidney Diseases,Dapagliflozin 10mg Tab (DRUG); Pentoxifylline 400 MG (DRUG),24906252,s5566,Chronic Kidney Diseases,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12866,NCT05986136,Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease,RECRUITING,PHASE2,Inflammatory Bowel Diseases,Mesalamine (DRUG); Dapagliflozin 10mg Tab (DRUG),24906252,s5566,Inflammatory Bowel Diseases,Bowel,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12867,NCT06711185,Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy,RECRUITING,PHASE3,Breast Cancer,Dapagliflozin 10 mg (DRUG); Placebo (OTHER),24906252,s5566,Breast Cancer,Breast,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12868,NCT06140537,Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients,RECRUITING,PHASE4,Kidney Transplant; Complications; Vascular Diseases; Diabetes,Dapagliflozin 10mg Tab (DRUG); Placebo (DRUG),24906252,s5566,Kidney Transplant; Complications; Vascular Diseases; Diabetes,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12869,NCT05250752,Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment,UNKNOWN,PHASE2,End Stage Renal Disease; Peritoneal Dialysis Complication,Dapagliflozin 10 MG [Farxiga] (DRUG),24906252,s5566,End Stage Renal Disease; Peritoneal Dialysis Complication,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12870,NCT04419337,Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke,UNKNOWN,PHASE2,Diabetes Mellitus; Stroke,Metformin plus Pioglitazone plus an SGLT2 inhibitor (DRUG),24906252,s5566,Diabetes Mellitus with Stroke,CNS/Brain,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12871,NCT05998837,GLUcose Transport and REnalPROtection in Chronic Kidney Disease,COMPLETED,PHASE2,"Chronic Kidney Disease; Diabetes Mellitus, Type 2; Hypertension",Dapagliflozin 10mg Tab (DRUG); Placebo (DRUG),24906252,s5566,"Chronic Kidney Disease; Diabetes Mellitus, Type 2; Hypertension",Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12872,NCT04724837,Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial),COMPLETED,PHASE2,Chronic Kidney Disease,Zibotentan (DRUG); Dapagliflozin (DRUG); Placebo (DRUG),24906252,s5566,Chronic Kidney Disease,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12873,NCT06759077,Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life,ACTIVE_NOT_RECRUITING,PHASE3,Kidney Diseases,Dapagliflozin (DAPA) (DRUG),24906252,s5566,Kidney Diseases,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12874,NCT05989347,Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy,RECRUITING,PHASE1,Breast Cancer; Hyperinsulinism; HER2-negative Breast Cancer,Dapagliflozin 10mg (DRUG),24906252,s5566,Breast Cancer; Hyperinsulinism; HER2-negative Breast Cancer,Breast,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12875,NCT05196347,Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease,COMPLETED,PHASE3,Chronic Kidney Diseases,Dapagliflozin (DRUG),24906252,s5566,Chronic Kidney Diseases,Kidney,"Dapagliflozin ((2S)-1,2-propanediol, hydrate)",SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved SGLT2 inhibitor for type 2 diabetes and heart failure.,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O,, +12876,NCT05696626,Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation,RECRUITING,PHASE3,Metastatic Breast Cancer,Lasofoxifene in combination with abemaciclib (DRUG); Fulvestrant in combination with abemaciclib (DRUG),44631912,Kisqali,Metastatic Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12877,NCT03090165,Ribociclib and Bicalutamide in AR+ TNBC,RECRUITING,PHASE1,Triple Negative Breast Cancer,ribociclib (DRUG); ribociclib (DRUG); Bicalutamide (DRUG),44631912,Kisqali,Triple Negative Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12878,NCT02159066,"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",COMPLETED,PHASE2,Melanoma,LGX818 (DRUG); MEK162 (DRUG); LEE011 (DRUG); BGJ398 (DRUG); BKM120 (DRUG); INC280 (DRUG),44631912,Kisqali,Melanoma,Skin,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12879,NCT05563220,Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer,RECRUITING,PHASE1,Breast Cancer; Metastatic Breast Cancer,Elacestrant (DRUG); Alpelisib (DRUG); Everolimus (DRUG); Ribociclib (DRUG); Palbociclib (DRUG); Capivasertib (DRUG); Abemaciclib (DRUG),44631912,Kisqali,Breast Cancer; Metastatic Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12880,NCT06953882,"Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy",NOT_YET_RECRUITING,PHASE2,HER2 Negative Breast Cancer,Ribociclib 400mg (DRUG); Letrozole 2.5mg (DRUG); Anastrazole 1mg (DRUG); Goserelin 3.6 MG (DRUG); Adjuvant chemotherapy (RADIATION),44631912,Kisqali,HER2 Negative Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12881,NCT06409390,Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer,RECRUITING,EARLY_PHASE1,Metastatic Breast Cancer,Taxotere (DRUG); Cytoxan (DRUG); Trastuzumab deruxtecan (DRUG); Sacituzumab govitecan (DRUG); Xeloda (DRUG); Fulvestrant (DRUG); Ribociclib (DRUG); Abemaciclib (DRUG),44631912,Kisqali,Metastatic Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12882,NCT02657343,"An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.",COMPLETED,PHASE1,Breast Cancer,Ribociclib (DRUG); T-DM1 (DRUG); Trastuzumab (DRUG); Fulvestrant (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12883,NCT02292550,Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.,COMPLETED,PHASE1,Non-small Cell Lung Cancer,Ribociclib (DRUG); Ceritinib (DRUG),44631912,Kisqali,Non-small Cell Lung Cancer,Lung,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12884,NCT06585969,"A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer",NOT_YET_RECRUITING,PHASE3,Metastatic Breast Cancer; ER-positive Breast Cancer; Luminal B; Her2 Enriched; Basal Like,Trastuzumab deruxtecan (T-DXd) (DRUG); Ribociclib with ET (DRUG); Abemaciclib with ET (DRUG),44631912,Kisqali,Metastatic Breast Cancer; ER-positive Breast Cancer; Luminal B; Her2 Enriched; Basal Like,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12885,NCT05296746,Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer,RECRUITING,PHASE2,Breast Cancer Stage II,Ribociclib (neoadjuvant) (DRUG); Chemotherapy (adjuvant) (DRUG); Ribociclib (adjuvant) (DRUG),44631912,Kisqali,Early Stage Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12886,NCT01777776,Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.,TERMINATED,PHASE1,Locally Advanced Metastatic BRAF Mutant Melanoma,LEE011 (DRUG); LGX818 (DRUG),44631912,Kisqali,Locally Advanced Metastatic BRAF Mutant Melanoma,Skin,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12887,NCT02154776,"Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.",COMPLETED,PHASE1,Advanced or Metastatic Breast Cancer,LEE011 (DRUG); Buparlisib (DRUG); Letrozole (DRUG),44631912,Kisqali,Advanced or Metastatic Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12888,NCT03248427,Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.,COMPLETED,PHASE2,Breast Cancer,Ribociclib (DRUG); Letrozole 2.5mg (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Paclitaxel (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12889,NCT05319873,"Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer",RECRUITING,PHASE1,Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Locally Advanced HER2-Positive Breast Carcinoma; Metastatic HER2-Positive Breast Carcinoma; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8,Carboplatin (DRUG); Docetaxel (DRUG); Fulvestrant (DRUG); Pertuzumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Ribociclib (DRUG); Trastuzumab (BIOLOGICAL); Tucatinib (DRUG),44631912,Kisqali,Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Locally Advanced HER2-Positive Breast Carcinoma; Metastatic HER2-Positive Breast Carcinoma; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12890,NCT01747876,Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma,TERMINATED,PHASE1,Malignant Rhabdoid Tumors (MRT); Neuroblastoma,LEE011 (DRUG),44631912,Kisqali,Malignant Rhabdoid Tumors (MRT); Neuroblastoma,CNS/Brain,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12891,NCT01872260,"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,LEE011 (DRUG); Letrozole (DRUG); BYL719 (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12892,NCT03355794,A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG),COMPLETED,PHASE1,Diffuse Intrinsic Pontine Glioma; Malignant Glioma of Brain; High Grade Glioma; Bithalamic High Grade Glioma; Brainstem Glioma; Glioblastoma; Anaplastic Astrocytoma,ribociclib (DRUG); Everolimus (DRUG),44631912,Kisqali,Diffuse Intrinsic Pontine Glioma; Malignant Glioma of Brain; High Grade Glioma; Bithalamic High Grade Glioma; Brainstem Glioma; Glioblastoma; Anaplastic Astrocytoma,CNS/Brain,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12893,NCT02344472,Detect V / CHEVENDO (Chemo vs. Endo),ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Breast Cancer,pertuzumab (DRUG); Trastuzumab (DRUG); Capecitabine (DRUG); Paclitaxel (DRUG); Vinorelbine (DRUG); Docetaxel (DRUG); Exemestane (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG); Ribociclib (DRUG); nab-Paclitaxel (DRUG); eribulin (DRUG); leuprorelin (DRUG); goserelin (DRUG),44631912,Kisqali,Metastatic Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12894,NCT06726148,Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors,RECRUITING,PHASE1,Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors,ECI830 (DRUG); ribociclib (DRUG); fulvestrant (DRUG),44631912,Kisqali,Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12895,NCT02985125,LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy,UNKNOWN,PHASE1,Metastatic Pancreatic Adenocarcinoma,LEE011 (DRUG); Everolimus (DRUG),44631912,Kisqali,Metastatic Pancreatic Adenocarcinoma,Pancreas,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12896,NCT05768139,First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors,RECRUITING,PHASE1,"Breast Cancer; Gynecologic Cancer; HNSCC; Solid Tumors, Adult",STX-478 (DRUG); Fulvestrant (DRUG); Ribociclib (DRUG); Palbociclib (DRUG),44631912,Kisqali,"Breast Cancer; Gynecologic Cancer; HNSCC; Solid Tumors, Adult",Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12897,NCT06065748,"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)",RECRUITING,PHASE3,"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer",Giredestrant (DRUG); Fulvestrant (DRUG); Abemaciclib (DRUG); Palbociclib (DRUG); Ribociclib (DRUG); LHRH Agonist (DRUG); FoundationOne Liquid CDx Assay (F1LCDx) (DIAGNOSTIC_TEST),44631912,Kisqali,"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer",Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12898,NCT03434262,SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors,COMPLETED,PHASE1,"Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Ganglioglioma; Anaplastic Meningioma; Anaplastic Oligodendroglioma; Pleomorphic Xanthoastrocytoma, Anaplastic; Atypical Teratoid/Rhabdoid Tumor; Brain Cancer; Brain Tumor; Central Nervous System Neoplasms; Choroid Plexus Carcinoma; CNS Embryonal Tumor With Rhabdoid Features; Ganglioneuroblastoma of Central Nervous System; CNS Tumor; Embryonal Tumor of CNS; Ependymoma; Glioblastoma; Glioma; Glioma, Malignant; Medulloblastoma; Medulloblastoma; Unspecified Site; Medulloepithelioma; Neuroepithelial Tumor; Neoplasms; Neoplasms, Neuroepithelial; Papillary Tumor of the Pineal Region (High-grade Only); Pediatric Brain Tumor; Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only); Pineoblastoma; Primitive Neuroectodermal Tumor; Recurrent Medulloblastoma; Refractory Brain Tumor; Neuroblastoma. CNS; Glioblastoma, IDH-mutant; Glioblastoma, IDH-wildtype; Medulloblastoma, Group 3; Medulloblastoma, Group 4; Glioma, High Grade; Neuroepithelial Tumor, High Grade; Medulloblastoma, SHH-activated and TP53 Mutant; Medulloblastoma, SHH-activated and TP53 Wildtype; Medulloblastoma, Chromosome 9q Loss; Medulloblastoma, Non-WNT Non-SHH, NOS; Medulloblastoma, Non-WNT/Non-SHH; Medulloblastoma, PTCH1 Mutation; Medulloblastoma, WNT-activated; Ependymoma, Recurrent; Glioma, Recurrent High Grade; Glioma, Recurrent Malignant; Embryonal Tumor, NOS; Glioma, Diffuse Midline, H3K27M-mutant; Embryonal Tumor With Multilayered Rosettes (ETMR); Ependymoma, NOS, WHO Grade III; Ependymoma, NOS, WHO Grade II; Medulloblastoma, G3/G4; Ependymoma, RELA Fusion Positive",Gemcitabine (DRUG); ribociclib (DRUG); sonidegib (DRUG); trametinib (DRUG); filgrastim (BIOLOGICAL),44631912,Kisqali,CNS Tumors and Neoplasms,CNS/Brain,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12899,NCT03834740,A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection,COMPLETED,EARLY_PHASE1,Glioblastoma Multiforme; Glioma of Brain,Ribociclib (DRUG); Everolimus (DRUG),44631912,Kisqali,Glioblastoma Multiforme; Glioma of Brain,CNS/Brain,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12900,NCT05467891,"Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer",RECRUITING,PHASE2,Locoregional Recurrence; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer,Ribociclib (DRUG); Fulvestrant (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG),44631912,Kisqali,Breast Cancer (ER+/HER2-),Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12901,NCT03294694,Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer,TERMINATED,PHASE1,Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer; HER2-Negative Breast Cancer; Metastatic Epithelial Ovarian Cancer,Ribociclib (DRUG); PDR001 (DRUG); Fulvestrant (DRUG),44631912,Kisqali,Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer; HER2-Negative Breast Cancer; Metastatic Epithelial Ovarian Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12902,NCT04000529,Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies,TERMINATED,PHASE1,Non-small Cell Lung Carcinoma; Head and Neck Squamous Cell Carcinoma; Esophageal SCC; Gastrointestinal Stromal Tumors; Colorectal Cancer,TNO155 (DRUG); Spartalizumab (DRUG); Ribociclib (DRUG),44631912,Kisqali,Non-small Cell Lung Carcinoma; Head and Neck Squamous Cell Carcinoma; Esophageal SCC; Gastrointestinal Stromal Tumors; Colorectal Cancer,Bowel,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12903,NCT02599363,A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer,COMPLETED,PHASE1,Advanced Breast Cancer,Ribociclib (LEE011) (DRUG); Paclitaxel (DRUG),44631912,Kisqali,Advanced Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12904,NCT03477396,Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer,COMPLETED,PHASE2,Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IV Breast Cancer AJCC v6 and v7,Aromatase Inhibitor (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacokinetic Study (OTHER); Questionnaire Administration (OTHER); Ribociclib (DRUG),44631912,Kisqali,Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IV Breast Cancer AJCC v6 and v7,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12905,NCT02608216,[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Breast Neoplasm; Metastatic Breast Cancer; Rb+ Breast Cancer,[18F]FLT (DRUG); PET/CT (DEVICE); ribociclib (DRUG); paclitaxel (DRUG),44631912,Kisqali,Breast Neoplasm; Metastatic Breast Cancer; Rb+ Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12906,NCT04585724,"Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases",WITHDRAWN,PHASE1,Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Prognostic Stage IV Breast Cancer AJCC v8,Abemaciclib (DRUG); Palbociclib (DRUG); Quality-of-Life Assessment (OTHER); Ribociclib (DRUG),44631912,Kisqali,Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Prognostic Stage IV Breast Cancer AJCC v8,CNS/Brain,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12907,NCT06656624,Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel),RECRUITING,PHASE2,Advanced Breast Cancer,Ribociclib combined with AI±OFS (DRUG); physician's choice of chemotherapy sequential Ribociclib combined with AI±OFS (DRUG),44631912,Kisqali,Advanced Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12908,NCT05827081,Phase IIIb Study of Ribociclib + ET in Early Breast Cancer,NOT_YET_RECRUITING,PHASE3,Early Breast Cancer,Ribociclib (DRUG); Letrozole (DRUG); Ansastrozole (DRUG); Goserelin (DRUG); Leuprolide (DRUG); Exemestane (DRUG),44631912,Kisqali,Early Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12909,NCT01781572,A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma,COMPLETED,PHASE1,Locally Advanced or Metastatic NRAS Mutant Melanoma,LEE011 (DRUG); MEK162 (DRUG),44631912,Kisqali,Locally Advanced or Metastatic NRAS Mutant Melanoma,Skin,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12910,NCT04213404,Ribociclib and Spartalizumab in R/M HNSCC,UNKNOWN,PHASE1,Head and Neck Squamous Cell Carcinoma,Ribociclib (DRUG); Spartalizumab (DRUG),44631912,Kisqali,Head and Neck Squamous Cell Carcinoma,Skin,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12911,NCT03285412,"CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer",RECRUITING,PHASE2,Breast Cancer,Ribociclib (DRUG); Endocrine therapy (OTHER),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12912,NCT05766410,"A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC",RECRUITING,PHASE2,Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Therapy,Palbociclib (DRUG); Ribociclib (DRUG); Abemaciclib (DRUG); Letrozole (DRUG),44631912,Kisqali,Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Therapy,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12913,NCT01919229,A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1),TERMINATED,PHASE2,Early Breast Cancer,LEE011 (ribociclib) (DRUG); letrozole (DRUG),44631912,Kisqali,Early Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12914,NCT02429089,Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck,TERMINATED,PHASE1,Squamous Cell Carcinoma of the Head and Neck,LEE011 (DRUG),44631912,Kisqali,Squamous Cell Carcinoma of the Head and Neck,Skin,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12915,NCT03944434,FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,"Ribociclib (DRUG); Aromatase Inhibitors, non steroideal (DRUG); LHRH agonist (DRUG)",44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12916,NCT04964934,Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6),ACTIVE_NOT_RECRUITING,PHASE3,ER-Positive HER2-Negative Breast Cancer,AZD9833 (DRUG); AZD9833 Placebo (DRUG); Anastrozole (DRUG); Anastrozole placebo (DRUG); Letrozole (DRUG); Letrozole placebo (DRUG); Palbociclib (DRUG); Abemaciclib (DRUG); Luteinizing hormone-releasing hormone (LHRH) agonist (DRUG); Ribociclib (DRUG),44631912,Kisqali,ER-Positive HER2-Negative Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12917,NCT05252416,(VELA) Study of BLU-222 in Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,Advanced Solid Tumors; HR+ Breast Cancer; CCNE1 Amplification; HER2-negative Breast Cancer; Ovarian Cancer; Endometrial Cancer; Gastric Cancer; Esophageal Adenocarcinoma; Carcinosarcoma,BLU-222 (DRUG); Carboplatin (DRUG); Ribociclib (DRUG); Fulvestrant (DRUG),44631912,Kisqali,Advanced Solid Tumors; HR+ Breast Cancer; CCNE1 Amplification; HER2-negative Breast Cancer; Ovarian Cancer; Endometrial Cancer; Gastric Cancer; Esophageal Adenocarcinoma; Carcinosarcoma,Esophagus/Stomach,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12918,NCT02345824,Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma,UNKNOWN,PHASE1,Glioblastoma; Glioma,Ribociclib (DRUG),44631912,Kisqali,Glioblastoma; Glioma,CNS/Brain,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12919,NCT02524119,LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma,TERMINATED,PHASE2,Hepatocellular Carcinoma,LEE011 (DRUG); Chemoembolization (PROCEDURE),44631912,Kisqali,Hepatocellular Carcinoma,Liver,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12920,NCT03439046,"Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant",COMPLETED,PHASE3,Breast Cancer,Ribociclib (DRUG); Letrozole (DRUG); Alpelisib (DRUG); Fulvestrant (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12921,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",COMPLETED,PHASE2,Breast Cancer,Ribociclib (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Goserelin (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12922,NCT04256941,"Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study",TERMINATED,PHASE2,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8,Abemaciclib (DRUG); Anastrozole (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Palbociclib (DRUG); Ribociclib (DRUG),44631912,Kisqali,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12923,NCT03913234,"Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients",UNKNOWN,PHASE1,HER2-positive Breast Cancer; Postmenopausal; Metastatic Breast Cancer,"Ribociclib, Trastuzumab, Letrozole (DRUG)",44631912,Kisqali,HER2-positive Breast Cancer; Postmenopausal; Metastatic Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12924,NCT05384119,Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer,TERMINATED,PHASE1,Breast Cancer,TTI-101 (DRUG); Palbociclib (DRUG); Aromatase inhibitor (AI) (DRUG); fulvestrant (DRUG); ribociclib (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12925,NCT03081234,Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer,WITHDRAWN,PHASE3,Breast Cancer,Ribociclib (DRUG); Placebo (DRUG); Adjuvant endocrine therapy (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12926,NCT03701334,A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Early Breast Cancer,Ribociclib (DRUG); Endocrine Therapy (OTHER),44631912,Kisqali,Early Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12927,NCT02732119,Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.,COMPLETED,PHASE1,Breast Cancer,Ribociclib (DRUG); Everolimus (DRUG); Exemestane (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12928,NCT05933395,Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor,RECRUITING,PHASE2,Advanced Breast Cancer,Fulvestrant (DRUG); Neratinib (DRUG); Alpelisib (DRUG); Everolimus (DRUG); Abemaciclib (DRUG),44631912,Kisqali,Advanced Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12929,NCT04920708,"Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression",RECRUITING,PHASE2,Metastatic Breast Cancer; ER+ Breast Cancer; Advanced Breast Cancer,Ipatasertib 300mg (DRUG); Fulvestrant 500g (DRUG); Palbociclib 75mg-125mg (DRUG); CDK4/6 Inhibitor (DRUG),44631912,Kisqali,Metastatic Breast Cancer; ER+ Breast Cancer; Advanced Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12930,NCT03839823,Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Docetaxel / Capecitabine (COMBINATION_PRODUCT); Capecitabine / Vinorelbine (COMBINATION_PRODUCT); Paclitaxel / Gemcitabine (COMBINATION_PRODUCT); Ribociclib (DRUG); Letrozole OR Anastrozole (DRUG); Goserelin (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12931,NCT05573555,TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B),RECRUITING,PHASE1,Breast Cancer,ARV-471 (DRUG); Ribociclib (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12932,NCT03008408,"A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma",ACTIVE_NOT_RECRUITING,PHASE2,Recurrent Endometrial Carcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Refractory Endometrial Carcinoma; Refractory Endometrial Endometrioid Adenocarcinoma; Stage III Uterine Corpus Cancer AJCC v8; Stage IIIA Uterine Corpus Cancer AJCC v8; Stage IIIB Uterine Corpus Cancer AJCC v8; Stage IIIC Uterine Corpus Cancer AJCC v8; Stage IIIC1 Uterine Corpus Cancer AJCC v8; Stage IIIC2 Uterine Corpus Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8,Everolimus (DRUG); Letrozole (DRUG); Ribociclib (DRUG),44631912,Kisqali,Recurrent Endometrial Carcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Refractory Endometrial Carcinoma; Refractory Endometrial Endometrioid Adenocarcinoma; Stage III Uterine Corpus Cancer AJCC v8; Stage IIIA Uterine Corpus Cancer AJCC v8; Stage IIIB Uterine Corpus Cancer AJCC v8; Stage IIIC Uterine Corpus Cancer AJCC v8; Stage IIIC1 Uterine Corpus Cancer AJCC v8; Stage IIIC2 Uterine Corpus Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8,Uterus,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12933,NCT06044623,Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients,RECRUITING,PHASE3,Metastatic Breast Cancer; Advanced Breast Cancer; Quality of Life; Toxicity; Older Patients,CDK 4/6 inhibitors (DRUG); Endocrine therapy (DRUG),44631912,Kisqali,Metastatic Breast Cancer; Advanced Breast Cancer; Quality of Life; Toxicity; Older Patients,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12934,NCT05161195,Roll-over Study to Allow Continued Access to Ribociclib,RECRUITING,PHASE4,Metastatic Breast Cancer,Ribociclib (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Goserelin (DRUG); Tamoxifen (DRUG); Fulvestrant (DRUG),44631912,Kisqali,Metastatic Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12935,NCT05816655,"Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer",RECRUITING,PHASE2,Metastatic Breast Cancer,Fulvestrant plus AI plus ribociclib (DRUG); AI plus ribociclib (DRUG),44631912,Kisqali,Metastatic Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12936,NCT02431481,Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011,COMPLETED,PHASE1,Normal Renal Function; Impaired Renal Function,LEE011 (DRUG),44631912,Kisqali,Normal Renal Function; Impaired Renal Function,Kidney,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12937,NCT03484923,Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma,COMPLETED,PHASE2,Melanoma,PDR001 (DRUG); LAG525 (DRUG); INC280 (DRUG); ACZ885 (DRUG); LEE011 (DRUG),44631912,Kisqali,Melanoma,Skin,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12938,NCT03905343,Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC,TERMINATED,PHASE3,Breast Cancer,Ribociclib (DRUG); Mono-chemotherapy (OTHER); Endocrine-Therapy (OTHER),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12939,NCT01820364,LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,TERMINATED,PHASE2,Melanoma,LGX818 (DRUG),44631912,Kisqali,Melanoma,Skin,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12940,NCT05826964,Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer,RECRUITING,PHASE2,Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer,AI+CDK4/6i (DRUG); SERD+CDK4/6i (DRUG); mTOR inhibitor + AI (DRUG); mTOR inhibitor + SERD (DRUG); mTOR inhibitor + Selective estrogen receptor modulator (DRUG); PI3K inhibitor + SERD (DRUG); PI3K inhibitor + AI (DRUG); Chemotherapy (DRUG); Oral SERD (DRUG),44631912,Kisqali,Metastatic ER-positive/HER2-negative Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12941,NCT02712723,"Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer",UNKNOWN,PHASE2,Breast Cancer,Letrozole (DRUG); Ribociclib (DRUG); Placebo (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12942,NCT03425838,Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Breast Neoplasm Female,CDK 4/6 inhibitor (DRUG); Non-Steroidal Aromatase Inhibitor (DRUG); Fulvestrant (DRUG),44631912,Kisqali,Female Breast Neoplasm,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12943,NCT05358249,Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation,ACTIVE_NOT_RECRUITING,PHASE1,"KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma; Nonsmall Cell Lung Cancer; Colorectal Cancer; Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumors; Neoplasms, Colorectal",JDQ443 (DRUG); trametinib (DRUG); Ribociclib (DRUG); cetuximab (BIOLOGICAL),44631912,Kisqali,"KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma; Nonsmall Cell Lung Cancer; Colorectal Cancer; Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumors; Neoplasms, Colorectal",Bowel,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12944,NCT02933736,Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,Glioblastoma Multiforme; Meningioma,Ribociclib (DRUG),44631912,Kisqali,Glioblastoma Multiforme; Meningioma,CNS/Brain,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12945,NCT02645149,Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma,RECRUITING,PHASE2,Melanoma,Standard therapy or clinical trial (DRUG); Matched targeted therapy (DRUG); Trametinib and / or supportive care (DRUG); CDK4/6 and MEK inhibitor (DRUG); Compassionate Access Targeted Therapy (DRUG),44631912,Kisqali,Melanoma,Skin,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12946,NCT05759949,First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,"PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid Tumor; Hormone Receptor Positive Tumor",RLY-5836 (DRUG); Fulvestrant (DRUG); Palbociclib (DRUG); Ribociclib (DRUG); Abemaciclib (DRUG),44631912,Kisqali,PIK3CA-Mutated Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12947,NCT02333370,"A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",COMPLETED,PHASE1,"Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",LEE011 (DRUG); Letrozole (DRUG); Tamoxifen (DRUG); Fulvestrant (DRUG); goserelin (DRUG),44631912,Kisqali,"Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12948,NCT05508906,"Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus",RECRUITING,PHASE1,Metastatic Breast Cancer; Advanced Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; Breast Cancer,OP-1250 (DRUG); Ribociclib (DRUG); Alpelisib (DRUG); Everolimus (DRUG),44631912,Kisqali,Metastatic Breast Cancer; Advanced Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12949,NCT05900206,Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer,RECRUITING,PHASE2,Breast Cancer,Trastuzumab deruxtecan (DRUG); Docetaxel (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); Ribociclib (DRUG); Letrozole (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12950,NCT05429502,Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors,RECRUITING,PHASE1,Neuroblastoma,Topotecan (DRUG); Temozolomide (DRUG); Ribociclib (DRUG),44631912,Kisqali,Neuroblastoma,CNS/Brain,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12951,NCT04417621,Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma,ACTIVE_NOT_RECRUITING,PHASE2,Melanoma,LXH254 (DRUG); LTT462 (DRUG); Trametinib (DRUG); Ribociclib (DRUG),44631912,Kisqali,Melanoma,Skin,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12952,NCT01958021,Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer,COMPLETED,PHASE3,"Advanced, Metastatic Breast Cancer",Ribociclib (DRUG); Letrozole (DRUG); Placebo (DRUG),44631912,Kisqali,"Advanced, Metastatic Breast Cancer",Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12953,NCT02088684,Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer,COMPLETED,PHASE1,Breast Cancer,LEE011 (DRUG); BYL719 (DRUG); fulvestrant (DRUG); BKM120 (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12954,NCT03283384,"Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.",ACTIVE_NOT_RECRUITING,PHASE2,Breast Neoplasms,Letrozole (DRUG); Chemotherapy (DRUG); Ribociclib plus letrozole (DRUG),44631912,Kisqali,Breast Neoplasms,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12955,NCT03333343,Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC,ACTIVE_NOT_RECRUITING,PHASE1,EGFR-mutant Non-small Cell Lung Cancer,EGF816 (DRUG); trametinib (DRUG); ribociclib (DRUG); LXH254 (DRUG); INC280 (DRUG); gefitinib (DRUG),44631912,Kisqali,EGFR-mutant Non-small Cell Lung Cancer,Lung,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12956,NCT05870579,"[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer",RECRUITING,PHASE1,Breast Cancer,[68Ga]Ga-NeoB (DRUG); [177Lu]Lu-NeoB (DRUG); Ribociclib (DRUG); Fulvestrant (DRUG); Goserelin (OTHER),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12957,NCT04657679,Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts,TERMINATED,PHASE4,Breast Cancer,Ribociclib (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12958,NCT02586675,TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer,COMPLETED,PHASE1,Breast Cancer; Breast Cancer - Female; Breast Cancer - Male,Tamoxifen (DRUG); Ribociclib (DRUG); Goserelin (DRUG),44631912,Kisqali,Breast Cancer; Breast Cancer - Female; Breast Cancer - Male,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12959,NCT03280563,A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,COMPLETED,PHASE1,Breast Neoplasms,"Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody (DRUG); Bevacizumab (DRUG); Entinostat (DRUG); Exemestane (DRUG); Fulvestrant (DRUG); Ipatasertib (DRUG); Tamoxifen (DRUG); Abemaciclib (DRUG)",44631912,Kisqali,Breast Neoplasms,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12960,NCT04862663,Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292),RECRUITING,PHASE3,Locally Advanced (Inoperable) or Metastatic Breast Cancer,Capivasertib (DRUG); Fulvestrant (DRUG); Palbociclib (DRUG); Ribociclib (DRUG); Abemaciclib (DRUG),44631912,Kisqali,Locally Advanced (Inoperable) or Metastatic Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12961,NCT06757634,"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)",NOT_YET_RECRUITING,PHASE3,Breast Cancer,Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant (DRUG); Arm B: Palbociclib or Ribociclib + Fulvestrant (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12962,NCT02607124,"A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy",TERMINATED,PHASE1,High Grade Glioma; Diffuse Intrinsic Pontine Glioma; Bithalamic High Grade Glioma,Ribociclib (DRUG),44631912,Kisqali,High Grade Glioma; Diffuse Intrinsic Pontine Glioma; Bithalamic High Grade Glioma,CNS/Brain,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12963,NCT02035813,DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).,COMPLETED,PHASE2,HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer; HER2-negative Circulating Tumor Cells; Postmenopausal Female Patients,Ribociclib (DRUG); Eribulin (DRUG),44631912,Kisqali,HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer; HER2-negative Circulating Tumor Cells; Postmenopausal Female Patients,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12964,NCT05452213,"Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients",RECRUITING,PHASE4,Breast Cancer; Breast Neoplasms; Breast Neoplasm Female; Breast Cancer Female; HER2-negative Breast Cancer; Hormone Receptor-positive Breast Cancer; Advanced Breast Cancer,Ribociclib (DRUG),44631912,Kisqali,Breast Cancer; Breast Neoplasms; Breast Neoplasm Female; Breast Cancer Female; HER2-negative Breast Cancer; Hormone Receptor-positive Breast Cancer; Advanced Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12965,NCT06377852,The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study,RECRUITING,PHASE3,Metastatic Breast Cancer,Palbociclib 125mg (DRUG); Ribociclib 600mg (DRUG); Ribociclib (DRUG); Palbociclib (DRUG),44631912,Kisqali,Metastatic Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12966,NCT04802759,A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer,RECRUITING,PHASE1,"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer",Giredestrant (DRUG); Abemaciclib (DRUG); Ipatasertib (DRUG); Inavolisib (DRUG); Ribociclib (DRUG); Everolimus (DRUG); Samuraciclib (DRUG); PH FDC SC (DRUG); Palbociclib (DRUG); Atezolizumab (DRUG),44631912,Kisqali,"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer",Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12967,NCT05163106,Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole,COMPLETED,PHASE2,Breast Cancer; HER2-negative Breast Cancer; ER-positive Breast Cancer; Locally Advanced Breast Cancer; Luminal A Breast Cancer; Luminal B Breast Cancer,Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet (DRUG); Goserelin (DRUG),44631912,Kisqali,Breast Cancer; HER2-negative Breast Cancer; ER-positive Breast Cancer; Locally Advanced Breast Cancer; Luminal A Breast Cancer; Luminal B Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12968,NCT06481956,T-DM1 Combined With CDK4/6 Inhibitor Ribociclib,ENROLLING_BY_INVITATION,PHASE2,HER2-positive Advanced Breast Cancer,Ribociclib Oral Tablet (DRUG),44631912,Kisqali,HER2-positive Advanced Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12969,NCT02734615,Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers,TERMINATED,PHASE1,Advanced or Metastatic ER+ Breast Cancer,LSZ102 (DRUG); LEE011 (DRUG); BYL719 (DRUG),44631912,Kisqali,Advanced or Metastatic ER+ Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12970,NCT05216432,"First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer",RECRUITING,PHASE1,"PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid Tumor; Endometrial Cancer",RLY-2608 (DRUG); Fulvestrant (DRUG); Palbociclib 125mg (DRUG); Ribociclib 400mg (DRUG); Ribociclib 600mg (DRUG); PF-07220060 100mg (DRUG); PF-07220060 300 mg (DRUG),44631912,Kisqali,"PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid Tumor; Endometrial Cancer",Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12971,NCT03179956,Impact of Ribociclib on Head and Neck Squamous Cell Cancer,TERMINATED,EARLY_PHASE1,Squamous Cell Carcinoma of the Head and Neck,Ribociclib (DRUG),44631912,Kisqali,Squamous Cell Carcinoma of the Head and Neck,Skin,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12972,NCT06849947,"Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer",NOT_YET_RECRUITING,PHASE2,Breast Cancer Metastatic,Ribociclib with fulvestrant (DRUG); Physician's choice treatments group (DRUG),44631912,Kisqali,Breast Cancer Metastatic,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12973,NCT04315233,Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics,RECRUITING,PHASE1,Metastatic Breast Cancer; Recurrent Ovarian Carcinoma,Ribociclib (DRUG); Belinostat (DRUG),44631912,Kisqali,Metastatic Breast Cancer; Recurrent Ovarian Carcinoma,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12974,NCT03056833,Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer,COMPLETED,PHASE1,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Carcinoma,ribociclib (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG),44631912,Kisqali,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Carcinoma,Ovary/Fallopian Tube,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12975,NCT03078751,Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Ribociclib (DRUG); Adjuvant endocrine therapy (DRUG); Placebo (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12976,NCT06380751,"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer",RECRUITING,PHASE3,Advanced Breast Cancer,Saruparib (AZD5305) (DRUG); Camizestrant (DRUG); Abemaciclib (DRUG); Ribociclib (DRUG); Palbociclib (DRUG); Fulvestrant (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Exemestane (DRUG),44631912,Kisqali,Advanced Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12977,NCT03462251,Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line,COMPLETED,PHASE3,Breast Cancer; Hormone Receptor Positive Tumor; HER 2 Negative Breast Cancer,Ribociclib and aromatase inhibitor or fulvestrant (COMBINATION_PRODUCT); Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab (COMBINATION_PRODUCT),44631912,Kisqali,Breast Cancer; Hormone Receptor Positive Tumor; HER 2 Negative Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12978,NCT05843253,Study of Ribociclib and Everolimus in HGG and DIPG,RECRUITING,PHASE2,"High Grade Glioma; Diffuse Intrinsic Pontine Glioma; Anaplastic Astrocytoma; Glioblastoma; Glioblastoma Multiforme; Diffuse Midline Glioma, H3 K27M-Mutant; Metastatic Brain Tumor; WHO Grade III Glioma; WHO Grade IV Glioma",Ribociclib (DRUG); Everolimus (DRUG),44631912,Kisqali,"High Grade Glioma; Diffuse Intrinsic Pontine Glioma; Anaplastic Astrocytoma; Glioblastoma; Glioblastoma Multiforme; Diffuse Midline Glioma, H3 K27M-Mutant; Metastatic Brain Tumor; WHO Grade III Glioma; WHO Grade IV Glioma",CNS/Brain,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12979,NCT05670054,Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients,UNKNOWN,PHASE3,Breast Cancer Stage IV,"comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival (DRUG)",44631912,Kisqali,Breast Cancer Stage IV,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12980,NCT03555877,Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer Metastatic,Ribociclib (DRUG); Anastrozole (DRUG); Letrozole (DRUG); Exemestane (DRUG); Fulvestrant (DRUG),44631912,Kisqali,Breast Cancer Metastatic,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12981,NCT02422615,Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.,COMPLETED,PHASE3,Advanced Breast Cancer,Ribociclib (DRUG); Fulvestrant (DRUG); Placebo (DRUG),44631912,Kisqali,Advanced Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12982,NCT06760637,Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease,RECRUITING,PHASE3,Breast Cancer,PF-07220060 (DRUG); letrozole (DRUG); abemaciclib (DRUG); palbociclib (DRUG); ribociclib (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12983,NCT05207709,Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype,ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Breast Cancer,Ribociclib + Letrozole OR Fulvestrant (DRUG); Palbociclib + Letrozole OR Fulvestrant (DRUG); Paclitaxel +/- Tislelizumab (DRUG),44631912,Kisqali,Metastatic Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12984,NCT06375707,Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer,RECRUITING,PHASE2,Advanced Breast Cancer,physician's choice of chemotherapy sequential Ribociclib combined with NSAI±OFS (DRUG); Ribociclib combined with NSAI±OFS (DRUG),44631912,Kisqali,Advanced Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12985,NCT05996107,"Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer",RECRUITING,PHASE1,Breast Cancer,Ribociclib (DRUG); Postoperative Radiation Therapy (RADIATION),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12986,NCT03616587,Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.,ACTIVE_NOT_RECRUITING,PHASE1,ER+ HER2- Advanced Breast Cancer,AZD9833 (DRUG); AZD9833 (DRUG); AZD9833 with palbociclib (DRUG); AZD9833 with palbociclib (DRUG); AZD9833 with everolimus (DRUG); AZD9833 with everolimus (DRUG); AZD9833 with abemaciclib (DRUG); AZD9833 with abemaciclib (DRUG); AZD9833 with capivasertib (DRUG); AZD9833 with capivasertib (DRUG); AZD9833 with ribociclib (DRUG); AZD9833 with ribociclib (DRUG); AZD9833 with anastrozole (DRUG); AZD9833 with anastrozole (DRUG),44631912,Kisqali,ER+ HER2- Advanced Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12987,NCT05625087,Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib,RECRUITING,PHASE2,Breast Cancer Stage IV,Alpelisib (DRUG); Ribociclib (DRUG),44631912,Kisqali,Breast Cancer Stage IV,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12988,NCT03227328,"CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO",COMPLETED,PHASE2,Hormone Receptor Positive Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Negative Breast Cancer,concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy (DRUG); chemotherapy plus endocrine therapy (administered either concomitantly or sequentially) (DRUG),44631912,Kisqali,Hormone Receptor Positive Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Negative Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12989,NCT05664893,"Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)",RECRUITING,PHASE1,HER2 Negative Breast Cancer Not Immediately Operated,Ribociclib Oral Tablet (DRUG),44631912,Kisqali,HER2 Negative Breast Cancer Not Immediately Operated,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12990,NCT01857193,Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer,COMPLETED,PHASE1,Breast Cancer,ribociclib (LEE011) (DRUG); Exemestane (DRUG); Everolimus (RAD001) (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12991,NCT02754011,Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative,COMPLETED,PHASE1,Breast Cancer,Combination of ribociclib + capecitabine (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12992,NCT04055493,"Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC",ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer Female,Ribociclib 200Mg Oral Tablet (DRUG),44631912,Kisqali,Breast Cancer Female,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12993,NCT05806671,"Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy",NOT_YET_RECRUITING,PHASE2,Breast Cancer,Dalpiciclib (DRUG); Pyrotinib (DRUG); Fulvestrant (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12994,NCT02657928,"Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer",COMPLETED,PHASE2,Estrogen Receptor Positive; Postmenopausal; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Laboratory Biomarker Analysis (OTHER); Letrozole (DRUG); Ribociclib (DRUG),44631912,Kisqali,Estrogen Receptor Positive; Postmenopausal; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Ovary/Fallopian Tube,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12995,NCT02780128,Next Generation Personalized Neuroblastoma Therapy,TERMINATED,PHASE1,Neuroblastoma; Cancer,Biopsy (PROCEDURE); Next Generation Sequencing (GENETIC); Tumor Scans (PROCEDURE); Bone marrow Tests (PROCEDURE); Physical Exam (OTHER); Eye Exam (OTHER); Labs (OTHER); Pregnancy Test (OTHER); Interviews (BEHAVIORAL); ECG (OTHER); Echocardiogram (OTHER); Ribociclib (DRUG); Ceritinib (DRUG),44631912,Kisqali,Neuroblastoma; Cancer,CNS/Brain,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12996,NCT04483505,"Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.",COMPLETED,PHASE1,Breast Cancer Metastatic; Hormone Receptor Positive Malignant Neoplasm of Breast,"Combination, Rogaratinib + palbociclib + fulvestrant (DRUG)",44631912,Kisqali,Breast Cancer Metastatic; Hormone Receptor Positive Malignant Neoplasm of Breast,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12997,NCT02632045,Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer; Breast Carcinoma,LEE-011 (DRUG); Fulvestrant (DRUG); Placebo (DRUG),44631912,Kisqali,Metastatic Breast Cancer; Breast Carcinoma,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12998,NCT02703571,Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors,TERMINATED,PHASE1,Solid Tumors for Phase Ib; Pancreatic Cancer for Phase II; Colorectal Cancer for Phase II,ribociclib (DRUG); Trametinib (DRUG),44631912,Kisqali,Solid Tumors for Phase Ib; Pancreatic Cancer for Phase II; Colorectal Cancer for Phase II,Bowel,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +12999,NCT02941926,Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC,COMPLETED,PHASE3,Breast Cancer,Ribociclib (DRUG); Letrozole (DRUG); Goserelin (DRUG); Leuprolide (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +13000,NCT03671330,"Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.",ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Ribociclib Placebo (DRUG); Ribociclib (DRUG); NSAI: Letrozole or Anastrazole (DRUG); Letrozole (DRUG); Goserelin (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +13001,NCT03387020,Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors,COMPLETED,PHASE1,"CNS Embryonal Tumor, Not Otherwise Specified; Malignant Glioma; Recurrent Atypical Teratoid/Rhabdoid Tumor; Recurrent Childhood Ependymoma; Recurrent Diffuse Intrinsic Pontine Glioma; Recurrent Medulloblastoma; Refractory Diffuse Intrinsic Pontine Glioma",Everolimus (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Ribociclib (DRUG),44631912,Kisqali,"CNS Embryonal Tumor, Not Otherwise Specified; Malignant Glioma; Recurrent Atypical Teratoid/Rhabdoid Tumor; Recurrent Childhood Ependymoma; Recurrent Diffuse Intrinsic Pontine Glioma; Recurrent Medulloblastoma; Refractory Diffuse Intrinsic Pontine Glioma",CNS/Brain,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +13002,NCT06188520,"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors",RECRUITING,PHASE1,ER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC),AZD8421 (DRUG); Camizestrant (DRUG); Ribociclib (DRUG); Palbociclib (DRUG); Abemaciclib (DRUG),44631912,Kisqali,Advanced Breast and Ovarian Cancer,Ovary/Fallopian Tube,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +13003,NCT02278120,"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",COMPLETED,PHASE3,Advanced Metastatic Breast Cancer,Ribociclib (DRUG); Tamoxifen (DRUG); Letrozole (DRUG); Anastrozole (DRUG); Goserelin (DRUG); Placebo (DRUG),44631912,Kisqali,Advanced Metastatic Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +13004,NCT05861830,Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES),RECRUITING,PHASE3,Advanced Breast Cancer,The combination of Dalpiciclib with physician-selected endocrine therapy (DRUG); Chemotherapy selected by the physician (DRUG),44631912,Kisqali,Advanced Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +13005,NCT02974725,A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma,TERMINATED,PHASE1,Non-Small Cell Lung Cancer; Melanoma,LXH254 (DRUG); LTT462 (DRUG); Trametinib (DRUG); Ribociclib (DRUG),44631912,Kisqali,Non-Small Cell Lung Cancer; Melanoma,Lung,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +13006,NCT06486883,Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype,NOT_YET_RECRUITING,PHASE2,Advanced Breast Cancer; Advanced Breast Carcinoma; Hormone Receptor Positive Breast Carcinoma,"Trastuzumab deruxtecan (T-DXd, DS-8201a) (DRUG); CDK4/6i plus ET (DRUG)",44631912,Kisqali,Advanced Hormone Receptor Positive Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +13007,NCT03424005,A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer,RECRUITING,PHASE1,Metastatic Breast Cancer,Capecitabine (DRUG); Atezolizumab (DRUG); Ipatasertib (DRUG); SGN-LIV1A (DRUG); Bevacizumab (DRUG); Chemotherapy (Gemcitabine + Carboplatin or Eribulin) (DRUG); Selicrelumab (DRUG); Tocilizumab (DRUG); Nab-Paclitaxel (DRUG); Sacituzumab Govitecan (DRUG); Abemaciclib (DRUG); Fulvestrant (DRUG); Ribociclib (dose #1) (DRUG); Inavolisib (dose #2) (DRUG); Trastuzumab Deruxtecan (DRUG); Ribociclib (dose #2) (DRUG); Letrozole (DRUG); Inavolisib (dose #1) (DRUG); Inavolisib (DRUG),44631912,Kisqali,Metastatic Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +13008,NCT03096847,Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer,COMPLETED,PHASE3,Advanced Metastatic Breast Cancer,ribociclib (DRUG); letrozole (DRUG); goserelin (DRUG),44631912,Kisqali,Advanced Metastatic Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +13009,NCT03050398,A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib,TERMINATED,PHASE3,Breast Cancer,Ribociclib (DRUG); letrozole (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +13010,NCT06062498,Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer,NOT_YET_RECRUITING,PHASE2,Estrogen-receptor-positive Breast Cancer; HER2/Neu-Negative Breast Cancer; Advanced Breast Cancerv; Metastatic Breast Cancer,"elacestrant, palbociclib, abemaciclib, ribociclib (DRUG)",44631912,Kisqali,Metastatic Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +13011,NCT06496620,A Study to Evaluate Solrikitug in Participants With COPD (ZION),RECRUITING,PHASE2,COPD,Biological: Solrikitug low dose (DRUG); Biological: Solrikitug high dose (DRUG); Placebo (OTHER),44631912,Kisqali,COPD,Lung,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +13012,NCT01964430,"Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the ""Apact"" Study)",COMPLETED,PHASE3,"Pancreatic Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Digestive System Diseases; Endocrine System Diseases; Gemcitabine; Antimetabolites, Antineoplastic",nab-Paclitaxel (DRUG); Gemcitabine (DRUG),44631912,Kisqali,"Pancreatic Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Digestive System Diseases; Endocrine System Diseases; Gemcitabine; Antimetabolites, Antineoplastic",Pancreas,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +13013,NCT04703868,"A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects",COMPLETED,PHASE1,Gastroesophageal Reflux Disease,Rabeprazole Sodium 10mg (DRUG); Rabeprazole Sodium 20mg (DRUG),44631912,Kisqali,Gastroesophageal Reflux Disease,Esophagus/Stomach,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +13014,NCT06496607,A Study to Evaluate Solriktug in Adult Participants With Asthma,RECRUITING,PHASE2,Asthma,NSI-8226 (BIOLOGICAL); NSI-8226 (BIOLOGICAL); NSI-8226 (BIOLOGICAL); Placebo (BIOLOGICAL),44631912,Kisqali,Asthma,Lung,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +13015,NCT00004861,Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,gemcitabine hydrochloride (DRUG); tacedinaline (DRUG),44631912,Kisqali,Pancreatic Cancer,Pancreas,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +13016,NCT00625898,BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab,TERMINATED,PHASE3,Breast Cancer,Docetaxel (DRUG); Trastuzumab (DRUG); Carboplatin (DRUG); Bevacizumab (DRUG); 5-Fluorouracil (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),44631912,Kisqali,Breast Cancer,Breast,Ribociclib,"CDK4, CDK6",inhibitor/antagonist,CDK inhibitor,yes,yes,Approved for human use in combination with letrozole for breast cancer.,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1.04,370.0 +13017,NCT04442126,A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors,TERMINATED,PHASE1,Advanced Solid Tumor; Non-small Cell Lung Cancer; Colorectal Cancer; Squamous Cell Carcinoma; Ovarian Carcinoma; Peritoneal Carcinoma; Fallopian Tube Cancer; Head and Neck Squamous Cell Carcinoma; Triple Negative Breast Cancer,NM21-1480 (BIOLOGICAL),2123,HMM,Advanced Solid Tumor; Non-small Cell Lung Cancer; Colorectal Cancer; Squamous Cell Carcinoma; Ovarian Carcinoma; Peritoneal Carcinoma; Fallopian Tube Cancer; Head and Neck Squamous Cell Carcinoma; Triple Negative Breast Cancer,Bowel,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13018,NCT01521143,Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment,TERMINATED,PHASE2,Epithelial Ovarian Cancer,Cvac (BIOLOGICAL); Placebo (BIOLOGICAL),2123,HMM,Ovarian Cancer,Ovary/Fallopian Tube,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13019,NCT02515695,Phase I BP Interferon (IFN) Beta-001,COMPLETED,PHASE1,"Multiple Sclerosis, Relapsing-Remitting",Interferon beta-1a (DRUG),2123,HMM,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13020,NCT05042076,BK With VST for Kidney Transplant Patients,COMPLETED,PHASE1,Kidney Transplant Infection; BK Virus Infection,BK-specific T cells from Donor Lymphocytes (DRUG),2123,HMM,Kidney Transplant Infection; BK Virus Infection,Kidney,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13021,NCT02600130,Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease,COMPLETED,PHASE1,Alzheimer's Disease,Longeveron Mesenchymal Stem Cells (BIOLOGICAL); Placebo (BIOLOGICAL),2123,HMM,Alzheimer's Disease,CNS/Brain,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13022,NCT00110396,Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis,COMPLETED,PHASE3,Multiple Sclerosis,Interferon-beta-1a FBS-free/HSA-free (BIOLOGICAL),2123,HMM,Multiple Sclerosis,CNS/Brain,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13023,NCT06299163,NM32-2668 in Adult Patients with Selected Advanced Solid Tumors,RECRUITING,PHASE1,"Ovarian Carcinoma; Fallopian Tube Carcinoma; Peritoneal Carcinoma; Endometrial Cancer; Adenocarcinoma of Lung; Triple Negative Breast Cancer; Liposarcoma; Leiomyosarcoma; Mesothelioma, Malignant; Adenocarcinoma - Gastroesophageal Junction (GEJ); Adenocarcinoma of the Stomach; Melanoma, Malignant; Renal Cell Carcinoma",NM32-2668 (BIOLOGICAL),2123,HMM,"Ovarian Carcinoma; Fallopian Tube Carcinoma; Peritoneal Carcinoma; Endometrial Cancer; Adenocarcinoma of Lung; Triple Negative Breast Cancer; Liposarcoma; Leiomyosarcoma; Mesothelioma, Malignant; Adenocarcinoma - Gastroesophageal Junction (GEJ); Adenocarcinoma of the Stomach; Melanoma, Malignant; Renal Cell Carcinoma",Lung,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13024,NCT04486781,A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma,RECRUITING,PHASE2,Metastatic Urothelial Carcinoma,Pembrolizumab + sEphB4-HSA (DRUG),2123,HMM,Metastatic Urothelial Carcinoma,Bladder/Urinary Tract,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13025,NCT02495896,Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors,TERMINATED,PHASE1,Head and Neck Squamous Cell Carcinoma; Metastatic Pancreatic Adenocarcinoma; Non-Resectable Cholangiocarcinoma; Pancreatic Adenocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Stage III Pancreatic Cancer; Stage IIIA Gallbladder Cancer; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Gallbladder Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Gallbladder Cancer; Stage IV Non-Small Cell Lung Cancer; Stage IV Pancreatic Cancer; Unresectable Gallbladder Carcinoma; Unresectable Pancreatic Cancer,Cisplatin (DRUG); Docetaxel (DRUG); Gemcitabine Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Paclitaxel Albumin-Stabilized Nanoparticle Formulation (DRUG); Pharmacological Study (OTHER); Recombinant EphB4-HSA Fusion Protein (BIOLOGICAL),2123,HMM,Head and Neck Squamous Cell Carcinoma; Metastatic Pancreatic Adenocarcinoma; Non-Resectable Cholangiocarcinoma; Pancreatic Adenocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Stage III Pancreatic Cancer; Stage IIIA Gallbladder Cancer; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Gallbladder Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Gallbladder Cancer; Stage IV Non-Small Cell Lung Cancer; Stage IV Pancreatic Cancer; Unresectable Gallbladder Carcinoma; Unresectable Pancreatic Cancer,Lung,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13026,NCT04091867,sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC,COMPLETED,PHASE1,Squamous Cell Carcinoma of Head and Neck,sEphB4-HSA with chemotherapy (DRUG); Cetuximab (DRUG); Radiation Therapy (RADIATION),2123,HMM,Squamous Cell Carcinoma of Head and Neck,Skin,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13027,NCT01078168,Alzheimer's Disease Acitretin Medication,COMPLETED,PHASE2,Alzheimer Disease,Acitretin (DRUG); Placebo (DRUG),2123,HMM,Alzheimer Disease,CNS/Brain,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13028,NCT03049618,"Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475",COMPLETED,PHASE2,ALK Gene Mutation; BRAF Gene Mutation; EGFR Gene Mutation; Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Carcinoma; Recurrent Head and Neck Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; ROS1 Gene Mutation; Stage III Non-Small Cell Lung Cancer; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Laboratory Biomarker Analysis (OTHER); Pembrolizumab (BIOLOGICAL); Recombinant EphB4-HSA Fusion Protein (BIOLOGICAL),2123,HMM,ALK Gene Mutation; BRAF Gene Mutation; EGFR Gene Mutation; Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Carcinoma; Recurrent Head and Neck Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; ROS1 Gene Mutation; Stage III Non-Small Cell Lung Cancer; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Lung,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13029,NCT01192555,Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma,ACTIVE_NOT_RECRUITING,PHASE1,Neuroblastoma,"Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells (BIOLOGICAL); Cytoxan (DRUG)",2123,HMM,Neuroblastoma,CNS/Brain,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13030,NCT02767921,"sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer",TERMINATED,PHASE1,Infiltrating Bladder Urothelial Carcinoma; Recurrent Bladder Carcinoma; Stage I Prostate Cancer; Stage I Renal Cell Cancer; Stage II Bladder Urothelial Carcinoma; Stage II Renal Cell Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage III Renal Cell Cancer,Cytology Specimen Collection Procedure (OTHER); Laboratory Biomarker Analysis (OTHER); Radical Cystectomy (PROCEDURE); Recombinant EphB4-HSA Fusion Protein (BIOLOGICAL); Therapeutic Conventional Surgery (PROCEDURE),2123,HMM,Infiltrating Bladder Urothelial Carcinoma; Recurrent Bladder Carcinoma; Stage I Prostate Cancer; Stage I Renal Cell Cancer; Stage II Bladder Urothelial Carcinoma; Stage II Renal Cell Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage III Renal Cell Cancer,Kidney,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13031,NCT06355479,A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia,COMPLETED,PHASE3,Hypoalbuminemia; Hepatic Cirrhosis,OsrHSA (DRUG); Plasbumin®-20 (DRUG),2123,HMM,Hypoalbuminemia; Hepatic Cirrhosis,Liver,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13032,NCT01186263,Predictive Value of 99mTc- Albumin Spheres Before 90Y- SIR Therapy,COMPLETED,PHASE2,Colorectal Cancer; Liver Metastases,MAA for diagnostic SPECT imaging (DRUG); Diagnostic B20- SPECT imaging. (DRUG),2123,HMM,Colorectal Cancer; Liver Metastases,Liver,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13033,NCT03038035,The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study,UNKNOWN,PHASE2,Alzheimer Disease,MLC901 (DRUG); Placebo (DRUG),2123,HMM,Alzheimer Disease,CNS/Brain,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13034,NCT03552796,sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer,WITHDRAWN,PHASE1,Recurrent Bladder Carcinoma; Bladder Cancer Stage 0; Bladder Cancer Stage I,Pharmacokinetic Study (OTHER); Recombinant EphB4-HSA Fusion Protein (BIOLOGICAL),2123,HMM,Recurrent Bladder Carcinoma; Bladder Cancer Stage 0; Bladder Cancer Stage I,Bladder/Urinary Tract,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13035,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),COMPLETED,PHASE3,Multiple Sclerosis,RNF (DRUG); RNF (DRUG); Placebo (DRUG),2123,HMM,Multiple Sclerosis,CNS/Brain,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13036,NCT06493552,Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors,RECRUITING,PHASE2,Muscle-Invasive Bladder Carcinoma; Metastatic Urothelial Carcinoma,SEphB4-HSA (DRUG); Pembrolizumab (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG); Enfortumab vedotin (DRUG),2123,HMM,Muscle-Invasive Bladder Carcinoma; Metastatic Urothelial Carcinoma,Bladder/Urinary Tract,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13037,NCT02717156,Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors,RECRUITING,PHASE2,Stage IV Bladder Urothelial Carcinoma; Prostate Cancer; Urothelial Carcinoma,Computed Tomography (PROCEDURE); Laboratory Biomarker Analysis (OTHER); Pembrolizumab (BIOLOGICAL); Positron Emission Tomography (PROCEDURE); Recombinant EphB4-HSA Fusion Protein (BIOLOGICAL),2123,HMM,Stage IV Bladder Urothelial Carcinoma; Prostate Cancer; Urothelial Carcinoma,Bladder/Urinary Tract,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13038,NCT02444637,Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD,COMPLETED,PHASE4,Alzheimer Disease; CVA (Cerebrovascular Accident),Rivastigmine (DRUG),2123,HMM,Alzheimer Disease; CVA (Cerebrovascular Accident),CNS/Brain,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13039,NCT02013700,Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER),TERMINATED,PHASE1,Idiopathic Pulmonary Fibrosis (IPF),Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs) (BIOLOGICAL); matched placebo (BIOLOGICAL),2123,HMM,Idiopathic Pulmonary Fibrosis (IPF),Lung,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13040,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),COMPLETED,PHASE3,Multiple Sclerosis; Clinically Isolated Syndrome,RNF (DRUG); RNF (DRUG); RNF (DRUG); Placebo (DRUG),2123,HMM,Multiple Sclerosis; Clinically Isolated Syndrome,CNS/Brain,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13041,NCT02517788,Phase I BP Interferon (IFN) Beta-004,COMPLETED,PHASE1,"Multiple Sclerosis, Relapsing-Remitting",Interferon beta-1a HSA-free biosimilar (DRUG); Interferon beta-1a HSA+ biosimilar (DRUG); Interferon beta-1a original (DRUG),2123,HMM,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13042,NCT02151578,Home Management of Malaria and Pneumonia,COMPLETED,PHASE4,Malaria; Pneumonia,home/community case management (OTHER),2123,HMM,Malaria; Pneumonia,Lung,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13043,NCT02032498,Evaluation of Two Techniques for the SLN Detection in BC Patients,UNKNOWN,PHASE2,Breast Cancer,Indocyanine Green (DRUG),2123,HMM,Breast Cancer,Breast,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13044,NCT00327418,CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events,COMPLETED,PHASE4,"Major Coronary Event; Cerebrovascular Accident; Coronary Artery Bypass Graft; Angina, Unstable; Revascularization",Atorvastatin (DRUG),2123,HMM,"Major Coronary Event; Cerebrovascular Accident; Coronary Artery Bypass Graft; Angina, Unstable; Revascularization",CNS/Brain,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13045,NCT02062463,Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma,COMPLETED,PHASE3,Asthma,Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX (DRUG); SYMBICORT TURBOHALER budesonide and formoterol fumarate (DRUG),2123,HMM,Asthma,Lung,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13046,NCT03570359,A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza,COMPLETED,PHASE2,Chronic Obstructive Pulmonary Disease (COPD),Interferon Beta-1A (DRUG); Placebo (OTHER),2123,HMM,Chronic Obstructive Pulmonary Disease (COPD),Lung,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13047,NCT03945188,Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis,COMPLETED,PHASE3,Ulcerative Colitis,Etrasimod (DRUG); Placebo (DRUG),2123,HMM,Ulcerative Colitis,Bowel,Altretamine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Used as a chemotherapy drug for ovarian cancer.,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,1.1,238.0 +13048,NCT03960437,The Effect of Etelcalcetide on CKD-MBD,COMPLETED,PHASE2,"Chronic Kidney Disease Mineral and Bone Disorder; Renal Osteodystrophy; Vascular Calcification; Hyperparathyroidism; Secondary, Renal",Etelcalcetide (DRUG),54680690,DMCT,"Chronic Kidney Disease Mineral and Bone Disorder; Renal Osteodystrophy; Vascular Calcification; Hyperparathyroidism; Secondary, Renal",Kidney,Demeclocycline,,inhibitor/antagonist,unclear,yes,yes,"Used off-label for SIADH, primarily an antibiotic.",CN(C)C1C2CC3C(C4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O,1.16,380.0 +13049,NCT02740933,Demeclocycline Fluorescence for Intraoperative Delineation Brain Tumors,UNKNOWN,PHASE1,Brain Tumor,Demeclocycline (DRUG),54680690,DMCT,Brain Tumor,CNS/Brain,Demeclocycline,,inhibitor/antagonist,unclear,yes,yes,"Used off-label for SIADH, primarily an antibiotic.",CN(C)C1C2CC3C(C4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O,1.16,380.0 +13050,NCT01345682,LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy,COMPLETED,PHASE3,"Head and Neck Neoplasms; Carcinoma, Squamous Cell",Afatinib (DRUG); Methotrexate (DRUG),10184653,Tovok,"Head and Neck Neoplasms; Carcinoma, Squamous Cell",Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13051,NCT01415674,Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients,COMPLETED,PHASE2,"Carcinoma, Squamous Cell of Head and Neck",Afatinib (DRUG),10184653,Tovok,Head and Neck Squamous Cell Carcinoma,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13052,NCT01743365,Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer,COMPLETED,PHASE2,Gastric Cancer; Gastroesophageal Junction Cancer,Cisplatin-5FU-Afatinib (DRUG),10184653,Tovok,Gastric Cancer; Gastroesophageal Junction Cancer,Esophagus/Stomach,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13053,NCT02470065,Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.,SUSPENDED,PHASE2,Non Small Cell Lung Cancer,Afatinib (DRUG); Immediate surgery (PROCEDURE),10184653,Tovok,Non Small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13054,NCT05818982,To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC,RECRUITING,PHASE2,Advanced Esophageal Squamous Cell Carcinoma,Afatinib (DRUG); Irinotecan (DRUG),10184653,Tovok,Advanced Esophageal Squamous Cell Carcinoma,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13055,NCT02695290,Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3),TERMINATED,PHASE4,"Carcinoma, Non-Small-Cell Lung; ErbB Receptors",Afatinib (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung; ErbB Receptors",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13056,NCT05070403,Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma,RECRUITING,PHASE2,Squamous Cell Carcinoma,Afatinib 40 MG (DRUG),10184653,Tovok,Squamous Cell Carcinoma,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13057,NCT06302621,Pemigatinib + Afatinib in Advanced Refractory Solid Tumors,RECRUITING,PHASE1,Advanced Solid Tumor; Unresectable Solid Tumor; Metastatic Solid Tumor; Cholangiocarcinoma,Afatinib (DRUG); Pemigatinib (DRUG),10184653,Tovok,Advanced Solid Tumor; Unresectable Solid Tumor; Metastatic Solid Tumor; Cholangiocarcinoma,Liver,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13058,NCT03399669,The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,gefitinib (DRUG),10184653,Tovok,Non-small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13059,NCT02597946,Afatinib in NSCLC With HER2 Mutation,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",afatinib (DRUG); paclitaxel (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13060,NCT05298176,"Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors",COMPLETED,PHASE2,Non-Small Cell Lung Cancer,"Afatinib, Osimertinib, Carboplatin and Pemetrexed (DRUG)",10184653,Tovok,Advanced Non-Small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13061,NCT03940976,Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01),UNKNOWN,PHASE2,Esophageal Squamous Cell Carcinoma,Afatinib (DRUG),10184653,Tovok,Esophageal Squamous Cell Carcinoma,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13062,NCT00977431,Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform,COMPLETED,PHASE1,Glioblastoma,Temozolomide (DRUG); Radiotherapy (PROCEDURE); BIBW2992 (DRUG); Radiotherapy (PROCEDURE); BIBW2992 (DRUG),10184653,Tovok,Glioblastoma,CNS/Brain,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13063,NCT04470076,Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation,UNKNOWN,PHASE2,Non Small Cell Lung Cancer; Surgery; EGFR Activating Mutation; Chemotherapy; EGFR TKI,"Neoadjuvant treatment: Afatinib, pemetrexed, gemcitabine, cisplatin, carboplatin (DRUG); Surgical treatment (PROCEDURE); Adjuvant treatment:afatinib (DRUG)",10184653,Tovok,Non Small Cell Lung Cancer; Surgery; EGFR Activating Mutation; Chemotherapy; EGFR TKI,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13064,NCT03810872,"An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation",UNKNOWN,PHASE2,"Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation",Afatinib (DRUG); Paclitaxel (DRUG),10184653,Tovok,"Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13065,NCT05364073,"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations",ACTIVE_NOT_RECRUITING,PHASE1,"Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; HER2 Exon 20 Mutations; EGFR Exon 20 Mutations; EGFR Uncommon Mutations, Including G719X and S768I",Furmonertinib (DRUG); Furmonertinib (DRUG); Furmonertinib (DRUG); Furmonertinib (DRUG); Furmonertinib (DRUG),10184653,Tovok,"Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; HER2 Exon 20 Mutations; EGFR Exon 20 Mutations; EGFR Uncommon Mutations, Including G719X and S768I",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13066,NCT02115048,Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone,TERMINATED,PHASE2,Breast Neoplasms,Letrozole (DRUG); Afatinib (DRUG),10184653,Tovok,Breast Neoplasms,Breast,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13067,NCT01853826,An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s),COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung",Afatinib (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13068,NCT01125566,LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment,COMPLETED,PHASE3,Breast Neoplasms,BIBW 2992 (DRUG); trastuzumab (DRUG); vinorelbine (DRUG); vinorelbine (DRUG),10184653,Tovok,Breast Neoplasms,Breast,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13069,NCT01288430,A Study of DS-2248 in Participants With Advanced Solid Tumors,TERMINATED,PHASE1,Solid Tumors; Non-small Cell Lung Carcinoma,DS-2248 (DRUG),10184653,Tovok,Solid Tumors and Non-small Cell Lung Carcinoma,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13070,NCT00730925,Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",BIBW2992 (DRUG); BIBW2992 + paclitaxel (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13071,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,COMPLETED,PHASE2,Breast Neoplasms,Vinorelbine 25 mg/m2 weekly (DRUG); Afatinib 40mg once daily (OD) (DRUG); Paclitaxel 80 mg/m2 weekly (DRUG),10184653,Tovok,Breast Neoplasms,Breast,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13072,NCT02438722,"S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Afatinib Dimaleate (DRUG); Cetuximab (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER),10184653,Tovok,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13073,NCT05204758,Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect,COMPLETED,PHASE3,Advanced Lung Adenocarcinoma,TCM Formula (DRUG); Placebo (DRUG),10184653,Tovok,Advanced Lung Adenocarcinoma,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13074,NCT01608022,A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus,COMPLETED,PHASE2,Esophageal Squamous Cell Carcinoma,PF804 (DRUG),10184653,Tovok,Esophageal Squamous Cell Carcinoma,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13075,NCT03711422,Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC,TERMINATED,PHASE1,Non-small Cell Lung Cancer; Leptomeningeal Disease; Central Nervous System Metastases,Afatinib (DRUG); Afatinib (DRUG),10184653,Tovok,Non-small Cell Lung Cancer; Leptomeningeal Disease; Central Nervous System Metastases,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13076,NCT06648096,Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC),RECRUITING,PHASE1,Fanconi Anemia; Head and Neck Squamous Cell Carcinoma,Afatinib (DRUG),10184653,Tovok,Fanconi Anemia; Head and Neck Squamous Cell Carcinoma,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13077,NCT01441596,Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases,COMPLETED,PHASE2,Breast Neoplasms; Neoplasm Metastasis,Vinorelbine (DRUG); Investigator's choice of treatment (DRUG); afatinib (DRUG); afatinib (DRUG),10184653,Tovok,Breast Neoplasms with Metastasis,Breast,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13078,NCT02191891,Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC),COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung",BI 836845 (DRUG); afatinib (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13079,NCT05516589,"Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC",RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma,Nab-paclitaxel (DRUG); Cisplatin (DRUG); Tislelizumab (BIOLOGICAL); Afatinib (DRUG),10184653,Tovok,Head and Neck Squamous Cell Carcinoma,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13080,NCT00711594,LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",BIBW 2992 MA2 40mg/day (DRUG); BIBW 2992 MA2 50mg/day (DRUG); BIBW 2992 MA2 20mg/day (DRUG); BIBW 2992 QD (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13081,NCT02488694,Maintaining ERBB Blockade in EGFR-mutated Lung Cancer,TERMINATED,PHASE2,Non-small-cell Lung Cancer With Somatic EGFR Mutations,Afatinib (DRUG); Pemetrexed (DRUG),10184653,Tovok,Non-small-cell Lung Cancer With Somatic EGFR Mutations,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13082,NCT00801294,A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer,COMPLETED,PHASE2,Colorectal Neoplasms,BIBF 1120 and BIBW 2992 (DRUG),10184653,Tovok,Colorectal Neoplasms,Bowel,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13083,NCT05445791,Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations,RECRUITING,PHASE3,Non Small Cell Lung Cancer,Metformin Hydrochloride (DRUG); Placebo (OTHER),10184653,Tovok,Non Small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13084,NCT02044380,Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations,COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung",Afatinib (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13085,NCT02906163,First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy,UNKNOWN,PHASE1,EGFR Mutation Positive Non Small Cell Lung Cancer,"Thymalfasin (Thymosin alpha 1, Ta1) (DRUG); SoC (tyrosine kinase inhibitor) (DRUG)",10184653,Tovok,EGFR Mutation Positive Non Small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13086,NCT06897735,Exploratory Study of Inhaled Afatinib Dimaleate PK Profile,NOT_YET_RECRUITING,PHASE1,Lung Cancer; Oral Cancer; Melanoma,Afatinib Dimaleat (DRUG); inhalation of afatinib dimaleate (BIOLOGICAL),10184653,Tovok,Lung Cancer; Oral Cancer; Melanoma,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13087,NCT01466660,LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung,COMPLETED,PHASE2,Lung Neoplasms,Afatinib (DRUG); gefitinib (DRUG),10184653,Tovok,Lung Neoplasms,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13088,NCT00826267,6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab,COMPLETED,PHASE2,Breast Neoplasms,lapatinib (DRUG); BIBW 2992 (DRUG); trastuzumab (DRUG),10184653,Tovok,Breast Neoplasms,Breast,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13089,NCT02122172,Afatinib in Advanced Refractory Urothelial Cancer,TERMINATED,PHASE2,Distal Urethral Cancer; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Urethral Cancer; Stage III Bladder Cancer; Stage III Urethral Cancer; Stage IV Bladder Cancer; Stage IV Urethral Cancer; Ureter Cancer,afatinib dimaleate (DRUG); laboratory biomarker analysis (OTHER),10184653,Tovok,Distal Urethral Cancer; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Urethral Cancer; Stage III Bladder Cancer; Stage III Urethral Cancer; Stage IV Bladder Cancer; Stage IV Urethral Cancer; Ureter Cancer,Bladder/Urinary Tract,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13090,NCT01732640,A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.,TERMINATED,PHASE1,Squamous Cell Carcinoma of the Head and Neck,Afatinib (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Intensity Modulated Radiation Therapy (RADIATION),10184653,Tovok,Squamous Cell Carcinoma of the Head and Neck,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13091,NCT00431067,Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy,COMPLETED,PHASE2,Breast Neoplasms,BIBW 2992 (DRUG),10184653,Tovok,Breast Neoplasms,Breast,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13092,NCT04413201,AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC,ACTIVE_NOT_RECRUITING,PHASE4,Non-squamous NSCLC,Afatinib (DRUG); Osimertinib (DRUG),10184653,Tovok,Non-Squamous Non-Small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13093,NCT05503667,Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma,RECRUITING,PHASE2,Lung Adenocarcinoma Stage III; Lung Adenocarcinoma Stage IV; EGFR Gene Mutation,Furmonertinib (DRUG); Bevacizumab (DRUG),10184653,Tovok,Lung Adenocarcinoma Stage III; Lung Adenocarcinoma Stage IV; EGFR Gene Mutation,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13094,NCT05927844,XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma,NOT_YET_RECRUITING,PHASE1,Esophageal Squamous Cell Carcinoma,XH-30002 capsule (DRUG); Afatiinb tablet (DRUG),10184653,Tovok,Esophageal Squamous Cell Carcinoma,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13095,NCT03157089,Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Afatinib (DRUG); pembrolizumab (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13096,NCT03727724,Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Afatinib (DRUG); Cetuximab (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13097,NCT02595840,Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE),TERMINATED,PHASE2,Non-small-cell Lung Cancer With Somatic EGFR Mutations,Afatinib (DRUG); Pemetrexed (DRUG),10184653,Tovok,Non-small-cell Lung Cancer With Somatic EGFR Mutations,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13098,NCT03115567,A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption,TERMINATED,PHASE2,Acneiform Rash; Papulopustular Eruption,Triamcinolone (DRUG),10184653,Tovok,Acneiform Rash; Papulopustular Eruption,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13099,NCT01522768,Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer,COMPLETED,PHASE2,Esophageal Cancer; Gastric Cancer,Afatinib and Paclitaxel (DRUG),10184653,Tovok,Esophageal and Gastric Cancer,Esophagus/Stomach,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13100,NCT02625168,Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC,COMPLETED,PHASE2,Lung Cancer,Afatinib (DRUG); Erlotinib (DRUG),10184653,Tovok,Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13101,NCT02975141,Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer,UNKNOWN,PHASE1,Metastatic Pancreatic Cancer,Afatinib 30Mg Tab (DRUG); Afatinib 40Mg Tab (DRUG); Gemzar (DRUG); Abraxane (DRUG),10184653,Tovok,Metastatic Pancreatic Cancer,Pancreas,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13102,NCT01953913,Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation,COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung",Afatinib (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13103,NCT01836341,Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation,WITHDRAWN,PHASE1,Non-small Cell Lung Cancer,Afatinib (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Radiation therapy (RADIATION),10184653,Tovok,Non-small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13104,NCT01480141,A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC),WITHDRAWN,PHASE2,Lung Cancer,BIBW 2992 (Afatinib) (DRUG),10184653,Tovok,Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13105,NCT02096718,Afatinib in Subjects With Kidney Dysfunction,COMPLETED,PHASE1,Renal Insufficiency,Afatinib healthy (DRUG); Afatinib severe renally impaired (DRUG); Afatinib moderate renally impaired (DRUG),10184653,Tovok,Renal Insufficiency,Kidney,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13106,NCT04356118,Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis,UNKNOWN,PHASE4,Leptomeningeal Metastasis,Recombinant Human Endostatin (DRUG); intrathcal methotrexate (DRUG); Targeted drugs for non-small cell lung cancer (DRUG),10184653,Tovok,Leptomeningeal Metastasis,CNS/Brain,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13107,NCT01824823,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,TERMINATED,PHASE2,Head and Neck Squamous Cell Carcinoma,afatinib (DRUG); placebo (OTHER),10184653,Tovok,Head and Neck Squamous Cell Carcinoma,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13108,NCT02876081,"Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex",WITHDRAWN,PHASE2,SMALL CELL LUNG CARCINOMA,Afatinib (DRUG),10184653,Tovok,SMALL CELL LUNG CARCINOMA,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13109,NCT02274012,Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment,WITHDRAWN,PHASE2,HER-2 Positive Gastric Cancer; Gastrooesophageal Cancer; Esophageal Cancer,Afatinib (DRUG); Paclitaxel (DRUG),10184653,Tovok,HER-2 Positive Gastric Cancer; Gastrooesophageal Cancer; Esophageal Cancer,Esophagus/Stomach,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13110,NCT03054038,Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer,TERMINATED,PHASE1,Non-Small Cell Lung Carcinoma,Afatinib (DRUG); Necitumumab (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER),10184653,Tovok,Non-Small Cell Lung Carcinoma,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13111,NCT01538381,Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck,COMPLETED,PHASE2,"Carcinoma, Squamous Cell of Head and Neck",Afatinib (DRUG); Observation (OTHER),10184653,Tovok,Head and Neck Squamous Cell Carcinoma,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13112,NCT06085755,Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer,RECRUITING,PHASE1,Stomach Neoplasm,Trastuzumab deruxtecan (DRUG); Afatinib (DRUG),10184653,Tovok,Stomach Neoplasm,Esophagus/Stomach,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13113,NCT03623750,E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C,COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung",EGFR-TK Inhibitor (DRUG); EGF-PTI (BIOLOGICAL); Cyclophosphamide (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13114,NCT00708214,BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms,BIBW 2992 (DRUG); BIBW 2992 (DRUG); Letrozole (DRUG); Letrozole (DRUG),10184653,Tovok,Breast Neoplasms,Breast,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13115,NCT02629523,Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA,COMPLETED,PHASE2,Lung Neoplasms; EGFR Gene Mutation,Afatinib (DRUG),10184653,Tovok,Lung Neoplasms; EGFR Gene Mutation,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13116,NCT00949650,BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation,COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung; Adenocarcinoma",Pemetrexed (DRUG); BIBW 2992 (DRUG); Cisplatin (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung; Adenocarcinoma",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13117,NCT04533321,A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma,UNKNOWN,PHASE2,Squamous Cell Carcinoma,Afatinib (DRUG),10184653,Tovok,Squamous Cell Carcinoma,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13118,NCT01531764,BIBW 2992 (Afatinib) and Vinorelbine,TERMINATED,PHASE2,Carcinoma Breast Stage IV,BIBW 2992 in combination with vinorelbine (DRUG),10184653,Tovok,Carcinoma Breast Stage IV,Breast,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13119,NCT00514943,BIBW 2992 (Afatinib) in Head & Neck Cancer,COMPLETED,PHASE2,"Head and Neck Neoplasms; Carcinoma, Squamous Cell",BIBW 2992 (DRUG); Cetuximab (DRUG),10184653,Tovok,"Head and Neck Neoplasms; Carcinoma, Squamous Cell",Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13120,NCT01085136,LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib,COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung",Investigator´s choice of chemotherapy (DRUG); BIBW 2992 (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13121,NCT00796549,BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",BiBW 2992 (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13122,NCT00656136,BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1),COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung",placebo (DRUG); BIBW 2992 (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13123,NCT02271906,The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting,TERMINATED,PHASE2,Lung Cancer,BIBW 2992 (DRUG),10184653,Tovok,Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13124,NCT03827070,Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma,UNKNOWN,PHASE1,Non Small Cell Lung Cancer,Afatinib (DRUG); Talcum powder (DRUG),10184653,Tovok,Non Small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13125,NCT01003899,A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR],COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",afatinib (BIBW 2992) (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13126,NCT03481842,"Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis",WITHDRAWN,PHASE1,"Endometriosis; Endometriosis Ovary; Endometriosis Externa; Endometriosis, Rectum",Linifanib (BIOLOGICAL); BIBW2992 (DRUG); Axitinib (DRUG),10184653,Tovok,"Endometriosis; Endometriosis Ovary; Endometriosis Externa; Endometriosis, Rectum",Uterus,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13127,NCT01553942,Afatinib With CT and RT for EGFR-Mutant NSCLC,ACTIVE_NOT_RECRUITING,PHASE2,Lung Cancer,Afatinib (DRUG); Radiation (RADIATION); Cisplatin (DRUG); Pemetrexed (DRUG); Surgery (PROCEDURE),10184653,Tovok,Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13128,NCT06486142,EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study,RECRUITING,PHASE3,Non-Small Cell Lung Cancer,Afatinib/Dacomitinib (DRUG); Osimertinib (DRUG),10184653,Tovok,Advanced Non-Small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13129,NCT00727506,BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma,COMPLETED,PHASE2,Glioma,BIBW 2992 (DRUG); TMZ (DRUG); BIBW 2992 plus TMZ (DRUG),10184653,Tovok,Glioma,CNS/Brain,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13130,NCT00993499,Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib,COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung",BIBW 2992 (DRUG); Sirolimus (rapamycin) (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13131,NCT03574402,Phase II Umbrella Study Directed by Next Generation Sequencing,UNKNOWN,PHASE2,"Carcinoma, Non-Small-Cell Lung",Avitinib Maleate (DRUG); Afatinib (DRUG); Crizotinib (DRUG); X-396 (DRUG); Chidamide (DRUG); Pyrotinib Maleate (DRUG); AZD3759 (DRUG); Pirotinib (DRUG); Nimotuzumab (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG); Sintilimab (DRUG); Gemcitabine (DRUG); Gemcitabine (DRUG); Carboplatin (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13132,NCT04132102,To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation,UNKNOWN,PHASE4,Lung Squamous Cell Carcinoma,Afatinib (DRUG),10184653,Tovok,Lung Squamous Cell Carcinoma,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13133,NCT04497584,Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC,RECRUITING,PHASE2,Advanced Squamous Non Small Cell Lung Cancer,Afatinib + Prednisone (DRUG),10184653,Tovok,Advanced Squamous Non Small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13134,NCT02541903,Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma,TERMINATED,PHASE2,Penile Squamous Cell Carcinoma (PSCC),Gilotrif (DRUG),10184653,Tovok,Penile Squamous Cell Carcinoma (PSCC),Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13135,NCT02501603,"Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer",COMPLETED,PHASE2,Gastric Cancer; Gastroesophageal Junction Cancer,afatinib (DRUG); paclitaxel (DRUG),10184653,Tovok,Gastric Cancer; Gastroesophageal Junction Cancer,Esophagus/Stomach,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13136,NCT02208843,Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation,COMPLETED,PHASE4,"Carcinoma, Non-Small-Cell Lung",Afatinib (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13137,NCT01919879,Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Cetuximab + Afatinib (DRUG); Cetuximab (DRUG),10184653,Tovok,Metastatic Colorectal Cancer,Bowel,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13138,NCT04448379,Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer,UNKNOWN,PHASE1,Locally Advanced or Metastatic Non-Small Cell Lung Cancer,JMT101 (DRUG),10184653,Tovok,Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13139,NCT06759857,FHND9041 Versus Afatinib for Non-small Cell Lung Cancer,ENROLLING_BY_INVITATION,PHASE3,Non Small Cell Lung Cancer,FHND9041 (DRUG); Afatinib (DRUG),10184653,Tovok,Non Small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13140,NCT00525148,"LUX Lung 2 Phase II Single Arm BIBW 2992 ""Afatinib"" in NSCLC With EGFR Activating Mutations",COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",BIBW 2992 (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13141,NCT06709859,Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC,NOT_YET_RECRUITING,PHASE2,"Carcinoma, Non-Small-Cell Lung",Afatinib plus chemotherapy as conversion treatment (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13142,NCT01298063,"Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib",COMPLETED,PHASE1,Liver Diseases; Healthy,Afatinib (DRUG); Afatinib (DRUG); Afatinib (DRUG),10184653,Tovok,Liver Diseases; Healthy,Liver,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13143,NCT02424617,A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Non-Small Cell Lung Cancer,Erlotinib (DRUG); Bemcentinib (DRUG); Bemcentinib (DRUG); Bemcentinib (DRUG),10184653,Tovok,Advanced Non-Small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13144,NCT05432518,Pilot Trial for Treatment of Recurrent Glioblastoma,RECRUITING,EARLY_PHASE1,Glioblastoma; Recurrent Disease; Recurrent Glioblastoma,Afatinib (DRUG); Dasatinib (DRUG); Palbociclib (DRUG); Everolimus (DRUG); Olaparib (DRUG),10184653,Tovok,Glioblastoma; Recurrent Disease; Recurrent Glioblastoma,CNS/Brain,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13145,NCT02736513,Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases,UNKNOWN,PHASE2,Lung Cancer,AZD9291 (DRUG),10184653,Tovok,Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13146,NCT06071013,Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients,RECRUITING,PHASE1,Non-small Cell Lung Cancer; EGFR Gene Mutation; EGFR-TKI Resistant Mutation,"Nintedanib, gefitinib, erlotinib, afatinib, osimertinib (DRUG)",10184653,Tovok,Non-small Cell Lung Cancer; EGFR Gene Mutation; EGFR-TKI Resistant Mutation,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13147,NCT03088059,Biomarker-based Study in R/M SCCHN,ACTIVE_NOT_RECRUITING,PHASE2,"Carcinoma, Squamous Cell of Head and Neck",Afatinib (DRUG); Palbociclib (DRUG); standard of care (DRUG); IPH2201 (DRUG); Durvalumab (DRUG); Niraparib (DRUG); INCAGN01876 (DRUG),10184653,Tovok,Head and Neck Squamous Cell Carcinoma,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13148,NCT00950742,Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.,COMPLETED,PHASE1,Breast Neoplasms,Trastuzumab (DRUG); BIBW 2992 (DRUG),10184653,Tovok,Breast Neoplasms,Breast,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13149,NCT02353936,A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus,UNKNOWN,PHASE2,Squamous Cell Carcinoma of Esophagus,BIBW2992 (DRUG),10184653,Tovok,Squamous Cell Carcinoma of Esophagus,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13150,NCT01523587,LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy,COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung",afatinib (DRUG); erlotinib (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13151,NCT02450656,Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer,UNKNOWN,PHASE1,"Colorectal Neoplasms; Gastrointestinal Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung",Afatinib (DRUG); Selumetinib (DRUG); Docetaxel (DRUG),10184653,Tovok,"Colorectal Neoplasms; Gastrointestinal Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung",Bowel,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13152,NCT02795156,Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,COMPLETED,PHASE2,"Non-small Cell Lung Carcinoma; Urothelial Carcinoma; Gastrointestinal Carcinoma, Non-colon; Upper Aerodigestive Tract Carcinoma",Afatinib (DRUG); Regorafenib (DRUG); Cabozantinib (DRUG),10184653,Tovok,"Non-small Cell Lung Carcinoma; Urothelial Carcinoma; Gastrointestinal Carcinoma, Non-colon; Upper Aerodigestive Tract Carcinoma",Bladder/Urinary Tract,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13153,NCT01152437,A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Neoplasms,BIBW 2992 (DRUG); Cetuximab (DRUG),10184653,Tovok,Colorectal Neoplasms,Bowel,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13154,NCT05865132,Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction,RECRUITING,PHASE2,Esophagus Squamous Cell Carcinoma,Palbociclib (DRUG); Afatinib (DRUG),10184653,Tovok,Esophagus Squamous Cell Carcinoma,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13155,NCT04201756,Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma,COMPLETED,PHASE2,Lung Adenocarcinoma Stage III; EGFR Gene Mutation,Afatinib (DRUG),10184653,Tovok,Lung Adenocarcinoma Stage III; EGFR Gene Mutation,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13156,NCT01542437,"Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer",COMPLETED,PHASE2,Non-Small Cell Lung Cancer; EGFR; HER-2,BIBW 2992 (DRUG),10184653,Tovok,Non-Small Cell Lung Cancer; EGFR; HER-2,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13157,NCT00425854,An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms,BIBW 2992 (DRUG),10184653,Tovok,Breast Neoplasms,Breast,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13158,NCT04158947,A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone,UNKNOWN,PHASE2,HER2-positive Breast Cancer; Brain Metastases,Afatinib (DRUG); T-DM1 (DRUG),10184653,Tovok,HER2-positive Breast Cancer with Brain Metastases,CNS/Brain,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13159,NCT02511847,Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib,UNKNOWN,PHASE2,Triple Negative Breast Cancer,Afatinib (DRUG),10184653,Tovok,Triple Negative Breast Cancer,Breast,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13160,NCT02098954,Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers,RECRUITING,PHASE2,"Carcinoma, Non-Small Cell Lung; EGFR Gene Mutation",Gemcitabine platinum combined with erlotinib (DRUG),10184653,Tovok,Non-Small Cell Lung Carcinoma with EGFR Mutation,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13161,NCT01746251,Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,Afatinib (DRUG),10184653,Tovok,Non Small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13162,NCT02451553,"Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer",COMPLETED,PHASE1,Advanced Malignant Solid Neoplasm; Bile Duct Carcinoma; Recurrent Malignant Solid Neoplasm; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IVA Pancreatic Cancer; Stage IVB Pancreatic Cancer,Afatinib Dimaleate (DRUG); Capecitabine (DRUG); Laboratory Biomarker Analysis (OTHER),10184653,Tovok,Advanced Malignant Solid Neoplasm; Bile Duct Carcinoma; Recurrent Malignant Solid Neoplasm; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IVA Pancreatic Cancer; Stage IVB Pancreatic Cancer,Pancreas,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13163,NCT01814553,ADAM-Afatinib Diarrhea Assessment and Management,COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung",afatinib (DRUG); loperamide (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13164,NCT02747953,Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib,COMPLETED,PHASE2,Non-small Cell Lung Cancer,Gilotrif (DRUG),10184653,Tovok,Non-small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13165,NCT02768337,Cambridge Brain Mets Trial 1,TERMINATED,PHASE1,Lung Cancer; Breast Cancer; Brain Cancer; Advanced Breast Cancer; Advanced Lung Cancer,Afatinib (DRUG); 2 Gy targeted radiotherapy (RADIATION); 4 Gy targeted radiotherapy (RADIATION),10184653,Tovok,Lung Cancer; Breast Cancer; Brain Cancer; Advanced Breast Cancer; Advanced Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13166,NCT01880515,Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib),COMPLETED,PHASE2,Skin Rash; Lung Cancer,Tetracycline (DRUG),10184653,Tovok,Skin Rash with Lung Cancer,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13167,NCT01999985,Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC),COMPLETED,PHASE1,Lung Cancer; Non-small Cell Lung Cancer (NSCLC),Dasatinib - 1A (DRUG); Afatinib - 1A (DRUG); Dasatinib - 1B (DRUG); Afatinib - 1B (DRUG),10184653,Tovok,Lung Cancer; Non-small Cell Lung Cancer (NSCLC),Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13168,NCT04814056,To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion,UNKNOWN,PHASE4,NRG1-fused Non-small Cell Lung Cancer,Afatinib Dimaleate (DRUG),10184653,Tovok,NRG1-fused Non-small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13169,NCT02364609,Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib,COMPLETED,PHASE1,Recurrent Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Afatinib Dimaleate (DRUG); Pembrolizumab (BIOLOGICAL),10184653,Tovok,Recurrent Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13170,NCT01783587,Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer,COMPLETED,PHASE1,Squamous Cell Carcinoma of the Head and Neck,Afatinib (DRUG); Docetaxel (DRUG); Radiation Therapy (RADIATION),10184653,Tovok,Squamous Cell Carcinoma of the Head and Neck,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13171,NCT03652233,Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck,WITHDRAWN,PHASE1,Recurrent Squamous Cell Carcinoma of the Head or Neck; Metastatic Squamous Cell Carcinoma of the Head or Neck; Squamous Cell Carcinoma,Nivolumab (DRUG); Afatinib (DRUG),10184653,Tovok,Recurrent Squamous Cell Carcinoma of the Head or Neck; Metastatic Squamous Cell Carcinoma of the Head or Neck; Squamous Cell Carcinoma,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13172,NCT04880811,Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification,UNKNOWN,PHASE2,Esophageal Squamous Cell Carcinoma,Afatinib (DRUG); Toripalimab (DRUG),10184653,Tovok,Esophageal Squamous Cell Carcinoma,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13173,NCT02183883,Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity,COMPLETED,PHASE2,Non-small Cell Lung Cancer,Afatinib (DRUG),10184653,Tovok,Non-small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13174,NCT01090011,Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer,COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung",Cetuximab (DRUG); Cetuximab (DRUG); BIBW 2992 (DRUG); BIBW 2992 (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13175,NCT01325428,Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms,Afatinib once daily (OD) (DRUG); Vinorelbine Weekly (DRUG),10184653,Tovok,Breast Neoplasms,Breast,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13176,NCT01647711,"A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations",COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung",Dose escalation followed by treatment with MTD (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13177,NCT01156545,BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC,COMPLETED,PHASE2,Non-small Cell Lung Cancer,BIBW 2992 (DRUG); simvastatin (DRUG),10184653,Tovok,Non-small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13178,NCT01594177,Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy,COMPLETED,PHASE2,Unilateral HER2 Positive Breast Cancer,Afatinib (DRUG); Trastuzumab (DRUG); Paclitaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),10184653,Tovok,Unilateral HER2 Positive Breast Cancer,Breast,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13179,NCT03486509,Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma,UNKNOWN,PHASE2,Squamous Cell Carcinoma,Afatinib (DRUG),10184653,Tovok,Squamous Cell Carcinoma,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13180,NCT04839471,BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study),COMPLETED,PHASE2,Esophageal Squamous Cell Carcinoma (ESCC),BI-754091 plus afatinib (DRUG),10184653,Tovok,Esophageal Squamous Cell Carcinoma,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13181,NCT01649271,Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.,COMPLETED,PHASE1,Breast Neoplasms; Stomach Neoplasms,Herceptin (DRUG); afatinib (DRUG); trastuzumab (DRUG); Herceptin (DRUG); afatinib (DRUG); afatinib (DRUG),10184653,Tovok,Breast Neoplasms; Stomach Neoplasms,Esophagus/Stomach,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13182,NCT02514174,Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older,COMPLETED,PHASE4,"Carcinoma, Non-Small-Cell Lung; ErbB Receptors",Afatinib (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung; ErbB Receptors",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13183,NCT02716311,Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer,COMPLETED,PHASE2,Non Small Cell Lung Cancer,Afatinib (DRUG); Cetuximab (DRUG),10184653,Tovok,Non Small Cell Lung Cancer,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13184,NCT01415011,Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Afatinib (BIBW 2992) (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13185,NCT01121393,BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC),COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung; Adenocarcinoma",Gemcitabine+Cisplatin (DRUG); BIBW 2992 (DRUG),10184653,Tovok,"Carcinoma, Non-Small-Cell Lung; Adenocarcinoma",Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13186,NCT01427478,Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck,COMPLETED,PHASE3,Head and Neck Squamous Cell Carcinoma,AFATINIB (DRUG); Placebo of AFATINIB (DRUG),10184653,Tovok,Head and Neck Squamous Cell Carcinoma,Skin,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13187,NCT04148898,Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis,UNKNOWN,PHASE2,Leptomeningeal Metastasis; Non-small Cell Lung Cancer; EGFR Activating Mutation,Osimertinib (DRUG); Bevacizumab (DRUG),10184653,Tovok,Leptomeningeal Metastasis; Non-small Cell Lung Cancer; EGFR Activating Mutation,Lung,Afatinib,"EGFR, ERBB2",inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,"Approved for treatment of certain cancers, such as non-small cell lung cancer.",CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,1.03,306.0 +13188,NCT03654274,SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain,COMPLETED,PHASE3,Endometriosis,Relugolix (DRUG); Estradiol/norethindrone acetate (DRUG),10348973,Orgovyx,Endometriosis,Uterus,Relugolix,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer and uterine fibroids treatment.,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,1.3,2417.0 +13189,NCT03412890,LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids,COMPLETED,PHASE3,Heavy Menstrual Bleeding; Uterine Fibroid,Relugolix (DRUG); Estradiol/norethindrone acetate (DRUG),10348973,Orgovyx,Uterine Disorders,Uterus,Relugolix,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer and uterine fibroids treatment.,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,1.3,2417.0 +13190,NCT02093390,A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects,COMPLETED,PHASE1,Prostate Cancer; Endometriosis,TAK-385 (DRUG); Fluconazole (DRUG); Atorvastatin (DRUG),10348973,Orgovyx,Prostate Cancer; Endometriosis,Uterus,Relugolix,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer and uterine fibroids treatment.,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,1.3,2417.0 +13191,NCT03204331,SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain,COMPLETED,PHASE3,Endometriosis Related Pain,Relugolix (DRUG); Estradiol/norethindrone acetate (DRUG); Estradiol/norethindrone acetate placebo (DRUG); Relugolix placebo (DRUG),10348973,Orgovyx,Endometriosis Related Pain,Uterus,Relugolix,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer and uterine fibroids treatment.,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,1.3,2417.0 +13192,NCT06671548,Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids,NOT_YET_RECRUITING,PHASE3,Heavy Menstrual Bleeding; Uterine Fibroids,Relugolix (DRUG); Relugolix placebo (DRUG),10348973,Orgovyx,Heavy Menstrual Bleeding; Uterine Fibroids,Uterus,Relugolix,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer and uterine fibroids treatment.,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,1.3,2417.0 +13193,NCT06439524,The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial,RECRUITING,PHASE3,Endometriosis,"40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate (DRUG)",10348973,Orgovyx,Endometriosis,Uterus,Relugolix,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer and uterine fibroids treatment.,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,1.3,2417.0 +13194,NCT03751124,Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids,COMPLETED,PHASE3,Uterine Leiomyoma; Uterine Fibroids,Relugolix (DRUG); Estradiol/norethindrone acetate (DRUG); Placebo for relugolix (DRUG); Placebo for E2/NETA (DRUG),10348973,Orgovyx,Uterine Leiomyoma; Uterine Fibroids,Uterus,Relugolix,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer and uterine fibroids treatment.,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,1.3,2417.0 +13195,NCT02655224,"A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids",COMPLETED,PHASE3,Uterine Fibroids,Relugolix (DRUG); Relugolix placebo (DRUG),10348973,Orgovyx,Uterine Fibroids,Uterus,Relugolix,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer and uterine fibroids treatment.,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,1.3,2417.0 +13196,NCT01458301,Efficacy and Safety of TAK-385 in the Treatment of Endometriosis,COMPLETED,PHASE2,Endometriosis,Placebo (DRUG); TAK-385 (DRUG); TAK-385 (DRUG); TAK-385 (DRUG); Leuprorelin acetate (DRUG),10348973,Orgovyx,Endometriosis,Uterus,Relugolix,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer and uterine fibroids treatment.,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,1.3,2417.0 +13197,NCT05862272,A Phase 3B Study to Evaluate Bone Mineral Density with Long-Term Use of Relugolix Combination Tablet in Women with Uterine Fibroids or Endometriosis,RECRUITING,PHASE3,Uterine Fibroids; Endometriosis,Relugolix Combination Tablet (DRUG),10348973,Orgovyx,Uterine Fibroids; Endometriosis,Uterus,Relugolix,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer and uterine fibroids treatment.,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,1.3,2417.0 +13198,NCT03204318,SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain,COMPLETED,PHASE3,Endometriosis Related Pain,Relugolix (DRUG); Estradiol/norethindrone acetate (DRUG); Estradiol/norethindrone acetate placebo (DRUG); Relugolix placebo (DRUG),10348973,Orgovyx,Endometriosis Related Pain,Uterus,Relugolix,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer and uterine fibroids treatment.,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,1.3,2417.0 +13199,NCT03049735,LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids,COMPLETED,PHASE3,Heavy Menstrual Bleeding; Uterine Fibroid,Relugolix (DRUG); Estradiol/norethindrone acetate (DRUG); Estradiol/norethindrone acetate placebo (DRUG); Relugolix placebo (DRUG),10348973,Orgovyx,Uterine Disorders,Uterus,Relugolix,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer and uterine fibroids treatment.,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,1.3,2417.0 +13200,NCT01452659,Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids,COMPLETED,PHASE2,Uterine Fibroids,TAK-385 (DRUG); TAK-385 (DRUG); TAK-385 (DRUG); Placebo (DRUG),10348973,Orgovyx,Uterine Fibroids,Uterus,Relugolix,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer and uterine fibroids treatment.,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,1.3,2417.0 +13201,NCT01452685,A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis,COMPLETED,PHASE2,Endometriosis,Placebo (DRUG); TAK-385 (DRUG); TAK-385 (DRUG); TAK-385 (DRUG); Leuprorelin acetate (DRUG),10348973,Orgovyx,Endometriosis,Uterus,Relugolix,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer and uterine fibroids treatment.,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,1.3,2417.0 +13202,NCT03931915,Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis,COMPLETED,PHASE3,Endometriosis,TAK-385 (DRUG); Leuprorelin acetate (DRUG),10348973,Orgovyx,Endometriosis,Uterus,Relugolix,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer and uterine fibroids treatment.,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,1.3,2417.0 +13203,NCT02655237,A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids,COMPLETED,PHASE3,Uterine Fibroids,Relugolix (DRUG); Relugolix Placebo (DRUG); Leuprorelin (DRUG); Leuprorelin Placebo (DRUG),10348973,Orgovyx,Uterine Fibroids,Uterus,Relugolix,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer and uterine fibroids treatment.,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,1.3,2417.0 +13204,NCT03103087,LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids,COMPLETED,PHASE3,Heavy Menstrual Bleeding; Uterine Fibroid,Relugolix (DRUG); Estradiol/norethindrone acetate (DRUG); Relugolix placebo (DRUG); Estradiol/norethindrone acetate placebo (DRUG),10348973,Orgovyx,Uterine Disorders,Uterus,Relugolix,GNRHR,inhibitor/antagonist,unclear,yes,yes,Approved for prostate cancer and uterine fibroids treatment.,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,1.3,2417.0 +13205,NCT05041582,SSRIs and TDCS Enhance Post-stroke Motor Recovery,NOT_YET_RECRUITING,PHASE3,Stroke; Motor,tDCS (DEVICE); Citalopram (DRUG); Rehabilitation (BEHAVIORAL),77995,Celexa,Stroke; Motor,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13206,NCT02458690,eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients,COMPLETED,PHASE2,Depression; Major Depressive Disorder; Dysthymic Disorder; Depressive Symptoms; Cardiovascular Diseases; Heart Diseases; Coronary Artery Disease; Stroke,Beating the Blues (BtB) (BEHAVIORAL); Problem Solving Treatment in Primary Care (PST-PC) (BEHAVIORAL); Antidepressant Medications (DRUG); Usual Care (OTHER),77995,Celexa,Depression; Major Depressive Disorder; Dysthymic Disorder; Depressive Symptoms; Cardiovascular Diseases; Heart Diseases; Coronary Artery Disease; Stroke,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13207,NCT03108846,Escitalopram for Agitation in Alzheimer's Disease,ACTIVE_NOT_RECRUITING,PHASE3,Dementia,Escitalopram (DRUG); Placebo (DRUG),77995,Celexa,Dementia,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13208,NCT00133276,Prophylaxis of Psychiatric Symptoms During Anti-HCV Treatment,COMPLETED,PHASE2,Hepatitis C,Escitalopram (DRUG); Placebo (OTHER),77995,Celexa,Hepatitis C,Liver,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13209,NCT03728673,A Study Utilizing Escitalopram in Glioma Patients,RECRUITING,PHASE2,Glioma of Brain; Glioma,Escitalopram Oral Capsules (DRUG),77995,Celexa,Glioma of Brain; Glioma,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13210,NCT01522092,Escitalopram in Anxiety Associated Chronic Obstructive Pulmonary Disease (COPD) Exacerbations,WITHDRAWN,PHASE3,Anxiety; COPD,escitalopram (DRUG),77995,Celexa,Anxiety; COPD,Lung,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13211,NCT01937182,The Efficacy of Citalopram Treatment in Acute Stroke,COMPLETED,PHASE2,"Stroke, Ischemic",Citalopram (DRUG); Placebo (DRUG),77995,Celexa,"Stroke, Ischemic",CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13212,NCT00387348,Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer,TERMINATED,PHASE3,Colorectal Cancer; Depression; Esophageal Cancer; Extrahepatic Bile Duct Cancer; Fatigue; Gallbladder Cancer; Gastric Cancer; Liver Cancer; Lung Cancer; Pancreatic Cancer,escitalopram oxalate (DRUG); Placebo (DRUG),77995,Celexa,Colorectal Cancer; Depression; Esophageal Cancer; Extrahepatic Bile Duct Cancer; Fatigue; Gallbladder Cancer; Gastric Cancer; Liver Cancer; Lung Cancer; Pancreatic Cancer,Bowel,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13213,NCT01551225,Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder,COMPLETED,PHASE4,Irritable Bowel Syndrome; Panic Disorder,Escitalopram (DRUG),77995,Celexa,Irritable Bowel Syndrome; Panic Disorder,Bowel,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13214,NCT04973930,Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Major Depressive Disorder; Breast Cancer; Venlafaxine,Interpersonal Psychotherapy (BEHAVIORAL); Venlafaxine HCl ER (DRUG),77995,Celexa,Major Depressive Disorder; Breast Cancer; Venlafaxine,Breast,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13215,NCT01841125,Escitalopram for the Treatment of Depression in Alzheimer's Disease,COMPLETED,PHASE4,Alzheimer's Disease,escitalopram (DRUG); Placebo (DRUG),77995,Celexa,Alzheimer's Disease,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13216,NCT06216535,Escitalopram in Asthma Patients with Frequent Exacerbation,NOT_YET_RECRUITING,PHASE2,Asthma,Escitalopram (DRUG); Placebo (DRUG),77995,Celexa,Asthma,Lung,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13217,NCT03746691,Effect of Citalopram on Reflux Episodes in Healthy Volunteers,COMPLETED,PHASE4,Gastro Esophageal Reflux,Citalopram HCl (DRUG); Placebos (DRUG),77995,Celexa,Gastro Esophageal Reflux,Esophagus/Stomach,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13218,NCT01961180,"The Effect of Cipralex on Quality of Life, Adrenal Activity Glucose Metabolism, Physical and Mental Health in PCOS",COMPLETED,PHASE4,Polycystic Ovary Syndrome,Cipralex (DRUG); Placebo (DRUG),77995,Celexa,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13219,NCT00151294,The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis,TERMINATED,PHASE4,Depression; Multiple Sclerosis,escitalopram oxalate antidepressant (DRUG),77995,Celexa,Depression; Multiple Sclerosis,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13220,NCT00933894,VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram,COMPLETED,PHASE1,Hepatitis C,Telaprevir; Escitalopram (DRUG),77995,Celexa,Hepatitis C,Liver,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13221,NCT00271596,Citalopram to Enhance Cognition in HD,COMPLETED,PHASE2,Huntington Disease; Chorea; Executive Dysfunction,20mg daily citalopram (DRUG); Placebo (DRUG),77995,Celexa,Huntington Disease; Chorea; Executive Dysfunction,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13222,NCT03843463,Escitalopram and Language Intervention for Subacute Aphasia,RECRUITING,PHASE2,Aphasia; Stroke,Escitalopram 10mg (DRUG); Placebo (DRUG); Computer-delivered naming treatment (BEHAVIORAL),77995,Celexa,Aphasia; Stroke,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13223,NCT00073658,Treating Behavioral Disturbances in Individuals With Dementia,COMPLETED,PHASE2,Dementia,Citalopram (DRUG); Risperidone (DRUG),77995,Celexa,Dementia,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13224,NCT00009204,Serotonergic Pharmacotherapy for Agitation of Dementia,COMPLETED,PHASE3,"Dementia; Alzheimer Disease; Dementia, Vascular",Citalopram [Celexa] (DRUG); Perphenazine [Trilafon] (DRUG),77995,Celexa,"Dementia; Alzheimer Disease; Dementia, Vascular",CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13225,NCT00594269,Dementia Antipsychotics And Antidepressants Discontinuation Study,COMPLETED,PHASE4,Dementia,Risperidone (DRUG); Escitalopram (DRUG); Citalopram (DRUG); Sertraline (DRUG); Paroxetine (DRUG),77995,Celexa,Dementia,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13226,NCT01561092,Escitalopram Treatment In Acute Stroke,WITHDRAWN,PHASE4,Stroke,Escitalopram (DRUG); Placebo (DRUG),77995,Celexa,Stroke,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13227,NCT05840692,The Effect of Escitalopram in PCOS,COMPLETED,PHASE4,Polycystic Ovary Syndrome,Escitalopram 20 mg (DRUG); Placebo (DRUG),77995,Celexa,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13228,NCT00477165,Citalopram in Irritable Bowel Syndrome,COMPLETED,PHASE2,Irritable Bowel Syndrome,Citalopram (DRUG); Placebo (DRUG),77995,Celexa,Irritable Bowel Syndrome,Bowel,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13229,NCT01244724,Lexapro for Major Depression in Patients With Epilepsy,TERMINATED,PHASE4,Major Depression; Epilepsy,Lexapro (DRUG),77995,Celexa,Major Depression; Epilepsy,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13230,NCT00260624,Escitalopram Treatment of Patients With Agitated Dementia,COMPLETED,PHASE4,Alzheimer's Disease; Psychomotor Agitation,Escitalopram (Lexapro) (DRUG),77995,Celexa,Alzheimer's Disease; Psychomotor Agitation,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13231,NCT00166296,Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients,COMPLETED,PHASE2,"Major Depressive Disorder; Hepatitis C, Chronic",Escitalopram (DRUG); Placebo (DRUG),77995,Celexa,"Major Depressive Disorder; Hepatitis C, Chronic",Liver,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13232,NCT05063604,Antidepressant Efficacy of Psychotherapy and Citalopram in Patients With Breast Cancer and Major Depression,TERMINATED,PHASE2,Breast Cancer; Major Depressive Episode,Citalopram (DRUG); Psychotherapy (BEHAVIORAL),77995,Celexa,Breast Cancer; Major Depressive Episode,Breast,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13233,NCT00317746,Trial of Citalopram for the Prevention of Depression,COMPLETED,PHASE3,Depression; HIV Infections; Hepatitis C,Citalopram (DRUG); Placebos (DRUG),77995,Celexa,Depression; HIV Infections; Hepatitis C,Liver,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13234,NCT00621946,Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder,COMPLETED,PHASE4,Severe Asthma; Moderate or Severe Major Depressive Disorder,Placebo (DRUG); Escitalopram (DRUG),77995,Celexa,Severe Asthma; Moderate or Severe Major Depressive Disorder,Lung,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13235,NCT04497168,Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease,ACTIVE_NOT_RECRUITING,PHASE2,Parkinson Disease,Citalopram 20mg (DRUG); Placebo (DRUG),77995,Celexa,Parkinson Disease,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13236,NCT00070941,SAM-e for the Treatment of Depression in Patients With Parkinson's Disease,COMPLETED,PHASE2,Parkinson's Disease; Depression,SAM-e (DRUG); oral escitalopram (DRUG); placebo (DRUG),77995,Celexa,Parkinson's Disease; Depression,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13237,NCT01876823,Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment,COMPLETED,PHASE2,Mild Cognitive Impairment; Major Depressive Disorder; Alzheimer's Disease,es-citalopram (DRUG); Memantine (DRUG),77995,Celexa,Mild Cognitive Impairment; Major Depressive Disorder; Alzheimer's Disease,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13238,NCT01119638,Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone,COMPLETED,PHASE4,Agitation; Psychosis; Alzheimer's Disease,Escitalopram (DRUG); Risperidone (DRUG),77995,Celexa,Agitation; Psychosis; Alzheimer's Disease,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13239,NCT00967408,Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients,UNKNOWN,PHASE4,Stroke,Escitalopram (DRUG); Placebo (DRUG); Rehabilitative treatment (OTHER),77995,Celexa,Stroke,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13240,NCT00595699,Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy,COMPLETED,PHASE4,Major Depression; Temporal Lobe Epilepsy,escitalopram (DRUG); placebo (DRUG),77995,Celexa,Major Depression; Temporal Lobe Epilepsy,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13241,NCT02865642,Cortical Ischemic Stroke and Serotonin,UNKNOWN,PHASE2,Stroke,Serotonin Uptake Inhibitors (DRUG); Placebo (DRUG),77995,Celexa,Stroke,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13242,NCT01841502,Interaction Between Paroxetine and Telaprevir,TERMINATED,PHASE2,Hepatitis C Infection; Depression,Paroxetine (DRUG); telaprevir (DRUG),77995,Celexa,Hepatitis C Infection; Depression,Liver,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13243,NCT00902421,Efficacy and Safety of Selective Serotonin Reuptake Inhibitor (SSRI) in Overactive Bladder Patients,COMPLETED,PHASE4,Overactive Bladder,Selective serotonin reuptake inhibitors (DRUG); Antimuscarinics (DRUG),77995,Celexa,Overactive Bladder,Bladder/Urinary Tract,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13244,NCT02175602,Study of Drug Combination on Pharmacokinetics in Healthy Volunteers,COMPLETED,PHASE1,Hepatitis C Infection,Escitalopram (DRUG); Sertraline (DRUG); DCV 3DAA FDC (DRUG); BMS-791325 (DRUG),77995,Celexa,Hepatitis C Infection,Liver,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13245,NCT00433121,Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD,COMPLETED,PHASE4,Dementia,Risperidone (DRUG); Olanzapine (DRUG); Haloperidole (DRUG); Quetiapin (DRUG); Escitalopram (DRUG); Citalopram (DRUG); Sertralin (DRUG),77995,Celexa,Dementia,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13246,NCT02407821,The Routine Use of SSRI's at the Initiation of End-stage Renal Disease Treatment (RoSIE),TERMINATED,PHASE2,End Stage Renal Disease,Escitalopram (DRUG); Placebo (DRUG),77995,Celexa,End Stage Renal Disease,Kidney,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13247,NCT01436643,Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression,TERMINATED,PHASE4,Depression; Relapsing-remitting Multiple Sclerosis,Venlafaxine (DRUG); Fluoxetine (DRUG); Citalopram (DRUG); Fingolimod (DRUG),77995,Celexa,Depression; Relapsing-remitting Multiple Sclerosis,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13248,NCT05289830,Escitalopram to Placebo in Patients With Localized Pancreatic Cancer,TERMINATED,PHASE2,Pancreatic Ductal Adenocarcinoma; Periampullary Cancer,Escitalopram (DRUG); Placebo (OTHER),77995,Celexa,Pancreatic Ductal Adenocarcinoma; Periampullary Cancer,Pancreas,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13249,NCT00108563,VISN 20: Prophylactic Treatment of Interferon-Induced Depression in Hepatitis C Patients,COMPLETED,PHASE4,Hepatitis C; Depression,Citalopram or Placebo (DRUG),77995,Celexa,Hepatitis C; Depression,Liver,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13250,NCT03274817,A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol,TERMINATED,PHASE1,Alzheimer Disease,Escitalopram Pill (DRUG); Venlafaxine Pill (DRUG); Placebo Oral Tablet (DRUG),77995,Celexa,Alzheimer Disease,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13251,NCT02386475,Effect of Serotonin and Levodopa in Ischemic Stroke,COMPLETED,PHASE4,Stroke,placebo (OTHER); citalopram (DRUG); sinemet plus (DRUG),77995,Celexa,Stroke,CNS/Brain,Citalopram (hydrobromide),SLC6A4,inhibitor/antagonist,unclear,yes,yes,Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,1.28,230.0 +13252,NCT04500704,"Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC",UNKNOWN,PHASE3,Non Small Cell Lung Cancer,Almonertinib (DRUG); Almonertinib plus carboplatin and pemetrexed (DRUG),162368359,ameile,Non Small Cell Lung Cancer,Lung,Almonertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved in China for NSCLC treatment.,CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC.CS(=O)(=O)O,1.0,57.0 +13253,NCT04671303,To Evaluate the Efficacy and Safety of Anlotinib Combined with Aumolertinib in Lung Cancer,COMPLETED,PHASE2,Lung Cancer,Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets (DRUG),162368359,ameile,Lung Cancer,Lung,Almonertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved in China for NSCLC treatment.,CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC.CS(=O)(=O)O,1.0,57.0 +13254,NCT04905550,Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC,UNKNOWN,PHASE2,Non-Small Cell Lung Cancer (NSCLC),Almonertinib (DRUG); Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT) (RADIATION),162368359,ameile,Non-Small Cell Lung Cancer (NSCLC),Lung,Almonertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved in China for NSCLC treatment.,CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC.CS(=O)(=O)O,1.0,57.0 +13255,NCT06417008,A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer,NOT_YET_RECRUITING,PHASE2,Non-Squamous Non-Small Cell Lung Cancer,HS-20117 (DRUG); Aumolertinib (DRUG),162368359,ameile,Non-Squamous Non-Small Cell Lung Cancer,Lung,Almonertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved in China for NSCLC treatment.,CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC.CS(=O)(=O)O,1.0,57.0 +13256,NCT06585059,Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers,NOT_YET_RECRUITING,PHASE1,Advanced Non-small Cell Lung Cancer,TQB2928 injection + Almonertinib Mesilate Tablets (DRUG),162368359,ameile,Advanced Non-small Cell Lung Cancer,Lung,Almonertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved in China for NSCLC treatment.,CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC.CS(=O)(=O)O,1.0,57.0 +13257,NCT02711826,Treg Therapy in Subclinical Inflammation in Kidney Transplantation,COMPLETED,PHASE1,Kidney Transplant; Adult Living Donor Kidney Transplant Recipients; Renal Transplant; Living Kidney Donor,"Polyclonal Regulatory T Cells (BIOLOGICAL); Everolimus (DRUG); Tacrolimus (DRUG); Mycophenolate mofetil (DRUG); Mycophenolic acid (DRUG); Acetaminophen (DRUG); Diphenhydramine (DRUG); Biopsy, Kidney (PROCEDURE); Blood Draw (PROCEDURE); Leukapheresis (PROCEDURE); IS regimen conversion (PROCEDURE)",3100,Nausen,Kidney Transplant; Adult Living Donor Kidney Transplant Recipients; Renal Transplant; Living Kidney Donor,Kidney,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13258,NCT06704620,Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer,NOT_YET_RECRUITING,PHASE3,Advanced and Metastatic NSCLC,Diphenhydramine (DRUG); Tislelizumab (DRUG); Pemetrexed (DRUG); Albumin paclitaxel (DRUG); Carboplatin (DRUG); Cisplatin (DRUG),3100,Nausen,Non-small Cell Lung Cancer Stage IV,Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13259,NCT03186326,Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer,UNKNOWN,PHASE2,Metastatic Colorectal Cancer; MSI,FOLFOX regimen (DRUG); FOLFIRI Protocol (DRUG); Avelumab (DRUG); Panitumumab (DRUG); Cetuximab (DRUG); Bevacizumab (DRUG); Aflibercept (DRUG),3100,Nausen,Metastatic Colorectal Cancer; MSI,Bowel,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13260,NCT01529320,Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers,COMPLETED,PHASE1,Allergic Contact Eczema,"Adventan® (methylprednisolone aceponate 0,1%) (DRUG)",3100,Nausen,Allergic Contact Eczema,Skin,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13261,NCT03554473,M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers,COMPLETED,PHASE1,"Carcinoma, Small Cell; Lung Cancer; Small Cell Lung Cancer",M7824 (DRUG); Topotecan (DRUG); Temozolomide (DRUG); EKG (DIAGNOSTIC_TEST); CT scan (DIAGNOSTIC_TEST); PET scan (DIAGNOSTIC_TEST); Acetaminophen (DRUG); Antihistamines (DRUG); Diphenhydramine (DRUG); Dexamethasone (DRUG); Epinephrine (DRUG),3100,Nausen,"Carcinoma, Small Cell; Lung Cancer; Small Cell Lung Cancer",Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13262,NCT05673590,Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer,RECRUITING,PHASE3,Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Utidelone Injection (DRUG); Docetaxel Injection (DRUG),3100,Nausen,Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13263,NCT04237090,Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel,COMPLETED,PHASE3,Breast Cancer; Lung Cancer; Ovarian Cancer; Oesophageal Cancer; Head Cancer Neck; Cervical Cancer; Endometrial Cancer,Diphenhydramine (DRUG); Cetirizine (DRUG); Lactose pill (DRUG); Sodium chloride 0.9% (DRUG),3100,Nausen,Breast Cancer; Lung Cancer; Ovarian Cancer; Oesophageal Cancer; Head Cancer Neck; Cervical Cancer; Endometrial Cancer,Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13264,NCT05824390,"A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy",UNKNOWN,PHASE4,IgA Nephropathy,rituximab group (DRUG),3100,Nausen,Kidney Diseases,Kidney,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13265,NCT03688464,Treatment of Nighttime Pruritus in Atopic Dermatitis,WITHDRAWN,EARLY_PHASE1,Atopic Dermatitis,Melatonin (DRUG); Diphenhydramine (DRUG); Placebos (DRUG),3100,Nausen,Atopic Dermatitis,Skin,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13266,NCT00655850,Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Paclitaxel (DRUG); Gemcitabine (DRUG); Avastin (BIOLOGICAL),3100,Nausen,Advanced Non-Small Cell Lung Cancer,Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13267,NCT03004976,Study of Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke,COMPLETED,PHASE2,"Stroke; Stroke, Acute; Brain Injury, Acute",Umbilical Cord Blood (BIOLOGICAL); Placebo (OTHER),3100,Nausen,"Stroke; Stroke, Acute; Brain Injury, Acute",CNS/Brain,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13268,NCT01905631,"Blinded, Randomized Study Evaluating Aurstat Versus Control in the Treatment of Atopic Dermatitis Associated Pruritus",COMPLETED,PHASE2,Pruritus; Atopic Dermatitis,Aurstat Anti-Itch Hydrogel (Aurstat) (DRUG),3100,Nausen,Pruritus; Atopic Dermatitis,Skin,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13269,NCT00515073,Papillary Serous Carcinoma of the Endometrium,COMPLETED,PHASE2,Endometrial Cancer,Paclitaxel (DRUG); Pelvic Radiation (RADIATION); Dexamethasone (DRUG); Cimetidine (DRUG); Diphenhydramine (DRUG),3100,Nausen,Endometrial Cancer,Uterus,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13270,NCT06663631,Study on Hibernation-like Therapy Based on Mechanical Thrombectomy,RECRUITING,PHASE1,Acute Ischemic Stroke,chlorpromazine and promethazine (DRUG); Placebo group (DRUG); endovascular thrombectomy (PROCEDURE); rt-PA (DRUG),3100,Nausen,Acute Ischemic Stroke,CNS/Brain,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13271,NCT03107182,Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer,COMPLETED,PHASE2,HPV-Related Squamous Cell Carcinoma; HNSCC,nab-paclitaxel (DRUG); Carboplatin (DRUG); Nivolumab (DRUG); Cisplatin (DRUG); Hydroxyurea (DRUG); 5-FU (DRUG); Dexamethasone (DRUG); Famotidine (DRUG); Diphenhydramine (DRUG); Paclitaxel (DRUG); Transoral robotic surgery (TORS) (PROCEDURE); Adjuvant RT (RADIATION); Chemoradiotherapy (RADIATION),3100,Nausen,HPV-Related Squamous Cell Carcinoma; HNSCC,Skin,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13272,NCT04629248,A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy,ACTIVE_NOT_RECRUITING,PHASE3,Primary Membranous Nephropathy,Obinutuzumab (DRUG); Tacrolimus (DRUG); Methylprednisolone (DRUG); Acetaminophen (DRUG); Diphenhydramine (DRUG),3100,Nausen,Primary Membranous Nephropathy,Kidney,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13273,NCT05807048,Daratumumab in STK11 Mutated NSCLC,RECRUITING,PHASE2,Non-small Cell Lung Cancer With STK11/LKB1 Mutation,Daratumumab and Hyaluronidase-fihj (DRUG); Pre-Intervention Medication (DRUG); Post-Intervention Medication (DRUG),3100,Nausen,Non-small Cell Lung Cancer With STK11/LKB1 Mutation,Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13274,NCT00445965,Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer,COMPLETED,PHASE2,Brain and Central Nervous System Tumors; Intraocular Melanoma; Lung Cancer; Melanoma (Skin); Metastatic Cancer; Neuroblastoma; Ovarian Cancer; Retinoblastoma; Sarcoma; Small Intestine Cancer,DNA analysis (GENETIC); immunologic technique (OTHER); pharmacological study (OTHER); iodine I 131 monoclonal antibody 3F8 (RADIATION); 131I-3F8 (RADIATION),3100,Nausen,Brain and Central Nervous System Tumors; Intraocular Melanoma; Lung Cancer; Melanoma (Skin); Metastatic Cancer; Neuroblastoma; Ovarian Cancer; Retinoblastoma; Sarcoma; Small Intestine Cancer,Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13275,NCT05232825,"A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis",ACTIVE_NOT_RECRUITING,PHASE3,Relapsing Multiple Sclerosis; Primary Progressive Multiple Sclerosis,Ocrelizumab IV (DRUG); Ocrelizumab SC (DRUG); Methylprednisolone IV (DRUG); Diphenhydramine IV (DRUG); Dexamethasone given orally (DRUG); Desloratadine given orally (DRUG),3100,Nausen,Relapsing Multiple Sclerosis; Primary Progressive Multiple Sclerosis,CNS/Brain,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13276,NCT01332630,TPI 287 in Breast Cancer Metastatic to the Brain,COMPLETED,PHASE2,Breast Cancer,TPI 287 (DRUG); Dexamethasone (DRUG); Benadryl (DRUG); Ranitidine (DRUG),3100,Nausen,Breast Cancer,Breast,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13277,NCT02797522,A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB),TERMINATED,PHASE1,Hepatitis B,ARC-521 Injection (DRUG); Placebo (OTHER); antihistamine (DRUG); acetaminophen (DRUG); entecavir (DRUG); tenofovir (DRUG),3100,Nausen,Hepatitis B,Liver,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13278,NCT00618826,"A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer",COMPLETED,PHASE2,Metastatic Breast Cancer,Paclitaxel (DRUG); Gemcitabine (DRUG); Avastin (DRUG),3100,Nausen,Metastatic Breast Cancer,Breast,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13279,NCT05627557,A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome,ACTIVE_NOT_RECRUITING,PHASE3,Childhood Idiopathic Nephrotic Syndrome,Obinutuzumab (DRUG); MMF (DRUG); Prednisone (DRUG); Methylprednisolone (DRUG); Acetaminophen/ Paracetamol (DRUG); Diphenhydramine Hydrochloride (DRUG),3100,Nausen,Childhood Idiopathic Nephrotic Syndrome,Kidney,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13280,NCT06132958,Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005),RECRUITING,PHASE3,Endometrial Cancer,Sacituzumab tirumotecan (BIOLOGICAL); Doxorubicin (DRUG); Paclitaxel (DRUG); Nab-paclitaxel (DRUG),3100,Nausen,Endometrial Cancer,Uterus,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13281,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,COMPLETED,PHASE3,Renal Cell Carcinoma,Sorafenib (DRUG); temsirolimus (Torisel) (DRUG),3100,Nausen,Renal Cell Carcinoma,Kidney,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13282,NCT06196658,Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer,NOT_YET_RECRUITING,EARLY_PHASE1,Pancreatic Cancer; Advanced Biliary Cancer,anti-EX02 CAR T cells (DRUG),3100,Nausen,Pancreatic Cancer; Advanced Biliary Cancer,Pancreas,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13283,NCT01985789,Anti-histamines and Methacholine Challenges.,COMPLETED,PHASE4,Asthma,Diphenhydramine (DRUG); cetirizine (DRUG); desloratadine (DRUG); placebo (DRUG),3100,Nausen,Asthma,Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13284,NCT01455389,TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer,TERMINATED,PHASE1,Lung Cancer,DOTAP:Chol-TUSC2 (DRUG); Erlotinib (DRUG); Dexamethasone (DRUG); Diphenhydramine (DRUG),3100,Nausen,Lung Cancer,Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13285,NCT02577029,Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV),TERMINATED,PHASE2,Hepatitis B; Hepatitis D,ARC-520 (DRUG); entecavir (DRUG); pegylated interferon alpha 2a (BIOLOGICAL); tenofovir disoproxil (DRUG); antihistamine (DRUG),3100,Nausen,Hepatitis B; Hepatitis D,Liver,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13286,NCT06152991,Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy,ENROLLING_BY_INVITATION,PHASE3,Non-Alcoholic Fatty Liver Disease,GODEX (DRUG); Placebo (DRUG),3100,Nausen,Non-Alcoholic Fatty Liver Disease,Liver,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13287,NCT01729494,Belatacept Early Steroid Withdrawal Trial,COMPLETED,PHASE4,Renal Transplantation,Alemtuzumab (DRUG); rabbit antithymocyte globulin (DRUG); Belatacept (DRUG); Tacrolimus (DRUG); Mycophenolate mofetil (DRUG); early cessation of steroids (DRUG),3100,Nausen,Renal Transplantation,Kidney,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13288,NCT00240994,Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients,COMPLETED,PHASE2,"Kidney Failure, Chronic; Kidney Transplantation; Immunosuppression",Alemtuzumab (DRUG); Tacrolimus (DRUG); Mycophenolate mofetil (DRUG); Sirolimus (DRUG),3100,Nausen,Chronic Kidney Failure and Transplantation,Kidney,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13289,NCT01248962,"Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer",COMPLETED,PHASE2,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer,carboplatin (DRUG); carboplatin (DRUG),3100,Nausen,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13290,NCT04165096,"KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)",ACTIVE_NOT_RECRUITING,PHASE2,"Carcinoma, Non-Small-Cell Lung",Pembrolizumab (BIOLOGICAL); Boserolimab (BIOLOGICAL); MK-4830 (BIOLOGICAL); diphenhydramine (DRUG); acetaminophen (DRUG); MK-0482 (BIOLOGICAL),3100,Nausen,"Carcinoma, Non-Small-Cell Lung",Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13291,NCT01303744,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074,COMPLETED,PHASE2,Alzheimer's Disease,CHF 5074 1x (DRUG); CHF 5074 2x (DRUG); CHF 5074 3x (DRUG); Placebo (DRUG),3100,Nausen,Alzheimer's Disease,CNS/Brain,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13292,NCT02414269,Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin,ACTIVE_NOT_RECRUITING,PHASE1,Malignant Pleural Disease; Mesothelioma; Metastases; Lung Cancer; Breast Cancer,iCasp9M28z T cell infusions (GENETIC); cyclophosphamide (DRUG); pembrolizumab (DRUG),3100,Nausen,Malignant Pleural Disease; Mesothelioma; Metastases; Lung Cancer; Breast Cancer,Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13293,NCT02604212,"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection",TERMINATED,PHASE2,Hepatitis B,ARC-520 (DRUG); Placebo (OTHER); entecavir (DRUG); antihistamine (DRUG); tenofovir (DRUG),3100,Nausen,Hepatitis B,Liver,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13294,NCT01847001,Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy,COMPLETED,PHASE2,Locally Advanced Malignant Neoplasm; Breast Cancer,Propranolol (DRUG); DOT imaging (OTHER); Paclitaxel (DRUG); Nab-paclitaxel (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); Doxorubicin (DRUG); Cyclophosphamide (DRUG); Surgery (PROCEDURE); Premedication (DRUG); Anti-nausea therapy (DRUG); Pegfilgrastim (DRUG),3100,Nausen,Locally Advanced Malignant Neoplasm; Breast Cancer,Breast,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13295,NCT00030992,BMS 247550 to Treat Kidney Cancer,COMPLETED,PHASE2,Renal Cell Carcinoma,BMS-247550 (DRUG); Ranitidine (DRUG); Diphenhydramine (DRUG),3100,Nausen,Renal Cell Carcinoma,Kidney,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13296,NCT02504489,Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC,COMPLETED,PHASE3,Non-Small Cell Lung Cancer,Docetaxel + Plinabulin (DP) (DRUG); Docetaxel (D) (DRUG),3100,Nausen,Advanced Non-Small Cell Lung Cancer,Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13297,NCT04224558,Stem Cell Transplantation in Crohn's Disease,RECRUITING,PHASE1,Crohn Disease,Mesna (DRUG); Cyclophosphamide (DRUG); Filgrastim (DRUG); Apheresis catheter placement (PROCEDURE); Leukapheresis (PROCEDURE); Fludarabine (DRUG); Methylprednisolone (DRUG); Diphenhydramine (DRUG); Acetaminophen (DRUG); anti-thymocyte globulin (rabbit) (DRUG); lymphocyte immune globulin (DRUG); Peripheral Blood Stem Cell Infusion (BIOLOGICAL); Cytoxan (DRUG),3100,Nausen,Crohn Disease,Bowel,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13298,NCT06120673,REmission in Membranous Nephropathy International Trial (REMIT),NOT_YET_RECRUITING,PHASE3,Primary Membranous Nephropathy,Obinutuzumab (DRUG); Oral prednisolone and cyclophosphamide (DRUG),3100,Nausen,Primary Membranous Nephropathy,Kidney,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13299,NCT02142712,Histamine Glutamate Antagonism in Stroke,COMPLETED,PHASE2,Acute Cerebrovascular Accident; Cerebral Edema,Diphenhydramine (DRUG); Pantoprazole (DRUG); Famotidine (DRUG); Dextromethorphan (DRUG),3100,Nausen,Acute Cerebrovascular Accident; Cerebral Edema,CNS/Brain,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13300,NCT00166712,A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression,TERMINATED,PHASE4,Kidney Transplant Failure and Rejection,Tacrolimus (TAC) (DRUG); Sirolimus (DRUG); Alemtuzumab (DRUG); Mycophenolate mofetil (MMF) (DRUG),3100,Nausen,Kidney Transplant Failure and Rejection,Kidney,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13301,NCT04474340,COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients,UNKNOWN,PHASE1,"Moderate COVID-19 Pneumonia, Severe COVID-19 Pneumonia; Pneumonia, Viral",COVID-19 Convalscent Plasma (DRUG),3100,Nausen,"Moderate COVID-19 Pneumonia, Severe COVID-19 Pneumonia; Pneumonia, Viral",Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13302,NCT04315467,Intraoperative Imaging of Pulmonary Nodules by SGM-101,COMPLETED,PHASE1,Lung Cancer; Lung Nodule; Non Small Cell Lung Cancer,SGM-101 (DRUG); Near infrared camera imaging system (DEVICE),3100,Nausen,Lung Cancer; Lung Nodule; Non Small Cell Lung Cancer,Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13303,NCT00837941,A Study of Single Dose Pain Therapy in Patients With Painful Diabetic Neuropathy (0000-115),WITHDRAWN,PHASE2,Painful Diabetic Neuropathy,Comparator: A: Pregabalin (DRUG); Comparator: B: Duloxetine (DRUG); Comparator: C: Diphenhydramine hydrochloride (DRUG),3100,Nausen,Painful Diabetic Neuropathy,Peripheral Nervous System,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13304,NCT06124118,Tumor Treating Fields for Locally Advanced NSCLC,RECRUITING,PHASE1,Non Small Cell Lung Cancer,carboplatin chemotherapy (RADIATION); NovoTTF-200T (TTFields) System (DEVICE); Durvalumab (DRUG),3100,Nausen,Non Small Cell Lung Cancer,Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13305,NCT02188719,Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation,TERMINATED,PHASE1,Liver Transplantation,Anti-Thymocyte Globulin - Rabbit (BIOLOGICAL); darTreg Infusion (BIOLOGICAL); Everolimus (DRUG); Tacrolimus (DRUG); Mycophenolate mofetil (DRUG); Prednisone (DRUG); Acetaminophen (DRUG); Diphenhydramine (DRUG); Anti-Infective Prophylaxis (DRUG); Leukapheresis (PROCEDURE); Blood draws (PROCEDURE); Liver biopsies (PROCEDURE); Liver transplantation (PROCEDURE),3100,Nausen,Liver Transplantation,Liver,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13306,NCT01638234,Effectiveness of Melatonin for Sleep Disturbances in Children With Atopic Dermatitis,COMPLETED,PHASE2,Atopic Dermatitis,Melatonin (DIETARY_SUPPLEMENT); Placebo (DIETARY_SUPPLEMENT),3100,Nausen,Atopic Dermatitis,Skin,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13307,NCT05265234,Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.,UNKNOWN,PHASE4,Eczema; Atopic Dermatitis,Dupilumab (DRUG); Optical Coherence Tomography (DEVICE); Reflectance confocal microscopy (DEVICE),3100,Nausen,Eczema; Atopic Dermatitis,Skin,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13308,NCT05768919,Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas,RECRUITING,PHASE1,Glioblastoma,Treatment Period 1 (DRUG); Treatment Period 2 (DRUG); Treatment Period 3 (DRUG); Treatment Period 4a (DRUG),3100,Nausen,Glioblastoma,CNS/Brain,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13309,NCT02347319,To Evaluate the Efficacy of DDB/Garlic Oil in Patients With Elevated Transaminase Chronic Liver Disease,COMPLETED,PHASE4,Chronic Liver Disease,Pennel (DRUG); Legalon (DRUG); Placebo (DRUG),3100,Nausen,Hepatic Impairment,Liver,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13310,NCT05039619,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants",RECRUITING,PHASE2,Lupus Nephritis,Obinutuzumab (DRUG); Placebo (DRUG); Mycophenolate Mofetil (DRUG); Acetaminophen/paracetamol (DRUG); Diphenhydramine hydrochloride (HCl) (DRUG); Methylprednisolone (DRUG); Prednisone (DRUG),3100,Nausen,Lupus Nephritis,Kidney,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13311,NCT00226941,"A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer",TERMINATED,PHASE1,Rectal Cancer; Colo-rectal Cancer,Cetuximab (DRUG); Oxaliplatin (DRUG); Capecitabine (DRUG); Radiotherapy (RADIATION); Diphenhydramine hydrochloride (HCl) (DRUG),3100,Nausen,Rectal Cancer; Colo-rectal Cancer,Bowel,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13312,NCT02792114,T-Cell Therapy for Advanced Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer; Metastatic HER2-negative Breast,Cyclophosphamide (DRUG); Mesothelin-targeted T cells (BIOLOGICAL); AP1903 (DRUG),3100,Nausen,Breast Cancer; Metastatic HER2-negative Breast,Breast,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13313,NCT01732510,A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003),TERMINATED,PHASE1,Atopic Dermatitis,MK-8226 (DRUG); Placebo (DRUG),3100,Nausen,Atopic Dermatitis,Skin,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13314,NCT05866510,Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer,UNKNOWN,PHASE2,Esophageal Cancer,Utidelone and anlotinib (DRUG),3100,Nausen,Esophageal Cancer,Esophagus/Stomach,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13315,NCT01846455,Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects,COMPLETED,PHASE4,Hepatic Failure; Hepatic Impairment; Chronic Hepatitis C Infection With Hepatic Coma,2.0mg Buprenorphine/0.5mg Naloxone (DRUG); Promethazine (DRUG),3100,Nausen,Hepatic Failure; Hepatic Impairment; Chronic Hepatitis C Infection With Hepatic Coma,Liver,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13316,NCT02738008,Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection,TERMINATED,PHASE2,Hepatitis B,ARC-520 Injection (DRUG); entecavir (DRUG); tenofovir (DRUG); antihistamine (DRUG),3100,Nausen,Hepatitis B,Liver,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13317,NCT00240123,Effect of Benadryl Sedation During ERCP or EUS,WITHDRAWN,PHASE1,Gallbladder Disease; Gallstones; Pancreatitis; Abdominal Pain; Jaundice,Benadryl versus Placebo (DRUG),3100,Nausen,Gallbladder Disease; Gallstones; Pancreatitis; Abdominal Pain; Jaundice,Pancreas,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13318,NCT01144650,Dapsone for Acute Ischemia Stroke Study,UNKNOWN,PHASE2,"Cerebral Stroke; Cerebrovascular Accident, Acute; Cerebrovascular Stroke; Stroke, Acute; Stroke",Dapsone (DRUG); Placebo (DRUG),3100,Nausen,"Cerebral Stroke; Cerebrovascular Accident, Acute; Cerebrovascular Stroke; Stroke, Acute; Stroke",CNS/Brain,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13319,NCT03644550,Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma,TERMINATED,PHASE2,Mesothelioma,LMB-100 (DRUG); Pembrolizumab (BIOLOGICAL),3100,Nausen,Mesothelioma,Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13320,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",ACTIVE_NOT_RECRUITING,PHASE3,Multiple Sclerosis,Ocrelizumab (DRUG); Ocrelizumab (DRUG); Antihistamine (DRUG); Methylprednisolone (DRUG),3100,Nausen,Multiple Sclerosis,CNS/Brain,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13321,NCT01953536,Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004),WITHDRAWN,PHASE2,Breast Neoplasms,Vintafolide 2.5 mg (DRUG); Paclitaxel 80 mg/m^2 (DRUG); Etarfolatide (DRUG); Folic acid (DRUG); Premedication for Paclitaxel (DRUG),3100,Nausen,Breast Neoplasms,Breast,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13322,NCT02604199,"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection",TERMINATED,PHASE2,Hepatitis B,ARC-520 Injection (DRUG); placebo (OTHER); entecavir (DRUG); tenofovir (DRUG); antihistamine (DRUG),3100,Nausen,Hepatitis B,Liver,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13323,NCT00199342,"A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma",TERMINATED,PHASE1,Stage IV Melanoma,KW-2871 (DRUG),3100,Nausen,Stage IV Melanoma,Skin,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13324,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",ACTIVE_NOT_RECRUITING,PHASE3,Multiple Sclerosis,Ocrelizumab (DRUG); Ocrelizumab (DRUG); Antihistamine (DRUG); Methylprednisolone (DRUG),3100,Nausen,Multiple Sclerosis,CNS/Brain,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13325,NCT01203384,"Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects",COMPLETED,PHASE1,Alzheimer's Disease,CHF5074 1x (DRUG); CHF5074 2x (DRUG); CHF5074 3x (DRUG); Placebo (DRUG),3100,Nausen,Alzheimer's Disease,CNS/Brain,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13326,NCT04375384,Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer,RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head-and-neck Squamous-cell Carcinoma,Cetuximab (DRUG); Questionnaire administration (OTHER); Quality of life assessment (OTHER),3100,Nausen,Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head-and-neck Squamous-cell Carcinoma,Skin,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13327,NCT04862221,TReatment for ImmUne Mediated PathopHysiology,RECRUITING,PHASE2,Acute Liver Failure; Fulminant Hepatic Failure; Hepatic Encephalopathy; Acute Liver Injury; Immune Dysregulation,High-dose methylprednisolone (DRUG); Equine anti-thymocyte globulin (DRUG); Prednisolone (DRUG); Placebo for prednisolone (DRUG); Placebo for infusions (DRUG); Diphenhydramine (DRUG); Methylprednisolone (DRUG),3100,Nausen,Acute Liver Failure; Fulminant Hepatic Failure; Hepatic Encephalopathy; Acute Liver Injury; Immune Dysregulation,Liver,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13328,NCT02029638,BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance,TERMINATED,PHASE2,Kidney Transplantation,anti-thymocyte globulin (BIOLOGICAL); Fludarabine (DRUG); Cyclophosphamide (DRUG); Total Body Irradiation (RADIATION); acetaminophen (DRUG); diphenhydramine (DRUG); methylprednisolone (DRUG); bone marrow transplant (BIOLOGICAL); MESNA (DRUG); mycophenolate mofetil (DRUG); prednisone (DRUG); filgrastim (DRUG),3100,Nausen,Kidney Transplantation,Kidney,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13329,NCT00076570,Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation,COMPLETED,PHASE2,Kidney Transplantation,Sirolimus (DRUG); Tacrolimus (DRUG),3100,Nausen,Kidney Transplantation,Kidney,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13330,NCT01723670,Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment,WITHDRAWN,PHASE2,Alzheimer's Disease,CHF 5074 1x (DRUG); CHF 5074 2x (DRUG); Placebo (DRUG),3100,Nausen,Alzheimer's Disease,CNS/Brain,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13331,NCT02260934,Rituximab and Belimumab for Lupus Nephritis,COMPLETED,PHASE2,Lupus Nephritis,Rituximab (BIOLOGICAL); Cyclophosphamide (DRUG); Prednisone (DRUG); Methylprednisolone (DRUG); Diphenhydramine (DRUG); Acetaminophen (DRUG); Rituximab (BIOLOGICAL); Cyclophosphamide (DRUG); Prednisone (DRUG); Methylprednisolone (DRUG); Diphenhydramine (DRUG); Acetaminophen (DRUG); Belimumab (BIOLOGICAL),3100,Nausen,Lupus Nephritis,Kidney,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13332,NCT04175834,Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab,COMPLETED,PHASE3,Multiple Sclerosis; Infusion Reaction,cetrizine (DRUG); diphenhydramine (DRUG),3100,Nausen,Multiple Sclerosis; Infusion Reaction,CNS/Brain,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13333,NCT00078559,Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults,COMPLETED,PHASE1,Kidney Transplantation; Kidney Disease,"Alemtuzumab (DRUG); Sirolimus (DRUG); Tacrolimus (DRUG); Kidney transplant (PROCEDURE); Methylprednisolone (or equivalent) (DRUG); Acetaminophen (DRUG); Diphenhydramine (DRUG); Trimethoprim (TMP)/Sulfa (Bactrim, Septra) (DRUG); Valgancyclovir (DRUG); Acyclovir (DRUG); Pentamidine (DRUG); Clotrimazole (DRUG); Nystatin (DRUG)",3100,Nausen,Kidney Transplantation; Kidney Disease,Kidney,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13334,NCT04382352,B002 in Patients With HER2-positive Breast Cancer,COMPLETED,PHASE1,Recurrent Breast Cancer; Metastatic Breast Cancer,Humanized Anti-HER2 Monoclonal Antibody Compound for Injection .R&D code: B002. (BIOLOGICAL),3100,Nausen,Recurrent Breast Cancer; Metastatic Breast Cancer,Breast,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13335,NCT02765256,Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease,COMPLETED,PHASE2,Crohn's Disease,Fluconazole (DRUG); Vancomycin (DRUG); Neomycin (DRUG); Ciprofloxacin (DRUG); Polyethylene Glycol 3350 (DRUG); Promethazine (DRUG); Fluconazole placebo (DRUG),3100,Nausen,Crohn's Disease,Bowel,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13336,NCT04308837,A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation,RECRUITING,PHASE2,Gastric Cancer; Stomach Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Dexamethasone (DRUG); Diphenhydramine (DRUG); Famotidine (DRUG); Palonosetron (DRUG); 3D conformal or intensity modulated radiotherapy (RADIATION); Surgical resection (PROCEDURE); Adjuvant Chemotherapy (RADIATION),3100,Nausen,Gastric Cancer; Stomach Cancer,Esophagus/Stomach,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13337,NCT02075632,Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream,COMPLETED,PHASE2,Eczema; Allergy Symptoms; Psoriasis; Itch,Alclometasone dipropionate cream (DRUG),3100,Nausen,Eczema; Allergy Symptoms; Psoriasis; Itch,Skin,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13338,NCT01258452,Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects,COMPLETED,PHASE1,Alzheimer's Disease,CHF 5074 (DRUG); CHF 5974 (DRUG),3100,Nausen,Alzheimer's Disease,CNS/Brain,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13339,NCT00954252,"Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male Subjects",COMPLETED,PHASE1,Alzheimer's Disease,CHF 5074 (DRUG); placebo (DRUG); CHF 5074 (DRUG); CHF 5074 (DRUG); CHF 5074 (DRUG); CHF 5074 (DRUG); CHF 5074 (DRUG),3100,Nausen,Alzheimer's Disease,CNS/Brain,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13340,NCT04862585,Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel,COMPLETED,PHASE2,Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Breast Carcinoma; Prognostic Stage 0 Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8,Cimetidine (DRUG); Dexamethasone (DRUG); Diphenhydramine (DRUG); Famotidine (DRUG); Paclitaxel (DRUG); Quality-of-Life Assessment (OTHER); Ranitidine (DRUG),3100,Nausen,Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Breast Carcinoma; Prognostic Stage 0 Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8,Breast,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13341,NCT01421056,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP),COMPLETED,PHASE2,Alzheimer's Disease,CHF 5074 1x (DRUG); CHF 5074 2x (DRUG); CHF 5074 3x (DRUG),3100,Nausen,Alzheimer's Disease,CNS/Brain,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13342,NCT02474199,Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction,COMPLETED,PHASE1,Liver Transplant Recipient; Living Donor (of the Respective Liver Transplant Recipient),darTregs (BIOLOGICAL); Acetaminophen (DRUG); Diphenhydramine (DRUG); Immunosuppression (IS) Withdrawal (DRUG); Study Mandated Procedures (PROCEDURE),3100,Nausen,Liver Transplant Recipient; Living Donor (of the Respective Liver Transplant Recipient),Liver,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13343,NCT01866449,Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme,COMPLETED,PHASE2,Glioblastoma Multiforme (GBM) WHO Grade IV,Cabazitaxel (DRUG),3100,Nausen,Glioblastoma Multiforme (GBM) WHO Grade IV,CNS/Brain,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13344,NCT06084845,"Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer",WITHDRAWN,PHASE2,Head and Neck Squamous Cell Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Oral Cavity Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Hypopharyngeal Carcinoma AJCC v8; Stage IV Laryngeal Cancer AJCC v8; Stage IV Lip and Oral Cavity Cancer AJCC v8; Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8,Biospecimen Collection (PROCEDURE); Carboplatin (DRUG); Chest Radiography (PROCEDURE); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Image Guided Radiation Therapy (RADIATION); Intensity-Modulated Radiation Therapy (RADIATION); Magnetic Resonance Imaging (PROCEDURE); Positron Emission Tomography (PROCEDURE); Xevinapant (DRUG),3100,Nausen,Head and Neck Squamous Cell Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Oral Cavity Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Hypopharyngeal Carcinoma AJCC v8; Stage IV Laryngeal Cancer AJCC v8; Stage IV Lip and Oral Cavity Cancer AJCC v8; Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8,Skin,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13345,NCT01967433,Diphenhydramine as an Adjunctive Sedative in Patients on Chronic Opioids,COMPLETED,PHASE4,Colonoscopy; Adjunct Anesthesia Medication,Diphenhydramine (DRUG); Placebo (DRUG),3100,Nausen,Colonoscopy; Adjunct Anesthesia Medication,Bowel,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13346,NCT00346151,Belatacept to Prevent Organ Rejection in Kidney Transplant Patients,TERMINATED,PHASE2,Renal Transplant,Belatacept (DRUG); Sirolimus (DRUG); Anti-thymocyte globulin (DRUG); methylprednisolone (DRUG),3100,Nausen,Renal Transplant,Kidney,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13347,NCT00282347,A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis,COMPLETED,PHASE3,Lupus Nephritis,Rituximab (DRUG); Placebo (DRUG); Mycophenolate mofetil (DRUG); Methylprednisolone (DRUG); Diphenhydramine (DRUG); Acetaminophen (DRUG); Prednisone (DRUG),3100,Nausen,Lupus Nephritis,Kidney,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13348,NCT04221477,A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis,ACTIVE_NOT_RECRUITING,PHASE3,Lupus Nephritis,Obinutuzumab (DRUG); MMF (DRUG); Prednisone (DRUG); Placebo (DRUG); Methylprednisolone (DRUG); Acetaminophen (DRUG); Diphenhydramine (DRUG),3100,Nausen,Lupus Nephritis,Kidney,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13349,NCT01208337,Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation,COMPLETED,PHASE2,Evidence of Liver Transplantation; Rejection; ALEMTUZUMAB,Alemtuzumab (DRUG),3100,Nausen,Evidence of Liver Transplantation; Rejection; ALEMTUZUMAB,Liver,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13350,NCT04840615,Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma,TERMINATED,PHASE1,Mesothelioma,LMB-100 (BIOLOGICAL); ipilimumab (DRUG); Diphenhydramine (DRUG); Famotidine (DRUG); Acetaminophen (DRUG); Dexamethasone (DRUG); Biopsy (PROCEDURE); FDG-PET (DIAGNOSTIC_TEST); CT CAP (DIAGNOSTIC_TEST); MRI (DIAGNOSTIC_TEST); ECG (DIAGNOSTIC_TEST); Echocardiogram (DIAGNOSTIC_TEST),3100,Nausen,Mesothelioma,Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13351,NCT02688985,Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS),COMPLETED,PHASE3,"Relapsing Multiple Sclerorsis; Multiple Sclerosis, Primary Progressive",Ocrelizumab (DRUG); Lumbar Puncture (PROCEDURE); Methyloprednisolone (DRUG); Antihistamine (DRUG),3100,Nausen,"Relapsing Multiple Sclerorsis; Multiple Sclerosis, Primary Progressive",CNS/Brain,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13352,NCT06074588,Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004),RECRUITING,PHASE3,Non-small Cell Lung Cancer (NSCLC),Sacituzumab tirumotecan (BIOLOGICAL); Docetaxel (DRUG); Pemetrexed (DRUG),3100,Nausen,Non-small Cell Lung Cancer (NSCLC),Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13353,NCT05461456,Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%,COMPLETED,PHASE1,Atopic Dermatitis; Atopic Dermatitis Eczema; Atopic Rash; Rash; Pruritus; Urticaria; Urticaria Chronic; Psoriasis; Psoriasis Vulgaris; Skin Rash; Skin Inflammation; Eczema,Fexofenadine Hydrochloride Topical Lotion 1% (OP2101) (DRUG),3100,Nausen,Atopic Dermatitis; Atopic Dermatitis Eczema; Atopic Rash; Rash; Pruritus; Urticaria; Urticaria Chronic; Psoriasis; Psoriasis Vulgaris; Skin Rash; Skin Inflammation; Eczema,Skin,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13354,NCT00103207,Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer,COMPLETED,PHASE2,Lung Cancer,cetuximab (BIOLOGICAL),3100,Nausen,Lung Cancer,Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13355,NCT06170788,Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007),RECRUITING,PHASE3,Non-small Cell Lung Cancer (NSCLC),Sacituzumab tirumotecan (BIOLOGICAL); Pembrolizumab (BIOLOGICAL),3100,Nausen,Non-small Cell Lung Cancer (NSCLC),Lung,Diphenhydramine,HRH1,inhibitor/antagonist,unclear,yes,yes,"Approved antihistamine, used for allergies and as a sleep aid.",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,1.09,319.0 +13356,NCT02315326,"Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)",RECRUITING,PHASE1,Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL); Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL),Ibrutinib (DRUG); HD- Methotrexate (MTX) (DRUG); Rituximab + HD- Methotrexate (MTX) (DRUG); procarbazine (DRUG),126941,MTX,Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL); Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL),CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13357,NCT00004748,Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis,COMPLETED,PHASE3,"Liver Cirrhosis, Biliary",colchicine (DRUG); methotrexate (DRUG); ursodiol (DRUG),126941,MTX,Biliary Liver Cirrhosis,Liver,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13358,NCT00235820,Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis,COMPLETED,PHASE3,Psoriasis,"adalimumab (DRUG); MTX (DRUG); placebo adalimumab, placebo MTX (DRUG)",126941,MTX,Psoriasis,Skin,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13359,NCT02772965,Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy,COMPLETED,PHASE3,Pediatric Crohn's Disease,Methotrexate (DRUG); Sugar pill (placebo) (OTHER),126941,MTX,Pediatric Crohn's Disease,Bowel,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13360,NCT01011920,Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma,COMPLETED,PHASE2,Central Nervous System Lymphoma,Methotrexate (DRUG); Ara-C (DRUG); Rituximab (DRUG); Thiotepa (DRUG); radiotherapy (RADIATION); BCNU (DRUG); APBSCT (OTHER),126941,MTX,Central Nervous System Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13361,NCT06454266,"First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)",COMPLETED,PHASE2,Primary Central Nervous System Lymphoma,ORM regimen (DRUG),126941,MTX,Primary Central Nervous System Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13362,NCT06476366,Comparison of Efficacy of Methotrexate and Azathioprine in Patients With Chronic Actinic Dermatitis: A Randomized Controlled Trial,RECRUITING,EARLY_PHASE1,Chronic Actinic Dermatitis,Azathioprine (DRUG); Methotrexate (DRUG),126941,MTX,Chronic Actinic Dermatitis,Skin,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13363,NCT01031420,Dose Dense MVAC for Muscle Invasive Bladder Cancer,COMPLETED,PHASE2,Muscle Invasive Bladder Cancer; High Risk Urothelial Carcinoma of the Upper Urinary Tracts,single arm dose dense MVAC (DRUG),126941,MTX,Muscle Invasive Bladder Cancer; High Risk Urothelial Carcinoma of the Upper Urinary Tracts,Bladder/Urinary Tract,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13364,NCT02066220,International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma,ACTIVE_NOT_RECRUITING,PHASE2,Brain Tumors,Radiotherapy without Carboplatin (RADIATION); Reduced-intensity maintenance chemotherapy (DRUG); Radiotherapy with Carboplatin (RADIATION); Maintenance chemotherapy (DRUG); WNT-HR < 16 years (RADIATION); WNT-HR >= 16 years (RADIATION); Induction Chemotherapy (DRUG); SHH-TP53 M0 (RADIATION); SHH-TP53 M+ (germline) (RADIATION); SHH-TP53 (somatic) (RADIATION); Vinblastin Maintenance (DRUG),126941,MTX,Brain Tumors,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13365,NCT00083031,Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,bevacizumab (DRUG); cyclophosphamide (DRUG); methotrexate (DRUG),126941,MTX,Breast Cancer,Breast,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13366,NCT00397501,BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain,WITHDRAWN,PHASE1,Brain and Central Nervous System Tumors; Breast Cancer; Cognitive/Functional Effects; Drug/Agent Toxicity by Tissue/Organ; Psychosocial Effects of Cancer and Its Treatment,trastuzumab (BIOLOGICAL); carboplatin (DRUG); methotrexate (DRUG); sodium thiosulfate (DRUG),126941,MTX,Brain and Central Nervous System Tumors; Breast Cancer; Cognitive/Functional Effects; Drug/Agent Toxicity by Tissue/Organ; Psychosocial Effects of Cancer and Its Treatment,Breast,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13367,NCT05222269,[68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients,TERMINATED,PHASE2,CNS Lymphoma,68Ga-PTF (DRUG),126941,MTX,CNS Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13368,NCT04931368,OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma,RECRUITING,PHASE3,Primary Central Nervous System Lymphoma,"Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix (DRUG); Control intervention: four courses of MATRix (DRUG)",126941,MTX,Primary Central Nervous System Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13369,NCT02097173,Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen,COMPLETED,PHASE1,Psoriasis,Methotrexate (DRUG),126941,MTX,Psoriasis,Skin,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13370,NCT01960192,Treatment of Primary CNS Lymphoma,UNKNOWN,PHASE4,Primary CNS Lymphoma (PCNSL),HD-MTX-Ara-C regimen (DRUG); FVD regimen (DRUG),126941,MTX,Primary CNS Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13371,NCT06543992,Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate in Breast Cancer With Leptomeningeal Metastasis,RECRUITING,PHASE2,Leptomeningeal Metastasis of Breast Cancer,Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir (DRUG),126941,MTX,Leptomeningeal Metastasis of Breast Cancer,Breast,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13372,NCT00863460,Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients,ACTIVE_NOT_RECRUITING,PHASE2,Primary Central Nervous System Lymphoma,cranial radiotherapy (RADIATION); intensive chemotherapy and hematopoietic stem cell rescue (DRUG); MTX based chemotherapy (DRUG),126941,MTX,Primary Central Nervous System Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13373,NCT05054426,Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL,RECRUITING,PHASE3,Diffuse Large B Cell Lymphoma; Central Nervous System Lymphoma,Methotrexate (DRUG),126941,MTX,Diffuse Large B Cell Lymphoma; Central Nervous System Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13374,NCT00153530,Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL),COMPLETED,PHASE4,Central Nervous System Lymphoma,methotrexate (DRUG); radiotherapy (RADIATION),126941,MTX,Central Nervous System Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13375,NCT01458730,Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma,COMPLETED,PHASE2,Central Nervous System Lymphoma,Immunochemotherapy (DRUG),126941,MTX,Central Nervous System Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13376,NCT05274139,Treatment of Primary CNS Lymphoma ( FTD ),COMPLETED,PHASE2,Primary CNS Lymphoma (PCNSL),HD-MTX-Ara-C regimen (DRUG); FTD regimen (DRUG),126941,MTX,Primary CNS Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13377,NCT00734773,Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL,WITHDRAWN,EARLY_PHASE1,Brain and Central Nervous System Tumors; Lymphoma; Neurotoxicity,Rituximab (BIOLOGICAL); Cytarabine (DRUG); Methotrexate (DRUG); Motexafin gadolinium (DRUG); Procarbazine hydrochloride (DRUG); Vincristine sulfate (DRUG); Radiation therapy (RADIATION),126941,MTX,Brain and Central Nervous System Conditions,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13378,NCT00577122,Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer,COMPLETED,PHASE2,Estrogen Receptor-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer,Medroxyprogesterone progesterone acetate (MPA) (DRUG); Medroxyprogesterone with Cyclophosphamide + Methotrexate (DRUG),126941,MTX,Estrogen Receptor-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer,Breast,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13379,NCT06940791,Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104),RECRUITING,PHASE2,Primary Central Nervous System Lymphoma,Tirabrutinib (DRUG); Placebo (DRUG),126941,MTX,Primary Central Nervous System Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13380,NCT02280694,Low Dose Metronomic Poly-chemotherapy for Metastatic CRC,COMPLETED,PHASE2,Colorectal Cancer,Capecitabine (DRUG); Cyclophosphamide (DRUG); Methotrexate (DRUG); Celecoxib (DRUG),126941,MTX,Colorectal Cancer,Bowel,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13381,NCT00194792,Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer,TERMINATED,PHASE2,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer,exemestane (DRUG); triptorelin pamoate (DRUG); capecitabine (DRUG); methotrexate (DRUG); vinorelbine tartrate (DRUG); paclitaxel (DRUG); therapeutic conventional surgery (PROCEDURE); radiation therapy (RADIATION); laboratory biomarker analysis (OTHER),126941,MTX,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer,Breast,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13382,NCT02313389,Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma,UNKNOWN,PHASE3,Primary Central Nervous System Lymphoma,"Rituximab, Methotrexate, Temozolomide (DRUG)",126941,MTX,Primary Central Nervous System Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13383,NCT02399189,MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma,UNKNOWN,PHASE2,Primary Central Nervous System Lymphoma,R-MT followed by auto-HSCT (DRUG),126941,MTX,Primary Central Nervous System Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13384,NCT02852694,Reduce Risk for Crohn's Disease Patients,COMPLETED,PHASE4,Crohn's Disease,Methotrexate (DRUG); Adalimumab (DRUG); Azathioprine / 6 Mercaptopurine (DRUG),126941,MTX,Crohn's Disease,Bowel,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13385,NCT02657460,Clinical Trial of Tumor Cell-derived Microparticles Packaging Chemotherapeutic Drugs to Treat Malignant Pleural Effusion,UNKNOWN,PHASE2,Malignant Pleural Effusion,tumor derived microparticles (BIOLOGICAL); cisplatin (DRUG),126941,MTX,Malignant Pleural Effusion,Lung,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13386,NCT03684980,LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma,RECRUITING,EARLY_PHASE1,Central Nervous System Lymphoma,Methotrexate (DRUG); Rituximab (DRUG); leucovorin (DRUG); Glucarpidase (DRUG),126941,MTX,Central Nervous System Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13387,NCT00455286,a Phase II Study in Primary Central Nervous System Lymphoma,UNKNOWN,PHASE2,Primary Central Nervous System Lymphoma,Methotrexate (DRUG); Methylprednisolone (DRUG); Temozolomide (DRUG),126941,MTX,Primary Central Nervous System Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13388,NCT05901324,"Efficacy of Lenalidomide Maintenance in Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma: a Phase II, Open-label, Single-arm Study",NOT_YET_RECRUITING,PHASE2,Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma,intensity-modulated radiotherapy (IMRT) (RADIATION),126941,MTX,Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13389,NCT02829424,Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis,ACTIVE_NOT_RECRUITING,PHASE4,Psoriasis,Methotrexate (DRUG); Methotrexate Placebo (DRUG),126941,MTX,Psoriasis,Skin,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13390,NCT00022516,Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer,COMPLETED,PHASE3,Breast Cancer,Cyclophosphamide (DRUG); Methotrexate (DRUG),126941,MTX,Breast Cancer,Breast,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13391,NCT01716039,Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC),TERMINATED,PHASE2,Ulcerative Colitis,MTX 12.5 (DRUG); MTX 25 (DRUG); Adalimumab (DRUG),126941,MTX,Ulcerative Colitis,Bowel,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13392,NCT05135858,Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma,RECRUITING,PHASE1,Primary Central Nervous System Lymphoma,Glucarpidase (DRUG); Methotrexate (MTX) (DRUG),126941,MTX,Primary Central Nervous System Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13393,NCT05600660,"Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma",RECRUITING,PHASE2,Primary Central Nervous System Lymphoma,Orelabrutinib (DRUG); Rituximab (DRUG); Methotrexate (DRUG),126941,MTX,Primary Central Nervous System Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13394,NCT02177695,"S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",COMPLETED,PHASE2,Bladder Cancer,Gemcitabine (DRUG); Cisplatin (DRUG); Methotrexate (DRUG); Vinblastine (DRUG); Doxorubicin (DRUG); Filgrastim (DRUG),126941,MTX,Bladder Cancer,Bladder/Urinary Tract,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13395,NCT02634801,A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment,COMPLETED,PHASE3,Plaque Psoriasis,Fumaric Acid Esters (DRUG); Methotrexate (DRUG); Ixekizumab (DRUG),126941,MTX,Plaque Psoriasis,Skin,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13396,NCT00149201,A Study of 5-FU Versus MTX+5-FU in Gastric Cancer With Peritoneal Metastasis,COMPLETED,PHASE3,Gastric Cancer; Neoplasm Metastasis,5-FU continuous infusion (DRUG); MTX + 5-FU sequential therapy (DRUG),126941,MTX,Gastric Cancer; Neoplasm Metastasis,Esophagus/Stomach,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13397,NCT03082144,Concurrent Involved-field Radiotherapy and Intrathecal Chemotherapy for Leptomeningeal Metastases From Solid Tumors,COMPLETED,PHASE2,Leptomeningeal Metastasis,MTX (DRUG); Ara-C (DRUG); Radiotherapy (RADIATION),126941,MTX,Leptomeningeal Metastasis,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13398,NCT00602667,"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",ACTIVE_NOT_RECRUITING,PHASE2,Brain and Central Nervous System Tumors,Induction Chemotherapy (DRUG); Low-Risk Therapy (DRUG); High-Risk Therapy (DRUG); Intermediate-Risk Therapy (DRUG),126941,MTX,Brain and Central Nervous System Tumors,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13399,NCT02934204,Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma,UNKNOWN,PHASE2,Primary CNS Lymphoma,methotrexate (DRUG); temozolomide (DRUG),126941,MTX,Primary CNS Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13400,NCT02196701,Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study,COMPLETED,PHASE3,Psoriasis,Adalimumab (DRUG); Methotrexate (DRUG),126941,MTX,Psoriasis,Skin,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13401,NCT02248792,"Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study.",UNKNOWN,PHASE4,Severe Plaque Type Psoriasis,Methotrexate (DRUG),126941,MTX,Severe Plaque Type Psoriasis,Skin,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13402,NCT02836158,Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL,RECRUITING,PHASE2,Primary Central Nervous System Lymphoma,R-IDARAM plus intrathecal chemotherapy (DRUG),126941,MTX,Primary Central Nervous System Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13403,NCT04831658,"A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma",UNKNOWN,PHASE1,Primary Central Nervous System Lymphoma,the dose-escalation phase (DRUG),126941,MTX,Primary Central Nervous System Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13404,NCT05303727,Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma,NOT_YET_RECRUITING,PHASE2,Neuroblastoma,Anti Thymocyte Globulin (DRUG); Fludarabine (DRUG); Cyclophosphamide injection (DRUG); Topotecan (DRUG); Melphalan (DRUG); Thiotepa (DRUG); Busulfan (DRUG); Cyclosporine (DRUG); Tacrolimus (DRUG); Mycophenolate Mofetil (DRUG); Methotrexate (DRUG),126941,MTX,Neuroblastoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13405,NCT02269358,Salvage Therapy With High/Low Methotrexate for Loss of Response to Infliximab Dose Escalation,COMPLETED,PHASE4,Crohn's Disease,METHOTREXATE (DRUG),126941,MTX,Crohn's Disease,Bowel,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13406,NCT00309569,Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients,COMPLETED,PHASE3,Early Stage Breast Cancer,Cyclophosphamide (DRUG); Methotrexate (DRUG); Fluorouracil (DRUG); Epirubicin (DRUG); Surgery (OTHER),126941,MTX,Early Stage Breast Cancer,Breast,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13407,NCT04628767,Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer,RECRUITING,PHASE2,Renal Pelvis and Ureter Urothelial Carcinoma,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Doxorubicin Hydrochloride (DRUG); Durvalumab (BIOLOGICAL); Gemcitabine Hydrochloride (DRUG); Magnetic Resonance Imaging (PROCEDURE); Methotrexate (DRUG); Pegfilgrastim (BIOLOGICAL); Therapeutic Conventional Surgery (PROCEDURE); Vinblastine Sulfate (DRUG),126941,MTX,Renal Pelvis and Ureter Urothelial Carcinoma,Bladder/Urinary Tract,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13408,NCT00006168,Ursodiol-Methotrexate for Primary Biliary Cirrhosis,COMPLETED,PHASE3,"Liver Cirrhosis, Biliary",Methotrexate (DRUG),126941,MTX,Biliary Liver Cirrhosis,Liver,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13409,NCT02045368,Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R,COMPLETED,PHASE1,Breast Cancer; Brain Cancer; Gastrointestinal Cancers; Genitourinary Cancers; Gynecologic Cancers; Head and Neck Cancers; Melanoma; Thoracic Cancers,IGF-Methotrexate conjugate (DRUG),126941,MTX,Breast Cancer; Brain Cancer; Gastrointestinal Cancers; Genitourinary Cancers; Gynecologic Cancers; Head and Neck Cancers; Melanoma; Thoracic Cancers,Bowel,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13410,NCT00251641,The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED),COMPLETED,PHASE3,Psoriasis,infliximab (DRUG); methotrexate (DRUG),126941,MTX,Psoriasis,Skin,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13411,NCT03912818,Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer,TERMINATED,PHASE2,"Bladder Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Squamous Cell Carcinoma; Bladder Urothelial Carcinoma; Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant; Infiltrating Bladder Urothelial Carcinoma With Giant Cells; Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation; Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation; Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant; Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant; Infiltrating Bladder Urothelial Carcinoma, Nested Variant; Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant",Carboplatin (DRUG); Cisplatin (DRUG); Cystectomy (PROCEDURE); Doxorubicin (DRUG); Durvalumab (BIOLOGICAL); Gemcitabine (DRUG); Methotrexate (DRUG); Vinblastine (DRUG),126941,MTX,"Bladder Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Squamous Cell Carcinoma; Bladder Urothelial Carcinoma; Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant; Infiltrating Bladder Urothelial Carcinoma With Giant Cells; Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation; Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation; Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant; Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant; Infiltrating Bladder Urothelial Carcinoma, Nested Variant; Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant",Skin,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13412,NCT02422641,Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis,RECRUITING,PHASE2,Metastatic Breast Cancer; Leptomeningeal Disease,High-dose Methotrexate (8 gm/m2; HD-MTX) (DRUG),126941,MTX,Metastatic Breast Cancer; Leptomeningeal Disease,Breast,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13413,NCT05347641,Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma,NOT_YET_RECRUITING,PHASE2,Primary Central Nervous System Lymphoma,Penpulimab (DRUG),126941,MTX,Primary Central Nervous System Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13414,NCT04841434,A Phase I/II Study to Investigate the Use of VORAXAZE™ As Intended Intervention in Patients with CNSL,COMPLETED,PHASE1,CNS Lymphoma,Voraxaze Injectable Product (DRUG),126941,MTX,CNS Lymphoma,CNS/Brain,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13415,NCT03217734,MAP Study: Methotrexate and Adalimumab in Psoriasis,COMPLETED,PHASE2,Psoriasis,Adalimumab (BIOLOGICAL); Methotrexate (DRUG); Placebo (DRUG),126941,MTX,Psoriasis,Skin,Methotrexate,DHFR,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Widely used for cancer and autoimmune diseases treatments.,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,1.04,243.0 +13416,NCT05239182,9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma,ACTIVE_NOT_RECRUITING,PHASE2,Pancreatic Adenocarcinoma,9-ING-41 (DRUG); Retifanlimab (DRUG); Gemcitabine (DRUG); Abraxane (DRUG),44582816,s9602,Pancreatic Adenocarcinoma,Pancreas,9-ING-41,GSK3B,inhibitor/antagonist,GSK3 inhibitor,no,yes,"Investigational drug, not approved for human use yet.",CN1C=C(C2=CC3=C(C=C21)OCO3)C4=C(C(=O)NC4=O)C5=COC6=C5C=C(C=C6)F,1.0,8.0 +13417,NCT04239092,9-ING-41 in Pediatric Patients with Refractory Malignancies.,RECRUITING,PHASE1,Refractory Cancer; Refractory Neoplasm; Cancer Pediatric; Refractory Tumor; Pediatric Cancer; Pediatric Brain Tumor; Neuroblastoma; Neuroblastoma Recurrent; Pediatric Lymphoma; Pediatric Meningioma; Diffuse Intrinsic Pontine Glioma,9-ING-41 (DRUG); Irinotecan (DRUG); Temozolomide (DRUG); Cyclophosphamide (DRUG); Topotecan (DRUG),44582816,s9602,Refractory Cancer; Refractory Neoplasm; Cancer Pediatric; Refractory Tumor; Pediatric Cancer; Pediatric Brain Tumor; Neuroblastoma; Neuroblastoma Recurrent; Pediatric Lymphoma; Pediatric Meningioma; Diffuse Intrinsic Pontine Glioma,CNS/Brain,9-ING-41,GSK3B,inhibitor/antagonist,GSK3 inhibitor,no,yes,"Investigational drug, not approved for human use yet.",CN1C=C(C2=CC3=C(C=C21)OCO3)C4=C(C(=O)NC4=O)C5=COC6=C5C=C(C=C6)F,1.0,8.0 +13418,NCT05077800,FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer,RECRUITING,PHASE2,Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic,FOLFIRNINOX (DRUG); Losartan (DRUG); 9-ING-41 (DRUG),44582816,s9602,Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic,Pancreas,9-ING-41,GSK3B,inhibitor/antagonist,GSK3 inhibitor,no,yes,"Investigational drug, not approved for human use yet.",CN1C=C(C2=CC3=C(C=C21)OCO3)C4=C(C(=O)NC4=O)C5=COC6=C5C=C(C=C6)F,1.0,8.0 +13419,NCT06896188,"9-ING-41 Combined with Retifanlimab, Plus Modified FOLFIRINOX for Patients with Advanced Pancreatic Adenocarcinoma (RiLEY)",NOT_YET_RECRUITING,PHASE1,Pancreatic Adenocarcinoma,Retifanlimab (DRUG); Chemotherapy (DRUG); 9-ING-41 (DRUG),44582816,s9602,Pancreatic Adenocarcinoma,Pancreas,9-ING-41,GSK3B,inhibitor/antagonist,GSK3 inhibitor,no,yes,"Investigational drug, not approved for human use yet.",CN1C=C(C2=CC3=C(C=C21)OCO3)C4=C(C(=O)NC4=O)C5=COC6=C5C=C(C=C6)F,1.0,8.0 +13420,NCT03678883,9-ING-41 in Patients with Advanced Cancers,ACTIVE_NOT_RECRUITING,PHASE2,"Cancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractory Non-Hodgkin Lymphoma; Pancreatic Adenocarcinoma; Resistant Cancer; Neoplasm Metastasis; Neoplasm of Bone; Neoplasm, Breast; Neoplasm of Lung; Neoplasms,Colorectal; Neoplasms Pancreatic; Malignant Glioma; Malignancies; Malignancies Multiple; Bone Metastases; Bone Neoplasm; Bone Cancer; Pancreas Cancer; Pancreatic Neoplasms; Breast Neoplasms; Acute T Cell Leukemia Lymphoma",9-ING-41 (DRUG); Gemcitabine - 21 day cycle (DRUG); Doxorubicin. (DRUG); Lomustine (DRUG); Carboplatin. (DRUG); Nab paclitaxel. (DRUG); Paclitaxel. (DRUG); Gemcitabine - 28 day cycle (DRUG); Irinotecan (DRUG),44582816,s9602,"Cancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractory Non-Hodgkin Lymphoma; Pancreatic Adenocarcinoma; Resistant Cancer; Neoplasm Metastasis; Neoplasm of Bone; Neoplasm, Breast; Neoplasm of Lung; Neoplasms,Colorectal; Neoplasms Pancreatic; Malignant Glioma; Malignancies; Malignancies Multiple; Bone Metastases; Bone Neoplasm; Bone Cancer; Pancreas Cancer; Pancreatic Neoplasms; Breast Neoplasms; Acute T Cell Leukemia Lymphoma",Pancreas,9-ING-41,GSK3B,inhibitor/antagonist,GSK3 inhibitor,no,yes,"Investigational drug, not approved for human use yet.",CN1C=C(C2=CC3=C(C=C21)OCO3)C4=C(C(=O)NC4=O)C5=COC6=C5C=C(C=C6)F,1.0,8.0 +13421,NCT04655157,Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma,TERMINATED,PHASE1,Melanoma,encorafenib (DRUG); nivolumab (DRUG); ipilimumab (DRUG); binimetinib (DRUG),10288191,Mektovi,Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13422,NCT02159066,"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",COMPLETED,PHASE2,Melanoma,LGX818 (DRUG); MEK162 (DRUG); LEE011 (DRUG); BGJ398 (DRUG); BKM120 (DRUG); INC280 (DRUG),10288191,Mektovi,Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13423,NCT02185690,"A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung",COMPLETED,PHASE1,Lungcancer,Binimetinib (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),10288191,Mektovi,Lungcancer,Lung,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13424,NCT05304546,Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma,NOT_YET_RECRUITING,PHASE2,Malignant Melanoma; Metastatic Melanoma; Immunotherapy; BRAF V600E; Malignant Melanoma Stage IV,Pembrolizumab (DRUG); Encorafenib (DRUG); Binimetinib (DRUG),10288191,Mektovi,Malignant Melanoma; Metastatic Melanoma; Immunotherapy; BRAF V600E; Malignant Melanoma Stage IV,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13425,NCT04375527,Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma,TERMINATED,PHASE2,Clinical Stage III Cutaneous Melanoma AJCC V8; Clinical Stage IV Cutaneous Melanoma AJCC V8; Locally Advanced Cutaneous Melanoma; Metastatic Cutaneous Melanoma; Pathologic Stage III Cutaneous Melanoma AJCC V8; Pathologic Stage IIIA Cutaneous Melanoma AJCC V8; Pathologic Stage IIIB Cutaneous Melanoma AJCC V8; Pathologic Stage IIIC Cutaneous Melanoma AJCC V8; Pathologic Stage IIID Cutaneous Melanoma AJCC V8; Pathologic Stage IV Cutaneous Melanoma AJCC V8; Unresectable Cutaneous Melanoma,Binimetinib (DRUG); Nivolumab (BIOLOGICAL); Questionnaire Administration (OTHER),10288191,Mektovi,Clinical Stage III Cutaneous Melanoma AJCC V8; Clinical Stage IV Cutaneous Melanoma AJCC V8; Locally Advanced Cutaneous Melanoma; Metastatic Cutaneous Melanoma; Pathologic Stage III Cutaneous Melanoma AJCC V8; Pathologic Stage IIIA Cutaneous Melanoma AJCC V8; Pathologic Stage IIIB Cutaneous Melanoma AJCC V8; Pathologic Stage IIIC Cutaneous Melanoma AJCC V8; Pathologic Stage IIID Cutaneous Melanoma AJCC V8; Pathologic Stage IV Cutaneous Melanoma AJCC V8; Unresectable Cutaneous Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13426,NCT04526782,ENCOrafenib With Binimetinib in bRAF NSCLC,ACTIVE_NOT_RECRUITING,PHASE2,Non Small Cell Lung Cancer; BRAF V600E,Encorafenib 75 MG (DRUG); Binimetinib 15 MG (DRUG),10288191,Mektovi,Non Small Cell Lung Cancer; BRAF V600E,Lung,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13427,NCT02276027,"A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer",COMPLETED,PHASE2,Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma,BYL719 (DRUG); INC280 (DRUG); LDK378 (DRUG); MEK162 (DRUG),10288191,Mektovi,Lung Adenocarcinoma and Squamous Cell Carcinoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13428,NCT01859026,A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation,COMPLETED,PHASE1,Lung Cancer; Non-Small Cell Lung Cancer,MEK162 (DRUG); Erlotinib (DRUG),10288191,Mektovi,Lung Cancer; Non-Small Cell Lung Cancer,Lung,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13429,NCT04044430,"Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer",TERMINATED,PHASE1,Metastatic Colon Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Microsatellite Stable Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Stage III Colon Cancer; Stage III Colorectal Cancer; Stage III Rectal Cancer; Stage IIIA Colon Cancer; Stage IIIA Colorectal Cancer; Stage IIIA Rectal Cancer; Stage IIIB Colon Cancer; Stage IIIB Colorectal Cancer; Stage IIIB Rectal Cancer; Stage IIIC Colon Cancer; Stage IIIC Colorectal Cancer; Stage IIIC Rectal Cancer; Stage IV Colon Cancer; Stage IV Colorectal Cancer; Stage IV Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Colorectal Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Colorectal Cancer; Stage IVB Rectal Cancer; Stage IVC Colon Cancer; Stage IVC Colorectal Cancer; Stage IVC Rectal Cancer,Binimetinib (DRUG); Encorafenib (DRUG); Nivolumab (BIOLOGICAL); Questionnaire Administration (OTHER),10288191,Mektovi,Metastatic Colon Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Microsatellite Stable Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Stage III Colon Cancer; Stage III Colorectal Cancer; Stage III Rectal Cancer; Stage IIIA Colon Cancer; Stage IIIA Colorectal Cancer; Stage IIIA Rectal Cancer; Stage IIIB Colon Cancer; Stage IIIB Colorectal Cancer; Stage IIIB Rectal Cancer; Stage IIIC Colon Cancer; Stage IIIC Colorectal Cancer; Stage IIIC Rectal Cancer; Stage IV Colon Cancer; Stage IV Colorectal Cancer; Stage IV Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Colorectal Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Colorectal Cancer; Stage IVB Rectal Cancer; Stage IVC Colon Cancer; Stage IVC Colorectal Cancer; Stage IVC Rectal Cancer,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13430,NCT02285439,Study of MEK162 for Children With Low-Grade Gliomas,ACTIVE_NOT_RECRUITING,PHASE1,"Low-Grade Gliomas; Malignant Neoplasms, Brain; Soft Tissue Neoplasms",MEK162 (DRUG),10288191,Mektovi,"Low-Grade Gliomas; Malignant Neoplasms, Brain; Soft Tissue Neoplasms",CNS/Brain,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13431,NCT00959127,A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer,COMPLETED,PHASE1,Advanced Solid Tumors; Advanced or Metastatic Biliary Cancer; Metastatic Colorectal Cancer,"ARRY-438162 (MEK162), MEK inhibitor; oral (DRUG)",10288191,Mektovi,Advanced Solid Tumors; Advanced or Metastatic Biliary Cancer; Metastatic Colorectal Cancer,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13432,NCT04494958,Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer,COMPLETED,PHASE1,Triple Negative Breast Cancer,"Combination, Palbociclib + Binimetinib (DRUG)",10288191,Mektovi,Triple Negative Breast Cancer,Breast,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13433,NCT03563729,Melanoma Metastasized to the Brain and Steroids,RECRUITING,PHASE2,Malignant Melanoma,Pembrolizumab Injection [Keytruda] (DRUG); Ipilimumab Injection [Yervoy] (DRUG); Nivolumab Injection [Opdivo] (DRUG); Encorafenib (DRUG); Binimetinib (DRUG); Dabrafenib (DRUG); Trametinib (DRUG),10288191,Mektovi,Malignant Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13434,NCT06470880,Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy,NOT_YET_RECRUITING,PHASE2,Melanoma,Adaptive Therapy (DRUG); Standard of Care (DRUG),10288191,Mektovi,Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13435,NCT05103891,Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations,UNKNOWN,PHASE1,Melanoma; BRAF V600 Mutation; Unresectable Melanoma; Metastatic Melanoma,Binimetinib Oral Tablet (DRUG),10288191,Mektovi,Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13436,NCT03637491,"A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors",TERMINATED,PHASE1,Pancreatic Cancer,Avelumab (DRUG); Binimetinib (DRUG); Talazoparib (DRUG),10288191,Mektovi,Pancreatic Cancer,Pancreas,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13437,NCT05926960,"A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma",ACTIVE_NOT_RECRUITING,PHASE2,Melanoma,encorafenib (DRUG); binimetinib (DRUG); pembrolizumab (DRUG); ipilimumab (DRUG); nivolumab (DRUG),10288191,Mektovi,Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13438,NCT04657991,"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma",ACTIVE_NOT_RECRUITING,PHASE3,Melanoma,Encorafenib (DRUG); Binimetinib (DRUG); Pembrolizumab (DRUG),10288191,Mektovi,Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13439,NCT02928224,Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer,COMPLETED,PHASE3,BRAF V600E-mutant Metastatic Colorectal Cancer,Encorafenib (DRUG); Binimetinib (DRUG); Cetuximab (DRUG); Irinotecan (DRUG); Folinic Acid (DRUG); 5-Fluorouracil (DRUG),10288191,Mektovi,BRAF V600E-mutant Metastatic Colorectal Cancer,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13440,NCT01801358,A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma,TERMINATED,PHASE1,Uveal Melanoma,AEB071 (DRUG); MEK162 (DRUG),10288191,Mektovi,Uveal Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13441,NCT02041481,"MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer",COMPLETED,PHASE1,Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,MEK inhibitor MEK162 (DRUG); leucovorin calcium (DRUG); fluorouracil (DRUG); oxaliplatin (DRUG); pharmacological study (OTHER); Laboratory Biomarker Analysis (OTHER),10288191,Mektovi,Advanced Colorectal Cancer,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13442,NCT05270044,Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.,ACTIVE_NOT_RECRUITING,PHASE3,Melanoma,Encorafenib and Binimetinib (DRUG); Placebo to match Encorafenib ; Placebo to match Binimetinib (DRUG),10288191,Mektovi,Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13443,NCT04759846,Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma,WITHDRAWN,PHASE1,BRAF V600 Mutation; Unresectable Melanoma; Metastatic Melanoma; Hepatic Impairment,Encorafenib + Binimetinib (DRUG); Encorafenib + Binimetinib (DRUG); Encorafenib + Binimetinib (DRUG),10288191,Mektovi,BRAF V600 Mutation; Unresectable Melanoma; Metastatic Melanoma; Hepatic Impairment,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13444,NCT04735068,Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small Cell Lung Cancer; KRAS Mutation-Related Tumors,Binimetinib Pill (DRUG); Hydroxychloroquine Pill (DRUG),10288191,Mektovi,Non-Small Cell Lung Cancer; KRAS Mutation-Related Tumors,Lung,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13445,NCT01781572,A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma,COMPLETED,PHASE1,Locally Advanced or Metastatic NRAS Mutant Melanoma,LEE011 (DRUG); MEK162 (DRUG),10288191,Mektovi,Locally Advanced or Metastatic NRAS Mutant Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13446,NCT05355701,A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.,RECRUITING,PHASE1,Melanoma; Non-Small-Cell Lung Cancer; Thyroid Cancer; Glioma,PF-07799933 (DRUG); binimetinib (DRUG); cetuximab (BIOLOGICAL),10288191,Mektovi,Melanoma; Non-Small-Cell Lung Cancer; Thyroid Cancer; Glioma,Lung,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13447,NCT02510001,MEK and MET Inhibition in Colorectal Cancer,COMPLETED,PHASE1,Solid Tumor; Colorectal Cancer,PF-02341066 (DRUG); PD-0325901 (DRUG); Binimetinib (DRUG),10288191,Mektovi,Solid Tumor; Colorectal Cancer,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13448,NCT03475004,"Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer",COMPLETED,PHASE2,Colorectal Cancer; Metastatic Cancer,Pembrolizumab (DRUG); Bevacizumab (DRUG); Binimetinib (DRUG),10288191,Mektovi,Colorectal Cancer; Metastatic Cancer,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13449,NCT03543969,Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,Melanoma (Skin); Skin Cancer; Skin Melanoma; Skin Carcinoma,Encorafenib (DRUG); Binimetinib (DRUG); Nivolumab (DRUG),10288191,Mektovi,Melanoma (Skin); Skin Cancer; Skin Melanoma; Skin Carcinoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13450,NCT04005144,Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer,TERMINATED,PHASE1,ALK Gene Rearrangement; Lung Non-Small Cell Carcinoma; Progressive Disease; ROS1 Gene Rearrangement; Stage IIIB Lung Cancer; Stage IIIC Lung Cancer; Stage IV Lung Cancer; Stage IVA Lung Cancer; Stage IVB Lung Cancer,Binimetinib (DRUG); Brigatinib (DRUG),10288191,Mektovi,ALK Gene Rearrangement; Lung Non-Small Cell Carcinoma; Progressive Disease; ROS1 Gene Rearrangement; Stage IIIB Lung Cancer; Stage IIIC Lung Cancer; Stage IV Lung Cancer; Stage IVA Lung Cancer; Stage IVB Lung Cancer,Lung,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13451,NCT02964689,Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.,COMPLETED,PHASE1,Advanced Non-small Cell Lung Cancer; KRAS Gene Mutation; Lung Cancer,Binimetinib (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG),10288191,Mektovi,Advanced Non-small Cell Lung Cancer; KRAS Gene Mutation; Lung Cancer,Lung,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13452,NCT02451865,"Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer",WITHDRAWN,PHASE1,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Binimetinib (DRUG); Docetaxel (DRUG); Laboratory Biomarker Analysis (OTHER),10288191,Mektovi,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Lung,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13453,NCT01849874,"A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer",TERMINATED,PHASE3,Low-grade Serous Ovarian Cancer; Low-grade Serous Fallopian Tube Cancer; Low-grade Serous Peritoneal Cancer,"MEK162, MEK inhibitor; oral (DRUG); Physician's choice chemotherapy (DRUG)",10288191,Mektovi,Low-grade Serous Ovarian Cancer; Low-grade Serous Fallopian Tube Cancer; Low-grade Serous Peritoneal Cancer,Ovary/Fallopian Tube,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13454,NCT01828034,"First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma",COMPLETED,PHASE1,Advanced Biliary Tract Carcinoma,Gemcitabine (DRUG); Cisplatin (DRUG); MEK162 (DRUG),10288191,Mektovi,Advanced Biliary Tract Carcinoma,Liver,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13455,NCT04074096,Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis,ACTIVE_NOT_RECRUITING,PHASE2,Malignant Melanoma; BRAF V600 Mutation; Brain Metastases,Stereotaxic radiosurgery (SRS) (RADIATION); Binimetinib Oral Tablet (DRUG); Encorafenib Oral Capsule (DRUG); Pembrolizumab (DRUG),10288191,Mektovi,Malignant Melanoma; BRAF V600 Mutation; Brain Metastases,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13456,NCT03878719,Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma,TERMINATED,PHASE1,Melanoma,binimetinib (DRUG); encorafenib (DRUG),10288191,Mektovi,Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13457,NCT05810740,Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations,COMPLETED,PHASE1,Melanoma; BRAF V600 Mutation; Unresectable Melanoma; Metastatic Melanoma,Binimetinib 15 MG (DRUG); Binimetinib 45 MG (DRUG),10288191,Mektovi,Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13458,NCT03911869,"An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis",TERMINATED,PHASE2,Brain Metastases,encorafenib (DRUG); binimetinib (DRUG),10288191,Mektovi,Brain Metastases,CNS/Brain,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13459,NCT04720768,"Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE",RECRUITING,PHASE1,Melanoma; Metastasis,Binimetinib (DRUG); Encorafenib (DRUG); Palbociclib (DRUG),10288191,Mektovi,Metastatic Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13460,NCT05554367,"Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial",RECRUITING,PHASE2,Exocrine Pancreas Carcinoma; Malignant Solid Neoplasm; Ovarian Low Grade Serous Adenocarcinoma; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Binimetinib (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Palbociclib (DRUG),10288191,Mektovi,Exocrine Pancreas Carcinoma; Malignant Solid Neoplasm; Ovarian Low Grade Serous Adenocarcinoma; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Pancreas,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13461,NCT05170334,Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma,RECRUITING,PHASE2,Metastatic Uveal Melanoma,Binimetinib (DRUG); Belinostat (DRUG),10288191,Mektovi,Metastatic Uveal Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13462,NCT04892017,A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors,RECRUITING,PHASE1,Non-Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Solid Tumor,Inlexisertib (DRUG); Trametinib (DRUG); Binimetinib (DRUG); Sotorasib (DRUG),10288191,Mektovi,Non-Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Solid Tumor,Lung,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13463,NCT04870034,"Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer",WITHDRAWN,EARLY_PHASE1,Colorectal Carcinoma; Lung Adenocarcinoma; Malignant Solid Neoplasm; Pancreatic Carcinoma,Binimetinib (DRUG); Palbociclib (DRUG); Therapeutic Conventional Surgery (PROCEDURE),10288191,Mektovi,Colorectal Carcinoma; Lung Adenocarcinoma; Malignant Solid Neoplasm; Pancreatic Carcinoma,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13464,NCT03026517,Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma,COMPLETED,PHASE1,Melanoma,Dabrafenib (DRUG); Trametinib (DRUG); Phenformin (DRUG),10288191,Mektovi,Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13465,NCT04965818,Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer,TERMINATED,PHASE1,Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations; Non-Small Cell Lung Cancer; KRAS Gene Mutation,Futibatinib and Binimetinib (DRUG),10288191,Mektovi,Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations; Non-Small Cell Lung Cancer; KRAS Gene Mutation,Lung,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13466,NCT05019534,"Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer",UNKNOWN,PHASE1,BRAF V600E-mutated /MSS Metastatic Colorectal Cancer; Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody,Vemurafenib Oral Tablet [Zelboraf] (DRUG); Cetuximab Injection [Erbitux] (DRUG); Camrelizumab (DRUG),10288191,Mektovi,BRAF V600E-mutated /MSS Metastatic Colorectal Cancer; Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13467,NCT04292119,Lorlatinib Combinations in Lung Cancer,UNKNOWN,PHASE1,Lung Cancer; Anaplastic Lymphoma Kinase Gene Translocation; ROS1 Rearrangement; Relapsed Cancer; MET Amplification; Resistant Cancer; NSCLC,Lorlatinib (DRUG); Crizotinib (DRUG); Binimetinib (DRUG); TNO155 (DRUG),10288191,Mektovi,Lung Cancer; Anaplastic Lymphoma Kinase Gene Translocation; ROS1 Rearrangement; Relapsed Cancer; MET Amplification; Resistant Cancer; NSCLC,Lung,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13468,NCT03973918,Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG,TERMINATED,PHASE2,High Grade Glioma; BRAF V600E; BRAF V600K; Anaplastic Astrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Gliosarcoma; Glioblastoma,Encorafenib (DRUG); Binimetinib (DRUG); Research Bloods (BIOLOGICAL); Tumor Tissue (BIOLOGICAL),10288191,Mektovi,High Grade Glioma; BRAF V600E; BRAF V600K; Anaplastic Astrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Gliosarcoma; Glioblastoma,CNS/Brain,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13469,NCT01927341,"Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors",COMPLETED,PHASE1,Metastatic Colorectal Cancer,MEK162 (DRUG); Panitumumab (DRUG),10288191,Mektovi,Metastatic Colorectal Cancer,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13470,NCT04903119,Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma,RECRUITING,PHASE1,Metastatic Melanoma; BRAF Gene Mutation,Nilotinib 100mg (DRUG); Nilotinib 200mg (DRUG); Nilotinib 300mg (DRUG); Nilotinib 400mg (DRUG); Dabrafenib (DRUG); Trametinib (DRUG); Encorafenib (DRUG); Binimetinib (DRUG),10288191,Mektovi,Advanced Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13471,NCT05615818,Personalized Medicine for Advanced Biliary Cancer Patients,RECRUITING,PHASE3,Biliary Tract Neoplasms,Futibatinib (DRUG); Ivosidenib (DRUG); Zanidatamab (DRUG); Trastuzumab (DRUG); Neratinib (DRUG); Encorafenib (DRUG); Binimetinib (DRUG); Niraparib (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG),10288191,Mektovi,Biliary Tract Neoplasms,Liver,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13472,NCT02105350,A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer,WITHDRAWN,PHASE1,Biliary Tract Carcinoma; Gallbladder Carcinoma,MEK 162 (DRUG); Gemcitabine (DRUG); Oxaliplatin (DRUG),10288191,Mektovi,Biliary Tract Carcinoma; Gallbladder Carcinoma,Liver,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13473,NCT03898908,Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Melanoma; Brain Metastases,encorafenib (DRUG); binimetinib (DRUG); Whole brain radiation therapy (RADIATION); Radiosurgery/stereotactic radiosurgery (RADIATION),10288191,Mektovi,Metastatic Melanoma; Brain Metastases,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13474,NCT04221438,Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement,ACTIVE_NOT_RECRUITING,PHASE2,Melanoma of Unknown Primary; Metastatic Malignant Neoplasm in Lymph Node; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Recurrent Cutaneous Melanoma,Binimetinib (DRUG); Computed Tomography (PROCEDURE); Conventional Surgery (PROCEDURE); Encorafenib (DRUG); Fluorothymidine F-18 (OTHER); Positron Emission Tomography (PROCEDURE),10288191,Mektovi,Melanoma of Unknown Primary; Metastatic Malignant Neoplasm in Lymph Node; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Recurrent Cutaneous Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13475,NCT05004350,A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.,COMPLETED,PHASE2,BRAF V600E; Metastatic Colorectal Cancer,Encorafenib (DRUG); Cetuximab (DRUG); FOLFIRI (DRUG),10288191,Mektovi,BRAF V600E; Metastatic Colorectal Cancer,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13476,NCT05510895,"Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer",RECRUITING,PHASE2,Colorectal Cancer; Colon Cancer; BRAF V600E; BRAF V600 Mutation; Localized Cancer,Binimetinib (DRUG),10288191,Mektovi,Colorectal Cancer; Colon Cancer; BRAF V600E; BRAF V600 Mutation; Localized Cancer,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13477,NCT03981614,Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Unresectable Carcinoma,Binimetinib (DRUG); Palbociclib (DRUG); Trifluridine and Tipiracil Hydrochloride (DRUG),10288191,Mektovi,Metastatic Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Unresectable Carcinoma,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13478,NCT02613650,"A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers",COMPLETED,PHASE1,Advanced KRAS Positive Metastatic Colorectal Cancer,MEK162 and mFOLFIRI (DRUG),10288191,Mektovi,Advanced KRAS Positive Metastatic Colorectal Cancer,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13479,NCT01763164,Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma,COMPLETED,PHASE3,Metastatic or Unresectable Cutaneous Melanoma,MEK162 (DRUG); Dacarbazine (DRUG),10288191,Mektovi,Metastatic or Unresectable Cutaneous Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13480,NCT01820364,LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,TERMINATED,PHASE2,Melanoma,LGX818 (DRUG),10288191,Mektovi,Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13481,NCT01649336,"A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer",COMPLETED,PHASE1,Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer,"MEK162, MEK inhibitor; oral (DRUG); Paclitaxel, mitotic inhibitor; intravenous (DRUG)",10288191,Mektovi,Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer,Ovary/Fallopian Tube,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13482,NCT02382549,A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib,TERMINATED,EARLY_PHASE1,Melanoma,BRAF inhibitor (DRUG); 6MHP (BIOLOGICAL); MEK inhibitor (DRUG),10288191,Mektovi,Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13483,NCT02902042,Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma,COMPLETED,PHASE1,Malignant Melanoma,Encorafenib (DRUG); Binimetinib (DRUG); Pembrolizumab (DRUG); Pembrolizumab alone (DRUG),10288191,Mektovi,Malignant Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13484,NCT03864042,Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors,COMPLETED,PHASE1,Advanced Solid Tumors; Metastatic Melanoma,losartan (DRUG); dextromethorphan (DRUG); caffeine (DRUG); omeprazole (DRUG); midazolam (DRUG); rosuvastatin (DRUG); bupropion immediate release (IR) (DRUG); encorafenib (DRUG); binimetinib (DRUG); modafinil (DRUG),10288191,Mektovi,Advanced Solid Tumors; Metastatic Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13485,NCT03170206,Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Lung Cancer,Binimetinib (DRUG); Palbociclib (DRUG),10288191,Mektovi,Lung Cancer,Lung,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13486,NCT01562899,A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors,TERMINATED,PHASE1,Metastatic Pancreatic Adenocarcinoma; BRAF Mutated Melanoma,MEK162 (DRUG); AMG 479 (DRUG),10288191,Mektovi,Metastatic Pancreatic Adenocarcinoma; BRAF Mutated Melanoma,Pancreas,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13487,NCT05340621,NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2),COMPLETED,PHASE1,RAS Mutation; NRAS Gene Mutation; Melanoma,OKI-179 + binimetinib (DRUG),10288191,Mektovi,RAS Mutation; NRAS Gene Mutation; Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13488,NCT05080621,Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST),WITHDRAWN,PHASE1,Gastrointestinal Stromal Tumors,Ripretinib (DRUG); binimetinib (DRUG),10288191,Mektovi,Gastrointestinal Stromal Tumors,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13489,NCT01991379,MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST),ACTIVE_NOT_RECRUITING,PHASE1,Gastrointestinal Stromal Tumor (GIST),MEK162 (DRUG); Imatinib Mesylate (Gleevec®; STI571; NSC #716051) (DRUG); Blood draws (OTHER); biopsy (PROCEDURE),10288191,Mektovi,Gastrointestinal Stromal Tumor (GIST),Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13490,NCT05564403,"Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)",RECRUITING,PHASE2,Advanced Biliary Tract Carcinoma; Advanced Gallbladder Carcinoma; Advanced Intrahepatic Cholangiocarcinoma; Recurrent Biliary Tract Carcinoma; Recurrent Gallbladder Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Stage III Distal Bile Duct Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage III Hilar Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Hilar Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Biliary Tract Carcinoma; Unresectable Gallbladder Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma,Binimetinib (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Fluorouracil (DRUG); Leucovorin Calcium (DRUG); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Oxaliplatin (DRUG),10288191,Mektovi,Advanced Biliary Tract Carcinoma; Advanced Gallbladder Carcinoma; Advanced Intrahepatic Cholangiocarcinoma; Recurrent Biliary Tract Carcinoma; Recurrent Gallbladder Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Stage III Distal Bile Duct Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage III Hilar Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Hilar Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Biliary Tract Carcinoma; Unresectable Gallbladder Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma,Liver,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13491,NCT03158103,A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST),COMPLETED,PHASE1,Gastrointestinal Stromal Tumor (GIST),MEK162 (DRUG); Pexidartinib (DRUG),10288191,Mektovi,Gastrointestinal Stromal Tumor (GIST),Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13492,NCT04390243,Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation,TERMINATED,PHASE2,Locally Advanced Pancreatic Carcinoma; Metastatic Pancreatic Carcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Binimetinib (DRUG); Encorafenib (DRUG),10288191,Mektovi,Locally Advanced Pancreatic Carcinoma; Metastatic Pancreatic Carcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Pancreas,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13493,NCT05767879,(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma,RECRUITING,PHASE2,Melanoma Stage III; In-Transit Metastasis of Cutaneous Melanoma,Encorafenib + Binimetinib (DRUG),10288191,Mektovi,Melanoma Stage III; In-Transit Metastasis of Cutaneous Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13494,NCT03693170,"Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer",COMPLETED,PHASE2,BRAF V600E-mutant Metastatic Colorectal Cancer,encorafenib (DRUG); Binimetinib (DRUG); Cetuximab (DRUG),10288191,Mektovi,BRAF V600E-mutant Metastatic Colorectal Cancer,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13495,NCT04511013,A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases,RECRUITING,PHASE2,Acral Lentiginous Melanoma; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Cutaneous Melanoma; Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Metastatic Mucosal Melanoma; Pathologic Stage IV Cutaneous Melanoma AJCC v8,Binimetinib (DRUG); Encorafenib (DRUG); Ipilimumab (BIOLOGICAL); Nivolumab (BIOLOGICAL),10288191,Mektovi,Acral Lentiginous Melanoma; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Cutaneous Melanoma; Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Metastatic Mucosal Melanoma; Pathologic Stage IV Cutaneous Melanoma AJCC v8,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13496,NCT02773459,MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer,COMPLETED,PHASE1,Biliary Tract Cancer,MEK162+capecitabine (DRUG),10288191,Mektovi,Biliary Tract Cancer,Liver,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13497,NCT05195632,Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients with Metastatic Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Non-Small Cell Lung Cancer,Encorafenib (DRUG); Binimetinib (DRUG),10288191,Mektovi,Advanced Non-Small Cell Lung Cancer,Lung,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13498,NCT03947385,Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions,RECRUITING,PHASE1,Metastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumors,IDE196 (DRUG); Binimetinib (DRUG); Crizotinib (DRUG),10288191,Mektovi,Metastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumors,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13499,NCT04913285,A Study to Evaluate KIN-2787 in Participants with BRAF And/or NRAS Mutation Positive Solid Tumors,RECRUITING,PHASE1,"Solid Tumor, Adult; Non-small Cell Lung Cancer; Melanoma",KIN-2787 (DRUG); KIN-2787 and binimetinib (DRUG),10288191,Mektovi,"Solid Tumor, Adult; Non-small Cell Lung Cancer; Melanoma",Lung,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13500,NCT02910700,"Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma,Binimetinib (DRUG); Dabrafenib (DRUG); Encorafenib (DRUG); Laboratory Biomarker Analysis (OTHER); Nivolumab (BIOLOGICAL); Pharmacological Study (OTHER); Trametinib (DRUG),10288191,Mektovi,Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma,CNS/Brain,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13501,NCT03106415,Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer,COMPLETED,PHASE1,Breast Adenocarcinoma; Metastatic Triple-Negative Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7,Binimetinib (DRUG); Laboratory Biomarker Analysis (OTHER); Pembrolizumab (BIOLOGICAL),10288191,Mektovi,Breast Adenocarcinoma; Metastatic Triple-Negative Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7,Breast,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13502,NCT03971409,"Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer",RECRUITING,PHASE2,Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Invasive Breast Carcinoma; Recurrent Breast Carcinoma; Triple-Negative Breast Carcinoma; Unresectable Breast Carcinoma,Anti-OX40 Antibody PF-04518600 (BIOLOGICAL); Avelumab (DRUG); Binimetinib (DRUG); Utomilumab (BIOLOGICAL); Liposomal Doxorubicin (DRUG); Sacituzumab Govitecan (DRUG),10288191,Mektovi,Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Invasive Breast Carcinoma; Recurrent Breast Carcinoma; Triple-Negative Breast Carcinoma; Unresectable Breast Carcinoma,Breast,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13503,NCT02631447,Sequential Combo Immuno and Target Therapy (SECOMBIT) Study,COMPLETED,PHASE2,Metastatic Melanoma,LGX818 (DRUG); MEK162 (DRUG); Nivolumab (DRUG); Ipilimumab (DRUG),10288191,Mektovi,Metastatic Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13504,NCT03915951,An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Non-small Cell Lung Cancer,encorafenib (DRUG); binimetinib (DRUG),10288191,Mektovi,Non-small Cell Lung Cancer,Lung,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13505,NCT05554354,Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial),TERMINATED,PHASE2,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma,Binimetinib (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Fulvestrant (DRUG); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE),10288191,Mektovi,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma,Breast,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13506,NCT03271047,Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation,COMPLETED,PHASE2,MSS; RAS-mutant Colorectal Cancer,binimetinib (DRUG); nivolumab (DRUG); ipilimumab (DRUG),10288191,Mektovi,MSS; RAS-mutant Colorectal Cancer,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13507,NCT05564377,"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial",RECRUITING,PHASE2,Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm,Alpelisib (DRUG); Binimetinib (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration (PROCEDURE); Bone Scan (PROCEDURE); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Fluorouracil (DRUG); Fulvestrant (DRUG); Ipatasertib (DRUG); Leucovorin (DRUG); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Mutation Carrier Screening (PROCEDURE); Neratinib Maleate (DRUG); Nilotinib Hydrochloride Monohydrate (DRUG); Olaparib (DRUG); Oxaliplatin (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Panitumumab (BIOLOGICAL); Positron Emission Tomography (PROCEDURE); Selumetinib Sulfate (DRUG); Sotorasib (DRUG),10288191,Mektovi,Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm,Ovary/Fallopian Tube,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13508,NCT03374254,Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651),COMPLETED,PHASE1,Metastatic Colorectal Cancer,Pembrolizumab (BIOLOGICAL); Binimetinib (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); 5-Fluorouracil [5-FU] (DRUG); Irinotecan (DRUG),10288191,Mektovi,Metastatic Colorectal Cancer,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13509,NCT03803553,Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer,RECRUITING,PHASE3,Metastatic Colon Cancer; Stage III Colon Cancer,FOLFIRI Protocol (DRUG); ACTIVE SURVEILLANCE (OTHER); Nivolumab Protocol (DRUG); Encorafenib/Binimetinib/Cetuximab Protocol (DRUG); Trastuzumab + Pertuzumab (DRUG),10288191,Mektovi,Metastatic Colon Cancer; Stage III Colon Cancer,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13510,NCT01909453,Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma,COMPLETED,PHASE3,Melanoma,LGX818 (DRUG); MEK162 (DRUG); vemurafenib (DRUG),10288191,Mektovi,Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13511,NCT02050815,MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function,TERMINATED,PHASE1,Hepatic Impairment,MEK162 (DRUG),10288191,Mektovi,Hepatic Impairment,Liver,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13512,NCT01320085,A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma,COMPLETED,PHASE2,BRAF or NRAS Mutant Metastatic Melanoma,MEK162 (DRUG),10288191,Mektovi,BRAF or NRAS Mutant Metastatic Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13513,NCT06207656,Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer,RECRUITING,PHASE2,Colorectal Cancer,EBC (DRUG),10288191,Mektovi,Colorectal Cancer,Bowel,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13514,NCT04543188,A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement,TERMINATED,PHASE1,"Malignant Melanoma; Carcinoma, Non-Small-Cell Lung; Brain Neoplasms, Primary; Brain Neoplasms; Malignant Neoplasms",PF-07284890 (DRUG); Binimetinib (DRUG); Midazolam (DRUG),10288191,Mektovi,"Malignant Melanoma; Carcinoma, Non-Small-Cell Lung; Brain Neoplasms, Primary; Brain Neoplasms; Malignant Neoplasms",Lung,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13515,NCT06887088,Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases,NOT_YET_RECRUITING,PHASE2,Melanoma BRAF V600E/K Mutated; Melanoma and Brain Metastases,Encorafenib + Binimetinib (DRUG); cemiplimab+fianlimab (DRUG),10288191,Mektovi,Melanoma BRAF V600E/K Mutated; Melanoma and Brain Metastases,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13516,NCT05370807,A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma,UNKNOWN,PHASE2,Melanoma Stage III; Melanoma Stage IV,Regorafenib 40 MG Oral Tablet (DRUG); Triplet therapy (DRUG),10288191,Mektovi,Melanoma Stage III; Melanoma Stage IV,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13517,NCT06159478,Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume),RECRUITING,PHASE2,Low-grade Glioma; Pancreatic Cancer,Binimetinib 15 MG (DRUG),10288191,Mektovi,Low-grade Glioma; Pancreatic Cancer,Pancreas,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13518,NCT04598009,Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma,RECRUITING,PHASE2,Melanoma Stage III; Melanoma Stage IV,Binimetinib (DRUG); Imatinib (DRUG),10288191,Mektovi,Melanoma Stage III; Melanoma Stage IV,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13519,NCT05111561,Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer,RECRUITING,PHASE1,Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm; Triple-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm,BET Bromodomain Inhibitor ZEN-3694 (DRUG); Binimetinib (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE),10288191,Mektovi,Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm; Triple-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm,Breast,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13520,NCT05097378,Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma,UNKNOWN,PHASE2,Melanoma; Cancer,Encorafenib + Binimetinib (DRUG); Standard Adjuvant Treatment (DRUG),10288191,Mektovi,Melanoma; Cancer,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13521,NCT05026983,Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases,RECRUITING,PHASE2,Clinical Stage IV Cutaneous Melanoma AJCC V8; Metastatic Melanoma; Pathologic Stage IV Cutaneous Melanoma AJCC V8,Binimetinib (DRUG); Encorafenib (DRUG); Questionnaire Administration (OTHER),10288191,Mektovi,Clinical Stage IV Cutaneous Melanoma AJCC V8; Metastatic Melanoma; Pathologic Stage IV Cutaneous Melanoma AJCC V8,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13522,NCT04741997,Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma,RECRUITING,EARLY_PHASE1,Melanoma Stage III; Melanoma Stage IV; BRAF V600 Mutation,Encorafenib Pill (DRUG); Binimetinib Pill (DRUG); Nivolumab (DRUG),10288191,Mektovi,Melanoma Stage III; Melanoma Stage IV; BRAF V600 Mutation,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13523,NCT03235245,Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib,ACTIVE_NOT_RECRUITING,PHASE2,Unresectable Stage III Melanoma; Stage IV Melanoma,Nivolumab + Ipilimumab (DRUG); Encorafenib + Binimetinib (DRUG),10288191,Mektovi,Unresectable Stage III Melanoma; Stage IV Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13524,NCT04585815,Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study),TERMINATED,PHASE1,"Carcinoma, Non-Small-Cell Lung",Sasanlimab Prefilled syringe (DRUG); Encorafenib (DRUG); Binimetinib (DRUG); Sasanlimab (DRUG); Axitinib (DRUG); SEA-TGT (DRUG),10288191,Mektovi,"Carcinoma, Non-Small-Cell Lung",Lung,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13525,NCT02263898,Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations,WITHDRAWN,PHASE2,Recurrent Melanoma; Stage IV Melanoma,Raf kinase inhibitor LGX818 (DRUG); binimetinib (DRUG); laboratory biomarker analysis (OTHER),10288191,Mektovi,Recurrent Melanoma; Stage IV Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13526,NCT04132505,Binimetinib and Hydroxychloroquine in Treating Patients with KRAS Mutant Metastatic Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC V8,Binimetinib (DRUG); Hydroxychloroquine (DRUG),10288191,Mektovi,Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC V8,Pancreas,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13527,NCT02094872,Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic,COMPLETED,PHASE2,Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma,cytology specimen collection procedure (OTHER); MEK 162 therapy or molecularly targeted therapy (DRUG); therapeutic procedure (PROCEDURE); laboratory biomarker analysis (OTHER); quality-of-life assessment (OTHER),10288191,Mektovi,Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma,Skin,Binimetinib,"MAP2K1, MAP2K2",inhibitor/antagonist,MEK inhibitor,no,yes,"Investigated for cancer, not approved for human use.",CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,1.03,416.0 +13528,NCT00948467,Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies,COMPLETED,PHASE1,Advanced Non-hematologic Malignancies; Advanced Metastatic Melanoma,TAK-733 (DRUG),24963252,IZG,Advanced Non-hematologic Malignancies; Advanced Metastatic Melanoma,Skin,TAK-733,MAP2K1,inhibitor/antagonist,MEK inhibitor,no,yes,Investigated as anti-cancer MEK inhibitor; not approved for human use.,CN1C2=C(C(=C(C1=O)F)NC3=C(C=C(C=C3)I)F)C(=O)N(C=N2)CC(CO)O,, +13529,NCT04809766,Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma,TERMINATED,PHASE1,Metastatic Pancreatic Ductal Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Autologous Mesothelin-specific TCR-T Cells (BIOLOGICAL); Cyclophosphamide (DRUG); Fludarabine (DRUG); Bendamustine (DRUG),65628,Bendamustine,Metastatic Pancreatic Ductal Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Pancreas,Bendamustine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in leukemia and lymphoma treatment.,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,1.03,340.0 +13530,NCT01891227,Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Capecitabine (DRUG); Bendamustine (DRUG),65628,Bendamustine,Breast Cancer,Breast,Bendamustine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in leukemia and lymphoma treatment.,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,1.03,340.0 +13531,NCT04115631,A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma,ACTIVE_NOT_RECRUITING,PHASE2,Liver Lymphoma; Mantle Cell Lymphoma,Acalabrutinib (DRUG); Bendamustine (DRUG); Bendamustine Hydrochloride (DRUG); Cytarabine (DRUG); Rituximab (BIOLOGICAL),65628,Bendamustine,Liver Lymphoma; Mantle Cell Lymphoma,Liver,Bendamustine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in leukemia and lymphoma treatment.,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,1.03,340.0 +13532,NCT00879073,Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors,TERMINATED,PHASE1,Brain Metastases,Bendamustine (DRUG),65628,Bendamustine,Brain Metastases,CNS/Brain,Bendamustine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in leukemia and lymphoma treatment.,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,1.03,340.0 +13533,NCT00661739,A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer,COMPLETED,PHASE1,Metastatic Breast Cancer,Bendamustine (DRUG),65628,Bendamustine,Metastatic Breast Cancer,Breast,Bendamustine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in leukemia and lymphoma treatment.,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,1.03,340.0 +13534,NCT00168922,Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC),UNKNOWN,PHASE2,Recurrent Small Cell Lung Cancer,Bendamustin/Ribomustin (DRUG),65628,Bendamustine,Recurrent Small Cell Lung Cancer,Lung,Bendamustine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in leukemia and lymphoma treatment.,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,1.03,340.0 +13535,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,75 approved agents (DRUG); COXEN (OTHER),65628,Bendamustine,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,Bladder/Urinary Tract,Bendamustine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in leukemia and lymphoma treatment.,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,1.03,340.0 +13536,NCT04792489,DALY II USA/ MB-CART2019.1 for DLBCL,RECRUITING,PHASE2,Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma; High Grade B-cell Lymphoma (HGBCL); Primary Mediastinal B-cell Lymphoma (PMBCL); Transformed Lymphoma; Central Nervous System Lymphoma; Mantle Cell Lymphoma (MCL); Richter Transformation,zamtocabtagene autoleucel (MB-CART2019.1) (BIOLOGICAL); Cyclophosphamide (DRUG); Fludarabine (DRUG); Bendamustine (DRUG),65628,Bendamustine,Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma; High Grade B-cell Lymphoma (HGBCL); Primary Mediastinal B-cell Lymphoma (PMBCL); Transformed Lymphoma; Central Nervous System Lymphoma; Mantle Cell Lymphoma (MCL); Richter Transformation,CNS/Brain,Bendamustine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in leukemia and lymphoma treatment.,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,1.03,340.0 +13537,NCT03997968,A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors,COMPLETED,PHASE1,Malignancy; Non-hodgkin Lymphoma; Multiple Myeloma; Breast Cancer; Ovarian Cancer; Soft Tissue Sarcoma; Head and Neck Cancer; DLBCL; Mantle Cell Lymphoma; Follicular Lymphoma; Pancreatic Cancer; CLL; Small Cell Lung Cancer; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Cancer,CYT-0851 (DRUG); CYT-0851 in combination with gemcitabine (DRUG); CYT-0851 in combination with capecitabine (DRUG); CYT-0851 in combination with rituximab and bendamustine (DRUG),65628,Bendamustine,Malignancy; Non-hodgkin Lymphoma; Multiple Myeloma; Breast Cancer; Ovarian Cancer; Soft Tissue Sarcoma; Head and Neck Cancer; DLBCL; Mantle Cell Lymphoma; Follicular Lymphoma; Pancreatic Cancer; CLL; Small Cell Lung Cancer; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Cancer,Lung,Bendamustine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in leukemia and lymphoma treatment.,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,1.03,340.0 +13538,NCT02130869,A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,COMPLETED,PHASE1,Neuroblastoma; Lymphoma; High-risk Tumor,CD133+ selected autologous stem cell infusion (BIOLOGICAL); IL-2 (BIOLOGICAL); hu14.18K322A (BIOLOGICAL); Busulfan (DRUG); Melphalan (DRUG); GM-CSF (BIOLOGICAL); Bendamustine (DRUG); Etoposide (DRUG); Cytarabine (DRUG); Carboplatin (DRUG); Haploidentical natural killer cell infusion (DEVICE); G-CSF (BIOLOGICAL); Etoposide phosphate (DRUG); CliniMACS (DEVICE),65628,Bendamustine,Neuroblastoma and Lymphoma,CNS/Brain,Bendamustine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in leukemia and lymphoma treatment.,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,1.03,340.0 +13539,NCT03392714,Bendamustine-based Combination Therapy for PCNSL,UNKNOWN,PHASE2,PCNSL,R-B(O)AD (DRUG),65628,Bendamustine,Primary Central Nervous System Lymphoma,CNS/Brain,Bendamustine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in leukemia and lymphoma treatment.,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,1.03,340.0 +13540,NCT00867503,Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer,COMPLETED,PHASE2,Ovarian Cancer,Bendamustine HCL (DRUG),65628,Bendamustine,Ovarian Cancer,Ovary/Fallopian Tube,Bendamustine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in leukemia and lymphoma treatment.,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,1.03,340.0 +13541,NCT00856830,Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer,COMPLETED,PHASE1,Small Cell Lung Cancer; Extensive Stage Lung Cancer; Chemonaive,Novel Drug Combination (DRUG),65628,Bendamustine,Small Cell Lung Cancer; Extensive Stage Lung Cancer; Chemonaive,Lung,Bendamustine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in leukemia and lymphoma treatment.,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,1.03,340.0 +13542,NCT00984542,Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,bendamustine hydrochloride (DRUG),65628,Bendamustine,Lung Cancer,Lung,Bendamustine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in leukemia and lymphoma treatment.,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,1.03,340.0 +13543,NCT06138132,A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis,ACTIVE_NOT_RECRUITING,PHASE1,"Multiple Sclerosis; Multiple Sclerosis, Primary Progressive; Multiple Sclerosis, Secondary Progressive",KYV-101 anti-CD19 CAR-T cell therapy (BIOLOGICAL); Standard lymphodepletion regimen (DRUG),65628,Bendamustine,"Multiple Sclerosis; Multiple Sclerosis, Primary Progressive; Multiple Sclerosis, Secondary Progressive",CNS/Brain,Bendamustine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in leukemia and lymphoma treatment.,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,1.03,340.0 +13544,NCT04727151,TAC T-cells for the Treatment of HER2-positive Solid Tumors,TERMINATED,PHASE1,HER2 Positive Gastric Cancer; Metastatic HER2 Positive Gastroesophageal Junction Cancer,TAC01-HER2 (BIOLOGICAL); TAC01-HER2 plus pembrolizumab (BIOLOGICAL),65628,Bendamustine,HER2 Positive Gastric Cancer; Metastatic HER2 Positive Gastroesophageal Junction Cancer,Esophagus/Stomach,Bendamustine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in leukemia and lymphoma treatment.,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,1.03,340.0 +13545,NCT02424851,Optimising Renal Outcome in Myeloma Renal Failure,COMPLETED,PHASE2,Multiple Myeloma; Chronic Kidney Disease,Bortezomib (DRUG); Thalidomide (DRUG); Bendamustine (DRUG); Dexamethasone (DRUG),65628,Bendamustine,Multiple Myeloma; Chronic Kidney Disease,Kidney,Bendamustine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in leukemia and lymphoma treatment.,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,1.03,340.0 +13546,NCT00834678,"Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer",COMPLETED,PHASE1,Breast Cancer,bendamustine (DRUG); erlotinib (DRUG); Maintenance erlotinib (DRUG),65628,Bendamustine,Breast Cancer,Breast,Bendamustine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in leukemia and lymphoma treatment.,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,1.03,340.0 +13547,NCT00823797,Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma,COMPLETED,PHASE2,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Neoplasm,Bendamustine Hydrochloride (DRUG); Quality-of-Life Assessment (OTHER),65628,Bendamustine,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Neoplasm,CNS/Brain,Bendamustine,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in leukemia and lymphoma treatment.,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,1.03,340.0 +13548,NCT01712074,Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil,TERMINATED,PHASE2,Alzheimer's Disease,PF-05212377 (SAM-760) (DRUG); Placebo (OTHER),110635,CIA,Alzheimer's Disease,CNS/Brain,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13549,NCT00446290,"Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer",COMPLETED,PHASE1,Stomach Cancer,"Docetaxel, Capecitabine and Oxaliplatin (DRUG)",110635,CIA,Stomach Cancer,Esophagus/Stomach,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13550,NCT02132390,"Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea",UNKNOWN,PHASE3,Breast Cancer; Chemotherapy Induced Amenorrhea; Ovarian Function Suppression,Goserelin (DRUG); Toremifene (DRUG),110635,CIA,Breast Cancer; Chemotherapy Induced Amenorrhea; Ovarian Function Suppression,Breast,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13551,NCT03020303,Aldosterone BloCkade for Health Improvement EValuation in End-stage Renal Disease,COMPLETED,PHASE3,Endstage Renal Disease,Spironolactone 25Mg Tablet (DRUG); Placebo Oral Tablet (DRUG),110635,CIA,Endstage Renal Disease,Kidney,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13552,NCT02783092,A Double-Blind Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epilepsy,UNKNOWN,PHASE3,Epilepsy,Cannabidiol (DRUG); Placebo (DRUG),110635,CIA,Epilepsy,CNS/Brain,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13553,NCT01284348,To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer,TERMINATED,PHASE2,"Anemia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small-Cell Lung; Bladder Cancer; Cancer of Head and Neck; Uterine Cervical Cancer",Sotatercept 15 mg (DRUG); Sotatercept 30 mg (DRUG),110635,CIA,"Anemia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small-Cell Lung; Bladder Cancer; Cancer of Head and Neck; Uterine Cervical Cancer",Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13554,NCT05862610,The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC,NOT_YET_RECRUITING,PHASE2,Breast Neoplasm,Trilaciclib plus chemotherapy (DRUG); Chemotherapy (DRUG),110635,CIA,Breast Neoplasm,Breast,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13555,NCT06055023,Phase I Clinical Study of ZL-82 Tablets,COMPLETED,PHASE1,Rheumatoid Arthritis (RA); Inflammatory Bowel Disease - IBD1,ZL-82 12.5mg (DRUG); ZL-82 25mg (DRUG); ZL-82 50mg (DRUG); ZL-82 100mg (DRUG); ZL-82 200mg (DRUG); ZL-82 300mg (DRUG); ZL-82 450mg (DRUG); ZL-82 600mg (DRUG); zL-82 placebo 12.5mg (DRUG); ZL-82 placebo 25mg (DRUG); ZL-82 placebo 50mg (DRUG); ZL-82 placebo 100mg (DRUG); ZL-82 placebo 200mg (DRUG); ZL-82 placebo 300mg (DRUG); ZL-82 placebo 450mg (DRUG); ZL-82 placebo 600mg (DRUG),110635,CIA,Rheumatoid Arthritis and Inflammatory Bowel Disease,Bowel,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13556,NCT00378014,Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy,COMPLETED,PHASE3,Liver Transplantation,everolimus (DRUG); basiliximab (DRUG); CNI (DRUG),110635,CIA,Liver Transplantation,Liver,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13557,NCT00784459,The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics,COMPLETED,PHASE2,Atopic Asthma,abatacept (DRUG); Placebo (DRUG),110635,CIA,Atopic Asthma,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13558,NCT05709574,Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer,RECRUITING,PHASE2,Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma,Tadalafil 20 MG (DRUG),110635,CIA,Gastric and Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13559,NCT01244620,"A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses",TERMINATED,PHASE1,Pulmonary Arterial Hypertension,sitaxentan (DRUG); tadalafil (DRUG); sitaxsentan (DRUG); tadalafil (DRUG); sitaxsentan (DRUG); sildenafil (DRUG),110635,CIA,Pulmonary Arterial Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13560,NCT01824290,A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH),COMPLETED,PHASE3,"Hypertension, Pulmonary",Tadalafil (DRUG); Placebo (DRUG); ERA as specific PAH treatment (DRUG),110635,CIA,Pulmonary Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13561,NCT02891850,Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy,COMPLETED,PHASE4,Pulmonary Arterial Hypertension,"Riociguat (Adempas, BAY63-2521) (DRUG); Sildenafil (DRUG); Tadalafil (DRUG)",110635,CIA,Pulmonary Arterial Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13562,NCT05179876,A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option,RECRUITING,PHASE3,"Hypertension, Pulmonary",Macitentan (DRUG); Selexipag (DRUG); Macitentan/Tadalafil FDC (DRUG),110635,CIA,Pulmonary Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13563,NCT01484431,A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension,COMPLETED,PHASE1,Pulmonary Arterial Hypertension,Tadalafil- Tablet or Oral suspension (DRUG),110635,CIA,Pulmonary Arterial Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13564,NCT02558231,The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension,COMPLETED,PHASE3,Pulmonary Arterial Hypertension,Macitentan (DRUG); Tadalafil (DRUG); Selexipag (DRUG),110635,CIA,Pulmonary Arterial Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13565,NCT01970176,Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2),COMPLETED,PHASE1,Cardiomyopathy; Renal Impairment,Tadalafil (DRUG); Placebo (DRUG),110635,CIA,Cardiomyopathy; Renal Impairment,Kidney,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13566,NCT05014776,"Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Pancreatic Cancer,Tadalafil (DRUG); Pembrolizumab (DRUG); Ipilimumab (DRUG); CRS-207 (DRUG),110635,CIA,Pancreatic Cancer,Pancreas,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13567,NCT01178073,A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH),COMPLETED,PHASE3,"Hypertension, Pulmonary",ambrisentan (DRUG); tadalafil (DRUG),110635,CIA,Pulmonary Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13568,NCT04500860,Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.,COMPLETED,PHASE1,Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence,"Low dose tadalafil 5 mg (DRUG); Tolterodine 4 Mg Oral Capsule, Extended Release (DRUG); Placebo (DRUG)",110635,CIA,Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence,Bladder/Urinary Tract,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13569,NCT05494567,Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB,UNKNOWN,PHASE4,Benign Prostatic Hyperplasia; Overactive Bladder,Tadalafil 5mg (DRUG); Tamsulosin Hcl 0.4 mg (DRUG); solifenacin 10 mg (DRUG),110635,CIA,Benign Prostatic Hyperplasia; Overactive Bladder,Bladder/Urinary Tract,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13570,NCT02544880,PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC,COMPLETED,PHASE1,Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer,Tadalafil (DRUG); Anti-MUC1 Vaccine (BIOLOGICAL); Anti-Influenza Vaccine (BIOLOGICAL); Tadalafil Placebo (OTHER); Anti-MUC1 Vaccine Placebo (OTHER); Standard of Care Treatment (OTHER); Anti-Influenza Vaccine Placebo (OTHER),110635,CIA,Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer,Skin,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13571,NCT01910389,Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure,TERMINATED,PHASE3,Heart Failure; Pulmonary Hypertension,Tadalafil (DRUG); Placebo for tadalafil (DRUG),110635,CIA,Heart Failure with Pulmonary Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13572,NCT02007629,Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor,COMPLETED,PHASE3,"Hypertension, Pulmonary","Riociguat (Adempas, BAY63-2521) (DRUG)",110635,CIA,Pulmonary Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13573,NCT05844462,Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease,RECRUITING,PHASE3,Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease,Tadalafil (DRUG); Placebo (DRUG),110635,CIA,Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13574,NCT01342224,Immunochemoradiotherapy in Patients With Pancreatic Cancer,COMPLETED,PHASE1,Locally Advanced Pancreatic Adenocarcinoma,tadalafil and vaccination (BIOLOGICAL),110635,CIA,Pancreatic Neoplasms,Pancreas,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13575,NCT05173896,Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial,ACTIVE_NOT_RECRUITING,PHASE2,"Cerebral Small Vessel Diseases; Stroke, Ischemic",Tadalafil 20 MG (DRUG); Placebo (DRUG),110635,CIA,"Cerebral Small Vessel Diseases; Stroke, Ischemic",CNS/Brain,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13576,NCT01042158,A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis,COMPLETED,PHASE4,Pulmonary Arterial Hypertension; Systemic Sclerosis; Scleroderma Spectrum of Diseases; Connective Tissue Disease; Pulmonary Hypertension,tadalafil and ambrisentan upfront combination therapy (DRUG),110635,CIA,Pulmonary Arterial Hypertension; Systemic Sclerosis; Scleroderma Spectrum of Diseases; Connective Tissue Disease; Pulmonary Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13577,NCT05537272,The Efficacy of Tamsulosin and Tadalafil Compared to Placebo in the Treatment and Prevention of Urinary Disorders After Transperineal Prostate Biopsy,UNKNOWN,PHASE4,Lower Urinary Tract Symptoms; Voiding Disorders; Pain; Quality of Life,Tadalafil 5mg (DRUG); Tamsulosin Hydrochloride 400 Microgram Prolonged-Release Oral Capsule (DRUG); Placebo (OTHER),110635,CIA,Lower Urinary Tract Symptoms; Voiding Disorders; Pain; Quality of Life,Bladder/Urinary Tract,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13578,NCT01197469,Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?,COMPLETED,PHASE2,Chronic Obstructive Pulmonary Disease; Pulmonary Hypertension,Tadalafil (DRUG); Placebo (DRUG),110635,CIA,Chronic Obstructive Pulmonary Disease; Pulmonary Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13579,NCT06466369,Administration of Tadalafil in Patients With Benign Prostatic Hyperplasia,COMPLETED,PHASE3,BPH With Other Lower Urinary Tract Symptoms,Tadalafil (DRUG),110635,CIA,BPH With Other Lower Urinary Tract Symptoms,Bladder/Urinary Tract,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13580,NCT02968901,Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA),TERMINATED,PHASE4,Pulmonary Arterial Hypertension,macitentan (DRUG); tadalafil (DRUG),110635,CIA,Pulmonary Arterial Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13581,NCT05955001,Efficacy of Tadalafil (5mg) For Treatment of Early Storage Symptoms and Erectile Dysfunction After Endoscopic Enucleation of Prostate,RECRUITING,PHASE2,Erectile Dysfunction; Lower Urinary Tract Symptoms,Tadalafil 5mg / Placebo (DRUG),110635,CIA,Erectile Dysfunction; Lower Urinary Tract Symptoms,Bladder/Urinary Tract,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13582,NCT03309592,Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension,WITHDRAWN,PHASE4,"Portopulmonary Hypertension; Pulmonary Hypertension; Cirrhosis, Liver",Ambrisentan Pill (DRUG); Tadalafil Pill (DRUG),110635,CIA,"Portopulmonary Hypertension; Pulmonary Hypertension; Cirrhosis, Liver",Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13583,NCT01302444,Treprostinil Combined With Tadalafil for Pulmonary Hypertension,TERMINATED,PHASE4,Pulmonary Arterial Hypertension,Tadalafil (DRUG); Placebo (DRUG),110635,CIA,Pulmonary Arterial Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13584,NCT03229889,"Trial of Tadalafil, Tamsulosin and Combination for Access Sheath Deployment",UNKNOWN,PHASE4,Nephrolithiasis,Cialis 5Mg Tablet (DRUG); Flomax 0.4Mg Capsule (DRUG); Cialis + Flomax (COMBINATION_PRODUCT); Placebo (DRUG),110635,CIA,Nephrolithiasis,Kidney,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13585,NCT02252367,Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms,COMPLETED,PHASE4,Prostatic Hyperplasia; Lower Urinary Tract Symptoms,Tadalafil (DRUG); Placebo (OTHER),110635,CIA,Prostatic Hyperplasia; Lower Urinary Tract Symptoms,Bladder/Urinary Tract,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13586,NCT01862536,Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease,COMPLETED,PHASE2,Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease (COPD),Tadalafil (DRUG); placebo (DRUG),110635,CIA,Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease (COPD),Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13587,NCT06491108,Medications for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia,RECRUITING,PHASE3,Enlarged Prostate With Lower Urinary Tract Symptoms,Vardenafil 5 Mg Oral Tablet (DRUG),110635,CIA,Enlarged Prostate With Lower Urinary Tract Symptoms,Bladder/Urinary Tract,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13588,NCT03785210,"Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers",COMPLETED,PHASE2,Hepatocellular Carcinoma; Hepatocellular Cancer; Metastatic Pancreatic Cancer; Metastatic Colorectal Cancer; Liver Metastasis,nivolumab (DRUG); tadalafil (DRUG); oral vancomycin (DRUG),110635,CIA,Hepatocellular Carcinoma; Hepatocellular Cancer; Metastatic Pancreatic Cancer; Metastatic Colorectal Cancer; Liver Metastasis,Bowel,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13589,NCT05487755,Investigational and Comparative Study in the Management of Diabetic Nephropathy,COMPLETED,PHASE3,Diabetic Nephropathy Type 2,Tadalafil 20Mg Oral Tablet (DRUG); Pentoxifylline 400 MG Oral Tablet (DRUG),110635,CIA,Diabetic Nephropathy Type 2,Kidney,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13590,NCT01553981,A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma,COMPLETED,PHASE3,"Lung Diseases, Interstitial",Tadalafil (DRUG); Placebo (DRUG),110635,CIA,"Lung Diseases, Interstitial",Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13591,NCT01757808,A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension,COMPLETED,PHASE1,Pulmonary Arterial Hypertension,Ranolazine (DRUG); Placebo (DRUG),110635,CIA,Pulmonary Arterial Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13592,NCT02058095,Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3),COMPLETED,PHASE1,Cardiomyopathy; Renal Impairment,Tadalafil (DRUG); Placebo (DRUG),110635,CIA,Cardiomyopathy; Renal Impairment,Kidney,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13593,NCT02999906,"Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension",WITHDRAWN,PHASE3,Pulmonary Arterial Hypertension,Oral Treprostinil (DRUG); Placebo (DRUG),110635,CIA,Pulmonary Arterial Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13594,NCT01324999,Tadalafil for Sarcoidosis Associated Pulmonary Hypertension,COMPLETED,PHASE2,Pulmonary Hypertension,Tadalafil (DRUG),110635,CIA,Pulmonary Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13595,NCT01966302,Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH),COMPLETED,PHASE2,Pulmonary Arterial Hypertension,BPS-314d-MR (DRUG),110635,CIA,Pulmonary Arterial Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13596,NCT00549302,Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs,COMPLETED,PHASE3,"Hypertension, Pulmonary",tadalafil (DRUG); tadalafil (DRUG),110635,CIA,Pulmonary Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13597,NCT02225548,Sagene 2014 - Parkinson's Disease and Erectile Dysfunction,UNKNOWN,PHASE4,Parkinson's Disease; Erectile Dysfunction,Selegiline (DRUG); Tadalafil (DRUG),110635,CIA,Parkinson's Disease; Erectile Dysfunction,CNS/Brain,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13598,NCT03236818,Goal Oriented Strategy to Preserve Ejection Fraction Trial,UNKNOWN,PHASE4,Pulmonary Arterial Hypertension,"ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan) (DRUG)",110635,CIA,Pulmonary Arterial Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13599,NCT00125918,PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension,COMPLETED,PHASE3,Pulmonary Hypertension,tadalafil (DRUG); tadalafil (DRUG); tadalafil (DRUG); tadalafil (DRUG); placebo (DRUG),110635,CIA,Pulmonary Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13600,NCT00894413,A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract,COMPLETED,PHASE2,Head and Neck Squamous Cell Carcinoma,Tadalafil (DRUG); Placebo Pill (OTHER),110635,CIA,Head and Neck Squamous Cell Carcinoma,Skin,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13601,NCT01697800,A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract,COMPLETED,PHASE2,Head and Neck Squamous Cell Carcinoma,Tadalafil (DRUG); Placebo (DRUG),110635,CIA,Head and Neck Squamous Cell Carcinoma,Skin,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13602,NCT02801032,Effect of Tadalafil on Cerebral Large Arteries in Stroke,COMPLETED,PHASE2,"Stroke, Lacunar; Cerebral Small Vessel Diseases",Tadalafil (DRUG); Placebo (DRUG),110635,CIA,"Stroke, Lacunar; Cerebral Small Vessel Diseases",CNS/Brain,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13603,NCT04069936,Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC,TERMINATED,PHASE2,"Non Small Cell Lung Cancer; Lung Cancer; Lung Cancer Metastatic; Lung Cancer, Non-small Cell; Non Small Cell Lung Cancer Metastatic; NSCLC; Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Metastatic",MILs™ - NSCLC (BIOLOGICAL); nivolumab (BIOLOGICAL); tadalafil (DRUG),110635,CIA,"Non Small Cell Lung Cancer; Lung Cancer; Lung Cancer Metastatic; Lung Cancer, Non-small Cell; Non Small Cell Lung Cancer Metastatic; NSCLC; Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Metastatic",Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13604,NCT01305252,A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).,COMPLETED,PHASE4,"Hypertension, Pulmonary",treprostinil inhalations (DRUG); tadalafil (DRUG),110635,CIA,Pulmonary Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13605,NCT02284737,A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH,TERMINATED,PHASE4,Pulmonary Arterial Hypertension,PADN (PROCEDURE); sham PADN (PROCEDURE); Sildenafil (DRUG),110635,CIA,Pulmonary Arterial Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13606,NCT02688387,A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects,COMPLETED,PHASE1,"Hypertension, Pulmonary",FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose (DRUG); Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently) (DRUG),110635,CIA,Pulmonary Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13607,NCT01960153,Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage,WITHDRAWN,PHASE3,Heart Failure; Pulmonary Hypertension,Tadalafil (DRUG); Placebo (DRUG),110635,CIA,Heart Failure with Pulmonary Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13608,NCT03993353,Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer,ACTIVE_NOT_RECRUITING,PHASE2,"Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Head and Neck Carcinoma; Head and Neck Cancer Stage III; Head and Neck Cancer Stage IV; Head and Neck Cancer Metastatic; Cancer; Cancer of Esophagus; Cancer, Metastatic; Cancer of Head and Neck; Cancer of Mouth; Cancer of Neck",Pembrolizumab (DRUG); Tadalafil (DRUG),110635,CIA,"Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Head and Neck Carcinoma; Head and Neck Cancer Stage III; Head and Neck Cancer Stage IV; Head and Neck Cancer Metastatic; Cancer; Cancer of Esophagus; Cancer, Metastatic; Cancer of Head and Neck; Cancer of Mouth; Cancer of Neck",Skin,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13609,NCT05937854,Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH,RECRUITING,PHASE2,Chronic Obstructive Pulmonary Disease; Pulmonary Hypertension; Dyspnea,Tadalafil (DRUG); Placebo (DRUG),110635,CIA,Chronic Obstructive Pulmonary Disease; Pulmonary Hypertension; Dyspnea,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13610,NCT02450253,Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial,COMPLETED,PHASE2,"Dementia, Vascular",Tadalafil (DRUG); Placebo (DRUG); Cognitive functioning tests (BEHAVIORAL); Neuropsychological tests (BEHAVIORAL); MRI Scan - Arterial Spin Labelling (OTHER),110635,CIA,"Dementia, Vascular",CNS/Brain,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13611,NCT04483115,Acute Haemodynamic Study of TPN171H in Patients with Pulmonary Arterial Hypertension,COMPLETED,PHASE2,Pulmonary Arterial Hypertension,TPN171H (DRUG); Placebo (DRUG); Tadalafil (DRUG),110635,CIA,Pulmonary Arterial Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13612,NCT00705588,Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.,UNKNOWN,PHASE4,Pulmonary Arterial Hypertension,Tadalafil (DRUG); Vardenafil (DRUG),110635,CIA,Pulmonary Arterial Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13613,NCT03904693,Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH),COMPLETED,PHASE3,Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH),FDC macitentan/tadalafil (DRUG); Macitentan 10 mg (DRUG); Tadalafil 40 mg (DRUG); Placebo FDC (DRUG); Placebo macitentan (DRUG); Placebo tadalafil (DRUG),110635,CIA,Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH),Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13614,NCT00617305,Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1),COMPLETED,PHASE4,Pulmonary Arterial Hypertension,Ambrisentan (DRUG); Placebo (DRUG); Sildenafil (DRUG); Tadalafil (DRUG),110635,CIA,Pulmonary Arterial Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13615,NCT06317805,Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients,RECRUITING,PHASE4,Pulmonary Arterial Hypertension,Generic treprostinil sodium + Standard of Care (Double Oral) (DRUG); Standard of Care - Double Oral (DRUG),110635,CIA,Pulmonary Arterial Hypertension,Lung,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13616,NCT06809205,"Efficacy and Safety of Tadalafil, Tamsulosin, and Their Combinations in Treating Lower Urinary Tract Symptoms in BPH Patients with Prostate Volumes ≤ 40 Ml: a Prospective Comparative Study",COMPLETED,PHASE4,BPH with Other Lower Urinary Tract Symptoms,Tamsulosin 0.4 mg (DRUG); Tadalafil 5mg (DRUG); Tamsulosin and Tadalafil (DRUG),110635,CIA,BPH with Other Lower Urinary Tract Symptoms,Bladder/Urinary Tract,Tadalafil,PDE5A,inhibitor/antagonist,unclear,yes,yes,Used for erectile dysfunction and pulmonary arterial hypertension.,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,1.05,331.0 +13617,NCT00496665,ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer,COMPLETED,PHASE1,Metastatic Breast Cancer,Vandetanib (DRUG); Cyclophosphamide (DRUG); Methotrexate (DRUG),3081361,Zactima,Metastatic Breast Cancer,Breast,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13618,NCT00500292,A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer,COMPLETED,PHASE2,Colorectal; Cancer,"Vandetanib (DRUG); FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid (DRUG)",3081361,Zactima,Colorectal; Cancer,Bowel,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13619,NCT00752986,ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial,TERMINATED,PHASE2,Breast Cancer,ZD6474 (Vandetanib at the dose of 100 mg) (DRUG); Placebo to match ZD6474 (Vandetanib at the dose of 100 mg) (DRUG); Fulvestrant (DRUG); ZD6474 (Vandetanib at the dose of 300 mg) (DRUG); Placebo to match ZD6474 (Vandetanib at the dose of 300 mg) (DRUG),3081361,Zactima,Breast Cancer,Breast,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13620,NCT00418886,Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients,COMPLETED,PHASE3,Non Small Cell Lung Cancer; Lung Cancer,Vandetanib (DRUG); Pemetrexed (DRUG),3081361,Zactima,Non Small Cell Lung Cancer; Lung Cancer,Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13621,NCT00410189,BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC,COMPLETED,PHASE2,Lung Cancer,ZD6474 (DRUG),3081361,Zactima,Lung Cancer,Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13622,NCT00404924,ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures,COMPLETED,PHASE3,Non-Small-Cell Lung Carcinoma,ZD6474 (vandetanib) (DRUG); Best Supportive Care (OTHER),3081361,Zactima,Non-Small-Cell Lung Carcinoma,Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13623,NCT00454116,"A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients",COMPLETED,PHASE2,Colorectal Cancer,Vandetanib (DRUG); FOLFIRI (DRUG),3081361,Zactima,Colorectal Cancer,Bowel,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13624,NCT00551096,Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors,COMPLETED,PHASE1,Malignant Solid Tumour; Biliary Cancer; Pancreatic Cancer,Gemcitabine (DRUG); Capecitabine (DRUG); ZD6474 (DRUG),3081361,Zactima,Malignant Solid Tumour; Biliary Cancer; Pancreatic Cancer,Pancreas,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13625,NCT00508001,Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC),COMPLETED,PHASE2,"Carcinoma, Hepatocellular",Vandetanib (DRUG); Vandetanib (DRUG); Best Supportive Care (DRUG),3081361,Zactima,"Carcinoma, Hepatocellular",Liver,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13626,NCT00533169,ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma,TERMINATED,PHASE1,Neuroblastoma,ZD6474 (DRUG); Retinoic Acid (DRUG),3081361,Zactima,Neuroblastoma,CNS/Brain,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13627,NCT00252746,ZD6474 Phase IIa Dose Finding Multicentre Study,COMPLETED,PHASE2,Non Small Cell Lung Carcinoma,ZD6474 (vandetanib) 100mg (DRUG); ZD6474 (vandetanib) 200mg (DRUG); ZD6474 (vandetanib) 300mg (DRUG),3081361,Zactima,Non Small Cell Lung Carcinoma,Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13628,NCT00597116,An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma,TERMINATED,PHASE2,Mesothelioma,Vinorelbine (DRUG); Vandetanib (DRUG),3081361,Zactima,Mesothelioma,Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13629,NCT00811369,"Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer",COMPLETED,PHASE2,Metastatic Breast Cancer,Fulvestrant + ZACTIMA (DRUG); Fulvestrant + Placebo (DRUG),3081361,Zactima,Metastatic Breast Cancer,Breast,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13630,NCT00472017,Vandetanib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Diffuse Brainstem Glioma,COMPLETED,PHASE1,Brain and Central Nervous System Tumors,vandetanib (DRUG),3081361,Zactima,Brain and Central Nervous System Tumors,CNS/Brain,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13631,NCT00880334,Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC,COMPLETED,PHASE2,Transitional Cell Carcinoma; Bladder Cancer,Docetaxel (DRUG); vandetanib (DRUG); Placebo (DRUG),3081361,Zactima,Transitional Cell Carcinoma; Bladder Cancer,Bladder/Urinary Tract,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13632,NCT01004419,Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer,WITHDRAWN,PHASE1,"Carcinoma, Non Small Cell Lung",ZD6474 (vandetanib) (DRUG); Faslodex (Fulvestrant) (DRUG),3081361,Zactima,Non-small Cell Lung Cancer (NSCLC),Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13633,NCT00862836,Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD),TERMINATED,PHASE1,Ovarian Cancer,Vandetanib (DRUG),3081361,Zactima,Ovarian Cancer,Ovary/Fallopian Tube,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13634,NCT00494481,E3 Breast Cancer Taxotere Combination,COMPLETED,PHASE2,Advanced Breast Cancer,Vandetanib (ZD6474) (DRUG); Docetaxel (DRUG),3081361,Zactima,Advanced Breast Cancer,Breast,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13635,NCT00753714,Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine,COMPLETED,PHASE2,Non Small Cell Lung Cancer,"ZD6474, Vandetanib (DRUG); Placebo to Match ZD6474, Vandetanib (DRUG); Gemcitabine (DRUG)",3081361,Zactima,Non Small Cell Lung Cancer,Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13636,NCT00499850,Phase I FOLFOX Combination,COMPLETED,PHASE1,Advanced Colorectal Carcinoma,ZD6474 (vandetanib) (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG),3081361,Zactima,Advanced Colorectal Carcinoma,Bowel,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13637,NCT00613223,Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas,COMPLETED,PHASE1,Gliosarcoma; Glioblastoma,Vandetanib and Etoposide (DRUG),3081361,Zactima,Gliosarcoma; Glioblastoma,CNS/Brain,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13638,NCT00566995,Phase II Study of Vandetanib in Individuals With Kidney Cancer,COMPLETED,PHASE2,Renal Cancer; Von Hippel Lindau,ZACTIMA (Vandetanib) (ZD6474) (DRUG),3081361,Zactima,Renal Cancer; Von Hippel Lindau,Kidney,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13639,NCT00445549,"Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",TERMINATED,PHASE2,Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms,Vandetanib (DRUG),3081361,Zactima,Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms,Ovary/Fallopian Tube,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13640,NCT00807170,Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases,TERMINATED,PHASE1,Non-small Cell Lung Cancer (NSCLC),ZD6474 (Vandetanib) (DRUG); Whole Brain Radiotherapy (WBRT) (RADIATION); ZD6474 (DRUG); ZD6474 (DRUG),3081361,Zactima,Non-small Cell Lung Cancer (NSCLC),Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13641,NCT00459121,"Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery",TERMINATED,PHASE2,Lung Cancer,carboplatin (DRUG); paclitaxel (DRUG); Zactima (DRUG); neoadjuvant therapy (PROCEDURE),3081361,Zactima,Lung Cancer,Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13642,NCT00459043,Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck,COMPLETED,PHASE2,Squamous Cell Carcinoma of Head and Neck,ZD6474 (DRUG); Docetaxel (DRUG),3081361,Zactima,Squamous Cell Carcinoma of Head and Neck,Skin,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13643,NCT00753675,Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer,COMPLETED,PHASE2,Biliary Tract Cancer; Gallbladder Cancer; Cancer Of The Extrahepatic Bile Duct; Ampullary Carcinoma,"ZD6474, Vandetanib (DRUG); ZD6474, Vandetanib (DRUG); Gemcitabine (DRUG); Placebo matching ZD6474 (DRUG)",3081361,Zactima,Biliary Tract Cancer; Gallbladder Cancer; Cancer Of The Extrahepatic Bile Duct; Ampullary Carcinoma,Liver,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13644,NCT00496275,Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC,COMPLETED,PHASE1,Non Small Cell Lung Cancer,Zactima (ZD6474) (DRUG); Vinorelbine plus cisplatin (DRUG); Gemcitabine plus cisplatin (DRUG),3081361,Zactima,Non Small Cell Lung Cancer,Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13645,NCT00441142,Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors,COMPLETED,PHASE1,Glioblastoma Multiforme; Gliosarcoma,ZD6474 (DRUG); temozolomide (DRUG); Radiation Therapy (RADIATION),3081361,Zactima,Glioblastoma Multiforme; Gliosarcoma,CNS/Brain,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13646,NCT00822887,Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas,COMPLETED,PHASE1,Malignant Gliomas,Vandetanib (DRUG); Fractionated Stereotactic Radiotherapy (RADIATION),3081361,Zactima,Malignant Gliomas,CNS/Brain,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13647,NCT00290537,Phase II Study of ZD6474 in Advanced NSCLC,TERMINATED,PHASE2,Lung Cancer,ZD6474 (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG),3081361,Zactima,Lung Cancer,Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13648,NCT00745732,Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC),TERMINATED,PHASE1,Non-Small Cell Lung Cancer,ZD6474 (ZACTIMA) (DRUG); Radiation Therapy (RADIATION),3081361,Zactima,Advanced Non-Small Cell Lung Cancer,Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13649,NCT00364351,Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy,COMPLETED,PHASE3,Non Small Cell Lung Cancer,Vandetanib (DRUG); Erlotinib (DRUG),3081361,Zactima,Non Small Cell Lung Cancer,Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13650,NCT00506051,ZD6474(Vandetanib) + Alimta Combo Study,COMPLETED,PHASE1,Carcinoma; Non-Small Cell Lung; Lung Cancer,ZD6474 (vandetanib) 100mg (DRUG); pemetrexed (DRUG); ZD6474 (vandetanib) 300mg (DRUG),3081361,Zactima,Carcinoma; Non-Small Cell Lung; Lung Cancer,Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13651,NCT00312377,ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer,COMPLETED,PHASE3,Non-small Cell Lung Cancer; Lung Cancer,Docetaxel (DRUG); Vandetanib (DRUG),3081361,Zactima,Non-small Cell Lung Cancer; Lung Cancer,Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13652,NCT00496509,Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,ZD6474 (Zactima) 100mg (DRUG); Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR) (PROCEDURE); Biomarker Draws (PROCEDURE); ZD6474 (Zactima) 300mg (DRUG),3081361,Zactima,Colorectal Cancer,Bowel,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13653,NCT00481845,Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer,TERMINATED,PHASE2,Breast Cancer,Vandetanib (DRUG); Anastrozole (DRUG),3081361,Zactima,Breast Cancer,Breast,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13654,NCT00681798,Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma,COMPLETED,PHASE1,Pancreatic Cancer,Vandetanib (DRUG),3081361,Zactima,Pancreatic Cancer,Pancreas,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13655,NCT00732745,"Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction",TERMINATED,PHASE1,Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer,docetaxel (DRUG); oxaliplatin (DRUG); vandetanib (DRUG); placebo (OTHER),3081361,Zactima,Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer,Esophagus/Stomach,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13656,NCT00613054,Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma,COMPLETED,PHASE1,Glioblastoma; Gliosarcoma,"Zactima, Gleevec, Hydroxyurea (DRUG)",3081361,Zactima,Glioblastoma,CNS/Brain,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13657,NCT01414426,Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions,COMPLETED,PHASE2,Lip and Oral Cavity Squamous Cell Carcinoma; Oral Cavity Verrucous Carcinoma; Precancerous Condition,vandetanib (DRUG); placebo (OTHER); immunohistochemistry staining method (OTHER); laboratory biomarker analysis (OTHER); biopsy (PROCEDURE); pharmacological study (OTHER),3081361,Zactima,Lip and Oral Cavity Squamous Cell Carcinoma; Oral Cavity Verrucous Carcinoma; Precancerous Condition,Skin,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13658,NCT00734890,Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma,COMPLETED,PHASE1,"Lung Cancer; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific",bevacizumab (BIOLOGICAL); vandetanib (DRUG); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),3081361,Zactima,"Lung Cancer; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13659,NCT02495103,Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma,TERMINATED,PHASE1,Renal Cell Carcinoma; Hereditary Leiomyomatosis; Renal Cell Cancer,Vandetanib (DRUG); Metformin (DRUG); Vandetanib/Metformin (DRUG),3081361,Zactima,Renal Cell Carcinoma; Hereditary Leiomyomatosis; Renal Cell Cancer,Kidney,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13660,NCT01823068,Vandetanib in Advanced NSCLC With RET Rearrangement,COMPLETED,PHASE2,Non Small Cell Lung Cancer,Vandetanib (DRUG),3081361,Zactima,Non Small Cell Lung Cancer,Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13661,NCT02117167,SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients,COMPLETED,PHASE2,Non-small Cell Lung Cancer Metastatic,AZD2014 (DRUG); AZD4547 (DRUG); AZD5363 (DRUG); AZD8931 (DRUG); Selumetinib (DRUG); Vandetanib (DRUG); Standard maintenance for squamous NSCLC (DRUG); Pemetrexed (DRUG); Durvalumab (DRUG); savolitinib (DRUG); Olaparib (DRUG),3081361,Zactima,Non-small Cell Lung Cancer Metastatic,Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13662,NCT00872989,"S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",COMPLETED,PHASE2,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,docetaxel (DRUG); vandetanib (DRUG),3081361,Zactima,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13663,NCT00821080,Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma,COMPLETED,PHASE1,Glioblastoma,Sirolimus (DRUG); Vandetanib (DRUG),3081361,Zactima,Glioblastoma,CNS/Brain,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13664,NCT01934335,Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer,TERMINATED,PHASE2,Invasive Breast Cancer,Vandetanib (DRUG); Placebo (OTHER),3081361,Zactima,Invasive Breast Cancer,Breast,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13665,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,75 approved agents (DRUG); COXEN (OTHER),3081361,Zactima,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,Bladder/Urinary Tract,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13666,NCT01191892,Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer,COMPLETED,PHASE2,Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Ureter Cancer; Urethral Cancer,carboplatin (DRUG); gemcitabine hydrochloride (DRUG); vandetanib (DRUG); Placebo (DRUG),3081361,Zactima,Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Ureter Cancer; Urethral Cancer,Bladder/Urinary Tract,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13667,NCT01586624,A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1),COMPLETED,PHASE1,Cancer; Non Small Cell Lung Cancer,"Vandetanib, Selumetinib (DRUG); Vandetanib, Selumetinib (DRUG); Vandetanib, Selumetinib (DRUG); Vandetanib, Selumetinib (DRUG); Vandetanib, Selumetinib (DRUG); Vandetanib, Selumetinib (DRUG); Vandetanib, Selumetinib (DRUG); Vandetanib, Selumetinib (DRUG)",3081361,Zactima,Cancer; Non Small Cell Lung Cancer,Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13668,NCT00937417,S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors,WITHDRAWN,PHASE1,"Breast Cancer; Head and Neck Cancer; Lung Cancer; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",docetaxel (DRUG); vandetanib (DRUG); proteomic profiling (GENETIC); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),3081361,Zactima,"Breast Cancer; Head and Neck Cancer; Lung Cancer; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13669,NCT00996723,Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG),COMPLETED,PHASE1,Diffuse Intrinsic Pontine Glioma,vandetanib and dasatinib (DRUG),3081361,Zactima,Diffuse Intrinsic Pontine Glioma,CNS/Brain,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13670,NCT01601808,Clinical Trial Comparing Gemcitabine and Vandetanib Therapy with Gemcitabine Alone in Pancreatic Carcinoma,COMPLETED,PHASE2,Pancreatic Cancer,Placebo (DRUG); Caprelsa (vandetanib) (DRUG),3081361,Zactima,Pancreatic Cancer,Pancreas,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13671,NCT02299999,SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Breast Cancer,AZD2014 (DRUG); AZD4547 (DRUG); AZD5363 (DRUG); AZD8931 (DRUG); Selumetinib (DRUG); Vandetanib (DRUG); Bicalutamide (DRUG); Olaparib (DRUG); Anthracyclines (DRUG); Taxanes (DRUG); cyclophosphamide (DRUG); DNA intercalators (DRUG); Methotrexate (DRUG); vinca alkaloids (DRUG); Platinum based chemotherapies (DRUG); Bevacizumab (DRUG); Mitomycin C (DRUG); Eribulin (DRUG); MEDI4736 (DRUG),3081361,Zactima,Metastatic Breast Cancer,Breast,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13672,NCT03291379,Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies,COMPLETED,EARLY_PHASE1,"Carcinoma, Hepatocellular; Metastatic Colorectal Cancer",BTG-002814 (DRUG),3081361,Zactima,"Carcinoma, Hepatocellular; Metastatic Colorectal Cancer",Bowel,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13673,NCT00066313,ZD6474 in Treating Patients With Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,vandetanib (DRUG); adjuvant therapy (PROCEDURE),3081361,Zactima,Lung Cancer,Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13674,NCT00532909,"Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer",COMPLETED,PHASE1,"Anal, Colon, and Rectal Cancers; Colorectal Neoplasms; Colon/Rectal Cancer",Vandetanib (DRUG); Capecitabine (DRUG); Oxaliplatin (DRUG); Bevacizumab (DRUG),3081361,Zactima,"Anal, Colon, and Rectal Cancers; Colorectal Neoplasms; Colon/Rectal Cancer",Bowel,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13675,NCT00995007,A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas,COMPLETED,PHASE2,Glioblastoma Multiforme; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Mixed Oligoastrocytoma,ZD6474 (Vandetanib) (DRUG); Carboplatin (DRUG),3081361,Zactima,Glioblastoma Multiforme; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Mixed Oligoastrocytoma,CNS/Brain,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13676,NCT00683787,Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer,TERMINATED,PHASE2,Gastric Cancer,docetaxel (DRUG); vandetanib (DRUG),3081361,Zactima,Gastric Cancer,Esophagus/Stomach,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13677,NCT00687297,Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer; Non Small Cell Lung Cancer,vandetanib induction (DRUG); Docetaxel (DRUG); Carboplatin (DRUG); Placebo (DRUG); Vandetanib maintenance (DRUG),3081361,Zactima,Lung Cancer; Non Small Cell Lung Cancer,Lung,Vandetanib,"EGFR, KDR",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for use in medullary thyroid cancer.,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,1.02,196.0 +13678,NCT03466450,Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma,COMPLETED,PHASE1,Glioblastoma,PF-04449913 (DRUG); Temozolomide Oral Capsule (DRUG),25166913,Glasdegib,Glioblastoma,CNS/Brain,Glasdegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Glasdegib is approved for acute myeloid leukemia.,CN1CCC(CC1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N,1.02,449.0 +13679,NCT03529448,TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma,ACTIVE_NOT_RECRUITING,PHASE1,Glioblastoma,TN-TC11G (DRUG); Temozolomide Oral Product (DRUG); Radiotherapy (RADIATION),25166913,Glasdegib,Glioblastoma,CNS/Brain,Glasdegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Glasdegib is approved for acute myeloid leukemia.,CN1CCC(CC1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N,1.02,449.0 +13680,NCT03596567,Glasdegib Renal Impairment Study,COMPLETED,PHASE1,Renal Impairment,Glasdegib single 100 mg dose in normal healthy subjects (DRUG); Glasdegib single 100 mg dose in moderate renal impairment subjects (DRUG); Glasdegib single 100 mg dose in severe renal impairment subjects (DRUG),25166913,Glasdegib,Renal Impairment,Kidney,Glasdegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Glasdegib is approved for acute myeloid leukemia.,CN1CCC(CC1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N,1.02,449.0 +13681,NCT03627754,A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib,COMPLETED,PHASE1,Hepatic Impairment,Glasdegib 100 mg single oral dose (DRUG),25166913,Glasdegib,Hepatic Impairment,Liver,Glasdegib,SMO,inhibitor/antagonist,Sonic inhibitor,yes,yes,Glasdegib is approved for acute myeloid leukemia.,CN1CCC(CC1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N,1.02,449.0 +13682,NCT00409071,Placebo-controlled Evaluation of Cocculine® Efficacy in the Management of Nausea After Chemotherapy in Breast Cancer.,COMPLETED,PHASE3,Breast Cancer,Cocculine® (DRUG); placebo (DRUG),5459308,Kukoline,Breast Cancer,Breast,Sinomenine,OPRM1,unclear,unclear,no,yes,Used in trials for pain and arthritis.,CN1CCC23CC(=O)C(=CC2C1CC4=C3C(=C(C=C4)OC)O)OC,1.0,0.0 +13683,NCT05375994,Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients,ACTIVE_NOT_RECRUITING,PHASE1,Non Small Cell Lung Cancer; KRAS Activating Mutation; Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung; Malignant Neoplastic Disease,avutometinib (VS-6766) and adagrasib (DRUG),138611145,KRAZATI,Non Small Cell Lung Cancer; KRAS Activating Mutation; Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung; Malignant Neoplastic Disease,Lung,Adagrasib,KRAS,inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for treating KRAS G12C-mutated non-small cell lung cancer.,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,1.032258064516129,2380.0 +13684,NCT04613596,Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7,RECRUITING,PHASE2,Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer,Adagrasib (DRUG); Adagrasib (DRUG); Adagrasib (DRUG); Adagrasib (DRUG); Pembrolizumab (DRUG),138611145,KRAZATI,Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer,Lung,Adagrasib,KRAS,inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for treating KRAS G12C-mutated non-small cell lung cancer.,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,1.032258064516129,2380.0 +13685,NCT04685135,Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation,ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer,MRTX849 (DRUG); Docetaxel (DRUG),138611145,KRAZATI,Metastatic Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer,Lung,Adagrasib,KRAS,inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for treating KRAS G12C-mutated non-small cell lung cancer.,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,1.032258064516129,2380.0 +13686,NCT05578092,A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway,RECRUITING,PHASE1,Solid Tumor; Advanced Solid Tumor; Non Small Cell Lung Cancer; Colo-rectal Cancer,MRTX0902 (DRUG); MRTX849 (DRUG),138611145,KRAZATI,Solid Tumor; Advanced Solid Tumor; Non Small Cell Lung Cancer; Colo-rectal Cancer,Lung,Adagrasib,KRAS,inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for treating KRAS G12C-mutated non-small cell lung cancer.,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,1.032258064516129,2380.0 +13687,NCT06875310,A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4),RECRUITING,PHASE3,"Carcinoma, Non-Small-Cell Lung",Adagrasib (DRUG); Pembrolizumab (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Placebo (DRUG); Cisplatin (DRUG),138611145,KRAZATI,"Carcinoma, Non-Small-Cell Lung",Lung,Adagrasib,KRAS,inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for treating KRAS G12C-mutated non-small cell lung cancer.,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,1.032258064516129,2380.0 +13688,NCT06026410,KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors,RECRUITING,PHASE1,Solid Tumors With HRAS Alterations; Non Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Clear Cell Renal Cell Carcinoma (ccRCC); Renal Cell Carcinoma (Kidney Cancer),KO-2806 (DRUG); Cabozantinib (DRUG); Adagrasib (DRUG),138611145,KRAZATI,Solid Tumors With HRAS Alterations; Non Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Clear Cell Renal Cell Carcinoma (ccRCC); Renal Cell Carcinoma (Kidney Cancer),Bowel,Adagrasib,KRAS,inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for treating KRAS G12C-mutated non-small cell lung cancer.,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,1.032258064516129,2380.0 +13689,NCT06248606,Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases,RECRUITING,PHASE2,Non Small Cell Lung Cancer; NSCLC; KRAS G12C,Adagrasib (DRUG); Stereotactic Radiosurgery (RADIATION),138611145,KRAZATI,Non Small Cell Lung Cancer; NSCLC; KRAS G12C,Lung,Adagrasib,KRAS,inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for treating KRAS G12C-mutated non-small cell lung cancer.,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,1.032258064516129,2380.0 +13690,NCT05722327,Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Colon Cancer; Colorectal Cancer,MRTX849 (DRUG); Irinotecan (DRUG); Cetuximab (DRUG),138611145,KRAZATI,Colon Cancer; Colorectal Cancer,Bowel,Adagrasib,KRAS,inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for treating KRAS G12C-mutated non-small cell lung cancer.,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,1.032258064516129,2380.0 +13691,NCT04793958,Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10),ACTIVE_NOT_RECRUITING,PHASE3,Advanced Colorectal Cancer; Metastatic Colorectal Cancer,MRTX849 (DRUG); Cetuximab (BIOLOGICAL); mFOLFOX6 Regimen (DRUG); FOLFIRI Regimen (DRUG),138611145,KRAZATI,Advanced Colorectal Cancer; Metastatic Colorectal Cancer,Bowel,Adagrasib,KRAS,inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for treating KRAS G12C-mutated non-small cell lung cancer.,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,1.032258064516129,2380.0 +13692,NCT05472623,Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab,ACTIVE_NOT_RECRUITING,PHASE2,Resectable Non-Small Cell Lung Cancer,Adagrasib (DRUG); Adagrasib/Nivolumab (COMBINATION_PRODUCT),138611145,KRAZATI,Resectable Non-Small Cell Lung Cancer,Lung,Adagrasib,KRAS,inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for treating KRAS G12C-mutated non-small cell lung cancer.,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,1.032258064516129,2380.0 +13693,NCT06130254,"Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers",RECRUITING,PHASE1,Advanced Solid Tumor; Non-small Cell Lung Cancers,Adagrasib (DRUG); Olaparib (DRUG),138611145,KRAZATI,Advanced Solid Tumor; Non-small Cell Lung Cancers,Lung,Adagrasib,KRAS,inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for treating KRAS G12C-mutated non-small cell lung cancer.,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,1.032258064516129,2380.0 +13694,NCT05634525,Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients,RECRUITING,PHASE1,Metastatic Pancreatic Cancer,MRTX849 (DRUG),138611145,KRAZATI,Metastatic Pancreatic Cancer,Pancreas,Adagrasib,KRAS,inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for treating KRAS G12C-mutated non-small cell lung cancer.,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,1.032258064516129,2380.0 +13695,NCT05848843,A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations,WITHDRAWN,PHASE1,Lung Cancer; Gastro-intestinal Cancer,Durvalumab (DRUG); Adagrasib (DRUG),138611145,KRAZATI,Lung Cancer; Gastro-intestinal Cancer,Lung,Adagrasib,KRAS,inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for treating KRAS G12C-mutated non-small cell lung cancer.,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,1.032258064516129,2380.0 +13696,NCT06497556,A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer,RECRUITING,PHASE3,Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer,Divarasib (DRUG); Sotorasib (DRUG); Adagrasib (DRUG),138611145,KRAZATI,Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer,Lung,Adagrasib,KRAS,inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for treating KRAS G12C-mutated non-small cell lung cancer.,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,1.032258064516129,2380.0 +13697,NCT05609578,Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation,RECRUITING,PHASE2,Advanced NSCLC; Metastatic Lung Cancer,Adagrasib oral dose of 400 mg twice daily tablets (DRUG); Pembrolizumab (COMBINATION_PRODUCT); Chemotherapy: Pemetrexed (COMBINATION_PRODUCT); Cisplatin/Carboplatin (COMBINATION_PRODUCT),138611145,KRAZATI,Advanced NSCLC; Metastatic Lung Cancer,Lung,Adagrasib,KRAS,inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for treating KRAS G12C-mutated non-small cell lung cancer.,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,1.032258064516129,2380.0 +13698,NCT06412198,"A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations",RECRUITING,PHASE1,Metastatic Colorectal Cancer; KRAS G12C Mutations,Cetuximab (DRUG); Cemiplimab (DRUG); Adagrasib (DRUG),138611145,KRAZATI,Metastatic Colorectal Cancer; KRAS G12C Mutations,Bowel,Adagrasib,KRAS,inhibitor/antagonist,RAS inhibitor,yes,yes,Approved for treating KRAS G12C-mutated non-small cell lung cancer.,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,1.032258064516129,2380.0 +13699,NCT01271920,Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab,COMPLETED,PHASE1,Advanced HER2-positive Breast Cancer,AUY922 (DRUG); Trastuzumab (DRUG),3578572,EMPM,Advanced HER2-positive Breast Cancer,Breast,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13700,NCT00951665,"A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer",COMPLETED,PHASE1,Metastatic Breast Cancer,paclitaxel (DRUG); pertuzumab [Perjeta] (DRUG); trastuzumab emtansine [Kadcyla] (DRUG); paclitaxel (DRUG); trastuzumab emtansine [Kadcyla] (DRUG),3578572,EMPM,Metastatic Breast Cancer,Breast,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13701,NCT03227926,Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance,COMPLETED,PHASE2,Colorectal Cancer,Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX] (DRUG); Molecular Screening (DIAGNOSTIC_TEST),3578572,EMPM,Colorectal Cancer,Bowel,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13702,NCT04053790,Lactobacillus LB as Treatment for Irritable Bowel Syndrome With Predominance of Diarrhea (IBS-D),COMPLETED,PHASE4,Irritable Bowel Syndrome With Diarrhea,lactobacillus LB (DRUG); placebo (OTHER),3578572,EMPM,Irritable Bowel Syndrome With Diarrhea,Bowel,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13703,NCT01872260,"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,LEE011 (DRUG); Letrozole (DRUG); BYL719 (DRUG),3578572,EMPM,Breast Cancer,Breast,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13704,NCT06173466,Postoperative Analgesia With Liposomal Bupivacaine Versus Standard Bupivacaine Combined With Dexamethasone,COMPLETED,PHASE4,Liver Cancer,Liposomal bupivacaine (DRUG); Bupivacaine Hydrochloride combined with dexamethasone (DRUG),3578572,EMPM,Liver Cancer,Liver,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13705,NCT03975829,Pediatric Long-Term Follow-up and Rollover Study,ACTIVE_NOT_RECRUITING,PHASE4,"Diffuse Astrocytoma; Anaplastic Astrocytoma; Astrocytoma; Oligodendroglioma, Childhood; Anaplastic Oligodendroglioma; Glioblastoma; Pilocytic Astrocytoma; Giant Cell Astrocytoma; Pleomorphic Xanthoastrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Angiocentric Glioma; Chordoid Glioma of Third Ventricle; Gangliocytoma; Ganglioglioma; Anaplastic Ganglioglioma; Dysplastic Gangliocytoma of Cerebrellum; Desmoplastic Infantile Astrocytoma and Ganglioglioma; Papillary Glioneuronal Tumor; Rosette-forming Glioneuronal Tumor; Central Neurocytoma; Extraventricular Neurocytoma; Cerebellar Liponeurocytoma; Neurofibromatosis Type 1",dabrafenib (DRUG); trametinib (DRUG),3578572,EMPM,Gliomas and Neuroglial Tumors,CNS/Brain,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13706,NCT04312360,Preoperative Endoscopic Treatment With Fosfomycin and Metronidazole in Patients With Right-sided Colon Cancer and Colon Adenoma (MEFO-trial),COMPLETED,PHASE2,Right-sided Colon Cancer; Right-sided Colon Adenoma,therapeutic endoscopy with metronidazole and fosfomycin disodium (DRUG),3578572,EMPM,Right-sided Colon Cancer; Right-sided Colon Adenoma,Bowel,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13707,NCT03182894,Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer,WITHDRAWN,PHASE1,Metastatic Colorectal Cancer,Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA) (DRUG),3578572,EMPM,Metastatic Colorectal Cancer,Bowel,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13708,NCT02928224,Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer,COMPLETED,PHASE3,BRAF V600E-mutant Metastatic Colorectal Cancer,Encorafenib (DRUG); Binimetinib (DRUG); Cetuximab (DRUG); Irinotecan (DRUG); Folinic Acid (DRUG); 5-Fluorouracil (DRUG),3578572,EMPM,BRAF V600E-mutant Metastatic Colorectal Cancer,Bowel,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13709,NCT00578396,Phase I Biomarker Study of Dietary Grape-derived Low Dose Resveratrol for Colon Cancer Prevention,WITHDRAWN,PHASE1,Colon Cancer,grapes (DIETARY_SUPPLEMENT); grapes (DIETARY_SUPPLEMENT); grapes (DIETARY_SUPPLEMENT),3578572,EMPM,Colon Cancer,Bowel,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13710,NCT05142696,"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab",RECRUITING,PHASE1,Extensive Stage Small Cell Lung Cancer,[177Lu]Lu-DOTA-TATE (DRUG); Atezolizumab (DRUG); [68Ga]Ga-DOTA-TATE (DRUG); Carboplatin (OTHER); Etoposide (OTHER),3578572,EMPM,Extensive Stage Small Cell Lung Cancer,Lung,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13711,NCT01801358,A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma,TERMINATED,PHASE1,Uveal Melanoma,AEB071 (DRUG); MEK162 (DRUG),3578572,EMPM,Uveal Melanoma,Skin,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13712,NCT04259944,Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial,ACTIVE_NOT_RECRUITING,PHASE2,Colon Cancer,CAPOX (DRUG); Capecitabine (DRUG); FOLFIRI (DRUG),3578572,EMPM,Colon Cancer,Bowel,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13713,NCT04068896,"Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy",COMPLETED,PHASE1,Pancreatic Cancer; Metastatic Castration-resistant Prostate Cancer; Bladder Cancer; Melanoma; Non-small Cell Lung Cancer; Colorectal Cancer; Gastric Cancer; Esophageal Cancer; Ovarian Cancer; Head Neck Squamous Cell Carcinoma; Prostate Cancer,NGM120 (BIOLOGICAL); NGM120 (BIOLOGICAL); NGM120 (BIOLOGICAL); NGM120 (BIOLOGICAL); NGM120 (BIOLOGICAL); NGM120 (BIOLOGICAL); Placebo (OTHER),3578572,EMPM,Pancreatic Cancer; Metastatic Castration-resistant Prostate Cancer; Bladder Cancer; Melanoma; Non-small Cell Lung Cancer; Colorectal Cancer; Gastric Cancer; Esophageal Cancer; Ovarian Cancer; Head Neck Squamous Cell Carcinoma; Prostate Cancer,Bowel,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13714,NCT05053165,A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants,COMPLETED,PHASE1,Rheumatoid Arthritis; Non-Alcoholic Steatohepatitis,LB-P6 (DRUG); LB-P8 (DRUG); Placebo (DRUG),3578572,EMPM,Rheumatoid Arthritis; Non-Alcoholic Steatohepatitis,Liver,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13715,NCT03504865,Post-Mastectomy Analgesia Using Exparel (Liposomal) Versus Standard Bupivacaine or Placebo,UNKNOWN,PHASE2,Mastectomy; Breast Cancer,Liposomal bupivacaine (DRUG); Standard bupivacaine (DRUG); Placebo (OTHER),3578572,EMPM,Mastectomy; Breast Cancer,Breast,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13716,NCT05869669,RewinD-LB - Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies,ACTIVE_NOT_RECRUITING,PHASE2,Dementia with Lewy Bodies,Neflamapimod (DRUG); Placebo (DRUG),3578572,EMPM,Dementia with Lewy Bodies,CNS/Brain,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13717,NCT04001517,Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies,COMPLETED,PHASE2,Dementia With Lewy Bodies (DLB),Neflamapimod (DRUG),3578572,EMPM,Dementia With Lewy Bodies (DLB),CNS/Brain,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13718,NCT02303041,Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma,TERMINATED,PHASE2,"Carcinoma, Basal Cell; Recurrent Skin Cancer; Skin Neoplasms; Basal Cell Nevus Syndrome",Buparlisib (DRUG); Sonidegib (DRUG),3578572,EMPM,"Carcinoma, Basal Cell; Recurrent Skin Cancer; Skin Neoplasms; Basal Cell Nevus Syndrome",Skin,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13719,NCT04995081,Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD),ACTIVE_NOT_RECRUITING,PHASE2,Parkinson Disease,Biological/Vaccine: Allogeneic HB-adMSCs (BIOLOGICAL); Placebo (OTHER),3578572,EMPM,Parkinson Disease,CNS/Brain,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13720,NCT04751955,"A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)",WITHDRAWN,PHASE1,Colorectal Cancer Metastatic,Olinvacimab added to Capecitabine (DRUG),3578572,EMPM,Colorectal Cancer Metastatic,Bowel,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13721,NCT06332755,Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors,RECRUITING,PHASE1,Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC); Renal Cell Carcinoma(RCC); Urothelial Carcinoma; Malignant Melanoma,LB-LR1109 (DRUG),3578572,EMPM,Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC); Renal Cell Carcinoma(RCC); Urothelial Carcinoma; Malignant Melanoma,Lung,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13722,NCT06490536,The Sagittarius Trial,RECRUITING,PHASE3,Colon Cancer Stage II; Colon Cancer Stage III,Oxaliplatin (DRUG); Capecitabine (DRUG); Folinic acid (DRUG); Fluorouracil (DRUG); Temozolomide (DRUG); Irinotecan (DRUG); Nivolumab (DRUG); Ipilimumab (DRUG); Trastuzumab (DRUG); Pertuzumab (DRUG); Panitumumab (DRUG),3578572,EMPM,Colon Cancer Stage II; Colon Cancer Stage III,Bowel,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13723,NCT06699121,A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC,NOT_YET_RECRUITING,PHASE2,Primary Sclerosing Cholangitis (PSC),LB-P8 low-dose (DRUG); LB-P8 high-dose (DRUG); Placebo (DRUG),3578572,EMPM,Primary Sclerosing Cholangitis (PSC),Liver,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13724,NCT06487702,A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma,NOT_YET_RECRUITING,PHASE2,Esophageal Squamous Cell Carcinoma,fruquintinib++Candonilimab+ Tegafur，Gimeracil and Oteracil Potassium (DRUG),3578572,EMPM,Esophageal Squamous Cell Carcinoma,Skin,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13725,NCT02088684,Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer,COMPLETED,PHASE1,Breast Cancer,LEE011 (DRUG); BYL719 (DRUG); fulvestrant (DRUG); BKM120 (DRUG),3578572,EMPM,Breast Cancer,Breast,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13726,NCT04919564,Low Dose Continuous Furosemide Effect on Cardiac Surgery Patients With Kidney Dysfunction,COMPLETED,PHASE2,Chronic Kidney Disease; Cardiac Disease,Furosemide in 0.9 % NaCl 100 Mg/100 mL (1 mg/mL) (DRUG); NaCl 0.9% (DRUG),3578572,EMPM,Chronic Kidney Disease; Cardiac Disease,Kidney,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13727,NCT04298918,A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer,TERMINATED,PHASE1,Breast Cancer,Placebo (DRUG); Venetoclax (DRUG); Trastuzumab emtansine (DRUG),3578572,EMPM,Breast Cancer,Breast,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13728,NCT06205706,BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors,RECRUITING,PHASE1,Solid Tumors; Non Small Cell Lung Cancer; Hepatocellular Carcinoma,BI-1910 (DRUG); Pembrolizumab (DRUG),3578572,EMPM,Solid Tumors; Non Small Cell Lung Cancer; Hepatocellular Carcinoma,Lung,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13729,NCT01388413,Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder,COMPLETED,PHASE4,Neurogenic Bladder; Urinary Tract Infection,Weekly Oral Cyclic Antibiotic programme (DRUG),3578572,EMPM,Neurogenic Bladder; Urinary Tract Infection,Bladder/Urinary Tract,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13730,NCT06476132,Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients,RECRUITING,PHASE2,Lung Transplant,Belumosudil (DRUG); Placebo for Belumosudil (DRUG),3578572,EMPM,Lung Transplant,Lung,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13731,NCT01471847,A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab,COMPLETED,PHASE1,Locally Advance Breast Cancer (LABC); Metastatic Breast Cancer (MBC),BEZ235 + Trastuzumab Phase l/Phase ll) (DRUG); Lapatinib + Capecitabine (Phase II) (DRUG),3578572,EMPM,Locally Advance Breast Cancer (LABC); Metastatic Breast Cancer (MBC),Breast,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13732,NCT00003993,Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma,COMPLETED,PHASE1,"Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific",aldesleukin (BIOLOGICAL); bryostatin 1 (DRUG),3578572,EMPM,"Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Bowel,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13733,NCT04755283,Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation,ACTIVE_NOT_RECRUITING,PHASE2,Atrial Fibrillation (AF); Stroke,Abelacimab (BIOLOGICAL); Rivaroxaban (DRUG),3578572,EMPM,Atrial Fibrillation (AF); Stroke,CNS/Brain,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13734,NCT00071461,Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis,COMPLETED,PHASE2,Idiopathic Pulmonary Fibrosis,bosentan (DRUG); Placebo (DRUG),3578572,EMPM,Idiopathic Pulmonary Fibrosis,Lung,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13735,NCT03934905,Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction,RECRUITING,PHASE1,Anthracycline Related Cardiotoxicity in Breast Cancer,sulforaphane (DRUG); Placebo Oral Tablet (DRUG),3578572,EMPM,Anthracycline Related Cardiotoxicity in Breast Cancer,Breast,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13736,NCT05224609,A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction,COMPLETED,PHASE1,Moderate Hepatic Impairment; Severe Hepatic Impairment; Healthy Volunteers,Lorlatinib (DRUG),3578572,EMPM,Moderate Hepatic Impairment; Severe Hepatic Impairment; Healthy Volunteers,Liver,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13737,NCT01484197,A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device,COMPLETED,PHASE2,Asthma,75 µg indacaterol maleate (LB) (DRUG); 75 µg indacaterol maleate (PoS) (DRUG); 37.5 µg indacaterol maleate (PoS) (DRUG); placebo to indacaterol (LB) (DRUG); placebo to indacaterol (PoS) (DRUG),3578572,EMPM,Asthma,Lung,LB-100,"PPP2CA, PPP2CB",inhibitor/antagonist,unclear,no,yes,LB-100 is in clinical trials for cancer treatment.,CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3,, +13738,NCT04322890,Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation,RECRUITING,PHASE2,Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROS1 Gene Mutation; MET Gene Mutation,"Osimertinib (DRUG); Alectinib 150 MG (DRUG); Crizotinib 250 MG (DRUG); Savolitinib, Crizotinib. (DRUG); Chemotherapy (DRUG)",25141092,YMX,Non-Small Cell Lung Cancer with Gene Mutations,Lung,Entrectinib,"NTRK1, NTRK2, NTRK3, ROS1, ALK",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for use in cancers with NTRK gene fusions.,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,1.14,541.0 +13739,NCT05238831,SMMART Adaptive Clinical Treatment (ACT) Trial,WITHDRAWN,EARLY_PHASE1,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Alectinib (DRUG); Alpelisib (DRUG); Anastrozole (DRUG); Atezolizumab (BIOLOGICAL); Bevacizumab (BIOLOGICAL); Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Capecitabine (DRUG); Carboplatin (DRUG); Cobimetinib (DRUG); Entrectinib (DRUG); Eribulin (DRUG); Fulvestrant (DRUG); Hyaluronidase-zzxf/Pertuzumab/Trastuzumab (BIOLOGICAL); Irinotecan (DRUG); Letrozole (DRUG); Nab-paclitaxel (DRUG); Niraparib (DRUG); Olaparib (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Pertuzumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Trastuzumab (BIOLOGICAL); Trastuzumab Emtansine (BIOLOGICAL); Vemurafenib (DRUG); Vinorelbine (DRUG); Vismodegib (DRUG),25141092,YMX,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Ovary/Fallopian Tube,Entrectinib,"NTRK1, NTRK2, NTRK3, ROS1, ALK",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for use in cancers with NTRK gene fusions.,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,1.14,541.0 +13740,NCT06528691,Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors,RECRUITING,PHASE2,High Grade Glioma; CNS Tumor,Entrectinib (DRUG); Cyclophosphamide (DRUG); Etoposide (DRUG); Carboplatin (DRUG); G-CSF (BIOLOGICAL); Pegfilgrastim (BIOLOGICAL); Surgery (PROCEDURE),25141092,YMX,High Grade Glioma; CNS Tumor,CNS/Brain,Entrectinib,"NTRK1, NTRK2, NTRK3, ROS1, ALK",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for use in cancers with NTRK gene fusions.,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,1.14,541.0 +13741,NCT05170204,"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)",RECRUITING,PHASE3,Non-Small Cell Lung Cancer,Alectinib (DRUG); Entrectinib (DRUG); Durvalumab (DRUG),25141092,YMX,Advanced Non-Small Cell Lung Cancer,Lung,Entrectinib,"NTRK1, NTRK2, NTRK3, ROS1, ALK",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for use in cancers with NTRK gene fusions.,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,1.14,541.0 +13742,NCT06671444,Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impairment,ACTIVE_NOT_RECRUITING,PHASE1,Insomnia; Renal Impairment,YZJ-1139 (DRUG),25141092,YMX,Insomnia; Renal Impairment,Kidney,Entrectinib,"NTRK1, NTRK2, NTRK3, ROS1, ALK",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for use in cancers with NTRK gene fusions.,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,1.14,541.0 +13743,NCT05770544,"DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.",RECRUITING,PHASE2,Solid Tumor; Haematological Malignancy; Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Brain Neoplasms; Melanoma; Glioma,Entrectinib (DRUG),25141092,YMX,Solid Tumor; Haematological Malignancy; Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Brain Neoplasms; Melanoma; Glioma,Skin,Entrectinib,"NTRK1, NTRK2, NTRK3, ROS1, ALK",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for use in cancers with NTRK gene fusions.,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,1.14,541.0 +13744,NCT02568267,"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)",ACTIVE_NOT_RECRUITING,PHASE2,"Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Primary Brain Tumors; Renal Cell Carcinoma; Sarcomas; Salivary Gland Cancers; Adult Solid Tumor",Entrectinib (DRUG),25141092,YMX,"Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Primary Brain Tumors; Renal Cell Carcinoma; Sarcomas; Salivary Gland Cancers; Adult Solid Tumor",Bowel,Entrectinib,"NTRK1, NTRK2, NTRK3, ROS1, ALK",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for use in cancers with NTRK gene fusions.,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,1.14,541.0 +13745,NCT04551495,Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE),ACTIVE_NOT_RECRUITING,PHASE2,Invasive Lobular Breast Carcinoma; ER+ Breast Cancer; HER2-negative Breast Cancer,Entrectinib (DRUG); Letrozole (DRUG); Goserelin (DRUG),25141092,YMX,Invasive Lobular Breast Carcinoma; ER+ Breast Cancer; HER2-negative Breast Cancer,Breast,Entrectinib,"NTRK1, NTRK2, NTRK3, ROS1, ALK",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for use in cancers with NTRK gene fusions.,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,1.14,541.0 +13746,NCT02587650,"Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma",TERMINATED,PHASE2,ALK Fusion Protein Expression; BRAF wt Allele; Invasive Skin Melanoma; MET Fusion Gene Positive; NRAS wt Allele; NTRK1 Fusion Positive; NTRK2 Fusion Positive; NTRK3 Fusion Positive; RET Fusion Positive; ROS1 Fusion Positive; Stage III Cutaneous Melanoma; Stage IIIA Cutaneous Melanoma; Stage IIIB Cutaneous Melanoma; Stage IIIC Cutaneous Melanoma; Stage IV Cutaneous Melanoma,Capmatinib (DRUG); Ceritinib (DRUG); Entrectinib (DRUG); Laboratory Biomarker Analysis (OTHER); Regorafenib (DRUG),25141092,YMX,Advanced Melanoma,Skin,Entrectinib,"NTRK1, NTRK2, NTRK3, ROS1, ALK",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for use in cancers with NTRK gene fusions.,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,1.14,541.0 +13747,NCT04589832,Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma,TERMINATED,PHASE1,Uveal Melanoma,PAC-1 (DRUG); Entrectinib (DRUG),25141092,YMX,Uveal Melanoma,Skin,Entrectinib,"NTRK1, NTRK2, NTRK3, ROS1, ALK",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for use in cancers with NTRK gene fusions.,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,1.14,541.0 +13748,NCT03178552,A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC),ACTIVE_NOT_RECRUITING,PHASE2,Non-Small Cell Lung Cancer,Alectinib (DRUG); Atezolizumab (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Gemcitabine (DRUG); Entrectinib (DRUG); Cobimetinib (DRUG); Vemurafenib (DRUG); Bevacizumab (DRUG); Divarasib (DRUG); Docetaxel (DRUG),25141092,YMX,Advanced Non-Small Cell Lung Cancer,Lung,Entrectinib,"NTRK1, NTRK2, NTRK3, ROS1, ALK",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for use in cancers with NTRK gene fusions.,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,1.14,541.0 +13749,NCT04644315,A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors,TERMINATED,PHASE2,"Neoplasms; Colorectal Neoplasms; Melanoma; Pancreatic Neoplasms; Sarcoma; Ovarian Neoplasms; Brain Neoplasms; Thyroid Neoplasms; Neuroendocrine Tumors; Cholangiocarcinoma; Salivary Gland Neoplasms; Head and Neck Neoplasms; Thyroid Cancer, Papillary; Lymphoma, Large-Cell, Anaplastic; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Central Nervous System",Alectinib (DRUG),25141092,YMX,"Neoplasms; Colorectal Neoplasms; Melanoma; Pancreatic Neoplasms; Sarcoma; Ovarian Neoplasms; Brain Neoplasms; Thyroid Neoplasms; Neuroendocrine Tumors; Cholangiocarcinoma; Salivary Gland Neoplasms; Head and Neck Neoplasms; Thyroid Cancer, Papillary; Lymphoma, Large-Cell, Anaplastic; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Central Nervous System",Bowel,Entrectinib,"NTRK1, NTRK2, NTRK3, ROS1, ALK",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for use in cancers with NTRK gene fusions.,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,1.14,541.0 +13750,NCT06671509,"Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment",COMPLETED,PHASE1,Insomnia; Hepatic Impairment,YZJ-1139 (DRUG),25141092,YMX,Insomnia; Hepatic Impairment,Liver,Entrectinib,"NTRK1, NTRK2, NTRK3, ROS1, ALK",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for use in cancers with NTRK gene fusions.,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,1.14,541.0 +13751,NCT04621188,Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS),ACTIVE_NOT_RECRUITING,PHASE2,Non Small Cell Lung Cancer Metastatic,Lorlatinib (DRUG),25141092,YMX,Stage IV Non-small Cell Lung Cancer,Lung,Entrectinib,"NTRK1, NTRK2, NTRK3, ROS1, ALK",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for use in cancers with NTRK gene fusions.,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,1.14,541.0 +13752,NCT04603807,A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases,RECRUITING,PHASE3,"Carcinoma, Non-Small-Cell Lung",Entrectinib (DRUG); Crizotinib (DRUG),25141092,YMX,"Carcinoma, Non-Small-Cell Lung",Lung,Entrectinib,"NTRK1, NTRK2, NTRK3, ROS1, ALK",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for use in cancers with NTRK gene fusions.,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,1.14,541.0 +13753,NCT04226833,A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic Function,COMPLETED,PHASE1,Hepatic Insufficiency,entrectinib (DRUG),25141092,YMX,Hepatic Insufficiency,Liver,Entrectinib,"NTRK1, NTRK2, NTRK3, ROS1, ALK",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for use in cancers with NTRK gene fusions.,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,1.14,541.0 +13754,NCT04302025,A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer,RECRUITING,PHASE2,Non-small Cell Lung Cancer,Alectinib (DRUG); Entrectinib (DRUG); Vemurafenib (Enrollment closed) (DRUG); Cobimetinib (Enrollment closed) (DRUG); Pralsetinib (Enrollment closed) (DRUG); Atezolizumab (DRUG); SBRT (DRUG); Resection (PROCEDURE); Chemotherapy (DRUG); Divarasib (DRUG),25141092,YMX,Non-small Cell Lung Cancer,Lung,Entrectinib,"NTRK1, NTRK2, NTRK3, ROS1, ALK",inhibitor/antagonist,Other TK inhibitor,yes,yes,Approved for use in cancers with NTRK gene fusions.,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,1.14,541.0 +13755,NCT02159066,"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",COMPLETED,PHASE2,Melanoma,LGX818 (DRUG); MEK162 (DRUG); LEE011 (DRUG); BGJ398 (DRUG); BKM120 (DRUG); INC280 (DRUG),25145656,s2788,Melanoma,Skin,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13756,NCT01737827,Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.,TERMINATED,PHASE2,Advanced Hepatocellular Carcinoma With c-MET Dysregulation,INC280 (DRUG),25145656,s2788,Advanced Hepatocellular Carcinoma With c-MET Dysregulation,Liver,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13757,NCT02276027,"A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer",COMPLETED,PHASE2,Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma,BYL719 (DRUG); INC280 (DRUG); LDK378 (DRUG); MEK162 (DRUG),25145656,s2788,Lung Adenocarcinoma and Squamous Cell Carcinoma,Skin,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13758,NCT04926831,Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC,TERMINATED,PHASE2,Non-small Cell Lung Cancer,capmatinib (DRUG),25145656,s2788,Non-small Cell Lung Cancer,Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13759,NCT02414139,"Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)",COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Capmatinib (DRUG),25145656,s2788,"Carcinoma, Non-Small-Cell Lung",Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13760,NCT03693339,Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation,UNKNOWN,PHASE2,Cancer; Lung Cancer Metastatic; MET Gene Mutation,Capmatinib (DRUG),25145656,s2788,Cancer; Lung Cancer Metastatic; MET Gene Mutation,Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13761,NCT02323126,Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer,TERMINATED,PHASE2,Non Small Cell Lung Cancer,EGF816 (DRUG); INC280 (DRUG); Nivolumab (DRUG),25145656,s2788,Non Small Cell Lung Cancer,Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13762,NCT04460729,"A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases",WITHDRAWN,PHASE2,Non-small Cell Lung Carcinoma (NSCLC),Capmatinib (DRUG),25145656,s2788,Non-small Cell Lung Carcinoma (NSCLC),Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13763,NCT06054191,Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations,NOT_YET_RECRUITING,PHASE2,NSCLC; BRAF V600 Mutation; MET Exon 14 Mutation,Dabrafenib + Trametinib (DRUG); Capmatinib (DRUG),25145656,s2788,Non-Small Cell Lung Cancer with Genetic Mutations,Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13764,NCT02795429,Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC,COMPLETED,PHASE1,Advanced Hepatocellular Carcinoma,Spartalizumab (DRUG); Capmatinib (DRUG),25145656,s2788,Advanced Hepatocellular Carcinoma,Liver,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13765,NCT01964235,Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma,WITHDRAWN,PHASE2,Advanced Hepatocellular Carcinoma,INC280 (DRUG); Placebo (DRUG),25145656,s2788,Advanced Hepatocellular Carcinoma,Liver,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13766,NCT05110196,Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.,RECRUITING,PHASE4,Non-Small Cell Lung Carcinoma,Capmatinib 150 mg (DRUG); Capmatinib 200 mg (DRUG),25145656,s2788,Non-Small Cell Lung Carcinoma,Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13767,NCT04677595,Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation,ACTIVE_NOT_RECRUITING,PHASE2,Non-Small Cell Lung Cancer (NSCLC),Capmatinib (DRUG),25145656,s2788,Non-Small Cell Lung Cancer (NSCLC),Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13768,NCT04427072,Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation,TERMINATED,PHASE3,"Carcinoma, Non-Small-Cell Lung",Capmatinib (DRUG); Docetaxel (DRUG),25145656,s2788,"Carcinoma, Non-Small-Cell Lung",Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13769,NCT02335944,Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.,TERMINATED,PHASE1,Non Small Cell Lung Cancer,Capmatinib (DRUG); Nazartinib (DRUG),25145656,s2788,Non Small Cell Lung Cancer,Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13770,NCT05435846,Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation,TERMINATED,PHASE1,Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer,Capmatinib (DRUG); Trametinib (DRUG),25145656,s2788,Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer,Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13771,NCT05642572,Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial),RECRUITING,PHASE2,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Capmatinib (DRUG); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Osimertinib (DRUG); Ramucirumab (BIOLOGICAL),25145656,s2788,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13772,NCT04139317,Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%,TERMINATED,PHASE2,Non-small Cell Lung Cancer (NSCLC),Capmatinib (DRUG); Pembrolizumab (BIOLOGICAL),25145656,s2788,Non-small Cell Lung Cancer (NSCLC),Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13773,NCT05243641,Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test,TERMINATED,PHASE1,Metastatic Breast Cancer; Breast Cancer,Neratinib (DRUG); Capmatinib (DRUG),25145656,s2788,Metastatic Breast Cancer; Breast Cancer,Breast,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13774,NCT04323436,Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations,TERMINATED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Spartalizumab (DRUG); Capmatinib (DRUG); spartalizumab placebo (DRUG),25145656,s2788,"Carcinoma, Non-Small-Cell Lung",Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13775,NCT05488314,A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,"Carcinoma, Non-Small-Cell Lung",Capmatinib (DRUG); Amivantamab (DRUG),25145656,s2788,"Carcinoma, Non-Small-Cell Lung",Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13776,NCT04816214,Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy,TERMINATED,PHASE3,"Carcinoma, Non-Small-Cell Lung",Capmatinib (DRUG); Osimertinib (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG); Carboplatin (DRUG),25145656,s2788,"Carcinoma, Non-Small-Cell Lung",Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13777,NCT05567055,Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations,WITHDRAWN,PHASE2,Non-small Cell Lung Cancer,Capmatinib (DRUG),25145656,s2788,Non-small Cell Lung Cancer,Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13778,NCT03484923,Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma,COMPLETED,PHASE2,Melanoma,PDR001 (DRUG); LAG525 (DRUG); INC280 (DRUG); ACZ885 (DRUG); LEE011 (DRUG),25145656,s2788,Melanoma,Skin,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13779,NCT02587650,"Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma",TERMINATED,PHASE2,ALK Fusion Protein Expression; BRAF wt Allele; Invasive Skin Melanoma; MET Fusion Gene Positive; NRAS wt Allele; NTRK1 Fusion Positive; NTRK2 Fusion Positive; NTRK3 Fusion Positive; RET Fusion Positive; ROS1 Fusion Positive; Stage III Cutaneous Melanoma; Stage IIIA Cutaneous Melanoma; Stage IIIB Cutaneous Melanoma; Stage IIIC Cutaneous Melanoma; Stage IV Cutaneous Melanoma,Capmatinib (DRUG); Ceritinib (DRUG); Entrectinib (DRUG); Laboratory Biomarker Analysis (OTHER); Regorafenib (DRUG),25145656,s2788,Advanced Melanoma,Skin,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13780,NCT01820364,LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,TERMINATED,PHASE2,Melanoma,LGX818 (DRUG),25145656,s2788,Melanoma,Skin,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13781,NCT03742349,Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).,TERMINATED,PHASE1,Triple Negative Breast Cancer (TNBC),spartalizumab (BIOLOGICAL); LAG525 (BIOLOGICAL); NIR178 (DRUG); capmatinib (DRUG); MCS110 (BIOLOGICAL); canakinumab (BIOLOGICAL),25145656,s2788,Triple Negative Breast Cancer (TNBC),Breast,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13782,NCT01610336,"A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment",COMPLETED,PHASE2,Non-small Cell Lung Cancer,INC280 (DRUG); Gefitinib (DRUG),25145656,s2788,Non-small Cell Lung Cancer,Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13783,NCT03333343,Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC,ACTIVE_NOT_RECRUITING,PHASE1,EGFR-mutant Non-small Cell Lung Cancer,EGF816 (DRUG); trametinib (DRUG); ribociclib (DRUG); LXH254 (DRUG); INC280 (DRUG); gefitinib (DRUG),25145656,s2788,EGFR-mutant Non-small Cell Lung Cancer,Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13784,NCT02474537,INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function,COMPLETED,PHASE1,Hepatic Impairment,INC280 (DRUG),25145656,s2788,Hepatic Impairment,Liver,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13785,NCT01911507,INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer,COMPLETED,PHASE1,Recurrent Non-small Cell Lung Cancer,INC280 (DRUG); erlotinib hydrochloride (DRUG),25145656,s2788,Recurrent Non-small Cell Lung Cancer,Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13786,NCT03647488,Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Capmatinib (DRUG); Spartalizumab (DRUG); Docetaxel (DRUG),25145656,s2788,"Carcinoma, Non-Small-Cell Lung",Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13787,NCT03240393,Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC),WITHDRAWN,PHASE2,Carcinoma; Non-Small-Cell Lung Cancer,INC280 (DRUG),25145656,s2788,Carcinoma; Non-Small-Cell Lung Cancer,Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13788,NCT06908993,Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated,NOT_YET_RECRUITING,PHASE3,Advanced Non Small Cell Lung Cancer; MET Exon 14 Mutation,Tepotinib (DRUG); Pemetrexed (Alimta) (DRUG); Vinorelbine (DRUG); Gemcitabine alone (DRUG); Docetaxel (DRUG); Paclitaxel (DRUG); Pembrolizumab (DRUG); Nivolumab (DRUG); Atezolizumab (DRUG),25145656,s2788,Advanced Non Small Cell Lung Cancer; MET Exon 14 Mutation,Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13789,NCT05135845,Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma,SUSPENDED,PHASE2,Oesophageal Adenocarcinoma; Gastric Adenocarcinoma,Capmatinib (DRUG); Spartalizumab (DRUG),25145656,s2788,Oesophageal Adenocarcinoma; Gastric Adenocarcinoma,Esophagus/Stomach,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13790,NCT02386826,INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme,COMPLETED,PHASE1,Glioblastoma Multiforme; Gliosarcoma; Colorectal Cancer; Renal Cell Carcinoma,INC280 (DRUG); bevacizumab (BIOLOGICAL),25145656,s2788,Glioblastoma Multiforme; Gliosarcoma; Colorectal Cancer; Renal Cell Carcinoma,Bowel,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13791,NCT02019693,A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer,COMPLETED,PHASE2,Kidney Cancer,INC280 (DRUG),25145656,s2788,Kidney Cancer,Kidney,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13792,NCT02468661,"A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification",TERMINATED,PHASE1,Non-Small Cell Lung Cancer,INC280 single agent (DRUG); erlotinib (DRUG),25145656,s2788,Advanced Non-Small Cell Lung Cancer,Lung,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13793,NCT02205398,"Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy",TERMINATED,PHASE1,Squamous Cell Carcinoma of Head and Neck (SCCHN); Metastatic Colorectal Cancer,INC280 (DRUG); cetuximab (DRUG),25145656,s2788,Squamous Cell Carcinoma of Head and Neck (SCCHN); Metastatic Colorectal Cancer,Bowel,Capmatinib,MET,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for NSCLC treatment by FDA in May 2020.,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1.21,1138.0 +13794,NCT04154774,A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function,COMPLETED,PHASE1,Hepatic Impairment,Apalutamide (DRUG),24872560,Erleada,Hepatic Impairment,Liver,Apalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Used for non-metastatic castration-resistant prostate cancer.,CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F,1.08,301.0 +13795,NCT05551117,A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors,COMPLETED,PHASE2,"Castration-Resistant Prostatic Cancer; Androgen-Independent Prostatic Cancer; Androgen-Insensitive Prostatic Cancer; Androgen-Resistant Prostatic Cancer; Hormone Refractory Prostatic Cancer; Anal Cancer; Anal Neoplasm; Carcinoma, Squamous Cell of Head and Neck; Head and Neck Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Oral Squamous Cell Carcinoma; Malignant Melanoma; Melanoma; Non-small Cell Lung Cancer; Non-small Cell Carcinoma; Small-cell Lung Cancer; Small Cell Carcinoma",vobramitamab duocarmazine 2.0 mg (Arm A) (BIOLOGICAL); vobramitamab duocarmazine 2.7 mg (Arm B) (BIOLOGICAL); vobramitamab duocarmazine (BIOLOGICAL); Abiraterone (DRUG); Enzalutamide (DRUG),24872560,Erleada,"Castration-Resistant Prostatic Cancer; Androgen-Independent Prostatic Cancer; Androgen-Insensitive Prostatic Cancer; Androgen-Resistant Prostatic Cancer; Hormone Refractory Prostatic Cancer; Anal Cancer; Anal Neoplasm; Carcinoma, Squamous Cell of Head and Neck; Head and Neck Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Oral Squamous Cell Carcinoma; Malignant Melanoma; Melanoma; Non-small Cell Lung Cancer; Non-small Cell Carcinoma; Small-cell Lung Cancer; Small Cell Carcinoma",Lung,Apalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Used for non-metastatic castration-resistant prostate cancer.,CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F,1.08,301.0 +13796,NCT04478279,A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,Glioblastoma; Melanoma Stage IV; Breast Cancer; Prostate Cancer; Glioblastoma Multiforme; GBM; Brain Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Prostate Cancer; Melanoma Recurrent; Prostate Cancer Metastatic; Recurrent Glioblastoma; Newly Diagnosed Glioblastoma,ST101 (DRUG); Temozolomide (DRUG); Radiation (RADIATION),24872560,Erleada,Glioblastoma; Melanoma Stage IV; Breast Cancer; Prostate Cancer; Glioblastoma Multiforme; GBM; Brain Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Prostate Cancer; Melanoma Recurrent; Prostate Cancer Metastatic; Recurrent Glioblastoma; Newly Diagnosed Glioblastoma,Skin,Apalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Used for non-metastatic castration-resistant prostate cancer.,CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F,1.08,301.0 +13797,NCT03840200,"A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.",COMPLETED,PHASE1,Breast Cancer; Prostate Cancer; Ovarian Cancer,Ipatasertib (DRUG); Rucaparib (DRUG),24872560,Erleada,"Breast, Prostate, and Ovarian Cancers",Ovary/Fallopian Tube,Apalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Used for non-metastatic castration-resistant prostate cancer.,CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F,1.08,301.0 +13798,NCT05521698,"Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer",NOT_YET_RECRUITING,PHASE1,Non-Muscle Invasive Bladder Urothelial Carcinoma; Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma,Apalutamide (DRUG); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Placebo Administration (DRUG); Questionnaire Administration (OTHER); Transurethral Resection of Bladder Tumor (PROCEDURE),24872560,Erleada,Non-Muscle Invasive Bladder Urothelial Carcinoma; Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma,Bladder/Urinary Tract,Apalutamide,AR,inhibitor/antagonist,Androgen receptor antagonist,yes,yes,Used for non-metastatic castration-resistant prostate cancer.,CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F,1.08,301.0 +13799,NCT03563157,QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine,TERMINATED,PHASE1,Colorectal Cancer Metastatic; mCRC,Aldoxorubicin Hydrochloride (BIOLOGICAL); ALT-803 (BIOLOGICAL); ETBX-011 (BIOLOGICAL); ETBX-021 (BIOLOGICAL); ETBX-051 (BIOLOGICAL); ETBX-061 (BIOLOGICAL); GI-4000 (BIOLOGICAL); GI-6207 (BIOLOGICAL); GI-6301 (BIOLOGICAL); haNK (BIOLOGICAL); Avelumab (DRUG); Capecitabine (DRUG); Cetuximab (DRUG); Cyclophosphamide (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG); Nab-paclitaxel (DRUG); Oxaliplatin (DRUG); Regorafenib (DRUG); SBRT (PROCEDURE),11167602,Stivarga,Colorectal Cancer Metastatic; mCRC,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13800,NCT03844620,Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Refractory Colorectal Carcinoma; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Best Practice (OTHER); Laboratory Procedure (OTHER); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); Regorafenib (DRUG); Trifluridine and Tipiracil Hydrochloride (DRUG),11167602,Stivarga,Refractory Colorectal Carcinoma; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13801,NCT00934882,"Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI",COMPLETED,PHASE1,Colorectal Neoplasms,Regorafenib (BAY73-4506) (DRUG),11167602,Stivarga,Colorectal Neoplasms,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13802,NCT05963490,Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer,RECRUITING,PHASE2,Microsatellite Stable Metastatic Colorectal Cancer,Regorafenib (DRUG); Toripalimab (DRUG); Radiotherapy (RADIATION); Regorafenib (DRUG),11167602,Stivarga,Microsatellite Stable Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13803,NCT03215264,"To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer",COMPLETED,PHASE1,Colorectal Cancer,hydroxychloroquine (DRUG); entinostat (DRUG); regorafenib (DRUG),11167602,Stivarga,Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13804,NCT03712943,Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer; Metastatic Colorectal Cancer; Colon Cancer,Regorafenib (DRUG); Nivolumab (DRUG),11167602,Stivarga,Colorectal Cancer; Metastatic Colorectal Cancer; Colon Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13805,NCT02287727,Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment,WITHDRAWN,PHASE2,Rectal Adenocarcinoma; Stage IIA Rectal Cancer; Stage IIB Rectal Cancer; Stage IIC Rectal Cancer; Stage IIIA Rectal Cancer; Stage IIIB Rectal Cancer,Laboratory Biomarker Analysis (OTHER); Regorafenib (DRUG),11167602,Stivarga,Rectal Adenocarcinoma; Stage IIA Rectal Cancer; Stage IIB Rectal Cancer; Stage IIC Rectal Cancer; Stage IIIA Rectal Cancer; Stage IIIB Rectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13806,NCT02119676,Study of Ruxolitinib in Colorectal Cancer Patients,TERMINATED,PHASE2,CRC (Colorectal Cancer),Ruxolitinib (DRUG); Regorafenib (DRUG); Placebo (DRUG),11167602,Stivarga,CRC (Colorectal Cancer),Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13807,NCT04701476,TATE and Pembrolizumab (MK3475) in mCRC and NSCLC,RECRUITING,PHASE2,Colorectal Cancer; Lung Cancer,TATE and pembrolizumab (DRUG); TAS-102 pill (DRUG); Regorafenib Pill (DRUG),11167602,Stivarga,Colorectal Cancer; Lung Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13808,NCT06949982,"Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes",RECRUITING,PHASE2,Metastatic Colorectal Cancer (mCRC); Colorectal Neoplasms,experimental group x-MAP (COMBINATION_PRODUCT); Regorafenib (BAY 73-4506) (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer (mCRC); Colorectal Neoplasms,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13809,NCT06558773,GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.,NOT_YET_RECRUITING,PHASE2,Colorectal Cancer,Eliglustat+Immune checkpoint inhibitor+Regorafenib (DRUG); Eliglustat+Immune checkpoint inhibitor (DRUG); Regorafenib+Immune checkpoint inhibitor (DRUG),11167602,Stivarga,Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13810,NCT05770882,Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC),TERMINATED,PHASE1,Hepatocellular Carcinoma (HCC),Chidamide (DRUG); Regorafenib (DRUG),11167602,Stivarga,Hepatocellular Carcinoma (HCC),Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13811,NCT02080260,A Study of Regorafenib in Advanced Pancreatic Cancer Patients,COMPLETED,PHASE2,Pancreatic Cancer,regorafenib (DRUG),11167602,Stivarga,Pancreatic Cancer,Pancreas,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13812,NCT02053376,A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy,COMPLETED,PHASE2,Metastatic Biliary Tract Carcinoma,Regorafenib (DRUG),11167602,Stivarga,Metastatic Biliary Tract Carcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13813,NCT04776148,Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017),COMPLETED,PHASE3,Colorectal Neoplasms,pembrolizumab (DRUG); lenvatinib (DRUG); regorafenib (DRUG); TAS-102 (trifluridine and tipiracil) (DRUG),11167602,Stivarga,Colorectal Neoplasms,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13814,NCT05900648,Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME),WITHDRAWN,PHASE2,Colorectal Cancer; Colon Cancer; Rectum Cancer,Regorafenib (DRUG); XmAb20717 (DRUG),11167602,Stivarga,Colorectal Cancer; Colon Cancer; Rectum Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13815,NCT00664326,A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC,COMPLETED,PHASE2,"Carcinoma, Renal Cell","Regorafenib (Stivarga, BAY73-4506) (DRUG)",11167602,Stivarga,"Carcinoma, Renal Cell",Kidney,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13816,NCT02926222,Regorafenib in Relapsed Glioblastoma,COMPLETED,PHASE2,Glioblastoma Multiforme,Regorafenib (DRUG); Lomustine (DRUG),11167602,Stivarga,Glioblastoma Multiforme,CNS/Brain,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13817,NCT06575725,"Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer",WITHDRAWN,PHASE2,Advanced Colon Adenocarcinoma; Advanced Colorectal Adenocarcinoma; Advanced Rectal Adenocarcinoma; Metastatic Colon Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Rectal Adenocarcinoma; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8,Balstilimab (BIOLOGICAL); Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Botensilimab (BIOLOGICAL); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Regorafenib (DRUG),11167602,Stivarga,Advanced Colon Adenocarcinoma; Advanced Colorectal Adenocarcinoma; Advanced Rectal Adenocarcinoma; Metastatic Colon Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Rectal Adenocarcinoma; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13818,NCT04362839,"Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Advanced Colon Adenocarcinoma; Metastatic Colon Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Stage III Colon Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Colon Cancer AJCC v8; Stage IIIA Rectal Cancer AJCC v8; Stage IIIB Colon Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Colon Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Stage IVA Colon Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Rectal Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Rectal Cancer AJCC v8; Stage IVC Colon Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage IVC Rectal Cancer AJCC v8,Ipilimumab (BIOLOGICAL); Nivolumab (BIOLOGICAL); Regorafenib (DRUG),11167602,Stivarga,Advanced Colon Adenocarcinoma; Metastatic Colon Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Stage III Colon Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Colon Cancer AJCC v8; Stage IIIA Rectal Cancer AJCC v8; Stage IIIB Colon Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Colon Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Stage IVA Colon Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Rectal Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Rectal Cancer AJCC v8; Stage IVC Colon Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage IVC Rectal Cancer AJCC v8,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13819,NCT02638766,Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST,COMPLETED,PHASE2,Gastrointestinal Stromal Tumors,regorafenib (DRUG),11167602,Stivarga,Gastrointestinal Stromal Tumors,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13820,NCT04476329,Optimization for Regorafenib in HCC,TERMINATED,PHASE2,Hepatocellular Carcinoma,Regorafenib 40 MG (DRUG),11167602,Stivarga,Hepatocellular Carcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13821,NCT01949194,Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,Regorafenib (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13822,NCT02368886,Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colon Adenocarcinoma; Rectal Adenocarcinoma; Stage III Colorectal Cancer AJCC v7; Stage IIIA Colorectal Cancer AJCC v7; Stage IIIB Colorectal Cancer AJCC v7; Stage IIIC Colorectal Cancer AJCC v7; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7,Clobetasol Propionate (DRUG); Pharmacological Study (OTHER); Quality-of-Life Assessment (OTHER); Regorafenib (DRUG),11167602,Stivarga,Colon Adenocarcinoma; Rectal Adenocarcinoma; Stage III Colorectal Cancer AJCC v7; Stage IIIA Colorectal Cancer AJCC v7; Stage IIIB Colorectal Cancer AJCC v7; Stage IIIC Colorectal Cancer AJCC v7; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13823,NCT05672316,"Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients with Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy",ACTIVE_NOT_RECRUITING,PHASE1,Advanced Colorectal Adenocarcinoma; Advanced Microsatellite Stable Colorectal Carcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Microsatellite Stable Colorectal Carcinoma; Stage III Colorectal Cancer AJCC V8; Stage IV Colorectal Cancer AJCC V8,Balstilimab (BIOLOGICAL); Biospecimen Collection (PROCEDURE); Botensilimab (BIOLOGICAL); Computed Tomography (PROCEDURE); Regorafenib (DRUG),11167602,Stivarga,Advanced Colorectal Adenocarcinoma; Advanced Microsatellite Stable Colorectal Carcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Microsatellite Stable Colorectal Carcinoma; Stage III Colorectal Cancer AJCC V8; Stage IV Colorectal Cancer AJCC V8,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13824,NCT01929616,Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C),COMPLETED,PHASE2,Advanced Chemorefractory Colorectal Adenocarcinoma,regorafenib (DRUG),11167602,Stivarga,Advanced Chemorefractory Colorectal Adenocarcinoma,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13825,NCT05366816,ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST,RECRUITING,PHASE2,Gastrointestinal Stromal Tumors,Sunitinib (DRUG); Regorafenib (DRUG),11167602,Stivarga,Gastrointestinal Stromal Tumors,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13826,NCT01913639,FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer,COMPLETED,PHASE2,Esophageal Cancer; Gastric Cancer,Regorafenib (DRUG); 5-Fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG),11167602,Stivarga,Esophageal and Gastric Cancer,Esophagus/Stomach,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13827,NCT05394740,Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy,ACTIVE_NOT_RECRUITING,PHASE1,Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma,Regorafenib (DRUG); Nivolumab (DRUG); CapeOX (DRUG); FOLFOX regimen (DRUG),11167602,Stivarga,Gastrointestinal Adenocarcinoma,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13828,NCT02164240,Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST,COMPLETED,PHASE1,Gastrointestinal Stromal Tumor,Sunitinib (DRUG); Regorafenib (DRUG),11167602,Stivarga,Gastrointestinal Stromal Tumor,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13829,NCT03347292,Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC,COMPLETED,PHASE1,"Carcinoma, Hepatocellular","Regorafenib(Stivarga, BAY73-4506) (DRUG); Pembrolizumab (DRUG)",11167602,Stivarga,"Carcinoma, Hepatocellular",Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13830,NCT02773524,A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer,UNKNOWN,PHASE3,Gastro-Oesophageal Cancer,Regorafenib (DRUG); Placebo (OTHER),11167602,Stivarga,Gastric Cancer,Esophagus/Stomach,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13831,NCT01774344,Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma,COMPLETED,PHASE3,"Carcinoma, Hepatocellular","Regorafenib (Stivarga, BAY73-4506) (DRUG); Placebo (DRUG)",11167602,Stivarga,"Carcinoma, Hepatocellular",Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13832,NCT02955940,An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib,ACTIVE_NOT_RECRUITING,PHASE2,Pancreatic Cancer; Colorectal Cancer (CRC); Breast Cancer; Lung Cancer,Ruxolitinib (DRUG); Capecitabine (DRUG); Regorafenib (DRUG),11167602,Stivarga,Pancreatic Cancer; Colorectal Cancer (CRC); Breast Cancer; Lung Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13833,NCT05425940,Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Colorectal Cancer,XL092 (DRUG); Atezolizumab (DRUG); Regorafenib (DRUG),11167602,Stivarga,Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13834,NCT02316340,Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,Vorinostat (DRUG); Hydroxychloroquine (DRUG); Regorafenib (DRUG),11167602,Stivarga,Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13835,NCT06902246,Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma,NOT_YET_RECRUITING,PHASE2,Unresectable Hepatocellular Carcinoma; Hepatocellular Carcinoma,Regorafenib (DRUG); TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization (RADIATION),11167602,Stivarga,Unresectable Hepatocellular Carcinoma; Hepatocellular Carcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13836,NCT01271712,Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST),COMPLETED,PHASE3,Gastrointestinal Stromal Tumors,"Regorafenib (Stivarga, BAY73-4506) (DRUG); Placebo (DRUG); Best supportive care (DRUG)",11167602,Stivarga,Gastrointestinal Stromal Tumors,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13837,NCT01068769,Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor,COMPLETED,PHASE2,Gastrointestinal Stromal Tumor,regorafenib (DRUG),11167602,Stivarga,Gastrointestinal Stromal Tumor,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13838,NCT04879368,RegoNivo vs Standard of Care Chemotherapy in AGOC,ACTIVE_NOT_RECRUITING,PHASE3,Gastro-Oesophageal Cancer,Regorafenib (DRUG); Nivolumab (BIOLOGICAL); Docetaxel (DRUG); Paclitaxel (DRUG); Irinotecan (DRUG); Trifluridine/Tipracil (DRUG),11167602,Stivarga,Gastric Cancer,Esophagus/Stomach,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13839,NCT03657641,Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Colorectal Cancer; Colorectal Cancer Metastatic,Pembrolizumab (BIOLOGICAL); Regorafenib (DRUG),11167602,Stivarga,Colorectal Cancer; Colorectal Cancer Metastatic,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13840,NCT03946917,JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer,UNKNOWN,PHASE1,Colorectal Cancer,JS001 (DRUG); regorafenib tablet (DRUG),11167602,Stivarga,Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13841,NCT05048017,Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma,RECRUITING,PHASE2,Hepatocellular Carcinoma; Regorafenib; PD-1 Inhibitor,Regorafenib (DRUG); PD-1 inhibitor (DRUG),11167602,Stivarga,Hepatocellular Carcinoma; Regorafenib; PD-1 Inhibitor,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13842,NCT05198934,Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation,ACTIVE_NOT_RECRUITING,PHASE3,Colorectal Cancer (CRC),Sotorasib (DRUG); Panitumumab (DRUG); Trifluridine and Tipiracil (DRUG); Regorafenib (DRUG),11167602,Stivarga,Colorectal Cancer (CRC),Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13843,NCT01853319,Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy,COMPLETED,PHASE3,Colorectal Neoplasms,"Regorafenib (Stivarga, BAY73- 4506) (DRUG)",11167602,Stivarga,Colorectal Neoplasms,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13844,NCT02402036,A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer,TERMINATED,PHASE2,Colon Cancer,Regorafenib (DRUG),11167602,Stivarga,Colon Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13845,NCT05382741,Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial,UNKNOWN,PHASE2,Colorectal Cancer Stage IV; No Evidence of Disease State,Durvalumab Injection for intravenous use 500 mg vial solution for infusion (DRUG); Regorafenib 30 mg capsules (DRUG),11167602,Stivarga,Colorectal Cancer Stage IV; No Evidence of Disease State,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13846,NCT06887218,5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer,NOT_YET_RECRUITING,PHASE2,Metastatic Colorectal Cancer (CRC),Regorafenib (BAY 73-4506) (DRUG); 5FU/LV (DRUG); Bevacizumab (DRUG); Trifluridine-tipiracil (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer (CRC),Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13847,NCT05328908,A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Colorectal Neoplasms,Nivolumab-relatlimab FDC (DRUG); Regorafenib (DRUG); TAS-102 (DRUG),11167602,Stivarga,Colorectal Neoplasms,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13848,NCT01939223,"Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy",TERMINATED,PHASE3,Colorectal Neoplasms,"Regorafenib (Stivarga, BAY73-4506) (DRUG); Placebo (DRUG)",11167602,Stivarga,Colorectal Neoplasms,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13849,NCT06006923,Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer,RECRUITING,PHASE2,MSI-H Colorectal Cancer,Regorafenib (DRUG); Pembrolizumab (DRUG),11167602,Stivarga,MSI-H Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13850,NCT04696055,Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors,COMPLETED,PHASE2,Hepatocellular Carcinoma,"Pembrolizumab (DRUG); Regorafenib (Stivarga, BAY73-4506) (DRUG)",11167602,Stivarga,Hepatocellular Carcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13851,NCT03722108,Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas,TERMINATED,PHASE1,Adenocarcinoma of the Stomach; Adenocarcinoma of the Gastroesophageal Junction,Regorafenib and Irinotecan (COMBINATION_PRODUCT); Irinotecan (DRUG),11167602,Stivarga,Gastric Adenocarcinoma,Esophagus/Stomach,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13852,NCT01103323,Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy,COMPLETED,PHASE3,Metastatic Colorectal Cancer,"Regorafenib (Stivarga, BAY73-4506) (DRUG); Placebo (DRUG); Best Supportive Care (BSC) (OTHER)",11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13853,NCT02587650,"Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma",TERMINATED,PHASE2,ALK Fusion Protein Expression; BRAF wt Allele; Invasive Skin Melanoma; MET Fusion Gene Positive; NRAS wt Allele; NTRK1 Fusion Positive; NTRK2 Fusion Positive; NTRK3 Fusion Positive; RET Fusion Positive; ROS1 Fusion Positive; Stage III Cutaneous Melanoma; Stage IIIA Cutaneous Melanoma; Stage IIIB Cutaneous Melanoma; Stage IIIC Cutaneous Melanoma; Stage IV Cutaneous Melanoma,Capmatinib (DRUG); Ceritinib (DRUG); Entrectinib (DRUG); Laboratory Biomarker Analysis (OTHER); Regorafenib (DRUG),11167602,Stivarga,Advanced Melanoma,Skin,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13854,NCT04450836,Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer,TERMINATED,PHASE2,Metastatic Colorectal Cancer,Regorafenib then Trifluridine/Tipiracil (DRUG); Trifluridine/Tipiracil then Regorafenib (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13855,NCT03520842,Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer,COMPLETED,PHASE2,KRAS Gene Mutation; Metastatic Malignant Neoplasm in the Brain; Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7,Methotrexate (DRUG); Pharmacokinetic Study (OTHER); Regorafenib (DRUG),11167602,Stivarga,KRAS Gene Mutation; Metastatic Malignant Neoplasm in the Brain; Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7,Lung,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13856,NCT02465502,Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer,COMPLETED,PHASE2,Colorectal Neoplasms,"Regorafenib (Stivarga, BAY73-4506) (DRUG)",11167602,Stivarga,Colorectal Neoplasms,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13857,NCT01289821,First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib,COMPLETED,PHASE2,Colorectal Neoplasms,"Regorafenib (Stivarga, BAY73-4506) (DRUG); Oxaliplatin (DRUG); Folinic acid (DRUG); 5-FU (mFOLFOX6) (DRUG)",11167602,Stivarga,Colorectal Neoplasms,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13858,NCT06047379,"Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",RECRUITING,PHASE1,"Diffuse Astrocytoma, IDH-Mutant; Glioblastoma, IDH-wildtype; Brain Metastases, Adult; Cervical Cancer; Colorectal Cancer; Esophageal Cancer; Esophageal Squamous Cell Carcinoma; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Head and Neck Squamous Cell Carcinoma; Melanoma; Merkel Cell Carcinoma; Microsatellite Instability-High Solid Malignant Tumor; Mismatch Repair Deficient Solid Malignant Tumor; Microsatellite Instability-High Colorectal Cancer; Mismatch Repair Deficient Colorectal Cancer; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Small Cell Lung Cancer; Squamous Cell Carcinoma; Urothelial Carcinoma",NEO212 Oral Capsule (DRUG); Ipilimumab (DRUG); Pembrolizumab (DRUG); Nivolumab (DRUG); Regorafenib (DRUG); Carboplatin (DRUG); Paclitaxel (DRUG); FOLFIRI Protocol (DRUG); Bevacizumab (DRUG),11167602,Stivarga,"Diffuse Astrocytoma, IDH-Mutant; Glioblastoma, IDH-wildtype; Brain Metastases, Adult; Cervical Cancer; Colorectal Cancer; Esophageal Cancer; Esophageal Squamous Cell Carcinoma; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Head and Neck Squamous Cell Carcinoma; Melanoma; Merkel Cell Carcinoma; Microsatellite Instability-High Solid Malignant Tumor; Mismatch Repair Deficient Solid Malignant Tumor; Microsatellite Instability-High Colorectal Cancer; Mismatch Repair Deficient Colorectal Cancer; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Small Cell Lung Cancer; Squamous Cell Carcinoma; Urothelial Carcinoma",Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13859,NCT02910843,Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer,TERMINATED,PHASE1,Rectal Cancer,Regorafenib (DRUG); Capecitabine (DRUG); Radiotherapy (RADIATION); Surgery (PROCEDURE),11167602,Stivarga,Rectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13860,NCT03564938,Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).,COMPLETED,PHASE4,Metastatic Colorectal Cancer,"Regorafenib (Stivarga, BAY73-4506) (DRUG)",11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13861,NCT01298570,Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer Metastatic,Regorafenib (BAY 73-4506) (DRUG); FOLFIRI (DRUG); Placebo (DRUG); FOLFIRI (DRUG),11167602,Stivarga,Colorectal Cancer Metastatic,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13862,NCT06087263,"Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.",RECRUITING,PHASE2,Gastrointestinal Stromal Tumors,Regorafenib (DRUG),11167602,Stivarga,Gastrointestinal Stromal Tumors,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13863,NCT03305913,Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy,COMPLETED,PHASE1,Pretreated Metastatic Colorectal Cancer,TAS 102 (DRUG); Regorafenib (DRUG),11167602,Stivarga,Pretreated Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13864,NCT02581059,Efficacy of Ginseng for Patients on Regorafenib,TERMINATED,PHASE2,Colorectal Cancer; Palliative Medicine; Supportive Care,Regorafenib (DRUG); Ginseng (DIETARY_SUPPLEMENT),11167602,Stivarga,Colorectal Cancer; Palliative Medicine; Supportive Care,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13865,NCT04327700,Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib,TERMINATED,PHASE2,Hepatocellular Carcinoma,TheraBionic (DEVICE); Regorafenib (DRUG),11167602,Stivarga,Hepatocellular Carcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13866,NCT05064059,A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007),COMPLETED,PHASE3,Colorectal Cancer,favezelimab/pembrolizumab (BIOLOGICAL); regorafenib (DRUG); TAS-102 (DRUG),11167602,Stivarga,Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13867,NCT02307500,Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy,COMPLETED,PHASE2,Pancreas Cancer; Ovarian Cancer; Melanoma; Sarcoma; Thymoma Type B3; Thymoma Type B2; Thymic Carcinoma,Regorafenib (DRUG),11167602,Stivarga,Pancreas Cancer; Ovarian Cancer; Melanoma; Sarcoma; Thymoma Type B3; Thymoma Type B2; Thymic Carcinoma,Pancreas,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13868,NCT03992456,"Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Colon Adenocarcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Colon Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIA Rectal Cancer AJCC v8; Stage IIIB Colon Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Colon Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Stage IVA Colon Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Rectal Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Rectal Cancer AJCC v8; Stage IVC Colon Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage IVC Rectal Cancer AJCC v8; Unresectable Colon Adenocarcinoma; Unresectable Colorectal Carcinoma; Unresectable Rectal Adenocarcinoma,Panitumumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); Regorafenib (DRUG); Trifluridine and Tipiracil Hydrochloride (DRUG),11167602,Stivarga,Metastatic Colon Adenocarcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Colon Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIA Rectal Cancer AJCC v8; Stage IIIB Colon Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Colon Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Stage IVA Colon Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Rectal Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Rectal Cancer AJCC v8; Stage IVC Colon Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage IVC Rectal Cancer AJCC v8; Unresectable Colon Adenocarcinoma; Unresectable Colorectal Carcinoma; Unresectable Rectal Adenocarcinoma,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13869,NCT02795156,Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,COMPLETED,PHASE2,"Non-small Cell Lung Carcinoma; Urothelial Carcinoma; Gastrointestinal Carcinoma, Non-colon; Upper Aerodigestive Tract Carcinoma",Afatinib (DRUG); Regorafenib (DRUG); Cabozantinib (DRUG),11167602,Stivarga,"Non-small Cell Lung Carcinoma; Urothelial Carcinoma; Gastrointestinal Carcinoma, Non-colon; Upper Aerodigestive Tract Carcinoma",Bladder/Urinary Tract,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13870,NCT01896856,Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer,COMPLETED,PHASE1,Previously Treated Metastatic Colorectal Cancer,SGI-110 Dose Escalation (DRUG); Regorafenib (DRUG); TAS-102 (DRUG); SGI-110 (DRUG); Irinotecan (DRUG),11167602,Stivarga,Previously Treated Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13871,NCT02651415,Phase II Study of Perindopril and Regorafenib in mCRC,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Regorafenib (DRUG); Perindopril (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13872,NCT05600309,A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study,COMPLETED,PHASE3,Colorectal Cancer,favezelimab/pembrolizumab (BIOLOGICAL); regorafenib (DRUG); TAS-102 (DRUG),11167602,Stivarga,Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13873,NCT05731947,Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,Colorectal Cancer; Solid Tumors,Revumenib (DRUG); Chemotherapy (DRUG),11167602,Stivarga,Colorectal Cancer; Solid Tumors,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13874,NCT04126733,Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable),COMPLETED,PHASE2,Colorectal Cancer,"Regorafenib (Stivarga, BAY73-4506) (DRUG); Nivolumab (Opdivo) (BIOLOGICAL)",11167602,Stivarga,Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13875,NCT04777851,Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7,ACTIVE_NOT_RECRUITING,PHASE3,"Carcinoma, Hepatocellular",Regorafenib in combination with pembrolizumab (DRUG); Loco-regional therapy (PROCEDURE),11167602,Stivarga,"Carcinoma, Hepatocellular",Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13876,NCT02096354,"A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer",COMPLETED,PHASE2,Colorectal Neoplasms,RRx-001 (DRUG); Regorafenib (DRUG); Irinotecan (DRUG),11167602,Stivarga,Colorectal Neoplasms,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13877,NCT02664077,A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer,TERMINATED,PHASE3,Stage III (IIIB or IIIC) Colon Cancer,Regorafenib (DRUG); Placebo (DRUG),11167602,Stivarga,Stage III (IIIB or IIIC) Colon Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13878,NCT01003015,Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma,COMPLETED,PHASE2,"Carcinoma, Hepatocellular",BAY73-4506 (DRUG),11167602,Stivarga,"Carcinoma, Hepatocellular",Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13879,NCT01187615,"Determination of Safety, Efficacy, and Pharmacokinetics of ""Regorafenib"" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer",TERMINATED,PHASE1,Small Cell Lung Carcinoma,Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed (DRUG); Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed (DRUG),11167602,Stivarga,Small Cell Lung Carcinoma,Lung,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13880,NCT02024607,A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,COMPLETED,PHASE1,Advanced Gastrointestinal Cancer,BBI608 (DRUG); Fluorouracil (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); Irinotecan (DRUG); Bevacizumab (DRUG); Capecitabine (DRUG); Regorafenib (DRUG),11167602,Stivarga,Advanced Gastrointestinal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13881,NCT04183088,Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma,UNKNOWN,PHASE2,Advanced Hepatocellular Carcinoma,Tislelizumab+regorafenib for part 1;Tislelizumab+regorafenib for group 1 of part 2; Regorafenib for group 2 of part 2. (DRUG),11167602,Stivarga,Advanced Hepatocellular Carcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13882,NCT02466009,Regorafenib in Metastatic Colorectal Cancer,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Regorafenib (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13883,NCT02195011,Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases,COMPLETED,PHASE2,Colorectal Neoplasms,SIR-Spheres (DEVICE); Regorafenib (DRUG),11167602,Stivarga,Colorectal Neoplasms,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13884,NCT02383433,Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer,TERMINATED,PHASE2,Metastatic Pancreatic Adenocarcinoma,Regorafenib (DRUG); Gemcitabine Hydrochloride (DRUG),11167602,Stivarga,Metastatic Pancreatic Adenocarcinoma,Pancreas,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13885,NCT04008511,Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer,UNKNOWN,PHASE1,Metastatic Colorectal Cancer,Regorafenib (DRUG); Regorafenib (DRUG); Capecitabine (DRUG); Oxaliplatin (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13886,NCT03627728,"Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer",COMPLETED,PHASE2,Gastric Cancer,Regorafenib (DRUG); placebo (OTHER),11167602,Stivarga,Gastric Cancer,Esophagus/Stomach,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13887,NCT03899428,Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC,RECRUITING,PHASE2,Hepatocellular Carcinoma,Durvalumab (DRUG); Sorafenib (DRUG); Lenvatinib (DRUG); Regorafenib (DRUG); Cabozantinib (DRUG),11167602,Stivarga,Hepatocellular Carcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13888,NCT05426811,Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients,NOT_YET_RECRUITING,PHASE1,Regorafenib; Raltitrexed; Colorectal Neoplasms; Third-line Treatment,Regorafenib (DRUG); Raltitrexed (DRUG),11167602,Stivarga,Regorafenib; Raltitrexed; Colorectal Neoplasms; Third-line Treatment,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13889,NCT04117945,"Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer",ACTIVE_NOT_RECRUITING,PHASE2,BRAF V600E Negative; KRAS Gene Mutation Negative; Locally Advanced Unresectable Colorectal Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; NRAS Gene Mutation Negative; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Cetuximab (BIOLOGICAL); Irinotecan (DRUG); Panitumumab (BIOLOGICAL); Regorafenib (DRUG),11167602,Stivarga,BRAF V600E Negative; KRAS Gene Mutation Negative; Locally Advanced Unresectable Colorectal Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; NRAS Gene Mutation Negative; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13890,NCT03880877,Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,Regorafenib (DRUG); UGT1A1 genotyping (TA6/TA6) (GENETIC); UGT1A1 genotyping (TA6/TA7) (GENETIC); UGT1A1 genotyping (TA7/TA7) (GENETIC); Leucovorin and 5-FU (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13891,NCT03970447,A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma,RECRUITING,PHASE2,Glioblastoma,Temozolomide (DRUG); Lomustine (DRUG); Regorafenib (DRUG); Radiation (RADIATION); Paxalisib (DRUG); VAL-083 (DRUG); VT1021 (DRUG); Troriluzole (DRUG); ADI-PEG 20 (BIOLOGICAL),11167602,Stivarga,Glioblastoma,CNS/Brain,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13892,NCT06557278,Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer,NOT_YET_RECRUITING,PHASE2,Metastatic Colorectal Cancer,AlloStim (BIOLOGICAL); Bavencio (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13893,NCT02288078,Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402),UNKNOWN,PHASE2,Rectal Cancer,General condition (OTHER); Blood pressure (OTHER); Patient Reported Outcome (OTHER); Clinical findings (OTHER); Hematology/blood chemistry (OTHER); Coagulation and fibrinolysis system (OTHER); Urinalysis (OTHER); Medication check (OTHER); Adverse event (OTHER); Thyroid function test (OTHER); Contrast-enhanced torso CT (OTHER); Brain MRI (OTHER); Dexamethasone (DRUG); Regorafenib (DRUG); Placebo (DRUG); Proton pump inhibitor (DRUG),11167602,Stivarga,Rectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13894,NCT06089330,A Study of JMT101 in Patients With Metastatic Colorectal Cancer,NOT_YET_RECRUITING,PHASE2,Metastatic Colorectal Cancer (mCRC),JMT101 (DRUG); SG001 (DRUG); Irinotecan (DRUG); Regorafenib (Stivarga) (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer (mCRC),Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13895,NCT01584830,Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy,COMPLETED,PHASE3,Colorectal Neoplasms,Regorafenib (BAY73-4506) (DRUG); Placebo (DRUG),11167602,Stivarga,Colorectal Neoplasms,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13896,NCT05194293,Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer,RECRUITING,PHASE2,Stage IB Hepatocellular Carcinoma AJCC v8; Stage II Hepatocellular Carcinoma AJCC v8; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8,Durvalumab (BIOLOGICAL); Regorafenib (DRUG),11167602,Stivarga,Stage IB Hepatocellular Carcinoma AJCC v8; Stage II Hepatocellular Carcinoma AJCC v8; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13897,NCT02425683,Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX,TERMINATED,PHASE2,Colorectal Neoplasms; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum,Regorafenib (DRUG),11167602,Stivarga,Colorectal Neoplasms; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13898,NCT02736305,Use of Regorafenib in Recurrent Epithelial Ovarian Cancer,COMPLETED,PHASE2,Ovarian Neoplasms,Regorafenib (DRUG),11167602,Stivarga,Ovarian Neoplasms,Ovary/Fallopian Tube,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13899,NCT04864054,T-Cell Therapy (ECT204) in Adults With Advanced HCC,RECRUITING,PHASE2,"Hepatocellular Carcinoma; Liver Cancer, Adult; Liver Neoplasm; Metastatic Liver Cancer","ECT204 T cells (BIOLOGICAL); Regorafenib (STIVARGA®, BAY73-4506) (DRUG)",11167602,Stivarga,"Hepatocellular Carcinoma; Liver Cancer, Adult; Liver Neoplasm; Metastatic Liver Cancer",Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13900,NCT04683965,Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer,UNKNOWN,PHASE2,Colorectal Neoplasms,Pemetrexed (DRUG); TAS-102 (DRUG); Bevacizumab (DRUG),11167602,Stivarga,Colorectal Neoplasms,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13901,NCT05730673,"Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer",WITHDRAWN,PHASE2,CCR5; Microsatellite Stable; Metastatic; Colorectal Cancer,700mg leronlimab weekly dose (DRUG); 80mg Regorafenib at week 1 (DRUG); 120mg Regorafenib at week2 (DRUG); 160 mg Regorafenib at week 3 (DRUG),11167602,Stivarga,CCR5; Microsatellite Stable; Metastatic; Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13902,NCT06199973,"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan",RECRUITING,PHASE3,Advanced Colorectal Cancer,"SHR-A1811 (DRUG); TAS-102, Regorafenib , Fruquintinib (DRUG)",11167602,Stivarga,Advanced Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13903,NCT05281926,"A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients",UNKNOWN,PHASE1,Hepatocellular Carcinoma,Poly ICLC (DRUG),11167602,Stivarga,Hepatocellular Carcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13904,NCT01189903,Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients,UNKNOWN,PHASE2,Asian Colorectal Cancer Patients,Regorafenib (DRUG),11167602,Stivarga,Asian Colorectal Cancer Patients,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13905,NCT06041490,Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation,NOT_YET_RECRUITING,PHASE2,Liver Transplant; Complications; Hepatocarcinoma; Recurrent Osteosarcoma; High-Risk Cancer,multi-kinase inhibitors in combination with bevacizumab (DRUG),11167602,Stivarga,Liver Transplant; Complications; Hepatocarcinoma; Recurrent Osteosarcoma; High-Risk Cancer,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13906,NCT03251612,Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer Metastatic,Based on sensitivity analysis (DRUG),11167602,Stivarga,Colorectal Cancer Metastatic,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13907,NCT05113368,Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer,RECRUITING,PHASE2,Ovarian Cancer; Serous Ovarian Cancer,Regorafenib (DRUG); Fulvestrant (DRUG),11167602,Stivarga,Ovarian Cancer; Serous Ovarian Cancer,Ovary/Fallopian Tube,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13908,NCT06326346,GIST Oral Paclitaxel(Liporaxel),NOT_YET_RECRUITING,PHASE2,Gastrointestinal Stromal Tumors,Liporaxel (DRUG),11167602,Stivarga,Gastrointestinal Stromal Tumors,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13909,NCT05917431,Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC,RECRUITING,PHASE2,Unresectable Hepatocellular Carcinoma; Oligometastatic Disease,SBRT plus tislelizumab and regorafenib (COMBINATION_PRODUCT),11167602,Stivarga,Unresectable Hepatocellular Carcinoma; Oligometastatic Disease,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13910,NCT03829462,Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients,ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Colorectal Cancer (mCRC),Regorafenib (DRUG); Irinotecan (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer (mCRC),Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13911,NCT04316182,Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION),COMPLETED,PHASE2,Hepatocellular Carcinoma,Cabozantinib (DRUG),11167602,Stivarga,Hepatocellular Carcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13912,NCT05582031,Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers,WITHDRAWN,PHASE2,Anal Squamous Cell Carcinoma; Colorectal Neoplasms; Soft Tissue Sarcoma; Malignant Pleural Mesothelioma; Small Cell Lung Carcinoma; Castrate Resistant Prostate Cancer; Neuroendocrine Carcinoma of Prostate; Gastroenteropancreatic Neuroendocrine Neoplasm,Regorafenib in combination with Tislelizumab (COMBINATION_PRODUCT),11167602,Stivarga,Anal Squamous Cell Carcinoma; Colorectal Neoplasms; Soft Tissue Sarcoma; Malignant Pleural Mesothelioma; Small Cell Lung Carcinoma; Castrate Resistant Prostate Cancer; Neuroendocrine Carcinoma of Prostate; Gastroenteropancreatic Neuroendocrine Neoplasm,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13913,NCT04030260,Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer,UNKNOWN,PHASE2,Colorectal Cancer Metastatic; MSS,Regorafenib and PD-1 antibody in Combination with Radiotherapy (DRUG); Radiation therapy (RADIATION),11167602,Stivarga,Colorectal Cancer Metastatic; MSS,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13914,NCT05289726,Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105,UNKNOWN,PHASE2,Hand and Foot Skin Reaction; Colorectal Cancer Stage IV,Traditional chinese medicine TDX105 (DRUG); Placebo (DRUG),11167602,Stivarga,Hand and Foot Skin Reaction; Colorectal Cancer Stage IV,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13915,NCT06335927,HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC,RECRUITING,PHASE2,Intrahepatic Cholangiocarcinoma,HAIC-GEMOX+Cadonilimab+Regorafenib (DRUG),11167602,Stivarga,Intrahepatic Cholangiocarcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13916,NCT02699073,Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib,COMPLETED,PHASE2,Metastatic Colorectal Cancer,regorafenib (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13917,NCT02619435,Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer,UNKNOWN,PHASE2,Advanced Colorectal Cancer,regorafenib (DRUG),11167602,Stivarga,Advanced Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13918,NCT02800330,The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib,COMPLETED,PHASE4,Colorectal Neoplasms; Gastrointestinal Stromal Tumors,Esomeprazole 40mg concomitantly (DRUG); Esomeprazole 40mg before (DRUG); Regorafenib 160mg or 120mg (DRUG),11167602,Stivarga,Colorectal Neoplasms; Gastrointestinal Stromal Tumors,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13919,NCT04446091,A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC),UNKNOWN,PHASE1,Colorectal Cancer,"Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.) (DRUG); Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan (DRUG)",11167602,Stivarga,Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13920,NCT05933980,"Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer",RECRUITING,PHASE2,Colorectal Cancer; Liver Metastases; MSS,Rego+Tori+Cele (DRUG),11167602,Stivarga,Colorectal Cancer; Liver Metastases; MSS,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13921,NCT04781192,The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers,RECRUITING,PHASE1,Advanced Biliary Tract Cancer,Durvalumab (DRUG); Regorafenib (DRUG),11167602,Stivarga,Advanced Biliary Tract Cancer,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13922,NCT01875380,Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Neoplasms; Metastatic Disease,Regorafenib (DRUG),11167602,Stivarga,Colorectal Neoplasms; Metastatic Disease,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13923,NCT02934529,Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab,COMPLETED,PHASE3,Metastatic Colorectal Cancer,Irinotecan (DRUG); Folinic Acid (DRUG); 5-FU (DRUG); 5-FU (DRUG); Cetuximab (DRUG); Bevacizumab (DRUG); Capecitabine (DRUG); regorafenib (DRUG); Irinotecan 125mg (DRUG); Cetuximab wkly (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13924,NCT02116894,Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,PF-03446962 (BIOLOGICAL); Regorafenib (DRUG),11167602,Stivarga,Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13925,NCT04503694,Neoadjuvant Regorafenib in Combination with Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer,RECRUITING,PHASE2,Rectal Cancer Stage II; Rectal Cancer Stage III,Nivolumab 10 MG/ML Intravenous Solution (DRUG); Regorafenib 30 MG Oral Tablet (DRUG); Radiotherapy (RADIATION); Surgery (PROCEDURE); Non-operative Management (PROCEDURE),11167602,Stivarga,Rectal Cancer Stage II; Rectal Cancer Stage III,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13926,NCT03081494,Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer,COMPLETED,PHASE1,Metastatic Colorectal Cancer,spartalizumab (PDR001) (DRUG); regorafenib (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13927,NCT03099486,Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC,TERMINATED,PHASE2,Colorectal Cancer,Regorafenib (DRUG); 5-FU (DRUG); Leucovorin (DRUG),11167602,Stivarga,Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13928,NCT06200363,A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer,RECRUITING,PHASE1,Advanced Colorectal Cancer,T3011 (DRUG); Regorafenib (DRUG),11167602,Stivarga,Advanced Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13929,NCT06322563,Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC,NOT_YET_RECRUITING,PHASE2,Advanced/Metastatic Colorectal Cancer,LTC004+regorafenib (DRUG),11167602,Stivarga,Advanced/Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13930,NCT04819516,Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer,RECRUITING,PHASE1,Colorectal Cancer,high-intensity focused ultrasound therapy (PROCEDURE); Toripalimab (DRUG),11167602,Stivarga,Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13931,NCT03190616,Apatinib in Refractory Colorectal Cancer,COMPLETED,PHASE2,Colorectal Neoplasms,apatinib (DRUG),11167602,Stivarga,Colorectal Neoplasms,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13932,NCT02835924,Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC,COMPLETED,PHASE2,Metastatic Colorectal Cancer,Regorafenib (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13933,NCT04775862,A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.,UNKNOWN,PHASE2,Colon Cancer,investigator choice re-challenge with anti EGFR Rx (DRUG),11167602,Stivarga,Colon Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13934,NCT05608044,A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Colorectal Cancer,Botensilimab (DRUG); Balstilimab (DRUG); Standard of Care (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13935,NCT03609424,PDR001 Plus Imatinib for Metastatic or Unresectable GIST,COMPLETED,PHASE1,Gastrointestinal Stromal Tumors,"PDR001, Imatinib (DRUG)",11167602,Stivarga,Gastrointestinal Stromal Tumors,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13936,NCT05673824,Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.,RECRUITING,PHASE4,Nephrotoxicity,Huaier Granule (DRUG); VEGFR-TKIs (DRUG),11167602,Stivarga,Nephrotoxicity,Kidney,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13937,NCT06275919,Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial),RECRUITING,PHASE2,"Meningioma, Malignant",Regorafenib 40 MG Oral Tablet (DRUG); Local Standard of Care (DRUG),11167602,Stivarga,"Meningioma, Malignant",CNS/Brain,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13938,NCT03944304,"Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.",RECRUITING,PHASE2,Gastrointestinal Stromal Tumors,Paclitaxel (DRUG),11167602,Stivarga,Gastrointestinal Stromal Tumors,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13939,NCT05152472,"A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined with Atezolizumab Versus Imatinib Resumption Alone in Patients with Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments",RECRUITING,PHASE2,Unresectable Gastrointestinal Stromal Tumor (GIST); Locally Advanced Gastrointestinal Stromal Tumor (GIST); Metastatic Gastrointestinal Stromal Tumor,Atezolizumab 1200 mg (DRUG); Imatinib 400 MG (DRUG),11167602,Stivarga,Unresectable Gastrointestinal Stromal Tumor (GIST); Locally Advanced Gastrointestinal Stromal Tumor (GIST); Metastatic Gastrointestinal Stromal Tumor,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13940,NCT04660812,An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Colorectal Cancer,AB680 (DRUG); Etrumadenant (DRUG); Zimberelimab (DRUG); Bevacizumab (DRUG); m-FOLFOX-6 regimen (DRUG); Regorafenib (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13941,NCT05160168,A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST),TERMINATED,PHASE1,"Gastrointestinal Stromal Tumors (GIST); Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasm; Digestive System Disease; Gastrointestinal Diseases",THE-630 (DRUG),11167602,Stivarga,"Gastrointestinal Stromal Tumors (GIST); Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasm; Digestive System Disease; Gastrointestinal Diseases",Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13942,NCT06841172,Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC,RECRUITING,PHASE3,OligoProgressive Metastatic Disease; Hepatocellular Carcinoma (HCC); Radiotherapy; Systemic Therapy,radiotherapy (RADIATION); Systemic therapy (Continuation of current first-line systemic therapy) (DRUG); Systemic therapy (Early switch to second-line systemic therapy) (DRUG),11167602,Stivarga,OligoProgressive Metastatic Disease; Hepatocellular Carcinoma (HCC); Radiotherapy; Systemic Therapy,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13943,NCT06283134,A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer,NOT_YET_RECRUITING,PHASE1,Colorectal Cancer Metastatic,BioTTT001 hepatic artery infusion (BIOLOGICAL); toripalimab (DRUG); regorafenib (DRUG),11167602,Stivarga,Colorectal Cancer Metastatic,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13944,NCT05462613,Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer,RECRUITING,PHASE2,Metastatic Colorectal Cancer,quality of life questionnaires (OTHER); Blood sample (PROCEDURE); Regorafenib (DRUG); Metronomic chemotherapies (DRUG); Aspirin (DRUG); Bevacizumab (DRUG); FOLFIRI or FOLFOX (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13945,NCT04787341,PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence,ACTIVE_NOT_RECRUITING,PHASE2,Colorectal Cancer,Regorafenib (DRUG); Panitumumab (DRUG),11167602,Stivarga,Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13946,NCT02459119,Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477),COMPLETED,PHASE2,"Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)",Regorafenib (DRUG),11167602,Stivarga,"Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)",Bladder/Urinary Tract,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13947,NCT05524155,Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis,UNKNOWN,PHASE2,Colorectal Cancer; Liver Metastasis,HAIC (DRUG); Sintilimab (DRUG); Regorafenib (DRUG),11167602,Stivarga,Colorectal Cancer; Liver Metastasis,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13948,NCT06592612,Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment,NOT_YET_RECRUITING,PHASE2,Hepatocellular Carcinoma; Oligoprogression,SBRT and second-line systemic therapy (RADIATION); Second-line systemic therapy (DRUG),11167602,Stivarga,Hepatocellular Carcinoma; Oligoprogression,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13949,NCT05962450,Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy,RECRUITING,PHASE2,Hepatocellular Carcinoma,iNKT Cells (BIOLOGICAL); PD-1 (DRUG); Regorafenib (DRUG),11167602,Stivarga,Hepatocellular Carcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13950,NCT01786538,Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines,WITHDRAWN,PHASE3,Metastatic Colorectal Cancer,Regorafenib/FOLFOX (DRUG); Placebo/FOLFOX (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13951,NCT05130021,A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,MAX-40279-01 (DRUG); regorafenib (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13952,NCT05135364,HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure,UNKNOWN,PHASE2,Unresectable Hepatocellular Carcinoma,Camrelizumab (DRUG); HAIC (DRUG); TKI (DRUG),11167602,Stivarga,Unresectable Hepatocellular Carcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13953,NCT02162914,Regorafenib Versus Placebo to Treat Cholangiocarcinoma,UNKNOWN,PHASE2,Cholangiocarcinoma,Regorafenib/active (DRUG); Regorafenib/placebo (DRUG),11167602,Stivarga,Cholangiocarcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13954,NCT02199223,Regorafenib + Panitumumab for Colorectal Cancers,TERMINATED,PHASE1,KRAS and NRAS Wild-type Colorectal Cancer,regorafenib + panitumumab (DRUG),11167602,Stivarga,KRAS and NRAS Wild-type Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13955,NCT04806243,Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）,UNKNOWN,PHASE2,Hepatocellular Carcinoma,Regorafenib Pill&Camrelizumab (DRUG),11167602,Stivarga,Hepatocellular Carcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13956,NCT05622136,Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma,RECRUITING,PHASE2,Liver Cancer; Hepatocellular Carcinoma,Regorafenib Oral Product (DRUG),11167602,Stivarga,Liver Cancer; Hepatocellular Carcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13957,NCT06543836,ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer,RECRUITING,PHASE2,Metastatic Colorectal Cancer,Sintilimab (DRUG); Fruquintinib or Regorafenib (DRUG); Fruquintinib (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13958,NCT06946849,"Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study",NOT_YET_RECRUITING,PHASE2,Intrahepatic Cholangiocarcinoma (Icc),radiotherapy (RADIATION); FOLFIRI or FOLFOX or Regorafenib (DRUG),11167602,Stivarga,Intrahepatic Cholangiocarcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13959,NCT05820906,Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer,RECRUITING,PHASE2,Advanced Biliary Tract Cancer,Cadonilimab+Regorafenib+GC (DRUG),11167602,Stivarga,Advanced Biliary Tract Cancer,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13960,NCT03828799,"Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer",COMPLETED,PHASE1,Metastatic Colorectal Cancer,Folfirinox + regorafenib (COMBINATION_PRODUCT),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13961,NCT02406170,Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma,COMPLETED,PHASE1,Esophageal Neoplasms; Stomach Neoplasms; Neoplasm Metastasis,Regorafenib (DRUG); Paclitaxel (DRUG),11167602,Stivarga,Esophageal Neoplasms; Stomach Neoplasms; Neoplasm Metastasis,Esophagus/Stomach,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13962,NCT02788006,Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .,COMPLETED,PHASE2,Colorectal Adenocarcinoma,Regorafenib 160 mg (DRUG),11167602,Stivarga,Colorectal Adenocarcinoma,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13963,NCT06363006,Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer,RECRUITING,PHASE1,Hepatocellular Carcinoma,TKI+Cardunilimab (DRUG),11167602,Stivarga,Hepatocellular Carcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13964,NCT03898102,Zinc Supplement in Regorafenib Treated mCRC Patient,COMPLETED,PHASE2,Colorectal Cancer Metastatic,Regorafenib (DRUG); Zinc gluconate supplement (DIETARY_SUPPLEMENT),11167602,Stivarga,Colorectal Cancer Metastatic,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13965,NCT05644379,A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma,RECRUITING,PHASE1,Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy,Cadonilimab Injection (DRUG); Regorafenib (DRUG),11167602,Stivarga,Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13966,NCT02788279,A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370),COMPLETED,PHASE3,Colorectal Cancer,"Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody (DRUG); Cobimetinib (DRUG); Regorafenib (DRUG)",11167602,Stivarga,Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13967,NCT06356584,Fruquintinib/Regorafenib Combined with Sintilimab ± Radiotherapy for Third-line Treatment of Metastatic Colorectal Cancer (FREST-CRC),RECRUITING,PHASE2,Colorectal Cancer; Immunotherapy; Radiotherapy; Targeted Therapy,Sintilimab (DRUG),11167602,Stivarga,Colorectal Cancer; Immunotherapy; Radiotherapy; Targeted Therapy,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13968,NCT06283303,A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer,NOT_YET_RECRUITING,PHASE1,Colorectal Cancer Metastatic,T3011 hepatic artery infusion (BIOLOGICAL); toripalimab (DRUG); regorafenib (DRUG),11167602,Stivarga,Colorectal Cancer Metastatic,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13969,NCT06911684,"Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.",RECRUITING,PHASE2,Rectal Cancer Patients,lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy (COMBINATION_PRODUCT); lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy (COMBINATION_PRODUCT),11167602,Stivarga,Rectal Cancer Patients,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13970,NCT04985136,A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC),TERMINATED,PHASE3,Advanced Hepatocellular Carcinoma (HCC),camrelizumab；Rivoceranib (DRUG); Rivoceranib (DRUG); Sorafenib (DRUG); Regorafenib (DRUG),11167602,Stivarga,Advanced Hepatocellular Carcinoma (HCC),Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13971,NCT06375317,HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure,NOT_YET_RECRUITING,PHASE2,HCC - Hepatocellular Carcinoma,PD-L1 inhibitor: Adebrelimab Injection；Regorafenib Tablets (DRUG),11167602,Stivarga,HCC - Hepatocellular Carcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13972,NCT06930118,"The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.",RECRUITING,PHASE2,Advanced Colorectal Cancer in the Third-line Treatment and Beyond; pMMR/MSS Advanced Colorectal Cancer,"chidamide, regorafenib, and iparomlimab/tuvonralimab (DRUG)",11167602,Stivarga,Advanced Colorectal Cancer in the Third-line Treatment and Beyond; pMMR/MSS Advanced Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13973,NCT06095375,"Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients",ACTIVE_NOT_RECRUITING,PHASE1,"Glioblastoma, IDH-wildtype; MGMT-Methylated Glioblastoma",Regorafenib (DRUG); Temozolomide (DRUG),11167602,Stivarga,"Glioblastoma, IDH-wildtype; MGMT-Methylated Glioblastoma",CNS/Brain,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13974,NCT06730100,CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer,NOT_YET_RECRUITING,PHASE2,Metastatic Microsatellite Stable Colorectal Carcinoma; Refractory Microsatellite Stable Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); pH Low Insertion Peptide-exatecan Conjugate CBX-12 (DRUG); X-Ray Imaging (PROCEDURE),11167602,Stivarga,Metastatic Microsatellite Stable Colorectal Carcinoma; Refractory Microsatellite Stable Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13975,NCT04483219,Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.,UNKNOWN,PHASE2,MSS; pMMR; Metastatic Colorectal Adenocarcinoma,TKI ± anti-PD-1 antibody (DRUG),11167602,Stivarga,MSS; pMMR; Metastatic Colorectal Adenocarcinoma,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13976,NCT05057052,Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis,RECRUITING,PHASE2,Liver Metastases; Colorectal Cancer Metastatic,Sintilimab (DRUG); Regorafenib (DRUG); US/CT-guided Percutaneous Cryoablation (COMBINATION_PRODUCT),11167602,Stivarga,Liver Metastases; Colorectal Cancer Metastatic,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13977,NCT05905887,Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor,RECRUITING,PHASE2,Gastrointestinal Stromal Tumors,"Rivoceranib Mesylate, Paclitaxel (DRUG)",11167602,Stivarga,Gastrointestinal Stromal Tumors,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13978,NCT05894837,Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases,NOT_YET_RECRUITING,PHASE2,Colorectal Cancer; Liver Metastases,Serplulimab+Regorafenib (DRUG); Hepatic Artery Bicarbonate Infusion (DRUG),11167602,Stivarga,Colorectal Cancer; Liver Metastases,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13979,NCT05201352,"Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine",RECRUITING,PHASE1,Metastatic Colorectal Cancer,trifluridine/tipiracil + XB2001 (DRUG); trifluridine/tipiracil + placebo (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13980,NCT05134532,Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC,UNKNOWN,PHASE2,Hepatocellular Carcinoma,regorafenib (DRUG),11167602,Stivarga,Hepatocellular Carcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13981,NCT03555149,A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC),TERMINATED,PHASE1,Colorectal Cancer,Regorafenib (DRUG); Atezolizumab (DRUG); Imprime PGG (DRUG); Bevacizumab (DRUG); Isatuximab (DRUG); Selicrelumab (DRUG); Idasanutlin (DRUG); AB928 (DRUG); LOAd703 (GENETIC),11167602,Stivarga,Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13982,NCT04051606,Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma,ACTIVE_NOT_RECRUITING,PHASE2,Recurrent Glioblastoma,Regorafenib (DRUG),11167602,Stivarga,Recurrent Glioblastoma,CNS/Brain,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13983,NCT04718909,Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC,UNKNOWN,PHASE2,Hepatocellular Carcinoma Non-resectable,Regorafenib + sintilimab (DRUG); Regorafenib (DRUG),11167602,Stivarga,Hepatocellular Carcinoma Non-resectable,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13984,NCT05485909,Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM,UNKNOWN,PHASE2,Colorectal Cancer Liver Metastases,Radiofrequency ablation (OTHER); Regorafenib and Toripalimab Combination (DRUG),11167602,Stivarga,Colorectal Cancer Liver Metastases,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13985,NCT03732547,Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma,UNKNOWN,PHASE2,"Carcinoma, Hepatocellular",PD-1 mAb (DRUG); PolyIC (DRUG),11167602,Stivarga,"Carcinoma, Hepatocellular",Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13986,NCT05535647,Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma,NOT_YET_RECRUITING,PHASE2,Intrahepatic Cholangiocarcinoma,Regorafenib and HAIC (DRUG); FOLFOX (DRUG),11167602,Stivarga,Intrahepatic Cholangiocarcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13987,NCT06772233,A Study of Regorafenib Combined with Envafolimab for Metastatic Gastrointestinal Stromal Tumors with Kit Gene Exon 17 Mutation That Failed Standard Treatment,RECRUITING,PHASE2,Metastatic Gastrointestinal Stromal Tumors (GIST),regorafenib combined with envafolimab (DRUG); Control Group (DRUG),11167602,Stivarga,Metastatic Gastrointestinal Stromal Tumors (GIST),Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13988,NCT02501551,"Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy",UNKNOWN,PHASE2,Melanoma,regorafenib (DRUG),11167602,Stivarga,Melanoma,Skin,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13989,NCT03353753,Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies,COMPLETED,PHASE3,Gastrointestinal Stromal Tumors,DCC-2618 (DRUG); Placebo Oral Tablet (DRUG),11167602,Stivarga,Gastrointestinal Stromal Tumors,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13990,NCT05278351,Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC,RECRUITING,PHASE2,Colorectal Neoplasms Malignant,Tislelizumab Combined With Cetuximab and Irinotecan (DRUG); Third-line regimens (DRUG),11167602,Stivarga,Colorectal Neoplasms Malignant,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13991,NCT03843853,Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer,WITHDRAWN,PHASE2,Colorectal Neoplasms,Pemetrexed (DRUG); S-1 (DRUG); Bevacizumab (DRUG),11167602,Stivarga,Colorectal Neoplasms,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13992,NCT03475953,A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors,RECRUITING,PHASE1,"Colorectal Cancer Not MSI-H or MMR-deficient; GIST; Oesophageal or Gastric Carcinoma; Biliary Tract Cancer; Hepatocellular Carcinoma; Soft-tissue Sarcoma; Thyroid Cancer; Gastro-enteropancreatic Neuroendocrine Tumor; Non-small Cell Lung Cancer; Solid Tumor, Adult; Urothelial Carcinoma; HPV-Related Carcinoma; Triple Negative Breast Cancer; Renal Carcinoma; Mesotheliomas Pleural",Phase 1 : Regorafenib (DRUG); Phase 1 : Avelumab (DRUG); Phase 2 : Regorafenib (DRUG); Phase 2 : Avelumab (DRUG); Phase 2: low-dose Regorafenib (DRUG),11167602,Stivarga,"Colorectal Cancer Not MSI-H or MMR-deficient; GIST; Oesophageal or Gastric Carcinoma; Biliary Tract Cancer; Hepatocellular Carcinoma; Soft-tissue Sarcoma; Thyroid Cancer; Gastro-enteropancreatic Neuroendocrine Tumor; Non-small Cell Lung Cancer; Solid Tumor, Adult; Urothelial Carcinoma; HPV-Related Carcinoma; Triple Negative Breast Cancer; Renal Carcinoma; Mesotheliomas Pleural",Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13993,NCT05489237,First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors,RECRUITING,PHASE1,Gastrointestinal Stromal Tumor (GIST); Digestive System Disease; Gastrointestinal Diseases; Metastatic Cancer,IDRX-42 (DRUG),11167602,Stivarga,Gastrointestinal Stromal Tumor (GIST); Digestive System Disease; Gastrointestinal Diseases; Metastatic Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13994,NCT05370807,A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma,UNKNOWN,PHASE2,Melanoma Stage III; Melanoma Stage IV,Regorafenib 40 MG Oral Tablet (DRUG); Triplet therapy (DRUG),11167602,Stivarga,Melanoma Stage III; Melanoma Stage IV,Skin,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13995,NCT04874207,Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients with Metastatic Colorectal Cancer Treated with REgorafenib,ACTIVE_NOT_RECRUITING,PHASE4,Colorectal Cancer Metastatic,Regorafenib (DRUG),11167602,Stivarga,Colorectal Cancer Metastatic,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13996,NCT06403709,"Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Colorectal Cancer,"Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab (DRUG)",11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13997,NCT04170556,Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING),COMPLETED,PHASE1,Hepatocellular Carcinoma,Regorafenib (DRUG); Nivolumab (DRUG),11167602,Stivarga,Hepatocellular Carcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13998,NCT05985109,KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer,RECRUITING,PHASE2,Colorectal Cancer,KN046 (DRUG); regorafenib (DRUG),11167602,Stivarga,Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +13999,NCT04310709,Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma,COMPLETED,PHASE2,"Carcinoma, Hepatocellular; Hepatoma",Regorafenib/Nivolumab (DRUG),11167602,Stivarga,"Carcinoma, Hepatocellular; Hepatoma",Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +14000,NCT06425133,Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers,RECRUITING,PHASE2,Metastatic Colorectal Cancer,Blood sample (PROCEDURE); Quality of life questionnaires (OTHER); Biopsy (PROCEDURE); Regorafenib (DRUG); Regorafenib + metronomic chemotherapy (COMBINATION_PRODUCT),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +14001,NCT02023333,Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Colorectal Adenocarcinoma,Regorafenib (DRUG),11167602,Stivarga,Metastatic Colorectal Adenocarcinoma,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +14002,NCT06243393,Sacituzumab Govitecan in Metastatic Colorectal Cancer,RECRUITING,PHASE2,Metastatic Colorectal Cancer,Sacituzumab Govitecan (SG) (DRUG); Physicians Choice (PhC). (DRUG),11167602,Stivarga,Metastatic Colorectal Cancer,Bowel,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +14003,NCT06280105,A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib,NOT_YET_RECRUITING,PHASE2,Hepatocellular Carcinoma,Cadonilimab+regorafenib (DRUG),11167602,Stivarga,Hepatocellular Carcinoma,Liver,Regorafenib,"BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TEK",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,"Used for metastatic colorectal cancer, GIST, HCC.",CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,1.02,351.0 +14004,NCT02892357,Efficacy of Traditional Chinese Medicine Combined With Omeprazole in Patients With Non-erosive Reflux Disease,UNKNOWN,PHASE1,Non-erosive Reflux Disease,Treatment group (DRUG); Control group (DRUG),5284443,URI,Gastroesophageal Reflux Disease,Esophagus/Stomach,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14005,NCT02309320,"A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171",COMPLETED,PHASE1,Respiratory Syncytial Virus Infection,ALX-0171 (BIOLOGICAL); Placebo (OTHER),5284443,URI,Respiratory Syncytial Virus Infection,Lung,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14006,NCT04590274,Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),WITHDRAWN,PHASE1,Covid19; SARS (Severe Acute Respiratory Syndrome),Hydroxychloroquine (DRUG); Vitamins and Minerals (DIETARY_SUPPLEMENT); Azithromycin (DRUG),5284443,URI,Covid19; SARS (Severe Acute Respiratory Syndrome),Lung,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14007,NCT06295120,The Optimal Antibiotic Treatment Duration for Community-acquired Pneumonia in Adults Diagnosed in General Practice in Denmark (CAP-D),RECRUITING,PHASE4,Community-acquired Pneumonia,Phenoxymethylpenicillin 1.2 MIE 4 times daily (DRUG),5284443,URI,Community-acquired Pneumonia,Lung,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14008,NCT02652520,"Evaluation of a Marine OXYgen Carrier: HEMO2Life® for hypOthermic Kidney Graft Preservation, Before Transplantation (OXYOP)",COMPLETED,PHASE1,End Stage Renal Diseases,HEMO2Life® use in organ preservation solution (PROCEDURE),5284443,URI,End Stage Renal Diseases,Kidney,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14009,NCT01069874,Trial of Vitamin D Supplementation for the Prevention of Influenza and Other Respiratory Infections (ViDiFlu),COMPLETED,PHASE2,Respiratory Tract Infections; Influenza,Cholecalciferol (Vitamin D/Vigantol oil) (DIETARY_SUPPLEMENT); Miglyol oil (DIETARY_SUPPLEMENT),5284443,URI,Respiratory Tract Infections; Influenza,Lung,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14010,NCT04244474,Effect of Vitamin D Supplementation on Improvement of Pneumonic Children,UNKNOWN,PHASE1,"Child, Hospitalized; Vitamin D Deficiency; Pneumonia",A single one ml injection (DRUG),5284443,URI,"Child, Hospitalized; Vitamin D Deficiency; Pneumonia",Lung,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14011,NCT04028466,Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features,TERMINATED,PHASE4,GERD; Gastro Esophageal Reflux,Vonoprazan (DRUG); Omeprazole (DRUG),5284443,URI,Gastroesophageal Reflux Disease,Esophagus/Stomach,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14012,NCT00798226,"Fish Oil Supplementation During Pregnancy for Prevention of Asthma, Eczema and Allergies in Childhood",ACTIVE_NOT_RECRUITING,PHASE1,Asthma; Eczema; Allergy,n-3 fatty acid (DIETARY_SUPPLEMENT); olive oil (DIETARY_SUPPLEMENT),5284443,URI,Asthma; Eczema; Allergy,Lung,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14013,NCT00423527,Levetiracetam in Central Pain in Multiple Sclerosis(MS),COMPLETED,PHASE4,Multiple Sclerosis,levetiracetam (DRUG),5284443,URI,Multiple Sclerosis,CNS/Brain,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14014,NCT04619420,A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease,ACTIVE_NOT_RECRUITING,PHASE2,Alzheimer Disease; Cognitive Dysfunction; Dementia,JNJ-63733657 (DRUG); Placebo (DRUG),5284443,URI,Alzheimer Disease; Cognitive Dysfunction; Dementia,CNS/Brain,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14015,NCT01439282,Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer,COMPLETED,PHASE2,Estrogen Receptor Positive Tumor; Breast Cancer,eribulin mesylate (DRUG); capecitabine (DRUG),5284443,URI,Estrogen Receptor Positive Tumor; Breast Cancer,Breast,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14016,NCT06056973,Jinghua Weikang Capsule in the Treatment of Reflux Esophagitis,NOT_YET_RECRUITING,PHASE4,Reflux Esophagitis,jinghua weikang capsule (DRUG),5284443,URI,Reflux Esophagitis,Esophagus/Stomach,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14017,NCT04519073,Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Vaccine Against Respiratory Syncytial Virus,COMPLETED,PHASE1,Acute Bronchiolitis Due to Respiratory Syncytial Virus,V-306 candidate vaccine (BIOLOGICAL),5284443,URI,Acute Bronchiolitis Due to Respiratory Syncytial Virus,Lung,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14018,NCT06887673,"Lipid Mediators & Cancer: Montelukast, SPM, and Almonds",NOT_YET_RECRUITING,EARLY_PHASE1,Colorectal Cancer; Sarcoma; Brain Tumors; Endometrial Cancer; Ovarian Cancer,No Interventions (OTHER); Sports Pro Resolve 4 g (DIETARY_SUPPLEMENT); Double Wood SPM 4 g (DIETARY_SUPPLEMENT); 20 California Sweet Almonds (DIETARY_SUPPLEMENT); Montelukast 10 Mg Oral Tablet (DRUG); Montelukast 10 Mg Oral Tablet and SPM 4 g (COMBINATION_PRODUCT); Cold- Pressed Almond Oil 30 mL (DIETARY_SUPPLEMENT),5284443,URI,Colorectal Cancer; Sarcoma; Brain Tumors; Endometrial Cancer; Ovarian Cancer,Bowel,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14019,NCT05488873,A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy,ACTIVE_NOT_RECRUITING,PHASE2,Chemotherapy-induced Peripheral Neuropathy,WST-057 Active (DRUG); Placebo (DRUG),5284443,URI,Chemotherapy-induced Peripheral Neuropathy,Peripheral Nervous System,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14020,NCT04021264,The Impact of an Epidural Anesthetic on the Consumption of Sevoflurane in Major Abdominal Surgery,WITHDRAWN,PHASE2,Bowel Disease; Liver Diseases; Pancreas Disease; Anesthesia; Functional,Ropivacaine-Sufentanil (DRUG); Dextrose 5 (DRUG),5284443,URI,Bowel Disease; Liver Diseases; Pancreas Disease; Anesthesia; Functional,Liver,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14021,NCT04282590,A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study),WITHDRAWN,PHASE2,Chemotherapy-induced Peripheral Neuropathy,TRK-750/Placebo (DRUG); Placebo/TRK-750 (DRUG),5284443,URI,Chemotherapy-induced Peripheral Neuropathy,Peripheral Nervous System,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14022,NCT00001903,Prevention of RSV Infections in Bone Marrow Transplant Recipients,COMPLETED,PHASE4,Respiratory Syncytial Virus Infection,RSV Polyclonal Immunoglobulin (DRUG),5284443,URI,Respiratory Syncytial Virus Infection,Lung,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14023,NCT03814590,"A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults",COMPLETED,PHASE1,Respiratory Syncytial Virus Infections,RSV Vaccine (GSK3844766A) unadjuvanted low dose (BIOLOGICAL); RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E (BIOLOGICAL); RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B (BIOLOGICAL); RSV Vaccine (GSK3844766A) unadjuvanted medium dose (BIOLOGICAL); RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E (BIOLOGICAL); RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B (BIOLOGICAL); RSV Vaccine (GSK3844766A) unadjuvanted high dose (BIOLOGICAL); RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E (BIOLOGICAL); RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B (BIOLOGICAL); Placebo (Saline solution) (DRUG),5284443,URI,Respiratory Syncytial Virus Infections,Lung,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14024,NCT03419403,UNITE Study: Understanding New Interventions With GBM ThErapy,TERMINATED,PHASE3,Glioblastoma Multiforme,Steroid eye drops (DRUG); Vasoconstrictor eye drops (DRUG); Cold compress (OTHER); Ophthalmic steroid ointment (DRUG); Depatuxizumab mafodotin (DRUG); Temozolomide (DRUG); Radiation (RADIATION),5284443,URI,Glioblastoma Multiforme,CNS/Brain,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14025,NCT06211790,Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma,RECRUITING,PHASE2,Kidney Cancer; Renal Cell Carcinoma; Renal Clear Cell Carcinoma,"Anlotinib, Everolimus and Tislelizumab (DRUG)",5284443,URI,Kidney Cancer; Renal Cell Carcinoma; Renal Clear Cell Carcinoma,Kidney,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14026,NCT03428412,Effects of Traditional Chinese Medicine on AECOPD Patients,UNKNOWN,PHASE3,"Pulmonary Disease, Chronic Obstructive; Acute Exacerbation; Medicine, Chinese Traditional",TCM and conventional drug (DRUG); TCM placebo and conventional drug (DRUG),5284443,URI,"Pulmonary Disease, Chronic Obstructive; Acute Exacerbation; Medicine, Chinese Traditional",Lung,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14027,NCT02613195,Clinical Trial of Hydrogen-Rich Celsior Solution Applied in Aging DBD Liver/Kidney Transplantation,UNKNOWN,PHASE3,Evidence of Liver Transplantation,Hydrogen-Rich Celsior Solution (DRUG),5284443,URI,Evidence of Liver Transplantation,Liver,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14028,NCT01091064,Impact Of A Health Care Protocol For Patients Suffering Symptoms Of Mild Acute Viral Bronchiolitis On Early Release In The Emergency Department,WITHDRAWN,PHASE2,Bronchiolitis,Randomization early depart (OTHER),5284443,URI,Bronchiolitis,Lung,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14029,NCT03199976,Efficacy of Intermittent Tiotropium in Early Childhood Wheezing,TERMINATED,PHASE4,Wheezy Bronchitis; Asthmatic Bronchitis; Wheezing; Obstruction Airway,Tiotropium Bromide (DRUG); Fluticasone Propionate (DRUG); Salbutamol (DRUG),5284443,URI,Wheezy Bronchitis; Asthmatic Bronchitis; Wheezing; Obstruction Airway,Lung,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14030,NCT01628627,Frequency Modulated Neural Stimulation (FREMS) in Symptomatic Diabetic Neuropathy,COMPLETED,PHASE4,"Diabetic Neuropathy, Painful",Frequency Modulated Neural Stimulation (FREMS) (Aptiva) (DEVICE); sham treatment (Aptiva) (DEVICE),5284443,URI,"Diabetic Neuropathy, Painful",Peripheral Nervous System,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14031,NCT06426160,Tocilizumab for Painful Chronic Pancreatitis,RECRUITING,PHASE2,"Pancreatitis, Chronic",Tocilizumab 20 MG/ML [Actemra] (DRUG); Sodium Chloride 0.9% Inj (DRUG),5284443,URI,"Pancreatitis, Chronic",Pancreas,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14032,NCT00669331,Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis,COMPLETED,PHASE3,Bronchiectasis,Inhaled mannitol (DRUG); Matched control (DRUG),5284443,URI,Bronchiectasis,Lung,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14033,NCT02054182,Effect of Vitamin D Supplementation in Young South African Children Hospitalized With Acute Lower Respiratory Infection,UNKNOWN,PHASE4,Acute Lower Respiratory Tract Infection; Pneumonia; Bronchiolitis,Vitamin D (DRUG),5284443,URI,Acute Lower Respiratory Tract Infection; Pneumonia; Bronchiolitis,Lung,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14034,NCT05655182,A Study of BLB-201 RSV Vaccine in Infants and Children,RECRUITING,PHASE1,Respiratory Syncytial Virus Infections,PIV5-vectored RSV Vaccine (BLB-201) Low Dose (BIOLOGICAL); PIV5-vectored RSV Vaccine (BLB-201) High Dose (BIOLOGICAL); Placebo (DRUG),5284443,URI,Respiratory Syncytial Virus Infections,Lung,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14035,NCT03746431,A Phase 1/2 Study of [225Ac]-FPI-1434 Injection,RECRUITING,PHASE1,Advanced Solid Tumours; Endometrial Cancer; Cervical Cancer; Ovarian Cancer; Breast Cancer; Triple Negative Breast Cancer (TNBC); HER2-negative Breast Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC); Adrenocortical Carcinoma; Uveal Melanoma,[111In]-FPI-1547 Injection (DRUG); [225Ac]-FPI-1434 Injection multi-dose (DRUG); FPI-1175 Infusion (BIOLOGICAL); [225Ac]-FPI-1434 Injection single-dose (DRUG),5284443,URI,Advanced Solid Tumours; Endometrial Cancer; Cervical Cancer; Ovarian Cancer; Breast Cancer; Triple Negative Breast Cancer (TNBC); HER2-negative Breast Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC); Adrenocortical Carcinoma; Uveal Melanoma,Skin,Phenylephrine (hydrochloride),"ADRA1A, ADRA1B, ADRA1D",activator/agonist,Adrenoceptor agonist,yes,yes,Widely used as a decongestant and in eye drops.,CNCC(C1=CC(=CC=C1)O)O.Cl,1.19,305.0 +14036,NCT02505048,A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature,COMPLETED,PHASE2,Metastatic Breast Cancer,rucaparib (DRUG),9931953,s1098,Metastatic Breast Cancer,Breast,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14037,NCT03992131,A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR),TERMINATED,PHASE1,Ovarian Cancer; Triple-negative Breast Cancer; Urothelial Carcinoma; Solid Tumor,Rucaparib (DRUG); Lucitanib (DRUG); Sacituzumab govitecan (DRUG),9931953,s1098,Ovarian Cancer; Triple-negative Breast Cancer; Urothelial Carcinoma; Solid Tumor,Breast,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14038,NCT04227522,Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients,COMPLETED,PHASE3,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Clear Cell Carcinoma,Rucaparib (DRUG); Placebos (DRUG),9931953,s1098,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Clear Cell Carcinoma,Ovary/Fallopian Tube,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14039,NCT02873962,A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib,ACTIVE_NOT_RECRUITING,PHASE2,Peritoneal Cancer; Ovarian Cancer; Fallopian Tube Cancer,Bevacizumab (DRUG); Nivolumab (DRUG); Rucaparib (DRUG),9931953,s1098,Peritoneal Cancer; Ovarian Cancer; Fallopian Tube Cancer,Ovary/Fallopian Tube,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14040,NCT03694262,"The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)",COMPLETED,PHASE2,Endometrial Cancer; Uterine Carcinosarcoma,Rucaparib (DRUG); Bevacizumab (DRUG); Atezolizumab (DRUG),9931953,s1098,Endometrial Cancer; Uterine Carcinosarcoma,Uterus,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14041,NCT03397394,Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma,TERMINATED,PHASE2,Bladder Cancer; Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Renal Pelvis Carcinoma; Ureter Carcinoma; Urinary Bladder Carcinoma; Urethra Carcinoma; Muscle Invasive Bladder Cancer,Rucaparib (DRUG),9931953,s1098,Bladder Cancer; Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Renal Pelvis Carcinoma; Ureter Carcinoma; Urinary Bladder Carcinoma; Urethra Carcinoma; Muscle Invasive Bladder Cancer,Bladder/Urinary Tract,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14042,NCT03845296,Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial),ACTIVE_NOT_RECRUITING,PHASE2,Deleterious BRCA1 Gene Mutation; Deleterious BRCA2 Gene Mutation; Loss of Heterozygosity; Lung Non-Small Cell Squamous Carcinoma; Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Lung Non-Small Cell Carcinoma; Recurrent Non-Squamous Non-Small Cell Lung Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Rucaparib (DRUG),9931953,s1098,Deleterious BRCA1 Gene Mutation; Deleterious BRCA2 Gene Mutation; Loss of Heterozygosity; Lung Non-Small Cell Squamous Carcinoma; Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Lung Non-Small Cell Carcinoma; Recurrent Non-Squamous Non-Small Cell Lung Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14043,NCT00664781,Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer,COMPLETED,PHASE2,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer; Ovarian Cancer,rucaparib (CO-338; formally AG-014699 or PF-01367338) (DRUG); protein expression analysis (GENETIC); western blotting (GENETIC); immunohistochemistry staining method (OTHER); liquid chromatography (OTHER); mass spectrometry (OTHER); pharmacological study (OTHER),9931953,s1098,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer; Ovarian Cancer,Breast,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14044,NCT01891344,"A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)",COMPLETED,PHASE2,Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer,Oral rucaparib (DRUG),9931953,s1098,Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer,Ovary/Fallopian Tube,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14045,NCT03824704,A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES),TERMINATED,PHASE2,Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma; High Grade Serous Carcinoma; Endometrioid Adenocarcinoma,Rucaparib (DRUG); Nivolumab (DRUG),9931953,s1098,Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma; High Grade Serous Carcinoma; Endometrioid Adenocarcinoma,Ovary/Fallopian Tube,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14046,NCT03795272,Rucaparib Maintenance Therapy in Advanced Cervical Cancer,WITHDRAWN,PHASE2,Cervical Cancer,Rucaparib (DRUG); Placebo (DRUG),9931953,s1098,Cervical Cancer,Cervix,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14047,NCT02855944,"ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients",COMPLETED,PHASE3,Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer,Chemotherapy (DRUG); Rucaparib (DRUG),9931953,s1098,Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer,Ovary/Fallopian Tube,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14048,NCT03522246,A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy,ACTIVE_NOT_RECRUITING,PHASE3,Epithelial Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancer; Newly Diagnosed; FIGO Stage III-IV; Partial Response; Complete Response,Rucaparib (DRUG); Nivolumab (DRUG); Placebo Oral Tablet (DRUG); Placebo IV Infusion (DRUG),9931953,s1098,Epithelial Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancer; Newly Diagnosed; FIGO Stage III-IV; Partial Response; Complete Response,Ovary/Fallopian Tube,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14049,NCT03995017,Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma,UNKNOWN,PHASE1,"Esophagus Cancer, Adenocarcinoma; Stomach Cancer, Adenocarcinoma",Rucaparib (DRUG); Ramucirumab (DRUG); Nivolumab (DRUG),9931953,s1098,"Esophagus Cancer, Adenocarcinoma; Stomach Cancer, Adenocarcinoma",Esophagus/Stomach,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14050,NCT02935634,A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer,COMPLETED,PHASE2,Advanced Gastric Cancer,Nivolumab (BIOLOGICAL); Ipilimumab (BIOLOGICAL); Relatlimab (BIOLOGICAL); BMS-986205 (BIOLOGICAL); Rucaparib (DRUG),9931953,s1098,Advanced Gastric Cancer,Esophagus/Stomach,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14051,NCT04676334,CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib,COMPLETED,PHASE3,Metastatic Castration-Resistant Prostate Cancer; Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Other Solid Tumor,Rucaparib (DRUG),9931953,s1098,Metastatic Castration-Resistant Prostate Cancer; Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Other Solid Tumor,Ovary/Fallopian Tube,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14052,NCT04209595,PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers,COMPLETED,PHASE1,Small Cell Lung Cancer; Extra-Pulmonary Small Cell Carcinomas,PLX038 (DRUG); Rucaparib (DRUG); Ondansetron (DRUG),9931953,s1098,Small Cell Lung Cancer; Extra-Pulmonary Small Cell Carcinomas,Lung,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14053,NCT03559049,Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Stage IV Non-small Cell Lung Cancer,Pembrolizumab (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG); Rucaparib (DRUG),9931953,s1098,Stage IV Non-small Cell Lung Cancer,Lung,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14054,NCT01968213,Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3),COMPLETED,PHASE3,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer,Rucaparib (DRUG); Placebo (DRUG),9931953,s1098,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14055,NCT04678102,"Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)",RECRUITING,PHASE1,Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Carcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma,PHI-101 administration (DRUG),9931953,s1098,Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Carcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14056,NCT03617679,Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Endometrial Cancer,Rucaparib (DRUG); Placebo Oral Tablet (DRUG),9931953,s1098,Metastatic Endometrial Cancer,Uterus,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14057,NCT03542175,A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy,ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer,Rucaparib (DRUG); Radiotherapy (RADIATION),9931953,s1098,Breast Cancer,Breast,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14058,NCT03140670,"Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy",TERMINATED,PHASE2,Pancreatic Cancer,RUCAPARIB (DRUG),9931953,s1098,Pancreatic Cancer,Pancreas,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14059,NCT03639935,Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy,ACTIVE_NOT_RECRUITING,PHASE2,Biliary Tract Cancer,Rucaparib (DRUG); Nivolumab (DRUG),9931953,s1098,Biliary Tract Cancer,Liver,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14060,NCT01074970,PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations,COMPLETED,PHASE2,Breast Cancer,Cisplatin (DRUG); Rucaparib (DRUG); Cisplatin (DRUG),9931953,s1098,Breast Cancer,Breast,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14061,NCT03840200,"A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.",COMPLETED,PHASE1,Breast Cancer; Prostate Cancer; Ovarian Cancer,Ipatasertib (DRUG); Rucaparib (DRUG),9931953,s1098,"Breast, Prostate, and Ovarian Cancers",Ovary/Fallopian Tube,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14062,NCT03337087,"Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Biliary Tract Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Malignant Digestive System Neoplasm; Metastatic Pancreatic Adenocarcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7,Fluorouracil (DRUG); Irinotecan Sucrosofate (DRUG); Laboratory Biomarker Analysis (OTHER); Leucovorin Calcium (DRUG); Rucaparib (DRUG),9931953,s1098,Metastatic Biliary Tract Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Malignant Digestive System Neoplasm; Metastatic Pancreatic Adenocarcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7,Bowel,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14063,NCT03654833,Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma,UNKNOWN,PHASE2,"Mesothelioma, Malignant",Rucaparib (DRUG); Abemaciclib (DRUG); pembrolizumab & bemcentinib (DRUG); Atezolizumab & Bevacizumab (DRUG); Dostarlimab and Niraparib (DRUG),9931953,s1098,Malignant Mesothelioma,Lung,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14064,NCT03911453,"Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors",COMPLETED,EARLY_PHASE1,Breast Cancer,Rucaparib (DRUG),9931953,s1098,Breast Cancer,Breast,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14065,NCT01482715,A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II),COMPLETED,PHASE1,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Advanced Solid Tumor With Evidence of Germline or Somatic BRCA,Rucaparib (DRUG),9931953,s1098,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Advanced Solid Tumor With Evidence of Germline or Somatic BRCA,Ovary/Fallopian Tube,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14066,NCT02042378,A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation,COMPLETED,PHASE2,Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma,Rucaparib (DRUG),9931953,s1098,Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma,Pancreas,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14067,NCT03572478,Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer,TERMINATED,PHASE1,Prostate Cancer; Endometrial Cancer,Rucaparib (DRUG); Nivolumab (DRUG),9931953,s1098,Prostate Cancer; Endometrial Cancer,Uterus,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14068,NCT03552471,"Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer",COMPLETED,PHASE1,BRCA1 Gene Mutation; BRCA2 Gene Mutation; Folate Receptor Alpha Positive; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Recurrent Uterine Serous Carcinoma; Recurrent Uterine Carcinosarcoma; Platinum Resistant Ovarian Cancer,Laboratory Biomarker Analysis (OTHER); Mirvetuximab Soravtansine (BIOLOGICAL); Pharmacokinetic Study (OTHER); Rucaparib Camsylate (DRUG),9931953,s1098,BRCA1 Gene Mutation; BRCA2 Gene Mutation; Folate Receptor Alpha Positive; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Recurrent Uterine Serous Carcinoma; Recurrent Uterine Carcinosarcoma; Platinum Resistant Ovarian Cancer,Ovary/Fallopian Tube,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14069,NCT04701645,"Microdevice in Ovarian, Fallopian Tube, and Peritoneal Cancer",RECRUITING,PHASE1,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Ovarian Cancer Stage III; Ovarian Cancer Stage IV; Fallopian Tube Cancer Stage IV; Fallopian Tube Cancer Stage III,Microdevice (COMBINATION_PRODUCT),9931953,s1098,Ovarian and Related Cancers,Ovary/Fallopian Tube,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14070,NCT03958045,Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma,COMPLETED,PHASE2,Small Cell Lung Cancer,Rucaparib and Nivolumab (COMBINATION_PRODUCT),9931953,s1098,Small Cell Lung Cancer,Lung,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14071,NCT03476798,Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium,COMPLETED,PHASE2,Cervical Cancer; Endometrial Cancer,Rucaparib (DRUG); Bevacizumab (DRUG),9931953,s1098,Cervical Cancer; Endometrial Cancer,Uterus,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14072,NCT04826198,"Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months",TERMINATED,PHASE1,Ovarian Cancer,AsiDNA (DRUG); Niraparib (DRUG); Olaparib (DRUG); Rucaparib (DRUG),9931953,s1098,Ovarian Cancer,Ovary/Fallopian Tube,Rucaparib (phosphate),"PARP1, PARP2, PARP3",inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Approved as a cancer therapy PARP inhibitor.,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O,, +14073,NCT06133062,Atezolizumab and Bevacizumab with Proton Radiotherapy for Unresectable Hepatocellular Carcinoma,RECRUITING,PHASE2,Hepatocellular Carcinoma Non-resectable,Atezolizumab (DRUG); Bevacizumab (DRUG); Proton radiotherapy (RADIATION),60606,CGE,Hepatocellular Carcinoma Non-resectable,Liver,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14074,NCT01257139,"Trial Involving Subjects Over 70 Years of Age With Non Small-cell Lung Cancer of Stage IV and Comparing a ""Classical"" Strategy of Treatment Allocation, With an""Optimized"" Strategy Allocating the Same Treatments",COMPLETED,PHASE3,Non Small-cell Lung Cancer,Dual-agent therapy or docetaxel alone or best supportive care (PROCEDURE),60606,CGE,Non Small-cell Lung Cancer,Lung,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14075,NCT02640924,Proton Radiotherapy Versus Radiofrequency Ablation for Patients With Medium or Large Hepatocellular Carcinoma,UNKNOWN,PHASE3,"Carcinoma, Hepatocellular",Proton radiotherapy (RADIATION); Radiofrequency Ablation (PROCEDURE),60606,CGE,"Carcinoma, Hepatocellular",Liver,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14076,NCT00495040,Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,Lung Cancer,Proton Radiotherapy (RADIATION),60606,CGE,Lung Cancer,Lung,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14077,NCT01553019,Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,Proton radiation (RADIATION); Gemcitabine (DRUG),60606,CGE,Pancreatic Cancer,Pancreas,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14078,NCT03267836,Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma,TERMINATED,PHASE1,"Meningioma; Meningioma, Adult",Avelumab (DRUG); Proton Therapy (RADIATION); Surgery (PROCEDURE),60606,CGE,"Meningioma; Meningioma, Adult",CNS/Brain,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14079,NCT02947984,Proton/Photon Rt - Benign Meningiomas(P92-13),COMPLETED,PHASE3,Benign Meningioma,Standard Treatment (RADIATION); Higher Dose (RADIATION),60606,CGE,Benign Meningioma,CNS/Brain,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14080,NCT03940248,Proton Accelerated Partial Breast Irradiation,WITHDRAWN,PHASE2,Breast Cancer,Proton Accelerated Partial Breast Irradiation (RADIATION),60606,CGE,Breast Cancer,Breast,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14081,NCT00915005,"Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence",COMPLETED,PHASE2,Non-Small-Cell Lung Carcinoma,Photon Therapy (RADIATION); Proton Therapy (RADIATION); Paclitaxel (DRUG); Carboplatin (DRUG),60606,CGE,Non-Small-Cell Lung Carcinoma,Lung,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14082,NCT05836766,Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion,RECRUITING,PHASE2,Acute Ischemic Stroke; Reperfusion; Large Vessel Occlusion,Y-6 sublingual tablets (DRUG); Placebo tablets of Y-6 sublingual tablet (DRUG),60606,CGE,Acute Ischemic Stroke; Reperfusion; Large Vessel Occlusion,CNS/Brain,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14083,NCT04884490,The Role of High Dose Co-trimoxazole in Severe Covid-19 Patients,COMPLETED,PHASE2,COVID-19 Pneumonia,Co-trimoxazole (DRUG); Placebo (DRUG),60606,CGE,COVID-19 Pneumonia,Lung,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14084,NCT03702582,Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation,COMPLETED,PHASE3,Atrial Fibrillation; Stroke; Bleeding,Rivaroxaban (DRUG); Warfarin (DRUG),60606,CGE,Atrial Fibrillation; Stroke; Bleeding,CNS/Brain,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14085,NCT03567473,Bronchiolitis in Infants Placebo Versus Epinephrine and Dexamethasone Study,RECRUITING,PHASE3,Bronchiolitis,Oral dexamethasone (DRUG); Nebulized Epinephrine (DRUG); Oral placebo (DRUG); Nebulized normal saline (DRUG); MDI Epinephrine (DRUG); MDI placebo (DRUG),60606,CGE,Bronchiolitis,Lung,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14086,NCT01747746,Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study,COMPLETED,PHASE4,Atrial Fibrillation; Stroke; Thrombo-embolism; Bleeding,Rivaroxaban (DRUG); Warfarin and Enoxaparin (DRUG),60606,CGE,Atrial Fibrillation; Stroke; Thrombo-embolism; Bleeding,CNS/Brain,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14087,NCT06138834,EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE),NOT_YET_RECRUITING,PHASE2,Acute Ischemic Stroke; Large Vessel Occlusion; Reperfusion,Low-dose Y-6 sublingual tablets (DRUG); High-dose Y-6 sublingual tablets (DRUG); Low-dose Cilostazol (DRUG); High-dose Cilostazol (DRUG); Placebo (DRUG),60606,CGE,Acute Ischemic Stroke; Large Vessel Occlusion; Reperfusion,CNS/Brain,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14088,NCT02779712,Remote Ischaemic Conditioning After Stroke Trial (ReCAST-2),COMPLETED,PHASE2,Stroke,Remote ischaemic conditioning (PROCEDURE); Sham (PROCEDURE),60606,CGE,Stroke,CNS/Brain,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14089,NCT02111564,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,COMPLETED,PHASE3,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Rivaroxaban, 10 mg (DRUG); Rivaroxaban, 7.5 mg (DRUG); Placebo (DRUG)",60606,CGE,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,CNS/Brain,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14090,NCT00517621,Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire,COMPLETED,PHASE2,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms,Paclitaxel (DRUG); EPO (DRUG),60606,CGE,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms,Ovary/Fallopian Tube,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14091,NCT01200121,Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers,COMPLETED,PHASE2,Malignant Ascites; Gastrointestinal Cancers,Bevacizumab (DRUG); Placebo (OTHER),60606,CGE,Malignant Ascites; Gastrointestinal Cancers,Bowel,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14092,NCT05914584,"""Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.",NOT_YET_RECRUITING,PHASE2,Hospital-acquired Pneumonia,Baricitinib 4 MG (DRUG),60606,CGE,Hospital-acquired Pneumonia,Lung,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14093,NCT01938248,Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation,COMPLETED,PHASE4,Atrial Fibrillation; Stroke,Apixaban (DRUG); aspirin (DRUG),60606,CGE,Atrial Fibrillation and Stroke,CNS/Brain,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14094,NCT00968617,A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002),TERMINATED,PHASE2,Anemia; Chronic Kidney Disease,MK2578 (DRUG); MK2578 (DRUG); MK2578 (DRUG); Comparator: darbepoetin alfa (DRUG),60606,CGE,Anemia; Chronic Kidney Disease,Kidney,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14095,NCT03143751,Continuous Hyperosomolar Therapy for Traumatic Brain-injured Patients,COMPLETED,PHASE3,Moderate to Severe Traumatic Brain Injury,NaCl20% (Continuous hyperosmolar therapy) (DRUG),60606,CGE,Moderate to Severe Traumatic Brain Injury,CNS/Brain,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14096,NCT01014156,Epoprostenol in Pulmonary Embolism,COMPLETED,PHASE4,Acute Pulmonary Embolism,epoprostenol (DRUG),60606,CGE,Acute Pulmonary Embolism,Lung,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14097,NCT04794088,Intravenous Imatinib in Mechanically Ventilated COVID-19 Patients,TERMINATED,PHASE2,ARDS; Acute Respiratory Distress Syndrome; Covid19; Endothelial Dysfunction; Pulmonary Edema,Imatinib Mesylate intravenous solution (DRUG); Placebo (DRUG),60606,CGE,ARDS; Acute Respiratory Distress Syndrome; Covid19; Endothelial Dysfunction; Pulmonary Edema,Lung,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14098,NCT00120978,Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial,UNKNOWN,PHASE4,Chronic Obstructive Pulmonary Disease,Advair (DRUG); Flovent (DRUG),60606,CGE,Chronic Obstructive Pulmonary Disease,Lung,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14099,NCT02457156,Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy,COMPLETED,PHASE3,Pancreatic Cancer,Blumgart Anastomosis (PROCEDURE); Cattell-Warren Anastomosis (PROCEDURE); Octreotide (DRUG),60606,CGE,Pancreatic Cancer,Pancreas,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14100,NCT00503698,The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis,TERMINATED,PHASE3,Chronic Kidney Disease; End-Stage Renal Disease,somatropin (DRUG); placebo (DRUG),60606,CGE,Chronic Kidney Disease; End-Stage Renal Disease,Kidney,Clopidogrel,P2RY12,inhibitor/antagonist,unclear,yes,yes,"Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.",COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,1.07,168.0 +14101,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,COMPLETED,PHASE3,"Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis",dimethyl fumarate (DRUG),637568,EOU,"Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis",CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14102,NCT04022473,Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers,COMPLETED,PHASE1,Multiple Sclerosis,Bafiertam (DRUG); Tecfidera (DRUG),637568,EOU,Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14103,NCT02090348,Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate,WITHDRAWN,PHASE4,Relapsing-Remitting Multiple Sclerosis; Multiple Sclerosis,dimethyl fumarate (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis; Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14104,NCT03255382,A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy,COMPLETED,PHASE3,Psoriasis,Fumaderm (DRUG); risankizumab (DRUG),637568,EOU,Psoriasis,Skin,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14105,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,COMPLETED,PHASE3,Relapsing-Remitting Multiple Sclerosis,BG00012 (DRUG); Placebo (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14106,NCT05417269,IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study,ACTIVE_NOT_RECRUITING,PHASE1,"Multiple Sclerosis, Relapsing-Remitting",IMCY-0141 (DRUG); Placebo (DRUG); Dimethyl Fumarate (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14107,NCT02461069,Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis,COMPLETED,PHASE4,"Multiple Sclerosis, Relapsing-Remitting",Dimethyl fumarate (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14108,NCT02217982,Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation,TERMINATED,PHASE4,Relapsing Remitting Multiple Sclerosis,Simethicone (DRUG); Loperamide (DRUG); Peanut Butter (OTHER),637568,EOU,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14109,NCT02428231,Tecfidera Slow-Titration Study,TERMINATED,PHASE3,Multiple Sclerosis,dimethyl fumarate (DRUG),637568,EOU,Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14110,NCT04792567,Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC),COMPLETED,PHASE4,Secondary Progressive Multiple Sclerosis,BAF312 (DRUG); Baseline disease modifying therapies (DMTs) (DRUG); BNT162 (BIOLOGICAL); mRNA-1273 (BIOLOGICAL),637568,EOU,Secondary Progressive Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14111,NCT02474082,Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.,COMPLETED,PHASE3,Psoriasis,Secukinumab (BIOLOGICAL); Fumaric acid (DRUG),637568,EOU,Psoriasis,Skin,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14112,NCT04890366,Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke,UNKNOWN,PHASE1,Acute Ischemic Stroke,Dimethyl Fumarate (DRUG),637568,EOU,Acute Ischemic Stroke,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14113,NCT02337426,"Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",COMPLETED,PHASE1,Adult Brain Glioblastoma; Adult Giant Cell Glioblastoma; Adult Gliosarcoma,Dimethyl Fumarate (DRUG); Temozolomide (DRUG); Radiation Therapy (RADIATION),637568,EOU,Adult Brain Glioblastoma; Adult Giant Cell Glioblastoma; Adult Gliosarcoma,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14114,NCT01088165,The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis,UNKNOWN,PHASE4,"Psoriasis; Cardiovascular Diseases; Diabetes Mellitus, Type 2",Adalimumab treatment arm (DRUG); Fumaric acid esters treatment group (DRUG); Narrow band UVB radiation (OTHER),637568,EOU,"Psoriasis; Cardiovascular Diseases; Diabetes Mellitus, Type 2",Skin,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14115,NCT02959658,Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis,COMPLETED,PHASE2,Primary Progressive Multiple Sclerosis,Dimethyl fumarate (DRUG); Placebo (DRUG),637568,EOU,Primary Progressive Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14116,NCT02471560,Tecfidera and the Gut Microbiota,COMPLETED,PHASE4,"Multiple Sclerosis, Relapsing-Remitting",dimethyl fumarate (DRUG); injectable MS DMT (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14117,NCT03331835,A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis,COMPLETED,PHASE4,Psoriasis Vulgaris,Brodalumab (BIOLOGICAL); Fumaric acid esters (DRUG),637568,EOU,Psoriasis Vulgaris,Skin,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14118,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,TERMINATED,PHASE3,"Multiple Sclerosis, Relapsing-Remitting",Dimethyl Fumarate (DRUG); Peginterferon Beta-1a (DRUG); Placebo (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14119,NCT04263610,Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy,COMPLETED,PHASE4,Plaque Psoriasis,Dimethyl fumarate (DMF) standard scheme (DRUG); Dimethyl fumarate (DMF) simplified scheme (DRUG); Tildrakizumab (DRUG),637568,EOU,Plaque Psoriasis,Skin,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14120,NCT02579681,Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012,COMPLETED,PHASE3,"Multiple Sclerosis, Relapsing-Remitting",dimethyl fumarate (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14121,NCT02634801,A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment,COMPLETED,PHASE3,Plaque Psoriasis,Fumaric Acid Esters (DRUG); Methotrexate (DRUG); Ixekizumab (DRUG),637568,EOU,Plaque Psoriasis,Skin,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14122,NCT00168701,Efficacy and Safety of BG00012 in MS,COMPLETED,PHASE2,Multiple Sclerosis,BG00012 (DRUG),637568,EOU,Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14123,NCT03092544,Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients,UNKNOWN,PHASE4,Multiple Sclerosis,dimethyl fumarate (DRUG),637568,EOU,Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14124,NCT02746744,RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.,COMPLETED,PHASE3,"Multiple Sclerosis, Relapsing-Remitting",Rituximab (DRUG); Dimethyl fumarate (DRUG); Sodium Chloride solution (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14125,NCT03345940,Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis,TERMINATED,PHASE4,Relapsing Remitting Multiple Sclerosis,Fingolimod (DRUG); Dimethyl Fumarate (DRUG),637568,EOU,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14126,NCT06663189,Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis),NOT_YET_RECRUITING,PHASE3,Relapsing-remitting Multiple Sclerosis (RRMS),treatment withdrawal (DRUG); Usual DMT continuation (DRUG); MRI (OTHER); Quality of Life questionnaires (BEHAVIORAL); Disability evaluation tests (OTHER),637568,EOU,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14127,NCT03093324,A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2,COMPLETED,PHASE3,Relapsing Remitting Multiple Sclerosis,ALKS 8700 (DRUG); Dimethyl Fumarate (DRUG),637568,EOU,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14128,NCT01838668,An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),COMPLETED,PHASE3,Relapsing-Remitting Multiple Sclerosis; Multiple Sclerosis,Placebo (DRUG); dimethyl fumarate (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis; Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14129,NCT02125604,Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany,COMPLETED,PHASE4,Relapsing-Remitting Multiple Sclerosis,dimethyl fumarate (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14130,NCT02117050,RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate,TERMINATED,PHASE4,Multiple Sclerosis,Rebif® (DRUG),637568,EOU,Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14131,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,COMPLETED,PHASE4,Relapsing-Remitting Multiple Sclerosis; Multiple Sclerosis,dimethyl fumarate (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis; Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14132,NCT01815723,Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis,WITHDRAWN,PHASE3,Plaque Psoriasis,FP187 (DRUG); Dimethyl fumarate (DRUG); FP187 placebo (DRUG); Fumaderm® placebo (DRUG),637568,EOU,Plaque Psoriasis,Skin,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14133,NCT02472938,Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis,WITHDRAWN,PHASE4,Relapsing Remitting Multiple Sclerosis,dimethyl fumarate (DRUG); Placebo (OTHER),637568,EOU,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14134,NCT04381936,Randomised Evaluation of COVID-19 Therapy,RECRUITING,PHASE3,Severe Acute Respiratory Syndrome,Lopinavir-Ritonavir (DRUG); Corticosteroid (DRUG); Hydroxychloroquine (DRUG); Azithromycin (DRUG); Convalescent plasma (BIOLOGICAL); Tocilizumab (DRUG); Immunoglobulin (BIOLOGICAL); Synthetic neutralising antibodies (DRUG); Aspirin (DRUG); Colchicine (DRUG); Baricitinib (DRUG); Anakinra (DRUG); Dimethyl fumarate (DRUG); High Dose Corticosteroid (DRUG); Empagliflozin (DRUG); Sotrovimab (DRUG); Molnupiravir (DRUG); Paxlovid (DRUG); Baloxavir Marboxil (DRUG); Oseltamivir (DRUG); Low-dose corticosteroids: Dexamethasone (DRUG); Low-dose corticosteroids: Dexamethasone (DRUG),637568,EOU,Severe Acute Respiratory Syndrome,Lung,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14135,NCT02201849,"A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults",COMPLETED,PHASE1,Multiple Sclerosis,Study Drug (DRUG); Active Control (DRUG); Placebo (DRUG),637568,EOU,Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14136,NCT02097849,Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.,COMPLETED,PHASE2,Relapsing Forms of Multiple Sclerosis,dimethyl fumarate (DRUG); tetanus diphtheria toxoids vaccine (BIOLOGICAL); 23-valent pneumococcal polysaccharide vaccine (BIOLOGICAL); meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent) (BIOLOGICAL); non-pegylated interferon (DRUG),637568,EOU,Relapsing Forms of Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14137,NCT02739542,Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS),COMPLETED,PHASE4,Multiple Sclerosis (MS),Tecfidera (DRUG); Placebo (DRUG),637568,EOU,Multiple Sclerosis (MS),CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14138,NCT04570670,Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects,COMPLETED,PHASE1,Relapsing Remitting Multiple Sclerosis,monomethyl fumarate 190 mg (DRUG); dimethyl fumarate 240 mg (DRUG),637568,EOU,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14139,NCT02901106,Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate,TERMINATED,PHASE4,"Multiple Sclerosis, Relapsing-Remitting",Dimethyl fumarate (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14140,NCT00273364,Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study,COMPLETED,PHASE2,Multiple Sclerosis,Hematopoietic Stem Cell Therapy (PROCEDURE); Standard treatment with a conventional drug (DRUG),637568,EOU,Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14141,NCT05658484,A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China,ACTIVE_NOT_RECRUITING,PHASE4,Multiple Sclerosis,Dimethyl fumarate (DRUG),637568,EOU,Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14142,NCT04890379,Dimethyl Fumarate for the Treatment of Intracerebral Hemorrhage,WITHDRAWN,PHASE2,Intracerebral Hemorrhage,Dimethyl fumarate (DRUG); Placebo (DRUG),637568,EOU,Intracerebral Hemorrhage,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14143,NCT02090413,Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis,COMPLETED,PHASE4,Relapsing-Remitting Multiple Sclerosis,dimethyl fumarate (DRUG); acetylsalicylic acid (DRUG); ASA-Placebo (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14144,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),COMPLETED,PHASE3,Relapsing-Remitting Multiple Sclerosis,dimethyl fumarate (DRUG); Placebo (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14145,NCT02683863,Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers,COMPLETED,PHASE4,Multiple Sclerosis,BG00012 (DMF) (Tecfidera®.) (DRUG),637568,EOU,Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14146,NCT01873417,Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States,COMPLETED,PHASE4,Relapsing Forms of Multiple Sclerosis,BG00012 (DMF) (DRUG),637568,EOU,Relapsing Forms of Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14147,NCT02428218,Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS),WITHDRAWN,PHASE3,Relapsing-Remitting Multiple Sclerosis; Relapsing Forms of Multiple Sclerosis,dimethyl fumarate (DRUG); Placebo (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis; Relapsing Forms of Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14148,NCT02343159,Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.,TERMINATED,PHASE4,Multiple Sclerosis,dimethyl fumarate (DRUG); Medication Event Monitoring System (MEMS) (DEVICE); Adherence counseling (BEHAVIORAL),637568,EOU,Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14149,NCT02675413,Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS,WITHDRAWN,PHASE4,"Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting",Dimethyl Fumarate (DRUG),637568,EOU,Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14150,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),COMPLETED,PHASE3,"Multiple Sclerosis, Relapsing-Remitting",dimethyl fumarate (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14151,NCT00837785,A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS,COMPLETED,PHASE1,Relapsing Remitting Multiple Sclerosis,BG00012 (DRUG); BG00012 (DRUG),637568,EOU,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14152,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,COMPLETED,PHASE2,"Multiple Sclerosis, Relapsing-Remitting",dimethyl fumarate (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14153,NCT02241785,Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies,TERMINATED,PHASE4,Relapsing Multiple Sclerosis,natalizumab (DRUG),637568,EOU,Relapsing Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14154,NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,TERMINATED,PHASE3,"Multiple Sclerosis, Secondary Progressive",dimethyl fumarate (DRUG); Placebo (OTHER),637568,EOU,"Multiple Sclerosis, Secondary Progressive",CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14155,NCT02975349,A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis,TERMINATED,PHASE2,Relapsing-remitting Multiple Sclerosis,Evobrutinib (DRUG); Evobrutinib (DRUG); Evobrutinib (DRUG); Placebo (DRUG); Tecfidera (DRUG); Evobrutinib (DRUG),637568,EOU,Relapsing-remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14156,NCT01726933,LAS41008 in Moderate to Severe Chronic Plaque Psoriasis,COMPLETED,PHASE3,Plaque Psoriasis,LAS41008 (DRUG); LASW1835 (DRUG); Placebo (DRUG),637568,EOU,Plaque Psoriasis,Skin,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14157,NCT04890353,Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke,TERMINATED,PHASE1,Acute Ischemic Stroke,Dimethyl fumarate (DRUG),637568,EOU,Acute Ischemic Stroke,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14158,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),ACTIVE_NOT_RECRUITING,PHASE3,Relapsing-Remitting Multiple Sclerosis,dimethyl fumarate (DRUG); Interferon β-1a (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14159,NCT04788615,Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS,ACTIVE_NOT_RECRUITING,PHASE3,Multiple Sclerosis,Ofatumumab (DRUG); First line DMT (DRUG),637568,EOU,Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14160,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,COMPLETED,PHASE3,Multiple Sclerosis,ALKS 8700 (DRUG),637568,EOU,Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14161,NCT06039007,A run-in Study on the Safety and Tolerability of a Fasting Mimicking Diet in Relapsing Remitting Multiple Sclerosis,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,Multiple Sclerosis,7-day Fasting-Mimicking Diet (7-DAY FMD) (DIETARY_SUPPLEMENT),637568,EOU,Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14162,NCT06850597,Efficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease,RECRUITING,PHASE2,"MCI; MCI-AD, Early Stage Alzheimer's Disease; Alzheimer's Disease",dimethyl fumarate (DRUG),637568,EOU,"MCI; MCI-AD, Early Stage Alzheimer's Disease; Alzheimer's Disease",CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14163,NCT02951533,A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis,COMPLETED,PHASE3,Psoriasis,Guselkumab (DRUG); Fumaric Acid Esters (DRUG),637568,EOU,Psoriasis,Skin,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14164,NCT02955693,Study of the Effects of the Organism on Monomethyl Fumarate (MMF) After the Administration of LAS41008,COMPLETED,PHASE1,Psoriasis,LAS41008 120 mg / Fumaderm® 120 mg (DRUG),637568,EOU,Psoriasis,Skin,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14165,NCT04891497,Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke,WITHDRAWN,PHASE2,Acute Ischemic Stroke,Dimethyl Fumarate (DRUG); Placebo (DRUG),637568,EOU,Acute Ischemic Stroke,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14166,NCT01156311,BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis,COMPLETED,PHASE2,Relapsing-Remitting Multiple Sclerosis; Multiple Sclerosis,dimethyl fumarate (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis; Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14167,NCT02907177,Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®),TERMINATED,PHASE3,Multiple Sclerosis,Ponesimod (DRUG); Placebo (OTHER),637568,EOU,Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14168,NCT02410278,Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera,COMPLETED,PHASE4,Multiple Sclerosis,dimethyl fumarate (DRUG); montelukast (DRUG); Placebo (DRUG),637568,EOU,Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14169,NCT03535298,Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS,ACTIVE_NOT_RECRUITING,PHASE4,"Multiple Sclerosis, Relapsing-Remitting",Early Highly Effective Therapies Group (DRUG); Escalation Therapies Group (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14170,NCT00811005,Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis,UNKNOWN,PHASE3,Pustular Palmoplantar Psoriasis,8-methoxypsoralen or 5- methoxypsoralen (RADIATION); 8-methoxypsoralen or 5methoxypsoralen (RADIATION),637568,EOU,Pustular Palmoplantar Psoriasis,Skin,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14171,NCT06715605,A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded TolDC As Treatment for MS,NOT_YET_RECRUITING,PHASE2,Multiple Sclerosis,tolerogenic dendritic cells (tolDC) (BIOLOGICAL); Standard-of-care (BIOLOGICAL),637568,EOU,Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14172,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,COMPLETED,PHASE3,Relapsing-Remitting Multiple Sclerosis,BG00012 (DRUG); Placebo (DRUG); Glatiramer Acetate (DRUG),637568,EOU,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Dimethyl fumarate,NFE2L2,activator/agonist,unclear,yes,yes,Approved for multiple sclerosis treatment.,COC(=O)C=CC(=O)OC,1.54,107.0 +14173,NCT02799069,Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy,COMPLETED,PHASE3,Actinic Keratosis,BF-200 ALA (DRUG); MAL Cream (DRUG); Vehicle (DRUG),157921,Metvixia,Actinic Keratosis,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14174,NCT03573076,Treatment of Photodamaged Skin of the décolleté,TERMINATED,PHASE4,Photodamaged Skin,Photodynamic therapy (COMBINATION_PRODUCT); Non-ablative Thulium laser (NAFL) (DEVICE); Radio-frequency microneedles (RF-MN) (DEVICE),157921,Metvixia,Photodamaged Skin,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14175,NCT02281682,IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis,UNKNOWN,PHASE4,"Keratosis, Actinic",Imiquimod (DRUG); 5-fluorouracil (DRUG); Ingenol mebutate (DRUG); methylaminolevulinate photodynamic therapy (PROCEDURE),157921,Metvixia,Actinic Keratosis,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14176,NCT00594425,Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne,COMPLETED,PHASE2,Acne Vulgaris,Methyl aminolevulinate (MAL) PDT (DRUG),157921,Metvixia,Acne Vulgaris,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14177,NCT00304239,Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp,COMPLETED,PHASE3,Actinic Keratosis,Metvix-PDT (COMBINATION_PRODUCT); Vehicle-PDT (COMBINATION_PRODUCT),157921,Metvixia,Actinic Keratosis,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14178,NCT02354391,Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis,UNKNOWN,PHASE2,Actinic Keratosis,"Ingenol mebutate Picato® and MAL PDT day 1, day 5 (DRUG); Ingenol mebutate Picato® day 2, 3, 4 (DRUG); MAL PDT day 5 (PROCEDURE)",157921,Metvixia,Actinic Keratosis,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14179,NCT01525329,Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease,TERMINATED,PHASE3,Actinic Keratosis; Organ or Tissue Transplant; Complications,5-Fluorouracil (DRUG),157921,Metvixia,Actinic Keratosis; Organ or Tissue Transplant; Complications,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14180,NCT02736760,Daylight-PDT With MAL for AK and Photodamaged Skin,COMPLETED,PHASE4,Actinic Keratoses; Photodamaged Skin,Daylight photodynamic therapy using Methylaminolevulinate (MAL) (DRUG); Cryosurgery (PROCEDURE),157921,Metvixia,Actinic Keratoses; Photodamaged Skin,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14181,NCT04269395,A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study,TERMINATED,PHASE3,"Keratosis, Actinic",MAL Cream (DRUG); Vehicle cream (DRUG),157921,Metvixia,Actinic Keratosis,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14182,NCT01245946,Photodynamic Therapy Compared to Adapalene 0.1% Gel Plus Doxycycline in the Treatment of Acne Vulgaris,COMPLETED,PHASE2,Acne,Photodynamic therapy (PROCEDURE); Conventional therapy (DRUG),157921,Metvixia,Acne,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14183,NCT01292668,Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer,COMPLETED,PHASE1,Basal Cell Carcinoma of the Skin; Pain; Recurrent Skin Cancer,methyl-5-aminolevulinate hydrochloride cream (DRUG); photodynamic therapy (DRUG); laser therapy (PROCEDURE),157921,Metvixia,Basal Cell Carcinoma of the Skin; Pain; Recurrent Skin Cancer,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14184,NCT00469417,Metvix Photodynamic Therapy (PDT) Versus Cryotherapy in Participants With Primary Superficial Basal Cell Carcinoma,COMPLETED,PHASE3,Superficial Basal Cell Carcinoma,Metvix® cream (DRUG); Hand held liquid nitrogen spray cryotherapy (PROCEDURE),157921,Metvixia,Superficial Basal Cell Carcinoma,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14185,NCT02666534,Efficacy of AFL-assisted PDT in Microinvasive Squamous Cell Carcinoma,COMPLETED,PHASE1,Microinvasive Squamous Cell Carcinoma,lidocaine-prilocaine 5% cream application (DRUG); 2940-nm Er:YAG AFL pretreatment (DEVICE); methyl-aminolevulinate application (DRUG); Illuminating using red light-emitting diode lamps (DEVICE),157921,Metvixia,Microinvasive Squamous Cell Carcinoma,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14186,NCT01000636,Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT),COMPLETED,PHASE4,Actinic Keratosis,Metvix PDT (PROCEDURE),157921,Metvixia,Actinic Keratosis,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14187,NCT02670655,Efficacy of Iontophoresis-assisted AFL-PDT in Actinic Keratosis,COMPLETED,PHASE1,Actinic Keratosis,lidocaine/prilocaine (5%) application (DRUG); 2940-nm Er:YAG AFL pretreatment (DEVICE); MAL application (DRUG); Iontophoresis application (DEVICE); irradiation with red light-emitting diode lamp (DEVICE),157921,Metvixia,Actinic Keratosis,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14188,NCT00472108,Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma,COMPLETED,PHASE3,Basal Cell Carcinoma,Photodynamic Therapy (PDT) (RADIATION); Metvix cream (DRUG); Placebo Cream (DRUG),157921,Metvixia,Basal Cell Carcinoma,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14189,NCT00473343,"Metvix PDT in Participant With ""High Risk"" Basal Cell Carcinoma",COMPLETED,PHASE3,Basal Cell Carcinoma,Metvix® cream (DRUG),157921,Metvixia,Basal Cell Carcinoma,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14190,NCT00472043,PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma,COMPLETED,PHASE3,Basal Cell Carcinoma,PDT with Metvix 160 mg/g cream (DRUG); Placebo (DRUG),157921,Metvixia,Basal Cell Carcinoma,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14191,NCT02018679,Er:YAG Ablative Fractional Laser Assisted-Photodynamic Therapy Versus Photodynamic Therapy for Basal Cell Carcinoma,COMPLETED,PHASE1,Nodular Basal Cell Carcinoma,Er:YAG AFL-PDT (PROCEDURE); MAL-PDT (PROCEDURE),157921,Metvixia,Nodular Basal Cell Carcinoma,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14192,NCT00472459,Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer,COMPLETED,PHASE3,Actinic Keratosis; Warts; Basal Cell Carcinoma; Bowens Disease; Squamous Cell Carcinoma,Photodynamic therapy with Metvix 160 mg/g cream (PROCEDURE),157921,Metvixia,Actinic Keratosis; Warts; Basal Cell Carcinoma; Bowens Disease; Squamous Cell Carcinoma,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14193,NCT00926952,Short Incubation Methylaminolevulinate Photodynamic Therapy Without Occlusion,COMPLETED,PHASE3,Actinic Keratosis,"Methylaminolevulinate (Metvix, Metvixia) (DRUG); Photodynamic Therapy (Aktilite) (DEVICE)",157921,Metvixia,Actinic Keratosis,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14194,NCT01260987,Fractional CO2 Laser Assisted Photodynamic Therapy,COMPLETED,PHASE2,Actinic Keratosis; Basal Cell Carcinoma,Conventional photodynamic therapy (DRUG); Fractional CO2 laser assisted PDT (DRUG),157921,Metvixia,Actinic Keratosis; Basal Cell Carcinoma,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14195,NCT03006185,Laser and Microdermabrasion Before Photodynamic Therapy for Actinic Keratoses in Field-cancerized Skin,COMPLETED,PHASE2,Actinic Keratosis; Sun Damaged Skin; Solar Keratosis; Solar Skin Damage,Ablative Fractional Carbon Dioxide (CO2) Laser (DEVICE); Microdermabrasion (DEVICE),157921,Metvixia,Actinic Keratosis; Sun Damaged Skin; Solar Keratosis; Solar Skin Damage,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14196,NCT00306800,Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp,COMPLETED,PHASE3,Actinic Keratosis,Photodynamic therapy with methyl aminolevulinate cream (PROCEDURE),157921,Metvixia,Actinic Keratosis,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14197,NCT02464709,Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL),COMPLETED,PHASE4,Actinic Keratosis; Natural Daylight Photodynamic Therapy,Aminolevulinic Acid (DRUG); Methyl 5-aminolevulinate (DRUG),157921,Metvixia,Actinic Keratosis; Natural Daylight Photodynamic Therapy,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14198,NCT02144077,Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy,COMPLETED,PHASE3,Basal Cell Carcinoma (BCC),BF-200 ALA (DRUG); methyl-aminolevulinate (DRUG),157921,Metvixia,Basal Cell Carcinoma (BCC),Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14199,NCT02647151,Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel,UNKNOWN,PHASE4,Actinic Keratosis,METHYLAMINOLEVULINATE HYDROCHLORIDE (DRUG); AMINOLEVULINIC ACID HYDROCHLORIDE (DRUG),157921,Metvixia,Actinic Keratosis,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14200,NCT00673933,Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris,COMPLETED,PHASE2,Acne Vulgaris,Methyl aminolevulinate (MAL) PDT (DRUG),157921,Metvixia,Acne Vulgaris,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14201,NCT03731988,Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Laser Density for Actinic Keratosis,COMPLETED,PHASE4,Actinic Keratosis,lidocaine/prilocaine (5%) application (DRUG); 2940-nm Er:YAG AFL pretreatment (DEVICE); MAL application (DRUG); Measurements of the fluorescence intensity (OTHER); irradiation with red light-emitting diode lamp (DEVICE),157921,Metvixia,Actinic Keratosis,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14202,NCT01349361,Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight,UNKNOWN,PHASE2,Photodynamic Therapy; Basal Cell Carcinomas,Daylight mediated photodynamic therapy (PROCEDURE),157921,Metvixia,Photodynamic Therapy; Basal Cell Carcinomas,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14203,NCT01491711,Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate,UNKNOWN,PHASE4,Superficial Basal Cell Carcinoma,Methylaminolevulinate PDT in 2 sessions (DRUG); Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT (DRUG),157921,Metvixia,Superficial Basal Cell Carcinoma,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14204,NCT02075671,Photodynamic Therapy for Papulopustular Rosacea,COMPLETED,PHASE4,Rosacea; Papulopustular Rosacea,Aminolevulinic acid topical solution 20% (DRUG); Blu-U Light Therapy (DEVICE); Placebo vehicle only (OTHER),157921,Metvixia,Rosacea; Papulopustular Rosacea,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14205,NCT02248298,Efficacy of AFL-assisted PDT With Short Incubation Time in Actinic Keratosis,COMPLETED,PHASE1,Actinic Keratosis,2h-AFL-PDT (DRUG); 3h-AFL-PDT (DRUG); 3hr-MAL-PDT (DRUG),157921,Metvixia,Actinic Keratosis,Skin,Methyl aminolevulinate (hydrochloride),,unclear,unclear,yes,yes,Used in photodynamic therapy for actinic keratosis.,COC(=O)CCC(=O)CN.Cl,1.0,79.0 +14206,NCT03539731,[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers,TERMINATED,PHASE1,Healthy Subject; Intracranial Neoplasm; Glioblastoma,Fluorine F 18 DASA-23 (DRUG); Positron Emission Tomography (PROCEDURE),4030,MBDZ,Healthy Subject; Intracranial Neoplasm; Glioblastoma,CNS/Brain,Mebendazole,"TUBA1A, TUBA1B, TUBA1C, TUBB, TUBB1, TUBB2A, TUBB3, TUBB4A, TUBB4B, TUBB6",inhibitor/antagonist,Microtubule inhibitor,yes,yes,Approved for treating parasitic worm infestations.,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,1.1,188.0 +14207,NCT04771520,Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors,RECRUITING,PHASE2,Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Melanoma; Locally Advanced Primary Malignant Central Nervous System Neoplasm; Locally Advanced Sarcoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Primary Malignant Central Nervous System Neoplasm; Metastatic Sarcoma; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Avapritinib (DRUG),4030,MBDZ,Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Melanoma; Locally Advanced Primary Malignant Central Nervous System Neoplasm; Locally Advanced Sarcoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Primary Malignant Central Nervous System Neoplasm; Metastatic Sarcoma; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Bowel,Mebendazole,"TUBA1A, TUBA1B, TUBA1C, TUBB, TUBB1, TUBB2A, TUBB3, TUBB4A, TUBB4B, TUBB6",inhibitor/antagonist,Microtubule inhibitor,yes,yes,Approved for treating parasitic worm infestations.,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,1.1,188.0 +14208,NCT03925662,Mebendazole as Adjuvant Treatment for Colon Cancer,RECRUITING,PHASE3,Colorectal Cancer,Folfox with avastin (DRUG); Mebendazole (DRUG),4030,MBDZ,Colorectal Cancer,Bowel,Mebendazole,"TUBA1A, TUBA1B, TUBA1C, TUBB, TUBB1, TUBB2A, TUBB3, TUBB4A, TUBB4B, TUBB6",inhibitor/antagonist,Microtubule inhibitor,yes,yes,Approved for treating parasitic worm infestations.,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,1.1,188.0 +14209,NCT05435729,A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease,COMPLETED,PHASE1,Levodopa-induced Dyskinesia; Parkinson's Disease,DSP-9632P 27.5 mg (DRUG); DSP-9632P 82.5 mg (DRUG); Placebo (DRUG); DSP-9632P 55.0 mg (DRUG); Levodopa formulation (DRUG),4030,MBDZ,Levodopa-induced Dyskinesia; Parkinson's Disease,CNS/Brain,Mebendazole,"TUBA1A, TUBA1B, TUBA1C, TUBB, TUBB1, TUBB2A, TUBB3, TUBB4A, TUBB4B, TUBB6",inhibitor/antagonist,Microtubule inhibitor,yes,yes,Approved for treating parasitic worm infestations.,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,1.1,188.0 +14210,NCT02644291,Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors,COMPLETED,PHASE1,"Medulloblastoma; Astrocytoma, Grade III; Glioblastoma; Anaplastic Astrocytoma; Brain Stem Neoplasms, Malignant; Oligodendroblastoma; Anaplastic Oligodendroglioma; Malignant Glioma",Mebendazole (DRUG),4030,MBDZ,"Medulloblastoma; Astrocytoma, Grade III; Glioblastoma; Anaplastic Astrocytoma; Brain Stem Neoplasms, Malignant; Oligodendroblastoma; Anaplastic Oligodendroglioma; Malignant Glioma",CNS/Brain,Mebendazole,"TUBA1A, TUBA1B, TUBA1C, TUBB, TUBB1, TUBB2A, TUBB3, TUBB4A, TUBB4B, TUBB6",inhibitor/antagonist,Microtubule inhibitor,yes,yes,Approved for treating parasitic worm infestations.,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,1.1,188.0 +14211,NCT05147194,The Effects of TMZ on Diabetic Nephropathy,UNKNOWN,PHASE2,Diabetic Nephropathies,Trimetazidine (DRUG),4030,MBDZ,Diabetic Nephropathies,Kidney,Mebendazole,"TUBA1A, TUBA1B, TUBA1C, TUBB, TUBB1, TUBB2A, TUBB3, TUBB4A, TUBB4B, TUBB6",inhibitor/antagonist,Microtubule inhibitor,yes,yes,Approved for treating parasitic worm infestations.,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,1.1,188.0 +14212,NCT01837862,A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas,COMPLETED,PHASE1,"Pilomyxoid Astrocytoma; Pilocytic Astrocytoma; Glioma, Astrocytic; Optic Nerve Glioma; Pleomorphic Xanthoastrocytoma; Glioblastoma Multiforme; Anaplastic Astrocytoma; Gliosarcoma; Diffuse Intrinsic Pontine Glioma; DIPG; Low-grade Glioma; Brainstem Glioma",Mebendazole (DRUG); Vincristine (DRUG); Carboplatin (DRUG); Temozolomide (DRUG); Bevacizumab (DRUG); Irinotecan (DRUG),4030,MBDZ,"Pilomyxoid Astrocytoma; Pilocytic Astrocytoma; Glioma, Astrocytic; Optic Nerve Glioma; Pleomorphic Xanthoastrocytoma; Glioblastoma Multiforme; Anaplastic Astrocytoma; Gliosarcoma; Diffuse Intrinsic Pontine Glioma; DIPG; Low-grade Glioma; Brainstem Glioma",CNS/Brain,Mebendazole,"TUBA1A, TUBA1B, TUBA1C, TUBB, TUBB1, TUBB2A, TUBB3, TUBB4A, TUBB4B, TUBB6",inhibitor/antagonist,Microtubule inhibitor,yes,yes,Approved for treating parasitic worm infestations.,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,1.1,188.0 +14213,NCT01729260,Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide,COMPLETED,PHASE1,Newly Diagnosed High-Grade Glioma,Mebendazole (DRUG),4030,MBDZ,Newly Diagnosed High-Grade Glioma,CNS/Brain,Mebendazole,"TUBA1A, TUBA1B, TUBA1C, TUBB, TUBB1, TUBB2A, TUBB3, TUBB4A, TUBB4B, TUBB6",inhibitor/antagonist,Microtubule inhibitor,yes,yes,Approved for treating parasitic worm infestations.,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,1.1,188.0 +14214,NCT06643689,Tranilast Vs. Steroids to Prevent Esophageal Stricture (TAPES) After Endoscopic Resection for Superficial Neoplasms,NOT_YET_RECRUITING,PHASE2,Esophageal Stricture; Esophageal Neoplasms,Tranilast (DRUG); Dexamethasone (DRUG),5282230,Rizaben,Esophageal Stricture; Esophageal Neoplasms,Esophagus/Stomach,Tranilast,"PLA2G2A, EGR1",inhibitor/antagonist,unclear,yes,yes,Approved for asthma and allergic disorders in some countries.,COC1=C(C=C(C=C1)C=CC(=O)NC2=CC=CC=C2C(=O)O)OC,1.0930232558139534,980.0 +14215,NCT06307288,Efficacy and Safety of Tranilast Combined With Minocycline in the Treatment of Rosacea,ENROLLING_BY_INVITATION,PHASE4,Rosacea,minocycline (DRUG); tranilast (DRUG),5282230,Rizaben,Rosacea,Skin,Tranilast,"PLA2G2A, EGR1",inhibitor/antagonist,unclear,yes,yes,Approved for asthma and allergic disorders in some countries.,COC1=C(C=C(C=C1)C=CC(=O)NC2=CC=CC=C2C(=O)O)OC,1.0930232558139534,980.0 +14216,NCT01939665,PANFIRE Study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma,COMPLETED,PHASE1,Locally Advanced Pancreatic Carcinoma (LAPC); Non-metastasized Unresectable Pancreatic Carcinoma; Pancreatic Cancer,"NanoKnife ""Irreversible electroporation (IRE)"" (DEVICE)",123631,IRE,Locally Advanced Pancreatic Carcinoma (LAPC); Non-metastasized Unresectable Pancreatic Carcinoma; Pancreatic Cancer,Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14217,NCT01369420,NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Adenocarcinoma,NanoKnife Low Energy Direct Current (LEDC) System Ablation (DEVICE),123631,IRE,Pancreatic Adenocarcinoma,Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14218,NCT03080974,Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma,RECRUITING,PHASE2,Pancreatic Adenocarcinoma,Nivolumab (DRUG); Irreversible Electroporation (PROCEDURE),123631,IRE,Pancreatic Adenocarcinoma,Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14219,NCT04212026,Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.,TERMINATED,PHASE2,Metastatic Pancreatic Cancer,Nivolumab (DRUG),123631,IRE,Metastatic Pancreatic Cancer,Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14220,NCT05113186,Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative,ACTIVE_NOT_RECRUITING,PHASE2,Hepatocellular Carcinoma,Lenvatinib Pill (DRUG),123631,IRE,Hepatocellular Carcinoma,Liver,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14221,NCT04873362,A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy,ACTIVE_NOT_RECRUITING,PHASE3,Breast Cancer,Atezolizumab (DRUG); Trastuzumab Emtansine (DRUG); Placebo (DRUG); Trastuzumab (DRUG),123631,IRE,Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14222,NCT03240224,Bioinformation Therapy for Breast Cancer,COMPLETED,PHASE2,Advanced Breast Cancer,Cancer ablation (DEVICE); Life information rehabilitation therapy (DRUG),123631,IRE,Advanced Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14223,NCT02926196,Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab,ACTIVE_NOT_RECRUITING,PHASE3,Triple Negative Breast Neoplasms,MSB0010718C (DRUG),123631,IRE,Triple Negative Breast Neoplasms,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14224,NCT03856658,Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases,ACTIVE_NOT_RECRUITING,PHASE2,Pancreatic Adenocarcinoma; Liver Metastases,Floxuridine (FUDR) (DRUG); Hepatic Artery Infusion Pump (DEVICE); Heparinized Saline (DRUG),123631,IRE,Pancreatic Adenocarcinoma; Liver Metastases,Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14225,NCT03448510,Irreversible Electroporation Versus Standard Medication for Benign Prostatic Obstruction,UNKNOWN,PHASE2,Lower Urinary Tract Symptoms,Irreversible electroporation (DEVICE); Standard Medication (DRUG),123631,IRE,Lower Urinary Tract Symptoms,Bladder/Urinary Tract,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14226,NCT04108481,Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer,TERMINATED,PHASE1,Colorectal Cancer Metastatic; Colon Cancer; Metastatic Colorectal Cancer; Rectal Cancer; Liver Metastasis Colon Cancer; Colo-rectal Cancer; Colorectal Adenocarcinoma; Colorectal Neoplasms; Liver Metastases; Colorectal Carcinoma,Durvalumab (DRUG); Yttrium-90 RadioEmbolization (RADIATION),123631,IRE,Colorectal Cancer Metastatic; Colon Cancer; Metastatic Colorectal Cancer; Rectal Cancer; Liver Metastasis Colon Cancer; Colo-rectal Cancer; Colorectal Adenocarcinoma; Colorectal Neoplasms; Liver Metastases; Colorectal Carcinoma,Bowel,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14227,NCT02187744,A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04),COMPLETED,PHASE3,Early Breast Cancer,PF-05280014 (BIOLOGICAL); Taxotere® (DRUG); Paraplatin® (DRUG); Trastuzumab-EU (BIOLOGICAL); Taxotere® (DRUG); Paraplatin® (DRUG),123631,IRE,Early Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14228,NCT01799044,Pilot-study: Non-thermal Ablation Using Irreversible Electroporation to Treat Colorectal Liver Metastases,COMPLETED,PHASE1,Colorectal Liver Metastases; Metastatic Liver Disease,Irreversible electroporation (IRE) (DEVICE),123631,IRE,Colorectal Liver Metastases; Metastatic Liver Disease,Liver,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14229,NCT03630640,Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation,COMPLETED,PHASE2,Hepatocellular Carcinoma,Nivolumab Injection [Opdivo] (DRUG),123631,IRE,Hepatocellular Carcinoma,Liver,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14230,NCT03183219,Safety and Efficiency of γδ T Cell Against Liver Cancer,COMPLETED,PHASE1,Liver Cancer,Cryosurgery or IRE surgery (PROCEDURE); γδ T cell (BIOLOGICAL); γδ T cells/ A Cryosurgery or IRE (OTHER),123631,IRE,Liver Cancer,Liver,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14231,NCT06630624,"Dose Finding, Efficacy and Immunological Response of IP-001 Following RFA, MWA or IRE for CRLM",RECRUITING,PHASE1,Colorectal Cancer; Liver Metastases; Liver Metastasis Colon Cancer,IP-001 (DRUG),123631,IRE,Colorectal Cancer; Liver Metastases; Liver Metastasis Colon Cancer,Bowel,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14232,NCT02298608,Efficacy and Safety of IRE for RMs,UNKNOWN,PHASE1,Kidney Cancer,Nano Knife (DEVICE),123631,IRE,Kidney Cancer,Kidney,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14233,NCT02592395,Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma,WITHDRAWN,PHASE1,Pancreatic Adenocarcinoma,FOLFIRINOX (DRUG); Electroporation (DEVICE),123631,IRE,Pancreatic Adenocarcinoma,Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14234,NCT06054555,A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma,RECRUITING,PHASE3,Melanoma,ABP 206 (DRUG); Nivolumab (DRUG),123631,IRE,Melanoma,Skin,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14235,NCT04318223,Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy,UNKNOWN,PHASE2,Metastatic Breast Cancer; Locally Advanced Breast Cancer,Palbociclib (DRUG),123631,IRE,Metastatic Breast Cancer; Locally Advanced Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14236,NCT06205849,Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer,RECRUITING,PHASE1,Pancreatic Cancer,IRE + intratumoral mitazalimab (CD40 antibody) injection (DRUG); NanoKnife (DEVICE),123631,IRE,Pancreatic Cancer,Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14237,NCT03899636,A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Stage III Pancreatic Cancer,Modified FOLFIRINOX Regimen (DRUG); NanoKnife System (DEVICE),123631,IRE,Stage III Pancreatic Cancer,Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14238,NCT03183206,Safety and Efficiency of γδ T Cell Against Breast Cancer,COMPLETED,PHASE1,Breast Cancer,"Cryosurgery , IRE surgery ,surgery (PROCEDURE); γδ T cells (BIOLOGICAL); γδ T cells/ Surgery (OTHER)",123631,IRE,Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14239,NCT03484299,Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma,RECRUITING,PHASE1,Pancreas Cancer,Irreversible Electroporation (IRE) (PROCEDURE); Gemcitabine (DRUG); FOLFIRINOX (DRUG),123631,IRE,Pancreas Cancer,Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14240,NCT02514421,Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma,COMPLETED,PHASE1,Pancreatic Adenocarcinoma,Electroporation (DEVICE); gemcitabine (DRUG); nab-paclitaxel (DRUG),123631,IRE,Pancreatic Adenocarcinoma,Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14241,NCT04835402,Electroporation Potentiated Immunotherapy in Cancer,ACTIVE_NOT_RECRUITING,PHASE2,"Pancreas Cancer, Metastatic",Pembrolizumab (DRUG); Irreversible electroporation (DEVICE),123631,IRE,"Pancreas Cancer, Metastatic",Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14242,NCT03239184,Bioinformation Therapy for Pancreatic Cancer,COMPLETED,PHASE2,Unresectable Pancreatic Cancer,Cancer ablation (DEVICE); Life information rehabilitation therapy (DRUG),123631,IRE,Unresectable Pancreatic Cancer,Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14243,NCT06938503,AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer,NOT_YET_RECRUITING,PHASE2,"Pancreatic Cancer, Adult",AG regimen (DRUG); Nimotuzumab (DRUG),123631,IRE,"Pancreatic Cancer, Adult",Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14244,NCT02718859,Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer,COMPLETED,PHASE1,Pancreatic Cancer,NK cells (BIOLOGICAL); irreversible electroporation (IRE ) (PROCEDURE),123631,IRE,Pancreatic Cancer,Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14245,NCT03183232,Safety and Efficiency of γδ T Cell Against Lung Cancer,COMPLETED,PHASE1,Lung Cancer,Cryosurgery or IRE surgery (PROCEDURE); γδ T cell (BIOLOGICAL); γδ T cells/ A Cryosurgery or IRE (OTHER),123631,IRE,Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14246,NCT03180437,Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer,COMPLETED,PHASE1,Pancreatic Cancer,IRE surgery (PROCEDURE); IRE plus γδ T cells (BIOLOGICAL),123631,IRE,Pancreatic Cancer,Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14247,NCT02388152,Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease,TERMINATED,PHASE1,Alzheimer Disease,"Lu AF20513, low dose (DRUG); Lu AF20513, medium dose (DRUG); Lu AF20513, high dose (DRUG); Lu AF20513, double high dose (DRUG)",123631,IRE,Alzheimer Disease,CNS/Brain,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14248,NCT02828709,Safety and Feasibility of IRE for SRMs,UNKNOWN,PHASE2,Kidney Cancer,Irreversible Electroporation (DEVICE),123631,IRE,Kidney Cancer,Kidney,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14249,NCT05435053,Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer,TERMINATED,PHASE2,Pancreas Cancer,Nivolumab (DRUG); Irreversible electroporation (IRE) (DEVICE),123631,IRE,Pancreas Cancer,Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14250,NCT03769753,Trial of IRE in Cholangiocarcinoma,COMPLETED,PHASE2,Cholangiocarcinoma,IRE Device (DEVICE),123631,IRE,Cholangiocarcinoma,Liver,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14251,NCT03350477,Bioinformation Therapy for Gastric Cancer,COMPLETED,PHASE2,Advanced Gastric Cancer,Cancer ablation (DEVICE); Life information rehabilitation therapy (DRUG),123631,IRE,Advanced Gastric Cancer,Esophagus/Stomach,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14252,NCT06047015,Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer,NOT_YET_RECRUITING,PHASE1,Liver Metastasis Colon Cancer,IRE plus checkpoint inhibitor (COMBINATION_PRODUCT); IRE plus Checkpoint Inhibitor plus CpG-ODN (COMBINATION_PRODUCT),123631,IRE,Metastatic Colon Cancer to Liver,Liver,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14253,NCT03673137,Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC,COMPLETED,PHASE2,Locally Advanced Pancreatic Adenocarcinoma,Irreversible electroporation (DEVICE); Gemcitabine (DRUG),123631,IRE,Pancreatic Neoplasms,Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14254,NCT06185556,COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases,RECRUITING,PHASE2,Colorectal Cancer; Liver Metastases; Liver Metastasis Colon Cancer; Unresectable Solid Tumor,Irreversible electroporation (PROCEDURE); Stereotactic body radiotherapy (RADIATION),123631,IRE,Colorectal Cancer; Liver Metastases; Liver Metastasis Colon Cancer; Unresectable Solid Tumor,Bowel,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14255,NCT05609656,Electroporation and Immunotherapy in Metastatic Colorectal Cancer,TERMINATED,PHASE2,Metastatic Colorectal Cancer,Irreversible electroporation (DEVICE); Calcium electroporation (DEVICE); Pembrolizumab (DRUG),123631,IRE,Metastatic Colorectal Cancer,Bowel,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14256,NCT04727307,"Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial",RECRUITING,PHASE2,Hepatocellular Carcinoma,Atezolizumab (neoadjuvant) (DRUG); Percutaneous Radiofrequency (PROCEDURE); Bevacizumab (adjuvant) (DRUG); Atezolizumab (adjuvant) (DRUG),123631,IRE,Hepatocellular Carcinoma,Liver,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14257,NCT01967407,IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy.,UNKNOWN,PHASE1,Kidney Tumor; Renal Cell Cancer,Irreversible Electroporation (IRE) (PROCEDURE),123631,IRE,Kidney Tumor; Renal Cell Cancer,Kidney,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14258,NCT02568111,Brimonidine Tartrate for the Treatment of Injection Related Erythema,WITHDRAWN,PHASE4,Relapsing-Remitting Multiple Sclerosis (RRMS),peginterferon beta-1a (DRUG); brimonidine tartrate (DRUG); Vehicle Gel (DRUG),123631,IRE,Relapsing Remitting Multiple Sclerosis,CNS/Brain,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14259,NCT02611661,Local Ablative Strategies After Endovascular Radioembolization,TERMINATED,PHASE1,Metastatic Colorectal Cancer,PET/MRI (DEVICE); Percutaneous ablation (RADIATION); Stereotactic body radiotherapy (RADIATION),123631,IRE,Metastatic Colorectal Cancer,Bowel,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14260,NCT04612530,PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer,UNKNOWN,PHASE1,Pancreatic Cancer; Metastatic Pancreatic Cancer,Irreversible Electroporation (IRE) (DEVICE); Nivolumab (DRUG); Toll-Like Receptor 9 (DRUG),123631,IRE,Pancreatic Cancer; Metastatic Pancreatic Cancer,Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14261,NCT03239171,Bioinformation Therapy for Lung Cancer,COMPLETED,PHASE2,Small-cell Lung Cancer,Cancer ablation (DEVICE); Life information rehabilitation therapy (DRUG),123631,IRE,Small-cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14262,NCT06378047,Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer,RECRUITING,PHASE1,Pancreatic Cancer; Locally Advanced Pancreatic Cancer,Pembrolizumab (DRUG); Irreversible Electroporation (DEVICE),123631,IRE,Pancreatic Cancer; Locally Advanced Pancreatic Cancer,Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14263,NCT03668405,A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD),TERMINATED,PHASE1,Alzheimer's Disease,Lu AF20513 (DRUG),123631,IRE,Alzheimer's Disease,CNS/Brain,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14264,NCT01017874,A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer,COMPLETED,PHASE3,Non Small Cell Lung Cancer,Pemetrexed (DRUG); Cisplatin (DRUG); Gefitinib (DRUG); Gefitinib (DRUG),123631,IRE,Non Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14265,NCT02039674,A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021),COMPLETED,PHASE1,Non-small Cell Lung Carcinoma,Pembrolizumab (BIOLOGICAL); Paclitaxel (DRUG); Carboplatin (DRUG); Bevacizumab (BIOLOGICAL); Pemetrexed (DRUG); Ipilimumab (BIOLOGICAL); Erlotinib (DRUG); Gefitinib (DRUG),123631,IRE,Non-small Cell Lung Carcinoma,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14266,NCT00231465,Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,docetaxel (Taxotere®) (DRUG); ZD1839 (DRUG),123631,IRE,Advanced Non-Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14267,NCT00807066,Randomized Gefitinib Trial,COMPLETED,PHASE3,Non Small Cell Lung Cancer,Gefitinib (DRUG); Platinum (DRUG),123631,IRE,Non Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14268,NCT00246974,Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT,COMPLETED,PHASE2,Bladder Cancer,Gemcitabine (DRUG); Cisplatin (DRUG); Gefitinib (DRUG),123631,IRE,Bladder Cancer,Bladder/Urinary Tract,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14269,NCT00086957,"Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer",COMPLETED,PHASE1,Breast Cancer,trastuzumab (BIOLOGICAL); docetaxel (DRUG); gefitinib (DRUG),123631,IRE,Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14270,NCT00006048,ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer,UNKNOWN,PHASE3,Lung Cancer,cisplatin (DRUG); gefitinib (DRUG); gemcitabine hydrochloride (DRUG),123631,IRE,Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14271,NCT04322890,Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation,RECRUITING,PHASE2,Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROS1 Gene Mutation; MET Gene Mutation,"Osimertinib (DRUG); Alectinib 150 MG (DRUG); Crizotinib 250 MG (DRUG); Savolitinib, Crizotinib. (DRUG); Chemotherapy (DRUG)",123631,IRE,Non-Small Cell Lung Cancer with Gene Mutations,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14272,NCT00234403,A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,gefitinib and fulvestrant (DRUG),123631,IRE,Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14273,NCT01510990,First Line Gefitinib by FDG-PET Metabolic Response,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,Gefitinib (DRUG),123631,IRE,Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14274,NCT02066038,Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation,UNKNOWN,PHASE2,"Lung, Carcinoma",Erlotinib (DRUG),123631,IRE,Lung Carcinoma,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14275,NCT03382795,Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients,UNKNOWN,PHASE2,EGFR Positive Non-small Cell Lung Cancer,EGFR (DRUG),123631,IRE,EGFR Positive Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14276,NCT01024712,"Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer",UNKNOWN,PHASE2,Lung Cancer,carboplatin (DRUG); gefitinib (DRUG); paclitaxel (DRUG); quality-of-life assessment (PROCEDURE),123631,IRE,Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14277,NCT00080743,Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,gefitinib (DRUG); tamoxifen citrate (DRUG); Placebo (DRUG),123631,IRE,Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14278,NCT01720901,Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy,SUSPENDED,PHASE4,Non-small Cell Lung Cancer,Icotinib (DRUG),123631,IRE,Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14279,NCT03399669,The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,gefitinib (DRUG),123631,IRE,Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14280,NCT01405846,Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib,TERMINATED,PHASE2,Lung Cancer; Head and Neck Cancer,Gefitinib (DRUG),123631,IRE,Lung Cancer; Head and Neck Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14281,NCT01732276,"The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer",UNKNOWN,PHASE2,Breast Cancer,gefitinib (DRUG),123631,IRE,Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14282,NCT01404260,Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer,COMPLETED,PHASE3,Non-small Cell Lung Cancer,Gefitinib (DRUG); Gemcitabine +Carboplatin (DRUG),123631,IRE,Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14283,NCT02804776,PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery,COMPLETED,PHASE2,Non-small Cell Lung Cancer,Gefitinib (DRUG),123631,IRE,Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14284,NCT01027676,Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC),UNKNOWN,PHASE1,Non-Small-Cell Lung Carcinoma,Study treatment (DRUG),123631,IRE,Non-Small-Cell Lung Carcinoma,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14285,NCT03944772,Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD),ACTIVE_NOT_RECRUITING,PHASE2,Non-Small Cell Lung Cancer,Osimertinib (DRUG); Savolitinib (DRUG); Gefitinib (DRUG); Necitumumab (DRUG); Durvalumab (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Alectinib (DRUG); Selpercatinib (DRUG); Selumetinib (DRUG); Etoposide (DRUG); Cisplatin (DRUG); Datopotamab deruxtecan (DRUG),123631,IRE,Advanced Non-Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14286,NCT00608868,SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients,COMPLETED,PHASE4,Non Small Cell Lung Carcinoma,Gefitinib (DRUG),123631,IRE,Non Small Cell Lung Carcinoma,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14287,NCT00234468,Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC,TERMINATED,PHASE3,Non Small Cell Lung Carcinoma,Iressa (Gefitinib) (DRUG),123631,IRE,Non Small Cell Lung Carcinoma,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14288,NCT01040780,Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients,COMPLETED,PHASE3,Non-small Cell Lung Cancer,Icotinib (DRUG); Gefitinib (DRUG),123631,IRE,Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14289,NCT00124280,Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,Non-small-cell Lung Carcinoma,RAD001 (DRUG),123631,IRE,Non-small-cell Lung Carcinoma,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14290,NCT02411448,A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY),ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Non-Small Cell Lung Cancer,Ramucirumab (DRUG); Placebo (DRUG); Erlotinib (DRUG); Gefitinib (DRUG); Osimertinib (DRUG),123631,IRE,Metastatic Non-Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14291,NCT02296125,AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer,AZD9291 80 mg/40 mg + placebo (DRUG); Placebo Erlotinib 150/100mg (DRUG); Placebo Gefitinib 250 mg (DRUG); Erlotinib 150/100 mg (DRUG); Gefitinib 250 mg (DRUG); Placebo AZD9291 80 mg/ 40 mg (DRUG),123631,IRE,EGFR-Positive Non-Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14292,NCT00077025,Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Gefitinib (DRUG); Anastrozole (DRUG),123631,IRE,Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14293,NCT00027625,Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma,COMPLETED,PHASE1,Brain and Central Nervous System Tumors,gefitinib (DRUG); temozolomide (DRUG),123631,IRE,Brain and Central Nervous System Tumors,CNS/Brain,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14294,NCT00144066,A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer,COMPLETED,PHASE3,Lung Cancer,platinum-based chemotherapy alone (up to six cycles) (DRUG); platinum-based chemotherapy followed by maintenance therapy with gefitinib (DRUG),123631,IRE,Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14295,NCT00085566,Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer,COMPLETED,PHASE1,Brain and Central Nervous System Tumors; Prostate Cancer,everolimus (DRUG); gefitinib (DRUG),123631,IRE,Brain and Central Nervous System Tumors; Prostate Cancer,CNS/Brain,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14296,NCT01288430,A Study of DS-2248 in Participants With Advanced Solid Tumors,TERMINATED,PHASE1,Solid Tumors; Non-small Cell Lung Carcinoma,DS-2248 (DRUG),123631,IRE,Solid Tumors and Non-small Cell Lung Carcinoma,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14297,NCT00493025,"Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery",TERMINATED,PHASE2,Esophageal Cancer,cisplatin (DRUG); gefitinib (DRUG); paclitaxel (DRUG); adjuvant therapy (PROCEDURE); radiation therapy (RADIATION),123631,IRE,Esophageal Cancer,Esophagus/Stomach,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14298,NCT00059722,This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",ZD6474 (DRUG); Placebo (DRUG); ZD1839 (DRUG),123631,IRE,"Carcinoma, Non-Small-Cell Lung",Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14299,NCT00066339,Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy,COMPLETED,PHASE2,Breast Cancer,gefitinib (DRUG),123631,IRE,Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14300,NCT02347839,NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.,WITHDRAWN,PHASE2,Lung Cancer,Gefitinib-surgery-gefitinib (PROCEDURE),123631,IRE,Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14301,NCT02416739,Anticancer Activity of Nicotinamide on Lung Cancer,UNKNOWN,PHASE2,Non-Small-Cell Lung Carcinoma,Nicotinamide (DRUG),123631,IRE,Non-Small-Cell Lung Carcinoma,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14302,NCT01192230,Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients,UNKNOWN,PHASE2,"Carcinoma, Non-Small-Cell Lung",Endostatins (DRUG); Docetaxel (DRUG),123631,IRE,"Carcinoma, Non-Small-Cell Lung",Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14303,NCT02788058,A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy,UNKNOWN,PHASE2,Lung Adenocarcinoma; EGFR Positive Non-small Cell Lung Cancer,EGFR-TKI (DRUG); Thoracic Hypofractionated Radiotherapy (RADIATION),123631,IRE,Lung Adenocarcinoma; EGFR Positive Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14304,NCT05204758,Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect,COMPLETED,PHASE3,Advanced Lung Adenocarcinoma,TCM Formula (DRUG); Placebo (DRUG),123631,IRE,Advanced Lung Adenocarcinoma,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14305,NCT01608022,A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus,COMPLETED,PHASE2,Esophageal Squamous Cell Carcinoma,PF804 (DRUG),123631,IRE,Esophageal Squamous Cell Carcinoma,Skin,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14306,NCT00135135,Therapy for Children With Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma,"Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid (DRUG); Radiation therapy, Surgery, Peripheral Stem cell transplant (PROCEDURE)",123631,IRE,Neuroblastoma,CNS/Brain,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14307,NCT00096486,Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer,everolimus (DRUG); gefitinib (DRUG),123631,IRE,Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14308,NCT01189435,Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib,TERMINATED,PHASE2,Lung Cancer,erlotinib (DRUG),123631,IRE,Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14309,NCT01498562,Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer,COMPLETED,PHASE2,Non Small Cell Lung Cancer (NSCLC),Gefitinib and Nimotuzumab (DRUG); Gefitinib (DRUG),123631,IRE,Non Small Cell Lung Cancer (NSCLC),Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14310,NCT00049062,Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,anastrozole (DRUG); gefitinib (DRUG),123631,IRE,Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14311,NCT04358562,Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib,UNKNOWN,PHASE2,Non-small Cell Lung Cancer; EGFR Gene Mutation,Gefitinib (DRUG); Anlotinib (DRUG),123631,IRE,Non-small Cell Lung Cancer; EGFR Gene Mutation,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14312,NCT00452244,Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,Lung Cancer,simvastatin (DRUG); gefitinib only (DRUG),123631,IRE,Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14313,NCT03595644,Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer,COMPLETED,PHASE2,Stage IV Non-small Cell Lung Cancer,SBRT+TKI (RADIATION); TKI (DRUG),123631,IRE,Stage IV Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14314,NCT00234429,A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma,COMPLETED,PHASE2,Colorectal Cancer,"Gefitinib, raltitrexed (DRUG)",123631,IRE,Colorectal Cancer,Bowel,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14315,NCT01602289,A Study of LY2875358 in Japanese Participants With Advanced Cancer,COMPLETED,PHASE1,"Solid Tumors; Lymphoma; Carcinoma, Non-Small-Cell Lung",LY2875358 (BIOLOGICAL); Erlotinib (DRUG); Gefitinib (DRUG),123631,IRE,"Solid Tumors; Lymphoma; Carcinoma, Non-Small-Cell Lung",Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14316,NCT04248829,Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301),ACTIVE_NOT_RECRUITING,PHASE3,Non-Small Cell Lung Cancer,Lazertinib 240 mg/160 mg (DRUG); Gefitinib 250 mg (DRUG); Lazertinib-matching placebo 240 mg/160 mg (DRUG); Gefitinib-matching placebo 250 mg (DRUG),123631,IRE,Advanced Non-Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14317,NCT00198380,Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature,COMPLETED,PHASE2,Pneumonic-type Adenocarcinoma (P-ADC); Lung Adenocarcinoma With Bronchiolo-alveolar Feature,Gefitinib (DRUG),123631,IRE,Pneumonic-type Adenocarcinoma (P-ADC); Lung Adenocarcinoma With Bronchiolo-alveolar Feature,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14318,NCT00113529,Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma,COMPLETED,PHASE1,"Carcinoma, Renal Cell",Gefitinib + Sunitinib (DRUG),123631,IRE,"Carcinoma, Renal Cell",Kidney,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14319,NCT00255489,A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer,COMPLETED,PHASE1,Non-small-cell Lung Cancer,Gefitinib (DRUG); palliative thoracic radiotherapy (PROCEDURE),123631,IRE,Non-small-cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14320,NCT00479089,Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer,TERMINATED,PHASE2,Bladder Cancer,Docetaxel (DRUG); ZD1839 (DRUG); Dexamethasone (DRUG),123631,IRE,Bladder Cancer,Bladder/Urinary Tract,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14321,NCT01556191,Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR,COMPLETED,PHASE2,Stage IV Lung Cancer,Gefitinib (DRUG); Fulvestrant (DRUG); Erlotinib (DRUG),123631,IRE,Stage IV Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14322,NCT00054691,ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin,COMPLETED,PHASE2,Skin Cancer,Iressa (DRUG),123631,IRE,Skin Cancer,Skin,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14323,NCT00040794,"Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer",COMPLETED,PHASE2,Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Bronchoalveolar Cell Lung Cancer; Large Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer,paclitaxel (DRUG); carboplatin (DRUG); gefitinib (DRUG); radiation therapy (RADIATION); laboratory biomarker analysis (OTHER),123631,IRE,Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Bronchoalveolar Cell Lung Cancer; Large Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14324,NCT00042991,Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas,COMPLETED,PHASE1,Untreated Childhood Anaplastic Astrocytoma; Untreated Childhood Anaplastic Oligodendroglioma; Untreated Childhood Brain Stem Glioma; Untreated Childhood Giant Cell Glioblastoma; Untreated Childhood Glioblastoma; Untreated Childhood Gliomatosis Cerebri; Untreated Childhood Gliosarcoma; Untreated Childhood Oligodendroglioma,gefitinib (DRUG); radiation therapy (RADIATION); pharmacological study (OTHER); laboratory biomarker analysis (OTHER),123631,IRE,Untreated Childhood Anaplastic Astrocytoma; Untreated Childhood Anaplastic Oligodendroglioma; Untreated Childhood Brain Stem Glioma; Untreated Childhood Giant Cell Glioblastoma; Untreated Childhood Glioblastoma; Untreated Childhood Gliomatosis Cerebri; Untreated Childhood Gliosarcoma; Untreated Childhood Oligodendroglioma,CNS/Brain,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14325,NCT00328562,ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Non-Small Cell Lung Carcinoma (NSCLC),ZD1839 (Iressa) (DRUG); Thoracic Radiotherapy (RADIATION),123631,IRE,Non-Small Cell Lung Carcinoma (NSCLC),Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14326,NCT00711594,LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",BIBW 2992 MA2 40mg/day (DRUG); BIBW 2992 MA2 50mg/day (DRUG); BIBW 2992 MA2 20mg/day (DRUG); BIBW 2992 QD (DRUG),123631,IRE,"Carcinoma, Non-Small-Cell Lung",Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14327,NCT00333294,Phase II Iressa + Irradiation Followed by Chemo in NSCLC,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Gefitinib (DRUG); Radiation therapy (PROCEDURE); Cisplatin (DRUG); Vinorelbine (DRUG),123631,IRE,Advanced Non-Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14328,NCT03264794,the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer),UNKNOWN,PHASE4,Non-small Cell Lung Cancer,Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial (DRUG); Gefitinib tablets (Yi Ruisha），First medication (DRUG); Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial. (DRUG),123631,IRE,Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14329,NCT00016991,ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse,COMPLETED,PHASE2,Brain and Central Nervous System Tumors,gefitinib (DRUG),123631,IRE,Brain and Central Nervous System Tumors,CNS/Brain,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14330,NCT03799094,Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations,UNKNOWN,PHASE1,"Carcinoma, Non-Small-Cell Lung",Vitamin C (DRUG); Tyrosine kinase inhibitor (DRUG),123631,IRE,"Carcinoma, Non-Small-Cell Lung",Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14331,NCT00071994,Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer),COMPLETED,PHASE2,Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer,gefitinib (DRUG); laboratory biomarker analysis (OTHER),123631,IRE,Primary Hepatocellular Carcinoma,Liver,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14332,NCT01391260,Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC),UNKNOWN,PHASE2,Non-small Cell Lung Cancer,Gefitinib (OTHER),123631,IRE,Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14333,NCT05445791,Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations,RECRUITING,PHASE3,Non Small Cell Lung Cancer,Metformin Hydrochloride (DRUG); Placebo (OTHER),123631,IRE,Non Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14334,NCT00098462,Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer,WITHDRAWN,PHASE1,Lung Cancer,gefitinib (DRUG); sirolimus (DRUG),123631,IRE,Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14335,NCT00062062,Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,carboplatin (DRUG); gefitinib (DRUG); paclitaxel (DRUG),123631,IRE,Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14336,NCT03374280,Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,pemetrexed/cisplatin intercalating gefitinib (DRUG); pemetrexed/cisplatin (DRUG),123631,IRE,Non Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14337,NCT01871480,CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer,TERMINATED,PHASE2,Non-Small Cell Lung Cancer,Group A:cytokine-induced killer cell +gefitinib (DRUG); Group B:Gefitinib (DRUG),123631,IRE,Advanced Non-Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14338,NCT03170180,Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer,COMPLETED,PHASE2,Stomach Neoplasms,Sunitinib (DRUG); Gefitinib (DRUG); Imatinib (DRUG),123631,IRE,Stomach Neoplasms,Esophagus/Stomach,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14339,NCT02906163,First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy,UNKNOWN,PHASE1,EGFR Mutation Positive Non Small Cell Lung Cancer,"Thymalfasin (Thymosin alpha 1, Ta1) (DRUG); SoC (tyrosine kinase inhibitor) (DRUG)",123631,IRE,EGFR Mutation Positive Non Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14340,NCT01580735,ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer,COMPLETED,PHASE2,Non-small-cell Lung Cancer,ARQ 197 (DRUG),123631,IRE,Non-small-cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14341,NCT00255463,Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study,COMPLETED,PHASE2,Breast Cancer,Anastrazole (DRUG); Gefitinib (DRUG),123631,IRE,Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14342,NCT00234416,IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer,COMPLETED,PHASE1,Pancreatic Cancer,Gefitinib (DRUG); Gemcitabine (DRUG),123631,IRE,Pancreatic Cancer,Pancreas,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14343,NCT00030524,ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,gefitinib (DRUG),123631,IRE,Colorectal Cancer,Bowel,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14344,NCT01570296,"A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR",COMPLETED,PHASE1,Non-Small Cell Lung Cancer; Solid Tumors,Gefitinib and BKM120 (DRUG),123631,IRE,Non-Small Cell Lung Cancer; Solid Tumors,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14345,NCT02759835,"Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib",COMPLETED,PHASE2,Lung Adenocarcinoma; Lung Neoplasms,osimertinib (DRUG); Local Ablative Therapy (LAT) (OTHER),123631,IRE,Lung Neoplasms,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14346,NCT00189358,"A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy",COMPLETED,PHASE2,Ovarian Cancer; Cancer of the Fallopian Tube; Peritoneal Cancer,ZD1839 (DRUG); tamoxifen (DRUG),123631,IRE,Ovarian Cancer; Cancer of the Fallopian Tube; Peritoneal Cancer,Ovary/Fallopian Tube,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14347,NCT01466660,LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung,COMPLETED,PHASE2,Lung Neoplasms,Afatinib (DRUG); gefitinib (DRUG),123631,IRE,Lung Neoplasms,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14348,NCT01928160,Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib,WITHDRAWN,PHASE2,Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,pemetrexed disodium (DRUG); carboplatin (DRUG); cisplatin (DRUG); erlotinib hydrochloride (DRUG); laboratory biomarker analysis (OTHER),123631,IRE,Non-small-cell Lung Carcinoma,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14349,NCT00247481,ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Gefitinib (DRUG); Docetaxel (DRUG),123631,IRE,Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14350,NCT00787410,"An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma",COMPLETED,PHASE2,Mesothelioma,ZD1839 (DRUG),123631,IRE,Mesothelioma,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14351,NCT00955695,Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer,UNKNOWN,PHASE3,Lung Cancer,erlotinib hydrochloride (DRUG); gefitinib (DRUG); questionnaire administration (OTHER); quality-of-life assessment (PROCEDURE); whole-brain radiation therapy (RADIATION),123631,IRE,Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14352,NCT00080340,Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,COMPLETED,PHASE3,Non Small Cell Lung Carcinoma,TLK286 (Telcyta) HCl for Injection (DRUG); gefitinib (Iressa) (DRUG),123631,IRE,Non Small Cell Lung Carcinoma,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14353,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,75 approved agents (DRUG); COXEN (OTHER),123631,IRE,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,Bladder/Urinary Tract,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14354,NCT01833572,Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001),COMPLETED,PHASE2,Non-small-cell Lung Cancer,Gefitinib (DRUG),123631,IRE,Non-small-cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14355,NCT00317772,"Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer",COMPLETED,PHASE1,Ovarian Cancer; Peritoneal Neoplasms; Fallopian Tube Cancer,Topotecan (DRUG); Gefitinib (DRUG),123631,IRE,Ovarian Cancer; Peritoneal Neoplasms; Fallopian Tube Cancer,Ovary/Fallopian Tube,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14356,NCT03653546,First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients with Central Nervous System (CNS) Metastases,COMPLETED,PHASE2,Non-small Cell Lung Cancer; EGFR Gene Mutation; Brain Metastases,AZD3759 (DRUG); Erlotinib (DRUG); Gefitinib (DRUG),123631,IRE,Non-small Cell Lung Cancer; EGFR Gene Mutation; Brain Metastases,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14357,NCT00052169,Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer,COMPLETED,PHASE2,Breast Neoplasms,ZD1839 in combination with docetaxel (DRUG),123631,IRE,Breast Neoplasms,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14358,NCT02031601,Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer,UNKNOWN,PHASE4,Non-Small-Cell Lung Cancer,Erlotinib (DRUG); Gefitinib (DRUG); Icotinib (DRUG); Docetaxel (DRUG); Pemetrexed (DRUG); Platinum (cisplatin or carboplatin) (DRUG); Erlotinib (DRUG); Gefitinib (DRUG); Icotinib (DRUG),123631,IRE,Non-Small-Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14359,NCT01167244,Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response,COMPLETED,PHASE2,Non-Small-Cell Lung Carcinoma,BMS-690514 (DRUG),123631,IRE,Non-Small-Cell Lung Carcinoma,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14360,NCT00206492,Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients,TERMINATED,PHASE2,Breast Cancer,Iressa (DRUG); Tamoxifen (DRUG),123631,IRE,Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14361,NCT03787992,Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）,ACTIVE_NOT_RECRUITING,PHASE3,Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer,Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo (DRUG); Placebo Gefitinib 250 mg (DRUG); Gefitinib 250 mg (DRUG); Placebo AST2818 80mg//40 mg (DRUG),123631,IRE,Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14362,NCT00615758,Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV,COMPLETED,PHASE2,Non Small Cell Lung Cancer,Erlotinib (DRUG),123631,IRE,Non Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14363,NCT00132158,ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors,COMPLETED,PHASE1,Glioblastoma; Rhabdomyosarcomas; Neuroblastoma; Osteosarcoma,"Irinotecan (Camptosar), Gefitinib (Iressa) (DRUG)",123631,IRE,Glioblastoma; Rhabdomyosarcomas; Neuroblastoma; Osteosarcoma,CNS/Brain,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14364,NCT00014144,"S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract",COMPLETED,PHASE2,Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer,gefitinib (DRUG),123631,IRE,Urinary Tract Cancers,Bladder/Urinary Tract,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14365,NCT03002844,EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism,UNKNOWN,PHASE2,Nonsmall Cell Lung Cancer; EGFR Gene Mutation,EGFR-TK Inhibitor (DRUG); EGFR-TKI (DRUG); EGFR-TKI and Chemotherapy (DRUG),123631,IRE,Nonsmall Cell Lung Cancer; EGFR Gene Mutation,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14366,NCT00290719,"Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery",TERMINATED,PHASE1,Esophageal Cancer,cisplatin (DRUG); gefitinib (DRUG); irinotecan hydrochloride (DRUG); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE); radiation therapy (RADIATION),123631,IRE,Esophageal Cancer,Esophagus/Stomach,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14367,NCT00428896,A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer,COMPLETED,PHASE2,Breast Cancer,ZD1839 (DRUG),123631,IRE,Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14368,NCT01951469,Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer,UNKNOWN,PHASE3,Non-small Cell Lung Cancer; Brain Metastases; EGFR Mutation,Gefitinib and Pemetrexed/platinum (DRUG); Gefitinib mono-therapy (DRUG),123631,IRE,Non-small Cell Lung Cancer; Brain Metastases; EGFR Mutation,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14369,NCT01749072,Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients,UNKNOWN,PHASE2,Non-small Cell Lung Cancer; Effects of Chemotherapy,"Gefitinib group (DRUG); Vinorelbine, Ifosfamide, Mesna (DRUG)",123631,IRE,Non-small Cell Lung Cancer; Effects of Chemotherapy,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14370,NCT00999804,Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer,Lapatinib (DRUG); Letrozole (DRUG); Trastuzumab (DRUG),123631,IRE,Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14371,NCT01000740,A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa,COMPLETED,PHASE4,Non-small Cell Lung Cancer,EGFR Mutation Test (GENETIC); Ki-67 protein expression (GENETIC),123631,IRE,Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14372,NCT00268346,Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer,COMPLETED,PHASE2,Esophageal Cancer,ZD1839 (DRUG),123631,IRE,Esophageal Cancer,Esophagus/Stomach,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14373,NCT00570401,Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib,COMPLETED,PHASE2,Lung Cancer,dasatinib (DRUG),123631,IRE,Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14374,NCT00082667,Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast,TERMINATED,PHASE2,Breast Cancer,gefitinib (DRUG); Surgery (PROCEDURE),123631,IRE,Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14375,NCT00824746,Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Gefitinib retreatment (DRUG),123631,IRE,"Carcinoma, Non-Small-Cell Lung",Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14376,NCT02088112,MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).,COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung",Gefitinib (DRUG); MEDI4736 (DRUG),123631,IRE,"Carcinoma, Non-Small-Cell Lung",Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14377,NCT03849768,A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients,UNKNOWN,PHASE3,Non Small Cell Lung Cancer,HS-10296 (DRUG); Gefitinib (DRUG),123631,IRE,Non Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14378,NCT03486496,Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation,UNKNOWN,PHASE2,Lung Adenocarcinoma; EGFR Mutation,gefitinib (DRUG); Berberine (DRUG),123631,IRE,Lung Adenocarcinoma; EGFR Mutation,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14379,NCT01854034,Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR,COMPLETED,PHASE2,Non Small Cell Lung Cancer,AUY922 (DRUG),123631,IRE,Non Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14380,NCT01196234,Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer,COMPLETED,PHASE2,Non Small Cell Lung Cancer,Paclitaxel/Carboplatin/Gefitinib (DRUG); Paclitaxel/Carboplatin (DRUG),123631,IRE,Non Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14381,NCT00087334,"Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer",TERMINATED,PHASE1,Colorectal Cancer,capecitabine (DRUG); gefitinib (DRUG); oxaliplatin (DRUG),123631,IRE,Colorectal Cancer,Bowel,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14382,NCT01480141,A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC),WITHDRAWN,PHASE2,Lung Cancer,BIBW 2992 (Afatinib) (DRUG),123631,IRE,Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14383,NCT03119519,Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer.,UNKNOWN,PHASE2,Stage IV Non-small Cell Lung Cancer,Local Definitive Radiotherapy (RADIATION); No Local Definitive Radiotherapy (DRUG),123631,IRE,Stage IV Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14384,NCT02025218,Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients,TERMINATED,PHASE2,Lung Cancer,Gefitinib standard dose (DRUG),123631,IRE,Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14385,NCT00057941,Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer,COMPLETED,PHASE2,Estrogen Receptor-positive Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer,anastrozole (DRUG); gefitinib (DRUG); fulvestrant (DRUG); laboratory biomarker analysis (OTHER),123631,IRE,Estrogen Receptor-positive Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14386,NCT00206219,Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX),COMPLETED,PHASE3,Squamous Cell Carcinoma of the Head and Neck,Gefitinib (DRUG); methotrexate (DRUG),123631,IRE,Squamous Cell Carcinoma of the Head and Neck,Skin,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14387,NCT00319618,Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer,Gefitinib (DRUG); Docetaxel (DRUG),123631,IRE,Metastatic Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14388,NCT00258323,"Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer",COMPLETED,PHASE2,Esophageal Cancer,cisplatin (DRUG); fluorouracil (DRUG); Iressa (DRUG); conventional surgery (PROCEDURE); radiation therapy (RADIATION),123631,IRE,Esophageal Cancer,Esophagus/Stomach,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14389,NCT02954523,Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations,TERMINATED,PHASE1,EGFR Gene Mutation; Nonsmall Cell Lung Cancer,Dasatinib (DRUG); Osimertinib (DRUG),123631,IRE,EGFR Gene Mutation; Nonsmall Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14390,NCT00268255,Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer,WITHDRAWN,PHASE1,Non-small Cell Lung Cancer,gefitinib (DRUG); adjuvant therapy (PROCEDURE); enzyme inhibitor therapy (PROCEDURE); neoadjuvant therapy (PROCEDURE); protein tyrosine kinase inhibitor therapy (PROCEDURE); radiation therapy (PROCEDURE); radiosensitization (PROCEDURE),123631,IRE,Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14391,NCT00025350,Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,gefitinib (DRUG),123631,IRE,Colorectal Cancer,Bowel,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14392,NCT02714010,EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC,UNKNOWN,PHASE3,Non-Small Cell Lung Cancer,EGFR-TKI (DRUG); whole brain radiotherapy (RADIATION),123631,IRE,Advanced Non-Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14393,NCT02876081,"Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex",WITHDRAWN,PHASE2,SMALL CELL LUNG CARCINOMA,Afatinib (DRUG),123631,IRE,SMALL CELL LUNG CARCINOMA,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14394,NCT00497250,Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy,UNKNOWN,PHASE1,"Carcinoma, Non-Small-Cell Lung",Gefitinib (DRUG); Radiation Therapy (DEVICE),123631,IRE,"Carcinoma, Non-Small-Cell Lung",Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14395,NCT00233623,"Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer",WITHDRAWN,PHASE2,Metastatic Colorectal Cancer,Iressa (Gefitinib) (DRUG); Irinotecan (DRUG); 5Fluorouracil (DRUG); Leucovorin (DRUG),123631,IRE,Metastatic Colorectal Cancer,Bowel,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14396,NCT00052208,Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme,COMPLETED,PHASE1,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma,gefitinib (DRUG); radiation therapy (RADIATION); laboratory biomarker analysis (OTHER),123631,IRE,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma,CNS/Brain,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14397,NCT01291823,Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer,UNKNOWN,PHASE2,Esophageal Cancer,gefitinib (DRUG); Thoracic radiotherapy (RADIATION),123631,IRE,Esophageal Cancer,Esophagus/Stomach,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14398,NCT00206414,"Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer",TERMINATED,PHASE2,BREAST CANCER,Iressa Day 1 given with Arimidex and Faslodex (DRUG); Iressa Day 21 given with Arimidex and Faslodex (DRUG),123631,IRE,BREAST CANCER,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14399,NCT01982955,Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT),COMPLETED,PHASE1,Non-small Cell Lung Cancer,Tepotinib (DRUG); Gefitinib (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG); Carboplatin (DRUG),123631,IRE,Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14400,NCT00126555,Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer,COMPLETED,PHASE2,Recurrent Skin Cancer; Squamous Cell Carcinoma of the Skin,Gefitinib (DRUG); Radiotherapy (RADIATION); Conventional surgery (PROCEDURE); laboratory biomarker analysis (OTHER),123631,IRE,Recurrent Skin Cancer; Squamous Cell Carcinoma of the Skin,Skin,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14401,NCT01967095,Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer,COMPLETED,PHASE1,EGFR-Mutant Lung Cancer,erlotinib (DRUG),123631,IRE,EGFR-Mutant Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14402,NCT01310855,Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma,TERMINATED,PHASE2,Glioblastoma,cediranib maleate (DRUG); gefitinib (DRUG); Placebo (DRUG),123631,IRE,Glioblastoma,CNS/Brain,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14403,NCT02025114,Selumetinib in Combination With Gefitinib in NSCLC Patients,COMPLETED,PHASE1,Non-small Cell Lung Cancer (NSCLC),selumetinib (DRUG),123631,IRE,Non-small Cell Lung Cancer (NSCLC),Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14404,NCT01755923,Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,Gefitinib (DRUG); Docetaxel (DRUG),123631,IRE,Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14405,NCT00632723,IRESSA™ (Gefitinib) in Breast Cancer Patients,COMPLETED,PHASE2,Breast Cancer,"gefitinib (IRESSA™, ZD1839) (DRUG)",123631,IRE,Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14406,NCT00352079,BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer,TERMINATED,PHASE3,Bladder Cancer,BCG vaccine (BIOLOGICAL); gefitinib (DRUG); quality-of-life assessment (PROCEDURE),123631,IRE,Bladder Cancer,Bladder/Urinary Tract,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14407,NCT02040064,Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients,COMPLETED,PHASE1,Non Small Cell Lung Cancer,Gefitinib (DRUG); Tremelimumab (DRUG),123631,IRE,Non Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14408,NCT00049543,"Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery",COMPLETED,PHASE3,Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Bronchoalveolar Cell Lung Cancer; Large Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IB Non-small Cell Lung Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIB Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer,gefitinib (DRUG); placebo (OTHER); laboratory biomarker analysis (OTHER),123631,IRE,Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Bronchoalveolar Cell Lung Cancer; Large Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IB Non-small Cell Lung Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIB Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14409,NCT00215995,"Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas",COMPLETED,PHASE2,Esophageal Cancer; Gastric Cancer,Cisplatin (DRUG); Irinotecan (DRUG); ZD 1839 (DRUG),123631,IRE,Esophageal and Gastric Cancer,Esophagus/Stomach,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14410,NCT01066195,Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy,UNKNOWN,PHASE3,Non-small Cell Lung Cancer,iressa (DRUG); alimta (DRUG),123631,IRE,Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14411,NCT01085136,LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib,COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung",Investigator´s choice of chemotherapy (DRUG); BIBW 2992 (DRUG),123631,IRE,"Carcinoma, Non-Small-Cell Lung",Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14412,NCT00006049,ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer,UNKNOWN,PHASE3,Lung Cancer,carboplatin (DRUG); gefitinib (DRUG); paclitaxel (DRUG),123631,IRE,Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14413,NCT01784549,Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine (DRUG),123631,IRE,Non Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14414,NCT00033449,Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer,TERMINATED,PHASE1,Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Oropharynx,gefitinib (DRUG); radiation therapy (RADIATION); cisplatin (DRUG); laboratory biomarker analysis (OTHER),123631,IRE,Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Oropharynx,Skin,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14415,NCT00656136,BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1),COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung",placebo (DRUG); BIBW 2992 (DRUG),123631,IRE,"Carcinoma, Non-Small-Cell Lung",Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14416,NCT01610336,"A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment",COMPLETED,PHASE2,Non-small Cell Lung Cancer,INC280 (DRUG); Gefitinib (DRUG),123631,IRE,Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14417,NCT00616499,Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer,UNKNOWN,PHASE2,Lung Cancer,gefitinib (DRUG); neoadjuvant therapy (PROCEDURE); therapeutic conventional surgery (PROCEDURE),123631,IRE,Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14418,NCT01997775,Metformin in Stage IV Lung Adenocarcinoma,TERMINATED,PHASE2,Non-small Cell Lung Cancer,METFORMIN (DRUG),123631,IRE,Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14419,NCT00090675,"Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer",WITHDRAWN,PHASE3,Non-Small-Cell Lung Carcinoma,ZD1839 (DRUG),123631,IRE,Non-Small-Cell Lung Carcinoma,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14420,NCT00173875,Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Iressa (DRUG),123631,IRE,Advanced Non-Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14421,NCT01158170,Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001),UNKNOWN,PHASE3,Non-small Cell Lung Cancer,Prophylactic cranial irradiation (RADIATION); Erlotinib /Gefitinib (DRUG),123631,IRE,Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14422,NCT00062270,Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer,cisplatin (DRUG); docetaxel (DRUG); gefitinib (DRUG); gemcitabine hydrochloride (DRUG); conventional surgery (PROCEDURE); neoadjuvant therapy (PROCEDURE); radiation therapy (RADIATION),123631,IRE,Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14423,NCT00409006,Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers,COMPLETED,PHASE2,Non-small Cell Lung Cancer,Pemetrexed (DRUG); Cisplatin (DRUG); Gefitinib (DRUG),123631,IRE,Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14424,NCT00234442,Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer,TERMINATED,PHASE2,Brain Neoplasms; Non Small Cell Lung Cancer,Iressa (Gefitinib) (DRUG),123631,IRE,Brain Neoplasms; Non Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14425,NCT00023699,Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer,COMPLETED,PHASE2,Ovarian Cancer; Primary Peritoneal Cavity Cancer,gefitinib (DRUG),123631,IRE,Ovarian Cancer,Ovary/Fallopian Tube,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14426,NCT00026299,Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,ZD1839 (DRUG); oxaliplatin (DRUG),123631,IRE,Colorectal Cancer,Bowel,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14427,NCT00005806,Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer,carboplatin (DRUG); gefitinib (DRUG); paclitaxel (DRUG),123631,IRE,Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14428,NCT00993499,Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib,COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung",BIBW 2992 (DRUG); Sirolimus (rapamycin) (DRUG),123631,IRE,"Carcinoma, Non-Small-Cell Lung",Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14429,NCT03123484,β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,"β-elemene (DRUG); EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) (DRUG)",123631,IRE,Non Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14430,NCT01017679,Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg,COMPLETED,PHASE2,Non-small Cell Lung Cancer,Gefitinib 500mg/Gefitinib 250mg (DRUG),123631,IRE,Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14431,NCT02139579,Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer,UNKNOWN,PHASE2,"Lung, Carcinoma",Bevacizumab (DRUG),123631,IRE,Lung Carcinoma,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14432,NCT02882984,Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid),UNKNOWN,PHASE3,Stage IV EGFR Mutated NSCL With Brain Metastases,Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib (DRUG); WBRT (RADIATION); HFSRS (RADIATION),123631,IRE,Stage IV EGFR Mutated NSCL With Brain Metastases,CNS/Brain,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14433,NCT01502202,Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers,UNKNOWN,PHASE2,Non Small Cell Lung Cancer; Adenocarcinoma,Gefitinib (DRUG); Placebo (DRUG); Pemetrexed plusCIsplatin (DRUG),123631,IRE,Non Small Cell Lung Cancer; Adenocarcinoma,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14434,NCT01774721,ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.,COMPLETED,PHASE3,Non-small Cell Lung Cancer With EGFR-Activating Mutations,Dacomitinib (PF-00299804) (DRUG); Gefitinib (DRUG),123631,IRE,Non-small Cell Lung Cancer With EGFR-Activating Mutations,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14435,NCT02518802,Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma,UNKNOWN,PHASE3,Lung Neoplasms,Gefitinib (DRUG); Pemetrexed (DRUG),123631,IRE,Lung Neoplasms,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14436,NCT02151721,Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer,UNKNOWN,PHASE1,Non-Small-Cell Lung Carcinoma,"Vorinostat, gefitinib (DRUG)",123631,IRE,Non-Small-Cell Lung Carcinoma,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14437,NCT00026364,"ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer",COMPLETED,PHASE1,Colorectal Cancer,fluorouracil (DRUG); gefitinib (DRUG); irinotecan hydrochloride (DRUG); leucovorin calcium (DRUG),123631,IRE,Colorectal Cancer,Bowel,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14438,NCT00986284,Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC),SUSPENDED,PHASE2,Non Small Cell Lung Cancer,gefitinib (DRUG),123631,IRE,Non Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14439,NCT03529084,Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations,WITHDRAWN,PHASE3,"Carcinoma, Non-small Cell Lung",EFG816 (DRUG); erlotinib or gefitinib (DRUG),123631,IRE,"Carcinoma, Non-small Cell Lung",Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14440,NCT01955421,Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc,UNKNOWN,PHASE2,Advanced Stage Non Small Cell Lung Cancer,Erlotinib 100mg qd (DRUG); Gefitinib 250mg qd (DRUG),123631,IRE,Advanced Stage Non Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14441,NCT01544179,A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone,COMPLETED,PHASE3,Non-Small Cell Lung Cancer,Gefitinib (DRUG); Placebo (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG),123631,IRE,Advanced Non-Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14442,NCT01192243,Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients,UNKNOWN,PHASE2,Toxicity; Non-small Cell Lung Cancer,Gefitinib (DRUG); Pemetrexed (DRUG); Cisplatin or carboplatin (DRUG),123631,IRE,Toxicity; Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14443,NCT00239343,Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer,COMPLETED,PHASE2,Breast Cancer,gefitinib (DRUG),123631,IRE,Breast Cancer,Breast,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14444,NCT03333343,Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC,ACTIVE_NOT_RECRUITING,PHASE1,EGFR-mutant Non-small Cell Lung Cancer,EGF816 (DRUG); trametinib (DRUG); ribociclib (DRUG); LXH254 (DRUG); INC280 (DRUG); gefitinib (DRUG),123631,IRE,EGFR-mutant Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14445,NCT00029003,Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Bronchoalveolar Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,gefitinib (DRUG); laboratory biomarker analysis (OTHER),123631,IRE,Bronchoalveolar Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14446,NCT01405079,Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation,UNKNOWN,PHASE3,Non-small Cell Lung Cancer,Gefitinib (DRUG); Vinorelbine+Cisplatin (DRUG),123631,IRE,Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14447,NCT00891579,Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations,COMPLETED,PHASE2,Non Small Cell Lung Cancer,Pemetrexed (Alimta) (DRUG); Gefitinib (IRESSA) (DRUG),123631,IRE,Non Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14448,NCT01039948,A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer,COMPLETED,PHASE1,"Carcinoma, Non-Small Cell-Lung; Lung Neoplasms; Lung Cancer; Respiratory Tract Neoplasms",AV-299 + gefitinib (BIOLOGICAL); Gefitinib (DRUG),123631,IRE,"Carcinoma, Non-Small Cell-Lung; Lung Neoplasms; Lung Cancer; Respiratory Tract Neoplasms",Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14449,NCT01121575,A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer,COMPLETED,PHASE1,Non Small Cell Lung Cancer,PF-02341066 (DRUG); PF-00299804 (DRUG); PF-02341066 (DRUG); PF-00299804 (DRUG),123631,IRE,Non Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14450,NCT04401059,Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study,RECRUITING,PHASE4,Carcinoma; Non-Small-Cell Lung Cancer; Adenocarcinoma,Elemene plus first or third generation EGFR-TKIs (DRUG); First or third generation EGFR-TKIs (DRUG),123631,IRE,Carcinoma; Non-Small-Cell Lung Cancer; Adenocarcinoma,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14451,NCT00025675,Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors,COMPLETED,PHASE2,Brain and Central Nervous System Tumors,gefitinib (DRUG),123631,IRE,Brain and Central Nervous System Tumors,CNS/Brain,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14452,NCT03768375,Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma,UNKNOWN,PHASE2,Cholangiocarcinoma of the Extrahepatic Bile Duct; Gallbladder Cancer,conventional chemotherapy(FORFIRINOX) combined with target agents (BIOLOGICAL); conventional chemotherapy(FORFIRINOX) (BIOLOGICAL),123631,IRE,Biliary Tract Cancers,Liver,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14453,NCT03122717,Osimertinib and Gefitinib in EGFR Inhibitor Naïve Advanced EGFR Mutant Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Non-Small Cell Lung Cancer,Gefitinib (DRUG); Osimertinib (DRUG),123631,IRE,Advanced Non-Small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14454,NCT01783834,Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients,COMPLETED,PHASE2,Previous Treated Metastatic Non-small Cell Lung Cancer,Gefitinib (DRUG); Pemetrexed (DRUG),123631,IRE,Previous Treated Metastatic Non-small Cell Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14455,NCT01530334,Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment,COMPLETED,PHASE2,Lung Cancer,Gefitinib 250mg (DRUG),123631,IRE,Lung Cancer,Lung,Gefitinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer.,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,1.02,170.0 +14456,NCT01772732,"Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC",UNKNOWN,PHASE1,Non-small Cell Lung Cancer,Simotinib Hydrochloride (DRUG),16735117,Simotinib,Non-small Cell Lung Cancer,Lung,Simotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,no,yes,"Investigated in trials, but not approved for human use.",COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCN4CC5(CC5)C6(C4)OCCO6,, +14457,NCT03451760,Feru-guard for Behavioral Symptoms in Dementia,UNKNOWN,PHASE2,Behavioral and Psychiatric Symptoms of Dementia,Feru-guard 100M (DRUG); Feru-guard 100M Placebo (OTHER),445858,Ferulicacid,Behavioral and Psychiatric Symptoms of Dementia,CNS/Brain,Ferulic acid,"FGFR1, FGFR2",inhibitor/antagonist,Other TK inhibitor,no,yes,Used in skincare; not an FDA-approved drug.,COC1=C(C=CC(=C1)C=CC(=O)O)O,1.0,160.0 +14458,NCT05736224,Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen,COMPLETED,PHASE1,Skin Cancer,Sunscreen (DRUG); UV Light (OTHER),445858,Ferulicacid,Skin Cancer,Skin,Ferulic acid,"FGFR1, FGFR2",inhibitor/antagonist,Other TK inhibitor,no,yes,Used in skincare; not an FDA-approved drug.,COC1=C(C=CC(=C1)C=CC(=O)O)O,1.0,160.0 +14459,NCT06170346,Effect of Topical Agents With Various Antioxidant Containts on Photodamage Skin Induced,COMPLETED,PHASE2,Photodamaged Skin,Antioxidants (COMBINATION_PRODUCT); Vehicle (COMBINATION_PRODUCT),445858,Ferulicacid,Photodamaged Skin,Skin,Ferulic acid,"FGFR1, FGFR2",inhibitor/antagonist,Other TK inhibitor,no,yes,Used in skincare; not an FDA-approved drug.,COC1=C(C=CC(=C1)C=CC(=O)O)O,1.0,160.0 +14460,NCT05670912,Efficacy and Safety of Wei Li Bai Capsules in the Treatment of Alzheimer's Disease,TERMINATED,PHASE2,Alzheimer Disease,Wei Li Bai capsules (DRUG); Placebo Comparator of Wei Li Bai capsules (DRUG),445858,Ferulicacid,Alzheimer Disease,CNS/Brain,Ferulic acid,"FGFR1, FGFR2",inhibitor/antagonist,Other TK inhibitor,no,yes,Used in skincare; not an FDA-approved drug.,COC1=C(C=CC(=C1)C=CC(=O)O)O,1.0,160.0 +14461,NCT03099564,Pembrolizumab Plus Y90 Radioembolization in HCC Subjects,UNKNOWN,EARLY_PHASE1,Hepatocellular Carcinoma,Pembrolizumab (DRUG); Y90 radioembolization (DEVICE),2179,ASW,Hepatocellular Carcinoma,Liver,Amsacrine,TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in the treatment of acute leukemias.,COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42,1.0,431.0 +14462,NCT06158139,Autologous CAR-T Cells Targeting B7-H3 in PDAC,RECRUITING,PHASE1,Pancreas Cancer; Relapse; Resistant Cancer,iC9-CAR.B7-H3 T cell infusion (BIOLOGICAL),2179,ASW,Pancreas Cancer; Relapse; Resistant Cancer,Pancreas,Amsacrine,TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in the treatment of acute leukemias.,COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42,1.0,431.0 +14463,NCT03783936,Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas,COMPLETED,PHASE2,Gastric Adenocarcinoma; Esophageal Adenocarcinoma; Metastasis; HER-2 Gene Amplification,Oxaliplatin (DRUG); Leucovorin (DRUG); 5 fluorouracil (DRUG); Trastuzumab (DRUG); Avelumab (DRUG),2179,ASW,Gastric Adenocarcinoma; Esophageal Adenocarcinoma; Metastasis; HER-2 Gene Amplification,Esophagus/Stomach,Amsacrine,TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in the treatment of acute leukemias.,COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42,1.0,431.0 +14464,NCT06483555,"Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel",RECRUITING,PHASE1,Pancreatic Adenocarcinoma; Metastatic Pancreatic Cancer; Basal Cell Neoplasm,Gemcitabine (DRUG); Nab paclitaxel (DRUG); Erlotinib (DRUG); NALIRIFOX (DRUG); Folfirinox (DRUG),2179,ASW,Pancreatic Adenocarcinoma; Metastatic Pancreatic Cancer; Basal Cell Neoplasm,Pancreas,Amsacrine,TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in the treatment of acute leukemias.,COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42,1.0,431.0 +14465,NCT04772885,A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS),COMPLETED,PHASE1,Healthy Volunteer; Atopic Dermatitis; Hidradenitis Suppurativa,KT-474/Placebo (DRUG); KT-474 (DRUG),2179,ASW,Healthy Volunteer; Atopic Dermatitis; Hidradenitis Suppurativa,Skin,Amsacrine,TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in the treatment of acute leukemias.,COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42,1.0,431.0 +14466,NCT00610909,Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS),COMPLETED,PHASE4,Irritable Bowel Syndrome,Paroxetine CR (DRUG); Placebo (DRUG),2179,ASW,Irritable Bowel Syndrome,Bowel,Amsacrine,TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in the treatment of acute leukemias.,COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42,1.0,431.0 +14467,NCT03977233,Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer,RECRUITING,PHASE2,"Pancreatic Ductal Adenocarcinoma (PDAC); Cancer of Pancreas; Pancreatic Cancer, Adult; Pancreas Adenocarcinoma; Pancreatic Neoplasms; Pancreatic Cancer Non-resectable; Pancreatic Cancer Resectable",Oxaliplatin (DRUG); Leucovorin (DRUG); Irinotecan Hydrochloride (DRUG); 5-FU (DRUG),2179,ASW,"Pancreatic Ductal Adenocarcinoma (PDAC); Cancer of Pancreas; Pancreatic Cancer, Adult; Pancreas Adenocarcinoma; Pancreatic Neoplasms; Pancreatic Cancer Non-resectable; Pancreatic Cancer Resectable",Pancreas,Amsacrine,TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in the treatment of acute leukemias.,COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42,1.0,431.0 +14468,NCT06453213,Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy,RECRUITING,PHASE4,Focal Onset Seizure,Cenobamate (DRUG),2179,ASW,Focal Onset Seizure,CNS/Brain,Amsacrine,TOP2A,inhibitor/antagonist,DNA synthesis/repair inhibitor,yes,yes,Used in the treatment of acute leukemias.,COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42,1.0,431.0 +14469,NCT01874145,Safety and Tolerability of Glatiramer Acetate,COMPLETED,PHASE3,Relapsing-Remitting Multiple Sclerosis,GA 20 mg/mL (DRUG); GA 40 mg/mL (DRUG),155074,D78345,Relapsing-Remitting Multiple Sclerosis,CNS/Brain,Berberine (chloride hydrate),,unclear,unclear,no,yes,"Used in trials for metabolic/heart diseases, not FDA-approved.",COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC.O.[Cl-],1.0,50.0 +14470,NCT04828486,"Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Advanced Hepatocellular Carcinoma; BCLC Stage A Hepatocellular Carcinoma; BCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma,Futibatinib (DRUG); Pembrolizumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER),71621331,Lytgobi,Advanced Hepatocellular Carcinoma; BCLC Stage A Hepatocellular Carcinoma; BCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma,Liver,Futibatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for cholangiocarcinoma; FDA approved.,COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC,1.088235294117647,538.0 +14471,NCT06263153,Futibatinib in Combination with Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy,RECRUITING,PHASE2,Bladder Urothelial Carcinoma; Muscle Invasive Bladder Carcinoma; Stage II Bladder Cancer AJCC V8; Stage IIIA Bladder Cancer AJCC V8,Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Durvalumab (BIOLOGICAL); Futibatinib (DRUG); Magnetic Resonance Imaging (PROCEDURE); Radical Cystectomy (PROCEDURE),71621331,Lytgobi,Bladder Urothelial Carcinoma; Muscle Invasive Bladder Carcinoma; Stage II Bladder Cancer AJCC V8; Stage IIIA Bladder Cancer AJCC V8,Bladder/Urinary Tract,Futibatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for cholangiocarcinoma; FDA approved.,COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC,1.088235294117647,538.0 +14472,NCT05727176,Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement,RECRUITING,PHASE2,Advanced Cholangiocarcinoma; FGFR2 Fusions; Gene Rearrangement,TAS-120 (DRUG),71621331,Lytgobi,Advanced Cholangiocarcinoma; FGFR2 Fusions; Gene Rearrangement,Liver,Futibatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for cholangiocarcinoma; FDA approved.,COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC,1.088235294117647,538.0 +14473,NCT04093362,Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements,TERMINATED,PHASE3,Advanced Cholangiocarcinoma; FGFR2 Gene Rearrangements,Futibatinib (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG),71621331,Lytgobi,Advanced Cholangiocarcinoma; FGFR2 Gene Rearrangements,Liver,Futibatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for cholangiocarcinoma; FDA approved.,COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC,1.088235294117647,538.0 +14474,NCT04965818,Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer,TERMINATED,PHASE1,Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations; Non-Small Cell Lung Cancer; KRAS Gene Mutation,Futibatinib and Binimetinib (DRUG),71621331,Lytgobi,Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations; Non-Small Cell Lung Cancer; KRAS Gene Mutation,Lung,Futibatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for cholangiocarcinoma; FDA approved.,COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC,1.088235294117647,538.0 +14475,NCT05945823,Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE2,Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Esophageal Adenocarcinoma; Esophageal Squamous Cell Cancer; Siewert Type 1 GEJ Cancer; Pancreatic Cancer,Futibatinib (DRUG); Pembrolizumab (DRUG); Cisplatin (DRUG); 5-FU (DRUG); Oxaliplatin (DRUG); Leucovorin (DRUG); Levoleucovorin (DRUG); Irinotecan (DRUG),71621331,Lytgobi,Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Esophageal Adenocarcinoma; Esophageal Squamous Cell Cancer; Siewert Type 1 GEJ Cancer; Pancreatic Cancer,Esophagus/Stomach,Futibatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for cholangiocarcinoma; FDA approved.,COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC,1.088235294117647,538.0 +14476,NCT04024436,A Study of TAS-120 in Patients With Metastatic Breast Cancer,COMPLETED,PHASE2,Metastatic Breast Cancer; FGFR 1 High Amplification; FGFR2 Amplification,Futibatinib (DRUG); Futibatinib plus Fulvestrant (DRUG),71621331,Lytgobi,Metastatic Breast Cancer; FGFR 1 High Amplification; FGFR2 Amplification,Breast,Futibatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for cholangiocarcinoma; FDA approved.,COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC,1.088235294117647,538.0 +14477,NCT04601857,Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma,ACTIVE_NOT_RECRUITING,PHASE2,Advanced and Metastatic Urothelial Cancer,futibatinib and pembrolizumab (KEYTRUDA®)) (DRUG),71621331,Lytgobi,Advanced and Metastatic Urothelial Cancer,Bladder/Urinary Tract,Futibatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for cholangiocarcinoma; FDA approved.,COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC,1.088235294117647,538.0 +14478,NCT05508737,Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Gastric and Gastroesophageal Junction Adenocarcinoma,"Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®) (DRUG)",71621331,Lytgobi,Gastric and Gastroesophageal Junction Adenocarcinoma,Esophagus/Stomach,Futibatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for cholangiocarcinoma; FDA approved.,COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC,1.088235294117647,538.0 +14479,NCT04999761,AB122 Platform Study,RECRUITING,PHASE1,Advanced or Metastatic Solid Tumor; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Non-small Cell Lung Cancer; Gastric Cancer; Alveolar Soft Part Sarcoma; Esophageal Cancer; Head and Neck Cancer; Biliary Tract Cancer,AB122 (DRUG); AB122 (DRUG); TAS-116 (DRUG); AB122 (DRUG); TAS-116 (DRUG); AB122 (DRUG); TAS-116 (DRUG); AB122 (DRUG); TAS-120 (DRUG); AB122 (DRUG); TAS-115 (DRUG); AB122 (DRUG); TAS-115 (DRUG); AB122 (DRUG); TAS-102 (DRUG); Ramucirumab (DRUG); AB122 (DRUG); TAS-102 (DRUG); Bevacizumab (DRUG); AB122 (DRUG); AB122 (DRUG); TAS-120 (DRUG); Fluorouracil (DRUG); Cisplatin (DRUG); AB122 (DRUG); TAS-120 (DRUG); AB154 (DRUG); AB122 (DRUG); TAS-120 (DRUG); Fluorouracil (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); AB122 (DRUG); TAS-120 (DRUG); AB154 (DRUG); AB122 (DRUG); TAS-120 (DRUG); Carboplatin (DRUG); nab-Paclitaxel (DRUG); AB122 (DRUG); TAS-120 (DRUG); Cisplatin (DRUG); Gemcitabine (DRUG); AB122 (DRUG); TAS-120 (DRUG); nab-Paclitaxel (DRUG); Gemcitabine (DRUG),71621331,Lytgobi,Advanced or Metastatic Solid Tumor; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Non-small Cell Lung Cancer; Gastric Cancer; Alveolar Soft Part Sarcoma; Esophageal Cancer; Head and Neck Cancer; Biliary Tract Cancer,Bowel,Futibatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for cholangiocarcinoma; FDA approved.,COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC,1.088235294117647,538.0 +14480,NCT02052778,A Study of TAS-120 in Patients With Advanced Solid Tumors,COMPLETED,PHASE1,Cholangiocarcinoma; Urothelial Cancer; Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors; Primary CNS Tumors; Breast Cancer; Gastric Cancer,Futibatinib (DRUG),71621331,Lytgobi,Cholangiocarcinoma; Urothelial Cancer; Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors; Primary CNS Tumors; Breast Cancer; Gastric Cancer,Esophagus/Stomach,Futibatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for cholangiocarcinoma; FDA approved.,COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC,1.088235294117647,538.0 +14481,NCT03829462,Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients,ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Colorectal Cancer (mCRC),Regorafenib (DRUG); Irinotecan (DRUG),71621331,Lytgobi,Metastatic Colorectal Cancer (mCRC),Bowel,Futibatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for cholangiocarcinoma; FDA approved.,COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC,1.088235294117647,538.0 +14482,NCT03305913,Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy,COMPLETED,PHASE1,Pretreated Metastatic Colorectal Cancer,TAS 102 (DRUG); Regorafenib (DRUG),71621331,Lytgobi,Pretreated Metastatic Colorectal Cancer,Bowel,Futibatinib,"FGFR1, FGFR2, FGFR3, FGFR4",inhibitor/antagonist,Other TK inhibitor,yes,yes,Used for cholangiocarcinoma; FDA approved.,COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC,1.088235294117647,538.0 +14483,NCT03793166,"Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study",ACTIVE_NOT_RECRUITING,PHASE3,Clear Cell Renal Cell Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Lymph Nodes; Metastatic Malignant Neoplasm in the Soft Tissue; Metastatic Malignant Neoplasm in the Viscera; Rhabdoid Tumor of the Kidney; Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Cabozantinib (DRUG); Computed Tomography (PROCEDURE); Ipilimumab (BIOLOGICAL); Magnetic Resonance Imaging (PROCEDURE); Nivolumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),25102846,Cometriq,Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14484,NCT02761057,"Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed",COMPLETED,PHASE2,Locally Advanced Papillary Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma,Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Cabozantinib S-malate (DRUG); Computed Tomography (PROCEDURE); Crizotinib (DRUG); Savolitinib (DRUG); Sunitinib Malate (DRUG),25102846,Cometriq,Locally Advanced Papillary Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14485,NCT05361720,"Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study",RECRUITING,PHASE2,Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8,Cabozantinib (DRUG); Ipilimumab (BIOLOGICAL); Nivolumab (BIOLOGICAL),25102846,Cometriq,Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14486,NCT05111574,Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery,RECRUITING,PHASE2,Anal Melanoma; Bladder Melanoma; Cervical Melanoma; Esophageal Melanoma; Gallbladder Melanoma; Head and Neck Mucosal Melanoma; Mucosal Melanoma; Nasopharyngeal Mucosal Melanoma; Oral Cavity Mucosal Melanoma; Penile Mucosal Melanoma; Rectal Melanoma; Recurrent Mucosal Melanoma; Sinonasal Mucosal Melanoma; Urethral Melanoma; Urinary System Mucosal Melanoma; Vaginal Melanoma; Vulvar Melanoma,Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Cabozantinib S-malate (DRUG); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Nivolumab (BIOLOGICAL); Placebo Administration (DRUG); Positron Emission Tomography (PROCEDURE),25102846,Cometriq,Anal Melanoma; Bladder Melanoma; Cervical Melanoma; Esophageal Melanoma; Gallbladder Melanoma; Head and Neck Mucosal Melanoma; Mucosal Melanoma; Nasopharyngeal Mucosal Melanoma; Oral Cavity Mucosal Melanoma; Penile Mucosal Melanoma; Rectal Melanoma; Recurrent Mucosal Melanoma; Sinonasal Mucosal Melanoma; Urethral Melanoma; Urinary System Mucosal Melanoma; Vaginal Melanoma; Vulvar Melanoma,Skin,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14487,NCT03945773,Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors,ACTIVE_NOT_RECRUITING,PHASE2,Locally Advanced or Metastatic Renal Cell Carcinoma,Cabozantinib (DRUG),25102846,Cometriq,Locally Advanced or Metastatic Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14488,NCT05281926,"A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients",UNKNOWN,PHASE1,Hepatocellular Carcinoma,Poly ICLC (DRUG),25102846,Cometriq,Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14489,NCT06934057,Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma,NOT_YET_RECRUITING,PHASE4,Kidney Cancer; Renal Cell Cancer,Nivolumab (DRUG); Cabozantinib (DRUG),25102846,Cometriq,Kidney Cancer; Renal Cell Cancer,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14490,NCT05122546,CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Advanced Clear Cell Renal Cell Carcinoma; Advanced Papillary Renal Cell Carcinoma; Advanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Clear Cell Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma,Cabozantinib S-malate (DRUG); Clostridium butyricum CBM 588 Probiotic Strain (DRUG); Nivolumab (BIOLOGICAL),25102846,Cometriq,Advanced Clear Cell Renal Cell Carcinoma; Advanced Papillary Renal Cell Carcinoma; Advanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Clear Cell Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14491,NCT04338269,A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment,COMPLETED,PHASE3,"Carcinoma, Renal Cell",Atezolizumab (DRUG); Cabozantinib (DRUG),25102846,Cometriq,"Carcinoma, Renal Cell",Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14492,NCT04868773,Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy,ACTIVE_NOT_RECRUITING,PHASE1,Colorectal Cancer; Colorectal Carcinoma; Metastatic Cancer; CRC,Cabozantinib (DRUG); TAS-102 (DRUG),25102846,Cometriq,Colorectal Cancer; Colorectal Carcinoma; Metastatic Cancer; CRC,Bowel,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14493,NCT02036476,Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma,TERMINATED,PHASE2,Merkel Cell Carcinoma; Skin Cancer,Cabozantinib (DRUG),25102846,Cometriq,Merkel Cell Carcinoma; Skin Cancer,Skin,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14494,NCT03866382,Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors,RECRUITING,PHASE2,Bladder Adenocarcinoma; Bladder Clear Cell Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Neuroendocrine Carcinoma; Bladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Collecting Duct Carcinoma; Invasive Bladder Giant Cell Urothelial Carcinoma; Invasive Bladder Lymphoepithelioma-Like Carcinoma; Invasive Bladder Nested Urothelial Carcinoma; Invasive Bladder Plasmacytoid Urothelial Carcinoma; Invasive Bladder Sarcomatoid Urothelial Carcinoma; Invasive Bladder Urothelial Carcinoma; Kidney Medullary Carcinoma; Large Cell Neuroendocrine Carcinoma; Malignant Testicular Leydig Cell Tumor; Malignant Testicular Sertoli Cell Tumor; Metastatic Bladder Carcinoma; Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma; Metastatic Bladder Giant Cell Urothelial Carcinoma; Metastatic Bladder Large Cell Neuroendocrine Carcinoma; Metastatic Bladder Lipid-Rich Urothelial Carcinoma; Metastatic Bladder Micropapillary Urothelial Carcinoma; Metastatic Bladder Plasmacytoid Urothelial Carcinoma; Metastatic Bladder Sarcomatoid Urothelial Carcinoma; Metastatic Bladder Small Cell Neuroendocrine Carcinoma; Metastatic Bladder Squamous Cell Carcinoma; Metastatic Chromophobe Renal Cell Carcinoma; Metastatic Kidney Medullary Carcinoma; Metastatic Malignant Genitourinary System Neoplasm; Metastatic Papillary Renal Cell Carcinoma; Metastatic Penile Carcinoma; Metastatic Prostate Small Cell Neuroendocrine Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Metastatic Urethral Carcinoma; Papillary Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage IV Bladder Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Urachal Adenocarcinoma; Urethral Clear Cell Adenocarcinoma,Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Cabozantinib S-malate (DRUG); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Ipilimumab (BIOLOGICAL); Magnetic Resonance Imaging (PROCEDURE); Nivolumab (BIOLOGICAL); Positron Emission Tomography (PROCEDURE),25102846,Cometriq,Bladder Adenocarcinoma; Bladder Clear Cell Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Neuroendocrine Carcinoma; Bladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Collecting Duct Carcinoma; Invasive Bladder Giant Cell Urothelial Carcinoma; Invasive Bladder Lymphoepithelioma-Like Carcinoma; Invasive Bladder Nested Urothelial Carcinoma; Invasive Bladder Plasmacytoid Urothelial Carcinoma; Invasive Bladder Sarcomatoid Urothelial Carcinoma; Invasive Bladder Urothelial Carcinoma; Kidney Medullary Carcinoma; Large Cell Neuroendocrine Carcinoma; Malignant Testicular Leydig Cell Tumor; Malignant Testicular Sertoli Cell Tumor; Metastatic Bladder Carcinoma; Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma; Metastatic Bladder Giant Cell Urothelial Carcinoma; Metastatic Bladder Large Cell Neuroendocrine Carcinoma; Metastatic Bladder Lipid-Rich Urothelial Carcinoma; Metastatic Bladder Micropapillary Urothelial Carcinoma; Metastatic Bladder Plasmacytoid Urothelial Carcinoma; Metastatic Bladder Sarcomatoid Urothelial Carcinoma; Metastatic Bladder Small Cell Neuroendocrine Carcinoma; Metastatic Bladder Squamous Cell Carcinoma; Metastatic Chromophobe Renal Cell Carcinoma; Metastatic Kidney Medullary Carcinoma; Metastatic Malignant Genitourinary System Neoplasm; Metastatic Papillary Renal Cell Carcinoma; Metastatic Penile Carcinoma; Metastatic Prostate Small Cell Neuroendocrine Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Metastatic Urethral Carcinoma; Papillary Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage IV Bladder Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Urachal Adenocarcinoma; Urethral Clear Cell Adenocarcinoma,Skin,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14495,NCT04316182,Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION),COMPLETED,PHASE2,Hepatocellular Carcinoma,Cabozantinib (DRUG),25102846,Cometriq,Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14496,NCT02260531,Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases,COMPLETED,PHASE2,Breast Cancer; Brain Tumor - Metastatic,Cabozantinib (DRUG); Trastuzumab (DRUG),25102846,Cometriq,Breast Cancer; Brain Tumor - Metastatic,Breast,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14497,NCT05092373,Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax,RECRUITING,PHASE1,Advanced Breast Carcinoma; Advanced Endometrial Carcinoma; Advanced Fallopian Tube Carcinoma; Advanced Hepatocellular Carcinoma; Advanced Malignant Abdominal Neoplasm; Advanced Malignant Female Reproductive System Neoplasm; Advanced Malignant Thoracic Neoplasm; Advanced Ovarian Carcinoma; Advanced Primary Peritoneal Carcinoma; Advanced Renal Cell Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Malignant Abdominal Neoplasm; Malignant Solid Neoplasm; Metastatic Breast Carcinoma; Metastatic Endometrial Carcinoma; Metastatic Fallopian Tube Carcinoma; Metastatic Hepatocellular Carcinoma; Metastatic Malignant Abdominal Neoplasm; Metastatic Malignant Female Reproductive System Neoplasm; Metastatic Malignant Thoracic Neoplasm; Metastatic Ovarian Carcinoma; Metastatic Primary Peritoneal Carcinoma; Metastatic Renal Cell Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Stage III Fallopian Tube Cancer AJCC v8; Stage III Hepatocellular Carcinoma AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage III Uterine Corpus Cancer AJCC v8; Stage IIIA Fallopian Tube Cancer AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Primary Peritoneal Cancer AJCC v8; Stage IIIA Uterine Corpus Cancer AJCC v8; Stage IIIA1 Fallopian Tube Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Fallopian Tube Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Fallopian Tube Cancer AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Primary Peritoneal Cancer AJCC v8; Stage IIIB Uterine Corpus Cancer AJCC v8; Stage IIIC Fallopian Tube Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Primary Peritoneal Cancer AJCC v8; Stage IIIC Uterine Corpus Cancer AJCC v8; Stage IIIC1 Uterine Corpus Cancer AJCC v8; Stage IIIC2 Uterine Corpus Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8,Atezolizumab (BIOLOGICAL); Cabozantinib S-malate (DRUG); Nab-paclitaxel (DRUG); Tumor Treating Fields Therapy (PROCEDURE),25102846,Cometriq,Advanced Breast Carcinoma; Advanced Endometrial Carcinoma; Advanced Fallopian Tube Carcinoma; Advanced Hepatocellular Carcinoma; Advanced Malignant Abdominal Neoplasm; Advanced Malignant Female Reproductive System Neoplasm; Advanced Malignant Thoracic Neoplasm; Advanced Ovarian Carcinoma; Advanced Primary Peritoneal Carcinoma; Advanced Renal Cell Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Malignant Abdominal Neoplasm; Malignant Solid Neoplasm; Metastatic Breast Carcinoma; Metastatic Endometrial Carcinoma; Metastatic Fallopian Tube Carcinoma; Metastatic Hepatocellular Carcinoma; Metastatic Malignant Abdominal Neoplasm; Metastatic Malignant Female Reproductive System Neoplasm; Metastatic Malignant Thoracic Neoplasm; Metastatic Ovarian Carcinoma; Metastatic Primary Peritoneal Carcinoma; Metastatic Renal Cell Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Stage III Fallopian Tube Cancer AJCC v8; Stage III Hepatocellular Carcinoma AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage III Uterine Corpus Cancer AJCC v8; Stage IIIA Fallopian Tube Cancer AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Primary Peritoneal Cancer AJCC v8; Stage IIIA Uterine Corpus Cancer AJCC v8; Stage IIIA1 Fallopian Tube Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Fallopian Tube Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Fallopian Tube Cancer AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Primary Peritoneal Cancer AJCC v8; Stage IIIB Uterine Corpus Cancer AJCC v8; Stage IIIC Fallopian Tube Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Primary Peritoneal Cancer AJCC v8; Stage IIIC Uterine Corpus Cancer AJCC v8; Stage IIIC1 Uterine Corpus Cancer AJCC v8; Stage IIIC2 Uterine Corpus Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8,Uterus,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14498,NCT03586973,A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma,COMPLETED,PHASE2,Advanced Hepatocellular Carcinoma,Cabozantinib (DRUG),25102846,Cometriq,Advanced Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14499,NCT06364631,CARE1 Pragmatic Clinical Trial,RECRUITING,PHASE3,Metastatic Kidney Cancer; Metastatic Kidney Carcinoma,Nivolumab (DRUG); Ipilimumab (DRUG); Pembrolizumab (DRUG); Cabozantinib (DRUG); Axitinib (DRUG); Lenvatinib (DRUG),25102846,Cometriq,Metastatic Kidney Cancer; Metastatic Kidney Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14500,NCT02867592,"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",ACTIVE_NOT_RECRUITING,PHASE2,Adrenal Cortical Carcinoma; Alveolar Soft Part Sarcoma; Central Nervous System Neoplasm; Childhood Clear Cell Sarcoma of Soft Tissue; Clear Cell Sarcoma of Soft Tissue; Ewing Sarcoma; Hepatoblastoma; Hepatocellular Carcinoma; Osteosarcoma; Recurrent Adrenal Cortical Carcinoma; Recurrent Alveolar Soft Part Sarcoma; Recurrent Clear Cell Sarcoma of Soft Tissue; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Hepatocellular Carcinoma; Recurrent Kidney Wilms Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Osteosarcoma; Recurrent Primary Malignant Central Nervous System Neoplasm; Recurrent Renal Cell Carcinoma; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Thyroid Gland Medullary Carcinoma; Refractory Adrenal Cortical Carcinoma; Refractory Alveolar Soft Part Sarcoma; Refractory Clear Cell Sarcoma of Soft Tissue; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Hepatocellular Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Osteosarcoma; Refractory Primary Central Nervous System Neoplasm; Refractory Primary Malignant Central Nervous System Neoplasm; Refractory Renal Cell Carcinoma; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Refractory Thyroid Gland Medullary Carcinoma; Refractory Wilms Tumor; Renal Cell Carcinoma; Rhabdomyosarcoma; Soft Tissue Sarcoma; Solid Neoplasm; Thyroid Gland Medullary Carcinoma; Wilms Tumor,Cabozantinib (DRUG); Cabozantinib S-malate (DRUG); Pharmacological Study (OTHER),25102846,Cometriq,Adrenal Cortical Carcinoma; Alveolar Soft Part Sarcoma; Central Nervous System Neoplasm; Childhood Clear Cell Sarcoma of Soft Tissue; Clear Cell Sarcoma of Soft Tissue; Ewing Sarcoma; Hepatoblastoma; Hepatocellular Carcinoma; Osteosarcoma; Recurrent Adrenal Cortical Carcinoma; Recurrent Alveolar Soft Part Sarcoma; Recurrent Clear Cell Sarcoma of Soft Tissue; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Hepatocellular Carcinoma; Recurrent Kidney Wilms Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Osteosarcoma; Recurrent Primary Malignant Central Nervous System Neoplasm; Recurrent Renal Cell Carcinoma; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Thyroid Gland Medullary Carcinoma; Refractory Adrenal Cortical Carcinoma; Refractory Alveolar Soft Part Sarcoma; Refractory Clear Cell Sarcoma of Soft Tissue; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Hepatocellular Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Osteosarcoma; Refractory Primary Central Nervous System Neoplasm; Refractory Primary Malignant Central Nervous System Neoplasm; Refractory Renal Cell Carcinoma; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Refractory Thyroid Gland Medullary Carcinoma; Refractory Wilms Tumor; Renal Cell Carcinoma; Rhabdomyosarcoma; Soft Tissue Sarcoma; Solid Neoplasm; Thyroid Gland Medullary Carcinoma; Wilms Tumor,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14501,NCT04586231,A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011),ACTIVE_NOT_RECRUITING,PHASE3,"Carcinoma, Renal Cell",Belzutifan (DRUG); Lenvatinib (DRUG); Cabozantinib (DRUG),25102846,Cometriq,"Carcinoma, Renal Cell",Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14502,NCT03667482,Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer,COMPLETED,PHASE1,Head and Neck Squamous Cell Cancer; Recurrent Head and Neck Squamous Cell Cancer; Metastatic Head and Neck Squamous Cell Cancer,Cabozantinib (DRUG); Cetuximab (DRUG),25102846,Cometriq,Head and Neck Squamous Cell Cancer; Recurrent Head and Neck Squamous Cell Cancer; Metastatic Head and Neck Squamous Cell Cancer,Skin,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14503,NCT03798626,"Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers",COMPLETED,PHASE1,Colorectal Cancer; Gastroesophageal Cancer; Renal Cell Carcinoma,Gevokizumab (DRUG); Bevacizumab (DRUG); Modified FOLFOX6 (DRUG); FOLFIRI (DRUG); Ramucirumab (DRUG); Paclitaxel (DRUG); Cabozantinib (DRUG),25102846,Cometriq,Colorectal and Gastroesophageal Cancers,Esophagus/Stomach,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14504,NCT03213626,Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma,TERMINATED,PHASE2,Pancreatic Adenocarcinoma Metastatic,Cabozantinib 40 MG (DRUG); Erlotinib 100Mg Tab (DRUG),25102846,Cometriq,Metastatic Pancreatic Adenocarcinoma,Pancreas,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14505,NCT06377722,Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer,TERMINATED,PHASE2,Renal Cell Carcinoma Metastatic; Renal Cell Carcinoma Stage IV; Renal Cell Carcinoma Stage III,Cabozantinib (DRUG),25102846,Cometriq,Renal Cell Carcinoma Metastatic; Renal Cell Carcinoma Stage IV; Renal Cell Carcinoma Stage III,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14506,NCT03967522,Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases,COMPLETED,PHASE2,Metastatic Renal Cell Carcinoma,Cabozantinib (DRUG),25102846,Cometriq,Metastatic Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14507,NCT05327686,"Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study",RECRUITING,PHASE2,Metastatic Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Renal Cell Carcinoma,Avelumab (BIOLOGICAL); Axitinib (DRUG); Cabozantinib (DRUG); Ipilimumab (BIOLOGICAL); Lenvatinib (DRUG); Nivolumab (BIOLOGICAL); Pembrolizumab (BIOLOGICAL); Stereotactic Ablative Radiotherapy (RADIATION),25102846,Cometriq,Metastatic Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14508,NCT03685448,ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB),UNKNOWN,PHASE2,Renal Cell Carcinoma; Papillary Renal Cell Carcinoma Type 1; Papillary Renal Cell Carcinoma Type 2; Chromophobe Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Xp11.2 Translocation-Related Renal Cell Carcinoma,Cabozantinib (DRUG),25102846,Cometriq,Renal Cell Carcinoma; Papillary Renal Cell Carcinoma Type 1; Papillary Renal Cell Carcinoma Type 2; Chromophobe Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Xp11.2 Translocation-Related Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14509,NCT03149822,Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma,COMPLETED,PHASE1,Metastatic Renal Cell Carcinoma,Cabozantinib (DRUG); Pembrolizumab (DRUG),25102846,Cometriq,Metastatic Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14510,NCT04878029,Cabozantinib in Combination with Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer,RECRUITING,PHASE1,Infiltrating Bladder Urothelial Carcinoma with Squamous Differentiation; Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma,Cabozantinib S-malate (DRUG); Enfortumab Vedotin (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),25102846,Cometriq,Infiltrating Bladder Urothelial Carcinoma with Squamous Differentiation; Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma,Bladder/Urinary Tract,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14511,NCT02293980,"A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)",ACTIVE_NOT_RECRUITING,PHASE1,ccRCC; RCC; Kidney Cancer; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma,MK-3795 (DRUG); Nivolumab (DRUG); Cabozantinib (DRUG); Bezlutifan (DRUG),25102846,Cometriq,ccRCC; RCC; Kidney Cancer; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14512,NCT04454762,"A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function",UNKNOWN,PHASE2,Hepatocellular Carcinoma,Cabozantinib (DRUG),25102846,Cometriq,Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14513,NCT03755791,Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy,ACTIVE_NOT_RECRUITING,PHASE3,Hepatocellular Carcinoma,Cabozantinib (DRUG); Cabozantinib (DRUG); Sorafenib (DRUG); Atezolizumab (DRUG),25102846,Cometriq,Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14514,NCT04151563,A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy,WITHDRAWN,PHASE1,"Carcinoma, Non-small Cell Lung Cancer",nivolumab (BIOLOGICAL); ipilimumab (BIOLOGICAL); cabozantinib (DRUG); docetaxel (BIOLOGICAL); ramucirumab (BIOLOGICAL); lucitanib (DRUG),25102846,Cometriq,"Carcinoma, Non-small Cell Lung Cancer",Lung,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14515,NCT03316586,A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer,COMPLETED,PHASE2,Breast Cancer,Nivolumab (DRUG); Cabozantinib (DRUG),25102846,Cometriq,Breast Cancer,Breast,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14516,NCT06811116,"Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin",NOT_YET_RECRUITING,PHASE1,Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8,Biospecimen Collection (PROCEDURE); Cabozantinib S-malate (DRUG); Imaging Procedure (PROCEDURE); Sapanisertib (DRUG),25102846,Cometriq,Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14517,NCT05136196,"BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study",RECRUITING,PHASE2,Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Locally Recurrent Head and Neck Squamous Cell Carcinoma; Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma; Locally Recurrent Laryngeal Squamous Cell Carcinoma; Locally Recurrent Oral Cavity Squamous Cell Carcinoma; Locally Recurrent Oropharyngeal Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Hypopharyngeal Squamous Cell Carcinoma; Metastatic Laryngeal Squamous Cell Carcinoma; Metastatic Melanoma; Metastatic Oral Cavity Squamous Cell Carcinoma; Metastatic Oropharyngeal Squamous Cell Carcinoma; Recurrent Melanoma; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IV Hypopharyngeal Carcinoma AJCC v8; Stage IV Laryngeal Cancer AJCC v8; Stage IV Lip and Oral Cavity Cancer AJCC v8; Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Unresectable Melanoma,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Cabozantinib S-malate (DRUG); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Nivolumab (BIOLOGICAL),25102846,Cometriq,Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Locally Recurrent Head and Neck Squamous Cell Carcinoma; Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma; Locally Recurrent Laryngeal Squamous Cell Carcinoma; Locally Recurrent Oral Cavity Squamous Cell Carcinoma; Locally Recurrent Oropharyngeal Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Hypopharyngeal Squamous Cell Carcinoma; Metastatic Laryngeal Squamous Cell Carcinoma; Metastatic Melanoma; Metastatic Oral Cavity Squamous Cell Carcinoma; Metastatic Oropharyngeal Squamous Cell Carcinoma; Recurrent Melanoma; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IV Hypopharyngeal Carcinoma AJCC v8; Stage IV Laryngeal Cancer AJCC v8; Stage IV Lip and Oral Cavity Cancer AJCC v8; Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Unresectable Melanoma,Skin,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14518,NCT03539822,Cabozantinib Plus Durvalumab with or Without Tremelimumab in Patients with Gastroesophageal Cancer and Other Gastrointestinal Malignancies,RECRUITING,PHASE1,Gastric Cancer; Esophageal Adenocarcinoma; Hepatocellular Carcinoma; Colorectal Cancer,Cabozantinib (DRUG); Durvalumab (DRUG); Tremelimumab (DRUG),25102846,Cometriq,Gastric Cancer; Esophageal Adenocarcinoma; Hepatocellular Carcinoma; Colorectal Cancer,Bowel,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14519,NCT05092958,"Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study",ACTIVE_NOT_RECRUITING,PHASE3,Advanced Bladder Urothelial Carcinoma; Advanced Renal Pelvis Urothelial Carcinoma; Advanced Ureter Urothelial Carcinoma; Advanced Urethral Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma; Metastatic Urethral Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8; Stage III Renal Pelvis and Ureter Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage III Urethral Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Renal Pelvis and Ureter Cancer AJCC v8; Stage IV Renal Pelvis Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8,Avelumab (DRUG); Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Cabozantinib S-malate (DRUG); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER),25102846,Cometriq,Advanced Bladder Urothelial Carcinoma; Advanced Renal Pelvis Urothelial Carcinoma; Advanced Ureter Urothelial Carcinoma; Advanced Urethral Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma; Metastatic Urethral Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8; Stage III Renal Pelvis and Ureter Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage III Urethral Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Renal Pelvis and Ureter Cancer AJCC v8; Stage IV Renal Pelvis Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8,Bladder/Urinary Tract,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14520,NCT02885324,Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children,TERMINATED,PHASE2,Glioblastoma Multiforme; Anaplastic Astrocytoma; Malignant Brain Tumor; High Grade Glioma,Cabozantinib (DRUG),25102846,Cometriq,Glioblastoma Multiforme; Anaplastic Astrocytoma; Malignant Brain Tumor; High Grade Glioma,CNS/Brain,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14521,NCT01709435,Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors,COMPLETED,PHASE1,Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Primary Central Nervous System Neoplasm; Recurrent Thyroid Gland Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Primary Central Nervous System Neoplasm; Thyroid Gland Medullary Carcinoma,Cabozantinib S-malate (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER),25102846,Cometriq,Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Primary Central Nervous System Neoplasm; Recurrent Thyroid Gland Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Primary Central Nervous System Neoplasm; Thyroid Gland Medullary Carcinoma,Skin,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14522,NCT03463681,A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma,COMPLETED,PHASE2,Metastatic Renal Cell Carcinoma,Cabometyx (DRUG),25102846,Cometriq,Metastatic Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14523,NCT05425004,Cabozantinib for Patients With Recurrent or Progressive Meningioma,RECRUITING,PHASE2,Meningioma,Cabozantinib (DRUG),25102846,Cometriq,Meningioma,CNS/Brain,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14524,NCT06835972,A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC),RECRUITING,PHASE1,Metastatic Renal Cell Carcinoma,Abemaciclib (DRUG); Cabozantinib (DRUG),25102846,Cometriq,Metastatic Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14525,NCT03534804,Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Metastatic Urothelial Carcinoma; Bladder Cancer,Cabozantinib (DRUG); Pembrolizumab (DRUG),25102846,Cometriq,Metastatic Urothelial Carcinoma; Bladder Cancer,Bladder/Urinary Tract,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14526,NCT03634540,"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)",ACTIVE_NOT_RECRUITING,PHASE2,"Renal Cell Carcinoma (RCC); Clear Cell Renal Cell Carcinoma (ccRCC); Kidney Cancer; Renal Cancer; Renal Cell Carcinoma; Renal Cell Cancer Metastatic; Renal Cell Carcinoma Recurrent; Renal Cell Cancer, Recurrent; Kidney",Belzutifan (DRUG); Cabozantinib (DRUG),25102846,Cometriq,"Renal Cell Carcinoma (RCC); Clear Cell Renal Cell Carcinoma (ccRCC); Kidney Cancer; Renal Cancer; Renal Cell Carcinoma; Renal Cell Cancer Metastatic; Renal Cell Carcinoma Recurrent; Renal Cell Cancer, Recurrent; Kidney",Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14527,NCT03299946,Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC),COMPLETED,PHASE1,Locally Advanced Hepatocellular Carcinoma,Cabozantinib (DRUG); Nivolumab (DRUG),25102846,Cometriq,Locally Advanced Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14528,NCT01493869,Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects,COMPLETED,PHASE1,Healthy; Hepatic Impairment,cabozantinib (DRUG),25102846,Cometriq,Healthy; Hepatic Impairment,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14529,NCT03425201,Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA),COMPLETED,PHASE1,Urothelial Cancer,Niraparib plus Cabozantinib (DRUG),25102846,Cometriq,Urothelial Cancer,Bladder/Urinary Tract,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14530,NCT03635892,A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma,ACTIVE_NOT_RECRUITING,PHASE2,Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma; Unclassified Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Fumarate Hydratase Deficient Renal Cell Carcinoma; Succinate Dehydrogenase Deficient Renal Cell Carcinoma; Collecting Duct Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma,cabozantinib (DRUG); nivolumab (DRUG),25102846,Cometriq,Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma; Unclassified Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Fumarate Hydratase Deficient Renal Cell Carcinoma; Succinate Dehydrogenase Deficient Renal Cell Carcinoma; Collecting Duct Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14531,NCT00960492,Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma,COMPLETED,PHASE1,Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma,XL184 (DRUG); temozolomide (DRUG); temozolomide (DRUG); Radiation Therapy (RADIATION); temozolomide (DRUG),25102846,Cometriq,Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma,CNS/Brain,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14532,NCT01835158,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,COMPLETED,PHASE2,Clear Cell Renal Cell Carcinoma; Metastatic Kidney Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7,Cabozantinib S-malate (DRUG); Laboratory Biomarker Analysis (OTHER); Sunitinib Malate (DRUG),25102846,Cometriq,Clear Cell Renal Cell Carcinoma; Metastatic Kidney Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14533,NCT05127824,Autologous Dendritic Cell Vaccine in Kidney Cancer,RECRUITING,PHASE2,"Carcinoma, Renal Cell",Autologous alpha-DC1/TBVA vaccine (BIOLOGICAL); Cabozantinib (DRUG),25102846,Cometriq,"Carcinoma, Renal Cell",Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14534,NCT01761773,A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function,COMPLETED,PHASE1,Healthy; Renal Impairment,cabozantinib (DRUG),25102846,Cometriq,Healthy; Renal Impairment,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14535,NCT05673824,Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.,RECRUITING,PHASE4,Nephrotoxicity,Huaier Granule (DRUG); VEGFR-TKIs (DRUG),25102846,Cometriq,Nephrotoxicity,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14536,NCT05859217,A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1),NOT_YET_RECRUITING,PHASE2,Lung Cancer; NSCLC Stage IV; Metastatic NSCLC - Non-Small Cell Lung Cancer; Advanced NSCLC,Cabozantinib (DRUG); Atezolizumab (DRUG),25102846,Cometriq,Lung Cancer; NSCLC Stage IV; Metastatic NSCLC - Non-Small Cell Lung Cancer; Advanced NSCLC,Lung,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14537,NCT03937219,Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma,ACTIVE_NOT_RECRUITING,PHASE3,Renal Cell Carcinoma,Cabozantinib (DRUG); Nivolumab (BIOLOGICAL); Ipilimumab (BIOLOGICAL); Cabozantinib-matched placebo (DRUG),25102846,Cometriq,Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14538,NCT01663272,A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer,COMPLETED,PHASE1,Pancreatic Cancer,CABOZANTINIB (DRUG); gemcitabine (DRUG),25102846,Cometriq,Pancreatic Cancer,Pancreas,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14539,NCT04300140,Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma,TERMINATED,PHASE1,Clear Cell Renal Cell Carcinoma,Batiraxcept (DRUG); Cabozantinib (Cabo) (DRUG); Nivolumab (DRUG),25102846,Cometriq,Clear Cell Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14540,NCT05663710,Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC,RECRUITING,PHASE1,Advanced Cancer; Clear Cell Renal Cell Carcinoma,177Lu girentuximab (DRUG); Nivolumab (DRUG); Cabozantinib (DRUG); ArabinoFuranosylGuanine [18F]F-AraG (DRUG),25102846,Cometriq,Advanced Cancer; Clear Cell Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14541,NCT06903312,Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.,NOT_YET_RECRUITING,PHASE4,Renal Cell Cancer; Kidney Neoplasm; Immunotherapy; Kidney Cancer; Surgery Programmed; Radiotherapy,Deferred Cytoreductive Nephrectomy + medical treatment (PROCEDURE); Radiotherapy + medical treatment (RADIATION); Medical therapy (DRUG),25102846,Cometriq,Renal Cell Cancer; Kidney Neoplasm; Immunotherapy; Kidney Cancer; Surgery Programmed; Radiotherapy,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14542,NCT04472767,Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma,RECRUITING,PHASE2,Hepatocellular Carcinoma; HCC,Nivolumab (DRUG); Ipilimumab (DRUG); Cabozantinib (DRUG); Transarterial Chemoembolization (PROCEDURE),25102846,Cometriq,Hepatocellular Carcinoma; HCC,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14543,NCT05048212,A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases,ACTIVE_NOT_RECRUITING,PHASE2,Brain Metastases; Renal Cell Carcinoma,Nivolumab (DRUG); Ipilimumab (DRUG); Cabozantinib (DRUG),25102846,Cometriq,Brain Metastases; Renal Cell Carcinoma,CNS/Brain,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14544,NCT03428217,CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma,COMPLETED,PHASE2,Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma,CB-839 (DRUG); Cabozantinib (DRUG); Placebo (DRUG),25102846,Cometriq,Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14545,NCT05536141,A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors,RECRUITING,PHASE1,Clear Cell Renal Cell Carcinoma; Solid Tumors,casdatifan (DRUG); Cabozantinib (DRUG); Zimberelimab (DRUG),25102846,Cometriq,Clear Cell Renal Cell Carcinoma; Solid Tumors,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14546,NCT03367741,"Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Advanced Endometrial Carcinoma; Metastatic Endometrial Carcinoma; Recurrent Endometrial Carcinoma; Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Cabozantinib S-malate (DRUG); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Nivolumab (BIOLOGICAL),25102846,Cometriq,Advanced Endometrial Carcinoma; Metastatic Endometrial Carcinoma; Recurrent Endometrial Carcinoma; Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8,Uterus,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14547,NCT03339219,A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma,COMPLETED,PHASE2,Advanced Renal Cell Carcinoma,Cabozantinib (DRUG),25102846,Cometriq,Advanced Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14548,NCT03468218,Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Head and Neck Carcinoma; Paranasal Sinus Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Oral Cavity Squamous Cell Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7; Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7; Unresectable Head and Neck Squamous Cell Carcinoma,Cabozantinib (DRUG); Pembrolizumab (BIOLOGICAL),25102846,Cometriq,Metastatic Head and Neck Carcinoma; Paranasal Sinus Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Oral Cavity Squamous Cell Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7; Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7; Unresectable Head and Neck Squamous Cell Carcinoma,Skin,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14549,NCT01100619,A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors,COMPLETED,PHASE1,Papillary Thyroid Cancer; Follicular Thyroid Cancer; Huerthle Cell Thyroid Cancer; Renal Cell Carcinoma,rosiglitazone (DRUG); XL184 (DRUG),25102846,Cometriq,Papillary Thyroid Cancer; Follicular Thyroid Cancer; Huerthle Cell Thyroid Cancer; Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14550,NCT04497038,Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy,TERMINATED,PHASE1,Advanced Adult Hepatocellular Carcinoma,Cabozantinib (DRUG),25102846,Cometriq,Advanced Adult Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14551,NCT04442581,Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer,TERMINATED,PHASE2,Advanced Hepatocellular Carcinoma; BCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma,Cabozantinib S-malate (DRUG); Pembrolizumab (BIOLOGICAL),25102846,Cometriq,Advanced Hepatocellular Carcinoma; BCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14552,NCT01866410,Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7,Cabozantinib S-malate (DRUG); Erlotinib Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER),25102846,Cometriq,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7,Lung,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14553,NCT06026410,KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors,RECRUITING,PHASE1,Solid Tumors With HRAS Alterations; Non Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Clear Cell Renal Cell Carcinoma (ccRCC); Renal Cell Carcinoma (Kidney Cancer),KO-2806 (DRUG); Cabozantinib (DRUG); Adagrasib (DRUG),25102846,Cometriq,Solid Tumors With HRAS Alterations; Non Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Clear Cell Renal Cell Carcinoma (ccRCC); Renal Cell Carcinoma (Kidney Cancer),Bowel,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14554,NCT02496208,Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors,ACTIVE_NOT_RECRUITING,PHASE1,Bladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Bladder Urothelial Carcinoma; Clear Cell Renal Cell Carcinoma; Invasive Bladder Plasmacytoid Urothelial Carcinoma; Invasive Bladder Sarcomatoid Urothelial Carcinoma; Invasive Sarcomatoid Urothelial Carcinoma; Kidney Medullary Carcinoma; Malignant Genitourinary System Neoplasm; Malignant Solid Neoplasm; Penile Carcinoma; Penile Squamous Cell Carcinoma; Renal Cell Carcinoma; Renal Pelvis Urothelial Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage III Bladder Cancer AJCC v8; Stage III Penile Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage III Renal Pelvis and Ureter Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage III Urethral Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Renal Pelvis and Ureter Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8; Ureter Urothelial Carcinoma; Urethral Urothelial Carcinoma,Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Cabozantinib S-malate (DRUG); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Ipilimumab (BIOLOGICAL); Magnetic Resonance Imaging (PROCEDURE); Nivolumab (BIOLOGICAL),25102846,Cometriq,Bladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Bladder Urothelial Carcinoma; Clear Cell Renal Cell Carcinoma; Invasive Bladder Plasmacytoid Urothelial Carcinoma; Invasive Bladder Sarcomatoid Urothelial Carcinoma; Invasive Sarcomatoid Urothelial Carcinoma; Kidney Medullary Carcinoma; Malignant Genitourinary System Neoplasm; Malignant Solid Neoplasm; Penile Carcinoma; Penile Squamous Cell Carcinoma; Renal Cell Carcinoma; Renal Pelvis Urothelial Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage III Bladder Cancer AJCC v8; Stage III Penile Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage III Renal Pelvis and Ureter Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage III Urethral Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Renal Pelvis and Ureter Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8; Ureter Urothelial Carcinoma; Urethral Urothelial Carcinoma,Skin,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14555,NCT05411081,"Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial",RECRUITING,PHASE2,Metastatic Papillary Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8,Atezolizumab (BIOLOGICAL); Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Cabozantinib S-malate (DRUG); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE),25102846,Cometriq,Metastatic Papillary Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14556,NCT04322955,CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition,RECRUITING,PHASE2,Kidney Cancer; Renal Cell Carcinoma,Cabozantinib (DRUG); Nivolumab (DRUG); Cytoreductive nephrectomy (PROCEDURE),25102846,Cometriq,Kidney Cancer; Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14557,NCT04091750,Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma,ACTIVE_NOT_RECRUITING,PHASE2,Melanoma,Nivolumab (DRUG); Ipilimumab (DRUG); Cabozantinib (DRUG),25102846,Cometriq,Melanoma,Skin,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14558,NCT04511455,Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment,COMPLETED,PHASE2,Hepatocellular Carcinoma Non-resectable; Metastatic Hepatocellular Carcinoma,Cabozantinib (DRUG),25102846,Cometriq,Hepatocellular Carcinoma Non-resectable; Metastatic Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14559,NCT06698250,Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA),RECRUITING,PHASE2,Hepatocellular Carcinoma,Zanzalintinib (DRUG); Durvalumab (DRUG); Tremelimumab (DRUG),25102846,Cometriq,Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14560,NCT04522908,Dose Escalation Study of Cabozantinib for Advanced HCC Patients with Preserved Liver Function,COMPLETED,PHASE2,Hepatocellular Carcinoma (HCC); Second Line Treatment,Cabozantinib Oral Tablet (DRUG),25102846,Cometriq,Hepatocellular Carcinoma (HCC); Second Line Treatment,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14561,NCT05052723,Cabozantinib and Pembrolizumab in Metastatic Pancreas,COMPLETED,PHASE2,Pancreatic Cancer,Cabozantinib (DRUG); Pembrolizumab (DRUG),25102846,Cometriq,Pancreatic Cancer,Pancreas,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14562,NCT04413123,Cabozantinib in Combo with NIVO + IPI in Advanced NCCRCC,ACTIVE_NOT_RECRUITING,PHASE2,Papillary Renal Cell Carcinoma; Unclassified Renal Cell Carcinoma; Translocation Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Collecting Duct Renal Cell Carcinoma; Renal Cell Carcinoma; Unresectable Advanced Renal Cell Carcinoma; Metastatic Ncc Renal Cell Carcinoma,Cabozantinib (DRUG); Nivolumab (DRUG); Ipilimumab (DRUG),25102846,Cometriq,Papillary Renal Cell Carcinoma; Unclassified Renal Cell Carcinoma; Translocation Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Collecting Duct Renal Cell Carcinoma; Renal Cell Carcinoma; Unresectable Advanced Renal Cell Carcinoma; Metastatic Ncc Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14563,NCT03387514,Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies,TERMINATED,PHASE2,Renal Cell Carcinoma,PSMA-based 18F-DCFPyL PET tracer for PET/CT exams (DRUG),25102846,Cometriq,Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14564,NCT05039281,Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma,RECRUITING,PHASE1,Recurrent Glioblastoma; Recurrent Gliosarcoma,Atezolizumab (BIOLOGICAL); Cabozantinib (DRUG),25102846,Cometriq,Recurrent Glioblastoma; Recurrent Gliosarcoma,CNS/Brain,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14565,NCT04071223,"Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study",RECRUITING,PHASE2,Advanced Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma; Collecting Duct Carcinoma; Kidney Medullary Carcinoma; Metastatic Malignant Neoplasm in the Bone; Papillary Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8; Unclassified Renal Cell Carcinoma,Biospecimen Collection (PROCEDURE); Bone Scan (PROCEDURE); Cabozantinib S-malate (DRUG); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Positron Emission Tomography (PROCEDURE); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); Radium Ra 223 Dichloride (RADIATION),25102846,Cometriq,Advanced Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma; Collecting Duct Carcinoma; Kidney Medullary Carcinoma; Metastatic Malignant Neoplasm in the Bone; Papillary Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8; Unclassified Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14566,NCT01639508,Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity,RECRUITING,PHASE2,Non-Small Cell Lung Cancer,Cabozantinib (DRUG),25102846,Cometriq,Advanced Non-Small Cell Lung Cancer,Lung,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14567,NCT05263050,Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors,RECRUITING,PHASE2,Metastatic Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma; Neuroendocrine Tumors; Carcinoid Tumor,Cabozantinib (DRUG); Nivolumab (DRUG),25102846,Cometriq,Metastatic Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma; Neuroendocrine Tumors; Carcinoid Tumor,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14568,NCT05327738,"Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma",WITHDRAWN,PHASE2,BCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma; Locally Advanced Hepatocellular Carcinoma; Recurrent Hepatocellular Carcinoma; Unresectable Hepatocellular Carcinoma,Atezolizumab (BIOLOGICAL); Biopsy (PROCEDURE); Cabozantinib S-malate (DRUG); Yttrium Y 90 Glass Microspheres (RADIATION),25102846,Cometriq,BCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma; Locally Advanced Hepatocellular Carcinoma; Recurrent Hepatocellular Carcinoma; Unresectable Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14569,NCT04022343,Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8,Cabozantinib (DRUG),25102846,Cometriq,Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14570,NCT05200143,"Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma",TERMINATED,PHASE2,Refractory Cutaneous Melanoma,Ipilimumab (DRUG); Nivolumab (DRUG); Cabozantinib (DRUG),25102846,Cometriq,Refractory Cutaneous Melanoma,Skin,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14571,NCT04066595,Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.,TERMINATED,PHASE2,Urothelial Carcinoma,Cabozantinib (DRUG),25102846,Cometriq,Urothelial Carcinoma,Bladder/Urinary Tract,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14572,NCT04204850,Cabozantinib to Treat Recurrent Liver Cancer Post Transplant,RECRUITING,PHASE2,Hepatocellular Carcinoma; Recurrent Cancer; Liver Transplant,Cabozantinib (DRUG),25102846,Cometriq,Hepatocellular Carcinoma; Recurrent Cancer; Liver Transplant,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14573,NCT05039736,"A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy",WITHDRAWN,PHASE2,Hepatocellular Carcinoma; Liver Cancer,Cabozantinib (DRUG); Nivolumab (DRUG),25102846,Cometriq,Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14574,NCT05135975,A Study of Cabozantinib As a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors,RECRUITING,PHASE2,Neuroblastoma; Sarcoma,Cabozantinib (DRUG),25102846,Cometriq,Neuroblastoma; Sarcoma,CNS/Brain,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14575,NCT01688999,Cabozantinib for Advanced Urothelial Cancer,COMPLETED,PHASE2,Urothelial Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Kidney Neoplasms,Cabozantinib (DRUG),25102846,Cometriq,Urothelial Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Kidney Neoplasms,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14576,NCT02960906,A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer,COMPLETED,PHASE2,Clear Cell Metastatic Renal Cell Carcinoma,Nivolumab (DRUG); Ipilimumab (DRUG); Pazopanib (DRUG); Sunitinib (DRUG),25102846,Cometriq,Clear Cell Metastatic Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14577,NCT03943602,Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen),UNKNOWN,PHASE2,Penile Squamous Cell Carcinoma,Cabozantinib (DRUG),25102846,Cometriq,Penile Squamous Cell Carcinoma,Skin,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14578,NCT04514484,Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV,ACTIVE_NOT_RECRUITING,PHASE1,Advanced Differentiated Thyroid Gland Carcinoma; Advanced Head and Neck Carcinoma; Advanced Hepatocellular Carcinoma; Advanced Kaposi Sarcoma; Advanced Lung Non-Small Cell Carcinoma; Advanced Lung Small Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Melanoma; Advanced Ovarian Carcinoma; Advanced Prostate Carcinoma; Advanced Renal Cell Carcinoma; Advanced Thyroid Gland Medullary Carcinoma; Advanced Triple-Negative Breast Carcinoma; Advanced Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Castration-Resistant Prostate Carcinoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; HIV Infection; Metastatic Differentiated Thyroid Gland Carcinoma; Metastatic Head and Neck Carcinoma; Metastatic Hepatocellular Carcinoma; Metastatic Kaposi Sarcoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Ovarian Carcinoma; Metastatic Prostate Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Thyroid Gland Medullary Carcinoma; Metastatic Triple-Negative Breast Carcinoma; Metastatic Urothelial Carcinoma; Recurrent Differentiated Thyroid Gland Carcinoma; Recurrent Head and Neck Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Kaposi Sarcoma; Recurrent Lung Non-Small Cell Carcinoma; Recurrent Lung Small Cell Carcinoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Recurrent Renal Cell Carcinoma; Recurrent Thyroid Gland Medullary Carcinoma; Recurrent Triple-Negative Breast Carcinoma; Recurrent Urothelial Carcinoma; Refractory Differentiated Thyroid Gland Carcinoma; Stage III Differentiated Thyroid Gland Carcinoma AJCC v8; Stage III Hepatocellular Carcinoma AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage III Thyroid Gland Medullary Carcinoma AJCC v8; Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Thyroid Gland Medullary Carcinoma AJCC v8,Biospecimen Collection (PROCEDURE); Cabozantinib S-malate (DRUG); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Nivolumab (BIOLOGICAL),25102846,Cometriq,Advanced Differentiated Thyroid Gland Carcinoma; Advanced Head and Neck Carcinoma; Advanced Hepatocellular Carcinoma; Advanced Kaposi Sarcoma; Advanced Lung Non-Small Cell Carcinoma; Advanced Lung Small Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Melanoma; Advanced Ovarian Carcinoma; Advanced Prostate Carcinoma; Advanced Renal Cell Carcinoma; Advanced Thyroid Gland Medullary Carcinoma; Advanced Triple-Negative Breast Carcinoma; Advanced Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Castration-Resistant Prostate Carcinoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; HIV Infection; Metastatic Differentiated Thyroid Gland Carcinoma; Metastatic Head and Neck Carcinoma; Metastatic Hepatocellular Carcinoma; Metastatic Kaposi Sarcoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Ovarian Carcinoma; Metastatic Prostate Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Thyroid Gland Medullary Carcinoma; Metastatic Triple-Negative Breast Carcinoma; Metastatic Urothelial Carcinoma; Recurrent Differentiated Thyroid Gland Carcinoma; Recurrent Head and Neck Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Kaposi Sarcoma; Recurrent Lung Non-Small Cell Carcinoma; Recurrent Lung Small Cell Carcinoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Recurrent Renal Cell Carcinoma; Recurrent Thyroid Gland Medullary Carcinoma; Recurrent Triple-Negative Breast Carcinoma; Recurrent Urothelial Carcinoma; Refractory Differentiated Thyroid Gland Carcinoma; Stage III Differentiated Thyroid Gland Carcinoma AJCC v8; Stage III Hepatocellular Carcinoma AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage III Thyroid Gland Medullary Carcinoma AJCC v8; Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Thyroid Gland Medullary Carcinoma AJCC v8,Lung,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14579,NCT03541902,Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma,ACTIVE_NOT_RECRUITING,PHASE2,Malignant Neoplasms of Urinary Tract; Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions; Sarcomatoid Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8; Unclassified Renal Cell Carcinoma,Cabozantinib (DRUG); Sunitinib Malate (DRUG),25102846,Cometriq,Malignant Neoplasms of Urinary Tract; Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions; Sarcomatoid Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8; Unclassified Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14580,NCT01835184,Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery,TERMINATED,PHASE1,"Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma; Unspecified Adult Solid Tumor, Protocol Specific",cabozantinib-s-malate (DRUG); vemurafenib (DRUG); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),25102846,Cometriq,"Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma; Unspecified Adult Solid Tumor, Protocol Specific",Skin,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14581,NCT06726421,Systemic Therapy Alone or with Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study),RECRUITING,PHASE3,Renal Cell Carcinoma (Kidney Cancer); Kidney Cancer Metastatic; Renal Cell Carcinoma Metastatic,"Stereotactic body radiotherapy (SBRT) (RADIATION); axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib (DRUG)",25102846,Cometriq,Renal Cell Carcinoma (Kidney Cancer); Kidney Cancer Metastatic; Renal Cell Carcinoma Metastatic,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14582,NCT01588821,Cabozantinib in Advanced Solid Malignancies,COMPLETED,PHASE2,Lung Cancer; Solid Tumor (Not Breast or Prostate Cancers),Cabozantinib (DRUG),25102846,Cometriq,Lung Cancer; Solid Tumor (Not Breast or Prostate Cancers),Lung,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14583,NCT04820179,"Atezolizumab + Cabozantinib in Patients W/ Metastatic, Refractory Pancreatic Cancer",RECRUITING,PHASE2,Pancreatic Cancer; Metastatic Pancreatic Cancer,Cabozantinib + Atezolizumab (DRUG),25102846,Cometriq,Pancreatic Cancer; Metastatic Pancreatic Cancer,Pancreas,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14584,NCT04131543,Phase II Study With Cabozantinib in Patients With RET Positive NSCLC,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,Cabozantinib 20 MG (DRUG); Cabozantinib 40 MG (DRUG); Cabozantinib 60 MG (DRUG),25102846,Cometriq,Non Small Cell Lung Cancer,Lung,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14585,NCT05559879,Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma,RECRUITING,PHASE1,Gynecologic Cancer; Carcinoma; Uterine Cancer; Endometrial Cancer,Cabo + Dostarlimab (DRUG),25102846,Cometriq,Gynecologic Cancer; Carcinoma; Uterine Cancer; Endometrial Cancer,Uterus,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14586,NCT04289779,Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Bladder Cancer,Cabozantinib (DRUG); Atezolizumab (DRUG); Cystectomy (PROCEDURE),25102846,Cometriq,Bladder Cancer,Bladder/Urinary Tract,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14587,NCT04164979,Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma,ACTIVE_NOT_RECRUITING,PHASE2,Gastric Adenocarcinoma; GastroEsophageal Cancer,Cabozantinib (DRUG); Pembrolizumab (DRUG),25102846,Cometriq,Gastric Adenocarcinoma; GastroEsophageal Cancer,Esophagus/Stomach,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14588,NCT04173338,"Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma",TERMINATED,PHASE1,Non Small Cell Lung Cancer; Non-squamous Non-small-cell Lung Cancer; Urothelial Carcinoma; Malignant Mesothelioma,Cabozantinib (DRUG); Pemetrexed (DRUG),25102846,Cometriq,Non Small Cell Lung Cancer; Non-squamous Non-small-cell Lung Cancer; Urothelial Carcinoma; Malignant Mesothelioma,Lung,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14589,NCT01738438,Cabozantinib for Metastatic Triple Negative BrCa,COMPLETED,PHASE2,Breast Cancer,Cabozantinib (DRUG),25102846,Cometriq,Breast Cancer,Breast,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14590,NCT00596648,A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer,COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung",XL184 (DRUG); erlotinib (DRUG),25102846,Cometriq,"Carcinoma, Non-Small-Cell Lung",Lung,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14591,NCT05613413,A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC),RECRUITING,PHASE2,Metastatic Squamous Non-Small Cell Lung Carcinoma,Cabozantinib 40 MG (DRUG); Pembrolizumab 200mg (DRUG); Pembrolizumab 400mg (DRUG),25102846,Cometriq,Metastatic Squamous Non-Small Cell Lung Carcinoma,Lung,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14592,NCT05487859,Acarbose in Combination with Standard Therapy in Metastatic Renal Cell Carcinoma (RCC),NOT_YET_RECRUITING,PHASE2,Kidney Cancer,Acarbose Tablets (DRUG),25102846,Cometriq,Kidney Cancer,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14593,NCT05168163,"Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer",RECRUITING,PHASE2,Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Unresectable Hepatocellular Carcinoma,Atezolizumab (BIOLOGICAL); Cabozantinib (DRUG); Lenvatinib (DRUG),25102846,Cometriq,Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Unresectable Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14594,NCT05007613,Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma,COMPLETED,PHASE2,Esophageal Cancer; Metastatic Cancer; Squamous Cell Carcinoma,Cabozantinib 40 MG (DRUG); Atezolizumab Injection (DRUG),25102846,Cometriq,Esophageal Cancer; Metastatic Cancer; Squamous Cell Carcinoma,Esophagus/Stomach,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14595,NCT05188118,Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma,RECRUITING,EARLY_PHASE1,Renal Cell Carcinoma,Cabozantinib (DRUG); Ipilimumab (DRUG); Nivolumab (DRUG); Lenvatinib (DRUG); Everolimus (DRUG),25102846,Cometriq,Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14596,NCT06535737,"A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab",NOT_YET_RECRUITING,PHASE2,Hepatocellular Carcinoma Non-resectable,Cabozantinib (DRUG),25102846,Cometriq,Hepatocellular Carcinoma Non-resectable,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14597,NCT02795156,Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,COMPLETED,PHASE2,"Non-small Cell Lung Carcinoma; Urothelial Carcinoma; Gastrointestinal Carcinoma, Non-colon; Upper Aerodigestive Tract Carcinoma",Afatinib (DRUG); Regorafenib (DRUG); Cabozantinib (DRUG),25102846,Cometriq,"Non-small Cell Lung Carcinoma; Urothelial Carcinoma; Gastrointestinal Carcinoma, Non-colon; Upper Aerodigestive Tract Carcinoma",Bladder/Urinary Tract,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14598,NCT04767906,Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors,COMPLETED,PHASE2,Hepatocellular Carcinoma,Cabozantinib (DRUG),25102846,Cometriq,Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14599,NCT03963206,Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE),COMPLETED,PHASE4,Hepatocellular Carcinoma,Cabozantinib group (DRUG),25102846,Cometriq,Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14600,NCT04205799,Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure,COMPLETED,PHASE2,Advanced/Metastatic Cervical Cancer,Cabozantinib (DRUG),25102846,Cometriq,Advanced/Metastatic Cervical Cancer,Cervix,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14601,NCT01441947,Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Cabozantinib (DRUG); Fulvestrant (DRUG),25102846,Cometriq,Breast Cancer,Breast,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14602,NCT03542877,Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,Oral Tablet: Cabozantinib (DRUG),25102846,Cometriq,Colorectal Cancer,Bowel,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14603,NCT04230954,"Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer",TERMINATED,PHASE2,Cervical Cancer; Recurrent Cervical Cancer; Metastatic Cervical Cancer; Persistent Cervical Cancer,Cabozantinib 40 MG oral once a day (DRUG); Pembrolizumab 200 mg IV every 3 weeks (DRUG),25102846,Cometriq,Cervical Cancer; Recurrent Cervical Cancer; Metastatic Cervical Cancer; Persistent Cervical Cancer,Cervix,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14604,NCT06171854,caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.,ACTIVE_NOT_RECRUITING,PHASE2,Refractory Colorectal Adenocarcinoma,Cabozantinib (DRUG),25102846,Cometriq,Refractory Colorectal Adenocarcinoma,Bowel,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14605,NCT03957551,Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma,ACTIVE_NOT_RECRUITING,PHASE1,Advanced Metastatic Melanoma,Cabozantinib (DRUG); Pembrolizumab (DRUG),25102846,Cometriq,Advanced Metastatic Melanoma,Skin,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14606,NCT01865747,A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma,COMPLETED,PHASE3,Renal Cell Carcinoma,Cabozantinib tablets (DRUG); Everolimus (Afinitor) tablets (DRUG),25102846,Cometriq,Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14607,NCT03141177,A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma,ACTIVE_NOT_RECRUITING,PHASE3,Renal Cell Carcinoma,Nivolumab (BIOLOGICAL); Cabozantinib (DRUG); Sunitinib (DRUG); Ipilimumab (BIOLOGICAL),25102846,Cometriq,Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14608,NCT04644432,Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma,UNKNOWN,PHASE2,Metastatic Renal Cell Carcinoma; Kidney Neoplasm; Urologic Neoplasms; Urogenital Neoplasms,Medication (A specification is listed under each arm) (DRUG); Patient reported outcomes measurement (OTHER),25102846,Cometriq,Metastatic Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14609,NCT01716715,"Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",COMPLETED,PHASE2,Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Cabozantinib S-malate (DRUG); Laboratory Biomarker Analysis (OTHER); Paclitaxel (DRUG),25102846,Cometriq,Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14610,NCT02216578,Ph II CABOGIST in GIST,COMPLETED,PHASE2,Metastatic Gastrointestinal Stromal Tumor,cabozantinib (DRUG),25102846,Cometriq,Metastatic Gastrointestinal Stromal Tumor,Bowel,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14611,NCT04310007,"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer",ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Cabozantinib S-malate (DRUG); Computed Tomography (PROCEDURE); Docetaxel (DRUG); Echocardiography Test (PROCEDURE); Gemcitabine Hydrochloride (DRUG); Nab-paclitaxel (DRUG); Nivolumab (BIOLOGICAL); Paclitaxel (DRUG); Ramucirumab (BIOLOGICAL),25102846,Cometriq,Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Lung,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14612,NCT00704288,Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme,COMPLETED,PHASE2,Glioblastoma Multiforme,XL184 (DRUG),25102846,Cometriq,Glioblastoma Multiforme,CNS/Brain,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14613,NCT04471428,Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy,COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung",Cabozantinib (DRUG); Atezolizumab (DRUG); Docetaxel (DRUG),25102846,Cometriq,"Carcinoma, Non-Small-Cell Lung",Lung,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14614,NCT03200587,Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC),COMPLETED,PHASE1,Renal Cell Carcinoma,Avelumab (DRUG); Cabozantinib (DRUG),25102846,Cometriq,Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14615,NCT02008383,Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,Panitumumab (BIOLOGICAL); Cabozantinib (DRUG),25102846,Cometriq,Colorectal Cancer,Bowel,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14616,NCT03899428,Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC,RECRUITING,PHASE2,Hepatocellular Carcinoma,Durvalumab (DRUG); Sorafenib (DRUG); Lenvatinib (DRUG); Regorafenib (DRUG); Cabozantinib (DRUG),25102846,Cometriq,Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14617,NCT05700461,Drug Screening Using Novel IMD in Renal Cell Carcinoma,RECRUITING,PHASE1,Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Kidney Cancer,Implantable Microdevice (IMD) (COMBINATION_PRODUCT),25102846,Cometriq,Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Kidney Cancer,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14618,NCT03911193,CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation,UNKNOWN,PHASE2,Non-Small Cell Lung Cancer,Cabozantinib (DRUG),25102846,Cometriq,Advanced Non-Small Cell Lung Cancer,Lung,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14619,NCT01658878,"An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer",COMPLETED,PHASE1,Hepatocellular Carcinoma,Nivolumab (BIOLOGICAL); Sorafenib (DRUG); Ipilimumab (DRUG); Cabozantinib (DRUG),25102846,Cometriq,Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14620,NCT05263245,The Pharmacological Effects of Using Cabozantinib With a Light Breakfast,RECRUITING,PHASE2,Renal Cell Carcinoma,Light breakfast (OTHER),25102846,Cometriq,Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14621,NCT01954745,Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma,COMPLETED,PHASE2,Bile Duct Cancer; Intrahepatic Cholangiocarcinoma; Cholangiocarcinoma of the Extrahepatic Bile Duct,Cabozantinib (DRUG),25102846,Cometriq,Bile Duct Cancer; Intrahepatic Cholangiocarcinoma; Cholangiocarcinoma of the Extrahepatic Bile Duct,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14622,NCT06132945,A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain,RECRUITING,PHASE1,Metastatic Renal Cell Carcinoma; Brain Metastases,Cabozantinib (DRUG); Nivolumab (DEVICE); Stereotactic Radiosurgery (SRS) (RADIATION),25102846,Cometriq,Metastatic Renal Cell Carcinoma; Brain Metastases,CNS/Brain,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14623,NCT05012371,Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8,Cabozantinib (DRUG); Everolimus (DRUG); Lenvatinib (DRUG); Questionnaire Administration (OTHER),25102846,Cometriq,Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14624,NCT01908426,Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib,COMPLETED,PHASE3,Hepatocellular Carcinoma,Cabozantinib tablets (DRUG); Placebo tablets (DRUG),25102846,Cometriq,Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14625,NCT02315430,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",COMPLETED,PHASE2,Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Cabozantinib S-malate (DRUG); Laboratory Biomarker Analysis (OTHER),25102846,Cometriq,Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14626,NCT05931393,Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC),RECRUITING,PHASE2,RCC; Renal Cell Carcinoma,Cabozantinib 80 MG (DRUG),25102846,Cometriq,RCC; Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14627,NCT05620771,Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk,SUSPENDED,PHASE2,Hepatocellular Carcinoma,Atezolizumab and Bevacizumab (DRUG); Y90 + TKI (DRUG),25102846,Cometriq,Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14628,NCT04963283,Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Colorectal Adenocarcinoma; Colon Cancer; Colon Adenocarcinoma; Rectum Cancer; Rectal Cancer; Rectal Adenocarcinoma; Colorectal Cancer,Cabozantinib (DRUG); Nivolumab (DRUG),25102846,Cometriq,Colorectal Adenocarcinoma; Colon Cancer; Colon Adenocarcinoma; Rectum Cancer; Rectal Cancer; Rectal Adenocarcinoma; Colorectal Cancer,Bowel,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14629,NCT04714697,Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma,UNKNOWN,PHASE2,Renal Cell Cancer,Cabometyx (DRUG),25102846,Cometriq,Renal Cell Cancer,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14630,NCT02132598,Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases,TERMINATED,PHASE2,Non Small Cell Lung Cancer (NSCLC); Metastases to the Brain,cabozantinib (DRUG),25102846,Cometriq,Non Small Cell Lung Cancer (NSCLC); Metastases to the Brain,Lung,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14631,NCT01835145,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery,COMPLETED,PHASE2,Recurrent Uveal Melanoma; Stage III Uveal Melanoma AJCC v7; Stage IIIA Uveal Melanoma AJCC v7; Stage IIIB Uveal Melanoma AJCC v7; Stage IIIC Uveal Melanoma AJCC v7; Stage IV Uveal Melanoma AJCC v7,Cabozantinib S-malate (DRUG); Dacarbazine (DRUG); Laboratory Biomarker Analysis (OTHER); Temozolomide (DRUG),25102846,Cometriq,Recurrent Uveal Melanoma; Stage III Uveal Melanoma AJCC v7; Stage IIIA Uveal Melanoma AJCC v7; Stage IIIB Uveal Melanoma AJCC v7; Stage IIIC Uveal Melanoma AJCC v7; Stage IV Uveal Melanoma AJCC v7,Skin,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14632,NCT03729245,A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC),TERMINATED,PHASE3,Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma,bempegaldesleukin (BIOLOGICAL); sunitinib (DRUG); nivolumab (BIOLOGICAL); cabozantinib (DRUG),25102846,Cometriq,Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14633,NCT04540705,A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread,COMPLETED,PHASE1,Renal Cell Carcinoma,Nivolumab (BIOLOGICAL); Axitinib (DRUG); Cabozantinib (DRUG),25102846,Cometriq,Renal Cell Carcinoma,Kidney,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14634,NCT05797805,A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma,RECRUITING,PHASE1,Advanced Hepatocellular Carcinoma,Tegavivint (DRUG); Lenvatinib (DRUG); Cabozantinib (DRUG),25102846,Cometriq,Advanced Hepatocellular Carcinoma,Liver,Cabozantinib (S-malate),"MET, KDR, AXL",inhibitor/antagonist,Multi-TK inhibitor,yes,yes,Approved for medullary thyroid cancer and renal cell carcinoma.,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O,1.1408450704225352,1570.0 +14635,NCT05712265,Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant,COMPLETED,PHASE1,Antipsychotic Induced Weight Gain; Non-alcoholic Steatohepatitis (NASH),Miricorilant (DRUG); Fluvoxamine (DRUG),5324346,FVX,Antipsychotic Induced Weight Gain; Non-alcoholic Steatohepatitis (NASH),Liver,Fluvoxamine,SLC6A4,unclear,unclear,yes,yes,SSRI approved for treating OCD and depression.,COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F,1.1,221.0 +14636,NCT01048229,Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease,TERMINATED,PHASE4,Early-stage Parkinson's Disease,Rasagiline (DRUG); Pramipexole (DRUG),5324346,FVX,Early-stage Parkinson's Disease,CNS/Brain,Fluvoxamine,SLC6A4,unclear,unclear,yes,yes,SSRI approved for treating OCD and depression.,COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F,1.1,221.0 +14637,NCT04711863,Fluvoxamine for Adults With Mild to Moderate COVID-19,SUSPENDED,PHASE2,Severe Acute Respiratory Syndrome Coronavirus 2; Coronavirus Infection; Mild to Moderate COVID-19,Fluvoxamine (DRUG); Placebo (DRUG),5324346,FVX,Severe Acute Respiratory Syndrome Coronavirus 2; Coronavirus Infection; Mild to Moderate COVID-19,Lung,Fluvoxamine,SLC6A4,unclear,unclear,yes,yes,SSRI approved for treating OCD and depression.,COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F,1.1,221.0 +14638,NCT03634345,Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.,COMPLETED,PHASE1,"Dermatitis, Atopic",Period 1 - Day 1: PF-04965842 administered (DRUG); Period 2: Cohort 1: Fluvoxamine & PF-04965842 (DRUG); Period 2: Cohort 2: Fluconazole & PF-04965842 (DRUG),5324346,FVX,"Dermatitis, Atopic",Skin,Fluvoxamine,SLC6A4,unclear,unclear,yes,yes,SSRI approved for treating OCD and depression.,COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F,1.1,221.0 +14639,NCT05712265,Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant,COMPLETED,PHASE1,Antipsychotic Induced Weight Gain; Non-alcoholic Steatohepatitis (NASH),Miricorilant (DRUG); Fluvoxamine (DRUG),9560989,Luvox,Antipsychotic Induced Weight Gain; Non-alcoholic Steatohepatitis (NASH),Liver,Fluvoxamine (maleate),,inhibitor/antagonist,unclear,yes,yes,Approved for treating OCD and depression-related disorders in humans.,COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F.C(=CC(=O)O)C(=O)O,1.17,247.0 +14640,NCT01048229,Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease,TERMINATED,PHASE4,Early-stage Parkinson's Disease,Rasagiline (DRUG); Pramipexole (DRUG),9560989,Luvox,Early-stage Parkinson's Disease,CNS/Brain,Fluvoxamine (maleate),,inhibitor/antagonist,unclear,yes,yes,Approved for treating OCD and depression-related disorders in humans.,COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F.C(=CC(=O)O)C(=O)O,1.17,247.0 +14641,NCT04711863,Fluvoxamine for Adults With Mild to Moderate COVID-19,SUSPENDED,PHASE2,Severe Acute Respiratory Syndrome Coronavirus 2; Coronavirus Infection; Mild to Moderate COVID-19,Fluvoxamine (DRUG); Placebo (DRUG),9560989,Luvox,Severe Acute Respiratory Syndrome Coronavirus 2; Coronavirus Infection; Mild to Moderate COVID-19,Lung,Fluvoxamine (maleate),,inhibitor/antagonist,unclear,yes,yes,Approved for treating OCD and depression-related disorders in humans.,COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F.C(=CC(=O)O)C(=O)O,1.17,247.0 +14642,NCT03634345,Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.,COMPLETED,PHASE1,"Dermatitis, Atopic",Period 1 - Day 1: PF-04965842 administered (DRUG); Period 2: Cohort 1: Fluvoxamine & PF-04965842 (DRUG); Period 2: Cohort 2: Fluconazole & PF-04965842 (DRUG),9560989,Luvox,"Dermatitis, Atopic",Skin,Fluvoxamine (maleate),,inhibitor/antagonist,unclear,yes,yes,Approved for treating OCD and depression-related disorders in humans.,COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F.C(=CC(=O)O)C(=O)O,1.17,247.0 +14643,NCT01394120,Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer,UNKNOWN,PHASE2,"Carcinoma, Pancreatic Ductal",Targeted Therapy Tailored Treatment (DRUG); Standard Chemotherapy (DRUG),176870,Tarceva,Pancreatic Ductal Carcinoma,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14644,NCT01487174,KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy,TERMINATED,PHASE3,"Carcinoma, Non-Small-Cell Lung",KD019 (DRUG); Erlotinib (DRUG),176870,Tarceva,"Carcinoma, Non-Small-Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14645,NCT01214720,A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer,COMPLETED,PHASE3,Pancreatic Cancer,bevacizumab [Avastin] (DRUG),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14646,NCT05081674,Brazilian Lung Immunotherapy Study,COMPLETED,PHASE2,Lung Neoplasm,Alectinib (DRUG); Pembrolizumab (DRUG); Nivolumab (DRUG); Erlotinib (DRUG),176870,Tarceva,Lung Neoplasm,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14647,NCT00392665,Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck,TERMINATED,PHASE2,Squamous Cell Carcinoma of the Head and Neck (SCCHN),Bevacizumab (DRUG); erlotinib (DRUG); Sulindac (DRUG),176870,Tarceva,Squamous Cell Carcinoma of the Head and Neck,Skin,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14648,NCT00096265,Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer,TERMINATED,PHASE3,Metastatic Malignant Neoplasm in the Brain; Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7,3-Dimensional Conformal Radiation Therapy (RADIATION); Erlotinib Hydrochloride (DRUG); Stereotactic Radiosurgery (RADIATION); Temozolomide (DRUG),176870,Tarceva,Metastatic Malignant Neoplasm in the Brain; Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14649,NCT00564720,"Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer",TERMINATED,PHASE2,Pancreatic Cancer,Gemcitabine (DRUG); Gemcitabine (DRUG); Erlotinib (DRUG); Oxaliplatin (DRUG),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14650,NCT02155465,Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib,COMPLETED,PHASE1,Lung Cancer,Ruxolitinib (DRUG); Erlotinib (DRUG),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14651,NCT02705820,Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy,COMPLETED,PHASE2,Metastatic Non Small Cell Lung Cancer,Pembrolizumab (DRUG),176870,Tarceva,Metastatic Non Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14652,NCT02039674,A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021),COMPLETED,PHASE1,Non-small Cell Lung Carcinoma,Pembrolizumab (BIOLOGICAL); Paclitaxel (DRUG); Carboplatin (DRUG); Bevacizumab (BIOLOGICAL); Pemetrexed (DRUG); Ipilimumab (BIOLOGICAL); Erlotinib (DRUG); Gefitinib (DRUG),176870,Tarceva,Non-small Cell Lung Carcinoma,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14653,NCT00574366,Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer,COMPLETED,PHASE1,Breast Cancer,erlotinib (DRUG); RAD001 (DRUG),176870,Tarceva,Breast Cancer,Breast,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14654,NCT02399566,Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma,UNKNOWN,PHASE4,Lung Adenocarcinoma,"Erlotinib, Pemetrexed (DRUG)",176870,Tarceva,Lung Adenocarcinoma,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14655,NCT00652366,A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,"Erlotinib, escalating dose (DRUG); Erlotinib, standard dose (DRUG); Gemcitabine (DRUG)",176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14656,NCT00885066,"Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer",COMPLETED,PHASE1,Pancreatic Cancer,capecitabine (DRUG); erlotinib hydrochloride (DRUG); gemcitabine hydrochloride (DRUG),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14657,NCT00091026,Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer,COMPLETED,PHASE2,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,cetuximab (BIOLOGICAL); gemcitabine hydrochloride (DRUG); bevacizumab (BIOLOGICAL); erlotinib hydrochloride (DRUG),176870,Tarceva,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14658,NCT00410826,Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer,COMPLETED,PHASE2,Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx,erlotinib hydrochloride (DRUG); cisplatin (DRUG); 3-dimensional conformal radiation therapy (RADIATION); intensity-modulated radiation therapy (RADIATION); quality-of-life assessment (PROCEDURE),176870,Tarceva,Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx,Skin,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14659,NCT00130520,Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer,COMPLETED,PHASE2,Ovarian Neoplasms,bevacizumab (DRUG); erlotinib (DRUG),176870,Tarceva,Ovarian Neoplasms,Ovary/Fallopian Tube,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14660,NCT00509431,Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma,COMPLETED,PHASE1,Brain and Central Nervous System Tumors,Erlotinib + Sirolimus (DRUG),176870,Tarceva,Brain and Central Nervous System Tumors,CNS/Brain,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14661,NCT00965731,"Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer",COMPLETED,PHASE1,Non-Small Cell Lung Cancer,Erlotinib (DRUG); Erlotinib (DRUG); PF-02341066 (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14662,NCT04165031,A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation,TERMINATED,PHASE1,Advanced Solid Tumor; Non-Small Cell Lung Cancer; Colorectal Cancer,LY3499446 (DRUG); Abemaciclib (DRUG); Cetuximab (DRUG); Erlotinib (DRUG); Docetaxel (DRUG),176870,Tarceva,Advanced Solid Tumor; Non-Small Cell Lung Cancer; Colorectal Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14663,NCT01069757,A Study of ARQ 197 in Combination With Erlotinib,COMPLETED,PHASE1,Non-small-cell Lung Cancer,ARQ 197 and Erlotinib (DRUG),176870,Tarceva,Non-small-cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14664,NCT01383148,Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer,TERMINATED,PHASE2,Non-Small-Cell Lung Carcinoma,TG4010 (BIOLOGICAL); placebo (DRUG),176870,Tarceva,Non-Small-Cell Lung Carcinoma,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14665,NCT00391248,Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL),COMPLETED,PHASE2,Non-small Cell Lung Cancer,Erlotinib (DRUG),176870,Tarceva,Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14666,NCT00376948,"Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",COMPLETED,PHASE2,Pancreatic Cancer,genistein (DIETARY_SUPPLEMENT); erlotinib hydrochloride (DRUG); gemcitabine hydrochloride (DRUG),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14667,NCT00642473,A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash,COMPLETED,PHASE2,Non-Squamous Non-Small Cell Lung Cancer,Erlotinib (DRUG); Metronidazole Actavis (DRUG); Non-active Moisturizing Cream (OTHER),176870,Tarceva,Non-Squamous Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14668,NCT00268684,Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC,UNKNOWN,PHASE3,"Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis","Erlotinib, Temozolomide (DRUG)",176870,Tarceva,"Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14669,NCT00466284,Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer,UNKNOWN,PHASE2,Non-Small Cell Lung Cancer,Tarceva (erlotinib) (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14670,NCT02314364,A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC,COMPLETED,PHASE2,"Non-small Cell Lung Cancer Metastatic; Targetable Oncogenes (EGFR, ALK, ROS1)",SBRT with protons or photons (RADIATION),176870,Tarceva,"Non-small Cell Lung Cancer Metastatic; Targetable Oncogenes (EGFR, ALK, ROS1)",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14671,NCT04322890,Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation,RECRUITING,PHASE2,Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROS1 Gene Mutation; MET Gene Mutation,"Osimertinib (DRUG); Alectinib 150 MG (DRUG); Crizotinib 250 MG (DRUG); Savolitinib, Crizotinib. (DRUG); Chemotherapy (DRUG)",176870,Tarceva,Non-Small Cell Lung Cancer with Gene Mutations,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14672,NCT00989690,Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer,UNKNOWN,PHASE3,Lung Cancer,docetaxel (DRUG); erlotinib hydrochloride (DRUG); pemetrexed disodium (DRUG); fluorescence in situ hybridization (GENETIC); mutation analysis (GENETIC); proteomic profiling (GENETIC); immunohistochemistry staining method (OTHER); laboratory biomarker analysis (OTHER); matrix-assisted laser desorption/ionization time of flight mass spectrometry (OTHER); breath test (PROCEDURE),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14673,NCT00823290,Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC),TERMINATED,PHASE1,Hepatocellular Carcinoma,Sorafenib + LBH589 (DRUG),176870,Tarceva,Hepatocellular Carcinoma,Liver,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14674,NCT02066038,Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation,UNKNOWN,PHASE2,"Lung, Carcinoma",Erlotinib (DRUG),176870,Tarceva,Lung Carcinoma,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14675,NCT01003938,Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer,TERMINATED,PHASE2,Ovarian Cancer,Topotecan (DRUG); Erlotinib (DRUG),176870,Tarceva,Ovarian Cancer,Ovary/Fallopian Tube,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14676,NCT00043823,Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer,Avastin (DRUG); Tarceva (DRUG),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14677,NCT00416650,Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,erlotinib hydrochloride (DRUG),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14678,NCT03382795,Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients,UNKNOWN,PHASE2,EGFR Positive Non-small Cell Lung Cancer,EGFR (DRUG),176870,Tarceva,EGFR Positive Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14679,NCT00200395,"OSI-774 (Erlotinib, Tarceva) in Elderly Patients",COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Tarceva (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14680,NCT01531712,Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable,TERMINATED,PHASE2,Pancreatic Cancer,Gemcitabine (DRUG); Radiotherapy (RADIATION); Tarceva (DRUG); Oxaliplatin (DRUG),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14681,NCT00988169,Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations,TERMINATED,PHASE2,Lung Cancer,oral erlotinib and pulsed doses of oral AT-101 (DRUG),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14682,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Sorafenib (DRUG); Erlotinib (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14683,NCT00778167,Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Recurrent Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,cixutumumab (BIOLOGICAL); erlotinib hydrochloride (DRUG); laboratory biomarker analysis (OTHER),176870,Tarceva,Recurrent Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14684,NCT00925769,"ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer",COMPLETED,PHASE1,Pancreatic Cancer,bevacizumab [Avastin] (DRUG); capecitabine [Xeloda] (DRUG); erlotinib [Tarceva] (DRUG),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14685,NCT01652469,Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.,COMPLETED,PHASE3,"Carcinoma, Non-Small-Cell Lung",Erlotinib (DRUG); Docetaxel (DRUG),176870,Tarceva,"Carcinoma, Non-Small-Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14686,NCT03399669,The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,gefitinib (DRUG),176870,Tarceva,Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14687,NCT00722969,Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer,UNKNOWN,PHASE2,Non-Small Cell Lung Cancer,sorafenib + erlotinib (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14688,NCT00030446,"Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",COMPLETED,PHASE2,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,carboplatin (DRUG); erlotinib hydrochloride (DRUG),176870,Tarceva,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14689,NCT00620269,Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III,UNKNOWN,PHASE2,Lung Cancer; NSCLC,Erlotinib (DRUG); Induction or consolidation IP chemotherapy (DRUG); CCRT with IP chemotherapy (Irinotecan + Cisplatin) (DRUG); CCRT (RADIATION),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14690,NCT00418327,Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma,COMPLETED,PHASE1,"Malignant Brain Tumor; Brain Stem Glioma,",Tarceva (Erlotinib Hydrochloride) (DRUG),176870,Tarceva,"Malignant Brain Tumor; Brain Stem Glioma,",CNS/Brain,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14691,NCT01110876,"Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)",TERMINATED,PHASE1,Brain Cancer; Glioblastoma Multiforme,Vorinostat (DRUG); Erlotinib (DRUG); Temozolomide (DRUG),176870,Tarceva,Brain Cancer; Glioblastoma Multiforme,CNS/Brain,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14692,NCT00934076,Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer,WITHDRAWN,PHASE1,"Carcinoma, Non Small Cell Lung",Tarceva plus AT-101 (DRUG),176870,Tarceva,Non-small Cell Lung Cancer (NSCLC),Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14693,NCT01091376,Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC),UNKNOWN,PHASE2,Non-small Cell Lung Cancer,Erlotinib (DRUG); Thoracic radiotherapy (RADIATION),176870,Tarceva,Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14694,NCT00039182,Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung,COMPLETED,PHASE2,Advanced Malignant Mesothelioma; Epithelial Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma,erlotinib hydrochloride (DRUG); laboratory biomarker analysis (OTHER),176870,Tarceva,Advanced Malignant Mesothelioma; Epithelial Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14695,NCT00975182,A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors,COMPLETED,PHASE1,"Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers",GDC-0941 (DRUG); erlotinib HCl (DRUG),176870,Tarceva,"Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14696,NCT00674973,A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,Erlotinib (DRUG); Placebo (DRUG),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14697,NCT02000531,Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population,COMPLETED,PHASE4,"Carcinoma, Non-Small-Cell Lung",Erlotinib (DRUG); Chemotherapy (DRUG),176870,Tarceva,"Carcinoma, Non-Small-Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14698,NCT02152631,A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Non Small Cell Lung Cancer,Abemaciclib (DRUG); Erlotinib (DRUG),176870,Tarceva,Non Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14699,NCT00837876,Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery,COMPLETED,PHASE2,Pancreatic Cancer,Sorafenib (DRUG); Erlotinb (DRUG),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14700,NCT01404260,Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer,COMPLETED,PHASE3,Non-small Cell Lung Cancer,Gefitinib (DRUG); Gemcitabine +Carboplatin (DRUG),176870,Tarceva,Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14701,NCT00910676,Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors,COMPLETED,PHASE2,Metastatic Colorectal Cancer; Non-Small-Cell Lung Carcinoma,Diprosone (DRUG),176870,Tarceva,Metastatic Colorectal Cancer; Non-Small-Cell Lung Carcinoma,Bowel,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14702,NCT00476476,Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar,COMPLETED,PHASE2,Squamous Cell Carcinoma,Erlotinib (DRUG),176870,Tarceva,Squamous Cell Carcinoma,Skin,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14703,NCT02095782,Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation,TERMINATED,PHASE2,Non-small-cell Lung Cancer,Intercalated combination of chemotherapy and erlotinib (DRUG),176870,Tarceva,Non-small-cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14704,NCT00702182,Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Non-Small Cell Lung Cancer,Vinorelbine (Navelbine) (DRUG); Vinorelbine (Navelbine) (DRUG); Erlotinib (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14705,NCT02355431,Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations,WITHDRAWN,PHASE2,Solid Tumors and Hematologic Malignancy; NSCLC (Non-small Cell Lung Carcinoma),Itacitinib (DRUG); erlotinib (DRUG); placebo (DRUG),176870,Tarceva,Solid Tumors and Hematologic Malignancy; NSCLC (Non-small Cell Lung Carcinoma),Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14706,NCT00072631,"Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer",COMPLETED,PHASE2,Advanced Non Small Cell Lung Cancer; Failed Prior Chemotherapy,"Tarceva (Trademark) (erlotinib HCl, OSI-774) (DRUG)",176870,Tarceva,Advanced Non Small Cell Lung Cancer; Failed Prior Chemotherapy,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14707,NCT01377376,"A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib",TERMINATED,PHASE3,Non-small-cell Lung Cancer,ARQ 197 and Erlotinib (DRUG); Placebo and Erlotinib (DRUG),176870,Tarceva,Non-small-cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14708,NCT01336192,Maintenance Gemcitabine in the Chinese Advanced Lung Cancer,UNKNOWN,PHASE4,Non Small Cell Lung Cancer,Gemcitabine (DRUG); Best supportive care (DRUG),176870,Tarceva,Non Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14709,NCT02117167,SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients,COMPLETED,PHASE2,Non-small Cell Lung Cancer Metastatic,AZD2014 (DRUG); AZD4547 (DRUG); AZD5363 (DRUG); AZD8931 (DRUG); Selumetinib (DRUG); Vandetanib (DRUG); Standard maintenance for squamous NSCLC (DRUG); Pemetrexed (DRUG); Durvalumab (DRUG); savolitinib (DRUG); Olaparib (DRUG),176870,Tarceva,Non-small Cell Lung Cancer Metastatic,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14710,NCT00313560,ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA),COMPLETED,PHASE2,Pancreatic Cancer,erlotinib hydrochloride (DRUG),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14711,NCT05442060,"To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer",RECRUITING,PHASE2,Non-small Cell Lung Cancer,30 μg OBI-833/100 μg OBI-821 (BIOLOGICAL); Erlotinib (150 mg daily) (DRUG),176870,Tarceva,Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14712,NCT00124280,Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,Non-small-cell Lung Carcinoma,RAD001 (DRUG),176870,Tarceva,Non-small-cell Lung Carcinoma,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14713,NCT00440167,Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine,UNKNOWN,PHASE3,Pancreatic Cancer,Gemcitabine (DRUG); Capecitabine (DRUG); Erlotinib (DRUG),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14714,NCT03497767,A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases,COMPLETED,PHASE2,Metastatic Non Small Cell Lung Cancer,Osimertinib (DRUG); Stereotactic Radiosurgery (SRS) (RADIATION),176870,Tarceva,Metastatic Non Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14715,NCT00049101,Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE1,Colorectal Cancer,erlotinib hydrochloride (DRUG); fluorouracil (DRUG); leucovorin calcium (DRUG); oxaliplatin (DRUG),176870,Tarceva,Colorectal Cancer,Bowel,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14716,NCT00550173,A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small-Cell Lung Cancer,pemetrexed (DRUG); erlotinib (DRUG),176870,Tarceva,Non-Small-Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14717,NCT00445848,S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,bevacizumab (BIOLOGICAL); erlotinib hydrochloride (DRUG),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14718,NCT02411448,A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY),ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Non-Small Cell Lung Cancer,Ramucirumab (DRUG); Placebo (DRUG); Erlotinib (DRUG); Gefitinib (DRUG); Osimertinib (DRUG),176870,Tarceva,Metastatic Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14719,NCT00709826,APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer; Metastatic Pancreatic Cancer,gemcitabine (DRUG); placebo (DRUG); Erlotinib (DRUG); apricoxib (DRUG),176870,Tarceva,Pancreatic Cancer; Metastatic Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14720,NCT00124657,Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma,COMPLETED,PHASE1,Brain and Central Nervous System Tumors,Erlotinib hydrochloride (DRUG),176870,Tarceva,Brain and Central Nervous System Tumors,CNS/Brain,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14721,NCT00101348,"Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer",COMPLETED,PHASE1,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Basal Cell Carcinoma of the Lip; Recurrent Colon Cancer; Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Non-small Cell Lung Cancer; Recurrent Pancreatic Cancer; Recurrent Rectal Cancer; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage III Adenoid Cystic Carcinoma of the Oral Cavity; Stage III Basal Cell Carcinoma of the Lip; Stage III Colon Cancer; Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Stage III Lymphoepithelioma of the Nasopharynx; Stage III Lymphoepithelioma of the Oropharynx; Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Stage III Mucoepidermoid Carcinoma of the Oral Cavity; Stage III Pancreatic Cancer; Stage III Rectal Cancer; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IIIB Non-small Cell Lung Cancer; Stage IV Adenoid Cystic Carcinoma of the Oral Cavity; Stage IV Basal Cell Carcinoma of the Lip; Stage IV Colon Cancer; Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Lymphoepithelioma of the Oropharynx; Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Stage IV Mucoepidermoid Carcinoma of the Oral Cavity; Stage IV Non-small Cell Lung Cancer; Stage IV Pancreatic Cancer; Stage IV Rectal Cancer; Stage IV Renal Cell Cancer; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Untreated Metastatic Squamous Neck Cancer With Occult Primary,erlotinib hydrochloride (DRUG); cetuximab (BIOLOGICAL); bevacizumab (BIOLOGICAL); laboratory biomarker analysis (OTHER),176870,Tarceva,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Basal Cell Carcinoma of the Lip; Recurrent Colon Cancer; Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Non-small Cell Lung Cancer; Recurrent Pancreatic Cancer; Recurrent Rectal Cancer; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage III Adenoid Cystic Carcinoma of the Oral Cavity; Stage III Basal Cell Carcinoma of the Lip; Stage III Colon Cancer; Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Stage III Lymphoepithelioma of the Nasopharynx; Stage III Lymphoepithelioma of the Oropharynx; Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Stage III Mucoepidermoid Carcinoma of the Oral Cavity; Stage III Pancreatic Cancer; Stage III Rectal Cancer; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IIIB Non-small Cell Lung Cancer; Stage IV Adenoid Cystic Carcinoma of the Oral Cavity; Stage IV Basal Cell Carcinoma of the Lip; Stage IV Colon Cancer; Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Lymphoepithelioma of the Oropharynx; Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Stage IV Mucoepidermoid Carcinoma of the Oral Cavity; Stage IV Non-small Cell Lung Cancer; Stage IV Pancreatic Cancer; Stage IV Rectal Cancer; Stage IV Renal Cell Cancer; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Untreated Metastatic Squamous Neck Cancer With Occult Primary,Bowel,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14722,NCT02296125,AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer,AZD9291 80 mg/40 mg + placebo (DRUG); Placebo Erlotinib 150/100mg (DRUG); Placebo Gefitinib 250 mg (DRUG); Erlotinib 150/100 mg (DRUG); Gefitinib 250 mg (DRUG); Placebo AZD9291 80 mg/ 40 mg (DRUG),176870,Tarceva,EGFR-Positive Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14723,NCT01149122,Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract Carcinoma,COMPLETED,PHASE3,"Unresectable, Metastatic Biliary Tract Carcinoma",Gemcitabine/Oxaliplatin (DRUG); Gemcitabine/Oxaliplatin with Erlotinib (Tarceva) (DRUG),176870,Tarceva,"Unresectable, Metastatic Biliary Tract Carcinoma",Liver,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14724,NCT00263822,"Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer",COMPLETED,PHASE3,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,erlotinib hydrochloride (DRUG),176870,Tarceva,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14725,NCT00602030,Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC,COMPLETED,PHASE1,"Non-Small-Cell Lung Carcinoma; Carcinoma, Non-Small Cell Lung",Entinostat (DRUG); Placebo (DRUG); Erlotinib (DRUG),176870,Tarceva,"Non-Small-Cell Lung Carcinoma; Carcinoma, Non-Small Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14726,NCT00954525,Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer,COMPLETED,PHASE1,Metastatic Pancreatic Cancer,Gemcitabine and Erlotinib (DRUG); Intravenous Vitamin C (DIETARY_SUPPLEMENT),176870,Tarceva,Metastatic Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14727,NCT00482625,Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,TERMINATED,PHASE2,Intraductal Papillary Mucinous Neoplasm of the Pancreas; Recurrent Pancreatic Cancer; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer,erlotinib hydrochloride (DRUG); conventional surgery (PROCEDURE); immunohistochemistry staining method (OTHER); protein expression analysis (GENETIC); biopsy (PROCEDURE); pharmacological study (OTHER); laboratory biomarker analysis (OTHER),176870,Tarceva,Intraductal Papillary Mucinous Neoplasm of the Pancreas; Recurrent Pancreatic Cancer; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14728,NCT03213626,Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma,TERMINATED,PHASE2,Pancreatic Adenocarcinoma Metastatic,Cabozantinib 40 MG (DRUG); Erlotinib 100Mg Tab (DRUG),176870,Tarceva,Metastatic Pancreatic Adenocarcinoma,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14729,NCT01859026,A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation,COMPLETED,PHASE1,Lung Cancer; Non-Small Cell Lung Cancer,MEK162 (DRUG); Erlotinib (DRUG),176870,Tarceva,Lung Cancer; Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14730,NCT01487265,Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib,COMPLETED,PHASE2,Non Small Cell Lung Cancer,BKM120 and Erlotinib (DRUG),176870,Tarceva,Non Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14731,NCT00987766,"Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer",COMPLETED,PHASE1,Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer; Pancreatic Cancer; Periampullary Adenocarcinoma; Small Intestine Cancer,erlotinib hydrochloride (DRUG); gemcitabine hydrochloride (DRUG); oxaliplatin (DRUG); laboratory biomarker analysis (OTHER),176870,Tarceva,Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer; Pancreatic Cancer; Periampullary Adenocarcinoma; Small Intestine Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14732,NCT00049166,Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer,COMPLETED,PHASE1,Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Squamous Cell Carcinoma of the Oropharynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Oropharynx,erlotinib hydrochloride (DRUG); cisplatin (DRUG); intensity-modulated radiation therapy (RADIATION); laboratory biomarker analysis (OTHER),176870,Tarceva,Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Squamous Cell Carcinoma of the Oropharynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Oropharynx,Skin,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14733,NCT06678230,Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer,NOT_YET_RECRUITING,PHASE2,Breast Cancer,Anlotinib (DRUG),176870,Tarceva,Breast Cancer,Breast,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14734,NCT00373425,A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors,COMPLETED,PHASE3,Non-small Cell Lung Cancer,Erlotinib (DRUG); Placebo (DRUG),176870,Tarceva,Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14735,NCT01288430,A Study of DS-2248 in Participants With Advanced Solid Tumors,TERMINATED,PHASE1,Solid Tumors; Non-small Cell Lung Carcinoma,DS-2248 (DRUG),176870,Tarceva,Solid Tumors and Non-small Cell Lung Carcinoma,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14736,NCT00634725,Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery,COMPLETED,PHASE3,Pancreatic Cancer,capecitabine (DRUG); erlotinib hydrochloride (DRUG); gemcitabine hydrochloride (DRUG); laboratory biomarker analysis (OTHER); radiation therapy (RADIATION),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14737,NCT01456325,A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung),COMPLETED,PHASE3,Non-Squamous Non-Small Cell Lung Cancer,Erlotinib (DRUG); Onartuzumab (MetMab) (DRUG); Placebo (DRUG),176870,Tarceva,Non-Squamous Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14738,NCT00095225,A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer),COMPLETED,PHASE2,"Non-Small-Cell Lung Carcinoma; Neoplasm Recurrence, Local",Avastin (bevacizumab) (DRUG); Tarceva (erlotinib HCl) (DRUG),176870,Tarceva,"Non-Small-Cell Lung Carcinoma; Neoplasm Recurrence, Local",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14739,NCT01407822,Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,Erlotinib (DRUG); Gemcitabine/cisplatin (DRUG),176870,Tarceva,Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14740,NCT00387322,Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors,COMPLETED,PHASE1,"Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",erlotinib hydrochloride (DRUG); pemetrexed disodium (DRUG),176870,Tarceva,"Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14741,NCT00137839,Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung,COMPLETED,PHASE2,Adenocarcinoma; Non-small Cell Lung Cancer,Erlotinib (DRUG),176870,Tarceva,Adenocarcinoma; Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14742,NCT05994339,Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer,NOT_YET_RECRUITING,PHASE2,Lung Cancer Stage III,Almonertinib (DRUG),176870,Tarceva,Lung Cancer Stage III,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14743,NCT00085839,Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,"Tarceva (Trademark) (erlotinib HCl, OSI-774) (DRUG); Combination carboplatin and paclitaxel (DRUG)",176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14744,NCT02134886,Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection,TERMINATED,PHASE1,HIV Infection; Recurrent Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Erlotinib Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Quality-of-Life Assessment (OTHER),176870,Tarceva,HIV Infection; Recurrent Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14745,NCT00351039,"Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer",TERMINATED,PHASE1,Non-Small Cell Lung Cancer,Bevacizumab (DRUG); Erlotinib (DRUG); Pemetrexed (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14746,NCT02416739,Anticancer Activity of Nicotinamide on Lung Cancer,UNKNOWN,PHASE2,Non-Small-Cell Lung Carcinoma,Nicotinamide (DRUG),176870,Tarceva,Non-Small-Cell Lung Carcinoma,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14747,NCT00230126,OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",erlotinib (DRUG),176870,Tarceva,"Carcinoma, Non-Small-Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14748,NCT00137826,Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma,COMPLETED,PHASE2,Mesothelioma,Erlotinib (DRUG); Bevacizumab (DRUG),176870,Tarceva,Mesothelioma,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14749,NCT01316757,"Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer",COMPLETED,PHASE2,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Tongue Cancer; Untreated Metastatic Squamous Neck Cancer With Occult Primary,cetuximab (BIOLOGICAL); paclitaxel (DRUG); carboplatin (DRUG); erlotinib hydrochloride (DRUG); laboratory biomarker analysis (OTHER),176870,Tarceva,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Tongue Cancer; Untreated Metastatic Squamous Neck Cancer With Occult Primary,Skin,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14750,NCT02277457,"Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations",WITHDRAWN,EARLY_PHASE1,Non-Small Cell Lung Cancer,PET-Adaptive RT (RADIATION); Erlotinib (DRUG); Crizotinib (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14751,NCT00954226,Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Recurrent Head and Neck Carcinoma; Recurrent Salivary Gland Carcinoma; Recurrent Skin Carcinoma; Skin Squamous Cell Carcinoma,Erlotinib Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER),176870,Tarceva,Recurrent Head and Neck Carcinoma; Recurrent Salivary Gland Carcinoma; Recurrent Skin Carcinoma; Skin Squamous Cell Carcinoma,Skin,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14752,NCT05987826,Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC,NOT_YET_RECRUITING,PHASE2,Non-Small Cell Lung Cancer,Furmonertinib (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14753,NCT00605722,A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.,COMPLETED,PHASE2,Liver Cancer,bevacizumab (Avastin) (DRUG); erlotinib (Tarceva) (DRUG),176870,Tarceva,Liver Cancer,Liver,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14754,NCT00287222,Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma,COMPLETED,PHASE2,Hepatocellular Carcinoma,Bevacizumab (DRUG); Erlotinib (DRUG),176870,Tarceva,Hepatocellular Carcinoma,Liver,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14755,NCT00187486,"Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors",COMPLETED,PHASE2,Glioblastoma Multiforme; Gliosarcoma,Tarceva (DRUG); Temodar (DRUG); Radiation Therapy (PROCEDURE),176870,Tarceva,Glioblastoma Multiforme; Gliosarcoma,CNS/Brain,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14756,NCT00339586,First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene,UNKNOWN,PHASE2,"Lung Neoplasms; Non-Small Cell Lung Cancer; Adenocarcinoma, Bronchiolo-Alveolar",Erlotinib (DRUG),176870,Tarceva,"Lung Neoplasms; Non-Small Cell Lung Cancer; Adenocarcinoma, Bronchiolo-Alveolar",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14757,NCT01887886,A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation,COMPLETED,PHASE3,Non-Squamous Non-Small Cell Lung Cancer,erlotinib (DRUG); onartuzumab (DRUG); placebo (DRUG),176870,Tarceva,Non-Squamous Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14758,NCT00391586,"Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung",TERMINATED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Erlotinib (DRUG); Platinum-based chemotherapy (DRUG),176870,Tarceva,"Carcinoma, Non-Small-Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14759,NCT02788058,A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy,UNKNOWN,PHASE2,Lung Adenocarcinoma; EGFR Positive Non-small Cell Lung Cancer,EGFR-TKI (DRUG); Thoracic Hypofractionated Radiotherapy (RADIATION),176870,Tarceva,Lung Adenocarcinoma; EGFR Positive Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14760,NCT05204758,Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect,COMPLETED,PHASE3,Advanced Lung Adenocarcinoma,TCM Formula (DRUG); Placebo (DRUG),176870,Tarceva,Advanced Lung Adenocarcinoma,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14761,NCT00063258,Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer,TERMINATED,PHASE2,Lung Cancer,Tarceva (OSI-774) (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14762,NCT01608022,A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus,COMPLETED,PHASE2,Esophageal Squamous Cell Carcinoma,PF804 (DRUG),176870,Tarceva,Esophageal Squamous Cell Carcinoma,Skin,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14763,NCT01189435,Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib,TERMINATED,PHASE2,Lung Cancer,erlotinib (DRUG),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14764,NCT00841035,"7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients",TERMINATED,PHASE2,Pancreatic Cancer,erlotinib (DRUG),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14765,NCT01822496,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,TERMINATED,PHASE2,Stage III Non-Small Cell Lung Cancer AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7; Stage IIIB Non-Small Cell Lung Cancer AJCC v7,Radiation Therapy (RADIATION); Carboplatin (DRUG); Cisplatin (DRUG); Crizotinib (DRUG); Erlotinib (DRUG); Etoposide (DRUG); Paclitaxel (DRUG),176870,Tarceva,Stage III Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14766,NCT00556322,"A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)",COMPLETED,PHASE3,Non-Small Cell Lung Cancer,Alimta or Taxotere (DRUG); erlotinib [Tarceva] (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14767,NCT01093222,"Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma",COMPLETED,PHASE2,Extrahepatic Bile Duct Adenocarcinoma; Gallbladder Adenocarcinoma; Gallbladder Adenocarcinoma With Squamous Metaplasia; Hilar Cholangiocarcinoma; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Undifferentiated Gallbladder Carcinoma; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma,Erlotinib Hydrochloride (DRUG); Sorafenib Tosylate (DRUG),176870,Tarceva,Extrahepatic Bile Duct Adenocarcinoma; Gallbladder Adenocarcinoma; Gallbladder Adenocarcinoma With Squamous Metaplasia; Hilar Cholangiocarcinoma; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Undifferentiated Gallbladder Carcinoma; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma,Liver,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14768,NCT01006096,Erlotinib for Treatment of Psoriasis,WITHDRAWN,PHASE2,Psoriasis,erlotinib (DRUG); placebo tablet (OTHER),176870,Tarceva,Psoriasis,Skin,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14769,NCT02273362,Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver,COMPLETED,PHASE1,Cirrhosis; Hepatocellular Carcinoma,Erlotinib (DRUG); Erlotinib Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Quality-of-Life Assessment (OTHER),176870,Tarceva,Cirrhosis; Hepatocellular Carcinoma,Liver,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14770,NCT00047762,"Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer",COMPLETED,PHASE1,Colorectal Cancer,Erlotinib (aka Tarceva or OSI-774) (DRUG); Bevacizumab (aka Avastin or Rhu MAb VEGF) (DRUG),176870,Tarceva,Colorectal Cancer,Bowel,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14771,NCT00365391,Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer,COMPLETED,PHASE2,Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer,bevacizumab (BIOLOGICAL); erlotinib hydrochloride (DRUG),176870,Tarceva,Primary Hepatocellular Carcinoma,Liver,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14772,NCT02064491,Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC,COMPLETED,PHASE2,Non-small Cell Lung Cancer,Erlotinib (DRUG); Chemotherapy (DRUG),176870,Tarceva,Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14773,NCT00283244,"Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC",COMPLETED,PHASE2,Lung Cancer,erlotinib hydrochloride (DRUG); gemcitabine hydrochloride (DRUG),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14774,NCT03595644,Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer,COMPLETED,PHASE2,Stage IV Non-small Cell Lung Cancer,SBRT+TKI (RADIATION); TKI (DRUG),176870,Tarceva,Stage IV Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14775,NCT01602289,A Study of LY2875358 in Japanese Participants With Advanced Cancer,COMPLETED,PHASE1,"Solid Tumors; Lymphoma; Carcinoma, Non-Small-Cell Lung",LY2875358 (BIOLOGICAL); Erlotinib (DRUG); Gefitinib (DRUG),176870,Tarceva,"Solid Tumors; Lymphoma; Carcinoma, Non-Small-Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14776,NCT00390429,Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors,COMPLETED,PHASE1,"Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",docetaxel (DRUG); erlotinib hydrochloride (DRUG),176870,Tarceva,"Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14777,NCT00663689,Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer,UNKNOWN,PHASE2,Non-Small Cell Lung Cancer; Brain Metastases,erlotinib (DRUG),176870,Tarceva,Non-Small Cell Lung Cancer; Brain Metastases,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14778,NCT01222689,Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,erlotinib hydrochloride (DRUG); selumetinib (DRUG); laboratory biomarker analysis (OTHER),176870,Tarceva,Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14779,NCT00380029,Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer,COMPLETED,PHASE2,Bladder Cancer,Erlotinib (DRUG); Radical Cystectomy (PROCEDURE),176870,Tarceva,Bladder Cancer,Bladder/Urinary Tract,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14780,NCT00287989,"Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer",COMPLETED,PHASE2,Lung Cancer,Carboplatin (DRUG); erlotinib hydrochloride (DRUG); Paclitaxel (DRUG); erlotinib hydrochloride (DRUG),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14781,NCT00581789,Erlotinib and Sunitinib in NSCLC,COMPLETED,PHASE1,Non Small Cell Lung Cancer,"erlotinib, sunitinib (DRUG)",176870,Tarceva,Non Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14782,NCT01131429,A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations,UNKNOWN,PHASE2,"Neoplasms, Lung; Carcinoma, Non-Small Cell Lung; Drug Therapy; Genes, EGFR",Erlotinib (DRUG); Docetaxel (DRUG); Cisplatin (DRUG); Docetaxel (DRUG); Cisplatin (DRUG); Erlotinib (DRUG),176870,Tarceva,"Neoplasms, Lung; Carcinoma, Non-Small Cell Lung; Drug Therapy; Genes, EGFR",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14783,NCT00198380,Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature,COMPLETED,PHASE2,Pneumonic-type Adenocarcinoma (P-ADC); Lung Adenocarcinoma With Bronchiolo-alveolar Feature,Gefitinib (DRUG),176870,Tarceva,Pneumonic-type Adenocarcinoma (P-ADC); Lung Adenocarcinoma With Bronchiolo-alveolar Feature,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14784,NCT01454180,Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets,COMPLETED,PHASE2,Advanced Pancreatic Carcinoma,"gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI. (DRUG); Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI (DRUG)",176870,Tarceva,Advanced Pancreatic Carcinoma,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14785,NCT01897480,A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations,ACTIVE_NOT_RECRUITING,PHASE2,"Carcinoma, Non-Small-Cell Lung",LY2875358 (BIOLOGICAL); Erlotinib (DRUG),176870,Tarceva,"Carcinoma, Non-Small-Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14786,NCT01555489,Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca,TERMINATED,PHASE2,Stage IV Pancreatic Cancer,Ascorbic Acid (DRUG),176870,Tarceva,Stage IV Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14787,NCT01259089,Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Adenocarcinoma of the Lung; Non-small Cell Lung Cancer,erlotinib hydrochloride (DRUG); Hsp90 inhibitor AUY922 (DRUG); laboratory biomarker analysis (OTHER); needle biopsy (PROCEDURE); mutation analysis (GENETIC); pharmacological study (OTHER),176870,Tarceva,Adenocarcinoma of the Lung; Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14788,NCT00633529,Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC,COMPLETED,PHASE1,Non-Small Cell Lung Cancer,IMO-2055 (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14789,NCT00217529,"Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",COMPLETED,PHASE1,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,pegfilgrastim (BIOLOGICAL); carboplatin (DRUG); docetaxel (DRUG); erlotinib hydrochloride (DRUG),176870,Tarceva,Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,Ovary/Fallopian Tube,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14790,NCT01455389,TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer,TERMINATED,PHASE1,Lung Cancer,DOTAP:Chol-TUSC2 (DRUG); Erlotinib (DRUG); Dexamethasone (DRUG); Diphenhydramine (DRUG),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14791,NCT01303029,Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Metastatic Pancreatic Cancer,Gemcitabine+erlotinib (DRUG); Gemcitabine+erlotinib+capecitabine (DRUG),176870,Tarceva,Metastatic Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14792,NCT01556191,Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR,COMPLETED,PHASE2,Stage IV Lung Cancer,Gefitinib (DRUG); Fulvestrant (DRUG); Erlotinib (DRUG),176870,Tarceva,Stage IV Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14793,NCT00754494,Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma,COMPLETED,PHASE2,Adenomatous Polyp; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage I Colon Cancer; Stage I Rectal Cancer; Stage IIA Colon Cancer; Stage IIA Rectal Cancer; Stage IIB Colon Cancer; Stage IIB Rectal Cancer; Stage IIC Colon Cancer; Stage IIC Rectal Cancer; Stage IIIA Colon Cancer; Stage IIIA Rectal Cancer; Stage IIIB Colon Cancer; Stage IIIB Rectal Cancer; Stage IIIC Colon Cancer; Stage IIIC Rectal Cancer,erlotinib hydrochloride (DRUG); placebo (OTHER); laboratory biomarker analysis (OTHER),176870,Tarceva,Adenomatous Polyp; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage I Colon Cancer; Stage I Rectal Cancer; Stage IIA Colon Cancer; Stage IIA Rectal Cancer; Stage IIB Colon Cancer; Stage IIB Rectal Cancer; Stage IIC Colon Cancer; Stage IIC Rectal Cancer; Stage IIIA Colon Cancer; Stage IIIA Rectal Cancer; Stage IIIB Colon Cancer; Stage IIIB Rectal Cancer; Stage IIIC Colon Cancer; Stage IIIC Rectal Cancer,Bowel,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14794,NCT00855894,A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Pertuzumab (DRUG); Erlotinib (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14795,NCT01244191,"Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer",TERMINATED,PHASE3,"Non Squamous, Non-small-cell Lung Cancer",Tivantinib (DRUG); Placebo (DRUG); Erlotinib (DRUG),176870,Tarceva,"Non Squamous, Non-small-cell Lung Cancer",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14796,NCT00294762,Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Tarceva (DRUG); carboplatin (DRUG); paclitaxel (DRUG),176870,Tarceva,"Carcinoma, Non-Small-Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14797,NCT00033462,"Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer",COMPLETED,PHASE2,Adult Primary Cholangiocellular Carcinoma; Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Cholangiocarcinoma of the Extrahepatic Bile Duct; Cholangiocarcinoma of the Gallbladder; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer; Recurrent Extrahepatic Bile Duct Cancer; Recurrent Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Cancer; Unresectable Gallbladder Cancer,erlotinib hydrochloride (DRUG); laboratory biomarker analysis (OTHER),176870,Tarceva,Adult Primary Cholangiocellular Carcinoma; Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Cholangiocarcinoma of the Extrahepatic Bile Duct; Cholangiocarcinoma of the Gallbladder; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer; Recurrent Extrahepatic Bile Duct Cancer; Recurrent Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Cancer; Unresectable Gallbladder Cancer,Liver,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14798,NCT01667562,A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer,COMPLETED,PHASE3,Non-Small Cell Lung Cancer,Erlotinib (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14799,NCT02004262,Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting,COMPLETED,PHASE2,"2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer",GVAX Pancreas Vaccine (BIOLOGICAL); CRS-207 (BIOLOGICAL); Chemotherapy (DRUG); cyclophosphamide (DRUG),176870,Tarceva,"2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer",Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14800,NCT00387894,Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,TERMINATED,PHASE2,Adult Brain Tumors,erlotinib hydrochloride (DRUG),176870,Tarceva,Adult Brain Tumors,CNS/Brain,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14801,NCT00711594,LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",BIBW 2992 MA2 40mg/day (DRUG); BIBW 2992 MA2 50mg/day (DRUG); BIBW 2992 MA2 20mg/day (DRUG); BIBW 2992 QD (DRUG),176870,Tarceva,"Carcinoma, Non-Small-Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14802,NCT03264794,the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer),UNKNOWN,PHASE4,Non-small Cell Lung Cancer,Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial (DRUG); Gefitinib tablets (Yi Ruisha），First medication (DRUG); Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial. (DRUG),176870,Tarceva,Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14803,NCT00039494,Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors,COMPLETED,PHASE2,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma,erlotinib hydrochloride (DRUG); 3-dimensional conformal radiation therapy (RADIATION); temozolomide (DRUG),176870,Tarceva,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma,CNS/Brain,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14804,NCT00428194,"Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer",WITHDRAWN,PHASE1,Cervical Cancer,cisplatin (DRUG); erlotinib hydrochloride (DRUG); radiation therapy (PROCEDURE),176870,Tarceva,Cervical Cancer,Cervix,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14805,NCT03799094,Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations,UNKNOWN,PHASE1,"Carcinoma, Non-Small-Cell Lung",Vitamin C (DRUG); Tyrosine kinase inhibitor (DRUG),176870,Tarceva,"Carcinoma, Non-Small-Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14806,NCT04455594,Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC,NOT_YET_RECRUITING,PHASE2,Non-Small Cell Lung Cancer Stage IIIA,Almonertinib (DRUG); Erlotinib (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG),176870,Tarceva,Non-Small Cell Lung Cancer Stage IIIA,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14807,NCT00531960,A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Erlotinib (DRUG); Bevacizumab (DRUG); Standard platinum-based chemotherapy (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14808,NCT05445791,Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations,RECRUITING,PHASE3,Non Small Cell Lung Cancer,Metformin Hydrochloride (DRUG); Placebo (OTHER),176870,Tarceva,Non Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14809,NCT00453362,A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib,COMPLETED,PHASE1,Non-Small Cell Lung Cancer,2-deoxy-2-[18F]fluoro-D-glucose (FDG) (OTHER); 3'-deoxy-3'-[18F]fluorothymidine (FLT) (OTHER); erlotinib HCl (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14810,NCT01378962,A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER),COMPLETED,PHASE2,Non-Squamous Non-Small Cell Lung Cancer,erlotinib (DRUG),176870,Tarceva,Non-Squamous Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14811,NCT00553462,Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery,COMPLETED,PHASE2,Lung Cancer,carboplatin (DRUG); erlotinib hydrochloride (DRUG); paclitaxel albumin-stabilized nanoparticle formulation (DRUG); radiation therapy (RADIATION),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14812,NCT00760929,A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).,TERMINATED,PHASE2,Non-Squamous Non-Small Cell Lung Cancer,Placebo (DRUG); Placebo (DRUG); RG1507 (DRUG); RG1507 (DRUG); erlotinib [Tarceva] (DRUG),176870,Tarceva,Non-Squamous Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14813,NCT02906163,First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy,UNKNOWN,PHASE1,EGFR Mutation Positive Non Small Cell Lung Cancer,"Thymalfasin (Thymosin alpha 1, Ta1) (DRUG); SoC (tyrosine kinase inhibitor) (DRUG)",176870,Tarceva,EGFR Mutation Positive Non Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14814,NCT01580735,ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer,COMPLETED,PHASE2,Non-small-cell Lung Cancer,ARQ 197 (DRUG),176870,Tarceva,Non-small-cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14815,NCT00470535,Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer,TERMINATED,PHASE2,Pancreatic Cancer,erlotinib hydrochloride (DRUG); immunohistochemistry staining method (OTHER); laboratory biomarker analysis (OTHER),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14816,NCT00878163,GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery,ACTIVE_NOT_RECRUITING,PHASE1,Adult Solid Neoplasm; Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer AJCC v6 and v7,Diagnostic Laboratory Biomarker Analysis (OTHER); Erlotinib Hydrochloride (DRUG); Gemcitabine Hydrochloride (DRUG); Vismodegib (DRUG),176870,Tarceva,Adult Solid Neoplasm; Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer AJCC v6 and v7,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14817,NCT00300586,IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer,COMPLETED,PHASE3,Stage IV Non-small Cell Lung Cancer,observation (DRUG); gemcitabine (DRUG); erlotinib (DRUG),176870,Tarceva,Stage IV Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14818,NCT00091663,A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE3,Lung Cancer; Non-small-cell Lung Carcinoma,Tarceva (erlotinib HCl) (DRUG),176870,Tarceva,Lung Cancer; Non-small-cell Lung Carcinoma,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14819,NCT01174563,A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy,COMPLETED,PHASE2,Non-Squamous Non-Small Cell Lung Cancer,erlotinib [Tarceva] (DRUG),176870,Tarceva,Non-Squamous Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14820,NCT00660816,Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,erlotinib hydrochloride (DRUG); pemetrexed disodium (DRUG); docetaxel (DRUG),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14821,NCT00600496,"A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)",ACTIVE_NOT_RECRUITING,PHASE1,Breast Cancer; Breast Neoplasms; Colon Cancer; Colonic Cancer; Colon Neoplasms; Lung Cancer; Melanoma; Kidney Cancer,AZD6244 (DRUG); Dacarbazine (DRUG); Erlotinib (DRUG); Docetaxel (DRUG); Temsirolimus (DRUG),176870,Tarceva,Breast Cancer; Breast Neoplasms; Colon Cancer; Colonic Cancer; Colon Neoplasms; Lung Cancer; Melanoma; Kidney Cancer,Bowel,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14822,NCT00922896,"Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer",COMPLETED,PHASE2,Metastatic Pancreatic Cancer,"Gemcitabine, Cisplatin, Erlotinib (Tarceva) (DRUG)",176870,Tarceva,Metastatic Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14823,NCT01570296,"A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR",COMPLETED,PHASE1,Non-Small Cell Lung Cancer; Solid Tumors,Gefitinib and BKM120 (DRUG),176870,Tarceva,Non-Small Cell Lung Cancer; Solid Tumors,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14824,NCT00385996,Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer,COMPLETED,PHASE2,"Carcinoma, Non-small Cell Lung",Tarceva (Erlotinib) (DRUG),176870,Tarceva,"Carcinoma, Non-small Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14825,NCT00940316,Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer,COMPLETED,PHASE2,Colorectal Cancer,panitumumab (BIOLOGICAL); erlotinib hydrochloride (DRUG); irinotecan hydrochloride (DRUG),176870,Tarceva,Colorectal Cancer,Bowel,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14826,NCT02759835,"Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib",COMPLETED,PHASE2,Lung Adenocarcinoma; Lung Neoplasms,osimertinib (DRUG); Local Ablative Therapy (LAT) (OTHER),176870,Tarceva,Lung Neoplasms,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14827,NCT00042835,Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer,TERMINATED,PHASE1,Adenocarcinoma of the Lung; Bronchoalveolar Cell Lung Cancer; Large Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer,cisplatin (DRUG); etoposide (DRUG); erlotinib hydrochloride (DRUG); radiation therapy (RADIATION); docetaxel (DRUG); paclitaxel (DRUG); carboplatin (DRUG); laboratory biomarker analysis (OTHER),176870,Tarceva,Adenocarcinoma of the Lung; Bronchoalveolar Cell Lung Cancer; Large Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14828,NCT01183858,A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS),COMPLETED,PHASE3,Non-Small Cell Lung Cancer,Erlotinib [Tarceva] (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14829,NCT00491816,Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Erlotinib with neoadjuvant chemotherapy (DRUG),176870,Tarceva,Breast Cancer,Breast,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14830,NCT01344824,"Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers",COMPLETED,PHASE2,Lung Cancer,bevacizumab (BIOLOGICAL); carboplatin (DRUG); erlotinib hydrochloride (DRUG); pemetrexed disodium (DRUG),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14831,NCT00619424,A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors,COMPLETED,PHASE1,"Lung Cancer, Non-Small Cell",pazopanib (DRUG); erlotinib (DRUG); pemetrexed (DRUG),176870,Tarceva,"Lung Cancer, Non-Small Cell",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14832,NCT00701558,A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-small Cell Lung Cancer Metastatic,Erlotinib (DRUG); Gemcitabine (DRUG),176870,Tarceva,Non-small Cell Lung Cancer Metastatic,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14833,NCT00570258,"Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy",TERMINATED,PHASE2,Metastatic Breast Cancer,Fulvestrant (DRUG); erlotinib (DRUG); Fulvestrant (DRUG); Placebo (DRUG),176870,Tarceva,Metastatic Breast Cancer,Breast,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14834,NCT00738335,Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases,WITHDRAWN,PHASE1,Lung Cancer; Metastatic Cancer,erlotinib hydrochloride (DRUG); immunoenzyme technique (OTHER); laboratory biomarker analysis (OTHER); liquid chromatography (OTHER); mass spectrometry (OTHER); pharmacological study (OTHER); stereotactic radiosurgery (RADIATION),176870,Tarceva,Metastatic Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14835,NCT01928160,Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib,WITHDRAWN,PHASE2,Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,pemetrexed disodium (DRUG); carboplatin (DRUG); cisplatin (DRUG); erlotinib hydrochloride (DRUG); laboratory biomarker analysis (OTHER),176870,Tarceva,Non-small-cell Lung Carcinoma,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14836,NCT00637910,Tarceva Italian Lung Optimization tRial,UNKNOWN,PHASE3,Non Small Cell Lung Cancer (NSCLC),Erlotinib (DRUG); Docetaxel (DRUG),176870,Tarceva,Non Small Cell Lung Cancer (NSCLC),Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14837,NCT00732810,SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716),COMPLETED,PHASE2,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung",SCH 727965 (DRUG); Capecitabine (DRUG); Erlotinib (DRUG),176870,Tarceva,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14838,NCT01230710,A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression,COMPLETED,PHASE4,Non-Small Cell Lung Cancer,Erlotinib (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14839,NCT00955695,Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer,UNKNOWN,PHASE3,Lung Cancer,erlotinib hydrochloride (DRUG); gefitinib (DRUG); questionnaire administration (OTHER); quality-of-life assessment (PROCEDURE); whole-brain radiation therapy (RADIATION),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14840,NCT00949910,An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE4,Non-Small Cell Lung Cancer,Erlotinib (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14841,NCT00365144,Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine,COMPLETED,PHASE2,Pancreatic Cancer,bevacizumab (BIOLOGICAL); erlotinib hydrochloride (DRUG); laboratory biomarker analysis (OTHER),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14842,NCT00536640,Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Erlotinib (DRUG); Bevacizumab (DRUG); Gemcitabine (DRUG); Cisplatin (DRUG),176870,Tarceva,"Carcinoma, Non-Small-Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14843,NCT00276744,Individualized Drug Treatment for Treating Patients With Pancreatic Cancer,TERMINATED,PHASE2,Pancreatic Cancer,cetuximab (BIOLOGICAL); capecitabine (DRUG); docetaxel (DRUG); Erlotinib (DRUG); Gemcitabine (DRUG); Irinotecan (DRUG); mitomycin C (DRUG); rapamycin (DRUG); conventional surgery (PROCEDURE),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14844,NCT00769067,A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen,COMPLETED,PHASE2,Non-small Cell Lung Cancer,Erlotinib (DRUG); PF-00299804 (DRUG),176870,Tarceva,Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14845,NCT02031744,A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer,COMPLETED,PHASE3,Non-Small Cell Lung Cancer,erlotinib [Tarceva] (DRUG); Placebo (DRUG); Onartuzumab [MetMAb] (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14846,NCT00692640,Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors,COMPLETED,PHASE1,Cancer; Non-small Cell Lung Cancer,XL147 (SAR245408) (DRUG); Erlotinib (DRUG),176870,Tarceva,Cancer; Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14847,NCT00652340,APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer,COMPLETED,PHASE2,Recurrent Non Small Cell Lung Cancer,apricoxib/erlotinib (DRUG); erlotinib/placebo (DRUG),176870,Tarceva,Recurrent Non Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14848,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,75 approved agents (DRUG); COXEN (OTHER),176870,Tarceva,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,Bladder/Urinary Tract,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14849,NCT02186301,TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy,TERMINATED,PHASE2,Non-Small Cell Lung Cancer,Rociletinib Mono-Therapy (DRUG); Erlotinib Mono-Therapy (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14850,NCT02044601,Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT),WITHDRAWN,PHASE1,Lung Cancer,Onartuzumab (DRUG); Erlotinib (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); Radiation Therapy (RADIATION),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14851,NCT00062101,Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,erlotinib hydrochloride (DRUG); celecoxib (DRUG); laboratory biomarker analysis (OTHER),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14852,NCT01204372,Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma,COMPLETED,PHASE2,Metastatic Pancreatic Adenocarcinoma,Gemcitabine - Trastuzumab - Erlotinib (DRUG),176870,Tarceva,Metastatic Pancreatic Adenocarcinoma,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14853,NCT00947167,A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors,TERMINATED,PHASE2,Neuroendocrine Tumors; Carcinoid Tumors; Adrenal Gland Tumors; Neuroblastoma; Pancreatic Neuroendocrine Tumors; Multiple Endocrine Neoplasia,pertuzumab (DRUG); erlotinib (DRUG),176870,Tarceva,Neuroendocrine Tumors; Carcinoid Tumors; Adrenal Gland Tumors; Neuroblastoma; Pancreatic Neuroendocrine Tumors; Multiple Endocrine Neoplasia,CNS/Brain,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14854,NCT03653546,First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients with Central Nervous System (CNS) Metastases,COMPLETED,PHASE2,Non-small Cell Lung Cancer; EGFR Gene Mutation; Brain Metastases,AZD3759 (DRUG); Erlotinib (DRUG); Gefitinib (DRUG),176870,Tarceva,Non-small Cell Lung Cancer; EGFR Gene Mutation; Brain Metastases,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14855,NCT02045446,Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial,COMPLETED,PHASE2,Stage IV Non-Small Cell Lung Cancer,Stereotactic Body Radiation Therapy (RADIATION); Maintenance chemotherapy (DRUG),176870,Tarceva,Stage IV Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14856,NCT00673569,Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment,COMPLETED,PHASE2,Lung Cancer,erlotinib hydrochloride (DRUG); gene expression analysis (GENETIC); protein expression analysis (GENETIC); immunoenzyme technique (OTHER); immunologic technique (OTHER); laboratory biomarker analysis (OTHER); needle biopsy (PROCEDURE),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14857,NCT00047346,Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction,COMPLETED,PHASE1,Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer,erlotinib hydrochloride (DRUG); pharmacological study (OTHER); laboratory biomarker analysis (OTHER),176870,Tarceva,Primary Hepatocellular Carcinoma,Liver,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14858,NCT02250846,Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC,UNKNOWN,PHASE2,Asymptomatic Brain Metastases of Non Small Cell Lung Cancer,EGFR-TKI (DRUG),176870,Tarceva,Asymptomatic Brain Metastases of Non Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14859,NCT01320501,Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer,SUSPENDED,PHASE4,Non-small Cell Lung Cancer Metastatic,Erlotinib (DRUG),176870,Tarceva,Non-small Cell Lung Cancer Metastatic,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14860,NCT00602667,"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",ACTIVE_NOT_RECRUITING,PHASE2,Brain and Central Nervous System Tumors,Induction Chemotherapy (DRUG); Low-Risk Therapy (DRUG); High-Risk Therapy (DRUG); Intermediate-Risk Therapy (DRUG),176870,Tarceva,Brain and Central Nervous System Tumors,CNS/Brain,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14861,NCT00459901,Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer,TERMINATED,PHASE2,Metastatic Colorectal Cancer,Erlotinib and capecitabine (DRUG),176870,Tarceva,Metastatic Colorectal Cancer,Bowel,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14862,NCT02031601,Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer,UNKNOWN,PHASE4,Non-Small-Cell Lung Cancer,Erlotinib (DRUG); Gefitinib (DRUG); Icotinib (DRUG); Docetaxel (DRUG); Pemetrexed (DRUG); Platinum (cisplatin or carboplatin) (DRUG); Erlotinib (DRUG); Gefitinib (DRUG); Icotinib (DRUG),176870,Tarceva,Non-Small-Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14863,NCT00975767,A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer,TERMINATED,PHASE1,"Advanced Malignancies, Non-small Cell Lung Cancer",MGCD265+erlotinib (DRUG); MGCD265+docetaxel (DRUG),176870,Tarceva,"Advanced Malignancies, Non-small Cell Lung Cancer",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14864,NCT00367601,Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Lung Cancer,Erlotinib (DRUG); Bevacizumab (DRUG),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14865,NCT00749567,Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer,TERMINATED,PHASE2,Non-small-cell Lung Cancer,Erlotinib (DRUG); Bevacizumab (DRUG),176870,Tarceva,Non-small-cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14866,NCT01167244,Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response,COMPLETED,PHASE2,Non-Small-Cell Lung Carcinoma,BMS-690514 (DRUG),176870,Tarceva,Non-Small-Cell Lung Carcinoma,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14867,NCT01026844,Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC),TERMINATED,PHASE1,Non-small Cell Lung Cancer,erlotinib (DRUG); hydroxychloroquine (DRUG),176870,Tarceva,Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14868,NCT00457392,A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone,COMPLETED,PHASE3,"Carcinoma, Non-Small Cell Lung",erlotinib (DRUG); sunitinib (DRUG); erlotinib (DRUG); placebo (DRUG),176870,Tarceva,"Carcinoma, Non-Small Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14869,NCT01402089,Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients,COMPLETED,PHASE4,Non Small-cell Lung Cancer; Renal-cell Cancer; Gastrointestinal Stroma Tumor,Sunitinib (DRUG); Erlotinib (DRUG); Midazolam (DRUG); Caffeine (DRUG),176870,Tarceva,Non Small-cell Lung Cancer; Renal-cell Cancer; Gastrointestinal Stroma Tumor,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14870,NCT00251589,A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025),TERMINATED,PHASE1,"Carcinoma, Non-Small-Cell Lung",Vorinostat (DRUG); Vorinostat (DRUG); Vorinostat (DRUG); Vorinostat (DRUG); erlotinib (DRUG),176870,Tarceva,"Carcinoma, Non-Small-Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14871,NCT04034589,Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer,UNKNOWN,PHASE2,Metastatic Breast Cancer,Pyrotinib combined with fulvestrant (DRUG),176870,Tarceva,Metastatic Breast Cancer,Breast,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14872,NCT00356889,Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors,COMPLETED,PHASE2,Cholangiocarcinoma of the Extrahepatic Bile Duct; Cholangiocarcinoma of the Gallbladder; Gastrointestinal Cancer; Recurrent Extrahepatic Bile Duct Cancer; Recurrent Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Cancer; Unresectable Gallbladder Cancer,erlotinib hydrochloride (DRUG); bevacizumab (BIOLOGICAL),176870,Tarceva,Cholangiocarcinoma of the Extrahepatic Bile Duct; Cholangiocarcinoma of the Gallbladder; Gastrointestinal Cancer; Recurrent Extrahepatic Bile Duct Cancer; Recurrent Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Cancer; Unresectable Gallbladder Cancer,Bowel,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14873,NCT00779389,Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family,COMPLETED,PHASE1,Head and Neck Cancer; Non Small Cell Lung Cancer,Erlotinib (DRUG); Dasatinib + Placebo (DRUG); Erlotinib plus Dasatinib (DRUG); Placebo (DRUG); Erlotinib (DRUG),176870,Tarceva,Head and Neck Cancer; Non Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14874,NCT00466089,Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung Cancer,UNKNOWN,PHASE2,"Carcinoma, Non-Small-Cell Lung",Erlotinib (Tarceva®) (DRUG),176870,Tarceva,"Carcinoma, Non-Small-Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14875,NCT02633189,Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer,UNKNOWN,PHASE3,Non-squamous Non-small Cell Lung Cancer,Erlotinib (DRUG); Bevacizumab (DRUG),176870,Tarceva,Non-squamous Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14876,NCT00749892,Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer,COMPLETED,PHASE2,Recurrent Bladder Urothelial Carcinoma; Recurrent Renal Pelvis Urothelial Carcinoma; Recurrent Ureter Urothelial Carcinoma; Recurrent Urethral Urothelial Carcinoma; Stage 0a Bladder Cancer AJCC v8; Stage 0a Renal Pelvis Cancer AJCC v8; Stage 0a Ureter Cancer AJCC v8; Stage 0a Urethral Cancer AJCC v8; Stage 0is Bladder Cancer AJCC v8; Stage 0is Renal Pelvis Cancer AJCC v8; Stage 0is Ureter Cancer AJCC v8; Stage 0is Urethral Cancer AJCC v8; Stage II Bladder Cancer AJCC v8; Stage II Renal Pelvis Cancer AJCC v8; Stage II Ureter Cancer AJCC v8; Stage II Urethral Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage III Urethral Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8,Erlotinib Hydrochloride (DRUG),176870,Tarceva,Recurrent Bladder Urothelial Carcinoma; Recurrent Renal Pelvis Urothelial Carcinoma; Recurrent Ureter Urothelial Carcinoma; Recurrent Urethral Urothelial Carcinoma; Stage 0a Bladder Cancer AJCC v8; Stage 0a Renal Pelvis Cancer AJCC v8; Stage 0a Ureter Cancer AJCC v8; Stage 0a Urethral Cancer AJCC v8; Stage 0is Bladder Cancer AJCC v8; Stage 0is Renal Pelvis Cancer AJCC v8; Stage 0is Ureter Cancer AJCC v8; Stage 0is Urethral Cancer AJCC v8; Stage II Bladder Cancer AJCC v8; Stage II Renal Pelvis Cancer AJCC v8; Stage II Ureter Cancer AJCC v8; Stage II Urethral Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage III Urethral Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8,Bladder/Urinary Tract,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14877,NCT00615758,Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV,COMPLETED,PHASE2,Non Small Cell Lung Cancer,Erlotinib (DRUG),176870,Tarceva,Non Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14878,NCT01108458,A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma,TERMINATED,PHASE2,Pancreatic Cancer,Pertuzumab (DRUG); Erlotinib (DRUG),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14879,NCT01251796,A Study of ARQ 197 in Combination With Erlotinib,COMPLETED,PHASE1,Advanced/Recurrent Non-small-cell Lung Cancer,ARQ 197 and Erlotinib (DRUG),176870,Tarceva,Advanced/Recurrent Non-small-cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14880,NCT00109265,A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy,COMPLETED,PHASE2,Breast Cancer,Erlotinib HCl (OSI-774) (DRUG),176870,Tarceva,Breast Cancer,Breast,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14881,NCT01342965,A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations,COMPLETED,PHASE3,Non-Small Cell Lung Cancer,Erlotinib (DRUG); Chemotherapy (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14882,NCT01688973,Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery,COMPLETED,PHASE2,Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma,Erlotinib Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Tivantinib (DRUG),176870,Tarceva,Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma,Kidney,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14883,NCT00696696,Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,Gemcitabine (DRUG); Erlotinib (DRUG); Sorafenib (DRUG),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14884,NCT00193258,"Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma",COMPLETED,PHASE1,Clear Cell Renal Cell Carcinoma,Bevacizumab (DRUG); Erlotinib (DRUG); Imatinib (DRUG),176870,Tarceva,Clear Cell Renal Cell Carcinoma,Kidney,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14885,NCT00054496,Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme,UNKNOWN,PHASE2,Brain and Central Nervous System Tumors,erlotinib hydrochloride (DRUG),176870,Tarceva,Brain and Central Nervous System Tumors,CNS/Brain,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14886,NCT01395758,Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Metastatic Non-Small Cell Lung Cancer,"ARQ 197 plus erlotinib (DRUG); Pemetrexed, docetaxel or gemcitabine (DRUG)",176870,Tarceva,Metastatic Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14887,NCT02001896,Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation,UNKNOWN,PHASE3,Non-Small Cell Lung Cancer,gemcitabine; cisplatin or carboplatin; erlotinib (DRUG); erlotinib (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14888,NCT02117024,A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,TERMINATED,PHASE2,Non Small Cell Lung Cancer,"Viagenpumatucel-L (DRUG); Metronomic Cyclophosphamide (DRUG); Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed) (DRUG)",176870,Tarceva,Non Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14889,NCT00265824,Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM),COMPLETED,PHASE3,Colorectal Cancer,"bevacizumab (DRUG); bevacizumab, erlotinib (DRUG)",176870,Tarceva,Colorectal Cancer,Bowel,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14890,NCT01250119,"A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.",COMPLETED,PHASE2,Non-Squamous Non-Small Cell Lung Cancer,erlotinib [Tarceva] (DRUG),176870,Tarceva,Non-Squamous Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14891,NCT02013219,A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE1,Non-Small Cell Lung Cancer,Alectinib (DRUG); Atezolizumab (DRUG); Erlotinib (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14892,NCT01217619,Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.,COMPLETED,PHASE2,Non Small Cell Lung Cancer,erlotinib (DRUG),176870,Tarceva,Non Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14893,NCT00816868,A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung,COMPLETED,PHASE2,Non-small Cell Lung Cancer,erlotinib in combination with capecitabine (DRUG),176870,Tarceva,Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14894,NCT00966472,Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC,COMPLETED,PHASE1,Squamous Cell Carcinoma; Non-Small Cell Lung Cancer,Erlotinib + Rosuvastatin (DRUG),176870,Tarceva,Squamous Cell Carcinoma; Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14895,NCT00072072,Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer,celecoxib (DRUG); erlotinib hydrochloride (DRUG),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14896,NCT02704767,Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma,UNKNOWN,PHASE2,Lung Cancer,Apatinib (DRUG); Tarceva (DRUG); Placebo (DRUG),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14897,NCT00088946,Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer,COMPLETED,PHASE2,Bladder Cancer,Polyphenon E (DIETARY_SUPPLEMENT); erlotinib hydrochloride (DRUG); Erlotinib placebo (OTHER); Polyphenon E (OTHER),176870,Tarceva,Bladder Cancer,Bladder/Urinary Tract,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14898,NCT01515969,Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC),TERMINATED,PHASE1,"Non-small Cell Lung Cancer (NSCLC), Recurrent; Non-small Cell Lung Cancer (NSCLC), Stage IV",Erlotinib hydrochloride (DRUG); Dovitinib lactate (DRUG),176870,Tarceva,"Non-small Cell Lung Cancer (NSCLC), Recurrent; Non-small Cell Lung Cancer (NSCLC), Stage IV",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14899,NCT00032110,Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer,COMPLETED,PHASE2,Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer,erlotinib hydrochloride (DRUG); pharmacological study (OTHER); laboratory biomarker analysis (OTHER),176870,Tarceva,Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer,Bowel,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14900,NCT00087412,S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Adenocarcinoma of the Lung; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,erlotinib hydrochloride (DRUG); laboratory biomarker analysis (OTHER),176870,Tarceva,Adenocarcinoma of the Lung; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14901,NCT01389440,Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Adenocarcinoma,Gemcitabine and Erlotinib (DRUG),176870,Tarceva,Pancreatic Adenocarcinoma,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14902,NCT00570401,Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib,COMPLETED,PHASE2,Lung Cancer,dasatinib (DRUG),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14903,NCT00353301,Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma,COMPLETED,PHASE2,Renal Cell Carcinoma,Erlotinib hydrochloride (DRUG); Sirolimus (DRUG),176870,Tarceva,Renal Cell Carcinoma,Kidney,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14904,NCT03115567,A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption,TERMINATED,PHASE2,Acneiform Rash; Papulopustular Eruption,Triamcinolone (DRUG),176870,Tarceva,Acneiform Rash; Papulopustular Eruption,Skin,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14905,NCT00642746,Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC),TERMINATED,PHASE2,Metastatic Colorectal Cancer,Erlotinib (DRUG); Fluorouracil (DRUG); Leucovorin (DRUG); Oxaliplatin (DRUG); Irinotecan (DRUG),176870,Tarceva,Metastatic Colorectal Cancer,Bowel,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14906,NCT00733746,Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,COMPLETED,PHASE2,Pancreatic Cancer,erlotinib hydrochloride (DRUG); gemcitabine hydrochloride (DRUG); therapeutic conventional surgery (PROCEDURE),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14907,NCT00556712,"A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)",COMPLETED,PHASE3,Non-Small Cell Lung Cancer,erlotinib [Tarceva] (DRUG); Placebo (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14908,NCT01578668,Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases,COMPLETED,PHASE2,Lung Adenocarcinoma; Brain Metastases,erlotinib (DRUG); pemetrexed (DRUG); cisplatin (DRUG); erlotinib (DRUG),176870,Tarceva,Lung Adenocarcinoma; Brain Metastases,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14909,NCT00087269,Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection,TERMINATED,PHASE2,Stage IA Non-small Cell Lung Cancer; Stage IB Non-small Cell Lung Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIB Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer,erlotinib hydrochloride (DRUG); therapeutic endoscopic surgery (PROCEDURE); laboratory biomarker analysis (OTHER),176870,Tarceva,Stage IA Non-small Cell Lung Cancer; Stage IB Non-small Cell Lung Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIB Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14910,NCT00393068,"Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer",COMPLETED,PHASE2,Esophageal Cancer,Erlotinib (DRUG); Bevacizumab (DRUG); Paclitaxel (DRUG); Carboplatin (DRUG); 5-FU (DRUG); Radiation therapy (PROCEDURE); Surgery (PROCEDURE),176870,Tarceva,Esophageal Cancer,Esophagus/Stomach,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14911,NCT01199068,CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC),COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung",CS-7017 (DRUG); Erlotinib (DRUG),176870,Tarceva,"Carcinoma, Non-Small-Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14912,NCT02318368,"A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label",TERMINATED,PHASE2,Non-small Cell Lung Cancer,Ficlatuzumab (DRUG); Erlotinib (DRUG); placebo (DRUG),176870,Tarceva,Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14913,NCT02625168,Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC,COMPLETED,PHASE2,Lung Cancer,Afatinib (DRUG); Erlotinib (DRUG),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14914,NCT00784667,Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib,UNKNOWN,PHASE2,Metastatic Colorectal Cancer,Cetuximab (DRUG); Erlotinib (DRUG),176870,Tarceva,Metastatic Colorectal Cancer,Bowel,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14915,NCT00901901,Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma,COMPLETED,PHASE3,"Carcinoma, Hepatocellular","Sorafenib (Nexavar, BAY43-9006) (DRUG); Erlotinib (Tarceva) (DRUG); Placebo (DRUG)",176870,Tarceva,"Carcinoma, Hepatocellular",Liver,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14916,NCT00532441,Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas,TERMINATED,PHASE2,Hepatocellular Carcinoma,Erlotinib (DRUG); Docetaxel (DRUG),176870,Tarceva,Hepatocellular Carcinoma,Liver,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14917,NCT01854034,Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR,COMPLETED,PHASE2,Non Small Cell Lung Cancer,AUY922 (DRUG),176870,Tarceva,Non Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14918,NCT00531934,A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Doxycline (DRUG); erlotinib [Tarceva] (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14919,NCT01350817,Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer,COMPLETED,PHASE2,Non Small Cell Lung Cancer,Erlotinib + docetaxel (DRUG); Docetaxel (DRUG),176870,Tarceva,Non Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14920,NCT00265317,A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone,COMPLETED,PHASE2,"Carcinoma, Non-Small-Cell Lung",erlotinib (DRUG); sunitinib (DRUG); erlotinib (DRUG); placebo (DRUG),176870,Tarceva,"Carcinoma, Non-Small-Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14921,NCT00452413,A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer,COMPLETED,PHASE1,Non-Small Cell Lung Cancer; Malignant Solid Tumor,enzastaurin (DRUG); erlotinib (DRUG),176870,Tarceva,Non-Small Cell Lung Cancer; Malignant Solid Tumor,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14922,NCT02069418,Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient,UNKNOWN,PHASE2,Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent; No EGFR Activating Mutation,18F-FLT-TEP (RADIATION); 18F-FDG-TEP (RADIATION),176870,Tarceva,Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent; No EGFR Activating Mutation,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14923,NCT00810719,Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Cancer,Erlotinib (DRUG); gemcitabine (DRUG),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14924,NCT01101334,Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer,COMPLETED,PHASE2,Advanced Non-small Cell Lung Cancer (NSCLC),CS-7017 (DRUG); erlotinib (DRUG),176870,Tarceva,Advanced Non-small Cell Lung Cancer (NSCLC),Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14925,NCT01480141,A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC),WITHDRAWN,PHASE2,Lung Cancer,BIBW 2992 (Afatinib) (DRUG),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14926,NCT01998919,A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,erlotinib [Tarceva] (DRUG); placebo (DRUG); gemcitabine (DRUG); cisplatin (DRUG); carboplatin (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14927,NCT00033241,Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors,COMPLETED,PHASE1,"Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",erlotinib hydrochloride (DRUG); gemcitabine hydrochloride (DRUG),176870,Tarceva,"Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14928,NCT00874419,Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation,COMPLETED,PHASE3,Non-small Cell Lung Cancer,erlotinib (DRUG); gemcitabine/carboplatin (DRUG),176870,Tarceva,Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14929,NCT01116219,"Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).",COMPLETED,PHASE2,Lung Cancer,"bevacizumab, erlotinib (BIOLOGICAL); bevacizumab, pemetrexed, cisplatin (DRUG)",176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14930,NCT02353741,Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC,TERMINATED,PHASE2,Non Small Cell Lung Cancer,EGFR-TKIs (DRUG); thoracic radiotherapy (RADIATION),176870,Tarceva,Non Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14931,NCT03119519,Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer.,UNKNOWN,PHASE2,Stage IV Non-small Cell Lung Cancer,Local Definitive Radiotherapy (RADIATION); No Local Definitive Radiotherapy (DRUG),176870,Tarceva,Stage IV Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14932,NCT01608841,The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib,UNKNOWN,PHASE2,Metastatic Pancreatic Cancer,Erlotinib (DRUG),176870,Tarceva,Metastatic Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14933,NCT00301418,Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma,COMPLETED,PHASE1,Glioblastoma Multiforme; Anaplastic Astrocytoma,Erlotinib (DRUG),176870,Tarceva,Glioblastoma Multiforme; Anaplastic Astrocytoma,CNS/Brain,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14934,NCT02507518,Role of PET Scan in the Evaluation of Early Response to Maintenance Treatment in Advanced Non-small-cell Lung Cancer,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,PET scan imaging (PROCEDURE),176870,Tarceva,Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14935,NCT01505413,"Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer",COMPLETED,PHASE2,Pancreatic Cancer,Erlotinib (DRUG); Gemcitabine (DRUG); Oxaliplatin (DRUG),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14936,NCT04356118,Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis,UNKNOWN,PHASE4,Leptomeningeal Metastasis,Recombinant Human Endostatin (DRUG); intrathcal methotrexate (DRUG); Targeted drugs for non-small cell lung cancer (DRUG),176870,Tarceva,Leptomeningeal Metastasis,CNS/Brain,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14937,NCT00568841,Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC),UNKNOWN,PHASE2,"Carcinoma, Non-Small-Cell Lung",erlotinib (DRUG); FDG-/FLT-PET (PROCEDURE),176870,Tarceva,"Carcinoma, Non-Small-Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14938,NCT00349219,TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer,COMPLETED,PHASE3,Advanced Non-Small Cell Lung Cancer,erlotinib (DRUG); cisplatin (DRUG); gemcitabine (DRUG); cisplatin (DRUG); gemcitabine (DRUG); erlotinib (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14939,NCT02146118,A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma,UNKNOWN,PHASE2,"Carcinoma, Non-Small-Cell Lung",Erlotinib (DRUG); Silybin-phytosome (DIETARY_SUPPLEMENT),176870,Tarceva,"Carcinoma, Non-Small-Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14940,NCT02694536,"A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer",COMPLETED,PHASE3,Pancreatic Cancer,Erlotinib (DRUG); Gemcitabine (DRUG),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14941,NCT01310036,A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations,COMPLETED,PHASE2,Non-Squamous Non-Small Cell Lung Cancer,Erlotinib (DRUG),176870,Tarceva,Non-Squamous Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14942,NCT03890055,Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride,UNKNOWN,PHASE4,Small Cell Lung Cancer,Anlotinib Hydrochloride (DRUG),176870,Tarceva,Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14943,NCT00461708,A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival,COMPLETED,PHASE2,Pancreatic Cancer,Erlotinib (DRUG); Gemcitabine (DRUG),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14944,NCT02954523,Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations,TERMINATED,PHASE1,EGFR Gene Mutation; Nonsmall Cell Lung Cancer,Dasatinib (DRUG); Osimertinib (DRUG),176870,Tarceva,EGFR Gene Mutation; Nonsmall Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14945,NCT06483555,"Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel",RECRUITING,PHASE1,Pancreatic Adenocarcinoma; Metastatic Pancreatic Cancer; Basal Cell Neoplasm,Gemcitabine (DRUG); Nab paclitaxel (DRUG); Erlotinib (DRUG); NALIRIFOX (DRUG); Folfirinox (DRUG),176870,Tarceva,Pancreatic Adenocarcinoma; Metastatic Pancreatic Cancer; Basal Cell Neoplasm,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14946,NCT00081614,A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma,COMPLETED,PHASE2,Renal Cell Carcinoma; Metastases,Avastin (bevacizumab) (DRUG); Tarceva (erlotinib HCl) (DRUG),176870,Tarceva,Renal Cell Carcinoma; Metastases,Kidney,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14947,NCT01866410,Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7,Cabozantinib S-malate (DRUG); Erlotinib Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER),176870,Tarceva,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14948,NCT02714010,EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC,UNKNOWN,PHASE3,Non-Small Cell Lung Cancer,EGFR-TKI (DRUG); whole brain radiotherapy (RADIATION),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14949,NCT02876081,"Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex",WITHDRAWN,PHASE2,SMALL CELL LUNG CARCINOMA,Afatinib (DRUG),176870,Tarceva,SMALL CELL LUNG CARCINOMA,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14950,NCT00063895,"Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck",COMPLETED,PHASE1,Recurrent Non-small Cell Lung Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IIIA Non-small Cell Lung Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IV Non-small Cell Lung Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx,erlotinib hydrochloride (DRUG); pharmacological study (OTHER); pharmacogenomic studies (OTHER); laboratory biomarker analysis (OTHER),176870,Tarceva,Recurrent Non-small Cell Lung Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IIIA Non-small Cell Lung Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IV Non-small Cell Lung Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14951,NCT01302808,Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Lung Cancer; Metastatic Cancer,Erlotinib plus Romidepsin (8 mg/m^2) (COMBINATION_PRODUCT); Erlotinib plus Romidepsin (10 mg/m^2) (COMBINATION_PRODUCT); Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis (COMBINATION_PRODUCT); (Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis (COMBINATION_PRODUCT),176870,Tarceva,Metastatic Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14952,NCT02926638,Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches,TERMINATED,PHASE2,MET Positive; Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7,Erlotinib Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Rilotumumab (BIOLOGICAL),176870,Tarceva,MET Positive; Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14953,NCT00854308,"A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)",COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Erlotinib HCl (DRUG); MetMAb (DRUG); placebo (0.9 % saline) (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14954,NCT00733408,Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer,COMPLETED,PHASE2,Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer,paclitaxel albumin-stabilized nanoparticle formulation (DRUG); bevacizumab (BIOLOGICAL); erlotinib hydrochloride (DRUG),176870,Tarceva,Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer,Breast,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14955,NCT00617708,S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery,COMPLETED,PHASE1,Stage IV Pancreatic Cancer,cixutumumab (BIOLOGICAL); erlotinib hydrochloride (DRUG); gemcitabine hydrochloride (DRUG),176870,Tarceva,Stage IV Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14956,NCT00743938,A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC,COMPLETED,PHASE2,Non Small Cell Lung Cancer,BMS-690514 (DRUG); Erlotinib (DRUG),176870,Tarceva,Non Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14957,NCT00126581,Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer,COMPLETED,PHASE2,Lung Adenocarcinoma; Lung Adenosquamous Carcinoma; Malignant Pericardial Effusion; Malignant Pleural Effusion; Minimally Invasive Lung Adenocarcinoma; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IV Lung Non-Small Cell Cancer AJCC v7,Carboplatin (DRUG); Erlotinib (DRUG); Erlotinib Hydrochloride (DRUG); Paclitaxel (DRUG),176870,Tarceva,Lung Adenocarcinoma; Lung Adenosquamous Carcinoma; Malignant Pericardial Effusion; Malignant Pleural Effusion; Minimally Invasive Lung Adenocarcinoma; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IV Lung Non-Small Cell Cancer AJCC v7,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14958,NCT00973310,Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer,UNKNOWN,PHASE2,"Carcinoma, Non-Small Cell Lung",Radiation Therapy and EGFR-TKI target therapy (OTHER),176870,Tarceva,"Carcinoma, Non-Small Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14959,NCT01703910,Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic,COMPLETED,PHASE2,Adenocarcinoma of Colon; Adenocarcinoma of Rectum; Metastatic Disease,Arm A chemotherapy (DRUG); arm B chemotherapy (DRUG),176870,Tarceva,Adenocarcinoma of Colon; Adenocarcinoma of Rectum; Metastatic Disease,Bowel,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14960,NCT01887795,"Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study",COMPLETED,PHASE3,Multiple Brain Metastases; Non-small-cell Lung Cancer,Erlotinib (DRUG); WBRT (DRUG),176870,Tarceva,Multiple Brain Metastases; Non-small-cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14961,NCT01729481,Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer,UNKNOWN,PHASE2,Metastatic Pancreatic Adenocarcinoma,Gemcitabine (DRUG); Erlotinib (DRUG); Oxaliplatin (DRUG); Folinic Acid (DRUG); Irinotecan (DRUG); 5-FU (DRUG),176870,Tarceva,Metastatic Pancreatic Adenocarcinoma,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14962,NCT00045110,Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma,COMPLETED,PHASE1,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Grade I Meningioma; Adult Grade II Meningioma; Adult Grade III Meningioma; Recurrent Adult Brain Tumor,erlotinib hydrochloride (DRUG); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),176870,Tarceva,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Grade I Meningioma; Adult Grade II Meningioma; Adult Grade III Meningioma; Recurrent Adult Brain Tumor,CNS/Brain,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14963,NCT01260181,A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations,COMPLETED,PHASE2,Non-Squamous Non-Small Cell Lung Cancer,Erlotinib (DRUG),176870,Tarceva,Non-Squamous Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14964,NCT01229150,Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...,COMPLETED,PHASE2,Non Small Cell Lung Carcinoma,AZD6244 (DRUG); Erlotinib (DRUG); AZD6244 + Erlotinib (DRUG),176870,Tarceva,Non Small Cell Lung Carcinoma,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14965,NCT01182350,Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG),TERMINATED,PHASE2,Diffuse Intrinsic Pontine Glioma,Bevacizumab (DRUG); Erlotinib (DRUG); Temozolomide (DRUG); Radiation (RADIATION),176870,Tarceva,Diffuse Intrinsic Pontine Glioma,CNS/Brain,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14966,NCT00280150,"Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer",COMPLETED,PHASE1,Lung Cancer,bevacizumab (BIOLOGICAL); carboplatin (DRUG); erlotinib hydrochloride (DRUG); paclitaxel (DRUG); 3-dimensional conformal radiation therapy (RADIATION),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14967,NCT01561014,"Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction",COMPLETED,PHASE1,Adenocarcinoma of the Esophagus; Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach; Squamous Cell Carcinoma of the Esophagus; Stage II Esophageal Cancer; Stage II Gastric Cancer; Stage III Esophageal Cancer; Stage III Gastric Cancer,erlotinib hydrochloride (DRUG); oxaliplatin (DRUG); fluorouracil (DRUG); radiation therapy (RADIATION); conventional surgery (PROCEDURE); immunohistochemistry staining method (OTHER); positron emission tomography (PROCEDURE); computed tomography (PROCEDURE); laboratory biomarker analysis (PROCEDURE); gene expression analysis (GENETIC); fludeoxyglucose F 18 (RADIATION),176870,Tarceva,Adenocarcinoma of the Esophagus; Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach; Squamous Cell Carcinoma of the Esophagus; Stage II Esophageal Cancer; Stage II Gastric Cancer; Stage III Esophageal Cancer; Stage III Gastric Cancer,Esophagus/Stomach,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14968,NCT01835938,Clinical Investigation of Erlotinib as an HCV Entry Inhibitor,UNKNOWN,PHASE1,Chronic Hepatitis C Infection; HCV Genotype 1b,1- Erlotinib (DRUG); placebo (DRUG),176870,Tarceva,Chronic Hepatitis C Infection; HCV Genotype 1b,Liver,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14969,NCT01565538,Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma,COMPLETED,PHASE2,Lung Cancer,Erlotinib (DRUG); Pemetrexed (DRUG),176870,Tarceva,Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14970,NCT00026338,Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer,COMPLETED,PHASE3,Pancreatic Cancer,erlotinib hydrochloride (DRUG); gemcitabine hydrochloride (DRUG),176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14971,NCT00257608,A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS),COMPLETED,PHASE3,Non-Small Cell Lung Cancer,bevacizumab (DRUG); placebo (DRUG); erlotinib HCl (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14972,NCT00569114,Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients,COMPLETED,PHASE1,Non-small Cell Lung Cancer,TG01 (DRUG),176870,Tarceva,Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14973,NCT00440414,Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE3,Non Small Cell Lung Cancer,Erlotinib (Tarceva) (DRUG); Pemetrexed (Alimta) (DRUG),176870,Tarceva,Non Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14974,NCT01104155,"Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer",COMPLETED,PHASE2,Non-small Cell Lung Cancer,eribulin mesylate + erlotinib (DRUG); eribulin mesylate + erlotinib (DRUG),176870,Tarceva,Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14975,NCT00033514,Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression,COMPLETED,PHASE1,Breast Cancer,trastuzumab (BIOLOGICAL); erlotinib hydrochloride (DRUG),176870,Tarceva,Breast Cancer,Breast,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14976,NCT01967095,Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer,COMPLETED,PHASE1,EGFR-Mutant Lung Cancer,erlotinib (DRUG),176870,Tarceva,EGFR-Mutant Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14977,NCT00686114,Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer,UNKNOWN,PHASE3,Esophageal Cancer,Paclitaxel (DRUG); Cisplatin (DRUG); Tarceva (DRUG); Radiotherapy (RADIATION); Radiotherapy (RADIATION),176870,Tarceva,Esophageal Cancer,Esophagus/Stomach,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14978,NCT00633750,Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery,COMPLETED,PHASE2,Breast Cancer,erlotinib hydrochloride (DRUG); TUNEL assay (GENETIC); protein expression analysis (GENETIC); immunohistochemistry staining method (OTHER); laboratory biomarker analysis (OTHER); liquid chromatography (OTHER); mass spectrometry (OTHER); matrix-assisted laser desorption ionization mass spectrometry (OTHER); therapeutic conventional surgery (PROCEDURE),176870,Tarceva,Breast Cancer,Breast,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14979,NCT00442455,"Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck",COMPLETED,PHASE3,Squamous Cell Carcinoma of the Head and Neck,Erlotinib chlorhydrate (DRUG); Cisplatin (DRUG); Radiation therapy (PROCEDURE),176870,Tarceva,Squamous Cell Carcinoma of the Head and Neck,Skin,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14980,NCT01839955,Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,erlotinib hydrochloride (DRUG); quinacrine dihydrochloride - Escalation dose (DRUG); laboratory biomarker analysis (OTHER); pharmacological study (OTHER); quinacrine dihydrochloride - Extension dose (DRUG),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14981,NCT01728181,A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation,WITHDRAWN,PHASE1,Non-small Cell Lung Cancer; Stage IV Disease; EGFR Unknown or Wild-type,Tivozanib (DRUG); Erlotinib (DRUG); Standard of Care treatment (OTHER),176870,Tarceva,Non-small Cell Lung Cancer; Stage IV Disease; EGFR Unknown or Wild-type,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14982,NCT01193881,RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer,TERMINATED,PHASE1,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Erlotinib Hydrochloride (DRUG); Gamma-Secretase Inhibitor RO4929097 (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER),176870,Tarceva,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14983,NCT00738881,Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer,TERMINATED,PHASE3,Recurrent Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Erlotinib Hydrochloride (DRUG); Pemetrexed Disodium (DRUG),176870,Tarceva,Recurrent Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14984,NCT05827614,"Study of the CHK1 Inhibitor BBI-355, an EcDNA-directed Therapy (ecDTx), in Subjects with Tumors with Oncogene Amplifications",RECRUITING,PHASE1,Non-small Cell Lung Cancer; Non-Small Cell Lung Adenocarcinoma; Non-Small Cell Squamous Lung Cancer; Head and Neck Squamous Cell Carcinoma; Esophageal Cancer; Gastric Cancer; Breast Cancer; Bladder Cancer; Ovarian Cancer; Endometrial Cancer; Liposarcoma,BBI-355 (DRUG); Erlotinib (DRUG); Futibatinib (DRUG),176870,Tarceva,Non-small Cell Lung Cancer; Non-Small Cell Lung Adenocarcinoma; Non-Small Cell Squamous Lung Cancer; Head and Neck Squamous Cell Carcinoma; Esophageal Cancer; Gastric Cancer; Breast Cancer; Bladder Cancer; Ovarian Cancer; Endometrial Cancer; Liposarcoma,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14985,NCT00499655,Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,erlotinib hydrochloride (DRUG); celecoxib (DRUG); placebo (OTHER); laboratory biomarker analysis (OTHER); immunohistochemistry staining method (OTHER); fluorescence in situ hybridization (GENETIC); mutation analysis (GENETIC); protein expression analysis (GENETIC); gene expression analysis (GENETIC),176870,Tarceva,Advanced Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14986,NCT02770014,Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer,TERMINATED,PHASE2,Epidermal Growth Factor Receptor; Non-Small Cell Lung Cancer,Erlotinib (DRUG),176870,Tarceva,Epidermal Growth Factor Receptor; Non-Small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14987,NCT01410214,Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations,UNKNOWN,PHASE2,Non-small Cell Lung Cancer Stage IIIA,Erlotinib (DRUG); vinorelbine/cisplatin (DRUG),176870,Tarceva,Non-small Cell Lung Cancer Stage IIIA,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14988,NCT00994123,A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung",MM-121 (DRUG); Erlotinib (DRUG),176870,Tarceva,"Carcinoma, Non-Small-Cell Lung",Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14989,NCT01755923,Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,Gefitinib (DRUG); Docetaxel (DRUG),176870,Tarceva,Non-small Cell Lung Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14990,NCT00871923,Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-small Cell Lung Cancer; Brain Cancer,Tarceva (Erlotinib hydrochloride) (DRUG); Radiation Therapy (RADIATION),176870,Tarceva,Non-small Cell Lung Cancer; Brain Cancer,Lung,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14991,NCT00032123,Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer,COMPLETED,PHASE2,Esophageal Cancer; Gastric Cancer,erlotinib hydrochloride (DRUG),176870,Tarceva,Esophageal and Gastric Cancer,Esophagus/Stomach,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14992,NCT00260364,Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer,COMPLETED,PHASE1,Pancreatic Cancer,"Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle (DRUG); Capecitabine orally days 1 -21 (DRUG); Erlotinib 100 mg orally days 1-28 (DRUG); Bevacizumab 5 mg/kg intravenously every 2 weeks (DRUG)",176870,Tarceva,Pancreatic Cancer,Pancreas,Erlotinib,EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for human use for non-small cell lung cancer.,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,1.0,384.0 +14993,NCT04586231,A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011),ACTIVE_NOT_RECRUITING,PHASE3,"Carcinoma, Renal Cell",Belzutifan (DRUG); Lenvatinib (DRUG); Cabozantinib (DRUG),117947097,Welireg,"Carcinoma, Renal Cell",Kidney,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +14994,NCT04994522,A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021),COMPLETED,PHASE1,End Stage Renal Disease; Renal Impairment,Belzutifan (DRUG),117947097,Welireg,End Stage Renal Disease; Renal Impairment,Kidney,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +14995,NCT03634540,"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)",ACTIVE_NOT_RECRUITING,PHASE2,"Renal Cell Carcinoma (RCC); Clear Cell Renal Cell Carcinoma (ccRCC); Kidney Cancer; Renal Cancer; Renal Cell Carcinoma; Renal Cell Cancer Metastatic; Renal Cell Carcinoma Recurrent; Renal Cell Cancer, Recurrent; Kidney",Belzutifan (DRUG); Cabozantinib (DRUG),117947097,Welireg,"Renal Cell Carcinoma (RCC); Clear Cell Renal Cell Carcinoma (ccRCC); Kidney Cancer; Renal Cancer; Renal Cell Carcinoma; Renal Cell Cancer Metastatic; Renal Cell Carcinoma Recurrent; Renal Cell Cancer, Recurrent; Kidney",Kidney,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +14996,NCT04626518,Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03),ACTIVE_NOT_RECRUITING,PHASE1,"Carcinoma, Renal Cell",Pembrolizumab (BIOLOGICAL); MK-4830 (BIOLOGICAL); Belzutifan (DRUG); Lenvatinib (DRUG); Pembrolizumab/Quavonlimab (BIOLOGICAL); Favezelimab/Pembrolizumab (BIOLOGICAL),117947097,Welireg,"Carcinoma, Renal Cell",Kidney,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +14997,NCT05899049,"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study",ACTIVE_NOT_RECRUITING,PHASE3,"Carcinoma, Renal Cell",Pembrolizumab (BIOLOGICAL); Belzutifan (DRUG); Pembrolizumab/Quavonlimab (BIOLOGICAL); Lenvatinib (DRUG),117947097,Welireg,"Carcinoma, Renal Cell",Kidney,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +14998,NCT02974738,"A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)",UNKNOWN,PHASE1,"Advanced Solid Tumors; Solid Tumor; Solid Carcinoma; Solid Tumor, Adult; ccRCC; RCC, Clear Cell Adenocarcinoma; RCC; Kidney Cancer; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma, Metastatic; Renal Cell Carcinoma Recurrent; Renal Cell Carcinoma, Clear Cell Adenocarcinoma; Glioblastoma; Glioblastoma, Adult; GBM; Glioblastoma Multiforme",Belzutifan (DRUG),117947097,Welireg,"Advanced Solid Tumors; Solid Tumor; Solid Carcinoma; Solid Tumor, Adult; ccRCC; RCC, Clear Cell Adenocarcinoma; RCC; Kidney Cancer; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma, Metastatic; Renal Cell Carcinoma Recurrent; Renal Cell Carcinoma, Clear Cell Adenocarcinoma; Glioblastoma; Glioblastoma, Adult; GBM; Glioblastoma Multiforme",CNS/Brain,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +14999,NCT04195750,A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005),ACTIVE_NOT_RECRUITING,PHASE3,"Carcinoma, Renal Cell",Belzutifan (DRUG); Everolimus (DRUG),117947097,Welireg,"Carcinoma, Renal Cell",Kidney,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +15000,NCT04736706,"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)",ACTIVE_NOT_RECRUITING,PHASE3,"Carcinoma, Renal Cell",Pembrolizumab (BIOLOGICAL); Belzutifan (DRUG); Pembrolizumab/Quavonlimab (BIOLOGICAL); Lenvatinib (DRUG),117947097,Welireg,"Carcinoma, Renal Cell",Kidney,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +15001,NCT04995484,A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020),COMPLETED,PHASE1,Moderate Hepatic Impairment,Belzutifan (DRUG),117947097,Welireg,Moderate Hepatic Impairment,Liver,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +15002,NCT04626479,Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A),ACTIVE_NOT_RECRUITING,PHASE1,"Carcinoma, Renal Cell",Pembrolizumab (BIOLOGICAL); Favezelimab/Pembrolizumab (BIOLOGICAL); Belzutifan (DRUG); Lenvatinib (DRUG); Pembrolizumab/Quavonlimab (BIOLOGICAL); Vibostolimab/Pembrolizumab (DRUG),117947097,Welireg,"Carcinoma, Renal Cell",Kidney,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +15003,NCT04924075,"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)",RECRUITING,PHASE2,Pheochromocytoma/Paraganglioma; Pancreatic Neuroendocrine Tumor; Von Hippel-Lindau Disease; Advanced Gastrointestinal Stromal Tumor; HIF-2α Mutated Cancers,Belzutifan (DRUG),117947097,Welireg,Pheochromocytoma/Paraganglioma; Pancreatic Neuroendocrine Tumor; Von Hippel-Lindau Disease; Advanced Gastrointestinal Stromal Tumor; HIF-2α Mutated Cancers,Bowel,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +15004,NCT03401788,"A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)",ACTIVE_NOT_RECRUITING,PHASE2,VHL - Von Hippel-Lindau Syndrome; VHL Gene Mutation; VHL Syndrome; VHL Gene Inactivation; VHL-Associated Renal Cell Carcinoma; VHL-Associated Clear Cell Renal Cell Carcinoma,Belzutifan (DRUG),117947097,Welireg,VHL - Von Hippel-Lindau Syndrome; VHL Gene Mutation; VHL Syndrome; VHL Gene Inactivation; VHL-Associated Renal Cell Carcinoma; VHL-Associated Clear Cell Renal Cell Carcinoma,Kidney,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +15005,NCT05239728,A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022),ACTIVE_NOT_RECRUITING,PHASE3,"Carcinoma, Renal Cell",Belzutifan (DRUG); Pembrolizumab (BIOLOGICAL); Placebo (DRUG),117947097,Welireg,"Carcinoma, Renal Cell",Kidney,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +15006,NCT04846920,A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018),ACTIVE_NOT_RECRUITING,PHASE1,"Carcinoma, Renal Cell",Belzutifan (DRUG),117947097,Welireg,"Carcinoma, Renal Cell",Kidney,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +15007,NCT04489771,A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013),ACTIVE_NOT_RECRUITING,PHASE2,"Carcinoma, Renal Cell",Belzutifan (DRUG),117947097,Welireg,"Carcinoma, Renal Cell",Kidney,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +15008,NCT05468697,A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024),RECRUITING,PHASE1,Renal Cell Carcinoma,Belzutifan (DRUG); Palbociclib (DRUG),117947097,Welireg,Renal Cell Carcinoma,Kidney,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +15009,NCT06234605,A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma,RECRUITING,PHASE1,Renal Cell Carcinoma,HC-7366 (DRUG); Belzutifan (DRUG),117947097,Welireg,Renal Cell Carcinoma,Kidney,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +15010,NCT06677190,Belzutifan in Recurrent Clear Cell Ovarian Carcinoma,RECRUITING,PHASE2,Ovarian Cancer; Ovarian Carcinoma,Belzutifan (DRUG),117947097,Welireg,Ovarian Cancer; Ovarian Carcinoma,Ovary/Fallopian Tube,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +15011,NCT05030506,A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010),ACTIVE_NOT_RECRUITING,PHASE1,Renal Cell Carcinoma,Belzutifan (DRUG); Pembrolizumab (BIOLOGICAL); Lenvatinib (DRUG),117947097,Welireg,Renal Cell Carcinoma,Kidney,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +15012,NCT06428396,Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029),RECRUITING,PHASE2,Metastatic Breast Cancer,Belzutifan (DRUG); Fulvestrant (DRUG); Everolimus (DRUG); Exemestane (DRUG),117947097,Welireg,Metastatic Breast Cancer,Breast,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +15013,NCT02293980,"A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)",ACTIVE_NOT_RECRUITING,PHASE1,ccRCC; RCC; Kidney Cancer; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma,MK-3795 (DRUG); Nivolumab (DRUG); Cabozantinib (DRUG); Bezlutifan (DRUG),117947097,Welireg,ccRCC; RCC; Kidney Cancer; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma,Kidney,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +15014,NCT04627064,ABEMA Alone or in COMBO With MK-6482,COMPLETED,PHASE1,Clear Cell Renal Cell Carcinoma,Abemaciclib (DRUG); MK-6482 (DRUG),117947097,Welireg,Clear Cell Renal Cell Carcinoma,Kidney,Belzutifan,EPAS1,inhibitor/antagonist,unclear,yes,yes,Approved for treating certain cancer types.,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,1.07,2537.0 +15015,NCT00787982,Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors,UNKNOWN,PHASE1,Brain Neoplasms,MRI-Guided Laser Induced Thermal Therapy (DEVICE),24776445,VIS,Brain Neoplasms,CNS/Brain,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15016,NCT04259684,Nitric Oxide During Cardiopulmonary Bypass in Neonates to Reduce Risk of Acute Kidney Injury,WITHDRAWN,PHASE2,Acute Kidney Injury; Congenital Heart Disease,gases Nitric Oxide (gNO) (DRUG),24776445,VIS,Acute Kidney Injury; Congenital Heart Disease,Kidney,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15017,NCT05654623,"A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE3,Advanced Breast Cancer,ARV-471 (DRUG); Fulvestrant (DRUG),24776445,VIS,Advanced Breast Cancer,Breast,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15018,NCT05757557,Perioperative Nitric Oxide Prevents Acute Kidney Injury in Cardiac Surgery Patients With Chronic Kidney Disease,COMPLETED,PHASE1,Acute Kidney Disease; Chronic Kidney Disease; Cardiac Surgery; Cardiopulmonary Bypass,Sham treatment (DRUG); 80-ppm NO (DRUG),24776445,VIS,Acute Kidney Disease; Chronic Kidney Disease; Cardiac Surgery; Cardiopulmonary Bypass,Kidney,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15019,NCT01915758,"W0265-104: A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers",COMPLETED,PHASE1,Acne Vulgaris,clindamycin1%/tretinoin 0.025% gel (DRUG); vehicle gel (DRUG),24776445,VIS,Acne Vulgaris,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15020,NCT01115322,A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers,COMPLETED,PHASE1,Acne Vulgaris,"Tazarotene Foam without irradiation (DRUG); Tazarotene Foam with UVA and UVB irradiation (DRUG); Tazarotene Foam with UVA, UVB, and visible light (DRUG); Vehicle Foam without irradiation (DRUG); Vehicle Foam with UVA and UVB irradiation (DRUG); Vehicle Foam with UVA and UVB and visible light irradiation (DRUG); No Treatment without irradiation (DRUG); No Treatment with UVA and UVB irradiation (DRUG); No Treatment with UVA and UVB and visible light irradiation (DRUG)",24776445,VIS,Acne Vulgaris,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15021,NCT01775280,Response of Hepatic Tumors to Radioembolization,WITHDRAWN,PHASE2,Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Liver Metastasis,Injection of Ytttrium-90 microspheres into the hepatic artery (RADIATION),24776445,VIS,Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Liver Metastasis,Liver,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15022,NCT06622291,Perioperative Nitric Oxide Prevents Acute Kidney Injury in Acute Type a Aortic Dissection Patients,RECRUITING,PHASE4,Acute Kidney Injury; Nitrous Oxide; Acute Type a Aortic Dissection,Nitric Oxide (DRUG); Placebo (OTHER),24776445,VIS,Acute Kidney Injury; Nitrous Oxide; Acute Type a Aortic Dissection,Kidney,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15023,NCT03897335,Preventing Acute Kidney Injury (AKI) in Pediatric Patients,UNKNOWN,PHASE3,Acute Kidney Injury,Aminophylline (DRUG); Placebo (DRUG),24776445,VIS,Acute Kidney Injury,Kidney,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15024,NCT05730816,MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI,RECRUITING,PHASE2,Mesothelioma,Magnesium sulfate (DRUG); Normal Saline (DRUG),24776445,VIS,Mesothelioma,Lung,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15025,NCT00800969,Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach,WITHDRAWN,PHASE2,Adenocarcinoma; Stomach Cancer; Cancer of Esophagogastric Junction,FDG-PET-CT (PROCEDURE),24776445,VIS,Adenocarcinoma; Stomach Cancer; Cancer of Esophagogastric Junction,Esophagus/Stomach,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15026,NCT00790140,Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery,UNKNOWN,PHASE4,Esophageal Cancer,Prosure (DIETARY_SUPPLEMENT); Ensure Plus (DIETARY_SUPPLEMENT),24776445,VIS,Esophageal Cancer,Esophagus/Stomach,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15027,NCT00652613,Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC),UNKNOWN,PHASE2,Squamous Cell Carcinoma of the Head and Neck,3 Dimensional Radiation Therapy (RADIATION); Intensity Modulated Radiation Therapy (RADIATION),24776445,VIS,Squamous Cell Carcinoma of the Head and Neck,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15028,NCT01560741,Telemedicine and Ventilator Titration in Chronic Respiratory Patients Initiating Non-invasive Ventilation,UNKNOWN,PHASE1,Chronic Obstructive Pulmonary Disease; Neuromuscular Disease; Chest Wall Disorders; Obesity Hypoventilation Syndrome,Telemonitoring tools (DEVICE); Usual Care (DEVICE),24776445,VIS,Chronic Obstructive Pulmonary Disease; Neuromuscular Disease; Chest Wall Disorders; Obesity Hypoventilation Syndrome,Lung,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15029,NCT04328636,Nebulized MgSO4 in Persistent Pulmonary Hypertension of Newborn,COMPLETED,PHASE1,Persistent Fetal Circulation; Persistent Pulmonary Hypertension of the Newborn; PPHN,Nebulized Magnesium Sulfate (DRUG); Intravenous Magnesium Sulfate (DRUG),24776445,VIS,Persistent Fetal Circulation; Persistent Pulmonary Hypertension of the Newborn; PPHN,Lung,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15030,NCT04898114,Nebulized Magnesium Sulfate and Sildenafil for Persistent Pulmonary Hypertension of Newborn,RECRUITING,PHASE1,Persistent Pulmonary Hypertension of Newborn,Magnesium sulfate (DRUG); Sildenafil Citrate (DRUG); Isotonic saline (OTHER),24776445,VIS,Persistent Pulmonary Hypertension of Newborn,Lung,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15031,NCT00047255,Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer,COMPLETED,PHASE3,Breast Cancer,trastuzumab (BIOLOGICAL); carboplatin (DRUG); docetaxel (DRUG); trastuxumab (BIOLOGICAL); Docetaxel (DRUG),24776445,VIS,Breast Cancer,Breast,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15032,NCT02836899,Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.,UNKNOWN,PHASE3,Acute Kidney Injury,Nitric Oxide (DRUG); Placebo (OTHER),24776445,VIS,Acute Kidney Injury,Kidney,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15033,NCT06901817,A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases,RECRUITING,PHASE2,Leptomeningeal Metastasis,Intraventricular Pemetrexed (DRUG); Intraventricular Nivolumab (DRUG); Intraventricular Dexamethasone (DRUG),24776445,VIS,Leptomeningeal Metastasis,CNS/Brain,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15034,NCT01119651,A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.,COMPLETED,PHASE1,Acne Vulgaris,Tazarotene (Patch application in Challenge Phase) (DRUG),24776445,VIS,Acne Vulgaris,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15035,NCT05105009,Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function,COMPLETED,PHASE1,Chronic Kidney Failure,Furosemide Injection (DRUG); Creatinine Powder (DRUG); Iohexol (DRUG),24776445,VIS,Chronic Kidney Failure,Kidney,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15036,NCT00237978,Control of Therapy of Acne Papulopustulosa by Visible Light With Waterfiltered Infrared and / or Adapalen (Differin Gel),UNKNOWN,PHASE4,Acne Papulopustulosa,Adapalen (DRUG); VIS and wIRA (RADIATION),24776445,VIS,Acne Papulopustulosa,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15037,NCT01929278,"W0265-103: A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, Phase 1 Clinical Trial Evaluating The Phototoxic Potential Of Topically Applied Clindamycin 1.0% - Tretinoin 0.025% Gel (Ct Gel) In Healthy Volunteers",COMPLETED,PHASE1,Acne Vulgaris,CT Gel (clindamycin 1% and tretinoin 0.025%) (DRUG); Vehicle gel patch (OTHER); Blank patch (OTHER),24776445,VIS,Acne Vulgaris,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15038,NCT03373461,Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation,COMPLETED,PHASE2,IgA Nephropathy,LNP023 (DRUG); Placebo (OTHER),24776445,VIS,Kidney Diseases,Kidney,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15039,NCT01367665,STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma,COMPLETED,PHASE2,Basal Cell Carcinoma,vismodegib (DRUG),24776445,VIS,Basal Cell Carcinoma,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15040,NCT02667574,Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC),COMPLETED,PHASE2,Basal Cell Carcinoma,ERIVEDGE (DRUG),24776445,VIS,Basal Cell Carcinoma,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15041,NCT01631331,Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC),COMPLETED,EARLY_PHASE1,Basal Cell Carcinoma of the Skin; Recurrent Skin Cancer,vismodegib (DRUG); Mohs surgery (PROCEDURE),24776445,VIS,Basal Cell Carcinoma of the Skin; Recurrent Skin Cancer,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15042,NCT05238831,SMMART Adaptive Clinical Treatment (ACT) Trial,WITHDRAWN,EARLY_PHASE1,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Alectinib (DRUG); Alpelisib (DRUG); Anastrozole (DRUG); Atezolizumab (BIOLOGICAL); Bevacizumab (BIOLOGICAL); Biopsy (PROCEDURE); Biospecimen Collection (PROCEDURE); Capecitabine (DRUG); Carboplatin (DRUG); Cobimetinib (DRUG); Entrectinib (DRUG); Eribulin (DRUG); Fulvestrant (DRUG); Hyaluronidase-zzxf/Pertuzumab/Trastuzumab (BIOLOGICAL); Irinotecan (DRUG); Letrozole (DRUG); Nab-paclitaxel (DRUG); Niraparib (DRUG); Olaparib (DRUG); Paclitaxel (DRUG); Palbociclib (DRUG); Pertuzumab (BIOLOGICAL); Quality-of-Life Assessment (OTHER); Trastuzumab (BIOLOGICAL); Trastuzumab Emtansine (BIOLOGICAL); Vemurafenib (DRUG); Vinorelbine (DRUG); Vismodegib (DRUG),24776445,VIS,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Ovary/Fallopian Tube,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15043,NCT00982592,Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer,COMPLETED,PHASE2,Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach; Recurrent Gastric Cancer; Stage IIIA Gastric Cancer; Stage IIIB Gastric Cancer; Stage IIIC Gastric Cancer; Stage IV Gastric Cancer,oxaliplatin (DRUG); leucovorin calcium (DRUG); fluorouracil (DRUG); placebo (OTHER); vismodegib (DRUG); laboratory biomarker analysis (OTHER),24776445,VIS,Gastric and Gastroesophageal Junction Cancer,Esophagus/Stomach,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15044,NCT01835626,Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma,COMPLETED,PHASE2,Locally Advanced Basal Cell Carcinoma; Skin Cancer; Cutaneous Malignancy,Vismodegib (DRUG); Radiation therapy (RADIATION),24776445,VIS,Locally Advanced Basal Cell Carcinoma; Skin Cancer; Cutaneous Malignancy,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15045,NCT02690948,Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer,COMPLETED,PHASE1,Skin Basal Cell Carcinoma,Pembrolizumab (BIOLOGICAL); Vismodegib (DRUG),24776445,VIS,Skin Basal Cell Carcinoma,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15046,NCT01064622,Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer,COMPLETED,PHASE2,Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer AJCC v6 and v7,Gemcitabine Hydrochloride (DRUG); Hydrocortisone/Placebo (OTHER); Vismodegib (DRUG),24776445,VIS,Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer AJCC v6 and v7,Pancreas,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15047,NCT03610022,Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1,COMPLETED,PHASE4,Metastatic Basal Cell Carcinoma; Locally Advanced Basal Cell Carcinoma,Treatment with vismodegib (DRUG),24776445,VIS,Metastatic Basal Cell Carcinoma; Locally Advanced Basal Cell Carcinoma,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15048,NCT02956889,To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma,TERMINATED,PHASE2,"Carcinoma, Basal Cell",Vismodegib (DRUG); Radiotherapy (RADIATION),24776445,VIS,Basal Cell Carcinoma,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15049,NCT00878163,GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery,ACTIVE_NOT_RECRUITING,PHASE1,Adult Solid Neoplasm; Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer AJCC v6 and v7,Diagnostic Laboratory Biomarker Analysis (OTHER); Erlotinib Hydrochloride (DRUG); Gemcitabine Hydrochloride (DRUG); Vismodegib (DRUG),24776445,VIS,Adult Solid Neoplasm; Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer AJCC v6 and v7,Pancreas,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15050,NCT02694224,Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients,UNKNOWN,PHASE2,Breast Cancer,vismodegib (DRUG); Paclitaxel (DRUG); Epirubicin (DRUG); Cyclophosphamide (DRUG),24776445,VIS,Breast Cancer,Breast,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15051,NCT02067104,Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention,TERMINATED,PHASE2,Basal Cell Carcinomas,Vismodegib (DRUG); Placebo (DRUG),24776445,VIS,Basal Cell Carcinomas,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15052,NCT01815840,A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas,COMPLETED,PHASE2,Basal Cell Carcinoma,Vismodegib (DRUG); Placebo (DRUG),24776445,VIS,Basal Cell Carcinoma,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15053,NCT03158389,NCT Neuro Master Match - N²M² (NOA-20),COMPLETED,PHASE1,"Glioblastoma, Adult",APG101 (DRUG); Alectinib (DRUG); Idasanutlin (DRUG); Atezolizumab (DRUG); Vismodegib (DRUG); Temsirolimus (DRUG); Palbociclib (DRUG),24776445,VIS,"Glioblastoma, Adult",CNS/Brain,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15054,NCT00833417,"A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma",COMPLETED,PHASE2,Basal Cell Carcinoma,Vismodegib 150 mg (DRUG),24776445,VIS,Basal Cell Carcinoma,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15055,NCT01713218,Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer,UNKNOWN,EARLY_PHASE1,Pancreatic Adenocarcinoma Resectable,gemcitabine (DRUG); Vismodegib (DRUG); Neoadjuvant chemotherapy (PROCEDURE),24776445,VIS,Pancreatic Adenocarcinoma Resectable,Pancreas,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15056,NCT02523014,"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas",RECRUITING,PHASE2,Intracranial Meningioma; Recurrent Meningioma; NF2 Gene Mutation,Vismodegib (DRUG); FAK Inhibitor GSK2256098 (DRUG); Capivasertib (DRUG); Abemaciclib (DRUG),24776445,VIS,Meningioma,CNS/Brain,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15057,NCT00636610,"A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer",COMPLETED,PHASE2,Metastatic Colorectal Cancer,Vismodegib 150 mg (DRUG); Placebo to vismodegib (DRUG); Bevacizumab (DRUG); Modified FOLFOX (DRUG); FOLFIRI (DRUG),24776445,VIS,Metastatic Colorectal Cancer,Bowel,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15058,NCT01543581,Vismodegib for Treatment of Basal Cell Carcinoma,COMPLETED,PHASE2,Basal Cell Carcinoma,Vismodegib (DRUG); Placebo (DRUG),24776445,VIS,Basal Cell Carcinoma,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15059,NCT06616623,Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer,RECRUITING,PHASE1,Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC V8,Atezolizumab (BIOLOGICAL); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Vismodegib (DRUG),24776445,VIS,Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC V8,Lung,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15060,NCT01944943,Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia,TERMINATED,PHASE2,Diffuse Large B-cell Lymphoma; Indolent Non-hodgkin Lymphoma; Primary Central Nervous System Lymphoma; Chronic Lymphocytic Leukemia,Vismodegib (DRUG),24776445,VIS,Diffuse Large B-cell Lymphoma; Indolent Non-hodgkin Lymphoma; Primary Central Nervous System Lymphoma; Chronic Lymphocytic Leukemia,CNS/Brain,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15061,NCT01700049,Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes,COMPLETED,PHASE2,Basal Cell Carcinoma,vismodegib (150 mg PO daily) (DRUG),24776445,VIS,Basal Cell Carcinoma,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15062,NCT01071564,RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery,TERMINATED,PHASE1,Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma,Gamma-Secretase Inhibitor RO4929097 (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacogenomic Study (OTHER); Pharmacological Study (OTHER); Vismodegib (DRUG),24776445,VIS,Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma,Breast,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15063,NCT00980343,GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,COMPLETED,PHASE2,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor,vismodegib (DRUG); therapeutic conventional surgery (PROCEDURE); laboratory biomarker analysis (OTHER); pharmacological study (OTHER),24776445,VIS,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor,CNS/Brain,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15064,NCT02639117,Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas,COMPLETED,PHASE1,Basal Cell Carcinoma,Vismodegib (DRUG),24776445,VIS,Basal Cell Carcinoma,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15065,NCT00887159,A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage,COMPLETED,PHASE2,Extensive Stage Small Cell Lung Carcinoma; Recurrent Small Cell Lung Carcinoma,Cisplatin (DRUG); Cixutumumab (BIOLOGICAL); Etoposide (DRUG); Laboratory Biomarker Analysis (OTHER); Vismodegib (DRUG),24776445,VIS,Extensive Stage Small Cell Lung Carcinoma; Recurrent Small Cell Lung Carcinoma,Lung,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15066,NCT01201915,A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma,COMPLETED,PHASE2,Basal Cell Carcinoma,Vismodegib (DRUG),24776445,VIS,Basal Cell Carcinoma,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15067,NCT01154452,Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma,COMPLETED,PHASE1,Adult Alveolar Soft Part Sarcoma; Adult Angiosarcoma; Adult Desmoplastic Small Round Cell Tumor; Adult Epithelioid Hemangioendothelioma; Adult Epithelioid Sarcoma; Adult Extraskeletal Myxoid Chondrosarcoma; Adult Extraskeletal Osteosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Malignant Mesenchymoma; Adult Malignant Peripheral Nerve Sheath Tumor; Adult Rhabdomyosarcoma; Adult Synovial Sarcoma; Adult Unclassified Pleomorphic Sarcoma; Chondrosarcoma; Clear Cell Sarcoma of the Kidney; Conjunctival Kaposi Sarcoma; Dermatofibrosarcoma Protuberans; Gastrointestinal Stromal Tumor; Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Metastatic Osteosarcoma; Ovarian Sarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Kaposi Sarcoma; Recurrent Osteosarcoma; Recurrent Uterine Corpus Sarcoma; Small Intestine Leiomyosarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Uterine Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IV Uterine Sarcoma; Unclassified Pleomorphic Sarcoma of Bone,Gamma-Secretase Inhibitor RO4929097 (DRUG); Laboratory Biomarker Analysis (OTHER); Pharmacological Study (OTHER); Vismodegib (DRUG),24776445,VIS,Adult Alveolar Soft Part Sarcoma; Adult Angiosarcoma; Adult Desmoplastic Small Round Cell Tumor; Adult Epithelioid Hemangioendothelioma; Adult Epithelioid Sarcoma; Adult Extraskeletal Myxoid Chondrosarcoma; Adult Extraskeletal Osteosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Malignant Mesenchymoma; Adult Malignant Peripheral Nerve Sheath Tumor; Adult Rhabdomyosarcoma; Adult Synovial Sarcoma; Adult Unclassified Pleomorphic Sarcoma; Chondrosarcoma; Clear Cell Sarcoma of the Kidney; Conjunctival Kaposi Sarcoma; Dermatofibrosarcoma Protuberans; Gastrointestinal Stromal Tumor; Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Metastatic Osteosarcoma; Ovarian Sarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Kaposi Sarcoma; Recurrent Osteosarcoma; Recurrent Uterine Corpus Sarcoma; Small Intestine Leiomyosarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Uterine Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IV Uterine Sarcoma; Unclassified Pleomorphic Sarcoma of Bone,Bowel,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15068,NCT01195415,Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer,COMPLETED,PHASE2,Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Gemcitabine Hydrochloride (DRUG); Laboratory Biomarker Analysis (OTHER); Vismodegib (DRUG),24776445,VIS,Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Pancreas,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15069,NCT00959647,A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study,COMPLETED,PHASE2,Ovarian Cancer; Basal Cell Carcinoma; Metastatic Colorectal Cancer,Vismodegib (DRUG); FOLFOX (DRUG); FOLFIRI (DRUG); Bevacizumab (DRUG),24776445,VIS,Ovarian Cancer; Basal Cell Carcinoma; Metastatic Colorectal Cancer,Bowel,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15070,NCT01774253,Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma,TERMINATED,PHASE2,Pontine Glioma,Vismodegib (DRUG),24776445,VIS,Pontine Glioma,CNS/Brain,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15071,NCT01096732,Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS),TERMINATED,PHASE2,Pancreatic Ductal Adenocarcinoma,GDC-0449 (DRUG),24776445,VIS,Pancreatic Ductal Adenocarcinoma,Pancreas,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15072,NCT01088815,Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas,COMPLETED,PHASE2,Metastatic Pancreatic Cancer,"Gemcitabine, nab-Paclitaxel, GDC-0449 (DRUG)",24776445,VIS,Metastatic Pancreatic Cancer,Pancreas,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15073,NCT03035188,Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma,COMPLETED,PHASE2,Basal Cell Carcinoma,Vismodegib (DRUG),24776445,VIS,Basal Cell Carcinoma,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15074,NCT01537107,Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery,COMPLETED,PHASE1,"Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",vismodegib (DRUG); sirolimus (DRUG); positron emission tomography (PROCEDURE); computed tomography (PROCEDURE); pharmacological study (OTHER); laboratory biomarker analysis (OTHER); fludeoxyglucose F 18 (RADIATION),24776445,VIS,"Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Pancreas,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15075,NCT05651828,Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma,RECRUITING,EARLY_PHASE1,Advanced Basal Cell Carcinoma,Vismodegib 150 MG Oral Capsule (DRUG),24776445,VIS,Advanced Basal Cell Carcinoma,Skin,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15076,NCT00739661,"A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission",COMPLETED,PHASE2,Ovarian Cancer,Vismodegib 150 mg (DRUG); Placebo to vismodegib (DRUG),24776445,VIS,Ovarian Cancer,Ovary/Fallopian Tube,Vismodegib,"SMO, ABCB1, ABCG2",inhibitor/antagonist,Sonic inhibitor,yes,yes,Approved for treating basal cell carcinoma.,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,1.02,350.0 +15077,NCT03616574,First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors,COMPLETED,PHASE1,Advanced or Metastatic Solid Tumors; Advanced or Metastatic Colorectal Cancer (mCRC),CA102N (DRUG); LONSURF (DRUG),4495,NIM,Advanced or Metastatic Solid Tumors; Advanced or Metastatic Colorectal Cancer (mCRC),Bowel,Nimesulide,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn in some countries due to safety concerns; not FDA-approved.,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,1.0,223.0 +15078,NCT06781073,"Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma",COMPLETED,PHASE3,Cervical Squamous Cell Carcinoma; Persistent,Nimotuzumab (DRUG); Paclitaxel (DRUG); Cisplatin (DRUG); Placebo (DRUG),4495,NIM,Cervical Squamous Cell Carcinoma; Persistent,Skin,Nimesulide,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn in some countries due to safety concerns; not FDA-approved.,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,1.0,223.0 +15079,NCT06409429,Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer,NOT_YET_RECRUITING,PHASE2,Pancreatic Cancer,Nimotuzumab (DRUG); GX (DRUG); Placebo (DRUG),4495,NIM,Pancreatic Cancer,Pancreas,Nimesulide,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn in some countries due to safety concerns; not FDA-approved.,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,1.0,223.0 +15080,NCT04532229,Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children,UNKNOWN,PHASE3,Diffuse Intrinsic Pontine Glioma,Nimotuzumab+CRT(concurrent IMRT and TMZ) (DRUG),4495,NIM,Diffuse Intrinsic Pontine Glioma,CNS/Brain,Nimesulide,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn in some countries due to safety concerns; not FDA-approved.,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,1.0,223.0 +15081,NCT02395016,A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer,COMPLETED,PHASE3,Pancreatic Cancer,nimotuzumab (DRUG); Gemcitabine (DRUG); Placebo (OTHER),4495,NIM,Pancreatic Cancer,Pancreas,Nimesulide,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn in some countries due to safety concerns; not FDA-approved.,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,1.0,223.0 +15082,NCT06389760,Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer,RECRUITING,PHASE2,Pancreatic Cancer,Nimotuzumab (DRUG); mFOLFIRINOX (DRUG); GX (DRUG),4495,NIM,Pancreatic Cancer,Pancreas,Nimesulide,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn in some countries due to safety concerns; not FDA-approved.,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,1.0,223.0 +15083,NCT06429904,Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Locally Advanced Pancreatic Cancer,Nimotuzumab+ NALIRIFOX (DRUG),4495,NIM,Locally Advanced Pancreatic Cancer,Pancreas,Nimesulide,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn in some countries due to safety concerns; not FDA-approved.,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,1.0,223.0 +15084,NCT05024019,Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery,NOT_YET_RECRUITING,PHASE2,Head and Neck Squamous Cell Carcinoma,Nimotuzumab (DRUG),4495,NIM,Head and Neck Squamous Cell Carcinoma,Skin,Nimesulide,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn in some countries due to safety concerns; not FDA-approved.,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,1.0,223.0 +15085,NCT03954314,DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery,TERMINATED,PHASE3,Bleeding; Surgical Blood Loss; Seizures,Tranexamic Acid (DRUG),4495,NIM,Bleeding; Surgical Blood Loss; Seizures,CNS/Brain,Nimesulide,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn in some countries due to safety concerns; not FDA-approved.,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,1.0,223.0 +15086,NCT06039202,Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer,NOT_YET_RECRUITING,PHASE2,Metastatic Colorectal Cancer,CA102N (DRUG); TAS-102 (DRUG); Bevacizumab (BIOLOGICAL),4495,NIM,Metastatic Colorectal Cancer,Bowel,Nimesulide,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn in some countries due to safety concerns; not FDA-approved.,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,1.0,223.0 +15087,NCT06333821,A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma,NOT_YET_RECRUITING,PHASE3,Cervical Cancer,Nimotuzumab (BIOLOGICAL); Cisplatin (DRUG); External Beam Radiotherapy (EBRT) (RADIATION); Brachytherapy (RADIATION); placebo for Nimotuzumab (DRUG),4495,NIM,Cervical Cancer,Cervix,Nimesulide,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn in some countries due to safety concerns; not FDA-approved.,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,1.0,223.0 +15088,NCT06781086,Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer,NOT_YET_RECRUITING,PHASE2,"Pancreatic Cancer, Adult",Nimotuzumab (DRUG); AG regimen (DRUG); Placebo (DRUG),4495,NIM,"Pancreatic Cancer, Adult",Pancreas,Nimesulide,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn in some countries due to safety concerns; not FDA-approved.,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,1.0,223.0 +15089,NCT06343116,Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer,NOT_YET_RECRUITING,PHASE3,Refractory Metastatic Colorectal Cancer,Nimotuzumab injection (DRUG); Placebo (DRUG); Trifluridine/tipiracil (DRUG),4495,NIM,Refractory Metastatic Colorectal Cancer,Bowel,Nimesulide,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn in some countries due to safety concerns; not FDA-approved.,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,1.0,223.0 +15090,NCT06422156,SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer,NOT_YET_RECRUITING,PHASE2,Advanced Pancreatic Cancer,Stereotactic body radiation (RADIATION); Nimotuzumab (DRUG); mono-chemotherapy (DRUG),4495,NIM,Advanced Pancreatic Cancer,Pancreas,Nimesulide,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn in some countries due to safety concerns; not FDA-approved.,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,1.0,223.0 +15091,NCT06405685,Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis,RECRUITING,PHASE2,Pancreatic Cancer,Nimotuzumab (DRUG); AG (DRUG),4495,NIM,Pancreatic Cancer,Pancreas,Nimesulide,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn in some countries due to safety concerns; not FDA-approved.,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,1.0,223.0 +15092,NCT06722911,Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer,RECRUITING,PHASE2,Pancreatic Cancer Resectable,Nimotuzumab (DRUG); AG (DRUG),4495,NIM,Pancreatic Cancer Resectable,Pancreas,Nimesulide,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn in some countries due to safety concerns; not FDA-approved.,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,1.0,223.0 +15093,NCT06718205,Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma,RECRUITING,PHASE2,Esophageal Cancer,Nimotuzumab (DRUG); Sintilimab (DRUG); Paclitaxel-albumin (DRUG); Cisplatin (DRUG),4495,NIM,Esophageal Cancer,Esophagus/Stomach,Nimesulide,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn in some countries due to safety concerns; not FDA-approved.,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,1.0,223.0 +15094,NCT01500577,A Prevention Trial in Subjects at High Risk for Breast Cancer,COMPLETED,PHASE2,Breast Cancer,nimesulide (DRUG); Simvastatin (DRUG); Placebo (OTHER),4495,NIM,Breast Cancer,Breast,Nimesulide,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn in some countries due to safety concerns; not FDA-approved.,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,1.0,223.0 +15095,NCT01257126,Efficacy of Diclofenac Potassium vs Nimesulide in the Treatment of Fever and Pain in Children With Upper Respiratory Tract Infection,WITHDRAWN,PHASE4,Upper Respiratory Tract Infections,diclofenac potassium (DRUG); nimesulide (DRUG),4495,NIM,Upper Respiratory Tract Infections,Lung,Nimesulide,PTGS2,inhibitor/antagonist,Cyclooxygenase inhibitor,no,yes,Withdrawn in some countries due to safety concerns; not FDA-approved.,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,1.0,223.0 +15096,NCT01761994,The Effect of Nafamostat Mesilate in Prolonging Filter Patency With Patients on Continuous Renal Replacement Therapy,COMPLETED,PHASE4,Acute Kidney Injury,Anticoagulation with nafamostat mesilate (DRUG),5311180,Futhan,Acute Kidney Injury,Kidney,Nafamostat (mesylate),,inhibitor/antagonist,unclear,yes,yes,"Approved in some countries, often used as anticoagulant.",CS(=O)(=O)O.CS(=O)(=O)O.C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N,1.041237113402062,1758.0 +15097,NCT02478242,Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy,COMPLETED,PHASE4,Acute Kidney Injury,Nafamostat mesilate (DRUG); Normal saline (DRUG),5311180,Futhan,Acute Kidney Injury,Kidney,Nafamostat (mesylate),,inhibitor/antagonist,unclear,yes,yes,"Approved in some countries, often used as anticoagulant.",CS(=O)(=O)O.CS(=O)(=O)O.C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N,1.041237113402062,1758.0 +15098,NCT01001403,Effect of Nafamostat on Postreperfusion Syndrome (PRS),COMPLETED,PHASE4,Liver Transplantation; Postreperfusion Syndrome,Nafamostat (DRUG); Normal saline (DRUG),5311180,Futhan,Liver Transplantation; Postreperfusion Syndrome,Liver,Nafamostat (mesylate),,inhibitor/antagonist,unclear,yes,yes,"Approved in some countries, often used as anticoagulant.",CS(=O)(=O)O.CS(=O)(=O)O.C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N,1.041237113402062,1758.0 +15099,NCT04871646,Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314,UNKNOWN,PHASE3,COVID-19 Pneumonia,CKD-314+SOC (DRUG); CKD-314 Placebo+SOC (DRUG),5311180,Futhan,COVID-19 Pneumonia,Lung,Nafamostat (mesylate),,inhibitor/antagonist,unclear,yes,yes,"Approved in some countries, often used as anticoagulant.",CS(=O)(=O)O.CS(=O)(=O)O.C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N,1.041237113402062,1758.0 +15100,NCT01486485,Nafamostat Efficacy and Safety in Critically Ill Patients(NICE),UNKNOWN,PHASE3,Acute Kidney Injury,heparinized saline priming group (DRUG); nafamostat infusion after heparinized saline priming (DRUG),5311180,Futhan,Acute Kidney Injury,Kidney,Nafamostat (mesylate),,inhibitor/antagonist,unclear,yes,yes,"Approved in some countries, often used as anticoagulant.",CS(=O)(=O)O.CS(=O)(=O)O.C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N,1.041237113402062,1758.0 +15101,NCT00170690,Preference Study With Elderly Patients Recurrent Ovarian Cancer,COMPLETED,PHASE3,Ovarian Cancer,Treosulfan (DRUG); Treosulfan (DRUG),2478,BUS,Ovarian Cancer,Ovary/Fallopian Tube,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15102,NCT00006246,Busulfan in Treating Children and Adolescents With Refractory CNS Cancer,COMPLETED,PHASE1,Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Leukemia; Lymphoma; Metastatic Cancer; Retinoblastoma; Sarcoma,busulfan (DRUG),2478,BUS,Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Leukemia; Lymphoma; Metastatic Cancer; Retinoblastoma; Sarcoma,CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15103,NCT00003060,Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma,TERMINATED,PHASE1,Melanoma (Skin),filgrastim (BIOLOGICAL); busulfan (DRUG); cyclophosphamide (DRUG); cyclosporine (DRUG); methotrexate (DRUG); allogeneic bone marrow transplantation (PROCEDURE),2478,BUS,Melanoma (Skin),Skin,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15104,NCT00801931,Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders,TERMINATED,PHASE1,Leukemia; Lymphoma; Neuroblastoma; Immunodeficiencies; Anemia,Alemtuzumab (DRUG); Total Body Irradiation (RADIATION); Melphalan (DRUG); Busulfan (DRUG); Phenytoin (DRUG); Fludarabine (DRUG); Cyclophosphamide (DRUG); Horse Antithymocyte Globulin (DRUG); Rabbit Antithymocyte Globulin (DRUG); Thiotepa (DRUG),2478,BUS,Leukemia; Lymphoma; Neuroblastoma; Immunodeficiencies; Anemia,CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15105,NCT00863460,Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients,ACTIVE_NOT_RECRUITING,PHASE2,Primary Central Nervous System Lymphoma,cranial radiotherapy (RADIATION); intensive chemotherapy and hematopoietic stem cell rescue (DRUG); MTX based chemotherapy (DRUG),2478,BUS,Primary Central Nervous System Lymphoma,CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15106,NCT00003926,Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors,TERMINATED,PHASE1,Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Chordoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Ovarian Cancer; Retinoblastoma; Sarcoma,amifostine trihydrate (DRUG); busulfan (DRUG); filgrastim (DRUG); melphalan (DRUG); thiotepa (DRUG); peripheral blood stem cell transplantation (PBSC) (PROCEDURE),2478,BUS,Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Chordoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Ovarian Cancer; Retinoblastoma; Sarcoma,Ovary/Fallopian Tube,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15107,NCT00006126,"Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery",WITHDRAWN,PHASE1,Breast Cancer; Kidney Cancer; Lung Cancer; Melanoma (Skin); Testicular Germ Cell Tumor,busulfan (DRUG); cyclophosphamide (DRUG); etoposide (DRUG); fludarabine phosphate (DRUG); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),2478,BUS,Breast Cancer; Kidney Cancer; Lung Cancer; Melanoma (Skin); Testicular Germ Cell Tumor,Lung,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15108,NCT06073886,Personalized Brain Stimulation to Treat Chronic Concussive Symptoms,NOT_YET_RECRUITING,PHASE2,"Post-Concussion Syndrome; Concussion, Brain; Mild Traumatic Brain Injury; Head Injury; Headache; Dizziness; Cognitive Symptom; Dysautonomia; Anxiety; Irritability; Syndrome; Depression; Post-traumatic Stress Disorder",Active cTBS (DEVICE); Inactive/Sham cTBS (DEVICE); Imaginal exposure (BEHAVIORAL),2478,BUS,"Post-Concussion Syndrome; Concussion, Brain; Mild Traumatic Brain Injury; Head Injury; Headache; Dizziness; Cognitive Symptom; Dysautonomia; Anxiety; Irritability; Syndrome; Depression; Post-traumatic Stress Disorder",CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15109,NCT03733327,BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT,UNKNOWN,PHASE2,Primary Central Nervous System Lymphoma; Autologous Hematopoietic Stem Cell Transplantation; Conditioning,Busulfan (BU) (DRUG); Cyclophosphamide (CY) (DRUG); Etoposide (VP-16) (DRUG),2478,BUS,Primary Central Nervous System Lymphoma; Autologous Hematopoietic Stem Cell Transplantation; Conditioning,CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15110,NCT01099930,Autologous Stem Cell Transplant for Multiple Sclerosis,COMPLETED,PHASE2,Multiple Sclerosis,"immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT), (OTHER); Standard Therapy (OTHER)",2478,BUS,Multiple Sclerosis,CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15111,NCT00003462,"Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal Tumors",COMPLETED,PHASE1,Brain and Central Nervous System Tumors,busulfan (DRUG),2478,BUS,Brain and Central Nervous System Tumors,CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15112,NCT01704716,High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN),RECRUITING,PHASE3,Neuroblastoma,Vincristine (DRUG); Aldesleukin (DRUG); ch14.18/CHO (DRUG); Carboplatin (DRUG); Etoposide (DRUG); Cisplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin (DRUG); G-CSF (DRUG); Busulfan (DRUG); Melphalan (DRUG),2478,BUS,Neuroblastoma,CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15113,NCT03126916,Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL),ACTIVE_NOT_RECRUITING,PHASE3,Ganglioneuroblastoma; Neuroblastoma,Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE); Biospecimen Collection (PROCEDURE); Bone Marrow Aspiration and Biopsy (PROCEDURE); Busulfan (DRUG); Carboplatin (DRUG); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Cyclophosphamide (DRUG); Dexrazoxane Hydrochloride (DRUG); Dinutuximab (BIOLOGICAL); Doxorubicin Hydrochloride (DRUG); Echocardiography (PROCEDURE); Etoposide Phosphate (DRUG); External Beam Radiation Therapy (RADIATION); Iobenguane I-123 (RADIATION); Iobenguane I-131 (RADIATION); Isotretinoin (DRUG); Lorlatinib (DRUG); Magnetic Resonance Imaging (PROCEDURE); Melphalan Hydrochloride (DRUG); Multigated Acquisition Scan (PROCEDURE); Positron Emission Tomography (PROCEDURE); Sargramostim (BIOLOGICAL); Therapeutic Conventional Surgery (PROCEDURE); Thiotepa (DRUG); Topotecan Hydrochloride (DRUG); Vincristine Sulfate (DRUG),2478,BUS,Ganglioneuroblastoma; Neuroblastoma,CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15114,NCT04221035,High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN),RECRUITING,PHASE3,High-Risk Neuroblastoma; Patient With Insufficient Response Chemoimmunotherapy,Vincristine (DRUG); Carboplatin (DRUG); Etoposide (DRUG); Vindesine (DRUG); Dacarbazine (DRUG); Ifosfamide (DRUG); Doxorubicin (DRUG); Busulfan (DRUG); Melphalan (DRUG); Thiotepa (DRUG); Radiotherapy (RADIATION); Dinutuximab Beta (DRUG); Cisplatin (DRUG); Temozolomide 100 MG (DRUG); Irinotecan (DRUG); Cyclophosphamid (DRUG),2478,BUS,High-Risk Neuroblastoma; Patient With Insufficient Response Chemoimmunotherapy,CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15115,NCT00084695,Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,UNKNOWN,PHASE2,"Childhood Langerhans Cell Histiocytosis; Fanconi Anemia; Leukemia; Lymphoma; Myelodysplastic Syndromes; Neuroblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific",anti-thymocyte globulin (BIOLOGICAL); busulfan (DRUG); cyclophosphamide (DRUG); fludarabine phosphate (DRUG); melphalan (DRUG); methylprednisolone (DRUG); radiation therapy (RADIATION),2478,BUS,"Childhood Langerhans Cell Histiocytosis; Fanconi Anemia; Leukemia; Lymphoma; Myelodysplastic Syndromes; Neuroblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific",CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15116,NCT02589340,"Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia",TERMINATED,PHASE1,Parkinson's Disease; Dyskinesias; Movement Disorders,Buspirone (DRUG); Placebo (DRUG),2478,BUS,Parkinson's Disease; Dyskinesias; Movement Disorders,CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15117,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,COMPLETED,PHASE2,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,75 approved agents (DRUG); COXEN (OTHER),2478,BUS,Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms,Bladder/Urinary Tract,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15118,NCT06900192,A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis,NOT_YET_RECRUITING,PHASE1,"Primary Progressive Multiple Sclerosis; Multiple Sclerosis; Multiple Sclerosis, Primary Progressive; Multiple Sclerosis, Secondary Progressive",Orca-Q (BIOLOGICAL); myeloablative regimen (DRUG),2478,BUS,"Primary Progressive Multiple Sclerosis; Multiple Sclerosis; Multiple Sclerosis, Primary Progressive; Multiple Sclerosis, Secondary Progressive",CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15119,NCT05303727,Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma,NOT_YET_RECRUITING,PHASE2,Neuroblastoma,Anti Thymocyte Globulin (DRUG); Fludarabine (DRUG); Cyclophosphamide injection (DRUG); Topotecan (DRUG); Melphalan (DRUG); Thiotepa (DRUG); Busulfan (DRUG); Cyclosporine (DRUG); Tacrolimus (DRUG); Mycophenolate Mofetil (DRUG); Methotrexate (DRUG),2478,BUS,Neuroblastoma,CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15120,NCT00003972,Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer,COMPLETED,PHASE3,Breast Cancer,filgrastim (BIOLOGICAL); sargramostim (BIOLOGICAL); busulfan (DRUG); carboplatin (DRUG); cyclophosphamide (DRUG); melphalan (DRUG); paclitaxel (DRUG); tamoxifen citrate (DRUG); thiotepa (DRUG); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),2478,BUS,Breast Cancer,Breast,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15121,NCT01798004,"Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma",COMPLETED,PHASE1,Ganglioneuroblastoma; Stage 1 Neuroblastoma; Stage 2 Neuroblastoma; Stage 2A Neuroblastoma; Stage 2B Neuroblastoma; Stage 3 Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma,Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE); Busulfan (DRUG); Cisplatin (DRUG); Cyclophosphamide (DRUG); Doxorubicin Hydrochloride (DRUG); Etoposide (DRUG); External Beam Radiation Therapy (RADIATION); Filgrastim (BIOLOGICAL); Laboratory Biomarker Analysis (OTHER); Melphalan (DRUG); Mesna (DRUG); Peripheral Blood Stem Cell Transplantation (PROCEDURE); Pharmacological Study (OTHER); Topotecan Hydrochloride (DRUG); Vincristine Sulfate (DRUG),2478,BUS,Ganglioneuroblastoma; Stage 1 Neuroblastoma; Stage 2 Neuroblastoma; Stage 2A Neuroblastoma; Stage 2B Neuroblastoma; Stage 3 Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma,CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15122,NCT00003101,Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma,COMPLETED,PHASE2,Brain and Central Nervous System Tumors,filgrastim (BIOLOGICAL); busulfan (DRUG); lomustine (DRUG); procarbazine hydrochloride (DRUG); thiotepa (DRUG); vincristine sulfate (DRUG); autologous bone marrow transplantation (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE),2478,BUS,Brain and Central Nervous System Tumors,CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15123,NCT02130869,A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,COMPLETED,PHASE1,Neuroblastoma; Lymphoma; High-risk Tumor,CD133+ selected autologous stem cell infusion (BIOLOGICAL); IL-2 (BIOLOGICAL); hu14.18K322A (BIOLOGICAL); Busulfan (DRUG); Melphalan (DRUG); GM-CSF (BIOLOGICAL); Bendamustine (DRUG); Etoposide (DRUG); Cytarabine (DRUG); Carboplatin (DRUG); Haploidentical natural killer cell infusion (DEVICE); G-CSF (BIOLOGICAL); Etoposide phosphate (DRUG); CliniMACS (DEVICE),2478,BUS,Neuroblastoma and Lymphoma,CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15124,NCT01857934,Therapy for Children With Advanced Stage Neuroblastoma,ACTIVE_NOT_RECRUITING,PHASE2,Neuroblastoma,cyclophosphamide (DRUG); topotecan (DRUG); hu14.18K322A (BIOLOGICAL); peripheral blood stem cell harvest (PROCEDURE); surgical resection (PROCEDURE); cisplatin (DRUG); etoposide (DRUG); doxorubicin (DRUG); vincristine (DRUG); busulfan (DRUG); melphalan (DRUG); peripheral blood stem cell transplantation (BIOLOGICAL); natural killer cell infusion (BIOLOGICAL); radiation therapy (RADIATION); GM-CSF (BIOLOGICAL); G-CSF (BIOLOGICAL); mesna (DRUG); levetiracetam (DRUG); interleukin-2 (BIOLOGICAL); Isotretinoin (DRUG); CliniMACS (DEVICE),2478,BUS,Neuroblastoma,CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15125,NCT00030719,"Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma",UNKNOWN,PHASE3,Neuroblastoma,filgrastim (BIOLOGICAL); monoclonal antibody Ch14.18 (BIOLOGICAL); busulfan (DRUG); carboplatin (DRUG); cyclophosphamide (DRUG); etoposide (DRUG); isotretinoin (DRUG); melphalan (DRUG); vincristine sulfate (DRUG); bone marrow ablation with stem cell support (PROCEDURE); conventional surgery (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),2478,BUS,Neuroblastoma,CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15126,NCT00025649,Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma,COMPLETED,PHASE2,Neuroblastoma,filgrastim (BIOLOGICAL); busulfan (DRUG); carboplatin (DRUG); cyclophosphamide (DRUG); doxorubicin hydrochloride (DRUG); etoposide (DRUG); melphalan (DRUG); vincristine sulfate (DRUG); autologous bone marrow transplantation (PROCEDURE); conventional surgery (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE),2478,BUS,Neuroblastoma,CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15127,NCT00060255,"High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors",COMPLETED,PHASE2,"Breast Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Testicular Germ Cell Tumor; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific",busulfan (DRUG); carboplatin (DRUG); carmustine (DRUG); cyclophosphamide (DRUG); etoposide (DRUG); melphalan (DRUG); thiotepa (DRUG); autologous bone marrow transplantation (PROCEDURE); bone marrow ablation with stem cell support (PROCEDURE); peripheral blood stem cell transplantation (PROCEDURE); radiation therapy (RADIATION),2478,BUS,"Breast Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Testicular Germ Cell Tumor; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific",Breast,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15128,NCT00670410,Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma,TERMINATED,PHASE1,Neuroblastoma,Related donor transplant (PROCEDURE); Cord blood transplant (PROCEDURE); Busulfan (DRUG); Thymoglobulin (DRUG); Fludarabine (DRUG),2478,BUS,Neuroblastoma,CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15129,NCT01156350,Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma,UNKNOWN,PHASE2,Neuroblastoma,Busulfan - Fludarabine - TBI (DRUG),2478,BUS,Neuroblastoma,CNS/Brain,Busulfan,,unclear,DNA synthesis/repair inhibitor,yes,yes,Approved for use in bone marrow transplantation.,CS(=O)(=O)OCCCCOS(=O)(=O)C,1.01,242.0 +15130,NCT00384384,Glycyrrhetinic Acid-Effect on Serum Potassium and Insulin Resistance in Dialysis Patients,COMPLETED,PHASE2,End Stage Renal Disease,oral 18B Glycyrrhetinic acid versus placebo (DRUG),10114,CBW,End Stage Renal Disease,Kidney,18β-Glycyrrhetinic acid,,unclear,unclear,no,yes,"Used in cosmetics, derived from licorice root, no approval for human drugs.",C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)(C)C(=O)O,, +15131,NCT00540436,"Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension",COMPLETED,PHASE2,"Hypertension, Pulmonary",GSK1325760A (DRUG),10114,CBW,Pulmonary Hypertension,Lung,18β-Glycyrrhetinic acid,,unclear,unclear,no,yes,"Used in cosmetics, derived from licorice root, no approval for human drugs.",C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)(C)C(=O)O,, +15132,NCT01649947,Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II,COMPLETED,PHASE2,Non-small Cell Lung Cancer; Advanced Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer,Paclitaxel (DRUG); Carboplatin (DRUG); Hydroxychloroquine (DRUG); Bevacizumab (DRUG),10114,CBW,Non-small Cell Lung Cancer; Advanced Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer,Lung,18β-Glycyrrhetinic acid,,unclear,unclear,no,yes,"Used in cosmetics, derived from licorice root, no approval for human drugs.",C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)(C)C(=O)O,, +15133,NCT05537948,Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients,ACTIVE_NOT_RECRUITING,PHASE4,Dyslipidemias; Hyperlipidemias; Liver Transplant Disorder; Immunosuppression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Statins,Pitavastatin (DRUG); PCSK9 inhibitor (DRUG),5282451,Livalo,Dyslipidemias; Hyperlipidemias; Liver Transplant Disorder; Immunosuppression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Statins,Liver,Pitavastatin (Calcium),HMGCR,inhibitor/antagonist,unclear,yes,yes,"Approved for lowering cholesterol, part of statins class of drugs.", C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.[Ca+2],1.23,189.0 +15134,NCT01043094,"Safety, Tolerability, and Pharmacokinetic of Single Dose of Pitavastatin 4 mg in Severe Renal Patients Versus Healthy Adult Volunteers",COMPLETED,PHASE4,Severe Renal Impairment,Pitavastatin 4mg (DRUG),5282451,Livalo,Severe Renal Impairment,Kidney,Pitavastatin (Calcium),HMGCR,inhibitor/antagonist,unclear,yes,yes,"Approved for lowering cholesterol, part of statins class of drugs.", C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.[Ca+2],1.23,189.0 +15135,NCT05747768,"A Clinical Study to Evaluate the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Healthy Volunteers and Renal Impairment Patients",UNKNOWN,PHASE4,Chronic Kidney Disease,"Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin (DRUG)",5282451,Livalo,Chronic Kidney Disease,Kidney,Pitavastatin (Calcium),HMGCR,inhibitor/antagonist,unclear,yes,yes,"Approved for lowering cholesterol, part of statins class of drugs.", C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.[Ca+2],1.23,189.0 +15136,NCT03311841,"Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)",COMPLETED,PHASE1,Renal Insufficiency,Midazolam oral solution (DRUG); Dabigatran and pitavastatin oral solution (DRUG); Atorvastatin and rosuvastatin oral solution (DRUG); Rifampin (DRUG),5282451,Livalo,Renal Insufficiency,Kidney,Pitavastatin (Calcium),HMGCR,inhibitor/antagonist,unclear,yes,yes,"Approved for lowering cholesterol, part of statins class of drugs.", C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.[Ca+2],1.23,189.0 +15137,NCT05977738,Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin,COMPLETED,EARLY_PHASE1,"Glioblastoma Multiforme, Adult; Recurrent Glioblastoma",Pitavastatin calcium (DRUG),5282451,Livalo,"Glioblastoma Multiforme, Adult; Recurrent Glioblastoma",CNS/Brain,Pitavastatin (Calcium),HMGCR,inhibitor/antagonist,unclear,yes,yes,"Approved for lowering cholesterol, part of statins class of drugs.", C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.[Ca+2],1.23,189.0 +15138,NCT02863185,Effect of Pitavastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease,COMPLETED,PHASE4,Chronic Kidney Disease,Pitavastatin (DRUG); Atorvastatin (DRUG),5282451,Livalo,Chronic Kidney Disease,Kidney,Pitavastatin (Calcium),HMGCR,inhibitor/antagonist,unclear,yes,yes,"Approved for lowering cholesterol, part of statins class of drugs.", C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.[Ca+2],1.23,189.0 +15139,NCT04705909,Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer,UNKNOWN,PHASE2,Breast Cancer,Pitavastatin (DRUG); placebo (DRUG),5282451,Livalo,Breast Cancer,Breast,Pitavastatin (Calcium),HMGCR,inhibitor/antagonist,unclear,yes,yes,"Approved for lowering cholesterol, part of statins class of drugs.", C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.[Ca+2],1.23,189.0 +15140,NCT01806857,Clinical Trial Nuedexta in Subjects With ALS,COMPLETED,PHASE2,Amyotrophic Lateral Sclerosis (ALS),Nuedexta (DRUG); Matching Placebo (DRUG),441074,QDN,Amyotrophic Lateral Sclerosis (ALS),CNS/Brain,Quinidine (15% dihydroquinidine),KCNH2,inhibitor/antagonist,unclear,yes,yes,Approved for arrhythmias as part of quinine alkaloids.,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O ,, +15141,NCT03393520,"Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",COMPLETED,PHASE3,Agitation in Patients With Dementia of the Alzheimer's Type,Placebo (DRUG); AVP-786 (DRUG),441074,QDN,Agitation in Patients With Dementia of the Alzheimer's Type,CNS/Brain,Quinidine (15% dihydroquinidine),KCNH2,inhibitor/antagonist,unclear,yes,yes,Approved for arrhythmias as part of quinine alkaloids.,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O ,, +15142,NCT01584440,"Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease",COMPLETED,PHASE2,Agitation; Alzheimer's Disease,AVP-923-20 (DRUG); Placebo (DRUG); AVP-923-30 (DRUG),441074,QDN,Agitation; Alzheimer's Disease,CNS/Brain,Quinidine (15% dihydroquinidine),KCNH2,inhibitor/antagonist,unclear,yes,yes,Approved for arrhythmias as part of quinine alkaloids.,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O ,, +15143,NCT01767129,Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients,COMPLETED,PHASE2,Dyskinesia; Parkinson's Disease,AVP-923-45 (DRUG); Placebo (DRUG),441074,QDN,Dyskinesia; Parkinson's Disease,CNS/Brain,Quinidine (15% dihydroquinidine),KCNH2,inhibitor/antagonist,unclear,yes,yes,Approved for arrhythmias as part of quinine alkaloids.,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O ,, +15144,NCT01799941,"Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)",COMPLETED,PHASE4,Pseudobulbar Affect (PBA); Stroke; Dementia; Traumatic Brain Injury (TBI),Nuedexta (DM 20 mg/Q 10 mg) (DRUG),441074,QDN,Pseudobulbar Affect (PBA); Stroke; Dementia; Traumatic Brain Injury (TBI),CNS/Brain,Quinidine (15% dihydroquinidine),KCNH2,inhibitor/antagonist,unclear,yes,yes,Approved for arrhythmias as part of quinine alkaloids.,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O ,, +15145,NCT03854019,Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease,COMPLETED,PHASE3,Huntington Disease; Irritability,Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) (DRUG); Placebo (DRUG),441074,QDN,Huntington Disease; Irritability,CNS/Brain,Quinidine (15% dihydroquinidine),KCNH2,inhibitor/antagonist,unclear,yes,yes,Approved for arrhythmias as part of quinine alkaloids.,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O ,, +15146,NCT04408755,"Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",TERMINATED,PHASE3,Agitation in Patients With Dementia of the Alzheimer's Type,AVP-786 (DRUG); Placebo (DRUG),441074,QDN,Agitation in Patients With Dementia of the Alzheimer's Type,CNS/Brain,Quinidine (15% dihydroquinidine),KCNH2,inhibitor/antagonist,unclear,yes,yes,Approved for arrhythmias as part of quinine alkaloids.,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O ,, +15147,NCT01832350,Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease,TERMINATED,PHASE4,Alzheimer's Disease; Pseudobulbar Affect (PBA),Nuedexta (20/10) (DRUG),441074,QDN,Alzheimer's Disease; Pseudobulbar Affect (PBA),CNS/Brain,Quinidine (15% dihydroquinidine),KCNH2,inhibitor/antagonist,unclear,yes,yes,Approved for arrhythmias as part of quinine alkaloids.,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O ,, +15148,NCT03883581,Impact of Nuedexta on Bulbar Physiology and Function in ALS,COMPLETED,PHASE1,Amyotrophic Lateral Sclerosis,dextromethorphan HBr and quinidine sulfate (DRUG),441074,QDN,Amyotrophic Lateral Sclerosis,CNS/Brain,Quinidine (15% dihydroquinidine),KCNH2,inhibitor/antagonist,unclear,yes,yes,Approved for arrhythmias as part of quinine alkaloids.,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O ,, +15149,NCT04464564,"Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",TERMINATED,PHASE3,Agitation in Patients With Dementia of the Alzheimer's Type,AVP-786 (DRUG); Placebo (DRUG),441074,QDN,Agitation in Patients With Dementia of the Alzheimer's Type,CNS/Brain,Quinidine (15% dihydroquinidine),KCNH2,inhibitor/antagonist,unclear,yes,yes,Approved for arrhythmias as part of quinine alkaloids.,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O ,, +15150,NCT02442765,"Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",COMPLETED,PHASE3,Agitation in Patients With Dementia of the Alzheimer's Type,AVP-786 (DRUG); Placebo (DRUG),441074,QDN,Agitation in Patients With Dementia of the Alzheimer's Type,CNS/Brain,Quinidine (15% dihydroquinidine),KCNH2,inhibitor/antagonist,unclear,yes,yes,Approved for arrhythmias as part of quinine alkaloids.,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O ,, +15151,NCT02446132,"Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",TERMINATED,PHASE3,Agitation in Patients With Dementia of the Alzheimer's Type,AVP-786 (DRUG),441074,QDN,Agitation in Patients With Dementia of the Alzheimer's Type,CNS/Brain,Quinidine (15% dihydroquinidine),KCNH2,inhibitor/antagonist,unclear,yes,yes,Approved for arrhythmias as part of quinine alkaloids.,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O ,, +15152,NCT01324232,Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis,COMPLETED,PHASE2,Central Neuropathic Pain; Multiple Sclerosis,AVP-923-45 (DRUG); AVP-923-30 (DRUG); AVP-923-20 (DRUG); Placebo (DRUG),441074,QDN,Central Neuropathic Pain; Multiple Sclerosis,CNS/Brain,Quinidine (15% dihydroquinidine),KCNH2,inhibitor/antagonist,unclear,yes,yes,Approved for arrhythmias as part of quinine alkaloids.,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O ,, +15153,NCT04783753,"Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects",COMPLETED,PHASE1,Hepatitis B,EDP-514 (DRUG); EDP-514 (DRUG); EDP-514 (DRUG); Itraconazole (DRUG); Carbamazepin (DRUG); Quinidine (DRUG),441074,QDN,Hepatitis B,Liver,Quinidine (15% dihydroquinidine),KCNH2,inhibitor/antagonist,unclear,yes,yes,Approved for arrhythmias as part of quinine alkaloids.,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O ,, +15154,NCT02442778,"Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type",COMPLETED,PHASE3,Agitation in Participants With Dementia of the Alzheimer's Type,AVP-786-18 (DRUG); Placebo (DRUG); AVP-786-28 (DRUG); AVP-786-42.63 (DRUG),441074,QDN,Agitation in Participants With Dementia of the Alzheimer's Type,CNS/Brain,Quinidine (15% dihydroquinidine),KCNH2,inhibitor/antagonist,unclear,yes,yes,Approved for arrhythmias as part of quinine alkaloids.,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O ,, +15155,NCT00113620,Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy,COMPLETED,PHASE3,Pain; Diabetic Neuropathy,Neurodex (DRUG),441074,QDN,Pain; Diabetic Neuropathy,Peripheral Nervous System,Quinidine (15% dihydroquinidine),KCNH2,inhibitor/antagonist,unclear,yes,yes,Approved for arrhythmias as part of quinine alkaloids.,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O ,, +15156,NCT00007605,"Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm",COMPLETED,PHASE3,"Atrial Fibrillation; Cerebrovascular Accident; Death, Sudden",Amiodarone (DRUG); Sotalol (DRUG),441074,QDN,"Atrial Fibrillation; Cerebrovascular Accident; Death, Sudden",CNS/Brain,Quinidine (15% dihydroquinidine),KCNH2,inhibitor/antagonist,unclear,yes,yes,Approved for arrhythmias as part of quinine alkaloids.,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O ,, +15157,NCT03610945,"Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers",COMPLETED,PHASE1,NASH - Nonalcoholic Steatohepatitis,Fluconazole (DRUG); Quinidine (DRUG); EDP-305 (DRUG); EDP-305 (DRUG),441074,QDN,Nonalcoholic Steatohepatitis,Liver,Quinidine (15% dihydroquinidine),KCNH2,inhibitor/antagonist,unclear,yes,yes,Approved for arrhythmias as part of quinine alkaloids.,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O ,, +15158,NCT00021697,Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS,COMPLETED,PHASE3,Amyotrophic Lateral Sclerosis,AVP-923 (DRUG),441074,QDN,Amyotrophic Lateral Sclerosis,CNS/Brain,Quinidine (15% dihydroquinidine),KCNH2,inhibitor/antagonist,unclear,yes,yes,Approved for arrhythmias as part of quinine alkaloids.,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O ,, +15159,NCT01759576,"A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function",COMPLETED,PHASE1,Renal Insufficiency; Healthy,Canagliflozin (JNJ-28431754) (DRUG),24997615,Invokana,Renal Insufficiency; Healthy,Kidney,Canagliflozin (hemihydrate),SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes.,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,1.1764705882352942,144.0 +15160,NCT04700839,SGLT2 Inhibitors in Patients With PCOS,COMPLETED,PHASE4,Polycystic Ovary Syndrome,SGLT2 inhibitors (DRUG); Metformin (DRUG),24997615,Invokana,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Canagliflozin (hemihydrate),SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes.,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,1.1764705882352942,144.0 +15161,NCT02065791,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,COMPLETED,PHASE3,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Canagliflozin (DRUG); Placebo (DRUG),24997615,Invokana,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Kidney,Canagliflozin (hemihydrate),SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes.,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,1.1764705882352942,144.0 +15162,NCT04073680,A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors,UNKNOWN,PHASE1,Breast Cancer; Endometrial Cancer; Lung Cancer; Colo-rectal Cancer; Head and Neck Cancer,Serabelisib (DRUG); Canagliflozin 300mg (DRUG),24997615,Invokana,Breast Cancer; Endometrial Cancer; Lung Cancer; Colo-rectal Cancer; Head and Neck Cancer,Lung,Canagliflozin (hemihydrate),SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes.,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,1.1764705882352942,144.0 +15163,NCT06256289,Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome,NOT_YET_RECRUITING,PHASE4,Polycystic Ovary Syndrome; Non-Alcoholic Fatty Liver Disease,Canagliflozin 100mg Tab (DRUG); Metformin Hydrochloride (DRUG),24997615,Invokana,Polycystic Ovary Syndrome; Non-Alcoholic Fatty Liver Disease,Ovary/Fallopian Tube,Canagliflozin (hemihydrate),SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes.,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,1.1764705882352942,144.0 +15164,NCT04973891,CANA/Met in Non-diabetic Women With PCOS,COMPLETED,PHASE1,Polycystic Ovary Syndrome,Canagliflozin combined with metformin (DRUG); metformin (DRUG),24997615,Invokana,Polycystic Ovary Syndrome,Ovary/Fallopian Tube,Canagliflozin (hemihydrate),SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes.,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,1.1764705882352942,144.0 +15165,NCT05507892,Renal Mechanism of SGLT2 Inhibition,UNKNOWN,PHASE2,Type 2 Diabetes; Diabetic Kidney Disease,canagliflozin (DRUG); Aminohippurate Sodium Inj 20% (DRUG),24997615,Invokana,Type 2 Diabetes; Diabetic Kidney Disease,Kidney,Canagliflozin (hemihydrate),SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes.,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,1.1764705882352942,144.0 +15166,NCT05090358,Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Breast Cancer; Breast Cancer Stage IV; Metastatic Breast Cancer,Ketogenic Diet (DIETARY_SUPPLEMENT); Low Carbohydrate Diet (DIETARY_SUPPLEMENT); Alpelisib (DRUG); Fulvestrant (DRUG); Canagliflozin (DRUG),24997615,Invokana,Breast Cancer; Breast Cancer Stage IV; Metastatic Breast Cancer,Breast,Canagliflozin (hemihydrate),SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes.,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,1.1764705882352942,144.0 +15167,NCT01064414,"An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment",COMPLETED,PHASE3,"Diabetes Mellitus, Type 2; Renal Insufficiency",Canagliflozin (DRUG); Placebo (DRUG),24997615,Invokana,"Diabetes Mellitus, Type 2; Renal Insufficiency",Kidney,Canagliflozin (hemihydrate),SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes.,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,1.1764705882352942,144.0 +15168,NCT04662723,Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.,RECRUITING,PHASE4,Glomerulonephritis; Immunoglobulin A Nephropathy,Corticosteroid (DRUG); Renin-angiotensin sytem blockers (DRUG); Sodium-glucose cotransporter 2 inhibitor (DRUG),24997615,Invokana,Glomerulonephritis,Kidney,Canagliflozin (hemihydrate),SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes.,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,1.1764705882352942,144.0 +15169,NCT06291155,Mechanism of SGLT2 Inhibition in the Kidney,RECRUITING,PHASE4,Type 2 Diabetes; Diabetic Kidney Disease,SGLT2 inhibitor (DRUG),24997615,Invokana,Type 2 Diabetes; Diabetic Kidney Disease,Kidney,Canagliflozin (hemihydrate),SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes.,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,1.1764705882352942,144.0 +15170,NCT06858436,SGLT2 Inhibitor Utilization Re-perfusion Therapy,NOT_YET_RECRUITING,PHASE4,Acute Ischemic Stroke From Large Vessel Occlusion,Canagliflozin 100mg (DRUG),24997615,Invokana,Acute Ischemic Stroke From Large Vessel Occlusion,CNS/Brain,Canagliflozin (hemihydrate),SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes.,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,1.1764705882352942,144.0 +15171,NCT04127084,Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes,UNKNOWN,PHASE4,Type 2 Diabetes; Diabetic Nephropathy,SGLT2 Inhibition (DRUG),24997615,Invokana,Type 2 Diabetes with Diabetic Nephropathy,Kidney,Canagliflozin (hemihydrate),SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes.,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,1.1764705882352942,144.0 +15172,NCT04419337,Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke,UNKNOWN,PHASE2,Diabetes Mellitus; Stroke,Metformin plus Pioglitazone plus an SGLT2 inhibitor (DRUG),24997615,Invokana,Diabetes Mellitus with Stroke,CNS/Brain,Canagliflozin (hemihydrate),SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes.,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,1.1764705882352942,144.0 +15173,NCT01186588,A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function,COMPLETED,PHASE1,Healthy; Hepatic Insufficiency,Canagliflozin (DRUG),24997615,Invokana,Healthy; Hepatic Insufficiency,Liver,Canagliflozin (hemihydrate),SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes.,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,1.1764705882352942,144.0 +15174,NCT03436693,Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy,COMPLETED,PHASE3,Diabetic Nephropathy,Canagliflozin (DRUG); Placebo (DRUG),24997615,Invokana,Diabetic Nephropathy,Kidney,Canagliflozin (hemihydrate),SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes.,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,1.1764705882352942,144.0 +15175,NCT06528405,The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease,RECRUITING,PHASE2,Acute Kidney Injury,dapagliflozin (DRUG); Other anti-diabetic drug or no anti-diabetic drug (OTHER); empagliflozin (DRUG); canagliflozin (DRUG),24997615,Invokana,Acute Kidney Injury,Kidney,Canagliflozin (hemihydrate),SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes.,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,1.1764705882352942,144.0 +15176,NCT06913647,Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis,NOT_YET_RECRUITING,PHASE2,ESRD; CKD (Chronic Kidney Disease) Stage 5D,Canagliflozin 300 MG (DRUG),24997615,Invokana,ESRD; CKD (Chronic Kidney Disease) Stage 5D,Kidney,Canagliflozin (hemihydrate),SLC5A2,inhibitor/antagonist,Glucose transporter inhibitor,yes,yes,Approved for type 2 diabetes.,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,1.1764705882352942,144.0 +15177,NCT03381274,Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study,ACTIVE_NOT_RECRUITING,PHASE1,"Carcinoma, Non-Small-Cell Lung",Oleclumab (BIOLOGICAL); Osimertinib (DRUG); AZD4635 (DRUG),78357807,Tagrisso,"Carcinoma, Non-Small-Cell Lung",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15178,NCT06918782,Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma,NOT_YET_RECRUITING,PHASE2,Lung Cancer (NSCLC),Osimertinib plus platinum doublet chemotherapy (DRUG),78357807,Tagrisso,Lung Cancer (NSCLC),Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15179,NCT06394674,"High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib",RECRUITING,PHASE2,Non-Small Cell Lung Cancer,Furmonertinib (DRUG),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15180,NCT02143466,AZD9291 in Combination With Ascending Doses of Novel Therapeutics,ACTIVE_NOT_RECRUITING,PHASE1,Advanced Non Small Cell Lung Cancer,Part A - AZD9291 in combination with AZD6094 (DRUG); Part A - AZD9291 in combination with continuous selumetinib (Asian subjects) (DRUG); Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects) (DRUG); Part A - AZD9291 in combination with intermittent selumetinib (DRUG); Part A - AZD9291 in combination with MEDI4736 (DRUG); Part B - AZD9291 in combination with AZD6094 (DRUG); Part B - AZD9291 in combination with selumetinib (DRUG); Part B - AZD9291 in combination with MEDI4736 (DRUG); Part C - AZD6094 monotherapy (Japan only) (DRUG); Part C - AZD9291 in combination with AZD6094 (Japan only) (DRUG); Part D - AZD9291 in combination with AZD6094 (DRUG),78357807,Tagrisso,Advanced Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15181,NCT05663866,Premedication to Reduce Amivantamab Associated Infusion Related Reactions,ACTIVE_NOT_RECRUITING,PHASE2,"Carcinoma, Non-Small-Cell Lung",Dexamethasone (DRUG); Montelukast (DRUG); Methotrexate (DRUG); Amivantamab (DRUG); Lazertinib (DRUG),78357807,Tagrisso,"Carcinoma, Non-Small-Cell Lung",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15182,NCT05546866,Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm,ACTIVE_NOT_RECRUITING,PHASE2,Non-small Cell Lung Cancer,Osimertinib (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15183,NCT05601973,"Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI",RECRUITING,PHASE2,Non Small Cell Lung Cancer,Amivantamab (DRUG); Lazertinib (DRUG); Zirabev (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15184,NCT02803203,Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers,COMPLETED,PHASE1,Non-small Cell Lung Cancer; EGFR-mutant Lung Cancers,osimertinib (DRUG); Bevacizumab (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer; EGFR-mutant Lung Cancers,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15185,NCT05256290,Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations,RECRUITING,PHASE1,Non-Small Cell Lung Cancer; Advanced Non-Small Cell Squamous Lung Cancer; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Cancer; NSCLC; Advanced Lung Carcinoma; Epidermal Growth Factor Receptor C797S; Epidermal Growth Factor Receptor G719X; EGF-R Positive Non-Small Cell Lung Cancer; EGFR-TKI Resistant Mutation,BDTX-1535 monotherapy (DRUG),78357807,Tagrisso,Non-Small Cell Lung Cancer; Advanced Non-Small Cell Squamous Lung Cancer; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Cancer; NSCLC; Advanced Lung Carcinoma; Epidermal Growth Factor Receptor C797S; Epidermal Growth Factor Receptor G719X; EGF-R Positive Non-Small Cell Lung Cancer; EGFR-TKI Resistant Mutation,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15186,NCT04322890,Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation,RECRUITING,PHASE2,Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROS1 Gene Mutation; MET Gene Mutation,"Osimertinib (DRUG); Alectinib 150 MG (DRUG); Crizotinib 250 MG (DRUG); Savolitinib, Crizotinib. (DRUG); Chemotherapy (DRUG)",78357807,Tagrisso,Non-Small Cell Lung Cancer with Gene Mutations,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15187,NCT06206850,Neo-Bio-ADAURA: a Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib,RECRUITING,PHASE2,Non-squamous NSCLC,Osimertinib (DRUG),78357807,Tagrisso,Non-Squamous Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15188,NCT02228369,"Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer",COMPLETED,PHASE1,EGFR Mutation Positive Advanced Non Small Cell Lung Cancer,AZD3759 (DRUG); AZD9291 (DRUG),78357807,Tagrisso,EGFR Mutation Positive Advanced Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15189,NCT03133546,Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER),COMPLETED,PHASE2,Non Small Cell Lung Cancer Metastatic,Osimertinib (DRUG); Bevacizumab (DRUG),78357807,Tagrisso,Stage IV Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15190,NCT03433469,Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery,ACTIVE_NOT_RECRUITING,PHASE2,Stage I Non-Small Cell Lung Cancer; Stage IA Non-Small Cell Lung Cancer; Stage IB Non-Small Cell Lung Cancer; Stage II Non-Small Cell Lung Cancer; Stage IIA Non-Small Cell Lung Cancer; Stage IIB Non-Small Cell Lung Cancer; Stage IIIA Non-Small Cell Lung Cancer,Osimertinib (DRUG); Therapeutic Conventional Surgery (PROCEDURE),78357807,Tagrisso,Stage I Non-Small Cell Lung Cancer; Stage IA Non-Small Cell Lung Cancer; Stage IB Non-Small Cell Lung Cancer; Stage II Non-Small Cell Lung Cancer; Stage IIA Non-Small Cell Lung Cancer; Stage IIB Non-Small Cell Lung Cancer; Stage IIIA Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15191,NCT05298176,"Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors",COMPLETED,PHASE2,Non-Small Cell Lung Cancer,"Afatinib, Osimertinib, Carboplatin and Pemetrexed (DRUG)",78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15192,NCT05394831,"A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC",RECRUITING,PHASE1,EGFR Mutant Advanced Non-small Cell Lung Cancer,JIN-A02 (DRUG),78357807,Tagrisso,EGFR Mutant Advanced Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15193,NCT06067776,"Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer",NOT_YET_RECRUITING,PHASE1,Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Cetuximab (BIOLOGICAL); Osimertinib (DRUG); Tucatinib (DRUG),78357807,Tagrisso,Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15194,NCT05805631,Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC,NOT_YET_RECRUITING,PHASE2,"Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor Receptor; Leptomeningeal Metastasis",Pemetrexed (DRUG),78357807,Tagrisso,"Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor Receptor; Leptomeningeal Metastasis",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15195,NCT06186076,"A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients",RECRUITING,PHASE1,"Carcinoma, Non-Small-Cell Lung; EGFR Mutant Advanced Non-Small Cell Lung Cancer",TRX-221 (DRUG),78357807,Tagrisso,"Carcinoma, Non-Small-Cell Lung; EGFR Mutant Advanced Non-Small Cell Lung Cancer",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15196,NCT03944772,Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD),ACTIVE_NOT_RECRUITING,PHASE2,Non-Small Cell Lung Cancer,Osimertinib (DRUG); Savolitinib (DRUG); Gefitinib (DRUG); Necitumumab (DRUG); Durvalumab (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG); Alectinib (DRUG); Selpercatinib (DRUG); Selumetinib (DRUG); Etoposide (DRUG); Cisplatin (DRUG); Datopotamab deruxtecan (DRUG),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15197,NCT03497767,A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases,COMPLETED,PHASE2,Metastatic Non Small Cell Lung Cancer,Osimertinib (DRUG); Stereotactic Radiosurgery (SRS) (RADIATION),78357807,Tagrisso,Metastatic Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15198,NCT05364073,"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations",ACTIVE_NOT_RECRUITING,PHASE1,"Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; HER2 Exon 20 Mutations; EGFR Exon 20 Mutations; EGFR Uncommon Mutations, Including G719X and S768I",Furmonertinib (DRUG); Furmonertinib (DRUG); Furmonertinib (DRUG); Furmonertinib (DRUG); Furmonertinib (DRUG),78357807,Tagrisso,"Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; HER2 Exon 20 Mutations; EGFR Exon 20 Mutations; EGFR Uncommon Mutations, Including G719X and S768I",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15199,NCT05489731,VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer,RECRUITING,PHASE1,Advanced Non-small Cell Lung Cancer,VIC-1911 (DRUG); Osimertinib Mesylate Tablets (DRUG),78357807,Tagrisso,Advanced Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15200,NCT02411448,A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY),ACTIVE_NOT_RECRUITING,PHASE3,Metastatic Non-Small Cell Lung Cancer,Ramucirumab (DRUG); Placebo (DRUG); Erlotinib (DRUG); Gefitinib (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Metastatic Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15201,NCT02296125,AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer,AZD9291 80 mg/40 mg + placebo (DRUG); Placebo Erlotinib 150/100mg (DRUG); Placebo Gefitinib 250 mg (DRUG); Erlotinib 150/100 mg (DRUG); Gefitinib 250 mg (DRUG); Placebo AZD9291 80 mg/ 40 mg (DRUG),78357807,Tagrisso,EGFR-Positive Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15202,NCT06194448,"To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations",RECRUITING,PHASE2,Lung Cancer,Osimertinib (DRUG); Cisplatin or Carboplatin; Pemetrexed or Paclitaxel (DRUG); Radiation (DRUG),78357807,Tagrisso,Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15203,NCT05458726,Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC,UNKNOWN,PHASE2,EGFR T790M; Osimertinib; Non-small Cell Lung Cancer; ddPCR,Osimertinib (DRUG),78357807,Tagrisso,EGFR T790M; Osimertinib; Non-small Cell Lung Cancer; ddPCR,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15204,NCT04517526,"Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study",UNKNOWN,PHASE2,Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT,pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT (DRUG),78357807,Tagrisso,Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15205,NCT03463525,Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases,COMPLETED,PHASE1,Non-small Cell Lung Cancer,Osimertinib (DRUG); [11C]osimertinib (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15206,NCT05017025,Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Advanced Lung Non-Squamous Non-Small Cell Carcinoma; Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Aurora A Kinase Inhibitor LY3295668 (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Advanced Lung Non-Squamous Non-Small Cell Carcinoma; Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15207,NCT03450330,"Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer",COMPLETED,PHASE1,Nonsmall Cell Lung Cancer,AZD4205 (DRUG),78357807,Tagrisso,Nonsmall Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15208,NCT06498986,A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,RECRUITING,PHASE2,Non-small Cell Lung Cancer,BL-B01D1 (DRUG); Osimertinib Mesylate Tablets (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15209,NCT06014827,Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma,RECRUITING,PHASE2,Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Osimertinib (DRUG); Positron Emission Tomography (PROCEDURE); Stereotactic Body Radiation Therapy (RADIATION); Survey Administration (OTHER),78357807,Tagrisso,Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15210,NCT06838273,A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer,RECRUITING,PHASE3,Non-small Cell Lung Cancer,BL-B01D1 (DRUG); Osimertinib (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15211,NCT02769286,Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA,COMPLETED,PHASE2,Lung Neoplasms; EGFR Gene Mutations,Osimertinib (DRUG),78357807,Tagrisso,Lung Neoplasms; EGFR Gene Mutations,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15212,NCT06109558,The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC,RECRUITING,PHASE1,Non Small Cell Lung Cancer; RET Gene Mutation; MET Amplification; EGF-R Positive Non-Small Cell Lung Cancer,LMV-12(HE003) (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer; RET Gene Mutation; MET Amplification; EGF-R Positive Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15213,NCT06557096,CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC,NOT_YET_RECRUITING,EARLY_PHASE1,Non Small Cell Lung Cancer; Circulating Tumor Cell; EGF-R Positive Non-Small Cell Lung Cancer,Osimertinib 80 MG (DRUG); Bevacizumab (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer; Circulating Tumor Cell; EGF-R Positive Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15214,NCT04487080,A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE3,"Carcinoma, Non-Small-Cell Lung",Amivantamab (DRUG); Osimertinib (DRUG); Lazertinib (DRUG); Placebo (DRUG),78357807,Tagrisso,"Carcinoma, Non-Small-Cell Lung",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15215,NCT03804580,First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Lung Cancer,osimertinib (DRUG),78357807,Tagrisso,Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15216,NCT03455829,"G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer",COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung; Lung Cancer; Non-small Cell Lung Cancer",G1T38 (DRUG); Osimertinib (DRUG),78357807,Tagrisso,"Carcinoma, Non-Small-Cell Lung; Lung Cancer; Non-small Cell Lung Cancer",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15217,NCT05801029,A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations,ACTIVE_NOT_RECRUITING,PHASE2,Non-Small Cell Lung Cancer (NSCLC),Osimertinib (DRUG); Amivantamab (DRUG),78357807,Tagrisso,Non-Small Cell Lung Cancer (NSCLC),Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15218,NCT05498389,EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer,UNKNOWN,PHASE1,Metastatic Lung Non-Small Cell Carcinoma; Advanced Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; EGFR Mutation-Related Tumors,EMB-01 (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Metastatic Lung Non-Small Cell Carcinoma; Advanced Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; EGFR Mutation-Related Tumors,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15219,NCT03858491,Pharmacokinetic Boosting of Osimertinib,COMPLETED,EARLY_PHASE1,Non Small Cell Lung Cancer,Cobicistat (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15220,NCT05284994,TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer,UNKNOWN,PHASE1,Nonsmall-cell Lung Cancer,"TQ-B3525 Tablets, Osimertinib Mesylate Tablets (DRUG)",78357807,Tagrisso,Nonsmall-cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15221,NCT05120960,"A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors",WITHDRAWN,PHASE1,Brain Tumor,tepotinib (DRUG); tepotinib plus osimertinib (DRUG),78357807,Tagrisso,Brain Tumor,CNS/Brain,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15222,NCT04181060,Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer,RECRUITING,PHASE3,Advanced Lung Non-Squamous Non-Small Cell Carcinoma; Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8,Bevacizumab (BIOLOGICAL); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Osimertinib (DRUG),78357807,Tagrisso,Advanced Lung Non-Squamous Non-Small Cell Carcinoma; Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15223,NCT03799094,Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations,UNKNOWN,PHASE1,"Carcinoma, Non-Small-Cell Lung",Vitamin C (DRUG); Tyrosine kinase inhibitor (DRUG),78357807,Tagrisso,"Carcinoma, Non-Small-Cell Lung",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15224,NCT04862780,(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC,TERMINATED,PHASE1,"Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Neoplasms; Neoplasms by Site; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Nerve Tissue; EGFR T790M; EGFR C797S; EGFR L858R; EGFR Gene Mutation; EGF-R Positive Non-Small Cell Lung Cancer; EGFR Exon 19 Deletion; EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance; EGFR Activating Mutation; Protein Kinase Inhibitors; Antineoplastic Agents; Thoracic Neoplasms",BLU-945 (DRUG); osimertinib (DRUG),78357807,Tagrisso,"Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Neoplasms; Neoplasms by Site; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Nerve Tissue; EGFR T790M; EGFR C797S; EGFR L858R; EGFR Gene Mutation; EGF-R Positive Non-Small Cell Lung Cancer; EGFR Exon 19 Deletion; EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance; EGFR Activating Mutation; Protein Kinase Inhibitors; Antineoplastic Agents; Thoracic Neoplasms",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15225,NCT03535363,Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC,COMPLETED,PHASE1,NSCLC; Non-small Cell Lung Cancer,Osimertinib (DRUG),78357807,Tagrisso,NSCLC; Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15226,NCT05089916,Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study,RECRUITING,PHASE2,NSCLC; EGFR Positive Non-small Cell Lung Cancer; Oligoprogression,Osimertinib (DRUG); Radiotherapy (RADIATION),78357807,Tagrisso,NSCLC; EGFR Positive Non-small Cell Lung Cancer; Oligoprogression,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15227,NCT03257124,Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS,UNKNOWN,PHASE2,Non-Small Cell Lung Cancer With EGFR T790M Mutation; With Brain and/or Leptomeningeal Metastasis; Failed Tyrosine Kinase Inhibitors,AZD9291 (DRUG),78357807,Tagrisso,Non-Small Cell Lung Cancer With EGFR T790M Mutation; With Brain and/or Leptomeningeal Metastasis; Failed Tyrosine Kinase Inhibitors,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15228,NCT05166616,Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer,RECRUITING,PHASE1,Advanced Lung Non-Small Cell Carcinoma; Locally Advanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Unresectable Lung Non-Small Cell Carcinoma,Biopsy (PROCEDURE); Osimertinib (DRUG); Triptolide Analog (DRUG),78357807,Tagrisso,Advanced Lung Non-Small Cell Carcinoma; Locally Advanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Unresectable Lung Non-Small Cell Carcinoma,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15229,NCT06670196,"A Study of SKB264 in Combination with Osimertinib Versus Osimertinib in Patients with Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer",RECRUITING,PHASE3,Non-Small Cell Lung Cancer,SKB264 (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15230,NCT04410796,Osimertinib Alone or with Chemotherapy for EGFR-Mutant Lung Cancers,RECRUITING,PHASE2,Metastatic Non-small Cell Lung Cancer,Osimertinib (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG),78357807,Tagrisso,Metastatic Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15231,NCT02317016,"Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer",COMPLETED,PHASE1,Non Small Cell Lung Cancer,Pharmacokinetic sampling - AZD9291 (PROCEDURE); AZD9291 tablet dosing (DRUG); Rosuvastatin (DRUG); Pharmacokinetic sampling - rosuvastatin (PROCEDURE); Pharmacokinetic sampling - AZ5140 and AZ7550 (PROCEDURE),78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15232,NCT05647122,First in Human Study of AZD9592 in Solid Tumors,RECRUITING,PHASE1,Advanced Solid Tumours; Carcinoma Non-small Cell Lung; Head and Neck Neoplasms; Colorectal Neoplasms,AZD9592 (DRUG); Osimertinib (DRUG); 5-Fluorouracil (5-FU) (DRUG); Leucovorin (DRUG); Bevacizumab (DRUG),78357807,Tagrisso,Advanced Solid Tumours; Carcinoma Non-small Cell Lung; Head and Neck Neoplasms; Colorectal Neoplasms,Bowel,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15233,NCT02759835,"Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib",COMPLETED,PHASE2,Lung Adenocarcinoma; Lung Neoplasms,osimertinib (DRUG); Local Ablative Therapy (LAT) (OTHER),78357807,Tagrisso,Lung Neoplasms,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15234,NCT04959981,A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC,COMPLETED,PHASE1,Advanced Non-squamous Non-small-cell Lung Cancer,ERAS-007 (DRUG); ERAS-601 (DRUG); Osimertinib (DRUG); Sotorasib (DRUG),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15235,NCT03239340,A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib,COMPLETED,PHASE2,EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Osimertinib (DRUG),78357807,Tagrisso,EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15236,NCT04141644,Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC,ACTIVE_NOT_RECRUITING,PHASE1,Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder),Ipilimumab (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder),Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15237,NCT02504346,"AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies",UNKNOWN,PHASE2,Lung Cancer; Targeted Therapy,AZD9291 (DRUG),78357807,Tagrisso,Lung Cancer; Targeted Therapy,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15238,NCT02997501,T790M Plasma Testing Methodology Comparison and Clinical Validation,COMPLETED,PHASE3,Lung Cancer,T790M+ Testing (PROCEDURE); Baseline Visit Blood & Urine Testing (PROCEDURE); Baseline ECG (PROCEDURE); Visual Slit-Lamp Testing (PROCEDURE); AZD9291 Dosing (DRUG); Plasma AZD9291 testing (PROCEDURE),78357807,Tagrisso,Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15239,NCT02971501,Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases,ACTIVE_NOT_RECRUITING,PHASE2,Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Neoplasm in the Brain; Stage IV Lung Cancer AJCC v8,Bevacizumab (BIOLOGICAL); Biopsy Procedure (PROCEDURE); Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Osimertinib (DRUG),78357807,Tagrisso,Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Neoplasm in the Brain; Stage IV Lung Cancer AJCC v8,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15240,NCT04413201,AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC,ACTIVE_NOT_RECRUITING,PHASE4,Non-squamous NSCLC,Afatinib (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Non-Squamous Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15241,NCT06436144,Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC,NOT_YET_RECRUITING,PHASE2,Non Small Cell Lung Cancer; EGFR Gene Mutation; Non Small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer Stage IV,Osimertinib (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer; EGFR Gene Mutation; Non Small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer Stage IV,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15242,NCT06631989,A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients with EGFRm+ Advanced Non-small Cell Lung Cancer,RECRUITING,PHASE1,EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer,WSD0922-FU (DRUG),78357807,Tagrisso,EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15243,NCT04335292,Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge,RECRUITING,PHASE2,Non-Small Cell Lung Cancer,Osimertinib First-Line (DRUG); Platinum + Pemetrexed Chemotherapy Second-Line (DRUG); Osimertinib Third-Line (DRUG),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15244,NCT05624996,"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer",RECRUITING,PHASE3,Locally Advanced Lung Non-Small Cell Carcinoma; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8,Carboplatin (DRUG); Cisplatin (DRUG); Computed Tomography (PROCEDURE); Durvalumab (BIOLOGICAL); Etoposide (DRUG); Image Guided Radiation Therapy (RADIATION); Nab-paclitaxel (DRUG); Paclitaxel (DRUG); Pemetrexed (DRUG); Positron Emission Tomography (PROCEDURE); Questionnaire Administration (OTHER); Stereotactic Body Radiation Therapy (RADIATION),78357807,Tagrisso,Locally Advanced Lung Non-Small Cell Carcinoma; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15245,NCT05528458,Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma,RECRUITING,PHASE2,Lung Adenocarcinoma,Osimertinib 80Mg Tab (DRUG),78357807,Tagrisso,Lung Adenocarcinoma,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15246,NCT05388669,A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Advanced or Metastatic Non-small Cell Lung Cancer,Lazertinib (DRUG); Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF) (DRUG); Amivantamab Intravenous (DRUG),78357807,Tagrisso,Advanced or Metastatic Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15247,NCT03392246,A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,Non-small Cell Lung Cancer,Osimertinib (DRUG); Selumetinib (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15248,NCT05020769,SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.,RECRUITING,PHASE2,Non-small Cell Lung Cancer,SI-B001 (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15249,NCT06525246,Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Stage IIIB Non-small Cell Lung Cancer; Stage IIIC Non-Small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer; Recurrent Non-Small Cell Lung Cancer; EGFR Mutation-Related Tumors,ONO-7475 (DRUG); Osimertinib Mesylate (DRUG),78357807,Tagrisso,Stage IIIB Non-small Cell Lung Cancer; Stage IIIC Non-Small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer; Recurrent Non-Small Cell Lung Cancer; EGFR Mutation-Related Tumors,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15250,NCT04780568,Osimertinib and Tegavivint As First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer,RECRUITING,PHASE1,Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC V8; Stage IVA Lung Cancer AJCC V8; Stage IVB Lung Cancer AJCC V8,Osimertinib (DRUG); Tegavivint (DRUG),78357807,Tagrisso,Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC V8; Stage IVA Lung Cancer AJCC V8; Stage IVB Lung Cancer AJCC V8,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15251,NCT05642572,Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial),RECRUITING,PHASE2,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Capmatinib (DRUG); Computed Tomography (PROCEDURE); Magnetic Resonance Imaging (PROCEDURE); Osimertinib (DRUG); Ramucirumab (BIOLOGICAL),78357807,Tagrisso,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15252,NCT05195619,Personalized DC Vaccines in Non Small Cell Lung Cancer,RECRUITING,PHASE1,Non-small Cell Lung Cancer,Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine) (BIOLOGICAL); Low dose cyclophosphamide (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15253,NCT06363734,"Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial",RECRUITING,PHASE2,Non-small Cell Lung Cancer; EGFR Activating Mutation; Cell Cycle Deregulation; EGFR-TKI Resistant Mutation,Osimertinib plus Dalpiciclib (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer; EGFR Activating Mutation; Cell Cycle Deregulation; EGFR-TKI Resistant Mutation,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15254,NCT06142617,A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.,NOT_YET_RECRUITING,PHASE2,Non Small Cell Lung Cancer; Immune Checkpoint Inhibitor; EGFR Exon 21 Mutation,"Pembrolizumab, pemetrexed, platinum (DRUG); Osimertinib (DRUG)",78357807,Tagrisso,Non Small Cell Lung Cancer; Immune Checkpoint Inhibitor; EGFR Exon 21 Mutation,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15255,NCT03909334,Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),ACTIVE_NOT_RECRUITING,PHASE2,Non Small Cell Lung Cancer; EGFR Gene Mutation; Advanced Cancer; Metastatic Cancer,Osimertinib (DRUG); Ramucirumab (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer; EGFR Gene Mutation; Advanced Cancer; Metastatic Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15256,NCT05338619,"A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy",RECRUITING,PHASE2,Non-small Cell Lung Cancer Stage III; EGFR Positive Non-small Cell Lung Cancer; Non-squamous Non-small-cell Lung Cancer,Lazertinib (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer Stage III; EGFR Positive Non-small Cell Lung Cancer; Non-squamous Non-small-cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15257,NCT06530719,A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery,NOT_YET_RECRUITING,PHASE2,"Lung Neoplasms; Lung Cancer, Nonsmall Cell",Osimertinib mesylate (DRUG),78357807,Tagrisso,"Lung Neoplasms; Lung Cancer, Nonsmall Cell",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15258,NCT05948813,TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases,RECRUITING,PHASE2,NSCLC; EGFR Activating Mutation; Brain Metastases,TY-9591 (DRUG); Osimertinib (DRUG),78357807,Tagrisso,NSCLC; EGFR Activating Mutation; Brain Metastases,CNS/Brain,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15259,NCT04356118,Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis,UNKNOWN,PHASE4,Leptomeningeal Metastasis,Recombinant Human Endostatin (DRUG); intrathcal methotrexate (DRUG); Targeted drugs for non-small cell lung cancer (DRUG),78357807,Tagrisso,Leptomeningeal Metastasis,CNS/Brain,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15260,NCT04099836,Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib,TERMINATED,PHASE2,Non Small Cell Lung Cancer,Atezolizumab (DRUG); Bevacizumab (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15261,NCT05009836,Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC,UNKNOWN,PHASE3,Non-small Cell Lung Cancer,Savolitinib (DRUG); Placebo (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15262,NCT02771314,Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,AZD9291 (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15263,NCT02954523,Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations,TERMINATED,PHASE1,EGFR Gene Mutation; Nonsmall Cell Lung Cancer,Dasatinib (DRUG); Osimertinib (DRUG),78357807,Tagrisso,EGFR Gene Mutation; Nonsmall Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15264,NCT05401110,"Study of Osimertinib with Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer",RECRUITING,PHASE1,Non Small Cell Lung Cancer; Lung Cancer,Osimertinib (DRUG); Carotuximab (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer; Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15265,NCT04545710,Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance,ACTIVE_NOT_RECRUITING,PHASE2,Lung Cancer,Abemaciclib (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15266,NCT05104281,Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer,UNKNOWN,PHASE3,"Carcinoma, Non-Small-Cell Lung",osimertinib oral and bevazizumab intravenously (DRUG),78357807,Tagrisso,"Carcinoma, Non-Small-Cell Lung",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15267,NCT04425681,Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer,UNKNOWN,PHASE2,Leptomeningeal Metastasis; Non-small Cell Lung Cancer; EGFR Activating Mutation,Osimertinib (DRUG); Bevacizumab (DRUG),78357807,Tagrisso,Leptomeningeal Metastasis; Non-small Cell Lung Cancer; EGFR Activating Mutation,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15268,NCT06477055,The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer,NOT_YET_RECRUITING,PHASE2,Non-small Cell Lung Cancer,Osimertinib (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15269,NCT05785208,Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.,RECRUITING,PHASE4,Non Small Cell Lung Cancer,Osimertinib (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15270,NCT06417814,A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer,RECRUITING,PHASE3,Metastatic Non-small Cell Lung Cancer,Dato-DXd (DRUG); Osimertinib (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG); Cisplatin (DRUG),78357807,Tagrisso,Metastatic Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15271,NCT04351555,A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE3,Non-Small Cell Lung Cancer,Osimertinib (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Placebo (DRUG); Pemetrexed (DRUG),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15272,NCT04816214,Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy,TERMINATED,PHASE3,"Carcinoma, Non-Small-Cell Lung",Capmatinib (DRUG); Osimertinib (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG); Carboplatin (DRUG),78357807,Tagrisso,"Carcinoma, Non-Small-Cell Lung",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15273,NCT05526755,A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC),ACTIVE_NOT_RECRUITING,PHASE2,Stage II-IIIB Non-small Cell Lung Carcinoma,Osimertinib 80 mg/40 mg (DRUG),78357807,Tagrisso,Stage II-IIIB Non-small Cell Lung Carcinoma,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15274,NCT05034055,Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,atezolizumab / tiragolumab (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15275,NCT06319950,High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases,NOT_YET_RECRUITING,PHASE2,"Lung Cancer, Nonsmall Cell",Furmonertinib (DRUG); Osimertinib (DRUG),78357807,Tagrisso,"Lung Cancer, Nonsmall Cell",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15276,NCT06818955,Orlistat Overcoming Third-generation EGFR-TKI Resistance,NOT_YET_RECRUITING,PHASE2,Lung Adenocarcinoma; Osimertinib,Orlistat 120 mg (DRUG),78357807,Tagrisso,Lung Adenocarcinoma; Osimertinib,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15277,NCT02474355,Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC,COMPLETED,PHASE3,Lung Cancer,T790M+ Testing (PROCEDURE); Baseline Visit Blood & Urine Testing (PROCEDURE); Baseline ECG (PROCEDURE); Visual Slit-Lamp Testing (PROCEDURE); AZD9291 Dosing (DRUG),78357807,Tagrisso,Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15278,NCT03769103,Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC,ACTIVE_NOT_RECRUITING,PHASE2,Lung Cancer Non-small Cell Stage IV; Brain Metastases,Osimertinib (DRUG); Stereotactic radiotherapy (RADIATION),78357807,Tagrisso,Lung Cancer Non-small Cell Stage IV; Brain Metastases,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15279,NCT03410043,"Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study",ACTIVE_NOT_RECRUITING,PHASE2,Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Osimertinib (DRUG); Radiation Therapy (RADIATION); Therapeutic Conventional Surgery (PROCEDURE),78357807,Tagrisso,Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15280,NCT02529995,"Phase I, Study in Chinese NSCLC Patients",COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive",AZD9291 40 mg (DRUG); AZD9291 80 mg (DRUG),78357807,Tagrisso,"Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15281,NCT04988295,A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure,ACTIVE_NOT_RECRUITING,PHASE3,"Carcinoma, Non-Small-Cell Lung",Lazertinib (DRUG); Amivantamab (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),78357807,Tagrisso,"Carcinoma, Non-Small-Cell Lung",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15282,NCT04029350,Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,Anlotinib Combined With Osimertinib (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15283,NCT02908750,Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC,COMPLETED,PHASE1,Non Small Cell Lung Cancer,Fexofenadine tablet dosing (DRUG); Osimertininb tablet dosing (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15284,NCT05163249,"Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC",ACTIVE_NOT_RECRUITING,PHASE2,"Carcinoma, Non-Small-Cell Lung",Osimertinib (DRUG); Savolitinib (DRUG),78357807,Tagrisso,"Carcinoma, Non-Small-Cell Lung",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15285,NCT05507606,Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,Osimertinib (DRUG); Bevacizumab Biosimilar IBI305 (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15286,NCT02442349,Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific,ACTIVE_NOT_RECRUITING,PHASE2,Non-Small Cell Lung Cancer,AZD9291 (DRUG),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15287,NCT05261399,Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment,RECRUITING,PHASE3,Carcinoma; Non-Small-Cell Lung,Savolitinib (DRUG); Osimertinib (DRUG); Pemetrexed (DRUG); Cisplatin (DRUG); Carboplatin (DRUG),78357807,Tagrisso,Carcinoma; Non-Small-Cell Lung,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15288,NCT05120349,A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection,ACTIVE_NOT_RECRUITING,PHASE3,Non-Small Cell Lung Cancer,Osimertinib (DRUG); Placebo (DRUG),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15289,NCT03784599,T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC,TERMINATED,PHASE2,"Carcinoma, Non-Small-Cell Lung",Trastuzumab emtansine (DRUG); Osimertinib (DRUG),78357807,Tagrisso,"Carcinoma, Non-Small-Cell Lung",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15290,NCT04665206,Study to Evaluate VT3989 in Patients with Metastatic Solid Tumors,RECRUITING,PHASE1,"Solid Tumor, Adult; Mesothelioma; NSCLC",VT3989 (DRUG); Nivolumab & Ipilimumab (DRUG); Osimertinib (DRUG),78357807,Tagrisso,"Solid Tumor, Adult; Mesothelioma; NSCLC",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15291,NCT02511106,"AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.",ACTIVE_NOT_RECRUITING,PHASE3,Stage IB-IIIA Non-small Cell Lung Carcinoma,AZD9291 80 mg/40 mg (DRUG); Placebo AZD9291 80 mg/40 mg (DRUG); Open-label AZD9291 80 mg/40 mg (DRUG),78357807,Tagrisso,Stage IB-IIIA Non-small Cell Lung Carcinoma,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15292,NCT05880706,A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,RECRUITING,PHASE2,Non-small Cell Lung Cancer,BL-B01D1 (DRUG); Osimertinib Mesylate Tablets (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15293,NCT06486142,EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study,RECRUITING,PHASE3,Non-Small Cell Lung Cancer,Afatinib/Dacomitinib (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15294,NCT04479306,Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Recurrent Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Alisertib (DRUG); Osimertinib (DRUG); Sapanisertib (DRUG),78357807,Tagrisso,Recurrent Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15295,NCT04762199,MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer,RECRUITING,PHASE1,Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Flt3/MerTK Inhibitor MRX-2843 (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15296,NCT06106802,Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment,NOT_YET_RECRUITING,PHASE2,Non-Small Cell Lung Cancer Metastatic,Lazertinib (DRUG); Tepotinib (DRUG),78357807,Tagrisso,Non-Small Cell Lung Cancer Metastatic,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15297,NCT04438902,Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment,TERMINATED,PHASE2,Non Small Cell Lung Cancer,osimertinib mesylate tablets and anlotinib hydrochloride capsules (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15298,NCT04591002,Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive),WITHDRAWN,PHASE2,Lung Cancer,Osimertinib 80 MG (DRUG),78357807,Tagrisso,Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15299,NCT04184921,Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients,COMPLETED,PHASE2,Lung Cancer Non-small Cell Stage IV,Aspirin 100mg (DRUG); Osimertinib 80 MG (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer Stage IV,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15300,NCT04233021,Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation,COMPLETED,PHASE2,Non Small Cell Lung Cancer Metastatic; Leptomeningeal Metastasis; Brain Metastases; EGFR Activating Mutation,Osimertinib (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer Metastatic; Leptomeningeal Metastasis; Brain Metastases; EGFR Activating Mutation,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15301,NCT03755102,A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.,COMPLETED,EARLY_PHASE1,EGFR Gene Mutation; Lung Cancer; Lung Cancer Metastatic,Dacomitinib (DRUG); Osimertinib (DRUG),78357807,Tagrisso,EGFR Gene Mutation; Lung Cancer; Lung Cancer Metastatic,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15302,NCT04974879,Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer,UNKNOWN,PHASE2,"Carcinoma, Non-Small-Cell Lung",Osimertinib Oral Tablet (DRUG),78357807,Tagrisso,"Carcinoma, Non-Small-Cell Lung",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15303,NCT06093503,Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein,WITHDRAWN,PHASE3,Non-Small Cell Lung Cancer,Telisotuzumab Vedotin (DRUG); Osimertinib (DRUG); Cisplatin (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15304,NCT03940703,A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2),ACTIVE_NOT_RECRUITING,PHASE2,Non-small Cell Lung Cancer,Tepotinib (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15305,NCT02841579,Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M,COMPLETED,PHASE2,Non-Small Cell Lung Cancer,Osimertinib (DRUG),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15306,NCT04448379,Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer,UNKNOWN,PHASE1,Locally Advanced or Metastatic Non-Small Cell Lung Cancer,JMT101 (DRUG),78357807,Tagrisso,Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15307,NCT05015608,Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification,UNKNOWN,PHASE3,Non-small Cell Lung Cancer,Savolitinib + Osimertinib (DRUG); Pemetrexed + Cisplatin /Carboplatin (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15308,NCT05153408,(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC,TERMINATED,PHASE1,"Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Neoplasms; Neoplasms by Site; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Nerve Tissue; EGFR C797S; EGFR C797A; EGFR L858R; EGFR Exon 19 Deletion; EGFR Gene Mutation; EGF-R Positive Non-Small Cell Lung Cancer; EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance; EGFR Activating Mutation; Thoracic Neoplasms; Antineoplastic Agents; Protein Kinase Inhibitors; EGFR C797G; EGFR C797X; Non Small Cell Lung Cancer",BLU-701 (DRUG); osimertinib (DRUG); carboplatin (DRUG); pemetrexed (DRUG),78357807,Tagrisso,"Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Neoplasms; Neoplasms by Site; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Nerve Tissue; EGFR C797S; EGFR C797A; EGFR L858R; EGFR Exon 19 Deletion; EGFR Gene Mutation; EGF-R Positive Non-Small Cell Lung Cancer; EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance; EGFR Activating Mutation; Thoracic Neoplasms; Antineoplastic Agents; Protein Kinase Inhibitors; EGFR C797G; EGFR C797X; Non Small Cell Lung Cancer",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15309,NCT06752408,Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer,NOT_YET_RECRUITING,PHASE2,Non Small Cell Lung Cancer,Aumolertinib (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15310,NCT06323148,Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022),NOT_YET_RECRUITING,PHASE3,Lung Cancer; EGFR Gene Mutation; Minimal Residual Disease,Osimertinib (DRUG); No adjuvant therapy (DRUG),78357807,Tagrisso,Lung Cancer; EGFR Gene Mutation; Minimal Residual Disease,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15311,NCT06829459,A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs,RECRUITING,PHASE3,Non-Small Cell Lung Cancer,Glumetinib (DRUG); Osimertinib mesylate (DRUG); Pemetrexed (DRUG); Cisplatin or carboplatin (DRUG),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15312,NCT04401059,Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study,RECRUITING,PHASE4,Carcinoma; Non-Small-Cell Lung Cancer; Adenocarcinoma,Elemene plus first or third generation EGFR-TKIs (DRUG); First or third generation EGFR-TKIs (DRUG),78357807,Tagrisso,Carcinoma; Non-Small-Cell Lung Cancer; Adenocarcinoma,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15313,NCT03460275,Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer,UNKNOWN,PHASE2,Non-small Cell Lung Cancer,Osimertinib Mesylate Tablets (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15314,NCT02664935,National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,"Non-Small Cell Lung Cancer; Carcinoma, Squamous Cell; Adenocarcinoma",AZD4547 (DRUG); Vistusertib (DRUG); Palbociclib (DRUG); Crizotinib (DRUG); Selumetinib (DRUG); Docetaxel (DRUG); AZD5363 (DRUG); Osimertinib (DRUG); Durvalumab (DRUG); Sitravatinib (DRUG); AZD6738 (DRUG),78357807,Tagrisso,"Non-Small Cell Lung Cancer; Carcinoma, Squamous Cell; Adenocarcinoma",Skin,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15315,NCT04035486,A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2),ACTIVE_NOT_RECRUITING,PHASE3,Non-Small Cell Lung Cancer,Osimertinib (DRUG); Pemetrexed/Carboplatin (DRUG); Pemetrexed/Cisplatin (DRUG),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15316,NCT04077463,A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,"Carcinoma, Non-Small-Cell Lung",Lazertinib (DRUG); Amivantamab (DRUG); Carboplatin (DRUG); Pemetrexed (DRUG),78357807,Tagrisso,"Carcinoma, Non-Small-Cell Lung",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15317,NCT02496663,Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Echocardiography Test (PROCEDURE); Magnetic Resonance Elastography (PROCEDURE); Multigated Acquisition Scan (PROCEDURE); Necitumumab (BIOLOGICAL); Osimertinib (DRUG),78357807,Tagrisso,Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15318,NCT03122717,Osimertinib and Gefitinib in EGFR Inhibitor Naïve Advanced EGFR Mutant Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Non-Small Cell Lung Cancer,Gefitinib (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15319,NCT03446417,A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer,COMPLETED,PHASE1,"Carcinoma, Non-Small-Cell Lung",ZN-e4 (DRUG),78357807,Tagrisso,"Carcinoma, Non-Small-Cell Lung",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15320,NCT02197234,Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC,COMPLETED,PHASE1,Non Small Cell Lung Cancer,Pharmacokinetic sampling - AZD9291 (PROCEDURE); Simvastatin (DRUG); AZD9291 tablet dosing (DRUG); Pharmacokinetic sampling - simvastatin (PROCEDURE); Pharmacokinetic sampling - AZ5140 and AZ7550 (PROCEDURE),78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15321,NCT02424617,A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Non-Small Cell Lung Cancer,Erlotinib (DRUG); Bemcentinib (DRUG); Bemcentinib (DRUG); Bemcentinib (DRUG),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15322,NCT02736513,Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases,UNKNOWN,PHASE2,Lung Cancer,AZD9291 (DRUG),78357807,Tagrisso,Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15323,NCT03434418,A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations,COMPLETED,PHASE2,Non Small Cell Lung Cancer,osimertinib (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15324,NCT06071013,Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients,RECRUITING,PHASE1,Non-small Cell Lung Cancer; EGFR Gene Mutation; EGFR-TKI Resistant Mutation,"Nintedanib, gefitinib, erlotinib, afatinib, osimertinib (DRUG)",78357807,Tagrisso,Non-small Cell Lung Cancer; EGFR Gene Mutation; EGFR-TKI Resistant Mutation,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15325,NCT04765059,A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC),ACTIVE_NOT_RECRUITING,PHASE3,Non-small Cell Lung Cancer,Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin (DRUG); Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15326,NCT03424759,Uncommon EGFR AZD9291,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,AZD9291 (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15327,NCT06185400,RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations,NOT_YET_RECRUITING,PHASE2,Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors; ERBB2 Gene Duplication; Disitamab Vedotin,Disitamab Vedotin (DRUG); third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) (DRUG); pyrotinib (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors; ERBB2 Gene Duplication; Disitamab Vedotin,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15328,NCT03567642,"A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers",ACTIVE_NOT_RECRUITING,PHASE1,Lung Cancer,Osimertinib (DRUG); Platinum (DRUG); Etoposide (DRUG),78357807,Tagrisso,Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15329,NCT02824952,Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC,UNKNOWN,PHASE2,"Lung Cancer, Non-small Cell",Tagrisso (DRUG),78357807,Tagrisso,"Lung Cancer, Non-small Cell",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15330,NCT03732352,18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma,COMPLETED,PHASE2,EGFR Gene Amplification; EGFR Gene Mutation; Glioblastoma; Recurrent Glioblastoma; Supratentorial Glioblastoma; TP53 Wt Allele,Fludeoxyglucose F-18 (OTHER); Osimertinib (DRUG); Positron Emission Tomography (PROCEDURE),78357807,Tagrisso,EGFR Gene Amplification; EGFR Gene Mutation; Glioblastoma; Recurrent Glioblastoma; Supratentorial Glioblastoma; TP53 Wt Allele,CNS/Brain,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15331,NCT04085315,Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer,RECRUITING,PHASE1,Lung Cancer Metastatic; EGFR Gene Mutation,Osimertinib (DRUG); Alisertib (DRUG),78357807,Tagrisso,Lung Cancer Metastatic; EGFR Gene Mutation,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15332,NCT05011487,Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC,RECRUITING,PHASE2,Non-Small Cell Lung Cancer,Osimertinib (DRUG); Cisplatin (DRUG); Pemetrexed (DRUG),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15333,NCT06618287,"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors",RECRUITING,PHASE1,Lung Cancer,BMS-986507 (DRUG); Osimertinib (DRUG); Pembrolizumab (DRUG),78357807,Tagrisso,Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15334,NCT06306456,A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC,RECRUITING,PHASE1,Non-Small Cell Lung Cancer With EGFR Mutation,GH21 (DRUG); Tagrisso (DRUG),78357807,Tagrisso,Non-Small Cell Lung Cancer With EGFR Mutation,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15335,NCT01802632,AZD9291 First Time In Patients Ascending Dose Study,COMPLETED,PHASE1,Advanced Non Small Cell Lung Cancer; Advanced (Inoperable) Non Small Cell Lung Cancer,AZD9291 (DRUG),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15336,NCT05816252,A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003),RECRUITING,PHASE2,Non-small Cell Lung Cancer,SKB264 (DRUG); Pembrolizumab (DRUG); Carboplatin (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15337,NCT06741085,A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain,RECRUITING,PHASE2,Non Small Cell Lung Cancer Metastatic,osimertinib (DRUG); stereotactic radiosurgery (SRS) (RADIATION),78357807,Tagrisso,Stage IV Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15338,NCT03891615,Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer,UNKNOWN,PHASE1,Lung Cancer,Niraparib (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15339,NCT03515837,Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789),COMPLETED,PHASE3,Non-small Cell Lung Cancer,pembrolizumab (BIOLOGICAL); pemetrexed (DRUG); carboplatin (DRUG); cisplatin (DRUG); saline solution (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15340,NCT04721015,Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,Advanced Solid Tumors Cancer; Non Small Cell Lung Cancer (NSCLC),ABBV-637 (DRUG); Docetaxel (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Advanced Solid Tumors Cancer; Non Small Cell Lung Cancer (NSCLC),Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15341,NCT03831932,Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Biospecimen Collection (PROCEDURE); Computed Tomography (PROCEDURE); Magnetic Resonance Elastography (PROCEDURE); Osimertinib (DRUG); Positron Emission Tomography (PROCEDURE); Telaglenastat Hydrochloride (DRUG); X-Ray Imaging (PROCEDURE),78357807,Tagrisso,Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15342,NCT05477615,Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases,NOT_YET_RECRUITING,PHASE2,Non-small Cell Lung Cancer,Lazertinib (DRUG); Pemetrexed (DRUG); Carboplatin (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15343,NCT02163733,Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer,COMPLETED,PHASE1,Advanced Non Small Cell Lung Cancer; Advanced (Inoperable) Non Small Cell Lung Cancer,AZD9291 tablets (DRUG); Pharmacokinetic sampling - AZD9291 (PROCEDURE); Dietary Fasted (OTHER); Dietary High Fat (OTHER); Pharmacokinetic sampling - AZ5140 and AZ7550 (PROCEDURE),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15344,NCT05215951,Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC,TERMINATED,PHASE2,Lung Cancer,osimertinib (DRUG),78357807,Tagrisso,Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15345,NCT02811354,Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA,UNKNOWN,PHASE2,"Carcinoma, Non-Small-Cell Lung",AZD9291 (DRUG),78357807,Tagrisso,"Carcinoma, Non-Small-Cell Lung",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15346,NCT04676477,HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Non-Small Cell Lung Cancer (NSCLC),HER3-DXd (DRUG); HER3-DXd (DRUG); Osimertinib (DRUG); Osimertinib (DRUG); HER3-DXd (DRUG); HER3-DXd (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Non-Small Cell Lung Cancer (NSCLC),Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15347,NCT06827145,Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC,ACTIVE_NOT_RECRUITING,PHASE2,Non-Small-Cell Lung Cancer,Vebreltinib (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Non-Small-Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15348,NCT04868877,"Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination",RECRUITING,PHASE1,Non-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma; Colorectal Cancer,MCLA-129 (DRUG); Osimertinib (DRUG); Chemotherapy (DRUG),78357807,Tagrisso,Non-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma; Colorectal Cancer,Bowel,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15349,NCT03521154,A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA),ACTIVE_NOT_RECRUITING,PHASE3,Non Small Cell Lung Cancer (Stage III),Osimertinib 80mg/40mg (DRUG); Placebo Osimertinib 80mg/40mg (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer (Stage III),Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15350,NCT06452433,Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.,NOT_YET_RECRUITING,PHASE2,Non-small Cell Lung Cancer,"gumarontinib (DRUG); third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib) (DRUG)",78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15351,NCT05085054,Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT),UNKNOWN,PHASE2,Non Small Cell Lung Cancer,Osimertinib Mesylate (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15352,NCT03758677,Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,Apatinib (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15353,NCT05132777,Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer,UNKNOWN,PHASE2,Locally Advanced or Metastatic Non-Small Cell Lung Cancer; EGFR Exon20 Insertion Mutations,JMT101 (DRUG); Osimertinib Mesylate Tablets (DRUG),78357807,Tagrisso,Locally Advanced or Metastatic Non-Small Cell Lung Cancer; EGFR Exon20 Insertion Mutations,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15354,NCT03586453,Osimertinib In EGFR Mutant Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,"Carcinoma, Non-Small-Cell Lung",Osimertinib (DRUG),78357807,Tagrisso,"Carcinoma, Non-Small-Cell Lung",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15355,NCT04001777,A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients,RECRUITING,PHASE1,EGFR Positive Non-small Cell Lung Cancer,APG-1252 (DRUG); Osimertinib Mesylate Tablets (DRUG),78357807,Tagrisso,EGFR Positive Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15356,NCT05228015,Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors,TERMINATED,PHASE1,"Solid Tumors, Adult; Solid Tumor; Malignant Pleural Mesothelioma (MPM); Epithelioid Hemangioendothelioma (EHE); NF2 Deficient Mesothelioma; Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes; NF2 Deficiency; YAP1 or TAZ Gene Fusions",IK-930 (DRUG); Osimertinib (DRUG),78357807,Tagrisso,"Solid Tumors, Adult; Solid Tumor; Malignant Pleural Mesothelioma (MPM); Epithelioid Hemangioendothelioma (EHE); NF2 Deficient Mesothelioma; Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes; NF2 Deficiency; YAP1 or TAZ Gene Fusions",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15357,NCT04644432,Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma,UNKNOWN,PHASE2,Metastatic Renal Cell Carcinoma; Kidney Neoplasm; Urologic Neoplasms; Urogenital Neoplasms,Medication (A specification is listed under each arm) (DRUG); Patient reported outcomes measurement (OTHER),78357807,Tagrisso,Metastatic Renal Cell Carcinoma,Kidney,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15358,NCT06567015,Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs,RECRUITING,PHASE1,Non-small Cell Lung Cancer (NSCLC),STX-241 (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer (NSCLC),Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15359,NCT03810807,Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Non-small Cell Lung Cancer,Dacomitinib (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Metastatic Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15360,NCT04541407,Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease,COMPLETED,PHASE1,Non Small Cell Lung Cancer; CNS Progression,Temozolomide plus Osimertinib (DRUG); Temozolomide plus Lorlatinib (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer; CNS Progression,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15361,NCT06868485,A Study to Assess the Efficacy of WSD0922-FU in Patients with C797S+ Advanced Non-small Cell Lung Cancer,NOT_YET_RECRUITING,PHASE2,Non Small Cell Lung Cancer,"WSD0922-FU Tablets, Dose level A (DRUG); WSD0922-FU Tablets, Dose level B (DRUG)",78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15362,NCT04135807,Implantable Microdevice In Primary Brain Tumors,UNKNOWN,EARLY_PHASE1,Grade II Glioma; Grade III Glioma; Grade IV Glioma; Astrocytoma; Oligodendroglioma of Brain; Anaplastic Astrocytoma of Brain; Anaplastic Oligodendroglioma; Glioblastoma,Microdevice (COMBINATION_PRODUCT),78357807,Tagrisso,Grade II Glioma; Grade III Glioma; Grade IV Glioma; Astrocytoma; Oligodendroglioma of Brain; Anaplastic Astrocytoma of Brain; Anaplastic Oligodendroglioma; Glioblastoma,CNS/Brain,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15363,NCT04988607,Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC,UNKNOWN,PHASE2,Lung Cancer,Osimertinib (DRUG); Bevacizumab (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15364,NCT06018688,Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.,NOT_YET_RECRUITING,PHASE2,Non Small Cell Lung Cancer; EGFR Gene Mutation,Osimertinib (DRUG); Aspirin (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer; EGFR Gene Mutation,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15365,NCT04770688,Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib,COMPLETED,PHASE1,Non-Small Cell Lung Cancer With EGFR Mutation; Locally Advanced Solid Tumor; Metastatic Cancer; Adenocarcinoma of Lung,Osimertinib (DRUG); Anlotinib (DRUG),78357807,Tagrisso,Non-Small Cell Lung Cancer With EGFR Mutation; Locally Advanced Solid Tumor; Metastatic Cancer; Adenocarcinoma of Lung,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15366,NCT02972333,"Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M",UNKNOWN,PHASE3,EGFR-TKI Resistant Mutation; Nonsmall Cell Lung Cancer; AZD9291; Brain Metastases,AZD9291 80mg oral each day (DRUG); Radiation therapy (RADIATION),78357807,Tagrisso,EGFR-TKI Resistant Mutation; Nonsmall Cell Lung Cancer; AZD9291; Brain Metastases,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15367,NCT03853551,Osimertinib Study in Indian Patients,COMPLETED,PHASE4,Non Small Cell Lung Cancer (NSCLC),Osimertinib (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer (NSCLC),Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15368,NCT02094261,Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours,COMPLETED,PHASE2,Non Small Cell Lung Cancer,AZD9291 (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15369,NCT06350097,"Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer",RECRUITING,PHASE3,Non-small Cell Lung Cancer,Osimertinib (DRUG); Datopotamab Deruxtecan (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15370,NCT04563871,Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC),COMPLETED,PHASE2,Non-small Cell Lung Cancer (NSCLC),80mg Osimertinib (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer (NSCLC),Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15371,NCT03255083,DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer,TERMINATED,PHASE1,Non-small Cell Lung Cancer (NSCLC),DS-1205c (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer (NSCLC),Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15372,NCT03865511,MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib,ACTIVE_NOT_RECRUITING,PHASE2,Non-small Cell Lung Cancer,TAGRISSO® 80mg (Osimertinib) (DRUG); Tumor biopsies (GENETIC); ctDNA analysis (GENETIC),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15373,NCT04882345,Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment,UNKNOWN,PHASE2,Lung Cancer; EGFR Gene Mutation,Almonertinib (DRUG),78357807,Tagrisso,Lung Cancer; EGFR Gene Mutation,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15374,NCT04769388,Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib,UNKNOWN,PHASE2,Non Small Cell Lung Cancer,Osimertinib (DRUG); Pemetrexed/Carboplatin (DRUG),78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15375,NCT05954871,"Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer",ACTIVE_NOT_RECRUITING,PHASE1,Colorectal Cancer; Non-Small Cell Lung Cancer,GDC-1971 (DRUG); Osimertinib (DRUG); Cetuximab (DRUG),78357807,Tagrisso,Colorectal Cancer; Non-Small Cell Lung Cancer,Bowel,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15376,NCT04285671,Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Metastatic Lung Non-Small Cell Carcinoma; Refractory Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Necitumumab (BIOLOGICAL); Osimertinib (DRUG); Quality-of-Life Assessment (OTHER); Questionnaire Administration (OTHER); Trastuzumab (BIOLOGICAL),78357807,Tagrisso,Metastatic Lung Non-Small Cell Carcinoma; Refractory Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15377,NCT02179671,"Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",COMPLETED,PHASE2,Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV),Gefitinib (DRUG); AZD9291 (DRUG); Selumetinib+Docetaxel (DRUG); Tremelimumab (DRUG),78357807,Tagrisso,Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV),Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15378,NCT03667820,Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC,ACTIVE_NOT_RECRUITING,PHASE2,Non-small Cell Lung Cancer (NSCLC),Osimertinib (DRUG); SABR (RADIATION),78357807,Tagrisso,Non-small Cell Lung Cancer (NSCLC),Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15379,NCT04606771,A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC,ACTIVE_NOT_RECRUITING,PHASE2,Non-Small Cell Lung Cancer,Osimertinib + Savolitinib (DRUG); Savolitinib + Placebo (DRUG),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15380,NCT03050411,Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer,UNKNOWN,PHASE1,Nonsmall Cell Lung Cancer,"Apatinib Mesylate Tablets (DRUG); EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib) (DRUG)",78357807,Tagrisso,Nonsmall Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15381,NCT05748093,Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat,RECRUITING,PHASE4,Non-small Cell Lung Cancer,Cobicistat (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15382,NCT02917993,An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Lung Cancer,Itacitinib (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15383,NCT06383728,Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma,RECRUITING,PHASE2,"Lung Cancer; Carcinoma, Squamous Cell",Osimertinib (DRUG),78357807,Tagrisso,"Lung Cancer; Carcinoma, Squamous Cell",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15384,NCT02157883,"Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)",COMPLETED,PHASE1,Advanced Non Small Cell Lung Cancer; Advanced (Inoperable) Non Small Cell Lung Cancer,Pharmacokinetic sampling (PROCEDURE); AZD9291 (DRUG); Itraconazole (DRUG),78357807,Tagrisso,Advanced Non-Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15385,NCT03543683,Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC,COMPLETED,PHASE2,Non-Small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer Stage IV; EGFR T790M,Osimertinib (DRUG); Aspirin (DRUG),78357807,Tagrisso,Non-Small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer Stage IV; EGFR T790M,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15386,NCT04148898,Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis,UNKNOWN,PHASE2,Leptomeningeal Metastasis; Non-small Cell Lung Cancer; EGFR Activating Mutation,Osimertinib (DRUG); Bevacizumab (DRUG),78357807,Tagrisso,Leptomeningeal Metastasis; Non-small Cell Lung Cancer; EGFR Activating Mutation,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15387,NCT04743505,Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC),RECRUITING,PHASE1,Metastatic Non Small Cell Lung Cancer,APL-101 (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Metastatic Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15388,NCT02197247,"Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC",COMPLETED,PHASE1,Non Small Cell Lung Cancer,Pharmacokinetic sampling - AZD9291 (PROCEDURE); Rifampicin (DRUG); AZD9291 tablet dosing (DRUG); Pharmacokinetic sampling - rifampicin (PROCEDURE); Pharmacokinetic sampling - AZ5140 and AZ7550 (PROCEDURE),78357807,Tagrisso,Non Small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15389,NCT02789345,A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer,COMPLETED,PHASE1,Non-small Cell Lung Cancer,Ramucirumab (DRUG); Necitumumab (DRUG); Osimertinib (DRUG),78357807,Tagrisso,Non-small Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15390,NCT06574347,Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.,RECRUITING,PHASE2,Non-Small-Cell Lung Cancer,Vebreltinib (DRUG); Osimertinib (DRUG); PLB1004 (DRUG),78357807,Tagrisso,Non-Small-Cell Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15391,NCT06296745,Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.,NOT_YET_RECRUITING,PHASE2,Leptomeningeal Metastasis,Pemetrexed (DRUG),78357807,Tagrisso,Leptomeningeal Metastasis,CNS/Brain,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15392,NCT06227897,Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).,WITHDRAWN,PHASE2,Lung Cancer,Aumolertinib (DRUG),78357807,Tagrisso,Lung Cancer,Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15393,NCT04486833,Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib,RECRUITING,PHASE1,"Carcinoma, Non-Small Cell Lung",quaratusugene ozeplasmid (BIOLOGICAL); osimertinib (DRUG); Platinum-Based Chemotherapy (DRUG),78357807,Tagrisso,"Carcinoma, Non-Small Cell Lung",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15394,NCT03833154,Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation,ACTIVE_NOT_RECRUITING,PHASE3,"Carcinoma, Non-Small-Cell Lung","Durvalumab (DRUG); Placebo (OTHER); (Osimertinib cohort, single-arm, open-label separate cohort) (DRUG)",78357807,Tagrisso,"Carcinoma, Non-Small-Cell Lung",Lung,Osimertinib (mesylate),EGFR,inhibitor/antagonist,EGFR/ERBB inhibitor,yes,yes,Approved for non-small cell lung cancer treatment.,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O ,1.01,1337.0 +15395,NCT01346774,Preventing Urinary Tract Infection Post-Surgery,COMPLETED,PHASE2,Urinary Tract Infection,Cranberry powder capsules (DRUG); Placebo powder capsules (DRUG),5282164,OZ,Urinary Tract Infection,Bladder/Urinary Tract,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15396,NCT06268665,Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy,RECRUITING,PHASE2,"Breast Cancer; Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer Stage IV; Invasive Breast Cancer; Ovarian Cancer; Ovarian Cancer Stage 1; Ovarian Cancer Stage II; Ovarian Cancer Stage III; Ovarian Cancer Stage IV; Ovarian Cancer Stage IA; Ovarian Cancer Stage IB; Ovarian Cancer Stage IC; Ovarian Cancer Stage 2; Ovarian Cancer Stage 3; Ovarian Cancer Stage IIIb; Ovarian Cancer Stage IIIC; Breast Cancer Stage IIIA; Breast Cancer Invasive; Breast Cancer, Stage IA; Breast Cancer, Stage IB; Breast Cancer Stage IIA; Breast Cancer Stage IIB; Breast Cancer Stage IIIB; Breast Cancer Stage IIIc; Cancer, Breast; Tumors, Breast; Mammary Cancer; Mammary Carcinoma; Breast Carcinoma; Breast Neoplasm; Malignant Breast Neoplasm; Malignant Tumor of Breast; Cancer of Ovary; Ovary Cancer; Ovary Neoplasm",Tart Cherry Juice (DRUG),5282164,OZ,"Breast Cancer; Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer Stage IV; Invasive Breast Cancer; Ovarian Cancer; Ovarian Cancer Stage 1; Ovarian Cancer Stage II; Ovarian Cancer Stage III; Ovarian Cancer Stage IV; Ovarian Cancer Stage IA; Ovarian Cancer Stage IB; Ovarian Cancer Stage IC; Ovarian Cancer Stage 2; Ovarian Cancer Stage 3; Ovarian Cancer Stage IIIb; Ovarian Cancer Stage IIIC; Breast Cancer Stage IIIA; Breast Cancer Invasive; Breast Cancer, Stage IA; Breast Cancer, Stage IB; Breast Cancer Stage IIA; Breast Cancer Stage IIB; Breast Cancer Stage IIIB; Breast Cancer Stage IIIc; Cancer, Breast; Tumors, Breast; Mammary Cancer; Mammary Carcinoma; Breast Carcinoma; Breast Neoplasm; Malignant Breast Neoplasm; Malignant Tumor of Breast; Cancer of Ovary; Ovary Cancer; Ovary Neoplasm",Breast,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15397,NCT01883648,Study to Evaluate Coconut Oil for Alzheimer's Disease,TERMINATED,PHASE2,Alzheimer's Disease,Coconut Oil Beverage (DRUG); Placebo Beverage (OTHER),5282164,OZ,Alzheimer's Disease,CNS/Brain,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15398,NCT00747084,Can Simple and Inexpensive Techniques Enhance Patient Comfort,TERMINATED,PHASE1,Colonoscopy,Colonoscopy (PROCEDURE),5282164,OZ,Colonoscopy,Bowel,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15399,NCT02147990,Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer,TERMINATED,PHASE2,Non-small Cell Lung Cancer,Rociletinib (DRUG),5282164,OZ,Non-small Cell Lung Cancer,Lung,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15400,NCT00756782,A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma,WITHDRAWN,PHASE2,Advanced Hepatocellular Carcinoma,TAC-101 (DRUG); Placebo (DRUG),5282164,OZ,Advanced Hepatocellular Carcinoma,Liver,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15401,NCT04129931,PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study,ACTIVE_NOT_RECRUITING,PHASE2,Asthma,MCT (DRUG); Clazakizumab (DRUG); Broncho-Vaxom (DRUG); Imatinib Mesylate (DRUG); Cavosonstat (DRUG); Placebo (OTHER),5282164,OZ,Asthma,Lung,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15402,NCT02719860,High Tea Consumption on Smoking Related Oxidative Stress,COMPLETED,PHASE2,Lung Cancer Prevention,Green tea (DIETARY_SUPPLEMENT); Black tea (DIETARY_SUPPLEMENT); Placebo tea (DIETARY_SUPPLEMENT),5282164,OZ,Lung Cancer Prevention,Lung,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15403,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",COMPLETED,PHASE2,Multiple Sclerosis,BIIB033 (DRUG); Placebo (OTHER); Avonex (DRUG),5282164,OZ,Multiple Sclerosis,CNS/Brain,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15404,NCT06604065,Essential Amino Acids and Parkinsons Disease,NOT_YET_RECRUITING,PHASE1,Parkinson Disease,AMS2434 (amino acids) (DRUG); Placebo (DRUG),5282164,OZ,Parkinson Disease,CNS/Brain,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15405,NCT04634539,Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE1,Advanced Pancreatic Adenocarcinoma; Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma,Gemcitabine (DRUG); Nab-paclitaxel (DRUG); L-glutamine (DRUG),5282164,OZ,Advanced Pancreatic Adenocarcinoma; Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma,Pancreas,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15406,NCT00681239,Atkins Plus KetoCal for Childhood Epilepsy,COMPLETED,PHASE3,Epilepsy,Modified Atkins diet and KetoCal (DIETARY_SUPPLEMENT),5282164,OZ,Epilepsy,CNS/Brain,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15407,NCT01547130,Yoga and Bolus Lukewarm Saline as Rapid Colonoscopy Preparation,COMPLETED,PHASE1,Colonic Neoplasms,Normal (0.9%) saline (DRUG); HalfLytely (DRUG),5282164,OZ,Colonic Neoplasms,Bowel,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15408,NCT05591027,Safety and Target Engagement of Centella Asiatica in Cognitive Impairment,RECRUITING,PHASE1,Mild Cognitive Impairment; Alzheimer's Disease,Centella asiatica product (DRUG); Placebo (DRUG),5282164,OZ,Mild Cognitive Impairment; Alzheimer's Disease,CNS/Brain,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15409,NCT01122329,A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease,COMPLETED,PHASE4,Alzheimer Disease,caprylidene (DIETARY_SUPPLEMENT); Placebo (DIETARY_SUPPLEMENT),5282164,OZ,Alzheimer Disease,CNS/Brain,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15410,NCT01282580,Dietary Fish and Omega 3 Fatty Acids for Breast Cancer Prevention,COMPLETED,PHASE1,Breast Cancer,"Lovaza-Omega 3 fatty acid capsules (DIETARY_SUPPLEMENT); Dietary fish (canned salmon, albacore) (OTHER)",5282164,OZ,Breast Cancer,Breast,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15411,NCT00687596,Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy,TERMINATED,PHASE2,Hepatocellular Carcinoma,TAC-101 (DRUG); Placebo (DRUG),5282164,OZ,Hepatocellular Carcinoma,Liver,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15412,NCT02294058,Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS),COMPLETED,PHASE3,Multiple Sclerosis,Ozanimod (DRUG); Interferon beta-1a (DRUG); Placebo to ozanimod (DRUG); Placebo to interferon beta-1a (DRUG),5282164,OZ,Multiple Sclerosis,CNS/Brain,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15413,NCT03667404,Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability Study,ACTIVE_NOT_RECRUITING,PHASE2,Parkinson Disease; Intestinal Bacteria Flora Disturbance; Dietary Modification,Resistant maltodextrin (DIETARY_SUPPLEMENT); maltodextrin (DIETARY_SUPPLEMENT),5282164,OZ,Parkinson Disease; Intestinal Bacteria Flora Disturbance; Dietary Modification,CNS/Brain,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15414,NCT06477146,Milk Thistle Clinical Trial in Pediatric NAFLD,RECRUITING,PHASE2,Non-Alcoholic Fatty Liver Disease (NAFLD),Milk thistle (MT) (DRUG); Placebo (DRUG); Lifestyle Modification (BEHAVIORAL); Fibroscan (DEVICE),5282164,OZ,Non-Alcoholic Fatty Liver Disease (NAFLD),Liver,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15415,NCT04229004,A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer,COMPLETED,PHASE3,Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma,Gemcitabine combined with nab-paclitaxel (DRUG); Dose -mFOLFIRINOX (DRUG); Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel (DRUG); Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine (DRUG); Drug: Dose -SM-88 (DRUG),5282164,OZ,Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma,Pancreas,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15416,NCT03592472,A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV),RECRUITING,PHASE3,Renal Cell Carcinoma,Pazopanib (DRUG); Abexinostat (DRUG); Placebo (OTHER),5282164,OZ,Renal Cell Carcinoma,Kidney,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15417,NCT06648434,MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma,NOT_YET_RECRUITING,PHASE1,Metastatic Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Cancer of the Pancreas,Zunsemetinib (DRUG); mFOLFIRINOX (DRUG),5282164,OZ,Metastatic Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Cancer of the Pancreas,Pancreas,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15418,NCT01748149,Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas,Vemurafenib (DRUG),5282164,OZ,Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas,CNS/Brain,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15419,NCT00889655,A Trial Comparing Bowel Preparation and Patient Tolerability of Miralax Versus Golytely,UNKNOWN,PHASE4,Colonoscopy,Golytely (polyethylene glycol) (DRUG); MiraLax (polyethylene glycol 3350) (DRUG),5282164,OZ,Colonoscopy,Bowel,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15420,NCT02322281,"TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy",TERMINATED,PHASE3,Non-small Cell Lung Cancer,Rociletinib (DRUG); Pemetrexed or gemcitabine or paclitaxel or docetaxel (DRUG),5282164,OZ,Non-small Cell Lung Cancer,Lung,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15421,NCT01477723,Evaluation of an Oral Nutritional Supplement in Older Hospitalized Patients,TERMINATED,PHASE3,Pneumonia,Experimental Oral Nutritional Supplement (OTHER),5282164,OZ,Pneumonia,Lung,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15422,NCT00779649,"MoviPrep® Versus HalfLytely®, Low-VolUme PEG Solutions for Colon Cleansing: An InvesTigator-blindEd, Randomized, Trial",COMPLETED,PHASE4,Colonoscopy,MoviPrep Kit (OTHER); HalfLytely and Bisacodyl Tablets Bowel Prep Kit (OTHER),5282164,OZ,Colonoscopy,Bowel,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15423,NCT05054036,MoviPrep® Versus GoLYTELY® Bowel Preparation in Hospitalized Patients Undergoing Colonoscopy,COMPLETED,PHASE4,Bowel Preparation Before Colonoscopy,MoviPrep (DRUG); Golytely (DRUG),5282164,OZ,Bowel Preparation Before Colonoscopy,Bowel,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15424,NCT01063049,Gatorade/Miralax With or Without Bisacodyl Versus NuLytely for Colonoscopy Preparation,COMPLETED,PHASE4,Preparation for Colonoscopy,Gatorade/Miralax (DRUG); NuLytely (DRUG); Bisacodyl (DRUG); Placebo (DRUG),5282164,OZ,Preparation for Colonoscopy,Bowel,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15425,NCT04734106,Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis,RECRUITING,EARLY_PHASE1,Interstitial Cystitis; Chronic Interstitial Cystitis; Bladder Pain Syndrome,Desert Harvest Aloe Vera Capsules (DRUG); Placebo Capsules (OTHER),5282164,OZ,Interstitial Cystitis; Chronic Interstitial Cystitis; Bladder Pain Syndrome,Bladder/Urinary Tract,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15426,NCT01968213,Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3),COMPLETED,PHASE3,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer,Rucaparib (DRUG); Placebo (DRUG),5282164,OZ,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Ovary/Fallopian Tube,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15427,NCT05589402,Temporary Inactivation of Strong Muscle Sensation to Improve Rehabilitation Interventions in SCI,RECRUITING,PHASE1,Spinal Cord Injuries; Spine Disease; Stroke,Lidocaine Cream 5% (DRUG); Rehabilitation Movement Training (OTHER),5282164,OZ,Spinal Cord Injuries; Spine Disease; Stroke,CNS/Brain,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15428,NCT06374459,Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis,RECRUITING,PHASE1,Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer,Zumsemetinib (DRUG); Capecitabine (DRUG); Zoledronic acid (DRUG); Denosumab (DRUG),5282164,OZ,Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer,Breast,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15429,NCT00953017,A Trial Comparing Split-Dose Miralax With Amitiza Pretreatment Versus Dulcolax Pretreatment Versus Golytely for Bowel Cleansing Prior to Colonoscopy,COMPLETED,PHASE4,Colonoscopy,Miralax (PEG 3350) (DRUG); Amitiza (Lubiprostone) (DRUG); Dulcolax (Bisacodyl) (DRUG); Golytely (polyethylene glycol) (DRUG),5282164,OZ,Colonoscopy,Bowel,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15430,NCT04989959,[18F]PT2385 PET/CT in Patients with Renal Cell Carcinoma,RECRUITING,PHASE1,Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma,[18F]PT2385 (DRUG); Positron Emission Tomography/Computed Tomography (PROCEDURE); Biopsy (PROCEDURE),5282164,OZ,Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma,Kidney,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15431,NCT00480870,The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients,COMPLETED,PHASE4,"Alzheimer Disease; Sleep Apnea, Obstructive",donepezil (DRUG); Placebo (DRUG),5282164,OZ,"Alzheimer Disease; Sleep Apnea, Obstructive",CNS/Brain,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15432,NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,COMPLETED,PHASE2,Non-Small-Cell Lung Carcinoma,BAY 43-9006 (Sorafenib) (DRUG),5282164,OZ,Non-Small-Cell Lung Carcinoma,Lung,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15433,NCT01170754,Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy,COMPLETED,PHASE4,Colon Cancer,PEG-3350 and Gatorade (DRUG); Golytely 4 liters (DRUG),5282164,OZ,Colon Cancer,Bowel,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15434,NCT05882877,"A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)",RECRUITING,PHASE3,Atopic Dermatitis,Rocatinlimab (DRUG); Placebo (OTHER),5282164,OZ,Atopic Dermatitis,Skin,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15435,NCT05365477,Empiric Versus Selective Prevention Strategies for Kidney Stone Disease,RECRUITING,PHASE4,Kidney Stones; Nephrolithiasis,Empiric Therapy: Diet (BEHAVIORAL); Empiric Therapy: Drug (DRUG); Selective Therapy: Diet (BEHAVIORAL); Selective Therapy: Drug (DRUG),5282164,OZ,Kidney Stones; Nephrolithiasis,Kidney,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15436,NCT01719653,A Comparison of 5 Low Volume Bowel Preparations,COMPLETED,PHASE4,Bowel Preparation for Colonoscopy,MiraLAX (DRUG); Gatorade (OTHER); MoviPrep (DRUG); SUPREP (DRUG),5282164,OZ,Bowel Preparation for Colonoscopy,Bowel,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15437,NCT01482715,A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II),COMPLETED,PHASE1,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Advanced Solid Tumor With Evidence of Germline or Somatic BRCA,Rucaparib (DRUG),5282164,OZ,Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Advanced Solid Tumor With Evidence of Germline or Somatic BRCA,Ovary/Fallopian Tube,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,, +15438,NCT04987307,Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis,TERMINATED,PHASE2,Ulcerative Colitis,Efavaleukin alfa (DRUG); Placebo (DRUG),5282164,OZ,Ulcerative Colitis,Bowel,γ-Oryzanol,,inhibitor/antagonist,DNA methyltransferase inhibitor,no,yes,Used in supplements; limited human data.,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,,